<SEC-DOCUMENT>0001104659-22-051436.txt : 20220428
<SEC-HEADER>0001104659-22-051436.hdr.sgml : 20220428
<ACCEPTANCE-DATETIME>20220427202422
ACCESSION NUMBER:		0001104659-22-051436
CONFORMED SUBMISSION TYPE:	S-4
PUBLIC DOCUMENT COUNT:		82
FILED AS OF DATE:		20220428
DATE AS OF CHANGE:		20220427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Avista Public Acquisition Corp. II
		CENTRAL INDEX KEY:			0001846253
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-264525
		FILM NUMBER:		22861717

	BUSINESS ADDRESS:	
		STREET 1:		C/O AVISTA CAPITAL HOLDINGS, LP
		STREET 2:		65 EAST 55TH STREET, 18TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		212-593-6900

	MAIL ADDRESS:	
		STREET 1:		C/O AVISTA CAPITAL HOLDINGS, LP
		STREET 2:		65 EAST 55TH STREET, 18TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4
<SEQUENCE>1
<FILENAME>ahpa-20220416xs4.htm
<DESCRIPTION>FORM - S-4
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8119.21675 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 4/27/2022 11:09:18 PM -->
      <!-- iXBRL Library version: 1.0.8119.21683 -->
      <!-- iXBRL Service Job ID: 4a35e8f5-8108-4938-8617-d22271cf1ace -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ahpa="http://AvistaPublicAcquisitionCorpII.com/20220416" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" xs:nil="true" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_lZEoWjr23kGWUV_psEI90Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" xs:nil="true" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" name="us-gaap:PreferredStockValue" id="Hidden_-kr0UHfvPkyTvSBDqmMFmA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" sign="-" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_MflBZkpiEkecqXC1OaZ9GA">0.03</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" sign="-" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_t9z7UsG5i0modg64DdHMtg">0.03</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_oIv_C0huWUWHJN148qo5_g">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_f60OhzulvUWffRFATFN0QQ" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_k2BHUUvoXEmMVvAsYFPM8w">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_5ZdjLnlv1ESof1_Jdhm7Sw">5750000</ix:nonFraction><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="ahpa:ThresholdBusinessDaysForRedemptionOfPublicShares" id="Hidden_MH-1shE-7UuVsRr2IwZGhQ">P10D</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_dLQndVmTokOqpzPEE6ShuQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_fiOqIe0ry0GFxCNERUdq_A">5321429</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_AvpvGzfBSk6euzkv_rNAng" decimals="2" name="ahpa:NumberOfWarrantsIssuedPerUnit" id="Hidden_d8ssFNr6LUCa3paVl1JKtw">0.33</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_ahpa_CommonClassaSubjectToRedemptionMember_q28zW_K4z0OVkxWsAfxczw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_Z_H04b9q5UCcSUgqEMG3_g">23000000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_1ubnyfPiU0eaQzavzDHJNg">5750000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_pHnMixOZ00u6gK01mog1ng">9857143</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_hskpw5GoZkCZsE4RzP1pWg">5321429</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" sign="-" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_6OA0VirRwEuN8iLMAj_gFA">0.03</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" sign="-" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden__fz-Sh5S5EuPKCGy7i67kQ">0.03</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_u3BgSj_pgUiqduil4GUdSQ">9857143</ix:nonFraction><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="dei:EntityRegistrantName" id="Hidden_nCFvCotUIEGnjq-A0N9Z0A">AVISTA PUBLIC ACQUISITION CORP. II</ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="dei:EntityCentralIndexKey" id="Tc_z9Owjk0kqEaouvYU7bw7LQ_2_1">0001846253</ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="dei:AmendmentFlag" id="Tc_IWrT9X4am0SCt6AaTwm5gA_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ahpa-20220416.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dKlB8yMYB0aeqkHBv0dRPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_16_2021_To_6_16_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember__BVIfHMD9Um_Bi-uIurswQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:FounderSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ahpa:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjNLK8smFEu-lbgIoNFmJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MNywhu2wKk6Z09hRF-PfiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_4_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jvgeKlnW-kGyt5FS8JRf2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_4_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gzEnwWnnx0WQYPJuULNY5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_4_2021_uo51c5vY7EuzHPYD_Z34hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_12_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_R55Po8B-UkKx2FU_T9LA_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rQSd3ig2NUquGWKI1v8ycg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WhjEOWhW9Eij5ZolTKJnCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_4_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Vb1595K4sEa1hL_hS2lBeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_4_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0VgzW0WvDkOhioKaphSgNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k3wFYri590eu2YfxnM5VTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_f0P--mGylEyLNj8LG5U35g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_12_2021_To_8_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_PromissoryNoteWithRelatedPartyMember_gpdKERCYWkCPAQ7cpRLRyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-12</xbrli:startDate><xbrli:endDate>2021-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_AdministrativeSupportAgreementMember_Km4Y9OkDw0uxggOurPog8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:AdministrativeSupportAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_AdministrativeSupportAgreementMember_NiMhJnR4mUi1x__B69WUPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:AdministrativeSupportAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_AdministrativeSupportAgreementMember_70Vvf8NJ3kSfQY4yJdgRgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:AdministrativeSupportAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_23_2021_To_6_23_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_PromissoryNoteWithRelatedPartyMember_w_DAgECzBE2Z5NwzDLL4EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-23</xbrli:startDate><xbrli:endDate>2021-06-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_15_2022_To_3_15_2022_us-gaap_ClassOfWarrantOrRightAxis_ahpa_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_sgLs6LqHfEWSJdAhO6MFKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ahpa:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-15</xbrli:startDate><xbrli:endDate>2022-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mvqSYAOLZUql2PhYI0lRvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RWEafoin-kCFfO1au4EhYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_23_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_JOtx4eLq2EWmvVpNUA4XHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_OmniabMember_K3bPyZi0602lWc8Dsxld3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:OmniabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_ahpa_CommonClassaSubjectToRedemptionMember_q28zW_K4z0OVkxWsAfxczw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ahpa:CommonClassaSubjectToRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_RHrFxFO2K0qVPKUowtOemA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_12_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_hpwJzLOcDk2-xk82YwbYBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_FMDt3RxfGEqzFwOF3AN7gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_d_YB9RSCPEWKNnaWk0ubPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5VcjzJoENE6qKN-GsE0NqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_6B_tQIqoTEmTyAmFq9B9mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_xNJIoD7-WEGyu2JOFYZBJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_12_2021_To_8_12_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_fKXwqT0SFUG_rtKtuXVz1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-12</xbrli:startDate><xbrli:endDate>2021-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_12_2021_To_8_12_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_hccbOwsxJ0e0grYvrrxaLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-12</xbrli:startDate><xbrli:endDate>2021-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_12_2021_To_8_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_ph3NAIUSSEif_XtyWxclIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-12</xbrli:startDate><xbrli:endDate>2021-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_12_2021_To_8_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_W782mJY-OkWY82NrBIIpRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-12</xbrli:startDate><xbrli:endDate>2021-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_-Ce3huUCEEmRf4OJGJJFJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_92SC9DBWKUyqMSwExfbIdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FE6zEVavvUymGkwGe3FEbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Gi4yVR_tj0CKg7dgp66JvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_07SLTebCGk63u2x-RfDH5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:FounderSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ahpa:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_FxrDQLlMwkKqESzq8z6bXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ahpa:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_c0jqdQLiPkuEslmiil_bNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_AdministrativeSupportAgreementMember_uzQQGS8H_0a5x4OT54OPfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:AdministrativeSupportAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_12_2021_To_2_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_dPb1k23M_k-pLZXh6JaJbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:FounderSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ahpa:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_HgSeUv3N6UGsnBDKOVV0aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_22_2021_To_3_22_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_PromissoryNoteWithRelatedPartyMember_CZvATsM0cEaCcdmjZWpMlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-22</xbrli:startDate><xbrli:endDate>2021-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_16_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_A7q41aYgok-ecWpRe_1YvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:FounderSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ahpa:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_QkwL0AKjOUOWUMGK6d_M2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:FounderSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ahpa:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_12_2021_To_8_12_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_AvpvGzfBSk6euzkv_rNAng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-12</xbrli:startDate><xbrli:endDate>2021-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tf5u2Z2hjkKPDF_uv_Xeig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_waiTR7W3qUWXhKuLp-042Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_eD2XDmIVE0OxfJPD7OTpMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_PromissoryNoteWithRelatedPartyMember_xyR3z7AzvE-9dwkUHu1Piw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_OmniabMember_Y-svE_WiIU2HjXgNBRRZFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:OmniabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_f60OhzulvUWffRFATFN0QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_c1CfbfmOgkajeLUmOnWY1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ahpa:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_V90sXGB5lUewxKhffVJUsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ahpa:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_Ng0NOicLVku1PX4eR69EBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ahpa:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_14_2022_us-gaap_ClassOfWarrantOrRightAxis_ahpa_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RZCYNy4TR02-s8x38wz2RQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ahpa:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mz3wLjizUUqg_78s5L5T6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PrivatePlacementWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_RelatedPartyLoansMember_t4HEn2WBv0-oLDiAcT-3nQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:RelatedPartyLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001846253</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_D_LMsaCzRsOkeKQp06MQlfMw"><xbrli:measure>ahpa:D</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_PXooaeoQc0ms4cDX_kIEHg"><xbrli:measure>ahpa:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_HhKYwaXu10-zi6ST7YVS-w"><xbrli:measure>ahpa:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><a id="_8eda44f8_19f4_4193_8b30_5978e1fa08da"></a><a id="_Hlk101228984"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">As filed with the Securities and Exchange Commission on April&#160;27, 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 0pt 0pt 27.35pt;"><b style="font-weight:bold;">Registration No.&#160;333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:4.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="dei:DocumentType" id="Narr_JeAebxnH-02SdlqaM5ZMrg"><b style="font-weight:bold;">S-4</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">REGISTRATION STATEMENT</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">UNDER</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-style:italic;font-weight:bold;">THE SECURITIES ACT OF 1933</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:4.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;line-height:1.19;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_nCFvCotUIEGnjq-A0N9Z0A;"><b style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-style:normal;font-weight:bold;">Avista Public Acquisition Corp. II</b></span><b style="font-weight:bold;">*</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">(Exact Name of Registrant as Specified in Its Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cayman Islands*</b></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">6770</b></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">98-1584818</b></p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;">(State or other jurisdiction of<br />incorporation or organization)</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;">(Primary Standard Industrial<br />Classification Code Number)</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;">(I.R.S. Employer</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;">Identification Number)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">65 East 55th Street, 18th Floor</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">New York, NY 10022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Telephone: 212-603-5500</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt 0pt 3pt 0pt;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices)</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ben Silbert</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">General Counsel and Secretary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Avista Public Acquisition Corp. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">65 East 55th Street, 18th Floor</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">New York, NY 10022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Telephone: (212)-593-6900</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt 0pt 3pt 0pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Copies to:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jaclyn L. Cohen</b><br /><b style="font-weight:bold;">Raymond O. Gietz</b><br /><b style="font-weight:bold;">Weil, Gotshal&#160;&amp; Manges LLP</b><br /><b style="font-weight:bold;">767 Fifth Avenue</b><br /><b style="font-weight:bold;">New York, NY 10153</b><br /><b style="font-weight:bold;">Tel: (212) 310-8000</b><br /><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Charles S. Berkman</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chief Legal Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">OmniAb,&#160;Inc.</b><br /><b style="font-weight:bold;">5980 Horton Street, Suite&#160;405</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Emeryville, CA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Tel: (510) 250-7800</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Matthew T. Bush</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">R. Scott Shean</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Anthony A. Gostanian</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Latham&#160;&amp; Watkins LLP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">12670 High Bluff Drive</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">San Diego, California 92130</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Tel: (858) 523-5400</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:4.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Approximate date of commencement of proposed sale of the securities to the public:</b> As soon as practicable after this registration statement is declared effective and all other conditions to the Business Combination described in the enclosed proxy statement/prospectus/information statement have been satisfied or waived.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 3pt 0pt;">If the securities being registered on this Form&#160;are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box: <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 3pt 0pt;">If this Form&#160;is filed to register additional securities for an offering pursuant to Rule&#160;462(b)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 3pt 0pt;">If this Form&#160;is a post-effective amendment filed pursuant to Rule&#160;462(d)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-indent:18pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:97.84%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.25pt 0.25pt 0.75pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:65.4%;margin:0pt;padding:0.25pt 0.25pt 0.75pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:34.23%;margin:0pt;padding:0.25pt 0.25pt 0.75pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.25pt 0.25pt 0.75pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.25pt 0.25pt 0.75pt 0.25pt;"></td><td style="vertical-align:top;width:65.4%;margin:0pt;padding:0.25pt 0.25pt 0.75pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">Large accelerated filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span> </p></td><td style="vertical-align:top;width:34.23%;margin:0pt;padding:0.25pt 0.25pt 0.75pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">Accelerated filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span> </p></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0.25pt 0.25pt 0.75pt 0.25pt;"></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:2pt 0.25pt 0.75pt 0.25pt;"></td><td style="vertical-align:top;width:65.4%;margin:0pt;padding:2pt 0.25pt 0.75pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="dei:EntityFilerCategory" id="Narr_itJrVe_E80m8UMN89boqLA"><span style="font-size:7pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;"> </span></p></td><td style="vertical-align:top;width:34.23%;margin:0pt;padding:2pt 0.25pt 0.75pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;">Smaller reporting company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="dei:EntitySmallBusiness" id="Narr_6lH5o6dLHU2fucsdh-sIiw"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric><span style="font-size:7pt;"> </span></p></td><td style="vertical-align:top;width:0.17%;margin:0pt;padding:2pt 0.25pt 0.75pt 0.25pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:0.17%;margin:0pt;padding:0.85pt 0.25pt 0.75pt 0.25pt;"></td><td style="vertical-align:top;white-space:nowrap;width:65.4%;margin:0pt;padding:0.85pt 0.25pt 0.75pt 0.25pt;"></td><td style="vertical-align:top;width:34.23%;margin:0pt;padding:0.85pt 0.25pt 0.75pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;">Emerging growth company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="dei:EntityEmergingGrowthCompany" id="Narr_8ZUsvMkh9E6SaW2kEAp8_Q"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;white-space:nowrap;width:0.17%;margin:0pt;padding:0.85pt 0.25pt 0.75pt 0.25pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:7pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B)&#160;of the Securities Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="dei:EntityExTransitionPeriod" id="Narr_WWYcHdojaEGtGC56hybKVQ"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 3pt 0pt;">If applicable, place an X in the box to designate the appropriate rule&#160;provision relied upon in conducting this transaction:</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 3pt 0pt;">Exchange Act Rule&#160;13e-4(i)&#160;(Cross-Border Issuer Tender Offer) <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-indent:18pt;margin:0pt;">Exchange Act Rule&#160;14d-l(d)&#160;(Cross-Border Third-Party Tender Offer) <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9pt;">*</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:7pt;">Prior to the consummation of the Merger described herein, Avista Public Acquisition Corp. II (&#8220;APAC&#8221;) intends to effect a deregistration under Section&#160;206 of the Companies Act (As Revised) of the Cayman Islands and a domestication under Section&#160;388 of the Delaware General Corporation Law, pursuant to which APAC&#8217;s jurisdiction of incorporation will be changed from the Cayman Islands to the State of Delaware (the &#8220;Domestication&#8221;). All securities being registered will be issued by the continuing entity following the Domestication, which will be renamed &#8220;OmniAb,&#160;Inc.&#8221; upon the consummation of the Domestication. As used herein, &#8220;New OmniAb&#8221; refers to APAC after the Domestication, including after such change of name.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt 0pt 2pt 0pt;"><span style="font-size:2pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_334f8c0d_90b9_4c90_b5e8_791a0351617d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXPLANATORY NOTE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Avista Public Acquisition Corp. II. (&#8220;APAC&#8221;) is filing this registration statement on Form&#160;S-4 to register shares of its common stock, par value $0.0001 per share, that will be issued in connection with the merger of Orwell Merger Sub&#160;Inc. (&#8220;Merger Sub&#8221;), which is a wholly owned subsidiary of APAC, with and into OmniAb,&#160;Inc. (&#8220;OmniAb&#8221;), which is currently a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated (&#8220;Ligand&#8221;), with OmniAb surviving the merger as a wholly owned subsidiary of APAC. Pursuant to the instructions on Form&#160;S-4, the proxy statement/prospectus/information statement which forms a part of this registration statement is also deemed filed pursuant to APAC&#8217;s obligations under Regulation 14A in connection with APAC&#8217;s extraordinary general meeting to approve the issuance of APAC common stock in connection with the merger and related proposals described herein. In addition, OmniAb will file a registration statement on Form&#160;10 to register shares of its common stock, par value $0.001 per share, which will be distributed to Ligand stockholders pursuant to a spin-off in connection with the merger. In the spin-off, all of Ligand&#8217;s stockholders would receive a pro rata number of shares of OmniAb common stock. Upon distribution, the OmniAb common stock will be immediately converted into shares of APAC common stock in the merger, following APAC&#8217;s domestication as a Delaware corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><div style="height:0pt;position:relative;width:100%;"><div style="left:1.79%;max-width:98.21%;position:absolute;top:23.86pt;width:49.4pt;z-index:251658240;"><div style="left:0pt;padding-bottom:1.2pt;position:relative;top:0pt;width:49.15pt;"><div style="left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:49.15pt;"><div style="align-items:flex-end;display:flex;left:0pt;position:relative;text-indent:0pt;top:0pt;transform:rotate(180.1deg);width:49.15pt;writing-mode:vertical-rl;-ms-writing-mode:tb-rl;"><div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;width:100%;margin:0pt;"><b style="color:#ff0000;font-weight:bold;">The information in this preliminary proxy statement/prospectus/information statement is not complete and may be changed. The registrant may not sell the securities described in this preliminary proxy statement/prospectus/information statement until the registration statement filed with the Securities and Exchange Commission is declared effective. This preliminary proxy statement/prospectus/information statement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</b></p></div></div></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:636.04pt;"><a id="_81f514cd_fe41_40b7_b31c_53f352c3a580"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#ff0000;font-weight:bold;">PRELIMINARY&#160;&#8212; SUBJECT TO COMPLETION, DATED APRIL&#160;27, 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">A Cayman Islands Exempted Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Company Number 306402)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">65 East 55th Street, 18th Floor</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">New York, NY 10022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">Dear Avista Public Acquisition Corp. II Shareholders:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">You are cordially invited to attend an extraordinary general meeting (the &#8220;extraordinary general meeting&#8221;) of Avista Public Acquisition Corp. II., a Cayman Islands exempted company (&#8220;APAC&#8221;), at the offices of Weil, Gotshal&#160;&amp; Manges LLP, located at 767 Fifth Avenue, New York, NY 10153, at [&#9679;], Eastern Time, on [&#9679;], 2022, or at such other time and place to which the meeting may be adjourned. Rather than attending in person, we encourage you to attend via live webcast at [&#9679;].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">At the extraordinary general meeting, APAC shareholders will be asked to consider and vote upon a proposal, which is called the &#8220;Business Combination Proposal&#8221; and described in further detail below, to approve the business combination between APAC and OmniAb,&#160;Inc. (&#8220;OmniAb&#8221;), a Delaware corporation that will own and operate the antibody discovery business of Ligand Pharmaceuticals Incorporated, a Delaware corporation and currently the parent company of OmniAb (&#8220;Ligand&#8221;). The business combination will be effected by the transaction steps set forth in the Agreement and Plan of Merger, dated as of March&#160;23, 2022 (as the same may be amended, the &#8220;Merger Agreement&#8221;), by and among Ligand, OmniAb, APAC, and Orwell Merger Sub&#160;Inc., a Delaware corporation and wholly-owned subsidiary of APAC (&#8220;Merger Sub&#8221;), and the related transaction documents named therein. The business combination is being accomplished through what is commonly referred to as a &#8220;Reverse Morris Trust&#8221; transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">As further described in the accompanying proxy statement/prospectus/information statement, the business combination of APAC and OmniAb contemplated by the Merger Agreement (the &#8220;Business Combination&#8221;) will be accomplished by way of the following transaction steps:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC&#8217;s jurisdiction of incorporation will be changed by its deregistering as an exempted company in the Cayman Islands and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware at least one (1)&#160;business day prior to the consummation of the Merger (as defined below) (the &#8220;Domestication&#8221;). As more fully described elsewhere in the accompanying proxy statement/prospectus/information statement, you will be asked to consider and vote upon a proposal to approve the Domestication (the &#8220;Domestication Proposal&#8221;). In connection with the consummation of the Domestication, APAC will change its name to &#8220;OmniAb,&#160;Inc.&#8221; (APAC, following the Domestication, is sometimes referred to in the proxy statement/prospectus/information statement as &#8220;New OmniAb&#8221;);</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 72pt;"><span style="margin-bottom:0pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3f02b9d5_0115_4209_81fa_8a985f76ca4b"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As a result of and upon the effective time of the Domestication, (1)&#160;each then issued and outstanding Class&#160;A ordinary share, par value $0.0001 per share, of APAC (the &#8220;APAC Class&#160;A Ordinary Shares&#8221;), will convert automatically, on a one-for-one basis, into a share of common stock, par value $0.0001 per share, of New OmniAb (the &#8220;New OmniAb Common Stock&#8221;), (2)&#160;each then issued and outstanding Class&#160;B ordinary share, par value $0.0001 per share, of APAC (the &#8220;APAC Class&#160;B Ordinary Shares&#8221;) will convert automatically, on a one-for-one basis, into a share of New OmniAb Common Stock, (3)&#160;each then issued and outstanding warrant of APAC (the &#8220;APAC Warrants&#8221;) will convert automatically into a warrant to acquire one share of New OmniAb Common Stock (the &#8220;New OmniAb Warrants&#8221;) pursuant to the Warrant Agreement, dated August&#160;9, 2021 (the &#8220;Warrant Agreement&#8221;), by and between APAC and Continental Stock Transfer&#160;&amp; Trust Company (&#8220;Continental&#8221;), a New York corporation, as warrant agent, and (4)&#160;each then issued and outstanding unit of APAC (the &#8220;APAC Units&#8221;), will separate and convert automatically into one share of New OmniAb Common Stock and one-third of one New OmniAb Warrant. As used in the accompanying proxy statement/prospectus/information statement, &#8220;public shares&#8221; shall mean the APAC Class&#160;A Ordinary Shares (including those that underlie the APAC Units) that were issued pursuant to APAC&#8217;s initial public offering and the shares of New OmniAb Common Stock issued as a matter of law upon the conversion thereof on the effective date of the Domestication, as applicable. For further details, see &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Shareholder Proposal No.&#160;2&#160;&#8212; The </i><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Domestication Proposal</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; in the accompanying proxy statement/prospectus/information statement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to a Separation and Distribution Agreement, dated as of March&#160;23, 2022, by and among Ligand, OmniAb and APAC (the &#8220;Separation Agreement&#8221;), Ligand will, among other things and subject to the terms and conditions of the Separation Agreement, transfer the OmniAb Business (as defined below), including certain related subsidiaries of Ligand, to OmniAb (the &#8220;Separation&#8221;) and make a contribution to the capital of OmniAb of $15,000,000, less certain transaction and other expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Following the Separation and on the day of the Merger described below, Ligand will distribute (the &#8220;Distribution&#8221;) to Ligand stockholders 100% of the common stock of OmniAb, par value $0.001 per share (the &#8220;OmniAb Common Stock&#8221;) on a pro rata basis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to the Employee Matters Agreement, dated March&#160;23, 2022 (the &#8220;Employee Matters Agreement&#8221;), by and among Ligand, OmniAb, APAC and Merger Sub, at the time of the Distribution, each existing Ligand equity award, with certain limited exceptions, will be split into (i)&#160;a new Ligand equity award and (ii)&#160;a new OmniAb Equity Award, with any accrued value in the original Ligand equity award split between such awards based on the relative post-closing stock values of Ligand and OmniAb;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to the Amended and Restated Forward Purchase Agreement, dated March&#160;23, 2022 (the &#8220;A&amp;R FPA&#8221;), by and among APAC, Avista Acquisition LP II (the &#8220;Sponsor&#8221;) and OmniAb, New OmniAb will issue and sell to the Sponsor 1,500,000 shares of New OmniAb Common Stock and warrants to acquire 1,666,667 shares of New OmniAb Common Stock for an aggregate purchase price of $15,000,000, with such purchase to be consummated following the Domestication and prior to the Merger (the &#8220;Forward Purchase&#8221;). In addition, pursuant to the A&amp;R FPA, the Sponsor has agreed to purchase up to an additional 10,000,000 shares of New OmniAb Common Stock (the &#8220;Redemption Backstop&#8221;) and up to an additional 1,666,667 New OmniAb Warrants, for an aggregate additional purchase price of up to $100,000,000, in order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds available to the combined company following the Business Combination from APAC&#8217;s trust account to be less than $100,000,000; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Following the above steps, Merger Sub will merge with and into OmniAb (the &#8220;Merger&#8221;), with OmniAb continuing as the surviving company in the Merger and a wholly-owned subsidiary of APAC. As a result of the Merger, the existing shares of OmniAb common stock will automatically convert into the right to receive shares of New OmniAb Common Stock in accordance with an exchange ratio described below. In addition, in connection with the consummation of the Merger and prior to the consummation of the Domestication</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, the surviving company will be renamed &#8220;OmniAb Operations,&#160;Inc.&#8221; (New OmniAb, following the consummation of the Business Combination, is sometimes referred to in the accompanying proxy statement/prospectus/information statement as the &#8220;combined company&#8221;).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 36pt;"><span style="margin-bottom:0pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d05c21da_2466_49d9_a9b7_e0420513c74a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the Business Combination Proposal and the Domestication Proposal, you will also be asked to consider and vote upon (1)&#160;a proposal to approve and adopt the proposed certificate of incorporation and bylaws of New OmniAb in connection with the Domestication (the &#8220;Organizational Documents Proposal&#8221;), (2)&#160;proposals to approve, on a non-binding advisory basis, certain material differences between APAC&#8217;s Amended and Restated Memorandum and Articles of Association (as it may be amended from time to time, the &#8220;Cayman Constitutional Documents&#8221;) and the proposed certificate of incorporation and bylaws of New OmniAb, presented separately in accordance with the United States Securities and Exchange Commission&#8217;s requirements (collectively, the &#8220;Non-Binding Governance Proposals&#8221;), (3)&#160;a proposal to approve for the purposes of complying with the applicable provisions of Nasdaq Stock Market Rule&#160;5635, the issuance of shares of New OmniAb Common Stock in connection with the Domestication, the Forward Purchase, the Redemption Backstop and the Merger (the &#8220;Stock Issuance Proposal&#8221;), (4)&#160;a proposal to approve the adoption by New OmniAb of the OmniAb,&#160;Inc. 2022 Incentive Award Plan (the &#8220;Incentive Plan Proposal&#8221;), (5)&#160;a proposal to approve the adoption by New OmniAb of the OmniAb,&#160;Inc. 2022 Employee Stock Purchase Plan (the &#8220;ESPP Proposal&#8221;), (6)&#160;a proposal to elect seven directors to the New OmniAb board of directors (the &#8220;New OmniAb Board&#8221;) effective as of the closing of the Business Combination (the &#8220;Closing&#8221;) (the &#8220;Director Election Proposal&#8221;), and (7)&#160;a proposal to approve the adjournment of the extraordinary general meeting to a later date or dates, if necessary, to permit further solicitation of proxies in the event that there are not sufficient votes to constitute a quorum or approve and adopt any one or more of the foregoing proposals at the extraordinary general meeting (the &#8220;Adjournment Proposal&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The transactions contemplated by the Merger Agreement will be consummated only if the Business Combination Proposal, the Domestication Proposal, the Organizational Documents Proposal, the Stock Issuance Proposal, the Incentive Plan Proposal, the ESPP Proposal, and the Director Election Proposal (collectively the &#8220;Condition Precedent Proposals&#8221;) are approved at the extraordinary general meeting. Each of the Condition Precedent Proposals is cross-conditioned on the approval of the others. Each of these proposals is more fully described in the accompanying proxy statement/prospectus/information statement, which each shareholder is encouraged to read carefully and in its entirety.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The total number of shares of New OmniAb Common Stock to be received by OmniAb&#8217;s stockholders (as of immediately after consummation of the Distribution) or reserved for issuance pursuant to the New OmniAb Equity Awards into which OmniAb Equity Awards are converted (other than the OmniAb Earnout Shares (as defined below)) will be equal to the quotient obtained by dividing (x)&#160;the sum of (i)&#160;$850,000,000, plus (ii)&#160;the aggregate exercise price of all in-the-money options to purchase OmniAb Common Stock that are outstanding immediately prior to the effective time of the Merger (the &#8220;Effective Time&#8221;), as determined on an aggregate basis (each, an &#8220;In-the-Money OmniAb Option&#8221;), by (y)&#160;$10.00 (the &#8220;Aggregate Merger Consideration&#8221;). In addition to the Aggregate Merger Consideration, holders of OmniAb Common Stock and equity awards will also receive at the Closing earnout consideration in the form of an additional 15,000,000 shares of New OmniAb Common Stock (the &#8220;OmniAb Earnout Shares&#8221;), with 50% of such earnout shares vesting upon the achievement of a post-transaction volume-weighted average price (&#8220;VWAP&#8221;) of $12.50 per share of New OmniAb Common Stock for any 20 trading&#160;days over a consecutive 30 trading-day period, and the remainder vesting upon achievement of a post-transaction VWAP of $15.00 per share of New OmniAb Common Stock for any 20 trading&#160;days over a consecutive 30 trading-day period, in each case provided such vesting occurs during the five-year period following the Closing; provided, that in the event of a Change of Control (as defined in the Merger Agreement) between the date of the Closing to and including the fifth anniversary of the date of the Closing pursuant to which New OmniAb or any of its stockholders have the right to receive, directly or indirectly, cash, securities or other property attributing a value of at least $12.50 (with respect to 50% of the OmniAb Earnout Shares) or $15.00 (with respect to all OmniAb Earnout Shares) per share of New OmniAb Common Stock, and such Change of Control has been approved by a majority of the independent directors of the New OmniAb Board, then such OmniAb Earnout Shares shall be deemed to have vested immediately prior to such Change of Control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of and upon the Closing, among other things, each outstanding share of OmniAb Common Stock (other than Treasury Shares (as defined below)), will be cancelled upon the Effective Time in exchange for the right to receive (i)&#160;a number of shares of New OmniAb Common Stock equal to the quotient obtained by dividing (x)&#160;the Aggregate Merger Consideration by (y)&#160;the aggregate number of shares of OmniAb Common Stock that are outstanding on a fully diluted basis as of immediately prior to the Effective Time (excluding any shares underlying options to purchase OmniAb Common Stock other than In-the-Money OmniAb Options), determined in accordance with the terms of the Merger Agreement (the &#8220;Base Exchange Ratio&#8221;), and (ii)&#160;a number of OmniAb Earnout Shares equal to the quotient obtained by dividing (x)&#160;15,000,000 by (y)&#160;the aggregate number of shares of OmniAb Common Stock that are outstanding on a fully diluted basis as of immediately prior to the Effective Time, determined in accordance with the terms of the Merger Agreement (the &#8220;Earnout Exchange Ratio&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In addition, all (i)&#160;options to purchase shares of OmniAb Common Stock (each, an &#8220;OmniAb Option&#8221;), (ii)&#160;restricted stock units relating to OmniAb Common Stock (each, an &#8220;OmniAb RSU&#8221;) and (iii)&#160;performance-vesting restricted stock units relating to OmniAb </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Common Stock (each, an &#8220;OmniAb PSU&#8221;), in each case, that are outstanding as of immediately prior to the Effective Time, will be converted into such number of (a)&#160;options to purchase shares of New OmniAb Common Stock (each, a &#8220;New OmniAb Option&#8221;), (b)&#160;restricted stock units relating to shares of New OmniAb Common Stock (each, a &#8220;New OmniAb RSU&#8221;) and (c)&#160;performance-vesting restricted stock units relating to shares of New OmniAb Common Stock (each, a &#8220;New OmniAb PSU&#8221;), respectively, in each case, equal to (1)&#160;the number of shares of OmniAb Common Stock underlying such OmniAb Equity Awards immediately prior to the Effective Time multiplied by (2)&#160;the Base Exchange Ratio. Each holder of an OmniAb Option, OmniAb RSU and/or OmniAb PSU will also receive a number of OmniAb Earnout Shares equal to the number of shares of OmniAb Common Stock underlying such OmniAb Options, OmniAb RSUs and/or OmniAb PSUs, as applicable, multiplied by the Earnout Exchange Ratio, and the exercise price of each outstanding New OmniAb Option will be equal to the exercise price of the pre-conversion OmniAb Option divided by the Base Exchange Ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is anticipated that, following the Business Combination, (1)&#160;APAC&#8217;s public shareholders are expected to own approximately 18.0% (assuming no public shareholders exercise their redemption rights in connection with the Business Combination (the &#8220;no redemption scenario&#8221;)) or 0% (assuming that 23,000,000 APAC Class&#160;A Ordinary Shares are redeemed in connection with the Business Combination and the Sponsor funds $100,000,000 pursuant to the Redemption Backstop provided for in the A&amp;R Forward Purchase Agreement (the &#8220;maximum redemption scenario&#8221;)) of the outstanding shares of New OmniAb Common Stock, (2)&#160;OmniAb stockholders (without taking into account any public shares held by OmniAb stockholders prior to the consummation of the Business Combination) are expected to own approximately 76.3% (assuming the no redemption scenario) or 85.0% (assuming the maximum redemption scenario) of the outstanding shares of New OmniAb Common Stock and (3)&#160;the Sponsor and related parties are expected to collectively own approximately 5.7% (assuming the no redemption scenario) or 15.0% (assuming the maximum redemption scenario) of the outstanding shares of New OmniAb Common Stock. These&#160;percentages (i)&#160;assume that (a)&#160;New OmniAb issues 97,431,885 shares of New OmniAb Common Stock to former stockholders of OmniAb as of immediately prior to the Effective Time, (b)&#160;that New OmniAb issues 1,500,000 shares of New OmniAb Common Stock to the Sponsor pursuant to the Forward Purchase and (c)&#160;solely in the case of the maximum redemption scenario, that New OmniAb issues an additional 10,000,000 shares of New OmniAb Common Stock to the Sponsor pursuant to the Redemption Backstop, (ii)&#160;exclude all New OmniAb Options that may be exercisable for shares of New OmniAb Common Stock, New OmniAb RSUs and New OmniAb PSUs, (iii)&#160;include the OmniAb Earnout Shares and (iv)&#160;exclude the impact of any New OmniAb Warrants that will be outstanding following the Business Combination. If the actual facts are different from the no redemption scenario or maximum redemption scenario, the&#160;percentage ownership of New OmniAb held by such constituencies will be different.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Business Combination, certain related agreements have been, or will be, entered into on or prior to the date of the Closing, including (i)&#160;the Separation Agreement, (ii)&#160;the A&amp;R Registration Rights Agreement (as defined below), (iii)&#160;the Tax Matters Agreement (as defined below), (iv)&#160;the Employee Matters Agreement, (v)&#160;the Transition Services Agreements (as defined below), (vi)&#160;the A&amp;R FPA, and (vii)&#160;the Sponsor Insider Agreement (as defined below). The A&amp;R Registration Rights Agreement will also provide that the Sponsor&#8217;s right to designate individuals to be appointed or nominated for election to the APAC Board will be reduced from three (3)&#160;individuals to one (1)&#160;individual, and that such right will only exist until the later of (i)&#160;such time as the Sponsor ceases to beneficially own at least 10% of APAC&#8217;s outstanding voting stock and (ii)&#160;subject to compliance with the rules&#160;of Nasdaq, the third anniversary of the date of the Merger Agreement. Moreover, any individual nominated by the Sponsor will require the consent of the New OmniAb Board, subject to certain exceptions. For additional information, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal &#8212; Summary of the Separation Agreement</i>&#8221; and &#8220;<i style="font-style:italic;">&#160;&#8212; Summary of the Ancillary Agreements</i>&#8221; in the accompanying proxy statement/prospectus/information statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Pursuant to the Cayman Constitutional Documents, any holder of public shares (a &#8220;public shareholder&#8221;), excluding shares held by the Sponsor and certain related parties, may request that APAC redeem all or a portion of such shareholder&#8217;s public shares for cash if the Business Combination is consummated. Holders of APAC Units must elect to separate the units into the underlying public shares and warrants prior to exercising redemption rights with respect to the public shares. If holders hold their APAC Units in an account at a brokerage firm or bank, holders must notify their broker or bank that they elect to separate the units into the underlying public shares and warrants, or if a holder holds APAC Units registered in its own name, the holder must contact Continental, APAC&#8217;s transfer agent, directly and instruct it to do so. <b style="font-weight:bold;">Public shareholders may elect to redeem their public shares even if they vote &#8220;for&#8221; the Business Combination Proposal or any other Condition Precedent Proposal.</b> If the Business Combination is not consummated, the public shares will be returned to the respective holder, broker or bank. If the Business Combination is consummated, and if a public shareholder properly exercises its right to redeem all or a portion of the public shares that it holds and timely delivers its shares to Continental, APAC will redeem such public shares for a per-share price, payable in cash, equal to the pro rata portion of the trust account established at the consummation of our initial public offering (the &#8220;trust account&#8221;), calculated as of two business&#160;days prior to the consummation of the Business Combination. For illustrative purposes, as of <b style="font-weight:bold;">[</b>&#9679;<b style="font-weight:bold;">]</b>, 2022, this would have amounted to approximately </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">$[&#9679;]<b style="font-weight:bold;"> </b>per issued and outstanding public share. If a public shareholder exercises its redemption rights in full, then it will be electing to exchange its public shares for cash and will no longer own public shares. The redemption takes place following the Domestication and, accordingly, it is shares of New OmniAb Common Stock that will be redeemed immediately after consummation of the Business Combination. See &#8220;<i style="font-style:italic;">Extraordinary General Meeting of APAC</i> <i style="font-style:italic;">&#8212;</i> <i style="font-style:italic;">Redemption Rights</i>&#8221; in the accompanying proxy statement/prospectus/information statement for a detailed description of the procedures to be followed if you wish to redeem your public shares for cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, a public shareholder, together with any affiliate of such public shareholder or any other person with whom such public shareholder is acting in concert or as a &#8220;group&#8221; (as defined in Section&#160;13(d)(3)&#160;of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its public shares with respect to more than an aggregate of 15% of the public shares. Accordingly, if a public shareholder, alone or acting in concert or as a group, seeks to redeem more than 15% of the public shares, then any such shares in excess of that 15% limit would not be redeemed for cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor and each director of APAC have agreed to, among other things, vote in favor of the Merger Agreement and the transactions contemplated thereby, including the Condition Precedent Proposals, and to waive their redemption rights in connection with the consummation of the Business Combination with respect to any ordinary shares held by them. Such persons agreed to waive their redemption rights in order to induce APAC and APAC&#8217;s underwriter to enter into the underwriting agreement executed and delivered in connection with the initial public offering. The Class&#160;B Ordinary Shares held by the Sponsor and such other persons will be excluded from the pro rata calculation used to determine the per-share redemption price. As of the date of the accompanying proxy statement/prospectus/information statement, the Sponsor and APAC&#8217;s directors, collectively, own 20% of the issued and outstanding ordinary shares of APAC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement provides that the obligations of the parties to consummate the Merger are conditioned on, among other things, (i)&#160;the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (ii)&#160;receipt of required consents and approvals from certain governmental authorities, (iii)&#160;no agreement between Ligand or APAC and any governmental authority pursuant to which Ligand or APAC has agreed not to consummate the Business Combination shall be in effect, (iv)&#160;no governmental authority of competent jurisdiction shall have enacted, issued or granted any law (whether temporary, preliminary or permanent), in each case that is in effect and which has the effect of restraining, enjoining or prohibiting the consummation of the transaction, (v)&#160;APAC shall have at least $5,000,001 of net tangible assets as of the Closing, (vi)&#160;the New OmniAb Common Stock issuable pursuant to the Business Combination shall have been approved for listing on Nasdaq, subject to official notice of issuance, (vii)&#160;Ligand, OmniAb, APAC and Merger Sub shall each have performed and complied in all material respects with the obligations, covenants and agreements required by the Merger Agreement to be performed or complied with by it at or prior to the Effective Time, (viii)&#160;customary bring down conditions related to the accuracy of the parties&#8217; respective representations and warranties in the Merger Agreement, (ix)&#160;the consummation of the Separation, the Distribution and the other transactions contemplated by the Separation Agreement, (x)&#160;each of APAC&#8217;s and OmniAb&#8217;s registration statements to be filed with the United States Securities and Exchange Commission shall have become effective, (xi) APAC&#8217;s shareholder approval of the Condition Precedent Proposals shall have been obtained and (xii) the receipt by Ligand and APAC of certain tax opinions. In addition, the respective obligations of OmniAb and Ligand to consummate the Business Combination are conditioned upon, among other items, the completion of the Forward Purchase and the Redemption Backstop, the resignation of all directors and all executive officers of APAC and the occurrence of the Domestication. APAC&#8217;s obligation to consummate the Business Combination is also conditioned on there having been no &#8220;Material Adverse Effect&#8221; on OmniAb since the date of the Merger Agreement that is continuing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement is also subject to the satisfaction or waiver of certain other closing conditions as described in the accompanying proxy statement/prospectus/information statement. There can be no assurance that the parties to the Merger Agreement would waive any such provision of the Merger Agreement if it is not satisfied as of the time of satisfaction of all other conditions precedent to the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">APAC is providing the accompanying proxy statement/prospectus/information statement and accompanying proxy card to APAC&#8217;s shareholders in connection with the solicitation of proxies to be voted at the extraordinary general meeting and at any adjournments of the extraordinary general meeting. Information about the extraordinary general meeting, the Business Combination and other related business to be considered by APAC&#8217;s shareholders at the extraordinary general meeting is included in the accompanying proxy statement/prospectus/information statement. <b style="font-weight:bold;">Whether or not you plan to attend the extraordinary general meeting, all of APAC&#8217;s shareholders are urged to read the accompanying proxy statement/prospectus/information statement, including the Annexes and other documents referred to therein, carefully and in their entirety. You should also carefully </b></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">consider the risk factors described in &#8220;</b><span style="font-style:italic;font-weight:bold;">Risk Factors</span><b style="font-weight:bold;">&#8221; beginning on page&#160;</b><span style="font-weight:bold;">70</span><b style="font-weight:bold;">&#160;of the accompanying proxy statement/prospectus/information statement.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">After careful consideration, the board of directors of APAC (the &#8220;APAC Board&#8221;) has unanimously approved the Business Combination and unanimously recommends that shareholders vote &#8220;FOR&#8221; the Business Combination Proposal and the Domestication Proposal and &#8220;FOR&#8221; all other proposals presented to APAC&#8217;s shareholders in the accompanying proxy statement/prospectus/information statement. When you consider the recommendation of these proposals by the APAC Board, you should keep in mind that APAC&#8217;s directors and officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#8220;</b><span style="font-style:italic;font-weight:bold;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#8212;Interests of APAC&#8217;s Directors and Executive Officers in the Business Combination</span><b style="font-weight:bold;">&#8221; in the accompanying proxy statement/prospectus/information statement for a further discussion of these considerations.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The approval of the Business Combination Proposal, the Domestication Proposal and the Organizational Documents Proposal each requires a special resolution under Cayman Islands law, being the affirmative vote of the holders of at least two-thirds majority of the APAC ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. The Non-Binding Governance Proposals (which are constituted of non-binding advisory proposals), the Director Election Proposal, the Stock Issuance Proposal, the Incentive Plan Proposal, the ESPP Proposal and the Adjournment Proposal each requires an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Your vote is very important.</span><b style="font-weight:bold;"> Whether or not you plan to attend the extraordinary general meeting, please vote as soon as possible by following the instructions in the accompanying proxy statement/prospectus/information statement to make sure that your shares are represented at the extraordinary general meeting. If you hold your shares in &#8220;street name&#8221; through a bank, broker or other nominee, you will need to follow the instructions provided to you by your bank, broker or other nominee to ensure that your shares are represented and voted at the extraordinary general meeting. In most cases you may vote by telephone or over the Internet as instructed. The transactions contemplated by the Merger Agreement will be consummated only if the Condition Precedent Proposals are approved at the extraordinary general meeting. Each of the Condition Precedent Proposals is cross-conditioned on the approval of the others. The Adjournment Proposal is not conditioned upon the approval of any other proposal set forth in the accompanying proxy statement/prospectus/information statement. The Non-Binding Governance Proposals are constituted of non-binding advisory proposals.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you sign, date and return your proxy card without indicating how you wish to vote, your proxy will be voted &#8220;FOR&#8221; each of the proposals presented at the extraordinary general meeting. If you fail to return your proxy card or fail to instruct your bank, broker or other nominee how to vote, and do not attend the extraordinary general meeting in person, the effect will be, among other things, that your shares will not be counted for purposes of determining whether a quorum is present at the extraordinary general meeting and will not be voted. An abstention will be counted towards the quorum requirement but will not count as a vote cast at the extraordinary general meeting. A broker non-vote, while considered present for the purposes of establishing a quorum, will not count as a vote cast at the extraordinary general meeting. If you are a shareholder of record and you attend the extraordinary general meeting and wish to vote in person, you may withdraw your proxy and vote in person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you have any questions or need assistance voting your ordinary shares, please contact D.F. King&#160;&amp; Co.,&#160;Inc., our proxy solicitor, by calling (888) 887-0082, or banks and brokers can call collect at (212) 269-5550 or by emailing AHPA@dfking.com.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TO EXERCISE YOUR REDEMPTION RIGHTS, YOU MUST DEMAND IN WRITING THAT YOUR PUBLIC SHARES ARE REDEEMED FOR A PRO RATA PORTION OF THE FUNDS HELD IN THE TRUST ACCOUNT AND TENDER YOUR SHARES TO APAC&#8217;S TRANSFER AGENT AT LEAST TWO BUSINESS&#160;DAYS PRIOR TO THE VOTE AT THE GENERAL MEETING. YOU MAY&#160;TENDER YOUR SHARES BY EITHER DELIVERING YOUR SHARE CERTIFICATE TO THE TRANSFER AGENT OR BY DELIVERING YOUR SHARES ELECTRONICALLY USING THE DEPOSITORY TRUST COMPANY&#8217;S DWAC (DEPOSIT WITHDRAWAL AT CUSTODIAN) SYSTEM. IF THE BUSINESS COMBINATION IS NOT COMPLETED, THEN THESE SHARES WILL BE RETURNED TO YOU OR YOUR ACCOUNT. IF YOU HOLD THE SHARES IN STREET NAME, YOU WILL NEED TO INSTRUCT THE ACCOUNT EXECUTIVE AT YOUR BANK OR BROKER TO WITHDRAW THE SHARES FROM YOUR ACCOUNT IN ORDER TO EXERCISE YOUR REDEMPTION RIGHTS.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">On behalf of the APAC Board, we would like to thank you for your support and look forward to the successful completion of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Sincerely,</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Thompson Dean</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chairman of the APAC Board</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED IN THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS/INFORMATION STATEMENT, PASSED UPON THE MERITS OR FAIRNESS OF THE BUSINESS COMBINATION OR RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS/INFORMATION STATEMENT. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are not licensed to conduct investment business in the Cayman Islands by the Cayman Islands Monetary Authority and the accompanying proxy statement/prospectus/information statement does not constitute an offer to members of the public of our issued share capital, whether by way of sale or subscription, in the Cayman Islands. Our issued share capital has not been offered or sold, will not be offered or sold and no invitation to subscribe for our ordinary shares will be made, directly or indirectly, to members of the public in the Cayman Islands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying proxy statement/prospectus/information statement is dated [&#9679;], 2022 and is first being mailed to shareholders on or about [&#9679;], 2022.</p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:56.08pt;"><a id="_0b53c6a5_eaeb_4b81_9f55_47b9efa9c252"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ahpa-20220416xs4006.jpg" alt="Graphic" style="display:inline-block;height:56.08pt;width:174.05pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">[&#160;&#9679;&#160;], 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Dear Ligand Stockholder:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November&#160;9, 2021, we announced we were pursuing plans to split our company into two separate, publicly traded companies, with one featuring the OmniAb business and the other featuring Ligand&#8217;s remaining businesses. We considered multiple ways to pursue a separation with the goals of ensuring a smooth transition of operations, a healthy balance sheet for both OmniAb and Ligand, and support from investors. On February&#160;17, 2022, we announced our intention to accomplish this separation via a distribution to our stockholders of outstanding shares of common stock of OmniAb,&#160;Inc. held by Ligand. Subsequently, we received an offer from Avista Public Acquistion Corp. II (&#8220;APAC&#8221;) to complete a business combination. The APAC team is comprised of high-quality healthcare operators and investors with an excellent track record. They have done extensive due diligence and see the potential and value of OmniAb, a highly competitive, leading platform with strong momentum given recent major clinical and regulatory successes. We are very pleased to partner with APAC and its shareholders to take OmniAb public.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The spin-off of OmniAb through the business combination with APAC is intended to create two companies with dedicated operational focus, business-specific capital allocation, agility to meet partner needs, and compelling focused investment profiles. OmniAb&#8217;s business will include the Ab Initio computational antigen design technology, Icagen&#8217;s ion channel technology, the xPloration high-throughput screening technology, and the suite of OmniAb transgenic animals used for antibody discovery. Ligand will continue to focus on its existing collection of core royalties and technologies, pipeline and contracts associated with the Pelican protein expression platform and the Captisol business. We believe more than ever that OmniAb offers one of the industry&#8217;s leading antibody discovery platforms and that the business is primed for success for&#160;years to come. We believe we have been operating two distinct, high-growth companies within Ligand. We are excited to create two independent companies and accelerate investment into the OmniAb platform and technologies to further drive value for our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The separation will provide current Ligand stockholders with ownership interests in both Ligand and OmniAb. The principal transactions described in this document include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Separation&#8212;Ligand and certain of Ligand&#8217;s subsidiaries will engage in a series of transactions to transfer OmniAb&#8217;s business, including certain related subsidiaries of Ligand, to OmniAb,&#160;Inc. and make a contribution to the capital of OmniAb of $15,000,000, less certain transaction and other expenses</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Distribution&#8212;Ligand will distribute to Ligand stockholders 100% of the common stock of OmniAb on a pro rata basis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Merger&#8212;Immediately after the distribution, OmniAb will merge with an APAC subsidiary and continue as a wholly owned subsidiary of APAC. As a result of the merger, the existing shares of OmniAb common stock will automatically convert into the right to receive shares of APAC common stock in accordance with an exchange ratio described below.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You do not need to take any action to receive the shares of OmniAb common stock to which you are entitled as a Ligand stockholder. You also do not need to pay any consideration or surrender or exchange any shares of Ligand Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">I encourage you to read the proxy statement/prospectus/information statement. The proxy statement/prospectus/information statement describes the separation, the distribution and the merger in detail and contains important business and financial information about OmniAb and APAC as well as the combined company.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">We believe the separation, distribution and merger collectively represent an exciting step in our company&#8217;s history, and we remain committed to working on your behalf to provide a meaningful return for our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Sincerely,</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">John L. Higgins</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Chief Executive Officer</i></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Ligand Pharmaceuticals Incorporated</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:52.6pt;"><a id="_46fee9b3_a147_4ac9_965a_134edba9885d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ahpa-20220416xs4007.jpg" alt="Graphic" style="display:inline-block;height:52.6pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:230.92pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">[&#160;&#9679;&#160;], 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Dear Future OmniAb Stockholder:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are excited to welcome you as a stockholder of New OmniAb, which will be a separate company after its upcoming spin-off from Ligand and business combination with APAC. We are proud of our accomplishments and growth to date and plan to further expand on our successes moving forward.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The OmniAb discovery platform provides our pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. We believe the OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our mission is to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies. We intend to achieve this mission by enabling the discovery of high-quality therapeutic candidates and by being the partner of choice for pharmaceutical and biotechnology companies. As a standalone company in partnership with the APAC team, we believe we will be well positioned to unleash the full potential of our platform through dedicated operational focus by all members of the new OmniAb team and a capital structure appropriate to our business strategy which will further our ability to meet our partners&#8217; needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">I personally invite you to learn more about OmniAb by reading the accompanying proxy statement/prospectus/information statement. We have applied to be listed on the Nasdaq Global Market under the symbol &#8220;OABI.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This is an exciting opportunity and the time is right to establish a standalone company. With our heritage and solid foundation derived from Ligand and the capital raised from the merger with APAC, we believe OmniAb is in an excellent place from which to launch an even brighter future. I and the whole team at OmniAb look forward to building a stronger and more successful company that benefits our stockholders, our other stakeholders and the world.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Sincerely,</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Matthew W. Foehr</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">President and Chief Executive Officer</i></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">OmniAb,&#160;Inc.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6903d110_2b3c_4fc9_a9ec_b7857e564260"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_REFERENCESTOADDITIONALINFORMATION"><span style="font-style:normal;font-weight:normal;">REFERENCES TO ADDITIONAL INFORMATION</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">5</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_TRADEMARKS"><span style="font-style:normal;font-weight:normal;">TRADEMARKS</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">6</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_SELECTEDDEFINITIONS"><span style="font-style:normal;font-weight:normal;">SELECTED DEFINITIONS</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">7</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_CAUTIONARYSTATEMENTREGARDINGFORW"><span style="font-style:normal;font-weight:normal;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">13</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_QUESTIONSANDANSWERS"><span style="font-style:normal;font-weight:normal;">QUESTIONS AND ANSWERS</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">15</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_SUMMARYOFTHEPROXYSTATEMENT"><span style="font-style:normal;font-weight:normal;">SUMMARY OF THE PROXY STATEMENT/PROSPECTUS/INFORMATION STATEMENT</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">37</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#MARKETPRICEANDDIVIDENDINFORMATION_903286"><span style="font-style:normal;font-weight:normal;">MARKET PRICE AND DIVIDEND INFORMATION</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">59</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#MAin_UNAUDITEDPROFORMACONDENSEDCOMBI"><span style="font-style:normal;font-weight:normal;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF APAC AND OMNIAB</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">60</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_RISKFACTORS"><span style="font-style:normal;font-weight:normal;">RISK FACTORS</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">70</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_EXTRAORDINARYGENERALMEETINGOFAP"><span style="font-style:normal;font-weight:normal;">EXTRAORDINARY GENERAL MEETING OF APAC</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">129</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_THEBUSINESSCOMBINATIONPROPOSAL"><span style="font-style:normal;font-weight:normal;">SHAREHOLDER PROPOSAL NO. 1 &#8211; THE BUSINESS COMBINATION PROPOSAL</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">134</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_THEDOMESTICATIONPROPOSAL"><span style="font-style:normal;font-weight:normal;">SHAREHOLDER PROPOSAL NO. 2 &#8211; THE DOMESTICATION PROPOSAL</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">180</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_THEORGANIZATIONALDOCUMENTSPROPOS"><span style="font-style:normal;font-weight:normal;">SHAREHOLDER PROPOSAL NO. 3 &#8211; THE ORGANIZATIONAL DOCUMENTS PROPOSAL</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">182</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_THENONBINDINGGOVERNANCEPROPOSAL"><span style="font-style:normal;font-weight:normal;">SHAREHOLDER PROPOSAL NO. 4 &#8211; THE NON-BINDING GOVERNANCE PROPOSAL</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">185</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_THESTOCKISSUANCEPROPOSAL"><span style="font-style:normal;font-weight:normal;">SHAREHOLDER PROPOSAL NO. 5 &#8211; THE STOCK ISSUANCE PROPOSAL</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">189</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_THEINCENTIVEPLANPROPOSAL"><span style="font-style:normal;font-weight:normal;">SHAREHOLDER PROPOSAL NO. 6 &#8211; THE INCENTIVE PLAN PROPOSAL</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">191</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_THEESPPPROPOSAL"><span style="font-style:normal;font-weight:normal;">SHAREHOLDER PROPOSAL NO. 7 &#8211; THE ESPP PROPOSAL</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">196</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_THEDIRECTORELECTIONPROPOSAL"><span style="font-style:normal;font-weight:normal;">SHAREHOLDER PROPOSAL NO. 8 &#8211; THE DIRECTOR ELECTION PROPOSAL</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">200</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#MAin_THEADJOURNMENTPROPOSAL"><span style="font-style:normal;font-weight:normal;">SHAREHOLDER PROPOSAL NO. 9 &#8211; THE ADJOURNMENT PROPOSAL</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">202</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_MATERIALUSFEDERALINCOMETAXCO"><span style="font-style:normal;font-weight:normal;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO APAC SHAREHOLDERS</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">203</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_DISTRIBUTIONANDMERGER"><span style="font-style:normal;font-weight:normal;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO LIGAND STOCKHOLDERS OF THE DISTRIBUTION AND MERGER</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">216</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_INFORMATIONABOUTAPACANDMERGERS"><span style="font-style:normal;font-weight:normal;">INFORMATION ABOUT APAC AND MERGER SUB</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">220</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_APACMANAGEMENTSDISCUSSIONANDAN"><span style="font-style:normal;font-weight:normal;">APAC MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">225</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_MANAGEMENTOFAPAC"><span style="font-style:normal;font-weight:normal;">MANAGEMENT OF APAC</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">230</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_INFORMATIONABOUTLIGAND"><span style="font-style:normal;font-weight:normal;">INFORMATION ABOUT LIGAND</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">236</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#MAin_INFORMATIONABOUTOMNIABBUSINESS"><span style="font-style:normal;font-weight:normal;">INFORMATION ABOUT THE OMNIAB BUSINESS</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">237</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_OMNIABMANAGEMENTSDISCUSSIONAND"><span style="font-style:normal;font-weight:normal;">OMNIAB MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">270</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_EXECUTIVEANDDIRECTORCOMPENSATION"><span style="font-style:normal;font-weight:normal;">EXECUTIVE AND DIRECTOR COMPENSATION OF OMNIAB</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">285</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_MANAGEMENTOFNEWOMNIABAFTERTHE"><span style="font-style:normal;font-weight:normal;">MANAGEMENT OF NEW OMNIAB AFTER THE BUSINESS COMBINATION</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">301</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_BENEFICIALOWNERSHIPOFSECURITIES"><span style="font-style:normal;font-weight:normal;">BENEFICIAL OWNERSHIP OF SECURITIES</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">308</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_CERTAINRELATIONSHIPSANDRELATEDP"><span style="font-style:normal;font-weight:normal;">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">311</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_SECURITYOWNERSHIPOFCERTAINBENEF"><span style="font-style:normal;font-weight:normal;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT OF OMNIAB</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">316</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_THESEPARATIONANDDISTRIBUTION"><span style="font-style:normal;font-weight:normal;">THE SEPARATION AND DISTRIBUTION</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">317</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_DESCRIPTIONOFCOMBINEDCOMPANYSEC"><span style="font-style:normal;font-weight:normal;">DESCRIPTION OF COMBINED COMPANY SECURITIES</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">318</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_COMPARISONOFCORPORATEGOVERNANCE"><span style="font-style:normal;font-weight:normal;">COMPARISON OF CORPORATE GOVERNANCE AND SHAREHOLDER RIGHTS</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">323</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_SECURITIESACTRESTRICTIONSONRESA"><span style="font-style:normal;font-weight:normal;">SECURITIES ACT RESTRICTIONS ON RESALE OF COMBINED COMPANY&#8217;S SECURITIES</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">330</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_DISSENTERSRIGHTSANDAPPRAISALRI"><span style="font-style:normal;font-weight:normal;">DISSENTERS&#8217; RIGHTS AND APPRAISAL RIGHTS</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">331</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_SUBMISSIONOFSHAREHOLDERPROPOSALS"><span style="font-style:normal;font-weight:normal;">SUBMISSION OF SHAREHOLDER PROPOSALS</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">332</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_FUTURESHAREHOLDERPROPOSALS"><span style="font-style:normal;font-weight:normal;">FUTURE SHAREHOLDER PROPOSALS</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">333</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_DELIVERYOFDOCUMENTSTOSHAREHOLDE"><span style="font-style:normal;font-weight:normal;">DELIVERY OF DOCUMENTS TO SHAREHOLDERS/HOUSEHOLDING</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">334</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_OTHERSHAREHOLDERCOMMUNICATIONS"><span style="font-style:normal;font-weight:normal;">OTHER SHAREHOLDER COMMUNICATIONS</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">335</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#main_LEGALMATTERS"><span style="font-style:normal;font-weight:normal;">LEGAL MATTERS</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">335</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_EXPERTS"><span style="font-style:normal;font-weight:normal;">EXPERTS</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">335</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_WHEREYOUCANFINDMOREINFORMATION"><span style="font-style:normal;font-weight:normal;">WHERE YOU CAN FIND MORE INFORMATION</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">336</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_INDEXTOFINANCIALSTATEMENTS"><span style="font-style:normal;font-weight:normal;">INDEX TO FINANCIAL STATEMENTS</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">F-</span><span style="font-size:9.5pt;">1</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#indextocombine"><span style="font-style:normal;font-weight:normal;">INDEX TO COMBINED FINANCIAL STATEMENTS</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">F-</span><span style="font-size:9.5pt;">1</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Annex_A"><span style="font-style:normal;font-weight:normal;">ANNEXES</span></a></p></td><td style="vertical-align:top;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">A</span><span style="font-size:10pt;">-1</span></p></td></tr><tr><td style="vertical-align:top;width:92.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:9.5pt;" href="#Main_INFORMATIONNOTREQUIREDINPROSPEC"><span style="font-style:normal;font-weight:normal;">INFORMATION NOT REQUIRED IN PROSPECTUS</span></a></p></td><td style="vertical-align:top;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9.5pt;">II-</span><span style="font-size:9.5pt;">1</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_77eb03b5_981b_4ebd_9655_3e717b58f8f8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">A Cayman Islands Exempted Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Company Number 306402)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">65 East 55th Street, 18th Floor</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">New York, NY 10022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTICE OF EXTRAORDINARY GENERAL MEETING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TO BE HELD ON [&#9679;], 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">TO THE SHAREHOLDERS OF AVISTA PUBLIC ACQUISITION CORP. II:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the &#8220;extraordinary general meeting&#8221;) of Avista Public Acquisition Corp. II, a Cayman Islands exempted company, company number 306402 (&#8220;APAC&#8221;), will be held at the offices of Weil, Gotshal&#160;&amp; Manges LLP, located at 767 Fifth Avenue, New York, NY 10153, at [&#9679;] Eastern Time, on [&#9679;], 2022. Cayman Islands law requires there to be a physical location for the extraordinary general meeting. However, given the ongoing global pandemic, the extraordinary general meeting will also be held virtually via live webcast. As such, APAC shareholders may attend the extraordinary general meeting by visiting the extraordinary general meeting website at [&#9679;], where they will be able to listen to the meeting live and vote during the meeting. We are pleased to utilize virtual shareholder meeting technology to (i)&#160;provide ready access and cost savings for APAC shareholders and APAC and (ii)&#160;protect the health and safety of our shareholders. You are cordially invited to attend the extraordinary general meeting, which will be held for the following purposes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Proposal No.&#160;1 &#8212; The Business Combination Proposal &#8212; </b>to consider and vote upon a proposal to approve by special resolution and adopt (i)&#160;the Agreement and Plan of Merger, dated as of March&#160;23, 2022 (the &#8220;Merger Agreement&#8221;), by and among APAC, Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#8220;Ligand&#8221;), OmniAb,&#160;Inc., a Delaware corporation and wholly-owned subsidiary of Ligand (&#8220;OmniAb&#8221;), and Orwell Merger Sub&#160;Inc., a Delaware corporation and wholly-owned subsidiary of APAC (&#8220;Merger Sub&#8221;), (ii)&#160;the Transaction Documents (as defined in the Merger Agreement) and (iii)&#160;each of the transactions contemplated thereby, in each case, in accordance with the terms and subject to the conditions set forth in the Merger Agreement and such Transaction Documents, as more fully described elsewhere in the accompanying proxy statement/prospectus/information statement (the &#8220;Business Combination Proposal&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Proposal No.&#160;2 &#8212; The Domestication Proposal &#8212; </b>to consider and vote upon a proposal to approve by special resolution the change of APAC&#8217;s jurisdiction of incorporation (the &#8220;Domestication&#8221;), by deregistering as an exempted company in the Cayman Islands and continuing and domesticating under the name &#8220;OmniAb,&#160;Inc.&#8221; as a corporation incorporated under the laws of the State of Delaware (the &#8220;Domestication Proposal&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Proposal No.&#160;3 &#8212; The Organizational Documents Proposal &#8212; </b>to consider and vote upon a proposal to approve by special resolution and adopt the proposed new certificate of incorporation (the &#8220;Proposed Certificate of Incorporation&#8221;) and the proposed new bylaws (the &#8220;Proposed Bylaws&#8221;) of APAC after giving effect to the Domestication (&#8220;New OmniAb&#8221;) (the &#8220;Organizational Documents Proposal&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Proposal No.&#160;4 &#8212; The Non-Binding Governance Proposals &#8212; </b>to consider and vote upon, on a non-binding advisory basis, certain material differences between APAC&#8217;s Amended and Restated Memorandum and Articles of Association (as it may be amended from time to time, the &#8220;Cayman Constitutional Documents&#8221;) and the Proposed Certificate of Incorporation and Proposed Bylaws, presented separately in accordance with the United States Securities and Exchange Commission requirements (collectively, the &#8220;Non-Binding Governance Proposals&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Proposal No.&#160;5 &#8212; The Stock Issuance Proposal &#8212; </b>to consider and vote upon a proposal to approve by ordinary resolution, for the purposes of complying with the applicable provisions of Nasdaq Rule&#160;5635, the issuance of shares of common stock, par value $0.0001, of New OmniAb pursuant to (a)&#160;the Domestication, (b)&#160;the Forward Purchase, (c)&#160;the Redemption Backstop and (d)&#160;the Merger, as each of the capitalized terms used in clauses (b), (c)&#160;and (d)&#160;are defined in the Merger Agreement and described in the accompanying proxy statement/prospectus/information statement (the &#8220;Stock Issuance Proposal&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Proposal No.&#160;6 &#8212; The Incentive Plan Proposal &#8212; </b>to consider and vote upon a proposal to approve by ordinary resolution, the OmniAb,&#160;Inc. 2022 Incentive Award Plan (the &#8220;Incentive Plan Proposal&#8221;);</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Proposal No.&#160;7 &#8212; The ESPP Proposal &#8212; </b>to consider and vote upon a proposal to approve by ordinary resolution, the <span style="color:#231f20;">OmniAb,&#160;Inc. 2022 Employee Stock Purchase Plan </span>(the &#8220;ESPP Proposal&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Proposal No.&#160;8 &#8212; The Director Election Proposal &#8212; </b>to consider and vote upon a proposal to elect seven directors to serve staggered terms on the New OmniAb Board upon the consummation of the Business Combination until the first, second and third annual meeting of stockholders following the date of effectiveness of the Proposed Certificate of Incorporation, as applicable, or until the election and qualification of their respective successors in office, subject to their earlier death, resignation or removal (the &#8220;Director Election Proposal&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Proposal No.&#160;9 &#8212; The Adjournment Proposal &#8212; </b>to consider and vote upon a proposal to approve the adjournment of the extraordinary general meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient shares represented to constitute a quorum necessary to conduct business at the extraordinary general meeting or for the approval of one or more proposals at the extraordinary general meeting or to the extent necessary to ensure that any required supplement or amendment to the accompanying proxy statement/prospectus/information statement is provided to APAC shareholders (the &#8220;Adjournment Proposal&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of Proposals No.&#160;1 through 3 and 5 through 8 (the &#8220;Condition Precedent Proposals&#8221;) are cross-conditioned on the approval of the others. Proposal No.&#160;9 is not conditioned upon the approval of any other proposal set forth in this proxy statement/prospectus/information statement. Proposal No.&#160;4 is constituted of non-binding advisory proposals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These items of business are described in the accompanying proxy statement/prospectus/information statement, which we encourage you to read carefully and in its entirety before voting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Only holders of record of APAC ordinary shares at the close of business on <b style="font-weight:bold;">[</b>&#9679;<b style="font-weight:bold;">]</b>, 2022 are entitled to notice of and to vote and have their votes counted at the extraordinary general meeting and any adjournment of the extraordinary general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying proxy statement/prospectus/information statement and accompanying proxy card is being provided to APAC&#8217;s shareholders in connection with the solicitation of proxies to be voted at the extraordinary general meeting and at any adjournment of the extraordinary general meeting. <b style="font-weight:bold;">Whether or not you plan to attend the extraordinary general meeting, all of APAC&#8217;s shareholders are urged to read this proxy statement/prospectus/information statement, including the Annexes and the documents referred to herein, carefully and in their entirety. You should also carefully consider the risk factors described in &#8220;</b><span style="font-style:italic;font-weight:bold;">Risk Factors</span><b style="font-weight:bold;">&#8221; beginning on page&#160;</b><span style="font-weight:bold;">70</span><b style="font-weight:bold;"> of the accompanying proxy statement/prospectus/information statement.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">After careful consideration, the APAC Board has unanimously approved the Business Combination and unanimously recommends that shareholders vote &#8220;FOR&#8221; the adoption of the Business Combination Proposal and the Domestication Proposal and &#8220;FOR&#8221; all other proposals to be presented to APAC&#8217;s shareholders at the extraordinary general meeting. When you consider the recommendation of these proposals by the APAC Board, you should keep in mind that APAC&#8217;s directors and officers have interests therein that may conflict with your interests as a shareholder. See the section entitled &#8220;</b><span style="font-style:italic;font-weight:bold;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;</span><span style="font-style:italic;font-weight:bold;">&#8212;</span><span style="font-style:italic;font-weight:bold;"> Interests of APAC&#8217;s Directors and Executive Officers in the Business Combination</span><b style="font-weight:bold;">&#8221; in the accompanying proxy statement/prospectus/information statement for a further discussion of these considerations.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Cayman Constitutional Documents, a holder of public shares (as defined in the accompanying proxy statement/prospectus/information statement) (a &#8220;public shareholder&#8221;) may request of APAC that APAC redeem all or a portion of its public shares for cash if the Business Combination is consummated. As a holder of public shares, you will be entitled to receive cash for any public shares to be redeemed only if you:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)&#160;hold public shares, or (b)&#160;if you hold public shares through units, you elect to separate your units into the underlying public shares and public warrants prior to exercising your redemption rights with respect to the public shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submit a written request to Continental Stock Transfer&#160;&amp; Trust (&#8220;Continental&#8221;), APAC&#8217;s transfer agent, in which you (i)&#160;</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">request that New OmniAb redeem all or a portion of your New OmniAb Common Stock for cash, and (ii)&#160;identify yourself as the beneficial holder of the New OmniAb Common Stock and provide your legal name, phone number and address; and</span></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">deliver your public shares to Continental, APAC&#8217;s transfer agent, physically or electronically through The Depository Trust Company (&#8220;DTC&#8221;).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Holders must complete the procedures for electing to redeem their public shares in the manner described above prior to 5:00&#160;p.m., Eastern Time, on [</b>&#9679;<b style="font-weight:bold;">], 2022 (two business&#160;days before the extraordinary general meeting) in order for their shares to be redeemed.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Holders of units must elect to separate the units into the underlying public shares and warrants prior to exercising redemption rights with respect to the public shares. If holders hold their units in an account at a brokerage firm or bank, holders must notify their broker or bank that they elect to separate the units into the underlying public shares and warrants, or if a holder holds units registered in its own name, the holder must contact Continental, APAC&#8217;s transfer agent, directly and instruct them to do so. Public shareholders may elect to redeem public shares regardless of how they vote in respect of the Business Combination Proposal. If the Business Combination is not consummated, the public shares will be returned to the respective holder, broker or bank.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Business Combination is consummated, and if a public shareholder properly exercises its right to redeem all or a portion of the public shares that it holds and timely delivers its shares to Continental, APAC&#8217;s transfer agent, APAC will redeem such public shares for a per-share price, payable in cash, equal to the pro rata portion of the trust account established at the consummation of our initial public offering (the &#8220;trust account&#8221;), calculated as of two business&#160;days prior to the consummation of the Business Combination. For illustrative purposes, as of <b style="font-weight:bold;">[</b>&#9679;<b style="font-weight:bold;">]</b>, 2022, this would have amounted to approximately $[&#9679;]<b style="font-weight:bold;"> </b>per issued and outstanding public share. If a public shareholder exercises its redemption rights in full, then it will be electing to exchange its public shares for cash and will no longer own public shares. The redemption takes place following the Domestication and, accordingly, it is shares of New OmniAb Common Stock that will be redeemed promptly after consummation of the Business Combination. See &#8220;<i style="font-style:italic;">Extraordinary General Meeting of APAC</i> <i style="font-style:italic;">&#8212;</i> <i style="font-style:italic;">Redemption Rights</i>&#8221; in the accompanying proxy statement/prospectus/information statement for a detailed description of the procedures to be followed if you wish to redeem your public shares for cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, a public shareholder, together with any affiliate of such public shareholder or any other person with whom such public shareholder is acting in concert or as a &#8220;group&#8221; (as defined in Section&#160;13(d)(3)&#160;of the Exchange Act), will be restricted from redeeming its public shares with respect to more than an aggregate of 15% of the public shares. Accordingly, if a public shareholder, alone or acting in concert or as a group, seeks to redeem more than 15% of the public shares, then any such shares in excess of that 15% limit would not be redeemed for cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Avista Acquisition LP II, a Cayman Islands exempted limited partnership and shareholder of APAC (the &#8220;Sponsor&#8221;), and each director of APAC have agreed to, among other things, vote in favor of the Business Combination Proposal and the transactions contemplated thereby, including the other Condition Precedent Proposals, and to waive their redemption rights in connection with the underwriting agreement entered into in connection with the initial public offering. The APAC Class&#160;B Ordinary Shares held by the Sponsor and such other persons will be excluded from the pro rata calculation used to determine the per-share redemption price. As of the date of the accompanying proxy statement/prospectus/information statement, the Sponsor and APAC&#8217;s directors, collectively, own 20% of the issued and outstanding ordinary shares of APAC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The approval of the Business Combination Proposal, Domestication Proposal and the Organizational Documents Proposal each requires a special resolution under Cayman Islands law, being the affirmative vote of the holders of at least two-thirds majority of the APAC ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. With respect to the Domestication Proposal, a holder of APAC Class&#160;B Ordinary Shares shall have ten votes for every APAC Class&#160;B Ordinary Share of which he or she is the holder and a holder of APAC Class&#160;A Ordinary Shares shall have one vote for every APAC Class&#160;A Ordinary Share of which he or she is the holder. The Non-Binding Governance Proposals (which are comprised of non-binding advisory proposals), the Director Election Proposal, the Stock Issuance Proposal, the Incentive Plan Proposal, the ESPP Proposal and the Adjournment Proposal each requires an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. With respect to the Director Election Proposal, only the holders of the APAC Class&#160;B Ordinary Shares are entitled to vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Your vote is very important.</span><b style="font-weight:bold;"> Whether or not you plan to attend the extraordinary general meeting, please vote as soon as possible by following the instructions in the accompanying proxy statement/prospectus/information statement to make sure that your shares are represented at the extraordinary general meeting. If you hold your shares in &#8220;street name&#8221; through a </b></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">bank, broker or other nominee, you will need to follow the instructions provided to you by your bank, broker or other nominee to ensure that your shares are represented and voted at the extraordinary general meeting. In most cases you may vote by telephone or over the Internet as instructed. The transactions contemplated by the Merger Agreement will be consummated only if the Condition Precedent Proposals are approved at the extraordinary general meeting. Each of the Condition Precedent Proposals is cross-conditioned on the approval of the others. The Adjournment Proposal is not conditioned upon the approval of any other proposal set forth in the accompanying proxy statement/prospectus/information statement. The Non-Binding Governance Proposals are constituted of non-binding advisory proposals.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you sign, date and return your proxy card without indicating how you wish to vote, your proxy will be voted FOR each of the proposals presented at the extraordinary general meeting. If you fail to return your proxy card or fail to instruct your bank, broker or other nominee how to vote, and do not attend the extraordinary general meeting either virtually or in person, the effect will be, among other things, that your shares will not be counted for purposes of determining whether a quorum is present at the extraordinary general meeting and will not be voted. An abstention will be counted towards the quorum requirement but will not count as a vote cast at the extraordinary general meeting. A broker non-vote, while considered present for the purposes of establishing a quorum, will not count as a vote cast at the extraordinary general meeting. If you are a shareholder of record and you attend the extraordinary general meeting and wish to vote virtually or in person, you may withdraw your proxy and vote either virtually or in person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Your attention is directed to the remainder of the accompanying proxy statement/prospectus/information statement following this notice (including the Annexes and other documents referred to herein) for a more complete description of the proposed Business Combination and related transactions and each of the proposals. You are encouraged to read the accompanying proxy statement/prospectus/information statement carefully and in its entirety, including the Annexes and other documents referred to herein. If you have any questions or need assistance voting your ordinary shares, please contact D.F. King&#160;&amp; Co.,&#160;Inc., our proxy solicitor, by calling (888) 887-0082, or banks and brokers can call collect at (212) 269-5550 or by emailing AHPA@dfking.com.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Thank you for your participation. We look forward to your continued support.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">By Order of the Board of Directors of Avista Public Acquisition Corp. II,<b style="font-weight:bold;"> [</b>&#9679;<b style="font-weight:bold;">]</b>, 2022</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Thompson Dean</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chairman of the APAC Board</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">TO EXERCISE YOUR REDEMPTION RIGHTS, YOU MUST DEMAND IN WRITING THAT YOUR PUBLIC SHARES ARE REDEEMED FOR A PRO RATA PORTION OF THE FUNDS HELD IN THE TRUST ACCOUNT AND TENDER YOUR SHARES TO APAC&#8217;S TRANSFER AGENT AT LEAST TWO BUSINESS&#160;DAYS PRIOR TO THE VOTE AT THE EXTRAORDINARY GENERAL MEETING. YOU MAY&#160;TENDER YOUR SHARES BY EITHER DELIVERING YOUR SHARE CERTIFICATE TO THE TRANSFER AGENT OR BY DELIVERING YOUR SHARES ELECTRONICALLY USING THE DEPOSITORY TRUST COMPANY&#8217;S DWAC (DEPOSIT WITHDRAWAL AT CUSTODIAN) SYSTEM. IF THE BUSINESS COMBINATION IS NOT CONSUMMATED, THEN THESE SHARES WILL BE RETURNED TO YOU OR YOUR ACCOUNT. IF YOU HOLD THE SHARES IN STREET NAME, YOU WILL NEED TO INSTRUCT THE ACCOUNT EXECUTIVE AT YOUR BANK OR BROKER TO WITHDRAW THE SHARES FROM YOUR ACCOUNT IN ORDER TO EXERCISE YOUR REDEMPTION RIGHTS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b0ef0d74_35c4_41cd_aadf_84b46002ff3d"></a><a id="Main_REFERENCESTOADDITIONALINFORMATION"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REFERENCES TO ADDITIONAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">This proxy statement/prospectus/information statement incorporates important business and financial information that is not included in or delivered with this proxy statement/prospectus/information statement. This information is available for you to review through the SEC&#8217;s website at www.sec.gov.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">You may request copies of this proxy statement/prospectus/information statement and any of the documents incorporated by reference into this proxy statement/prospectus/information statement or other publicly available information concerning APAC, without charge, by written request to APAC at Avista Public Acquisition Corp. II, 65 East 55th Street, 18th Floor, New York, NY 10022, or by telephone request at (212)-593-6900; or D.F. King&#160;&amp; Co.,&#160;Inc., APAC&#8217;s proxy solicitor, by calling (888) 877-0082 or banks and brokers can call collect at (212) 269-5550, or by emailing AHPA@dfking.com; or from the SEC through the SEC website at the address provided above.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">In order for APAC&#8217;s shareholders to receive timely delivery of the documents in advance of the extraordinary general meeting of APAC to be held on [</b>&#9679;<b style="font-weight:bold;">], 2022, you must request the information no later than [</b>&#9679;<b style="font-weight:bold;">], 2022, five business&#160;days prior to the date of the extraordinary general meeting.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e2b17c4a_bd91_4968_ba75_41e5fe0fd6bf"></a><a id="Main_TRADEMARKS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">TRADEMARKS</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">This document contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this proxy statement/prospectus/information statement may appear without the </span><span style="font-size:7.5pt;">&#174;</span><span style="font-size:10pt;"> or </span><span style="font-size:7.5pt;">TM</span><span style="font-size:10pt;"> symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. APAC does not intend its use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of it by, any other companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_76a092ad_c438_4d20_af98_292105ab6353"></a><a id="Main_SELECTEDDEFINITIONS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">SELECTED DEFINITIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise stated in this proxy statement/prospectus/information statement or the context otherwise requires, references to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;A&amp;R FPA&#8221; are to that certain Amended and Restated Forward Purchase Agreement, dated March&#160;23, 2022, by and among APAC, the Sponsor and OmniAb, which is attached hereto as Annex D;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;A&amp;R Registration Rights Agreement&#8221; are to the Amended and Restated Registration and Stockholder Rights Agreement to be entered into at the Closing by and among Ligand, APAC, the Sponsor, the existing holders party to the Original Registration Rights Agreement and the new holders party thereto, the form of which is attached to this proxy statement/prospectus/information statement as Annex G;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Aggregate Merger Consideration&#8221; are to a number of shares of New OmniAb Common Stock equal to the quotient obtained by dividing (i)&#160;the sum of (a)&#160;$850,000,000, plus (b)&#160;the aggregate exercise price of the OmniAb Options that are issued and outstanding immediately prior to the Effective Time, by (ii)&#160;$10.00, provided, that if the &#8220;Aggregate Merger Consideration&#8221; as so calculated (together with the number of Included OmniAb Shares, calculated including shares underlying OmniAb Options, as applicable) would result in the product of (x)&#160;the Base Exchange Ratio, multiplied by (y)&#160;$10.00, being less than the exercise price of any of the OmniAb Options issued and outstanding as of immediately prior to the Effective Time, then the calculation described in this definition shall be repeated by excluding the exercise price of all of the OmniAb Options with the highest exercise price per share from the calculation of the aggregate exercise price described in clause (i)(b)&#160;of this definition and excluding any shares underlying such OmniAb Options from the calculation of Included OmniAb Shares, in each case, on an iterative basis until the resulting calculations of Aggregate Merger Consideration and Included OmniAb Shares cause the product of (I)&#160;the Base Exchange Ratio and (II)&#160;$10.00 to be equal to or in excess of the exercise price of all of the OmniAb Options included in such calculations, and the Aggregate Merger Consideration so calculated shall be the &#8220;Aggregate Merger Consideration&#8221;;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;APAC,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; are to Avista Public Acquisition Corp. II, a Cayman Islands exempted company prior to its domestication as a corporation in the State of Delaware, and, following its domestication, to New OmniAb or OmniAb,&#160;Inc.;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;APAC Board&#8221; are to the board of directors of APAC;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;APAC Class&#160;A Ordinary Shares&#8221; are to APAC&#8217;s Class&#160;A ordinary shares, par value $0.0001 per share;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;APAC Class&#160;B Ordinary Shares&#8221; are to APAC&#8217;s Class&#160;B ordinary shares, par value $0.0001 per share;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;APAC Private Placement Warrants&#8221; are to the 8,233,333 APAC Warrants that were issued to the Sponsor in a private placement in connection with APAC&#8217;s initial public offering and are issued and outstanding immediately prior to the Domestication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;APAC Public Warrants&#8221; are to the 7,666,667 APAC Warrants, a fraction equal to one-third of which was included in each unit sold as part of APAC&#8217;s initial public offering and are issued and outstanding immediately prior to the Domestication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;APAC Units&#8221; are to each issued and outstanding unit of APAC prior to the Domestication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;APAC Warrants&#8221; are to warrants to purchase one (1)&#160;APAC Class&#160;A Ordinary Share at an exercise price of $11.50;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Base Exchange Ratio&#8221; are to the quotient obtained by dividing (i)&#160;the number of shares constituting the Aggregate Merger Consideration by (ii)&#160;the number of Included OmniAb Shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Business Combination&#8221; are to the combination of APAC and OmniAb pursuant to the transactions provided for and contemplated in the Merger Agreement;</span></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Cayman Constitutional Documents&#8221; are to APAC&#8217;s Amended and Restated Memorandum and Articles of Association, as amended from time to time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Cayman Islands Companies Act&#8221; are to the Companies Act (As Revised) of the Cayman Islands;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Closing&#8221; are to the closing of the Business Combination;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Condition Precedent Approvals&#8221; are to the approval at the extraordinary general meeting of the Condition Precedent Proposals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Condition Precedent Proposals&#8221; are to the Business Combination Proposal, the Domestication Proposal, the Organizational Documents Proposal, the Stock Issuance Proposal, the Incentive Plan Proposal, the ESPP Proposal, and the Director Election Proposal, collectively;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Continental&#8221; are to Continental Stock Transfer&#160;&amp; Trust Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;DGCL&#8221; are to the General Corporation Law of the State of Delaware;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Domestication&#8221; are to the domestication of APAC as a corporation incorporated in the State of Delaware;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Earnout Exchange Ratio&#8221; are to the quotient obtained by dividing (i)&#160;15,000,000 by (ii)&#160;the number of Fully-Diluted OmniAb Shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Effective Time&#8221; are to the time at which the Merger shall become effective in accordance with the terms of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Employee Matters Agreement&#8221; are to that certain Employee Matters Agreement, dated March&#160;23, 2022, by and among APAC, Ligand, Merger Sub and OmniAb;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Exchange Act&#8221; are to the Securities Exchange Act of 1934, as amended;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;extraordinary general meeting&#8221; are to the extraordinary general meeting of APAC duly called by the APAC Board and held for the purpose of considering and voting upon the proposals set forth in this proxy statement/prospectus/information statement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Forward Purchase&#8221; are to the purchase of shares and warrants of New OmniAb Common Stock to be issued to the Sponsor in a private placement transaction following the Domestication and immediately prior to the Merger pursuant to the A&amp;R FPA, excluding the Redemption Backstop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;founder shares&#8221; are to the APAC Class&#160;B Ordinary Shares, and the shares of New OmniAb Common Stock to be issued to the Sponsor and certain related parties in respect thereof in connection with the Domestication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Fully-Diluted OmniAb Shares&#8221; are to (without duplication) the aggregate number of shares of OmniAb Common Stock that are (i)&#160;issued and outstanding immediately prior to the Effective Time or (ii)&#160;issuable upon, or subject to, the exercise or settlement of OmniAb Options (whether or not then vested or exercisable), OmniAb RSUs and OmniAb PSUs, in each case, that are issued and outstanding immediately prior to the Effective Time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;GAAP&#8221; are to accounting principles generally accepted in the United States of America;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;HSR Act&#8221; are to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Included OmniAb Shares&#8221; are to (without duplication) the aggregate number of shares of OmniAb Common Stock that are (i)&#160;issued and outstanding immediately prior to the Effective Time or (ii)&#160;issuable upon, or subject to, the exercise or </span></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">settlement (as applicable) of OmniAb Options (whether or not then vested or exercisable, but excluding any OmniAb Options excluded from the definition of &#8220;Aggregate Common Consideration Shares&#8221; set forth in the Merger Agreement pursuant to the proviso thereto), OmniAb RSUs and OmniAb PSUs, in each case, that are issued and outstanding immediately prior to the Effective Time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;initial public offering&#8221; are to APAC&#8217;s initial public offering, which was consummated on August&#160;12, 2021;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Investment Company Act&#8221; are to the Investment Company Act of 1940, as amended;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;IPO registration statement&#8221; are to the Registration Statement on Form&#160;S-1 (333-257177) filed by APAC in connection with its initial public offering, which became effective on August&#160;9, 2021;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;IRS&#8221; are to the U.S. Internal Revenue Service;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;JOBS Act&#8221; are to the Jumpstart Our Business Startups Act of 2012;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Ligand&#8221; are to Ligand Pharmaceuticals Incorporated, a Delaware corporation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Ligand Board&#8221; are to the board of directors of Ligand;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Ligand Common Stock&#8221; are to shares of common stock of Ligand, par value $0.001 per share;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Ligand Contribution&#8221; are to the cash contribution of $15,000,000, less certain transaction and other expenses, by Ligand to OmniAb prior to the Distribution pursuant to the Separation Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Ligand Convertible Notes&#8221; are to Ligand&#8217;s 0.75% Convertible Senior Notes&#160;due 2023;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Ligand Record Date&#8221; are to the date to be determined by the Ligand Board as the record date for determining stockholders of Ligand entitled to receive shares of OmniAb Common Stock in the Distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Merger&#8221; are to the merger of Merger Sub with and into OmniAb, with OmniAb surviving the merger as a wholly-owned subsidiary of APAC in accordance with the terms and subject to the conditions set forth in the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Merger Agreement&#8221; are to that certain Agreement and Plan of Merger, dated as of March&#160;23, 2022, by and among APAC, Ligand, Merger Sub and OmniAb, a copy of which is attached to this proxy statement/prospectus/information statement as Annex A;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Merger Sub&#8221; are to Orwell Merger Sub&#160;Inc., a Delaware corporation and a wholly-owned subsidiary of APAC;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Nasdaq&#8221; are to the Nasdaq Capital Market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;New OmniAb&#8221; are to APAC, following the Domestication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;New OmniAb Board&#8221; are to the board of directors of New OmniAb;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;New OmniAb Common Stock&#8221; are to shares of common stock of New OmniAb, par value $0.0001 per share;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;New OmniAb Equity Award&#8221; are to equity awards into which OmniAb Equity Awards are converted upon the Closing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;New OmniAb Options&#8221; are to options to purchase shares of New OmniAb Common Stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;New OmniAb PSUs&#8221; are to performance-vesting restricted stock units relating to shares of New OmniAb Common Stock;</span></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;New OmniAb RSUs&#8221; are to restricted stock units relating to shares of New OmniAb Common Stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;New OmniAb Warrants&#8221; are to warrants to purchase one share of New OmniAb Common Stock at an exercise price of $11.50, including those issued as a matter of law upon conversion of the APAC Warrants at the time of the Domestication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;OmniAb&#8221; are to OmniAb,&#160;Inc., a Delaware corporation and, prior to the Distribution, a wholly-owned subsidiary of Ligand, and after the Distribution, include the ownership of the OmniAb Business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;OmniAb Business&#8221; are to Ligand&#8217;s antibody discovery business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;OmniAb Common Stock&#8221; are to shares of common stock of OmniAb, par value $0.001 per share, outstanding prior to the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;OmniAb Earnout Shares&#8221; are to the earnout consideration in the form of 15,000,000 shares of New OmniAb Common Stock that the holders of OmniAb Common Stock and OmniAb Equity Awards will receive at the Closing, all of which will be automatically forfeited for no consideration if an applicable OmniAb Triggering Event has not occurred with respect to such OmniAb Earnout Shares during the period from the date of the Closing to and including the fifth anniversary of the date of the Closing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;OmniAb Equity Awards&#8221; are to, collectively, the OmniAb Options, OmniAb RSUs and OmniAb PSUs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;OmniAb Options&#8221; are to options to purchase shares of OmniAb Common Stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;OmniAb PSUs&#8221; are to performance-vesting restricted stock units relating to shares of OmniAb Common Stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;OmniAb RSUs&#8221; are to restricted stock units relating to shares of OmniAb Common Stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;OmniAb Triggering Event&#8221; are to (a)&#160;with respect to 50% of the OmniAb Earnout Shares, the date on which the VWAP equals or exceeds $12.50 on any 20 trading&#160;days in any 30 consecutive trading-day period, and (b)&#160;with respect any OmniAb Earnout Shares for which an OmniAb Triggering Event has not occurred with respect to clause (a), the date on which the VWAP equals or exceeds $15.00 on any 20 trading&#160;days in any 30 consecutive trading-day period; provided, that in the event of a Change of Control (as defined in the Merger Agreement) between the date of the Closing to and including the fifth anniversary of the date of the Closing pursuant to which New OmniAb or any of its stockholders have the right to receive, directly or indirectly, cash, securities or other property attributing a value of at least $12.50 (with respect to 50% of the OmniAb Earnout Shares) or $15.00 (with respect to all OmniAb Earnout Shares) per share of New OmniAb Common Stock, and such Change of Control has been approved by a majority of the independent directors of the New OmniAb Board, then an OmniAb Triggering Event shall be deemed to have occurred immediately prior to such Change of Control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;ordinary shares&#8221; are to the APAC Class&#160;A Ordinary Shares and the APAC Class&#160;B Ordinary Shares, collectively;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Person&#8221; are to any individual, firm, corporation, partnership, limited liability company, incorporated or unincorporated association, joint venture, joint stock company, governmental authority or instrumentality or other entity of any kind;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;pro forma&#8221; are to giving pro forma effect to the Business Combination;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Proposed Bylaws&#8221; are to the proposed bylaws of New OmniAb upon the effective date of the Domestication attached to this proxy statement/prospectus/information statement as Annex I;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Proposed Certificate of Incorporation&#8221; are to the proposed certificate of incorporation of New OmniAb upon the effective date of the Domestication attached to this proxy statement/prospectus/information statement as Annex H;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Proposed Organizational Documents&#8221; are to the Proposed Certificate of Incorporation and the Proposed Bylaws;</span></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;public shareholders&#8221; are to holders of public shares, whether acquired in APAC&#8217;s initial public offering or acquired in the secondary market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;public shares&#8221; are to the APAC Class&#160;A Ordinary Shares (including those included in the units) that were offered and sold by APAC in its initial public offering and registered pursuant to the IPO registration statement or the shares of New OmniAb Common Stock issued as a matter of law upon the conversion thereof at the time of the Domestication, as the context requires;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;redemption&#8221; are to each redemption of public shares for cash pursuant to the Cayman Constitutional Documents and the Proposed Organizational Documents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Redemption Backstop&#8221; are to the purchase of shares and warrants of New OmniAb Common Stock, if any, to be issued to the Sponsor in a private placement transaction following the Domestication and immediately prior to the Merger pursuant to the A&amp;R FPA to the extent necessary to backstop redemptions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Registration Rights Agreement&#8221; are to the Amended and Restated Registration and Stockholders Rights Agreement to be entered into at the Closing, by and among APAC, the Sponsor, the directors of APAC, and certain directors and officers of OmniAb and Ligand;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Sarbanes Oxley Act&#8221; are to the Sarbanes-Oxley Act of 2002;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;SEC&#8221; are to the United States Securities and Exchange Commission;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Securities Act&#8221; are to the Securities Act of 1933, as amended;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Sponsor&#8221; are to Avista Acquisition LP II, a Cayman Islands exempted limited partnership;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Sponsor Insider Agreement&#8221; are to that certain Sponsor Insider Letter Agreement, dated as of March&#160;23, 2022, by and between APAC, the Sponsor, OmniAb and certain insiders of APAC, a copy of which is attached to this proxy statement/prospectus/information statement as Annex C;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Sponsor Earnout Shares&#8221; are to the founder shares beneficially owned by Sponsor on March&#160;23, 2022, in an aggregate number equal to (i)&#160;1,916,667 minus (ii)&#160;(A)&#160;718,750 multiplied by (B)&#160;a number the numerator of which is the number of shares of New OmniAb Common Stock actually purchased pursuant to the Redemption Backstop in connection with the Closing and the denominator of which is 10,000,000, all or fifty&#160;percent of which shares will be automatically forfeited for no consideration if an applicable Sponsor Triggering Event has not occurred with respect to such Sponsor Earnout Shares during the period from the date of the Closing to and including the fifth anniversary of the date of the Closing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Sponsor Triggering Event&#8221; are to, (a)&#160;with respect to 50% of the Sponsor Earnout Shares, the date on which the VWAP equals or exceeds $12.50 on any 20 trading&#160;days in any 30 consecutive trading-day period, and (b)&#160;with respect any Sponsor Earnout Shares for which a Sponsor Triggering Event has not occurred with respect to clause (a), the date on which the VWAP equals or exceeds $15.00 on any 20 trading&#160;days in any 30 consecutive trading-day period; provided, that in the event of a Change of Control (as defined in the Merger Agreement) between the date of the Closing to and including the fifth anniversary of the date of the Closing pursuant to which New OmniAb or any of its stockholders have the right to receive, directly or indirectly, cash, securities or other property attributing a value of at least $12.50 (with respect to 50% of the Sponsor Earnout Shares) or $15.00 (with respect to all Sponsor Earnout Shares) per share of New OmniAb Common Stock, as agreed in good faith by the Sponsor and the New OmniAb Board, then a Sponsor Triggering Event shall be deemed to have occurred immediately prior to such Change of Control (as defined in the Merger Agreement);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Tax Matters Agreement&#8221; are to the Tax Matters Agreement to be entered into at the Closing by and among APAC, Ligand and OmniAb, the form of which is attached proxy statement/prospectus/information statement as Annex E;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Transaction Documents&#8221; are to the Separation Agreement, the Employee Matters Agreement, the Tax Matters Agreement, the Transition Services Agreements, the A&amp;R FPA, the Sponsor Insider Agreement and the A&amp;R Registration Rights </span></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Agreement, in each case, including all annexes, exhibits, schedules, attachments and appendices thereto, and any certificate or other instrument delivered by any party to any other party pursuant to the Merger Agreement or any of the foregoing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Transition Services Agreements&#8221; are to each of the Transition Services Agreements to be entered into at the Closing by and between Ligand and OmniAb, the forms of which are attached hereto as Annex F-1 and Annex F-2;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;trust account&#8221; are to the trust account established at the consummation of APAC&#8217;s initial public offering and maintained by Continental, acting as trustee;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Treasury Shares&#8221; are to the shares of OmniAb Common Stock held in OmniAb&#8217;s treasury, which will be cancelled for no consideration in connection with the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Trust Agreement&#8221; are to the Investment Management Trust Agreement, dated August&#160;9, 2021, by and between APAC and Continental, as trustee;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Trust Amount&#8221; are to the amount of cash available in the trust account as of the Closing, after deducting the amount required to satisfy APAC&#8217;s obligations to its shareholders (if any) that exercise their redemption rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;VWAP&#8221; are to the volume-weighted average price; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;working capital loans&#8221; are to the funds that the Sponsor or an affiliate of the Sponsor, or certain of APAC&#8217;s officers and directors may loan to APAC as may be required.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise stated in this proxy statement/prospectus/information statement or the context otherwise requires, all references in this proxy statement/prospectus/information statement to APAC Class&#160;A Ordinary Shares, public shares, APAC Public Warrants or APAC Warrants include any such securities underlying the APAC Units, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c7892b4d_2cdb_4a33_9307_9fc69e336cdd"></a><a id="Main_CAUTIONARYSTATEMENTREGARDINGFORW"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This proxy statement/prospectus/information statement contains forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;would&#8221; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. All statements other than statements of historical facts contained in this proxy statement/prospectus/information statement, including statements regarding the expected timing and structure of the Separation, Distribution and Merger, the ability of the parties to complete the Business Combination, the expected benefits of the Business Combination, the tax consequences of the Separation, Distribution and Merger, the amount of gross proceeds expected to be available to OmniAb after the Closing and giving effect to any redemptions by APAC shareholders, OmniAb&#8217;s future results of operations and financial position, business strategy and its expectations regarding the application of, and the rate and degree of market acceptance of, the OmniAb technology platform and other technologies, OmniAb&#8217;s expectations regarding the addressable markets for our technologies, including the growth rate of the markets in which it operates, the potential for and timing of receipt of milestones and royalties under OmniAb&#8217;s license agreements with partners, are forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of Ligand, OmniAb and APAC, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The forward-looking statements contained in this proxy statement/prospectus/information statement and in any document incorporated by reference in this proxy statement/prospectus/information statement are based on current expectations and beliefs concerning future developments and their potential effects on APAC, Ligand or OmniAb. There can be no assurance that future developments affecting APAC, Ligand or OmniAb will be those that APAC, Ligand or OmniAb have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond APAC&#8217;s control or the control of OmniAb or Ligand) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; beginning on page&#160;70 of this proxy statement/prospectus/information statement and the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that the Business Combination may not be completed in a timely manner or at all, which may adversely affect the price of Ligand&#8217;s or APAC&#8217;s securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that APAC shareholder approval of the Condition Precedent Proposals is not obtained;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, the amount of funds available to New OmniAb following any redemptions by APAC&#8217;s shareholders, after giving effect to the Forward Purchase and the Redemption Backstop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the failure to receive certain governmental and regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in general economic conditions, geopolitical risk, including as a result of the COVID-19 pandemic or the conflict between Russia and Ukraine;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcome of litigation related to or arising out of the Business Combination, or any adverse developments therein or delays or costs resulting therefrom;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effect of the announcement or pendency of the transactions on Ligand&#8217;s, OmniAb&#8217;s or APAC&#8217;s business relationships, operating results, and businesses generally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to continue to meet Nasdaq&#8217;s listing standards following the consummation of the Business Combination;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs related to the Business Combination;</span></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that the price of APAC&#8217;s or Ligand&#8217;s securities may be volatile due to a variety of factors, including Ligand&#8217;s, APAC&#8217;s or OmniAb&#8217;s inability to implement their business plans or meet or exceed their financial projections and changes in the combined capital structure; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">factors relating to the business, operations and financial performance of OmniAb and its subsidiaries, including:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as a result of the Separation, OmniAb will lose Ligand&#8217;s brand, reputation, capital base and other resources, and may experience difficulty operating as a standalone company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the anticipated benefits of the Separation may not be achieved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb&#8217;s historical combined financial data and pro forma financial statements are not necessarily representative of the results OmniAb would have achieved as a standalone company and may not be a reliable indicator of its future results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb&#8217;s operating results and financial performance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance by new and existing partners in OmniAb&#8217;s market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb&#8217;s future success is dependent on the eventual approval and commercialization of products developed by its partners for which we have no control over the clinical development plan, regulatory strategy or commercialization efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb&#8217;s ability to manage and grow its business and execution of its business and growth strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks arising from changes in technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the competitive environment in the life sciences and biotechnology platform market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to maintain, protect and defend our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in government laws and regulations, including laws governing intellectual property, and the enforcement thereof affecting our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties with performance of third parties we will rely on for our business growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties developing and sustaining relationships with commercial counterparties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb may not be able to engage in certain transactions and equity issuances following the Distribution; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb may have certain indemnification obligations to Ligand under the Tax Matters Agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Should one or more of these risks or uncertainties materialize, or should any of APAC&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. None of APAC, Ligand or OmniAb undertakes any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before any APAC shareholder grants its proxy or instructs how its vote should be cast or votes on the proposals to be put to the extraordinary general meeting, such shareholder should be aware that the occurrence of the events described in the &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; section and elsewhere in this proxy statement/prospectus/information statement may adversely affect APAC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_aa4736cf_30f8_4937_8309_0a02d5be1118"></a><a id="Main_QUESTIONSANDANSWERS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">QUESTIONS AND ANSWERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The questions and answers below highlight only selected information from this document and only briefly address some commonly asked questions about the proposals to be presented at the extraordinary general meeting, including with respect to the proposed Business Combination. The following questions and answers do not include all the information that is important to APAC&#8217;s shareholders. APAC urges shareholders to read this proxy statement/prospectus/information statement, including the Annexes and the other documents referred to herein, carefully and in their entirety to fully understand the proposed Business Combination and the voting procedures for the extraordinary general meeting.</i></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">How do I attend the meeting virtually?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">The extraordinary general meeting will be accessible virtually via a live webcast at [&#9679;].com, at [&#9679;], Eastern Time, on [&#9679;], 2022. To participate in the virtual meeting, including the voting of shares, APAC shareholders of record will need (a)&#160;the 16-digit control number included on their proxy card or instructions that accompanied their proxy materials, if applicable, or (b)&#160;to obtain a proxy form from their broker, bank or other nominee.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">The extraordinary general meeting webcast will begin promptly at [&#9679;], Eastern Time. APAC shareholders are encouraged to access the extraordinary general meeting prior to the start time. If you encounter any difficulties accessing the virtual meeting or during the meeting time, please call the technical support number that will be posted on the virtual meeting login page.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Can I attend the extraordinary general meeting in person?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Yes. APAC shareholders will be able to attend the extraordinary general meeting in person, which will be held on [&#9679;], 2022, at [&#9679;], Eastern Time, at the offices of Weil, Gotshal&#160;&amp; Manges LLP, located at 767 Fifth Avenue, New York, NY 10153. However, given the ongoing global pandemic, APAC encourages its shareholders to attend via live webcast on the Internet.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Why am I receiving this proxy statement/prospectus/information statement?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">You are receiving these materials because you are a shareholder of record or a beneficial holder of APAC on [&#9679;], the record date (the &#8220;APAC Record Date&#8221;) for the extraordinary general meeting. APAC and Ligand have agreed to combine Ligand&#8217;s OmniAb Business with APAC in a series of transactions subject to the terms and conditions of the Separation Agreement, the Merger Agreement and the other Transaction Documents. Copies of the Separation Agreement and the Merger Agreement are attached as Annexes B and A, respectively. APAC shareholders are being asked to consider and vote upon a proposal to approve the Business Combination and a number of other proposals. See the section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal</i>&#8221; for more detail.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE VOTE OF SHAREHOLDERS IS IMPORTANT. SHAREHOLDERS ARE ENCOURAGED TO VOTE AS SOON AS POSSIBLE AFTER CAREFULLY REVIEWING THIS PROXY STATEMENT/PROSPECTUS/INFORMATION STATEMENT IN ITS ENTIRETY, INCLUDING THE ANNEXES AND THE ACCOMPANYING FINANCIAL STATEMENTS OF APAC AND OMNIAB.</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What are the transactions described in this document?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">On March&#160;23, 2022, APAC, Ligand, OmniAb and Merger Sub entered into the Merger Agreement, and, on the same day, APAC, Ligand and OmniAb entered into the Separation Agreement. These agreements provide for Ligand to combine the OmniAb Business with APAC in a transaction commonly referred to as a &#8220;Reverse Morris Trust&#8221; transaction. The principal transactions to effect the Business Combination include the following:</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Domestication</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. APAC&#8217;s jurisdiction of incorporation will be changed by its deregistering as an exempted company in the Cayman Islands and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware at least one (1)&#160;business day prior to the consummation of the Merger. In connection with the consummation of the Domestication, APAC will change its name to &#8220;OmniAb,&#160;Inc.&#8221; As a result of and upon the effective time of the Domestication, (1)&#160;each then issued and outstanding APAC Class&#160;A Ordinary Share, will convert automatically, on a one-for-one basis, into a share of New OmniAb Common Stock, (2)&#160;each then issued and outstanding APAC Class&#160;B Ordinary Share will convert automatically, on a one-for-one basis, into a share of New OmniAb Common Stock, (3)&#160;each then issued and </span></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding APAC Warrant will convert automatically into a New OmniAb Warrant pursuant to the Warrant Agreement, and (4)&#160;each then issued and outstanding APAC Unit, will separate and convert automatically into one share of New OmniAb Common Stock and one-third of one New OmniAb Warrant.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Separation</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Ligand will transfer the OmniAb Business, including certain related subsidiaries of Ligand, to OmniAb and make a contribution to the capital of OmniAb of $15,000,000 less certain transaction and other expenses.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Distribution</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Following the Separation and on the day of the Merger described below, Ligand will distribute to Ligand stockholders 100% of the OmniAb Common Stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">A&amp;R Forward Purchase Agreement</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. New OmniAb will issue and sell to the Sponsor 1,500,000 shares of New OmniAb Common Stock and warrants to acquire 1,666,667 shares of New OmniAb Common Stock for an aggregate purchase price of $15,000,000, with such purchases to be consummated following the Domestication and prior to the Merger.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Redemption Backstop</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. The Sponsor has agreed to purchase up to an additional 10,000,000 shares of New OmniAb Common Stock and up to an additional 1,666,667 New OmniAb Warrants, for an aggregate additional purchase price of up to $100,000,000, in order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds to be available to the combined company following the Business Combination from APAC&#8217;s trust account to be less than $100,000,000.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Merger</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Following the above steps, Merger Sub will merge with and into OmniAb, with OmniAb continuing as the surviving company in the Merger and a wholly-owned subsidiary of New OmniAb. As a result of the Merger, the existing shares of OmniAb common stock will automatically convert into the right to receive shares of New OmniAb Common Stock.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">New OmniAb, which will be the parent entity of OmniAb after the Merger, will be renamed to &#8220;OmniAb,&#160;Inc.,&#8221; effective as of the consummation of the Domestication (and after OmniAb has changed its name to &#8220;OmniAb Operations,&#160;Inc.&#8221;). New OmniAb Common Stock will be listed on Nasdaq under the trading symbol &#8220;OABI.&#8221;</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What is a Reverse Morris Trust transaction?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A Reverse Morris Trust transaction allows a parent company (in this case, Ligand) to distribute all of the stock of a subsidiary (in this case, OmniAb) and combine it with an acquirer (in this case, APAC). The first step of such a transaction is a distribution of the subsidiary&#8217;s stock to the parent company stockholders (in this case, Ligand&#8217;s distribution of the stock of OmniAb to the Ligand stockholders in the Distribution) in a transaction that is generally tax-free under Section&#160;355 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). The distributed subsidiary then combines with a third party (in this case, APAC through the Merger) in a reorganization that is generally tax-free under Section&#160;368 of the Code. Such a transaction can qualify as generally tax-free for U.S. federal income tax purposes for the parent company and its stockholders if the transaction structure meets all applicable requirements, including that the parent company stockholders own more than 50% of the stock of the combined entity immediately after the combination.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">For information about the material U.S. federal income tax consequences of the Distribution and the Merger that are relevant to Ligand stockholders, see &#8220;<i style="font-style:italic;">Material U.S. Federal Income Tax Consequences to Ligand Stockholders of the Distribution and Merger.</i>&#8221;</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What will happen in the Separation?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Ligand and certain of Ligand&#8217;s subsidiaries will engage in a series of transactions so that Ligand&#8217;s OmniAb Business is held by OmniAb and its subsidiaries and is separated from the remainder of Ligand&#8217;s businesses. See &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;&#8212; Summary of the Separation Agreement.</i>&#8221;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What will happen in the Distribution?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">After the Separation, Ligand will distribute to its stockholders all of the issued and outstanding shares of OmniAb Common Stock held by Ligand by way of a pro rata distribution.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Ligand will effect the Distribution by way of a spin-off. In a spin-off, the Ligand Board will establish a record date and a distribution date. Each share of Ligand Common Stock outstanding as of the Ligand Record Date for the Distribution will entitle its holder to receive one share of OmniAb Common Stock. Based on approximately [&#9679;] shares of Ligand Common Stock outstanding as of [&#9679;], 2022 and applying the Distribution ratio of 1:1, OmniAb expects that a total of approximately [&#9679;] shares of OmniAb Common Stock will be distributed to Ligand stockholders and no shares of OmniAb Common Stock will continue to be owned by Ligand. The Distribution will be effected by Ligand delivering to the distribution agent a book-entry authorization representing the shares of OmniAb Common Stock being distributed in the Distribution for the account of Ligand&#8217;s stockholders. The distribution agent will hold such book-entry shares for the account of OmniAb&#8217;s stockholders (as of immediately after consummation of the Distribution) pending the Merger. The shares of OmniAb Common Stock will not be transferrable prior to the exchange of such shares for the shares of New OmniAb Common Stock pursuant to the Merger. See &#8220;<i style="font-style:italic;">The Separation and Distribution</i>.&#8221;</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What will happen in the Merger?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Immediately following the Distribution, OmniAb and Merger Sub will engage in a reverse triangular merger, in which Merger Sub will merge with and into OmniAb, with OmniAb surviving as a direct, wholly-owned subsidiary of APAC. In the Merger, each share of OmniAb Common Stock will be automatically converted into the right to receive shares of New OmniAb Common Stock.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Will the Distribution and the Merger occur on the same day?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Yes, the Merger will occur on the same day and immediately following the Distribution.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Who will serve on the New OmniAb Board following the Closing?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">The Merger Agreement provides that, as of the Closing, the New OmniAb Board will consist of seven (7)&#160;members:</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">John L. Higgins;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Sarah Boyce;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jennifer Cochran, Ph.D;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Sunil Patel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Carolyn Bertozzi, Ph.D;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Matthew W. Foehr; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">[</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">].</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">See &#8220;<i style="font-style:italic;">Management of New OmniAb after the Business Combination</i>.&#8221;</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Who will manage New OmniAb after the Closing?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">The Merger Agreement provides that, as of the Closing:</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Matthew W. Foehr, the current Chief Operating Officer of Ligand, will become President and Chief Executive Officer of New OmniAb;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Kurt Gustafson will become Executive Vice President, Finance and Chief Financial Officer of New OmniAb; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Charles S. Berkman, the current Senior Vice President, General Counsel and Secretary of Ligand, will become Chief Legal Officer and Secretary of New OmniAb.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Is the completion of the Merger subject to any conditions?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Yes. The respective obligations of each party to effect the Closing of the Business Combination are subject to the fulfillment (or, to the extent permitted by applicable law, waiver) of certain conditions specified in the Merger Agreement. See &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination&#8212;Summary of the Merger Agreement&#160;&#8212; Conditions to Closing</i>.&#8221;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Has Ligand set the Ligand Record Date for the Distribution?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">No.&#160;Ligand will publicly announce the Ligand Record Date for the Distribution when it has been determined. This announcement will be made prior to the completion of the Separation, the Distribution and the Merger.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What do Ligand stockholders need to do to participate in the Distribution?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Ligand stockholders as of the Ligand Record Date are not required to take any action to receive OmniAb Common Stock in the Distribution, but they are urged to read this entire proxy statement/prospectus/information statement carefully. No Ligand stockholder approval of the Distribution is required, and Ligand stockholders are not being asked for a proxy. Ligand stockholders also do not need to pay any consideration, exchange or surrender their existing shares of Ligand Common Stock or take any other action to receive the shares of OmniAb Common Stock to which they are entitled. The Distribution will not affect the number of outstanding shares of Ligand Common Stock or any rights of Ligand stockholders, although it will affect the market value of each outstanding share of Ligand Common Stock.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What are holders of the Ligand Convertible Notes&#160;entitled to in the Distribution?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Holders of the Ligand Convertible Notes&#160;are not entitled to participate in the Distribution solely by virtue of their holding these notes. Such holders will participate only if they have exercised their conversion rights under their notes and received Ligand Common Stock prior to the Ligand Record Date for the Distribution. If holders of the Ligand Convertible Notes&#160;have exercised their conversion rights and received Ligand Common Stock prior to the Ligand Record Date for the Distribution, they will be entitled to participate in the Distribution in the same manner as any other holder of Ligand Common Stock. For a more detailed description, see &#8220;<i style="font-style:italic;">The Separation and Distribution</i>.&#8221;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">How will shares of New OmniAb Common Stock be issued?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Ligand stockholders will receive shares of New OmniAb Common Stock through the same or substantially similar channels that they currently use to hold or trade Ligand Common Stock (whether through a brokerage account, 401(k)&#160;plan or other channel). Receipt of shares of New OmniAb Common Stock will be documented for Ligand stockholders in substantially the same manner that stockholders typically receive stockholder updates, such as&#160;monthly broker statements and 401(k)&#160;statements.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">The Distribution of OmniAb Common Stock will be effected by Ligand delivering to the distribution agent, Computershare Trust Company, N.A. (&#8220;Computershare&#8221;), a book-entry authorization representing the shares of OmniAb Common Stock being distributed in the Distribution for the account of Ligand&#8217;s stockholders. The distribution agent will hold such book-entry shares for the account of OmniAb&#8217;s stockholders (as of immediately after consummation of the Distribution) pending the Merger. The shares of OmniAb Common Stock will not be transferrable prior to the exchange of such shares for the shares of New OmniAb Common Stock pursuant to the Merger. See &#8220;The Separation and Distribution.&#8221; Immediately thereafter, as a result of and upon </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">the Closing of the Merger, each outstanding share of OmniAb Common Stock (other than Treasury Shares) will be cancelled in exchange for the right to receive a number of shares of New OmniAb Common Stock equal to the Base Exchange Ratio, and a number of OmniAb Earnout Shares equal to the Earnout Exchange Ratio. Computershare, as exchange agent, will electronically distribute shares of New OmniAb Common Stock and OmniAb Earnout Shares to holders of Ligand Common Stock on the Ligand Record Date or to the stockholders brokerage firm on the stockholders&#8217; behalf by way of direct registration in book-entry form. Computershare will mail the stockholders a book-entry account statement that reflects their shares of New OmniAb Common Stock and OmniAb Earnout Shres, or the stockholders&#8217; bank or brokerage firm will credit their account for such shares. OmniAb Earnout Shares may not be transferred until the applicable OmniAb Triggering Event has occurred. See &#8220;Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;&#8212; Summary of the Merger Agreement&#160;&#8212; Merger Consideration.&#8221;</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What will happen to the</b><b style="font-weight:bold;"> listing of Ligand Common Stock?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">After the Distribution, Ligand Common Stock will continue to trade on Nasdaq under the symbol &#8220;LGND.&#8221; Holders of Ligand Common Stock will retain all their shares of Ligand Common Stock.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Will the Distribution affect the market price of shares of Ligand Common Stock?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Yes. As a result of the Distribution, Ligand expects the trading price of shares of Ligand Common Stock immediately following the Distribution to be lower than the &#8220;regular-way&#8221; trading price of such shares immediately prior to the Distribution because the trading price will no longer reflect the value of the antibody discovery business. There can be no assurance that the aggregate market value of the Ligand Common Stock plus the pro rata portion of Aggregate Merger Consideration a Ligand stockholder is entitled to in the Merger, including the aggregate market value of New OmniAb Common Stock following the Distribution and Merger, will be higher or lower than the market value of Ligand Common Stock if the Distribution and Merger did not occur.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Will Ligand shareholders who sell their ordinary shares of Ligand shortly before the completion of the Distribution and Merger still be entitled to receive shares of OmniAb Common Stock with respect to the ordinary shares of Ligand that were sold?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Ligand Common Stock is currently listed on Nasdaq under the ticker symbol &#8220;LGND.&#8221; It is currently expected that beginning not earlier than one business day before the Ligand Record Date to be established for the Distribution, and continuing through the Closing, there will be two markets in Ligand Common Stock on Nasdaq: a &#8220;regular way&#8221; market and an &#8220;ex-distribution&#8221; market.</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If a Ligand shareholder sells Ligand Common Stock in the &#8220;regular way&#8221; market under the symbol &#8220;LGND&#8221; during this time period, that Ligand shareholder will be selling both his or her ordinary shares of Ligand and the right to receive shares of OmniAb Common Stock that will be converted into shares of New OmniAb Common Stock, and cash in lieu of fractional shares (if any), at the Closing. Ligand shareholders should consult their brokers before selling their ordinary shares of Ligand in the &#8220;regular way&#8221; market during this time period to be sure they understand the effect of the Nasdaq &#8220;due-bill&#8221; procedures.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If a Ligand shareholder sells Ligand Common Stock in the &#8220;ex-distribution&#8221; market during this time period, that Ligand shareholder will be selling only his or her Ligand Common Stock, and will retain the right to receive shares of OmniAb Common Stock that will be converted into shares of New OmniAb Common Stock, and cash in lieu of fractional shares (if any), at the Closing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">After the Closing, Ligand Common Stock will no longer trade in the &#8220;ex-distribution&#8221; market, and Ligand Common Stock that is sold in the &#8220;regular way&#8221; market will no longer reflect the right to receive shares of OmniAb Common Stock that will be converted into shares of New OmniAb Common Stock, and cash in lieu of fractional shares (if any), at the Closing. The receipt of cash in lieu of fractional shares generally will be taxable to the recipient stockholders for U.S. federal income tax purposes as described in &#8220;<i style="font-style:italic;">Material U.S. Federal Income Tax Consequences to Ligand Stockholders of the Distribution and Merger.</i>&#8221;</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What are the material U.S. federal income tax consequences to Ligand stockholders resulting from the Distribution and the Merger?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Ligand stockholders are not expected to recognize any gain or loss as a result of the Distribution and the Merger, except for any gain or loss attributable to the receipt of cash in lieu of a fractional shares of stock pursuant to the Distribution or Merger. The material U.S. federal income tax consequences of the Distribution and the Merger that are relevant to Ligand stockholders are described in more detail under &#8220;<i style="font-style:italic;">Material U.S. Federal Income Tax Consequences to Ligand Stockholders of the Distribution and Merger.</i>&#8221; Ligand shareholders should consult their own tax advisors for a full understanding of the tax consequences to them of the Distribution and the Merger.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What are the material U.S. federal income tax consequences to APAC shareholders resulting from the Distribution and the Merger?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">APAC shareholders are not expected to recognize any gain or loss as a result of the Distribution or the Merger. APAC shareholders should consult their own tax advisors for a full understanding of the tax consequences to them of the Distribution and the Merger. The material U.S. federal income tax consequences to APAC shareholders are described under &#8220;<i style="font-style:italic;">Material U.S. Federal Income Tax Consequences to APAC Shareholders.</i>&#8221;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Does Ligand have to pay anything to APAC if the Merger Agreement is terminated?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">In the event that the Merger Agreement is terminated by Ligand in connection with its entering into a definitive agreement in respect of a Ligand Acquisition Proposal, concurrently with such termination, Ligand shall be obligated to pay APAC a termination fee of (i)&#160;if terminated within 60&#160;days of the date of the Merger Agreement, $40,000,000, (ii)&#160;if terminated between 61 and 120&#160;days after the date of the Merger Agreement, $50,000,000, and (iii)&#160;if terminated between 121 and 180&#160;days after the date of the Merger Agreement, $70,000,000 (each such amount, the &#8220;Termination Fee&#8221;), by wire transfer of immediately available funds to an account designated by APAC in writing, and, in addition to payment of the Termination Fee, Ligand also shall pay the APAC Expenses (the &#8220;APAC Expenses Reimbursement&#8221;) by wire transfer of immediately available funds to an account designated by APAC in writing no later than two business&#160;days after the date on which APAC delivers to Ligand a written invoice for the APAC Expenses. As used in this subsection, &#8220;APAC Expenses&#8221; means the amount of all reasonable and documented out-of-pocket fees and expenses, but not to exceed $7,500,000, incurred or paid by APAC and its affiliates in connection with the Merger Agreement and the Business Combination, including fees and expenses of law firms, accounting firms, financial advisors, outside experts and consultants. For a discussion of the circumstances under which Ligand may have to pay a termination fee, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;&#8212; Summary of the Merger Agreement&#160;&#8212; Termination Fees and Expenses Payable in Certain Circumstances</i>.&#8221; The A&amp;R FPA also provides that in the event the Merger Agreement is terminated by Ligand under circumstances in which the Termination Fee would be payable under the Merger Agreement, Ligand shall pay the Sponsor a termination fee of $12,500,000 in connection therewith. The A&amp;R FPA is attached to this proxy statement/prospectus/information statement as Annex D.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What proposals are shareholders of APAC being asked to vote upon?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">At the extraordinary general meeting, APAC is asking holders of ordinary shares to consider and vote upon:</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a proposal to approve by special resolution and adopt (i)&#160;the Merger Agreement, (ii)&#160;the Transaction Documents and (iii)&#160;each of the transactions contemplated thereby, in each case, in accordance with the terms and subject to the conditions set forth in the Merger Agreement and such Transaction Documents, as more fully described elsewhere in this proxy statement/prospectus/information statement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a proposal to adopt and approve by special resolution the Domestication and change in the jurisdiction of incorporation of APAC from the Cayman Islands to the State of Delaware;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a proposal to approve by special resolution and adopt the Proposed Certificate of Incorporation and the Proposed Bylaws of APAC in connection with the Domestication, and the change of its name from APAC to OmniAb,&#160;Inc.;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proposals to approve, on a non-binding advisory basis, certain material differences between APAC&#8217;s Amended and Restated Memorandum and Articles of Association and the Proposed Certificate of Incorporation and Proposed Bylaws;</span></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a proposal to approve by ordinary resolution the election of seven directors to serve staggered terms, who, upon consummation of the Merger, will be the directors of New OmniAb;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a proposal to approve by ordinary resolution the OmniAb,&#160;Inc. 2022 Incentive Award Plan as described by the Employee Matters Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a proposal to approve by ordinary resolution the OmniAb,&#160;Inc. 2022 Employee Stock Purchase Plan as described by the Employee Matters Agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a proposal to approve the adjournment of the extraordinary general meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes present to constitute a quorum or for the approval of one or more proposals at the extraordinary general meeting.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If APAC&#8217;s shareholders do not approve each of the Condition Precedent Proposals, then unless certain conditions in the Merger Agreement are waived by the applicable parties to the Merger Agreement, the Merger Agreement could terminate and the Business Combination may not be consummated. See &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal</i>,&#8221; &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;2&#160;&#8212; The Domestication Proposal</i>,&#8221; &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;3&#160;&#8212; The Organizational Documents Proposal</i>,&#8221; &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;4&#160;&#8212; The Non-Binding Governance Proposals</i>,&#8221; &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;5&#160;&#8212; The Stock Issuance Proposal</i>,&#8221; &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;6&#160;&#8212; The Incentive Plan Proposal</i>,&#8221; &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;7&#160;&#8212; The ESPP Proposal</i>,&#8221; &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;8&#160;&#8212; The Director Election Proposal</i>&#8221; and &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;9&#160;&#8212; The Adjournment Proposal</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC will hold the extraordinary general meeting to consider and vote upon these proposals. This proxy statement/prospectus/information statement contains important information about the Business Combination and the other matters to be acted upon at the extraordinary general meeting. Shareholders of APAC should read it carefully.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">After careful consideration, the APAC Board has determined that the Business Combination Proposal, the Domestication Proposal, the Organizational Documents Proposal, the Non-Binding Governance Proposals, the Director Election Proposal, the Stock Issuance Proposal, the Incentive Plan Proposal, the ESPP Proposal and the Adjournment Proposal are in the best interests of APAC and its shareholders and unanimously recommends that you vote or give instruction to vote &#8220;FOR&#8221; each of those proposals.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The existence of financial and personal interests of one or more of APAC&#8217;s directors may result in a conflict of interest on the part of such director(s)&#160;between what he, she or they may believe is in the best interests of APAC and its shareholders and what he, she or they may believe is best for himself, herself or themselves in determining to recommend that shareholders vote for the proposals. In addition, APAC&#8217;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#8212;Interests of APAC&#8217;s Directors and Executive Officers in the Business Combination</i>&#8221; for a further discussion of these considerations.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Are the proposals conditioned on one another?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Yes. Each of the Condition Precedent Proposals is cross-conditioned on the approval of the others. The Adjournment Proposal is not conditioned upon the approval of any other proposal set forth in this proxy statement/prospectus/information statement. The Non-Binding Governance Proposals are comprised of non-binding advisory proposals.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Why is APAC proposing the Business Combination?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">APAC was incorporated to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination, with one or more businesses or entities.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Based on our due diligence investigations of OmniAb, the management of OmniAb and the industry in which it operates, including the financial and other information provided by OmniAb in the course of these due diligence investigations, the APAC Board believes that the Business Combination with OmniAb is in the best interests of APAC and its shareholders and presents an opportunity to increase shareholder value. However, there is no assurance of this. See &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#8212;The APAC Board&#8217;s Reasons for the Business Combination</i>&#8221; for additional information.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Although the APAC Board believes that the Business Combination with OmniAb presents an attractive business combination opportunity and is in the best interests of APAC and its shareholders, the APAC Board did consider certain potentially material negative factors in arriving at that conclusion. These factors are discussed in greater detail in the section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#8212;The APAC Boards&#8217; Reasons for the Business Combination</i>,&#8221; as well as in the sections entitled &#8220;<i style="font-style:italic;">Risk Factors</i>.&#8221;</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What will OmniAb stockholders receive in return for APAC&#8217;s acquisition of all of the issued and outstanding equity interests of OmniAb?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><span style="font-style:italic;font-weight:bold;">Common Stock.&#160;&#160;&#160;&#160;&#160;</span>As a result of and upon the Closing, among other things, each outstanding share of OmniAb Common Stock (other than Treasury Shares), will be cancelled upon the Effective Time in exchange for the right to receive a number of shares of New OmniAb Common Stock equal to the Base Exchange Ratio. For further details, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;&#8212; </i><i style="font-style:italic;">Summary of the Merger Agreement&#160;&#8212; Merger Consideration</i>.&#8221;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Earnout Shares.&#160;&#160;&#160;&#160;&#160;</span>In addition, as a result of and upon the Closing, among other things, each outstanding share of OmniAb Common Stock (other than Treasury Shares), will be cancelled upon the Effective Time in exchange for the right to receive a number of OmniAb Earnout Shares equal to the Earnout Exchange Ratio. Holders of OmniAb Common Stock and equity awards will receive earnout consideration in the form of an additional 15,000,000 OmniAb Earnout Shares, all of which will be automatically forfeited for no consideration if an applicable OmniAb Triggering Event has not occurred with respect to such OmniAb Earnout Shares during the period from the date of the Closing to and including the fifth anniversary of the date of the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">The total number of shares of New OmniAb Common Stock to be received by OmniAb&#8217;s stockholders or reserved for issuance pursuant to the New OmniAb Equity Awards into which OmniAb Equity Awards are to be converted will be equal to the Aggregate Merger Consideration. In addition to the Aggregate Merger Consideration, holders of OmniAb Common Stock and equity awards will also receive earnout consideration in the form of the OmniAb Earnout Shares. For further details, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;&#8212; </i><i style="font-style:italic;">Summary of the Merger Agreement&#160;&#8212; Merger Consideration</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Equity Awards</span>.<span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</span>In addition, all (i)&#160;OmniAb Options, (ii)&#160;OmniAb RSUs and (iii)&#160;OmniAb PSUs, in each case, that are outstanding as of immediately prior to the Effective Time, will be converted into such number of (a)&#160;New OmniAb Options, (b)&#160;New OmniAb RSUs and (c)&#160;New OmniAb PSUs, respectively, in each case, equal to (1)&#160;the number of shares of OmniAb Common Stock underlying such OmniAb Equity Awards immediately prior to the Effective Time multiplied by (2)&#160;the Base Exchange Ratio. Each holder of an OmniAb Option, OmniAb RSU and/or OmniAb PSU will also receive a number of OmniAb Earnout Shares equal to the number of shares of OmniAb Common Stock underlying such OmniAb Options, OmniAb RSUs and/or OmniAb PSUs, as applicable, multiplied by the Earnout Exchange Ratio, and the exercise price of each outstanding New OmniAb Option will be equal to the exercise price of the pre-conversion OmniAb Option divided by the Base Exchange Ratio. For further details, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The </i><i style="font-style:italic;">Business Combination Proposal&#160;&#8212; Consideration, Treatment of OmniAb Options, OmniAb RSUs and OmniAb PSUs.</i>&#8221;</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What equity stake will current APAC shareholders and OmniAb stockholders (after the Distribution) hold in New OmniAb immediately after the consummation of the Business Combination?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">As of the date of this proxy statement/prospectus/information statement, there are 28,750,000 ordinary shares of APAC issued and outstanding, which include the 5,750,000 founder shares held by the Sponsor (including APAC&#8217;s directors) and the 23,000,000 public shares. As of the date of this proxy statement/prospectus/information statement, there are outstanding an aggregate of 15,900,000 APAC Warrants, which include the 8,233,333 APAC Private Placement Warrants held by the Sponsor and the 7,666,667 APAC Public Warrants. Each whole warrant entitles the holder thereof to purchase one APAC Class&#160;A Ordinary Share and, following the Domestication, will entitle the holder thereof to purchase one share of New OmniAb Common Stock. Therefore, as of the date of this proxy statement/prospectus/information statement (without giving effect to the Business Combination), the APAC fully diluted share capital is 44,650,000. It is anticipated that, following the Business Combination, (1)&#160;APAC&#8217;s public shareholders are expected to own approximately 18.0% of the outstanding shares of New OmniAb Common Stock, (2)&#160;OmniAb stockholders (without taking into account any public shares held by OmniAb stockholders prior to the consummation of the Business Combination) are expected to own approximately 76.3% of the outstanding shares of New OmniAb Common Stock and (3)&#160;the Sponsor and related parties are expected to collectively own approximately 5.7% of the outstanding shares of New OmniAb Common Stock. These&#160;percentages (i)&#160;assume (a)&#160;that no public shareholders exercise their redemption rights in connection with the Business Combination, (b)&#160;that New OmniAb issues 97,431,885 shares of New OmniAb Common Stock to former stockholders of OmniAb as of immediately prior to the Effective Time and (c)&#160;that New OmniAb issues 1,500,000 shares of New OmniAb Common Stock to the Sponsor pursuant to the Forward Purchase, (ii)&#160;exclude all New OmniAb Options that may be exercisable for shares of New OmniAb Common Stock, New OmniAb RSUs and New OmniAb PSUs, (iii)&#160;include the OmniAb Earnout Shares and (iv)&#160;exclude the impact of any New OmniAb Warrants that will be outstanding following the Business Combination (we refer to this set of assumptions as the &#8220;no redemption scenario&#8221;). If the actual facts are different from the no redemption scenario, the&#160;percentage ownership of New OmniAb held by such constituencies will be different.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">The following table illustrates varying ownership levels in New OmniAb immediately following the consummation of the Business Combination based on the no redemption scenario and, alternatively (i)&#160;based on the assumption that 11,500,000 APAC Class&#160;A Ordinary Shares are redeemed in connection with the Business Combination at approximately $10.25 per share (we refer to this set of assumptions as the &#8220;50% redemption scenario&#8221;) and (ii)&#160;based on the assumption that 23,000,000 APAC Class&#160;A Ordinary Shares are redeemed in connection with the Business Combination at approximately $10.25 per share, and the Sponsor funds $100,000,000 pursuant to the Redemption Backstop provided for in the A&amp;R FPA (we refer to this set of assumptions as the &#8220;maximum redemption scenario&#8221;). Please see &#8220;<i style="font-style:italic;">Risk Factors&#160;&#8212; Risks Related to Redemption</i>&#8221; for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:28.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:28.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:67.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share&#160;Ownership&#160;in&#160;New&#160;OmniAb</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.22%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">No&#160;Redemption&#160;Scenario</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.21%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">50%&#160;Redemption&#160;Scenario</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:1.85%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maximum&#160;Redemption&#160;Scenario</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Outstanding</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Outstanding</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.88%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Outstanding</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">APAC&#8217;s public shareholders</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">23,000,000</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.57%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">18.0</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">11,500,000</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">9.9</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.81%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:28.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sponsor and related parties<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)(4)(6)</sup></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7,250,000</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5.7</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7,250,000</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">6.2</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">17,250,000</p></td><td style="vertical-align:bottom;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">15.0</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:28.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">OmniAb (Ligand) stockholders<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)(6)</sup></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">97,431,885</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">76.3</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">97,431,885</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">83.9</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">97,431,885</p></td><td style="vertical-align:bottom;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">85.0</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:28.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.88%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)(8)</sup></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">127,681,885</b></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.57%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">100.0</b></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">%</b></p></td><td style="vertical-align:bottom;width:9.79%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">116,181,885</b></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.56%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">100.0</b></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">%</b></p></td><td style="vertical-align:bottom;width:9.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">114,681,885</b></p></td><td style="vertical-align:bottom;width:1.88%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.81%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">100.0</b></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Assumes redemptions of 11,500,000 APAC Class&#160;A Ordinary Shares in connection with the Business Combination.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Assumes redemptions of 23,000,000 APAC Class&#160;A Ordinary Shares in connection with the Business Combination.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes 5,750,000 Class&#160;B Ordinary Shares that will be converted in New OmniAb Common Stock. The Sponsor Earnout Shares were included in the pro forma capitalization as, during the Earnout Period, holders of the Sponsor Earnout Shares are entitled to vote such Sponsor Earnout Shares and receive dividends and other distribution in respect thereof, pursuant to the Sponsor Insider Agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to the A&amp;R FPA, includes 1,500,000 shares of New OmniAb Common Stock purchased by the Sponsor in the Forward Purchase in the no redemption and maximum redemption scenarios and 10,000,000 New OmniAb Common Stock purchased by the Sponsor in the Redemption Backstop in the maximum redemption scenario.</span></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes 15,000,000 OmniAb Earnout Shares as, during the Earnout Period, OmniAb Earnout Shares are entitled to exercise the voting rights carried by such Earnout Shares and receive any dividends or other distributions in respect of such OmniAb Earnout Shares.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The table below sets forth the share ownership in New OmniAb assuming that the Sponsor Earnout Shares and the OmniAb Earnout Shares are forfeited according to their terms:</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:28.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:67.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share&#160;Ownership&#160;in&#160;New&#160;OmniAb</b></p></td><td style="vertical-align:bottom;width:1.55%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.43%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">No&#160;Redemption&#160;Scenario</b></p></td><td style="vertical-align:bottom;width:1.73%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">50%&#160;Redemption&#160;Scenario</b></p></td><td style="vertical-align:bottom;width:1.76%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maximum&#160;Redemption&#160;Scenario</b></p></td><td style="vertical-align:bottom;width:1.55%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.78%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Outstanding</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.73%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.76%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Outstanding</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.85%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Outstanding</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.55%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">APAC&#8217;s public shareholders</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">23,000,000</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.78%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">20.8</p></td><td style="vertical-align:bottom;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">11,500,000</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.76%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">11.6</p></td><td style="vertical-align:bottom;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.85%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Sponsor and related parties</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,333,333</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">4.8</p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,333,333</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5.4</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">16,052,083</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">16.3</p></td><td style="vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">OmniAb (Ligand) stockholders</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">82,431,885</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">74.4</p></td><td style="vertical-align:bottom;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">82,431,885</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">83.0</p></td><td style="vertical-align:bottom;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">82,431,885</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">83.7</p></td><td style="vertical-align:bottom;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.73%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.55%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">110,765,218</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">100.0</p></td><td style="vertical-align:bottom;width:1.73%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.88%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">99,265,218</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.76%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">100.0</p></td><td style="vertical-align:bottom;width:1.76%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.85%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">98,483,968</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">100.0</p></td><td style="vertical-align:bottom;width:1.55%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The table excludes the following:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">10,636,952  unexercised OmniAb stock options;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">793,628 OmniAb RSUs and OmniAb PSUs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7,666,667 unexercised APAC Public Warrants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8,233,333 unexercised APAC Private Placement Warrants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,666,667 unexercised APAC Warrants issued in the Forward Purchase; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,666,667 unexercised APAC Warrants issued in the Backstop Redemption in the maximum redemption scenario.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(8)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If all of the Sponsor&#8217;s APAC Warrants are exercised, which include the 8,233,333 APAC Private Placement Warrants, the 1,666,667 APAC Warrants issued in the Forward Purchase and the 1,666,667 APAC Warrants issued in the Backstop Redemption in the maximum redemption scenario, Sponsor would own: (1)&#160;approximately 12.5% of the shares of New OmniAb in the no redemption scenario, (2)&#160;approximately 13.6% of the shares of New OmniAb in the 50% redemption scenario or (3)&#160;approximately 22.8% of the shares of New OmniAb in the maximum redemption scenario.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For further details, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal</i> <i style="font-style:italic;">&#8212; The Merger Agreement</i> <i style="font-style:italic;">&#8212; Consideration</i>.&#8221;</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">How has the announcement of the Business Combination affected the trading price of the APAC Class&#160;A Ordinary Shares?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">On March&#160;22, 2022, the last trading date before the public announcement of the execution of the Merger Agreement, the reported closing price on Nasdaq of the APAC Units, APAC Class&#160;A Ordinary Shares and APAC Public Warrants was $10.14, $10.01 and $0.30, respectively. On [&#9679;], 2022, the most recent practicable date prior to the date of this proxy statement/prospectus/information statement, the reported closing price on Nasdaq of the APAC Units, APAC Class&#160;A Ordinary Shares and APAC Public Warrants was $[&#9679;], $[&#9679;] and $[&#9679;], respectively.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Will APAC and OmniAb obtain new financing in connection with the Business Combination?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;">Yes. The Sponsor has agreed to purchase in the aggregate 1,500,000 shares of New OmniAb Common Stock and warrants to acquire 1,666,667 shares of New OmniAb Common Stock for $15,000,000 of gross proceeds, or $10.00 per share of New </p></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">OmniAb Common Stock, in the Forward Purchase. Ligand has agreed to contribute $15,000,000 (less certain transaction and other expenses) to OmniAb prior to the Distribution pursuant to the Separation Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">In addition, the Sponsor has agreed to purchase in the aggregate up to 10,000,000 shares of New OmniAb Common Stock, for up to $100,000,000, or $10.00 per share of New OmniAb Common Stock, in the Redemption Backstop as well as up to an additional 1,666,667 New OmniAb Warrants. The number of shares to be purchased in the Redemption Backstop, if any, will be in an amount sufficient to backstop redemptions by public shareholders in the event shareholder redemptions would result in less than $100,000,000 of cash proceeds being available to the combined company following the Business Combination from APAC&#8217;s trust account. The Forward Purchase is contingent upon, among other things, the Closing. See &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;&#8212; </i><i style="font-style:italic;">Summary of the Ancillary Agreements&#160;&#8212;</i><i style="font-style:italic;"> Amended and Restated Forward Purchase Agreement</i>.&#8221;</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Why is APAC proposing the Domestication?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">The APAC Board believes that there are significant advantages to us that will arise as a result of a change of APAC&#8217;s domicile to Delaware. Further, the APAC Board believes that any direct benefit that the DGCL provides to a corporation also indirectly benefits its stockholders, who are the owners of the corporation. The APAC Board believes that there are several reasons why a reincorporation in Delaware is in the best interests of APAC and its shareholders, including, (i)&#160;the prominence, predictability and flexibility of the DGCL, (ii)&#160;Delaware&#8217;s well-established principles of corporate governance and (iii)&#160;the increased ability for Delaware corporations to attract and retain qualified directors. Each of the foregoing are discussed in greater detail in the section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;2&#160;&#8212; The Domestication Proposal&#8212;Reasons for the Domestication</i>.&#8221; To effect the Domestication, APAC will file the documents required pursuant to the Cayman Islands Companies Act with the Cayman Islands Registrar of Companies, and file a certificate of incorporation and a certificate of corporate domestication with the Secretary of State of the State of Delaware.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Will the Domestication and the Merger occur on the same day?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">No.&#160;The Domestication will occur on or prior to the business day immediately prior to the Merger.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What changes will be made to the current constitutional documents of APAC?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">APAC&#8217;s shareholders are being asked to consider and vote upon a proposal to approve the replacement of APAC&#8217;s Cayman Constitutional Documents under the Cayman Islands Companies Act with the Proposed Organizational Documents under the DGCL, which will be materially modified from the Cayman Constitutional Documents in the following respects:</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">change the purpose of New OmniAb to engage in &#8220;any lawful act or activity for which a corporation may be organized under the DGCL;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that the affirmative vote of the holders of at least 66 2/3% of the voting power of all then-outstanding shares of New OmniAb Common Stock entitled to vote generally in the election of directors, voting together as a single class, is required to adopt, amend or repeal the Proposed Bylaws and the provisions in the Proposed Certificate of Incorporation related to Directors, Indemnification and Limitation on Liability of Directors, Forum Selection and Amendments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">change the name of APAC to &#8220;OmniAb,&#160;Inc.,&#8221; delete the provisions relating to APAC&#8217;s status as a blank check company and retain the default of perpetual existence under the DGCL;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">change the authorized shares of all classes of capital stock to 1,100,000,000 shares, consisting of 1,000,000,000 shares of New OmniAb Common Stock and 100,000,000 shares of preferred stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adopt Delaware as the exclusive forum for certain stockholder litigation that could be brought in the future against New OmniAb and its directors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">classify the OmniAb board of directors into three (3)&#160;classes, with only one class of directors being elected in each&#160;year and each class serving a three (3)-year term.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;3&#160;&#8212; The Organizational Documents Proposal</i>&#8221; for additional information.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">How will the Domestication affect my APAC ordinary shares, warrants and units?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">As a result of and upon the effective time of the Domestication, (1)&#160;each then issued and outstanding APAC Class&#160;A Ordinary Share will convert automatically, on a one-for-one basis, into a share of New OmniAb Common Stock, (2)&#160;each then issued and outstanding APAC Class&#160;B Ordinary Share will convert automatically, on a one-for-one basis, into a share of New OmniAb Common Stock; (3)&#160;each then issued and outstanding APAC warrant will convert automatically into a New OmniAb Warrant, pursuant to the Warrant Agreement and (4)&#160;each then issued and outstanding unit of APAC that has not been previously separated into the underlying APAC Class&#160;A Ordinary Share and underlying fractional APAC Warrant upon the request of the holder thereof, will be separated and will entitle the holder thereof to one share of New OmniAb Common Stock and one-third of one New OmniAb Warrant. See &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;2&#160;&#8212; The </i><i style="font-style:italic;">Domestication Proposal</i>&#8221; for additional information.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What are the material U.S. federal income tax consequences of the Domestication?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">As discussed more fully under &#8220;<i style="font-style:italic;">Material U.S. Federal Income Tax Consequences to APAC Shareholders</i>,&#8221; the Domestication will qualify as a reorganization within the meaning of Section&#160;368(a)(1)(F)&#160;of the Code. U.S. Holders (as defined in &#8220;<i style="font-style:italic;">Material U.S. Federal Income Tax Consequences to APAC Shareholders</i>&#8221;) of APAC Public Securities on the date of the Domestication may be subject to Section&#160;367(b)&#160;of the Code, which applies to the domestication of a foreign corporation in a reorganization, and imposes U.S. federal income tax on certain U.S. persons in connection with transactions that would generally otherwise be tax-deferred. As a result:</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A U.S. Holder who beneficially owns (actually or constructively) APAC Class&#160;A Ordinary Shares with a fair market value totaling $50,000 or more but who, on the date of the Domestication, owns (actually or constructively) less than 10% of the total combined voting power of all classes of APAC shares entitled to vote and less than 10% of the total value of all classes of APAC shares generally should recognize gain (but not loss) on the exchange of APAC Class&#160;A Ordinary Shares for New OmniAb Common Stock pursuant to the Domestication. As an alternative to recognizing gain, such U.S. Holder may file an election to include in income as a deemed dividend the all &#8220;earnings and profits amount&#8221; (as defined in the Treasury Regulations under Section&#160;367 of the Code) attributable to such U.S. Holder&#8217;s APAC Class&#160;A Ordinary Shares, provided certain other requirements are satisfied; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A U.S. Holder who beneficially owns (actually or constructively) APAC Class&#160;A Ordinary Shares with a fair market value totaling less than $50,000 on the date of the Domestication generally should not be required to recognize any gain or loss or include any part of APAC&#8217;s all &#8220;earnings and profits amount&#8221; in income.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">APAC does not expect to have significant cumulative earnings and profits, if any, on the date of the Domestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If APAC were to be treated as a &#8220;passive foreign investment company&#8221; (&#8220;PFIC&#8221;) for U.S. federal income tax purposes, certain U.S. Holders may be subject to adverse tax consequences as a result of the Domestication. As discussed more fully below under the caption &#8220;<i style="font-style:italic;">Material U.S. Federal Income Tax </i><i style="font-style:italic;">Consequences</i><i style="font-style:italic;"> to APAC Shareholders&#8212; Passive Foreign Investment Company Rules,</i>&#8221; because APAC is a blank check company with no current active business, it is possible the IRS could assert that APAC is a PFIC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If finalized in their proposed form, proposed Treasury Regulations may require taxable gain recognition by a U.S. Holder with respect to its exchange of APAC Class&#160;A Ordinary Shares for New OmniAb Common Stock pursuant to the Domestication if APAC were classified as a PFIC at any time during such U.S. Holder&#8217;s holding period for such APAC Class&#160;A Ordinary Shares. The tax on any such recognized gain would be imposed based on a complex set of computational rules. Such rules&#160;are discussed more fully below under &#8220;<i style="font-style:italic;">Material U.S. Federal Income Tax Consequences </i><i style="font-style:italic;">to APAC Shareholders</i>.&#8221; However, a U.S. Holder may be able to avoid the PFIC gain and certain other tax consequences associated with PFIC status with respect to its APAC Class&#160;A Ordinary Shares if such U.S. Holder either (i)&#160;is eligible to and makes a timely and valid QEF Election (as defined and described below under &#8220;<i style="font-style:italic;">Material U.S. Federal Income Tax Consequences </i><i style="font-style:italic;">to APAC Shareholders</i>&#8221;) in the first taxable&#160;year in which such U.S. Holder held (or was deemed to hold) APAC Class&#160;A Ordinary Shares and in which APAC was classified as a PFIC or (ii)&#160;makes a Mark-to-Market Election (as described below under &#8220;<i style="font-style:italic;">Material U.S. Federal Income Tax Consequences </i><i style="font-style:italic;">to APAC Shareholders</i>&#8221;) with respect to such U.S. Holder&#8217;s APAC Class&#160;A Ordinary Shares.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, the Domestication is not expected to result in material U.S. federal income tax consequences to Non-U.S. Holders (as defined in &#8220;<i style="font-style:italic;">Material </i><i style="font-style:italic;">U.S. Federal Income Tax Consequences</i><i style="font-style:italic;"> to APAC Shareholders</i>&#8221;) of APAC Public Securities. However, Non-U.S. Holders may become subject to U.S. federal income withholding taxes on any amounts treated as dividends paid (or deemed paid) in respect of such Non-U.S. Holder&#8217;s New OmniAb Common Stock after the Domestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The rules&#160;governing the U.S. tax treatment of the Domestication are complex and will depend on a Holder&#8217;s particular circumstances. All Holders are urged to consult their tax advisor regarding the tax consequences to them of the Domestication, including without limitation the applicability and effect of U.S. federal, state, local and non-U.S. tax laws. For a more complete discussion of the U.S. federal income tax consequences of the Domestication, see &#8220;<i style="font-style:italic;">Material </i><i style="font-style:italic;">U.S. Federal Income Tax Consequences</i><i style="font-style:italic;"> to APAC Shareholders</i>.&#8221;</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Do I have redemption rights?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">If you are a holder of public shares, you have the right to request that we redeem all or a portion of your public shares for cash provided that you follow the procedures and deadlines described elsewhere in this proxy statement/prospectus/information statement. <b style="font-weight:bold;">Public shareholders may elect to redeem all or a portion of the public shares held by them regardless of how they vote in respect of the Business Combination Proposal</b>. If you wish to exercise your redemption rights, please see the answer to the question: &#8220;<i style="font-style:italic;">How do I exercise my redemption rights?</i>&#8221;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Notwithstanding the foregoing, a public shareholder, together with any affiliate of such public shareholder or any other person with whom such public shareholder is acting in concert or as a &#8220;group&#8221; (as defined in Section&#160;13(d)(3)&#160;of the Exchange Act), will be restricted from redeeming its public shares with respect to more than an aggregate of 15% of the public shares. Accordingly, if a public shareholder, alone or acting in concert or as a group, seeks to redeem more than 15% of the public shares, then any such shares in excess of that 15% limit would not be redeemed for cash. The Sponsor has agreed to waive its redemption rights with respect to all of the founder shares in connection with the consummation of the Business Combination. The founder shares will be excluded from the pro rata calculation used to determine the per-share redemption price.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Will how I vote affect my ability to exercise redemption rights?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">No.&#160;You may exercise your redemption rights whether you vote your APAC Class&#160;A Ordinary Shares for or against or abstain from voting on the Business Combination Proposal or any other proposal to be voted upon at the extraordinary general meeting. As a result, the Business Combination can be approved by shareholders who will redeem their shares and no longer remain shareholders.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">How do I exercise my redemption rights?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">If you are a public shareholder and wish to exercise your right to redeem your public shares, you must:</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)&#160;hold public shares, or (b)&#160;if you hold public shares through units, you must elect to separate your units into the underlying public shares and public warrants prior to exercising your redemption rights with respect to the public shares;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">submit a written request to Continental Stock Transfer&#160;&amp; Trust (&#8220;Continental&#8221;), APAC&#8217;s transfer agent, in which you (i)&#160;<span style="color:#231f20;">request that New OmniAb redeem all or a portion of your New OmniAb Common Stock for cash, and (ii)&#160;identify yourself as the beneficial holder of the New OmniAb Common Stock and provide your legal name, phone number and address; and</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">deliver your public shares to Continental, APAC&#8217;s transfer agent, physically or electronically through The Depository Trust Company (&#8220;DTC&#8221;).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders must complete the procedures for electing to redeem their public shares in the manner described above prior to 5:00&#160;p.m., Eastern Time, on [&#9679;], 2022 (two business&#160;days before the extraordinary general meeting) in order for their shares to be redeemed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The address of Continental, APAC&#8217;s transfer agent, is listed under the question &#8220;<i style="font-style:italic;">Who can help answer my questions?</i>&#8221; below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Holders of units must elect to separate the units into the underlying public shares and public warrants prior to exercising redemption rights with respect to the public shares. If holders hold their units in an account at a brokerage firm or bank, holders must </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">notify their broker or bank that they elect to separate the units into the underlying public shares and public warrants, or if a holder holds units registered in its own name, the holder must contact Continental, APAC&#8217;s transfer agent, directly and instruct them to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Public shareholders will be entitled to request that their public shares be redeemed for a pro rata portion of the amount then on deposit in the trust account calculated as of two business&#160;days prior to the consummation of the Business Combination, including interest earned on the funds held in the trust account and not previously released to us (net of taxes payable). For illustrative purposes, as of [&#9679;], 2022, this would have amounted to approximately $[&#9679;] per issued and outstanding public share. However, the proceeds deposited in the trust account could become subject to the claims of APAC&#8217;s creditors, if any, which could have priority over the claims of the public shareholders, regardless of whether such public shareholder votes or, if they do vote, irrespective of if they vote for or against the Business Combination Proposal. Therefore, the per share distribution from the trust account in such a situation may be less than originally expected due to such claims. Whether you vote, and if you do vote, irrespective of how you vote on any proposal, including the Business Combination Proposal, will have no impact on the amount you will receive upon exercise of your redemption rights. It is expected that the funds to be distributed to public shareholders electing to redeem their public shares will be distributed promptly after the consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An APAC shareholder may not withdraw a redemption request once submitted to APAC unless the APAC Board determines (in its sole discretion) to permit the withdrawal of such redemption request (which the APAC Board may do in whole or in part). If you submit a redemption request to Continental, APAC&#8217;s transfer agent, and later decide prior to the extraordinary general meeting not to elect redemption, you may request to withdraw the redemption request. You may make such request by contacting Continental, APAC&#8217;s transfer agent, at the phone number or address listed in see &#8220;<i style="font-style:italic;">Questions and answers</i> &#8211; <i style="font-style:italic;">Q: Who can help answer my questions?</i>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any corrected or changed written exercise of redemption rights must be received by Continental, APAC&#8217;s transfer agent, prior to the vote taken on the Business Combination Proposal at the extraordinary general meeting. <b style="font-weight:bold;">No request for redemption will be honored unless the holder&#8217;s public shares have been delivered (either physically or electronically) to Continental, APAC&#8217;s agent, at least two business&#160;days prior to the vote at the extraordinary general meeting</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a holder of public shares properly makes a request for redemption and the public shares are delivered as described above, then, if the Business Combination is consummated, New OmniAb will redeem the public shares for a pro rata portion of funds deposited in the trust account, calculated as of two business&#160;days prior to the consummation of the Business Combination. The redemption will take place following the Domestication and, accordingly, it is shares of New OmniAb Common Stock that will be redeemed immediately after consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you are a holder of public shares and you exercise your redemption rights, such exercise will not result in the loss of any warrants that you may hold.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">If I am a holder of units, can I exercise redemption rights with respect to my units?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">No.&#160;Holders of issued and outstanding units must elect to separate the units into the underlying public shares and public warrants prior to exercising redemption rights with respect to the public shares. If you hold your units in an account at a brokerage firm or bank, you must notify your broker or bank that you elect to separate the units into the underlying public shares and public warrants, or if you hold units registered in your own name, you must contact Continental, APAC&#8217;s transfer agent, directly and instruct them to do so. You are requested to cause your public shares to be separated and delivered to Continental, APAC&#8217;s transfer agent, by 5:00&#160;p.m., Eastern Time, on [&#9679;], 2022 (two business&#160;days before the extraordinary general meeting) in order to exercise your redemption rights with respect to your public shares.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What are the material U.S. federal income tax consequences of exercising my redemption rights?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;">The receipt of cash by a Holder (as defined below in &#8220;<i style="font-style:italic;">Material U.S. Federal Income Tax Consequences </i><i style="font-style:italic;">to APAC Shareholders</i>&#8221;) of New OmniAb Common Stock in redemption of such stock will be a taxable event for U.S. federal income tax purposes in the case of a U.S. Holder (as defined below in &#8220;<i style="font-style:italic;">Material U.S. Federal Income Tax Consequences </i><i style="font-style:italic;">to APAC Shareholders</i>&#8221;) and may be a taxable event for U.S. federal income tax purposes in the case of a Non-U.S. Holder (defined below in &#8220;<i style="font-style:italic;">Material U.S. Federal Income Tax Consequences </i><i style="font-style:italic;">to APAC Shareholders</i>&#8221;). Please see the discussion below under the caption &#8220;<i style="font-style:italic;">Material U.S. Federal Income Tax Consequences to APAC Shareholders&#160;&#8212;U.S. Federal Income Taxation of U.S. Holders&#8212;Redemption of New </i></p></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">OmniAb Stock</i>&#8221; or &#8220;<i style="font-style:italic;">Material U.S. Federal Income Tax Consequences to APAC Shareholders&#160;&#8212;U.S. Federal Income Taxation of Non-U.S. Holders&#8212;Redemption of New OmniAb Stock</i>,&#8221; as applicable, for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Additionally, because the Domestication will occur prior to the redemption of any Holder, U.S. Holders exercising redemption rights will be subject to the potential tax consequences of Section&#160;367 of the Code as well as potential tax consequences of the U.S. federal income tax rules&#160;relating to PFICs. The tax consequences of Section&#160;367 of the Code and the PFIC rules&#160;are discussed more fully below under &#8220;<i style="font-style:italic;">Material </i><i style="font-style:italic;">U.S. Federal Income Tax </i><i style="font-style:italic;">Consequences</i><i style="font-style:italic;"> to APAC Shareholders</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">All Holders should consult with, and rely solely upon, their own tax advisors with respect to the U.S. federal income tax consequences of the transaction, including exercising such redemption rights.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What happens to the funds deposited in the trust account after consummation of the Business Combination?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Following the closing of APAC&#8217;s initial public offering, an amount equal to $235,750,000 of the net proceeds from APAC&#8217;s initial public offering and the sale of the APAC Private Placement Warrants was placed in the trust account. As of April 21 2022, funds in the trust account totaled approximately $235,818,000 and were comprised entirely of cash, U.S. government treasury obligations with a maturity of 185&#160;days or less or of money market funds meeting certain conditions under Rule&#160;2a-7 under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;), which invest only in direct U.S. government treasury obligations. These funds will remain in the trust account, except for the withdrawal of interest to pay taxes, if any, until the earliest of (1)&#160;the completion of a business combination (including the Business Combination), (2)&#160;the redemption of any public shares properly tendered in connection with a shareholder vote to amend the Cayman Constitutional Documents to modify the substance or timing of APAC&#8217;s obligation to redeem 100% of the public shares if it does not complete a business combination by February&#160;12, 2023 and (3)&#160;the redemption of all of the public shares if APAC is unable to complete a business combination by February&#160;12, 2023 (or if such date is further extended at a duly called extraordinary general meeting, such later date), subject to applicable law.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Upon consummation of the Business Combination, the funds deposited in the trust account will be released to pay holders of New OmniAb public shares who properly exercise their redemption rights, to pay transaction fees and expenses associated with the Business Combination and for working capital and general corporate purposes of OmniAb following the Business Combination. See &#8220;<i style="font-style:italic;">Summary of the Proxy Statement/Prospectus/Information Statement&#8212;Sources and Uses of Funds for the Business Combination</i>.&#8221;</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What happens if a substantial number of the public shareholders vote in favor of the Business Combination Proposal and exercise their redemption rights?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Our public shareholders may vote in favor of the Business Combination and exercise their redemption rights. Accordingly, the Business Combination may be consummated even though the funds available from the trust account and the number of public shareholders are reduced as a result of redemptions by public shareholders.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">The Merger Agreement provides that the obligations of the parties to consummate the Merger are conditioned on, among other things, that as of the Closing and, to the extent necessary, the Redemption Backstop shall have been consummated. If such condition is not met, and such condition is not waived under the terms of the Merger Agreement, then the Merger Agreement could terminate and the proposed Business Combination may not be consummated. In addition, with fewer public shares and public shareholders, the trading market for our New OmniAb Common Stock may be less liquid than the market for our APAC Class&#160;A Ordinary Shares was prior to the Closing and we may not be able to continue to meet the listing standards for Nasdaq. With less funds available from the trust account, the working capital infusion from the trust account into New OmniAb&#8217;s business will be reduced. Further, in no event will we redeem public shares in an amount that would cause New OmniAb&#8217;s net tangible assets (as determined in accordance with Rule&#160;3a5 1-1 (g)(1)&#160;of the Exchange Act) to be less than $5,000,001.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What conditions must be satisfied to complete the Business Combination?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;">The Merger Agreement provides that the obligations of the parties to consummate the Merger are conditioned on, among other things, (i)&#160;the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (ii)&#160;receipt of required consents and approvals from certain governmental authorities, (iii)&#160;no agreement between Ligand or APAC and any governmental authority pursuant to which Ligand or APAC has agreed not to consummate the Business </p></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Combination shall be in effect, (iv)&#160;no governmental authority of competent jurisdiction shall have enacted, issued or granted any law (whether temporary, preliminary or permanent), in each case that is in effect and which has the effect of restraining, enjoining or prohibiting the consummation of the transaction, (v)&#160;APAC shall have at least $5,000,001 of net tangible assets as of the Closing, (vi)&#160;the New OmniAb Common Stock issuable pursuant to the Business Combination shall have been approved for listing on Nasdaq, subject to official notice of issuance, (vii)&#160;Ligand, OmniAb, APAC and Merger Sub shall each have performed and complied in all material respects with the obligations, covenants and agreements required by the Merger Agreement to be performed or complied with by it at or prior the Effective Time (viii)&#160;customary bring down conditions related to the accuracy of the parties&#8217; respective representations and warranties in the Merger Agreement, (ix)&#160;the consummation of the Separation, the Distribution and the other transactions contemplated by the Separation Agreement, (x)&#160;each of APAC&#8217;s and OmniAb&#8217;s registration statements to be filed with the United States Securities and Exchange Commission shall have become effective, (xi) APAC&#8217;s shareholder approval of the Condition Precedent Proposals shall have been obtained and (xii) the receipt by Ligand and APAC of certain tax opinions. In addition, the respective obligations of OmniAb and Ligand to consummate the Business Combination is conditioned upon, among other items, the completion of the Forward Purchase and the Redemption Backstop, the resignation of all directors and all executive officers of APAC and the occurrence of the Domestication. APAC&#8217;s obligation to consummate the Business Combination is also conditioned on there having been no &#8220;Material Adverse Effect&#8221; on OmniAb since the date of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">For more information about conditions to the consummation of the Business Combination, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#8212;The Merger Agreement</i>.&#8221;</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">When do you expect the Business Combination to be completed?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">The Business Combination is expected to be completed in the third quarter of 2022.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Do I have appraisal rights in connection with the proposed Business Combination and the proposed Domestication?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Neither APAC&#8217;s shareholders nor APAC&#8217;s warrant holders have appraisal rights in connection with the Business Combination or the Domestication under the Cayman Islands Companies Act or under the DGCL.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Do I have dissenters&#8217; rights or appraisal rights in connection with the proposed Business Combination and the proposed Merger?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">As APAC is not a constituent party to the Merger between Merger Sub and OmniAB, shareholders of APAC do not have dissenters&#8217; rights in connection with the Merger under Cayman Islands law.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">APAC&#8217;s warrant holders do not have appraisal rights in connection with the Business Combination or the Merger under the Cayman Islands Companies Act or under the DGCL.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What do I need to do now?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">APAC urges you to read this proxy statement/prospectus/information statement, including the Annexes and the documents referred to herein, carefully and in their entirety and to consider how the Business Combination will affect you as a shareholder or warrant holder of APAC. APAC&#8217;s shareholders should then vote as soon as possible in accordance with the instructions provided in this proxy statement/prospectus/information statement and on the enclosed proxy card.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">How do I vote?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">The extraordinary general meeting will be held at [&#9679;], Eastern Time, on [&#9679;], 2022, at the offices of Weil, Gotshal&#160;&amp; Manges LLP, located at 767 Fifth Avenue, New York, NY 10153 and via live webcast at [&#9679;].com, where you will be able to listen to the meeting live and vote during the meeting. If you are a holder of record of ordinary shares on the APAC Record Date for the extraordinary general meeting, you may vote at the extraordinary general meeting in person, via the virtual meeting platform or by submitting a proxy for the extraordinary general meeting, in any of the following ways, if available:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vote by Mail</i>: by signing, dating and returning the enclosed proxy card in the accompanying prepaid reply envelope. By signing the proxy card and returning it in the enclosed prepaid envelope to the specified address, you are authorizing the individuals </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">named on the proxy card to vote your shares at the extraordinary general meeting in the manner you indicate. We encourage you to sign and return the proxy card even if you plan to attend the extraordinary general meeting so that your shares will be voted if you are unable to attend the extraordinary general meeting. If you receive more than one proxy card, it is an indication that your shares are held in multiple accounts. Please sign and return all proxy cards to ensure that all of your shares are voted. If you hold your shares in &#8220;street name&#8221; through a bank, broker or other nominee, you will need to follow the instructions provided to you by your bank, broker or other nominee to ensure that your shares are represented and voted at the extraordinary general meeting. If you sign and return the proxy card but do not give instructions on how to vote your shares, your ordinary shares will be voted as recommended by the APAC Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vote by Internet</i>: visit www. [&#9679;].com, 24 hours a day, seven&#160;days a week, until 11:59&#160;p.m., Eastern Time on [&#9679;], 2022 (have your proxy card in hand when you visit the website);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vote by Phone</i>: by calling toll-free (within the U.S. or Canada) [&#9679;] (have your proxy card in hand when you call); or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vote at the extraordinary general meeting</i>: you can attend the extraordinary general meeting in person or via the virtual meeting platform and vote during the meeting by following the instructions on your proxy card. You can access the extraordinary general meeting by visiting the website [&#9679;]. You will need your control number for access. Instructions on how to virtually attend and participate at the extraordinary general meeting are available at [&#9679;].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">If you hold your shares in &#8220;street name,&#8221; which means your shares are held of record by a broker, bank or nominee, you should contact your broker, bank or nominee to ensure that votes related to the shares you beneficially own are properly counted. In this regard, you must provide the broker, bank or nominee with instructions on how to vote your shares or, if you wish to attend the extraordinary general meeting and vote in person, obtain a valid proxy from your broker, bank or nominee. In most cases you may vote by telephone or over the Internet as instructed.</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">If my shares are held in &#8220;street name,&#8221; will my broker, bank or nominee automatically vote my shares for me?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">No.&#160;If your shares are held in a stock brokerage account or by a bank or other nominee, you are considered the &#8220;beneficial holder&#8221; of the shares held for you in what is known as &#8220;street name.&#8221; If this is the case, this proxy statement/prospectus/information statement may have been forwarded to you by your brokerage firm, bank or other nominee, or its agent, and you may need to obtain a proxy form from the institution that holds your shares and follow the instructions included on that form regarding how to instruct your broker, bank or nominee as to how to vote your shares. Under the rules&#160;of various national and regional securities exchanges, your broker, bank, or nominee cannot vote your shares with respect to non-discretionary matters unless you provide instructions on how to vote in accordance with the information and procedures provided to you by your broker, bank, or nominee. We believe all the proposals presented to the shareholders will be considered non-discretionary and therefore your broker, bank, or nominee cannot vote your shares without your instruction. Your bank, broker, or other nominee can vote your shares only if you provide instructions on how to vote. As the beneficial holder, you have the right to direct your broker, bank or other nominee as to how to vote your shares and you should instruct your broker to vote your shares in accordance with directions you provide. If you do not provide voting instructions to your broker on a particular proposal on which your broker does not have discretionary authority to vote, your shares will not be voted on that proposal. This is called a &#8220;broker non-vote.&#8221; A broker non-vote, while considered present for the purposes of establishing a quorum, will not count as a vote cast at the extraordinary general meeting.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">When and where will the extraordinary general meeting be held?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">The extraordinary general meeting will be held on [&#9679;], 2022 at [&#9679;], Eastern Time, at the offices of Weil, Gotshal&#160;&amp; Manges LLP, located at 767 Fifth Avenue, New York, NY 10153. Cayman Islands law requires there be a physical location for the meeting. However, given the ongoing global pandemic, APAC encourages its shareholders to attend, via live webcast at [&#9679;].com. To participate in the virtual meeting, an APAC shareholder of record will need the 16-digit control number included on their proxy card or instructions that accompanied their proxy materials, if applicable, or to obtain a proxy form from their broker, bank or other nominee. The extraordinary general meeting webcast will begin promptly at [&#9679;], Eastern Time. APAC shareholders are encouraged to access the APAC extraordinary general meeting prior to the start time. If you encounter any difficulties accessing the virtual meeting or during the meeting time, please call the technical support number that will be posted on the virtual meeting login page.</p></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Who is entitled to vote at the extraordinary general meeting?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">APAC has fixed [&#9679;], 2022 as the APAC Record Date for the extraordinary general meeting. If you were a shareholder of APAC at the close of business on the APAC Record Date, you are entitled to vote on matters that come before the extraordinary general meeting. However, a shareholder may only vote his or her shares if he or she is present in person or is represented by proxy at the extraordinary general meeting.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">How many votes do I have?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">APAC shareholders are entitled to one vote at the extraordinary general meeting for each ordinary share held of record as of the APAC Record Date. As of the close of business on the APAC Record Date for the extraordinary general meeting, there were 23,000,000 APAC Class&#160;A Ordinary Shares issued and outstanding, and 5,750,000 APAC Class&#160;B Ordinary Shares issued and outstanding.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What constitutes a quorum?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A quorum of APAC shareholders is necessary to hold a valid meeting. A quorum will be present at the extraordinary general meeting if one or more shareholders who together hold not less than one-third of the issued and outstanding ordinary shares entitled to vote at the extraordinary general meeting are in attendance in person or by proxy. As of the APAC Record Date for the extraordinary general meeting, 9,583,334 ordinary shares would be required to achieve a quorum.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What vote is required to approve each proposal at the extraordinary general meeting?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">The following votes are required for each proposal at the extraordinary general meeting:</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Business Combination Proposal:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The approval of the Business Combination Proposal requires a special resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of at least two-thirds of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Domestication Proposal:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The approval of the Domestication Proposal requires a special resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of at least two-thirds of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. With respect to the Domestication Proposal, a holder of APAC Class&#160;B Ordinary Shares shall have ten votes for every APAC Class&#160;B Ordinary Share of which he or she is the holder and a holder of APAC Class&#160;A Ordinary Shares shall have one vote for every APAC Class&#160;A Ordinary Share of which he or she is the holder.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Organizational Documents Proposal:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The approval of the Organizational Documents Proposal requires a special resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of at least two-thirds of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Non-Binding Governance Proposals:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Non-Binding Governance Proposals are constituted of non-binding advisory proposals, and may be approved by ordinary resolution, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(v)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Director Election Proposal:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The approval of the Director Election Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. With respect to the Director Election Proposal, only the holders of the APAC Class&#160;B Ordinary Shares are entitled to vote.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(vi)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Stock Issuance Proposal:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The approval of the Stock Issuance Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting.</span></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(vii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Incentive Plan Proposal:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The approval of the Incentive Plan Proposal may be approved by an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(viii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">ESPP Proposal:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The approval of the ESPP Proposal may be approved by an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(ix)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Adjournment Proposal:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The approval of the Adjournment Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What are the recommendations of the APAC Board?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">The APAC Board believes that the Business Combination Proposal and the other proposals to be presented at the extraordinary general meeting are in the best interest of APAC&#8217;s shareholders and unanimously recommends that its shareholders vote &#8220;FOR&#8221; the Business Combination Proposal, &#8220;FOR&#8221; the Domestication Proposal, &#8220;FOR&#8221; the Organizational Documents Proposal, and &#8220;FOR&#8221; all of the other proposals. The existence of financial and personal interests of one or more of APAC&#8217;s directors may result in a conflict of interest on the part of such director(s)&#160;between what he, she or they may believe is in the best interests of APAC and its shareholders and what he, she or they may believe is best for himself, herself or themselves in determining to recommend that shareholders vote for the proposals. In addition, APAC&#8217;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The </i><i style="font-style:italic;">Business Combination Proposal&#8212;Interests of APAC&#8217;s Directors and Executive Officers in the Business Combination</i>&#8221; for a further discussion of these considerations.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">How does the Sponsor intend to vote its shares?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Unlike some other blank check companies in which the initial shareholders agree to vote their shares in accordance with the majority of the votes cast by the public shareholders in connection with an initial business combination, the Sponsor has agreed to vote all the founder shares and any public shares purchased during or after APAC&#8217;s initial public offering in favor of the Business Combination. As of the date of this proxy statement/prospectus/information statement, the Sponsor (including APAC&#8217;s directors) owns 20% of the issued and outstanding ordinary shares.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">The Sponsor and APAC&#8217;s directors, officers, advisors or their respective affiliates may purchase shares or warrants in privately negotiated transactions or in the open market either prior to or following the completion of the Business Combination. However, they have no current commitments, plans or intentions to engage in any such transactions and have not formulated any terms or conditions for any such transactions. None of the funds in the trust account will be used to purchase shares or warrants in such transactions. If they engage in such transactions, they will not make any such purchases when they are in possession of any material non-public information not disclosed to the seller or if such purchases are prohibited by Regulation M under the Exchange Act. Such a purchase may include a contractual acknowledgement that such shareholder, although still the record holder of APAC&#8217;s shares, is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">In the event that the Sponsor or APAC&#8217;s directors, officers, advisors or their affiliates purchase shares in privately negotiated transactions from public shareholders who have already elected to exercise their redemption rights, such selling shareholders would be required to revoke their prior elections to redeem their shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">The purpose of such purchases would be to (i)&#160;vote such shares in favor of the Business Combination proposed in other proposals to be voted upon at the extraordinary general meeting and thereby increase the likelihood of obtaining shareholder approval of the Business Combination or (ii)&#160;ensure that APAC&#8217;s net tangible assets are at least $5,000,001, where it appears that such requirement would otherwise not be met. Any such purchases of our securities may result in the completion of the Business Combination that may not otherwise have been possible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">In addition, if such purchases are made, the public &#8220;float&#8221; of APAC Class&#160;A Ordinary Shares may be reduced and the number of beneficial holders of our securities may be reduced, which may make it difficult to maintain or obtain the quotation, listing or trading of our securities on a national securities exchange.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">The Sponsor and APAC&#8217;s officers, directors and/or their affiliates anticipate that they may identify the shareholders with whom the Sponsor or APAC&#8217;s officers, directors or their affiliates may pursue privately negotiated purchases by either the shareholders contacting us directly or by our receipt of redemption requests submitted by shareholders (in the case of Class&#160;A Ordinary Shares) following our mailing of proxy materials in connection with the Business Combination. To the extent that the Sponsor or APAC&#8217;s officers, directors, advisors or their affiliates enter into a private purchase, they would identify and contact only potential selling shareholders who have expressed their election to redeem their shares for a pro rata share of the trust account or vote against the Business Combination Proposal but only if such shares have not already been voted at the extraordinary general meeting. The Sponsor and APAC&#8217;s officers, directors, advisors or their affiliates will only purchase shares if such purchases comply with Regulation M under the Exchange Act and the other federal securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Any purchases by the Sponsor or APAC&#8217;s officers, directors and/or their affiliates who are affiliated purchasers under Rule&#160;10b-18 under the Exchange Act will only be made to the extent such purchases are able to be made in compliance with Rule&#160;10b-18, which is a safe harbor from liability for manipulation under Section&#160;9(a)(2)&#160;and Rule&#160;10b-5 of the Exchange Act. Rule&#160;10b-18 has certain technical requirements that must be complied with in order for the safe harbor to be available to the purchaser. The Sponsor and APAC&#8217;s officers, directors and/or their affiliates will not make purchases of APAC Class&#160;A Ordinary Shares if the purchases would violate Section&#160;9(a)(2)&#160;or Rule&#160;10b-5 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">The existence of financial and personal interests of one or more of APAC&#8217;s directors may result in a conflict of interest on the part of such director(s)&#160;between what he, she or they may believe is in the best interests of APAC and its shareholders and what he, she or they may believe is best for himself, herself or themselves in determining to recommend that shareholders vote for the proposals. In addition, APAC&#8217;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#8212;Interests of APAC&#8217;s Directors and Executive Officers in the Business Combination</i>&#8221; for a further discussion of these considerations.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What happens if I sell my APAC ordinary shares before the extraordinary general meeting?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">The APAC Record Date for the extraordinary general meeting is earlier than the date of the extraordinary general meeting and earlier than the date that the Business Combination is expected to be completed. If you transfer your public shares after the applicable APAC Record Date, but before the extraordinary general meeting, unless you grant a proxy to the transferee, you will retain your right to vote at such general meeting but the transferee, and not you, will have the ability to redeem such shares (if time permits).</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">May&#160;I change my vote after I have delivered my signed proxy card or voting instruction card?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Yes. If you are a shareholder of record of APAC ordinary shares as of the close of business on the APAC Record Date, you can change or revoke your proxy before it is voted at the meeting in one of the following ways:</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submit a new proxy card bearing a later date; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Vote in person or electronically at the extraordinary general meeting by visiting www.[&#9679;].com and entering the control number found on your proxy card, voting instruction form or notice you previously received. Please note that your attendance at the extraordinary general meeting will not alone serve to revoke your proxy.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What happens if I fail to take any action with respect to the extraordinary general meeting?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">If you fail to take any action with respect to the extraordinary general meeting and the Business Combination is approved by shareholders and the Business Combination is consummated, you will become a stockholder or warrant holder of New OmniAb. If you fail to take any action with respect to the extraordinary general meeting and the Business Combination Proposal and the other Condition Precedent Proposals are not approved, you will remain a shareholder or warrant holder of APAC. However, if you fail to vote with respect to the extraordinary general meeting, you will nonetheless be eligible to elect to redeem your public shares in connection with the Business Combination.</p></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What happens if I attend the extraordinary general meeting and abstain or do not vote?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">For purposes of the APAC extraordinary general meeting, an abstention occurs when a shareholder is present at the APAC extraordinary general meeting and does not vote or returns a proxy with an &#8220;abstain&#8221; vote.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">If you are a APAC shareholder that attends the APAC extraordinary general meeting in person or virtually and fails to vote on the Business Combination Proposal, the Domestication Proposal, the Organizational Documents Proposal, the Non-Binding Governance Proposals, the Director Election Proposal, the Stock Issuance Proposal, the Incentive Plan Proposal, the ESPP Proposal or the Adjournment Proposal, or if you respond to such proposals with an &#8220;abstain&#8221; vote, your failure to vote or your &#8220;abstain&#8221; vote, in each case, will have no effect on the vote count for such proposals.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What should I do with my APAC share certificates, warrant certificates or unit certificates?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">APAC shareholders who exercise their redemption rights must deliver (either physically or electronically) their share certificates to Continental, APAC&#8217;s transfer agent, prior to the extraordinary general meeting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Holders must complete the procedures for electing to redeem their public shares in the manner described above prior to 5:00&#160;p.m., Eastern Time, on [&#9679;], 2022 (two business&#160;days before the extraordinary general meeting) in order for their shares to be redeemed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">APAC warrant holders should not submit the certificates relating to their warrants. Public shareholders who do not elect to have their public shares redeemed for the pro rata share of the trust account should not submit the certificates relating to their public shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Upon the Domestication, holders of APAC Units, APAC Class&#160;A Ordinary Shares, APAC Class&#160;B Ordinary Shares and APAC Warrants will receive shares of New OmniAb Common Stock and New OmniAb Warrants, as the case may be, without needing to take any action and, accordingly, such holders should not submit any certificates relating to their units, APAC Class&#160;A Ordinary Shares (unless such holder elects to redeem the public shares in accordance with the procedures set forth above), APAC Class&#160;B Ordinary Shares or APAC Warrants.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What should I do if I receive more than one set of voting materials?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">APAC shareholders may receive more than one set of voting materials, including multiple copies of this proxy statement/prospectus/information statement and multiple proxy cards or voting instruction cards. For example, if you hold your shares in more than one brokerage account, you will receive a separate voting instruction card for each brokerage account in which you hold shares. If you are a holder of record and your shares are registered in more than one name, you will receive more than one proxy card. Please complete, sign, date and return each proxy card and voting instruction card that you receive in order to cast a vote with respect to all of your APAC ordinary shares.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Who will solicit and pay the cost of soliciting proxies for the extraordinary general meeting?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">APAC will pay the cost of soliciting proxies for the extraordinary general meeting. APAC has engaged D.F. King&#160;&amp; Co.,&#160;Inc. (&#8220;D.F. King&#8221;) to assist in the solicitation of proxies for the extraordinary general meeting. APAC has agreed to pay D.F. King a fee of $25,000, plus disbursements (to be paid with non-trust account funds). APAC will also reimburse banks, brokers and other custodians, nominees and fiduciaries representing beneficial owners of APAC Class&#160;A Ordinary Shares for their expenses in forwarding soliciting materials to beneficial owners of APAC Class&#160;A Ordinary Shares and in obtaining voting instructions from those owners. APAC&#8217;s directors and officers may also solicit proxies by telephone, by facsimile, by mail, on the Internet or in person. They will not be paid any additional amounts for soliciting proxies.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Where can I find the voting results of the extraordinary general meeting?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">The preliminary voting results will be expected to be announced at the extraordinary general meeting. APAC will publish final voting results of the extraordinary general meeting in a Current Report on Form&#160;8-K within four business&#160;days after the extraordinary general meeting.</p></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Who can help answer my questions?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">If you have questions about the Business Combination or if you need additional copies of this proxy statement/prospectus/information statement, any document incorporated by reference in this proxy statement/prospectus/information statement or the enclosed proxy card, you should contact:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">D.F. King&#160;&amp; Co,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">48 Wall Street, 22nd Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">New York, NY 10005</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Call Toll-Free: (888) 887-0082</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Banks and Brokers Call: (212) 269-5550</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">AHPA@dfking.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">You also may obtain additional information about APAC from documents filed with the SEC by following the instructions in the section entitled &#8220;<i style="font-style:italic;">Where You Can Find More Information</i>.&#8221; If you are a holder of public shares and you intend to seek redemption of your public shares, you will need to deliver your public shares (either physically or electronically) to Continental, APAC&#8217;s transfer agent, at the address below prior to the extraordinary general meeting. <b style="font-weight:bold;">Holders must complete the procedures for electing to redeem their public shares in the manner described above prior to 5:00&#160;p.m., Eastern Time, on [</b>&#9679;<b style="font-weight:bold;">], 2022 (two business&#160;days before the extraordinary general meeting) in order for their shares to be redeemed.</b> If you have questions regarding the certification of your position or delivery of your stock, please contact:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Continental Stock Transfer&#160;&amp; Trust Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">1 State Street, 30th floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">New York, NY 10004</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Attention: Mark Zimkind</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">E-Mail: mzimkind@continentalstock.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><a id="_068fa4a9_587d_43b9_bfd3_11984b10aec1"></a><a id="Main_SUMMARYOFTHEPROXYSTATEMENT"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">SUMMARY OF THE PROXY STATEMENT/PROSPECTUS/INFORMATION STATEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This summary highlights selected information from this proxy statement/prospectus/information statement and does not contain all of the information that is important to you. To better understand the proposals to be submitted for a vote at the extraordinary general meeting, including the Business Combination, you should read this proxy statement/prospectus/information statement, including the Annexes and other documents referred to herein, carefully and in their entirety. The Merger Agreement is the primary legal document that governs the Business Combination and the other transactions that will be undertaken in connection with the Business Combination. The Merger Agreement is also described in detail in this proxy statement/prospectus/information statement in the section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;&#8212; Summary of the Merger Agreement</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise specified, all share calculations (1)&#160;assume no exercise of redemption rights by the public shareholders in connection with the Business Combination and (2)&#160;do not include any shares issuable upon the exercise of the New OmniAb Warrants or underlying New OmniAb Equity Awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Parties to the Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">APAC</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August&#160;12, 2021, APAC consummated its initial public offering of 23,000,000 units, including the issuance of 3,000,000 units as a result of the underwriter&#8217;s exercise in full of their over-allotment option (the &#8220;IPO&#8221;), with each unit consisting of one Class&#160;A ordinary share of APAC, par value $0.0001 per share, and one-third of one redeemable warrant of APAC, each whole warrant entitling the holder thereof to purchase one APAC Class&#160;A Ordinary Share at an exercise price of $11.50 per share, subject to adjustment (the &#8220;APAC Units&#8221;). The APAC Units were sold at a price of $10.00 per APAC Unit, generating gross proceeds of $230,000,000. Substantially concurrently with the closing of the IPO, APAC completed the private sale of the APAC Private Placement Warrants to the Sponsor, generating gross proceeds to APAC of $12,350,000. The APAC Private Placement Warrants are identical to the warrants sold as part of the APAC Units in the IPO, except that, so long as they are held by the Sponsor or its permitted transferees: (i)&#160;they (including the APAC Class&#160;A Ordinary Shares issuable upon exercise of these warrants) may not, subject to certain limited exceptions, be transferred, assigned or sold by the Sponsor until 30&#160;days after the completion of APAC&#8217;s initial business combination and (ii)&#160;they (including the APAC Class&#160;A Ordinary Shares issuable upon exercise of these warrants) are entitled to registration rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A total of $235,750,000, comprised of the proceeds from the IPO and a portion of the sale of the Private Placement Warrants, were placed in a U.S.-based trust account at JP Morgan Chase Bank, N.A., maintained by Continental, acting as trustee. Except with respect to interest earned on the funds held in the trust account that may be released to APAC to pay its taxes if such funds are held in an interest-bearing account, the proceeds from the IPO will not be released from the trust account until the earliest to occur of: (i)&#160;the completion of APAC&#8217;s initial business combination; (ii)&#160;the redemption of any public shares properly tendered in connection with a shareholder vote to amend APAC&#8217;s amended and restated memorandum and articles of association (a)&#160;to modify the substance or timing of APAC&#8217;s obligation to provide holders of the APAC Class&#160;A Ordinary Shares the right to have their shares redeemed in connection with APAC&#8217;s initial business combination or to redeem 100% of its public shares if APAC does not complete its initial business combination within 18&#160;months from the closing of the IPO or (b)&#160;with respect to any other provision relating to the rights of holders of the APAC Class&#160;A Ordinary Shares; or (iii)&#160;the redemption of all of APAC&#8217;s public shares if it has not completed its initial business combination within 18&#160;months from the closing of the IPO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The APAC Units, APAC Class&#160;A Ordinary Shares and APAC warrants are currently listed on the Nasdaq under the symbols &#8220;AHPAU,&#8221; &#8220;AHPA&#8221; and &#8220;AHPAW,&#8221; respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s principal executive office is located at 65 East 55th Street, 18th Floor, New York, NY 10022. Its telephone number is (212) 593-6900.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Merger Sub</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC Merger Sub&#160;Inc. (&#8220;Merger Sub&#8221;) is a Delaware corporation and a wholly-owned subsidiary of APAC. The Merger Sub does not own any material assets or operate any business and was formed for the purpose of participating in the Merger transaction.</p></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ligand</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand Common Stock is listed on The Nasdaq Global Market under the symbol &#8220;LGND.&#8221; Ligand was incorporated under the laws of the State of Delaware on May&#160;18, 1995. Ligand&#8217;s principal executive offices are located at 5980&#160;Horton Street, Suite&#160;405, Emeryville, CA 94608, and its telephone number is (858)&#160;550-7500.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OmniAb</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb was incorporated under the laws of the State of Delaware on December&#160;14, 2015 under the name Schrader&#160;2 Acquisition,&#160;Inc. It is a wholly-owned subsidiary of Ligand. On January&#160;8, 2016, Ligand acquired Open Monoclonal Technology,&#160;Inc., another Delaware corporation, pursuant to a multi-step transaction that resulted in the merger of that other company into Schrader&#160;2 Acquisition,&#160;Inc. On January&#160;8, 2016, Schrader&#160;2 Acquisition,&#160;Inc. changed its name to Open Monoclonal Technology,&#160;Inc., and on November&#160;10, 2021 Open Monoclonal Technology,&#160;Inc. changed its name to OmniAb,&#160;Inc. OmniAb&#8217;s principal executive offices are located at 5980&#160;Horton Street, Suite&#160;405, Emeryville, CA 94608, and its telephone number is (510)&#160;250-7800. The OmniAb Business involves a suite of technologies, including a core competence focused on ion channels and transporters and a patent-protected transgenic animal platform used in the discovery of fully human monoclonal and bispecific therapeutic antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Transaction Steps</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Business Combination will be accomplished by way of the following transaction steps:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Domestication will be effected, whereby APAC&#8217;s jurisdiction of incorporation will be changed by its deregistering as an exempted company in the Cayman Islands and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware at least one (1)&#160;business day prior to the consummation of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Separation will be effected, whereby Ligand will, among other things and subject to the terms and conditions of the Separation Agreement, transfer the OmniAb Business, including certain related subsidiaries of Ligand, to OmniAb and make a contribution to the capital of OmniAb of $15,000,000 less certain transaction and other expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Distribution will be effected, whereby Ligand will distribute to Ligand stockholders 100% of the OmniAb Common Stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to the Employee Matters Agreement, at the time of the Distribution, each existing Ligand equity award, with certain limited exceptions, will be split into (i)&#160;a new Ligand equity award and (ii)&#160;a new OmniAb Equity Award, with any accrued value in the original Ligand equity award split between such awards based on the relative post-closing values of Ligand and OmniAb;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to the A&amp;R FPA, OmniAb, New OmniAb and the Sponsor will effect the Forward Purchase, whereby New OmniAb will issue and sell to the Sponsor 1,500,000 shares of New OmniAb Common Stock and warrants to acquire 1,666,667 shares of New OmniAb Common Stock for an aggregate purchase price of $15,000,000, with such purchases to be consummated following the Domestication and prior to the Merger. In addition to the Forward Purchase, the Sponsor has agreed to effect the Redemption Backstop (to the extent necessary), whereby the Sponsor will purchase up to an additional 10,000,000 shares of New OmniAb Common Stock and up to an additional 1,666,667 New OmniAb Warrants, for an aggregate additional purchase price of up to $100,000,000, in order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds to be available to the combined company following the Business Combination from APAC&#8217;s trust account to be less than $100,000,000; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Following the above steps, the Merger will be effected, whereby Merger Sub will merge with and into OmniAb, with OmniAb continuing as the surviving company in the Merger and a wholly owned subsidiary of New OmniAb.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Proposals to be Put to the Shareholders of APAC at the Extraordinary General Meeting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the proposals to be put to the extraordinary general meeting of APAC and certain transactions contemplated by the Merger Agreement. Each of the Condition Precedent Proposals is cross-conditioned on the approval of the others. The Adjournment Proposal is not conditioned upon the approval of any other proposal set forth in this proxy statement/prospectus/information statement. The Non-Binding Governance Proposals are constituted of non-binding advisory proposals. The transactions contemplated by the Merger Agreement will be consummated only if the Condition Precedent Proposals are approved at the extraordinary general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Business Combination Proposal</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the extraordinary general meeting, APAC shareholders will be asked to consider and vote upon the Business Combination Proposal. Pursuant to the Business Combination Proposal, APAC shareholders will vote upon adoption of the Merger Agreement, the Transaction Documents and the transactions contemplated thereby. The Merger Agreement provides for, among other things, following the Domestication, the Separation, the Distribution, the Forward Purchase and the Redemption Backstop, if necessary, the merger of Merger Sub with and into OmniAb (the &#8220;Merger&#8221;), with OmniAb surviving the merger as a wholly-owned subsidiary of APAC, in accordance with the terms and subject to the conditions of the Merger Agreement as more fully described elsewhere in this proxy statement/prospectus/information statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After consideration of the factors identified and discussed in the section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;&#8212; The APAC Boards&#8217; Reasons for the Business Combination</i>,&#8221; the APAC Board concluded that the Business Combination met all of the requirements disclosed in the prospectus for APAC&#8217;s initial public offering, including that the business of OmniAb and its subsidiaries had a fair market value equal to at least 80% of the net assets held in trust (net of amounts disbursed to management for working capital purposes and excluding the amount of any deferred underwriting discount held in trust).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Merger Consideration</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The total number of shares of New OmniAb Common Stock to be received by OmniAb&#8217;s stockholders (as of immediately after consummation of the Distribution) or reserved for issuance pursuant to the New OmniAb Equity Awards into which OmniAb Equity Awards are to be converted will be equal to the Aggregate Merger Consideration. In addition to the Aggregate Merger Consideration, holders of OmniAb Common Stock and equity awards will also receive earnout consideration in the form of an additional 15,000,000 OmniAb Earnout Shares, with 50% of such earnout shares vesting upon the achievement of a post-transaction VWAP of $12.50 per share of New OmniAb Common Stock for any 20 trading&#160;days over a consecutive 30 trading-day period, and the remainder vesting upon achievement of a post-transaction VWAP of $15.00 per share of New OmniAb Common Stock for any 20 trading&#160;days over a consecutive 30 trading-day period, in each case provided such vesting occurs during the five-year period following the Closing. For further details, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#8212;Merger Consideration</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of and upon the Closing, among other things, each outstanding share of OmniAb Common Stock (other than Treasury Shares), will be cancelled upon the Effective Time in exchange for the right to receive (i)&#160;a number of shares of New OmniAb Common Stock equal to the Base Exchange Ratio, and (ii)&#160;a number of OmniAb Earnout Shares equal to the Earnout Exchange Ratio. For further details, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#8212;Merger Consideration</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, all (i)&#160;OmniAb Options, (ii)&#160;OmniAb RSUs and (iii)&#160;OmniAb PSUs, in each case, that are outstanding as of immediately prior to the Effective Time, will be converted into such number of (a)&#160;New OmniAb Options, (b)&#160;New OmniAb RSUs and (c)&#160;New OmniAb PSUs, respectively, in each case, equal to (1)&#160;the number of shares of OmniAb Common Stock underlying such OmniAb Equity Awards immediately prior to the Effective Time multiplied by (2)&#160;the Base Exchange Ratio. Each holder of an OmniAb Option, OmniAb RSU and/or OmniAb PSU will also receive a number of OmniAb Earnout Shares equal to the number of shares of OmniAb Common Stock underlying such OmniAb Options, OmniAb RSUs and/or OmniAb PSUs, as applicable, multiplied by the Earnout Exchange Ratio, and the exercise price of each outstanding New OmniAb Option will be equal to the exercise price of the pre-conversion OmniAb Option divided by the Base Exchange Ratio. For further details, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;&#8212; Consideration, Treatment of OmniAb Options, OmniAb RSUs and OmniAb PSUs.</i>&#8221;</p></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Closing Conditions</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement provides that the obligations of the parties to consummate the Merger are conditioned on, among other things, (i)&#160;the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (ii)&#160;receipt of required consents and approvals from certain governmental authorities, (iii)&#160;no agreement between Ligand or APAC and any governmental authority pursuant to which Ligand or APAC has agreed not to consummate the Business Combination shall be in effect, (iv)&#160;no governmental authority of competent jurisdiction shall have enacted, issued or granted any law (whether temporary, preliminary or permanent), in each case that is in effect and which has the effect of restraining, enjoining or prohibiting the consummation of the transaction, (v)&#160;APAC shall have at least $5,000,001 of net tangible assets as of the Closing, (vi)&#160;the New OmniAb Common Stock issuable pursuant to the Business Combination shall have been approved for listing on Nasdaq, subject to official notice of issuance, (vii)&#160;Ligand, OmniAb, APAC and Merger Sub shall each have performed and complied in all material respects with the obligations, covenants and agreements required by the Merger Agreement to be performed or complied with by it at or prior to the Effective Time (viii)&#160;customary bring down conditions related to the accuracy of the parties&#8217; respective representations and warranties in the Merger Agreement, (ix)&#160;the consummation of the Separation, the Distribution and the other transactions contemplated by the Separation Agreement, (x)&#160;each of APAC&#8217;s and OmniAb&#8217;s registration statements to be filed with the United States Securities and Exchange Commission shall have become effective, (xi) APAC&#8217;s shareholder approval of the Condition Precedent Proposals shall have been obtained and (xii) the receipt by Ligand and APAC of certain tax opinions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the respective obligations of OmniAb and Ligand to consummate the Business Combination is conditioned upon, among other items, the completion of the Forward Purchase and the Redemption Backstop, the resignation of all directors and all executive officers of APAC and the occurrence of the Domestication. APAC&#8217;s obligation to consummate the Business Combination is also conditioned on there having been no &#8220;Material Adverse Effect&#8221; on OmniAb since the date of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For further details, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;&#8212; Summary of the Merger Agreement.</i>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Domestication Proposal</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC will ask its shareholders to approve by special resolution the Domestication Proposal. As a condition to closing the Business Combination pursuant to the terms of the Merger Agreement, the APAC Board has unanimously approved the Domestication Proposal. If approved, APAC&#8217;s jurisdiction of incorporation will be changed by its deregistering as an exempted company in the Cayman Islands and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware at least one (1)&#160;business day prior to the consummation of the Merger (the &#8220;Domestication&#8221;). As more fully described elsewhere in this proxy statement/prospectus/information statement, you will be asked to consider and vote upon a proposal to approve the Domestication (the &#8220;Domestication Proposal&#8221;). In connection with the consummation of the Domestication, APAC will change its name to &#8220;OmniAb,&#160;Inc.&#8221; (APAC, following the Domestication, is sometimes referred to in the proxy statement/prospectus/information statement as &#8220;New OmniAb&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of and upon the effective time of the Domestication, (1)&#160;each then issued and outstanding Class&#160;A ordinary share, par value $0.0001 per share, of APAC (the &#8220;APAC Class&#160;A Ordinary Shares&#8221;), will convert automatically, on a one-for-one basis, into a share of common stock, par value $0.0001 per share, of New OmniAb (the &#8220;New OmniAb Common Stock&#8221;), (2)&#160;each then issued and outstanding Class&#160;B ordinary share, par value $0.0001 per share, of APAC (the &#8220;APAC Class&#160;B Ordinary Shares&#8221;) will convert automatically, on a one-for-one basis, into a share of New OmniAb Common Stock, (3)&#160;each then issued and outstanding warrant of APAC (the &#8220;APAC Warrants&#8221;) will convert automatically into a warrant to acquire one share of New OmniAb Common Stock (the &#8220;New OmniAb Warrants&#8221;) pursuant to the Warrant Agreement, dated August&#160;9, 2021 (the &#8220;Warrant Agreement&#8221;), by and between APAC and Continental Stock Transfer&#160;&amp; Trust Company (&#8220;Continental&#8221;), a New York corporation, as warrant agent, and (4)&#160;each then issued and outstanding unit of APAC (the &#8220;APAC Units&#8221;), will separate and convert automatically into one share of New OmniAb Common Stock and one-third of one New OmniAb Warrant. As used in this proxy statement/prospectus/information statement, &#8220;public shares&#8221; shall mean the APAC Class&#160;A Ordinary Shares (including those that underlie the APAC Units) that were issued pursuant to APAC&#8217;s initial public offering and the shares of New OmniAb Common Stock issued as a matter of law upon the conversion thereof on the effective date of the Domestication, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For further details, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;2&#160;&#8212; The </i><i style="font-style:italic;">Domestication Proposal</i>.&#8221;</p></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Organizational Documents Proposal</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC will also ask its shareholders to approve a proposal to approve and adopt the proposed certificate of incorporation and bylaws of New OmniAb in connection with the Domestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For further details, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;3&#160;&#8212; The Organizational Documents Proposal</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Non-Binding Governance Proposals</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s shareholders are also being asked to consider and vote upon proposals to approve, on a non-binding advisory basis, certain material differences between APAC&#8217;s Amended and Restated Memorandum and Articles of Association (as it may be amended from time to time, the &#8220;Cayman Constitutional Documents&#8221;) and the proposed certificate of incorporation and bylaws of New OmniAb, presented separately in accordance with the United States Securities and Exchange Commission&#8217;s requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Proposed Organizational Documents differ in certain material respects from the Cayman Constitutional Documents and APAC encourages shareholders to carefully review the information set out in the sections entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;3&#160;&#8212; The Organizational Documents Proposal</i>,&#8221; &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;4&#160;&#8212; The Non-Binding Governance Proposals</i>,&#8221; the Cayman Constitutional Documents of APAC, attached hereto as Annex J and the Proposed Organizational Documents of New OmniAb, attached hereto as Annex H and Annex I.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Issuance Proposal</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s shareholders are also being asked to approve a proposal for the purposes of complying with the applicable provisions of Nasdaq Rule&#160;5635, the issuance of shares of New OmniAb Common Stock in connection with the Domestication, the Forward Purchase, the Redemption Backstop and the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For additional information, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;5&#160;&#8212; The Stock Issuance Proposal</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Incentive Plan Proposal</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s shareholders are also being asked to approve a proposal for the adoption by New OmniAb of the OmniAb,&#160;Inc. 2022 Incentive Award Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For additional information, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;6&#160;&#8212; Incentive Plan Proposal</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">ESPP Proposal</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s shareholders are also being asked to approve a proposal for the adoption by New OmniAb of the OmniAb,&#160;Inc. 2022 Employee Stock Purchase Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For additional information, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;7&#160;&#8212; ESPP Proposal</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Director Election Proposal</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s shareholders are also being asked to approve a proposal to elect seven directors to the New OmniAb Board effective as of the closing of the Merger as contemplated by the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For additional information on the proposed directors, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;8&#160;&#8212; The Director Election Proposal</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adjournment Proposal</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s shareholders are also being asked to approve a proposal for the adjournment of the extraordinary general meeting to a later date or dates, if necessary, to permit further solicitation of proxies in the event that there are not sufficient votes to constitute a quorum or approve and adopt any one or more of the foregoing proposals at the extraordinary general meeting.</p></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For additional information, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;9&#160;&#8212; Adjournment Proposal</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The APAC Boards&#8217; Reasons for the Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In evaluating the Business Combination, the APAC Board consulted with APAC&#8217;s management and financial, legal and other advisors and considered a number of factors. In particular, the APAC Board considered, among other things, the following factors, although not weighted or in any order of significance:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Due Diligence</span>. APAC and certain of its advisors conducted a diligence review of OmniAb and its business, including review of relevant documentation and discussions with OmniAb&#8217;s management and OmniAb&#8217;s financial, legal and other advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Other Alternatives</span>. After a review of other business combination opportunities reasonably available to APAC, the APAC Board believes that the proposed Business Combination represents the best potential business combination for APAC and the most attractive opportunity for APAC&#8217;s shareholders based upon the process utilized to evaluate and assess other potential acquisition targets, and that such process has not presented a better alternative.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Negotiated Transaction</span>. The financial and other terms and condition of the Merger Agreement are, in the view of the APAC Board, reasonable and were the product of arm&#8217;s length negotiations between APAC and Ligand and its advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a more complete description of the APAC Boards&#8217; reasons for approving the Business Combination, including other factors and risks considered by the APAC Board, see the section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;&#8212; The APAC Boards&#8217; Reasons for the Business Combination</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Related Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This section describes certain additional agreements entered into or to be entered into pursuant to the Merger Agreement. For additional information, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;</i><i style="font-style:italic;">&#8212;</i><i style="font-style:italic;"> Summary of the Separation Agreement</i>&#8221; and &#8220;<i style="font-style:italic;">&#8212; Summary of the Ancillary Agreements</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Separation Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, Ligand, OmniAb and APAC entered into the Separation Agreement which sets forth the principal actions to be taken in connection with the Separation. The Separation Agreement identifies assets to be transferred, liabilities to be assumed and contracts to be assigned to each of Ligand and OmniAb as part of the internal reorganization described therein and requires the Ligand Contribution to be made to OmniAb. The Separation Agreement also sets forth other agreements that govern certain aspects of OmniAb&#8217;s relationship with Ligand following the Business Combination. Pursuant to the Separation Agreement, OmniAb will issue additional shares of OmniAb Common Stock to Ligand. Ligand will then distribute on a pro rata basis all of the outstanding shares of OmniAb Common Stock to the holders of Ligand Common Stock as of the Ligand Record Date set for the Distribution by delivering to the distribution agent a book-entry authorization representing the shares of OmniAb Common Stock being distributed for the account of Ligand&#8217;s stockholders. The distribution agent will hold such book-entry shares for the account of OmniAb&#8217;s stockholders (as of immediately after consummation of the Distribution) pending the Merger. The Separation Agreement is attached to this proxy statement/prospectus/information statement as Annex B.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employee Matters Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, APAC, Ligand, OmniAb and Merger Sub entered into the Employee Matters Agreement, which sets forth the terms and conditions of certain employee-related matters in connection with the transaction, including allocation of benefit plan assets and liabilities between Ligand and OmniAb, treatment of incentive equity awards in the Distribution and the Business Combination and related covenants and commitments of the parties. Pursuant to the Employee Matters Agreement, with limited exceptions, each existing Ligand equity award will be split into (i)&#160;a new Ligand equity award and (ii)&#160;a new OmniAb Equity Award, with any accrued value in the original Ligand equity award split between </p></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">such awards based on the relative post-Closing values of Ligand and OmniAb. The Employee Matters Agreement is attached to this proxy statement/prospectus/information statement as Annex K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sponsor Insider Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, OmniAb, the Sponsor and the directors and officers of APAC (the &#8220;Insiders&#8221;) entered into the Sponsor Insider Agreement, pursuant to which, among other things, the Insiders agreed to vote any APAC securities held by them to approve the Business Combination Proposal and the other APAC shareholder matters required pursuant to the Merger Agreement, and not to seek redemption of any of their APAC securities in connection with the consummation of the Business Combination. Pursuant to the Sponsor Insider Agreement, the Sponsor also agreed to subject up to all 1,916,667 Sponsor Earnout Shares to forfeiture if an applicable Sponsor Triggering Event has not occurred with respect to such Sponsor Earnout Shares during the period from the date of the Closing to and including the fifth anniversary of the date of the Closing. The Sponsor Insider Agreement is attached to this proxy statement/prospectus/information statement as Annex C.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amended&#160;&amp; Restated Forward Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, APAC entered into the A&amp;R FPA with the Sponsor and OmniAb. Pursuant to the A&amp;R FPA, APAC has agreed that, in connection with the consummation of the Business Combination, it will issue and sell to the Sponsor 1,500,000 shares of New OmniAb Common Stock and warrants to acquire 1,666,667 shares of New OmniAb Common Stock for an aggregate purchase price of $15,000,000 in the Forward Purchase. In addition to the Forward Purchase, the Sponsor has agreed to purchase up to an additional 10,000,000 shares of New OmniAb Common Stock and up to an additional 1,666,667 APAC warrants in the Redemption Backstop, for an aggregate additional purchase price of up to $100,000,000 in order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds to be available to the combined company following the Business Combination from APAC&#8217;s trust account to be less than $100,000,000. The A&amp;R FPA also provides that in the event the Merger Agreement is terminated by Ligand under circumstances in which the Termination Fee would be payable under the Merger Agreement, Ligand shall pay the Sponsor a termination fee of $12,500,000 in connection therewith. The A&amp;R FPA is attached to this proxy statement/prospectus/information statement as Annex D.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amended&#160;&amp; Restated Registration and Stockholder Rights Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrently with the completion of the Business Combination, APAC, Sponsor, the existing holders party to the original Registration and Stockholder Rights Agreement, dated August&#160;9, 2021 (the &#8220;Original Registration Rights Agreement&#8221;), and the new holders to become party to the A&amp;R Registration Rights Agreement, will enter into an Amended&#160;&amp; Restated Registration and Stockholder Rights Agreement, the form of which is attached to this proxy statement/prospectus/information statement as Annex G (the &#8220;A&amp;R Registration Rights Agreement&#8221;). The Original Registration Rights Agreement will be amended to, among other things, require APAC to use commercially reasonable efforts to, within thirty (30)&#160;days after the Closing, file a registration statement on Form&#160;S-1 to permit the public resale of all of the Registrable Securities (as defined in the A&amp;R Registration Rights Agreement) held by the holders from time to time as permitted by Rule&#160;415 under the Securities Act, and to provide certain equityholders of OmniAb as of immediately prior to the Closing of the Business Combination with customary registration rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Tax Matters Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Distribution, APAC, OmniAb, and Ligand will enter into the Tax Matters Agreement that will govern each party&#8217;s respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and certain other matters regarding taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, APAC and OmniAb will be liable for all U.S. federal, state, local and foreign taxes (and any related interest, penalties or audit adjustments) that are (i)&#160;imposed with respect to tax returns that include both OmniAb and Ligand, to the extent such taxes are attributable to OmniAb or the OmniAb Business, or (ii)&#160;imposed with respect to tax returns that include OmniAb but not Ligand, in each case, for tax periods (or portions thereof) beginning after the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, APAC and OmniAb may be liable for certain taxes resulting from the restructuring transactions undertaken to effectuate the Distribution.</p></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Distribution, together with certain related transactions, is intended to qualify as a reorganization under Sections 355 and 368(a)(1)(D)&#160;of the Code. Pursuant to the Tax Matters Agreement, taxes incurred by Ligand, APAC or OmniAb relating to or arising out of the failure of the intended tax treatment will generally be shared equally by Ligand, on the one hand, and APAC and OmniAb, on the other hand. If, however, such failure is attributable to certain acts or omissions by APAC or OmniAb, inaccuracies, misrepresentations or misstatements relating to APAC or OmniAb or certain events involving the stock of APAC or OmniAb or assets of OmniAb, APAC and OmniAb will generally bear all such taxes. Under certain circumstances, including if the failure is attributable to Ligand or an event involving Ligand&#8217;s stock or assets, Ligand will bear all such taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Tax Matters Agreement will require APAC and OmniAb to comply with the representations made in the materials submitted to legal counsel in connection with the Distribution Tax Opinion that Ligand expects to receive regarding the intended tax treatment of the Distribution and certain related transactions. The Tax Matters Agreement will also restrict OmniAb&#8217;s and APAC&#8217;s ability to take or fail to take any action if such action or failure to act could reasonably be expected to adversely affect the intended tax treatment. In particular, in the two&#160;years following the Distribution, APAC and OmniAb will be subject to certain restrictions, generally including being prevented from (i) entering into any transaction which could, when combined with other transactions (including the Merger), result in a 45% or greater change in ownership of APAC&#8217;s or OmniAb&#8217;s equity as part of a plan or series of related transactions that includes the Distribution, (ii)&#160;ceasing the active conduct of certain of OmniAb&#8217;s businesses, (iii)&#160;voluntarily dissolving or liquidating APAC or OmniAb and (iv)&#160;causing, permitting, or agreeing to the sale, transfer, or disposal of assets of OmniAb that, in the aggregate, constitute more than 30% of the consolidated gross assets of OmniAb, in each case, unless OmniAb obtains a private letter ruling from the IRS, an unqualified opinion of a nationally recognized tax advisor that such action will not cause a failure of the intended tax treatment, or Ligand consents to the undertaking of such action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding receipt of such ruling, opinion or consent, in the event that such action causes a failure of the intended tax treatment, APAC and OmniAb could be responsible for all taxes arising therefrom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s and OmniAb&#8217;s obligations under the Tax Matters Agreement are not limited in amount or subject to any cap. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transition Services Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Separation, OmniAb and Ligand will enter into two Transition Services Agreements pursuant to which Ligand and its affiliates and OmniAb and its affiliates will provide to each other various non-scientific and non-technical services set forth in the applicable Transition Services Agreement, which services are of the type that OmniAb and Ligand provided to, and received from, each other prior to the Separation. The fees for each of the transition services are set forth in the applicable Transition Services Agreement as a flat&#160;monthly fee, and the receiving party will reimburse the providing party for all reasonable out-of-pocket costs and expenses that the providing party incurs in connection with providing the transition services. Each of the Transition Services Agreements will terminate on the expiration of the term of the last service provided under it, unless earlier terminated by the receiving party with prior written notice, by either party in the event of an uncured material breach by the other party or its applicable affiliates, upon bankruptcy or insolvency of the other party, or by mutual agreement of the parties. The transition services are generally expected to last up to one&#160;year and the receiving party for a particular service may terminate such service prior to the scheduled expiration date with prior written notice. OmniAb does not anticipate that its net costs associated with the Transition Services Agreements will be materially different than the historical costs that have been allocated by Ligand to OmniAb related to these same services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Ownership of APAC following Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">As of the date of this proxy statement/prospectus/information statement, there are 28,750,000 ordinary shares of APAC issued and outstanding, which include the 5,750,000 founder shares held by the Sponsor (including APAC&#8217;s directors) and the 23,000,000 public shares. As of the date of this proxy statement/prospectus/information statement, there are outstanding an aggregate of 15,900,000 APAC Warrants, which include the 8,233,333 APAC Private Placement Warrants held by the Sponsor and the 7,666,667 APAC Public Warrants. Each whole warrant entitles the holder thereof to purchase one APAC Class&#160;A Ordinary Share and, following the Domestication, will entitle the holder thereof to purchase one share of New OmniAb Common Stock. Therefore, as of the date of this proxy statement/prospectus/information statement (without giving effect to the Business Combination), the APAC fully diluted share capital would be 44,650,000. It is anticipated that, following the Business Combination, (1)&#160;APAC&#8217;s public shareholders are expected to own approximately 18.0% of the outstanding shares of New OmniAb Common Stock, (2)&#160;OmniAb stockholders (without taking into account any public shares held by OmniAb stockholders prior to the consummation of the Business Combination) are expected to own approximately 76.3% of the outstanding shares of New OmniAb Common Stock and (3)&#160;the Sponsor and related parties are expected to collectively own approximately 5.7% of the outstanding shares of New OmniAb Common Stock. </p></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">These&#160;percentages (i)&#160;assume (a)&#160;that no public shareholders exercise their redemption rights in connection with the Business Combination, (b)&#160;that New OmniAb issues 97,431,885 shares of New OmniAb Common Stock to former stockholders of OmniAb as of immediately prior to the Effective Time and (c)&#160;that New OmniAb issues 1,500,000 shares of New OmniAb Common Stock to the Sponsor pursuant to the Forward Purchase, (ii)&#160;exclude all New OmniAb Options that may be exercisable for shares of New OmniAb Common Stock, New OmniAb RSUs and New OmniAb PSUs, (iii)&#160;include the OmniAb Earnout Shares (as defined in the Merger Agreement) and (iv)&#160;exclude the impact of any New OmniAb Warrants that will be outstanding following the Business Combination (we refer to this set of assumptions as the &#8220;no redemption scenario&#8221;). If the actual facts are different from the no redemption scenario, the&#160;percentage ownership of New OmniAb held by such constituencies will be different.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table illustrates varying ownership levels in New OmniAb immediately following the consummation of the Business Combination based on the no redemption scenario and, alternatively (i)&#160;based on the assumption that 11,500,000 APAC Class&#160;A Ordinary Shares are redeemed in connection with the Business Combination at approximately $10.25 per share (we refer to this set of assumptions as the &#8220;50% redemption scenario&#8221;) and (ii)&#160;based on the assumption that 23,000,000 APAC Class&#160;A Ordinary Shares are redeemed in connection with the Business Combination at approximately $10.25 per share, and the Sponsor funds $100,000,000 pursuant to the Redemption Backstop provided for in the A&amp;R FPA (we refer to this set of assumptions as the &#8220;maximum redemption scenario&#8221;). Please see &#8220;<i style="font-style:italic;">Risk Factors&#160;&#8212; Risks Related to Redemption</i>&#8221; for additional information.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:66.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share&#160;Ownership&#160;in&#160;New&#160;OmniAb</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">No&#160;Redemption&#160;Scenario</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">50%&#160;Redemption&#160;Scenario</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maximum&#160;Redemption&#160;Scenario</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"> (2)</sup></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.43%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Outstanding</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.45%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Outstanding</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.86%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.43%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Outstanding</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">APAC&#8217;s public shareholders</p></td><td style="vertical-align:middle;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">23,000,000</p></td><td style="vertical-align:middle;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:9.43%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">18.0</p></td><td style="vertical-align:middle;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:top;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">11,500,000</p></td><td style="vertical-align:middle;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:9.45%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">9.9</p></td><td style="vertical-align:middle;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:middle;width:9.8%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:middle;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;width:9.43%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0.0</p></td><td style="vertical-align:middle;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:29.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sponsor and related parties<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)(4)(6)</sup></p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7,250,000</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5.7</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7,250,000</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">6.2</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:top;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">17,250,000</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">15.0</p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:29.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">OmniAb (Ligand) stockholders <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)(6)</sup></p></td><td style="vertical-align:middle;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">97,431,885</p></td><td style="vertical-align:middle;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">76.3</p></td><td style="vertical-align:middle;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:top;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">97,431,885</p></td><td style="vertical-align:middle;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">83.9</p></td><td style="vertical-align:middle;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:top;width:9.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">97,431,885</p></td><td style="vertical-align:middle;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">85.0</p></td><td style="vertical-align:middle;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:29.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)(8)</sup></p></td><td style="vertical-align:middle;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.79%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">127,681,885</b></p></td><td style="vertical-align:middle;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.43%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">100.0</b></p></td><td style="vertical-align:middle;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">%</b></p></td><td style="vertical-align:top;width:9.79%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">116,181,885</b></p></td><td style="vertical-align:middle;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.45%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">100.0</b></p></td><td style="vertical-align:middle;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">%</b></p></td><td style="vertical-align:top;width:9.8%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">114,681,885</b></p></td><td style="vertical-align:middle;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.43%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">100.0</b></p></td><td style="vertical-align:middle;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Assumes redemptions of 11,500,000 APAC Class&#160;A Ordinary Shares in connection with the Business Combination.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Assumes redemptions of 23,000,000 APAC Class&#160;A Ordinary Shares in connection with the Business Combination.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes 5,750,000 Class&#160;B Ordinary Shares that will be converted in New OmniAb Common Stock. The Sponsor Earnout Shares were included in the pro forma capitalization as, during the Earnout Period, holders of the Sponsor Earnout Shares are entitled to vote such Sponsor Earnout Shares and receive dividends and other distribution in respect thereof, pursuant to the Sponsor Insider Agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to the A&amp;R FPA, includes 1,500,000 shares of New OmniAb Common Stock purchased by the Sponsor in the Forward Purchase in the no redemption and maximum redemption scenarios and an additional 10,000,000 New OmniAb Common Stock purchased by the Sponsor in the Redemption Backstop in the maximum redemption scenario.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes 15,000,000 OmniAb Earnout Shares as, during the Earnout Period, OmniAb Earnout Shares are entitled to exercise the voting rights carried by such Earnout Shares and receive any dividends or other distributions in respect of such OmniAb Earnout Shares.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The table below sets forth the share ownership in New OmniAb assuming that the Sponsor Earnout Shares and the OmniAb Earnout Shares are forfeited according to their terms:</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_Hlk100975037"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:67.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share&#160;Ownership&#160;in&#160;New&#160;OmniAb</b></p></td><td style="vertical-align:bottom;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">No&#160;Redemption&#160;Scenario</b></p></td><td style="vertical-align:bottom;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">50%&#160;Redemption&#160;Scenario</b></p></td><td style="vertical-align:bottom;width:1.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.29%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maximum&#160;Redemption&#160;Scenario</b></p></td><td style="vertical-align:bottom;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:29.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.61%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Outstanding</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.71%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.63%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Outstanding</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.69%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.74%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Outstanding</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">APAC&#8217;s public shareholders</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">23,000,000</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.61%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">20.8</p></td><td style="vertical-align:bottom;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.71%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">11,500,000</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.63%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">11.6</p></td><td style="vertical-align:bottom;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.74%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:29.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Sponsor and related parties</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,333,333</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">4.8</p></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,333,333</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5.4</p></td><td style="vertical-align:bottom;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">16,052,083</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">16.3</p></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:29.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">OmniAb (Ligand) stockholders</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">82,431,885</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">74.4</p></td><td style="vertical-align:bottom;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">82,431,885</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">83.0</p></td><td style="vertical-align:bottom;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">82,431,885</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">83.7</p></td><td style="vertical-align:bottom;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:29.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.69%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.79%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">110,765,218</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.61%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">100.0</p></td><td style="vertical-align:bottom;width:1.65%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.71%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">99,265,218</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.63%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">100.0</p></td><td style="vertical-align:bottom;width:1.69%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.69%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">98,483,968</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.74%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">100.0</p></td><td style="vertical-align:bottom;width:1.54%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The table excludes the following:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">10,636,952  unexercised OmniAb stock options;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">793,628 OmniAb RSUs and OmniAb PSUs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7,666,667 unexercised APAC Public Warrants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8,233,333 unexercised APAC Private Placement Warrants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,666,667 unexercised APAC Warrants issued in the Forward Purchase; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,666,667 unexercised APAC Warrants issued in the Backstop Redemption in the maximum redemption scenario.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(8)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If all of the Sponsor&#8217;s APAC Warrants are exercised, which include the 8,233,333 APAC Private Placement Warrants, the 1,666,667 APAC Warrants issued in the Forward Purchase and the 1,666,667 APAC Warrants issued in the Backstop Redemption in the maximum redemption scenario, Sponsor would own: (1) approximately&#160;12.5% of the shares of New OmniAb in the no redemption scenario, (2) approximately&#160;13.6% of the shares of New OmniAb in the 50% redemption scenario or (3) approximately&#160;22.8% of the shares of New OmniAb in the maximum redemptions scenario.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table illustrates the effective deferred underwriting commission on a percentage basis for public shares at each redemption level identified below.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">No</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">50%</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maximum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Redemption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Redemption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Redemption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">(in thousands, except share amounts)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Scenario</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Scenario</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Scenario</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Unredeemed public shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,000,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,500,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Trust proceeds to New OmniAb</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 235,750</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 117,875</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred underwriting commission</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,050</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,050</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,050</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Effective deferred underwriting fee (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3.41</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6.83</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Effective deferred underwriting fee per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.35</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.70</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Date, Time and Place of Extraordinary General Meeting of APAC&#8217;s Shareholders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The extraordinary general meeting of the shareholders of APAC will be held at [&#9679;], Eastern Time, on [&#9679;], 2022, at the offices of Weil, Gotshal&#160;&amp; Manges LLP, located at 767 Fifth Avenue, New York, NY 10153 and virtually via live webcast at [&#9679;].com, to consider and vote upon the proposals to be put to the extraordinary general meeting, including if necessary, the Adjournment Proposal, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the extraordinary general meeting, each of the Condition Precedent Proposals have not been approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Voting Power; APAC Record Date</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">APAC shareholders will be entitled to vote or direct votes to be cast at the extraordinary general meeting if they owned ordinary shares at the close of business on [&#9679;], 2022, which is the APAC Record Date for the extraordinary general meeting. Shareholders will </p></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">have one vote for each ordinary share owned at the close of business on the APAC Record Date. If your shares are held in &#8220;street name&#8221; or are in a margin or similar account, you should contact your broker to ensure that votes related to the shares you beneficially own are properly counted. APAC Warrants do not have voting rights. As of the close of business on the APAC Record Date, there were 23,000,000 APAC Class&#160;A Ordinary Shares issued and outstanding, and 5,750,000 APAC Class&#160;B Ordinary Shares issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Quorum and Vote of APAC Shareholders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A quorum of APAC shareholders is necessary to hold a valid meeting. A quorum will be present at the APAC extraordinary general meeting if one-third of the issued and outstanding ordinary shares entitled to vote at the extraordinary general meeting are represented in person or by proxy. Abstentions and broker non-votes, while considered present for the purposes of establishing a quorum, will not count as votes cast at the extraordinary general meeting. As of the APAC Record Date for the extraordinary general meeting, 9,583,334 ordinary shares would be required to achieve a quorum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor has agreed to vote all of its ordinary shares in favor of the proposals being presented at the extraordinary general meeting. As of the date of this proxy statement/prospectus/information statement, the Sponsor (including APAC&#8217;s directors) owns 20% of the issued and outstanding ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The proposals presented at the extraordinary general meeting require the following votes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Business Combination Proposal:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The approval of the Business Combination Proposal requires a special resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of at least two-thirds of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Domestication Proposal:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The approval of the Domestication Proposal requires a special resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of at least two-thirds of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. With respect to the Domestication Proposal, a holder of APAC Class&#160;B Ordinary Shares shall have ten votes for every APAC Class&#160;B Ordinary Share of which he, she or they is or are the holder and a holder of APAC Class&#160;A Ordinary Shares shall have one vote for every APAC Class&#160;A Ordinary Share of which he, she or they is or are the holder.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Organizational Documents Proposal:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The approval of the Organizational Documents Proposal requires a special resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of at least two-thirds of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Non-Binding Governance Proposals:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Non-Binding Governance Proposals are constituted of non-binding advisory proposals, and require an ordinary resolution under Cayman Island law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Director Election Proposal:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The approval of the Director Election Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. With respect to the Director Election Proposal, only the holders of the APAC Class&#160;B Ordinary Shares are entitled to vote.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Stock Issuance Proposal:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The approval of the Stock Issuance Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Incentive Plan Proposal:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The approval of the Incentive Plan Proposal may be approved by an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting.</span></td></tr></table></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">ESPP Proposal:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The approval of the ESPP Proposal may be approved by an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Adjournment Proposal:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The approval of the Adjournment Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Redemption Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Cayman Constitutional Documents, an APAC shareholder may request of APAC that APAC redeem all or a portion of its APAC Class&#160;A Ordinary Shares for cash, out of funds legally available therefor, if the Business Combination is consummated. As a holder of APAC Class&#160;A Ordinary Shares, you will be entitled to receive cash for any APAC Class&#160;A Ordinary Shares to be redeemed only if you:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hold APAC Class&#160;A Ordinary Shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submit a written request to Continental, APAC&#8217;s transfer agent, in which you (i)&#160;request that APAC redeem all or a portion of your APAC Class&#160;A Ordinary Shares for cash, and (ii)&#160;identify yourself as the beneficial holder of the APAC Class&#160;A Ordinary Shares and provide your legal name, phone number and address; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">deliver your APAC Class&#160;A Ordinary Shares to Continental, APAC&#8217;s transfer agent, physically or electronically through DTC.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Holders must complete the procedures for electing to redeem their APAC Class&#160;A Ordinary Shares in the manner described above prior to 5:00&#160;p.m., Eastern Time, on [</b>&#9679;<b style="font-weight:bold;">], 2022 (two business&#160;days before the extraordinary general meeting) in order for their shares to be redeemed.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The redemption rights include the requirement that a holder must identify itself in writing as a beneficial holder and provide its legal name, phone number and address to Continental in order to validly redeem its shares. APAC&#8217;s public shareholders may elect to redeem all or a portion of the public shares held by them regardless of if or how they vote in respect of the Business Combination Proposal. </b>If the Business Combination is not consummated, the public shares will be returned to the respective holder, broker or bank. If the Business Combination is consummated, and if a public shareholder properly exercises its right to redeem all or a portion of the public shares that it holds and timely delivers its shares to Continental, APAC&#8217;s transfer agent, APAC will redeem such public shares for a per-share price, payable in cash, equal to the pro rata portion of the trust account, calculated as of two business&#160;days prior to the consummation of the Business Combination. For illustrative purposes, as of [&#9679;], 2022, this would have amounted to approximately $[&#9679;] per issued and outstanding public share. If a public shareholder exercises its redemption rights in full, then it will be electing to exchange its APAC Class&#160;A Ordinary Shares for cash and will no longer own APAC Class&#160;A Ordinary Shares. The redemption takes place following the Domestication and accordingly it is New OmniAb Common Stock that will be redeemed immediately after consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you hold the shares in &#8220;street name,&#8221; you will have to coordinate with your broker to have your shares certificated or delivered electronically. Shares that have not been tendered (either physically or electronically) in accordance with these procedures will not be redeemed for cash. There is a nominal cost associated with this tendering process and the act of certificating the shares or delivering them through DTC&#8217;s DWAC system. The transfer agent will typically charge the tendering broker $80 and it would be up to the broker whether or not to pass this cost on to the redeeming shareholder. In the event the proposed Business Combination is not consummated this may result in an additional cost to shareholders for the return of their shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any written request for redemption, once made by a holder of APAC Class&#160;A Ordinary Shares, may not be withdrawn once submitted to APAC unless the APAC Board determines (in its sole discretion) to permit the withdrawal of such redemption request (which it may do in whole or in part). If you submit a redemption request to Continental, APAC&#39;s transfer agent, and later decide prior to the extraordinary general meeting not to elect redemption, you may request to withdraw the redemption request. You may make such request by contacting Continental, APAC&#39;s transfer agent, at the phone number or address listed in see &#8220;<i style="font-style:italic;">Questions and answers&#8201;-&#8201;Q: Who can help answer my questions?</i>&#8221;.</p></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any corrected or changed written exercise of redemption rights must be received by Continental, APAC&#8217;s transfer agent, prior to the vote taken on the Business Combination Proposal at the extraordinary general meeting. No request for redemption will be honored unless the holder&#8217;s APAC Class&#160;A Ordinary Share certificates (if any) and other redemption forms have been delivered to Continental, APAC&#8217;s transfer agent, physically or electronically through DTC, at least two business&#160;days prior to the vote at the extraordinary general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, a public shareholder, together with any affiliate of such public shareholder or any other person with whom such public shareholder is acting in concert or as a &#8220;group&#8221; (as defined in Section&#160;13(d)(3)&#160;of the Exchange Act), will be restricted from redeeming its APAC Class&#160;A Ordinary Shares with respect to more than an aggregate of 15% of the APAC Class&#160;A Ordinary Shares. Accordingly, if a public shareholder, alone or acting in concert or as a group, seeks to redeem more than 15% of the APAC Class&#160;A Ordinary Shares, then any such shares in excess of that 15% limit would not be redeemed for cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor and each director of APAC has agreed to, among other things, vote all of their founder shares and any other APAC Class&#160;A Ordinary Shares purchased during APAC&#8217;s initial public offering in favor of the proposals being presented at the extraordinary general meeting and waive their redemption rights with respect to such shares in connection with the consummation of the Business Combination. The APAC Class&#160;B Ordinary Shares held by the Sponsor and such other persons will be excluded from the pro rata calculation used to determine the per-share redemption price. As of the date of this proxy statement/prospectus/information statement, the Sponsor and APAC&#8217;s directors, collectively, own approximately 20% of the issued and outstanding ordinary shares of APAC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The closing price of APAC Class&#160;A Ordinary Shares on [&#9679;], 2022 was $[&#9679;]. For illustrative purposes, as of [&#9679;], 2022, funds in the trust account plus accrued interest thereon totaled approximately $[&#9679;] or approximately $[&#9679;] per issued and outstanding APAC Class&#160;A Ordinary Share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to exercising redemption rights, APAC&#8217;s public shareholders should verify the market price of APAC Class&#160;A Ordinary Shares as they may receive higher proceeds from the sale of their APAC Class&#160;A Ordinary Shares in the public market than from exercising their redemption rights if the market price per share is higher than the redemption price. APAC cannot assure its shareholders that they will be able to sell their APAC Class&#160;A Ordinary Shares in the open market, even if the market price per share is higher than the redemption price stated above, as there may not be sufficient liquidity in its securities when its shareholders wish to sell their shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Dissenters&#8217; Rights and Appraisal Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As APAC is not a constituent party to the Merger between Merger Sub and OmniAb, shareholders of APAC do not have dissenters&#8217; rights in connection with the Merger under Cayman Islands law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s warrant holders do not have appraisal rights in connection with the Business Combination or the Merger under the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Proxy Solicitation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Proxies may be solicited by mail, telephone or in person. APAC has engaged D.F. King to assist in the solicitation of proxies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a shareholder grants a proxy, it may still vote its shares in person if it revokes its proxy before the extraordinary general meeting. A shareholder also may change its vote by submitting a later-dated proxy as described in the section entitled &#8220;<i style="font-style:italic;">Extraordinary General Meeting of APAC&#8201;-&#8201;Revoking Your Proxy</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interests of APAC&#8217;s Directors and Executive Officers in the Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">When you consider the recommendation of the APAC Board in favor of approval of the Business Combination Proposal, you should keep in mind that the initial shareholders, including APAC&#8217;s directors and executive officers, have interests in such proposal </p></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">that are different from, or in addition to, those of APAC&#8217;s shareholders generally. These interests include, among other things, the interests listed below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Prior to APAC&#8217;s initial public offering, the Sponsor purchased 5,750,000 Class&#160;B Ordinary Shares for an aggregate purchase price of $25,000, or approximately $0.004 per share, and the Sponsor later transferred 35,000 Class&#160;B Ordinary Shares to each of William E. Klitgaard, L&#226;le White and Wendel Barr, each of whom serve on the APAC Board. If APAC does not consummate a business combination by February&#160;12, 2023 (or if such date is extended at a duly called extraordinary general meeting, such later date), it would cease all operations except for the purpose of winding up, redeeming all of the outstanding public shares for cash and, subject to the approval of its remaining shareholders and the APAC Board, dissolving and liquidating, subject in each case to its obligations under the Cayman Islands Companies Act (As Revised) to provide for the claims of creditors and the requirements of other applicable law. In such event, the 5,750,000 APAC Class&#160;B Ordinary Shares collectively owned by the Sponsor and three directors (William E. Klitgaard, L&#226;le White and Wendel Barr) would be worthless because following the redemption of the public shares, APAC would likely have few, if any, net assets and because the Sponsor and APAC&#8217;s directors and officers have agreed to waive their respective rights to liquidating dissolutions from the trust account in respect of any APAC Class&#160;A Ordinary Shares and APAC Class&#160;B Ordinary Shares held by them, as applicable, if APAC fails to complete a business combination within the required period. Additionally, in such event, the 8,233,333 APAC Private Placement Warrants purchased by the Sponsor simultaneously with the consummation of APAC&#8217;s initial public offering for an aggregate purchase price of $12,350,000 will also expire worthless. Certain of APAC&#8217;s directors and officers, including Thompson Dean and David Burgstahler, also have a direct or indirect economic interest in such APAC Private Placement Warrants and the 5,645,000 APAC Class&#160;B Ordinary Shares owned by the Sponsor.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The 5,750,000 shares of New OmniAb Common Stock into which the 5,750,000 APAC Class&#160;B Ordinary Shares collectively held by the Sponsor and three of our directors will automatically convert in connection with the Domestication, if unrestricted and freely tradeable, would have had an aggregate market value of $[&#9679;] based upon the closing price of $[&#9679;] per APAC Class&#160;A Ordinary Share on the Nasdaq on [&#9679;], 2022, the most recent practicable date prior to the date of this proxy statement/prospectus/information statement. However, given that such shares of New OmniAb Common Stock will be subject to certain restrictions, including those described above, APAC believes that such shares have less value. The 8,233,333 New OmniAb Warrants into which the 8,233,333 APAC Private Placement Warrants held by the Sponsor will automatically convert in connection with the Domestication, if unrestricted and freely tradeable, would have had an aggregate market value of $[&#9679;] based upon the closing price of $[&#9679;] per APAC Warrant on Nasdaq on [&#9679;], 2022, the most recent practicable date prior to the date of this proxy statement/prospectus/information statement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC&#8217;s executive officers and directors, or any of their respective affiliates, including the Sponsor and other entities affiliated with APAC and the Sponsor, will be reimbursed for any out-of-pocket expenses incurred in connection with activities on APAC&#8217;s behalf, such as identifying potential target businesses and performing due diligence on suitable business combinations (including the Business Combination).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In the event that APAC fails to consummate a business combination within the prescribed time frame (pursuant to the Cayman Constitutional Documents), or upon the exercise of a redemption right in connection with the Business Combination, APAC will be required to provide for payment of claims of creditors that were not waived that may be brought against APAC within the ten&#160;years following such redemption. In order to protect the amounts held in APAC&#8217;s trust account, the Sponsor has agreed that it will be liable to APAC if and to the extent any claims by a third party (other than APAC&#8217;s independent auditors) for services rendered or products sold to APAC, or a prospective target business with which APAC has discussed entering into a transaction agreement, reduce the amount of funds in the trust account to below the lesser of (i)&#160;$10.25 per public share and (ii)&#160;the actual amount per public share held in the trust account as of the date of the liquidation of the trust account if less than $10.25 per public share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay APAC&#8217;s tax obligations, provided that such liability will not apply to any claims by a third-party or prospective target business that executed a waiver of any and all rights to seek access to the trust account nor will it apply to any claims under APAC&#8217;s indemnity of the underwriters of this offering against certain liabilities, including liabilities under the Securities Act.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Sponsor, or an affiliate of the Sponsor, or certain of APAC&#8217;s officers and directors have advanced funds to APAC for working capital purposes, including $500,000 as of March&#160;15, 2022. These outstanding advances have been documented in a promissory note, dated as of March&#160;14, 2022 (the &#8220;Promissory Note&#8221;) issued by APAC to the Sponsor, pursuant to which APAC may borrow up to $750,000 from the Sponsor (including those amounts which are currently outstanding). The </span></td></tr></table></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Promissory Note&#160;is non-interest bearing, unsecured and due and payable in full on the earlier of the date APAC consummates its initial business combination and the winding up of APAC. If APAC does not complete its initial business combination within the required period, it may use a portion of its working capital held outside the trust account to repay such advances and any other working capital advances made to APAC, but no proceeds held in the trust account would be used to repay such advances and any other working capital advances made to APAC, and such related party may not be able to recover the value it has loaned to APAC and any other working capital advances it may make.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC and the Sponsor have entered into the A&amp;R FPA in order to ensure adequate cash is available to the combined company following the Closing and, if necessary, to backstop redemptions by APAC&#8217;s shareholders in connection with the Business Combination, in an amount of up to $100,000,000 (at a purchase price of $10.00 per share). Pursuant to the A&amp;R FPA, APAC has agreed that, in connection with the consummation of the Business Combination, it will issue and sell to the Sponsor 1,500,000 shares of New OmniAb Common Stock and warrants to acquire 1,666,667 shares of New OmniAb Common Stock for an aggregate purchase price of $15 million. In addition, the Sponsor has agreed to purchase up to an additional 10,000,000 shares of New OmniAb Common Stock and up to an additional 1,666,667 New OmniAb Warrants in order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds available to the combined company </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">following the Business Combination </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">from APAC&#8217;s trust account to be less than $100,000,000. The A&amp;R FPA also provides that in the event the Merger Agreement is terminated by Ligand under circumstances in which the Termination Fee would be payable thereunder, Ligand shall pay the Sponsor a termination fee of $12,500,000 in connection therewith.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On August&#160;9, 2021, the Insiders entered into a Sponsor Insider Agreement, pursuant to which, among other things, the Insiders agreed to vote any APAC securities held by them to approve a proposed business combination (including any proposals recommended by the Board in connection with such business combination) and not to redeem any APAC shares held by them in connection with such shareholder approval in order to induce APAC and the underwriters in APAC&#8217;s initial public offering to enter into an underwriting agreement and to proceed with APAC&#8217;s initial public offering.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Sponsor, the Insiders and OmniAb entered into the Sponsor Insider Agreement, pursuant to which, among other things, the Insiders agreed to vote any APAC securities held by them to approve the Business Combination and the other APAC shareholder matters required pursuant to the Merger Agreement, and not to seek redemption of any of their APAC securities in connection with the consummation of the Business Combination. Pursuant to the Sponsor Insider Agreement, the Sponsor also agreed to subject up to all 1,916,667 Sponsor Earnout Shares to forfeiture if an applicable Sponsor Triggering Event has not occurred with respect to such Sponsor Earnout Shares during the period from the date of the Closing to and including the fifth anniversary of the date of the Closing.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to the Registration Rights Agreement, the Sponsor and certain related parties will have customary registration rights, including piggy-back rights, subject to cooperation and cut-back provisions with respect to the shares of New OmniAb Common Stock and New OmniAb Warrants held by such parties following the consummation of the Business Combination. See &#8220;</span><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Certain Relationships and Related Person Transactions&#160;&#8212; APAC</i><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.&#8221;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor (including its representatives and affiliates) and APAC&#8217;s directors and officers, are, or may in the future become, affiliated with entities that are engaged in a similar business to APAC. The Sponsor and APAC&#8217;s directors and officers are not prohibited from sponsoring, or otherwise becoming involved with, any other blank check companies prior to APAC completing its initial business combination. Moreover, certain of APAC&#8217;s directors and officers have time and attention requirements for investment funds of which affiliates of the Sponsor are the investment managers. APAC&#8217;s directors and officers also may become aware of business opportunities which may be appropriate for presentation to APAC, and the other entities to which they owe certain fiduciary or contractual duties. Accordingly, they may have had conflicts of interest in determining to which entity a particular business opportunity should be presented. These conflicts may not be resolved in APAC&#8217;s favor and such potential business opportunities may be presented to other entities prior to their presentation to APAC, subject to applicable fiduciary duties under the Cayman Islands Companies Act. APAC&#8217;s Cayman Constitutional Documents provide that APAC renounces its interest in any corporate opportunity offered to any director or officer of APAC unless such opportunity is expressly offered to such person solely in his or her capacity as a director or officer of APAC and it is an opportunity that APAC is able to complete on a reasonable basis. This provision in APAC&#8217;s Cayman Constitutional Documents may present a conflict of interest in the event that a director or officer of APAC is offered a corporate opportunity in a capacity other than his or her capacity as a director or officer of APAC that is suitable for APAC. APAC does not believe that such potential conflict of interest impacted APAC&#8217;s search for a business combination target.</p></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s existing directors and officers will be eligible for continued indemnification and continued coverage under APAC&#8217;s directors&#8217; and officers&#8217; liability insurance after the Merger and pursuant to the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor has agreed to vote all the founder shares and any other public shares purchased during or after APAC&#8217;s initial public offering in favor of the Business Combination, regardless of how our public shareholders vote. Unlike some other blank check companies in which the initial shareholders agree to vote their shares in accordance with the majority of the votes cast by the public shareholders in connection with an initial business combination, the Sponsor and each director of APAC have agreed to, among other things, vote in favor of the Condition Precedent Proposals. As of the date of this proxy statement/prospectus/information statement, the Sponsor (together with APAC&#8217;s directors) owns 20% of the issued and outstanding ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor and APAC&#8217;s directors, officers, advisors or their respective affiliates may purchase shares or warrants in privately negotiated transactions or in the open market either prior to or following the completion of the Business Combination. However, they have no current commitments, plans or intentions to engage in any such transactions and have not formulated any terms or conditions for any such transactions. None of the funds in the trust account will be used to purchase shares or warrants in such transactions. If they engage in such transactions, they will not make any such purchases when they are in possession of any material non-public information not disclosed to the seller or if such purchases are prohibited by Regulation M under the Exchange Act or other federal securities laws. Such a purchase may include a contractual acknowledgement that such shareholder, although still the record holder of APAC&#8217;s shares, is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that the Sponsor or APAC&#8217;s directors, officers, advisors or their affiliates purchase shares in privately negotiated transactions from public shareholders who have already elected to exercise their redemption rights, such selling shareholders would be required to revoke their prior elections to redeem their shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purpose of such purchases would be to (i)&#160;vote such shares in favor of the Business Combination and thereby increase the likelihood of obtaining shareholder approval of the Business Combination or (ii)&#160;to ensure that APAC&#8217;s net tangible assets are at least $5,000,001, where it appears that such requirement would otherwise not be met. The purpose of any such purchases of warrants could be to reduce the number of warrants outstanding or to vote such warrants on any matters submitted to the warrant holders for approval in connection with the Business Combination. Any such purchases of our securities may result in the completion of the Business Combination that may not otherwise have been possible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if such purchases are made, the public &#8220;float&#8221; of APAC Class&#160;A Ordinary Shares may be reduced and the number of beneficial holders of our securities may be reduced, which may make it difficult to maintain or obtain the quotation, listing or trading of our securities on a national securities exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor and APAC&#8217;s officers, directors and/or their affiliates anticipate that they may identify the shareholders with whom the Sponsor or APAC&#8217;s officers, directors or their affiliates may pursue privately negotiated purchases by either the shareholders contacting us directly or by our receipt of redemption requests submitted by shareholders (in the case of Class&#160;A Ordinary Shares) following our mailing of proxy materials in connection with the Business Combination. To the extent that the Sponsor or APAC&#8217;s officers, directors, advisors or their affiliates enter into a private purchase, they would identify and contact only potential selling shareholders who have expressed their election to redeem their shares for a pro rata share of the trust account or vote against the Business Combination but only if such shares have not already been voted at the extraordinary general meeting. The Sponsor and APAC&#8217;s officers, directors, advisors or their affiliates will only purchase shares if such purchases comply with Regulation M under the Exchange Act and the other federal securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any purchases by the Sponsor or APAC&#8217;s officers, directors and/or their affiliates who are affiliated purchasers under Rule&#160;10b-18 under the Exchange Act will only be made to the extent such purchases are able to be made in compliance with Rule&#160;10b-18, which is a safe harbor from liability for manipulation under Section&#160;9(a)(2)&#160;and Rule&#160;10b-5 of the Exchange Act. Rule&#160;10b-18 has certain technical requirements that must be complied with in order for the safe harbor to be available to the purchaser. The Sponsor and APAC&#8217;s officers, directors and/or their affiliates will not make purchases of APAC Class&#160;A Ordinary Shares if the purchases would violate Section&#160;9(a)(2)&#160;or Rule&#160;10b-5 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The existence of financial and personal interests of one or more of APAC&#8217;s directors may result in a conflict of interest on the part of such director(s)&#160;between what he, she or they may believe is in the best interests of APAC and its shareholders and what he, she or they may believe is best for himself, herself or themselves in determining to recommend that shareholders vote for the proposals. In addition, APAC&#8217;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the </p></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#8201;&#8212;&#8201;Interests of APAC&#8217;s Directors and Executive Officers in the Business Combination</i>&#8221; for a further discussion of these considerations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interests of OmniAb&#8217;s Directors and Executive Officers in the Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb&#8217;s directors and executive officers have interests in the Business Combination that are different from, or in addition to, those of APAC&#8217;s shareholders generally. These interests include, among other things, the interests listed below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Executive Officer Transitions</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Certain of Ligand&#8217;s directors and executive officers are expected to become directors and/or executive officers of OmniAb upon the Closing. Specifically, the following individuals who are currently executive officers of Ligand are expected to become executive officers of OmniAb upon the Closing, serving in the following offices: (i)&#160;Matthew W. Foehr, Chief Executive Officer, and (ii)&#160;Charles S. Berkman, Chief Legal Officer and Secretary.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Treatment of Outstanding Equity Awards</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Certain of Ligand&#8217;s directors and executive officers who are expected to become directors and/or executive officers of OmniAb upon the Closing hold outstanding Ligand equity awards.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Employee Matters Agreement, at the time of the Distribution, each existing Ligand equity award granted prior to March&#160;2, 2022 will generally be split into a new Ligand equity award and a new OmniAb Equity Award, with any accrued value in the original Ligand equity award split between such awards based on the relative post-Closing values of Ligand and OmniAb. The adjusted Ligand equity awards and OmniAb Equity Awards generally will be subject to the same terms and conditions, including the same vesting and share payment timing provisions, as applied to the applicable Ligand equity awards immediately prior to the Distribution; provided, that the performance metrics for the outstanding Ligand PSU awards may be amended to reflect the Distribution as mutually agreed between Ligand and OmniAb; and provided further, that the Ligand PSU awards granted in 2021 and tied to relative total shareholder return (&#8220;TSR&#8221;) will be amended to vest solely based on continued service through the end of the three-year performance period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Employee Matters Agreement, at the time of the Distribution, each existing Ligand equity award granted after March&#160;2, 2022 and held by an individual who is an OmniAb service provider generally will be adjusted solely into an OmniAb Equity Award at the time of the Distribution. Following the Distribution, the intrinsic value of the resulting OmniAb Equity Award should approximately equal the intrinsic value as of immediately prior to the Distribution of the underlying Ligand equity award. The adjusted OmniAb Equity Awards generally will be subject to the same terms and conditions, including the same vesting and share payment timing provisions, as applied to the applicable Ligand equity awards immediately prior to the Distribution; provided, that the performance metrics for the outstanding PSU awards may be amended to reflect the Distribution as mutually agreed between Ligand and OmniAb, including an amendment to provide that such PSUs will vest solely based on continued service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Effective Time, all OmniAb Options, OmniAb RSUs and OmniAb PSUs, in each case, that are outstanding as of immediately prior to the Merger, will be converted into New OmniAb Options, New OmniAb RSUs and New OmniAb PSUs, respectively, in each case, with substantially the same terms and conditions as were applicable to the OmniAb equity award immediately prior to the Closing (other than terms that have been rendered inoperative by the Distribution and Business Combination), including with respect to vesting and termination-related provisions, as adjusted by the Base Exchange Ratio. In addition, at the Effective Time, each holder of an OmniAb Equity Award will be issued a number of Earnout Shares equal to the product of the number of shares of OmniAb Common Stock subject to the OmniAb Equity Award multiplied by the Earnout Exchange Ratio, which Earnout Shares will be subject to the restrictions set forth in the Merger Agreement. See &#8220;<i style="font-style:italic;">Executive and Director Compensation&#8212;Narrative to Summary Compensation Table &#8212; Treatment of Outstanding Equity Awards at the Time of the Distribution</i>&#8221; for additional details.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Severance and Change in Control Arrangements</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Ligand maintains a severance plan and has entered into change in control severance agreements with OmniAb&#8217;s executive officers, which agreements provide each executive officer with severance protections. In connection with the Business Combination, we expect to adopt a severance plan and enter into change in control severance agreements with certain of New OmniAb&#8217;s executive officers, including the named executive officers, on substantially the same terms as the Ligand arrangements. See &#8220;&#8212;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Executive and Director Compensation&#8212;Narrative to Summary Compensation Table&#8212;Severance and Change in Control Arrangements</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; for additional details.</span></td></tr></table></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Director Compensation Program</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> In connection with the Business Combination, we expect to adopt a non-employee director compensation policy that will provide for annual cash retainer fees and initial and annual stock option and RSU awards for our non-employee directors. See &#8220;&#8212;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Executive and Director Compensation&#8212;Director Compensation</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; for additional details.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">CFO Offer Letter</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> In connection with his commencement of employment as the Executive Vice President, Finance and Chief Financial Officer of OmniAb, Ligand and OmniAb entered into an amended employment offer letter with Kurt Gustafson, dated February&#160;9, 2022. Pursuant to the offer letter, Mr.&#160;Gustafson is eligible to receive an initial base salary of $440,000, a one-time sign-on bonus of $50,000, a target bonus opportunity equal to 40% of his base salary, an equity award comprised of Ligand stock options vesting over four&#160;years and Ligand RSU awards vesting over three&#160;years, and eligibility to participate in company-sponsored benefits. Mr.&#160;Gustafson&#8217;s employment is at-will. Mr.&#160;Gustafson&#8217;s Ligand RSU awards were granted under the 2002 Plan, and Mr.&#160;Gustafson&#8217;s Ligand options were granted as a standalone &#8220;employment inducement&#8221; award within the meaning of Nasdaq Stock Market Rule&#160;5635(c)(4)&#160;(the &#8220;Gustafson Inducement Award&#8221;). Pursuant to the Employee Matters Agreement, Mr.&#160;Gustafson&#8217;s Ligand stock options and Ligand RSU awards will convert solely into OmniAb stock options and OmniAb RSU awards in connection with the Distribution. Pursuant to his offer letter, if Mr.&#160;Gustafson&#8217;s employment is terminated without cause prior to the Distribution (and such termination occurs prior to a change in control), Mr.&#160;Gustafson will be eligible to receive the following payments and benefits in lieu of any severance benefits to which he may be entitled under any severance plan or policy maintained by Ligand or OmniAb: (i)&#160;his&#160;monthly base salary for 12&#160;months following the date of termination; (ii)&#160;an amount equal to his maximum target bonus for the fiscal&#160;year in which the termination occurs; (iii)&#160;an amount equal to 12 multiplied by the&#160;monthly premium he would be required to pay for continued health coverage for himself and his eligible dependents; and (iv)&#160;accelerated vesting of all of his outstanding stock awards and extension of the post-termination exercise period for such awards to the nine-month period following the date of termination. The foregoing severance amounts are subject to Mr.&#160;Gustafson&#8217;s execution of a general release of claims acceptable to Ligand and continued compliance with the proprietary information and inventions agreement, and will be payable with respect to items (i)-(iii)&#160;in a lump sum following his termination of employment. Upon a termination of Mr.&#160;Gustafson&#8217;s employment without cause or for good reason within 24&#160;months following a change in control, Mr.&#160;Gustafson will be eligible to receive severance benefits in accordance with a change in control severance agreement to be entered into with Mr.&#160;Gustafson, which will contain substantially the same terms as the corresponding Ligand agreements discussed above. Mr.&#160;Gustafson will also be eligible to participate in our severance plan. See &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Executive and Director Compensation&#8212;Narrative to Summary Compensation Table&#8212;Gustafson Offer Letter</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; for additional details.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recommendation to Shareholders of APAC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The APAC Board believes that the Business Combination Proposal and the other proposals to be presented at the extraordinary general meeting are in the best interest of APAC&#8217;s shareholders and unanimously recommends that its shareholders vote &#8220;FOR&#8221; the Business Combination Proposal, &#8220;FOR&#8221; the Domestication Proposal, &#8220;FOR&#8221; the Non-Binding Governance Proposals, &#8220;FOR&#8221; the Stock Issuance Proposal, &#8220;FOR&#8221; the Organizational Documents Proposal, &#8220;FOR&#8221; the Director Election Proposal, &#8220;FOR&#8221; the Incentive Plan Proposal, &#8220;FOR&#8221; the ESPP Proposal, and &#8220;FOR&#8221; the Adjournment Proposal, in each case, if presented to the extraordinary general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The existence of financial and personal interests of one or more of APAC&#8217;s directors may result in a conflict of interest on the part of such director(s)&#160;between what he, she or they may believe is in the best interests of APAC and its shareholders and what he, she or they may believe is best for himself, herself or themselves in determining to recommend that shareholders vote for the proposals. In addition, APAC&#8217;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#8201;&#8212;&#8201;Interests of APAC&#8217;s Directors and Executive Officers in the Business Combination</i>&#8221; for a further discussion of these considerations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Sources and Uses of Funds for the Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The following table summarizes the sources and uses for funding the Business Combination. These figures assume (a)&#160;that no public shareholders exercise their redemption rights in connection with the Business Combination, (b) that Ligand contributes to </p></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">OmniAb $15,000,000 (less certain transaction and other expenses) and (c)&#160;that New OmniAb issues 1,500,000 shares of New OmniAb Common Stock to the Sponsor pursuant to the Forward Purchase.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;width:55.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Sources</b></p></td><td style="vertical-align:bottom;width:2.36%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="4" style="vertical-align:bottom;width:41.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Uses</b></p></td><td style="vertical-align:bottom;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:40.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash and investments held in trust account (1)</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">235,750,000</p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:28.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash to balance sheet</p></td><td style="vertical-align:bottom;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">237,525,000</p></td><td style="vertical-align:bottom;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Ligand Contribution(2)</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">15,000,000</p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred Underwriting Fee</p></td><td style="vertical-align:bottom;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">8,050,000</p></td><td style="vertical-align:bottom;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Forward Purchase (3)</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">15,000,000</p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:28.34%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Transaction and Other Expenses (4)</p></td><td style="vertical-align:bottom;width:2.25%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">20,175,000</p></td><td style="vertical-align:bottom;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Total sources</b></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.74%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">265,750,000</p></td><td style="vertical-align:bottom;width:2.36%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:28.34%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Total uses</b></p></td><td style="vertical-align:bottom;width:2.25%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.48%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.25%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">265,750,000</p></td><td style="vertical-align:bottom;width:0.46%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Calculated as of December&#160;31, 2021.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The amount will be reduced by certain transaction and other expenses.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shares issued in the Forward Purchase are at a deemed value of $10.00 per share.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This amount assumes (i) $8.775 million in expenses for OmniAb, (ii) $8.0 million expenses for APAC and (iii) $3.4 million in expenses for Ligand.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table also summarizes the sources and uses for funding the Business Combination, assuming that (a) all the public shareholders exercise their redemption rights in connection with the Business Combination, (b) that Ligand contributes to OmniAb $15,000,000 (less certain transaction and other expenses), (c) New OmniAb issues 1,500,000 shares of New OmniAb Common Stock to the Sponsor pursuant to the Forward Purchase, and (d) New OmniAb issues 10,000,000 shares of New OmniAb Common Stock to the Sponsor pursuant to the Redemption Backstop. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:29.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;width:53.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Sources</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:43.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Uses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.74%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash and investments held in trust account(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:29.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash to balance sheet</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">101,775,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Ligand Contribution(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">15,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:29.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred Underwriting Fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">8,050,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Forward Purchase (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">15,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:29.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Transaction and Other Expenses(5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">20,175,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Redemption Backstop(4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">100,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total sources</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.91%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">130,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:29.75%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Total uses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.91%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">130,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">(1) APAC Class A Ordinary Shares are estimated to be redeemed at $10.25 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">(2) The amount will be reduced by certain transaction and other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">(3) Shares issued in the Forward Purchase are at a deemed value of $10.00 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">(4) Shares issued in the Redemption Backstop are at a deemed value of $10.00 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">(5) This amount assumes (i) $8.775 million in expenses for OmniAb, (ii) $8.0 million in expenses for APAC and (iii) $3.4 million in expenses for Ligand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Material U.S. Federal Income Tax Consequences</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a discussion summarizing the material U.S. federal income tax consequences of the Domestication and exercise of redemption rights, please see &#8220;<i style="font-style:italic;">Material U.S. Federal Income Tax Consequences to APAC Shareholders</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a discussion summarizing the material U.S. federal income tax consequences of the Distribution and the Merger to Ligand stockholders, please see &#8220;<i style="font-style:italic;">Material U.S. Federal Income Tax Consequences to Ligand Stockholders of the Distribution and Merger.</i>&#8221;</p></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Expected Accounting Treatment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Domestication</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There will be no accounting effect or change in the carrying amount of the consolidated assets and liabilities of APAC as a result of the Domestication. The business, capitalization, assets and liabilities and financial statements of APAC immediately following the Domestication will be the same as those of APAC immediately prior to the Domestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Business Combination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect the Business Combination to be accounted for as a &#8220;reverse recapitalization&#8221; in accordance with GAAP. Under the guidance in ASC 805, APAC is expected to be treated as the &#8220;acquired&#8221; company for financial reporting purposes. Accordingly, the Business Combination is expected to be reflected as the equivalent of OmniAb issuing stock for the net assets of APAC, accompanied by a recapitalization whereby no goodwill or other intangible assets are recorded. Operations prior to the Business Combination will be those of OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb has been determined to be the accounting acquirer in the Business Combination based on the following predominate factors:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb&#8217;s existing stockholders will have the greatest voting interest in the combined entity under the no redemption and maximum redemption scenarios with over 75% of the voting interest in each scenario;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb will have the ability to nominate a majority of the initial members of the New OmniAb Board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb&#8217;s senior management will be the senior management of the combined entity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb is the larger entity based on historical operating activity and has the larger employee base; and</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the post-combination company will assume an OmniAb branded name: &#8220;OmniAb, Inc.&#8221;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><a id="_62b0f5b7_6910_45bd_9542_cfeb58da5980"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SUMMARY UNAUDITED PRO FORMA</b></p><a id="Main_SUMMARYUNAUDITEDPROFORMA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONDENSED COMBINED FINANCIAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following summary unaudited pro forma condensed combined financial data (the &#8220;summary pro forma data&#8221;) gives effect to the Business Combination described in the section entitled &#8220;<i style="font-style:italic;">Unaudited Pro Forma Condensed Combined Financial Information of APAC and OmniAb</i>.&#8221; The Business Combination is expected to be accounted for as a reverse recapitalization in accordance with GAAP, whereby APAC is treated as the acquired company and OmniAb is treated as the acquirer. Accordingly, for accounting purposes, the Business Combination will be treated as the equivalent of OmniAb issuing stock for the net assets of APAC, accompanied by a recapitalization. The net assets of APAC will be stated at historical cost, with no goodwill or other intangible assets recorded. Subsequently, results of operations presented for the period prior to the Business Combination will be those of OmniAb. The summary unaudited pro forma condensed combined balance sheet data as of December&#160;31, 2021 gives the pro forma effect to the Business Combination as if it had occurred on December&#160;31, 2021. The summary unaudited pro forma condensed combined statement of operations data for the&#160;year ended December&#160;31, 2021 give the pro forma effect to the Business Combination as if it had been consummated on January&#160;1, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The summary pro forma data has been derived from, and should be read in conjunction with, the unaudited pro forma condensed combined financial information of the combined company appearing elsewhere in this proxy statement/prospectus/information statement and the accompanying notes. The unaudited pro forma condensed combined financial information is based upon, and should be read in conjunction with, the historical consolidated financial statements of OmniAb and APAC and related notes included in this proxy statement/prospectus/information statement. The summary pro forma data has been presented for informational purposes only and is not necessarily indicative of what the combined company&#8217;s financial position or results of operations actually would have been had the Business Combination been completed as of the dates indicated. In addition, the summary pro forma data does not purport to project the future financial position or operating results of the combined company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table presents summary pro forma data after giving effect to the Business Combination, assuming two redemption scenarios as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Assuming No Redemptions:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> This presentation assumes that none of the holders of APAC&#8217;s Class&#160;A Ordinary Shares will exercise redemption rights with respect to their public shares; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Assuming Maximum Redemptions:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> This presentation assumes that holders of 23,000,000 APAC Class&#160;A Ordinary Shares will exercise redemption rights with respect to their public shares for their pro rata share (approximately $10.25 per share) of the funds in the Trust Account, and APAC has received $100,000,000 from the Sponsor as of Closing for the Redemption Backstop pursuant to the A&amp;R FPA.</span></td></tr></table><div style="margin-top:12pt;"><a id="_Hlk101150961"></a></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pro Forma Combined</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pro Forma Combined</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Assuming No</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Assuming Maximum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Redemptions)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:16.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Redemptions)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:36.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Summary Unaudited Pro Forma Condensed Combined</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Statement of Operations Data For The Year Ended December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Revenue</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">34,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:14.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">34,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Operating expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">70,827</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">70,827</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Loss from operations</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(36,079)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:14.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(36,079)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(33,523)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(33,523)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Basic and diluted net loss per share</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(0.30)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:14.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(0.34)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Basic and diluted weighted average shares outstanding</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">110,765,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">98,483,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Selected Unaudited Pro Forma Condensed Combined</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-weight:bold;letter-spacing:-0.2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Balance Sheet Data as of December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Total assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">542,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">407,175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Total liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">70,596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:14.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">70,596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Total stockholders&#8217; equity</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">472,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">336,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 4.24% 0pt 4.24%;padding:10pt 1.63% 10pt 1.63%;"><div style="clear:both;max-width:100%;position:relative;"><a id="_60517e74_e724_43fa_9098_ca0b038eaf5d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Regulatory Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the HSR Act and the rules that have been promulgated thereunder by the Federal Trade Commission (&#8220;FTC&#8221;), certain transactions may not be consummated unless information has been furnished to the Antitrust Division of the Department of Justice (&#8220;Antitrust Division&#8221;) and the FTC and certain waiting period requirements have been satisfied. The Business Combination is subject to these requirements and may not be completed until the expiration of a 30-day waiting period following the filing of the required Notification and Report Form by each Party with the Antitrust Division and the FTC. If the FTC or the Antitrust Division issues a Request for Additional Information and Document Materials (a &#8220;Second Request&#8221;) within the initial 30-day waiting period, the waiting period with respect to the Transactions will be extended for an additional period of 30 calendar days, which will begin on the date on which the filing parties each certify compliance with the Second Request. On April 6, 2022, APAC and OmniAb filed their respective required forms under the HSR Act with respect to the Business Combination with the Antitrust Division and the FTC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">At any time before or after consummation of the Business Combination, notwithstanding termination of the respective waiting periods under the HSR Act, the Department of Justice or the FTC, or any state or foreign governmental authority could take such action under applicable antitrust laws as such authority deems necessary or desirable in the public interest, including seeking to enjoin the consummation of the Business Combination, conditionally approving the Business Combination upon divestiture of assets, subjecting the completion of the Business Combination to regulatory conditions or seeking other remedies. Private parties may also seek to take legal action under the antitrust laws under certain circumstances. APAC cannot assure you that the Antitrust Division, the FTC, any state attorney general or any other government authority will not attempt to challenge the Business Combination on antitrust grounds, and, if such a challenge is made, APAC cannot assure you as to its result.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Neither APAC nor OmniAb is aware of any material regulatory approvals or actions that are required for completion of the Business Combination other than the expiration of the waiting period under the HSR Act. It is presently contemplated that if any such additional regulatory approvals or actions are required, those approvals or actions will be sought. There can be no assurance, however, that any additional approvals or actions will be obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Emerging Growth Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">APAC is an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in APAC&#8217;s periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Further, section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. APAC has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, APAC, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of APAC&#8217;s financial statements with certain other public companies difficult or impossible because of the potential differences in accounting standards used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We will remain an emerging growth company until the earlier of: (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of APAC&#8217;s initial public offering, (b) in which we have total annual gross revenue of at least $1.07 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common equity that is held by non-affiliates exceeds $700 million as of the end of the prior fiscal year&#8217;s second fiscal quarter; and (2) the date on which we have issued more than $1.00 billion in non-convertible debt securities during the prior three-year period. References herein to &#8220;emerging growth company&#8221; shall have the meaning associated with it in the JOBS Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In evaluating the proposals to be presented at the APAC extraordinary general meeting, a shareholder should carefully read this proxy statement/prospectus/information statement and especially consider the factors discussed in the section entitled &#8220;<i style="font-style:italic;">Risk Factors</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div></div><div style="margin-left:4.24%;margin-right:4.24%;max-width:100%;padding-left:1.63%;padding-right:1.63%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.5%;border:0;margin:30pt 4.25% 30pt 4.25%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_dde6e9b0_27cb_439c_91e0_ff15364293c5"></a><a id="MARKETPRICEANDDIVIDENDINFORMATION_903286"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MARKET PRICE AND DIVIDEND INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">APAC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Market Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC Units began trading on Nasdaq on August 10, 2021. Each APAC Unit consists of one Class A ordinary share and one-third of one redeemable warrant to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment. On September 27, 2021, APAC announced that holders of APAC Units could elect to separately trade the Class A ordinary shares and redeemable warrants included in the APAC Units on September 30, 2021. Any APAC Units not separated continue to trade on Nasdaq under the symbol &#8220;AHPAU.&#8221; Any underlying Class A ordinary shares and warrants that were separated trade on Nasdaq under the symbols &#8220;AHPA&#8221; and &#8220;AHPAW,&#8221; respectively. Each warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment as described in APAC&#8217;s final prospectus dated August 9, 2021, which was filed with the SEC on August 11, 2021. Only whole warrants may be exercised for Class A ordinary shares and will become exercisable on the later of 30 days after the completion of the Business Combination or 12 months after the initial public offering closing date. APAC&#8217;s warrants expire five years after the completion of the Business Combination or earlier upon redemption or liquidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Holders</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 27, 2022, there was one holder of record of APAC Units, one holder of record of APAC&#8217;s separately traded Class A ordinary shares, two holders of record of APAC&#8217;s warrants and four holders of record of APAC&#8217;s Class B ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC has not paid any cash dividends on its Class A ordinary shares to date and does not intend to pay cash dividends prior to the completion of the Business Combination. The payment of cash dividends in the future will be dependent upon APAC&#8217;s revenues and earnings, if any, capital requirements and general financial condition subsequent to completion of the Business Combination. The payment of any cash dividends subsequent to the Business Combination will be within the discretion of the APAC Board. In addition, the APAC Board is not currently contemplating and does not anticipate declaring stock dividends in the foreseeable future. Further, if APAC incurs any indebtedness in connection with the Business Combination, APAC&#8217;s ability to declare dividends may be limited by restrictive covenants it may agree to in connection therewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OmniAb</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Summary Historical Market Price</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Historical market price data for OmniAb does not exist, as OmniAb currently is a wholly-owned subsidiary of Ligand. As such, shares of OmniAb Common Stock are not currently listed on a public stock exchange and are not publicly traded. Therefore, no market data is available for OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7c5ed3fe_9d2c_4d9c_98af_620452f65a36"></a><a id="MAin_UNAUDITEDPROFORMACONDENSEDCOMBI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF APAC AND OMNIAB</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following unaudited pro forma condensed combined financial information presents the combination of the financial information of OmniAb and APAC adjusted to give effect to the Business Combination. The following unaudited pro forma condensed combined financial information has been prepared in accordance with Article&#160;11 of Regulation S-X.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC is a blank check company incorporated in the Cayman Islands on February&#160;5, 2021. APAC was incorporated for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. APAC has neither engaged in any operations nor generated any revenue to date. On August&#160;12, 2021, APAC consummated its initial public offering of 23,000,000 units at $10.00 per unit, generating gross proceeds of $230,000,000. Simultaneously with the closing of the initial public offering, APAC consummated the sale of 8,233,333 warrants at a price of $1.50 per warrant to the Sponsor, generating proceeds of approximately $12,350,000. Upon the closing of the initial public offering and the sale of the private placement warrants, an amount equal to $235,750,000 was placed in a Trust Account. The Trust Account may be invested only in U.S. government securities with a maturity of 185&#160;days or less or in money market funds meeting certain conditions under Rule&#160;2a-7 under the Investment Company Act of 1940, as amended, which invest only in direct U.S. government obligations. As of December&#160;31, 2021, funds in the Trust Account totaled approximately $235,750,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb is a biotechnology company with a Biological Intelligence powered multi-species antibody platform for the discovery of mono and bispecific therapeutic human antibodies. OmniAb primarily derives revenue from license fees for technology access, milestones from partnered programs and service revenue from research programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined balance sheet as of December&#160;31, 2021 combines the historical balance sheets of OmniAb and APAC on a pro forma basis as if the Business Combination had been consummated on December&#160;31, 2021. The unaudited pro forma condensed combined statements of operations for the&#160;year ended December&#160;31, 2021 combine the historical statements of operations of OmniAb and APAC for such period on a pro forma basis as if the Business Combination had been consummated on January&#160;1, 2021, the beginning of the earliest period presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The pro forma condensed combined financial information may not be useful in predicting the future financial condition and results of operations of the post-combination company. The actual financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The information should be read together with the accompanying notes to the unaudited pro forma condensed combined financial statements, audited financial statements of OmniAb and APAC included in this proxy statement/ prospectus/ information statement, the sections titled <i style="font-style:italic;">&#8220;OmniAb&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;</i> and <i style="font-style:italic;">&#8220;APAC&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221;</i> and other information relating to OmniAb and APAC contained in this proxy statement/ prospectus/ information statement, including the Merger Agreement and the description of certain terms thereof set forth in the section entitled <i style="font-style:italic;">&#8220;Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal</i>.<i style="font-style:italic;">&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Business Combination is expected to be accounted for as a reverse recapitalization in accordance with GAAP, whereby APAC is treated as the acquired company and OmniAb is treated as the acquirer. Accordingly, for accounting purposes, the Business Combination will be treated as the equivalent of OmniAb issuing stock for the net assets of APAC, accompanied by a recapitalization. The net assets of APAC will be stated at historical cost, with no goodwill or other intangible assets recorded. Subsequent presentations of the results of operations presented for the period prior to the Business Combination will be for those of OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb has been determined to be the accounting acquirer in the Business Combination based on the following predominate factors:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb&#8217;s existing stockholders will have the greatest voting interest in the combined entity under the no redemption and maximum redemption scenarios with over 75% of the voting interest in each scenario;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb will have the ability to nominate a majority of the initial members of the New OmniAb Board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb&#8217;s senior management will be the senior management of the combined entity;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb is the larger entity based on historical operating activity and has the larger employee base; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The post-combination company will assume an OmniAb branded name: &#8220;OmniAb,&#160;Inc.&#8221;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Cayman Constitutional Documents, APAC&#8217;s public shareholders may request that APAC redeem all or a portion of such shareholder&#8217;s public shares for cash equal to their pro rata share of the aggregate amount on deposit (as of two business&#160;days prior to the Closing) in the Trust Account if the Business Combination is consummated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined financial statements present two redemption scenarios as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Assuming No Redemptions:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> This presentation assumes that none of the holders of APAC&#8217;s Class&#160;A Ordinary Shares will exercise redemption rights with respect to their public shares; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Assuming Maximum Redemptions:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> This presentation assumes that holders of 23,000,000 APAC Class&#160;A Ordinary Shares will exercise redemption rights with respect to their public shares for their pro rata share (approximately $10.25 per share) of the funds in the Trust Account, and APAC has received $100,000,000 from the Sponsor as of Closing for the Redemption Backstop pursuant to the A&amp;R FPA.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Description of the Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Business Combination will be accomplished by way of the following transaction steps:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Domestication will be effected, whereby APAC&#8217;s jurisdiction of incorporation will be changed by its deregistering as an exempted company in the Cayman Islands and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware at least one (1)&#160;business day prior to the consummation of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Separation will be effected, whereby Ligand will, among other things and subject to the terms and conditions of the Separation Agreement, transfer the OmniAb Business, including certain related subsidiaries of Ligand, to OmniAb and make a contribution to the capital of OmniAb of $15,000,000 less certain transaction and other expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Distribution will be effected, whereby Ligand will distribute to Ligand stockholders 100% of the OmniAb Common Stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to the Employee Matters Agreement, at the time of the Distribution, each existing Ligand equity award, with certain limited exceptions, will be split into (i)&#160;a new Ligand equity award and (ii)&#160;a new OmniAb Equity Award, with any accrued value in the original Ligand equity award split between such awards based on the relative post-closing values of Ligand and OmniAb;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to the A&amp;R FPA, OmniAb, New OmniAb and the Sponsor will effect the Forward Purchase, whereby New OmniAb will issue and sell to the Sponsor 1,500,000 shares of New OmniAb Common Stock and warrants to acquire 1,666,667 shares of New OmniAb Common Stock for an aggregate purchase price of $15,000,000, with such purchases to be consummated following the Domestication and prior to the Merger. In addition to the Forward Purchase, the Sponsor has agreed to effect the Redemption Backstop (to the extent necessary), whereby the Sponsor will purchase up to an additional 10,000,000 shares of New OmniAb Common Stock and up to an additional 1,666,667 New OmniAb Warrants, for an aggregate additional purchase price of up to $100,000,000, in order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds to be available to the combined company following the Business Combination from APAC&#8217;s trust account to be less than $100,000,000; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Following the above steps, the Merger will be effected, whereby Merger Sub will merge with and into OmniAb, with OmniAb continuing as the surviving company in the Merger and a wholly-owned subsidiary of New OmniAb. In addition, in connection with the consummation of the Merger and prior to the consummation of the Domestication, the surviving company will be renamed &#8220;OmniAb Operations,&#160;Inc.&#8221;</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of the Merger, the existing shares of OmniAb Common Stock will automatically convert into the right to receive shares of New OmniAb Common Stock in accordance with an exchange ratio described elsewhere in this proxy statement/prospectus/information statement. The total number of shares of New OmniAb Common Stock to be received by OmniAb&#8217;s stockholders (as of immediately after consummation of the Distribution) or reserved for issuance pursuant to the New OmniAb Equity Awards into which OmniAb Equity Awards are to be converted will be equal to the Aggregate Merger Consideration. In addition to the Aggregate Merger Consideration, holders of OmniAb Common Stock and OmniAb Equity Awards will also receive earnout consideration in the form of an additional 15,000,000 OmniAb Earnout Shares, with 50% of such earnout shares vesting upon the achievement of a post-transaction VWAP of $12.50 per share of New OmniAb Common Stock for any 20 trading&#160;days over a consecutive 30 trading-day period, and the remainder vesting upon achievement of a post-transaction VWAP of $15.00 per share of New OmniAb Common Stock for any 20 trading&#160;days over a consecutive 30 trading-day period, in each case provided such vesting occurs during the five-year period following the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For more information about the Business Combination, please see the section titled <i style="font-style:italic;">&#8220;Shareholder Proposal No.&#160;1: The Business Combination Proposal.&#8221;</i> A copy of the Merger Agreement is attached to the accompanying proxy statement/prospectus/information statement as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex A</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following summarizes the pro forma capitalization of the post-combination company expected immediately following the Closing, presented under the two redemption scenarios:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:25.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assuming&#160;No&#160;Redemptions</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:22.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assuming&#160;Maximum&#160;Redemptions</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.22%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">%</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:10.34%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:10.37%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">APAC&#8217;s public shareholders</p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">23,000,000</p></td><td style="vertical-align:bottom;white-space:normal;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">18.0</p></td><td style="vertical-align:bottom;white-space:normal;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:10.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.37%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Sponsor and related parties <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)(2)</sup></p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">7,250,000</p></td><td style="vertical-align:bottom;white-space:normal;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">5.7</p></td><td style="vertical-align:bottom;white-space:normal;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">17,250,000</p></td><td style="vertical-align:bottom;white-space:normal;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">15.0</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">OmniAb (Ligand) stockholders <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">97,431,885</p></td><td style="vertical-align:bottom;white-space:normal;width:2.22%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">76.3</p></td><td style="vertical-align:bottom;white-space:normal;width:2.08%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:10.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">97,431,885</p></td><td style="vertical-align:bottom;white-space:normal;width:2.08%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">85.0</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Pro Forma Common Stock </b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(4)(5)</sup></p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.13%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">127,681,885</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.22%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">100.0</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.08%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">%</b></p></td><td style="vertical-align:bottom;width:10.34%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">114,681,885</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.08%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.37%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">100.0</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes 1,916,667 Sponsor Earnout Shares in the no redemption scenario and 1,197,917 Sponsor Earnout Shares in the maximum redemption scenario. The Sponsor Earnout Shares were included in the pro forma capitalization as, during the Earnout Period, holders of the Sponsor Earnout Shares are entitled to vote such Sponsor Earnout Shares and receive dividends and other distributions in respect thereof, pursuant to the Sponsor Insider Agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to the A&amp;R FPA, includes 1,500,000 shares of New OmniAb Common Stock purchased by the Sponsor in the Forward Purchase in the no redemption and maximum redemption scenarios and 10,000,000 shares of New OmniAb Common Stock purchased by the Sponsor in the Redemption Backstop in the maximum redemption scenario.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes 15,000,000 OmniAb Earnout Shares as, during the Earnout Period, OmniAb Earnout Shares are entitled to exercise the voting rights carried by such OmniAb Earnout Shares and receive any dividends or other distributions in respect of such OmniAb Earnout Shares.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The pro forma capitalization excludes the following:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10,636,952 unexercised OmniAb stock options</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">793,628 OmniAb RSUs and OmniAb PSUs</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7,666,667 unexercised APAC Public Warrants</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8,233,333 unexercised APAC Private Placement Warrants</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,666,667 unexercised APAC Warrants issued in the Forward Purchase</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,666,667 unexercised APAC Warrants issued in the Backstop Redemption in the maximum redemption scenario</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If all of the Sponsor&#8217;s APAC Warrants are exercised, which include the 8,233,333 APAC Private Placement Warrants, the 1,666,667 APAC Warrants issued in the Forward Purchase and the 1,666,667 APAC Warrants issued in the Backstop Redemption in the maximum redemption scenario, Sponsor would own approximately 12.5% of the shares of New OmniAb in the no redemption scenario, or approximately 22.8% of the shares of New OmniAb in the maximum redemptions scenario.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assumptions and estimates underlying the unaudited pro forma adjustments included in the unaudited pro forma condensed combined financial statements are described in the accompanying notes. The unaudited pro forma condensed combined financial statements have been presented for illustrative purposes only and are not necessarily indicative of the operating results and financial position that would have been achieved had the Business Combination occurred on the dates indicated. Further, the unaudited pro forma condensed combined financial statements do not purport to project the future operating results or financial position of the post-combination company following the completion of the Business Combination. The unaudited pro forma adjustments represent management&#8217;s estimates based on information available as of the date on which these unaudited pro forma condensed combined financial statements are prepared and are subject to change as additional information becomes available and analyses are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b2be9cd6_9b0e_448b_abe4_de088c934e9e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS OF DECEMBER&#160;31, 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Transaction</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Transaction</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Accounting</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Accounting</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Pro&#160;Forma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Pro&#160;Forma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">(Assuming</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Combined</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">(Assuming&#160;No</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Combined</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Maximum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">(Assuming</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">OmniAb</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">APAC</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Redemptions)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">(Assuming&#160;No</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Redemptions)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Maximum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">(Historical)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">(Historical)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">(Note&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Redemptions)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">(Note&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.15pt;">Redemptions)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Cash and cash equivalents</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">11,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(a)</p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">237,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">(235,750)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(j)</p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">101,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">235,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(b)</p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(k)</p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">(8,050)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(c)</p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">(16,775)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(d)</p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">15,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(e)</p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Accounts receivable, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">21,136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">21,136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">21,136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Other current assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,406</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">22,542</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">935</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">237,525</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">261,002</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">(135,750)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">125,252</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Cash held in Trust Account</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">235,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">(235,750)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(b)</p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Intangible assets, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">176,321</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">176,321</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">176,321</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Goodwill</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">83,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">83,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">83,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Opearating lease assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">13,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">13,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">13,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Other assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">304,465</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">236,685</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">1,775</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">542,925</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">(135,750)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">407,175</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,924</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Accrued liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">423</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">4,169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">4,169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Current portion of contingent liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Current portion of deferred revenue</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">10,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">10,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">10,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Current portion of operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Current portion of finance lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">20,577</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">438</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">21,015</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">21,015</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Long-term contingent liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">4,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">4,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">4,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Deferred underwriting fee payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">8,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">(8,050)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(c)</p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Deferred income taxes, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">21,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">21,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">21,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Long-term operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">13,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">13,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">13,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Long-term portion of deferred revenue</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">9,226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">9,226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">9,226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Other long-term liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">70,158</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">8,488</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">(8,050)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">70,596</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">70,596</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Commitments and contingencies</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Class A ordinary shares subject</span> <span style="letter-spacing:0.2pt;">to possible redemption</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">235,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">(235,750)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(f)</p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Preference shares</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Ordinary shares</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Class A</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(f)</p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:7pt;letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(g)</p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Class B</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(g)</p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Parent company net</span> <span style="letter-spacing:0.2pt;">investment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">234,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">11,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(a)</p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:7pt;letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">(245,907)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(h)</p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">New OmniAb Common</span> <span style="letter-spacing:0.2pt;">Stock</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(e)</p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(j)</p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:7pt;letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(g)</p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(k)</p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:7pt;letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(h)</p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Additional paid-in capital</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">(8,775)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(d)</p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">472,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">(235,748)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(j)</p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">336,567</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:7pt;letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">235,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(f)</p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">99,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(k)</p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:7pt;letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">15,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(e)</p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:7pt;letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">245,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(h)</p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:7pt;letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">(15,554)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(i)</p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Accumulated deficit</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">(7,554)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">(8,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(d)</p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:7pt;letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">15,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(i)</p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Total stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">234,307</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.6%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">(7,553)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">245,575</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.84%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">472,329</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">(135,750)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.7%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">336,579</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Total liabilities and stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.01%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">304,465</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:7.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">236,685</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">1,775</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:8.84%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">542,925</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">(135,750)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:8.7%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">407,175</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1e9928e6_186d_4f2e_989d_36e3c6667cc1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">FOR THE&#160;YEAR ENDED DECEMBER&#160;31, 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk101164109"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">February&#160;5, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(inception)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">through</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.88%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accounting</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accounting</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pro Forma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pro Forma</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Combined</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Assuming</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Combined</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Assuming No</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Assuming</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maximum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Assuming</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">OmniAb</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">APAC</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Redemptions)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">No</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Redemptions)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maximum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Historical)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Historical)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (Note 3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Redemptions)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Note 3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Redemptions)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Revenues:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">License and milestone revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">14,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">14,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">14,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Service revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">20,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">20,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">20,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">34,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">34,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">34,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expense:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">39,232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">39,232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">39,232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">16,947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">516</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(46)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(aa)</p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">17,417</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">17,417</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Amortization of intangibles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">12,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">12,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">12,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other operating expense&#8201;&#8211;&#8201;net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">70,357</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">516</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">(46)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">70,827</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">70,827</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">(35,609)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">(516)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">46</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">(36,079)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">(36,079)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(8,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(bb)</p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(6,734)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(6,734)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(8,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(6,741)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(6,741)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(34,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(516)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(7,954)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(42,820)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(42,820)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Income tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">7,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(cc)</p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">9,297</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">9,297</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">(27,042)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">(516)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">(5,965)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">(33,523)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">(33,523)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:8pt;text-indent:-8pt;margin:0pt;">Basic and diluted weighted average shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">15,178,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">95,586,646</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(dd)</p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">110,765,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(12,281,250)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(ee)</p></td><td style="vertical-align:bottom;width:1.04%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">98,483,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:8pt;text-indent:-8pt;margin:0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(0.03)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(0.30)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(0.34)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_06b819d3_a351_4c7b_a510_f34ecdcf63a9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES&#160;TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></span><b style="font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Business Combination is expected to be accounted for as a reverse recapitalization in accordance with GAAP, whereby APAC is treated as the acquired company and OmniAb is treated as the acquirer. Accordingly, for accounting purposes, the Business Combination is expected to be treated as the equivalent of OmniAb issuing stock for the net assets of APAC, accompanied by a recapitalization. The net assets of APAC will be stated at historical cost, with no goodwill or other intangible assets recorded. Subsequently, results of operations presented for the period prior to the Business Combination will be those of OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined balance sheet as of December&#160;31, 2021 gives pro forma effect to the Business Combination as if it had been consummated on December&#160;31, 2021. The unaudited pro forma condensed combined statement of operations for the&#160;year ended December&#160;31, 2021 give pro forma effect to the Business Combination as if it had been consummated on January&#160;1, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined balance sheet as of December&#160;31, 2021 has been prepared using, and should be read in conjunction with, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb&#8217;s audited combined balance sheet as of December&#160;31, 2021 and the related notes included elsewhere in this proxy statement/ prospectus/ information statement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC&#8217;s audited balance sheet as of December&#160;31, 2021 and the related notes included elsewhere in this proxy statement/ prospectus/ information statement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined statement of operations for the&#160;year ended December&#160;31, 2021 has been prepared using, and should be read in conjunction with, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb&#8217;s audited combined statement of operations for the&#160;year ended December&#160;31, 2021 and the related notes included elsewhere in this proxy statement/ prospectus/ information statement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC&#8217;s audited statement of operations for the period from February&#160;5, 2021 (inception) through December&#160;31, 2021 and the related notes included elsewhere in this proxy statement/ prospectus/ information statement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management has made significant estimates and assumptions in its determination of the pro forma adjustments. As the unaudited pro forma condensed combined financial information has been prepared based on these preliminary estimates, the final amounts recorded may differ materially from the information presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined financial information does not give effect to any synergies, operating efficiencies, tax savings or cost savings that may be associated with the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The pro forma adjustments reflecting the completion of the Business Combination are based on currently available information and assumptions and methodologies that management believes are reasonable under the circumstances. The unaudited condensed pro forma adjustments, which are described in the accompanying notes, may be revised as additional information becomes available and is evaluated. Therefore, it is likely that the actual adjustments will differ from the pro forma adjustments and it is possible the difference may be material. Management believes that its assumptions and methodologies provide a reasonable basis for presenting all of the significant effects of the Business Combination based on information available to management at the current time and that the pro forma adjustments give appropriate effect to those assumptions and are properly applied in the unaudited pro forma condensed combined financial information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The unaudited pro forma condensed combined financial information is not necessarily indicative of what the actual results of operations and financial position would have been had the Business Combination taken place on the dates indicated, nor are they indicative of the future consolidated results of operations or financial position of the post-combination company. They should be read in conjunction with the historical financial statements and notes thereto of OmniAb and APAC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_097ef0d5_4756_4c36_a502_83fe477dd4ae"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></span><b style="font-weight:bold;">Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Upon consummation of the Business Combination, management will perform a comprehensive review of OmniAb&#8217;s and APAC&#8217;s accounting policies. As a result of the review, management may identify differences between the accounting policies of the two entities which, when conformed, could have a material impact on the financial statements of the post-combination company. Based on its initial analysis, management did not identify any differences that would have a material impact on the unaudited pro forma condensed combined financial information.</p><a id="_fab3eaaf_a3c1_4a3e_a584_4c17a7047cfd"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></span><b style="font-weight:bold;">Adjustments to Unaudited Pro Forma Condensed Combined Financial Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following unaudited pro forma condensed combined financial information has been prepared in accordance with Article&#160;11 of Regulation S-X. The unaudited pro forma condensed combined financial information has been prepared to illustrate the effect of the Business Combination and has been prepared for informational purposes only.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The pro forma combined provision for income taxes does not necessarily reflect the amounts that would have resulted had the post-combination company filed consolidated income tax returns during the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined consolidated statement operations does not reflect an adjustment for the Transition Services Agreement as management does not anticipate that the net costs associated with the Transition Services Agreements will be materially different than the historical costs that have been allocated by Ligand to OmniAb related to these same services. Additionally, the unaudited pro forma condensed combined financial information does not give effect to increased costs of operating OmniAb as a separate public company or support functions that OmniAb may incur following the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The pro forma basic and diluted earnings per share amounts presented in the unaudited pro forma condensed combined consolidated statement of operations are based upon the number of APAC&#8217;s shares outstanding, assuming the Business Combination occurred on January&#160;1, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transaction Accounting Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The pro forma adjustments included in the unaudited pro forma condensed combined balance sheet as of December&#160;31, 2021 are as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents Ligand&#8217;s contribution to OmniAb of $11,600,000 prior to the Distribution in accordance with the Separation and Distribution Agreement. The $11,600,000 contribution amount represents $15,000,000 less approximately $3,400,000 of certain transaction and other expenses previously incurred by Ligand, which are eligible to be offset against the contribution amount in accordance with the Separation and Distribution Agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reflects the reclassification of cash held in the Trust Account that becomes available following the Business Combination, assuming no redemptions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reflects the settlement of $8,050,000 in deferred underwriting fee payable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents preliminary estimated transaction costs expected to be incurred by OmniAb and APAC of approximately $8,775,000 and $8,000,000, respectively, for legal, financial advisory and other professional fees.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 36pt;">OmniAb&#8217;s estimated transaction costs were capitalized and offset against the proceeds from the Business Combination and reflected as a decrease in additional paid-in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 36pt;">APAC&#8217;s estimated transaction costs exclude the deferred underwriting commissions as described in Note&#160;3(c)&#160;above. APAC&#8217;s estimated transaction costs were reflected as an adjustment to accumulated deficit as of December&#160;31, 2021. The costs expensed through accumulated deficit are included in the unaudited pro forma condensed combined statement of operations for the&#160;year ended December&#160;31, 2021 as discussed in Note&#160;3(bb) below.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(e)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reflects proceeds of $15,000,000 from the issuance and sale of 1,500,000 shares of New OmniAb Common Stock, par value of $0.0001 per share, and 1,666,667 Warrants in the Forward Purchase. The APAC Warrants issued in the Forward Purchase </span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are expected to be equity classified under Financial Accounting Standards Board (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">&#8220;FASB&#8221;</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) Accounting Standards Codification (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">&#8220;ASC&#8221;</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) Topic 815-40, Derivatives and Hedging&#160;- Contracts in Entity&#8217;s Own Equity (</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">&#8220;ASC 815-40&#8221;</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(f)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reflects the reclassification of $235,750,000 of APAC Class&#160;A Ordinary Shares, par value of $0.0001 per share, subject to possible redemption to permanent equity, assuming no redemptions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(g)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reflects the conversion of 23,000,000 APAC Class&#160;A Ordinary Shares and 5,750,000 APAC Class&#160;B Ordinary Shares into 28,750,000 shares of New OmniAb Common Stock in the Domestication.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(h)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reflects the recapitalization of OmniAb&#8217;s parent company net investment into 97,431,885 shares of New OmniAb Common Stock, par value of $0.0001 per share. The shares of New OmniAb Common Stock include 82,431,885 shares of New OmniAb Common Stock issued to holders of OmniAb Common Stock and 15,000,000 OmniAb Earnout Shares. The OmniAb Earnout Shares, which will be issued and legally outstanding upon the closing of the Business Combination, are expected to be equity classified under ASC 815-40.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reflects the elimination of APAC&#8217;s historical accumulated deficit after recording the transaction costs to be incurred by APAC as described in Note&#160;3(d)&#160;above.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(j)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents the maximum redemption of 23,000,000 APAC Class&#160;A Ordinary Shares for $235,750,000 allocated to shares of New OmniAb Common Stock and additional paid-in capital using par value of $0.0001 per share and at a redemption price of $10.25 per share.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(k)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reflects proceeds of $100,000,000 from the issuance and sale of 10,000,000 shares of New OmniAb Common Stock, par value of $0.0001 per share, and 1,666,667 Warrants to the Sponsor in the Redemption Backstop. The Warrants issued in the Redemption Backstop are expected to be equity classified under ASC 815-40.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transaction Accounting Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The pro forma adjustments included in the unaudited pro forma condensed combined statements of operations for the&#160;year ended December&#160;31, 2021 are as follows:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">(aa)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Represents pro forma adjustment to eliminate historical expenses related to APAC&#8217;s administrative, financial and support services paid to the Sponsor, which will terminate upon consummation of the Business Combination.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">(bb)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Reflects preliminary estimated APAC transaction costs that will be expensed upon the closing of the Business Combination. These costs are reflected as if incurred on January&#160;1, 2021, the date the Business Combination is deemed to have occurred for the purposes of the unaudited pro forma condensed combined statement of operations. This is a non-recurring item.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><span style="color:#231f20;">(cc)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Reflects the adjustment to income tax expense as a result of the tax impact on the pro forma adjustments at the estimated combined statutory tax rate of 25.0%.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">(dd) Reflects the issuance of 82,431,885 shares of New OmniAb Common Stock to holders of OmniAb Common Stock, and an adjustment to APAC&#8217;s weighted average shares outstanding of 13,571,428 to assume APAC&#8217;s shares were outstanding since January 1, 2021, the beginning of the earliest period presented, and the issuance of 1,500,000 shares of New OmniAb Common Stock in the Forward Purchase. Excludes 1,916,667 Sponsor Earnout Shares subject to certain vesting restrictions pursuant to the Sponsor Insider Agreement and the Merger Agreement, which are considered contingently issuable shares for which the milestones have not yet been achieved. Refer to Note 4 &#8220;Loss Per Share&#8221; of this Unaudited Pro Forma Condensed Combined Financial Information for further information on the calculation of pro forma weighted average shares outstanding. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">(ee) Reflects the redemption of 23,000,000 APAC Class A Ordinary Shares, the issuance of 10,000,000 shares of New OmniAb Common Stock to the Sponsor in the Redemption Backstop, and pursuant to the Sponsor Insider Agreement, a decrease of 718,750 Sponsor Earnout Shares in the maximum redemption scenario. Refer to Note 4 &#8220;Loss Per Share&#8221; of this Unaudited Pro Forma Condensed Combined Financial Information for further information on the calculation of pro forma weighted average shares outstanding.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_d24bf7ff_a16d_4c7d_a756_bc951d9b0897"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></span><b style="font-weight:bold;">Loss per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Represents the net loss per share calculated using the historical weighted average shares outstanding, and the issuance of additional shares in connection with the Business Combination, assuming the shares were outstanding since January&#160;1, 2021. As the Business Combination is being reflected as if it had occurred at the beginning of the periods presented, the calculation of weighted average shares outstanding for basic and diluted net loss per share assumes that the shares issuable relating to the Business Combination have been outstanding for the entire period presented. When assuming maximum redemption, this calculation is adjusted to eliminate such shares for the entire period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assuming No</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assuming Maximum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Redemptions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:12.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Redemptions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Pro&#160;forma net loss (in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(33,523)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(33,523)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Pro&#160;forma weighted average shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">110,765,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">98,483,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Pro&#160;forma net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(0.30)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(0.34)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Pro&#160;forma weighted average shares calculation, basic and diluted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">APAC&#8217;s public shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">23,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sponsor &amp; related parties<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5,333,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">16,052,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">OmniAb (Ligand) stockholders<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">82,431,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">82,431,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Pro&#160;forma weighted average shares calculation, basic and diluted</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">110,765,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">98,483,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The pro forma basic and diluted shares exclude 1,916,667 Sponsor Earnout Shares in the no redemption scenario and 1,197,917 Sponsor Earnout Shares in the maximum redemption scenarios. The Sponsor Earnout Shares are subject to certain vesting restrictions pursuant to the Sponsor Insider Agreement and the Merger Agreement and are considered contingently issuable shares for which the milestones have not yet been achieved.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The pro forma basic and diluted shares includes 1,500,000 shares of New OmniAb Common Stock purchased by the Sponsor in the Forward Purchase in the no redemption and maximum redemption scenarios and 10,000,000 shares of New OmniAb Common Stock purchased by the Sponsor in the Redemption Backstop in the maximum redemption scenario.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The pro forma basic and diluted shares exclude 15,000,000 OmniAb Earnout Shares subject to certain vesting restrictions pursuant to the Merger Agreement. These Earnout Shares are considered contingently issuable shares for which the milestones have not yet been achieved.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The pro forma diluted shares exclude the following because including them would be antidilutive:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10,636,952 unexercised OmniAb stock options</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">793,628 OmniAb RSUs and OmniAb PSUs</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7,666,667 unexercised APAC Public Warrants</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8,233,333 unexercised APAC Private Placement Warrants</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,666,667 unexercised APAC Warrants issued in the Forward Purchase</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,666,667 unexercised APAC Warrants issued in the Backstop Redemption in the maximum redemption scenario</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e0c3f988_0276_420e_bfb5_d438a3fe60ba"></a><a id="Main_RISKFACTORS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RISK FACTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unless the context otherwise requires, references in this subsection &#8220;&#8212;Risk Factors&#8221; to &#8220;OmniAb,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; generally refer to OmniAb following the Business Combination.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Business of OmniAb</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should carefully consider the risks and uncertainties described below, together with the information included elsewhere in this proxy statement/prospectus/information statement. The risks and uncertainties described below are those that we have identified as material but are not the only risks and uncertainties facing us. Our business is also subject to general risks and uncertainties that affect many other companies, such as market conditions, economic conditions, geopolitical events, changes in laws, regulations or accounting rules, fluctuations in interest rates, terrorism, wars or conflicts, major health concerns, natural disasters or other disruptions of expected business conditions. Additional risks and uncertainties not currently known to us or that we currently believe are immaterial also may impair our business, including our results of operations, liquidity and financial condition.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have </span><span style="font-style:italic;font-weight:bold;">incurred</span><span style="font-style:italic;font-weight:bold;"> losses on an as-reported basis for the last three&#160;years, and we may not be able to generate sufficient revenue to achieve and maintain profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Historically, we have incurred net losses, as reported on a combined basis. For the&#160;years ended December&#160;31, 2021, 2020 and 2019, our revenue was $34.7 million, $23.3 million and $18.3 million, respectively. For the&#160;years ended December&#160;31, 2021, 2020 and 2019, our net loss was $(27.0 million), $(17.6 million)&#160;and $(13.6 million), respectively. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we invest in research and development activities to improve our OmniAb technology platform, market and sell our technologies to existing and new partners, add operational, financial and management information systems and personnel to support our operations and incur additional costs associated with operating as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our expenses could increase beyond expectations for a variety of reasons, including as a result of our growth strategy and the expansion of our operations. We will need to generate significant additional revenue to achieve and sustain profitability and even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. We may never be able to generate sufficient revenue to achieve or sustain profitability and our recent and historical growth should not be considered indicative of our future performance. Our failure to become and remain profitable may have an adverse effect on the value of our company and could impair our ability to raise capital, expand our business and maintain our research and development efforts. A decline in the value of our company could also cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our </span><span style="font-style:italic;font-weight:bold;">revenue</span><span style="font-style:italic;font-weight:bold;"> has fluctuated from period to period, and our revenue for any historical period may not be indicative of results that may be expected for any future period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Service and license revenue are generated by research activities that we perform for our partners and technology access fees, the timing and nature of which are dictated by the commencement of discovery campaigns selected by our partners. We also generate milestone payments upon the achievement of development milestones by our partners with respect to the antibodies discovered using our platform and royalties based on the net sales of any products commercialized by our partners. As a result, we will be prone to fluctuations in our revenue depending on the timing of our entry into license agreements with our partners, our partners initiating discovery programs, and our partners achieving development milestones or commercial sales with respect to therapeutic candidates utilizing antibodies discovered using our platform. The timing and likelihood of payments to us under these agreements is dependent on our partners&#8217; successful utilization of the antibodies discovered using our platform, which is outside of our control. Because of these factors, our revenue could vary materially from quarter to quarter from our forecasts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our </span><span style="font-style:italic;font-weight:bold;">operating</span><span style="font-style:italic;font-weight:bold;"> results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of demand for our technology platform and solutions, which may vary significantly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and cost of, and level of investment in, research, development and commercialization activities relating to our platform and technology and any of our internal development programs, which may change from time to time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the start and completion of programs in which our platform is utilized;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the introduction of new technologies, platform features or software, by us or others in our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenditures that we may incur to acquire, develop or commercialize additional platform technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the degree of competition in our industry and any change in the competitive landscape of our industry, including consolidation among our competitors or future partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of demand for any products commercialized by our partners, which may vary significantly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">natural disasters, outbreaks of disease or public health crises, such as the&#160;COVID-19&#160;pandemic;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and nature of any future acquisitions or strategic partnerships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future accounting pronouncements or changes in our accounting policies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in general market and economic conditions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results and revenues. This variability and unpredictability could result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our commercial success depends on the quality of our antibody discovery platform and technological capabilities and their acceptance by new and existing partners in our market.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We utilize our OmniAb technology platform to discover antibodies for further development and potential commercialization by our partners. As a result, the quality and sophistication of our platform is critical to our ability to conduct our research discovery activities and to deliver more promising antibodies and other drugs and to accelerate and lower the costs of discovery as compared to traditional methods for our partnerships. In particular, our business depends, among other things, on:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our platform&#8217;s ability to successfully identify antibodies with therapeutic potential on the desired timeframes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to execute on our strategy to enter into new partnerships with new or existing partners with economic terms that are acceptable to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to increase awareness of the capabilities of our technology and solutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our partners&#8217; and potential partners&#8217; willingness to adopt new technologies;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether our platform reliably provides advantages over legacy and other alternative technologies and is perceived by partners to be cost effective;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate of adoption of our technologies by pharmaceutical and biotechnology companies of all sizes and capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prices we charge for our technology access and the research services we perform;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the relative reliability and robustness of our platform;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to develop new solutions for partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether competitors develop a platform that enables antibody discovery more effectively than our platform;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the status of the market for next-generation biologics, which may become less attractive due to business, competitive or regulatory factors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and scope of any approval that may be required by the U.S.&#160;Food and Drug Administration (FDA), European Medicines Agency (EMA), comparable foreign authorities or any other regulatory body to commercialize therapeutic candidates that are developed based on antibodies or other drugs discovered using our platform;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of our investments in innovation and commercial growth; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to further validate our technology through research and accompanying publications.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that we will successfully address any of these or other factors that may affect the market acceptance of our platform. Failure of antibodies discovered using our platform can occur at any stage of discovery, preclinical or clinical development, and any such failures may reduce our partners&#8217; confidence in our platform. We also believe that pharmaceutical and biotechnology companies are likely to be particularly sensitive to defects and errors in the use of our platform, including if our platform fails to deliver meaningful acceleration of certain research timelines accompanied by results at least as good as the results generated using legacy or other alternative technologies. There can be no guarantee that our platform will meet the expectations of pharmaceutical and biotechnology companies. If we are unsuccessful in achieving and maintaining market acceptance of our platform, our business, financial condition, results of operations and prospects could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our </span><span style="font-style:italic;font-weight:bold;">future</span><span style="font-style:italic;font-weight:bold;"> success is dependent on the eventual approval and commercialization of products developed by our partners for which we have no control over the clinical development plan, regulatory strategy or commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business model is dependent on the eventual progression of therapeutic candidates discovered or initially developed utilizing our platform into clinical trials and commercialization. This requires us to attract partners and enter into agreements with them that contain obligations for the partners to pay us milestone payments as well as royalties on sales of approved products for the therapeutic candidates they develop that are generated utilizing our platform. Given the nature of our relationships with our partners, we do not control the progression, clinical development, regulatory strategy or eventual commercialization, if approved, of these therapeutic candidates. As a result, our future success and the potential to receive milestones and royalties are entirely dependent on our partners&#8217; efforts over which we have no control. If our partners determine not to proceed with the future development of a drug candidate discovered or initially developed utilizing our platform, or if they implement clinical or regulatory strategies that ultimately do not result in the further development or approval of the therapeutic candidates, we will not receive the benefits of our partnerships, which may have a material and adverse effect on our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, biopharmaceutical development is inherently uncertain and very few therapeutic candidates ultimately progress through clinical development and receive approval for commercialization. If our partners do not receive regulatory approval for a sufficient number of therapeutic candidates originating from our partnerships, we may not be able to sustain our business model. Further, we have little control over how diversified our portfolio of potential milestone payments or royalties will end up being.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In addition, we do not control the timing of disclosure by our partners of any milestones or other information related to any therapeutic candidates generated using our platform. Any disclosure by us or our partners of data or other information regarding any </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">such therapeutic candidates that is perceived as negative may have a material adverse impact on our stock price or overall valuation. Our stock price may also decline as a result of negative clinical trial results, including adverse safety events involving any drug candidate that is subject to one of our partnerships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may need to raise additional capital to fund our existing operations and achieve our goals. If we are unable to raise additional capital when needed on acceptable terms or generate cash flows necessary to maintain or expand our operations, we may not be able to compete successfully, which would harm our business, results of operations, and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on our current business plan, we believe our cash and cash equivalents following the Business Combination, together with our anticipated cash flows from operations, will be sufficient to meet our working capital and capital expenditure needs over at least the next 12&#160;months following the date of this proxy statement/prospectus/information statement. If such cash and cash equivalents, together with our anticipated cash flow from operations, are insufficient to satisfy our liquidity requirements including because of increased expenditures or lower demand for our platform, or the realization of other risks described in this proxy statement/prospectus/information statement, we may be required to raise additional capital prior to such time through issuances of public or private equity or debt financings or other capital sources. Such additional financing may not be available on terms acceptable to us or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In any event, we may consider raising additional capital in the future to expand our business, to pursue strategic investments or acquisitions, to take advantage of favorable market conditions or financing opportunities or for other reasons, even if we believe we have sufficient funds for our current or future operating plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our future capital requirements will depend on many factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve revenue growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of expanding our operations, including our business development and marketing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our rate of progress in selling access to our platform and marketing activities associated therewith;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our rate of progress in, and cost of research and development activities associated with, our platform technologies and our internal development programs to the extent we pursue any such programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effect of competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the continued impact of the COVID-19 pandemic on global social, political and economic conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patents and other intellectual property and proprietary rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any technologies that we may in-license or acquire.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The various ways we could raise additional capital carry potential risks. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain adequate financing, if we require it, when needed or on terms acceptable to us, our ability to continue to pursue our business objectives and to respond to business opportunities, challenges, or unforeseen circumstances could be significantly limited, and could have a material adverse effect on our business, financial condition, results of operations and prospects.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we cannot maintain and expand current partnerships and enter into new partnerships, our future operating results would be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We primarily focus our efforts on the discovery of antibodies for our partners, who can select a target and define the antibody properties needed for therapeutic development or use our technology directly in their own labs. As a result, our success depends on our ability to maintain and expand the number and scope of our partnerships. Many factors may impact the success of these partnerships, including our ability to perform our obligations, our partners&#8217; satisfaction with our solutions and technologies, our partners&#8217; ability to successfully develop, secure regulatory approval for and commercialize therapeutic candidates using antibodies discovered using our platform, our partners&#8217; internal priorities (including fluctuations in research and developments budgets), our partners&#8217; resource allocation decisions and competitive opportunities, disagreements with partners, the costs required of either party to the partnerships and related financing needs, and operating, legal and other risks in any relevant jurisdiction. Our existing partners may cease to use our technologies depending on their own technological developments, availability of other competing technologies and internal decisions regarding allocation of time and resources to the discovery and development of therapeutic candidates, over which we have no control. Our existing and future partners may have limited bandwidth to initiate new programs, which could limit their adoption or scale of application of our technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We engage in conversations with companies regarding potential partnerships on an ongoing basis. These conversations may not result in a commercial agreement. Even if an agreement is reached, the resulting relationship may not be successful, including due to our inability to discover any usable antibodies for the selected targets or the antibodies that we do discover may not be successfully developed or commercialized by our partners. In such circumstances, we would not generate any substantial revenues from such a partnership in the form of technology access fees, service fees, milestone payments, royalties or otherwise. Speculation in the industry about our existing or potential partnerships may be a catalyst for adverse speculation about us, or our platform, which can adversely affect our reputation and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot assure investors that we will be able to maintain or expand our existing partnerships or that our technologies will achieve adequate market adoption among new partners. Any failure to increase penetration in our existing markets or new markets would adversely affect our ability to improve our operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">In recent </span><span style="font-style:italic;font-weight:bold;">periods</span><span style="font-style:italic;font-weight:bold;">, we have depended on a limited number of partners for our revenue, the loss of any of which could have an adverse impact on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In recent periods, a limited number of partners accounted for a significant portion of our revenue. For the&#160;years ended December&#160;31, 2021 and 2020, three of our partners accounted for 28%, 24% and 11% and 26%, 21% and 10%, respectively, of our revenue, and 28 and 35 partners accounted for the remaining 37% and 43%, respectively, of our revenue. While moving forward we expect to diversify the number of partners and programs, in the near term these partners represent a large portion of potential revenue. Our license agreements are typically terminable by our partners without penalty with specified notice, which would terminate their access to our technology platform, although we would retain downstream economics on any OmniAb-derived antibody. As a result, if we fail to maintain our relationships with these partners or if these partners discontinue their programs, our future results of operations could be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Biopharmaceutical development is inherently uncertain, and it is possible that none of the therapeutic candidates discovered using </span><span style="font-style:italic;font-weight:bold;">our</span><span style="font-style:italic;font-weight:bold;"> platform that are further developed by our partners will become viable commercial products, on a timely basis or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We use our platform to offer antibody drug-discovery programs to partners who are engaged in drug discovery and development. These partners include pharmaceutical and biotechnology companies of all sizes. While we receive upfront payments generated through our receipt of service revenue and technology access fees, we expect that the vast majority of the economic value of the agreements we enter into with our partners is in the downstream payments that we may receive upon achievement of development milestones and royalties on sales of any approved products. As a result, our future growth is dependent on the ability of our partners to successfully develop and commercialize therapies based on antibodies discovered using our platform. Due to our reliance on our partners, the risks relating to product development, regulatory clearance, authorization or approval and commercialization apply to us derivatively through the activities of our partners. While we believe our platform is capable of identifying high quality antibodies, there can be no assurance that our partners will successfully develop, secure marketing approvals for and commercialize any therapeutic candidates based on the antibodies discovered using our platform. As a result, we may not realize the intended benefits of our partnerships.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Neither we nor our partners are permitted to market any therapeutic candidate in the United States until we or they receive regulatory approval of a New Drug Application (NDA) or Biologics License Application (BLA) from the FDA or until we or they receive regulatory approval from foreign regulatory authorities. The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many&#160;years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a therapeutic candidate&#8217;s clinical development and may vary among jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For instance, the regulatory landscape related to clinical trials in the EU recently evolved. The EU Clinical Trials Regulation (CTR) which was adopted in April&#160;2014 and repeals the EU Clinical Trials Directive, became applicable on January&#160;31, 2022. While the Clinical Trials Directive required a separate clinical trial application (CTA) to be submitted in each member state, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials whose CTA was made under the Clinical Trials Directive before January&#160;31, 2022, the Clinical Trials Directive will continue to apply on a transitional basis for three&#160;years. Additionally, sponsors may still choose to submit a CTA under either the Clinical Trials Directive or the CTR until January&#160;31, 2023 and, if authorized, those will be governed by the Clinical Trials Directive until January&#160;31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is currently unclear to what extent the United Kingdom (UK) will seek to align its regulations with the EU. The UK regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into UK law, through secondary legislation). On January&#160;17, 2022, the UK Medicines and Healthcare products Regulatory Agency (MHRA) launched an eight-week consultation on reframing the UK legislation for clinical trials. The consultation closed on March&#160;14, 2022 and aims to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The outcome of the consultation will be closely watched and will determine whether the UK chooses to align with the regulation or diverge from it to maintain regulatory flexibility. A decision by the UK not to closely align its regulations with the new approach that will be adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries and/or make it harder to seek a marketing authorization in the EU for our product candidates on the basis of clinical trials conducted in the UK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we or our partners are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, development plans may be impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to obtaining approval to commercialize a therapeutic candidate in the United States or abroad, our partners must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA, EMA or comparable foreign regulatory agencies, that such therapeutic candidates are safe and effective, or in the case of biologics in the U.S., safe, pure, and potent, for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we or our partners believe the nonclinical or clinical data for any therapeutic candidates are promising, such data may not be sufficient to support approval by the FDA and other comparable regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA or comparable foreign regulatory bodies can delay, limit or deny approval of therapeutic candidates or could require our partners to conduct additional nonclinical or clinical testing or abandon a program for a number of reasons. Due to the uncertain, time-consuming and costly clinical development and regulatory approval process, our partners may not successfully develop any therapeutic candidates with the antibodies discovered using our platform, or our partners may choose to discontinue the development of these therapeutic candidates for a variety of reasons, including due to safety, risk versus benefit profile, exclusivity, competitive landscape, commercialization potential, production limitations or prioritization of their resources. It is possible that substantially all of these therapeutic candidates will never receive regulatory approval and, even if approved, such therapeutic candidates may never be successfully commercialized.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, even if these therapeutic candidates receive regulatory approval in the United States, our partners may never obtain approval or commercialize such therapeutic candidates outside of the United States, which would limit their full market potential and therefore our ability to realize their potential downstream value. Furthermore, approved therapeutic candidates may not achieve broad market acceptance among physicians, patients, the medical community and third-party payors, in which case revenue generated from their sales would be limited. Likewise, our partners have to make decisions about which clinical stage and pre-clinical therapeutic candidates to develop and advance, and our partners may not have the resources to invest in all of the therapeutic candidates that contain antibodies discovered using our platform, or clinical data and other development considerations may not support the advancement of one or more therapeutic candidates. Decision-making about which therapeutic candidates to prioritize involves inherent uncertainty, and our partners&#8217; development program decision-making and resource prioritization decisions, which are outside of our control, may adversely affect the potential value of those partnerships. Additionally, subject to its contractual obligations to us, if one more of our partners is involved in a business combination, the partner might deemphasize or terminate the development or commercialization of any drug candidate that utilizes an OmniAb-derived antibody. If one of our strategic partners terminates its agreement with us, we may find it more difficult to attract new partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are also subject to industry-wide FDA and other regulatory risk. The number of BLAs and NDAs approved by the FDA varies significantly over time and if there were to be an extended reduction in the number of BLAs or NDAs approved by the FDA, the industry would contract and our business would be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our partners&#8217; failure to effectively advance, market and sell suitable therapeutic candidates with the antibodies that discovered using our platform could have a material adverse effect on our business, financial condition, results of operations and prospects, and cause the market price of our common stock to decline. In addition to the inherent uncertainty in drug development addresses above, our ability to forecast our future revenues may be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The failure of our partners to meet their contractual obligations to us could adversely affect our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our reliance on our partners poses a number of additional risks, including the risk that they may not perform their contractual obligations to us, in compliance with applicable legal or contractual requirements, in a timely manner or at all; they may not maintain the confidentiality of our proprietary information; and disagreements or disputes could arise that could cause delays in, or termination of, the research, development or commercialization of products using our antibodies or result in litigation or arbitration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, certain of our partners are large, multinational organizations that run many programs concurrently, and we are dependent on their ability to accurately track and make milestone payments to us pursuant to the terms of our agreements with them. Any failure by them to inform us when milestones are reached and make related payments to us could adversely affect our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, some of our partners are located in markets subject to political and social risk, corruption, infrastructure problems and natural disasters, and are often subject to country-specific privacy and data security risk, as well as burdensome legal and regulatory requirements. Any of these factors could adversely impact their financial condition and results of operations, which could impair their ability to meet their contractual obligations to us, which may have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our partners have significant discretion in determining when and whether to make announcements, if any, about the status of our partnerships, including about clinical developments and timelines for advancing collaborative programs, and the price of our </span><span style="font-style:italic;font-weight:bold;">common</span><span style="font-style:italic;font-weight:bold;"> stock may decline as a result of announcements of unexpected results or developments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our partners have significant discretion in determining when and whether to make announcements about the status of our partnerships, including about preclinical and clinical developments and timelines for advancing antibodies discovered using our platform. We do not plan to disclose the development status and progress of individual therapeutic candidates of our partners, unless and until those partners do so first. Our partners may wish to report such information more or less frequently than we desire to or may not wish to report such information at all, in which case we would not report that information either. In addition, if partners choose to announce a collaboration with us, there is no guarantee that we will recognize research discovery fees in that quarter or even the following quarter, as such fees are not payable to us until our partner begins discovery activities. The price of our common stock may decline as a result of the public announcement of unexpected results or developments in our partnerships, or as a result of our partners withholding such information.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our partners may not achieve projected discovery and development milestones and other anticipated key events in the expected timelines or at all, which could have an adverse impact on our business and could cause the price of our common stock to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may make public statements regarding the expected timing of certain milestones and key events, as well as regarding developments and milestones under our partnerships, to the extent that our partners have publicly disclosed such information or permit us to make such disclosures. Our partners may from time to time make statements about their goals and expectations for partnerships with us. The actual timing of these events can vary dramatically due to a number of factors such as delays or failures in our or our current and future partners&#8217; discovery and development programs, the amount of time, effort, and resources committed by us and our current and future partners, and the numerous uncertainties inherent in the development of therapeutics. As a result, there can be no assurance that our partners&#8217; current and future programs will advance or be completed in the time frames we or they expect. If our partners fail to achieve one or more of these milestones or other key events as planned, our business could be materially and adversely affected and the price of our common stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be unable to manage our current and future growth effectively, which could make it difficult to execute our business strategy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As we continue to execute on our business strategy, we anticipate further growth in our business operations. This growth requires managing complexities across all aspects of our business, including complexities associated with increased research and development and business development and marketing operations. As we seek to increase the number of our partnered programs, expand the scope of our existing partnerships and further develop our technological capabilities, we may need to incorporate new equipment, implement new technology systems and laboratory processes and hire new personnel with specialized qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher technology development costs, declining technology development quality, deteriorating program management success, and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our platform, and could damage our reputation and the prospects for our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To manage our anticipated growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Also, our management team may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing our growth. If our management is unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance, and our ability to develop and commercialize our platform and compete effectively, will depend, in part, on our ability to effectively manage increased program demand and the growth in our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our platform utilizes various species of animals that could contract disease or die and could otherwise subject us to controversy and adverse publicity, which may interrupt our business operations or harm our reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our platform utilizes animals to discover and produce antibodies. We cannot completely eliminate the risks of animals contracting disease, which from time to time has occurred, or a natural or man-made disaster that could cause death to valuable production animals, in our vivarium&#160;facilities, which house our chickens, or those of the contract research organizations (CROs) that maintain our mouse and rat colonies. We cannot make any assurance that we or our CROs will be able to contain or reverse any such instance of disease. Although we maintain backup colonies of our animals, disease or death on a broad scale could materially interrupt business operations as animals are a key part of our antibody discovery programs, which could have a material adverse effect on our results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, genetic engineering and testing of animals has been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals in the United States, the European Union (EU) and other jurisdictions have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities and the ability for us and our partners to use our technology platform could be interrupted or delayed, our costs could increase and our reputation could be harmed.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have invested, and expect to continue to invest, in research and development efforts that further enhance our antibody discovery </span><span style="font-style:italic;font-weight:bold;">platform</span><span style="font-style:italic;font-weight:bold;">. Such investments in technology are inherently risky and may affect our operating results. If the return on these investments is lower or develops more slowly than we expect, our revenue and operating results may suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have historically dedicated a substantial portion of our resources on the development of our platform and the technology that it incorporates. These investments may involve significant time, risks, and uncertainties, including the risk that the expenses associated with these investments may affect operating results and that such investments may not generate sufficient technological advantage relative to alternatives in the market which would, in turn, impact revenues to offset liabilities assumed and expenses associated with these new investments. The industry in which we operate changes rapidly as a result of technological and drug developments, which may render our solutions less desirable. We believe that we must continue to invest a significant amount of time and resources in our platform and technology to maintain and improve our competitive position. If we do not achieve the benefits anticipated from these investments, if the achievement of these benefits is delayed, or if our technology platform is not able to accelerate the process of antibody drug discovery as quickly as we anticipate, our revenue and operating results may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business is subject to risks arising from COVID-19 and other epidemic diseases.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 worldwide pandemic has presented substantial public health and economic challenges and is affecting our employees, partners, communities and business operations, as well as the U.S. and global economies and financial markets. International and U.S. governmental authorities in impacted regions have taken and continue to take actions in an effort to slow the spread of COVID-19, including issuing varying forms of &#8220;stay-at-home&#8221; orders, and restricting business functions outside of one&#8217;s home. We have generally restricted in-person access to our executive offices, our administrative employees are working remotely on an intermittent basis, and we have limited the number of staff in our research and development laboratories and other facilities. To date, we have not experienced material disruptions in our business operations. While it is not possible at this time to estimate the impact that COVID-19 could have on our business in the future, the continued spread of COVID-19 or variants thereof and the measures taken by the governmental authorities, and any future epidemic disease outbreaks, could: disrupt the supply chain and the manufacture or shipment of products and supplies for use by us in our discovery activities and by our partners for their discovery and development activities; delay, limit or prevent us or our partners from continuing research and development activities; impede our negotiations with partners and potential partners; impede testing, monitoring, data collection and analysis and other related activities by us and our partners; interrupt or delay the operations of the FDA, EMA, comparable foreign authorities or other regulatory bodies, which may impact review and approval timelines for initiation of clinical trials or marketing; impede the launch or commercialization of any approved products; any of which could delay our partnership programs, increase our operating costs, and have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if COVID-19 infects our genetically modified animals, which form the basis of our platform, or if there is an outbreak among our employees or our subcontractor&#8217;s employees who maintain and care for these animals, we and our partners may be unable to produce antibodies for development. The COVID-19 pandemic and mitigation measures have had and may continue to have, and any future epidemic disease outbreak may have, an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which the COVID-19 pandemic impacts our results of operations will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the virus and new variants and the actions to contain its impact.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The life sciences and biotech platform technology market is highly competitive, and if we cannot compete successfully with our </span><span style="font-style:italic;font-weight:bold;">competitors</span><span style="font-style:italic;font-weight:bold;">, we may be unable to increase or sustain our revenue, or sustain profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We face significant competition in the market for technologies that enable the discovery and development of therapeutic antibodies. Our technologies address antibody therapeutic discovery challenges that are addressed by other platform technologies controlled by companies that have a variety of business models, including the development of internal pipelines of therapeutics, technology licensing, and the sale of instruments and devices. Examples of technical competition at different steps of our technology platform include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in discovery using genetically engineered rodents, we face technical competition from companies that provide access to similar technologies, such as AbCellera&#160;Inc., Ablexis LLC, Alloy Therapeutics,&#160;Inc. Crescendo Biologics&#160;Ltd., Harbour Antibodies BV, Merus N.V., Regeneron Pharmaceuticals,&#160;Inc. and RenBio&#160;Inc.;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the field of single-cell screening, we face technical competition from companies that provide access to similar technologies, such as AbCellera&#160;Inc., Berkeley Lights&#160;Inc., HiFiBio&#160;Inc., and Sphere Fluidics&#160;Ltd.; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in ion channel drug discovery, we face technical competition from companies that provide similar technologies, or biological expertise, such as Charles River Labs&#160;Inc., Evotec SE, Metrion Biosciences&#160;Ltd., and WuXi AppTec.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also face direct business competition from companies that provide antibody discovery services using technologies, such as hybridoma and display. Companies with discovery business models that include downstream payments include AbCellera&#160;Inc. and Adimab&#160;LLC. In addition, we compete with a variety of fee-for-service contract research organizations that provide services, in most cases using legacy technologies, that compete with one or more steps in our technology platform. In addition, our partners may also elect to develop their workflows on legacy systems rather than rely on our platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our competitors and potential competitors may enjoy a number of competitive advantages over us. For example these may include longer operating histories, larger customer bases, greater brand recognition and market penetration, greater financial resources, greater technological and research and development resources, better system reliability and robustness, greater selling and marketing capabilities, and integrated manufacturing capabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result, our competitors and potential competitors may be able to respond more quickly to changes in customer requirements, devote greater resources to the development, promotion and sale of their platforms or instruments than we can or sell their platforms or instruments, or offer solutions competitive with our platform and solutions at prices designed to win significant levels of market share. In addition, we may encounter challenges in marketing our solutions with our pricing model, which is structured to capture the potential downstream revenues associated with therapeutic candidates that were discovered using our platform. Our partners and potential partners may prefer one or more pricing models employed by our competitors that involve upfront payments rather than downstream revenues. We may not be able to compete effectively against these organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, competitors may be acquired by, receive investments from or enter into other commercial relationships with larger, well-established and well-financed companies. Certain of our competitors may be able to secure key inputs from vendors on more favorable terms, devote greater resources to marketing and promotional campaigns, adopt more aggressive pricing policies and devote substantially more resources to technology and platform development than we can. If we are unable to compete successfully against current and future competitors, we may be unable to increase market adoption and sales of our platform, which could prevent us from increasing our revenue or sustaining profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our management uses certain key business metrics to evaluate our business, measure our performance, identify trends affecting our </span><span style="font-style:italic;font-weight:bold;">business</span><span style="font-style:italic;font-weight:bold;">, formulate financial projections and make strategic decisions and such metrics may not accurately reflect all of the aspects of our business needed to make such evaluations and decisions, in particular as our business continues to grow.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to our financial results, our management regularly reviews a number of operating and financial metrics, including the number of active partners, the number of active programs, the number and progress of active clinical programs, and the number and commercial progress of approved products, to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that these metrics are representative of our current business; however, these metrics may not accurately reflect all aspects of our business, and we anticipate that these metrics may change or may be substituted for additional or different metrics as our business grows and as we introduce new solutions. In addition, we are highly dependent on information provided by our partners as to the status of their development programs. To the extent such information is later shown to be inaccurate, our metrics and forecasts could be materially and adversely affected. If our management fails to review other relevant information or change or substitute the key business metrics they review as our business grows, or if our metrics prove inaccurate or unrepresentative based on information provided by our partners or otherwise, their ability to accurately formulate financial projections and make strategic decisions may be compromised and our business, financial results and future growth prospects may be adversely impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties to host our mouse and rat colonies and expect to continue to do so for the foreseeable future, and these third parties may not perform satisfactorily which could delay, prevent or impair our partnership programs and research and development efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">We do not own or operate vivarium facilities for our mouse and rat colonies and have no plans to expand our vivarium facilities beyond those that house our chickens. We rely, and expect to continue to rely, on third-party CROs to host our mice and rats and to </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">conduct certain research services for us and our partners, such as animal breeding, genotyping and animal distribution. We have limited control over the performance by these third parties, including with respect to maintaining adequate quality control, quality assurance and qualified personnel, and to performing their services in compliance with applicable scientific and regulatory requirements. If these third parties are unable to continue maintaining our mice and rats in accordance with our specifications or on commercially reasonable terms, or otherwise perform in a substandard manner, the discovery activities for our partners may be delayed. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties on commercially reasonable terms or at all. Switching or adding additional vivarium facilities involves additional cost and requires our management&#8217;s time and focus. In addition, there is a natural transition period when a new facility commences work. As a result, delays may occur, which can materially impact our ability to meet our partners&#8217; discovery timelines. Though we carefully manage our relationships with these third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, results of operations, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on a limited number of suppliers for laboratory equipment and materials and may not be able to find replacements or </span><span style="font-style:italic;font-weight:bold;">immediately</span><span style="font-style:italic;font-weight:bold;"> transition to alternative suppliers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We rely on a limited number of suppliers, or in some cases single suppliers, to provide certain consumables and equipment that we use in our laboratory operations, as well as reagents and other laboratory materials involved in the development of our technology. Fluctuations in the availability and price of laboratory materials and equipment could have an adverse effect on our ability to meet our technology development goals with our partners and thus our results from operations as well as future partnership opportunities. An interruption in our laboratory operations or technology transfer could occur if we encounter delays, quality issues or other difficulties in securing these consumables, equipment, reagents or other materials, and if we cannot then obtain an acceptable substitute. In addition, while we believe suitable additional or alternative suppliers are available to accommodate our operations, if needed, any transition to new or additional suppliers may cause delays in our processing of samples or development and commercialization of our technology. Any such interruption could significantly affect our business, financial condition, results of operations and reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The sizes of the markets and forecasts of market growth for the demand of our OmniAb technology platform and other of our key performance </span><span style="font-style:italic;font-weight:bold;">indicators</span><span style="font-style:italic;font-weight:bold;"> are based on a number of complex assumptions and estimates, and may be inaccurate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We estimate annual total addressable markets and forecasts of market growth for our platform and technologies and for antibody-based therapeutics generally. We have also developed a standard set of key performance indicators in order to enable us to assess the performance of our business in and across multiple markets, and to forecast future revenue. These estimates, forecasts and key performance indicators are based on a number of complex assumptions, internal and third party estimates and other business data, including assumptions and estimates relating to our ability to generate revenue from the development of new workflows. While we believe our assumptions and the data underlying our estimates and key performance indicators are reasonable, there are inherent challenges in measuring or forecasting such information. As a result, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors and indicators. As a result, our estimates of the annual total addressable market and our forecasts of market growth and future revenue from technology access fees, service fees, milestone payments or royalties may prove to be incorrect, and our key business metrics may not reflect our actual performance. For example, if the annual total addressable market or the potential market growth for our platform is smaller than we have estimated or if the key business metrics we utilize to forecast revenue are inaccurate, it may impair our sales growth and have an adverse impact on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third-party payor coverage and reimbursement status of newly approved therapeutics is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for current or future products and services could limit our partners&#8217; ability to fully commercialize therapeutic candidates generated using our platform, which would decrease our ability to generate revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford any therapeutics generated using our platform that our partners may develop and sell. In addition, because the therapeutics we generate may represent new classes of treatments for diseases, we and our partners cannot accurately estimate how such therapeutics would be priced, whether reimbursement could be obtained or any potential revenue generated. Sales of such therapeutics will depend substantially, both domestically and internationally, on the extent to which the costs of such therapeutics are paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, our partners may not be able to successfully commercialize some therapeutics generated with our </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">technology. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow our partners to establish or maintain pricing sufficient to realize a sufficient return on their investment in such therapeutics, and may lead to discontinuation or deprioritization of marketing and sales efforts for such products. Changes in the reimbursement landscape may occur, which are outside of our control, and may impact the commercial viability of our technology development services and/or therapeutics generated using our technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly cleared, authorized or approved therapeutics in the United States, the EU and other jurisdictions. Due to the trend toward value-based pricing and coverage, the increasing influence of health maintenance organizations and additional legislative changes, we expect our partners to experience pricing pressures on therapeutics generated using our platform that our partners may commercialize. The downward pressure on healthcare costs in general, particularly novel therapeutics, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products, which would negatively impact our ability to generate revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare reform efforts aimed at lowering the price of biopharmaceutical products may impact our ability to maintain sufficient profits.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs and those methods are not always specifically adapted for new technologies. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In particular, in the United States, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (ACA), was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars; addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of January&#160;1, 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D; and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA. On June&#160;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an Executive Order to initiate a special enrollment period from February&#160;15, 2021 through August&#160;15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules&#160;that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administrations, if any, will impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, on March&#160;11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January&#160;1, 2024. Further, in August&#160;2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal&#160;year, which went into effect in April&#160;2013, and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020 through March&#160;31, 2022 and a 1% reduction from April&#160;1, 2022 through June&#160;30, 2022, unless additional Congressional action is taken.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Further, there has been heightened governmental scrutiny recently over the manner in which product manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">manufacturer patient programs, and reform government program reimbursement methodologies for products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that additional U.S. federal or foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government or foreign governments will pay for healthcare products and services, which could result in reduced demand for our products and therapeutic candidates, if approved, or additional pricing pressures. If efforts to contain the price of biopharmaceutical products are successful, the magnitude of milestone payments and royalties we would expect to receive in connection with our partners&#8217; future prioritization and investment in developing novel biologics may be impacted. For instance, in December&#160;2021, Regulation No 2021/2282 on Health Technology Assessment (HTA) amending Directive 2011/24/EU, was adopted in the European Union (EU). This regulation which entered into force in January&#160;2022 intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and providing the basis for cooperation at the EU level for joint clinical assessments in these areas. The regulation foresees a three-year transitional period and will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We must adapt to rapid and significant technological change and respond to introductions of new products and technologies by competitors to remain competitive.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We provide our antibody discovery solutions and capabilities in industries that are characterized by significant enhancements and evolving industry standards. As a result, our partners&#8217; needs are rapidly evolving. If we do not appropriately innovate and invest in new technologies, our platform may become less desirable in the markets we serve, and our partners could move to new technologies offered by our competitors, or engage in antibody discovery themselves. Without the timely introduction of new solutions and technological enhancements, our offerings will likely become less competitive over time, in which case our competitive position and operating results could suffer. Accordingly, we focus significant efforts and resources on the development and identification of new technologies and markets to further broaden and deepen our capabilities and expertise in antibody drug discovery and development. To the extent we fail to timely introduce new and innovative technologies or solutions, adequately predict our partners&#8217; needs or fail to obtain desired levels of market acceptance, our business may suffer and our operating results could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We depend on our information technology systems, and any failure of these systems could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We depend on information technology and telecommunications systems for significant elements of our operations, including our laboratory information management system, our computational biology system, our knowledge management system, our customer reporting, our platform, our advanced automation systems, and advanced application software. We have installed, and expect to expand, a number of enterprise software systems that affect a broad range of business processes and functional areas, including for example, systems handling human resources, financial controls and reporting, contract management, regulatory compliance and other infrastructure operations. These implementations were expensive and required a significant effort in terms of both time and effort. In addition to the aforementioned business systems, we intend to extend the capabilities of both our preventative and detective security controls by augmenting the monitoring and alerting functions, the network design and the automatic countermeasure operations of our technical systems. These information technology and telecommunications systems support a variety of functions, including laboratory operations, data analysis, quality control, customer service and support, billing, research and development activities, scientific and general administrative activities. A significant risk in implementing these systems, for example, is the integration of separate information technology and telecommunications systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Information technology and telecommunications systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious software, bugs or viruses, human acts and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Any disruption or loss of information technology or telecommunications systems on which critical aspects of our operations depend could have an adverse effect on our business and our reputation, and we may be unable to regain or repair our reputation in the future.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business development and marketing organizations are currently limited, and if we are unable to expand our personnel to reach our existing and potential partners, our business may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business development and marketing functions are currently limited, with only two dedicated business development and two marketing employees, as of December&#160;31, 2021. We have supported these functions with research and development staff attending a variety of scientific conferences which has helped increase the business development pipeline. We will need to expand our commercial organization in order to effectively market our solutions to existing and new partners. Competition for employees capable of negotiating and entering into partnerships with pharmaceutical and biotechnology companies is intense. We may not be able to attract and retain personnel or be able to build an efficient and effective sales organization, which could negatively impact sales and market acceptance of our platform and limit our revenue growth and potential profitability. In addition, the time and cost of establishing a specialized sales, marketing and service force for a particular service may be difficult to justify in light of the revenue generated or projected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our expected future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees. Our future financial performance and our ability to successfully sell our programs and to compete effectively will depend, in part, on our ability to manage this potential future growth effectively, without compromising quality.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our success is dependent on our ability to attract and retain highly qualified management and other scientific and engineering personnel.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our success depends in part on our continued ability to attract, retain, manage, and motivate highly qualified management, scientific and engineering personnel, and we face significant competition for experienced personnel. We are highly dependent upon our senior management, as well as our senior scientists and engineers and other members of our management team. The individual and collective efforts of these employees will be important as we continue to develop and market our platform and technology. The loss or incapacity of existing members of our senior management team could adversely affect our operations if we experience difficulties in hiring qualified successors. Although we intend to execute employment agreements or offer letters with each member of our senior management team, these agreements will be terminable at will with or without notice and, therefore, we may not be able to retain their services as expected. We do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may not be able to attract or retain qualified scientists and engineers in the future due to the competition for qualified personnel among life science businesses. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific and engineering personnel. We may have difficulties locating, recruiting or retaining qualified salespeople. Recruiting and retention difficulties can limit our ability to support our research and development and sales programs. A key risk in this area, for example, is that certain of our employees are at-will, which means that either we or the employee may terminate their employment at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have made technology acquisitions and expect to acquire businesses or assets or make investments in other companies or technologies that could negatively affect our operating results, dilute our stockholders&#8217; ownership, increase our debt or cause us to incur significant expense.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Our business includes numerous acquisitions completed by Ligand, including the acquisition of Crystal Bioscience in October&#160;2017, Ab Initio in July&#160;2019, the Icagen ion channel platform through the acquisition of the core assets of Icagen in April&#160;2020, xCella Biosciences in September&#160;2020, and Taurus Biosciences in September&#160;2020. We expect to pursue additional acquisitions of businesses and assets in the future. We may not be able to find suitable partners or acquisition or asset purchase candidates in the future, and we may not be able to complete such transactions on favorable terms, if at all. The competition for strategic partners or acquisition candidates may be intense, and the negotiation process will be time-consuming and complex. If we make any additional acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, these acquisitions may not strengthen our competitive position, the transactions may be viewed negatively by partners or investors, we may be unable to retain key employees of any acquired business, relationships with key suppliers, manufacturers or partners of any acquired business may be impaired due to changes in management and ownership, and we could assume unknown or contingent liabilities. In addition, we will likely experience significant charges to earnings in connection with our efforts, if any, to consummate acquisitions. For transactions that are ultimately not consummated, these charges may include fees and expenses for investment bankers, attorneys, accountants and other advisors in connection with our efforts. Even if our efforts are successful, we may incur, as </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">part of a transaction, substantial charges for closure costs associated with elimination of duplicate operations and facilities and acquired in process research and development charges. In either case, the incurrence of these charges could adversely affect our results of operations for particular quarterly or annual periods. Any future acquisitions also could result in the incurrence of debt, contingent liabilities or future write-offs of intangible assets or goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects. We cannot guarantee that we will be able to fully recover the costs of any acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Integration of an acquired company also may disrupt ongoing operations and require management resources that we would otherwise focus on developing our existing business. We may not realize the anticipated benefits of any acquisition, technology license, strategic alliance or joint venture. We also may experience losses related to investments in other companies, which could have a material adverse effect on our business, financial condition, results of operations and prospects. Acquisitions may also expose us to a variety of international and business related risks, including intellectual property, regulatory laws, local laws, tax and accounting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To finance any acquisitions or asset purchase, we may choose to issue securities as consideration, which would dilute the ownership of our stockholders. Additional funds may not be available on terms that are favorable to us, or at all. If the price of our common stock is low or volatile, we may not be able to acquire companies or assets using our securities as consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our operating facilities becomes damaged or inoperable or if we move or are otherwise required to vacate our facilities, our ability to conduct and pursue our research and development efforts may be jeopardized.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our scientific and engineering research and development and testing is conducted at our facilities located in Emeryville, California, Durham, North Carolina, and Tucson, Arizona. Our facilities and equipment could be harmed or rendered inoperable or inaccessible by natural or man-made disasters or other circumstances beyond our control, including fire, earthquake, power loss, communications failure, war or terrorism, or another catastrophic event, such as a pandemic or similar outbreak or public health crisis, which may render it difficult or impossible for us to support our partners and develop updates, upgrades and other improvements to our platform, advanced automation systems, and advanced application and workflow software for some period of time. The inability to address system issues could develop if our facilities are inoperable or suffer a loss of utilization for even a short period of time, may result in the loss of partners or harm to our reputation, and we may be unable to regain those partners or repair our reputation in the future. Furthermore, our facilities and the equipment we use to perform our research and development work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facilities, to locate and qualify a new facility or license or transfer our proprietary technology to a third party. Even in the event we are able to find a third party to assist in research and development efforts, we may be unable to negotiate commercially reasonable terms to engage with the third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our business, may not provide coverage in amounts sufficient to cover our potential losses and may not continue to be available to us on acceptable terms, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we plan to plan to move and expand the vivarium facilities housing our chickens in 2022. Such a move could disrupt our operations as we ramp up the new facility, result in animal injury or death, or otherwise impair the research services conducted using such animals. Adverse consequences resulting from our planned move could harm our relationships with our partners and our reputation, and could affect our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not carry insurance for all categories of risk that our business may encounter and our policies have limits and significant deductibles. Some of the policies we currently maintain include general liability, property, umbrella and directors&#8217; and officers&#8217; insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any additional insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. A successful liability claim or series of claims in which judgments exceed our insurance coverage could adversely affect our business, financial condition, results of operations and prospects, including preventing or limiting the use of our platform to discover antibodies.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also expect that operating as a public company will make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business, we generate and store sensitive data, including research data, intellectual property and proprietary business information owned or controlled by ourselves or our employees, partners and other parties. We manage and maintain our applications and data utilizing a combination of on-site systems and cloud-based data centers. We utilize external security and infrastructure vendors to manage parts of our data centers. These applications and data encompass a wide variety of business-critical information, including research and development information, commercial information and business and financial information. We face a number of risks relative to protecting this critical information, including loss of access risk, inappropriate use or disclosure, accidental exposure, unauthorized access, inappropriate modification and the risk of our being unable to adequately monitor and audit and modify our controls over our critical information. This risk extends to the third party vendors and subcontractors we use to manage this sensitive data or otherwise process it on our behalf. Further, to the extent our employees are working at home during the COVID-19 pandemic, additional risks may arise as a result of depending on the networking and security put into place by the employees. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may experience security breaches that may remain undetected for an extended period. Our third-party service providers and partners are also subject to these heightened risks. The secure processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take reasonable measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or infections by viruses or other malware or breached due to erroneous actions or inactions by our employees or contractors, malfeasance or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, breach, or other loss of information could result in legal claims or proceedings. Unauthorized access, loss or dissemination could also disrupt our operations and damage our reputation, any of which could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, although we maintain cybersecurity insurance coverage, we cannot be certain that such coverage will be adequate for data security liabilities actually incurred, will cover any indemnification claims against us relating to any incident, will continue to be available to us on economically reasonable terms, or at all, or that any insurer will not deny coverage as to any future claim. The successful assertion of one or more large claims against us that exceed available insurance coverage, or the occurrence of changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, could adversely affect our reputation, business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business could become subject to more extensive government regulation than we currently anticipate, and regulatory compliance obligations and the investigational exemption and approval processes to which our animals may become subject are expensive, time-consuming and uncertain both in timing and in outcome.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">We believe our operations are currently subject to limited direct regulation by the FDA, comparable foreign authorities or other regulatory bodies. However, our business could in future become subject to more direct oversight by the FDA, EMA or other comparable domestic or international agencies. For example, we may be subject to evolving and variable regulations governing the production of genetically engineered organisms. In particular, the FDA regulates animals whose genomes have been intentionally altered, and the FDA considers such alterations to be new animal drugs that may require approvals or exemptions in order to be commercially marketed or for investigational use in the United States. For example, we have been in communication with the FDA regarding the regulatory requirements applicable to our OmniChickens designed to produce human immunoglobulins, and the FDA has advised us that such approvals or exemptions are not required in light of the early stage of our research. However, the FDA may determine that we are not in compliance with the conditions imposed upon us to avoid the requirement for such approvals or exemptions at present or we may later become subject to such approvals or exemptions. Furthermore, while we have no active plans to operate a manufacturing facility designed to comply with current good manufacturing practices (cGMPs), future market pressures or </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">the lack of available capacity at cGMP manufacturing facilities may necessitate our entry into this market. Complying with such regulations may be expensive, time-consuming and uncertain, and if we fail to comply with any applicable requirements enforced by the FDA with respect to our intentionally genetically altered animals or otherwise, we may be subject to administratively or judicially imposed sanctions, including restrictions on our products or operations, warning or untitled letters, civil or criminal penalties, injunctions, product seizures, product detentions, import bans, product recalls, or adverse publicity requirements, any of which could have an adverse effect on our business, financial condition and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business operations and current and future relationships with investigators, healthcare professionals, and partners may be subject to applicable fraud and abuse and other healthcare laws and regulations, which could expose us and/or our partners to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and future earnings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Healthcare professionals, physicians and third-party payors will play a primary role in the recommendation and prescription of any therapeutic candidates generated by our platform for which our partners obtain marketing approval. Our arrangements with our partners may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct our business. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal False Claims Act and civil monetary penalties laws, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. The government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g.,&#160;public or private) and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or service. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report to the Department of Health and Human Services information related to certain financial interactions with physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, anesthesiology assistants and certified nurse midwives), and teaching hospitals, as well as the ownership and investment interests of physicians and their immediate family members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous state laws and regulations, such as state anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare professionals or marketing expenditures and pricing information; and</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">EU and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities may conclude that our or our partners&#8217; business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our or our partners&#8217; operations were to be found to be in violation of any of these laws or any other governmental regulations that may apply, we and/or our partners may be subject to the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Further, defending against any such actions can be costly, time consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in and actual or perceived failures to comply with applicable data privacy, security and protection laws, regulations, standards and contractual obligations may adversely affect our business, operations and financial performance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We and our partners may be subject to federal, state, and foreign laws and regulations that govern data privacy and security. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues, which may affect our business and may increase our compliance costs and exposure to liability. In the United States, numerous federal and state laws and regulations govern the collection, use, disclosure, and protection of personal information, including state data breach notification laws, federal and state health information privacy laws, and federal and state consumer protection laws. Each of these laws is subject to varying interpretations by courts and government agencies, creating complex compliance issues. If we fail to comply with applicable laws and regulations we could be subject to penalties or sanctions, including criminal penalties if we knowingly obtain or disclose individually identifiable health information from a covered entity in a manner that is not authorized or permitted by HIPAA or applicable state laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are also or may become subject to rapidly evolving data protection laws, rules&#160;and regulations in foreign jurisdictions. For example, the European Union General Data Protection Regulation (GDPR) governs certain collection and other processing activities involving personal data about individuals in the European Economic Area (EEA). Among other things, the GDPR imposes requirements regarding the security of personal data, the rights of data subjects to access and delete personal data, requires having lawful bases on which personal data can be processed, includes requirements relating to the consent of individuals to whom the personal data relates, requires detailed notices for clinical trial participants and investigators and regulates transfers of personal data from the EEA to third countries that have not been found to provide adequate protection to such personal data, including the United States. In addition, the GDPR imposes substantial fines for breaches and violations (up to the greater of &#8364;20.0 million or 4% of our annual global revenue). The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Further, from January&#160;1, 2021, companies have been subject to the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g.&#160;fines up to the greater of &#8364;20.0 million (&#163;17.5 million) or 4% of global turnover. The European Commission has adopted an adequacy decision in favor of the UK, enabling data transfers from EU member states to the UK without additional safeguards. However, the UK adequacy decision will automatically expire in June&#160;2025 unless the European Commission re-assesses and renews/extends that decision, and remains under review by the Commission during this period. The relationship between the UK and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the UK will be regulated in the long term. These changes may lead to additional costs and increase our overall risk exposure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Compliance with applicable data privacy and security laws, rules&#160;and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners&#8217; ability to operate in certain jurisdictions. Each of these constantly evolving laws can be subject to varying interpretations. If we fail to comply with any such laws, rules&#160;or regulations, we may face government investigations and/or enforcement actions, fines, civil or criminal penalties, private litigation or adverse publicity that could adversely affect our business, financial condition and results of operations.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Separation and Distribution, the Private Placement and Our Relationship with Ligand</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">As a result of the Separation, we will lose Ligand&#8217;s brand, reputation, capital base and other resources, and may experience difficulty operating as a standalone company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe our association with Ligand has contributed to our building relationships with our customers due to Ligand&#8217;s globally recognized brand and reputation for innovation in drug discovery and development. The Separation could adversely affect our ability to attract and retain customers, which could result in reduced sales of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The loss of Ligand&#8217;s scale, capital base and financial strength may also prompt suppliers to reprice, modify or terminate their relationships with us. In addition, Ligand&#8217;s elimination of its ownership of our company could potentially cause some of our existing agreements and licenses to be terminated. We cannot predict with certainty the effect that the Separation, Distribution or Merger will have on our business, our clients, vendors or other persons, or whether our OmniAb brand will be accepted in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, because we have not operated as a standalone company in the past, we may have difficulty doing so. We may need to acquire assets and resources in addition to those provided by Ligand to our company, and in connection with the Separation, may also face difficulty in separating our assets from Ligand&#8217;s assets and integrating newly acquired assets into our business. Our business, financial condition and results of operations could be materially and adversely affected if we have difficulty operating as a standalone company, fail to acquire assets that prove to be important to our operations or incur unexpected costs in separating our assets from Ligand&#8217;s assets or integrating newly-acquired assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will incur significant charges in connection with the Separation and incremental costs as a standalone public company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will need to replicate or replace certain functions, systems and infrastructure to which we will no longer have the same access after the Separation. We may also need to make investments or hire additional employees, or out-source certain functions, systems and infrastructure through contracts with third parties, to operate without access to Ligand&#8217;s existing operational and administrative infrastructure. These initiatives may be costly to implement. Due to the scope and complexity of the underlying projects relative to these efforts, the amount of total costs could be materially higher than our estimate, and the timing of the incurrence of these costs is subject to change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ligand currently performs or supports many important corporate functions for our company. Our combined financial statements reflect charges for these services on an allocated basis. Following the Separation, many of these services will be governed by our Transition Services Agreement. Under the Transition Services Agreement we will be able to use these Ligand services for a fixed term established on a service-by-service basis. The Transition Services Agreement may be terminated by us with prior written notice, by either party in the event of an uncured material breach by the other party or its applicable affiliates, upon bankruptcy or insolvency of the other party, or by mutual agreement of the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will pay Ligand fees for the transition services as a flat monthly fee and reimburse Ligand for all reasonable out-of-pocket expenses that it incurs in connection with providing the transition services. In addition, while these services are being provided to us by Ligand, our operational flexibility to modify or implement changes with respect to such services or the amounts we pay for them will be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may not be able to replace these services or enter into appropriate third-party and conditions, including cost, those that we will receive from Ligand under our Transition Services Agreement. Additionally, after the Transition Services Agreement terminates, we may be unable to sustain the services at the same levels or obtain the same benefits as when we were receiving such services and benefits from Ligand. When we begin to operate these functions separately, if we do not have our own adequate systems and business functions in place, or are unable to obtain them from other providers, we may not be able to operate our business effectively or at comparable costs, and our profitability may decline. In addition, we have historically received informal support from Ligand, which may not be addressed in our Transition Services Agreement. The level of this informal support will diminish or be eliminated following the Separation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, our historical combined financial statements include the attribution of certain assets and liabilities that historically have been held at the Ligand corporate level but which are specifically identifiable or attributable to the businesses being transferred to us in connection with the Separation. The value of the assets and liabilities we assume in connection with the Separation could ultimately be materially different than such attributions, which could have a material adverse effect on our financial condition.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Separation, we will also enter into a second Transition Services Agreement under which we will provide services relating to corporate functions, legal administration and other administrative functions to Ligand. These will be services that we historically provided to Ligand prior to the Separation. Under this Transition Services Agreement, Ligand will be able to use our services for a fixed term established on a service-by-service basis. The Transition Services Agreement may be terminated by Ligand with prior written notice, by either party in the event of an uncured material breach by the other party or its applicable affiliates, upon bankruptcy or insolvency of the other party, or by mutual agreement of the parties. Ligand will pay us fees for the transition services as a flat monthly fee and will reimburse us for all reasonable out-of-pocket expenses that we incur in connection with providing the transition services. In addition, while these services are being provided to Ligand by us, our operational flexibility to modify or implement changes with respect to our capabilities to provide such services will be limited, and we may be obligated to maintain certain functions and capabilities solely to be able to meet our obligations to Ligand under the Transition Services Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our historical combined financial data and pro forma financial statements are not necessarily representative of the results we would have achieved as a standalone company and may not be a reliable indicator of our future results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our historical combined financial data included in this proxy statement/prospectus/information statement does not reflect the financial condition, results of operations or cash flows we would have achieved as a standalone company during the periods presented or those we will achieve in the future. This is primarily the result of the following factors:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our historical combined financial data does not reflect the Business Combination;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our historical combined financial data reflects expense allocations for certain support functions that are provided on a centralized basis within Ligand, such as expenses for executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations that may be higher or lower than the comparable expenses we would have actually incurred, or will incur in the future, as a standalone company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our cost of debt and our capital structure will be different from that reflected in our historical combined financial statements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant increases may occur in our cost structure as a result of the Business Combination, including costs related to public company reporting, investor relations and compliance with the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Separation may have a material effect on our customers and other business relationships, including supplier relationships, and may result in the loss of preferred pricing available by virtue of our reduced relationship with Ligand.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our financial condition and future results of operations, after giving effect to the Business Combination, will be materially different from amounts reflected in our historical combined financial statements included elsewhere in this proxy statement/prospectus/information statement. As a result of the Business Combination, it may be difficult for investors to compare our future results to historical results or to evaluate our relative performance or trends in our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ligand may compete with us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ligand will not be restricted from competing with us in the antibody discovery business. Although Ligand has informed us it has no current intention to compete with us in the antibody discovery business, if Ligand in the future decides to engage in the type of business we conduct, it may have a competitive advantage over us, which may cause our business, financial condition and results of operations to be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Certain of our officers or directors may have actual or potential conflicts of interest because of their equity interests in or positions with Ligand.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Following the Business Combination, one of our directors will retain their position as an employee with Ligand. In addition, our officers or directors may own Ligand Common Stock or equity awards. Following the Distribution and Merger, it is expected that outstanding Ligand equity awards held by our employees generally will be split into two equity awards which will include a Ligand equity award and a New OmniAb Equity Award as described under &#8220;<i style="font-style:italic;">Executive and Director Compensation of OmniAb &#8212; Narrative to Summary Compensation Table &#8212; Treatment of Outstanding Equity Awards at the Time of the Distribution</i>.&#8221; All of our current directors, certain of our director nominees and all of our officers have holdings of Ligand Common Stock or equity awards that may have a material monetary value based on the trading price of Ligand Common Stock, including, as of December&#160;31, 2021: 335,095 </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Ligand shares, 61,289 Ligand shares underlying Ligand RSUs and PSUs (at target levels), and 511,857 Ligand shares underlying Ligand options held by Mr.&#160;Higgins; 2,892 Ligand shares, 1,107 Ligand shares underlying Ligand RSUs, and 11,020 Ligand shares underlying Ligand options held by Ms.&#160;Boyce; 1,161 Ligand shares underlying Ligand RSUs, and 4,508 Ligand shares underlying Ligand options held by Dr.&#160;Cochran; and 28,820 Ligand shares, 630 Ligand shares underlying Ligand RSUs, and 23,133 Ligand shares underlying Ligand options held by Mr.&#160;Patel. For a description of Ligand equity held by our named executive officers and non-employee directors see &#8220;<i style="font-style:italic;">Executive and Director Compensation of OmniAb</i>.&#8221; In addition, it is anticipated that one such individual, our director Mr.&#160;Higgins, will upon the completion of the Business Combination continue to serve as the Chief Executive Officer and a director of Ligand. Mr.&#160;Higgins&#8217; position at Ligand and the ownership by our officers and directors of any Ligand equity or equity awards creates, or may create the appearance of, conflicts of interest when these officers or directors are faced with decisions that could have different implications for Ligand than for us. These potential conflicts could arise, for example, over matters such as the desirability of changes in our business and operations, funding and capital matters, regulatory matters, possible acquisitions or other corporate opportunities, matters arising with respect to the Merger Agreement, the Separation Agreement and other agreements with Ligand relating to the Separation or otherwise, employee retention or recruiting, or our dividend policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the Distribution, together with certain related transactions, fails to qualify as a reorganization under Sections&#160;355 and 368(a)(1)(D)&#160;of the Code, or the Merger fails to qualify as a reorganization under Section&#160;368(a)&#160;of the Code, Ligand and its stockholders could incur significant tax liabilities, and APAC and OmniAb could be required to indemnify Ligand for taxes that could be material pursuant to indemnification obligations under the Tax Matters Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ligand expects to receive the Distribution Tax Opinion from Latham&#160;&amp; Watkins LLP, tax counsel to Ligand, which shall provide that the Distribution will qualify as a reorganization under Sections 355 and 368(a)(1)(D)&#160;of the Code and that the Merger will not cause Section&#160;355(e)&#160;of the Code to apply to the Distribution. In addition, the obligations of Ligand and OmniAb to complete the Merger are conditioned upon, among other things, Ligand&#8217;s receipt of the Distribution Tax Opinion and an opinion of Latham&#160;&amp; Watkins LLP that the Merger will be treated as a reorganization under Section&#160;368(a)&#160;of the Code. The obligation of APAC to complete the Merger is conditioned upon, among other things, receipt of an opinion of Weil, Gotshal&#160;&amp; Manges LLP, tax counsel to APAC, that the Merger will be treated as a reorganization under Section&#160;368(a)&#160;of the Code. The opinions will be based on, among other things, certain facts, assumptions, representations and undertakings from Ligand, OmniAb and APAC, including those regarding the past and future conduct of the Companies&#8217; respective businesses and other matters. If any of these facts, assumptions, representations, or undertakings are incorrect or not satisfied, Ligand may not be able to rely on the opinions, and Ligand and its stockholders could be subject to significant U.S. federal income tax liabilities. In addition, the opinions will not be binding on the IRS or the courts. Notwithstanding the opinions, the IRS could determine on audit that the Distribution or Merger does not qualify as a reorganization if it determines that any of the facts, assumptions, representations or undertakings on which the opinions are based are not correct or have been violated or that the Distribution or Merger should be taxable for other reasons, including as a result of a significant change in stock or asset ownership after the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Distribution, together with certain related transactions, is ultimately determined not to qualify as a reorganization, the Distribution could be treated as a taxable disposition of shares of OmniAb stock by Ligand and as a taxable dividend or capital gain to Ligand&#8217;s stockholders for U.S. federal income tax purposes. If the Merger is ultimately determined not to qualify as a reorganization, the Merger could be treated as a taxable disposition of OmniAb stock by Ligand stockholders. In either such case, Ligand and its stockholders that are subject to U.S. federal income tax could incur significant U.S. federal income tax liabilities. For a more detailed discussion, see the section entitled &#8220;<i style="font-style:italic;">Material U.S. Federal Income Tax Consequences to Ligand Stockholders of the Distribution and Merger</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Tax Matters Agreement that APAC and OmniAb will enter into with Ligand, APAC and OmniAb will generally be required to indemnify Ligand against taxes incurred by Ligand that arise as a result of certain actions or omissions by APAC or OmniAb that prevent the Distribution, together with certain related transactions, from qualifying as a reorganization under Sections 355 and 368(a)(1)(D)&#160;of the Code. Further, even if APAC and OmniAb are not responsible for tax liabilities of Ligand under the Tax Matters Agreement, OmniAb nonetheless could be liable under applicable U.S. federal tax law for such liabilities if Ligand were to fail to pay them. If APAC or OmniAb is required to pay any liabilities under the circumstances set forth in the Tax Matters Agreement or pursuant to applicable tax law, the amounts may be significant. For more information, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;</i><i style="color:#231f20;font-style:italic;">1&#8212;The Business Combination Proposal&#8212;Summary of the Related Agreements</i><i style="font-style:italic;">&#8212;Tax Matters Agreement</i>.&#8221;</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">APAC might not be able to engage in certain transactions and equity issuances following the Distribution.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s ability to engage in equity transactions could be limited or restricted after the Distribution in order to preserve, for U.S. federal income tax purposes, the qualification of the Distribution, together with certain related transactions, as a reorganization under Sections 355 and 368(a)(1)(D)&#160;of the Code. Even if the Distribution otherwise qualifies for tax-free treatment to Ligand&#8217;s stockholders under Section&#160;355 of the Code, it may result in corporate-level taxable gain to Ligand if there is a 50% or greater change in ownership, by vote or value, of APAC ordinary shares, OmniAb stock, Ligand&#8217;s stock or the stock of a successor of any of the foregoing occurring as part of a plan or series of related transactions that includes the Distribution. Any acquisitions or issuances of APAC ordinary shares, OmniAb stock or Ligand&#8217;s stock within two&#160;years of the Distribution are generally presumed to be part of such a plan, although APAC, OmniAb or Ligand may be able to rebut that presumption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Tax Matters Agreement that APAC and OmniAb will enter into with Ligand, APAC and OmniAb will be required to comply with the representations made in the materials submitted to legal counsel in connection with the Distribution Tax Opinion that Ligand expects to receive regarding the intended tax treatment of the Distribution and certain related transactions. The Tax Matters Agreement will also restrict APAC&#8217;s ability to take or fail to take any action if such action or failure to act could adversely affect the intended tax treatment. In particular, except in specific circumstances, in the two&#160;years following the Distribution, APAC and OmniAb will be restricted from, among other things, (i)&#160;entering into certain transactions pursuant to which all or a portion of APAC&#8217;s ordinary shares would be acquired, whether by merger, consolidation, certain stock issuances, or otherwise and (ii)&#160;ceasing to actively conduct certain of the OmniAb businesses. These restrictions may limit for a period of time APAC&#8217;s ability to pursue certain transactions that APAC may believe to be in the best interests of APAC&#8217;s stockholders or that might increase the value of APAC&#8217;s businesses. For more information, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;</i><i style="color:#231f20;font-style:italic;">1&#8212;The Business Combination Proposal&#8212;Summary of the Related Agreements</i><i style="font-style:italic;">&#8212;Tax Matters Agreement</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The anticipated benefits of the Business Combination may not be achieved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may not be able to achieve the full strategic and financial benefits expected to result from the Business Combination, including the potential that the Business Combination will:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allow each business to pursue its own operational and strategic priorities and more quickly respond to trends, developments and opportunities in its respective markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">create two separate and distinct management teams focused on each business&#8217;s unique strategic priorities, target markets and corporate development opportunities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">give each business opportunity and flexibility by pursuing its own investment, capital allocation and growth strategies consistent with its long-term objectives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allow investors to separately value each business based on the unique merits, performance and future prospects of each business, providing investors with two distinct investment opportunities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enhance the ability of each business to attract and retain qualified management and to better align incentive-based compensation with the performance of each separate business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">give each of OmniAb and Ligand its own equity currency for use in connection with acquisitions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may not achieve the anticipated benefits of the Business Combination for a variety of reasons. Further, such benefits, if ultimately achieved, may be delayed. In addition, the Business Combination could materially and adversely affect our business, financial condition and results of operations.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Potential indemnification obligations to Ligand pursuant to the Separation Agreement could materially and adversely affect our businesses, financial condition, results of operations and cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Separation Agreement, among other things, provides for indemnification obligations (for uncapped amounts) designed to make us financially responsible for all liabilities that Ligand may incur or may exist relating to our business activities (as currently and historically conducted), whether incurred prior to or after the Separation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Separation, Ligand will indemnify us for certain liabilities. However, there can be no assurance that such indemnity will be sufficient to insure us against the full amount of such liabilities, or that Ligand&#8217;s ability to satisfy its indemnification obligations will not be impaired in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Separation Agreement and certain other agreements with Ligand, Ligand will agree to indemnify us for certain liabilities as discussed further in &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;&#8212; Summary of the Separation Agreement</i>.&#8221; However, third parties could also seek to hold us responsible for any of the liabilities that Ligand has agreed to retain, and there can be no assurance that the indemnity from Ligand will be sufficient to protect us against the full amount of such liabilities, or that Ligand will be able to fully satisfy its indemnification obligations. In addition, Ligand&#8217;s insurance will not necessarily be available to us for liabilities associated with occurrences of indemnified liabilities prior to the Separation, and in any event Ligand&#8217;s insurers may deny coverage to us for liabilities associated with certain occurrences of indemnified liabilities prior to the Separation. Moreover, even if we ultimately succeed in recovering from Ligand or such insurance providers any amounts for which we are held liable, we may be temporarily required to bear these losses. Each of these risks could negatively affect our businesses, financial position, results of operations and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Separation and Distribution may expose us to potential liabilities arising out of state and federal fraudulent conveyance laws and legal dividend requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Separation and Distribution are subject to review under various state and federal fraudulent conveyance laws. Fraudulent conveyance laws generally provide that an entity engages in a constructive fraudulent conveyance when (i)&#160;the entity transfers assets and does not receive fair consideration or reasonably equivalent value in return; and (ii)&#160;the entity: (a)&#160;is insolvent at the time of the transfer or is rendered insolvent by the transfer; (b)&#160;has unreasonably small capital with which to carry on its business; or (c)&#160;intends to incur or believes it will incur debts beyond its ability to repay its debts as they mature. An unpaid creditor or an entity acting on behalf of a creditor (including without limitation a trustee or debtor-in-possession in a bankruptcy by us or Ligand or any of our respective subsidiaries) may bring an action alleging that the Separation or Distribution or any of the related transactions constituted a constructive fraudulent conveyance. If a court accepts these allegations, it could impose a number of remedies, including without limitation, voiding our claims against Ligand, requiring our stockholders to return to Ligand some or all of the shares of our common stock issued in the Distribution, or providing Ligand with a claim for money damages against us in an amount equal to the difference between the consideration received by Ligand and our fair market value at the time of the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The measure of insolvency for purposes of the fraudulent conveyance laws will vary depending on which jurisdiction&#8217;s law is applied. Generally, an entity would be considered insolvent if (i)&#160;the present fair saleable value of its assets is less than the amount of its liabilities (including contingent liabilities); (ii)&#160;the present fair saleable value of its assets is less than its probable liabilities on its debts as such debts become absolute and matured; (iii)&#160;it cannot pay its debts and other liabilities (including contingent liabilities and other commitments) as they mature; or (iv)&#160;it has unreasonably small capital for the business in which it is engaged. We cannot assure you what standard a court would apply to determine insolvency or that a court would determine that we, Ligand or any of our respective subsidiaries were solvent at the time of or after giving effect to the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Distribution of our common stock is also subject to review under state corporate distribution statutes. Under the DGCL, a corporation may only pay dividends to its stockholders either (i)&#160;out of its surplus (net assets minus capital) or (ii)&#160;if there is no such surplus, out of its net profits for the fiscal&#160;year in which the dividend is declared or the preceding fiscal&#160;year. Although Ligand intends to make the Distribution of our common stock entirely from surplus, we cannot assure you that a court will not later determine that some or all of the Distribution to Ligand stockholders was unlawful.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain and maintain sufficient intellectual property protection for our platform and technology, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technologies or a platform similar or identical to ours, and our ability to successfully sell our platform and services may be impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We rely on patent protection, as well as trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions, to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep a competitive advantage. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us. In addition, we may incur substantial litigation costs in our attempts to recover or restrict the use of our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property does not provide adequate coverage to exclude our competitors from making products or providing services claimed in our patents, our competitive position could be adversely affected, as could our business. Both the patent application process and the process of managing patent disputes can be time-consuming and expensive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our success depends in large part on our ability to obtain and maintain adequate protection of the intellectual property we may own solely and jointly with others or otherwise have rights to, particularly patents, in the United States and in other countries with respect to our platform, our software and our technologies, without infringing the intellectual property rights of others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We strive to protect and enhance the proprietary technologies that we believe are important to our business, including seeking patents intended to cover our platform and related technologies and uses thereof, as we deem appropriate. Certain of our patents and patent applications in the United States and certain foreign jurisdictions relate to our technology. However, obtaining and enforcing patents in our industry is costly, time-consuming and complex, and we may fail to apply for patents on important products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions. There can be no assurance that the claims of our patents (or any patent application that issues as a patent), will exclude others from making, using, importing, offering for sale, or selling our products or services that are substantially similar to ours. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. In countries where we have not sought and do not seek patent protection, third parties may be able to manufacture and sell our technology without our permission, and we may not be able to stop them from doing so. We may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is possible that none of our pending patent applications will result in issued patents in a timely fashion or at all, and even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products or services, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties or deemed unenforceable by a court. It is possible that others will design around our current or future patented technologies. As a result, our owned and licensed patents and patent applications comprising our patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar to any of our technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">It is possible that in the future some of our patents, licensed patents or patent applications may be challenged in court in the United States or outside of the United States, at the United States Patent and Trademark Office (USPTO) or in proceedings before the patent offices of other jurisdictions. We may not be successful in defending any such challenges made against our patents or patent applications. Any successful third party challenge to our patents could result in loss of exclusivity, patent claims being narrowed, or the unenforceability or invalidity of such patents, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, limit the duration of the patent protection of our technology, and increase competition to our business. We may have to challenge the patents or patent applications of third parties. The outcome of patent litigation or other proceedings can be uncertain, and any attempt by us to enforce our patent rights against others or to challenge </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">the patent rights of others may not be successful, or, if successful, may take substantial time and involve substantial cost, and may divert our efforts and attention from other aspects of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any changes we make to our technology, including changes that may be required for commercialization or that cause them to have what we view as more advantageous properties, may not be covered by our existing patent portfolio, and we may be required to file new applications and/or seek other forms of protection for any such alterations to our technology. There can be no assurance that we would be able to secure patent protection that would adequately cover an alternative to our technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The patent positions of life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in such companies&#8217; patents has emerged to date in the United States or elsewhere. Courts frequently render opinions in the biotechnology field that may affect the patentability of certain inventions or discoveries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our technology.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Changes in either the patent laws or in interpretations of patent laws in the United States or other countries or regions may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third party patents. We may not develop additional proprietary platforms, methods and technologies that are patentable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming that other requirements for patentability are met, prior to March&#160;16, 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. On or after March&#160;16, 2013, under the Leahy-Smith America Invents Act (the America Invents Act), the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO on or after March&#160;16, 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i)&#160;file any patent application related to our technology or (ii)&#160;invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The America Invents Act also includes a number of significant changes that affect the way patent applications are now prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the patent position of companies in the biotechnology field is particularly uncertain. Various courts, including the United States Supreme Court, have rendered decisions that affect the scope of patentability of certain inventions or discoveries relating to biotechnology. These decisions state, among other things, that a patent claim that recites an abstract idea, natural phenomenon or law of nature (for example, the relationship between particular genetic variants and cancer) are not themselves patentable. Precisely what constitutes a law of nature or abstract idea is uncertain, and it is possible that certain aspects of our technology could be considered natural laws. Accordingly, the evolving case law in the United States may adversely affect our and our licensors&#8217; ability to obtain new patents or to enforce existing patents and may facilitate third party challenges to any owned or licensed patents.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Issued patents directed to our platform and technology could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Some of our patents or patent applications (including licensed patents) may be challenged at a future point in time in opposition, derivation, reexamination, inter partes review, post-grant review or interference. Any successful third party challenge to our patents in this or any other proceeding could result in the unenforceability or invalidity of such patents or amendment to our patents in such a way that any resulting protection may lead to increased competition to our business, which could harm our business. In addition, in patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on certain aspects of our platform technologies. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2020, Regeneron Pharmaceuticals filed an opposition to our European Patent No.&#160;2931030 directed to human-rat chimeric antibodies. The opposition is ongoing. If the opposition is successful in invalidating the claims of the patent, or narrowing their scope, the loss in ability to assert the patent in its current form may lead to increased competition to our business, which could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may not be aware of all third party intellectual property rights potentially relating to our platform or technology. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18&#160;months after filing or, in some cases, not until such patent applications issue as patents. We or our licensors might not have been the first to make the inventions included in each of our pending patent applications and we or our licensors might not have been the first to file patent applications for these inventions. There is also no assurance that all of the potentially relevant prior art relating to our patents and patent applications or licensed patents and patent applications has been found, which could be used by a third party to challenge their validity, or prevent a patent from issuing from a pending patent application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO that could result in substantial cost to us. The outcome of such proceedings is uncertain. No assurance can be given that other patent applications will not have priority over our patent applications. In addition, changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and management distraction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on in-licenses from third parties. If we lose these rights, our business may be materially and adversely affected, our ability to develop improvements to our technology platform and antibody discovery platform may be negatively and substantially impacted, and if disputes arise, we may be subjected to future litigation, as well as the potential loss of or limitations on our ability to incorporate the technology covered by these license agreements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are party to royalty-bearing license agreements that grant us rights to practice certain patent rights that are related to our systems, including our microcapillary assay technology, methods for selecting agents that bind to transmembrane receptors in a conformationally selective manner, and bovine antibody humanization technology. We may need to obtain additional licenses from others to advance our research, development and commercialization activities. Some of our license agreements impose, and we expect that any future in-license agreements will impose, various development, diligence, commercialization and other obligations on us. We may enter into engagements in the future, with other licensors or other third parties under which we obtain certain intellectual property rights relating to our platform and technology. These engagements may take the form of an exclusive license or purchase of intellectual property rights or technology from third parties. Our rights to use the technology we license are subject to the continuation of and compliance with the terms of those agreements. In some cases, we may not control the prosecution, maintenance or filing of the patents to which we hold licenses, or the enforcement of those patents against third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, disputes may arise with respect to our licensing or other upstream agreements, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the agreements and other interpretation-related issues;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our systems and consumables, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sublicensing of patent and other rights under our license agreements with our partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations under the license agreements and what activities satisfy those diligence obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the priority of invention of patented technology.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In spite of our efforts to comply with our obligations under our in-license agreements, our licensors might conclude that we have materially breached our obligations under our license agreements and might therefore, including in connection with any aforementioned disputes, terminate the relevant license agreement, thereby removing or limiting our ability to develop and commercialize technology covered by these license agreements. If any such in-license is terminated, or if the licensed patents fail to provide the intended exclusivity, competitors or other third parties might have the freedom to market or develop technologies similar to ours. In addition, absent the rights granted to us under our license agreements, we may infringe the intellectual property rights that are the subject of those agreements, we may be subject to litigation by the licensor, and if such litigation by the licensor is successful we may be required to pay damages to our licensor, or we may be required to cease our development and commercialization activities that are deemed infringing, and in such event we may ultimately need to modify our activities or technologies to design around such infringement, which may be time- and resource-consuming, and which ultimately may not be successful. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, our rights to certain components of our technology platform, are licensed to us on a non-exclusive basis. The owners of these non-exclusively licensed technologies are therefore free to license them to third parties, including our competitors, on terms that may be superior to those offered to us, which could place us at a competitive disadvantage. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, certain of our agreements with third parties may provide that intellectual property arising under these agreements, such as data that could be valuable to our business, will be owned by the third party, in which case, we may not have adequate rights to use such data or have exclusivity with respect to the use of such data, which could result in third parties, including our competitors, being able to use such data to compete with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we cannot acquire or license rights to use technologies on reasonable terms or if we fail to comply with our obligations under such agreements, we may not be able to commercialize new technologies or services in the future and our business could be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the future, we may identify third party intellectual property and technology we may need to acquire or license in order to engage in our business, including to develop or commercialize new technologies or services, and the growth of our business may depend in part on our ability to acquire, in-license or use this technology. However, such licenses may not be available to us on acceptable terms or at all. The licensing or acquisition of third party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater development or commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Even if such licenses are available, we may be required to pay the licensor in return for the use of such licensor&#8217;s technology, lump-sum payments, payments based on certain milestones such as sales volumes, or royalties based on sales of our platform. In addition, such licenses may be non-exclusive, which could give our competitors access to the same intellectual property licensed to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize technology covered by these license agreements. If these licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. Additionally, termination of these license agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology or impede, or delay or prohibit the further development or commercialization of one or more technologies that rely on such agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot prevent third parties from also accessing those technologies. In addition, our licenses may place restrictions on our future business opportunities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the above risks, intellectual property rights that we license in the future may include sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our or our partners&#8217; ability to further commercialize our technology or products generated using our technology may be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, we may not have the right to control the prosecution, maintenance and enforcement of all of our licensed and sublicensed intellectual property, and even when we do have such rights, we may require the cooperation of our licensors and upstream licensors, which may not be forthcoming. Our business could be adversely affected if we or our licensors are unable to prosecute, maintain and enforce our licensed and sublicensed intellectual property effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents and patent applications we in-license. If other third parties have ownership rights to patents or patent applications we in-license, they may be able to license such patents to our competitors, and our competitors could market competing technology and services. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business, financial condition, results of operations and prospects could be materially and adversely affected if we are unable to enter into necessary agreements on acceptable terms or at all, if any necessary licenses are subsequently terminated, if the licensors fail to abide by the terms of the licenses or fail to prevent infringement by third parties, or if the acquired or licensed patents or other rights are found to be invalid or unenforceable. Moreover, we could encounter delays in the introduction of new technology or services while we attempt to develop alternatives. Defense of any lawsuit or failure to obtain any of these licenses on favorable terms could prevent us from commercializing our platform and technology and advancing partnerships, which could harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting and defending patents on our platform, technology, software, systems, workflows and processes in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Whether filed in the United States or abroad, our patent applications may be challenged or may fail to result in issued patents. Further, we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in some or all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own platform or technologies and may also sell their products or services to territories where we have patent protection, but enforcement is not as strong as that in the United States. These platforms and technologies may compete with ours. Our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to other parties. Furthermore, many countries limit the enforceability of patents against other parties, including government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of any patents. In many foreign countries, patent applications and/or issued patents, or parts thereof, must be translated into the native language. If our patent applications or issued patents are translated incorrectly, they may not adequately cover our technologies; in some countries, it may not be possible to rectify an incorrect translation, which may result in patent protection that does not adequately cover our technologies in those countries.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the misappropriation or other violations of our intellectual property rights including infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, or that are initiated against us, and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technologies and the enforcement of intellectual property. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make products that are similar to any therapeutic candidates generated by our platform that our partners may develop but that are not covered by the claims of the patents that we or our partners have or license or may own or license in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our current or future partners, might not have been the first to make the inventions covered by the issued patents and pending patent applications that we or our partners have or license or may have or license in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our current or future partners, might not have been the first to file patent applications covering certain of our or their inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our pending patent applications or those that we may hold in the future will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable technology or therapeutic candidates of our partners or will provide us or our partners with any competitive advantages;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we cannot ensure that our commercial activities or partners&#8217; therapeutic candidates will not infringe the patents of others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we cannot ensure that we will be able to further commercialize our technology on a substantial scale, if approved, before the relevant patents that we hold or license expire;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents or intellectual property rights of others may harm our business; and</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our information and our trade secrets, the value of our technology could be materially and adversely affected and our business could be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information, including parts of our technology platform, and to maintain our competitive position. However, trade secrets and know-how can be difficult to protect. In addition to pursuing patents on our technology, we take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, academic institutions, corporate partners and, when needed, our advisers. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure, which could adversely impact our ability to establish or maintain a competitive advantage in the market. If we are required to assert our rights against such party, it could result in significant cost and distraction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Monitoring unauthorized disclosure and detection of unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable. In addition, some courts both within and outside the United States may be less willing, or unwilling, to protect trade secrets. Further, we may need to share our trade secrets and confidential know-how with current or future partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor or other third party, absent patent protection, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. If any of our trade secrets were to be disclosed to or independently discovered by a competitor or other third party, it could harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have employed and expect to employ individuals who were previously employed at universities or other companies. Although we try to ensure that our employees, consultants, advisors and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that our employees, advisors, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information of their former employers or other third parties, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights and face increased competition to our business. A loss of key research personnel work product could hamper or prevent our ability to commercialize potential technologies and solutions, which could harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Any of the foregoing could harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect and enforce our trademarks and trade names, or build name recognition in our markets of interest thereby harming our competitive position.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The registered or unregistered trademarks or trade names that we own may be challenged, infringed, circumvented, declared generic, lapsed or determined to be infringing on or dilutive of other marks. We may not be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition. In addition, third parties may in the future file for registration of trademarks similar or identical to our trademarks, thereby impeding our ability to build brand identity and possibly leading to market confusion. If they succeed in registering or developing common law rights in such trademarks, and if we are not successful in challenging such rights, we may not be able to use these trademarks to develop brand recognition of our technologies or platform. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Further, we have and may in the future enter into agreements with owners of such third party trade names or trademarks to avoid potential trademark litigation which may limit our ability to use our trade names or trademarks in certain fields of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not yet registered certain of our trademarks in all of our potential markets. If we apply to register these trademarks in other countries, and/or other trademarks in the United States and other countries, our applications may not be allowed for registration in a timely fashion or at all; and further, our registered trademarks may not be maintained or enforced. In addition, opposition or cancellation proceedings may in the future be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. In addition, third parties may file first for our trademarks in certain countries. If they succeed in registering such trademarks, and if we are not successful in challenging such third party rights, we may not be able to use these trademarks to market our technologies in those countries. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, which could harm our business, financial condition, results of operations and prospects. And, over the long-term, if we are unable to establish name recognition based on our trademarks, then our marketing abilities may be materially and adversely impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We or our licensors may be subject to claims that former employees, partners or other third parties have an interest in our or our in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. Litigation may be necessary to defend against these and other claims challenging inventorship of our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our systems, including our software, workflows, consumables, reagents, and transgenic animals. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees, and certain partners or partners may defer engaging with us until the particular dispute is resolved. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may from time to time become involved in litigation and other proceedings related to intellectual property, which could be time-intensive and costly and may adversely affect our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology, pharmaceutical and drug discovery industries, including patent infringement lawsuits, declaratory judgment litigation and adversarial proceedings before the USPTO, including interferences, derivation proceedings, ex parte reexaminations, post-grant review and&#160;inter partes&#160;review, as well as corresponding proceedings in foreign courts and foreign patent offices.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are, and may, in the future, become involved with litigation or actions at the USPTO or foreign patent offices with various third parties. We expect that the number of such claims may increase as our business, visibility and partnership base expands, and as the level of competition in our industry increases. Any infringement claim, regardless of its validity, could harm our business by, among other things, resulting in time-consuming and costly litigation, diverting management&#8217;s time and attention from the development of the business, requiring the payment of monetary damages (including treble damages, attorneys&#8217; fees, costs and expenses) or royalty payments, or result in potential or existing partners delaying entering into engagements with us pending resolution of the dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It may be necessary for us to pursue litigation or adversarial proceedings before the patent office in order to enforce our patent and proprietary rights or to determine the scope, coverage and validity of the proprietary rights of others. The outcome of any such litigation might not be favorable to us, and even if we were to prevail, such litigation could result in substantial costs and diversion of resources and could have a material adverse effect on our business, operating results or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Third parties may assert that we are employing their proprietary technology without authorization. Given that the therapeutics discovery field is a highly competitive areas, there may be third-party intellectual property rights that others believe could relate to our technologies. The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. An unfavorable outcome in any such proceeding could require us to cease using the related technology or developing or commercializing our technology, or to attempt to license rights to it from the prevailing party, which may not be available on commercially reasonable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because patent applications can take many&#160;years to issue, there may be currently pending patent applications that may later result in issued patents that our current or future products, technologies and services may infringe. We cannot be certain that we have identified or addressed all potentially significant third-party patents in advance of an infringement claim being made against us. In addition, similar to what other companies in our industry have experienced, we expect our competitors and others may have patents or may in the future obtain patents and claim that making, having made, using, selling, offering to sell or importing our technologies infringes these patents. Defense of infringement and other claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell products or services and could result in the award of substantial damages against us, including treble damages, attorney&#8217;s fees, costs and expenses if we are found to have willfully infringed. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties and obtain one or more licenses from third parties, or be prohibited from selling certain products or services. We may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all, or these licenses may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we could encounter delays in product or service introductions while we attempt to develop alternative products or services to avoid infringing third-party patents or proprietary rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing products or services, and the prohibition of sale of any of our technologies could materially affect our business and our ability to gain market acceptance for our technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, our agreements with some of our partners, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any uncertainties resulting from the initiation and continuation of any litigation or administrative proceeding could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on issued United States and most foreign patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States at several stages over the lifetime of the patents and/or applications in order to maintain such patents and patent applications. We have systems in place to remind us to pay these fees, and we engage an outside service and rely on those services and our outside counsel to pay these fees. The USPTO and various non-U.S.&#160;governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals and services to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, if we or our licensors fail to maintain the patents and patent applications covering our technology and products, our competitors may be able to enter the market with similar or identical technology or products without infringing our patents and this circumstance would have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent terms may be inadequate to protect our competitive position on our technology for an adequate amount of time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S.&#160;non-provisional filing date. This term can be reduced by the filing of a terminal disclaimer. Some of our patents have terminal disclaimers. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our platform or technology are obtained, once the patent life has expired, we may be open to competition from others. If our platform or technologies require extended development and/or regulatory review, patents protecting our platform or technologies might expire before or shortly after we are able to successfully commercialize them. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing processes or technologies similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our use of open source software could compromise our ability to offer our data packages and subject us to possible litigation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We use open source software in connection with our technology and computational engine of our platform. Companies that incorporate open source software into their technologies and services have, from time to time, faced claims challenging their use of open source software and compliance with open source license terms. As a result, we could be subject to lawsuits by parties claiming ownership of what we believe to be open source software or claiming noncompliance with open source licensing terms. Some open source software licenses require users who distribute software containing open source software to publicly disclose all or part of the source code to the licensee&#8217;s software that incorporates, links or uses such open source software, and make available to third parties for no cost, any derivative works of the open source code created by the licensee, which could include the licensee&#8217;s own valuable proprietary code. While we monitor our use of open source software and try to ensure that none is used in a manner that would require us to disclose our proprietary source code or that would otherwise breach the terms of an open source agreement, such use could inadvertently occur, or could be claimed to have occurred, in part because open source license terms are often ambiguous. There is little legal precedent in this area and any actual or claimed requirement to disclose our proprietary source code or pay damages for breach of contract could harm our business and could help third parties, including our competitors, develop technologies that are similar to or better than ours. Any of the foregoing could harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Some of our intellectual property rights may have been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S.&#160;manufacturers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Some of our intellectual property rights may have been generated through the use of U.S.&#160;government funding and are therefore subject to certain federal regulations. As a result, the U.S.&#160;government may have certain rights to intellectual property embodied in our technology pursuant to the Bayh-Dole Act of 1980 (Bayh-Dole Act), and implementing regulations. These U.S.&#160;government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">license to use inventions for any governmental purpose. In addition, the U.S.&#160;government has the right to require us or our licensors to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. These time limits have recently been changed by regulation, and may change in the future. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S.&#160;government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S.&#160;manufacturers may limit our ability to contract with non-U.S.&#160;product manufacturers for products covered by such intellectual property. To the extent any of our future intellectual property is generated through the use of U.S.&#160;government funding, the provisions of the Bayh-Dole Act may similarly apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, and insider trading.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of fraud or other misconduct by our employees, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the applicable laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. These laws and regulations may restrict or prohibit a wide range of pricing, discounting and other business arrangements. Such misconduct could result in legal or regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and any other precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant civil, criminal and administrative penalties, which could have a significant impact on our business. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees and divert the attention of management in defending ourselves against any of these claims or investigations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We use biological and hazardous materials that require considerable expertise and expense for handling, storage and disposal and may result in claims against us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We work with materials, including chemicals, biological agents and compounds that could be hazardous to human health and safety or the environment. Our operations also produce hazardous and biological waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. We are subject to periodic inspections by state and federal authorities to ensure compliance with applicable laws. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental laws and regulations may restrict our operations. If we do not comply with applicable regulations, we may be subject to fines and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes, which could cause an interruption of our commercialization efforts, research and development programs and business operations, as well as environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations. In the event of contamination or injury, we could be liable for damages or penalized with fines in an amount exceeding our resources and our operations could be suspended or otherwise adversely affected. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. We could face criminal liability and other serious consequences for violations, which could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, and anti-corruption and anti-money laundering laws and regulations, including the US Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the US Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, CROs, contractors and other collaborators and partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, CROs, contractors and other collaborators and partners, even if we do not explicitly authorize or have actual knowledge of such activities. We are also subject to other U.S. laws and regulations governing export controls, as well as economic sanctions and embargoes on certain countries and persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, the global credit and financial markets have experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that future deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will incur significant increased costs as a result of operating as a standalone public company, and our management will be required to devote substantial time to new compliance initiatives.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a standalone public company, we will incur significant legal, accounting, insurance and other expenses that we did not incur as a private company. We will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, Sarbanes-Oxley, as well as rules&#160;subsequently adopted by the SEC and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules&#160;and regulations in these areas, such as mandatory &#8220;say on pay&#8221; voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect the rules&#160;and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules&#160;and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no securities or industry analysts commence coverage of our company, the trading price for our common stock would likely be negatively impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrades our common stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our shares could decrease, which might cause our stock price and trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have identified a material weakness in our internal control over financial reporting. If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management has concluded that our procedures and internal controls over financial reporting were not effective as of December&#160;31, 2020, due solely to a material weakness in internal controls over financial reporting related to recording transactions between us and Ligand. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented, or detected and corrected on a timely basis. Management identified an error in the accumulation of information for the preparation of the carve-out financial statements. The errors resulted in a $7.0 million understatement of accounts receivable, net, as well as a $7.0 million overstatement of cash flows from operating activities, and a $7.0 million understatement of cash flows from financing activities. As a result of the errors, management restated the financial statements at December&#160;31, 2020 and 2019 and the&#160;years then ended. See <i style="font-style:italic;">Note&#160;(2), Restatement of Previously Issued Combined Financial Statements</i> in OmniAb&#8217;s combined financial statements included in this proxy statement/prospectus/information statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Effective internal controls are necessary for us to provide reliable financial reports and prevent fraud. We continue to evaluate steps to remediate the material weakness, including implementing changes to our process for preparing the carve-out financial statements. These remediation measures may be time consuming and costly and there is no assurance that these initiatives will ultimately have the intended effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we identify any new material weaknesses in the future, any such newly identified material weakness could limit our ability to prevent or detect a misstatement of our accounts or disclosures that could result in a material misstatement of our annual or interim financial statements. In such case, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting and our stock price may decline as a result. We cannot assure you that the measures we have taken to date, or any measures we may take in the future, will be sufficient to avoid potential future material weaknesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Upon completion of the Distribution and Merger, we will become subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized, and reported within the time periods specified in the rules&#160;and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Business Combination and APAC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">APAC has no operating history and its results of operations and those of OmniAb may differ significantly from the unaudited pro forma financial data included in this proxy statement/prospectus/information statement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC is a blank check company, and it has no operating history or results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This proxy statement/prospectus/information statement includes unaudited pro forma combined financial statements for APAC and OmniAb. The unaudited pro forma combined balance sheet as of December&#160;31, 2021 combines the audited balance sheet of APAC as of December&#160;31, 2021 and the audited combined balance sheet of the OmniAb Business as of December&#160;31, 2021 on a pro forma basis as if the Business Combination had been consummated on December&#160;31, 2021. The unaudited statement of operations as of December&#160;31, 2021 combines the audited statement of operations of APAC for the period from January&#160;1, 2021 and the audited consolidated statement of operations of the OmniAb Business for the quarter ended December&#160;31, 2021 on a pro forma basis as if the Business Combination had been consummated on December&#160;31, 2021, the beginning of the earliest period presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma combined financial information is based upon, and should be read together with the accompanying notes to the unaudited pro forma combined financial statements, the audited financial statements of APAC and related notes, the OmniAb audited consolidated financial statements and related notes, the sections of this proxy statement/prospectus/information statement entitled &#8220;<i style="font-style:italic;">APAC Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; &#8220;OmniAb Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</i>&#8221; and other financial information included elsewhere in this proxy statement/prospectus/information statement. The unaudited pro forma combined financial information has been presented for informational purposes only and is not necessarily indicative of what OmniAb&#8217;s financial position or results of operations would have been had the Business Combination and related transactions been completed as of the dates indicated. In addition, the unaudited pro forma combined financial information does not purport to project the future financial position or operating results of the combined company following the consummation of the Business Combination. For more information, see the section entitled &#8220;<i style="font-style:italic;">Unaudited Pro Forma Condensed Combined Financial Information of APAC and OmniAb</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Sponsor has agreed to vote in favor of the Business Combination, regardless of how APAC&#8217;s public shareholders vote.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unlike some other blank check companies in which the initial shareholders agree to vote their founder shares in accordance with the majority of the votes cast by the public shareholders in connection with an initial business combination, the Sponsor and each director of APAC have agreed to, among other things, vote in favor of the Merger Agreement and the transactions contemplated thereby. As of the date of this proxy statement/prospectus/information statement, the Sponsor (including APAC&#8217;s directors) owns 20% of the issued and outstanding ordinary shares of APAC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">APAC may not be able to complete the Business Combination or any other business combination within the prescribed time frame, in which case APAC would cease all operations, except for the purpose of winding up, and APAC would redeem the APAC Class&#160;A Ordinary Shares and liquidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">If APAC does not complete an initial business combination by February&#160;12, 2023, it must cease operation and redeem 100% of the outstanding APAC Class&#160;A Ordinary Shares. APAC may not be able to consummate the Business Combination or any other business combination by such date. If APAC has not completed any initial business combination by such date (or if such date is extended at a duly called extraordinary general meeting, such later date), it will: (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than ten business&#160;days thereafter, redeem the APAC Class&#160;A Ordinary Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest (which interest shall be net of taxes payable) divided by the number of then outstanding APAC Class&#160;A Ordinary Shares, which redemption will completely extinguish the rights of holders of APAC Class&#160;A Ordinary Shares as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of APAC&#8217;s remaining shareholders and the APAC Board, dissolve and liquidate, </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">subject in each case to APAC&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Since the Sponsor and APAC&#8217;s directors and executive officers have interests that are different, or in addition to (and which may conflict with), the interests of our shareholders, a conflict of interest may have existed in determining whether the Business Combination with OmniAb is appropriate as our initial business combination. Such interests include that Sponsor will lose its entire investment in us if our business combination is not completed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">When you consider the recommendation of the APAC Board in favor of approval of the Business Combination Proposal, you should keep in mind that the Sponsor and APAC&#8217;s directors and officers have interests in such proposal that are different from, or in addition to, those of APAC shareholders and warrant holders generally. These interests include, among other things, the interests listed below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to APAC&#8217;s initial public offering, the Sponsor purchased 5,750,000 APAC Class&#160;B Ordinary Shares for an aggregate purchase price of $25,000, or approximately $0.004 per share, and Sponsor later transferred 35,000 APAC Class&#160;B Ordinary Shares to each of William E. Klitgaard, L&#226;le White and Wendel Barr, each of whom serve on the APAC Board, for no consideration, resulting in an aggregate 5,750,000 Class&#160;B Ordinary Shares issued and outstanding, 5,645,000 of which are held by the Sponsor, and 105,000 of which, in the aggregate, are held by our directors. If APAC does not consummate a business combination by February&#160;12, 2023 (or if such date is extended at a duly called extraordinary general meeting, such later date), it would cease all operations except for the purpose of winding up, redeeming all of the outstanding public shares for cash and, subject to the approval of its remaining shareholders and the APAC Board, dissolving and liquidating, subject in each case to its obligations under the Cayman Islands Companies Act to provide for claims of creditors and the requirements of other applicable law. In such event, the 5,750,000 APAC Class&#160;B Ordinary Shares collectively owned by the Sponsor and three members of the APAC Board (William E. Klitgaard, L&#226;le White and Wendel Barr) would be worthless because following the redemption of the public shares, APAC would likely have few, if any, net assets and because the Sponsor and APAC&#8217;s directors and officers have agreed to waive their respective rights to liquidating distributions from the trust account in respect of any APAC Class&#160;A Ordinary Shares and APAC Class&#160;B Ordinary Shares held by it or them, as applicable, if APAC fails to complete a business combination within the required period. Additionally, in such event, the 8,233,333 APAC Private Placement Warrants purchased by the Sponsor simultaneously with the consummation of APAC&#8217;s initial public offering for an aggregate purchase price of $12,350,000 will also expire worthless. Certain of APAC&#8217;s directors, including William E. Klitgaard, L&#226;le White and Wendel Barr, each also own 35,000 APAC Class&#160;B Ordinary Shares. The 5,750,000 shares of New OmniAb Common Stock into which the 5,750,000 APAC Class&#160;B Ordinary Shares collectively held by the Sponsor, William E. Klitgaard, L&#226;le White and Wendel Barr will automatically convert in connection with the Merger (including after giving effect to the Domestication), if unrestricted and freely tradable, would have had an aggregate market value of $[&#9679;] based upon the closing price of $[&#9679;] per public share on Nasdaq on [&#9679;], 2022, the most recent practicable date prior to the date of this proxy statement/prospectus/information statement. However, given that such shares of New OmniAb Common Stock will be subject to certain restrictions, including those described above, APAC believes such shares have less value. The 8,233,333 New OmniAb Warrants into which the 8,233,333 APAC Private Placement Warrants held by the Sponsor will automatically convert in connection with the Merger (including after giving effect to the Domestication), if unrestricted and freely tradable, would have had an aggregate market value of $[&#9679;] based upon the closing price of $[&#9679;] per public warrant on Nasdaq on [&#9679;], 2022, the most recent practicable date prior to the date of this proxy statement/prospectus/information statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of the low initial purchase price (consisting of $25,000 for the 5,750,000 APAC Class B Ordinary Shares, or approximately $0.004 per share, and $12,350,000 for the Private Placement Warrants), the Sponsor, its affiliates and APAC&#8217;s management team and advisors stand to earn a positive rate of return or profit on their investment, even if other shareholders, such as APAC&#8217;s public shareholders, experience a negative rate of return because the post-business combination company subsequently declines in value. Thus, the Sponsor, our officers and directors, and their respective affiliates may have more of an economic incentive for us to, rather than liquidate if we fail to complete our initial business combination by February 12, 2023, enter into an initial business combination on potentially less favorable terms with a potentially less favorable, riskier, weaker-performing or financially unstable business, or an entity lacking an established record of revenues or earnings, than would be the case if such parties had paid the full offering price for their Class B ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Pursuant to the Original Forward Purchase Agreement, the Sponsor agreed to purchase 10,000,000 APAC Class&#160;A Ordinary Shares, plus an aggregate of 3,333,333 redeemable warrants to purchase one APAC Class&#160;A Ordinary Share at $11.50 per share, for an aggregate purchase price of $100,000,000, or $10.00 per APAC Class&#160;A Ordinary Share, in a private placement to occur concurrently with the closing of APAC&#8217;s initial business combination. On March&#160;23, 2022, the Forward Purchase Agreement was amended and </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">restated in its entirety by the A&amp;R FPA in connection with the Business Combination. Pursuant to the A&amp;R FPA, APAC has agreed that it will issue and sell to the Sponsor 1,500,000 shares of New OmniAb Common Stock and warrants to acquire 1,666,667 shares of New OmniAb Common Stock for an aggregate purchase price of $15,000,000 with such purchases to be consummated immediately following the Domestication and prior to the Merger. In addition to the Forward Purchase, the Sponsor has agreed to purchase up to an additional 10,000,000 shares of New OmniAb Common Stock and up to an additional 1,666,667 New OmniAb Warrants, for an aggregate additional purchase price of up to $100,000,000, in order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds available to New OmniAb from APAC&#8217;s trust account being less than $100,000,000 as of immediately prior to the Closing. The A&amp;R FPA also provides that, in the event the Merger Agreement is terminated by Ligand under circumstances in which the Termination Fee would be payable thereunder, Ligand shall pay the Sponsor a termination fee of $12,500,000 in connection therewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">[&#9679;] is expected to be a director of APAC after the consummation of the Business Combination. As such, in the future, [&#9679;] may receive fees for their service as director, which may consist of cash or stock-based awards, and any other remuneration that the New OmniAb Board determines to pay to its non-employee directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor (including its representatives and affiliates) and APAC&#8217;s directors and officers, are, or may in the future become, affiliated with entities that are engaged in a similar business to APAC. The Sponsor and APAC&#8217;s directors and officers are not prohibited from sponsoring, or otherwise becoming involved with, any other blank check companies prior to APAC completing its initial business combination. Moreover, certain of APAC&#8217;s directors and officers have time and attention requirements for investment funds of which affiliates of the Sponsor are the investment managers. APAC&#8217;s directors and officers also may become aware of business opportunities which may be appropriate for presentation to APAC, and the other entities to which they owe certain fiduciary or contractual duties. Accordingly, they may have had conflicts of interest in determining to which entity a particular business opportunity should be presented. These conflicts may not be resolved in APAC&#8217;s favor and such potential business opportunities may be presented to other entities prior to their presentation to APAC, subject to applicable fiduciary duties under the Cayman Islands Companies Act. APAC&#8217;s Cayman Constitutional Documents provide that APAC renounces its interest in any corporate opportunity offered to any director or officer of APAC unless such opportunity is expressly offered to such person solely in his or her capacity as a director or officer of APAC and it is an opportunity that APAC is able to complete on a reasonable basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s existing directors and officers will be eligible for continued indemnification and continued coverage under APAC&#8217;s directors&#8217; and officers&#8217; liability insurance after the Merger and pursuant to the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that APAC fails to consummate a business combination within the prescribed time frame (pursuant to the Cayman Constitutional Documents), or upon the exercise of a redemption right in connection with the Business Combination, APAC will be required to provide for payment of claims of creditors that were not waived that may be brought against APAC within the ten&#160;years following such redemption. In order to protect the amounts held in APAC&#8217;s trust account, the Sponsor has agreed that it will be liable to APAC if and to the extent any claims by a third party (other than APAC&#8217;s independent registered public accounting firm) for services rendered or products sold to APAC, or a prospective target business with which APAC has discussed entering into a transaction agreement, reduce the amount of funds in the trust account to below the lesser of (i)&#160;$10.25 per public share or (ii)&#160;the actual amount per public share held in the trust account as of the date of the liquidation of the trust account, due to reductions in value of the trust assets, in each case, net of the amount of interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the trust account and except as to any claims under the indemnity of the underwriters of APAC&#8217;s initial public offering against certain liabilities, including liabilities under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Commencing on the effective date of the prospectus/information statement filed in connection with our initial public offering, we agreed to reimburse our Sponsor for out-of-pocket expenses through the completion of the Business Combination or APAC&#8217;s liquidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Sponsor, or an affiliate of the Sponsor, has advanced funds to APAC for working capital purposes, including $500,000 as of March&#160;15, 2022. These outstanding advances have been documented in a promissory note, dated March&#160;14, 2022 (the &#8220;Promissory Note&#8221;) issued by APAC to the Sponsor, pursuant to which APAC may borrow up to $750,000 from the Sponsor (including those amounts which are currently outstanding). The Promissory Note&#160;is non-interest bearing, unsecured and due and payable in full on the earlier of the date APAC consummates its initial business combination and the date that winding up of APAC is effective. If APAC does not complete its initial business combination within the required period, it may use a portion of its working capital held outside the trust account to repay such advances and any other working capital advances made to APAC, but no proceeds held in the trust </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">account would be used to repay such advances and any other working capital advances made to APAC, and such related party may not be able to recover the value it has loaned to APAC and any other working capital advances it may make.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, APAC&#8217;s executive officers and directors, or any of their respective affiliates, including the Sponsor and other entities affiliated with APAC and the Sponsor, are entitled to reimbursement of any out-of-pocket expenses incurred by them in connection with activities on APAC&#8217;s behalf, such as identifying potential target businesses and performing due diligence on suitable business combinations. There is no cap or ceiling on the reimbursement of out-of-pocket expenses incurred by such persons in connection with activities on our behalf. However, if APAC fails to consummate a business combination by February 12, 2023, they will not have any claim against the trust account for reimbursement. APAC&#8217;s officers and directors, and their affiliates, expect to incur (or guaranty) approximately $[&#8226;] of transaction expenses (excluding the deferred underwriting commissions being held in the trust account). Accordingly, APAC may not be able to reimburse these expenses if the Business Combination or another business combination, is not completed by such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the A&amp;R Registration Rights Agreement, the Sponsor will have customary registration rights, including shelf registration and piggy-back rights, subject to cooperation and cut-back provisions with respect to the shares of New OmniAb Common Stock and warrants held by such parties following the consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The existence of financial and personal interests of one or more of APAC&#8217;s directors may result in a conflict of interest on the part of such director(s)&#160;between what he, she or they may believe is in the best interests of APAC and its shareholders and what he, she or they may believe is best for himself, herself or themselves in determining to recommend that shareholders vote for the proposals. In addition, APAC&#8217;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;&#8212; Interests of APAC&#8217;s Directors and Executive Officers in the Business Combination</i>&#8221; for a further discussion of these considerations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The personal and financial interests of the Sponsor as well as the APAC Board and officers may have influenced their motivation in identifying and selecting OmniAb as a business combination target, completing an initial business combination with OmniAb and influencing the operation of the business following the initial business combination. In considering the recommendations of the APAC Board to vote for the proposals, its shareholders should consider these interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The exercise of APAC&#8217;s directors&#8217; and executive officers&#8217; discretion in agreeing to changes or waivers in the terms of the Business Combination may result in a conflict of interest when determining whether such changes to the terms of the Business Combination or waivers of conditions are appropriate and in APAC&#8217;s shareholders&#8217; best interest.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the period leading up to the Closing, events may occur that, pursuant to the Merger Agreement, would require APAC to agree to amend the Merger Agreement, to consent to certain actions taken by OmniAb or to waive rights to which APAC is entitled to under the Merger Agreement. Such events could arise because of changes in the course of OmniAb&#8217;s business or a request by OmniAb to undertake actions that would otherwise be prohibited by the terms of the Merger Agreement. In any of such circumstances, it would be at APAC&#8217;s discretion to grant its consent or waive those rights. The existence of financial and personal interests of one or more of the directors described in the preceding risk factors (and described elsewhere in this proxy statement/prospectus/information statement) may result in a conflict of interest on the part of such director(s)&#160;between what he, she or they may believe is best for APAC and its shareholders and what he, she or they may believe is best for himself, herself or themselves in determining whether or not to take the requested action. As of the date of this proxy statement/prospectus/information statement, APAC does not believe there will be any changes or waivers that APAC&#8217;s directors and executive officers would be likely to make after shareholder approval of the Business Combination Proposal has been obtained. While certain changes could be made without further shareholder approval, APAC will circulate a new or amended proxy statement/prospectus/information statement and resolicit APAC&#8217;s shareholders if changes to the terms of the transaction that would have a material impact on its shareholders are required prior to the vote on the Business Combination Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">APAC and OmniAb will incur significant transaction and transition costs in connection with the Business Combination.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC and OmniAb have both incurred and expect to incur significant, non-recurring costs in connection with consummating the Business Combination and operating as a public company following the consummation of the Business Combination. APAC and OmniAb may also incur additional costs to retain key employees. Certain transaction expenses incurred in connection with the Merger Agreement (including the Business Combination), including all legal, accounting, consulting, investment banking and other fees, expenses and costs, will be paid by APAC following the closing of the Business Combination.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Legal proceedings in connection with the Business Combination, the outcomes of which are uncertain, could delay or prevent the completion of the business combination.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with business combination transactions similar to the proposed Business Combination, it is not uncommon for lawsuits to be filed against the parties and/or their respective directors and officers alleging, among other things, that the proxy statement/prospectus/information statement provided to shareholders contains false and misleading statements and/or omits material information concerning the transaction. Although no such lawsuits have yet been filed in connection with the Business Combination, it is possible that such actions may arise and, if such actions do arise, they generally seek, among other things, injunctive relief and an award of attorneys&#8217; fees and expenses. Defending such lawsuits could require OmniAb and APAC to incur significant costs and draw the attention of OmniAb&#8217;s and APAC&#8217;s management teams away from the consummation of the Business Combination. Further, the defense or settlement of any lawsuit or claim that remains unresolved at the time the Business Combination is consummated may adversely affect the combined company&#8217;s business, financial condition, results of operations and cash flows. Such legal proceedings could delay or prevent the Business Combination from being consummated within the expected timeframe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The announcement of the proposed Business Combination could disrupt OmniAb&#8217;s relationships with its customers, suppliers, business partners and others, as well as its operating results and business generally.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks relating to the impact of the announcement of the Business Combination on OmniAb&#8217;s business include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its employees may experience uncertainty about their future roles, which might adversely affect OmniAb&#8217;s ability to retain and hire key personnel and other employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">customers, suppliers, business partners and other parties with which OmniAb maintains business relationships may experience uncertainty about its future and seek alternative relationships with third parties, seek to alter their business relationships with OmniAb or fail to extend an existing relationship with OmniAb; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb has expended and will continue to expend significant costs, fees and expenses for professional services and transaction costs in connection with the proposed Business Combination.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any of the aforementioned risks were to materialize, they could lead to significant costs which may impact the combined company&#8217;s results of operations and cash available to fund its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Subsequent to consummation of the Business Combination, we may be exposed to unknown or contingent liabilities and may be required to subsequently take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on our financial condition, results of operations and our share price, which could cause you to lose some or all of your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot assure you that the due diligence conducted in relation to OmniAb and the OmniAb Business has identified all material issues or risks associated with OmniAb or the industry in which it competes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, we cannot assure you that factors outside of OmniAb&#8217;s and our control will not later arise. As a result of these factors, we may be exposed to liabilities and incur additional costs and expenses and we may be forced to later write-down or write-off assets, restructure our operations, or incur impairment or other charges that could result in our reporting losses. Even if our due diligence has identified certain risks, unexpected risks may arise and previously known risks may materialize in a manner not consistent with our preliminary risk analysis. If any of these risks materialize, this could have a material adverse effect on the combined company&#8217;s financial condition and results of operations and could contribute to negative market perceptions about our securities or the combined company. Additionally, we have no indemnification rights against Ligand or its stockholders under the Merger Agreement, and all of the purchase price consideration will be delivered at the Closing to Ligand&#8217;s stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, any shareholders or warrant holders of APAC who choose to remain New OmniAb stockholders or warrant holders following the Business Combination could suffer a reduction in the value of their shares, warrants and units. Such shareholders or warrant holders are unlikely to have a remedy for such reduction in value unless they are able to successfully claim that the reduction was due to the breach by our directors or officers of a duty of care or other fiduciary duty owed to them, or if they are able to successfully bring a private claim under securities laws that the registration statement or proxy statement/prospectus/information statement relating to the Business Combination contained an actionable material misstatement or material omission.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Investors may not have the same benefits as an investor in an underwritten public offering.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC is already a publicly traded company. Therefore, the Business Combination and the transactions described in this proxy statement/prospectus/information statement are not an underwritten initial public offering of our securities and differ from an underwritten initial public offering in several significant ways, which include, but are not limited to, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Like other business combinations and spin-offs, in connection with the Business Combination, investors will not receive the benefits of the diligence performed by the underwriters in an underwritten public offering. Investors in an underwritten public offering may benefit from the role of the underwriters in such an offering. In an underwritten public offering, an issuer initially sells its securities to the public market via one or more underwriters, who distribute or resell such securities to the public. Underwriters have liability under the U.S. securities laws for material misstatements or omissions in a registration statement pursuant to which an issuer sells securities. Because the underwriters have a &#8220;due diligence&#8221; defense to any such liability by, among other things, conducting a reasonable investigation, the underwriters and their counsel conduct a due diligence investigation of the issuer. Due diligence entails engaging legal, financial and/or other experts to perform an investigation as to the accuracy of an issuer&#8217;s disclosure regarding, among other things, its business and financial results. Auditors of the issuer will also deliver a &#8220;comfort&#8221; letter with respect to the financial information contained in the registration statement. In making their investment decision, investors have the benefit of such diligence in underwritten public offerings. Our investors must rely on the information in this proxy statement/prospectus/information statement and will not have the benefit of an independent review and investigation of the type normally performed by an independent underwriter in a public securities offering. While sponsors, private investors and management in a business combination undertake a certain level of due diligence, it is not necessarily the same level of due diligence undertaken by an underwriter in a public securities offering and, therefore, there could be a heightened risk of an incorrect valuation of our business or material misstatements or omissions in this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, because there are no underwriters engaged in connection with the Business Combination, prior to the opening of trading on Nasdaq on the trading day immediately following the Closing, there will be no traditional &#8220;roadshow&#8221; or book building process, and no price at which underwriters initially sold shares to the public to help inform efficient and sufficient price discovery with respect to the initial post-closing trades on Nasdaq. Therefore, buy and sell orders submitted prior to and at the opening of initial post-closing trading of our securities will not have the benefit of being informed by a published price range or a price at which the underwriters initially sold shares to the public, as would be the case in an underwritten initial public offering. There will be no underwriters assuming risk in connection with an initial resale of our securities or helping to stabilize, maintain or affect the public price of our securities following the Closing. Moreover, we will not engage in, and have not and will not, directly or indirectly, request financial advisors to engage in, any special selling efforts or stabilization or price support activities in connection with our securities that will be outstanding immediately following the Closing. In addition, since we will become public through a merger, securities analysts of major brokerage firms may not provide coverage of us since there is no incentive to brokerage firms to recommend the purchase of our common stock. No assurance can be given that brokerage firms will, in the future, want to conduct any offerings on our behalf. All of these differences from an underwritten public offering of our securities could result in a more volatile price for our securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, since there will be no traditional &#8220;roadshow,&#8221; there can be no guarantee that any information made available in this proxy statement/prospectus/information statement and/or otherwise disclosed or filed with the SEC will have the same impact on investor education as a traditional &#8220;roadshow&#8221; conducted in connection with an underwritten initial public offering. As a result, there may not be efficient or sufficient price discovery with respect to the securities or sufficient demand among potential investors immediately after the Closing, which could result in a more volatile price for the securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the Sponsor, certain members of the APAC Board and its officers, as well as their respective affiliates and permitted transferees, have interests in the Business Combination that are different from or are in addition to those of holders of our securities following completion of the Business Combination, and that would not be present in an underwritten public offering of our securities. Such interests may have influenced the APAC Board in making their recommendation that APAC shareholders vote in favor of the approval of the Business Combination and the other proposals described in this proxy statement/prospectus/information statement. See the section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;- Interests of APAC&#8217;s Directors and Executive Officers in the Business Combination</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Such differences from an underwritten public offering may present material risks to unaffiliated investors that would not exist if we became a publicly listed company through an underwritten initial public offering instead of upon completion of the Business Combination.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The historical financial results of OmniAb and unaudited pro forma financial information included elsewhere in this proxy statement/prospectus/information statement may not be indicative of what APAC&#8217;s actual financial position or results of operations would have been.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The historical financial results of OmniAb included in this proxy statement/prospectus/information statement do not reflect the financial condition, results of operations or cash flows they would have achieved as a standalone company during the periods presented or those the combined company will achieve in the future. This is primarily the result of the following factors: (i)&#160;the combined company will incur additional ongoing costs as a result of the Business Combination, including costs related to public company reporting, investor relations and compliance with the Sarbanes-Oxley Act; and (ii)&#160;the combined company&#8217;s capital structure will be different from that reflected in OmniAb&#8217;s historical financial statements. The combined company&#8217;s financial condition and future results of operations will be materially different from amounts reflected in APAC&#8217;s historical financial statements included elsewhere in this proxy statement/prospectus/information statement, so it may be difficult for investors to compare the combined company&#8217;s future results to historical results or to evaluate its relative performance or trends in its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similarly, the unaudited pro forma financial information in this proxy statement/prospectus/information statement is presented for illustrative purposes only and has been prepared based on a number of assumptions including, but not limited to, APAC being treated as the &#8220;acquired&#8221; company for financial reporting purposes in the Business Combination and the number of APAC Class&#160;A Ordinary Shares that are redeemed in connection with the Business Combination. Accordingly, such pro forma financial information may not be indicative of the combined company&#8217;s future operating or financial performance and APAC&#8217;s actual financial condition and results of operations may vary materially from APAC&#8217;s pro forma results of operations and balance sheet contained elsewhere in this proxy statement/prospectus/information statement, including as a result of such assumptions not being accurate. See <i style="font-style:italic;">&#8220;Unaudited Pro Forma Condensed Combined Financial Information of APAC and OmniAb.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The calculation of the number of shares of New OmniAb to be issued to OmniAb stockholders in the transactions will not be adjusted if there is a change in the value of OmniAb before the Business Combination is completed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The number of shares of New OmniAb Common Stock to be issued to OmniAb&#8217;s stockholders (as of immediately after consummation of the Distribution) in the transactions will not be adjusted if there is a change in the value of OmniAb before the closing of the transactions. As a result, the actual value of the New OmniAb Common Stock to be received by OmniAb&#8217;s stockholders (as of immediately after consummation of the Distribution) in the transactions will depend on the value of such shares at and after the closing of the Business Combination. Additionally, if the&#160;percentage of outstanding shares of New OmniAb Common Stock to be received by OmniAb&#8217;s stockholders (as of immediately after consummation of the Distribution) is less than 50.1% of all of the outstanding stock of APAC (subject to certain exceptions and qualifications), then Ligand may be entitled to contribute additional capital to OmniAb that will be converted into shares of New OmniAb Common Stock pursuant to the Merger Agreement and dilute the&#160;percentage interest of APAC shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Neither OmniAb stockholders nor APAC&#8217;s shareholders will be entitled to appraisal rights in connection with the transactions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Appraisal rights are statutory rights that, if applicable under law, enable stockholders to dissent from an extraordinary transaction, such as a merger, and to demand that the corporation pay the fair value for their shares as determined by a court in a judicial proceeding instead of receiving the consideration offered to stockholders in connection with the extraordinary transaction. Neither OmniAb stockholders nor APAC&#8217;s shareholders are entitled to appraisal rights in connection with the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Business Combination is subject to the satisfaction of certain conditions, which may not be satisfied on a timely basis, if at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consummation of the Business Combination is subject to customary closing conditions for transactions involving special purpose acquisition companies, including, among others:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of required consents and approvals from certain governmental authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no agreement between Ligand or APAC and any governmental authority pursuant to which Ligand or APAC has agreed not to consummate the Business Combination shall have been effected;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no governmental authority of competent jurisdiction shall have enacted, issued or granted any law (whether temporary, preliminary or permanent), in each case that is in effect and which has the effect of restraining, enjoining or prohibiting the consummation of the transaction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC shall have at least $5,000,001 of net tangible assets as of the Closing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the New OmniAb Common Stock issuable pursuant to the Business Combination shall have been approved for listing on Nasdaq, subject to official notice of issuance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ligand, OmniAb, APAC and Merger Sub shall each have performed and complied in all material respects with the obligations, covenants and agreements required by the Merger Agreement to be performed or complied with by it at or prior to filing, or a later date as agreed to by the parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">customary bring down conditions related to the accuracy of the parties&#8217; respective representations, warranties and pre-Closing covenants in the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the consummation of the Distribution, Reorganization and other transactions contemplated by the Separation Agreement shall have occurred;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of APAC&#8217;s and OmniAb&#8217;s registration statements to be filed with the United States Securities and Exchange Commission shall have become effective;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC&#8217;s shareholder approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the receipt by Ligand and APAC of certain tax opinions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, APAC&#8217;s obligation to consummate the Business Combination is also subject to there having been no &#8220;Material Adverse Effect&#8221; on OmniAb since the date of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, the obligations of OmniAb to consummate or cause to be consummated the Business Combination is subject to the satisfaction of the following additional conditions, any one (1)&#160;or more of which may be waived in writing by the OmniAb, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the completion of the Forward Purchase and the Redemption Backstop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the resignation of all directors and all executive officers of APAC; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the occurrence of the Domestication.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1</i> <i style="font-style:italic;">&#8212;</i> <i style="font-style:italic;">The Business Combination Proposal</i> <i style="font-style:italic;">&#8212;</i> <i style="font-style:italic;">Summary of the Merger Agreement</i> <i style="font-style:italic;">&#8212;</i> <i style="font-style:italic;">Conditions to Closing</i>&#8221; for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">APAC did not obtain a third-party valuation or fairness opinion in determining whether or not to proceed with the Business Combination.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The APAC Board did not obtain a third-party valuation or fairness opinion in connection with its determination to approve the Business Combination. The officers and directors of APAC, including APAC&#8217;s co-founder, Mr.&#160;Burgstahler, have substantial experience in evaluating the operating and financial merits of companies from a wide range of industries and concluded that their experience and backgrounds, together with the experience and sector expertise of APAC&#8217;s other advisors, enabled them to perform the necessary analyses and make determinations regarding the Business Combination. As a result, APAC&#8217;s shareholders will be relying solely on the judgment of the APAC Board, taking into account the information and advice received from APAC&#8217;s management and APAC&#8217;s advisors, in valuing OmniAb, and assuming the risk that the APAC Board may not have properly valued such businesses. The lack of a third-party valuation or fairness opinion may also lead an increased number of APAC&#8217;s shareholders to vote against the proposed Business Combination or demand redemption of their shares for cash.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Following the consummation of the Business Combination, our only significant asset will be our ownership interest in OmniAb, and such ownership may not be sufficient to pay dividends or make distributions or loans to enable us to pay any dividends on New OmniAb Common Stock or satisfy our other financial obligations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the consummation of the Business Combination, we will have no direct operations and no significant assets other than our ownership of OmniAb. Our investors and the stockholders of OmniAb immediately prior to the Business Combination will become stockholders of New OmniAb. We will depend on OmniAb for distributions, loans and other payments to generate the funds necessary to meet our financial obligations, including our expenses as a publicly traded company and to pay any dividends with respect to New OmniAb Common Stock. The financial condition and operating requirements of OmniAb may limit our ability to obtain cash from OmniAb. The earnings from, or other available assets of, OmniAb may not be sufficient to pay dividends or make distributions or loans to enable us to pay any dividends on New OmniAb Common Stock or satisfy our other financial obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This lack of diversification may subject us to numerous economic, competitive and regulatory risks, any or all of which may have a substantial adverse impact upon our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have no specified maximum redemption threshold. The absence of such a redemption threshold may make it possible for us to complete a business combination with which a substantial majority of our shareholders do not agree.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As provided in the Cayman Constitutional Documents, in no event will we redeem our public shares in an amount that would cause our net tangible assets to be less than $5,000,001 (so that we do not then become subject to the SEC&#8217;s &#8220;penny stock&#8221; rules). As a result, we may be able to complete the Business Combination even though a substantial majority of APAC&#8217;s public shareholders do not agree with the transaction and have redeemed their shares. However, each redemption of APAC&#8217;s public shares by APAC&#8217;s public shareholders will reduce the amount in our trust account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Sponsor, directors, executive officers, advisors and their affiliates may elect to purchase shares or warrants from public shareholders prior to the consummation of the Business Combination, which may influence the vote on the Business Combination and reduce the public &#8220;float&#8221; of our securities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor and APAC&#8217;s directors, officers, advisors or their respective affiliates may purchase shares or warrants in privately negotiated transactions or in the open market either prior to or following the completion of the Business Combination. However, they have no current commitments, plans or intentions to engage in any such transactions and have not formulated any terms or conditions for any such transactions. None of the funds in the trust account will be used to purchase shares or warrants in such transactions. If any such persons engage in such transactions, they will not make any such purchases when they are in possession of any material non-public information not disclosed to the seller or if such purchases are prohibited by Regulation M under the Exchange Act or other federal securities laws. Such a purchase may include a contractual acknowledgement that such shareholder, although still the record holder of APAC&#8217;s shares, is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that the Sponsor or APAC&#8217;s directors, officers, advisors or their affiliates purchase shares in privately negotiated transactions from public shareholders who have already elected to exercise their redemption rights, such selling shareholders would be required to revoke their prior elections to redeem their shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purpose of such purchases would be to (i)&#160;vote such shares in favor of the Business Combination and thereby increase the likelihood of obtaining shareholder approval of the Business Combination or (ii)&#160;to ensure that APAC&#8217;s net tangible assets are at least $5,000,001. The purpose of any such purchases of warrants could be to reduce the number of warrants outstanding or to vote such warrants on any matters submitted to the warrant holders for approval in connection with the Business Combination. Any such purchases of our securities may result in the completion of the Business Combination that may not otherwise have been possible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if such purchases are made, the public &#8220;float&#8221; of APAC Class&#160;A Ordinary Shares may be reduced and the number of beneficial holders of our securities may be reduced, which may make it difficult to maintain or obtain the quotation, listing or trading of our securities on a national securities exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Sponsor and APAC&#8217;s officers, directors and/or their affiliates anticipate that they may identify the shareholders with whom the Sponsor or APAC&#8217;s officers, directors or their affiliates may pursue privately negotiated purchases by either the shareholders contacting us directly or by our receipt of redemption requests submitted by shareholders (in the case of Class&#160;A Ordinary Shares) following our mailing of proxy materials in connection with the Business Combination. To the extent that the Sponsor or APAC&#8217;s </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">officers, directors, advisors or their affiliates enter into a private purchase, they would identify and contact only potential selling shareholders who have expressed their election to redeem their shares for a pro rata share of the trust account or vote against the Business Combination but only if such shares have not already been voted at the extraordinary general meeting. The Sponsor and APAC&#8217;s officers, directors, advisors or their affiliates will only purchase shares if such purchases comply with Regulation M under the Exchange Act and the other federal securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any purchases by the Sponsor or APAC&#8217;s officers, directors and/or their affiliates who are affiliated purchasers under Rule&#160;10b-18 under the Exchange Act will only be made to the extent such purchases are able to be made in compliance with Rule&#160;10b-18, which is a safe harbor from liability for manipulation under Section&#160;9(a)(2)&#160;and Rule&#160;10b-5 of the Exchange Act. Rule&#160;10b-18 has certain technical requirements that must be complied with in order for the safe harbor to be available to the purchaser. The Sponsor and APAC&#8217;s officers, directors and/or their affiliates will not make purchases of APAC Class&#160;A Ordinary Shares if the purchases would violate Section&#160;9(a)(2)&#160;or Rule&#160;10b-5 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If third parties bring claims against us, the proceeds held in the trust account could be reduced and the per-share redemption amount received by shareholders may be less than $10.25 per share (which was the amount per unit initially held in the trust account following our initial public offering).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our placing of funds in the trust account may not protect those funds from third-party claims against us. Although we have sought and will seek to have all vendors, service providers (other than our independent auditors), prospective target businesses and other entities with which we do business execute agreements with us waiving any right, title, interest or claim of any kind in or to any monies held in the trust account, there is no guarantee that they will execute such agreements or even if they execute such agreements that they would be prevented from bringing claims against the trust account, including, but not limited to, fraudulent inducement, breach of fiduciary responsibility or other similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain advantage with respect to a claim against our assets, including the funds held in the trust account. If any third party refuses to execute an agreement waiving such claims to the monies held in the trust account, our management will perform an analysis of the alternatives available to it and will enter into an agreement with a third party that has not executed a waiver only if management believes that such third party&#8217;s engagement would be significantly more beneficial to us than any alternative.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Examples of possible instances where we may engage a third party that refuses to execute a waiver include the engagement of a third party consultant whose particular expertise or skills are believed by management to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where management is unable to find a service provider willing to execute a waiver. In addition, there is no guarantee that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with us and will not seek recourse against the trust account for any reason. Upon redemption of our public shares, if we have not completed our business combination within the required time period, or upon the exercise of a redemption right in connection with our business combination, we will be required to provide for payment of claims of creditors that were not waived that may be brought against us within the 10&#160;years following redemption. Accordingly, the per-share redemption amount received by public shareholders could be less than the $10.25 per public share initially held in the trust account, due to claims of such creditors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor has agreed that it will be liable to us if and to the extent any claims by a third party (other than our independent auditors) for services rendered or products sold to us, or a prospective target business with which we have discussed entering into a transaction agreement, reduce the amount of funds in the trust account to below (1)&#160;$10.25 per public share or (2)&#160;such lesser amount per public share held in the trust account as of the date of the liquidation of the trust account due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the trust account and except as to any claims under our indemnity of the underwriters of this offering against certain liabilities, including liabilities under the Securities Act. Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. We have not independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and believe that the Sponsor&#8217;s only assets are securities of our company. The Sponsor may not have sufficient funds available to satisfy those obligations. We have not asked the Sponsor to reserve for such obligations, and therefore, no funds are currently set aside to cover any such obligations. As a result, if any such claims were successfully made against the trust account, the funds available for our business combination and redemptions could be reduced to less than $10.25 per public share. In such event, we may not be able to complete our business combination, and you would receive such lesser amount per share in connection with any redemption of your public shares. None of our directors or officers will indemnify us for claims by third parties including, without limitation, claims by vendors and prospective target businesses.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If, after we distribute the proceeds in the trust account to our public shareholders, APAC files a winding-up or bankruptcy petition or an involuntary winding-up or bankruptcy petition is filed against us that is not dismissed, a bankruptcy court may seek to recover such proceeds, and we and our board of directors may be exposed to claims of punitive damages.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If, after we distribute the proceeds in the trust account to our public shareholders, we file a winding-up or bankruptcy petition or an involuntary winding-up or bankruptcy petition is filed against us that is not dismissed, any distributions received by shareholders could be viewed under applicable debtor/creditor and/or insolvency laws as a voidable preference. As a result, a liquidator could seek to recover all amounts received by our shareholders. In addition, our board of directors may be viewed as having breached its fiduciary duty to our creditors or having acted in bad faith, thereby exposing it and us to claims of punitive damages, by paying public shareholders from the trust account prior to addressing the claims of creditors. We cannot assure you that claims will not be brought against us for these reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If, before distributing the proceeds in the trust account to our public shareholders, we file a winding-up or bankruptcy petition or an involuntary winding-up or bankruptcy petition is filed against us that is not dismissed, the claims of creditors in such proceeding may have priority over the claims of our shareholders and the per share amount that would otherwise be received by our shareholders in connection with our liquidation may be reduced.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If, before distributing the proceeds in the trust account to our public shareholders, we file a winding-up or bankruptcy petition or an involuntary winding-up or bankruptcy petition is filed against us that is not dismissed, the proceeds held in the trust account could be subject to applicable insolvency law, and may be included in our liquidation estate and subject to the claims of third parties with priority over the claims of our shareholders. To the extent any liquidation claims deplete the trust account, the per share amount that would otherwise be received by our shareholders in connection with our liquidation may be reduced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our shareholders may be held liable for claims by third parties against us to the extent of distributions received by them upon redemption of their shares.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are forced to enter into an insolvent liquidation, any distributions received by shareholders could be viewed as an unlawful payment if it was proved that immediately following the date on which the distribution was made, we were unable to pay our debts as they fall due in the ordinary course of business. As a result, a liquidator could seek to recover all amounts received by our shareholders. Furthermore, our directors may be viewed as having breached their fiduciary duties to us or our creditors or may have acted in bad faith, and thereby exposing themselves and our company to claims, by paying public shareholders from the trust account prior to addressing the claims of creditors. We cannot assure you that claims will not be brought against us for these reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our public shareholders will experience immediate dilution as a consequence of the issuance of New OmniAb Common Stock as consideration in the Business Combination, the Forward Purchase and the Redemption Backstop, if any, and due to future issuances pursuant to the 2022 Plan. Having a minority share position may reduce the influence that our current shareholders have on the management of the combined company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is anticipated that, immediately following the Business Combination, (1)&#160;our public shareholders are expected to own approximately 18.0% (assuming the no redemption scenario) and 0% (assuming the maximum redemption scenario) of the outstanding New OmniAb Common Stock, (2)&#160;the Ligand stockholders (without taking into account any of our public shares held by the Ligand stockholders prior to the consummation of the Business Combination) are expected to collectively own approximately 76.3% (assuming the no redemption scenario) or 85.0% (assuming the maximum redemption scenario) of the outstanding New OmniAb Common Stock, and (3)&#160;the Sponsor and related parties are expected to collectively own approximately 5.7% (assuming the no redemption scenario) or 15.0% (assuming the maximum redemption scenario) of the outstanding New OmniAb Common Stock. These&#160;percentages (i)&#160;assume that (a)&#160;New OmniAb issues 97,431,885 shares of New OmniAb Common Stock to former stockholders of OmniAb as of immediately prior to the Effective Time, (b)&#160;that New OmniAb issues 1,500,000 shares of New OmniAb Common Stock to the Sponsor pursuant to the Forward Purchase and (c)&#160;solely in the case of the maximum redemption scenario, that New OmniAb issues an additional 10,000,000 shares of New OmniAb Common Stock to the Sponsor pursuant to the Redemption Backstop, (ii)&#160;exclude all New OmniAb Options that may be exercisable for shares of New OmniAb Common Stock, New OmniAb RSUs and New OmniAb PSUs, (iii)&#160;include the OmniAb Earnout Shares and (iv)&#160;exclude the impact of any New OmniAb Warrants that will be outstanding following the Business Combination. If the actual facts are different from these assumptions, the&#160;percentage ownership retained by APAC&#8217;s existing public shareholders in the combined company will be different.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, OmniAb employees and consultants hold, and after Business Combination, are expected to be granted, equity awards under the 2022 Plan and purchase rights under the ESPP. You will experience additional dilution when those equity awards and purchase rights become vested and settled or exercisable, as applicable, for shares of New OmniAb Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The issuance of additional common stock will significantly dilute the equity interests of existing holders of APAC securities and may adversely affect prevailing market prices for our public shares or public warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Upon completion of the Business Combination, the Sponsor will beneficially own a significant equity interest in OmniAb and may take actions that conflict with the interests of APAC&#8217;s public shareholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interests of the Sponsor may not align with the interests of APAC&#8217;s public shareholders in the future. The Sponsor and its affiliates are in the business of making investments in companies and may acquire and hold interests in businesses that compete directly or indirectly with APAC. The Sponsor and its affiliates, may also pursue acquisition opportunities that may be complementary to OmniAb&#8217;s business and, as a result, those acquisition opportunities may not be available to the combined company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the Sponsor may have an interest in OmniAb pursuing acquisitions, divestitures and other transactions that, in their judgment, could enhance their investment, even though such transactions might involve risks to the combined company and its stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants will become exercisable for New OmniAb Common Stock, which would increase the number of shares eligible for future resale in the public market and result in dilution to our shareholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Outstanding warrants to purchase an aggregate of 15,900,000 shares of New OmniAb Common Stock will become exercisable in accordance with the terms of the warrant agreement governing those securities. These warrants will become exercisable at any time commencing on the later of 30&#160;days after the completion of the Business Combination and 12&#160;months from the closing of our initial public offering. The exercise price of these warrants will be $11.50 per share. To the extent such warrants are exercised, additional shares of New OmniAb Common Stock will be issued, which will result in dilution to the holders of New OmniAb Common Stock and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market or the fact that such warrants may be exercised could adversely affect the market price of New OmniAb Common Stock. However, there is no guarantee that the public warrants will ever be in the money prior to their expiration, and as such, the warrants may expire worthless. See &#8220;- <i style="font-style:italic;">Even if the Business Combination is consummated, the public warrants may never be in the money, and they may expire worthless and the terms of the warrants may be amended in a manner adverse to a holder if holders of at least 50% of the then outstanding public warrants approve of such amendment</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If APAC&#8217;s shareholders fail to properly demand redemption rights, they will not be entitled to redeem their APAC Class&#160;A Ordinary Shares for a pro rata portion of the trust account.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s shareholders may demand that APAC redeem their APAC Class&#160;A Ordinary Shares for a pro rata portion of the trust account in connection with the completion of the Business Combination. In order to exercise their redemption rights, APAC&#8217;s shareholders must deliver their APAC Class&#160;A Ordinary Shares (either physically or electronically) to APAC&#8217;s transfer agent at least two (2)&#160;business&#160;days prior to the vote on the Business Combination at the extraordinary general meeting. Any APAC public shareholder who fails to properly demand redemption rights will not be entitled to redeem his, her, or its shares for a pro rata portion of the trust account. See the section of this proxy statement/prospectus/information statement titled &#8220;<i style="font-style:italic;">Extraordinary General Meeting of APAC</i> <i style="font-style:italic;">&#8212;</i> <i style="font-style:italic;">Redemption Rights</i>&#8221; for the procedures to be followed if you wish to redeem your APAC shares for cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">APAC&#8217;s shareholders will not have any rights or interests in funds from the trust account, except under certain limited circumstances. APAC&#8217;s shareholders may therefore be forced to redeem or sell their APAC Class&#160;A Ordinary Shares or APAC Public Warrants in order to liquidate their investment, potentially at a loss.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">APAC&#8217;s shareholders will be entitled to receive funds from the trust account only: (i)&#160;in connection with a shareholder vote to amend the Cayman Constitutional Documents (A)&#160;to modify the substance or timing of APAC&#8217;s obligation to provide holders of APAC Class&#160;A Ordinary Shares the right to have their shares redeemed in connection with an initial business combination or to redeem 100% of APAC Class&#160;A Ordinary Shares if APAC does not complete an initial business combination within 18&#160;months from the initial public offering closing date or (B)&#160;with respect to any other provision relating to the rights of holders of APAC Class&#160;A Ordinary Shares, (ii)&#160;in connection with the redemption of all of the outstanding APAC Class&#160;A Ordinary Shares if APAC is unable to </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">complete an initial business combination by February&#160;12, 2023, subject to applicable law and as further described herein, and (iii)&#160;if APAC&#8217;s shareholders redeem their respective shares for cash upon the completion of the Business Combination. In addition, if APAC plans to redeem the APAC Class&#160;A Ordinary Shares because APAC is unable to complete a business combination by February&#160;12, 2023, for any reason, compliance with Cayman Islands law may require that APAC submit a plan of dissolution to APAC&#8217;s then-existing shareholders for approval prior to the distribution of the proceeds held in the trust account. In that case, APAC&#8217;s shareholders may be forced to wait beyond February&#160;12, 2023, before they receive funds from the trust account. Accordingly, in order for APAC&#8217;s shareholders to liquidate their investment, they may be forced to sell their APAC Class&#160;A Ordinary Shares or APAC Public Warrants, potentially at a loss. See the section of this proxy statement/prospectus/information statement titled &#8220;<i style="font-style:italic;">Extraordinary General Meeting of APAC</i> <i style="font-style:italic;">&#8212;</i> <i style="font-style:italic;">Redemption Rights</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">APAC is relying on the availability of the funds from the Redemption Backstop to potentially be used as part of the cash available to the combined company following the Business Combination. If the purchases under the Redemption Backstop fail to close, APAC may lack sufficient funds to complete the Business Combination.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The funds from the Redemption Backstop will be used to provide cash for working capital and other purposes in New OmniAb. The obligations under the Redemption Backstop are intended to provide APAC with a minimum funding level for the Business Combination. However, if the Redemption Backstop does not close, APAC may lack sufficient funds to complete the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if the Business Combination is consummated, the public warrants may never be in the money, and they may expire worthless and the terms of the warrants may be amended in a manner adverse to a holder if holders of at least 50% of the then outstanding public warrants approve of such amendment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The warrants were issued in registered form under a Warrant Agreement, dated August&#160;9, 2021, by and between Continental Stock Transfer&#160;&amp; Trust Company, as warrant agent, and APAC. The Warrant Agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval by the holders of at least 50% of the then outstanding public warrants to make any change that adversely affects the interests of the registered holders of public warrants. Accordingly, we may amend the terms of the public warrants in a manner adverse to a holder if holders of at least 50% of the then outstanding public warrants approve of such amendment. Although our ability to amend the terms of the public warrants with the consent of at least 50% of the then outstanding public warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the warrants, shorten the exercise period or decrease the number of shares of New OmniAb Common Stock purchasable upon exercise of a warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may redeem your unexpired warrants prior to their exercise at a time that is disadvantageous to you, thereby making your warrants worthless.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have the ability to redeem the outstanding warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per warrant if, among other things, the last reported sale price of New OmniAb&#8217;s Common Stock for any 20 trading&#160;days within a 30-trading day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders equals or exceeds $18.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like). If and when the warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. As a result, we may redeem the warrants as set forth above even if the holders are otherwise unable to exercise the warrants. Redemption of the outstanding warrants as described above could force you to: (i)&#160;exercise your warrants and pay the exercise price therefor at a time when it may be disadvantageous for you to do so; (ii)&#160;sell your warrants at the then-current market price when you might otherwise wish to hold your warrants; or (iii)&#160;accept the nominal redemption price which, at the time the outstanding warrants are called for redemption, we expect would be substantially less than the market value of your warrants. None of the New OmniAb Private Placement Warrants will be redeemable by us (subject to limited exceptions) so long as they are held by our Sponsor or its permitted transferees. APAC does not intend to pay cash dividends for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the Business Combination, APAC currently intends to retain its future earnings, if any, to finance the further development and expansion of its business and does not intend to pay cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of the New OmniAb Board and will depend on its financial condition, results of operations, capital requirements and future agreements and financing instruments, business prospects and such other factors as the New OmniAb Board deems relevant.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If APAC&#8217;s due diligence investigation of OmniAb was inadequate, then APAC&#8217;s shareholders (as stockholders of New OmniAb following the business combination) could lose some or all of their investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even though APAC conducted a due diligence investigation of OmniAb, APAC cannot be sure that this diligence uncovered all material issues that may be present with respect to OmniAb&#8217;s businesses, or that it would be possible to uncover all material issues through a customary amount of due diligence, or that factors outside of OmniAb and outside of their respective control will not later arise that could adversely affect their respective businesses, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nasdaq may not list New OmniAb&#8217;s securities on its exchange, which could limit investors&#8217; ability to make transactions in New OmniAb&#8217;s securities and subject APAC to additional trading restrictions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Business Combination, in order to continue to maintain the listing of our securities on Nasdaq, we will be required to demonstrate compliance with Nasdaq&#8217;s initial listing requirements, which are more rigorous than Nasdaq&#8217;s continued listing requirements. We will apply to have New OmniAb&#8217;s securities listed on Nasdaq upon consummation of the Business Combination. We cannot assure you that we will be able to meet all initial listing requirements. Even if New OmniAb&#8217;s securities are listed on Nasdaq, New OmniAb may be unable to maintain the listing of its securities in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If New OmniAb fails to meet the initial listing requirements and Nasdaq does not list its securities on its exchange, neither we nor OmniAb or Ligand would be required to consummate the Business Combination. In the event that we, OmniAb and Ligand elected to waive this condition, and the Business Combination was consummated without New OmniAb&#8217;s securities being listed on Nasdaq or on another national securities exchange, New OmniAb could face significant material adverse consequences, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a limited availability of market quotations for APAC&#8217;s securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced liquidity for New OmniAb&#8217;s securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination that New OmniAb Common Stock is a &#8220;penny stock&#8221; which will require brokers trading in New OmniAb Common Stock to adhere to more stringent rules&#160;and possibly result in a reduced level of trading activity in the secondary trading market for New OmniAb&#8217;s securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a limited amount of news and analyst coverage; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decreased ability to issue additional securities or obtain additional financing in the future.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as &#8220;covered securities.&#8221; If New OmniAb&#8217;s securities were not listed on Nasdaq, such securities would not qualify as covered securities and we would be subject to regulation in each state in which we offer our securities because states are not preempted from regulating the sale of securities that are not covered securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">APAC&#8217;s and OmniAb&#8217;s ability to consummate the Business Combination, and the operations of New OmniAb following the Business Combination, may be materially adversely affected by the recent coronavirus (COVID-19) pandemic.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The&#160;COVID-19&#160;pandemic has resulted in governmental authorities worldwide implementing numerous measures to contain the virus, including travel restrictions, quarantines,&#160;shelter-in-place&#160;orders and business limitations and shutdowns. More generally, the pandemic raises the possibility of an extended global economic downturn and has caused volatility in financial markets. The pandemic may also amplify many of the other risks described in this proxy statement/prospectus/information statement, which may delay or prevent the consummation of the Business Combination, and the business of OmniAb or New OmniAb following the Business Combination could be materially and adversely affected. The extent of such impact will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The parties will be required to consummate the Business Combination even if OmniAb, its business, financial condition and results of operations are materially affected by COVID-19. The disruptions posed by COVID-19 have continued, and other matters of global concern may continue, for an extensive period of time, and if OmniAb is unable to recover from business disruptions due to COVID-19 or other matters of global concern on a timely basis, OmniAb&#8217;s ability to consummate the Business Combination and New </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">OmniAb&#8217;s financial condition and results of operations following the Business Combination may be materially adversely affected. Each of OmniAb and APAC may also incur additional costs due to delays caused by COVID-19, which could adversely affect New OmniAb&#8217;s financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Because the market price of shares of New OmniAb Common Stock will fluctuate, OmniAb&#8217;s stockholders (as of immediately after consummation of the Distribution) cannot be sure of the value of the Business Combination consideration they will receive. In addition, there can be no assurance that any OmniAb Earnout Shares will vest.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The market value of New OmniAb securities at the effective time of the Business Combination may vary significantly from their respective values on the date the Merger Agreement was executed or at other dates. Because the exchange ratio with respect to the shares of New OmniAb Common Stock to be issued in the Business Combination is fixed and will not be adjusted to reflect any changes in the market value of shares of APAC Class&#160;A Ordinary Shares, the market value of the shares of New OmniAb Common Stock issued in connection with the Business Combination may be higher or lower than the values of those shares on earlier dates, and may be higher or lower than the value used to determine the exchange ratio. Stock price changes may result from a variety of factors, including changes in the business, operations or prospects of APAC, regulatory considerations, and general business, market, industry or economic conditions. Many of these factors are outside of the control of APAC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, vesting of the OmniAb Earnout Shares is tied to the VWAP of New OmniAb Common Stock during a five-year period following the Closing. As such, the number of OmniAb Earnout Shares that ultimately vest will not be determined until after the Closing, and, if an applicable OmniAb Triggering Event has not occurred with respect to such OmniAb Earnout Shares during the five-year period following the Closing, no OmniAb Earnout Shares will vest at all. Accordingly, at the effective time of the Business Combination, OmniAb&#8217;s stockholders (as of immediately after consummation of the Distribution) will not know or be able to calculate the market value of the OmniAb Earnout Shares they will receive at the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market price of shares of New OmniAb Common Stock after the Business Combination may be affected by factors different from those currently affecting the price of shares of APAC.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon completion of the Business Combination, Ligand&#8217;s stockholders will become holders of shares of New OmniAb Common Stock. Prior to the Business Combination, APAC has had limited operations. Upon completion of the Business Combination, New OmniAb&#8217;s results of operations will depend upon the performance of OmniAb, which is affected by factors that are different from those currently affecting the results of operations of APAC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the Business Combination&#8217;s benefits do not meet the expectations of financial analysts, the market price of New OmniAb Common Stock may decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The market price of the New OmniAb Common Stock may decline as a result of the Business Combination if the combined company does not achieve the perceived benefits of the Business Combination as rapidly, or to the extent anticipated by, financial analysts or the effect of the Business Combination on the combined company&#8217;s financial results is not consistent with the expectations of financial analysts. Accordingly, holders of APAC securities may experience a loss as a result of a decline in the market price of New OmniAb Common Stock. In addition, a decline in the market price of New OmniAb Common Stock could adversely affect New OmniAb&#8217;s ability to issue additional securities and to obtain additional financing in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulatory approvals may not be received, may take longer than expected or may impose conditions that are not presently anticipated or cannot be met.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Before the transactions contemplated by the Merger Agreement can be completed, approval must be obtained under the HSR Act. In deciding whether to grant antitrust clearance, the relevant governmental authorities will consider a variety of factors, including the effect of the Business Combination on competition within their relevant jurisdiction. The terms and conditions of the approvals that are granted may impose requirements, limitations or costs, or place restrictions on the conduct of APAC&#8217;s business. The requirements, limitations or costs imposed by the relevant governmental authorities could delay the closing of the Business Combination or diminish the anticipated benefits of the Business Combination. Additionally, the completion of the Business Combination is conditioned on the resolution of certain orders, injunctions or decrees by any court or regulatory authority of competent jurisdiction that would prohibit or make illegal the completion of the Business Combination. APAC and OmniAb believe that the Business Combination should not raise significant regulatory concerns and that APAC and OmniAb will be able to obtain all requisite regulatory approvals in a timely manner. However, APAC and OmniAb cannot be certain when or if regulatory approvals will be obtained or, if obtained, the </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">conditions that may be imposed. In addition, neither APAC nor OmniAb can provide assurance that any such conditions, terms, obligations or restrictions will not result in delay. See &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1</i> <i style="font-style:italic;">&#8212;</i> <i style="font-style:italic;">The Business Combination</i> <i style="font-style:italic;">&#8212;</i> <i style="font-style:italic;">Summary of the Merger Agreement</i> <i style="font-style:italic;">&#8212;</i> <i style="font-style:italic;">Closing Conditions</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">APAC may waive one or more of the conditions to the Business Combination.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC may agree to waive, in whole or in part, one or more of the conditions to APAC&#8217;s obligations to complete the Business Combination, to the extent permitted by the Cayman Constitutional Documents and applicable laws. For example, it is a condition to APAC&#8217;s obligations to close the Business Combination that OmniAb have performed and complied in all material respects with the obligations required to be performed or complied with by OmniAb under the Merger Agreement. However, if the APAC Board determines that a breach of this obligation is not material, then the APAC Board may elect to waive that condition and close the Business Combination. Please see the section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1</i> <i style="font-style:italic;">&#8212;The Business Combination&#8212;Summary of the Merger Agreement&#8212;Closing Conditions</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination of the Merger Agreement could negatively impact APAC.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Business Combination is not completed for any reason, including as a result of APAC shareholders declining to approve the proposals required to effect the Business Combination, the ongoing businesses of APAC may be adversely impacted and, without realizing any of the anticipated benefits of completing the Business Combination, APAC would be subject to a number of risks, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC may experience negative reactions from the financial markets, including negative impacts on its share price (including to the extent that the current market price reflects a market assumption that the Business Combination will be completed);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC will have incurred substantial expenses and will be required to pay certain costs relating to the Business Combination, whether or not the Business Combination is completed; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">since the Merger Agreement restricts the conduct of APAC&#8217;s businesses prior to completion of the Business Combination, APAC may not have been able to take certain actions during the pendency of the Business Combination that would have benefitted it as an independent company, and the opportunity to take such actions may no longer be available (see the section entitled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Shareholder Proposal No.&#160;1 &#8212; The Business Combination</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">&#8212; Summary of the Merger Agreement &#8212; Covenants</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; of this proxy statement/prospectus/information statement for a description of the restrictive covenants applicable to APAC).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger Agreement is terminated and the APAC Board seeks another business combination target, APAC shareholders cannot be certain that APAC will be able to find another acquisition target that would constitute a business combination or that such other business combination will be completed. See &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1 &#8212; The Business Combination &#8212; Summary of the Merger Agreement &#8212; Termination</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OmniAb will be subject to business uncertainties and contractual restrictions while the Business Combination is pending.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Uncertainty about the effect of the Business Combination on employees and other business participants may have an adverse effect on OmniAb and consequently on APAC. These uncertainties may impair OmniAb&#8217;s ability to attract, retain and motivate key personnel until the Business Combination is completed, and could cause others that deal with OmniAb to seek to change existing business relationships with OmniAb. Retention of certain employees may be challenging during the pendency of the Business Combination, as certain employees may experience uncertainty about their future roles. If key employees depart because of issues relating to the uncertainty or a desire not to remain with the business, the combined company&#8217;s business following the Business Combination could be negatively impacted. In addition, the Merger Agreement restricts OmniAb from making certain expenditures and taking other specified actions without the consent of APAC until the Business Combination occurs. These restrictions may prevent OmniAb from pursuing attractive business opportunities that may arise prior to the completion of the Business Combination. See &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1 &#8212; The Business Combination &#8212; Summary of the Merger Agreement &#8212; Covenants.</i>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Business Combination will result in changes to the APAC Board that may affect the strategy of APAC.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">If the parties complete the Business Combination, the composition of the APAC Board will change from the current APAC Board. The New OmniAb Board will consist of Matthew W. Foehr, John L. Higgins, Carolyn R. Bertozzi, Ph.D, Sarah Boyce, </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Jennifer Cochran, Ph.D, Sunil Patel and [&#9679;]. This new composition of the New OmniAb Board may affect the business strategy and operating decisions of the combined company upon the completion of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Neither APAC nor its shareholders will have the protection of any indemnification, escrow, purchase price adjustment or other provisions that allow for a post-closing adjustment to be made to the Aggregate Merger Consideration in the event that any of the representations and warranties made by OmniAb in the Merger Agreement ultimately proves to be inaccurate or incorrect.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The representations and warranties contained in the Merger Agreement will not survive the completion of the Business Combination, and only the covenants and agreements that by their terms survive such time will do so. As a result, APAC and its shareholders will not have the protection of any indemnification, escrow, purchase price adjustment or other provisions that allow for a post-closing adjustment to be made to the Aggregate Merger Consideration if any representation or warranty made by OmniAb in the Merger Agreement proves to be inaccurate or incorrect. Accordingly, to the extent such representations or warranties are incorrect, our financial condition or results of operations could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Combined Company&#8217;s Common Stock Following the Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market price of the combined company&#8217;s common stock is likely to be highly volatile, and you may lose some or all of your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the Business Combination, the market price of the combined company&#8217;s common stock may fluctuate significantly due to a number of factors, some of which may be beyond our control, including those factors discussed in this &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; section and many others, such&#160;as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated fluctuations in the combined company&#8217;s financial condition and operating results, including fluctuations in its quarterly and annual results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the combined company&#8217;s inability to establish additional partnerships, the termination of license agreements by our existing partners or announcements by our partners regarding therapeutic candidates generated using our platform;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the introduction of new technologies or enhancements to existing technology by the combined company or others in the industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">departures of key scientific or management personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by the combined company or its competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the combined company&#8217;s failure to meet the estimates and projections of the investment community or that it may otherwise provide to the public;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publication of research reports about the combined company or its industry, or antibody discovery in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the market valuations of similar companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overall performance of the equity markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements or actions taken by Ligand as the combined company&#8217;s previous principal stockholder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of the combined company&#8217;s common stock by the combined company or its stockholders in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of the combined company&#8217;s common stock;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes or other developments relating to proprietary rights, including patents, litigation matters and the combined company&#8217;s ability to obtain patent protection for its technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant lawsuits, including patent or stockholder litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of any natural disasters or public health emergencies, such as the COVID-19 pandemic;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions other events or factors, many of which are beyond the combined company&#8217;s control; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in accounting standards, policies, guidelines, interpretations or principles.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, in the past, stockholders have initiated class action lawsuits against biotechnology and biopharmaceutical companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert our management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Volatility in the combined company&#8217;s share price could subject the combined company to securities class&#160;action litigation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the past, securities class&#160;action litigation has often been brought against a company following a decline in the market price of its securities. If the combined company faces such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or reports about the combined company, or publish negative reports, then the combined company&#8217;s stock price and trading volume could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The trading market for the combined company&#8217;s common stock will depend, in part, on the research and reports that securities or industry analysts publish about the combined company. The combined company does not have any control over these analysts. If the combined company&#8217;s financial performance fails to meet analyst estimates or one or more of the analysts who cover the combined company downgrade its common stock or change their opinion, then the combined company&#8217;s stock price would likely decline. If one or more of these analysts cease coverage of the combined company or fail to regularly publish reports on the combined company, it could lose visibility in the financial markets, which could cause the combined company&#8217;s stock price or trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The combined company does not currently intend to pay dividends on its common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of the combined company&#8217;s common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The combined company has never declared or paid any cash dividend on its common stock. The combined company currently anticipates that it will retain future earnings for the development, operation and expansion of the business and does not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock. There is no guarantee that shares of the combined company&#8217;s common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Future sales of shares of the combined company&#8217;s common stock may depress its stock price.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Subject to certain exceptions, the A&amp;R Registration Rights Agreement will provide for certain restrictions on transfer with respect to the securities of New OmniAb, including Founder Shares, Private Placement Warrants, Backstop Warrants, Forward Purchase Warrants, and securities held by directors and officers of APAC and certain directors and officers of OmniAb and Ligand. Such restrictions will begin upon closing and end (i)&#160;with respect to the Founder Shares, at the earliest of (A)&#160;one&#160;year after the closing date and (B)&#160;the first date on which (x)&#160;the last reported sale price of a share of New OmniAb Common Stock equals or exceeds $12.00 per share for any 20 trading&#160;days within any 30-trading day period commencing at least 150&#160;days after the closing date or (y)&#160;APAC completing a liquidation, merger, share exchange, reorganization or other similar transaction that results in the New OmniAb stockholders having the right to exchange their shares of New OmniAb Common Stock for cash, securities or other property; (ii)&#160;with respect to the Private Placement Warrants, Backstop Warrants and Forward Purchase Warrants that are held by the initial purchasers of such warrants (or permitted transferees under the A&amp;R Registration Rights Agreement), and any of the shares of New OmniAb Common Stock issued or issuable upon the exercise or conversion of such warrants and that are held by the initial purchasers </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">of the applicable warrants being converted (or permitted transferees under the A&amp;R Registration Rights Agreement), the period ending 30&#160;days after the closing; and (iii)&#160;with respect to the shares of New OmniAb Common Stock issued to the New Holders (as defined in the A&amp;R Registration Rights Agreement) in connection with the consummation of the Merger and held by the New Holders (or their permitted transferees under the A&amp;R Registration Rights Agreement), the period ending on the earlier of (A)&#160;three&#160;months after the closing and (B)&#160;the date on which New OmniAb completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of New OmniAb&#8217;s stockholders having the right to exchange their shares of New OmniAb Common Stock for cash, securities or other property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">However, following the expiration of the applicable lock-up period, such equityholders will not be restricted from selling shares of the combined company&#8217;s common stock held by them, other than by applicable securities laws. Further, because the combined company is not expected to generate revenue in the near future, there is a likelihood that it will need to continue to raise capital through one or more equity financings in order to continue developing its product candidates. As such, sales of a substantial number of shares of the combined company&#8217;s common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of the combined company&#8217;s common stock. As restrictions on resale end and registration statements (filed after the Closing to provide for the resale of such shares from time to time) are available for use, the sale or possibility of sale of these shares could have the effect of increasing the volatility in the combined company&#8217;s share price or the market price of the combined company&#8217;s common stock could decline if the holders of currently restricted shares sell them or are perceived by the market as intending to sell them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Provisions in the Proposed Certificate of Incorporation and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Proposed Certificate of Incorporation and Proposed Bylaws that will be in effect immediately prior to the Business Combination will contain provisions that could significantly reduce the value of the combined company shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of the New OmniAb Board. The provisions in the combined company&#8217;s charter documents will include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the exclusive right of the combined company&#8217;s board of directors, unless the board of directors grants such a right to the holders of any series of preferred stock, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the required approval of at least 66-2/3% of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of the combined company&#8217;s board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of the combined company&#8217;s board of directors to alter the combined company&#8217;s amended and restated bylaws without obtaining stockholder approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the required approval of at least 66-2/3% of the shares entitled to vote to adopt, amend or repeal the combined company&#8217;s amended and restated bylaws or repeal the provisions of its amended and restated certificate of incorporation regarding the election and removal of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the requirement that a special meeting of stockholders may be called only by the board of directors, the chair of the board of directors, the chief executive officer or the president, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advance notice procedures that stockholders must comply with in order to nominate candidates to the combined company&#8217;s board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of the combined company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The combined company is also subject to the anti-takeover provisions contained in Section&#160;203 of the Delaware General Corporation Law. Under Section&#160;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three&#160;years or, among other exceptions, the board of directors has approved the transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The combined company&#8217;s Proposed Certificate of Incorporation will provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between the combined company and its stockholders and that the federal district courts shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, which could limit the combined company&#8217;s stockholders&#8217; ability to obtain a favorable judicial forum for disputes with it or its directors, officers or employees or the underwriters or any offering giving rise to such claim.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Proposed Certificate of Incorporation will provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on the combined company&#8217;s behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against the combined company arising pursuant to the Delaware General Corporation Law, the combined company&#8217;s Proposed Certificate of Incorporation or the Proposed Bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that this provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. In addition, the combined company&#8217;s Proposed Certificate of Incorporation provides that, unless the combined company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. For the avoidance of doubt, this provision is intended to benefit and may be enforced by the combined company, its officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. The combined company notes, however, that there is uncertainty as to whether a court would enforce this provision and that investors cannot waive compliance with the federal securities laws and the rules&#160;and regulations thereunder. Section&#160;22 of the Securities Act creates concurrent jurisdiction for state and federal courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules&#160;and regulations thereunder. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with the combined company or its directors and officers, which may discourage such lawsuits against the combined company and its directors and officers. If a court were to find the choice of forum provisions in the combined company&#8217;s Proposed Certificate of Incorporation to be inapplicable or unenforceable in an action, the combined company may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect its business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The combined company is an emerging growth company and smaller reporting company, and the combined company cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make its shares less attractive to investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">After the completion of the Business Combination, the combined company will be an emerging growth company, as defined in the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;). For as long as the combined company continues to be an emerging growth company, it may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;emerging growth companies,&#8221; including exemption from compliance with the auditor attestation requirements under Section&#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. The combined company will remain an emerging growth company until the earlier of </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">(1)&#160;the last day of the fiscal&#160;year (a)&#160;following the fifth anniversary of the closing of the IPO (December&#160;31, 2026), (b)&#160;in which the combined company has total annual gross revenue of at least $1.07&#160;billion or (c)&#160;in which the combined company is deemed to be a large accelerated filer, which means the market value of shares of the combined company&#8217;s common stock that are held by&#160;non-affiliates&#160;exceeds $700.0 million as of the prior June&#160;30</span><sup style="font-size:6.37pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-size:10pt;">, and (2)&#160;the date on which the combined company has issued more than $1.0 billion in&#160;non-convertible&#160;debt during the prior three-year period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. The combined company has elected to use this extended transition period for complying with new or revised accounting standards and, therefore, the combined company will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the Business Combination, we will also be a smaller reporting company as defined in the Exchange Act. Even after the combined company no longer qualifies as an emerging growth company, it may still qualify as a &#8220;smaller reporting company,&#8221; which would allow it to take advantage of many of the same exemptions from disclosure requirements including exemption from compliance with the auditor attestation requirements of Section&#160;404 and reduced disclosure obligations regarding executive compensation in this proxy statement/prospectus/information statement and the combined company&#8217;s periodic reports and proxy statements. The combined company will be able to take advantage of these scaled disclosures for so long as its voting and&#160;non-voting&#160;common stock held by&#160;non-affiliates&#160;is less than $250.0 million measured on the last business day of its second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal&#160;year and its voting and&#160;non-voting&#160;common stock held by&#160;non-affiliates&#160;is less than $700.0&#160;million measured on the last business day of its second fiscal quarter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The combined company cannot predict if investors will find its common stock less attractive because the combined company may rely on these exemptions. If some investors find the combined company&#8217;s common stock less attractive as a result, there may be a less active trading market for the common stock and its market price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the Combined Company&#8217;s estimates or judgments relating to its critical accounting policies prove to be incorrect or financial reporting standards or interpretations change, combined company&#8217;s results of operations could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The combined company will base its estimates on historical experience, known trends and events, and various other factors that it believes to be reasonable under the circumstances, as provided in &#8220;OmniAb Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Critical Accounting Policies and Estimates.&#8221; The results of these estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Significant assumptions and estimates used in preparing our financial statements include the estimated variable consideration included in the transaction price in the combined company&#8217;s contracts with customers, stock-based compensation, and valuation of the combined company&#8217;s equity investments in early-stage biotechnology companies. The combined company&#8217;s results of operations may be adversely affected if its assumptions change or if actual circumstances differ from those in its assumptions, which could cause its results of operations to fall below the expectations of securities analysts and investors, resulting in a decline in the trading price of its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, the combined company will regularly monitor its compliance with applicable financial reporting standards and review new pronouncements and drafts thereof that are relevant to it. As a result of new standards, changes to existing standards and changes in their interpretation, the combined company might be required to change its accounting policies, alter its operational policies, and implement new or enhance existing systems so that they reflect new or amended financial reporting standards, or the combined company may be required to restate its published financial statements. Such changes to existing standards or changes in their interpretation may have an adverse effect on its reputation, business, financial position, and profit.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Redemption</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Public shareholders who wish to redeem their public shares for a pro rata portion of the trust account must comply with specific requirements for redemption that may make it more difficult for them to exercise their redemption rights prior to the deadline. If shareholders fail to comply with the redemption requirements specified in this proxy statement/prospectus/information statement, they will not be entitled to redeem their public shares for a pro rata portion of the funds held in the trust account.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A public shareholder will be entitled to receive cash for any public shares to be redeemed only if such public shareholder: (1)(a)&#160;holds public shares, or (b)&#160;if the public shareholder holds public shares through units, the public shareholder elects to separate its units into the underlying public shares and warrants prior to exercising its redemption rights with respect to the public shares; (2)&#160;prior to 5:00&#160;p.m., Eastern Time on [&#9679;], 2022 (two business&#160;days before the scheduled date of the extraordinary general meeting) submits a written request to Continental, our transfer agent, that we redeem all or a portion of your public shares for cash, affirmatively certifying in your request if you &#8220;ARE&#8221; or &#8220;ARE NOT&#8221; acting in concert or as a &#8220;group&#8221; (as defined in Section&#160;13d-3 of the Exchange Act) with any other shareholder with respect to shares of our common stock; and (3)&#160;delivers its public shares to our transfer agent physically or electronically through DTC. In order to obtain a physical share certificate, a shareholder&#8217;s broker or clearing broker, DTC and our transfer agent will need to act to facilitate this request. It is our understanding that shareholders should generally allot at least two weeks to obtain physical certificates from our transfer agent. However, because we do not have any control over this process or over DTC, it may take significantly longer than two weeks to obtain a physical stock certificate. If it takes longer than anticipated to obtain a physical certificate, public shareholders who wish to redeem their public shares may be unable to obtain physical certificates by the deadline for exercising their redemption rights and thus will be unable to redeem their shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If a public shareholder fails to receive notice of our offer to redeem public shares in connection with the Business Combination, or fails to comply with the procedures for tendering its shares, such shares may not be redeemed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If, despite our compliance with the proxy rules, a public shareholder fails to receive our proxy materials, such public shareholder may not become aware of the opportunity to redeem his, her or its public shares. In addition, the proxy materials that we are furnishing to holders of public shares in connection with the Business Combination describe the various procedures that must be complied with in order to validly redeem the public shares. In the event that a public shareholder fails to comply with these procedures, its public shares may not be redeemed. Please see the section entitled &#8220;<i style="font-style:italic;">Extraordinary General Meeting of APAC&#160;&#8212; Redemption Rights</i>&#8221; for additional information on how to exercise your redemption rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If you or a &#8220;group&#8221; of shareholders of which you are a part are deemed to hold an aggregate of more than 15% of the public shares, you (or, if a member of such a group, all of the members of such group in the aggregate) will lose the ability to redeem all such shares in excess of 15% of the public shares.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A public shareholder, together with any of his, her or its affiliates or any other person with whom it is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Exchange Act), will be restricted from redeeming in the aggregate his, her or its shares or, if part of such a group, the group&#8217;s shares, in excess of 15% of the public shares. In order to determine whether a shareholder is acting in concert or as a group with another shareholder, we will require each public shareholder seeking to exercise redemption rights to certify to us whether such shareholder is acting in concert or as a group with any other shareholder. Such certifications, together with other public information relating to stock ownership available to us at that time, such as Section&#160;13D, Section&#160;13G and Section&#160;16 filings under the Exchange Act, will be the sole basis on which we make the above-referenced determination. Your inability to redeem any such excess shares will reduce your influence over our ability to consummate the Business Combination and you could suffer a material loss on your investment in us if you sell such excess shares in open market transactions. Additionally, you will not receive redemption distributions with respect to such excess shares if we consummate the Business Combination. As a result, you will continue to hold that number of shares aggregating to more than 15% of the public shares and, in order to dispose of such excess shares, would be required to sell your stock in open market transactions, potentially at a loss. We cannot assure you that the value of such excess shares will appreciate over time following the Business Combination or that the market price of the public shares will exceed the per-share redemption price. Notwithstanding the foregoing, shareholders may challenge our determination as to whether a shareholder is acting in concert or as a group with another shareholder in a court of competent jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">However, our shareholders&#8217; ability to vote all of their shares (including such excess shares) for or against the Business Combination is not restricted by this limitation on redemption.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">There is no guarantee that a shareholder&#8217;s decision whether to redeem its shares for a pro rata portion of the trust account will put the shareholder in a better future economic position.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We can give no assurance as to the price at which a shareholder may be able to sell its public shares in the future following the Closing or any alternative business combination. Certain events following the consummation of any initial business combination, including the Business Combination, may cause an increase in our share price, and may result in a lower value realized now than a shareholder of APAC might realize in the future had the shareholder not redeemed its shares. Similarly, if a shareholder does not redeem its shares, the shareholder will bear the risk of ownership of the public shares after the consummation of any initial business combination, and there can be no assurance that a shareholder can sell its shares in the future for a greater amount than the redemption price set forth in this proxy statement/prospectus/information statement. A shareholder should consult the shareholder&#8217;s own tax and/or financial advisor for assistance on how this may affect his, her or its individual situation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">APAC directors may decide not to enforce the indemnification obligation of the Sponsor, resulting in a reduction in the amount of funds in the trust account available for distribution to public shareholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that the proceeds in the trust account are reduced below (i)&#160;$10.25 per share or (ii)&#160;such lesser amount per share held in the trust account as of the date of the liquidation of the trust account due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay taxes, and the Sponsor asserts that it is unable to satisfy its indemnification obligations or that it has no indemnification obligations related to a particular claim, APAC&#8217;s independent directors would determine whether to take legal action against the Sponsor to enforce its indemnification obligations. While APAC currently expects that its independent directors would take legal action on APAC&#8217;s behalf against the Sponsor to enforce its indemnification obligations to us, it is possible that APAC&#8217;s independent directors in exercising their business judgment and subject to APAC&#8217;s fiduciary duties may choose not to do so in any particular instance. If APAC&#8217;s independent directors choose not to enforce these indemnification obligations, the amount of funds in the trust account available for distribution to public shareholders may be reduced below $10.25 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks if the Adjournment Proposal is Not Approved</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the Adjournment Proposal is not approved, and an insufficient number of votes have been obtained to authorize the consummation of the Business Combination and the Domestication, our board of directors will not have the ability to adjourn the extraordinary general meeting to a later date in order to solicit further votes, and, therefore, the Business Combination will not be approved, and, therefore, the Business Combination may not be consummated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors is seeking approval to adjourn the extraordinary general meeting to a later date or dates if, at the extraordinary general meeting, based upon the tabulated votes, there are insufficient votes to approve each of the Condition Precedent Proposals. If the Adjournment Proposal is not approved, our board of directors will not have the ability to adjourn the extraordinary general meeting to a later date and, therefore, will not have more time to solicit votes to approve the Condition Precedent Proposals. In such events, the Business Combination would not be completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8257bfb0_2e3b_4da7_93e1_f2605be7ab3b"></a><a id="Main_EXTRAORDINARYGENERALMEETINGOFAP"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXTRAORDINARY GENERAL MEETING OF APAC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">APAC is furnishing this proxy statement/prospectus/information statement to the APAC shareholders as part of the solicitation of proxies by the APAC Board for use at the extraordinary general meeting to be held on [&#9679;], 2022, and at any adjournment thereof. This proxy statement is first being furnished to the APAC shareholders on or about [&#9679;], 2022 in connection with the vote on the proposals described in this proxy statement/prospectus/information statement. This proxy statement provides the APAC shareholders with information they need to know to be able to vote or instruct their vote to be cast at the extraordinary general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Date, Time and Place</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The extraordinary general meeting of APAC will be held at the offices of Weil, Gotshal&#160;&amp; Manges LLP, located at 767 Fifth Avenue, New York, NY 10153, at [&#9679;] Eastern Time, on [&#9679;], 2022. Cayman Islands law requires there to be a physical location for the extraordinary general meeting. However, given the ongoing global pandemic, the extraordinary general meeting will also be held virtually via live webcast. As such, APAC shareholders may attend the extraordinary general meeting by visiting the extraordinary general meeting website at [&#9679;], where they will be able to listen to the meeting live and vote during the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Purpose of the Extraordinary General Meeting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">At the extraordinary general meeting, APAC is asking APAC shareholders to consider and vote upon:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Proposal No.&#160;1 &#8212; The Business Combination Proposal</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212; to consider and vote upon a proposal to approve and adopt by special resolution the Agreement and Plan of Merger, dated as of March&#160;23, 2022, (the &#8220;Merger Agreement&#8221;), by and among APAC, Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#8220;Ligand&#8221;), OmniAb,&#160;Inc., a Delaware corporation and wholly-owned subsidiary of Ligand (&#8220;OmniAb&#8221;), and Orwell Merger Sub&#160;Inc., a Delaware corporation and wholly-owned subsidiary of APAC (&#8220;Merger Sub&#8221;), (ii)&#160;the Transaction Documents (as defined in the Merger Agreement) and (iii)&#160;each of the transactions contemplated thereby, in each case, in accordance with the terms and subject to the conditions set forth in the Merger Agreement and the Transaction Documents, as more fully described elsewhere in this proxy statement/prospectus/information statement (the &#8220;Business Combination Proposal&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Proposal No.&#160;2 &#8212; The Domestication Proposal </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212; to consider and vote upon a proposal to approve by special resolution the change of APAC&#8217;s jurisdiction of incorporation by deregistering as an exempted company in the Cayman Islands and continuing and domesticating under the name &#8220;OmniAb,&#160;Inc.&#8221; as a corporation incorporated under the laws of the State of Delaware (the &#8220;Domestication Proposal&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Proposal No.&#160;3 &#8212; The Organizational Documents Proposal</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212; to consider and vote upon a proposal to approve by special resolution and adopt the proposed new certificate of incorporation (the &#8220;Proposed Certificate of Incorporation&#8221;) and the proposed new bylaws (the &#8220;Proposed Bylaws&#8221;) of APAC after giving effect to the Domestication (APAC, following the Domestication, &#8220;New OmniAb&#8221;) (the &#8220;Organizational Documents Proposal&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Proposal No.&#160;4 &#8212;The Non-Binding Governance Proposals </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212; to consider and vote upon, on a non-binding advisory basis, certain material differences between APAC&#8217;s Amended and Restated Memorandum and Articles of Association (as may be amended from time to time, the &#8220;Cayman Constitutional Documents&#8221;) and the Proposed Certificate of Incorporation and Proposed Bylaws, presented separately in accordance with the United States Securities and Exchange Commission requirements (collectively, the &#8220;Non-Binding Governance Proposals&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Proposal No.&#160;5 &#8212; The Stock Issuance Proposal</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212; to consider and vote upon a proposal to approve by ordinary resolution, for the purposes of complying with the applicable provisions of Nasdaq Rule&#160;5635, the issuance of shares of New OmniAb Common Stock pursuant to (a)&#160;the Domestication, (b)&#160;the Forward Purchase, (c)&#160;the Redemption Backstop and (d)&#160;the Merger (the &#8220;Stock Issuance Proposal&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Proposal No.&#160;6 &#8212; The Incentive Plan Proposal</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212; to consider and vote upon a proposal to approve by ordinary resolution, the OmniAb,&#160;Inc. 2022 Incentive Award Plan (the &#8220;Incentive Plan Proposal&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">7.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Proposal No.&#160;7 &#8212; The ESPP Proposal</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212; to consider and vote upon a proposal to approve by ordinary resolution, the OmniAb,&#160;Inc. 2022 Employee Stock Purchase Plan (the &#8220;ESPP Proposal&#8221;);</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">8.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Proposal No.&#160;8 &#8212; The Director Election Proposal </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212; to consider and vote upon a proposal to to elect seven directors to serve staggered terms on the New OmniAb Board upon the consummation of the Business Combination until the first, second and third annual meeting of stockholders following the date of effectiveness of the Proposed Certificate of Incorporation, as applicable, or until the election and qualification of their respective successors in office, subject to their earlier death, resignation or removal (the &#8220;Director Election Proposal&#8221;); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">9.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Proposal No.&#160;9 &#8212; The Adjournment Proposal</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212; to consider and vote upon a proposal to approve the adjournment of the extraordinary general meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes to constitute a quorum or for the approval of one or more proposals at the extraordinary general meeting (the &#8220;Adjournment Proposal&#8221;)</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Each of Proposals No.&#160;1 through 3 and 5 through 7 (the &#8220;Condition Precedent Proposals&#8221;) are cross-conditioned on the approval of the others. If our shareholders do not approve each of the Condition Precedent Proposals, then unless certain conditions in the Merger Agreement are waived by the applicable parties to the Merger Agreement, the Merger Agreement may be terminated and the Business Combination may not be consummated. Each of the Condition Precedent Proposals is conditioned on the approval and adoption of each of the other Condition Precedent Proposals unless such condition is waived by the applicable parties to the Merger Agreement. Proposal No.&#160;8 is not conditioned upon the approval of any other proposal set forth in this proxy statement/prospectus/information statement. Proposal No.&#160;4 is constituted of non-binding advisory proposals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recommendation of the APAC Board</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The APAC Board believes that the Business Combination Proposal and the other proposals to be presented at the extraordinary general meeting are in the best interest of APAC and its shareholders and recommends that its shareholders vote &#8220;FOR&#8221; the Business Combination Proposal, &#8220;FOR&#8221; the Domestication Proposal, &#8220;FOR&#8221; the Organizational Documents Proposal, &#8220;FOR&#8221; the Non-Binding Governance Proposals, &#8220;FOR&#8221; the Stock Issuance Proposal, &#8220;FOR&#8221; the Incentive Stock Proposal, &#8220;FOR&#8221; the ESPP Proposal, &#8220;FOR&#8221; the Director Election Proposal and &#8220;FOR&#8221; the Adjournment Proposal, in each case, if presented to the extraordinary general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The existence of financial and personal interests of one or more of APAC&#8217;s directors may result in a conflict of interest on the part of such director(s)&#160;between what he, she or they may believe is in the best interests of APAC and its shareholders and what he, she, or they may believe is best for himself, herself, or themselves in determining to recommend that shareholders vote for the proposals. In addition, APAC&#8217;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1 &#8212; The Business Combination Proposal &#8212; Interests of APAC&#8217;s Directors and Officers in the Business Combination</i>&#8221; for a further discussion of these considerations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">APAC Record Date; Who is Entitled to Vote</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">APAC shareholders will be entitled to vote or direct votes to be cast at the extraordinary general meeting if they owned APAC ordinary shares at the close of business on [&#61623;], 2022, which is the APAC Record Date for the extraordinary general meeting. Shareholders will have one vote for each APAC ordinary share owned at the close of business on the APAC Record Date. If your shares are held in &#8220;street name&#8221; or are in a margin or similar account, you should contact your broker to ensure that votes related to the shares you beneficially own are properly counted. As of the close of business on the APAC Record Date, there were 23,000,000 APAC Class&#160;A Ordinary Shares issued and outstanding, and 5,750,000 APAC Class&#160;B Ordinary Shares issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Quorum</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A quorum of APAC shareholders is necessary to hold a valid meeting. A quorum will be present at the extraordinary general meeting if one or more shareholders who together hold not less than one-third of the issued and outstanding APAC ordinary shares entitled to vote at the extraordinary general meeting are represented in person or by proxy at the extraordinary general meeting. As of the APAC Record Date for the extraordinary general meeting, 9,583,334 APAC ordinary shares would be required to achieve a quorum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Abstentions and Broker Non-Votes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Proxies that are marked &#8220;abstain&#8221; and proxies relating to &#8220;street name&#8221; shares that are returned to APAC but marked by brokers as &#8220;not voted&#8221; will be treated as shares present for purposes of determining the presence of a quorum on all matters. Abstentions and broker non-votes, while considered present for the purposes of establishing a quorum, will not count as votes cast at the extraordinary general meeting, and otherwise will have no effect on a particular proposal. If a shareholder does not give the broker voting </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">instructions, under applicable self-regulatory organization rules, its broker may not vote its shares on &#8220;non-routine&#8221; proposals, such as the Business Combination Proposal or any of the other Condition Precedent Proposals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Vote Required for Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The approval of each of the Stock Issuance Proposal, the Non-Binding Governance Proposals, the Incentive Plan Proposal, the ESPP Proposal, the Director Election Proposal and the Adjournment Proposal require an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of the APAC ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. Pursuant to the Cayman Constitutional Documents, only the holders of the APAC Class&#160;B Ordinary Shares are entitled to vote on the Director Election Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The approval of each of the Business Combination Proposal, the Domestication Proposal and the Organizational Documents Proposal require a special resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of at least two-thirds of the APAC ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. With respect to the Domestication Proposal, a holder of APAC Class&#160;B Ordinary Shares shall have ten votes for every APAC Class&#160;B Ordinary Share of which he or she is the holder and a holder of APAC Class&#160;A Ordinary Shares shall have one vote for every APAC Class&#160;A Ordinary Share of which he or she is the holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Each of the Business Combination Proposal, the Domestication Proposal, the Organizational Documents Proposal, Stock Issuance Proposal, the Incentive Plan Proposal, the ESPP Proposal and the Director Election Proposal is conditioned on the approval and adoption of each of the other Condition Precedent Proposals unless such condition is waived by the parties to the Merger Agreement. The Adjournment Proposal and the Non-Binding Governance Proposals are not conditioned on any other approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Voting Your Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Each APAC ordinary share that you own in your name entitles you to one vote. Your proxy card shows the number of APAC ordinary shares that you own. If your shares are held in &#8220;street name&#8221; or are in a margin or similar account, you should contact your broker to ensure that votes related to the shares you beneficially own are properly counted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There are four ways to vote your APAC ordinary shares at the extraordinary general meeting:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">You can vote by signing and returning the enclosed proxy card. If you vote by proxy card, your &#8220;proxy,&#8221; whose name is listed on the proxy card, will vote your shares as you instruct on the proxy card. If you sign and return the proxy card but do not give instructions on how to vote your shares, your shares will be voted as recommended by the APAC Board &#8220;FOR&#8221; the Business Combination Proposal, &#8220;FOR&#8221; the Domestication Proposal, &#8220;FOR&#8221; the Organizational Documents Proposal, &#8220;FOR&#8221; the Non-Binding Governance Proposals, &#8220;FOR&#8221; the Stock Issuance Proposal, &#8220;FOR&#8221; the Incentive Plan Proposal, &#8220;FOR&#8221; the ESPP Proposal, &#8220;FOR&#8221; the Director Election Proposal and &#8220;FOR&#8221; the Adjournment Proposal, in each case, if presented to the extraordinary general meeting. Votes received after a matter has been voted upon at the extraordinary general meeting will not be counted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#231f20;">You can vote online by visiting</span> www. [&#9679;].com, 24 hours a day, seven&#160;days a week, until 11:59&#160;p.m., Eastern Time on [&#9679;], 2022 (have your proxy card in hand when you visit the website).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#231f20;">You can </span>vote by phone by calling toll-free (within the U.S. or Canada) [&#9679;] (have your proxy card in hand when you call).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">You can attend the extraordinary general meeting in person or via internet webcast and vote electronically.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Revoking Your Proxy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If you are an APAC shareholder and you give a proxy, you may revoke it at any time before it is exercised by doing any one of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">you may send another proxy card with a later date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">you may notify APAC&#8217;s president in writing before the extraordinary general meeting that you have revoked your proxy; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">you may attend the extraordinary general meeting in person or electronically, revoke your proxy, and vote in person or electronically, as indicated above.</span></td></tr></table><div style="margin-top:10pt;"></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Who Can Answer Your Questions About Voting Your APAC Ordinary Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If you are a shareholder and have any questions about how to vote or direct a vote in respect of your APAC ordinary shares, you may call D.F. King, APAC&#8217;s proxy solicitor, by calling (888) 887-0082, or banks and brokers can call collect at (212) 269-5550, or by emailing AHPA@dfking.com.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Redemption Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the Cayman Constitutional Documents, an APAC shareholder may request of APAC that APAC redeem all or a portion of its APAC Class&#160;A Ordinary Shares for cash, out of funds legally available therefor, if the Business Combination is consummated. As a holder of APAC Class&#160;A Ordinary Shares, you will be entitled to receive cash for any APAC Class&#160;A Ordinary Shares to be redeemed only if you:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:28.8pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hold APAC Class&#160;A Ordinary Shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:28.8pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(v)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submit a written request to Continental, APAC&#8217;s transfer agent, in which you (i)&#160;request that APAC redeem all or a portion of your APAC Class&#160;A Ordinary Shares for cash, and (ii)&#160;identify yourself as the beneficial holder of the APAC Class&#160;A Ordinary Shares and provide your legal name, phone number and address; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:28.8pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(vi)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">deliver your APAC Class&#160;A Ordinary Shares to Continental, APAC&#8217;s transfer agent, physically or electronically through DTC.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Holders must complete the procedures for electing to redeem their APAC Class&#160;A Ordinary Shares in the manner described above prior to 5:00&#160;p.m., Eastern Time, on [</b>&#9679;<b style="font-weight:bold;">], 2022 (two business&#160;days before the extraordinary general meeting) in order for their shares to be redeemed.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">The redemption rights include the requirement that a holder must identify itself in writing as a beneficial holder and provide its legal name, phone number and address to Continental in order to validly redeem its shares. APAC&#8217;s public shareholders may elect to redeem all or a portion of the APAC Class&#160;A Ordinary Shares held by them regardless of if or how they vote in respect of the Business Combination Proposal.</b> If the Business Combination is not consummated, the APAC Class&#160;A Ordinary Shares submitted for redemption will be returned to the respective holder, broker or bank. If the Business Combination is consummated, and if a public shareholder properly exercises its right to redeem all or a portion of the APAC Class&#160;A Ordinary Shares that it holds and timely delivers its shares to Continental, APAC&#8217;s transfer agent, APAC will redeem such APAC Class&#160;A Ordinary Shares for a per-share price, payable in cash, equal to the pro rata portion of the trust account, calculated as of two business&#160;days prior to the consummation of the Business Combination. For illustrative purposes, as of [&#9679;], 2022, this would have amounted to approximately $[&#9679;] per issued and outstanding APAC public share. If a public shareholder exercises its redemption rights in full, then it will be electing to exchange its APAC Class&#160;A Ordinary Shares for cash and will no longer own APAC Class&#160;A Ordinary Shares. The redemption takes place following the Domestication and accordingly it is New OmniAb Common Stock that will be redeemed immediately after consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If you hold the shares in &#8220;street name,&#8221; you will have to coordinate with your broker to have your shares certificated or delivered electronically. APAC ordinary shares that have not been tendered (either physically or electronically) in accordance with these procedures will not be redeemed for cash. There is a nominal cost associated with this tendering process and the act of certificating the shares or delivering them through DTC&#8217;s DWAC system. The transfer agent will typically charge the tendering broker $80 and it would be up to the broker whether or not to pass this cost on to the redeeming shareholder. In the event the proposed Business Combination is not consummated this may result in an additional cost to shareholders for the return of their shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any request for redemption, once made by a holder of APAC Class&#160;A Ordinary Shares, may not be withdrawn once submitted to APAC unless the APAC Board determines (in its sole discretion) to permit the withdrawal of such redemption request (which it may do in whole or in part). If you submit a redemption request to Continental, APAC&#8217;s transfer agent, and later decide prior to the extraordinary general meeting not to elect redemption, you may request to withdraw the redemption request. You may make such request by contacting Continental, APAC&#8217;s transfer agent, at the phone number or address listed in see &#8220;<i style="font-style:italic;">Questions and answers&#8201;&#8212;&#8201;Q: Who can help answer my questions?</i>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Any corrected or changed written exercise of redemption rights must be received by Continental, APAC&#8217;s transfer agent, prior to the vote taken on the Business Combination Proposal at the extraordinary general meeting. No request for redemption will be honored unless the holder&#8217;s APAC Class&#160;A Ordinary Share certificates (if any) and other redemption forms have been delivered (either </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">physically or electronically) to Continental, APAC&#8217;s transfer agent, at least two business&#160;days prior to the vote at the extraordinary general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Notwithstanding the foregoing, a public shareholder, together with any affiliate of such public shareholder or any other person with whom such public shareholder is acting in concert or as a &#8220;group&#8221; (as defined in Section&#160;13(d)(3)&#160;of the Exchange Act), will be restricted from redeeming its APAC Class&#160;A Ordinary Shares with respect to more than an aggregate of 15% of the APAC Class&#160;A Ordinary Shares. Accordingly, if an APAC public shareholder, alone or acting in concert or as a group, seeks to redeem more than 15% of the APAC Class&#160;A Ordinary Shares, then any such shares in excess of that 15% limit would not be redeemed for cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Sponsor&#160;has, pursuant to the Sponsor Insider Agreement, agreed to, among other things, vote all of its APAC Class&#160;A Ordinary Shares and founder shares (as defined in the Sponsor Insider Agreement) in favor of the proposals being presented at the extraordinary general meeting and waive its redemption rights with respect to such shares in connection with the consummation of the Business Combination. Such shares will be excluded from the pro rata calculation used to determine the per-share redemption price. As of the date of this proxy statement/prospectus/information statement, the Sponsor owns approximately 5,645,000 of the issued and outstanding ordinary shares. See &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#8212;The Business Combination Proposal&#8212;Summary of the Related Agreements&#8212;Sponsor Insider Agreement&#8221;</i> in this proxy statement/prospectus/information statement for more information related to the Sponsor Insider Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The closing price of the APAC Class&#160;A Ordinary Shares on [&#9679;], 2022 was $[&#9679;]. For illustrative purposes, as of [&#9679;], 2022, funds in the trust account plus accrued interest thereon totaled approximately $[&#9679;] or approximately $[&#9679;] per issued and outstanding APAC Class A Ordinary Share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Prior to exercising redemption rights, APAC&#8217;s public shareholders should verify the market price of the APAC Class&#160;A Ordinary Shares as they may receive higher proceeds from the sale of their APAC Class&#160;A Ordinary Shares in the public market than from exercising their redemption rights if the market price per share is higher than the redemption price. APAC cannot assure its shareholders that they will be able to sell their APAC Class&#160;A Ordinary Shares in the open market, even if the market price per share is higher than the redemption price stated above, as there may not be sufficient liquidity in its securities when its shareholders wish to sell their shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Dissenter&#8217;s Rights Appraisal Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As APAC is not a constituent party to the Merger between Merger Sub and OmniAb, shareholders of APAC do not have dissenters&#8217; rights in connection with the Merger under Cayman Islands law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">APAC&#8217;s warrant holders do not have appraisal rights in connection with the Business Combination or the Merger under the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Proxy Solicitation Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">APAC is soliciting proxies on behalf of the APAC Board. This solicitation is being made by mail but also may be made by telephone or in person. APAC and its directors, officers and employees may also solicit proxies in person, by telephone or by other electronic means. APAC will bear the cost of the solicitation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">APAC has engaged D.F. King to assist in the proxy solicitation process. APAC will pay D.F. King a fee of $25,000 plus disbursements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">APAC will ask banks, brokers and other institutions, nominees and fiduciaries to forward the proxy materials to their principals and to obtain their authority to execute proxies and voting instructions. APAC will reimburse them for their reasonable expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f24a888e_d1cf_4a4c_b592_a5d7f349aa1d"></a><a id="Main_THEBUSINESSCOMBINATIONPROPOSAL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SHAREHOLDER PROPOSAL NO.&#160;1&#160;&#8212; THE BUSINESS COMBINATION PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s public shareholders are being asked to approve the Business Combination of APAC with OmniAb described in this proxy statement/prospectus/information statement, including (a)&#160;approving and adopting the Merger Agreement, (b)&#160;approving the other Transaction Documents named in the Merger Agreement and (c)&#160;approving the transactions contemplated by the Merger Agreement and such other Transaction Documents. The discussion in this proxy statement/prospectus/information statement of the Business Combination and the principal terms of the Merger Agreement and other Transaction Documents is subject to, and is qualified in its entirety by reference to the Merger Agreement, which is attached as Annex A to this proxy statement/prospectus/information statement and such other Transaction Documents that are attached as Annexes to this proxy statement/prospectus/information statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You should read carefully this proxy statement/prospectus/information statement in its entirety for more detailed information concerning the Merger Agreement and the other Transaction Documents. Please see the subsections entitled &#8220;<i style="font-style:italic;">&#8212;Summary of to the Merger Agreement</i>&#8221; and &#8220;<i style="font-style:italic;">&#8212;Summary of the Ancillary Agreements</i>&#8221; below, for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Structure of the Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Business Combination will be accomplished by way of the following transaction steps:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Domestication will be effected, whereby APAC&#8217;s jurisdiction of incorporation will be changed by its deregistering as an exempted company in the Cayman Islands and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware at least one (1)&#160;business day prior to the consummation of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Separation will be effected, whereby Ligand will, among other things and subject to the terms and conditions of the Separation Agreement, transfer the OmniAb Business, including certain related subsidiaries of Ligand, to OmniAb and make a contribution to the capital of OmniAb of $15 million less certain transaction and other expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Distribution will be effected, whereby Ligand will distribute to Ligand stockholders 100% of the OmniAb Common Stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to the Employee Matters Agreement, at the time of the Distribution, each existing Ligand equity award, with certain limited exceptions, will be split into (i)&#160;a new Ligand equity award and (ii)&#160;a new OmniAb Equity Award, with any accrued value in the original Ligand equity award split between such awards based on the relative post-closing values of Ligand and OmniAb;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to the A&amp;R FPA, OmniAb, New OmniAb and the Sponsor will effect the Forward Purchase, whereby New OmniAb will issue and sell to the Sponsor 1,500,000 shares of New OmniAb Common Stock and warrants to acquire 1,666,667 shares of New OmniAb Common Stock for an aggregate purchase price of $15,000,000, with such purchases to be consummated following the Domestication and prior to the Merger. In addition to the Forward Purchase, the Sponsor has agreed to effect the Redemption Backstop (to the extent necessary), whereby the Sponsor will purchase up to an additional 10,000,000 shares of New OmniAb Common Stock and up to an additional 1,666,667 New OmniAb Warrants, for an aggregate additional purchase price of up to $100,000,000, in order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds to be available to the combined company following the Business Combination from APAC&#8217;s trust account to be less than $100,000,000; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Following the above steps, the Merger will be effected, whereby Merger Sub will merge with and into OmniAb, with OmniAb continuing as the surviving company in the Merger and a wholly-owned subsidiary of New OmniAb.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:264.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Diagram of Transactions Structure and Transaction Steps</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Simplified Existing Structures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><img src="ahpa-20220416xs4014.jpg" alt="Graphic" style="display:inline-block;height:205.94pt;width:338.21pt;" /></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>OMT 1, lnc. and OMT 2, Inc. are wholly owned subsidiaries of OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</span></span>Consists of Ab lnitio Biotherapeutics, lnc., Crystal Bioscience, lnc., lcagen, LLC, Taurus Biosciences, LLC and xCella Biosciences, lnc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Structure Following the Separation but</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Before the Distribution and Merger</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><img src="ahpa-20220416xs4016.jpg" alt="Graphic" style="display:inline-block;height:263.87pt;left:0%;padding-bottom:0.15pt;position:relative;top:0pt;width:329.84pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:277.72pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Structure Following the Separation and the </span><span style="font-style:italic;font-weight:bold;"><br /></span><span style="font-style:italic;font-weight:bold;">Distribution but Before the Merger</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><img src="ahpa-20220416xs4017.jpg" alt="Graphic" style="display:inline-block;height:241.78pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:314.32pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Structure Following the Merger</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><img src="ahpa-20220416xs4018.jpg" alt="Graphic" style="display:inline-block;height:277.72pt;width:177.31pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(3)</span></span>APAC will complete the Domestication prior to the Merger.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Merger Consideration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Merger Agreement, the outstanding securities of OmniAb will be converted into the right to receive the Merger Consideration as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Common Stock</span>. As a result of and upon the Closing, among other things, each outstanding share of OmniAb Common Stock (other than Treasury Shares), will be cancelled upon the Effective Time in exchange for the right to receive a number of shares of New OmniAb Common Stock equal to the Base Exchange Ratio. For further details, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#8212;Merger Consideration</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Earnout Shares</span>. In addition, as a result of and upon the Closing, among other things, each outstanding share of OmniAb Common Stock (other than Treasury Shares), will be cancelled upon the Effective Time in exchange for the right to receive a number of OmniAb Earnout Shares equal to the Earnout Exchange Ratio. Holders of OmniAb Common Stock and equity awards will receive earnout consideration in the form of an additional 15,000,000 OmniAb Earnout Shares, all of which will be automatically forfeited for no consideration if an applicable OmniAb Triggering Event has not occurred with respect to such OmniAb Earnout Shares during the period from the date of the Closing to and including the fifth anniversary of the date of the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The total number of shares of New OmniAb Common Stock to be received by OmniAb&#8217;s stockholders (as of immediately after consummation of the Distribution) or reserved for issuance pursuant to the New OmniAb Equity Awards into which OmniAb Equity Awards are to be converted will be equal to the Aggregate Merger Consideration. In addition to the Aggregate Merger Consideration, holders of OmniAb Common Stock and equity awards will also receive earnout consideration in the form of OmniAb Earnout Shares. For further details, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#8212;Merger Consideration</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity Awards</span>. In addition, all (i)&#160;OmniAb Options, (ii)&#160;OmniAb RSUs and (iii)&#160;OmniAb PSUs, in each case, that are outstanding as of immediately prior to the Effective Time, will be converted into such number of (a)&#160;New OmniAb Options, (b)&#160;New OmniAb RSUs and (c)&#160;New OmniAb PSUs, respectively, in each case, equal to (1)&#160;the number of shares of OmniAb Common Stock underlying such OmniAb Equity Awards immediately prior to the Effective Time multiplied by (2)&#160;the Base Exchange Ratio. Each holder of an OmniAb Option, OmniAb RSU and/or OmniAb PSU will also receive a number of OmniAb Earnout Shares equal to the number of shares of OmniAb Common Stock underlying such OmniAb Options, OmniAb RSUs and/or OmniAb PSUs, as applicable, multiplied by the Earnout Exchange Ratio, and the exercise price of each outstanding New OmniAb Option will be equal to the exercise price of the pre-conversion OmniAb Option divided by the Base Exchange Ratio. For further details, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;&#8212; Consideration, Treatment of OmniAb Options, OmniAb RSUs and OmniAb PSUs.</i>&#8221; For further details, see &#8220;<i style="font-style:italic;">Executive and Director Compensation&#8212;Narrative to Summary Compensation Table &#8212; Treatment of Outstanding Equity Awards at the Time of the Distribution</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Ownership of APAC after the Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of the date of this proxy statement/prospectus/information statement, there are 28,750,000 ordinary shares of APAC issued and outstanding, which include the 5,750,000 founder shares held by the Sponsor (including APAC&#8217;s directors) and the 23,000,000 public shares. As of the date of this proxy statement/prospectus/information statement, there are outstanding an aggregate of 15,900,000 APAC Warrants, which include the 8,233,333 APAC Private Placement Warrants held by the Sponsor and the 7,666,667 APAC Public Warrants. Each whole warrant entitles the holder thereof to purchase one APAC Class&#160;A Ordinary Share and, following the Domestication, will entitle the holder thereof to purchase one share of New OmniAb Common Stock. Therefore, as of the date of this proxy statement/prospectus/information statement (without giving effect to the Business Combination), the APAC fully diluted share capital is 44,650,000. It is anticipated that, following the Business Combination, (1)&#160;APAC&#8217;s public shareholders are expected to own approximately 18.0% (assuming the no redemption scenario) or 0% (assuming the maximum redemption scenario) of the outstanding shares of New OmniAb Common Stock, (2)&#160;OmniAb stockholders (without taking into account any public shares held by OmniAb stockholders prior to the consummation of the Business Combination) are expected to own approximately 76.3% (assuming the no redemption scenario) or 85.0% (assuming the maximum redemption scenario) of the outstanding shares of New OmniAb Common Stock and (3)&#160;the Sponsor and related parties are expected to collectively own approximately 5.7% (assuming the no redemption scenario) or 15.0% (assuming the maximum redemption scenario) of the outstanding shares of New OmniAb Common Stock. These&#160;percentages reflect the assumptions set forth in the definitions of the &#8220;no redemption scenario&#8221; and &#8220;maximum redemption scenario.&#8221; If the actual facts are different from the no redemption scenario, the&#160;percentage ownership of New OmniAb held by such constituencies will be different.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table illustrates varying ownership levels in New OmniAb immediately following the consummation of the Business Combination based on the no redemption scenario, the 50% redemption scenario and the maximum redemption scenario. Please see &#8220;<i style="font-style:italic;">Risk Factors&#160;&#8212; Risks Related to Redemption</i>&#8221; for additional information.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:top;width:69.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share Ownership in New OmniAb</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">No Redemption Scenario</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">50% Redemption Scenario</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maximum Redemption Scenario</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.89%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.41%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage of Outstanding Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.89%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.41%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage of Outstanding Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.89%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.41%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage of Outstanding Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:27.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">APAC&#8217;s public shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:9.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">23,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:9.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:top;width:9.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">11,500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:9.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">9.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:top;width:9.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:9.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Sponsor and related parties<sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(3)(4)(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7,250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:top;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7,250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:top;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">17,250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">15.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:27.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">OmniAb (Ligand) stockholders <sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(5)(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">97,431,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">76.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:top;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">97,431,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">83.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:top;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">97,431,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">85.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total<sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(7)(8)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.89%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">127,681,885</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">100.0</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:top;width:9.89%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">116,181,885</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">100.0</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:top;width:9.89%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">114,681,885</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><b style="font-weight:bold;">100.0</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Assumes redemptions of 11,500,000 APAC Class&#160;A Ordinary Shares in connection with the Business Combination.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Assumes redemptions of 23,000,000 APAC Class&#160;A Ordinary Shares in connection with the Business Combination.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes 5,750,000 Class&#160;B Ordinary Shares that will be converted in New OmniAb Common Stock. The Sponsor Earnout Shares were included in the pro forma capitalization as, during the Earnout Period, holders of the Sponsor Earnout Shares are entitled to vote such Sponsor Earnout Shares and receive dividends and other distribution in respect thereof, pursuant to the Sponsor Insider Agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to the A&amp;R FPA, includes 1,500,000 shares of New OmniAb Common Stock purchased by the Sponsor in the Forward Purchase in the no redemption and maximum redemption scenarios and 10,000,000 New OmniAb Common Stock purchased by the Sponsor in the Redemption Backstop in the maximum redemption scenario.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes 15,000,000 OmniAb Earnout Shares as, during the Earnout Period, OmniAb Earnout Shares are entitled to exercise the voting rights carried by such Earnout Shares and receive any dividends or other distributions in respect of such OmniAb Earnout Shares.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The table below sets forth the share ownership in New OmniAb assuming that the Sponsor Earnout Shares and the OmniAb Earnout Shares are forfeited according to their terms:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:top;width:69.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share Ownership in New OmniAb</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">No Redemption Scenario</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:22.29%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">50% Redemption Scenario</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:22.36%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maximum Redemption Scenario</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage of Outstanding Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.01%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage of Outstanding Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.62%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage of Outstanding Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:27.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">APAC&#8217;s public shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:9.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">23,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:9.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">20.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:top;width:11.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">11,500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:9.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">11.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:top;width:10.87%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:9.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Sponsor and related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,333,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">4.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:top;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,333,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:top;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">16,052,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">16.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:27.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">OmniAb (Ligand) stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">82,431,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">74.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:top;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">82,431,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">83.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:top;width:10.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">82,431,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">83.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">110,765,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:top;width:11.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">99,265,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:top;width:10.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">98,483,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The table excludes the following:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10,636,952 unexercised OmniAb stock options;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">793,628 OmniAb RSUs and OmniAb PSUs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7,666,667 unexercised APAC Public Warrants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8,233,333 unexercised APAC Private Placement Warrants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,666,667 unexercised APAC Warrants issued in the Forward Purchase; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,666,667 unexercised APAC Warrants issued in the Backstop Redemption in the maximum redemption scenario.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(8)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If all of the Sponsor&#8217;s APAC Warrants are exercised, which include the 8,233,333 APAC Private Placement Warrants, the 1,666,667 APAC Warrants issued in the Forward Purchase and the 1,666,667 APAC Warrants issued in the Backstop Redemption in the maximum redemption scenario, Sponsor would own: (1)&#160;approximately 12.5% of the shares of New OmniAb in the no redemption scenario, (2)&#160;approximately 13.6% of the shares of New OmniAb in the 50% redemption scenario or (3)&#160;approximately 22.8% of the shares of New OmniAb in the maximum redemptions scenario.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">The following table illustrates the effective deferred underwriting commission on a percentage basis for public shares at each redemption level identified below.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:58.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">No&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">50%&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maximum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share amounts)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Redemptions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Redemption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Redemption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.73%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Unredeemed public shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,000,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,500,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Trust proceeds to New OmniAb</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 235,750</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 117,875</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred underwriting commission</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,050</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,050</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,050</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Effective deferred underwriting fee (%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3.41</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6.83</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Effective deferred underwriting fee per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.35</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.70</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of the Merger Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The summary of the material provisions of the Merger Agreement set forth below and elsewhere in this proxy statement/prospectus/information statement is qualified in its entirety by reference to the Merger Agreement, a copy of which is attached to this proxy statement/prospectus/information statement as Annex A, and which is incorporated by reference in this proxy statement/prospectus/information statement. All shareholders are encouraged to read the Merger Agreement in its entirety for a more complete description of the terms and conditions of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Closing of the Transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Closing is expected to take place three business&#160;days following the satisfaction or waiver of the conditions described below under the subsection entitled &#8220;&#8212;<i style="font-style:italic;">Conditions to Closing</i>,&#8221; unless APAC, Ligand and OmniAb agree in writing to another time or unless the Merger Agreement is terminated. The Business Combination is expected to be consummated promptly after the approval of APAC&#8217;s public shareholders at the extraordinary general meeting of such shareholders described in this proxy statement/prospectus/information statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Merger Consideration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement provides that, at the Effective Time, each outstanding share of OmniAb Common Stock (other than Treasury Shares), will be cancelled in exchange for the right to receive (i)&#160;a number of shares of New OmniAb Common Stock equal to the Base Exchange Ratio, and (ii)&#160;a number of OmniAb Earnout Shares equal to the Earnout Exchange Ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, all (i)&#160;OmniAb Options, (ii)&#160;OmniAb RSUs and (iii)&#160;OmniAb PSUs, in each case, that are outstanding as of immediately prior to the Effective Time, will be converted into such number of (a)&#160;New OmniAb Options, (b)&#160;New OmniAb RSUs and (c)&#160;New OmniAb PSUs, respectively, in each case, equal to (1)&#160;the number of shares of OmniAb Common Stock underlying such OmniAb Equity Awards immediately prior to the Effective Time multiplied by (2)&#160;the Base Exchange Ratio. Each holder of an OmniAb Option, OmniAb RSU and/or OmniAb PSU will also receive a number of OmniAb Earnout Shares equal to the number of shares of OmniAb Common Stock underlying such OmniAb Options, OmniAb RSUs and/or OmniAb PSUs, as applicable, multiplied by the Earnout Exchange Ratio, and the exercise price of each outstanding New OmniAb Option will be equal to the exercise price of the pre-conversion OmniAb Option divided by the Base Exchange Ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Effective Time</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement provides that the Merger will become effective upon the filing of a certificate of merger with the Secretary of State of the State of Delaware, or at such later time as the parties may specify in such certificate of merger.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Representations and Warranties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement contains representations and warranties of Ligand relating, among other things, to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">corporate organization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the authorization and enforceability of the Merger Agreement and Transaction Documents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">government consents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no conflict;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">litigation and proceedings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">brokers&#8217; fees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">7.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">internal controls; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">8.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">equity awards.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement contains representations and warranties by Ligand in respect of the OmniAb Business relating, among other things, to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">corporate organization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the authorization and enforceability of the Merger Agreement and Transaction Documents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">capitalization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subsidiaries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">capitalization of subsidiaries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">governmental consents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">7.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no conflict;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">8.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sufficiency of assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">9.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial statements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">10.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no undisclosed liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">11.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">litigation and proceedings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">12.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">real property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">13.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">14.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">absence of changes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">15.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">material contracts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">16.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">labor relations;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">17.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with law, permits;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">18.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">benefit plans;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">19.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">20.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">environmental matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">21.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">affiliate matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">22.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">brokers&#8217; fees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">23.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proxy statement, registration statement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">24.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">board and shareholder approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">25.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ligand capital stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">26.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Healthcare regulatory matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">27.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Data privacy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">28.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">anti-bribery, anti-corruption and anti-money laundering;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">29.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sanctions, import, and export controls; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">30.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no other representations and warranties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement contains representations and warranties of APAC and Merger Sub relating, among other things, to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">corporate organization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the authorization and enforceability of the Merger Agreement and Transaction Documents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">capital stock and other matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">governmental consents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no conflict;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">internal controls, listing, financial statements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">7.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no undisclosed liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">8.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">litigation and proceedings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">9.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">10.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">absence of changes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">11.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">brokers&#8217; fees</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">12.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proxy statement, registration statements;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">13.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">SEC filings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">14.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trust account;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">15.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Investment Company Act, JOBS Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">16.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">indebtedness;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">17.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stock market quotation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">18.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">19.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">section 280G; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">20.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no other representations and warranties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Material Adverse Effect</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Merger Agreement, certain representations and warranties of APAC, Ligand and OmniAb are qualified in whole or in part by a material adverse effect standard for purposes of determining whether a breach of such representations and warranties has occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">APAC Material Adverse Effect</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Merger Agreement, a material adverse effect with respect to APAC (&#8220;APAC Material Adverse Effect&#8221;) means any change, event, development, condition, occurrence or effect that (a)&#160;has, or would reasonably be expected to have, individually or in the aggregate with any other change, event, development, condition, occurrence or effect, a material adverse effect on the business or financial condition of APAC or Merger Sub, taken as a whole, or (b)&#160;has, or would reasonably be expected to, individually or in the aggregate, materially impair or materially delay the ability of APAC to perform its obligations under the Merger Agreement or under the Separation Agreement, or to consummate the Transactions, including the Merger and the Separation, or prevent it from performing such obligations or consummating the Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">However, in no event would any of the following, alone or in combination, be deemed to constitute, or be taken into account in determining whether there has been or will be, an APAC Material Adverse Effect:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes resulting from general market, economic, financial, capital markets or regulatory conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any general changes in the credit, debt, financial or capital markets or changes in interest or exchange rates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes in applicable law or GAAP (or, in each case, authoritative interpretations thereof);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes resulting from any natural disaster, including any hurricane, storm, flood, tornado, volcanic eruption, earthquake, other weather-related events, or other comparable events, or any worsening thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(v)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes resulting from local, national or international political conditions, including the outbreak or escalation of any military conflict, declared or undeclared war, armed hostilities, acts of foreign or domestic terrorism or civil unrest;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(vi)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes generally affecting the industries in which APAC conducts its businesses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(vii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes directly resulting from the execution of the Merger Agreement or the Transaction Documents or the announcement or the pendency of the Merger or the Transactions, including actions of suppliers, landlords, distributors, partners or governmental authorities and any loss of employees, relationships or customers resulting from the transactions contemplated by the Merger Agreement (provided, that this clause (vii)&#160;shall not apply to any representation or warranty to the extent the purpose of such representation or warranty is to address, as applicable, the consequences resulting from the </span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">execution of the Merger Agreement or the Separation Agreement or the announcement or the pendency of the Merger or the Separation);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(viii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes resulting from any action required to be taken by the terms of the Merger Agreement or at the request or direction of Ligand;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(ix)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the failure to meet any internal or analysts&#8217; expectations, projections or results of operations (but not, in each case, the underlying cause of any such changes, unless such underlying cause would otherwise be excepted by another clause of this definition);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(x)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes resulting from any epidemics, pandemics or disease (including COVID-19 or any COVID-19 Measures or any change in COVID-19 Measures following the date hereof); or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(xi)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">elections to redeem APAC Class&#160;A Ordinary Shares in connection with APAC&#8217;s extraordinary general meeting as required by APAC&#8217;s governing documents.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The incremental disproportionate impact of any event referred to in clauses (i), (ii), (iii), (iv), (v), (vi)&#160;and (x), above may be taken into account in determining if an APAC Material Adverse Effect has occurred to the extent such event disproportionately impacts APAC or Merger Sub, taken as a whole, as compared to other participants in similar industries to the industries in which APAC operates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OmniAb Material Adverse Effect</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Merger Agreement, a material adverse effect with respect to OmniAb (&#8220;OmniAb Material Adverse Effect&#8221;) means any change, event, development, condition, occurrence or effect that (a)&#160;has, or would reasonably be expected to have, individually or in the aggregate with any other change, event, development, condition, occurrence or effect, a material adverse effect on the business, financial condition or results of operations of the OmniAb Business, taken as a whole or (b)&#160;has, or would reasonably be expected to, individually or in the aggregate, materially impair or materially delay the ability of OmniAb to perform its obligations under the Merger Agreement or under the Separation Agreement, or to consummate the Transactions, including the Merger and the Separation, or prevent it from performing such obligations or consummating the Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">However, in no event would any of the following, alone or in combination, be deemed to constitute, or be taken into account in determining whether there has been or will be, an OmniAb Material Adverse Effect:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes resulting from general market, economic, financial, capital markets or regulatory conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any general changes in the credit, debt, financial or capital markets or changes in interest or exchange rates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes in applicable law or GAAP (or, in each case, authoritative interpretations thereof);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(iv)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes resulting from any natural disaster, including any hurricane, storm, flood, tornado, volcanic eruption, earthquake, other weather-related events, or other comparable events, or any worsening thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(v)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes resulting from local, national or international political conditions, including the outbreak or escalation of any military conflict, declared or undeclared war, armed hostilities, acts of foreign or domestic terrorism or civil unrest;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(vi)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes generally affecting the industries in which the OmniAb entities conduct their businesses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(vii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes directly resulting from the execution of the Merger Agreement or the Separation Agreement or the announcement or the pendency of the Merger or the Separation, including actions of suppliers, landlords, distributors, partners or governmental authorities and any loss of employees, relationships or customers resulting from the transactions contemplated by the Merger Agreement (provided, that this clause (vii)&#160;shall not apply to any representation or warranty to the extent the purpose of such representation or warranty is to address, as applicable, the consequences resulting from the execution of the Merger Agreement or the Separation Agreement or the announcement or the pendency of the Merger or the Separation);</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(viii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes resulting from any action required to be taken by the terms of the Merger Agreement (other than the first sentence of Section&#160;7.2 therein) or at the request or direction of APAC or Merger Sub;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(ix)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the failure to meet any internal or analysts&#8217; expectations, projections or results of operations (but not, in each case, the underlying cause of any such changes, unless such underlying cause would otherwise be excepted by another clause of this definition); or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;">(x)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes resulting from any epidemics, pandemics or disease (including COVID-19 or any COVID-19 Measures or any change in COVID-19 Measures following the date hereof).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The incremental disproportionate impact of any event referred to in clauses (i), (ii), (iii), (iv), (v), (vi)&#160;and (x), above may be taken into account in determining if an OmniAb Material Adverse Effect has occurred to the extent such event disproportionately impacts the OmniAb entities or the OmniAb Business, taken as a whole, as compared to other participants in similar industries to the industries in which the OmniAb Business operates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Covenants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of the parties to the Merger Agreement have agreed to use reasonable best efforts to obtain required consents and approvals from any governmental authority or commercially reasonable efforts in the case of consents from third parties. Each of the parties to the Merger Agreement have also agreed to (a)&#160;cooperate and use their respective commercially reasonable efforts to take or cause to be taken such other actions as may be necessary to consummate the Business Combination as promptly as practicable, and (b)&#160;use commercially reasonable efforts to take such other action as may reasonably be necessary or as another party may reasonably request to satisfy the conditions of the other party or otherwise to comply with the Merger Agreement and to consummate the Business Combination as soon as practicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Closing, each of OmniAb and Ligand have agreed to, and agreed to cause their respective subsidiaries to, operate the OmniAb Business in the ordinary course of business in all material respects, including recent past practice in light of the current COVID-19 pandemic. APAC has agreed to, and agreed to cause its subsidiaries to, operate its business in the ordinary course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of OmniAb and Ligand have agreed that, unless otherwise required or permitted under the Merger Agreement, required by law or in connection with certain pre-Closing restructuring transactions contemplated to be entered into by OmniAb and Ligand prior to the Closing and subject to certain disclosed exceptions, neither OmniAb nor its subsidiaries will take, among others, the following actions during the interim period between signing of the Merger Agreement and Closing without the prior written consent of APAC (which consent will not be unreasonably conditioned, withheld, delayed or denied):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amend, modify, restate, waive, rescind or otherwise change the governing documents of any of OmniAb and OmniAb&#8217;s subsidiaries, other than an amendment to the certificate of incorporation of OmniAb to increase the number of authorized or outstanding shares of OmniAb&#8217;s common stock in connection with the distribution in accordance with the Merger Agreement and the Transaction Documents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other than as required for the Distribution, (i)&#160;declare, set aside or pay any dividends on or make other distributions in respect of any of the interests of any of OmniAb or OmniAb&#8217;s subsidiaries (whether in cash, securities or property), except for the declaration and payment of cash dividends or distributions paid on or with respect to a class of interests of any of OmniAb or OmniAb&#8217;s subsidiaries that is wholly-owned directly or indirectly by OmniAb, (ii)&#160;split, combine, subdivide, reduce, or reclassify any of the interests of any of OmniAb or OmniAb&#8217;s subsidiaries or issue or authorize or propose the issuance of any other securities in respect of, in lieu of, or in substitution for, interests of OmniAb or OmniAb&#8217;s subsidiaries or (iii)&#160;redeem, repurchase or otherwise acquire, or permit any subsidiary to redeem, repurchase or otherwise acquire, any interests (including any securities convertible or exchangeable into such interests) (except for the acquisition by Ligand or any of its subsidiaries of any shares of capital stock, membership interests or other equity interests of Ligand or its subsidiaries in connection with the forfeiture of any Ligand equity awards, in each case, in accordance with their respective terms as in effect as of the date of the Merger Agreement);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other than as contemplated by the Distribution, issue, sell, pledge, dispose of, grant, transfer or encumber, any shares of capital stock of, any other interests in, or any of OmniAb&#8217;s voting debt of, any of OmniAb or OmniAb&#8217;s subsidiaries of </span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any class, or securities convertible into, or exchangeable or exercisable for, any shares of such capital stock or other interests in any of OmniAb or OmniAb&#8217;s subsidiaries, or any options, warrants, stock units, or other rights of any kind to acquire any shares of capital stock or other interests or such convertible or exchangeable securities, or any other ownership interest (including any such interest represented by contract right), or any &#8220;phantom&#8221; stock, &#8220;phantom&#8221; stock rights, stock appreciation rights or stock based performance rights, in each case, of OmniAb or OmniAb&#8217;s subsidiaries, other than (i)&#160;the issuance by OmniAb or any of OmniAb&#8217;s subsidiaries that is a wholly-owned subsidiary of OmniAb of its capital stock or other interests to OmniAb or another wholly-owned subsidiary of OmniAb or (ii)&#160;the issuance of capital stock or other interests upon the exercise, vesting or settlement of Ligand equity awards outstanding as of the date of the Merger Agreement and, in each case, in accordance with their respective terms as in effect as of the date of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell, assign, transfer, convey, lease, license, abandon, mortgage, pledge or permit any lien on (other than a permitted lien) or otherwise dispose of any of OmniAb&#8217;s assets (excluding intellectual property);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;purchase, sell, license, sublicense, lease, pledge, covenant not to assert, assign, transfer, abandon, cancel, let lapse or expire, or otherwise dispose, transfer or grant any other rights in or with respect to any intellectual property (other than with respect to (A)&#160;immaterial or obsolete OmniAb owned intellectual property or (B)&#160;the grant of non-exclusive licenses of OmniAb owned intellectual property in the ordinary course of business consistent with past practice); or (ii)&#160;disclose any material trade secrets of the OmniAb Business to any other person (other than in the ordinary course of business consistent with past practice to a person bound by adequate and enforceable use restrictions and confidentiality obligations with respect to such trade secrets);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receive, collect, use, store, process, share, safeguard, secure (technically, physically or administratively), dispose of, destroy, disclose, or transfer (including cross-border) any personal information (or fail to do any of the foregoing, as applicable) in material violation of any privacy requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">merge, combine or consolidate (pursuant to a plan of merger or otherwise) any of OmniAb or OmniAb&#8217;s subsidiaries with any person or adopt a plan of complete or partial liquidation or resolutions providing for a complete or partial liquidation, dissolution, restructuring, recapitalization or other reorganization of any of OmniAb or OmniAb&#8217;s subsidiaries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire (including by merger, consolidation, or acquisition of shares or assets), lease or license, (i)&#160;any interest in any person or (ii)&#160;any assets of any person that would be an asset of OmniAb or OmniAb&#8217;s subsidiaries at the Effective Time, other than, in the case of clause (ii), (A)&#160;in the ordinary course of business with respect to assets having a value not exceeding $2,000,000, individually, or $4,000,000, in the aggregate, the purchase price for which will be paid by Ligand or any of its subsidiaries prior to the distribution date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">repurchase, repay, prepay, refinance or incur any indebtedness for borrowed money, issue any debt securities, engage in any securitization transactions or similar arrangements or assume, guarantee or endorse, or otherwise as an accommodation become responsible for (whether directly, contingently or otherwise), the obligations of any person for borrowed money other than in the ordinary course of business consistent with past practice and in an aggregate amount not to exceed $500,000;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">make any material loans, material capital contributions or material investments in, or advances of money to, in each case, in excess of $2,000,000 individually or $4,000,000 in the aggregate, to any person (other than OmniAb or OmniAb&#8217;s subsidiaries), in each case, except for (i)&#160;advances to employees or officers of any of OmniAb or OmniAb&#8217;s subsidiaries for expenses incurred in the ordinary course of the OmniAb Business consistent with past practice and in accordance with Ligand&#8217;s and its subsidiaries&#8217; policies in respect thereof or (ii)&#160;extended payment terms for customers in the ordinary course of the OmniAb Business consistent with past practice;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(A)&#160;amend or modify in any material respect, terminate (excluding any expiration in accordance with its terms), or waive any material right, benefit or remedy under, any OmniAb material contract or (B)&#160;enter into any contract that if entered into prior to the date hereof would be an OmniAb material contract;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">except as contemplated by the Transaction Documents, as required by applicable law or as required by any existing Ligand benefit plan, or in the ordinary course of business consistent with past practice, (i)&#160;adopt, enter into, amend or alter in any respect or terminate any Ligand benefit plan in respect of any OmniAb trade secret (other than the grant of equity awards in the ordinary course of business consistent with past practice), or any OmniAb benefit plan, (ii)&#160;grant or agree to grant any material increase in the wages, salary, bonus or other compensation, remuneration or benefits of any OmniAb service provider, or that would result in any material liability to any of OmniAb or OmniAb&#8217;s subsidiaries, (iii)&#160;grant or provide any change-in-control, severance, termination, retention or similar payments or benefits to any OmniAb service provider, or that would result in any material liability to any of OmniAb or OmniAb&#8217;s subsidiaries, (iv)&#160;hire or engage, or make an offer to hire or engage, any officer, employee, service provider or individual independent contractor of any of OmniAb or OmniAb&#8217;s subsidiaries whose annual base pay exceeds $250,000, or (v)&#160;terminate (without cause) the employment of any OmniAb Employee or engagement of any OmniAb Independent contractor whose annual base pay or retainer exceeds $250,000;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">except as required or permitted by GAAP, make any material change to any financial accounting principles, methods or practices of any of OmniAb or OmniAb&#8217;s subsidiaries or with respect to the OmniAb Business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">waive, release, settle, compromise or otherwise resolve any action, litigation or other proceedings, except where such waivers, releases, settlements or compromises involve only the payment of monetary damages in an amount less than $375,000 in the aggregate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;make, change or revoke any material tax election in respect of the OmniAb Business that would bind any of OmniAb or OmniAb&#8217;s subsidiaries for periods following the Effective Time (other than an election reasonably required in connection with the separation) or (ii)&#160;settle or compromise any material tax liability for which any of OmniAb or OmniAb&#8217;s subsidiaries would be responsible under any Transaction Documents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">make or commit to make any capital expenditures, on an annualized basis, in the aggregate, in excess of $2,000,000, in the aggregate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enter into any collective bargaining agreement or other similar contract with a labor union, works&#8217; council, employee representative body or labor organization that would constitute an OmniAb collective bargaining agreement or in respect of which APAC or its subsidiaries will have any liability or obligations following the Effective Time, or amend or modify any of OmniAb&#8217;s collective bargaining agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disclose or agree to disclose to any person (other than APAC or any of its representatives) any material trade secret or any other material confidential or proprietary information, know-how or process of Ligand or any of its subsidiaries, in each case other than in the ordinary course of business consistent with past practice and pursuant to customary contractual obligations or fiduciary or professional duty to maintain the confidentiality thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">terminate without replacement or fail to use reasonable efforts to maintain any license or permit that is material to the conduct of the business of Ligand and its subsidiaries, taken as a whole;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">waive the restrictive covenant obligations of any current officer of Ligand or any of OmniAb or OmniAb&#8217;s subsidiaries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;limit the right of Ligand or any of OmniAb or OmniAb&#8217;s subsidiaries to engage in any line of business or in any geographic area, to develop, market or sell products or services, or to compete with any person or (ii)&#160;grant any exclusive or similar rights to any person, in each case, except where such limitation or grant does not, and would not be reasonably likely to, individually or in the aggregate, materially and adversely affect, or materially disrupt, the ordinary course operation of the businesses of Ligand or any of OmniAb or OmniAb&#8217;s subsidiaries, taken as a whole;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">terminate without replacement or amend in a manner materially detrimental to Ligand and its subsidiaries, taken as a whole, any insurance policy insuring the business of Ligand or any of OmniAb or OmniAb&#8217;s subsidiaries; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize or enter into any contract to do any of the foregoing or otherwise agree or make any commitment to do any of the foregoing.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC has agreed that, unless otherwise required or permitted under the Merger Agreement, and subject to certain disclosed exceptions, neither APAC nor its subsidiaries will take the following actions during the interim period between signing of the Merger Agreement and Closing, among others, without the prior written consent of OmniAb and Ligand (which consent will not be unreasonably conditioned, withheld, delayed or denied):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek any approval from APAC&#8217;s shareholders to amend, modify, restate, waive, rescind or otherwise change the trust agreement or the governing documents of APAC or Merger Sub (other than as contemplated by the transaction proposals);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;make or declare any dividend or distribution to APAC&#8217;s shareholders or make any other distributions in respect of any of APAC&#8217;s equity interests or Merger Sub capital stock, share capital or equity interests, (ii)&#160;split, combine, reclassify or otherwise amend any terms of any shares or series of APAC&#8217;s equity interests or Merger Sub capital stock or equity interests, or (iii)&#160;purchase, repurchase, redeem or otherwise acquire any issued and outstanding share capital, outstanding shares of capital stock, share capital or membership interests, warrants or other equity interests of APAC or Merger Sub, other than a redemption of shares of New OmniAb Class&#160;A Common Stock made as part of the redemptions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">make, change or revoke any material tax election or (ii)&#160;settle or compromise any material tax liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enter into, renew or amend in any material respect, any transaction or contract with an Affiliate of APAC or Merger Sub (including, for the avoidance of doubt, (i)&#160;the Sponsor and (ii)&#160;any person in which the Sponsor has a direct or indirect legal, contractual or beneficial ownership interest of 5% or greater);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur or assume any indebtedness or guarantee any indebtedness of another person, issue or sell any debt securities or warrants or other rights to acquire any debt securities of Ligand or any of Ligand&#8217;s subsidiaries or guaranty any debt securities of another person, other than any indebtedness (x)&#160;for borrowed money or guarantee from its affiliates and stockholders in order to meet its reasonable capital requirements, with any such loans to be made only as reasonably required by the operation of APAC in due course on a non-interest basis and otherwise with arm&#8217;s-length terms and conditions and repayable at the Closing, and in any event in an aggregate amount not to exceed $100,000 (or, in the case of working capital loans, up to $150,000), or (y)&#160;incurred between APAC and Merger Sub;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;issue any APAC securities or securities exercisable for or convertible into APAC securities, other than issuances contemplated by the transactions, (ii)&#160;grant any options, warrants or other equity-based awards with respect to APAC securities not outstanding on the date hereof or (iii)&#160;amend, modify or waive any of the material terms or rights set forth in any APAC Warrant or the warrant agreement, including any amendment, modification or reduction of the warrant price set forth therein; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enter into any agreement to do any action prohibited by the foregoing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Securities Law Filings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC, Ligand and OmniAb agreed to jointly prepare and APAC agreed to file with the SEC, the registration statement on Form&#160;S-4 of which this proxy statement/prospectus/information statement is a part (the &#8220;S-4&#8221;) relating to the transactions contemplated by the Merger Agreement. APAC, Ligand and OmniAb agreed to jointly prepare and Ligand agreed to file with the SEC, the information statement on Form&#160;10 that forms a part of this proxy statement/prospectus/information statement (the &#8220;Form&#160;10&#8221;) relating to the transactions contemplated by the Merger Agreement. Each of APAC, Ligand and OmniAb agreed to use their reasonable best efforts to: (i)&#160;cause the S-4 and Form&#160;10 to comply in all material respects with the applicable U.S. federal securities laws; (ii)&#160;have the S-4 and Form&#160;10 declared effective as promptly as practicable after it is filed with the SEC; (iii)&#160;keep the S-4 and Form&#160;10 effective as long as is necessary to consummate the Business Combination; (iv)&#160;cooperate and provide one another with a reasonable opportunity to review any amendment or supplement to the S-4 and Form&#160;10; and (v)&#160;promptly notify the other of, cooperate with each other with respect to any response to, and respond promptly to any comments of the SEC or its staff on the S-4 and Form&#160;10.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Antitrust Approvals</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Promptly, and in any event within ten business&#160;days, following the execution of the Merger Agreement, APAC and Ligand are each required to make all pre-merger notification filings required under the HSR Act. The parties submitted filings required under the HSR Act in connection with the transactions contemplated by the Merger Agreement on April&#160;6, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Modification in Recommendation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement provides that the APAC Board will not withdraw, amend, qualify or modify its recommendation to APAC&#8217;s shareholders that they vote in favor of the Condition Precedent Proposals (together with any withdrawal, amendment, qualification or modification of its recommendation to APAC&#8217;s shareholders, a &#8220;Modification in Recommendation&#8221;); provided, that the APAC Board may make a Modification in Recommendation if it determines in good faith, after consultation with its outside legal counsel, in response to an Intervening Event (as defined below), that a failure to make a Modification in Recommendation would be inconsistent with its fiduciary obligations to APAC&#8217;s shareholders under applicable law; provided, further, that: (i)&#160;APAC shall have delivered written notice to Ligand of its intention to make a Modification in Recommendation at least five business&#160;days prior to the taking of such action by APAC, (ii)&#160;during such period and prior to making a Modification in Recommendation, if requested by Ligand, APAC shall have negotiated in good faith with Ligand regarding any revisions or adjustments proposed by Ligand to the terms and conditions of the Merger Agreement as would enable the APAC Board to reaffirm its recommendation and not make such Modification in Recommendation and (iii)&#160;if Ligand requested negotiations in accordance with clause (ii), APAC may make a Modification in Recommendation only if the APAC Board, after considering in good faith any revisions or adjustments to the terms and conditions of the Merger Agreement that Ligand shall have, prior to the expiration of the five business day period, offered in writing to APAC, continues to determine in good faith that failure to make a Modification in Recommendation would be inconsistent with its fiduciary duties to APAC&#8217;s shareholders under applicable law. To the fullest extent permitted by applicable law, APAC&#8217;s obligations to establish a record date for, duly call, give notice of, convene and hold the extraordinary general meeting shall not be affected by any Modification in Recommendation, and APAC has agreed to establish a record date for, duly call, give notice of, convene and hold the extraordinary general meeting and submit for approval the Condition Precedent Proposals irrespective of whether a Modification in Recommendation has occurred. As used in this section, &#8220;Intervening Event&#8221; means any change, event, development, condition, occurrence or effect that (i)&#160;was not known to or reasonably foreseeable by the APAC Board as of the date of the Merger Agreement and (ii)&#160;does not relate to (A)&#160;any business combination (other than the Merger or the other transactions contemplated by the Merger Agreement) or (B)&#160;clearance of the Business Combination by any governmental authority; provided, that (1)&#160;any change in the price or trading volume of APAC Class&#160;A Ordinary Shares shall not be taken into account for purposes of determining whether an Intervening Event has occurred and (2)&#160;Ligand&#8217;s, OmniAb&#8217;s or any of their respective subsidiaries&#8217; meeting, failing to meet or exceeding projections (in and of itself, but not the underlying causes thereof) shall not be taken into account for purposes of determining whether an Intervening Event has occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Merger Agreement provides that Ligand shall immediately cease, and shall cause its subsidiaries and shall use reasonable best efforts to cause its representatives to immediately cease, any discussions or negotiations with any person (other than APAC or its affiliates) that may be ongoing with respect to an OmniAb Proposal (as defined below), or any inquiry, proposal or offer that would reasonably be expected to lead to an OmniAb Proposal, and shall promptly request that each person that has been provided with any confidential information in connection with any OmniAb Proposal prior to the date of the Merger Agreement promptly return or destroy such information, including promptly terminating any access by any person to any physical or electronic data room relating to any OmniAb Proposal. From the date of the Merger Agreement until the earlier to occur of (a)&#160;the termination of the Merger Agreement pursuant to its terms and (b)&#160;the Effective Time, Ligand shall not, and shall cause its subsidiaries and shall use reasonable best efforts to cause its representatives not to: (i)&#160;solicit, initiate, knowingly encourage or knowingly facilitate (including by way of furnishing information that has not been previously publicly disseminated) any proposal from or on behalf of a third party relating to, directly or indirectly, any acquisition (whether by merger, purchase of Interests, purchase of assets or otherwise), exclusive license, joint venture, partnership, recapitalization, liquidation, dissolution or other transaction involving any portion of the business or assets of Ligand and its subsidiaries that, individually or in the aggregate, constitutes 15% or more of the net revenues, net income or assets of the OmniAb Business (taken as a whole) (any of the foregoing, an &#8220;OmniAb Proposal&#8221;), or any inquiry, proposal or offer which would reasonably be expected to lead to an OmniAb Proposal, (ii)&#160;engage in any discussions or negotiations regarding, or furnish to any person any nonpublic information relating to the OmniAb Business, any OmniAb Assets or OmniAb or any of its subsidiaries in connection with, any OmniAb Proposal or any inquiry, proposal, effort or attempt related to or that would reasonably be expected to lead to, an OmniAb Proposal, (iii)&#160;adopt, approve or recommend, or publicly propose to adopt, approve or recommend, any OmniAb </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">148</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Proposal or (iv)&#160;approve or authorize, or cause or permit Ligand or any of its subsidiaries to enter into, any merger agreement, acquisition agreement, reorganization agreement, letter of intent, memorandum of understanding, agreement in principle, option agreement, joint venture agreement, partnership agreement or similar agreement or document relating to, or providing for, any OmniAb Proposal; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that the foregoing shall limit Ligand&#8217;s ability to pursue or engage in any transaction relating to substantially all of the business of Ligand and its subsidiaries, taken as a whole (as opposed to solely the OmniAb Business), so long as such transaction would not prevent or materially impair or materially delay Ligand&#8217;s ability to comply with its obligations under the Merger Agreement and under the Separation Agreement or to consummate the transactions contemplated thereby; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</span>, that the foregoing shall not affect any of the obligations of Ligand and OmniAb or its subsidiaries under the Merger Agreement or any other Transaction Document (as defined therein).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement provides that, at any time prior to the earlier of (i)&#160;180&#160;days after the date thereof or (ii)&#160;the S-4 being declared effective by the SEC, Ligand may: (x)&#160;furnish information in response to a request therefor (including nonpublic information regarding Ligand or any of its subsidiaries) to any person or its representatives who makes an unsolicited proposal to acquire all or at least seventy-five&#160;percent (75%) of the voting securities of Ligand or at least seventy-five (75%) of the assets of Ligand and its subsidiaries, taken as a whole, that is conditioned on the termination of the Merger Agreement (any such proposal, a &#8220;Ligand Acquisition Proposal&#8221;), in each case, provided, that prior to furnishing any such information, the person making such Ligand Acquisition Proposal enters into a confidentiality agreement with Ligand at least as restrictive as the existing confidentiality agreement between OmniAb and APAC; and (y)&#160;engage or participate in any discussions or negotiations with any person regarding such Ligand Acquisition Proposal. Ligand also agreed to promptly (and, in any event, within two business&#160;days) give notice to APAC if any Ligand Acquisition Proposal is received by Ligand, setting forth in such notice the material terms and conditions of any such proposals or offers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement provides that, at any time prior to the earlier of (i)&#160;180&#160;days after the date of the Merger Agreement or (ii)&#160;the S-4 being declared effective by the SEC, Ligand may elect to terminate the Merger Agreement, pursuant to and subject to the terms of Section&#160;9.1(i)&#160;and Section&#160;9.3 thereof, in order to enter into a definitive agreement with respect to a Ligand Acquisition Proposal; provided, that, prior to entering into any such definitive agreement with respect to a Ligand Acquisition Proposal, (x)&#160;Ligand must have delivered notice to APAC of its intention to enter into such definitive agreement at least five business&#160;days prior to the taking of such action by Ligand and (y)&#160;during such five-business day period, and prior to entering into such definitive agreement, if requested by APAC, Ligand shall negotiate in good faith with APAC regarding any revisions or adjustments proposed by APAC to the terms and conditions of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement further provides that APAC shall immediately cease and shall use reasonable best efforts to cause its Representatives to immediately cease, any discussions or negotiations with any Person (other than the Ligand or its affiliates) that may be ongoing with respect to an APAC Proposal (as defined below), or any inquiry, proposal or offer that would reasonably be expected to lead to an APAC Proposal. From the date of the Merger Agreement until the earlier to occur of (i)&#160;the termination of the Merger Agreement pursuant to Article&#160;IX therein and (ii)&#160;the Effective Time, APAC shall not and shall use reasonable best efforts to cause its Representatives not to: (w)&#160;solicit, initiate, knowingly encourage or knowingly facilitate (including by way of furnishing information that has not been previously publicly disseminated) any proposal from or on behalf of a third party relating to, directly or indirectly, any merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination involving APAC (any of the foregoing, an &#8220;APAC Proposal&#8221;), or any inquiry, proposal or offer which would reasonably be expected to lead to an APAC Proposal, (x)&#160;engage in any discussions or negotiations regarding, or exchange with any person any nonpublic information in connection with, any APAC Proposal or any inquiry, proposal, effort or attempt related to or that would reasonably be expected to lead to, an APAC Proposal, (y)&#160;adopt, approve or recommend, or publicly propose to adopt, approve or recommend, any APAC Proposal or (z)&#160;approve or authorize, or cause or permit APAC to enter into, any merger agreement, acquisition agreement, reorganization agreement, letter of intent, memorandum of understanding, agreement in principle, option agreement, joint venture agreement, partnership agreement or similar agreement or document relating to, or providing for, any APAC Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Covenants and Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement contains other covenants and agreements, including covenants related to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the intended tax treatment of the transactions contemplated by the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ligand and APAC providing each other with reasonable access to the properties, books and records and appropriate senior-level officers and employees of each respective party and their subsidiaries, and furnishing such other party and its </span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">149</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">representatives with their accounting (including accountants&#8217; work papers), financial and operating data and other information concerning their affairs, in each case, as such party and its representatives may reasonably request for the purposes of furthering the transactions or for purposes of preparing for the operation of APAC and the surviving corporation post-closing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">confidentiality and publicity relating to the Merger Agreement and the transactions contemplated thereby;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">procedures and obligations of each party in connection with litigation relating to the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC, OmniAb and Ligand taking all steps as may be required (to the extent permitted by applicable Law) to cause any dispositions of OmniAb Common Stock (including derivative securities with respect to OmniAb Common Stock) or acquisitions of New OmniAb Common Stock resulting from the transactions, including the Distribution, directly or indirectly, by each individual, if any, who is subject to Section&#160;16(a)&#160;of the Exchange Act with respect to APAC or OmniAb, as applicable, as an officer or director thereof to be exempt under Rule&#160;16b-3 promulgated under the Exchange Act, such steps to be taken in accordance with (and to the extent permitted by) applicable SEC rules&#160;and regulations and interpretations of the SEC staff;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb taking all actions necessary to authorize the issuance of a number of, or stock split of, shares of OmniAb Common Stock such that the total number of shares of OmniAb Common Stock outstanding immediately prior to the Effective Time will equal the number of shares of Ligand Common Stock entitled to receive the Distribution outstanding immediately prior to the Effective Time in accordance with the terms of the Separation Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC&#8217;s Domestication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC using its reasonable best efforts to maintain the listing of the APAC Class&#160;A Ordinary Shares on NASDAQ, and, if required, preparing and submitting to NASDAQ a listing application for the New OmniAb Stock issuable in the Merger and the Domestication; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">certain financial reporting requirements of Ligand to APAC.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Survival of Representations and Warranties; Indemnification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The representations, warranties, agreements and covenants in the Merger Agreement terminate at the Effective Time, except for the covenants and agreements which by their terms expressly apply in whole or in part after such time (and only with respect to breaches occurring after the Closing), covenants and agreements relevant to the conversion of securities and allocation of aggregate consideration and the representations and warranties of the parties thereto regarding exclusivity of representations and warranties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Conditions to Closing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General Conditions</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consummation of the Business Combination is conditioned on the approval of the Business Combination Proposal, the Domestication Proposal, the Organizational Documents Proposal, the Stock Issuance Proposal, <span style="color:#231f20;">the Incentive Plan Proposal, the ESPP Proposal </span>and the Director Election Proposal as described in this proxy statement/prospectus/information statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the consummation of the Business Combination is conditioned upon, among other things, the following mutual conditions to closing, any one (1)&#160;or more of which may be waived in writing by the Companies, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;the waiting period (or any extension thereof) under the HSR Act with respect to the Merger shall have expired or been terminated pursuant to the HSR Act; (ii)&#160;all other requisite regulatory approvals shall have been obtained and shall remain in full force and effect and all statutory waiting periods (and any extensions thereof) in respect thereof shall have expired or been terminated; and (iii)&#160;there shall not be in effect any voluntary agreement between the APAC or Ligand and any governmental authority pursuant to which APAC or Ligand has agreed not to consummate the transactions for any period of time;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">150</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Separation and the Distribution and the other transactions contemplated by the Separation Agreement shall have been consummated in accordance therewith;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;each of APAC&#8217;s and OmniAb&#8217;s respective registration statements shall have become effective in accordance with the Securities Act or the Exchange Act, as applicable, and neither shall be the subject of any stop order by the SEC or actual or threatened proceedings by a government authority seeking such a stop order; and (ii)&#160;the applicable notice periods required by applicable stock exchange rules&#160;or securities laws in connection with the Distribution, if any, shall have expired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no governmental authority of competent jurisdiction shall have enacted, issued or granted any Law (whether temporary, preliminary or permanent), in each case that is in effect and which has the effect of restraining, enjoining or prohibiting the consummation of the Business Combination;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC shall have at least $5,000,001 of net tangible assets (as determined in accordance with Rule&#160;3a51-1(g)(1)&#160;of the Exchange Act); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the shares of New OmniAb Common Stock issuable pursuant to the transactions shall have been approved for listing on Nasdaq, subject to official notice of issuance.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">APAC and Merger Sub Conditions to Closing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The obligations of APAC and Merger Sub to consummate or cause to be consummated the Business Combination is subject to the satisfaction of the following additional conditions, any one (1)&#160;or more of which may be waived in writing by Ligand and OmniAb, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of OmniAb and Ligand shall each have performed and complied in all material respects with the obligations, covenants and agreements required by the Merger Agreement to be performed or complied with by it at or prior to the Effective Time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the accuracy of all representations and warranties made by Ligand and OmniAb (subject to customary bring-down standards, including in most instances, OmniAb Material Adverse Effect);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no OmniAb Material Adverse Effect shall have occurred between the date of the Merger Agreement and the Closing that is continuing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ligand shall have delivered to APAC a certificate dated as of the Closing signed by an authorized officer of Ligand certifying that (i)&#160;the Separation and Distribution have been completed, (ii)&#160;the conditions relating to the bring-down of Ligand&#8217;s and OmniAb&#8217;s respective representations and warranties and compliance by Ligand and OmniAb with their respective covenants have been satisfied and (iii)&#160;there has been no OmniAb Material Adverse Effect since the date of the Merger Agreement that is continuing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ligand (or such other applicable subsidiary of Ligand) shall have executed and delivered each of the applicable transaction documents, and to the extent applicable, performed and complied with the obligations, covenants and agreements to be performed thereunder by them prior to the Effective Time in all material respects, and each such agreement shall be in full force and effect;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC shall have received an opinion of Weil, Gotshal&#160;&amp; Manges LLP that the Merger will be treated as a reorganization under Section&#160;368(a)&#160;of the Code and a copy of the tax opinions delivered to Ligand by Latham&#160;&amp; Watkins LLP; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ligand shall have, or shall have caused OmniAb to have, delivered to APAC a FIRPTA certificate and related documents.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">151</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Ligand and OmniAb Conditions to Closing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The obligations of Ligand and OmniAb to consummate or cause to be consummated the Business Combination is subject to the satisfaction of the following additional conditions, any one (1)&#160;or more of which may be waived in writing by Ligand and OmniAb, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC and Merger Sub shall each have performed and complied in all material respects with the obligations, covenants and agreements required by the Merger Agreement to be performed or complied with by it at or prior to the Effective Time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the accuracy of all representations and warranties made by APAC and Merger Sub (subject to customary bring-down standards, including in most instances, APAC Material Adverse Effect);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC shall have delivered to Ligand a certificate dated as of the Closing signed by an authorized officer of APAC certifying that (i)&#160;APAC shall have at least $5,000,001 of net tangible assets as of the Closing and (ii)&#160;that the conditions relating to the bring-down of APAC&#8217;s and Merger Sub&#8217;s respective representations and warranties and compliance by APAC and Merger Sub with their respective covenants have been satisfied;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC and Merger Sub shall have executed and delivered the applicable transaction documents, and to the extent applicable, performed and complied with the obligations, covenants and agreements thereunder required to be performed by them prior to the Effective Time in all material respects, and each such agreement shall be in full force and effect;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Domestication shall have been completed and a time-stamped copy of the certificate issued by the Secretary of State of the State of Delaware in relation thereto shall have been delivered to Ligand;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Forward Purchase and the Redemption Backstop shall have been consummated in accordance with the terms of the A&amp;R FPA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other than those Persons identified as continuing as directors of the combined company, all members of the APAC Board and all executive officers of APAC shall have executed and delivered written resignations effective as of the Effective Time; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ligand shall have received (1)&#160;an opinion of Latham&#160;&amp; Watkins LLP, that the Distribution, together with certain related transactions, will qualify as a &#8220;reorganization&#8221; within the meaning of Sections 368(a)(1)(D)&#160;and 355(a)&#160;of the Code and that the Merger will not cause Section&#160;355(e)&#160;of the Code to apply to the Distribution, (2)&#160;an opinion of Latham&#160;&amp; Watkins LLP that the Merger will be treated as a reorganization under Section&#160;368(a)&#160;of the Code and (3)&#160;a copy of the tax opinion delivered to APAC by Weil, Gotshal&#160;&amp; Manges&#160;LLP.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Waiver</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any party of the Merger Agreement may, at any time prior to the Closing of the Merger Agreement, by action taken by its board of directors or equivalent governing body or authority, or officers thereunto duly authorized, waive any of the terms or conditions of the Merger Agreement by an agreement in writing executed in the same manner as the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement may be terminated and the transactions abandoned, but not later than the Closing, as follows, provided that no party may terminate the Merger Agreement if its failure to fulfill any obligation thereunder has been the primary cause of, or primarily resulted in, the failure of the Closing to occur on or before such date:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by mutual written agreement of Ligand and APAC;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by Ligand or APAC, if the Closing shall not have occurred on or prior to the date that is nine (9)&#160;months after the date of the Merger Agreement (&#8220;Outside Date&#8221;); provided, that this right to terminate the Merger Agreement shall not be available to </span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">152</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any party whose action or failure to comply with its obligations under the Merger Agreement or any of the other transaction documents has been the primary cause of, or has primarily resulted in, the failure of the Closing to occur on or prior to such date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by Ligand or APAC, if any law shall have been promulgated, entered, enforced, enacted or issued and in effect or shall have been deemed to be applicable to the Merger or the other transactions, including the Separation and the Distribution, by any governmental authority of competent jurisdiction which permanently prohibits, restrains or makes illegal the consummation of the Merger or the other transactions, and such law shall have become final and non-appealable; provided, that this right to terminate the Merger Agreement shall not be available to any party whose action or failure to perform any of its obligations under the Merger Agreement or any of the transaction documents is the primary cause of, or primarily resulted in, the enactment or issuance of any such law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by APAC upon written notice to Ligand, in the event of a breach of any representation, warranty, covenant or agreement on the part of Ligand or OmniAb, such that the related bring-down conditions would not be satisfied at the Closing, and which, (i)&#160;with respect to any such breach that is capable of being cured, is not cured by Ligand or OmniAb by the earlier of: (x)&#160;thirty (30)&#160;days after receipt of written notice thereof; or (y)&#160;the Outside Date, or (ii)&#160;is incapable of being cured prior to the Outside Date; provided, that APAC shall not have this right to terminate the Merger Agreement if APAC or Merger Sub is then in breach of any of its representations, warranties, covenants or agreements set forth in the Merger Agreement to the extent such breach or breaches would give rise to the failure of a condition to Closing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by Ligand upon written notice to APAC, in the event of a breach of any representation, warranty, covenant or agreement contained in the Merger Agreement on the part of APAC or Merger Sub such that the related bring-down conditions would not be satisfied at the Closing, and which, (i)&#160;with respect to any such breach that is capable of being cured, is not cured by APAC by the earlier of: (x)&#160;thirty (30)&#160;days after receipt of written notice thereof; or (y)&#160;the Outside Date, or (ii)&#160;is incapable of being cured prior to the Outside Date; provided, that Ligand shall not have this right to terminate the Merger Agreement if Ligand or OmniAb is then in breach of any of its representations, warranties, covenants or agreements set forth in the Merger Agreement to the extent such breach or breaches would give rise to the failure of a condition to Closing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by Ligand or APAC, if APAC&#8217;s shareholder approval shall not have been obtained upon a vote taken thereon at APAC&#8217;s shareholders Meeting, duly convened therefor, or at any adjournment or postponement thereof; provided, that this right to terminate the Merger Agreement shall not be available to APAC if APAC&#8217;s actions or failure to perform any of its obligations under the Merger Agreement is the primary cause of, or primarily resulted in, the failure to obtain such approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by Ligand, if the APAC Board shall have effected a APAC adverse recommendation change prior to APAC&#8217;s shareholders meeting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by Ligand, if all of the conditions to Closing have been met (other than those conditions that by their terms are to be satisfied at Closing) other than the condition that the Forward Purchase and the Redemption Backstop shall have been consummated in accordance with the terms of the A&amp;R FPA; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by Ligand, prior to the earlier of (i)&#160;180&#160;days after the date of the Merger Agreement or (ii)&#160;the S-4 being declared effective by the SEC, in order to accept a Ligand Acquisition Proposal and enter into, immediately following such termination, a binding and definitive written contract with respect to such Ligand Acquisition Proposal; provided, that (x)&#160;Ligand has materially complied with its covenants and agreements under the exclusivity provisions of the Merger Agreement, (y)&#160;Ligand pays the Termination Fee to APAC in accordance with Section&#160;9.3(a)&#160;of the Merger Agreement and (z)&#160;Ligand pays the FPA termination fee to the Sponsor pursuant to the terms of the A&amp;R Forward Purchase Agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination Fees and Expenses Payable in Certain Circumstances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In the event that the Merger Agreement is terminated by Ligand in connection with its entering into a definitive agreement in respect of a Ligand Acquisition Proposal as described in the immediately preceding section, concurrently with such termination, Ligand shall be obligated to pay APAC a termination fee of (i)&#160;if terminated within 60&#160;days of the date of the Merger Agreement, $40,000,000, (ii)&#160;if terminated between 61 and 120&#160;days after the date of the Merger Agreement, $50,000,000, and (iii)&#160;if terminated between 121 and 180&#160;days after the date of the Merger Agreement, $70,000,000 (each such amount, the &#8220;Termination Fee&#8221;), by wire transfer of immediately available funds to an account designated by APAC in writing, and, in addition to payment of the Termination </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">153</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Fee, Ligand also shall pay the APAC Expenses (the &#8220;APAC Expenses Reimbursement&#8221;) by wire transfer of immediately available funds to an account designated by APAC in writing no later than two business&#160;days after the date on which APAC delivers to Ligand a written invoice for the APAC Expenses. As used in this subsection, &#8220;APAC Expenses&#8221; means the amount of all reasonable and documented out-of-pocket fees and expenses, but not to exceed $7,500,000, incurred or paid by APAC and its affiliates in connection with the Merger Agreement and the Business Combination, including fees and expenses of law firms, accounting firms, financial advisors, outside experts and consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Effect of Termination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of proper termination by APAC, Ligand or OmniAb, the Merger Agreement will become void and have no effect (other than with respect to certain surviving obligations specified in the Merger Agreement), without any liability on the part of any party or its respective affiliates, officers, directors, employees, shareholders or stockholders, other than liability of any party for any Willful Breach (as defined in the Merger Agreement) of the Merger Agreement by such party occurring prior to such termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fees and Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as otherwise provided in the Separation Agreement, all fees and expenses incurred in connection with the Merger Agreement and the transactions contemplated thereby will be paid by the party incurring such expenses, except for filing fees payable to any governmental authority in connection with any required approvals, which shall be borne equally by Ligand and APAC in the event the Merger Agreement is terminated in accordance with its terms prior to the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amendments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement may be amended or modified in whole or in part, only by a duly authorized agreement in writing executed in the same manner as the Merger Agreement and which makes reference to the Merger Agreement. The approval of the Merger Agreement by the members or equityholders of any of the parties therein shall not restrict the ability of the board of directors (or other body or entity performing similar functions) of any of the parties to terminate the Merger Agreement or, subject to applicable law, including the DGCL, to cause such party to enter into an amendment to the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Governing Law; Consent to Jurisdiction</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement, and all claims or causes of action based upon, arising out of, or related to the Merger Agreement is governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to principles or rules&#160;of conflict of laws to the extent such principles or rules&#160;would require or permit the application of laws of another jurisdiction; provided that the Domestication shall be consummated pursuant to both the laws of the State of Delaware and Cayman Islands law. All legal actions and proceedings arising out of or relating to the Merger Agreement will be heard and determined exclusively in any Delaware Chancery Court; provided, that if jurisdiction is not then available in the Delaware Chancery Court, then any such action or proceeding may be brought in any federal court located in the State of Delaware. The parties submit to the exclusive jurisdiction of the aforesaid courts and agree not to commence any such action or proceeding arising out of or relating to the Merger Agreement except in the courts described above in the State of Delaware. Notice as provided in the Merger Agreement will constitute sufficient service of process and the parties further waive any argument that such service is insufficient. Each of the parties waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any such action or proceeding arising out of or relating to the Merger Agreement or the Business Combination, any claim (a)&#160;that it is not personally subject to the jurisdiction of the courts in Delaware as described in the Merger Agreement for any reason or (b)&#160;that any action or proceeding in any such court is brought in an inconvenient forum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of the Separation Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ligand, OmniAb and APAC have entered into a Separation Agreement which sets forth the principal actions to be taken in connection with the Separation. It also sets forth other agreements that govern certain aspects of OmniAb&#8217;s relationship with Ligand following the Business Combination.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">154</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transfer of Assets and Assumption of Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Separation Agreement identifies assets to be transferred, liabilities to be assumed and contracts to be assigned to each of Ligand and OmniAb as part of the internal reorganization transaction described herein, and describes when and how these transfers, assumptions and assignments will occur, though some of the transfers, assumptions and assignments may have already occurred prior to the parties&#8217; entering into the Separation Agreement. The Separation Agreement provides for those transfers of assets and assumptions of liabilities that are necessary in connection with the Separation so that OmniAb and Ligand retain the assets necessary to operate their respective businesses and retain or assume the liabilities allocated in accordance with the Separation. The Separation Agreement also provides for the settlement or extinguishment of certain liabilities and other obligations between OmniAb and Ligand. In particular, the Separation Agreement provides that, subject to the terms and conditions contained in the Separation Agreement:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;OmniAb Assets&#8221; (as defined in the Separation Agreement), including, but not limited to, the equity interests of OmniAb&#8217;s subsidiaries, including Ab Initio Biotherapeutics,&#160;Inc., Crystal Bioscience,&#160;Inc., Icagen, LLC, Taurus Biosciences, LLC and xCella Biosciences,&#160;Inc., assets reflected on OmniAb&#8217;s pro forma balance sheet and assets exclusively relating to the OmniAb Business, will be retained by or transferred to OmniAb or one of its subsidiaries, except as set forth in the Separation Agreement or one of the other agreements described below;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;OmniAb Liabilities&#8221; (as defined in the Separation Agreement), including, but not limited to, the following, will be retained by or transferred to OmniAb or one of its subsidiaries:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all of the liabilities (whether accrued, contingent or otherwise, and subject to certain exceptions) to the extent related to, arising out of or resulting from the OmniAb Business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liabilities (whether accrued, contingent or otherwise) reflected on OmniAb&#8217;s pro forma balance sheet;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liabilities (whether accrued, contingent or otherwise) relating to, arising out of, or resulting from, any infringement, misappropriation or other violation of any intellectual property of any other person related to the conduct of the OmniAb Business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any environmental liabilities to the extent relating to, arising out of or resulting from the past, present or future operation of the OmniAb Business or use of its assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liabilities relating to, arising out of, or resulting from any indebtedness of any subsidiary of OmniAb or any indebtedness secured exclusively by any of OmniAb&#8217;s assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liabilities (whether accrued, contingent or otherwise) relating to, arising out of or resulting from any form, registration statement, schedule or similar disclosure document filed or furnished with the SEC by OmniAb or any of its subsidiaries after the Distribution, other than the disclosure documents referred to the next point below; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all other liabilities (whether accrued, contingent or otherwise) relating to, arising out of or resulting from disclosure documents filed or furnished with the SEC by OmniAb or Ligand that are related to the Distribution or Merger (including this proxy statement/prospectus/information statement) to the extent related to OmniAb, the Distribution or the Merger.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, all assets and liabilities (whether accrued, contingent or otherwise) of Ligand will be retained by or transferred to Ligand or one of its subsidiaries (other than OmniAb or one of its subsidiaries), except as set forth in the Separation Agreement or one of the other agreements described below and except for other limited exceptions that will result in OmniAb retaining or assuming certain other specified liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The allocation of liabilities with respect to taxes, except for payroll taxes and reporting and other tax matters expressly covered by the Employee Matters Agreement, are solely covered by the Tax Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Except as expressly set forth in the Separation Agreement or any ancillary agreement, all assets will be transferred on an &#8220;as is,&#8221; &#8220;where is&#8221; basis and the respective transferees will bear the economic and legal risks that any conveyance will prove to be insufficient </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">155</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">to vest in the transferee good title, free and clear of any security interest, that any necessary consents or governmental approvals are not obtained and that any requirements of laws or judgments are not complied with. In general, neither OmniAb nor Ligand will make any representations or warranties regarding any assets or liabilities transferred or assumed, any consents or approvals that may be required in connection with such transfers or assumptions, or any other matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Information in this proxy statement/prospectus/information statement with respect to the assets and liabilities of the parties following the Separation is presented based on the allocation of such assets and liabilities pursuant to the Separation Agreement, unless the context otherwise requires. Certain of the liabilities and obligations to be assumed by one party or for which one party will have an indemnification obligation under the Separation Agreement and the other agreements relating to the Separation are, and following the Separation may continue to be, the legal or contractual liabilities or obligations of another party. Each such party that continues to be subject to such legal or contractual liability or obligation will rely on the applicable party that assumed the liability or obligation or the applicable party that undertook an indemnification obligation with respect to the liability or obligation, as applicable, under the Separation Agreement, to satisfy the performance and payment obligations or indemnification obligations with respect to such legal or contractual liability or obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contribution</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Separation, Ligand will contribute to OmniAb $15.0 million in cash. This cash contribution will be decreased by the amount of certain transaction expenses and other reimbursable expenses relating to the costs paid by Ligand for the newly hired chief financial officer of OmniAb and increased by the amount of certain potential milestone payments to the extent received and retained by Ligand prior to the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Distribution</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On the date of the Distribution, Ligand will distribute on a pro rata basis all of the outstanding shares of OmniAb Common Stock to the holders of Ligand Common Stock as of the Ligand Record Date set for the Distribution. The Distribution will be effected by Ligand delivering to the distribution agent a book-entry authorization representing the shares of OmniAb Common Stock being distributed in the Distribution for the account of Ligand&#8217;s stockholders. The distribution agent will hold such book-entry shares for the account of OmniAb&#8217;s stockholders (as of immediately after consummation of the Distribution) pending the Merger. The shares of OmniAb Common Stock will not be transferrable prior to the exchange of such shares for the shares of New OmniAb Common Stock pursuant to the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Conditions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Distribution will be made on the date set for the Distribution, provided that the following conditions will have been satisfied (or waived by Ligand in its sole discretion, other than as noted below):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Separation shall have been completed substantially in accordance with the reorganization plan referenced therein, other than the transfer of assets or assumption of liabilities that may occur after the Distribution in accordance with the terms of the Separation Agreement (which condition may not be waived without APAC&#8217;s written consent, not to be unreasonably withheld);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the transaction agreements relating to the separation will have been duly executed and delivered by the parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of the conditions in the Merger Agreement to Ligand&#8217;s obligations to consummate the Merger shall have been satisfied or waived (other than those relating to the internal reorganization, the Ligand Contribution and the Distribution and the other transactions contemplated by the Separation Agreement, and those conditions that by their nature are to be satisfied contemporaneously with the Distribution and/or the Merger, provided they are capable of being satisfied at such time); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC shall have irrevocably confirmed to Ligand that each condition in the Merger Agreement to APAC&#8217;s obligations to consummate the Merger has been satisfied, will be satisfied at the time of the Distribution or is or has been waived by APAC (other than those relating to the internal reorganization, the Ligand Contribution and the Distribution and the other transactions contemplated by the Separation Agreement).</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">156</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Further Assurances; Separation of Guarantees</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent that any transfers of assets or assumptions of liabilities contemplated by the Separation Agreement have not been consummated on or prior to the date of the Separation, the parties will agree to cooperate with each other to effect such transfers or assumptions while holding such assets or liabilities for the benefit of the appropriate party so that all the benefits and burdens relating to such asset or liability inure to the party entitled to receive or assume such asset or liability. Each party will agree to use commercially reasonable efforts to take or to cause to be taken all actions, and to do, or to cause to be done, all things reasonably necessary under applicable law or contractual obligations to consummate and make effective the transactions contemplated by the Separation Agreement and other transaction agreements. Additionally, OmniAb and Ligand will use commercially reasonable efforts to remove OmniAb and its subsidiaries as a guarantor of liabilities (including surety bonds) retained by Ligand and its subsidiaries and to remove Ligand and its subsidiaries as a guarantor of liabilities (including surety bonds) to be assumed by OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Shared Contracts</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain shared contracts are to be assigned or amended to facilitate the Separation of the OmniAb Business from Ligand. If such contracts may not be assigned or amended, the parties are required to take reasonable actions to cause the appropriate party to receive the benefit of the contract for a specified period of time after the Separation is complete.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Release of Claims and Indemnification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as otherwise provided in the Separation Agreement or any Ancillary Agreement (as defined in the Separation Agreement, including the Transition Services Agreements, the Employee Matters Agreement, the Tax Matters Agreement, conveyancing and assumption instruments and other agreements to be entered into between OmniAb and Ligand in connection with the Separation and Distribution), OmniAb and Ligand each release and forever discharge the other party and its subsidiaries and affiliates from all liabilities existing or arising from any acts or events occurring or failing to occur or alleged to have occurred or to have failed to occur or any conditions existing or alleged to have existed on or before the Separation. The releases will not extend to obligations or liabilities under any agreements between the parties that remain in effect following the Separation pursuant to the Separation Agreement or any Ancillary Agreement. These releases will be subject to certain exceptions set forth in the Separation Agreement. APAC also releases Ligand and its subsidiaries and affiliates to a similar extent as OmniAb releases Ligand and its subsidiaries and affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Separation Agreement provides for cross-indemnities that, except as otherwise provided in the Separation Agreement, are principally designed to place financial responsibility for the obligations and liabilities allocated to OmniAb under the Separation Agreement with OmniAb and financial responsibility for the obligations and liabilities allocated to Ligand under the Separation Agreement with Ligand. Specifically, each party indemnifies, defends and holds harmless the other party, its affiliates and subsidiaries and each of its officers, directors, employees and agents for any losses arising out of or due to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the liabilities or alleged liabilities the indemnifying party assumed or retained pursuant to the Separation Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the assets the indemnifying party assumed or retained pursuant the Separation Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the operation of the indemnifying party&#8217;s business, whether prior to, at, or after the Separation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any breach by the indemnifying party of any provision of the Separation Agreement or any other agreement unless such other agreement expressly provides for separate indemnification therein.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each party&#8217;s aforementioned indemnification obligations are uncapped; provided that the amount of each party&#8217;s indemnification obligations will be subject to reduction by any insurance proceeds (net of premium increases) received by the party being indemnified. The Separation Agreement also specifies procedures with respect to claims subject to indemnification and related matters. Indemnification with respect to taxes will be governed by the Tax Matters Agreement and the Employee Matters Agreement. Following consummation of the Merger, APAC will indemnify Ligand and its affiliates and subsidiaries, and each of its officers, directors, employees and agents to the extent OmniAb has not paid for indemnifiable losses for which it has provided indemnification pursuant to the Separation Agreement.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">157</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Legal Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as otherwise set forth in the Separation Agreement or any Ancillary Agreement (or as otherwise described above), each party to the Separation Agreement assumes the liability for, and control of, all pending, threatened and future legal matters related to its own business or its assumed or retained liabilities and indemnifies the other party for any liability arising out of or resulting from such legal matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Insurance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as otherwise set forth in the Separation Agreement or any Ancillary Agreement, following the Separation, OmniAb will be responsible for obtaining and maintaining at its own cost its own insurance coverage. With respect to certain claims arising prior to the Separation, OmniAb may seek coverage under Ligand third-party insurance policies to the extent that coverage may be available thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Exchange of Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb and Ligand agree to provide each other with information, including without limitation, relating to the other party or the conduct of its business prior to the Separation, that is needed to perform under the agreements related to the Separation, and that is reasonably necessary to prepare financial statements and any reports or filings to be made with any governmental authority or in connection with litigation or other proceedings. OmniAb and Ligand also agree to retain such information in accordance with Ligand&#8217;s record retention policies as in effect immediately prior to the Distribution and to afford each other access to their respective officers, directors, employees and agents to be witnesses as reasonably required in connection with any relevant litigation. OmniAb and Ligand also agree to keep each other&#8217;s information confidential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">No Restriction on Competition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None of the provisions of the Separation Agreement includes any non-competition or other similar restrictive arrangements with respect to the range of business activities which may be conducted by either party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dispute Resolution</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a dispute arises between the parties under the Separation Agreement, the general counsels or chief legal officers of the parties or such other representatives as the parties may designate will negotiate to resolve any disputes for a reasonable period of time. If the parties are unable to resolve the dispute in this manner then, each party to the dispute will be entitled to seek relief in a court with jurisdiction as set forth in the Separation Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Separation Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as otherwise provided in the Separation Agreement or as otherwise agreed in writing among Ligand, OmniAb and APAC, Ligand and OmniAb shall each be responsible for its owns fees and costs incurred in connection with the Separation, Distribution and Merger. OmniAb will reimburse Ligand for all such fees and costs of OmniAb that have been paid by Ligand through and including the date of the Distribution by Ligand&#8217;s deducting such amount from the cash portion of the contribution to be made by Ligand to OmniAb in connection with the Separation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Treatment of Intercompany Loans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon completion of the Separation, all loans between Ligand or any subsidiary of Ligand (other than OmniAb and its subsidiaries), on the one hand, and OmniAb or any of its subsidiaries, on the other hand, will be terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Term/Termination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The term of the Separation Agreement is indefinite. The Separation Agreement may not be terminated or modified without the prior written consent of each of Ligand, OmniAb and APAC, except that it shall terminate immediately upon termination of the Merger Agreement if the Merger Agreement is terminated in accordance with its terms prior to the Distribution.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">158</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of the Ancillary Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This section describes certain additional agreements entered into or to be entered into pursuant to the Merger Agreement, but does not purport to describe all of the terms thereof. The following summary is qualified in its entirety by reference to the complete text of each of the agreements. The Employee Matters Agreement, the Sponsor Insider Agreement, the A&amp;R FPA, the form of Tax Matters Agreement, the form of A&amp;R Registration Rights Agreement, the forms of Transition Services Agreements are attached hereto as Annex K, Annex C, Annex D, Annex E, Annex G, Annex F-1, and Annex F-2 respectively. You are urged to read such agreements in their entirety prior to voting on the proposals presented at the extraordinary general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employee Matters Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, APAC, Ligand, OmniAb and Merger Sub entered into the Employee Matters Agreement, which sets forth the terms and conditions of certain employee-related matters in connection with the transaction, including allocation of benefit plan assets and liabilities between Ligand and OmniAb, treatment of incentive equity awards in the Distribution and the Business Combination and related covenants and commitments of the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Employee Matters Agreement provides for the treatment of outstanding Ligand equity awards held by our employees upon completion of the Distribution and the treatment of outstanding OmniAb Equity Awards in connection with the Business Combination, each as described in further detail in the section entitled &#8220;<i style="font-style:italic;">Executive and Director Compensation of OmniAb&#8212;Long-Term Performance-Based Equity Awards&#8212;Going Forward</i>,&#8221; and also provides for certain other incentive arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Employee Matters Agreement provides that, following the Distribution and Business Combination, our employees generally will continue to participate in benefit plans sponsored or maintained by Ligand until the earlier to occur of (i)&#160;January&#160;1, 2023 or (ii)&#160;such earlier date as may be agreed among the parties. Following the respective plan transition date, our employees will commence participation in our respective benefit plans, which are expected to be generally similar to the existing Ligand benefit plans. Additionally, the Employee Matters Agreement provides that APAC shall approve and adopt, subject to shareholder approval, the 2022 Plan and the ESPP, each effective as of the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Employee Matters Agreement also sets forth the general principles relating to employee matters, including with respect to the assignment and transfer of employees, the assumption and retention of liabilities and related assets, workers&#8217; compensation, payroll taxes, regulatory filings, the provision of comparable benefits, employee service credit, the sharing of employee information, and the duplication or acceleration of benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Employee Matters Agreement may be amended or modified only by a written agreement among the parties and will terminate automatically upon the termination of the Merger Agreement.</p><a id="SponsorInsiderAgreement_238776"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sponsor Insider Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, OmniAb, the Sponsor, APAC and the Insiders entered into the Sponsor Insider Agreement, pursuant to which, among other things, the Insiders agreed to vote any APAC securities held by them to approve the Business Combination and the other APAC shareholder matters required pursuant to the Merger Agreement, and not to seek redemption of any of their APAC securities in connection with the consummation of the Business Combination. Pursuant to the Sponsor Insider Agreement, the Sponsor also agreed to subject up to all 1,916,667 of the Sponsor Earnout Shares to forfeiture if an applicable Sponsor Triggering Event has not occurred with respect to such Sponsor Earnout Shares during the period from the date of the Closing to and including the fifth anniversary of the date of the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor Insider Agreement also provides, among other things, that the holders of the Sponsor Earnout Shares may not transfer their Sponsor Earnout Shares until the date in which vesting has occurred, other than in a distribution made by the Sponsor to its members in accordance with the Cayman Governance Documents of APAC and the A&amp;R Registration Rights Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor Insider Agreement will terminate on the earlier of (i)&#160;termination of the Merger Agreement or (ii)&#160;the vesting in full of all Sponsor Earnout Shares. The Sponsor Insider Agreement is attached to this proxy statement/prospectus/information statement as Annex C.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">159</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="AmendedRestatedForwardPurchaseAgreement_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amended&#160;&amp; Restated Forward Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, APAC entered into the A&amp;R FPA with the Sponsor and OmniAb. Pursuant to the A&amp;R FPA, APAC has agreed that, in connection with the consummation of the Business Combination, it will issue and sell to the Sponsor 1,500,000 shares of New OmniAb Common Stock and warrants to acquire 1,666,667 shares of New OmniAb Common Stock for an aggregate purchase price of $15,000,000 in the Forward Purchase. In addition to the Forward Purchase, the Sponsor has agreed to purchase up to an additional 10,000,000 shares of New OmniAb Common Stock and up to an additional 1,666,667 New OmniAb warrants in the Redemption Backstop, for an aggregate additional purchase price of up to $100,000,000, in order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds available to the combined company following the Business Combination from APAC&#8217;s trust account to be less than $100,000,000. Each of the warrants issued in connection with the Forward Purchase and the Redemption Backstop will entitle the holder to purchase one share of New OmniAb Common Stock at a price of $11.50 per share. Such warrants will become exercisable 30&#160;days after the closing and will expire five&#160;years after the closing or upon redemption or the liquidation of APAC, if earlier. The closing of the Forward Purchase and the Redemption Backstop will be held on the closing date and immediately prior to the Merger. The A&amp;R FPA also provides that in the event the Merger Agreement is terminated by Ligand under circumstances in which the Termination Fee would be payable under the Merger Agreement, Ligand shall pay the Sponsor a termination fee of $12,500,000 in connection therewith. The A&amp;R FPA is attached to this proxy statement/prospectus/information statement as Annex D.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Form&#160;of Tax Matters Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Distribution, APAC, OmniAb, and Ligand will enter into the Tax Matters Agreement that will govern each party&#8217;s respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and certain other matters regarding taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, APAC and OmniAb will be liable for all U.S. federal, state, local and foreign taxes (and any related interest, penalties or audit adjustments) that are (i)&#160;imposed with respect to tax returns that include both OmniAb and Ligand, to the extent such taxes are attributable to OmniAb or the OmniAb Business, or (ii)&#160;imposed with respect to tax returns that include OmniAb but not Ligand, in each case, for tax periods (or portions thereof) beginning after the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, APAC and OmniAb may be liable for certain taxes resulting from the restructuring transactions undertaken to effectuate the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Distribution, together with certain related transactions, is intended to qualify as a reorganization under Sections 355 and 368(a)(1)(D)&#160;of the Code. Pursuant to the Tax Matters Agreement, taxes incurred by Ligand, APAC or OmniAb relating to or arising out of the failure of the intended tax treatment will generally be shared equally by Ligand, on the one hand, and APAC and OmniAb, on the other hand. If, however, such failure is attributable to certain acts or omissions by APAC or OmniAb, inaccuracies, misrepresentations or misstatements relating to APAC or OmniAb or certain events involving the stock of APAC or OmniAb or assets of OmniAb, APAC and OmniAb will generally bear all such taxes. Under certain circumstances, including if the failure is attributable to Ligand or an event involving Ligand&#8217;s stock or assets, Ligand will bear all such taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Tax Matters Agreement will require APAC and OmniAb to comply with the representations made in the materials submitted to legal counsel in connection with the Distribution Tax Opinion that Ligand expects to receive regarding the intended tax treatment of the Distribution and certain related transactions. The Tax Matters Agreement will also restrict OmniAb&#8217;s and APAC&#8217;s ability to take or fail to take any action if such action or failure to act could reasonably be expected to adversely affect the intended tax treatment. In particular, in the two&#160;years following the Distribution, APAC and OmniAb will be subject to certain restrictions, generally including being prevented from (i)&#160;entering into any transaction which could, when combined with other transactions (including the Merger), result in a 45% or greater change in ownership of APAC&#8217;s or OmniAb&#8217;s equity as part of a plan or series of related transactions that includes the Distribution, (ii)&#160;ceasing the active conduct of certain of OmniAb&#8217;s businesses, (iii)&#160;voluntarily dissolving or liquidating APAC or OmniAb and (iv)&#160;causing, permitting, or agreeing to the sale, transfer, or disposal of assets of OmniAb that, in the aggregate, constitute more than 30% of the consolidated gross assets of OmniAb, in each case, unless OmniAb obtains a private letter ruling from the IRS, an unqualified opinion of a nationally recognized tax advisor that such action will not cause a failure of the intended tax treatment, or Ligand consents to the undertaking of such action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding receipt of such ruling, opinion or consent, in the event that such action causes a failure of the intended tax treatment, APAC and OmniAb could be responsible for all taxes arising therefrom.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">160</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s and OmniAb&#8217;s obligations under the Tax Matters Agreement are not limited in amount or subject to any cap.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Form&#160;of Amended and Restated Registration and Stockholders Rights Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrently with the completion of the Business Combination, APAC, the Sponsor, the existing holders party to the Original Registration Rights Agreement, and the new holders to become party to the A&amp;R Registration Rights Agreement, will enter into the A&amp;R Registration Rights Agreement, the form of which is attached to this proxy statement/prospectus/information statement as Annex G. The Original Registration Rights Agreement will be amended to, among other things, require APAC to use commercially reasonable efforts to, within 30&#160;days after the Closing, file a registration statement on Form&#160;S-1 to permit the public resale of all of the Registrable Securities (as defined in the A&amp;R Registration Rights Agreement) held by the holders from time to time as permitted by Rule&#160;415 under the Securities Act, and to provide certain equityholders of OmniAb as of immediately prior to the Closing of the Business Combination with customary registration rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, subject to certain exceptions, the A&amp;R Registration Rights Agreement will provide for certain restrictions on transfer with respect to the securities of New OmniAb, including Founder Shares, Private Placement Warrants, Backstop Warrants, Forward Purchase Warrants, and securities held by directors and officers of APAC and certain directors and officers of OmniAb and Ligand. Such restrictions will begin upon closing and end (i)&#160;with respect to the Founder Shares, at the earliest of (A)&#160;one&#160;year after the closing date and (B)&#160;the first date on which (x)&#160;the last reported sale price of a share of New OmniAb Common Stock equals or exceeds $12.00 per share for any 20 trading&#160;days within any 30-trading day period commencing at least 150&#160;days after the closing date or (y)&#160;APAC completing a liquidation, merger, share exchange, reorganization or other similar transaction that results in the New OmniAb stockholders having the right to exchange their shares of New OmniAb Common Stock for cash, securities or other property; (ii)&#160;with respect to the Private Placement Warrants, Backstop Warrants and Forward Purchase Warrants that are held by the initial purchasers of such warrants (or permitted transferees under the A&amp;R Registration Rights Agreement), and any of the shares of New OmniAb Common Stock issued or issuable upon the exercise or conversion of such warrants and that are held by the initial purchasers of the applicable warrants being converted (or permitted transferees under the A&amp;R Registration Rights Agreement), the period ending 30&#160;days after the closing; and (iii)&#160;mean with respect to the shares of New OmniAb Common Stock issued to the New Holders (as defined in the A&amp;R Registration Rights Agreement) in connection with the consummation of the Merger and held by the New Holders (or their permitted transferees under the A&amp;R Registration Rights Agreement), the period ending on the earliest of (A)&#160;three&#160;months after the closing and (B)&#160;the date on which New OmniAb completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of New OmniAb&#8217;s stockholders having the right to exchange their shares of New OmniAb Common Stock for cash, securities or other property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The A&amp;R Registration Rights Agreement will also provide that the Sponsor&#8217;s right to designate individuals to be appointed or nominated for election to the APAC Board will be reduced from three (3)&#160;individuals to one (1)&#160;individual, and that such right will only exist until the later of (i)&#160;such time as the Sponsor ceases to beneficially own at least ten&#160;percent (10%) of APAC&#8217;s outstanding voting stock and (ii)&#160;subject to compliance with the rules&#160;of Nasdaq, the third anniversary of the date of the Merger Agreement. Moreover, any individual nominated by the Sponsor will require the consent of the New OmniAb Board, subject to certain exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Forms of Transition Services Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Separation, OmniAb and Ligand will enter into two Transition Services Agreements pursuant to which Ligand and its affiliates and OmniAb and its affiliates will provide to each other various non-scientific and non-technical services set forth in the applicable Transition Services Agreement, which services are of the type that OmniAb and Ligand provided to, and received from, each other prior to the Separation. Ligand will provide services relating to information technology, facilities, accounting and finance, business development, investor relations, human resources, and other corporate and administrative functions, and OmniAb will provide services relating to corporate functions, legal administration, and other administrative functions. The fees for each of the transition services are set forth in the applicable Transition Services Agreement as a flat&#160;monthly fee, and the receiving party will reimburse the providing party for all reasonable out-of-pocket costs and expenses that the providing party incurs in connection with providing the transition services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of the Transition Services Agreements will terminate on the expiration of the term of the last service provided under it, unless earlier terminated by the receiving party with prior written notice, by either party in the event of an uncured material breach by the other party or its applicable affiliates, upon bankruptcy or insolvency of the other party, or by mutual agreement of the parties. The transition services are generally expected to last up to one&#160;year and the receiving party for a particular service may terminate such service prior to the scheduled expiration date with prior written notice.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">161</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb does not anticipate that its net costs associated with the Transition Services Agreements will be materially different than the historical costs that have been allocated by Ligand to OmniAb related to these same services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Background of the Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC is a blank check company incorporated on February&#160;5, 2021 as a Cayman Islands exempted company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Business Combination is the result of an extensive search for a potential transaction using the network, investing and operating experience of APAC&#8217;s management team and the APAC Board. The terms of the Merger Agreement and the other Transaction Documents referenced therein were the result of arm&#8217;s-length negotiations between APAC and Ligand (and their respective affiliates) over the course of approximately one (1)&#160;month. The following is a brief description of the background of these negotiations, the Business Combination and the other related transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August&#160;12, 2021, APAC completed its initial public offering. Prior to the consummation of APAC&#8217;s initial public offering, neither APAC nor anyone acting on its behalf contacted any prospective target business or had any substantive discussions, formal or otherwise, with respect to a transaction with APAC. Credit Suisse acted in the capacity of the Book- Running Manager for APAC&#8217;s initial public offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the completion of its initial public offering, APAC commenced an active search for prospective business combination targets and considered numerous potential target businesses with the objective of consummating its initial business combination. Representatives of APAC contacted and were contacted by numerous individuals and entities who presented potential business combination opportunities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In evaluating potential businesses and assets to acquire, APAC and the Sponsor surveyed the landscape of potential acquisition opportunities based on their knowledge of, and familiarity with, the M&amp;A marketplace. This survey included North American and European based healthcare-related businesses. In general, APAC looked for acquisition targets that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operate healthcare-related businesses in North America or Europe and are well-positioned to benefit from the broad network and strategic expertise of APAC&#8217;s management team, the APAC Board and the Sponsor;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">feature an attractive financial profile and stable free cash flow;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are appropriately capitalized and in a strong liquidity position, or will be upon completion of the Business Combination;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstrate clear opportunities to generate outsized returns on invested capital to support and strengthen the business&#8217;s competitive position;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have a strong, seasoned executive leadership team with a distinguished track record of generating attractive returns and shareholder value; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are operating at scale and prepared to make the transition to the public markets but can benefit from the guidance and advice of APAC&#8217;s management team in developing a clear message describing the business model and investment opportunity to public investors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb was determined by APAC&#8217;s management and the APAC Board to be an attractive potential acquisition target because, among other things, OmniAb satisfied a number of the foregoing criteria. APAC determined not to pursue a business combination transaction with other potential candidates that it had considered because, in the judgement of APAC&#8217;s management and the APAC Board, OmniAb offered a superior opportunity based on the foregoing criteria for the potential to enhance shareholder value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In the process that led to identifying OmniAb as an attractive investment opportunity, other than OmniAb, APAC&#8217;s management team (i)&#160;made contact with representatives of seventeen (17) potential combination targets to discuss the potential for a business combination transaction, (ii)&#160;entered into non-disclosure agreements with respect to six (6)&#160;such potential combination targets, the terms of each of which were customary and did not contain standstill obligations, and (iii)&#160;ultimately engaged in detailed discussions with, and reviewed detailed financial information of, four (4)&#160;potential combination targets. APAC entered into a non-binding letter of </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">162</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">intent and exclusive negotiations with one (1)&#160;such party. APAC allowed the exclusive period of negotiations with respect to this party to terminate in early February&#160;2022 as a result of the passage of time and did not seek to renew such exclusivity period due to, among other things, changes in the market view of valuation of similar businesses during the exclusivity term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of its evaluation of potential acquisition targets, APAC&#8217;s management and the APAC Board discussed on a regular basis the status of management&#8217;s and its representatives&#8217; discussions with various potential combination targets. These updates generally addressed the potential targets under consideration and the status of the discussions, if any, with the respective combination targets. These updates continued from August&#160;2021 to March&#160;2022, the period during which APAC evaluated various combination targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the course of its evaluation of potential acquisition targets, APAC identified OmniAb as a potential combination target following Ligand&#8217;s public announcement on November&#160;9, 2021 that it was pursuing plans to split into two separate publicly-traded companies, with one featuring the OmniAb Business. Credit&#160;Suisse was acting in the capacity of Ligand&#8217;s financial advisor in connection with its separation transaction. On February&#160;15, 2022, representatives of APAC and Credit Suisse held a virtual meeting to discuss several businesses as potential combination targets for APAC, including OmniAb. Shortly thereafter, representatives of APAC requested an opportunity for an initial meeting with the OmniAb management team.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February&#160;18, 2022, Credit Suisse facilitated an introductory virtual meeting among representatives of APAC and Ligand. Participating for APAC were Thompson Dean, APAC&#8217;s Executive Chairman, David Burgstahler, APAC&#8217;s President and Chief Executive Officer, and other APAC representatives. Matt Foehr, Ligand&#8217;s President and Chief Operating Officer, Matt Korenberg, Ligand&#8217;s Executive Vice President, Finance and Chief Financial Officer and other Ligand representatives participated on behalf of Ligand. The participants discussed OmniAb&#8217;s business model, capabilities, customers and key performance indicators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also on February&#160;18, 2022, a representative of APAC provided representatives of OmniAb a draft of a confidentiality agreement (the &#8220;Confidentiality Agreement&#8221;) for the purpose of facilitating the exchange of non-public information and continuing discussions regarding a potential business combination transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February&#160;21, 2022, APAC and OmniAb executed the Confidentiality Agreement. The Confidentiality Agreement did not impose standstill obligations on either party. Thereafter, Ligand began providing preliminary confidential information to APAC regarding OmniAb and its subsidiaries and the OmniAb Business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February&#160;25, 2022, representatives of APAC and representatives of Ligand, including Credit Suisse, held a virtual meeting to continue their discussions of a potential business combination involving APAC and the OmniAb Business. Messrs.&#160;Dean and Burgstahler and other APAC representatives attended for APAC, and John Higgins, Ligand&#8217;s Chief Executive Officer, Mr.&#160;Foehr and Mr.&#160;Korenberg attended for Ligand. The participants continued their discussion of OmniAb&#8217;s business model, capabilities, customers and key performance indicators and reviewed financial projections for OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February&#160;28, 2022, representatives of APAC and representatives of Ligand, including Credit Suisse, held a virtual meeting to discuss the OmniAb business model and transaction opportunity. Certain representatives of APAC participated in this meeting, as did Simon Latimer, Ligand&#8217;s Corporate Development Manager. The participants reviewed and discussed in further detail OmniAb&#8217;s business model and financial projections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;1, 2022, representatives of APAC and Ligand held a virtual meeting to discuss process and a potential path forward. APAC indicated it was preparing a non-binding letter of intent, and there was a preliminary and general discussion on potential transaction terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;2, 2022, representatives of APAC sent representatives of Ligand, including Credit Suisse an initial draft of a non-binding letter of intent (except for the exclusivity provisions thereof) (the &#8220;LOI&#8221;), which included, among other terms, (i)&#160;a proposed total pre-money equity valuation of OmniAb of $820,000,000, (ii)&#160;that Ligand would capitalize OmniAb&#8217;s balance sheet with $20,000,000 of net cash funding and a normalized level of working capital, (iii)&#160;that the Sponsor would agree to commit up to $100,000,000 of equity capital in the form of a backstop of redemptions from the trust account through a common equity investment, such that the combined company would receive a minimum of $120,000,000 of cash funding in the transaction (before fees and expenses), and such backstop would be reduced on a dollar-for-dollar basis by any cash proceeds received from the trust account subject to a minimum equity contribution of $30,000,000, (iv)&#160;that APAC would use reasonable efforts to file within thirty (30)&#160;days of closing of the business combination a registration statement on Form&#160;S-1 and (v)&#160;a fourteen (14)-day exclusivity period.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">163</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;3, 2022, representatives of Ligand, including Messrs.&#160;Higgins and Korenberg and Credit Suisse, and representatives of APAC, including Messrs.&#160;Dean and Burgstahler, discussed and negotiated the draft LOI, following which they agreed in principle that (i)&#160;the total pre-money equity valuation of OmniAb for purposes of the proposed transaction would be $850,000,000, (ii)&#160;the Sponsor would fund a minimum of $15,000,000 through a common equity investment in APAC and up to an additional $95,000,000 as a backstop for redemptions in connection with the proposed transaction, (iii)&#160;Ligand would make a capital contribution to OmniAb of $15,000,000 of net cash funding prior to its separation as an independent company, (iv)&#160;3,833,333 founder shares (which represent two-thirds of the aggregate 5,750,000 founder shares) would vest at closing, and up to 1,916,667 founder shares that do not vest at closing would be subjected to performance vesting criteria such that 50% of the unvested founder shares would vest upon the post-transaction volume-weighted average per share price of the combined company&#8217;s shares being at or above $12.50 per share for 20 trading&#160;days over a consecutive 30- trading day period, and the remaining unvested founder shares subject to such performance vesting criteria would vest upon the post-Merger volume-weighted average per share price being at or above $15.00 for any 20 trading&#160;days over a consecutive 30-trading day period and (v)&#160;15 million earnout shares would be issued to OmniAb&#8217;s stockholders (after giving effect to the Distribution), subject to the same performance vesting criteria. Throughout the day and through March&#160;8, 2022, representatives of Ligand, including Credit Suisse, and representatives of APAC continued to discuss and negotiate the proposed terms and conditions of the LOI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Later on March&#160;3, 2022, representatives of Weil, Gotshal&#160;&amp; Manges LLP, legal counsel to APAC (&#8220;Weil&#8221;), were granted access to a virtual data room containing due diligence materials regarding OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;4, 2022, representatives of APAC, Ligand, Weil, Latham&#160;&amp; Watkins, LLP, legal counsel to Ligand (&#8220;Latham&#8221;) and Credit Suisse, held a virtual meeting to discuss the process and timeline for the potential transaction, including the due diligence process and drafting and negotiation of definitive legal documentation. Throughout the period from March&#160;4, 2022 until the execution of the Merger Agreement on March&#160;23, 2022, these parties held periodic virtual meetings to discuss the status of and process for completing the due diligence review and definitive legal documentation necessary for the transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also on March&#160;4, 2022, a representative of APAC sent representatives of Ligand, including Credit Suisse, a revised draft of the LOI reflecting the discussions and negotiations that occurred on March&#160;3, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also on March&#160;4, 2022, APAC engaged Centri Business Consulting, LLC, tax and accounting advisor to APAC (&#8220;Centri&#8221;), to conduct tax and accounting due diligence on OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;5, 2022, representatives of Weil sent representatives of Latham a preliminary legal due diligence request list, which covered general corporate, capitalization, financing, material contracts, labor and employment, employee benefits, litigation, intellectual property, data privacy, real property, regulatory, environmental, health and safety matters and tax questions related to the spin-off and proposed business combination. Thereafter, representatives of Weil, Latham and Credit Suisse continued to correspond with respect to various legal diligence questions from and answers to Ligand&#8217;s management team, including in the form of virtual meetings and e-mail exchanges regarding follow-up questions and document requests. In particular, representatives of APAC, Ligand, Weil and Latham held conference calls coordinated by Credit Suisse on (i)&#160;March&#160;10, 2022 to discuss various topics relating to legal due diligence matters and (ii)&#160;March&#160;21, 2022, to discuss legal due diligence matters relating to intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;6, 2022, a representative of Latham uploaded initial drafts of the Separation Agreement, the Employee Matters Agreement and the Transition Services Agreements to a virtual data room containing due diligence materials. Such agreements continued to be discussed and negotiated among the parties through March&#160;23, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;7, 2022, representatives of APAC and Ligand had a conference call to discuss the timeline for the business combination and transaction fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also on March&#160;7, 2022, a representative of Latham uploaded an initial draft of the Tax Matters Agreement to a virtual data room containing due diligence materials. Following such date and through March&#160;23, 2022, Weil and Latham continued to negotiate and revise the Tax Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Later on March&#160;7, 2022, representatives of APAC sent representatives of Ligand, including Credit Suisse, a revised draft of the LOI, which provided (i)&#160;that the Sponsor would fund up to an additional amount of $100,000,000 as a backstop for redemptions in connection with the proposed transaction, instead of the $95,000,000 previously contemplated by the draft LOI circulated on March&#160;3, </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">164</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">2022 and (ii)&#160;for the vesting of a portion of the warrants to be received by the Sponsor in the proposed transaction in proportion to its funding of the $100,000,000 backstop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;8, 2022, the APAC Board convened a virtual meeting, during which APAC&#8217;s management provided an update on APAC&#8217;s discussions with Ligand. The APAC Board discussed with APAC management the proposed terms of the LOI, including with respect to valuation of the OmniAb business, the consideration to be issued to OmniAb stockholders and holders of OmniAb Equity Awards in the transaction, the Sponsor&#8217;s commitments to provide equity financing for the transaction, the vesting terms for the shares to be subject to performance vesting in the transaction, conditions to closing and transaction timing. Following discussion, the APAC Board unanimously approved APAC&#8217;s execution of the LOI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Later on March&#160;8, 2022, APAC and OmniAb executed the LOI on the terms last proposed by representatives of APAC. The executed LOI provided that the exclusive period of negotiation agreed to by the parties would expire on the date that is fourteen (14)&#160;days following the execution of the LOI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;9, 2022 and March&#160;15, 2022, representatives of APAC and Ligand held virtual meetings coordinated by Credit Suisse to discuss business due diligence matters, including competitive landscape, research and development capabilities and planned projects, intellectual property strategy and acquisition strategy and opportunities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From March&#160;9, 2022 through March&#160;15, 2022, representatives of APAC and its advisors conducted several due diligence meetings with representatives of Ligand regarding tax, financial, ESG and business due diligence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;9, 2022, a representative of Weil sent representatives of Latham a supplemental legal due diligence request list, which covered general corporate, capitalization, financing, material contracts, labor and employment, employee benefits, litigation, intellectual property, data privacy, real property, regulatory, environmental, health and safety matters and tax questions related to the spin-off and proposed business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Later on March&#160;9, 2022, representatives of Weil sent representatives of Latham an initial draft of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;11, 2022, representatives of ACA Group, information technology advisor to APAC (&#8220;ACA&#8221;), APAC and Ligand held a virtual meeting coordinated by Credit Suisse to discuss IT diligence matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also on March&#160;11, 2022, representatives of APAC and Ligand held a virtual meeting coordinated by Credit Suisse to discuss additional questions with respect to the OmniAb business model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;13, 2022, representatives of Centri, APAC and Ligand held a virtual meeting coordinated by Credit Suisse to discuss draft financial statements of OmniAb previously furnished to APAC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;14, 2022, representatives of Malk Sustainability Partners, environmental, social and governance (&#8220;ESG&#8221;) advisor to APAC (&#8220;Malk&#8221;), APAC and Ligand held a virtual meeting coordinated by Credit Suisse to discuss further ESG due diligence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also on March&#160;14, 2022, representatives of and a consultant to APAC conducted an in-person site visit at 5980 Horton Street, Suite&#160;405, Emeryville, CA 94608, OmniAb&#8217;s headquarters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Later on March&#160;14, 2022, a representative of Latham sent representatives of Weil a revised draft of the Merger Agreement and the Separation Agreement, which, among other terms and conditions, provided that (i)&#160;the exchange ratio mechanics to determine the number of shares of New OmniAb Common Stock to be received by OmniAb stockholders and treatment of OmniAb Equity Awards remained subject to negotiation by the parties, (ii)&#160;if OmniAb stockholders (after giving effect to the Distribution) do not own at least fifty&#160;percent (50%) of New OmniAb&#8217;s voting stock (the &#8220;Tax Savings Minimum Ownership Threshold&#8221;) immediately following the Merger, the merger consideration exchange ratio automatically would be adjusted (resulting in the dilution of other New OmniAb stockholders) until the Tax Savings Minimum Ownership Threshold is achieved (the &#8220;Tax Savings Adjustment&#8221;), (iii)&#160;Ligand&#8217;s contribution of $15,000,000 to the capital of OmniAb would be net of certain transaction and other expenses of Ligand and OmniAb, (iv)&#160;Ligand would be permitted, from the signing of the Merger Agreement until the time APAC&#8217;s shareholders voted on the various shareholder proposals at the extraordinary general meeting, to terminate the Merger Agreement to accept a superior offer for either OmniAb or Ligand (including the OmniAb Business) (the &#8220;Superior Offer Termination Event&#8221;), subject to payment of a termination fee of $21,250,000, (v)&#160;the outside date for completion of the Merger would be nine (9)&#160;months after the date of the Merger </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">165</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Agreement, subject to a three (3)-month extension in the event antitrust and/or APAC shareholder approvals have not been obtained by such time, (vi)&#160;the tax opinion required by Ligand as a condition precedent to consummation of the Merger must meet certain requirements, and (vii)&#160;directors and officers of Ligand and OmniAb would not be subject to a six (6)-month lock-up following the closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;15, 2022, a science and technology consultant for APAC, and representatives of APAC and Ligand, held a virtual meeting coordinated by Credit Suisse to discuss science and technology due diligence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;16, 2022, the APAC Board met virtually to discuss the proposed Business Combination, with representatives of APAC management and Weil participating. A representative of Weil reviewed with the APAC Board its fiduciary duties and a representative of APAC management summarized the current negotiations of material terms of the transaction documents, including those contained in the Merger Agreement and related agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;17, 2022, a representative of Weil sent representatives of Latham a revised draft of the Merger Agreement and the Separation Agreement, which, among other terms and conditions, (i)&#160;updated the merger consideration exchange ratio mechanics to reflect negotiations between the parties, (ii)&#160;removed the Tax Savings Adjustment provisions, (iii)&#160;provided that Ligand&#8217;s $15,000,000 capital contribution to OmniAb would not be net of fees and expenses, (iv)&#160;removed provisions regarding Superior Offer Termination Events and the related proposed termination fee, (v)&#160;provided that the outside date under the Merger Agreement would be nine (9)&#160;months, but not subject to extension, (vi)&#160;modified the requirements for the tax opinion to be delivered to Ligand as a condition precedent to consummation of the transaction, and (vii)&#160;directors and officers of Ligand and OmniAb would be subject to a six (6)-month lock-up following the closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also on March&#160;17, 2022, representatives of APAC and a representative of Credit Suisse had a telephone conference to discuss these terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;19, 2022, a representative of Latham sent representatives of Weil a revised draft of the Merger Agreement and the Separation Agreement, which, among other terms and conditions, (i)&#160;re-inserted the Tax Savings Adjustment provisions, subject to further discussion between the parties, (ii)&#160;re-inserted that Ligand&#8217;s $15,000,000 capital contribution to OmniAb would be net of certain fees and expenses, (iii)&#160;re-inserted the Superior Offer Termination Event and related proposed termination fee, but limited the Superior Offer Termination Event trigger to (x)&#160;offers to acquire all or a majority of the voting securities or assets of Ligand and its subsidiaries taken as a whole and (y)&#160;increased the proposed termination fee payable to APAC pursuant to the Merger Agreement and to the Sponsor in connection with the A&amp;R FPA to an aggregate of $30,000,000, (iv)&#160;reverted to its prior formulation of the tax opinion condition, and (v)&#160;reduced the lock-up period on directors and officers of Ligand and OmniAb from six (6)&#160;months to three (3)&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Later on March&#160;19, 2022, the APAC Board met virtually to discuss and evaluate the proposed Business Combination, with representatives of APAC management and Weil participating. A representative of Weil reviewed with the APAC Board the legal structure of the transactions and updates on the terms under negotiation. The representative of Weil also discussed the agreements and approvals that would be required from the APAC Board and shareholders in connection with the transaction. Representatives of APAC management presented on business and other diligence conducted in the transaction, and provided an update on commercial terms, negotiations and financial information regarding the target, including a qualitative discussion about the OmniAb Business and comparable companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From March&#160;20, 2022 to March&#160;23, 2022, representatives of Weil and Latham, and representatives of Ligand, OmniAb and APAC continued to negotiate the open issues under the Merger Agreement and other Transaction Documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;21, 2022, the APAC Board met virtually to discuss and evaluate the proposed Business Combination, with representatives of APAC management and Weil participating. A representative of Weil provided an update on the remaining terms being negotiated and discussed the transaction&#8217;s structure and related tax matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also on March&#160;21, 2022, a representative of Weil sent representatives of Latham a supplemental legal due diligence request list, which covered intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">On March&#160;22, 2022, the APAC Board met virtually to discuss and evaluate the proposed Business Combination, with representatives of APAC management and Weil participating. A representative of Weil provided an update on the remaining terms </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">166</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">being negotiated. Upon a motion duly made and seconded, the APAC Board unanimously (i)&#160;determined that the Merger Agreement and the transactions contemplated thereby are in the best interests of APAC&#8217;s shareholders, (ii)&#160;determined that the fair market value of OmniAb is equal to at least 80% of the amount held in the trust account (less any deferred underwriting commissions and taxes payable on interest earned) as of such date, (iii)&#160;approved the transactions contemplated by the Merger Agreement as a business combination, and (iv)&#160;adopted a resolution recommending the Merger Agreement and the other transaction documents and the transactions contemplated thereby be adopted by APAC&#8217;s shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Also on March&#160;22, 2022, the APAC audit committee met virtually. During such meeting, the APAC audit committee approved APAC&#8217;s entry into the definitive agreements that may constitute related party transactions, including the Sponsor Insider Letter and the A&amp;R FPA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;23, 2022, APAC, Merger Sub, Ligand and OmniAb executed the Merger Agreement. Concurrently with the execution of the Merger Agreement, APAC, OmniAb and Ligand executed the Separation Agreement; APAC, the Sponsor, OmniAb and the Insiders executed the Sponsor Insider Agreement; APAC, the Sponsor and OmniAb executed the A&amp;R FPA; and Ligand, OmniAb, APAC and Merger Sub executed the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Later on March&#160;23, 2022, APAC and Ligand issued a joint press release announcing the execution of the Merger Agreement, which APAC filed with a Current Report on Form&#160;8-K along with an investor presentation and transcript of audio in connection therewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On the morning of March&#160;24, 2022, before the stock market opened, APAC and Ligand filed the Merger Agreement, the Separation Agreement, the Sponsor Insider Agreement, the A&amp;R FPA and the Employee Matters Agreement with a Current Report on Form&#160;8-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Projected Financial Information </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ligand and OmniAb provided APAC with internally prepared annual forecasts for the OmniAb Business for the period ending December 31, 2045. Ligand and OmniAb do not, as a matter of general practice, publicly disclose forecasts or internal projections of future performance, revenue, financial condition or other results. The OmniAb forecasts were prepared solely for internal use and not with a view toward public disclosure, or with a view toward complying with the published guidelines of the SEC regarding projections or the guidelines established by the American Institute of Certified Public Accountants for preparation and presentation of prospective financial information or U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The financial projections include EBITDA, a non-GAAP financial measure. Ligand and OmniAb included such measure in the financial projections because they believed that such measure may be useful in evaluating, on a prospective basis, the potential operating performance of the OmniAb Business. This non-GAAP measure should not be considered in isolation from, or as a substitute for, financial information presented in compliance with GAAP, and non-GAAP financial measures such as those used in the financial projections may not be comparable to similarly titled amounts used by other companies or persons. The SEC rules, which otherwise would require a reconciliation of a non-GAAP measure to a GAAP measure, do not apply to non-GAAP measures provided to a board of directors or financial advisors in connection with a proposed business combination transaction such as the proposed transaction if the disclosure is included in a document such as this proxy statement/prospectus/information statement. Accordingly, no such reconciliation is provided. In the view of Ligand&#8217;s and OmniAb&#8217;s management, the financial projections were prepared on a reasonable basis reflecting such management&#8217;s currently available estimates and judgments at the time of such preparation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The inclusion of financial projections in this proxy statement/prospectus/information statement should not be regarded as an indication that APAC, the APAC Board, or their respective affiliates, advisors or other representatives considered, or now considers, such financial projections to be fact or necessarily to be predictive of actual future results, and these financial projections should not be relied upon as such. The financial projections are not being included to influence you to vote for or against the Business Combination Proposal, and, accordingly, you are cautioned not to rely on the projections in making a decision regarding the Business Combination. We will not refer back to the financial projections in our future periodic reports filed under the Exchange Act. </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">167</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The financial projections reflect numerous estimates and assumptions with respect to general business, economic, regulatory, market and financial conditions and other future events, as well as matters specific to the OmniAb Business, all of which are difficult to predict and many of which are beyond OmniAb&#8217;s and APAC&#8217;s control. The financial projections are forward-looking statements that are inherently subject to significant uncertainties and contingencies, many of which are beyond OmniAb&#8217;s and APAC&#8217;s control. The various risks and uncertainties include those set forth in the <i style="font-style:italic;">&#8220;Risk Factors,&#8221; &#8220;OmniAb Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; </i>and<i style="font-style:italic;"> &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221;</i> sections of this proxy statement/prospectus/information statement. As a result, there can be no assurance that the projected results will be realized or that actual results will not be significantly higher or lower than projected. Since the financial projections cover multiple years, such information by its nature becomes less reliable with each successive year. These financial projections are subjective in many respects and thus are susceptible to multiple interpretations and periodic revisions based on actual experience and business developments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The projected financial information included in this document has been prepared by, and is the responsibility of, Ligand&#8217;s and OmniAb&#8217;s management. The financial projections do not take into account any circumstances or events occurring after the date they were prepared. Ernst &amp; Young LLP, OmniAb&#8217;s independent registered accounting firm, has not audited, reviewed, compiled, examined nor applied agreed-upon procedures with respect to the financial projections included below and, accordingly, Ernst &amp; Young LLP does not express an opinion or any other form of assurance with respect thereto. The Ernst &amp; Young LLP report included in this document relates to OmniAb&#8217;s historical financial statements. It does not extend to the projected financial information and should not be read to do so. Nonetheless, a summary of the financial projections is provided in this proxy statement/prospectus/inormation statement because they were made available to APAC and the APAC Board in connection with their review of the proposed Business Combination. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The key elements of the projections provided by management of Ligand and OmniAb to APAC are summarized in the table below ($ in millions):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.018520355%;padding-left:0pt;padding-right:0pt;width:100.03%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:14.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:top;width:5.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:top;width:5.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:top;width:5.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:4.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:4.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:4.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2027</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:4.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2028</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:4.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2029</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2030</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2031</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2032</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:5.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2033</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2pt;">Total Revenue<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;width:4.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;width:4.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">239</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">336</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2pt;">EBITDA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;width:4.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2pt;">FCF (EBITDA &#8211; Capex)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;width:4.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">(9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;width:4.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">(4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(23)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">557</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:3.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.018520355%;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.03%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:14.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:14.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:5.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2034</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:5.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2035</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:5.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2036</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2037</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2038</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2039</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:5.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2040</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.36%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2041</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2042</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2043</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2044</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2045</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.32%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2pt;">Total Revenue<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,225</p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,524</p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,800</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,100</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,411</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,735</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,108</p></td><td style="vertical-align:bottom;white-space:normal;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,450</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,608</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,997</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">4,187</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">4,258</p></td><td style="vertical-align:bottom;white-space:normal;width:0.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2pt;">EBITDA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,024</p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,317</p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,586</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,881</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,184</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,502</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,868</p></td><td style="vertical-align:bottom;white-space:normal;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,203</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,354</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,735</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,917</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,980</p></td><td style="vertical-align:bottom;white-space:normal;width:0.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:14.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 2pt;">FCF (EBITDA &#8211; Capex)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,019</p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,312</p></td><td style="vertical-align:bottom;white-space:normal;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,581</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,876</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,179</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,497</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,863</p></td><td style="vertical-align:bottom;white-space:normal;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,198</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,349</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,730</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,912</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:4.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,795</p></td><td style="vertical-align:bottom;white-space:normal;width:0.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Revenue estimates may include the receipt of certain milestone payments, the receipt of which are inherently uncertain, which was acknowledged by the APAC Board in its consideration of this information.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">EBITDA is defined as net earnings (loss) adjusted for interest, taxes, depreciation and amortization and stock-based compensation expense.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Projected revenue is based on a variety of operational assumptions, including demand growth in existing markets, expansions to new markets, the addition of new programs and investigational new drug application (IND) filings, achievement of milestones and the revenue from royalties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">EXCEPT TO THE EXTENT REQUIRED BY APPLICABLE FEDERAL SECURITIES LAWS, BY INCLUDING IN THIS PROXY STATEMENT/PROSPECTUS/INFORMATION STATEMENT A SUMMARY OF THE FINANCIAL PROJECTIONS FOR OMNIAB, APAC, LIGAND AND OMNIAB UNDERTAKE NO OBLIGATIONS AND EACH EXPRESSLY DISCLAIMS ANY RESPONSIBILITY TO UPDATE OR REVISE, OR PUBLICLY DISCLOSE ANY UPDATE OR REVISION TO, THESE FINANCIAL PROJECTIONS TO REFLECT CIRCUMSTANCES OR EVENTS, INCLUDING UNANTICIPATED EVENTS, THAT MAY HAVE OCCURRED OR THAT MAY OCCUR AFTER THE PREPARATION OF THESE FINANCIAL PROJECTIONS, EVEN IN THE EVENT THAT ANY OR ALL OF THE ASSUMPTIONS UNDERLYING THE FINANCIAL PROJECTIONS ARE SHOWN TO BE IN ERROR OR CHANGE.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">168</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain Financial Analysis</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparable Company Analysis</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">APAC&#8217;s management primarily relied upon a comparable company analysis to assess the value that the public markets could ascribe to the post-combination company, and this analysis was shared with the APAC Board. The comparable company analysis was based on publicly-traded companies selected by APAC management in each of the diversified drug discovery sector, the next-generation discovery and production technologies sector, and the computationally-enabled drug discovery sector. The selected companies in each sector were chosen because they were determined by APAC&#8217;s management to be relevant benchmarks in their particular sector (but, for the avoidance of doubt, none of the selected companies is necessarily a direct competitor of OmniAb, except for AbCellera Biologics Inc. (&#8220;AbCellera&#8221;)). The comparable companies within (1) the diversified drug discovery sector were: Evotec A.G. (&#8220;Evotec&#8221;), AbCellera  and Absci Corporation (&#8220;Absci&#8221;); (2) the next-generation discovery and production technologies sector were: Ginkgo Bioworks, Inc. (&#8220;Ginkgo Bioworks&#8221;), Twist Biosciences Corporation (&#8220;Twist Biosciences&#8221;), Adaptive Biotechnologies Corp (&#8220;Adaptive&#8221;) and Codexis, Inc. (&#8220;Codexis&#8221;); and (3) the computationally-enabled drug discovery sector were: Relay Therapeutics, Inc. (&#8220;Relay Therapeutics&#8221;), Schrodinger, Inc. (&#8220;Schrodinger&#8221;) and Exscientia PLC (&#8220;Exscientia&#8221;). While these companies may share certain characteristics that are similar to those of OmniAb, APAC management and the APAC Board recognized that no company was identical in nature to OmniAb.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Using publicly available information and information from certain data sources, APAC&#8217;s management provided to the APAC Board for each of the selected companies an enterprise value (defined as equity value <i style="font-style:italic;">plus</i> net debt <i style="font-style:italic;">plus</i> minority investments <i style="font-style:italic;">minus</i> unconsolidated investments (where minority investments and/or unconsolidated investments are material) calculated based upon a multiple of sell-side consensus (as per FactSet) estimated revenues for calendar year 2022. The total enterprise value (in millions) for each selected company is shown in the table below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:top;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total&#160;Enterprise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Selected Public Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value&#160;(in&#160;millions)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.55%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Diversified Drug Discovery Sector</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Evotec</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5,337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">AbCellera</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Absci</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:82.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Next-Generation Discovery &amp; Production Technologies Sector</p></td><td style="vertical-align:top;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:82.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Ginkgo Bioworks</p></td><td style="vertical-align:top;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:82.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Twist Biosciences</p></td><td style="vertical-align:top;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,336</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:82.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Adaptive</p></td><td style="vertical-align:top;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,397</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:82.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Codexis</p></td><td style="vertical-align:top;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:82.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:82.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Computationally-Enabled Drug Discovery Sector</p></td><td style="vertical-align:top;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:82.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Relay Therapeutics</p></td><td style="vertical-align:top;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:82.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Schrodinger</p></td><td style="vertical-align:top;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:82.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exscientia</p></td><td style="vertical-align:top;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on this review, the APAC Board noted that OmniAb&#8217;s pro forma enterprise valuation of $884,000,000 compared favorably to these comparable company valuations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Illustrative Discounted Cash Flow Analysis</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Using the forecast provided by Ligand, and OmniAb APAC&#8217;s management also performed an illustrative discounted cash flow analysis (the &#8220;DCF&#8221;) to derive a range of illustrative present enterprise values for OmniAb. This analysis also was provided to the APAC Board but was not a material consideration in the APAC Board&#8217;s approval of the Transactions. The DCF is comprised of adding a discounted terminal value and discounted free cash flows to arrive at a present range of enterprise values for OmniAb. A wide range of discount rates of 10-15%, reflecting estimates of OmniAb&#8217;s weighted average cost of capital, was selected by APAC&#8217;s management based on its judgment and experience evaluating companies with a risk profile similar of that of OmniAb.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">169</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The terminal value was derived based on information obtained by APAC from Ligand&#8217;s and OmniAb&#8217;s management, and was calculated based on a growth methodology that assumed a 3% long-term growth rate, and based upon Ligand&#8217;s and OmniAb&#8217;s estimated terminal year EBITDA as reflected in the OmniAb forecasts.  APAC&#8217;s management discounted the terminal value and OmniAb&#8217;s estimated free cash flows from 2022 to 2045 to complete the valuation exercise. This DCF analysis resulted in a range of enterprise values for OmniAb of between approximately $3.5 billion and $10.0 billion. See &#8220;</span><i style="font-style:italic;">Projected Financial Information</i>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The APAC Board&#8217;s Reasons for the Approval of the Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The APAC Board, in evaluating the Business Combination, consulted with APAC&#8217;s management and legal and financial advisors. In unanimously deciding to (a)&#160;adopt the Merger Agreement and approve the transactions contemplated thereby, including the Business Combination, and (b)&#160;recommend that APAC shareholders vote to approve and adopt the Merger Agreement and the Transaction Documents (as defined in the Merger Agreement) and approve the transactions contemplated thereby, the APAC Board considered a range of factors, including but not limited to, the factors discussed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In light of the number and wide variety of factors the members of the APAC Board considered in connection with evaluating and approving the Business Combination, the APAC Board did not consider it practicable to, and did not attempt to, quantify or otherwise assign relative weights to the specific factors it considered in reaching its determination. The APAC Board&#8217;s evaluation and determination regarding the Business Combination was necessarily based on the information available and the factors presented to and considered by it at the time. In addition, individual directors may have given different weight to different factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This summary of the APAC Board&#8217;s reasons for approval of the Business Combination, along with all other information presented in this section is forward-looking in nature and, therefore, should be read in light of the factors discussed under &#8220;<i style="font-style:italic;">Cautionary Statement&#160;Regarding Forward-Looking Statements</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In approving the Business Combination, the APAC Board determined not to obtain a third-party valuation or fairness opinion. The officers and directors of APAC have substantial experience in evaluating the operating and financial merits of companies from a wide range of industries and concluded that their experience and backgrounds, together with the experience and sector expertise of APAC&#8217;s other advisors, enabled them to make the necessary analyses and determinations regarding the Business Combination with OmniAb. In addition, APAC&#8217;s officers and directors and APAC&#8217;s advisors have substantial experience with mergers and acquisitions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In considering the Business Combination, the members of the APAC Board considered a number of factors pertaining to the Business Combination as generally supporting their decision to enter into the Merger Agreement and the Transaction Documents described therein and approve the transactions contemplated thereby, including, but not limited to, the following factors:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Antibody Discovery Industry and Trends. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The OmniAb Business is based in an industry and addressable market that has seen substantial growth in recent periods and that the APAC Board, following a review of industry trends and other industry factors, considered attractive and expects to have continued growth potential in future periods;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Attractive Value Proposition.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The OmniAb Business&#8217;s antibody discovery platform offers a number of advantages versus &#8220;traditional&#8221; antibody discovery methods, including increased antibody diversity, increased speed of development, increased safety relative to peer companies, and APAC&#8217;s diligence investigations and analyses of the industry have supported the APAC Board&#8217;s view that the OmniAb Business is considered one of the leaders in its field and has one of the strongest track records among peer companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Strong Commercial Momentum.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The potential for commercial growth demonstrated by the OmniAb Business&#8217;s recent increases in number of active partners and programs, as well as its having recently obtained approvals in China and having recently filed for FDA approval, and the fact that the majority of the OmniAb Business&#8217;s active programs are in oncology, one of the fastest growing therapeutic areas;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Scalable Business Model.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The potential to scale the OmniAb Business&#8217;s model as a result of its limited involvement in the drug development cycle following the &#8220;discovery/preclinical&#8221; stage, while still retaining substantial upside potential from future milestone and royalty payments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Financial Condition.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The APAC Board also considered factors such as the OmniAb Business&#8217;s historical financial results, outlook and financial plan. In considering these factors, the APAC Board reviewed the OmniAb Business&#8217;s recent </span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">170</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance, the current prospects for growth if the OmniAb Business achieves its business plans and various historical and current balance sheet items;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Carve-Out Facilitates Additional Investment</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. The potential to grow the OmniAb Business by investing in commercial organization and business development efforts, exploration of potential acquisition opportunities and/or accretive research and development projects that were not high priorities while the business was operated as a part of Ligand, given the need to manage near term financial performance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Experienced and Proven Management Team.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The OmniAb Business has an experienced management team with a proven record and diverse experience, and with whom the APAC management had the opportunity to engage and evaluate in the course of its due diligence review. In addition, the senior management of the OmniAb Business intend to remain with New OmniAb following the Business Combination, which the APAC Board expects will provide helpful continuity in advancing OmniAb&#8217;s strategic and growth goals.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Due Diligence.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> APAC&#8217;s management and advisors conducted significant due diligence investigations of the OmniAb Business, including: meetings and calls with OmniAb&#8217;s management regarding OmniAb&#8217;s business model, operations and forecasts; commercial, financial, tax, accounting, ESG, scientific and technology and legal due diligence, and conducting discussions with the management of Ligand (including the management of the OmniAb Business) and APAC&#8217;s financial, tax, accounting, ESG, technology and legal advisors concerning such due diligence investigations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Lock-Up.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The agreement by the Insiders, the Sponsor and the directors and officers of Ligand and/or OmniAb to be subject to a post-Closing lockup in respect of shares of New OmniAb Common Stock, subject to certain customary exceptions (including the attainment of certain VWAP-related thresholds), which will provide important stability to the leadership and governance of New OmniAb for a period of time following the Business Combination;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Fully-Funded Balance Sheet Post-Closing. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The combined company is expected to, in the view of OmniAb&#8217;s management, have net cash proceeds following the Business Combination (after giving effect to the Contribution, the Forward Purchase and the Redemption Backstop, if any) sufficient to support the go-forward business plan of the OmniAb Business, which reduces the market risk and potential overhang of dilution from future equity financings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Diverse Stockholder Base Post-Closing.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The combined company will have a diverse stockholder base relative to other SPACs following their initial business combinations as a result of the fact that the Merger will be consummated immediately following the Distribution, which will result in New OmniAb having an initial stockholder base more similar to a typical public company than a typical private-company SPAC target, which should facilitate stockholder liquidity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Reasonableness of Merger Consideration. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Following a review of the financial data provided to APAC, including the historical financial statements of the OmniAb Business and certain unaudited prospective financial information discussed in &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Shareholder Proposal No. 1</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212; </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Projected Financial Information</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">&#8220;&#8212; Certain Financial Analysis,</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and APAC&#8217;s due diligence review and financial and valuation analyses of the OmniAb Business, the APAC Board considered the Aggregate Merger Consideration and OmniAb Earnout Shares to be issued to OmniAb&#8217;s stockholders (after giving effect to the Distribution) and determined that the consideration was reasonable in light of such data and financial information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Other Alternatives</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. After a review of other business combination opportunities reasonably available to APAC, the APAC Board believes that the proposed Business Combination represents the best potential business combination for APAC and the most attractive opportunity for APAC&#8217;s shareholders based upon the process utilized to evaluate and assess other potential acquisition targets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Negotiated Transaction</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. The terms and conditions of the Merger Agreement and the related agreements and the transactions contemplated thereby, each party&#8217;s representations, warranties and covenants, the conditions to each party&#8217;s obligation to consummate the Business Combination and the termination provisions, as well as the strong commitment by APAC, Ligand and OmniAb to complete the Business Combination. The APAC Board also considered the financial and other terms of the Merger Agreement and the fact that such terms and conditions are, in their view, reasonable and were the product of arm&#8217;s-length negotiations among APAC, Ligand and OmniAb;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">171</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Redemption Backstop.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The fact that the Sponsor has agreed to provide the Redemption Backstop, if necessary, to backstop potential redemptions by APAC public shareholders, which will help ensure that the combined company is well capitalized following closing of the Business Combination; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Post-Closing Governance. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The facts that (i)&#160;APAC negotiated the right to nominate one (1)&#160;member of the combined company&#8217;s board of directors following the Business Combination and (ii)&#160;the other proposed directors and officers of the combined company represent a strong and experienced management team, including certain directors and officers that are current members of the Ligand senior management team involved with operating the OmniAb Business, which will provide helpful continuity in advancing the combined company&#8217;s strategic goals.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The APAC Board also considered a variety of uncertainties, risks and other potentially negative factors concerning the Business Combination including but not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Commercialization and Pricing Risks.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The OmniAb Business is subject to meaningful development and approval risk given its milestone and royalty revenue model, which may provide greater upside potential in the long-run, but also leads to more commercialization- and pricing-related risks, which APAC believes can be mitigated by the fact that the OmniAb Business has a wide variety of partnered programs representing opportunities for additional future revenue streams;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Exposure to Biotech Funding Cycle.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The OmniAb Business is exposed to counterparty risk with small- to mid-size biopharmaceutical companies that typically rely on external financing sources to fund research and development expenses, and, while biotech funding has continued to be robust over the last several&#160;years, it is possible there could be a downturn in the funding cycle;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Exposure to Pharmaceutical Industry Regulatory Reform.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The risk that any potential pharmaceutical industry pricing reforms could reduce the expected return on investment of new drug development and could impact the OmniAb Business by reducing future royalty revenues, and could also have a corollary effect on investment in drug discovery and/or development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Forecast Reliant on Continuing to Sign Up New Programs.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The OmniAb Business&#8217;s long-term performance will rely on continuing to generate new programs and progressing earlier stage preclinical programs throughout development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Competitive End-Market.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The significant number of providers of both transgenic models (particularly for transgenic mice) and screening technologies used in antibody discovery;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Macroeconomic Risks. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Macroeconomic uncertainty, including the potential impact of the COVID-19 pandemic, and the effects it could have on the combined company&#8217;s revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Shareholder Vote. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The risk that APAC&#8217;s shareholders may fail to approve the Condition Precedent Proposals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Closing Conditions. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The fact that the completion of the Business Combination is conditioned on the satisfaction of certain closing conditions that are not within APAC&#8217;s control, including the receipt of certain required regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">APAC Public Shareholders holding a Minority Position in the Combined Company. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The risks associated with APAC public shareholders holding a minority position in the combined company (approximately 18%, assuming no redemptions and excluding the impact of the APAC Class&#160;A Ordinary Shares underlying the APAC Warrants), which may reduce the influence that APAC public shareholders have on the management of the combined company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Litigation. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The possibility of litigation challenging the Business Combination or that an adverse judgment granting permanent injunctive relief could indefinitely enjoin consummation of the Business Combination;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Listing Risks. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The challenges associated with preparing OmniAb and its subsidiaries, which are private subsidiaries of the public company, Ligand, for the applicable disclosure and listing requirements to which OmniAb will be subject as a publicly traded company on the Nasdaq;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">172</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Liquidation of APAC. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The risks and costs to APAC if the Business Combination is not completed, including the risk of diverting management focus and resources from other business combination opportunities, which could result in APAC being unable to effect an initial business combination by February&#160;12, 2023;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Benefits may not be Achieved.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The risk that the potential benefits of the Business Combination may not be fully achieved or may not be achieved within the expected timeframe;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">No Third Party Valuation. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The fact that the APAC Board did not obtain a third-party valuation or fairness opinion in connection with the Business Combination; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Fees and Expenses. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The fees and expenses associated with completing the Business Combination.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to considering the factors above, the APAC Board also considered other factors including, without limitation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Interests of Certain Persons.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Some officers and directors of APAC have interests in the Business Combination. See &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Proposal No.&#160;1&#8212;The Business Combination Proposal&#8212;Interests of APAC&#8217;s Directors and Officers and Others in the Business Combination</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Other Risk Factors. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Various other risk factors associated with the OmniAb Business, as described in the section entitled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Risk Factors</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.&#8221;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The APAC Board concluded that the potential benefits that it expected APAC and APAC&#8217;s shareholders to achieve as a result of the Business Combination outweighed the potentially negative factors and other risks associated with the Business Combination. The APAC Board also noted that APAC shareholders would have a substantial economic interest in the combined company (depending on the level of redemptions by APAC public shareholders). Accordingly, the APAC Board unanimously determined that the Merger Agreement, the Transaction Documents referenced therein, and the transactions contemplated thereby were advisable to and in the best interests of APAC and its shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interests of APAC&#8217;s Directors and Executive Officers in the Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">When you consider the recommendation of the APAC Board in favor of approval of the Business Combination Proposal, you should keep in mind that the initial shareholders, including APAC&#8217;s directors and executive officers, have interests in such proposal that are different from, or in addition to, those of APAC&#8217;s shareholders generally. These interests include, among other things, the interests listed below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Prior to APAC&#8217;s initial public offering, the Sponsor purchased 5,750,000 Class&#160;B Ordinary Shares for an aggregate purchase price of $25,000, or approximately $0.004 per share, and the Sponsor later transferred 35,000 Class&#160;B Ordinary Shares to each of William E. Klitgaard, L&#226;le White and Wendel Barr, each of whom serve on the APAC Board. If APAC does not consummate a business combination by February&#160;12, 2023 (or if such date is extended at a duly called extraordinary general meeting, such later date), it would cease all operations except for the purpose of winding up, redeeming all of the outstanding public shares for cash and, subject to the approval of its remaining shareholders and the APAC Board, dissolving and liquidating, subject in each case to its obligations under the Cayman Islands Companies Act (As Revised) to provide for the claims of creditors and the requirements of other applicable law. In such event, the 5,750,000 APAC Class&#160;B Ordinary Shares collectively owned by the Sponsor and three directors (William E. Klitgaard, L&#226;le White and Wendel Barr) would be worthless because following the redemption of the public shares, APAC would likely have few, if any, net assets and because the Sponsor and APAC&#8217;s directors and officers have agreed to waive their respective rights to liquidating dissolutions from the trust account in respect of any APAC Class&#160;A Ordinary Shares and APAC Class&#160;B Ordinary Shares held by them, as applicable, if APAC fails to complete a business combination within the required period. Additionally, in such event, the 8,233,333 APAC Private Placement Warrants purchased by the Sponsor simultaneously with the consummation of APAC&#8217;s initial public offering for an aggregate purchase price of $12,350,000 will also expire worthless. Certain of APAC&#8217;s directors and officers, including Thompson Dean and David Burgstahler, also have a direct or indirect economic interest in such APAC Private Placement Warrants and the 5,645,000 APAC Class&#160;B Ordinary Shares owned by the Sponsor.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">173</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The 5,750,000 shares of New OmniAb Common Stock into which the 5,750,000 APAC Class&#160;B Ordinary Shares collectively held by the Sponsor and three of our directors will automatically convert in connection with the Domestication, if unrestricted and freely tradeable, would have had an aggregate market value of $[&#9679;] based upon the closing price of $[&#9679;] per APAC Class&#160;A Ordinary Share on the Nasdaq on [&#9679;], 2022, the most recent practicable date prior to the date of this proxy statement/prospectus/information statement. However, given that such shares of New OmniAb Common Stock will be subject to certain restrictions, including those described above, APAC believes that such shares have less value. The 8,233,333 New OmniAb Warrants into which the 8,233,333 APAC Private Placement Warrants held by the Sponsor will automatically convert in connection with the Domestication, if unrestricted and freely tradeable, would have had an aggregate market value of $[&#9679;] based upon the closing price of $[&#9679;] per APAC Warrant on Nasdaq on [&#9679;], 2022, the most recent practicable date prior to the date of this proxy statement/prospectus/information statement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC&#8217;s executive officers and directors, or any of their respective affiliates, including the Sponsor and other entities affiliated with APAC and the Sponsor, will be reimbursed for any reasonable fees and out-of-pocket expenses incurred in connection with activities on APAC&#8217;s behalf such as identifying potential target businesses and performing due diligence on suitable business combinations (including the Business Combination).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In the event that APAC fails to consummate a business combination within the prescribed time frame (pursuant to the Cayman Constitutional Documents), or upon the exercise of a redemption right in connection with the Business Combination, APAC will be required to provide for payment of claims of creditors that were not waived that may be brought against APAC within the ten&#160;years following such redemption. In order to protect the amounts held in APAC&#8217;s trust account, the Sponsor has agreed that it will be liable to APAC if and to the extent any claims by a third party (other than APAC&#8217;s independent auditors) for services rendered or products sold to APAC, or a prospective target business with which APAC has discussed entering into a transaction agreement, reduce the amount of funds in the trust account to below the lesser of (i)&#160;$10.25 per public share and (ii)&#160;the actual amount per public share held in the trust account as of the date of the liquidation of the trust account if less than $10.25 per public share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay APAC&#8217;s tax obligations, provided that such liability will not apply to any claims by a third-party or prospective target business that executed a waiver of any and all rights to seek access to the trust account nor will it apply to any claims under APAC&#8217;s indemnity of the underwriters of this offering against certain liabilities, including liabilities under the Securities Act.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Sponsor, or an affiliate of the Sponsor, or certain of APAC&#8217;s officers and directors has advanced funds to APAC for working capital purposes, including $500,000 as of March&#160;15, 2022. These outstanding advances have been documented in a promissory note, dated as of March&#160;14, 2022 (the &#8220;Promissory Note&#8221;) issued by APAC to the Sponsor, pursuant to which APAC may borrow up to $750,000 from the Sponsor (including those amounts which are currently outstanding). The Promissory Note&#160;is non-interest bearing, unsecured and due and payable in full on the earlier of the date APAC consummates its initial business combination and the winding up of APAC. If APAC does not complete its initial business combination within the required period, it may use a portion of its working capital held outside the trust account to repay such advances and any other working capital advances made to APAC, but no proceeds held in the trust account would be used to repay such advances and any other working capital advances made to APAC, and such related party may not be able to recover the value it has loaned to APAC and any other working capital advances it may make.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC and the Sponsor have entered into the A&amp;R FPA in order to ensure adequate cash is available to the combined company following the Closing and, if necessary, to backstop redemptions by APAC&#8217;s shareholders in connection with the Business Combination, in an amount of up to $100,000,000 (at a purchase price of $10.00 per share). Pursuant to the A&amp;R FPA, APAC has agreed that, in connection with the consummation of the Business Combination, it will issue and sell to the Sponsor 1,500,000 shares of New OmniAb Common Stock and warrants to acquire 1,666,667 shares of New OmniAb Common Stock for an aggregate purchase price of $15 million. In addition, the Sponsor has agreed to purchase up to an additional 10,000,000 shares of New OmniAb Common Stock and up to an additional 1,666,667 New OmniAb Warrants in order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds available to the combined company following the Business Combination from APAC&#8217;s trust account to be less than $100,000,000. The A&amp;R FPA also provides that in the event the Merger Agreement is terminated by Ligand under circumstances in which the Termination Fee would be payable thereunder, Ligand shall pay the Sponsor a termination fee of $12,500,000 in connection therewith.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">174</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On August&#160;9, 2021, the Insiders entered into a Sponsor Insider Agreement, pursuant to which, among other things, the Insiders agreed to vote any APAC securities held by them to approve a proposed business combination (including any proposals recommended by the APAC Board in connection with such business combination and not to redeem any APAC shares held by them in connection with such shareholder approval in order to induce APAC and the underwriters in APAC&#8217;s initial public offering to enter into an underwriting agreement and to proceed with APAC&#8217;s initial public offering.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Sponsor, the Insiders and OmniAb entered into the Sponsor Insider Agreement, pursuant to which, among other things, the Insiders agreed to vote any APAC securities held by them to approve the Business Combination and the other APAC shareholder matters required pursuant to the Merger Agreement, and not to seek redemption of any of their APAC securities in connection with the consummation of the Business Combination. Pursuant to the Sponsor Insider Agreement, the Sponsor also agreed to subject up to all 1,916,667 Sponsor Earnout Shares to forfeiture if an applicable Sponsor Triggering Event has not occurred with respect to such Sponsor Earnout Shares during the period from the date of the Closing to and including the fifth anniversary of the date of the Closing.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to the Registration Rights Agreement, the Sponsor and certain related parties will have customary registration rights, including piggy-back rights, subject to cooperation and cut-back provisions with respect to the shares of New OmniAb Common Stock and New OmniAb warrants held by such parties following the consummation of the Business Combination. See &#8220;</span><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Certain Relationships and Related Person Transactions&#160;&#8212; APAC</i><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.&#8221;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor (including its representatives and affiliates) and APAC&#8217;s directors and officers, are, or may in the future become, affiliated with entities that are engaged in a similar business to APAC. The Sponsor and APAC&#8217;s directors and officers are not prohibited from sponsoring, or otherwise becoming involved with, any other blank check companies prior to APAC completing its initial business combination. Moreover, certain of APAC&#8217;s directors and officers have time and attention requirements for investment funds of which affiliates of the Sponsor are the investment managers. APAC&#8217;s directors and officers also may become aware of business opportunities which may be appropriate for presentation to APAC, and the other entities to which they owe certain fiduciary or contractual duties. Accordingly, they may have had conflicts of interest in determining to which entity a particular business opportunity should be presented. These conflicts may not be resolved in APAC&#8217;s favor and such potential business opportunities may be presented to other entities prior to their presentation to APAC, subject to applicable fiduciary duties under the Cayman Islands Companies Law. APAC&#8217;s Cayman Constitutional Documents provide that APAC renounces its interest in any corporate opportunity offered to any director or officer of APAC unless such opportunity is expressly offered to such person solely in his or her capacity as a director or officer of APAC and it is an opportunity that APAC is able to complete on a reasonable basis. This provision in APAC&#8217;s Cayman Constitutional Documents may present a conflict of interest in the event that a director or officer of APAC is offered a corporate opportunity in a capacity other than his or her capacity as a director or officer of APAC that is suitable for APAC. APAC does not believe that such potential conflict of interest impacted APAC&#8217;s search for a business combination target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s existing directors and officers will be eligible for continued indemnification and continued coverage under APAC&#8217;s directors&#8217; and officers&#8217; liability insurance after the Merger and pursuant to the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor has agreed to vote all the founder shares and any other public shares purchased during or after APAC&#8217;s initial public offering in favor of the Business Combination, regardless of how our public shareholders vote. Unlike some other blank check companies in which the initial shareholders agree to vote their shares in accordance with the majority of the votes cast by the public shareholders in connection with an initial business combination, the Sponsor and each director of APAC have agreed to, among other things, vote in favor of the Condition Precedent Proposals. As of the date of this proxy statement/prospectus/information statement, the Sponsor (together with APAC&#8217;s directors) owns 20% of the issued and outstanding ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor and APAC&#8217;s directors, officers, advisors or their respective affiliates may purchase shares or warrants in privately negotiated transactions or in the open market either prior to or following the completion of the Business Combination. However, they have no current commitments, plans or intentions to engage in any such transactions and have not formulated any terms or conditions for any such transactions. None of the funds in the trust account will be used to purchase shares or warrants in such transactions. If they engage in such transactions, they will not make any such purchases when they are in possession of any material non-public information not disclosed to the seller or if such purchases are prohibited by Regulation M under the Exchange Act or other federal securities laws. Such a purchase may include a contractual acknowledgement that such shareholder, although still the record holder of APAC&#8217;s shares, is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">175</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that the Sponsor or APAC&#8217;s directors, officers, advisors or their affiliates purchase shares in privately negotiated transactions from public shareholders who have already elected to exercise their redemption rights, such selling shareholders would be required to revoke their prior elections to redeem their shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purpose of such purchases would be to (i)&#160;vote such shares in favor of the Business Combination and thereby increase the likelihood of obtaining shareholder approval of the Business Combination or (ii)&#160;to ensure that APAC&#8217;s net tangible assets are at least $5,000,001, where it appears that such requirement would otherwise not be met. The purpose of any such purchases of warrants could be to reduce the number of warrants outstanding or to vote such warrants on any matters submitted to the warrant holders for approval in connection with the Business Combination. Any such purchases of our securities may result in the completion of the Business Combination that may not otherwise have been possible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if such purchases are made, the public &#8220;float&#8221; of APAC Class&#160;A Ordinary Shares may be reduced and the number of beneficial holders of our securities may be reduced, which may make it difficult to maintain or obtain the quotation, listing or trading of our securities on a national securities exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor and APAC&#8217;s officers, directors and/or their affiliates anticipate that they may identify the shareholders with whom the Sponsor or APAC&#8217;s officers, directors or their affiliates may pursue privately negotiated purchases by either the shareholders contacting us directly or by our receipt of redemption requests submitted by shareholders (in the case of Class&#160;A Ordinary Shares) following our mailing of proxy materials in connection with the Business Combination. To the extent that the Sponsor or APAC&#8217;s officers, directors, advisors or their affiliates enter into a private purchase, they would identify and contact only potential selling shareholders who have expressed their election to redeem their shares for a pro rata share of the trust account or vote against the Business Combination but only if such shares have not already been voted at the extraordinary general meeting. The Sponsor and APAC&#8217;s officers, directors, advisors or their affiliates will only purchase shares if such purchases comply with Regulation M under the Exchange Act and the other federal securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any purchases by the Sponsor or APAC&#8217;s officers, directors and/or their affiliates who are affiliated purchasers under Rule&#160;10b-18 under the Exchange Act will only be made to the extent such purchases are able to be made in compliance with Rule&#160;10b-18, which is a safe harbor from liability for manipulation under Section&#160;9(a)(2)&#160;and Rule&#160;10b-5 of the Exchange Act. Rule&#160;10b-18 has certain technical requirements that must be complied with in order for the safe harbor to be available to the purchaser. The Sponsor and APAC&#8217;s officers, directors and/or their affiliates will not make purchases of APAC Class&#160;A Ordinary Shares if the purchases would violate Section&#160;9(a)(2)&#160;or Rule&#160;10b-5 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The existence of financial and personal interests of one or more of APAC&#8217;s directors may result in a conflict of interest on the part of such director(s)&#160;between what he, she or they may believe is in the best interests of APAC and its shareholders and what he, she or they may believe is best for himself, herself or themselves in determining to recommend that shareholders vote for the proposals. In addition, APAC&#8217;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#8201;&#8212;&#8201;Interests of APAC&#8217;s Directors and Executive Officers in the Business Combination</i>&#8221; for a further discussion of these considerations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Board of Directors Following the Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The New OmniAb Board following consummation of the Business Combination will consist of seven directors. If all of the director nominees are elected, Matthew W. Foehr and Jennifer Cochran will be Class&#160;I directors serving until the annual meeting of stockholders to be held in 2023, Sarah Boyce and Sunil Patel will be Class&#160;II directors serving until the annual meeting to be held in 2024 and John L. Higgins, Carolyn Bertozzi, and [&#9679;] will be Class&#160;III directors serving until the annual meeting to be held in 2025 and, in each case, until their successors are elected and qualified or until their earlier death, resignation, retirement or removal for cause. Carolyn Bertozzi, Sarah Boyce, Jennifer Cochran, Matthew W. Foehr, John L. Higgins, Sunil Patel and [&#160;&#9679;&#160;] <span style="color:#231f20;">have each been nominated to serve as directors of New OmniAb upon completion of the Business Combination.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please see the sections entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;8 &#8212;The Director Election Proposal</i>&#8221; and &#8220;<i style="font-style:italic;">Management of New OmniAb after the Business Combination</i>&#8221; for additional information.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">176</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Redemption Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Cayman Constitutional Documents, an APAC shareholder may request of APAC that APAC redeem all or a portion of its APAC Class&#160;A Ordinary Shares for cash, out of funds legally available therefor, if the Business Combination is consummated. As a holder of APAC Class&#160;A Ordinary Shares, you will be entitled to receive cash for any APAC Class&#160;A Ordinary Shares to be redeemed only if you:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hold APAC Class&#160;A Ordinary Shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submit a written request to Continental, APAC&#8217;s transfer agent, in which you (i)&#160;request that APAC redeem all or a portion of your APAC Class&#160;A Ordinary Shares for cash, and (ii)&#160;identify yourself as the beneficial holder of the APAC Class&#160;A Ordinary Shares and provide your legal name, phone number and address; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">deliver your APAC Class&#160;A Ordinary Shares to Continental, APAC&#8217;s transfer agent, physically or electronically through DTC.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Holders must complete the procedures for electing to redeem their APAC Class&#160;A Ordinary Shares in the manner described above prior to 5:00&#160;p.m., Eastern Time, on [</b>&#9679;<b style="font-weight:bold;">], 2022 (two business&#160;days before the Extraordinary General Meeting) in order for their shares to be redeemed.</b></p><a id="_Hlk101066381"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The redemption rights include the requirement that a holder must identify itself in writing as a beneficial holder and provide its legal name, phone number and address to Continental in order to validly redeem its shares. APAC&#8217;s public shareholders may elect to redeem all or a portion of the public shares held by them regardless of if or how they vote in respect of the Business Combination Proposal. </b>If the Business Combination is not consummated, the public shares will be returned to the respective holder, broker or bank. If the Business Combination is consummated, and if a public shareholder properly exercises its right to redeem all or a portion of the public shares that it holds and timely delivers its shares to Continental, APAC&#8217;s transfer agent, APAC will redeem such public shares for a per-share price, payable in cash, equal to the pro rata portion of the trust account, calculated as of two business&#160;days prior to the consummation of the Business Combination. For illustrative purposes, as of [&#9679;], 2022, this would have amounted to approximately $[&#9679;] per issued and outstanding public share. If a public shareholder exercises its redemption rights in full, then it will be electing to exchange its APAC Class&#160;A Ordinary Shares for cash and will no longer own APAC Class&#160;A Ordinary Shares. The redemption takes place following the Domestication and accordingly it is New OmniAb Common Stock that will be redeemed immediately after consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you hold the shares in &#8220;street name,&#8221; you will have to coordinate with your broker to have your shares certificated or delivered electronically. Shares that have not been tendered (either physically or electronically) in accordance with these procedures will not be redeemed for cash. There is a nominal cost associated with this tendering process and the act of certificating the shares or delivering them through DTC&#8217;s DWAC system. The transfer agent will typically charge the tendering broker $80 and it would be up to the broker whether or not to pass this cost on to the redeeming shareholder. In the event the proposed Business Combination is not consummated this may result in an additional cost to shareholders for the return of their shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any written request for redemption, once made by a holder of APAC Class&#160;A Ordinary Shares, may not be withdrawn once submitted to APAC unless the APAC Board determines (in its sole discretion) to permit the withdrawal of such redemption request (which they may do in whole or in part). If you submit a redemption request to Continental, APAC&#8217;s transfer agent, and later decide prior to the extraordinary general meeting not to elect redemption, you may request to withdraw the redemption request. You may make such request by contacting Continental, APAC&#8217;s transfer agent, at the phone number or address listed in see &#8220;<i style="font-style:italic;">Questions and answers&#8201;&#8212;&#8201;Q: Who can help answer my questions?</i>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any corrected or changed written exercise of redemption rights must be received by Continental, APAC&#8217;s transfer agent, prior to the vote taken on the Business Combination Proposal at the extraordinary general meeting. No request for redemption will be honored unless the holder&#8217;s APAC Class&#160;A Ordinary Share certificates (if any) and other redemption forms have been delivered to Continental, APAC&#8217;s transfer agent, physically or electronically through DTC, at least two business&#160;days prior to the vote at the extraordinary general meeting.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">177</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, a public shareholder, together with any affiliate of such public shareholder or any other person with whom such public shareholder is acting in concert or as a &#8220;group&#8221; (as defined in Section&#160;13(d)(3)&#160;of the Exchange Act), will be restricted from redeeming its APAC Class&#160;A Ordinary Shares with respect to more than an aggregate of 15% of the APAC Class&#160;A Ordinary Shares. Accordingly, if a public shareholder, alone or acting in concert or as a group, seeks to redeem more than 15% of the APAC Class&#160;A Ordinary Shares, then any such shares in excess of that 15% limit would not be redeemed for cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor and each director of APAC has agreed to, among other things, vote all of their founder shares and any other APAC Class&#160;A Ordinary Shares purchased during APAC&#8217;s initial public offering in favor of the proposals being presented at the extraordinary general meeting and waive their redemption rights with respect to such shares in connection with the consummation of the Business Combination. The APAC Class&#160;B Ordinary Shares held by the Sponsor and such other persons will be excluded from the pro rata calculation used to determine the per-share redemption price. As of the date of this proxy statement/prospectus/information statement, the Sponsor and APAC&#8217;s directors, collectively, own approximately 20% of the issued and outstanding ordinary shares of APAC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The closing price of APAC Class&#160;A Ordinary Shares on [&#9679;], 2022 was $[&#9679;]. For illustrative purposes, as of [&#9679;], 2022, funds in the trust account plus accrued interest thereon totaled approximately $[&#9679;] or approximately $[&#9679;] per issued and outstanding APAC Class&#160;A Ordinary Share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Prior to exercising redemption rights, APAC&#8217;s public shareholders should verify the market price of APAC Class&#160;A Ordinary Shares as they may receive higher proceeds from the sale of their APAC Class&#160;A Ordinary Shares in the public market than from exercising their redemption rights if the market price per share is higher than the redemption price. APAC cannot assure its shareholders that they will be able to sell their APAC Class&#160;A Ordinary Shares in the open market, even if the market price per share is higher than the redemption price stated above, as there may not be sufficient liquidity in its securities when its shareholders wish to sell their shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Satisfaction of 80% Test</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">It is a requirement under the Cayman Constitutional Documents that any business acquired by APAC have an aggregate fair market value equal to at least 80% of the balance of the funds in the trust account at the time of the execution of a definitive agreement for an initial business combination. Based on the financial information provided to the APAC Board in connection with approval of the transaction, the APAC Board determined that this requirement was met. The APAC Board believes that the financial skills and background of its members qualify it to conclude that the Business Combination with OmniAb met this requirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Accounting Treatment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Business Combination is expected to be accounted for as a reverse recapitalization in accordance with GAAP, whereby APAC is treated as the acquired company and OmniAb is treated as the acquirer. Accordingly, for accounting purposes, the Business Combination will be treated as the equivalent of OmniAb issuing stock for the net assets of APAC, accompanied by a recapitalization. The net assets of APAC will be stated at historical cost, with no goodwill or other intangible assets recorded. Subsequently, results of operations presented for the period prior to the Business Combination will be those of OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">OmniAb has been determined to be the accounting acquirer in the Business Combination based on the following predominate factors:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb&#8217;s existing stockholders will have the greatest voting interest in the combined entity under the no redemption and maximum redemption scenarios with over 75% of the voting interest in each scenario;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb will have the ability to nominate a majority of the initial members of the New OmniAb Board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb&#8217;s senior management will be the senior management of the combined entity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmniAb is the larger entity based on historical operating activity and has the larger employee base; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The post-combination company will assume an OmniAb branded name: &#8220;OmniAb, Inc.&#8221;</span></td></tr></table><div style="margin-top:10pt;"></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">178</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Vote Required for Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The approval of the Business Combination Proposal requires a special resolution under Cayman Islands law, being the affirmative vote of a majority of at least two-thirds of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. Abstentions and broker non-votes, while considered present for the purposes of establishing a quorum, will not count as votes cast at the extraordinary general meeting, and otherwise will have no effect on the proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Resolution to be Voted Upon</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The full text of the resolution to be passed is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">&#8220;<b style="font-weight:bold;">RESOLVED</b>, as a special resolution, that (i)&#160;APAC&#8217;s entry into the Merger Agreement, dated as of March&#160;23, 2022 (the &#8220;Merger Agreement&#8221;), by and among APAC, Orwell Merger Sub,&#160;Inc., a Delaware corporation and wholly-owned subsidiary of APAC (&#8220;Merger Sub&#8221;), Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#8220;Ligand&#8221;), and OmniAb,&#160;Inc., a Delaware corporation and, prior to the effective time of the Merger, wholly-owned subsidiary of Ligand (&#8220;OmniAb&#8221;), (a copy of which is attached to the proxy statement/prospectus/information statement as Annex A), (ii)&#160;APAC&#8217;s entry into each of the other Transaction Documents (as defined in the Merger Agreement) and (iii)&#160;the transactions contemplated by the Merger Agreement and such Transaction Documents, including, following the Domestication, as described below, the merger of Merger Sub with and into OmniAb (the &#8220;Merger&#8221;), with OmniAb surviving the Merger as a wholly-owned subsidiary of the Company, in accordance with the terms and subject to the conditions of the Merger Agreement, be approved, adopted, ratified and confirmed in all respects.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recommendation of the APAC Board</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">THE APAC BOARD RECOMMENDS THAT APAC SHAREHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE BUSINESS COMBINATION PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 2pt 0pt;">The existence of financial and personal interests of one or more of APAC&#8217;s directors may result in a conflict of interest on the part of such director(s)&#160;between what he, she or they may believe is in the best interests of APAC and its shareholders and what he, she or they may believe is best for himself, herself or themselves in determining to recommend that shareholders vote for the proposals. In addition, APAC&#8217;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#8212;The Business Combination Proposal&#8212;Interests of APAC&#8217;s Directors and Executive Officers in the Business Combination</i>&#8221; for a further discussion of these considerations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">179</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bb288193_cb70_40ad_8687_c0b5eb0b707b"></a><a id="Main_THEDOMESTICATIONPROPOSAL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SHAREHOLDER PROPOSAL NO.&#160;2&#160;&#8212; THE DOMESTICATION PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As discussed in this proxy statement/prospectus/information statement, APAC is asking its shareholders to approve the Domestication Proposal. Under the terms of the Merger Agreement, the approval of the Domestication Proposal is also a condition to the consummation of the Business Combination. If this proposal is not approved, the Business Combination will not occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To effect the Domestication, APAC will file an application to deregister with the Cayman Islands Registrar of Companies, together with the necessary accompanying documents, and file with the Secretary of State of the State of Delaware a certificate of corporate domestication, together with the necessary accompanying documents, and make all filings required to be made with the Cayman Islands Registrar of Companies and the Secretary of State of the State of Delaware to effect the Domestication. If approved, the Domestication will occur at least one business day prior to the Closing Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Domestication, at least one business day prior to the Closing Date, among other things (a)&#160;each APAC Class&#160;A Ordinary Share will be converted into one share of New OmniAb Common Stock, (b)&#160;each APAC Class&#160;B Ordinary Share that is issued and outstanding immediately prior to the Domestication will be converted, on a one-for-one basis, into one share of New OmniAb Common Stock, (c)&#160;each issued and outstanding APAC Warrant will automatically convert into a warrant to acquire one share of New OmniAb Common Stock, pursuant to the Warrant Agreement, (d)&#160;each then issued and outstanding APAC unit will separate and convert automatically into one share of New OmniAb Common Stock and one-third of one New OmniAb Warrant, (e)&#160;the Proposed Certificate of Incorporation will be adopted and filed with the Secretary of State of the State of Delaware pursuant to the DGCL, and the Proposed Certificate of Incorporation and Proposed Bylaws will become the governing documents of New OmniAb and (f)&#160;APAC will change its name to &#8220;OmniAb,&#160;Inc.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Domestication Proposal, if approved, will approve a change of APAC&#8217;s jurisdiction of incorporation from the Cayman Islands to Delaware. Accordingly, while APAC is currently incorporated as an exempted company under the Cayman Islands Companies Act, upon the Domestication, New OmniAb will be continued as a corporation under, and governed by, the DGCL. We encourage shareholders to carefully consult the information on the Proposed Certificate of Incorporation and Proposed Bylaws set out below under &#8220;<i style="font-style:italic;">Comparison of Corporate Governance and Shareholder Rights</i>.&#8221; The Proposed Certificate of Incorporation and Proposed Bylaws differ in certain material respects from the Cayman Constitutional Documents, and we encourage shareholders to carefully consult the information set out below under &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;3&#8212;The Organizational Documents Proposal</i>,&#8221; and the Proposed Certificate of Incorporation and Proposed Bylaws, attached to this proxy statement/prospectus/information statement as Annex H and Annex I, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Domestication Proposal is conditioned on the approval of each of the other APAC Condition Precedent Proposals to be voted on at the extraordinary general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reasons for the Domestication</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The APAC Board believes that there are significant advantages to APAC that will arise as a result of a change of domicile to Delaware. Delaware provides a favorable legal, regulatory, tax and political environment in which to operate. Further, the APAC Board believes that any direct benefit that the DGCL provides to a corporation also indirectly benefits its stockholders, who are the owners of the corporation. The APAC Board believes that because of these reasons, a change of domicile to Delaware is in the best interests of APAC and its shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The approval of the Domestication Proposal is a condition to the closing of the Merger under the Merger Agreement. The approval of the Domestication Proposal requires a special resolution under the Cayman Islands Companies Law, being the affirmative vote of the holders of a majority of at least two-thirds of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. Abstentions, while considered present for the purposes of establishing a quorum, will not count as votes cast at the extraordinary general meeting. A broker non-vote, while considered present for the purposes of establishing a quorum, will not count as a vote cast at the extraordinary general meeting.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">180</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Expected Accounting Treatment of the Domestication</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There will be no accounting effect or change in the carrying amount of the consolidated assets and liabilities of APAC as a result of the Domestication. The business, capitalization, assets and liabilities and financial statements of New OmniAb immediately following the Domestication will be the same as those of APAC immediately prior to the Domestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Vote Required for Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The approval of the Domestication Proposal requires a special resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of at least two-thirds of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. Abstentions and broker non-votes, while considered present for the purposes of establishing a quorum, will not count as votes cast at the extraordinary general meeting, and otherwise will have no effect on the proposal. With respect to the Domestication Proposal, a holder of APAC Class&#160;B Ordinary Shares shall have ten votes for every APAC Class&#160;B Ordinary Share of which he or she is the holder and a holder of APAC Class&#160;A Ordinary Shares shall have one vote for every APAC Class&#160;A Ordinary Share of which he or she is the holder. The Sponsor, who holds 5,645,000 APAC Class B Ordinary Shares, has agreed to vote all such shares in favor of the Domestication Proposal, and such vote will be sufficient to approve the Domestication Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Resolution to be Voted Upon</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The full text of the resolution to be passed is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">RESOLVED</b>, as a special resolution, that APAC be transferred by way of continuation from the Cayman Islands to Delaware and become domesticated as a Delaware corporation in accordance with Section&#160;388 of the DGCL and de-register as a Cayman Islands exempted company in accordance with Section&#160;206 of the Cayman Islands Companies Law and, immediately upon being de-registered in the Cayman Islands, APAC be registered as a corporation under the laws of Delaware and, conditional upon, and with effect from, the registration of APAC as a corporation in Delaware, the name of APAC be changed from &#8220;Avista Public Acquisition Corp. II&#8221; to &#8220;OmniAb,&#160;Inc.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recommendation of the APAC Board</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE APAC BOARD RECOMMENDS THAT APAC SHAREHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE DOMESTICATION PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The existence of financial and personal interests of one or more of APAC&#8217;s directors may result in a conflict of interest on the part of such director(s)&#160;between what he or they may believe is in the best interests of APAC and its shareholders and what he or they may believe is best for himself or themselves in determining to recommend that shareholders vote for the proposals. In addition, APAC&#8217;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#8212;The Business Combination Proposal&#8212;Interests of APAC&#8217;s Directors and Executive Officers in the Business Combination</i>&#8221; for a further discussion of these considerations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">181</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bb750ece_940f_43cc_9678_387670fd3ea0"></a><a id="Main_THEORGANIZATIONALDOCUMENTSPROPOS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SHAREHOLDER PROPOSAL NO.&#160;3&#160;&#8212; THE ORGANIZATIONAL DOCUMENTS PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC is asking its shareholders to approve the adoption of the Proposed Certificate of Incorporation and Proposed Bylaws in the forms attached hereto as Annex H and Annex I, which, in the judgment of the APAC Board, is necessary to adequately address the needs of New OmniAb following the Domestication and consummation of the Business Combination. The Proposed Organizational Documents will replace APAC&#8217;s current Cayman Constitutional Documents<span style="color:#231f20;">, as described above in &#8220;</span><i style="color:#231f20;font-style:italic;">Shareholder Proposal No.&#160;2&#8212;Domestication Proposal</i><span style="color:#231f20;">.&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the key changes effected by the Proposed Organizational Documents, but this summary is qualified in its entirety by reference to the full text of the Proposed Certificate of Incorporation and the Proposed Bylaws, copies of which are included as Annex H and Annex I, respectively:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">change the purpose of New OmniAb to engage in &#8220;any lawful act or activity for which a corporation may be organized under the General Corporation Law of the State of Delaware&#8221;;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that the affirmative vote of the holders of at least 66 2/3% of the voting power of all then-outstanding New OmniAb Common Stock entitled to vote generally in the election of directors, voting together as a single class, is required to adopt, amend or repeal the Proposed Bylaws and the provisions in the Proposed Certificate of Incorporation related to preferred stock, the board of directors, stockholders, limitation on liability and indemnification of directors, forum selection and amendments to the Proposed Certificate of Incorporation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">change the name of APAC to &#8220;OmniAb, Inc.&#8221; and delete the provisions relating to APAC&#8217;s status as a blank check company and retain the default of perpetual existence under the DGCL;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">change the authorized shares of all classes of capital stock to 1,100,000,000 shares, consisting of 1,000,000,000, shares of New OmniAb Common Stock and 100,000,000 shares of preferred stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adopt Delaware as the exclusive forum for certain stockholder litigation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide for transfer restrictions with respect to shares of New OmniAb Common Stock issued as consideration to stockholders of OmniAb and certain stockholders of APAC in connection with their respective earnouts; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">classify the New OmniAb Board into three classes, with only one class of directors being elected in each year and each class serving a three-year term.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reasons for the Amendments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of these amendments was negotiated as part of the Business Combination. The APAC Boards&#8217; reasons for proposing each of these key changes effected by the Proposed Organizational Documents are set forth below.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Providing that the purpose of New OmniAb is &#8220;to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware.&#8221; The APAC Board believes this change is appropriate to remove language applicable to a blank check company.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The supermajority voting requirements are appropriate at this time to protect all stockholders against the potential self-interested actions by one or a few large stockholders. In reaching this conclusion, the APAC Board was cognizant of the potential for certain stockholders to hold a substantial portion of the beneficial ownership of New OmniAb Common Stock following the Business Combination. The APAC Board further believes that, going forward, a supermajority voting requirement encourages any person or group seeking control of New OmniAb to negotiate with the New OmniAb Board to reach terms that are appropriate for all stockholders.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">182</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Changing the name from &#8220;Avista Public Acquisition Corp II&#8221; to &#8220;OmniAb, Inc.&#8221; and deleting provisions specific to APAC&#8217;s status as a blank check company. These revisions are desirable because they will serve no purpose following the Business Combination.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change to authorized shares of New OmniAb Common Stock and preferred stock of New OmniAb. The greater number of authorized shares of capital stock is desirable for New OmniAb to have sufficient shares to complete the Business Combination. Additionally, the APAC Board believes that it is important for New OmniAb to have available for issuance a number of authorized shares sufficient to support its growth and to provide flexibility for future corporate needs (including, if needed, as part of financing for potential future growth acquisitions). The shares would be issuable for any proper corporate purpose, including future acquisitions, capital raising transactions consisting of equity or convertible debt, stock dividends or issuances under current and any future stock incentive plans, pursuant to which New OmniAb may provide equity incentives to employees, officers and directors. The APAC Board believes that these additional shares will provide New OmniAb with needed flexibility to issue shares in the future in a timely manner and under circumstances New OmniAb considers favorable without incurring the risk, delay and potential expense incident to obtaining stockholder approval for a particular issuance.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Adopting Delaware as the exclusive forum for certain stockholder litigation is intended to assist New OmniAb in avoiding multiple lawsuits in multiple jurisdictions regarding the same matter. The ability to require such claims to be brought in a single forum will help to assure consistent consideration of the issues, the application of a relatively known body of case law and level of expertise and should promote efficiency and cost-savings in the resolutions of such claims. The APAC Board believes that the Delaware courts are best suited to address disputes involving such matters given that after the Domestication, New OmniAb will be incorporated in Delaware.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Providing for transfer restrictions with respect to certain shares of New OmniAb Common Stock. As part of the consideration to the parties to the Merger Agreement, certain shares issued to the stockholders of OmniAb and certain stockholders of APAC are subject to restrictions on transfer and forfeiture provisions, as set forth in the Merger Agreement. The APAC Board believes that such transfer restrictions will align the parties with respect to the long-term success of New OmniAb.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The APAC Board believes that a classified board of directors is in the best interest of New OmniAb because it is designed to assure the continuity and stability of New OmniAb&#8217;s leadership and policies by ensuring that at any given time a majority of the directors will have prior experience with New OmniAb and, therefore, will be familiar with its business and operations. The APAC Board also believes that this classification will assist New OmniAb in protecting the interests of our stockholders in the event of an unsolicited offer for New OmniAb by encouraging any potential acquirer to negotiate directly with the New OmniAb Board.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Vote Required for Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The approval of the Organizational Documents Proposal requires a special resolution under Cayman Islands Law, being the affirmative vote of the holders of a majority of two-thirds of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. Abstentions, while considered present for the purposes of establishing a quorum, will not count as votes cast at the extraordinary general meeting. A broker non-vote, while considered present for the purposes of establishing a quorum, will not count as a vote cast at the extraordinary general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Organizational Documents Proposal is conditioned on the approval of each of the other Condition Precedent Proposals. Therefore, if each of the other Condition Precedent Approvals is not approved, the Organizational Documents Proposal will have no effect, even if approved by holders of ordinary shares.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">183</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Resolution</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The full text of the resolution to be passed is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">RESOLVED,</b> as a special resolution, that with effect from the date of the Domestication, the Cayman Constitutional Documents currently in effect be amended and restated by the deletion in their entirety and the substitution in their place of the Proposed Certificate of Incorporation and Proposed Bylaws (copies of which are attached to the proxy statement/prospectus/information statement as Annex H and Annex I, respectively) and that the name of APAC be changed from Avista Public Acquisition Corp. II to OmniAb,&#160;Inc.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recommendation of the APAC Board</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE APAC BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT APAC SHAREHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE ORGANIZATIONAL DOCUMENTS PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">184</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cf180f03_8569_4d74_9adf_502414ae359d"></a><a id="Main_THENONBINDINGGOVERNANCEPROPOSAL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SHAREHOLDER PROPOSAL NO.&#160;4&#160;&#8212; THE NON-BINDING GOVERNANCE PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC is asking its shareholder to vote on the governance provisions referred to below, which are included in the Proposed Certificate of Incorporation. In accordance with SEC guidance, this proposal is being presented as separate sub-proposals to give stockholders the opportunity to present their separate views on important corporate governance provisions, and each sub-proposal will be voted upon on a non-binding advisory basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the judgment of the APAC Board, these provisions are necessary to adequately address the needs of New OmniAb and its stockholders following the consummation of the Business Combination. Accordingly, regardless of the outcome of the non-binding advisory vote on these proposals, APAC intends that the Proposed Certificate of Incorporation and the Proposed Bylaws, in the form set forth on Annex H and Annex I, respectively, will take effect at consummation of the Business Combination, assuming adoption of the Organizational Documents Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Proposal No.&#160;4A: Change the Authorized Capital Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Description of Amendment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The amendment is intended to authorize the change in the authorized capital stock of APAC from (i)&#160;500,000,000 APAC Class&#160;A Ordinary Shares, 50,000,000 APAC Class&#160;B Ordinary Shares and 5,000,000 preference shares, par value $0.0001 per share, of APAC to (ii)&#160;1,000,000,000 shares of New OmniAb common stock and 100,000,000 shares of New OmniAb preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reasons for Amendment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The principal purpose of this proposal is to provide for an authorized capital structure of New OmniAb that will enable it to continue as a company governed by the DGCL. The APAC Board believes that it is important for us to have available for issuance a number of authorized shares of common stock and preferred stock sufficient to support our growth and to provide flexibility for future corporate needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Proposal No.&#160;4B: Change the Stockholder Vote Required to Amend the Certificate of Incorporation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Description of Amendment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The additional amendment would require, that the affirmative vote of holders of at least 66 2/3% of the voting power of all then-outstanding New OmniAb Common Stock entitled to vote generally in the election of directors, voting together as a single class, to adopt, amend or repeal the Proposed Bylaws and the provisions in the Proposed Certificate of Incorporation related to preferred stock, the board of directors, stockholders, limitation on liability and indemnification of directors, forum selection and amendments to the Proposed Certificate of Incorporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reasons for Amendment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The amendment is intended to protect key provisions of the Proposed Certificate of Incorporation from arbitrary amendment and to prevent a simple majority of stockholders from taking actions that may be harmful to other stockholders or making changes to provisions that are intended to protect all stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Proposal No.&#160;4C: Establish a Classified Board of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Description of Amendment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The amendment would divide the New OmniAb Board into three classes, with only one class of directors being elected in each&#160;year and each class serving a three-year term.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">185</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reasons for Amendment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The APAC Board believes that a classified board of directors is in the best interest of New OmniAb because it is designed to assure the continuity and stability of New OmniAb&#8217;s leadership and policies by ensuring that at any given time a majority of the directors will have prior experience with New OmniAb and, therefore, will be familiar with its business and operations. The APAC Board also believes that this classification will assist New OmniAb in protecting the interests of its stockholders in the event of an unsolicited offer for New OmniAb by encouraging any potential acquirer to negotiate directly with the New OmniAb Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Proposal No.&#160;4D: Action by Written Consent Stockholders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Description of Amendment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Cayman Constitutional Documents permit shareholders to approve matters by unanimous written consent. In contrast, the Proposed Certificate of Incorporation provides that any action required or permitted to be taken by the New OmniAb Stockholders may be effected at a duly called annual or special meeting of such stockholders, and may not be taken by written consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reasons for the Amendment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Proposed Organizational Documents, New OmniAb&#8217;s stockholders will have the ability to propose items of business (subject to the restrictions set forth therein) at duly convened stockholder meetings. Eliminating the right of stockholders to act by written consent limits the circumstances under which stockholders can act on their own initiative to remove directors, or alter or amend the Proposed Organizational Documents outside of a duly called annual or special meeting of the stockholders. Further, the APAC Board believes continuing to limit stockholders&#8217; ability to act by written consent will (i)&#160;reduce the time and effort the New OmniAb Board and management would need to devote to Shareholder Proposals, which time and effort could distract our directors and management from other important company business and (ii)&#160;facilitate transparency and fairness by allowing all stockholders to consider, discuss, and vote on pending stockholder actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the elimination of the stockholders&#8217; ability to act by written consent may have certain anti-takeover effects by forcing a potential acquirer to take control of the New OmniAb Board only at a duly called annual or special meeting. However, this proposal is not in response to any effort of which APAC is aware to obtain control of New OmniAb, and APAC and its management do not presently intend to propose other anti-takeover measures in future proxy solicitations. Further, the APAC Board does not believe that the effects of the elimination of stockholder action by written consent will create a significant impediment to a tender offer or other effort to take control of New OmniAb. Inclusion of these provisions in the Proposed Organizational Documents might also increase the likelihood that a potential acquirer would negotiate the terms of any proposed transaction with the New OmniAb Board and thereby help protect stockholders from the use of abusive and coercive takeover tactics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Proposal No.&#160;4E: Removal of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Description of Amendment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Cayman Constitutional Documents currently permit the holders of APAC Class&#160;B Ordinary Shares to remove directors by ordinary resolution prior to the consummation of a business combination. The Cayman Constitutional Documents provide that following a business combination, the APAC shareholders could remove any director by ordinary resolution. In contrast, the Proposed Certificate of Incorporation provides that New OmniAb stockholders may remove directors from office but only for cause and only by the affirmative move of at least 66 2/3% of the voting power of the outstanding New OmniAb Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reasons for the Amendment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The APAC Board believes that increasing the&#160;percentage of voting power required to remove a director from office is a prudent corporate governance measure to reduce the possibility that a relatively small number of stockholders could seek to implement a sudden and opportunistic change in control of the New OmniAb Board without the support of the then incumbent board of directors. These changes will enhance the likelihood of continuity and stability in the composition of the New OmniAb Board, avoid costly takeover battles, reduce the New OmniAb Board&#8217;s vulnerability to a hostile change of control and enhance the ability of the New OmniAb Board to maximize shareholder value in connection with any unsolicited offer to acquire New OmniAb. The amendment is also intended align the provisions of the Proposed Organizational Documents to other similarly situated public companies.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">186</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Proposal No.&#160;4F: Delaware as Exclusive Forum</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Description of Amendment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">New OmniAb&#8217;s Proposed Certificate of Incorporation provides that, unless New OmniAb consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, in the event the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) shall be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (A)&#160;any derivative action or proceeding brought on behalf of New OmniAb; (B)&#160;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any current or former director, officer or any stockholder to New OmniAb or New OmniAb&#8217;s stockholders; (C)&#160;any action or proceeding asserting a claim arising pursuant to any provision of the DGCL, the Proposed Certificate of Incorporation or the Proposed Bylaws (as each may be amended from time to time); (D)&#160;any action asserting a claim against New OmniAb governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law. However, this provision will not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction. In addition, unless New OmniAb consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reasons for Amendment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Adopting Delaware as the exclusive forum for certain stockholder litigation is intended to assist New OmniAb in avoiding multiple lawsuits in multiple jurisdictions regarding the same matter. The ability to require such claims to be brought in a single forum will help to assure consistent consideration of the issues, the application of a relatively known body of case law and level of expertise and should promote efficiency and cost-savings in the resolutions of such claims. The APAC Board believes that the Delaware courts are best suited to address disputes involving such matters given that after the Domestication, New OmniAb will be incorporated in Delaware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Vote Required</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The approval of the Governance Proposal requires an ordinary resolution under the Cayman Islands Companies Law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. Abstentions, while considered present for the purposes of establishing a quorum, will not count as votes cast at the extraordinary general meeting. A broker non-vote, while considered present for the purposes of establishing a quorum, will not count as a vote cast at the extraordinary general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As discussed above, a vote to approve the Governance Proposal is an advisory vote, and therefore, is not binding on APAC, New OmniAb or their respective boards of directors. Accordingly, regardless of the outcome of the non-binding advisory vote, APAC and New OmniAb intend that the Proposed Certificate of Incorporation and the Proposed Bylaws, in the forms set forth on Annex H and Annex I, respectively, and containing the provisions noted above, will take effect at consummation of the Business Combination, assuming adoption of the Organizational Documents Proposal and other Condition Precedent Approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Resolution to be Voted Upon</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The full text of the resolution to be passed is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">RESOLVED,</b> as an ordinary resolution, on a non-binding advisory basis, to approve each of the following proposals (Organizational Proposals No.&#160;4A&#160;&#8212; 4F):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Proposal No.&#160;4A: Change the Authorized Capital Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To approve and adopt provisions in the Proposed Certificate of Incorporation to authorize the change in the authorized capital stock of APAC from (i)&#160;500,000,000 APAC Class&#160;A Ordinary Shares, 50,000,000 APAC Class&#160;B Ordinary Shares and 5,000,000 preference shares, par value $0.0001 per share, of APAC to (ii)&#160;1,000,000,000 shares of New OmniAb common stock and 100,000,000 shares of New OmniAb preferred stock.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">187</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Proposal No.&#160;4B: Change the Stockholder Vote Required to Amend the Certificate of Incorporation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To approve and adopt provisions in the Proposed Certificate of Incorporation to require that the affirmative vote of holders of at least 66 2/3% of the voting power of all then-outstanding New OmniAb Common Stock entitled to vote generally in the election of directors, voting together as a single class, to adopt, amend or repeal the Proposed Bylaws and the provisions in the Proposed Certificate of Incorporation related to preferred stock, the board of directors, stockholders, limitation on liability and indemnification of directors, forum selection and amendments to the Proposed Certificate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Proposal No.&#160;4C: Establish a Classified Board of Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To approve and adopt provisions in the Proposed Certificate of Incorporation to would divide the New OmniAb Board of directors into three classes, with only one class of directors being elected in each&#160;year and each class serving a three-year term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Proposal No.&#160;4D: Action by Written Consent Stockholders</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To approve and adopt provisions in the Proposed Certificate of Incorporation to provide that any action required or permitted to be taken by the New OmniAb Stockholders may be effected at a duly called annual or special meeting of such stockholders, and may not be taken by written consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Proposal No.&#160;4E: Removal of Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To approve and adopt provisions in the Proposed Certificate of Incorporation to require the affirmative vote of the holders of at least 66 2/3% of the voting power of the outstanding shares of New OmniAb entitled to vote to remove a director for cause.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Proposal No.&#160;4F: Delaware as Exclusive Forum</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To approve and adopt provisions in the Proposed Certificate of Incorporation to provide that, unless New OmniAb consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for the types of actions or proceedings under Delaware statutory or common law for the actions described in the proxy statement/prospectus/information statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recommendation of the APAC Board</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE APAC BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT APAC SHAREHOLDERS VOTE &#8220;FOR&#8221; THE GOVERNANCE PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">188</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_99adc712_ae1d_43d2_a093_6f10e049209a"></a><a id="Main_THESTOCKISSUANCEPROPOSAL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SHAREHOLDER PROPOSAL NO.&#160;5&#160;&#8212; THE STOCK ISSUANCE PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As discussed in this proxy statement/prospectus/information statement, APAC is asking its shareholders&#8201;to consider and vote upon a proposal to approve by ordinary resolution for the purposes of complying with the applicable provisions of Nasdaq Listing Rules&#160;5635(a), (b)&#160;and (d), the issuance of shares of New OmniAb Common Stock in connection with the Domestication, the Forward Purchase, the Redemption Backstop and the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming the Business Combination Proposal is approved, New OmniAb will issue (a)&#160;23,000,000 shares of New OmniAb Common Stock in connection with the Domestication to shareholders of APAC and (b)&#160;additional shares of New OmniAb Common Stock in connection with the Closing to the Sponsor in connection with the Forward Purchase and the Redemption Backstop, if any, and to OmniAb&#8217;s stockholders and holders of OmniAb Equity Awards (as of immediately after consummation of the Distribution) pursuant to the Merger Agreement. For the avoidance of doubt, references to OmniAb stockholders in this proposal are intended to refer to such holders after giving effect to the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on the assumptions set forth in this proxy statement/prospectus/information statement, APAC expects 97,431,855 shares of New OmniAb Common Stock to be issued as consideration to OmniAb&#8217;s stockholders (as of immediately after consummation of the Distribution) in the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC has also entered into the A&amp;R FPA with Sponsor, pursuant to which New OmniAb will issue and sell to the Sponsor 1,500,000 shares of New OmniAb Common Stock (together with 1,666,667 New OmniAb Warrants) for an aggregate purchase price of $15,000,000 in connection with the Forward Purchase. In addition to the Forward Purchase, pursuant to the A&amp;R FPA the Sponsor has agreed to purchase up to an additional 10,000,000 shares of New OmniAb Common Stock (together with up to an additional 1,666,667 New OmniAb Warrants) in connection with the Redemption Backstop, for an aggregate additional purchase price of up to $100,000,000, in order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds available to the combined company following the Business Combination from APAC&#8217;s trust account to be less than $100,000,000. The terms of the stock consideration in the Business Combination, the Forward Purchase and the Redemption Backstop are complex and only briefly summarized above. For further information, please see the full text of the Merger Agreement, which is attached as Annex A to this proxy statement/prospectus/information statement and the A&amp;R FPA, which is attached as Annex D to this proxy statement/prospectus/information statement. The discussion herein is qualified in its entirety by reference to such documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reasons for the Approval for Purposes of Nasdaq Listing Rule&#160;5635</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are seeking shareholder approval in order to comply with Nasdaq Listing Rules&#160;5635(a), (b)&#160;and (d).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Nasdaq Listing Rule&#160;5635(a), shareholder approval is required prior to the issuance of common stock or other securities convertible into or exercisable for common stock, in connection with the acquisition of the stock or assets of another company, if such securities are not issued in a public offering for cash and (i)&#160;the common stock has, or will have upon issuance, voting power equal to or in excess of 20% of the voting power outstanding before the issuance of such securities, or (ii)&#160;the number of shares of common stock to be issued is or will be equal to or in excess of 20% of the number of shares of common stock outstanding before the issuance of such securities. Collectively, New OmniAb may issue 20% or more of our outstanding common stock or securities representing 20% or more of the voting power, in each case outstanding before the issuance, pursuant to the issuance of New OmniAb Common Stock in connection with the Business Combination, the Forward Purchase and the Redemption Backstop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Nasdaq Listing Rule&#160;5635(b), shareholder approval is required where the issuance of securities will result in a change of control. Because the issuances to OmniAb stockholders in the Business Combination and to the Sponsor in connection with the Forward Purchase and Redemption Backstop, in each case as described above, will result in a majority of the outstanding New OmniAb Common Stock being held by the OmniAb stockholders immediately after consummation of the Business Combination, such issuances may be deemed a change of control. Therefore, we are seeking the approval of our shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Under Nasdaq Listing Rule&#160;5635(d), shareholder approval is required for a transaction other than a public offering involving the sale, issuance or potential issuance by an issuer of common stock (or securities convertible into or exercisable for common stock) at a price that is less than the lower of (i)&#160;the closing price immediately preceding the signing of the binding agreement or (ii)&#160;the average closing price of the common stock for the five trading&#160;days immediately preceding the signing of the binding agreement, if the number </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">189</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">of shares of common stock (or securities convertible into or exercisable for common stock) to be issued equals to 20% or more of the common stock, or 20% or more of the voting power, outstanding before the issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that this proposal is not approved by APAC shareholders, the Business Combination cannot be consummated. In the event that this proposal is approved by APAC shareholders, but the Merger Agreement is terminated (without the Business Combination being consummated) prior to the issuance of shares of New OmniAb Common Stock pursuant to the Merger Agreement, the Forward Purchase or Redemption Backstop, such shares of New OmniAb Common Stock will not be issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Effect of Proposal on Current Shareholders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Nasdaq Proposal is adopted and the Business Combination are consummated, it is estimated that up to 97,431,885 shares of New OmniAb Common Stock could be issued pursuant to the terms of the Merger Agreement as stock consideration in the Business Combination, which collectively represents approximately 424% of the 23,000,000 APAC Class A Ordinary Shares outstanding on the date hereof. Additionally, in connection with the Forward Purchase, New OmniAb will issue 1,500,000 shares of New OmniAb Common Stock and warrants to acquire 1,666,667 shares of New OmniAb Common Stock and in connection with the Redemption Backstop, New OmniAb may issue up to 10,000,000 shares of New OmniAb Common Stock and up to an additional 1,666,667 New OmniAb Warrants, for an aggregate additional purchase price of up to $100,000,000. Also, in connection with the split of current Ligand equity awards into (i) a new Ligand equity award and (ii) a New OmniAb Equity Award, up to 11,430,580 shares of New OmniAb Common Stock underlying the New OmniAb Equity Awards could be issued. The issuance of such shares would result in significant dilution to New OmniAb&#8217;s stockholders, and would afford New OmniAb&#8217;s stockholders a smaller&#160;percentage interest in the voting power, liquidation value and aggregate book value of New OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Vote Required for Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The approval of the Stock Issuance Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. Abstentions and broker non-votes, while considered present for the purposes of establishing a quorum, will not count as votes cast at the extraordinary general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Stock Issuance Proposal is conditioned on the approval of each of the other Condition Precedent Proposals. Therefore, if each of the other proposals presented at the extraordinary general meeting is not approved, the Stock Issuance Proposal will have no effect, even if approved by holders of APAC&#8217;s ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Resolution to be Voted Upon</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The full text of the resolution to be passed is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">RESOLVED</b>, as an ordinary resolution, that, for the purposes of complying with the applicable provisions of Nasdaq Listing Rules&#160;5635(a), (b)&#160;and (d), the issuance of shares of APAC common stock pursuant to the Merger Agreement and in connection with the Domestication, the Forward Purchase, the Redemption Backstop and the Merger, including to existing APAC shareholders, OmniAb stockholders, holders of OmniAb Equity Awards and the Sponsor be approved in all respects.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recommendation of the APAC Board</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE APAC BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT APAC SHAREHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE STOCK ISSUANCE PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The existence of financial and personal interests of one or more of APAC&#8217;s directors may result in a conflict of interest on the part of such director(s)&#160;between what he, she or they may believe is in the best interests of APAC and its shareholders and what he, she or they may believe is best for himself, herself or themselves in determining to recommend that shareholders vote for the proposals. In addition, APAC&#8217;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled <i style="font-style:italic;">&#8220;Shareholder Proposal No.&#160;1&#8212;The Business Combination Proposal&#8212;Interests of APAC&#8217;s Directors and Executive Officers in the Business Combination&#8221;</i> for a further discussion of these considerations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">190</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_940c6ca9_1bb2_4cf3_aa9e_948ccede0306"></a><a id="Main_THEINCENTIVEPLANPROPOSAL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SHAREHOLDER PROPOSAL NO.&#160;6&#160;&#8212; THE INCENTIVE PLAN PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC is asking its shareholders to approve the OmniAb,&#160;Inc. 2022 Incentive Award Plan (the &#8220;2022 Plan&#8221;) and the material terms thereunder. The APAC Board adopted and approved the 2022 Plan prior to the extraordinary general meeting, subject to shareholder approval at the extraordinary general meeting. The 2022 Plan will become effective, if at all, upon the Closing of the Business Combination, subject to consummation of the Business Combination and subject to APAC shareholder approval. If the 2022 Plan is not approved by APAC&#8217;s shareholders, or if the Merger Agreement is terminated prior to the consummation of the Business Combination, the 2022 Plan will not become effective. The provisions of the 2022 Plan give effect to the Domestication and references in the 2022 Plan and this proposal to APAC are to New OmniAb and to shares are to New OmniAb Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the Distribution, OmniAb will maintain the OmniAb,&#160;Inc. 2022 Incentive Award Plan (Ligand Service Provider Awards), the OmniAb,&#160;Inc. 2022 Incentive Award Plan (OmniAb Service Provider Awards) and the Gustafson Inducement Award (the &#8220;OmniAb Plans&#8221;), as described under the heading &#8220;<i style="font-style:italic;">Executive and Director Compensation of OmniAb&#8212;Equity Compensation Plans</i>.&#8221; APAC does not maintain any incentive plans. In connection with the Business Combination, APAC will assume the OmniAb Plans and all awards outstanding under the OmniAb Plans. Following the Distribution, no future awards will be granted under the OmniAb Plans, but all awards under the OmniAb Plans that are outstanding as of the Closing will continue to be governed by the terms, conditions and procedures set forth in the OmniAb Plans and any applicable award agreements, as those terms may be equitably adjusted in connection with the Business Combination, as described in this proxy statement/prospectus/information statement under the heading &#8220;<i style="font-style:italic;">Executive and Director Compensation of OmniAb&#160;&#8212; Treatment of Outstanding Equity Awards at the Time of the Distribution.</i>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2022 Plan is described in more detail below. A copy of the 2022 Plan is attached to this proxy statement/prospectus/information statement as Annex&#160;L.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The 2022 Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purpose of the 2022 Plan is to enhance our ability to attract, retain and motivate persons who make (or are expected to make) important contributions to us by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. The APAC Board believes that equity awards will be necessary for us to remain competitive in our industry and will be essential to recruiting and retaining highly qualified employees to help us meet our goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Description of the Material Features of the 2022 Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This section summarizes certain principal features of the 2022 Plan. The summary is qualified in its entirety by reference to the complete text of the 2022 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Eligibility and Administration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Employees, consultants and directors of the combined company and its subsidiaries will be eligible to receive awards under the 2022 Plan. Following the Closing, the combined company is expected to have approximately [&#9679;] employees, [&#9679;] non-employee&#160;directors&#160;and [&#9679;] other individual service providers who will be eligible to receive awards under the 2022 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the Closing, the 2022 Plan will be administered by the New OmniAb Board, which may delegate its duties and responsibilities to one or more committees of its directors and/or officers (referred to collectively as the plan administrator), subject to the limitations imposed under the 2022 Plan, Section&#160;16 of the Exchange Act, stock exchange rules&#160;and other applicable laws. The plan administrator will have the authority to take all actions and make all determinations under the 2022 Plan, to interpret the 2022 Plan and award agreements and to adopt, amend and repeal rules&#160;for the administration of the 2022 Plan as it deems advisable. The plan administrator will also have the authority to determine which eligible service providers receive awards, grant awards and set the terms and conditions of all awards under the 2022 Plan, including any vesting and vesting acceleration provisions, subject to the conditions and limitations in the 2022 Plan.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">191</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Shares Available for Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The initial aggregate number of shares of New OmniAb Common Stock that will be available for issuance under the 2022 Plan will be equal to the sum of (i)&#160;14% of the number of fully-diluted shares of New OmniAb Common Stock outstanding as of the Closing, and (ii)&#160;any shares which, as of the effective date of the 2022 Plan, are subject to awards under the OmniAb Plans which, on or following the effective date of the 2022 Plan, become available for issuance pursuant to the 2022 Plan recycling provisions, described below. In addition, the number of shares of our common stock available for issuance under the 2022 Plan will be annually increased on January&#160;1 of each calendar&#160;year beginning in 2023 and ending in 2032 by an amount equal to the lesser of (i)&#160;a number equal to 5% of the fully-diluted shares on the final day of the immediately preceding calendar&#160;year or (ii)&#160;such smaller number of shares as is determined by the New OmniAb Board. The maximum number of shares that may be issued pursuant to the exercise of incentive stock options (&#8220;ISOs&#8221;) granted under the 2022 Plan, will be [&#9679;]. The number of shares that may be issued under the 2022 Plan shall not exceed an aggregate of [&#9679;] shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If an award under the 2022 Plan or the OmniAb Plans expires, lapses or is terminated, exchanged for or settled in cash, any shares subject to such award (or portion thereof) may, to the extent of such expiration, lapse, termination or cash settlement, be used again for new grants under the 2022 Plan. Shares tendered or withheld to satisfy the exercise price or tax withholding obligation for any award under the 2022 Plan or the OmniAb Plans may, to the extent of such tender or withholding, be used for new grants under the 2022 Plan. Further, the payment of dividend equivalents in cash in conjunction with any awards under the 2022 Plan will not reduce the shares available for grant under the 2022 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Awards granted under the 2022 Plan upon the assumption of, or in substitution for, awards authorized or outstanding under a qualifying equity plan maintained by an entity with which we enter into a merger or similar corporate transaction will not reduce the shares available for grant under the 2022 Plan but will count against the maximum number of shares that may be issued upon the exercise of ISOs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2022 Plan provides that the sum of any cash compensation and the aggregate grant date fair value (determined as of the date of the grant under Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of all awards granted to a non-employee director as compensation for services as a non-employee director during any fiscal&#160;year, or director limit, may not exceed an amount equal to $750,000 (increased to $1,000,000 in the calendar&#160;year of a non-employee director&#8217;s initial service as a non-employee director or any calendar&#160;year during which a non-employee director serves as chairman of the board or lead independent director) (which limits shall not apply to the compensation for any non-employee director who serves in any capacity in addition to that of a non-employee director for which he or she receives additional compensation).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2022 Plan provides for the grant of stock options, including ISOs and nonqualified stock options (&#8220;NSOs&#8221;), SARs, restricted stock, dividend equivalents, restricted stock units (&#8220;RSUs&#8221;) and other stock or cash based awards. Certain awards under the 2022 Plan may constitute or provide for payment of &#8220;nonqualified deferred compensation&#8221; under Section&#160;409A of the Code, which may impose additional requirements on the terms and conditions of such awards. All awards under the 2022 Plan will be evidenced by award agreements, which will detail the terms and conditions of awards, including any applicable vesting and payment terms and post-termination exercise limitations. Awards other than cash awards generally will be settled in shares of our common stock, but the applicable award agreement may provide for cash settlement of any award. A brief description of each award type follows.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Stock Options and SARs</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Stock options provide for the purchase of shares of our common stock in the future at an exercise price set on the grant date. ISOs, in contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Code are satisfied. SARs entitle their holder, upon exercise, to receive from us an amount equal to the appreciation of the shares subject to the award between the grant date and the exercise date. Unless otherwise determined by the board, the exercise price of a stock option or SAR may not be less than 100% of the fair market value of the underlying share on the grant date (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to certain substitute awards granted in connection with a corporate transaction. The term of a stock option or SAR may not be longer than ten&#160;years (or five&#160;years in the case of ISOs granted to certain significant stockholders).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Restricted Stock</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Restricted stock is an award of nontransferable shares of our common stock that are subject to certain vesting conditions and other restrictions.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">192</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">RSUs</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. RSUs are contractual promises to deliver shares of our common stock in the future, which may also remain forfeitable unless and until specified conditions are met and may be accompanied by the right to receive the equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares (i.e., dividend equivalent rights). The plan administrator may provide that the delivery of the shares underlying RSUs will be deferred on a mandatory basis or at the election of the participant. The terms and conditions applicable to RSUs will be determined by the plan administrator, subject to the conditions and limitations contained in the 2022 Plan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Other Stock or Cash Based Awards</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Other stock or cash based awards are awards of cash, fully vested shares of our common stock and other awards valued wholly or partially by referring to, or otherwise based on, shares of our common stock. Other stock or cash based awards may be granted to participants and may also be available as a payment form in the settlement of other awards, as standalone payments and as payment in lieu of compensation to which a participant is otherwise entitled.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Dividend Equivalents</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Dividend equivalents represent the right to receive the equivalent value of dividends paid on shares of our common stock and may be granted alone or in tandem with awards other than stock options or SARs. Dividend equivalents are credited as of the dividend record dates during the period between the date an award is granted and the date such award vests, is exercised, is distributed or expires, as determined by the plan administrator. Dividend equivalents payable with respect to an award prior to the vesting of such award instead will be paid out to the participant only to the extent that the vesting conditions are subsequently satisfied and the award vests.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Certain Transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The plan administrator has broad discretion to take action under the 2022 Plan, as well as make adjustments to the terms and conditions of existing and future awards, to prevent the dilution or enlargement of intended benefits and facilitate necessary or desirable changes in the event of certain transactions and events affecting our common stock, such as stock dividends, stock splits, mergers, acquisitions, consolidations and other corporate transactions. In addition, in the event of certain non-reciprocal transactions with our stockholders known as &#8220;equity restructurings,&#8221; the plan administrator will make equitable adjustments to the 2022 Plan and outstanding awards. In the event of a change in control (as defined in the 2022 Plan), to the extent that the surviving entity declines to continue, convert, assume or replace outstanding awards, then all such awards will become fully vested and exercisable in connection with the transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Repricing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The New OmniAb Board may, without approval of the stockholders, reduce the exercise price of any stock option or SAR, or cancel any stock option or SAR in exchange for cash, other awards or stock options or SARs with an exercise price per share that is less than the exercise price per share of the original stock options or SARs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Plan Amendment and Termination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The New OmniAb Board or its compensation committee may amend or terminate the 2022 Plan at any time; however, no amendment, other than an amendment that increases the number of shares available under the 2022 Plan, may materially and adversely affect an award outstanding under the 2022 Plan without the consent of the affected participant, and stockholder approval will be obtained for any amendment to the extent necessary to comply with applicable laws. The 2022 Plan will remain in effect until the tenth anniversary of the earlier of the date the APAC Board adopted the 2022 Plan or the date the APAC shareholders approve the 2022 Plan, unless earlier terminated. No awards may be granted under the 2022 Plan after its termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Foreign Participants, Claw-Back Provisions, Transferability and Participant Payments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The plan administrator may modify award terms, establish subplans and/or adjust other terms and conditions of awards, subject to the share limits described above, in order to facilitate grants of awards subject to the laws and/or stock exchange rules&#160;of countries outside of the United States. All awards will be subject to any company clawback policy as set forth in such clawback policy or the applicable award agreement. Awards under the 2022 Plan are generally non-transferable, except by will or the laws of descent and distribution, or, subject to the plan administrator&#8217;s consent, pursuant to a domestic relations order, and are generally exercisable only by the participant. With regard to tax withholding, exercise price and purchase price obligations arising in connection with awards under the 2022 Plan, the plan administrator may, in its discretion, accept cash or check, shares of our common stock that meet specified conditions, a &#8220;market sell order&#8221; or such other consideration as it deems suitable.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">193</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Material U.S. Federal Income Tax Consequences</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a general summary under current law of the principal United States federal income tax consequences related to awards under the 2022 Plan. This summary deals with the general federal income tax principles that apply and is provided only for general information. Some kinds of taxes, such as state, local and foreign income taxes and federal employment taxes, are not discussed. This summary is not intended as tax advice to participants, who should consult their own tax advisors.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Non-Qualified Stock Options</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. If an optionee is granted an NSO under the 2022 Plan, the optionee should not have taxable income on the grant of the option. Generally, the optionee should recognize ordinary income at the time of exercise in an amount equal to the fair market value of the shares acquired on the date of exercise, less the exercise price paid for the shares. The optionee&#8217;s basis in our common stock for purposes of determining gain or loss on a subsequent sale or disposition of such shares generally will be the fair market value of our common stock on the date the optionee exercises such option. Any subsequent gain or loss will be taxable as a long-term or short-term capital gain or loss. Our subsidiaries or affiliates generally should be entitled to a federal income tax deduction at the time and for the same amount as the optionee recognizes ordinary income.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Incentive Stock Options</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. A participant receiving ISOs should not recognize taxable income upon grant. Additionally, if applicable holding period requirements are met, the participant should not recognize taxable income at the time of exercise. However, the excess of the fair market value of the shares of our common stock received over the option exercise price is an item of tax preference income potentially subject to the alternative minimum tax. If stock acquired upon exercise of an ISO is held for a minimum of two&#160;years from the date of grant and one&#160;year from the date of exercise and otherwise satisfies the ISO requirements, the gain or loss (in an amount equal to the difference between the fair market value on the date of disposition and the exercise price) upon disposition of the stock will be treated as a long-term capital gain or loss, and we will not be entitled to any deduction. If the holding period requirements are not met, the ISO will be treated as one that does not meet the requirements of the Code for ISOs and the participant will recognize ordinary income at the time of the disposition equal to the excess of the amount realized over the exercise price, but not more than the excess of the fair market value of the shares on the date the ISO is exercised over the exercise price, with any remaining gain or loss being treated as capital gain or capital loss. We or our subsidiaries or affiliates generally are not entitled to a federal income tax deduction upon either the exercise of an ISO or upon disposition of the shares acquired pursuant to such exercise, except to the extent that the participant recognizes ordinary income on disposition of the shares.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Other Awards</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. The current federal income tax consequences of other awards authorized under the 2022 Plan generally follow certain basic patterns: SARs are taxed and deductible in substantially the same manner as NSOs; nontransferable restricted stock subject to a substantial risk of forfeiture results in income recognition equal to the excess of the fair market value over the price paid, if any, only at the time the restrictions lapse (unless the recipient elects to accelerate recognition as of the date of grant through a Section&#160;83(b)&#160;election); RSUs, dividend equivalents and other stock or cash based awards are generally subject to tax at the time of payment. Our subsidiaries or affiliates generally should be entitled to a federal income tax deduction at the time and for the same amount as the optionee recognizes ordinary income.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section&#160;409A of the Code</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain types of awards under the 2022 Plan may constitute, or provide for, a deferral of compensation subject to Section&#160;409A of the Code. Unless certain requirements set forth in Section&#160;409A of the Code are complied with, holders of such awards may be taxed earlier than would otherwise be the case (e.g., at the time of vesting instead of the time of payment) and may be subject to an additional 20% penalty tax (and, potentially, certain interest, penalties and additional state taxes). To the extent applicable, the 2022 Plan and awards granted under the 2022 Plan are intended to be structured and interpreted in a manner intended to either comply with or be exempt from Section&#160;409A of the Code and the Department of Treasury regulations and other interpretive guidance that may be issued under Section&#160;409A of the Code. To the extent determined necessary or appropriate by the plan administrator, the 2022 Plan and applicable award agreements may be amended to further comply with Section&#160;409A of the Code or to exempt the applicable awards from Section&#160;409A of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">New Plan Benefits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Grants under the 2022 Plan will be made at the discretion of the plan administrator and are not currently determinable. The value of the awards granted under the 2022 Plan will depend on a number of factors, including the fair market value of the New OmniAb </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">194</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Common Stock on future dates, the exercise decisions made by the participants and the extent to which any applicable performance goals necessary for vesting or payment are achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Vote Required for Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The approval of the Incentive Plan Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. Abstentions and broker non-votes, while considered present for the purposes of establishing a quorum, will not count as votes cast at the extraordinary general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Closing is conditioned on the approval of each of the Condition Precedent Proposals. It is important for you to note that in the event that the Condition Precedent Proposals do not receive the requisite vote for approval, APAC will not consummate the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recommendation of the APAC Board</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">THE APAC BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT APAC SHAREHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE INCENTIVE PLAN PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">195</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_76624620_99dd_4072_835e_a14ae03f99d7"></a><a id="Main_THEESPPPROPOSAL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SHAREHOLDER PROPOSAL NO.&#160;7&#160;&#8212; THE ESPP PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC is asking its shareholders to approve the OmniAb,&#160;Inc. 2022 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) and the material terms thereunder. The APAC Board adopted and approved the ESPP prior to the extraordinary general meeting, subject to shareholder approval at the extraordinary general meeting. The ESPP will become effective, if at all, upon the Closing of the Business Combination, subject to consummation of the Business Combination and subject to APAC shareholder approval. If the ESPP is not approved by APAC&#8217;s shareholders, or if the Merger Agreement is terminated prior to the consummation of the Business Combination, the ESPP will not become effective. The provisions of the ESPP give effect to the Domestication and references in the ESPP and this proposal to APAC are to New OmniAb and to shares are to New OmniAb Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ESPP is described in more detail below. A copy of the ESPP is attached to this proxy statement/prospectus/information statement as Annex P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The ESPP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purpose of the ESPP is to provide <span style="color:#231f20;">our </span>employees with the opportunity to purchase APAC Domesticated Common Stock through accumulated payroll deductions. We believe that the ESPP is a key factor in retaining our existing employees, recruiting and retaining new employees and aligning the interests of our employees with those of our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Description of the Material Features</b><b style="color:#231f20;font-weight:bold;"> of the ESPP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This section summarizes certain principal features of the ESPP. This summary is qualified in its entirety by reference to the complete text of the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ESPP is comprised of two distinct components in order to provide increased flexibility to grant purchase rights under the ESPP to U.S. and to non-U.S. employees. Specifically, the ESPP authorizes (i)&#160;the grant of purchase rights to U.S. employees that are intended to qualify for favorable U.S. federal tax treatment under Section&#160;423 of the Code (the &#8220;Section&#160;423 Component&#8221;) and (ii)&#160;the grant of purchase rights that are not intended to be tax-qualified under Section&#160;423 of the Code to facilitate participation for employees located outside of the United States who do not benefit from favorable U.S. tax treatment and to provide flexibility to comply with non-U.S. law and other considerations (the &#8220;Non-Section&#160;423 Component&#8221;). Where possible under local law and custom, we expect that the Non-Section&#160;423 Component generally will be operated and administered on terms and conditions similar to the Section&#160;423 Component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Administration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">The human capital management and </span>compensation committee of the New OmniAb Board, or any other committee to whom the New OmniAb Board delegates such power or authority, will serve as the administrator of the ESPP. The plan administrator may delegate administrative tasks under the ESPP to agents or employees to assist in the administration of the ESPP. Subject to the terms and conditions of the ESPP, the plan administrator has the authority to determine when rights to purchase shares will be offered and the provisions of each offering under the ESPP, to determine which subsidiaries will participate as &#8220;designated subsidiaries&#8221; in the ESPP (including in the Non-Section&#160;423 and the Section&#160;423 Components), and to make all other determinations and to take all other actions necessary or advisable for the administration of the ESPP. The plan administrator is also authorized to establish, amend or revoke rules&#160;relating to administration of the ESPP and to adopt annexes or sub-plans that apply to certain participating subsidiaries or jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Shares Available for Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The aggregate number of shares of our common stock that may be issued pursuant to rights granted under the ESPP will equal 1.5% of the number of fully-diluted shares of New OmniAb Common Stock outstanding as of the Closing. In addition, on the first day of each calendar&#160;year beginning on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, the number of shares available for issuance under the ESPP will be increased by a number of shares equal to the lesser of (i)&#160;1% of the fully diluted shares outstanding on the final day of the immediately preceding calendar&#160;year, and (ii)&#160;such smaller number of shares as determined by the New OmniAb Board. If any right granted under the ESPP terminates for any reason without having been exercised, the shares subject thereto that are </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">196</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">not purchased under such right will again be available for issuance under the ESPP. Notwithstanding the foregoing, no more than<span style="color:#231f20;"> [&#160;&#9679;&#160;] shares of common stock </span>may be issued under the Section&#160;423 Component of the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Eligible Employees</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Employees eligible to participate in the ESPP for a given offering generally include employees who are employed by us or one of our designated subsidiaries on the first trading day of the offering period, or the enrollment date. However, an employee who owns (or is deemed to own through attribution) 5% or more of the combined voting power or value of all classes of our or one of our subsidiaries&#8217; stock will not be allowed to participate in the ESPP (unless otherwise required under applicable law). In addition, the plan administrator may provide that an employee may not be eligible to participate in an offering under the Section&#160;423 Component if the employee is a citizen or resident of a non-U.S. jurisdiction and the grant of a right to purchase shares would be prohibited under applicable law or would cause the Section&#160;423 Component (or any offering thereunder) to violate the requirements of Section&#160;423 of the Code. Additionally, the plan administrator may provide that certain highly compensated, seasonal and/or part-time employees may not be eligible to participate in an offering or, with respect to offerings under the Non-Section&#160;423 Component, that only certain employees are eligible to participate in such offerings (regardless of the foregoing rules).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following<span style="color:#231f20;"> the Closing, the combined company is expected to have approximately </span>[&#160;&#9679;&#160;] employees who will be eligible to participate in the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Participation; Offerings; Purchase Periods</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Employees may become participants in the ESPP for an offering period by completing a subscription agreement prior to the enrollment date of the applicable offering period, which will designate a whole&#160;percentage of the employee&#8217;s compensation to be withheld by us as payroll deductions under the ESPP during the offering period.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Offerings; Purchase Periods</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Under the ESPP, participants are offered the right to purchase shares of our common stock at a discount during a series of offering periods. The length of the offering periods under the ESPP will be determined by the plan administrator and may be up to twenty-seven (27)&#160;months long. Accumulated employee payroll deductions will be used to purchase shares of our common stock on each purchase date during an offering period. The number of purchase periods within, and purchase dates during, each offering will be established by the plan administrator. Offering periods under the ESPP will commence when determined by the plan administrator. The plan administrator may, in its discretion, modify the terms of future offerings.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Enrollment and Contributions</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. The ESPP permits participants to purchase our common stock through payroll deductions of a whole&#160;percentage of their eligible compensation, which may not be less than 1% and may be up to a maximum&#160;percentage determined by the plan administrator (which, in the absence of a contrary designation, will be 20% of eligible compensation). The plan administrator will establish a maximum number of shares that may be purchased by a participant during any offering period or purchase period, which, in the absence of a contrary designation, will be 100,000 shares for an offering period and 100,000 shares for a purchase period. In addition, a participant may not, with respect to the Section&#160;423 Component, subscribe for more than $25,000 worth of shares under the ESPP per calendar&#160;year in which such rights to purchase stock are outstanding (considered together with any other ESPP maintained by us or certain parent or subsidiary entities) based on the fair market value of the shares at the time the purchase right is granted.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Purchase Rights</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. On the first trading day of each offering period, each participant will automatically be granted an option to purchase shares of our common stock. Unless a participant has previously withdrawn his or her participation in, or has otherwise become ineligible to participate in, the ESPP prior to any applicable purchase date, the option will be exercised on the applicable purchase date(s)&#160;during the offering period to the extent of the payroll deductions accumulated during the offering period. The participant will purchase the maximum number of whole shares of our common stock that his or her accumulated payroll deductions will buy at the purchase price, subject to the participation limitations described above, and any fractional shares will be credited to the participant&#8217;s account and carried forward and applied toward the purchase of whole shares on the next purchase date, unless the plan administrator provides that such amounts should be returned to the participant in a lump sum.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Purchase Price. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The purchase price for each offering period will be designated by the plan administrator in the applicable offering document (which purchase price, for purposes of the Section&#160;423 Component, will not be less than 85% of the </span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">197</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">closing trading price of a share of our common stock on the enrollment date or purchase date of the applicable offering period, whichever is lower) or, in the absence of a designation by the plan administrator, the purchase price will be the lower of 85% of the closing trading price per share of our common stock on the enrollment date of the applicable offering period or 85% of the closing trading price per share on the applicable purchase date, which will be the last trading day of each purchase period.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Payroll Deduction Changes; Withdrawals; Terminations of Employment</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. A participant may decrease (but not increase) or suspend his or her payroll deductions once during any offering period. In addition, a participant may withdraw his or her participation from the ESPP at any time by submitting written notice to us at least one week prior to the end of the then-current offering period for the offering in which such participant is enrolled. Upon any withdrawal, the participant will receive a refund of the participant&#8217;s account balance in cash, and his or her payroll deductions shall cease. Participation in the ESPP ends automatically upon a participant&#8217;s termination of employment.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transfer Restrictions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A participant may not transfer (other than by will or the laws of descent and distribution) any right granted under the ESPP and, during a participant&#8217;s lifetime, purchase rights granted under the ESPP shall be exercisable only by such participant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adjustments; Changes in Capitalization</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of certain transactions or events affecting our common stock, such as any stock dividend or other distribution, change in control, reorganization, merger, consolidation or other corporate transaction, the ESPP administrator will make equitable adjustments to the ESPP and outstanding rights. In addition, in the event of the foregoing transactions or events or certain significant transactions, including a change in control or change in applicable law or accounting principles, the plan administrator may, in order to prevent the dilution or enlargement of intended benefits under the ESPP or facilitate or give effect to such transactions, events or changes, provide for one or more of the following: (i)&#160;either the replacement of outstanding rights with other rights or property or termination of outstanding rights in exchange for cash, (ii)&#160;the assumption or substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, (iii)&#160;the adjustment in the number and type of shares of stock subject to outstanding rights, (iv)&#160;the use of participants&#8217; accumulated payroll deductions to purchase stock on a new purchase date prior to the next scheduled purchase date and termination of any rights under ongoing offering periods or (v)&#160;the termination of all outstanding rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amendment and Termination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The plan administrator may amend, suspend or terminate the ESPP at any time, subject to stockholder approval to increase the number (or change the type) of securities that may be issued under the ESPP or to change the corporations or classes of corporations whose employees may be granted rights under the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Material U.S. Federal Income Tax Consequences</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a general summary under current law of the principal United States federal income tax consequences related to participation in the ESPP. This summary deals with the general federal income tax principles that apply and is provided only for general information. Some kinds of taxes, such as state, local and foreign income taxes and federal employment taxes, are not discussed. This summary is not intended as tax advice to participants, who should consult their own tax advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Section&#160;423 Component</i>. The Section&#160;423 Component of the ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For federal income tax purposes, a participant in the Section&#160;423 Component of the ESPP generally will not recognize taxable income on the grant of an option under the ESPP, nor will we be entitled to any deduction at that time. Additionally, if applicable holding period requirements are met, the participant should not recognize taxable income at the time of exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">If stock acquired upon exercise of an option acquired under the Section&#160;423 Component of the ESPP is held for a minimum of two&#160;years from the date of grant and one (1)&#160;year from the date of exercise, the participant (or the participant&#8217;s estate) will recognize ordinary income measured as the lesser of (i)&#160;the excess of the fair market value of the shares at the time of such sale or disposition (or </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">198</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">death) over the purchase price or (ii)&#160;the excess of the fair market value of the shares on the date the option was granted over the purchase price. Any additional gain will be treated as long-term capital gain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the holding period requirements are not met, the participant will recognize ordinary income at the time of the disposition equal to the excess of the fair market value of the shares on the date the option is exercised over the purchase price, with any remaining gain or loss being treated as capital gain or capital loss. However, if the holding period requirements are not met and the amount realized at the time of disposition is less than the fair market value of the shares at the time of exercise, the participant will recognize ordinary income to the extent of the excess of the fair market value of such shares on the date the option was exercised over the purchase price for such shares, and a capital loss to the extent the fair market value of such shares on the exercise date exceeds the amount realized upon disposition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We or our subsidiaries or affiliates generally are not entitled to a federal income tax deduction upon either the exercise of an option or upon disposition of the shares acquired pursuant to such exercise, except to the extent that the participant recognizes ordinary income on disposition of the shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Non-Section&#160;423 Component</i>. The Non-Section&#160;423 Component of the ESPP is not intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code. Accordingly, certain tax benefits available to participants in a Section&#160;423 plan are not available under the Non-Section&#160;423 Component of the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For federal income tax purposes, a participant in the Non-Section&#160;423 Component of the ESPP generally will not recognize taxable income on the grant of an option under the ESPP, nor will we be entitled to any deduction at that time. Upon the exercise of an ESPP option, a participant will recognize ordinary income, and we will be entitled to a corresponding deduction, in an amount equal to the difference between the fair market value of the shares of our common stock on the exercise date and the purchase price paid for the shares. A participant&#8217;s basis in shares of our common stock received on exercise, for purposes of determining the participant&#8217;s gain or loss on subsequent disposition of such shares of our common stock, generally, will be the fair market value of the shares of our common stock on the date the participant exercises his or her option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the subsequent sale of the shares acquired upon the exercise of an option acquired under the Non-Section&#160;423 Component of the ESPP, the participant will recognize capital gain or loss (long-term or short-term, depending on how long the shares were held following the date they were purchased by the participant prior to disposing of them).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We or our subsidiaries or affiliates will generally be entitled to a federal income tax deduction upon the exercise of the option to the extent that the participant recognizes ordinary income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">New Plan Benefits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because the number of shares that may be purchased under the ESPP will depend on each employee&#8217;s voluntary election to participate and on the fair market value of our common stock at various future dates, the actual number of shares that may be purchased by any individual cannot be determined in advance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Vote Required for Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The approval of the ESPP Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. Abstentions and broker non-votes, while considered present for the purposes of establishing a quorum, will not count as votes cast at the extraordinary general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Closing is conditioned on the approval of each of the Condition Precedent Proposals. It is important for you to note that in the event that the Condition Precedent Proposals do not receive the requisite vote for approval, APAC will not consummate the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recommendation of the APAC Board</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">THE APAC BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT APAC SHAREHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE ESPP PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">199</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7ca44489_1a4e_4e8a_89c7_f759e2e4560c"></a><a id="Main_THEDIRECTORELECTIONPROPOSAL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SHAREHOLDER PROPOSAL NO.&#160;8&#160;&#8212; THE DIRECTOR ELECTION PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Director Election Proposal&#160;&#8212;</b>&#160;to consider and vote upon a proposal, assuming the Business Combination Proposal, the Domestication Proposal and the Organizational Documents Proposal, to elect seven directors who, upon consummation of the Business Combination, will be the directors of New OmniAb (the &#8220;Director Election Proposal&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s shareholders are also being asked to approve, by ordinary resolution, the Director Election Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Nominees</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The New OmniAb Board following consummation of the Business Combination will consist of seven directors:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(i)</span>six of whom who have been designated by OmniAb and who will initially be Carolyn Bertozzi, Sarah Boyce, Jennifer Cochran, Matthew W. Foehr, John L. Higgins and Sunil Patel, and will thereafter be designated, nominated and elected as contemplated by the Proposed Organizational Documents; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(ii)</span>one of whom has been designated by APAC and who will initially be [&#160;&#9679;&#160;] and will thereafter be designated, nominated and elected as contemplated by the Proposed Organizational Documents, subject to the right of the Sponsor to appoint a director pursuant to the A&amp;R Registration Rights Agreement.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, the APAC Board has nominated each of Carolyn Bertozzi, Ph.D., Sarah Boyce, Jennifer Cochran, Ph.D., Matthew W. Foehr, John L. Higgins, Sunil Patel and [&#160;&#9679;&#160;] to serve as directors of the New OmniAb Board upon the consummation of the Business Combination, with John L. Higgins to serve as the Chairperson of the New OmniAb Board, in each case, in accordance with the terms and subject to the conditions of the Proposed Organizational Documents. If all of the director nominees are elected, Matthew W. Foehr and Jennifer Cochran will be Class&#160;I directors serving until the annual meeting of stockholders to be held in 2023, Sarah Boyce and Sunil Patel will be Class&#160;II directors serving until the annual meeting to be held in 2024 and John L. Higgins, Carolyn Bertozzi, and [&#9679;] will be Class&#160;III directors serving until the annual meeting to be held in 2025 and, in each case, until their successors are elected and qualified or until their earlier death, resignation, retirement or removal for cause.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For more information on the experience of each of these director nominees, please see the section&#160;titled &#8220;<i style="font-style:italic;">Management of New OmniAb after the Business Combination</i>&#8221; of this proxy statement/prospectus/information statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Vote Required for Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The approval of the Director Election Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. Pursuant to the Cayman Constitutional Documents, only the holders of the APAC Class&#160;B Ordinary Shares are entitled to vote on the Director Election Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Director Election Proposal is conditioned on the approval of each of the Condition Precedent Approvals. Therefore, if the Condition Precedent Approvals are not approved, the Director Election Proposal will have no effect, even if approved by holders of the APAC Class&#160;B Ordinary Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Resolution to be Voted Upon</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The full text of the resolution to be passed is as follows:</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">200</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">&#8220;<b style="font-weight:bold;">RESOLVED</b>, as an ordinary resolution, that the seven (7)&#160;persons listed below be elected to serve on New OmniAb Board upon the consummation of the Business Combination to serve staggered terms until the 2023, 2024 and 2025 annual meetings of stockholders, as applicable, or until their respective successors are duly elected and qualified or until their earlier death, resignation, retirement or removal for cause:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of Director</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td></tr><tr><td style="vertical-align:bottom;width:49%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Matthew W. Foehr</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Class I Director and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">John L. Higgins</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Class III Director, Chairman of the New OmniAb Board</p></td></tr><tr><td style="vertical-align:bottom;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Carolyn Bertozzi, Ph.D.</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Class III Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Sarah Boyce</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Class II Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jennifer Cochran, Ph.D.</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Class I Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Sunil Patel</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Class II Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">[ &#9679; ]</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Class III Director</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recommendation of the APAC Board</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE APAC BOARD UNANIMOUSLY RECOMMENDS THAT APAC SHAREHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE DIRECTOR ELECTION PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The existence of financial and personal interests of one or more of APAC&#8217;s directors may result in a conflict of interest on the part of such director(s)&#160;between what he, she or they may believe is in the best interests of APAC and its shareholders and what he, she or they may believe is best for himself, herself or themselves in determining to recommend that shareholders vote for the proposals. In addition, APAC&#8217;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled <i style="font-style:italic;">&#8220;Shareholder Proposal No.&#160;1&#8212;The Business Combination Proposal&#8212;Interests of APAC&#8217;s Directors and Executive Officers in the Business Combination&#8221;</i> for a further discussion of these considerations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">201</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0bed6084_519b_4ea2_8390_50a1fb5befe3"></a><a id="MAin_THEADJOURNMENTPROPOSAL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SHAREHOLDER PROPOSAL NO.&#160;9&#160;&#8212;</b><b style="color:#231f20;font-weight:bold;"> THE </b><b style="font-weight:bold;">ADJOURNMENT PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Adjournment Proposal allows the APAC Board to submit a proposal to approve, by ordinary resolution, the adjournment of the extraordinary general meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event, based on the tabulated votes, there are not sufficient votes at the time of the extraordinary general meeting to constitute a quorum or to approve any of the proposals presented at the extraordinary general meeting. The purpose of the Adjournment Proposal is to permit further solicitation of proxies and votes that would increase the likelihood of obtaining a favorable vote on the proposals presented at the extraordinary general meeting. See &#8220;<i style="font-style:italic;">Proposal&#8201;No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;-&#8201;Interests of APAC&#8217;s Directors and Executive Officers in the Business Combination.</i>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consequences if the Adjournment Proposal is Not Approved</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Adjournment Proposal is presented to the extraordinary general meeting and is not approved by the shareholders, the APAC Board may not be able to adjourn the extraordinary general meeting to a later date in the event that, based on the tabulated votes, there are not sufficient votes at the time of the extraordinary general meeting to constitute a quorum or to approve any of the proposals presented at the extraordinary general meeting. In such events, the Business Combination would not be completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Vote Required for Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The approval of the Adjournment Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. Abstentions and broker non-votes, while considered present for the purposes of establishing a quorum, will not count as votes cast at the extraordinary general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Adjournment Proposal is not conditioned upon any other proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Resolution to be Voted Upon</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The full text of the resolution to be passed is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">RESOLVED,</b> as an ordinary resolution, that the adjournment of the extraordinary general meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes to constitute a quorum or to approve one or more proposals at the extraordinary general meeting be approved.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recommendation of the APAC Board</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE APAC BOARD UNANIMOUSLY RECOMMENDS THAT APAC SHAREHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE ADJOURNMENT PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The existence of financial and personal interests of one or more of APAC&#8217;s directors may result in a conflict of interest on the part of such director(s)&#160;between what he, she or they may believe is in the best interests of APAC and its shareholders and what he, she or they may believe is best for himself, herself or themselves in determining to recommend that shareholders vote for the proposals. In addition, APAC&#8217;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#8201;&#8212;&#8201;Interests of APAC&#8217;s Directors and Executive Officers in the Business Combination</i>&#8221; for a further discussion of these considerations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">202</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ebfbddb0_095b_4dd7_acfa_67b368afcec8"></a><a id="Main_MATERIALUSFEDERALINCOMETAXCO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO APAC SHAREHOLDERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the material U.S. federal income tax consequences to beneficial owners (&#8220;Holders&#8221;) of APAC Class&#160;A Ordinary Shares and APAC Public Warrants (collectively, &#8220;<span style="font-style:italic;font-weight:bold;">APAC Public Securities</span>&#8221;) immediately prior to the Business Combination with respect to the (i)&#160;Domestication, (ii)&#160;the exercise of redemption rights, and (iii)&#160;the ownership and disposition of New OmniAb Common Stock and New OmniAb Warrants (collectively, the &#8220;<span style="font-style:italic;font-weight:bold;">New OmniAb Securities</span>&#8221;) following the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This discussion applies only to APAC Public Securities that are held as &#8220;capital assets&#8221; within the meaning of Section&#160;1221 of the Code for U.S. federal income tax purposes (generally, property held for investment). This discussion is based on the provisions of the Code, U.S. Treasury Regulations, administrative rules, and judicial decisions, all as in effect on the date hereof, and all of which are subject to change or differing interpretations, possibly with retroactive effect. Any such change or differing interpretation could affect the accuracy of the statements set forth herein. APAC has not sought, and will not seek, any rulings from the IRS with respect to the statements made and the positions or conclusions described in this summary. Such statements, positions and conclusions are not free from doubt, and there can be no assurance that your tax advisor, the IRS or a court will agree with such statements, positions and conclusions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following discussion does not purport to be a complete analysis of all potential tax effects resulting from the completion of the Business Combination and does not address the tax treatment of any other transactions occurring in connection with the Business Combination. Furthermore, it does not address all aspects of U.S. federal income taxation that may be relevant to particular Holders in light of their personal circumstances. In addition, this summary does not address the Medicare tax on certain investment income, U.S. federal estate or gift tax laws, any U.S. state, local, or non-U.S. tax laws, any tax treaties or tax considerations applicable to investors that may be subject to special treatment under the U.S. federal income tax laws, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">banks, insurance companies, or other financial institutions&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-exempt or governmental organizations&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;qualified foreign pension funds&#8221; as defined in Section&#160;897(l)(2)&#160;of the Code (or any entities all of the interests of which are held by a qualified foreign pension fund)&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">dealers in securities or foreign currencies&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons whose functional currency is not the U.S. dollar&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">traders in securities that use the mark-to-market method of accounting for U.S. federal income tax purposes&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; and corporations that accumulate earnings to avoid U.S. federal income tax&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons deemed to sell APAC Public Securities under the constructive sale provisions of the Code&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons that acquired APAC Public Securities through the exercise of employee stock options or otherwise as compensation or through a tax-qualified retirement plan&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons that hold APAC Public Securities as part of a straddle, appreciated financial position, synthetic security, hedge, conversion transaction, or other integrated investment or risk reduction transaction&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">certain former citizens or long-term residents of the United States&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. Holders (as defined below) whose functional currency is not the U.S. dollar;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">except as specifically provided below, persons that actually or constructively hold 5% or more (by vote or value) of any class of shares of APAC or New OmniAb&#894;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">203</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the holders of APAC founder shares, and APAC&#8217;s or New OmniAb&#8217;s Sponsor, officers or directors; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">S-corporations, partnerships or other pass-through entities for U.S. federal income tax purposes or holders of interests therein.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a partnership (including an entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds APAC Public Securities (or New OmniAb Securities), the tax treatment of a partner in such partnership generally will depend upon the status of the partner, upon the activities of the partnership and upon certain determinations made at the partner level. Accordingly, partners in partnerships (including entities or arrangements treated as partnerships for U.S. federal income tax purposes) holding APAC Public Securities (or New OmniAb Securities) should consult with, and rely solely upon, their tax advisors regarding the U.S. federal income tax consequences to them relating to the matters discussed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INVESTORS SHOULD CONSULT WITH, AND RELY SOLELY UPON, THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS (INCLUDING ANY POTENTIAL FUTURE CHANGES THERETO) TO THEIR PARTICULAR SITUATIONS, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY U.S. STATE, LOCAL, NON-U.S. OR OTHER TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">U.S. Federal Income Taxation of U.S. Holders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This section applies to you if you are a &#8220;<i style="font-style:italic;">U.S. Holder</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of this discussion, a &#8220;U.S. Holder&#8221; is a Holder that, for U.S. federal income tax purposes, is:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an individual who is a citizen or resident of the United States&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of Columbia&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an estate the income of which is subject to U.S. federal income tax regardless of its source&#894; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a trust (i)&#160;the administration of which is subject to the primary supervision of a U.S. court and which has one or more &#8220;United States persons&#8221; (within the meaning of Section&#160;7701(a)(30) of the Code) who have the authority to control all substantial decisions of the trust or (ii)&#160;that has made a valid election under applicable U.S. Treasury Regulations to be treated as a United States person.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ALL HOLDERS SHOULD CONSULT WITH, AND RELY SOLELY UPON, THEIR TAX ADVISORS REGARDING THE TAX CONSEQUENCES OF THE DOMESTICATION TO THEM, INCLUDING THE EFFECTS OF U.S. FEDERAL, STATE, LOCAL, NON-U.S. AND OTHER TAX LAWS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Domestication</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The discussion under this heading &#8220;&#8212;<i style="font-style:italic;">U.S. Federal Income Taxation of U.S. Holders&#8212;The Domestication</i>&#8221; constitutes the opinion of Weil, Gotshal&#160;&amp; Manges LLP, U.S. tax counsel, insofar as it discusses the material U.S. federal income tax consequences applicable to U.S. Holders of APAC Public Securities as a result of the Domestication, based on, and subject to, customary assumptions, qualifications, and, and the assumptions, qualifications, and limitations herein. The U.S. federal income tax consequences of the Domestication will depend primarily upon whether the Domestication qualifies as a &#8220;reorganization&#8221; within the meaning of Section&#160;368 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Section&#160;368(a)(1)(F)&#160;of the Code, a reorganization is a &#8220;mere change in identity, form, or place of organization of one corporation, however effected&#8221; (such a reorganization, an &#8220;F Reorganization&#8221;). Pursuant to the Domestication, APAC will change its jurisdiction of incorporation and its name (to New OmniAb). The Domestication will qualify as an F Reorganization.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">204</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under generally applicable tax rules, if the Domestication qualifies as an F Reorganization, for U.S. federal income tax purposes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">APAC should be treated (i)&#160;as having transferred all of its assets and liabilities to New OmniAb in exchange for all of the outstanding common stock of New OmniAb, and then (ii)&#160;as having distributed the common stock to the shareholders APAC in liquidation of APAC, and the taxable&#160;year of APAC should end on the date of the Domestication&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject to certain rules&#160;discussed under &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">&#8212;U.S. Federal Income Taxation of U.S. Holders&#8212;Effects of Section&#160;367(b)</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">&#8212;U.S. Federal Income Taxation of U.S. Holders&#8212;Passive Foreign Investment Company Rules</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; below, a U.S. Holder that exchanges its APAC Public Securities for New OmniAb Securities in the Domestication should not recognize any gain or loss on such exchange&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject to certain rules&#160;discussed under &#8220;&#8212;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">U.S. Federal Income Taxation of U.S. Holders</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Passive Foreign Investment Company Rules</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; below, the tax basis of a New OmniAb Security received by a U.S. Holder in the Domestication should be equal to the U.S. Holder&#8217;s adjusted tax basis in the APAC Public Security surrendered in exchange therefor, increased by any amount included in the income of such U.S. Holder pursuant to Section&#160;367(b)&#160;of the Code&#894; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the holding period for a New OmniAb Security as received by a U.S. Holder should include such U.S. Holder&#8217;s holding period for the APAC Public Security surrendered in exchange therefor.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Domestication fails to qualify as an F Reorganization, subject to the PFIC rules&#160;discussed below, a U.S. Holder generally would recognize gain or loss with respect to each of its APAC Public Securities in an amount equal to the difference, if any, between the fair market value of the corresponding New OmniAb Securities received in the Domestication and the U.S. Holder&#8217;s adjusted tax basis in the APAC Public Securities surrendered in exchange therefor. In such event, such U.S. Holder&#8217;s tax basis in the New OmniAb Securities received in the Domestication would be equal to the fair market value of that New OmniAb Securities on the date of the Domestication, and such U.S. Holder&#8217;s holding period for the New OmniAb Securities received in the Domestication would begin on the day following the date of the Domestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because the Domestication will occur prior to the redemption of New OmniAb Common Stock described in the subsection of this proxy statement/prospectus/information statement entitled &#8220;<i style="font-style:italic;">Extraordinary General Meeting of APAC&#8212;Redemption Rights</i>,&#8221; U.S. Holders exercising their redemption rights with respect to their New OmniAb Common Stock will be subject to the potential tax consequences of the Domestication. All U.S. Holders considering exercising their redemption rights with respect to their New OmniAb Common Stock should consult with, and rely solely upon, their tax advisors with respect to the potential tax consequences to them of the Domestication and exercise of redemption rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE RULES&#160;GOVERNING THE U.S. FEDERAL INCOME TAX TREATMENT OF THE DOMESTICATION ARE COMPLEX. U.S. HOLDERS OF APAC PUBLIC SECURITIES SHOULD CONSULT WITH, AND RELY SOLELY UPON, THEIR TAX ADVISORS REGARDING THE POTENTIAL TAX CONSEQUENCES TO THEM OF THE DOMESTICATION, INCLUDING IF IT WERE TO FAIL TO QUALIFY AS AN F REORGANIZATION.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Effects of Section&#160;367(b)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;367(b)&#160;of the Code applies to certain non-recognition transactions involving foreign corporations, including the domestication of a foreign corporation in an F Reorganization. When it applies, Section&#160;367(b)&#160;imposes U.S. federal income tax on certain U.S. persons in connection with transactions that otherwise would generally be tax-free. Section&#160;367(b)&#160;may apply with respect to U.S. Holders on the date of the Domestication. Because the Domestication will occur prior to the redemption of U.S. Holders that exercise redemption rights with respect to their New OmniAb Common Stock, U.S. Holders exercising such redemption rights will be subject to the potential tax consequences of Section&#160;367(b)&#160;of the Code as a result of the Domestication.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">A.</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">U.S. Holders that Own Less than 10&#160;Percent (by Vote and Value) of APAC</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">A U.S. Holder who, on the date of the Domestication, beneficially owns (actually or constructively, including by taking into account a U.S. Holder&#8217;s ownership of APAC Public Warrants) APAC Class&#160;A Ordinary Shares with a fair market value of $50,000 or more but with less than 10% of the total combined voting power of all classes of APAC Class&#160;A Ordinary Shares entitled to vote and less than 10% of the total value of all classes of APAC Class&#160;A Ordinary Shares, will recognize gain (but not loss) with respect to the </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">205</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Domestication or, in the alternative, may elect to recognize the &#8220;all earnings and profits&#8221; amount attributable to such U.S. Holder, as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless a U.S. Holder makes the &#8220;all earnings and profits&#8221; election described below, such U.S. Holder generally must recognize gain (but not loss) with respect to its New OmniAb Common Stock and New OmniAb Warrants received in the Domestication in an amount equal to the excess of the fair market value of such New OmniAb Common Stock and New OmniAb Warrants over the U.S. Holder&#8217;s adjusted tax basis in the APAC Class&#160;A Ordinary Shares and APAC Public Warrants surrendered in exchange therefor. Subject to the PFIC rules&#160;discussed below, such gain would be capital gain, and would be long-term capital gain if the U.S. Holder held the APAC Public Securities for longer than one&#160;year (subject to the suspension of the applicable holding period for the reasons described in &#8220;&#8212;<i style="font-style:italic;">U.S. Federal Income Taxation of U.S. Holders&#8212;Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of New OmniAb Securities</i>&#8221; below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In lieu of recognizing any gain as described in the preceding paragraph, a U.S. Holder may elect to include in income the &#8220;all earnings and profits amount&#8221; attributable to its APAC Public Securities under Section&#160;367(b)&#160;of the Code. There are, however, strict conditions for making this election. The election must comply with applicable U.S. Treasury Regulations and generally must include, among other things, (i)&#160;a statement that the Domestication is a Section&#160;367(b)&#160;exchange (within the meaning of the applicable U.S. Treasury Regulations), (ii)&#160;a complete description of the Domestication, (iii)&#160;a description of any stock, securities or other consideration transferred or received in the Domestication, (iv)&#160;a statement describing the amounts required to be taken into account for U.S. federal income tax purposes, (v)&#160;a statement that the U.S. Holder is making the election that includes (A)&#160;a copy of the information that the U.S. Holder received from New OmniAb establishing and substantiating the U.S. Holder&#8217;s &#8220;all earnings and profits amount&#8221; with respect to the U.S. Holder&#8217;s APAC Public Securities and (B)&#160;a representation that the U.S. Holder has notified New OmniAb that the U.S. Holder is making the election, and (vi)&#160;certain other information required to be furnished with the U.S. Holder&#8217;s U.S. federal income tax return or otherwise furnished pursuant to the Code or the U.S. Treasury Regulations. APAC does not expect to have significant cumulative earnings and profits, if any, on the date of the Domestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The election must be attached by the electing U.S. Holder to such U.S. Holder&#8217;s timely filed U.S. federal income tax return for the&#160;year of the Domestication, and the U.S. Holder must send notice that it is making the election to New OmniAb no later than the date such tax return is filed. In connection with this election, we intend to provide each U.S. Holder eligible to make such an election with information regarding APAC&#8217;s earnings and profits upon written request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EACH U.S. HOLDER SHOULD CONSULT WITH, AND RELY SOLELY UPON, ITS TAX ADVISOR REGARDING THE CONSEQUENCES TO IT OF MAKING THE ELECTION DESCRIBED HEREIN AND THE APPROPRIATE FILING REQUIREMENTS WITH RESPECT TO SUCH ELECTION.</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">B.</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">U.S. Holders that Own APAC Public Securities with a Fair Market Value of Less than $50,000</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A U.S. Holder who, on the date of the Domestication, beneficially owns (actually or constructively) APAC Public Securities with a fair market value of less than $50,000 generally should not be required to recognize any gain or loss under Section&#160;367(b)&#160;of the Code in connection with the Domestication or to include any part of the &#8220;all earnings and profits amount&#8221; in income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ALL U.S. HOLDERS SHOULD CONSULT WITH, AND RELY SOLELY UPON, THEIR TAX ADVISORS WITH RESPECT TO THE EFFECT OF SECTION&#160;367(b)&#160;OF THE CODE TO THEIR PARTICULAR CIRCUMSTANCES.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Passive Foreign Investment Company Rules</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the discussion under &#8220;&#8212;<i style="font-style:italic;">U.S. Federal Income Taxation of U.S. Holders&#8212;Effects of Section&#160;367(b)</i>,&#8221; the Domestication may also be a taxable event for U.S. Holders under the &#8220;passive foreign investment company&#8221; (or &#8220;<span style="font-style:italic;font-weight:bold;">PFIC</span>&#8221;) provisions of the Code to the extent APAC is treated as a PFIC.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">A.</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">PFIC Status of APAC</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In general, a foreign (i.e., non-U.S.) corporation will be treated as a PFIC with respect to a U.S. Holder in any taxable&#160;year in which, after applying certain look-through rules, either: (i)&#160;at least 75% of its gross income for such taxable&#160;year consists of passive income (e.g., dividends, interest, rents (other than rents derived from the active conduct of a trade or business), and gains from the </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">206</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">disposition of passive assets) or (ii)&#160;the average&#160;percentage (ordinarily averaged quarterly over the&#160;year) by value of its assets during such taxable&#160;year that produce or are held for the production of passive income is at least 50%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because APAC is a blank check company, with no current active business, APAC believes that it is likely to may exceed the thresholds of the PFIC asset or income test for our current taxable&#160;year. However, pursuant to a start-up exception, a corporation will not be a PFIC for the first taxable&#160;year the corporation has gross income (the &#8220;start-up&#160;year&#8221;), if (1)&#160;no predecessor of the corporation was a PFIC; (2)&#160;the corporation satisfies the IRS that it will not be a PFIC for either of the two taxable&#160;years following the start-up&#160;year; and (3)&#160;the corporation is not in fact a PFIC for either of those&#160;years. While APAC believes that it may be eligible for the start-up exception, the application of such exception is subject to uncertainty and there can be no assurance with respect to APAC&#8217;s status as a PFIC for the 2021 taxable&#160;year or the 2022 taxable&#160;year (APAC&#8217;s current taxable&#160;year that is expected to end on the date of the Domestication).</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">B.</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Effects of PFIC Rules&#160;on the Domestication</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;1291(f)&#160;of the Code requires that, to the extent provided in U.S. Treasury Regulations, a U.S. Holder that disposes of stock of a PFIC recognizes gain notwithstanding any other provision of the Code. No final U.S. Treasury Regulations are currently in effect under Section&#160;1291(f)&#160;of the Code. However, proposed U.S. Treasury Regulations under Section&#160;1291(f)&#160;of the Code have been promulgated, with a retroactive effective date once they become final. If finalized in their proposed form, those proposed U.S. Treasury Regulations may require taxable gain recognition by a U.S. Holder with respect to its exchange of APAC Public Securities for New OmniAb Securities in the Domestication if APAC were classified as a PFIC at any time during such U.S. Holder&#8217;s holding period for such APAC Public Securities. The U.S. tax on any such recognized gain would be imposed based on a complex set of computational rules. However, as discussed in more detail below, a U.S. Holder may be able to avoid the PFIC gain and other tax consequences described below with respect to its APAC Public Securities if such U.S. Holder either (i)&#160;is eligible to and makes a timely and valid QEF Election (as defined and described below) in the first taxable&#160;year in which such U.S. Holder held (or was deemed to hold) APAC Public Securities and in which APAC was classified as a PFIC or (ii)&#160;makes a Mark-to-Market Election (as defined and described below) with respect to its APAC Public Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Under these rules:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. Holder&#8217;s gain would be allocated ratably over the U.S. Holder&#8217;s aggregate holding period for such U.S. Holder&#8217;s APAC Class&#160;A Ordinary Shares&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amount of gain allocated to the U.S. Holder&#8217;s taxable&#160;year in which the U.S. Holder realized the gain, or to the portion of the U.S. Holder&#8217;s holding period prior to the first day of APAC&#8217;s taxable&#160;year in which APAC was a PFIC, would be taxed as ordinary income&#894; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amount of gain allocated to each of the other taxable&#160;years (or portions thereof) of the U.S. Holder would be subject to tax at the highest rate of tax in effect for the U.S. Holder for that&#160;year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other taxable&#160;year (or portion thereof).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The proposed U.S. Treasury Regulations provide coordinating rules&#160;with Section&#160;367(b)&#160;of the Code, whereby, if the gain recognition rule&#160;of the proposed U.S. Treasury Regulations under Section&#160;1291(f)&#160;of the Code applies to a disposition of PFIC stock that results from a transfer with respect to which Section&#160;367(b)&#160;of the Code requires the shareholder to recognize gain or include an amount in income as discussed under &#8220;<i style="font-style:italic;">&#8212;Effects of Section&#160;367(b)</i>,&#8221; the gain realized on the transfer is taxable under the PFIC rules&#160;discussed above, and the excess, if any, of the amount to be included in income under Section&#160;367(b)&#160;of the Code over the gain realized under Section&#160;1291 of the Code is taxable as provided under Section&#160;367(b)&#160;of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is not possible to predict whether, in what form, and with what effective date the proposed U.S. Treasury Regulations under Section&#160;1291(f)&#160;of the Code will become final. Therefore, U.S. Holders of APAC Public Securities that have not made a timely QEF Election or a Mark-to-Market Election (both as defined and described below) may, pursuant to the proposed U.S. Treasury Regulations, be subject to taxation on the Domestication to the extent their APAC Class&#160;A Ordinary Shares or APAC Public Warrants have a fair market value in excess of their tax basis.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">207</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">C.</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">QEF Election with Respect to APAC Public Securities</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The impact of the PFIC rules&#160;on a U.S. Holder with respect to its APAC Class&#160;A Ordinary Shares will depend on whether such U.S. Holder is eligible to and makes a timely and valid election to treat APAC as a &#8220;qualified electing fund&#8221; under Section&#160;1295 of the Code (which we refer to as a &#8220;<span style="font-style:italic;font-weight:bold;">QEF Election</span>&#8221;) for the first taxable&#160;year in which such U.S. Holder held (or was deemed to hold) APAC Class&#160;A Ordinary Shares and APAC is classified as a PFIC. Generally, a QEF Election should be made on or before the due date for filing such U.S. Holder&#8217;s U.S. federal income tax return for such taxable&#160;year. A QEF Election is made by an individual U.S. Holder (and, once made, can be revoked only with the consent of the IRS) and generally requires such U.S. Holder to include annually in gross income its pro rata share of the ordinary earnings (as ordinary income) and net capital gains (as long-term capital gain), if any, of APAC, regardless of whether APAC makes distributions to such U.S. Holder. However, in order to comply with the QEF Election requirements, a U.S. Holder must receive a PFIC annual information statement from APAC. Upon written request, APAC will endeavor to provide to a U.S. Holder such information as the IRS may require, including a PFIC annual information statement, in order to enable the U.S. Holder to make and maintain a QEF Election. There is no assurance, however, that APAC will timely provide such required information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The application of the PFIC rules&#160;to APAC Public Warrants is uncertain. However, a U.S. Holder may not make a QEF Election with respect to its APAC Public Warrants. As a result, if a U.S. Holder sells or otherwise disposes of APAC Public Warrants (other than upon exercise of such warrants for cash) and APAC was a PFIC at any time during the period the U.S. Holder held the APAC Public Warrants, any gain recognized may be subject to the special tax and interest charge rules&#160;treating the gain as an excess distribution. If a U.S. Holder that exercises such warrants properly makes a QEF Election with respect to the New OmniAb Common Stock (or has previously made a QEF Election with respect to the APAC Class&#160;A Ordinary Shares), the QEF Election will apply to the newly acquired New OmniAb Common Stock. Notwithstanding such QEF Election, the adverse tax consequences relating to PFIC shares discussed above, adjusted to take into account the current income inclusions resulting from the QEF Election, will continue to apply with respect to such New OmniAb Common Stock (which generally will be deemed to have a holding period for purposes of the PFIC rules&#160;that includes the period the U.S. Holder held the warrants), unless the U.S. Holder makes a purging election under the PFIC rules. Under the purging election, the U.S. Holder will be deemed to have sold such shares at their fair market value and any gain recognized on such deemed sale will be treated as an excess distribution, as described above. As a result of the purging election, the U.S. Holder will have a new basis and holding period in the New OmniAb Common Stock acquired upon the exercise of the warrants for purposes of the PFIC rules. U.S. Holders are urged to consult their tax advisors as to the application of the rules&#160;governing purging elections to their particular circumstances (including a potential separate &#8220;deemed dividend&#8221; purging election that may be available if we are a controlled foreign corporation).</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">D.</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Mark-to-Market Election with Respect to APAC Public Securities</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The impact of the PFIC rules&#160;on a U.S. Holder with respect to its APAC Class&#160;A Ordinary Shares may also depend on whether such U.S. Holder is eligible to and makes a timely and valid &#8220;Mark-to-Market Election&#8221; under Section&#160;1296 of the Code with respect to its APAC Class&#160;A Ordinary Shares. No assurance can be given that the APAC Class&#160;A Ordinary Shares are considered to be &#8220;marketable stock&#8221; (which generally would include stock that is regularly traded on a national securities exchange that is registered with the Securities and Exchange Commission, including the New York Stock Exchange (on which APAC Class&#160;A Ordinary Shares have been listed)) for purposes of the Mark-to-Market Election. If such an election is available and has been made by a U.S. Holder, such U.S. Holder generally will not be subject to the PFIC rules&#160;described above. However, if the Mark-to-Market Election is made by a U.S. Holder after the first taxable&#160;year of the U.S. Holder in which the U.S. Holder holds (or is deemed to hold) APAC Class&#160;A Ordinary Shares and in which APAC was classified as a PFIC, then the PFIC rules&#160;will continue to apply to certain dispositions of, distributions on and other amounts taxable with respect to APAC Class&#160;A Ordinary Shares. Currently, a Mark-to-Market Election may not be made with respect to APAC Public Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE PFIC RULES&#160;(INCLUDING THE RULES&#160;WITH RESPECT TO THE QEF ELECTION AND THE MARK-TO-MARKET ELECTION) ARE VERY COMPLEX, ARE AFFECTED BY VARIOUS FACTORS IN ADDITION TO THOSE DESCRIBED ABOVE, AND THEIR APPLICATION IS UNCERTAIN. U.S. HOLDERS SHOULD CONSULT WITH, AND RELY SOLELY UPON, THEIR TAX ADVISORS TO DETERMINE THE APPLICATION OF THE PFIC RULES&#160;TO THEM IN THEIR PARTICULAR CIRCUMSTANCES AND ANY RESULTING TAX CONSEQUENCES.</b></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">208</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Redemption of New OmniAb Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that a U.S. Holder&#8217;s New OmniAb Common Stock is redeemed pursuant to the redemption provisions described in the subsection of this proxy statement/prospectus/information statement entitled &#8220;<i style="font-style:italic;">Extraordinary General Meeting of APAC&#8212;Redemption Rights</i>&#8221; the treatment of the transaction for U.S. federal income tax purposes will depend on whether the redemption qualifies as sale of the New OmniAb Common Stock under Section&#160;302 of the Code. If the redemption qualifies as a sale of New OmniAb Common Stock, the U.S. Holder will be treated as described under &#8220;&#8212;<i style="font-style:italic;">U.S. Federal Income Taxation of U.S. Holders&#8212;Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of New OmniAb Securities</i>&#8221; below. If the redemption does not qualify as a sale of New OmniAb Common Stock, the U.S. Holder will be treated as receiving a distribution from New OmniAb with the tax consequences described below under &#8220;&#8212;<i style="font-style:italic;">U.S. Federal Income Taxation of U.S. Holders&#8212;Taxation of Distributions with Respect to New OmniAb Common Stock</i>.&#8221; Whether a redemption qualifies for sale treatment will depend largely on the total number of shares of our stock treated as held by the U.S. Holder relative to all of our shares outstanding both before and after the redemption. The redemption of New OmniAb Common Stock generally will be treated as a sale of New OmniAb Common Stock (rather than as a distribution from APAC) if the redemption (i)&#160;is &#8220;substantially disproportionate&#8221; with respect to the U.S. Holder, (ii)&#160;results in a &#8220;complete termination&#8221; of the U.S. Holder&#8217;s interest in APAC or (iii)&#160;is &#8220;not essentially equivalent to a dividend&#8221; with respect to the U.S. Holder. These tests are explained more fully below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In determining whether any of the foregoing tests is satisfied, a U.S. Holder takes into account not only stock actually owned by the U.S. Holder, but also shares of our stock that are constructively owned by it. A U.S. Holder may constructively own, in addition to stock owned directly, stock owned by certain related individuals and entities in which the U.S. Holder has an interest or that have an interest in such U.S. Holder, as well as any stock the U.S. Holder has a right to acquire by exercise of an option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to meet the substantially disproportionate test, the&#160;percentage of APAC&#8217;s outstanding voting stock actually and constructively owned by the U.S. Holder immediately following the redemption of our New OmniAb Common Stock must, among other requirements, be less than 80% of the&#160;percentage of APAC outstanding voting stock actually and constructively owned by the U.S. Holder immediately before the redemption. Prior to the Business Combination, the New OmniAb Common Stock may not be treated as voting stock for this purpose and, consequently, this substantially disproportionate test may not be applicable. There will be a complete termination of a U.S. Holder&#8217;s interest if either (i)&#160;all of the shares of our stock actually and constructively owned by the U.S. Holder are redeemed or (ii)&#160;all of the shares of our stock actually owned by the U.S. Holder are redeemed, the U.S. Holder is eligible to waive (and effectively waives in accordance with specific rules) the attribution of stock owned by certain family members, and the U.S. Holder does not constructively own any other shares of our stock. The redemption of New OmniAb Common Stock will not be essentially equivalent to a dividend if a U.S. Holder&#8217;s redemption results in a &#8220;meaningful reduction&#8221; of the U.S. Holder&#8217;s proportionate interest in APAC. Whether the redemption will result in a meaningful reduction in a U.S. Holder&#8217;s proportionate interest in APAC will depend on the particular facts and circumstances. However, the IRS has indicated in a published ruling that even a small reduction in the proportionate interest of a small minority stockholder in a publicly held corporation who exercises no control over corporate affairs may constitute such a &#8220;meaningful reduction.&#8221; A U.S. Holder should consult with, and rely solely upon, its own tax advisors as to the tax consequences of a redemption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If none of the foregoing tests is satisfied, the redemption will be treated as a distribution from APAC and the tax considerations will be as described under &#8220;&#8212;<i style="font-style:italic;">U.S. Federal Income Taxation of U.S. Holders&#8212;Taxation of Distributions with Respect to New OmniAb Common Stock</i>&#8221; below. After the application of those rules, any remaining tax basis of the U.S. Holder in the redeemed New OmniAb Common Stock will be added to the U.S. Holder&#8217;s adjusted tax basis in its remaining stock, or, if it has none, to the U.S. Holder&#8217;s adjusted tax basis in possibly its other shares of our stock constructively owned by it.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">U.S. Holders who actually or constructively own five&#160;percent (or, if the New OmniAb Common Stock is not then publicly traded, one&#160;percent) or more of our stock (by vote or value) may be subject to special reporting requirements with respect to a redemption of the New OmniAb Common Stock, and such U.S. Holders should consult with, and rely solely upon, their own tax advisors with respect to their reporting requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because the Domestication will occur prior to the redemption of U.S. Holders that exercise redemption rights with respect to their New OmniAb Common Stock, U.S. Holders exercising such redemption rights will be subject to the potential tax consequences of the Domestication. All U.S. Holders considering exercising redemption rights with respect to their New OmniAb Common Stock should consult with, and rely solely upon, their tax advisors with respect to the potential tax consequences to them of the Domestication and exercise of redemption rights.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">209</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Taxation of Distributions with Respect to New OmniAb Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If APAC pays distributions of cash or other property to U.S. Holders of shares of New OmniAb Common Stock, such distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from APAC&#8217;s current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of current and accumulated earnings and profits will constitute a non-taxable return of capital to the extent of a U.S. Holder&#8217;s adjusted tax basis in its New OmniAb Common Stock, that will be applied against and reduce (but not below zero) the U.S. Holder&#8217;s adjusted tax basis in its New OmniAb Common Stock. Any remaining excess will be treated as gain realized on the sale or other disposition of New OmniAb Common Stock and will be treated as described under &#8220;&#8212;<i style="font-style:italic;">U.S. Federal Income Taxation of U.S. Holders&#8212;Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of New OmniAb Securities</i>&#8221; below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Distributions treated as dividends that APAC pays to a U.S. Holder that is treated as a corporation for U.S. federal income tax purposes generally will qualify for the dividends received deduction if the requisite holding period is satisfied. With certain exceptions (including, but not limited to, dividends treated as investment income for purposes of investment interest deduction limitations), and provided certain holding period requirements are met, dividends APAC pays to a non-corporate U.S. Holder generally will constitute &#8220;qualified dividends&#8221; that will be subject to U.S. federal income tax at the maximum tax rate accorded to long-term capital gains. If the holding period requirements are not satisfied, a corporate U.S. Holder may not be able to qualify for the dividends received deduction and would have taxable income equal to the entire dividend amount, and a non-corporate U.S. Holder may be subject to tax on such dividend at regular ordinary income tax rates instead of the preferential rate that applies to qualified dividend income. It is unclear whether the redemption rights that applied with respect to the APAC Class&#160;A Ordinary Shares prior to the Domestication may prevent a U.S. Holder of New OmniAb Common Stock from taking the holding period of its APAC Class&#160;A Ordinary Shares into account when determining whether it has satisfied the applicable holding period requirements with respect to the dividends received deduction or the preferential tax rate on qualified dividend income, as the case may be, with respect to such U.S. Holder&#8217;s New OmniAb Common Stock held after the Domestication. U.S. Holders should consult with, and rely solely upon, their tax advisors regarding the availability of the dividends received deduction or the lower preferential rate for qualified dividend income, as the case may be, for any dividends paid with respect to New OmniAb Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of New OmniAb Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon a sale or other taxable disposition of New OmniAb Securities (which, in general, would include a redemption of New OmniAb Common Stock), a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the amount realized and the U.S. Holder&#8217;s adjusted tax basis in its New OmniAb Securities. Any such capital gain or loss generally will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the New OmniAb Securities so disposed of exceeds one&#160;year. It is unclear whether the redemption rights that applied with respect to the APAC Public Securities prior to the Domestication may prevent a U.S. Holder of APAC Public Securities from taking the holding period of its APAC Public Securities into account when determining whether it has satisfied the applicable holding period with respect to its New OmniAb Securities held after the Domestication for this purpose. If the one-year holding period requirement is not satisfied, any gain on a sale or other taxable disposition of the New OmniAb Securities would be subject to short-term capital gain treatment and would be taxed at regular ordinary income tax rates. Long-term capital gains recognized by non-corporate U.S. Holders will be eligible to be taxed at reduced rates. The deductibility of capital losses is subject to limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Generally, the amount of gain or loss recognized by a U.S. Holder is an amount equal to the difference between (i)&#160;the sum of the amount of cash and the fair market value of any property received in such disposition and (ii)&#160;the U.S. Holder&#8217;s adjusted tax basis in its New OmniAb Securities so disposed of. A U.S. Holder&#8217;s adjusted tax basis in its New OmniAb Securities generally will equal the U.S. Holder&#8217;s acquisition cost of the APAC Public Securities exchanged therefore (see the tax basis discussion above under the caption &#8220;&#8212;<i style="font-style:italic;">U.S. Federal Income Taxation of U.S. Holders&#8212;The Domestication</i>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Exercise, Lapse or Redemption of New OmniAb Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Except as discussed below with respect to the cashless exercise of a warrant, a U.S. Holder will generally not recognize gain or loss upon the exercise of a New OmniAb Warrant for cash. New OmniAb Common Stock acquired pursuant to the exercise of a New OmniAb Warrant for cash will generally have a tax basis equal to the U.S. Holder&#8217;s tax basis in the warrant, increased by the amount paid to exercise the warrant. It is unclear whether a U.S. Holder&#8217;s holding period for the New OmniAb Common Stock will commence on the date of exercise of the warrant or the day following the date of exercise of the warrant; in either case, the holding period will not include the U.S. Holder&#8217;s holding period for the New OmniAb Warrant. If a New OmniAb Warrant is allowed to lapse </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">210</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">unexercised, a U.S. Holder will generally recognize a capital loss equal to such U.S. Holder&#8217;s tax basis in the warrant. Such loss generally will be long-term if the U.S. Holder&#8217;s holding period for such warrant is more than one (1)&#160;year. U.S. Holders should consult, and rely solely upon, their tax advisors regarding the tax consequences of New OmniAb Warrants, including when a U.S. Holder&#8217;s holding period would commence with respect to the shares of New OmniAb Common Stock received upon exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because of the absence of authority specifically addressing the treatment of a cashless exercise of warrants under U.S. federal income tax law, the treatment of such a cashless exercise is unclear. A cashless exercise may not be taxable, either because the exercise is not a realization event or because the exercise is treated as a &#8220;recapitalization&#8221; for U.S. federal income tax purposes. In either tax-free situation, a U.S. Holder&#8217;s tax basis in the New OmniAb Common Stock received would generally equal the U.S. Holder&#8217;s tax basis in the New OmniAb Warrants exercised. If a cashless exercise is not treated as a realization event, it is unclear whether a U.S. Holder&#8217;s holding period for the New OmniAb Common Stock received on exercise will be treated as commencing on the date of exercise of the warrant or the following day. If a cashless exercise is treated as a recapitalization, the holding period of the New OmniAb Common Stock received will generally include the holding period of the New OmniAb Warrants exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is also possible that a cashless exercise may be treated as a taxable exchange in which gain or loss would be recognized. In such event, a U.S. Holder could be deemed to have surrendered a number of New OmniAb Warrants having an aggregate fair market value equal to the exercise price for the total number of New OmniAb Warrants to be exercised. In this case, the U.S. Holder would recognize capital gain or loss in an amount equal to the difference between the fair market value of the warrants deemed surrendered and the U.S. Holder&#8217;s tax basis in such warrants. A U.S. Holder&#8217;s tax basis in the New OmniAb Common Stock received would equal the sum of the U.S. Holder&#8217;s tax basis in the New OmniAb Warrants exercised and the exercise price of such warrants. It is unclear whether a U.S. Holder&#8217;s holding period for the New OmniAb Common Stock received would commence on the date of exercise of the warrant or the day following the date of exercise of the warrant; in either case, the holding period will not include the U.S. Holder&#8217;s holding period for the New OmniAb Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">New OmniAb expects a U.S. Holder&#8217;s cashless exercise of our New OmniAb Warrants (including after we provide notice of our intent to redeem warrants for cash) to be treated as a recapitalization for U.S. federal income tax purposes. However, due to the absence of authority on the U.S. federal income tax treatment of a cashless exercise of New OmniAb Warrants, there can be no assurance which, if any, of the alternative tax consequences and holding periods described above would be adopted by the IRS or a court of law. Accordingly, U.S. Holders should consult their tax advisors regarding the tax consequences of a cashless exercise of New OmniAb Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If New OmniAb redeems New OmniAb Warrants for cash pursuant to the redemption provisions of the warrants or if New OmniAb purchases New OmniAb Warrants for cash in an open market transaction, such redemption or purchase will generally be treated as a taxable disposition by the U.S. Holder, treated as described above under &#8220;&#8212;<i style="font-style:italic;">Taxation on the Disposition of New OmniAb Securities</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Possible Constructive Distributions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The terms of each New OmniAb Warrant provide for an adjustment to the number of shares of New OmniAb Common Stock for which the warrant may be exercised or to the exercise price of the warrant in certain events. An adjustment which has the effect of preventing dilution generally is not taxable. The U.S. Holders of the warrants would, however, be treated as receiving a constructive distribution from New OmniAb if, for example, the adjustment increases such U.S. Holders&#8217; proportionate interest in New OmniAb&#8217;s assets or earnings and profits as a result of a distribution of cash or other property to the Holders of New OmniAb Common Stock. Such constructive distribution would be subject to tax as described under that section in the same manner as if the U.S. Holders of the New OmniAb Warrants received a cash distribution from us equal to the fair market value of such increased interest and would increase a U.S. Holder&#8217;s adjusted tax basis in its warrants to the extent that such distribution is treated as a dividend.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Information Reporting and Backup Withholding</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Information reporting requirements generally will apply to dividends paid to a U.S. Holder of New OmniAb Common Stock and to the proceeds of the sale or other disposition of New OmniAb Securities, unless the U.S. Holder is an exempt recipient and certifies to such exempt status. Backup withholding may apply to such payments if the U.S. Holder fails to provide a taxpayer identification number or a certification of exempt status or has been notified by the IRS that it is subject to backup withholding (and such notification has not been withdrawn).</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">211</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Backup withholding is not an additional tax. Rather, the U.S. federal income tax liability (if any) of persons subject to backup withholding will be reduced by the amount of tax withheld. If backup withholding results in an overpayment of taxes, a refund generally may be obtained, provided that the required information is timely furnished to the IRS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">U.S. Federal Income Taxation of Non-U.S. Holders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This section applies to you if you are a &#8220;Non-U.S. Holder.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A &#8220;Non-U.S. Holder&#8221; is a Holder that is, for U.S. federal income tax purposes, an individual, corporation, estate or trust and that is not a U.S. Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Domestication</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC does not expect the Domestication to result in any material U.S. federal income tax consequences to Non-U.S. Holders of APAC Public Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NON-U.S. HOLDERS SHOULD CONSULT WITH, AND RELY SOLELY UPON, THEIR TAX ADVISORS TO DETERMINE THE U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF THE DOMESTICATION.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Redemption of New OmniAb Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The characterization for U.S. federal income tax purposes of the redemption of a Non-U.S. Holder&#8217;s New OmniAb Common Stock pursuant to the redemption provisions described in the subsection of this proxy statement/prospectus/information statement entitled &#8220;<i style="font-style:italic;">Extraordinary General Meeting of APAC&#8212;Redemption Rights</i>,&#8221; generally will correspond to the U.S. federal income tax characterization of such a redemption of a U.S. Holder&#8217;s New OmniAb Common Stock, as described under <i style="font-style:italic;">&#8220;&#8212;U.S. Federal Income Taxation of U.S. Holders&#8212; New OmniAb Common Stock</i>&#8221; above, and the consequences of the redemption to the Non-U.S. Holder will correspond to that described below in &#8220;&#8212;<i style="font-style:italic;">U.S. Federal Income Taxation of U.S. Holders&#8212;Taxation of Distributions with Respect to New OmniAb Common Stock</i>&#8221; and &#8220;&#8212;<i style="font-style:italic;">U.S. Federal Income Taxation of U.S. Holders&#8212;Gain on Sale, Taxable Exchange or Other Taxable Disposition of New OmniAb Securities</i>,&#8221; as applicable. It is possible that because the applicable withholding agent may not be able to determine the proper characterization of a redemption of a Non-U.S. Holder&#8217;s New OmniAb Common Stock, the withholding agent might treat the redemption as a distribution subject to withholding tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Taxation of Distributions with Respect to New OmniAb Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Distributions (including constructive distributions) of cash or property on New OmniAb Common Stock, if any, will constitute dividends for U.S. federal income tax purposes to the extent paid out of New OmniAb&#8217;s current or accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent those distributions exceed New OmniAb&#8217;s current and accumulated earnings and profits, the distributions will be treated as a nontaxable return of capital to the extent of the Non-U.S. Holder&#8217;s tax basis in its New OmniAb Common Stock and thereafter as capital gain from the sale or exchange of such New OmniAb Common Stock. See &#8220;&#8212;<i style="font-style:italic;">U.S. Federal Income Taxation of Non-U.S. Holders&#8212;Gain on Sale, Taxable Exchange or Other Taxable Disposition of New OmniAb Securities</i>&#8221; below. Subject to the withholding requirements under FATCA (as defined below) and with respect to effectively connected dividends, each of which is discussed below, any distribution made to a Non-U.S. Holder on its New OmniAb Common Stock generally will be subject to U.S. withholding tax at the rate of 30% of the gross amount of the distribution unless an applicable income tax treaty provides for a lower rate. To receive the benefit of a reduced treaty rate, a Non-U.S. Holder must provide the applicable withholding agent with an IRS Form&#160;W-8BEN or IRS Form&#160;W-8BEN-E (or other applicable or successor form) certifying qualification for the reduced rate. In the case of any constructive dividend, it is possible that this tax would be withheld from any amount owed to a Non-U.S. Holder by the applicable withholding agent, including cash distributions on other property or other property subsequently paid or credited to such Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Dividends paid to a Non-U.S. Holder that are effectively connected with a trade or business conducted by the Non-U.S. Holder in the United States (and, if required by an applicable income tax treaty, are treated as attributable to a permanent establishment maintained by the Non-U.S. Holder in the United States) generally will be taxed on a net income basis at the rates and in the manner generally applicable to United States persons. Such effectively connected dividends will not be subject to U.S. withholding tax if the Non-U.S. Holder satisfies certain certification requirements by providing the applicable withholding agent with a properly executed IRS Form&#160;W-8ECI certifying eligibility for exemption. If the Non-U.S. Holder is a corporation for U.S. federal income tax purposes, it </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">212</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">may also be subject to a branch profits tax (at a 30% rate or such lower rate as specified by an applicable income tax treaty) on its effectively connected earnings and profits (as adjusted for certain items), which will include effectively connected dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Gain on Sale, Taxable Exchange or Other Taxable Disposition of New OmniAb Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the discussion below under &#8220;&#8212;<i style="font-style:italic;">U.S. Federal Income Taxation of Non-U.S. Holders&#8212;Information Reporting and Backup Withholding</i>,&#8221; a Non-U.S. Holder generally will not be subject to U.S. federal income or withholding tax on any gain realized upon the sale or other disposition of New OmniAb Securities unless:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Non-U.S. Holder is an individual who is present in the United States for a period or periods aggregating 183&#160;days or more during the calendar&#160;year in which the sale or disposition occurs and certain other conditions are met&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the gain is effectively connected with a trade or business conducted by the Non-U.S. Holder in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment maintained by the Non-U.S. Holder in the United States)&#894; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">New OmniAb Securities constitute United States real property interests by reason of New OmniAb&#8217;s status as a &#8220;United States real property holding corporation&#8221; (a &#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">USRPHC</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) for U.S. federal income tax purposes and as a result such gain is treated as effectively connected with a trade or business conducted by the Non-U.S. Holder in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A Non-U.S. Holder described in the first bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate as specified by an applicable income tax treaty) on the amount of such gain, which generally may be offset by U.S. source capital losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A Non-U.S. Holder whose gain is described in the second bullet point above or, subject to the exceptions described in the next paragraph, the third bullet point above, generally will be taxed on a net income basis at the rates and in the manner generally applicable to United States persons unless an applicable income tax treaty provides otherwise. If the Non-U.S. Holder is a corporation for U.S. federal income tax purposes whose gain is described in the second bullet point above, such gain would also be included in its effectively connected earnings and profits (as adjusted for certain items), which may be subject to a branch profits tax (at a 30% rate or such lower rate as specified by an applicable income tax treaty).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Generally, a corporation is a USRPHC if the fair market value of its United States property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests and its other assets used or held for use in a trade or business, as determined for U.S. federal income tax purposes. New OmniAb does not believe that it will be a USRPHC for U.S. federal income tax purposes, and New OmniAb does not expect to become a USRPHC for the foreseeable future. However, in the event that New OmniAb were to become a USRPHC, as long as the New OmniAb Securities continues to be &#8220;regularly traded on an established securities market&#8221; (within the meaning of the U.S. Treasury Regulations, referred to herein as &#8220;regularly traded&#8221;), only a Non-U.S. Holder that actually or constructively owns, or owned at any time during the shorter of the five-year period ending on the date of the disposition or the Non-U.S. Holder&#8217;s holding period for applicable security, more than 5% of the New OmniAb Securities will be treated as disposing of a United States real property interest and will be taxable on gain realized on the disposition thereof as a result of New OmniAb&#8217;s status as a USRPHC. New OmniAb can provide no assurance as to its future status as a USRPHC or as to whether the New OmniAb Securities will be treated as regularly traded. If New OmniAb were to become a USRPHC and its New OmniAb Securities were not considered to be regularly traded, a Non-U.S. Holder (regardless of the&#160;percentage of New OmniAb Common Stock owned) would be treated as disposing of a United States real property interest and would be subject to U.S. federal income tax on a taxable disposition of New OmniAb Securities, and a 15% withholding tax would apply to the gross proceeds from such disposition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Non-U.S. Holders should consult with, and rely solely upon, their tax advisors regarding the tax consequences related to ownership in a USRPHC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Exercise, Lapse or Redemption of New OmniAb Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The U.S. federal income tax treatment of a Non-U.S. Holder&#8217;s exercise of a New OmniAb Warrant, or the lapse of a New OmniAb Warrant held by a Non-U.S. Holder, generally will correspond to the U.S. federal income tax treatment of the exercise or lapse of a warrant held by a U.S. Holder, as described above under &#8220;&#8212;<i style="font-style:italic;">U.S. Holders</i>&#8212;<i style="font-style:italic;">Exercise, Lapse or Redemption of New OmniAb </i></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">213</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrant</i>,&#8221; although to the extent a cashless exercise results in a taxable exchange, the consequences would be similar to those described above under &#8220;<i style="font-style:italic;">&#8212;U.S. Holders&#8212;Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of New OmniAb Securities</i>.&#8221; If New OmniAb redeems New OmniAb Warrants for cash or if it purchases New OmniAb Warrants in an open market transaction, such redemption or purchase generally will be treated as a disposition to the Non-U.S. Holder, the consequences of which would be similar to those described above under &#8220;<i style="font-style:italic;">&#8212;U.S. Holders&#8212;Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of New OmniAb Securities</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Possible Constructive Distributions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As described above under &#8220;&#8212;<i style="font-style:italic;">U.S. Holders&#8212;Possible Constructive Distributions</i>,&#8221; certain adjustments with respect to the New OmniAb Warrants can give rise to a constructive distribution. Any constructive distribution received by a Non-U.S. Holder would be subject to U.S. federal income tax (including any applicable withholding) in the same manner as if such Non-U.S. Holder received a cash distribution from New OmniAb equal to the fair market value of such increased interest. If withholding applies to any constructive distribution received by a Non-U.S. Holder, it is possible that the tax would be withheld from any amount paid to or held on behalf of the Non-U.S. Holder by the applicable withholding agent. The rules&#160;governing constructive distributions as a result of certain adjustments with respect to New OmniAb Warrants are complex, and Non-U.S. Holders should consult with, and rely solely upon, their tax advisors on the tax consequences any such constructive distribution with respect to a New OmniAb Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Information Reporting and Backup Withholding</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any dividends paid to a Non-U.S. Holder must be reported annually to the IRS and to the Non-U.S. Holder. Copies of these information returns may be made available to the tax authorities in the country in which the Non-U.S. Holder resides or is established. Payments of dividends to a Non-U.S. Holder generally will not be subject to backup withholding if the Non-U.S. Holder establishes an exemption by properly certifying its non-U.S. status on an IRS Form&#160;W-8BEN or IRS Form&#160;W-8BEN-E (or other applicable or successor form).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payments of the proceeds from a sale or other disposition by a Non-U.S. Holder of New OmniAb Common Stock effected by or through a U.S. office of a broker generally will be subject to information reporting and backup withholding (at the applicable rate) unless the Non-U.S. Holder establishes an exemption by properly certifying its non-U.S. status on an IRS Form&#160;W-8BEN or IRS Form&#160;W-8BEN-E (or other applicable or successor form) and certain other conditions are met. Information reporting and backup withholding generally will not apply to any payment of the proceeds from a sale or other disposition of New OmniAb Common Stock effected outside the United States by a non-U.S. office of a broker. However, unless such broker has documentary evidence in its records that the Non-U.S. Holder is not a United States person and certain other conditions are met, or the Non-U.S. Holder otherwise establishes an exemption, information reporting will apply to a payment of the proceeds of the disposition of New OmniAb Common Stock effected outside the United States by such a broker if it has certain relationships within the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Backup withholding is not an additional tax. Rather, the U.S. federal income tax liability (if any) of persons subject to backup withholding will be reduced by the amount of tax withheld. If backup withholding results in an overpayment of taxes, a refund generally may be obtained, provided that the required information is timely furnished to the IRS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NON-U.S. HOLDERS SHOULD CONSULT WITH, AND RELY SOLELY UPON, THEIR TAX ADVISORS TO DETERMINE THE U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF THEIR OWNERSHIP OF NEW OMNIAB SECURITIES FOLLOWING THE BUSINESS COMBINATION.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Additional Withholding Requirements under FATCA</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Sections 1471 through 1474 of the Code, and the U.S. Treasury Regulations and administrative guidance issued thereunder (&#8220;FATCA&#8221;), impose a 30% withholding tax on any dividends (including constructive dividends) paid on New OmniAb Common Stock if paid to a &#8220;foreign financial institution&#8221; or a &#8220;non-financial foreign entity&#8221; (each as defined in the Code) (including, in some cases, when such foreign financial institution or non-financial foreign entity is acting as an intermediary), unless (i)&#160;in the case of a foreign financial institution, such institution enters into an agreement with the U.S. government to withhold on certain payments, and to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are non-U.S. entities with U.S. owners), (ii)&#160;in the case of a non-financial foreign entity, such entity certifies that it does not have any &#8220;substantial United States owners&#8221; (as defined in the Code) or provides the applicable withholding agent with a certification identifying the direct and indirect </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">214</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">substantial United States owners of the entity (in either case, generally on an IRS Form&#160;W-8BEN-E), or (iii)&#160;the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these rules&#160;and provides appropriate documentation (such as an IRS Form&#160;W-8BEN-E). Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing these rules&#160;may be subject to different rules. Under certain circumstances, a Holder might be eligible for refunds or credits of such taxes. Holders should consult with, and rely solely upon, their own tax advisors regarding the effects of FATCA on their ownership of New OmniAb Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE FOREGOING DISCUSSION IS NOT A COMPREHENSIVE DISCUSSION OF ALL OF THE U.S. FEDERAL INCOME TAX CONSEQUENCES TO HOLDERS OF NEW OMNIAB SECURITIES. SUCH HOLDERS SHOULD CONSULT WITH, AND RELY SOLELY UPON, THEIR TAX ADVISORS TO DETERMINE THE SPECIFIC TAX CONSEQUENCES TO THEM OF THE BUSINESS COMBINATION (INCLUDING THE DOMESTICATION AND ANY EXERCISE OF THEIR REDEMPTION RIGHTS) AND, TO THE EXTENT APPLICABLE, OF OWNING NEW OMNIAB SECURITIES FOLLOWING THE COMPLETION OF THE BUSINESS COMBINATION, INCLUDING THE APPLICABILITY AND EFFECT OF ANY U.S. FEDERAL, STATE, LOCAL, OR NON-U.S. TAX LAWS AND TAX TREATIES (AND ANY POTENTIAL FUTURE CHANGES THERETO).</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">215</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7048d926_02a8_416a_b3f7_47dcfae41ed1"></a><a id="Main_DISTRIBUTIONANDMERGER"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO LIGAND STOCKHOLDERS OF THE DISTRIBUTION AND MERGER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the material U.S. federal income tax consequences of the Distribution and Merger to Ligand stockholders that are U.S. Holders (as defined above) of Ligand Common Stock. This summary is based on the Code, the Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the IRS, in each case as of the date of this proxy statement/prospectus/information statement. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a U.S. Holder. There can be no assurance that the IRS or a court will not take a contrary position to that discussed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This summary is limited to U.S. Holders who hold Ligand Common Stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This summary does not address all U.S. federal income tax consequences relevant to a U.S. Holder&#8217;s particular circumstances, including the impact of the Medicare contribution tax on net investment income. In addition, it does not address consequences relevant to U.S. Holders subject to special rules, including, without limitation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. expatriates and former citizens or long-term residents of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">dealers or brokers in securities, commodities or currencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-exempt organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">banks, insurance companies or other financial institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mutual funds;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulated investment companies and real estate investment trusts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">corporations that accumulate earnings to avoid U.S. federal income tax;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. Holders who hold individual retirement or other tax-deferred accounts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. Holders who acquired Ligand Common Stock pursuant to the exercise of stock options, the settlement of restricted stock units or otherwise as compensation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. Holders who own, or are deemed to own, at least 10% or more of Ligand Common Stock by vote or value;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. Holders who hold Ligand Common Stock or OmniAb Common Stock as part of a hedge, appreciated financial position, straddle, constructive sale, conversion transaction or other risk reduction transaction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">traders in securities who elect to apply a mark-to-market method of accounting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. Holders who have a functional currency other than the U.S. dollar;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. Holders who are subject to the alternative minimum tax;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons subject to special tax accounting rules&#160;as a result of any item of gross income with respect to Ligand Common Stock being taken into account in an applicable financial statement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partnerships or other pass-through entities or investors in such entities; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;qualified foreign pension funds&#8221; as defined in Section&#160;897(l)(2)&#160;of the Code and entities all of the interests of which are held by qualified foreign pension funds.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">216</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds Ligand Common Stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding Ligand Common Stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">THE FOLLOWING IS A SUMMARY OF THE MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE DISTRIBUTION AND MERGER FOR U.S. HOLDERS OF LIGAND COMMON STOCK UNDER CURRENT LAW. THE FOLLOWING DOES NOT PURPORT TO ADDRESS ALL U.S. FEDERAL INCOME TAX CONSEQUENCES OR TAX CONSEQUENCES THAT MAY&#160;ARISE UNDER THE TAX LAWS OR THAT MAY&#160;APPLY TO PARTICULAR CATEGORIES OF STOCKHOLDERS. EACH LIGAND STOCKHOLDER IS ENCOURAGED TO CONSULT ITS TAX ADVISOR AS TO THE PARTICULAR TAX CONSEQUENCES OF THE DISTRIBUTION AND MERGER TO SUCH STOCKHOLDER, INCLUDING THE APPLICATION OF U.S. FEDERAL, STATE, LOCAL AND FOREIGN TAX LAWS, AND THE EFFECT OF POSSIBLE CHANGES IN TAX LAWS THAT MAY&#160;AFFECT THE TAX CONSEQUENCES DESCRIBED BELOW.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Treatment of the Distribution</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Distribution is conditioned upon Ligand&#8217;s receipt of an opinion of Latham &amp; Watkins LLP, tax counsel to Ligand, that the Distribution, together with certain related transactions, will qualify as a &#8220;reorganization&#8221; within the meaning of Sections 368(a)(1)(D) and 355(a) of the Code and that the Merger will not cause Section 355(e) of the Code to apply to the Distribution (the &#8220;Distribution Tax Opinion&#8221;). If the Distribution, together with certain related transactions, qualifies as a reorganization, then for U.S. federal income tax purposes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject to the discussion below regarding Section 355(e) of the Code, and except for taxable income or gain possibly arising as a result of certain internal transactions undertaken prior to or in anticipation of the Distribution (including with respect to any &#8220;intercompany transaction&#8221; required to be taken into account by Ligand under the Treasury Regulations related to consolidated U.S.federal income tax returns), Ligand will not recognize gain or loss in connection with the Distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no gain or loss will be recognized by, or be includible in the income of, a U.S. Holder for U.S. federal income tax purposes solely as a result of the receipt of shares of OmniAb Common Stock in the Distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the aggregate tax basis of the shares of Ligand Common Stock and shares of OmniAb Common Stock in the hands of a U.S. Holder immediately after the Distribution will be the same as the aggregate tax basis of the shares of Ligand Common Stock held by the U.S. Holder immediately before the Distribution, allocated between the Ligand stock and OmniAb Common Stock, including any fractional share interest for which cash is received, in proportion to their relative fair market values on the date of the Distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the holding period with respect to shares of OmniAb Common Stock received by a U.S. Holder will include the holding period of its shares of Ligand Common Stock; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a U.S. Holder who receives cash in lieu of a fractional share of OmniAb Common Stock in the Distribution will be treated as having sold such fractional share for cash and generally will recognize capital gain or loss in an amount equal to the difference between the amount of cash received and such U.S. Holder&#8217;s adjusted tax basis in the fractional share. That gain or loss will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for its shares of Ligand Common Stock exceeds one&#160;year.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Treasury Regulations generally provide that if a U.S. Holder holds different blocks of Ligand Common Stock (generally shares of Ligand Common Stock purchased or acquired on different dates or at different prices), the aggregate basis for each block of Ligand Common Stock purchased or acquired on the same date and at the same price will be allocated, to the greatest extent possible, between the shares of OmniAb Common Stock received in the Distribution in respect of such block of Ligand Common Stock and such block of Ligand Common Stock, in proportion to their respective fair market values, and the holding period of the shares of OmniAb Common Stock received in the Distribution in respect of such block of Ligand Common Stock will include the holding period of such block of Ligand Common Stock, provided that such block of Ligand Common Stock was held as a capital asset on the date of the Distribution. If a U.S. Holder is not able to identify which particular shares of OmniAb Common Stock are received in the Distribution with respect to a particular block of Ligand Common Stock, for purposes of applying the rules&#160;described above, the U.S. Holder may designate which shares of OmniAb Common Stock are received in the Distribution in respect of a particular block of </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">217</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Ligand Common Stock, provided that such designation is consistent with the terms of the Distribution. Holders of Ligand Common Stock are encouraged to consult their own tax advisors regarding the application of these rules&#160;to their particular circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Distribution Tax Opinion will be based on, among other things, certain factual assumptions, representations and undertakings from Ligand, OmniAb and APAC, including those regarding the past and future conduct of the companies&#8217; respective businesses and other matters. If any of these factual assumptions, representations, or undertakings are incorrect or not satisfied, Ligand may not be able to rely on the opinion. An opinion of counsel represents counsel&#8217;s best legal judgment but is not binding on the Internal Revenue Service or the courts, so there can be no certainty that the Internal Revenue Service will not challenge the conclusions reflected in the opinion or that a court will not sustain such a challenge. Ligand, OmniAb, and APAC have not requested and do not intend to request any ruling from the Internal Revenue Service as to the United States federal income tax consequences of the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If, notwithstanding the conclusion in the Distribution Tax Opinion, the Distribution is ultimately determined not to qualify as a reorganization under Sections 355 and 368(a)(1)(D)&#160;of the Code, Ligand would recognize gain in an amount equal to the excess of the fair market value of the OmniAb Common Stock distributed to Ligand stockholders on the Distribution date over Ligand&#8217;s tax basis in such shares. In addition, each U.S. Holder who receives shares of OmniAb Common Stock in the Distribution would be treated as receiving a taxable distribution in an amount equal to the fair market value of the OmniAb Common Stock that was distributed to the U.S. Holder. Specifically, the full value of the OmniAb Common Stock distributed to a U.S. Holder generally would be treated first as a taxable dividend to the extent of the U.S. Holder&#8217;s pro rata share of Ligand&#8217;s current and accumulated earnings and profits, then as a non-taxable return of capital to the extent of the U.S. Holder&#8217;s basis in the Ligand Common Stock, and finally as capital gain from the sale or exchange of Ligand Common Stock with respect to any remaining value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if the Distribution qualifies as a reorganization under Sections 355 and 368(a)(1)(D)&#160;of the Code, the Distribution may result in corporate-level taxable gain to Ligand under Section&#160;355(e)&#160;of the Code if there is a 50% or greater change in ownership, by vote or value, of OmniAb Common Stock, Ligand Common Stock or stock of a successor of either (including APAC after the Merger) occurring as part of a plan or series of related transactions that includes the Distribution. For this purpose, any acquisitions or issuances of Ligand Common Stock within two&#160;years before the Distribution, and any acquisitions or issuances of OmniAb Common Stock, Ligand Common Stock, or APAC shares within two&#160;years after the Distribution, are generally presumed to be part of such a plan, although APAC, OmniAb or Ligand may be able to rebut that presumption. For purposes of this test, the Merger will be treated as part of a plan with the Distribution, but the Merger standing alone will not cause the Distribution to be taxable to Ligand under Section&#160;355(e)&#160;of the Code because Holders of OmniAb Common Stock will own more than 50% of New OmniAb Common Stock. If another acquisition or issuance of APAC Class&#160;A Ordinary Shares, OmniAb Common Stock or Ligand Common Stock triggers the application of Section&#160;355(e)&#160;of the Code, Ligand would recognize taxable gain as described above and such gain would be subject to U.S. federal income tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Treatment of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately following the receipt by a U.S. Holder of Ligand stock of shares of OmniAb Common Stock in the Distribution, the shares of OmniAb Common Stock so received will be exchanged for New OmniAb Common Stock and OmniAb Earnout Shares pursuant to the Merger. The obligations of Ligand and OmniAb to complete the Merger are conditioned upon, among other things, Ligand&#8217;s receipt of the Distribution Tax Opinion and an opinion of Latham&#160;&amp; Watkins LLP, tax counsel to Ligand, that the Merger will be treated as a reorganization under Section&#160;368(a)&#160;of the Code. The obligation of APAC to complete the Merger is conditioned upon, among other things, receipt of an opinion of Weil, Gotshal&#160;&amp; Manges LLP, tax counsel to APAC, that the Merger will be treated as a reorganization under Section&#160;368(a)&#160;of the Code. If the Merger qualifies as a reorganization, then for U.S. federal income tax purposes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a U.S. Holder of OmniAb Common Stock will not recognize any gain or loss solely as a result of the exchange of shares of OmniAb Common Stock for New OmniAb Common Stock and OmniAb Earnout Shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a U.S. Holder&#8217;s aggregate tax basis of New OmniAb Common Stock and OmniAb Earnout Shares received in the Merger will be the same as the aggregate tax basis of the OmniAb Common Stock for which it is exchanged, allocated between the New OmniAb Common Stock and OmniAb Earnout Shares, including any fractional share interest for which cash is received, in proportion to their relative fair market values on the date of the Merger;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">218</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a U.S. Holder&#8217;s holding period of New OmniAb Common Stock and OmniAb Earnout Shares received in exchange for shares of OmniAb Common Stock will include the holding period of the OmniAb Common Stock for which it is exchanged; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a U.S. Holder who receives cash in lieu of a fractional share of New OmniAb Common Stock in the Merger will be treated as having sold such fractional share for cash and generally will recognize capital gain or loss in an amount equal to the difference between the amount of cash received and such U.S. Holder&#8217;s adjusted tax basis in the fractional share. That gain or loss will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for its shares of OmniAb Common Stock exceeds one&#160;year.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The tax opinions regarding the Merger will be based on, among other things, certain factual assumptions, representations and undertakings from Ligand, OmniAb and APAC. If any of these factual assumptions, representations, or undertakings are incorrect or not satisfied, Ligand, OmniAb, and APAC may not be able to rely on the opinions. An opinion of counsel represents counsel&#8217;s best legal judgment but is not binding on the Internal Revenue Service or the courts, so there can be no certainty that the Internal Revenue Service will not challenge the conclusions reflected in the opinion or that a court will not sustain such a challenge. Ligand, OmniAb, and APAC have not requested and do not intend to request any ruling from the Internal Revenue Service as to the United States federal income tax consequences of the Merger. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the IRS were to successfully challenge the treatment of the Merger described above, the tax consequences could differ, perhaps substantially, from those described herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preceding discussion is intended only as a general discussion of the material U.S. federal income tax consequences of the Merger. It is not a complete analysis or discussion of all potential tax effects that may be important to you. Thus, you are strongly encouraged to consult your tax advisor as to the specific tax consequences resulting from the Merger, including tax return reporting requirements, the applicability and effect of federal, state, local, and other tax laws and the effect of any proposed changes in the tax laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Information Reporting and Backup Withholding</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">U.S. Treasury regulations require certain stockholders who receive stock in a Distribution to attach to their U.S. federal income tax return for the&#160;year in which the Distribution occurs a detailed statement setting forth certain information relating to the tax-free nature of the Distribution. In addition, payments of cash to a Ligand or OmniAb stockholder in lieu of fractional shares of OmniAb or APAC in the Distribution or Merger may be subject to information reporting and backup withholding, and backup withholding may apply to such payments if the U.S. Holder fails to provide a taxpayer identification number or a certification of exempt status or has been notified by the IRS that it is subject to backup withholding (and such notification has not been withdrawn).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules&#160;may be allowed as a refund or a credit against a U.S. Holder&#8217;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. U.S. Holders should consult their tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">219</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_343d8887_45ad_42b7_b7a3_ee97d8f37a96"></a><a id="Main_INFORMATIONABOUTAPACANDMERGERS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INFORMATION ABOUT APAC AND MERGER SUB</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">References in this section to &#8220;APAC,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221; refer to Avista Public Acquisition Corp. II.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC is not presently engaged in and APAC will not engage in, any substantive commercial business until it completes the Business Combination with OmniAb or another target business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC is a blank check company incorporated on February&#160;5, 2021 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Although APAC&#8217;s efforts to identify a prospective target were not limited to any particular industry, it focused on identifying a prospective target business in the healthcare industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February&#160;12, 2021, the Sponsor paid an aggregate of $25,000 in exchange for the issuance of 5,750,000 APAC Class&#160;B Ordinary Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;23, 2022, APAC entered into the Merger Agreement and the A&amp;R FPA, pursuant to which APAC has agreed to issue and sell to the Sponsor 1,500,000 shares of New OmniAb Common Stock and warrants to acquire 1,666,667 shares of New OmniAb Common Stock for an aggregate purchase price of $15,000,000 in the Forward Purchase. In addition to the Forward Purchase, the Sponsor has agreed to purchase up to an additional 10,000,000 shares of New OmniAb Common Stock and up to an additional 1,666,667 New OmniAb warrants in the Redemption Backstop, for an aggregate additional purchase price of up to $100,000,000, in order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds to be available to the combined company following the Business Combination from APAC&#8217;s trust account to be less than $100,000,000 as of immediately prior to the Closing. See &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#8212;The Business Combination Proposal&#8212;Summary of the Related Agreements&#8212;Amended and Restated Forward Purchase Agreement</i>&#8221; commencing on page&#160;160.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;23, 2022, APAC also entered into a Sponsor Insider Agreement, pursuant to which the Insiders agreed to vote any APAC securities held by them to approve the Business Combination and the other APAC shareholder matters required pursuant to the Merger Agreement, and not seek redemption of any of their APAC securities in connection with the consummation of the Business Combination. The Sponsor also agreed, pursuant to the Sponsor Insider Agreement, to subject up to all 1,916,667 Sponsor Earnout Shares to forfeiture if an applicable Sponsor Triggering Event has not occurred with respect to such Sponsor Earnout Shares during the period from the date of the Closing to and including the fifth anniversary of the date of the Closing. See &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#8212;The Business Combination Proposal&#8212;Summary of the Related Agreements&#8212;Sponsor Insider Agreement</i>&#8221; commencing on page&#160;159.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Initial Public Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August&#160;12, 2021, APAC consummated the initial public offering of 23,000,000 APAC units, at a price of $10.00 per APAC unit, including 3,000,000 APAC units sold pursuant to the full exercise of the underwriters&#8217; option to purchase additional APAC units to cover over-allotments. Each such unit consisted of one APAC Class&#160;A Ordinary Share and one-third of one redeemable warrant (each, an &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">APAC Public Warrant</span>&#8221;). Each whole APAC Public Warrant entitles the holder to purchase one APAC Class&#160;A Ordinary Share at an exercise price of $11.50 per share following consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Simultaneously with the closing of APAC&#8217;s initial public offering, APAC consummated the sale of 8,233,333 APAC Private Placement Warrants at a price of $1.50 per APAC Private Placement Warrant in a private placement to the Sponsor, generating gross proceeds of $12,350,000. The APAC Private Placement Warrants are identical to the APAC Public Warrants sold in the initial public offering, except that (a)&#160;subject to certain exceptions, the APAC Private Placement Warrants are not transferable, assignable or saleable until 30&#160;days after the completion of APAC&#8217;s initial business combination, (b)&#160;the APAC Private Placement Warrants are exercisable on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees and (c)&#160;the Sponsor is entitled to registration rights in respect of the APAC Private Placement Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Following the consummation of APAC&#8217;s initial public offering on August&#160;12, 2021, an amount of $236,000,000 from the net proceeds of the sale of the APAC units in the initial public offering and the sale of the APAC Private Placement Warrants was placed in the trust account, with the funds, if invested, only to be invested in U.S. government securities, within the meaning set forth in </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">220</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185&#160;days or less, or in any open-ended investment company that holds itself out as a money market fund meeting certain conditions of Rule&#160;2a-7 of the Investment Company Act, as determined by APAC, until the earlier of: (i)&#160;APAC&#8217;s completion of its initial business combination or (ii)&#160;the distribution of the funds in the trust account to APAC shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August&#160;9, 2021, APAC entered into the Forward Purchase Agreement with Sponsor. Pursuant to the Forward Purchase Agreement, Sponsor agreed to purchase 10,000,000 APAC Class&#160;A Ordinary Shares, plus an aggregate of 3,333,333 redeemable warrants to purchase one APAC Class&#160;A Ordinary Share at $11.50 per share, for an aggregate purchase price of $100,000,000, or $10.00 for one APAC Class&#160;A Ordinary Share and one-third of one warrant, in a private placement to occur concurrently with the closing of a business combination. The warrants to be sold as part of the Forward Purchase Agreement were contemplated to be identical to the APAC Private Placement Warrants. The Forward Purchase Agreement was amended and restated in its entirety on March&#160;23, 2022, by the A&amp;R FPA, pursuant to which APAC has agreed that it will issue and sell to the Sponsor 1,500,000 shares of New OmniAb Common Stock and warrants to acquire 1,666,667 shares of New OmniAb Common Stock for an aggregate purchase price of $15,000,000 with such purchases to be consummated immediately following the Domestication and prior to the Merger. Also pursuant to the A&amp;R FPA, the Sponsor agreed to purchase up to an additional 10,000,000 shares of New OmniAb Common Stock and up to an additional 1,666,667 New OmniAb Warrants, for an aggregate additional purchase price of up to $100,000,000, in order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds to be available to the combined company following the Business Combination from APAC&#8217;s trust account to be less than $100,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Offering Proceeds Held in Trust</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the closing of APAC&#8217;s initial public offering on August&#160;12, 2021 and the sale of the APAC Private Placement Warrants, an amount of $235,750,000 (implied value of $10.25 per APAC unit) of the proceeds from APAC&#8217;s initial public offering and sale of APAC Private Placement Warrants were placed in the trust account. Except with respect to interest earned on the funds in the trust account that may be released to APAC to pay its franchise and income taxes and expenses relating to the administration of the trust account, the proceeds from APAC&#8217;s initial public offering and the private placement for APAC Private Placement Warrants held in the trust account will not be released until the earliest of (a)&#160;the completion of APAC&#8217;s initial business combination, (b)&#160;the redemption of any public shares properly tendered in connection with a shareholder vote to amend the Cayman Constitutional Documents (i)&#160;to modify the substance or timing of its obligation to redeem 100% of its APAC Class&#160;A Ordinary Shares if APAC does not complete its initial business combination within 18&#160;months from the closing of APAC&#8217;s initial public offering or (ii)&#160;with respect to any other provisions relating to shareholders&#8217; rights or pre-initial business combination activity, and (c)&#160;the redemption of all of the APAC Class&#160;A Ordinary Shares if it is unable to complete its business combination within 18&#160;months from the closing of APAC&#8217;s initial public offering, subject to applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Fair Market Value of Target Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The target business or businesses that APAC acquires must collectively have a fair market value equal to at least 80% of the assets held in the trust account (excluding the amount of deferred underwriting discounts held in, and taxes payable on, the income earned on the trust account) at the time of the execution of a definitive agreement for APAC&#8217;s initial business combination. The APAC Board has determined that the proposed Business Combination with OmniAb meets the 80% test.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Redemption Rights in Connection with Shareholder Approval of Business Combinations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Cayman Constitutional Documents, if APAC is required by law or elects to seek shareholder approval of its initial business combination, holders of APAC Class&#160;A Ordinary Shares must be given the opportunity to redeem their APAC Class&#160;A Ordinary Shares in connection with the proxy solicitation for the applicable shareholder meeting, regardless of whether they vote for or against the Business Combination, subject to the limitations described in the prospectus for APAC&#8217;s initial public offering. Accordingly, in connection with the Business Combination, holders of APAC Class&#160;A Ordinary Shares may seek to redeem their APAC Class&#160;A Ordinary Shares in accordance with the procedures set forth in this proxy statement/prospectus/information statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Voting Obligations in Connection with the Extraordinary General Meeting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Sponsor Insider Agreement, the Sponsor and Insiders have agreed to vote all of the APAC securities held by them in favor of the Business Combination proposal and the other shareholder proposals and not to seek to have any shares redeemed in connection with the Business Combination.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">221</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Redemption of APAC Class&#160;A Ordinary Shares and Liquidation if No Initial Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Insiders and APAC&#8217;s officers and directors have agreed, and the Cayman Constitutional Documents provide, that we have only eighteen&#160;months from the closing of APAC&#8217;s initial public offering, which is until February&#160;12, 2023, to complete an initial business combination. If we have not completed an initial business combination within eighteen&#160;months from the closing of APAC&#8217;s initial public offering, or February&#160;12, 2023, we will: (a)&#160;cease all operations except for the purpose of winding up, (b)&#160;as promptly as reasonably possible but not more than ten business&#160;days thereafter, subject to lawfully available funds therefor, redeem 100% of the outstanding APAC Class&#160;A Ordinary Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to us to pay our taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then outstanding APAC Class&#160;A Ordinary Shares, redemption will completely extinguish all of the rights of the holders of APAC Class&#160;A Ordinary Shares rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (c)&#160;as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and the APAC Board, liquidate and dissolve, subject in each case to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. If APAC does not complete its initial business combination by February&#160;12, 2023 or such later date as may be approved by the APAC shareholders in accordance with the Cayman Constitutional Documents, the proceeds from the sale of the APAC Private Placement Warrants held in the trust account will be used to fund a portion of the redemptions of the APAC Class&#160;A Ordinary Shares (subject to the requirements of applicable law) and the APAC Private Placement Warrants will expire worthless. Furthermore, if APAC does not complete its initial business combination by February&#160;12, 2023 and APAC liquidates the funds held in the trust account, holders of APAC Public Warrants will not receive any funds with respect to their APAC Public Warrants, nor will they receive any distribution from APAC&#8217;s assets held outside of the trust account with respect to such APAC Public Warrants. Accordingly, the APAC Public Warrants may expire worthless.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC expects all of the costs and expenses associated with implementing any plan of dissolution, as well as payments to any creditors, will be funded from amounts remaining out of the cash held by APAC outside the trust account (which was $189,971 as of December&#160;31, 2021) plus up to $100,000 of funds from the trust account available to APAC to pay dissolution expenses, although APAC cannot assure you that there will be sufficient funds for such purpose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If APAC was to expend all of the net proceeds of APAC&#8217;s initial public offering and the sale of the APAC Private Placement Warrants, other than the proceeds deposited in the trust account, and without taking into account interest earned on the trust account, the per-share redemption amount received by APAC&#8217;s public shareholders upon APAC&#8217;s dissolution would be approximately $10.25. The proceeds deposited in the trust account could, however, become subject to the claims of APAC&#8217;s creditors, which would have higher priority than the claims of APAC shareholders. APAC cannot assure you that the actual per-share redemption amount received by APAC&#8217;s public shareholders will not be substantially less than $10.25.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although APAC will continue to seek to have all vendors, service providers (other than our independent registered public accounting firm) and other entities with which we do business execute agreements with us waiving any right, title, interest or claim of any kind in or to any monies held in the trust account for the benefit of APAC&#8217;s public shareholders, there is no guarantee that they will execute such agreements or even if they execute such agreements that they would be prevented from bringing claims against the trust account, including, but not limited to fraudulent inducement, breach of fiduciary responsibility or other similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain an advantage with respect to a claim against our assets, including the funds held in the trust account. If any third party refuses to execute an agreement waiving such claims to the monies held in the trust account, our management will perform an analysis of the alternatives available to it and will only enter into an agreement with a third party that has not executed a waiver if management believes that such third party&#8217;s engagement would be significantly more beneficial to us than any alternative.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC has access to up to approximately $189,971 from the proceeds of APAC&#8217;s initial public offering and sale of the APAC Private Placement Warrants with which to pay any potential claims (including costs and expenses incurred in connection with liquidation, currently estimated to be no more than approximately $100,000). In the event that APAC liquidates and it is subsequently determined that the reserve for claims and liabilities is insufficient, shareholders who received funds from the trust account could be liable for claims made by creditors, however, such liability will not be greater than the amount of funds from the trust account received by any such shareholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Under Cayman Islands law, shareholders may be held liable for claims by third parties against a corporation to the extent of distributions received by them in a dissolution. The portion of APAC&#8217;s trust account distributed to APAC&#8217;s public shareholders upon </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">222</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">the redemption of 100% of outstanding APAC Class&#160;A Ordinary Shares in the event APAC does not complete its initial business combination within eighteen&#160;months from the closing of APAC&#8217;s initial public offering, or February&#160;12, 2023, may be considered a liquidation distribution under Cayman Islands law. If the corporation complies with certain procedures as required by Cayman Islands law intended to ensure that it makes reasonable provision for all claims against it, including a 60-day notice period during which any third-party claims can be brought against the corporation, a 90-day period during which the corporation may reject any claims brought, and an additional 150-day waiting period before any liquidating distributions are made to shareholders, any liability of shareholders with respect to a liquidating distribution is limited to the lesser of such shareholder&#8217;s pro rata share of the claim or the amount distributed to the shareholder, and any liability of the shareholder would be barred after the third anniversary of the dissolution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, if the pro rata portion of the trust account distributed to holders of APAC Class&#160;A Ordinary Shares upon the redemption of APAC Class&#160;A Ordinary Shares in the event APAC does not complete its initial business combination within eighteen&#160;months from the closing of APAC&#8217;s initial public offering, or February&#160;12, 2023, is not considered a liquidating distribution under Cayman Islands law and such redemption distribution is deemed to be unlawful (potentially due to the imposition of legal proceedings that a party may bring or due to other circumstances that are currently unknown), then pursuant to Cayman Islands law, the statute of limitation for claims of creditors could then be six&#160;years after the unlawful redemption distribution, instead of three&#160;years, as in the case of a liquidating distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If APAC files a bankruptcy or winding-up petition or an involuntary bankruptcy or winding-up petition is filed against us that is not dismissed, the proceeds held in the trust account could be subject to applicable bankruptcy or insolvency law, and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our shareholders. To the extent any bankruptcy claims deplete the trust account, APAC cannot assure you we will be able to return $10.25 per share to APAC&#8217;s public shareholders. Additionally, if APAC files a bankruptcy or winding-up petition or an involuntary bankruptcy or winding-up petition is filed against us that is not dismissed, any distributions received by shareholders could be viewed under applicable debtor/creditor and/or bankruptcy or insolvency laws as either a &#8220;preferential transfer&#8221; or a &#8220;fraudulent conveyance.&#8221; As a result, a bankruptcy or insolvency court could seek to recover some or all amounts received by our shareholders. Furthermore, the APAC Board may be viewed as having breached its fiduciary duty to our creditors and/or to have acted in bad faith, thereby exposing us or the APAC Board to claims of punitive damages, by paying APAC shareholders from the trust account prior to addressing the claims of creditors. APAC cannot assure you that claims will not be brought against us for these reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of APAC Class&#160;A Ordinary Shares will be entitled to receive funds from the trust account only upon the earliest to occur of: (a)&#160;APAC&#8217;s completion of its initial business combination, (b)&#160;the redemption of APAC Class&#160;A Ordinary Shares properly tendered in connection with a shareholder vote to amend the APAC Organizational Documents (i)&#160;to modify the substance or timing of APAC&#8217;s obligation to allow redemption in connection with our initial business combination or to redeem 100% of the outstanding APAC Class&#160;A Ordinary Shares if we do not complete an initial business combination within eighteen&#160;months from the closing of APAC&#8217;s initial public offering, or February&#160;12, 2023 or (ii)&#160;with respect to any other provisions relating to the rights of holders of APAC Class&#160;A Ordinary Shares and (c)&#160;the redemption of 100% of the APAC Class&#160;A Ordinary Shares if we have not completed our initial business combination within eighteen&#160;months from the closing of APAC&#8217;s initial public offering, or February&#160;12, 2023, subject to applicable law. In no other circumstances will an APAC shareholder have any right or interest of any kind to or in the trust account. An APAC shareholder&#8217;s voting in connection with the Business Combination alone will not result in such shareholder&#8217;s redeeming its APAC Class&#160;A Ordinary Shares for an applicable pro rata share of the trust account. Such shareholder must have also exercised its redemption rights described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Limitation on Redemption Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Cayman Constitutional Documents provide that a holder of APAC Class&#160;A Ordinary Shares, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Exchange Act), will be restricted from seeking redemption rights with respect to more than an aggregate of 15% of the APAC Class&#160;A Ordinary Shares sold in APAC&#8217;s initial public offering without APAC&#8217;s prior consent. APAC believes this restriction will discourage shareholders from accumulating large blocks of shares, and subsequent attempts by such holders to use their ability to exercise their redemption rights against a business combination as a means to force APAC or APAC&#8217;s management to purchase their shares at a significant premium to the then-current market price or on other undesirable terms. Absent this provision, a shareholder holding more than an aggregate of 15% of the APAC Class&#160;A Ordinary Shares could threaten to exercise its redemption rights if such holder&#8217;s shares are not purchased by APAC, the Insiders or APAC&#8217;s management at a premium to the then-current market price or on other undesirable terms. By limiting the shareholders&#8217; ability to redeem no more than 15% of the APAC Class&#160;A Ordinary Shares </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">223</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">without APAC&#8217;s prior consent, we believe we will limit the ability of a small group of shareholders to unreasonably attempt to block our ability to complete a business combination. However, APAC is not restricting our shareholders&#8217; ability to vote all of their shares for or against the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Facilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC currently maintains its executive offices at 65 East 55th St., 18th Floor, New York, NY 10022. The cost for the use of this space is included in the $10,000 per&#160;month fee paid to the Sponsor for office space and administrative support services. APAC considers our current office space adequate for our current operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Human Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC has seven executive officers. These individuals are not obligated to devote any specific number of hours to APAC&#8217;s matters but they intend to devote as much time as they deem necessary to APAC affairs until we have completed our initial business combination. APAC does not intend to have any full time employees prior to the consummation of our initial business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that our management team is well positioned to identify attractive risk-adjusted returns in the marketplace and that its contacts and transaction sources, ranging from industry executives, private owners, private equity funds, and investment bankers, will enable us to pursue a broad range of opportunities. Our management believes that its ability to identify and implement value creation initiatives will remain central to its differentiated acquisition strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is no material litigation, arbitration or governmental proceeding currently pending against APAC or any members of APAC&#8217;s management team in their capacity as such, and APAC and the members of APAC&#8217;s management team have not been subject to any such proceeding in the twelve&#160;months preceding the date of this filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">224</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8ebc43be_acd4_4e6b_a321_0b8da58e574d"></a><a id="Main_APACMANAGEMENTSDISCUSSIONANDAN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">APAC MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF</b><b style="font-weight:bold;"> OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Unless the context otherwise requires, references in this subsection </b><span style="font-style:italic;font-weight:bold;">&#8220;&#8212;APAC&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; </span><b style="font-weight:bold;">to</b><span style="font-style:italic;font-weight:bold;"> &#8220;APAC,&#8221; &#8220;we,&#8221; &#8220;us&#8221; </span><b style="font-weight:bold;">and</b><span style="font-style:italic;font-weight:bold;"> &#8220;our&#8221; </span><b style="font-weight:bold;">generally refer to APAC prior to the Business Combination.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This proxy statement/prospectus/information statement includes &#8220;forward-looking statements&#8221; that are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this proxy statement/prospectus/information statement including, without limitation, statements in this &#8220;APAC&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; regarding APAC&#8217;s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;seek&#8221; and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management&#8217;s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; beginning on page&#160;70 of this proxy statement/prospectus/information statement. APAC&#8217;s securities filings can be accessed on the EDGAR section of the SEC&#8217;s website at www.sec.gov. Except as expressly required by applicable securities law, APAC disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a blank check company incorporated on February&#160;5, 2021 as a Cayman Island exempted company and formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. We intend to effectuate our initial business combination using cash from the proceeds of our initial public offering and the private placement of the APAC Private Placement Warrants, the proceeds of the sale of our shares in connection with our initial business combination (pursuant to forward purchase agreements or backstop agreements we may enter into following the consummation of the initial public offering or otherwise), shares issued to the owners of the target, debt issued to bank or other lenders or the owners of the target, or a combination of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;23, 2022, we entered into the Merger Agreement, pursuant to which we will consummate the proposed Business Combination. Also on March&#160;23, 2022, and in connection with the execution of the Merger Agreement, (a)&#160;APAC, Ligand, OmniAb and Merger Sub entered into the Employee Matters Agreement, (b)&#160;OmniAb and the Sponsor entered into the Sponsor Insider Agreement with APAC and the Insiders and (c)&#160;we amended and restated that certain forward purchase agreement, dated August&#160;9, 2021, by entering into the A&amp;R FPA, by and among APAC, the Sponsor and OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;14, 2022, APAC entered into a promissory note with the Sponsor (the &#8220;Second Promissory Note&#8221;) pursuant to which APAC could borrow up to an aggregate of $750,000. The loan under the Second Promissory Note&#160;is non-interest bearing and payable upon the earlier of (i)&#160;completion of the APAC&#8217;s initial business combination or (ii)&#160;the date that the winding up of APAC is effective. The unpaid principal balance on the loan may be convertible into warrants at the option of the Sponsor at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. On March&#160;15, 2022, APAC drew down $500,000 under the Second Promissory Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Agreement and Plan of Merger</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Closing, each share of OmniAb Common Stock outstanding after the Distribution and immediately prior to the effective time of the Merger will be converted into a number of shares of New OmniAb Common Stock based on an exchange ratio determined by reference to a pre-money equity value for OmniAb of $850,000,000. Holders of OmniAb options, restricted stock units and performance stock units (determined after the Distribution and the division of Ligand equity awards into both Ligand equity awards and OmniAb Equity Awards pursuant to the Employee Matters Agreement) will have their awards rolled over into equity awards of New OmniAb and adjusted pursuant to the terms of the Employee Matters Agreement.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">225</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, at the Closing, holders of OmniAb Common Stock and equity awards will also receive the OmniAb Earnout Shares, with 50% of such earnout shares vesting upon the combined company&#8217;s achievement of a post-transaction VWAP of $12.50 per share of New OmniAb Common Stock for any 20 trading&#160;days over a consecutive 30 trading-day period, and the remainder vesting upon achievement of a post-transaction VWAP of $15.00 per share of New OmniAb Common Stock for any 20 trading&#160;days over a consecutive 30 trading-day period, in each case provided such vesting occurs during the five-year period following the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the proposed Business Combination, upon the Domestication (i)&#160;all issued and outstanding APAC Class&#160;A Ordinary Shares and APAC Class&#160;B Ordinary Shares will convert automatically, on a one-for-one basis, into shares of New OmniAb Common Stock, (ii)&#160;all issued and outstanding warrants will convert automatically into warrants to acquire shares of New OmniAb Common Stock and (iii)&#160;all issued and outstanding APAC Units will separate and convert automatically into one share of New OmniAb Common Stock and one-third of one warrant to purchase New OmniAb Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Separation Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, we entered into the Separation Agreement with OmniAb and Ligand, pursuant to which, among other things, (i)&#160;Ligand will undertake a series of internal reorganization and restructuring transactions to effect the transfer of its (direct or indirect) ownership of the OmniAb Business to OmniAb in the Separation and (ii)&#160;immediately prior to the Merger and after the Separation, Ligand will distribute 100% of the outstanding shares of OmniAb Common Stock to Ligand&#8217;s stockholders in the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Separation Agreement also sets forth other agreements among Ligand and OmniAb related to the Separation, including provisions concerning the termination and settlement of intercompany accounts and the obtaining of necessary governmental approvals and third-party consents. The Separation Agreement also sets forth agreements that will govern certain aspects of the relationship between Ligand and OmniAb after the Distribution, including provisions with respect to release of claims, indemnification, access to financial and other information and access to and provision of records.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employee Matters Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, APAC, Ligand, OmniAb and Merger Sub entered into the Employee Matters Agreement, which will provide for employee-related matters in connection with the transaction, including allocation of benefit plan assets and liabilities between Ligand and OmniAb, treatment of incentive equity awards in the proposed Business Combination and related covenants and commitments of the parties. Each existing Ligand equity award will generally be split into (i)&#160;a new Ligand equity award and (ii)&#160;a new OmniAb Equity Award, with any accrued value in the original Ligand equity award split between such awards based on the relative post-Closing values of Ligand and OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sponsor Insider Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, OmniAb and the Sponsor entered into the Sponsor Insider Agreement with APAC and the Insiders, pursuant to which, among other things, the Insiders agreed to vote any of our securities held by them to approve the proposed Business Combination and the other Company shareholder matters required pursuant to the Merger Agreement, and not to seek redemption of any of their Company securities in connection with the consummation of the proposed Business Combination. Pursuant to the Sponsor Insider Agreement, the Sponsor also agreed to subject up to 1,916,667 Sponsor Earnout Shares, to the same price-based vesting conditions as the OmniAb Earnout Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amended and Restated Forward Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, we entered into the A&amp;R FPA with the Sponsor and OmniAb. Pursuant to the A&amp;R FPA, we have agreed that, in connection with the consummation of the proposed Business Combination, we will issue and sell to the Sponsor 1,500,000 shares of New OmniAb Common Stock and warrants to acquire 1,666,667 shares of New OmniAb Common Stock for an aggregate purchase price of $15,000,000 with such purchase to be consummated immediately following the Domestication and prior to the proposed Business Combination. In addition to the Forward Purchase, the Sponsor has agreed to purchase up to an additional 10,000,000 shares of New OmniAb Common Stock and up to an additional 1,666,667 warrants, for an aggregate additional purchase price of up to $100,000,000, in order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds to be received by OmniAb stockholders from the Trust Account to be less than $100,000,000. The A&amp;R FPA also provides that in the event the Merger Agreement is terminated by Ligand under circumstances in which the Termination Fee would be payable under the Merger Agreement, Ligand shall pay the Sponsor a termination fee of $12,500,000 in connection therewith.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">226</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Certain Other Transaction Documents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Certain additional agreements will be entered into in connection with the transactions contemplated by the Merger Agreement, the Separation Agreement and the other agreements described above, including, among others:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a Tax Matters Agreement by and among Ligand, OmniAb and APAC, which governs, among other things, Ligand&#8217;s, OmniAb&#8217;s and APAC&#8217;s respective rights, responsibilities and obligations with respect to taxes, tax attributes and the preparation and filing of tax returns and responsibility for and preservation of the expected tax-free status of the transactions contemplated by the Separation Agreement and the Merger Agreement, and certain other tax matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an Amended and Restated Registration and Stockholder Rights Agreement by and among APAC, the Sponsor and the other parties signatory thereto, pursuant to which our the Original Registration Rights Agreement will be amended and restated in order to, among other things, provide certain equityholders of OmniAb as of immediately prior to the Closing of the proposed Merger with customary registration rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a Transition Services Agreement by and between Ligand and OmniAb, pursuant to which Ligand will, on a transitional basis, provide OmniAb with certain non-scientific and non-technical support services and other assistance after the Closing; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a Transition Services Agreement by and between Ligand and OmniAb, pursuant to which OmniAb will, on a transitional basis, provide Ligand with certain non-scientific and non-technical support services and other assistance after the Closing.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The consummation of the proposed Business Combination is subject to certain conditions as further described in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For more information about the Merger Agreement and the proposed Business Combination, see the section entitled &#8220;<i style="font-style:italic;">Proposal No.&#160;1&#8212;Business Combination Proposal.</i>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have neither engaged in any operations nor generated any revenues to date. Our only activities for the period from February&#160;5, 2021 (inception) through December&#160;31, 2021 were organizational activities, those necessary to prepare for the initial public offering, described below, and, after our initial public offering, identifying a target company for a business combination and related activities. We do not expect to generate any operating revenues until after the completion of our initial business combination. We will generate non-operating income in the form of interest income on cash and cash equivalents derived from the initial public offering. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For the period from February&#160;5, 2021 (inception) through December&#160;31, 2021, we had a net loss of $516,442 which resulted entirely from formation and operating costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For the period from February&#160;5, 2021 (inception) through December&#160;31, 2021, net cash used in operating activities was $1,136,926, which was due to our net loss of ($516,442) and by changes in prepaid expenses of $744,542 offset by changes in accounts payable of $15,440, due to related party of $884 and changes in accrued expenses of $107,734.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For the period from February&#160;5, 2021 (inception) through December&#160;31, 2021, net cash used in investing activities was $235,750,000, which was due to the investment of cash into the Trust Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For the period from February&#160;5, 2021 (inception) through December&#160;31, 2021, net cash provided by financing activities was $237,076,897, which was due to proceeds from initial public offering, net of underwriter&#8217;s discounts paid of $225,400,000, proceeds from sale of the APAC Private Placement Warrants of $12,350,000, proceeds from sponsor note of $175,000, proceeds from the issuance of APAC Class&#160;B Ordinary Shares to the Sponsor of $25,000, partially offset by the repayment of sponsor note of $175,000, and payment of offering costs of $698,103.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">On August&#160;12, 2021, we consummated the initial public offering of 23,000,000 units, including 3,000,000 units that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at $10.00 per unit, generating gross proceeds of </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">227</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">$230,000,000. Each unit consisted of one APAC Class&#160;A Ordinary Share and one-third of one redeemable warrant to purchase one APAC Class&#160;A Ordinary Share at an exercise price of $11.50 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Simultaneously with the closing of the initial public offering, the Sponsor purchased an aggregate of 8,233,333 APAC Private Placement Warrants, including 900,000 APAC Private Placement Warrants that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at a price of $1.50 per unit ($12,350,000 in the aggregate). Each APAC Private Placement Warrant is exercisable to purchase one APAC Class&#160;A Ordinary Share at a price of $11.50 per share. The proceeds from the sale of the APAC Private Placement Warrants were added to the net proceeds from the initial public offering held in the Trust Account. If we do not complete our initial business combination within 18&#160;months from August&#160;12, 2021, the proceeds from the sale of the APAC Private Placement Warrants will be used to fund the redemption of the public shares (subject to the requirements of applicable law) and the APAC Private Placement Warrants will expire worthless.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (less taxes payable and deferred underwriting commissions), to complete our initial business combination. We may withdraw interest income (if any) to pay income taxes, if any. Our annual income tax obligations will depend on the amount of interest and other income earned on the amounts held in the Trust Account. We expect the interest income earned on the amount in the Trust Account (if any) will be sufficient to pay our franchise and income taxes. To the extent that our equity or debt is used, in whole or in part, as consideration to complete our initial business combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, APAC had $189,971 in cash held outside of the Trust Account and a working capital surplus of $496,302. APAC anticipates that the cash held outside of the Trust Account as of December&#160;31, 2021 will be not sufficient to allow APAC to operate for at least the next 12&#160;months from the issuance of the financial statements, assuming that a business combination is not consummated during that time. APAC has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. These conditions raise substantial doubt about APAC&#8217;s ability to continue as a going concern for a period of time within one&#160;year after the date that the financial statements are issued. Management plans to address this uncertainty through the Business Combination as discussed above. There is no assurance that APAC&#8217;s plans to consummate the Business Combination will be successful or successful by February&#160;12, 2023. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We did not have any off-balance sheet arrangements as of December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Contractual Obligations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Promissory Note&#160;&#8212; Related Party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February&#160;12, 2021, APAC issued an unsecured promissory note to the sponsor (the &#8220;First Promissory Note&#8221;), pursuant to which APAC could borrow up to an aggregate of $300,000 to cover expenses related to the initial public offering. The First Promissory Note&#160;was non-interest bearing and was payable on the earlier of (i)&#160;December&#160;31, 2021 or (ii)&#160;the consummation of the initial public offering. APAC&#8217;s sponsor paid certain offering costs totaling $55,725, which was included in the outstanding balance of the First Promissory Note&#160;as of March&#160;22, 2021, and APAC borrowed $119,275 on June&#160;23, 2021. On August&#160;12, 2021, APAC repaid the outstanding balance under the First Promissory Note&#160;of $175,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Administrative Support Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC entered into an agreement, commencing on August&#160;9, 2021, to pay an affiliate of the sponsor a total of $10,000 per&#160;month for administrative, financial and support services. Upon the completion of an initial business combination, APAC will cease paying these&#160;monthly fees. Under this agreement, $46,129 of expenses were incurred during the period from February&#160;5, 2021 (inception) through December&#160;31, 2021.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">228</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Underwriting Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The underwriters were paid a cash underwriting discount of $0.20 per APAC Unit, or $4,600,000 in the aggregate, upon the closing of the initial public offering and exercise of the over-allotment in full on August&#160;12, 2021. In addition, $0.35 per unit, or $8,050,000 in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that APAC completes an initial business combination, subject to the terms of the underwriting agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following critical accounting policies<i style="font-style:italic;">:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class&#160;A Ordinary Shares Subject to Possible Redemption</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of the 23,000,000 APAC Class&#160;A Ordinary Shares sold as part of the APAC Units in the initial public offering contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company&#8217;s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company&#8217;s amended and restated certificate of incorporation. In accordance with SEC and its staff&#8217;s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of APAC require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all APAC Class&#160;A Ordinary Shares have been classified outside of permanent equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional paid-in capital and accumulated deficit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss Per Ordinary Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. APAC has not considered the effect of the warrants sold in the initial public offering and private placement to purchase an aggregate of 15,900,000 shares in the calculation of diluted income per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, Debt&#160;&#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#160;&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if converted method for all convertible instruments. ASU 2020-06 is effective for APAC on January&#160;1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January&#160;1, 2021. APAC adopted ASU 2020-06 effective January&#160;1, 2021 using the modified retrospective method of transition. The adoption of ASU 2020-06 did not have a material impact on the financial statements for the period from February&#160;5, 2021 (inception) through December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">229</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_45ffb014_66df_4034_b17d_3c06883bfccc"></a><a id="Main_MANAGEMENTOFAPAC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MANAGEMENT OF APAC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Directors and Executive Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">References in this section to &#8220;APAC,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221; refer to Avista Public Acquisition Corp. II.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">APAC&#8217;s current directors and officers are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td></tr><tr><td style="vertical-align:bottom;width:45%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Thompson Dean</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">63</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Executive Chairman and Director</p></td></tr><tr><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">David Burgstahler</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">53</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">President, Chief Executive Officer and Director</p></td></tr><tr><td style="vertical-align:bottom;width:45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Sriram Venkataraman</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">49</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Executive Vice President</p></td></tr><tr><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Robert Girardi</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">40</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Executive Vice President</p></td></tr><tr><td style="vertical-align:bottom;width:45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">John Cafasso</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">49</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Benjamin Silbert</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">51</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General Counsel</p></td></tr><tr><td style="vertical-align:bottom;width:45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">William E. Klitgaard</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">69</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">L&#226;le White</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">66</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Wendel Barr</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">60</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Director</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Thompson Dean</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Thompson Dean has served as a Director and as the Executive Chairman of the APAC Board since February&#160;12, 2021. Mr.&#160;Dean is a Managing Partner and Chairman of the Sponsor and has served in various capacities at Avista Capital Partners (&#8220;Avista&#8221;) since its founding in 2005. From 1995 to 2005, Mr.&#160;Dean served as Co-Managing Partner of Donaldson, Lufkin&#160;&amp; Jenrette (&#8220;DLJMB&#8221;) and was Chairman of the investment committees of DLJMB I, DLJMB II, DLJMB III and DLJ Growth Capital Partners. Mr.&#160;Dean currently serves on the board of directors of Cooper Consumer Health, National Spine&#160;&amp; Pain Centers, eMolecules, Probo Medical and Vision Healthcare. Mr.&#160;Dean previously served on the board of directors of Acino International AG, Charles River Laboratories, ConvaTec Group, Fisher Scientific, Nycomed, Trimb Healthcare, VWR and Zest Dental Solutions. Mr.&#160;Dean is a former trustee of Choate Rosemary Hall and The Eaglebrook School. Mr.&#160;Dean received a B.A. from the University of Virginia, where he was an Echols Scholar, and an M.B.A. with high distinction from Harvard Business School, where he was a Baker Scholar. We believe that Mr.&#160;Dean&#8217;s executive level management experience at Avista, board and advisory experience with other companies in and outside of the healthcare industry and his extensive experience in the areas of finance, strategy, international business transactions and mergers and acquisitions makes him well-qualified to serve as a member of the APAC Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">David Burgstahler</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">David Burgstahler has served as a Director on the APAC Board and as our President and Chief Executive Officer since February&#160;12, 2021. Mr.&#160;Burgstahler is a Managing Partner and Chief Executive Officer of Avista and has served in various capacities at Avista since its founding in 2005. Prior to forming Avista, he was a Partner of DLJMB from 2004 to 2005 and served in various capacities at DLJMB and its affiliates from 1995 to 2005. Prior to DLJMB, Mr.&#160;Burgstahler worked at Andersen Consulting (now known as Accenture) and McDonnell Douglas (now known as Boeing). He currently serves as on the board of directors of Cosette Pharmaceuticals, Inform Diagnostics, RVL Pharmaceuticals (NASDAQ: RVL), United BioSource Corporation, XIFIN and other private company boards. Mr.&#160;Burgstahler also previously served on the board of directors of AngioDynamics (NASDAQ: ANGO), Arcadia Consumer Healthcare, Armored AutoGroup, BioReliance Corp., ConvaTec Group, Focus Diagnostics,&#160;Inc., INC Research Holdings (NASDAQ: INCR), Lantheus Holdings, MPI Research,&#160;Inc., Strategic Partners, LLC, Visant Corp., WideOpenWest (NYSE: WOW) and Warner Chilcott PLC (NASDAQ: WCRX). Mr.&#160;Burgstahler received a B.S. in Aerospace Engineering from the University of Kansas and an M.B.A. from Harvard Business School. We believe that Mr.&#160;Burgstahler&#8217;s extensive experience serving as a director for a diverse group of private and public companies, including those in the healthcare industry, makes him well-qualified to serve as a member of the APAC Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sriram Venkataraman</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Sriram Venkataraman has been our Executive Vice President since February&#160;12, 2021. Mr.&#160;Venkataraman is currently a Partner at Avista and originally joined Avista in 2007. Prior to joining Avista, Mr.&#160;Venkataraman was a Vice President in the Healthcare Investment Banking group at Credit Suisse which he joined in 2001. Prior to Credit Suisse, Mr.&#160;Venkataraman worked at GE </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">230</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;">Healthcare (formerly known as GE Medical Systems). Mr.&#160;Venkataraman currently serves on the board of directors of Cosette Pharmaceuticals, eMolecules, Inform Diagnostics, National Spine&#160;&amp; Pain Centers, Probo Medical, RVL Pharmaceuticals (NASDAQ: RVL), Solmetex and XIFIN and has previously served as s director of AngioDynamics (NASDAQ: ANGO), Lantheus Holdings (NASDAQ: LNTH), OptiNose (NASDAQ: OPTN) and Zest Dental Solutions. Mr.&#160;Venkataraman received a M.S. in Electrical Engineering from the University of Illinois, Urbana-Champaign and an M.B.A. with honors from The Wharton School at the University of Pennsylvania.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Robert Girardi</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Robert Girardi has been our Executive Vice President since February&#160;12, 2021. Mr.&#160;Girardi is currently a Partner at Avista and originally joined Avista in 2010. Prior to joining Avista, Mr.&#160;Girardi was a Senior Associate at Quadrangle Group where he focused on private equity investments in the media and communications industries. Prior to joining Quadrangle, Mr.&#160;Girardi was an Associate at Bear Stearns Merchant Banking where he focused on private equity investments across a range of industries. Mr.&#160;Girardi also worked as an Analyst in the investment banking division at J.P. Morgan. Mr.&#160;Girardi currently serves on the board of directors of GCM Holding Corporation, ACP Northern Holdings and United BioSource Corporation and previously served on the board of directors of Arcadia Consumer Healthcare, DataBank Holdings, MPI Research,&#160;Inc. and Telular Corporation. Mr.&#160;Girardi received a B.S. with highest distinction in business administration from the University of North Carolina at Chapel Hill and an M.B.A. with honors from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amanda Heravi</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Amanda Heravi has been our Investor Relations Officer since February&#160;12, 2021. Ms.&#160;Heravi is the Head of Investor Relations at Avista and was one of the founding members of Avista in 2005. Prior to Avista, Ms.&#160;Heravi was the Director of Finance and Administration at Dorset Capital Management, which she joined in 1999, where she was responsible for investor relations and the financial, operational and administrative aspects of the fund. Prior to Dorset, Ms.&#160;Heravi worked at Montgomery Securities. Ms.&#160;Heravi received a B.A. from the University of California, Berkeley.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">John Cafasso</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">John Cafasso has been our Chief Financial Officer since February&#160;12, 2021. Mr.&#160;Cafasso joined Avista in 2011. Prior to joining Avista, Mr.&#160;Cafasso was in the asset management division of Credit Suisse from 2001 to 2011, where he was responsible for the accounting and reporting for Credit Suisse&#8217;s direct private equity funds. Prior to joining Credit Suisse, Mr.&#160;Cafasso was a Manager at KPMG, LLP in the financial services practice. Mr.&#160;Cafasso is a Certified Public Accountant and received a B.B.A. degree from Hofstra University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Benjamin Silbert</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Benjamin Silbert has been our General Counsel and Secretary since February&#160;12, 2021. Mr.&#160;Silbert is the Chief Administrative Officer and General Counsel at Avista and was one of the founding members of Avista in 2005. Prior to joining Avista, Mr.&#160;Silbert was at DLJMB from 2001 to 2005. While at DLJMB, Mr.&#160;Silbert acted as internal counsel on a number of investments and divestitures, in addition to fund and partnership matters. Prior to joining DLJMB, Mr.&#160;Silbert was a lawyer in the private equity and mergers and acquisitions practice groups of Morgan, Lewis&#160;&amp; Bockius LLP, which he joined in 1996. Mr.&#160;Silbert received a B.A. from Haverford College and a J.D. from Columbia Law School.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">William E. Klitgaard</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">William E. Klitgaard has served as a Director on the APAC Board since August&#160;12, 2021. Mr.&#160;Klitgaard is an operating executive at Avista, where was retained in 2020. Mr.&#160;Klitgaard has over two decades of experience leading and advising healthcare businesses in the Healthcare IT and outsourced pharma services space. Mr.&#160;Klitgaard most recently served as President of Enlighten Health, a division of LabCorp (NYSE:LH) that focuses on innovation and creation of new information-based services utilizing core assets of LabCorp and Covance,&#160;Inc. Previously, he spent 19&#160;years at Covance, one of the world&#8217;s largest contract research organizations, where he served for three&#160;years as Corporate Senior Vice President and Chief Information Officer, and nearly twelve&#160;years as Corporate Senior Vice President and Chief Financial Officer. Prior to his time at Covance, Mr.&#160;Klitgaard held finance leadership positions at Kenetech Corporation, a wind turbine manufacturer, and Consolidated Freightways,&#160;Inc., a freight service and logistics company. Mr.&#160;Klitgaard currently serves as a director and chairman of the audit committee of Syneos Health,&#160;Inc. (NASDAQ: SYNH), since March&#160;2017, as a director of Inform Diagnostics, since December&#160;2019 and as a director of XIFIN,&#160;Inc. (&#8220;XIFIN&#8221;) since </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">231</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;">January&#160;2020. Mr.&#160;Klitgaard previously served as a director of Liaison Technologies, Bioclinica,&#160;Inc. and Certara,&#160;L.P. Mr.&#160;Klitgaard earned a B.A. in Economics from the University of California at Berkeley, and a Master&#8217;s degree from the Sloan Management School, Massachusetts Institute of Technology. We believe that Mr.&#160;Klitgaard&#8217;s extensive experience leading and advising healthcare businesses makes him well-qualified to serve as a member of the APAC Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">L&#226;le White</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">L&#226;le White has served as a Director since August&#160;12, 2021. Ms.&#160;White is the Executive Chairman, Chief Executive Officer and founder of XIFIN,&#160;Inc. (&#8220;XIFIN&#8221;), a health information technology company that leverages diagnostic information to improve the quality and economics of healthcare. Ms.&#160;White founded XIFIN in 1997 and has over 25&#160;years of experience in information systems development and medical billing. Ms.&#160;White lectures extensively on these topics and has consulted for major laboratories and laboratory associations throughout the U.S. Ms.&#160;White worked with HCFA and the U.S. Office of the Inspector General to develop the first OIG Model Compliance Program. She has chaired the state and federal contractor committees for California Clinical Laboratory Association for&#160;years, maintaining a working relationship with the Medicare Administrative Contractors and Department of Health and Human Services. Ms.&#160;White was previously Vice President of Finance of Laboratory Corporation of America, one of the largest clinical reference laboratories in the United States, and its predecessor National Health Laboratories, where she led the software development of several accounts receivable, inventory, cost accounting and financial management systems for the laboratory industry. Ms.&#160;White currently serves as a director of Cardiff Oncology,&#160;Inc. (NASDAQ: CRDF) and previously served as a director of bioTheranostics while it was a BioMerieux subsidiary and CombiMatrix Corporation, until its acquisition by Invitae Corporation in 2017. Ms.&#160;White has a B.A. in Finance and an M.B.A. from Florida International University. We believe that Ms.&#160;White&#8217;s extensive executive experience with the strategic, financial and operational requirements of healthcare organizations makes her well-qualified to serve as a member of the APAC Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Wendel Barr</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Wendel Barr has served as a Director since August&#160;12, 2021. Mr.&#160;Barr has over 25&#160;years of experience on the leading edge in the medical devices and life sciences industries. From September&#160;2017 through November&#160;2019, Mr.&#160;Barr was the Chief Executive Officer, President and director of Vium,&#160;Inc., a translational medicine and biotechnology company focused on improving the success of drug development through the creation of more precise and reproducible disease models. Prior to Vium, Mr.&#160;Barr was the Chief Executive Officer and director of Synteract,&#160;Inc., a full-service, global contract research organization dedicated to the clinical research needs of biotechnology, medical device and pharmaceutical companies. Prior to Synteract, Mr.&#160;Barr was at Covance from 2000 through 2011, where he had multiple roles, including Chief Operating Officer and Executive Vice President. Prior to Covance, Wendel Barr was Vice President and General Manager at Marconi Medical Systems and also held several positions of increasing responsibility with GE Healthcare including General Manager from 1984 to 1999. Mr.&#160;Barr earned a B.S. in Electronics Engineering from DeVry University and a M.B.A. from National University. We believe that Mr.&#160;Barr&#8217;s extensive experience leading companies in the medical devices and life sciences space makes him well-qualified to serve as a member of the APAC Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Corporate Governance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Number and Terms of Office of Officers and Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The APAC Board consists of five members. Holders of APAC Class&#160;B Ordinary Shares have the right to elect all of APAC&#8217;s directors prior to consummation of our initial business combination and holders of APAC Class&#160;A Ordinary Shares do not have the right to vote on the appointment of directors during such time. These provisions of the Cayman Constitutional Documents may only be amended if approved by special resolution passed by at least 90% of such shareholders as, being entitled to vote thereon in person or by proxy at a general meeting or by way of a unanimous written resolution. Each of APAC&#8217;s directors holds office for a two-year term. Subject to any other special rights applicable to the shareholders, any vacancies on the APAC Board may be filled by the affirmative vote of a majority of the remaining directors of the APAC Board or by ordinary resolution passed by the holders of APAC ordinary shares following a business combination (or, prior to our a business combination, passed by the holders of APAC Class&#160;B Ordinary Shares).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Pursuant to an agreement entered into in connection with the initial public offering, the Sponsor, upon and following consummation of a business combination, will be entitled to nominate three individuals for appointment to the APAC Board, as long as the Sponsor holds any securities covered by the Original Registration Rights Agreement.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">232</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Our officers are appointed by the APAC Board and serve at the discretion of the APAC Board, rather than for specific terms of office. The APAC Board is authorized to appoint persons to the offices set forth in the Cayman Constitutional Documents as it deems appropriate. The Cayman Constitutional Documents provide that our officers may consist of one or more of chairman of the APAC Board, chief executive officer, president, chief financial officer, vice presidents, secretary, treasurer and such other offices as may be determined by the APAC Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Director Independence</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Nasdaq listing standards generally require that a majority of the APAC Board be independent. An &#8220;independent director&#8221; is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the opinion of the APAC Board, would interfere with the director&#8217;s exercise of independent judgment in carrying out the responsibilities of a director. However, under Nasdaq listing rule&#160;5615(b)(1), a company listing in connection with its initial public offering is permitted to phase in its compliance with the majority independent board requirements. Additionally, under the Nasdaq corporate governance standards, a company of which more than 50% of the voting power is held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate governance requirements, including the requirements that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we have a board that includes a majority of &#8220;independent directors,&#8221; as defined under the rules&#160;of Nasdaq;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we have a compensation committee of our board that is comprised entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we have a nominating and corporate governance committee of our board that is comprised entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities.</span></td></tr></table><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The APAC Board has determined to take advantage of the phase-in and &#8220;controlled company&#8221; exemptions to not have a majority independent board, with Mr.&#160;Klitgaard and Mr.&#160;Barr being &#8220;independent directors&#8221; as defined in the Nasdaq listing standards. Our independent directors have regularly scheduled meetings at which only independent directors are present.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Executive Officer and Director Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">None of APAC&#8217;s executive officers or directors have received any cash compensation for services rendered to APAC. Since the consummation of our initial public offering and until the earlier of consummation of our initial business combination or our liquidation, APAC reimburses the Sponsor for office space, secretarial and administrative services provided to APAC in the amount of $10,000 per&#160;month. In addition, our Sponsor, executive officers and directors, or their respective affiliates are reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable Business Combinations. Our audit committee reviews on a quarterly basis all payments that were made by us to our Sponsor, executive officers or directors, or their affiliates. Any such payments prior to a business combination were or will be made using funds held outside the trust account. Other than quarterly audit committee review of such reimbursements, we do not have any additional controls in place governing our reimbursement payments to our directors and executive officers for their out-of-pocket expenses incurred in connection with our activities on our behalf in connection with identifying and consummating a business combination. Other than these payments and reimbursements, no compensation of any kind, including finder&#8217;s and consulting fees, will be paid by APAC to the Sponsor, executive officers and directors, or their respective affiliates, prior to completion of our initial business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">We are not party to any agreements with our executive officers and directors that provide for benefits upon termination of employment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Committees of the APAC Board</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The APAC Board has three standing committees: an audit committee, a nominating committee and a compensation committee. Subject to phase-in rules&#160;and limited exceptions, among other things, Nasdaq rules&#160;require that the compensation committee and the nominating committee of a listed company be comprised solely of independent directors. However, subject to certain phase-in exemptions provided by Nasdaq listing rule&#160;5615(b)(1), and the exemptions available to a &#8220;controlled company&#8221; noted above, our nomination committee and compensation committee are currently not comprised solely of independent directors.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">233</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Further, subject to the phase-in exceptions set forth in Rule&#160;10A-3(b)(1)(iv)(A)&#160;under the Exchange Act and Nasdaq listing rule&#160;5615(b)(1), our audit committee is currently not comprised solely of independent directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Audit Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">APAC has established an audit committee of the APAC Board. Mr.&#160;Klitgaard, Mr.&#160;Barr and Ms.&#160;White serve as members of our audit committee. Mr.&#160;Klitgaard serves as the chairman of the audit committee. Each member of the audit committee is financially literate and the APAC Board has determined that each of Mr.&#160;Klitgaard and Mr.&#160;Barr qualify as an &#8220;audit committee financial expert&#8221; as defined in applicable SEC rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The primary functions of our audit committee include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">meeting with our independent registered public accounting firm regarding, among other issues, audits and adequacy of our accounting and control systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">monitoring the independence of our independent registered public accounting firm&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inquiring and discussing with management our compliance with applicable laws and regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pre-approving all audit services and permitted non-audit services to be performed by our independent registered public accounting firm, including the fees and terms of the services to be performed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">appointing or replacing the independent registered public accounting firm;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determining the compensation and oversight of the work of the independent registered public accounting firm (including resolution of disagreements between management and the independent auditor regarding financial reporting) for the purpose of preparing or issuing an audit report or related work;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or reports which raise material issues regarding our financial statements or accounting policies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">monitoring compliance on a quarterly basis with the terms of the initial public offering and, if any noncompliance is identified, immediately taking all action necessary to rectify such noncompliance or otherwise causing compliance with the terms of the initial public offering; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving all payments made to our existing shareholders, executive officers or directors and their respective affiliates. Any payments made to members of our audit committee will be reviewed and approved by the APAC Board, with the interested director or directors abstaining from such review and approval.</span></td></tr></table><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The audit committee is a separately designated standing committee established in accordance with Section&#160;3(a)(58)(A)&#160;of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Compensation Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">APAC has established a compensation committee of the APAC Board. The members of our compensation committee are Mr.&#160;Klitgaard, Mr.&#160;Barr and Ms.&#160;White. Mr.&#160;Klitgaard serves as chairman of the compensation committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">APAC adopted a compensation committee charter, which details the principal functions of the compensation committee, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Financial Officer&#8217;s and Chief Executive Officer&#8217;s compensation, evaluating our Chief Financial Officer&#8217;s and Chief Executive Officer&#8217;s performance </span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">234</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer and Chief Financial Officer based on such evaluation&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving the compensation of all of our other Section&#160;16 executive officers&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing our executive compensation policies and plans&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">implementing and administering our incentive compensation equity-based remuneration plans&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assisting management in complying with our proxy statement and annual report disclosure requirements&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers and employees&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">producing a report on executive compensation to be included in our annual proxy statement&#894; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.</span></td></tr></table><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The charter also provides that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Compensation Committee Interlocks and Insider Participation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Aside from Mr.&#160;Burgstahler and Mr.&#160;Venkataraman, who sit on the compensation committee of XIFIN, where Ms.&#160;White serves as the Chief Executive Officer, none of our executive officers currently serves, and in the past&#160;year has not served, (i)&#160;as a member of the compensation committee of another entity, one of whose executive officers served on our compensation committee, or (ii)&#160;as a member of the compensation committee of another entity, one of whose executive officers served on the APAC Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nominating Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">APAC has established a nominating committee of the APAC Board. The members of our nominating committee are Mr.&#160;Klitgaard, Mr.&#160;Barr and Ms.&#160;White. Mr.&#160;Klitgaard serves as chairman of the nominating committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The nominating committee is responsible for overseeing the selection of persons to be nominated to serve on the APAC Board. The nominating committee considers persons identified by its members, management, shareholders, investment bankers and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The nominating committee will consider a number of qualifications relating to management and leadership experience, background and integrity and professionalism in evaluating a person&#8217;s candidacy for membership on the board of directors. The nominating committee may require certain skills or attributes, such as financial or accounting experience, to meet specific board needs that arise from time to time and will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of board members. The nominating committee does not distinguish among nominees recommended by shareholders and other persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Code of Ethics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC has adopted a code of ethics applicable to APAC&#8217;s directors, officers and employees. A copy of the code of ethics is available on our website at https://avistapac.com/ahpac/ and will be provided without charge upon request from APAC in writing at 65 East 55th Street, 18th Floor, New York, NY 10022. APAC intends to disclose any amendments to or waivers of certain provisions of APAC&#8217;s code of ethics in a Current Report on Form&#160;8-K.&#160;See the section of this proxy statement/prospectus/information statement entitled &#8220;<i style="font-style:italic;">Where You Can Find More Information</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">235</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ecc47870_b07c_4985_8c73_89af179f0a22"></a><a id="Main_INFORMATIONABOUTLIGAND"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INFORMATION ABOUT LIGAND</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand specializes in drug discovery, early-stage drug development, product reformulation and partnering with other pharmaceutical companies (who conduct late-stage development, regulatory management and commercialization) ultimately to generate Ligand&#8217;s revenue. Ligand has established multiple alliances, licenses and other business relationships with the world&#8217;s leading pharmaceutical companies including Amgen, Merck, Pfizer, Sanofi, Janssen, Takeda, Servier, Gilead Sciences and Baxter International.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Separation, Ligand&#8217;s business consisted of the OmniAb Business, and other platforms including the Captisol&#174; platform and Pelican Expression Technology&#174;. The Captisol&#174; platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand&#8217;s Pelican Expression Technology&#174; is a robust, validated, cost-effective and scalable platform for recombinant protein production that is especially well-suited for complex, large-scale protein production where traditional systems are not.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Ligand&#8217;s principal executive offices are located at 5980 Horton Street, Suite&#160;405, Emeryville, CA 94608, and its telephone number is (858) 550-7500. Ligand Common Stock are listed on The Nasdaq Global Market under the symbol &#8220;LGND.&#8221; Ligand was incorporated under the laws of the State of Delaware on May&#160;18, 1995. Ligand&#8217;s internet address is www.ligand.com. The information contained on Ligand&#8217;s website is not incorporated by reference into this proxy statement/prospectus/information statement or any future documents that may be filed with the SEC and should not be considered part of this document.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">236</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f5711388_8dff_49a7_8861_38d14a3358ae"></a><a id="MAin_INFORMATIONABOUTOMNIABBUSINESS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INFORMATION ABOUT THE OMNIAB BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Unless the context otherwise requires, references in this subsection &#8220;&#8212;Information About the OmniAb Business&#8221; to &#8220;OmniAb,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; generally refer to OmniAb prior to the Business Combination.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our mission is to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies. We intend to achieve this mission by enabling the discovery of high-quality therapeutic candidates and by being the partner of choice for pharmaceutical and biotechnology companies. We believe that pairing the large and diverse antibody repertoires generated from our proprietary transgenic animals with our cutting-edge and high-throughput validated screening tools will deliver high-quality therapeutic candidates for a wide range of diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our OmniAb technology platform creates and screens diverse antibody pools and is designed to quickly identify optimal antibodies for our partners&#8217; drug development efforts. We harness the power of Biological Intelligence, which we built into our proprietary transgenic animals and paired with our high-throughput screening technologies to enable the discovery of high-quality, fully-human antibody therapeutic candidates. We believe these antibodies are high quality because they are naturally optimized in our proprietary host systems for affinity, specificity, developability and functional performance. Our partners have access to these antibody candidates that are based on unmatched biological diversity and optimized through integration across a full range of technologies, including antigen design, transgenic animals, deep screening and characterization. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized antibody discovery solutions. As of December&#160;31, 2021, we had 57&#160;active partners and over 250 active programs, including 25 OmniAb-derived antibodies in clinical development and two approved products, zimberelimab, which was approved in China for the treatment of recurrent or refractory classical Hodgkin&#8217;s lymphoma, and sugemalimab, which was approved in China for the first-line treatment of metastatic (stage IV) non-small cell lung cancer in combination with chemotherapy. Our robust experience and development activity with our partners gives us critical insights into the industry and creates a positive feedback loop through which we plan to continue to advance our platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the heart of the OmniAb technology platform lies the Biological Intelligence of our proprietary transgenic animals, including OmniRat, OmniMouse and OmniChicken, that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. Biological Intelligence refers to the ability of the immune system in our transgenic animals to create optimized antibodies through a process that has evolved over 500&#160;million&#160;years. The immune system function is to adaptively respond to a given target through an iterative process of diversification and selection that produces novel antibodies with high affinity, specificity, and expression levels. Through its proprietary and carefully designed transgenes, OmniAb&#8217;s Biological Intelligence taps into this powerful <i style="font-style:italic;">in vivo</i> process to generate human antibodies directly from its transgenic animals. OmniFlic and OmniClic are common light-chain rats and chickens, respectively, designed to generate bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets. To our knowledge, we are the industry&#8217;s only four-species <i style="font-style:italic;">in vivo </i>antibody discovery platform, making OmniAb the most diverse host system available in the industry. We believe natural antibodies are superior to other antibody generation methods because they are naturally optimized through an iterative <i style="font-style:italic;">in vivo</i> process that preferentially selects antibodies to effectively bind to a specific antigen. Our technology can be leveraged to develop multiple therapeutic formats including mono-, bi- and multi-specific antibodies, antibody-drug conjugates (ADCs) and chimeric antigen receptor T cell (CAR-T). By generating large and diverse pools of high-quality antibodies, we believe Biological Intelligence increases the probability of success of therapeutic antibody discovery and helps limit the attrition of antibody product candidates in the clinic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Our technology investments are methodical and deliberate, designed to enable our partner-centric business model to leverage the most cutting-edge solutions to solve the biggest challenges in antibody drug discovery. Some partners prefer integrated end-to-end discovery capabilities, while others prefer to use certain of our technologies within their own labs. This flexibility not only provides value to our partners, but also allows for greater scalability of our business since we do not have to build out capacity for partners that prefer to use some of their own technologies in the process. The breadth and depth of our partner-centric model benefits our investment decision making by providing critical insights into the needs and direction of the industry. Our current OmniAb clinical stage and approved partner pipeline is depicted in the figure below.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">237</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:335.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 1: The OmniAb Clinical Stage and Approved Partner Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ahpa-20220416xs4023.jpg" alt="Graphic" style="display:inline-block;height:335.2pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:460.4pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to <i style="font-style:italic;">Vaccines</i> journal, antibodies are among the fastest growing class of drugs and are used across multiple therapeutic areas including oncology, inflammation, neurodegeneration. In 2021, approved antibody-based therapeutics accounted for over $215.0&#160;billion in sales and 49 antibody therapeutics reached blockbuster status in 2021 with sales higher than $1.0&#160;billion, according to data published by La Merie Publishing. Furthermore, Fatpos Global estimates that antibody-based therapeutic sales are expected to grow to over $375.0 billion by 2030. The favorable drug-like properties of antibodies, including high specificity, limited off-target toxicity, superior immune stimulation, and the ability to modulate half-life circulation in serum, have accelerated investment in antibody therapeutics. This has resulted in higher success rates for antibody therapeutics when compared to small molecule modalities, according to Clinical Development Success Rates and Contributing Factors 2011-2020, a study of over 9,000 clinical development programs published by PharmaIntelligence. These factors have led to substantial investment in antibody discovery, which we believe will continue to expand the total addressable market for antibody discovery technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Despite industry momentum that has resulted in an overall increase in the number of antibody therapeutic approvals per&#160;year, drug discovery and development has become increasingly fragmented, outdated and non-robust. While many biotechnology companies bring a focused approach to science, their biological hypotheses are often tested utilizing suboptimal antibody discovery methods due to reliance on legacy technologies. Meanwhile, many larger companies have also continued to rely on legacy technologies, often due to the inability to selectively integrate newer technologies at their facilities or because the benefits of technological updates are limited by outdated workflows. Additionally, outsourced technologies that have tried to address these shortcomings often lack flexibility. These legacy approaches are burdened with critical disadvantages including low antibody diversity, lengthy discovery timelines, limited functional parameter data, excess costs or lack of flexibility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">We believe that by eliminating the need for each company to build a comprehensive antibody discovery engine, we can unlock innovation and value across a broad network of partners. Many emerging and established life sciences companies have been built around technologies that focus on a single or a limited number of steps in the discovery process, including antigen design, transgenic </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">238</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:246.56pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">animal platforms, single-cell analysis, sequencing, bioinformatics, and proprietary assays. We believe our comprehensive, biologically-driven technology platform provides the industry with a cutting-edge solution for all critical components of the antibody discovery continuum. By providing leading antibody discovery solutions to the industry, we aim to increase the probability of success, reduce costs and shorten development timelines for our partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As depicted in Figure 2 below, our technology platform is a suite of integrated technologies designed to discover a wide range of high-quality therapeutic antibodies that leverage the inherent diversity produced by our transgenic animals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 2: The OmniAb Technology Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ahpa-20220416xs4024.jpg" alt="Graphic" style="display:inline-block;height:246.56pt;width:462.69pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our technologies within the OmniAb platform improve the productivity and efficiency of each step of the discovery process:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Create Diverse Antibody Pools.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We believe generating large and diverse pools of high-quality antibodies increases the likelihood of discovering the antibody with the most desirable therapeutic characteristics. At the heart of the OmniAb technology platform is the Biological Intelligence of our proprietary transgenic animals, technology that we own. Our animals have been genetically modified to produce a large number of naturally optimized, high-quality, fully-human antibodies. We offer the industry&#8217;s only four-species platform to address a wide range of biological challenges facing our partners in their antibody discovery efforts. We pair our Biological Intelligence with computational antigen design to generate robust antibody responses to biological targets, including but not limited to difficult and complex targets such as ion channels, G&#160;protein-coupled receptors (GPCRs), transporters, and other transmembrane proteins. Our antigen design technology includes transmembrane and cell-surface protein technology that we own or exclusively license.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Screen Antibody Candidates.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Our proprietary xPloration microcapillary technology, which we own or license, and Gel Encapsulated Microenvironment (GEM) technology, which we own, screen pools of antibody-secreting B cells at a single-cell level to quickly identify antibodies in as little as a few hours, saving weeks compared to traditional technologies. xPloration characterizes tens of millions of antibody producing cells on multiple parameters, then leverages AI to analyze immense amounts of phenotypic data to automatically select and rank thousands of promising therapeutic candidates. Our industry-leading throughput allows for the discovery of rare antibodies that may otherwise be missed with traditional technologies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Identify the Right Antibody.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Our discovery teams are able, as needed, to work closely with partners to identify the right antibody for a particular target profile. Antibody candidates identified through our screening technologies are further </span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">239</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">characterized through a cascade of performance assays. The data from multi-parameter screening and performance assays is used in combination with bioinformatics to analyze the antibody repertoire and enable our partners to select the right antibody.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to our antibody discovery solutions, we possess extensive biological capabilities focused on ion channels, transporters and x-ray fluorescence. Ion channels and transporters are key components in a wide variety of biological processes and have broad therapeutic applicability across cancer, metabolic disease, pain, neurological diseases, infectious diseases and others. In the search for new drugs, ion channels are a frequent, but challenging target. We believe our capabilities in the ion channel area are leverageable for both small molecule and antibody approaches to therapeutic development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We partner with pharmaceutical and biotechnology companies that vary in size, clinical stage, geography and therapeutic focus. Our license agreements are negotiated separately for each discovery partner, and as a result, the financial terms and contractual provisions vary from agreement to agreement. We structure our license agreements with partners to typically include: (i)&#160;payments for technology access and payments for performance of research services; (ii)&#160;downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones; and (iii)&#160;royalties on net sales of our partners&#8217; products, if any. We succeed when our partners are successful and our agreements are structured to align economic and scientific interests. As of December&#160;31, 2021, we had 57 active partners and over 250 active programs, including 25 OmniAb-derived antibodies in clinical development and two approved products in China. An active program is counted once an antigen is introduced into our animals and remains so as long as the program is actively being developed or commercialized. An active partner is counted if such partner has an active program or has executed a license agreement in advance of initiating an active program. As of December&#160;31, 2021, our partners with active antibody programs included Amgen, Boehringer Ingelheim, Genmab, Janssen, Merck KGaA, Pfizer, Sanofi, and Seagen, among others. In addition, we work with academic partners including The Scripps Research Institute, Oxford University, University of Maryland, and the Wistar Institute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the&#160;years ended December&#160;31, 2021, 2020 and 2019, our revenue was $34.7 million, $23.3 million and $18.3 million, respectively. For the&#160;years ended December&#160;31, 2021, 2020 and 2019, our net loss was $(27.0 million), $(17.6 million) and $(13.6 million), respectively. Historically, our revenue has been derived from payments for technology access, collaborative research services and milestones. We believe the long-term value of our business will be driven by partner royalties as such payments are based on global sales of potential future partner antibodies, which generally provide for larger and recurring payments as compared to technology access, research and milestone payments. While we expect our first royalty payments to come from the sales of zimberelimab and sugemalimab in China, we believe our revenue will be materially driven by milestones, in the shorter term, and by royalties, in the longer term, from our partnered programs in the United States and Europe. However, drug discovery and development has significant uncertainty in timing and likelihood of reaching marketing authorization, and we cannot be certain when, if at all, royalty payments will be a material portion of our revenue. Furthermore, we do not control the progression, clinical development, regulatory strategy or eventual commercialization of antibodies discovered using our platform, and as a result, we are entirely dependent on our partners&#8217; efforts and decisions with respect to such antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our mission is to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies. We intend to achieve this mission by enabling the discovery of high-quality therapeutic candidates and by being the partner of choice for pharmaceutical and biotechnology companies. Our strategy to accomplish this is as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Enable discovery of high-quality antibody candidates through our platform.</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a technologically differentiated platform that provides our partners with end-to-end antibody discovery capabilities, as well as customized solutions for individual steps of the antibody discovery process. We believe that pairing the power of Biological Intelligence built into our proprietary transgenic animals with our high-throughput screening technologies will continue to enable the discovery of high-quality, fully-human antibody therapeutic candidates for a wide range of diseases.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Expand upon our existing partnerships.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;We have 57 active partners, consisting of pharmaceutical and biotechnology organizations, varying in size, clinical stage, geography and therapeutic focus. We intend to continue to identify and capture new opportunities with existing partners by building upon our trusted relationships. The quality and breadth of our platform enables our partners to succeed in new campaigns and has also enabled them to pursue programs that would otherwise not be pursued due to technical challenges. In addition, collaboration between our scientists and partners has expanded partners&#8217; usage to other offerings within our technology platform, such as bispecific, screening, and antigen technologies.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">240</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Increase the number of our partnerships.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;We intend to forge new partnerships with pharmaceutical and biotechnology companies focused on antibody development. We plan to continue to gain new customers through increased business development activities, and through continued technological expansion. We also intend to increase the number of partnerships with smaller early-stage biotechnology companies by offering flexible deal structures and offerings. Through continual investment and expansion of our capabilities, we believe we have the opportunity to further enable our partners to capture additional value from our technologies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Further our technological differentiation through intelligent expansion.</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We employ a methodical and deliberate approach to expanding our technology platform. Serving a broad partner base has provided us a unique insight into the needs and direction of the industry, and we continue to leverage this insight for our decision-making. In recent&#160;years, we have successfully integrated a number of technology acquisitions covering antigen generation, additional animal species, deep screening capabilities, and ion channel expertise. We intend to continue to invest in enabling technologies and evaluate strategic technology acquisitions to broaden our capabilities in the antibody discovery continuum.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Drive partner adoption through a customizable and flexible offering.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;We meet our partners&#8217; specific needs by offering access to all or certain components of our technology platform. Some partners prefer integrated end-to-end discovery capabilities, while others prefer to use our technologies within their own labs. This flexibility not only provides value to our partners, but it allows for greater scalability of our business since we do not have to build capacity for partners that prefer to use some of their own resources in the process. This approach helps increase the partnership funnel and provides an initial forum for us to expand our relationship moving forward.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Key Competitive Strengths</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe the following capabilities and competitive strengths will enable us to become the partner of choice for antibody discovery:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">A validated discovery platform with a track record of success.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;As of December&#160;31, 2021, of the 25 antibodies generated using our platform that our partners have progressed into the clinic, 23 are in clinical trials and two have been approved for marketing in China. In December&#160;2021, a second antibody generated using our platform was approved for marketing. We believe that clinical success, including regulatory approval, has validated our platform and reduced the technical risk associated with our technology, which may lead to new partnerships and expansion of existing partnerships.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">A complete antibody discovery solution, leveraging proprietary and differentiated technologies.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;We have built a cutting-edge end-to-end antibody discovery solution using state-of-the-art genetic engineering technologies. Our technology platform includes a suite of next-generation transgenic animals, computationally powered antigen design, high-throughput microcapillary single-cell analysis, next-generation sequencing, proprietary assays and bioinformatics. Our&#160;end-to-end&#160;solution allows us to efficiently generate and deliver lead antibodies for our partners&#8217; development efforts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Proprietary Biological Intelligence that is designed to yield one of the industry&#8217;s most diverse set of high-quality antibodies.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Not all genetically engineered antibody discovery technologies are created equal. Each host animal provides a distinct immune response profile, and we believe the availability of multiple species provides an increased probability of success to find the ideal therapeutic candidate. Our animals have been genetically modified to produce naturally optimized, high-quality, antibodies with human sequences. Our technologies were developed by industry leaders in genetic engineering to elicit strong immune responses not only to biologically validated targets but also to the most difficult targets. Our team of world-renowned genetic engineers continue to work on next-generation transgenic animals to address industry challenges. To our knowledge, we are the only four-species platform with a transgenic rat, mouse, and chicken, as well as cow antibody humanization technology.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Rapid deep sequencing of immune repertoires.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our xPloration and GEM technologies can screen tens of millions of cells and recover thousands of antibody-secreting B cells for further analysis in a matter of hours. Our technologies generate multidimensional profiling data on a single-cell level that provides higher resolution. To our knowledge, xPloration has the industry&#8217;s highest screening and recovery throughput of single-cell deep profiling and sorting platforms. This throughput enables us to capture a significant portion of the antibody repertoire, including rare cells that might be missed with traditional or competing systems. We believe these technologies combined with our OmniAb transgenic animals reduce timelines, costs and technical risk associated with traditional antibody generation methods.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">241</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Ion channel target capabilities.</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have extensive biological capabilities focused on ion channels and transporters, along with an established track record in novel drug discovery from screening to lead optimization. These capabilities provide novel reagent generation and proprietary assays that can support OmniAb antibody discovery programs and other therapeutic modalities which can be accessed by partners as part of the OmniAb Technology Platform when pursuing targets.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Diversified and scalable business model.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our business is built on the success of our partners and the strength of our technology. Our business applies to a broad universe of potential partners and aligns with their economic and scientific interests. Furthermore, our technologies are modular whereby each step feeds into the next, creating a complete and scalable solution. Certain of our technology can also be used directly by our partners, enhancing the flexibility of our offerings. We believe this capital-efficient model allows us to build a diversified portfolio of royalty streams that reach far into the future therapeutic antibody market. Because we focus on improving the process of drug discovery, we will continue to make critical investments in technology that benefit the entire industry.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Robust IP portfolio with multiple long duration patent families.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our patent portfolio reflects our innovative position and&#160;end-to-end&#160;capabilities in antibody discovery, including antigen design, transgenic animals, microcapillary single-cell screening, and ion channel assays. As of December&#160;31, 2021, we have 309 issued patents with expiry dates to 2039, and 134 pending patent applications worldwide. Our license agreements with our partners are often structured with royalties that are linked to the patents for the antibodies discovered using OmniAb, thereby creating royalty rights that extend longer than our current technology patent coverage.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Industry Background</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Antibodies: 500 Million&#160;Years of Immune System Evolution</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Antibodies are blood proteins produced by the adaptive immune system in response to a specific foreign antigen. Antibodies bind to substances which the body recognizes as foreign, such as bacteria, viruses, cancer cells, and proteins in the blood. Antibodies can also be used to target cell surface proteins critical to biological functions and disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The immune system creates antibodies through a process of random shuffling of DNA fragments known as V(D)J recombination. During this process two separate genes, referred to as the heavy and light chain, are assembled to create a Y-shaped antibody protein. The shuffling of these DNA fragments, as well as random DNA insertions, deletions and edits, results in over 100 trillion different antibody possibilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At any one time, the human body typically has approximately one billion different antibodies circulating in the bloodstream. Each antibody is created by one immune B cell. When antibody expressing B cell binds to an antigen, the B&#160;cell quickly proliferates and differentiates into a family of closely related cells producing slightly differentiated antibodies. This iterative process preferentially selects antibodies that are naturally optimized to be most effective in neutralizing the specific antigen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This process, referred to as <i style="font-style:italic;">in vivo</i> affinity maturation, has evolved over 500&#160;million&#160;years to naturally select antibodies that are optimized for their intended function. Antibodies discovered from natural immune systems generally have favorable therapeutic characteristics, such as high specificity, limited off-target toxicity, superior immune stimulation, and the ability to modulate half-life circulation in serum. Despite man-made technologies that try to imitate the natural selection process, over 90% of approved therapeutics are derived from natural immune systems. Our OmniAb transgenic animals take advantage of the immune system&#8217;s ability to produce high-quality antibodies, and have been genetically modified so the antibodies generated have human sequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The evolutionary divergence of different species has resulted in some animals developing unique mechanisms that increase their immune system effectiveness to certain antigens. Each species taps a signature combination of antigen recognition, diversification mechanisms, and distinct structural features that support survival in the face of persistent exposure to evolving environmental threats. Our four-species platform harnesses these characteristics, while maintaining the human genetic sequences needed to generate diverse pools of high-quality, fully-human therapeutic antibodies that fit almost any discovery campaign.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Market Opportunity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">According to <i style="font-style:italic;">Vaccines</i> journal, antibodies are among the fastest growing class of drugs and are used across many therapeutic areas, including oncology, inflammation and neurodegeneration. EvaluatePharma data indicates that monoclonal antibodies have </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">242</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:228.72pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">represented the majority of the top 10 bestselling drugs over the last five&#160;years. In 2021, approved antibody-based therapeutics accounted for over $215.0&#160;billion in sales, according to data published by La Merie Publishing. Also according to La Merie Publishing, in 2021, 49 antibody therapeutics reached blockbuster status with sales higher than $1.0&#160;billion, up from 41 antibodies in 2020. Furthermore, Fatpos Global estimates that antibody-based therapeutic sales are expected to grow to over $375.0&#160;billion by 2030.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Despite advances in other therapeutic modalities, investment in antibodies has accelerated over the past decade, which has translated into clinical productivity and ultimately new drug approvals. According to data from the Antibody Society, the number of antibodies in the clinic has increased at an estimated 11% CAGR from approximately 500 in 2015 to approximately 950 in 2021. The expansion of clinical development has led to an accelerating pace of regulatory approvals as depicted in Figure&#160;4 below. The FDA approved the first therapeutic antibody in 1986. By 2015, the FDA approved its 50th antibody, and 6&#160;years later in 2021, approved its 100th antibody. As of December&#160;31, 2021, we estimate that there were over 100 approved antibody therapeutics in the U.S. and EU. As of December&#160;31, 2021, we estimate that 19 antibodies were under review for approval by the FDA or the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 3: Antibody Sales (US and EU)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ahpa-20220416xs4025.jpg" alt="Graphic" style="display:inline-block;height:228.72pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:311.89pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(Source: Fatpos Global, Global Next-Generation Antibody Therapeutics Market Report: 2019-2030, March&#160;11, 2021; La Merie Publishing, 2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars&#160;&amp; Other Biologics, March&#160;11, 2021)</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">243</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:242.21pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 4: Antibody Regulatory Approvals (FDA and EMA)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ahpa-20220416xs4026.jpg" alt="Graphic" style="display:inline-block;height:242.21pt;width:387.55pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(Source:</span></span>The Antibody Society Database of Antibody Regulatory Approvals, December&#160;31, 2021.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Much of the success of antibodies as a therapeutic class is attributable to their favorable qualities relative to other therapeutic modalities. Antibodies can offer high affinity, potency and specificity, limited off-target toxicity, low immunogenicity, superior immune stimulation and the ability to modulate half-life circulation in serum. Industry statistics suggest that these properties have also translated to an increased probability of success relative to other modalities. According to PharmaIntelligence&#8217;s Clinical Development Success Rates and Contributing Factors 2011-2020, which summarizes a study of over 9,000 drugs being developed for the U.S. market, monoclonal antibodies and monoclonal antibody conjugate drugs have had an approximately 12% likelihood of receiving market authorization from the start of Phase&#160;1 clinical trials. This is higher than the success rate of small molecule modalities, which had an 8% likelihood of receiving market authorization from the start of Phase&#160;1 clinical trials in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business model allows us to participate in the high growth antibody therapeutic market through technology access fees and services fees, as well as downstream success-based payments in the form of milestones and royalties on therapeutic candidates that have been discovered using our platform. As of December&#160;31, 2021, we had 57 active partners and over 250 active programs, including 25 OmniAb-derived antibodies in clinical development and two approved products in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Existing Industry Limitations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Despite industry momentum which has resulted in an overall increase in the number of antibody therapeutic approvals per&#160;year, drug discovery and development has become increasingly fragmented, outdated and non-robust.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Reduced large pharmaceutical investment has intensified fragmentation and created ripple effects for small biotechnology companies due to reduced investment in enabling technologies. While many of these biotechnology companies bring a focused approach to science that prioritizes nimble movement and efficient decision making, their biological hypotheses are often tested utilizing suboptimal antibody discovery methods due to reliance on legacy technologies. Meanwhile, many larger companies have also continued to rely on legacy technologies for many processes related to antibody discovery, often due to the inability to selectively integrate newer technologies at their facilities or because the benefits of technological updates are limited by outdated workflows. Key examples of the frequently utilized legacy technologies and their shortcomings include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Humanized wild-type antibodies</i><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> This process has been utilized over the last 25&#160;years and attempts to capture the benefits of natural antibody optimization. However, the process that converts the animal antibody into a human format introduces </span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">244</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conformational changes that impact the desired therapeutic properties of the antibody and may cause immunogenicity concerns.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">First generation transgenics.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Earlier transgenic systems demonstrated proof-of-concept and did deliver therapeutic antibodies, however it became apparent that flaws in transgene design limited the robustness of immune responses from these animals. In addition, other technical issues, legacy agreement structures and industry consolidation presented further obstacles for the access to and use of the early platforms.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Display technology</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. The commonly utilized technologies were invented over 35&#160;years ago and do not benefit from </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vivo</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> affinity maturation and optimization. Some display libraries are engineered to capture benefits from natural immune systems, however they still carry limitations including loss of the heavy and light chain pairing, need for high quality soluble antigen, and they often require downstream sequence optimization for high production in a mammalian manufacturing cell line.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Hybridoma screening</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. This method has been utilized for over 45&#160;years and results in a loss of over 99% of antibody diversity, drastically reducing the pool of potential therapeutic candidates to choose from.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is a significant and growing disparity between today&#8217;s widely used legacy antibody discovery tools and the latest advances in antibody discovery technologies. Despite the increased investment into antibody drug development, there is often a slow adoption of newer technologies due to the lack of flexibility integrating these technologies into existing workflows. These existing industry approaches are burdened with critical disadvantages including low antibody diversity, lengthy discovery timelines, limited functional parameter data, excess costs and lack of flexibility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our OmniAb technology platform is designed to enable the efficient discovery of high-quality, fully-human antibodies for a wide range of diseases. This platform aims to overcome the existing industry challenges and provides our partners access to antibody candidates based on unparalleled biological diversity that are optimized through tight integration across a full range of discovery technologies. These technologies include computationally powered antigen design, transgenic animals, high-throughput microcapillary single-cell analysis, next-generation sequencing, proprietary assays and bioinformatics. We believe that by providing our partners with access to these technologies we will ultimately shorten the discovery timelines, reduce costs, and increase the probability of success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Our investments in our technologies are methodical and deliberate, with the goal to continue to provide our partners with the most cutting-edge technologies to solve the biggest challenges in antibody discovery. Our technologies are modular and sequential, creating a complete and scalable solution. These technologies also can be individually integrated into our partners internal or external workflows, which allows us to provide our partners with both integrated end-to-end discovery solutions and highly customizable, program-by-program offerings, which address critical industry challenges and provide our partners with optimized antibody discovery solutions. As depicted below, our technology platform is a suite of integrated technologies designed to discover a wide range of high-</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">245</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:246.56pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">quality therapeutic antibodies that leverage the inherent diversity produced by transgenic animals and high throughput single-cell screening.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ahpa-20220416xs4024.jpg" alt="Graphic" style="display:inline-block;height:246.56pt;width:462.69pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our technologies within the OmniAb platform improve the productivity and efficiency of each step of the discovery process:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Create Diverse Antibody Pools.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We believe generating large and diverse pools of high-quality antibodies increases the chances of discovering the antibody with the most desirable therapeutic characteristics. At the heart of the OmniAb technology platform is the Biological Intelligence of our proprietary transgenic animals, technology that we own. Our animals have been genetically modified to produce a large number of naturally optimized, high-quality, antibodies with human sequences. We offer the industry&#8217;s only four-species platform to address a wide range of biological challenges facing our partners in their antibody discovery efforts. We can pair our Biological Intelligence with computational antigen design to generate robust antibody responses to biological targets, including but not limited to difficult and complex targets such as ion channels, GPCRs, transporters, and other transmembrane proteins. Our antigen design technology includes transmembrane and cell-surface protein technology that we own or exclusively license.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Screen Antibody Candidates.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Our proprietary xPloration microcapillary technology, which we own or license, and GEM technology, which we own, screen antibody pools at a single-cell level to quickly identify antibodies in as little as a few hours, saving weeks compared to traditional technologies. xPloration screens tens of millions of immune cells on multiple parameters, then leverages AI to analyze immense amounts of phenotypic data to automatically select and rank thousands of promising therapeutic candidates. Our industry-leading throughput allows for the discovery of rare antibodies that may otherwise be missed with traditional technologies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Identify the Right Antibody.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Our discovery teams are flexibly positioned to work closely with partners to identify the right antibody for a particular target profile. Antibody candidates identified through our screening technologies are further characterized through a cascade of performance assays. The data from multi-parameter screening and performance assays is used in combination with bioinformatics to analyze the antibody repertoire and enable our partners to select the right antibody.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Create Diverse Antibody Pools</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">We believe generating large and diverse pools of high-quality antibodies increases the chances of discovering the antibody with the most desirable therapeutic characteristics. We have assembled a suite of transgenic animal and antigen technologies that are </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">246</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:128.23pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">designed to generate a large and diverse pool of high-quality antibodies. The heart of the OmniAb technology platform is the Biological Intelligence of our proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through <i style="font-style:italic;">in vivo</i> affinity maturation. We combine our transgenic animals with proprietary antigen technology and immunization techniques to generate high-quality antibodies for even the most difficult biological challenges. The various OmniAb animal technologies are depicted in Figure&#160;5 below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 5: OmniAb Animal Technologies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ahpa-20220416xs4028.jpg" alt="Graphic" style="display:inline-block;height:128.23pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:341.95pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that natural antibodies are superior to other antibody generation methods due to the immune system&#8217;s ability to naturally select quality, and already optimized antibodies through a process that has evolved over 500&#160;million&#160;years. According to the TAB Database of Therapeutic Antibodies, as of December&#160;30, 2021, over 90% of all approved antibody drugs had been derived from natural immune systems, which we believe is due to their superior drug-like properties. The evolutionary divergence of different species has resulted in some animals developing unique mechanisms that increase their immune system effectiveness to certain antigens. Our four-species platform harnesses these characteristics, while maintaining the human genetic sequences needed to generate diverse pools of high-quality, fully-human therapeutic antibodies that fit almost any discovery campaign.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our team of world-renowned scientists use a variety of gene editing techniques to alter the genomes of animals to produce antibodies that use human sequences, while retaining the animal&#8217;s ability to illicit a strong immune response to antigen. We then set up breeding colonies of our genetically modified animals for use in partner&#8217;s discovery efforts. While there are several options when considering transgenic mice, OmniAb is the only four-species platform, with the world&#8217;s only transgenic mouse, rat, chicken, and cow antibody humanization technology. Each animal has unique characteristics which address key challenges in antibody discovery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We pair our animal technologies with antigen design to further enhance the robust antibody repertoires for antibody campaigns. Ab Initio offers antigen design technology, which we own or exclusively license, for production of challenging therapeutic targets. Most drug targets are membrane proteins which are inherently unstable and challenging to investigate. The technology produces full-length membrane proteins, including multi-Tm proteins, such as ion channels and GPCRs, the largest class of therapeutic drug targets. Our antigen production works in tandem with our therapeutic antibody discovery platform, providing access to high-quality membrane protein antigens for immunization campaigns. Guided by molecular modeling and protein design capabilities, our antigen design team manages the cloning, expression, purification, reconstitution, and quality control of purified native-conformation membrane proteins for immunization and screening purposes. Antigens can be prepared in particular conformations with protein or small molecule conformational chaperones. The range of accessible antigen formats improves the probability of success in generating robust immune response with desired specificities from any of the OmniAb animals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Collectively, we believe our transgenic animal and antigen technologies provide the foundation for a successful drug discovery campaign.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Screen Antibody Candidates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finding the best antibody means finding the best antibody producing cell. Each antibody is made by an antibody producing cell, known as a B&#160;cell, that contains the genetic sequence that encodes its unique antibody. When presented with an antigen, the immune system will respond by creating millions of different antibodies and preferentially selecting antibodies that best neutralize the perceived threat. These large antibody pools can present a challenge in identifying the antibodies with the most optimal candidate drug profiles from millions of possibilities.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">247</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the enormous number of different antibodies generated, individual B&#160;cells are microscopic, generate only a miniscule amount of antibody protein, and are difficult to grow in culture conditions. The amount of antibody produced by an individual B&#160;cell is too small to be tested directly in conventional 96-well plates. Because of this, scientists have relied on the hybridoma method for antibody discovery for the past 45&#160;years. During this process, B&#160;cells are fused with a certain type of cancer cell, which immortalizes the B&#160;cell allowing them to be grown into sufficient quantities for the antibodies to be tested in conventional 96-well plates. This process takes approximately 8 to 12 weeks, and is extremely inefficient, leading to losses of 99.9% of the relevant immune diversity from the beginning of the process. Despite these significant limitations, hybridoma remains a commonly used technology in the industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">We analyze B&#160;cells individually using microcapillaries and industry leading throughput with our proprietary xPloration and GEM platforms. The xPloration platform is an AI-powered single-cell microcapillary platform that provides multi-dimensional profiling data on tens of millions of cells. Our proprietary technology uses a chip with 1.5&#160;million microscopic capillaries that are loaded with B&#160;cells. Chips are processed through automated imaging, then AI-powered algorithms analyze and identify thousands of B&#160;cells that express antibodies with the desired characteristics. Our AI algorithms are empowered by the industry leading LandingLens</span><sup style="font-size:6.37pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-size:10pt;"> platform developed by Landing AI. Using technology we own or license from Stanford University, thousands of AI-selected B&#160;cells are recovered within minutes using lasers that break the capillary forces and drop the B&#160;cell into wells for sequencing. The whole process can screen up to 40&#160;million cells and recover thousands of paired sequences all within a few hours.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe the xPloration platform represents industry-leading screening and cell recovery. The screening throughput enables the discovery of rare cells that would be missed with other systems that only evaluate a small sliver of the repertoire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Identify the Right Antibody</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Both xPloration and GEM identify potentially thousands of therapeutic antibody candidates which must then be narrowed to a small number of lead candidates. Our OmniAb team is flexibly positioned to work directly with partners to develop work plans and screening cascades that are customized to their antibody design specifications. We also assist our partners in their own downstream activities to ultimately find the right antibody for further development. Paired chains are cloned in high throughput and expressed as recombinant antibodies in a variety of format options for confirmation and further characterization. Assays include high throughput epitope binning and kinetics analysis, and target-specific functional assays. Functional data combined with the large amounts of data generated from xPloration provide a comprehensive view of the immune response and allow our partners to select antibodies with even the most stringent design criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Often the right antibody must be further modified to enhance certain desired characteristics in a process known as antibody optimization. Introducing changes to the DNA sequence that enhance one characteristic, can be detrimental to others. This results in a process that is lengthy, costly, and reliant on trial-and-error experimentation. We believe many of these challenges are averted by using natural immune systems that have evolved over 500&#160;million&#160;years to naturally selects antibodies that are optimized for their intended function. Our antibody pools are large, diverse, and full of high-quality antibodies that provide our partners with a significant number of fully optimized leads. In the most challenging discovery programs, our team can provide hit expansion through xPloration deep dives and/or NGS data mining to identify variants of confirmed clones with improved affinity, improved manufacturability, or other favorable characteristics, while avoiding the time and technical risk associated with traditional optimization methods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In situations where characteristics need to be improved beyond what is available in the repertoire, we can filter sequence variants through a battery of <i style="font-style:italic;">in silico</i> evaluations to remove sequences with liabilities or potential developability problems, and potentially improve potency. Optimized sequences are then re-expressed in antibody format of choice and performance is further evaluated in analytical and bioassay evaluation to create a ranked list of potential leads.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Partnership Business Model</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We partner with pharmaceutical and biotechnology companies that vary in size, clinical stage, geography and therapeutic focus. Our partners have access to wide repertoires of antibodies and state-of-the-art screening technologies designed to enable efficient discovery of next-generation novel therapeutics and deliver high-quality therapeutic antibody candidates for a wide range of diseases. Our partners can select a target and define the antibody properties needed for therapeutic development or use certain of our technologies directly in their own laboratories. We typically structure our license agreements with each partner so that they are indifferent to the species used to generate antibodies. To the extent our partners request us to provide additional discovery work beyond screening, we capture additional fees either in terms of upfront payments or downstream via additional milestones or royalties.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">248</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:220.52pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our license agreements with partners typically include: (i)&#160;upfront or annual payments for technology access and payments for performance of research services; (ii)&#160;downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones; and (iii)&#160;royalties on net sales of our partners&#8217; products, if any. We succeed when our partners are successful and our agreements are structured to take advantage of the upside of approved antibody therapeutics. Our license agreements typically include annual reporting requirements which provide us updates from our partners on the status of their programs. In addition, we track our active partnered programs by reviewing our partners&#8217; public announcements and maintaining close communications with our partners to the extent possible. In some instances, a partner may not publicly announce milestones in which case we are generally dependent on our partners to track and disclose milestones at the time of achievement. Our license agreements are typically terminable by our partners without penalty with specified notice. However, all milestone payments and royalties survive termination and continue with respect to any OmniAb-derived antibodies. The royalty term is typically the longer of 10&#160;years from the first commercial sale or through the last expiration in any jurisdiction of the patents covering such OmniAb-derived antibody. We believe the long-term value of our business will be driven by downstream royalty payments. Our typical royalty rates for antibody discovery contracts are currently in the low- to mid-single digits, and can vary depending on other economic terms in the agreement. Although our license agreements typically include technology access fees, milestone payments and royalties, each agreement is negotiated separately and as a result, the financial terms and contractual provisions vary from agreement to agreement. By providing a full suite of antibody discovery technologies with streamlined economics, we believe we offer an attractive option to industry stakeholders that are often forced to pay multiple royalty obligations for enabling technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Figure 6 below shows the growth in active partners, active programs and clinical programs since our acquisition by Ligand in January&#160;2016 and the number of programs that have entered clinical trials. As of December&#160;31, 2021, we estimate our partners have started over 500 antibody discovery campaigns, and we estimate there are currently over 250 active antibody programs. An active program is counted once an antigen is introduced into our animals and includes active clinical programs and approved products. An active partner is one that has an active program or has executed a license agreement in advance of initiating an active program. Active clinical programs represents the number of unique programs for which an IND or equivalent under other regulatory regimes has been filed based on an OmniAb-derived antibody and which are in clinical development. Approved products represents an OmniAb-derived antibody for which our partner has received marketing approval. We do not include academic partners with a license to the OmniAb platform in our active partner count.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 6: Active Partners, Active Programs, and Active Clinical Programs and Approved Products</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ahpa-20220416xs4029.jpg" alt="Graphic" style="display:inline-block;height:220.47pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:456.97pt;" /></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">249</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">*Active programs not tracked prior to acquisition of Open Monoclonal Technology,&#160;Inc. in January&#160;2016.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Technology</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foundational technologies that power our OmniAb Technology Platform are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OmniRat</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniRat was launched in 2012 and is the first example of a successful knock-out of the endogenous rat immunoglobulin genes coupled with transgenesis of human counterparts. OmniRat produces a diverse repertoire of antibodies with human idiotypes and immunological characteristics that are comparable to antibodies from wildtype animals. OmniRat provides cross-reactivity against a mouse, which may streamline preclinical development by obviating the need for surrogate antibodies, and thereby may decrease clinical risks. The OmniRat has been engineered to contain functional recombinant immunoglobulin loci, use genes with similar frequency as humans, and rearrange functional human immunoglobulin genes. The animals are bred on a mixed genetic background to further diversify the antibody repertoire and feature different light chain isotypes which is designed to provide flexibility around partners&#8217; needs and technology. The OmniRat shows high expression, normal human CDR-H3 length distribution, and normal hypermutation and affinity maturation. As of December&#160;31, 2021, there are two approved OmniRat-derived antibodies and 16 additional antibodies in clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OmniMouse</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniMouse was launched in 2014, and we designed this technology using the same transgenes as OmniRat to deliver fully human antibodies utilizing standard mouse-based protocols. OmniMouse expands the sequence diversity of our rat-based platforms (OmniRat and OmniFlic), offering easy conversion from wildtype mice while utilizing the same protocols. OmniMouse produces a diverse repertoire of antibodies with human idiotypes and provides a complementary murine system for additional sequence diversity. Like OmniRat, OmniMouse is currently bred to generate a mixed genetic background to further increase sequence diversity. For partners who prefer to work with mice, OmniMouse provides a rapid solution to deliver fully-human antibodies. As of December&#160;31, 2021, there are two OmniMouse-derived antibodies in clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OmniChicken</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniChicken was launched in 2016 and is the first successfully engineered bird with an immune system that can efficiently generate human sequence antibody repertoires for the discovery of therapeutic antibodies. OmniChicken and OmniClic, our bispecific transgenic chicken platform, offer affinity matured antibodies in an evolutionarily distant chicken host environment. As depicted in Figure&#160;7 below, more than 300&#160;million&#160;years of evolutionary distance drives divergence between mammalian and avian orthologs, which are genes in different species that evolved from a common ancestral gene by speciation. This evolutionary distance enables generation of a diverse repertoire of antibody panels to highly conserved therapeutic target antigens that are not immunogenic in mammals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniChicken features a high level of functional diversity, with sequence diversity focused on the CDR regions, while maintaining conserved, well-validated human framework regions. OmniChicken antibodies bind to diverse epitopes on human targets with high affinity, and therefore we believe offer excellent developability profiles. As of December&#160;31, 2021, there is one OmniChicken-derived antibody in clinical development.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">250</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:162.03pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 7: OmniChicken Yields Greater Antibody Diversity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ahpa-20220416xs4030.jpg" alt="Graphic" style="display:inline-block;height:161.33pt;left:0%;padding-bottom:0.7pt;position:relative;top:0pt;width:462.69pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Due to the phylogenic evolutionary distance between humans and chickens, the OmniChicken can generate an immune response against targets that are not immunogenic in mammals.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OmniTaur</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniTaur was launched in 2020 and provides cow-derived ultralong CDR-H3 antibodies with a human framework. CDR-H3 is the region of the antibody that makes primary contact with the target and ultralong CDR-H3 antibodies have been shown to bind to targets with deep or cryptic epitopes. We believe these antibodies could be leveraged for a variety of targets with cryptic epitopes which may be difficult to reach with conventional antibodies, including channel blockers, ion channels, transporters, and viral proteins. As depicted below in Figure&#160;8, OmniTaur features a fully human variable framework, and a CDR-H3 region, which we believe makes OmniTaur antibodies well suited for therapeutic development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 8: Cow Antibodies Have Unique Characteristics for Binding Cryptic Epitopes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ahpa-20220416xs4031.jpg" alt="Graphic" style="display:inline-block;height:84.41pt;width:315.5pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OmniChicken with cow-inspired properties (in development)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are currently developing a next generation OmniChicken with cow-inspired CDR-H3 motifs. If successful, this will combine the OmniChicken&#8217;s ability to generate antibodies against highly conserved targets, with OmniTaur&#8217;s ability to target highly cryptic epitopes. We believe these combined benefits may enable antibody discovery for a number of high-value targets that are undruggable with today&#8217;s technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Bispecific antibody platforms</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">We offer the only rat and chicken platform for generation of bispecific antibodies. Although bispecific antibody drugs have been researched for more than 30&#160;years, only a limited number of bispecific antibodies have achieved regulatory approval. There are very few successful examples of large-scale manufacturing for a bispecific antibody, and the &#8220;common light chain format&#8221; is a technology designed to simplify and improve the efficiency of the production and purification of a whole IgG&#8212;type bispecific antibody. Our bispecific antibodies are IgG antibodies, with a common light chain and different heavy chains. Common light chain antibodies allow for combining targeting arms for bispecific and multi-specific antibodies without the complexity of correct heavy and light chain pairing. Using this IgG format, the bispecific function can be introduced while maintaining the natural shape of the antibody. Both </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">251</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:85.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">OmniFlic, our bispecific rat, and OmniClic, our bispecific chicken, express the same light chain which enables the formation of bispecific therapeutics through the combination of antibodies generated from either platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that the characteristics of our platforms offer several advantages over current generation bispecific antibody technologies. To generate bispecific antibodies, we conduct parallel immunizations with two antigens and then engineer the two targeting arms of the antibody as depicted in Figure 8 below. We then use functional screening to identify heavy chain pairs with balanced affinities for their targets and support robust purification of the bispecific antibodies for manufacturing purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OmniFlic (Bispecific rat platform)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniFlic was launched in 2014 and is a fixed light-chain variation of OmniRat. The OmniFlic transgenic rat expresses a fixed VK3-15 light chain. OmniFlic features the same heavy chain transgene as OmniRat, which generates diverse repertoires upon immunization. OmniFlic is a fixed light-chain transgenic rat developed to facilitate the generation of bispecific antibodies. As of December&#160;31, 2021, there are three OmniFlic-derived antibodies in clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OmniClic (Bispecific chicken platform)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniClic was launched in 2019 and is a common light-chain transgenic chicken developed to facilitate the generation of bispecific antibodies. OmniClic was engineered to focus sequence diversity on the CDRs of the VH domain. OmniAb expresses the VH3-23 and VK3-15 light chains, with a modified light chain transgene to minimize diversification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 9: Bispecific antibody platforms</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ahpa-20220416xs4032.jpg" alt="Graphic" style="display:inline-block;height:84.86pt;left:0%;padding-bottom:0.65pt;position:relative;top:0pt;width:317.21pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our bispecific antibodies are IgG, antibodies, with a common light chain and different heavy chains. To generate these antibodies, we conduct parallel immunizations with two antigens and then engineer a bespoke version of the transgenic platform to generate a diverse set of heavy chains and ultimately bispecific therapeutic antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">HCO chicken (in development)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb scientists are currently developing a next generation OmniChicken designed to express antibodies comprised of principally heavy chains, without the light chains found in conventional IgG antibodies, also referred to as heavy chain only (HCO) antibodies. In addition to other unique benefits and uses, HCO antibodies, similar to common light chain antibodies, can be used to generate bispecific and multispecific antibodies while avoiding the complexity of correct heavy and light chain pairing. HCO antibodies resemble camelid antibodies, which are smaller than conventional antibodies, allowing for the targeting of cryptic epitopes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Screening Technologies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that the xPloration platform offers greatly improved screening and cell recovery compared to other leading, commercially available single-cell multi-dimensional profiling technologies. The xPloration screening throughput is designed to enable the discovery of rare cells that would likely be missed with other systems that are only able to evaluate a small sliver of the repertoire. We pair this with next-generation sequencing to further expand the repertoire for potential hit expansion downstream if necessary. Our laser-based recovery process retains heavy/light chain paring of the antibodies, which directly provides potential lead antibody sequences bypassing the need for pairing algorithms that attempt to reconstruct the repertoire. The considerable throughput combined with retaining heavy/light chain antibody pairing can cut weeks or&#160;months of traditional discovery workflows.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">252</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:168.43pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For certain development programs, we leverage our proprietary GEM technology. The GEM technology incorporates many of the same principles of the xPloration platform by isolating and performing multi-dimensional profiling of single B cells from an immunized animal. Small droplets encapsulate single B cells and Reporters that present the target antigen on the surface of a bead or cell. Secreted antibodies from the B Cell diffuse locally in the microenvironment where they can bind to Reporters, which in turn can be detected with a fluorescent probe. Using different types of Reporters in the microenvironment can generate a multi-parameter binding profile of each antibody. Antigen specificity is determined by colocalization of signal with alternative bead and/or cell types. Millions of GEMs can be examined in parallel. GEMs containing B cells and antibodies of interest can be harvested, cloned, and expressed as recombinant antibodies for further characterization studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Both xPloration and GEM are compatible with a wide variety of assay formats, including cell surface binding assays, reporter cell stimulation, multiplex target binding, and cross-reactivity screening. These assays enable us to tackle high value, challenging targets, such as ion channels and GPCRs. High throughput B-cell screening is particularly valuable within the OmniAb ecosystem because of our unique animal offerings. While mouse hybridoma techniques have been available for decades, the hybridoma generation methods for other species including chickens, and cows is not available. As such, B-cell screening with OmniAb&#8217;s platforms enable the discovery of unique antibodies from any host systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 10: xPloration Core Components</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ahpa-20220416xs4033.jpg" alt="Graphic" style="display:inline-block;height:168.43pt;width:462.69pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Next generation xPloration (in development)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">OmniAb scientists and engineers are currently developing a next generation xPloration platform as depicted in Figure 11 below. We believe this platform has the potential to further expand our position as the industry leader in speed, throughput, reliability, and ease of use. The next generation xPloration is designed as a deployable instrument that could give certain strategic partners or collaborators the option to access xPloration in their own labs for their OmniAb discovery efforts.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">253</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:319.91pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 11: Prototype Next Generation xPloration Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ahpa-20220416xs4034.jpg" alt="Graphic" style="display:inline-block;height:319.91pt;width:462.69pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ion Channel Differentiated Capabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ion channels and transporters are key components in a wide variety of biological processes that involve rapid changes in cells and have broad therapeutic applicability across multiple therapeutic areas including oncology, metabolic disease, pain, neurological diseases, infectious diseases and others. Ion channels make particularly challenging drug targets due to (i)&#160;difficulty with antigen purification (ii)&#160;poor immunogenicity (iii)&#160;high homology with rodents used in immunization campaigns and (iv)&#160;small binding regions with the majority of protein embedded in cell membranes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to these challenges in developing effective therapeutics, patients suffering from ion channel and transporter related diseases are severely underserved. Icagen has extensive biological capabilities focused on ion channels and transporters, and decades of experience in novel drug discovery from screening to lead optimization, with an active set of big pharma discovery and asset-based partnerships. The differentiated core capabilities at Icagen can provide novel reagent generation and proprietary assays that can also support antibody discovery programs and can be accessed by partners when pursuing ion channels and transporter targets. We believe we are well positioned to provide the tools necessary to generate and discover antibodies and small molecules to target ion channel and transporter targets. Our computational antigen generation technology has been validated in successfully generating, stabilizing, and purifying antigen for these targets and our four-species transgenic animal platform is validated in successfully generating antibodies for poorly immunogenic, high homology, and cryptic targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the drug design challenges, it is difficult to develop effective functional assays to test potential therapeutics. OmniAb&#8217;s proprietary Icagen ion channel platform leverages proprietary expertise in the combination of biological assays, medicinal chemistry, and <i style="font-style:italic;">in silico</i> and computational chemistry applications to enable the discovery of ion channel targeting therapeutics. We believe this suite of technologies provides and differentiated capability for advancing high value ion channel and transporter drug discovery programs regardless of modality including small molecules, mono-, bi- and multi-specific antibodies, and antibody-drug conjugates (ADCs).</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">254</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Investing in Differentiated Technology</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">We built the OmniAb technology platform through acquisition, investment, and innovation. We acquired OMT in January&#160;2016, Crystal Bioscience in October&#160;2017, Ab Initio in July&#160;2019, Icagen in April&#160;2020, xCella Biosciences in September&#160;2020 and Taurus Biosciences in September&#160;2020. In addition to acquisitions, we have advanced our technology platform through internal investment and innovation. Over the past five&#160;years, the OmniAb team has launched new transgenic animals, introduced computational antigen design, expanded internal capabilities in downstream processing, and developed internal data management and bioinformatics software. We have several internal projects in development including multiple new transgenic animals, a next generation high-throughput microcapillary deep screening platform, and a number of undisclosed projects. The key technologies obtained through acquisition are listed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.97%;"><tr><td style="vertical-align:bottom;width:38.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Business</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:23.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Acquisition&#160;Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:31.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Technologies&#160;Acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Open Monoclonal Technology (OMT)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.04%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">January 2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.68%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">OmniRat OmniMouse OmniFlic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Crystal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">October 2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">OmniChicken GEM screening</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Ab Initio</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">July 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Antigen design</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Icagen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">April 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Ion channel technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">xCella</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">September 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">xPloration screening</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Taurus</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">September 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">OmniTaur</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Technology in Action &#8212; Selected Case Studies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Partner A: Emerging Biotech</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Problem</i>: Partner wanted to generate antibodies against a novel multi-transmembrane target for triple negative breast cancer. All previously-known antibodies for the target could only bind to denatured or fixed form, therefore unsuitable for therapeutic use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Solution</i>: Our antigen technology was applied to deliver mg-scale quantities of purified receptor in native conformation for immunization and screening. We then performed an OmniChicken immunization campaign which led to discovery of a large and diverse panel of fully-human antibodies capable of binding target on live tissues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Partner B: Big Pharma</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Problem</i>: Partner attempted to generate antibodies using internal discovery tools towards a growth factor target that is highly conserved among mammals. The human version of the target is non-immunogenic in other rodents, therefore no titer was achieved despite numerous immunization attempts by the partner. Additionally, the genetic knockout of target gene attempted in mice was lethal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Solution</i>: An OmniChicken immunization campaign led to robust titers and diverse antibody panels. &gt;90% of sequences recovered had excellent developability profiles based on multi-parameter <i style="font-style:italic;">in silico</i> analysis, and the partner was able to proceed with the program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Partner C: Established Biotech</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Problem</i>: Partner has a history of success in developing antibodies, with a large discovery group and expanding novel biology. The partner needed a flexible, scalable, antibody discovery solution to start dozens of new programs every&#160;year to achieve development objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Solution</i>: OmniAb technologies were transferred to the partner, with an OmniRat breeding colony established. In its own labs, the partner utilizes the OmniAb technology to discover multiple OmniAb antibodies each&#160;year, with clinical candidates routinely identified, and currently targeting Phase&#160;1 and&#160;2 data readouts in the next 18&#160;months, and multiple candidates to enter clinical development in the coming&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Outcomes</i>: As a result of the solutions that OmniAb provided and our expertise in genetic engineering, Partner C entered a deep collaboration for OmniAb to develop next generation rodents, which were tested in parallel with active novel programs. OmniAb wholly owns rights to next-generation animals and can include them in the OmniAb technology offering to other partners.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">255</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Partner D: Global Pharma</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Problem</i>: Partner is an Asia-based global pharma company that is establishing a new and substantial presence in the antibody space with large investment and expansion of its global antibody team. Partner D needed our antibody discovery engine to power their growth in the antibody space.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Solution</i>: Partner D selected OmniAb as its core technology to feed robust discovery and development efforts. Satisfaction with the relationship resulted in a three-way collaboration with deep repertoire analysis to rapidly identify best binders for bispecific antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The market for technologies that enable the discovery and development of therapeutic antibodies, such as ours, is global, characterized by intense competition and subject to significant intellectual property barriers. The solutions and applications offered by our competitors vary in size, breadth and scope, and given the broad promise of antibody therapeutics, we face competition from many different sources, including companies developing single-cell screening technologies, transgenic animals and antibody engineering technologies, using a variety of business models, including the development of internal pipelines of therapeutics, technology licensing, and the sale of instruments and devices. We also face competition from companies who use internal resources and technologies for their discovery capabilities, as well as integrated contract research organizations that use traditional hybridoma, phage, and yeast display technologies in discovery. Due to the significant interest and growth in antibody therapeutics more broadly, we expect the intensity of this competition to increase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We seek to provide our partners with the most advanced technologies for antibody drug discovery, including antigen design, transgenic animal platforms and single-cell analysis. Many emerging and established life sciences companies have been built around technologies that focus on one or a limited number of these steps. Examples include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in discovery using genetically engineered rodents, we face technical competition from companies that provide access to similar technologies, such as AbCellera&#160;Inc., Ablexis LLC, Alloy Therapeutics,&#160;Inc. Crescendo Biologics&#160;Ltd., Harbour Antibodies BV, Merus N.V., Regeneron Pharmaceuticals,&#160;Inc. and RenBio&#160;Inc.;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the field of single-cell screening, we face technical competition from companies that provide access to similar technologies, such as AbCellera&#160;Inc., Berkeley Lights&#160;Inc., HiFiBio&#160;Inc., and Sphere Fluidics&#160;Ltd.; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in ion channel drug discovery, we face technical competition from companies that provide similar technologies, or biological expertise, such as Charles River Labs&#160;Inc., Evotec SE, Metrion Biosciences&#160;Ltd., and WuXi AppTec.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also face direct business competition from companies that provide antibody discovery services using technologies, such as hybridoma and display. Companies with discovery business models that include downstream payments include AbCellera&#160;Inc. and Adimab&#160;LLC. In addition, we compete with a variety of&#160;fee-for-service&#160;contract research organizations that provide services, in most cases using legacy technologies, that compete with one or more steps in our technology platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a discussion of the risks we face relating to competition, see &#8220;<i style="font-style:italic;">Risk Factors&#8212;Risks Related to the Business of OmniAb&#8212;The life sciences and biotech platform technology market is highly competitive, and if we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue, or sustain profitability</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that patents and other proprietary rights are important to our business. Our practice is to file patent applications to protect technology, inventions and improvements to our inventions that are considered important to the development of our business. We also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Patents are issued or pending for the technology families described below. The scope and type of patent protection provided by each patent family is defined by the claims in the various patents. Patent term may vary by jurisdiction and depend on a number of factors including potential patent term adjustments, patent term extensions, and disclaimers, and patent terms referenced below do not </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">256</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">take into consideration such adjustments, extensions, or disclaimers. For each technology family, the patents and/or applications referred to are in force in at least the United States, European jurisdictions, Japan and other jurisdictions as indicated. The patents and patent applications referenced below are in each case, as of December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">OmniAb Technology Platform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our OmniAb therapeutic antibody platforms, including OmniRat, OmniMouse and OmniChicken, produce naturally optimized antibodies with human sequences in animals. Our OmniAb antibody platform patent portfolio includes patents and applications obtained upon the acquisition of Open Monoclonal Technology,&#160;Inc. in January&#160;2016 and Crystal Bioscience in October&#160;2017. We own patents directed to OmniAb animals and related inventions, including 24 issued patents in the United States, six issued patents in Europe, six issued patents in Japan, three issued patents in China, and counterpart patents granted in other countries. These patents include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four U.S. patents directed to rodent germ cells, transgenic rodents, methods of generating transgenic rodents, and antibodies produced from transgenic rodents, and foreign counterparts including in Europe, Japan, China, and Canada, all having an expiration date in 2028 without accounting for potentially available patent term adjustments and extensions or disclaimers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two U.S. patents directed to our GEM assay, including gel microdrops, their use, and their method of manufacture, and foreign counterparts including in Europe, Japan, and Canada, all having an expiration date in 2029 without accounting for potentially available patent term adjustments and extensions or disclaimers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seven U.S. patents directed to transgenic animals including chickens, B cells isolated from transgenic chickens, and methods of producing antibodies, and foreign counterparts including in Japan, all having an expiration date in 2030 without accounting for potentially available patent term adjustments and extensions or disclaimers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two U.S. patents directed to avian gonocytes and their method of manufacture, each having an expiration date in 2031 without accounting for potentially available patent term adjustments and extensions or disclaimers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three U.S. patents directed to transgenic chickens and chicken germ cells, and foreign counterparts including in Europe and Canada, all having an expiration date in 2032 without accounting for potentially available patent term adjustments and extensions or disclaimers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three U.S. patents directed to transgenic chickens, methods of producing antibodies, and isolated antibody-producing cells, all having an expiration date in 2032 without accounting for potentially available patent term adjustments and extensions or disclaimers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two U.S. patents directed to transgenic rodents, methods of producing antibodies, and chimeric polynucleotides, and foreign counterparts including in Europe, China, and Japan, all having an expiration date in 2033 without accounting for potentially available patent term adjustments and extensions or disclaimers; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one U.S. patent directed to transgenic chickens and methods of producing antibodies having an expiration date in 2036 without accounting for potentially available patent term adjustments and extensions or disclaimers.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also own 13 pending U.S. patent applications, nine pending European patent applications, six pending Japanese patent applications, three pending Chinese patent applications, and counterpart patent applications pending in other countries. Any patents issuing from these applications are expected to expire between 2028 and 2041, without accounting for potentially available patent term adjustments and extensions or disclaimers. Our partners who use the OmniAb patented technology to generate novel antibodies may be entitled to separate, additional patent protection on such antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Icagen Ion Channel Platform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In April&#160;2020, we acquired the core assets of Icagen, LLC, an early-stage drug discovery company focused on ion channel and transporter targets. Icagen owns a portfolio of issued patent and pending patent applications directed to X-ray fluorescence-based detection of binding events and transport across barriers and related inventions, including 22 issued patents in the Unites States, six </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">257</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">issued patents in Europe, eight issued patents in Japan, and three issued patents in China. Icagen&#8217;s portfolio also includes four pending U.S. patent applications and two pending European patent applications. These patents and applications are directed to methods and apparatus. Icagen also owns a pending Patent Cooperation Treaty patent application directed to branched-chain amino acid aminotransferase modulator composition-of-matter and method of use. The patents and applications in Icagen&#8217;s portfolio are expected to expire between 2023 and 2040, without accounting for potentially available patent term adjustments and extensions or disclaimers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">xCella Biosciences</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2020, we acquired xCella Biosciences. xCella&#8217;s technology includes a microcapillary platform that can screen single B cells for specificity and bioactivity, which expand our existing single- B cell assay capabilities in the OmniAb technology platform. xCella owns a patent portfolio that includes three issued patents in the United States, four pending U.S. patent applications, four pending European patent applications, three pending Japanese patent applications, two pending Chinese patent applications, counterpart patent applications pending in other countries, and one pending Patent Cooperation Treaty patent application. These patents and applications are directed to methods and apparatus. The patents and applications in xCella&#8217;s owned portfolio are expected to expire between 2036 and 2040, without accounting for potentially available patent term adjustments and extensions or disclaimers. Through xCella, we also have a non-exclusive license from Stanford University to a patent family directed to methods for extracting samples from microcapillary arrays, which includes two issued patents in the U.S., one issued patent in Europe, three issued patents in Japan, two issued patents in China, and pending applications in the U.S. and Europe. These licensed patents and applications have an expected expiry date in 2033, without accounting for potentially available patent term adjustments and extensions or disclaimers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Taurus Biosciences</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2020, we acquired Taurus Biosciences, which added technologies for discovery and humanization of antibodies from immunized cows or cow-derived libraries to our OmniAb platform technology platform. These antibodies feature some of the longest CDR-H3s of any species, with unique genetic and structural diversity that can enable binding to challenging antigens with application in therapeutics, diagnostics and research. Through this acquisition, we own issued patents and pending patent applications relating to screening methods and antibody engineering. Taurus&#8217; owned patent portfolio includes five U.S. patents, one pending U.S. patent application, one granted European patent, two granted Japanese patents, one pending Japanese patent application, one granted Australian patent, one granted Chinese patent, one pending Chinese patent application, and one pending Canadian patent application. These patents and applications are directed to methods of generating combinatorial human antibody libraries, methods of affinity maturation of antibodies, humanized antibodies with ultralong CDRs, and bovinized human antibodies comprising ultralong CDRs. The patents and applications in Taurus&#8217; owned portfolio are expected to expire between 2029 and 2034, without accounting for potentially available patent term adjustments and extensions or disclaimers. Through Taurus, we also have an exclusive license from The Scripps Research Institute to technology related to ultralong CDR-H3s. This licensed portfolio includes two issued patents in the U.S., one issued patent in Europe, one issued patent in Japan, and two issued patents in Australia. These licensed patents have an expected expiry date in 2033, without accounting for potentially available patent term adjustments and extensions or disclaimers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ab Initio</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2019, we acquired Ab Initio. Ab Initio owns a portfolio of issued patents and pending patent applications directed to SIRP-gamma polypeptides and apelin (APJ) receptor binding domains that includes two issued patents in the United States, one issued patent in Europe, one pending U.S. patent application, one pending patent application in Europe, one pending patent application in Japan, one pending patent application in China, one pending patent application in Canada, and one pending Patent Cooperation Treaty patent application. These patents and applications are directed to composition-of-matter and methods of use. The patents and applications in Ab Initio&#8217;s owned portfolio are expected to expire between 2036 and 2040, without accounting for potentially available patent term adjustments and extensions or disclaimers. Through Ab Initio, we also have an exclusive license from Stanford University directed to screening methods using transmembrane and cell-surface proteins and related compositions and kits. This licensed portfolio includes four issued patents in the U.S., one issued patent in Europe, and pending applications in Europe and Japan. The patents and application in the licensed portfolio are expected to expire between 2034 and 2035, without accounting for potentially available patent term adjustments and extensions or disclaimers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">We also use trademark rights to protect our brand. As of December&#160;31, 2021, we own a total of 21 registered United States trademarks, 9 pending United States trademarks, 104 registered foreign trademarks in various countries including China, the European Union, and Japan, and 32 pending foreign trademarks in various countries around the world. Our trademarks include our company name OMNIAB and product-specific names such as OMNICHICKEN, OMNICLIC, OMNIFLIC, OMNIMOUSE, OMNIRAT, and </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">258</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">OMNITAUR, as well as slogans and marketing taglines such as &#8220;3 SPECIES, 1 LICENSE,&#8221; &#8220;ABSOLUTELY OMNIAB,&#8221; &#8220;ANIMAL INTELLIGENCE,&#8221; &#8220;BIOLOGICAL INTELLIGENCE,&#8221; and &#8220;NATURALLY OPTIMIZED HUMAN ANTIBODIES.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Commercial</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our license agreements are negotiated separately for each discovery partner, and as a result, the financial terms and contractual provisions vary from agreement to agreement. We structure our license agreements with our partners to include: (i)&#160;payments for technology access and payments for performance of research services; (ii)&#160;downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones; and (iii)&#160;royalties on net sales of our partners&#8217; products, if any. We succeed when our partners are successful and our agreements are structured to align economic and scientific interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We partner with drug developers of all sizes, from large cap pharmaceutical to small biotechnology companies. Our partners are predominantly based in the United States, Europe, and China. As of December&#160;31, 2021, we had a total of 57 active partners. For the&#160;year ended December&#160;31, 2021, our top three partners represented 63% of revenue. See &#8220;&#8212; Partner License Agreements&#8221; below for a description of our license agreements with these three partners. We do not believe the loss of any one or more of our partners would have a material adverse effect on us and our subsidiaries taken as a whole.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, we had 74 full-time employees in the United States including 69 employees engaged in research and development. We expect approximately seven additional employees currently working at Ligand to transfer to OmniAb in connection with the Separation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our strategy involves:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Providing the best antibody discovery engine to our partners through continued investment and innovation</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Giving our partners optionality and flexibility to use components of our technology to broaden our potential customer base</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Working with partners to guide our investment and development priorities to expand our current partnerships</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Expand the reach of our technology to new partners of all sizes in the drug development industry</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Deliver a complete solution through investment in infrastructure, resources and expertise to execute early-stage discovery</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, our business development and marketing function had one dedicated business development professional, and two dedicated marketing professionals. Our business development and marketing team has been complemented with research and development staff attending a variety of scientific conferences, which has helped increase the business development pipeline. We plan to further expand our commercial sales, marketing and business development teams.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Partner License Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Antibody License Agreement with CNA Development&#160;LLC</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2012, we entered into an Antibody License Agreement (the CNA Agreement) with CNA Development LLC, an affiliate of Janssen Pharmaceuticals,&#160;Inc. (CNA). Under the CNA Agreement, we granted to CNA a fee-bearing, non-exclusive, worldwide, sublicensable license under our patent rights relating to the generation of human antibodies using our transgenic rat platform to develop and commercialize pharmaceutical products derived from antibodies generated and selected during the research term against a low single digit number of antigens provided to us by CNA. Upon payment of a commercial fee, CNA became the sole and exclusive owner of such antibodies and any products generated from such antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the CNA Agreement, we received from CNA an initial research fee in the low six digits and a commercial fee in the mid six digits. We are eligible to receive development and commercialization milestone payments from CNA of up to an aggregate of $42.0 million for the first product directed to each antigen, regardless of the number of products directed to each such antigen that reaches the development milestones.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">259</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the CNA Agreement will continue until all of CNA&#8217;s payment obligations are met. CNA has the right to terminate the CNA Agreement at its discretion upon prior written notice. Either party may terminate the CNA Agreement for the other party&#8217;s uncured material breach after a certain notice and cure period, or immediately if such breach is incurable. Either party may terminate the CNA Agreement for the other party&#8217;s insolvency. Unless we terminate the CNA Agreement for CNA&#8217;s material breach, under all other termination scenarios CNA may continue to develop and commercialize licensed products for which it has paid one or more milestone payments, provided it continues to pay us the remaining milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research, Development and Commercialization Agreement with the Cystic Fibrosis Foundation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2018, we entered into Research, Development and Commercialization Agreement (the CFF Agreement), with the Cystic Fibrosis Foundation (CFF), as amended in June&#160;2018, April&#160;2020 and September&#160;2021. Under the CFF Agreement, CFF agreed to fund a research program under which we will attempt to identify lead compounds from a third party compound library for potential treatment of cystic fibrosis and other rare diseases, and will endeavor to develop and commercialize a product based on a lead compound, subject to the third party compound library owner&#8217;s option to develop and commercialize such product itself. We are solely responsible for the conduct of research programs in accordance with research plans and agreed to use commercially reasonable efforts to complete such plans, identify lead compounds and, if appropriate at our sole discretion, develop and commercialize a product derived from such lead compounds in the U.S. and major European countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we develop and commercialize the product under the CFF Agreement, we are obligated to pay CFF milestone payments of up to an aggregate of approximately $56.0 million upon achievement of certain regulatory and commercial milestone events. We are also obligated to pay CFF tiered royalties equal to low-single digit&#160;percentages on net sales of each product developed under the CFF Agreement. Furthermore, if we undergo a change of control or enter into a transaction in which we license, sell or otherwise transfer a product developed under the CFF Agreement to a third party prior to the first commercial sale of such product, we are obligated to pay to CFF a royalty equal to a low-double digit&#160;percentage of the consideration we receive in connection with such change of control or other transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the CFF Agreement will continue until all of our payment obligations to CFF are fulfilled. CFF has the right to terminate the CFF Agreement at its discretion upon prior written notice. We have the right to terminate the CFF Agreement for scientific cause, such as a lack of safety or efficacy, upon prior notice to and an opportunity for discussion with CFF. Either party may terminate the CFF Agreement for the other party&#8217;s uncured material breach after a notice and cure period or for the other party&#8217;s insolvency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amended and Restated License Agreement with F. Hoffman-La Roche Ltd and Hoffman-La Roche&#160;Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2018, we entered into an Amended and Restated License Agreement (the Roche Agreement), with F.&#160;Hoffman-La Roche Ltd and Hoffman-La Roche&#160;Inc. (&#8220;Roche&#8221;), as amended in June&#160;2021. Under the Roche Agreement, we granted Roche an exclusive, world-wide, non-transferable, sublicensable license under certain of our patent rights and know-how relating to our ion channel integrated drug discovery platform to research, develop, manufacture, and commercialize small molecule compounds (and products containing such compounds) that modulate specified targets for all therapeutic, prophylactic and diagnostic uses. We agreed to collaborate with Roche to use commercially reasonable efforts to conduct, at Roche&#8217;s cost, research programs in accordance with research plans and as overseen by a committee, to discover and identify compounds that modulate each specified target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Roche Agreement, we received an upfront payment from Roche of $5.0 million. For the second target and each target thereafter, if we and Roche agree to begin any new research programs, we will receive an initiation payment from Roche in the low-single digit millions for each new research program. We are eligible to receive development milestone payments from Roche up to an aggregate of $144.0 million for each selected target, regardless of the number of products directed to such target that reach the development milestones. We are eligible to receive sales milestone payments of up to an aggregate of $130.0 million for each product if total worldwide nets sales of such product exceeds certain thresholds. Further, Roche is obligated to pay us tiered royalties on a product-by-product basis ranging from low-single digit to high-single digit&#160;percentages on net sales of the applicable product, subject to certain customary reductions and offsets. Roche&#8217;s obligation to pay us royalties will expire on a product-by-product and country-by-country basis on the later of (i)&#160;ten&#160;years after the first commercial sale of such product in such country or (ii)&#160;the expiration of the last-to-expire licensed patent claim covering the composition of matter of such product in such country. Such last-to-expire licensed patent claims are expected to expire in 2042, without accounting for potential patent term adjustment or extension.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">260</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the Roche Agreement will continue until the expiration of all royalty and payment obligations. Either party may terminate the Roche Agreement in its entirety or on a country-by-country basis for the other party&#8217;s uncured material breach after a certain notice and cure period. Either party may terminate the Roche Agreement in its entirety for the other party&#8217;s insolvency. Roche has the right to terminate the Roche Agreement at its discretion in its entirety or on a product-by-product or country-by-country basis upon prior written notice. If we or Roche undergo a change of control during the term of the Roche Agreement, there will be restrictions on the acquirer&#8217;s ability to use sensitive information of the non-acquired party, and the non-acquired party may restrict the acquired party&#8217;s participation in certain committees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacturing, quality control, safety, effectiveness, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drugs and biological products such as those that our partners develop. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. If we or our partners fail to comply with applicable laws or regulations at any time, we or our partners may become subject to administrative or judicial sanctions or other legal consequences, including among other things, restrictions on marketing or manufacturing, withdrawal of products, product recalls, fines, warning letters, untitled letters, clinical holds on clinical studies, refusal of the FDA or foreign regulatory authorities to approve pending applications or supplements to approved applications, suspension or revocation of product approvals, product seizure or detention, refusal to permit the import or export of products, consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs, mandated modification of promotional materials, issuance of safety alerts, Dear Healthcare Provider letters, injunctions or the imposition of civil or criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our partners must obtain the requisite approvals from the applicable regulatory authority prior to the commencement of clinical studies or marketing of a drug or biological product in any country in which they wish to initiate such activities. In the United States, the U.S. Food and Drug Administration (FDA) regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations, and biologics under the FDCA and the Public Health Service Act and their implementing regulations. FDA approval of a New Drug Application (NDA) or Biologics License Application (BLA) or supplement is required before any new unapproved drug, biologic or dosage form, including a new use of a previously approved drug or biologic, can be marketed in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before such therapeutic candidates may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of extensive preclinical laboratory tests and preclinical animal studies, which may need to be performed in accordance with the Good Laboratory Practices (GLP) regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an investigational new drug application (IND) which must become effective before human clinical trials may begin and must be updated annually;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent Institutional Review Board (IRB) or ethics committee representing each clinical site before each clinical study may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical studies in accordance with Good Clinical Practice (GCP) requirements to establish the safety and efficacy, or with respect to biologics, the safety, purity and potency of the therapeutic candidate for each proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation of and submission to the FDA of an NDA or BLA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential review of the product application by an FDA advisory committee, where appropriate and if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination by the FDA within 60&#160;days of its receipt of an NDA or BLA to file the application for review;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">261</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities where the proposed product drug substance and drug product are produced to assess compliance with current Good Manufacturing Practice requirements (cGMPs), and audits of selected clinical trial sites to ensure compliance with GCP; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of an NDA or BLA prior to any commercial marketing or sale of the drug or biologic in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as <i style="font-style:italic;">in vitro</i> and animal studies to assess potential safety and efficacy. The conduct of certain preclinical studies is subject to federal regulations and requirements, including GLP regulations applicable to certain safety/toxicology studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol for the proposed clinical trial. The IND also includes results of animal and <i style="font-style:italic;">in vitro</i> studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the therapeutic candidate, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP, which includes the requirement that all research subjects, or their legal representative, provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board or committee, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may recommend that the clinical trial be halted if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. Study sponsors also must comply with requirements governing the reporting of clinical trials and clinical study results to public registries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The clinical investigation of a drug is generally divided into three phases. Although the phases are usually conducted sequentially, they may overlap or be combined.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1. The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2. The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically </span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">262</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for labeling.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Post-marketing studies, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, such as with drugs approved under FDA&#8217;s accelerated approval pathway, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the characteristics of the therapeutic candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the therapeutic candidate and must include methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of clinical development, nonclinical studies and clinical trials are submitted to the FDA as part of an NDA or BLA requesting approval to market the therapeutic candidate for one or more indications. The submission of an NDA or BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the FDA evaluates an NDA or BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced and of select clinical trial sites, the FDA may issue an approval letter or a Complete Response Letter (CRL). An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL will describe all of the deficiencies that the FDA has identified in the NDA or BLA, except that where the FDA determines that the data. supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the NDA or BLA in condition for approval, including requests for additional information or clarification. Even with the submission of additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may include limitations on the indicated uses for which such product may be marketed. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any drugs or biologics manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, many changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are annual program fees for any marketed products. Drug and biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The FDA may withdraw any marketing authorization if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks, or imposition of distribution restrictions or other restrictions. Other potential consequences include, among other things: restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, product recalls, fines, warning letters, untitled letters, clinical holds on clinical studies, refusal of the FDA to approve pending applications or supplements to approved applications, product seizures or detention, refusal to permit the import or export of </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">263</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">products, consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs, the issuance of corrective information, injunctions, or the imposition of civil or criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">FDA Regulation of Animals with Intentionally Altered Genomic DNA</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDCA provides FDA with authority to regulate as a drug the portion of an animal&#8217;s genome that has been intentionally altered, including where such animals with intentionally altered genomes are intended to produce medical products, such as human drugs. In particular, the FDCA defines the term &#8220;drug&#8221; to include, among other things, articles (other than food) intended to affect the structure or any function of the body of man or other animals. Subject to certain exceptions, the FDA considers each specific DNA alteration utilized in genetically modified animals to be an article meeting the FDCA&#8217;s definition of a new animal drug, because such altered DNA is intended to affect the structure or function of the body of the animal. Consequently, the FDA considers intentionally genetically altered (IGA) animals to be subject to regulation under the new animal drug provisions of the FDCA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, any new animal drug is deemed unsafe and adulterated unless FDA has approved a new animal drug application (NADA) for its intended use, or unless such drug is only for investigational use and conforms to specified exemptions for such use under an Investigational New Animal Drug (INAD) exemption. However, although IGA animals may be subject to premarket approval requirements or the requirement for an INAD when used in research and development, in some circumstances the FDA has not required INADs or NADAs for such IGA animals. For example, in a draft guidance issued in January&#160;2017, FDA stated its intention to exercise enforcement discretion in a risk-based manner with regard to INAD and NADA requirements for certain IGA animals that are nonfood-producing species, taking into consideration the relative human, animal and environmental risks posed by such animals. The FDA has also stated it may modify its approach with respect to INAD or NADA requirements for other kinds or uses of animals based on its evaluation of risks. Failure to comply with applicable requirements may subject a company to FDA enforcement action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Foreign Government Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Regulation Governing Medicinal Products in the European Union</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similarly to the United States, our partners are subject to stringent regulations governing the development, and marketing of medicinal products in the European Union (EU). The various phases of non-clinical and clinical research in the EU are subject to significant regulatory controls.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Non-clinical studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical studies must be conducted in compliance with the principles of good laboratory practice (GLP) as set forth in EU Directive 2004/10/EC. In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules&#160;and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Conference on Harmonization (ICH) guidelines on Good Clinical Practice (GCP) as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU member states, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation (CTR) which was adopted in April&#160;2014 and repeals the EU Clinical Trials Directive, became applicable on January&#160;31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">While the Clinical Trials Directive required a separate clinical trial application (CTA) to be submitted in each member state, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">264</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials whose CTA was made under the Clinical Trials Directive before January&#160;31, 2022, the Clinical Trials Directive will continue to apply on a transitional basis for three&#160;years. Additionally, sponsors may still choose to submit a CTA under either the Clinical Trials Directive or the CTR until January&#160;31, 2023 and, if authorized, those will be governed by the Clinical Trials Directive until January&#160;31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Medicines used in clinical trials must be manufactured in accordance with good manufacturing practice (GMP). Other national and EU-wide regulatory requirements may also apply and compliance with these requirements is subject to inspections by competent authorities of the EU member states.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of non-clinical studies and clinical trials are submitted to the European Medicines Agency (EMA) or national competent authorities of the EU member states as part of a marketing authorization application (MAA) requesting authorization to market the therapeutic candidate for one or more indications. The submission of a MAA requires payment of a substantial application fee to the EMA or national competent authorities depending on the approval procedure used by the applicant, subject to some exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the EU, the process for submitting a MAA depends, among other things, on the nature of the medicinal product candidate. There are two types of MAs:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Centralized MAs&#8221; are issued by the European Commission through the centralized procedure, based on the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and are valid throughout the EU. It is compulsory for certain types of products, such as (i)&#160;medicinal products derived from biotechnological processes, (ii)&#160;designated orphan medicinal products, (iii)&#160;advanced-therapy medicinal products (ATMPs) such as gene therapy, somatic cell-therapy or tissue-engineered medicines and (iv)&#160;medicinal products containing a new active substance indicated for the treatment of HIV/AIDS, cancer, neurodegenerative diseases, diabetes, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for any other products containing new active substances not authorized in the EU or for product candidates which constitute a significant therapeutic, scientific, or technical innovation or for which the granting of authorization would be in the interests of public health in the EU.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;National MAs&#8221; are issued by the competent authorities of the EU member states, only cover their respective territory, and are available for product candidates not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in an EU member state, this national MA can be recognized in another member state through the Mutual Recognition Procedure. If the product has not received a national MA in any member state at the time of application, it can be approved simultaneously in various member states through the decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the competent authorities of each of the member states in which the MA is sought, one of which is selected by the applicant as the reference member state.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">MAs have an initial duration of five&#160;years. After these five&#160;years, the authorization may be renewed for an unlimited period on the basis of a reevaluation of the risk-benefit balance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Moreover, in the EU, a &#8220;conditional&#8221; MA may be granted in cases where all the required safety and efficacy data are not yet available. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one&#160;year and has to be renewed annually until fulfillment of all the conditions. Once the pending studies are provided, it can become a &#8220;normal&#8221; MA. However, if the conditions are not fulfilled within the timeframe set by the EMA, the MA ceases to be renewed. Furthermore, MA may also be granted &#8220;under exceptional circumstances&#8221; when the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. This may arise in particular when the intended indications are very </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">265</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. This MA is close to the conditional MA as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of a MA. However, unlike the conditional MA, the applicant does not have to provide the missing data and will never have to. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually and the MA is withdrawn in case the risk-benefit ratio is no longer favorable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similar to the United States, both MA holders, manufacturers and distributors of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the EU member states.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All new MAA must include a risk management plan (RMP) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety and/or efficacy studies. Similar to the FDA, the EMA or national competent authorities of the EU member states may limit further marketing of the product based on the results of these post-authorization safety and/or efficacy studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Compliance with substantial requirements is imposed to manufacturers and distributors of medicinal products. Manufacturing and distribution activities are subject to authorizations in the EU member states where these activities take place, referred to as manufacturing and wholesale distribution authorizations. Such authorizations are only valid for the authorized product categories and specific types of manufacturing/distribution activities. Medicinal products must be manufactured in accordance with the principles of GMP and compliance with GMP requirements is monitored via periodic unannounced inspections by the competent regulatory authorities of the EU member states. EU legislation also requires investigation and correction of any deviations from GMP and imposes reporting requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The aforementioned EU rules&#160;are generally applicable in the European Economic Area (EEA) which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Brexit and the Regulatory Framework in the United Kingdom</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The United Kingdom (UK) left the EU on January&#160;31, 2020, following which existing EU medicinal product legislation continued to apply in the UK during the transition period under the terms of the EU-UK Withdrawal Agreement. The transition period, which ended on December&#160;31, 2020, maintained access to the EU single market and to the global trade deals negotiated by the EU on behalf of its members. The transition period provided time for the UK and EU to negotiate a framework for partnership for the future, which was then crystallized in the Trade and Cooperation Agreement (TCA) and became effective on the January&#160;1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">EU laws which have been transposed into UK law through secondary legislation continue to be applicable as &#8220;retained EU law.&#8221; However, new legislation such as the EU CTR will not be applicable. The UK government has passed a new Medicines and Medical Devices Act 2021, which introduces delegated powers in favor of the Secretary of State or an &#8216;appropriate authority&#8217; to amend or supplement existing regulations in the area of medicinal products and medical devices. This allows new rules&#160;to be introduced in the future by way of secondary legislation, which aims to allow flexibility in addressing regulatory gaps and future changes in the fields of human medicines, clinical trials and medical devices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">As of January&#160;1, 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) is the UK&#8217;s standalone medicines and medical devices regulator. As a result of the Northern Ireland protocol, different rules&#160;will apply in Northern Ireland than in </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">266</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">England, Wales, and Scotland, together, Great Britain, or GB. Broadly, Northern Ireland will continue to follow the EU regulatory regime, but its national competent authority will remain the MHRA. The MHRA has published a guidance on how various aspects of the UK regulatory regime for medicines will operate in GB and in Northern Ireland following the expiry of the Brexit transition period on December&#160;31, 2020. The guidance includes clinical trials, importing, exporting, and pharmacovigilance and is relevant to any business involved in the research, development, or commercialization of medicines in the UK. The new guidance was given effect via the Human Medicines Regulations (Amendment etc.) (EU Exit) Regulations 2019 (the Exit Regulations).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment and a rolling review procedure. All existing EU MAs for centrally authorized products were automatically converted or grandfathered into UK MAs, effective in GB (only), free of charge on January&#160;1, 2021, unless the MA holder chooses to opt-out. After Brexit, companies established in the UK cannot use the centralized procedure and instead must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures to obtain an MA to commercialize products in the UK. The MHRA may rely on a decision taken by the European Commission on the approval of a new (centralized procedure) MA when determining an application for a GB authorization; or use the MHRA&#8217;s decentralized or mutual recognition procedures which enable MAs approved in EU member states (or Iceland, Liechtenstein, Norway) to be granted in GB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other U.S. and Foreign Regulatory Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to FDA and EMA regulation, pharmaceutical and biologics companies are also subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business and may constrain the financial arrangements and relationships through which such companies research, as well as sell, market and distribute any products for which we obtain marketing authorization. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, data privacy and security, and transparency laws and regulations related to drug pricing and payments and other transfers of value made to physicians and other healthcare providers. If their operations are found to be in violation of any of such laws or any other governmental regulations that apply, they may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and imprisonment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Coverage and Reimbursement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. These third-party payors are increasingly reducing reimbursements for medical products, drugs and services. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product and also have a material adverse effect on sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Healthcare Reform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, there have been, and continue to be, legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of therapeutic candidates, restrict or regulate post-approval activities, and affect the profitable sale of therapeutic candidates, and similar healthcare laws and regulations exist in the European Union (EU) and other jurisdictions. Among policy makers and payors in the United States, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">By way of example, in March&#160;2010, the Patient Protection and Affordable Care Act (the ACA) was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">267</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">industry. The ACA, among other things, increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the average manufacturer price; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs; implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; creates a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its enactment, there have been judicial, executive and political challenges to certain aspects of the ACA. On June&#160;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, on March&#160;11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January&#160;1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs and suppliers will be included in their healthcare programs Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Data Privacy&#160;&amp; Security</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Numerous state, federal and foreign laws, regulations, and standards govern the collection, use, access to, confidentiality and security of health-related and other personal information, including clinical trial data, and could apply now or in the future to our operations or the operations of our partners. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Facilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our corporate headquarters and research and development facilities are located in Emeryville, California, where we lease approximately 22,000 square feet of space under leases expiring between 2022 and 2032. In 2022, we are expanding our headquarters and research and development facilities in Emeryville and will lease approximately 35,000 square feet of space under leases expiring in 2032. Icagen, our wholly-owned subsidiary, leases approximately 27,000 square feet of research and development space in Durham, North Carolina and Tucson, Arizona, under leases that expire between 2022 and 2026. In 2022, Icagen is planning to move into a new research and development lab in Durham, North Carolina under a lease that expires in 2029, expanding its facilities to a total of approximately 30,000 square feet. We believe our facilities are adequate and suitable for our current needs and that, should it be needed, suitable additional or alternative space will be available to accommodate our operations.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">268</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Employees and Human Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recognize and take care of our employees by offering a wide range of competitive pay, recognition, and benefit programs. We are proud to provide our employees the opportunity to grow and advance as we invest in their education and career development. As of December&#160;31, 2021, we have 74 employees, including 69 employees engaged in research and development. We expect approximately seven additional employees currently working at Ligand to transfer to OmniAb in connection with the Separation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We rely on skilled, experienced, and innovative employees to conduct the operations of our company. Our key human capital objectives include identifying, recruiting, retaining, incentivizing and integrating our existing and new employees. We frequently benchmark our compensation practices and benefits programs against those of comparable industries and in the geographic areas where our facilities are located. We believe that our compensation and employee benefits are competitive and allow us to attract and retain skilled labor throughout our organization. Our notable health, welfare and retirement benefits include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">equity awards;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subsidized health insurance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">401(k)&#160;Plan with matching contributions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tuition assistance program; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">paid time off.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We strive to maintain an inclusive environment free from discrimination of any kind, including sexual or other discriminatory harassment. Our employees have multiple avenues available through which inappropriate behavior can be reported, including a confidential hotline. All reports of inappropriate behavior are promptly investigated with appropriate action taken to stop such behavior.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. However, regardless of outcome, litigation can have an adverse impact on our business because of defense and settlement costs, diversion of management resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">269</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7f71b936_c6fd_480b_abfe_8de5f6f04cda"></a><a id="Main_OMNIABMANAGEMENTSDISCUSSIONAND"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">OMNIAB MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONDITION AND RESULTS OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unless the context otherwise requires, references in this subsection &#8220;&#8212;OmniAb Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; to &#8220;OmniAb,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; generally refer to OmniAb prior to the Business Combination.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This MD&amp;A is designed to provide a reader of our financial statements with a narrative from the perspective of the OmniAb Business&#8217;s management. This MD&amp;A should be read in conjunction with &#8220;<i style="font-style:italic;">Unaudited Pro Forma Combined Financial Statements of APAC and OmniAb</i>&#8221; and OmniAb&#8217;s audited Combined Financial Statements included elsewhere in this proxy statement/prospectus/information statement. This MD&amp;A includes forward-looking statements. For a discussion of important factors that could cause actual results to differ materially from the results referred to in these forward-looking statements, see &#8220;<i style="font-style:italic;">Cautionary Statement Concerning Forward-Looking Statements</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Separation from Ligand</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to completion of the Separation, OmniAb will be a wholly-owned subsidiary of Ligand. We have historically operated as part of Ligand and not as a separate, publicly-traded company. Our combined financial statements have been derived from Ligand&#8217;s historical accounting records and are presented on a carve-out basis. All sales and costs as well as assets and liabilities directly associated with our business activity are included as a component of the combined financial statements. The combined financial statements also include allocations of certain general, administrative, sales and marketing expenses and cost of sales from Ligand&#8217;s corporate office and from other Ligand businesses to us and allocations of related assets, liabilities, and Ligand&#8217;s investment, as applicable. We believe the allocations have been determined on a reasonable basis; however, the amounts are not necessarily representative of the amounts that would have been reflected in the combined financial statements had we been an entity that operated separately from Ligand during the periods presented. Further, the historical financial statements may not be reflective of what our results of operations, income (loss), historical financial position, equity or cash flows might be in the future as a separate public company. We have entered into or will enter into the Separation Agreement and various other agreements with Ligand (and in certain cases APAC and/or Merger Sub) to provide for the allocation between us and Ligand of Ligand&#8217;s assets, employees, liabilities and obligations attributable to periods prior to, at and after the Separation and will govern certain relationships between us and Ligand after the Separation. Following the Separation, we expect Ligand to continue to provide certain services to us on a transitional basis for associated fees, including services related to information technology, facilities, certain accounting and other financial functions and administrative functions, and we will provide transitional services to Ligand, including services related to legal, corporate, and other administrative functions as we and Ligand may decide from time to time. For additional information regarding the Separation Agreement, Transition Services Agreements and other agreements related to the Separation, please see the sections &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;&#8212; Summary of the Separation Agreement</i>&#8221; and &#8220;<i style="font-style:italic;">&#8212;Summary of the Ancillary Agreements.</i>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying audited combined financial statements present the historical financial position, results of operations, changes in equity and cash flows of OmniAb in accordance with GAAP for the preparation of carved-out combined financial statements. We are a biotechnology company enabling the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies. Our partners include pharmaceutical and biotechnology companies engaged in drug development. OmniAb&#8217;s products are marketed to partners primarily under the OmniAb brand name. Historically, our business has comprised the OmniAb Business of Ligand Pharmaceuticals Incorporated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our historical Combined Financial Statements include expense allocations for certain support functions that are provided on a centralized basis within Ligand, such as corporate costs, shared services and other general and administrative costs that benefit OmniAb, among others. Following the Separation, pursuant to agreements with Ligand, we expect that Ligand will continue to provide us with some of the services related to these functions on a transitional basis in exchange for agreed-upon fees, and we expect to incur other costs to replace the services and resources that will not be provided by Ligand. We will also incur additional costs as a separate public company. As a separate public company, our total costs related to such support functions may differ from the costs that were historically allocated to us.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">270</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These additional costs are primarily for the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional personnel costs, including salaries, benefits and potential bonuses and/or stock-based compensation awards for staff additions to replace support provided by Ligand that is not covered by the Transition Services Agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">corporate governance costs, including board of director compensation and expenses, insurance costs, audit and other professional services fees, annual report and proxy statement costs, SEC filing fees, transfer agent fees, consulting and legal fees and stock exchange listing fees.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain factors could impact the nature and amount of these separate public company costs, including the finalization of our staffing and infrastructure needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, OmniAb&#8217;s combined balance sheet may not be comparable to the opening balance sheet of the separate company, which we expect will reflect the transfer by Ligand of $15.0 million in cash (less certain transaction and other expenses) along with certain corporate entities. For a detailed description of OmniAb&#8217;s unaudited pro forma combined financial statements, see &#8220;<i style="font-style:italic;">Unaudited Pro Forma Combined Financial Statements of APAC and OmniAb</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of its plan to separate Ligand&#8217;s OmniAb Business into a stand-alone publicly traded company, Ligand proposes to effect the Distribution of 100% of the outstanding shares of OmniAb&#8217;s common stock, immediately followed by the Merger of Merger Sub with and into OmniAb. Upon the Closing of the Merger, among other things, each outstanding share of OmniAb Common Stock (other than Treasury Shares), will be cancelled upon the Effective Time in exchange for the right to receive (i)&#160;a number of shares of New OmniAb Common Stock equal to the Base Exchange Ratio, and (ii)&#160;a number of OmniAb Earnout Shares equal to the Earnout Exchange Ratio. In addition, all (i)&#160;OmniAb Options, (ii)&#160;OmniAb RSUs and (iii)&#160;OmniAb PSUs, in each case, that are outstanding as of immediately prior to the Effective Time, will be converted into such number of (a)&#160;New OmniAb Options, (b)&#160;New OmniAb RSUs and (c)&#160;New OmniAb PSUs, respectively, in each case, equal to (1)&#160;the number of shares of OmniAb Common Stock underlying such OmniAb Equity Awards immediately prior to the Effective Time multiplied by (2)&#160;the Base Exchange Ratio. Each holder of an OmniAb Option, OmniAb RSU and/or OmniAb PSU will also receive a number of OmniAb Earnout Shares equal to the number of shares of OmniAb Common Stock underlying such OmniAb Options, OmniAb RSUs and/or OmniAb PSUs, as applicable, multiplied by the Earnout Exchange Ratio, and the exercise price of each outstanding New OmniAb Option will be equal to the exercise price of the pre-conversion OmniAb Option divided by the Base Exchange Ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Distribution and Merger are subject to the satisfaction or waiver of various conditions as described elsewhere in this proxy statement/prospectus/information statement. In addition, the respective obligations of the parties to consummate the Business Combination are conditioned upon, among other items, (i)&#160;the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (ii)&#160;receipt of required consents and approvals from certain governmental authorities, (iii)&#160;no agreement between Ligand or APAC and any governmental authority pursuant to which Ligand or APAC has agreed not to consummate the Business Combination shall be in effect, (iv)&#160;no governmental authority of competent jurisdiction shall have enacted, issued or granted any law (whether temporary, preliminary or permanent), in each case that is in effect and which has the effect of restraining, enjoining or prohibiting the consummation of the transaction, (v)&#160;APAC shall have at least $5,000,001 of net tangible assets as of the Closing, (vi)&#160;the New OmniAb Common Stock issuable pursuant to the Business Combination shall have been approved for listing on Nasdaq, subject to official notice of issuance, (vii)&#160;Ligand, OmniAb, APAC and Merger Sub shall each have performed and complied in all material respects with the obligations, covenants and agreements required by the Merger Agreement to be performed or complied with by it at or prior the Effective Time (viii)&#160;customary bring down conditions related to the accuracy of the parties&#8217; respective representations and warranties in the Merger Agreement, (ix)&#160;the consummation of the Separation, the Distribution and the other transactions contemplated by the Separation Agreement, (x)&#160;each of APAC&#8217;s and OmniAb&#8217;s registration statements to be filed with the United States Securities and Exchange Commission shall have become effective, (xi) APAC&#8217;s shareholder approval of the Condition Precedent Proposals shall have been obtained and (xii) the receipt by Ligand and APAC of certain tax opinions. In addition, the respective obligations of OmniAb and Ligand to consummate the Business Combination is conditioned upon, among other items, the completion of the Forward Purchase and the Redemption Backstop, the resignation of all directors and all executive officers of APAC and the occurrence of the Domestication. APAC&#8217;s obligation to consummate the Business Combination is also conditioned on there having been no &#8220;Material Adverse Effect&#8221; on OmniAb since the date of the Merger Agreement. There can be no assurance that the parties to the Merger Agreement would waive any such provision of the Merger Agreement if it is not satisfied as of the time of satisfaction of all other conditions precedent to the Merger.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">271</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb has historically operated as part of Ligand and not as a stand-alone company. The financial statements have been derived from Ligand&#8217;s historical accounting records and are presented on a carve-out basis. All revenues and costs as well as assets and liabilities directly associated with the business activity of OmniAb are included as a component of the financial statements. The financial statements also include allocations of certain general and administrative expenses from Ligand&#8217;s corporate office. The allocations have been determined on a reasonable basis; however, the amounts are not necessarily representative of the amounts that would have been reflected in the financial statements had OmniAb been an entity that operated independently of Ligand. Further, the historical financial statements may not be reflective of what our results of operations, comprehensive income, historical financial position, equity or cash flows might be in the future as a separate public company. Certain factors could impact the nature and amount of these separate public company costs, including the finalization of our staffing and infrastructure needs. Following the Separation, pursuant to agreements with Ligand, we expect that Ligand will continue to provide us with some of the services related to these functions on a transitional basis in exchange for agreed-upon fees, and we expect to incur other costs to replace the services and resources that will not be provided by Ligand. Related party allocations are discussed further in Note&#160;9, &#8220;Relationship with Parent and Related Entities&#8221; in the accompanying audited Combined Financial Statements contained elsewhere in this proxy statement/prospectus/information statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of Ligand, OmniAb is dependent on Ligand for all of its working capital and financing requirements, which utilizes a centralized approach to cash management and financing of its operations. Financing transactions relating to OmniAb are accounted for through the Net Parent investment account of OmniAb. Accordingly, none of Ligand&#8217;s cash, cash equivalents or debt has been assigned to OmniAb in the accompanying audited Combined Financial Statements included elsewhere in this proxy statement/prospectus/information statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net Parent investment, which includes retained earnings, represents Ligand&#8217;s interest in the recorded net assets of OmniAb. All significant transactions between OmniAb and Ligand have been included in the accompanying combined financial statements. Transactions with Ligand are reflected in the accompanying Combined Statements of Equity as &#8220;Transfers (to) from Parent, net&#8221; and in the accompanying Combined Balance Sheets within &#8220;Net Parent investment.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our mission is to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies. We intend to achieve this mission by enabling the discovery of high-quality therapeutic candidates and by being the partner of choice for pharmaceutical and biotechnology companies. We believe that pairing the large and diverse antibody repertoires generated from our proprietary transgenic animals with our cutting-edge and high-throughput validated screening tools will deliver high-quality therapeutic candidates for a wide range of diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our OmniAb technology platform creates and screens diverse antibody pools and is designed to quickly identify optimal antibodies for our partners&#8217; drug development efforts. We harness the power of Biological Intelligence, which we built into our proprietary transgenic animals and paired with our high-throughput screening technologies to enable the discovery of high-quality, fully-human antibody therapeutic candidates. We believe these antibodies are high quality because they are naturally optimized in our validated host systems for affinity, specificity, developability, and functional performance. Our partners have access to these antibody candidates that are based on unmatched biological diversity and optimized through integration across a full range of technologies, including antigen design, transgenic animals, deep screening and characterization. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized antibody discovery solutions. As of December&#160;31, 2021, we had 57&#160;active&#160;partners and over 250&#160;active programs, including 25&#160;OmniAb-derived antibodies in clinical development and two approved products: (i)&#160;zimberelimab, which was approved in China for the treatment of recurrent or refractory classical Hodgkin&#8217;s lymphoma; and (ii)&#160;sugemalimab, which was approved in China for the first-line treatment of metastatic (stage IV) non-small cell lung cancer in combination with chemotherapy. Our robust experience and development activity with our partners gives us critical insights into the industry and creates a positive feedback loop through which we plan to continue to advance our platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">We partner with numerous pharmaceutical and biotechnology companies, varying in size, clinical stage, geography and therapeutic focus. Our license agreements are negotiated separately for each discovery partner, and as a result, the financial terms and contractual provisions vary from agreement to agreement. We structure our license agreements with partners to typically include: (i)&#160;upfront or annual payments for technology access (license revenue) and payments for performance of research services (service revenue); (ii)&#160;downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones (milestone revenue); and (iii)&#160;royalties on net sales of our partners&#8217; products, if any. We succeed when our partners are successful and </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">272</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:223.85pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">our agreements are structured to align economic and scientific interests. Our typical royalty rates for antibody discovery contracts are currently in the low- to mid-single digits, and can vary depending on the other economic terms in the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the&#160;years ended December&#160;31, 2021, 2020 and 2019, our revenue was $34.7 million, $23.3 million and $18.3 million, respectively. Historically, our revenue has been derived from payments for technology access, collaborative research services and milestones. We believe the long-term value of our business will be driven by partner royalties as such payments are based on global sales of potential future partner antibodies, which generally provide for larger and recurring payments as compared to technology access, research and milestone payments. While we expect our first royalty payments to come from the sales of zimberelimab and sugemalimab in China, we believe our revenue will be materially driven by milestones, in the shorter term, and by royalties, in the longer term, from our partnered programs in the United States and Europe. However, drug discovery and development has significant uncertainty in timing and likelihood of reaching marketing authorization, and we cannot be certain when, if at all, royalty payments will be a material portion of our revenue. Furthermore, we do not control the progression, clinical development, regulatory strategy or eventual commercialization of antibodies discovered using our platform, and as a result, we are entirely dependent on our partners&#8217; efforts and decisions with respect to such antibodies. The figure below shows the growth in active partners, active programs, and active clinical programs and approved products since 2014.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><img src="ahpa-20220416xs4029.jpg" alt="Graphic" style="display:inline-block;height:223.85pt;width:463.98pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">* Active programs not tracked prior to acquisition of Open Monoclonal Technology,&#160;Inc. in January&#160;2016.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ligand built the OmniAb technology platform through acquisition, investment, and innovation. Ligand acquired us (Open Monoclonal Technology,&#160;Inc. or OMT) in January&#160;2016, Crystal Bioscience in October&#160;2017, Ab Initio in July&#160;2019, Icagen in April&#160;2020, xCella Biosciences in September&#160;2020 and Taurus Biosciences in September&#160;2020. In addition to acquisition, we have advanced our technology platform through internal investment and innovation. Over the past five&#160;years, the OmniAb team has launched new transgenic animals, introduced computational antigen design, expanded our internal capabilities in downstream processing, and developed internal data management and bioinformatics software. We have several internal projects in development including multiple new transgenic animals, a next generation high-throughput microcapillary deep screening platform, and a number of undisclosed projects. For a further description of these acquisitions, see <i style="font-style:italic;">Note&#160;(4)&#160;Acquisitions</i> in OmniAb&#8217;s combined financial statements included in this proxy statement/prospectus/information statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">For the&#160;years ended December&#160;31, 2021, 2020 and 2019, our net loss was $(27.0 million), $(17.6 million) and $(13.6 million), respectively. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we invest in research and development activities to improve our technology and platform, market and sell our solutions to existing and new partners, and add operational, financial and management information systems and personnel to support our operations. In addition, following the Separation, we will be required to establish policies, procedures and practices as a stand-alone public company necessary to comply with our obligations under the Exchange Act and related rules&#160;and regulations. As a result, we will incur additional costs, including internal audit, investor relations, stock administration and regulatory compliance costs. These additional </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">273</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">costs may differ from the costs that were historically allocated to us from Ligand. To operate as a stand-alone public company, we expect to incur costs to replace certain services previously provided by Ligand, which costs may be higher than those reflected in our historical combined financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Key Factors Affecting Our Results of Operations and Future Performance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that our financial performance has been, and in the foreseeable future will continue to be, primarily driven by multiple factors as described below, each of which presents growth opportunities for our business. These factors also pose important challenges that we must successfully address in order to sustain our growth and improve our results of operations. Our ability to successfully address these challenges is subject to various risks and uncertainties, including those described in the section of this proxy statement/prospectus/information statement titled &#8220;<i style="font-style:italic;">Risk Factors</i>.&#8221;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Expanding existing partnerships and increasing the number of partnerships.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Our potential to grow revenue, in both the near and long term, is dependent on our ability to expand upon our existing partnerships and increase the number of partnerships we have. Our technology investments are methodical and deliberate, with a goal to enable our partner-centric business model to leverage the most cutting-edge solutions that solve the biggest challenges in antibody drug discovery. As of December&#160;31, 2021, we had 57 active partners and over 250 active programs, including 25 OmniAb-derived antibodies in clinical development and two approved products in China. Some partners prefer integrated end-to-end discovery capabilities, while others prefer to use our technologies within their own labs. The flexible workstreams we offer not only provide value to our partners, but it allows for greater scalability of our business since we do not have to build out capacity for partners that prefer to use some of their own technologies in the process. We believe that we have a significant opportunity to continue to increase the number of partners who have programs based on our platform. Our ability to continue to grow the number of programs under license agreements is dependent upon our ability to educate the market and support the business through investment in our business development and marketing efforts and through further research and development to enhance our technological differentiation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">The success of our partners in developing and commercializing antibodies discovered using our platform.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> While the majority of our historical revenue reflects annual access fees, milestones and service revenue from research programs, we believe the long-term value of our business will be driven by downstream royalty payments from the success of our partners and long-term growth of antibody sales. As a result, we believe our business and our future results of operations will be highly reliant on the degree to which our partners successfully develop and commercialize the antibodies discovered using our platform. As our partners continue to advance development of OmniAb-derived antibodies that we have discovered, we expect to start receiving additional milestone payments and, in the longer term, royalties if any partners commence commercial sales of such antibodies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Furthering our technological differentiation through intelligent expansion.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Our ability to maintain and expand our partnerships is dependent on the advantages our technology platform delivers to our partners. We employ a methodical and deliberate approach to expanding our technology platform. Serving a broad partner base has provided us a unique insight into the needs and direction of the industry, and we continue to leverage this insight for our decision-making. In recent&#160;years, we have successfully integrated a number of technology acquisitions covering antigen generation, additional animal species, deep screening capabilities, and ion channel expertise. We will continue to invest in enabling technologies and evaluate strategic technology acquisitions to broaden our capabilities in the antibody discovery continuum. We intend to devote substantial resources to continue to improve our technological differentiation which will impact our financial performance.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">274</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Key Business Metrics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that the following metrics are important to understanding our current business. These metrics may change or may be substituted for additional or different metrics as our business continue to grow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.017593384%;padding-left:0pt;padding-right:0pt;width:100.03%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:20.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:11.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:11.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:20.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Metric</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b><b style="font-weight:bold;"><br /></b>&#160;<b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b>&#160;<br /><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b>&#160;<br /><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:20.8%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Active partners</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.26%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.78%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:11.54%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.8%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.58%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:20.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Active programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">207</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">207</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:20.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Active clinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:20.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Approved products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">not meaningful</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Active partners</span> represents the number of partners that have an active program or have executed a license agreement in advance of initiating an active program. We do not include academic partners with a license to the OmniAb platform in our active partner count. We view this metric as an indication of the competitiveness of our platform and our current level of market penetration. The metric also relates to our opportunities to secure additional active programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Active programs</span> represents a program for which an antigen is introduced into our animals and remains so as long as the program is actively being developed or commercialized. This number includes active clinical programs and approved products separately disclosed below. We view this metric as an indication of the usage of our technology and the potential for mid- and long-term milestone and royalty payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Active clinical programs</span> represents the number of unique programs for which an Investigational New Drug (&#8220;IND&#8221;) or equivalent under other regulatory regimes has been filed based on an OmniAb-derived antibody and which are in clinical development and we continue to count programs as active as long as they are actively being developed or commercialized. Where the date of such application is not known to us, we use the official start date from clinical trial registries for the purpose of calculating this metric. This number includes approved products separately disclosed below. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Approved products</span> represents an OmniAb-derived antibody for which our partner has received marketing approval. We view this metric as an indication of our near- and mid-term potential revenue from royalty payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Impact of COVID-19 Pandemic</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To date, we have not experienced material disruptions in our business operations or financial impacts as a result of the COVID-19 pandemic. While it is not possible at this time to estimate the impact that COVID-19 could have on our business in the future, the continued spread of COVID-19 and variants of the virus, the rate of vaccinations regionally and globally and the measures taken by the government authorities, and any future epidemic disease outbreaks, could: disrupt the supply chain and the manufacture or shipment of products and supplies for use by us in our discovery activities and by our partners for their discovery and development activities; delay, limit or prevent us or our partners&#8217; from continuing research and development activities; impede our negotiations with partners and potential partners; impede testing, monitoring, data collection and analysis and other related activities, by us and our partners; interrupt or delay the operations of the FDA or other regulatory authorities, which may impact review and approval timelines for initiation of clinical trials or marketing; impede the launch or commercialization of any approved products; any of which could delay our partnership programs, increase our operating costs, and have a material adverse effect on our business, financial condition and results of operations. In addition, if COVID-19 infects our genetically modified animals, which form the basis of our platform, or if there is an outbreak among our employees or subcontractor&#8217;s employees who maintain and care for these animals, we and our partners may be unable to produce antibodies for development.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">275</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Components of Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our revenue is typically derived from license agreements with our partners and consists of: (i)&#160;upfront or annual payments for technology access (license revenue) and payments for performance of research services (service revenue); (ii)&#160;downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones (milestone revenue); and (iii)&#160;royalties on net sales of our partners&#8217; products, if any. To date, while we have generated revenue from technology access and service fees, as well as intellectual property and development milestones, we have not generated any revenue from commercial milestone payments or royalties on product sales because all of the current programs of our partners are in the target selection, discovery, preclinical or clinical development stages. We expect revenue to increase over time as we enter into additional license agreements with partners and as our partners advance therapeutic candidates into and through clinical development and commercialization. We expect that our revenue will fluctuate from period to period due to the timing of executing additional partnerships, the uncertainty of the timing of milestone achievements and our dependence on the program decisions of our partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses.</i> Research and development (R&amp;D) expenses primarily consist of salaries, benefits, incentive compensation, share-based compensation, laboratory supplies and materials expenses for employees and contractors engaged in research and product development. We expense all research and development costs in the period in which they are incurred. Research and development activities consist of discovery research for partners as well as our internal platform development. We derive improvements to our platform and technologies from both types of activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur substantial research and development expenses as we conduct discovery research for our partners; however future estimates of expenditures are primarily driven by the decisions of our partners which are outside of our control and the results of discovery and research work, all of which are inherently difficult to predict. In addition, we plan to continue to invest in research and development to enhance our solutions and offerings to our partners, including hiring additional employees and continuing research and development projects obtained through strategic technology acquisitions. As a result, we expect that our research and development expenses will continue to increase in absolute dollars in future periods and vary from period to period as a&#160;percentage of revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expenses.</i> General and administrative expenses primarily consist of salaries, benefits and share-based compensation costs for employees in our executive, accounting and finance, corporate development, office administration, facility, legal and human resources functions as well as professional services fees, such as consulting, audit, tax and legal fees, general corporate costs and allocated overhead expenses. We expect that our general and administrative expenses will continue to increase in absolute dollars in future periods, primarily due to increased headcount to support anticipated growth in the business and due to incremental costs associated with operating as a public company, including costs to comply with the rules&#160;and regulations applicable to companies listed on a securities exchange and costs related to compliance and reporting obligations pursuant to the rules&#160;and regulations of the SEC and stock exchange listing standards, public relations, director and officer insurance and professional services. We expect these expenses to vary from period to period as a&#160;percentage of revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amortization of Intangibles.</i> We amortize to operating expenses capitalized costs of intangible assets acquired from our acquisitions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Operating Income, Net</i>. Other operating income, net, consists of fair value adjustments on contingent earnout liabilities from acquisitions. See <i style="font-style:italic;">Note&#160;(4), Acquisitions</i>, and <i style="font-style:italic;">Note&#160;(5)&#160;Fair Value Measurement</i> in OmniAb&#8217;s combined financial statements included in this proxy statement/prospectus/information statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Income (Expense)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interest Expense.</i> Interest expense consists of interest paid for equipment leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Income, Net. </i>Other income, net, consists of a gain from sale of an equity security in 2021 and a gain from a sale of an intellectual property license in 2020.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">276</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Tax Benefit (Expense)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our effective tax rate will be affected by many factors including changes in tax laws, regulations or rates, new interpretations of existing laws or regulations, uncertain tax positions, share-based compensation, and permanent differences between book and taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain information related to the&#160;year ended December&#160;31, 2020 and 2019 has been adjusted to reflect the restatement and revision of OmniAb&#8217;s combined financial statements as described in Note&#160;2 of the notes to the combined financial statements of the OmniAb Business included herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the&#160;Years Ended December&#160;31, 2021 and 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">(Dollars in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">License fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.14%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">4,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">4,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Milestone revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10,164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">3,039</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Service revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">20,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">11,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">8,201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">34,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.42%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">23,268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11.87%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">11,480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Total revenue increased $11.5 million, or 49%, in 2021 as compared to 2020 driven primarily by (1)&#160;additional service revenue from Icagen after its acquisition in April&#160;2020, and (2)&#160;increase in milestone revenue in 2021, of which $7.0 million was related to one partner reaching multiple development milestones during the&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Operating Expenses</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:12.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">(Dollars in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:12.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.4pt;"><td style="vertical-align:bottom;width:37.78%;margin:0pt;padding:0pt;"><div style="height:10.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:10.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="10" style="vertical-align:bottom;width:57.85%;margin:0pt;padding:0pt;"><div style="height:10.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(As Restated)</b></p></div></div></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><div style="height:10.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:37.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">39,232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">24,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">14,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:37.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">16,947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">6,722</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:37.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Amortization of intangibles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">12,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">11,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:37.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other operating expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2,070</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(860)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(42)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.59%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">70,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.11%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.37%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">48,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.77%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11.84%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">21,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Total operating expenses for 2021 increased $21.5 million or 44% as compared to 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our R&amp;D expenses increased&#160;year over&#160;year in 2021 primarily due to (1)&#160;$7.2 million additional R&amp;D expense incurred by Icagen after its acquisition in April&#160;2020, and (2)&#160;additional salaries and lab costs driven by our increased investment in the growth and development of the OmniAb Business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses increased&#160;year over&#160;year in 2021 primarily due to the additional share-based compensation expense driven by the employees from the Icagen acquisition and additional headcount during the&#160;year to support the business growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Amortization of intangibles increased&#160;year over&#160;year in 2021 primarily due to the full&#160;year amortization on the additional intangibles acquired from the acquisitions in 2020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other operating expense, net, consisted of fair value adjustments to contingent earnout liabilities issued in connection with acquisitions.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">277</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><span style="font-style:italic;font-weight:bold;">Other income (expense)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100.01%;"><tr><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">(Dollars in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:37.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">1,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">1,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(634)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total other income (expense,) net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">1,259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.42%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">1,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11.87%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(636)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(34)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Interest expense for both 2021 and 2020 was related to certain equipment financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other income, net in 2021 included a gain from sale of an equity security. Other income, net in 2020 included a gain from a sale of an intellectual property license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><span style="font-style:italic;font-weight:bold;">Income tax benefit (expense)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><span style="font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:12.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">(Dollars in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">(As&#160;Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Loss before income tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(34,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(23,728)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(10,622)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:37.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Income tax benefit (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">7,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.39%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">(27,042)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.42%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">(17,557)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11.87%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">(9,485)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Effective Tax Rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:2.15%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.42%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:2.15%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.87%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our effective tax rate for 2021 and 2020 was 21% and 26%, respectively. Our tax rate is affected by recurring items, such as the U.S. federal and state statutory tax rates and the relative amounts of income we earn in those jurisdictions. The tax rate is also affected by discrete items that may occur in any given&#160;year, but are not consistent from&#160;year to&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the&#160;Years Ended December&#160;31, 2020 and 2019</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:12.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">(Dollars in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">(As&#160;Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">License fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">4,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(1,440)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:37.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Milestone revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">7,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">7,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:37.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Service revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">11,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5,568</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.14%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.39%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">23,268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.47%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">18,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11.87%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">4,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Total revenue increased $5.0 million, or 27%, in 2020 as compared to 2019 driven primarily by $9.5 million service revenue from Icagen after its acquisition in April&#160;2020, partially offset by the decrease in other serve revenue and license fees in 2020, of which $1.0 million decrease in license fee was due to a certain partner terminating its discovery license, as compared to 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><span style="font-style:italic;font-weight:bold;">Operating Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:12.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">(Dollars in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b><br /><b style="font-weight:bold;">(As&#160;Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">(As&#160;Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">24,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">13,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">11,588</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:37.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">10,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">8,651</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,574</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:37.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Amortization of intangibles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">11,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">10,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:37.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other operating expense (income), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,070</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(818)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,888</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(353)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.47%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">48,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.47%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">31,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11.85%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">17,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Total operating expenses for 2020 increased $17.5 million or 56% as compared to 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our R&amp;D expenses increased&#160;year over&#160;year in 2020 primarily due to a $10.4 million increase driven by increased salaries and lab costs.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">278</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses increased&#160;year over&#160;year in 2020 primarily due to acquisition and integration related expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Amortization of intangibles increased&#160;year over&#160;year in 2020 primarily due to additional intangibles acquired from an acquisition in 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other operating expense (income), net, consisted of fair value adjustments to contingent earnout liabilities issued in connection with acquisitions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><span style="font-style:italic;font-weight:bold;">Other income (expense)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:12.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">(Dollars in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">(5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">(5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">NM</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(1)</p></td></tr><tr><td style="vertical-align:top;width:37.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">NM</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(1)</p></td></tr><tr><td style="vertical-align:top;width:37.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total other income (expense,) net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">NM</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(1)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amount is not meaningful.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Interest expense in 2020 was related to certain equipment financing. There was no interest expense in 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other income, net in 2020 included a gain from a sale of an intellectual property license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><span style="font-style:italic;font-weight:bold;">Income tax benefit (expense)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:12.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">(Dollars in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b><br /><b style="font-weight:bold;">(As&#160;Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b><br /><b style="font-weight:bold;">(As&#160;Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Loss before income tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(23,728)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(13,027)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(10,701)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:37.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Income tax benefit (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(562)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(1,198)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:37.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.47%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(17,557)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:9.47%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(13,589)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11.85%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(3,968)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:37.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Effective tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.13%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.47%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:2.15%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.47%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:2.15%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.85%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.06%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our effective tax rate for 2020 and 2019 was 26% and (4)%, respectively. Our tax rate is affected by recurring items, such as the U.S. federal and state statutory tax rates and the relative amounts of income we earn in those jurisdictions. The tax rate is also affected by discrete items that may occur in any given&#160;year, but are not consistent from&#160;year to&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the completion of the Separation and the Merger, including $15.0 million capital contribution from Ligand, the $15.0 million Forward Purchase and assuming the maximum redemption scenario and the purchase of $100.0 million by the Sponsor in the Redemption Backstop, we expect that our cash and cash equivalents will be approximately $102.0 million, after the payment of certain Separation-related expenses. We have historically participated in Ligand&#8217;s centralized approach to cash management and financing of its operations. Accordingly, none of the cash and cash equivalents, short-term investments or debt at the corporate level have been assigned to our company in the combined financial statements. Prior to the Separation, transfers of cash to and from Ligand have been reflected in parent company net investment in the historical combined balance sheets, statements of cash flows and statements of changes in parent company net investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the Separation, our capital structure and sources of liquidity will change significantly from our historical capital structure. We expect to use cash flows generated from operations, together with the cash contribution from Ligand and the closing of the private placement pursuant to the Forward Purchase and the Redemption Backstop, after the payment of certain Separation-related expenses, as our primary sources of liquidity. Based on our current business plan, we believe that such sources of liquidity will be sufficient to meet our working capital and capital expenditure needs for at least the next 12&#160;months.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">279</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If our anticipated cash flows from operations and funding from Ligand, the private placement pursuant to the Forward Purchase and Redemption Backstop, are insufficient to satisfy our liquidity requirements including because of increased expenditures or lower demand for our platform, or the realization of other risks described in this proxy statement/prospectus/information statement, we may be required to raise additional capital prior to such time through issuances of public or private equity or debt financings or other capital sources. Such additional financing may not be available on terms acceptable to us or at all. In any event, we may consider raising additional capital in the future to expand our business, to pursue strategic investments or acquisitions, to take advantage of favorable market conditions or financing opportunities or for other reasons. Our future capital requirements will depend on many factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve revenue growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of expanding our operations, including our business development and marketing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our rate of progress in selling access to our platform and marketing activities associated therewith;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our rate of progress in, and cost of research and development activities associated with, our platform technologies and our internal developed programs to the extent we pursue any such programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effect of competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the continued impact of the COVID-19 pandemic on global social, political and economic conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patents and other intellectual property and proprietary rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any technologies that we may in-license or acquire.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We anticipate that our principal uses of cash in the future will be primarily to fund our operations, working capital needs, capital expenditures and other general corporate purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flow Summary</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:36.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b><br /><b style="font-weight:bold;">(As&#160;Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b><br /><b style="font-weight:bold;">(As&#160;Restated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Net cash provided by (used in):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12.25pt;text-indent:-12.25pt;margin:0pt 0pt 0pt 5.75pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(5,672)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(5,195)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12.25pt;text-indent:-12.25pt;margin:0pt 0pt 0pt 5.75pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(4,025)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(26,980)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(12,095)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12.25pt;text-indent:-12.25pt;margin:0pt 0pt 0pt 5.75pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">9,697</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">23,361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">17,290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Cash Provided by (Used in) Operating Activities:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2021, cash used in operating activities of $(5.7) million primarily reflected our net losses of $(27.0) million for the period, adjusted by non-cash charges of $24.0 million, which primarily included $15.1&#160;million in share-based compensation, $15.0&#160;million in depreciation of fixed assets and amortization of intangibles and $1.2 million fair value adjustment on CVR, partially offset by $(7.3)&#160;million of deferred income taxes, as well as changes in our working capital accounts in amount of $(1.3) million, primarily consisting of an increase in accounts receivable, a decrease in deferred revenue and an increase in accounts payable and accrued liabilities.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">280</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2020, cash provided by operating activities of $3.6 million primarily reflected our net losses of $(17.6) million for the period, adjusted by non-cash charges of $17.8 million, which primarily included $12.6&#160;million in depreciation of fixed assets and amortization of intangibles, $9.2&#160;million in share-based compensation and $2.1 million fair value adjustment on CVR, partially offset by $(6.2)&#160;million of deferred income taxes, as well as cash inflow from our working capital accounts in amount of $5.2 million, primarily consisting of an increase in accounts payable and accrued liabilities and an increases in deferred revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2019, cash used in operating activities of $(5.2) million primarily reflected our net losses of $(13.6) million for the period, adjusted by non-cash charges of $17.0 million, which primarily included $10.6&#160;million in depreciation of fixed assets and amortization of intangibles and $6.7&#160;million in share-based compensation, as well as changes in our working capital accounts in amount of $(8.6) million, primarily consisting of a decrease in accounts receivable, a decrease in deferred revenue and decreases in other assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Cash Provided by (Used in) Investing Activities:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2021, cash used in investing activities of $(4.0) million resulted from $(4.1)&#160;million paid for property and equipment, $(1.2) million payments made to contingent value rights (&#8220;CVR&#8221;) holders and other, partially offset by the $1.3 million proceeds from sale of short-term investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2020, cash used in investing activities of $(27.0) million resulted from $(27.1) million cash paid for the acquisition of Icagen, xCella Biosciences and Taurus Biosciences (net of cash acquired), $(1.8)&#160;million paid for property and equipment, partially offset by $1.9&#160;million proceeds received from sale of intellectual property license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2019, cash used in investing activities of $(12.1) million resulted from $(11.8) million cash paid for the acquisition of Ab Initio (net of cash acquired) and $(0.3)&#160;million paid for property and equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Cash Provided by Financing Activities:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As Ligand managed our cash and financing arrangements prior to the completion of the Separation, all excess cash generated through earnings was deemed remitted to Ligand and all sources of cash were deemed funded by Ligand. Cash provided by financing activities in fiscal&#160;years 2021, 2020 and 2019 primarily include cash transferred to us from Ligand based on changes in our cash used for operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2021, cash provided by financing activities was $9.7 million, which consisted of $10.7 million net transfer from parent, partially offset by $(1.0) million payments to CVR holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2020, cash provided by financing activities was $23.4 million, which consisted of $25.7 million net transfer from parent, partially offset by $(2.3) million payments to CVR holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2019, cash provided by financing activities was $17.3 million, which consisted of $20.3 million net transfer from parent, partially offset by $(3.0) million payments to CVR holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent liabilities in the combined financial statements and accompanying notes. The SEC has defined a company&#8217;s critical accounting policies as the ones that are most important to the portrayal of the company&#8217;s financial condition and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition, we have identified the critical accounting policies and judgments addressed below. We also have other key accounting policies, which involve the use of estimates, judgments, and assumptions that are significant to understanding our results. For additional information, see <i style="font-style:italic;">Note&#160;(3), Basis of Presentation and Summary of Significant Accounting Policies</i> in the notes to OmniAb&#8217;s combined financial statements included in this proxy statement/prospectus/information statement. Although we believe that our estimates, assumptions, and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments, or conditions.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">281</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">License revenue is generally recognized at a point in time once we grant access to our intellectual property rights. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our contracts with customers often will include future contingent milestone based payments. We include contingent milestone based payments in the estimated transaction price when the milestones are determined to be probable of being achieved. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For research and development services that we recognize over time, we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a&#160;percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one&#160;year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We occasionally have sub-license obligations related to arrangements for which we receive license fees, milestones and royalties. We evaluate the determination of gross as a principal versus net as an agent reporting based on each individual agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets and Other Long-Lived Assets&#8212;Impairment Assessments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We regularly perform reviews to determine if the carrying values of our long-lived assets are impaired. A review of identifiable intangible assets and other long-lived assets is performed when an event occurs indicating the potential for impairment. If indicators of impairment exist, we first assess the impairment evaluation and then assess the recoverability of the affected long-lived assets and compare their fair values to the respective carrying amounts if needed. An impairment evaluation is based on an undiscounted cash flow analysis at the lowest level at which cash flows of the long-lived assets are largely independent of other groups of assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to estimate the fair value of identifiable intangible assets and other long-lived assets, we estimate the present value of future cash flows from those assets. The key assumptions that we use in our discounted cash flow model are the amount and timing of estimated future cash flows to be generated by the asset over an extended period of time and a rate of return that considers the relative risk of achieving the cash flows, the time value of money, and other factors that a willing market participant would consider. Significant judgment is required to estimate the amount and timing of future cash flows and the relative risk of achieving those cash flows.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">282</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assumptions and estimates about future values and remaining useful lives are complex and often subjective. They can be affected by a variety of factors, including external factors such as industry and economic trends, and internal factors such as changes in our business strategy and our internal forecasts. For example, if our future operating results do not meet current forecasts or if we experience a sustained decline in our market capitalization that is determined to be indicative of a reduction in fair value of our reporting unit, we may be required to record future impairment charges for purchased intangible assets. Impairment charges could materially decrease our future net income and result in lower asset values on our balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have historically operated as part of Ligand and not as a stand-alone company. We determined the OmniAb income tax provision as if OmniAb had filed a consolidated federal income tax return and combined state income tax returns separate from Ligand. We recorded a current state income tax expense for the tax&#160;years ended December&#160;31, 2021, 2020 and 2019 for certain OmniAb state minimum taxes. We recorded a deferred federal and state income tax benefit for the&#160;year ended December&#160;31, 2021 and 2020 to reflect the change in the net deferred tax liability for the period. We recorded a deferred federal tax benefit and deferred state tax expense for the&#160;year ended December&#160;31, 2019 to reflect the change in the net deferred tax liability for the period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our provision for income taxes, deferred tax assets and liabilities, and reserves for unrecognized tax benefits reflect our best assessment of estimated future taxes to be paid. Significant judgments and estimates based on interpretations of existing tax laws or regulations in the United States are required in determining our provision for income taxes. Changes in tax laws, statutory tax rates, and estimates of our future taxable income could impact the deferred tax assets and liabilities provided for in the combined financial statements and would require an adjustment to the provision for income taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating our ability to recover deferred tax assets within the jurisdiction which they arise, we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three&#160;years, scheduled reversals of deferred tax liabilities, our history of earnings and reliability of our forecasts, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the summary of recent accounting pronouncements applicable to OmniAb&#8217;s combined financial statements, see<i style="font-style:italic;"> Note&#160;(3), Basis of Presentation and Summary of Significant Accounting Policies</i> in the notes to OmniAb&#8217;s combined financial statements included in this proxy statement/prospectus/information statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Implications of Being an Emerging Growth Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). As an emerging growth company, we may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">being permitted to provide only two&#160;years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended (the Sarbanes-Oxley Act);</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">283</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, unless the SEC determines the new rules&#160;are necessary for protecting the public;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced disclosure obligations regarding executive compensation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may take advantage of these provisions until the earlier of: (1)&#160;the last day of the fiscal&#160;year (a)&#160;following the fifth anniversary of the closing of APAC&#8217;s initial public offering, (b)&#160;in which we have total annual gross revenue of at least $1.07 billion or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common equity that is held by non-affiliates exceeds $700.0 million as of the end of the prior fiscal&#160;year&#8217;s second fiscal quarter; and (2)&#160;the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have elected to take advantage of certain of the reduced disclosure obligations in this proxy statement/prospectus/information statement and in the registration statement of which this proxy statement/prospectus/information statement is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information in this proxy statement/prospectus/information statement and that we provide to our stockholders in the future may be different than what you might receive from other public reporting companies in which you hold equity interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. We intend to rely on this and other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section&#160;404(b)&#160;of Sarbanes-Oxley.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Rate Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect our cash and cash equivalents will consist of cash in readily available checking accounts and money market funds. As a result, the fair value of our portfolio is relatively insensitive to interest rate changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Effects of Inflation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inflation generally affects us by increasing our cost of labor and research and development contract costs. We do not believe inflation has had a material effect on our results of operations during the periods presented in OmniAb&#8217;s combined financial statements included in this proxy statement/prospectus/information statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">284</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_7b933788_a604_441d_9336_4741589e25c1"></a><a id="Main_EXECUTIVEANDDIRECTORCOMPENSATION"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXECUTIVE AND DIRECTOR COMPENSATION OF OMNIAB</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Executive Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following section provides compensation information applicable to &#8220;emerging growth companies&#8221; under the SEC disclosure rules.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately prior to the Distribution, we will be a wholly-owned subsidiary of Ligand. For purposes of this proxy statement/prospectus/information statement, our executive officers whose compensation is discussed in this Executive Compensation section and whom we refer to as our named executive officers are Matthew W. Foehr, who serves as our President and Chief Executive Officer, and Charles S. Berkman, who serves as our Chief Legal Officer and Secretary. Decisions regarding past compensation of our named executive officers have been made by Ligand&#8217;s Human Capital Management and Compensation Committee. Kurt Gustafson, who serves as our Executive Vice President, Finance and Chief Financial Officer, commenced employment with us in March&#160;2022 and is therefore not included in the following discussion as it relates to prior&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Executive Compensation section sets forth certain information regarding total compensation earned by our named executive officers for fiscal&#160;years 2020 and 2021. Our compensation package for our named executive officers primarily consists of salary, an annual performance bonus, and long-term equity incentive awards. The New OmniAb Board will form its own human capital management and compensation committee and it may choose to change such programs, objectives and framework following the completion of the Distribution. This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt following the completion of the Distribution and the Business Combination may differ materially from the currently planned programs summarized in this discussion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary Compensation Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The following table provides certain information regarding the compensation earned by our named executive officers during the fiscal&#160;years ended December&#160;31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:5.37%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.77%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:13.91%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:13.91%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.46%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:18.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name and Principal Position</b></p></td><td style="vertical-align:bottom;width:1.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:5.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Salary</b><br /><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b><br /><b style="font-weight:bold;">Awards</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup><br /><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b><br /><b style="font-weight:bold;">Awards</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup><br /><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Non-Equity</b><br /><b style="font-weight:bold;">Incentive Plan</b><br /><b style="font-weight:bold;">Compensation</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"><br /></sup><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">All Other</b><br /><b style="font-weight:bold;">Compensation</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(3)</sup><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"><br /></sup><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b><br /><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:18.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Matthew W. Foehr</b></p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.37%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">518,933</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">3,146,844</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.77%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,226,357</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">259,467</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">130,603</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.46%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,282,204</p></td><td style="vertical-align:bottom;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:18.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">Chief Executive Officer</i></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.37%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2020</p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">503,750</p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,242,269</p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.77%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,303,366</p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.91%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">277,063</p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.91%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">158,001</p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.46%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">3,484,449</p></td><td style="vertical-align:bottom;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:18.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Charles S. Berkman</b></p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.37%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.01%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">451,682</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,665,811</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.77%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">649,308</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.91%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">203,257</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.91%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10,890</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.46%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2,980,948</p></td><td style="vertical-align:bottom;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:18.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">Chief Legal Officer and Secretary</i></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.37%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2020</p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">441,917</p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">644,168</p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.77%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">675,820</p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.91%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">176,767</p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.91%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">6,180</p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.46%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,944,852</p></td><td style="vertical-align:bottom;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reflects the grant date fair value for stock and option awards covering shares of Ligand Common Stock granted by Ligand in 2020 and 2021, calculated in accordance with FASB ASC Topic 718, Compensation&#8212;Stock Compensation, (Topic 718). The assumptions used to calculate the value of stock and option awards granted in 2020 and 2021 are set forth under Note&#160;9 of the Notes&#160;to Consolidated Financial Statements included in Ligand&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2021, filed with the SEC on February&#160;28, 2022. The grant date fair value of the RSUs granted in 2020 and 2021 was determined based on the closing price per share of Ligand Common Stock on the date of grant for each RSU granted.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">With respect to the PSU awards included in the Summary Compensation Table, these amounts include the grant date fair value of such PSUs granted to the named executive officers based on the estimated probable outcome of the performance based objectives applicable to such awards on the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">With respect to the PSUs granted in 2020, the number of PSUs that are eligible to vest will be determined based on the measurement of two equally weighted metrics, the compound annual growth rate for Ligand&#8217;s adjusted EPS over a two-year performance period and Ligand&#8217;s relative TSR ranked on a&#160;percentile basis against the NASDAQ Biotechnology Index over a three-year performance period measured from January&#160;1, 2020. The grant date fair value of the PSUs granted during 2020 </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">285</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">included in this column that are tied to the compound annual growth rate for Ligand&#8217;s adjusted EPS was calculated based on the probable achievement of the performance goals as determined at the date of grant, which was determined to be the target level of performance. The grant date fair value of the PSUs that are tied to relative TSR was calculated using the Monte Carlo simulation which utilizes the stock volatility, dividend yield and market correlation of OmniAb and the NASDAQ Biotechnology Index. For the PSUs granted during 2020, such inputs consisted of: (a)&#160;an expected term that was based on the actual 2.81&#160;year term of the award; (b)&#160;a risk-free interest rate of 0.4% derived from the yield on U.S. government bonds of appropriate term from the U.S. Department of Treasury; (c)&#160;a dividend yield of 0.0% based on historic and future dividend yield estimates; (d)&#160;stock price volatility of 39.75% based on an analysis of the historical stock price volatility of Ligand and each company in the NASDAQ Biotechnology Index over the three&#160;years prior to the date of grant to conform to the term of the awards; and (e)&#160;initial TSR performance of&#160;-11.48% based on actual historical TSR performance for Ligand and each company in the NASDAQ Biotechnology Index. Based on this methodology, the valuation of the PSUs tied to relative TSR performance granted during 2020 was 52.81% of the closing price of Ligand Common Stock on the date of grant. The highest level of performance that may be achieved for the PSUs is 200% of the target. The full grant date fair value of the PSUs awarded to our named executive officers during fiscal&#160;year 2020, assuming maximum achievement of the applicable performance objectives, is $1,049,603 for Mr.&#160;Foehr and $544,291 for Mr.&#160;Berkman.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">With respect to the PSUs granted in 2021, the number of PSUs that are eligible to vest will be determined based on the measurement of two equally weighted metrics, the initiation of partnered OmniAb antibody programs over a two-year performance period measured from January&#160;1, 2021 and Ligand&#8217;s relative TSR ranked on a&#160;percentile basis against the NASDAQ Biotechnology Index over a three-year performance period measured from January&#160;1, 2021. The grant date fair value of the PSUs granted during 2021 included in this column that are tied to the initiation of partnered OmniAb antibody programs was calculated based on the probable achievement of the performance goals as determined at the date of grant, which was determined to be the target level of performance. The grant date fair value of the PSUs that are tied to relative TSR was calculated using the Monte Carlo simulation which utilizes the stock volatility, dividend yield and market correlation of OmniAb and the NASDAQ Biotechnology Index. For the PSUs granted during 2021, such inputs consisted of: (a)&#160;an expected term that was based on the actual 2.9&#160;year term of the award; (b)&#160;a risk-free interest rate of 0.18% derived from the yield on U.S. government bonds of appropriate term from the U.S. Department of Treasury; (c)&#160;a dividend yield of 0.0% based on historic and future dividend yield estimates; (d)&#160;stock price volatility of 52.56% based on an analysis of the historical stock price volatility of Ligand and each company in the NASDAQ Biotechnology Index over the three&#160;years prior to the date of grant to conform to the term of the awards; and (e)&#160;initial TSR performance of 84.38% based on actual historical TSR performance for Ligand and each company in the NASDAQ Biotechnology Index. Based on this methodology, the valuation of the PSUs tied to relative TSR performance granted during 2020 was 176.27% of the closing price of Ligand Common Stock on the date of grant. The highest level of performance that may be achieved for the PSUs is 200% of the target. The full grant date fair value of the PSUs awarded to our named executive officers during fiscal&#160;year 2021, assuming maximum achievement of the applicable performance objectives, is $2,333,894 for Mr.&#160;Foehr and $1,235,551 for Mr.&#160;Berkman.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents performance bonus awards under Ligand&#8217;s annual performance-based bonus program.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For Mr.&#160;Berkman, represents life insurance premiums paid by Ligand of $1,380 for each of 2021 and 2020, taxable fringe benefits of $3,510 for 2021, and 401(k)&#160;matching funds paid by Ligand of $6,000 in 2021 and $4,800 in 2020.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to the management rights letter between Viking Therapeutics,&#160;Inc. (Viking) and Ligand dated May&#160;21, 2014, Ligand nominated Mr.&#160;Foehr to serve as a member of Viking&#8217;s board of directors. During 2021, in connection with Mr.&#160;Foehr&#8217;s service as a director of Viking, Mr.&#160;Foehr received (1)&#160;$38,000 in cash payments and (2)&#160;$85,603 in option awards (representing the aggregate grant date fair value of the option awards as reported by Viking, computed in accordance with authoritative accounting guidance). Additionally, Mr.&#160;Foehr received life insurance premiums paid by Ligand for 2021 of $900, taxable fringe benefits of $100, and $6,000 in 401(k)&#160;matching funds paid by Ligand in 2021.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During 2020, in connection with Mr.&#160;Foehr&#8217;s service as a director of Viking, Mr.&#160;Foehr received (1)&#160;$38,000 in cash payments and (2)&#160;$114,001 in option awards (representing the aggregate grant date fair value of the option awards as reported by Viking, computed in accordance with authoritative accounting guidance). Additionally, Mr.&#160;Foehr received life insurance premiums paid by Ligand for 2020 of $900, taxable fringe benefits of $300, and $4,800 in 401(k)&#160;matching funds paid by Ligand in 2020.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">286</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Narrative to Summary Compensation Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Base Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Ligand Practice</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Annual base salary increases are based upon the performance of the executive officers, internal pay equity considerations, and peer practices, as assessed by the chief executive officer (for executives other than himself) and approved by Ligand&#8217;s Human Capital Management and Compensation Committee. Ligand&#8217;s Human Capital Management and Compensation Committee assesses these factors with respect to the chief executive officer. Ligand provides its executive officers with a base salary that falls between the 25</span><sup style="font-size:6.37pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-size:10pt;">&#160;and 50</span><sup style="font-size:6.37pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-size:10pt;">&#160;percentiles for similar positions at its peer group, but may vary from such level based on the factors listed above.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For 2021, our named executive officers each received an approximately 3% increase to his base salary, effective as of February&#160;1, 2021. This increase was determined to be appropriate by the Human Capital Management and Compensation Committee to ensure that the base salaries of Ligand&#8217;s executive officers (including our named executive officers) continued to be generally consistent with its pay positioning philosophy, as described above. The base salary paid to our named executive officers for 2021 was $520,200 for Mr.&#160;Foehr and $456,300 for Mr.&#160;Berkman.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Going Forward</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our human capital management and compensation committee will set base salary levels for executive officers taking into account base salary levels for positions with similar roles and scope of responsibilities within our peer group, as well as the executive officer&#8217;s performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Annual Performance-Based Cash Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Ligand Practice</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ligand&#8217;s Human Capital Management and Compensation Committee aims to have a substantial portion of each executive officer&#8217;s compensation contingent upon company performance. Ligand&#8217;s annual performance-based bonus program provides for cash bonus payments tied to achievement of key annual corporate performance objectives established by the Ligand Board for such purpose. Ligand&#8217;s annual performance-based bonus program is intended to complement its long-term equity program, which more directly aligns realized executive compensation with longer-term share price and corporate objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Target Annual Bonus Opportunities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Ligand sets annual incentive targets so that each executive&#8217;s total target cash compensation (inclusive of base salary) is positioned between the 25</span><sup style="font-size:6.37pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-size:10pt;"> and 50</span><sup style="font-size:6.37pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-size:10pt;">&#160;percentiles of target total cash opportunities offered by its peer group. The target incentive opportunity for Mr.&#160;Berkman for 2021 was increased from 40% to 45% of his base salary. The target incentive opportunity for Mr.&#160;Foehr for 2021 did not increase as compared to his 2020 target. Each named executive officer&#8217;s annual bonus for 2021 is tied 100% to corporate performance. For 2021, Mr.&#160;Foehr&#8217;s target incentive opportunity was 50% of his base salary, and Mr.&#160;Berkman&#8217;s target incentive opportunity was 45% of his base salary.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">2021 Corporate Performance Objectives and Achievements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the beginning of each&#160;year, the Ligand Board sets corporate objectives for the&#160;year in a number of areas after considering management input and its overall strategic objectives. Following the conclusion of each&#160;year, Ligand&#8217;s Human Capital Management and Compensation Committee assesses the level of achievement relative to these corporate objectives. This achievement level is then applied to each executive officer&#8217;s target bonus to determine that&#160;year&#8217;s total annual bonus. The Human Capital Management and Compensation Committee retains the discretion to reduce the final bonus payout to an executive officer based on other factors deemed relevant to assessing the company&#8217;s performance in comparison to its peers and the industry.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">287</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2021, Ligand&#8217;s Human Capital Management and Compensation Committee and the Ligand Board approved the performance objectives for the 2021 annual bonus program. The metrics were established after careful consideration of key short-term corporate goals. While Ligand&#8217;s business was considerably impacted by the COVID-19 pandemic, the goals set at the beginning of the&#160;year were not adjusted to take into account the impact of the pandemic. Objectives included the following: finance (revenue, EBITDA), licensing (completion of at least three new major contracts from the Icagen and Pfenex technology platforms), OmniAb (build computer-aided antigen design capability and position antigen library to leverage in partnerships, acquire or build new cell screening and discovery capabilities, complete at least one out-license or major buy-out transaction), Captisol (expand IP footprint, optimize cost structure and processing efficiencies), and pipeline (management of partners and portfolio to support high-value, late-stage assets).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2022, Ligand&#8217;s Board and Human Capital Management and Compensation Committee determined to pay the following bonus amounts to our named executive officers for 2021 based on Ligand&#8217;s achievement of the performance objectives discussed above: $259,467 for Mr.&#160;Foehr and $203,257 for Mr.&#160;Berkman.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Going Forward</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our human capital management and compensation committee will develop an annual performance-based cash compensation plan focused on corporate objectives that support our long-term business goals, while also allowing for meaningful pay differentiation tied to performance of individuals and groups.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Long-Term Performance-Based Equity Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Ligand Practice</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ligand&#8217;s long-term performance-based compensation is designed to link the ultimate level of an executive officer&#8217;s compensation to Ligand&#8217;s stock price performance and long-term stockholder interests while creating an incentive for sustained growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ligand provides equity compensation to its executive officers through grants of stock options, performance stock units (PSUs) and restricted stock units (RSUs). For 2021, these equity vehicles were weighted at 40%, 33%, and 27%, respectively.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Time-based stock options</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;granted to the executive officers generally have a four-year vesting schedule designed to provide an incentive for continued employment. Options have a ten-year term and an exercise price equal to 100% of the fair market value of the underlying stock on the date of grant. Accordingly, options will provide a return to the executive officer only if the market price of the shares appreciates over the option term.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Time-based restricted stock units</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;generally vest in equal installments over three&#160;years.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Performance stock units</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;are a significant component of Ligand&#8217;s annual long-term equity incentive awards for executive officers that vest based on key corporate and financial objectives over multi-year performance periods.&#160;At the time of grant, Ligand&#8217;s Human Capital Management and Compensation Committee conducts a review of the performance measures and associated payout levels, the rigor of the performance goals and their alignment with performance.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Human Capital Management and Compensation Committee views granting equity awards as a retention device and therefore also reviews the status of vesting and number of vested versus unvested awards at the time of grant. Guidelines for the number of equity awards granted to each executive officer are determined using a procedure approved by the Human Capital Management and Compensation Committee based upon several factors, including the executive officer&#8217;s level of responsibility, salary grade, performance and the value of the equity awards at the time of grant.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">288</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Given the position of executive cash compensation relative to market (which is set between the 25</span><sup style="font-size:6.37pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-size:10pt;"> and 50</span><sup style="font-size:6.37pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-size:10pt;">&#160;percentiles), the Human Capital Management and Compensation Committee has emphasized long-term equity incentive compensation to ensure total compensation is competitive. The long-term equity incentive awards granted to its executive officers in 2021 fell between the 50</span><sup style="font-size:6.37pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-size:10pt;">&#160;and 75</span><sup style="font-size:6.37pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-size:10pt;">&#160;percentiles of equity awards for similar positions at the peer group companies, adjusted using the above factors and taking into consideration such equivalency factors as the number of shares outstanding and market capitalization, compared to the peer group companies. As a result of the weighting of the short-term cash and long-term equity components of total compensation, the total target annual compensation for Ligand&#8217;s executive officers approximates the 50</span><sup style="font-size:6.37pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-size:10pt;">&#160;to 75</span><sup style="font-size:6.37pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-size:10pt;">&#160;percentile range of the peer group.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">2021 Long-Term Incentive Awards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In January&#160;2021, Ligand&#8217;s Human Capital Management and Compensation Committee approved long-term incentive awards to our named executive officers as described in the table below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Name</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Stock Option Target Value (40%)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Stock Options Granted</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total RSU Target Value (27%)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of RSUs Granted</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total PSU Target Value (33%)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of PSUs Granted</b> <b style="font-weight:bold;">(at Target)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Matthew W. Foehr</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,360,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.65%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">13,136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">918,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.65%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6,595</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,122,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">8,060</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Charles S. Berkman</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">720,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">486,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">594,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">4,267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The actual number of options awarded was calculated using the Black-Scholes option pricing model (utilizing the same assumptions that Ligand utilizes in the preparation of its financial statements).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The actual number of RSUs and PSUs awarded is calculated by dividing (a)&#160;the target grant value of the RSU award, by (b)&#160;the average closing price per share of Ligand&#8217;s common stock on the Nasdaq Global Market (or such other established stock exchange or national quotation system on which the stock is quoted) for the 30-calendar day period through and including February&#160;3, 2021.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consistent with prior&#160;years, the PSUs granted by the Human Capital Management and Compensation Committee in 2021 (the 2021 PSUs) were divided into two equally weighted components: one subject to three-year relative TSR performance conditions and one subject to two-year OmniAb program initiation performance conditions. The Human Capital Management and Compensation Committee selected the foregoing performance measures in order to drive the key behaviors that the Human Capital Management and Compensation Committee wants to reinforce and align pay with stockholder returns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Threshold, target and maximum performance levels for both components of the 2021 PSUs were established (which, for relative TSR performance, equate to 50%, 100% and 200% payout levels, respectively, with performance between these levels determined by linear interpolation, for OmniAb program initiation performance, equate to 50%,100%, and 150% payout levels, respectively, with performance between levels determined by rounding down to the nearest achievement level, and, in each case, no payout for performance below threshold). The Human Capital Management and Compensation Committee selected the foregoing performance measures because they represent the key financial and operational performance metrics for which the executives are responsible as well as align with stockholders&#8217; interests, thereby creating the clearest link between executive actions, corporate results and Ligand&#8217;s continued long-term success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Relative TSR Component</b>. The performance-based vesting requirement for the 2021 PSUs tied to relative TSR is based on the&#160;percentile level of Ligand&#8217;s TSR for the three-year performance period from January&#160;1, 2021 through December&#160;31, 2023, relative to the members of the NASDAQ Biotechnology Index. The NASDAQ Biotechnology Index was selected for comparison because it enables the Human Capital Management and Compensation Committee to assess Ligand&#8217;s performance against an objective peer group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:78.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:17.63%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:78.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">TSR PERCENTILE VS. NASDAQ BIOTECHNOLOGY INDEX</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">%&#160;OF&#160;TARGET&#160;PAID</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:78.58%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:10pt;">95</span><sup style="font-size:6.37pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-size:10pt;">&#160;percentile</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:78.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:10pt;">55</span><sup style="font-size:6.37pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-size:10pt;">&#160;percentile</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:78.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:10pt;">30</span><sup style="font-size:6.37pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-size:10pt;">&#160; percentile</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:78.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:10pt;">&lt; 30</span><sup style="font-size:6.37pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-size:10pt;">&#160;percentile</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">289</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To receive the earned shares, an executive officer must generally remain employed with Ligand through the last day of the applicable performance period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">OmniAb Program Initiation Component</b>. The second performance-based vesting component for the 2021 PSUs is tied to the initiation of a number of partnered OmniAb antibody programs during the two-year performance period from January&#160;1, 2021 through December&#160;31, 2022. The programs may be a combination of new platform rodent partnerships, cow or heavy chain-only technology programs and/or programs leveraging the OmniChicken technology and services. Each program must be potentially royalty-bearing. A &#8220;new&#8221; platform rodent partnership is defined as rodent programs initiated by partners that are added during the performance period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:82.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.72%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:82.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Number of OmniAb Programs</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">%&#160;of&#160;Target&#160;Paid</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:82.5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">35 or more</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:82.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:82.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:82.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">&lt; 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The time-based stock options and RSUs granted to our named executive officers in 2021 vest in accordance with the standard vesting schedules described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">2019 Performance-Based Restricted Stock Units Earned</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2019, our named executive officers were granted PSUs (the 2019 PSUs) that were eligible to vest based on the following two equally-weighted objectives (and a possible performance multiplier of 150% for &#8220;maximum&#8221; performance relative to both objectives):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The vesting of the first component of the 2019 PSUs was tied to Ligand&#8217;s incremental revenue from acquisitions, new licensing deals and Captisol sales above projections for the two&#160;year performance period commencing January&#160;1, 2019 and ending December&#160;31, 2020.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The vesting of the second component of the 2019 PSUs was tied to new licenses for internally funded programs during the performance period commencing January&#160;1, 2019 and ending December&#160;31, 2021.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In January&#160;2021, the Human Capital Management and Compensation Committee certified Ligand&#8217;s achievement relative to the incremental revenue objective for purposes of the 2019 PSUs following the end of the applicable two-year performance period. The threshold, target and maximum performance levels for the incremental revenue component of these awards are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:20.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.83%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.32%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.34%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.36%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:11.37%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:20.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Objective</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighting</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Threshold</b><br /><b style="font-weight:bold;">(0%)</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Target</b><br /><b style="font-weight:bold;">(100%)</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maximum</b><br /><b style="font-weight:bold;">(150%)</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Actual</b><br /><b style="font-weight:bold;">Performance</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage</b><br /><b style="font-weight:bold;">Earned</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:20.85%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Incremental Revenue(1)</p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.83%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">50</p></td><td style="vertical-align:bottom;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.32%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10&#160;million</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">15&#160;million</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:10.36%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">20&#160;million</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:11.37%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">109&#160;million</p></td><td style="vertical-align:bottom;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">150</p></td><td style="vertical-align:bottom;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The actual number of units that vested and issued in January&#160;2021 with respect to the portion of the 2019 PSUs tied to incremental revenue was 5,604 for Mr.&#160;Foehr and 2,401 for Mr.&#160;Berkman.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The &#8220;target&#8221; number of 2019 PSUs that remain eligible to vest based on new licenses for internally funded programs objective are reported in the &#8220;Outstanding Equity Awards at Fiscal&#160;Year-End&#8221; table below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Acceleration of Equity Awards upon a Change in Control</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Equity awards granted under Ligand&#8217;s 2002 Stock Incentive Plan (the 2002 Plan) to our named executive officers may be subject to accelerated vesting in the event of a &#8220;change in control.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ligand equity award agreements under the 2002 Plan entered into by our named executive officers provide that such equity awards will automatically vest in the event of a &#8220;change in control&#8221; where the option is not assumed or replaced by a successor.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">290</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the 2002 Plan, a &#8220;change in control&#8221; is generally defined as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a merger, consolidation or reorganization of the company in which 50% or more of Ligand&#8217;s voting securities change ownership;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sale, transfer or other disposition of all or substantially all of Ligand&#8217;s assets in complete liquidation or dissolution of the company; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a change in control of the company effected through a successful tender offer for more than 50% of Ligand&#8217;s outstanding common stock or through a change in the majority of the Ligand Board as a result of one or more contested elections for board membership.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The PSUs granted to our named executive officers in 2021 contain additional vesting provisions that will apply in the event of a change in control. In the event of a change in control prior to December&#160;31, 2022, the number of PSUs in which the officer will be eligible to vest under each PSU will be set at the &#8220;target&#8221; number of units, which &#8220;target&#8221; PSUs will continue to be eligible to vest based solely on the officer&#8217;s continued employment or service, with 50% of such &#8220;target&#8221; PSUs vesting on December&#160;31, 2022 and 50% of such &#8220;target&#8221; PSUs vesting on December&#160;31, 2023. In the event of a change in control after December&#160;31, 2022 but prior to December&#160;31, 2023, the remaining number of PSUs in which the officer will be eligible to vest under each PSU will be set at 50% of the &#8220;target&#8221; number of PSUs, which &#8220;target&#8221; PSUs will continue to be eligible to vest based solely on the officer&#8217;s continued employment or service through December&#160;31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the PSUs granted to our named executive officers in 2020 contain additional vesting provisions that will apply in the event of a change in control. In the event of a change in control prior to December&#160;31, 2021, the number of PSUs in which the officer will be eligible to vest under each PSU will be set at the &#8220;target&#8221; number of units, which &#8220;target&#8221; PSUs will continue to be eligible to vest based solely on the officer&#8217;s continued employment or service, with 50% of such &#8220;target&#8221; PSUs vesting on December&#160;31, 2021 and 50% of such &#8220;target&#8221; PSUs vesting on December&#160;31, 2022. In the event of a change in control after December&#160;31, 2021 but prior to December&#160;31, 2022, the remaining number of PSUs in which the officer will be eligible to vest under each PSU will be set at 50% of the &#8220;target&#8221; number of PSUs, which &#8220;target&#8221; PSUs will continue to be eligible to vest based solely on the officer&#8217;s continued employment or service through December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Going Forward</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Treatment of Outstanding Equity Awards at the Time of the Distribution</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each outstanding Ligand stock option, RSU award and PSU award held by current Ligand&#160;and OmniAb service providers as of the time of the Distribution and granted prior to March&#160;2, 2022 (the &#8220;Equity Cutoff Date&#8221;) generally will be split at the time of the Distribution into two equity awards which will include a Ligand equity award and an OmniAb Equity Award. Following the Distribution, the combined intrinsic value of the resulting Ligand and OmniAb Equity Awards should approximately equal the intrinsic value as of immediately prior to the Distribution of the underlying Ligand equity award. The adjusted Ligand equity awards and OmniAb Equity Awards generally will be subject to the same terms and conditions, including the same vesting and share payment timing provisions, as applied to the applicable Ligand equity awards immediately prior to the Distribution; provided, that the performance metrics for the outstanding Ligand PSU awards may be amended to reflect the Distribution as mutually agreed between Ligand and OmniAb; and provided further, that the Ligand PSU awards granted in 2021 and tied to relative TSR will be amended to vest solely based on continued service through the end of the three-year performance period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each outstanding Ligand stock option, RSU award and PSU award that is granted after the Equity Cutoff Date to an individual who is a current or former Ligand service provider as of the time of the Distribution generally will be adjusted solely into a Ligand equity award at the time of the Distribution. Following the Distribution, the intrinsic value of the resulting Ligand equity award should approximately equal the intrinsic value as of immediately prior to the Distribution of the underlying Ligand equity award. The adjusted Ligand equity awards generally will be subject to the same terms and conditions, including the same vesting and share payment timing provisions, as applied to the applicable Ligand equity awards immediately prior to the Distribution; provided, that the performance metrics for the outstanding PSU awards may be amended to reflect the Distribution as mutually agreed between Ligand and OmniAb, including an amendment to provide that such PSUs will vest solely based on continued service.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">291</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each outstanding Ligand stock option, RSU award and PSU award that is granted after the Equity Cutoff Date to an individual who is a current OmniAb service provider as of&#160;the time of the Distribution generally will be adjusted solely into an OmniAb Equity Award at the time of the Distribution. Following the Distribution, the intrinsic value of the resulting OmniAb Equity Award should approximately equal the intrinsic value as of immediately prior to the Distribution of the underlying Ligand equity award. The adjusted OmniAb Equity Awards generally will be subject to the same terms and conditions, including the same vesting and share payment timing provisions, as applied to the applicable Ligand equity awards immediately prior to the Distribution; provided, that the performance metrics for the outstanding PSU awards may be amended to reflect the Distribution as mutually agreed between Ligand and OmniAb, including an amendment to provide that such PSUs will vest solely based on continued service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the Effective Time, all (i)&#160;OmniAb options, (ii)&#160;OmniAb RSU awards and (iii)&#160;OmniAb PSU awards, in each case, that are outstanding as of immediately prior to the Effective Time will be converted into (a)&#160;options to purchase shares of New OmniAb Common Stock, (b)&#160;the right to receive restricted stock units relating to shares of New OmniAb Common Stock and (c)&#160;rights to receive performance-vesting restricted stock units relating to shares of New OmniAb Common Stock, respectively, in each case, with substantially the same terms and conditions as were applicable to the OmniAb Equity Award immediately prior to the Closing (other than terms that have been rendered inoperative by the Distribution and Business Combination), including with respect to vesting and termination-related provisions, as adjusted by the Base Exchange Ratio. In addition, at the Effective Time, each holder of an OmniAb Equity Award will be issued a number of Earnout Shares equal to the product of the number of shares of OmniAb common stock subject to the OmniAb Equity Award multiplied by the Earnout Exchange Ratio, which Earnout Shares will be subject to the restrictions set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the foregoing adjustments, in the case of Ligand awards that are converted into both adjusted Ligand awards and OmniAb awards (or, following the Closing, New OmniAb awards), continued employment with or service to Ligand or its affiliates will be treated as employment or other continued service with OmniAb and its affiliates (including New OmniAb) with respect to OmniAb awards (or, following the Closing, New OmniAb awards) held by Ligand service providers, and continued employment with or other service to OmniAb and its affiliates (including New OmniAb) will be treated as employment or other continued service with Ligand and its affiliates with respect to Ligand awards held by OmniAb service providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, with respect to any unvested OmniAb award (or, following the Closing, New OmniAb award) or unvested Ligand award granted or adjusted, as applicable, in connection with the Distribution and Business Combination, if the original Ligand award was subject to accelerated vesting provisions in connection with a termination of service with Ligand and/or a &#8220;change in control&#8221; (as defined in the applicable award agreements or equity plan) of Ligand, then the OmniAb award (or, following the Closing, New OmniAb award) or Ligand award, as applicable, will be subject to the same acceleration provisions in connection with the holder&#8217;s termination of service with his or her post-spin employer, as applicable, and/or change in control of such entity. In addition, any unvested OmniAb award (or, following the Closing, New OmniAb award) granted to a Ligand service provider in connection with the Distribution and Business Combination will vest in full upon a change in control of New OmniAb, and any unvested Ligand award held by an OmniAb service provider that is adjusted in connection with the Distribution and Business Combination will vest in full upon a change in control of Ligand. Additionally, if, following the Distribution and Business Combination, the New OmniAb Board or the Ligand Board, as applicable, determines to accelerate in full the vesting of all of such entity&#8217;s equity awards that are held by its current and former service providers, then such board of directors shall also accelerate in full the vesting of all of its equity awards that are held by current and former service providers of the other entities, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the completion of the Distribution, our long-term incentive award program will initially be similar to Ligand&#8217;s program. Our human capital management and compensation committee will review the program with the goal of ensuring it is effective in attracting, retaining and motivating skilled executives and aligning the interests of management and stockholders.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">292</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Distribution Equity Awards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Distribution, we expect to grant equity awards to our named executive officers and employees, which will represent such executives&#8217; and employees&#8217; annual equity awards for 2022. We expect that such awards will be comprised of stock options and RSUs and contain terms substantially similar to those of the Ligand equity awards described above. We expect the equity awards granted to our named executive officers to have the following aggregate grant date fair values: $[&#9679;] for Mr.&#160;Foehr and $[&#9679;] for Mr.&#160;Berkman. In connection with his commencement of employment, in April&#160;2022, Mr.&#160;Gustafson was granted 40,000 Ligand options and 8,000 Ligand RSUs. Mr.&#160;Gustafson&#8217;s Ligand RSUs were granted under the 2002 Plan, and the options subject to the Gustafson Inducement Award were granted as a standalone &#8220;employment inducement&#8221; award within the meaning of Nasdaq Stock Market Rule&#160;5635(c)(4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity Compensation Plans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Equity awards granted to our named executive officers have been granted under Ligand&#8217;s 2002 Stock Incentive Plan (the 2002 Plan).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Distribution, OmniAb will adopt the OmniAb,&#160;Inc. 2022 Incentive Award Plan (Ligand Service Provider Awards) and the OmniAb,&#160;Inc. 2022 Incentive Award Plan (OmniAb Service Provider Awards) (together with the Gustafson Inducement Award, the OmniAb Plans), which will govern the OmniAb Equity Awards issued upon adjustment of outstanding Ligand awards in connection with the Distribution as described above under &#8220;&#8212;<i style="font-style:italic;">Treatment of Outstanding Equity Awards at the Time of the Distribution</i>.&#8221; The terms and conditions of the OmniAb Plans will each be substantively the same as the terms and conditions set forth in Ligand&#8217;s 2002 Plan. In connection with the Business Combination, APAC will assume the OmniAb Plans and all OmniAb awards outstanding under the OmniAb Plans. Following the Distribution, no future awards will be granted under the OmniAb Plans, but all awards under the OmniAb Plans that are outstanding as of the Closing will continue to be governed by the terms, conditions and procedures set forth in the OmniAb Plans and any applicable award agreements, as those terms may be equitably adjusted in connection with the Business Combination, as described above under &#8220;&#8212;<i style="font-style:italic;">Treatment of Outstanding Equity Awards at the Time of the Distribution</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Closing of the Business Combination, APAC intends to adopt the 2022 Incentive Award Plan (the 2022 Plan) and the 2022 Employee Stock Purchase Plan (the ESPP), each of which will be effective upon the Closing of the Business Combination. For additional information about the 2022 Plan and ESPP, please see the sections titled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;6&#160;&#8212; Incentive Plan Proposal</i>&#8221; and &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;6&#160;&#8212; The ESPP Proposal</i>&#8221; below, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Severance and Change in Control Arrangements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Ligand Practice</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Change in Control Severance Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ligand has entered into a change in control severance agreement with each of our named executive officers. In the event that the named executive officer&#8217;s employment is terminated by Ligand without cause or he resigns for good reason within 24&#160;months following a change in control of Ligand, he will be eligible to receive a severance benefit equal to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one times the annual rate of base salary in effect at the time of involuntary termination; plus</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one times the greater of: (a)&#160;the maximum target bonus for the fiscal&#160;year in which the termination occurs; or (b)&#160;the maximum target bonus for the fiscal&#160;year in which the change in control occurs, if different; plus</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twelve multiplied by the&#160;monthly premium he would be required to pay for continued health coverage for himself and his eligible dependents.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foregoing severance amount will be payable in a lump sum following the officer&#8217;s termination of employment, subject to the officer&#8217;s execution of a general release of claims acceptable to Ligand.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">293</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The change in control severance agreement also provides that all of the named executive officer&#8217;s outstanding stock awards will vest in the event of such a termination. In addition, the post-termination exercise period of the named executive officer&#8217;s stock options will be extended from three&#160;months to the date that is nine&#160;months following the date of termination (but in no event beyond the original expiration date of such options).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of the change in control severance agreement, an involuntary termination is either a termination of the named executive officer&#8217;s employment by us without cause or his resignation for good reason. &#8220;Cause&#8221; is generally defined as an officer&#8217;s conviction of, or plea of &#8220;guilty&#8221; or &#8220;no contest&#8221; to, a felony under the laws of the United States or any state thereof, an officer&#8217;s willful and material breach of any obligation or duty under the employment agreement, any confidentiality and proprietary rights agreement or any written employment or other written policies that have previously been furnished to the officer, which breach is not cured within 30&#160;days after written notice thereof is received by the officer, if such breach is capable of cure, the officer&#8217;s gross negligence or willful misconduct, including without limitation, fraud, dishonesty or embezzlement, in the performance of his duties, or the officer&#8217;s continuing failure or refusal to perform his assigned duties or to comply with reasonable directives of the board of directors that are consistent with the officer&#8217;s job duties (which directives are not in conflict with applicable law), which failure is not cured within 30&#160;days after written notice thereof is received by the officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of the change in control severance agreement, &#8220;good reason&#8221; is generally defined as a material diminution in the officer&#8217;s authority, duties or responsibilities, a material diminution in the officer&#8217;s base compensation, a material change in the geographic location at which the officer must perform his duties, or any other action or inaction that constitutes a material breach by us or any successor or affiliate of its obligations to the officer under the employment agreement. An officer must provide written notice to us of the occurrence of any of the foregoing events or conditions without his written consent within 90&#160;days of the occurrence of such event. Ligand will have a period of 30&#160;days to cure such event or condition after receipt of written notice of such event from the officer. Any voluntary termination of an officer&#8217;s employment for &#8220;good reason&#8221; must occur no later than the date that is six&#160;months following the initial occurrence of one of the foregoing events or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of the change in control severance agreement, a &#8220;change in control&#8221; has generally the same definition as given to such term under the 2002 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Amended and Restated Severance Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ligand maintains the Ligand Pharmaceuticals Incorporated Amended and Restated Severance Plan to provide severance payments to its employees and the employees of its subsidiaries upon an involuntary termination of employment without cause. Our named executive officers are each eligible to participate in the severance plan, provided that he is not subject to disciplinary action or a formal performance improvement plan at the time of termination. However, if, as a result of his involuntary termination by Ligand without &#8220;cause,&#8221; the named executive officer would be eligible to receive severance under any individual change in control severance agreement, employment agreement or other arrangement providing severance benefits, as approved by the Ligand Board or a committee thereof, the named executive officer will not be eligible for benefits under the severance plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the severance plan, the named executive officer will be eligible to receive (1)&#160;a lump sum payment in cash for his fully earned but unpaid base salary and accrued but unused vacation through the date of termination, (2)&#160;an amount equal to his base salary for the severance period, which period will be equal to (a)&#160;two&#160;months plus (b)&#160;one week for each&#160;year of service as of the date of termination and (c)&#160;continued health coverage at the same cost as was in effect for the named executive officer at the date of termination throughout such severance period, provided that such named executive officer elects continued coverage under COBRA. The foregoing cash severance benefit will be payable in a lump sum following the officer&#8217;s termination of employment, subject to the officer&#8217;s execution of a general release of claims acceptable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of the severance plan, &#8220;cause&#8221; is generally defined as an officer&#8217;s conviction of (or entry of a plea of no contest to) any felony or any other criminal act, an officer&#8217;s commission of any act of fraud or embezzlement, an officer&#8217;s unauthorized use or disclosure of Ligand&#8217;s confidential or proprietary information or trade secrets, an officer&#8217;s commission of any material violation of Ligand&#8217;s policies, or an officer&#8217;s commission of any other intentional misconduct which adversely affects Ligand&#8217;s business or affairs in a material manner.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">294</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Gustafson Offer Letter</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with his commencement of employment as the Executive Vice President, Finance and Chief Financial Officer of OmniAb, Ligand and OmniAb entered into an employment offer letter with Kurt Gustafson, dated February&#160;9, 2022. Pursuant to the offer letter, Mr.&#160;Gustafson is eligible to receive an initial base salary of $440,000, a one-time sign-on bonus of $50,000, a target bonus opportunity equal to 40% of his base salary, an equity award comprised of Ligand stock options vesting over four&#160;years and Ligand RSU awards vesting over three&#160;years, and eligibility to participate in company-sponsored benefits. Mr.&#160;Gustafson&#8217;s employment is at-will. Mr.&#160;Gustafson&#8217;s Ligand RSU awards were granted under the 2002 Plan, and the options subject to the Gustafson Inducement Award were granted as a standalone &#8220;employment inducement&#8221; award within the meaning of Nasdaq Stock Market Rule&#160;5635(c)(4). Under the terms of the Employee Matters Agreement, Mr.&#160;Gustafson&#8217;s Ligand stock options and Ligand RSU awards will convert solely into OmniAb stock options and OmniAb RSU awards in connection with the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the offer letter, if Mr.&#160;Gustafson&#8217;s employment is terminated without cause prior to the Distribution (and such termination occurs prior to a change in control), Mr.&#160;Gustafson will be eligible to receive the following payments and benefits in lieu of any severance benefits to which he may be entitled under any severance plan or policy maintained by Ligand or OmniAb: (i)&#160;his&#160;monthly base salary for 12&#160;months following the date of termination; (ii)&#160;an amount equal to his maximum target bonus for the fiscal&#160;year in which the termination occurs; (iii)&#160;an amount equal to 12 multiplied by the&#160;monthly premium he would be required to pay for continued health coverage for himself and his eligible dependents; and (iv)&#160;accelerated vesting of all of his outstanding stock awards and extension of the post-termination exercise period for such awards to the nine-month period following the date of termination. The foregoing severance amounts are subject to Mr.&#160;Gustafson&#8217;s execution of a general release of claims acceptable to Ligand and continued compliance with the proprietary information and inventions agreement, and will be payable with respect to items (i)-(iii)&#160;in a lump sum following his termination of employment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon a termination of Mr.&#160;Gustafson&#8217;s employment without cause or for good reason within 24&#160;months following a change in control, Mr.&#160;Gustafson will be eligible to receive severance benefits in accordance with a change in control severance agreement to be entered into with Mr.&#160;Gustafson, which will contain terms generally similar to those described above under &#8220;&#8212;Change in Control Severance Agreements.&#8221; Mr.&#160;Gustafson will also be eligible to participate in our severance plan, which will contain terms generally similar to those described above under &#8220;&#8212;Amended and Restated Severance Plan.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Going Forward</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our change in control and severance arrangements will generally be similar to those of Ligand immediately prior to completion of the Distribution. Our human capital management and compensation committee will review these programs and benefits and may make changes to align them with our business needs and strategic priorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Elements of Compensation and Perquisites</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Ligand Practice</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our named executive officers are eligible for the following benefits and perquisites offered by Ligand to its employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Health and Welfare Benefits</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each named executive officer and his spouse and children are eligible for such health, dental and vision insurance coverage as Ligand may from time to time make available to its other executives of the same level of employment. Ligand pays a portion of the premiums for this insurance for all employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our named executive officers are also eligible for such disability and/or life insurance as Ligand may from time to time make available to its other employees of the same level of employment. Ligand pays the premiums for this life insurance coverage for the named executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Defined Contribution Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Ligand and its designated affiliates offer the Section&#160;401(k)&#160;Savings/Retirement Plan (the 401(k)&#160;Plan), a tax-qualified retirement plan, to their eligible employees. The 401(k)&#160;Plan permits eligible employees to defer from 1% to 90% of their annual eligible </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">295</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">compensation, subject to certain limitations imposed by the Internal Revenue Code. The employees&#8217; elective deferrals are immediately vested and non-forfeitable in the 401(k)&#160;Plan. Ligand also makes matching contributions to the 401(k)&#160;Plan. In 2021, the match was equal to 50% with respect to the first $12,000 contributed by an employee up to an annual maximum of $6,000 per employee per&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Employee Stock Purchase Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ligand&#8217;s 2002 Employee Stock Purchase Plan, as amended, which is intended to qualify under Section&#160;423 of the Internal Revenue Code, permits participants to purchase Ligand stock on favorable terms. Plan participants are granted a purchase right to acquire shares of common stock at a price that is 85% of the stock price on either the first day of the six&#160;month offering period or the stock price on the last day of the six&#160;month offering period, whichever is lower. The purchase dates occur on the last business&#160;days of December&#160;and June&#160;of each&#160;year. To pay for the shares, each participant may authorize periodic payroll deductions from 1% to 10% of his or her cash compensation, subject to certain limitations imposed by the Internal Revenue Code. All payroll deductions collected from the participant in an offering period are automatically applied to the purchase of common stock on that offering period&#8217;s purchase date provided the participant remains an eligible employee and has not withdrawn from the employee stock purchase plan prior to that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Limited Perquisites and Other Benefits</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ligand makes available certain other perquisites or fringe benefits to executive officers and other employees, such as tuition reimbursement, professional society dues and food and recreational fees incidental to official company functions, including board meetings. The aggregate of these other benefits was less than $10,000 for each of our named executive officers in the last fiscal&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">No Tax&#160;Gross-Ups</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ligand has not made&#160;gross-up&#160;payments to cover our named executive officers&#8217; personal income taxes that may pertain to any of the compensation paid or provided by Ligand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 12.2pt;"><i style="font-style:italic;">Going Forward</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our benefits and retirement programs will generally be similar to those of Ligand immediately prior to completion of the Distribution. Our human capital management and compensation committee will review these programs and benefits and may make changes to align them with our business needs and strategic priorities.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">296</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Outstanding Equity Awards at Fiscal&#160;Year-End</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The following table provides information on all stock and option awards held by our named executive officers as of December&#160;31, 2021. All outstanding equity awards are in shares of Ligand Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="9" style="vertical-align:bottom;width:45.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option&#160;Awards</b></p></td><td style="vertical-align:bottom;width:1.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="7" style="vertical-align:bottom;width:38.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock&#160;Awards</b></p></td><td style="vertical-align:bottom;width:0.32%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;width:1.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:8.1%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b><br /><b style="font-weight:bold;">Securities</b><br /><b style="font-weight:bold;">Underlying</b><br /><b style="font-weight:bold;">Unexercised</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Options&#160;(#)</b><br /><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;width:1.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:10.62%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b><br /><b style="font-weight:bold;">Securities</b><br /><b style="font-weight:bold;">Underlying</b><br /><b style="font-weight:bold;">Unexercised</b><br /><b style="font-weight:bold;">Options&#160;(#)</b><br /><b style="font-weight:bold;">Unexercisable(1)</b></p></td><td style="vertical-align:bottom;width:1.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:8.1%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b><br /><b style="font-weight:bold;">Incentive</b><br /><b style="font-weight:bold;">Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Awards:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b><br /><b style="font-weight:bold;">Securities</b><br /><b style="font-weight:bold;">Underlying</b><br /><b style="font-weight:bold;">Unexercised</b><br /><b style="font-weight:bold;">Unearned</b><br /><b style="font-weight:bold;">Options&#160;(#)</b></p></td><td style="vertical-align:bottom;width:1.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:6.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b><br /><b style="font-weight:bold;">Exercise</b><br /><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;width:1.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:7.32%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b><br /><b style="font-weight:bold;">Expiration</b><br /><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:1.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:8.42%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b><br /><b style="font-weight:bold;">Shares&#160;or</b><br /><b style="font-weight:bold;">Units&#160;of</b><br /><b style="font-weight:bold;">Stock&#160;That</b><br /><b style="font-weight:bold;">Have&#160;Not</b><br /><b style="font-weight:bold;">Vested&#160;(#)(2)</b></p></td><td style="vertical-align:bottom;width:1.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:8.42%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Market</b><br /><b style="font-weight:bold;">Value&#160;of</b><br /><b style="font-weight:bold;">Shares</b><br /><b style="font-weight:bold;">or&#160;Units</b><br /><b style="font-weight:bold;">of&#160;Stock</b><br /><b style="font-weight:bold;">That</b><br /><b style="font-weight:bold;">Have&#160;Not</b><br /><b style="font-weight:bold;">Vested&#160;($)(3)</b></p></td><td style="vertical-align:bottom;width:1.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:7.92%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b><br /><b style="font-weight:bold;">Incentive</b><br /><b style="font-weight:bold;">Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Awards:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b><br /><b style="font-weight:bold;">Unearned</b><br /><b style="font-weight:bold;">Shares,</b><br /><b style="font-weight:bold;">Unit&#160;or</b><br /><b style="font-weight:bold;">Other</b><br /><b style="font-weight:bold;">Rights&#160;That</b><br /><b style="font-weight:bold;">Have&#160;Not</b><br /><b style="font-weight:bold;">Vested&#160;(#)</b></p></td><td style="vertical-align:bottom;width:1.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b><br /><b style="font-weight:bold;">incentive</b><br /><b style="font-weight:bold;">Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Awards:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Market</b><br /><b style="font-weight:bold;">or&#160;Payout</b><br /><b style="font-weight:bold;">Value&#160;of</b><br /><b style="font-weight:bold;">Unearned</b><br /><b style="font-weight:bold;">Shares,</b><br /><b style="font-weight:bold;">Units&#160;or&#160;Other</b><br /><b style="font-weight:bold;">Rights&#160;That</b><br /><b style="font-weight:bold;">Have&#160;Not</b><br /><b style="font-weight:bold;">Vested&#160;($)(3)</b></p></td><td style="vertical-align:bottom;width:0.32%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Matthew W. Foehr</b></p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">63,210</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">74.42</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2/11/2024</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">40,358</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">56.26</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2/10/2025</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">25,938</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">85.79</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2/11/2026</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">24,348</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">100.38</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2/24/2027</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">19,007</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,267</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">159.01</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">3/2/2028</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">24,212</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">9,969</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">117.97</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2/11/2029</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">15,222</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">17,988</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">95.68</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2/13/2030</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2,737</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10,399</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">177.50</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2/3/2031</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">14,015</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(4)</p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2,164,757</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7,396</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(5)</p></td><td style="vertical-align:bottom;width:9.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,142,386</p></td><td style="vertical-align:bottom;width:0.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">8,060</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(6)</p></td><td style="vertical-align:bottom;width:9.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,244,948</p></td><td style="vertical-align:bottom;width:0.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Charles S. Berkman</b></p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,948</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">56.26</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2/10/2025</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">4,153</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">85.79</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2/11/2026</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">6,830</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">100.38</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2/24/2027</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">8,711</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">581</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">159.01</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">3/2/2028</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10,377</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">4,272</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">117.97</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2/11/2029</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7,893</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">9,327</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">95.68</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2/13/2030</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,450</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,505</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">177.50</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2/3/2031</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7,114</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(7)</p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,098,828</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:0.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">3,835</p></td><td style="vertical-align:bottom;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(5)</p></td><td style="vertical-align:bottom;width:9.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">592,354</p></td><td style="vertical-align:bottom;width:0.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.1%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.32%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.42%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">4,267</p></td><td style="vertical-align:bottom;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">(6)</p></td><td style="vertical-align:bottom;width:9.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.9pt 0pt 0pt;">659,081</p></td><td style="vertical-align:bottom;width:0.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Each option grant to the named executive officers has a ten&#160;year term from the date of grant. Except as described below, each option vests 12.5% after six&#160;months from grant and the remainder in 42 equal&#160;monthly installments. For a description of the change in control provisions applicable to the stock option awards, see &#8220;Acceleration of Equity Awards upon a Change in Control&#8221; above.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">The RSU awards granted to the named executive officers vest over a three&#160;year period in equal installments on February&#160;15 of the first three calendar&#160;years following the&#160;year in which the date of grant occurs. For a description of the change in control provisions applicable to the stock awards, see &#8220;Acceleration of Equity Awards upon a Change in Control&#8221; above.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Computed by multiplying the closing market price of Ligand&#8217;s common stock on December&#160;31, 2021, the last trading day of 2021, of $154.46, by the number of shares of common stock subject to such award.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">The table above reflects the remaining unvested RSUs from the following grants of RSUs to Mr.&#160;Foehr, which vest in equal installments over a three&#160;year period: 2,490 unvested RSUs granted on February&#160;11, 2019, 4,930 unvested RSUs granted on February&#160;13, 2020, and 6,595 unvested RSUs granted on February&#160;3, 2021. For a description of the change in control provisions applicable to the stock awards, see &#8220;Acceleration of Equity Awards upon a Change in Control&#8221; above.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Represents the &#8220;target&#8221; number of PSUs granted to the named executive officers in 2020. The PSUs granted in 2020 will vest based on objectives related to the compound annual growth rate of Ligand&#8217;s adjusted EPS growth for the two&#160;year performance period commencing January&#160;1, 2020 and ending December&#160;31, 2021 and Ligand&#8217;s relative TSR for the three&#160;year performance period commencing January&#160;1, 2020 and ending December&#160;31, 2022, with each such objective equally weighted (and a possible performance multiplier of 200% for &#8220;maximum&#8221; performance relative to earnings per share growth objective). Threshold performance levels, below which no vesting will be awarded, were also established for each performance objective. For a description of the change in control provisions applicable to the foregoing equity awards, see &#8220;Acceleration of Equity Awards upon a Change in Control&#8221; above. The &#8220;target&#8221; number of PSUs granted to the named executive officers reflected in the column above is 7,396 for Mr.&#160;Foehr and 3,835 for Mr.&#160;Berkman.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Represents the &#8220;target&#8221; number of PSUs granted to the named executive officers in 2021. The PSUs granted in 2021 will vest based on objectives related to the initiation of a number of partnered OmniAb antibody programs for the two&#160;year performance period commencing January&#160;1, 2021 and ending December&#160;31, 2022 and Ligand&#8217;s relative TSR for the three&#160;year performance period commencing January&#160;1, 2021 and ending December&#160;31, 2023, with each such objective equally weighted. Threshold performance levels, below which no vesting will be awarded, were also established for each performance objective. For a description of the change in control provisions applicable to the foregoing equity awards, see &#8220;Acceleration of Equity Awards upon a Change in Control&#8221; above. The &#8220;target&#8221; number of PSUs granted to the named executive officers reflected in the column above is 8,060 for Mr.&#160;Foehr and 4,267 for Mr.&#160;Berkman.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">The table above reflects the remaining unvested RSUs from the following grants of RSUs to Mr.&#160;Berkman, which vest in equal installments over a three&#160;year period: 1,067 unvested RSUs granted February&#160;11, 2019, 2,556 unvested RSUs granted on February&#160;13, 2020, and 3,491 unvested RSUs granted on February&#160;3, 2021. For a description of the change in control provisions applicable to the stock awards, see &#8220;Acceleration of Equity Awards upon a Change in Control&#8221; above.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">297</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Director Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ligand Practice</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Cash Compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Ligand&#8217;s non-employee director compensation policy in effect during 2021, each director is eligible to receive an annual retainer of $50,000. No meeting fees are paid. In addition, the chair of the Ligand Board will receive an additional annual retainer of $30,000. Non-employee directors also receive additional annual retainers for service on committees of the Ligand Board, as provided in the table below. Directors may elect to receive their retainers in cash or vested shares of Ligand&#8217;s common stock, which shares are issued under the 2002 Plan, although none of Ligand&#8217;s directors elected to do so during 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Non-employee members of the Ligand Board are also reimbursed for expenses incurred in connection with such service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Service</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Annual&#160;Retainer</b><br /><b style="font-weight:bold;">(Chair)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Annual&#160;Retainer</b><br /><b style="font-weight:bold;">(Member)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:66.78%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Audit Committee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Human Capital Management and Compensation Committee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">15,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">7,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Nominating and Corporate Governance Committee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Equity Compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Pursuant to Ligand&#8217;s non-employee director compensation policy, each new non-employee director receives an initial grant of stock options and RSUs under Ligand&#8217;s 2002 Plan, as set forth in the table below. These initial awards are granted effective on the date on which a recipient first becomes a non-employee director of Ligand. In addition, effective on the date of each annual meeting of stockholders, each non-employee director receives an annual grant of stock options and RSUs under the 2002 Plan, as set forth in the table below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Target&#160;Value&#160;of</b><br /><b style="font-weight:bold;">RSU Award(1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Target&#160;Value&#160;of</b><br /><b style="font-weight:bold;">Option&#160;Award(2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total&#160;Target&#160;Value</b><br /><b style="font-weight:bold;">of Award</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Initial Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">145,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">280,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">425,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:54.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Annual Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">85,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">175,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">260,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The actual number of RSUs to be awarded is calculated by dividing (a)&#160;the target grant value of the RSU award, by (b)&#160;the average closing price per share of Ligand&#8217;s common stock on the Nasdaq Global Market (or such other established stock exchange or national quotation system on which the stock is quoted) for the 60-calendar day period prior to the date of grant.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The actual number of options to be awarded is calculated using the Black-Scholes option pricing model (utilizing the same assumptions that Ligand utilizes in the preparation of its financial statements).</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">The exercise price of options granted to Ligand directors is equal to the fair market value of Ligand&#8217;s common stock on the Nasdaq Global Market on the effective date of grant. The initial awards vest in three equal annual installments on each of the first three anniversaries following the date of grant. The annual awards vest in full on the earlier of (1)&#160;the date of the annual meeting of stockholders following the grant date, and (2)&#160;on the first anniversary of the date of grant. In addition, all awards will vest in full in the event of a change in control or a hostile take-over, each as defined under the 2002 Plan. A non-employee director is able to exercise his or her stock options that were vested at the time of his or her cessation of board service until the first to occur of (1)&#160;the third anniversary of the date of his or her cessation of board service, or (2)&#160;the original expiration date of the term of such stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 9pt 18pt;"><i style="font-style:italic;">Non-Employee Director Ownership Guidelines</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">Ligand&#8217;s non-employee director compensation policy contains ownership guidelines so that members of the Ligand Board are required to own shares with a value of at least three times the then-current annual retainer after they have completed three&#160;years of board service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Going Forward</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">We have not, to date, paid any of our directors who are also our employees or employees of Ligand compensation for their service on the Ligand Board in addition to the compensation payable for their service as our employees. In 2021, all of our directors were </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">298</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 9pt 0pt;">employed by Ligand, and we therefore did not pay any cash or equity compensation to our directors for their service on the Ligand Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">In connection with the Business Combination, we intend to adopt the initial terms of our non-employee director compensation policy. The material terms of the non-employee director compensation policy, as it is currently contemplated, are summarized below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 9pt 18pt;"><i style="font-style:italic;">Cash Compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">Under our non-employee director compensation policy, each director will be eligible to receive an annual retainer of $50,000. No meeting fees will be paid. In addition, the chair of the OmniAb Board will receive an additional annual retainer of $30,000. Non-employee directors also receive additional annual retainers for service on committees of the OmniAb Board, as provided in the table below. Directors may elect to receive their retainers in cash or vested shares of our common stock, which shares will be issued under the 2022 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Non-employee members of the OmniAb Board will also be reimbursed for expenses incurred in connection with such service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Service</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Annual&#160;Retainer</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">(Chair)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Annual&#160;Retainer</b><br /><b style="font-weight:bold;">(Member)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.77%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Audit Committee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Human Capital Management and Compensation Committee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">15,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">7,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Nominating and Corporate Governance Committee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Equity Compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Pursuant to our non-employee director compensation policy, each new non-employee director who commences service at the Closing of the Business Combination will receive an initial grant of stock options and RSUs under the 2022 Plan. These initial awards will be granted effective on the date on which a recipient first becomes a non-employee director (or such later date as is permissible under applicable securities laws). Our non-employee directors who previously served on the Ligand Board will not, however, receive an initial award at the time of the Closing of the Business Combination. In addition, on the date of each annual meeting of our stockholders following the Closing of the Business Combination, each non-employee director will receive an annual grant of stock options and RSUs under the 2022 Plan. The equity compensation to be provided to our non-employee directors is provided in the table below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Target&#160;Value&#160;of</b><br /><b style="font-weight:bold;">RSU&#160;Award(1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Target&#160;Value&#160;of</b><br /><b style="font-weight:bold;">Option&#160;Award(2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total&#160;Target&#160;Value</b><br /><b style="font-weight:bold;">of Award</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Initial Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">145,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">280,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">425,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Annual Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">85,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">175,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">260,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The actual number of RSUs to be awarded is calculated by dividing (a)&#160;the target grant value of the RSU award, by (b)&#160;the average closing price per share of our common stock on the Nasdaq Global Market (or such other established stock exchange or national quotation system on which the stock is quoted) for the 60-calendar day period prior to the date of grant (or, for any awards to be granted at the time of the Closing, the closing price per share of our common stock on the date of the Closing).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The actual number of options to be awarded is calculated using the Black-Scholes option pricing model (utilizing the same assumptions that we utilize in the preparation of our financial statements).</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">The exercise price of options granted to non-employee directors will be equal to the fair market value of our common stock on the Nasdaq Global Market (or such other established stock exchange or national quotation system on which the stock is quoted) on the effective date of grant. The initial awards vest in three equal annual installments on each of the first three anniversaries following the date of grant. The annual awards vest in full on the earlier of (1)&#160;the date of the annual meeting of stockholders following the grant date, and (2)&#160;on the first anniversary of the date of grant. In addition, all awards will vest in full in the event of a change in control, as defined under the 2022 Plan. A non-employee director is able to exercise his or her stock options that were vested at the time of his or her cessation of board service until the first to occur of (1)&#160;the third anniversary of the date of his or her cessation of board service, or (2)&#160;the original expiration date of the term of such stock options.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">299</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 9pt 18pt;"><i style="font-style:italic;">Distribution Equity Awards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">At the time of the Closing of the Business Combination (or such later date as may be required under applicable securities laws), we expect to grant equity awards to Dr.&#160;Bertozzi with an aggregate grant date fair value of $425,000 (comprised of a stock option having a value of $280,000 and a RSU award having a value of $145,000), in accordance with the terms of the non-employee director compensation policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Limitations of Liability and Indemnification Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will indemnify our directors and officers to the fullest extent permitted by the Delaware General Corporation Law, which prohibits our amended and restated certificate of incorporation from limiting the liability of our directors for the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any breach of the director&#8217;s duty of loyalty to us or our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unlawful payment of dividends or unlawful stock repurchases or redemptions; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any transaction from which the director derived an improper personal benefit.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">Our amended and restated certificate of incorporation and our amended and restated bylaws also provide that if Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. This limitation of liability does not apply to liabilities arising under the federal securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">Our amended and restated certificate of incorporation and our amended and restated bylaws also provide that we shall have the power to indemnify our employees and agents to the fullest extent permitted by law. Our amended and restated bylaws also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in this capacity, regardless of whether our amended and restated bylaws would permit indemnification. We have obtained directors&#8217; and officers&#8217; liability insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">We have entered into separate indemnification agreements with our directors and executive officers, in addition to indemnification provided for in our amended and restated certificate of incorporation and amended and restated bylaws. These agreements, among other things, provide for indemnification of our directors and executive officers for expenses, judgments, fines and settlement amounts incurred by this person in any action or proceeding arising out of this person&#8217;s services as a director or executive officer or at our request. We believe that these provisions in our amended and restated certificate of incorporation and amended and restated bylaws and indemnification agreements are necessary to attract and retain qualified persons as directors and executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">The above description of the indemnification provisions of our amended and restated certificate of incorporation, our amended and restated bylaws and our indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this proxy statement/prospectus/information statement is a part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit us and our stockholders. A stockholder&#8217;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">300</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Main_MANAGEMENTOFNEWOMNIABAFTERTHE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MANAGEMENT OF NEW OMNIAB AFTER THE BUSINESS COMBINATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following sets forth certain information, as of April&#160;[&#160;&#9679;&#160;], 2022, concerning the persons who are expected to serve as directors and executive officers of New OmniAb following the consummation of the Business Combination and assuming the election of the nominees at the extraordinary general meeting as set forth in &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;8&#160;&#8212; The Director Election Proposal</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Executive Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The following table sets forth information with respect to the individuals who are expected to serve as the executive officers of New OmniAb after the Business Combination, including their positions, and is followed by a biography of each such individual.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:22.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:20.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:48.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:22.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:20.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:48.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:22.5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Matthew W. Foehr</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.67%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.63%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">President, Chief Executive Officer and Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Charles S. Berkman</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Legal Officer and Secretary</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Kurt A. Gustafson</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Executive Vice President, Finance and Chief Financial Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Matthew W. Foehr</span> has served as a member of OmniAb&#8217;s board of directors since December&#160;2015 and previously served as OmniAb&#8217;s Vice President until March&#160;2022, when he became OmniAb&#8217;s President and Chief Executive Officer. Mr.&#160;Foehr will serve as President and Chief Executive Officer of New OmniAb and is a nominee to serve as a member of the New OmniAb Board following the completion of the Merger. Mr.&#160;Foehr has served as Ligand&#8217;s President and Chief Operating Officer since January&#160;2015. Prior to that time, Mr.&#160;Foehr served as Ligand&#8217;s Executive Vice President and Chief Operating Officer since 2011, and has more than 20&#160;years of experience managing global research and development programs. Prior to joining Ligand in 2011, he was Vice President and Head of Consumer Dermatology R&amp;D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline (NYSE: GSK). Following GSK&#8217;s acquisition of Stiefel in 2009, Mr.&#160;Foehr led the R&amp;D integration of Stiefel into GSK. At Stiefel Laboratories,&#160;Inc., Mr.&#160;Foehr served as Senior Vice President of Global R&amp;D Operations, Senior Vice President of Product Development&#160;&amp; Support, and Vice President of Global Supply Chain Technical Services. Prior to Stiefel, Mr.&#160;Foehr held various executive roles at Connetics Corporation including Senior Vice President of Technical Operations and Vice President of Manufacturing. Mr.&#160;Foehr serves on the board of directors of Viking Therapeutics,&#160;Inc. (Nasdaq: VKTX), a publicly-traded biotechnology company and served as a director of Ritter Pharmaceuticals,&#160;Inc. from February&#160;2015 until its merger with Qualigen Therapeutics,&#160;Inc. (Nasdaq: QLGN) in May&#160;2020. Mr.&#160;Foehr is the author of multiple scientific publications and is named on numerous U.S. patents. He received his B.S. degree in biology from Santa Clara University. Mr.&#160;Foehr&#8217;s experience as an executive officer of Ligand and intimate knowledge of the OmniAb Business contributed to OmniAb&#8217;s decision to designate Mr.&#160;Foehr to serve as a director of New OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Charles S. Berkman </span>has served as a member of OmniAb&#8217;s board of directors and as OmniAb&#8217;s Secretary since December&#160;2015 and as OmniAb&#8217;s Chief Legal Officer since March&#160;2022. Mr.&#160;Berkman will serve as Chief Legal Officer and Secretary at New OmniAb following the completion of the Merger. Mr.&#160;Berkman has served as Ligand&#8217;s Senior Vice President, General Counsel and Secretary since January&#160;2018 and prior to that as its Vice President, General Counsel and Secretary since April&#160;2007. Mr.&#160;Berkman joined Ligand in November&#160;2001 and served as Associate General Counsel and Chief Patent Counsel (and Secretary since March&#160;2007). Prior to joining Ligand, Mr.&#160;Berkman was an attorney at the international law firm of Baker&#160;&amp; McKenzie from November&#160;2000 to November&#160;2001. Before that he served as an attorney at the law firm of Lyon&#160;&amp; Lyon from 1993 to November&#160;2000, where he specialized in intellectual property law. Mr.&#160;Berkman earned a B.S. in chemistry from the University of Texas and a J.D. from the University of Texas School of Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Kurt A. Gustafson</span> has served as OmniAb&#8217;s Executive Vice President, Finance and Chief Financial Officer since March&#160;2022. Mr.&#160;Gustafson will continue to serve as Executive Vice President, Finance and Chief Financial Officer of OmniAb following the completion of the Distribution and as New OmniAb&#8217;s Executive Vice President, Finance and Chief Financial Officer following the completion of the Merger. Prior to joining OmniAb, Mr.&#160;Gustafson served as Executive Vice President and Chief Financial Officer of Spectrum Pharmaceuticals,&#160;Inc., a publicly traded biopharmaceutical company, a position he has held since June&#160;2013. Prior to joining Spectrum, Mr.&#160;Gustafson served as Vice President and Chief Financial Officer at Halozyme Therapeutics,&#160;Inc., a publicly traded biopharmaceutical company, where he was responsible for finance, information technology, facilities, and human resources. Before joining Halozyme in 2009, Mr.&#160;Gustafson worked at Amgen&#160;Inc. for over 18&#160;years, most recently as Vice President, Finance, with responsibility for financial planning and cost accounting for worldwide manufacturing covering seven manufacturing sites. During his tenure at Amgen, Mr.&#160;Gustafson also served as Treasurer, Vice President, Finance and Chief Financial Officer of Amgen International based in Switzerland. Mr.&#160;Gustafson is currently a member of the board of directors of Xencor,&#160;Inc., a clinical stage biopharmaceutical </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">301</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">company and is also a member of the board of directors of ChromaDex Corporation, a proprietary ingredient company. Mr.&#160;Gustafson received a B.A. in accounting at North Park University and an M.B.A. from the University of California, Los&#160;Angeles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Board of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The following table sets forth information with respect to the individuals who are expected, to serve on the New OmniAb Board following the consummation of the Business Combination and assuming the election of the nominees at the extraordinary general meeting as set forth in &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;8&#160;&#8212; The Director Election Proposal</i>,&#8221; and is followed by a biography of each such individual.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:32.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:7.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:53.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.49%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Matthew W. Foehr</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 3pt 0pt 0pt;">49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:53.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Class I Director Nominee, President and Chief Executive Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">John L. Higgins<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 3pt 0pt 0pt;">51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Class III Director Nominee, Chairman of the New OmniAb Board</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Carolyn R. Bertozzi, Ph.D<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 3pt 0pt 0pt;">55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:53.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Class III Director Nominee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sarah Boyce<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 3pt 0pt 0pt;">50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Class II Director Nominee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Jennifer Cochran, Ph.D.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 3pt 0pt 0pt;">49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:53.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Class I Director Nominee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sunil Patel<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 3pt 0pt 0pt;">50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Class II Director Nominee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">[ &#9679; ]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">[ &#9679; ]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:53.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Class III Director Nominee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Member of the human capital management and compensation committee</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Member of the audit committee</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Member of the nominating and corporate governance committee</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The biography of Matthew W. Foehr is set forth under the section entitled &#8220;&#8212;Executive Officers.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">John L. Higgins</span> served as OmniAb&#8217;s President from December&#160;2015 until March&#160;2022 and has served a member of OmniAb&#8217;s board of directors since December&#160;2015. Mr.&#160;Higgins is a nominee to serve as a member of the New OmniAb Board following the Merger. Mr.&#160;Higgins has served as Ligand&#8217;s Chief Executive Officer since January&#160;2007 and a member of the Ligand Board since March&#160;2007. Prior to joining Ligand, Mr.&#160;Higgins served as Chief Financial Officer at Connetics Corporation (Connetics), a specialty pharmaceutical company, since 1997, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics until its acquisition by Stiefel Laboratories,&#160;Inc. in December&#160;2006. Before joining Connetics, he was a member of the executive management team at BioCryst Pharmaceuticals&#160;Inc. (Nasdaq: BCRX). Prior to BioCryst, Mr.&#160;Higgins was a member of the healthcare banking team of Dillon, Read&#160;&amp; Co.&#160;Inc., an investment banking firm. Mr.&#160;Higgins serves on the board, audit committee and nominations and governance committee of Bio-Techne Corporation (Nasdaq: TECH), a publicly-traded life sciences services company. Mr.&#160;Higgins has served as a director on numerous public and private companies. He also serves as the chairperson of the board of trustees of Academy of Whole Learning, a non-profit organization dedicated to providing educational and therapy services to children of underrepresented communities. He graduated Magna Cum Laude from Colgate University with an A.B. in economics. Mr.&#160;Higgins&#8217; executive experience operating and managing public biotechnology companies, his intimate knowledge of the OmniAb Business, his prior service on other company boards and his financial transaction experience as an investment banker in the biopharmaceutical industry contributed to OmniAb&#8217;s decision to designate Mr.&#160;Higgins to serve as a director of New OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Carolyn R. Bertozzi, Ph.D. </span>is a director nominee to serve as a member of the New OmniAb Board following the Merger. Since June&#160;2015, Dr.&#160;Bertozzi has served at Stanford University, where she is currently the Anne T. and Robert M. Bass Professor of Chemistry, a professor of Chemical and Systems Biology and Radiology and the Baker Family Co-Director of Stanford ChEM-H. Since 2000, Dr.&#160;Bertozzi has also served as an Investigator at the Howard Hughes Medical Institute. From 1996 to 2015, she was a professor of Chemistry and Molecular and Cell Biology at the University of California, Berkeley. Previously, Dr.&#160;Bertozzi served as a member of the board of directors of Eli Lilly and Company (NYSE: LLY) from February&#160;2017 to August&#160;2021. She holds an undergraduate degree in Chemistry from Harvard University and a Ph.D. in Chemistry from the University of California, Berkeley and was awarded the 2022 Wolf Prize in Chemistry. Dr.&#160;Bertozzi&#8217;s deep expertise in chemistry and biology and her corporate governance experience in the pharmaceutical industry contributed to OmniAb&#8217;s decision to designate Ms.&#160;Bertozzi to serve as a director of New OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Sarah Boyce</span> is a director nominee to serve as a member of the New OmniAb Board following the Merger. Ms.&#160;Boyce has served on the Ligand Board since October&#160;2019, and is currently expected to resign from the Ligand board prior to the Distribution. Since </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">302</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">October&#160;2019, Ms.&#160;Boyce has served as President and Chief Executive Officer of Avidity Biosciences,&#160;Inc., a publicly-traded biotechnology company. Prior to joining Avidity, she served as a Director and President of Akcea Therapeutics (Nasdaq: AKCA), a publicly-traded biopharmaceutical company focused on serious and rare diseases, from April&#160;2018 through September&#160;2019. Ms.&#160;Boyce served as Chief Business Officer at Ionis Pharmaceuticals,&#160;Inc. (Nasdaq: IONS) from January&#160;2015 to April&#160;2018, where she was responsible for business development, alliance management, patient advocacy and investor relations. Prior to joining Ionis, she served as Vice President, Head of International Business Strategy and Operations at Forest Laboratories,&#160;Inc. Ms.&#160;Boyce held various positions with Alexion Pharmaceuticals&#160;Inc., Novartis Group AG (NYSE: NVS), Bayer AG and F. Hoffmann-La Roche AG. Ms.&#160;Boyce also currently serves on the board of directors of Berkeley Lights&#160;Inc. (Nasdaq: BLI), a publicly-held biopharmaceutical company. Ms.&#160;Boyce received a B.S. degree in microbiology from the University of Manchester, England. Ms.&#160;Boyce&#8217;s executive experience in the biopharmaceutical industry and knowledge of the OmniAb Business contributed to OmniAb&#8217;s decision to designate Ms.&#160;Boyce to serve a director of New OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jennifer Cochran, Ph.D.</span> is a director nominee to serve as a member of the New OmniAb Board following the Merger. Dr.&#160;Cochran has served on the Ligand Board since July&#160;2021, and is currently expected to resign from the Ligand board prior to the distribution. She has served in numerous roles at Stanford University since 2005, where she is currently a Professor of Bioengineering and (by courtesy) of Chemical Engineering (appointed to the faculty as an Assistant Professor in January&#160;2005, promoted to Professor in 2018), and the Shriram Chair of Bioengineering, a position she has held since September&#160;2017. Dr.&#160;Cochran also serves as the Chief Scientific Advisor to Red Tree Venture Capital, a life-sciences-focused investment fund, since she co-founded it in August&#160;2020. Dr.&#160;Cochran was also the Chief Scientist of Lagunita Biosciences, a healthcare investment company and incubator, from October&#160;2015 to April&#160;2020. Prior to Stanford, she held several research positions at the Massachusetts Institute of Technology, most recently as a Postdoctoral Fellow. Dr.&#160;Cochran currently serves on the boards of directors of privately-held biotechnology companies Virsti Therapeutics,&#160;Inc., Revel Pharmaceuticals, and Trapeze Therapeutics,&#160;Inc. She has also served on the boards of directors of privately-held biotechnology companies Nodus Therapeutics,&#160;Inc. and Combangio,&#160;Inc., as well as xCella Biosciences until its acquisition by Ligand in 2020. Dr.&#160;Cochran received a B.S. degree in biochemistry from the University of Delaware and a Ph.D. in biological chemistry from the Massachusetts Institute of Technology. Dr.&#160;Cochran&#8217;s extensive bioengineering background and knowledge of the biopharmaceutical industry contributed to OmniAb&#8217;s decision to designate Dr.&#160;Cochran as a director of New OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sunil Patel</span> is a director nominee to serve as a member of the New OmniAb Board following the Merger. Mr.&#160;Patel has served on the Ligand Board since October&#160;2010, and is currently expected to resign from the Ligand board prior to the Distribution. He has more than 20&#160;years of senior management and R&amp;D experience in the biotechnology industry. Mr.&#160;Patel has worked as an independent consultant to biotechnology companies advising on strategy and corporate development initiatives since March&#160;2018. From 2009 to March&#160;2018, Mr.&#160;Patel served in executive roles of increasing responsibility at OncoMed Pharmaceuticals,&#160;Inc. (Nasdaq: OMED), a publicly-traded biotechnology company, most recently as Executive Vice President and Chief Financial Officer. Mr.&#160;Patel has held senior management positions in corporate development, marketing, and strategy with BiPar Sciences,&#160;Inc., Allos Therapeutics,&#160;Inc., Connetics, Abgenix,&#160;Inc. and Gilead Sciences&#160;Inc. (Nasdaq: GILD). Mr.&#160;Patel also worked at McKinsey&#160;&amp; Company serving biotechnology and pharmaceutical clients and has held scientific research positions at ZymoGenetics,&#160;Inc. and ProCyte Corporation. Mr.&#160;Patel received his undergraduate degree in Chemistry at the University of California, Berkeley, and master&#8217;s degree in Molecular Bioengineering/Biotechnology at the University of Washington. Mr.&#160;Patel&#8217;s executive and corporate development experience in the biopharmaceutical industry contributed to OmniAb&#8217;s decision to designate Mr.&#160;Patel to serve as a director of New OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">[&#160;&#9679;&#160;]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The New OmniAb Board Composition and Election of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Director Independence</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Following the Merger, the New OmniAb Board will consist of seven (7)&#160;members. The APAC Board has determined that all of New OmniAb&#8217;s anticipated directors, other than Mr.&#160;Foehr and Mr.&#160;Higgins, are independent directors in accordance with the listing requirements of Nasdaq. The Nasdaq independence definition includes a series of objective tests, including that the director is not, and has not been for at least three&#160;years, one of New OmniAb&#8217;s employees and that neither the director nor any of his, her or their family members has engaged in various types of business dealings with New OmniAb. In addition, as required by Nasdaq rules, the APAC Board has made a subjective determination as to each independent director that no relationships exist, which, in the opinion of the APAC Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of the director. In making these determinations, the APAC Board reviewed and discussed information provided by the directors and OmniAb with regard to each </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">303</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">director&#8217;s business and personal activities and relationships as they may relate to the OmniAb Business, New OmniAb and Domestic APAC&#8217;s management. There are no family relationships among any of New OmniAb&#8217;s expected directors or executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Classified Board of Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming the Organizational Documents Proposal is approved, the New OmniAb Board will be divided into three classes with staggered, three-year terms, in accordance with the terms of the Proposed Certificate of Incorporation. At each annual meeting of stockholders, the directors whose terms then expire will be eligible for reelection until the third annual meeting following reelection. Effective upon the Merger, assuming the Director Election Proposal is approved, the directors will be divided among the three classes as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Class&#160;I directors will be Dr.&#160;Cochran and Mr.&#160;Foehr, and their terms will expire at our first annual meeting of stockholders following the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Class&#160;II directors will be Ms.&#160;Boyce and Mr.&#160;Patel, and their terms will expire at our second annual meeting of stockholders following the Merger; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Class&#160;III directors will be [&#160;&#9679;&#160;], Dr.&#160;Bertozzi and Mr.&#160;Higgins, and their terms will expire at our third annual meeting of stockholders following the Merger.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Proposed Certificate of Incorporation provides that the authorized number of directors may be changed only by resolution of the New OmniAb Board. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. The division of the New OmniAb Board into three classes with staggered three-year terms may delay or prevent a change of the New OmniAb Board or a change in control of New OmniAb. New OmniAb&#8217;s directors may be removed only for cause by the affirmative vote of the holders of at least two-thirds of New OmniAb&#8217;s outstanding voting stock then entitled to vote in an election of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Board Leadership Structure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The New OmniAb Board will be chaired by Mr.&#160;Higgins. The APAC Board recognizes that it is important to determine an optimal board leadership structure to ensure the independent oversight of management as New OmniAb continues to grow. New OmniAb separates the roles of chief executive officer and chair of the board of directors in recognition of the differences between the two roles. The chief executive officer is responsible for setting the strategic direction for New OmniAb and the day-to-day leadership and performance of New OmniAb, while the chair of the New OmniAb Board provides guidance to the chief executive officer and presides over meetings of the full New OmniAb Board. The New OmniAb Board believes that this separation of responsibilities provides a balanced approach to managing the New OmniAb Board and overseeing New OmniAb. The APAC Board has concluded that the expected leadership structure is appropriate. However, the New OmniAb Board will continue to periodically review New OmniAb&#8217;s leadership structure and may make such changes in the future as it deems appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Role of Board in Risk Oversight Process</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The New OmniAb Board will have responsibility for the oversight of New OmniAb&#8217;s risk management processes and, either as a whole or through its committees, will regularly discuss with management New OmniAb&#8217;s major risk exposures, their potential impact on New OmniAb&#8217;s business and the steps New OmniAb takes to manage them. The risk oversight process will include receiving regular reports from board committees and members of senior management to enable the New OmniAb Board to understand New OmniAb&#8217;s risk identification, risk management and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory, strategic and reputational risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The audit committee will review information regarding liquidity and operations, and oversees New OmniAb&#8217;s management of financial risks. Periodically, the audit committee will review New OmniAb&#8217;s policies with respect to risk assessment, risk management, loss prevention and regulatory compliance. Oversight by the audit committee will include direct communication with New OmniAb&#8217;s external auditors, and discussions with management regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The compensation committee will be responsible for assessing whether any of New OmniAb&#8217;s compensation policies or programs has the potential to encourage excessive risk-taking. The nominating and corporate governance committee will manage risks associated with the independence of the New OmniAb Board, corporate disclosure </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">304</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">practices and potential conflicts of interest. While each committee will be responsible for evaluating certain risks and overseeing the management of such risks, the entire New OmniAb Board will be regularly informed through committee reports about such risks. Matters of significant strategic risk will be considered by the New OmniAb Board as a whole.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Board Committees and Independence</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The New OmniAb Board will consist of an audit committee, a human capital management and compensation committee and a nominating and corporate governance. The expected composition of each committee following the Merger is set forth below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Audit Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The audit committee&#8217;s main function will be to oversee New OmniAb&#8217;s accounting and financial reporting processes and the audits of New OmniAb&#8217;s financial statements. This committee&#8217;s responsibilities will include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">appointing New OmniAb&#8217;s independent registered public accounting firm;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluating the qualifications, independence and performance of New OmniAb&#8217;s independent registered public accounting firm;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approving the audit and non-audit services to be performed by New OmniAb&#8217;s independent registered public accounting firm;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing the design, implementation, adequacy and effectiveness of New OmniAb&#8217;s internal accounting controls and critical accounting policies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discussing with management and the independent registered public accounting firm the results of New OmniAb&#8217;s annual audit and the review of New OmniAb&#8217;s quarterly unaudited financial statements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing, overseeing and monitoring the integrity of New OmniAb&#8217;s financial statements and compliance with legal and regulatory requirements as they relate to financial statements or accounting matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing on a periodic basis, or as appropriate, any investment policy and recommending to the New OmniAb Board any changes to such investment policy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing with management and New OmniAb&#8217;s auditors any earnings announcements and other public announcements regarding our results of operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparing the report that the SEC requires in New OmniAb&#8217;s annual proxy statement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving any related party transactions and reviewing and monitoring compliance with New OmniAb&#8217;s code of conduct and ethics; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and evaluating, at least annually, the performance of the audit committee and its members including compliance of the audit committee with its charter.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The members of New OmniAb&#8217;s audit committee will be Dr.&#160;Patel, Ms.&#160;Boyce and Dr.&#160;Cochran. Dr.&#160;Patel will serve as the chair of the committee. All members of New OmniAb&#8217;s audit committee meet the requirements for financial literacy under the applicable rules&#160;and regulations of the SEC and Nasdaq. The APAC Board has determined that Dr.&#160;Patel is an &#8220;audit committee financial expert&#8221; as defined by applicable SEC rules&#160;and has the requisite financial sophistication as defined under the applicable Nasdaq listing standards. The APAC Board has determined each of Dr.&#160;Patel, Ms.&#160;Boyce and Dr.&#160;Cochran is independent under the applicable rules&#160;of the SEC and Nasdaq. Upon the listing of our common stock on Nasdaq, the audit committee will operate under a written charter that satisfies the applicable standards of the SEC and Nasdaq.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">305</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Human Capital Management and Compensation Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">New OmniAb&#8217;s human capital management and compensation committee will approve policies relating to compensation and benefits of New OmniAb&#8217;s officers and employees. The human capital management and compensation committee will approve corporate goals and objectives relevant to the compensation of New OmniAb&#8217;s Chief Executive Officer and other executive officers, evaluate the performance of these officers in light of those goals and objectives and approve the compensation of these officers based on such evaluations. The human capital management and compensation committee will also approve the issuance of stock options and other awards under New OmniAb&#8217;s equity plans. The human capital management and compensation committee will review and evaluate, at least annually, the performance of the human capital management and compensation committee and its members, including compliance by the committee with its charter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The members of New OmniAb&#8217;s human capital management and compensation committee will be Ms.&#160;Boyce, Dr.&#160;Patel and Mr.&#160;Higgins. Ms.&#160;Boyce will serve as the chair of the committee. The APAC Board has determined that each of Ms.&#160;Boyce and Dr.&#160;Patel is independent under the applicable Nasdaq listing standards and is a &#8220;non-employee director&#8221; as defined in Rule&#160;16b-3 promulgated under the Exchange Act. The human capital management and compensation committee will operate under a written charter, which the human capital management and compensation committee will review and evaluate at least annually.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nominating and Corporate Governance Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The nominating and corporate governance committee will be responsible for assisting the New OmniAb Board in discharging the board of directors&#8217; responsibilities regarding the identification of qualified candidates to become board members, the selection of nominees for election as directors at New OmniAb&#8217;s annual meetings of stockholders (or special meetings of stockholders at which directors are to be elected), and the selection of candidates to fill any vacancies on the New OmniAb Board and any committees thereof. In addition, the nominating and corporate governance committee will be responsible for overseeing New OmniAb&#8217;s corporate governance policies, reporting and making recommendations to the New OmniAb Board concerning governance matters and oversight of the evaluation of the New OmniAb Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The members of New OmniAb&#8217;s nominating and corporate governance committee will be Dr.&#160;Cochran, Mr.&#160;Higgins and Dr.&#160;Bertozzi. Dr.&#160;Cochran will serve as the chair of the committee. The APAC Board has determined that each of Dr.&#160;Cochran and Dr.&#160;Bertozzi is independent under the applicable Nasdaq listing standards. The nominating and corporate governance committee will operate under a written charter, which the nominating and corporate governance committee will review and evaluate at least annually.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Compensation Committee Interlocks and Insider Participation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No member of the human capital management and compensation committee serves or served during the fiscal&#160;year ended December&#160;31, 2021, as a member of the New OmniAb Board or compensation committee of a company that has one or more executive officers serving as a member of the board of directors or compensation committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Board Diversity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the Merger, New OmniAb&#8217;s nominating and corporate governance committee will be responsible for reviewing with the New OmniAb Board, on an annual basis, the appropriate characteristics, skills and experience required for the New OmniAb Board as a whole and its individual members. In evaluating the suitability of individual candidates (both new candidates and current members) for election or appointment, the nominating and corporate governance committee and the New OmniAb Board will take into account many factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">personal and professional integrity, ethics and values;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">experience in corporate management, such as serving as an officer or former officer of a publicly-held company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">experience as a board member or executive officer of another publicly-held company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strong finance experience;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">306</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversity of expertise and experience in substantive matters pertaining to our business relative to other board members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place of residence and specialized experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">experience relevant to our business industry and with relevant social policy concerns; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relevant academic expertise or other proficiency in an area of our business operations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Currently, OmniAb&#8217;s board of directors evaluates, and following the Merger, the New OmniAb Board will evaluate, each individual in the context of the board of directors as a whole, with the objective of assembling a group that can best maximize the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Nasdaq Board Diversity Matrix</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The following Board Diversity Matrix presents the anticipated New OmniAb Board diversity statistics in accordance with Nasdaq Rule&#160;5606, as self-disclosed by the director nominees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="9" style="vertical-align:bottom;width:99.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board Diversity Matrix (As of [&#8226;], 2022)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:37.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 4pt;"><b style="font-weight:bold;">Total Number of Directors</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="7" style="vertical-align:bottom;width:59.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">7</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:8.34%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Female</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Male</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:14.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Non-Binary</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:17.87%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Did Not Disclose Gender</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Part I: Gender Identity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Part II: Demographic Background</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 4pt;">African American or Black</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 4pt;">Alaskan Native or Native American</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 4pt;">Asian</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 4pt;">Hispanic or Latinx</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 4pt;">Native Hawaiian or Pacific Islander</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 4pt;">White</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 4pt;">Two or More Races or Ethnicities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 4pt;">LGBTQ+</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 4pt;">Did Not Disclose Demographic Background</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Code of Business Conduct and Ethics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">New OmniAb plans to adopt a written code of business conduct and ethics that applies to its directors, officers and employees, including its principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, which will be effective upon the Merger. Following the Merger, New OmniAb&#8217;s code of business conduct and ethics will be available under the Corporate Governance section of New OmniAb&#8217;s website at www.omniab.com. In addition, New OmniAb intends to post on its website all disclosures that are required by law or the listing standards of Nasdaq concerning any amendments to, or waivers from, any provision of the code. The reference to New OmniAb&#8217;s website address does not constitute incorporation by reference of the information contained at or available through it&#8217;s website, and you should not consider it to be a part of this proxy statement/prospectus/information statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">307</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8ad93e38_66cb_43b5_9882_ee5da70a71ab"></a><a id="Main_BENEFICIALOWNERSHIPOFSECURITIES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BENEFICIAL OWNERSHIP OF SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The following table and accompanying footnotes set forth information with respect to (i)&#160;the beneficial ownership of APAC Class&#160;A Ordinary Shares and APAC Class&#160;B Ordinary Shares, as of [&#9679;], 2022, the APAC Record Date for the extraordinary general meeting and (ii)&#160;the expected beneficial ownership of New OmniAb Common Stock immediately following the consummation of the Business Combination, assuming that no shares are redeemed, and alternatively that all of the public shares are redeemed, for:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:17.4pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>each person known by us to be, or who is expected to be upon consummation of the Business Combination, the beneficial owner of more than 5% of any class of our outstanding ordinary shares;</div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:17.4pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>each member of the APAC Board and each of APAC&#8217;s executive officers who beneficially owns our ordinary shares;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:17.4pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>each person who will become a member of the New OmniAb Board or an executive officer of New OmniAb upon the consummation of the Business Combination who is expected to beneficially own shares of New OmniAb Common Stock; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:17.4pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>all of the members of the APAC Board and APAC&#8217;s executive officers as a group, and all members of the New OmniAb Board and the executive officers of New OmniAb following consummation of the Business Combination as a group.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of [&#9679;], 2022, APAC had 28,750,000 ordinary shares issued and outstanding, consisting of (i)&#160;23,000,000&#160;shares of APAC Class&#160;A Ordinary Shares owned by [&#9679;] holders of record and (ii)&#160;5,750,000&#160;shares of APAC Class&#160;B Ordinary Shares owned by [&#9679;] holders of record. Such numbers do not include DTC participants or beneficial owners holding shares through nominee names.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The number of shares and the&#160;percentages of beneficial ownership below on a pre-Business Combination basis are based on the number of APAC&#8217;s ordinary shares issued and outstanding as of [&#9679;], 2022. In computing the number of APAC&#8217;s ordinary shares beneficially owned by a person and the&#160;percentage ownership of such person, APAC deemed to be outstanding all ordinary shares subject to options held by the person that are currently exercisable or exercisable within 60&#160;days of [&#9679;], 2022. APAC did not deem such shares outstanding, however, for the purpose of computing the&#160;percentage ownership of any other person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expected beneficial ownership of shares of New OmniAb Common Stock post-Business Combination, assuming no APAC Class&#160;A Ordinary Shares are redeemed, has been determined based upon the following assumptions: (i)&#160;no public shareholder has exercised its redemption rights to receive cash from the trust account in exchange for its public shares, (ii)&#160;there will be an aggregate of 127,681,885 shares of New OmniAb Common Stock issued and outstanding at the closing of the Business Combination, (iii)&#160;1,500,000 shares of New OmniAb Common Stock have been issued in connection with the Forward Purchase, (iv)&#160;no shares of New OmniAb Common Stock have been issued in connection with the Redemption Backstop, (v)&#160;97,431,885 shares of New OmniAb Common Stock are issued to the former stockholders of OmniAb as consideration in the Merger, (vi)&#160;5,750,000 APAC Class&#160;B Ordinary Shares shall have converted into 5,750,000 shares of New OmniAb Common Stock and (vii)&#160;none of the public warrants or APAC Private Placement Warrants have been exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expected beneficial ownership of shares of New OmniAb Common Stock post-Business Combination, assuming all of the APAC Class&#160;A Ordinary Shares are redeemed, has been determined based upon the following assumptions: (i)&#160;public shareholders have exercised their redemption rights with respect to all of the APAC Class&#160;A Ordinary Shares, (ii)&#160;there will be an aggregate of 114,681,885 shares of New OmniAb Common Stock issued and outstanding at the closing of the Business Combination, (iii)&#160;1,500,000 shares of New OmniAb Common Stock have been issued in connection with the Forward Purchase, (iv)&#160;10,000,000 shares of New OmniAb Common Stock have been issued in connection with the Redemption Backstop, (v)&#160;97,431,885 shares of New OmniAb Common Stock are issued to the former stockholders of OmniAb as consideration in the Merger, (vi)&#160;5,750,000 APAC Class&#160;B Ordinary Shares shall have converted into 5,750,000 shares of New OmniAb Common Stock and (vii)&#160;none of the public warrants or APAC Private Placement Warrants have been exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the actual facts are different from the foregoing assumptions, ownership figures in the combined company and the columns under the title &#8220;After the Business Combination&#8221; in the following table will be different.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Beneficial ownership for the purposes of the following table is determined in accordance with the rules&#160;and regulations of the SEC. A person is a &#8220;beneficial owner&#8221; of a security if that person has or shares &#8220;voting power,&#8221; which includes the power to vote or to </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">308</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">direct the voting of the security, or &#8220;investment power,&#8221; which includes the power to dispose of or to direct the disposition of the security or has the right to acquire such powers within 60&#160;days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Unless otherwise noted in the footnotes to the following table, and subject to applicable community property laws, the persons and entities named in the table have sole voting and investment power with respect to their beneficially owned ordinary shares or common stock, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.017593384%;padding-left:0pt;padding-right:0pt;width:100.03%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:23.88%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;width:38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Before the Business Combination</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;width:35.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">After the Business Combination</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:17.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assuming No Redemptions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:17.27%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assuming Maximum Redemptions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class A Ordinary Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class B Ordinary Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name and Address of Beneficial Owner</b><sup style="font-size:4.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;of&#160;Class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;of&#160;Class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;of&#160;Total&#160;Voting</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Power</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:6.71%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;of&#160;Outstanding&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:6.71%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;of&#160;Outstanding&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">Avista Capital Holdings, LP <sup style="font-size:4.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5,645,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">19.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">7,145,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">17,145,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">Thompson Dean<sup style="font-size:4.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5,645,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">19.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">7,145,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">17,145,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">David Burgstahler<sup style="font-size:4.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5,645,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">19.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">7,145,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">17,145,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">Beryl Capital Management LLC<sup style="font-size:4.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,716,936</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,716,936</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">Polar Asset Management Partners Inc<sup style="font-size:4.5pt;line-height:100%;top:0pt;vertical-align:top;">.(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,549,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,549,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">Citadel Advisors LLC<sup style="font-size:4.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,417,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,417,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">HGC Investment Management Inc.<sup style="font-size:4.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,386,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,386,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">Integrated Core Strategies<sup style="font-size:4.5pt;line-height:100%;top:0pt;vertical-align:top;">(8)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,269,543</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,269,543</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">William E. Kligaard<sup style="font-size:4.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">35,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">35,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">35,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">L&#226;le White<sup style="font-size:4.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">35,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">35,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">35,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">Wendel Barr<sup style="font-size:4.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">35,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">35,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">35,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><b style="font-weight:bold;">All directors and executive officers of APAC as a group (10 individuals)</b><sup style="font-size:4.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5,750,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Directors and Executive Officers of New OmniAb After Consummation of the Business Combination</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">Matthew W. Foehr</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">Charles S. Berkman</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">Kurt Gustafson</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">John Higgins</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">Carolyn Bertozzi, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">Sarah Boyce</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">Jennifer Cochran, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">Sunil Patel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;">[&#9679;]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><b style="font-weight:bold;">All Directors and Executive Officers of New OmniAb After Consummation of the Business Combination (7 individuals)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Other 5% Shareholders</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:8.1pt;text-indent:-8.1pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9pt;">*</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Denotes less than 1%.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9pt;">**</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Percentage of total voting power represents voting power with respect to all APAC Class A Ordinary Shares and APAC Class B Ordinary Shares, as a single class.</span></p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Unless otherwise noted, the business address of each of the following entities or individuals is c/o Avista Public Acquisition Corp. II, 65 East 55th Street, 18th Floor New York, NY 10022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Interests shown consist solely of founder shares, classified as APAC Class B Ordinary Shares. Such shares are convertible into APAC Class A Ordinary Shares on a one-for-one basis, subject to adjustment pursuant to the anti-dilution provisions contained therein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">The shares reported above are held in the name of the Sponsor. Mr. Dean and Mr. Burgstahler may be deemed to beneficially own shares held by our sponsor by virtue of their shared control over Avista Acquisition GP LLC II, which is the general partner of the Sponsor. Each of Messrs. Dean and Burgstahler disclaims beneficial ownership of our ordinary shares held by the Sponsor.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Based solely on Amendment No. 1 to the Schedule 13G filed jointly on February 14, 2022, by (i) Beryl Capital Management LLC (&#8220;Beryl&#8221;), (ii) Beryl Capital Management LP (&#8220;Beryl GP&#8221;), (iii) Beryl Capital Partners II LP (only 1,525,428 shares) (the &#8220;Partnership&#8221;) and (iv) David A. Witkin (collectively, the &#8220;Filers&#8221;). Each filer has shared voting and dipositive power of the shares held (except for the Partnership which only shares voting and dispositive control over 1,525,428 shares). Each Filer disclaims beneficial ownership of the shares except to the extent of that person&#8217;s pecuniary interest therein. The address of the shareholder, as reported in the Schedule 13G is 1611 S. Catalina Ave., Suite 309, Redondo Beach, CA 90277.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Based solely on the Schedule 13G filed on February 7, 2022 by Polar Asset Management Partners Inc., a company incorporated under the laws of Ontario, Canada, which serves as the investment advisor to Polar Multi-Strategy Master Fund, a Cayman Islands exempted company (&#8220;PMSMF&#8221;) and certain managed accounts (together with PMSMF, the &#8220;Polar Vehicles&#8221;) with respect to the Shares (as defined below) directly held by the Polar Vehicles. The business address of Polar Asset Management Partners Inc. is 16 York Street, Suite 2900, Toronto, ON, Canada M5J 0E6.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">309</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Based solely on the Amendment No. 1 to the Schedule 13G jointly filed on February 14, 2022, by Citadel Advisors LLC (&#8220;Citadel Advisors&#8221;), Citadel Advisors Holdings LP (&#8220;CAH&#8221;), Citadel GP LLC (&#8220;CGP&#8221;), Citadel Securities LLC (&#8220;Citadel Securities&#8221;), CALC IV LP (&#8220;CALC4&#8221;), Citadel Securities GP LLC (&#8220;CSGP&#8221;) and Mr. Kenneth Griffin with respect to APAC Class A Ordinary Shares owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company (&#8220;CM&#8221;), and Citadel Securities. Citadel Advisors is the portfolio manager for CM. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP. The business address for all reporting persons is 131 S. Dearborn Street, 32nd Floor, Chicago, Illinois 60603.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Based solely on the Schedule 13G filed on February 14, 2022 by HGC Investment Management Inc., a company incorporated under the laws of Canada, which serves as the investment manager to The HGC Fund LP, an Ontario limited partnership (the &#8220;Fund&#8221;), with respect to the Shares held by HGX Investment Management Inc. on behalf of the Fund. The business address for HGC Investment Management Inc. is 1073 Yonge Street, 2nd Floor, Toronto, Ontario M4W 2L2, Canada.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(8)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Based solely on the Schedule 13G filed jointly on August 16, 2021 by (i) Integrated Core Strategies (US) LLC, a Delaware limited liability company (&#8220;Integrated Core Strategies&#8221;), beneficial owner of 250,000 of APAC Class A Ordinary Shares&#894; (ii) Riverview Group LLC, a Delaware limited liability company (&#8220;Riverview Group&#8221;), beneficial owner of 650,000 of APAC Class A Ordinary Shares&#894; and (iii) ICS Opportunities, Ltd., an exempted company incorporated under the laws of the Cayman Islands (&#8220;ICS Opportunities&#8221;), beneficial owner of 369,543 of APAC&#8217;s Class A ordinary shares, which together with the Class A ordinary shares beneficially owned by Integrated Core Strategies and Riverview Group represented 1,269,543 of APAC Class A Ordinary Shares outstanding. Millennium International Management LP, a Delaware limited partnership (&#8220;Millennium International Management&#8221;), is the investment manager to ICS Opportunities and may be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities. Millennium Management LLC, a Delaware limited liability company (&#8220;Millennium Management&#8221;), is the general partner of the managing member of Integrated Core Strategies and Riverview Group and may be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies and Riverview Group. Millennium Management is also the general partner of the 100% owner of ICS Opportunities and may also be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities. Millennium Group Management LLC, a Delaware limited liability company (&#8220;Millennium Group Management&#8221;), is the managing member of Millennium Management and may also be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies and Riverview Group. Millennium Group Management is also the general partner of Millennium International Management and may also be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities. The managing member of Millennium Group Management is a trust of which Israel A. Englander, a United States citizen (&#8220;Mr. Englander&#8221;), currently serves as the sole voting trustee. Therefore, Mr. Englander may also be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies, Riverview Group and ICS Opportunities. The address of the principal business office of each of Integrated Core Strategies, Riverview Group, ICS Opportunities, Millennium International Management, Millennium Management, Millennium Group Management, and Mr. Englander is 399 Park Avenue, New York, New York 10022</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">310</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2191d098_369f_481a_93b9_d1d27b1fb8d2"></a><a id="Main_CERTAINRELATIONSHIPSANDRELATEDP"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">APAC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Founder Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On February&#160;12, 2021, the Sponsor paid an aggregate of $25,000, or approximately $0.004 per share, to cover certain APAC expenses in consideration of 5,750,000 Class&#160;B Ordinary Shares, par value $0.0001. The number of APAC Class&#160;B Ordinary Shares issued was determined based on the expectation that such APAC Class&#160;B Ordinary Shares would represent 20% of the outstanding shares upon completion of the offering. Prior to the closing of APAC&#8217;s initial public offering, the Sponsor transferred 35,000 APAC Class&#160;B Ordinary Shares to each of William E. Klitgaard, L&#226;le White and Wendel Barr, each of whom serve on the APAC Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">APAC Private Placement Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On August&#160;12, 2021, APAC completed the sale to the Sponsor of an aggregate of 8,233,333 APAC Private Placement Warrants for a purchase price of $1.50 per whole warrant for an aggregate of $12,350,000. Each Private Placement Warrant entitles the holder to purchase one APAC Class&#160;A Ordinary Share at $11.50 per share. The APAC Private Placement Warrants (including the APAC Class&#160;A Ordinary Shares issuable upon exercise thereof) may not, subject to certain limited exceptions, be transferred, assigned or sold by the holder until 30&#160;days after the completion by APAC of an initial business combination and entitles the holders thereof to certain registration rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Original Sponsor Insider Letter Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On August&#160;9, 2021, APAC entered into the Sponsor Insider Letter Agreements with each of the Insiders, pursuant to which, among other things, the Insiders agreed to vote any APAC securities held by them to approve a proposed business combination (including any proposals recommended by the APAC Board in connection with such business combination and not to redeem any APAC shares held by them in connection with such shareholder approval in order to induce APAC and the underwriters in APAC&#8217;s initial public offering to enter into an underwriting agreement and to proceed with APAC&#8217;s initial public offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sponsor Insider Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, OmniAb, the Sponsor, APAC and the Insiders entered into the Sponsor Insider Agreement, pursuant to which, among other things, the Insiders agreed to vote any APAC securities held by them to approve the Business Combination and the other APAC shareholder matters required pursuant to the Merger Agreement, and not to seek redemption of any of their APAC securities in connection with the consummation of the Business Combination. Pursuant to the Sponsor Insider Agreement, the Sponsor also agreed to subject up to all 1,916,667 Sponsor Earnout Shares to forfeiture if an applicable Sponsor Triggering Event has not occurred with respect to such Sponsor Earnout Shares during the period from the date of the Closing to and including the fifth anniversary of the date of the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Sponsor Insider Agreement also provides, among other things, that the holders of the Sponsor Earnout Shares may not transfer their Sponsor Earnout Shares until the date in which vesting has occurred, other than in a distribution made by the Sponsor to its members in accordance with the Cayman Governance Documents of APAC and the A&amp;R Registration Rights Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Sponsor Insider Agreement will terminate on the earlier of (i)&#160;termination of the Merger Agreement or (ii)&#160;the vesting in full of all Sponsor Earnout Shares. The Sponsor Insider Agreement is attached to this proxy statement/prospectus/information statement as Annex C.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Related Party Loans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In order to finance transaction costs in connection with a business combination, the Sponsor or an affiliate of the Sponsor, or certain of APAC&#8217;s officers and directors may, but are not obligated, to loan APAC funds as may be required (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Working Capital Loans</span>&#8221;). If the Business Combination is completed, APAC would repay the Working Capital Loans out of the proceeds of the trust account released to APAC. In the event that the Business Combination does not close, APAC may use a portion of the proceeds held outside of the trust account to repay the Working Capital Loans but no proceeds held in the trust account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a business combination, without interest, or, at the lender&#8217;s discretion, up to $2,000,000 of such Working Capital Loans may be convertible into up to an additional 1,333,333 warrants of New OmniAb at a price of $1.50 per warrant. These warrants would be identical to the APAC Private </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">311</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Placement Warrants. On February&#160;12, 2021, APAC and the Sponsor entered into promissory notes pursuant to which the Sponsor agreed to loan up to an aggregate of $300,000 to APAC for working capital purposes (the &#8220;First Promissory Note&#8221;). The Sponsor paid certain offering costs totaling $55,725, which was included in the outstanding balance of the promissory note as of March&#160;22, 2021. On June&#160;23, 2021, APAC borrowed $119,275 under a Working Capital Loan. On August&#160;12, 2021, APAC repaid the outstanding balance under the promissory note of $175,000. On March&#160;14, 2022, APAC entered into a promissory note with the Sponsor (the &#8220;Second Promissory Note&#8221;) pursuant to which APAC could borrow up to an aggregate of $750,000. The loan under the Second Promissory Note&#160;is non-interest bearing and payable upon the earlier of (i)&#160;completion of the APAC&#8217;s initial business combination or (ii)&#160;the date that the winding up of APAC is effective. The unpaid principal balance on the loan may be convertible into warrants at the option of the Sponsor at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. On March&#160;15, 2022, APAC drew down $500,000 under the Second Promissory Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Administrative Services Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC is party to an administrative services agreement pursuant to which APAC will pay the Sponsor a total of $10,000 per&#160;month, until the earlier of the completion of the Business Combination and the liquidation of the trust assets, for office space, utilities, administrative and support services. For the period from February&#160;5, 2021 (inception) through December&#160;31, 2021, APAC incurred and accrued $46,129 of administrative services under this arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Registration Rights</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the closing of the Merger, New OmniAb, the Sponsor and the other parties thereto will enter into the A&amp;R Registration Rights Agreement, which will amend and restate APAC&#8217;s Original Registration Rights Agreement in its entirety. <span style="color:#231f20;">The holders of New OmniAb Common Stock, the New OmniAb Private Placement Warrants, and warrants that may be issued upon conversion of Working Capital Loans (and any shares of New OmniAb Common Stock issuable upon the exercise of the New OmniAb Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to shelf registration rights pursuant to the </span>A&amp;R Registration Rights Agreement<span style="color:#231f20;"> requiring New OmniAb</span> to use commercially reasonable efforts to, within thirty (30)&#160;days after the Closing, file a registration statement on Form&#160;S-1 to permit the public resale of all of the Registrable Securities (as defined in the A&amp;R Registration Rights Agreement) held by the holders from time to time as permitted by Rule&#160;415 under the Securities Act<span style="color:#231f20;">. In addition, the holders have </span>certain customary &#8220;piggy back&#8221; registration rights with respect to registration statements filed subsequent to the completion of a business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the entry into the A&amp;R Registration Rights Agreement, the Original Registration Rights Agreement will be terminated as of the Effective Time, and replaced with the A&amp;R Registration Rights Agreement. See the section titled &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1 &#8212; The Business Combination Proposal &#8212; Related Agreements&#160;&#8212; Amended and Restated Registration and Stockholders Rights Agreement</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Forward Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">On August&#160;9, 2021, APAC entered into the Forward Purchase Agreement with Sponsor. Pursuant to the Forward Purchase Agreement, the Sponsor agreed to purchase 10,000,000 APAC Class&#160;A Ordinary Shares, plus an aggregate of 3,333,333 redeemable warrants to purchase one APAC Class&#160;A Ordinary Share at $11.50 per share, for an aggregate purchase price of $100,000,000, or $10.00 per APAC Class&#160;A Ordinary Shares, in a private placement to occur concurrently with the closing of APAC&#8217;s initial business combination. On March&#160;23, 2022, the Forward Purchase Agreement was amended and restated in its entirety by the A&amp;R FPA in connection with the pending Business Combination, and entered into by APAC, Sponsor and OmniAb. Pursuant to the A&amp;R FPA, APAC has agreed that it will issue and sell to the Sponsor 1,500,000 shares of New OmniAb Common Stock and warrants to acquire 1,666,667 shares of New OmniAb Common Stock for an aggregate purchase price of $15,000,000, with such purchases to be consummated immediately following the Domestication and prior to the Merger. In addition to the Forward Purchase, the Sponsor has agreed to purchase up to an additional 10,000,000 shares of New OmniAb Common Stock and up to an additional 1,666,667 New OmniAb Warrants, for an aggregate additional purchase price of up to $100,000,000, in order to backstop shareholder redemptions to the extent such redemptions would result in the cash proceeds available to the combined company following the Business Combination from APAC&#8217;s trust account to be less than $100,000,000 as of immediately prior to the Closing. The A&amp;R FPA also </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">312</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">provides that in the event the Merger Agreement is terminated by Ligand under circumstances in which the Termination Fee would be payable thereunder, Ligand shall pay the Sponsor a termination fee of $12,500,000 in connection therewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No compensation of any kind, including finder&#8217;s and consulting fees, will be paid to the Sponsor, the Insiders, or any of their respective affiliates, for services rendered prior to or in connection with the completion of the Business Combination. However, these individuals will be reimbursed for any out-of-pocket expenses incurred in connection with activities on APAC&#8217;s behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. APAC&#8217;s audit committee will review on a quarterly basis all payments that were made to the Sponsor, APAC&#8217;s officers or directors, or any of their affiliates. Any such payments prior to the Business Combination will be made using funds held outside the trust account. Other than quarterly audit committee review of such reimbursements, APAC does not expect to have any additional controls in place governing its reimbursement payments to its directors and officers for their out-of-pocket expenses incurred in connection with APAC&#8217;s activities on its behalf in connection with identifying and completing the Business Combination. Other than these payments and reimbursements, no compensation of any kind, including finder&#8217;s and consulting fees, will be paid by APAC to the Sponsor, APAC&#8217;s officers and directors, or any of their respective affiliates, prior to completion of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Policy for Approval of Related Party Transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The audit committee of the APAC Board has adopted an audit committee charter, providing for the review, approval and/or ratification of all &#8220;related party transactions&#8221; (which are those transactions required to be disclosed pursuant to Item&#160;404(a)&#160;under the Exchange Act). At its meetings, the audit committee shall be provided with the details of each new, existing or proposed related party transaction, including the terms of the transaction, any contractual restrictions that APAC has already committed to, the business purpose of the transaction and the benefits of the transaction to APAC and to the relevant related party. Any member of the audit committee who has an interest in the related party transaction under review by the audit committee shall abstain from voting on the approval of the related party transaction, but may, if so requested by the chairman of the audit committee, participate in some or all of the audit committee&#8217;s discussions of the related party transaction. Upon completion of its review of the related party transaction, the audit committee may determine to permit or to prohibit the related party transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OmniAb</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Agreements with Ligand</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the Business Combination, OmniAb and Ligand will operate separately, each as a public company. In connection with the Separation, OmniAb has entered into or will enter into various agreements to effect the Separation and provide a framework for OmniAb&#8217;s relationship with Ligand after the Separation, including the Separation Agreement, two Transition Services Agreements, an Employee Matters Agreement and a Tax Matters Agreement. These agreements will provide for the allocation between OmniAb and Ligand of Ligand&#8217;s assets, employees, liabilities and obligations (including its property and employee benefits and tax-related assets and liabilities) attributable to periods prior to, at and after OmniAb&#8217;s separation from Ligand and will govern certain relationships between OmniAb and Ligand after the Separation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following summaries of each of the agreements listed above are qualified in their entireties by reference to the full text of the applicable agreements which are filed as exhibits to the registration statement of which this proxy statement/prospectus/information statement forms a part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Separation Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, Ligand, OmniAb and APAC entered into the Separation Agreement which sets forth the principal actions to be taken in connection with the Separation. The Separation Agreement identifies assets to be transferred, liabilities to be assumed and contracts to be assigned to each of Ligand and OmniAb as part of the internal reorganization described therein and requires the Ligand Contribution to be made to OmniAb. The Separation Agreement also sets forth other agreements that govern certain aspects of OmniAb&#8217;s relationship with Ligand following the Separation, Distribution and Merger. Pursuant to the Separation Agreement, OmniAb will issue additional shares of OmniAb Common Stock to Ligand. Ligand will then distribute on a pro rata basis all of the outstanding shares of OmniAb Common Stock to the holders of Ligand Common Stock as of the Ligand Record Date set for the Distribution by delivering to the distribution agent a book-entry authorization representing the shares of OmniAb Common Stock being distributed for the account of Ligand&#8217;s stockholders. The distribution agent </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">313</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">will hold such book-entry shares for the account of OmniAb&#8217;s stockholders (as of immediately after consummation of the Distribution) pending the Merger. For a more detailed description of the Separation Agreement, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;&#8212; Summary of the Separation Agreement</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Transition Services Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Separation, OmniAb and Ligand will enter into two Transition Services Agreements pursuant to which Ligand and its affiliates and OmniAb and its affiliates will provide to each other various non-scientific and non-technical services set forth in the applicable Transition Services Agreement, which services are of the type that OmniAb and Ligand provided to, and received from, each other prior to the Separation. Ligand will provide services relating to information technology, facilities, accounting and finance, business development, investor relations, human resources, and other corporate and administrative functions, and OmniAb will provide services relating to corporate functions, legal administration, and other administrative functions. The fees for each of the transition services are set forth in the applicable Transition Services Agreement as a flat&#160;monthly fee, and the receiving party will reimburse the providing party for all reasonable out-of-pocket costs and expenses that the providing party incurs in connection with providing the transition services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of the Transition Services Agreements will terminate on the expiration of the term of the last service provided under it, unless earlier terminated by the receiving party with prior written notice, by either party in the event of an uncured material breach by the other party or its applicable affiliates, upon bankruptcy or insolvency of the other party, or by mutual agreement of the parties. The transition services are generally expected to last up to one&#160;year and the receiving party for a particular service may terminate such service prior to the scheduled expiration date with prior written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb does not anticipate that its net costs associated with the Transition Services Agreements will be materially different than the historical costs that have been allocated by Ligand to OmniAb related to these same services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Tax Matters Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Distribution, APAC, OmniAb, and Ligand will enter into the Tax Matters Agreement that will govern each party&#8217;s respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and certain other matters regarding taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, APAC and OmniAb will be liable for all U.S. federal, state, local and foreign taxes (and any related interest, penalties or audit adjustments) that are (i)&#160;imposed with respect to tax returns that include both OmniAb and Ligand, to the extent such taxes are attributable to OmniAb or the OmniAb Business, or (ii)&#160;imposed with respect to tax returns that include OmniAb but not Ligand, in each case, for tax periods (or portions thereof) beginning after the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, APAC and OmniAb may be liable for certain taxes resulting from the restructuring transactions undertaken to effectuate the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Distribution, together with certain related transactions, is intended to qualify as a reorganization under Sections 355 and 368(a)(1)(D)&#160;of the Code. Pursuant to the Tax Matters Agreement, taxes incurred by Ligand, APAC or OmniAb relating to or arising out of the failure of the intended tax treatment will generally be shared equally by Ligand, on the one hand, and APAC and OmniAb, on the other hand. If, however, such failure is attributable to certain acts or omissions by APAC or OmniAb, inaccuracies, misrepresentations or misstatements relating to APAC or OmniAb or certain events involving the stock of APAC or OmniAb or assets of OmniAb, APAC and OmniAb will generally bear all such taxes. Under certain circumstances, including if the failure is attributable to Ligand or an event involving Ligand&#8217;s stock or assets, Ligand will bear all such taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Tax Matters Agreement will require APAC and OmniAb to comply with the representations made in the materials submitted to legal counsel in connection with the Distribution Tax Opinion that Ligand expects to receive regarding the intended tax treatment of the Distribution and certain related transactions. The Tax Matters Agreement will also restrict OmniAb&#8217;s and APAC&#8217;s ability to take or fail to take any action if such action or failure to act could reasonably be expected to adversely affect the intended tax treatment. In particular, in the two&#160;years following the Distribution, APAC and OmniAb will be subject to certain restrictions, generally including being prevented from (i)&#160;entering into any transaction which could, when combined with other transactions (including the Merger), result in a 45% or greater change in ownership of APAC&#8217;s or OmniAb&#8217;s equity as part of a plan or series of related transactions that includes the Distribution, (ii)&#160;ceasing the active conduct of certain of OmniAb&#8217;s businesses, (iii)&#160;voluntarily dissolving or liquidating </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">314</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">APAC or OmniAb and (iv)&#160;causing, permitting, or agreeing to the sale, transfer, or disposal of assets of OmniAb that, in the aggregate, constitute more than 30% of the consolidated gross assets of OmniAb, in each case, unless OmniAb obtains a private letter ruling from the IRS, an unqualified opinion of a nationally recognized tax advisor that such action will not cause a failure of the intended tax treatment, or Ligand consents to the undertaking of such action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding receipt of such ruling, opinion or consent, in the event that such action causes a failure of the intended tax treatment, APAC and OmniAb could be responsible for all taxes arising therefrom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s and OmniAb&#8217;s obligations under the Tax Matters Agreement are not limited in amount or subject to any cap.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Employee Matters Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, APAC, Ligand, OmniAb and Merger Sub entered into the Employee Matters Agreement, which sets forth the terms and conditions of certain employee-related matters in connection with the transaction, including allocation of benefit plan assets and liabilities between Ligand and OmniAb, treatment of incentive equity awards in the Distribution and the Business Combination and related covenants and commitments of the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Employee Matters Agreement provides for the treatment of outstanding Ligand equity awards held by our employees upon completion of the Distribution and the treatment of outstanding OmniAb Equity Awards in connection with the Business Combination, each as described in further detail in the section entitled &#8220;<i style="font-style:italic;">Executive and Director Compensation of OmniAb &#8212; Narrative to Summary Compensation Table &#8212; Treatement of Outstanding Equity Awards at the Time of the Distribution</i>,&#8221; and also provides for certain other incentive arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Employee Matters Agreement provides that, following the Distribution and Business Combination, our employees generally will continue to participate in benefit plans sponsored or maintained by Ligand until the earlier to occur of (i)&#160;January&#160;1, 2023 or (ii)&#160;such earlier date as may be agreed among the parties. Following the respective plan transition date, our employees will commence participation in our respective benefit plans, which are expected to be generally similar to the existing Ligand benefit plans. Additionally, the Employee Matters Agreement provides that APAC shall approve and adopt the 2022 Plan and the ESPP, effective as of the Closing of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Employee Matters Agreement also sets forth the general principles relating to employee matters, including with respect to the assignment and transfer of employees, the assumption and retention of liabilities and related assets, workers&#8217; compensation, payroll taxes, regulatory filings, the provision of comparable benefits, employee service credit, the sharing of employee information, and the duplication or acceleration of benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Employee Matters Agreement may be amended or modified only by a written agreement among the parties and will terminate automatically upon the termination of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Policies and Procedures for Related Person Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb&#8217;s board of directors will adopt a written related person transaction policy, to be effective upon the distribution, setting forth the policies and procedures for the review and approval or ratification of related-person transactions. This policy will cover, with certain exceptions set forth in Item&#160;404 of Regulation&#160;S-K under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships in which OmniAb was or are to be a participant, where the amount involved exceeds the lesser of $120,000 or one&#160;percent of the average of OmniAb&#8217;s total assets at&#160;year-end for the last two completed fiscal&#160;years, and a related person had or will have a direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by OmniAb of a related person. In reviewing and approving any such transactions, OmniAb&#8217;s audit committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm&#8217;s length transaction and the extent of the related person&#8217;s interest in the transaction. All of the transactions described in this section will occur prior to the adoption of this policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">315</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_4f2ea399_b07a_41fd_8121_943437f26227"></a><a id="Main_SECURITYOWNERSHIPOFCERTAINBENEF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT OF OMNIAB</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before the Distribution, all of the outstanding shares of OmniAb Common Stock will be owned beneficially and of record by Ligand. After the Distribution, Ligand will own none of OmniAb Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following tables set forth information with respect to the expected beneficial ownership of OmniAb Common Stock immediately after the Distribution and prior to the Merger by: (1)&#160;each person expected to beneficially own more than five&#160;percent of OmniAb Common Stock, (2)&#160;each expected director and named executive officer, and (3)&#160;all of OmniAb&#8217;s expected directors and executive officers as a group based upon the Distribution ratio. The share amounts are based on each person&#8217;s beneficial ownership of Ligand Common Stock as of&#160;[&#9679;], 2022, assuming a Distribution ratio of one share of OmniAb Common Stock for every one share of common stock of Ligand, which assumes that holders of the Ligand Convertible Notes&#160;do not convert their notes prior to the Ligand Record Date for the Distribution. Solely for the purposes of this table, it is assumed that&#160;[&#9679;] of OmniAb&#8217;s shares of common stock were issued and outstanding as of&#160;[&#9679;], 2022 based on Ligand Common Stock outstanding as of such date and the Distribution ratio. The actual number of shares of OmniAb Common Stock to be outstanding following the Distribution will be determined on the Ligand Record Date for the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Unless otherwise indicated, the address of each beneficial owner listed below is c/o OmniAb,&#160;Inc., 5980 Horton Street, Suite&#160;405, Emeryville, CA 94608. OmniAb believes, based on information provided to it, that each of the stockholders listed below has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:50.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.36%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:50.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;stock</b><br /><b style="font-weight:bold;">beneficially</b><br /><b style="font-weight:bold;">owned before</b><br /><b style="font-weight:bold;">the&#160;Distribution</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.87%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;stock</b><br /><b style="font-weight:bold;">beneficially</b><br /><b style="font-weight:bold;">owned&#160;after&#160;the</b><br /><b style="font-weight:bold;">Distribution</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:50.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name and address of Beneficial Owner</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.62%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.41%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.87%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.36%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></th></tr><tr><td style="vertical-align:bottom;width:50.86%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;"><b style="font-weight:bold;">5% Beneficial Owner</b></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.36%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Ligand Pharmaceuticals Incorporated(1)</p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">100</p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.36%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;"><b style="font-weight:bold;">Named Executive Officers and Directors</b></p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.36%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Matthew W. Foehr</p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.41%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.36%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Charles S. Berkman</p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.36%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Kurt Gustafson</p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.41%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.36%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Carolyn Bertozzi</p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.36%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Sarah Boyce</p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.41%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.36%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Jennifer Cochran, Ph.D.</p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.36%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">John L. Higgins</p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.41%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.36%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">Sunil Patel</p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.36%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">All executive officers and directors as a group (8&#160;persons)</p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.62%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.41%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.36%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ligand&#8217;s address is 5980&#160;Horton Street, Suite&#160;405, Emeryville, CA 94608.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">316</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b4cb9a61_8688_4e70_893f_0ed6e859a570"></a><a id="Main_THESEPARATIONANDDISTRIBUTION"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE SEPARATION AND DISTRIBUTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March&#160;23, 2022, in connection with the execution of the Merger Agreement, Ligand, OmniAb and APAC entered into the Separation Agreement which sets forth the principal actions to be taken in connection with the Separation. The Separation Agreement identifies assets to be transferred, liabilities to be assumed and contracts to be assigned to each of Ligand and OmniAb as part of the internal reorganization described therein and requires the Ligand Contribution to be made to OmniAb. The Separation Agreement also sets forth other agreements that govern certain aspects of OmniAb&#8217;s relationship with Ligand following the Business Combination. Pursuant to the Separation Agreement, OmniAb will issue additional shares of OmniAb Common Stock to Ligand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming the conditions to the Distribution set forth in the Separation Agreement have been satisfied, Ligand will on the date of the Distribution distribute on a pro rata basis all of the outstanding shares of OmniAb Common Stock to the holders of Ligand Common Stock as of the Ligand Record Date set for the Distribution. The Distribution will be effected by Ligand delivering to the distribution agent a book-entry authorization representing the shares of OmniAb Common Stock being distributed in the Distribution for the account of Ligand&#8217;s stockholders. The distribution agent will hold such book-entry shares for the account of OmniAb&#8217;s stockholders (as of immediately after consummation of the Distribution) pending the Merger. The shares of OmniAb Common Stock will not be transferrable prior to the exchange of such shares for the shares of New OmniAb Common Stock pursuant to the Merger. As of the date of this proxy statement/prospectus/information statement, the Ligand Board has not set the Ligand Record Date. Ligand will publicly announce the Ligand Record Date when it has been determined, and prior to the completion of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a more detailed description of the Separation Agreement, see &#8220;<i style="font-style:italic;">Shareholder Proposal No.&#160;1&#160;&#8212; The Business Combination Proposal&#160;&#8212; Summary of the Separation Agreement</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">317</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d4652cbb_583a_438f_a98b_976d5e600e57"></a><a id="Main_DESCRIPTIONOFCOMBINEDCOMPANYSEC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DESCRIPTION OF COMBINED COMPANY SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Subject to approval of the Domestication Proposal, in connection with the Domestication, APAC will amend its Proposed Certificate of Incorporation and Proposed Bylaws. The following is a description of the material terms of, and is qualified in its entirety by, the Proposed Certificate of Incorporation and Proposed Bylaws. See &#8220;</i><i style="font-style:italic;">Shareholder Proposal No.&#160;2&#160;&#8212; The </i><i style="font-style:italic;">Domestication Proposal&#8221; for further details. Because this is only a summary, it may not contain all the information that is important to you.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Unless the context otherwise requires, references in this subsection to &#8220;OmniAb,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; generally refer to the combined company following the Business Combination.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb&#8217;s authorized capital stock consists of 1,000,000,000 shares of common stock, $0.0001 par value per share, and 100,000,000 shares of preferred stock, $0.0001 par value per share. Immediately following the Distribution, OmniAb expects that approximately&#160;[&#9679;]&#160;shares of OmniAb Common Stock will be issued and outstanding and that no shares of preferred stock will be issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Common stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of OmniAb Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock OmniAb may issue may be entitled to elect. Subject to supermajority votes for some matters, other matters shall be decided by the affirmative vote of OmniAb stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally available funds. In the event of OmniAb&#8217;s liquidation, dissolution or winding up, the holders of common stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of OmniAb&#8217;s debts and other liabilities, subject to the prior rights of any preferred stock then outstanding. Holders of common stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable to the common stock. All outstanding shares of common stock are, and the common stock to be outstanding upon the Distribution will be, duly authorized, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that OmniAb may designate and issue in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Preferred stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Proposed Certificate of Incorporation, which will become effective immediately following the Domestication, OmniAb&#8217;s board of directors has the authority, without further action by OmniAb&#8217;s stockholders, to issue up to 100,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb&#8217;s board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of OmniAb Common Stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deterring or preventing a change in OmniAb&#8217;s control and may adversely affect the market price of the common stock and the voting and other rights of the holders of OmniAb Common Stock. OmniAb has no current plans to issue any shares of preferred stock.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">318</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Registration rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the A&amp;R Registration Rights Agreement, certain stockholders, OmniAb will be required to use commercially reasonable efforts to, within thirty (30)&#160;days after the Closing, file a registration statement on Form&#160;S-1 to permit the public resale of all of the Registrable Securities (as defined in the A&amp;R Registration Rights Agreement) held by the holders from time to time as permitted by Rule&#160;415 under the Securities Act, and to provide certain equityholders of OmniAb as of immediately prior to the Closing of the Business Combination with customary registration rights. See &#8220;<i style="font-style:italic;">Summary of the Proxy Statement/Prospectus/Information Statement &#8212; Related Agreements &#8212; Amended &amp; Restated Registration and Stockholder Rights Agreement</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Transfer restrictions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transfer Restrictions Applicable to the Sponsor and the Directors and Officers of the Combined Company</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The A&amp;R Registration Rights Agreement will provide for certain restrictions on transfer with respect to the securities of OmniAb, including Founder Shares, Private Placement Warrants, Backstop Warrants, Forward Purchase Warrants, and securities held by directors and officers of APAC and certain directors and officers of OmniAb and Ligand. Such restrictions will begin upon closing and end (i)&#160;with respect to the Founder Shares, at the earliest of (A)&#160;one&#160;year after the closing date and (B)&#160;the first date on which (x)&#160;the last reported sale price of a share of OmniAb common stock equals or exceeds $12.00 per share for any 20 trading&#160;days within any 30-trading day period commencing at least 150&#160;days after the closing date or (y)&#160;APAC completing a liquidation, merger, share exchange, reorganization or other similar transaction that results in the OmniAb stockholders having the right to exchange their shares of OmniAb common stock for cash, securities or other property; (ii)&#160;with respect to the Private Placement Warrants, Backstop Warrants and Forward Purchase Warrants that are held by the initial purchasers of such warrants (or permitted transferees under the A&amp;R Registration Rights Agreement), and any of the shares of OmniAb common stock issued or issuable upon the exercise or conversion of such warrants and that are held by the initial purchasers of the applicable warrants being converted (or permitted transferees under the A&amp;R Registration Rights Agreement), the period ending 30&#160;days after the closing; and (iii)&#160;mean with respect to the shares of OmniAb common stock issued to the New Holders (as defined in the A&amp;R Registration Rights Agreement) in connection with the consummation of the Merger and held by the New Holders (or their permitted transferees under the A&amp;R Registration Rights Agreement), the period ending on the earliest of (A)&#160;three&#160;months after the closing and (B)&#160;the date on which OmniAb completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of OmniAb&#8217;s stockholders having the right to exchange their shares of OmniAb common stock for cash, securities or other property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Earnout Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Merger Agreement and the Proposed Bylaws, OmniAb Earnout Shares and Sponsor Earnout Shares may not be transferred until the applicable OmniAb Triggering Event or a Sponsor Triggering Event has occurred. OmniAb Earnout Shares and Sponsor Earnout Shares are issued and outstanding will be automatically forfeited for no consideration if an applicable OmniAb Triggering Event or Sponsor Triggering Event has not occurred with respect to such OmniAb Earnout Shares or Sponsor Triggering during the period from the date of the Closing to and including the fifth anniversary of the date of the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Anti-takeover effects of Delaware law and OmniAb&#8217;s certificate of incorporation and bylaws</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Some provisions of Delaware law, OmniAb&#8217;s amended and restated certificate of incorporation and OmniAb&#8217;s amended and restated bylaws contain provisions that could make the following transactions more difficult: an acquisition of OmniAb by means of a tender offer; an acquisition of OmniAb by means of a proxy contest or otherwise; or the removal of OmniAb&#8217;s incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in OmniAb&#8217;s best interests, including transactions which provide for payment of a premium over the market price for OmniAb&#8217;s shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of OmniAb to first negotiate with OmniAb&#8217;s board of directors. OmniAb believes that the benefits of the increased protection of its potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure OmniAb outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">319</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Undesignated preferred stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ability of OmniAb&#8217;s board of directors, without action by the stockholders, to issue up to&#160;100,000,000&#160;shares of undesignated preferred stock with voting or other rights or preferences as designated by the board of directors could impede the success of any attempt to change control of OmniAb. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stockholder meetings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Proposed Certificate of Incorporation provides that a special meeting of stockholders may be called only by OmniAb&#8217;s board of directors or chair of the board of directors, chief executive officer or president.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Requirements for advance notification of stockholder nominations and proposals</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Proposed Bylaws establish advance notice procedures with respect to Shareholder Proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elimination of stockholder action by written consent</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Proposed Certificate of Incorporation will expressly eliminate the right of OmniAb&#8217;s stockholders to act by written consent. Stockholder action must take place at the annual or a special meeting of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Staggered board of directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Proposed Certificate of Incorporation provides that OmniAb&#8217;s board of directors will be divided into three classes. The directors in each class will serve for a three-year term, with one class being elected each&#160;year by OmniAb&#8217;s stockholders. For more information on the classified board of directors, see &#8220;<i style="font-style:italic;">Management of New OmniAb After the Business Combination &#8212; The New OmniAb Board Composition and Election of Directors</i>.&#8221; This system of electing directors may tend to discourage a third party from attempting to obtain control of OmniAb, because it generally makes it more difficult for stockholders to replace a majority of the directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Removal of directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Proposed Certificate of Incorporation provides that no member of OmniAb&#8217;s board of directors may be removed from office except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of the total voting power of all of OmniAb&#8217;s outstanding voting stock then entitled to vote in the election of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stockholders not entitled to cumulative voting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Proposed Certificate of Incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of OmniAb Common Stock who entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of OmniAb&#8217;s preferred stock may be entitled to elect.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">320</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Delaware anti-takeover statute</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb will be subject to Section&#160;203 of the Delaware General Corporation Law, which prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three&#160;years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three&#160;years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors.</p><a id="_Hlk101231881"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Choice of forum</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Proposed Certificate of Incorporation provides that, unless OmniAb consents in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware (or, in the event the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on OmniAb&#8217;s behalf; (ii) any action asserting a claim of breach of a fiduciary duty by any of OmniAb&#8217;s directors, officers or stockholders to OmniAb or OmniAb&#8217;s stockholders; (iii) any action asserting a claim arising pursuant to any provision of the DGCL, the Proposed Certificate of Incorporation or the Proposed Bylaws (as each may be amended from time to time); or (iv) any action asserting a claim governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law. The provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction. In addition, the Proposed Certificate of Incorporation provides that, unless OmniAb consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. For the avoidance of doubt, this provision is intended to benefit and may be enforced by OmniAb, OmniAb&#8217;s officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. However, OmniAb notes that there is uncertainty as to whether a court would enforce this provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Section 22 of the Securities Act creates concurrent jurisdiction for state and federal courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. OmniAb&#8217;s amended and restated certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in any security of OmniAb will be deemed to have notice of and to have consented to these choice of forum provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amendment of charter provisions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The provisions of Delaware law, the Proposed Certificate of Incorporation and the Proposed Bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of OmniAb Common Stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of OmniAb&#8217;s board of directors and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Proposed Certificate of Incorporation will provide that the affirmative vote of the holders of at least two-thirds of the total voting power of OmniAb&#8217;s outstanding shares entitled to vote thereon, voting as a single class, is required to amend certain provisions relating to the issuance of preferred stock, the number, term, classification, removal and filling of vacancies with respect to the board of directors, the advance notice to be given for nominations for elections of directors, the calling of special meetings of stockholders, stockholder action by written consent, forum selection, the ability to amend the bylaws, the elimination of liability of directors to the extent permitted by Delaware law, director and officer indemnification and any provision relating to the amendment of any of these provisions.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">321</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amendment of bylaws</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Proposed Certificate of Incorporation and Proposed Bylaws will provide that OmniAb&#8217;s bylaws may only be amended by the board of directors or by the affirmative vote of holders of at least two-thirds of the total voting power of OmniAb&#8217;s outstanding shares entitled to vote thereon, voting as a single class. Additionally, the Proposed Certificate of Incorporation will provide that OmniAb&#8217;s bylaws may be adopted, amended, altered or repealed by OmniAb&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Transfer Agent and Registrar</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The transfer agent and registrar for OmniAb Common Stock will be Computershare Trust Company, N.A. The transfer agent and registrar&#8217;s address is 150 Royall Street, Canton, Massachusetts 02021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Nasdaq Global Market Listing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb has applied to have its common stock listed on the Nasdaq Global Market under the symbol &#8220;OABI.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Limitations of Liability and Indemnification Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a discussion of liability and indemnification, see &#8220;<i style="font-style:italic;">Executive and Director Compensation of OmniAb &#8212; Limitations of Liability and Indemnification Matters</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">322</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_22d473d8_e8c7_4cbe_b47b_46163b586755"></a><a id="Main_COMPARISONOFCORPORATEGOVERNANCE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMPARISON OF CORPORATE GOVERNANCE AND SHAREHOLDER RIGHTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC is an exempted company incorporated under the Cayman Islands Companies Law. The Cayman Islands Companies Law, Cayman Islands common law and APAC&#8217;s memorandum and articles of association govern the rights of its shareholders. The Cayman Islands Companies Law differs in some material respects from laws generally applicable to United States corporations and their stockholders. As a result, when you become a stockholder of New OmniAb your rights will differ in some regards as compared to when you were a shareholder of APAC. The following chart &#8220;Domestication Impact on Stockholder Rights&#8221; summarizes important similarities and differences in stockholder rights prior to and following the Domestication, resulting from the differences in the Cayman Islands Company Law and the laws generally applicable to United States corporations and their stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, APAC&#8217;s memorandum and articles of association will differ in certain material respects from the Proposed Articles of Incorporation and Proposed Bylaws presented for adoption in the Organizational Documents Proposal. Further, the Proposed Articles of Incorporation and Proposed Bylaws will differ in certain material respects from the governance documents determining the existing rights of Ligand&#8217;s stockholders prior to the Separation and the Merger. Therefore, stockholders of Ligand will experience certain changes in their previous rights as stockholders of Ligand as compared to their new rights as stockholders of New OmniAb, following the Reorganization and the Merger. The following chart &#8220;Comparison of Stockholder Rights Under Relevant Governance Documents&#8221; summarizes important similarities and differences in the corporate governance and stockholder rights associated with each of APAC, New OmniAb, and Ligand according to each entity&#8217;s applicable organizational documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This summary is qualified by reference to the complete text of the Cayman Constitutional Documents of APAC, attached to this proxy statement/prospectus/information statement as Annex J, the complete text of the Proposed Certificate of Incorporation, a copy of which is attached to this proxy statement/prospectus/information statement as Annex H, the complete text of the Proposed Bylaws, a copy of which is attached to this proxy statement/prospectus/information statement as Annex I and the complete text of the existing bylaws and charter of Ligand. You should review each of these organizational documents, as well as the Delaware corporate law and corporate laws of the Cayman Islands, including the Cayman Islands Companies Law, to understand how these laws apply to New OmniAb, APAC and Ligand, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Domestication Impact on Stockholders Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.01%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:32%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Delaware</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:28.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cayman Islands</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.01%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:32%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:28.98%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:35.01%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Stockholder/Shareholder Approval of Business Combinations</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Mergers generally require approval of a majority of all outstanding shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Mergers in which less than 20% of the acquirer&#8217;s stock is issued generally do not require acquirer stockholder approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Mergers in which one corporation owns 90% or more of a second corporation may be completed without the vote of the second corporation&#8217;s board of directors or stockholders.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:28.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Mergers under the Cayman Islands Companies Law require a special resolution, and any other authorization as may be specified in the relevant articles of association. Parties holding certain security interests in the constituent companies must also consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">All mergers (other than parent/subsidiary mergers) require shareholder approval &#8211; there is no exception for smaller mergers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Where a bidder in connection with a tender offer/contractual acquisition of equity (i.e. not a statutory merger under Cayman Islands Companies Law) has acquired 90% or more of the shares in a Cayman Islands company to which the offer relates, it can compel the acquisition of the shares of the remaining shareholders and thereby become the sole shareholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">A Cayman Islands company may also be acquired through a &#8220;scheme of arrangement&#8221; sanctioned by a Cayman Islands court subject to approval at a specially convened meeting by a majority in number representing 75% in value of shareholders in attendance, either by person or by proxy, and voting at a shareholders&#8217; meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">323</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.01%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:32%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Delaware</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:28.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cayman Islands</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.01%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:32%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:28.98%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:35.01%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Stockholder/Shareholder Votes for Routine Matters</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Generally, approval of routine corporate matters that are put to a stockholder vote require the affirmative vote of holders of the majority of shares present in person or represented by proxy at the meeting and entitled to vote on the subject matter.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:28.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Under the Cayman Islands Companies Law and APAC&#8217;s amended and restated memorandum and articles of association, routine corporate matters, requiring shareholder approval, may be approved by an ordinary resolution (being a resolution passed by the holders of a majority of the ordinary shares represented in person, virtually or by proxy and entitled to vote thereon and who votes at a general meeting or extraordinary general meeting and which includes a unanimous written resolution).</p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:35.01%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:34%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:30.98%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:35.01%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Dissenters&#8217; Rights and Appraisal Rights</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Generally, a stockholder of a publicly traded corporation does not have appraisal rights in connection with a merger.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:28.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Minority shareholders that dissent from a merger are entitled to be paid the fair value of their shares, which if necessary may ultimately be determined by the court.</p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:35.01%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:34%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:30.98%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:35.01%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Inspection of Books and Records</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Any stockholder may inspect the corporation&#8217;s books and records for a proper purpose during the usual hours for business.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:28.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Shareholders generally do not have any rights to inspect or obtain copies of the register of shareholders or other corporate records of a company.</p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:35.01%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:34%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:30.98%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:35.01%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Stockholder/Shareholder Lawsuits</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">A stockholder may bring a derivative suit subject to procedural requirements (including adopting Delaware as the exclusive forum as per the Non-Binding Governance Proposals).</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:28.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">In the Cayman Islands, the decision to institute proceedings on behalf of a company is generally taken by the company&#8217;s board of directors. A shareholder may be entitled to bring a derivative action on behalf of the company, but only in certain limited circumstances.</p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:35.01%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:34%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:30.98%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:35.01%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Fiduciary Duties of Directors</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Directors must exercise a duty of care and duty of loyalty and good faith to the company and its stockholders.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:28.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">A director owes fiduciary duties to a Cayman Islands exempted company, including to exercise powers for the purposes conferred, exercise independent judgment, not make secret profits, avoid conflicts of interest and act in good faith in the best interests of the company as a whole.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">In addition to fiduciary duties, directors of APAC owe a duty of care, diligence and skill. Such duties are owed to the company but may be owed direct to creditors or shareholders in certain limited circumstances.</p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:35.01%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:34%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:30.98%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:35.01%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Indemnification of Directors and Officers</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">A corporation is generally permitted to indemnify its directors and officers acting in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation.</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:28.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">A Cayman Islands exempted company generally may indemnify its directors or officers except with regard to fraud, willful neglect or willful default.</p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:35.01%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:34%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:30.98%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:35.01%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Limited Liability of Directors</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Permits limiting or eliminating the monetary liability of a director to a corporation or its stockholders, except with regard to breaches of duty of loyalty, intentional misconduct, unlawful repurchases or dividends, or improper personal benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:28.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Liability of directors may be unlimited, except with regard to their own fraud, willful neglect or willful default.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">324</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Comparison of Stockholder Rights Under Relevant Governance Documents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:23.44%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.24%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:20.36%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:23.44%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">APAC</b></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:33.24%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">New OmniAb</b></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:20.36%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ligand</b></p></td></tr><tr><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Anti-Takeover Provisions and Other Stockholder Protections</b></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.44%;border-top:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">APAC&#8217;s memorandum and articles of association do not provide restrictions on takeovers of APAC by a related shareholder.</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.24%;border-top:1px solid #000000;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">The anti-takeover provisions and other stockholder protections included in the Proposed Bylaws include a prohibition on stockholder action by written consent. Section 203 of the DGCL prohibits a Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; (i.e. a stockholder owning 15% or more of New OmniAb&#8217;s voting stock) for three (3) years following the time that the &#8220;interested stockholder&#8221; becomes such, subject to certain exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:20.36%;border-top:1px solid #000000;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">The Ligand bylaws also include a prohibition on shareholder action by written consent, and Section 23 of the DGCL is also applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Number &amp; Qualification of Directors</b></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.44%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">APAC&#8217;s memorandum and articles of association provide that, the number of directors on the APAC Board will not be less than one (1) person and the number of directors may be increased or reduced by ordinary resolution.</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.24%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Subject to any rights of holders of preferred stock with respect to the election of directors, between New OmniAb and certain of its stockholders and the Amended and Restated Registration Rights Agreement, the number of directors will be fixed from time to time solely by resolution adopted by the New OmniAb Board. The initial New OmniAb Board will be comprised of seven (7) members.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">The Ligand Board is comprised of ten (10) members. The Ligand Board may expand its membership from time to time solely by resolution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Authorized Stock/Share Capital</b></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.44%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Under APAC&#8217;s memorandum and articles of association, APAC has an authorized share capital of $55,500 divided into (a)&#160;500,000,000 APAC Class A Ordinary Shares, par value $0.0001 per share, and (b)&#160;50,000,000 APAC Class B Ordinary Shares, par value $0.0001 per share, and (c)&#160;5,000,000 preference shares, par value $0.0001 per share. Under APAC&#8217;s memorandum and articles of association an increase in share capital requires shareholder approval by ordinary resolution.</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.24%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">New OmniAb will be authorized to issue 1,100,000,000 shares of capital stock, consisting of (i) 1,000,000,000 shares of Common Stock, par value $0.0001 per share, and (ii) 100,000,000 shares of Preferred Stock, par value $0.0001 per share. Upon consummation of the Business Combination, New OmniAb expects there will be approximately 127,681,885 shares of New OmniAb Common Stock (assuming no redemptions) outstanding. Following consummation of the Business Combination, New OmniAb is not expected to have any preferred stock outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:20.36%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Under Ligand&#8217;s charter, Ligand is currently authorized to issue 65,000,000 shares, consisting of (a)&#160;60,000,000 shares of Common Stock, par value $0.001 per share, and (b) 5,000,000 shares of Preferred Stock, par value $0.001 per share.</p></td></tr><tr><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Classification of the Board of Directors</b></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.44%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">APAC&#8217;s memorandum and articles of association does not provide for a classified board.</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.24%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">New OmniAb&#8217;s Proposed Article of Incorporation provides that the New OmniAb Board will be initially divided into three (3) classes, Class I, Class II and Class III, with members of each class serving staggered three-year terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:20.36%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Ligand&#8217;s amended and restated certificate of incorporation does not provide for a classified board.</p></td></tr><tr><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Election of Directors</b></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.44%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Prior to a Business Combination, as defined in APAC&#8217;s articles of association, only Class B shareholders may appoint directors by ordinary resolution. Directors hold office until the second annual meeting following their election, or until his or her successor is duly elected and qualified, subject to such director&#8217;s earlier death, resignation or removal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.24%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">The stockholders shall elect directors, each of whom will hold office until his or her successor is duly elected or qualified at the annual meeting for the year in which his or her term expires, or until his or her earlier death, resignation, disqualification or removal.</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:20.36%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">At Ligand&#8217;s annual meeting, stockholders elect directors to hold office until the next annual meeting, or until his or her successor is duly elected and qualified, subject to such director&#8217;s earlier death, resignation or removal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">The election of directors is determined by a plurality of the votes cast at an annual meeting of stockholders by holders of Ligand&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">325</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:23.44%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">APAC</b></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:33.24%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">New OmniAb</b></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:20.36%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ligand</b></p></td></tr><tr><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Removal of Directors</b></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.44%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Prior to the Business Combination, as defined in APAC&#8217;s articles of association, only Class B shareholders may remove directors by ordinary resolution.</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.24%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Subject to any special rights of the holders preferred stock, the Board or any individual director may be removed from office at any time, but only for cause and only by the affirmative vote of the holders of at least two-thirds (66 and 2/3%) of the voting power of all the then outstanding shares of voting stock of the Corporation entitled to vote generally in an election of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.36%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Subject to the rights of the holders of any series of preferred stock, any or all of the directors may be removed from office at any time, with or without cause, by the affirmative vote of holders of a majority of the voting power of all then outstanding shares of capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Voting</b></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.44%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Holders of APAC ordinary shares are entitled to one vote for each share held on each matter submitted to a vote of shareholders; save that, holders of Class A ordinary shares shall have no right to vote on the appointment or removal of directors prior to a business combination and holders of Class B ordinary shares shall have ten votes for each such share held in respect of voting on any special resolution approving any continuation of APAC outside of the Cayman Islands (and, prior to a business combination the article providing for the same may only be amended by a special resolution passed by the holders of the Class B ordinary shares).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.24%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Except as otherwise required by law or New OmniAb&#8217;s Proposed Certificate of Incorporation, holders of the New OmniAb common stock will possess all voting power with respect to New OmniAb. The holders of shares of New OmniAb common stock shall be entitled to one vote for each such share on each matter properly submitted to New OmniAb&#8217;s stockholders on which the holders of shares of common stock are entitled to vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Except as otherwise required by applicable law, holders of New OmniAb&#8217;s common stock will not be entitled to vote on any amendment to New OmniAb&#8217;s Proposed Certificate of Incorporation that relates solely to the terms of one or more outstanding series of New OmniAb preferred stock if the holders of such affected series of New OmniAb preferred stock are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Proposed Certificate of Incorporation or applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.36%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Except as otherwise required by law or Ligand&#8217;s amended and restated certificate of incorporation and bylaws, holders of Ligand Common Stock shall have the right to vote on matters submitted to the stockholders, and shall be entitled to notice of any stockholders&#8217; meeting in accordance with the bylaws of this corporation, and shall be entitled to vote upon such matters and in such manner as may be provided by law. </p></td></tr><tr><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Cumulative Voting</b></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.44%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Cayman Islands law does not specifically prohibit cumulative voting, but APAC&#8217;s memorandum and articles of association do not provide for cumulative voting.</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.24%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Delaware law allows for cumulative voting only if provided for in the charter; however, the Proposed Bylaws and Proposed Articles of Incorporation do not authorize cumulative voting.</p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.36%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Delaware law allows for cumulative voting only if provided for in a corporation&#8217;s certificate of incorporation; however, Ligand&#8217;s current Amended and Restated Certificate of Incorporation does not authorize cumulative voting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Vacancies on the Board of Directors</b></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.44%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">APAC&#8217;s memorandum and articles of association provide that any vacancy on the APAC Board, including a vacancy resulting from an enlargement of the board, may be filled by a majority vote of the remaining directors then in office, even if less than a quorum or by a sole remaining director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.24%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">The Proposed Articles of Incorporation provide that any vacancy on the New OmniAb Board, including a vacancy resulting from an enlargement of the board, may be filled only by a majority vote of the remaining directors then in office, even if less than a quorum or by a sole remaining director (other than any directors elected by the separate vote of one or more outstanding series of preferred stock).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.36%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Ligand&#8217;s amended and restated certificate of incorporation provides that any vacancy on the Ligand Board, including a vacancy resulting from an enlargement of the board, may be filled by a majority vote of the remaining directors then in office, even if less than a quorum or by a sole remaining director.</p></td></tr><tr><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Shareholder / Stockholder Action by Written Consent</b></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.44%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">A resolution in writing (including a special resolution) signed by or on behalf of all of the members for the time being entitled to receive notice of and to attend and vote at general meetings shall be as valid and effective as if the resolution had been passed at a general meeting of APAC duly convened and held.</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.24%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Under the Proposed Articles of Incorporation , any action required or permitted to be taken by the stockholders of New OmniAb must be effected at an annual or special meeting of the stockholders and may not be effected by written consent. Notwithstanding the foregoing, any action required or permitted to be taken by the holders of any series of preferred stock, may be taken without a meeting, without prior notice and without a vote, to the extent expressly so provided by the applicable certificate of designation relating to such series of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.36%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Under Ligand&#8217;s bylaws, no action shall be taken by the stockholders except at an annual or special meeting and no action</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">shall be taken by the stockholders by written consent. </p></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">326</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Amendment to Certificate of Incorporation / memorandum of association</b></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.44%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">APAC&#8217;s memorandum and articles of association provide that most provisions of its memorandum of association may be amended by special resolution of its members, and that certain amendments relating to its share capital may be made by ordinary resolution of its members.</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.24%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Pursuant to Delaware law, an amendment to the charter generally requires the approval of the New OmniAb Board and a majority of the combined voting power of the then-outstanding shares of voting stock, voting together as a single class.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Under the Proposed Articles of Incorporation, in addition to any vote required by DGCL, certain key sections of the Proposed Articles of Incorporation may be amended only by the affirmative vote of the holders of at least&#160;two-thirds&#160;(66 2/3%) of the total voting power of the then outstanding shares of stock of New OmniAb entitled to vote thereon, voting together as a single class.</p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.36%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Pursuant to Delaware law, an amendment to the charter generally requires the approval of the board and a majority of the combined voting power of the then-outstanding shares of voting stock, voting together as a single class.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Amendment of the Bylaws</b></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.44%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">APAC&#8217;s memorandum and articles of association provide that its articles of association may be amended by special resolution of its members save for articles 29.4 and 47.2.</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.24%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Under the Proposed Bylaws the New OmniAb Board is expressly empowered to adopt, amend or repeal the bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">The stockholders also shall have power to adopt, amend or repeal the bylaws; provided, however, in addition to any vote of the holders of any class or series of stock of New OmniAb required by applicable law or by the Proposed Certificate of Incorporation (including any certificate of designation in respect of one or more series of Preferred Stock), the adoption, amendment or repeal of the bylaws by the stockholders shall require the affirmative vote of the holders of at least two-thirds (66 and 2/3%) of the voting power of all of the then outstanding shares of voting stock entitled to vote generally in an election of directors, voting together as a single class.</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.36%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">The Ligand bylaws may generally be altered or amended adopted by the affirmative vote of a majority of the voting power of all of the then outstanding shares of capital stock of Ligand entitled to vote generally in the election of Directors; provided that certain sections of the bylaws shall require the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then outstanding shares of the voting stock, voting together as a single class, to alter or amend.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">The Ligand Board shall also have the power to amend the bylaws.</p></td></tr><tr><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Quorum</b></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.44%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Board of Directors. </i>A majority of the APAC Board, unless otherwise fixed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Shareholders.</i> The holders of one-third of the shares being individuals present in person or by proxy or if a corporation or other non-natural person by its duly authorized representative or proxy shall be a quorum.</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.24%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Board of Directors.</i> At all meetings of the New OmniAb Board, unless otherwise provided by the Proposed Certificate of Incorporation, a majority of the total number of directors shall constitute a quorum for the transaction of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Stockholders.</i>&#160;The holders of a majority in voting power of the stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.36%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Board of Directors</i>. At all meetings of the Ligand Board a majority of the directors shall constitute a quorum for the transaction of business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Stockholders</i>. The holders of a majority of the stock issued and outstanding and entitled to vote thereat, present in person or represented by proxy, shall constitute a quorum at all meetings of the stockholders for the transaction of business except as otherwise provided by statute or by the Certificate of Incorporation.</p></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">327</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Interested Directors</b></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.44%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">No person shall be disqualified from the office of director or prevented by such office from contracting with APAC, either as vendor, purchaser or otherwise, nor shall any such contract or any contract or transaction entered into by or on behalf of APAC in which any director shall be in any way interested be or be liable to be avoided, nor shall any director so contracting or being so interested be liable to account to APAC for any profit realized by or arising in connection with any such contract or transaction by reason of such director holding office or of the fiduciary relationship thereby established. A director may vote in respect of any contract or transaction in which he or she is interested provided that the nature of the interest of any director in any such contract or transaction shall be disclosed by him or her at or prior to its consideration and any vote thereon.</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.24%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">New OmniAb will be governed by DGCL Section&#160;203.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.36%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Ligand is governed by DGCL Section&#160;203.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Special Meeting of the Shareholders / Stockholders</b></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.44%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">The directors, the chief executive officer or the chairman of the board of directors may call general meetings.</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.24%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Subject to the special rights of the holders of one or more series of Preferred Stock, special meetings may be called, for any purpose or purposes, at any time only by or at the direction of the New OmniAb Board, the Chairperson of the New OmniAb Board, the Chief Executive Officer, or the President.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.36%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Special meetings of the stockholders for any purpose or purposes, unless otherwise prescribed by statute or by the Certificate of Incorporation, may be called only by the Chairman of the Ligand Board, by the Ligand Board, pursuant to a resolution approved by a majority of the entire Ligand Board, or by the Secretary of Ligand, following his or her receipt of one or more written demands to call a special meeting of the stockholders in accordance with, and subject to, Section 7 of the bylaws, from stockholders of record as of the record date fixed in accordance with Section 7(d) of the bylaws who hold, in the aggregate, at least ten percent (10%) of the voting power of the outstanding shares of Ligand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">328</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Notice of Shareholder / Stockholder Meeting</b></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.44%;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">At least five clear days&#8217; notice shall be given of any general meeting. Every notice shall specify the place, the day and the hour of the meeting and the general nature of the business to be conducted at the general meeting and shall be given in the manner hereinafter mentioned or in such other manner if any as may be prescribed by APAC, provided that a general meeting of APAC shall be deemed to have been duly convened if it is so agreed:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">(a) in the case of an annual general meeting, by all of the members entitled to attend and vote thereat;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">(b) in the case of an extraordinary general meeting, by a majority in number of the members having a right to attend and vote at the meeting, together holding not less than ninety-five per cent in par value of the Shares giving that right.</p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.24%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Unless otherwise provided by DGCL, the notice of any meeting of stockholders shall be sent or otherwise given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting. The notice shall specify the place, if any, date and time of the meeting, the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.48%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.36%;margin:0pt;padding:0.25pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Unless otherwise provided by DGCL, the notice of any meeting of stockholders shall be sent or otherwise given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting. The notice shall specify the place, if any, date and time of the meeting, the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">329</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f7a2a03d_43dd_480a_8059_eb5b0e46a748"></a><a id="Main_SECURITIESACTRESTRICTIONSONRESA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECURITIES ACT RESTRICTIONS ON RESALE OF COMBINED COMPANY&#8217;S SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Rule&#160;144 under the Securities Act (&#8220;Rule&#160;144&#8221;), a person who has beneficially owned restricted New OmniAb Common Stock or OmniAb Warrants for at least six&#160;months would be entitled to sell their securities provided that (i)&#160;such person is not deemed to have been an affiliate of New OmniAb at the time of, or at any time during the three&#160;months preceding, a sale and (ii)&#160;New OmniAb is subject to the Exchange Act periodic reporting requirements for at least three&#160;months before the sale and have filed all required reports under Section&#160;13 or 15(d)&#160;of the Exchange Act during the 12&#160;months (or such shorter period as New OmniAb was required to file reports) preceding the sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Persons who have beneficially owned restricted shares of New OmniAb Common Stock or New OmniAb Warrants for at least six&#160;months but who are affiliates of New OmniAb at the time of, or at any time during the three&#160;months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1% of the total number of New OmniAb Common Stock then outstanding; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the average weekly reported trading volume of New OmniAb Common Stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Sales by affiliates of New OmniAb under Rule&#160;144 are also limited by manner of sale provisions and notice requirements and to the availability of current public information about New OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Restrictions on the Use of Rule&#160;144 by Shell Companies or Former Shell Companies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Rule&#160;144 is not available for the resale of securities initially issued by shell companies (other than business combination related shell companies) or issuers that have been at any time previously a shell company. However, Rule&#160;144 also includes an important exception to this prohibition if the following conditions are met:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuer of the securities that was formerly a shell company has ceased to be a shell company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result, the Sponsor will be able to sell their founder shares and private placement warrants, as applicable, pursuant to Rule&#160;144 without registration one&#160;year after the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC anticipates that following the consummation of the Business Combination, OmniAb will no longer be a shell company, and so, once the conditions set forth in the exceptions listed above are satisfied, Rule&#160;144 will become available for the resale of the above noted restricted securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">330</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d3ba2d81_ca58_440a_80af_b09aee6d3eda"></a><a id="Main_DISSENTERSRIGHTSANDAPPRAISALRI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DISSENTERS&#8217; RIGHTS AND APPRAISAL RIGHTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As APAC is not a constituent party to the Merger between Merger Sub and OmniAb, shareholders of APAC do not have dissenters&#8217; rights in connection with the Merger under Cayman Islands law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC&#8217;s warrant holders do not have appraisal rights in connection with the Business Combination or the Merger under the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">331</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2063368f_65e6_47a6_b81a_8e2eb151294b"></a><a id="Main_SUBMISSIONOFSHAREHOLDERPROPOSALS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SUBMISSION OF SHAREHOLDER PROPOSALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The APAC Board is aware of no matters other than the Business Combination Proposal, Domestication Proposal, Organizational Documents Proposal, Non-Binding Governance Proposals, Director Election Proposal, Stock Issuance Proposal, Equity Award Proposal and Adjournment Proposal that may be brought before the extraordinary general meeting. However, if any other matter should properly come before the extraordinary general meeting, the persons named in the enclosed proxies will vote such proxies in accordance with their judgment on any such matters. Under Cayman Islands law, only the business that is specified in the notice of meeting to shareholders for the extraordinary general meeting may be transacted at the extraordinary general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">332</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cfa0b2b1_822a_49fa_9b25_b34455b94993"></a><a id="Main_FUTURESHAREHOLDERPROPOSALS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FUTURE SHAREHOLDER PROPOSALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming the Business Combination is completed, APAC currently does not expect to hold its 2022 annual meeting of shareholders. If the Business Combination is consummated, you will be entitled to attend and participate in New OmniAb&#8217;s annual meetings of stockholders. If New OmniAb holds a 2022 annual meeting of stockholders, it will provide notice of or otherwise publicly disclose the date on which the 2022 annual meeting will be held.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">333</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_341fa8ec_2237_4e46_aaf3_ea6742f7923a"></a><a id="Main_DELIVERYOFDOCUMENTSTOSHAREHOLDE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DELIVERY OF DOCUMENTS TO SHAREHOLDERS/HOUSEHOLDING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the rules&#160;of the SEC, unless it has received a contrary instruction, APAC (and the services APAC employs to deliver communications to its shareholders) may send a single copy of this proxy statement/prospectus/information statement and any other proxy statement/prospectus/information statement or annual report delivered to APAC shareholders to two or more shareholders sharing the same address, if APAC believes that the shareholders are members of the same family. This process, known as &#8220;householding,&#8221; reduces the volume of duplicate information received at any one household and helps to reduce APAC&#8217;s expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon request, APAC will deliver a separate copy of this proxy statement/prospectus/information statement and/or any annual report or proxy statement/prospectus/information statement to any shareholder at a shared address to which a single copy of such document was delivered. Shareholders receiving multiple copies of such documents may likewise request that APAC deliver single copies of such documents in the future. Shareholders may notify APAC of their requests by calling (212) 593-6900 or writing to APAC at its principal executive offices at Avista Public Acquisition Corp. II., Attn: General Counsel, 65 East 55th Street, 18th Floor, New York, NY 10022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the Business Combination, New OmniAb shareholders should send any such requests in writing to 5980 Horton Street, Emeryville, CA 94608, Attn: General Counsel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">334</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_851c63e6_b2dd_454d_881c_8742bd061868"></a><a id="Main_OTHERSHAREHOLDERCOMMUNICATIONS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OTHER SHAREHOLDER COMMUNICATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC shareholders and interested parties may communicate with the APAC Board, any committee chairperson or the non-management directors as a group by writing to Avista Public Acquisition Corp. II, Attn: General Counsel, 65 East 55th Street, 18th Floor, New York, NY 10022. Following the Business Combination, New OmniAb stockholders should send any communications to the New OmniAb Board, any committee chairperson or the non-management directors of New OmniAb to 5980 Horton Street, Suite&#160;405, Emeryville, CA 94608, Attn: General Counsel. Any such communication will be reviewed and, to the extent such communication falls within the scope of matters generally considered by the APAC Board, forwarded to the APAC Board, the appropriate committee chairperson or the non-management directors, as appropriate, based on the subject matter of the communication. The acceptance and forwarding of communications to the members of the APAC Board or the New OmniAb Board, as applicable, or to an executive officer of APAC or New OmniAb does not imply or create any fiduciary duty of such director or executive officer to the person submitting the communications.</p><a id="_5826670d_8b59_495e_aae8_53d151aee48a"></a><a id="main_LEGALMATTERS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LEGAL MATTERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Weil, Gotshal&#160;&amp; Manges LLP will pass upon the validity of the New OmniAb Common Stock to be issued in connection with the Business Combination and certain other legal matters related to this proxy statement/prospectus/information statement.</p><a id="_fb3994b0_5260_43b3_bbb3_3c078a05354f"></a><a id="Main_EXPERTS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXPERTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The financial statements of Avista Public Acquisition Corp. II as of December&#160;31, 2021, and for the period from February&#160;5, 2021 (inception) through December&#160;31, 2021, appearing in this proxy statement/prospectus/information statement have been audited by Marcum LLP, independent registered public accounting firm, as set forth in their report thereon, appearing elsewhere in this proxy statement/prospectus/information statement, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The combined financial statements of OmniAb,&#160;Inc. at December&#160;31, 2021 and 2020, and for each of the three&#160;years in the period ended December&#160;31, 2021, included in this proxy statement/prospectus/information statement of Avista Public Acquisition Corp. II, which is referred to and made a part of this proxy statement/prospectus/information statement, have been audited by Ernst&#160;&amp; Young LLP, independent registered public accounting firm, as set forth in their report appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">335</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3ec93e7e_0fc2_45b9_83fb_5fc5e2670fbb"></a><a id="Main_WHEREYOUCANFINDMOREINFORMATION"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC files reports, proxy statements/prospectuses/information statements and other information with the SEC as required by the Exchange Act. You may read APAC&#8217;s SEC filings, including this proxy statement/prospectus/information statement and any other reports, proxy statements/prospectuses/information statements and other information filed by APAC with the SEC, on the SEC website at http://www.sec.gov.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 1pt;">This proxy statement/prospectus/information statement is available without charge to APAC shareholders upon written or oral request. If you would like additional copies of this proxy statement/prospectus/information statement or need to obtain proxy cards, or if you have questions about the Business Combination or the proposals to be presented at the extraordinary general meeting, you should contact APAC or D.F. King&#160;&amp; Co.,&#160;Inc., its proxy solicitor, at the information below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Avista Public Acquisition Corp. II</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Attn.: General Counsel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">65 East 55th Street, 18th Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">New York, NY 10022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Tel.: (212) 593-6900</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">or:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">D.F. King&#160;&amp; Co,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">48 Wall Street, 22nd Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">New York, NY 10005</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Call Toll-Free: (888) 887-0082</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Banks and Brokers Call: (212) 269-5550</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">AHPA@dfking.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Information and statements contained in this proxy statement/prospectus/information statement or any Annex to this proxy statement/prospectus/information statement are qualified in all respects by reference to the copy of the relevant contract or other Annex filed as an exhibit to this proxy statement/prospectus/information statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All information contained in this document relating to APAC, including Merger Sub, has been supplied by APAC, all information relating to Ligand Pharmaceuticals Incorporated and OmniAb,&#160;Inc. has been supplied by such parties. Information provided by one entity does not constitute any representation, estimate or projection of the other entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None of APAC, OmniAb or Ligand have authorized anyone to give any information or make any representation about the Business Combination or their companies that is different from, or in addition to, that included in this proxy statement/prospectus/information statement or in any of the materials that have been incorporated in this proxy statement/prospectus/information statement. Therefore, if anyone does give you information of this sort, you should not rely on it. The information included in this proxy statement/prospectus/information statement speaks only as of the date of this proxy statement/prospectus/information statement unless the information specifically indicates that another date applies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">336</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_a59eb9cd_cf86_4044_b1a1_0ffcd29afe55"></a><a id="Main_INDEXTOFINANCIALSTATEMENTS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">INDEX TO FINANCIAL STATEMENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:90%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Avista Public Acquisition Corp. II</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"></td></tr><tr><td style="vertical-align:bottom;width:90%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">References to the &#8220;Company&#8221; in the Avista Public Acquisition Corp. II financial statements are to Avista Public Acquisition Corp. II.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:90%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Report of Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:bottom;width:90%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#BALANCESHEET_585563_1"><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Balance Sheet as of December 31, 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:bottom;width:90%;background:#cceeff;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#STATEMENTOFOPERATIONS_315083_1"><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Statement of Operations for the period from February&#160;5, 2021 (Inception) through December&#160;31, 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:bottom;width:90%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#STATEMENTOFCHANGESINSHAREHOLDERSDET_1"><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Statement of Changes in Shareholders&#8217; Deficit for the period from February&#160;5, 2021 (Inception) through December&#160;31, 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:bottom;width:90%;background:#cceeff;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#STATEMENTOFCASHFLOWS_701301_1"><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Statement of Cash Flows for the period from February&#160;5, 2021 (Inception) through December&#160;31, 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:bottom;width:90%;margin:0pt;padding:3.5pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#NOTE1DESCRIPTIONOFORGAN_917745_1"><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Notes to Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:3.5pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="indextocombine"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">INDEX TO COMBINED FINANCIAL STATEMENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:90%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">OmniAb, Inc.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"></td></tr><tr><td style="vertical-align:bottom;width:90%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublic_2"><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Report of Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-21</p></td></tr><tr><td style="vertical-align:bottom;width:90%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#COMBINEDBALANCESHEETS_758984_2"><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Combined Balance Sheets as of December&#160;31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-22</p></td></tr><tr><td style="vertical-align:bottom;width:90%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#COMBINEDSTATEMENTSOFOPERATIONS_2"><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Combined Statements of Operations for the Years Ended December&#160;2021, 2020 and 2019</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-23</p></td></tr><tr><td style="vertical-align:bottom;width:90%;background:#cceeff;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#STATEMENTSOFCHANGES_831092_2"><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Combined Statements of Changes in Parent Company Net Investment for the Years Ended December&#160;31, 2021, 2020 and 2019</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-24</p></td></tr><tr><td style="vertical-align:bottom;width:90%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#CASHFLOWS_855792_2"><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Combined Statements of Cash Flows for the Years Ended December&#160;31, 2021, 2020 and 2019</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-25</p></td></tr><tr><td style="vertical-align:bottom;width:90%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#a1OrganizationandNature_2"><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Notes to Combined Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-26</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_570246e3_df4c_4368_962b_f48d753bc484"></a><a id="REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.49;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">To the Shareholders and Board of Directors of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Avista Public Acquisition Corp. II</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We have audited the accompanying balance sheet of Avista Public Acquisition Corp. II (the &#8220;Company&#8221;) as of December 31, 2021, the related statements of operations, changes in shareholders&#8217; deficit and cash flows for the period from February 5, 2021 (inception) through December 31, 2021, and the related notes (collectively referred to as the &#8220;financial statements&#8221;).  In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021, and the results of its operations and its cash flows for the period from February 5, 2021 (inception) through December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Explanatory Paragraph &#8212; Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1 to the financial statements, the Company&#8217;s business plan is dependent on the completion of a business combination and the Company&#8217;s cash and working capital as of December 31, 2021 are not sufficient to complete its planned activities for a reasonable period of time, which is considered to be one year from the issuance date of the financial statements. These conditions raise substantial doubt about the Company&#39;s ability to continue as a going concern. Management&#39;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These financial statements are the responsibility of the Company&#39;s management. Our responsibility is to express an opinion on the Company&#39;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&quot;PCAOB&quot;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#39;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Marcum LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Marcum LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">We have served as the Company&#8217;s auditor since 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">New York, NY <br />March 25, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c415a581_4628_4c2b_9df3_eb55ba8dabb4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><a id="BALANCESHEET_585563_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">BALANCE SHEET</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DECEMBER 31, 2021</b></p><a id="_3c68b537_3aa2_4ee9_85d8_a5869547635c"></a><a id="Tc_hnS2Gs6qk0qHhftoukfiCQ_1_0"></a><a id="Tc__bFcO7v_206aGkJHZqACqw_2_0"></a><a id="Tc_J3Z-1arwZEmW4tXlxIy94Q_3_0"></a><a id="Tc_rf2soAADx0SLWc_iQLBHew_3_2"></a><a id="Tc_YhkyafKFtEOCiMJHPkSeXA_4_0"></a><a id="Tc_Y672aKmS5kSaDhr67tXE6w_5_0"></a><a id="Tc_iScGK2fkXEe6pGkyvGjYow_6_0"></a><a id="Tc_8Q8hTrOeSEO8J44REwKoaA_7_0"></a><a id="Tc_Hd1Lb3N-_EeTG_3-0LAppA_7_2"></a><a id="Tc_B8iY8zujf0WwXQFyRGGCww_9_0"></a><a id="Tc_eSD0aEZ4PE2Th52cc_DzbA_10_0"></a><a id="Tc_fi2EQ35k3k6y-tjNJFSlPQ_11_0"></a><a id="Tc_zQk_nAkwqUCkli_ux2b7ew_12_0"></a><a id="Tc_zpsCgwEEO0GDHf1l55_PYg_13_0"></a><a id="Tc_gXuqe_oQ2kmLg2dz03Kbxg_14_0"></a><a id="Tc_Rgv_vRO3PkKsjs4W_C6azg_15_0"></a><a id="Tc_qY3rWvJ6lEyZMEs2HkxGKg_16_0"></a><a id="Tc_R81BDJqkUEObWAYbNvYuuA_17_0"></a><a id="Tc_zqpZ6MfVTEOfcNkkqIVe3w_19_0"></a><a id="Tc_8gS09YYQs06valSAZxDjsw_20_0"></a><a id="Tc_zN8VIBwAk06785eJYWFzZg_22_0"></a><a id="Tc_g4IEofjN_EelFsPrV5aNqg_23_0"></a><a id="Tc_xgRLuFQU5EisGsJxNnx2wg_24_0"></a><a id="Tc__jyq6JQKwk2LspuqVBgVgQ_24_3"></a><a id="Tc_4v5mJqvtQEq0tzoF9u7LHw_25_0"></a><a id="Tc_N3SbQtklnU2ZdCzxv-lFJg_26_0"></a><a id="Tc_yil_pGn4JECm698SmJG33Q_26_3"></a><a id="Tc_AHT6kjRZp0GpR_J25NKuMw_27_0"></a><a id="Tc__Ro6Fjm21E2E1LAjnWwz6A_28_0"></a><a id="Tc_SRpuKMcjmk2RmQIn6JNXeQ_29_0"></a><a id="Tc_4AM4Pew190GN3nrjyqoeOg_29_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.1111145%;padding-left:0pt;padding-right:0pt;width:100.22%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_hfos66Cemk21vjICGTJvzw_3_3">189,971</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_RQC41xz_KEiJlJ2yWtGxjg_4_3">744,542</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_NYAsgvO_n0ewcwk7q-xAew_5_3">934,513</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash held in trust account</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldInTrustNoncurrent" scale="0" id="Tc_jjVnhHvVTEiRUgcO9JsFmg_6_3">235,750,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_pJcGUDgGSkyucZqcpoRapw_7_3">236,684,513</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND SHAREHOLDERS&#39; DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_1aK8L3pZrk2B5VaM5HOT1w_11_3">15,440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="ahpa:AccruedExpenseRelatedPartyCurrent" scale="0" id="Tc_y_wg8asb902aVl4DVWN8wQ_12_3">107,734</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accrued offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="ahpa:AccruedOfferingCostsAndExpensesCurrent" scale="0" id="Tc_5CAyrXb7REuIS7FtdONwyg_13_3">314,153</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Due to related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Tc_zjoXIU5jGEWc7sT12_OQzA_14_3">884</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_EnkSiqTqPka9uFc77371Hw_15_3">438,211</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred underwriting fee payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="ahpa:DeferredOfferingCostsNoncurrent" scale="0" id="Tc_fj33QL002E-HjhM1LMWvxQ_16_3">8,050,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_etURX6P5DkqQlTn0AM-RiA_17_3">8,488,211</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Commitments (see Note 6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Class A ordinary shares, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_ahpa_CommonClassaSubjectToRedemptionMember_q28zW_K4z0OVkxWsAfxczw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_N3-Z0UYRkE6FD6Tmw0AZkA">0.0001</ix:nonFraction> par value, subject to possible redemption; <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_ahpa_CommonClassaSubjectToRedemptionMember_q28zW_K4z0OVkxWsAfxczw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_WZbeqyVQK0aTQfpnJ05Jrg">23,000,000</ix:nonFraction> shares at redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_V8fdhb6ZlkCCv3orsHZn9w_20_3">235,750,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shareholders&#39; Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Preference shares, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_XaOraFcZQ0OceKzjEOSCqQ">0.0001</ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_LovODYejW0m7cj2pDTllDg">5,000,000</ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_Ckn7wyfk30esysRsOj9FlA">none</ix:nonFraction> issued and <span style="-sec-ix-hidden:Hidden_oIv_C0huWUWHJN148qo5_g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-kr0UHfvPkyTvSBDqmMFmA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Class&#160;A ordinary shares, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_f60OhzulvUWffRFATFN0QQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_IS9t-mhQhEqGhcDuoytEjQ">0.0001</ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_f60OhzulvUWffRFATFN0QQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr__7hpkfu0KUi3MGX_6cqO8g">500,000,000</ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_f60OhzulvUWffRFATFN0QQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_olPTrtCEr0GDDHMyy0X6TQ">no</ix:nonFraction> shares issued and <span style="-sec-ix-hidden:Hidden_k2BHUUvoXEmMVvAsYFPM8w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> (excluding <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_ahpa_CommonClassaSubjectToRedemptionMember_q28zW_K4z0OVkxWsAfxczw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_XzCnKKIjnkGB-2E4PCc8ng">23,000,000</ix:nonFraction> shares subject to possible redemption)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Class&#160;B ordinary shares, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_d-MCLzVTSEq6fRmxDkxJyw">0.0001</ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_JpquoZUhEka_lw5NDJZsRA">50,000,000</ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_PF_PErwWnE2Poh7XDfMrvw">5,750,000</ix:nonFraction> shares issued and <span style="-sec-ix-hidden:Hidden_5ZdjLnlv1ESof1_Jdhm7Sw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_KZBZWuvFuEW2ymXKGubLdw_25_3">575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_BGEKrGqmf0KjKK1MCfR5-A_27_3">7,554,273</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Shareholders&#39; Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Sq79z-Lz1EijTtXENU2pdA_28_3">7,553,698</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES AND SHAREHOLDERS&#39; DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_zqb8jlhSQk2phD7pG_bVBA_29_3">236,684,513</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_23996ba4_b8b4_4484_bae5_bbb29f6426da"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><a id="STATEMENTOFOPERATIONS_315083_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FOR THE PERIOD FROM FEBRUARY 5, 2021 (INCEPTION) THROUGH DECEMBER 31, 2021</b></p><a id="_67b8a6da_1fea_48e6_9f59_6e4ff13d6ba0"></a><a id="Tc_BjQDf1bctEmT5px8yn2CzQ_1_0"></a><a id="Tc_VNTkAl8t80Wbp8b00Ww7Tw_1_2"></a><a id="Tc_WdBp90gylUG1ayzDl8mR-g_2_0"></a><a id="Tc_9m0nfbTtAEq1Q9Y0shX11Q_2_2"></a><a id="Tc_J0FSA8hCB02eNzeFa0nICA_4_0"></a><a id="Tc_aQbx2C2x-0WcgmNbHv3RJA_5_0"></a><a id="Tc_jUm1EQ_-JUWDjIVjvGY1nQ_6_0"></a><a id="Tc_gnmd54aQ1kq31ftRJbftPA_7_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Formation and operating costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" id="Tc_XvMro7GRSkuUIBFfSYsNSw_1_3">516,442</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_yKavmBc9CkSMH2DDOrNxUA_2_3">516,442</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted weighted average shares <span style="-sec-ix-hidden:Hidden_u3BgSj_pgUiqduil4GUdSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, Class A ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_BAJyI1rEs0KNuNjowgn3Iw_4_3">9,857,143</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share, Class A ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_MflBZkpiEkecqXC1OaZ9GA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Wxv50j8TFkqVDN-lrtLYwA_5_3">0.03</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted weighted average shares <span style="-sec-ix-hidden:Hidden_fiOqIe0ry0GFxCNERUdq_A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, Class B ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_lvNYrvLuQkOHeMpGxI0CKQ_6_3">5,321,429</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share, Class B ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_t9z7UsG5i0modg64DdHMtg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_NHsgobGVDUCfLoo3xZKK3w_7_3">0.03</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_76ff8dfc_f5f8_45a9_9ff1_1c7fd0302cf4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><a id="STATEMENTOFCHANGESINSHAREHOLDERSDET_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT OF CHANGES IN SHAREHOLDERS&#8217; DEFICIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FOR THE PERIOD FROM FEBRUARY 5, 2021 (INCEPTION) THROUGH DECEMBER 31, 2021</b></p><a id="_8a49166c_8d21_4757_a95b_7501d61ad02d"></a><a id="Tc_fae3GXRYeUKuX0EjVOyWRQ_1_12"></a><a id="Tc_vRs4pexSr0OK6zBTp6lpVw_1_18"></a><a id="Tc_8HgoflntCUiH6wsbIlMP3A_2_2"></a><a id="Tc_Cl6IJwFPHEa14-C9Z3CSMw_2_7"></a><a id="Tc_n_nbwvCZdUCRtLaYBOMpzQ_2_12"></a><a id="Tc_uCw6UZYFrEqDIceU_nPUww_2_15"></a><a id="Tc_jz12OMfZG0i_-CosSZxEyw_2_18"></a><a id="Tc_oN6Rn0qiakON7FbnoT9DAA_3_2"></a><a id="Tc_1kzH8WxCGESHcaNemFq16A_3_4"></a><a id="Tc_ZpD0klWGZE6j3a7fJ7XBhw_3_7"></a><a id="Tc_ergwEtb2UUuNqc_ZAT1b8A_3_9"></a><a id="Tc_9iudAZwf3E62DcpKZ0aYHw_3_12"></a><a id="Tc_deyt65xRxEimnyIHLmgU0g_3_15"></a><a id="Tc_XlZwBSoX2k21H8IBWKc2jQ_3_18"></a><a id="Tc_HyFDs2z16kS7BkQERyrUoA_4_0"></a><a id="Tc_YA-v-AmzDUWU7vzY54AMQA_4_4"></a><a id="Tc_Lq6v5kKnh0ekKtkWzq6cjA_4_9"></a><a id="Tc_U-DUjrz12Ei9d6ZCY-3jVA_4_12"></a><a id="Tc_6uMAAAKRak-JdqJb9_bEqQ_4_15"></a><a id="Tc_68Q847p6m06-cka2yHe0dQ_4_18"></a><a id="Tc_5B6ET3Ltak2RIRMpgLGeuA_5_0"></a><a id="Tc_NO0ojuC6wUCgd9oeHpzLuQ_5_2"></a><a id="Tc_2RgRgddW60m4v1srTb_OBA_5_5"></a><a id="Tc_JKzVP6Du80SormNg19-Kag_5_16"></a><a id="Tc_GW3hIF03e0aCuZwJxBoMNg_6_0"></a><a id="Tc_J20y_u_jpEmGm9TEsSd4Mg_6_2"></a><a id="Tc_VgR2ihS5_E-Ys6pHVC5EQw_6_5"></a><a id="Tc_rItIkLZ92UeFrpjqI727VA_6_7"></a><a id="Tc_xEuCIx7ruEC-qlLlJwXgwA_6_10"></a><a id="Tc_YAL8IUPGsEGrw5faws2dvQ_6_16"></a><a id="Tc_8H42MqDvU0Wcawh6PvG_FA_7_0"></a><a id="Tc_4UPFc7SSDUOaRVnzz9zl4w_7_2"></a><a id="Tc_L_icaJi3H0Ok6nd6zXpLRA_7_5"></a><a id="Tc_lAVy57WuRkGWCoJ21L1SFQ_7_7"></a><a id="Tc_W7YjS5LXr0qwKJEpfDU_Vw_7_10"></a><a id="Tc_5UMo6TX6V0OwCAlhEPOHgA_7_16"></a><a id="Tc_jSuQ-Dnq00yqUHLcihZ1dg_8_0"></a><a id="Tc_Y2TxcYGTlUqovW1cIKjmZQ_8_2"></a><a id="Tc_nZzqrbtir06P4e0M3g4vEQ_8_5"></a><a id="Tc_CL6gHp1KLkOhDZJ63qFFEw_8_7"></a><a id="Tc_MgiXQhkOi0eYvj1dqVhS6Q_8_10"></a><a id="Tc_FXZ1BUIVZ0S29kPRymOjZw_9_0"></a><a id="Tc_lm9cb3MdZEyczLjpan-jAA_9_2"></a><a id="Tc_hXCyvdAi7EG11p5Tfo-m-Q_9_5"></a><a id="Tc_9iDryRJ8hU-BwVjTowD3jA_9_7"></a><a id="Tc_lHQrpScmrESsTkiY8Sk5Ug_9_10"></a><a id="Tc_ItnFOSHvf02K_qr60sBh3w_9_13"></a><a id="Tc__PM1tCfdzESGZ9eHCIxE1g_10_0"></a><a id="Tc_Wu0C-Caky0-1CHjOO3dKnw_10_2"></a><a id="Tc_KkNMJbzEbUacL2UQDMedSw_10_4"></a><a id="Tc_UgNb-N_6gUOE70zuviU6Yw_10_5"></a><a id="Tc_ynmmU4m6tU6PBoTYxzQ-IA_10_9"></a><a id="Tc_h42VWtnRoEmXeFBgMp9lqQ_10_12"></a><a id="Tc_89lm1VQpJkKB90UwwwnPbg_10_13"></a><a id="Tc_klXQz-KFPUqEBMcfSg9ubg_10_15"></a><a id="Tc_noNzUIH2WkCcMfO-7l3ckQ_10_18"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class&#160;A&#160;Ordinary Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class&#160;B&#160;Ordinary Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shareholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;at February 5, 2021 (inception)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_2_4_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0VgzW0WvDkOhioKaphSgNQ" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="0" id="Tc_ZtMDLyTMFU-dA8XI7DUcHg_4_2">&#8212;</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_2_4_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0VgzW0WvDkOhioKaphSgNQ" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_cugU9C2hw0Sag3ELzDrmkg_4_5">&#8212;</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_2_4_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Vb1595K4sEa1hL_hS2lBeg" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="0" id="Tc_CbVlxr62bUaj6OIXHo_6-g_4_7">&#8212;</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_2_4_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Vb1595K4sEa1hL_hS2lBeg" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_jYg7SBTa7E6BqdQePNdYqw_4_10">&#8212;</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_2_4_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gzEnwWnnx0WQYPJuULNY5A" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Wfr2yVS9ck-ZlK39diQIzQ_4_13">&#8212;</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_2_4_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jvgeKlnW-kGyt5FS8JRf2A" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_jxMaer8x0UStqGA-XuMABQ_4_16">&#8212;</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_2_4_2021_uo51c5vY7EuzHPYD_Z34hQ" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="Tc_cq8r4Canc0e9ZfY5bqpn4Q_4_19">&#8212;</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:34.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of Class B ordinary shares to Sponsor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjNLK8smFEu-lbgIoNFmJw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_6aAyHbbYvkyjrSkqNanHDA_5_7">5,750,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjNLK8smFEu-lbgIoNFmJw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_ofc_RzX8LEakO3udWxKTgg_5_10">575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dKlB8yMYB0aeqkHBv0dRPQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc__hgyC_V1QEylHpmEn6TXog_5_13">24,425</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_N95ZNJtkckSt2acNkbpZ6g_5_19">25,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from Initial Public Offering Costs allocated to Public Warrants (net of offering costs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_d_YB9RSCPEWKNnaWk0ubPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_JK83tBQ6WkePqK1V80DQLQ_6_13">9,232,604</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_HgSeUv3N6UGsnBDKOVV0aw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_lwUDDyByRE2kbpFxWO_jew_6_19">9,232,604</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from sale of Private Placement Warrants to the Sponsor (net of offering costs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5VcjzJoENE6qKN-GsE0NqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_ts3xkiutt0KN52_xV-TnIA_7_13">12,298,375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_6B_tQIqoTEmTyAmFq9B9mg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_9sprgmIcvkiKDQJThEMPbw_7_19">12,298,375</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Re-measurement of Class A ordinary shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dKlB8yMYB0aeqkHBv0dRPQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_MTNfNYNcQ0W8eq4Ovl5Hjw_8_13">21,555,404</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RWEafoin-kCFfO1au4EhYA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_ExB167yezUSnUC-GCfEtvw_8_16">7,037,831</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_dzrn-SvDX06D3z8kdpLuiA_8_19">28,593,235</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:34.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RWEafoin-kCFfO1au4EhYA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_cg0PhIpdo0KU-T5q1rly0A_9_16">516,442</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_-mQ7-ijHtECi69t3aC6Reg_9_19">516,442</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:34.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WhjEOWhW9Eij5ZolTKJnCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_tuo8jx26X0KtelrUUKCEgQ_10_7">5,750,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WhjEOWhW9Eij5ZolTKJnCw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_SyiDBMLSJUODr03Rg0HHcQ_10_10">575</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MNywhu2wKk6Z09hRF-PfiQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_XUIVUDdYW0GG3-nCIFID9Q_10_16">7,554,273</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_lHCChnZOuke_wbItnNNT3w_10_19">7,553,698</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bf9a4606_5dcf_4bda_a5c1_943432434fb3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><a id="STATEMENTOFCASHFLOWS_701301_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT OF CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FOR THE PERIOD FROM FEBRUARY 5, 2021 (INCEPTION) THROUGH DECEMBER 31, 2021</b></p><a id="_065ce1a5_62e3_42f9_a2d1_d9064e5b5e97"></a><a id="Tc_dntAMPMTX0OjSUSCXMQH-w_1_0"></a><a id="Tc_yMpwCDR5N0mmbpWaKOVkUg_2_0"></a><a id="Tc_KhlrAtcDjE2T6Wp-6A0fHw_2_2"></a><a id="Tc_t5vyYXVKDUOcJmlPHpal-w_3_0"></a><a id="Tc_WQRPJN3mnkK1kNjCreh8ug_4_0"></a><a id="Tc_bqy6zmaTwkeGtUQUEqe5Bw_5_0"></a><a id="Tc_WEjaUs5ejEm9d2_bez1-bA_6_0"></a><a id="Tc_JnZLNmdld0S-8-BSEgLWvQ_7_0"></a><a id="Tc_u5DoCXlsEU-ik0de6oUkvg_8_0"></a><a id="Tc_5Kfjcfw380SgrVTad5nN6w_10_0"></a><a id="Tc_uqcjBrWfmU-iDWuMTwsOZQ_11_0"></a><a id="Tc_OWCZ-NjoxU-2aEPLqy_gqQ_12_0"></a><a id="Tc__0I371tU-EeuZ12onUQy-Q_14_0"></a><a id="Tc_m8UlAEIaYUqN1rN4961kAA_15_0"></a><a id="Tc_3ApCnp-Pr0K3_wz1TveCoA_16_0"></a><a id="Tc_XSr57rfbP0Wa8PMiUaPmFA_17_0"></a><a id="Tc_ism5j7qBb0-Wi7NPo3RHzg_18_0"></a><a id="Tc_1-rwH3234USLyMtfmYOtGA_19_0"></a><a id="Tc_qXszNaBKrk2VP9MCBZXJEg_20_0"></a><a id="Tc_apHEkcF5SkCQnyhyjeMFwQ_21_0"></a><a id="Tc_AsI3s-qpXUysQoAH3mFgGQ_23_0"></a><a id="Tc_CmF0zizXeEWf_k517YXtBg_24_0"></a><a id="Tc_RRTP_DlbTUyJhWAdiN61hA_24_3"></a><a id="Tc_bF78eky0Fke4RA6mkaYqRw_25_0"></a><a id="Tc_M0W8OQ8SskWg4hgbozcHqA_25_2"></a><a id="Tc_ZhAKipY0EEGDVqXYstv9-A_27_0"></a><a id="Tc_TWsUWZExpECtxVxDJbl-tw_28_0"></a><a id="Tc_oF5mSqlGb0eMuHhldiH6vg_28_2"></a><a id="Tc_fcduDKDpOk224wzz-KVgGw_29_0"></a><a id="Tc_VyEDYI36_UKtQVQuYMUqYw_29_2"></a><a id="Tc_DxvwXlbSw0a1uE2OI1Bsjg_30_0"></a><a id="Tc_b7WGld54U0u04AlspSRwkQ_30_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Flows from Operating Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="Tc_irXY-IgZLkWfx0xVT46h2Q_2_3">516,442</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" id="Tc_jb5f_1DQq0C7JF7Y32dQeA_4_3">744,542</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="0" id="Tc_G5BfcQSgsk6eEGEGGd-AXw_5_3">15,440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Due to related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" scale="0" id="Tc_muwyKxFxiUamYOMPLr6YGw_6_3">884</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="ahpa:IncreaseDecreaseInAccruedLiabilitiesRelatedParties" scale="0" id="Tc_8pVJWAmVUkGP-qs9mvBSGQ_7_3">107,734</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 12pt;"><b style="font-weight:bold;">Net cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_Fj736qVeckqRhhuKQBsqIQ_8_3">1,136,926</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;"><span style="font-weight:bold;margin-bottom:0pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Flows from Investing Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Investment of cash into Trust Account</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="ahpa:PaymentsForInvestmentOfCashInTrustAccount" scale="0" id="Tc_Cx88RoX3OEGWtXs15VbmYQ_11_3">235,750,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 12pt;"><b style="font-weight:bold;">Net cash used in investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_EjP-KmLPZE6WCdSfWVH0cA_12_3">235,750,000</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Flows from Financing Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of Class B ordinary shares to Sponsor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_JprRMnGXnESGzktryMzDIg_15_3">25,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Proceeds from initial public offering, net of underwriter&#39;s discount paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="ahpa:ProceedsFromIssuanceInitialPublicOfferingNet" scale="0" id="Tc_H6j-xrU2xUC2GCezjb_cdQ_16_3">225,400,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Proceeds from sale of Private Placement Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" id="Tc_lwY2if9SgEWUrqXYz_hAYQ_17_3">12,350,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Proceeds from Sponsor note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" id="Tc_g2-Z4zCIbk60S_r-ECSRbQ_18_3">175,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Repayment of Sponsor note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="ahpa:Repaymentfromrelatedpartydebt" scale="0" id="Tc_GzsXh6aLEEGvzIMbmmVKxg_19_3">175,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Payment of offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Tc_Itm_aHC520uuTI7X7nxesQ_20_3">698,103</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;"><b style="font-weight:bold;">Net cash provided by financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_C64tm9ZuCUuU1PeaYrCBrg_21_3">237,076,897</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net change in cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" id="Tc_tKoNW7SlxkCHc6WRnAAN9w_23_3">189,971</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Cash &#8211; beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash &#8211; end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_R4gW6Mf_sUWrNMQa4qES3Q_25_3">189,971</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"> <span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-cash investing and financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Re-measurement of Class A ordinary shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="ahpa:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" scale="0" id="Tc_DblCcpW0Xk-ol5MKU3e79w_28_3">28,593,235</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Offering costs included in accrued offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="ahpa:OfferingCostsIncludedInAccountsPayableAccruedExpenses" scale="0" id="Tc_zTfG-hzV_EyyA4ysark_IQ_29_3">314,153</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Deferred underwriting fee payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="ahpa:DeferredUnderwritingFeePayable" scale="0" id="Tc_LZEflZxx-kyPQ_oUInN1MQ_30_3">8,050,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_300573"></a><a id="NOTE1DESCRIPTIONOFORGAN_917745_1"></a><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="us-gaap:NatureOfOperations" id="Tb_uMgxTMwWwUmRJD_2TtNjkw" continuedAt="Tb_uMgxTMwWwUmRJD_2TtNjkw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</b><b style="font-weight:bold;"> AND LIQUIDITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Avista Public Acquisition Corp. II (the &#8220;Company&#8221;) is a blank check company incorporated in the Cayman Islands on February 5, 2021. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with <ix:nonFraction unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="INF" format="ixt-sec:numwordsen" name="ahpa:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" scale="0" id="Narr_LG5K14ZWb0y45uoIMJ1tfQ">one</ix:nonFraction> or more businesses (a &#8220;Business Combination&#8221;). The Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2021, the Company had not commenced any operations. All activity for the period from February 5, 2021 (inception) through December&#160;31,&#160;2021 relates to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;), which is described below. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on August 9, 2021. On August 12, 2021, the company consummated the Initial Public Offering of <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_hccbOwsxJ0e0grYvrrxaLw" decimals="INF" format="ixt:numdotdecimal" name="ahpa:UnitsIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Wu_rnwuYpEmLzCMGR24sZw">23,000,000</ix:nonFraction> units (the &#8220;Units&#8221; and, with respect to the Class&#160;A ordinary shares included in the Units sold, the &#8220;Public Shares&#8221;), including <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_fKXwqT0SFUG_rtKtuXVz1Q" decimals="INF" format="ixt:numdotdecimal" name="ahpa:UnitsIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_OoQjYKtW3kCedv51GTXcoA">3,000,000</ix:nonFraction> Units that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_8_12_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_R55Po8B-UkKx2FU_T9LA_Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_W8_JOq5_u0qn6fC_q31peQ">10.00</ix:nonFraction> per Unit, generating gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_hccbOwsxJ0e0grYvrrxaLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" id="Narr_r_BQwnuDQU-N--yK1lyRmQ">230,000,000</ix:nonFraction> (see Note&#160;3).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mz3wLjizUUqg_78s5L5T6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_0K3QK9hmeECIZ_D13eZ_8w">8,233,333</ix:nonFraction> warrants (the &#8220;Private Placement Warrants&#8221;), including <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_RHrFxFO2K0qVPKUowtOemA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_wJd_vhlcwU2YZx8AaMlgaA">900,000</ix:nonFraction> Private Placement Warrants that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mz3wLjizUUqg_78s5L5T6g" decimals="2" format="ixt:numdotdecimal" name="ahpa:ClassOfWarrantOrRightPriceOfWarrantsOrRights" scale="0" id="Narr_jLKb5pU6YkKuqEGyIVY6Dw">1.50</ix:nonFraction> per Private Placement Warrant in a private placement to Avista Acquisition LP II (the &#8220;Sponsor&#8221;), generating gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mvqSYAOLZUql2PhYI0lRvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" id="Narr_MR76zzA3tkWBJkuffilTcQ">12,350,000</ix:nonFraction> (see Note&#160;4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transaction costs amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="ahpa:TransactionCosts" scale="0" id="Narr_G08Nb1ixOUq8tN174FbQig">13,662,256</ix:nonFraction> consisting of $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="ahpa:SaleOfStockUnderwritingFees" scale="0" id="Narr_21o1LOLHHE-iY_9kZUpi3Q">4,600,000</ix:nonFraction> of underwriting fees, $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="ahpa:DeferredOfferingCostsNoncurrent" scale="0" id="Narr_xgbjvs38zEaygq4cp6afZQ">8,050,000</ix:nonFraction> of deferred underwriting fees, and $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="ahpa:SaleOfStockOtherOfferingCosts" scale="0" id="Narr_uG34oKy3FUiolgorfZW7Lg">1,012,256</ix:nonFraction> of other offering costs. In addition, as of December 31, 2021, cash of $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Narr_tFnPisYWGUSyeq5mUkWZ7g">189,971</ix:nonFraction> is held outside of the Trust Account (as defined below) and is available for the payment of accrued offering costs and for working capital purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon closing of the Initial Public Offering and the sale of the Private Placement Warrants, a total of $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Gi4yVR_tj0CKg7dgp66JvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="0" id="Narr_KSN1_gIPkkyS4mE-6F9MyQ">235,750,000</ix:nonFraction> ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k3wFYri590eu2YfxnM5VTw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_cGlkmfPm_kGxTODgvZ1xxg">10.25</ix:nonFraction> per Public Share) was placed in a trust account (the &#8220;Trust Account&#8221;) and will be invested only in U.S. government treasury obligations with maturities of <ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" format="ixt-sec:durwordsen" name="ahpa:InvestmentsMaximumMaturityTerm" id="Narr_gkIWx7DYn06HR7noZL_0Pw">185 days</ix:nonNumeric> or less or in money market funds meeting certain conditions under Rule&#160;2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of: (i)&#160;the consummation of the initial Business Combination within <ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" format="ixt-sec:durwordsen" name="ahpa:MonthsToCompleteInitialBusinessCombination" id="Narr__J-ATPSHG0-eLgaEFkIxHA">18 months</ix:nonNumeric> from the closing of the Initial Public&#160;Offering, (ii) the redemption of the Company&#8217;s Public Shares if the Company has not consummated an Business Combination within <ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" format="ixt-sec:durwordsen" name="ahpa:MonthsToCompleteInitialBusinessCombination" id="Narr_5fkjJ9oCV0ajEwRaH8mLrw">18 months</ix:nonNumeric> from the closing of the Company&#8217;s Initial Public Offering, subject to applicable law, and (iii) the redemption of the Company&#8217;s Public Shares properly submitted in connection with a shareholder vote to approve an amendment to the Amended and Restated Memorandum and Articles of Association (A) that would modify the substance or timing of the obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem <ix:nonFraction unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="INF" format="ixt:numdotdecimal" name="ahpa:PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" scale="-2" id="Narr_wsXsSyh6YkOcQ9kHWIfwVg">100</ix:nonFraction>% of the Company&#8217;s Public Shares if the Company does not complete the initial Business Combination within <ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" format="ixt-sec:durwordsen" name="ahpa:MonthsToCompleteInitialBusinessCombination" id="Narr_8ppjIBpaEESEJ0-ThCj4Zg">18 months</ix:nonNumeric> from the closing the Company&#8217;s Initial Public Offering or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will provide its holders of the outstanding Public Shares (the &#8220;public shareholders&#8221;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a shareholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_waiTR7W3qUWXhKuLp-042Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_nCZsdcED1k-tkWZQiGuYgQ">10.25</ix:nonFraction> per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants. The Public Shares subject to redemption was recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480, <i style="font-style:italic;">Distinguishing Liabilities from Equity </i>(&#8220;ASC 480&#8221;)<i style="font-style:italic;">.</i></p></ix:nonNumeric></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_uMgxTMwWwUmRJD_2TtNjkw_cont1" continuedAt="Tb_uMgxTMwWwUmRJD_2TtNjkw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_waiTR7W3qUWXhKuLp-042Q" decimals="0" format="ixt:numdotdecimal" name="ahpa:MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" scale="0" id="Narr__Mf2vZ3KnEOkJbAtdp6K5A">5,000,001</ix:nonFraction> either prior to or upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association (the &#8220;Amended and Restated Memorandum and Articles of Association&#8221;), conduct the redemptions pursuant to the tender offer rules&#160;of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required by law, or the Company decides to obtain shareholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules&#160;and not pursuant to the tender offer rules. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note&#160;5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each public shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or don&#8217;t vote at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the above, if the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Amended and Restated Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more than an aggregate of <ix:nonFraction unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="2" format="ixt:numdotdecimal" name="ahpa:ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" scale="-2" id="Narr_skRnBtB2NkOECUPyKWjUpA">15</ix:nonFraction>% or more of the Public Shares, without the prior consent of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor has agreed to waive (i) redemption rights with respect to its Founder Shares and Public Shares held by it in connection with the completion of a Business Combination, (ii)&#160;redemption rights with respect to any Founder Shares and Public Shares held by it in connection with a shareholder vote to amend the Amended and Restated Memorandum and Articles of Association to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with an initial Business Combination or to redeem <ix:nonFraction unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tf5u2Z2hjkKPDF_uv_Xeig" decimals="INF" format="ixt:numdotdecimal" name="ahpa:PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" scale="-2" id="Narr_cEocf_RyB0m87xPdUd1JCA">100</ix:nonFraction>% of its Public Shares if the Company does not complete an initial Business Combination within <ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tf5u2Z2hjkKPDF_uv_Xeig" format="ixt-sec:durwordsen" name="ahpa:MonthsToCompleteInitialBusinessCombination" id="Narr_8vdQIdJwUkaHYeT54uk1zg">18 months</ix:nonNumeric> from the closing of the Initial Public Offering or with respect to any other material provision relating to shareholders&#8217; rights or pre-initial Business Combination activity and (iii) rights to liquidating distributions from the Trust Account with respect to any Founder Shares held if the Company fails to complete an initial Business Combination within <ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tf5u2Z2hjkKPDF_uv_Xeig" format="ixt-sec:durwordsen" name="ahpa:MonthsToCompleteInitialBusinessCombination" id="Narr_dgCk6upRBkGhFnx0P__QCA">18 months</ix:nonNumeric> from the closing of the Initial Public Offering. However, if the Sponsor acquires Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within <ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tf5u2Z2hjkKPDF_uv_Xeig" format="ixt-sec:durwordsen" name="ahpa:MonthsToCompleteInitialBusinessCombination" id="Narr_N_jGlSzrIEuS2NamigPOEw">18 months</ix:nonNumeric> from the closing of the Initial Public Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has until <ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tf5u2Z2hjkKPDF_uv_Xeig" format="ixt-sec:durwordsen" name="ahpa:MonthsToCompleteInitialBusinessCombination" id="Narr_NDbyLU47qkOO35_I9uuSGw">18 months</ix:nonNumeric> from the closing of the Initial Public Offering to complete a Business Combination (the &#8220;Combination Period&#8221;). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up; (ii)&#160;as promptly as reasonably possible but no more than <span style="-sec-ix-hidden:Hidden_MH-1shE-7UuVsRr2IwZGhQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> business&#160;days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay income taxes, if any (less up to $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="ahpa:MaximumNetInterestToPayDissolutionExpenses" scale="0" id="Narr_2qYAnzb52kGTYA-YZRH5kg">100,000</ix:nonFraction> of interest to pay dissolution expenses) divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish public shareholders&#8217; rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining shareholders and board of directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#8217;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note&#160;6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_waiTR7W3qUWXhKuLp-042Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr__zvB-qia2kSPkXg4E80Bgw">10.00</ix:nonFraction>).</p></ix:continuation></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_uMgxTMwWwUmRJD_2TtNjkw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Indemnity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company (other than the Company&#8217;s independent registered public accounting firm), or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i)&#160;$<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_waiTR7W3qUWXhKuLp-042Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_oY6P_zak6EuM289XvjQJNg">10.25</ix:nonFraction> per Public Share and (ii)&#160;the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_waiTR7W3qUWXhKuLp-042Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_xPytZVRvfEKnVpeCWZvO8g">10.25</ix:nonFraction> per Public Share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay tax obligations, provided that such liability will not apply to any claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Narr_gU9NUmsGJE2NUa0ugBdfkA">189,971</ix:nonFraction> in cash held outside of the Trust Account and a working capital surplus of $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="ahpa:WorkingCapitalSurplus" scale="0" id="Narr_wjM5q3sH-kqOgtdhzjw3SA">496,302</ix:nonFraction>. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. Moreover, the Company may need to obtain additional financing either to complete a Business Combination or if the Company becomes obligated to redeem a significant number of public shares upon completion of a Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination. Of the total proceeds from the Initial Public Offering and sale of the Private Placement Warrants, an amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="-6" format="ixt:numdotdecimal" name="ahpa:ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" scale="6" id="Narr_qryYtUIV-ECKgXxzI-NbJQ">2</ix:nonFraction><span style="white-space:pre-wrap;"> million was deposited in an operating account for the Company&#8217;s working capital needs. The amounts held in the operating account are not  expected to provide the Company with sufficient funds to meet its operational and liquidity obligations over the next twelve months.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Going Concern Consideration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Narr_lZ03agFI302Q5Uf0-6GTpg">189,971</ix:nonFraction> in cash held outside of the Trust Account and a working capital surplus of $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="ahpa:WorkingCapitalSurplus" scale="0" id="Narr_NRRauEasaESXIQxxwgP_ew">496,302</ix:nonFraction>. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company ability to continue as a going concern for a period of time within one year after the date that the financial statements are issued. Management plans to address this uncertainty through the Business Combination as discussed above. There is no assurance that the Company&#8217;s plans to consummate the Business Combination will be successful or successful within the Combination Period. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s financial position, results of its operations, and/or search for a prospective partner company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_Zl7r0ucpHkmVzRL9xd7xww" continuedAt="Tb_Zl7r0ucpHkmVzRL9xd7xww_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_UsngzD_rtU6Yi7K60yvM0Q" continuedAt="Tb_UsngzD_rtU6Yi7K60yvM0Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Zl7r0ucpHkmVzRL9xd7xww_cont1" continuedAt="Tb_Zl7r0ucpHkmVzRL9xd7xww_cont2"><ix:continuation id="Tb_UsngzD_rtU6Yi7K60yvM0Q_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="ahpa:EmergingGrowthCompanyPolicyTextBlock" id="Tb_vnCTVmp4fEqq23PB7n_53g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section&#160;102(b)(1)&#160;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="us-gaap:UseOfEstimates" id="Tb__3-ZSaM8ekCdPITj_jUskA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_sP2WtZ4v7kmri_hsNVaENQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2021.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="ahpa:CommonStockSubjectToPossibleRedemptionPolicyTextBlock" id="Tb_DX85C11gRkWbduYm5XUO7w" continuedAt="Tb_DX85C11gRkWbduYm5XUO7w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class A Ordinary Shares Subject to Possible Redemption</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of the <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_92SC9DBWKUyqMSwExfbIdQ" decimals="INF" format="ixt:numdotdecimal" name="ahpa:UnitsIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_m0bDokW0VE2HE4_V2K-1Tg">23,000,000</ix:nonFraction> shares of Class A ordinary shares sold as part of the Units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company&#8217;s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company&#8217;s amended and restated certificate of incorporation. In accordance with SEC and its staff&#8217;s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class A ordinary shares have been classified outside of permanent equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional paid-in capital and accumulated deficit.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_3jN-LkVTJkSYXknTcDhIPQ_1_0"></a><a id="Tc_Vqj_Bg1xfE6uXh3oTVoY7Q_1_2"></a><a id="Tc_SjtBH6VuikSPMtk8EISa_g_2_0"></a><a id="Tc_kltrLBjdX0-dfyM59yLtng_3_0"></a><a id="Tc_L4n6aslb40G37UaySUbH1g_4_0"></a><a id="Tc_wWyGK8N7o0G-4IrdqKnjCQ_5_0"></a><a id="Tc_2UNp_yz2skyHYW1JPmMAIQ_6_0"></a><a id="Tc_oIzWr2izx02HqR9gmrj5hw_7_0"></a><a id="Tc_ZFv3H2RQA0avAHYlFjRCjA_7_2"></a><ix:continuation id="Tb_Zl7r0ucpHkmVzRL9xd7xww_cont2" continuedAt="Tb_Zl7r0ucpHkmVzRL9xd7xww_cont3"><ix:continuation id="Tb_DX85C11gRkWbduYm5XUO7w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">As of December 31, 2021, the Class A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table:</p><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="us-gaap:TemporaryEquityTableTextBlock" id="Tb_0vtrPU72xku59ZpGbmkutw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Gross proceeds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="0" id="Tc_O9B8lPYtW06gF4x84BfA2w_1_3">230,000,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Proceeds allocated to Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="ahpa:TemporaryEquityProceedsAllocatedToWarrants" sign="-" scale="0" id="Tc_BbAz6kXdNkGlhGfasHEBog_3_3">9,813,334</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Issuance costs allocated to Class A ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="ahpa:TemporaryEquityIssuanceCosts" sign="-" scale="0" id="Tc_770iXVUbj0ClGe6zNSDf4w_4_3">13,029,901</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Plus:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Accretion of carrying value to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_gXNzBZ1tmE6aCdqW5_VuGg_6_3">28,593,235</ix:nonFraction></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A ordinary shares subject to possible redemption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_Q4YAyOUINkmx9uN_-3Gj-w_7_3">235,750,000</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="us-gaap:DeferredChargesPolicyTextBlock" id="Tb_sxe0cMuVgEmJiPD24wFUKw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Offering Costs associated with the Initial Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company complies with the requirements of ASC 340-10-S99-1 and SEC Staff Accounting Bulletin Topic 5A - <i style="font-style:italic;">Expenses of Offering</i>. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="ahpa:TransactionCosts" scale="0" id="Narr_sYasLXKgS0qICqQehy5h0g">13,662,256</ix:nonFraction> as a result of the Initial Public Offering (consisting of $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="ahpa:SaleOfStockUnderwritingFees" scale="0" id="Narr_6evRhFwRWkmmGIYxEIh2tQ">4,600,000</ix:nonFraction> of cash underwriting discounts, $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="ahpa:DeferredOfferingCostsNoncurrent" scale="0" id="Narr_AAF1TbcqAkmA7KpM8kkz2A">8,050,000</ix:nonFraction> in deferred underwriting fees and $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="ahpa:SaleOfStockOtherOfferingCosts" scale="0" id="Narr_dyAVekKGSkCjyz9od6KChQ">1,012,256</ix:nonFraction> of other offering costs). As such, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="ahpa:OfferingCostsReductionOfTemporaryEquity" scale="0" id="Narr_lN4_MWace02gGwUCI3f2Ug">13,029,901</ix:nonFraction> of offering costs as a reduction of temporary equity and $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Narr_j72B93bPtUK6R4SN3yRcrg">632,355</ix:nonFraction> of offering costs as a reduction of permanent equity in connection with the issuance of the Units in the Initial Public Offering and the Private Placement Warrants.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_DvugoViq_UysPSJwyBSnsw" continuedAt="Tb_DvugoViq_UysPSJwyBSnsw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under ASC 740, <i style="font-style:italic;">Income Taxes</i> (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statements recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. Based on the Company&#8217;s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company&#8217;s financial statements. Since the Company was incorporated on February 5, 2021, the evaluation was performed for the 2021 tax year which will be the only period subject to examination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_P9gwm0E0YEG_dxREKLemSg">no</ix:nonFraction> unrecognized tax benefits and <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" id="Narr_ECvrXwTxlE6_w8tEGfIjZg">no</ix:nonFraction> amounts accrued for interest and penalties as of December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is considered an exempted Cayman Islands Company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. Consequently, income taxes are not reflected in the Company&#8217;s financial statement.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_1LE9n6GxW06f3vx7fCYlbA_1_2"></a><a id="Tc_vRyj-BGRqUKRmrt9pum_RA_2_2"></a><a id="Tc_OSv4t-h_EkmtcuQL8RGf6w_3_2"></a><a id="Tc_NF5vOkcYqUmS_hX0wYJ01Q_4_2"></a><a id="Tc__NNuH3iQ9EWuVU26gWaPVQ_4_5"></a><a id="Tc_VWokvk5xeEyRFtOD80U0DQ_5_0"></a><a id="Tc_iaBMky23-USzg3oLP60vxw_6_0"></a><a id="Tc_dask56Hr4U6yaZDkw9x0lw_7_0"></a><a id="Tc_oDQZI7_zHkCVSPyveU1Ggw_7_2"></a><a id="Tc_MfnPtZufvkWySLXMsoANww_7_5"></a><a id="Tc_jp3dfe7Jsky3bal07FH5bQ_8_0"></a><a id="Tc_AKQaBusj4UiCwXqSdI3X1A_9_0"></a><a id="Tc_pAcWsTmxrUi8_Yf4cJr3qA_10_0"></a><ix:continuation id="Tb_Zl7r0ucpHkmVzRL9xd7xww_cont3" continuedAt="Tb_Zl7r0ucpHkmVzRL9xd7xww_cont4"><ix:continuation id="Tb_DvugoViq_UysPSJwyBSnsw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_3vwY8VX25EeA1fKa0r7OFA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss Per Ordinary Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_FMDt3RxfGEqzFwOF3AN7gg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_-puOhCAA8Ea1SbZEW9mPYg">15,900,000</ix:nonFraction> shares in the calculation of diluted income per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts):</p><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_279CO8URfUijB3nu2HTIVA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Period from February 5,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021 (inception) Through</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class B</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_YzAGv4SdZkuEJGaA0R1gIg_7_3">335,384</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_ytRdCFbcy0mzhA3fDZ7D6w_7_6">181,058</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 12pt;">Basic and diluted weighted average shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_lMvHgXViQkiyPBPCpyYjHg_9_3">9,857,143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_bDoMoa_nY0-4lSxqIT4vHg_9_6">5,321,429</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_6OA0VirRwEuN8iLMAj_gFA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_CLVkFsdT-Ums_wZ4OX5ykw_10_3">0.03</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__fz-Sh5S5EuPKCGy7i67kQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_hzXF0rUP20y1UMKhSCzKow_10_6">0.03</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_cP6F0SsNdk-23pF6250S7Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashFDICInsuredAmount" scale="0" id="Narr_yTLyPxOW4kSZrQ72jx2M5Q">250,000</ix:nonFraction>. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_65Mza2VFBEGxYMK8SPrTMw" continuedAt="Tb_65Mza2VFBEGxYMK8SPrTMw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company applies ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts reflected in the balance sheet for cash, deferred offering costs, accrued offering costs, promissory note &#8212; related party, and advance from anchor investor approximate fair value due to their short-term nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 1 &#8212; Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 2 &#8212; Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 3 &#8212; Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Zl7r0ucpHkmVzRL9xd7xww_cont4"><ix:continuation id="Tb_65Mza2VFBEGxYMK8SPrTMw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_-BfWiPs-bUSo5iJ4h-YYIQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if converted method for all convertible instruments. ASU 2020-06 is effective for the Company on January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company adopted ASU 2020-06 effective January 1, 2021 using the modified retrospective method of transition. The adoption of ASU 2020-06 did not have a material impact on the financial statements for the period from February 5, 2021 (inception) through December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="ahpa:InitialPublicOfferingTextBlock" id="Tb_icUv1krY606lVZGF0Y7URA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;3. INITIAL PUBLIC OFFERING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on August 9, 2021. On August 12, 2021, the Company completed its Initial Public Offering of <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_W782mJY-OkWY82NrBIIpRA" decimals="INF" format="ixt:numdotdecimal" name="ahpa:UnitsIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Kux2AAeR_U-_ahSh4rAKfQ">23,000,000</ix:nonFraction> Units, including <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_ph3NAIUSSEif_XtyWxclIw" decimals="0" format="ixt:numdotdecimal" name="ahpa:UnitsIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr__KCrj6N5wkCjZzN3DlYsyQ">3,000,000</ix:nonFraction> Units that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_8_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rQSd3ig2NUquGWKI1v8ycg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_zpdTi1so3Ey0FM2fY5J5Pg">10.00</ix:nonFraction> per Unit, generating gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_W782mJY-OkWY82NrBIIpRA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" id="Narr_HhpvT09KIUuCaavTvRmkJA">230,000,000</ix:nonFraction>. Each Unit consists of <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_AvpvGzfBSk6euzkv_rNAng" decimals="INF" format="ixt-sec:numwordsen" name="ahpa:NumberOfSharesIssuedPerUnit" scale="0" id="Narr_jCZL0J2JWUqPaA4hWWJ_Xw">one</ix:nonFraction> Class A ordinary share and <span style="-sec-ix-hidden:Hidden_d8ssFNr6LUCa3paVl1JKtw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-third of one</span></span> redeemable warrant (&#8220;Public Warrant&#8221;). Each Public Warrant entitles the holder to purchase <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_8_12_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_hpwJzLOcDk2-xk82YwbYBA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_1W__zrDhi0CH-AGpFjMr1g">one</ix:nonFraction> Class A ordinary share at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_8_12_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_hpwJzLOcDk2-xk82YwbYBA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Pa3fjcrl9ESYKQNtEG0mng">11.50</ix:nonFraction>&#160;per whole share (see Note 7).</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="ahpa:PrivatePlacementTextBlock" id="Tb_rcFpbT1tG0OpoSSDf9QCJA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;4. PRIVATE PLACEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mz3wLjizUUqg_78s5L5T6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr__6INo3ImkU6zNHYlRe-FUA">8,233,333</ix:nonFraction> Private Placement Warrants, including <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_RHrFxFO2K0qVPKUowtOemA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_OLYIH6DHqEG69qkFnWfQvQ">900,000</ix:nonFraction> Private Placement Warrants that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mz3wLjizUUqg_78s5L5T6g" decimals="2" format="ixt:numdotdecimal" name="ahpa:ClassOfWarrantOrRightPriceOfWarrantsOrRights" scale="0" id="Narr_jl7CBV2ejESNUabV0pUTyQ">1.50</ix:nonFraction> per Private Placement Warrant ($<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mvqSYAOLZUql2PhYI0lRvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" id="Narr_aGAfoYPiokWzyJ45L1roWQ">12,350,000</ix:nonFraction> in the aggregate). Each Private Placement Warrant is exercisable to purchase <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mz3wLjizUUqg_78s5L5T6g" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_O-C-YJnJk0uPa0cXfaGm0Q">one</ix:nonFraction> Class A ordinary share at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mz3wLjizUUqg_78s5L5T6g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_3ky14D1jIEm7djMvo333Ug">11.50</ix:nonFraction> per share. The proceeds from the Private Placement Warrants were added to the net proceeds from the Initial Public Offering to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Placement Warrants.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_USKgkCNLbU6h1uk1OOWokA" continuedAt="Tb_USKgkCNLbU6h1uk1OOWokA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;5. RELATED PARTY TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Founder Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 12, 2021, the Sponsor paid an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_dPb1k23M_k-pLZXh6JaJbQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Narr_qW25s06B0UO3_Lw0_jA4Aw">25,000</ix:nonFraction> to cover certain expenses on behalf of the Company in exchange for the issuance of <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_dPb1k23M_k-pLZXh6JaJbQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_K4wcte2EIk6aKya3ArIHew">5,750,000</ix:nonFraction> Class B ordinary shares (the &#8220;Founder Shares&#8221;). The Founder Shares include an aggregate of up to <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_2_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_QkwL0AKjOUOWUMGK6d_M2w" decimals="INF" format="ixt:numdotdecimal" name="ahpa:NumberOfSharesSubjectToForfeiture" scale="0" id="Narr_QgRYFs0J2kiK4RYa5i5qJg">750,000</ix:nonFraction> Class B ordinary shares subject to forfeiture by the Sponsor to the extent that the underwriters&#8217; over-allotment option is not exercised in full or in part, so that the holders of the Founder Shares will own, on an as-converted basis, <ix:nonFraction unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A" contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_dPb1k23M_k-pLZXh6JaJbQ" decimals="2" format="ixt:numdotdecimal" name="ahpa:PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" scale="-2" id="Narr_TtxD3UIuVkqSQjJmcc5Vlg">20</ix:nonFraction>% of the Company&#8217;s issued and outstanding shares after the Initial Public Offering. On June 16, 2021, the Company transferred <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_6_16_2021_To_6_16_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember__BVIfHMD9Um_Bi-uIurswQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_UeA7xUquA0662FVy6Ytr5g">35,000</ix:nonFraction> Class B ordinary shares each to three members of the Company&#8217;s board of directors (or <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_6_16_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_A7q41aYgok-ecWpRe_1YvQ" decimals="INF" format="ixt:numdotdecimal" name="ahpa:NumberOfSharesSubjectToForfeiture" scale="0" id="Narr_YEGlT5Xwq0OEcGedLuPOzA">105,000</ix:nonFraction> Class B ordinary shares in total) at their original cost (see Note 7). The underwriters exercised their over-allotment option in full on August 12, 2021; thus, no ordinary shares remain subject to forfeiture (see Note 6).</p></ix:nonNumeric></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_USKgkCNLbU6h1uk1OOWokA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor has agreed that, subject to certain limited exceptions, the Founder Shares will not be transferred, assigned, or sold until the earlier of (i)&#160;<ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_07SLTebCGk63u2x-RfDH5A" format="ixt-sec:durwordsen" name="ahpa:ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" id="Narr_2qdwkq2Ysk2PypvCFNE-hw">one year</ix:nonNumeric>&#160;after the completion of a Business Combination or (ii) the date on which the Company completes a liquidation, merger, share exchange or other similar transaction after an initial Business Combination that results in all of the Company&#8217;s shareholders having the right to exchange their Class A ordinary shares for cash, securities or other property. Notwithstanding the foregoing, if (1) the closing price of the Company&#8217;s Class A ordinary shares equals or exceeds $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_07SLTebCGk63u2x-RfDH5A" decimals="2" format="ixt:numdotdecimal" name="ahpa:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" scale="0" id="Narr_haU8QwFmn0ijEWIF9gxfjw">12.00</ix:nonFraction> per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any <ix:nonFraction unitRef="Unit_Standard_D_LMsaCzRsOkeKQp06MQlfMw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_07SLTebCGk63u2x-RfDH5A" decimals="INF" format="ixt:numdotdecimal" name="ahpa:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" scale="0" id="Narr_g2X-aQeQL0OYcqpsZbCTgA">20</ix:nonFraction> trading days within any <ix:nonFraction unitRef="Unit_Standard_D_LMsaCzRsOkeKQp06MQlfMw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_07SLTebCGk63u2x-RfDH5A" decimals="INF" format="ixt:numdotdecimal" name="ahpa:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" scale="0" id="Narr_R3hqFGpzpUKsDHEPYCbILA">30</ix:nonFraction>- trading day period commencing at least <ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_07SLTebCGk63u2x-RfDH5A" format="ixt-sec:durwordsen" name="ahpa:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" id="Narr_aEo1S8xJ_0WMVmL3SRO41w">150 days</ix:nonNumeric> after an initial Business Combination or (2) if the Company consummates a transaction after an initial Business Combination which results in the Company&#8217;s shareholders having the right to exchange their shares for cash, securities or other property, the Founder Shares will be released from the lock-up.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Promissory Note&#160;&#8212; Related Party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 12, 2021, the Company issued an unsecured promissory note to the Sponsor (the &#8220;Promissory Note&#8221;), pursuant to which the Company could borrow up to an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_2_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_PromissoryNoteWithRelatedPartyMember_xyR3z7AzvE-9dwkUHu1Piw" decimals="0" format="ixt:numdotdecimal" name="ahpa:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" scale="0" id="Narr_y0RRFoiYWEKTYsRDEtgdvg">300,000</ix:nonFraction> to cover expenses related to the Initial Public Offering. The Promissory Note was non-interest bearing and was payable on the earlier of (i) December 31, 2021 or (ii) the consummation of the Initial Public Offering. The Company&#8217;s Sponsor paid certain offering costs totaling $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_3_22_2021_To_3_22_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_PromissoryNoteWithRelatedPartyMember_CZvATsM0cEaCcdmjZWpMlg" decimals="0" format="ixt:numdotdecimal" name="ahpa:OfferingCostsIncludedInPromissoryNoteRelatedParty" scale="0" id="Narr_HFZaMfl76kSRbYXi6wcIUg">55,725</ix:nonFraction>, which was included in the outstanding balance of the Promissory Note as of March 22, 2021, and the Company borrowed $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_6_23_2021_To_6_23_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_PromissoryNoteWithRelatedPartyMember_w_DAgECzBE2Z5NwzDLL4EA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" id="Narr_qhZErcudTUmGWDQ4NHtaWA">119,275</ix:nonFraction> on June 23, 2021. On August 12, 2021, the Company repaid the outstanding balance under the Promissory Note of $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_PromissoryNoteWithRelatedPartyMember_gpdKERCYWkCPAQ7cpRLRyQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" id="Narr_MxfQDddtckSKKjy4Ez_irA">175,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Administrative Support Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company entered into an agreement, commencing on August 9, 2021, to pay an affiliate of the Sponsor a total of $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_AdministrativeSupportAgreementMember_uzQQGS8H_0a5x4OT54OPfw" decimals="0" format="ixt:numdotdecimal" name="ahpa:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" scale="0" id="Narr_TqGmEOFU3EK_4rNWcd8UQg">10,000</ix:nonFraction> per month for administrative, financial and support services. Upon the completion of an initial Business Combination, the Company will cease paying these monthly fees. Under this agreement, $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_AdministrativeSupportAgreementMember_70Vvf8NJ3kSfQY4yJdgRgg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Narr_kc_TEbNfbEqMY5lsNn3ruQ"><ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_AdministrativeSupportAgreementMember_NiMhJnR4mUi1x__B69WUPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Narr_poC66TzfakGYgUctDs0s6g"><ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_4_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_AdministrativeSupportAgreementMember_Km4Y9OkDw0uxggOurPog8g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Narr_sdw-ptjKJ0K3_4mfvlqPPg">46,129</ix:nonFraction></ix:nonFraction></ix:nonFraction> of expenses were incurred during the period from February 5, 2021 (inception) through December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Due to Related Party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to related party consists of advances from the Sponsor to pay for offering costs and formation costs on behalf of the Company and are payable on demand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Related Party Loans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">In order to finance transaction costs in connection with an intended initial Business Combination, the Company&#8217;s sponsor or an affiliate of the sponsor or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (the &#8220;Working Capital Loans&#8221;). If the Company completes the initial Business Combination, it may repay such loaned amounts out of the proceeds of the trust account released to us. Otherwise, such loans may be repaid only out of funds held outside the trust account. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the trust account to repay such loaned amounts but no proceeds from the Company&#8217;s trust account would be used to repay such loaned amounts. Up to $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_RelatedPartyLoansMember_t4HEn2WBv0-oLDiAcT-3nQ" decimals="0" format="ixt:numdotdecimal" name="ahpa:MaximumLoansConvertibleIntoWarrants" scale="0" id="Narr_BtEe5AJ7GUWUaUm3B59hGA">2,000,000</ix:nonFraction> of such loans may be convertible into warrants of the post-Business Combination entity at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_RelatedPartyLoansMember_t4HEn2WBv0-oLDiAcT-3nQ" decimals="2" format="ixt:numdotdecimal" name="ahpa:ClassOfWarrantOrRightPriceOfWarrantsOrRights" scale="0" id="Narr_5GHx5SXmwk2F-QRDnTM7eg">1.50</ix:nonFraction>&#160;per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. Except as set forth above, the terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans. Prior to the completion of the initial Business Combination, the Company does not expect to seek loans from parties other than the Company&#8217;s sponsor, its affiliates or any members of the management team as the Company does not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in the trust account. As of December 31, 2021, there was <ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_RelatedPartyLoansMember_t4HEn2WBv0-oLDiAcT-3nQ" decimals="0" format="ixt-sec:numwordsen" name="ahpa:WorkingCapitalLoansOutstanding" scale="0" id="Narr_Vx68voBvfU6y4q6ySTfpIQ">no</ix:nonFraction> balance outstanding under the Working Capital Loans.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_nSRiIsv9VkOfNCWpr9Kr2A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;6. COMMITMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Registration and Shareholder Rights Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to a registration rights agreement entered into on August 9, 2021, the holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants issued upon conversion of the Working Capital Loans) will have registration and shareholder rights to require the Company to register a sale of any of its securities held by them pursuant to a registration and shareholder rights agreement to be signed prior to or on the effective date of the Initial Public Offering. The holders of these securities are entitled to make up to <ix:nonFraction unitRef="Unit_Standard_item_HhKYwaXu10-zi6ST7YVS-w" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="INF" format="ixt-sec:numwordsen" name="ahpa:MaximumNumberOfDemandsForRegistrationOfSecurities" scale="0" id="Narr_AQ7UFWkNhEyWrq2xIBg1Dw">three</ix:nonFraction> demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of an initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Underwriting Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The underwriters were paid a cash underwriting discount of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="2" format="ixt:numdotdecimal" name="ahpa:DeferredFeePerUnit" scale="0" id="Narr_EmTUDw_WbEqYl-11-bahfg">0.20</ix:nonFraction>&#160;per Unit, or $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="ahpa:AggregateDeferredUnderwritingFeePayable" scale="0" id="Narr_FOrZUAbntU2BE1gs15OW1Q">4,600,000</ix:nonFraction> in the aggregate, upon the closing of the Initial Public Offering and exercise of the over-allotment in full on August 12, 2021. In addition, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="2" format="ixt:numdotdecimal" name="ahpa:UnderwritingCashDiscountPerUnit" scale="0" id="Narr_q9ZjD5ZWJkGPmoD6E_wWjw">0.35</ix:nonFraction> per unit, or $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="0" format="ixt:numdotdecimal" name="ahpa:UnderwriterCashDiscount" scale="0" id="Narr_LjOIy2AvHE-OBCOv5cC5rg">8,050,000</ix:nonFraction> in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Forward Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the consummation of the Initial Public Offering, the Company entered into a forward purchase agreement with the Sponsor, Avista Acquisition LP II, a Cayman Islands exempted limited partnership, which provides for the purchase of an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA" decimals="INF" format="ixt:numdotdecimal" name="ahpa:SharesToBePurchasedPursuantToAgreements" scale="0" id="Narr_M3e79GyPLEypj5wittA_Qw">10,000,000</ix:nonFraction> Class A ordinary shares plus an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" decimals="INF" format="ixt:numdotdecimal" name="ahpa:WarrantsToBePurchasedPursuantToAgreements" scale="0" id="Narr_Fpc6jDfQmkejksZjhH36Zg">3,333,333</ix:nonFraction> redeemable warrants to purchase Class A ordinary shares at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_3CFn1LJs9Uy6L8uwedBzdQ">11.50</ix:nonFraction> per share, for an aggregate purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_eD2XDmIVE0OxfJPD7OTpMA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="0" id="Narr_ZgZGvLw0_EeE9KyvB_ymxA">100,000,000</ix:nonFraction>, in the private placement. The obligations under the forward purchase agreement do not depend on whether any Class A ordinary shares are redeemed by the Company&#8217;s public shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The forward purchase securities will be issued in connection with the closing of the initial Business Combination. The proceeds from the sale of forward purchase securities will be used as part of the consideration to the sellers in the Company&#8217;s initial Business Combination, expenses in connection with the initial Business Combination or for working capital in the post-transaction company.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_6Jjr4VQbY0-AQaRlfUtXeQ" continuedAt="Tb_6Jjr4VQbY0-AQaRlfUtXeQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;7. SHAREHOLDERS&#8217; DEFICIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preference shares&#8212;</span> The Company is authorized to issue <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_1W28NVJsoUa0QwYUmpgEng">5,000,000</ix:nonFraction> preference shares with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_6TBjQu1jgEG8Q4AAOo0raQ">0.0001</ix:nonFraction> per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. As of December&#160;31,&#160;2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_LrotKBWfqk6tGRWqtfznBg">no</ix:nonFraction> preference shares issued or <span style="-sec-ix-hidden:Hidden_dLQndVmTokOqpzPEE6ShuQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class&#160;A ordinary shares&#8212;</span> The Company is authorized to issue <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_f60OhzulvUWffRFATFN0QQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_HqHb4Efe_Eit9dOuEQlvOA">500,000,000</ix:nonFraction> Class A ordinary shares with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_f60OhzulvUWffRFATFN0QQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_wu-Bxs6YlkeIuQ3p71aM8g">0.0001</ix:nonFraction> per share. Holders of Class A ordinary shares are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_PXooaeoQc0ms4cDX_kIEHg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_f60OhzulvUWffRFATFN0QQ" decimals="INF" format="ixt-sec:numwordsen" name="ahpa:CommonStockNumberOfVotesPerShare" scale="0" id="Narr_W5tpnZMLo0KG9vbiivk1tg">one</ix:nonFraction> vote for each share. At December&#160;31,&#160;2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_ahpa_CommonClassaSubjectToRedemptionMember_q28zW_K4z0OVkxWsAfxczw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_gSSeO15Ni0m-U2tVw8AYfw">23,000,000</ix:nonFraction> Class A ordinary shares issued and <span style="-sec-ix-hidden:Hidden_Z_H04b9q5UCcSUgqEMG3_g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, including <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_qHJgeIL9FU6Q-JQ7icgz2Q">23,000,000</ix:nonFraction> Class A ordinary shares subject to possible redemption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class&#160;B ordinary shares&#8212;</span> The Company is authorized to issue <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_torzilxiYEmZNzeYabqgSw">50,000,000</ix:nonFraction> Class B ordinary shares with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_vt4rzJS7iUCPhiyRnTukXw">0.0001</ix:nonFraction> per share. Holders of Class B ordinary shares are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_PXooaeoQc0ms4cDX_kIEHg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug" decimals="INF" format="ixt-sec:numwordsen" name="ahpa:CommonStockNumberOfVotesPerShare" scale="0" id="Narr_LKYi7GABFEKNRud2Uioehw">one</ix:nonFraction> vote for each share. As of December 31, 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_wfh4QEOn2UiI0eiseuE0TA">5,750,000</ix:nonFraction> Class B ordinary shares issued and <span style="-sec-ix-hidden:Hidden_1ubnyfPiU0eaQzavzDHJNg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, and the holders of the Founder Shares own, on an as-converted basis, <ix:nonFraction unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg" decimals="2" format="ixt:numdotdecimal" name="ahpa:ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" scale="-2" id="Narr_HKnifrM9AUWd0TPYExr6KA">20</ix:nonFraction>% of the Company&#8217;s issued and outstanding shares.</p></ix:nonNumeric></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_6Jjr4VQbY0-AQaRlfUtXeQ_cont1" continuedAt="Tb_6Jjr4VQbY0-AQaRlfUtXeQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Except as described below, holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company&#8217;s shareholders except as required by law. Unless specified in the Company&#8217;s Amended and Restated Memorandum and Articles of Association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the ordinary shares that are voted is required to approve any such matter voted on by the shareholders. Approval of certain actions will require a special resolution under Cayman Islands law, being the affirmative vote of at least two-thirds of the ordinary shares that are voted, and pursuant to the Amended and Restated Memorandum and Articles of Association; such actions include amending the Amended and Restated Memorandum and Articles of Association and approving a statutory merger or consolidation with another company. The Company&#8217;s board of directors is divided into three classes, each of which will generally serve for a term of three years with only one class of directors being appointed in each year. There is no cumulative voting with respect to the appointment of directors, with the result that the holders of more than <ix:nonFraction unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg" decimals="0" format="ixt:numdotdecimal" name="ahpa:ConvertibleStockConversionRatios" scale="0" id="Narr_cQifdEEDrECbgi55w-oLXA">50</ix:nonFraction>% of the shares voted for the appointment of directors can appoint all of the directors. The Company&#8217;s shareholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally available therefor. Prior to the Company&#8217;s initial Business Combination, (i) only holders of the founder shares will have the right to vote on the appointment of directors and (ii) in a vote to continue the Company in a jurisdiction outside the Cayman Islands (which requires the approval of at least two thirds of the votes of all ordinary shares), holders of the Company&#8217;s Class B ordinary shares will have ten votes for every Class B ordinary share and holders of the Class A ordinary shares will have one vote for every Class A ordinary share. These provisions of the Company&#8217;s Amended and Restated Memorandum and Articles of Association may only be amended by a special resolution passed by not less than 90% of the ordinary shares who attend and vote at the Company&#8217;s general meeting which shall include the affirmative vote of a simple majority of the Class B ordinary shares. Holders of the public shares will not be entitled to vote on the appointment of directors prior to the initial Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, prior to the completion of an initial Business Combination, holders of a majority of the founder shares may remove a member of the board of directors for any reason. In connection with the initial Business Combination, the Company may enter into a shareholders agreement or other arrangements with the shareholders of the target with respect to voting and other corporate governance matters following completion of the initial Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Redeemable Warrants&#8212;</span> Each whole warrant entitles the registered holder to purchase one Class A ordinary share at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_f0P--mGylEyLNj8LG5U35g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_1y_QzmMYf0-EUYFBJ16o6A">11.50</ix:nonFraction> per share , subject to adjustment as discussed below, at any time commencing <ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_HgSeUv3N6UGsnBDKOVV0aw" format="ixt-sec:durwordsen" name="ahpa:WarrantExercisePeriodConditionTwo" id="Narr_eXwT6CFs-Eeh8H1QXns7sg">30 days</ix:nonNumeric>&#160;after the completion of the Company&#8217;s initial Business Combination, except as discussed in the immediately succeeding paragraph. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of Class A ordinary shares. This means only a whole warrant may be exercised at a given time by a warrant holder. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Accordingly, unless you purchase at least three units, you will not be able to receive or trade a whole warrant. The warrants will expire <ix:nonNumeric contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_c0jqdQLiPkuEslmiil_bNQ" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_Y8RAdwZbXUa-UpH07nkqMw">five years</ix:nonNumeric>&#160;after the completion of the initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will not be obligated to deliver any Class A ordinary shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class A ordinary shares underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company&#8217;s satisfying of the obligations described below with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable and the Company will not be obligated to issue a Class A ordinary share upon exercise of a warrant unless the Class A ordinary share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the Class A ordinary share underlying such unit. </p></ix:continuation></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_6Jjr4VQbY0-AQaRlfUtXeQ_cont2" continuedAt="Tb_6Jjr4VQbY0-AQaRlfUtXeQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has agreed that as soon as practicable, but in no event later than <ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_eD2XDmIVE0OxfJPD7OTpMA" format="ixt-sec:durday" name="ahpa:MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" id="Narr_KYgwQYE9wUC2TNS5A7l1pA">20</ix:nonNumeric> business&#160;days after the closing of the initial Business Combination, the Company will use commercially reasonable efforts to file with the SEC a registration statement (which may be a post-effective amendment to the registration statement of which the Company&#8217;s prospectus is a part or any other applicable registration statement) for the registration, under the Securities Act, of the Class A ordinary shares issuable upon exercise of the warrants, and the Company will use commercially reasonable efforts to cause the same to become effective within <ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_eD2XDmIVE0OxfJPD7OTpMA" format="ixt-sec:durday" name="ahpa:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" id="Narr_o9WOa8vGLUK-7ArsWQzTxw">60</ix:nonNumeric>&#160;business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Company&#8217;s Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section 18(b)(1) of the Securities Act, the Company may, at it&#8217;s option, require holders of warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, will not be required to file or maintain in effect a registration statement, and will use commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent available. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section 3(a)(9) of the Securities Act or another exemption, and the Company will use commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class A ordinary shares equal to the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the &#8220;fair market value&#8221; (defined below) less the exercise price of the warrants by (y) the fair market value. The &#8220;fair market value&#8221; as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the <ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_V90sXGB5lUewxKhffVJUsQ" format="ixt-sec:durday" name="ahpa:RedemptionPeriod" id="Narr_H1R_ijc1h0mbAELSGarBJw">10</ix:nonNumeric> trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Redemption of warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in whole and not in part;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at a price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_Ng0NOicLVku1PX4eR69EBg" decimals="2" format="ixt:numdotdecimal" name="ahpa:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" scale="0" id="Narr_AS4g0qu0eEuQdSKlmUM4QA">0.01</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per warrant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">upon not less than </span><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_Ng0NOicLVku1PX4eR69EBg" format="ixt-sec:durwordsen" name="ahpa:RedemptionPeriod" id="Narr_uuuuMw0jWEaxTpch_8DhOA"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30 days</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8217; prior written notice of redemption to each warrant holder; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if, and only if, the closing price of the Class A ordinary shares equals or exceeds </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_Ng0NOicLVku1PX4eR69EBg" decimals="2" format="ixt:numdotdecimal" name="ahpa:WarrantRedemptionConditionMinimumSharePrice" scale="0" id="Narr_7L7VhW2eYECwT9wOLiKRVw">18.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any </span><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_Ng0NOicLVku1PX4eR69EBg" format="ixt-sec:durday" name="ahpa:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" id="Narr_5wFSr_FYO06qk9e3UroADg"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> trading days within a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_D_LMsaCzRsOkeKQp06MQlfMw" contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_Ng0NOicLVku1PX4eR69EBg" decimals="INF" format="ixt:numdotdecimal" name="ahpa:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" scale="0" id="Narr_dAFMVCdeNEOgn8F8kJvR3g">30</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">-</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the Class A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class A ordinary shares is available throughout the <ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_Ng0NOicLVku1PX4eR69EBg" format="ixt-sec:durday" name="ahpa:RedemptionPeriod" id="Narr_TRy5y-Gf9UCTO8MKaAA7NA">30</ix:nonNumeric>-day redemption period. If and when the warrants become redeemable by the Company, the Company may exercise the Company&#8217;s redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and the Company issues a notice of redemption of the warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the Class A ordinary shares may fall below the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_V90sXGB5lUewxKhffVJUsQ" decimals="2" format="ixt:numdotdecimal" name="ahpa:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" scale="0" id="Narr_RYjASgN_pkudwpUusDcczw">18.00</ix:nonFraction> redemption trigger price (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) as well as the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_c1CfbfmOgkajeLUmOnWY1w" decimals="2" format="ixt:numdotdecimal" name="ahpa:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" scale="0" id="Narr_eDaHKybCBEmrz4klUNsjMQ">11.50</ix:nonFraction> (for whole shares) warrant exercise price after the redemption notice is issued. </p></ix:continuation></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_6Jjr4VQbY0-AQaRlfUtXeQ_cont3" continuedAt="Tb_6Jjr4VQbY0-AQaRlfUtXeQ_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No fractional Class A ordinary shares will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, the Company will round down to the nearest whole number of the number of Class A ordinary shares to be issued to the holder. If, at the time of redemption, the warrants are exercisable for a security other than the Class A ordinary shares pursuant to the warrant agreement (for instance, if the Company is not the surviving company in the Company&#8217;s initial Business Combination), the warrants may be exercised for such security. At such time as the warrants become exercisable for a security other than the Class A ordinary shares, the Company (or surviving company) will use its commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of the warrants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the number of outstanding Class A ordinary shares is increased by a capitalization or share dividend payable in Class A ordinary shares, or by a sub-division of ordinary shares or other similar event, then, on the effective date of such capitalization or share dividend, sub-division or similar event, the number of Class A ordinary shares issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding ordinary shares. A rights offering made to all or substantially all holders of ordinary shares entitling holders to purchase Class A ordinary shares at a price less than the &#8220;historical fair market value&#8221; (as defined below) will be deemed a share dividend of a number of Class A ordinary shares equal to the product of (i) the number of Class A ordinary shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Class A ordinary shares) and (ii) one minus the quotient of (x) the price per Class A ordinary share paid in such rights offering and (y) the historical fair market value. For these purposes, (i) if the rights offering is for securities convertible into or exercisable for Class A ordinary shares, in determining the price payable for Class A ordinary shares, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) &#8220;historical fair market value&#8221; means the volume weighted average price of Class A ordinary shares as reported during the <ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_V90sXGB5lUewxKhffVJUsQ" format="ixt-sec:durday" name="ahpa:RedemptionPeriod" id="Narr_ESl1E4yHxUWqIxHTRebEzQ">10</ix:nonNumeric> trading day period ending on the trading day prior to the first date on which the Class A ordinary shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if the Company, at any time while the warrants are outstanding and unexpired, pays a dividend or makes a distribution in cash, securities or other assets to all or substantially all of the holders of the Class A ordinary shares on account of such Class A ordinary shares (or other securities into which the warrants are convertible), other than (a) as described above, (b) any cash dividends or cash distributions which, when combined on a per share basis with all other cash dividends and cash distributions paid on the Class A ordinary shares during the <ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_V90sXGB5lUewxKhffVJUsQ" format="ixt-sec:durwordsen" name="ahpa:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" id="Narr_O8Zd72Wt-kymHIHE-YUUcw">365-day</ix:nonNumeric> period ending on the date of declaration of such dividend or distribution does not exceed $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_FxrDQLlMwkKqESzq8z6bXg" decimals="2" format="ixt:numdotdecimal" name="ahpa:SharePriceTriggerUsedToMeasureDilutionOfWarrants" scale="0" id="Narr_7_YYjVdCYEuRyUsjn0vlqw">0.50</ix:nonFraction> (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions that resulted in an adjustment to the exercise price or to the number of Class A ordinary shares issuable on exercise of each warrant) but only with respect to the amount of the aggregate cash dividends or cash distributions equal to or less than $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_FxrDQLlMwkKqESzq8z6bXg" decimals="2" format="ixt:numdotdecimal" name="ahpa:SharePriceTriggerUsedToMeasureDilutionOfWarrants" scale="0" id="Narr_Xkqq48NZ_k6J7vFT57Rf6A">0.50</ix:nonFraction> per share , (c) to satisfy the redemption rights of the holders of Class A ordinary shares in connection with a proposed initial Business Combination, (d) to satisfy the redemption rights of the holders of Class A ordinary shares in connection with a shareholder vote to amend the Amended and Restated Memorandum and Articles of Association (A) to modify the substance or timing of the Company&#8217;s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem <ix:nonFraction unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A" contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_V90sXGB5lUewxKhffVJUsQ" decimals="0" format="ixt:numdotdecimal" name="ahpa:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" scale="0" id="Narr_x_-O4bMpNE61M_uE0iHIyA">100</ix:nonFraction>% of the public shares if the Company does not complete its initial Business Combination within 18 months from the closing of the Initial Public Offering or (B) with respect to any other provision relating to the rights of holders of the Company&#8217;s Class A ordinary shares, or (e) in connection with the redemption of the Company&#8217;s public shares upon failure to complete the Company&#8217;s initial Business Combination, then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each Class A ordinary share in respect of such event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Whenever the number of Class A ordinary shares purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of Class A ordinary shares purchasable upon the exercise of the warrants immediately prior to such adjustment and (y) the denominator of which will be the number of Class A ordinary shares so purchasable immediately thereafter. </p></ix:continuation></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_6Jjr4VQbY0-AQaRlfUtXeQ_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_c0jqdQLiPkuEslmiil_bNQ" decimals="2" format="ixt:numdotdecimal" name="ahpa:SharePriceTriggerUsedToMeasureDilutionOfWarrants" scale="0" id="Narr_u3Ij7HdO-0S6GyJQ9Ed1CA">9.20</ix:nonFraction> per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Company&#8217;s sponsor or its affiliates, without taking into account any founder shares held by the sponsor or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than <ix:nonFraction unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_HgSeUv3N6UGsnBDKOVV0aw" decimals="0" format="ixt:numdotdecimal" name="ahpa:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" scale="0" id="Narr_Gfhnuiw3eUCOHNYjMf8j3A">60</ix:nonFraction>% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Class A ordinary shares during the <ix:nonFraction unitRef="Unit_Standard_D_LMsaCzRsOkeKQp06MQlfMw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_HgSeUv3N6UGsnBDKOVV0aw" decimals="INF" format="ixt:numdotdecimal" name="ahpa:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" scale="0" id="Narr_jo0llk4l3US4rM__V9NzZg">20</ix:nonFraction> trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the &#8220;Market Value&#8221;) is below $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_c0jqdQLiPkuEslmiil_bNQ" decimals="2" format="ixt:numdotdecimal" name="ahpa:SharePriceTriggerUsedToMeasureDilutionOfWarrants" scale="0" id="Narr_htSpMjbDCU6_Wl_G7hk2jA">9.20</ix:nonFraction> per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to <ix:nonFraction unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_HgSeUv3N6UGsnBDKOVV0aw" decimals="0" format="ixt:numdotdecimal" name="ahpa:WarrantExercisePriceAdjustmentMultiple" scale="0" id="Narr_y0VAX4Upe0uWAFIHSTNx3Q">115</ix:nonFraction>% of the higher of the Market Value and the Newly Issued Price, the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_Ng0NOicLVku1PX4eR69EBg" decimals="2" format="ixt:numdotdecimal" name="ahpa:WarrantRedemptionConditionMinimumSharePrice" scale="0" id="Narr_hQM6T2ABBES9dlfqh-FabA">18.00</ix:nonFraction> per share redemption trigger price described above under &#8220;Redemption of warrants&#8221; will be adjusted (to the nearest cent) to be equal to <ix:nonFraction unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_HgSeUv3N6UGsnBDKOVV0aw" decimals="0" format="ixt:numdotdecimal" name="ahpa:WarrantRedemptionPriceAdjustmentMultiple" scale="0" id="Narr_h9Ywmh7eE0mDa_vY8pTKHw">180</ix:nonFraction>% of the higher of the Market Value and the Newly Issued Price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No fractional warrants will be issued upon separation of the units and only whole warrants will trade. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exercise, round down to the nearest whole number the number of Class A ordinary shares to be issued to the warrant holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Private Placement Warrants have terms and provisions that are identical to those of the warrants being sold as part of the units in the Company&#8217;s Initial Public Offering except that the Private Placement Warrants (including the Class A ordinary shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until <ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_HgSeUv3N6UGsnBDKOVV0aw" format="ixt-sec:durwordsen" name="ahpa:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" id="Narr_rqMq1VBnREil2kape6GUPg">30 days</ix:nonNumeric>&#160;after the completion of the initial Business Combination (except pursuant to limited exceptions to the Company&#8217;s officers and directors and other persons or entities affiliated with the initial purchasers of the Private Placement Warrants). The Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the units being sold in the Initial Public Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Company accounts for the <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tf5u2Z2hjkKPDF_uv_Xeig" decimals="INF" format="ixt:numdotdecimal" name="ahpa:UnitsIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_mKnsBjEyqUOa-mTRbi8xmQ">15,900,000</ix:nonFraction> warrants issued in connection with the Initial Public Offering (including <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FE6zEVavvUymGkwGe3FEbA" decimals="INF" format="ixt:numdotdecimal" name="ahpa:UnitsIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_hUkzNfvXrEqjlQI5bvwiJw">7,666,667</ix:nonFraction> Public Warrants and <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Gi4yVR_tj0CKg7dgp66JvQ" decimals="INF" format="ixt:numdotdecimal" name="ahpa:UnitsIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_cguSDQPOT0mJq6TMYZV4Dg">8,233,333</ix:nonFraction> Private Placement Warrants), and will account for the <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_-Ce3huUCEEmRf4OJGJJFJQ" decimals="INF" format="ixt:numdotdecimal" name="ahpa:UnitsIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_nyDs8SA9rkmqZo-_5ohUWw">3,333,333</ix:nonFraction> Forward Purchase Warrants to be issued in connection with the initial Business Combination, in accordance with the guidance contained in ASC 815-40, <i style="font-style:italic;">Derivatives and Hedging</i>. Such guidance provides that the warrants described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk98843512"></a><a id="_cp_text_1_97"></a><a id="_cp_text_1_98"></a><ix:nonNumeric contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug" name="us-gaap:SubsequentEventsTextBlock" id="Tb_4ZOUv1Lej0aj4LFdRHVWgw" continuedAt="Tb_4ZOUv1Lej0aj4LFdRHVWgw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;8. SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than the items disclosed below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">On March 14, 2022, the Company entered into a promissory note pursuant to the Working Capital Loans terms as outlined in Note 5 with the Sponsor (the &#8220;Sponsor Working Capital Loan&#8221;) to which the Company could borrow up to an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_3_14_2022_us-gaap_ClassOfWarrantOrRightAxis_ahpa_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RZCYNy4TR02-s8x38wz2RQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtDefaultLongtermDebtAmount" scale="0" id="Narr_7mbtHTukdEaW5WmElBbQTg">750,000</ix:nonFraction>. The Sponsor Working Capital Loan is non-interest bearing and payable upon the earlier of (i) completion of the initial Business Combination or (ii) the date that the winding up of the Company is effective. The unpaid principal balance on the Sponsor Working Capital Loan may be convertible into warrants at the option of the Sponsor at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_3_14_2022_us-gaap_ClassOfWarrantOrRightAxis_ahpa_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RZCYNy4TR02-s8x38wz2RQ" decimals="2" format="ixt:numdotdecimal" name="ahpa:ClassOfWarrantOrRightPriceOfWarrantsOrRights" scale="0" id="Narr_pydLU-U7Qk2onFciQz-Vsw">1.50</ix:nonFraction> per warrant. The warrants would be identical to the Private Placement Warrants. On March 15, 2022, the Company drew down $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_3_15_2022_To_3_15_2022_us-gaap_ClassOfWarrantOrRightAxis_ahpa_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_sgLs6LqHfEWSJdAhO6MFKg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" id="Narr_TJCMrsXKxUWgPT9qU9tHxw">500,000</ix:nonFraction> under the Sponsor Working Capital Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Proposed Business Combination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">On March 23, 2022, we entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), by and among the Company, Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#8220;Ligand&#8221;), OmniAb, Inc., a Delaware corporation and wholly-owned subsidiary of Ligand (&#8220;OmniAb&#8221; and, together with Ligand, collectively, the &#8220;Companies&#8221;), and Orwell Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;), pursuant to which we will combine with OmniAb, Ligand&#8217;s antibody discovery business (the &#8220;OmniAb Business&#8221;), in a Reverse Morris Trust transaction. Also on March 23, 2022, and </p></ix:nonNumeric></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cp_text_1_99"></a><a id="_cp_text_1_100"></a><a id="_cp_text_1_101"></a><a id="_cp_text_1_102"></a><a id="_cp_text_1_103"></a><a id="_cp_text_1_104"></a><a id="_cp_text_1_105"></a><ix:continuation id="Tb_4ZOUv1Lej0aj4LFdRHVWgw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;">in connection with the execution of the Merger Agreement, (a) the Company, Ligand, OmniAb and Merger Sub entered into that certain Employee Matters Agreement (the &#8220;Employee Matters Agreement&#8221;), (b) OmniAb and our sponsor entered into that certain sponsor insider letter agreement (the &#8220;Sponsor Insider Agreement&#8221;) with the Company and certain insiders of the Company (the &#8220;Insiders&#8221;) and (c) we amended and restated that certain forward purchase agreement, dated August 9, 2021, by entering into the amended and restated forward purchase agreement (the &#8220;A&amp;R FPA&#8221;), by and among the Company<span style="white-space:pre-wrap;">, our sponsor and OmniAb.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Immediately prior to the Merger (as defined below) and pursuant to a Separation and Distribution Agreement, dated as of March 23, 2022, among the Company, Ligand and OmniAb (the &#8220;Separation Agreement&#8221;), Ligand will, among other things and subject to the terms and conditions of the Separation Agreement, transfer the OmniAb Business, including certain related subsidiaries of Ligand, to OmniAb and, in connection therewith, will distribute (the &#8220;Distribution&#8221;) to Ligand stockholders 100% of the common stock of OmniAb, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_3_23_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_JOtx4eLq2EWmvVpNUA4XHg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_du2fPvnHPkKSEpplU68FxA">0.001</ix:nonFraction><span style="white-space:pre-wrap;"> (the &#8220;OmniAb Common Stock&#8221;).  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Immediately following the Distribution, in accordance with and subject to the terms and conditions of the Merger Agreement, Merger Sub will merge with and into OmniAb (the &#8220;Merger&#8221;), with OmniAb continuing as the surviving company in the Merger and as a wholly-owned subsidiary of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The Merger Agreement, along with the Separation Agreement and the other transaction documents to be entered into in connection therewith, provides for, among other things, the consummation of the following transactions (collectively, the &#8220;OmniAb Business Combination&#8221;): (i) we will redomicile by way of continuation from the Cayman Islands to Delaware and domesticate as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law and with Section 206 of the Cayman Islands Companies Act (As Revised) at least one business day prior to the closing of the proposed OmniAb Business Combination (the &#8220;Domestication&#8221;), (ii) Ligand will transfer the OmniAb Business (the &#8220;Separation&#8221;) to its wholly-owned subsidiary, OmniAb, and contribute $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_OmniabMember_Y-svE_WiIU2HjXgNBRRZFQ" decimals="-6" format="ixt:numdotdecimal" name="ahpa:ContributionFromSubsidiaries" scale="6" id="Narr_tVMvoahYmUKBQgYK--DICA">15</ix:nonFraction> million in capital thereto (less certain transaction and other expenses), and (iii) following the Separation, Ligand will distribute 100% of the shares of OmniAb Common Stock, to Ligand stockholders by way of the Distribution. Following the completion of the foregoing transactions and subject to the satisfaction or waiver of certain other conditions set forth in the Merger Agreement, the parties shall consummate the Merger. The Distribution and Merger are intended to qualify as &#8220;tax-free&#8221; transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Upon consummation of the proposed OmniAb Business Combination, and after the Domestication, we will have one class of common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_OmniabMember_K3bPyZi0602lWc8Dsxld3Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_3Pl_YLTVL0ueFBOyumWN4w">0.0001</ix:nonFraction> per share (the &#8220;APAC Common Stock&#8221;), which will be listed on Nasdaq under the ticker symbol &#8220;OABI.&#8221; Our then-outstanding warrants will be listed on Nasdaq under the ticker symbol &#8220;OABIW.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">At the time the proposed OmniAb Business Combination is effected (the &#8220;Closing&#8221;), each share of OmniAb Common Stock outstanding after the Distribution and immediately prior to the effective time of the Merger will be converted into a number of shares of APAC Common Stock based on an exchange ratio determined by reference to a pre-money equity value for OmniAb of $<ix:nonFraction unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_OmniabMember_K3bPyZi0602lWc8Dsxld3Q" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="6" id="Narr_g9PewK3FsEueoUgz2S9o6w">850</ix:nonFraction> million. Holders of OmniAb options, restricted stock units and performance stock units (determined after the Distribution and the division of Ligand equity awards into both Ligand equity awards and OmniAb equity awards pursuant to the Employee Matters Agreement) will have their awards rolled over into equity awards of the Company and adjusted pursuant to the exchange ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">In addition, at the Closing, holders of OmniAb Common Stock and equity awards will also receive earnout consideration in the form of an additional <ix:nonFraction unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_OmniabMember_K3bPyZi0602lWc8Dsxld3Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_qMFXvdxdj0-R-S-v70V8Fw">15,000,000</ix:nonFraction> shares of APAC Common Stock (the &#8220;OmniAb Earnout Shares&#8221;), with 50% of such earnout shares vesting upon the combined company&#8217;s achievement of a post-transaction volume-weighted average price (&#8220;VWAP&#8221;) of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_OmniabMember_Y-svE_WiIU2HjXgNBRRZFQ" decimals="2" format="ixt:numdotdecimal" name="ahpa:WeightedAverageSharesPricePerShare" scale="0" id="Narr_nRjyWBQybUm__B47wATIsg">12.50</ix:nonFraction> per share of APAC Common Stock for any 20 trading days over a consecutive 30 trading-day period, and the remainder vesting upon achievement of a post-transaction VWAP of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg" contextRef="Duration_1_1_2021_To_12_31_2021_xNJIoD7-WEGyu2JOFYZBJg" decimals="2" format="ixt:numdotdecimal" name="ahpa:WeightedAverageSharesPricePerShare" scale="0" id="Narr_WDOHhSVTLUGUeUrGm7ZGrQ">15.00</ix:nonFraction> per share of APAC Common Stock for any 20 trading days over a consecutive 30 trading-day period, in each case provided such vesting occurs during the five-year period following the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">In connection with the proposed OmniAb Business Combination, upon the Domestication (i) all issued and outstanding Class A ordinary shares and Class B ordinary shares will convert automatically, on a one-for-one basis, into shares of APAC Common Stock, (ii) all issued and outstanding warrants will convert automatically into warrants to acquire shares of APAC Common Stock and (iii) all issued and outstanding Units will separate and convert automatically into one share of APAC Common Stock and one-third of one warrant to purchase APAC Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The consummation of the proposed OmniAb Business Combination is subject to certain conditions as further described in the Merger Agreement.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_31fb8ee7_7914_4d41_bf9d_2a19cc9172b4"></a><a id="ReportofIndependentRegisteredPublic_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">To the Board of Directors and Management of Ligand Pharmaceuticals Incorporated</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying combined balance sheets of OmniAb, Inc., Crystal Bioscience, Inc., xCella Biosciences, Inc., Taurus Biosciences LLC, Icagen, Inc. and Ab Initio Biotherapeutics, Inc., (each of which is a subsidiary of Ligand Pharmaceuticals Incorporated, collectively &#8220;OmniAb, A Business of Ligand Pharmaceuticals Incorporated,&#8221; or the &#8220;Company&#8221;) as of December 31, 2021 and 2020, the related combined statements of operations, changes in parent company net investment, and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;combined financial statements&#8221;). In our opinion, the combined financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for the each of the three years in the period ended December 31, 2021 in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Restatement of the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As discussed in Note 2 to the combined financial statements, the December 31, 2020 and December 31, 2019 combined financial statements have been restated to correct misstatements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">/s/ Ernst&#160;&amp; Young LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">We have served as the Company&#8217;s auditor since 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">San Diego, California</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">April 27,2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_752936fa_1c1a_4b99_bd4c_7ab1b6eb512d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">OmniAb,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(A Business of Ligand Pharmaceuticals Incorporated)</b></p><a id="COMBINEDBALANCESHEETS_758984_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMBINED BALANCE SHEETS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 21,136</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,875</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,406</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 774</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 36pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22,542</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,649</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 176,321</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 186,644</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 83,979</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 83,979</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,795</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,480</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,332</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,499</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,496</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,129</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 36pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 304,465</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 295,380</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND PARENT COMPANY NET INVESTMENT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,924</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 469</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,746</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,956</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Current portion of contingent liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,538</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,115</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Current portion of deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,790</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,157</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Current portion of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 578</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 579</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Current portion of finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 36pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,577</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,277</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Long-term contingent liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,826</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,089</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Deferred income taxes, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 21,962</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 28,925</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Long-term operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,272</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,012</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Long-term portion of deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,226</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,232</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 295</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,308</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 36pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 70,158</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 59,843</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Commitments and contingencies <i style="font-style:italic;">(Note 10)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Parent company net investment:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Parent company net investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 234,307</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 235,537</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 36pt;">Total liabilities and parent company net investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 304,465</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 295,380</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to these combined financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_86e7b046_6ba6_4b22_9b58_afecdf5125fb"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">OmniAb,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(A Business of Ligand Pharmaceuticals Incorporated)</b></p><a id="COMBINEDSTATEMENTSOFOPERATIONS_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMBINED STATEMENTS OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;Restated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenues:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">License and milestone revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,664</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,385</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,750</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Service revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,084</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,883</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,568</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 36pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 34,748</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23,268</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,318</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 39,232</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 24,796</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,208</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,947</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,225</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,651</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Amortization of intangibles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,968</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,800</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,304</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Other operating expense (income), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,210</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,070</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (818)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 36pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 70,357</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 48,891</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 31,345</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (35,609)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (25,623)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,027)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other income (expense):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (7)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (5)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,266</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,900</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,259</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,895</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (34,350)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (23,728)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,027)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Income tax benefit (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,308</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,171</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (562)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (27,042)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,557)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,589)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to these combined financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_24d59ff6_fb8b_4f3e_ac79_19ad621fa2ed"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">OmniAb,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(A Business of Ligand Pharmaceuticals Incorporated)</b></p><a id="STATEMENTSOFCHANGES_831092_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMBINED STATEMENTS OF CHANGES IN P</b><b style="font-weight:bold;">ARENT COMPANY NET INVESTMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Parent&#160;company&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">net&#160;investment</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Opening balance at January 1, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 204,882</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Net loss (as restated)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,589)</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Parent allocation of share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,660</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Net transfers from parent company (as restated)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,290</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2019 (as restated)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 218,243</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Net loss (as restated)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,557)</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Parent allocation of share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,165</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Net transfers from parent company (as restated)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 25,686</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2020 (as restated)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 235,537</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (27,042)</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Parent allocation of share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,065</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Net transfers from parent company</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,747</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 234,307</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to these combined financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5b535015_4369_4f9a_85e8_c42ffd4fe007"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">OmniAb,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(A Business of Ligand Pharmaceuticals Incorporated)</b></p><a id="CASHFLOWS_855792_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMBINED STATEMENTS OF CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;Restated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (27,042)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,557)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,589)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 18pt;">Change in estimated fair value of contingent liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,210</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,070</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (818)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 18pt;">Depreciation of fixed assets and amortization of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,954</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,627</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,593</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 18pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,065</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,165</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,660</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 18pt;">Deferred income taxes, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (7,325)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6,185)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 557</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 18pt;">Loss (gain) from short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,265)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 18pt;">Gain from sale of intellectual property license</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,900)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 64</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 161</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 18pt;">Changes in operating assets and liabilities, net of acquisitions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 36pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 339</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4,290)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 36pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (632)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (497)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (14)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 36pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,513</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,759</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (570)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 36pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6,717)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,328</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,875)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 36pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,516)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,309</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,849)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 54pt;">Net cash provided by (used in) operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (5,672)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,619</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (5,195)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from sale of short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,265</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for acquisitions, net of cash and restricted cash acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (27,127)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (11,840)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4,070)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,753)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (255)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from sale of intellectual property license</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,900</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Payments to CVR holders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (720)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (500)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 54pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4,025)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (26,980)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (12,095)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Payment to CVR holders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,050)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,325)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,000)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net transfer from parent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,747</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 25,686</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,290</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 54pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,697</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23,361</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,290</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net increase in cash, cash equivalents, and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental disclosure of cash flow information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue recorded in accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,344</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,451</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,425</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of fixed assets recorded in accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,231</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 471</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to these combined financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c1b7cfeb_c6fc_4904_96c4_d3293705fd3c"></a><a id="a1OrganizationandNature_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Organization and Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The accompanying combined financial statements include all of the assets, liabilities and results of operations of six subsidiaries of Ligand Pharmaceuticals Incorporated (&#8220;Ligand&#8221; or the &#8220;Parent&#8221;), which are Ab Initio Biotherapeutics,&#160;Inc. (Ab Initio), Crystal Bioscience,&#160;Inc. (Crystal), Icagen, LLC (Icagen), Open Monoclonal Technology,&#160;Inc. (OMT), Taurus Biosciences, LLC (Taurus) and xCella Biosciences,&#160;Inc. (xCella) (collectively, &#8220;OmniAb,&#8221; &#8220;the company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;). OmniAb is a biotechnology company with a Biological Intelligence powered multi-species antibody platform for the discovery of mono and bispecific therapeutic human antibodies. OmniAb primarily derives revenue from license fees for technology access, milestones from partnered programs and service revenue from research programs. On January&#160;8, 2016, Ligand acquired OMT, pursuant to a multi-step transaction that resulted in Ligand&#8217;s acquisition of OMT. On November&#160;10, 2021 OMT&#8217;s name was changed to OmniAb,&#160;Inc. In connection with the separation of OmniAb from Ligand, Ab Initio, Crystal, Icagen, Taurus and xCella will become wholly owned subsidiaries of OmniAb,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ef28411a_b1b1_4709_bcd2_0834c437a586"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2. Restatement of Previously Issued Combined Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subsequent to the issuance of the audited combined financial statements for the year ended December 31, 2020 and 2019, the Company determined the balance of accounts receivable, net, as of December 31, 2020, was understated by $7.0 million and general and administrative expense was understated by $0.7 million for the year ended December 31, 2019. The error as of December 31, 2020 was the result of the omission of an unbilled amount which was also improperly excluded from net transfers from parent company in the combined statement of changes in parent company net investment for the year ended December 31, 2020, resulting in an understatement of parent company net investment. The error as of December 31, 2019 related to bad debt expense that was not properly included in general and administrative expense on the combined statements of operations and was improperly recorded as part of the net transfers from parent company in the combined statements of changes in parent company net investment. The errors identified as of December 31, 2020 and 2019, each resulted in the overstatement of cash provided by operating activities and an understatement of cash provided by financing activities in the combined statements of cash flows, in the respective periods. The Company has concluded that the errors identified were material to the combined financial statements as of and for the year ended December 31, 2020 and 2019. Accordingly, previously reported amounts have been revised to reflect the correction of the error as well as other immaterial errors identified through the process of compiling the carve-out financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following tables present the revised results for the&#160;year ended December&#160;31, 2020, the adjustments made and the previously reported amounts to summarize the effect of the restatement on the previously-issued combined financial statements for the periods impacted (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Combined Balance Sheets</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 24pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,870</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,005</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,875</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 24pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,644</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,005</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,649</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 24pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 186,592</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 52</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 186,644</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 24pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 84,066</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (87)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 83,979</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 24pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 288,410</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,970</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 295,380</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 24pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,456</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,956</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 24pt;">Current portion of finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 24pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,790</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 487</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,277</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 24pt;">Deferred income taxes, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 29,185</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (260)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 28,925</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 24pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,295</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,308</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 24pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 59,603</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 240</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 59,843</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Parent company net investment:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 24pt;">Parent company net investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 228,807</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,730</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 235,537</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 24pt;">Total liabilities and parent company net investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 288,410</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,970</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 295,380</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Combined Statements of Operations</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 24,894</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (98)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 24,796</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,240</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (15)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,225</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 49,004</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (113)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 48,891</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (25,736)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 113</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (25,623)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (23,841)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 113</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (23,728)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Income tax benefit (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,945</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 226</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,171</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,896)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 339</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,557)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Combined Statements of changes in Parent Company Net Investment</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Parent company net investment&#8201;&#8211;&#8201;January 1, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">218,185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">218,243</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,896)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 339</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,557)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Net transfers from parent company</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19,353</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,333</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 25,686</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Parent company net investment &#8211; December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 228,807</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,730</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 235,537</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Combined Statements of Cash Flows</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,896)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 339</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,557)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 42pt;">Deferred income taxes, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (5,960)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (225)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6,185)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 42pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 161</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 161</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 42pt;">Changes in operating assets and liabilities, net of acquisitions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 60pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,096)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,435</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 339</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 60pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,337</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 422</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,759</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 60pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,779</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (8,451)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,328</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 60pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,323</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (14)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,309</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Net cash provided by operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,952</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6,333)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,619</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Net transfer from parent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19,353</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,333</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 25,686</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 18pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,028</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,333</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23,361</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Supplemental disclosure of cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-bottom:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-bottom:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-bottom:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 5.75pt;">Deferred revenue recorded in accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8,451</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8,451</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following tables present the revised results for the&#160;year ended December&#160;31, 2019, the adjustments made and the previously reported amounts to summarize the effect of the restatement on the previously-issued combined financial statements for the periods impacted (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Combined Balance Sheets</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,774</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 150</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,924</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,795</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 150</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,945</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 77,108</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (86)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 77,022</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 262,320</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 64</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 262,384</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 806</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 71</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 877</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Current portion of finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,139</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 78</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,217</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Deferred income taxes, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 35,388</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (86)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 35,302</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 295</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 309</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 44,135</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 44,141</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Parent company net investment:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Parent company net investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 218,185</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 58</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 218,243</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 24pt;">Total liabilities and parent company net investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 262,320</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 64</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 262,384</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Combined Statements of Operations</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">License and milestone revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,685</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 65</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,750</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Service revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,528</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 40</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,568</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,213</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 105</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,318</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,137</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 71</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,208</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,976</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 675</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,651</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 30,599</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 746</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 31,345</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (12,386)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (641)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,027)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (12,386)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (641)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,027)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Income tax benefit (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (657)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 95</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (562)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,043)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (546)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,589)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Combined Statements of changes in Parent Company Net Investment</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,043)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (546)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (13,589)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Net transfers from parent company</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19,686</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 604</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,290</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Parent company net investment &#8211; December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 218,185</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 58</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 218,243</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Combined Statements of Cash Flows</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (13,043)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (546)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (13,589)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 36pt;">Deferred income taxes, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 653</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (96)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 557</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 36pt;">Changes in operating assets and liabilities, net of acquisitions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 54pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,565)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> 1,275</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,290)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 54pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (648)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 78</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (570)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 54pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(450)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">(1,425)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(1,875)</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 54pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,959)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 110</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,849)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,591)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (604)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,195)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Net transfer from parent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,686</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 604</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,290</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,686</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 604</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,290</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Supplemental disclosure of cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Deferred revenue recorded in accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,425</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,425</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_29e439c9_e067_4eac_9bfd_b0a576129033"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Basis of Presentation and Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation and Combination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying combined financial statements have been prepared on a stand-alone basis and are derived from Ligand&#8217;s consolidated financial statement accounting records. The combined financial statements include the historical results of operations, financial position and cash flows of OmniAb in conformity with United States generally accepted accounting principles (U.S. GAAP). The operations comprising OmniAb are in various legal entities wholly owned by Ligand. Accordingly, Ligand&#8217;s net investment in these operations is shown in lieu of stockholder&#8217;s equity in the combined financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb comprises certain stand-alone legal entities for which discrete financial information is available. As Ligand records transactions at the legal entity level, allocation methodologies were applied to certain accounts to allocate amounts to OmniAb as discussed further below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb entities were under the common control of the Parent as a result of, among other factors, Ligand&#8217;s ownership. As the entities were under common control, the financial statements report the financial position, results of operations and cash flows of the Company as though the transfer of net assets and equity interests had occurred as of January&#160;2016. Transactions between Ligand and the Company are accounted through Parent company net investment in OmniAb. The total net effect of the settlement of these intercompany transactions is reflected in our combined balance sheets as Parent company net investment in OmniAb. All significant intercompany transactions with Ligand are deemed to have been paid in the period the costs were incurred. Expenses related to corporate allocations from Ligand to OmniAb are considered to be effectively settled for cash in the combined financial statements at the time the transaction was recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The combined financial statements include all revenues and expenses as well as assets and liabilities directly associated with the business activity of OmniAb as well as an allocation of certain general and administrative expenses related to facilities, functions and services provided by our Parent. These corporate expenses have been allocated to OmniAb based on direct usage or benefit, where identifiable, with the remainder allocated based on headcount or a&#160;percentage of total operating expenses or other measures that management believes are consistent and reasonable. See <i style="font-style:italic;">Note&#160;(9)&#160;Relationship with Parent and Related Entities</i>.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Parent maintains various share-based compensation plans at a corporate level. OmniAb employees participate in those programs, and a portion of the compensation cost associated with those plans is included in OmniAb&#8217;s combined statements of operations. However, the share-based compensation expense has been included within Parent company net investment. The amounts presented in the combined financial statements are not necessarily indicative of future awards and may not reflect the results that OmniAb would have experienced as a stand-alone entity. See <i style="font-style:italic;">Note&#160;(9)&#160;Relationship with Parent and Related Entities</i> for additional discussion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of the allocations and estimates in the combined financial statements are based on assumptions that management believes are reasonable. However, the combined financial statements included herein may not be indicative of the financial position, results of operations and cash flows of OmniAb in the future or if OmniAb had been a separate, stand-alone publicly traded entity during the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity and Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of Ligand, OmniAb was dependent upon Ligand for all of its working capital and financing requirements, as Ligand uses a centralized approach to cash management and financing its operations. There were no cash amounts specifically attributable to OmniAb for the historical periods presented; therefore, there is no cash reflected in the combined financial statements. Accordingly, cash and cash equivalents, debt or related interest expense have not been allocated to OmniAb in the combined financial statements. Financing transactions related to OmniAb are accounted for as a component of net Parent investment in the combined balance sheets and as a financing activity including an interest expense component allocation on the accompanying combined statements of cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the&#160;years ended December&#160;31, 2021, 2020 and 2019, OmniAb&#8217;s revenue was $34.7&#160;million, $23.3&#160;million and $18.3&#160;million, respectively. For the&#160;years ended December&#160;31, 2021, 2020 and 2019, OmniAb&#8217;s net loss was ($27.0 million), ($17.6 million) and ($13.6 million), respectively. OmniAb expects to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we invest in research and development activities to improve our technology and platform, market and sell our solutions to existing and new partners, add operational, financial and management information systems and personnel to support our operations and incur additional costs associated with operating as a public company. OmniAb&#8217;s ability to continue its operations is dependent upon our ability to obtain additional capital in the future and generate cash flows from operations. Funding from Ligand is our primary source of liquidity and Ligand has both the intent and ability to provide such funding to support our operations through at least 12&#160;months following the issuance date of the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying combined financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb qualifies as an &#8220;emerging growth company&#8221; (EGC) as defined in Section&#160;2(a)&#160;of the Securities Act of 1933, as amended, (Securities Act), as modified by the Jumpstart Our Business Startups Act of 2012 (JOBS Act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;102(b)(1)&#160;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. OmniAb has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, OmniAb, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OmniAb&#8217;s historical results are included as a part of the Parent&#8217;s financial statements which are filed with the Securities and Exchange Commission (SEC). As a result, OmniAb tracks the effective dates and adopts all guidance applicable to it consistent with the manner that the Parent tracks and adopts all applicable guidance. However, OmniAb intends to adopt future standards at the appropriate date for emerging growth companies once it is established as a stand-alone company.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This may make comparison of OmniAb&#8217;s financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period, difficult because of the potential differences in accounting standards used</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the company&#8217;s chief operating decision-maker in deciding how to allocate resources and in assessing performance. OmniAb currently operates in one reportable business segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of combined financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the combined financial statements and the accompanying notes. Actual results may differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations of Business Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year-ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Partner A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 28</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 26</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Partner B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 24</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 21</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Partner C</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Partner A, B and C in 2019 represent different customers than 2020 and 2021.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounts Receivable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our accounts receivable represents the amounts we have billed our partners and that are due to us unconditionally for services we have performed. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During 2021, we considered the current and expected future economic and market conditions including, but not limited to, the anticipated unfavorable impacts of the surrounding novel coronavirus (COVID-19) pandemic on our business and recorded an adjustment of $0.1&#160;million of allowance for credit losses as of December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from three to ten&#160;years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Acquisitions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, including fair value estimates, as of the business combination date and to refine those estimates as necessary during the measurement period (defined as the period, not to exceed one&#160;year, in which we may adjust the provisional amounts recognized for a business combination).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We measure goodwill as of the acquisition date as the excess of consideration transferred, which we also measure at fair value, over the net of the acquisition date amounts of the identifiable assets acquired and liabilities assumed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill, Intangible Assets and Other Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Goodwill attributed to OmniAb&#8217;s combined balance sheets represents the historical goodwill balances in the OmniAb legal entities. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. We operate in one reporting unit. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, the overall financial performance, and events affecting the reporting unit. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on OmniAb and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment during the fourth quarter of 2021 and 2020, noting no impairment indicators under the qualitative assessment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Our identifiable intangible assets are composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. Identifiable intangible assets with finite lives are generally amortized on a straight-line basis over the assets&#8217; respective estimated useful life. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles and other long-lived assets at December&#160;31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our revenue is generated primarily from license fees for technology access, development, regulatory and sales based milestone payments and service revenue for performance of research. We apply the following five-step model in accordance with ASC 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i>, in order to determine the revenue: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our revenue is typically derived from our license agreements with our partners and consists of: (i)&#160;upfront or annual payments for technology access (license revenue) and payments for performance of research services; (service revenue); (ii)&#160;downstream payments in the form of preclinical, intellectual property, clinical, regulatory, and commercial milestones (milestone revenue) and (iii)&#160;royalties on net sales from our partners&#8217; product sales, if any. To date, while we have generated revenue from intellectual property and development milestones, we have not generated any revenue from commercial milestone payments or royalties on product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">License fees are generally recognized at a point in time once we grant our customers access to our intellectual property rights. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recognize service revenue for contracted R&amp;D services performed for our customers over time. We measure our progress using an input method based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a&#160;percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make estimates and use judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We include contingent milestone based payments in the estimated transaction price when there is a basis to reasonably estimate the amount of the payment and is probable of being achieved. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our licenses of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon or after the development milestone or regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Deferred Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the combined balance sheet. We generally receive payment at the point we satisfy our obligation or soon after. Any fees billed in advance of being earned are recorded as deferred revenue. During the&#160;year ended December&#160;31, 2021, the amount recognized as revenue that was previously deferred at December&#160;31, 2020 was $7.4&#160;million. During the&#160;year ended December&#160;31, 2020, the amount recognized as revenue that was previously deferred at December&#160;31, 2019 was $0.4&#160;million. During the&#160;year ended December&#160;31, 2019, the amount recognized as revenue that was previously deferred at December&#160;31, 2018 was $2.4&#160;million.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Disaggregation of Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table represents disaggregation of service revenue, license fees and milestone revenue (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">License fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,260</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,700</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Milestone revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,164</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,125</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,050</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Service revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,084</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,883</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,568</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 34,748</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23,268</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,318</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Milestone revenue represents variable consideration in the contracts where uncertainties have been resolved and the development milestones are probable of being achieved or were achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our combined balance sheet and we expense them as the services are provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Share-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain of our employees participated in our Parent&#8217;s equity-based incentive plans. We incur share-based compensation expense related to restricted stock, shares issued under Ligand&#8217;s Employee Stock Purchase Plan (as amend and restated in 2019) (ESPP) and stock options. The Company has not issued any share-based compensation instruments on a standalone basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Restricted stock units (RSU) and performance stock units (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of the Parent&#8217;s common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represent right to receive a certain number of shares of common stock based on the achievement of the Parent&#8217;s corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We use the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under the ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatilities of Ligand stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which our Parent declared a cash dividend on its common stock of $2.50 per share, our Parent has not paid any dividends on our common stock in the past and currently does not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We grant options, RSUs and PSUs to employees and non-employee directors under Ligand&#8217;s equity plan. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one&#160;year from the date of grant. Options granted to employees typically vest 1/8 on the six&#160;month anniversary of the date of grant, and 1/48 each&#160;month thereafter for forty-two&#160;months. RSUs and PSUs granted to employees vest over three&#160;years. All option awards generally expire ten&#160;years from the date of grant.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Income taxes as presented herein include current and deferred income taxes of Ligand allocated to our standalone financial statements in a manner that is systematic, rational and consistent with the asset and liability method prescribed by the Accounting Standards Codification (&#8220;ASC&#8221;) Topic 740, <i style="font-style:italic;">Income Taxes</i> (&#8220;Topic 740&#8221;). Accordingly, our income tax provision was prepared following the &#8220;Separate Return Method.&#8221; The Separate Return Method applies Topic 740 to the standalone financial statements of the OmniAb members of the consolidated group as if the group member were a separate taxpayer which joined in filing a consolidated federal income tax return and combined state income tax returns separate from Ligand. As a result, actual tax transactions included in the consolidated financial statements of Ligand may not be included in the combined financial statements of OmniAb. Similarly, the tax treatment of certain items reflected in the combined financial statements of OmniAb may not be reflected in the consolidated financial statements and tax returns of Ligand; therefore, items such as net operating losses, credit carryforwards and valuation allowances may exist in the standalone financial statements that may or may not exist in Ligand&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We provide for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates in effect when the differences are expected to reverse. If necessary, deferred tax assets are reduced by a valuation allowance to reflect the uncertainty associated with their ultimate realization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for uncertain tax positions recognized in the combined financial statements in accordance with the provisions of Topic 740 by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. We evaluate uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect our income tax provision in future periods. Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as a provision for income tax in our combined statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, the taxable loss of OmniAb for the tax&#160;years ended December&#160;31, 2021, 2020 and 2019 was included in Ligand&#8217;s U.S. consolidated federal and combined state income tax returns, where applicable. As such, separate income tax returns were not prepared for OmniAb. Consequently, income taxes currently payable are deemed to have been remitted to Ligand in the period the liability arose and income taxes currently receivable are deemed to have been received from Ligand in the period that a refund could have been recognized by OmniAb had we been a separate taxpayer, if applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impact of COVID-19 Pandemic</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 worldwide pandemic has presented substantial public health and economic challenges and is affecting us, as well as our employees, partners, communities and business operations, as well as the U.S. and global economies and financial markets. International and U.S. governmental authorities in impacted regions have been taking actions since the onset of the pandemic in an effort to slow the spread of COVID-19 initially, including issuing varying forms of &#8220;stay-at-home&#8221; orders, and restricting business functions outside of one&#8217;s home. We have generally restricted in-person access to our executive offices, our administrative employees are working remotely on an intermittent basis, and we have limited the number of staff in our research and development laboratories and other facilities. To date, we have not experienced material disruptions in our business operations or financial impacts. While it is not possible at this time to estimate the impact that COVID-19 could have on our business in the future, the continued spread of COVID-19 and variants of the virus, the rate of vaccinations regionally and globally and the measures taken by the government authorities, and any future epidemic disease outbreaks, could: disrupt the supply chain and the manufacture or shipment of products and supplies for use by us in our antibody discovery activities and by our partners for their discovery and development activities; delay, limit or prevent us or our partners&#8217; from continuing research and development activities; impede our negotiations with partners and potential partners; impede testing, monitoring, data collection and analysis and other related activities, by us and our partners; interrupt or delay the operations of the FDA or other regulatory authorities, which may impact review and approval timelines for initiation of clinical trials or marketing by our partners; impede the launch or commercialization of any approved products; any of which could delay our partnership programs, increase our operating costs, and have a material adverse effect on our business, financial condition and results of operations.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if COVID-19 infects our genetically modified animals, which form the basis of our platform, or if there is an outbreak among our employees who maintain and care for these animals, we and our partners may be unable to produce antibodies for development. The COVID-19 pandemic and mitigation measures have had and may continue to have, and any future epidemic disease outbreak may have, an adverse impact on global economic conditions, which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which the COVID-19 pandemic impacts our results of operations will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the virus and new variants and the actions to contain its impact.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Standards Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our combined financial statements or disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Subsequent Events</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">We consider events or transactions that have occurred after the balance sheet date of December&#160;31, 2021, but prior to the filing of the financial statements with the SEC to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the filing of this registration statement on Form S-4, of which this proxy statement/prospectus/information statement forms a part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3a642b4f_4d32_421e_be19_c18f2c60bf5c"></a><a id="a4Acquisitions_259057_I"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Acquisitions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As set forth below, we completed four acquisitions from January&#160;1, 2019 through December&#160;31, 2021, of which two (Icagen and Ab Initio) were accounted for as business combinations and Taurus and xCella were accounted for as asset acquisitions. For business combinations, we applied the acquisition method of accounting. Accordingly, we recorded the tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the applicable date of acquisition. We did not incur any material acquisition related costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Taurus Acquisition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September&#160;9, 2020, we acquired Taurus, which discovers and humanize antibodies from immunized cows and cow-derived libraries. These antibodies feature some of the longest CDR-H3s of any species, with unique genetic and structural diversity that can enable binding to challenging antigens with application in therapeutics, diagnostics and research.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purchase price of $5.2&#160;million included $4.6&#160;million in cash, and a $0.5&#160;million holdback to satisfy indemnification obligations which were settled in September&#160;2021. Taurus stockholders also received nontransferable contingent value rights (CVRs) representing the right to receive up to $4.5&#160;million tied to partnered and internal research and development and up to $25.0&#160;million as a 25% share of post-clinical Taurus product revenues (including milestone payments) received by us. We evaluated this acquisition in accordance with ASC 805, <i style="font-style:italic;">Business Combinations</i>, to discern whether the assets and operations of Taurus met the definition of a business. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology. As an asset acquisition, for the contingent consideration, we record that when the contingency is resolved and the consideration becomes payable, and as such no amounts were recorded as of the date of acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets as follows (in thousands)</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Cash included in Parent company net investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 47</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Intangibles assets with finite-life&#8201;&#8211;&#8201;core technologies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,155</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,202</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The core technology is being amortized on a straight-line basis over the estimated useful life of 10&#160;years.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">xCella Acquisition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September&#160;8, 2020, we acquired xCella Biosciences, an antibody discovery company. xCella&#8217;s xPloration platform is a proprietary microcapillary platform that can screen single B&#160;cells for specificity and bioactivity which expand our existing single B-cell assay capabilities in the OmniAb technology platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We paid $7.1&#160;million in cash (including a $0.5&#160;million holdback to satisfy indemnification obligations which was settled in September&#160;2021), and issued earnout rights for up to $5.0&#160;million tied to our use of the xCella technology for partnered research and development and for up to $25.75&#160;million as a 25% share of any future milestone payments we received under a certain existing xCella partner arrangement. We evaluated this acquisition in accordance with ASC&#160;805 to discern whether the assets and operations of xCella met the definition of a business. We accounted for this transaction as an asset acquisition as we concluded that substantially all of the fair value of the gross assets acquired was concentrated in the acquired core technology. As an asset acquisition, for the contingent consideration, we record that when the contingency is resolved and the consideration becomes payable, and as such no amounts were recorded as of the date of acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The allocation of the consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash included in Parent company net investment and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 240</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (142)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred tax liabilities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (320)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Intangibles assets with finite-life&#8201;&#8211;&#8201;core technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,298</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,076</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The core technology is being amortized on a straight-line basis over the estimated useful life of 15&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Icagen Acquisition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;1, 2020, we acquired the core assets of Icagen and certain of its affiliates. The Icagen Technology Platform leverages proprietary expertise in the combination of biological assays, medicinal chemistry, and in silico and computational chemistry applications for the discovery of therapeutics targeting ion channel pathways. Icagen is partnered with several globally recognized pharmaceutical companies for ion channel drug discovery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purchase price of $19.9&#160;million included $15.1&#160;million cash consideration paid upon acquisition, and a contingent earnout payment to the selling shareholders of up to $25.0&#160;million of cash payments based on certain revenue milestones with an estimated fair value of $4.8&#160;million. The fair value of the earnout liability was determined using a probability weighted income approach incorporating the estimated future cash flows from expected future milestones. These cash flows were then discounted to present value using a discount rate based on the market participants&#8217; cost of debt reflective of Icagen. Refer to <i style="font-style:italic;">Note&#160;5, Fair Value Measurement</i>, for further discussion. The liability will be periodically assessed based on events and circumstances related to the underlying milestones, and any change in fair value will be recorded in our combined statements of operations. The carrying amount of the liability may fluctuate significantly and the actual amount paid may be materially different than the carrying amount of the liability. The results of Icagen have been included in our results of operations since the date of acquisition.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,173</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Prepaids and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 588</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Liabilities assumed</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (812)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,685)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 821</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Acquired intangibles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,800</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,055</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19,940</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Goodwill represents the excess of the purchase price over the preliminary fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Icagen and expected synergies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The majority of the goodwill is deductible for tax purposes. Acquired intangibles include $11.1&#160;million of customer relationships and $1.7&#160;million of core technology. The fair values of the customer relationships were based on a discounted cash flow analysis incorporating the estimated future cash flows from these relationships during the contractual term. These cash flows were then discounted to present value using a discount rate of 17%. The fair value of the customer relationships is being amortized on a straight-line basis over the weighted average estimated useful life of 9.6&#160;years. The fair value of the core technology was based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of 17%. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of 10&#160;years. The total acquired intangibles are being amortized on a straight-line basis over the estimated weighted average useful life of 9.7&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ab Initio Acquisition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July&#160;23, 2019, we acquired Ab Initio, an antigen-discovery company located in South San Francisco, California. Ab Initio has licensed a patented antigen technology owned by Stanford for the discovery of therapeutic antibodies including against difficult-to-access cellular targets. Ab Initio has a collaboration agreement with Pfizer to discover novel therapeutic antibodies against an undisclosed target in the GPCR superfamily.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purchase price of $12.0&#160;million included $11.9&#160;million cash consideration paid upon acquisition, net of cash acquired, and a $0.15&#160;million cash holdback for potential indemnification claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Cash and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 28</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (83)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (196)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Intangible assets with finite-life - core technologies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,400</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,862</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,011</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Goodwill represents the excess of the purchase price over the fair value of the underlying assets acquired and liabilities assumed. Goodwill is attributable to the assembled workforce of experienced personnel at Ab Initio and expected synergies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">None of the goodwill is deductible for tax purposes. The fair value of the core technologies was determined based on the discounted cash flow method that estimated the present value of the hypothetical royalty/milestone streams from the licensing of the antigen-discovery technology and collaboration agreement. These projected cash flows were discounted to present value using a discount rate of 12.0%. The fair value of the core technologies is being amortized on a straight-line basis over the weighted average estimated useful life of approximately 20&#160;years.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7c2bc1be_54ac_4998_bdfe_a7bdfae98603"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5. Fair Value Measurement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We measure certain financial liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described below with level 1 having the highest priority and level 3 having the lowest:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Level 1&#8201;&#8212;&#8201;Observable inputs such as quoted prices in active markets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Level 2&#8201;&#8212;&#8201;Inputs other than the quoted prices in active markets that are observable either directly or indirectly</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Level 3&#8201;&#8212;&#8201;Unobservable inputs in which there is little or no market data, which require our company to develop its own assumptions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liabilities Measured on a Recurring Basis</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table presents the hierarchy for our liabilities measured at fair value (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:28.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:28.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Crystal contingent liabilities<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 800</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 800</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Icagen contingent liabilities<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,364</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,364</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,404</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,404</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,364</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,364</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,204</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,204</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We acquired Crystal Bioscience in October&#160;2017. The fair value of Crystal contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on development or regulatory milestones as defined in the merger agreement with Crystal. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. Changes in these estimates may materially affect the fair value. During the&#160;year ended December&#160;31, 2020, we paid $1.8&#160;million contingent liability on development milestones to former Crystal shareholders. During the&#160;year ended December&#160;31, 2021, we made no payments former Crystal shareholders for contingent liability on development milestones.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The fair value of Icagen contingent liabilities was determined using a probability weighted income approach. Most of the contingent payments are based on certain revenue milestones as defined in the asset purchase agreement with Icagen. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s estimates regarding the timing and probability of achievement of certain developmental and regulatory milestones. Changes in these estimates may materially affect the fair value. During the&#160;year ended December&#160;31, 2020, we paid $0.5&#160;million contingent liability based on revenue milestones to former Icagen shareholders. During the&#160;year ended December&#160;31, 2021, we paid $1.1 million contingent liability based on revenue milestones to former Icagen shareholders.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of the level&#160;3 financial instruments as of December&#160;31, 2021 and 2020 is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of level 3 financial instruments as of January 1, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,659</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Payments to CVR holders and other contingent payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,325)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Fair value adjustments to contingent liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,070</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Contingent liabilities from Icagen acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,800</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of level 3 financial instruments as of December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,204</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Payments on contingent liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,770)</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Fair value adjustments to contingent liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,210</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Contingent liabilities from xCella asset acquisition<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 720</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,364</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The xCella contingent liabilities is determined when the contingency is resolved and the consideration becomes payable. Management concluded that no earnout liability would be recognized at the acquisition date in September&#160;2020. During the&#160;year </span></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ended December&#160;31, 2021, management paid $0.7 million of earnout liability to be allocated to the cost of the acquired assets due to contingencies being met as part of the acquisition agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts reported in our combined balance sheets for accounts receivable, other assets, accounts payable and other accrued expenses approximate fair value due to relatively short periods to maturity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Assets Measured on a Non-Recurring Basis</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We apply fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets, and long-lived assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level&#160;3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on Level&#160;3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">There were no impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the&#160;years ended December&#160;31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cb5a79b8_2199_48c7_aaed_3303ab7c071f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6. Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain legal entities included in this combined financials lease office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to ten&#160;years, some of which include options to extend the leases for up to ten&#160;years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities, and our finance leases are immaterial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12&#160;months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2021, we entered into several new lease agreements including our Emeryville headquarter and animal facility expansion and a new Icagen office lease, which resulted in an increase in operating lease right of use assets of $12.7 million and lease liabilities of $13.2 million as of December&#160;31, 2021 for the portion of the lease with a starting accounting lease commencement date during the period.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Operating Lease Assets and Liabilities (in thousands):</i></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,332</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,499</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 578</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 579</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Long-term operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,272</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,012</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,850</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,591</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Maturity of Operating Lease Liabilities as of December&#160;31, 2021 (in thousands):</i></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Maturity Dates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;Leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,122</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,178</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,249</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,384</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,433</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,414</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,780</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,603)</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Less tenant improvement allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,327)</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,850</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">As of December&#160;31, 2021, our operating leases have a weighted-average remaining lease term of 9.3&#160;years and a weighted-average discount rate of 4%. As of December&#160;31, 2020, our operating leases have a weighted-average remaining lease term of 4.7&#160;years and a weighted-average discount rate of 7%. Cash paid for amounts included in the measurement of operating lease liabilities was $1.1&#160;million and $0.7 million for the&#160;years ended December&#160;31, 2021 and 2020, respectively. Operating lease expense was $1.6&#160;million, $0.7&#160;million and $0.5&#160;million for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_87145068_c2f8_4e18_a0d4_2ac33118357b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. Balance Sheet Account Details</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property and equipment are stated at cost and consist of the following (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times';font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times';font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Lab and office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,410</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,872</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,495</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 732</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 182</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 182</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,087</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,786</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,292)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,306)</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,795</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,480</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which range from three to ten&#160;years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $2.0&#160;million, $0.8&#160;million and $0.3&#160;million was recognized for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively, and was included in operating expenses.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill and identifiable intangible assets consist of the following (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Indefinite-lived intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 83,979</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 83,979</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Definite-lived intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Complete technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 227,403</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 224,758</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Less: Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (60,099)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (48,321)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Customer relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,100</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Less: Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,083)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (893)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total goodwill and other identifiable intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 260,300</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 270,623</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of up to 20&#160;years. Amortization expense of $13.0&#160;million, $11.8&#160;million and $10.3&#160;million was recognized for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively. Estimated amortization expense for the&#160;years ending December&#160;31, 2022 through 2026 is $13.0&#160;million per&#160;year. For each of the&#160;years ended December&#160;31, 2021, 2020 and 2019, there was no impairment of intangible assets with finite lives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accrued liabilities consist of the following (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,320</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,495</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 67</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Royalties owed to third parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 296</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 272</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Subcontractor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 482</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Acquisitions related liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,500</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 63</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 185</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,746</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,956</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8169c73b_592f_4fed_8f73_a86c9e881e56"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have historically operated as part of Ligand and not as a stand-alone company. We determined the OmniAb income tax provision as if OmniAb had joined in the consolidated federal income tax return and combined state income tax returns separate from Ligand. We recorded a current state income tax expense for the tax&#160;years ended December&#160;31, 2021, 2020 and 2019 for certain OmniAb state minimum taxes. We recorded a deferred federal and state income tax benefit for the&#160;year ended December&#160;31, 2021 and 2020 to reflect the change in the net deferred tax liability for the period. We recorded a deferred federal tax benefit and deferred state tax expense for the&#160;year ended December&#160;31, 2019 to reflect the change in the net deferred tax liability for the period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current expense (benefit):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred expense (benefit):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6,756)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,662)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,779)</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (569)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,523)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,336</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (7,325)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6,185)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 557</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (7,308)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6,171)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 562</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net loss from continuing operations is summarized as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Tax at federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (7,214)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4,983)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,736)</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">State, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (350)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (188)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (207)</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Contingent liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (168)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (12)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (172)</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,143</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,253</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 847</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,064)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (573)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Change in uncertain tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 119</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">State tax rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 37</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,596)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,840</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 228</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (39)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (66)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (10)</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (7,308)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6,171)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 562</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. Significant components of the our deferred tax assets and liabilities as of December&#160;31, 2021 and 2020 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to use the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of the our deferred tax assets will be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a non-current deferred income tax asset or liability (as applicable). Deferred tax assets (liabilities) are comprised of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,618</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,492</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Research credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,803</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,991</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,703</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,373</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,768</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 772</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,088</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 577</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,488</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,015</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance for deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (526)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (403)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,942</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,817</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Identified intangibles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (35,114)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (37,479)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,973)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (560)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (817)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (703)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (38,904)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (38,742)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred income taxes, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (21,962)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (28,925)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, we had federal net operating loss carryforwards set to expire through 2037 of $27.3&#160;million and $12.6&#160;million of state net operating loss carryforwards that begin to expire in 2032. We also have $1.9 million of federal research and development credit carryforwards, which expire through 2028. We have $2.0 million of California research and development credit carryforwards that have no expiration date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Section&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2021 are net of any previous limitations due to Sections 382 and 383.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying combined balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2021, 2020 and 2019 is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Balance at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 766</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 589</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 556</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Additions based on tax positions related to the current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 128</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 94</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Additions for tax positions of prior years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 87</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 33</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Reductions for tax positions in prior years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Balance at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 894</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 766</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 589</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Included in the balance of unrecognized tax benefits at December&#160;31, 2021 is $0.8&#160;million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2021, 2020 and 2019, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States and various state jurisdictions with varying statutes of limitations. The federal statute of limitation remains open for the 2018 tax&#160;year to the present.&#160;The state income tax returns generally remain open for the 2017 tax&#160;year through the present.&#160;Net operating loss and research credit carryforwards arising prior to these&#160;years are also open to examination if and when utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e6e894b9_502f_4ff6_9944_41c3620bd7e8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9. Relationship with Parent and Related Entities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Historically, the OmniAb business has been managed and operated in the normal course of business consistent with other affiliates of the Parent. Accordingly, certain shared costs have been allocated to OmniAb and reflected as expenses in the combined financial statements. Management considers the allocation methodologies used to be reasonable and appropriate reflections of the historical Parent expenses attributable to OmniAb for purposes of the stand-alone financial statements. However, the expenses reflected in the combined financial statements may not be indicative of the actual expenses that would have been incurred during the periods presented if OmniAb historically operated as a separate, stand-alone entity. In addition, the expenses reflected in the combined financial statements may not be indicative of related expenses that will be incurred in the future by OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General Corporate Overhead</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The combined statements of operations include expenses for certain centralized functions (such as information systems, accounting, treasury, audit, purchasing, human resources, legal and facilities), executive compensation and other programs provided and/or administered by Parent that are charged directly to us. A portion of these costs benefits us and is allocated to us using a pro-rata method based on project-related costs or other measures that management believes are consistent and reasonable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Costs of $6.1&#160;million, $3.6&#160;million and $2.8&#160;million for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively, have been reflected in the general and administrative expenses in our combined statements of operations for our allocated share of Parent&#8217;s corporate overhead.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Management and Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We participate in Ligand&#8217;s centralized cash management and financing programs and will continue to participate in Ligand&#8217;s centralized cash management until the OmniAb business becomes an independent publicly-traded company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Disbursements are made through centralized accounts payable systems which are operated by Ligand. Cash receipts are transferred to centralized accounts, also maintained by Ligand. As cash is disbursed and received by Ligand, it is accounted for by us </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">through the Parent company net investment. All obligations are financed by Ligand and financing decisions are determined by central Ligand treasury operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ligand intends to transfer the assets, liabilities and operations of its OmniAb business, pursuant to the terms of a separation agreement, to be entered into between Ligand and OmniAb. Completion of the separation and distribution is subject to certain conditions, including final approval by Ligand&#8217;s board of directors. Ligand is targeting the separation of OmniAb during the second quarter of 2022. The separation is anticipated to be tax-free to Ligand stockholders. Accordingly, after the anticipated tax-free separation, all of the related tax attributes of Ligand will remain with Ligand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity-Based Incentive Plans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain of our employees participate in our Parent&#8217;s equity-based incentive plans. Under the Ligand 2002 Stock Incentive Plan (2002 Plan), our employees, directors, managers and advisors were awarded share-based incentive awards in a number of forms, including nonqualified stock options. Under the 2002 Plan, our employees can be awarded share-based incentive awards which includes non-statutory stock options or incentive stock options, restricted stock units (RSUs), performance stock units (PSUs) and other cash-based or share-based awards. Awards granted to our employees under the incentive plans typically vest 1/8 on the six&#160;month anniversary of the date of grant, and 1/48 each&#160;month thereafter for forty-two&#160;months. We measure share-based compensation for all share-based incentive awards at fair value on the grant date. Share-based compensation expense is generally recognized on a straight-line basis over the requisite service periods of the awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Compensation costs associated with our employees&#8217; participation in the incentive plans have been specifically identified for employees who exclusively support our operations and are allocated to us as part of the cost allocations from our Parent. Total costs charged to us related to our employees&#8217; participation in our Parent&#8217;s incentive plans, depending on the nature of the employee&#8217;s role in our operations, were $15.1&#160;million ($9.0&#160;million in research and development expenses and $6.1&#160;million in general and administrative expenses), $9.2&#160;million ($5.6&#160;million in research and development expenses and $3.6&#160;million in general and administrative expenses) and $6.7&#160;million ($3.9&#160;million in research and development expenses and $2.8&#160;million in general and administrative expenses) during the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our eligible employees participate in our Parent&#8217;s ESPP. The ESPP permits eligible participants to purchase Ligand&#8217;s shares at a discount through regular payroll deductions of up to 10% of their eligible compensation during the offering period. The ESPP is typically implemented through consecutive six-month offering periods. The purchase price of the shares is 85% of the lesser of the fair market value of the closing price per share on the first day of the offering period and the fair market value of the closing price per share on the last day of the offering period. No participant may purchase more than $25,000 worth of common stock per calendar&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Costs charged to us related to our employees&#8217; participation in our Parent&#8217;s ESPP were $0.2&#160;million, $0.1&#160;million and $0.1&#160;million for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e36e98e6_744e_4515_a327_ab2678947543"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10. Commitments and Contingencies: Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we have been and may be involved in various legal proceedings arising in our ordinary course of business. In the opinion of management, resolution of any pending claims (either individually or in the aggregate) is not expected to have a material adverse impact on our combined financial statements, cash flows or financial position and it is not possible to provide an estimated amount of any such loss. However, the outcome of disputes is inherently uncertain. Therefore, although management considers the likelihood of such an outcome to be remote, an unfavorable resolution of one or more matters could materially affect our future results of operations or cash flows, or both, in a particular period.</p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6b508c40_1a47_4a14_bf8e_fbea9e55d03a"></a><a id="_Hlk101198037"></a><a id="Annex_A"></a><a id="AnnexA_695339"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Annex A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Execution Version</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">AGREEMENT AND PLAN OF MERGER</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">DATED AS OF MARCH&#160;23, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">by and among</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">LIGAND PHARMACEUTICALS INCORPORATED,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">OMNIAB,&#160;INC.,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">AVISTA PUBLIC ACQUISITION CORP. II</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">ORWELL MERGER SUB INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f15a56a7_6f9f_4a46_bf41_9fdcf45ec652"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:14.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:6.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td colspan="2" style="vertical-align:top;width:93.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_ARTICLE_I"><span style="font-style:normal;font-weight:normal;">Article&#160;I DEFINITIONS</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-3</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section1_1_Definitions"><span style="font-style:normal;font-weight:normal;">Section&#160;1.1</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section1_1_Definitions"><span style="font-style:normal;font-weight:normal;">Definitions</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-16</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_1_2_Cross_References"><span style="font-style:normal;font-weight:normal;">Section&#160;1.2</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_1_2_Cross_References"><span style="font-style:normal;font-weight:normal;">Cross References</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-16</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_1_3_Interpretation"><span style="font-style:normal;font-weight:normal;">Section&#160;1.3</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_1_3_Interpretation"><span style="font-style:normal;font-weight:normal;">Interpretation</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-17</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_ARTICLE_II"><span style="font-style:normal;font-weight:normal;">Article&#160;II THE MERGER</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-18</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_2_1_The_Merger"><span style="font-style:normal;font-weight:normal;">Section&#160;2.1</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_2_1_The_Merger"><span style="font-style:normal;font-weight:normal;">The Merger</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-18</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_2_2_Closing"><span style="font-style:normal;font-weight:normal;">Section&#160;2.2</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_2_2_Closing"><span style="font-style:normal;font-weight:normal;">Closing</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-18</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_2_3"><span style="font-style:normal;font-weight:normal;">Section&#160;2.3</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_2_3"><span style="font-style:normal;font-weight:normal;">Closing Deliverables; Effective Time</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-19</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_2_4"><span style="font-style:normal;font-weight:normal;">Section&#160;2.4</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_2_4"><span style="font-style:normal;font-weight:normal;">Certificate of Incorporation and Bylaws of the Surviving Corporation; Directors and Officers of the Surviving Corporation</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-20</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_2_5"><span style="font-style:normal;font-weight:normal;">Section&#160;2.5</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_2_5"><span style="font-style:normal;font-weight:normal;">Governance Matters</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-20</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_ARTICLE_III"><span style="font-style:normal;font-weight:normal;">Article&#160;III CONVERSION OF SHARES</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-20</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_3_1"><span style="font-style:normal;font-weight:normal;">Section&#160;3.1</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_3_1"><span style="font-style:normal;font-weight:normal;">Effect on Capital Stock</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-20</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_3_2"><span style="font-style:normal;font-weight:normal;">Section&#160;3.2</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_3_2"><span style="font-style:normal;font-weight:normal;">Surrender and Payment</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-21</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_3_3"><span style="font-style:normal;font-weight:normal;">Section&#160;3.3</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_3_3"><span style="font-style:normal;font-weight:normal;">Earnout</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-23</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_3_4"><span style="font-style:normal;font-weight:normal;">Section&#160;3.4</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_3_4"><span style="font-style:normal;font-weight:normal;">Appraisal Rights</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-24</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_3_5"><span style="font-style:normal;font-weight:normal;">Section&#160;3.5</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_3_5"><span style="font-style:normal;font-weight:normal;">Treatment of SpinCo Equity Awards</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-24</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_ARTICLE_IV"><span style="font-style:normal;font-weight:normal;">Article&#160;IV REPRESENTATIONS AND WARRANTIES OF THE COMPANY RELATING TO THE COMPANY</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-24</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_4_1"><span style="font-style:normal;font-weight:normal;">Section&#160;4.1</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_4_1"><span style="font-style:normal;font-weight:normal;">Organization of the Company</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-25</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_4_2"><span style="font-style:normal;font-weight:normal;">Section&#160;4.2</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_4_2"><span style="font-style:normal;font-weight:normal;">Due Authorization</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-25</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_4_3"><span style="font-style:normal;font-weight:normal;">Section&#160;4.3</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_4_3"><span style="font-style:normal;font-weight:normal;">Governmental Consents</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-25</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_4_4"><span style="font-style:normal;font-weight:normal;">Section&#160;4.4</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_4_4"><span style="font-style:normal;font-weight:normal;">No Conflict</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-25</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_4_5"><span style="font-style:normal;font-weight:normal;">Section&#160;4.5</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_4_5"><span style="font-style:normal;font-weight:normal;">Litigation and Proceedings</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-26</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_4_6"><span style="font-style:normal;font-weight:normal;">Section&#160;4.6</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_4_6"><span style="font-style:normal;font-weight:normal;">Brokers&#8217; Fees</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-26</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_4_7"><span style="font-style:normal;font-weight:normal;">Section&#160;4.7</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_4_7"><span style="font-style:normal;font-weight:normal;">Internal Controls</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-26</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_4_8"><span style="font-style:normal;font-weight:normal;">Section&#160;4.8</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_4_8"><span style="font-style:normal;font-weight:normal;">Company Equity Awards</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-26</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_ARTICLE_V"><span style="font-style:normal;font-weight:normal;">Article&#160;V REPRESENTATIONS AND WARRANTIES OF THE COMPANY RELATING TO SPINCO</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-26</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_1"><span style="font-style:normal;font-weight:normal;">Section&#160;5.1</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_1"><span style="font-style:normal;font-weight:normal;">Organization of SpinCo</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-27</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_2"><span style="font-style:normal;font-weight:normal;">Section&#160;5.2</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_2"><span style="font-style:normal;font-weight:normal;">Due Authorization</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-27</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_3"><span style="font-style:normal;font-weight:normal;">Section&#160;5.3</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_3"><span style="font-style:normal;font-weight:normal;">Capitalization of SpinCo</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-27</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_4"><span style="font-style:normal;font-weight:normal;">Section&#160;5.4</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_4"><span style="font-style:normal;font-weight:normal;">Subsidiaries</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-27</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_5"><span style="font-style:normal;font-weight:normal;">Section&#160;5.5</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_5"><span style="font-style:normal;font-weight:normal;">Capitalization of Subsidiaries</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-28</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_6"><span style="font-style:normal;font-weight:normal;">Section&#160;5.6</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_6"><span style="font-style:normal;font-weight:normal;">Governmental Consents</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-28</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_7"><span style="font-style:normal;font-weight:normal;">Section&#160;5.7</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_7"><span style="font-style:normal;font-weight:normal;">No Conflict</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-28</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_8"><span style="font-style:normal;font-weight:normal;">Section&#160;5.8</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_8"><span style="font-style:normal;font-weight:normal;">Sufficiency of the SpinCo Assets</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-28</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_9"><span style="font-style:normal;font-weight:normal;">Section&#160;5.9</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_9"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-28</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_10"><span style="font-style:normal;font-weight:normal;">Section&#160;5.10</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_10"><span style="font-style:normal;font-weight:normal;">No Undisclosed Liabilities</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-29</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_11"><span style="font-style:normal;font-weight:normal;">Section&#160;5.11</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_11"><span style="font-style:normal;font-weight:normal;">Litigation and Proceedings</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-29</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_12"><span style="font-style:normal;font-weight:normal;">Section&#160;5.12</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_12"><span style="font-style:normal;font-weight:normal;">Real Property</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-29</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_13"><span style="font-style:normal;font-weight:normal;">Section&#160;5.13</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_13"><span style="font-style:normal;font-weight:normal;">Tax Matters</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-29</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_14"><span style="font-style:normal;font-weight:normal;">Section&#160;5.14</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_14"><span style="font-style:normal;font-weight:normal;">Absence of Changes</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-30</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_15"><span style="font-style:normal;font-weight:normal;">Section&#160;5.15</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_15"><span style="font-style:normal;font-weight:normal;">Material Contracts</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-30</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_16"><span style="font-style:normal;font-weight:normal;">Section&#160;5.16</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_16"><span style="font-style:normal;font-weight:normal;">Labor Relations</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-32</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_17"><span style="font-style:normal;font-weight:normal;">Section&#160;5.17</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_17"><span style="font-style:normal;font-weight:normal;">Compliance with Law; Permits</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-32</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_18"><span style="font-style:normal;font-weight:normal;">Section&#160;5.18</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_18"><span style="font-style:normal;font-weight:normal;">SpinCo Benefit Plans</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-33</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_19"><span style="font-style:normal;font-weight:normal;">Section&#160;5.19</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_19"><span style="font-style:normal;font-weight:normal;">Intellectual Property</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-34</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_20"><span style="font-style:normal;font-weight:normal;">Section&#160;5.20</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_20"><span style="font-style:normal;font-weight:normal;">Environmental Matters</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-36</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_21"><span style="font-style:normal;font-weight:normal;">Section&#160;5.21</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_21"><span style="font-style:normal;font-weight:normal;">Affiliate Matters</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-37</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_22"><span style="font-style:normal;font-weight:normal;">Section&#160;5.22</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_22"><span style="font-style:normal;font-weight:normal;">Brokers&#8217; Fees</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-37</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_23"><span style="font-style:normal;font-weight:normal;">Section&#160;5.23</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_23"><span style="font-style:normal;font-weight:normal;">Proxy Statement; Registration Statements</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-37</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_24"><span style="font-style:normal;font-weight:normal;">Section&#160;5.24</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_24"><span style="font-style:normal;font-weight:normal;">Board and Shareholder Approval</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-37</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_25"><span style="font-style:normal;font-weight:normal;">Section&#160;5.25</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_25"><span style="font-style:normal;font-weight:normal;">Parent Capital Stock</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-37</p></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:14.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:6.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_26"><span style="font-style:normal;font-weight:normal;">Section&#160;5.26</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_26"><span style="font-style:normal;font-weight:normal;">Healthcare Regulatory Matters</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-37</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_27"><span style="font-style:normal;font-weight:normal;">Section&#160;5.27</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_27"><span style="font-style:normal;font-weight:normal;">Data Privacy</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-38</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_28"><span style="font-style:normal;font-weight:normal;">Section&#160;5.28</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_28"><span style="font-style:normal;font-weight:normal;">Anti-Bribery, Anti-Corruption and Anti-Money Laundering</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-38</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_29"><span style="font-style:normal;font-weight:normal;">Section&#160;5.29</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_29"><span style="font-style:normal;font-weight:normal;">Sanctions,&#160;Import, and Export Controls</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-39</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_30"><span style="font-style:normal;font-weight:normal;">Section&#160;5.30</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_5_30"><span style="font-style:normal;font-weight:normal;">No Other Representations and Warranties</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-39</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_ARTICLE_VI"><span style="font-style:normal;font-weight:normal;">Article&#160;VI REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-40</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_1"><span style="font-style:normal;font-weight:normal;">Section&#160;6.1</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_1"><span style="font-style:normal;font-weight:normal;">Organization of Parent and Merger Sub</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-40</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_2"><span style="font-style:normal;font-weight:normal;">Section&#160;6.2</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_2"><span style="font-style:normal;font-weight:normal;">Due Authorization</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-40</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_3"><span style="font-style:normal;font-weight:normal;">Section&#160;6.3</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_3"><span style="font-style:normal;font-weight:normal;">Capital Stock and Other Matters</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-41</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_4"><span style="font-style:normal;font-weight:normal;">Section&#160;6.4</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_4"><span style="font-style:normal;font-weight:normal;">Governmental Consents</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-42</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_5"><span style="font-style:normal;font-weight:normal;">Section&#160;6.5</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_5"><span style="font-style:normal;font-weight:normal;">No Conflict</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-42</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_6"><span style="font-style:normal;font-weight:normal;">Section&#160;6.6</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_6"><span style="font-style:normal;font-weight:normal;">Internal Controls; Listing; Financial Statements</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-42</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_7"><span style="font-style:normal;font-weight:normal;">Section&#160;6.7</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_7"><span style="font-style:normal;font-weight:normal;">No Undisclosed Liabilities</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-43</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_8"><span style="font-style:normal;font-weight:normal;">Section&#160;6.8</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_8"><span style="font-style:normal;font-weight:normal;">Litigation and Proceedings</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-43</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_9"><span style="font-style:normal;font-weight:normal;">Section&#160;6.9</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_9"><span style="font-style:normal;font-weight:normal;">Tax Matters</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-43</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_10"><span style="font-style:normal;font-weight:normal;">Section&#160;6.10</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_10"><span style="font-style:normal;font-weight:normal;">Absence of Changes</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-44</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_11"><span style="font-style:normal;font-weight:normal;">Section&#160;6.11</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_11"><span style="font-style:normal;font-weight:normal;">Brokers&#8217; Fees</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-44</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_12"><span style="font-style:normal;font-weight:normal;">Section&#160;6.12</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_12"><span style="font-style:normal;font-weight:normal;">Proxy Statement; Registration Statements</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-44</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_13"><span style="font-style:normal;font-weight:normal;">Section&#160;6.13</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_13"><span style="font-style:normal;font-weight:normal;">SEC Filings</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-44</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_14"><span style="font-style:normal;font-weight:normal;">Section&#160;6.14</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_14"><span style="font-style:normal;font-weight:normal;">Trust Account.</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-45</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_15"><span style="font-style:normal;font-weight:normal;">Section&#160;6.15</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_15"><span style="font-style:normal;font-weight:normal;">Investment Company Act; JOBS Act.</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-45</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_16"><span style="font-style:normal;font-weight:normal;">Section&#160;6.16</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_16"><span style="font-style:normal;font-weight:normal;">Indebtedness</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-45</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_17"><span style="font-style:normal;font-weight:normal;">Section&#160;6.17</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_17"><span style="font-style:normal;font-weight:normal;">Stock Market Quotation</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-45</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_18"><span style="font-style:normal;font-weight:normal;">Section&#160;6.18</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_18"><span style="font-style:normal;font-weight:normal;">Business Activities</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-45</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_19"><span style="font-style:normal;font-weight:normal;">Section&#160;6.19</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_19"><span style="font-style:normal;font-weight:normal;">Section&#160;280G</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-46</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_20"><span style="font-style:normal;font-weight:normal;">Section&#160;6.20</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_6_20"><span style="font-style:normal;font-weight:normal;">No Other Representations and Warranties</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-46</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_ARTICLE_VII"><span style="font-style:normal;font-weight:normal;">Article&#160;VII COVENANTS</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-47</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_1"><span style="font-style:normal;font-weight:normal;">Section&#160;7.1</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_1"><span style="font-style:normal;font-weight:normal;">Conduct of Business by Parent and Merger Sub Pending the Merger</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-47</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_2"><span style="font-style:normal;font-weight:normal;">Section&#160;7.2</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_2"><span style="font-style:normal;font-weight:normal;">Conduct of SpinCo Business Pending the Merger</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-48</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_3"><span style="font-style:normal;font-weight:normal;">Section&#160;7.3</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_3"><span style="font-style:normal;font-weight:normal;">Tax Matters</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-50</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_4"><span style="font-style:normal;font-weight:normal;">Section&#160;7.4</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_4"><span style="font-style:normal;font-weight:normal;">Preparation of the Registration Statements and Prospectus; Parent Shareholders Meeting</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-51</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_5"><span style="font-style:normal;font-weight:normal;">Section&#160;7.5</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_5"><span style="font-style:normal;font-weight:normal;">Modification in Recommendation</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-53</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_6"><span style="font-style:normal;font-weight:normal;">Section&#160;7.6</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_6"><span style="font-style:normal;font-weight:normal;">Reasonable Best Efforts</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-53</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_7"><span style="font-style:normal;font-weight:normal;">Section&#160;7.7</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_7"><span style="font-style:normal;font-weight:normal;">[Intentionally Omitted]</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-54</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_8"><span style="font-style:normal;font-weight:normal;">Section&#160;7.8</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_8"><span style="font-style:normal;font-weight:normal;">Access to Information</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-55</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_9"><span style="font-style:normal;font-weight:normal;">Section&#160;7.9</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_9"><span style="font-style:normal;font-weight:normal;">Exclusivity</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-55</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_10"><span style="font-style:normal;font-weight:normal;">Section&#160;7.10</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_10"><span style="font-style:normal;font-weight:normal;">Public Announcements</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-56</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_11"><span style="font-style:normal;font-weight:normal;">Section&#160;7.11</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_11"><span style="font-style:normal;font-weight:normal;">Defense of Litigation</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-57</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_12"><span style="font-style:normal;font-weight:normal;">Section&#160;7.12</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_12"><span style="font-style:normal;font-weight:normal;">Section&#160;16 Matters</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-57</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_13"><span style="font-style:normal;font-weight:normal;">Section&#160;7.13</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_13"><span style="font-style:normal;font-weight:normal;">Control of Other Party&#8217;s Business</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-57</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_14"><span style="font-style:normal;font-weight:normal;">Section&#160;7.14</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_14"><span style="font-style:normal;font-weight:normal;">SpinCo Share Issuance</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-57</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_15"><span style="font-style:normal;font-weight:normal;">Section&#160;7.15</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_15"><span style="font-style:normal;font-weight:normal;">Domestication</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-57</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_16"><span style="font-style:normal;font-weight:normal;">Section&#160;7.16</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_16"><span style="font-style:normal;font-weight:normal;">Transaction Documents</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-58</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_17"><span style="font-style:normal;font-weight:normal;">Section&#160;7.17</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_17"><span style="font-style:normal;font-weight:normal;">NASDAQ Listing</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-58</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_18"><span style="font-style:normal;font-weight:normal;">Section&#160;7.18</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_18"><span style="font-style:normal;font-weight:normal;">Takeover Statutes</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-58</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_19"><span style="font-style:normal;font-weight:normal;">Section&#160;7.19</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_19"><span style="font-style:normal;font-weight:normal;">Obligations of Merger Sub and SpinCo</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-58</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_20"><span style="font-style:normal;font-weight:normal;">Section&#160;7.20</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_20"><span style="font-style:normal;font-weight:normal;">Further Assurances</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-58</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_21"><span style="font-style:normal;font-weight:normal;">Section&#160;7.21</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_21"><span style="font-style:normal;font-weight:normal;">Sole Shareholder Approvals</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-58</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_22"><span style="font-style:normal;font-weight:normal;">Section&#160;7.22</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_7_22"><span style="font-style:normal;font-weight:normal;">Financial Information</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-58</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_ARTICLE_VIII"><span style="font-style:normal;font-weight:normal;">Article&#160;VIII CONDITIONS TO THE MERGER</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-59</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_8_1"><span style="font-style:normal;font-weight:normal;">Section&#160;8.1</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_8_1"><span style="font-style:normal;font-weight:normal;">Conditions to the Obligations of SpinCo, the Company, Parent and Merger Sub to Effect the Merger</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-59</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_8_2"><span style="font-style:normal;font-weight:normal;">Section&#160;8.2</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_8_2"><span style="font-style:normal;font-weight:normal;">Additional Conditions to the Obligations of the Company and SpinCo</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-60</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_8_3"><span style="font-style:normal;font-weight:normal;">Section&#160;8.3</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_8_3"><span style="font-style:normal;font-weight:normal;">Additional Conditions to the Obligations of Parent and Merger Sub</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-61</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_ARTICLE_IX"><span style="font-style:normal;font-weight:normal;">Article&#160;IX TERMINATION</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-62</p></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:14.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:6.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_9_1"><span style="font-style:normal;font-weight:normal;">Section&#160;9.1</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_9_1"><span style="font-style:normal;font-weight:normal;">Termination</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-62</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_9_2"><span style="font-style:normal;font-weight:normal;">Section&#160;9.2</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_9_2"><span style="font-style:normal;font-weight:normal;">Effect of Termination</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-63</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_9_3"><span style="font-style:normal;font-weight:normal;">Section&#160;9.3</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_9_3"><span style="font-style:normal;font-weight:normal;">Termination Fee.</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-63</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_9_4"><span style="font-style:normal;font-weight:normal;">Section&#160;9.4</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_9_4"><span style="font-style:normal;font-weight:normal;">Fees and Expenses</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-63</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_ARTICLE_X"><span style="font-style:normal;font-weight:normal;">Article&#160;X MISCELLANEOUS</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-64</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_1"><span style="font-style:normal;font-weight:normal;">Section&#160;10.1</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_1"><span style="font-style:normal;font-weight:normal;">Trust Account Waiver</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-64</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_2"><span style="font-style:normal;font-weight:normal;">Section&#160;10.2</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_2"><span style="font-style:normal;font-weight:normal;">Non-Survival of Representations, Warranties and Agreements</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-64</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_3"><span style="font-style:normal;font-weight:normal;">Section&#160;10.3</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_3"><span style="font-style:normal;font-weight:normal;">Governing Law; Jurisdiction</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-65</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_4"><span style="font-style:normal;font-weight:normal;">Section&#160;10.4</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_4"><span style="font-style:normal;font-weight:normal;">Notices</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-65</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_5"><span style="font-style:normal;font-weight:normal;">Section&#160;10.5</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_5"><span style="font-style:normal;font-weight:normal;">Headings</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-66</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_6"><span style="font-style:normal;font-weight:normal;">Section&#160;10.6</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_6"><span style="font-style:normal;font-weight:normal;">Entire Agreement</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-66</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_7"><span style="font-style:normal;font-weight:normal;">Section&#160;10.7</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_7"><span style="font-style:normal;font-weight:normal;">Amendments and Waivers</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-66</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_8"><span style="font-style:normal;font-weight:normal;">Section&#160;10.8</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_8"><span style="font-style:normal;font-weight:normal;">Assignment; Parties in Interest; Non-Parties</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-66</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_9"><span style="font-style:normal;font-weight:normal;">Section&#160;10.9</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_9"><span style="font-style:normal;font-weight:normal;">Specific Performance</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-66</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_10"><span style="font-style:normal;font-weight:normal;">Section&#160;10.10</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_10"><span style="font-style:normal;font-weight:normal;">WAIVER OF JURY TRIAL</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-67</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_11"><span style="font-style:normal;font-weight:normal;">Section&#160;10.11</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_11"><span style="font-style:normal;font-weight:normal;">Severability</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-67</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_12"><span style="font-style:normal;font-weight:normal;">Section&#160;10.12</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_12"><span style="font-style:normal;font-weight:normal;">Counterparts</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-67</p></td></tr><tr><td style="vertical-align:top;width:14.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_13"><span style="font-style:normal;font-weight:normal;">Section&#160;10.13</span></a></p></td><td style="vertical-align:top;width:79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_13"><span style="font-style:normal;font-weight:normal;">Disclosure Schedules</span></a></p></td><td style="vertical-align:top;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-67</p></td></tr><tr><td style="vertical-align:top;width:14.51%;margin:0pt;padding:0pt 0pt 0pt 18pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_14"><span style="font-style:normal;font-weight:normal;">Section&#160;10.14</span></a></p></td><td style="vertical-align:top;width:79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#A_Section_10_14"><span style="font-style:normal;font-weight:normal;">Conflicts and Privilege</span></a></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">A-68</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">EXHIBITS</b></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exhibit&#160;A</p></td><td style="vertical-align:top;width:89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Separation and Distribution Agreement</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exhibit&#160;B</p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Form&#160;of Tax Matters Agreement</p></td></tr><tr><td style="vertical-align:top;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exhibit&#160;C</p></td><td style="vertical-align:top;width:89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Employee Matters Agreement</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exhibit&#160;D-1</p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Form&#160;of Transition Services Agreement (Company-Provided)</p></td></tr><tr><td style="vertical-align:top;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exhibit&#160;D-2</p></td><td style="vertical-align:top;width:89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Form&#160;of Transition Services Agreement (SpinCo-Provided)</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exhibit&#160;E</p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Form&#160;of A&amp;R Registration Rights Agreement</p></td></tr><tr><td style="vertical-align:top;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exhibit&#160;F</p></td><td style="vertical-align:top;width:89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Form&#160;of Sponsor Insider Agreement</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exhibit&#160;G</p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Form&#160;of Parent Charter</p></td></tr><tr><td style="vertical-align:top;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exhibit&#160;H</p></td><td style="vertical-align:top;width:89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Form&#160;of Parent Bylaws</p></td></tr><tr><td style="vertical-align:top;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exhibit&#160;I</p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">A&amp;R Forward Purchase Agreement</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-iii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a58ecef6_4593_4e48_829c_d23eb0da69bb"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AGREEMENT AND PLAN OF MERGER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This AGREEMENT AND PLAN OF MERGER, dated as of March&#160;23, 2022, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</span>&#8221;), OmniAb,&#160;Inc., a Delaware corporation and wholly owned Subsidiary of the Company (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo</span>&#8221;), Avista Public Acquisition Corp. II, a Cayman Islands exempted company (which will migrate to and domesticate as a Delaware corporation prior to the Closing (as defined below)) (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent</span>&#8221;), and Orwell Merger Sub Inc., a Delaware corporation and wholly owned Subsidiary of Parent (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Sub</span>&#8221;). Each of the foregoing parties is referred to herein as a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Party</span>&#8221; and collectively as the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</span>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>Parent is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</span></span>At least one day prior to the Effective Time (as defined below), as the first step in the consummation of the Transactions and subject to the conditions set forth in this Agreement, Parent shall migrate to and domesticate as a Delaware corporation (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Domestication</span>&#8221;) in accordance with Section&#160;388 of the Delaware General Corporation Law, as amended (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DGCL</span>&#8221;) and the Cayman Islands Companies Act (As Revised) (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CICA</span>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(3)</span></span>Concurrently with the Domestication, Parent shall file a certificate of incorporation with the Secretary of State of the State of Delaware and adopt bylaws substantially in the forms attached as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibits G</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">H</span> hereto, respectively, with such changes as may be agreed in writing by Parent and the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(4)</span></span>In connection with the Domestication, (i)&#160;each then issued and outstanding share of Parent Class&#160;A Common Stock (as defined below) shall convert automatically, on a one-for-one basis, into one share of common stock, par value $0.0001, per share of Parent (after its domestication as a corporation incorporated in the State of Delaware) (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Domesticated Parent Common Stock</span>&#8221;); (ii)&#160;each then issued and outstanding share of Parent Class&#160;B Common Stock (as defined below) shall convert automatically, on a one-for-one basis, into one share of Domesticated Parent Common Stock; (iii)&#160;each then issued and outstanding Parent Warrant (as defined below) shall convert automatically into a warrant to acquire one share of Domesticated Parent Common Stock (each, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Domesticated Parent Warrant</span>&#8221;), pursuant to the Warrant Agreement (as defined below); and (iv)&#160;each then issued and outstanding unit of Parent (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Units</span>&#8221;) shall separate and convert automatically into one share of Domesticated Parent Common Stock and one-third of one Domesticated Parent Warrant;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(5)</span></span>SpinCo is a wholly owned, direct Subsidiary of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(6)</span></span>Contemporaneously with the execution of this Agreement, the Company, SpinCo and Parent are entering into the Separation and Distribution Agreement, pursuant to which the Company will, upon the terms and conditions set forth therein and in accordance with the Internal Reorganization, separate the SpinCo Business such that, after giving effect to the Separation (as defined in the Separation and Distribution Agreement), the SpinCo Business is held by the SpinCo Entities (each foregoing capitalized term as defined below);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_734028c8_b90c_49f2_8274_56dcbfa4ff55"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(7)</span></span>Prior to the Distribution (as defined below), in accordance with the Separation and Distribution Agreement, the Company will make the Contribution (as defined below) to SpinCo;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(8)</span></span>Upon the terms and subject to the conditions set forth in the Separation and Distribution Agreement, on the Distribution Date (as defined below), the Company will distribute all of the shares of SpinCo Common Stock (as defined below) to the Company stockholders without consideration on a <i style="font-style:italic;">pro rata </i>basis as set forth in the Separation and Distribution Agreement (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Distribution</span>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(9)</span></span>Following the Domestication and the Distribution, at the Effective Time, (i)&#160;the Parties will effect the merger of Merger Sub with and into SpinCo, with SpinCo continuing as the surviving corporation (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger</span>&#8221;), upon the terms and subject to the conditions set forth herein and (ii)&#160;Parent will change its name to &#8220;OmniAb,&#160;Inc.&#8221;;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(10)</span></span>Pursuant to the Merger, shares of SpinCo Common Stock will be exchanged for shares of Domesticated Parent Stock (as defined below), on the terms and subject to the conditions set forth herein;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(11)</span></span>The board of directors of Parent (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Board</span>&#8221;) unanimously has (a)&#160;determined that the terms of this Agreement and the Transactions (as defined below) are in the best interests of Parent, (b)&#160;approved and declared advisable the execution, delivery and performance of this Agreement and the consummation of the Transactions, on the terms and subject to the conditions set forth herein, (c)&#160;resolved to recommend that the shareholders of Parent approve the Transaction Proposals (as defined below), on the terms and subject to the conditions set forth herein (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Board Recommendation</span>&#8221;), and (d)&#160;directed that each of the Transaction Proposals be submitted to a vote at a meeting of Parent&#8217;s shareholders;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(12)</span></span>The board of directors of Merger Sub has determined that the Merger and this Agreement are advisable, has approved this Agreement and the Transactions, including the Merger, and has recommended the approval of this Agreement and the Merger to the sole stockholder of Merger Sub;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(13)</span></span>Parent, as the sole stockholder of Merger Sub, immediately following the execution and delivery of this Agreement, will approve and adopt this Agreement and the Transactions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(14)</span></span>The board of directors of the Company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Board</span>&#8221;) unanimously has approved this Agreement and the Transactions, subject to such further action by the Company Board required to establish the Record Date and the Distribution Date (each as defined below), and the declaration of the Distribution by the Company Board (the effectiveness of which is subject to the satisfaction or, to the extent permitted by applicable Law, waiver of the conditions set forth in the Separation and Distribution Agreement);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(15)</span></span>The board of directors of SpinCo (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Board</span>&#8221;) has determined that the Merger and this Agreement are advisable, has approved this Agreement and the Transactions and has recommended the approval of this Agreement and the Merger to the sole stockholder of SpinCo;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(16)</span></span>The Company, as the sole stockholder of SpinCo, immediately following the execution and delivery of this Agreement, will approve and adopt this Agreement and the Transactions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(17)</span></span>In accordance with the terms of this Agreement, Parent shall provide an opportunity to holders of the Parent Class&#160;A Common Stock to have their outstanding shares redeemed on the terms and subject to the conditions set forth in this Agreement and Parent&#8217;s Governing Documents (as defined below) in connection with obtaining the Parent Shareholder Approval (as defined below);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(18)</span></span>Concurrently with the execution and delivery of this Agreement, Parent entered into the A&amp;R Forward Purchase Agreement (as defined below) with the Sponsor (as defined below) pursuant to which, and on the terms and subject to the conditions of which, Sponsor has agreed to purchase from Parent the shares of Domesticated Parent Common Stock and Domesticated Parent Warrants described therein, such purchases to be consummated following the Domestication and immediately prior to the Distribution;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(19)</span></span>At the Effective Time, Parent, the Sponsor, the independent directors of Parent, and the other Persons named as parties therein shall amend and restate that certain Registration and Shareholder Rights Agreement, dated August&#160;9, 2021, by and among Parent, the Sponsor and the other Persons party thereto, substantially in the form attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;E</span> (as so amended and restated, and with such further changes as may be agreed in writing by Parent and the Company, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">A&amp;R Registration Rights </span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</span>&#8221;), to, among other things, include a three (3)&#160;month lockup on shares issued to directors and officers of the Company and SpinCo;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(20)</span></span>Concurrently with the execution and delivery of this Agreement, the Sponsor, Parent and the other Persons named as parties therein have entered into that certain sponsor insider letter agreement (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sponsor Insider Agreement</span>&#8221;), pursuant to which, among other things, in connection with the Closing, the Sponsor shall subject the shares of Domesticated Parent Common Stock described therein to potential forfeiture in the event that certain funding and/or share price targets are not achieved, upon the terms and subject to the conditions set forth therein; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(21)</span></span>It is the intention of the Parties that, for U.S. federal income Tax purposes: (a)&#160;the Domestication qualify as a &#8220;reorganization&#8221; under Section&#160;368(a)(1)(F)&#160;of the Code, (b)&#160;the Contribution and the Distribution, taken together, qualify as a &#8220;reorganization&#8221; under Sections 368(a)(1)(D)&#160;and 355(a)&#160;of the Code; (c)&#160;the Merger qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code; and (d)&#160;each of this Agreement and the Separation and Distribution Agreement constitute a &#8220;plan of reorganization&#8221; for purposes of Section&#160;368 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">NOW, THEREFORE:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In consideration of the premises and mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</p><a id="A_ARTICLE_I"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="color:#010000;">ARTICLE&#160;I</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">DEFINITIONS</p><a id="A_Section1_1_Definitions"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</span>. As used herein, the following terms have the following meanings; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that terms that are defined by reference to a defined term in the Separation and Distribution Agreement and include herein the term &#8220;SpinCo&#8221; shall be understood to be referring to the correlative defined term for &#8220;SpinCo&#8221; used in the Separation and Distribution Agreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">A&amp;R Forward Purchase Agreement</span>&#8221; means the Amended and Restated Forward Purchase Agreement, dated as of the date hereof, by and among Parent, the Sponsor and the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">A&amp;R Registration Rights Agreement</span>&#8221; has the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(3)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Action</span>&#8221; means any claim, action, suit, litigation, arbitration, mediation, inquiry, investigation or other proceeding, in each case, by any Person or Governmental Authority, in each case, before, heard by or otherwise involving any Governmental Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(4)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Actual Fraud</span>&#8221; means, with respect to a Party, an actual and intentional fraud with respect to the making of the representations and warranties pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IV</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VI</span> (as applicable); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that such actual and intentional fraud shall only be deemed to exist if the applicable representations and warranties were, to the Knowledge of the Company or SpinCo, in the case of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IV</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</span>, or to the Knowledge of Parent, in the case of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VI</span>, actually breached when made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(5)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjusted Parent Equity Award</span>&#8221; has the meaning set forth in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(6)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjusted Parent Option</span>&#8221; has the meaning set forth in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(7)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjusted Parent PSU Award</span>&#8221; has the meaning set forth in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(8)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjusted Parent RSU Award</span>&#8221; has the meaning set forth in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(9)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliate</span>&#8221; means, with respect to any Person, any other Person that, directly or indirectly, controls, is controlled by, or is under common control with, such Person, through one or more intermediaries or otherwise. For the avoidance of doubt, following the Effective Time, Affiliates of Parent shall include the SpinCo Entities.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(10)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Aggregate Common Consideration Shares</span>&#8221; means the quotient of (i)&#160;the sum of (a)&#160;$850,000,000, plus (b)&#160;an amount equal to the aggregate exercise price of SpinCo Options that are issued and outstanding as of immediately prior to the Effective Time, divided by (ii)&#160;$10; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that if the Aggregate Common Consideration Shares as so calculated (together with the number of Included SpinCo Shares, calculated including shares underlying SpinCo Options, as applicable) would result in the product of (x)&#160;the Base Exchange Ratio, multiplied by (y)&#160;$10, being less than the exercise price of any of the SpinCo Options issued and outstanding as of immediately prior to the Effective Time, then the calculation described in this definition shall be repeated by excluding the exercise price of all of the SpinCo Options with the highest exercise price per share from the calculation of the aggregate exercise price described in clause (i)(b)&#160;of this definition and excluding any shares underlying such SpinCo Options from the calculation of Included SpinCo Shares, in each case, on an iterative basis until the resulting calculations of Aggregate Common Consideration Shares and Included SpinCo Shares causes the product of (I)&#160;the Base Exchange Ratio and (II)&#160;$10 to be equal to or in excess of the exercise price of all of the SpinCo Options included in such calculations, and the number of Aggregate Common Consideration Shares so calculated shall be the &#8220;Aggregate Common Consideration Shares&#8221; for the purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(11)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</span>&#8221; means this Agreement and Plan of Merger, including all Annexes, Exhibits and Schedules hereto (including the SpinCo Disclosure Schedule, the Company Disclosure Schedule and the Parent Disclosure Schedule), as it may be amended, restated, modified or supplemented from time to time in accordance with its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(12)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Antitrust Laws</span>&#8221; means the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, the HSR Act and all other applicable Laws issued by a Governmental Authority that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade or lessening of competition through merger or acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(13)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Balance Sheet Date</span>&#8221; means December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(14)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Exchange Ratio</span>&#8221; means the quotient of (i)&#160;the Aggregate Common Consideration Shares, divided by (ii)&#160;the number of Included SpinCo Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(15)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Benefit Plan</span>&#8221; has the meaning given to such term in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(16)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">BLA</span>&#8221; means a biologics license application submitted to the FDA pursuant to 42 U.S.C. &#167; 262 and 21 C.F.R. Part&#160;601, and all supplements, amendments, variations, extensions and renewals thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(17)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Combination</span>&#8221; has the meaning set forth in Parent&#8217;s Governing Documents as in effect on the date hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(18)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Day</span>&#8221; means any day that is not a Saturday, a Sunday or other day on which banking institutions in New York, New York or Governmental Authorities in the Cayman Islands (for so long as Parent remains domiciled in the Cayman Islands) are authorized or obligated by Law to be closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(19)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cayman Registrar</span>&#8221; means the Registrar of Companies of the Cayman Islands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(20)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change of Control</span>&#8221; means any transaction or series of transactions (a)&#160;in which the holders of all of the outstanding voting securities of Parent immediately prior to the consummation of such transaction do not directly or indirectly (including through Affiliates) own beneficially or of record immediately upon the consummation of such transaction a majority of the combined outstanding voting securities of the surviving entity in such transaction or of a parent of the surviving entity in such transaction, (b)&#160;in which a majority of Parent&#8217;s voting securities (outstanding after such transaction) are transferred to or acquired by any Person, or any two or more Persons acting as a &#8220;group&#8221; (as defined in the Exchange Act), and all Affiliates of such Person or Persons (each, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Group</span>&#8221;), (c)&#160;constituting a merger, consolidation, reorganization or other business combination, however effected, following which any Person or Group of Persons (other than Parent, SpinCo or any of their respective Subsidiaries) has direct or indirect beneficial ownership of securities (or rights convertible into or exchangeable into securities) representing fifty percent (50%) or more of the voting power of or economic rights or interests in Parent or SpinCo or the surviving Person after such merger, consolidation, reorganization or combination or (d)&#160;the result of which is a sale of all or substantially all of the assets of Parent or SpinCo to any Person (other than Parent, SpinCo or any of their respective Subsidiaries).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(21)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</span>&#8221; means the Internal Revenue Code of 1986, as amended.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(22)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Benefit Plan</span>&#8221; has the meaning given to such term in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(23)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Common Stock</span>&#8221; means the common stock, par value $0.001 per share, of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(24)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Distribution Tax Representations</span>&#8221; means the representations of an officer of the Company and/or SpinCo, dated as of the Closing Date, in form and substance reasonably satisfactory to LW, delivered to LW in connection with the Company Distribution Tax Opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(25)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Disclosure Schedule</span>&#8221; means the Disclosure Schedule delivered by the Company to Parent on the date hereof and identified as such.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(26)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Equity Award</span>&#8221; has the meaning given to such term in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(27)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Material Adverse Effect</span>&#8221; means any Effect that has, or would reasonably be expected to, individually or in the aggregate, materially impair, materially delay or otherwise have a material adverse effect on the ability of the Company to perform its obligations hereunder or under the other Transaction Documents or to consummate the Transactions, including the Separation and the Distribution, or prevent it from performing such obligations or consummating such Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(28)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Option</span>&#8221; has the meaning given to such term in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(29)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company PSU Award</span>&#8221; has the meaning given to such term in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(30)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Real Property</span>&#8221; means any real property owned, leased, subleased, licensed or otherwise occupied by the Company or any of its Subsidiaries (other than the SpinCo Entities), in each case, that is used in connection with the SpinCo Business as it is currently conducted or contemplated to be conducted in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(31)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company RSU Award</span>&#8221; has the meaning given to such term in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(32)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company SEC Documents</span>&#8221; means all forms, reports, Schedules, statements and other documents required to be filed or furnished by the Company or SpinCo with the SEC since January&#160;1, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(33)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Service Provider</span>&#8221; has the meaning given to such term in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(34)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Tax Opinions</span>&#8221; means the Company Distribution Tax Opinion and the Company Merger Tax Opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(35)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality Agreement</span>&#8221; means that certain Confidentiality Agreement, by and between Parent and the Company, dated as of February&#160;21, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(36)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consent</span>&#8221; means any consent, clearance, expiration or termination of a waiting period, approval, exemption, waiver, authorization, filing, registration or notification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(37)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contract</span>&#8221; means any legally binding contract, agreement, understanding, arrangement, loan or credit agreement, note, bond, indenture, lease, warranty, purchase order, sublicense or license or other instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(38)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contribution</span>&#8221; has the meaning set forth in the Separation and Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(39)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COVID-19</span>&#8221; means SARS-CoV-2 or COVID-19, and any evolutions or mutations thereof or related or associated epidemics, pandemics or disease outbreaks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(40)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COVID-19 Measures</span>&#8221; means any quarantine, &#8220;shelter in place,&#8221; &#8220;stay at home,&#8221; social distancing, shut down, closure, sequester, workplace safety or similar Law, directive, guidelines or recommendations promulgated by any industry group or any Governmental Authority, including the Centers for Disease Control and Prevention and the World Health Organization, in each case, in connection with or in response to COVID-19, including the CARES Act and Families First Coronavirus Response Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(41)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DGCL</span>&#8221; has the meaning set forth in the Recitals.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(42)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Distribution Date</span>&#8221; has the meaning set forth in the Separation and Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(43)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Distribution Time</span>&#8221; has the meaning set forth in the Separation and Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(44)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Domesticated Parent Common Stock</span>&#8221; has the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(45)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Domesticated Parent Stock</span>&#8221; means the Domesticated Parent Common Stock and the Earnout Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(46)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Domesticated Parent Warrant</span>&#8221; has the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(47)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Earnout Exchange Ratio</span>&#8221; means the quotient of (i)&#160;15,000,000, divided by (ii)&#160;the number of Fully Diluted SpinCo Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(48)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect</span>&#8221; means any change, event, development, condition, occurrence or effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(49)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employee Matters Agreement</span>&#8221; means the Employee Matters Agreement, dated as of the date hereof, by and among Parent, the Company and SpinCo, attached as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;C</span> to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(50)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entity</span>&#8221; means any Person that is a legal entity; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that when used in reference to Parent or SpinCo, &#8220;Entity&#8221; means Parent or SpinCo, in each case together with its respective Subsidiaries, taken as a whole.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(51)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Environmental Laws</span>&#8221; means any Law relating to pollution or protection of the environment, natural resources, or human health and safety (to the extent related to exposure to Hazardous Materials or hazardous conditions).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(52)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ERISA</span>&#8221; means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated and rulings issued thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(53)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ERISA Affiliate</span>&#8221; means, with respect to any entity, trade or business, any other entity, trade or business that is a member of a group described in Section&#160;414(b), (c), (m)&#160;or (o)&#160;of the Code or Section&#160;4001(b)(1)&#160;of ERISA that includes the first entity, trade or business, or that is a member of the same &#8220;controlled group&#8221; as the first entity, trade or business pursuant to Section&#160;4001(a)(14) of ERISA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(54)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Act</span>&#8221; means the Securities Exchange Act of 1934, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(55)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EY</span>&#8221; means Ernst&#160;&amp; Young LLP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(56)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FDA</span>&#8221; means the United States Food and Drug Administration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(57)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FDCA</span>&#8221; means the Food, Drug and Cosmetic Act, 21 U.S.C. &#167; 301 et seq., as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(58)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Foreign Benefit Plan</span>&#8221; means any Company Benefit Plan or SpinCo Benefit Plan that is maintained (i)&#160;primarily for the benefit of employees outside the United States or (ii)&#160;pursuant to the Laws of a country other than the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(59)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Former Company Service Provider</span>&#8221; has the meaning given to such term in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(60)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fully Diluted SpinCo Shares</span>&#8221; means, without duplication, the sum of (a)&#160;the aggregate number of issued and outstanding shares of SpinCo Common Stock as of immediately prior to the Effective Time, plus (b)&#160;the aggregate number of shares of SpinCo Common Stock issuable upon the exercise of all SpinCo Options (whether vested or unvested) as of immediately prior to the Effective Time, plus (c)&#160;the aggregate number of shares of SpinCo Common Stock issuable upon the vesting of all SpinCo RSU Awards as of immediately prior to the Effective Time, plus (d)&#160;the aggregate number of shares of SpinCo Common Stock issuable upon the vesting of all SpinCo PSU Awards as of immediately prior to the Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(61)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GAAP</span>&#8221; means generally accepted accounting principles in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(62)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Clinical Practices</span>&#8221; means the then current requirements of Law for the conduct of clinical trials (including all applicable requirements relating to protection of human subjects), as set forth in the FDCA and applicable regulations promulgated </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">thereunder, as amended from time to time, and such applicable regulations for the conduct of human clinical trials (including all applicable requirements relating to protection of human subjects) as are enforced by any Regulatory Authority in any countries other than the United States in which the SpinCo Products are the subject of clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(63)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Laboratory Practices</span>&#8221; means the then current requirements of Law for conducting nonclinical laboratory studies, as set forth in the FDCA and applicable regulations promulgated thereunder, as amended from time to time, and such applicable regulations governing the conduct of nonclinical laboratory studies as are enforced by Regulatory Authorities in any country other than the United States in which the SpinCo Products are studied in nonclinical laboratory studies to which requirements apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(64)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Documents</span>&#8221; means the legal document(s)&#160;by which any Person (other than an individual) establishes its legal existence or which govern its internal affairs. For example, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Documents</span>&#8221; of a corporation are its certificate of incorporation and by-laws, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Documents</span>&#8221; of a limited partnership are its limited partnership agreement and certificate of limited partnership, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Documents</span>&#8221; of a limited liability company are its operating agreement and certificate of formation and the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Documents</span>&#8221; of an exempted company are its memorandum and articles of association (in each case, as amended, restated, amended and restated or otherwise modified from time to time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(65)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Authority</span>&#8221; means any federal, state, local, transnational, supranational or foreign government, any Person exercising executive, legislative, judicial, regulatory or administrative function of or pertaining to government or Law, including any regulatory, self-regulatory or quasi-regulatory authority, agency, commission, body, department or other instrumentality, and any court, arbitral body or tribunal of competent jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(66)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Government Official</span>&#8221; means any officer or employee of a Governmental Authority or any department, agency, or instrumentality thereof, including any political subdivision thereof or any corporation or other Person owned or controlled in whole or in part by any Governmental Authority or any sovereign wealth fund, or of a public international organization, or any Person acting in an official capacity for or on behalf of any such government or department, agency, or instrumentality, or for or on behalf of any such public international organization, or any political party, party official, or candidate thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(67)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hazardous Material</span>&#8221; means any toxic, reactive, corrosive, ignitable or flammable chemical or chemical compound, or hazardous or toxic substance, material or waste, or any pollutant or contaminant, whether solid, liquid or gas, or any other substance, material or waste that is subject to regulation, control or remediation or for which liability or standards of care are imposed under any Environmental Law, including petroleum (including crude oil or any fraction thereof), radon, asbestos, radioactive materials, per- and polyfluoroalkyl substances and polychlorinated biphenyls.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(68)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Healthcare Laws</span>&#8221; means (a)&#160;the FDCA, and the regulations promulgated thereunder, (b)&#160;the Public Health Service Act (42 U.S.C. 201 et seq.), and the regulations promulgated thereunder, (c)&#160;all federal and state fraud and abuse Laws, including the Federal Anti-Kickback Statute, the civil False Claims Act, the Anti-Inducement Law, the exclusion Laws, and the regulations promulgated pursuant to such statutes, (d)&#160;the Health Insurance Portability and Accountability Act of 1996, and the regulations promulgated thereunder, and comparable state Laws, (e)&#160;Titles XVIII and XIX of the Social Security Act, and the regulations promulgated thereunder and (f)&#160;all other applicable healthcare Laws, rules&#160;and regulations, ordinances, judgments, decrees, orders, writs and injunctions administered by Regulatory Authorities, each of clause (a)&#160;through (f), as may be amended from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(69)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">HSR Act</span>&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules&#160;and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(70)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">INAD</span>&#8221; means an investigational new animal drug exemption pursuant to 21 C.F.R. Part&#160;511.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(71)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Included SpinCo Shares</span>&#8221; means, without duplication, the sum of (a)&#160;the aggregate number of issued and outstanding shares of SpinCo Common Stock as of immediately prior to the Effective Time, plus (b)&#160;the aggregate number of shares of SpinCo Common Stock issuable upon the exercise of all SpinCo Options (whether vested or unvested) as of immediately prior to the Effective Time, other than SpinCo Options excluded from the definition of Aggregate Common Consideration Shares pursuant to the proviso thereto, plus (c)&#160;the aggregate number of shares of SpinCo Common Stock issuable upon the vesting of all SpinCo RSU Awards as of immediately prior to the Effective Time, plus (d)&#160;the aggregate number of shares of SpinCo Common Stock issuable upon the vesting of all SpinCo PSU Awards as of immediately prior to the Effective Time.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(72)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IND</span>&#8221; means an investigational new drug application submitted to the FDA pursuant to 21 C.F.R. Part&#160;312 to permit the introduction of an investigational drug into interstate commerce in the United States for the purposes of conducting human clinical trials, and all supplements, amendments, variations, extensions and renewals thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(73)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</span>&#8221; has the meaning set forth in the Separation and Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(74)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interests</span>&#8221; means shares, partnership interests, limited liability company interests or any other equity interest in any Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(75)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Internal Reorganization</span>&#8221; has the meaning set forth in the Separation and Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(76)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intervening Event</span>&#8221; means any Effect that (i)&#160;was not known to or reasonably foreseeable by the Parent Board as of the date of this Agreement and (ii)&#160;does not relate to (A)&#160;any Business Combination (other than the Merger or the other Transactions) or (B)&#160;clearance of the Transaction by any Governmental Authority, including Effects relating to actions taken pursuant to or required to be taken pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.6</span>; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that (1)&#160;any change in the price or trading volume of Parent Common Stock shall not be taken into account for purposes of determining whether an Intervening Event has occurred and (2)&#160;the Company&#8217;s, SpinCo&#8217;s or any of their respective Subsidiaries&#8217; meeting, failing to meet or exceeding projections (in and of itself, but not the underlying causes thereof) shall not be taken into account for purposes of determining whether an Intervening Event has occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(77)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investment Company Act</span>&#8221; means the Investment Company Act of 1940, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(78)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IRS</span>&#8221; means the United States Internal Revenue Service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(79)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IT Assets</span>&#8221; has the meaning set forth in the Separation and Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(80)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Knowledge</span>&#8221; means (a)&#160;with respect to the Company, the actual knowledge of the persons set forth in Section&#160;1.1(a)&#160;of the Company Disclosure Schedule, after reasonable investigation, (b)&#160;with respect to SpinCo, the knowledge of the persons set forth in Section&#160;1.1(a)&#160;of the SpinCo Disclosure Schedule, after reasonable investigation and (c)&#160;with respect to Parent, the actual knowledge of the persons set forth in Section&#160;1.1(a)&#160;of the Parent Disclosure Schedule, after reasonable investigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(81)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Law</span>&#8221; means, with respect to any Person, any law, statute, code, ordinance, order, decree, award, directive, judgment, ruling, rule, regulation or similar requirement issued, promulgated, enforced or enacted by or under the authority of a Governmental Authority that is binding upon or applicable to such Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(82)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Liability</span>&#8221; means any liability (whether known or unknown, whether asserted or unasserted, whether absolute or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, whether direct or indirect, and whether due or to become due).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(83)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lien</span>&#8221; means any mortgage, deed of trust, pledge, hypothecation, encumbrance, easement, encroachment, license, option, right of first refusal, security interest or other lien or restriction of any kind.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(84)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ligand Retained Assets</span>&#8221; has the meaning set forth in the Separation and Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(85)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ligand Retained Business</span>&#8221; has the meaning set forth in the Separation and Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(86)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Losses</span>&#8221; means any and all Liabilities, claims, losses, damages, costs, expenses, interest, awards, judgments and penalties (including reasonable attorneys&#8217; and consultants&#8217; fees and expenses).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(87)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LW</span>&#8221; means Latham&#160;&amp; Watkins LLP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(88)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Tax Opinions</span>&#8221; means the Company Merger Tax Opinion and the Parent Merger Tax Opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(89)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Multiemployer Plan</span>&#8221; means any &#8220;multiemployer plan&#8221; within the meaning of Section&#160;3(37) or Section&#160;4001(a)(3)&#160;of ERISA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(90)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NADA</span>&#8221; means a new animal drug application submitted to the FDA pursuant to 21 U.S.C. &#167; 360b to market a new animal drug in the United States, and all supplements, amendments, variations, extensions and renewals thereto.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(91)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NASDAQ</span>&#8221; means the Nasdaq Capital Market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(92)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NDA</span>&#8221; means a new drug application submitted to the FDA pursuant to 21&#160;U.S.C. &#167; 355(b), and all amendments or supplements thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(93)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Business Combination Proposal</span>&#8221; means any inquiry, offer, proposal or indication of interest (whether written or oral, binding or non-binding, and other than an inquiry, offer, proposal or indication of interest made or submitted by Parent to the Company or by the Company to Parent) contemplating or otherwise relating to any potential Business Combination (other than the Merger or the other Transactions).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(94)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Class&#160;A Common Stock</span>&#8221; means the Class&#160;A ordinary fully paid shares, par value $0.0001 each per share in the capital of Parent prior to the Domestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(95)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Class&#160;B Common Stock</span>&#8221; means the Class&#160;B ordinary fully paid shares, par value $0.0001 each per share in the capital of Parent prior to the Domestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(96)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Common Stock</span>&#8221; means the Parent Class&#160;A Common Stock and the Parent Class&#160;B Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(97)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Disclosure Schedule</span>&#8221; means the Disclosure Schedule delivered by Parent to the Company and SpinCo on the date hereof and identified as such.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(98)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Distribution Tax Representations</span>&#8221; means the representations of an officer of Parent, dated as of the Closing Date, in form and substance reasonably satisfactory to LW, delivered to LW in connection with the Company Distribution Tax Opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(99)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Equity Plan</span>&#8221; has the meaning set forth in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(100)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent ESPP</span>&#8221; has the meaning set forth in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(101)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Material Adverse Effect</span>&#8221; means any Effect that (a)&#160;has, or would reasonably be expected to have, individually or in the aggregate with any other Effects, a material adverse effect on the business or financial condition of the Parent or Merger Sub, taken as a whole; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that none of the following shall be deemed in themselves, either alone or in combination, to constitute, and none of the following shall be taken into account in determining whether there has been or would reasonably be expected to be, individually or in the aggregate, a Parent Material Adverse Effect for purposes of this clause (a): (i)&#160;any changes resulting from general market, economic, financial, capital markets or regulatory conditions, (ii)&#160;any general changes in the credit, debt, financial or capital markets or changes in interest or exchange rates, (iii)&#160;any changes in applicable Law or GAAP (or, in each case, authoritative interpretations thereof), (iv)&#160;any changes resulting from any natural disaster, including any hurricane, storm, flood, tornado, volcanic eruption, earthquake, other weather-related events, or other comparable events, or any worsening thereof, (v)&#160;any changes resulting from local, national or international political conditions, including the outbreak or escalation of any military conflict, declared or undeclared war, armed hostilities, acts of foreign or domestic terrorism or civil unrest, (vi)&#160;any changes generally affecting the industries in which the Parent conducts its businesses, (vii)&#160;any changes directly resulting from the execution of this Agreement or the Transaction Documents or the announcement or the pendency of the Merger or the Transactions, including actions of suppliers, landlords, distributors, partners or Governmental Authorities and any loss of employees, relationships or customers resulting from the transactions contemplated by this Agreement (<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that this clause (vii)&#160;shall not apply to any representation or warranty to the extent the purpose of such representation or warranty is to address, as applicable, the consequences resulting from the execution of this Agreement or the Separation and Distribution Agreement or the announcement or the pendency of the Merger or the Separation), (viii)&#160;any changes resulting from any action required to be taken by the terms of this Agreement or at the request or direction of the Company, (ix)&#160;the failure to meet any internal or analysts&#8217; expectations, projections or results of operations (but not, in each case, the underlying cause of any such changes, unless such underlying cause would otherwise be excepted by another clause of this definition), (x)&#160;any changes resulting from any epidemics, pandemics or disease (including COVID-19 or any COVID-19 Measures or any change in COVID-19 Measures following the date hereof) or (xi)&#160;elections to redeem shares of Parent Class&#160;A Common Stock in connection with the Parent Shareholders Meeting as required by Parent&#8217;s Governing Documents; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that in the case of clauses (i), (ii), (iii), (iv), (v), (vi)&#160;and (x), if such Effect disproportionately impacts the Parent or Merger Sub, taken as a whole, as compared to other participants in similar industries to the industries in which Parent operates, the incremental disproportionate impact thereof may be taken into account in determining whether a Parent Material Adverse Effect has occurred or would reasonably be expected to occur; or (b)&#160;has, or would reasonably be expected to, individually or in the aggregate, materially impair or materially delay the ability of Parent </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">to perform its obligations hereunder or under the Separation and Distribution Agreement, or to consummate the Transactions, including the Merger and the Separation, or prevent it from performing such obligations or consummating the Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(102)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Merger Tax Representations</span>&#8221; means the representations of an officer of Parent, dated as of the Closing Date, in form and substance reasonably satisfactory to LW and Weil, delivered to LW and Weil in connection with the Merger Tax Opinions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(103)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Private Placement Warrant</span>&#8221; means a warrant to purchase one (1)&#160;share of Parent Class&#160;A Common Stock at an exercise price of eleven dollars fifty cents ($11.50) issued to the Sponsor prior to consummation of Parent&#8217;s initial public offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(104)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Public Warrant</span>&#8221; means a warrant to purchase one (1)&#160;share of Parent Class&#160;A Common Stock at an exercise price of eleven dollars fifty cents ($11.50), a fraction equal to one-third of which was included in each unit sold as part of Parent&#8217;s initial public offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(105)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Registration Statement</span>&#8221; means the registration statement on Form&#160;S-4 to be filed by Parent with the SEC (as amended and supplemented from time to time) to effect the registration under the Securities Act of the issuance of (a)&#160;the shares of Domesticated Parent Common Stock and the Earnout Shares that will be issued to holders of SpinCo Common Stock and holders of SpinCo Equity Awards pursuant to the Merger, (b)&#160;the shares of Domesticated Parent Common Stock and the Domesticated Parent Warrants that will be issued to holders of Parent Common Stock and Parent Public Warrants in the Domestication and the shares of Domesticated Parent Common Stock underlying such Domesticated Parent Warrants and (c)&#160;the Adjusted Parent Equity Awards into which the SpinCo Equity Awards are converted pursuant to the Merger and the shares of Domesticated Parent Common Stock underlying such Adjusted Parent Equity Awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(106)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent SEC Documents</span>&#8221; means all forms, reports, schedules, statements and other documents required to be filed or furnished by Parent with the SEC since August&#160;12, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(107)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Share Issuance</span>&#8221; means the issuance of shares of Domesticated Parent Stock pursuant to the Domestication, the PIPE Investment, the Redemption Backstop and the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(108)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Share Redemption</span>&#8221; means the election of an eligible holder of Parent Class&#160;A Common Stock (as determined in accordance with Parent&#8217;s Governing Documents) to redeem all or a portion of the shares of Parent Class&#160;A Common Stock held by such holder at a per-share price, payable in cash, equal to the pro rata share of the aggregate amount on deposit in the Trust Account (including any interest earned on the funds held in the Trust Account) represented by such redeemed shares (as determined in accordance with Parent&#8217;s Governing Documents and the Trust Agreement) in connection with the Transaction Proposals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(109)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Share Redemption Amount</span>&#8221; means the aggregate amount payable with respect to all Parent Share Redemptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(110)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Shareholder Approval</span>&#8221; means the approval of (i)&#160;those Transaction Proposals identified in clauses (A), (B)&#160;and (C)&#160;of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.4(e)(ii)</span>, in each case, by a special resolution under the CICA (being the affirmative vote of the holders of at least two-thirds (2/3) of the ordinary shares who, being present and entitled to vote at the Parent Shareholders Meeting, vote at the Parent Shareholders Meeting), (ii)&#160;those Transaction Proposals identified in clauses (D), (E), (F)&#160;and (I)&#160;of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.4(e)(ii)</span>, in each case, by an ordinary resolution under the CICA (being the affirmative vote of the holders of a majority of the ordinary shares who, being present and entitled to vote at the Parent Shareholders Meeting, vote at the Parent Shareholders Meeting) and (iii)&#160;those Transaction Proposals identified in clauses (G)&#160;and (H)&#160;of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.4(e)(ii)</span>, in each case, by an affirmative vote of the number of holders of Parent Common Stock required to approve such Transaction Proposals under applicable Law and the Governing Documents of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(111)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Subsidiaries</span>&#8221; means all direct and indirect Subsidiaries of Parent. For the avoidance of doubt, following the Effective Time, the Parent Subsidiaries shall include the SpinCo Entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(112)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8220;Parent Tax Opinions</span>&#8221; means the Parent Domestication Tax Opinion and the Parent Merger Tax Opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(113)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Tax Representations</span>&#8221; means the Parent Distribution Tax Representations and the Parent Merger Tax Representations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(114)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Trading Price</span>&#8221; means the share price equal to the volume weighted average closing sale price of one share of Domesticated Parent Common Stock as reported on NASDAQ (or the exchange on which the shares of Domesticated Parent Common </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Stock are then listed) for a period of at least 20 days out of 30 consecutive trading days ending on the trading day immediately prior to the date of determination (as adjusted as appropriate to reflect any stock splits, reverse stock splits, stock dividends (including any dividend or distribution of securities convertible into Domesticated Parent Common Stock), extraordinary cash dividend, reorganization, recapitalization, reclassification, combination, exchange of shares or other like change or transaction with respect to Domesticated Parent Common Stock).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(115)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Unit</span>&#8221; has the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(116)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Warrant</span>&#8221; means any Parent Private Placement Warrant or Parent Public Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(117)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent</span>&#8221; has the meaning set forth in the Separation and Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(118)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permits</span>&#8221; means licenses, franchises, permits, certificates, approvals and authorizations from Governmental Authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(119)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permitted Liens</span>&#8221; means (a)&#160;statutory Liens arising by operation of Law with respect to a Liability incurred in the ordinary course of business and which is not delinquent; (b)&#160;requirements and restrictions of zoning, licensing, permitting, building and other similar land-use Laws which are not violated by the present use or occupancy of the real property subject thereto; (c)&#160;Liens for Taxes or mechanics&#8217;, materialmen&#8217;s and similar Liens arising or incurred in the ordinary course of business and with respect to any amounts, in each case (i)&#160;not yet due and payable or (ii)&#160;which are being contested in good faith by appropriate proceedings and for which adequate reserves have been established in accordance with GAAP; (d)&#160;non-exclusive licenses of Intellectual Property granted to customers in the ordinary course of business consistent with past practice; (e)&#160;all encroachments, overlaps, overhangs, variations in area or measurement, rights of parties in possession, servitudes or easements (including conservation easements and public trust easements, rights-of-way, road use Contracts, covenants, conditions, restrictions, reservations, licenses, Contracts and other similar non-monetary matters) of public record or any other similar matters not of record which would be disclosed by an accurate survey or physical inspection of the applicable real property; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that such Liens, individually or in the aggregate, do not or would not reasonably be expected to materially impair or interfere with the operation or use of such real property in the ordinary course operation of the respective businesses of SpinCo and its Subsidiaries or Parent and its Subsidiaries, as applicable, in each case, as currently conducted thereon; (f)&#160;with respect to any real property, (i)&#160;the interests and rights of the respective lessors with respect thereto, including any statutory landlord liens and any Lien on the lessor&#8217;s interest therein and (ii)&#160;any Liens encumbering the underlying fee title of the real property; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that such Liens, individually or in the aggregate, do not or would not reasonably be expected to materially impair or interfere with the operation or use of such real property in the ordinary course operation of the respective businesses of SpinCo and its Subsidiaries or Parent and its Subsidiaries, as applicable, in each case, as currently conducted thereon; (g)&#160;any real property Liens that do not, individually or in the aggregate, result in a Parent Material Adverse Effect or SpinCo Material Adverse Effect, as applicable; (h)&#160;reversionary rights in favor of landlords under any real property leases with respect to any of the buildings or other improvements owned by SpinCo, Parent or any of their Subsidiaries, as applicable; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that such Liens, individually or in the aggregate, do not or would not reasonably be expected to materially impair or interfere with the operation or use of such real property in the ordinary course operation of the respective businesses of SpinCo and its Subsidiaries or Parent and its Subsidiaries, as applicable, in each case, as currently conducted thereon; (i)&#160;purchase money Liens and Liens securing rental payments under capital lease agreements; (j)&#160;pledges or deposits made in the ordinary course of business in connection with workers&#8217; compensation, unemployment insurance and other types of social security (other than pursuant to Section&#160;303(k)&#160;or 4068 of ERISA or Section&#160;430(k)&#160;of the Code) or to secure the performance of tenders, statutory obligations, surety and appeal bonds, bids, performance and return of money bonds and similar obligations; (k)&#160;liens arising under conditional sales Contracts and equipment leases with third parties entered into in the ordinary course of business to the extent not subject to any default; (l)&#160;pledges or deposits to secure public or statutory obligations unrelated to any default or violation of any Law; (m)&#160;Liens arising under or created by this Agreement or any Transaction Document (other than as a result of a breach or default under such Contracts); (n)&#160;Liens securing the Financing; (o)&#160;Liens described on Section&#160;1.1(b)&#160;of the SpinCo Disclosure Schedule or Section&#160;1.1(b)&#160;of the Parent Disclosure Schedule, as applicable; and (p)&#160;Liens (other than Liens on Intellectual Property) that do not, individually or in the aggregate, materially affect or disrupt the ordinary course operation of the respective businesses of SpinCo and its Subsidiaries or Parent and its Subsidiaries, as applicable, in each case, taken as a whole.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(120)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Person</span>&#8221; means any individual, firm, corporation, partnership, limited liability company, incorporated or unincorporated association, joint venture, joint stock company, Governmental Authority or other organization or entity of any kind.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(121)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Personal Information</span>&#8221; means all information in any form or media that identifies or could be used to identify an individual person (including any current, prospective, or former customer, end user or employee), in addition to any definition for </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">&#8220;personal information&#8221; or any similar term provided by applicable Law or by the Company or SpinCo in any of its privacy policies, notices or contracts (e.g., &#8220;personal data,&#8221; &#8220;personally identifiable information&#8221; or &#8220;PII&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(122)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PIPE Investment</span>&#8221; means the purchase of shares of Domesticated Parent Common Stock and Domesticated Parent Warrants pursuant to the A&amp;R Forward Purchase Agreement with a purchase price equal to the PIPE Investment Amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(123)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PIPE Investment Amount</span>&#8221; means the aggregate gross purchase price of $15,000,000 payable to Parent prior to or substantially concurrently with the Effective Time for shares of Domesticated Parent Common Stock and Domesticated Parent Warrants in the PIPE Investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(124)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PIPE Investor</span>&#8221; means Sponsor or any Person to whom such right and obligation is assigned by Sponsor as permitted by the terms of the A&amp;R Forward Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(125)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Privacy Laws</span>&#8221; means applicable Laws, and self-regulatory guidelines (including of any applicable foreign jurisdiction) relating to the receipt, collection, compilation, use, storage, processing, sharing, safeguarding, security (technical, physical or administrative), disposal, destruction, disclosure or transfer (including cross-border) of any Personal Information, including the Federal Trade Commission Act, California Consumer Privacy Act (CCPA), Payment Card Industry Data Security Standard (PCI-DSS), EU General Data Protection Regulation (GDPR), any and all applicable Laws relating to breach notification, the use of biometric identifiers, and the use of Personal Information for marketing purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(126)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Privacy Requirements</span>&#8221; means all applicable Privacy Laws and all of the Company&#8217;s and SpinCo&#8217;s policies, notices, and contractual obligations relating to the receipt, collection, compilation, use, storage, processing, sharing, safeguarding, security (technical, physical and administrative), disposal, destruction, disclosure, or transfer (including cross-border) of Personal Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(127)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proxy Statement</span>&#8221; means the proxy statement to be mailed to the shareholders of Parent relating to the Parent Shareholders Meeting, including any amendments or supplements thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(128)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Qualified SpinCo Common Stock</span>&#8221; means SpinCo Common Stock received by holders of Company Common Stock pursuant to the Distribution, except for any SpinCo Common Stock that is acquired, directly or indirectly, pursuant to a plan (or series of related transactions) that includes the Distribution, within the meaning of Section&#160;355(e)&#160;of the Code and the Treasury Regulations promulgated thereunder. This definition (and the application thereof) is intended to monitor compliance with Section&#160;355(e)&#160;of the Code and shall be interpreted accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(129)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Record Date</span>&#8221; means 5:00 p.m.&#160;New York time on the date determined by the Company Board as the record date for determining stockholders of the Company entitled to receive shares of SpinCo Common Stock in the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(130)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Redemption Backstop</span>&#8221; means the purchase of up to 10,000,000 shares of Domesticated Parent Common Stock at a purchase price of $10.00 per share pursuant to the A&amp;R Forward Purchase Agreement, excluding the Domesticated Parent Common Stock subject to the PIPE Investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(131)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Authority</span>&#8221; means the FDA or any other comparable Governmental Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(132)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Authorizations</span>&#8221; means any approvals, clearances, authorizations, registrations, certifications, licenses, exemptions and permits granted by any Regulatory Authority, including any INDs, NDAs, BLAs, NADAs, and INADs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(133)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release</span>&#8221; means any spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, depositing, escaping, leaching, disposing or dumping into the environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(134)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representative</span>&#8221; means, with respect to any Person, such Person&#8217;s directors, managers, members, officers, employees, agents, partners, attorneys, financial advisors, financing sources, consultants, advisors or other Persons acting on behalf of such Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(135)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Requisite Regulatory Approvals</span>&#8221; means the expiration or termination of the applicable waiting period under the HSR Act (and any extension thereof under the HSR Act) and all regulatory authorizations, consents, clearances, orders, approvals or expirations of applicable waiting periods set forth on Section&#160;1.1(c)&#160;of the Parent Disclosure Schedule.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(136)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities Act</span>&#8221; means the Securities Act of 1933, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(137)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation and Distribution Agreement</span>&#8221; means that Separation and Distribution Agreement, dated as of the date hereof, by and among the Company, Parent and SpinCo, attached as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</span> to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(138)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Software</span>&#8221; has the meaning set forth in the Separation and Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(139)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Affiliate Contract</span>&#8221; means any Contract, whether or not in writing, (a)&#160;between any SpinCo Entity, on the one hand, and any present or former officer or director of the SpinCo Entities or &#8220;immediate family member&#8221; thereof (as defined in Rule&#160;16a-1 under the Exchange Act), on the other hand, or (b)&#160;between any SpinCo Entity, on the one hand, and the Company and/or any of its Subsidiaries (other than a SpinCo Entity), on the other hand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(140)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Assets</span>&#8221; has the meaning set forth in the Separation and Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(141)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Benefit Plan</span>&#8221; has the meaning set forth in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(142)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Business</span>&#8221; has the meaning set forth in the Separation and Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(143)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Common Stock</span>&#8221; means the common stock, par value $0.001 per share, of SpinCo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(144)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Contract</span>&#8221; has the meaning set forth in the Separation and Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(145)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Datasite</span>&#8221; means the datasite established by the Company for purposes of due diligence of the SpinCo Entities and the SpinCo Business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(146)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Disclosure Schedule</span>&#8221; means the Disclosure Schedule delivered by the Company and SpinCo to Parent on the date hereof and identified as such.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(147)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Entities</span>&#8221; means SpinCo and the SpinCo Subsidiaries, after giving effect to (or assuming the effect of, as applicable) the Internal Reorganization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(148)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Employee</span>&#8221; has the meaning set forth in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(149)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Equity Award</span>&#8221; has the meaning set forth in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(150)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Financial Statements</span>&#8221; means, collectively, the draft, combined statements of operations of the SpinCo Business for the fiscal years ended December&#160;31, 2019, December&#160;31, 2020 and December&#160;31, 2021, and the draft, combined balance sheets of the SpinCo Business for the fiscal years ended December&#160;31, 2020 and December&#160;31, 2021, attached to Section&#160;5.9 of the SpinCo Disclosure Schedules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(151)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo IT Systems</span>&#8221; means all IT Assets owned, leased or used by or on behalf of (i)&#160;as of the date hereof, the Company or any of its Subsidiaries with respect to the SpinCo Business, and (ii)&#160;as of the Distribution, any of the SpinCo Entities, including, in each case, all IT Assets included in the SpinCo Assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(152)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8220;SpinCo Independent Contractor</span>&#8221; has the meaning set forth in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(153)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Licensed Intellectual Property</span>&#8221; means all Intellectual Property licensed from a third party pursuant to a written Contract to, (a)&#160;as of the date hereof, the Company or any of its Subsidiaries with respect to the SpinCo Business, and (b)&#160;as of the Distribution, any of the SpinCo Entities, that, in each case of clauses (a)&#160;and (b), is used, practiced or held for use or practice by or on behalf of (i)&#160;as of the date hereof, the Company or any of its Subsidiaries with respect to the SpinCo Business, and (ii)&#160;as of the Distribution, any of the SpinCo Entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(154)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Material Adverse Effect</span>&#8221; means any Effect that (a)&#160;has, or would reasonably be expected to have, individually or in the aggregate with any other Effects, a material adverse effect on the business, financial condition or results of operations of the SpinCo Business, taken as a whole; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that none of the following shall be deemed in themselves, either alone or in </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">combination, to constitute, and none of the following shall be taken into account in determining whether there has been or would reasonably be expected to be, individually or in the aggregate, a SpinCo Material Adverse Effect for purposes of this clause (a): (i)&#160;any changes resulting from general market, economic, financial, capital markets or regulatory conditions, (ii)&#160;any general changes in the credit, debt, financial or capital markets or changes in interest or exchange rates, (iii)&#160;any changes in applicable Law or GAAP (or, in each case, authoritative interpretations thereof), (iv)&#160;any changes resulting from any natural disaster, including any hurricane, storm, flood, tornado, volcanic eruption, earthquake, other weather-related events, or other comparable events, or any worsening thereof, (v)&#160;any changes resulting from local, national or international political conditions, including the outbreak or escalation of any military conflict, declared or undeclared war, armed hostilities, acts of foreign or domestic terrorism or civil unrest, (vi)&#160;any changes generally affecting the industries in which the SpinCo Entities conduct their businesses, (vii)&#160;any changes directly resulting from the execution of this Agreement or the Separation and Distribution Agreement or the announcement or the pendency of the Merger or the Separation, including actions of suppliers, landlords, distributors, partners or Governmental Authorities and any loss of employees, relationships or customers resulting from the transactions contemplated by this Agreement (<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that this clause (vii)&#160;shall not apply to any representation or warranty to the extent the purpose of such representation or warranty is to address, as applicable, the consequences resulting from the execution of this Agreement or the Separation and Distribution Agreement or the announcement or the pendency of the Merger or the Separation), (viii)&#160;any changes resulting from any action required to be taken by the terms of this Agreement (other than the first sentence of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.2)</span> or at the request or direction of Parent or Merger Sub, (ix)&#160;the failure to meet any internal or analysts&#8217; expectations, projections or results of operations (but not, in each case, the underlying cause of any such changes, unless such underlying cause would otherwise be excepted by another clause of this definition), or (x)&#160;any changes resulting from any epidemics, pandemics or disease (including COVID-19 or any COVID-19 Measures or any change in COVID-19 Measures following the date hereof); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that in the case of clauses (i), (ii), (iii), (iv), (v), (vi)&#160;and (x), if such Effect disproportionately impacts the SpinCo Entities or the SpinCo Business, taken as a whole, as compared to other participants in similar industries to the industries in which the SpinCo Business operates, the incremental disproportionate impact thereof may be taken into account in determining whether a SpinCo Material Adverse Effect has occurred or would reasonably be expected to occur; or (b)&#160;has, or would reasonably be expected to, individually or in the aggregate, materially impair or materially delay the ability of SpinCo to perform its obligations hereunder or under the Separation and Distribution Agreement, or to consummate the Transactions, including the Merger and the Separation, or prevent it from performing such obligations or consummating the Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(155)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Merger Tax Representations</span>&#8221; means the representations of an officer of SpinCo, dated as of the Closing Date, in form and substance reasonably satisfactory to LW and Weil, delivered to LW and Weil in connection with the Merger Tax Opinions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(156)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Option</span>&#8221; has the meaning given to such term in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(157)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Owned Intellectual Property</span>&#8221; means all Intellectual Property owned or purported to be owned by any of the SpinCo Entities as of the Distribution, including the SpinCo Intellectual Property (as defined in the Separation and Distribution Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(158)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Products</span>&#8221; means any investigational animal created, used, provided, or otherwise made available by or on behalf of the SpinCo Business, and any antibodies or other products derived from such animals by the SpinCo Business; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that &#8220;SpinCo Products&#8221; shall not include any such products or product candidates to the extent developed, tested, marketed, manufactured, advertised, promoted or commercialized by customers of the SpinCo Business, in each case, that are not proprietary to, or owned or purported to be owned by, (i)&#160;as of the date hereof, the Company or any of its Subsidiaries with respect to the SpinCo Business, or (ii)&#160;as of the Distribution, any of the SpinCo Entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(159)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo PSU Award</span>&#8221; has the meaning given to such term in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(160)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Registration Statement</span>&#8221; means the registration statement on Form&#160;10 to be filed by SpinCo with the SEC to effect the registration under the Exchange Act of the shares of SpinCo Common Stock in connection with the Distribution, as such registration statement may be amended or supplemented from time to time prior to the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(161)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo RSU Award</span>&#8221; has the meaning given to such term in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(162)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Service Provider</span>&#8221; has the meaning given to such term in the Employee Matters Agreement.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(163)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Subsidiaries</span>&#8221; means all direct and indirect Subsidiaries of SpinCo, after giving effect to the Internal Reorganization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(164)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sponsor</span>&#8221; means Avista Acquisition LP II, a Cayman Islands exempted limited partnership and an Affiliate of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(165)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sponsor Insider Agreement</span>&#8221; has the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(166)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsidiary</span>&#8221; means, with respect to any Person, a corporation or other entity of which more than 50% of the voting power of the equity securities or Interests that by their terms have ordinary voting power to elect a majority of the board of directors or other similar body is owned or controlled, directly or indirectly, by such Person, or any organization of which such Person or any of its Subsidiaries is, directly or indirectly, a general partner or managing member or holds a similar role.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(167)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Matters Agreement</span>&#8221; has the meaning set forth in the Separation and Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(168)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Returns</span>&#8221; has the meaning set forth in the Tax Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(169)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</span>&#8221; has the meaning set forth in the Tax Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(170)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trade Secret</span>&#8221; has the meaning set forth in the Separation and Distribution Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(171)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trademark</span>&#8221; has the meaning set forth in the Separation and Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(172)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transaction Documents</span>&#8221; means the Separation and Distribution Agreement, the Employee Matters Agreement, the Tax Matters Agreement, the Transition Services Agreements, the A&amp;R Forward Purchase Agreement, the Sponsor Insider Agreement and the A&amp;R Registration Rights Agreement, in each case, including all annexes, Exhibits, Schedules, attachments and appendices thereto, and any certificate or other instrument delivered by any Party to any other Party pursuant to this Agreement or any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(173)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transaction Process</span>&#8221; means all matters relating to the separation, disposition or sale of the SpinCo Business and the review of strategic alternatives with respect to the SpinCo Business (including the potential spin-off of the SpinCo Business), including matters relating to (a)&#160;the solicitation of proposals from and negotiations with third parties in connection with the disposition or sale of the SpinCo Business or SpinCo Assets or (b)&#160;the drafting, negotiation or interpretation of any of the provisions of this Agreement or the other Transaction Documents, or the determination of the allocation of any assets or Liabilities pursuant to the foregoing agreements or the transactions contemplated thereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(174)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transactions</span>&#8221; shall mean the Domestication, the Separation, the Distribution, the Merger and the other transactions contemplated by this Agreement and the Transaction Documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(175)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Services Agreements</span>&#8221; has the meaning set forth in the Separation and Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(176)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Treasury Regulations</span>&#8221; means the regulations promulgated by the U.S. Treasury Department under the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(177)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trust Amount</span>&#8221; means the amount of cash available in the Trust Account following the Parent Shareholders Meeting, after deducting the amount required to satisfy the Parent Share Redemption Amount (prior to payment of any unpaid transaction expenses).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(178)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Warrant Agreement</span>&#8221; means the Warrant Agreement, dated as of August&#160;9, 2021, between Parent and Continental Stock Transfer&#160;&amp; Trust Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(179)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Weil</span>&#8221; means Weil, Gotshal&#160;&amp; Manges LLP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(180)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Willful Breach</span>&#8221; means, with respect to any obligation, covenant or agreement of a Party in this Agreement, any material breach of or material failure to perform such obligation, covenant or agreement that such Party intentionally takes (or intentionally fails to take or perform) with actual knowledge that such action or omission or failure to perform would, or would reasonably be expected to, cause or result in a material breach of this Agreement.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(181)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Working Capital Loans</span>&#8221; means any loan made to Parent by any of the Sponsor, any Affiliate of the Sponsor, or any of Parent&#8217;s officers or directors, and evidenced by a promissory note, for the purpose of financing working capital or costs incurred in connection with a Business Combination.</p><a id="A_Section_1_2_Cross_References"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cross References</span>. Each of the following terms is defined in the Section&#160;set forth opposite such term:</p><a id="A_Section_1_3_Interpretation"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:73%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Term &#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:25%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Section&#160;</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:73%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:25%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">A&amp;R Registration Rights Agreement</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Antitrust Division</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;7.6(b)</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Certificate of Merger</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;2.3(d)</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chosen Courts</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;10.3</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">CICA</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Class&#160;A Merger Consideration</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;3.1(a)(i)</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Closing</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;2.2</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Closing Date</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;2.2</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">COBRA</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;5.18(h)</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Company</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Company Board</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Company Distribution Tax Opinion</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;7.3(b)</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Company Group</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;10.14(b)</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">DGCL</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Distribution</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Distribution Documents</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;5.23</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Domesticated Parent Common Stock</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Domesticated Parent Warrant</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Domestication</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Effective Time</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;2.3(d)</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Evaluation Material</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;10.2</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exchange Agent</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;3.2(b)</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exchange Agent Agreement</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;3.2(b)</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exchange Fund</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;3.2(b)</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">FTC</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;7.6(b)</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Government Contract</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;5.15(a)(xiv)</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Interim Period</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;7.1</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Investment</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;6.3(f)</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">JOBS Act</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;6.6(a)</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Merger</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Merger Consideration</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;3.1(a)(i)</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Merger Sub</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Merger Sub Common Stock</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;3.1(a)(vi)</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Merger Sub Shareholder Approval</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;7.21</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Modification in Recommendation</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;7.5</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outside Date</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;9.1(b)</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Parent</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Parent Board</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Parent Board Recommendation</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Parent Bylaws</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;7.15</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Parent Charter</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;7.15</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Parent Domestication Tax Opinion</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;7.3(d)</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Parent SEC Filings</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;6.13</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Parent Securities</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;6.3(a)</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Parent Shareholders Meeting</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;7.4(e)(i)</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Parent Units</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Party</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Personnel IP Contract</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;5.19(h)</p></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:73%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Term &#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:25%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Section&#160;</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:73%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:25%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Prospectus</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;10.1</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Remedies Exception</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;4.2</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">SpinCo</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">SpinCo Board</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">SpinCo CBA</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;5.16(c)</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">SpinCo Material Contracts</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;5.15(a)</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">SpinCo Proposal</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;7.9(a)</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">SpinCo Real Property Lease</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;5.15(a)(ix)</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">SpinCo Registered Intellectual Property</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;5.19(a)</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">SpinCo Shareholder Approval</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;5.24</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">SpinCo Voting Debt</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;5.3(b)</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Sponsor Insider Agreement</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Subsequent Audited Annual SpinCo Financial Statements</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;7.22(a)</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Subsequent Period SpinCo Financial Statements</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;7.22(a)</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Subsequent Unaudited SpinCo Financial Statements</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;7.22(a)</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Surviving Corporation</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;2.1</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Tax-Free Status</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;7.3(a)</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Transaction Litigation</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;7.11</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Transaction Proposals</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;7.4(e)(ii)</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Trust Account</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;10.1</p></td></tr><tr><td style="vertical-align:top;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Unpaid Transaction Expenses</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;2.3(c)</p></td></tr><tr><td style="vertical-align:top;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">WARN</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Section&#160;5.16(e)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Unless the context of this Agreement otherwise requires:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>(a)&#160;words of any gender include each other gender and neuter form; (b)&#160;words using the singular or plural number also include the plural or singular number, respectively; (c)&#160;derivative forms of defined terms will have correlative meanings; (d)&#160;the terms &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby,&#8221; &#8220;hereto,&#8221; &#8220;herewith,&#8221; &#8220;hereunder&#8221; and derivative or similar words refer to this entire Agreement; (e)&#160;the terms &#8220;Article,&#8221; &#8220;Section,&#8221; &#8220;Annex,&#8221; &#8220;Exhibit,&#8221; &#8220;Schedule,&#8221; and &#8220;Disclosure Schedule&#8221; refer to the specified Article, Section, Annex, Exhibit, Schedule or Disclosure Schedule of this Agreement and references to &#8220;paragraphs&#8221; or &#8220;clauses&#8221; shall be to separate paragraphs or clauses of the Section&#160;or subsection in which the reference occurs; (f)&#160;the words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221;; and (g)&#160;the word &#8220;or&#8221; shall be disjunctive but not exclusive;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>any Law defined or referred to in this Agreement or in any agreement or instrument that is referred to herein means such Law as from time to time amended, modified or supplemented, including (in the case of statutes) by succession of comparable successor Laws and the related regulations thereunder and published interpretations thereof, and references to any Contract or instrument are to that Contract or instrument as from time to time amended, modified or supplemented; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that for purposes of any representations and warranties contained in this Agreement that are made as of a specific date or dates, references to any Law shall be deemed to refer to such Law, as amended, and the related regulations thereunder and published interpretations thereof, in each case, as of such date or dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>references to any federal, state, local, or foreign statute or Law shall include all regulations promulgated thereunder; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>references to any Person include references to such Person&#8217;s successors and permitted assigns, and in the case of any Governmental Authority, to any Person succeeding to its functions and capacities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The language used in this Agreement shall be deemed to be the language chosen by the Parties to express their mutual intent. The Parties acknowledge that each Party and its attorney has reviewed and participated in the drafting of this Agreement and that any rule&#160;of construction to the effect that any ambiguities are to be resolved against the drafting Party, or any similar rule&#160;operating against the drafter of an agreement, shall not be applicable to the construction or interpretation of this Agreement.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Nothing herein (including the SpinCo Disclosure Schedule, Company Disclosure Schedule and the Parent Disclosure Schedule) shall be deemed an admission by any Party or any of its Affiliates, in any Action, that such Party or any such Affiliate, or any third party, is or is not in breach or violation of, or in default in, the performance or observance of any term or provisions of any Contract or any Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Whenever this Agreement refers to a number of days, such number shall refer to calendar days unless Business Days are specified. If any action is to be taken or given on or by a particular calendar day, and such calendar day is not a Business Day, then such action may be deferred until the next Business Day.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>When calculating the period of time before which, within which or following which any act is to be done or step taken pursuant to this Agreement, the date that is the reference date in calculating such period shall be excluded and if the last day of such period is not a Business Day, the period shall end on the next succeeding Business Day.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>The phrase &#8220;to the extent&#8221; shall mean the degree to which a subject or other thing extends, and such phrase shall not mean simply &#8220;if.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>The term &#8220;writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>All accounting terms used herein and not expressly defined herein shall have the meanings given to them under GAAP, unless the context otherwise requires.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>All monetary figures shall be in United States dollars unless otherwise specified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span>No reference in this Agreement to dollar amount thresholds shall be deemed to be evidence of a SpinCo Material Adverse Effect, Company Material Adverse Effect or Parent Material Adverse Effect, as applicable, or materiality.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span>The phrases &#8220;furnished,&#8221; &#8220;provided,&#8221; &#8220;delivered&#8221; or &#8220;made available&#8221; when used with respect to information or documents means that such information or documents have been (i)&#160;physically or electronically delivered to the relevant Party (and includes such information or documents that have been furnished to its Representatives acting on its behalf or posted to the SpinCo Datasite) or (ii)&#160;are otherwise Parent SEC Reports or Company SEC Reports and made publicly available on the SEC&#8217;s EDGAR website by Parent or the Company, as applicable, in each case, not later than forty eight hours prior to the execution of this Agreement.</p><a id="A_ARTICLE_II"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="color:#010000;">ARTICLE&#160;II</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">THE MERGER</p><a id="A_Section_2_1_The_Merger"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Merger</span>. At the Effective Time and upon the terms and subject to the conditions of this Agreement, Merger Sub shall be merged with and into SpinCo in accordance with the applicable provisions of the DGCL, the separate existence of Merger Sub shall cease and SpinCo shall continue as the surviving corporation of the Merger (sometimes referred to herein as the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surviving Corporation</span>&#8221;) and shall succeed to and assume all the rights, powers and privileges and be subject to all of the obligations of Merger Sub in accordance with the DGCL. As a result of the Merger, SpinCo shall become a direct, wholly owned Subsidiary of Parent. References herein to &#8220;SpinCo&#8221; with respect to the period from and after the Effective Time shall be deemed to be references to the Surviving Corporation. At the Effective Time, the effects of the Merger shall be as provided in this Agreement, the Certificate of Merger and the applicable provisions of the DGCL.</p><a id="A_Section_2_2_Closing"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing</span>. Unless the Transactions shall have been abandoned and this Agreement terminated pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.1</span>, the closing of the Merger (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing</span>&#8221;) shall take place at 10:00 a.m., New York City time, on the third Business Day after the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VIII</span> (other than those, including the Distribution, that are to be satisfied at or immediately prior to the Closing, but subject to the satisfaction or, to the extent permitted by applicable Law, waiver of such conditions at the Closing) have been satisfied or, to the extent permitted by applicable Law, waived, by electronic exchange of documents and signatures or at the offices of Weil, Gotshal&#160;&amp; Manges LLP, 767 Fifth Avenue, New York, New York 10153, unless another date, time or place is agreed to in writing by the Company and Parent. The date on which the Closing actually occurs is hereinafter referred to as the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing Date</span>.&#8221;</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="A_Section_2_3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing Deliverables; Effective Time</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>At the Closing, the Company or SpinCo, as applicable, will deliver or cause to be delivered:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>to Parent, a certificate signed by an authorized officer of the Company, dated as of the Closing Date, certifying that, to the knowledge and belief of such authorized officer, the conditions specified in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.3(a)</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(b)</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(c)</span>, and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(e)</span>&#160;have been satisfied;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>to Parent, the A&amp;R Registration Rights Agreement, duly executed by the parties set forth on Section&#160;2.3(a)(ii)&#160;of the Company Disclosure Schedule;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>to Parent, a certificate on behalf of SpinCo, prepared in a manner consistent and in accordance with the requirements of Treasury Regulations Sections 1.897-2(g), (h)&#160;and 1.1445-2(c)(3), certifying that no interest in the Company is, or has been during the relevant period specified in Section&#160;897(c)(1)(A)(ii)&#160;of the Code, a &#8220;U.S. real property interest&#8221; within the meaning of Section&#160;897(c)&#160;of the Code, and a form of notice to the Internal Revenue Service prepared in accordance with the provisions of Treasury Regulations Section&#160;1.897-2(h)(2), together with written authorization for Parent to deliver such documentation to the Internal Revenue Service on behalf of SpinCo after the Closing;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>to Parent, copies of resolutions and actions taken by the Company&#8217;s and SpinCo&#8217;s board of directors and stockholders in connection with the approval of this Agreement and the Transactions; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span>to Parent, all other documents, instruments or certificates required to be delivered by the Company at or prior to the Closing pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.3</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>At the Closing, Parent will deliver or cause to be delivered:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>to the Exchange Agent, the shares of Domesticated Parent Stock to be paid in respect of shares of SpinCo Common Stock in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)</span>, for further distribution to such holders pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2</span>;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>to the Company, a certificate signed by an authorized officer of Parent, dated the Closing Date, certifying that, to the knowledge and belief of such authorized officer, the conditions specified in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.1(f)</span>&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.2(a)</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(b)</span>&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(d)</span>&#160;have been satisfied;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>to the Company, the A&amp;R Registration Rights Agreement, duly executed by a duly authorized representative of Parent and the Sponsor;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>to the Company, the written resignations of all of the directors and officers of Parent (other than those Persons identified as the initial directors and officers, respectively, of Parent after the Effective Time, in accordance with the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span>), effective as of the Effective Time;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span>to the Company, copies of resolutions and actions taken by Parent&#8217;s and Merger Sub&#8217;s board of directors and stockholders (or managers, as applicable) in connection with the approval of this Agreement and the Transactions; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</span></span>to the Company, all other documents, instruments or certificates required to be delivered by Parent at or prior to the Closing pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.2</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>On the Closing Date, concurrently with the Effective Time, Parent shall pay or cause to be paid by wire transfer of immediately available funds, all accrued transaction expenses of Parent and those incurred, accrued, paid or payable by Parent&#8217;s Affiliates on Parent&#8217;s behalf as set forth on a written statement to be delivered to the Company not less than two (2)&#160;Business Days prior to the Closing Date (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Unpaid Transaction Expenses</span>&#8221;), which shall include the respective amounts and wire transfer instructions for the payment thereof, together with corresponding invoices for the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>On the Closing Date, SpinCo and Merger Sub shall file a certificate of merger relating to the Merger (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certificate of Merger</span>&#8221;) with the Secretary of State of the State of Delaware in accordance with the relevant provisions of the DGCL and shall make all other filings or recordings required under the DGCL. The Merger shall become effective at the time the Certificate of </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Merger shall have been duly filed with the Secretary of State of the State of Delaware, or such later time as Parent and SpinCo shall agree and specify in the Certificate of Merger (such time as the Merger becomes effective being the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Time</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>For the avoidance of doubt, the Closing and the Effective Time shall occur no sooner than the date that is the day after the completion of the Domestication.</p><a id="A_Section_2_4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certificate of Incorporation and Bylaws of the Surviving Corporation; Directors and Officers of the Surviving Corporation</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The certificate of incorporation of Merger Sub in effect immediately prior to the Effective Time shall be the certificate of incorporation of the Surviving Corporation until amended in accordance with applicable Law, except the name of the Surviving Corporation shall be as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4(b)</span>&#160;and the reference to the incorporator shall be deleted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The bylaws of Merger Sub in effect immediately prior to the Effective Time shall be the bylaws of the Surviving Corporation until amended in accordance with applicable Law, except the name of the Surviving Corporation shall be such name as selected by SpinCo in its absolute discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>From and after the Effective Time, until successors are duly elected or appointed and qualified in accordance with applicable Law, (i)&#160;the directors of SpinCo as of immediately prior to the Effective Time shall be the directors of the Surviving Corporation and (ii)&#160;the officers of SpinCo as of immediately prior to the Effective Time shall be the officers of the Surviving Corporation.</p><a id="A_Section_2_5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governance Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The Parties shall use reasonable best efforts to ensure that the individuals listed on Section&#160;2.5(a)&#160;of the Company Disclosure Schedule are nominated and elected as directors of Parent effective immediately after the Closing, and the identities of such individuals shall be made publicly available as promptly as practicable following the date hereof (but in any event prior to the date on which the Parent Registration Statement is filed with the SEC in definitive form).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Subject to the terms of Parent&#8217;s Governing Documents, Parent shall take all such action within its power as may be necessary or appropriate such that immediately following the Effective Time (i)&#160;the Parent Board shall have a majority of &#8220;independent&#8221; directors for purposes of NASDAQ and (ii)&#160;the initial officers of Parent shall be as set forth on Section&#160;2.5(b)&#160;of the Company Disclosure Schedule, in each case, each of whom shall serve in such capacity in accordance with the terms of Parent&#8217;s Governing Documents following the Effective Time.</p><a id="A_ARTICLE_III"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="color:#010000;">ARTICLE&#160;III</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">CONVERSION OF SHARES</p><a id="A_Section_3_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect on Capital Stock</span>. At the Effective Time, by virtue of the Merger and without any action on the part of any party to this Agreement or any holder of the capital stock of the Company, SpinCo, Merger Sub or Parent:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><i style="font-style:italic;">SpinCo Common Stock and Merger Sub Common Stock</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>Each share of SpinCo Common Stock issued and outstanding as of immediately prior to the Effective Time (other than shares canceled in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(ii))</span> shall be automatically converted into the right to receive (A)&#160;a number of fully paid and non-assessable shares of Domesticated Parent Common Stock equal to the Base Exchange Ratio, subject to adjustment in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(iv)</span>, with cash paid in lieu of fractional shares of Domesticated Parent Common Stock in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2(e)</span>&#160;(the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Class&#160;A Merger Consideration</span>&#8221;) and (B)&#160;a number of fully paid and non-assessable Earnout Shares equal to the Earnout Exchange Ratio, subject to adjustment in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(iv)</span>&#160;(together with the Class&#160;A Merger Consideration, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Consideration</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>Each share of SpinCo Common Stock held by SpinCo as treasury stock or by Parent or Merger Sub, in each case, as of immediately prior to the Effective Time shall automatically be canceled and shall cease to exist and no stock or other consideration shall be issued or delivered in exchange therefor or in respect thereof.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>Each share of SpinCo Common Stock issued and outstanding as of immediately prior to the Effective Time, when converted in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1</span>, shall no longer be outstanding and shall automatically be canceled and shall cease to exist, and each holder of such shares shall cease to have any rights with respect thereto, except the right to receive the Merger Consideration as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(i)</span>&#160;and any dividends or distributions and other amounts payable in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2(d)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>The Base Exchange Ratio and the Earnout Exchange Ratio shall be adjusted to the extent appropriate to reflect the effect of any stock split, split-up, reverse stock split, stock dividend or distribution of Parent Common Stock, or securities convertible into any such securities, reorganization, recapitalization, reclassification or other like change (any such change, an &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Adjustment</span>&#8221;) with respect to Parent Common Stock having a record date occurring on or after the date of this Agreement and prior to the Effective Time; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that nothing in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(iv)</span>&#160;shall be construed to permit Parent to take or to permit any of its Subsidiaries to take any action with respect to its securities that is prohibited by the terms of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span>If the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.2(h)</span>&#160;would be unable to be satisfied because immediately after the Effective Time, the percentage of outstanding shares of Domesticated Parent Common Stock to be received by the former holders of SpinCo Common Stock with respect to Qualified SpinCo Common Stock would be less than 50.1% (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Threshold Percentage</span>&#8221;) of all of the stock of Parent (excluding Earnout Shares and, including (i)&#160;any other instruments that are treated as stock for U.S. federal income Tax purposes; and (ii)&#160;any other stock that may be issued after the Effective Time that may be regarded as having been acquired or issued as part of a &#8220;plan&#8221; of which the Distribution is a part within the meaning of Section&#160;355(e)&#160;of the Code), then (x)&#160;SpinCo shall promptly provide notice to Parent setting forth in detail the reasons the condition set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.2(h)</span>&#160;would be unable to be satisfied, (y)&#160;SpinCo shall consider in good faith any comments provided by Parent, (z)&#160;(A)&#160;at the Company&#8217;s sole option, the Company may contribute the necessary additional capital to SpinCo to increase, dollar-for-dollar, the pre-money equity valuation of SpinCo and, in such event, the Aggregate Common Consideration Shares, the Base Exchange Ratio and the aggregate number of shares of Domesticated Parent Common Stock into which the shares of SpinCo Common Stock are converted pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1</span> shall be increased to take into account such additional capital contribution such that the number of shares of Domesticated Parent Common Stock to be received by the former holders of SpinCo Common Stock with respect to Qualified SpinCo Common Stock equals the Threshold Percentage, or (B)&#160;if the Company does not elect to make the capital contribution in clause (A), at Parent&#8217;s sole option, Parent may elect to increase, with no additional capital contribution by the Company, the aggregate number of shares of Domesticated Parent Common Stock into which the shares of SpinCo Common Stock are converted pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1,</span> such that the number of shares of Domesticated Parent Common Stock to be received by the former holders of SpinCo Common Stock with respect to Qualified SpinCo Common Stock equals the Threshold Percentage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</span></span>At the Effective Time, all of the shares of common stock, par value $0.01 per share, of Merger Sub (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Sub Common Stock</span>&#8221;) issued and outstanding immediately prior to the Effective Time shall be automatically converted into one fully paid and nonassessable share of common stock, par value $0.01 per share, of the Surviving Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><i style="font-style:italic;">Parent Securities</i>. Each share of Domesticated Parent Stock and each Domesticated Parent Warrant that is issued and outstanding immediately prior to and at the Effective Time shall remain outstanding immediately following the Effective Time.</p><a id="A_Section_3_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surrender and Payment</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Pursuant to Section&#160;3.2 of the Separation and Distribution Agreement, the Exchange Agent shall hold, for the account of the relevant SpinCo stockholders, book-entry shares representing all of the outstanding shares of SpinCo Common Stock distributed in the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Prior to the Effective Time, Parent shall designate a nationally recognized commercial bank or trust company reasonably acceptable to the Company to act as agent (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Agent</span>&#8221;) for the benefit of the holders of shares of SpinCo Common Stock and SpinCo Equity Awards whose shares of SpinCo Common Stock and/or SpinCo Equity Awards are exchanged in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2(b), Section&#160;3.3</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.5</span>. At or substantially concurrently with the Effective Time, Parent shall deposit, or shall cause to be deposited, with the Exchange Agent, for the benefit of the holders of shares of SpinCo Common Stock and/or SpinCo Equity Awards, for exchange in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2(b)</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.5</span> promptly after the Effective Time, book-entry shares representing (i)&#160;the Merger Consideration issuable to holders of shares of SpinCo Common Stock as of immediately prior to the Effective Time pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(i)</span>&#160;and/or (ii)&#160;the Earnout Shares issuable </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">to holders of SpinCo Equity Awards immediately prior to the Effective Time pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.5</span> (in the case of each of clauses (i)&#160;and (ii), without duplication) (such book-entry shares of Domesticated Parent Stock, together with any cash received by the Exchange Agent in respect of dividends or distributions with respect thereto pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2(d)</span>, as applicable, and other amounts payable in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2(e)</span>, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Fund</span>&#8221;). The Exchange Agent shall, following the Effective Time, pursuant to irrevocable instructions from Parent, deliver the Merger Consideration to be issued pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;III</span> out of the Exchange Fund. The cash portion, if any, of the Exchange Fund shall be invested by the Exchange Agent as directed by Parent; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that (i)&#160;no such investment of or losses thereon shall relieve Parent from making or causing to be made the payments required by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2</span> or elsewhere in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;III</span>, or affect the amount payable in respect of the shares of SpinCo Common Stock and/or SpinCo Equity Awards outstanding as of immediately prior to the Effective Time, (ii)&#160;to the extent the Exchange Fund is insufficient at any time to make such payments, Parent shall promptly provide additional funds to the Exchange Agent in the amount of any such deficiency and (iii)&#160;no such investment shall have maturities that would reasonably be expected to prevent or delay the payments to be made pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2</span>. Any interest or other income from such investments shall be paid to and become the property of Parent. The Exchange Fund shall not be used for any purpose other than as specified in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2(b)</span>. No later than five (5)&#160;Business Days prior to the Effective Time, Parent shall enter into an agreement with the Exchange Agent, in form and substance reasonably satisfactory to the Company, to effect the applicable terms of this Agreement (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Agent Agreement</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>As promptly as practicable after the Effective Time, Parent shall cause the Exchange Agent to deliver to each holder of shares of SpinCo Common Stock and/or SpinCo Equity Awards as of immediately prior to the Effective Time, from the Exchange Fund, the shares of Domesticated Parent Stock issuable in respect of such shares of SpinCo Common Stock and/or SpinCo Equity Awards pursuant to the Merger, which shares shall, for the sake of clarity, be delivered to the same Persons who received shares of SpinCo Common Stock and/or SpinCo Equity Awards in the Distribution. Each holder of shares of SpinCo Common Stock and/or SpinCo Equity Awards as of immediately prior to the Effective Time shall be entitled to receive in respect of such shares of SpinCo Common Stock and/or SpinCo Equity Awards held by such Person (i)&#160;a book-entry authorization representing the number of whole shares of Domesticated Parent Common Stock that such holder has the right to receive pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(i)(A)</span>&#160;(and cash in lieu of fractional shares of Domesticated Parent Common Stock, as contemplated by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2(e)</span>, and any dividends or distributions and other amounts pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2(d)</span>) and/or (ii)&#160;a book-entry authorization representing the number of Earnout Shares that such holder has the right to receive pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(i)(B)</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.5</span>, in each case, without duplication. The Exchange Agent shall not be entitled to vote or exercise any rights of ownership with respect to Domesticated Parent Stock held by it from time to time hereunder or under the Exchange Agent Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><i style="font-style:italic;">Distributions After the Effective Time</i>. Subject to the following sentence, no dividends or other distributions declared after the Effective Time with respect to Domesticated Parent Common Stock shall be paid with respect to any shares of Domesticated Parent Stock that are not able to be delivered by the Exchange Agent promptly after the Effective Time, whether due to a legal impediment to such delivery or otherwise. Subject to the effect of abandoned property, escheat, Tax or other applicable Laws, following the delivery of any such previously undelivered shares of Domesticated Parent Stock, there shall be paid to the record holder of such shares of Domesticated Parent Common Stock, without interest, at the time of delivery, to the extent not previously paid, (i)&#160;the amount of cash payable in lieu of a fractional share of Domesticated Parent Common Stock to which such holder is entitled pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2(e)</span>&#160;and (ii)&#160;the amount of dividends or other distributions with a record date after the Effective Time theretofore paid with respect to such whole shares of Domesticated Parent Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><i style="font-style:italic;">No Fractional Shares</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>No certificates or scrip representing fractional shares of Domesticated Parent Stock or book-entry credit of the same shall be issued on conversion of SpinCo Common Stock and/or SpinCo Equity Awards, and such fractional share interests will not entitle the owner thereof to vote, or to any other rights of a stockholder of Parent. All fractional shares of Domesticated Parent Common Stock that a holder of shares of SpinCo Common Stock would otherwise be entitled to receive as a result of the Merger shall be aggregated by the Exchange Agent. The Exchange Agent shall cause the whole shares obtained thereby to be sold on behalf of such holders that would otherwise have been entitled to receive a fractional share of Domesticated Parent Common Stock pursuant to the Merger in the open market (or otherwise as reasonably directed by Parent), in each case at then-prevailing market prices as soon as reasonably practicable and in no case later than ten (10)&#160;Business Days after the Effective Time. The Exchange Agent shall make available the net proceeds thereof, subject to the deduction of the amount of any withholding Taxes as contemplated in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2(j)</span>&#160;and brokerage charges, commissions and conveyance and similar Taxes, to the holders of SpinCo Common Stock that would otherwise have been entitled to </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 36pt;">receive a fractional share of Domesticated Parent Common Stock pursuant to the Merger (after the aggregation contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2(e)</span>) on a pro rata basis based on such fractional interest, without interest, as soon as practicable thereafter. The payment of cash in lieu of fractional shares is solely for the purpose of avoiding the expense and inconvenience of issuing fractional shares and does not represent separately bargained-for consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>Notwithstanding anything to the contrary herein, no fraction of an Earnout Share will be issued by virtue of the Merger, and each holder of SpinCo Common Stock and/or SpinCo Equity Awards who would otherwise be entitled to a fraction of an Earnout Share (after aggregating all fractional Earnout Shares that otherwise would be received by such holder of SpinCo Common Stock and/or SpinCo Equity Awards) shall not receive from Parent any shares of Domesticated Parent Stock or other consideration in lieu of any such fractional share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><i style="font-style:italic;">No Further Ownership Rights in SpinCo Common Stock</i>. All shares of Domesticated Parent Stock issued in respect of shares of SpinCo Common Stock and/or SpinCo Equity Awards in accordance with the terms of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2</span> (including any cash paid pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2(d)</span>&#160;or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2(e)</span>) shall be deemed to have been issued in full satisfaction of all rights pertaining to such shares of SpinCo Common Stock and/or SpinCo Equity Awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><i style="font-style:italic;">Termination of Exchange Fund</i>. Any portion of the Exchange Fund made available to the Exchange Agent that remains undistributed to the former holders of SpinCo Common Stock and/or SpinCo Equity Awards on the one-year anniversary of the Effective Time shall be delivered to Parent, and any former holders of SpinCo Common Stock and/or SpinCo Equity Awards who have not received shares of Domesticated Parent Stock in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;III</span> shall thereafter look only to Parent for (i)&#160;in the case of former holders of SpinCo Common Stock, the Merger Consideration to which they are entitled pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)(i),</span> any cash in lieu of fractional shares of Domesticated Parent Common Stock to which they are entitled pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2(e)</span>&#160;and any dividends or other distributions with respect to the Domesticated Parent Common Stock to which they are entitled pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2(d)</span>&#160;(subject to any applicable abandoned property, escheat or similar Law) and (ii)&#160;in the case of former holders of SpinCo Equity Awards, the Earnout Shares to which they are entitled pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.5</span> and any dividends or other distributions with respect to the Earnout Shares to which they are entitled pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2(d)</span>&#160;or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(g)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><i style="font-style:italic;">No Liability</i>. None of the Company, the Surviving Corporation, Parent, Merger Sub, the Exchange Agent or any other Person shall be liable to any holder of SpinCo Common Stock, Company Common Stock, SpinCo Equity Awards or Company Equity Awards for shares of Domesticated Parent Stock (or dividends or distributions with respect thereto or with respect to SpinCo Common Stock) or cash properly delivered to a public official pursuant to any applicable abandoned property, escheat or similar Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><i style="font-style:italic;">Closing of Transfer Books</i>. From and after the Effective Time, the stock transfer books of SpinCo shall be closed and no transfer shall be made of any shares of capital stock of SpinCo that were outstanding as of immediately prior to the Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span><i style="font-style:italic;">Tax Withholding</i>. Parent, the Company, SpinCo, Merger Sub and the Exchange Agent shall each be entitled to deduct and withhold from the consideration otherwise payable pursuant to this Agreement to any holder of SpinCo Common Stock or any holder of SpinCo Equity Awards such amounts as are required to be deducted and withheld with respect to the making of such payment under the Code, or under any provision of state, local or foreign Tax Law (including, for the avoidance of doubt, any withholding to be made in respect of any Merger Consideration delivered to SpinCo Service Providers through payroll). To the extent that amounts are so deducted or withheld and paid over to the appropriate Governmental Authority, such deducted or withheld amounts will be treated for all purposes of this Agreement as having been paid to the Person in respect of which such deduction or withholding was made.</p><a id="A_Section_3_3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Earnout</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Pursuant to the Merger, there shall be issued to each holder of a share of SpinCo Common Stock and each holder of a SpinCo Equity Award, their pro rata portion, as determined in accordance with the terms of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1(a)</span>&#160;and the Employee Matters Agreement, as applicable, of an aggregate of 15,000,000 shares of Domesticated Parent Common Stock (without duplication), subject to the forfeiture provisions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(d)</span>&#160;(the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Earnout Shares</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The Earnout Shares shall be subject to the following vesting conditions:</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>If, at any time during the period commencing on the Closing Date and ending on the date that is five years after the Closing Date (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Earnout Period</span>&#8221;), the Parent Trading Price is greater than or equal to $12.50, 50% of the Earnout Shares held by each holder of Earnout Shares shall immediately vest and no longer be subject to the forfeiture conditions provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(d)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>If, at any time during the Earnout Period, the Parent Trading Price is greater than or equal to $15.00, the remaining 50% of the Earnout Shares held by each holder of Earnout Shares shall immediately vest and no longer be subject to the forfeiture conditions provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(d)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>For the avoidance of doubt, if the vesting conditions applicable to more than one of the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(b)</span>&#160;have been satisfied at any one time, then all of the Earnout Shares subject to such satisfied vesting conditions shall immediately vest and no longer be subject to the forfeiture conditions provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(d)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>If, upon the expiration of the Earnout Period, the vesting of any of the Earnout Shares has not occurred, then the applicable Earnout Shares that failed to vest pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(b)</span>, as applicable, shall be automatically forfeited and deemed transferred to Parent for cancellation for no consideration, and no Person (other than Parent) shall have any further right with respect thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>If, during the Earnout Period, the Domesticated Parent Common Stock outstanding as of immediately following the Merger Effective Time shall have been changed into a different number of shares or a different class, by reason of any Equity Adjustment, or any similar event shall have occurred, then the applicable Parent Trading Price specified in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(b)</span>&#160;shall be equitably adjusted to reflect such change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>If, during the applicable portion of the Earnout Period, there is a Change of Control that will result in the holders of Domesticated Parent Common Stock receiving a per share price equal to or in excess of the applicable Parent Trading Price required in connection with an applicable vesting event (an &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acceleration Event</span>&#8221;), then immediately prior to the consummation of such Change of Control, any applicable Earnout Shares that have not previously been vested shall be deemed vested; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that such Earnout Shares shall be deemed vested (and such vesting event achieved) only (x)&#160;if such Change of Control has been approved by a majority of the independent directors on the Parent Board and (y)&#160;to the extent the price per share of Domesticated Parent Common Stock in the Change of Control equals or exceeds the applicable Parent Trading Price required in connection with such vesting event. For the avoidance of doubt, in the event of a Change of Control, including where the consideration payable is other than a specified price per share, for purposes of determining whether a Parent Trading Price required in connection with an applicable vesting event has been achieved, the price paid per share of Domesticated Parent Common Stock shall be calculated taking into account all of the Earnout Shares (whether or not then vested).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>For so long as any Earnout Shares remains subject to the vesting and forfeiture conditions specified in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(b)</span>&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3(d)</span>, the holder thereof shall be entitled to (i)&#160;exercise the voting rights carried by such Earnout Shares and (ii)&#160;receive any dividends or other distributions in respect of such Earnout Shares. For the avoidance of doubt, prior to vesting in accordance with the terms of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3</span>, holders of the Earnout Shares shall not be entitled to transfer such shares, and such shares shall bear a legend prohibiting transfer until such time as the vesting conditions with respect to such share have been satisfied (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer Restriction</span>&#8221;). Any attempted transfer in violation of the Transfer Restriction shall be void <i style="font-style:italic;">ab initio</i>. For the avoidance of doubt, the Company, Parent, SpinCo and any other applicable withholding agent shall each be entitled to deduct and withhold from any amounts payable or distributions made in respect of the Earnout Shares.</p><a id="A_Section_3_4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appraisal Rights.</span> In accordance with Section&#160;262 of the DGCL, no appraisal rights shall be available to the holders of SpinCo Common Stock in connection with the Merger.</p><a id="A_Section_3_5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Treatment of SpinCo Equity Awards.</span> Each SpinCo Equity Award that is outstanding as of the Effective Time shall be treated as set forth in the Employee Matters Agreement.</p><a id="A_ARTICLE_IV"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="color:#010000;">ARTICLE&#160;IV</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">REPRESENTATIONS AND WARRANTIES OF THE COMPANY RELATING TO THE COMPANY</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as otherwise disclosed or identified in (a)&#160;the Company SEC Documents filed and publicly available on the SEC&#8217;s EDGAR database at least two (2)&#160;Business Days prior to the date hereof (excluding any disclosures of factors or risks contained or references therein under the captions &#8220;Risk Factors&#8221; or &#8220;Forward-Looking Statements&#8221; to the extent they are forward-looking statements and any other similar general, predictive or cautionary statements) or (b)&#160;the Company Disclosure Schedule (to the extent that it is reasonably apparent on the face of such disclosure that it is relevant to or applies to such representation or warranty of the Company under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IV</span>), the Company hereby represents and warrants to Parent and Merger Sub as follows:</p><a id="A_Section_4_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization of the Company. </span>The Company has been duly incorporated and is validly existing and in good standing as a Delaware corporation. The Company has all requisite corporate power and authority to own, lease and operate its properties and assets in the manner in which such assets and properties are now owned, leased and operated and to conduct its business as it is now being conducted. The Company has made available to Parent and Merger Sub true and complete copies of the Governing Documents of the Company as in effect on the date hereof. The Company is duly licensed or qualified and in good standing (or equivalent status as applicable) in each jurisdiction in which the assets owned or leased by it or the character of its activities require it to be so licensed or qualified or in good standing (or equivalent status as applicable), except as would not, individually or in the aggregate, have a Company Material Adverse Effect.</p><a id="A_Section_4_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Due Authorization</span>. The Company has all requisite corporate power and authority to execute and deliver this Agreement and the Transaction Documents to which it is or will be a party and to consummate the Transactions, except for such further action of the Company Board required, if applicable, to establish the Record Date and the Distribution Date, and the declaration of the Distribution by the Company Board (the effectiveness of which is subject to the satisfaction or, to the extent permitted by applicable Law, waiver, of the conditions set forth in the Separation and Distribution Agreement). The execution and delivery by the Company of this Agreement and the Transaction Documents to which it is or will be a party as of the Effective Time and the consummation of the Transactions have been duly authorized by all necessary and proper corporate action on its part, and no other corporate action on the part of the Company is necessary to authorize this Agreement or the Transaction Documents to which it is or will be a party as of the Effective Time or, subject to such further action of the Company Board required, if applicable, to establish the Record Date and the Distribution Date, and the declaration of the Distribution by the Company Board (the effectiveness of which is subject to the satisfaction or, to the extent permitted by applicable Law, waiver of the conditions set forth in the Separation and Distribution Agreement), consummate the Transactions. Each of this Agreement and the Transaction Documents to which the Company is or will be a party as of the Effective Time has been or will be duly and validly executed and delivered by it and (assuming that this Agreement or such other applicable Transaction Documents to which each of Parent and Merger Sub is or will be a party as of the Effective Time constitutes a legal, valid and binding obligation of each of Parent and Merger Sub (as applicable)), constitutes or will when executed and delivered constitute the legal, valid and binding obligation of the Company, enforceable against it in accordance with its terms, subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar Laws affecting creditors&#8217; rights generally and subject, as to enforceability, to general principles of equity (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remedies Exception</span>&#8221;).</p><a id="A_Section_4_3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Consents</span>. No Consent of, with or to any Governmental Authority is required to be obtained or made by the Company in connection with the execution or delivery by the Company of this Agreement or the Transaction Documents to which it is or will be a party or the consummation by the Company of the Transactions, except for or in compliance with (a)&#160;any Premerger Notification and Report Form&#160;required under and compliance with the HSR Act or other filings in connection with the Requisite Regulatory Approvals; (b)&#160;the filing of the Certificate of Merger and the Parent Charter with the Secretary of State of the State of Delaware pursuant to the provisions of the DGCL; (c)&#160;the rules&#160;and regulations of NASDAQ; (d)&#160;applicable requirements of state securities or &#8220;blue sky&#8221; Laws, the Securities Act and the Exchange Act; (e)&#160;Consents described in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.6</span> and Consents set forth on Section&#160;4.3 of the SpinCo Disclosure Schedule; and (f)&#160;Consents the failure of which to be made or obtained would not reasonably be expected to, individually or in the aggregate, have a Company Material Adverse Effect or a SpinCo Material Adverse Effect.</p><a id="A_Section_4_4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflict</span>. Subject to the receipt of the Consents set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.3</span>, the execution and delivery by the Company of this Agreement and the Transaction Documents to which it is or will be a party as of the Effective Time and the consummation by the Company of the Transactions (for the avoidance of doubt, including performance of the Transaction Documents following the Closing) do not and will not as of the Effective Time, (a)&#160;violate any provision of, or result in the breach of, any Law applicable to the Company or by which any of its assets or properties is bound; (b)&#160;with or without lapse of time or the giving of notice or both, require a consent or approval under, conflict with, result in a violation or breach of, or constitute a default under, result in the acceleration of, create in any party the right to accelerate, terminate or cancel any Contract to which the Company is a party or by which its assets or properties are bound; or (c)&#160;breach or violate any provision of the Governing Documents of the Company, except, </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">in the case of each of clauses (a)&#160;and (b), as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect.</p><a id="A_Section_4_5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Litigation and Proceedings</span>. (a)&#160;There are no Actions pending or, to the Knowledge of the Company, threatened before or by any Governmental Authority against the Company or any Company Subsidiary that, individually or in the aggregate, would reasonably be expected to result in a Company Material Adverse Effect, and (b)&#160;neither the Company nor any of its Subsidiaries is subject to any judgment, decree, injunction or order of any Governmental Authority that, in each case, would reasonably be expected to result, individually or in the aggregate, in a Company Material Adverse Effect.</p><a id="A_Section_4_6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brokers&#8217; Fees</span>. No broker, investment banker, or other Person is entitled to any brokerage fee, finders&#8217; fee or other similar commission for which Parent or any of its Subsidiaries, including Merger Sub, the Surviving Corporation or the SpinCo Entities, would be liable in connection with the transactions contemplated by this Agreement based on arrangements made on behalf of the Company or any of its Affiliates (other than the SpinCo Entities).</p><a id="A_Section_4_7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Internal Controls</span>. The Company has established and maintains a system of internal controls over financial reporting (as defined in Rule&#160;13a-l5(f)&#160;or 15d-15(f), as applicable, under the Exchange Act (collectively, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Internal Controls</span>&#8221;)) that are designed to provide reasonable assurances that (i)&#160;transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii)&#160;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets, (iii)&#160;access to assets is permitted only in accordance with management&#8217;s general or specific authorization and (iv)&#160;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Internal Controls are overseen by the audit committee of the Company Board (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Audit Committee</span>&#8221;). Since January&#160;1, 2019, the Company&#8217;s principal executive officer and its principal financial officer have disclosed to the Company&#8217;s independent auditor and the Company Audit Committee (a)&#160;any significant deficiency or material weakness in the Company&#8217;s Internal Controls and (b)&#160;any fraud involving management or other employees who have a significant role in the Company&#8217;s Internal Controls. Since January&#160;1, 2019, neither the Company nor any Company Subsidiary has received any material, unresolved complaint, allegation, assertion or claim regarding the impropriety of any accounting or auditing practices, procedures, methodologies or methods of the Company or any Company Subsidiary or their respective internal accounting controls.</p><a id="A_Section_4_8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Equity Awards</span>. Section&#160;4.8 of the Company Disclosure Schedule sets forth a true, correct and complete list of all Company Options, Company RSU Awards and Company PSU Awards that are outstanding as of the date hereof and any other rights to purchase or receive shares of Company Common Stock, and, for each such award or other right, (i)&#160;the number of shares of Company Common Stock or any of its Subsidiaries subject thereto, (ii)&#160;the equity plan under which the award is governed, (iii)&#160;the terms of vesting (including the extent to which it will become accelerated as a result of the consummation of the Transactions) and vesting status, (iv)&#160;the grant and expiration dates, (v)&#160;the exercise price, if applicable, (vi)&#160;the name of the holder thereof, (vii)&#160;whether such award or other right is intended to be an &#8220;incentive stock option&#8221; as defined in Section&#160;422 of the Code or a non-qualified stock option, and (viii)&#160;whether such Company Equity Award is held by a Company Service Provider, Former Company Service Provider or SpinCo Service Provider. All Company Options were granted with an exercise price per share no lower than the fair market value of one (1)&#160;share of stock underlying such Company Equity Award on the date of the corporate action effectuating the applicable grant and are exempt under Section&#160;409A of the Code. All Company Equity Awards were granted in accordance with the applicable equity plan under which such award is governed, the applicable award agreement, and applicable Law in all material respects.</p><a id="A_ARTICLE_V"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="color:#010000;">ARTICLE&#160;V</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">REPRESENTATIONS AND WARRANTIES OF THE COMPANY RELATING TO SPINCO</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as otherwise disclosed or identified in (a)&#160;the Company SEC Documents filed and publicly available on the SEC&#8217;s EDGAR database at least two (2)&#160;Business Days prior to the date hereof (excluding any disclosures of factors or risks contained or references therein under the captions &#8220;Risk Factors&#8221; or &#8220;Forward-Looking Statements&#8221; to the extent they are forward-looking statements and any other similar general, predictive or cautionary statements) or (b)&#160;the corresponding section or subsection of the SpinCo Disclosure Schedule (it being understood that each such disclosure shall also apply to each other representation and warranty contained in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</span> to the extent that it is reasonably apparent on the face of such disclosure that it is relevant to or applies to such representation or warranty), the Company hereby represents and warrants to Parent and Merger Sub as follows:</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="A_Section_5_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization of SpinCo</span>. SpinCo has been duly incorporated and is validly existing and in good standing as a Delaware corporation and has all requisite corporate power and authority to own, lease and operate its assets in the manner in which such assets are now (or as of the Effective Time will be) owned, leased or operated and to conduct its business as it is now being conducted. SpinCo has made available to Parent and Merger Sub true and complete copies of the Governing Documents of SpinCo. SpinCo is duly licensed or qualified and in good standing (or equivalent status as applicable) in each jurisdiction in which the assets owned or leased by it or the character of its activities require it to be so licensed or qualified or in good standing (or equivalent status as applicable), except as would not, individually or in the aggregate, reasonably be expected to have a SpinCo Material Adverse Effect.</p><a id="A_Section_5_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Due Authorization</span>. SpinCo has all requisite corporate power and authority to execute and deliver this Agreement and the Transaction Documents to which it is or will be a party at the Effective Time and to consummate the Transactions (subject, in the case of the Merger, to the SpinCo Shareholder Approval, which will occur immediately after the execution of this Agreement), and except for such further action of the Company Board required, if applicable, to establish the Record Date and the Distribution Date, and the effectiveness of the declaration of the Distribution by the Company (which is subject to the satisfaction or, to the extent permitted by applicable Law, waiver of the conditions set forth in the Separation and Distribution Agreement). The execution and delivery by SpinCo of this Agreement and the Transaction Documents to which it is or will be a party at the Effective Time and the consummation by SpinCo of the Transactions have been duly and validly authorized and approved by all necessary and proper corporate action on its part and, except for the SpinCo Shareholder Approval, no other corporate action on the part of SpinCo is necessary to authorize this Agreement or the Transaction Documents to which it is or will be a party at the Effective Time. Each of this Agreement and the Transaction Documents to which it is or will be a party at the Effective Time has been, or when executed and delivered will be, duly and validly executed and delivered by SpinCo and (assuming that this Agreement or such other applicable Transaction Document to which Parent or Merger Sub is or will be a party at the Effective Time constitutes a legal, valid and binding obligation of Parent or Merger Sub (as applicable)) constitutes or will constitute a legal, valid and binding obligation of SpinCo, enforceable against SpinCo in accordance with its terms, subject to the Remedies Exception.</p><a id="A_Section_5_3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capitalization of SpinCo</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>As of the date hereof, (i)&#160;the authorized capital stock of SpinCo consists of 1,000 shares of SpinCo Common Stock, (ii)&#160;the issued and outstanding shares of capital stock of SpinCo consists of 1,000 shares of SpinCo Common Stock, and (iii)&#160;no shares of SpinCo Common Stock are being held by SpinCo in its treasury. All of the issued and outstanding shares of SpinCo Common Stock are, as of the date hereof (and as of immediately prior to the Distribution will be), owned, of record and beneficially, by the Company and have been duly authorized and validly issued, are fully paid and nonassessable and have not been issued in violation of any preemptive or similar rights. Immediately prior to the Effective Time, there will be outstanding a number of shares of SpinCo Common Stock determined in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.14</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>No bonds, debentures, notes or other indebtedness of any SpinCo Entity having the right to vote (or convertible into or exercisable for securities having the right to vote) on any matters on which holders of shares of capital stock of SpinCo (including SpinCo Common Stock) may vote (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Voting Debt</span>&#8221;) are issued or outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>There are no (i)&#160;outstanding options, warrants, rights or other securities convertible into or exchangeable or exercisable for shares of capital stock of SpinCo, or any other commitments or agreements providing for the issuance, sale, repurchase or redemption of shares of capital stock of SpinCo, (ii)&#160;agreements of any kind which may obligate SpinCo to issue, purchase, redeem or otherwise acquire any of its shares of capital stock or (iii)&#160;voting trusts, proxies or other agreements or understandings with respect to the voting shares of capital stock of SpinCo.</p><a id="A_Section_5_4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsidiaries</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.4(a)</span>&#160;of the SpinCo Disclosure Schedule sets forth a list of the SpinCo Subsidiaries (after giving effect to the Internal Reorganization) and their respective jurisdictions of organization as of the date hereof. Each SpinCo Subsidiary has been, or will be at the Closing, duly organized and is, or will be at the Closing, validly existing and in good standing (to the extent applicable under the Laws of its jurisdiction of formation) under the Laws of its jurisdiction of organization and has all requisite organizational power and authority to own, lease and operate its assets in the manner such assets are now (or as of the Effective Time will be) owned, leased, or operated and to conduct its business as it is now being conducted.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Each SpinCo Subsidiary is, or will be at the Closing, duly licensed or qualified and in good standing (or equivalent status as applicable) in each jurisdiction in which the assets owned or leased by it or the character of its activities require it to be so licensed or qualified or in good standing (or equivalent status as applicable), as applicable, except as would not, individually or in the aggregate, reasonably be expected to have a SpinCo Material Adverse Effect. Other than the SpinCo Subsidiaries set forth on Section&#160;5.4(a)&#160;of the SpinCo Disclosure Schedule, as of the date hereof (giving effect to the Internal Reorganization), SpinCo does not own or hold, directly or indirectly, any Interest in any other Person.</p><a id="A_Section_5_5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capitalization of Subsidiaries</span>. The issued and outstanding Interests of each of the SpinCo Subsidiaries have been, or will be at the Closing, duly authorized and are (or will then be) validly issued and, as applicable, fully paid and nonassessable. SpinCo, directly or indirectly, owns, or will own at the Closing, of record and beneficially, all the issued and outstanding Interests of the SpinCo Subsidiaries, free and clear of any Liens (other than those set forth in their respective Governing Documents or arising pursuant to applicable securities Laws or created by this Agreement). There are no outstanding options, warrants, rights or other securities exercisable or exchangeable for Interests of such SpinCo Subsidiaries, any other commitments or agreements providing for the issuance, sale, repurchase or redemption of Interests of such SpinCo Subsidiaries, and there are no agreements of any kind which may obligate any SpinCo Subsidiary to issue, purchase, redeem or otherwise acquire any of its Interests.</p><a id="A_Section_5_6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Consents</span>. No Consent of, with or to any Governmental Authority is required to be obtained or made by any SpinCo Entity in connection with the execution or delivery by SpinCo of this Agreement or the Transaction Documents to which SpinCo is or will be a party at the Effective Time or the consummation by SpinCo of the Transactions, except for: (a)&#160;applicable requirements of the HSR Act (b)&#160;the filing of the Certificate of Merger with the Secretary of State of the State of Delaware pursuant to the provisions of the DGCL; (c)&#160;applicable requirements of state securities or &#8220;blue sky&#8221; Laws, the Securities Act and the Exchange Act; (d)&#160;Consents described in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.3</span> and Consents set forth on Section&#160;5.6 of the SpinCo Disclosure Schedule; and (f)&#160;Consents the failure of which to be made or obtained would not reasonably be expected to, individually or in the aggregate, have a SpinCo Material Adverse Effect.</p><a id="A_Section_5_7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflict</span>. Subject to the receipt of the Consents described in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.6</span>, the execution and delivery by SpinCo of this Agreement and the Transaction Documents to which SpinCo is or will be a party at the Effective Time and the consummation by SpinCo of the Transactions (for the avoidance of doubt, including performance of the Transaction Documents following the Closing by the SpinCo Entities) do not and will not: (a)&#160;violate any provision of, or result in the material breach of, any Law applicable to any SpinCo Entity or by which any of its assets or properties is bound; (b)&#160;with or without lapse of time or the giving of notice or both, require a consent or approval under, conflict with, result in a violation or breach of, or constitute a default under, result in the acceleration of, or create in any party the right to accelerate, terminate or cancel any Contract to which a SpinCo Entity is a party or by which their assets or properties is (or will at the Closing be) bound; (c)&#160;result in the creation of any Lien upon any of the properties or assets of SpinCo or any of SpinCo&#8217;s Subsidiaries; or (d)&#160;violate any provision of the Governing Documents of the SpinCo Entities, except, in the case of clauses (a), (b)&#160;and (c), as would not, individually or in the aggregate, reasonably be expected to have a SpinCo Material Adverse Effect.</p><a id="A_Section_5_8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sufficiency of the SpinCo Assets</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>As of the Effective Time (assuming receipt of all consents, approvals and authorizations relating to the matters set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.3</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.6</span>), after giving effect to the Internal Reorganization, the SpinCo Assets owned by the SpinCo Entities will, taking into account all Transaction Documents (including the services available under the Transition Services Agreements and the other Transaction Documents), constitute all of the assets, properties and rights reasonably necessary for Parent and the SpinCo Entities to conduct the SpinCo Business immediately following the Closing in all material respects in the same manner as it is conducted on the date hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Except for Permitted Liens or Liens created by or through Parent or Merger Sub, SpinCo and the Company collectively have, and at the Closing (after giving effect to the Internal Reorganization and the other Transactions) the SpinCo Entities shall have, good, valid and marketable title to, or a valid leasehold in, license to or other legal right to use, as the case may be, all of the material SpinCo Assets, free and clear of any Liens.</p><a id="A_Section_5_9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Statements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Set forth on Section&#160;5.9 of the SpinCo Disclosure Schedule are copies of the SpinCo Financial Statements. Each of the SpinCo Financial Statements fairly presents, in all material respects, the financial condition and results of operations and cash </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">flows of the SpinCo Business, as of the dates indicated therein and for the periods referred to therein; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that the SpinCo Financial Statements and the representations and warranties in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.9(a)</span>&#160;are qualified by the fact that (i)&#160;the SpinCo Business has not operated on a separate standalone basis and has historically been reported within the Company&#8217;s combined financial statements, (ii)&#160;the SpinCo Financial Statements assume certain allocated charges and credits, which do not necessarily reflect amounts that would have resulted from arm&#8217;s-length transactions or that the SpinCo Business would incur on a standalone basis, including after the Closing and (iii)&#160;the SpinCo Financial Statements are subject to changes prior to the provision of final audited SpinCo Financial Statements, none of which are expected to be material. The SpinCo Financial Statements were prepared based on the accrual basis of accounting consistently applied by the Company during the periods involved and were derived from the financial reporting systems and the consolidated financial statements of the Company, which consolidated financial statements were prepared in accordance with GAAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>As of the date hereof, neither SpinCo nor any of its Subsidiaries is required to file or furnish any form, report, registration statement, prospectus or other document with the SEC.</p><a id="A_Section_5_10"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Undisclosed Liabilities</span>. There is no Liability of the SpinCo Entities or related to the SpinCo Business (excluding any Liabilities related or attributable to Taxes) whether or not of a type required to be reflected or reserved for on a consolidated balance sheet of the SpinCo Business or in the notes thereto prepared in accordance with GAAP, except for (a)&#160;Liabilities reflected or reserved for in the combined balance sheets as of December&#160;31, 2021 included in the SpinCo Financial Statements; (b)&#160;Liabilities that have arisen since the Balance Sheet Date in the ordinary course of the operation of the SpinCo Business; (c)&#160;Liabilities arising out of or in connection with this Agreement, the Transaction Documents and the Transactions; or (d)&#160;Liabilities that, individually or in the aggregate, would not reasonably be expected to be material to the SpinCo Entities taken as a whole.</p><a id="A_Section_5_11"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Litigation and Proceedings</span>. As of the date hereof, there are no Actions pending or, to the Knowledge of the Company or SpinCo, threatened before or by any Governmental Authority against any SpinCo Entity or with respect to the SpinCo Business, and neither the Company nor any of its Subsidiaries (solely as they relate to the SpinCo Business or any SpinCo Entity) is subject to any judgment, decree, injunction or order of or investigation or inquiry by any Governmental Authority, except, in each case, as would not reasonably be expected, individually or in the aggregate, to be material to the SpinCo Entities taken as a whole.</p><a id="A_Section_5_12"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.12</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Real Property</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The SpinCo Entities do not own and at no time previously have owned, any real property. With respect to the Company Real Property, (i)&#160;the Company or its applicable Subsidiary has good and valid title (or the applicable local equivalent) or a valid and enforceable leasehold interest, as applicable, in such Company Real Property, free and clear of any Liens, subject to the Remedies Exception and other than Permitted Liens, and (ii)&#160;neither the Company nor any of its Subsidiaries has received written notice of any pending condemnation, expropriation, eminent domain or similar Action affecting all or any portion of such Company Real Property (to the extent relating to or affecting the SpinCo Business).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Subject to the terms of the Transaction Documents, including the Separation and Distribution Agreement, the SpinCo Entities have, or will have at the Effective Time, a valid and enforceable leasehold interest in the SpinCo Real Property, except as has not and would not reasonably be expected, individually or in the aggregate, to result in any material Liability to the SpinCo Business, taken as a whole. Other than the SpinCo Real Property Leases set forth on Section&#160;5.15(a)(viii)&#160;of the SpinCo Disclosure Schedule, there are no Contracts granting to any Person (other than any SpinCo Entity or any landlord of such property pursuant to a SpinCo Real Property Lease and other than any Person who would be entitled to access any such property in the ordinary course of business in accordance with the applicable SpinCo Real Property Lease) the right of use or occupancy of any SpinCo Real Property.</p><a id="A_Section_5_13"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.13</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except as would not, individually or in the aggregate, have a SpinCo Material Adverse Effect:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>(A)&#160;All Tax Returns required to be filed by or with respect to a SpinCo Entity or the SpinCo Business have been timely filed (taking into account applicable extensions), (B)&#160;all such Tax Returns are true, correct and complete, and (C)&#160;all Taxes, whether or not shown as due on such Tax Returns, in respect of each SpinCo Entity and the SpinCo Business have been paid, in the case of each of clauses&#160;(A)&#160;through (C), except to the extent adequate reserves therefor in accordance with GAAP have been provided on the SpinCo Financial Statements;</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>(A)&#160;No Governmental Authority has asserted any written claim, assessment or deficiency for Taxes against any SpinCo Entity or the SpinCo Business (and, to the Knowledge of the Company and SpinCo, no such claim, assessment or deficiency has been threatened or proposed in writing), except for deficiencies which have been satisfied by payment, settled or withdrawn and (B)&#160;no claim, audit or other proceeding by any Governmental Authority is pending or threatened in writing with respect to any Taxes of any SpinCo Entity or the SpinCo Business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>No SpinCo Entity has any Liability for Taxes of any other Person (other than the Company or any of its subsidiaries) under Treasury Regulations section 1.1502-6 (or any similar provision of state, local or non-U.S. Law), as a transferee or successor or by contract or operation of Law or otherwise;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>Other than in connection with the Separation, within the past two years, no SpinCo Entity has constituted either a &#8220;distributing corporation&#8221; or a &#8220;controlled corporation&#8221; (within the meaning of Section&#160;355(a)(1)(A)&#160;of the Code) in a distribution of stock qualifying for tax-free treatment under Section&#160;355 of the Code;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span>No SpinCo Entity has participated in, or is currently participating in, a &#8220;listed transaction&#8221; within the meaning of Treasury Regulations Section&#160;1.6011-4(b)(2); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</span></span>There are no Liens for Taxes (other than Permitted Liens) upon the assets of any SpinCo Entity or the SpinCo Business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Neither the Company nor any of its Subsidiaries has taken or agreed to take any action or knows of any fact, agreement, plan or other circumstance that could reasonably be expected to prevent or impede (i)&#160;the Domestication from qualifying as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)(1)(F), (ii)&#160;the Tax-Free Status, (iii)&#160;the Company from receiving the Company Tax Opinions or (iv)&#160;Parent from receiving the Parent Tax Opinions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>The representations and warranties set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.13</span> and, to the extent relating to Tax matters, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.18</span>, constitute the sole and exclusive representations and warranties of the Company regarding Tax matters.</p><a id="A_Section_5_14"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.14</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Absence of Changes</span>. Since the Balance Sheet Date until the date of this Agreement, (a)&#160;there has not been any SpinCo Material Adverse Effect and (b)&#160;except in connection with the Transaction Process or as contemplated by this Agreement and the other Transaction Documents,&#160;since the Balance Sheet Date and through the date hereof, the Company and its Subsidiaries, including the SpinCo Entities, have, in all material respects, conducted the SpinCo Business in the ordinary course of business.</p><a id="A_Section_5_15"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.15</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Material Contracts</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except as set forth in Section&#160;5.15(a)&#160;of the SpinCo Disclosure Schedule and except for Contracts that do not constitute SpinCo Assets or SpinCo Liabilities, as of the date hereof, neither the Company nor any of its Subsidiaries (other than the SpinCo Entities) (solely with respect to the SpinCo Business), or any of the SpinCo Entities, is party to or otherwise bound by or subject to Contracts of the following types (together with any SpinCo Affiliate Contracts, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Material Contracts</span>&#8221;):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>any Contract that relates to the purchase or sale of goods or services pursuant to which the SpinCo Business has received more than $2,000,000 or paid more than $2,000,000 in the past twelve (12) months;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>any Contract that limits or purports to limit in any material respect the ability of the SpinCo Business to compete with any Person or in any line of business or in any geographic region in the world;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>any Contract that grants exclusive rights to a customer or a supplier or (to the extent material to the SpinCo Business) any other commercial counterparty that will relate to or affect the SpinCo Business after the Closing;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>any Contract that requires any future capital expenditures by the SpinCo Business in excess of $2,000,000 that will not be paid prior to the Closing;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span>any Contract that requires any milestone, earn out or similar payments to be made by the SpinCo Business in excess of $2,000,000 that will not be paid prior to the Closing;</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</span></span>any Contract that relates to the creation, incurrence, assumption or guarantee of any indebtedness for borrowed money or any bonds, debentures, notes or similar instruments, in each case, in excess of $2,000,000;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vii)</span></span>any Contract pursuant to which (A)&#160;any Person grants to any of the SpinCo Entities or, with respect to the SpinCo Business, to the Company or any of its Subsidiaries other than the SpinCo Entities, any license, right, permission, consent, non-assertion or release with respect to any Intellectual Property that is material to the SpinCo Business, other than (1)&#160;non-exclusive click-wrap, shrink-wrap or off-the-shelf Software licenses that are commercially available on standard and reasonable terms to the public generally with license, maintenance, support and other fees of less than $200,000 in any twelve (12)-month period, (2)&#160;non-disclosure agreements entered into in the ordinary course of business consistent with past practice and (3)&#160;non-exclusive licenses granted by any suppliers or service providers to any of the SpinCo Entities in the ordinary course of business consistent with past practice solely for the receipt of services from such supplier or service provider, and solely where such licenses are ancillary to the primary purpose of such Contract, or (B)&#160;any of the SpinCo Entities or, with respect to the SpinCo Business, the Company or any of its Subsidiaries other than the SpinCo Entities, grants any license, right, permission, consent, non-assertion or release with respect to any Intellectual Property that is material to the SpinCo Business, other than (1)&#160;non-exclusive licenses granted to customers of any of the SpinCo Entities in the ordinary course of business consistent with past practice, (2)&#160;non-exclusive licenses granted to any suppliers or service providers by any of the SpinCo Entities in the ordinary course of business consistent with past practice solely for the benefit of such SpinCo Entity and (3)&#160;non-disclosure agreements entered into in the ordinary course of business consistent with past practice;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(viii)</span></span>any Contract to which any of the SpinCo Entities or, with respect to the SpinCo Business, the Company or any of its Subsidiaries other than the SpinCo Entities, is a party with any Governmental Authority or any university, college, research institute, or other educational institution that provides for the provision of funding by or to any of the SpinCo Entities or the Company or any of its Subsidiaries, in each case, for any research or development activities involving the invention, creation, conception or development of any Intellectual Property that is material to the SpinCo Business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ix)</span></span>any lease, sublease, occupancy agreement or license for real property (each, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Real Property Lease</span>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(x)</span></span>any Contract that is a settlement, conciliation or similar agreement with any Governmental Authority or that otherwise involves any settled or threatened claim, action, suit or proceeding pursuant to which the SpinCo Business has (or will have after the Closing) any monetary or other material outstanding obligation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xi)</span></span>any Contract that contains &#8220;most favored nation&#8221; pricing provisions for the benefit of the relevant counterparty that will relate to or affect the SpinCo Business after the Closing;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xii)</span></span>any joint venture, strategic alliance, joint development, partnership or similar arrangement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xiii)</span></span>any Contract relating to the acquisition or disposal or divestiture of, or investment in, any joint venture, partnership or similar arrangement or any material assets or businesses;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xiv)</span></span>any prime contract, subcontract, purchase order, task order, delivery order, teaming agreement, joint venture agreement, strategic alliance agreement, basic ordering agreement, pricing agreement, letter contract or other similar arrangement of any kind where the counterparty or the ultimate customer is, or the work performed under such contract was funded by, a Governmental Authority (each a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Government Contract</span>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xv)</span></span>any Contract not otherwise described in any other subsection of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.15(a)</span>&#160;that would be required to be filed by SpinCo as a &#8220;material contract&#8221; (as such term is defined in Item 601(b)(10)&#160;of Regulation S-K of the SEC) if SpinCo were subject to the reporting requirements of the Exchange Act as of the date hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has made available to Parent copies of each SpinCo Material Contract that are correct and complete. Each SpinCo Material Contract is valid and binding on the Company or its applicable Subsidiary, including any applicable SpinCo Entity and, to the Knowledge of the Company or SpinCo, the counterparty thereto, and is in full force and effect and enforceable in accordance with its terms, subject to the Remedies Exception. Neither the Company nor its applicable Subsidiary, including any SpinCo Entity is, and to the Knowledge of the Company or SpinCo, no counterparty thereto is, in breach of, or default under, any SpinCo Material Contract in any material respect.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="A_Section_5_16"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.16</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Labor Relations</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Section&#160;5.16(a)&#160;of the SpinCo Disclosure Schedules sets forth a true and complete list of all SpinCo Employees, and includes each SpinCo Employee&#8217;s name, title, work location, status (e.g., full- or part-time or temporary), overtime classification (e.g., exempt or non-exempt), rate of base salary or hourly wage, target annual bonus opportunity or other cash incentive opportunity, the amount of accrued but unused paid time off, and whether the employee is on leave (and if so, the category of leave, the date on which such leave commenced and the date of expected return to work). As of the date hereof, all SpinCo Employees are employed by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Section&#160;5.16(b)&#160;of the SpinCo Disclosure Schedules sets forth a true and complete list of all SpinCo Independent Contractors. The Company has made available to Parent and Merger Sub true and complete copies of each services agreement with each SpinCo Independent Contractor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Neither the Company nor any of its Subsidiaries, including any SpinCo Entity, is a party to any agreement with any trade union, works council, employee representative body or labor organization (covered by the National Labor Relations Act) that represents (or that otherwise governs or relates to the employment of) any of the SpinCo Employees(each, a &#8220;SpinCo CBA&#8221;). To the Knowledge of the Company or SpinCo, (i) no petition for recognition of a labor organization or other body for the representation of the SpinCo Employees is pending or threatened, and (ii) there has not during the last five (5) years been any (or threat of any), there are no pending and no Person has threatened to commence any, strike, slowdown, work stoppage, lockout, job action, picketing, labor dispute, question concerning representation, union organizing activity, or any threat thereof, or any similar activity or dispute, affecting the Company or any of its Subsidiaries (with respect to the SpinCo Business) or any of the SpinCo Entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>There are no pending, or to the Knowledge of the Company or SpinCo, anticipated or threatened, unfair labor or other employment-related practice charges, complaints or other grievances or Actions by or before any Governmental Authority, arising under any applicable Law governing labor or employment (or pursuant to any SpinCo CBA), SpinCo Service Providers or other Persons (in respect of which any SpinCo Entity will have any material Liability at the Effective Time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>For the past three (3)&#160;years, the Company has been in compliance in all material respects with all Laws relating to terms and conditions of employment, employment practices, employment discrimination and harassment, civil rights, the Worker Adjustment and Retraining Notification Act (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">WARN</span>&#8221;) and any similar state or local plant closures and mass layoffs Laws, wages (including minimum wage and overtime), hours of work, meal and rest breaks, withholdings and deductions, classification and payment of employees, independent contractors and consultants, employment equity, collective bargaining, occupational health and safety, workers&#8217; compensation, immigration, child labor, employment equity, workforce reduction and all other labor or employment related matters with respect to any SpinCo Service Provider. During the prior three (3)&#160;years, there has been no &#8220;mass layoff&#8221; or &#8220;plant closing&#8221; (as defined by WARN) with respect to the Company or any of its Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>The execution, delivery and performance of this Agreement and the consummation of the Transactions do not require the Company or any of its Subsidiaries, including any SpinCo Entity, to seek or obtain any consent, engage in consultation with, or issue any notice to or make any filing with (as applicable) any unions, labor organizations, or groups of employees of the Company, or any Governmental Authority, with respect to any SpinCo Employee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>No judgment, consent decree, or arbitration award imposes continuing remedial obligations or otherwise limits or affects the Company&#8217;s or any of its Subsidiaries&#8217;, including any SpinCo Entity&#8217;s, ability to manage the SpinCo Service Providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>Except as would not reasonably be expected to result in material Liability to the SpinCo Business (taken as a whole), for the past three (3)&#160;years, neither the Company nor any of its Subsidiaries, including any SpinCo Entity, has incurred, and no circumstances exist under which the Company or any of its Subsidiaries would reasonably be expected to incur with respect to any SpinCo Service Provider, any liability arising from (i)&#160;the failure to pay wages (including overtime wages), (ii)&#160;the misclassification of employees as independent contractors or (iii)&#160;the misclassification of employees as exempt from the requirements of the Fair Labor Standards Act or similar state Laws.</p><a id="A_Section_5_17"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.17</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Law; Permits</span>.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except for Environmental Laws (which are addressed exclusively as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.20</span>), the Company and the Company&#8217;s Subsidiaries (in each case, solely with respect to the SpinCo Business) and the SpinCo Entities are, and, during the past two (2)&#160;years the SpinCo Entities and, solely with respect to their conduct and operation of the SpinCo Business, the Company and its other Subsidiaries (i)&#160;have been in compliance with all applicable Laws, except where noncompliance has not been and would not reasonably be expected to be material to the SpinCo Business, taken as a whole, and (ii)&#160;have not received notice from any Governmental Authority alleging any material non-compliance with or possible material violation of any applicable Law or that the Company or any of its Subsidiaries (with respect to the SpinCo Business) or the SpinCo Entities, is subject to any inspection, investigation, survey, audit or other review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Except with respect to Permits required under applicable Environmental Laws (which are addressed exclusively in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.20</span>), and except, in each case, as would not reasonably be expected to have, individually or in the aggregate, a SpinCo Material Adverse Effect, (i)&#160;the Company and its Subsidiaries (with respect to the SpinCo Business) and the SpinCo Entities hold all Permits necessary to conduct the SpinCo Business substantially as conducted as of the date hereof and in compliance with applicable Law and (ii)&#160;such Permits are valid and in full force and effect and the Company or its applicable Subsidiary or the applicable SpinCo Entity is in compliance with the terms thereof.</p><a id="A_Section_5_18"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.18</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Benefit Plans</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Section&#160;5.18(a)&#160;of the SpinCo Disclosure Schedule sets forth a list of each material Company Benefit Plan. As of the date hereof, there are no SpinCo Benefit Plans or Foreign Benefit Plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>As applicable with respect to each of the Company Benefit Plans and SpinCo Benefit Plans, the Company has made available to Parent true and complete copies of (i)&#160;the applicable plan document (including all amendments thereto), (ii)&#160;the most recent summary plan description including any summary of material modifications provided to participants, (iii)&#160;the last filed Form&#160;5500 series and all schedules thereto, and (iv)&#160;the most recent determination, opinion or advisory letter issued by the IRS and (v)&#160;any material, non-routine communications with any Governmental Authority in the past three years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Each SpinCo Benefit Plan and Company Benefit Plan intended to be qualified under Section&#160;401(a)&#160;of the Code has received a favorable determination letter from the IRS (or is entitled to rely upon a favorable opinion letter issued by the IRS), and no such determination or opinion letter has been revoked nor, to the Knowledge of the Company, has any fact or circumstance occurred that could reasonably be expected to cause the loss of such qualification or the imposition of material Liability to the SpinCo Business (taken as a whole).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Each of the Company Benefit Plans and SpinCo Benefit Plans has been operated, funded and administered in all material respects in accordance with its terms and in compliance with applicable Law, including ERISA and the Code. Except as would not reasonably be expected to result in material Liability to the SpinCo Business (taken as a whole), there are no pending or, to the Knowledge of the Company, threatened claims, actions, investigations or audits (other than routine claims for benefits) involving any Company Benefit Plan or SpinCo Benefit Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Within the last six (6)&#160;years, neither any Company Benefit Plan nor any SpinCo Benefit Plan has been, and none of the Company, SpinCo nor any of their ERISA Affiliates has maintained, established, sponsored, participated in, contributed to, or had liability in respect of, an employee benefit plan subject to Section&#160;302 or Title IV of ERISA or Section&#160;412, 430 or 4971 of the Code. None of the Company, SpinCo nor any of their ERISA Affiliates has, at any time during the preceding six (6)&#160;years, contributed to, been obligated to contribute to or had any liability (including any contingent liability) with respect to, any Multiemployer Plan or a plan that has two (2)&#160;or more contributing sponsors, at least two (2)&#160;of whom are not under common control, within the meaning of Section&#160;4063 of ERISA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>Except as would not reasonably be expected to result in material Liability to the SpinCo Business (taken as a whole), no Action with respect to the administration or the investment of the assets of any SpinCo Benefit Plan or Company Benefit Plan (other than routine claims for benefits) is pending, or to the Knowledge of the Company or SpinCo, threatened. Except as would not reasonably be expected to result in material Liability to the SpinCo Business (taken as a whole), with respect to each SpinCo Benefit Plan and Company Benefit Plan, (i)&#160;all required contributions have been made or properly accrued, (ii)&#160;there have been no &#8220;prohibited transactions&#8221; (as that term is defined in Section&#160;406 of ERISA or Section&#160;4975 of the Code) and (iii)&#160;all reports, returns, and similar documents required to be filed with any Governmental Authority or distributed to any SpinCo Benefit Plan or Company Benefit Plan participant have been timely filed or distributed. The Company and SpinCo have complied in all material </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">respects with their respective obligations under any plan, program or arrangement that is sponsored, maintained or administered by any Governmental Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>Except as set forth in this Agreement or the Employee Matters Agreement, the consummation of the Transactions shall not, either alone or in combination with another event: (i)&#160;entitle any current or former SpinCo Service Provider, to severance pay, unemployment compensation or any other benefits or payments; or (ii)&#160;accelerate the time of payment, funding or vesting, or increase the amount of any payments or benefits due to any SpinCo Service Provider.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>Except as set forth in Section&#160;5.18(h)&#160;of the SpinCo Disclosure Schedule, no Company Benefit Plan or SpinCo Benefit Plan provides for, and SpinCo does not have any current or contingent Liability in respect of, post-retirement or other postemployment health or welfare benefits, other than health care continuation coverage as required by Section&#160;4980B of the Code or any similar state Law (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COBRA</span>&#8221;) or ERISA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby or by the Transaction Documents shall, either alone or in combination with any other event(s), result in the payment of any amount to any SpinCo Service Provider or any other current or former employee, director, officer or independent contractor of any SpinCo Entity that could, individually or in combination with any other such payment, constitute an &#8220;excess parachute payment&#8221; as defined in Section&#160;280G(b)(1)&#160;of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span>Each Company Benefit Plan that is (and each SpinCo Benefit Plan that will be) a &#8220;nonqualified deferred compensation plan&#8221; (as such term is defined in Section&#160;409A(d)(1)&#160;of the Code and the guidance thereunder) is (or will be, as applicable) in material compliance in both form and operation with Section&#160;409A of the Code, and no Taxes are owed (or will be owed, as applicable) under Section&#160;409A(a)(1)&#160;for any such plan or arrangement. No SpinCo Entity is under the obligation to gross up any Taxes, including under Section&#160;409A of the Code or Sections 280G or 4999 of the Code.</p><a id="A_Section_5_19"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.19</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Section&#160;5.19(a)&#160;of the SpinCo Disclosure Schedule sets forth a list of, as of the date hereof, all SpinCo Owned Intellectual Property that is the subject of any registration, issuance, or application for registration or issuance, with any Governmental Authority or Internet domain name registrar (specifying for each such item (i)&#160;the record owner (and, if different from the record owner, the beneficial owner), (ii)&#160;the jurisdiction in which such item has been issued, registered or filed, (iii)&#160;the issuance, registration or application date and (iv)&#160;the issuance, registration or application number) (any Intellectual Property set forth or required to be set forth on Section&#160;5.19(a)&#160;of the SpinCo Disclosure Schedule, collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Registered Intellectual Property</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>All SpinCo Registered Intellectual Property that is material to the SpinCo Business is subsisting, and, to the Knowledge of the Company or SpinCo, valid and enforceable. Except as scheduled in Section&#160;5.19(b)&#160;of the SpinCo Disclosure Schedule, to the Knowledge of the Company or SpinCo, none of the SpinCo Registered Intellectual Property has been or is subject to any interference, derivation, reexamination, (including ex parte reexamination, inter partes reexamination, inter partes review, post grant review or Covered Business Method (CBM) review), cancellation or opposition proceeding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>As of the date hereof, to the Knowledge of the Company or SpinCo, the Company and each of its Subsidiaries, and, as of the Distribution, each of the SpinCo Entities, have prepared and are preparing to file patent applications for all potentially patentable inventions included in the SpinCo Owned Intellectual Property that are material to the SpinCo Business as currently conducted and as currently proposed to be conducted, except, where in the exercise of reasonable business judgment, the Company, such Subsidiary or such SpinCo Entity has decided not to file or has decided to defer filing a patent application on a potentially patentable invention. The Company, each of its Subsidiaries, and each of the SpinCo Entities has complied and does comply in all material respects with all Laws regarding the duty of disclosure, candor and good faith in connection with each Patent included in the SpinCo Registered Intellectual Property. To the Knowledge of the Company or SpinCo, no public disclosure bar by the Company, any of its Subsidiaries, or any of the SpinCo Entities has occurred, nor has any on-sale bar by the Company, any of its Subsidiaries, or any of the SpinCo Entities arisen, which has rendered any Patent included in the SpinCo Registered Intellectual Property that is material to the SpinCo Business, invalid, unenforceable or unpatentable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>As of the date hereof, (i)&#160;the Company and its Subsidiaries solely and exclusively own, and as of the Distribution, a SpinCo Entity solely and exclusively owns, all rights, title and interest in and to the SpinCo Owned Intellectual Property, in each </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">case, free and clear of all Liens (other than Permitted Liens) and (ii)&#160;to the Knowledge of the Company or SpinCo the Company or one of its Subsidiaries has, and, as of the Distribution, a SpinCo Entity has, valid and enforceable rights to use and exploit, pursuant to a written SpinCo Contract, all other Intellectual Property (except for such other Intellectual Property in the public domain for which no license is necessary) used or practiced by the SpinCo Business that is material to the SpinCo Business. The SpinCo Owned Intellectual Property and such SpinCo Licensed Intellectual Property collectively constitute all Intellectual Property used in, and necessary and sufficient for, the conduct and operation of the SpinCo Business, as currently conducted; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that the foregoing representation shall not in any way be construed as a representation of non-infringement or other violation of the Intellectual Property rights of any Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>To the Knowledge of the Company or SpinCo, in the past six (6)&#160;years with respect to Patents or in the past three (3)&#160;years with respect to all other Intellectual Property, none of the SpinCo Entities or, with respect to the SpinCo Business, the Company or any of its Subsidiaries other than the SpinCo Entities, the conduct of the SpinCo Business, or any SpinCo Owned Intellectual Property has infringed, misappropriated (or constituted or resulted from a misappropriation of), diluted or otherwise violated, or is infringing, misappropriating (or constitutes or results from the misappropriation of), diluting or otherwise violating any Intellectual Property of any Person. To the Knowledge of the Company or SpinCo, none of the SpinCo Entities or, with respect to the SpinCo Business, the Company or any of its Subsidiaries other than the SpinCo Entities, has received from any Person in the past three (3)&#160;years any written notice, charge, complaint, claim or other assertion: (i)&#160;of any infringement, misappropriation, dilution or other violation of any Intellectual Property of any Person or (ii)&#160;challenging the ownership, use, validity or enforceability of any SpinCo Owned Intellectual Property that is material to the SpinCo Business as currently conducted and as currently proposed to be conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>To the Knowledge of the Company or SpinCo, no other Person has infringed, misappropriated, diluted or violated, or is infringing, misappropriating, diluting or violating, any SpinCo Owned Intellectual Property or any SpinCo Licensed Intellectual Property exclusively licensed to the Company, any of its Subsidiaries, or any of the SpinCo Entities, in each case, that is material to the SpinCo Business. No such claims have been made in writing or, to the Knowledge of the Company or SpinCo, otherwise made against any Person by any of the SpinCo Entities or, with respect to the SpinCo Business, the Company or any of its Subsidiaries other than the SpinCo Entities in the past three (3)&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>To the Knowledge of the Company or SpinCo, each of the SpinCo Entities and, with respect to the SpinCo Business, the Company and each of its Subsidiaries other than the SpinCo Entities, have taken and currently takes adequate and commercially reasonable steps to maintain the secrecy and confidentiality of all Trade Secrets included in the SpinCo Owned Intellectual Property and all Trade Secrets of any Person to whom any of the SpinCo Entities or, with respect to the SpinCo Business, the Company or any of its Subsidiaries other than the SpinCo Entities, has a confidentiality obligation with respect to such Trade Secrets. No Trade Secret material to the SpinCo Business has been authorized by the Company, any of its Subsidiaries, or any of the SpinCo Entities to be disclosed (or, to the Knowledge of the Company or SpinCo, has been disclosed) to any Person other than (i)&#160;pursuant to a written agreement adequately restricting the disclosure and use of such Trade Secret or (ii)&#160;to a Person who otherwise has a duty to protect such Trade Secret.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>Each of the past and present employees, consultants and independent contractors of the Company, any of its Subsidiaries, or any of the SpinCo Entities who has been or is engaged in inventing, creating, conceiving or developing any Intellectual Property that is material to the SpinCo Business as currently conducted and as currently proposed to be conducted for any of the SpinCo Entities or, with respect to the SpinCo Business, the Company or any of its Subsidiaries other than the SpinCo Entities has executed and delivered to the Company or such Subsidiary or SpinCo Entity, as applicable, a written agreement, pursuant to which such Person has (x)&#160;agreed to hold all confidential information of the SpinCo Business in confidence both during and after such Person&#8217;s employment or retention, as applicable, and (y)&#160;presently assigned to the Company, such Subsidiary, or such SpinCo Entity, as applicable, all of such Person&#8217;s rights, title and interest in and to all Intellectual Property invented, created, conceived or developed in the course of such Person&#8217;s employment or engagement thereby (each, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Personnel IP Contract</span>&#8221;). To the Knowledge of the Company or SpinCo, there is no uncured breach by any such Person with respect to any Intellectual Property that is material to the SpinCo Business as currently conducted and as currently proposed to be conducted under any such Personnel IP Contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>No funding, facilities or personnel of any Governmental Authority or any university, college, research institute or other educational institution has been or is being used to invent, create, conceive or develop, in whole or in part, (i)&#160;any SpinCo Owned Intellectual Property or (ii)&#160;to the Knowledge of the Company or SpinCo any SpinCo Licensed Intellectual Property exclusively licensed to the Company, any of its Subsidiaries, or any of the SpinCo Entities, in each case of clauses (i)&#160;and (ii), that is material </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">to the SpinCo Business as currently conducted and as currently proposed to be conducted, except for any such funding or use of facilities or personnel that (A)&#160;does not result in such Governmental Authority, university, college, research institute or other educational institution obtaining or retaining, or having the right to obtain or retain ownership of, or use rights to (except for use rights during the term of the applicable SpinCo Contract with such Governmental Authority, university, college, research institute or other educational institution), any SpinCo Owned Intellectual Property, or (B)&#160;does not require or otherwise obligate the Company, any of its Subsidiaries, or any of the SpinCo Entities to grant or offer to any Governmental Authority, university, college, research institute or other educational institution any license or other right to, or covenant not to assert with respect to, any SpinCo Owned Intellectual Property (except for use rights during the term of the applicable SpinCo Contract with such Governmental Authority, university, college, research institute or other educational institution).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span>As of the date hereof, none of the Company or any of its Subsidiaries owns or purports to own any Software included in the SpinCo Owned Intellectual Property that is material to the SpinCo Business, and, as of the Distribution, none of the SpinCo Entities owns or purports to own any Software included in the SpinCo Owned Intellectual Property that is material to the SpinCo Business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span>To the Knowledge of the Company or SpinCo, (i)&#160;as of the date hereof, the Company or one of its Subsidiaries, and (ii)&#160;as of the Distribution, a SpinCo Entity, owns or has a valid right to access and use pursuant to a written SpinCo Contract, all SpinCo IT Systems in the manner in which they are currently accessed or used in the conduct of the SpinCo Business. To the Knowledge of the Company or SpinCo, except for the IT Assets utilized by Company to provide services to SpinCo pursuant to the applicable Transition Services Agreement, the SpinCo IT Systems are adequate in all material respects for the operation and conduct of the SpinCo Business as currently conducted. To the Knowledge of the Company or SpinCo, the SpinCo IT Systems have not materially malfunctioned or failed for the past three (3)&#160;years. To the Knowledge of the Company or SpinCo, during the past three (3)&#160;years, there has been no unauthorized access to or use of, or breach or other violation of, any SpinCo IT Systems, in each case, that has had, individually or in the aggregate, a material adverse effect on the SpinCo Business or the SpinCo IT Systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</span></span>Neither the execution of this Agreement or any of the other Transaction Documents nor the consummation of the Transaction Process will result in (i)&#160;the loss or impairment of, or any Lien on, any material SpinCo Owned Intellectual Property or material SpinCo Licensed Intellectual Property; (ii)&#160;the release, disclosure or delivery of any source code included in the SpinCo Owned Intellectual Property to any Person; or (iii)&#160;the payment of any additional consideration to, or the reduction of any amount(s)&#160;payable from, any Person, in each case, with respect to any SpinCo Owned Intellectual Property or SpinCo Licensed Intellectual Property, and where the applicable consideration or amount(s)&#160;exceeds $200,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_5_20"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.20</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Environmental Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except as would not otherwise reasonably be expected to have, individually or in the aggregate, a SpinCo Material Adverse Effect:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>With respect to their operation of the SpinCo Business, the Company and its Subsidiaries are, and during the past three (3)&#160;years the Company and its Subsidiaries have been, in compliance with applicable Environmental Laws, which compliance includes obtaining, maintaining, and complying with all Permits required under Environmental Laws for the operation of the SpinCo Business, all of which Permits are in full force and effect;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>With respect to their operation of the SpinCo Business, the Company and its Subsidiaries have not received notice from any Governmental Authority or Person alleging any non-compliance with or Liability under any applicable Environmental Law by the Company or any of its Subsidiaries;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>No Actions pursuant to any Environmental Law to the extent affecting the SpinCo Business or any SpinCo Assets are pending or threatened in writing or, to the Knowledge of the Company or SpinCo, threatened orally against the Company or any of its Subsidiaries; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>Neither the Company nor any of its Subsidiaries nor, to the Knowledge of the Company or SpinCo, any other Person has Released Hazardous Materials at, on, upon, into or from any SpinCo Real Property at concentrations or under conditions that would result in the Company or any Subsidiary incurring Liability under Environmental Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="A_Section_5_21"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.21</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliate Matters</span>. Except for Contracts solely between or among the SpinCo Entities or Contracts for employment, compensation or benefit agreements or arrangements with directors, officers and employees made in the ordinary course of business or as set forth in Section&#160;5.21 of the SpinCo Disclosure Schedule, no SpinCo Entity is party to any SpinCo Affiliate Contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_5_22"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.22</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brokers&#8217; Fees</span>. No broker, finder, investment banker or other Person is entitled to any brokerage fee, finders&#8217; fee or other similar commission, for which Parent, Merger Sub or any of the SpinCo Entities would be liable in connection with the transactions contemplated by this Agreement or any other Transaction Document based upon arrangements made by or on behalf of any SpinCo Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_5_23"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.23</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proxy Statement; Registration Statements</span>. None of the information regarding any of the Company or any of its Subsidiaries (including the SpinCo Entities), the SpinCo Business, or the Transactions to be provided by the Company or SpinCo or any of their respective Subsidiaries specifically for inclusion in, or incorporation by reference into, the Proxy Statement, the Parent Registration Statement, the SpinCo Registration Statement or the documents relating to the Distribution that are filed with the SEC and/or distributed to Company stockholders or Parent shareholders (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Distribution Documents</span>&#8221;) will, in the case of the Proxy Statement and the Distribution Documents or any amendment or supplement thereto, at the time of the first mailing of the Proxy Statement and the Distribution Documents and of any amendment or supplement thereto, or, in the case of the Parent Registration Statement or the SpinCo Registration Statement, at the time such registration statement becomes effective, on the date of the Parent Shareholders Meeting, at the Distribution Time or at the Effective Time, contain an untrue or false statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they are made, not false or misleading. The SpinCo Registration Statement will comply as to form in all material respects with the provisions of the Securities Act, except that no representation is made by the Company or SpinCo with respect to information provided by Parent specifically for inclusion in, or incorporation by reference into, the SpinCo Registration Statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_5_24"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.24</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board and Shareholder Approval</span>. Each of the Company Board and the SpinCo Board, at a meeting duly called and held or by written consent, has by unanimous vote of all directors present or unanimous consent, (a)&#160;approved this Agreement, the Separation and Distribution Agreement and the other Transaction Documents and authorized and approved the execution, delivery and performance hereof and thereof and the consummation of the Transactions, including the Merger and the Separation, and (b)&#160;declared each of them advisable, fair to and in the best interests of the Company, SpinCo and their respective stockholders. As of the date hereof, the sole shareholder of SpinCo is (and as of immediately prior to the Distribution the sole shareholder of SpinCo will be) the Company. Immediately after the execution of this Agreement, the Company will approve and adopt, as SpinCo&#8217;s sole shareholder, this Agreement and the Transaction Documents and the Transactions, including the Merger (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Shareholder Approval</span>&#8221;). The SpinCo Shareholder approval is the only approval of the shareholders of the Company or any of its Subsidiaries required to approve the Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_5_25"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.25</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Capital Stock</span>. Neither the Company nor any of its Subsidiaries, including SpinCo owns (directly or indirectly, beneficially or of record) or will own on the Closing Date nor is a party to any Contract for the purpose of acquiring, holding, voting or disposing of, in each case, any shares of capital stock of Parent (other than as contemplated by this Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_5_26"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.26</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Healthcare Regulatory Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>SpinCo and its Subsidiaries are, and for the past three (3)&#160;years have been, in compliance with all applicable Healthcare Laws, except where such failure to so comply would not reasonably be expected, individually or in the aggregate, to have a material impact on the SpinCo Business. Neither SpinCo nor any of its Subsidiaries has received any written notice or other written communication from any Regulatory Authority alleging any material violation of any applicable Healthcare Law that remains unresolved. There are no investigations, suits, claims, actions or proceedings pending or, to the Knowledge of the Company, threatened against SpinCo or any of its Subsidiaries with respect to any of the SpinCo Products or alleging any material violation by SpinCo or the SpinCo Products of any such applicable Healthcare Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Neither SpinCo nor any of its Subsidiaries holds any Regulatory Authorization, or has any such application for a Regulatory Authorization pending with the FDA or any other applicable Regulatory Authority or, to the Knowledge of the Company, has at any time in the past three (3)&#160;years has been required to hold a Regulatory Authorization in connection with the SpinCo Products or operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Neither SpinCo nor any of its Subsidiaries is conducting or sponsoring, and during the past three (3)&#160;years, has not conducted or sponsored, any pre-clinical studies or clinical trials that are or were required under any applicable Healthcare Laws to be conducted in compliance with Good Laboratory Practices or Good Clinical Practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>None of the SpinCo Entities or, to the Knowledge of the Company, any person acting on behalf of any SpinCo Entity has during the past three (3)&#160;years, with respect to any SpinCo Product: (i)&#160;been subject to a shutdown or import or export prohibition imposed by any Regulatory Authority; or (ii)&#160;received any FDA Form&#160;483, or other written notice of inspectional observations, &#8220;warning letters,&#8221; &#8220;untitled letters&#8221; or any similar written correspondence from any Regulatory Authority in respect of such SpinCo Entity or its business operations, alleging or asserting material noncompliance with any applicable Healthcare Law or Regulatory Authorization, and, to the Knowledge of the Company, no Regulatory Authority has threatened such action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>None of the SpinCo Entities has (i)&#160;made an untrue statement of a material fact or fraudulent statement to any Regulatory Authority, (ii)&#160;failed to disclose a material fact required to be disclosed to any Regulatory Authority or (iii)&#160;committed an act, made a disclosure, or failed to commit an act or make a disclosure, including with respect to any scientific data or information, that, at the time of such action, failure to act, disclosure or failure to disclose (as applicable), would reasonably be expected to provide a basis for the FDA to invoke its policy respecting &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221;, set forth in 56 Fed. Reg. 46191 (September&#160;10, 1991), and any amendments thereto, or for the FDA or any other Regulatory Authority to invoke any similar policy. None of SpinCo or, to the Knowledge of SpinCo, any of its officers, employees or agents has been convicted of any crime or engaged in any conduct that has resulted in, or would reasonably be expected to result in, debarment from participation in any program related to pharmaceutical products pursuant to 21 U.S.C. Section&#160;335a (a)&#160;or (b)&#160;or exclusion from participation in any federal health care program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_5_27"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.27</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Data Privacy</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>(i)&#160;SpinCo and its Subsidiaries (and, with respect to the SpinCo Business, the Company and each of its Subsidiaries other than the SpinCo Entities) are, and have for the past three (3)&#160;years been, in material compliance with all Privacy Requirements. During the past three&#160;(3)&#160;years, neither SpinCo nor any of its Subsidiaries (and, with respect to the SpinCo Business, neither the Company nor any of its Subsidiaries other than the SpinCo Entities) has received any written notice of any claims, charges, investigations, or regulatory inquiries related to or alleging the violation of any Privacy Requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Each of the SpinCo Entities (and, with respect to the SpinCo Business, the Company and each of its Subsidiaries other than the SpinCo Entities), has (i)&#160;implemented, and for the past three (3)&#160;years has maintained, commercially reasonable technical and organizational safeguards to protect Personal Information and other confidential data in its possession or under its control, and (ii)&#160;taken commercially reasonable steps to ensure that any third party with access to any Personal Information collected by or on behalf of any of the SpinCo Entities (or, with respect to the SpinCo Business, the Company or any of its Subsidiaries other than the SpinCo Entities) has implemented and maintained commercially reasonable safeguards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>During the past three (3)&#160;years: (i)&#160;there have been no material breaches, security incidents, misuse of or unauthorized access to or disclosure of any Personal Information (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Security Incident</span>&#8221;) maintained by SpinCo or any of its Subsidiaries (or, with respect to the SpinCo Business, the Company or any of its Subsidiaries other than the SpinCo Entities); nor (ii)&#160;to the Knowledge of the Company or SpinCo, has any Person processing Personal Information on behalf of the SpinCo Entities (and, with respect to the SpinCo Business, the Company or any of its Subsidiaries other than the SpinCo Entities) experienced any Security Incidents with respect to such Personal Information. SpinCo and its Subsidiaries (and, with respect to the SpinCo Business, the Company and its Subsidiaries other than the SpinCo Entities) have implemented reasonable disaster recovery and business continuity plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>To the Knowledge of the Company or SpinCo, the transfer of Personal Information in connection with the Transactions will not violate in any material respect any Privacy Requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="A_Section_5_28"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.28</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Anti-Bribery, Anti-Corruption and Anti-Money Laundering</span>. None of the Company or the Company&#8217;s Subsidiaries (in each case, with respect to the SpinCo Business), the SpinCo Entities, or any of their respective directors, officers, employees, agents, or any other Person acting for or on behalf of the SpinCo Business or SpinCo Entities has, directly or indirectly, for the previous five (5)&#160;years, (a)&#160;made, offered, or promised to make or offer any payment, loan, or transfer of anything of value, including any reward, advantage, or benefit of any kind, to or for the benefit of any Government Official, candidate for public office, political party, or political campaign, for the purpose of (i)&#160;influencing any act or decision of such Government Official, candidate, party or </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">campaign, (ii)&#160;inducing such Government Official, candidate, party or campaign to do or omit to do any act in violation of a lawful duty, (iii)&#160;obtaining or retaining business for or with any Person, (iv)&#160;expediting or securing the performance of official acts of a routine nature, or (v)&#160;otherwise securing any improper advantage; (b)&#160;paid, offered, or promised to pay or offer any bribe, payoff, influence payment, kickback, unlawful rebate, or other similar unlawful payment of any nature; (c)&#160;made, offered or promised to make or offer any unlawful contributions, gifts, entertainment, or other unlawful expenditures; (d)&#160;established or maintained any unlawful fund of corporate monies or other properties; (e)&#160;created or caused the creation of any false or inaccurate books and records of the Company or the Company&#8217;s Subsidiaries (in each case, with respect to the SpinCo Business) or the SpinCo Entities; or (f)&#160;otherwise violated any provision of the Foreign Corrupt Practices Act of 1977, 15 U.S.C. &#167;&#167; 78dd-1, et seq., the Money Laundering Control Act, the Currency and Foreign Transactions Reporting Act, The Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, or any other Laws relating to corruption, bribery, or money laundering, in each case of clauses&#160;(a)-(e), in a manner that would result in a violation of any of the Laws described in clause (f). Within the past five (5)&#160;years, none of the Company, the Company&#8217;s Subsidiaries, or the SpinCo Entities has made any voluntary disclosure to any Governmental Authority relating to corruption, bribery, or money laundering Laws; been the subject of any investigation or inquiry regarding compliance with such Laws; or been assessed any fine or penalty under such Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_5_29"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.29</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sanctions,&#160;Import, and Export Controls</span>. None of the Company or the Company&#8217;s Subsidiaries (in each case, with respect to the SpinCo Business), the SpinCo Entities, or any of their respective directors, officers, employees, agents, or any other Person acting for or on behalf of the SpinCo Business or SpinCo Entities (a)&#160;is a Person with whom transactions are prohibited or limited under any economic sanctions Laws, including those administered by the U.S. government (including, without limitation, the Department of the Treasury&#8217;s Office of Foreign Assets Control, the Department of State, or the Department of Commerce), the United Nations Security Council, the European Union, or Her Majesty&#8217;s Treasury, or (b)&#160;has violated any Laws relating to economic sanctions within the last five (5)&#160;years. The Company and the Company&#8217;s Subsidiaries (in each case, with respect to the SpinCo Business) and the SpinCo Entities are and for the past five (5)&#160;years have been in possession of and in compliance with any and all licenses, registrations, and permits that may be required for their lawful conduct under economic sanctions, import, and export control Laws, including without limitation the Export Administration Regulations, 15 C.F.R. &#167; 730 et seq. Within the past five (5)&#160;years, none of the Company, the Company&#8217;s Subsidiaries, or the SpinCo Entities has made any voluntary disclosure to any Governmental Authority relating to sanctions, import, or export control Laws; been the subject of any investigation or inquiry regarding compliance with such Laws; or been assessed any fine or penalty under such Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_5_30"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.30</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Other Representations and Warranties</span>. Except as expressly set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VI</span> or in any Transaction Document, (a)&#160;the Company and SpinCo each acknowledges and agrees that neither Parent, Merger Sub nor any of their Affiliates, nor any of their respective Representatives has made, or is making, any express or implied representation or warranty whatsoever with respect to Parent, Merger Sub or any of its Affiliates, or any of their respective businesses, operations, assets, liabilities, conditions (financial or otherwise) or prospects, and (b)&#160;the Company and SpinCo each further acknowledges and agrees that neither Parent nor any of its Affiliates shall be liable in respect of the accuracy or completeness of any information provided to the Company, SpinCo or any of its respective Affiliates or Representatives. Without limiting the generality of the foregoing, except as expressly set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VI</span> or in any Transaction Document, each of the Company and SpinCo acknowledges and agrees that no representations or warranties are made with respect to any projections, forecasts, estimates or budgets with respect to Parent or any of its Subsidiaries that may have been made available to the Company, SpinCo or any of their Representatives, and expressly disclaim reliance on any other representations, warranties, statements, information or inducements, oral or written, express or implied, or as to the accuracy or completeness of any statements or other information, made to, or made available to, itself or any of its Representatives, in each case with respect to, or in connection with, the negotiation, execution or delivery of this Agreement, any instrument or other document delivered pursuant to this Agreement or the transactions contemplated by this Agreement, and notwithstanding the distribution, disclosure or other delivery to the Company, SpinCo or any of their Representatives of any document or other information with respect to any one or more of the foregoing, and waive any claims or causes of actions relating thereto, other than those for Actual Fraud. Without limiting the generality of the foregoing, it is understood that any cost estimates, financial or other projections or other predictions that may be contained or referred to in this Agreement (including the Parent Disclosure Schedule), any information, documents or other materials (including any such materials reviewed by the Company, SpinCo or any of their respective Affiliates or Representatives) or management presentations that have been or shall hereafter be provided to the Company, SpinCo or any of their respective Affiliates or Representatives are not and will not be deemed to be representations or warranties of Parent or Merger Sub, and no representation or warranty is made as to the accuracy or completeness of any of the foregoing except as expressly set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VI</span> (including the Disclosure Schedule) of this Agreement or in any Transaction Document. In entering into this Agreement, the Company and SpinCo acknowledge and agree that they have relied solely upon their own investigation and analysis; and the Company and SpinCo acknowledge and agree, to the fullest extent permitted by Law, that Parent, Merger Sub and their Affiliates and their respective Representatives shall not have any Liability or responsibility whatsoever to the Company or SpinCo or any of their </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">respective Representatives on any basis (including in contract or tort, under federal or state securities Laws or otherwise) based upon any information provided or made available, or statements made (or any omissions therefrom), to the Company or SpinCo or their Affiliates or any of their respective Representatives, including in respect of the specific representations and warranties set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VI</span> of this Agreement or any Transaction Document, except as and only to the extent expressly set forth herein or therein with respect to such representations and warranties and subject to the limitations and restrictions contained herein or therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_ARTICLE_VI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="color:#010000;">ARTICLE&#160;VI</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Except as otherwise disclosed or identified in (a) the Parent SEC Documents filed and publicly available on the SEC&#8217;s EDGAR database at least two (2) Business Days prior to the date hereof (excluding any disclosures of factors or risks contained or references therein under the captions &#8220;Risk Factors&#8221; or &#8220;Forward-Looking Statements&#8221; to the extent they are forward-looking statements and any other similar general, predictive or cautionary statements) or (b) the corresponding section or subsection of the Parent Disclosure Schedule (it being understood that each such disclosure shall also apply to each other representation and warranty contained in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VI</span> to the extent that it is reasonably apparent on the face of such disclosure that it is relevant to or applies to such representation or warranty), Parent and Merger Sub hereby represent and warrant to the Company and SpinCo as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization of Parent and Merger Sub</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Parent has been duly incorporated and is validly existing and in good standing as a Cayman Islands exempted company and has all requisite corporate power and authority to own, lease and operate its assets in the manner in which such assets are now owned, leased and operated and to conduct its business as it is now being conducted. Parent has made available to the Company true and complete copies of the Governing Documents of Parent. Parent is duly licensed or qualified and in good standing (or equivalent status as applicable) in each jurisdiction in which the assets owned or leased by it or the character of its activities require it to be so licensed or qualified or in good standing (or equivalent status as applicable), except as would not, individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Merger Sub is a corporation duly incorporated, validly existing and in good standing under the Laws of Delaware. Merger Sub is a wholly owned Subsidiary of Parent. The copies of the Governing Documents of Merger Sub which were previously furnished or made available to the Company are true and complete copies of such documents as in effect on the date of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Due Authorization</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Each of Parent and Merger Sub has all requisite corporate power and authority to execute and deliver this Agreement and the Transaction Documents to which it is or will be a party at the Effective Time and (subject to the receipt of the Consents described in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.4</span>, the Parent Shareholder Approval and the Merger Sub Shareholder Approval) to consummate the Transactions. The execution and delivery by each of Parent and Merger Sub of this Agreement and the Transaction Documents to which it is or will be a party at the Effective Time and the consummation by each of Parent and Merger Sub of the Transactions have been duly and validly authorized and approved by all necessary and proper corporate action on its part, and, except for the Parent Shareholder Approval and the Merger Sub Shareholder Approval, no other corporate action on the part of Parent or Merger Sub is necessary to authorize this Agreement or the Transaction Documents to which it is or will be a party at the Effective Time. Each of this Agreement and the Transaction Documents to which it is or will be a party at the Effective Time has been, or when executed and delivered will be, duly and validly executed and delivered by Parent and (assuming that this Agreement or such other applicable Transaction Documents to which each of the Company or SpinCo is or will be a party at the Effective Time constitutes a legal, valid and binding obligation of each of the Company and SpinCo (as applicable)) constitutes or will constitute a legal, valid and binding obligation of Parent and Merger Sub (as applicable), enforceable against Parent and Merger Sub (as applicable) in accordance with its terms, subject to the Remedies Exception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Assuming that a quorum (as determined pursuant to Parent&#8217;s Governing Documents) is present:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>each of those Transaction Proposals identified in clauses <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(A)</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(B)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(C)</span> of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(e)(ii)</span> shall require approval by a special resolution under the CICA (being the affirmative vote of the holders of at least two-thirds of the ordinary shares who, being present and entitled to vote at the Parent Shareholders Meeting, vote at the Parent Shareholders Meeting);</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="color:#010000;"> </span>each of those Transaction Proposals identified in clauses <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(D)</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(E)</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(F)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(I)</span>, of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(e)(ii)</span>, in each case, shall require approval by an ordinary resolution (being the affirmative vote of the holders of a majority of the ordinary shares who, being present and entitled to vote at the Parent Shareholders Meeting, vote at the Parent Shareholders Meeting); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>each of those Transaction Proposals identified in clauses <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(G)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(H)</span>, of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(e)(ii)</span>, in each case, shall require approval by the number of holders of Parent Common Stock required to approve such Transaction Proposals under applicable Law and the Governing Documents of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>The foregoing votes are the only votes of any of Parent&#8217;s share capital necessary in connection with entry into this Agreement by Parent and Merger Sub and the consummation of the Transactions, including the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>At a meeting duly called and held, the Parent Board has unanimously approved the Transactions as a Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.3</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capital Stock and Other Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>As of the date of this Agreement, the authorized share capital of Parent is 555,000,000 shares, divided into (i) 500,000,000 shares of Parent Class A Common Stock, 23,000,000 of which are issued and outstanding as of the date of this Agreement, (ii) 50,000,000 shares of Parent Class B Common Stock, of which 5,750,000 shares are issued and outstanding as of the date of this Agreement, and (iii) 5,000,000 preferred shares of par value $0.0001 each, of which no shares are issued and outstanding as of the date of this Agreement ((i), (ii) and (iii) collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Securities</span>&#8221;). The foregoing represents all of the issued and outstanding Parent Securities as of the date of this Agreement. All issued and outstanding Parent Securities (i) have been duly authorized and validly issued and are fully paid and non-assessable; (ii) have been offered, sold and issued in compliance with applicable Law, including federal and state securities Laws, and all requirements set forth in (1) Parent&#8217;s Governing Documents, and (2) any other applicable Contracts governing the issuance of such securities; and (iii) are not subject to, nor have they been issued in violation of, any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right under any provision of any applicable Law, Parent&#8217;s Governing Documents or any Contract to which Parent is a party or otherwise bound.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Subject to the terms of conditions of the Warrant Agreement, the Domesticated Parent Warrants will be exercisable after giving effect to the Merger for one share of Domesticated Parent Common Stock at an exercise price of eleven Dollars fifty cents ($11.50) per share. As of the date of this Agreement, 7,666,667 Parent Common Warrants and 8,233,333 Parent Private Placement Warrants are issued and outstanding. The Parent Warrants are not exercisable until the later of (x) August 12, 2022 and (y) thirty (30) days after the Closing. All outstanding Parent Warrants (i) have been duly authorized and validly issued and constitute valid and binding obligations of Parent, enforceable against Parent in accordance with their terms, subject to the Remedies Exemption; (ii) have been offered, sold and issued in compliance with applicable Law, including federal and state securities Laws, and all requirements set forth in (1) Parent&#8217;s Governing Documents and (2) any other applicable Contracts governing the issuance of such securities; and (iii) are not subject to, nor have they been issued in violation of, any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right under any provision of any applicable Law, Parent&#8217;s Governing Documents or any Contract to which Parent is a party or otherwise bound. Except for the A&amp;R Forward Purchase Agreement, Parent&#8217;s Governing Documents and this Agreement, there are no outstanding Contracts of Parent to repurchase, redeem or otherwise acquire any Parent Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Except as set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.3</span> or as contemplated by this Agreement or the other documents contemplated hereby, and other than in connection with the PIPE Investment and the Redemption Backstop, Parent has not granted any outstanding options, stock appreciation rights, warrants, rights or other securities convertible into or exchangeable or exercisable for Parent Securities, or any other commitments or agreements providing for the issuance of additional shares, the sale of treasury shares, for the repurchase or redemption of any Parent Securities or the value of which is determined by reference to the Parent Securities, and there are no Contracts of any kind which may obligate Parent to issue, purchase, redeem or otherwise acquire any of its Parent Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Subject to obtaining the Parent Shareholder Approval, the shares of Domesticated Parent Stock comprising the Merger Consideration, when issued in accordance with the terms hereof, shall be duly authorized and validly issued, fully paid and non-assessable and issued in compliance with all applicable state and federal securities Laws and not subject to, and not issued in </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">violation of, any Lien, purchase, option, call option, right of first refusal, preemptive right, subscription right or any similar right under any provision of applicable Law, Parent&#8217;s Governing Documents, or any Contract to which Parent is a party or otherwise bound.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>On or prior to the date of this Agreement, Parent has entered into the A&amp;R Forward Purchase Agreement with the Sponsor, pursuant to which, and on the terms and subject to the conditions of which, Sponsor has agreed, subject to the terms and conditions therein and in connection with the Transactions, to make the PIPE Investment and the Redemption Backstop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>Parent has no Subsidiaries apart from Merger Sub, and does not own, directly or indirectly, any Interest or other interest or investment (whether equity or debt) in any Person, whether incorporated or unincorporated (each, an &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investment</span>&#8221;). Parent is not party to any Contract that obligates Parent to invest money in, loan money to or make any capital contribution to any other Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.4</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Consents</span>. No consent, waiver, approval or authorization of, or designation, declaration or filing with, or notification to, any Governmental Authority or other Person is required on the part of Parent or Merger Sub with respect to Parent&#8217;s or Merger Sub&#8217;s execution or delivery of this Agreement or the consummation of the Transactions, except for (i) applicable requirements of the HSR Act, (ii) in connection with the Domestication, the applicable requirements and required approval of the Cayman Registrar, and (iii) as otherwise disclosed on Section 6.4 of the Parent Disclosure Schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.5</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflict</span>. Subject to the receipt of the Consents described in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.4</span> and the Parent Shareholder Approval, the execution and delivery by each of Parent and Merger Sub of this Agreement and the other Transaction Documents to which it is or will be a party at the Effective Time and the consummation by Parent and Merger Sub of the Transactions (for the avoidance of doubt, including performance of the Transaction Documents following the Closing by Parent and the Parent Subsidiaries, other than the SpinCo Entities) do not and will not as of the Effective Time: (a) violate any provision of, or result in the material breach of, any Law applicable to Parent and the Parent Subsidiaries or by which any of its assets or properties is bound; (b) with or without lapse of time or the giving of notice or both, require a consent or approval under, conflict with, result in a violation or breach of, or constitute a default under, result in the acceleration of, or create in any party the right to accelerate, terminate or cancel any Parent Material Contract; or (c) violate any provision of the Governing Documents of Parent, or Merger Sub, except, in the case of clauses (a) and (b), as would not, individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.6</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Internal Controls; Listing; Financial Statements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except as not required in reliance on exemptions from various reporting requirements by virtue of Parent&#8217;s status as an &#8220;emerging growth company&#8221; within the meaning of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">JOBS Act</span>&#8221;), Parent has established and maintains disclosure controls and procedures (as defined in Rule 13a-15 under the Exchange Act). Such disclosure controls and procedures are designed to ensure that material information relating to Parent, including its consolidated Subsidiaries, if any, is made known to Parent&#8217;s principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared. To Parent&#8217;s Knowledge, such disclosure controls and procedures are effective in timely alerting Parent&#8217;s principal executive officer and principal financial officer to material information required to be included in Parent&#8217;s periodic reports required under the Exchange Act. Parent has established and maintained a system of internal controls over financial reporting (as defined in Rule 13a-15 under the Exchange Act) that, to Parent&#8217;s Knowledge, are sufficient to provide reasonable assurance regarding the reliability of Parent&#8217;s financial reporting and the preparation of Parent&#8217;s financial statements for external purposes in accordance with GAAP and there have been no significant deficiencies or material weakness in Parent&#8217;s internal control over financial reporting (whether or not remediated) and no change in Parent&#8217;s control over financial reporting that has materially affected, or is reasonably likely to materially affect Parent&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>As of the date hereof, each director and executive officer of Parent has filed with the SEC on a timely basis all statements required by Section 16(a) of the Exchange Act and the rules and regulations promulgated thereunder. Parent has not taken any action prohibited by Section 402 of the Sarbanes-Oxley Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>The Parent Class A Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is listed for trading on NASDAQ. There is no Action pending or, to the Knowledge of Parent, threatened against Parent by NASDAQ or the SEC with respect to any intention by such entity to deregister the Parent Class A Common Stock or prohibit or terminate the listing of Parent Class A Common Stock on NASDAQ.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>The financial statements and notes contained or incorporated by reference in the Parent SEC Filings fairly present in all material respects the financial condition and the results of operations, changes in stockholders&#8217; equity and cash flows of Parent as at the respective dates of, and for the periods referred to, in such financial statements, all in accordance with: (i) GAAP; and (ii) Regulation S-X or Regulation S-K, as applicable, subject, in the case of interim financial statements, to normal recurring year-end adjustments (the effect of which will not, individually or in the aggregate, be material) and the omission of notes to the extent permitted by Regulation S-X or Regulation S-K, as applicable. Parent has no off-balance sheet arrangements that are not disclosed in the Parent SEC Filings. No financial statements other than those of Parent are required by GAAP to be included in the consolidated financial statements of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>There are no outstanding loans or other extensions of credit made by Parent to any executive officer (as defined in Rule 3b-7 under the Exchange Act) or director of Parent. Parent has not taken any action prohibited by Section 402 of the Sarbanes-Oxley Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>Neither Parent (including any employee thereof) nor Parent&#8217;s independent auditors has identified or been made aware of (i) any significant deficiency or material weakness in the system of internal accounting controls utilized by Parent, (ii) any Actual Fraud, whether or not material, that involves Parent&#8217;s management or other employees who have a role in the preparation of financial statements or the internal accounting controls utilized by Parent or (iii) any claim or allegation regarding any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.7</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Undisclosed Liabilities</span>. Except for any fees and expenses payable by Parent or Merger Sub as a result of or in connection with the consummation of the Transactions, there is no liability, debt or obligation of or claim or judgment against Parent or Merger Sub (whether direct or indirect, absolute or contingent, accrued or unaccrued, known or unknown, liquidated or unliquidated, or due or to become due), except for liabilities and obligations (i) reflected or reserved for on the financial statements or disclosed in the notes thereto included in Parent SEC Filings, (ii) that have arisen since the date of the most recent balance sheet included in the Parent SEC Filings in the ordinary course of business of Parent and Merger Sub, or (iii) which would not be, or would not reasonably be expected to be, material to Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.8</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Litigation and Proceedings</span>. As of the date of this Agreement, there are no pending or, to the Knowledge of Parent, threatened Actions against Parent or Merger Sub, their respective properties or assets, or, to the Knowledge of Parent, any of their respective directors, managers, officers or employees (in their capacity as such). As of the date of this Agreement, there are no investigations or other inquiries pending or, to the Knowledge of Parent, threatened by any Governmental Authority, against Parent or Merger Sub, their respective properties or assets, or, to the Knowledge of Parent, any of their respective directors, managers, officers or employees (in their capacity as such). As of the date of this Agreement, there is no outstanding Governmental Order imposed upon Parent or Merger Sub, nor are any assets of Parent or Merger Sub&#8217;s respective businesses bound or subject to any Governmental Order the violation of which would, individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect. From their respective dates of inception to the date of this Agreement, Parent and Merger Sub have not received any written notice of or been charged with the violation of any Laws, except where such violation has not been, individually or in the aggregate, that would reasonably be expected to have a Parent Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.9</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except as would not, individually or in the aggregate, have a Parent Material Adverse Effect:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>(A) All Tax Returns required to be filed by Parent or Merger Sub have been timely filed (taking into account applicable extensions), (B) all such Tax Returns are true, correct and complete, and (C) all Taxes, whether or not shown as due on such Tax Returns, have been paid, in the case of each of clauses (A) through (C), except to the extent adequate reserves therefor in accordance with GAAP have been provided on the financial statements of Parent contained in the Parent SEC Documents;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="color:#010000;"> </span>(A) No Governmental Authority has asserted any written claim, assessment or deficiency for Taxes against Parent or any Parent Subsidiary (and, to the Knowledge of Parent, no such claim, assessment or deficiency has been threatened or proposed in writing), except for deficiencies which have been satisfied by payment, settled or withdrawn and (B) no claim, audit or other proceeding by any Governmental Authority is pending or threatened in writing with respect to any Taxes of Parent or Merger Sub;</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>Neither Parent nor any Parent Subsidiary has any Liability for Taxes of any other Person (other than Parent or any Parent Subsidiary) under Treasury Regulations section 1.1502-6 (or any similar provision of state, local or non-U.S. Law), as a transferee or successor or by contract or operation of Law or otherwise;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>Within the past two years, neither Parent nor any Parent Subsidiary has constituted either a &#8220;distributing corporation&#8221; or a &#8220;controlled corporation&#8221; (within the meaning of Section 355(a)(1)(A) of the Code) in a distribution of stock qualifying for tax-free treatment under Section 355 of the Code;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span><span style="color:#010000;"> </span>Neither Parent nor any Parent Subsidiary has participated in, or is currently participating in, a &#8220;listed transaction&#8221; within the meaning of Treasury Regulations Section 1.6011-4(b)(2); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</span></span>There are no Liens for Taxes (other than Permitted Liens) upon the assets of Parent or Merger Sub.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Neither Parent nor Merger Sub has taken or agreed to take any action or knows of any fact, agreement, plan or other circumstance that could reasonably be expected to prevent or impede (i) the Domestication from qualifying as a &#8220;reorganization&#8221; within the meaning of Section 368(a)(1)(F), (ii) the Tax-Free Status, (iii) the Company from receiving the Company Tax Opinions or (iv) Parent from receiving the Parent Tax Opinions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Merger Sub was formed solely for the purpose of engaging in the Merger, and does not have any assets and has not engaged in any business activities or conducted any operations other than in connection with the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>The representations and warranties set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.9</span> constitute the sole and exclusive representations and warranties of Parent regarding Tax matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_10"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.10</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Absence of Changes</span>. Since the Balance Sheet Date until the date of this Agreement, (a) there has not been any event or occurrence that has had, or would not reasonably be expected to have, individually or in the aggregate a Parent Material Adverse Effect and (b) except as set forth in Section 6.10 of the Parent Disclosure Schedule, Parent and Merger Sub have, in all material respects, conducted their business and operated their properties in the ordinary course of business consistent with past practice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_11"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.11</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brokers&#8217; Fees</span>. No broker, finder, investment banker or other Person is entitled to any brokerage fee, finders&#8217; fee or other similar commission, for which Parent, Merger Sub or the SpinCo Entities would be liable in connection with the transactions contemplated by this Agreement based upon arrangements made by Parent or any Parent Subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_12"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.12</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proxy Statement; Registration Statements</span>. None of the information regarding Parent, Merger Sub or the Transactions to be provided by Parent specifically for inclusion in, or incorporation by reference into, the Proxy Statement, the Parent Registration Statement, the SpinCo Registration Statement or the Distribution Documents will, in the case of the Proxy Statement and the Distribution Documents or any amendment or supplement thereto, at the time of the first mailing of the Proxy Statement and the Distribution Documents and of any amendment or supplement thereto, or, in the case of the Parent Registration Statement and the SpinCo Registration Statement, at the time such registration statement becomes effective, on the date of the Parent Shareholders Meeting, at the Distribution Time and at the Effective Time, contain an untrue or false statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they are made, not false or misleading. The Proxy Statement and the Parent Registration Statement will comply as to form in all material respects with the provisions of the Securities Act and the Exchange Act, as the case may be, except that no representation is made by Parent with respect to information provided by the Company or SpinCo specifically for inclusion in, or incorporation by reference into, the Proxy Statement or the Parent Registration Statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_13"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.13</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SEC Filings</span>. Parent has timely filed or furnished all statements, prospectuses, registration statements, forms, reports and documents required to be filed by it with the SEC since August 12, 2021, pursuant to the Exchange Act or the Securities Act (collectively, as they have been amended since the time of their filing through the date hereof, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent SEC Filings</span>&#8221;). Each of the Parent SEC Filings, as of the respective date of its filing (or if amended or superseded by a filing prior to the date of this Agreement or the Closing Date, then on the date of such filing), complied in all material respects with the applicable requirements of the Securities Act, the Exchange Act, the Sarbanes-Oxley Act and any rules and regulations promulgated thereunder applicable to the Parent SEC Filings. As of the respective date of its filing (or if amended or superseded by a filing prior to the date of this Agreement or the </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Closing Date, then on the date of such filing), the Parent SEC Filings did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements made therein, in light of the circumstances under which they were made, not misleading. As of the date hereof, there are no outstanding or unresolved comments in comment letters received from the SEC with respect to the Parent SEC Filings. To the Knowledge of Parent, none of the Parent SEC Filings filed on or prior to the date hereof is subject to ongoing SEC review or investigation as of the date hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_14"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.14</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trust Account</span>. As of the date of this Agreement, Parent has at least $235,750,000 in the Trust Account (including an aggregate of approximately $8,050,000 of deferred underwriting commissions and other fees being held in the Trust Account), such monies invested in United States government securities or money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act pursuant to the Investment Management Trust Agreement, dated as of August 9, 2021, between Parent and Continental Stock Transfer &amp; Trust Company, as trustee (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trustee</span>&#8221;) (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trust Agreement</span>&#8221;). There are no separate Contracts, side letters or other arrangements or understandings (whether written or unwritten, express or implied) that would cause the description of the Trust Agreement in the Parent SEC Filings to be inaccurate or that would entitle any Person (other than the Parent Shareholders holding shares of Parent Common Stock sold in Parent&#8217;s initial public offering who shall have elected to redeem their shares of Parent Common Stock pursuant to Parent&#8217;s Governing Documents and the underwriters of Parent&#8217;s initial public offering with respect to deferred underwriting commissions) to any portion of the proceeds in the Trust Account. Prior to the Closing, none of the funds held in the Trust Account may be released other than (i) to pay Taxes and (ii) payments with respect to all Parent Share Redemptions. There are no claims or proceedings pending or, to the Knowledge of Parent, threatened with respect to the Trust Account. Parent has performed all material obligations required to be performed by it to date under, and is not in material default, breach or delinquent in performance or any other respect (claimed or actual) in connection with, the Trust Agreement, and no event has occurred which, with due notice or lapse of time or both, would constitute such a default or breach thereunder. As of the Effective Time, the obligations of Parent to dissolve or liquidate pursuant to Parent&#8217;s Governing Documents shall terminate, and as of the Effective Time, Parent shall have no obligation whatsoever pursuant to Parent&#8217;s Governing Documents to dissolve and liquidate the assets of Parent by reason of the consummation of the Transactions. To Parent&#8217;s Knowledge, as of the date hereof, following the Effective Time, no shareholder of Parent shall be entitled to receive any amount from the Trust Account except to the extent such shareholder of Parent is exercising a Parent Share Redemption. As of the date hereof, assuming the accuracy of the representations and warranties of the Company contained herein and the compliance by the Company and SpinCo with its obligations hereunder and under the other Transaction Documents, neither Parent or Merger Sub have any reason to believe that any of the conditions to the use of funds in the Trust Account will not be satisfied or funds available in the Trust Account will not be available to Parent and Merger Sub on the Closing Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_15"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.15</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investment Company Act; JOBS Act</span>. Parent is not an &#8220;investment company&#8221; or a Person directly or indirectly &#8220;controlled&#8221; by or acting on behalf of an &#8220;investment company&#8221;, in each case within the meaning of the Investment Company Act. Parent constitutes an &#8220;emerging growth company&#8221; within the meaning of the JOBS Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_16"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.16</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indebtedness</span>. Section 6.16 of the Parent Disclosure Schedule sets forth the principal amount of all of the outstanding Indebtedness, as of the date hereof, of Parent and Merger Sub.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_17"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.17</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Market Quotation</span>. As of the date hereof, the Parent Class A Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is listed for trading on NASDAQ under the symbol &#8220;AHPA&#8221;. As of the date hereof, the Public Parent Warrants are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on NASDAQ under the symbol &#8220;AHPAW.&#8221; As of the date hereof, the Parent Units are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on NASDAQ under the symbol &#8220;AHPAU.&#8221; There is no Action or proceeding pending or, to the Knowledge of Parent, threatened against Parent by NASDAQ or the SEC with respect to any intention by such entity to deregister the Parent Class A Common Stock or Parent Warrants or terminate the listing of Parent Class A Common Stock or Parent Warrants on NASDAQ. None of Parent, Merger Sub or their respective Affiliates has taken any action in an attempt to terminate the registration of the Parent Class A Common Stock or Parent Warrants under the Exchange Act except as contemplated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_18"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.18</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Activities</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Since formation, neither Parent nor Merger Sub have conducted any business activities other than activities related to Parent&#8217;s initial public offering or directed toward the accomplishment of a Business Combination. Except as set forth in Parent&#8217;s Governing Documents or as otherwise contemplated by this Agreement or the Transaction Documents and the Transactions and thereby, there is no agreement, commitment, or Governmental Order binding upon Parent or Merger Sub or to which Parent or Merger Sub is a party which has or would reasonably be expected to have the effect of prohibiting or impairing any business </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">practice of Parent or Merger Sub or any acquisition of property by Parent or Merger Sub or the conduct of business by Parent or Merger Sub as currently conducted or as contemplated to be conducted as of the Closing, other than such effects, individually or in the aggregate, which have not been and would not reasonably be expected to have a Parent Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Except for Merger Sub and the Transactions, Parent does not own or have a right to acquire, directly or indirectly, any Investment in any corporation, partnership, joint venture, business, trust or other entity. Except for this Agreement and the Transaction Documents and the Transactions and thereby, Parent has no material interests, rights, obligations or Liabilities with respect to, and is not party to, bound by or has its assets or property subject to, in each case whether directly or indirectly, any Contract or transaction which is, or would reasonably be interpreted as constituting, a Business Combination. Except for the Transactions, Merger Sub does not own or have a right to acquire, directly or indirectly, any Investment in any corporation, partnership, joint venture, business, trust or other entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Merger Sub was formed solely for the purpose of effecting the Transactions and has not engaged in any business activities or conducted any operations other than incident to the Transactions and has no, and at all times prior to the Effective Time, except as expressly contemplated by this Agreement, the Transaction Documents and the other documents and Transactions, will have no, assets, liabilities or obligations of any kind or nature whatsoever other than those incident to its formation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>As of the date hereof and except for this Agreement, the Transaction Documents and the other documents and Transactions (other than with respect to expenses and fees incurred in connection therewith and the Business Combination), neither Parent nor Merger Sub are party to any Contract with any other Person that would require payments by Parent or any of its Subsidiaries after the date hereof in excess of $150,000 in the aggregate with respect to any individual Contract, other than Working Capital Loans. Section 6.18(d) of the Parent Disclosure Schedule sets forth a true and complete list of all outstanding Working Capital Loans as of the date hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="A_Section_6_19"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.19</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 280G</span>. Neither the execution and delivery of this Agreement nor the consummation of the Transactions contemplated hereby or by the Transaction Documents shall, either alone or in connection with any other event(s), result in the payment of any amount to any current or former employee, officer, director or independent contractor of Parent or other Person that could, individually or in the aggregate, or in combination with any other such payment, constitute an &#8220;excess parachute payment&#8221; as defined in Section 280G(b)(1) of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_6_20"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.20</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Other Representations and Warranties</span>. Except as expressly set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article IV</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> or in any Transaction Document, (a) each of Parent and Merger Sub acknowledges and agrees that neither the Company nor any of its Affiliates (including the SpinCo Entities), nor any of their respective Representatives has made, or is making, any representation or warranty whatsoever to with respect to the Company or any of its Affiliates (including the SpinCo Entities), or any of their respective businesses, operations, assets, liabilities, conditions (financial or otherwise) or prospects, and (b) each of Parent and Merger Sub further acknowledges and agrees that neither the Company nor any of its Affiliates shall be liable in respect of the accuracy or completeness of any information provided to Parent, Merger Sub or any of its respective Affiliates or Representatives. Without limiting the generality of the foregoing, except as expressly set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article IV</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> or in any Transaction Document, each of Parent and Merger Sub acknowledges and agrees that no representations or warranties are made with respect to any projections, forecasts, estimates or budgets with respect to the Company, SpinCo, any of the SpinCo Entities or the SpinCo Business that may have been made available, in the SpinCo Datasite or otherwise, to Parent, Merger Sub or any of their Representatives, and expressly disclaim reliance on any other representations, warranties, statements, information or inducements, oral or written, express or implied, or as to the accuracy or completeness of any statements or other information, made to, or made available to, itself or any of its Representatives, in each case with respect to, or in connection with, the negotiation, execution or delivery of this Agreement, any instrument or other document delivered pursuant to this Agreement or the transactions contemplated by this Agreement, and notwithstanding the distribution, disclosure or other delivery to Parent, Merger Sub or any of their Representatives of any document or other information with respect to any one or more of the foregoing, and waive any claims or causes of actions relating thereto, other than those for Actual Fraud. Without limiting the generality of the foregoing, it is understood that any cost estimates, financial or other projections or other predictions that may be contained or referred to in this Agreement (including the SpinCo Disclosure Schedule), any information, documents or other materials (including any such materials contained in the SpinCo Datasite or otherwise reviewed by Parent, Merger Sub or any of their respective Affiliates or Representatives) or management presentations that have been or shall hereafter be provided to Parent, Merger Sub or any of their respective Affiliates or Representatives are not and will not be deemed to be representations or warranties of the Company or SpinCo, and no representation or warranty is made as to the accuracy or completeness of any of the foregoing except as expressly set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article IV</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> of this Agreement or in any Transaction </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Document. In entering into this Agreement, Parent and Merger Sub acknowledge and agree that they have relied solely upon their own investigation and analysis; and Parent and Merger Sub acknowledge and agree, to the fullest extent permitted by Law, that the Company, the SpinCo Entities and their Affiliates and their respective Representatives shall not have any Liability or responsibility whatsoever to Parent or its Subsidiaries or any of their respective Representatives on any basis (including in contract or tort, under federal or state securities Laws or otherwise) based upon any information provided or made available, or statements made (or any omissions therefrom), to Parent or its Subsidiaries or any of their respective Representatives, including in respect of the specific representations and warranties set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article IV</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> of this Agreement or any Transaction Document, except as and only to the extent expressly set forth herein or therein with respect to such representations and warranties and subject to the limitations and restrictions contained herein or therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_ARTICLE_VII"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="color:#010000;">ARTICLE VII</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">COVENANTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.1</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conduct of Business by Parent and Merger Sub Pending the Merger</span>. From the date hereof and prior to the Effective Time (or the earlier termination of this Agreement) (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interim Period</span>&#8221;), except as (i) required or otherwise contemplated by this Agreement (including as set forth in Section 7.1 of the Parent Disclosure Schedule), the Transaction Documents, the PIPE Investment, the Redemption Backstop or in connection with the Domestication, (ii) as consented to by the Company in writing (which consent shall not be unreasonably withheld, conditioned, delayed or denied) or (iii) as required by applicable Law, Parent shall, and shall cause its Subsidiaries, including Merger Sub, as applicable, to, conduct its operations in the ordinary course of business in all material respects. During the Interim Period, Parent shall, and shall cause its Subsidiaries, including Merger Sub, to comply with, and continue performing under, as applicable, the Governing Documents of Parent, the Trust Agreement and all other agreements or Contracts to which Parent or its Subsidiaries may be a party. Without limiting the generality of the foregoing, during the Interim Period, except as (i) required or otherwise contemplated by this Agreement (including as set forth in Section 7.1 of the Parent Disclosure Schedule), the Transaction Documents, the PIPE Investment or in connection with the Domestication, (ii) as consented to by the Company in writing (which consent shall not be unreasonably withheld, conditioned, delayed or denied, other than with respect to subsection (b), with respect to which consent may be withheld at the Company&#8217;s sole discretion) or (iii) as required by applicable Law, Parent shall not, and shall cause its Subsidiaries, including Merger Sub, as applicable, not to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>seek any approval from the Parent Shareholders to amend, modify, restate, waive, rescind or otherwise change the Trust Agreement or the Governing Documents of Parent or Merger Sub (other than as contemplated by the Transaction Proposals);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>(i) make or declare any dividend or distribution to the Parent Shareholders or make any other distributions in respect of any of Parent&#8217;s equity interests or Merger Sub capital stock, share capital or equity interests, (ii) split, combine, reclassify or otherwise amend any terms of any shares or series of Parent&#8217;s equity interests or Merger Sub capital stock or equity interests, or (iii) purchase, repurchase, redeem or otherwise acquire any issued and outstanding share capital, outstanding shares of capital stock, share capital or membership interests, warrants or other equity interests of Parent or Merger Sub, other than a redemption of shares of Parent Class A Common Stock made as part of the Parent Share Redemptions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>make, change or revoke any material Tax election or (ii) settle or compromise any material Tax liability;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>enter into, renew or amend in any material respect, any transaction or Contract with an Affiliate of Parent or Merger Sub (including, for the avoidance of doubt, (i) the Sponsor and (ii) any Person in which the Sponsor has a direct or indirect legal, contractual or beneficial ownership interest of 5% or greater);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>incur or assume any Indebtedness or guarantee any Indebtedness of another Person, issue or sell any debt securities or warrants or other rights to acquire any debt securities of the Company or any of the Company&#8217;s Subsidiaries or guaranty any debt securities of another Person, other than any indebtedness (x) for borrowed money or guarantee from its Affiliates and stockholders in order to meet its reasonable capital requirements, with any such loans to be made only as reasonably required by the operation of Parent in due course on a non-interest basis and otherwise on arm&#8217;s-length terms and conditions and repayable at the Closing, and in any event in an aggregate amount not to exceed $100,000 (or, in the case of Working Capital Loans, up to $150,000), or (y) incurred between Parent and Merger Sub;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>(i) issue any Parent Securities or securities exercisable for or convertible into Parent Securities, other than issuances contemplated by the Transactions, (ii) grant any options, warrants or other equity-based awards with respect to Parent Securities </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">not outstanding on the date hereof or (iii) amend, modify or waive any of the material terms or rights set forth in any Parent Warrant or the Warrant Agreement, including any amendment, modification or reduction of the warrant price set forth therein; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>enter into any agreement to do any action prohibited under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.1</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.2</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conduct of SpinCo Business Pending the Merger</span>. During the Interim Period (solely with respect to the SpinCo Entities or the SpinCo Business), except as (i) required or otherwise contemplated by this Agreement (including as set forth in Section 7.2 of the SpinCo Disclosure Schedule), the Internal Reorganization or the Transaction Documents, (ii) as consented to by Parent in writing (which consent shall not be unreasonably withheld, conditioned or delayed) or (iii) as required by applicable Law or any COVID-19 Measures, the Company and the SpinCo Entities shall, and shall cause and ensure that their respective Subsidiaries (including the SpinCo Entities), to (x) conduct the SpinCo Business in the ordinary course of business in all material respects, (y) use commercially reasonable efforts to manage the SpinCo Business&#8217; working capital and maintain the books and records related to the SpinCo Business consistent with past practice and (z) use commercially reasonable efforts to maintain their respective relations and goodwill with all material suppliers, material customers and other material commercial counterparties and Governmental Authorities (in each case, as related to the SpinCo Business). Without limiting the generality of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2(a)</span>, during the Interim Period (solely with respect to the SpinCo Entities or the SpinCo Business), except as (A) required or contemplated by this Agreement (including as set forth in Section 7.2 of the SpinCo Disclosure Schedule), the Internal Reorganization or the Transaction Documents, (B) as consented to by Parent in writing (which consent shall not be unreasonably withheld, conditioned or delayed, other than with respect to subsection (b) or (c), with respect to which consent may be withheld at the Company&#8217;s sole discretion) or (C) as required by applicable Law or any COVID-19 Measures, the Company and SpinCo shall not, and each shall cause its respective Subsidiaries not to (in each case solely with respect to the SpinCo Entities or the SpinCo Business):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>amend, modify, restate, waive, rescind or otherwise change the Governing Documents of any of the SpinCo Entities, other than an amendment to the certificate of incorporation of SpinCo to increase the number of authorized or outstanding shares of SpinCo Common Stock in connection with the Distribution in accordance with this Agreement and the Transaction Documents;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>other than as required for the Distribution, (i) declare, set aside or pay any dividends on or make other distributions in respect of any of the Interests of any of the SpinCo Entities (whether in cash, securities or property), except for the declaration and payment of cash dividends or distributions paid on or with respect to a class of Interests of any SpinCo Entity that is wholly owned directly or indirectly by SpinCo, (ii) split, combine, subdivide, reduce, or reclassify any of the Interests of any of the SpinCo Entities or issue or authorize or propose the issuance of any other securities in respect of, in lieu of, or in substitution for, Interests of the SpinCo Entities or (iii) redeem, repurchase or otherwise acquire, or permit any Subsidiary to redeem, repurchase or otherwise acquire, any Interests (including any securities convertible or exchangeable into such Interests) (except for the acquisition by the Company or any of its Subsidiaries of any shares of capital stock, membership interests or other equity interests of the Company or its Subsidiaries in connection with the forfeiture of any Company Equity Awards, in each case, in accordance with their respective terms as in effect as of the date hereof);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>other than as contemplated by the Distribution, issue, sell, pledge, dispose of, grant, transfer or encumber, any shares of capital stock of, any other Interests in, or any SpinCo Voting Debt of, any of the SpinCo Entities of any class, or securities convertible into, or exchangeable or exercisable for, any shares of such capital stock or other Interests in any of the SpinCo Entities, or any options, warrants, stock units, or other rights of any kind to acquire any shares of capital stock or other Interests or such convertible or exchangeable securities, or any other ownership interest (including any such interest represented by Contract right), or any &#8220;phantom&#8221; stock, &#8220;phantom&#8221; stock rights, stock appreciation rights or stock based performance rights, in each case, of the SpinCo Entities, other than (i) the issuance by a SpinCo Entity that is a wholly owned Subsidiary of SpinCo of its capital stock or other Interests to SpinCo or another wholly owned Subsidiary of SpinCo or (ii) the issuance of capital stock or other Interests upon the exercise, vesting or settlement of Company Equity Awards outstanding as of the date hereof and, in each case, in accordance with their respective terms as in effect as of the date hereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>sell, assign, transfer, convey, lease, license, abandon, mortgage, pledge or permit any Lien on (other than a Permitted Lien) or otherwise dispose of any SpinCo Assets (excluding Intellectual Property, which is the subject of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2(e)</span> below);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>(i) purchase, sell, license, sublicense, lease, pledge, covenant not to assert, assign, transfer, abandon, cancel, let lapse or expire, or otherwise dispose, transfer or grant any other rights in or with respect to any Intellectual Property (other than with respect to (A) immaterial or obsolete SpinCo Owned Intellectual Property or (B) the grant of non-exclusive licenses of SpinCo </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Owned Intellectual Property in the ordinary course of business consistent with past practice); or (ii) disclose any material Trade Secrets of the SpinCo Business to any other Person (other than in the ordinary course of business consistent with past practice to a Person bound by adequate and enforceable use restrictions and confidentiality obligations with respect to such Trade Secrets);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>receive, collect, use, store, process, share, safeguard, secure (technically, physically or administratively), dispose of, destroy, disclose, or transfer (including cross-border) any Personal Information (or fail to do any of the foregoing, as applicable) in material violation of any Privacy Requirements;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>merge, combine or consolidate (pursuant to a plan of merger or otherwise) any of the SpinCo Entities with any Person or adopt a plan of complete or partial liquidation or resolutions providing for a complete or partial liquidation, dissolution, restructuring, recapitalization or other reorganization of any of the SpinCo Entities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>acquire (including by merger, consolidation, or acquisition of shares or assets), lease or license, (i) any interest in any Person or (ii) any assets of any Person that would be an asset of the SpinCo Entities at the Effective Time, other than, in the case of clause (ii), (A) in the ordinary course of business with respect to assets having a value not exceeding $2,000,000, individually, or $4,000,000, in the aggregate, the purchase price for which will be paid by the Company or any of its Subsidiaries prior to the Distribution Date;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>repurchase, repay, prepay, refinance or incur any indebtedness for borrowed money, issue any debt securities, engage in any securitization transactions or similar arrangements or assume, guarantee or endorse, or otherwise as an accommodation become responsible for (whether directly, contingently or otherwise), the obligations of any Person for borrowed money other than in the ordinary course of business consistent with past practice and in an aggregate amount not to exceed $500,000;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span>make any material loans, material capital contributions or material investments in, or advances of money to, in each case, in excess of $2,000,000 individually or $4,000,000 in the aggregate, any Person (other than the SpinCo Entities), in each case, except for (i) advances to employees or officers of any SpinCo Entity for expenses incurred in the ordinary course of the SpinCo Business consistent with past practice and in accordance with the Company&#8217;s and its Subsidiaries&#8217; policies in respect thereof or (ii) extended payment terms for customers in the ordinary course of the SpinCo Business consistent with past practice;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span>(A) amend or modify in any material respect, terminate (excluding any expiration in accordance with its terms), or waive any material right, benefit or remedy under, any SpinCo Material Contract or (B) enter into any Contract that if entered into prior to the date hereof would be required to be listed on Section 5.7 or Section 5.15(a) of the SpinCo Disclosure Schedule;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</span></span><span style="color:#010000;"> </span>Except as contemplated by the Transaction Documents, as required by applicable Law or as required by any existing Company Benefit Plan, or in the ordinary course of business consistent with past practice, (i) adopt, enter into, amend or alter in any respect or terminate any Company Benefit Plan in respect of any SpinCo Service Provider (other than the grant of equity awards in the ordinary course of business consistent with past practice), or any SpinCo Benefit Plan, (ii) grant or agree to grant any material increase in the wages, salary, bonus or other compensation, remuneration or benefits of any SpinCo Service Provider, or that would result in any material Liability to any SpinCo Entity, (iii) grant or provide any change-in-control, severance, termination, retention or similar payments or benefits to any SpinCo Service Provider, or that would result in any material Liability to any SpinCo Entity, (iv) hire or engage, or make an offer to hire or engage, any officer, employee, service provider or individual independent contractor of any SpinCo Entity whose annual base pay exceeds $250,000, or (v) terminate (without cause) the employment of any SpinCo Employee or engagement of any SpinCo Independent Contractor whose annual base pay or retainer exceeds $250,000;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(m)</span></span><span style="color:#010000;"> </span>except as required or permitted by GAAP, make any material change to any financial accounting principles, methods or practices of any SpinCo Entity or with respect to the SpinCo Business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(n)</span></span>waive, release, settle, compromise or otherwise resolve any Action, litigation or other proceedings, except where such waivers, releases, settlements or compromises involve only the payment of monetary damages in an amount less than $375,000 in the aggregate;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(o)</span></span>(i) make, change or revoke any material Tax election in respect of the SpinCo Business that would bind any SpinCo Entity for periods following the Effective Time (other than an election reasonably required in connection with the Separation) or </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">(ii) settle or compromise any material Tax liability for which a SpinCo Entity would be responsible under any Transaction Document;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(p)</span></span>make or commit to make any capital expenditures, on an annualized basis, in the aggregate, in excess of $2,000,000, in the aggregate;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(q)</span></span>enter into any collective bargaining agreement or other similar Contract with a labor union, works&#8217; council, employee representative body or labor organization that would constitute a SpinCo CBA or in respect of which Parent or its Subsidiaries will have any Liability or obligations following the Effective Time, or amend or modify any SpinCo CBA;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(r)</span></span>disclose or agree to disclose to any Person (other than Parent or any of its representatives) any material Trade Secret or any other material confidential or proprietary information, know-how or process of the Company or any of its Subsidiaries, in each case other than in the ordinary course of business consistent with past practice and pursuant to customary contractual obligations or fiduciary or professional duty to maintain the confidentiality thereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(s)</span></span>terminate without replacement or fail to use reasonable efforts to maintain any license or permit that is material to the conduct of the business of the Company and its Subsidiaries, taken as a whole;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(t)</span></span>waive the restrictive covenant obligations of any current officer of the Company or any of the SpinCo Entities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(u)</span></span>(i) limit the right of the Company or any of the SpinCo Entities to engage in any line of business or in any geographic area, to develop, market or sell products or services, or to compete with any Person or (ii) grant any exclusive or similar rights to any Person, in each case, except where such limitation or grant does not, and would not be reasonably likely to, individually or in the aggregate, materially and adversely affect, or materially disrupt, the ordinary course operation of the businesses of the Company or any of the SpinCo Entities, taken as a whole;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span>terminate without replacement or amend in a manner materially detrimental to the Company and its Subsidiaries, taken as a whole, any insurance policy insuring the business of the Company or any of the SpinCo Entities; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(w)</span></span><span style="color:#010000;"> </span>authorize or enter into any Contract to do any of the foregoing or otherwise agree or make any commitment to do any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.3</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>This Agreement is intended to constitute a &#8220;plan of reorganization&#8221; for purposes of Section 368 of the Code and the Parties hereby adopt it as such. From and after the date of this Agreement and until the Effective Time, each Party shall use its reasonable best efforts to (A) ensure that (i) the Domestication will qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a)(1)(F), (ii) the Contribution and Distribution, taken together, will qualify as a &#8220;reorganization&#8221; within the meaning of Sections 368(a)(1)(D) and 355(a) of the Code, (iii) the Merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code and (iv) the Merger (taking into account the PIPE Investment) will not cause Section 355(e) of the Code to apply to the Distribution (with respect clauses (ii)-(iv), the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax-Free Status</span>&#8221;) and (B) not take any action, cause or permit any action to be taken, fail to take any action or cause any action to fail to be taken, which action or failure to act could prevent (i) the Domestication from qualifying as a &#8220;reorganization&#8221; within the meaning of Section 368(a)(1)(F) or (ii) the Tax-Free Status. Following the Effective Time, none of the Company, Parent or any of their respective Affiliates shall take any action, cause or permit any action to be taken, fail to take any action or cause any action to fail to be taken, which action or failure to act could prevent the Tax-Free Status.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Each of the Company, SpinCo and Parent shall cooperate with one another and shall use its reasonable best efforts for the Company to obtain a written opinion of LW, reasonably satisfactory in form and substance to the Company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Distribution Tax Opinion</span>&#8221;), dated as of the Closing Date, to the effect that, on the basis of the facts, customary representations and assumptions set forth or referred to in such opinion, (i) the Contribution and Distribution, taken together, will qualify as a &#8220;reorganization&#8221; within the meaning of Sections 368(a)(1)(D) and 355(a) of the Code and (ii) the Merger will not cause Section 355(e) of the Code to apply to the Distribution. In delivering the Company Distribution Tax Opinion, LW shall be entitled to receive and rely upon the Parent Distribution Tax Representations and the Company Distribution Tax Representations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Company and SpinCo, on the one hand, and Parent, on the other hand, shall cooperate with one another in obtaining, and shall use their respective reasonable best efforts to obtain, a written opinion of LW (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Merger Tax Opinion</span>&#8221;), in the case of Company and SpinCo, and a written opinion of Weil (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Merger Tax Opinion</span>&#8221;), in the case of Parent, reasonably satisfactory in form and substance to the Company and Parent, respectively, dated as of the Closing Date, to the effect that, on the basis of the facts, customary representations and assumptions set forth or referred to in such opinion, the Merger will be treated as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code. In delivering the Company Merger Tax Opinion and the Parent Merger Tax Opinion, LW and Weil shall both be entitled to receive and rely upon the SpinCo Merger Tax Representations and the Parent Merger Tax Representations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Company and SpinCo, on the one hand, and Parent, on the other hand, shall cooperate with one another in obtaining, and Parent shall use its reasonable best efforts to obtain a written opinion of Weil (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Domestication Tax Opinion</span>&#8221;) reasonably satisfactory in form and substance to Parent, dated as of the Closing Date, to the effect that, on the basis of the facts, customary representations and assumptions set forth or referred to in such opinion, the Domestication will qualify as a &#8220;reorganization&#8221; under Section 368(a)(1)(F) of the Code. In delivering the Parent Domestication Tax Opinion, Weil shall be entitled to receive and rely upon representations, as necessary, of an officer of each of the Company, SpinCo and Parent dated as of the Closing Date, in form and substance reasonably satisfactory to Weil and delivered to Weil in connection with the Domestication. For the avoidance of doubt, the receipt of the Parent Domestication Tax Opinion is not a condition to closing under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VIII</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>The Company and SpinCo, on the one hand, and Parent, on the other hand, shall cooperate with each other in obtaining, and shall use their respective reasonable best efforts to obtain, any Tax opinions required to be filed with the SEC in connection with the filing of the Parent Registration Statement and shall each use its respective reasonable best efforts to cause such opinions to be timely filed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>Parent will promptly notify the Company if, before the Effective Time, it knows or has reason to believe that Parent is not reasonably expected to be able to obtain the Parent Merger Tax Opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>The Company will promptly notify Parent if, before the Effective Time, it knows or has reason to believe that the Company is not reasonably expected to be able to obtain any of the Company Tax Opinions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.4</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Preparation of the Registration Statements and Prospectus; Parent Shareholders Meeting</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>As promptly as practicable after the execution of this Agreement, to the extent such filings are required by Law in connection with the transactions contemplated by this Agreement: (i) Parent, the Company and SpinCo shall jointly prepare and Parent shall file with the SEC the Parent Registration Statement; (ii) Parent, the Company and SpinCo shall jointly prepare and SpinCo shall file with the SEC the SpinCo Registration Statement; (iii) Parent, the Company and SpinCo shall jointly prepare and Parent shall file with the SEC the Proxy Statement (which Proxy Statement may form a part of the Parent Registration Statement); and (iv) the Parties shall jointly prepare and cause to be filed such other filings required under applicable securities Laws in connection with the Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Each of Parent, the Company and SpinCo shall use its reasonable best efforts to have the Parent Registration Statement and the SpinCo Registration Statement declared effective as promptly as practicable after such filing (including by responding to comments of the SEC) and to keep such registration statements effective for as long as is necessary to consummate the Transactions, and, prior to the effective date of the Parent Registration Statement and the SpinCo Registration Statement, each of Parent, the Company and SpinCo shall take all action reasonably required (other than qualifying to do business in any jurisdiction in which it is not now so qualified or filing a general consent to service of process in any such jurisdiction) to be taken under any applicable securities Laws in connection with the Parent Share Issuance and the Distribution. As promptly as practicable after the Parent Registration Statement and the SpinCo Registration Statement shall have become effective, each of the Company and Parent, as applicable, shall cause the Distribution Documents or the Parent Registration Statement (which shall include the Proxy Statement), as applicable, to be mailed or made available to the Company&#8217;s stockholders or the Parent&#8217;s stockholders, as applicable, in each case, pursuant to applicable Law. No filing of, or amendment or supplement to, the Parent Registration Statement or the Proxy Statement will be made by Parent without providing the Company and SpinCo with a reasonable opportunity to review and comment thereon (and such comments shall be reasonably considered by Parent in good faith). No filing of, or amendment or supplement to, the SpinCo Registration Statement will be made by the Company or SpinCo without providing Parent with a reasonable opportunity to review and comment thereon (and such comments shall be reasonably </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">considered by the Company in good faith). Each Party (as applicable) will use its reasonable best efforts to cause the Distribution Documents and the Parent Registration Statement to comply in all material respects with the applicable requirements of U.S. federal securities Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Each of Parent, the Company and SpinCo shall ensure that none of the information supplied by or on its behalf for inclusion or incorporation by reference in (A) the Parent Registration Statement or SpinCo Registration Statement will, at the time filed with the SEC, at each time at which it is amended and at the time it becomes effective under the Securities Act, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, not misleading, (B) the Proxy Statement will, at the date it is first mailed or made available to the Parent&#8217;s shareholders and at the time of the Parent Shareholders&#8217; Meeting, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading or (C) the Distribution Documents will, at the date they are mailed or made available to the Company&#8217;s stockholders, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>If, at any time prior to the Effective Time, any information relating to Parent, the Company or SpinCo, or any of their respective Affiliates, directors or officers, should be discovered by Parent, the Company or SpinCo, which should be set forth in an amendment or supplement to the Parent Registration Statement, the Proxy Statement or the SpinCo Registration Statement, so that any such document would not include any misstatement of a material fact or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, the Party that discovers such information shall promptly notify the other Party and an appropriate amendment or supplement describing such information shall be promptly filed with the SEC, and, to the extent required by Law, disseminated to the shareholders of Parent or the Company, as applicable. Each Party shall notify the other Party promptly of the time when the Parent Registration Statement or the SpinCo Registration Statement has become effective and of the issuance of any stop order or suspension of the qualification of the shares of Domesticated Parent Stock issuable pursuant to the Merger or shares of SpinCo Common Stock issuable in the Distribution for offering or sale in any jurisdiction. In addition, each Party agrees to provide the other Party and their respective counsel promptly with copies of any written comments or requests for amendments or supplements, and shall promptly inform the other Party of any oral comments or requests for amendments or supplements, that such Party or its counsel may receive from time to time from the SEC with respect to the Parent Registration Statement, the Proxy Statement or the SpinCo Registration Statement promptly after receipt of such comments, and shall provide the other Party with copies of any written or oral responses or correspondence between it or its Affiliates and the SEC related thereto. Each Party and their respective counsel shall be given a reasonable opportunity to review in advance any such written responses and to participate in any discussions or oral material communications with the SEC, and each Party shall reasonably consider in good faith the additions, deletions, comments or changes suggested thereto by the other Party and its counsel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><i style="font-style:italic;">Parent Shareholders Meeting</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>Parent shall call, give notice of, convene and hold a general meeting (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Shareholders Meeting</span>&#8221;) as promptly as reasonably practicable following the date on which the Parent Registration Statement is declared effective, and in any case, no later than thirty (30) Business Days thereafter, for the purpose of obtaining the Parent Shareholder Approval; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that subject to the requirements of any applicable Law, Parent may (and, in the case of clause (C) on up to two (2) occasions upon the reasonable request of the Company (and for no more than five (5) Business Days each) shall) postpone or adjourn the Parent Shareholders Meeting (A) if a quorum has not been established; (B) after consultation with the Company, to allow reasonable additional time for the filing and mailing of any supplement or amendment to the Proxy Statement as may be required under applicable Law and for such supplement or amendment to be disseminated and reviewed by Parent&#8217;s shareholders sufficiently in advance of the Parent Shareholders Meeting; (C) to allow reasonable additional time to solicit additional proxies, if and to the extent the requisite Parent Shareholder Approval would not otherwise be obtained; (D) after consultation with the Company, if otherwise required by applicable Law; or (E) with the prior written consent of the Company; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that the Parent Shareholders&#8217; Meeting will not be adjourned to a date that is more than thirty (30) days after the date for which the Parent Shareholders&#8217; Meeting was originally scheduled (excluding any adjournments required by applicable Law). Parent shall advise the Company upon request on a daily basis during each of the last five (5) Business Days prior to the date of the Parent Shareholders Meeting as to the aggregate tally of proxies received by Parent with respect to the Parent Shareholder Approval and at additional times upon the reasonable request of the Company. Parent agrees that it shall </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">provide the holders of shares of Parent Class A Common Stock the opportunity to elect redemption of such shares of Parent Class A Common Stock in connection with the Parent Shareholders&#8217; Meeting, as required by Parent&#8217;s Governing Documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="color:#010000;"> </span>Parent shall, through the Parent Board, unanimously recommend to its shareholders (A) adoption and approval of the Domestication and change in the jurisdiction of incorporation of Parent from the Cayman Islands to the State of Delaware, (B) amendment and restatement of Parent&#8217;s existing Governing Documents in connection with the Domestication, including any separate or unbundled proposals as are required to implement the foregoing and the change of Parent&#8217;s name to OmniAb, Inc. as set forth in the Parent Charter, (C) adoption and approval of this Agreement, the Transaction Documents and the Transactions contemplated hereby and thereby, in each case, in accordance with applicable Law and exchange rules and regulations, (D) approval of the issuance of shares of Domesticated Parent Stock in connection with the Domestication, the PIPE Investment, the Redemption Backstop and the Merger, (E) approval of the adoption by Parent of the Parent Equity Plan and Parent ESPP, each as described in the Employee Matters Agreement, (F) election of directors to the Parent Board effective as of the Closing as contemplated by this Agreement, (G) adoption and approval of any other proposals as the SEC (or staff thereof) may indicate are necessary in its comments to the Proxy Statement or the Parent Registration Statement or correspondence related thereto, (H) adoption and approval of any other proposals as reasonably agreed by Parent and the Company to be necessary or appropriate in connection with the Transactions and (I) adjournment of the Parent Shareholders Meeting, if necessary, to permit further solicitation of proxies because there are not sufficient votes to constitute a quorum or approve and adopt any of the foregoing (such proposals in (A) through (I), together, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transaction Proposals</span>&#8221;), and include such Parent Board Recommendation in the Proxy Statement (subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.5)</span> and, provided there has been no Modification in Recommendation in response to an Intervening Event in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.5</span>, use its reasonable best efforts to (1) solicit from its shareholders proxies in favor of the approval of the proposals required under the Parent Shareholder Approval, and (2) take all other action necessary or advisable to secure the Parent Shareholder Approval. Except as expressly permitted by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.5</span>, neither the Parent Board nor any committee thereof shall effect a Modification in Recommendation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.5</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Modification in Recommendation</span>. The Parent Board shall not withdraw, amend, qualify or modify its recommendation to the Parent Shareholders that they vote in favor of the Transaction Proposals (together with any withdrawal, amendment, qualification or modification of its recommendation to the Parent Shareholders, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Modification in Recommendation</span>&#8221;); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that the Parent Board may make a Modification in Recommendation if it determines in good faith, after consultation with its outside legal counsel, in response to an Intervening Event, that a failure to make a Modification in Recommendation would be inconsistent with its fiduciary obligations to the Parent Shareholders under applicable Law; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</span>, that: (i) Parent shall have delivered written notice to the Company of its intention to make a Modification in Recommendation at least five (5) Business Days prior to the taking of such action by Parent, (ii) during such period and prior to making a Modification in Recommendation, if requested by the Company, Parent shall have negotiated in good faith with the Company regarding any revisions or adjustments proposed by the Company to the terms and conditions of this Agreement as would enable the Parent Board to reaffirm its recommendation and not make such Modification in Recommendation and (iii) if the Company requested negotiations in accordance with clause (ii), Parent may make a Modification in Recommendation only if the Parent Board, after considering in good faith any revisions or adjustments to the terms and conditions of this Agreement that the Company shall have, prior to the expiration of the five (5) Business Day period, offered in writing to Parent, continues to determine in good faith that failure to make a Modification in Recommendation would be inconsistent with its fiduciary duties to the Parent Shareholders under applicable Law. To the fullest extent permitted by applicable Law, Parent&#8217;s obligations to establish a record date for, duly call, give notice of, convene and hold the Parent Shareholders Meeting shall not be affected by any Modification in Recommendation and Parent agrees to establish a record date for, duly call, give notice of, convene and hold the Parent Shareholders Meeting and submit for approval the Transaction Proposals irrespective of whether a Modification in Recommendation has occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.6</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reasonable Best Efforts</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Subject to the terms of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.20</span>, which shall govern with respect to the subject matter thereof, each of Parent, the Company and their respective Subsidiaries shall use its reasonable best efforts to promptly take, or cause to be taken, all actions, and to promptly do, or cause to be done, and to assist and cooperate with the other in doing, all things reasonably necessary, proper or advisable under applicable Laws to consummate and make effective the Merger and the other transactions contemplated by this Agreement and the other Transaction Documents, as promptly as practicable and in any event prior to the Outside Date, including (i) the obtaining of all necessary actions or nonactions, waivers, consents, clearances, approvals, and expirations or terminations of waiting periods, from Governmental Authorities and the making of all necessary registrations and filings in connection therewith, and (ii) using its commercially reasonable efforts to obtain all necessary consents, approvals or waivers </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">from third parties; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that in no event shall the Company, Parent or their respective Subsidiaries be required to pay any fee, penalty or other consideration to any third party for any consent or approval required for the consummation of the transactions contemplated by this Agreement under any Contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The Company and Parent shall (i) promptly, but in no event later than ten (10) Business Days after the date hereof, file (or cause to be filed) any and all required pre-merger notification and report forms under the HSR Act with respect to the Merger, and (ii) make, as promptly as practicable and advisable, any appropriate filings with other Governmental Authorities, if necessary or advisable, pursuant to any other Antitrust Law. The Company and Parent shall (and, to the extent required, shall cause its Affiliates to) request early termination of any applicable waiting periods under the Antitrust Laws (if available) and shall respectively use their reasonable best efforts to cause the expiration or termination of such waiting periods, and shall supply to the Antitrust Division of the United States Department of Justice (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Antitrust Division</span>&#8221;) or the United States Federal Trade Commission (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FTC</span>&#8221;) as promptly as reasonably practicable and advisable any additional information or documents that may be requested pursuant to any Law or by any of them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>In furtherance of the covenants of the parties contained in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.6</span> (i) if any administrative or judicial action or proceeding, including any proceeding by a private party, is instituted (or threatened to be instituted) challenging the Merger as violative of any Antitrust Law, each of the parties hereto shall take all action required to contest and resist any such action or proceeding and to have vacated, lifted, reversed or overturned any decree, judgment, injunction, or other order, whether temporary, preliminary or permanent, that results from such action or proceeding and that prohibits, prevents or restricts consummation of the Merger on or before the Outside Date and (ii) Parent and the Company each shall take all such further action as may be necessary to avoid or eliminate each and every impediment under any Antitrust Law so as to enable the Closing to occur as promptly as practicable (and in any event no later than the Outside Date), including proposing, negotiating, committing and effecting, by consent decree, hold separate order, or otherwise, to (x) sell, divest, license, dispose of or otherwise hold separate (including by establishing a trust or otherwise), any of the businesses, assets or properties of Parent, the SpinCo Entities or any of their respective Subsidiaries (other than the Company and its Subsidiaries following the Closing), including the SpinCo Business and the SpinCo Assets, (y) terminate, amend or assign any existing Contracts or relationships of Parent, the SpinCo Entities or any of their respective Subsidiaries (other than the Company and its Subsidiaries following the Closing), including the SpinCo Business and the SpinCo Assets, and (z) otherwise take or commit to take actions that after the Closing would limit such Party&#8217;s freedom of action with respect to, or its ability to operate and/or retain any of the businesses, assets or properties of Parent, the SpinCo Entities or any of their respective Subsidiaries (other than the Company and its Subsidiaries following the Closing), including the SpinCo Business and the SpinCo Assets; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that neither Parent nor the Company shall be required to take any action under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.6</span> that would materially impact Parent&#8217;s or the Company&#8217;s expected benefits resulting from the Transactions. Notwithstanding anything in this Agreement to the contrary, the Company and its Subsidiaries shall not be obligated to take or agree or commit to take any action (A) that is not conditioned on the Closing or (B) that relates to any Ligand Retained Assets or the Ligand Retained Business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Parent and the Company shall cooperate and consult with each other in connection with the making of all filings, notifications, communications, submissions, and any other actions pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.6</span>, and, subject to applicable legal limitations and the instructions of any Governmental Authority, Parent and the Company shall keep each other apprised on a current basis of the status of matters relating to the completion of the Transactions, including promptly furnishing the other with copies of notices or other communications received by Parent and the Company, as the case may be, or any of their respective Subsidiaries or Affiliates, from any third party and/or any Governmental Authority with respect to such Transactions. Subject to applicable Law relating to the exchange of information, Parent and the Company shall permit counsel for the other party reasonable opportunity to review in advance, and consider in good faith the views of the other party in connection with, any proposed notifications or filings and any substantive written communications or submissions to any Governmental Authority; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that materials may be redacted (i) to remove references concerning the valuation of the SpinCo Business and the SpinCo Assets or information concerning the Transaction Process, or proposals from third parties with respect thereto, (ii) as necessary to comply with contractual agreements, and (iii) as necessary to address reasonable privilege or confidentiality concerns. Parent and the Company agree not to participate in any pre-scheduled meeting or discussion, either in person, by video conference, or by telephone, with any Governmental Authority in connection with the Transactions unless it consults with the other party in advance and, to the extent not prohibited by such Governmental Authority, gives the other party a reasonable opportunity to attend and participate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.7</span></span> [Intentionally Omitted].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="A_Section_7_8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.8</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Access to Information</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#010000;">T</span>he Company shall, and shall cause its Subsidiaries, on the one hand, and Parent shall, and shall cause its Subsidiaries, on the other hand, to afford to the other Party and to its respective Representatives, reasonable access, during normal business hours and subject to bona fide policies and procedures established by the other Party (including in response to COVID-19), during the Interim Period, in such manner as to not interfere with Parent&#8217;s and its Subsidiaries&#8217; business&#8217;s or the SpinCo Business&#8217;s (as applicable) normal operations, the properties, books and records and appropriate senior-level officers and employees of Parent and its Subsidiaries or the Company and its Subsidiaries (including the SpinCo Entities) that are related to the SpinCo Business (as applicable), and shall furnish such Party and its Representatives with such accounting (including accountants&#8217; work papers), financial and operating data and other information concerning the affairs of Parent and its Subsidiaries or the SpinCo Business or the SpinCo Entities (as applicable), in each case, as such Party and its Representatives may reasonably request for the purposes of furthering the Transactions or for purposes of preparing for the operation of Parent and the Surviving Corporation post-Closing; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span><span style="white-space:pre-wrap;">, that (x) such investigation shall only be upon reasonable notice and at the sole cost and expense of the investigating Party; and (y)  nothing in this Agreement shall require any Party to permit any inspection or disclose any information to any other Party that (i) would unreasonably interfere with the conduct of such Party&#8217;s business or result in damage to property (other than immaterial damage), except with such other Party&#8217;s prior written consent (which may be withheld or denied at its sole discretion), (ii) would cause a violation of any Law, privacy policy or any confidentiality obligations and similar restrictions that may be applicable to such information, or (iii) would jeopardize the attorney-client privilege or other disclosure privilege or protection to such Party; </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that the Party that would otherwise be required to disclose information to the other shall take any and all reasonable action necessary to permit such disclosure without such loss of privilege or violation of agreement, policy, Law or other restriction, including through the use of commercially reasonable efforts to obtain any required consent or waiver to the disclosure of such information from any third party and through the implementation of appropriate and mutually agreeable &#8220;clean room&#8221; or other similar procedures designed to limit any such adverse effect of sharing such information by each Party). Notwithstanding anything in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.8</span> to the contrary, (but without limiting the Company&#8217;s obligations under this Agreement, including <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4)</span>, the Company and SpinCo shall not be required to provide access to, or make any disclosure with respect to, any information of or relating to the Company, any of its Affiliates or any of their respective businesses, other than information relating to the SpinCo Business, the SpinCo Entities, the SpinCo Assets or the SpinCo Liabilities. All requests for such access to any Party shall be made to such Party or its designated Representative.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The Parties hereby agree that the provisions of the Confidentiality Agreement shall apply to all information and material furnished by any Party or its Representatives thereunder and hereunder. The Confidentiality Agreement shall survive any termination of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.9</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exclusivity</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The Company shall immediately cease, and shall cause its Subsidiaries and shall use reasonable best efforts to cause its Representatives to immediately cease, any discussions or negotiations with any Person (other than Parent or its Affiliates) that may be ongoing with respect to a SpinCo Proposal, or any inquiry, proposal or offer that would reasonably be expected to lead to a SpinCo Proposal, and shall promptly request that each Person that has been provided with any confidential information in connection with any SpinCo Proposal prior to the date of this Agreement promptly return or destroy such information, including promptly terminating any access by any Person to any physical or electronic data room relating to any SpinCo Proposal (as defined below). From the date hereof until the earlier to occur of (a) the termination of this Agreement pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article IX</span> and (b) the Effective Time, the Company shall not, and shall cause its Subsidiaries and shall use reasonable best efforts to cause its Representatives not to: (i) solicit, initiate, knowingly encourage or knowingly facilitate (including by way of furnishing information that has not been previously publicly disseminated) any proposal from or on behalf of a third party relating to, directly or indirectly, any acquisition (whether by merger, purchase of Interests, purchase of assets or otherwise), exclusive license, joint venture, partnership, recapitalization, liquidation, dissolution or other transaction involving any portion of the business or assets of the Company and its Subsidiaries that, individually or in the aggregate, constitutes 15% or more of the net revenues, net income or assets of the SpinCo Business (taken as a whole) (any of the foregoing, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Proposal</span>&#8221;), or any inquiry, proposal or offer which would reasonably be expected to lead to a SpinCo Proposal, (ii) engage in any discussions or negotiations regarding, or furnish to any Person any nonpublic information relating to the SpinCo Business, SpinCo Assets or SpinCo Entities in connection with, any SpinCo Proposal or any inquiry, proposal, effort or attempt related to or that would reasonably be expected to lead to, a SpinCo Proposal, (iii) adopt, approve or recommend, or publicly propose to adopt, approve or recommend, any SpinCo Proposal or (iv) approve or authorize, or cause or permit the Company or any Company Subsidiary to enter into, any merger agreement, acquisition agreement, reorganization agreement, letter of intent, memorandum of </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">understanding, agreement in principle, option agreement, joint venture agreement, partnership agreement or similar agreement or document relating to, or providing for, any SpinCo Proposal; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that nothing in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.9</span> shall limit the Company&#8217;s ability to pursue or engage in any transaction relating to substantially all of the business of the Company and its Subsidiaries, taken as a whole (as opposed to solely the SpinCo Business), so long as such transaction would not prevent or materially impair or materially delay the Company&#8217;s ability to comply with its obligations hereunder and under the Separation and Distribution Agreement or to consummate the Transactions; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</span>, that the foregoing shall not affect any of the obligations of the Company and SpinCo or the SpinCo Entities under this Agreement or any other Transaction Document.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Notwithstanding the terms of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.9(a)</span>, at any time prior to the earlier of (i) 180 days after the date of this Agreement or (ii) the Parent Registration Statement being declared effective by the SEC, the Company may: (x) furnish information in response to a request therefor (including nonpublic information regarding the Company or any of its Subsidiaries) to any Person or its Representatives who makes an unsolicited proposal to acquire all or at least seventy-five percent (75%) of the voting securities of the Company or at least seventy-five (75%) of the assets of the Company and its Subsidiaries, taken as a whole, that is conditioned on the termination of this Agreement (any such proposal, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Acquisition Proposal</span>&#8221;), in each case, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided,</span> that prior to furnishing any such information, the Person making such Company Acquisition Proposal enters into a confidentiality agreement with the Company at least as restrictive as the Confidentiality Agreement; and (y) engage or participate in any discussions or negotiations with any Person regarding such Company Acquisition Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>The Company shall promptly (and, in any event, within two (2) Business Days) give notice to Parent if any Company Acquisition Proposal is received by the Company, setting forth in such notice the material terms and conditions of any such proposals or offers. Parent shall keep such information confidential pursuant to the terms of the Confidentiality Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Notwithstanding anything to the contrary set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.9</span>, at any time prior to the earlier of (i) 180 days after the date of this Agreement or (ii) the Parent Registration Statement being declared effective by the SEC, the Company may elect to terminate this Agreement pursuant to and subject to the terms of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1(i)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.3</span> in order to enter into a definitive agreement with respect to a Company Acquisition Proposal; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that, prior to entering into any such definitive agreement with respect to a Company Acquisition Proposal, (x) the Company must have delivered notice to the Parent of its intention to enter into such definitive agreement at least five (5) Business Days prior to the taking of such action by the Company and (y) during such five (5) Business-Day period and prior to entering into such definitive agreement, if requested by Parent, the Company shall negotiate in good faith with Parent regarding any revisions or adjustments proposed by Parent to the terms and conditions of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Parent shall immediately cease and shall use reasonable best efforts to cause its Representatives to immediately cease, any discussions or negotiations with any Person (other than the Company or its Affiliates) that may be ongoing with respect to a Parent Business Combination Proposal, or any inquiry, proposal or offer that would reasonably be expected to lead to a Parent Business Combination Proposal. From the date hereof until the earlier to occur of (i) the termination of this Agreement pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article IX</span> and (ii) the Effective Time, Parent shall not and shall use reasonable best efforts to cause its Representatives not to: (w) solicit, initiate, knowingly encourage or knowingly facilitate (including by way of furnishing information that has not been previously publicly disseminated) any proposal from or on behalf of a third party relating to, directly or indirectly, any Business Combination, or any inquiry, proposal or offer which would reasonably be expected to lead to a Parent Business Combination Proposal, (x) engage in any discussions or negotiations regarding, or exchange with any Person any nonpublic information in connection with, any Parent Business Combination Proposal or any inquiry, proposal, effort or attempt related to or that would reasonably be expected to lead to, a Parent Business Combination Proposal, (y) adopt, approve or recommend, or publicly propose to adopt, approve or recommend, any Parent Business Combination Proposal or (z) approve or authorize, or cause or permit Parent to enter into, any merger agreement, acquisition agreement, reorganization agreement, letter of intent, memorandum of understanding, agreement in principle, option agreement, joint venture agreement, partnership agreement or similar agreement or document relating to, or providing for, any Parent Business Combination Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_10"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.10</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Public Announcements</span>. Except (a) as otherwise expressly contemplated by this Agreement, (b) in connection with any press release, public statement or filing to be issued or made by Parent with respect to any Modification in Recommendation, and (c) for the separate or joint press releases to be issued by the Parties in the forms agreed by the Parties (or any public statement or disclosure that contains or reflects only such information previously disclosed in press releases or other public disclosures made in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.10</span>), neither Parent nor the Company will, and each of Parent and the Company will cause its Subsidiaries not to, issue any press release or otherwise make any public statements or disclosure with respect to the Transactions without the prior written consent of the other Party. Notwithstanding the foregoing, to the extent such disclosure is required by </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">applicable Law or the rules of any stock exchange, the Party seeking to make such disclosure will promptly notify the other Party thereof and the Party making such statement will use efforts reasonable under the circumstances to consult in good faith with the other Party thereto prior to making such disclosure in order to allow a mutually agreeable release or announcement to be issued. Notwithstanding the foregoing, any Party may make statements that are consistent with previous public releases made by such Party in compliance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.10</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_11"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.11</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Defense of Litigation</span>. Parent and the Company shall provide the other Party prompt notice in writing of any Action brought by any shareholder or purported shareholder of such Party against it, any of its Subsidiaries or any of their respective directors and officers (including, with respect to the Company, SpinCo) relating to this Agreement, the Transactions, the Transaction Documents and any of the matters contemplated hereby or thereby (collectively, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transaction Litigation</span>&#8221;), and shall keep the other Party informed on a reasonably current basis with respect to the status thereof and consider any comments or suggestions made by the other Party with respect to the strategy therefor; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that prior to the Effective Time, no Party shall compromise, settle, come to an arrangement regarding or agree to compromise, settle or come to an arrangement regarding any Action arising or resulting from the Transactions or consent to the same, without the prior written consent of the other Party to the extent (a) such Action includes the other Party or any of its Subsidiaries, directors or officers as named defendants or (b) such compromise, settlement or arrangement would reasonably be expected to prevent, materially impair, materially delay or otherwise have a material adverse effect on the ability of the Parties to perform their respective obligations hereunder, or to consummate the Transactions in a timely manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_12"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.12</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 16 Matters</span>. Prior to the Effective Time, each of Parent, the Company and SpinCo shall take all such steps as may be required (to the extent permitted by applicable Law) to cause any dispositions of SpinCo Common Stock (including derivative securities with respect to SpinCo Common Stock) or acquisitions of Parent Common Stock or Domesticated Parent Stock resulting from the Transactions, including the Distribution, directly or indirectly, by each individual, if any, who is subject to Section 16(a) of the Exchange Act with respect to Parent or SpinCo, as applicable, as an officer or director thereof to be exempt under Rule 16b-3 promulgated under the Exchange Act, such steps to be taken in accordance with (and to the extent permitted by) applicable SEC rules and regulations and interpretations of the SEC staff.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_13"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.13</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Control of Other Party&#8217;s Business</span>. Nothing contained in this Agreement shall give the Company or SpinCo, directly or indirectly, the right to control or direct Parent&#8217;s operations prior to the Effective Time. Nothing contained in this Agreement shall give Parent, directly or indirectly, the right to control or direct the operations of the Company, including the SpinCo Business, prior to the Effective Time. Prior to the Effective Time, each of the Company, SpinCo and Parent shall exercise, consistent with the terms and conditions of this Agreement, complete control and supervision over its respective operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_14"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.14</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Share Issuance</span>. Prior to the Effective Time, SpinCo will take all actions necessary to authorize the issuance of a number of, or stock split of, shares of SpinCo Common Stock such that the total number of shares of SpinCo Common Stock outstanding immediately prior to the Effective Time will equal the number of shares of Company Common Stock entitled to receive the Distribution outstanding immediately prior to the Effective Time in accordance with the terms of the Separation and Distribution Agreement. Each of the Company and SpinCo shall effect such amendments, filings or other actions with respect to its respective Governing Documents as are necessary to effect the Distribution in accordance with the terms of this Agreement and the Separation and Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_15"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.15</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Domestication</span>. Subject to receipt of the Parent Shareholder Approval, no later than the date that is one day prior to the Effective Time, Parent shall cause the Domestication to become effective, including by (a) filing with the Secretary of State of the State of Delaware a Certificate of Domestication with respect to the Domestication, in form and substance reasonably acceptable to Parent and the Company, together with the Parent Charter substantially in the form attached as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit G</span> hereto (with such changes as may be agreed in writing by Parent and the Company, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Charter</span>&#8221;), in each case, in accordance with the provisions thereof and applicable Law, (b) completing, making and procuring all those filings required to be made with the Cayman Registrar in connection with the Domestication and (c) obtaining a certificate of de-registration from the Cayman Registrar. In accordance with applicable Law, the Domestication shall provide that at the effective time of the Domestication, by virtue of the Domestication, and without any action on the part of any shareholder of Parent, (i) each then issued and outstanding share of Parent Class A Common Stock shall convert automatically, on a one-for-one basis, into a share of Domesticated Parent Common Stock; (ii) each then issued and outstanding share of Parent Class B Common Stock shall convert automatically, on a one-for-one basis, into a share of Domesticated Parent Common Stock; (iii) each then issued and outstanding Parent Warrant shall convert automatically into a Domesticated Parent Warrant, pursuant to the Warrant Agreement; (iv) each then issued and outstanding Parent Unit shall separate and convert automatically into one share of Domesticated Parent Common Stock and one-third of one Domesticated Parent Warrant; </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">and (v) Parent&#8217;s bylaws from and after the effective time of the Domestication shall be substantially in the form attached as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit H</span> hereto (with such changes as may be agreed in writing by Parent and the Company, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Bylaws</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_16"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.16</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transaction Documents</span>. Parent shall, or shall cause its applicable Subsidiaries to, execute and deliver to the Company at or prior to the Closing each of the Transaction Documents to which it or any such Subsidiary is or will be a party at the Effective Time. The Company shall, or shall cause its applicable Subsidiaries to, execute and deliver to Parent at or prior to the Closing each of the Transaction Documents to which it or any such Subsidiary is or will be a party at the Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_17"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.17</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NASDAQ Listing</span>. From the date hereof through the Effective Time, Parent shall use its reasonable best efforts to maintain the listing of the Parent Class A Common Stock on NASDAQ, and shall prepare and submit to NASDAQ a listing application, if required under NASDAQ rules, covering the shares of Domesticated Parent Stock issuable in the Merger and the Domestication, and shall use its reasonable best efforts to cause the shares of Domesticated Parent Stock issuable pursuant to the Transactions to be approved for listing on the NASDAQ, subject to official notice of issuance, as promptly as practicable after the date of this Agreement, and in any event prior to the Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_18"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.18</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Takeover Statutes</span>. If any &#8220;fair price,&#8221; &#8220;moratorium,&#8221; &#8220;control share acquisition,&#8221; &#8220;business combination&#8221; or other form of antitakeover Law shall become applicable to the Transactions, Parent, Merger Sub and their respective boards of directors shall use all reasonable efforts to grant such approvals and take such actions as are reasonably necessary so that the Transactions may be consummated as promptly as practicable on the terms contemplated hereby and otherwise act to eliminate or minimize the effects of such statute or regulation on the Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_19"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.19</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Obligations of Merger Sub and SpinCo</span>. Parent shall take all action necessary to cause Merger Sub to perform its obligations and take any actions contemplated or required under this Agreement or the Transaction Documents or to consummate the Transactions, including the Merger, upon the terms and subject to the conditions set forth in this Agreement. The Company shall take all action necessary prior to the Effective Time to cause SpinCo to perform its obligations and to take any actions contemplated or required to be taken by SpinCo under this Agreement or the Transaction Documents to consummate the Transactions, including the Merger, upon the terms and subject to the conditions set forth in this Agreement and the Separation and Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_20"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.20</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances</span>. Except as otherwise expressly provided in this Agreement, the Parties shall, and shall cause their respective Affiliates to, use their respective commercially reasonable efforts to take, or cause to be taken, all appropriate action, to do, or cause to be done, and to assist and cooperate with the other Parties in doing, all things necessary, proper or advisable under this Agreement, any other Transaction Document or applicable Law as may be required to carry out the provisions of this Agreement or such other Transaction Document, as applicable, and to consummate and make effective the Merger and the other Transactions (other than with respect to the matters covered in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.6</span>, which shall be governed by the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.6</span> and any consents required in connection with the Separation, which shall solely be governed by the Separation and Distribution Agreement). In furtherance and not in limitation of the foregoing, each Party shall use commercially reasonable efforts to obtain all consents, approvals or waivers from third parties necessary in connection with the Merger (other than with respect to the matters covered in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.6</span>, which shall be governed by the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.6</span> and any consents required in connection with the Separation, which shall solely be governed by the Separation and Distribution Agreement); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that no Party or any of its Affiliates shall be required to commence any litigation, offer or pay any money, or otherwise grant any accommodation (financial or otherwise) to any third party with respect to the foregoing. The failure to obtain any consents, approvals or waivers from third parties shall not in and of itself constitute a breach of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_21"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.21</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sole Shareholder Approvals</span>. Immediately after the execution of this Agreement, (a) the Company will deliver the SpinCo Shareholder Approval to Parent, and (b) Parent, as the sole shareholder of Merger Sub, acting by written consent, will adopt this Agreement and approve the consummation of the Transactions, upon the terms and subject to the conditions stated herein and in accordance with the applicable provisions of the DGCL (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Sub Shareholder Approval</span>&#8221;) and deliver a copy of the Merger Sub Shareholder Approval to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_7_22"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.22</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Information</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#010000;">T</span>he Company shall, from the date hereof until the Closing Date, prepare and deliver to Parent, (i) as promptly as reasonably practicable and no later than seventy-five (75) calendar days after the end of any fiscal quarter, the unaudited combined balance sheet of the SpinCo Business as of the end of such fiscal quarter and the related unaudited combined statements of income, comprehensive income, equity and cash flows of the SpinCo Business for such fiscal quarter, together with </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">comparable financial statements for the corresponding periods of the prior fiscal years, in each case, to the extent required to be included or incorporated by reference in the Parent Registration Statement (including the Proxy Statement), SpinCo Registration Statement or Distribution Documents (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsequent Unaudited SpinCo Financial Statements</span>&#8221;) and (ii) if necessary, as promptly as reasonably practicable and no later than one-hundred (100) calendar days after the end of any fiscal year, the audited combined balance sheet of the SpinCo Business as of the end of such fiscal year of SpinCo and the related audited combined statements of income, comprehensive income, equity and cash flows of the SpinCo Business for such fiscal year, together with comparable financial statements for the prior fiscal years, in each case, to the extent required to be included or incorporated by reference in the Parent Registration Statement (including the Proxy Statement), SpinCo Registration Statement or Distribution Documents (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsequent Audited Annual SpinCo Financial Statements</span>&#8221; and, together with the Subsequent Unaudited SpinCo Financial Statements, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsequent Period SpinCo Financial Statements</span>&#8221;). The Subsequent SpinCo Financial Statements shall be prepared from the books and records of the Company and its Subsidiaries and in accordance with GAAP applied on a consistent basis throughout the periods involved (except as may otherwise be required under GAAP) and the applicable rules and regulations of the SEC, including the requirements of Regulation S-X. The Subsequent Unaudited SpinCo Financial Statements shall have been reviewed by the independent accountant for SpinCo in accordance with the procedures specified by the Public Company Accounting Oversight Board (United States) in AU Section 722 and each of the Subsequent Audited Annual SpinCo Financial Statements shall be accompanied by an audit report, without qualification or exception from the independent accountant for SpinCo. When delivered, the Subsequent Period SpinCo Financial Statements shall present fairly in all material respects the combined financial position and combined and consolidated results of operations of the SpinCo Business as of the dates and for the periods shown therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The Company agrees to use reasonable best efforts to provide Parent as promptly as practicable after the date of this Agreement, audited financial statements, including combined balance sheets as of December 31, 2021 and December 31, 2020 and combined statements of income and comprehensive income, equity and cash flows of the SpinCo Business for the fiscal years ended December 31, 2021, December 31, 2020 and December 31, 2019, in each case, prepared in accordance with GAAP and Regulation S-X and audited in accordance with the auditing standards of the PCAOB; provided, that such audited financial statements shall not be required to include a signed audit opinion, which signed audit opinion shall be delivered immediately prior to the initial filing of the SpinCo Registration Statement with the SEC. During the Interim Period and from and after the Closing, the Company shall use reasonable best efforts, in connection with the filing of the SpinCo Registration Statement and any other applicable SEC filings, to (i) cooperate with Parent to prepare pro forma financial statements that comply with the rules and regulations of the SEC to the extent required for SEC filings, including the requirements of Regulation S-X, and (ii) provide and make reasonably available upon reasonable notice, the senior management employees of the Company to discuss the materials prepared and delivered pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.22(b)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_ARTICLE_VIII"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="color:#010000;">ARTICLE VIII</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">CONDITIONS TO THE MERGER</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_8_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 8.1</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions to the Obligations of SpinCo, the Company, Parent and Merger Sub to Effect the Merger</span>. The respective obligations of each Party to consummate the Merger shall be subject to the fulfillment (or, to the extent permitted by applicable Law, waiver by the Company and Parent) at or prior to the Closing of the following conditions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>(i) the waiting period (or any extension thereof) under the HSR Act with respect to the Merger shall have expired or been terminated pursuant to the HSR Act; (ii) all other Requisite Regulatory Approvals shall have been obtained and shall remain in full force and effect and all statutory waiting periods (and any extensions thereof) in respect thereof shall have expired or been terminated; and (iii) there shall not be in effect any voluntary agreement between the Parent or the Company and any Governmental Authority pursuant to which Parent or the Company has agreed not to consummate the Transactions for any period of time;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>the Internal Reorganization, the Contribution and the Distribution and the other transactions contemplated by the Separation and Distribution Agreement shall have been consummated in accordance with the Separation and Distribution Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>(i) each of the Parent Registration Statement and the SpinCo Registration Statement shall have become effective in accordance with the Securities Act or the Exchange Act, as applicable, and neither shall be the subject of any stop order by the SEC or actual or threatened proceedings by a Governmental Authority seeking such a stop order; and (ii) the applicable notice </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">periods required by applicable stock exchange rules or securities Laws in connection with the Distribution, if any, shall have expired;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>the Parent Shareholder Approval shall have been obtained;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>no Governmental Authority of competent jurisdiction shall have enacted, issued or granted any Law (whether temporary, preliminary or permanent), in each case that is in effect and which has the effect of restraining, enjoining or prohibiting the consummation of the Transactions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>Parent shall have at least $5,000,001 of net tangible assets (as determined in accordance with Rule 3a51-1(g)(1) of the Exchange Act); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>the shares of Domesticated Parent Stock issuable pursuant to the Transactions shall have been approved for listing on NASDAQ, subject to official notice of issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_8_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 8.2</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Conditions to the Obligations of the Company and SpinCo</span>. The obligation of the Company and SpinCo to consummate the Merger shall be subject to the fulfillment (or, to the extent permitted by applicable Law, waiver by the Company) at or prior to the Closing of the following additional conditions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Parent and Merger Sub shall each have performed and complied in all material respects with the obligations, covenants and agreements required by this Agreement to be performed or complied with by it at or prior to the Effective Time;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>all representations and warranties made by Parent and Merger Sub set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VI</span> (other than the representations and warranties referenced in the second and third sentences of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.2(b)</span>), without giving effect to materiality, Parent Material Adverse Effect or similar qualifications, shall be true and correct in all respects at and as of the date hereof and as of the Closing Date as though such representations and warranties were made at and as of the Closing Date (except in the case of any representation or warranty that by its terms addresses matters only as of another specified date, which shall be so true and correct only as of such specified date), except to the extent the failure of such representations and warranties to be true and correct (without giving effect to materiality, Parent Material Adverse Effect or similar qualifications) would not have, individually or in the aggregate, a Parent Material Adverse Effect. The representations and warranties made by Parent set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1(a)</span>, the first and third sentences of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1(b)</span>, the entirety of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.2</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.3</span> (other than the first two sentences of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.3(a)</span> and the second sentence of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.3(b)</span>) and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.11</span> shall be true and correct in all material respects at and as of the date hereof and as of the Closing Date as though such representations and warranties were made at and as of the Closing Date (except in the case of any representation or warranty that by its terms addresses matters only as of another specified date, which shall be so true and correct only as of such specified date). The representations and warranties made by Parent set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.10(a)</span>, the first two (2) sentences of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.3(a)</span> and the second sentence of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.3(b)</span> shall be true and correct in all respects at and as of the date hereof and as of the Closing Date as though such representations and warranties were made at and as of the Closing Date (other than for <i style="font-style:italic;">de minimis </i>deviations in the case of the representations and warranties set forth in the first two (2) sentences of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.3(a)</span> and the second sentence of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.3(b)</span>, and except in the case of any representation or warranty that by its terms addresses matters only as of another specified date, which shall be so true and correct only as of such specified date);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Parent shall have delivered to the Company the certificate referenced in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3(b)(ii)</span> dated as of the Closing Date signed by an authorized officer of Parent certifying that each of the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1(f)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.2(a)</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(b)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(d)</span> have been satisfied;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Parent and Merger Sub shall have executed and delivered the applicable Transaction Documents, and to the extent applicable, performed and complied with the obligations, covenants and agreements thereunder required to be performed by them prior to the Effective Time in all material respects, and each such agreement shall be in full force and effect;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>the Domestication shall have been completed as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.15</span> and a time-stamped copy of the certificate issued by the Secretary of State of the State of Delaware in relation thereto shall have been delivered to the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>the PIPE Investment and the Redemption Backstop shall have been consummated in accordance with the terms of the A&amp;R Forward Purchase Agreement;</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>other than those Persons identified as continuing directors on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.2(g)</span> of the Company Disclosure Schedule, all members of the Parent Board and all executive officers of Parent shall have executed and delivered written resignations effective as of the Effective Time; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>The Company shall have received the Company Tax Opinions from LW and a copy of the Parent Merger Tax Opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_8_3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 8.3</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Conditions to the Obligations of Parent and Merger Sub</span>. The obligation of Parent and Merger Sub to consummate the Merger shall be subject to the fulfillment (or, to the extent permitted by applicable Law, waiver by Parent) at or prior to the Closing of the following additional conditions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Each of SpinCo and the Company shall each have performed and complied in all material respects with the obligations, covenants and agreements required by this Agreement to be performed or complied with by it at or prior to the Effective Time;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>all representations and warranties made by the Company set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article IV</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> (other than the representations and warranties referenced in the second and third sentences of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.3(b)</span>), without giving effect to materiality, &#8220;Company Material Adverse Effect&#8221;, &#8220;SpinCo Material Adverse Effect&#8221; or similar qualifications, shall be true and correct in all respects at and as of the date hereof and as of the Closing Date as though such representations and warranties were made at and as of the Closing Date (except in the case of any representation or warranty that by its terms addresses matters only as of another specified date, which shall be so true and correct only as of such specified date), except to the extent the failure of such representations and warranties to be true and correct (without giving effect to materiality, &#8220;Company Material Adverse Effect&#8221;, &#8220;SpinCo Material Adverse Effect&#8221; or similar qualifications) would not have, individually or in the aggregate, a SpinCo Material Adverse Effect, solely with respect to the representations and warranties set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span>, or Company Material Adverse Effect, solely with respect to the representations and warranties set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article IV</span>. The representations and warranties made by the Company set forth in the first three (3) sentences of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.1</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.2</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.6</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.7</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1</span>, the entirety of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.2</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3</span> (other than the first sentence of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3(a)</span> and the entirety of each of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3(b)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3(c)</span>), <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.5</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.22</span> shall be true and correct in all material respects at and as of the date hereof and as of the Closing Date as though such representations and warranties were made at and as of the Closing Date (except in the case of any representation or warranty that by its terms addresses matters only as of another specified date, which shall be so true and correct only as of such specified date). The representations and warranties made by the Company set forth in the first sentence of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3(a)</span> and the entirety of each of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3(c)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.24</span> shall be true and correct in all respects at and as of the date hereof and as of the Closing Date as though such representations and warranties were made at and as of the Closing Date (other than for <i style="font-style:italic;">de minimis </i>deviations in the case of the representations and warranties set forth in the first sentence of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3(a)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3(c)</span>, and except in the case of other than in the case of any representation or warranty that by its terms addresses matters only as of another specified date, which shall be so true and correct only as of such specified date);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>No SpinCo Material Adverse Effect shall have occurred between the date of this Agreement and the Closing Date that is continuing;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>The Company shall have delivered to Parent the certificate referenced in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3(a)(i)</span> dated as of the Closing Date signed by an authorized officer of the Company certifying that each of the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1(b)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.3(a)</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(b)</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(c)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(e)</span> have been satisfied;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>SpinCo and the Company (or such other applicable Subsidiary of the Company) shall have executed and delivered each of the applicable Transaction Documents, and to the extent applicable, performed and complied with the obligations, covenants and agreements to be performed thereunder by them prior to the Effective Time in all material respects, and each such agreement shall be in full force and effect;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>Parent shall have received the Parent Merger Tax Opinion from Weil and a copy of the Company Tax Opinions; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>The Company shall have, or shall have caused SpinCo to have, delivered to Parent the certificate and other documents described in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3(a)(iii)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="A_ARTICLE_IX"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="color:#010000;">ARTICLE IX</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">TERMINATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_9_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.1</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</span>. This Agreement may be terminated and the Transactions may be abandoned at any time prior to the Effective Time, whether before or after the Parent Shareholder Approval:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>by mutual written agreement of the Company and Parent;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>by the Company or Parent, if the Closing shall not have occurred on or prior to the date that is nine (9) months after the date of this Agreement (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Outside Date</span>&#8221;); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that the right to terminate this Agreement pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1(b)</span> shall not be available to any Party whose action or failure to comply with its obligations under this Agreement or any of the other Transaction Documents has been the primary cause of, or has primarily resulted in, the failure of the Closing to occur on or prior to such date;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>by the Company or Parent, if any Law shall have been promulgated, entered, enforced, enacted or issued and in effect or shall have been deemed to be applicable to the Merger or the other Transactions, including the Internal Reorganization and the Distribution, by any Governmental Authority of competent jurisdiction which permanently prohibits, restrains or makes illegal the consummation of the Merger or the other Transactions, and such Law shall have become final and non-appealable; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that the right to terminate this Agreement pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1(c)</span> shall not be available to any Party whose action or failure to perform any of its obligations under this Agreement or any of the Transaction Documents is the primary cause of, or primarily resulted in, the enactment or issuance of any such Law;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>by Parent upon written notice to the Company, in the event of a breach of any representation, warranty, covenant or agreement on the part of the Company or SpinCo, such that the conditions specified in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.3(a)</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.3(b)</span> would not be satisfied at the Closing, and which, (i) with respect to any such breach that is capable of being cured, is not cured by the Company or SpinCo by the earlier of: (x) thirty (30) days after receipt of written notice thereof; or (y) the Outside Date, or (ii) is incapable of being cured prior to the Outside Date; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that Parent shall not have the right to terminate this Agreement pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1(d)</span> if Parent or Merger Sub is then in breach of any of its representations, warranties, covenants or agreements set forth in this Agreement to the extent such breach or breaches would give rise to the failure of a condition set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.2(a)</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.2(b)</span>;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>by the Company upon written notice to Parent, in the event of a breach of any representation, warranty, covenant or agreement contained in this Agreement on the part of Parent or Merger Sub such that the conditions specified in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.2(a)</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.2(b)</span> would not be satisfied at the Closing, and which, (i) with respect to any such breach that is capable of being cured, is not cured by Parent by the earlier of: (x) thirty (30) days after receipt of written notice thereof; or (y) the Outside Date, or (ii) is incapable of being cured prior to the Outside Date; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that the Company shall not have the right to terminate this Agreement pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1(e)</span> if the Company or SpinCo is then in breach of any of its representations, warranties, covenants or agreements set forth in this Agreement to the extent such breach or breaches would give rise to the failure of a condition set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.3(a)</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.3(b)</span>;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>by the Company or Parent, if the Parent Shareholder Approval shall not have been obtained upon a vote taken thereon at the Parent Shareholders Meeting, duly convened therefor, or at any adjournment or postponement thereof; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that the right to terminate this Agreement pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1(f)</span> shall not be available to Parent if Parent&#8217;s actions or failure to perform any of its obligations under this Agreement is the primary cause of, or primarily resulted in, the failure to obtain such approval;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>by the Company, if the Parent Board shall have effected a Parent Adverse Recommendation Change prior to the Parent Shareholders Meeting;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>by the Company, if all of the conditions to Closing set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VIII</span> have been met (other than those conditions that by their terms are to be satisfied at Closing) other than the condition specified in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.2(f)</span>; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="color:#010000;"> </span>by the Company, prior to the earlier of (i) 180 days after the date of this Agreement or (ii) the Parent Registration Statement being declared effective by the SEC, in order to accept a Company Acquisition Proposal and enter into, immediately following such termination, a binding and definitive written Contract with respect to such Company Acquisition Proposal; </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that (x) the Company has materially complied with its covenants and agreements under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.9,</span> (y) the Company pays the Termination Fee to Parent in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.3(a)</span> and (z) the Company pays the FPA Termination Fee to Sponsor pursuant to the terms of the A&amp;R Forward Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_9_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.2</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Termination</span>. In the event of termination of this Agreement pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1</span>, this Agreement shall forthwith become null and void and have no effect, without any Liability on the part of any Party; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that no such termination shall relieve any Party of any liability or damages resulting from Actual Fraud or Willful Breach; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</span>, that <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.8(b)</span>, this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.2</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.4</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article X</span> hereof shall survive any termination of this Agreement. The Confidentiality Agreement shall not be affected by any termination of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_9_3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.3</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Fee</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>In the event that this Agreement is terminated pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1(i)</span>, concurrently with such termination, the Company shall be obligated to pay Parent or its designee(s) a termination fee of (i) if terminated within 60 days of the date of this Agreement, $40,000,000, (ii) if terminated between 61 and 120 days after the date of this Agreement, $50,000,000, and (iii) if terminated between 121 and 180 days after the date of this Agreement, $70,000,000 (each such amount, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Fee</span>&#8221;), by wire transfer of immediately available funds to an account designated by Parent in writing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>In addition to payment of the Termination Fee, in the event that this Agreement is terminated pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1(i)</span>, the Company also shall pay the Parent Expenses (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Expenses Reimbursement</span>&#8221;) by wire transfer of immediately available funds to an account designated by Parent in writing no later than two (2) Business Days after the date on which Parent delivers to the Company a written invoice for the Parent Expenses. As used herein, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Expenses</span>&#8221; means the amount of all reasonable and documented out-of-pocket fees and expenses, but not to exceed $7,500,000, incurred or paid by Parent and its Affiliates in connection with this Agreement and the Transactions, including fees and expenses of law firms, accounting firms, financial advisors, outside experts and consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Notwithstanding anything to the contrary set forth in this Agreement, except in the case of Actual Fraud or Willful Breach, if the Termination Fee and the Parent Expenses Reimbursement are paid pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.3(a)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.3(b)</span>, respectively, such payment(s) shall constitute the sole and exclusive remedy of Parent, Merger Sub, any of their respective Subsidiaries or any of their respective former, current or future general or limited partners, shareholders, Representatives or assignees against the Company, SpinCo, any of their respective Subsidiaries and any of their respective former, current or future general or limited partners, shareholders, Representatives or assignees (together with the Company, collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Related Parties</span>&#8221;) for all losses and damages suffered as a result of the failure of the Transactions to be consummated or for a breach or failure to perform hereunder or otherwise, and none of the Company Related Parties shall have any further liability or obligation relating to or arising out of this Agreement or the Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>If the Company fails to pay promptly any amount due under this Section 9.3, as applicable, and in order to obtain such payment, the Parent commences an Action that results in a judgment against the Company for any amount owed thereby under this Section 9.3, as applicable, the Company shall reimburse Parent for its reasonable and documented costs and expenses (including reasonable and documented attorneys&#8217; fees) in connection with such Action, together with interest on such amount at a rate equal to (x) the prime rate as published in <i style="font-style:italic;">The Wall Street Journal</i> in effect on the date such payment was required to be made through the date such payment was actually received, plus (y) five percent (5%).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Each of the Parties acknowledges that (i) the agreements contained in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.3</span> are an integral part of the Transactions, (ii) without these agreements, the Parties would not enter into this Agreement and (iii) the Termination Fee does not constitute a penalty, but rather is liquidated damages in a reasonable amount that will compensate Parent for the efforts and resources expended and opportunities foregone while negotiating this Agreement and in reliance on this Agreement and on the expectation of the consummation of the Transactions, which amount would otherwise be impossible to calculate with precision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_9_4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.4</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fees and Expenses</span>. Except as otherwise provided in the Separation and Distribution Agreement or this Agreement, including this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.4</span>, and except for filing fees payable to any Governmental Authority in connection with the approvals required under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.5(b)</span>, which shall be borne equally by the Company and Parent in the event that this Agreement is terminated in accordance with its terms and by SpinCo in the event that the Closing occurs, all fees and expenses incurred by the Parties shall be borne solely by the Party that has incurred such fees and expenses, whether or not the Merger is consummated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="A_ARTICLE_X"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="color:#010000;">ARTICLE X</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">MISCELLANEOUS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_10_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 10.1</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trust Account Waiver</span>. The Company acknowledges that Parent is a blank check company with the powers and privileges to effect a Business Combination. The Company further acknowledges that, as described in the prospectus dated August 9, 2021 (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prospectus</span>&#8221;) available at www.sec.gov, substantially all of Parent&#8217;s assets consist of the cash proceeds of Parent&#8217;s initial public offering and private placements of its securities and substantially all of those proceeds have been deposited in a trust account for the benefit of Parent, certain of its public stockholders and the underwriters of Parent&#8217;s initial public offering (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trust Account</span>&#8221;). The Company acknowledges that it has been advised by Parent that, except with respect to interest earned on the funds held in the Trust Account that may be released to Parent to pay its franchise Tax, income Tax and similar obligations, the Trust Agreement provides that cash in the Trust Account may be disbursed only (i) if Parent completes one or more transactions that constitute a Business Combination, then to those Persons and in such amounts as described in the Prospectus; (ii) if Parent fails to complete a Business Combination within the allotted time period and liquidates, subject to the terms of the Trust Agreement, to Parent in limited amounts to permit Parent to pay the costs and expenses of its liquidation and dissolution, and then to Parent&#8217;s public stockholders; and (iii) if Parent holds a shareholder vote to amend Parent&#8217;s amended and restated memorandum and articles of association to modify the substance or timing of the obligation to redeem 100% of the shares of Parent Common Stock if Parent fails to complete a Business Combination within the allotted time period, then for the redemption of any shares of Parent Common Stock properly tendered in connection with such vote. For and in consideration of Parent entering into this Agreement, the receipt and sufficiency of which are hereby acknowledged, the Company hereby irrevocably waives any right, title, interest or claim of any kind it has or may have in the future in or to any monies in the Trust Account (including any distributions therefrom) and agrees not to seek recourse against the Trust Account or any funds distributed therefrom as a result of, or arising out of, this Agreement and any negotiations, Contracts or agreements with Parent; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, (x) that nothing herein shall serve to limit or prohibit the Company&#8217;s right to pursue a claim against Parent for legal relief against monies or other assets held outside the Trust Account, for specific performance or other equitable relief in connection with the consummation of the Transactions (including a claim for Parent to specifically perform its obligations under this Agreement and cause the disbursement of the balance of the cash remaining in the Trust Account (after giving effect to the Parent Share Redemptions) to Parent in accordance with the terms of this Agreement and the Trust Agreement) so long as such claim would not affect Parent&#8217;s ability to fulfill its obligation to effectuate the Parent Share Redemptions, and (y) nothing herein shall serve to limit or prohibit any claims the Company may have in the future against Parent&#8217;s assets or funds that are not held in the Trust Account (including any funds that have been released from the Trust Account to Parent and any assets that have been purchased or acquired with any such funds). The Company agrees and acknowledges that such irrevocable waiver is material to this Agreement and specifically relied upon by Parent to induce it to enter in this Agreement, and the Company further intends and understands such waiver to be valid, binding and enforceable under applicable Law. To the extent the Company commences any Action or proceeding based upon, in connection with, relating to or arising out of any matter relating to Parent, which proceeding seeks, in whole or in part, monetary relief against Parent, the Company hereby acknowledges and agrees that its sole remedy shall be against funds held outside of the Trust Account and that such claim shall not permit the Company (or any party claiming on the Company&#8217;s behalf or in lieu of the Company) to have any claim against the Trust Account (including any distributions therefrom) or any amounts contained therein. In the event that the Company commences any Action or proceeding based upon, in connection with, relating to or arising out of any matter relating to Parent, which proceeding seeks, in whole or in part, relief against the Trust Account (including any distributions therefrom) or the holders of Parent Common Stock, whether in the form of money damages or injunctive relief, the prevailing party shall be entitled to recover from the other party the associated legal fees and costs in connection with any such Action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_10_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 10.2</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Survival of Representations, Warranties and Agreements</span>. The obligations, covenants and agreements that by their terms are to be performed following the Closing pursuant to any Transaction Document, including the Separation and Distribution Agreement, or this Agreement shall survive the Effective Time in accordance with their terms and all other obligations, covenants and agreements herein and therein shall terminate and shall not survive the Closing. None of the representations or warranties in this Agreement or in any certificate or instrument delivered pursuant to this Agreement shall survive the Effective Time. The Confidentiality Agreement shall survive the execution and delivery of this Agreement and any termination of this Agreement, and the provisions of the Confidentiality Agreement shall apply to all information and material furnished by any Party or its Representatives thereunder or hereunder; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that, following the Effective Time, Parent shall have no obligations under the Confidentiality Agreement with respect to information related solely to the SpinCo Entities, the SpinCo Business or the SpinCo Assets, which information shall no longer be considered &#8220;Evaluation Material&#8221; for purposes thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="A_Section_10_3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 10.3</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law; Jurisdiction</span>. This Agreement, and all claims, disputes, controversies or causes of action (whether in contract, tort, equity or otherwise) that may be based upon, arise out of or relate to this Agreement (including any schedule or exhibit hereto) or the negotiation, execution or performance of this Agreement (including any claim, dispute, controversy or cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this Agreement or as an inducement to enter into this Agreement), shall be governed by and construed in accordance with the Laws of the State of Delaware, without regard to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that the Domestication shall be effected in accordance with both the DGCL and the CICA (as applicable), without giving effect to principles or rules of conflict of laws to the extent such principles or rules would require or permit the application of Laws of another jurisdiction. Each of the Parties agrees that any Action related to this agreement shall be brought exclusively in the Court of Chancery of the State of Delaware or, if under applicable Law, exclusive jurisdiction over such matter is vested in the federal courts, any federal court in the State of Delaware and any appellate court from any thereof (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chosen Courts</span>&#8221;). By executing and delivering this Agreement, each of the Parties irrevocably: (i) accepts generally and unconditionally submits to the exclusive jurisdiction of the Chosen Courts for any Action relating to this Agreement, including any Action brought for any remedy contemplated by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.9</span>; (ii) waives any objections which such party may now or hereafter have to the laying of venue of any such Action contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.3</span> and hereby further irrevocably waives and agrees not to plead or claim that any such Action has been brought in an inconvenient forum; (iii) agrees that it will not attempt to deny or defeat the personal jurisdiction of the Chosen Courts by motion or other request for leave from any such court; (iv) agrees that it will not bring any Action contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.3</span> in any court other than the Chosen Courts; (v) agrees that service of all process, including the summons and complaint, in any Action may be made by registered or certified mail, return receipt requested, to such party at their respective addresses provided in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.4</span> or in any other manner permitted by Law; and (vi) agrees that service as provided in the preceding clause (v) is sufficient to confer personal jurisdiction over such party in the Action, and otherwise constitutes effective and binding service in every respect. Each of the parties hereto agrees that a final judgment in any Action in a Chosen Court as provided above may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law, and each party further agrees to the non-exclusive jurisdiction of the Chosen Courts for the enforcement or execution of any such judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_10_4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 10.4</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</span>. All notices and other communications among the Parties shall be in writing and shall be deemed to have been duly given (a) when delivered in person, (b) when delivered after posting in the national mail having been sent registered or certified mail return receipt requested, postage prepaid, (c) when delivered by FedEx or other internationally recognized overnight delivery service or (d) when delivered by facsimile (solely if receipt is confirmed) or email (so long as the sender of such email does not receive an automatic reply from the recipient&#8217;s email server indicating that the recipient did not receive such email), addressed as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">if to the Company or SpinCo, to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">Ligand Pharmaceuticals Incorporated</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">with a copy (which shall not constitute notice) to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">Latham &amp; Watkins, LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">12670 High Bluff Dr.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">San Diego, CA 92130</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">Attention:&#160;&#160;&#160;&#160;Matthew Bush</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 72pt;">&#160;&#160;&#160;&#160;&#160;&#160;Scott Shean</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">Email:matt.&#160;&#160;bush@lw.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 72pt;">&#160;&#160;&#160;&#160;&#160;&#160;scott.shean@lw.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">if to Parent, to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">Avista Public Acquisition Corp. II</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">with a copy (which shall not constitute notice) to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">Weil, Gotshal &amp; Manges LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">767 5<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Avenue</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">New York, NY 10153</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">Attention:&#160;&#160;&#160;&#160;Jaclyn L. Cohen, Esq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 72pt;">&#160;&#160;&#160;&#160;&#160;&#160;Raymond O. Gietz, Esq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">Email:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;jackie.cohen@weil.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 72pt;">&#160;&#160;&#160;&#160;&#160;&#160;raymond.gietz@weil.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">or to such other address or addresses as the Parties may from time to time designate in writing by like notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_10_5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 10.5</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings</span>. The headings contained in this Agreement are inserted for convenience only and shall not be considered in interpreting or construing any of the provisions contained in this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_10_6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 10.6</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</span>. This Agreement (including the Exhibits and Schedules hereto), the Confidentiality Agreement and the Transaction Documents constitute the entire agreement between the Parties with respect to the subject matter hereof and supersede all prior agreements and understandings between the Parties with respect to such subject matter; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that for the sake of clarity, it is understood that this Agreement shall not supersede the terms and provisions of the Confidentiality Agreement, which shall survive and remain in effect until expiration or termination thereof in accordance with its respective terms (subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.2</span>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_10_7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 10.7</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments and Waivers</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Any Party may, at any time prior to the Closing, by action taken by its board of directors, or officers thereunto duly authorized, waive any of the terms or conditions of this Agreement or (without limiting <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.7(b)</span>) agree to an amendment or modification to this Agreement by an agreement in writing executed in the same manner (but not necessarily by the same Persons) as this Agreement. No waiver by any of the Parties of any breach hereunder shall be deemed to extend to any prior or subsequent breach hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence. No waiver by any of the Parties of any of the provisions hereof shall be effective unless explicitly set forth in writing and executed by the Party sought to be charged with such waiver.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>This Agreement may be amended or modified, in whole or in part, only by a duly authorized agreement in writing executed by the Parties in the same manner (but not necessarily by the same Persons) as this Agreement, and which makes reference to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_10_8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 10.8</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment; Parties in Interest; Non-Parties</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>No Party may assign its rights or delegate its duties under this Agreement without the prior written consent of the other Parties. Any attempted assignment or delegation in breach of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.8</span> shall be null and void. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective permitted successors and assigns. Nothing expressed or implied in this Agreement is intended or shall be construed to confer upon or give any Person, other than the Parties, any rights or remedies under or by reason of this Agreement, except as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.8(b)</span> (which is intended to be for the benefit of the Persons covered thereby and may be enforced by such Persons).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Notwithstanding anything to the contrary in this Agreement, it is hereby agreed and acknowledged that this Agreement may only be enforced against, and any claims of action that may be based upon, arise out of or relate to this Agreement or the negotiation, execution or performance of this Agreement may only be made against, the Parties hereto, and no former, current or future Affiliates, officers, directors, managers, employees, equityholders, lenders, financing sources, managers, members, partners, agents or representatives of any Party, in each case, who is not a Party to this Agreement, shall have any liability for any obligations of the Parties hereto or for any claim based on, in respect of, or by reason of, the Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_10_9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 10.9</span></span> <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specific Performance</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The Parties agree and acknowledge that the failure to perform under this Agreement will cause an actual, immediate and irreparable harm and injury and that the Parties would not have any adequate remedy at law in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. Accordingly, it is agreed that, (i) each of the Parties shall be entitled to an injunction or injunctions to prevent breaches or threatened breaches of this Agreement by any other Party and to specifically enforce the terms and provisions of this Agreement, and (ii) prior to the </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Closing or any termination of this Agreement in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1</span>, damages shall be awarded only in a case where a court of competent jurisdiction shall have determined that, notwithstanding the Parties&#8217; intention for specific performance to be the applicable remedy prior to termination or the Closing, such specific performance is not available or otherwise will not be granted as a remedy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The Parties further agree that (i) by seeking the remedies provided for in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.9</span>, a Party shall not in any respect waive its right to seek any other form of relief that may be available to a party under this Agreement, including monetary damages, subject to the terms hereof, (ii) nothing contained in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.9</span> shall require any Party to institute any proceeding for (or limit any Party&#8217;s right to institute any proceeding for) specific performance under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.9</span> before exercising any termination right under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1</span> (and pursuing damages after such termination), nor shall the commencement of any Action pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.9</span> or anything contained in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.9</span> restrict or limit any Party&#8217;s right to terminate this Agreement in accordance with the terms of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1</span> or to pursue any other remedies under this Agreement that may be available then or thereafter and (iii) no Person shall be required to obtain, furnish or post any bond or similar instrument in connection with or as a condition to obtaining any remedy referred to in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.9</span>, and each Party irrevocably waives any right it may have to require the obtaining, furnishing or posting of any such bond or similar instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>To the extent either party hereto brings any Action to enforce specifically the performance of the terms and provisions of this Agreement in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.9</span>, the Outside Date shall automatically be extended by (i) the amount of time during which such Action is pending, plus twenty (20) Business Days, or (ii) such other time period established by the court presiding over such Action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_10_10"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 10.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">WAIVER OF JURY TRIAL</span>. THE PARTIES HEREBY UNCONDITIONALLY AND IRREVOCABLY WAIVE THEIR RIGHT TO TRIAL BY JURY IN ANY JUDICIAL PROCEEDING IN ANY COURT RELATING TO ANY DISPUTE, CONTROVERSY OR CLAIM ARISING OUT OF, RELATING TO OR IN CONNECTION WITH THIS AGREEMENT OR ANY TRANSACTION DOCUMENT (INCLUDING ANY SCHEDULE OR EXHIBIT HERETO AND THERETO) OR THE BREACH, TERMINATION OR VALIDITY OF SUCH AGREEMENTS OR THE NEGOTIATION, EXECUTION OR PERFORMANCE OF SUCH AGREEMENTS. NO PARTY TO THIS AGREEMENT SHALL SEEK A JURY TRIAL IN ANY LAWSUIT, PROCEEDING, COUNTERCLAIM OR ANY OTHER LITIGATION PROCEDURE BASED UPON, OR ARISING OUT OF, THIS AGREEMENT OR ANY RELATED INSTRUMENTS. NO PARTY WILL SEEK TO CONSOLIDATE ANY SUCH ACTION IN WHICH A JURY TRIAL HAS BEEN WAIVED WITH ANY OTHER ACTION IN WHICH A JURY TRIAL CANNOT BE OR HAS NOT BEEN WAIVED. EACH PARTY TO THIS AGREEMENT CERTIFIES THAT IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT OR INSTRUMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS SET FORTH ABOVE IN THIS <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 10.10</span>. NO PARTY HAS IN ANY WAY AGREED WITH OR REPRESENTED TO ANY OTHER PARTY THAT THE PROVISIONS OF THIS <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 10.10</span> WILL NOT BE FULLY ENFORCED IN ALL INSTANCES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_10_11"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 10.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</span>. If any provision of this Agreement or any Transaction Document, or the application of any such provision to any Person or circumstance, shall be held invalid, illegal or unenforceable in any respect by a court of competent jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision hereof. The Parties further agree that if any provision contained herein is, to any extent, held invalid or unenforceable in any respect under the Laws governing this Agreement, they shall take any actions necessary to render the remaining provisions of this Agreement valid and enforceable to the fullest extent permitted by Law and, to the extent necessary, shall amend or otherwise modify this Agreement to replace any provision contained herein that is held invalid or unenforceable with a valid and enforceable provision giving effect to the intent of the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_10_12"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 10.12</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</span>. This Agreement may be executed in two or more counterparts (including by electronic or .pdf transmission), each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of any signature page by facsimile, electronic or .pdf transmission shall be binding to the same extent as an original signature page.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_10_13"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 10.13</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure Schedules</span>. The Company Disclosure Schedule, the SpinCo Disclosure Schedule and the Parent Disclosure Schedule (each, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure Schedule</span>&#8221; and, collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure Schedules</span>&#8221;) (including, in each case, any section thereof) referenced herein are a part of this Agreement as if fully set forth herein. All references herein to the Company Disclosure Schedule, SpinCo Disclosure Schedule and Parent Disclosure Schedule (including, in each case, any section thereof) shall be deemed references to such parts of this Agreement, unless the context shall otherwise require. Certain information set forth in the Disclosure Schedules is included solely for informational purposes and may not be required to be disclosed pursuant to this </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Agreement. The disclosure of any information in any Disclosure Schedule shall not be deemed to constitute in itself an acknowledgment that such information is required to be disclosed in connection with this Agreement, nor shall such information be deemed to establish a standard of materiality.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="A_Section_10_14"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 10.14</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conflicts and Privilege</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Parent, SpinCo and the Company, on behalf of their respective successors and assigns (in the case of Parent, including, after the Closing, each of the SpinCo Entities), hereby agree that, in the event a dispute with respect to this Agreement or the Transactions arises after the Closing between or among the Sponsor, Parent, the shareholders or holders of other equity interests of Parent or the Sponsor or any of their respective directors, members, partners, officers, employees or Affiliates of any of the foregoing (including any of the SpinCo Entities) (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Group</span>&#8221;), on the one hand, and the Company or any other member of the Company Group (as defined below), on the other hand, any legal counsel (including Weil) that represented Parent or the Sponsor prior to the Closing may represent the Sponsor or any other member of the Parent Group in such dispute, regardless of whether the interests of any such Persons may be directly adverse to Parent or the applicable member of the Parent Group, and even though such counsel may have represented Parent or another member of the Parent Group in a matter substantially related to such dispute, or may be handling ongoing matters for Parent, the Sponsor or any other member of the Parent Group. Parent, SpinCo and the Company further agree that, as to all legally privileged communications prior to the Closing between or among any legal counsel (including Weil) that represented Parent, the Sponsor or any other member of the Parent Group prior to the Closing, on the one hand, and any one or more of such Persons, on the other hand, that relate in any way to this Agreement or the Transactions, the attorney/client privilege and the expectation of client confidence belongs to the Parent Group, shall be controlled by the Parent Group, and shall not pass to or be claimed or controlled by the Company or any of its Subsidiaries (after giving effect to the Closing). Notwithstanding the foregoing, any privileged communications or information shared prior to the Closing by the Company or any of its Subsidiaries (other than the SpinCo Entities), on the one hand, with Parent, the Sponsor or any other member of the Parent Group (other than the SpinCo Entities) (in any capacity), on the other hand, under a common interest agreement shall remain the privileged communications or information of the Company Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Parent, SpinCo and the Company, on behalf of their respective successors and assigns (in the case of Parent, including, after the Closing, each of the SpinCo Entities) hereby agree that, in the event a dispute with respect to this Agreement or the Transactions arises after the Closing between or among the Company, any Subsidiary of the Company (other than any of the SpinCo Entities), the shareholders or holders of other equity interests of the Company, any Subsidiary of the Company (other than any of the SpinCo Entities) or any of their respective directors, members, partners, officers, employees or Affiliates of any of the foregoing (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Group</span>&#8221;), on the one hand, and the Surviving Corporation or any other member of the Parent Group, on the other hand, any legal counsel (including LW) that represented the Company or any other member of the Company Group prior to the Closing may represent any member of the Company Group in such dispute, regardless of whether the interests of any such Persons may be directly adverse to the Surviving Corporation or any other member of the Parent Group, and even though such counsel may have represented Parent or any other member of the Parent Group in a matter substantially related to such dispute, or may be handling ongoing matters for the Surviving Corporation or any other member of the Parent Group. Parent, SpinCo and the Company further agree that, as to all legally privileged communications prior to the Closing between or among any legal counsel (including LW) that represented the Company or any other member of the Company Group prior to the Closing, on the one hand, and any one or more of such Persons, on the other hand, that relate in any way to this Agreement or the Transactions, the attorney/client privilege and the expectation of client confidence belongs to the Company Group, shall be controlled by the Company Group, and shall not pass to or be claimed or controlled by Parent or any other member of the Parent Group. Notwithstanding the foregoing, any privileged communications or information shared prior to the Closing by Parent or any other member of the Parent Group, on the one hand, with any member of the Company Group, on the other hand, under a common interest agreement shall remain the privileged communications or information of the SpinCo Entities and, following the Closing, the Parent Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">[<i style="font-style:italic;">Signature page follows.</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">A-68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_83c64840_eecb_4e79_9205_ddb620c8a0e8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed by their respective authorized officers as of the day and year first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">LIGAND PHARMACEUTICALS INCORPORATED</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Matthew Korenberg</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Matthew Korenberg</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Executive Vice President, Finance and Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">OMNIAB, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Matthew W. Foehr</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Matthew W. Foehr</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Benjamin Silbert</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Benjamin Silbert</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General Counsel</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">ORWELL MERGER SUB INC.</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ David Burgstahler</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">David Burgstahler</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">President</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6877ed13_37d9_4ddb_b4ea_ff909bde0a8d"></a><a id="_Hlk101190663"></a><a id="_Hlk101313988"></a><a id="AnnexB_187430"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">Annex B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0pt 36pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Execution Version</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">SEPARATION AND DISTRIBUTION AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">by and among</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">LIGAND PHARMACEUTICALS INCORPORATED,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">OMNIAB,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">AVISTA PUBLIC ACQUISITION CORP. II</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Dated as of March&#160;23, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;text-align:center;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e339ba9d_5073_4cee_8451_b4a4b255c415"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">TABLE OF CONTENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">Page</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_ARTICLEIDEFINITIONSANDINTERPRETATION"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;I DEFINITIONS AND INTERPRETATION</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-2</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section1_1_General"><span style="font-style:normal;font-weight:normal;">Section&#160;1.1</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section1_1_General"><span style="font-style:normal;font-weight:normal;">General</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-2</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_1_2_References_Interpretation"><span style="font-style:normal;font-weight:normal;">Section&#160;1.2</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_1_2_References_Interpretation"><span style="font-style:normal;font-weight:normal;">References; Interpretation</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-15</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_ARTICLEII_THESEPARATION"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;II THE SEPARATION </span></a> </p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-16</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_1General"><span style="font-style:normal;font-weight:normal;">Section&#160;2.1</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_1General"><span style="font-style:normal;font-weight:normal;">General</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-16</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_2_RestructuringTransferof"><span style="font-style:normal;font-weight:normal;">Section&#160;2.2</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_2_RestructuringTransferof"><span style="font-style:normal;font-weight:normal;">Restructuring: Transfer of Assets; Assumption of Liabilities</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-16</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_3_TreatmentofSharedContra"><span style="font-style:normal;font-weight:normal;">Section&#160;2.3</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_3_TreatmentofSharedContra"><span style="font-style:normal;font-weight:normal;">Treatment of Shared Contracts</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-17</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_4_IntercompanyAccountsLoa"><span style="font-style:normal;font-weight:normal;">Section&#160;2.4</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_4_IntercompanyAccountsLoa"><span style="font-style:normal;font-weight:normal;">Intercompany Accounts, Loans and Agreements</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-18</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_5_LimitationofLiabilityI"><span style="font-style:normal;font-weight:normal;">Section&#160;2.5</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_5_LimitationofLiabilityI"><span style="font-style:normal;font-weight:normal;">Limitation of Liability; Intercompany Contracts</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-18</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_6_TransfersNotEffectedat"><span style="font-style:normal;font-weight:normal;">Section&#160;2.6</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_6_TransfersNotEffectedat"><span style="font-style:normal;font-weight:normal;">Transfers Not Effected at or Prior to the Distribution Time; Transfers Deemed Effective as of the Distribution Time</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-18</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_7_ConveyancingandAssumptio"><span style="font-style:normal;font-weight:normal;">Section&#160;2.7</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_7_ConveyancingandAssumptio"><span style="font-style:normal;font-weight:normal;">Conveyancing and Assumption Instruments</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-20</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_8_FurtherAssurancesAncill"><span style="font-style:normal;font-weight:normal;">Section&#160;2.8</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_8_FurtherAssurancesAncill"><span style="font-style:normal;font-weight:normal;">Further Assurances; Ancillary Agreements</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-21</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_9_NovationofLiabilitiesI"><span style="font-style:normal;font-weight:normal;">Section&#160;2.9</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_9_NovationofLiabilitiesI"><span style="font-style:normal;font-weight:normal;">Novation of Liabilities; Indemnification</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-22</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_10_GuaranteesCreditSuppor"><span style="font-style:normal;font-weight:normal;">Section&#160;2.10</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_10_GuaranteesCreditSuppor"><span style="font-style:normal;font-weight:normal;">Guarantees; Credit Support Instruments</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-23</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_11_DisclaimerofRepresentat"><span style="font-style:normal;font-weight:normal;">Section&#160;2.11</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_11_DisclaimerofRepresentat"><span style="font-style:normal;font-weight:normal;">Disclaimer of Representations and Warranties</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-24</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_12_CashManagementConsider"><span style="font-style:normal;font-weight:normal;">Section&#160;2.12</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_2_12_CashManagementConsider"><span style="font-style:normal;font-weight:normal;">Cash Management; Consideration</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-24</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_ARTICLEIIICOMPLETIONOFTHEDISTR"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;III COMPLETION OF THE DISTRIBUTION </span></a> </p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-25</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_3_1ActionsPriortotheDistr"><span style="font-style:normal;font-weight:normal;">Section&#160;3.1</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_3_1ActionsPriortotheDistr"><span style="font-style:normal;font-weight:normal;">Actions Prior to the Distribution</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-25</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_3_2_EffectingtheDistribution"><span style="font-style:normal;font-weight:normal;">Section&#160;3.2</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_3_2_EffectingtheDistribution"><span style="font-style:normal;font-weight:normal;">Effecting the Distribution</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-26</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_3_3_ConditionstotheDistributi"><span style="font-style:normal;font-weight:normal;">Section&#160;3.3</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_3_3_ConditionstotheDistributi"><span style="font-style:normal;font-weight:normal;">Conditions to the Distribution</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-26</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_ARTICLEIVCERTAINCOVENANTS"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;IV CERTAIN COVENANTS</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-27</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_4_1_Cooperation"><span style="font-style:normal;font-weight:normal;">Section&#160;4.1</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_4_1_Cooperation"><span style="font-style:normal;font-weight:normal;">Cooperation</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-27</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_4_2_RetainedNames"><span style="font-style:normal;font-weight:normal;">Section&#160;4.2</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_4_2_RetainedNames"><span style="font-style:normal;font-weight:normal;">Retained Names</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-27</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_4_3_LigandLimitedLicenseGra"><span style="font-style:normal;font-weight:normal;">Section&#160;4.3</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_4_3_LigandLimitedLicenseGra"><span style="font-style:normal;font-weight:normal;">Ligand Limited License</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-28</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_4_4_NoRestrictiononCompetit"><span style="font-style:normal;font-weight:normal;">Section&#160;4.4</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_4_4_NoRestrictiononCompetit"><span style="font-style:normal;font-weight:normal;">No Restriction on Competition</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-28</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_ARTICLEVINDEMNIFICATION"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;V INDEMNIFICATION</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-28</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_5_1_ReleaseofPreDistributio"><span style="font-style:normal;font-weight:normal;">Section&#160;5.1</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_5_1_ReleaseofPreDistributio"><span style="font-style:normal;font-weight:normal;">Release of Pre-Distribution Claims</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-28</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_5_2_IndemnificationbyLigand"><span style="font-style:normal;font-weight:normal;">Section&#160;5.2</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_5_2_IndemnificationbyLigand"><span style="font-style:normal;font-weight:normal;">Indemnification by Ligand</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-31</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_5_3_Indemnificationby"><span style="font-style:normal;font-weight:normal;">Section&#160;5.3</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_5_3_Indemnificationby"><span style="font-style:normal;font-weight:normal;">Indemnification by OmniAb and APAC</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-31</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_5_4_ProceduresforIndemnifica"><span style="font-style:normal;font-weight:normal;">Section&#160;5.4</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_5_4_ProceduresforIndemnifica"><span style="font-style:normal;font-weight:normal;">Procedures for Indemnification</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-31</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_5_5_CooperationinDefenseand"><span style="font-style:normal;font-weight:normal;">Section&#160;5.5</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_5_5_CooperationinDefenseand"><span style="font-style:normal;font-weight:normal;">Cooperation in Defense and Settlement</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-33</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_5_6_IndemnificationPayments"><span style="font-style:normal;font-weight:normal;">Section&#160;5.6</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_5_6_IndemnificationPayments"><span style="font-style:normal;font-weight:normal;">Indemnification Payments</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-33</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_5_7_IndemnificationObligation"><span style="font-style:normal;font-weight:normal;">Section&#160;5.7</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_5_7_IndemnificationObligation"><span style="font-style:normal;font-weight:normal;">Indemnification Obligations Net of Insurance Proceeds and Other Amounts</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-33</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_5_8_Contribution"><span style="font-style:normal;font-weight:normal;">Section&#160;5.8</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_5_8_Contribution"><span style="font-style:normal;font-weight:normal;">Contribution</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-34</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_5_9_AdditionalMattersSurviv"><span style="font-style:normal;font-weight:normal;">Section&#160;5.9</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_5_9_AdditionalMattersSurviv"><span style="font-style:normal;font-weight:normal;">Additional Matters; Survival of Indemnities</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-34</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:27pt;text-indent:-27pt;margin:0pt;"><a href="#B_ARTICLEVIPRESERVATIONOFRECORDS"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;VI PRESERVATION OF RECORDS; ACCESS TO INFORMATION; CONFIDENTIALITY; PRIVILEGE</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-34</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_1_PreservationofCorporate"><span style="font-style:normal;font-weight:normal;">Section&#160;6.1</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_1_PreservationofCorporate"><span style="font-style:normal;font-weight:normal;">Preservation of Corporate Records</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-34</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_2_AccesstoInformatio"><span style="font-style:normal;font-weight:normal;">Section&#160;6.2</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_2_AccesstoInformatio"><span style="font-style:normal;font-weight:normal;">Access to Information</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-35</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_3_AuditorsandAudits"><span style="font-style:normal;font-weight:normal;">Section&#160;6.3</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_3_AuditorsandAudits"><span style="font-style:normal;font-weight:normal;">Auditors and Audits</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-36</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_4_WitnessServices"><span style="font-style:normal;font-weight:normal;">Section&#160;6.4</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_4_WitnessServices"><span style="font-style:normal;font-weight:normal;">Witness Services</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-36</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_5_Reimbursement"><span style="font-style:normal;font-weight:normal;">Section&#160;6.5</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_5_Reimbursement"><span style="font-style:normal;font-weight:normal;">Reimbursement; Other Matters</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-37</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_6_Confidentiality"><span style="font-style:normal;font-weight:normal;">Section&#160;6.6</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_6_Confidentiality"><span style="font-style:normal;font-weight:normal;">Confidentiality</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-37</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_7_PrivilegeMatters"><span style="font-style:normal;font-weight:normal;">Section&#160;6.7</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_7_PrivilegeMatters"><span style="font-style:normal;font-weight:normal;">Privilege Matters</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-38</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_8_OwnershipofInformation"><span style="font-style:normal;font-weight:normal;">Section&#160;6.8</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_8_OwnershipofInformation"><span style="font-style:normal;font-weight:normal;">Ownership of Information</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-39</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_9_ProcessingofPersonal"><span style="font-style:normal;font-weight:normal;">Section&#160;6.9</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_9_ProcessingofPersonal"><span style="font-style:normal;font-weight:normal;">Processing of Personal Information</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-39</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_10_OtherAgreements"><span style="font-style:normal;font-weight:normal;">Section&#160;6.10</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_6_10_OtherAgreements"><span style="font-style:normal;font-weight:normal;">Other Agreements</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-39</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:27pt;text-indent:-27pt;margin:0pt;"><a href="#B_ARTICLEVIIDISPUTERESOLUTION"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;VII DISPUTE RESOLUTION</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-40</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_7_1_Negotiation"><span style="font-style:normal;font-weight:normal;">Section&#160;7.1</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_7_1_Negotiation"><span style="font-style:normal;font-weight:normal;">Negotiation</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-40</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_7_2_ReliefinCourt"><span style="font-style:normal;font-weight:normal;">Section&#160;7.2</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_7_2_ReliefinCourt"><span style="font-style:normal;font-weight:normal;">Relief in Court</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-40</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_7_3_ContinuityofService"><span style="font-style:normal;font-weight:normal;">Section&#160;7.3</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_7_3_ContinuityofService"><span style="font-style:normal;font-weight:normal;">Continuity of Service and Performance</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-40</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:27pt;text-indent:-27pt;margin:0pt;"><a href="#B_ARTICLEVIIIINSURANCE"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;VIII INSURANCE</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-40</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_8_1_InsuranceMatters"><span style="font-style:normal;font-weight:normal;">Section&#160;8.1</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_8_1_InsuranceMatters"><span style="font-style:normal;font-weight:normal;">Insurance Matters</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-40</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:27pt;text-indent:-27pt;margin:0pt;"><a href="#B_ARTICLESIXMISCELLANEOUS"><span style="font-style:normal;font-weight:normal;">ARTICLE&#160;IX MISCELLANEOUS</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-41</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_1_EntireAgreement"><span style="font-style:normal;font-weight:normal;">Section&#160;9.1</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_1_EntireAgreement"><span style="font-style:normal;font-weight:normal;">Entire Agreement; Construction</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-41</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_2_AncillaryAgreements"><span style="font-style:normal;font-weight:normal;">Section&#160;9.2</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_2_AncillaryAgreements"><span style="font-style:normal;font-weight:normal;">Ancillary Agreements</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-41</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_3_Counterparts"><span style="font-style:normal;font-weight:normal;">Section&#160;9.3</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_3_Counterparts"><span style="font-style:normal;font-weight:normal;">Counterparts</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-42</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_4_SurvivalofAgreements"><span style="font-style:normal;font-weight:normal;">Section&#160;9.4</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_4_SurvivalofAgreements"><span style="font-style:normal;font-weight:normal;">Survival of Agreements</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-42</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_5_Expenses"><span style="font-style:normal;font-weight:normal;">Section&#160;9.5</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_5_Expenses"><span style="font-style:normal;font-weight:normal;">Expenses</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-42</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_6_Notices"><span style="font-style:normal;font-weight:normal;">Section&#160;9.6</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_6_Notices"><span style="font-style:normal;font-weight:normal;">Notices</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-42</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_7_Consents"><span style="font-style:normal;font-weight:normal;">Section&#160;9.7</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_7_Consents"><span style="font-style:normal;font-weight:normal;">Consents</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-43</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_8_Assignment"><span style="font-style:normal;font-weight:normal;">Section&#160;9.8</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_8_Assignment"><span style="font-style:normal;font-weight:normal;">Assignment</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-43</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_9_Successors"><span style="font-style:normal;font-weight:normal;">Section&#160;9.9</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_9_Successors"><span style="font-style:normal;font-weight:normal;">Successors and Assigns</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-43</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_10_Termination"><span style="font-style:normal;font-weight:normal;">Section&#160;9.10</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_10_Termination"><span style="font-style:normal;font-weight:normal;">Termination and Amendment</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-43</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_11_PaymentTerms"><span style="font-style:normal;font-weight:normal;">Section&#160;9.11</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_11_PaymentTerms"><span style="font-style:normal;font-weight:normal;">Payment Terms</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-43</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_12_Subsidiaries"><span style="font-style:normal;font-weight:normal;">Section&#160;9.12</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_12_Subsidiaries"><span style="font-style:normal;font-weight:normal;">Subsidiaries</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-44</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_13_ThirdParty"><span style="font-style:normal;font-weight:normal;">Section&#160;9.13</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_13_ThirdParty"><span style="font-style:normal;font-weight:normal;">Third Party Beneficiaries</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-44</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_14_Title"><span style="font-style:normal;font-weight:normal;">Section&#160;9.14</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_14_Title"><span style="font-style:normal;font-weight:normal;">Title and Headings</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-44</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_15_Exhibits"><span style="font-style:normal;font-weight:normal;">Section&#160;9.15</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_15_Exhibits"><span style="font-style:normal;font-weight:normal;">Exhibits&#160;and Schedules</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-44</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_16_GoverningLawandVenue"><span style="font-style:normal;font-weight:normal;">Section&#160;9.16</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_16_GoverningLawandVenue"><span style="font-style:normal;font-weight:normal;">Governing Law and Venue; Submission to Jurisdiction; Selection of Forum; Waiver of Trial by Jury</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-44</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_17_SpecificPerformance"><span style="font-style:normal;font-weight:normal;">Section&#160;9.17</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_17_SpecificPerformance"><span style="font-style:normal;font-weight:normal;">Specific Performance</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-45</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_18_Severability"><span style="font-style:normal;font-weight:normal;">Section&#160;9.18</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_18_Severability"><span style="font-style:normal;font-weight:normal;">Severability</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-45</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_19_Interpretation"><span style="font-style:normal;font-weight:normal;">Section&#160;9.19</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_19_Interpretation"><span style="font-style:normal;font-weight:normal;">Interpretation</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-45</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_20_NoDuplication"><span style="font-style:normal;font-weight:normal;">Section&#160;9.20</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_20_NoDuplication"><span style="font-style:normal;font-weight:normal;">No Duplication; No Double Recovery</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-45</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_21_TaxTreatment"><span style="font-style:normal;font-weight:normal;">Section&#160;9.21</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_21_TaxTreatment"><span style="font-style:normal;font-weight:normal;">Tax Treatment of Payments</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-45</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_22_NoWaiver"><span style="font-style:normal;font-weight:normal;">Section&#160;9.22</span></a></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_22_NoWaiver"><span style="font-style:normal;font-weight:normal;">No Waiver</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-46</p></td></tr><tr><td style="vertical-align:bottom;width:15%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 27pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_23_NoAdmission"><span style="font-style:normal;font-weight:normal;">Section&#160;9.23</span></a></p></td><td style="vertical-align:bottom;width:80%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#B_Section_9_23_NoAdmission"><span style="font-style:normal;font-weight:normal;">No Admission of Liability</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">B-46</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">List of Schedules</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">1.1(75)&#160;&#160;</p></td><td style="vertical-align:bottom;width:90%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Ligand Retained Liabilities</p></td></tr><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">1.1(76)&#160;&#160;</p></td><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Ligand Retained Names</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">1.1(86)(ii)</p></td><td style="vertical-align:bottom;width:90%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">OmniAb Assets &#8212; General</p></td></tr><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">1.1(86)(v)</p></td><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">OmniAb Assets &#8212; Leases/Subleases</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">1.1(86)(vi)</p></td><td style="vertical-align:bottom;width:90%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">OmniAb Assets &#8212; Contracts</p></td></tr><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">1.1(86)(vii)</p></td><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">OmniAb Assets &#8212; Intellectual Property</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">1.1(86)(x)</p></td><td style="vertical-align:bottom;width:90%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">OmniAb Assets &#8212; IT Assets</p></td></tr><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">1.1(97)(ii)</p></td><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">OmniAb Liabilities &#8212; General</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">1.1(97)(vii)</p></td><td style="vertical-align:bottom;width:90%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">OmniAb Liabilities &#8212; Actions</p></td></tr><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2.3(a)&#160;&#160;&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Shared Contracts</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2.10(a)(i)&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:90%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Guarantees Provided by OmniAb Group</p></td></tr><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2.10(a)(ii)&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Guarantees Provided by Ligand Group</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2.12(c)&#160;&#160;&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:90%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other Reimbursable Expenses</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">List of Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exhibit&#160;A</p></td><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Reorganization Plan</p></td></tr><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exhibit&#160;B</p></td><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Illustrative Adjustments pursuant to Section&#160;2.12(c)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;text-align:center;margin:0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-iii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_54a578fd_f373_458c_881f_e3722e29e2ab"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEPARATION AND DISTRIBUTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">This SEPARATION AND DISTRIBUTION AGREEMENT (this &#8220;<span style="font-style:italic;font-weight:bold;">Agreement</span>&#8221;), dated as of March&#160;23, 2022, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#8220;<span style="font-style:italic;font-weight:bold;">Ligand</span>&#8221;), OmniAb,&#160;Inc., a Delaware corporation and a wholly owned subsidiary of Ligand (&#8220;<span style="font-style:italic;font-weight:bold;">OmniAb</span>&#8221;), and Avista Public Acquisition Corp. II, a Cayman Islands exempted company (which will migrate to and domesticate as a Delaware corporation prior to the Closing (the &#8220;<span style="font-style:italic;font-weight:bold;">Domestication</span>&#8221;)) (&#8220;<span style="font-style:italic;font-weight:bold;">APAC</span>&#8221;). &#8220;<span style="font-style:italic;font-weight:bold;">Party</span>&#8221; or &#8220;<span style="font-style:italic;font-weight:bold;">Parties</span>&#8221; means Ligand or OmniAb, individually or collectively, as the case may be. Capitalized terms used and not defined herein shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.1</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">W I T N E S S E T H:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, Ligand owns 100% of the common stock, par value $0.001 per share, of OmniAb (the &#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Stock</span>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, Ligand, acting through its direct and indirect Subsidiaries, currently conducts the Ligand Retained Business and the OmniAb Business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, the Board of Directors of Ligand (the &#8220;<span style="font-style:italic;font-weight:bold;">Ligand Board</span>&#8221;) has determined that it is appropriate, desirable and in the best interests of Ligand and its stockholders to separate Ligand into two separate companies, one for each of (i)&#160;the Ligand Retained Business, which shall be owned and conducted, directly or indirectly, by Ligand and its Subsidiaries (other than OmniAb and its Subsidiaries) and (ii)&#160;the OmniAb Business, which shall be owned and conducted, directly or indirectly, by OmniAb and its Subsidiaries (the &#8220;<span style="font-style:italic;font-weight:bold;">Separation</span>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, in order to effect the Separation, the Ligand Board has determined that it is appropriate, desirable and in the best interests of Ligand and its stockholders for Ligand to undertake the Internal Reorganization and, in connection therewith, effect the Contribution to OmniAb;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, the Ligand Board has further determined that it is appropriate and desirable, on the terms and conditions contemplated hereby, following such separation to make a distribution of the OmniAb Business to the holders of common stock, par value $0.001 per share, of Ligand (the &#8220;<span style="font-style:italic;font-weight:bold;">Ligand Stock</span>&#8221;) on the Record Date through the distribution of all of the outstanding shares of OmniAb Stock to holders of Ligand on the Record Date on a pro rata basis in accordance with a distribution ratio to be determined by the Ligand Board (the &#8220;<span style="font-style:italic;font-weight:bold;">Distribution</span>&#8221;), in each case, on the terms and conditions set forth in this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, immediately following the Distribution, Ligand will hold none of the outstanding shares of OmniAb Stock;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, the Ligand Board has further determined that it is appropriate and desirable, on the terms and conditions contemplated in the Agreement and Plan of Merger, dated as of the date hereof (the &#8220;<span style="font-style:italic;font-weight:bold;">Merger Agreement</span>&#8221;), among Ligand, OmniAb, APAC and Orwell Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of APAC (&#8220;<span style="font-style:italic;font-weight:bold;">Merger Sub</span>&#8221;), following the Domestication, Separation and Distribution, Merger Sub will merge with and into OmniAb, with OmniAb continuing as the surviving corporation (the &#8220;<span style="font-style:italic;font-weight:bold;">Merger</span>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, pursuant to the Merger, shares of OmniAb Stock will be exchanged for shares of Domesticated Parent Common Stock, on the terms and conditions set forth in the Merger Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, Ligand and OmniAb will prepare, and OmniAb will file with the SEC, the Form&#160;10, which will include the Information Statement and will set forth certain disclosure concerning OmniAb, the Separation, the Distribution and the Merger;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, (i)&#160;the Ligand Board has (x)&#160;determined that the transactions contemplated by this Agreement, the Merger Agreement and the Ancillary Agreements have a valid business purpose, are in furtherance of and consistent with its business strategy and are in the best interests of Ligand and its stockholders and (y)&#160;approved this Agreement, the Merger Agreement and each of the Ancillary Agreements and (ii)&#160;the Board of Directors of OmniAb (the &#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Board</span>&#8221;) has approved this Agreement, the Merger Agreement and each of the Ancillary Agreements (to the extent OmniAb is a party thereto);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, the board of directors of APAC has approved this Agreement and the Merger Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, the Parties and APAC desire to set forth the principal corporate transactions required to effect the Separation and the Distribution, and certain other agreements relating to the relationship of Ligand and OmniAb and their respective Subsidiaries following the Distribution;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, it is the intention of the Parties and APAC that the (i)&#160;Contribution and Distribution, together with certain related transactions, will qualify as a &#8220;reorganization&#8221; under Sections&#160;355 and 368(a)(1)(D)&#160;of the Internal Revenue Code of 1986, as amended (the &#8220;<span style="font-style:italic;font-weight:bold;">Code;</span>&#8221;) and (ii)&#160;the Merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, this Agreement is intended to be, and is hereby adopted as, a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations&#160;Sections&#160;1.368-2(g)&#160;and 1.368-3(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">NOW, THEREFORE, in consideration of the foregoing and the mutual agreements, provisions and covenants contained in this Agreement, the Parties and APAC hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="B_ARTICLEIDEFINITIONSANDINTERPRETATION"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DEFINITIONS AND INTERPRETATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="B_Section1_1_General"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</span>. As used in this Agreement, the following terms shall have the following meanings:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Action</span>&#8221; shall mean any demand, action, claim, suit, countersuit, arbitration, inquiry, subpoena, case, litigation, proceeding or investigation (whether civil, criminal, administrative or investigative) by or before any court or grand jury, any Governmental Entity or any arbitration or mediation tribunal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Affiliate</span>&#8221; shall mean, when used with respect to a specified Person and at a point in, or with respect to a period of, time, a Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such specified Person at such point in or during such period of time. For the purposes of this definition, &#8220;control&#8221;, when used with respect to any specified Person shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities or other interests, by Contract or otherwise. It is expressly agreed that, from and after the Distribution Time, solely for purposes of this Agreement, (i) no member of the OmniAb Group shall be deemed an Affiliate of any member of the Ligand Group and (ii) no member of the Ligand Group shall be deemed an Affiliate of any member of the OmniAb Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(3)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Agent</span>&#8221; means Computershare Trust Company, N.A., as the distribution agent appointed by Ligand to distribute to the stockholders of Ligand all of the outstanding shares of OmniAb Stock pursuant to the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(4)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Agreement</span>&#8221; shall have the meaning set forth in in the Preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(5)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Amended Financial Report</span>&#8221; shall have the meaning set forth in Section 6.3(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(6)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Ancillary Agreements</span>&#8221; shall mean the Transition Services Agreements, the Employee Matters Agreement, the Tax Matters Agreement, any Continuing Arrangements, any and all Conveyancing and Assumption Instruments, and any other agreements to be entered into by and between any member of the Ligand Group, on one hand, and any member of the OmniAb Group, on the other hand, at, prior to or after the Distribution Time in connection with the Separation, the Distribution and the other transactions contemplated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(7)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">APAC</span>&#8221; shall have the meaning set forth in the Preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(8)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">APAC Released Liabilities</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(a)(iii)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(9)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Assets</span>&#8221; shall mean all rights (including Intellectual Property), title and ownership interests in and to all properties, claims, Contracts, businesses, or assets (including goodwill), wherever located (including in the possession of vendors or other third parties or elsewhere), of every kind, character and description, whether real, personal or mixed, tangible or intangible, whether accrued, contingent or otherwise, in each case, whether or not recorded or reflected on the books and records or financial statements of any </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Person. Except as otherwise specifically set forth herein, in the Employee Matters Agreement or in the Tax Matters Agreement, the rights and obligations of the Parties with respect to Taxes shall be governed by the Tax Matters Agreement and, therefore, Tax assets (including any Tax items, attributes or rights to receive any Refunds (as defined in the Tax Matters Agreement)) shall not be treated as Assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(10)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Asset Transferors</span>&#8221; shall mean the entities transferring Assets to OmniAb or one of its Subsidiaries in order to consummate the transactions contemplated hereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(11)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Assume</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(c)</span>; and the terms &#8220;<span style="font-style:italic;font-weight:bold;">Assumed</span>&#8221; and &#8220;<span style="font-style:italic;font-weight:bold;">Assumption</span>&#8221; shall have their correlative meanings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(12)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Business</span>&#8221; shall mean the Ligand Retained Business or the OmniAb Business, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(13)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Business Day</span>&#8221; shall mean any day other than Saturday or Sunday and any other day on which commercial banking institutions located in New York, New York are required, or authorized by Law, to remain closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(14)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Business Entity</span>&#8221; shall mean any corporation, partnership, limited liability company, joint venture or other entity which may legally hold title to Assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(15)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Cash Equivalents</span>&#8221; shall mean (i) cash and (ii) checks, certificates of deposit having a maturity of less than one year, money orders, marketable securities, money market funds, commercial paper, short-term instruments and other cash equivalents, funds in time and demand deposits or similar accounts, and any evidence of indebtedness issued or guaranteed by any Governmental Entity, minus the amount of any outbound checks, plus the amount of any deposits in transit. For the purposes of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.12</span>, &#8220;<span style="font-style:italic;font-weight:bold;">Cash Equivalents</span>&#8221; shall not include any cash in transit at the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(16)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Chosen Courts</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.16(b)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(17)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Closing</span>&#8221; shall have the meaning set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(18)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Code</span>&#8221; shall have the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(19)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Commission</span>&#8221; shall mean the United States Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(20)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Confidential Information</span>&#8221; shall mean all non-public, confidential or proprietary Information to the extent concerning a Party, its Group and/or its Subsidiaries or with respect to OmniAb, the OmniAb Business, any OmniAb Assets or any OmniAb Liabilities or with respect to Ligand, the Ligand Retained Business, any Ligand Retained Assets or any Ligand Retained Liabilities, including any such Information that was acquired by any Party after the Distribution Time pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VI</span> or otherwise in accordance with this Agreement, or that was provided to a Party by a third party in confidence, including (a) any and all technical information relating to the design, operation, testing, test results, development, and manufacture of any Party&#8217;s products, compounds, technologies or biological, chemical or other materials or that of a Party&#8217;s partners (including specifications and documentation; engineering, design, and manufacturing drawings, diagrams, layouts, maps and illustrations; formulations and material specifications; laboratory studies and benchmark tests; preclinical and clinical data; quality assurance policies, procedures and specifications; evaluation and validation studies; process control and/or shop-floor control strategy, logic or algorithms; assembly code, Software, firmware, programming data, databases, and all information referred to in the same); costs, margins and pricing; as well as product marketing studies and strategies; all other methodologies, procedures, techniques and Know-How related to discovery, research, engineering, development and manufacturing; (b) information, documents and materials relating to the Party&#8217;s financial condition, management and other business conditions, prospects, plans, procedures, partners, infrastructure, security, information technology procedures and systems, and other business or operational affairs; (c) pending unpublished patent applications and Trade Secrets; and (d) any other data or documentation resident, existing or otherwise provided in a database or in a storage medium, permanent or temporary, intended for confidential, proprietary and/or privileged use by a Party; except for any Information that is (i) in the public domain or known to the public through no fault of the receiving Party or its Subsidiaries, (ii) lawfully acquired after the Distribution Time by such Party or its Subsidiaries from other sources not known to be subject to confidentiality obligations with respect to such Information or (iii) independently developed by the receiving Party after the Distribution Time without reference to any Confidential Information. As used herein, by example and without limitation, Confidential Information shall include any information of a Party intended or marked as confidential, proprietary and/or privileged.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(21)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Consents</span>&#8221; shall mean any consents, waivers, notices, reports or other filings to be obtained from or made, including with respect to any Contract, or any registrations, licenses, permits, authorizations to be obtained from, or approvals from, or notification requirements to, any third parties, including any third party to a Contract and any Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(22)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Continuing Arrangements</span>&#8221; shall mean:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>this Agreement and the Ancillary Agreements (and each other Contract expressly contemplated by this Agreement or any Ancillary Agreement to be entered into or continued by any of the Parties or any of the members of their respective Groups); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>any Contracts or intercompany accounts solely between or among members of the OmniAb Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(23)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Contract</span>&#8221; shall mean any agreement, contract, subcontract, obligation, binding understanding, note, indenture, instrument, option, lease, promise, arrangement, release, warranty, license, sublicense, insurance policy, benefit plan, purchase order or legally binding commitment or undertaking of any nature (whether written or oral and whether express or implied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(24)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Contribution</span>&#8221; shall mean (i) the Transfer, directly or indirectly, of the capital stock of or membership or other equity interests in the Transferred Entities and the other OmniAb Assets from Ligand or its Subsidiaries to OmniAb or its Subsidiaries, (ii) the contribution by Ligand to OmniAb of $15,000,000 (fifteen million dollars) in cash, decreased by the amount of Reimbursable Transaction-related Expenses and Other Reimbursable Expenses, and increased by the amount of any Specific Milestone Payments, and (iii) the Assumption of Liabilities, directly or indirectly, by OmniAb or its Subsidiaries pursuant to the Internal Reorganization or otherwise relating to, arising out of or resulting from the transactions contemplated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(25)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Conveyancing and Assumption Instruments</span>&#8221; shall mean, collectively, the various Contracts, including the related local asset transfer agreements and local stock transfer agreements, and other documents entered into prior to the Distribution Time and to be entered into to effect the Transfer of Assets and the Assumption of Liabilities in the manner contemplated by this Agreement, or otherwise relating to, arising out of or resulting from the transactions contemplated by this Agreement, in such form or forms as the applicable Parties thereto agree.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(26)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Covered Matter</span>&#8221; shall have the meaning set forth in Section 8.1(i).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(27)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Credit Support Instruments</span>&#8221; shall mean any letters of credit, performance bonds, surety bonds, bankers acceptances, or other similar arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(28)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Dispute Notice</span>&#8221; shall have the meaning set forth in Section 7.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(29)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Disputes</span>&#8221; shall have the meaning set forth in Section 7.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(30)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Distribution</span>&#8221; shall have the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(31)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Distribution Date</span>&#8221; shall mean the date on which Ligand, through the Agent, distributes all of the issued and outstanding shares of OmniAb Stock to holders of Ligand Stock in the Distribution, and &#8220;<span style="font-style:italic;font-weight:bold;">Distribution Time</span>&#8221; shall mean the time at which the Distribution occurs on the Distribution Date, which shall be deemed to be 12:01 a.m., New York time on the Distribution Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(32)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Domesticated Parent Common Stock</span>&#8221; shall have the meaning set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(33)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Domestication</span>&#8221; shall have the meaning set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(34)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Effective Time</span>&#8221; shall have the meaning set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(35)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Employee Matters Agreement</span>&#8221; shall mean that certain Employee Matters Agreement to be entered into between Ligand and OmniAb or any members of their respective Groups in connection with the Separation, the Distribution, the Merger or the other transactions contemplated by this Agreement, as such agreement may be modified or amended from time to time in accordance with its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(36)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Environmental Laws</span>&#8221; shall mean all Laws relating to pollution or protection of human health or safety or the environment, including Laws relating to the exposure to, or Release, threatened Release or the presence of Hazardous Substances, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, transport or handling of Hazardous Substances and all Laws with regard to recordkeeping, notification, disclosure and reporting requirements respecting Hazardous Substances, and all laws relating to endangered or threatened species of fish, wildlife and plants and the management or use of natural resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(37)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Environmental Liabilities</span>&#8221; shall mean Liabilities relating to Environmental Law or the Release or threatened Release of or exposure to Hazardous Substances, including, without limitation, the following: (i) actual or alleged violations of or non-compliance with any Environmental Law, including a failure to obtain, maintain or comply with any Environmental Permits; (ii) obligations arising under or pursuant to any applicable Environmental Law or Environmental Permit; (iii) the presence of Hazardous Substances or the introduction of Hazardous Substances to the environment at, in, on, under or migrating from any of the building, facility, structure or real property, including Liabilities relating to, resulting from or arising out of the investigation, remediation, or monitoring of such Hazardous Substances; (iv) natural resource damages, property damages, personal or bodily injury or wrongful death relating to the presence of or exposure to Hazardous Substances (including asbestos-containing materials), at, in, on, under or migrating to or from any building, facility, structure or real property; (v) the transport, disposal, recycling, reclamation, treatment or storage, Release or threatened Release of Hazardous Substances at Off-Site Locations; and (vi) any agreement, decree, judgment, or order relating to the foregoing. The term &#8220;<span style="font-style:italic;font-weight:bold;">Environmental Liabilities</span>&#8221; does not include Liabilities arising in connection with claims for injuries to persons or property from products sold by or services provided by the OmniAb Group, the Ligand Group or their predecessors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(38)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Environmental Permit</span>&#8221; shall mean any permit, license, approval or other authorization under any applicable Law or of any Governmental Entity relating to Environmental Laws or Hazardous Substances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(39)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Exchange Act</span>&#8221; shall mean the United States Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(40)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Excluded Environmental Liabilities</span>&#8221; shall mean any and all Environmental Liabilities whether arising before, at or after the Distribution Time, to the extent relating to, resulting from, or arising out of the past, present or future operation, conduct or actions of any Ligand Retained Business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(41)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Final Determination</span>&#8221; shall have the meaning set forth in the Tax Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(42)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Form 10</span>&#8221; means the registration statement on Form 10 filed by OmniAb with the SEC to effect the registration of the OmniAb Stock pursuant to Section 12(b) or 12(g) of the Exchange Act in connection with the Distribution, including any amendments or supplements thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(43)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Former Business</span>&#8221; shall mean any corporation, partnership, entity, division, business unit or business (in each case, including any assets and liabilities comprising the same) that has been sold, conveyed, assigned, transferred, spun-off, split-off or otherwise disposed of or divested (in whole or in part) to a Person or Persons that is not a member of the OmniAb Group or the Ligand Group or the operations, activities or production of which has been discontinued, abandoned, completed or otherwise terminated (in whole or in part), in each case, prior to the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(44)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Governmental Approvals</span>&#8221; shall mean any notices or reports to be submitted to, or other registrations or filings to be made with, or any consents, approvals, licenses, permits or authorizations to be obtained from, any Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(45)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Governmental Filing</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.5(c)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(46)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Governmental Entity</span>&#8221; shall mean any nation or government, any state, municipality or other political subdivision thereof and any entity, body, agency, commission, department, board, bureau or court, whether domestic, foreign, multinational, or supranational exercising executive, legislative, judicial, regulatory, self-regulatory or administrative functions of or pertaining to government and any executive official thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(47)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Group</span>&#8221; shall mean (i) with respect to Ligand, the Ligand Group and (ii) with respect to OmniAb, the OmniAb Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(48)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Hazardous Substance</span>&#8221; shall mean (a) any substances defined, listed, classified or regulated as &#8220;hazardous substances,&#8221; &#8220;hazardous wastes,&#8221; &#8220;hazardous materials,&#8221; &#8220;extremely hazardous wastes,&#8221; &#8220;restricted hazardous wastes,&#8221; &#8220;toxic substances,&#8221; &#8220;toxic pollutants,&#8221; &#8220;contaminants,&#8221; &#8220;pollutants,&#8221; &#8220;wastes,&#8221; &#8220;radioactive materials,&#8221; &#8220;petroleum,&#8221; &#8220;oils&#8221; or designations of similar import under any Environmental Law, or (b) any other chemical, material or substance that is regulated or for which liability can be imposed under any Environmental Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(49)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Indebtedness</span>&#8221; shall mean, with respect to any Person, (i) the principal amount, prepayment and redemption premiums and penalties (if any), unpaid fees and other monetary obligations in respect of any indebtedness for borrowed money, whether short term or long term, and all obligations evidenced by bonds, debentures, notes, other debt securities or similar instruments, (ii) any indebtedness arising under any capital leases (excluding, for the avoidance of doubt, any real estate leases), whether short term or long term, (iii) all liabilities secured by any Security Interest on any assets of such Person, (iv) all liabilities under any interest rate, currency, commodity or other swap, collar, cap or other hedging or similar agreements or arrangements, (v) all liabilities under any interest rate protection agreement, interest rate future agreement, interest rate option agreement, interest rate swap agreement or other similar agreement designed to protect such Person against fluctuations in interest rates, (vi) all interest bearing indebtedness for the deferred purchase price of property or services, (vii) all liabilities under any Credit Support Instruments, (viii) all interest, fees and other expenses owed with respect to indebtedness described in the foregoing clauses (i) through (vii), and (ix) without duplication, all guarantees of indebtedness referred to in the foregoing clauses (i) through (viii), excluding in each case any obligations related to Taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(50)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Indemnifiable Loss</span>&#8221; and &#8220;<span style="font-style:italic;font-weight:bold;">Indemnifiable Losses</span>&#8221; shall mean any and all damages, losses, deficiencies, Liabilities, obligations, penalties, judgments, settlements, claims, payments, fines, interest, costs and expenses (including the costs and expenses of any and all Actions and demands, assessments, judgments, settlements and compromises relating thereto and the costs and expenses of attorneys&#8217;, accountants&#8217;, consultants&#8217; and other professionals&#8217; fees and expenses incurred in the investigation or defense thereof or the enforcement of rights hereunder).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(51)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Indemnifying Party</span>&#8221; shall have the meaning set forth in Section 5.4(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(52)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Indemnitee</span>&#8221; shall have the meaning set forth in Section 5.4(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(53)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Indemnity Payment</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.7(a)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(54)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Information</span>&#8221; shall mean information, content and data (including Personal Information) in written, oral, electronic, computerized, digital or other tangible or intangible media, including (i) books and records, whether accounting, legal or otherwise, ledgers, studies, reports, surveys, designs, specifications, drawings, blueprints, diagrams, models, prototypes, samples, flow charts, marketing plans, customer names and information (including prospects), technical information relating to the design, operation, testing, test results, development, and manufacture of any Party&#8217;s or its Group&#8217;s, or any of their partners&#8217;, products, compounds, technologies or biological, chemical or other materials or facilities (including specifications and documentation; engineering, design and manufacturing drawings, diagrams, layouts, maps and illustrations; formulations and material specifications; laboratory studies and benchmark tests; preclinical and clinical data; quality assurance policies, procedures and specifications; evaluation and validation studies; process control and/or shop-floor control strategy, logic or algorithms; assembly code, Software, firmware, programming data, databases, and all information referred to in the same); costs, margins and pricing; as well as product marketing studies and strategies; all other methodologies, procedures, techniques and Know-How related to discovery, research, engineering, development and manufacturing; communications, correspondence, materials, product literature, artwork, files, documents; and (ii) financial and business information, including earnings reports and forecasts, macro-economic reports and forecasts, all cost information (including partner and supplier records and lists), sales and pricing data, business plans, market evaluations, surveys, credit-related information, and other such information as may be needed for reasonable compliance with reporting, disclosure, filing or other requirements, including under applicable securities laws or regulations of securities exchanges.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(55)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Information Statement</span>&#8221; shall mean the Information Statement attached as an exhibit to the Form 10 and any related documents to be provided to the holders of Ligand Stock in connection with the Distribution, including any potential revision of such Information Statement to be a combined proxy statement, prospectus and/or information statement in connection with the Merger, and including any amendment or supplement thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(56)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Insurance Proceeds</span>&#8221; shall mean those monies: (a) received by an insured Person from any insurer, insurance underwriter, mutual protection and indemnity club or other risk collective; or (b) paid on behalf of an insured Person by any insurer, insurance underwriter, mutual protection and indemnity club or other risk collective, on behalf of the insured, in either such case net of any costs or expenses incurred in the collection thereof; provided, however, that with respect to a captive insurance arrangement, Insurance Proceeds shall only include net amounts received by the captive insurer from a Third Party in respect of any captive reinsurance arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(57)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Intellectual Property</span>&#8221; shall mean all U.S. and foreign rights, title and interest (whether statutory, common law or otherwise) in or relating to any intellectual property, including all: (i) trademarks, trade dress, service marks, certification marks, logos, slogans, design rights, names, corporate names, trade names, brand names and other similar designations of source or origin, together with the goodwill symbolized by any of the foregoing, and all applications, registrations, renewals and extensions of any of the foregoing (collectively, &#8220;<span style="font-style:italic;font-weight:bold;">Trademarks</span>&#8221;); (ii) patents and patent applications, and all related national or international counterparts thereto, including any divisionals, continuations, continuations-in-part, reissues, reexaminations, substitutions provisionals, renewals, extensions, patents of addition, supplementary protection certificates, utility models, inventors&#8217; certificates, or the like, and any foreign equivalents of any of the foregoing (including certificates of invention and any applications therefor) and all rights to claim priority from any of the foregoing (collectively, &#8220;<span style="font-style:italic;font-weight:bold;">Patents</span>&#8221;); (iii) copyrights and copyrightable subject matter, whether or not registered or published, and all applications, registrations, reversions, extensions and renewals of any of the foregoing, and all moral rights, however denominated; (iv) trade secrets, and all other confidential or proprietary information, ideas, technology, Software, compositions, discoveries, improvements, know-how, inventions, designs, processes, techniques, formulae, models, and methodologies, in each case, whether or not patentable or copyrightable, but excluding issued Patents (collectively, &#8220;<span style="font-style:italic;font-weight:bold;">Know-How</span>,&#8221; and trade secrets together with confidential Know-How, &#8220;<span style="font-style:italic;font-weight:bold;">Trade Secrets</span>&#8221;); (v) Internet domain names and social media accounts and addresses, and all registrations for any of the foregoing (collectively, &#8220;<span style="font-style:italic;font-weight:bold;">Domain Names</span>&#8221;); and (vi) rights and remedies with respect to any past, present, or future infringement, misappropriation, or other violation of any of the foregoing in clauses (i) through (v).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(58)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Intellectual Property Documentation</span>&#8221; shall mean: (i) all correct and complete physical and electronic copies of all prosecution and maintenance files and dockets, registration certificates, litigation files and related opinions of counsel and correspondence for all issued, registered and applied-for items of OmniAb Intellectual Property; (ii) all litigation files to the extent relating to any Actions brought for the infringement, dilution, misappropriation or other violation of any of the OmniAb Intellectual Property; (iii) all books, records, files, ledgers or similar documentation used to track, organize or maintain any of the OmniAb Intellectual Property; and (iv) copies of all acquisition agreements relating to the acquisition of any of the OmniAb Intellectual Property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(59)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Internal Reorganization</span>&#8221; shall mean the allocation and transfer or assignment of Assets and Liabilities, including by means of the Conveyancing and Assumption Instruments, resulting in (i) the OmniAb Group owning and operating the OmniAb Business, and (ii) the Ligand Group continuing to own and operate the Ligand Retained Business, as described in the internal reorganization plan attached hereto as Exhibit A (the &#8220;<span style="font-style:italic;font-weight:bold;">Reorganization Plan</span>&#8221;), as may be amended prior to the Distribution Date only by written consent of Ligand, OmniAb and APAC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(60)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">IT Assets</span>&#8221; shall mean all information technology, Software, computers, computer systems, communication systems, telecommunications equipment, databases, internet protocol addresses, data rights and documentation, reference, resource and training materials relating to any of the foregoing, and all Contracts (including Contract rights) relating to any of the foregoing (including Software license agreements, source code escrow agreements, support and maintenance agreements, electronic database access contracts, Domain Name registration agreements, website hosting agreements, Software or website development agreements, outsourcing agreements, service provider agreements, interconnection agreements, governmental permits, radio licenses and telecommunications agreements).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(61)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Joint Claim</span>&#8221; shall mean any claim or series of related claims under any insurance policy that results or could reasonably be expected to result in the payment of Insurance Proceeds to or for the benefit of both one or more members of the Ligand Group and one or more members of the OmniAb Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(62)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Law</span>&#8221; shall mean any applicable U.S. or non-U.S. federal, national, supranational, state, provincial, local or similar statute, law, ordinance, regulation, rule, code, income tax treaty, order, requirement or rule of law (including common law) or other binding directives promulgated, issued, entered into or taken by any Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(63)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Liabilities</span>&#8221; shall mean any and all Indebtedness, liabilities, costs, expenses, interest and obligations, whether accrued or fixed, absolute or contingent, matured or unmatured, known or unknown, reserved or unreserved, or determined or determinable, including those arising under any Law (including Environmental Law), Action, whether asserted or unasserted, or order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Entity and those arising under any Contract or any fines, damages or equitable relief which may be imposed and including all costs and expenses related thereto. Except as otherwise specifically set forth herein, in the Employee Matters Agreement or in the Tax Matters Agreement, the rights and obligations of the Parties with respect to Taxes shall be governed by the Tax Matters Agreement and, therefore, Taxes shall not be treated as Liabilities governed by this Agreement other than for purposes of indemnification related to the Spin-off Disclosure Documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(64)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Liable Party</span>&#8221; shall have the meaning set forth in Section 2.9(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(65)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Ligand</span>&#8221; shall have the meaning set forth in the Preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(66)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Ligand Board</span>&#8221; shall have the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(67)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Ligand CSIs</span>&#8221; shall have the meaning set forth in Section 2.10(d).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(68)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Ligand Former Business</span>&#8221; shall mean any Former Business (other than the OmniAb Business or the OmniAb Former Businesses) that, at the time of sale, conveyance, assignment, transfer, disposition, divestiture (in whole or in part) or discontinuation, abandonment, completion or termination of the operations, activities or production thereof, was primarily managed by or associated with the Ligand Retained Business as then conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(69)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Ligand Group</span>&#8221; shall mean (i) Ligand, the Ligand Retained Business and each Person that is a direct or indirect Subsidiary of Ligand as of immediately following the Distribution Time and (ii) each Business Entity that becomes a Subsidiary of Ligand after the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(70)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Ligand Indemnitees</span>&#8221; shall mean each member of the Ligand Group and each of their respective Affiliates from and after the Distribution Time and each member of the Ligand Group&#8217;s and such Affiliates&#8217; respective current, former and future directors, officers, employees and agents (solely in their respective capacities as current, former and future directors, officers, employees or agents of any member of the Ligand Group or their respective Affiliates) and each of the heirs, executors, successors and assigns of any of the foregoing, except, for the avoidance of doubt, the OmniAb Indemnitees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(71)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Ligand Released Liabilities</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(a)(i)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(72)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Ligand Retained Assets</span>&#8221; shall mean:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>any and all Assets that are expressly contemplated by this Agreement or any Ancillary Agreement as Assets to be retained by Ligand or any other member of the Ligand Group, including for the avoidance of doubt all Ligand Retained IP;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>any and all Assets that are owned, leased or licensed, at or prior to the Distribution Time, by Ligand and/or any of its Subsidiaries, that are not OmniAb Assets; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>any and all Assets that are acquired or otherwise become an Asset of the Ligand Group after the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(73)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Ligand Retained Business</span>&#8221; shall mean (i) those businesses operated by the Ligand Group prior to the Distribution Time other than the OmniAb Business, (ii) those Business Entities or businesses acquired or established by or for any member of the Ligand Group after the Distribution Time, and (iii) any Ligand Former Business; provided that Ligand Retained Business shall not include any OmniAb Former Business or OmniAb Former Real Property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(74)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Ligand Retained IP</span>&#8221; shall mean (i) all Intellectual Property owned or controlled by the Ligand Group other than OmniAb Intellectual Property and (ii) the Ligand Retained Names.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(75)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Ligand Retained Liabilities</span>&#8221; shall mean:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>any and all Liabilities that are expressly contemplated by this Agreement or any Ancillary Agreement as Liabilities to be retained or assumed by Ligand or any other member of the Ligand Group, and all agreements, obligations and other Liabilities of Ligand or any member of the Ligand Group under this Agreement or any of the Ancillary Agreements, including as set forth in Section 2.12(c)(ii);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>any and all Liabilities of a member of the Ligand Group to the extent relating to, arising out of or resulting from any Ligand Retained Assets (other than Liabilities arising under any Shared Contracts to the extent such Liabilities relate to the OmniAb Business);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>the Liabilities listed on Schedule 1.1(75); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>any and all Liabilities of Ligand and each of its Subsidiaries that are not OmniAb Liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Notwithstanding the foregoing, the Ligand Retained Liabilities shall not include any Liabilities for Taxes that are governed by the Tax Matters Agreement or the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(76)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Ligand Retained Names</span>&#8221; shall mean the names and marks set forth in Schedule 1.1(76), and any Trademarks containing or comprising any of such names or marks, and any Trademarks derivative thereof or confusingly similar thereto, or any telephone numbers or other alphanumeric addresses or mnemonics containing any of the foregoing names or marks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(77)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Ligand Stock</span>&#8221; shall have the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(78)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Litigation Hold</span>&#8221; shall have the meaning set forth in Section 6.1.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(79)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Merger</span>&#8221; shall have the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(80)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Merger Agreement</span>&#8221; shall have the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(81)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Merger Sub</span>&#8221; shall have the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(82)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Negotiation Period</span>&#8221; shall have the meaning set forth in Section 7.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(83)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Off-Site Location</span>&#8221; shall mean any third party location that is not now nor has ever been owned, leased or operated by the Ligand Group or the OmniAb Group or any of their respective predecessors. &#8220;<span style="font-style:italic;font-weight:bold;">Off-Site Location</span>&#8221; does not include any property that is adjacent to or neighboring any property formerly, currently or in the future owned, leased or operated by the Ligand Group, the OmniAb Group, or their respective predecessors that has been impacted by any Release of a Hazardous Substance from such properties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(84)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">OmniAb</span>&#8221; shall have the meaning set forth in the Preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(85)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Asset Transferee</span>&#8221; shall mean any Business Entity that is or will be a member of the OmniAb Group or a Subsidiary of OmniAb to which OmniAb Assets shall be or have been transferred at or prior to the Distribution Time, or which is contemplated by the Internal Reorganization or this Agreement or the Ancillary Agreements to occur after the Distribution Time, by an Asset Transferor in order to consummate the transactions contemplated hereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(86)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Assets</span>&#8221; shall mean, without duplication:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>all interests in the capital stock of, or membership or other equity interests in, the members of the OmniAb Group (other than OmniAb) held, directly or indirectly, by Ligand immediately prior to the Distribution Time;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>the Assets set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.1(86)(ii)</span> (which for the avoidance of doubt is not a comprehensive listing of all OmniAb Assets and is not intended to limit other clauses of this definition of OmniAb Assets);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>any and all Assets that are expressly contemplated by this Agreement or any Ancillary Agreement as Assets which have been or are to be Transferred to or retained by any member of the OmniAb Group;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>any and all Assets (other than Cash Equivalents, which shall be governed solely by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.12</span>) reflected on the OmniAb Balance Sheet or the accounting records supporting such balance sheet and any Assets acquired by or for OmniAb or any member of the OmniAb Group subsequent to the date of the OmniAb Balance Sheet which, had they been so acquired on or before such date and owned as of such date, would have been reflected on the OmniAb Balance Sheet if prepared on a consistent basis, subject to any dispositions of any of such Assets subsequent to the date of the OmniAb Balance Sheet;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span>all rights, title and interest in, to and under the leases or subleases of the real property set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.1(86)(v)</span> and other leases exclusively related to the OmniAb Business, including, to the extent provided for in such leases or subleases, any land and land improvements, structures, buildings and building improvements, other improvements and appurtenances (the &#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Leased Real Property</span>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</span></span>all Contracts set forth on Schedule 1.1(86)(vi) and all other Contracts exclusively related to the OmniAb Business or the OmniAb Intellectual Property and any rights or claims arising under any of the foregoing (the &#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Contracts</span>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vii)</span></span>all Intellectual Property exclusively used, exclusively practiced, exclusively held for the use or practice, or otherwise exclusively related to the OmniAb Business, including the Intellectual Property applications, registrations and issuances set forth on Schedule 1.1(86)(vii) (the &#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Intellectual Property</span>&#8221;), and all Intellectual Property Documentation relating to any of the foregoing;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(viii)</span></span>all licenses, permits, registrations, approvals and authorizations which have been issued by any Governmental Entity and are held by a member of the OmniAb Group, or to the extent transferable, relate exclusively to or, are used exclusively in the OmniAb Business (other than to the extent that any member of the Ligand Group benefits from such licenses, permits, registrations, approvals and authorizations in connection with the Ligand Retained Business);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ix)</span></span>all Information exclusively related to, or exclusively used in, the OmniAb Business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(x)</span></span>excluding any OmniAb Intellectual Property (which is addressed in Section 1.1(86)(vii) above), all IT Assets listed on Schedule 1.1(86)(x) and other IT Assets exclusively used or exclusively held for use in the OmniAb Business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xi)</span></span>all goodwill exclusively related to the OmniAb Business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xii)</span></span>all office equipment and furnishings located at the physical site of which the ownership or a leasehold or sub leasehold interest is being transferred to or retained by a member of the OmniAb Group, and which as of the Distribution Time is not subject to a lease or sublease back to a member of the Ligand Group (excluding any office equipment and furnishings owned by persons other than Ligand and its Subsidiaries);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xiii)</span></span>subject to Article VIII, any rights of any member of the OmniAb Group under any insurance policies held solely by one or more members of the OmniAb Group and which provide coverage solely to one or more members of the OmniAb Group (excluding any insurance policies issued by any captive insurance company of the Ligand Group); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xiv)</span></span>all other Assets (other than Assets that are of the type that would be listed in clauses (v), (vii), (viii), (x), (xii) and (xiii)) that are held by the OmniAb Group or the Ligand Group immediately prior to the Distribution Time and that are exclusively used and exclusively held for use in the OmniAb Business as conducted immediately prior to the Distribution Time (the intention of this clause (xiv) is only to rectify an inadvertent omission of transfer or assignment of any Asset that, had the Parties given specific consideration to such Asset as of the date of this Agreement, would have otherwise been classified as an OmniAb Asset based on the principles of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1.1(86))</span>; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that no Asset shall be an OmniAb Asset solely as a result of this clause (xiv) unless a written claim with respect thereto is made by OmniAb on or prior to the date that is twenty-four (24) months after the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Notwithstanding anything to the contrary herein, the OmniAb Assets shall not include (i) any Assets that are expressly contemplated by this Agreement or by any Ancillary Agreement (or the Schedules hereto or thereto) as Assets to be retained by or Transferred to any member of the Ligand Group (including all Ligand Retained Assets), or (ii) any Assets governed by the Tax Matters Agreement or Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(87)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Balance Sheet</span>&#8221; shall mean OmniAb&#8217;s unaudited pro forma combined condensed balance sheet, including the notes thereto, as of December 31, 2021, as included in the Form 10.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(88)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Board</span>&#8221; shall have the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(89)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Business</span>&#8221; shall mean the businesses comprising the OmniAb Group, including the businesses and operations conducted prior to the Distribution Time by any member of the OmniAb Group and any other businesses or operations conducted </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">primarily through the use of the OmniAb Assets, as such businesses are described in the Form 10, or established by or for OmniAb or any of its Subsidiaries after the Distribution Time and shall include the OmniAb Former Businesses; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that the OmniAb Business shall not include any Ligand Former Business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(90)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Debt Obligations</span>&#8221; shall mean all Indebtedness of OmniAb or any other member of the OmniAb Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(91)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Disclosure</span>&#8221; shall mean any form, statement, schedule or other material (other than the Spin-off Disclosure Documents) filed with or furnished to the Commission, including in connection with OmniAb&#8217;s obligations under the Securities Act and the Exchange Act, any other Governmental Entity, or holders of any securities of any member of the OmniAb Group, in each case, on or after the Distribution Time by or on behalf of any member of the OmniAb Group in connection with the registration, sale, or distribution of securities or disclosure related thereto (including periodic disclosure obligations).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(92)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Environmental Liabilities</span>&#8221; shall mean any and all Environmental Liabilities, whether arising before, at or after the Distribution Time, to the extent relating to or resulting from or arising out of (i) the past, present or future operation, conduct or actions of the OmniAb Group, OmniAb Business or the past, present or future use of the OmniAb Assets or (ii) the OmniAb Former Businesses or OmniAb Former Real Property, including, without limitation, any agreement, decree, judgment, or order relating to the foregoing entered into by Ligand or any Affiliate of Ligand prior to the Distribution Time, but in any event excluding the Excluded Environmental Liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(93)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Former Businesses</span>&#8221; shall mean any Former Business that, at the time of sale, conveyance, assignment, transfer, disposition, divestiture (in whole or in part) or discontinuation, abandonment, completion or termination of the operations, activities or production thereof, was (a) primarily managed by or associated with the OmniAb Business as then conducted or (b) part of a business the majority of which as of the Distribution Time is or was transferred to OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(94)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Former Real Property</span>&#8221; shall mean any real property that at the time of sale, conveyance, assignment, transfer, disposition, divestiture (in whole or in part) or discontinuation, abandonment, completion or termination of the operations, activities or production thereof, was primarily owned, leased or operated in connection with the OmniAb Business or any of the OmniAb Former Businesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(95)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Group</span>&#8221; shall mean OmniAb and each Person that is a direct or indirect Subsidiary of OmniAb as of the Distribution Time (but after giving effect to the Internal Reorganization) including the Transferred Entities, and each Person that becomes a Subsidiary of OmniAb after the Distribution Time; provided, however, that for the avoidance of doubt, no member of the Ligand Group shall be treated as a member of the OmniAb Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(96)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Indemnitees</span>&#8221; shall mean each member of the OmniAb Group and each of their respective Affiliates from and after the Distribution Time and each member of the OmniAb Group&#8217;s and such respective Affiliates&#8217; respective current, former and future directors, officers, employees and agents (solely in their respective capacities as current, former and future directors, officers, employees or agents of any member of the OmniAb Group or their respective Affiliates) and each of the heirs, administrators, executors, successors and assigns of any of the foregoing, except, for the avoidance of doubt, the Ligand Indemnitees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(97)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Liabilities</span>&#8221; shall mean:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>any and all Liabilities to the extent relating to, arising out of or resulting from (a) the operation or conduct of the OmniAb Business, as conducted at any time prior to, at or after the Distribution Time (including any Liability relating to, arising out of or resulting from any act or failure to act by any director, officer, employee, agent or representative (whether or not such act or failure to act is or was within such Person&#8217;s authority) of the OmniAb Group and any and all Liability relating to, arising out of or resulting from any unclaimed property); (b) the operation or conduct of any business conducted by any member of the OmniAb Group at any time after the Distribution Time (including any Liability relating to, arising out of or resulting from any act or failure to act by any director, officer, employee, agent or representative (whether or not such act or failure to act is or was within such Person&#8217;s authority) of the OmniAb Group and any and all Liability relating to, arising out of or resulting from any unclaimed property); or (c) any OmniAb Asset, whether arising before, at or after the Distribution Time (including any Liability relating to, arising out of or resulting from OmniAb Contracts, Shared Contracts (to the extent such Liability relates to the OmniAb Business) and any real property and leasehold interests):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>the Liabilities set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.1(97)(ii)</span> and any and all other Liabilities that are expressly provided by this Agreement or any of the Ancillary Agreements as Liabilities to be assumed by OmniAb or any other member of the OmniAb Group, and all agreements, obligations and Liabilities of OmniAb or any other member of the OmniAb Group under this Agreement or any of the Ancillary Agreements;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>any and all Liabilities reflected on the OmniAb Balance Sheet or the accounting records supporting such balance sheet and any Liabilities incurred by or for OmniAb or any member of the OmniAb Group subsequent to the date of the OmniAb Balance Sheet which, had they been so incurred on or before such date, would have been reflected on the OmniAb Balance Sheet if prepared on a consistent basis, subject to any discharge of any of such Liabilities subsequent to the date of the OmniAb Balance Sheet;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>any and all Liabilities to the extent relating to, arising out of, or resulting from, whether prior to, at or after the Distribution Time, any infringement, misappropriation or other violation of any Intellectual Property of any other Person related to the conduct of the OmniAb Business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span>any and all OmniAb Environmental Liabilities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</span></span>any and all Liabilities (including under applicable federal and state securities Laws) relating to, arising out of or resulting from (A) the Spin-off Disclosure Documents or (B) any OmniAb Disclosure;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vii)</span></span>for the avoidance of doubt, and without limiting any other matters that may constitute OmniAb Liabilities, any Liabilities resulting from any Action to the extent relating to, arising out of or resulting from the OmniAb Business, including all Actions listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.1(97)(vii)</span>;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(viii)</span></span>all Liabilities relating to, arising out of or resulting from any Indebtedness of any member of the OmniAb Group or any Indebtedness secured exclusively by any of the OmniAb Assets; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ix)</span></span>any and all other Liabilities that are held by the OmniAb Group or the Ligand Group immediately prior to the Distribution Time that were inadvertently omitted or assigned that, had the parties given specific consideration to such Liability as of the date of this Agreement, would have otherwise been classified as an OmniAb Liability based on the principles set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1.1(97)</span>; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that no Liability shall be an OmniAb Liability solely as a result of this clause (ix) unless a claim with respect thereto is made by Ligand on or prior to the date that is twenty-four (24) months after the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Notwithstanding the foregoing, the OmniAb Liabilities shall not include any Liabilities that are (A) expressly contemplated by this Agreement or by any Ancillary Agreement (or the Schedules hereto or thereto) as Liabilities to be Assumed by any member of the Ligand Group, (B) expressly discharged pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.4</span> of this Agreement, (C) Ligand Retained Liabilities or (D) for Taxes that are governed by the Tax Matters Agreement or Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">(98)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Released Liabilities</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(a)(ii)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">(99)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Stock</span>&#8221; shall have the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(100)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Other Party</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.9(a)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(101)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Other Reimbursable Expenses</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.12(c)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(102)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Party</span>&#8221; and &#8220;<span style="font-style:italic;font-weight:bold;">Parties</span>&#8221; shall have the meanings set forth in the Preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(103)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Person</span>&#8221; shall mean any natural person, firm, individual, corporation, business trust, joint venture, association, bank, land trust, trust company, company, limited liability company, partnership, or other organization or entity, whether incorporated or unincorporated, or any Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(104)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Personal Information</span>&#8221; shall mean any data or information that identifies, relates to, describes, is reasonably capable of being associated with, or could reasonably be linked, directly or indirectly, with a particular natural person or household (including any information related to the health of a person) and any information derived from any of the foregoing, in addition to any definition </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">for &#8220;personal information&#8221; or any similar term provided by applicable Law or by the applicable Party&#8217;s privacy policies, notices or contracts (e.g., &#8220;personal data,&#8221; &#8220;personally identifiable information&#8221; or &#8220;PII&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(105)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Policies</span>&#8221; or &#8220;<span style="font-style:italic;font-weight:bold;">Policy</span>&#8221; shall mean insurance policies and insurance contracts of any kind, including primary, excess and umbrella, comprehensive general liability, fiduciary, directors and officers, automobile, products, workers&#8217; compensation, employee dishonesty, property and crime insurance policies and self-insurance and captive insurance arrangements, and interests in insurance pools and programs held in the name of Ligand or any of its Affiliates, together with the rights, benefits and privileges thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(106)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Prime Rate</span>&#8221; shall mean the rate last quoted as of the time of determination by The Wall Street Journal as the &#8220;Prime Rate&#8221; in the United States or, if the Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Federal Reserve Board in Federal Reserve Statistical Release H.15 (519) (Selected Interest Rates) as the &#8220;bank prime loan&#8221; rate as of such time, or, if such rate is no longer quoted therein, any similar rate quoted therein (as determined by Ligand) or any similar release by the Federal Reserve Board (as determined by Ligand).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(107)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Privacy Laws</span>&#8221; shall mean any and all applicable Laws, legal requirements and self-regulatory guidelines (including of any applicable foreign jurisdiction) relating to the Processing of any Personal Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(108)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Privacy Requirements</span>&#8221; shall mean all applicable Privacy Laws and all applicable policies, notices, and contractual obligations relating to the Processing of any Personal Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(109)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Privilege</span>&#8221; shall have the meaning set forth in Section 6.7(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(110)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Privileged Information</span>&#8221; shall have the meaning set forth in Section 6.7(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(111)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Processing</span>&#8221; shall mean any operation or set of operations which is performed on any Personal Information or on any sets of any Personal Information, whether or not by automated means, such as, without limitation: receipt; collection; compilation; use; disposal; destruction; disclosure or transfer (including cross-border); recording; organization; structuring; safeguarding; storage; security (technical, physical and/or administrative); sharing; adaptation or alteration; retrieval; consultation; disclosure by transmission, dissemination or otherwise making available; alignment or combination; restriction; erasure; and/or destruction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(112)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Record Date</span>&#8221; shall mean 5:00 p.m. New York time on the date to be determined by the Ligand Board as the record date for determining stockholders of Ligand entitled to receive shares of OmniAb Stock in the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(113)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Record Holders</span>&#8221; shall mean the holders of record of Ligand Stock as of the Record Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(114)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Reimbursable Transaction-related Expenses</span>&#8221; shall have the meaning set forth in Section 9.5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(115)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Release</span>&#8221; shall mean any release, spill, emission, discharge, leaking, pumping, injection, deposit, disposal, dispersal, leaching or migration into the indoor or outdoor environment (including ambient air, surface water, groundwater and surface or subsurface strata) or into or out of any property, including the movement of Hazardous Substances through or in the air, soil, surface water, groundwater or property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(116)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Securities Act</span>&#8221; shall mean the Securities Act of 1933, together with the rules and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(117)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Security Interest</span>&#8221; shall mean any mortgage, security interest, pledge, lien, charge, claim, option, right to acquire, voting or other restriction, right-of-entry, covenant, condition, easement, encroachment, restriction on transfer, or other encumbrance of any nature whatsoever, excluding restrictions on transfer under securities Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(118)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Separation</span>&#8221; shall have the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(119)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Shared Contract</span>&#8221; shall have the meaning set forth in Section 2.3(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(120)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Software</span>&#8221; shall mean all: (i) computer programs, including all software implementations of algorithms, models and methodologies, whether in source code, object code, human readable form or other form; (ii) databases and compilations, including all data and collections of data, whether machine readable or otherwise; (iii) descriptions, flow charts and other work products used to </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">design, plan, organize and develop any of the foregoing, screens, user interfaces, report formats, firmware, development tools, templates, menus, buttons, icons, web content and links; and (iv) documentation relating to any of the foregoing, including user manuals and other training documentation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(121)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Specific Milestone Payments</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.12(c)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(122)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Spin-off Disclosure Documents</span>&#8221; shall mean the Form 10 and all exhibits thereto including the Information Statement, and any current reports on Form 8-K, in each case as filed or furnished by OmniAb with or to the Commission in connection with the Distribution or Merger or filed or furnished by Ligand with or to the Commission solely to the extent such documents relate to OmniAb, the Distribution or the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(123)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Subsidiary</span>&#8221; shall mean with respect to any Person (i) a corporation, fifty percent (50%) or more of the voting or capital stock of which is, as of the time in question, directly or indirectly owned by such Person and (ii) any other Person in which such Person, directly or indirectly, owns fifty percent (50%) or more of the equity or economic interest thereof or has the power to elect or direct the election of fifty percent (50%) or more of the members of the governing body of such entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(124)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Tax</span>&#8221; or &#8220;<span style="font-style:italic;font-weight:bold;">Taxes</span>&#8221; shall have the meaning set forth in the Tax Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(125)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Tax Contest</span>&#8221; shall have the meaning as set forth in the Tax Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(126)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Tax Matters Agreement</span>&#8221; shall mean that certain Tax Matters Agreement to be entered into between Ligand and OmniAb in connection with the Separation, the Distribution or the other transactions contemplated by this Agreement, as such agreement may be modified or amended from time to time in accordance with its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(127)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Tax Returns</span>&#8221; shall have the meaning set forth in the Tax Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(128)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Taxing Authority</span>&#8221; shall have the meaning set forth in the Tax Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(129)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Third Party Agreements</span>&#8221; shall mean any agreements, arrangements, commitments or understandings between or among a Party (or any member of its Group) and any other Persons (other than either Party or any member of its respective Groups) (it being understood that to the extent that the rights and obligations of the Parties and the members of their respective Groups under any such Contracts constitute OmniAb Assets or OmniAb Liabilities, or Ligand Retained Assets or Ligand Retained Liabilities, such Contracts shall be assigned or retained pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article II</span>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(130)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Third Party Claim</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.4(b)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(131)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Third Party Proceeds</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.7(a).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(132)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Transaction-related Expenses</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.5</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(133)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Transfer</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(b)(i)</span>; and the term &#8220;<span style="font-style:italic;font-weight:bold;">Transferred</span>&#8221; shall have its correlative meaning.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(134)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Transferred Entities</span>&#8221; shall mean Ab Initio Biotherapeutics, Inc., Crystal Bioscience, Inc., Icagen, LLC, Taurus Biosciences, LLC and xCella Biosciences, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(135)</span></span>&#8220;<span style="font-style:italic;font-weight:bold;">Transition Services Agreements</span>&#8221; shall mean either or both, as applicable, of those certain Transition Services Agreements to be entered into between Ligand and OmniAb or any members of their respective Groups in connection with the Distribution or the other transactions contemplated by this Agreement, as such agreements may be modified or amended from time to time in accordance with their terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_1_2_References_Interpretation"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 1.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">References; Interpretation</span>. References in this Agreement to any gender include references to all genders, and references to the singular include references to the plural and vice versa. Unless the context otherwise requires, the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; when used in this Agreement shall be deemed to be followed by the phrase &#8220;without limitation&#8221;. Unless the context otherwise requires, references in this Agreement to Articles, Sections, Annexes, Exhibits and Schedules shall be deemed </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">references to Articles and Sections of, and Annexes, Exhibits and Schedules to, this Agreement. Unless the context otherwise requires, the words &#8220;hereof&#8221;, &#8220;hereby&#8221; and &#8220;herein&#8221; and words of similar meaning when used in this Agreement refer to this Agreement in its entirety and not to any particular Article, Section or provision of this Agreement. The words &#8220;written request&#8221; when used in this Agreement shall include email. Reference in this Agreement to any time shall be to New York City, New York time unless otherwise expressly provided herein. Unless the context requires otherwise, references in this Agreement to &#8220;<span style="font-style:italic;font-weight:bold;">Ligand</span>&#8221; shall also be deemed to refer to the applicable member of the Ligand Group, references to &#8220;<span style="font-style:italic;font-weight:bold;">OmniAb</span>&#8221; shall also be deemed to refer to the applicable member of the OmniAb Group and, in connection therewith, any references to actions or omissions to be taken, or refrained from being taken, as the case may be, by Ligand or OmniAb shall be deemed to require Ligand or OmniAb, as the case may be, to cause the applicable members of the Ligand Group or the OmniAb Group, respectively, to take, or refrain from taking, any such action. In the event of any inconsistency or conflict which may arise in the application or interpretation of any of the definitions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1.1</span>, for the purpose of determining what is and is not included in such definitions, any item explicitly included on a Schedule referred to in any such definition shall take priority over any provision of the text thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_ARTICLEII_THESEPARATION"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">THE SEPARATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_2_1General"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 2.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</span>. Subject to the terms and conditions of this Agreement, the Parties shall use, and shall cause their respective Affiliates to use, their respective commercially reasonable efforts to consummate the transactions contemplated hereby, including the completion of the Internal Reorganization, a portion of which may have already been implemented prior to the date hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_2_2_RestructuringTransferof"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 2.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restructuring: </span>Transfer<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> of Assets; Assumption of Liabilities</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Internal Reorganization</span>. Prior to the Distribution Time, except for Transfers contemplated by the Internal Reorganization or this Agreement or the Ancillary Agreements to occur after the Distribution Time, the Parties shall complete the Internal Reorganization, including by taking the actions referred to in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 2.2(b)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.2(c)</span> below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer of Assets</span>. At or prior to the Distribution Time (it being understood that some of such Transfers may occur following the Distribution Time in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(a)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.6</span>), pursuant to the Conveyancing and Assumption Instruments and in connection with the Contribution:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>Ligand shall, and shall cause the applicable Asset Transferors to, transfer, contribute, distribute, assign and/or convey or cause to be transferred, contributed, distributed, assigned and/or conveyed (&#8220;<span style="font-style:italic;font-weight:bold;">Transfer</span>&#8221;) to OmniAb and/or the respective OmniAb Asset Transferees, all of its and the applicable Asset Transferors&#8217; right, title and interest in and to the OmniAb Assets, and the applicable OmniAb Asset Transferees shall accept from Ligand and the applicable members of the Ligand Group all of Ligand&#8217;s and the other members of the Ligand Group&#8217;s respective direct or indirect rights, title and interest in and to the applicable Assets, including all of the outstanding shares of capital stock or other ownership interests, that are included in the OmniAb Assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>Any costs and expenses incurred after the Distribution Time to effect any Transfer contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(b)</span> (including any transfer effected pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.6</span>) shall be paid by the Parties as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.5</span>. Other than costs and expenses incurred in accordance with the foregoing sentence, nothing in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(b)</span> shall require any member of any Group to incur any material obligation or grant any material concession for the benefit of any member of any other Group in order to effect any transaction contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(b)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">For the avoidance of doubt any OmniAb Assets already held by OmniAb prior to the Internal Reorganization shall not need to be Transferred and shall remain with OmniAb prior to and following the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assumption of Liabilities</span>. Except as pursuant to this Agreement or as otherwise specifically set forth in any Ancillary Agreement, in connection with the Internal Reorganization and the Contribution or, if applicable, from and after, the Distribution Time (i) pursuant to this Agreement or the applicable Conveyancing and Assumption Instruments, OmniAb shall, or shall cause a member of the OmniAb Group to accept, assume (or, as applicable, retain) and perform, discharge and fulfill, in accordance with their respective terms (&#8220;<span style="font-style:italic;font-weight:bold;">Assume</span>&#8221;), all of the OmniAb Liabilities and (ii) pursuant to this Agreement or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">the</span> applicable Conveyancing and Assumption Instruments, Ligand shall, or shall cause a member of the Ligand Group to, Assume all of the Ligand Retained Liabilities, in each case, regardless of (A) when or where such Liabilities arose or arise, (B) whether the facts upon which they are based occurred prior to, at or subsequent to the Distribution Time, (C) whether accruals for such Liabilities </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">have been transferred to OmniAb or included on a combined balance sheet of the OmniAb Business or whether any such accruals are sufficient to cover such Liabilities, (D) where or against whom such Liabilities are asserted or determined, (E) whether arising from or alleged to arise from negligence, gross negligence, recklessness, violation of Law, fraud or misrepresentation by any member of the Ligand Group or the OmniAb Group, as the case may be, or any of their past or present respective directors, officers, employees, agents, Subsidiaries or Affiliates, (F) which entity is named in any Action associated with any Liability, or (G) any benefits, or lack thereof, that have been or may be obtained by the Ligand Group or the OmniAb Group in respect of such Liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consents</span>. The Parties shall use their commercially reasonable efforts to obtain the Consents required to Transfer any Assets, Contracts, licenses, permits and authorizations issued by any Governmental Entity or parts thereof as contemplated by this Agreement. Notwithstanding anything herein to the contrary, no Contract or other Asset shall be transferred if it would violate applicable Law or, in the case of any Contract, the rights of any third party to such Contract; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.6</span>, to the extent provided therein, shall apply thereto. The foregoing shall not preclude OmniAb or any member of the OmniAb Group from disputing in good faith with any third party (other than Ligand or any member of the Ligand Group) the validity of any OmniAb Liabilities or raising any available defenses in connection therewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>It is understood and agreed by the Parties that certain of the Transfers referenced in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(b)</span> or Assumptions referenced in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(c)</span> have occurred prior to the date hereof and, as a result, no additional Transfers or Assumptions by any <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">member</span> of the Ligand Group or the OmniAb Group, as applicable, shall be deemed to occur upon the execution of this Agreement with respect thereto. Moreover, to the extent that any member of the Ligand Group or the OmniAb Group, as applicable, is liable for any Ligand Retained Liability or OmniAb Liability, respectively, by operation of law immediately following any Transfer in accordance with this Agreement or any Conveyancing and Assumption Instruments, there shall be no need for any other member of the Ligand Group or the OmniAb Group, as applicable, to Assume such Liability in connection with the operation of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(c)</span> and, accordingly, no other member of such Group shall Assume any such Liability in connection with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(c)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_2_3_TreatmentofSharedContra"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 2.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Treatment of Shared Contracts</span>. Without limiting the generality of the obligations set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 2.2(a)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(b)</span>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Unless the Parties otherwise agree or the benefits of any Contract described in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3</span> are expressly conveyed to the applicable Party pursuant to an Ancillary Agreement, and other than as provided by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VIII</span>, any Contract that is listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 2.3(a)</span> (a &#8220;<span style="font-style:italic;font-weight:bold;">Shared Contract</span>&#8221;) shall be assigned in part to the applicable member(s) of the applicable Group, if so assignable, or appropriately amended prior to, at or after the Distribution Time, so that each Party or the members of their respective Groups as of the Distribution Time shall be entitled to the rights and benefits, and shall Assume the related portion of any Liabilities, inuring to their respective Businesses; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that (x) in no event shall any member of any Group be required to assign (or amend) any Shared Contract in its entirety or to assign a portion of any Shared Contract which is not assignable (or cannot be amended) by its terms (including any terms imposing consents or conditions on an assignment where such consents or conditions have not been obtained or fulfilled, subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(d)</span>), and (y) if any Shared Contract cannot be so partially assigned by its terms or otherwise, cannot be amended or has not for any other reason been assigned or amended, or if such assignment or amendment would impair the benefit the parties thereto derive from such Shared Contract, (A) at the reasonable request of the Party (or the member of such Party&#8217;s Group) to which the benefit of such Shared Contract inures in part, the Party for which such Shared Contract is, as applicable, a Ligand Retained Asset or OmniAb Asset shall, and shall cause each of its respective Subsidiaries to, for a period ending not later than six (6) months after the Distribution Date (unless the term of a Shared Contract (excluding any extensions thereof) ends at a later date, in which case for a period ending on such date), take such other reasonable and permissible actions to cause such member of the OmniAb Group or the Ligand Group, as the case may be, to receive the benefit of that portion of each Shared Contract that relates to the OmniAb Business or the Ligand Retained Business, as the case may be (in each case, to the extent so related) as if such Shared Contract had been assigned to (or amended to allow) a member of the applicable Group pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3</span> and to bear the burden of the corresponding Liabilities (including any Liabilities that may arise by reason of such arrangement) as if such Liabilities had been Assumed by a member of the applicable Group pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3</span>; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that the Party for which such Shared Contract is a Ligand Retained Asset or an OmniAb Asset, as applicable, shall be indemnified for all Indemnifiable Losses or other Liabilities arising out of any actions (or omissions to act) of such retaining Party taken at the direction of the other Party (or relevant member of its Group) in connection with and relating to such Shared Contract, as the case may be, and (B) the Party to which the benefit of such Shared Contract inures in part shall use commercially reasonable efforts to enter into a separate contract pursuant to which it procures such rights and obligations as are necessary such that it no longer needs to avail itself of the arrangements provided pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3(a)</span>; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that, the Party for which such Shared Contract is, as applicable, a Ligand Retained Asset or OmniAb </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Asset, any such Party&#8217;s applicable Subsidiaries shall not be liable for any actions or omissions taken in accordance with clause (y) of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3(a)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Unless the Parties otherwise agree, each of Ligand and OmniAb shall, and shall cause the members of its Group to, (A) treat for all Tax purposes the portion of each Shared Contract inuring to its respective Businesses as Assets owned by, and/or Liabilities of, as applicable, such Party as of the Distribution Time and (B) neither report nor take any Tax position (on a Tax Return or otherwise) inconsistent with such treatment (unless required by applicable Law or good faith resolution of a Tax Contest).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_2_4_IntercompanyAccountsLoa"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intercompany Accounts, Loans and Agreements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(b)</span>, all intercompany receivables and payables (other than (x) intercompany loans (which shall be governed by Section 2.4(c)), and (y) payables created or required by this Agreement, any Ancillary Agreement or any Continuing Arrangements) and intercompany balances, including in respect of any cash balances, any cash balances representing deposited checks or drafts or any cash held in any centralized cash management system between any member of the Ligand Group, on the one hand, and any member of the OmniAb Group, on the other hand, which exist and are reflected in the accounting records of the relevant Parties immediately prior to the Distribution Time, shall be paid, performed or otherwise settled on or prior to the Distribution Time, and all arrangements, understandings and agreements relating thereto are hereby terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>As between the Parties (and the members of their respective Group) all payments and reimbursements received after the Distribution Time by one Party (or member of its Group) that relate to a Business, Asset or Liability of the other Party (or member of its Group), shall be held by such Party in trust for the use and benefit of the Party entitled thereto (at the expense of the Party entitled thereto) and, promptly upon receipt by such Party of any such payment or reimbursement, such Party shall pay or shall cause the applicable member of its Group to pay over to the Party entitled thereto the amount of such payment or reimbursement without right of set-off.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Each of Ligand or any member of the Ligand Group, on the one hand, and OmniAb or any member of the OmniAb Group, on the other hand, will settle with the other Party, as the case may be, all intercompany loans, including any promissory notes, owned or owed by the other Party on or prior to the Distribution Time, it being understood and agreed by the Parties that all guarantees and Credit Support Instruments shall be governed by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.10</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_2_5_LimitationofLiabilityI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 2.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitation of Liability; Intercompany Contracts</span>. No Party nor any Subsidiary thereof shall be liable to the other Party or any Subsidiary of the other Party based upon, arising out of or resulting from any Contract, arrangement, course of dealing or understanding between or among it and the other Party existing at or prior to the Distribution Time (other than pursuant to this Agreement, any Ancillary Agreement, any Continuing Arrangements, any Third Party Agreements, or pursuant to any other Contract entered into in connection herewith or in order to consummate the transactions contemplated hereby or thereby) and each Party hereby terminates any and all Contracts, arrangements, courses of dealing or understandings between or among it and the other Party effective as of the Distribution Time (other than as set forth in this Agreement, any Ancillary Agreement, any Continuing Arrangements, any Third Party Agreements, or pursuant to any Contract entered into in connection herewith or in order to consummate the transactions contemplated hereby or thereby), provided, however, that with respect to any Contract, arrangement, course of dealing or understanding between or among the Parties or any Subsidiaries thereof discovered after the Distribution Time, the Parties agree that such Contract, arrangement, course of dealing or understanding shall nonetheless be deemed terminated as of the Distribution Time with the only liability of the Parties in respect thereof to be the obligations incurred between the Parties pursuant to such Contract, arrangement, course of dealing or understanding between the Distribution Time and the time of discovery or later termination of any such Contract, arrangement, course of dealing or understanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_2_6_TransfersNotEffectedat"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 2.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfers Not Effected at or Prior to the Distribution Time</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">; Transfers Deemed Effective as of the Distribution Time</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>To the extent that any Transfers or Assumptions contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article II</span> shall not have been consummated at or prior to the Distribution Time, the Parties shall use commercially reasonable efforts (taking into account any applicable restrictions or considerations, in each case relating to the contemplated Tax treatment of the transactions contemplated hereby) to effect such Transfers or Assumptions as promptly following the Distribution Time as shall be practicable. Nothing herein shall be deemed to require or constitute the Transfer of any Assets or the Assumption of any Liabilities which by their terms or operation of Law cannot be Transferred; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that the Parties and their respective Subsidiaries shall cooperate and use </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">commercially reasonable efforts to seek to obtain, in accordance with applicable Law, any necessary Consents or Governmental Approvals for the Transfer of all Assets and Assumption of all Liabilities contemplated to be Transferred and Assumed pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article II</span> to the fullest extent permitted by applicable Law. In the event that any such Transfer of Assets or Assumption of Liabilities has not been consummated, from and after the Distribution Time, (i) the Party (or relevant member in its Group) retaining such Asset shall thereafter hold (or shall cause such member in its Group to hold) such Asset in trust for the use and benefit of the Party entitled thereto (at the expense of the Party entitled thereto) and (ii) the Party intended to Assume such Liability shall, or shall cause the applicable member of its Group to, pay or reimburse the Party retaining such Liability for all amounts paid or incurred in connection with the retention of such Liability. To the extent the foregoing applies to any Contracts (other than Shared Contracts, which shall be governed solely by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3</span>) to be assigned for which any necessary Consents or Governmental Approvals are not received prior to the Distribution Time, the treatment of such Contracts shall, for the avoidance of doubt, be subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.8</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.9</span>, to the extent applicable. In addition, the Party retaining such Asset or Liability (or relevant member of its Group) shall (or shall cause such member in its Group to) treat, insofar as reasonably possible and to the extent permitted by applicable Law, such Asset or Liability in the ordinary course of business in accordance with past practice and take such other actions as may be reasonably requested by the Party to which such Asset is to be Transferred or by the Party Assuming such Liability in order to place such Party, insofar as reasonably possible and to the extent permitted by applicable Law, in the same position as if such Asset or Liability had been Transferred or Assumed as contemplated hereby and so that all the benefits and burdens relating to such Asset or Liability, including possession, use, risk of loss, potential for income and gain, and dominion, control and command over such Asset or Liability, are to inure from and after the Distribution Time to the relevant member or members of the Ligand Group or the OmniAb Group entitled to the receipt of such Asset or required to Assume such Liability. In furtherance of the foregoing, the Parties agree that, as of the Distribution Time, subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(c)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.9(b)</span>, each Party shall be deemed to have acquired complete and sole beneficial ownership over all of the Assets, together with all rights, powers and privileges incident thereto, and shall be deemed to have Assumed in accordance with the terms of this Agreement all of the Liabilities, and all duties, obligations and responsibilities incident thereto, which such Party is entitled to acquire or required to Assume pursuant to the terms of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>If and when the Consents, Governmental Approvals and/or conditions, the absence or non-satisfaction of which caused the deferral of Transfer of any Asset or deferral of the Assumption of any Liability pursuant to Section 2.6(a), are obtained or satisfied, the Transfer, assignment, Assumption or novation of the applicable Asset or Liability shall be effected without further consideration in accordance with and subject to the terms of this Agreement (including Section 2.2) and/or the applicable Ancillary Agreement, and shall, to the extent possible without the imposition of any undue cost on any Party, be deemed to have become effective as of the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>The Party (or relevant member of its Group) retaining any Asset or Liability due to the deferral of the Transfer of such Asset or the deferral of the Assumption of such Liability pursuant to Section 2.6(a) or otherwise shall (i) not be obligated, in connection with the foregoing, to expend any money unless the necessary funds are advanced, assumed, or agreed in advance to be reimbursed by the Party (or relevant member of its Group) entitled to such Asset or the Person intended to be subject to such Liability, other than reasonable attorneys&#8217; fees and recording or similar or other incidental fees, all of which shall be promptly reimbursed by the Party (or relevant member of its Group) entitled to such Asset or the Person intended to be subject to such Liability and (ii) be indemnified for all Indemnifiable Losses or other Liabilities arising out of any actions (or omissions to act) of such retaining Party taken at the direction of the other Party (or relevant member of its Group) in connection with and relating to such retained Asset or Liability, as the case may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>After the Distribution Time, each Party (or any member of its Group) may receive mail, packages, electronic mail or other electronic communications and any other written communications properly belonging to another Party (or any member of its Group). Accordingly, at all times after the Distribution Time, each Party is hereby authorized to receive and, if reasonably necessary to identify the proper recipient in accordance with this Section 2.6(d), open all mail, packages, electronic mail or other electronic communication and any other written communications received by such Party that belongs to such other Party, and to the extent that they do not relate to the business of the receiving Party, the receiving Party shall promptly deliver such mail, packages, electronic mail or other electronic communication or any other written communications (or, in case the same also relates to the business of the receiving Party or another Party, copies thereof) to such other Party as provided for in Section 9.6; it being understood that if a Party receives a telephone call that relates to the business of the other Party, then the receiving Party shall inform the person making such telephone call to contact the other Party. The provisions of this Section 2.6(d) are not intended to, and shall not, be deemed to constitute an authorization by any Party to permit the other to accept service of process on its behalf and no Party is or shall be deemed to be the agent of any other Party for service of process purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>With respect to Assets and Liabilities described in Section 2.6(a), each of Ligand and OmniAb shall, and shall cause the members of its respective Group to, (i) treat for all Tax purposes (A) the deferred Assets as assets having been Transferred to and owned by the Party entitled to such Assets not later than the Distribution Time and (B) the deferred Liabilities as liabilities having been Assumed and owned by the Person intended to be subject to such Liabilities not later than the Distribution Time and (ii) neither report nor take any Tax position (on a Tax Return or otherwise) inconsistent with such treatment (unless required by applicable Law or good faith resolution of a Tax Contest).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_2_7_ConveyancingandAssumptio"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 2.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conveyancing and Assumption Instruments</span>. In connection with, and in furtherance of, the Transfers of Assets and the Assumptions of Liabilities contemplated by this Agreement, the Parties shall execute or cause to be executed, on or after the date hereof by the appropriate entities to the extent not executed prior to the date hereof, any Conveyancing and Assumption Instruments necessary to evidence the valid Transfer to the applicable Party or member of such Party&#8217;s Group of all right, title and interest in and to its accepted Assets and the valid and effective Assumption by the applicable Party of its Assumed Liabilities for Transfers and Assumptions to be effected pursuant to Delaware Law or the Laws of one of the other states of the United States or, if not appropriate for a given Transfer or Assumption, and for Transfers or Assumptions to be effected pursuant to non-U.S. Laws, in such form as the Parties shall reasonably agree, including the Transfer of real property by mutually acceptable conveyance deeds as may be appropriate and in form and substance as may be required by the jurisdiction in which the real property is located; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that the allocation of Assets and Liabilities provided for in any Conveyancing and Assumption Instruments shall be consistent with the terms of this Agreement, unless otherwise approved in writing by the Parties and APAC . The Transfer of capital stock shall, to the extent necessary to evidence a valid Transfer, be effected by means of executed stock powers and notation on the stock record books of the corporation or other legal entities involved, or by such other means as may be required in any non-U.S. jurisdiction to Transfer title to stock and, only to the extent required by applicable Law, by notation on public registries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="B_Section_2_8_FurtherAssurancesAncill"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 2.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances; Ancillary Agreements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>In addition to and without limiting the actions specifically provided for elsewhere in this Agreement and subject to the limitations expressly set forth in this Agreement, including <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.6</span>, each of the Parties shall cooperate with each other and use (and shall cause its respective Subsidiaries and Affiliates to use) commercially reasonable efforts, at and after the Distribution Time, to take, or to cause to be taken, all actions, and to do, or to cause to be done, all things reasonably necessary on its part under applicable Law or contractual obligations to consummate and make effective the transactions contemplated by this Agreement and the Ancillary Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Without limiting the foregoing, at and after the Distribution Time, each Party shall cooperate with the other Party, and without any further consideration, but at the expense of the requesting Party (except as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 2.2(b)(ii)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.6(c)</span>) from and after the Distribution Time, to execute and deliver, or use commercially reasonable efforts to cause to be executed and delivered, all instruments, including instruments of Transfer or title, and to make all filings with, and to obtain all Consents and/or Governmental Approvals, any permit, license, Contract, indenture or other instrument (including any Consents or Governmental Approvals), and to take all such other actions as such Party may reasonably be requested to take by any other Party from time to time, consistent with the terms of this Agreement and the Ancillary Agreements, in order to effectuate the provisions and purposes of this Agreement and the Ancillary Agreements and the Transfers of the applicable Assets and the assignment and Assumption of the applicable Liabilities and the other transactions contemplated hereby and thereby. Without limiting the foregoing, each Party shall, at the reasonable request, cost and expense of any other Party (except as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 2.2(b)(ii)</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.6(c)</span>), take such other actions as may be reasonably necessary to vest in such other Party such title and such rights as possessed by the transferring Party to the Assets allocated to such other Party under this Agreement or any of the Ancillary Agreements, free and clear of any Security Interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Without limiting the foregoing, in the event that any Party (or member of such Party&#8217;s Group) receives or retains any Assets (including the receipt of payments made pursuant to Contracts and proceeds from accounts receivable with respect to such Asset) or is liable for any Liability that is otherwise allocated to any Person that is a member of the other Group pursuant to this Agreement or the Ancillary Agreements, such Party agrees to promptly Transfer, or cause to be Transferred such Asset or Liability to the other Party so entitled thereto (or member of such other Party&#8217;s Group as designated by such other Party) at such other Party&#8217;s expense. Prior to any such Transfer, such Asset or Liability, as the case may be, shall be held in accordance with the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.6</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>At or prior to the Distribution Time, each of Ligand and OmniAb shall enter into, and/or (where applicable) shall cause a member or members of their respective Group to enter into, the Ancillary Agreements and any other Contracts reasonably necessary or appropriate in connection with the transactions contemplated hereby and thereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>On or prior to the Distribution Time, Ligand and OmniAb in their respective capacities as direct or indirect stockholders of their respective Subsidiaries, shall each ratify any actions that are reasonably necessary or desirable to be taken by any Subsidiary of Ligand or Subsidiary of OmniAb, as the case may be, to effectuate the transactions contemplated by this Agreement and the Ancillary Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_2_9_NovationofLiabilitiesI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 2.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Novation of Liabilities; Indemnification</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Each Party, at the request of any member of the other Party&#8217;s Group (such other Party, the &#8220;<span style="font-style:italic;font-weight:bold;">Other Party</span>&#8221;), shall use commercially reasonable efforts (taking into account any applicable restrictions or considerations, in each case relating to the contemplated Tax treatment of the transactions contemplated hereby) to obtain, or to cause to be obtained, any Consent, Governmental Approval, substitution or amendment required to novate or assign to the fullest extent permitted by applicable Law all obligations under Contracts (other than Shared Contracts, which shall be governed by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3</span>) and Liabilities (other than with regard to guarantees or Credit Support Instruments, which shall be governed by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.10</span>), but solely to the extent that the Parties are jointly or each severally liable with regard to any such Contracts or Liabilities and such Contracts or Liabilities have been, in whole, but not in part, allocated to the first Party, or, if permitted by applicable Law, to obtain in writing the unconditional release of the applicable Other Party so that, in any such case, the members of the applicable Group shall be solely responsible for such Contracts or Liabilities; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that no Party shall be obligated to pay any consideration therefor to any third party from whom any such Consent, Governmental Approval, substitution or amendment is requested (unless such Party is fully reimbursed by the requesting Party). In addition, with respect to any Action where any Party hereto is a defendant, when and if requested by such Party, the Other Party at its own cost will use commercially reasonable efforts to remove the requesting Party as a defendant to the extent that such Action relates solely to Assets or Liabilities that the Other Party (or any member of such requesting Party&#8217;s Group) has been allocated pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article II</span>, and the Other Party will cooperate and assist in any required communication with any plaintiff or other related third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>If the Parties are unable to obtain, or to cause to be obtained, any such required Consent, Governmental Approval, release, substitution or amendment referenced in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.9(a)</span>, the Other Party or a member of such Other Party&#8217;s Group shall continue to be bound by such Contract, license or other obligation that does not constitute a Liability of such Other Party and, unless not permitted by Law or the terms thereof, as agent or subcontractor for such Party, the Party or member of such Party&#8217;s Group who Assumed or retained such Liability as set forth in this Agreement (the &#8220;<span style="font-style:italic;font-weight:bold;">Liable Party</span>&#8221;) shall, or shall cause a member of its Group to, pay, perform and discharge fully all the obligations or other Liabilities of such Other Party or member of such Other Party&#8217;s Group thereunder from and after the Distribution Time. For the avoidance of doubt, in furtherance of the foregoing, the Liable Party or a member of such Liable Party&#8217;s Group, as agent or subcontractor of the Other Party or a member of such Other Party&#8217;s Group, to the extent reasonably necessary to pay, perform and discharge fully any Liabilities, or retain the benefits (including pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.6)</span> associated with such Contract or license, is hereby granted the right to, among other things, (i) prepare, execute and submit invoices under such Contract or license in the name of the Other Party (or the applicable member of such Other Party&#8217;s Group), (ii) send correspondence relating to matters under such Contract or license in the name of the Other Party (or the applicable member of such Other Party&#8217;s Group), (iii) file Actions in the name of the Other Party (or the applicable member of such Other Party&#8217;s Group) in connection with such Contract or license and (iv) otherwise exercise all rights in respect of such Contract or license in the name of the Other Party (or the applicable member of such Other Party&#8217;s Group); provided that (y) such actions shall be taken in the name of the Other Party (or the applicable member of such Other Party&#8217;s Group) only to the extent reasonably necessary or advisable in connection with the foregoing and (z) to the extent that there shall be a conflict between the provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.9(b)</span> and the provisions of any more specific arrangement between a member of such Liable Party&#8217;s Group and a member of such Other Party&#8217;s Group, such more specific arrangement shall control. The Liable Party shall indemnify each Other Party and hold each of them harmless against any Liabilities (other than Liabilities of such Other Party) arising in connection therewith; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that the Liable Party shall have no obligation to indemnify the Other Party with respect to any matter to the extent that such Liabilities arise from such Other Party&#8217;s willful breach, knowing violation of Law, fraud, misrepresentation or gross negligence in connection therewith, in which case such Other Party shall be responsible for such Liabilities; it being understood that any exercise of rights under this Agreement by such Other Party shall not be deemed to be willful breach, knowing violation of Law, fraud, misrepresentation or gross negligence. The Other Party shall, without further consideration, promptly pay and remit, or cause to be promptly paid or remitted, to the Liable Party or, at the direction of the Liable Party, to another member of the Liable Party&#8217;s Group, all money, rights and other consideration received by it or any </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">member of its Group in respect of such performance by the Liable Party (unless any such consideration is an Asset of such Other Party pursuant to this Agreement). If and when any such Consent, Governmental Approval, release, substitution or amendment shall be obtained or such agreement, lease, license or other rights or obligations shall otherwise become assignable or able to be novated, the Other Party shall, to the fullest extent permitted by applicable Law, promptly Transfer or cause the Transfer of all rights, obligations and other Liabilities thereunder of such Other Party or any member of such Other Party&#8217;s Group to the Liable Party or to another member of the Liable Party&#8217;s Group without payment of any further consideration and the Liable Party, or another member of such Liable Party&#8217;s Group, without the payment of any further consideration, shall Assume such rights and Liabilities to the fullest extent permitted by applicable Law. Each of the applicable Parties shall, and shall cause their respective Subsidiaries to, take all actions and do all things reasonably necessary on its part, or such Subsidiaries&#8217; part, under applicable Law or contractual obligations to consummate and make effective the transactions contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.9</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_2_10_GuaranteesCreditSuppor"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 2.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Guarantees; Credit Support Instruments</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except as otherwise specified in any Ancillary Agreement, at or prior to the Distribution Time or as soon as practicable thereafter, (i) Ligand shall (with the reasonable cooperation of the applicable member of the OmniAb Group) use its commercially reasonable efforts to have each member of the OmniAb Group removed as guarantor of or obligor for any Ligand Retained Liability to the fullest extent permitted by applicable Law, including in respect of those guarantees set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 2.10(a)(i)</span>, to the extent that they relate to Ligand Retained Liabilities and (ii) OmniAb shall (with the reasonable cooperation of the applicable member of the Ligand Group) use commercially reasonable efforts to have each member of the Ligand Group removed as guarantor of or obligor for any OmniAb Liability, to the fullest extent permitted by applicable Law, including in respect of those guarantees set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 2.10(a)(ii)</span>, to the extent that they relate to OmniAb Liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>At or prior to the Distribution Time, to the extent required to obtain a release from a guaranty:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>of any member of the Ligand Group, OmniAb shall execute a guaranty agreement substantially in the form of the existing guaranty or such other form as is agreed to by the relevant parties to such guaranty agreement, except to the extent that such existing guaranty contains representations, covenants or other terms or provisions either (A) with which OmniAb would be reasonably unable to comply or (B) which would be reasonably expected to be breached; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>of any member of the OmniAb Group, Ligand shall execute a guaranty agreement substantially in the form of the existing guaranty or such other form as is agreed to by the relevant parties to such guaranty agreement, except to the extent that such existing guaranty contains representations, covenants or other terms or provisions either (A) with which Ligand would be reasonably unable to comply or (B) which would be reasonably expected to be breached.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>If Ligand or OmniAb is unable to obtain, or to cause to be obtained, any such required removal as set forth in clauses (a) and (b) of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.10</span>, (i) Ligand, to the extent a member of the Ligand Group has assumed the underlying Liability with respect to such guaranty or OmniAb, to the extent a member of the OmniAb Group has assumed the underlying Liability with respect to such guaranty, as the case may be, shall indemnify and hold harmless the guarantor or obligor for any Indemnifiable Loss arising from or relating thereto (in accordance with the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span>) and shall or shall cause one of its Subsidiaries, as agent or subcontractor for such guarantor or obligor to pay, perform and discharge fully all the obligations or other Liabilities of such guarantor or obligor thereunder, (ii) OmniAb shall reimburse the applicable member of the Ligand Group for all out-of-pocket expenses incurred by it arising out of or related to any such guaranty; and (iii) each of Ligand and OmniAb, on behalf of themselves and the members of their respective Groups, agree not to renew or extend the term of, increase its obligations under, or Transfer to a third party, any loan, guaranty, lease, contract or other obligation for which another Party or member of such Party&#8217;s Group is or may be liable without the prior written consent of such other Party, unless all obligations of such other Party and the other members of such Party&#8217;s Group with respect thereto are thereupon terminated by documentation reasonably satisfactory in form and substance to such Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Ligand and OmniAb shall cooperate and OmniAb shall use commercially reasonable efforts to replace all Credit Support Instruments issued by Ligand or other members of the Ligand Group on behalf of or in favor of any member of the OmniAb Group or the OmniAb Business (the &#8220;<span style="font-style:italic;font-weight:bold;">Ligand CSIs</span>&#8221;) as promptly as practicable with Credit Support Instruments from OmniAb or a member of the OmniAb Group as of the Distribution Time. With respect to any Ligand CSIs that remain outstanding after the Distribution Time, (i) OmniAb shall, and shall cause the members of the OmniAb Group to, jointly and severally indemnify and hold harmless the Ligand Indemnitees for any Liabilities arising from or relating to such Credit Support Instruments, including, without limitation, any fees in connection with the issuance and maintenance thereof and any funds drawn by (or for the benefit </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">of), or disbursements made to, the beneficiaries of such Ligand CSIs in accordance with the terms thereof, (ii) OmniAb shall reimburse the applicable member of the Ligand Group for all out of pocket expenses incurred by it arising out of or related to any such Credit Support Instrument, and (iii) without the prior written consent of Ligand, OmniAb shall not, and shall not permit any member of the OmniAb Group to, enter into, renew or extend the term of, increase its obligations under, or transfer to a third party, any loan, lease, Contract or other obligation in connection with which Ligand or any member of the Ligand Group has issued any Credit Support Instruments which remain outstanding. Neither Ligand nor any member of the Ligand Group will have any obligation to renew any Credit Support Instruments issued on behalf of or in favor of any member of the OmniAb Group or the OmniAb Business after the expiration of any such Credit Support Instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_2_11_DisclaimerofRepresentat"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 2.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclaimer of Representations and Warranties</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>EACH OF LIGAND (ON BEHALF OF ITSELF AND EACH MEMBER OF THE LIGAND GROUP), OMNIAB (ON BEHALF OF ITSELF AND EACH MEMBER OF THE OMNIAB GROUP) AND APAC UNDERSTANDS AND AGREES THAT, EXCEPT AS EXPRESSLY SET FORTH HEREIN, IN ANY ANCILLARY AGREEMENT OR IN ANY CONTINUING ARRANGEMENT, NO PARTY TO THIS AGREEMENT, ANY ANCILLARY AGREEMENT OR ANY OTHER AGREEMENT OR DOCUMENT CONTEMPLATED BY THIS AGREEMENT, ANY ANCILLARY AGREEMENTS OR OTHERWISE, IS REPRESENTING OR WARRANTING IN ANY WAY, AND HEREBY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, AS TO THE ASSETS, BUSINESSES OR LIABILITIES CONTRIBUTED, TRANSFERRED OR ASSUMED AS CONTEMPLATED HEREBY OR THEREBY, AS TO ANY CONSENTS OR GOVERNMENTAL APPROVALS REQUIRED IN CONNECTION HEREWITH OR THEREWITH, AS TO THE VALUE OR FREEDOM FROM ANY SECURITY INTERESTS OF, AS TO NONINFRINGEMENT, VALIDITY OR ENFORCEABILITY OR ANY OTHER MATTER CONCERNING, ANY ASSETS OR BUSINESS OF SUCH PARTY, OR AS TO THE ABSENCE OF ANY DEFENSES OR RIGHT OF SETOFF OR FREEDOM FROM COUNTERCLAIM WITH RESPECT TO ANY ACTION OR OTHER ASSET, INCLUDING ACCOUNTS RECEIVABLE, OF ANY PARTY, OR AS TO THE LEGAL SUFFICIENCY OF ANY CONTRIBUTION, ASSIGNMENT, DOCUMENT, CERTIFICATE OR INSTRUMENT DELIVERED HEREUNDER TO CONVEY TITLE TO ANY ASSET OR THING OF VALUE UPON THE EXECUTION, DELIVERY AND FILING HEREOF OR THEREOF. FOR THE AVOIDANCE OF DOUBT, THIS <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 2.11</span> SHALL HAVE NO EFFECT ON ANY REPRESENTATION OR WARRANTY MADE HEREIN, IN THE MERGER AGREEMENT OR IN ANY ANCILLARY AGREEMENT OR ANY OTHER AGREEMENT OR DOCUMENT CONTEMPLATED BY THIS AGREEMENT, THE MERGER AGREEMENT OR ANY ANCILLARY AGREEMENT. EXCEPT AS MAY EXPRESSLY BE SET FORTH HEREIN OR THEREIN, ALL SUCH ASSETS ARE BEING TRANSFERRED ON AN &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AS IS, WHERE IS</span>&#8221; BASIS (AND, IN THE CASE OF ANY REAL PROPERTY, BY MEANS OF A QUITCLAIM OR SIMILAR FORM DEED OR CONVEYANCE) AND THE RESPECTIVE TRANSFEREES SHALL BEAR THE ECONOMIC AND LEGAL RISKS THAT (I) ANY CONVEYANCE SHALL PROVE TO BE INSUFFICIENT TO VEST IN THE TRANSFEREE GOOD TITLE, FREE AND CLEAR OF ANY SECURITY INTEREST AND (II) ANY NECESSARY CONSENTS OR GOVERNMENTAL APPROVALS ARE NOT OBTAINED OR THAT ANY REQUIREMENTS OF LAWS OR JUDGMENTS ARE NOT COMPLIED WITH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Each of Ligand (on behalf of itself and each member of the Ligand Group), OmniAb (on behalf of itself and each member of the OmniAb Group) and APAC further understands and agrees that if the disclaimer of express or implied representations and warranties contained in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.11(a)</span> is held unenforceable or is unavailable for any reason under the Laws of any jurisdiction outside the United States or if, under the Laws of a jurisdiction outside the United States, both Ligand or any member of the Ligand Group, on the one hand, and OmniAb or any member of the OmniAb Group, on the other hand, are jointly or severally liable for any Ligand Retained Liability or any OmniAb Liability, respectively, then, the Parties and APAC intend that, notwithstanding any provision to the contrary under the Laws of such foreign jurisdictions, the provisions of this Agreement, the Merger Agreement and the Ancillary Agreements (including the disclaimer of all representations and warranties (except as otherwise provided in any such agreements), allocation of Liabilities among the Parties and their respective Subsidiaries, releases, indemnification and contribution of Liabilities) shall prevail for any and all purposes among the Parties and APAC and their respective Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>OmniAb hereby waives compliance by Ligand and each and every member of the Ligand Group with the requirements and provisions of any &#8220;bulk-sale&#8221; or &#8220;bulk transfer&#8221; Laws of any jurisdiction that may otherwise be applicable with respect to the transfer or sale of any or all of the OmniAb Assets to OmniAb or any member of the OmniAb Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_2_12_CashManagementConsider"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 2.12</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash Management; Consideration</span>.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except as provided in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.12</span>, all cash and Cash Equivalents held by any member of the OmniAb Group as of the Distribution Time shall be an OmniAb Asset and all cash and Cash Equivalents held by any member of the Ligand Group as of the Distribution Time shall be a Ligand Retained Asset. To the extent that following the Distribution Time any Cash Equivalents are required to be transferred from any member of the Ligand Group to any member of the OmniAb Group or from any member of the OmniAb Group to any member of the Ligand Group to make effective the Internal Reorganization or the Contribution pursuant to this Agreement and the Ancillary Agreements (including if required by Law or regulation to effect the foregoing), the Party receiving such Cash Equivalents shall promptly transfer an amount in cash equal to such transferred Cash Equivalents back to the transferring Party so as not to override the allocations of Assets, Liabilities and expenses related to the Internal Reorganization and the Contribution contemplated by this Agreement and the Ancillary Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>In exchange for the Contribution, OmniAb agrees, on or prior to the Distribution Date, to issue to Ligand a number of newly issued, fully paid and nonassessable shares of OmniAb Stock as is necessary to effect the Distribution and such that immediately following the Distribution Ligand will hold none of the outstanding shares of OmniAb Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Notwithstanding anything to the contrary in this Agreement, the Merger Agreement or any Ancillary Document, and except as otherwise provided in Section 9.5 (relating to Reimbursable Transaction-related Expenses) or the Tax Matters Agreement (relating to Taxes), (i) Ligand shall have all rights to and shall retain all payments received or accrued by it, any member of the Ligand Group or any member of the OmniAb Group at any time up to and until the Distribution Time relating to current accounts receivable of any member of the OmniAb Group (such current accounts receivable being included in Ligand Retained Assets), and (ii) Ligand shall pay all costs and expenses relating to current accounts payable and current accrued liabilities of any member of the OmniAb Group that are outstanding or accrued at any time up to and until the Distribution Time (such current accounts payable and current accrued liabilities being included in Ligand Retained Liabilities). For illustrative purposes only, an example showing such current accounts receivable, accounts payable and accrued liabilities being retained by Ligand is attached to this Agreement as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</span>. Notwithstanding the foregoing and anything to the contrary in this Agreement, the Merger Agreement or any Ancillary Document, the cash portion of the Contribution to be made by Ligand in connection with the Separation shall be (i) increased by any amounts received by any member of the Ligand Group or the OmniAb Group that is actually retained by any member of the Ligand Group in respect of a Commercial Milestone Event (as defined in that certain Platform License Agreement, by and between Open Monoclonal Technologies Inc. and CNA Development LLC, dated as of October 4, 2013) (the &#8220;<span style="font-style:italic;font-weight:bold;">Specific Milestone Payments</span>&#8221;) (such amounts being included in OmniAb Assets) and (ii) decreased by those certain costs and expenses relating solely to the OmniAb Business paid by Ligand through and including the Distribution Date that are set forth on Schedule 2.12(c) (the &#8220;<span style="font-style:italic;font-weight:bold;">Other Reimbursable Expenses</span>&#8221;) (such costs and expenses being included in OmniAb Liabilities).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_ARTICLEIIICOMPLETIONOFTHEDISTR"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COMPLETION OF THE DISTRIBUTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_3_1ActionsPriortotheDistr"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 3.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Actions Prior to the Distribution</span>. Prior to the Distribution Time, subject to the terms and conditions set forth herein, the Parties shall take, or cause to be taken, the following actions in connection with the Distribution:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice to Nasdaq</span>. Ligand shall give Nasdaq not less than ten (10) days&#8217; advance notice of the Record Date in compliance with Rule 10b-17 under the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities Law Matters</span>. OmniAb shall file with the Commission any amendments or supplements to the Form 10 as may be necessary or advisable in order to cause the Form 10 to become and remain effective as required by the Commission or federal, state or other applicable securities Laws. Ligand and OmniAb shall take all such action as may be necessary or advisable under the securities or &#8220;blue sky&#8221; Laws of the United States (and any comparable Laws under any non-U.S. jurisdiction) in connection with the transactions contemplated by this Agreement, the Merger Agreement and the Ancillary Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authorized Number of Shares</span>. Prior to the Distribution, the Parties shall take all necessary action required to file an amendment to the Certificate of Incorporation of OmniAb with the Secretary of State of the State of Delaware to increase the number of authorized shares of OmniAb Stock so that OmniAb Stock then authorized shall be equal to the number of shares of OmniAb Stock necessary to effect the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Availability of Information</span>. Ligand shall, as soon as is reasonably practicable after the Form 10 is declared effective under the Exchange Act and the Ligand Board has approved the Distribution, cause the Information Statement to be mailed to the Record Holders or, in connection with the delivery of a notice of Internet availability of the Information Statement to such holders, posted on the Internet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Distribution Agent</span>. Ligand shall enter into a distribution agent agreement with the Agent or otherwise provide instructions to the Agent regarding the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Officers and Directors</span>. At or prior to the Distribution Time, the Parties shall take all necessary action so that, as of the Distribution Time, the executive officers and directors of OmniAb will be as set forth in the Information Statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Satisfying Conditions to the Distribution</span>. Each of Ligand, OmniAb and APAC shall cooperate to cause the conditions to the Distribution set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.3</span> to be satisfied and to effect the Distribution at the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Resignations and Removals</span>. On or prior to the Distribution Date or as soon thereafter as practicable, (i) Ligand shall cause all its employees and any employees of its Subsidiaries (excluding any employees of any member of the OmniAb Group) to resign or be removed, effective as of the Distribution Time, from all positions as officers or directors of any member of the OmniAb Group in which they serve, and (ii) OmniAb shall cause all its employees and any employees of its Subsidiaries to resign, effective as of the Distribution Time, from all positions as officers or directors of any members of the Ligand Group in which they serve. Notwithstanding the foregoing, no Person shall be required by any Party to resign from any position or office with another Party if such Person is disclosed in the Form 10 as a Person who is to hold such position or office following the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contribution</span>. On or prior to the Distribution Date, the Contribution shall have been made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_3_2_EffectingtheDistribution"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 3.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effecting the Distribution</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delivery of OmniAb Stock</span>. Upon consummation of the Distribution, Ligand shall deliver to the Agent, a book-entry authorization representing the OmniAb Stock being distributed in the Distribution for the account of the Record Holders and shall take all such other actions (including delivering any other instruments of transfer required by applicable law) as may be necessary to effect the Distribution. The Agent shall hold such book-entry shares for the account of the Record Holders pending the Merger, as provided in Section 3.2 of the Merger Agreement. Immediately after the Distribution Time and prior to the Effective Time, the shares of OmniAb Stock shall not be transferable and the transfer agent for the OmniAb Stock shall not transfer any shares of OmniAb Stock; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, for the avoidance of doubt, that the exchange of such shares of OmniAb Stock for shares of Domesticated Parent Common Stock pursuant to the Merger shall not be deemed a transfer subject to the foregoing restrictions. The Distribution shall be deemed to be effective at the Distribution Time upon written authorization from Ligand to the Agent to proceed with the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_3_3_ConditionstotheDistributi"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions to the Distribution</span>. The consummation of the Distribution shall be subject to the satisfaction or waiver by Ligand in its sole and absolute discretion, of the following conditions (other than the condition set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.3(a)</span>, which prior to the termination of the Merger Agreement may not be waived without APAC&#8217;s written consent, which consent shall not be unreasonably withheld, conditioned or delayed):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Completion of the Separation. The Separation shall have been completed substantially in accordance with the Reorganization Plan, other than any Transfers and Assumptions or other actions that may occur after the Distribution Time in accordance with the terms of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Execution of Ancillary Agreements. Each of the Ancillary Agreements shall have been duly executed and delivered by the parties thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Conditions to Ligand Obligations in Merger Agreement. Each of the conditions in Section 8.1 (other than Section 8.1(b)) and Section 8.2 of the Merger Agreement to Ligand&#8217;s obligations to consummate the Merger shall have been satisfied or waived (other than those conditions that by their nature are to be satisfied contemporaneously with the Distribution and/or the Merger; provided, that such conditions are capable of being satisfied at such time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Confirmation of Satisfaction of APAC Conditions in Merger Agreement. APAC shall have irrevocably confirmed to Ligand that each condition in Section 8.1 (other than Section 8.1(b)) and Section 8.3 of the Merger Agreement to APAC&#8217;s obligations to consummate the Merger (i) has been satisfied, (ii) will be satisfied at the time of the Distribution, or (iii) subject to applicable Law, is or has been waived by APAC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_ARTICLEIVCERTAINCOVENANTS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE IV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTAIN COVENANTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_4_1_Cooperation"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 4.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation</span>. From and after the Distribution Time, and subject to the terms of and limitations contained in this Agreement and the Ancillary Agreements, each Party shall, and shall cause each of its respective Affiliates and employees to, (i) provide reasonable cooperation and assistance to the other Party (and any member of its respective Group) in connection with the completion of the transactions contemplated herein and in each Ancillary Agreement, (ii) reasonably assist the other Party in the orderly and efficient transition in becoming a separate company to the extent set forth in the Transition Services Agreements or as otherwise set forth herein (including, but not limited to, complying with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Articles V</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">VI</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">VIII</span>) and (iii) reasonably assist the other Party to the extent such Party is providing or has provided services, as applicable, pursuant to the Transition Services Agreements in connection with requests for information from, audits or other examinations of, such other Party by a Governmental Entity; in each case, except as otherwise set forth in this Agreement or may otherwise be agreed to by the Parties in writing, at no additional cost to the Party requesting such assistance other than for the actual out-of-pocket costs (which shall not include the costs of salaries and benefits of employees of such Party or any pro rata portion of overhead or other costs of employing such employees which would have been incurred by such employees&#8217; employer regardless of the employees&#8217; service with respect to the foregoing) incurred by any such Party, if applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_4_2_RetainedNames"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 4.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Retained Names</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>No later than ninety (90) days following the Distribution Date, OmniAb shall, and shall cause the members of the OmniAb Group, to change their respective names and cause their certificates of incorporation and bylaws (or equivalent organizational documents), as applicable, to be amended to remove the Ligand Retained Names.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Subject to Section 4.2(c), following the Distribution Date, unless otherwise directed by Ligand in writing, OmniAb shall, and shall cause the members of the OmniAb Group to, as soon as reasonably practicable, but in no event later than six (6) months following the Distribution Date, cease to make any use of any Ligand Retained Names. In furtherance thereof, as soon as reasonably practicable but in no event later than six (6) months following the Distribution Date, OmniAb shall, and shall cause the members of the OmniAb Group, to remove, strike over, or otherwise obliterate all Ligand Retained Names from all assets and other materials owned by or in the possession of any member of the OmniAb Group, including any vehicles, business cards, schedules, stationery, packaging materials, displays, signs, promotional materials, manuals, forms, websites, email, Software and other materials and systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Notwithstanding anything to the contrary in this Section 4.2, no member of the OmniAb Group shall (i) be obligated to cease using or displaying any of the Ligand Retained Names on any (A) non-public-facing, non-customer facing and non-vendor facing documents or materials or (B) executed copies of any Contract, in each case of (A) and (B), in existence, used or disseminated as of the Distribution Date which bear any of the Ligand Retained Names, or (ii) be in breach of this Section 4.2 if, after the Distribution Date, it (x) uses any of the Ligand Retained Names in a nominative manner in textual sentences referencing the historical relationship between Ligand and the Ligand Group, on the one hand, and the OmniAb Group, on the other hand, which references are factually accurate and reasonably necessary to describe such historical relationship, (y) retains any copies of any books, records or other materials that, as of the Distribution Date, contain or display any of the Ligand Retained Names and such copies are used solely for internal or archival purposes (and not public display) or (z) uses any of the Ligand Retained Names to comply with applicable Laws or stock exchange regulations or for litigation, regulatory or corporate filings and documents filed by a member of the OmniAb Group or any of its Affiliates with any Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Ligand hereby grants to the OmniAb Group a non-exclusive, royalty-free, non-transferable, license to use and display the Ligand Retained Names for the periods set forth in this Section 4.2 as permitted by this Section 4.2 in connection with the transactions contemplated herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Any and all use of the Ligand Retained Names by the OmniAb Group and the goodwill afforded thereby shall inure to the sole benefit of Ligand. Any use by the members of the OmniAb Group of any of the Ligand Retained Names as permitted in </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">this Section 4.2 is subject to their use of the Ligand Retained Names in a form and manner, and with standards of quality, of that in effect for the Ligand Retained Names as of the Distribution Date. OmniAb and the other members of the OmniAb Group shall not use the Ligand Retained Names in a manner that reflects negatively on the Ligand Retained Names or on Ligand or any member of the Ligand Group. Upon expiration or termination of the rights granted to the OmniAb Group pursuant to this Section 4.2, OmniAb hereby assigns, and shall cause the other members of the OmniAb Group to assign, to Ligand their respective rights (if any) to any Trademarks forming a part of the Ligand Retained Names. Ligand shall have the right to terminate the foregoing license, effective immediately, if any member of the OmniAb Group fails to comply with the foregoing terms and conditions in this Section 4.2 in any material respect or otherwise fails to comply with any reasonable written direction of Ligand in relation to any member of the OmniAb Group&#8217;s use of the Ligand Retained Names, and, in each case, such member of the OmniAb Group has not cured such failure within thirty (30) days after such member of the OmniAb Group&#8217;s receipt of written notice from Ligand of such failure. OmniAb shall indemnify, defend and hold harmless Ligand and the members of the Ligand Group from and against any and all Indemnifiable Losses arising from or relating to the use by any member of the OmniAb Group of the Ligand Retained Names pursuant to this Section 4.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>Each of the Parties acknowledges and agrees that the remedy at Law for any breach of the requirements of this Section 4.2 would be inadequate and agrees and consents that without intending to limit any additional remedies that may be available, Ligand and the members of the Ligand Group shall be entitled to a temporary or permanent injunction, without proof of actual damage or inadequacy of legal remedy, and without posting any bond or other undertaking, in any Action which may be brought to enforce any of the provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.2</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_4_3_LigandLimitedLicenseGra"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 4.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ligand Limited License Grant</span>. Solely to the extent that any Patents or Know-How owned by any member of the Ligand Group are used, practiced or otherwise exploited in the OmniAb Business immediately prior to the Distribution Time, Ligand hereby grants, on behalf of itself and each member of the Ligand Group, to each member of the OmniAb Group, a royalty-free, fully paid-up, perpetual, irrevocable, non-sublicensable (except to subcontractors), non-transferable (except in connection with the transfer of all or substantially all of (i) the assets of the OmniAb Business or (ii) the capital stock of OmniAb), worldwide, non-exclusive license in, to and under such Patents or Know-How to use, practice and otherwise exploit such Patents and Know-How solely in or for the conduct of the OmniAb Business as conducted on or prior to the Distribution Time (and natural evolutions thereof).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_4_4_NoRestrictiononCompetit"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 4.4</span></span>No Restriction on Competition. It is the explicit intent of each of the Parties that the provisions of this Agreement shall not include any non-competition or other similar restrictive arrangements with respect to the range of business activities which may be conducted by the Parties. Accordingly, each of the Parties acknowledges and agrees that nothing set forth in this Agreement shall be construed to create any explicit or implied restriction or other limitation on (i) the ability of any party hereto to engage in any business or other activity which competes with the business of any other Party hereto or (ii) the ability of any party to engage in any specific line of business or engage in any business activity in any specific geographic area.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="B_ARTICLEVINDEMNIFICATION"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">INDEMNIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_5_1_ReleaseofPreDistributio"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 5.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release of Pre-Distribution Claims</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except (i) as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(b)</span>, (ii) as may be otherwise expressly provided in this Agreement or in any Ancillary Agreement and (iii) for any matter for which any Party is entitled to indemnification pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>Ligand, for itself and each member of the Ligand Group, its Affiliates as of the Distribution Time and, to the extent permitted by Law, all Persons who at any time prior to the Distribution Time were directors, officers, agents or employees of any member of the Ligand Group (in their respective capacities as such), in each case, together with their respective heirs, executors, administrators, successors and assigns, does hereby remise, release and forever discharge OmniAb and the other members of the OmniAb Group, its Affiliates and all Persons who at any time prior to the Distribution Time were stockholders, directors, officers, agents or employees of any member of the OmniAb Group (in their respective capacities as such), in each case, together with their respective heirs, executors, administrators, successors and assigns, from any and all Ligand Retained Liabilities, whether at Law or in equity (including any right of contribution), whether arising under any Contract, by operation of Law or otherwise, in each case, existing or arising from any acts or events occurring or failing to occur or alleged to have occurred or to have failed to occur or any conditions existing or alleged to have existed at or before the Distribution Time, including in connection with the Internal Reorganization, the Separation, the Distribution, the Merger and any of the other transactions contemplated hereunder and under the Merger Agreement and the Ancillary Agreements </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">(such liabilities, the &#8220;<span style="font-style:italic;font-weight:bold;">Ligand Released Liabilities</span>&#8221;) and in any event shall not, and shall cause its respective Subsidiaries not to, bring any Action against any member of the OmniAb Groups in respect of any Ligand Released Liabilities; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that nothing in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(a)(i)</span> shall relieve any Person released in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(a)(i)</span> who, after the Distribution Time, is a director, officer or employee of any member of the OmniAb Group and is no longer a director, officer or employee of any member of the Ligand Group from Liabilities arising out of, relating to or resulting from his or her service as a director, officer or employee of any member of the OmniAb Group after the Distribution Time. Notwithstanding the foregoing, nothing in this Agreement shall be deemed to limit Ligand, any member of the Ligand Group, or their respective Affiliates from commencing any Actions against any OmniAb officer, director, agent or employee, or their respective heirs, executors, administrators, successors and assigns with regard to matters arising from, or relating to, (i) theft of Ligand Trade Secrets or (ii) intentional criminal acts by any such officers, directors, agents or employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>OmniAb, for itself and each member of the OmniAb Group, its Affiliates as of the Distribution Time and, to the extent permitted by Law, all Persons who at any time prior to the Distribution Time were directors, officers, agents or employees of any member of the OmniAb Group (in their respective capacities as such), in each case, together with their respective heirs, executors, administrators, successors and assigns, does hereby remise, release and forever discharge Ligand and the other members of the Ligand Group, its Affiliates and all Persons who at any time prior to the Distribution Time were stockholders, directors, officers, agents or employees of any member of the Ligand Group (in their respective capacities as such), in each case, together with their respective heirs, executors, administrators, successors and assigns, from any and all OmniAb Liabilities, whether at Law or in equity (including any right of contribution), whether arising under any Contract, by operation of Law or otherwise, in each case, existing or arising from any acts or events occurring or failing to occur or alleged to have occurred or to have failed to occur or any conditions existing or alleged to have existed at or before the Distribution Time, including in connection with the Internal Reorganization, the Separation, the Distribution, the Merger and any of the other transactions contemplated hereunder and under the Merger Agreement and the Ancillary Agreements (such liabilities, the &#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Released Liabilities</span>&#8221;) and in any event shall not, and shall cause its respective Subsidiaries not to, bring any Action against any member of the Ligand Group in respect of any OmniAb Released Liabilities; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span> that for purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(a)(ii)</span>, the members of the OmniAb Group shall also release and discharge any officers or other employees of any member of the Ligand Group, to the extent any such officers or employees served as a director or officer of any members of the OmniAb Group prior to the Distribution Time, from any and all Liability, obligation or responsibility for any and all past actions or failures to take action, in each case in their capacity as a director or officer of any such member of the OmniAb Group, prior to the Distribution Time, including actions or failures to take action that may be deemed to have been negligent or grossly negligent. Notwithstanding the foregoing, nothing in this Agreement shall be deemed to limit OmniAb, any member of the OmniAb Group, or their respective Affiliates from commencing any Actions against any Ligand officer, director, agent or employee, or their respective heirs, executors, administrators, successors and assigns with regard to matters arising from, or relating to, (i) theft of OmniAb Trade Secrets or (ii) intentional criminal acts by any such officers, directors, agents or employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>APAC, for itself and each of its Affiliates as of the Distribution Time and, to the extent permitted by Law, all Persons who at any time prior to the Distribution Time were directors, officers, agents or employees of APAC or any of its Affiliates (in their respective capacities as such), in each case, together with their respective heirs, executors, administrators, successors and assigns, does hereby remise, release and forever discharge Ligand and the other members of the Ligand Group, its Affiliates and all Persons who at any time prior to the Distribution Time were stockholders, directors, officers, agents or employees of any member of the Ligand Group (in their respective capacities as such), in each case, together with their respective heirs, executors, administrators, successors and assigns, from any and all OmniAb Liabilities, whether at Law or in equity (including any right of contribution), whether arising under any Contract, by operation of Law or otherwise, in each case, existing or arising from any acts or events occurring or failing to occur or alleged to have occurred or to have failed to occur or any conditions existing or alleged to have existed at or before the Distribution Time, including in connection with the Internal Reorganization, the Separation, the Distribution, the Merger and any of the other transactions contemplated hereunder and under the Merger Agreement and the Ancillary Agreements (such liabilities, the &#8220;<span style="font-style:italic;font-weight:bold;">APAC Released Liabilities</span>&#8221;) and in any event shall not, and shall cause its respective Subsidiaries not to, bring any Action against any member of the Ligand Group in respect of any APAC Released Liabilities; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span> that for purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(a)(iii)</span>, APAC and each of its Affiliates shall also release and discharge any officers or other employees of any member of the Ligand Group, to the extent any such officers or employees served as a director or officer of any members of the OmniAb Group prior to the Distribution Time, from any and all Liability, obligation or responsibility for any and all past actions or failures to take action, in each case in their capacity as a director or officer of any such member of the OmniAb Group, prior to the Distribution Time, including actions or failures to take action that may be deemed to have been negligent </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">or grossly negligent. Notwithstanding the foregoing, nothing in this Agreement shall be deemed to limit APAC or any of its Affiliates from commencing any Actions against any Ligand officer, director, agent or employee, or their respective heirs, executors, administrators, successors and assigns with regard to matters arising from, or relating to, (i) theft of OmniAb Trade Secrets or (ii) intentional criminal acts by any such officers, directors, agents or employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Nothing contained in this Agreement, including <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(a)</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.5</span>, shall impair or otherwise affect any right of any Party or APAC and, as applicable, a member of such Party&#8217;s Group or any of its Affiliates, as well as their respective heirs, executors, administrators, successors and assigns, to enforce this Agreement, the Merger Agreement any Ancillary Agreement or any agreements, arrangements, commitments or understandings contemplated in this Agreement, the Merger Agreement or in any Ancillary Agreement to continue in effect after the Distribution Time. In addition, nothing contained in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(a)</span> shall release any person from:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>any Liability Assumed, Transferred or allocated to a Party or a member of such Party&#8217;s Group pursuant to or as contemplated by, or any other Liability of any member of such Group under, this Agreement or any Ancillary Agreement, including (A) with respect to Ligand, any Ligand Retained Liability and (B) with respect to OmniAb, any OmniAb Liability;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>any Liability provided for in or resulting from any other Contract or arrangement that is entered into after the Distribution Time between any Party (and/or a member of such Party&#8217;s or Parties&#8217; Group), on the one hand, and any other Party or Parties (and/or a member of such Party&#8217;s or Parties&#8217; Group), on the other hand;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>any Liability with respect to any Continuing Arrangements;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>any Liability that the Parties may have with respect to indemnification pursuant to this Agreement or otherwise for Actions brought against the Parties by third Persons, which Liability shall be governed by the provisions of this Agreement and, in particular, this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> and, if applicable, the appropriate provisions of the Ancillary Agreements;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span>the obligations of Ligand, OmniAb, APAC or the other parties to the Merger Agreement to consummate the Merger and the other transactions expressly contemplated to occur at the Closing, subject to the terms and conditions of the Merger Agreement; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</span></span>any Liability the release of which would result in a release of any Person other than the Persons released in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(a)</span>; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that the Parties and APAC agree not to bring any Action or permit any other member of their respective Group or any of their Affiliates to bring any Action against a Person released in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(a)</span> with respect to such Liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In addition, nothing contained in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(a)</span> shall release: (i) Ligand from indemnifying any director, officer or employee of the OmniAb Group who was a director, officer or employee of Ligand or any of its Affiliates prior to the Distribution Time, as the case may be, to the extent such director, officer or employee is or becomes a named defendant in any Action with respect to which he or she was entitled to such indemnification pursuant to then-existing obligations; it being understood that if the underlying obligation giving rise to such Action is an OmniAb Liability, OmniAb shall indemnify Ligand for such Liability (including Ligand&#8217;s costs to indemnify the director, officer or employee) in accordance with the provisions set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span>; and (ii) OmniAb from indemnifying any director, officer or employee of the Ligand Group who was a director, officer or employee of OmniAb or any of its Affiliates prior to the Distribution Time, as the case may be, to the extent such director, officer or employee is or becomes a named defendant in any Action with respect to which he or she was entitled to such indemnification pursuant to then-existing obligations; it being understood that if the underlying obligation giving rise to such Action is a Ligand Retained Liability, Ligand shall indemnify OmniAb for such Liability (including OmniAb&#8217;s costs to indemnify the director, officer or employee) in accordance with the provisions set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Each Party and APAC shall not, and shall not permit any member of its Group or any of their respective Affiliates to, make any claim for offset, or commence any Action, including any claim of contribution or any indemnification, against any other Party or APAC or any member of any other Party&#8217;s Group or their respective Affiliates, or any other Person released pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(a)</span>, with respect to any Liabilities released pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(a)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>If any Person associated with a Party or APAC (including any director, officer or employee of a Party or APAC) initiates any Action with respect to claims released by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1</span>, the Party or APAC with which such Person is associated shall be responsible for the fees and expenses of counsel of the other Party or APAC, as the case may be (and/or the members of such </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Party&#8217;s Group or their Affiliates, as applicable) and such other Party or APAC, as the case may be, shall be indemnified for all Liabilities incurred in connection with such Action in accordance with the provisions set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_5_2_IndemnificationbyLigand"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 5.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification by Ligand</span>. In addition to any other provisions of this Agreement requiring indemnification and except as otherwise specifically set forth in any provision of this Agreement or of any Ancillary Agreement, following the Distribution Time, Ligand shall indemnify, defend and hold harmless the OmniAb Indemnitees from and against any and all Indemnifiable Losses of the OmniAb Indemnitees to the extent relating to, arising out of, by reason of or otherwise in connection with (a) the Ligand Retained Liabilities, including the failure of any member of the Ligand Group or any other Person to pay, perform or otherwise discharge any Ligand Retained Liability in accordance with its respective terms, whether arising prior to, at or after the Distribution Time, (b) any Ligand Retained Asset or Ligand Retained Business, whether arising prior to, at or after the Distribution Time, or (c) any breach by Ligand of any provision of this Agreement or any Ancillary Agreement unless such Ancillary Agreement expressly provides for separate indemnification therein, in which case any such indemnification claims shall be made thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_5_3_Indemnificationby"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 5.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification by </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OmniAb and APAC</span>. In addition to any other provisions of this Agreement requiring indemnification and except as otherwise specifically set forth in any provision of this Agreement or of any Ancillary Agreement, following the Distribution Time, OmniAb shall and shall cause the other members of the OmniAb Group to indemnify, defend and hold harmless the Ligand Indemnitees from and against any and all Indemnifiable Losses of the Ligand Indemnitees to the extent relating to, arising out of, by reason of or otherwise in connection with (a) the OmniAb Liabilities, including the failure of any member of the OmniAb Group or any other Person to pay, perform or otherwise discharge any OmniAb Liability in accordance with its respective terms, whether prior to, at or after the Distribution Time, (b) any OmniAb Asset or OmniAb Business, whether arising prior to, at or after the Distribution Time, or (c) any breach by OmniAb of any provision of this Agreement or any Ancillary Agreement unless such Ancillary Agreement expressly provides for separate indemnification therein, in which case any such indemnification claims shall be made thereunder. From and following the Closing, APAC shall and shall cause its Subsidiaries to indemnify, defend and hold harmless the Ligand Indemnitees from and against any and all Indemnifiable Losses of the Ligand Indemnitees pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> to the extent not paid by a member of the OmniAb Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_5_4_ProceduresforIndemnifica"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 5.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Procedures for Indemnification</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Direct Claims</span>. Other than with respect to Third Party Claims, which shall be governed by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.4(b)</span>, each Ligand Indemnitee and OmniAb Indemnitee (each, an &#8220;<span style="font-style:italic;font-weight:bold;">Indemnitee</span>&#8221;) shall notify in writing, with respect to any matter that such Indemnitee has determined has given or could give rise to a right of indemnification under this Agreement or any Ancillary Agreement, the Party which is or may be required pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> or pursuant to any Ancillary Agreement to make such indemnification (the &#8220;<span style="font-style:italic;font-weight:bold;">Indemnifying Party</span>&#8221;), within forty-five (45) days of such determination, stating in such written notice the amount of the Indemnifiable Loss claimed, if known, and, to the extent practicable, method of computation thereof, and referring to the provisions of this Agreement in respect of which such right of indemnification is claimed by such Indemnitee or arises; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that the failure to provide such written notice shall not release the Indemnifying Party from any of its obligations except and solely to the extent the Indemnifying Party shall have been actually materially prejudiced as a result of such failure. The Indemnifying Party will have a period of forty-five (45) days after receipt of a notice under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.4(a)</span> within which to respond thereto. If the Indemnifying Party fails to respond within such period, the Liability specified in such notice from the Indemnitee shall be conclusively determined to be a Liability of the Indemnifying Party hereunder. If such Indemnifying Party responds within such period and rejects such claim in whole or in part, the disputed matter shall be resolved in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VII</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Claims</span>. If a claim or demand is made against an Indemnitee by any Person who is not a member of the Ligand Group or the OmniAb Group or APAC or their respective Affiliates (a &#8220;<span style="font-style:italic;font-weight:bold;">Third Party Claim</span>&#8221;) as to which such Indemnitee is or may be entitled to indemnification pursuant to this Agreement or any Ancillary Agreement, such Indemnitee shall notify the Indemnifying Party in writing (which notice obligation may be satisfied by providing copies of all notices and documents received by the Indemnitee relating to the Third Party Claim), and in reasonable detail, of the Third Party Claim promptly (and in any event within the earlier of (x) forty-five (45) days or (y) two (2) Business Days prior to the final date of the applicable response period under such Third Party Claim) after receipt by such Indemnitee of written notice of the Third Party Claim; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that the failure to provide notice of any such Third Party Claim pursuant to this or the preceding sentence shall not release the Indemnifying Party from any of its obligations except and solely to the extent the Indemnifying Party shall have been actually materially prejudiced as a result of such failure. Thereafter, the Indemnitee shall deliver to the Indemnifying Party, promptly (and in any event within ten (10) Business Days) after the Indemnitee&#8217;s receipt thereof, copies of all notices and </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">documents (including court papers) received by the Indemnitee relating to the Third Party Claim. For all purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.4(b)</span>, each Party shall be deemed to have notice of the matters set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.1(97)(vii)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Other than in the case of (i) Taxes addressed in the Tax Matters Agreement or Employee Matters Agreement, which shall be addressed as set forth therein or (ii) indemnification by a beneficiary Party of a guarantor Party pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.10(c)</span> (the defense of which shall be controlled by the beneficiary Party), the Indemnifying Party shall be entitled, if it so chooses, to assume the defense thereof, and if it does not assume the defense of such Third Party Claim, to participate in the defense of any Third Party Claim in accordance with the terms of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.5</span> at such Indemnifying Party&#8217;s own cost and expense and by such Indemnifying Party&#8217;s own counsel, that is reasonably acceptable to the Indemnitee, within thirty (30) days of the receipt of an indemnification notice from such Indemnitee; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that the Indemnifying Party shall not be entitled to assume the defense of any Third Party Claim to the extent such Third Party Claim (x) is an Action by a Governmental Entity, (y) involves an allegation of a criminal violation or (z) seeks injunctive relief against the Indemnitee. In connection with the Indemnifying Party&#8217;s defense of a Third Party Claim, such Indemnitee shall have the right to employ separate counsel and to participate in (but not control) the defense, compromise, or settlement thereof, at its own expense and, in any event, shall cooperate with the Indemnifying Party in such defense and make available to the Indemnifying Party, at the Indemnifying Party&#8217;s expense, all witnesses, pertinent Information, materials and information in such Indemnitee&#8217;s possession or under such Indemnitee&#8217;s control relating thereto as are reasonably required by the Indemnifying Party; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that in the event of a conflict of interest between the Indemnifying Party and the applicable Indemnitee(s), or in the event that any Third Party Claim seeks equitable relief which would restrict or limit the future conduct of the Indemnitee&#8217;s business or operations, such Indemnitee(s) shall be entitled to retain, at the Indemnifying Party&#8217;s expense, separate counsel as required by the applicable rules of professional conduct with respect to such matter; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided further</span>, that if the Indemnifying Party has assumed the defense of the Third Party Claim but has specified, and continues to assert, any reservations or exceptions to such defense or to its liability therefor, then, in any such case, the reasonable fees and expenses of one separate counsel for all Indemnitees shall be borne by the Indemnifying Party. The Indemnifying Party shall have the right to compromise or settle a Third Party Claim the defense of which it shall have assumed pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.4(c)</span> and any such settlement or compromise made or caused to be made of a Third Party Claim in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> shall be binding on the Indemnitee, in the same manner as if a final judgment or decree had been entered by a court of competent jurisdiction in the amount of such settlement or compromise. Notwithstanding the foregoing sentence, the Indemnifying Party shall not settle any such Third Party Claim without the written consent of the Indemnitee unless such settlement (A) completely and unconditionally releases the Indemnitee in connection with such matter, (B) provides relief consisting solely of money damages borne by the Indemnifying Party and (C) does not involve any admission by the Indemnitee of any wrongdoing or violation of Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>If an Indemnifying Party fails for any reason to assume responsibility for defending a Third Party Claim within the period specified in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.4</span>, such Indemnitee may defend such Third Party Claim at the cost and expense of the Indemnifying Party. If an Indemnifying Party has failed to assume the defense of the Third Party Claim within the time period specified in clause (c) above, it shall not be a defense to any obligation to pay any amount in respect of such Third Party Claim that the Indemnifying Party was not consulted in the defense thereof, that such Indemnifying Party&#8217;s views or opinions as to the conduct of such defense were not accepted or adopted, that such Indemnifying Party does not approve of the quality or manner of the defense thereof or that such Third Party Claim was incurred by reason of a settlement rather than by a judgment or other determination of liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Except as otherwise set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.6</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.3</span>, or to the extent set forth in any Ancillary Agreement, absent fraud or willful misconduct by an Indemnifying Party, the indemnification provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> shall be the sole and exclusive remedy of an Indemnitee for any monetary or compensatory damages or losses resulting from any breach of this Agreement or any Ancillary Agreement and each Indemnitee expressly waives and relinquishes any and all rights, claims or remedies such Person may have with respect to the foregoing other than under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> against any Indemnifying Party. For the avoidance of doubt, all disputes in respect of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> shall be resolved in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VII</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>Notwithstanding the foregoing, to the extent any Ancillary Agreement provides procedures for indemnification that differ from the provisions set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.4</span>, the terms of the Ancillary Agreement will govern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>The provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> shall apply to Third Party Claims that are already pending or asserted as well as Third Party Claims brought or asserted after the date of this Agreement. There shall be no requirement under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.4</span> to give a notice with respect to any Third Party Claim that exists as of the Distribution Time. The Parties acknowledge that Liabilities for Actions (regardless of the parties to the Actions) may be partly Ligand Liabilities and partly OmniAb Liabilities. If the Parties </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">cannot agree on the allocation of any such Liabilities for Actions, they shall resolve the matter pursuant to the procedures set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VII</span>. Neither Party shall, nor shall either Party permit its Subsidiaries to, file Third Party claims or cross-claims against the other Party or its Subsidiaries in an Action in which a Third Party Claim is being resolved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_5_5_CooperationinDefenseand"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 5.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation in Defense and Settlement</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>With respect to any Third Party Claim that implicates both the OmniAb Group (or APAC and its Subsidiaries, as applicable) and the Ligand Group in any material respect due to the allocation of Liabilities, responsibilities for management of defense and related indemnities pursuant to this Agreement or any of the Ancillary Agreements, OmniAb (or APAC, as applicable) and Ligand agree to use commercially reasonable efforts to cooperate fully and maintain a joint defense (in a manner that, to the extent reasonably practicable, will preserve for all Parties any Privilege with respect thereto). The Party that is not responsible for managing the defense of any such Third Party Claim shall, upon reasonable request, be consulted with respect to significant matters relating thereto and may, if necessary or helpful, retain counsel to assist in the defense of such claims. Notwithstanding the foregoing, nothing in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.5(a)</span> shall derogate from any Party&#8217;s rights to control the defense of any Action in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.4</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Notwithstanding anything to the contrary in this Agreement, with respect to any Action (i) by a Governmental Entity against OmniAb relating to matters involving anti-bribery, anti-corruption, anti-money laundering, export control and similar laws, where the facts and circumstances giving rise to the Action occurred prior to the Distribution Time and (ii) where the resolution of such Action by order, judgment, settlement or otherwise, would reasonably be expected to include any condition, limitation or other stipulation that adversely impacts the conduct of the Ligand Retained Businesses, Ligand shall have, at Ligand&#8217;s expense, the reasonable opportunity to consult, advise and comment on preparation regarding any such Action, including with regard to any drafts of notices and other conferences and communications to be provided or submitted by OmniAb to any third party involved in such Action (including any Governmental Entity), to the extent that Ligand&#8217;s participation does not affect the defense of any such Action or any privilege in an adverse manner; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that to the extent that any such action requires the submission by OmniAb of any content relating to any current or former officer or director of Ligand, such content will only be submitted in a form approved by Ligand in its reasonable discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Notwithstanding anything to the contrary in this Agreement, with respect to any notices or reports to be submitted to, or reporting, disclosure, filing or other requirements to be made with, any Governmental Entity by OmniAb or its Subsidiaries (&#8220;<span style="font-style:italic;font-weight:bold;">Governmental Filing</span>&#8221;) where the Governmental Filing requires disclosure of facts, information or data that relate, in whole or in part, to periods prior to the Distribution Time, Ligand shall have the reasonable opportunity to consult, advise and comment on the preparation and content of any such Governmental Filing in advance of its submission to a Governmental Entity, and OmniAb shall in good faith consider and take into account any comments so provided by Ligand with respect to such Governmental Filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Each of Ligand and OmniAb agrees that at all times from and after the Distribution Time, if an Action is commenced by a third party naming two (2) or more Parties (or any member of such Parties&#8217; respective Groups) as defendants and with respect to which one or more named Parties (or any member of such Party&#8217;s respective Group) is a nominal defendant and/or such Action is otherwise not a Liability allocated to such named Party under this Agreement or any Ancillary Agreement, then the other Party or Parties shall use commercially reasonable efforts at its own expense to cause such nominal defendant to be removed from such Action, as soon as reasonably practicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_5_6_IndemnificationPayments"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 5.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification Payments</span>. Indemnification required by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> shall be made by periodic payments of the amount of Indemnifiable Losses in a timely fashion during the course of the investigation or defense, as and when bills are received or an Indemnifiable Loss incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_5_7_IndemnificationObligation"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 5.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification Obligations Net of I</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">nsurance Proceeds and Other Amounts</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Any recovery by any Indemnitee for any Indemnifiable Loss subject to indemnification pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> shall be calculated (i) net of Insurance Proceeds actually received by such Indemnitee with respect to any Indemnifiable Loss (which such proceeds shall be reduced by the present value, based on that Party&#8217;s then cost of short-term borrowing, of future premium increases known at such time) and (ii) net of any proceeds actually received by the Indemnitee from any unaffiliated third party with respect to any such Liability corresponding to the Indemnifiable Loss (&#8220;<span style="font-style:italic;font-weight:bold;">Third Party Proceeds</span>&#8221;). Accordingly, the amount which any Indemnifying Party is required to pay pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> to any Indemnitee pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> shall be reduced by any Insurance Proceeds or Third Party Proceeds theretofore actually recovered by or on behalf of the Indemnitee </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">corresponding to the related Indemnifiable Loss. If an Indemnitee receives a payment required by this Agreement from an Indemnifying Party corresponding to any Indemnifiable Loss (an &#8220;<span style="font-style:italic;font-weight:bold;">Indemnity Payment</span>&#8221;) and subsequently receives Insurance Proceeds or Third Party Proceeds, then the Indemnitee shall pay to the Indemnifying Party an amount equal to the excess of the Indemnity Payment received over the amount of the Indemnity Payment that would have been due if the Insurance Proceeds or Third Party Proceeds had been received, realized or recovered before the Indemnity Payment was made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Any Indemnity Payment shall be increased as necessary so that after making all payments corresponding to Taxes imposed on or attributable to such Indemnity Payment, the Indemnitee receives an amount equal to the sum it would have received had no such Taxes been imposed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>The Parties hereby agree that an insurer or other third party that would otherwise be obligated to pay any amount shall not be relieved of the responsibility with respect thereto or have any subrogation rights with respect thereto by virtue of any provision contained in this Agreement or any Ancillary Agreement, and that no insurer or any other third party shall be entitled to a &#8220;windfall&#8221; (<i style="font-style:italic;">e.g.</i>, a benefit they would not otherwise be entitled to receive, or the reduction or elimination of an insurance coverage obligation that they would otherwise have, in the absence of the indemnification or release provisions) by virtue of any provision contained in this Agreement or any Ancillary Agreement. Each Party shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to collect or recover, or allow the Indemnifying Party to collect or recover, or cooperate with each other in collecting or recovering, any Insurance Proceeds that may be collectible or recoverable respecting the Liabilities for which indemnification may be available under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span>. Notwithstanding the foregoing, an Indemnifying Party may not delay making any indemnification payment required under the terms of this Agreement, or otherwise satisfying any indemnification obligation, pending the outcome of any Actions to collect or recover Insurance Proceeds, and an Indemnitee need not attempt to collect any Insurance Proceeds prior to making a claim for indemnification or receiving any Indemnity Payment otherwise owed to it under this Agreement or any Ancillary Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_5_8_Contribution"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 5.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contribution</span>. If the indemnification provided for in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> is unavailable for any reason to an Indemnitee (other than failure to provide notice with respect to any Third Party Claims in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.4(b)</span>) in respect of any Indemnifiable Loss, then the Indemnifying Party shall, in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.8</span>, contribute to the Indemnifiable Losses incurred, paid or payable by such Indemnitee as a result of such Indemnifiable Loss in such proportion as is appropriate to reflect the relative fault of OmniAb and each other member of the OmniAb Group, on the one hand, and Ligand and each other member of the Ligand Group, on the other hand, in connection with the circumstances which resulted in such Indemnifiable Loss. With respect to any Indemnifiable Losses arising out of or related to information contained in the Spin-off Disclosure Documents or other securities law filing, the relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact relates to information regarding the OmniAb Business supplied by a member of the OmniAb Group, on the one hand, or regarding the Ligand Retained Business supplied by a member of the Ligand Group, on the other hand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_5_9_AdditionalMattersSurviv"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 5.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Matters; Survival of </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnities</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The indemnity agreements contained in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> shall remain operative and in full force and effect, regardless of (i) any investigation made by or on behalf of any Indemnitee; and (ii) the knowledge by the Indemnitee of Indemnifiable Losses for which it might be entitled to indemnification hereunder. The indemnity agreements contained in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> shall survive the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The rights and obligations of any member of the Ligand Group, any member of the OmniAb Group or APAC, in each case, under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> shall survive (i) the sale or other Transfer by any Party or its Affiliates of any Assets or businesses or the assignment by it of any Liabilities and (ii) any merger, consolidation, business combination, restructuring, recapitalization, reorganization or similar transaction involving either Party or any of its Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="B_ARTICLEVIPRESERVATIONOFRECORDS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE VI</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PRESERVATION OF RECORDS; ACCESS TO INFORMATION;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;"> CONFIDENTIALITY; PRIVILEGE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_6_1_PreservationofCorporate"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Preservation of Corporate Records</span>. Except as otherwise required or agreed in writing, or as otherwise provided in any Ancillary Agreement, with regard to any Information referenced in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.2</span>, each Party shall use its commercially reasonable efforts, at such Party&#8217;s sole cost and expense, to retain, until the latest of, as applicable, (i) the date on which such Information is no </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">longer required to be retained pursuant to the applicable record retention policy of Ligand or such other member of the Ligand Group, respectively, as in effect immediately prior to the Distribution Time, including, without limitation, pursuant to any &#8220;<span style="font-style:italic;font-weight:bold;">Litigation Hold</span>&#8221; issued by Ligand or any of its Subsidiaries prior to the Distribution Time, (ii) the concluding date of any period as may be required by any applicable Law, (iii) the concluding date of any period during which such Information relates to a pending or threatened Action which is known to the members of the Ligand Group or the OmniAb Group, as applicable, in possession of such Information at the time any retention obligation with regard to such Information would otherwise expire, and (iv) the concluding date of any period during which the destruction of such Information could interfere with a pending or threatened investigation by a Governmental Entity which is known to the members of the Ligand Group or the OmniAb Group, as applicable, in possession of such Information at the time any retention obligation with regard to such Information would otherwise expire; provided that with respect to any pending or threatened Action arising after the Distribution Time, clause (iii) of this sentence applies only to the extent that whichever member of the Ligand Group or the OmniAb Group, as applicable, is in possession of such Information has been notified in writing pursuant to a &#8220;<span style="font-style:italic;font-weight:bold;">Litigation Hold</span>&#8221; by the other Party of the relevant pending or threatened Action. The Parties agree that upon written request from the other that certain Information relating to the OmniAb Business, the Ligand Retained Businesses or the transactions contemplated hereby be retained in connection with an Action, the Parties shall use reasonable efforts to preserve and not to destroy or dispose of such Information without the consent of the requesting Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_6_2_AccesstoInformatio"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Access to Informatio</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">n</span>. Other than in circumstances in which indemnification is sought pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> (in which event the provisions of such <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> shall govern) or for matters related to provision of Tax records (in which event the provisions of the Tax Matters Agreement and Employee Matters Agreement shall govern) and subject to appropriate restrictions for Privileged Information or Confidential Information:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>After the Distribution Time, and subject to compliance with the terms of the Ancillary Agreements, upon the prior written reasonable request by, and at the expense of, OmniAb for specific and identified Information:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>that (x) relates to OmniAb or the OmniAb Business, as the case may be, prior to the Distribution Time or (y) is necessary for OmniAb to comply with the terms of, or otherwise perform under, any Ancillary Agreement to which Ligand and/or OmniAb are parties, Ligand shall provide, as soon as reasonably practicable following the receipt of such request, appropriate copies of such Information (or the originals thereof if OmniAb has a reasonable need for such originals) in the possession or control of Ligand or any of its Affiliates or Subsidiaries, but only to the extent such items so relate and are not already in the possession or control of OmniAb; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that, to the extent any originals are delivered to OmniAb pursuant to this Agreement or the Ancillary Agreements, OmniAb shall, at its own expense, return them to Ligand within a reasonable time after the need to retain such originals has ceased; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided further</span> that, such obligation to provide any requested Information shall terminate and be of no further force and effect on the date that is the first anniversary of the date of this Agreement; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided further</span> that, in the event that Ligand, in its sole discretion, determines that any such access or the provision of any such Information (including information requested under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.3</span>) would violate any Law or Contract with a third party or could reasonably result in the waiver of any Privilege, Ligand shall not be obligated to provide such Information requested by OmniAb;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>that (x) is required by OmniAb with regard to reasonable compliance with reporting, disclosure, filing or other requirements imposed on OmniAb (including under applicable securities laws) by a Governmental Entity having jurisdiction over OmniAb, or (y) is for use in any other judicial, regulatory, administrative or other proceeding or in order to satisfy audit, accounting, claims, regulatory, litigation, Action or other similar requirements, as applicable, Ligand shall provide, as soon as reasonably practicable following the receipt of such request, appropriate copies of such Information (or the originals thereof if OmniAb has a reasonable need for such originals) in the possession or control of Ligand or any of its Affiliates or Subsidiaries, but only to the extent such items so relate and are not already in the possession or control of OmniAb; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that, to the extent any originals are delivered to OmniAb pursuant to this Agreement or the Ancillary Agreements, OmniAb shall, at its own expense, return them to Ligand within a reasonable time after the need to retain such originals has ceased; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided further</span> that, in the event that Ligand, in its sole discretion, determines that any such access or the provision of any such Information (including information requested under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.3</span>) would violate any Law or Contract with a third party or waive any Privilege, Ligand shall not be obligated to provide such Information requested by OmniAb; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>After the Distribution Time, and subject to compliance with the terms of the Ancillary Agreements, upon the prior written reasonable request by, and at the expense of, Ligand for specific and identified Information:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>that (x) relates to matters prior to the Distribution Time or (y) is necessary for Ligand to comply with the terms of, or otherwise perform under, any Ancillary Agreement to which Ligand and/or OmniAb are parties, OmniAb shall provide, as soon as reasonably practicable following the receipt of such request, appropriate copies of such Information (or the originals thereof if Ligand has a reasonable need for such originals) in the possession or control of OmniAb or any of its Affiliates or Subsidiaries, but only to the extent such items so relate and are not already in the possession or control of Ligand; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that, to the extent any originals are delivered to Ligand pursuant to this Agreement or the Ancillary Agreements, Ligand shall, at its own expense, return them to OmniAb within a reasonable time after the need to retain such originals has ceased; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided further</span> that, in the event any such access or the provision of any such Information (including information requested under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.3</span>) would violate any Law or Contract with a third party or waive any Privilege, OmniAb shall not be obligated to provide such Information requested by Ligand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>that (x) is required by Ligand with regard to reasonable compliance with reporting, disclosure, filing or other requirements imposed on Ligand (including under applicable securities laws) by a Governmental Entity having jurisdiction over Ligand, or (y) is for use in any other judicial, regulatory, administrative or other proceeding or in order to satisfy audit, accounting, claims, regulatory, litigation, Action or other similar requirements, as applicable, OmniAb shall provide, as soon as reasonably practicable following the receipt of such request, appropriate copies of such Information (or the originals thereof if Ligand has a reasonable need for such originals) in the possession or control of OmniAb or any of its Affiliates or Subsidiaries, but only to the extent such items so relate and are not already in the possession or control of Ligand; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that, to the extent any originals are delivered to Ligand pursuant to this Agreement or the Ancillary Agreements, Ligand shall, at its own expense, return them to OmniAb within a reasonable time after the need to retain such originals has ceased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Each of Ligand and OmniAb shall inform their respective officers, employees, agents, consultants, advisors, authorized accountants, counsel and other designated representatives who have or have access to the other Party&#8217;s Confidential Information or other information provided pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VI</span> of their obligation to hold such information confidential in accordance with the provisions of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_6_3_AuditorsandAudits"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Auditors and Audits</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Until the first OmniAb fiscal year end occurring after the Distribution Time and for a reasonable period of time afterwards as required for each Party to prepare consolidated financial statements or complete a financial statement audit for the fiscal year during which the Distribution Date occurs, each Party shall provide or provide access to the other Party on a timely basis, all information reasonably required to meet its schedule for the preparation, printing, filing, and public dissemination of its annual financial statements and for management&#8217;s assessment of the effectiveness of its disclosure controls and procedures and its internal control over financial reporting in accordance with Items 307 and 308, respectively, of Regulation S-K promulgated by the Commission and, to the extent applicable to such Party, its auditor&#8217;s audit of its internal control over financial reporting and management&#8217;s assessment thereof in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 and the Commission&#8217;s and Public Company Accounting Oversight Board&#8217;s rules and auditing standards thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>In the event a Party restates any of its financial statements that include such Party&#8217;s audited or unaudited financial statements with respect to any balance sheet date or period of operation as of the end of and for the 2021 fiscal year and the five (5) year period ending December 31, 2021, such Party will deliver to the other Party a substantially final draft, as soon as the same is prepared, of any report to be filed by such first Party with the Commission that includes such restated audited or unaudited financial statements (the &#8220;<span style="font-style:italic;font-weight:bold;">Amended Financial Report</span>&#8221;); provided, however, that such first Party may continue to revise its Amended Financial Report prior to its filing thereof with the Commission, which changes will be delivered to the other Party as soon as reasonably practicable; provided, further, however, that such first Party&#8217;s financial personnel will actively consult with the other Party&#8217;s financial personnel regarding any changes which such first Party may consider making to its Amended Financial Report and related disclosures prior to the anticipated filing of such report with the Commission, with particular focus on any changes which would have an effect upon the other Party&#8217;s financial statements or related disclosures. Each Party will reasonably cooperate with, and permit and make any necessary employees available to, the other Party, in connection with the other Party&#8217;s preparation of any Amended Financial Reports.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_6_4_WitnessServices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Witness Services</span>. At all times from and after the Distribution Time, each of Ligand and OmniAb shall use its commercially reasonable efforts to make available to the other, upon reasonable written request, its and its Subsidiaries&#8217; officers, directors, employees and agents (taking into account the business demands of such individuals) as witnesses to the extent that (i) such Persons may reasonably be required to testify in connection with the prosecution or defense of any Action in which the requesting </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Party may from time to time be involved (except for claims, demands or Actions in which one or more members of one Group is adverse to one or more members of the other Group) and (ii) there is no conflict in the Action between the requesting Party and the other Party. A Party providing a witness to the other Party under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.4</span> shall be entitled to receive from the recipient of such witness services, upon the presentation of invoices therefor, payments for such amounts, relating to supplies, disbursements and other out-of-pocket expenses (which shall not include the costs of salaries and benefits of employees who are witnesses or any pro rata portion of overhead or other costs of employing such employees which would have been incurred by such employees&#8217; employer regardless of the employees&#8217; service as witnesses), as may be reasonably incurred and properly paid under applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_6_5_Reimbursement"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reimbursement; Other Matters</span>. Except to the extent otherwise contemplated by this Agreement or any Ancillary Agreement, a Party providing Information or access to Information to the other Party under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VI</span> shall be entitled to receive from the recipient, upon the presentation of invoices therefor, payments for such amounts, relating to supplies, disbursements and other out-of-pocket expenses (which shall not include the costs of salaries and benefits of employees of such Party or any pro rata portion of overhead or other costs of employing such employees which would have been incurred by such employees&#8217; employer regardless of the employees&#8217; service with respect to the foregoing), as may be reasonably incurred in providing such Information or access to such Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_6_6_Confidentiality"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Notwithstanding any termination of this Agreement, and except as otherwise provided in the Ancillary Agreements, each of Ligand and OmniAb shall hold, and shall cause their respective Affiliates and their officers, employees, agents, consultants and advisors to hold, in strict confidence (and not to disclose or release or, except as otherwise permitted by this Agreement or any Ancillary Agreement, use, including for any ongoing or future commercial purpose, without the prior written consent of the Party to whom the Confidential Information relates (which may be withheld in such Party&#8217;s sole and absolute discretion, except where disclosure is required by applicable Law)), any and all Confidential Information concerning or belonging to the other Party or its Affiliates; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that each Party may disclose, or may permit disclosure of, Confidential Information (i) to its respective auditors, attorneys, financial advisors, bankers and other appropriate consultants and advisors who have a need to know such Information for auditing and other non-commercial purposes and are informed of the obligation to hold such Information confidential and in respect of whose failure to comply with such obligations, the applicable Party will be responsible, (ii) if any Party or any of its respective Subsidiaries is required or compelled to disclose any such Confidential Information by judicial or administrative process or by other requirements of Law or stock exchange rule or is advised by outside counsel in connection with a proceeding brought by a Governmental Entity that it is advisable to do so, (iii) as required in connection with any legal or other proceeding by one Party against the other Party or in respect of claims by one Party against the other Party brought in a proceeding, (iv) as necessary in order to permit a Party to prepare and disclose its financial statements in connection with any regulatory filings or Tax Returns, (v) as necessary for a Party to enforce its rights or perform its obligations under this Agreement (including pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3</span>) or an Ancillary Agreement, (vi) to Governmental Entities in accordance with applicable procurement regulations and contract requirements or (vii) to other Persons in connection with their evaluation of, and negotiating and consummating, a potential strategic transaction, to the extent reasonably necessary in connection therewith, provided an appropriate and customary confidentiality agreement has been entered into with the Person receiving such Confidential Information. Notwithstanding the foregoing, in the event that any demand or request for disclosure of Confidential Information is made by a third party pursuant to clause (ii), (iii), (v) or (vi) above, each Party, as applicable, shall promptly notify (to the extent permissible by Law) the Party to whom the Confidential Information relates of the existence of such request, demand or disclosure requirement and shall provide such affected Party a reasonable opportunity to seek an appropriate protective order or other remedy, which such Party will cooperate in obtaining to the extent reasonably practicable. In the event that such appropriate protective order or other remedy is not obtained, the Party which faces the disclosure requirement shall furnish only that portion of the Confidential Information that is required to be disclosed and shall take commercially reasonable steps to ensure that confidential treatment is accorded such Confidential Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Each Party acknowledges that it and the other members of its Group may have in its or their possession confidential or proprietary Information of third parties that was received under confidentiality or non-disclosure agreements with such third party while such Party and/or members of its Group were part of the Ligand Group. Each Party shall comply, and shall cause the other members of its Group to comply, and shall cause its and their respective officers, employees, agents, consultants and advisors (or potential buyers) to comply, with all terms and conditions of any such third-party agreements entered into prior to the Distribution Time, with respect to any confidential and proprietary Information of third parties to which it or any other member of its Group has had access.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Notwithstanding anything to the contrary set forth herein, (i) the Parties shall be deemed to have satisfied their obligations hereunder with respect to Confidential Information if they exercise at least the same degree of care that applies to Ligand&#8217;s confidential and proprietary information pursuant to policies in effect as of the Distribution Time and (ii) confidentiality obligations provided for in any Contract between each Party or its Subsidiaries and their respective employees shall remain in full force and effect. Notwithstanding anything to the contrary set forth herein, Confidential Information of any Party in the possession of and used by any other Party as of the Distribution Time may continue to be used by such Party in possession of the Confidential Information in and only in the operation of the OmniAb Business (in the case of the OmniAb Group) or the Ligand Retained Business (in the case of the Ligand Group); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that such Confidential Information may only be used by such Party and its officers, employees, agents, consultants and advisors in the specific manner and for the specific purposes for which it is used as of the date of this Agreement, and may only be shared with additional officers, employees, agents, consultants and advisors of such Party on a need-to-know basis exclusively with regard to such specified use; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided further</span> that such Confidential Information may be used only so long as the Confidential Information is maintained in confidence and not disclosed in violation of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.6(a)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>The Parties agree that irreparable damage may occur in the event that the provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.6</span> were not performed in accordance with their specific terms. Accordingly, it is hereby agreed that the Parties shall be entitled to seek an injunction or injunctions to enforce specifically the terms and provisions hereof in any court having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>For the avoidance of doubt and notwithstanding any other provision of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.6</span>, (i) the disclosure and sharing of Privileged Information shall be governed solely by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.7</span>, and (ii) Information that is subject to any confidentiality provision or other disclosure restriction in any Ancillary Agreement shall be governed by the terms of such Ancillary Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>For the avoidance of doubt and notwithstanding any other provision of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.6</span>, following the Distribution Time, the confidentiality obligations under this Agreement shall continue to apply to any and all Confidential Information concerning or belonging to each Party or its Affiliates that is shared or disclosed with the other Party or its Affiliates, whether or not such Confidential Information is shared pursuant to this Agreement, any Ancillary Agreement or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_6_7_PrivilegeMatters"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Privilege Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pre-Distribution Services</span>. The Parties recognize that legal and other professional services that have been and will be provided prior to the Distribution Time have been and will be rendered for the collective benefit of each of the members of the Ligand Group and the OmniAb Group, and that each of the members of the Ligand Group and the OmniAb Group should be deemed to be the client with respect to such pre-Distribution services for the purposes of asserting all privileges, immunities, or other protections from disclosure which may be asserted under applicable Law, including, but not limited to, the attorney-client privilege, business strategy privilege, joint defense privilege, common interest privilege, and protection under the work-product doctrine (&#8220;<span style="font-style:italic;font-weight:bold;">Privilege</span>&#8221;). The Parties shall have a shared Privilege with respect to all Information subject to Privilege (&#8220;<span style="font-style:italic;font-weight:bold;">Privileged Information</span>&#8221;) which relates to such pre-Distribution services. For the avoidance of doubt, Privileged Information within the scope of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.7</span> includes, but is not limited to, services rendered by legal counsel retained or employed by any Party (or any member of such Party&#8217;s respective Group), including outside counsel and in-house counsel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Post-Distribution Services</span>. The Parties recognize that legal and other professional services will be provided following the Distribution Time to each of Ligand and OmniAb. The Parties further recognize that certain of such post-Distribution services will be rendered solely for the benefit of Ligand or OmniAb, as the case may be, while other such post-Distribution services may be rendered with respect to claims, proceedings, litigation, disputes, or other matters which involve both Ligand and OmniAb. With respect to such post-Distribution services and related Privileged Information, the Parties agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>All Privileged Information relating to any claims, proceedings, litigation, disputes or other matters which involve both Ligand and OmniAb shall be subject to a shared Privilege among the Parties involved in the claims, proceedings, litigation, disputes, or other matters at issue; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>Except as otherwise provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.7(c)(i)</span>, Privileged Information relating to post-Distribution services provided solely to one of Ligand or OmniAb shall not be deemed shared between the Parties, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that the foregoing shall not be construed or interpreted to restrict the right or authority of the Parties (x) to enter into any further agreement, not </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">otherwise inconsistent with the terms of this Agreement, concerning the sharing of Privileged Information or (y) otherwise to share Privileged Information without waiving any Privilege which could be asserted under applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>The Parties agree as follows regarding all Privileged Information with respect to which the Parties shall have a shared Privilege under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.7(a) or (b)</span>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>Subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.7(c)(iii)</span>, neither Party may waive, allege or purport to waive, any Privilege which could be asserted under any applicable Law, and in which the other Party has a shared Privilege, without the written consent of the other Party, which shall not be unreasonably withheld or delayed;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>If a dispute arises between or among the Parties or their respective Subsidiaries regarding whether a Privilege should be waived to protect or advance the interest of any Party, each Party agrees that it shall negotiate in good faith, and shall endeavor to minimize any prejudice to the rights of the other Party. Neither party shall unreasonably withhold consent to any request for waiver by the other Party, and each Party specifically agrees that it shall not withhold consent to waive for any purpose except to protect its own legitimate interests; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>In the event of any litigation or dispute between the Parties, or any members of their respective Groups, either such Party may waive a Privilege in which the other Party or member of such Group has a shared Privilege, without obtaining the consent of the other Party; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that such waiver of a shared Privilege shall be effective only as to the use of Privileged Information with respect to the litigation or dispute between the Parties and/or the applicable members of their respective Groups, and shall not operate as a waiver of the shared Privilege with respect to third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>The <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">transfer</span> of all Information pursuant to this Agreement is made in reliance on the agreement of Ligand and OmniAb as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.6</span> and this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.7</span>, to maintain the confidentiality of Privileged Information and to assert and maintain any applicable Privilege. The access to Information being granted pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.5</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.2</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.3</span> , the agreement to provide witnesses and individuals pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.5</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.4</span>, the furnishing of notices and documents and other cooperative efforts contemplated by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.5</span>, and the transfer of Privileged Information between the Parties and their respective Subsidiaries pursuant to this Agreement shall not be deemed a waiver of any Privilege that has been or may be asserted under this Agreement or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_6_8_OwnershipofInformation"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ownership of Information</span>. Any Information owned by one Party or any of its Subsidiaries that is provided to a requesting Party pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VI</span> shall be deemed to remain the property of the providing Party. Unless expressly set forth herein, or unless expressly agreed in a subsequent and separate agreement, nothing contained in this Agreement shall be construed as granting a license or other rights to any Party with respect to any such Information, whether by implication, estoppel or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_6_9_ProcessingofPersonal"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Processing of Personal </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Information</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Both Parties shall cooperate to ensure that their respective Processing of Personal Information hereunder does and will materially comply with all applicable Privacy Requirements and take all reasonable precautions to avoid acts that place the other Party in breach of its obligations under any applicable Privacy Requirements. Nothing in this Section 6.9 shall be deemed to prevent any Party from taking the steps it reasonably deems necessary to comply with any applicable Privacy Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>To the extent required to do so by applicable Privacy Requirements as a result of or in connection with the transactions contemplated hereby, including the completion of the Internal Reorganization, the Parties agree to enter into such data processing agreements as required to comply with applicable Privacy Laws and shall act reasonably and in good faith in doing so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>It is understood and agreed by the Parties that the transfer of Personal Information in connection with the Transfer of Assets will not violate any Privacy Requirements in any material respect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_6_10_OtherAgreements"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 6.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Agreements</span>. The rights and obligations granted under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VI</span> are subject to any specific limitations, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">qualifications</span> or additional provisions on the sharing, exchange or confidential treatment of Information set forth in any Ancillary Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="B_ARTICLEVIIDISPUTERESOLUTION"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE VII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DISPUTE RESOLUTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_7_1_Negotiation"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Negotiation</span>. Except as otherwise provided in any Ancillary Agreement, in the event of a controversy, dispute or Action arising out of, in connection with, or in relation to the interpretation, performance, nonperformance, validity or breach of this Agreement or the Ancillary Agreements or otherwise arising out of, or in any way related to, this Agreement or the Ancillary Agreements or the transactions contemplated hereby, including any Action based on contract, tort, statute or constitution (collectively, &#8220;<span style="font-style:italic;font-weight:bold;">Disputes</span>&#8221;), where such Dispute is between the Parties or between Ligand and APAC, the general counsels or chief legal officers of the parties to the Dispute (or such other individuals designated by the respective general counsels or chief legal officers) and/or the executive officers designated by the parties to the Dispute shall negotiate for a reasonable period of time to settle such Dispute; provided, that such reasonable period shall not, unless otherwise agreed by the parties to such Dispute in writing, exceed sixty (60) days (the &#8220;<span style="font-style:italic;font-weight:bold;">Negotiation Period</span>&#8221;) from the time of receipt by a party to such Dispute of written notice of such Dispute (&#8220;<span style="font-style:italic;font-weight:bold;">Dispute Notice</span>&#8221;) and settlement of such Dispute pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.1</span> shall be confidential, and no written or oral statements or offers made by the parties to the Dispute during such settlement negotiations shall be admissible for any purpose in any subsequent proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_7_2_ReliefinCourt"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Relief in Court</span>. If the Dispute has not been resolved for any reason after the Negotiation Period, each party to such Dispute shall be entitled to seek relief in a court of competent jurisdiction pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.16</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_7_3_ContinuityofService"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 7.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continuity of Service </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">and Performance</span>. Unless otherwise agreed in writing, the Parties shall continue to provide service and honor all other commitments under this Agreement and each Ancillary Agreement during the course of dispute resolution pursuant to the provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article VII</span> with respect to all matters not subject to such dispute resolution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_ARTICLEVIIIINSURANCE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE VIII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">INSURANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_8_1_InsuranceMatters"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 8.1</span></span>Insurance<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> Matters</span>. The provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1</span> shall apply only to the extent not otherwise provided for in the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The Parties intend by this Agreement that, to the extent permitted under the terms of any applicable insurance policy, OmniAb, each other member of the OmniAb Group and each of their respective directors, officers and employees will be successors in interest and/or additional insureds and will have and be fully entitled to continue to exercise all rights that any of them may have as of the Distribution Time (with respect to events occurring or claimed to have occurred before the Distribution Time) as a Subsidiary, Affiliate, division, director, officer or employee of Ligand before the Distribution Time under any insurance policy, including any rights that OmniAb, any other member of the OmniAb Group or any of its or their respective directors, officers, or employees may have as an insured or additional named insured, Subsidiary, Affiliate, division, director, officer or employee to avail itself, himself or herself of any policy of insurance or any agreements related to the policies in effect before the Distribution Time, with respect to events occurring before the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>After the Distribution Time, Ligand (and each other member of the Ligand Group) and OmniAb (and each other member of the OmniAb Group) shall not, without the consent of OmniAb or Ligand, respectively (such consent not to be unreasonably withheld, conditioned or delayed), provide any insurance carrier with a release or amend, modify or waive any rights under any insurance policy if such release, amendment, modification or waiver thereunder would materially adversely affect any rights of any member of the Group of the other Party with respect to insurance coverage otherwise afforded to such other Party for pre-Distribution claims; provided, however, that the foregoing shall not (i) preclude any member of any Group from presenting any claim or from exhausting any policy limit, (ii) require any member of any Group to pay any premium or other amount or to incur any Liability or (iii) require any member of any Group to renew, extend or continue any policy in force.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>The provisions of this Agreement are not intended to relieve any insurer of any Liability under any policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>No member of the Ligand Group or any Ligand Indemnitee will have any Liabilities whatsoever as a result of the insurance policies as in effect at any time before the Distribution Time, including as a result of (i) the level or scope of any insurance, (ii) the creditworthiness of any insurance carrier, (iii) the terms and conditions of any policy, or (iv) the adequacy or timeliness of any notice to any insurance carrier with respect to any claim or potential claim.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Except to the extent otherwise provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1(b)</span>, in no event will Ligand, any other member of the Ligand Group or any Ligand Indemnitee have any Liability or obligation whatsoever to any member of the OmniAb Group if any insurance policy is terminated or otherwise ceases to be in effect for any reason, is unavailable or inadequate to cover any Liability of any member of the OmniAb Group for any reason whatsoever or is not renewed or extended beyond the current expiration date of any such insurance policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>This Agreement shall not be considered as an attempted assignment of any policy of insurance or as a contract of insurance and shall not be construed to waive any right or remedy of any members of the Ligand Group in respect of any insurance policy or any other contract or policy of insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>Nothing in this Agreement will be deemed to restrict any member of the OmniAb Group from acquiring at its own expense any other insurance policy in respect of any Liabilities or covering any period. After the Distribution Time, OmniAb will acquire its own insurance policies covering the OmniAb Group and each of their respective directors, officers and employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>To the extent that any insurance policy provides for the reinstatement of policy limits, and both Ligand and OmniAb desire to reinstate such limits, the cost of reinstatement will be shared by Ligand and OmniAb as the Parties may agree. If either Party, in its sole discretion, determines that such reinstatement would not be beneficial, that Party shall not contribute to the cost of reinstatement and will not make any claim thereunder nor otherwise seek to benefit from the reinstated policy limits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>For purposes of this Agreement, &#8220;<span style="font-style:italic;font-weight:bold;">Covered Matter</span>&#8221; shall mean any matter, whether arising before or after the Distribution Time, with respect to which any OmniAb Indemnitee may seek to exercise any right under any insurance policy pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1</span>. If OmniAb receives notice or otherwise learns of any Covered Matter, OmniAb shall promptly give Ligand written notice thereof. Any such notice shall describe the Covered Matter in reasonable detail. With respect to each Covered Matter and any Joint Claim, OmniAb shall have sole responsibility for reporting the claim to the insurance carrier and will provide a copy of such report to OmniAb. If Ligand or another member of the Ligand Group fails to notify OmniAb within fifteen (15) days that it has submitted an insurance claim with respect to a Covered Matter or Joint Claim, OmniAb shall be permitted to submit (on behalf of the applicable OmniAb Indemnitee) such insurance claim.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span>Each of OmniAb and Ligand will share such information as is reasonably necessary in order to permit the other Party to manage and conduct its insurance matters in an orderly fashion and provide the other Party with any assistance that is reasonably necessary or beneficial in connection with such Party&#8217;s insurance matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="B_ARTICLESIXMISCELLANEOUS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE IX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_1_EntireAgreement"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">; Construction</span>. This Agreement, including the Exhibits and Schedules, and the Ancillary Agreements shall constitute the entire agreement among the Parties and APAC with respect to the subject matter hereof and shall supersede all previous negotiations, commitments, course of dealings and writings with respect to such subject matter. In the event of any inconsistency between this Agreement and any Schedule hereto, the Schedule shall prevail. In the event and to the extent that there shall be a conflict between the provisions of (a) this Agreement and the provisions of any Ancillary Agreement or Continuing Arrangement, such Ancillary Agreement or Continuing Arrangement shall control (except with respect to any Conveyancing and Assumption Instruments, in which case this Agreement shall control) and (b) this Agreement and any agreement which is not an Ancillary Agreement, this Agreement shall control unless specifically stated otherwise in such agreement. For the avoidance of doubt, the Conveyancing and Assumption Instruments are intended to be ministerial in nature and only to effect the transactions contemplated by this Agreement with respect to the applicable local jurisdiction and shall not expand or modify the rights and obligations of the Parties, APAC or their respective Affiliates under this Agreement or any of the Ancillary Agreements that are not Conveyancing and Assumption Instruments. Except as expressly set forth in this Agreement or any Ancillary Agreement: (i) all matters relating to Taxes and Tax Returns of the Parties and their respective Subsidiaries shall be governed exclusively by the Tax Matters Agreement; and (ii) for the avoidance of doubt, in the event of any conflict between this Agreement or any Ancillary Agreement (other than the Tax Matters Agreement), on the one hand, and the Tax Matters Agreement, on the other hand, with respect to such matters, the terms and conditions of the Tax Matters Agreement shall govern, except as otherwise provided in the Tax Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_2_AncillaryAgreements"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ancillary Agreements</span>. Except as expressly set forth herein, this Agreement is not intended to address, and should not be interpreted to address, the matters specifically and expressly covered by the Ancillary Agreements.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_3_Counterparts"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</span>. This Agreement may be executed in more than one counterpart, all of which shall be considered one and the same agreement, and shall become effective when one or more such counterparts have been signed by each of the Parties and APAC and delivered to each of the Parties and APAC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_4_SurvivalofAgreements"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival of Agreements</span>. Except as otherwise contemplated by this Agreement or any Ancillary Agreement, all covenants and agreements of the Parties and APAC contained in this Agreement and each Ancillary Agreement shall survive the Distribution Time and remain in full force and effect in accordance with their applicable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_5_Expenses"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses</span>. Except as otherwise specified in this Agreement or the Ancillary Agreements, or as otherwise agreed in writing among Ligand, OmniAb and APAC, Ligand and OmniAb shall each be responsible for its own fees, costs and expenses paid or incurred in connection with this Agreement, any Ancillary Agreement and the Form 10 and the consummation of the Internal Reorganization, the Contribution, the Distribution and the Merger (the &#8220;<span style="font-style:italic;font-weight:bold;">Transaction-related Expenses</span>&#8221;). OmniAb shall reimburse Ligand for all documented, out-of-pocket Transaction-related Expenses of OmniAb that have been paid by Ligand through and including the Distribution Date (the &#8220;<span style="font-style:italic;font-weight:bold;">Reimbursable Transaction-related Expenses</span>&#8221;) by Ligand&#8217;s deducting such amount from the cash portion of the Contribution to be made by it in connection with the Separation. On or prior to the date that is three (3) Business Days prior to the Distribution Date, Ligand shall furnish to APAC a schedule of the Reimbursable Transaction-related Expenses, together with supporting documentation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_6_Notices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</span>. All notices, requests, claims, demands and other communications under this Agreement and, to the extent applicable and unless otherwise provided therein, under each of the Ancillary Agreements shall be in English, shall be in writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by delivery in person, by overnight courier service, by registered or certified mail (return receipt requested), or by email (provided confirmation of transmission is electronically generated and kept on file by the sending party and so long as the sender of such email does not receive an automatic reply from the recipient&#8217;s email server indicating that the recipient did not receive such email), to the respective Parties or APAC at the following addresses (or at such other address for a Party or APAC as shall be specified in a notice given in accordance with this Section 9.6):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">To Ligand:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Ligand Pharmaceuticals Incorporated<br />3911 Sorrento Valley Blvd., Suite 110<br />San Diego, CA 92121<br />Attn: Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Email: tespinoza@ligand.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;">With a copy (which shall not constitute notice) to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;">Latham &amp; Watkins, LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;">12670 High Bluff Dr.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;">San Diego, California 92130</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Attn:</span></span>Matthew Bush</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 90pt;">Scott Shean</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Email:</span></span>matt.bush@lw.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 90pt;">scott.shean@lw.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">To OmniAb:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">OmniAb, Inc.<br />5980 Horton Street, Suite 405<br />Emeryville, CA 94608<br />Attn: Chief Legal Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Email: cberkman@omniab.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;">With a copy (which shall not constitute notice) to:</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="white-space:pre-wrap;"> Latham &amp; Watkins, LLP</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;">12670 High Bluff Dr.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;">San Diego, California 92130</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Attn:</span></span>Matthew Bush</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 90pt;">Scott Shean</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Email:</span></span>matt.bush@lw.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 90pt;">scott.shean@lw.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 72pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">To APAC:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Avista Public Acquisition Corp. II</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">65 East 55th Street, 18th Floor<br />New York, New York 10022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Attn: Benjamin Silbert, General Counsel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Email: Silbert@avistacap.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;">with a copy (which shall not constitute notice) to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;">Weil, Gotshal &amp; Manges LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;">767 5th Avenue </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;">New York, NY 10153</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Attn:</span></span>Jaclyn L. Cohen, Esq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 90pt;">Raymond O. Gietz, Esq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Email:</span></span>jackie.cohen@weil.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 90pt;">raymond.gietz@weil.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 72pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="B_Section_9_7_Consents"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consents</span>. Any consent required or permitted to be given by any Party or APAC to the other Party or APAC under this Agreement shall be in writing and signed by the Party or APAC, as the case may be, giving such consent and shall be effective only against such Party (and its Group) or APAC (and its Affiliates), as the case may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_8_Assignment"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</span>. This Agreement shall not be assignable, in whole or in part, directly or indirectly, by any Party or APAC without the prior written consent of the other Party and APAC, and any attempt to assign any rights or obligations arising under this Agreement without such consents shall be void. Notwithstanding the foregoing, and subject to any restrictions on assignment pursuant to Article IV of the Tax Matters Agreement, this Agreement shall be assignable to a bona fide third party in connection with a merger, reorganization, consolidation or the sale of all or substantially all the assets of a party hereto so long as the resulting, surviving or transferee entity assumes all the obligations of the relevant party hereto by operation of law or pursuant to an agreement in form and substance reasonably satisfactory to the other parties to this Agreement; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided, however,</span> that no assignment permitted by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.8</span> shall release the assigning Party or APAC, as the case may be, from liability for the full performance of its obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_9_Successors"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> and Assigns</span>. The provisions of this Agreement and the obligations and rights hereunder shall be binding upon, inure to the benefit of and be enforceable by (and against) the Parties, APAC and their respective successors and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_10_Termination"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> and Amendment</span>. This Agreement may not be terminated, modified or amended except by an agreement in writing signed by each of Ligand, OmniAb and APAC; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that this Agreement shall terminate immediately upon termination of the Merger Agreement if the Merger Agreement is terminated in accordance with its terms prior to the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_11_PaymentTerms"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment Terms</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> or as otherwise expressly provided to the contrary in this Agreement or in any Ancillary Agreement, any amount to be paid or reimbursed by a Party or APAC (and/or a member of such Party&#8217;s Group or its Affiliates), on the one hand, to the other Party or APAC (and/or a member of such Party&#8217;s Group or its Affiliate), on the other hand, under this Agreement shall be paid or reimbursed hereunder within forty-five (45) days after presentation of an invoice or a written </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">demand therefor and setting forth, or accompanied by, reasonable documentation or other reasonable explanation supporting such amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Except as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> or as expressly provided to the contrary in this Agreement or in any Ancillary Agreement, any amount not paid when due pursuant to this Agreement (and any amount billed or otherwise invoiced or demanded and properly payable that is not paid within forty-five (45) days of such bill, invoice or other demand) shall bear interest at a rate per annum equal to the Prime Rate, from time to time in effect, calculated for the actual number of days elapsed, accrued from the date on which such payment was due up to the date of the actual receipt of payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Without the consent of the Party or APAC, as the case may be, receiving any payment under this Agreement specifying otherwise, all payments to be made by either Party or APAC under this Agreement shall be made in US Dollars. Except as expressly provided herein, any amount which is not expressed in US Dollars shall be converted into US Dollars by using the exchange rate published on Bloomberg at 5:00 pm Eastern Standard time (EST) on the day before the relevant date or in the Wall Street Journal on such date if not so published on Bloomberg. Except as expressly provided herein, in the event that any indemnification payment required to be made hereunder or under any Ancillary Agreement may be denominated in a currency other than US Dollars, the amount of such payment shall be converted into US Dollars on the date in which notice of the claim is given to the Indemnifying Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_12_Subsidiaries"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.12</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsidiaries</span>. Each of the Parties and APAC shall cause to be performed, and hereby guarantees the performance of, all actions, agreements and obligations set forth herein to be performed by any Subsidiary of such Party or APAC, as the case may be, or by any entity that becomes a Subsidiary of such Party or APAC, as the case may be, at and after the Distribution Time, to the extent such Subsidiary remains a Subsidiary of the applicable Party or APAC, as the case may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_13_ThirdParty"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.13</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Beneficiaries</span>. Except (i) as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article V</span> relating to Indemnitees and for the release under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1</span> of any Person provided therein and (ii) as specifically provided in any Ancillary Agreement, this Agreement is solely for the benefit of the Parties and APAC and should not be deemed to confer upon third parties any remedy, claim, liability, reimbursement, claim of Action or other right in excess of those existing without reference to this Agreement. For the avoidance of doubt, no stockholder of Ligand, OmniAb or APAC shall be third-party beneficiaries for any purpose prior to the Distribution, and no stockholder (or Party or APAC on behalf of their respective stockholders) shall be entitled to bring any claim for damages prior to the Distribution based on a decrease in share value or lost premiums.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_14_Title"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.14</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> and Headings</span>. Titles and headings to sections herein are inserted for the convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_15_Exhibits"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.15</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibits</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> and Schedules</span>. The Exhibits and Schedules shall be construed with and as an integral part of this Agreement to the same extent as if the same had been set forth verbatim herein. Nothing in the Exhibits or Schedules constitutes an admission of any liability or obligation of any member of the Ligand Group or the OmniAb Group or any of their respective Affiliates to any third party, nor, with respect to any third party, an admission against the interests of any member of the Ligand Group or the OmniAb Group or any of their respective Affiliates. The inclusion of any item or liability or category of item or liability on any Exhibit or Schedule is made solely for purposes of allocating potential liabilities among the Parties and shall not be deemed as or construed to be an admission that any such liability exists.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_16_GoverningLawandVenue"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.16</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law and Venue</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">; Submission to Jurisdiction; Selection of Forum; Waiver of Trial by Jury</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>This Agreement and any dispute arising out of, in connection with or relating to this Agreement shall be governed by and construed in accordance with the Laws of the State of Delaware, without giving effect to the conflicts of laws principles thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Each of the Parties and APAC agrees that any Action related to this agreement shall be brought exclusively in the Court of Chancery of the State of Delaware or, if under applicable Law, exclusive jurisdiction over such matter is vested in the federal courts, any federal court in the State of Delaware and any appellate court from any thereof (the &#8220;<span style="font-style:italic;font-weight:bold;">Chosen Courts</span>&#8221;). By executing and delivering this Agreement, each of the Parties and APAC irrevocably: (i) accepts generally and unconditionally submits to the exclusive jurisdiction of the Chosen Courts for any Action relating to this Agreement, including any Action brought for any remedy contemplated by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.17</span>; (ii) waives any objections which such Party or APAC, as the case may be, may now or hereafter have to the laying of venue of any such Action contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.16(b)</span> and hereby further irrevocably waives and agrees not to plead or claim that any such Action has been brought in an inconvenient forum; (iii) agrees that it will </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">not attempt to deny or defeat the personal jurisdiction of the Chosen Courts by motion or other request for leave from any such court; (iv) agrees that it will not bring any Action contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.16(b)</span> in any court other than the Chosen Courts; (v) agrees that service of all process, including the summons and complaint, in any Action may be made by registered or certified mail, return receipt requested, to such party at their respective addresses provided in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.6</span> or in any other manner permitted by Law; and (vi) agrees that service as provided in the preceding clause (v) is sufficient to confer personal jurisdiction over such Party or APAC in the Action, and otherwise constitutes effective and binding service in every respect. Each of the Parties and APAC agrees that a final judgment in any Action in a Chosen Court as provided above may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law, and each Party and APAC further agrees to the non-exclusive jurisdiction of the Chosen Courts for the enforcement or execution of any such judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>EACH OF LIGAND, OMNIAB AND APAC HEREBY UNCONDITIONALLY AND IRREVOCABLY WAIVE THEIR RIGHT TO TRIAL BY JURY IN ANY JUDICIAL PROCEEDING IN ANY COURT RELATING TO ANY DISPUTE, CONTROVERSY OR CLAIM ARISING OUT OF, RELATING TO OR IN CONNECTION WITH THIS AGREEMENT OR ANY INSTRUMENT OR DOCUMENT DELIVERED PURSUANT TO THIS AGREEMENT (INCLUDING ANY SCHEDULE OR EXHIBIT HERETO AND THERETO) OR THE BREACH, TERMINATION OR VALIDITY OF SUCH AGREEMENT, INSTRUMENTS OR DOCUMENTS OR THE NEGOTIATION, EXECUTION OR PERFORMANCE OF SUCH AGREEMENTS, INSTRUMENTS OR DOCUMENTS. NEITHER LIGAND, OMNIAB NOR APAC SHALL SEEK A JURY TRIAL IN ANY LAWSUIT, PROCEEDING, COUNTERCLAIM OR ANY OTHER LITIGATION PROCEDURE BASED UPON, OR ARISING OUT OF, THIS AGREEMENT OR ANY RELATED INSTRUMENTS OR DOCUMENTS. NEITHER LIGAND, OMNIAB NOR APAC WILL SEEK TO CONSOLIDATE ANY SUCH ACTION IN WHICH A JURY TRIAL HAS BEEN WAIVED WITH ANY OTHER ACTION IN WHICH A JURY TRIAL CANNOT BE OR HAS NOT BEEN WAIVED. EACH OF LIGAND, OMNIAB AND APAC CERTIFIES THAT IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT, INSTRUMENT OR DOCUMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS SET FORTH ABOVE IN THIS <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 9.16(c)</span>. NONE OF LIGAND, OMNIAB OR APAC HAS IN ANY WAY AGREED WITH OR REPRESENTED TO ANY OF THE OTHERS THAT THE PROVISIONS OF THIS <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 9.16(c)</span> WILL NOT BE FULLY ENFORCED IN ALL INSTANCES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_17_SpecificPerformance"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.17</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specific Performance</span>. From and after the Distribution Time, in the event of any actual or threatened default in, or breach of, any of the terms, conditions and provisions of this Agreement or any Ancillary Agreement, the Parties and APAC agree that APAC and the Party or Parties to this Agreement or such Ancillary Agreement who are or are to be thereby aggrieved shall have the right to specific performance and injunctive or other equitable relief of its or their rights under this Agreement or such Ancillary Agreement, in addition to any and all other rights and remedies at law or in equity, and all such rights and remedies shall be cumulative. The Parties and APAC agree that, from and after the Distribution Time, the remedies at law for any breach or threatened breach of this Agreement or any Ancillary Agreement, including monetary damages, are inadequate compensation for any Indemnifiable Loss, that any defense in any action for specific performance that a remedy at law would be adequate is hereby waived, and that any requirements for the securing or posting of any bond with such remedy are hereby waived.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_18_Severability"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.18</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</span>. In the event any one or more of the provisions contained in this Agreement should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein and therein shall not in any way be affected or impaired thereby. The Parties and APAC shall endeavor in good-faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions, the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_19_Interpretation"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.19</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</span>. The Parties and APAC have participated jointly in the negotiation and drafting of this Agreement. This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the Party or APAC, as the case may be, drafting or causing any instrument to be drafted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_20_NoDuplication"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.20</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Duplication</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">; No Double Recovery</span>. Nothing in this Agreement is intended to confer to or impose upon any Party or APAC a duplicative right, entitlement, obligation or recovery with respect to any matter arising out of the same facts and circumstances (including with respect to the rights, entitlements, obligations and recoveries that may arise out of one or more of the following Sections: <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.2</span>; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3</span>; and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.4</span>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_21_TaxTreatment"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.21</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Treatment </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">of Payments</span>. Unless otherwise required by a Final Determination, this Agreement or the Tax Matters Agreement or otherwise agreed to among the Parties and APAC, for U.S. federal Tax purposes, any payment made pursuant to this Agreement (other than any payment of interest pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.11</span>) by: (i) OmniAb to Ligand shall be treated for all Tax </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">purposes as a distribution by OmniAb to Ligand with respect to stock of OmniAb occurring on or immediately before the Distribution Time; or (ii) Ligand to OmniAb shall be treated for all Tax purposes as a tax-free contribution by Ligand to OmniAb with respect to its stock occurring on or immediately before the Distribution Time; and in each case, no Party or APAC shall take any position inconsistent with such treatment. In the event that a Taxing Authority asserts that a Party&#8217;s treatment of a payment pursuant to this Agreement should be other than as set forth in the preceding sentence, such Party shall use its commercially reasonable efforts to contest such challenge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_22_NoWaiver"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.22</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Waiver</span>. No failure to exercise and no delay in exercising, on the part of any Party, any right, remedy, power or privilege hereunder or under the other Ancillary Agreements shall operate as a waiver hereof or thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder or thereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="B_Section_9_23_NoAdmission"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 9.23</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Admission</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> of Liability</span>. The allocation of Assets and Liabilities herein (including on the Schedules hereto) is solely for the purpose of allocating such Assets and Liabilities between Ligand and OmniAb and is not intended as an admission of liability or responsibility for any alleged Liabilities vis-&#224;-vis any third party, including with respect to the Liabilities of any non-wholly owned Subsidiary of Ligand or OmniAb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">[<i style="font-style:italic;">Signature Page Follows</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bc899b01_2d90_40cd_9d16_9186f5b05204"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, each of Ligand, OmniAb and APAC have caused this Agreement to be duly executed as of the day and year first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:50.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">LIGAND PHARMACEUTICALS INCORPORATED</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:50.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:47.64%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Matthew Korenberg</p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Matthew Korenberg</p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Executive Vice President, Finance and Chief Financial Officer</p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:50.32%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:50.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">OMNIAB, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:50.32%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:47.64%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Matthew W. Foehr </p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Matthew W. Foehr</p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:50.32%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:50.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:50.32%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:47.64%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Benjamin Silbert</p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Benjamin Silbert</p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General Counsel</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">B-47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cd5090a3_c1cc_4fca_aa63_743eaf8639fe"></a><a id="AnnexC_741582"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Annex C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Execution Version</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">March 23, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Avista Public Acquisition Corp. II<br />65 East 55th Street, 18th Floor<br />New York, NY 10022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Re: <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Letter Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Ladies and Gentlemen:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Reference is made to that certain Agreement and Plan of Merger, dated as of March&#160;23, 2022 (the &#8220;<span style="font-style:italic;font-weight:bold;">Merger Agreement</span>&#8221;), by and among Ligand Pharmaceuticals Incorporated (&#8220;<span style="font-style:italic;font-weight:bold;">Ligand</span>&#8221;), a Delaware corporation, OmniAb,&#160;Inc., a Delaware corporation (&#8220;<span style="font-style:italic;font-weight:bold;">SpinCo</span>&#8221;, and together with Ligand, the &#8220;<span style="font-style:italic;font-weight:bold;">Companies</span>&#8221;), Avista Public Acquisition Corp. II, a Cayman Islands exempted company (&#8220;<span style="font-style:italic;font-weight:bold;">Parent</span>&#8221;), and Orwell Merger Sub Inc., a Delaware corporation. This letter agreement (this &#8220;<span style="font-style:italic;font-weight:bold;">Letter Agreement</span>&#8221;) is being entered into and delivered by Parent, Avista Acquisition LP II (the &#8220;<span style="font-style:italic;font-weight:bold;">Sponsor</span>&#8221;), SpinCo and each of the undersigned, each of whom is a member of Parent&#8217;s management team and/or Parent&#8217;s Board of Directors (the &#8220;<span style="font-style:italic;font-weight:bold;">Board</span>&#8221;) (each, an &#8220;<span style="font-style:italic;font-weight:bold;">Insider</span>&#8221;), in connection with the transactions contemplated by the Merger Agreement (the &#8220;<span style="font-style:italic;font-weight:bold;">Merger</span>&#8221;). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In order to induce the Companies to enter into the Merger Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Sponsor and each Insider hereby agrees with Parent as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</span>. As used herein, (i)&#160;&#8221;<span style="font-style:italic;font-weight:bold;">Earnout Period</span>&#8221; shall mean the period from the Closing Date to and including the fifth (5th) anniversary of the Closing Date; (ii)&#160;&#8221;<span style="font-style:italic;font-weight:bold;">Founder Shares</span>&#8221; shall mean the 5,750,000 shares of Domesticated Parent Common Stock into which the 5,750,000 Class&#160;B ordinary shares of Parent are to be converted in the Domestication, equitably adjusted for stock splits, reverse stock splits, stock dividends, reorganizations, recapitalizations, reclassifications, combinations, exchanges of shares or other like changes or transactions with respect to such Founder Shares; (iii)&#160;&#8221;<span style="font-style:italic;font-weight:bold;">Post-Transaction VWAP</span>&#8221; shall mean the daily volume-weighted average share price for any 20 Trading Days over any consecutive 30-day period; (iv)&#160;&#8221;<span style="font-style:italic;font-weight:bold;">Trading Day</span>&#8221; shall mean any day on which Domesticated Parent Common Stock are actually traded on the principal securities exchange or securities market on which shares of Domesticated Parent Common Stock are then traded; and (v)&#160;&#8221;<span style="font-style:italic;font-weight:bold;">Triggering Event</span>&#8221; shall mean, (a)&#160;with respect to fifty percent (50%) of the Earnout Founder Shares (as hereinafter defined), the first date during the Earnout Period on which the Post-Transaction VWAP is $12.50 per share or higher, and (b)&#160;with respect any Earnout Founder Shares for which a Triggering Event has not occurred with respect to clause (a), the first date during the Earnout Period on which the Post-Transaction VWAP is $15.00 per share or higher; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that in the event of a Change of Control during the Earnout Period pursuant to which Parent or any of its stockholders have the right to receive, directly or indirectly, cash, securities or other property attributing a value of at least $12.50 (with respect to fifty percent (50%) of the Earnout Founder Shares) or $15.00 (with respect to all Earnout Founder Shares) per share of Domesticated Parent Common Stock, as agreed in good faith by the Sponsor and the Board), then a Triggering Event shall be deemed to have occurred immediately prior to such Change of Control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties</span>. Each Insider hereby severally represents and warrants to Parent that as of the date hereof such Insider holds the number of issued and outstanding Founder Shares set forth next to such Insider&#8217;s name on the signature pages&#160;hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Combination Vote</span>. The Sponsor and each Insider agrees that if Parent seeks shareholder approval of the Merger, then in connection with the Merger, the Sponsor or such Insider shall vote all of the (a)&#160;Parent Class&#160;A Common Stock and Founder Shares, in each case owned by such Person (beneficially or of record) as of the date hereof and (b)&#160;any additional Parent Class&#160;A Common Stock or Founder Shares (or any securities convertible into or exercisable or exchangeable for Parent Class&#160;A Common Stock or Founder Shares) of which the Sponsor or such Insider acquires record or beneficial ownership on or after the date hereof (including by purchase, as a result of stock splits, reverse stock splits, stock dividends, reorganizations, recapitalizations, reclassifications, combinations, exchanges of shares or other like changes or transactions) (clauses (a)&#160;and (b), the &#8220;<span style="font-style:italic;font-weight:bold;">Covered Shares</span>&#8221;) held by the Sponsor or such Insider in favor of the Merger (including the Transaction Proposals and any other proposals recommended </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">C-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">by the Board in connection with the Merger) and not elect to redeem any Covered Shares held by the Sponsor and each Insider in connection with such shareholder approval or the Merger (including, without limitation, the Transactions).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Founder Shares Earnout</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Upon and subject to the Closing, a number of Founder Shares beneficially owned by Sponsor as of the date hereof equal to (i)&#160;1,916,667 minus (ii)&#160;(A)&#160;718,750 multiplied by (B)&#160;a number, the numerator of which is the number of shares of Domesticated Parent Common Stock actually purchased pursuant to the Redemption Backstop in connection with the Closing and the denominator of which is 10,000,000 (the &#8220;<span style="font-style:italic;font-weight:bold;">Earnout Founder Shares</span>&#8221;), all or fifty percent (50%) of which shall be automatically forfeited for no consideration if an applicable Triggering Event has not occurred with respect to such Earnout Founder Shares during the Earnout Period, with such Earnout Founder Shares vesting (and therefore no longer subject to forfeiture), if at all, in accordance with the terms of this Letter Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The holders of the Earnout Founder Shares shall not (i)&#160;sell, transfer, assign, pledge, encumber, hypothecate, or similarly dispose of, (ii)&#160;enter into, establish or increase a put or equivalent position or liquidation with respect to, or increase a call equivalent position with respect to, (iii)&#160;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of, whether any such transaction is to be settled by delivery of securities, in cash or otherwise, or (iv)&#160;announce the intent to take any of the actions set forth in clauses (i)-(iii)&#160;with respect to, any Earnout Founder Shares until the date on which a Triggering Event has occurred; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that the Sponsor may distribute the Earnout Founder Shares held by it to its members in accordance with its Governing Documents and the A&amp;R Registration Rights Agreement, in each case, provided that the recipient of such distribution enters into a joinder to this Letter Agreement substantially in the form attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Any certificates or book entries representing the Earnout Founder Shares shall bear a legend referencing that they are subject to forfeiture pursuant to the provisions of this Letter Agreement, and any transfer agent for the shares of Domesticated Parent Common Stock will be given appropriate stop transfer orders that will be applicable until the Earnout Founder Shares are vested; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, however, that upon the vesting of any Earnout Founder Shares in accordance with the terms herein, Parent shall immediately cause the removal of such legend and direct such transfer agent that such stop transfer orders are no longer applicable. Holders of the Earnout Founder Shares shall be entitled to vote such Earnout Founder Shares and receive dividends and other distributions in respect thereof prior to the vesting of such Earnout Founder Shares in accordance with the terms herein; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that any such dividends and other distributions in respect of the Earnout Founder Shares that are subject to vesting pursuant to the terms herein shall be set aside by Parent and shall only be paid to the holder of such Earnout Founder Shares upon the vesting thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>The Earnout Founder Shares shall immediately become fully vested and no longer subject to forfeiture upon the occurrence of the applicable Triggering Event during the Earnout Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>If Parent at any time combines or subdivides the Domesticated Parent Common Stock (by any stock split, stock dividend, recapitalization, reorganization, merger, amendment of the applicable Governing Documents, scheme, arrangement or otherwise or extraordinary dividend resulting from an asset sale or leveraged recapitalization), the number of Earnout Founder Shares and the share prices set forth in the definition of &#8220;Triggering Events&#8221; shall be equitably adjusted by Parent in good faith to take into account such stock split, stock dividend, recapitalization, reorganization, merger, amendment of the applicable Governing Documents, scheme, arrangement or extraordinary dividend or other applicable transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment to Original Letter Agreements; Effects of Termination</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The first sentence of paragraph 4(b)&#160;of each of the Letter Agreements (collectively, as amended and restated pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">paragraph 5(a)</span>, the &#8220;<span style="font-style:italic;font-weight:bold;">Existing Letter Agreements</span>&#8221;), dated August&#160;9, 2021, entered into between Parent, on the one hand, and each of the Sponsor and each Insider, on the other hand, is hereby amended and restated in its entirety as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;">&#8220;The Insider acknowledges that the Insider has no right, title, interest or claim of any kind in or to any monies held in the Trust Account as a result of any liquidation of the Company with respect to the Founder Shares held by the Insider, if any.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The last sentence of paragraph 12(a)&#160;of each of the Existing Letter Agreements, is hereby amended and restated as follows:</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">C-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;">&#8220;This Letter Agreement may not be changed, amended, modified or waived (other than to correct a typographical error) as to any particular provision, except by a written instrument (i)&#160;executed by all parties hereto and (ii)&#160;solely with respect to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">paragraph 5</span> and prior to the Closing or valid termination of the OmniAb Merger Agreement (as defined below), in accordance with its terms, with the consent of OmniAb. &#8220;OmniAb Merger Agreement&#8221; means that certain Agreement and Plan of Merger, dated as of March&#160;23, 2022 (the &#8220;<span style="font-style:italic;font-weight:bold;">OmniAb Merger Agreement</span>&#8221;), by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#8220;<span style="font-style:italic;font-weight:bold;">Ligand</span>&#8221;), OmniAb,&#160;Inc., a Delaware corporation and wholly-owned subsidiary of Ligand, the Company, and Orwell Merger Sub Inc., a Delaware corporation.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Except as expressly modified by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">paragraph 5(a)</span>, the terms, representations, warranties, covenants and other provisions of the Existing Letter Agreements shall remain unchanged and are and shall continue to be in full force and effect in accordance with their respective terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>This Letter Agreement shall terminate on the earlier of (i)&#160;termination of the Merger Agreement or (ii)&#160;the vesting in full of all Earnout Founder Shares; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that terms and conditions set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">paragraph 5</span> shall survive any such termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</span>. This Letter Agreement and each of the Existing Letter Agreements constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and thereof and supersede all prior understandings, agreements or representations by or among the parties hereto and thereto, written or oral, to the extent they relate in any way to the subject matter hereof or thereof or the transactions contemplated hereby or thereby. This Letter Agreement may not be changed, amended, modified or waived (other than to correct a typographical error) as to any particular provision, except by a written instrument executed by all parties hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</span>. No party hereto may assign either this Letter Agreement or any of its rights, interests or obligations hereunder without the prior written consent of the other parties. Any purported assignment in violation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title to the purported assignee. This Letter Agreement shall be binding on the Sponsor and each Insider and each of their respective successors, heirs, personal representatives and assigns and permitted transferees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</span>. This Letter Agreement may be executed in any number of original or facsimile counterparts, and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Headings</span>. The paragraph headings herein are for convenience only and are not part of this Letter Agreement and shall not affect the interpretation thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</span>. This Letter Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Letter Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Letter Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</span>. This Letter Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. The parties hereto (i)&#160;all agree that any action, proceeding, claim or dispute arising out of, or relating in any way to, this Letter Agreement shall be brought and enforced in the Court of Chancery of the State of Delaware, and irrevocably submit to such jurisdiction and venue, which jurisdiction and venue shall be exclusive, and (ii)&#160;waive any objection to such exclusive jurisdiction and venue or that such courts represent an inconvenient forum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</span>. Any notice, consent or request to be given in connection with any of the terms or provisions of this Letter Agreement shall be in writing and shall be sent by express mail or similar private courier service, by certified mail (return receipt requested), by hand delivery or facsimile or other electronic transmission to the address set forth for such person on the signature page&#160;hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature Page&#160;Follows]</i></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">C-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Sincerely,</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">AVISTA ACQUISITION LP II</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:43%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Benjamin Silbert</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Benjamin Silbert</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Authorized Signatory</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">email:</p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Silbert@avistacap.com</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address:</p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">65 East 55th Street</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">18th Floor </p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">New York, NY 10022</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Thompson Dean</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;border-top:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Thompson Dean</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Number of issued and outstanding Founder Shares: 0</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ David Burgstahler</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;border-top:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">David Burgstahler</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Number of issued and outstanding Founder Shares: 0</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Sriram Venkataraman</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;border-top:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Sriram Venkataraman</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Number of issued and outstanding Founder Shares: 0</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Robert Girardi</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Robert Girardi</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Number of issued and outstanding Founder Shares: 0</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Amanda Heravi</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Amanda Heravi</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Number of issued and outstanding Founder Shares: 0</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ John Cafasso</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">John Cafasso</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Number of issued and outstanding Founder Shares: 0 </p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">C-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Benjamin Silbert</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Benjamin Silbert</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Number of issued and outstanding Founder Shares: 0</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ William E. Klitgaard</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">William E. Klitgaard</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Number of issued and outstanding Founder Shares: 35,000</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ L&#226;le White</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">L&#226;le White</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Number of issued and outstanding Founder Shares: 35,000</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Wendel Barr</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;border-top:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Wendel Barr</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Number of issued and outstanding Founder Shares: 35,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">C-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Acknowledged and Agreed:</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP.&#160;&#160;II</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Benjamin Silbert</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name: Benjamin Silbert</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title: General Counsel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">email: Silbert@avistacap.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address: 65 East 55th Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">18th Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">New York, NY 10022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Benjamin Silbert</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">email: Silbert@avistacap.com</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">OMNIAB,&#160;INC.</b></p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Benjamin Silbert</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0.25pt 0pt 0.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name: Matthew W. Foehr</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title: President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices : 5980 Horton Street</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Suite 405</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Emeryville, CA 94608</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Matt Foehr </p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Email: matt@omniab.com</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">C-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;OF JOINDER TO LETTER AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">[</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">], 20&#160;&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Reference is made to the Letter Agreement, dated as of March&#160;23, 2022, by and among Avista Public Acquisition Corp. II, a Cayman Islands exempted company (&#8220;<span style="font-style:italic;font-weight:bold;">Parent</span>&#8221;), Avista Acquisition LP II (the &#8220;<span style="font-style:italic;font-weight:bold;">Sponsor</span>&#8221;) and the other signatories thereto (the &#8220;<span style="font-style:italic;font-weight:bold;">Insiders</span>&#8221;), each of whom is a member of Parent&#8217;s management team and/or the Board (the &#8220;Letter Agreement&#8221;). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Letter Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Each of the Parent, Sponsor, the Insiders and each of the undersigned holder of Domesticated Parent Common Stock (each, a &#8220;<span style="font-style:italic;font-weight:bold;">New Stockholder Party</span>&#8221;) agrees that this Joinder to the Letter Agreement (this &#8220;<span style="font-style:italic;font-weight:bold;">Joinder</span>&#8221;) is being executed and delivered for good and valuable consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Each undersigned New Stockholder Party hereby agrees to and does become party to the Letter Agreement and to be subject to the same rights, remedies or obligations as the Sponsor thereunder. This Joinder shall serve as a counterpart signature page&#160;to the Letter Agreement and by executing below each undersigned New Stockholder Party is deemed to have executed the Letter Agreement with the same force and effect as if originally named a party thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">This Joinder may be executed in multiple counterparts, including by means of facsimile or electronic signature, each of which shall be deemed an original, but all of which together shall constitute the same instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">[<i style="font-style:italic;">Remainder of Page&#160;Intentionally Left Blank.</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6.09pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">C-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_beecd481_02ba_47e2_84bf_f0e53a305d81"></a><a id="AnnexD_88451"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Annex D</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Execution Version</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">AMENDED AND RESTATED FORWARD PURCHASE AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">This Amended and Restated Forward Purchase Agreement (this &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</span>&#8221;) is entered into as of March&#160;23, 2022, by and among Avista Public Acquisition Corp. II, a Cayman Islands exempted company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</span>&#8221;), Avista Acquisition LP II, a Cayman Islands exempted limited partnership (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchaser</span>&#8221;), and OmniAb,&#160;Inc., a Delaware corporation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo</span>&#8221;), and amends and restates in its entirety that certain Forward Purchase Agreement (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Original Agreement</span>&#8221;), dated as of August&#160;9, 2021, by and between the Company and the Purchaser. Capitalized terms used but not defined in this Agreement shall have the meanings ascribed to such terms in that certain Merger Agreement, dated as of the date of this Agreement, by and among the Company, Orwell Merger Sub Inc., a Delaware corporation and wholly owned Subsidiary of the Company, Ligand Pharmaceuticals Incorporated, a Delaware corporation, and SpinCo (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Agreement</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, the parties wish to amend and restate the Original Agreement as set forth in this Agreement, pursuant to which at the Closing under the Merger Agreement (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Closing</span>&#8221;), the Company shall issue and sell, and the Purchaser shall purchase, on a private placement basis, 1,500,000 shares of Domesticated Parent Common Stock (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Forward Purchase Shares</span>&#8221;) and 1,666,667 Domesticated Parent Warrants (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Forward Purchase Warrants</span>&#8221; and together with the Forward Purchase Shares, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Forward Purchase Securities</span>&#8221;) on the terms and conditions set forth herein; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, in connection with the entry into the Merger Agreement, an allocation of up to $100,000,000.00 of committed capital of the Purchaser has been made to subscribe for up to 10,000,000 shares of Domesticated Parent Common Stock and up to 1,666,667 Domesticated Parent Warrants to the extent that the number of shares of Domesticated Parent Common Stock that are redeemed in connection with the consummation of the Transactions would result in the Trust Amount being less than $100,000,000.00, on the terms and conditions set forth herein (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Backstop Commitment</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">NOW, THEREFORE, in consideration of the premises, representations, warranties and the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt, sufficiency and adequacy of which are hereby acknowledged, the parties hereto agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">1.</span>Backstop Subscription; Funding Notice.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Backstop Subscription</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">To the extent that the Trust Amount is less than $100,000,000 immediately prior to the Effective Time, the Purchaser agrees to purchase (i)&#160;a number of shares of Domesticated Parent Common Stock equal to (A)&#160;(x)&#160;$100,000,000 minus (y)&#160;the Trust Amount (such amount, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Backstop Subscription Amount</span>&#8221;), divided by (B)&#160;$10.00, rounded down to the nearest whole number (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Backstop Shares</span>&#8221;) and (ii)&#160;a number of Domesticated Parent Warrants equal to (I)&#160;1,666,667 multiplied by (II)&#160;a number, the numerator of which is the Backstop Subscription Amount and the denominator of which is $100,000,000 (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Backstop Warrants</span>&#8221; and, together with the Backstop Shares, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Backstop Securities</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Funding Notice</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">On the date by which Avista Shareholder Redemptions are required to be made in accordance with the Company&#8217;s memorandum and articles of association, as they may be amended from time to time (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Memorandum and Articles</span>&#8221;) (which date is two (2)&#160;Business Days prior to the date of the Parent Shareholders Meeting), the Company shall deliver a written notice (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Funding Notice</span>&#8221;) to the Purchaser setting forth:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>the Parent Share Redemption Amount;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>the Backstop Subscription Amount (as calculated in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1(a)</span>&#160;of this Agreement);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>the number of Backstop Shares;</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">D-1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>the number of Backstop Warrants;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span>the anticipated Closing Date; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</span></span>the Company&#8217;s wire instructions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Notwithstanding the foregoing, for the avoidance of doubt, the &#8220;Backstop Subscription Amount&#8221; shall be finally calculated without including any shares of Domesticated Parent Common Stock subject to the Parent Shareholder Redemption that have been offered for redemption but subsequently and validly withdrawn by the applicable holder in accordance with the Company&#8217;s Memorandum and Articles and applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">2.</span>Sale and Purchase.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Forward Purchase Securities; Backstop Securities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>The Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the Company, on a private placement basis, 1,500,000 Forward Purchase Shares and 1,666,667 Forward Purchase Warrants for an aggregate purchase price of $15,000,000 (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FPS Purchase Price</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>Subject to the terms and conditions hereof, the Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the Company, on a private placement basis, the Backstop Shares and the Backstop Warrants for an aggregate purchase price equal to the Backstop Subscription Amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>Each Forward Purchase Warrant and Backstop Warrant will have the same terms as the Parent Private Placement Warrants, and will be subject to the terms and conditions of the Warrant Agreement. Each Forward Purchase Warrant and Backstop Warrant will entitle the holder thereof to purchase one share of Domesticated Parent Common Stock at a price of $11.50 per share, subject to adjustment as described in the Warrant Agreement. The Forward Purchase Warrants and Backstop Warrants will become exercisable thirty (30) days after the Merger Closing and will expire five (5)&#160;years after the Merger Closing or upon redemption or the liquidation of the Company, if earlier, as described in the Warrant Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>The delivery of the Funding Notice hereunder shall serve as notice to the Purchaser that the Purchaser will be required to pay the FPS Purchase Price and the Backstop Subscription Amount, and acquire the Forward Purchase Securities and the Backstop Securities, at the FPS/BPS Closing (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span>The closing of the sale of the Forward Purchase Securities and the Backstop Securities (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FPS/BPS Closing</span>&#8221;) shall be held on the Closing Date and immediately prior to the Merger Closing. At the FPS/BPS Closing, the Company will issue to the Purchaser the Forward Purchase Securities and the Backstop Securities, if any, each registered in the name of the Purchaser, against (and concurrently with) the payment of the FPS Purchase Price and the Backstop Subscription Amount to the Company by wire transfer of immediately available funds to the account notified to the Purchaser by the Company in the Funding Notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delivery of Securities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>The Company shall register the Purchaser as the owner of the Forward Purchase Securities and the Backstop Securities purchased by the Purchaser hereunder (together, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities</span>&#8221;) on the Company&#8217;s share register and with the Company&#8217;s transfer agent by book entry on or promptly after (but in no event more than two (2)&#160;Business Days after) the date of the FPS/BPS Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>Each register and book entry for the Securities shall contain a notation, and each certificate (if any) evidencing the Securities shall be stamped or otherwise imprinted with a legend, in substantially the following form:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">D-2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">&#8220;THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY&#160;NOT BE TRANSFERRED IN VIOLATION OF SUCH ACT AND LAWS.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Legend Removal</span>. If the Securities are eligible to be sold without restriction under, and without the Company being in compliance with the current public information requirements of, Rule&#160;144 under the Securities Act, then at the Purchaser&#8217;s request, the Company will cause the Company&#8217;s transfer agent to remove the legend set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2(b)(ii)</span>. In connection therewith, if required by the Company&#8217;s transfer agent, the Company will promptly cause an opinion of counsel to be delivered to and maintained with its transfer agent, together with any other authorizations, certificates and directions required by the transfer agent that authorize and direct the transfer agent to transfer such Securities without any such legend; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that the Company will not be required to deliver any such opinion, authorization or certificate or direction if it reasonably believes that removal of the legend could result in or facilitate transfers of the Securities in violation of applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registration Rights</span>. The Purchaser shall have registration rights with respect to the Securities as referenced in the Amended and Restated Registration Rights Agreement that will be entered into by and among the Company, the Purchaser, SpinCo and certain other parties thereto in connection with the consummation of the Transactions and the form of which is attached to the Merger Agreement as Exhibit&#160;E (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registration Rights Agreement</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustments to Notional Amounts</span>. In the event of any change to the capital structure of the Company, whether dilutive or otherwise, by way of a share dividend, share split, or any other similar transaction however described, the number of Forward Purchase Securities and Backstop Securities, and/or the FPS Purchase Price and Backstop Subscription Amount, as applicable, will be adjusted as necessary to account for such changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</span></span>Representations and Warranties of the Purchaser. The Purchaser represents and warrants to each of the Company and SpinCo as follows, as of the date hereof:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization and Power</span>. The Purchaser is duly organized, validly existing, and in good standing under the Laws of the jurisdiction of its formation and has all requisite power and authority to carry on its business as presently conducted and as proposed to be conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authorization</span>. The Purchaser has full power and authority to enter into this Agreement. This Agreement, when executed and delivered by the Purchaser, will constitute the valid and legally binding obligation of the Purchaser, enforceable in accordance with its terms, except (a)&#160;as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any other Laws of general application affecting enforcement of creditors&#8217; rights generally, (b)&#160;as limited by Laws relating to the availability of specific performance, injunctive relief or other equitable remedies, or (c)&#160;to the extent the indemnification provisions contained in the Registration Rights Agreement may be limited by applicable federal or state securities Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Consents and Filings</span>. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority is required on the part of the Purchaser in connection with the consummation of the transactions contemplated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Other Instruments</span>. The execution, delivery and performance by the Purchaser of this Agreement and the consummation by the Purchaser of the transactions contemplated by this Agreement will not result in any violation or default (i)&#160;of any provisions of its organizational documents, (ii)&#160;of any instrument, judgment, order, writ or decree to which it is a party or by which it is bound, (iii)&#160;under any note, indenture or mortgage to which it is a party or by which it is bound, (iv)&#160;under any lease, agreement, contract or purchase order to which it is a party or by which it is bound or (v)&#160;of any provision of federal or state statute, rule&#160;or regulation applicable to the Purchaser, in each case (other than clause (i)), which would have a material adverse effect on the Purchaser or its ability to consummate the transactions contemplated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchase Entirely for Own Account</span>. This Agreement is made with the Purchaser in reliance upon the Purchaser&#8217;s representation to the Company, which by the Purchaser&#8217;s execution of this Agreement, the Purchaser hereby confirms, that the Securities to be acquired by the Purchaser will be acquired for investment for the Purchaser&#8217;s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Purchaser has no present intention of </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">D-3</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">selling, granting any participation in, or otherwise distributing the same in violation of Law. By executing this Agreement, the Purchaser further represents that the Purchaser does not presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participations to such Person or to any third Person, with respect to any of the Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure of Information</span>. The Purchaser has had an opportunity to discuss the Company&#8217;s existing and planned or expected business, management, financial affairs and the terms and conditions of the purchase and sale of the Securities, as well as the terms of the Transactions, with the Company&#8217;s management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Securities</span>. The Purchaser understands that the offer and sale of the Securities to the Purchaser has not been, and will not be, registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Purchaser&#8217;s representations as expressed herein. The Purchaser understands that the Securities are &#8220;restricted securities&#8221; under applicable U.S. federal and state securities Laws and that, pursuant to these Laws, the Purchaser must hold the Securities indefinitely unless they are registered with the SEC and qualified by state authorities, or an exemption from such registration and qualification requirements is available. The Purchaser acknowledges that the Company has no obligation to register or qualify the Securities, or any securities into which the Securities may be converted into or exercised for, for resale, except pursuant to the Registration Rights Agreement. The Purchaser further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Securities, and on requirements relating to the Company which are outside of the Purchaser&#8217;s control, and which the Company is under no obligation and may not be able to satisfy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">High Degree of Risk</span>. The Purchaser understands that its agreement to purchase the Securities involves a high degree of risk, which could cause the Purchaser to lose all or part of its investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accredited Investor</span>. The Purchaser is an &#8220;accredited investor&#8221; as defined in Rule&#160;501(a)&#160;of Regulation D promulgated under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No General Solicitation</span>. Neither the Purchaser, nor any of its officers, directors, employees, agents, stockholders or partners has either directly or indirectly, including, through a broker or finder (i)&#160;to its knowledge, engaged in any general solicitation, or (ii)&#160;published any advertisement in connection with the purchase and sale of the Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Public Information</span>. The Purchaser acknowledges its obligations under applicable securities Laws with respect to the treatment of material non-public information relating to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adequacy of Financing</span>. The Purchaser will have at the FPS/BPS Closing available to it sufficient funds to satisfy its obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(m)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliation of Certain FINRA Members</span>. The Purchaser is neither a person associated nor affiliated with any underwriter of the IPO or, to its actual knowledge, any other member of the Financial Industry Regulatory Authority (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FINRA</span>&#8221;) that participated in the IPO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(n)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Other Representations and Warranties; Non-Reliance</span>. Except for the specific representations and warranties contained in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3</span> and in any certificate or agreement delivered pursuant hereto, none of the Purchaser nor any person acting on behalf of the Purchaser nor any of the Purchaser&#8217;s affiliates (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchaser Parties</span>&#8221;) has made, makes or shall be deemed to make any other express or implied representation or warranty with respect to the Purchaser or the purchase and sale of the Securities, and the Purchaser Parties disclaim any such representation or warranty. Except for the specific representations and warranties expressly made by the Company in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4</span> of this Agreement and in any certificate or agreement delivered pursuant hereto, the Purchaser Parties specifically disclaim that they are relying upon any other representations or warranties that may have been made by the Company, any person on behalf of the Company or any of the Company&#8217;s affiliates (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Parties</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">D-4</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</span></span>Representations and Warranties of the Company. The Company represents and warrants to the Purchaser as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(a)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Incorporation and Corporate Power</span>.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>Until the occurrence of the Domestication, the Company is an exempted company duly incorporated, validly existing and in good standing under the Laws of the Cayman Islands and has all requisite corporate power and authority to carry on its business as presently conducted and as proposed to be conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>Upon the occurrence of the Domestication, the Company will be a corporation duly incorporated, validly existing and in good standing under the Laws of the State of Delaware and will have all requisite corporate power and authority to carry on its business as presently conducted and as proposed to be conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>The Company has no subsidiaries other than Merger Sub.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(b)</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capitalization</span>. The authorized share capital of the Company consists, as of the date hereof, of:</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>500,000,000 shares of Parent Class&#160;A Common Stock, 23,000,000 of which are issued and outstanding. All of the issued and outstanding shares of Parent Class&#160;A Common Stock have been duly authorized, are fully paid and nonassessable and were issued in compliance with all applicable federal and state securities Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>50,000,000 shares of Parent Class&#160;B Common Stock, 5,750,000 of which are issued and outstanding. All of the issued and outstanding shares of Parent Class&#160;B Common Stock have been duly authorized, are fully paid and nonassessable and were issued in compliance with all applicable federal and state securities Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>5,000,000 shares of Parent Preferred Stock, none of which are issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authorization</span>. All corporate action required to be taken by the Company&#8217;s Board of Directors and shareholders in order to authorize the Company to enter into this Agreement, and to issue the Securities at the FPS/BPS Closing, and the securities issuable upon conversion or exercise of the Securities, has been taken or will be taken prior to the FPS/BPS Closing, as applicable. All action on the part of the shareholders, directors and officers of the Company necessary for the execution and delivery of this Agreement, the performance of all obligations of the Company under this Agreement to be performed as of the FPS/BPS Closing, and the issuance and delivery of the Securities and the securities issuable upon conversion or exercise of the Securities has been taken or will be taken prior to the FPS/BPS Closing. This Agreement, when executed and delivered by the Company, shall constitute a valid and legally binding obligation of the Company, enforceable against the Company in accordance with its terms except (i)&#160;as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other Laws of general application relating to or affecting the enforcement of creditors&#8217; rights generally, (ii)&#160;as limited by Laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, or (iii)&#160;to the extent the indemnification provisions contained in the Registration Rights Agreement may be limited by applicable federal or state securities Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Valid Issuance of Securities</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>The Securities, when issued, sold and delivered in accordance with the terms and for the consideration set forth in this Agreement and registered in the register of members of the Company, and the securities issuable upon conversion or exercise of the Securities, when issued in accordance with the terms of the Securities and this Agreement, and registered on the Company&#8217;s share register, will be validly issued, fully paid and nonassessable and free of all preemptive or similar rights, liens, encumbrances and charges with respect to the issue thereof and restrictions on transfer other than restrictions on transfer specified under this Agreement, applicable state and federal securities Laws and liens or encumbrances created by or imposed by the Purchaser. Assuming the accuracy of the representations of the Purchaser in this Agreement and subject to the filings described in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4(e)</span>&#160;below, the Securities and the securities issuable upon conversion of the Securities will be issued in compliance with all applicable federal and state securities Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>No &#8220;bad actor&#8221; disqualifying event described in Rule&#160;506(d)(1)(i)-(viii)&#160;of the Securities Act (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disqualification Event</span>&#8221;) is applicable to the Company or, to the Company&#8217;s knowledge, any Company Covered Person (as defined below), </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">D-5</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">except for a Disqualification Event as to which Rule&#160;506(d)(2)(ii &#8211; iv) or (d)(3), is applicable. &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Covered Person</span>&#8221; means, with respect to the Company as an &#8220;issuer&#8221; for purposes of Rule&#160;506 promulgated under the Securities Act, any Person listed in the first paragraph of Rule&#160;506(d)(1).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Consents and Filings</span>. Assuming the accuracy of the representations and warranties made by the Purchaser in this Agreement, no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority is required on the part of the Company in connection with the consummation of the transactions contemplated by this Agreement, except for filings pursuant to Regulation D of the Securities Act, applicable state securities Laws and pursuant to the Registration Rights Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Other Instruments</span>. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in any violation or default (i)&#160;of any provisions of the Company&#8217;s Governing Documents, as they may be amended from time to time, (ii)&#160;of any instrument, judgment, order, writ or decree to which the Company is a party or by which it is bound, (iii)&#160;under any note, indenture or mortgage to which the Company is a party or by which it is bound, (iv)&#160;under any lease, agreement, contract or purchase order to which the Company is a party or by which it is bound or (v)&#160;of any provision of federal or state statute, rule&#160;or regulation applicable to the Company, in each case (other than clause (i)) which would have a material adverse effect on the Company or its ability to consummate the transactions contemplated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operations</span>. As of the date hereof, the Company has not conducted any operations other than organizational activities and activities in connection with its initial public offering (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IPO</span>&#8221;), its search for a potential business combination and financing in connection therewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Foreign Corrupt Practices</span>. Neither the Company, nor any director, officer, agent, employee or other Person acting on behalf of the Company has, in the course of its actions for, or on behalf of, the Company (i)&#160;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii)&#160;made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii)&#160;violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv)&#160;made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Anti-Money Laundering Laws</span>. The operations of the Company are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements and all other applicable U.S. and non-U.S. anti-money laundering Laws and regulations, including, but not limited to, those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the USA PATRIOT Act of 2001 and the applicable money laundering statutes of all applicable jurisdictions, the rules&#160;and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Anti-Money Laundering Laws</span>&#8221;), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Absence of Litigation</span>. There is no Action before or by any Governmental Authority or, to the Knowledge of the Company, threatened against or affecting the Company or any of the Company&#8217;s officers or directors, whether of a civil or criminal nature or otherwise, in their capacities as such.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No General Solicitation</span>. Neither the Company, nor any of its officers, directors, employees, agents or shareholders has either directly or indirectly, including, through a broker or finder (i)&#160;engaged in any general solicitation, or (ii)&#160;published any advertisement in connection with the offer and sale of the Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Other Representations and Warranties; Non-Reliance</span>. Except for the specific representations and warranties contained in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4</span> and in any certificate or agreement delivered pursuant hereto, none of the Company Parties has made, makes or shall be deemed to make any other express or implied representation or warranty with respect to the Company, the transactions contemplated by the Merger Agreement or the offer and sale of the Securities, and the Company Parties disclaim any such representation or warranty. Except for the specific representations and warranties expressly made by the Purchaser in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3</span> of this Agreement and in any certificate or agreement delivered pursuant hereto, the Company Parties specifically disclaim that they are relying upon any other representations or warranties that may have been made by the Purchaser Parties.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">D-6</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</span></span>Additional Agreements, Acknowledgements and Waivers of the Purchaser.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trust Account</span>. The Purchaser acknowledges that the Company is a blank check company with the powers and privileges to effect a Business Combination. The Purchaser further acknowledges that, as described in the prospectus included in the registration statement of the Company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prospectus</span>&#8221;) available at www.sec.gov, substantially all of the Company&#8217;s assets consist of the cash proceeds of the IPO and private placements of its securities, and substantially all of those proceeds have been deposited in a trust account for the benefit of the Company, certain of its public shareholders and the underwriters of the IPO (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trust Account</span>&#8221;). The Purchaser acknowledges that, except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its franchise Tax, income Tax and similar obligations, the Trust Agreement provides that cash in the Trust Account may be disbursed only (i)&#160;if the Company completes one or more transactions that constitute a Business Combination, then to those Persons and in such amounts as described in the Prospectus; (ii)&#160;if the Company fails to complete a Business Combination within the allotted time period and liquidates, subject to the terms of the Trust Agreement, to the Company in limited amounts to permit the Company to pay the costs and expenses of its liquidation and dissolution, and then to the Company&#8217;s public shareholders; and (iii)&#160;if the Company holds a shareholder vote to amend the Company&#8217;s Governing Documents to modify the substance or timing of the obligation to redeem 100% of the shares of Parent Common Stock if the Company fails to complete a Business Combination within the allotted time period, then for the redemption of any shares of Parent Common Stock properly tendered in connection with such vote. For and in consideration of the Company entering into this Agreement, the receipt and sufficiency of which are hereby acknowledged, the Purchaser hereby irrevocably waives any right, title, interest or claim of any kind they have or may have in the future in or to any monies in the Trust Account (including any distributions therefrom) and agree not to seek recourse against the Trust Account or any funds distributed therefrom as a result of, or arising out of, this Agreement and any negotiations, Contracts or agreements with the Company; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that nothing herein shall serve to limit or prohibit the Purchaser&#8217;s right to pursue a claim against the Company for legal relief against monies or other assets held outside the Trust Account, for specific performance or other equitable relief in connection with the consummation of the Transactions so long as such claim would not affect the Company&#8217;s ability to fulfill its obligation to effectuate the Parent Share Redemptions. The Purchaser agrees and acknowledges that such irrevocable waiver is material to this Agreement and specifically relied upon by the Company to induce it to enter in this Agreement, and the Purchaser further intends and understands such waiver to be valid, binding and enforceable under applicable Law. To the extent the Purchaser commences any action or proceeding based upon, in connection with, relating to or arising out of any matter relating to the Company, which proceeding seeks, in whole or in part, monetary relief against the Company, the Purchaser hereby acknowledges and agrees that its sole remedy shall be against funds held outside of the Trust Account and that such claim shall not permit the Purchaser (or any party claiming on the Purchaser&#8217;s behalf or in lieu of the Purchaser) to have any claim against the Trust Account (including any distributions therefrom) or any amounts contained therein. In the event that the Purchaser commences any action or proceeding based upon, in connection with, relating to or arising out of any matter relating to the Company, which proceeding seeks, in whole or in part, relief against the Trust Account (including any distributions therefrom) or the holders of Parent Common Stock, whether in the form of money damages or injunctive relief, the Company shall be entitled to recover from the Purchaser the associated legal fees and costs in connection with any such action, in the event the Company prevails in such action or proceeding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Short Sales</span>. The Purchaser hereby agrees that neither it, nor any person or entity acting on its behalf or pursuant to any understanding with it, will engage in any Short Sales with respect to securities of the Company prior to the Merger Closing. For purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5</span>, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Short Sales</span>&#8221; shall include, without limitation, all &#8220;short sales&#8221; as defined in Rule&#160;200 promulgated under Regulation SHO under the Exchange Act and all types of direct and indirect stock pledges (other than pledges in the ordinary course of business as part of prime brokerage arrangements), forward sale contracts, options, puts, calls, swaps and similar arrangements (including on a total return basis), and sales and other transactions through non-U.S. broker dealers or foreign regulated brokers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voting</span>. The Purchaser hereby agrees that if the Company seeks shareholder approval of the Transaction Proposals, then the Purchaser shall vote any shares of Parent Class&#160;A Common Stock owned by it in favor of such Transaction Proposals. If the Purchaser fails to vote any shares of Parent Class&#160;A Common Stock it is required to vote hereunder in favor of the Transaction Proposals, the Purchaser hereby grants hereunder to the Company and any representative designated by the Company, without further action by the Purchaser or any other Person, a limited irrevocable power of attorney to effect such vote on behalf of the Purchaser, which power of attorney shall be deemed to be coupled with an interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">D-7</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">QEF Election Information</span>. The Company shall use commercially reasonable efforts to determine whether, in any year, the Company or any subsidiary of the Company is deemed to be a &#8220;passive foreign investment company&#8221; (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PFIC</span>&#8221;) within the meaning of U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</span>&#8221;). If the Company determines that the Company or any subsidiary of the Company is a PFIC in any year, for the year of determination and for each year thereafter during which the Purchaser holds an equity interest in the Company, including any Parent Warrants, the Company or such subsidiary shall use commercially reasonable efforts to (a)&#160;make available to the Purchaser the information that may be required to make or maintain a &#8220;qualified electing fund&#8221; election under the Code with respect to the Company and (b)&#160;furnish the information required to be reported under Section&#160;1298(f)&#160;of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Listing</span>. The Company will use commercially reasonable efforts to maintain the listing of the Parent Class&#160;A Common Stock and Domesticated Class&#160;A Common Stock (as applicable) on the NASDAQ (or another national securities exchange).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</span></span>FPS/BPS Closing Conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The obligation of the Purchaser to purchase the Securities at the FPS/BPS Closing under this Agreement shall be subject to the fulfillment, at or prior to the FPS/BPS Closing of each of the following conditions, any of which, to the extent permitted by applicable Laws, may be waived by the Purchaser:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>The Transactions shall be completed substantially concurrently with, and (except in the case of the Domestication) immediately following, the purchase and sale of the Securities hereunder;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>The Company shall not have delivered to the Purchaser a revocation of the Funding Notice;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>The representations and warranties of the Company set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4</span> of this Agreement shall have been true and correct as of the date hereof and shall be true and correct as of the FPS/BPS Closing, as applicable, with the same effect as though such representations and warranties had been made on and as of such date (other than any such representation or warranty that is made by its terms as of a specified date, which shall be true and correct as of such specified date), except where the failure to be so true and correct would not have a material adverse effect on the Company, or its ability to consummate the transactions contemplated by this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>The Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company, at or prior to the FPS/BPS Closing; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span>No order, writ, judgment, injunction, decree, determination, or award shall have been entered by or with any governmental, regulatory, or administrative authority or any court, tribunal, or judicial, or arbitral body, and no other legal restraint or prohibition shall be in effect, preventing the purchase by the Purchaser of the Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The obligation of the Company to sell the Securities at the FPS/BPS Closing under this Agreement shall be subject to the fulfillment, at or prior to the FPS/BPS Closing of each of the following conditions, any of which, to the extent permitted by applicable Laws, may be waived by the Company:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>The Transactions shall be completed substantially concurrently with, and (except in the case of the Domestication) immediately following, the purchase and sale of the Securities hereunder;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>The representations and warranties of the Purchaser set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3</span> of this Agreement shall have been true and correct as of the date hereof and shall be true and correct as of the FPS/BPS Closing, as applicable, with the same effect as though such representations and warranties had been made on and as of such date (other than any such representation or warranty that is made by its terms as of a specified date, which shall be true and correct as of such specified date), except where the failure to be so true and correct would not have a material adverse effect on the Purchaser or its ability to consummate the transactions contemplated by this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">D-8</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>The Purchaser shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Purchaser at or prior to the FPS/BPS Closing; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>No order, writ, judgment, injunction, decree, determination, or award shall have been entered by or with any governmental, regulatory, or administrative authority or any court, tribunal, or judicial, or arbitral body, and no other legal restraint or prohibition shall be in effect, preventing the purchase by the Purchaser of the Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.</span></span>Termination. This Agreement may be terminated at any time prior to the FPS/BPS Closing:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>by mutual written consent of the Company, the Purchaser and SpinCo; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>automatically:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>if a Business Combination is not completed within eighteen (18) months from the closing of the IPO, or such later date as may be approved by the Company&#8217;s shareholders in accordance with its Governing Documents; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>upon the termination of the Merger Agreement in accordance with the terms and conditions thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In the event of any termination of this Agreement pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9</span>, the FPS Purchase Price and the Backstop Subscription Amount (and interest thereon, if any), if previously paid, and all Purchaser&#8217;s funds paid in connection herewith shall be promptly returned to the Purchaser, and thereafter this Agreement shall forthwith become null and void and have no effect, without any liability on the part of the Purchaser or the Company and their respective directors, officers, employees, partners, managers, members, or shareholders and all rights and obligations of each party shall cease; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that nothing contained in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9</span> shall relieve either party from liabilities or damages arising out of any fraud or willful breach by such party of any of its representations, warranties, covenants or agreements contained in this Agreement. Notwithstanding anything herein to the contrary, from and after any termination of this Agreement pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9(b)</span>, the Original Agreement shall automatically resume and continue in full force and effect in accordance with its terms as though it were never amended and restated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</span></span>Termination Fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>In the event that this Agreement is terminated by reason of a termination of the Merger Agreement pursuant to Section&#160;9.1(i)&#160;thereof, then, concurrently with and as a condition to such termination, the Company shall pay the Purchaser or its designee(s)&#160;a termination fee of $12,500,000.00 (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FPA Termination Fee</span>&#8221;) by wire transfer of immediately available funds to an account designated by the Purchaser in writing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Notwithstanding anything to the contrary set forth in this Agreement, except in the case of Actual Fraud or Willful Breach, if the FPA Termination Fee is paid pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10(a)</span>, such payment shall constitute the sole and exclusive remedy of the Purchaser, any of its Subsidiaries or any of its or their respective former, current or future general or limited partners, shareholders, Representatives or assignees against the Company Related Parties for all losses and damages suffered as a result of the failure of the Transactions to be consummated or for a breach or failure to perform hereunder or otherwise, and none of the Company Related Parties shall have any further liability or obligation to Purchaser and such other Persons relating to or arising out of this Agreement or the Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>If the Company fails to pay promptly the FPA Termination Fee when due under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10</span>, and in order to obtain such payment, the Purchaser commences an Action that results in a judgment against the Company for any amount owed thereby under this Section&#160;10, the Company shall reimburse the Purchaser for its reasonable and documented costs and expenses (including reasonable and documented attorneys&#8217; fees) in connection with such Action, together with interest on such amount at a rate equal to (x)&#160;the prime rate as published in The Wall Street Journal in effect on the date such payment was required to be made through the date such payment was actually received, plus (y)&#160;five percent (5%).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Each of the parties acknowledges that (i)&#160;the agreements contained in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10</span> are an integral part of the Transactions, (ii)&#160;without these agreements, the parties would not enter into this Agreement and (iii)&#160;the FPA Termination Fee does not constitute a penalty, but rather represents liquidated damages in a reasonable amount that will compensate the Purchaser </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">D-9</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">for the efforts and resources expended and opportunities foregone while negotiating this Agreement and in reliance on this Agreement and on the expectation of the consummation of the Transactions, which amount would otherwise be impossible to calculate with precision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.</span></span>General Provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</span>. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt, or (i)&#160;personal delivery to the party to be notified, (ii)&#160;when sent, if sent by electronic mail or facsimile (if any) during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient&#8217;s next Business Day, (iii)&#160;five (5)&#160;Business Days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv)&#160;one (1)&#160;Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next Business Day delivery, with written verification of receipt. All communications sent to the Company shall be sent to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">Avista Public Acquisition Corp. II</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">65 East 55th Street, 18th Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">New York, New York 10022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">Attn: Benjamin Silbert, General Counsel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">email: Silbert@avistacap.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">with a copy to the Company&#8217;s counsel (which shall not constitute notice) at:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt 0.25pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;">Weil, Gotshal &amp; Manges LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;">767 Fifth Avenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;">New York, New York 10153</p></td></tr><tr><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0.25pt 0.25pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;">Attn:</p></td><td style="vertical-align:top;width:88.33%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jaclyn L. Cohen, Esq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Raymond O. Gietz,&#160;Esq.</p></td></tr><tr><td style="vertical-align:top;width:11.66%;margin:0pt;padding:0.25pt 0.25pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;">email:</p></td><td style="vertical-align:top;width:88.33%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Jackie.Cohen@weil.com<br />Raymond.Gietz@weil.com</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">All communications to the Purchaser or SpinCo shall be sent to the Purchaser&#8217;s or SpinCo&#8217;s address as set forth on the signature page&#160;hereof, or to such e-mail address, facsimile number (if any) or address as subsequently modified by written notice given in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;11(a)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Finder&#8217;s Fees</span>. Each party represents that it neither is nor will be obligated for any finder&#8217;s fee or commission in connection with this transaction. The Purchaser agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finder&#8217;s or broker&#8217;s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which the Purchaser or any of its officers, employees or representatives is responsible. The Company agrees to indemnify and hold harmless the Purchaser from any liability for any commission or compensation in the nature of a finder&#8217;s or broker&#8217;s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival of Representations and Warranties</span>. All of the representations and warranties contained herein shall survive the FPS/BPS Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</span>. This Agreement, together with any documents, instruments and writings that are delivered pursuant hereto or referenced herein, constitutes the entire agreement and understanding of the parties hereto in respect of its subject matter and supersedes all prior understandings, agreements or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated hereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors</span>. All of the terms, agreements, covenants, representations, warranties and conditions of this Agreement are binding upon, and inure to the benefit of and are enforceable by, the parties hereto and their respective successors. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">D-10</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignments</span>. Except as otherwise specifically provided herein, no party hereto may assign either this Agreement or any of its rights, interests, or obligations hereunder without the prior written approval of the other parties except that the Purchaser may assign its rights, interests or obligations hereunder to any of its affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</span>. This Agreement may be executed in two or more counterparts, each of which will be deemed an original but all of which together will constitute one and the same instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings</span>. The section headings contained in this Agreement are inserted for convenience only and will not affect in any way the meaning or interpretation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</span>. This Agreement, the entire relationship of the parties hereto, and any dispute between the parties (whether at law or in equity, and whether grounded in contract, tort or statute) shall be governed by, construed in accordance with, and interpreted pursuant to the Laws of the State of Delaware, without giving effect to its choice of laws principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Jurisdiction</span>. The parties (a)&#160;hereby irrevocably and unconditionally submit to the jurisdiction of the Court of Chancery of the State of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b)&#160;agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the Court of Chancery of the State of Delaware, and (c)&#160;hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Jury Trial</span>. The parties hereto hereby waive any right to a jury trial in connection with any litigation pursuant to this Agreement and the transactions contemplated hereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments</span>. This Agreement may not be amended, modified or waived as to any particular provision, except with the prior written consent of the Company, the Purchaser and SpinCo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(m)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</span>. The provisions of this Agreement will be deemed severable and the invalidity or unenforceability of any provision will not affect the validity or enforceability of the other provisions hereof; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that if any provision of this Agreement, as applied to any party hereto or to any circumstance, is adjudged by a governmental authority, arbitrator, or mediator not to be enforceable in accordance with its terms, the parties hereto agree that the governmental authority, arbitrator, or mediator making such determination will have the power to modify the provision in a manner consistent with its objectives such that it is enforceable, and/or to delete specific words or phrases, and in its reduced form, such provision will then be enforceable and will be enforced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(n)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses</span>. Each of the Company and the Purchaser will bear its own costs and expenses incurred in connection with the preparation, execution and performance of this Agreement and the consummation of the transactions contemplated hereby, including all fees and expenses of agents, representatives, financial advisors, legal counsel and accountants. The Company shall be responsible for the fees of its transfer agent, stamp taxes and all of The Depository Trust Company&#8217;s fees associated with the issuance of the Securities and the securities issuable upon conversion or exercise of the Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(o)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Construction</span>. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. If an ambiguity or question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the parties hereto and no presumption or burden of proof will arise favoring or disfavoring any party hereto because of the authorship of any provision of this Agreement. Any reference to any federal, state, local or foreign Law will be deemed also to refer to Law as amended and all rules&#160;and regulations promulgated thereunder, unless the context requires otherwise. The words &#8220;<i style="font-style:italic;">include</i>,&#8221; &#8220;<i style="font-style:italic;">includes</i>&#8221; and &#8220;<i style="font-style:italic;">including</i>&#8221; will be deemed to be followed by &#8220;<i style="font-style:italic;">without limitation</i>.&#8221; Pronouns in masculine, feminine, and neuter genders will be construed to include any other gender, and words in the singular form will be construed to include the plural and vice versa, unless the context otherwise requires. The words &#8220;<i style="font-style:italic;">this Agreement</i>,&#8221; &#8220;<i style="font-style:italic;">herein</i>,&#8221; &#8220;<i style="font-style:italic;">hereof</i>,&#8221; &#8220;<i style="font-style:italic;">hereby</i>,&#8221; &#8220;<i style="font-style:italic;">hereunder</i>&#8221; and </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">D-11</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">words of similar import refer to this Agreement as a whole and not to any particular subdivision unless expressly so limited. The parties hereto intend that each representation, warranty and covenant contained herein will have independent significance. If any party hereto has breached any representation, warranty or covenant contained herein in any respect, the fact that there exists another representation, warranty or covenant relating to the same subject matter (regardless of the relative levels of specificity) which such party hereto has not breached will not detract from or mitigate the fact that such party hereto is in breach of the first representation, warranty or covenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(p)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</span>. No waiver by any party hereto of any default, misrepresentation or breach of warranty or covenant hereunder, whether intentional or not, may be deemed to extend to any prior or subsequent default, misrepresentation or breach of warranty or covenant hereunder or affect in any way any rights arising because of any prior or subsequent occurrence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(q)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</span>. Except as may be required by Law, regulation or applicable stock exchange listing requirements, unless and until the transactions contemplated hereby and the terms hereof are publicly announced or otherwise publicly disclosed by the Company, the parties hereto shall keep confidential and shall not publicly disclose the existence or terms of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(r)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specific Performance; Enforcement</span>. Each party hereto agrees that irreparable damage may occur in the event any provision of this Agreement was not performed by the Purchaser in accordance with the terms hereof and that the other party(ies) shall be entitled to specific performance of the terms hereof, in addition to any other remedy at law or in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">[<i style="font-style:italic;">Signature Page&#160;Follows</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">D-12</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_750869a8_3f53_4c66_9ee1_fce0ae00cb70"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, the undersigned have executed this Agreement to be effective as of the date first set forth above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">PURCHASER:</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Avista Acquisition LP II</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By: Avista Acquisition GP LLC II, its general partner</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td colspan="2" style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Benjamin Silbert</p></td><td style="vertical-align:top;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td colspan="2" style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Benjamin Silbert</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td colspan="2" style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Authorized Signatory</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">65 East 55th Street</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">18th Floor</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">New York, NY 10022</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Benjamin Silbert</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">email:Silbert@avistacap.com</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td colspan="2" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">COMPANY:</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Avista Public Acquisition Corp. II</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:top;width:17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Benjamin Silbert</p></td><td style="vertical-align:top;width:30%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name: Benjamin Silbert</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title: General Counsel</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn: Benjamin Silbert</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">email:Silbert@avistacap.com</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td colspan="2" style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="4" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">SPINCO:</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="4" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="4" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">OmniAb,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="4" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Matthew W. Foehr</p></td><td style="vertical-align:top;width:30%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td colspan="2" style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Matthew W. Foehr</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title: </p></td><td colspan="2" style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address for Notices:</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">5980 Horton Street</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Suite&#160;405</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Emeryville, CA 94608</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Attn:Matt Foehr</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">email:matt@omniab.com</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6.09pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">D-13</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_46bbcfa4_8eba_4b25_8dc1_63756bdaa7df"></a><a id="AnnexE_433829"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Annex E</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Final Form</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">TAX MATTERS AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">by and among</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">AVISTA PUBLIC ACQUISITION CORP. II<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">LIGAND PHARMACEUTICALS INCORPORATED</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">OMNIAB,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Dated as of March&#160;23, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup> &#160;&#160;&#160;&#160;&#160;Note to Draft: To update to Avista&#8217;s name post-domestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_42de11ea_e66b_4b4f_89ff_51e2d0d45166"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">TABLE OF CONTENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></th></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:bottom;width:93.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">ARTICLE&#160;I DEFINITIONS</p></td><td colspan="2" style="vertical-align:bottom;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section1_1_General"><span style="font-style:normal;font-weight:normal;">1.1</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section1_1_General"><span style="font-style:normal;font-weight:normal;">General</span></a></p></td><td colspan="2" style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-2</p></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:bottom;width:93.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">ARTICLE&#160;II PAYMENTS AND TAX REFUNDS</p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section2_1_AllocationofFederalTaxes"><span style="font-style:normal;font-weight:normal;">2.1</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section2_1_AllocationofFederalTaxes"><span style="font-style:normal;font-weight:normal;">Allocation of Federal Taxes</span></a></p></td><td colspan="2" style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-8</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section2_2AllocationofStateTaxes"><span style="font-style:normal;font-weight:normal;">2.2</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section2_2AllocationofStateTaxes"><span style="font-style:normal;font-weight:normal;">Allocation of State Taxes</span></a></p></td><td colspan="2" style="vertical-align:bottom;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-8</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section2_3AllocationofForeignTaxes"><span style="font-style:normal;font-weight:normal;">2.3</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section2_3AllocationofForeignTaxes"><span style="font-style:normal;font-weight:normal;">Allocation of Foreign Taxes</span></a></p></td><td colspan="2" style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-9</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section2_4CertainTransactionTaxes"><span style="font-style:normal;font-weight:normal;">2.4</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section2_4CertainTransactionTaxes"><span style="font-style:normal;font-weight:normal;">Certain Transaction Taxes</span></a></p></td><td colspan="2" style="vertical-align:bottom;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-9</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section2_5DeterminationsRegardingthe"><span style="font-style:normal;font-weight:normal;">2.5</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section2_5DeterminationsRegardingthe"><span style="font-style:normal;font-weight:normal;">Determinations Regarding the Allocation and Attribution of Taxes</span></a></p></td><td colspan="2" style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-10</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section2_6AllocationofEmploymentTax"><span style="font-style:normal;font-weight:normal;">2.6</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section2_6AllocationofEmploymentTax"><span style="font-style:normal;font-weight:normal;">Allocation of Employment Taxes</span></a></p></td><td colspan="2" style="vertical-align:bottom;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-10</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section2_7TaxRefunds"><span style="font-style:normal;font-weight:normal;">2.7</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section2_7TaxRefunds"><span style="font-style:normal;font-weight:normal;">Tax Refunds</span></a></p></td><td colspan="2" style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-10</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section2_8TaxBenefits"><span style="font-style:normal;font-weight:normal;">2.8</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section2_8TaxBenefits"><span style="font-style:normal;font-weight:normal;">Tax Benefits</span></a></p></td><td colspan="2" style="vertical-align:bottom;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-10</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section2_9PriorAgreements"><span style="font-style:normal;font-weight:normal;">2.9</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section2_9PriorAgreements"><span style="font-style:normal;font-weight:normal;">Prior Agreements</span></a></p></td><td colspan="2" style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-10</p></td></tr><tr style="height:1pt;"><td colspan="5" style="vertical-align:bottom;width:100%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">ARTICLE&#160;III PREPARATION AND FILING OF TAX RETURNS</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section3_1RemaincosResponsibility"><span style="font-style:normal;font-weight:normal;">3.1</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section3_1RemaincosResponsibility"><span style="font-style:normal;font-weight:normal;">Remainco&#8217;s Responsibility</span></a></p></td><td style="vertical-align:bottom;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-11</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section3_2SpincosResponsibility"><span style="font-style:normal;font-weight:normal;">3.2</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section3_2SpincosResponsibility"><span style="font-style:normal;font-weight:normal;">Spinco&#8217;s Responsibility</span></a></p></td><td style="vertical-align:bottom;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-11</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section3_3RightToReviewTaxReturns"><span style="font-style:normal;font-weight:normal;">3.3</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section3_3RightToReviewTaxReturns"><span style="font-style:normal;font-weight:normal;">Right To Review Tax Returns</span></a></p></td><td style="vertical-align:bottom;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-11</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section3_4Cooperation"><span style="font-style:normal;font-weight:normal;">3.4</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section3_4Cooperation"><span style="font-style:normal;font-weight:normal;">Cooperation</span></a></p></td><td style="vertical-align:bottom;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-11</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section3_5TaxReportingPractices"><span style="font-style:normal;font-weight:normal;">3.5</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section3_5TaxReportingPractices"><span style="font-style:normal;font-weight:normal;">Tax Reporting Practices</span></a></p></td><td style="vertical-align:bottom;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-11</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section3_6ReportingofReorganization"><span style="font-style:normal;font-weight:normal;">3.6</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section3_6ReportingofReorganization"><span style="font-style:normal;font-weight:normal;">Reporting of Reorganization</span></a></p></td><td style="vertical-align:bottom;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-11</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section3_7PaymentofTaxes"><span style="font-style:normal;font-weight:normal;">3.7</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section3_7PaymentofTaxes"><span style="font-style:normal;font-weight:normal;">Payment of Taxes</span></a></p></td><td style="vertical-align:bottom;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-12</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section3_8AmendedReturnsandCarrybac"><span style="font-style:normal;font-weight:normal;">3.8</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section3_8AmendedReturnsandCarrybac"><span style="font-style:normal;font-weight:normal;">Amended Returns and Carrybacks</span></a></p></td><td style="vertical-align:bottom;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-13</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section3_9TaxAttributes"><span style="font-style:normal;font-weight:normal;">3.9</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section3_9TaxAttributes"><span style="font-style:normal;font-weight:normal;">Tax Attributes</span></a></p></td><td style="vertical-align:bottom;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-13</p></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:bottom;width:93.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">ARTICLE&#160;IV TAX-FREE STATUS OF THE DISTRIBUTION</p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section4_1RepresentationsandWarranti"><span style="font-style:normal;font-weight:normal;">4.1</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section4_1RepresentationsandWarranti"><span style="font-style:normal;font-weight:normal;">Representations and Warranties</span></a></p></td><td style="vertical-align:bottom;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-13</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section4_2RestrictionsRelatingtothe"><span style="font-style:normal;font-weight:normal;">4.2</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section4_2RestrictionsRelatingtothe"><span style="font-style:normal;font-weight:normal;">Restrictions Relating to the Distribution</span></a></p></td><td style="vertical-align:bottom;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-14</p></td></tr><tr style="height:1pt;"><td colspan="5" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">ARTICLE&#160;V INDEMNITY OBLIGATIONS</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section5_1IndemnityObligations"><span style="font-style:normal;font-weight:normal;">5.1</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section5_1IndemnityObligations"><span style="font-style:normal;font-weight:normal;">Indemnity Obligations</span></a></p></td><td style="vertical-align:bottom;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-15</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section5_2IndemnificationPayments"><span style="font-style:normal;font-weight:normal;">5.2</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section5_2IndemnificationPayments"><span style="font-style:normal;font-weight:normal;">Indemnification Payments</span></a></p></td><td style="vertical-align:bottom;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-16</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section5_3PaymentMechanics"><span style="font-style:normal;font-weight:normal;">5.3</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section5_3PaymentMechanics"><span style="font-style:normal;font-weight:normal;">Payment Mechanics</span></a></p></td><td style="vertical-align:bottom;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-16</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section5_4TreatmentofPayments"><span style="font-style:normal;font-weight:normal;">5.4</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section5_4TreatmentofPayments"><span style="font-style:normal;font-weight:normal;">Treatment of Payments</span></a></p></td><td style="vertical-align:bottom;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-17</p></td></tr><tr style="height:1pt;"><td colspan="5" style="vertical-align:bottom;width:100%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">ARTICLE&#160;VI TAX CONTESTS</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section6_1Notice"><span style="font-style:normal;font-weight:normal;">6.1</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section6_1Notice"><span style="font-style:normal;font-weight:normal;">Notice</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-17</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section6_2SeparateReturns"><span style="font-style:normal;font-weight:normal;">6.2</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section6_2SeparateReturns"><span style="font-style:normal;font-weight:normal;">Separate Returns</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-17</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section6_3JointReturn"><span style="font-style:normal;font-weight:normal;">6.3</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section6_3JointReturn"><span style="font-style:normal;font-weight:normal;">Joint Return</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-17</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section6_4ObligationofContinuedNoti"><span style="font-style:normal;font-weight:normal;">6.4</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section6_4ObligationofContinuedNoti"><span style="font-style:normal;font-weight:normal;">Obligation of Continued Notice</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-17</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section6_5SettlementRights"><span style="font-style:normal;font-weight:normal;">6.5</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section6_5SettlementRights"><span style="font-style:normal;font-weight:normal;">Settlement Rights</span><span style="display:inline-block;width:0.61pt;"></span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-17</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section6_6TaxContestParticipation"><span style="font-style:normal;font-weight:normal;">6.6</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section6_6TaxContestParticipation"><span style="font-style:normal;font-weight:normal;">Tax Contest Participation</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-18</p></td></tr><tr style="height:1pt;"><td colspan="5" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">ARTICLE&#160;VII COOPERATION</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section7_1General"><span style="font-style:normal;font-weight:normal;">7.1</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section7_1General"><span style="font-style:normal;font-weight:normal;">General</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-18</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section7_2ConsistentTreatment"><span style="font-style:normal;font-weight:normal;">7.2</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section7_2ConsistentTreatment"><span style="font-style:normal;font-weight:normal;">Consistent Treatment</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-18</p></td></tr><tr style="height:1pt;"><td colspan="5" style="vertical-align:bottom;width:100%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">ARTICLE&#160;VIII RETENTION OF RECORDS; ACCESS</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section8_1RetentionofRecords"><span style="font-style:normal;font-weight:normal;">8.1</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section8_1RetentionofRecords"><span style="font-style:normal;font-weight:normal;">Retention of Records</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-18</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section8_2AccesstoTaxRecords"><span style="font-style:normal;font-weight:normal;">8.2</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section8_2AccesstoTaxRecords"><span style="font-style:normal;font-weight:normal;">Access to Tax Records</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-19</p></td></tr><tr style="height:1pt;"><td colspan="5" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">ARTICLE&#160;IX DISPUTE RESOLUTION</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section9_1DisputeResolution"><span style="font-style:normal;font-weight:normal;">9.1</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section9_1DisputeResolution"><span style="font-style:normal;font-weight:normal;">Dispute Resolution</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-19</p></td></tr><tr style="height:1pt;"><td colspan="5" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">ARTICLE&#160;X MISCELLANEOUS PROVISIONS</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_1EntireAgreementConstruct"><span style="font-style:normal;font-weight:normal;">10.1</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_1EntireAgreementConstruct"><span style="font-style:normal;font-weight:normal;">Entire Agreement; Construction</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-19</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_2InterestonLatePayments"><span style="font-style:normal;font-weight:normal;">10.2</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_2InterestonLatePayments"><span style="font-style:normal;font-weight:normal;">Interest on Late Payments</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-19</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_3SuccessorsandAssigns"><span style="font-style:normal;font-weight:normal;">10.3</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_3SuccessorsandAssigns"><span style="font-style:normal;font-weight:normal;">Successors and Assigns</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-19</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_4Subsidiaries"><span style="font-style:normal;font-weight:normal;">10.4</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_4Subsidiaries"><span style="font-style:normal;font-weight:normal;">Subsidiaries</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-20</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section_10_5Assignability"><span style="font-style:normal;font-weight:normal;">10.5</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section_10_5Assignability"><span style="font-style:normal;font-weight:normal;">Assignability</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-20</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_6NoFiduciaryRelationship"><span style="font-style:normal;font-weight:normal;">10.6</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_6NoFiduciaryRelationship"><span style="font-style:normal;font-weight:normal;">No Fiduciary Relationship</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-20</p></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></th></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_7FurtherAssurances"><span style="font-style:normal;font-weight:normal;">10.7</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_7FurtherAssurances"><span style="font-style:normal;font-weight:normal;">Further Assurances</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-20</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_8Survival"><span style="font-style:normal;font-weight:normal;">10.8</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_8Survival"><span style="font-style:normal;font-weight:normal;">Survival</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-20</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_9Notices"><span style="font-style:normal;font-weight:normal;">10.9</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_9Notices"><span style="font-style:normal;font-weight:normal;">Notices</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-20</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_10Counterparts"><span style="font-style:normal;font-weight:normal;">10.10</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_10Counterparts"><span style="font-style:normal;font-weight:normal;">Counterparts</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-21</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_11Consents"><span style="font-style:normal;font-weight:normal;">10.11</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_11Consents"><span style="font-style:normal;font-weight:normal;">Consents</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-21</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_12Expenses"><span style="font-style:normal;font-weight:normal;">10.12</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_12Expenses"><span style="font-style:normal;font-weight:normal;">Expenses</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-21</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_13TerminationandAmendment"><span style="font-style:normal;font-weight:normal;">10.13</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_13TerminationandAmendment"><span style="font-style:normal;font-weight:normal;">Termination and Amendment</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-21</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_14TitlesandHeadings"><span style="font-style:normal;font-weight:normal;">10.14</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_14TitlesandHeadings"><span style="font-style:normal;font-weight:normal;">Titles and Headings</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-21</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_15Severability"><span style="font-style:normal;font-weight:normal;">10.15</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_15Severability"><span style="font-style:normal;font-weight:normal;">Severability</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-21</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_16Interpretation"><span style="font-style:normal;font-weight:normal;">10.16</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_16Interpretation"><span style="font-style:normal;font-weight:normal;">Interpretation</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-21</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_17NoDuplicationNoDouble"><span style="font-style:normal;font-weight:normal;">10.17</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_17NoDuplicationNoDouble"><span style="font-style:normal;font-weight:normal;">No Duplication; No Double Recovery</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-21</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_18NoWaiver"><span style="font-style:normal;font-weight:normal;">10.18</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_18NoWaiver"><span style="font-style:normal;font-weight:normal;">No Waiver</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-21</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_19GoverningLaw"><span style="font-style:normal;font-weight:normal;">10.19</span></a></p></td><td style="vertical-align:bottom;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_19GoverningLaw"><span style="font-style:normal;font-weight:normal;">Governing Law</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-21</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 14.4pt;"><a href="#E_Section10_20DistributionTime"><span style="font-style:normal;font-weight:normal;">10.20</span></a></p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#E_Section10_20DistributionTime"><span style="font-style:normal;font-weight:normal;">Distribution Time</span></a></p></td><td colspan="3" style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">E-21</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_29c6aa6b_8dfc_493f_aaea_64ef40b5a2ab"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">TAX MATTERS AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">This TAX MATTERS AGREEMENT (this &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</span>&#8221;), is entered into as of March&#160;23, 2022 by and among Avista Public Acquisition Corp. II, a Delaware corporation<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent</span>&#8221;), Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remainco</span>&#8221;), and OmniAb,&#160;Inc., a Delaware corporation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Spinco</span>&#8221; and, together with Parent and Remainco, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</span>&#8221;). Capitalized terms used in this Agreement and not otherwise defined herein shall have the meanings ascribed to such terms in the Separation and Distribution Agreement, dated as of the date hereof, by and between the Parties (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Agreement</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">R E C I T A L S</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, the board of directors of Remainco has determined that it is in the best interests of Remainco to separate Remainco&#8217;s business from Spinco&#8217;s business pursuant to the Separation Agreement (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation</span>&#8221;) and, following the Separation, to undertake the Distribution;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, Remainco will effect certain restructuring transactions for the purpose of aggregating Spinco&#8217;s business in the Spinco Group (as defined below) prior to the Distribution (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reorganization</span>&#8221;) and in connection therewith, undertake the Contribution to Spinco which, in exchange therefor, Spinco shall issue to Remainco shares of Spinco Common Stock;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, Remainco intends to effect the Distribution in a transaction that, together with the Contribution, is intended to qualify as a &#8220;reorganization&#8221; under Sections 355 and 368(a)(1)(D)&#160;of the Code;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, pursuant to that Merger Agreement entered into as of March&#160;23, 2022 by and among Remainco, Spinco, Parent, and Merger Sub (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Agreement</span>&#8221;), following the completion of the Distribution, Merger Sub will be merged with and into Spinco, with Spinco continuing as the surviving corporation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, the Parties intend that the Merger (as defined below) will qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, certain members of the Remainco Group (as defined below), on the one hand, and certain members of the Spinco Group, on the other hand, file certain Tax Returns on a consolidated, combined or unitary basis for certain federal, state, local and foreign Tax purposes; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, the Parties desire to (a)&#160;provide for the payment of Tax liabilities and entitlement to refunds thereof, allocate responsibility for, and cooperation in, the filing of Tax Returns, and provide for certain other matters relating to Taxes and (b)&#160;set forth certain covenants and indemnities relating to the preservation of the tax-free status of the Distribution combined with certain steps in the Reorganization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> &#160;&#160;&#160;&#160;&#160;Note to Draft: To update to Avista&#8217;s name post-domestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_759df345_710d_4a69_a88b_21b1fe8b2ea4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">NOW, THEREFORE, in consideration of the mutual agreements, provisions and covenants contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DEFINITIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section1_1_General"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</span>. As used in this Agreement, the following terms shall have the following meanings:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustment</span>&#8221; shall mean an adjustment of any item of income, gain, loss, deduction, credit or any other item affecting Taxes of a taxpayer pursuant to a Final Determination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliate</span>&#8221; shall mean, with respect to a Person, any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, the specified Person. For this purpose, &#8220;control&#8221; of a Person means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such Person, whether through ownership of voting securities, by contract or otherwise. The term &#8220;Affiliate&#8221; shall refer to Affiliates of a Person as determined immediately after the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(3)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</span>&#8221; shall have the meaning set forth in the preamble hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(4)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ancillary Agreements</span>&#8221; shall have the meaning set forth in the Separation Agreement; provided, however, this Agreement shall not be considered an &#8220;Ancillary Agreement.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(5)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Day</span>&#8221; shall have the meaning set forth in the Separation Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(6)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Controlling Party</span>&#8221; shall mean, with respect to a Tax Contest, the Party entitled to control such Tax Contest pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 6.2</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.3</span> of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(7)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</span>&#8221; shall mean the Internal Revenue Code of 1986, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(8)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contribution</span>&#8221; shall have the meaning set forth in the Separation Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(9)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Distribution</span>&#8221; shall have the meaning set forth in the Separation Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(10)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Distribution Date</span>&#8221; shall mean the date on which the Distribution is completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(11)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Distribution Taxes</span>&#8221; means any Taxes incurred solely as a result of the failure of the Tax-Free Status of the Internal Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(12)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Distribution Time</span>&#8221; shall have the meaning set forth in the Separation Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(13)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employee Matters Agreement</span>&#8221; shall have the meaning set forth in the Separation Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(14)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employment Tax</span>&#8221; shall mean those Liabilities (as defined in the Separation Agreement) for Taxes which are allocable pursuant to the provisions of the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(15)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Awards</span>&#8221; means options, share appreciation rights, restricted shares, share units or other compensatory rights with respect to Spinco Common Stock or Parent stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(16)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Federal Income Tax</span>&#8221; shall mean any Tax imposed by Subtitle A of the Code other than an Employment Tax, and any interest, penalties, additions to tax, or additional amounts in respect of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(17)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Federal Other Tax</span>&#8221; any Tax imposed by the federal government of the United States other than any Federal Income Tax and any interest, penalties, additions to Tax, or additional amounts in respect of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(18)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Federal Tax</span>&#8221; means any Federal Income Tax or Federal Other Tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(19)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Final Determination</span>&#8221; shall mean the final resolution of liability for any Tax for any Tax Period, by or as a result of (a)&#160;a final decision, judgment, decree or other order by any court of competent jurisdiction that can no longer be appealed, (b)&#160;a final settlement with the IRS, a closing agreement or accepted offer in compromise under Sections 7121 or 7122 of the Code, or a comparable agreement under the Laws of other jurisdictions, which resolves the entire Tax liability for any Tax Period, (c)&#160;any allowance of a refund or credit in respect of an overpayment of Tax, but only after the expiration of all periods during which such refund or credit may be recovered by the jurisdiction imposing the Tax, or (d)&#160;any other final resolution, including by reason of the expiration of the applicable statute of limitations or the execution of a pre-filing agreement with the IRS or other Taxing Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(20)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Foreign Income Tax</span>&#8221; shall mean any Tax imposed by any foreign country or any possession of the United States, or by any political subdivision of any foreign country or United States possession, which is an income Tax as defined in Treasury Regulations &#167; 1.901-2, and any interest, penalties, additions to tax, or additional amounts in respect of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(21)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Foreign Other Tax</span>&#8221; shall mean any Tax imposed by any foreign country or any possession of the United States, or by any political subdivision of any foreign country or United States possession, other than any Foreign Income Taxes, and any interest, penalties, additions to tax or additional amounts in respect of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(22)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Foreign Tax</span>&#8221; shall mean any Foreign Income Taxes or Foreign Other Taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(23)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Entity</span>&#8221; shall have the meaning set forth in the Separation Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(24)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Group</span>&#8221; shall mean the Remainco Group, the Spinco Group or the Parent Group, as the context requires.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(25)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnifying Party</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.2</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(26)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnitee</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.2</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(27)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IRS</span>&#8221; shall mean the United States Internal Revenue Service or any successor thereto, including, but not limited to its agents, representatives, and attorneys.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(28)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Joint Return</span>&#8221; shall mean any Tax Return that actually includes, by election or otherwise, or is required to include under applicable Law, one or more members of the Remainco Group together with one or more members of the Spinco Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(29)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Law</span>&#8221; shall have the meaning set forth in the Separation Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(30)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger</span>&#8221; shall have the meaning set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(31)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Sub</span>&#8221; shall have the meaning set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(32)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Controlling Party</span>&#8221; shall mean, with respect to a Tax Contest, the Party that is not entitled to control such Tax Contest pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 6.2</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.3</span> of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(33)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent</span>&#8221; shall have the meaning set forth in the preamble hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(34)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Group</span>&#8221; shall mean Parent and each of its direct and indirect Subsidiaries after the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(35)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</span>&#8221; shall mean the parties to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(36)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Past Practices</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.5</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(37)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Person</span>&#8221; shall have the meaning set forth in the Separation Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(38)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Post-Distribution Period</span>&#8221; shall mean any Tax Period (or portion thereof) beginning after the Distribution Date, including for the avoidance of doubt, the portion of any Straddle Period beginning after the Distribution Date.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(39)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Post-Distribution Ruling</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.2(c)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(40)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pre-Distribution Period</span>&#8221; shall mean any Tax Period (or portion thereof) ending on or before the Distribution Date, including for the avoidance of doubt, the portion of any Straddle Period ending at the end of the day on the Distribution Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(41)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prohibited Acts</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.2</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(42)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proposed Acquisition Transaction</span>&#8221; shall mean a transaction or series of transactions (or any agreement, understanding or arrangement, within the meaning of Section&#160;355(e)&#160;of the Code and Treasury Regulations &#167; 1.355-7, or any other regulations promulgated thereunder, to enter into a transaction or series of transactions), whether such transaction is supported by Spinco or Parent management or shareholders, is a hostile acquisition, or otherwise, as a result of which Spinco (or any successor thereto) or Parent would merge or consolidate with any other Person or as a result of which one or more Persons would (directly or indirectly) acquire, or have the right to acquire, an amount of stock of Spinco or Parent that would, when combined with any other changes in ownership of Spinco stock or Parent stock pertinent for purposes of Section&#160;355(e)&#160;of the Code (including the Merger), comprise 45% or more of (a)&#160;the value of all outstanding shares of stock of Spinco or Parent, as applicable, as of the date of such transaction, or in the case of a series of transactions, the date of the last transaction of such series, or (b)&#160;the total combined voting power of all outstanding shares of voting stock of Spinco or Parent, as applicable, as of the date of such transaction, or in the case of a series of transactions, the date of the last transaction of such series. Notwithstanding the foregoing, a Proposed Acquisition Transaction shall not include (i)&#160;the adoption by Spinco or Parent of a shareholder rights plan, (ii)&#160;issuances by Spinco or Parent that satisfy Safe Harbor VIII (relating to acquisitions in connection with a person&#8217;s performance of services) or Safe Harbor IX (relating to acquisitions by a retirement plan of an employer) of Treasury Regulations &#167; 1.355-7(d), including such issuances net of exercise price and/or tax withholding (provided, however, that any sale of such stock in connection with a net exercise or tax withholding is not exempt under this clause (ii)&#160;unless it satisfies the requirements of Safe Harbor VII of Treasury Regulations &#167; 1.355-7(d)) or (iii)&#160;acquisitions that satisfy Safe Harbor VII of Treasury Regulations &#167; 1.355-7(d). For purposes of determining whether a transaction constitutes an indirect acquisition, any recapitalization resulting in a shift of voting power or any redemption of shares of stock shall be treated as an indirect acquisition of shares of stock by the non-exchanging shareholders. For purposes of this definition, each reference to Spinco shall include a reference to any entity treated as a successor thereto. This definition and the application thereof is intended to monitor compliance with Section&#160;355(e)&#160;of the Code and the Treasury Regulations promulgated thereunder and shall be interpreted accordingly. Any clarification of, or change in, the statute or regulations promulgated under Section&#160;355(e)&#160;of the Code shall be incorporated in this definition and its interpretation. For the avoidance of doubt, the Merger shall not constitute a proposed Acquisition Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(43)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protective Section&#160;336(e)&#160;Elections</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6(b)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(44)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reasonable Basis</span>&#8221; shall mean reasonable basis within the meaning of Section&#160;6662(d)(2)(B)(ii)(II)&#160;of the Code and the Treasury Regulations promulgated thereunder (or such other level of confidence required by the Code at that time to avoid the imposition of penalties).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(45)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Refund</span>&#8221; shall mean any refund, reimbursement, offset, credit, or other similar benefit in respect of Taxes (including any overpayment of Taxes that can be refunded or, alternatively, applied against other Taxes payable), including any interest paid on or with respect to such refund of Taxes; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that the amount of any refund of Taxes shall be net of any Taxes imposed on, related to, or attributable to, the receipt of or accrual of such refund, including any Taxes imposed by way of withholding or offset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(46)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remainco</span>&#8221; shall have the meaning set forth in the preamble hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(47)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remainco Affiliated Group</span>&#8221; shall mean an affiliated group (as that term is defined in Section&#160;1504 of the Code and the regulations thereunder) of which a member of the Remainco Group is a member.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(48)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remainco Common Stock</span>&#8221; shall mean the common stock of Remainco, par value $0.001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(49)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remainco Disqualifying Action</span>&#8221; means, with respect to any Distribution Taxes, (a)&#160;any act, or failure or omission to act, including, without limitation, the breach of any covenant contained herein or in the Tax Materials, by any member of the Remainco Group that results in any Party (or any of its Affiliates) being liable for such Distribution Taxes pursuant to a Final Determination, (b)&#160;any event (or series of events) involving capital stock of Remainco or any assets of any member of the Remainco Group or (c)&#160;any </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">failure to be true, inaccuracy in, or breach of any of the representations or statements contained in the Tax Materials; <i style="font-style:italic;">provided, however</i>, a Remainco Disqualifying Action shall not include any failure to be true, inaccuracy in, or breach of any of the representations, warranties, statements or covenants contained in the Tax Materials that is a failure to be true, inaccuracy in, or breach of the representations, warranties, statements or covenants contained in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.1(c)</span>&#160;that Parent or Spinco is responsible for pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.1(c)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(50)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remainco Federal Consolidated Income Tax Return</span>&#8221; shall mean any U.S. federal income Tax Return for a Remainco Affiliated Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(51)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remainco Group</span>&#8221; shall mean Remainco and each Person that is a Subsidiary of Remainco; provided, however, that no member of the Spinco Group shall be a member of the Remainco Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(52)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remainco Retained Business</span>&#8221; shall have the meaning given to the term &#8220;Ligand Retained Business&#8221; in the Separation Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(53)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remainco Separate Return</span>&#8221; shall mean any Tax Return of or including any member of the Remainco Group (including any consolidated, combined, or unitary return) that does not include any member of the Spinco Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(54)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reorganization</span>&#8221; shall have the meaning set forth in the recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(55)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Responsible Party</span>&#8221; shall mean, with respect to any Tax Return, the Party having responsibility for preparing and filing such Tax Return pursuant to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(56)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Period</span>&#8221; shall mean the period which begins with the Distribution Date and ends two (2)&#160;years thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(57)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;336(e)&#160;Allocation Statement</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6(c)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(58)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;336(e)&#160;Tax Benefit Percentage</span>&#8221; means, with respect to any Distribution Taxes and Tax-Related Losses attributable thereto, the percentage equal to one hundred percent (100%) minus the percentage of such Distribution Taxes and Tax-Related Losses for which Remainco is entitled to indemnification under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(59)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separate Return</span>&#8221; shall mean a Remainco Separate Return or a Spinco Separate Return, as the case may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(60)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation</span>&#8221; shall have the meaning set forth in the recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(61)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Agreement</span>&#8221; shall have the meaning set forth in the preamble hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(62)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Spinco</span>&#8221; shall have the meaning set forth in the preamble hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(63)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Spinco Business</span>&#8221; shall have the meaning given to the term &#8220;OmniAb Business&#8221; in the Separation Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(64)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Spinco Common Stock</span>&#8221; shall mean the Common Stock, par value $0.001 per share, of Spinco.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(65)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Spinco Disqualifying Action</span>&#8221; means, with respect to any Distribution Taxes, (a)&#160;any act, or failure or omission to act, including, without limitation, the breach of any covenant contained herein or in the Tax Materials, by Parent or any member of the Spinco Group that results in any Party (or any of its Affiliates) being liable for such Distribution Taxes pursuant to a Final Determination, regardless of whether such act or failure to act is covered by a Post-Distribution Ruling or Unqualified Tax Opinion, (b)&#160;any event (or series of events) involving capital stock of Parent or Spinco or any assets of any member of the Parent Group or Spinco Group, or (c)&#160;any failure to be true, inaccuracy in, or breach of any of the representations or statements contained herein; <i style="font-style:italic;">provided however</i>, that a Spinco Disqualifying Action shall not include a failure to be true, inaccuracy in, or breach of the representations, warranties, statements or covenants in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.1(c)</span>&#160;that is the responsibility of Remainco pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.1(c)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(66)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Spinco Group</span>&#8221; shall mean Spinco and each Person that will be a Subsidiary of Spinco as of immediately after the Distribution Time; provided, that, for the avoidance of doubt, no member of the Remainco Group shall be a member of the Spinco Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(67)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Spinco Separate Return</span>&#8221; shall mean any Tax Return of or including any member of the Spinco Group (including any consolidated, combined, or unitary return) that does not include any member of the Remainco Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(68)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Straddle Period</span>&#8221; shall mean any taxable year or other Tax Period that begins on or before the Distribution Date and ends after the Distribution Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(69)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">State Income Tax</span>&#8221; means any Tax imposed by any State of the United States or by any political subdivision of any such State that is imposed on or measured by income, including state or local franchise or similar Taxes measured by income, as well as any state or local franchise or similar Taxes imposed in lieu of or in addition to a tax imposed on or measured by income and any interest, penalties, additions to tax, or additional amounts in respect of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(70)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">State Other Tax</span>&#8221; means any Tax imposed by any state of the United States or by any political subdivision of any such state or the District of Columbia, other than any State Income Tax, and any interest, penalties, additions to tax, or additional amounts in respect of the foregoing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(71)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">State Taxes</span>&#8221; means any State Income Tax or any State Other Tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(72)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsidiary</span>&#8221; shall have the meaning set forth in the Separation Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(73)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax</span>&#8221; or &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</span>&#8221; shall mean (i)&#160;all taxes, charges, fees, duties, levies, imposts, rates or other assessments or governmental charges of any kind imposed by any federal, state, local or non-U.S. Governmental Entity or political subdivision thereof, including, without limitation, income, gross receipts, employment, estimated, excise, severance, stamp, occupation, premium, windfall profits, environmental, custom duties, property, sales, use, license, capital stock, transfer, franchise, registration, payroll, withholding, social security, unemployment, disability, value added, alternative or add-on minimum or other taxes, whether disputed or not, and including any interest, penalties, charges or additions attributable thereto, (ii)&#160;liability for the payment of any amount of the type described in clause (i)&#160;above arising as a result of being (or having been) a member of any group or being (or having been) included or required to be included in any Tax Return related thereto, and (iii)&#160;liability for the payment of any amount of the type described in clauses (i)&#160;or (ii)&#160;above as a result of any express or implied obligation to indemnify or otherwise assume or succeed to the liability of any other Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(74)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Attribute</span>&#8221; shall mean net operating losses, capital losses, research and experimentation credit carryovers, investment tax credit carryovers, earnings and profits, foreign tax credit carryovers, overall foreign losses, overall domestic losses, previously taxed income, separate limitation losses and any other losses, deductions, credits or other comparable items that could affect a Tax liability for a past or future Tax Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(75)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Benefit</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.8</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(76)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Certificates</span>&#8221; shall mean any certificates of officers of Parent, Remainco and Spinco, provided to Latham&#160;&amp; Watkins LLP, Weil, Gotshal&#160;&amp; Manges LLP or any other law or accounting firm in connection with any Tax Opinion issued in connection with the Reorganization, Distribution, or Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(77)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Contest</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.1</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(78)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8220;Tax-Free Status of the Internal Transactions</span>&#8221; shall mean the qualification of the Contribution and the Distribution, taken together, (A)&#160;as a reorganization under Sections 355 and 368(a)(1)(D)&#160;of the Code, (B)&#160;as a transaction in which the stock distributed thereby is &#8220;qualified property&#8221; for purposes of Sections 355(c)&#160;and 361(c)&#160;of the Code and (C)&#160;as a transaction in which Remainco, Spinco and the holders of Remainco Common Stock recognize no income or gain for U.S. federal income tax purposes pursuant to Sections 355, 361 and 1032 of the Code, other than, in the case of the holders of Remainco Common Stock for cash in lieu of fractional shares of Spinco Common Stock and in the case of Remainco and Spinco, amounts subject to Section&#160;356 of the Code and intercompany items or excess loss accounts taken into account pursuant to the Treasury Regulations promulgated pursuant to Section&#160;1502 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(79)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax-Free Status of the Merger</span>&#8221; shall mean the qualification of the Merger as a reorganization under 368(a)&#160;of the Code and as a transaction in which the shareholders of Spinco recognize no income or gain pursuant to Section&#160;354(a)&#160;of the Code (except to the extent of any cash received in lieu of fractional shares of Parent stock).</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(80)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax-Free Status of the Transactions</span>&#8221; shall mean both the Tax-Free Status of the Internal Transactions and the Tax-Free Status of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(81)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Item</span>&#8221; shall mean any item of income, gain, loss, deduction, or credit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(82)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Law</span>&#8221; shall mean the law of any Taxing Authority or political subdivision thereof relating to any Tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(83)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Materials</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.1(a)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(84)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Opinion</span>&#8221; shall mean any written opinion of Latham&#160;&amp; Watkins LLP, Weil, Gotshal&#160;&amp; Manges LLP or any other Law or accounting firm, regarding certain tax consequences of certain transactions executed as part of the Separation, the Reorganization, the Contribution, the Distribution or the Merger, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(85)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Period</span>&#8221; means, with respect to any Tax, the period for which such Tax is reported as provided under the Code or other applicable Tax Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(86)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Records</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.1</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(87)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax-Related Losses</span>&#8221; shall mean with respect to any Taxes, (i)&#160;all accounting, legal and other professional fees, and court costs incurred in connection with such Taxes, as well as any other out-of-pocket costs incurred in connection with such Taxes; and (ii)&#160;all costs, expenses and damages associated with stockholder litigation or controversies and any amount paid by Remainco (or any of its Affiliates) or Spinco (or any of its Affiliates) in respect of the liability of shareholders, whether paid to shareholders or to the IRS or any other Taxing Authority, in each case, resulting from the failure of the Tax-Free Status of the Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(88)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Return</span>&#8221; shall mean any return, report, certificate, form or similar statement or document (including any related supporting information or schedule attached thereto and any information return, amended tax return, claim for refund or declaration of estimated tax) supplied to or filed with, or required to be supplied to or filed with, a Taxing Authority, in each case, in connection with the determination, assessment or collection of any Tax or the administration of any laws, regulations or administrative requirements relating to any Tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(89)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxing Authority</span>&#8221; shall mean any Governmental Entity or any subdivision, agency, commission or entity thereof or any quasi-governmental or private body having jurisdiction over the assessment, determination, collection or imposition of any Tax (including the IRS).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(90)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transactions</span>&#8221; shall mean the Contribution, Distribution and Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(91)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transaction Taxes</span>&#8221; shall mean all Taxes imposed on the Remainco Group or the Spinco Group in connection with the Separation, the Reorganization, the Contribution or the Distribution other than Distribution Taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(92)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Treasury Regulations</span>&#8221; shall mean the regulations promulgated from time to time under the Code as in effect for the relevant Tax Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(93)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Unqualified Tax Opinion</span>&#8221; shall mean a &#8220;will&#8221; opinion, without substantive qualifications, of a nationally recognized law firm or accounting firm, to the effect that a transaction will not affect the Tax-Free Status of the Transactions. Any such opinion may assume that the Tax-Free Status of the Transactions would apply if not for the occurrence of the transaction in question.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PAYMENTS AND TAX REFUNDS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section2_1_AllocationofFederalTaxes"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allocation of Federal Taxes</span>. Except as otherwise provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span>, Federal Taxes shall be allocated as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Federal Income Taxes</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>Remainco shall be responsible for any and all Federal Income Taxes (including any increase in such Taxes as a result of a Final Determination) due with respect to or required to be reported on (A)&#160;any Joint Return<i style="font-style:italic;">; provided, however</i>, that Parent and Spinco shall be responsible for any and all such Taxes that are attributable to the Spinco Business with respect to any Post-Distribution Period, (B)&#160;any Remainco Separate Return, or (C)&#160;any Spinco Separate Return with respect to any Pre-Distribution Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>Parent and Spinco shall be responsible for any and all Federal Income Taxes (including any increase in such Taxes as a result of a Final Determination) required to be reported on any Spinco Separate Return with respect to any Post-Distribution Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Federal Other Taxes Relating to Joint Returns</span>. Remainco shall be responsible for any and all Federal Other Taxes (including any increase in such Taxes as a result of a Final Determination) required to be reported on any Joint Return<i style="font-style:italic;">; provided, however</i>, that Parent and Spinco shall be responsible for any and all such Taxes that are attributable to the Spinco Business with respect to any Post-Distribution Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Federal Other Taxes Relating to Separate Returns</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>Remainco shall be responsible for any and all Federal Other Taxes (including any increase in such Taxes as a result of a Final Determination) required to be reported on (A)&#160;any Remainco Separate Return or (B)&#160;any Spinco Separate Return with respect to any Pre-Distribution Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>Parent and Spinco shall be responsible for any and all Federal Other Taxes (including any increase in such Taxes as a result of a Final Determination) required to be reported on any Spinco Separate Return with respect to any Post-Distribution Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section2_2AllocationofStateTaxes"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allocation of State Taxes.</span> Except as otherwise provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span>, State Taxes shall be allocated as follows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">State Income Taxes Relating to Joint Returns</span>. Remainco shall be responsible for any and all State Income Taxes (including any increase in such Taxes as a result of a Final Determination) required to be reported on any Joint Return<i style="font-style:italic;">; provided, however</i>, that Parent and Spinco shall be responsible for any and all such Taxes that are attributable to the Spinco Business with respect to any Post-Distribution Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">State Income Taxes Relating to Separate Returns.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>Remainco shall be responsible for any and all State Income Taxes (including any increase in such Taxes as a result of a Final Determination) required to be reported on (A)&#160;any Remainco Separate Return or (B)&#160;any Spinco Separate Return with respect to any Pre-Distribution Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>Parent and Spinco shall be responsible for any and all State Income Taxes (including any increase in such Taxes as a result of a Final Determination) required to be reported on any Spinco Separate Return with respect to any Post-Distribution Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">State Other Taxes Relating to Joint Returns</span>. Remainco shall be responsible for any and all State Other Taxes (including any increase in such Taxes as a result of a Final Determination) required to be reported on any Joint Return<i style="font-style:italic;">; provided, however</i>, that Parent and Spinco shall be responsible for any and all such Taxes that are attributable to the Spinco Business with respect to any Post-Distribution Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">State Other Taxes Relating to Separate Returns</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>Remainco shall be responsible for any and all State Other Taxes (including any increase in such Taxes as a result of a Final Determination) required to be reported on (A)&#160;any Remainco Separate Return or (B)&#160;any Spinco Separate Return with respect to any Pre-Distribution Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>Parent and Spinco shall be responsible for any and all State Other Taxes (including any increase in such Taxes as a result of a Final Determination) required to be reported on any Spinco Separate Return for any Post-Distribution Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section2_3AllocationofForeignTaxes"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allocation of Foreign Taxes</span> . Except as otherwise provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span>, Foreign Taxes shall be allocated as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Foreign Income Taxes Relating to Joint Returns.</span> Remainco shall be responsible for any and all Foreign Income Taxes (including any increase in such Taxes as a result of a Final Determination) required to be reported on any Joint Return<i style="font-style:italic;">; provided, however</i>, that Parent and Spinco shall be responsible for any and all such Taxes that are attributable to the Spinco Business with respect to any Post-Distribution Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Foreign Income Taxes Relating to Separate Returns.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>Remainco shall be responsible for any and all Foreign Income Taxes (including any increase in such Taxes as a result of a Final Determination) required to be reported on (A)&#160;any Remainco Separate Return or (B)&#160;any Spinco Separate Return with respect to any Pre-Distribution Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>Parent and Spinco shall be responsible for any and all Foreign Income Taxes (including any increase in such Taxes as a result of a Final Determination) required to be reported on any Spinco Separate Return with respect to any Post-Distribution Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Foreign Other Tax Relating to Joint Returns</span>. Remainco shall be responsible for any and all Foreign Other Taxes (including any increase in such Taxes as a result of a Final Determination) required to be reported on any Joint Return<i style="font-style:italic;">; provided, however</i>, that Parent and Spinco shall be responsible for any and all such Taxes that are attributable to the Spinco Business with respect to any Post-Distribution Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Foreign Other Tax Relating to Separate Returns.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>Remainco shall be responsible for any and all Foreign Other Taxes (including any increase in such Taxes as a result of a Final Determination) required to be reported on (A)&#160;any Remainco Separate Return or (B)&#160;any Spinco Separate Return with respect to any Pre-Distribution Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>Parent and Spinco shall be responsible for any and all Foreign Other Taxes (including any increase in such Taxes as a result of a Final Determination) required to be reported on any Spinco Separate Return with respect to any Post-Distribution Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section2_4CertainTransactionTaxes"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Transaction Taxes</span>. Notwithstanding the provisions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections&#160;2.1</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.2</span>, and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.3</span>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Parent and Spinco shall pay and be responsible for any Transaction Taxes in excess of the Transaction Taxes that would have been imposed on the Separation, the Reorganization, the Contribution, or the Distribution had such transactions been consummated but the Merger was not consummated; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Remainco shall pay and be responsible for any and all Transaction Taxes other than those Transaction Taxes described in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4(a)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="E_Section2_5DeterminationsRegardingthe"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Determinations Regarding the Allocation and Attribution of Taxes</span>. For purposes of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections&#160;2.1</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.2</span>, and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.3</span>, Taxes shall be allocated, to the extent relevant, in accordance with the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>With respect to the Remainco Federal Consolidated Income Tax Return for the taxable year that includes the Distribution Date, Remainco shall use the closing of the books method under Treasury Regulations &#167; 1.1502-76, unless otherwise agreed by Remainco and Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Remainco, Parent, and Spinco shall take all actions necessary or appropriate to close the taxable year of each member of the Spinco Group for all Tax purposes as of the close of the Distribution Date to the extent permitted by applicable Law. With respect to Taxes for any Straddle Period, (a)&#160;if applicable Law does not permit a member of the Spinco Group to close its taxable year on the Distribution Date, then the allocation of income or deductions required to determine any Taxes or other amounts attributable to the portion of the Straddle Period ending on, or beginning after, the Distribution Date shall be made by means of a closing of the books and records of such member as of the close of the Distribution Date; provided that exemptions, allowances, or deductions that are calculated on an annual or periodic basis shall be allocated between such portions in proportion to the number of days in each such portion, and (b)&#160;any other Taxes, including property Taxes, that are calculated on an annual or periodic basis and not assessed with respect to a transaction or series of transactions shall be allocated to the portion of the Straddle Period ending on the Distribution Date and the portion of the Straddle Period beginning after the Distribution Date in proportion to the number of days in each such portion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section2_6AllocationofEmploymentTax"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allocation of Employment Taxes</span>. Liability for Employment Taxes shall be determined pursuant to the Employee Matters Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section2_7TaxRefunds"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Refunds</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Remainco shall be entitled to all Refunds related to Taxes the liability for which is allocated to Remainco pursuant to this Agreement. Spinco shall be entitled to all Refunds related to Taxes the liability for which is allocated to Spinco pursuant to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Parent or Spinco shall pay to Remainco any Refund received by Parent or Spinco or any member of the Spinco Group or Parent Group that is allocable to Remainco pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.7</span> no later than thirty (30) Business Days after the receipt of such Refund. Remainco shall pay to Spinco any Refund received by Remainco or any member of the Remainco Group that is allocable to Spinco pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.7</span> no later than thirty (30) Business Days after the receipt of such Refund. For purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.7</span>, any Refund that arises as a result of an offset, credit, or other similar benefit in respect of Taxes other than a receipt of cash shall be deemed to be received on the earlier of (i)&#160;the date on which a Tax Return is filed claiming such offset, credit, or other similar benefit and (ii)&#160;the date on which payment of the Tax which would have otherwise been paid absent such offset, credit, or other similar benefit is due (determined without taking into account any applicable extensions). To the extent that the amount of any Refund in respect of which a payment was made under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.7</span> is later reduced by a Taxing Authority or in a Tax Contest, such reduction shall be allocated to the Party to which such Refund was allocated pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.7</span> and an appropriate adjusting payment shall be made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section2_8TaxBenefits"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Benefits</span>. Except with respect to any Tax Benefit arising as a result of the Protective 336(e)&#160;Elections, if (a)&#160;one Party is responsible for a Tax pursuant to this Agreement and (b)&#160;the other Party is entitled to a deduction, credit or other Tax benefit relating to such Tax (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Benefit</span>&#8221;), then the Party entitled to such Tax Benefit shall pay to the Party responsible for such Tax the amount of any cash Tax savings realized by the entitled Party as a result of such Tax Benefit, net of any Taxes imposed by any Taxing Authority on, related to, or attributable to, the receipt of or accrual of such Tax Benefit, including any Taxes imposed by way of withholding or offset, no later than thirty (30) Business Days after such cash Tax savings are realized. To the extent that the amount of any Tax Benefit in respect of which a payment was made under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.8</span> is later reduced by a Taxing Authority or in a Tax Contest, the Party that received such payment shall refund such payment to the Party that made such payment to the extent of such reduction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section2_9PriorAgreements"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prior Agreements</span>. Except as set forth in this Agreement and in consideration of the mutual indemnities and other obligations of this Agreement, any and all prior Tax sharing or allocation agreements or practices between any member of the Remainco Group and any member of the Spinco Group shall be terminated with respect to the Spinco Group and the Remainco Group as of the Distribution Date. No member of either the Spinco Group or the Remainco Group shall have any continuing rights or obligations under any such agreement.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PREPARATION AND FILING OF TAX RETURNS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section3_1RemaincosResponsibility"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remainco&#8217;s Responsibility</span>. Remainco shall prepare and file, or shall cause to be prepared and filed, when due (taking into account any applicable extensions) all Joint Returns, and all Remainco Separate Returns, including any such amended Joint Returns or Separate Returns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section3_2SpincosResponsibility"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Spinco&#8217;s Responsibility</span>. Parent or Spinco shall prepare and file, or shall cause to be prepared and filed, when due (taking into account any applicable extensions) all Spinco Separate Returns, including any such amended Spinco Separate Returns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section3_3RightToReviewTaxReturns"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right To Review Tax Returns</span>. To the extent that a Party (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reviewing Party</span>&#8221;) would reasonably be expected to be adversely affected by the positions taken on any Tax Return or could reasonably be required by the terms of this Agreement to provide an indemnity or make a payment for any Taxes reported or required to be reported on any Tax Return is not the Responsible Party, the Responsible Party shall prepare the portions of such Tax Return that could affect or result in indemnification by the Reviewing Party, shall provide a draft of such portions of such Tax Return to the Reviewing Party for its review and comment at least thirty (30) days prior to the due date for such Tax Return, and shall modify such portions of such Tax Return before filing to include the Reviewing Party&#8217;s reasonable comments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section3_4Cooperation"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation</span>. The Parties shall provide, and shall cause their Affiliates to provide, assistance and cooperation to one another in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VII</span> with respect to the preparation and filing of Tax Returns, including providing information required to be provided under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VIII</span>. Notwithstanding anything to the contrary in this Agreement, Remainco shall not be required to disclose to Parent or Spinco any consolidated, combined, unitary, or other similar Joint Return of which a member of the Remainco Group is the common parent or any information related to such a Joint Return other than information relating solely to the Spinco Group; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">that</span> Remainco shall provide such additional information that is reasonably required in order for Spinco to determine the Taxes attributable to the Spinco Business. If an amended Separate Return for which Parent or Spinco is responsible under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;III</span> is required to be filed as a result of an amendment made to a Joint Return pursuant to an audit adjustment, then the Parties shall use their respective commercially reasonable efforts to ensure that such amended Separate Return can be prepared and filed in a manner that preserves confidential information including through the use of confidentiality agreements or third party preparers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section3_5TaxReportingPractices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Reporting Practices</span>. Except as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6</span>, with respect to any Tax Return for any Tax Period that begins on or before the second anniversary of the Distribution Date with respect to which Parent or Spinco is the Responsible Party, such Tax Return shall be prepared in a manner (i)&#160;consistent with past practices, accounting methods, elections and conventions (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Past Practices</span>&#8221;) used with respect to the Tax Returns in question (unless there is no Reasonable Basis for the use of such Past Practices), and to the extent any items are not covered by Past Practices (or in the event that there is no Reasonable Basis for the use of such Past Practices), in accordance with reasonable Tax accounting practices selected by Spinco; and (ii)&#160;that, to the extent consistent with clause (i), minimizes the overall amount of Taxes due and payable on such Tax Return for all of the Parties by cooperating in making such elections or applications for group or other relief or allowances available in the taxing jurisdiction in which such Tax Return is filed. Neither Parent nor Spinco shall take any action inconsistent with the assumptions (including with respect to any Tax Item) made in determining all estimated or advance payments of Taxes on or prior to the Distribution Date. In addition, neither Parent nor Spinco shall be permitted, and shall not permit any member of the Spinco Group or Parent Group, without Remainco&#8217;s prior written consent (not to be unreasonably withheld, conditioned or delayed), to make a change in any of its methods of accounting for Tax purposes until all applicable statutes of limitations for all Pre-Distribution Periods have expired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section3_6ReportingofReorganization"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reporting of Reorganization</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The Tax treatment of any step in or portion of the Separation, the Reorganization, the Contribution and the Distribution shall be reported on each applicable Tax Return consistently with the Tax-Free Status of the Transactions, taking into account the jurisdiction in which such Tax Returns are filed, unless there is no Reasonable Basis for such Tax treatment. In the event that a Party shall determine that there is no Reasonable Basis for such Tax treatment, such Party shall notify the other Party no later than twenty (20) Business Days prior to filing the relevant Tax Return and the Parties shall attempt in good faith to agree on the manner in which the relevant portion of the Separation, the Reorganization, the Contribution or the Distribution (as applicable) shall be reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>If Remainco determines, in its reasonable discretion, that protective elections under Section&#160;336(e)&#160;of the Code (and any applicable state or local Tax Law) shall be made with respect to the Distribution for Spinco and each member of the Spinco Group that is a domestic corporation for Federal Income Tax purposes (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protective Section&#160;336(e)&#160;Elections</span>&#8221;), then Remainco and Spinco shall enter into a written, binding agreement to make the Protective Section&#160;336(e)&#160;Elections, and Remainco and Spinco shall timely make the Protective Section&#160;336(e)&#160;Elections in accordance with Treasury Regulations &#167; 1.336-2(h). For the avoidance of doubt, such agreement is intended to constitute a &#8220;written, binding agreement&#8221; to make the Protective Section&#160;336(e)&#160;Elections within the meaning of Treasury Regulations &#167; 1.336-2(h)(1)(i).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Remainco, Parent and Spinco shall cooperate in making the Protective Section&#160;336(e)&#160;Elections, if any, including filing any statements, amending any Tax Returns or undertaking such other actions reasonably necessary to carry out the Protective Section&#160;336(e)&#160;Elections. Remainco shall determine the &#8220;aggregate deemed asset disposition price&#8221; and the &#8220;adjusted grossed-up basis&#8221; (each as defined under applicable Treasury Regulations) and the allocation of such aggregate deemed asset disposition price and adjusted grossed-up basis among the assets of the applicable member or members of the Remainco Group or Spinco Group, each in accordance with the applicable provisions of Section&#160;336(e)&#160;of the Code and applicable Treasury Regulations (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;336(e)&#160;Allocation Statement</span>&#8221;). Each Party agrees not to take any position (and to cause each of its Affiliates not to take any position) that is inconsistent with the Protective Section&#160;336(e)&#160;Elections, including the Section&#160;336(e)&#160;Allocation Statement, on any Tax Return, in connection with any Tax Contest or for any other Tax purposes (in each case, excluding any position taken for financial accounting purposes), except as may be required by a Final Determination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>In the event of a failure of the Tax-Free Status of the Transactions, if Remainco is not entitled to indemnification for one hundred percent (100%) of any Distribution Taxes and Tax-Related Losses attributable thereto arising from such failure, Remainco shall be entitled to quarterly payments from Parent or Spinco equal to the Section&#160;336(e)&#160;Tax Benefit Percentage of the actual Tax savings if, as and when realized by the Spinco Group arising from the increase in Tax basis (including, for the avoidance of doubt, any such increase in Tax basis attributable to payments made pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6(d)</span>) resulting from the Protective Section&#160;336(e)&#160;Election, determined on a &#8220;with and without&#8221; basis (treating any deductions or amortization attributable to the increase in Tax basis resulting from the Protective 336(e)&#160;Election, or any other recovery of such increase in Tax basis, as the last items claimed for any taxable year, including after the utilization of any available net operating loss carryforwards); provided, however, that such payments: (i)&#160;shall be reduced by all reasonable costs incurred by any member of the Spinco Group to amend any Tax Returns or other governmental filings related to such Protective Section&#160;336(e)&#160;Election and (ii)&#160;shall not exceed the amount of any Distribution Taxes and Tax-Related Losses attributable thereto of the Remainco Group (not taking into account this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6(d)</span>) arising from such failure of the Tax-Free Status of the Transactions and for which Remainco is not entitled to indemnification under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section3_7PaymentofTaxes"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment of Taxes</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>With respect to any Tax Return required to be filed pursuant to this Agreement, the Responsible Party shall remit or cause to be remitted to the applicable Taxing Authority in a timely manner any Taxes due in respect of any such Tax Return.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>In the case of any Tax Return for which the Party that is not the Responsible Party is obligated pursuant to this Agreement to pay all or a portion of the Taxes reported as due on such Tax Return, the Responsible Party shall notify the other Party, in writing, of its obligation to pay such Taxes and, in reasonably sufficient detail, its calculation of the amount due by such other Party and the Party receiving such notice shall pay such amount to the Responsible Party upon the later of five (5)&#160;Business Days prior to the date on which such payment is due and thirty (30) Business Days after the receipt of such notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>For the avoidance of doubt, with respect to any Taxes that are estimated Taxes, (i)&#160;the Party that is or will be the Responsible Party with respect to any Tax Return that will reflect (or otherwise give credit for) such estimated Taxes shall remit or cause to be remitted to the applicable Taxing Authority in a timely manner any estimated Taxes due, and (ii)&#160;in the case of any estimated Taxes for which the Party that is not the Responsible Party is obligated pursuant to this Agreement to pay all or a portion of the Taxes that will be reported as due on any Tax Return that will reflect (or otherwise give credit for) such estimated Taxes, the Responsible Party shall notify the other Party, in writing, of its obligation to pay such estimated Taxes and, in reasonably sufficient detail, its calculation of the amount due by such other Party and the Party receiving such notice shall pay such amount to the Responsible Party upon the later of five (5)&#160;Business Days prior to the date on which such payment is due and thirty (30) Business Days after the receipt of such notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="E_Section3_8AmendedReturnsandCarrybac"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amended Returns and Carrybacks</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Parent and Spinco shall not, and shall not permit any member of the Spinco Group to, file or allow to be filed any request for an Adjustment for any Pre-Distribution Period without the prior written consent of Remainco, such consent not to be unreasonably withheld, conditioned or delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Except as required by applicable Law, Remainco shall not, and shall not permit any member of the Remainco Group to, file or allow to be filed any amended Tax Return or request for an Adjustment for any Pre-Distribution Period or Straddle Period if the result would be to materially increase any liability of Spinco or any member of the Spinco Group (other than any such increase to the extent attributable to an adjustment to a Tax Attribute) either (i)&#160;under this Agreement or (ii)&#160;for a Post-Distribution Period, in each case without the prior written consent of Spinco, such consent not to be unreasonably withheld, conditioned or delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Except as prohibited by applicable Law, Parent and Spinco shall, and shall cause each member of the Spinco Group to, make any available elections to waive the right to carry back any Tax Attribute from a Post-Distribution Period to a Pre-Distribution Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Parent and Spinco shall not, and shall cause each member of the Spinco Group not to, without the prior written consent of Remainco, make any affirmative election to carry back any Tax Attribute from a Post-Distribution Period to a Pre-Distribution Period, such consent to be exercised in Remainco&#8217;s sole discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Receipt of consent by Parent, Spinco, or a member of the Spinco Group from Remainco pursuant to the provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.8</span> shall not limit or modify Parent&#8217;s or Spinco&#8217;s continuing indemnification obligation pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section3_9TaxAttributes"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Attributes</span>. Remainco shall in good faith advise Spinco in writing of the amount, if any, of any Tax Attributes, which Remainco determines, in its good faith discretion, shall be allocated or apportioned to the Spinco Group under applicable Law. Parent, Spinco and all members of the Parent Group shall prepare all Tax Returns in accordance with such written notice. For the avoidance of doubt, Remainco may elect in its reasonable discretion, in order to comply with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.9</span>, to create or cause to be created books and records or reports or other documents based thereon (including, without limitation, &#8220;earnings&#160;&amp; profits studies,&#8221; &#8220;basis studies&#8221; or similar determinations) that it does not typically maintain or prepare in the ordinary course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;IV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TAX-FREE STATUS OF THE DISTRIBUTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section4_1RepresentationsandWarranti"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Remainco, on behalf of itself and all other members of the Remainco Group, hereby represents and warrants that (i)&#160;it has examined any and all Tax Opinions all materials delivered or deliverable in connection with the Tax Certificates or the rendering of any Tax Opinions (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Materials</span>&#8221;), (ii)&#160;the facts presented and representations that have been or will be made therein, to the extent descriptive of or otherwise relating to Remainco or any member of the Remainco Group or the Remainco Retained Business, were or will be at the time presented or represented and from such time until and including the Distribution Time true, correct and complete in all material respects, and (iii)&#160;it has delivered copies of the Tax Materials to Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Remainco, on behalf of itself and all other members of the Remainco Group, hereby confirms and agrees to comply with any and all covenants and agreements in the Tax Materials applicable to Remainco or any member of the Remainco Group or the Remainco Retained Business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Spinco, on behalf of itself and all other members of the Spinco Group, hereby represents and warrants or covenants and agrees, as appropriate, that it has examined the Tax Materials and the facts presented and representations that have been or will be made therein, to the extent descriptive of or otherwise relating to (i)&#160;the Spinco Group or Parent Group (including the business purposes for the Distribution) and the plans, proposals, intentions and policies of the Spinco Group or Parent Group after the Distribution Time, and (ii)&#160;the actions or non-actions of the Spinco Group or Parent Group to be taken (or not taken, as the case may be) after the Distribution Time, are, or will be from the time presented or made through and including the Distribution Time (and thereafter as relevant) true, correct and complete in all material respects, <i style="font-style:italic;">provided that</i>, for the avoidance of doubt, </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">notwithstanding anything to the contrary in this Agreement, Remainco rather than Spinco or Parent shall be responsible for the accuracy of, or compliance with, any such representation, warranty, statement, or covenant with respect to the Spinco Group or the Spinco Business at the time presented or made (and, if applicable, through and including the Distribution Time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Parent and Spinco, on behalf of themselves and all other members of their respective Groups, hereby confirm and agree to comply with any and all covenants and agreements in the Tax Materials applicable to Parent, Spinco or any member of their respective Groups or the Spinco Business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Each of Remainco, on behalf of itself and all other members of the Remainco Group, Spinco, on behalf of itself and all other members of the Spinco Group, and Parent, represents and warrants that it knows of no fact (after due inquiry) that may cause the failure of the Tax-Free Status of the Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>Each of Remainco, on behalf of itself and all other members of the Remainco Group, Spinco, on behalf of itself and all other members of the Spinco Group, and Parent represents and warrants that it has no plan or intent to take any action which is inconsistent with any statements or representations made in the Tax Materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section4_2RestrictionsRelatingtothe"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restrictions Relating to the Distribution</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Remainco, on behalf of itself and all other members of the Remainco Group, hereby covenants and agrees that no member of the Remainco Group will take, fail to take, or to permit to be taken: (i)&#160;any action where such action or failure to act would be inconsistent with or cause to be untrue any statement, information, covenant or representation in the Tax Materials, (ii)&#160;any action where such action or failure to act would adversely affect, or could reasonably be expected to adversely affect, the Tax-Free Status of the Transactions or (iii)&#160;any action which constitutes a Remainco Disqualifying Action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Each of Spinco and Parent, on behalf of itself and all other members of their respective Groups, hereby covenants and agrees that no member of their Group will take, fail to take, or permit to be taken: (i)&#160;any action where such action or failure to act would be inconsistent with or cause to be untrue any statement, information, covenant or representation in the Tax Materials, (ii)&#160;any action where such action or failure to act would reasonably be expected to adversely affect the Tax-Free Status of the Transactions or (iii)&#160;any action which constitutes a Spinco Disqualifying Action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>During the Restricted Period, Parent and Spinco:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>shall continue and cause to be continued the active conduct of the Spinco Business for purposes of Section&#160;355(b)(2)&#160;of the Code, taking into account Section&#160;355(b)(3)&#160;of the Code, as conducted immediately prior to the Distribution,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>shall not voluntarily dissolve or liquidate themselves or any member of the Spinco Group (including any action that is a liquidation for U.S. federal income tax purposes),</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>shall not (1)&#160;enter into any Proposed Acquisition Transaction or, to the extent Spinco or Parent has the right to prohibit any Proposed Acquisition Transaction, permit any Proposed Acquisition Transaction to occur (whether by (A)&#160;redeeming rights under a shareholder rights plan, (B)&#160;finding a tender offer to be a &#8220;permitted offer&#8221; under any such plan or otherwise causing any such plan to be inapplicable or neutralized with respect to any Proposed Acquisition Transaction, (C)&#160;approving any Proposed Acquisition Transaction, whether for purposes of Section&#160;203 of the General Corporation Law of the State of Delaware or any similar corporate statute, any &#8220;fair price&#8221; or other provision of the charter or bylaws of Parent or Spinco, (D)&#160;amending its certificate of incorporation to declassify its board of directors or approving any such amendment, or (E)&#160;otherwise), (2)&#160;redeem or otherwise repurchase (directly or through an Affiliate) any stock, or rights to acquire stock except (A)&#160;to the extent such repurchases satisfy Section&#160;4.05(1)(b)&#160;of Revenue Procedure 96-30 (as in effect prior to the amendment of such Revenue Procedure by Revenue Procedure 2003-48), (B)&#160;to the extent reasonably necessary to pay the total tax liability arising from the vesting of an Equity Award, or (C)&#160;through a net exercise of an Equity Award, (3)&#160;amend its certificate of incorporation (or other organizational documents), or take any other action, whether through a stockholder vote or otherwise, affecting the relative voting rights of its capital stock (including through the conversion of any capital stock into another class of capital stock), (4)&#160;merge or consolidate, or agree to merge or consolidate, Parent or Spinco with any other Person (other than pursuant to the Merger) unless, in the case of a merger or consolidation, Parent or Spinco (as applicable) is the survivor of such merger or consolidation or (5)&#160;take any other action or actions (including any action or </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">transaction that would be reasonably likely to be inconsistent with any representation made in the Tax Materials) which in the aggregate (and taking into account the Merger) would, when combined with any other direct or indirect changes in ownership of Parent or Spinco capital stock pertinent for purposes of Section&#160;355(e)&#160;of the Code, have the effect of causing or permitting one or more Persons (whether or not acting in concert) to acquire directly or indirectly stock representing a fifty percent (50%) or greater interest in Parent or Spinco or would reasonably be expected to result in a failure to preserve the Tax-Free Status of the Transactions; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>shall not and shall not permit any member of the Spinco Group, to sell, transfer, or otherwise dispose of or agree to, sell, transfer or otherwise dispose (including in any transaction treated for U.S. federal income tax purposes as a sale, transfer or disposition) of assets (including, any shares of capital stock of a Subsidiary) that, in the aggregate, constitute more than thirty percent (30%) of the consolidated gross assets of Spinco or the Spinco Group; provided, that this clause (iv)&#160;shall not apply to (1)&#160;sales, transfers, or dispositions of assets in the ordinary course of business, (2)&#160;any cash paid to acquire assets from an unrelated Person in an arm&#8217;s-length transaction, (3)&#160;any assets transferred to a Person that is disregarded as an entity separate from the transferor for U.S. federal income tax purposes or (4)&#160;any mandatory or optional repayment (or pre-payment) of any indebtedness of Spinco or any member of the Spinco Group; provided, further that the percentages of gross assets or consolidated gross assets of Spinco or the Spinco Group, as the case may be, sold, transferred, or otherwise disposed of, shall be based on the fair market value of the gross assets of Spinco and the members of the Spinco Group as of the Distribution Date. For purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.2(c)(iv),</span> a merger of Spinco or one of its Subsidiaries with and into any Person that is not a wholly owned Subsidiary of Spinco shall constitute a disposition of all of the assets of Spinco or such Subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Notwithstanding the restrictions imposed by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 4.2(b)</span>&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.2(c)</span>, Parent, Spinco or a member of the Spinco Group may take any of the actions or transactions described therein if Spinco either (i)&#160;obtains an Unqualified Tax Opinion in form and substance reasonably satisfactory to Remainco, (ii)&#160;obtains a ruling from the IRS to the effect that such actions or transactions will not affect the Tax-Free Status of the Transactions (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Post-Distribution Ruling</span>&#8221;) or (iii)&#160;obtains the prior written consent of Remainco waiving the requirement that Spinco obtain an Unqualified Tax Opinion or Post-Distribution Ruling, such waiver to be provided in Remainco&#8217;s sole and absolute discretion. Remainco shall cooperate in good faith with any reasonable requests of Spinco in connection with securing any Post-Distribution Ruling or Unqualified Tax Opinion. Remainco&#8217;s evaluation of an Unqualified Tax Opinion may consider, among other factors, the appropriateness of any underlying assumptions, representations, and covenants made in connection with such opinion. Spinco shall bear all costs and expenses of securing any such Unqualified Tax Opinion or Post-Distribution Ruling and shall reimburse Remainco for all reasonable out-of-pocket expenses that Remainco or any of its Affiliates may incur in good faith in connection with obtaining or evaluating any such Unqualified Tax Opinion or Post-Distribution Ruling. Except as otherwise provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.1(d)</span>, neither the delivery of an Unqualified Tax Opinion, receipt of a Post-Distribution Ruling nor Remainco&#8217;s waiver of Spinco&#8217;s obligation to deliver an Unqualified Tax Opinion or obtain a Post-Distribution Ruling shall limit or modify Parent&#8217;s or Spinco&#8217;s continuing indemnification obligation Pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">INDEMNITY OBLIGATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section5_1IndemnityObligations"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnity Obligations</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Remainco shall indemnify and hold harmless Spinco from and against, and will reimburse Spinco for, (i)&#160;all liability for Taxes allocated to Remainco pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;II</span>, (ii)&#160;all Taxes and Tax-Related Losses attributable thereto arising out of, based upon, or relating or attributable to any breach of or inaccuracy in, or failure to perform, as applicable, any representation, covenant, or obligation of any member of the Remainco Group pursuant to this Agreement, (iii)&#160;the amount of any Refund received by any member of the Remainco Group that is allocated to Spinco pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.7(a)</span>&#160;and (iv)&#160;any Distribution Taxes and Tax-Related Losses attributable to a Remainco Disqualifying Action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Except as otherwise provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;Error! Reference source not found.</span>, without regard to whether an Unqualified Tax Opinion may have been provided, any Post-Distribution Ruling obtained or whether any action is permitted or consented to hereunder and notwithstanding anything else to the contrary contained herein, in the Separation Agreement, the Merger Agreement or other Ancillary Agreement, Parent and Spinco shall indemnify and hold harmless Remainco from and against, and will reimburse Remainco for, (i)&#160;all liability for Taxes allocated to Spinco pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;II</span>, (ii)&#160;all Taxes and Tax-Related Losses attributable thereto arising out of, based upon, or relating or attributable to any breach of or inaccuracy in, or failure to </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">perform, as applicable, any representation, covenant, or obligation of any member of the Spinco Group pursuant to this Agreement, (iii)&#160;the amount of any Refund received by any member of the Spinco Group that is allocated to Remainco pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.7(a)</span>&#160;and (iv)&#160;any Distribution Taxes and Tax-Related Losses attributable to a Spinco Disqualifying Action .</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Except as otherwise provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;Error! Reference source not found.</span>, if any Distribution Taxes are (i)&#160;not attributable to either a Remainco Disqualifying Action or a Spinco Disqualifying Action or (ii)&#160;attributable to both a Remainco Disqualifying Action and a Spinco Disqualifying Action, then Remainco shall bear fifty percent (50%) and Parent and Spinco shall bear fifty percent (50%) of such Distribution Taxes and corresponding Tax-Related Losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>If any Distribution Taxes or Tax-Related Losses attributable thereto are attributable to any action or transaction constituting a Spinco Disqualifying Action with respect to which Spinco obtains both (i)&#160;the prior written consent of Remainco in satisfaction of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.2(d)(iii)</span>&#160;and (ii)&#160;either an Unqualified Tax Opinion in form and substance reasonably satisfactory to Remainco in satisfaction of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.2(d)(i)</span>&#160;or a Post-Distribution Ruling in satisfaction of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.2(d)(ii)</span>, then Remainco shall bear fifty percent (50%) and Parent and Spinco shall bear fifty percent (50%) of such Distribution Taxes and corresponding Tax-Related Losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section5_2IndemnificationPayments"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification Payments</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except as otherwise provided in this Agreement, if either Party (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnitee</span>&#8221;) is required to pay to a Taxing Authority a Tax or to another Person a payment in respect of a Tax that the other Party (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnifying Party</span>&#8221;) is liable for under this Agreement, including as the result of a Final Determination, the Indemnitee shall notify the Indemnifying Party, in writing, of its obligation to pay such Tax and, in reasonably sufficient detail, its calculation of the amount due by such Indemnifying Party to the Indemnitee, including any Tax-Related Losses attributable thereto. The Indemnifying Party shall pay such amount, including any Tax-Related Losses attributable thereto, to the Indemnitee no later than the later of (i)&#160;five (5)&#160;Business Days prior to the date on which such payment is due to the applicable Taxing Authority or (ii)&#160;thirty (30) Business Days after the receipt of notice from the other Party. Any Tax indemnity payment required to be made pursuant to this Agreement shall be reduced by any corresponding Tax Benefit payment required to be made to the Indemnifying Party by the Indemnitee pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.8</span>. For the avoidance of doubt, a Tax Benefit payment is treated as corresponding to a Tax indemnity payment to the extent the Tax Benefit realized is directly attributable to the same Tax item (or adjustment of such Tax item pursuant to a Final Determination) that gave rise to the Tax indemnity payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>If, as a result of any change or redetermination, any amount previously allocated to and borne by one Party pursuant to the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;II</span> is thereafter allocated to the other Party, then, no later than thirty (30) Business Days after such change or redetermination, such other Party shall pay to such Party the amount previously borne by such Party which is allocated to such other Party as a result of such change or redetermination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>If an Indemnitee receives a Refund with respect to a Tax Contest for which the Indemnifying Party made an indemnity payment to the Indemnitee pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.2(a)</span>, the Indemnitee shall pay the amount of such Refund to the Indemnifying Party, such payment to the Indemnifying Party not to exceed such indemnity payment, no later than thirty (30) Business Days after the receipt of such Refund.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section5_3PaymentMechanics"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment Mechanics</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>All payments under this Agreement shall be made by Remainco directly to Spinco and by Spinco directly to Remainco; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that if the Parties mutually agree with respect to any such indemnification payment, any member of the Remainco Group, on the one hand, may make such indemnification payment to any member of the Spinco Group, on the other hand, and vice versa. All indemnification payments shall be treated in the manner described in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.4</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>In the case of any payment of Taxes made by a Responsible Party or Indemnitee pursuant to this Agreement for which such Responsible Party or Indemnitee, as the case may be, has received a payment from the other Party, such Responsible Party or Indemnitee shall provide to the other Party a copy of any official government receipt received with respect to the payment of such Taxes to the applicable Taxing Authority (or, if no such official governmental receipts are available, executed bank payment forms or other reasonable evidence of payment).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="E_Section5_4TreatmentofPayments"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Treatment of Payments</span>. The Parties agree that any payment made among the Parties pursuant to this Agreement (other than any payment of interest accruing after the Distribution Date) shall be treated, to the extent permitted by Law, for all U.S. federal income tax purposes as either (i)&#160;a non-taxable contribution by Remainco to Spinco or (ii)&#160;a distribution by Spinco to Remainco, and, with respect to any payment made among the Parties pursuant to this Agreement after the Distribution, such payment shall be treated as having been made immediately prior to the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;VI</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TAX CONTESTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section6_1Notice"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice</span>. Each Party shall notify the other Party in writing within ten (10)&#160;Business Days after receipt by such Party or any member of its Group of a written communication from any Taxing Authority with respect to any pending or threatened audit, claim, dispute, suit, action, proposed assessment or other proceeding (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Contest</span>&#8221;) concerning any Taxes for which the other Party may be liable pursuant to this Agreement, and thereafter shall promptly forward or make available to such Party copies of notices and communications relating to such Tax Contest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section6_2SeparateReturns"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separate Returns</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>If, pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;II</span> hereof, Spinco has sole liability for the Taxes that are the subject of a Tax Contest with respect to any Separate Return, then subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.5</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.6</span>, Spinco shall have the sole responsibility and right to control the prosecution of such Tax Contest, including the exclusive right to communicate with agents of the applicable Taxing Authority and to control, resolve, settle, or agree to any deficiency, claim or adjustment proposed, asserted or assessed in connection with or as a result of such Tax Contest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>With respect to any Tax Contest other than those described in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.2(a)</span>, subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.5</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.6</span>, Remainco shall have the sole responsibility and right to control the prosecution of such Tax Contest, including the exclusive right to communicate with agents of the applicable Taxing Authority and to control, resolve, settle, or agree to any deficiency, claim or adjustment proposed, asserted or assessed in connection with or as a result of such Tax Contest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section6_3JointReturn"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Joint Return</span>. In the case of any Tax Contest with respect to any Joint Return, Remainco shall, subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.5</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.6</span>, have the sole responsibility and right to control the prosecution of such Tax Contest, including the exclusive right to communicate with agents of the applicable Taxing Authority and to control, resolve, settle or agree to any deficiency, claim or adjustment proposed, asserted, or assessed in connection with or as a result of such Tax Contest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section6_4ObligationofContinuedNoti"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Obligation of Continued Notice</span>. During the pendency of any Tax Contest or threatened Tax Contest, each of the Parties shall provide prompt notice to the other Party of any written communication received by it or a member of its respective Group from a Taxing Authority regarding any Tax Contest for which it is indemnified by the other Party hereunder or for which it may be required to indemnify the other Party hereunder. Such notice shall attach copies of the pertinent portion of any written communication from a Taxing Authority and contain factual information (to the extent known) describing any asserted Tax liability in reasonable detail and shall be accompanied by copies of any notice and other documents received from any Taxing Authority in respect of any such matters. Such notice shall be provided in a reasonably timely fashion; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that in the event that timely notice is not provided, a Party shall be relieved of its obligation to indemnify the other Party only to the extent that such delay results in actual increased costs or actual prejudice to such other Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section6_5SettlementRights"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Settlement Rights</span>. Unless waived by the Parties in writing, in connection with any potential adjustment in a Tax Contest as a result of which adjustment the Non-Controlling Party may reasonably be expected to become liable to make any indemnification payment to the Controlling Party under this Agreement: (i)&#160;the Controlling Party shall keep the Non-Controlling Party informed in a timely manner of all actions taken or proposed to be taken by the Controlling Party with respect to such potential adjustment in such Tax Contest; (ii)&#160;the Controlling Party shall timely provide the Non-Controlling Party with copies of any correspondence or filings submitted to any Taxing Authority or judicial authority in connection with such potential adjustment in such Tax Contest; (iii)&#160;the Controlling Party shall defend such Tax Contest diligently and in good faith; and (iv)&#160;the Controlling Party shall not settle or agree to any deficiency, claim or adjustment proposed, asserted or assessed without the prior written consent of the Non-Controlling Party (not to be unreasonably withheld, conditioned or delayed). The failure of the Controlling Party to take any action specified in the preceding sentence with respect to the Non-Controlling Party shall not relieve the Non-Controlling Party of any liability and/or obligation which it may have to the Controlling Party under this Agreement, except to the extent the Non-Controlling </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Party is actually harmed thereby, and in no event shall such failure relieve the Non-Controlling Party from any other liability or obligation which it may have to the Controlling Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section6_6TaxContestParticipation"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Contest Participation</span>. Unless waived by the Parties in writing, the Controlling Party shall provide the Non-Controlling Party with written notice reasonably in advance of, and the Non-Controlling Party shall have the right to attend and participate in, any formally scheduled meetings with Taxing Authorities or hearings or proceedings before any judicial authorities in connection with any potential adjustment in a Tax Contest pursuant to which the Non-Controlling Party may reasonably be expected to become liable to make any indemnification payment to the Controlling Party under this Agreement (including any Tax Contest related to the Tax-Free Status of the Transactions) or may reasonably be expected to give rise to Tax liabilities of the Non-Controlling Party for any Post-Distribution Period. The failure of the Controlling Party to provide any notice specified in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.7</span> to the Non-Controlling Party shall not relieve the Non-Controlling Party of any liability and/or obligation which it may have to the Controlling Party under this Agreement except to the extent that the Non-Controlling Party was actually harmed by such failure, and in no event shall such failure relieve the Non-Controlling Party from any other liability or obligation which it may have to the Controlling Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;VII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COOPERATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section7_1General"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Each Party shall fully cooperate, and shall cause all members of such Party&#8217;s Group to fully cooperate, with all reasonable requests in writing from the other Party, or from an agent, representative or advisor to such Party, in connection with the preparation and filing of any Tax Return, claims for Refunds, the conduct of any Tax Contest, and calculations of amounts required to be paid pursuant to this Agreement, in each case, related or attributable to or arising in connection with Taxes of either Party or any member of either Party&#8217;s Group covered by this Agreement and the establishment of any reserve required in connection with any financial reporting (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Matter</span>&#8221;). Such cooperation shall include the provision of any information reasonably necessary or helpful in connection with a Tax Matter and shall include, without limitation, at each Party&#8217;s own cost:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>the provision of any Tax Returns of either Party or any member of either Party&#8217;s Group, books, records (including information regarding ownership and Tax basis of property), documentation and other information relating to such Tax Returns, including accompanying schedules, related work papers, and documents relating to rulings or other determinations by Taxing Authorities; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>the execution of any document (including any power of attorney) in connection with any Tax Contest of either Party or any member of either Party&#8217;s Group, or the filing of a Tax Return or a Refund claim of either Party or any member of either Party&#8217;s Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Each Party shall make its employees and facilities available, without charge, on a mutually convenient basis to facilitate such cooperation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section7_2ConsistentTreatment"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consistent Treatment</span>. Unless and until there has been a Final Determination to the contrary, each Party agrees not to take any position on any Tax Return, in connection with any Tax Contest or otherwise that is inconsistent with (a)&#160;the treatment of payments between the Remainco Group and the Spinco Group as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.4</span>, (b)&#160;the Tax Materials or (c)&#160;the Tax-Free Status of the Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;VIII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RETENTION OF RECORDS; ACCESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section8_1RetentionofRecords"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;8.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Retention of Records</span>. For so long as the contents thereof may become material in the administration of any matter under applicable Tax Law, but in any event until the later of (i)&#160;sixty (60) days after the expiration of any applicable statutes of limitation (including any waivers or extensions thereof) and (ii)&#160;seven (7)&#160;years after the Distribution Date, the Parties shall retain records, documents, accounting data and other information (including computer data) necessary for the preparation and filing of all Tax Returns (collectively, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Records</span>&#8221;) in respect of Taxes of any member of either the Remainco Group or the Spinco Group for any Pre-Distribution Period or Post-Distribution Period or for any Tax Contests relating to such Tax Returns. At any time after the Distribution Date when the Remainco Group proposes to destroy any Tax Records, the Remainco Group shall first notify the Parent </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Group in writing, and the Parent Group shall be entitled to receive such records or documents proposed to be destroyed. At any time after the Distribution Date when the Spinco Group or Parent Group proposes to destroy any Tax Records, Spinco or Parent, as appropriate, shall first notify Remainco in writing and the Remainco Group shall be entitled to receive such records or documents proposed to be destroyed. The Parties will notify each other in writing of any waivers or extensions of the applicable statute of limitations that may affect the period for which the foregoing records or other documents must be retained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section8_2AccesstoTaxRecords"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;8.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Access to Tax Records</span>. The Parties and their respective Affiliates shall make available to each other for inspection and copying during normal business hours upon reasonable notice all Tax Records (including, for the avoidance of doubt, any pertinent underlying data accessed or stored on any computer program or information technology system) in their possession and shall permit the other Party and its Affiliates, authorized agents and representatives and any representative of a Taxing Authority or other Tax auditor direct access, during normal business hours upon reasonable notice to any computer program or information technology system used to access or store any Tax Records, in each case to the extent reasonably required by the other Party in connection with the preparation of Tax Returns or financial accounting statements, audits, litigation, or the resolution of items pursuant to this Agreement. The Party seeking access to the records of the other Party shall bear all costs and expenses associated with such access, including any professional fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;IX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DISPUTE RESOLUTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section9_1DisputeResolution"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dispute Resolution</span>. In the event of any dispute between the Parties as to any financial matter covered by this Agreement, the Parties shall appoint a nationally recognized independent public accounting firm (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accounting Firm</span>&#8221;) to resolve such dispute. In this regard, the Accounting Firm shall make determinations with respect to the disputed items based solely on representations made by Remainco, Spinco, Parent, and their respective representatives, and not by independent review, and shall function only as an expert and not as an arbitrator and shall be required to make a determination in favor of one Party only. The Parties shall require the Accounting Firm to resolve all disputes no later than ninety (90) days after the submission of such dispute to the Accounting Firm, but in no event later than the due date for the payment of Taxes or the filing of the applicable Tax Return, if applicable, and agree that all decisions by the Accounting Firm with respect thereto shall be final and conclusive and binding on the Parties. The Accounting Firm shall resolve all disputes in a manner consistent with this Agreement and, to the extent not inconsistent with this Agreement, in a manner consistent with the Past Practices of Remainco and its Subsidiaries, except as otherwise required by applicable Law. The Parties shall require the Accounting Firm to render all determinations in writing and to set forth, in reasonable detail, the basis for such determination. The fees and expenses of the Accounting Firm shall be borne equally by Remainco, on the one hand, and Parent and Spinco, on the other hand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;X</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MISCELLANEOUS PROVISIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section10_1EntireAgreementConstruct"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement; Construction</span>. This Agreement shall constitute the entire agreement between the Parties with respect to the subject matter hereof and shall supersede all previous negotiations, commitments, course of dealings and writings with respect to such subject matter. Except as expressly set forth in this Agreement, the Separation Agreement or any Ancillary Agreement: (i)&#160;all matters relating to Taxes and Tax Returns of the Parties and their respective Subsidiaries shall be governed exclusively by this Agreement and (ii)&#160;for the avoidance of doubt, in the event of any conflict between this Agreement, on the one hand, and the Separation Agreement or any Ancillary Agreement, on the other hand, with respect to such matters, the terms and conditions of this Agreement shall govern. Notwithstanding the foregoing, in the event of any conflict between this Agreement and the Employee Matters Agreement with respect to the Ligand Equity Awards, the OmniAb Equity Awards (as such terms are defined in the Employee Matters Agreement), payroll Taxes, or Code Section&#160;409A, the Employee Matters Agreement shall govern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section10_2InterestonLatePayments"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interest on Late Payments</span>. With respect to any payment between the Parties pursuant to this Agreement not made by the due date set forth in this Agreement for such payment, the outstanding amount will accrue interest at a rate per annum equal to the rate in effect for underpayments under Section&#160;6621 of the Code from such due date to and including the payment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section10_3SuccessorsandAssigns"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</span>. The provisions of this Agreement and the obligations and rights hereunder shall be binding upon, inure to the benefit of and be enforceable by (and against) the Parties and their respective successors and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="E_Section10_4Subsidiaries"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsidiaries</span>. Each of the Parties shall cause to be performed, and hereby guarantees the performance of, all actions, agreements and obligations set forth herein to be performed by any Subsidiary of such Party or by any entity that becomes a Subsidiary of such Party at and after the Distribution Time, to the extent such Subsidiary remains a Subsidiary of the applicable Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section_10_5Assignability"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignability</span>. This Agreement shall not be assignable, in whole or in part, directly or indirectly, by any party hereto without the prior written consent of the other Party, and any attempt to assign any rights or obligations arising under this Agreement without such consent shall be void.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section10_6NoFiduciaryRelationship"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Fiduciary Relationship</span>. The duties and obligations of the Parties, and their respective successors and permitted assigns, contained herein are the extent of the duties and obligations contemplated by this Agreement; nothing in this Agreement is intended to create a fiduciary relationship between the Parties hereto, or any of their successors and permitted assigns, or create any relationship or obligations other than those explicitly described.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section10_7FurtherAssurances"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances</span>. Subject to the provisions hereof, the Parties hereto shall make, execute, acknowledge and deliver such other instruments and documents, and take all such other actions, as may be reasonably required in order to effectuate the purposes of this Agreement and to consummate the transactions contemplated hereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section10_8Survival"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</span>. Notwithstanding any other provision of this Agreement to the contrary, all representations, covenants and obligations contained in this Agreement shall survive until the expiration of the applicable statute of limitations with respect to any such matter (including extensions thereof).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section10_9Notices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</span>. All notices, requests, claims, demands and other communications under this Agreement and, to the extent applicable shall be in English, shall be in writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by delivery in person, by overnight courier service, by registered or certified mail (return receipt requested), or by e-mail (provided confirmation of transmission is electronically generated and kept on file by the sending party), to the respective Parties at the following addresses (or at such other address for a Party as shall be specified in a notice given in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10.9</span>):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">If to Remainco, to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Ligand Pharmaceuticals Incorporated</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">3911 Sorrento Valley Blvd., Suite&#160;110</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">San Diego, CA 92121</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Attn: Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">E-mail: tespinoza@ligand.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">If to Spinco, to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">OmniAb,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">5980 Horton Street, Suite&#160;405</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Emeryville, CA 94608</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Attn: Chief Legal Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">E-mail: cberkman@omniab.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">If to Parent, to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Avista Public Acquisition Corp. II</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">65 East 55th Street, 18th Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">New York, New York 10022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Attn: Benjamin Silbert, General Counsel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Email: Silbert@avistacap.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="E_Section10_10Counterparts"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</span>. This Agreement may be executed in more than one counterpart, all of which shall be considered one and the same agreement, and shall become effective when one or more such counterparts have been signed by each of the Parties and delivered to each of the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section10_11Consents"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consents</span>. Any consent required or permitted to be given by any Party to the other Party under this Agreement shall be in writing and signed by the Party giving such consent and shall be effective only against such Party (and its Group).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section10_12Expenses"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.12</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses</span>. Except as otherwise specified in this Agreement, or as otherwise agreed in writing between Remainco, Parent, and Spinco, Remainco, Parent, and Spinco shall each be responsible for its own fees, costs and expenses paid or incurred in connection with this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section10_13TerminationandAmendment"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.13</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination and Amendment</span>. This Agreement may not be terminated, modified or amended except by an agreement in writing signed by Remainco, Parent, and Spinco.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section10_14TitlesandHeadings"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.14</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Titles and Headings</span>. Titles and headings to articles&#160;herein are inserted for the convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section10_15Severability"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.15</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</span>. In the event any one or more of the provisions contained in this Agreement should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. The Parties shall endeavor in good-faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions, the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section10_16Interpretation"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.16</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</span>. The Parties have participated jointly in the negotiation and drafting of this Agreement. This Agreement shall be construed without regard to any presumption or rule&#160;requiring construction or interpretation against the Party drafting or causing any instrument to be drafted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section10_17NoDuplicationNoDouble"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.17</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Duplication; No Double Recovery</span>. Nothing in this Agreement is intended to confer to or impose upon any Party a duplicative right, entitlement, obligation or recovery with respect to any matter arising out of the same facts and circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section10_18NoWaiver"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.18</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Waiver</span>. No failure to exercise and no delay in exercising, on the part of any Party, any right, remedy, power or privilege hereunder shall operate as a waiver hereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section10_19GoverningLaw"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.19</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</span>. This Agreement and any dispute arising out of, in connection with or relating to this Agreement shall be governed by and construed in accordance with the Laws of the State of Delaware, without giving effect to the conflicts of laws principles thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="E_Section10_20DistributionTime"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.20</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Distribution Time</span>. This Agreement shall become effective only upon the Distribution Time on the Distribution Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">[<i style="font-style:italic;">Signature Page&#160;Follows</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">E-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_486cbd5e_4d87_49bc_93d3_baa34ad3eaf4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, the Parties hereto have duly executed this Agreement as of the day and year first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="3" style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="4" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="4" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name: </p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">[&#160;<span style="font-family:'Times New Roman';">&#9679;</span>&#160;]</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title: </p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">[&#160;<span style="font-family:'Times New Roman';">&#9679;</span>&#160;]</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="4" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="4" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">LIGAND PHARMACEUTICALS INCORPORATED</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="4" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">[&#160;<span style="font-family:'Times New Roman';">&#9679;</span>&#160;]</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">[&#160;<span style="font-family:'Times New Roman';">&#9679;</span>&#160;]</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="4" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="4" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">OMNIAB,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="4" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">[&#160;<span style="font-family:'Times New Roman';">&#9679;</span>&#160;]</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">[&#160;<span style="font-family:'Times New Roman';">&#9679;</span>&#160;]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup> Note to Draft: To update to Avista&#8217;s name post-domestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f8db5e03_94fb_448a_8a9f_78a2ee00b59d"></a><a id="AnnexF1_497487"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Annex F-1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Execution Copy</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">TRANSITION SERVICES AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">This TRANSITION SERVICES AGREEMENT (this &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</span>&#8221;), effective as of the Distribution Time of the Separation and Distribution Agreement (as defined below) (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</span>&#8221;), by and between Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ligand</span>&#8221; or &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Provider</span>&#8221;), and OmniAb,&#160;Inc., a Delaware Corporation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OmniAb</span>&#8221;). Each of Provider and OmniAb may be referred to herein individually as a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Party</span>&#8221; and collectively as the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</span>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, Ligand and OmniAb are parties to a certain Separation and Distribution Agreement dated as of March&#160;23, 2022 (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation and Distribution Agreement</span>&#8221;), pursuant to which Ligand has agreed to perform, and OmniAb has agreed to receive, certain Transition Services (as defined below) with respect to OmniAb&#39;s operation of the OmniAb Business (as defined in the Separation and Distribution Agreement), subject to, and in accordance with, the terms and conditions contained herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions hereinafter set forth and set forth in the Separation and Distribution Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as set forth herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DEFINITIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Defined Terms</span>. Unless otherwise specifically provided herein, capitalized terms used, but not otherwise defined, herein shall have the meanings ascribed thereto in the Separation and Distribution Agreement. As used herein, the following terms have the following meanings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliate(s)</span>&#8221; means, with respect to a particular entity or Person, any Person that controls, is controlled by, or is under common control with that Party. For the purpose of this definition, &#8220;control&#8221; will mean, direct or indirect ownership of more than 50% of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or more than 50% of the equity interest in the case of any other type of legal entity, status as a general partner in any partnership, or any other arrangement whereby the entity or Person controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity, or the ability to cause the direction of the management or policies of a corporation or other entity. For purposes of this Agreement, Ligand and OmniAb shall not be considered Affiliates of each other.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Authority</span>&#8221; means (a)&#160;any court, agency, department, authority or other instrumentality of any national, state, county, city or other political subdivision; (b)&#160;any public international organization; or (c)&#160;any department, agency or instrumentality thereof, including any company, business, enterprise or other entity owned or controlled, in whole or in part, by any government.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</span>&#8221; means any and all intellectual property and other proprietary rights throughout the world, including any and all state, United States, international and/or foreign or other territorial or regional rights in, arising out of or associated with any of the following: (a)&#160;all patents and applications therefor, including all related provisionals, continuations, continuations-in-part, divisionals, reissues, renewals and extensions (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patents</span>&#8221;), (b)&#160;all inventions (whether patentable or not), invention disclosures, improvements, trade secrets, proprietary information, know how (including formulations, specifications, formulae, manufacturing and other processes, operating procedures, methods, techniques and all research and development information), technology, technical data and customer lists, and all documentation relating to any of the foregoing, (c)&#160;all copyrights, copyrightable works, copyright registrations and applications therefor, including all rights of authorship, use, publication, reproduction, distribution, performance and transformation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Copyrights</span>&#8221;), (d)&#160;all industrial designs and any registrations and applications therefor, (e)&#160;all domain names, uniform resource locators and other names and locators associated with the internet (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Domain Names</span>&#8221;), and all social media accounts and handles and app registrations, (f)&#160;all trade names, logos, common law trademarks and service marks, trademark and service mark registrations and applications therefor and all goodwill associated therewith (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trademarks</span>&#8221;), (g)&#160;all rights in databases and data collections, (h)&#160;all moral and economic rights of authors and inventors, however denominated, (i)&#160;rights in computer software (including source code, object code, firmware, algorithms, </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">operating systems and specifications) and related technology, (j)&#160;all rights in content (including text, graphics, images, audio, video and data) and computer software included on or used to operate and maintain any websites, including all rights in documentation, files, cgi and other scripts and programming code, (k)&#160;all rights of publicity or privacy, including with respect to name, likeness or persona, and (l)&#160;all rights to sue or recover and retain damages and costs and attorneys&#39; fees for the past, present or future infringement, dilution, misappropriation, or other violation of any of the foregoing anywhere in the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Law</span>&#8221; means any law (including common law), statute, code, ordinance, rule, regulation, order or charge of any Governmental Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Person</span>&#8221; means any individual, partnership, limited liability company, firm, corporation, association, trust, unincorporated organization or other entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Personal Information</span>&#8221; means&#160;any data or&#160;information that identifies,&#160;relates to, describes, is reasonably capable of being associated with, or could reasonably be linked, directly or indirectly, with a particular natural person or household (including any information related to the health of a person) and any information derived from the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representatives</span>&#8221; means, as to any Person, such Person&#39;s Affiliates and its and their successors, owners, controlling Persons, directors, officers, employees, agents, representatives, subcontractors, or other third party acting for or on its behalf, including, as to Provider, any Vendor providing any Transition Services as permitted in this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recipient</span>&#8221; means, with respect to a particular Transition Service, either OmniAb or the applicable member of the OmniAb Group (as defined in the Separation and Distribution Agreement) receiving such Transition Service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TRANSITION SERVICES PROVIDED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Services.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Upon the terms and subject to the conditions set forth in this Agreement, Provider shall provide, or cause one or more of its Representatives to provide, to Recipient each of the services set forth on Schedule A attached hereto (hereinafter referred to individually as a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Service</span>&#8221;, and collectively as the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Services</span>&#8221;), at the corresponding costs set forth on Schedule A, and Recipient agrees to receive the Transition Services and pay the costs therefor during the time period specified for each such Transition Service in such Schedule or for such other time period as permitted pursuant to this Agreement (hereinafter referred to collectively as the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Service Periods</span>&#8221; for all of the Transition Services, and individually a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Service Period</span>&#8221; for each Transition Service). The Parties may amend the scale and scope of the Transition Services from time to time upon mutual agreement by executing a signed amendment to Schedule A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>If, within three (3)&#160;months following the Effective Date, Recipient identifies in good faith any service that was provided by Provider or one of its Affiliates (excluding the OmniAb Group) to the OmniAb Business during the six (6)&#160;month period (or twelve (12) month period solely with respect to activities that are customarily performed on an annual basis) prior to the Effective Date that is not listed on Schedule A and is necessary to effectuate the Separation (an &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Omitted Service</span>&#8221;), then Recipient shall notify Provider thereof and Schedule A will be deemed amended to include such Omitted Service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Personnel; Affiliates; Vendors</span>. In providing the Transition Services, Provider may, as it deems necessary or appropriate, (i)&#160;use the qualified personnel of Provider or its Affiliates, and (ii)&#160;employ the services of qualified third parties (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vendors</span>&#8221;) to the extent that, and subject to the condition that, such Vendor&#39;s services (A)&#160;were utilized by or for the benefit of the OmniAb Business prior to the Effective Date, (B)&#160;are routinely utilized to provide similar services to other businesses of Provider or (C)&#160;are reasonably necessary for the efficient performance of such Transition Services. Furthermore, each Party shall, and shall cause its Representatives to, comply, in all material respects, with all Laws which may be applicable to the Transition Services. Each Party shall be responsible for its Representatives, including for such Representatives adhering to any health, safety, and security regulations and other published policies of the other Party while on the other Party&#39;s premises or when given access to any equipment, computer, databases, systems, software, network or other files (collectively, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Systems</span>&#8221;) owned or controlled by the other Party. If a Party or one or more of its Representatives needs access to the premises or Systems of the other Party or one or more of its Representatives to provide or receive the Transition Services (as applicable), then (x)&#160;the accessing Party shall advise the other Party in writing in advance of such access of </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">the name of each of the accessing Party&#39;s Representatives who shall require such access, (y)&#160;the accessing Party and its Representatives shall not attempt to obtain access to, use or interfere with any of the premises or Systems of the other Party or such other Party&#39;s Representatives, except to the extent permitted by the other Party or required to do so to provide or receive the Transition Services (as applicable), and (z)&#160;the accessing Party and its Representatives shall not intentionally damage, disrupt or impair the normal operation of any of the premises or Systems of the other Party or such other Party&#39;s Representatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Coordinators</span>. Each of Provider and Recipient shall nominate a representative to act as its primary contact person to coordinate the provision of all Transition Services (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Primary Coordinators</span>&#8221;). Each Primary Coordinator may designate one or more service coordinators for each specific Transition Service (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Service Coordinators</span>&#8221;). Each Party may treat an act of a Primary Coordinator or Service Coordinator of another Party as being authorized by such other Party without inquiring behind such act or ascertaining whether such Primary Coordinator or Service Coordinator had authority to so act, <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that no such Primary Coordinator or Service Coordinator has authority to amend this Agreement. Provider and Recipient shall advise each other promptly (in any case no more than five (5)&#160;business days) in writing of any change in the Primary Coordinators and any Service Coordinator for a particular Transition Service, setting forth the name of the Primary Coordinator or Service Coordinator to be replaced and the name of the replacement, and certifying that the replacement Primary Coordinator or Service Coordinator is authorized to act for such Party in all matters relating to this Agreement, in the case of a Primary Coordinator or, in the case of a Service Coordinator, with respect to the Transition Service for which such Service Coordinator has been designated. Provider and Recipient each agrees that all communications relating to the provision of the Transition Services shall be directed to the Service Coordinators for such Transition Service with copies to the Primary Coordinators. Provider&#39;s initial Primary Coordinator shall be Matthew Korenberg. Recipient&#39;s initial Primary Coordinator shall be Matt Foehr.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level of Transition Services</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Recipient acknowledges and agrees that Provider is not in the business of providing services to third parties and is entering into this Agreement only in connection with the Separation and Distribution Agreement. Provider shall, and shall cause each of its Representatives to, provide the Transition Services with substantially the same degree of skill, quality and standard of care as that utilized by Provider (or its Affiliates) to perform similar activities in the six (6)&#160;month period (or twelve (12) month period solely with respect to activities that are customarily performed on an annual basis) prior to the Effective Date, and, in any event, no less than with commercially reasonable care and diligence (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Services Standard</span>&#8221;). Under no circumstances shall Provider or any of its Representatives be held accountable to a greater standard of care, efforts or skill than the Services Standard in the performance of the Transition Services. Recipient acknowledges and agrees that (i)&#160;the Transition Services do not include the exercise of business judgment or general management for Provider and (ii)&#160;NEITHER PROVIDER NOR ANY OF ITS AFFILIATES MAKES ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED,&#160;INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE TRANSITION SERVICES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>If the Transition Services to be provided to Recipient materially increase in scale or in scope as compared to the level of the similar services provided in connection with the operation of the OmniAb Business as of the Effective Date, Provider may, at its election, choose to not provide such increased scale or scope of Transition Services, and if Provider elects to perform such increased scale or scope of Transition Services, all costs incurred in connection therewith shall be mutually agreed upon by Provider and Recipient prior to the time such additional Transition Services are performed, shall be set forth in an amended Schedule A, and shall be borne by Recipient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>In addition to being subject to the terms and conditions of this Agreement for the provision of the Transition Services, Provider and Recipient each agree that the Transition Services provided by any Vendor shall be subject to the terms and conditions of any agreements between Provider and such Vendor, which agreements shall be on substantially the same conditions as Provider would enter into with such Vendor for its own account, and no such agreements shall be binding on Recipient after the Term hereof without Recipient&#39;s express written consent. Provider shall consult with Recipient concerning the terms and conditions of any such agreements to be entered into, or proposed to be entered into, or amended, with any Vendors after the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Without relieving Provider of its obligation to perform the Transition Services in accordance with the Services Standard, Provider shall not be (i)&#160;obligated to perform the Transition Services to the extent that such performance would be unlawful or that would require Provider to violate applicable Law; (ii)&#160;obligated to perform the Transition Services to the extent that such performance, in Provider&#39;s reasonable determination, could create deficiencies in Provider&#39;s controls over financial information or </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">adversely affect the maintenance of Provider&#39;s financial books and records or the preparation of its financial statements; (iii)&#160;obligated to hire any additional employees to perform the Transition Services or maintain the employment of any specific employee; (iv)&#160;obligated to hire replacements for employees that resign, retire or are terminated; (v)&#160;obligated to enter into retention agreements with employees or otherwise provide any incentive beyond payment of regular salary and benefits; (vi)&#160;prevented from transferring after the Effective Date any employees who were supporting the business operations as of the Effective Date to support other business operations for Provider or its Affiliates or to assume other roles with Provider or its Affiliates to the extent such employees are not required to provide Transition Services; (vii)&#160;prevented from determining, in its sole discretion, the individual employees who will provide Transition Services; or (viii)&#160;obligated to purchase, lease or license any additional equipment or software.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transitional Nature of Services</span>. Recipient acknowledges and agrees that the Transition Services are intended only to be transitional in nature, and shall be furnished by Provider only during the Service Periods. Recipient shall use commercially reasonable efforts to have sufficient resources available to it at the end of the Service Periods to perform the Transition Services (or have the Transition Services performed) without the involvement of Provider, its Affiliates or any of its or their respective employees or agents upon the termination or expiration of a Service Period for an applicable Transition Service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Location of Services Provided; Travel Expenses</span>. Provider shall provide the Transition Services to Recipient from locations of Provider&#39;s choice in its sole discretion except to the extent the nature of the Transition Services necessitates performance at a specific location, as mutually agreed upon by the Parties. Subject to Section&#160;3.1, should the provision of the Transition Services require any directors, officers, employees, agents, representatives, or subcontractors of Provider or its Affiliates to travel beyond fifty (50) miles from his or her employment location, Recipient shall reimburse Provider for all reasonable travel-related out-of-pocket costs, consistent with Provider&#39;s travel policy as provided to Recipient in advance in writing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitation of Liability</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Parties hereto acknowledge and agree that the Transition Services are provided by Provider: (a)&#160;at the request of Recipient in order to accommodate it following the closing under the Separation and Distribution Agreement; (b)&#160;at the costs set forth on Schedule A hereto and with no expectation of profit being made by Provider thereon; and (c)&#160;with the expectation that Provider is not assuming any financial or operational risks, including those usually assumed by a service provider, except for those risks explicitly set forth herein. Accordingly, each Party agrees that, absent gross negligence or willful misconduct, and except for breaches of Article&#160;V (Confidentiality) and except for a Party&#39;s obligations under Section&#160;2.8 (Indemnification), the other Party, its Affiliates and their directors, officers, employees, representatives, consultants and agents shall not be liable for any indirect, special, incidental or consequential damages, including lost profits or savings, whether or not such damages are foreseeable, or for any third party claims relating to the Transition Services or each Party&#39;s performance under this Agreement. Notwithstanding anything to the contrary contained herein, in the event Provider commits an error with respect to or incorrectly performs or fails to perform any Transition Service, at Recipient&#39;s request, Provider shall use commercially reasonable efforts and in good faith attempt to correct such error, re-perform or perform such Transition Service at no additional cost to Recipient; <i style="font-style:italic;">provided </i>that, absent gross negligence or willful misconduct, and assuming that Provider uses commercially reasonable data backup processes, Provider shall have no obligation to recreate any lost or destroyed data to the extent the same cannot be cured by the re-performance of the Transition Service in question.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Recipient shall indemnify, defend and hold harmless Provider and its Affiliates and its and their respective officers, directors, employees, representatives, subcontractors and agents from and against any and all damages, liabilities, losses, taxes, fines, penalties, costs and expenses (including, without limitation, reasonable fees of counsel) incurred by any of them in connection with any Third Party Claim (as defined below) (each, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Loss</span>&#8221; and, collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Losses</span>&#8221;) relating to, arising out of or resulting from or based on (i)&#160;Recipient&#39;s material breach of this Agreement or (ii)&#160;any gross negligence or willful misconduct of Recipient, (iii)&#160;Provider&#39;s provision of the Transition Services as directed or requested by Recipient, or (iv)&#160;Recipient&#39;s use or exploitation of any work product provided by Provider in the performance of the Transition Services, except in each case (i), (ii), (iii), and (iv)&#160;to the extent such Losses are subject to indemnification pursuant to Section&#160;2.8(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Provider hereby agrees to indemnify, defend and hold harmless Recipient and its Affiliates and its and their respective officers, directors, employees, representatives, subcontractors and agents from and against any and all Losses relating to, arising out of or resulting from (i)&#160;Provider&#39;s material breach of this Agreement or (ii)&#160;any gross negligence or willful misconduct in the </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">performance of its obligations under this Agreement, except in each case of (i)&#160;and (ii)&#160;to the extent such Losses are subject to indemnification pursuant to Section&#160;2.8(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>To the maximum extent permitted by applicable Law, each Party&#39;s and its Affiliates&#39; and each of its and their respective subcontractors&#39; officers&#39;, directors&#39;, employees&#39; and agents&#39; sole and exclusive remedy with respect to any and all claims relating to the Transition Services shall be pursuant to the indemnification provisions set forth in this Section&#160;2.8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification Procedures</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>If any claim or demand is made by a third party (including any action or proceeding commenced or threatened to be commenced) with respect to which a Party seeking indemnification (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Party</span>&#8221;) intends to seek indemnity under Section&#160;2.8 (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Claim</span>&#8221;), the Indemnified Party shall promptly give written notice thereof to the other Party (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnifying Party</span>&#8221;) indicating, with reasonable specificity, the nature of such Third Party Claim, the basis therefor, and a copy of any documentation received from such third party. A failure by the Indemnified Party to give notice and to tender the defense of any action or proceeding in a timely manner pursuant to this Section&#160;2.9(a)&#160;shall not limit the obligation of the Indemnifying Party under Section&#160;2.8, except to the extent such Indemnifying Party is actually and materially prejudiced thereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Upon receipt of a notice for indemnity from the Indemnified Party pursuant to Section&#160;2.9(a)&#160;with respect to any Third Party Claim, the Indemnifying Party shall have the right to assume the defense of, at its own expense and by its own counsel, any such Third Party Claim. If the Indemnifying Party shall, in accordance with the immediately preceding sentence, undertake to compromise or defend any such Third Party Claim, it shall notify the Indemnified Party of its intention to do so, and the Indemnified Party shall agree to cooperate with the Indemnifying Party and its counsel in the compromise of, or defense against, any such Third Party Claim; <i style="font-style:italic;">provided </i>that the Indemnifying Party shall not settle or compromise any such Third Party Claim without the written consent of the Indemnified Party (not to be unreasonably withheld, conditioned or delayed) unless such settlement or compromise fully and irrevocably releases the Indemnified Party in connection with such Third Party Claim and provides relief consisting solely of money damages borne by the Indemnifying Party. Notwithstanding an election of the Indemnifying Party to assume the defense of such Third Party Claim, the Indemnified Party shall have the right to employ separate legal counsel, its own cost and expense, and to participate in the defense thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Modification of Transition Services Procedures</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Subject to the procedure set forth in this Section&#160;2.10 to the extent applicable, Provider may make changes from time to time in its standards and procedures for performing the Transition Services, <i style="font-style:italic;">provided</i> that any such change shall not interfere in any material respect with the continued provision or cost of the Transition Services. Notwithstanding the foregoing sentence, unless required by Law, Provider shall not implement any substantial or material changes to such standards and procedures in a manner affecting the operation of the OmniAb Business unless Recipient agrees in writing to such changes and Provider gives Recipient ten (10)&#160;business days to adapt its operations to accommodate such changes to the extent commercially reasonable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>During the term of this Agreement, if Recipient intends to make any changes that may affect the provision of any of the Transition Services, Recipient shall provide Provider with a plan identifying any changes as soon as reasonably practicable, but in any case no less than ten (10)&#160;business days before implementing such changes; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that Provider shall not be required to alter the method in which it provides any of the Transition Services or increase the level of any such Transition Services in any material manner except as expressly provided herein; <i style="font-style:italic;">provided, further, however, </i>that the failure of Recipient to provide such notice shall not alter or diminish Provider&#39;s obligations to provide the Transition Services on the terms set forth herein except where the failure to provide notice has materially increased Provider&#39;s cost or burden to provide such Transition Service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation</span>. The Parties will use commercially reasonable efforts to reasonably cooperate and cause each of their respective Representatives to reasonably cooperate in a professional and workmanlike manner with each other to the extent necessary to assist the other Party in performance of its obligations under this Agreement, including with respect to the provision and receipt of the Transition Services. Such cooperation shall include exchanging information relevant to and reasonably necessary for the provision or receipt of the Transition Services hereunder and the performance of such other duties and tasks as may be reasonably required for the provision or receipt of the Transition Services. Without limiting the foregoing:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Recipient shall permit Provider and its Representatives reasonable access during regular business hours (or otherwise upon reasonable prior notice) to any data, records and personnel involved in receiving or overseeing the Transition Services as reasonably requested by Provider to facilitate Provider&#39;s performance of this Agreement. Any such data and records shall be subject to Article&#160;V. Before the Parties exchange any Personal Information in connection with the Transition Services, the Parties will enter into a data processing agreement in accordance with applicable Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Provider shall use commercially reasonable efforts to obtain any consents, licenses, waivers or approvals necessary to permit Provider to perform its obligations hereunder; <i style="font-style:italic;">provided, however,</i> that under no circumstances shall Provider be obligated to provide the relevant part of any Transition Services to the extent that (i)&#160;Provider is unable to obtain necessary third party consents, licenses, waivers or approvals relating to such part of the Transition Services on commercially reasonable terms, (ii)&#160;in order to provide such part of the Transition Services, Provider will have an obligation to make any payments to any Third Party or incur any obligations in respect of any such consents, licenses, waivers or approvals, which payments are not subject to reimbursement by Recipient or which other obligations are not assumed by Recipient hereunder, (iii)&#160;Provider would be obligated to make any alternative arrangements in the event that any such consents, licenses, waivers or approvals are not obtained (but only to the extent such arrangements would not be commercially reasonable) or (iv)&#160;Provider would be required to seek broader rights or more favorable terms with respect to any consents, licenses, waivers or approvals than those applicable immediately prior to the date hereof where the costs of obtaining the same are not subject to reimbursement by Recipient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Recipient shall obtain all necessary consents, licenses, waivers and approvals necessary for it to receive the Transition Services and perform its obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consideration</span>. As consideration for the Transition Services, Recipient shall pay to Provider the amount specified for each such Transition Service as set forth in Schedule A, including any &#8220;pass-through costs&#8221; expressly identified as such in Schedule A. The fees set forth on Schedule A will be equitably reduced if any Transition Service is suspended, terminated or removed from the scope of this Agreement and will be equitably prorated for partial months. In addition, Recipient shall reimburse Provider (upon receipt of applicable receipts and other reasonable supporting documentation if requested by Provider) for all reasonable documented out of pocket costs of Provider in connection with performance of the Transition Services by Provider, including: (a)&#160;shipping and transportation costs (including the cost of any insurance related thereto), duties and other taxes (excluding taxes on Provider&#39;s income); (b)&#160;travel-related costs, (c)&#160;out of pocket costs or expenses incurred with third parties by Provider, its Affiliates or subcontractors, including for the extraction, conversion and transfer of data and (d)&#160;any other out of pocket costs and expenses incurred with third parties described herein as reimbursable by Provider (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reimbursable Expenses</span>&#8221;); <i style="font-style:italic;">provided</i> that if any particular Reimbursable Expense exceeds Ten Thousand Dollars ($10,000), Provider must obtain Recipient&#39;s consent prior to any obligation of Recipient to reimburse Provider for such Reimbursable Expense; <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided, further</i> that until Recipient consents to such Reimbursable Expenses exceeding Ten Thousand Dollars ($10,000), Provider shall not be required to provide the relevant part of the Transition Services for which such Reimbursable Expenses exceeding Ten Thousand Dollars ($10,000) is necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Invoices</span>. Provider shall, on a monthly basis on the last day of each calendar month, submit a single itemized invoice to Recipient for all Transition Services provided to Recipient during such month. All invoices shall be sent to the attention of the Primary Coordinators at the address set forth in Section&#160;7.5 hereof or to such other address as Recipient shall have specified by notice in writing to Provider.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment of Invoices</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Recipient shall pay any undisputed invoice for Transition Services promptly but in no event later than thirty (30) days after the date of receipt of such invoice and such payment shall be made by wire transfer of immediately available funds to such bank account as shall have been notified in writing to Recipient by Provider. Payment of all invoices in respect of the Transition Services shall be made by check or electronic funds transmission in U.S. Dollars, without any offset or deduction of any nature whatsoever (except that offset or deduction may be made in regard to other invoiced amounts due under this Agreement or to the extent of a dispute in good faith concerning amounts due under this Agreement). All payments shall be made to the account designated by Provider to Recipient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>If any payment is not paid when due (except to the extent disputed in good faith) and Recipient does not make such payment within thirty (30) days of receiving a past-due notice from Provider, Provider shall have the right, without any liability to Recipient, or anyone claiming by or through Recipient, to, upon written notice to Recipient, immediately cease providing any or all of the Transition Services provided by Provider to Recipient and/or to terminate this Agreement in its entirety, which right may be exercised by Provider in its sole and absolute discretion. Notwithstanding the above, Provider shall not cease providing any Transition Service or terminate this Agreement if such lack of payment is due to a good faith dispute, the details of which Recipient has indicated to Provider in writing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;IV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OWNERSHIP OF INTELLECTUAL PROPERTY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ownership; Delivery</span>. Except as expressly set forth herein, neither Party will obtain, by virtue of this Agreement or the Transition Services, by implication or otherwise, any rights of ownership or use of any property or Intellectual Property owned by the other. All Intellectual Property conceived, created or made by Provider or any of its Representatives (whether alone or jointly with Recipient) in the course of Provider&#39;s performance of the Transition Services and other activities under this Agreement that are (a)&#160;exclusively related to the OmniAb Business and/or (b)&#160;based on, derived from, or improvements of any of Recipient&#39;s background Intellectual Property (altogether, (a)&#160;and (b), the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assigned IP</span>&#8221;) shall be solely owned by Recipient, and Provider hereby assigns to Recipient all of Provider&#39;s right, title, and interest in and to such Assigned IP. All other Intellectual Property conceived, created or made by Provider or any of its Representatives in the course of Provider&#39;s or such Representative&#39;s performance of any Transition Services or other activities under this Agreement shall be solely owned by Provider.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limited Licenses</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Recipient (on behalf of itself and its controlled Affiliates) hereby grants to Provider a limited, non-exclusive, royalty-free, non-transferable license, with the right to grant sublicenses to its Affiliates and its and their subcontractors during the Service Periods, under the Intellectual Property owned or controlled by Recipient, solely to the extent necessary for Provider and its Affiliates and its and their subcontractors to perform the Transition Services hereunder for the benefit of Recipient during the applicable Services Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Provider (on behalf of itself and its controlled Affiliates) hereby grants to Recipient and its Affiliates a limited, non-exclusive, royalty-free, non-transferable license, with the right to grant sublicenses to its and their Affiliates and subcontractors, under the Intellectual Property owned or controlled by Provider, solely to the extent necessary for Recipient and its Affiliates and its and their subcontractors to (i)&#160;receive the Transition Services during the applicable Service Period and/or (ii)&#160;use or exploit any deliverables provided by Provider to Recipient as part of the Transition Services in the operation of the OmniAb Business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CONFIDENTIALITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Each Party recognizes that in the performance of this Agreement, or as a result of the Parties&#39; ongoing relationship, non-public, Confidential Information (as defined in the Separation and Distribution Agreement) belonging to the other Party regarding the Transition Services may be disclosed or become known to the Party or its Affiliates. Unless otherwise expressed in writing to the other Party, confidential information and confidential materials concerning a Party&#39;s business and products (including information and materials contained in technical data, information concerning the OmniAb Business, financial information and data, strategies and marketing and customer information), including that expressed orally, that is exchanged between the Parties in connection with the performance of this Agreement shall be considered to be Confidential Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Notwithstanding any termination of this Agreement, Provider and Recipient shall hold and shall cause their respective Representatives to hold, in strict confidence (and not to disclose or release or, except as otherwise permitted by this Agreement or the Separation and Distribution Agreement, use, including for any ongoing or future commercial purpose, without the prior written consent of the Party to whom the Confidential Information relates (which may be withheld in such Party&#39;s sole and absolute discretion, except where disclosure is required by applicable Law), any and all Confidential Information concerning or </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">belonging to the other Party or its Affiliates; <i style="font-style:italic;">provided</i> that each Party may disclose, or may permit disclosure of, Confidential Information: (i)&#160;to its respective auditors, attorneys, financial advisors, bankers and other appropriate consultants and advisors who have a need to know such Information (as defined in the Separation and Distribution Agreement) for auditing and other non-commercial purposes and are informed of the obligation to hold such Information confidential and in respect of whose failure to comply with such obligations, the applicable Party will be responsible, (ii)&#160;if any Party or its Affiliates or any of its respective Subsidiaries is required or compelled to disclose any such Confidential Information by judicial or administrative process or by other requirements of Law or stock exchange rule&#160;or is advised by outside counsel in connection with a proceeding brought by a Governmental Authority that it is advisable to do so, (iii)&#160;as required in connection with any legal or other proceeding by one Party against the other Party or in respect of claims by one Party against the other Party brought in a proceeding, (iv)&#160;as necessary in order to permit a Party to prepare and disclose its financial statements in connection with any regulatory filings or tax returns, (v)&#160;as necessary for a Party to enforce its rights or perform its obligations under this Agreement or the Separation and Distribution Agreement, (vi)&#160;to Governmental Authorities in accordance with applicable procurement regulations and contract requirements or (vii)&#160;to other Persons in connection with their evaluation of, and negotiating and consummating, a potential strategic transaction, to the extent reasonably necessary in connection therewith, provided an appropriate and customary confidentiality agreement has been entered into with the Person receiving such Confidential Information at least as protective of such Confidential Information as this Agreement. Notwithstanding the foregoing, in the event that any demand or request for disclosure of Confidential Information is made by a third party pursuant to clause (ii), (iii), (v)&#160;or (vi)&#160;above, each Party, as applicable, shall promptly notify (to the extent permissible by Law) the Party to whom the Confidential Information relates of the existence of such request, demand or disclosure requirement and shall provide such affected Party a reasonable opportunity to seek an appropriate protective order or other remedy, which such Party will cooperate in obtaining to the extent reasonably practicable. In the event that such appropriate protective order or other remedy is not obtained, the Party which faces the disclosure requirement shall furnish only that portion of the Confidential Information that is required to be disclosed and shall take commercially reasonable steps to ensure that confidential treatment is accorded such Confidential Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Each Party acknowledges that it and its Affiliates may have in its or their possession confidential or proprietary Information of third parties that was received under confidentiality or non-disclosure agreements with such third party while such Party and/or its Affiliates were part of the Ligand Group. Each Party shall comply, shall cause its Affiliates to comply, and shall cause its and their respective officers, employees, agents, consultants and advisors (or potential buyers) to comply, with all terms and conditions of any such third-party agreements entered into prior to the Effective Date, with respect to any confidential and proprietary Information of third parties to which it or any other member of its Group has had access.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Notwithstanding anything to the contrary set forth herein, (i)&#160;the Parties shall be deemed to have satisfied their obligations hereunder with respect to Confidential Information if they exercise at least the same degree of care that applies to Ligand&#39;s confidential and proprietary information pursuant to policies in effect as of the Effective Date and (ii)&#160;confidentiality obligations provided for in any Contract between each Party or its Affiliates or Subsidiaries and their respective employees shall remain in full force and effect. Notwithstanding anything to the contrary set forth herein, Confidential Information of a Party in the possession of and used by the other Party as of the Effective Date may continue to be used by such Party in possession of the Confidential Information in and only in the operation of the OmniAb Business; <i style="font-style:italic;">provided</i> that such Confidential Information may only be used by such Party and its officers, employees, agents, consultants and advisors in the specific manner and for the specific purposes for which it is used as of the Effective Date, and may only be shared with additional officers, employees, agents, consultants and advisors of such Party on a need-to-know basis exclusively with regard to such specified use; <i style="font-style:italic;">provided further</i> that such Confidential Information may be used only so long as the Confidential Information is maintained in confidence and not disclosed in violation of this Section&#160;5.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>The Parties agree that irreparable damage may occur in the event that the provisions of this Section&#160;5.1 were not performed in accordance with their specific terms. Accordingly, it is hereby agreed that the Parties shall be entitled to seek an injunction or injunctions to enforce specifically the terms and provisions hereof in any court having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>Upon expiration of the Service Periods or termination of this Agreement for any reason whatsoever, except for such retention and use as expressly provided for in the Separation and Distribution Agreement, each Party shall not disclose and shall make no further use of the other Party&#39;s Confidential Information and upon written request shall immediately destroy or, with respect to Confidential Information in written or other tangible form (including all copies thereof), return to the other Party, all such Confidential Information; <i style="font-style:italic;">provided</i> that (i)&#160;each Party shall be entitled to retain one record copy in its legal department solely to determine the extent of its continuing obligations or as otherwise required to comply with applicable Law, and </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">(ii)&#160;neither Party nor its Representatives shall be required to expunge Confidential Information from computer archiving conducted as part of established record retention policies (<i style="font-style:italic;">provided</i> that the foregoing shall not be deemed to permit the accessing, retrieval or use of any Confidential Information).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;VI</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TERM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</span>. This Agreement shall commence on the Effective Date and shall continue in full force and effect until the earliest of (a)&#160;the date on which this Agreement is terminated in accordance with this Article&#160;VI or (b)&#160;the expiration of the last Service Period, such that Provider is no longer obligated to provide any Transition Services pursuant to this Agreement (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</span>&#8221;). If no expiration date is provided for any Transition Service, then such Transition Service will terminate twelve (12) months after the Effective Date, <i style="font-style:italic;">provided</i> that Recipient shall have the right to an extension of each or any Transition Service for up to six (6)&#160;months by providing written notice to Provider in advance of the original termination date for such Transition Service if, prior to such request for extension, Recipient has used commercially reasonable efforts to establish analogous capabilities of its own. The Parties will discuss in good faith any subsequent requests to further extend the Transition Services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Services</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Recipient may, at any time prior to the end of the Service Period for any Transition Service(s)&#160;and upon thirty (30) days&#39; prior written notice to Provider, terminate any Transition Service(s)&#160;or this Agreement in its entirety, whereupon, from and after the date of termination specified in such written notice, Provider&#39;s obligation to provide such Transition Service(s)&#160;to Recipient shall cease and Recipient shall have no obligation to pay Provider for such Transition Service(s)&#160;(other than with respect to those Transition Services for which costs will be incurred by Provider as a result of non-cancellable commitments that Provider incurred in good faith in order to provide such Transition Services); <i style="font-style:italic;">provided</i> that if termination of any Transition Service materially inhibits Provider&#39;s ability to provide or prevents Provider from providing any other Transition Services (as determined in Provider&#39;s sole discretion), Provider shall promptly notify Recipient of such determination and such other Transition Services shall also shall be deemed terminated, subject to Recipient&#39;s prior written consent of such termination; and <i style="font-style:italic;">provided further</i> that partial reduction of any specific Transition Service may only be made with the prior written consent of Provider, which consent shall not be unreasonably withheld, delayed or conditioned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Except as set forth in Section&#160;3.3(b), in the event that either Party breaches any of its material obligations under this Agreement (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Breaching Party</span>&#8221;), the other Party may terminate this Agreement in its entirety upon thirty (30) days&#39; prior written notice (such thirty (30) day period, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice Period</span>&#8221;) to the Breaching Party, specifying the breach and its claim of right to terminate; <i style="font-style:italic;">provided</i>, that the termination of this Agreement shall not become effective at the end of the Notice Period if (i)&#160;the Breaching Party cures such breach during the Notice Period or (ii)&#160;such breach cannot be cured during the Notice Period and the Breaching Party commences and diligently pursues actions to cure such breach within the Notice Period, in which case the Breaching Party shall have an additional thirty (30) day period to cure such breach before such termination shall become effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Either Party may terminate this Agreement in its entirety immediately upon written notice to the other Party if the other Party (i)&#160;files in any court or with any other Governmental Authority, pursuant to any Law of any state or country, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of such other Party or of its assets; (ii)&#160;is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is not dismissed within sixty (60) days after the filing thereof; (iii)&#160;consents to the appointment or taking possession by a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of such other Party or for any substantial part of its property or makes any assignment for the benefit of creditors; (iv)&#160;admits in writing its inability to pay its debts generally as they become due; or (v)&#160;has issued or levied against its property any judgment, writ, warrant of attachment or execution or similar process that represents a substantial portion of its property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Any Transition Service, or this Agreement in its entirety, may be terminated upon the mutual written agreement of Provider and Recipient at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Obligations.</span> Recipient specifically agrees and acknowledges that all obligations of Provider to provide each Transition Service shall immediately cease upon the expiration of the Service Period (as may be extended as set forth in this </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Agreement) for such Transition Service, and Provider&#39;s obligations to provide all of the Transition Services shall immediately cease upon termination of this Agreement. Recipient shall bear sole responsibility for instituting permanent services, or obtaining replacement services, in respect of any Transition Service terminated in accordance with the provisions hereof, and, except to the extent provided in the Schedules, Provider shall bear no liability for Recipient&#39;s failure to implement or obtain such service or for any difficulties in transitioning from the Transition Service to such permanent or replacement service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accrued Rights</span>. Termination or expiration of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration shall not relieve a Party from obligations that are expressly indicated to survive the termination or expiration of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surviving Obligations</span>. Without limiting the foregoing, Article&#160;I, Article&#160;V and Article&#160;VII and Sections 2.7, 2.8, 2.9, 3.2 (solely with respect to accrued, unpaid fees as of such termination or expiration), 3.3 (solely with respect to accrued, unpaid fees as of such termination or expiration), 4.1, 4.2(b)(ii), 6.3 and 6.5 shall survive the termination or expiration of this Agreement for any reason.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;VII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Solicitation</span>. During the Term of this Agreement and for a period of one (1)&#160;month after the Term, neither Party shall, directly or indirectly, in any manner solicit or induce for employment, or hire or engage the services of, any employee of the other Party without the other Party&#39;s prior written consent. A general advertisement or notice of a job listing or opening or other similar general publication of a job search or availability of employment positions, including on the internet, shall not be construed as a solicitation or inducement for the purposes of this provision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Force Majeure</span>. Provider shall not be liable for any failure to perform or any delays in performance (other than the payment of money owed and the providing of indemnity and defense), and Provider shall not be deemed to be in breach or default of its obligations set forth in this Agreement, if, to the extent and for so long as, such failure or delay is due to any causes that are beyond its reasonable control and not to its fault or negligence, including, such causes as acts of God, epidemic, pandemic, natural disasters, fire, flood, severe storm, earthquake, civil disturbance, strike, lockout, riot, order of any court or administrative body, embargo, acts of government, war (whether or not declared), acts of terrorism, or other similar causes. For clarity, in the event of any such delay, the time for performance shall be extended for a period equal to the time lost by reason of the delay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Complete Agreement: Construction</span>. This Agreement, including the Schedules hereto, shall constitute the entire agreement between the Parties with respect to the subject matter hereof and shall supersede all previous negotiations, commitments and writings with respect to such subject matter. In the event of any inconsistency between this Agreement and any Schedule hereto, this Agreement shall prevail. No rule&#160;of construction that disfavors the drafting party will apply to this Agreement. As used in this Agreement, &#8220;including&#8221; and words of similar import mean &#8220;including but not limited to.&#8221; The use of &#8220;or&#8221; will not be deemed to be exclusive<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</span>. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become effective when one or more such counterparts have been signed by each of the Parties and delivered to the other Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</span>. All notices and other communications hereunder shall be in writing and hand delivered or mailed by registered or certified mail (return receipt requested) or sent by any means of electronic message transmission with delivery confirmed (by read receipt, voice or otherwise) to the parties at the following addresses (or at such other addresses for a party as shall be specified by like notice) and will be deemed given on the date on which such notice is received:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">To Ligand:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Ligand Pharmaceuticals Incorporated</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">3911 Sorrento Valley Blvd., Suite&#160;110</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">San Diego, CA 92121</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Attn: Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Email: tespinoza@ligand.com</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">To OmniAb:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">OmniAb Incorporated</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">5980 Horton St., Suite&#160;405</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Emeryville, California 94608</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Attn: Chief Legal Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Email: cberkman@omniab.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waivers</span>. The failure of any Party to require strict performance by any other Party of any provision in this Agreement will not waive or diminish that Party&#39;s right to demand strict performance thereafter of that or any other provision hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments</span>. This Agreement may not be modified or amended except by an agreement in writing signed by each of the Parties hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</span>. This Agreement shall not be assignable, in whole or in part, directly or indirectly; <i style="font-style:italic;">provided, however</i>, that (a)&#160;either Party may assign this Agreement without the other&#39;s consent to any of its controlled Affiliates and (b)&#160;either Party may assign this Agreement in its entirety to any successor to its business, whether by merger, reorganization or otherwise; <i style="font-style:italic;">provided, further</i>, that any such assignment shall not relieve the assignor of its obligations under this Agreement. Any attempt to assign any rights or obligations arising under this Agreement in contravention with this paragraph shall be null and void <i style="font-style:italic;">ab initio</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</span>. The provisions of this Agreement shall be binding upon, inure to the benefit of and be enforceable by the Parties and their respective successors and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Beneficiaries</span>. This Agreement is solely for the benefit of the Parties hereto and should not be deemed to confer upon third parties any remedy, claim, liability, reimbursement, claim of action or other right in excess of those existing without reference to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title and Headings</span>. Titles and headings to sections herein are inserted for the convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.12</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedules</span>. The Schedules to this Agreement shall be construed with and as an integral part of this Agreement to the same extent as if the same had been set forth verbatim herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.13</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</span>. This Agreement shall be governed by and construed in accordance with the laws of the State of California (without regard to its conflicts of Law doctrines).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.14</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</span>. In the event any one or more of the provisions contained in this Agreement should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein and therein shall not in any way be affected or impaired thereby. The Parties shall endeavor in good-faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions, the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.15</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Relationship of Parties</span>. Nothing in this Agreement shall be deemed or construed by the Parties or any third party as creating a partnership or the relationship of principal and agent or joint venturer between the Parties, it being understood and agreed that no provision contained herein, and no act of the Parties, shall be deemed to create any relationship between the Parties other than the relationship of Provider and Recipient of the Transition Services nor be deemed to vest any rights, interests or claims in any third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.16</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</span>. During the Term, Provider shall carry commercially appropriate and customary levels of insurance with a reputable insurance provider covering business interruptions and general liability insurance (including errors&#160;&amp; omissions and contractual liability) to protect its own business and property interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.17</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Audit</span>. During the term of this Agreement and for one (1)&#160;year thereafter (or such longer period as may be required by applicable Law), Provider and Recipient shall each use commercially reasonable efforts to maintain complete and accurate records </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">related to any Transition Service provided, fees invoiced and payments made hereunder (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Service Records</span>&#8221;). Recipient may request a certified audit of Provider&#39;s Service Records from the date of commencement of the Transition Services to be performed by an independent certified public accountant which (a)&#160;is reasonably acceptable to Provider and (b)&#160;may not be compensated on a contingency basis or otherwise have any financial interest in the outcome of such audit. Any such audit shall be at the expense of Recipient. Recipient may not request such an audit more than one (1)&#160;time within any twelve (12) month period with respect to any particular Transition Service. The accountant shall be required to execute a confidentiality and non-disclosure agreement if requested by Provider and shall hold all information confidential. The accountant may reveal to Recipient only the amounts of any underpayment or under reimbursement, or overbilling, as applicable. The accountant shall provide to Provider a final report of its work, including both overbilling and underpayment information. The audit shall take place during normal business hours and upon reasonable notice and such accountant shall use commercially reasonable efforts to minimize interference with the normal business activities of Provider. If any audit reveals an overpayment by Recipient, Provider shall promptly refund to Recipient any such overpayment. In addition, if any audit reveals an overpayment by Recipient exceeding five percent (5%) during the audited period, Provider shall reimburse Recipient for the costs of conducting such audit. If any audit reveals an underpayment by Recipient, Recipient shall promptly pay Provider such underpayment amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Signature Page&#160;Follows)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-style:italic;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_761b08d9_1d67_4530_b69a_c9c24414274c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Execution Copy</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;width:50.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">LIGAND PHARMACEUTICALS INCORPORATED</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:45.51%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45.51%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">OMNIAB,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:45.51%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45.51%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1684d00d_b5ba_4ea5_88ad_3c683864a44a"></a><a id="AnnexF2_966364"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Annex F-2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Execution Copy</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">TRANSITION SERVICES AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">This TRANSITION SERVICES AGREEMENT (this &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</span>&#8221;), effective as of the Distribution Time of the Separation and Distribution Agreement (as defined below) (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</span>&#8221;), by and between OmniAb,&#160;Inc., a Delaware corporation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OmniAb</span>&#8221; or &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Provider</span>&#8221;), and Ligand Pharmaceuticals Incorporated, a Delaware Corporation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ligand</span>&#8221;). Each of Provider and Ligand may be referred to herein individually as a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Party</span>&#8221; and collectively as the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</span>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, OmniAb and Ligand are parties to a certain Separation and Distribution Agreement dated as of March&#160;23, 2022 (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation and Distribution Agreement</span>&#8221;), pursuant to which OmniAb has agreed to perform, and Ligand has agreed to receive, certain Transition Services (as defined below) with respect to Ligand&#39;s operation of the Ligand Retained Business (as defined in the Separation and Distribution Agreement), subject to, and in accordance with, the terms and conditions contained herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions hereinafter set forth and set forth in the Separation and Distribution Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as set forth herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;VIII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DEFINITIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Defined Terms</span>. Unless otherwise specifically provided herein, capitalized terms used, but not otherwise defined, herein shall have the meanings ascribed thereto in the Separation and Distribution Agreement. As used herein, the following terms have the following meanings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliate(s)</span>&#8221; means, with respect to a particular entity or Person, any Person that controls, is controlled by, or is under common control with that Party. For the purpose of this definition, &#8220;control&#8221; will mean, direct or indirect ownership of more than 50% of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or more than 50% of the equity interest in the case of any other type of legal entity, status as a general partner in any partnership, or any other arrangement whereby the entity or Person controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity, or the ability to cause the direction of the management or policies of a corporation or other entity. For purposes of this Agreement, OmniAb and Ligand shall not be considered Affiliates of each other.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Authority</span>&#8221; means (a)&#160;any court, agency, department, authority or other instrumentality of any national, state, county, city or other political subdivision; (b)&#160;any public international organization; or (c)&#160;any department, agency or instrumentality thereof, including any company, business, enterprise or other entity owned or controlled, in whole or in part, by any government.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</span>&#8221; means any and all intellectual property and other proprietary rights throughout the world, including any and all state, United States, international and/or foreign or other territorial or regional rights in, arising out of or associated with any of the following: (a)&#160;all patents and applications therefor, including all related provisionals, continuations, continuations-in-part, divisionals, reissues, renewals and extensions (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patents</span>&#8221;), (b)&#160;all inventions (whether patentable or not), invention disclosures, improvements, trade secrets, proprietary information, know how (including formulations, specifications, formulae, manufacturing and other processes, operating procedures, methods, techniques and all research and development information), technology, technical data and customer lists, and all documentation relating to any of the foregoing, (c)&#160;all copyrights, copyrightable works, copyright registrations and applications therefor, including all rights of authorship, use, publication, reproduction, distribution, performance and transformation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Copyrights</span>&#8221;), (d)&#160;all industrial designs and any registrations and applications therefor, (e)&#160;all domain names, uniform resource locators and other names and locators associated with the internet (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Domain Names</span>&#8221;), and all social media accounts and handles and app registrations, (f)&#160;all trade names, logos, common law trademarks and service marks, trademark and service mark registrations and applications therefor and all goodwill associated therewith (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trademarks</span>&#8221;), (g)&#160;all rights in databases and data collections, (h)&#160;all moral and economic rights of authors and inventors, however denominated, (i)&#160;rights in computer software (including source code, object code, firmware, algorithms, </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">operating systems and specifications) and related technology, (j)&#160;all rights in content (including text, graphics, images, audio, video and data) and computer software included on or used to operate and maintain any websites, including all rights in documentation, files, cgi and other scripts and programming code, (k)&#160;all rights of publicity or privacy, including with respect to name, likeness or persona, and (l)&#160;all rights to sue or recover and retain damages and costs and attorneys&#39; fees for the past, present or future infringement, dilution, misappropriation, or other violation of any of the foregoing anywhere in the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Law</span>&#8221; means any law (including common law), statute, code, ordinance, rule, regulation, order or charge of any Governmental Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Person</span>&#8221; means any individual, partnership, limited liability company, firm, corporation, association, trust, unincorporated organization or other entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>&#160;&#8221;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Personal Information</span>&#8221; means&#160;any data or&#160;information that identifies,&#160;relates to, describes, is reasonably capable of being associated with, or could reasonably be linked, directly or indirectly, with a particular natural person or household (including any information related to the health of a person) and any information derived from the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representatives</span>&#8221; means, as to any Person, such Person&#39;s Affiliates and its and their successors, owners, controlling Persons, directors, officers, employees, agents, representatives, subcontractors, or other third party acting for or on its behalf, including, as to Provider, any Vendor providing any Transition Services as permitted in this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recipient</span>&#8221; means, with respect to a particular Transition Service, either Ligand or the applicable member of the Ligand Group (as defined in the Separation and Distribution Agreement) receiving such Transition Service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;IX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TRANSITION SERVICES PROVIDED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Services.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Upon the terms and subject to the conditions set forth in this Agreement, Provider shall provide, or cause one or more of its Representatives to provide, to Recipient each of the services set forth on Schedule A attached hereto (hereinafter referred to individually as a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Service</span>&#8221;, and collectively as the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Services</span>&#8221;), at the corresponding costs set forth on Schedule A, and Recipient agrees to receive the Transition Services and pay the costs therefor during the time period specified for each such Transition Service in such Schedule or for such other time period as permitted pursuant to this Agreement (hereinafter referred to collectively as the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Service Periods</span>&#8221; for all of the Transition Services, and individually a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Service Period</span>&#8221; for each Transition Service). The Parties may amend the scale and scope of the Transition Services from time to time upon mutual agreement by executing a signed amendment to Schedule A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>If, within three (3)&#160;months following the Effective Date, Recipient identifies in good faith any service that was provided by Provider or one of its Affiliates (excluding the Ligand Group) to the Ligand Retained Business during the six (6)&#160;month period (or twelve (12) month period solely with respect to activities that are customarily performed on an annual basis) prior to the Effective Date that is not listed on Schedule A and is necessary to effectuate the Separation (an &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Omitted Service</span>&#8221;), then Recipient shall notify Provider thereof and Schedule A will be deemed amended to include such Omitted Service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Personnel; Affiliates; Vendors</span>. In providing the Transition Services, Provider may, as it deems necessary or appropriate, (i)&#160;use the qualified personnel of Provider or its Affiliates, and (ii)&#160;employ the services of qualified third parties (&#8220;Vendors&#8221;) to the extent that, and subject to the condition that, such Vendor&#39;s services (A)&#160;were utilized by or for the benefit of the Ligand Retained Business prior to the Effective Date, (B)&#160;are routinely utilized to provide similar services to other businesses of Provider or (C)&#160;are reasonably necessary for the efficient performance of such Transition Services. Furthermore, each Party shall, and shall cause its Representatives to, comply, in all material respects, with all Laws which may be applicable to the Transition Services. Each Party shall be responsible for its Representatives, including for such Representatives adhering to any health, safety, and security regulations and other published policies of the other Party while on the other Party&#39;s premises or when given access to any equipment, computer, databases, systems, software, network or other files (collectively, &#8220;Systems&#8221;) owned or controlled by the other Party. If a Party or one or more of its Representatives needs access to the premises or Systems of the other Party or one or more of its Representatives to provide or receive the Transition Services (as applicable), then (x)&#160;the accessing Party shall advise the other Party in writing in </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">advance of such access of the name of each of the accessing Party&#39;s Representatives who shall require such access, (y)&#160;the accessing Party and its Representatives shall not attempt to obtain access to, use or interfere with any of the premises or Systems of the other Party or such other Party&#39;s Representatives, except to the extent permitted by the other Party or required to do so to provide or receive the Transition Services (as applicable), and (z)&#160;the accessing Party and its Representatives shall not intentionally damage, disrupt or impair the normal operation of any of the premises or Systems of the other Party or such other Party&#39;s Representatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Coordinators</span>. Each of Provider and Recipient shall nominate a representative to act as its primary contact person to coordinate the provision of all Transition Services (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Primary Coordinators</span>&#8221;). Each Primary Coordinator may designate one or more service coordinators for each specific Transition Service (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Service Coordinators</span>&#8221;). Each Party may treat an act of a Primary Coordinator or Service Coordinator of another Party as being authorized by such other Party without inquiring behind such act or ascertaining whether such Primary Coordinator or Service Coordinator had authority to so act, <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that no such Primary Coordinator or Service Coordinator has authority to amend this Agreement. Provider and Recipient shall advise each other promptly (in any case no more than five (5)&#160;business days) in writing of any change in the Primary Coordinators and any Service Coordinator for a particular Transition Service, setting forth the name of the Primary Coordinator or Service Coordinator to be replaced and the name of the replacement, and certifying that the replacement Primary Coordinator or Service Coordinator is authorized to act for such Party in all matters relating to this Agreement, in the case of a Primary Coordinator or, in the case of a Service Coordinator, with respect to the Transition Service for which such Service Coordinator has been designated. Provider and Recipient each agrees that all communications relating to the provision of the Transition Services shall be directed to the Service Coordinators for such Transition Service with copies to the Primary Coordinators. Provider&#39;s initial Primary Coordinator shall be Matt Foehr. Recipient&#39;s initial Primary Coordinator shall be Matthew Korenberg.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level of Transition Services</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Recipient acknowledges and agrees that Provider is not in the business of providing services to third parties and is entering into this Agreement only in connection with the Separation and Distribution Agreement. Provider shall, and shall cause each of its Representatives to, provide the Transition Services with substantially the same degree of skill, quality and standard of care as that utilized by Provider (or its Affiliates) to perform similar activities in the six (6)&#160;month period (or twelve (12) month period solely with respect to activities that are customarily performed on an annual basis) prior to the Effective Date, and, in any event, no less than with commercially reasonable care and diligence (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Services Standard</span>&#8221;). Under no circumstances shall Provider or any of its Representatives be held accountable to a greater standard of care, efforts or skill than the Services Standard in the performance of the Transition Services. Recipient acknowledges and agrees that (i)&#160;the Transition Services do not include the exercise of business judgment or general management for Provider and (ii)&#160;NEITHER PROVIDER NOR ANY OF ITS AFFILIATES MAKES ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED,&#160;INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE TRANSITION SERVICES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>If the Transition Services to be provided to Recipient materially increase in scale or in scope as compared to the level of the similar services provided in connection with the operation of the Ligand Retained Business as of the Effective Date, Provider may, at its election, choose to not provide such increased scale or scope of Transition Services, and if Provider elects to perform such increased scale or scope of Transition Services, all costs incurred in connection therewith shall be mutually agreed upon by Provider and Recipient prior to the time such additional Transition Services are performed, shall be set forth in an amended Schedule A, and shall be borne by Recipient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>In addition to being subject to the terms and conditions of this Agreement for the provision of the Transition Services, Provider and Recipient each agree that the Transition Services provided by any Vendor shall be subject to the terms and conditions of any agreements between Provider and such Vendor, which agreements shall be on substantially the same conditions as Provider would enter into with such Vendor for its own account, and no such agreements shall be binding on Recipient after the Term hereof without Recipient&#39;s express written consent. Provider shall consult with Recipient concerning the terms and conditions of any such agreements to be entered into, or proposed to be entered into, or amended, with any Vendors after the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Without relieving Provider of its obligation to perform the Transition Services in accordance with the Services Standard, Provider shall not be (i)&#160;obligated to perform the Transition Services to the extent that such performance would be unlawful or that would require Provider to violate applicable Law; (ii)&#160;obligated to perform the Transition Services to the extent that such performance, in Provider&#39;s reasonable determination, could create deficiencies in Provider&#39;s controls over financial information or </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">adversely affect the maintenance of Provider&#39;s financial books and records or the preparation of its financial statements; (iii)&#160;obligated to hire any additional employees to perform the Transition Services or maintain the employment of any specific employee; (iv)&#160;obligated to hire replacements for employees that resign, retire or are terminated; (v)&#160;obligated to enter into retention agreements with employees or otherwise provide any incentive beyond payment of regular salary and benefits; (vi)&#160;prevented from transferring after the Effective Date any employees who were supporting the business operations as of the Effective Date to support other business operations for Provider or its Affiliates or to assume other roles with Provider or its Affiliates to the extent such employees are not required to provide Transition Services; (vii)&#160;prevented from determining, in its sole discretion, the individual employees who will provide Transition Services; or (viii)&#160;obligated to purchase, lease or license any additional equipment or software.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transitional Nature of Services</span>. Recipient acknowledges and agrees that the Transition Services are intended only to be transitional in nature, and shall be furnished by Provider only during the Service Periods. Recipient shall use commercially reasonable efforts to have sufficient resources available to it at the end of the Service Periods to perform the Transition Services (or have the Transition Services performed) without the involvement of Provider, its Affiliates or any of its or their respective employees or agents upon the termination or expiration of a Service Period for an applicable Transition Service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Location of Services Provided; Travel Expenses</span>. Provider shall provide the Transition Services to Recipient from locations of Provider&#39;s choice in its sole discretion except to the extent the nature of the Transition Services necessitates performance at a specific location, as mutually agreed upon by the Parties. Subject to Section&#160;3.1, should the provision of the Transition Services require any directors, officers, employees, agents, representatives, or subcontractors of Provider or its Affiliates to travel beyond fifty (50) miles from his or her employment location, Recipient shall reimburse Provider for all reasonable travel-related out-of-pocket costs, consistent with Provider&#39;s travel policy as provided to Recipient in advance in writing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitation of Liability</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Parties hereto acknowledge and agree that the Transition Services are provided by Provider: (a)&#160;at the request of Recipient in order to accommodate it following the closing under the Separation and Distribution Agreement; (b)&#160;at the costs set forth on Schedule A hereto and with no expectation of profit being made by Provider thereon; and (c)&#160;with the expectation that Provider is not assuming any financial or operational risks, including those usually assumed by a service provider, except for those risks explicitly set forth herein. Accordingly, each Party agrees that, absent gross negligence or willful misconduct, and except for breaches of Article&#160;V (Confidentiality) and except for a Party&#39;s obligations under Section&#160;2.8 (Indemnification), the other Party, its Affiliates and their directors, officers, employees, representatives, consultants and agents shall not be liable for any indirect, special, incidental or consequential damages, including lost profits or savings, whether or not such damages are foreseeable, or for any third party claims relating to the Transition Services or each Party&#39;s performance under this Agreement. Notwithstanding anything to the contrary contained herein, in the event Provider commits an error with respect to or incorrectly performs or fails to perform any Transition Service, at Recipient&#39;s request, Provider shall use commercially reasonable efforts and in good faith attempt to correct such error, re-perform or perform such Transition Service at no additional cost to Recipient; <i style="font-style:italic;">provided </i>that, absent gross negligence or willful misconduct, and assuming that Provider uses commercially reasonable data backup processes, Provider shall have no obligation to recreate any lost or destroyed data to the extent the same cannot be cured by the re-performance of the Transition Service in question.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Recipient shall indemnify, defend and hold harmless Provider and its Affiliates and its and their respective officers, directors, employees, representatives, subcontractors and agents from and against any and all damages, liabilities, losses, taxes, fines, penalties, costs and expenses (including, without limitation, reasonable fees of counsel) incurred by any of them in connection with any Third Party Claim (as defined below) (each, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Loss</span>&#8221; and, collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Losses</span>&#8221;) relating to, arising out of or resulting from or based on (i)&#160;Recipient&#39;s material breach of this Agreement or (ii)&#160;any gross negligence or willful misconduct of Recipient, (iii)&#160;Provider&#39;s provision of the Transition Services as directed or requested by Recipient, or (iv)&#160;Recipient&#39;s use or exploitation of any work product provided by Provider in the performance of the Transition Services, except in each case (i), (ii), (iii), and (iv)&#160;to the extent such Losses are subject to indemnification pursuant to Section&#160;2.8(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Provider hereby agrees to indemnify, defend and hold harmless Recipient and its Affiliates and its and their respective officers, directors, employees, representatives, subcontractors and agents from and against any and all Losses relating to, arising out of or resulting from (i)&#160;Provider&#39;s material breach of this Agreement or (ii)&#160;any gross negligence or willful misconduct in the </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">performance of its obligations under this Agreement, except in each case of (i)&#160;and (ii)&#160;to the extent such Losses are subject to indemnification pursuant to Section&#160;2.8(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>To the maximum extent permitted by applicable Law, each Party&#39;s and its Affiliates&#39; and each of its and their respective subcontractors&#39; officers&#39;, directors&#39;, employees&#39; and agents&#39; sole and exclusive remedy with respect to any and all claims relating to the Transition Services shall be pursuant to the indemnification provisions set forth in this Section&#160;2.8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification Procedures</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>If any claim or demand is made by a third party (including any action or proceeding commenced or threatened to be commenced) with respect to which a Party seeking indemnification (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Party</span>&#8221;) intends to seek indemnity under Section&#160;2.8 (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Claim</span>&#8221;), the Indemnified Party shall promptly give written notice thereof to the other Party (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnifying Party</span>&#8221;) indicating, with reasonable specificity, the nature of such Third Party Claim, the basis therefor, and a copy of any documentation received from such third party. A failure by the Indemnified Party to give notice and to tender the defense of any action or proceeding in a timely manner pursuant to this Section&#160;2.9(a)&#160;shall not limit the obligation of the Indemnifying Party under Section&#160;2.8, except to the extent such Indemnifying Party is actually and materially prejudiced thereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Upon receipt of a notice for indemnity from the Indemnified Party pursuant to Section&#160;2.9(a)&#160;with respect to any Third Party Claim, the Indemnifying Party shall have the right to assume the defense of, at its own expense and by its own counsel, any such Third Party Claim. If the Indemnifying Party shall, in accordance with the immediately preceding sentence, undertake to compromise or defend any such Third Party Claim, it shall notify the Indemnified Party of its intention to do so, and the Indemnified Party shall agree to cooperate with the Indemnifying Party and its counsel in the compromise of, or defense against, any such Third Party Claim; <i style="font-style:italic;">provided </i>that the Indemnifying Party shall not settle or compromise any such Third Party Claim without the written consent of the Indemnified Party (not to be unreasonably withheld, conditioned or delayed) unless such settlement or compromise fully and irrevocably releases the Indemnified Party in connection with such Third Party Claim and provides relief consisting solely of money damages borne by the Indemnifying Party. Notwithstanding an election of the Indemnifying Party to assume the defense of such Third Party Claim, the Indemnified Party shall have the right to employ separate legal counsel, its own cost and expense, and to participate in the defense thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Modification of Transition Services Procedures</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Subject to the procedure set forth in this Section&#160;2.10 to the extent applicable, Provider may make changes from time to time in its standards and procedures for performing the Transition Services, <i style="font-style:italic;">provided</i> that any such change shall not interfere in any material respect with the continued provision or cost of the Transition Services. Notwithstanding the foregoing sentence, unless required by Law, Provider shall not implement any substantial or material changes to such standards and procedures in a manner affecting the operation of the Ligand Retained Business unless Recipient agrees in writing to such changes and Provider gives Recipient ten (10)&#160;business days to adapt its operations to accommodate such changes to the extent commercially reasonable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>During the term of this Agreement, if Recipient intends to make any changes that may affect the provision of any of the Transition Services, Recipient shall provide Provider with a plan identifying any changes as soon as reasonably practicable, but in any case no less than ten (10)&#160;business days before implementing such changes; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that Provider shall not be required to alter the method in which it provides any of the Transition Services or increase the level of any such Transition Services in any material manner except as expressly provided herein; <i style="font-style:italic;">provided, further, however, </i>that the failure of Recipient to provide such notice shall not alter or diminish Provider&#39;s obligations to provide the Transition Services on the terms set forth herein except where the failure to provide notice has materially increased Provider&#39;s cost or burden to provide such Transition Service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation</span>. The Parties will use commercially reasonable efforts to reasonably cooperate and cause each of their respective Representatives to reasonably cooperate in a professional and workmanlike manner with each other to the extent necessary to assist the other Party in performance of its obligations under this Agreement, including with respect to the provision and receipt of the Transition Services. Such cooperation shall include exchanging information relevant to and reasonably necessary for the provision or receipt of the Transition Services hereunder and the performance of such other duties and tasks as may be reasonably required for the provision or receipt of the Transition Services. Without limiting the foregoing:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Recipient shall permit Provider and its Representatives reasonable access during regular business hours (or otherwise upon reasonable prior notice) to any data, records and personnel involved in receiving or overseeing the Transition Services as reasonably requested by Provider to facilitate Provider&#39;s performance of this Agreement. Any such data and records shall be subject to Article&#160;V. Before the Parties exchange any Personal Information in connection with the Transition Services, the Parties will enter into a data processing agreement in accordance with applicable Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Provider shall use commercially reasonable efforts to obtain any consents, licenses, waivers or approvals necessary to permit Provider to perform its obligations hereunder; <i style="font-style:italic;">provided, however,</i> that under no circumstances shall Provider be obligated to provide the relevant part of any Transition Services to the extent that (i)&#160;Provider is unable to obtain necessary third party consents, licenses, waivers or approvals relating to such part of the Transition Services on commercially reasonable terms, (ii)&#160;in order to provide such part of the Transition Services, Provider will have an obligation to make any payments to any Third Party or incur any obligations in respect of any such consents, licenses, waivers or approvals, which payments are not subject to reimbursement by Recipient or which other obligations are not assumed by Recipient hereunder, (iii)&#160;Provider would be obligated to make any alternative arrangements in the event that any such consents, licenses, waivers or approvals are not obtained (but only to the extent such arrangements would not be commercially reasonable) or (iv)&#160;Provider would be required to seek broader rights or more favorable terms with respect to any consents, licenses, waivers or approvals than those applicable immediately prior to the date hereof where the costs of obtaining the same are not subject to reimbursement by Recipient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Recipient shall obtain all necessary consents, licenses, waivers and approvals necessary for it to receive the Transition Services and perform its obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;X</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consideration</span>. As consideration for the Transition Services, Recipient shall pay to Provider the amount specified for each such Transition Service as set forth in Schedule A, including any &#8220;pass-through costs&#8221; expressly identified as such in Schedule A. The fees set forth on Schedule A will be equitably reduced if any Transition Service is suspended, terminated or removed from the scope of this Agreement and will be equitably prorated for partial months. In addition, Recipient shall reimburse Provider (upon receipt of applicable receipts and other reasonable supporting documentation if requested by Provider) for all reasonable documented out of pocket costs of Provider in connection with performance of the Transition Services by Provider, including: (a)&#160;shipping and transportation costs (including the cost of any insurance related thereto), duties and other taxes (excluding taxes on Provider&#39;s income); (b)&#160;travel-related costs, (c)&#160;out of pocket costs or expenses incurred with third parties by Provider, its Affiliates or subcontractors, including for the extraction, conversion and transfer of data and (d)&#160;any other out of pocket costs and expenses incurred with third parties described herein as reimbursable by Provider (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reimbursable Expenses</span>&#8221;); <i style="font-style:italic;">provided</i> that if any particular Reimbursable Expense exceeds Ten Thousand Dollars ($10,000), Provider must obtain Recipient&#39;s consent prior to any obligation of Recipient to reimburse Provider for such Reimbursable Expense; <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided, further</i> that until Recipient consents to such Reimbursable Expenses exceeding Ten Thousand Dollars ($10,000), Provider shall not be required to provide the relevant part of the Transition Services for which such Reimbursable Expenses exceeding Ten Thousand Dollars ($10,000) is necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Invoices</span>. Provider shall, on a monthly basis on the last day of each calendar month, submit a single itemized invoice to Recipient for all Transition Services provided to Recipient during such month. All invoices shall be sent to the attention of the Primary Coordinators at the address set forth in Section&#160;7.5 hereof or to such other address as Recipient shall have specified by notice in writing to Provider.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment of Invoices</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Recipient shall pay any undisputed invoice for Transition Services promptly but in no event later than thirty (30) days after the date of receipt of such invoice and such payment shall be made by wire transfer of immediately available funds to such bank account as shall have been notified in writing to Recipient by Provider. Payment of all invoices in respect of the Transition Services shall be made by check or electronic funds transmission in U.S. Dollars, without any offset or deduction of any nature whatsoever (except that offset or deduction may be made in regard to other invoiced amounts due under this Agreement or to the extent of a dispute in good faith concerning amounts due under this Agreement). All payments shall be made to the account designated by Provider to Recipient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>If any payment is not paid when due (except to the extent disputed in good faith) and Recipient does not make such payment within thirty (30) days of receiving a past-due notice from Provider, Provider shall have the right, without any liability to Recipient, or anyone claiming by or through Recipient, to, upon written notice to Recipient, immediately cease providing any or all of the Transition Services provided by Provider to Recipient and/or to terminate this Agreement in its entirety, which right may be exercised by Provider in its sole and absolute discretion. Notwithstanding the above, Provider shall not cease providing any Transition Service or terminate this Agreement if such lack of payment is due to a good faith dispute, the details of which Recipient has indicated to Provider in writing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;XI</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OWNERSHIP OF INTELLECTUAL PROPERTY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ownership; Delivery</span>. Except as expressly set forth herein, neither Party will obtain, by virtue of this Agreement or the Transition Services, by implication or otherwise, any rights of ownership or use of any property or Intellectual Property owned by the other. All Intellectual Property conceived, created or made by Provider or any of its Representatives (whether alone or jointly with Recipient) in the course of Provider&#39;s performance of the Transition Services and other activities under this Agreement that are (a)&#160;exclusively related to the Ligand Retained Business and/or (b)&#160;based on, derived from, or improvements of any of Recipient&#39;s background Intellectual Property (altogether, (a)&#160;and (b), the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assigned IP</span>&#8221;) shall be solely owned by Recipient, and Provider hereby assigns to Recipient all of Provider&#39;s right, title, and interest in and to such Assigned IP. All other Intellectual Property conceived, created or made by Provider or any of its Representatives in the course of Provider&#39;s or such Representative&#39;s performance of any Transition Services or other activities under this Agreement shall be solely owned by Provider.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limited Licenses</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Recipient (on behalf of itself and its controlled Affiliates) hereby grants to Provider a limited, non-exclusive, royalty-free, non-transferable license, with the right to grant sublicenses to its Affiliates and its and their subcontractors during the Service Periods, under the Intellectual Property owned or controlled by Recipient, solely to the extent necessary for Provider and its Affiliates and its and their subcontractors to perform the Transition Services hereunder for the benefit of Recipient during the applicable Services Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Provider (on behalf of itself and its controlled Affiliates) hereby grants to Recipient and its Affiliates a limited, non-exclusive, royalty-free, non-transferable license, with the right to grant sublicenses to its and their Affiliates and subcontractors, under the Intellectual Property owned or controlled by Provider, solely to the extent necessary for Recipient and its Affiliates and its and their subcontractors to (i)&#160;receive the Transition Services during the applicable Service Period and/or (ii)&#160;use or exploit any deliverables provided by Provider to Recipient as part of the Transition Services in the operation of the Ligand Retained Business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;XII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CONFIDENTIALITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Each Party recognizes that in the performance of this Agreement, or as a result of the Parties&#39; ongoing relationship, non-public, Confidential Information (as defined in the Separation and Distribution Agreement) belonging to the other Party regarding the Transition Services may be disclosed or become known to the Party or its Affiliates. Unless otherwise expressed in writing to the other Party, confidential information and confidential materials concerning a Party&#39;s business and products (including information and materials contained in technical data, information concerning the Ligand Retained Business, financial information and data, strategies and marketing and customer information), including that expressed orally, that is exchanged between the Parties in connection with the performance of this Agreement shall be considered to be Confidential Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Notwithstanding any termination of this Agreement, Provider and Recipient shall hold and shall cause their respective Representatives to hold, in strict confidence (and not to disclose or release or, except as otherwise permitted by this Agreement or the Separation and Distribution Agreement, use, including for any ongoing or future commercial purpose, without the prior written consent of the Party to whom the Confidential Information relates (which may be withheld in such Party&#39;s sole and absolute discretion, except where disclosure is required by applicable Law), any and all Confidential Information concerning or </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">belonging to the other Party or its Affiliates; <i style="font-style:italic;">provided</i> that each Party may disclose, or may permit disclosure of, Confidential Information: (i)&#160;to its respective auditors, attorneys, financial advisors, bankers and other appropriate consultants and advisors who have a need to know such Information (as defined in the Separation and Distribution Agreement) for auditing and other non-commercial purposes and are informed of the obligation to hold such Information confidential and in respect of whose failure to comply with such obligations, the applicable Party will be responsible, (ii)&#160;if any Party or its Affiliates or any of its respective Subsidiaries is required or compelled to disclose any such Confidential Information by judicial or administrative process or by other requirements of Law or stock exchange rule&#160;or is advised by outside counsel in connection with a proceeding brought by a Governmental Authority that it is advisable to do so, (iii)&#160;as required in connection with any legal or other proceeding by one Party against the other Party or in respect of claims by one Party against the other Party brought in a proceeding, (iv)&#160;as necessary in order to permit a Party to prepare and disclose its financial statements in connection with any regulatory filings or tax returns, (v)&#160;as necessary for a Party to enforce its rights or perform its obligations under this Agreement or the Separation and Distribution Agreement, (vi)&#160;to Governmental Authorities in accordance with applicable procurement regulations and contract requirements or (vii)&#160;to other Persons in connection with their evaluation of, and negotiating and consummating, a potential strategic transaction, to the extent reasonably necessary in connection therewith, provided an appropriate and customary confidentiality agreement has been entered into with the Person receiving such Confidential Information at least as protective of such Confidential Information as this Agreement. Notwithstanding the foregoing, in the event that any demand or request for disclosure of Confidential Information is made by a third party pursuant to clause (ii), (iii), (v)&#160;or (vi)&#160;above, each Party, as applicable, shall promptly notify (to the extent permissible by Law) the Party to whom the Confidential Information relates of the existence of such request, demand or disclosure requirement and shall provide such affected Party a reasonable opportunity to seek an appropriate protective order or other remedy, which such Party will cooperate in obtaining to the extent reasonably practicable. In the event that such appropriate protective order or other remedy is not obtained, the Party which faces the disclosure requirement shall furnish only that portion of the Confidential Information that is required to be disclosed and shall take commercially reasonable steps to ensure that confidential treatment is accorded such Confidential Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Each Party acknowledges that it and its Affiliates may have in its or their possession confidential or proprietary Information of third parties that was received under confidentiality or non-disclosure agreements with such third party while such Party and/or its Affiliates were part of the Ligand Group. Each Party shall comply, shall cause its Affiliates to comply, and shall cause its and their respective officers, employees, agents, consultants and advisors (or potential buyers) to comply, with all terms and conditions of any such third-party agreements entered into prior to the Effective Date, with respect to any confidential and proprietary Information of third parties to which it or any other member of its Group has had access.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Notwithstanding anything to the contrary set forth herein, (i)&#160;the Parties shall be deemed to have satisfied their obligations hereunder with respect to Confidential Information if they exercise at least the same degree of care that applies to Ligand&#39;s confidential and proprietary information pursuant to policies in effect as of the Effective Date and (ii)&#160;confidentiality obligations provided for in any Contract between each Party or its Affiliates or Subsidiaries and their respective employees shall remain in full force and effect. Notwithstanding anything to the contrary set forth herein, Confidential Information of a Party in the possession of and used by the other Party as of the Effective Date may continue to be used by such Party in possession of the Confidential Information in and only in the operation of the Ligand Retained Business; <i style="font-style:italic;">provided</i> that such Confidential Information may only be used by such Party and its officers, employees, agents, consultants and advisors in the specific manner and for the specific purposes for which it is used as of the Effective Date, and may only be shared with additional officers, employees, agents, consultants and advisors of such Party on a need-to-know basis exclusively with regard to such specified use; <i style="font-style:italic;">provided further</i> that such Confidential Information may be used only so long as the Confidential Information is maintained in confidence and not disclosed in violation of this Section&#160;5.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>The Parties agree that irreparable damage may occur in the event that the provisions of this Section&#160;5.1 were not performed in accordance with their specific terms. Accordingly, it is hereby agreed that the Parties shall be entitled to seek an injunction or injunctions to enforce specifically the terms and provisions hereof in any court having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>Upon expiration of the Service Periods or termination of this Agreement for any reason whatsoever, except for such retention and use as expressly provided for in the Separation and Distribution Agreement, each Party shall not disclose and shall make no further use of the other Party&#39;s Confidential Information and upon written request shall immediately destroy or, with respect to Confidential Information in written or other tangible form (including all copies thereof), return to the other Party, all such Confidential Information; <i style="font-style:italic;">provided</i> that (i)&#160;each Party shall be entitled to retain one record copy in its legal department solely to determine the extent of its continuing obligations or as otherwise required to comply with applicable Law, and </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">(ii)&#160;neither Party nor its Representatives shall be required to expunge Confidential Information from computer archiving conducted as part of established record retention policies (<i style="font-style:italic;">provided</i> that the foregoing shall not be deemed to permit the accessing, retrieval or use of any Confidential Information).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;XIII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TERM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</span>. This Agreement shall commence on the Effective Date and shall continue in full force and effect until the earliest of (a)&#160;the date on which this Agreement is terminated in accordance with this Article&#160;VI or (b)&#160;the expiration of the last Service Period, such that Provider is no longer obligated to provide any Transition Services pursuant to this Agreement (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</span>&#8221;). If no expiration date is provided for any Transition Service, then such Transition Service will terminate twelve (12) months after the Effective Date, <i style="font-style:italic;">provided</i> that Recipient shall have the right to an extension of each or any Transition Service for up to six (6)&#160;months by providing written notice to Provider in advance of the original termination date for such Transition Service if, prior to such request for extension, Recipient has used commercially reasonable efforts to establish analogous capabilities of its own. The Parties will discuss in good faith any subsequent requests to further extend the Transition Services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Services</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Recipient may, at any time prior to the end of the Service Period for any Transition Service(s)&#160;and upon thirty (30) days&#39; prior written notice to Provider, terminate any Transition Service(s)&#160;or this Agreement in its entirety, whereupon, from and after the date of termination specified in such written notice, Provider&#39;s obligation to provide such Transition Service(s)&#160;to Recipient shall cease and Recipient shall have no obligation to pay Provider for such Transition Service(s)&#160;(other than with respect to those Transition Services for which costs will be incurred by Provider as a result of non-cancellable commitments that Provider incurred in good faith in order to provide such Transition Services); <i style="font-style:italic;">provided</i> that if termination of any Transition Service materially inhibits Provider&#39;s ability to provide or prevents Provider from providing any other Transition Services (as determined in Provider&#39;s sole discretion), Provider shall promptly notify Recipient of such determination and such other Transition Services shall also shall be deemed terminated, subject to Recipient&#39;s prior written consent of such termination; and <i style="font-style:italic;">provided further</i> that partial reduction of any specific Transition Service may only be made with the prior written consent of Provider, which consent shall not be unreasonably withheld, delayed or conditioned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Except as set forth in Section&#160;3.3(b), in the event that either Party breaches any of its material obligations under this Agreement (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Breaching Party</span>&#8221;), the other Party may terminate this Agreement in its entirety upon thirty (30) days&#39; prior written notice (such thirty (30) day period, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice Period</span>&#8221;) to the Breaching Party, specifying the breach and its claim of right to terminate; <i style="font-style:italic;">provided</i>, that the termination of this Agreement shall not become effective at the end of the Notice Period if (i)&#160;the Breaching Party cures such breach during the Notice Period or (ii)&#160;such breach cannot be cured during the Notice Period and the Breaching Party commences and diligently pursues actions to cure such breach within the Notice Period, in which case the Breaching Party shall have an additional thirty (30) day period to cure such breach before such termination shall become effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Either Party may terminate this Agreement in its entirety immediately upon written notice to the other Party if the other Party (i)&#160;files in any court or with any other Governmental Authority, pursuant to any Law of any state or country, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of such other Party or of its assets; (ii)&#160;is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is not dismissed within sixty (60) days after the filing thereof; (iii)&#160;consents to the appointment or taking possession by a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of such other Party or for any substantial part of its property or makes any assignment for the benefit of creditors; (iv)&#160;admits in writing its inability to pay its debts generally as they become due; or (v)&#160;has issued or levied against its property any judgment, writ, warrant of attachment or execution or similar process that represents a substantial portion of its property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Any Transition Service, or this Agreement in its entirety, may be terminated upon the mutual written agreement of Provider and Recipient at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Obligations.</span> Recipient specifically agrees and acknowledges that all obligations of Provider to provide each Transition Service shall immediately cease upon the expiration of the Service Period (as may be extended as set forth in this </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Agreement) for such Transition Service, and Provider&#39;s obligations to provide all of the Transition Services shall immediately cease upon termination of this Agreement. Recipient shall bear sole responsibility for instituting permanent services, or obtaining replacement services, in respect of any Transition Service terminated in accordance with the provisions hereof, and, except to the extent provided in the Schedules, Provider shall bear no liability for Recipient&#39;s failure to implement or obtain such service or for any difficulties in transitioning from the Transition Service to such permanent or replacement service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accrued Rights</span>. Termination or expiration of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration shall not relieve a Party from obligations that are expressly indicated to survive the termination or expiration of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surviving Obligations</span>. Without limiting the foregoing, Article&#160;I, Article&#160;V and Article&#160;VII and Sections 2.7, 2.8, 2.9, 3.2 (solely with respect to accrued, unpaid fees as of such termination or expiration), 3.3 (solely with respect to accrued, unpaid fees as of such termination or expiration), 4.1, 4.2(b)(ii), 6.3 and 6.5 shall survive the termination or expiration of this Agreement for any reason.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;XIV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Solicitation</span>. During the Term of this Agreement and for a period of one (1)&#160;month after the Term, neither Party shall, directly or indirectly, in any manner solicit or induce for employment, or hire or engage the services of, any employee of the other Party without the other Party&#39;s prior written consent. A general advertisement or notice of a job listing or opening or other similar general publication of a job search or availability of employment positions, including on the internet, shall not be construed as a solicitation or inducement for the purposes of this provision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Force Majeure</span>. Provider shall not be liable for any failure to perform or any delays in performance (other than the payment of money owed and the providing of indemnity and defense), and Provider shall not be deemed to be in breach or default of its obligations set forth in this Agreement, if, to the extent and for so long as, such failure or delay is due to any causes that are beyond its reasonable control and not to its fault or negligence, including, such causes as acts of God, epidemic, pandemic, natural disasters, fire, flood, severe storm, earthquake, civil disturbance, strike, lockout, riot, order of any court or administrative body, embargo, acts of government, war (whether or not declared), acts of terrorism, or other similar causes. For clarity, in the event of any such delay, the time for performance shall be extended for a period equal to the time lost by reason of the delay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Complete Agreement: Construction</span>. This Agreement, including the Schedules hereto, shall constitute the entire agreement between the Parties with respect to the subject matter hereof and shall supersede all previous negotiations, commitments and writings with respect to such subject matter. In the event of any inconsistency between this Agreement and any Schedule hereto, this Agreement shall prevail. No rule&#160;of construction that disfavors the drafting party will apply to this Agreement. As used in this Agreement, &#8220;including&#8221; and words of similar import mean &#8220;including but not limited to.&#8221; The use of &#8220;or&#8221; will not be deemed to be exclusive<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</span>. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become effective when one or more such counterparts have been signed by each of the Parties and delivered to the other Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</span>. All notices and other communications hereunder shall be in writing and hand delivered or mailed by registered or certified mail (return receipt requested) or sent by any means of electronic message transmission with delivery confirmed (by read receipt, voice or otherwise) to the parties at the following addresses (or at such other addresses for a party as shall be specified by like notice) and will be deemed given on the date on which such notice is received:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">To OmniAb:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">OmniAb Incorporated</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">5980 Horton St., Suite&#160;405</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Emeryville, California 94608</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Attn: Chief Legal Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Email: cberkman@omniab.com</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">To Ligand:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Ligand Pharmaceuticals Incorporated</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">3911 Sorrento Valley Blvd., Suite&#160;110</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">San Diego, CA 92121</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Attn: Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Email: tespinoza@ligand.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waivers</span>. The failure of any Party to require strict performance by any other Party of any provision in this Agreement will not waive or diminish that Party&#39;s right to demand strict performance thereafter of that or any other provision hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments</span>. This Agreement may not be modified or amended except by an agreement in writing signed by each of the Parties hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</span>. This Agreement shall not be assignable, in whole or in part, directly or indirectly; <i style="font-style:italic;">provided, however</i>, that (a)&#160;either Party may assign this Agreement without the other&#39;s consent to any of its controlled Affiliates and (b)&#160;either Party may assign this Agreement in its entirety to any successor to its business, whether by merger, reorganization or otherwise; <i style="font-style:italic;">provided, further</i>, that any such assignment shall not relieve the assignor of its obligations under this Agreement. Any attempt to assign any rights or obligations arising under this Agreement in contravention with this paragraph shall be null and void <i style="font-style:italic;">ab initio</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</span>. The provisions of this Agreement shall be binding upon, inure to the benefit of and be enforceable by the Parties and their respective successors and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Beneficiaries</span>. This Agreement is solely for the benefit of the Parties hereto and should not be deemed to confer upon third parties any remedy, claim, liability, reimbursement, claim of action or other right in excess of those existing without reference to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title and Headings</span>. Titles and headings to sections herein are inserted for the convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.12</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedules</span>. The Schedules to this Agreement shall be construed with and as an integral part of this Agreement to the same extent as if the same had been set forth verbatim herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.13</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</span>. This Agreement shall be governed by and construed in accordance with the laws of the State of California (without regard to its conflicts of Law doctrines).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.14</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</span>. In the event any one or more of the provisions contained in this Agreement should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein and therein shall not in any way be affected or impaired thereby. The Parties shall endeavor in good-faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions, the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.15</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Relationship of Parties</span>. Nothing in this Agreement shall be deemed or construed by the Parties or any third party as creating a partnership or the relationship of principal and agent or joint venturer between the Parties, it being understood and agreed that no provision contained herein, and no act of the Parties, shall be deemed to create any relationship between the Parties other than the relationship of Provider and Recipient of the Transition Services nor be deemed to vest any rights, interests or claims in any third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.16</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</span>. During the Term, Provider shall carry commercially appropriate and customary levels of insurance with a reputable insurance provider covering business interruptions and general liability insurance (including errors&#160;&amp; omissions and contractual liability) to protect its own business and property interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.17</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Audit</span>. During the term of this Agreement and for one (1)&#160;year thereafter (or such longer period as may be required by applicable Law), Provider and Recipient shall each use commercially reasonable efforts to maintain complete and accurate records </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">related to any Transition Service provided, fees invoiced and payments made hereunder (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Service Records</span>&#8221;). Recipient may request a certified audit of Provider&#39;s Service Records from the date of commencement of the Transition Services to be performed by an independent certified public accountant which (a)&#160;is reasonably acceptable to Provider and (b)&#160;may not be compensated on a contingency basis or otherwise have any financial interest in the outcome of such audit. Any such audit shall be at the expense of Recipient. Recipient may not request such an audit more than one (1)&#160;time within any twelve (12) month period with respect to any particular Transition Service. The accountant shall be required to execute a confidentiality and non-disclosure agreement if requested by Provider and shall hold all information confidential. The accountant may reveal to Recipient only the amounts of any underpayment or under reimbursement, or overbilling, as applicable. The accountant shall provide to Provider a final report of its work, including both overbilling and underpayment information. The audit shall take place during normal business hours and upon reasonable notice and such accountant shall use commercially reasonable efforts to minimize interference with the normal business activities of Provider. If any audit reveals an overpayment by Recipient, Provider shall promptly refund to Recipient any such overpayment. In addition, if any audit reveals an overpayment by Recipient exceeding five percent (5%) during the audited period, Provider shall reimburse Recipient for the costs of conducting such audit. If any audit reveals an underpayment by Recipient, Recipient shall promptly pay Provider such underpayment amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Signature Page&#160;Follows)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">OMNIAB,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">LIGAND PHARMACEUTICALS INCORPORATED</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6.09pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6575ece5_f154_4ea6_9ba6_fc211254e2eb"></a><a id="AnnexG_313259"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Annex G</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Final Form</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">FORM&#160;OF AMENDED AND RESTATED REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">THIS AMENDED AND RESTATED REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT (this &#8220;<i style="font-style:italic;">Agreement</i>&#8221;), dated as of [&#160;&#160;&#160;&#160;&#160;&#160;], 2022, is made and entered into by and among OmniAb,&#160;Inc., a Delaware corporation, formerly known as Avista Public Acquisition Corp. II, a Cayman Islands exempted company (the &#8220;<i style="font-style:italic;">Company</i>&#8221;), Avista Acquisition LP II, a Cayman Islands exempted limited partnership (the &#8220;<i style="font-style:italic;">Sponsor</i>&#8221;), the undersigned parties listed under Existing Holder on the signature page&#160;hereto (each such party, together with the Sponsor and any person or entity deemed an &#8220;Existing Holder&#8221; who hereafter becomes a party to this Agreement pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.2</span> of this Agreement, an &#8220;<i style="font-style:italic;">Existing Holder</i>&#8221; and, collectively, the &#8220;<i style="font-style:italic;">Existing Holders</i>&#8221;), the undersigned directors and officers of Ligand (as defined below) and/or OmniAb, as applicable, who are listed as New Holders on the signature pages&#160;hereto (each such party, together with any person or entity deemed a &#8220;New Holder&#8221; who hereafter becomes a party to this Agreement pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.2</span> of this Agreement<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">,</span> a &#8220;<i style="font-style:italic;">New Holder</i>&#8221; and collectively the &#8220;<i style="font-style:italic;">New Holders</i>&#8221;) and solely with respect to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2.1</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;4</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.14</span>, Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#8220;<i style="font-style:italic;">Ligand</i>&#8221;). Capitalized terms used but not otherwise defined in this Agreement shall have the meaning ascribed to such terms in the Merger Agreement (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">RECITALS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, on August&#160;9, 2021, the Company, the Sponsor and certain other parties thereto entered into that certain Registration Rights and Shareholder Rights Agreement (the &#8220;<i style="font-style:italic;">Existing Agreement</i>&#8221;), pursuant to which the Company granted the Existing Holders certain registration rights with respect to certain securities of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Company has entered into that certain Agreement and Plan of Merger (the &#8220;<i style="font-style:italic;">Merger Agreement</i>&#8221;), dated as of March&#160;23, 2022, by and among the Company, Orwell Merger Sub,&#160;Inc., a Delaware corporation, Ligand, and [&#61623;] (formerly known as OmniAb,&#160;Inc.), a Delaware corporation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, in connection with the closing of the Transactions and subject to the terms and conditions set forth in the Merger Agreement and the other Transaction Documents, the Existing Holders and New Holders were issued shares of common stock, par value $0.0001 per share, of the Company (the &#8220;<i style="font-style:italic;">Domesticated Parent Common Stock</i>&#8221;), in each case, in such amounts and subject to such terms and conditions set forth in the Merger Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, in order to finance the Company&#8217;s transaction costs in connection with an intended Business Combination (as defined below), the Sponsor or certain of the Company&#8217;s officers or directors may, but are not obligated to, loan the Company funds as the Company may require, of which up to $2,000,000 of such loans may be convertible into an additional 1,333,333 Private Placement Warrants (as defined below) (the &#8220;<i style="font-style:italic;">Working Capital Warrants</i>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, pursuant to Section&#160;6.8 of the Existing Agreement, any of the provisions, covenants and conditions set forth therein may be amended or modified upon the written consent of the Company and the Holders (as defined therein) of at least a majority-in-interest of the Registrable Securities (as defined therein) at the time in question; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Company, Sponsor and the other parties to the Existing Agreement desire to amend and restate the Existing Agreement in order to provide the Existing Holders and the New Holders certain registration rights with respect to certain securities of the Company, as set forth in this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the mutual representations, covenants and agreements contained herein, and certain other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">G-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">DEFINITIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">1.1 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</span>. The terms defined in this <i style="font-style:italic;">Article&#160;I</i> shall, for all purposes of this Agreement, have the respective meanings set forth below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Adverse Disclosure</i>&#8221; shall mean any public disclosure of material non-public information, which disclosure, in the good faith judgment of the Board or the Chairman, Chief Executive Officer or Chief Financial Officer of the Company, after consultation with counsel to the Company, (i)&#160;would be required to be made in any Registration Statement or Prospectus in order for the applicable Registration Statement or Prospectus not to contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements contained therein (in the case of any prospectus and any preliminary prospectus, in the light of the circumstances under which they were made) not misleading, (ii)&#160;would not be required to be made at such time if the Registration Statement were not being filed, declared effective or used, as the case may be, and (iii)&#160;the Company has a bona fide business purpose for not making such information public.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Agreement</i>&#8221; shall have the meaning given in the Preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Backstop Shares</i>&#8221; shall have the meaning set forth in the A&amp;R Forward Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Backstop Warrants</i>&#8221; shall have the meaning set forth in the A&amp;R Forward Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Board</i>&#8221; shall mean the Board of Directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Commission</i>&#8221; shall mean the U.S. Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Company</i>&#8221; shall have the meaning given in the Preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">D&amp;O Lock-Up Period</i>&#8221; shall mean with respect to the shares of Domesticated Parent Common Stock issued to the New Holders in connection with the consummation of the Merger and held by the New Holders or their Permitted Transferees, the period ending on the earliest of (A)&#160;three months after the date hereof and (B)&#160;the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the Company&#8217;s stockholders having the right to exchange their shares of Domesticated Parent Common Stock for cash, securities or other property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Domesticated Parent Common Stock</i>&#8221; shall have the meaning given in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Exchange Act</i>&#8221; shall mean the Securities Exchange Act of 1934, as it may be amended from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Existing Agreement</i>&#8221; shall have the meaning given in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Existing Holders</i>&#8221; shall have the meaning given in the Preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Form&#160;S-1</i>&#8221; shall mean Form&#160;S-1 or any similar long-form registration statement that may be available at such time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Form&#160;S-3</i>&#8221; shall have the meaning given in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.2.1</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Forward Purchase Shares</i>&#8221; shall have the meaning set forth in the A&amp;R Forward Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Forward Purchase Warrants</i>&#8221; shall have the meaning set forth in the A&amp;R Forward Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Founder Shares</i>&#8221; shall mean all shares of Domesticated Parent Common Stock issued to the Existing Holders in respect of the shares of Parent Class&#160;B Common Stock held by the Existing Holders pursuant to the Domestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">&#8220;<i style="font-style:italic;">Founder Shares Lock-Up Period</i>&#8221; shall mean, with respect to the Founder Shares, the period ending on the earliest of (A)&#160;one year after the date hereof and (B)&#160;the first date on which, (x)&#160;the last reported sales price of a share of Domesticated Parent Common Stock equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">G-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">like) for any twenty (20) trading days within any thirty (30)-trading day period commencing at least one hundred fifty (150) days after the date hereof or (y)&#160;the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the Company&#8217;s stockholders having the right to exchange their shares of Domesticated Parent Common Stock for cash, securities or other property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Holder Information</i>&#8221; shall have the meaning given in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 4.1.2</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Holders</i>&#8221; shall mean the Existing Holders, the New Holders, and, solely with respect to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2.1</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;4</span>, the [L] Equity Award Holders and any person or entity who hereafter becomes a party to this Agreement pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.2</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Insider Letter</i>&#8221; shall mean any of those certain letter agreements, dated as of August&#160;9, 2021 (as amended by the Sponsor Insider Agreement entered into on the Closing Date), by and between the Company, the Sponsor and each of the Company&#8217;s officers, directors and director nominees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Ligand Equity Award Holders</i>&#8221; shall mean any Company Service Provider (as defined in the Employee Matters Agreement, dated as of March&#160;23, 2022) who hold Registrable Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Lock-Up Period</i>&#8221; shall mean the Founder Shares Lock-Up Period, the D&amp;O Lock-Up Period or the Private Warrant Lock-Up Period, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Maximum Number of Securities</i>&#8221; shall have the meaning given in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.1.2</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Merger Agreement</i>&#8221; shall have the meaning given in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Misstatement</i>&#8221; shall mean an untrue statement of a material fact or an omission to state a material fact required to be stated in a Registration Statement or Prospectus, or necessary to make the statements in a Registration Statement or Prospectus (in the case of a Prospectus, in the light of the circumstances under which they were made) not misleading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">New Holders</i>&#8221; shall have the meaning given in the Preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Permitted Transferees</i>&#8221; shall mean any person or entity to whom a Holder is permitted to Transfer such securities prior to the expiration of the applicable Lock-Up Period as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 3.6.2</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Piggyback Registration</i>&#8221; shall have the meaning given in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.1.1</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Private Placement Warrants</i>&#8221; shall mean the 8,233,333 Domesticated Parent Warrants to be issued to holders of Parent Private Placement Warrants pursuant to the Domestication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Private Warrant Lock-Up Period</i>&#8221; shall mean, with respect to Private Placement Warrants, Backstop Warrants and Forward Purchase Warrants that are held by the initial purchasers of such warrants or their Permitted Transferees, and any of the shares of Domesticated Parent Common Stock issued or issuable upon the exercise or conversion of such warrants and that are held by the initial purchasers of the applicable warrants being converted or their Permitted Transferees, the period ending thirty (30) days after the date hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Prospectus</i>&#8221; shall mean the prospectus included in any Registration Statement, as supplemented by any and all prospectus supplements and as amended by any and all post-effective amendments and including all material incorporated by reference in such prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">&#8220;<i style="font-style:italic;">Registrable Security</i>&#8221; shall mean (a)&#160;the Founder Shares (including any shares of Domesticated Parent Common Stock or other equivalent equity security issued or issuable upon the conversion of any such Founder Shares or exercisable for shares of Domesticated Parent Common Stock), (b)&#160;the Backstop Shares, (c)&#160;the Forward Purchase Shares, (d)&#160;the Private Placement Warrants (including any shares of Domesticated Parent Common Stock issued or issuable upon the exercise of any such Private Placement Warrants), (e)&#160;the Working Capital Warrants (including any shares of Domesticated Parent Common Stock issued or issuable upon the exercise of any such Working Capital Warrants), (f)&#160;the Backstop Warrants (including any shares of Domesticated Parent Common Stock issued or issuable upon the conversion of any such Backstop Warrants), (g)&#160;the Forward Purchase Warrants (including any </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">G-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">shares of Domesticated Parent Common Stock issued or issuable upon the conversion of any such Forward Purchase Warrants), (h)&#160;shares of Domesticated Parent Common Stock issued to a New Holder as consideration pursuant to the Merger, (i)&#160;shares of Domesticated Parent Common Stock issuable upon vesting, settlement, or exercise of restricted stock units, performance stock units, options, warrants, or other rights held by a New Holder; (j)&#160;shares of Domesticated Parent Common Stock held by, or issuable upon vesting, settlement, or exercise of restricted stock units, performance stock units, options, warrants, or other rights held by, a Ligand Equity Award Holder) and (k)&#160;any other equity security of the Company issued or issuable with respect to any such Domesticated Parent Common Stock by way of a share capitalization or share split or in connection with a combination of shares, recapitalization, merger, consolidation or reorganization; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that, as to any particular Registrable Security, such securities shall cease to be Registrable Securities when: (i)&#160;a Registration Statement with respect to the sale of such securities shall have become effective under the Securities Act and such securities shall have been sold, transferred, disposed of or exchanged in accordance with such Registration Statement; (ii)&#160;such securities shall have been otherwise transferred, new certificates for such securities not bearing a legend restricting further transfer shall have been delivered by the Company and subsequent public distribution of such securities shall not require registration under the Securities Act; (iii)&#160;such securities shall have ceased to be outstanding; (iv)&#160;such securities may be sold without registration pursuant to Rule&#160;144 or any successor rule&#160;promulgated under the Securities Act (but with no volume or other restrictions or limitations, including as to manner or timing of sale); or (v)&#160;such securities have been sold to, or through, a broker, dealer or underwriter in a public distribution or other public securities transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Registration</i>&#8221; shall mean a registration effected by preparing and filing a registration statement or similar document in compliance with the requirements of the Securities Act, and the applicable rules&#160;and regulations promulgated thereunder, and such registration statement becoming effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Registration Expenses</i>&#8221; shall mean the out-of-pocket expenses of a Registration, including, without limitation, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(A)&#160;all registration and filing fees (including fees with respect to filings required to be made with the Financial Industry Regulatory Authority,&#160;Inc.) and any securities exchange on which the shares of Domesticated Parent Common Stock are then listed;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(B)&#160;fees and expenses of compliance with securities or blue sky laws (including reasonable fees and disbursements of counsel for the Underwriters in connection with blue sky qualifications of Registrable Securities);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(C)&#160;printing, messenger, telephone and delivery expenses;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(D)&#160;reasonable fees and disbursements of counsel for the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(E)&#160;reasonable fees and disbursements of all independent registered public accountants of the Company incurred specifically in connection with such Registration; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(F)&#160;in an Underwritten Offering or other offering involving an Underwriter, reasonable fees and expenses of one (1)&#160;legal counsel selected by the majority-in-interest of the Takedown Requesting Holders initiating an Underwritten</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shelf Takedown, not to exceed $50,000 without the consent of the Company (not to be unreasonably withheld, conditioned or delayed).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Registration Statement</i>&#8221; shall mean any registration statement that covers the Registrable Securities pursuant to the provisions of this Agreement, including the Prospectus included in such registration statement, amendments (including post-effective amendments) and supplements to such registration statement, and all exhibits to and all material incorporated by reference in such registration statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Restricted Shares</i>&#8221; shall have the meaning given in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 3.6.1</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Rule&#160;415</i>&#8221; shall have the meaning given in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.2.1</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Securities Act</i>&#8221; shall mean the Securities Act of 1933, as amended from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Shelf</i>&#8221; shall mean a registration statement filed pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.2.1</span>.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">G-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Sponsor</i>&#8221; shall have the meaning given in the Recitals hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Sponsor Director</i>&#8221; means an individual elected to the Board that has been nominated by the Sponsor pursuant to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Subsequent Shelf Registration</i>&#8221; shall have the meaning given in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.2.2</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Takedown Requesting Holder</i>&#8221; shall have the meaning given in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.2.3</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Transfer</i>&#8221; shall mean a registration statement filed pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 3.6.1</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Underwriter</i>&#8221; shall mean a securities dealer who purchases any Registrable Securities as principal in an Underwritten Offering and not as part of such dealer&#8217;s market-making activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Underwritten Registration</i>&#8221; or &#8220;<i style="font-style:italic;">Underwritten Offering</i>&#8221; shall mean a Registration in which securities of the Company are sold to an Underwriter in a firm commitment underwriting for distribution to the public.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Underwritten Shelf Takedown</i>&#8221; shall have the meaning given in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.2.3</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<i style="font-style:italic;">Working Capital Warrants</i>&#8221; shall have the meaning given in the Recitals hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">REGISTRATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">2.1 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Piggyback Registration</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.1.1 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Piggyback Rights</span>. If, at any time on or after the date hereof, the Company proposes to file a Registration Statement under the Securities Act with respect to an offering of equity securities, or securities or other obligations exercisable or exchangeable for, or convertible into equity securities, for its own account or for the account of stockholders of the Company (or by the Company and by the stockholders of the Company), other than a Registration Statement (i)&#160;filed in connection with any employee share option or other benefit plan, (ii)&#160;for an exchange offer or offering of securities solely to the Company&#8217;s existing stockholders, (iii)&#160;pursuant to a Registration Statement on Form&#160;S-4 (or similar form that relates to a transaction subject to Rule&#160;145 under the Securities Act or any successor rule&#160;thereto), (iv)&#160;for an offering of debt that is convertible into equity securities of the Company or (v)&#160;for a dividend reinvestment plan, then the Company shall give written notice of such proposed filing to all of the Holders of Registrable Securities as soon as practicable but not less than seven (7)&#160;days before the anticipated filing date of such Registration Statement, which notice shall (A)&#160;describe the amount and type of securities to be included in such offering, the intended method(s)&#160;of distribution, and the name of the proposed managing Underwriter or Underwriters, if any, in such offering, and (B)&#160;offer to all of the Holders of Registrable Securities the opportunity to register the sale of such number of Registrable Securities as such Holders may request in writing within three (3)&#160;business days after receipt of such written notice (such Registration a &#8220;<i style="font-style:italic;">Piggyback Registration</i>&#8221;). The Company shall, in good faith, cause such Registrable Securities to be included in such Piggyback Registration and shall use its commercially reasonable efforts to cause the managing Underwriter or Underwriters of a proposed Underwritten Offering to permit the Registrable Securities requested by the Holders pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.1.1</span> to be included in a Piggyback Registration on the same terms and conditions as any similar securities of the Company included in such Registration and to permit the sale or other disposition of such Registrable Securities in accordance with the intended method(s)&#160;of distribution thereof. All such Holders proposing to distribute their Registrable Securities through an Underwritten Offering under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.1.1</span> shall enter into an underwriting agreement in customary form with the Underwriter(s)&#160;selected for such Underwritten Offering by the Company. The notice periods set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.1.1</span> shall not apply to an Underwritten Shelf Takedown conducted in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.2.3.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">2.1.2 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reduction of Piggyback Registration</span>. If the managing Underwriter or Underwriters in an Underwritten Registration that is to be a Piggyback Registration (other than Underwritten Shelf Takedown), in good faith, advises the Company and the Holders of Registrable Securities participating in the Piggyback Registration in writing that the dollar amount or number of the shares of Domesticated Parent Common Stock that the Company desires to sell, taken together with (i)&#160;the shares of Domesticated Parent Common Stock, if any, as to which Registration has been demanded pursuant to separate written contractual arrangements with persons or entities other than the Holders of Registrable Securities hereunder, (ii)&#160;the Registrable Securities as to which registration has been requested pursuant <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1</span> hereof, and (iii)&#160;the shares of Domesticated Parent Common Stock, if any, as to which Registration has been requested pursuant to separate written contractual piggy-back registration rights of other stockholders of the </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">G-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Company, exceeds the maximum dollar amount or maximum number of equity securities that can be sold in the Underwritten Offering without adversely affecting the proposed offering price, the timing, the distribution method, or the probability of success of such offering (such maximum dollar amount or maximum number of such securities, as applicable, the &#8220;<i style="font-style:italic;">Maximum Number of Securities</i>&#8221;), then:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(a)&#160; If the Registration is undertaken for the Company&#8217;s account, the Company shall include in any such Registration (A)&#160;first, the shares of Domesticated Parent Common Stock or other equity securities that the Company desires to sell, which can be sold without exceeding the Maximum Number of Securities; and (B)&#160;second, to the extent that the Maximum Number of Securities has not been reached under the foregoing clause (A), the Registrable Securities of Holders exercising their rights to register their Registrable Securities pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.1.1</span> hereof, pro rata based on the respective number of Registrable Securities that each Holder has requested be included in such Underwritten Registration and the aggregate number of Registrable Securities that the Holders have requested be included in such Underwritten Registration (such proportion is referred to herein as &#8220;<i style="font-style:italic;">Pro Rata</i>&#8221;) exercising its rights to register its Registrable Securities pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.1.1</span> hereof, which can be sold without exceeding the Maximum Number of Securities; and (C)&#160;third, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (A)&#160;and (B), the shares of Domesticated Parent Common Stock, if any, as to which Registration has been requested pursuant to written contractual piggy-back registration rights of other stockholders of the Company, which can be sold without exceeding the Maximum Number of Securities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(b)&#160; If the Registration is pursuant to a request by persons or entities other than the Holders of Registrable Securities, then the Company shall include in any such Registration (A)&#160;first, the shares of Domesticated Parent Common Stock or other equity securities, if any, of such requesting persons or entities, other than the Holders of Registrable Securities, which can be sold without exceeding the Maximum Number of Securities; (B)&#160;second, to the extent that the Maximum Number of Securities has not been reached under the foregoing clause (A), the Registrable Securities of Holders exercising their rights to register their Registrable Securities pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.1.1</span>, Pro Rata, which can be sold without exceeding the Maximum Number of Securities; (C)&#160;third, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (A)&#160;and (B), the shares of Domesticated Parent Common Stock or other equity securities that the Company desires to sell, which can be sold without exceeding the Maximum Number of Securities; and (D)&#160;fourth, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (A), (B)&#160;and (C), the shares of Domesticated Parent Common Stock or other equity securities for the account of other persons or entities that the Company is obligated to register pursuant to separate written contractual arrangements with such persons or entities, which can be sold without exceeding the Maximum Number of Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.1.3 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Piggyback Registration Withdrawal</span>. Any Holder of Registrable Securities shall have the right to withdraw from a Piggyback Registration for any or no reason whatsoever upon written notification to the Company and the Underwriter or Underwriters (if any) of his, her or its intention to withdraw from such Piggyback Registration prior to the effectiveness of the Registration Statement filed with the Commission with respect to such Piggyback Registration. The Company (whether on its own good faith determination or as the result of a request for withdrawal by persons pursuant to separate written contractual obligations) may withdraw a Registration Statement filed with the Commission in connection with a Piggyback Registration at any time prior to the effectiveness of such Registration Statement. Notwithstanding anything to the contrary in this Agreement, the Company shall be responsible for the Registration Expenses incurred in connection with the Piggyback Registration prior to its withdrawal under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.1.3</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">2.2 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shelf Registrations</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">2.2.1 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Registration.</span> The Company shall use commercially reasonable efforts to, within thirty (30) days after the date hereof, file a Registration Statement under the Securities Act to permit the public resale of all the Registrable Securities held by the Holders from time to time as permitted by Rule&#160;415 under the Securities Act (or any successor or similar provision adopted by the Commission then in effect) (&#8220;<i style="font-style:italic;">Rule&#160;415</i>&#8221;) on the terms and conditions specified in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2.1</span> and shall use its commercially reasonable efforts to cause such Registration Statement to be declared effective as soon as practicable after the filing thereof. The Registration Statement filed with the Commission pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2.1</span> shall be a shelf registration statement on Form&#160;S-1 or such other form of registration statement as is then available to effect a registration for resale of such Registrable Securities, covering such Registrable Securities, and shall contain a Prospectus in such form as to permit any Holder to sell such Registrable Securities pursuant to Rule&#160;415 at any time beginning on the effective date for such Registration Statement. A Registration Statement filed pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2.1</span> shall provide for the resale pursuant to any method or combination of methods legally available to, and requested by, the Holders. The Company shall use its commercially reasonable efforts to cause a Registration Statement filed pursuant to this </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">G-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2.1</span> to remain effective, and to be supplemented and amended to the extent necessary to ensure that such Registration Statement is available or, if not available, that another Registration Statement is available, for the resale of all the Registrable Securities held by the Holders until all such Registrable Securities have ceased to be Registrable Securities. As soon as practicable following the effective date of a Registration Statement filed pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2.1</span>, the Company shall notify the Holders of the effectiveness of such Registration Statement. When effective, a Registration Statement filed pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.3.1</span> (including the documents incorporated therein by reference) will comply as to form in all material respects with all applicable requirements of the Securities Act and will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading (in the case of any prospectus contained in such Registration Statement, in the light of the circumstances under which such statement is made). In the event the Company files a Shelf on Form&#160;S-1, the Company shall use its commercially reasonable efforts to convert the Form&#160;S-1 to a shelf registration statement on Form&#160;S-3 (&#8220;<i style="font-style:italic;">Form&#160;S-3</i>&#8221;) as soon as practicable after the Company is eligible to use Form&#160;S-3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.2.2 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsequent Shelf Registration</span>. If any Shelf ceases to be effective under the Securities Act for any reason at any time while Registrable Securities included thereon are still outstanding or if the Prospectus included in such Registration Statement, as then in effect, includes a Misstatement<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;</span>for any reason at any time while Registrable Securities are still outstanding, the Company shall, subject to&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.4</span>,&#160;use its commercially reasonable efforts to as promptly as is reasonably practicable cause such Shelf to again become effective under the Securities Act (including using its commercially reasonable efforts to obtain the prompt withdrawal of any order suspending the effectiveness of such Shelf) and correct any such Misstatement, and shall use its commercially reasonable efforts to as promptly as is reasonably practicable amend such Shelf in a manner reasonably expected to result in the withdrawal of any order suspending the effectiveness of such Shelf or file an additional registration statement (a &#8220;<i style="font-style:italic;">Subsequent Shelf Registration</i>&#8221;) registering the resale of all Registrable Securities including on such Shelf (determined as of two (2)&#160;business days prior to such filing), and pursuant to any method or combination of methods legally available to, and requested by, any Holder. If a Subsequent Shelf Registration is filed, the Company shall use its commercially reasonable efforts to (i)&#160;cause such Subsequent Shelf Registration to become effective under the Securities Act as promptly as is reasonably practicable after the filing thereof and (ii)&#160;keep such Subsequent Shelf Registration continuously effective and available for use to permit the Holders named therein to sell their Registrable Securities included therein, and in compliance with the provisions of the Securities Act&#160;until such time as there are no longer any Registrable Securities included thereon. Any such Subsequent Shelf Registration shall be on Form&#160;S-3 to the extent that the Company is eligible to use such form. Otherwise, such Subsequent Shelf Registration shall be on another appropriate form. In the event that any Holder holds Registrable Securities that are not registered for resale on a delayed or continuous basis, the Company, upon written request of a Holder shall promptly use its commercially reasonable efforts to cause the resale of such Registrable Securities to be covered by either, at the Company&#8217;s option, a Shelf (including by means of a post-effective amendment) or a Subsequent Shelf Registration and cause the same to become effective as soon as practicable after such filing and such Shelf or Subsequent Shelf Registration shall be subject to the terms hereof; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, the Company shall only be required to cause such Registrable Securities to be so covered once annually after inquiry of the Holder. The Company&#8217;s obligation under this&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2.2</span>, shall, for the avoidance of doubt, be subject to&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.4</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.2.3 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Requests for Underwritten Shelf Takedowns</span>. Subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.4</span>, following the expiration of the applicable Lock-Up Period, the Sponsor may request to sell all or any portion of its Registrable Securities in an underwritten offering that is registered pursuant to the Shelf (each, an &#8220;<i style="font-style:italic;">Underwritten Shelf Takedown</i>&#8221;); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that the Company shall only be obligated to effect an Underwritten Shelf Takedown if such offering shall include securities with a total offering price (including piggy-back securities and before deduction of underwriting discounts) reasonably expected to exceed, in the aggregate, $15,000,000. All requests for Underwritten Shelf Takedowns shall be made by giving written notice to the Company at least 48 hours prior to the public announcement of such Underwritten Shelf Takedown, which shall specify the approximate number of Registrable Securities proposed to be sold in the Underwritten Shelf Takedown and the expected price range (net of underwriting discounts and commissions) of such Underwritten Shelf Takedown. The Company shall include in any Underwritten Shelf Takedown the securities requested to be included by any Holder (each a &#8220;<i style="font-style:italic;">Takedown Requesting Holder</i>&#8221;) at least 48 hours prior to the public announcement of such Underwritten Shelf Takedown pursuant to written contractual piggy-back registration rights of such holder (including to those set forth herein). The Sponsor shall have the right to select the underwriter(s)&#160;for such offering (which shall consist of one or more reputable nationally recognized investment banks), subject to the Company&#8217;s prior approval which shall not be unreasonably withheld, conditioned or delayed. The Sponsor may demand not more than one (1)&#160;Underwritten Shelf Takedowns pursuant to this&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2.3</span>&#160;in any six (6)-month period. Notwithstanding anything to the contrary in this Agreement, the Company may effect any Underwritten Offering pursuant to any then effective Registration Statement, including a Form&#160;S-3,&#160;that is then available for such offering, subject to the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1</span>.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">G-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.2.4 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reduction of Underwritten Offering</span>. If the managing Underwriter or Underwriters in an Underwritten Shelf Takedown, in good faith, advises the Company, the Sponsor and the Takedown Requesting Holders (if any) in writing that the dollar amount or number of Registrable Securities that the Sponsor and the Takedown Requesting Holders (if any) desire to sell, taken together with all other shares of Domesticated Parent Common Stock or other equity securities that the Company desires to sell, exceeds the Maximum Number of Securities, then the Company shall include in such Underwritten Shelf Takedown, as follows: (i)&#160;first, the Registrable Securities of the Sponsor that can be sold without exceeding the Maximum Number of Securities; (ii)&#160;second, to the extent that the Maximum Number of Securities has not been reached under the foregoing clause (i), the shares of Domesticated Parent Common Stock or other equity securities that the Company desires to sell, which can be sold without exceeding the Maximum Number of Securities; and (iii)&#160;third, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (i)&#160;and (ii), the shares of Domesticated Parent Common Stock or other equity securities of the Takedown Requesting Holders, if any, that can be sold without exceeding the Maximum Number of Securities, determined Pro Rata based on the respective number of Registrable Securities that each Takedown Requesting Holder has so requested to be included in such Underwritten Shelf Takedown.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.2.5 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withdrawal</span>. The Sponsor shall have the right to withdraw from an Underwritten Shelf Takedown for any or no reason whatsoever upon written notification to the Company and the Underwriter or Underwriters (if any) of its intention to withdraw from such Underwritten Shelf Takedown prior to the public announcement of such Underwritten Shelf Takedown. If so withdrawn, a demand for an Underwritten Shelf Takedown shall constitute a demand for an Underwritten Shelf Takedown by the Sponsor for purposes of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.2.3</span>, unless either (i)&#160;the Sponsor has not previously withdrawn any Underwritten Shelf Takedown or (ii)&#160;the Sponsor reimburses the Company for all Registration Expenses with respect to such Underwritten Shelf Takedown (or, if there is more than one Takedown Requesting Holders, a pro rata portion of such Registration Expenses based on the respective number of Registrable Securities that each Takedown Requesting Holder has requested be included in such Underwritten Shelf Takedown). Notwithstanding anything to the contrary in this Agreement, the Company shall be responsible for the Registration Expenses incurred in connection with an Underwritten Shelf Takedown prior to and including a withdrawal under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.2.5</span>, unless the Sponsor elect to pay such Registration Expenses pursuant to clause (ii)&#160;of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.2.5</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.3 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Market Stand-off</span>.&#160;In connection with any Underwritten Offering of equity securities of the Company, if requested by the managing Underwriters, each Holder that is an executive officer, director or Holder in excess of five percent (5%) of the outstanding Common Stock agrees that it shall not Transfer any equity securities of the Company (other than those included in such offering pursuant to this Agreement), without the prior written consent of the Company, during the ninety (90)-day period (or such shorter time agreed to by the managing Underwriters) beginning on the date of pricing of such offering, except as expressly permitted by such lock-up agreement or in the event the managing Underwriters otherwise agree by written consent. Each such Holder that participates and sells Registrable Securities in such Underwritten Offering agrees to execute a customary lock-up agreement in favor of the Underwriters to such effect (in each case on substantially the same terms and conditions as all such Holders that execute a lock-up agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">COMPANY PROCEDURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.1 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Procedures</span>. If at any time the Company is required to effect the Registration of Registrable Securities, the Company shall use its commercially reasonable efforts to effect such Registration to permit the sale of such Registrable Securities in accordance with the intended plan of distribution thereof, and pursuant thereto the Company shall, in a timely manner:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.1.1 prepare and file with the Commission as soon as reasonably practicable a Registration Statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such Registration Statement to become effective and remain effective until all Registrable Securities covered by such Registration Statement have ceased to be Registrable Securities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.1.2 prepare and file with the Commission such amendments and post-effective amendments to the Registration Statement, and such supplements to the Prospectus, as may be reasonably requested by the Holders or any Underwriter of Registrable Securities or as may be required by the rules, regulations or instructions applicable to the registration form used by the Company or by the Securities Act or rules&#160;and regulations thereunder to keep the Registration Statement effective until the earlier of (a)&#160;all Registrable Securities covered by such Registration Statement are sold in accordance with the intended plan of distribution set forth in such Registration Statement or supplement to the Prospectus or (b)&#160;the termination of this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">3.1.3 prior to filing a Registration Statement or Prospectus, or any amendment or supplement thereto, furnish without charge to the Underwriters, if any, and the Holders of Registrable Securities included in such Registration, and such Holders&#8217; legal counsel, </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">G-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">copies of such Registration Statement as proposed to be filed, each amendment and supplement to such Registration Statement (in each case including all exhibits thereto and documents incorporated by reference therein), the Prospectus included in such Registration Statement (including each preliminary Prospectus), and such other documents as the Underwriters and the Holders of Registrable Securities included in such Registration or the legal counsel for any such Holders may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Holders;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.1.4 prior to any public offering of Registrable Securities, use its commercially reasonable efforts to (i)&#160;register or qualify the Registrable Securities covered by the Registration Statement under such securities or &#8220;blue sky&#8221; laws of such jurisdictions in the United States as the Holders of Registrable Securities included in such Registration Statement (in light of their intended plan of distribution) may request and (ii)&#160;take such action necessary to cause such Registrable Securities covered by the Registration Statement to be registered with or approved by such other governmental authorities as may be necessary by virtue of the business and operations of the Company and do any and all other acts and things that may be necessary or advisable to enable the Holders of Registrable Securities included in such Registration Statement to consummate the disposition of such Registrable Securities in such jurisdictions; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that the Company shall not be required to qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify or take any action to which it would be subject to general service of process or taxation in any such jurisdiction where it is not then otherwise so subject;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.1.5 use commercially reasonable efforts to cause all such Registrable Securities to be listed on each national securities exchange on which similar securities issued by the Company are then listed;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.1.6 provide a transfer agent or warrant agent, as applicable, and registrar for all such Registrable Securities no later than the effective date of such Registration Statement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.1.7 advise each seller of such Registrable Securities, promptly after it shall receive notice or obtain knowledge thereof, of the issuance of any stop order by the Commission suspending the effectiveness of such Registration Statement or the initiation or threatening of any proceeding for such purpose and promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal if such stop order should be issued;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.1.8 at least five (5)&#160;days prior to the filing of any Registration Statement or Prospectus or any amendment or supplement to such Registration Statement or Prospectus other than by way of a document incorporated by reference &#160;(or such shorter period of time as may be (a)&#160;necessary in order to comply with the Securities Act, the Exchange Act, and the rules&#160;and regulations promulgated under the Securities Act or Exchange Act, as applicable or (b)&#160;advisable in order to reduce the number of days that sales are suspended pursuant to&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.4</span>) furnish a copy thereof to each seller of such Registrable Securities or its counsel, excluding any exhibits thereto and any filing made under the Exchange Act that is to be incorporated by reference therein;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.1.9 notify the Holders at any time when a Prospectus relating to such Registration Statement is required to be delivered under the Securities Act, of the happening of any event as a result of which the Prospectus included in such Registration Statement, as then in effect, includes a Misstatement, and then to correct such Misstatement as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.4</span> hereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.1.10 in the event of an Underwritten Offering or a sale by a placement agent or sales agent pursuant to such Registration, permit a representative of the Holders, the Underwriters, if any, and any attorney or accountant retained by such Holders, Underwriter, placement agent or sales agent to participate, at each such person&#8217;s own expense, in the preparation of the Registration Statement, and cause the Company&#8217;s officers, directors and employees to supply all information reasonably requested by any such representative, Underwriter, placement agent, sales agent attorney or accountant in connection with the Registration; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that such representatives, Underwriters, placement agents, sales agents, attorneys or accountant enter into a confidentiality agreement, in form and substance reasonably satisfactory to the Company, prior to the release or disclosure of any such information; and&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</span>, that the Company will not include the name of any Holder or any information regarding any Holder not participating in such sale pursuant to such Registration unless required by the Commission or any applicable law, rules&#160;or regulations;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.1.11 obtain a &#8220;cold comfort&#8221; letter from the Company&#8217;s independent registered public accountants in the event of an Underwritten Registration, in customary form and covering such matters of the type customarily covered by &#8220;cold comfort&#8221; letters as the managing Underwriter may reasonably request, and reasonably satisfactory to a majority-in-interest of the participating Holders;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">3.1.12 in the event of an Underwritten Offering or a sale by a placement agent or sales agent pursuant to such Registration, on the date the Registrable Securities are delivered for sale pursuant to such Registration, obtain an opinion, dated such date, of counsel </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">G-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">representing the Company for the purposes of such Registration, addressed to the Holders, the placement agent or sales agent, if any, and the Underwriters, if any, covering such legal matters with respect to the Registration in respect of which such opinion is being given as the Holders, placement agent, sales agent, or Underwriter may reasonably request and as are customarily included in such opinions and negative assurance letters, and reasonably satisfactory to a majority in interest of the participating Holders;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.1.13 in the event of any Underwritten Offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing Underwriter of such offering;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.1.14 &#160;otherwise use its commercially reasonable efforts to&#160;make available to its security holders, as soon as reasonably practicable, an earnings statement covering the period of at least twelve (12) months beginning with the first day of the Company&#8217;s first full calendar quarter after the effective date of the Registration Statement which satisfies the provisions of Section&#160;11(a)&#160;of the Securities Act and Rule&#160;158 thereunder (or any successor rule&#160;promulgated thereafter by the Commission), and which requirement will be deemed satisfied if the Company timely files complete and accurate information on Forms&#160;10-Q,&#160;10-K&#160;and&#160;8-K&#160;under the Exchange Act and otherwise complies with Rule&#160;158 under the Securities Act (or any successor rule&#160;promulgated thereafter by the Commission);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.1.15 with respect to an Underwritten Offering pursuant to&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2.3</span>,&#160;if the Registration involves the Registration of Registrable Securities involving gross proceeds in excess of $50,000,000, use its commercially reasonable efforts to make available senior executives of the Company to participate in customary &#8220;road show&#8221; presentations that may be reasonably requested by the Underwriter in such Underwritten Offering; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.1.16 otherwise, in good faith, cooperate reasonably with, and take such customary actions as may reasonably be requested by the participating Holders, consistent with the terms of this Agreement,&#160;in connection with such Registration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, the Company shall not be required to provide any documents or information to an Underwriter or other sales agent or placement agent if such Underwriter or other sales agent or placement agent has not then been named with respect to the applicable Underwritten Offering or other offering involving a Registration and an Underwriter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.2 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registration Expenses</span>. The Registration Expenses of all Registrations shall be borne by the Company. It is acknowledged by the Holders that the Holders shall bear all incremental selling expenses relating to the sale of Registrable Securities, such as Underwriters&#8217; commissions and discounts, brokerage fees, Underwriter marketing costs and, other than as set forth in the definition of &#8220;Registration Expenses,&#8221; all reasonable fees and expenses of any legal counsel representing the Holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.3 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Requirements for Participation in Underwritten Offerings</span>. Notwithstanding anything in this Agreement to the contrary, if any Holder does not provide the Company with its requested Holder Information, the Company may exclude such Holder&#8217;s Registrable Securities from the applicable Registration Statement or Prospectus if the Company determines, based on the advice of counsel, that such information is necessary to effect the Registration. No person may participate in any Underwritten Offering or other offering involving a Registration and an Underwriter for equity securities of the Company pursuant to a Registration initiated by the Company hereunder unless such person (i)&#160;agrees to sell such person&#8217;s securities on the basis provided in any arrangements approved by the Company and (ii)&#160;completes and executes all customary questionnaires, powers of attorney, indemnities, lock-up agreements, underwriting agreements and other customary documents as may be reasonably required under the terms of such arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.4 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Suspension of Sales; Adverse Disclosure; &#160;Restrictions on Registration Rights</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.4.1 Upon receipt of written notice from the Company that a Registration Statement or Prospectus contains a Misstatement, or in the opinion of counsel for the Company it is necessary to supplement or amend such Prospectus to comply with law, each of the Holders shall forthwith discontinue disposition of Registrable Securities until it has received copies of a supplemented or amended Prospectus correcting the Misstatement (it being understood that the Company hereby covenants to prepare and file such supplement or amendment as soon as practicable after the time of such notice), or until it is advised in writing by the Company that the use of the Prospectus may be resumed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">3.4.2 If the filing, initial effectiveness or continued use of a Registration Statement in respect of any Registration at any time would (i)&#160;require the Company to make an Adverse Disclosure, (ii)&#160;would require the inclusion in such Registration Statement of financial statements that are unavailable to the Company for reasons beyond the Company&#8217;s control, (iii)&#160;in the good faith judgment of the majority of the Board, be seriously detrimental to the Company and the majority of the Board concludes as a result that it is </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">G-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">essential to defer such filing, the Company may, upon giving prompt written notice of such action to the Holders, delay the filing or initial effectiveness of, or suspend use of, such Registration Statement for the shortest period of time, but in no event more than thirty (30)&#160;days, determined in good faith by the Company to be necessary for such purpose. In the event the Company exercises its rights under the preceding sentence, the Holders agree to suspend, immediately upon their receipt of the notice referred to above, their use of the Prospectus relating to any Registration in connection with any sale or offer to sell Registrable Securities, and in each case maintain the confidentiality of such notice and its contents. The Company shall immediately notify the Holders of the expiration of any period during which it exercised its rights under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 3.4.2</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.4.3 Subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 3.4.4</span>, if (i)&#160;during the period starting with the date sixty (60) days prior to the Company&#8217;s good faith estimate of the date of the filing of, and ending on a date one hundred twenty (120) days (or such shorter time as the managing Underwriters may agree) after the effective date of, a Company-initiated Registration and provided that the Company continues to actively employ, in good faith, all reasonable efforts to cause the applicable Registration Statement to become effective or maintain the effectiveness of the applicable Registration Statement, or (ii)&#160;pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.2.3</span>, Holders have requested an Underwritten Shelf Takedown and the Company and Holders are unable to obtain the commitment of underwriters to firmly underwrite such offering, then, in each case, the Company may, upon giving prompt written notice of such action to the Holders, delay any other registered offering pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.2.3</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.4.4 The right to delay or suspend any filing, initial effectiveness or continued use of a Registration Statement pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 3.4.2</span> or a registered offering pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 3.4.3</span> shall be exercised by the Company, in either case, for not more than sixty (60) consecutive calendar days or more than one hundred twenty (120) total calendar days during any twelve (12)-month period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.4.5 Notwithstanding anything to the contrary set forth herein, the Company shall not be required provide any Holder with any material, nonpublic information regarding the Company other than to the extent that providing notice to such Holder hereunder constitutes material, nonpublic information regarding the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.5 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reporting Obligations</span>. As long as any Holder shall own Registrable Securities, the Company, at all times while it shall be a reporting company under the Exchange Act, covenants to use commercially reasonable efforts to file timely (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to Sections 13(a)&#160;or 15(d)&#160;of the Exchange Act and to promptly furnish the Holders with true and complete copies of all such filings; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>&#160;that any documents publicly filed or furnished with the Commission pursuant to the Electronic Data Gathering, Analysis and Retrieval System shall be deemed to have been furnished or delivered to the Holders pursuant to this&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.5</span>. The Company further covenants that it shall take such further action as any Holder may reasonably request, all to the extent required from time to time to enable such Holder to sell shares of Domesticated Parent Common Stock held by such Holder without registration under the Securities Act within the limitation of the exemptions provided by Rule&#160;144 promulgated under the Securities Act (or any successor rule&#160;then in effect), including providing any customary&#160;legal opinions. Upon the request of any Holder, the Company shall deliver to such Holder a written certification of a duly authorized officer as to whether it has complied with such requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.6 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer Restrictions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">3.6.1 Except with respect to a Transfer to a Permitted Transferee, during the applicable Lock-Up Periods, no Existing Holder or New Holder shall, directly or indirectly, (a)&#160;offer, sell, contract to sell, pledge, hypothecate, grant any option to purchase, make any short sale or otherwise dispose of or distribute, establish or increase a put equivalent position or liquidation with respect to or decrease of a call equivalent position within the meaning of Section&#160;16 of the Exchange Act with respect to, any security, (b)&#160;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any security, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise, or (c)&#160;publicly announce any intention to effect any transaction specified in clause (a)&#160;or (b)&#160;(each, a &#8220;<i style="font-style:italic;">Transfer</i>&#8221;) any (i)&#160;shares of Domesticated Parent Common Stock or any other shares of the Company&#8217;s capital stock, (ii)&#160;options or warrants to purchase any shares of Domesticated Parent Common Stock or any other shares of the Company&#8217;s capital stock or (iii)&#160;securities convertible into, exercisable for, exchangeable for or that represent the right to receive shares of Domesticated Parent Common Stock or any other shares of the Company&#8217;s capital stock, in each case, whether now owned or hereinafter acquired, that are owned directly by such Existing Holder or New Holder (including securities held as a custodian) or with respect to which such Existing Holder or New Holder has beneficial ownership within the rules&#160;and regulations of the Commission (collectively, the &#8220;<i style="font-style:italic;">Restricted Shares</i>&#8221;). The foregoing restriction is expressly agreed to preclude each Existing Holder and New Holder from engaging in any hedging or other transaction which is designed to or which reasonably could be expected to lead to or result in a sale or disposition of the Restricted Shares even if such Restricted Shares would </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">G-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">be disposed of by someone other than such Existing Holder or each New Holder, as applicable. Such prohibited hedging or other transactions include any short sale or any purchase, sale or grant of any right (including any put or call option) with respect to any of the Restricted Shares of the applicable Existing Holder or New Holder or with respect to any security that includes, relates to, or derives any significant part of its value from such Restricted Shares; provided, however, that the foregoing restrictions are not intended to cover liens established in the ordinary course in favor of a broker-dealer over property held in an account with such broker-dealer generally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.6.2 Notwithstanding the provisions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 3.6.1</span>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(a)&#160; with respect to any Existing Holder, Transfers of Registrable Securities are permitted during the applicable Lock-Up Period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>to the Company&#8217;s officers or directors, any Affiliate or family member of any of the Company&#8217;s officers or directors,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>to any members or partners of the Sponsor or their Affiliates, any Affiliates of the Sponsor, or any employees of such Affiliates;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>in the case of an individual, by gift to a member of one of the individual&#8217;s immediate family or to a trust, the beneficiary of which is a member of the individual&#8217;s immediate family, an affiliate of such person or to a charitable organization;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>in the case of an individual, by virtue of laws of descent and distribution upon death of the individual;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span>in the case of an individual, pursuant to a qualified domestic relations order;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</span></span>by virtue of the Sponsor&#8217;s organizational documents upon liquidation or dissolution of the Sponsor;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vii)</span></span>to the Company for no value for cancellation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(viii)</span></span><span style="white-space:pre-wrap;">in connection with a liquidation, merger, amalgamation, stock exchange, reorganization, tender offer approved by the Board or a duly authorized committee thereof or other similar transactions which results in all of  the Company&#39;s  stockholders having the right to exchange their shares of common stock for cash, securities or other property;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that in the case of any Transfer pursuant to clauses (a)(i), (ii), (iii), (iv), (v), (vi)&#160;and (vii)&#160;such Transfer shall not involve a disposition for value; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</span> that in the case of any Transfer pursuant to clauses (a)(i), (ii), (iii), (iv)&#160;and (vi), each donee, devisee, transferee or distributee enters into a written agreement with the Company agreeing to be bound to the restrictions set forth herein; and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</span>, that in the case of any permitted Transfer no public filing, report or announcement shall be voluntarily made and if any filing under Section&#160;16(a)&#160;of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Domesticated Parent Common Stock in connection with such Transfer shall be legally required during the applicable Lock-Up Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(b)&#160; with respect to any New Holder, Transfers of Domesticated Parent Common Stock are permitted during the applicable Lock-Up Period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>to any New Holder&#8217;s Affiliate;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>in the case of an individual, by gift to a member of one of the individual&#8217;s immediate family or to a trust, the beneficiary of which is a member of the individual&#8217;s immediate family, an affiliate of such person or to a charitable organization;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>in the case of an individual, by virtue of laws of descent and distribution upon death of the individual;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>in the case of an individual, pursuant to a qualified domestic relations order;</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">G-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span>to the Company for no value for cancellation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</span></span>in connection with a liquidation, merger, amalgamation, stock exchange, reorganization, tender offer approved by the Board or a duly authorized committee thereof or other similar transactions which results in all of the Company&#8217;s stockholders having the right to exchange their shares of Domesticated Parent Common Stock for cash, securities or other property;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vii)</span></span>to the Company from an employee of the Company upon death, disability or termination of employment, in each case, of such employee;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(viii)</span></span>to the Company in connection with the vesting, settlement, or exercise of restricted stock units, performance stock units, options, warrants or other rights to purchase shares of Domesticated Parent Common Stock (including, in each case, by way of &#8220;net&#8221; or &#8220;cashless&#8221; exercise), including for the payment of exercise price and tax and remittance payments due as a result of the vesting, settlement, or exercise of such restricted stock units, performance stock units, options, warrants or rights; provided that any such restricted stock units, performance stock units, options, warrants or other rights are held by a New Holder pursuant to an agreement or equity awards granted under a stock incentive plan or other equity award plan;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ix)</span></span>as part of a sale of Domesticated Parent Common Stock to cover the payment of any exercise price and tax and remittance payment due as the result of the vesting, settlement, or exercise of restricted stock units, performance stock units, options, warrants or other rights to purchase shares of Domesticated Parent Common Stock; provided that any such restricted stock units, performance stock units, options, warrants or other rights are held by a New Holder pursuant to an agreement or equity awards granted under a stock incentive plan or other equity award plan;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(x)</span></span>to the Company in connection with the vesting or settlement of the Earnout Shares received for the payment of tax and remittance payments due as a result of the vesting of such Earnout Shares;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xi)</span></span>as part of a sale of Domesticated Parent Common Stock to cover the payment of any tax and remittance payment due as the result of the vesting of Earnout Shares; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xii)</span></span>as part of a sale of Domesticated Parent Common Stock acquired in open market transactions after the date hereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that in the case of any Transfer pursuant to clauses (b)(i), (ii), (iii), (iv), (v)&#160;and (vii)&#160;such Transfer shall not involve a disposition for value; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</span> that in the case of any Transfer pursuant to clauses (b)(i), (ii)&#160;and (iii), each donee, devisee, transferee or distributee enters into a written agreement with the Company agreeing to be bound to the restrictions set forth herein; and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</span>, that in the case of any permitted Transfer no public filing, report or announcement shall be voluntarily made and if any filing under Section&#160;16(a)&#160;of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Domesticated Parent Common Stock in connection with such Transfer shall be legally required during the applicable Lock-Up Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(c)&#160; the Board may, in its sole discretion, determine to waive, amend, or repeal the lock-up obligations set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 3.6.1</span>; provided that any such waiver, amendment or repeal shall require, in addition to any other vote of the members of the Board required to take such action pursuant to these bylaws or applicable law, the affirmative vote of the Sponsor Director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.6.3 Each Existing Holder and each New Holder hereby represents and warrants that it now has and, except as contemplated by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6.2</span> for the duration of the applicable Lock-Up Period, will have good and marketable title to its Restricted Shares, free and clear of all liens, encumbrances, and claims that could impact the ability of such Existing Holder or New Holder, as applicable, to comply with the foregoing restrictions. Each Existing Holder and each New Holder agrees and consents to the entry of stop transfer instructions with the Company&#8217;s transfer agent against the Transfer of any Restricted Shares during the applicable Lock-Up Period, except in compliance with the foregoing restrictions.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">G-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">INDEMNIFICATION AND CONTRIBUTION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">4.1 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">4.1.1 The Company agrees to indemnify, to the extent permitted by law, each Holder of Registrable Securities, its officers and directors and each person who controls such Holder (within the meaning of the Securities Act) against all losses, claims, damages, liabilities and expenses (including attorneys&#8217; fees) caused by any untrue or alleged untrue statement of material fact contained in any Registration Statement, Prospectus or preliminary Prospectus or any amendment thereof or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as the same are caused by or contained in any information furnished in writing to the Company by such Holder expressly for use therein. The Company shall indemnify the Underwriters, their officers and directors and each person who controls such Underwriters (within the meaning of the Securities Act) to the same extent as provided in the foregoing with respect to the indemnification of the Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">4.1.2 In connection with any Registration Statement in which a Holder of Registrable Securities is participating, such Holder shall furnish to the Company in writing such information and affidavits as the Company reasonably requests for use in connection with any such Registration Statement or Prospectus &#160;(the &#8220;<i style="font-style:italic;">Holder Information</i>&#8221;) and, to the extent permitted by law, shall indemnify the Company, its directors and officers and agents and each person who controls the Company (within the meaning of the Securities Act) against any losses, claims, damages, liabilities and expenses (including without limitation reasonable attorneys&#8217; fees) resulting from any untrue or alleged untrue statement of material fact contained or incorporated by reference in the Registration Statement, Prospectus or preliminary Prospectus or any amendment thereof or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading, but only to the extent that such untrue statement or omission is contained in (or not contained in, in the case of an omission) any information or affidavit so furnished in writing by or on behalf of such Holder expressly for use therein; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that the obligation to indemnify shall be several, not joint and several, among such Holders of Registrable Securities, and the liability of each such Holder of Registrable Securities shall be in proportion to and limited to the net proceeds received by such Holder from the sale of Registrable Securities pursuant to such Registration Statement. The Holders of Registrable Securities shall indemnify the Underwriters, their officers, directors and each person who controls such Underwriters (within the meaning of the Securities Act) to the same extent as provided in the foregoing with respect to indemnification of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">4.1.3 Any person entitled to indemnification herein shall (i)&#160;give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification (provided that the failure to give prompt notice shall not impair any person&#8217;s right to indemnification hereunder to the extent such failure has not materially prejudiced the indemnifying party) and (ii)&#160;unless in such indemnified party&#8217;s reasonable judgment a conflict of interest between such indemnified and indemnifying parties may exist with respect to such claim, permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party. If such defense is assumed, the indemnifying party shall not be subject to any liability for any settlement made by the indemnified party without its consent (but such consent shall not be unreasonably withheld). An indemnifying party who is not entitled to, or elects not to, assume the defense of a claim shall not be obligated to pay the fees and expenses of more than one counsel for all parties indemnified by such indemnifying party with respect to such claim, unless in the reasonable judgment of any indemnified party a conflict of interest may exist between such indemnified party and any other of such indemnified parties with respect to such claim. No indemnifying party shall, without the consent of the indemnified party, consent to the entry of any judgment or enter into any settlement, which (a)&#160;cannot be settled in all respects by the payment of money (and such money is so paid by the indemnifying party pursuant to the terms of such settlement), (b)&#160;includes a statement or admission of fault and culpability on the part of such indemnified party&#160;or (c)&#160;does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">4.1.4 The indemnification provided for under this Agreement shall remain in full force and effect regardless of any investigation made by or on behalf of the indemnified party or any officer, director or controlling person of such indemnified party and shall survive the Transfer of securities. The Company and each Holder of Registrable Securities participating in an offering also agrees to make such provisions as are reasonably requested by any indemnified party for contribution to such party in the event the Company&#8217;s or such Holder&#8217;s indemnification is unavailable for any reason.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">4.1.5 If the indemnification provided under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.1</span> hereof from the indemnifying party is unavailable or insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities and expenses referred to herein, then the </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">G-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">indemnifying party, in lieu of indemnifying the indemnified party, shall contribute to the amount paid or payable by the indemnified party as a result of such losses, claims, damages, liabilities and expenses in such proportion as is appropriate to reflect the relative fault of the indemnifying party and the indemnified party, as well as any other relevant equitable considerations. The relative fault of the indemnifying party and indemnified party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact, was made by, or relates to information supplied by, such indemnifying party or indemnified party, and the indemnifying party&#8217;s and indemnified party&#8217;s relative intent, knowledge, access to information and opportunity to correct or prevent such action; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that the liability of any Holder under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 4.1.5</span> shall be limited to the amount of the net proceeds received by such Holder in such offering giving rise to such liability. The amount paid or payable by a party as a result of the losses or other liabilities referred to above shall be deemed to include, subject to the limitations set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsections 4.1.1</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.1.2</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.1.3</span> above, any legal or other fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. The parties hereto agree that it would not be just and equitable if contribution pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 4.1.5</span> were determined by pro rata allocation or by any other method of allocation, which does not take account of the equitable considerations referred to in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 4.1.5</span>. No person guilty of fraudulent misrepresentation (within the meaning of Section&#160;11(f)&#160;of the Securities Act) shall be entitled to contribution pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 4.1.5</span> from any person who was not guilty of such fraudulent misrepresentation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">STOCKHOLDER RIGHTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5.1 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stockholder Rights</span>. At any time and from time to time on or after the date hereof and until the later of (i)&#160;such time as the Sponsor ceases to beneficially own at least ten percent (10%) of the Company&#8217;s outstanding voting stock and (ii)&#160;subject to compliance with the rules&#160;of The Nasdaq Stock Market, the third anniversary of the date of this Merger Agreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5.1.1 The Sponsor shall have the right, but not the obligation, to designate one individual to be appointed or nominated, as the case may be, for election to the Board (including any successor, each, a &#8220;<i style="font-style:italic;">Nominee</i>&#8221;) as a Class&#160;III director by giving written notice to the Company on or before the time such information is reasonably requested by the Board or the Nominating Committee of the Board, as applicable, for inclusion in a proxy statement for a meeting of stockholders provided to the Sponsor. Any Nominee shall be subject to the consent of the Board (not to be unreasonably withheld, conditioned or delayed); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that the Board&#8217;s consent shall not be required if such Nominee is Josh Tamaroff, Garrett Lustig, or any individual who is a director of the Company as of the date of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5.1.2 The Company will, as promptly as practicable, use its commercially reasonable efforts to ensure that there is one Sponsor Director serving on the Board at all times that the Sponsor shall be entitled to nominate a Director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5.1.3 The Company shall, to the fullest extent permitted by applicable law, use its commercially reasonable efforts to ensure that: (i)&#160;the Nominee is included in the Board&#8217;s slate of nominees to the stockholders of the Company for each election of the applicable class of Directors; and (ii)&#160;the Nominee is included in the proxy statement prepared by management of the Company in connection with soliciting proxies for such meeting of the stockholders of the Company called with respect to the election of members of the Board, and at every adjournment or postponement thereof, and on every action or approval by written consent of the stockholders of the Company or the Board with respect to the election of members of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5.1.4 If a vacancy occurs because of the death, disability, disqualification, resignation, or removal (or for any other reason) of a Sponsor Director, the Sponsor shall be entitled to designate such person&#8217;s successor, and the Company will promptly following such designation use its commercially reasonable efforts to ensure that such vacancy shall be filled with such successor Nominee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5.1.5 If a Nominee is not elected for any reason, the Sponsor shall be entitled to designate promptly another Nominee and the Company will use its commercially reasonable efforts to ensure that the director position for which such Nominee was nominated shall not be filled pending such designation or that the size of the Board shall be increased by one and such vacancy shall be filled with such successor Nominee as promptly as practicable following such designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5.1.6 Promptly following the request of any Sponsor Director, the Company shall enter into an indemnification agreement with such Sponsor Director, in the form entered into with the other members of the Board. The Company shall pay the reasonable, documented out-of-pocket expenses incurred by the Sponsor Director in connection with his or her services provided to or on behalf of the Company, including attending meetings or events attended explicitly on behalf of the Company at the Company&#8217;s request.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">G-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5.1.7 Any Nominee will be subject to the Company&#8217;s customary due diligence process, including its review of a completed questionnaire and a background check. Based on the foregoing, the Company may object to any Nominee provided (a)&#160;it does so in good faith, and (b)&#160;such objection is based upon any of the following: (i)&#160;such Nominee was convicted in a criminal proceeding or is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses), (ii)&#160;such Nominee was the subject of any order, judgment or decree not subsequently reversed, suspended or vacated of any court of competent jurisdiction, permanently or temporarily enjoining such proposed director from, or otherwise limiting, the following activities: (A)&#160;engaging in any type of business practice, or (B)&#160;engaging in any activity in connection with the purchase or sale of any security or in connection with any violation of federal or state securities laws, (iii)&#160;such Nominee was the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any federal or state authority barring, suspending or otherwise limiting the right of such person to engage in any activity described in clause (ii)(B), or to be associated with persons engaged in such activity, (iv)&#160;such proposed director was found by a court of competent jurisdiction in a civil action or by the Commission to have violated any federal or state securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended or vacated, or (v)&#160;such proposed director was the subject of, or a party to any federal or state judicial or administrative order, judgment, decree or finding, not subsequently reversed, suspended or vacated, relating to a violation of any federal or state securities laws or regulations. In the event the Board reasonably finds the Nominee to be unsuitable based upon one or more of the foregoing clauses (i)&#160;through (v)&#160;and reasonably objects to the identified director, the Sponsor shall be entitled to propose a different nominee to the Board within thirty (30) calendar days of the Company&#8217;s notice to the Sponsor of its objection to the Nominee and such replacement Nominee shall be subject to the review process outlined above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">MISCELLANEOUS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.1 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</span>. Any notice or communication under this Agreement must be in writing and given by (i)&#160;deposit in the United States mail, addressed to the party to be notified, postage prepaid and registered or certified with return receipt requested, (ii)&#160;delivery in person or by courier service providing evidence of delivery, or (iii)&#160;transmission by hand delivery, electronic mail, telecopy, telegram or facsimile. Each notice or communication that is mailed, delivered or transmitted in the manner described above shall be deemed sufficiently given, served, sent, and received, in the case of mailed notices, on the third business day following the date on which it is mailed and, in the case of notices delivered by courier service, hand delivery, electronic mail, telecopy, telegram or facsimile, at such time as it is delivered to the addressee (with the delivery receipt or the affidavit of messenger) or at such time as delivery is refused by the addressee upon presentation. Any notice or communication under this Agreement must be addressed, if to the Company, to: OmniAb,&#160;Inc. 5980 Horton Street, Suite&#160;405, Emeryville, CA 94608, Attention: Charles Berkman, with copy to: Latham&#160;&amp; Watkins LLP, 12670 High Bluff Drive, San Diego, California 92130, Attention: Matthew T. Bush,&#160;Esq., and, if to any Holder, at such Holder&#8217;s address or facsimile number as set forth in the Company&#8217;s books and records. Any party may change its address for notice at any time and from time to time by written notice to the other parties hereto, and such change of address shall become effective thirty (30) days after delivery of such notice as provided in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.1</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.2 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment; No Third Party Beneficiaries</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.2.1 This Agreement and the rights, duties and obligations of the Company hereunder may not be assigned or delegated by the Company in whole or in part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.2.2 Prior to the expiration of the applicable Lock-Up Period, as the case may be, no Holder may assign or delegate such Holder&#8217;s rights, duties or obligations under this Agreement, in whole or in part, except in connection with a Transfer of Registrable Securities by such Holder to a Permitted Transferee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.2.3 This Agreement and the provisions hereof shall be binding upon and shall inure to the benefit of each of the parties and its successors and the permitted assigns of the Holders, which shall include Permitted Transferees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.2.4 This Agreement shall not confer any rights or benefits on any persons that are not parties hereto, other than as expressly set forth in this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">6.2.5 No assignment by any party hereto of such party&#8217;s rights, duties and obligations hereunder shall be binding upon or obligate the Company unless and until the Company shall have received (i)&#160;written notice of such assignment as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.1</span> hereof and (ii)&#160;the written agreement of the assignee, in a form reasonably satisfactory to the Company, to be bound by the terms and </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">G-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">provisions of this Agreement (which may be accomplished by an addendum or certificate of joinder to this Agreement). Any Transfer or assignment made other than as provided in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.2</span> shall be null and void.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.3 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</span>. This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible that is valid and enforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.4 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</span>. This Agreement may be executed in multiple counterparts (including facsimile or PDF counterparts), each of which shall be deemed an original, and all of which together shall constitute the same instrument, but only one of which need be produced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.5 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</span>. This Agreement constitutes the entire agreement of the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements (including the Existing Agreement), representations, understandings, negotiations and discussions between the parties, whether oral or written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.6 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law; Venue</span>. NOTWITHSTANDING THE PLACE WHERE THIS AGREEMENT MAY&#160;BE EXECUTED BY ANY OF THE PARTIES HERETO, THE PARTIES EXPRESSLY AGREE THAT (1)&#160;THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED UNDER THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE CONFLICT OF LAW PROVISIONS OF SUCH JURISDICTION AND (2)&#160;THE VENUE FOR ANY ACTION TAKEN WITH RESPECT TO THIS AGREEMENT SHALL BE ANY STATE OR FEDERAL COURT IN NEW YORK COUNTY IN THE STATE OF NEW YORK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.7 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">WAIVER OF TRIAL BY JURY</span>. EACH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES THE RIGHT TO A TRIAL BY JURY IN ANY ACTION, SUIT, COUNTERCLAIM OR OTHER PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF, CONNECTED WITH OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.8 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments and Modifications</span>. Upon the written consent of the Company and the Holders of at least a majority-in-interest of the Registrable Securities at the time in question, compliance with any of the provisions, covenants and conditions set forth in this Agreement may be waived, or any of such provisions, covenants or conditions may be amended or modified; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that notwithstanding the foregoing, any amendment hereto or waiver hereof that adversely affects one Holder, solely in its capacity as a holder of the shares of the Company, in a manner that is materially different from the other Holders (in such capacity) shall require the consent of the Holder so affected; and provided, further, that the Company may waive the lockup restrictions as set forth in Section&#160;3.6.2. No course of dealing between any Holder or the Company and any other party hereto or any failure or delay on the part of a Holder or the Company in exercising any rights or remedies under this Agreement shall operate as a waiver of any rights or remedies of any Holder or the Company. No single or partial exercise of any rights or remedies under this Agreement by a party shall operate as a waiver or preclude the exercise of any other rights or remedies hereunder or thereunder by such party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.9 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Titles and Headings</span>. Titles and headings of sections of this Agreement are for convenience only and shall not affect the construction of any provision of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.10 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waivers and Extensions</span>. Any party to this Agreement may waive any right, breach or default which such party has the right to waive, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that such waiver will not be effective against the waiving party unless it is in writing, is signed by such party, and specifically refers to this Agreement. Waivers may be made in advance or after the right waived has arisen or the breach or default waived has occurred. Any waiver may be conditional. No waiver of any breach of any agreement or provision herein contained shall be deemed a waiver of any preceding or succeeding breach thereof nor of any other agreement or provision herein contained. No waiver or extension of time for performance of any obligations or acts shall be deemed a waiver or extension of the time for performance of any other obligations or acts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">6.11 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remedies Cumulative</span>. In the event that the Company fails to observe or perform any covenant or agreement to be observed or performed under this Agreement, the Holders may proceed to protect and enforce its rights by suit in equity or action at law, whether for specific performance of any term contained in this Agreement or for an injunction against the breach of any such term or in aid of the exercise of any power granted in this Agreement or to enforce any other legal or equitable right, or to take any one or more of such actions, without being required to post a bond. None of the rights, powers or remedies conferred under this Agreement </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">G-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">shall be mutually exclusive, and each such right, power or remedy shall be cumulative and in addition to any other right, power or remedy, whether conferred by this Agreement or now or hereafter available at law, in equity, by statute or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.12 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Registration Rights</span>. The Company represents and warrants that no person, other than a Holder of Registrable Securities, has any right to require the Company to register any securities of the Company for sale or to include such securities of the Company in any Registration filed by the Company for the sale of securities for its own account or for the account of any other person. Further, the Company represents and warrants that this Agreement supersedes any other registration rights agreement or agreement with similar terms and conditions and in the event of a conflict between any such agreement or agreements and this Agreement, the terms of this Agreement shall prevail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.13 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Holder Information</span>. Each Holder agrees, if requested in writing, to represent to the Company the total number of Registrable Securities held by such Holder, to the extent necessary for the Company to make determinations hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.14 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Third-Party Beneficiaries</span>. In Ligand&#8217;s sole discretion, Ligand may enforce the provisions of Section&#160;1.1 (definition of Holder), <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection 2.2.1</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IV</span>, to the extent applicable, on behalf of the Ligand Equity Award Holders. For the avoidance of doubt, none of the Ligand Equity Award Holders is or is intended to be a third-party beneficiary of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.15 <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</span>. This Agreement shall terminate upon the earlier of (i)&#160;the fifth anniversary of the date of this Agreement and (ii)&#160;with respect to any Holder, on the date that such Holder no longer holds any Registrable Securities. The provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.5</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IV</span> shall survive any termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">[</i>SIGNATURE PAGES FOLLOW<i style="font-style:italic;">]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:0pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">G-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2de454ff_cb46_4f57_b43c_9265b9141e61"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed as of the date first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">COMPANY:</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">OMNIAB, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;">[<i style="font-style:italic;">Signature Page to A&amp;R Registration Rights Agreement</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">HOLDERS:</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">AVISTA ACQUISITION LP II&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By: Avista Acquisition GP LLC II, its general partner</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">David Burgstahler</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Manager</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;">[<i style="font-style:italic;">Signature Page&#160;to A&amp;R Registration Rights Agreement</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:43.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">WILLIAM KLITGAARD</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address:</p></td><td style="vertical-align:top;width:43.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;">[<i style="font-style:italic;">Signature Page&#160;to A&amp;R Registration Rights Agreement</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:43.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">L&#194;LE WHITE</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address:</p></td><td style="vertical-align:top;width:43.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;">[<i style="font-style:italic;">Signature Page&#160;to A&amp;R Registration Rights Agreement</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:43.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">WENDEL BARR</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Address:</p></td><td style="vertical-align:top;width:43.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">NEW HOLDERS:</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">[&#160;&#160;&#160;&#160;]</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By: <b style="font-weight:bold;">[&#160;&#160;&#160;&#160;]</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">[&#160;&#160;&#160;&#160;]</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">[__]</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Solely with respect to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2.1</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;4</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.14</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">LIGAND PHARMACEUTICALS INCORPORATED</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">[<i style="font-style:italic;">Signature Page&#160;to A&amp;R Registration Rights Agreement</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5364fb49_d7f9_4068_96df_0085c159a481"></a><a id="AnnexH_950033"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Annex H</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">CERTIFICATE OF INCORPORATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">OF</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">[OMNIAB,&#160;INC.]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE&#160;I</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">NAME</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The name of the corporation is [OmniAb,&#160;Inc.] (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Corporation</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE&#160;II</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">REGISTERED OFFICE AND AGENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The address of the Corporation&#8217;s registered office in the State of Delaware is [Corporation Service Company, 251 Little Falls Drive, in the City of Wilmington, County of New Castle, 19808], and the name of its registered agent at such address is [Corporation Service Company.]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE&#160;III</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">PURPOSE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DGCL</span>&#8221;) as it now exists or may hereafter be amended and supplemented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE&#160;IV</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">CAPITAL STOCK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Corporation is authorized to issue two classes of stock to be designated, respectively, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Common Stock</span>,&#8221; and &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Preferred Stock</span>.&#8221; The total number of shares of capital stock which the Corporation shall have authority to issue is 1,100,000,000. The total number of shares of Common Stock that the Corporation is authorized to issue is 1,000,000,000, having a par value of $0.0001 per share, and the total number of shares of Preferred Stock that the Corporation is authorized to issue is 100,000,000, having a par value of $0.0001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Upon the filing and effectiveness of this Certificate with the Secretary of State of the State of Delaware (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Time</span>&#8221;), each Class&#160;A ordinary fully paid share, par value $0.0001 per share, and each Class&#160;B ordinary fully paid share, par value $0.0001 per share, of Avista Public Acquisition Corp. II, a Cayman Islands exempted company and the Corporation&#8217;s predecessor prior to its domestication as a Delaware corporation, issued and outstanding or held in treasury immediately prior to the Effective Time (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Old Common Stock</span>&#8221;) and without any action on the part of the holder thereof, shall be reclassified as and converted into one share of Common Stock, with a par value of $0.0001 per share. Any stock certificate or book entry representing shares of Old Common Stock shall thereafter represent a number of whole shares of Common Stock into which such shares of Old Common Stock shall have been reclassified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The designations and the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COMMON STOCK</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</span>.&#160;&#160;&#160;&#160;&#160;The voting, dividend, liquidation, and other rights and powers of the Common Stock are subject to and qualified by the rights, powers and preferences of any series of Preferred Stock as may be designated by the Board of Directors of the Corporation (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board of Directors</span>&#8221;) and outstanding from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voting</span>.&#160;&#160;&#160;&#160;&#160;Except as otherwise provided herein or expressly required by law, each holder of Common Stock, as such, shall be entitled to vote on each matter submitted to a vote of stockholders and shall be entitled to one (1)&#160;vote for each share of Common Stock held of record by such holder as of the record date for determining stockholders entitled to vote on such matter. Except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this Certificate </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">H-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(including any Certificate of Designation (as defined below)) that relates solely to the terms of any outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to this Certificate (including any Certificate of Designation) or pursuant to the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Subject to the rights of any holders of any outstanding series of Preferred Stock, the number of authorized shares of Common Stock or Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding), in each case by the affirmative vote of the holders of a majority of the stock of the Corporation entitled to vote, irrespective of the provisions of Section&#160;242(b)(2)&#160;of the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dividends</span>. Subject to applicable law and the rights and preferences of any holders of any outstanding series of Preferred Stock, the holders of Common Stock, as such, shall be entitled to the payment of dividends on the Common Stock when, as and if declared by the Board of Directors in accordance with applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Liquidation</span>. Subject to the rights and preferences of any holders of any shares of any outstanding series of Preferred Stock, in the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Corporation, and after payment or provision for payment of the debts and other liabilities of the Corporation, if any, the funds and assets of the Corporation that may be legally distributed to the Corporation&#8217;s stockholders shall be distributed among the holders of the then outstanding Common Stock <i style="font-style:italic;">pro rata</i> in accordance with the number of shares of Common Stock held by each such holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">B.</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PREFERRED STOCK</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Shares of Preferred Stock may be issued from time to time in one or more series, each of such series to have such terms as stated or expressed herein and in the resolution or resolutions providing for the creation and issuance of such series adopted by the Board of Directors hereinafter provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Authority is hereby expressly granted to the Board of Directors from time to time to issue the Preferred Stock in one or more series, and in connection with the creation of any such series, by adopting a resolution or resolutions providing for the issuance of the shares thereof and by filing a certificate of designation relating thereto in accordance with the DGCL (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certificate of Designation</span>&#8221;), to determine and fix the number of shares of such series and such voting powers, full or limited, or no voting powers, and such designations, preferences and relative participating, optional or other special rights, and qualifications, limitations or restrictions thereof, including without limitation thereof, dividend rights, conversion rights, redemption privileges and liquidation preferences, and to increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series as shall be stated and expressed in such resolutions, all to the fullest extent now or hereafter permitted by the DGCL. Without limiting the generality of the foregoing, the resolution or resolutions providing for the creation and issuance of any series of Preferred Stock may provide that such series shall be superior or rank equally or be junior to any other series of Preferred Stock to the extent permitted by law and this Certificate (including any Certificate of Designation). Except as otherwise required by law, holders of any series of Preferred Stock shall be entitled only to such voting rights, if any, as shall expressly be granted thereto by this Certificate (including any Certificate of Designation).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of the Corporation entitled to vote, irrespective of the provisions of Section&#160;242(b)(2)&#160;of the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE&#160;V</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">BOARD OF DIRECTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">For the management of the business and for the conduct of the affairs of the Corporation it is further provided that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">A. Other than those directors, if any, elected by the holders of any series of Preferred Stock, the directors of the Corporation shall be classified with respect to the time for which they severally hold office into three (3)&#160;classes, as nearly equal in number as possible, designated as Class&#160;I, Class&#160;II and Class&#160;III. Except for the terms of such additional directors, if any, as elected by the holders of any series of Preferred Stock, each director shall serve for a term ending on the date of the third (3rd) annual meeting of stockholders following the annual meeting at which the director was elected. The initial Class&#160;I directors shall serve for a term expiring at the first (1st) annual meeting of the stockholders following the date of this Certificate; the initial Class&#160;II directors shall serve for a term expiring at the second (2nd) annual meeting of the stockholders following the date of this Certificate; and the initial Class&#160;III directors shall serve for a term expiring at the third (3rd) annual meeting of the stockholders following the date of this Certificate. At each </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">H-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">annual meeting of the stockholders of the Corporation beginning with the first annual meeting of the stockholders following the date of this Certificate, the successors of the class of directors whose term expires at that meeting shall be elected to hold office for a term expiring at the annual meeting of the stockholders held in the third year following the year of their election. If the number of directors is changed, any increase or decrease shall be apportioned among the classes so as to maintain the number of directors in each class as nearly equal as possible, and any additional director of any class elected to fill a vacancy resulting from an increase in such class or from the removal from office, death, resignation, retirement, disqualification, removal of a director or other cause shall hold office for a term that shall coincide with the remaining term of that class. In no event, will a decrease in the number of directors have the effect of removing or shortening the term of any incumbent director. The Board of Directors is authorized to assign members of the Board of Directors already in office to Class&#160;I, Class&#160;II and Class&#160;III.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">B. Except as otherwise expressly provided by the DGCL or this Certificate, the business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors. Except as otherwise provided for or fixed pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Part&#160;E</span> of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</span> relating to the rights of the holders of any series of Preferred Stock to elect additional directors, the number of directors which shall constitute the whole Board of Directors shall be fixed exclusively by one or more resolutions adopted from time to time by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">C. Subject to any special rights of the holders of one or more outstanding series of Preferred Stock to elect directors, the Board of Directors or any individual director may be removed from office at any time, but only for cause and only by the affirmative vote of the holders of at least two-thirds (66 and 2/3%) of the voting power of all of the then outstanding shares of voting stock of the Corporation entitled to vote generally in an election of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">D. Subject to any special rights of the holders of one or more outstanding series of Preferred Stock to elect directors, except as otherwise provided by law, any vacancies on the Board of Directors resulting from death, resignation, retirement, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors shall be filled exclusively by the affirmative vote of a majority of the directors then in office, even though less than a quorum, or by a sole remaining director (other than any directors elected by the separate vote of one or more outstanding series of Preferred Stock), and shall not be filled by the stockholders. Any director appointed in accordance with the preceding sentence shall hold office until the expiration of the term of the class to which such director shall have been appointed or until his or her earlier death, resignation, retirement, disqualification, or removal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">E. Whenever the holders of any one or more series of Preferred Stock issued by the Corporation shall have the right, voting separately as a series or separately as a class with one or more such other series, to elect directors at an annual or special meeting of stockholders, the election, term of office, removal and other features of such directorships shall be governed by the terms of this Certificate (including any Certificate of Designation). Notwithstanding anything to the contrary in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</span>, the number of directors that may be elected by the holders of any such series of Preferred Stock shall be in addition to the number fixed pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Part&#160;B</span> of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</span>, and the total number of directors constituting the whole Board of Directors shall be automatically adjusted accordingly. Except as otherwise provided in the Certificate of Designation(s)&#160;in respect of one or more series of Preferred Stock, whenever the holders of any series of Preferred Stock having such right to elect additional directors are divested of such right pursuant to the provisions of such Certificate of Designation(s), the terms of office of all such additional directors elected by the holders of such series of Preferred Stock, or elected to fill any vacancies resulting from the death, resignation, retirement, disqualification or removal of such additional directors, shall forthwith terminate (in which case each such director thereupon shall cease to be qualified as, and shall cease to be, a director) and the total authorized number of directors of the Corporation shall automatically be reduced accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">F. In furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to adopt, amend or repeal the Bylaws of the Corporation (as amended and/or restated from time to time, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bylaws</span>&#8221;). The stockholders of the Corporation shall also have power to adopt, amend or repeal the Bylaws; provided, however, in addition to any vote of the holders of any class or series of stock of the Corporation required by applicable law or by this Certificate (including any Certificate of Designation in respect of one or more series of Preferred Stock) or the Bylaws of the Corporation, the adoption, amendment or repeal of the Bylaws of the Corporation by the stockholders of the Corporation shall require the affirmative vote of the holders of at least two-thirds (66 and 2/3%) of the voting power of all of the then outstanding shares of voting stock of the Corporation entitled to vote generally in an election of directors, voting together as a single class.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">G. The directors of the Corporation need not be elected by written ballot unless the Bylaws so provide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">H-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE&#160;VI</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">STOCKHOLDERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">A. Any action required or permitted to be taken by the stockholders of the Corporation may be effected only at a duly called annual or special meeting of stockholders and may not be effected by any consent in writing by such stockholders in lieu of such meeting. Notwithstanding the foregoing, any action required or permitted to be taken by the holders of any series of Preferred Stock, voting separately as a series or separately as a class with one or more other such series, may be taken without a meeting, without prior notice and without a vote, to the extent expressly so provided by the applicable Certificate of Designation relating to such series of Preferred Stock, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding shares of the relevant series of Preferred Stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation in accordance with the applicable provisions of the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">B. Subject to the special rights of the holders of one or more series of Preferred Stock, special meetings of the stockholders of the Corporation may be called, for any purpose or purposes, at any time only by or at the direction of (i)&#160;the Board of Directors, (ii)&#160;the Chairperson of the Board of Directors, (iii)&#160;the Chief Executive Officer, or (iv)&#160;the President, and shall not be called by any other person or persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">C. Advance notice of stockholder nominations for the election of directors and of other business proposed to be brought by stockholders before any meeting of the stockholders of the Corporation shall be given in the manner provided in the Bylaws of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE&#160;VII</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">LIABILITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">No director of the Corporation shall have any personal liability to the Corporation or its stockholders for monetary damages for any breach of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL as the same exists or hereafter may be amended. Any amendment, repeal or modification of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VII</span>, or the adoption of any provision of the Certificate inconsistent with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VII</span>, shall not adversely affect any right or protection of a director of the Corporation with respect to any act or omission occurring prior to the time of such amendment, repeal, modification or adoption. If the DGCL is amended after approval by the stockholders of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VII</span> to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL as so amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE&#160;VIII</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">INDEMNIFICATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Corporation shall have the power to provide rights to indemnification and advancement of expenses to its current and former officers, directors, employees and agents and to any person who is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE&#160;IX</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">FORUM SELECTION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Unless the Corporation consents in writing to the selection of an alternative forum, (a)&#160;the Court of Chancery (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chancery Court</span>&#8221;) of the State of Delaware (or, in the event that the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&#160;any derivative action, suit or proceeding (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proceeding</span>&#8221;) brought on behalf of the Corporation, (ii)&#160;any Proceeding asserting a claim of breach of a fiduciary duty owed by any director, officer or stockholder of the Corporation to the Corporation or to the Corporation&#8217;s stockholders, (iii)&#160;any Proceeding arising pursuant to any provision of the DGCL, this Certificate or the Bylaws (in each case, as may be amended from time to time) or (iv)&#160;any Proceeding asserting a claim against the Corporation governed by the internal affairs doctrine; and (b)&#160;subject to the preceding provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span>, to the extent permitted by applicable law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. If any action the subject matter of which is within the scope of clause (a)&#160;of the immediately preceding sentence is filed in a court other than the courts in the State of Delaware (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Foreign Action</span>&#8221;) in the name of any stockholder, such stockholder shall be deemed to have consented to (x)&#160;the personal jurisdiction </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">H-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">of the state and federal courts in the State of Delaware in connection with any action brought in any such court to enforce the provisions of clause (a)&#160;of the immediately preceding sentence and (y)&#160;having service of process made upon such stockholder in any such action by service upon such stockholder&#8217;s counsel in the Foreign Action as agent for such stockholder. If any action the subject matter of which is within the scope of clause (b)&#160;of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span> is filed in a court other than the federal district courts of the United States of America (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Foreign Securities Act Action</span>&#8221;) in the name of any stockholder, such stockholder shall be deemed to have consented to (i)&#160;the personal jurisdiction of the federal district courts of the United States of America in connection with any action brought in any such court to enforce clause (b)&#160;(a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities Act Enforcement Action</span>&#8221;), and (ii)&#160;having service of process made upon such stockholder in any such Securities Act Enforcement Action by service upon such stockholder&#8217;s counsel in the Foreign Securities Act Action as agent for such stockholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">For the avoidance of doubt, clause (b)&#160;of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span> is intended to benefit and may be enforced by the Corporation, its officers and directors, the underwriters to any offering giving rise to any Proceeding, and any other professional or entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Any person or entity purchasing or otherwise acquiring any interest in any security of the Corporation shall be deemed to have notice of and consented to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Notwithstanding the foregoing, the provisions of this Article&#160;IX shall not apply to suits brought to enforce any liability or duty created by the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts of the United States have exclusive jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">If any provision or provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span> shall be held to be invalid, illegal or unenforceable as applied to any circumstance for any reason whatsoever, (i)&#160;the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span> (including, without limitation, each portion of any paragraph of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span> containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and (ii)&#160;the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE&#160;X</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">AMENDMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">A. Notwithstanding anything contained in this Certificate to the contrary, in addition to any vote required by applicable law, the following provisions in this Certificate may be amended, altered, repealed or rescinded, in whole or in part, or any provision inconsistent therewith or herewith may be adopted, only by the affirmative vote of the holders of at least two-thirds (66 and 2/3%) of the total voting power of all of the then outstanding shares of stock of the Corporation entitled to vote thereon, voting together as a single class: <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Part&#160;B</span> of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IV</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VI</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VII</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;VIII</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span>, and this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;X</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">B. If any provision or provisions of this Certificate shall be held to be invalid, illegal or unenforceable as applied to any circumstance for any reason whatsoever: (i)&#160;the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Certificate (including, without limitation, each portion of any paragraph of this Certificate containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) shall not, to the fullest extent permitted by applicable law, in any way be affected or impaired thereby and (ii)&#160;to the fullest extent permitted by applicable law, the provisions of this Certificate (including, without limitation, each such portion of any paragraph of this Certificate containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to permit the Corporation to protect its directors, officers, employees and agents from personal liability in respect of their good faith service to or for the benefit of the Corporation to the fullest extent permitted by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature Page&#160;Follows]</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:0pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">H-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_503136f6_2466_40a7_a26d_d7ab1de4d7fb"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, the Corporation has caused this Certificate to be signed by a duly authorized officer of the Corporation, on [&#8226;], 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">[OMNIAB, INC.]</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">[&#160;<span style="font-family:'Times New Roman';">&#9679;</span>&#160;]</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">[&#160;<span style="font-family:'Times New Roman';">&#9679;</span>&#160;]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature Page to Certificate of Incorporation]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1f45554b_93c8_4c99_aff2_9cb6257952bf"></a><a id="AnnexI_90446"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Annex&#160;I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Confidential</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Bylaws of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">[OmniAb,&#160;Inc.]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(a Delaware corporation)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4e5b4366_c533_4143_8b3d_55f73c2a7112"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TABLE OF CONTENTS</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:92.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:92.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_ARTICLEICORPORATEOFFICES_516887"><span style="font-style:normal;font-weight:normal;">Article&#160;I - Corporate Offices</span></a></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-1</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:92.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section11RegisteredOffice_696341"><span style="font-style:normal;font-weight:normal;">1.1</span></a></p></td><td style="vertical-align:bottom;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section11RegisteredOffice_696341"><span style="font-style:normal;font-weight:normal;">Registered Office</span></a></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-1</p></td></tr><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section12OtherOffices_238215"><span style="font-style:normal;font-weight:normal;">1.2</span></a></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section12OtherOffices_238215"><span style="font-style:normal;font-weight:normal;">Other Offices</span></a></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-1</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:92.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_ARTICLEIIMEETINGSOFSTOCKHOLDERS_227489"><span style="font-style:normal;font-weight:normal;">Article&#160;II - MEETINGS OF STOCKHOLDERS</span></a></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-1</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section21PlaceofMeetings_468283"><span style="font-style:normal;font-weight:normal;">2.1</span></a></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section21PlaceofMeetings_468283"><span style="font-style:normal;font-weight:normal;">Place of Meetings</span></a></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-1</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section22AnnualMeeting_465294"><span style="font-style:normal;font-weight:normal;">2.2</span></a></p></td><td style="vertical-align:bottom;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section22AnnualMeeting_465294"><span style="font-style:normal;font-weight:normal;">Annual Meeting</span></a></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-1</p></td></tr><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section23SpecialMeeting_642230"><span style="font-style:normal;font-weight:normal;">2.3</span></a></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section23SpecialMeeting_642230"><span style="font-style:normal;font-weight:normal;">Special Meeting</span></a></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-1</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section24NoticeofBusiness_615507"><span style="font-style:normal;font-weight:normal;">2.4</span></a></p></td><td style="vertical-align:bottom;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section24NoticeofBusiness_615507"><span style="font-style:normal;font-weight:normal;">Notice of Business to be Brought before a Meeting</span></a></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-1</p></td></tr><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section25NoticeofNominations_444123"><span style="font-style:normal;font-weight:normal;">2.5</span></a></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section25NoticeofNominations_444123"><span style="font-style:normal;font-weight:normal;">Notice of Nominations for Election to the Board</span></a></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-4</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section26NoticeofStockholders_42237"><span style="font-style:normal;font-weight:normal;">2.6</span></a></p></td><td style="vertical-align:bottom;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section26NoticeofStockholders_42237"><span style="font-style:normal;font-weight:normal;">Notice of Stockholders&#8217; Meetings</span></a></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-6</p></td></tr><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section27MannerofGiving_509880"><span style="font-style:normal;font-weight:normal;">2.7</span></a></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section27MannerofGiving_509880"><span style="font-style:normal;font-weight:normal;">Manner of Giving Notice; Affidavit of Notice</span></a></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-6</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section28Quorum_888689"><span style="font-style:normal;font-weight:normal;">2.8</span></a></p></td><td style="vertical-align:bottom;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section28Quorum_888689"><span style="font-style:normal;font-weight:normal;">Quorum</span></a></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-7</p></td></tr><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section29AdjournedMeetingNotice_151692"><span style="font-style:normal;font-weight:normal;">2.9</span></a></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section29AdjournedMeetingNotice_151692"><span style="font-style:normal;font-weight:normal;">Adjourned Meeting; Notice</span></a></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-7</p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section210ConductofBusiness_912762"><span style="font-style:normal;font-weight:normal;">2.10</span></a></p></td><td style="vertical-align:bottom;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section210ConductofBusiness_912762"><span style="font-style:normal;font-weight:normal;">Conduct of Business</span></a></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-7</p></td></tr><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section211Voting_662299"><span style="font-style:normal;font-weight:normal;">2.11</span></a></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section211Voting_662299"><span style="font-style:normal;font-weight:normal;">Voting</span></a></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-8</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section212RecordDate_157643"><span style="font-style:normal;font-weight:normal;">2.12</span></a></p></td><td style="vertical-align:bottom;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section212RecordDate_157643"><span style="font-style:normal;font-weight:normal;">Record Date for Stockholder Meetings and Other Purposes</span></a></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-8</p></td></tr><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section213Proxies_714030"><span style="font-style:normal;font-weight:normal;">2.13</span></a></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section213Proxies_714030"><span style="font-style:normal;font-weight:normal;">Proxies</span></a></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-8</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section214ListofStockholders_144059"><span style="font-style:normal;font-weight:normal;">2.14</span></a></p></td><td style="vertical-align:bottom;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section214ListofStockholders_144059"><span style="font-style:normal;font-weight:normal;">List of Stockholders Entitled to Vote</span></a></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-8</p></td></tr><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section215InspectorsofElection_173837"><span style="font-style:normal;font-weight:normal;">2.15</span></a></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section215InspectorsofElection_173837"><span style="font-style:normal;font-weight:normal;">Inspectors of Election</span></a></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-9</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section216DeliverytotheCorp_48293"><span style="font-style:normal;font-weight:normal;">2.16</span></a></p></td><td style="vertical-align:bottom;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section216DeliverytotheCorp_48293"><span style="font-style:normal;font-weight:normal;">Delivery to the Corporation</span></a></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-9</p></td></tr><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section217StockholderAction"><span style="font-style:normal;font-weight:normal;">2.17</span></a></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section217StockholderAction"><span style="font-style:normal;font-weight:normal;">Stockholder Action by Written Consent Without a Meeting</span></a></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-9</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:92.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_ARTICLEIIIDIRECTORS_585329"><span style="font-style:normal;font-weight:normal;">Article III &#8212; DIRECTORS</span></a></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-10</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:92.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section31Powers_574621"><span style="font-style:normal;font-weight:normal;">3.1</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section31Powers_574621"><span style="font-style:normal;font-weight:normal;">Powers</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-10</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section32NumberofDirectors_205163"><span style="font-style:normal;font-weight:normal;">3.2</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section32NumberofDirectors_205163"><span style="font-style:normal;font-weight:normal;">Number of Directors</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-10</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section33ElectionQualification_433638"><span style="font-style:normal;font-weight:normal;">3.3</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section33ElectionQualification_433638"><span style="font-style:normal;font-weight:normal;">Election, Qualification and Term of Office of Directors</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-10</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section34ResignationandVaca_554826"><span style="font-style:normal;font-weight:normal;">3.4</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section34ResignationandVaca_554826"><span style="font-style:normal;font-weight:normal;">Resignation and Vacancies</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-10</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section35PlaceofMeetings_483833"><span style="font-style:normal;font-weight:normal;">3.5</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section35PlaceofMeetings_483833"><span style="font-style:normal;font-weight:normal;">Place of Meetings; Meetings by Telephone</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-10</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#Section36RegularMeetings_561436_I"><span style="font-style:normal;font-weight:normal;">3.6</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Section36RegularMeetings_561436_I"><span style="font-style:normal;font-weight:normal;">Regular Meetings</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-11</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section37SpecialMeetingsNotice_713621"><span style="font-style:normal;font-weight:normal;">3.7</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section37SpecialMeetingsNotice_713621"><span style="font-style:normal;font-weight:normal;">Special Meetings; Notice</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-11</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section38Quorum_854477"><span style="font-style:normal;font-weight:normal;">3.8</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section38Quorum_854477"><span style="font-style:normal;font-weight:normal;">Quorum</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-11</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section39BoardAction_99847"><span style="font-style:normal;font-weight:normal;">3.9</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section39BoardAction_99847"><span style="font-style:normal;font-weight:normal;">Board Action by Written Consent without a Meeting</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-11</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section310FeesandCompensation_272710"><span style="font-style:normal;font-weight:normal;">3.10</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section310FeesandCompensation_272710"><span style="font-style:normal;font-weight:normal;">Fees and Compensation of Directors</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-11</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section311RemovalofDirectors_458011"><span style="font-style:normal;font-weight:normal;">3.11</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section311RemovalofDirectors_458011"><span style="font-style:normal;font-weight:normal;">Removal of Directors</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-12</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_ARTICLEIVCOMMITTEES_373489"><span style="font-style:normal;font-weight:normal;">Article IV - COMMITTEES</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-12</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section41CommitteesofDirectors_911707"><span style="font-style:normal;font-weight:normal;">4.1</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section41CommitteesofDirectors_911707"><span style="font-style:normal;font-weight:normal;">Committees of Directors</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-12</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section42CommitteeMinutes_147257"><span style="font-style:normal;font-weight:normal;">4.2</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section42CommitteeMinutes_147257"><span style="font-style:normal;font-weight:normal;">Committee Minutes</span></a></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-12</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section43MeetingsandActions_720103"><span style="font-style:normal;font-weight:normal;">4.3</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section43MeetingsandActions_720103"><span style="font-style:normal;font-weight:normal;">Meetings and Actions of Committees</span></a></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-12</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section44Subcommittees_229181"><span style="font-style:normal;font-weight:normal;">4.4</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section44Subcommittees_229181"><span style="font-style:normal;font-weight:normal;">Subcommittees</span></a></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-13</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td colspan="2" style="vertical-align:bottom;width:92.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:92.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_ARTICLEVOFFICERS_139004"><span style="font-style:normal;font-weight:normal;">Article&#160;V - OFFICERS</span></a></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-13</p></td></tr><tr><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section51Officers_765372"><span style="font-style:normal;font-weight:normal;">5.1</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section51Officers_765372"><span style="font-style:normal;font-weight:normal;">Officers</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-13</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section52AppointmentofOfficers_124847"><span style="font-style:normal;font-weight:normal;">5.2</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section52AppointmentofOfficers_124847"><span style="font-style:normal;font-weight:normal;">Appointment of Officers</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-13</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section53SubordinateOfficers_114592"><span style="font-style:normal;font-weight:normal;">5.3</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section53SubordinateOfficers_114592"><span style="font-style:normal;font-weight:normal;">Subordinate Officers</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-13</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section54RemovalandResignation_834611"><span style="font-style:normal;font-weight:normal;">5.4</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section54RemovalandResignation_834611"><span style="font-style:normal;font-weight:normal;">Removal and Resignation of Officers</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-13</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section55VacanciesinOffices_214942"><span style="font-style:normal;font-weight:normal;">5.5</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section55VacanciesinOffices_214942"><span style="font-style:normal;font-weight:normal;">Vacancies in Offices</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-13</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section56RepresentationofShares_259852"><span style="font-style:normal;font-weight:normal;">5.6</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section56RepresentationofShares_259852"><span style="font-style:normal;font-weight:normal;">Representation of Shares of Other Corporations</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-13</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section57AuthorityandDuties_847791"><span style="font-style:normal;font-weight:normal;">5.7</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section57AuthorityandDuties_847791"><span style="font-style:normal;font-weight:normal;">Authority and Duties of Officers</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-14</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section58Compensation_534007"><span style="font-style:normal;font-weight:normal;">5.8</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section58Compensation_534007"><span style="font-style:normal;font-weight:normal;">Compensation</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-14</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:92.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_ARTICLEVIRECORDS_393670"><span style="font-style:normal;font-weight:normal;">Article&#160;VI - RECORDS</span></a></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-14</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:92.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:92.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_ARTICLEVIIGENERALMATTERS_263642"><span style="font-style:normal;font-weight:normal;">Article&#160;VII - GENERAL MATTERS</span></a></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-14</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section71ExecutionofCorporate_24875"><span style="font-style:normal;font-weight:normal;">7.1</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section71ExecutionofCorporate_24875"><span style="font-style:normal;font-weight:normal;">Execution of Corporate Contracts and Instruments</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-14</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section72StockCertificates_59692"><span style="font-style:normal;font-weight:normal;">7.2</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section72StockCertificates_59692"><span style="font-style:normal;font-weight:normal;">Stock Certificates</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-14</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section73SpecialDesignation_998775"><span style="font-style:normal;font-weight:normal;">7.3</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section73SpecialDesignation_998775"><span style="font-style:normal;font-weight:normal;">Special Designation of Certificates</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-15</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section74LostCertificates_778832"><span style="font-style:normal;font-weight:normal;">7.4</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section74LostCertificates_778832"><span style="font-style:normal;font-weight:normal;">Lost Certificates</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-15</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section75SharesWithout_866623"><span style="font-style:normal;font-weight:normal;">7.5</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section75SharesWithout_866623"><span style="font-style:normal;font-weight:normal;">Shares Without Certificates</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-15</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section76Construction_346247"><span style="font-style:normal;font-weight:normal;">7.6</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section76Construction_346247"><span style="font-style:normal;font-weight:normal;">Construction; Definitions</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-15</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section77Dividends_494899"><span style="font-style:normal;font-weight:normal;">7.7</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section77Dividends_494899"><span style="font-style:normal;font-weight:normal;">Dividends</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-15</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section78FiscalYear_592689"><span style="font-style:normal;font-weight:normal;">7.8</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section78FiscalYear_592689"><span style="font-style:normal;font-weight:normal;">Fiscal Year</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-15</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section79Seal_816838"><span style="font-style:normal;font-weight:normal;">7.9</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section79Seal_816838"><span style="font-style:normal;font-weight:normal;">Seal</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-15</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section710TransferofStock_118360"><span style="font-style:normal;font-weight:normal;">7.10</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section710TransferofStock_118360"><span style="font-style:normal;font-weight:normal;">Transfer of Stock</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-16</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section711StockTransfer_128740"><span style="font-style:normal;font-weight:normal;">7.11</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section711StockTransfer_128740"><span style="font-style:normal;font-weight:normal;">Stock Transfer Restrictions; Stock Forfeitures</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-16</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section712RegisteredStock_398770"><span style="font-style:normal;font-weight:normal;">7.12</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section712RegisteredStock_398770"><span style="font-style:normal;font-weight:normal;">Registered Stockholders</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-16</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section713WaiverofNotice_972371"><span style="font-style:normal;font-weight:normal;">7.13</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section713WaiverofNotice_972371"><span style="font-style:normal;font-weight:normal;">Waiver of Notice</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-16</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:92.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_ARTICLEVIIINOTICE_944409"><span style="font-style:normal;font-weight:normal;">Article VIII - NOTICE</span></a></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-16</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:92.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section81DeliveryofNotice_512518"><span style="font-style:normal;font-weight:normal;">8.1</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section81DeliveryofNotice_512518"><span style="font-style:normal;font-weight:normal;">Delivery of Notice; Notice by Electronic Transmission</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-16</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_ARTICLEIXINDEMNIFICATION_874383"><span style="font-style:normal;font-weight:normal;">Article IX - INDEMNIFICATION</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-17</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section91Indemnification_65369"><span style="font-style:normal;font-weight:normal;">9.1</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section91Indemnification_65369"><span style="font-style:normal;font-weight:normal;">Indemnification of Directors and Officers</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-17</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section92Indemnificationof_194376"><span style="font-style:normal;font-weight:normal;">9.2</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section92Indemnificationof_194376"><span style="font-style:normal;font-weight:normal;">Indemnification of Others</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-17</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section93PrepaymentofExpenses_529491"><span style="font-style:normal;font-weight:normal;">9.3</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section93PrepaymentofExpenses_529491"><span style="font-style:normal;font-weight:normal;">Prepayment of Expenses</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-18</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section94Determination_834603"><span style="font-style:normal;font-weight:normal;">9.4</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section94Determination_834603"><span style="font-style:normal;font-weight:normal;">Determination; Claim</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-26</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section95NonExclusivity_329070"><span style="font-style:normal;font-weight:normal;">9.5</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section95NonExclusivity_329070"><span style="font-style:normal;font-weight:normal;">Non-Exclusivity of Rights</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-18</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section96Insurance_881924"><span style="font-style:normal;font-weight:normal;">9.6</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section96Insurance_881924"><span style="font-style:normal;font-weight:normal;">Insurance</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-18</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section97OtherIndemnification_843266"><span style="font-style:normal;font-weight:normal;">9.7</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section97OtherIndemnification_843266"><span style="font-style:normal;font-weight:normal;">Other Indemnification</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-18</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section98Continuation_459073"><span style="font-style:normal;font-weight:normal;">9.8</span></a></p></td><td style="vertical-align:top;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section98Continuation_459073"><span style="font-style:normal;font-weight:normal;">Continuation of Indemnification</span></a></p></td><td style="vertical-align:top;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-18</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 21.6pt;"><a href="#I_Section99Amendment_654665"><span style="font-style:normal;font-weight:normal;">9.9</span></a></p></td><td style="vertical-align:top;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_Section99Amendment_654665"><span style="font-style:normal;font-weight:normal;">Amendment or Repeal; Interpretation</span></a></p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-18</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:92.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_ARTICLEXAMENDMENTS_983065"><span style="font-style:normal;font-weight:normal;">Article&#160;X - AMENDMENTS</span></a></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-19</p></td></tr><tr><td style="vertical-align:bottom;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:92.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#I_ARTICLEXIDEFINITIONS_199693"><span style="font-style:normal;font-weight:normal;">Article&#160;XI - DEFINITIONS</span></a></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">I-19</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_aa03819a_5f71_4570_94aa_60e9e714a467"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Bylaws of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">[OmniAb,&#160;Inc.]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_ARTICLEICORPORATEOFFICES_516887"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;I &#8212; </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CORPORATE OFFICES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section11RegisteredOffice_696341"></a><a id="Section11RegisteredOffice_31499"></a><a id="Section11RegisteredOffice_696341"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registered Office</span>. The address of the registered office of [OmniAb,&#160;Inc.] (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Corporation</span>&#8221;) in the State of Delaware, and the name of its registered agent at such address, shall be as set forth in the Corporation&#8217;s certificate of incorporation, as the same may be amended and/or restated from time to time (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certificate of Incorporation</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section12OtherOffices_238215"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Offices</span>. The Corporation may have additional offices at any place or places, within or outside the State of Delaware, as the Corporation&#8217;s board of directors (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</span>&#8221;) may from time to time establish or as the business of the Corporation may require.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_ARTICLEIIMEETINGSOFSTOCKHOLDERS_227489"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;II &#8212; </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MEETINGS OF STOCKHOLDERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section21PlaceofMeetings_468283"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Place of Meetings</span>. Meetings of stockholders shall be held at any place, within or outside the State of Delaware, designated by the Board. The Board may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication as authorized by Section&#160;211(a)&#160;of the General Corporation Law of the State of Delaware (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DGCL</span>&#8221;). In the absence of any such designation or determination, stockholders&#8217; meetings shall be held at the Corporation&#8217;s principal executive office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section22AnnualMeeting_465294"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual Meeting</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Board shall designate the date and time of the annual meeting. At the annual meeting, directors shall be elected and other proper business properly brought before the meeting in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span> may be transacted. The Board may postpone, reschedule or cancel any previously scheduled annual meeting of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section23SpecialMeeting_642230"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Special Meeting</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Special meetings of the stockholders may be called only by such persons and only in such manner as set forth in the Certificate of Incorporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">No business may be transacted at any special meeting of stockholders other than the business specified in the notice of such meeting. The Board may postpone, reschedule or cancel any previously scheduled special meeting of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section24NoticeofBusiness_615507"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Business to be Brought before a Meeting</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>At an annual meeting of the stockholders, only such business shall be conducted as shall have been properly brought before the meeting. To be properly brought before an annual meeting, business must be (i)&#160;specified in a notice of meeting given by or at the direction of the Board, (ii)&#160;if not specified in a notice of meeting, otherwise brought before the meeting by the Board or the Chairperson of the Board or (iii)&#160;otherwise properly brought before the meeting by a stockholder present in person who (A)&#160;(1)&#160;was a record owner of shares of the Corporation both at the time of giving the notice provided for in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span> and at the time of the meeting, (2)&#160;is entitled to vote at the meeting and (3)&#160;has complied with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span> in all applicable respects or (B)&#160;properly made such proposal in accordance with Rule&#160;14a-8 under the Securities Exchange Act of 1934, as amended, and the rules&#160;and regulations thereunder (as so amended and inclusive of such rules&#160;and regulations, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Act</span>&#8221;). The foregoing clause (iii)&#160;shall be the exclusive means for a stockholder to propose business to be brought before an annual meeting of the stockholders. The only matters that may be brought before a special meeting are the matters specified in the notice of meeting given by or at the direction of the person calling the meeting pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.3</span>, and stockholders shall not be permitted to propose business to be brought before a special meeting of the stockholders. For purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span>, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">present in person</span>&#8221; shall mean that the stockholder proposing that the business be brought before the annual meeting of the Corporation, or a qualified representative of such proposing stockholder, appear at such annual meeting in person, or by remote communication, if applicable. A &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">qualified representative</span>&#8221; of such proposing stockholder shall be a duly authorized officer, manager or partner of such stockholder or any other person authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders. Stockholders seeking to nominate persons for election to the Board must comply with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span>, and this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span> shall not be applicable to nominations except as expressly provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Without qualification, for business to be properly brought before an annual meeting by a stockholder, the stockholder must (i)&#160;provide Timely Notice (as defined below) thereof in writing and in proper form to the Secretary of the Corporation and (ii)&#160;provide any updates or supplements to such notice at the times and in the forms required by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span>. To be timely, a stockholder&#8217;s notice must be delivered to, or mailed and received at, the principal executive offices of the Corporation not less than ninety (90) days nor more than one hundred twenty (120) days prior to the one-year anniversary of the preceding year&#8217;s annual meeting; <i style="font-style:italic;">provided, however</i>, that if no annual meeting was held in the preceding year, to be timely, a stockholder&#8217;s notice must be so delivered, or mailed and received, not earlier than the close of business on the one hundred and twentieth (120<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>) day prior to such annual meeting and not later than the close of business on the later of the ninetieth (90<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>) day prior to such annual meeting or, if later, the tenth (10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>) day following the day on which public disclosure of the date of such annual meeting was first made by the Corporation; <i style="font-style:italic;">provided, further</i>, that if the date of the annual meeting is more than thirty (30) days before or more than sixty (60) days after such anniversary date, to be timely, a stockholder&#8217;s notice must be so delivered, or mailed and received, not later than the ninetieth (90<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>) day prior to such annual meeting or, if later, the tenth (10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>) day following the day on which public disclosure of the date of such annual meeting was first made by the Corporation (such notice within such time periods, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Timely Notice</span>&#8221;). In no event shall any adjournment or postponement of an annual meeting or the announcement thereof commence a new time period for the giving of Timely Notice as described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>To be in proper form for purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span>, a stockholder&#8217;s notice to the Secretary of the Corporation shall set forth:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>As to each Proposing Person (as defined below), (A)&#160;the name and address of such Proposing Person (including, if applicable, the name and address that appear on the Corporation&#8217;s books and records); and (B)&#160;the class or series and number of shares of the Corporation that are, directly or indirectly, owned of record or beneficially owned (within the meaning of Rule&#160;13d-3 under the Exchange Act) by such Proposing Person, except that such Proposing Person shall in all events be deemed to beneficially own any shares of any class or series of the Corporation as to which such Proposing Person has a right to acquire beneficial ownership at any time in the future (the disclosures to be made pursuant to the foregoing clauses (A)&#160;and (B)&#160;are referred to as &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stockholder Information</span>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>As to each Proposing Person, (A)&#160;the full notional amount of any securities that, directly or indirectly, underlie any &#8220;derivative security&#8221; (as such term is defined in Rule&#160;16a-1(c)&#160;under the Exchange Act) that constitutes a &#8220;call equivalent position&#8221; (as such term is defined in Rule&#160;16a-1(b)&#160;under the Exchange Act) (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Synthetic Equity Position</span>&#8221;) and that is, directly or indirectly, held or maintained by such Proposing Person with respect to any shares of any class or series of shares of the Corporation; <i style="font-style:italic;">provided</i> that, for the purposes of the definition of &#8220;Synthetic Equity Position,&#8221; the term &#8220;derivative security&#8221; shall also include any security or instrument that would not otherwise constitute a &#8220;derivative security&#8221; as a result of any feature that would make any conversion, exercise or similar right or privilege of such security or instrument becoming determinable only at some future date or upon the happening of a future occurrence, in which case the determination of the amount of securities into which such security or instrument would be convertible or exercisable shall be made assuming that such security or instrument is immediately convertible or exercisable at the time of such determination; and, <i style="font-style:italic;">provided, further</i>, that any Proposing Person satisfying the requirements of Rule&#160;13d-1(b)(1)&#160;under the Exchange Act (other than a Proposing Person that so satisfies Rule&#160;13d-1(b)(1)&#160;under the Exchange Act solely by reason of Rule&#160;13d-1(b)(1)(ii)(E)) shall not be deemed to hold or maintain the notional amount of any securities that underlie a Synthetic Equity Position held by such Proposing Person as a hedge with respect to a bona fide derivatives trade or position of such Proposing Person arising in the ordinary course of such Proposing Person&#8217;s business as a derivatives dealer, (B)&#160;any rights to dividends on the shares of any class or series of shares of the Corporation owned beneficially by such Proposing Person that are separated or separable from the underlying shares of the Corporation, (C)&#160;any material pending or threatened legal proceeding in which such Proposing Person is a party or material participant involving the Corporation or any of its officers or directors, or any affiliate of the Corporation, (D)&#160;any other material relationship between such Proposing Person, on the one hand, and the Corporation or any affiliate of the Corporation, on the other hand, (E)&#160;any direct or indirect material interest in any material contract or agreement of such Proposing Person with the Corporation or any affiliate of the Corporation (including, in any such case, any employment agreement, collective bargaining agreement or consulting agreement), (F)&#160;a representation that such Proposing Person intends or is part of a group that intends to deliver a proxy statement or form of proxy to holders of at least the percentage of the Corporation&#8217;s outstanding capital stock required to approve or adopt the proposal or otherwise solicit proxies from stockholders in support of such proposal and (G)&#160;any other information relating to such Proposing Person that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies or consents by such Proposing Person in support of the business proposed to be brought before the meeting pursuant to Section&#160;14(a)&#160;of the Exchange Act (the disclosures to be made pursuant to the foregoing clauses (A)&#160;through (G)&#160;are </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">referred to as &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosable Interests</span>&#8221;); <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that Disclosable Interests shall not include any such disclosures with respect to the ordinary course business activities of any broker, dealer, commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder directed to prepare and submit the notice required by these bylaws on behalf of a beneficial owner; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>As to each item of business that the stockholder proposes to bring before the annual meeting, (A)&#160;a brief description of the business desired to be brought before the annual meeting, the reasons for conducting such business at the annual meeting and any material interest in such business of each Proposing Person, (B)&#160;the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend the bylaws, the language of the proposed amendment), (C)&#160;a reasonably detailed description of all agreements, arrangements and understandings (x)&#160;between or among any of the Proposing Persons or (y)&#160;between or among any Proposing Person and any other person or entity (including their names) in connection with the proposal of such business by such stockholder, and (D)&#160;any other information relating to such item of business that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies in support of the business proposed to be brought before the meeting pursuant to Section&#160;14(a)&#160;of the Exchange Act; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that the disclosures required by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4(c)(iii)</span>&#160;shall not include any disclosures with respect to any broker, dealer, commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder directed to prepare and submit the notice required by these bylaws on behalf of a beneficial owner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">For purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span>, the term &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proposing Person</span><i style="font-style:italic;">&#8221; </i>shall mean (i)&#160;the stockholder providing the notice of business proposed to be brought before an annual meeting, (ii)&#160;the beneficial owner or beneficial owners, if different, on whose behalf the notice of the business proposed to be brought before the annual meeting is made, and (iii)&#160;any participant (as defined in paragraphs (a)(ii)-(vi)&#160;of Instruction 3 to Item 4 of Schedule 14A) with such stockholder in such solicitation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>A Proposing Person shall update and supplement its notice to the Corporation of its intent to propose business at an annual meeting, if necessary, so that the information provided or required to be provided in such notice pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span> shall be true and correct as of the record date for stockholders entitled to vote at the meeting and as of the date that is ten (10)&#160;business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary of the Corporation at the principal executive offices of the Corporation not later than five (5)&#160;business days after the record date for stockholders entitled to vote at the meeting (in the case of the update and supplement required to be made as of such record date), and not later than eight (8)&#160;business days prior to the date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of ten (10)&#160;business days prior to the meeting or any adjournment or postponement thereof). For the avoidance of doubt, the obligation to update and supplement as set forth in this paragraph or any other Section&#160;of these bylaws shall not limit the Corporation&#8217;s rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any proposal or to submit any new proposal, including by changing or adding matters, business or resolutions proposed to be brought before a meeting of the stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Notwithstanding anything in these bylaws to the contrary, no business shall be conducted at an annual meeting that is not properly brought before the meeting in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span>. The presiding officer of the meeting shall, if the facts warrant, determine that the business was not properly brought before the meeting in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span>, and if he or she should so determine, he or she shall so declare to the meeting and any such business not properly brought before the meeting shall not be transacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>This <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span> is expressly intended to apply to any business proposed to be brought before an annual meeting of stockholders other than any proposal made in accordance with Rule&#160;14a-8 under the Exchange Act and included in the Corporation&#8217;s proxy statement. In addition to the requirements of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span> with respect to any business proposed to be brought before an annual meeting, each Proposing Person shall comply with all applicable requirements of the Exchange Act with respect to any such business. Nothing in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span> shall be deemed to affect the rights of stockholders to request inclusion of proposals in the Corporation&#8217;s proxy statement pursuant to Rule&#160;14a-8 under the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>For purposes of these bylaws, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">public disclosure</span>&#8221; shall mean disclosure in a press release reported by a national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Sections 13, 14 or 15(d)&#160;of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section25NoticeofNominations_444123"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Nominations for Election to the Board</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Subject in all respects to the provisions of the Certificate of Incorporation, nominations of any person for election to the Board at an annual meeting or at a special meeting (but only if the election of directors is a matter specified in the notice of meeting given by or at the direction of the person calling such special meeting) may be made at such meeting only (i)&#160;by or at the direction of the Board, including by any committee or persons authorized to do so by the Board or these bylaws, or (ii)&#160;by a stockholder present in person (A)&#160;who was a record owner of shares of the Corporation both at the time of giving the notice provided for in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span> and at the time of the meeting, (B)&#160;is entitled to vote at the meeting, and (C)&#160;has complied with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span> as to such notice and nomination. For purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span>, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">present in person</span>&#8221; shall mean that the stockholder proposing that the business be brought before the meeting of the Corporation, or a qualified representative of such stockholder, appear at such meeting in person, or by remote communication, if applicable. A &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">qualified representative</span>&#8221; of such proposing stockholder shall be a duly authorized officer, manager or partner of such stockholder or any other person authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders. The foregoing clause (iii)&#160;shall be the exclusive means for a stockholder to make any nomination of a person or persons for election to the Board at an annual meeting or special meeting other than in accordance with the provisions of the Certificate of Incorporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>(i)&#160;For a stockholder to make any nomination of a person or persons for election to the Board at an annual meeting, the stockholder must (1)&#160;provide Timely Notice (as defined in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span>) thereof in writing and in proper form to the Secretary of the Corporation, (2)&#160;provide the information, agreements and questionnaires with respect to such stockholder and its candidate for nomination as required to be set forth by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span> and (3)&#160;provide any updates or supplements to such notice at the times and in the forms required by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>If the election of directors is a matter specified in the notice of meeting given by or at the direction of the person calling a special meeting, then for a stockholder to make any nomination of a person or persons for election to the Board at a special meeting, the stockholder must (i)&#160;provide Timely Notice thereof in writing and in proper form to the Secretary of the Corporation at the principal executive offices of the Corporation, (ii)&#160;provide the information with respect to such stockholder and its candidate for nomination as required by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span> and (iii)&#160;provide any updates or supplements to such notice at the times and in the forms required by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span>. To be timely, a stockholder&#8217;s notice for nominations to be made at a special meeting must be delivered to, or mailed and received at, the principal executive offices of the Corporation not earlier than the one hundred twentieth (120<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>) day prior to such special meeting and not later than the ninetieth (90<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>) day prior to such special meeting or, if later, the tenth (10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>) day following the day on which public disclosure (as defined in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span>) of the date of such special meeting was first made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>In no event shall any adjournment or postponement of an annual meeting or special meeting or the announcement thereof commence a new time period for the giving of a stockholder&#8217;s notice as described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span>In no event may a Nominating Person provide Timely Notice with respect to a greater number of director candidates than are subject to election by stockholders at the applicable meeting. If the Corporation shall, subsequent to such notice, increase the number of directors subject to election at the meeting, such notice as to any additional nominees shall be due on the later of (i)&#160;the conclusion of the time period for Timely Notice, (ii)&#160;the date set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5(b)(ii)</span>&#160;or (iii)&#160;the tenth day following the date of public disclosure (as defined in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4</span>) of such increase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>To be in proper form for purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span>, a stockholder&#8217;s notice to the Secretary of the Corporation shall set forth:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>As to each Nominating Person (as defined below), the Stockholder Information (as defined in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4(c)(i)</span>&#160;of these bylaws), except that for purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span>, the term &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nominating Person</span>&#8221; shall be substituted for the term &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proposing Person</span>&#8221; in all places it appears in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4(c)(i)</span>);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>As to each Nominating Person, any Disclosable Interests (as defined in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4(c)(ii)</span>, except that for purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span>, the term &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nominating Person</span>&#8221; shall be substituted for the term &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proposing Person</span>&#8221; in all places it appears in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4(c)(ii)</span>&#160;and the disclosure with respect to the business to be brought before the meeting in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4(c)(ii)</span>&#160;shall be made with respect to the election of directors at the meeting); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>As to each candidate whom a Nominating Person proposes to nominate for election as a director, (A)&#160;all information with respect to such candidate for nomination that would be required to be set forth in a stockholder&#8217;s notice pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span> if such candidate for nomination were a Nominating Person, (B)&#160;all information relating to such candidate for nomination that is required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors in a contested election pursuant to Section&#160;14(a)&#160;under the Exchange Act (including such candidate&#8217;s written consent to being named in the proxy statement as a nominee and to serving as a director if elected), (C)&#160;a description of any direct or indirect material interest in any material contract or agreement between or among any Nominating Person, on the one hand, and each candidate for nomination or his or her respective associates or any other participants in such solicitation, on the other hand, including, without limitation, all information that would be required to be disclosed pursuant to Item 404 under Regulation S-K if such Nominating Person were the &#8220;registrant&#8221; for purposes of such rule&#160;and the candidate for nomination were a director or executive officer of such registrant and (D)&#160;a completed and signed questionnaire, representation and agreement as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5(f)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">For purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span>, the term &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nominating Person</span>&#8221; shall mean (i)&#160;the stockholder providing the notice of the nomination proposed to be made at the meeting, (ii)&#160;the beneficial owner or beneficial owners, if different, on whose behalf the notice of the nomination proposed to be made at the meeting is made, and (iii)&#160;any other participant (as defined in paragraphs (a)(ii)-(vi)&#160;of Instruction 3 to Item 4 of Schedule 14A) in such solicitation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>A stockholder providing notice of any nomination proposed to be made at a meeting shall further update and supplement such notice, if necessary, so that the information provided or required to be provided in such notice pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span> shall be true and correct as of the record date for stockholders entitled to vote at the meeting and as of the date that is ten (10)&#160;business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary of the Corporation at the principal executive offices of the Corporation not later than five (5)&#160;business days after the record date for stockholders entitled to vote at the meeting (in the case of the update and supplement required to be made as of such record date), and not later than eight (8)&#160;business days prior to the date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of ten (10)&#160;business days prior to the meeting or any adjournment or postponement thereof). For the avoidance of doubt, the obligation to update and supplement as set forth in this paragraph or any other Section&#160;of these bylaws shall not limit the Corporation&#8217;s rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any nomination or to submit any new nomination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>In addition to the requirements of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span> with respect to any nomination proposed to be made at a meeting, each Nominating Person shall comply with all applicable requirements of the Exchange Act with respect to any such nominations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>To be eligible to be a candidate for election as a director of the Corporation at an annual or special meeting, a candidate must be nominated in the manner prescribed in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span> and the candidate for nomination, whether nominated by the Board or by a stockholder of record, must have previously delivered (in accordance with the time period prescribed for delivery in a notice to such candidate given by or on behalf of the Board), to the Secretary of the Corporation at the principal executive offices of the Corporation, (i)&#160;a completed written questionnaire (in a form provided by the Corporation) with respect to the background, qualifications, stock ownership and independence of such proposed nominee and (ii)&#160;a written representation and agreement (in form provided by the Corporation) that such candidate for nomination (A)&#160;is not and, if elected as a director during his or her term of office, will not become a party to (1)&#160;any agreement, arrangement or understanding with, and has not given and will not give any commitment or assurance to, any person or entity as to how such proposed nominee, if elected as a director of the Corporation, will act or vote on any issue or question (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voting Commitment</span>&#8221;) or (2)&#160;any Voting Commitment that could limit or interfere with such proposed nominee&#8217;s ability to comply, if elected as a director of the Corporation, with such proposed nominee&#8217;s fiduciary duties under applicable law, (B)&#160;is not, and will not become a party to, any agreement, arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation or </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">reimbursement for service as a director that has not been disclosed to the Corporation and (C)&#160;if elected as a director of the Corporation, will comply with all applicable corporate governance, conflict of interest, confidentiality, stock ownership and trading and other policies and guidelines of the Corporation applicable to directors and in effect during such person&#8217;s term in office as a director (and, if requested by any candidate for nomination, the Secretary of the Corporation shall provide to such candidate for nomination all such policies and guidelines then in effect).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>The Board may also require any proposed candidate for nomination as a Director to furnish such other information as may reasonably be requested by the Board in writing prior to the meeting of stockholders at which such candidate&#8217;s nomination is to be acted upon in order for the Board to determine the eligibility of such candidate for nomination to be an independent director of the Corporation in accordance with the Corporation&#8217;s corporate governance guidelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>A candidate for nomination as a director shall further update and supplement the materials delivered pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span>, if necessary, so that the information provided or required to be provided pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span> shall be true and correct as of the record date for stockholders entitled to vote at the meeting and as of the date that is ten (10)&#160;business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary of the Corporation at the principal executive offices of the Corporation (or any other office specified by the Corporation in any public announcement) not later than five (5)&#160;business days after the record date for stockholders entitled to vote at the meeting (in the case of the update and supplement required to be made as of such record date), and not later than eight (8)&#160;business days prior to the date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of ten (10)&#160;business days prior to the meeting or any adjournment or postponement thereof). For the avoidance of doubt, the obligation to update and supplement as set forth in this paragraph or any other Section&#160;of these bylaws shall not limit the Corporation&#8217;s rights with respect to any deficiencies in any materials delivered pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span> by a candidate for director, extend any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any proposal or to submit any new proposal, including by changing or adding nominees, matters, business or resolutions proposed to amend or update any nomination or to submit any new nomination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>No candidate shall be eligible for nomination as a director of the Corporation unless such candidate for nomination and the Nominating Person seeking to place such candidate&#8217;s name in nomination has complied with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span>. The presiding officer at the meeting shall, if the facts warrant, determine that a nomination was not properly made in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span>, and if he or she should so determine, he or she shall so declare such determination to the meeting, the defective nomination shall be disregarded and any ballots cast for the candidate in question (but in the case of any form of ballot listing other qualified nominees, only the votes cast for the nominee in question) shall be void and of no force or effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span>Notwithstanding anything in these bylaws to the contrary, no candidate for nomination shall be eligible to be seated as a director of the Corporation unless nominated and elected in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.5</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section26NoticeofStockholders_42237"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Stockholders&#8217; Meetings</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Unless otherwise provided by law, the Certificate of Incorporation or these bylaws, the notice of any meeting of stockholders shall be sent or otherwise given in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.1</span> not less than ten (10)&#160;nor more than sixty (60) days before the date of the meeting to each stockholder entitled to vote at such meeting. The notice shall specify the place, if any, date and time of the meeting, the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section27MannerofGiving_509880"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manner of Giving Notice; Affidavit of Notice</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Notice of any meeting of stockholders shall be deemed given:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>if mailed, when deposited in the U.S. mail, postage prepaid, directed to the stockholder at his or her address as it appears on the Corporation&#8217;s records; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>if electronically transmitted as provided in the DGCL.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">An affidavit of the secretary or an assistant secretary of the Corporation or of the transfer agent or any other agent of the Corporation that the notice has been given by mail or by a form of electronic transmission, as applicable, shall, in the absence of fraud, be prima facie evidence of the facts stated therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section28Quorum_888689"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quorum</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Unless otherwise provided by law, the Certificate of Incorporation or these bylaws, the holders of a majority in voting power of the stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. A quorum, once established at a meeting, shall not be broken by the withdrawal of enough votes to leave less than a quorum. If, however, a quorum is not present or represented at any meeting of the stockholders, then either (i)&#160;the person presiding over the meeting or (ii)&#160;a majority in voting power of the stockholders entitled to vote at the meeting, present in person, or by remote communication, if applicable, or represented by proxy, shall have power to recess the meeting or adjourn the meeting from time to time in the manner provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.9</span> until a quorum is present or represented. At any recessed or adjourned meeting at which a quorum is present or represented, any business may be transacted that might have been transacted at the meeting as originally noticed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section29AdjournedMeetingNotice_151692"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjourned Meeting; Notice</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">When a meeting is adjourned to another time or place, unless these bylaws otherwise require, notice need not be given of the adjourned meeting if the time, place, if any, thereof, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken. At any adjourned meeting, the Corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty (30) days, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. If after the adjournment a new record date for determination of stockholders entitled to vote is fixed for the adjourned meeting, the Board shall fix as the record date for determining stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote at the adjourned meeting, and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such meeting as of the record date so fixed for notice of such adjourned meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section210ConductofBusiness_912762"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conduct of Business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced at the meeting by the person presiding over the meeting. The Board may adopt by resolution such rules&#160;and regulations for the conduct of the meeting of stockholders as it shall deem appropriate. At every meeting of the stockholders, the Chairperson of the Board, or in his or her absence or inability to act, the Chief Executive Officer, or in his or her absence or inability to act, the officer or director whom the Board shall appoint, shall act as chairperson of, and preside at the meeting. Except to the extent inconsistent with such rules&#160;and regulations as adopted by the Board, the person presiding over any meeting of stockholders shall have the right and authority to convene and (for any or no reason) to recess and/or adjourn the meeting, to prescribe such rules, regulations and procedures (which need not be in writing) and to do all such acts as, in the judgment of such presiding person, are appropriate for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the Board or prescribed by the person presiding over the meeting, may include, without limitation, the following: (i)&#160;the establishment of an agenda or order of business for the meeting; (ii)&#160;rules&#160;and procedures for maintaining order at the meeting and the safety of those present (including, without limitation, rules&#160;and procedures for removal of disruptive persons from the meeting); (iii)&#160;limitations on attendance at or participation in the meeting to stockholders entitled to vote at the meeting, their duly authorized and constituted proxies or such other persons as the person presiding over the meeting shall determine; (iv)&#160;restrictions on entry to the meeting after the time fixed for the commencement thereof; and (v)&#160;limitations on the time allotted to questions or comments by participants. The presiding person at any meeting of stockholders, in addition to making any other determinations that may be appropriate to the conduct of the meeting (including, without limitation, determinations with respect to the administration and/or interpretation of any of the rules, regulations or procedures of the meeting, whether adopted by the Board or prescribed by the person presiding over the meeting), shall, if the facts warrant, determine and declare to the meeting that a matter of business was not properly brought before the meeting and if such presiding person should so determine, such presiding person shall so declare to the meeting and any such matter or business not properly brought before the meeting shall not be transacted or considered. Unless and to the extent determined by the Board or the person presiding over the meeting, meetings of stockholders shall not be required to be held in accordance with the rules&#160;of parliamentary procedure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="I_Section211Voting_662299"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voting</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Except as may be otherwise provided in the Certificate of Incorporation, these bylaws or the DGCL, each stockholder shall be entitled to one (1)&#160;vote for each share of capital stock held by such stockholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Except as otherwise provided by the Certificate of Incorporation, at all duly called or convened meetings of stockholders at which a quorum is present, for the election of directors, a plurality of the votes cast shall be sufficient to elect a director. Except as otherwise provided by the Certificate of Incorporation, these bylaws, the rules&#160;or regulations of any stock exchange applicable to the Corporation, or applicable law or pursuant to any regulation applicable to the Corporation or its securities, each other matter presented to the stockholders at a duly called or convened meeting at which a quorum is present shall be decided by the affirmative vote of the holders of a majority in voting power of the votes cast (excluding abstentions and broker non-votes) on such matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section212RecordDate_157643"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.12</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Record Date for Stockholder Meetings and Other Purposes</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board, and which record date shall, unless otherwise required by law, not be more than sixty (60) days nor less than ten (10)&#160;days before the date of such meeting. If the Board so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be the close of business on the next day preceding the day on which notice is first given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <i style="font-style:italic;">provided, however</i>, that the Board may fix a new record date for determination of stockholders entitled to vote at the adjourned meeting; and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance herewith at the adjourned meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment or any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of capital stock, or for the purposes of any other lawful action, the Board may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than sixty (60) days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board adopts the resolution relating thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section213Proxies_714030"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.13</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proxies</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Each stockholder entitled to vote at a meeting of stockholders may authorize another person or persons to act for such stockholder by proxy authorized by an instrument in writing or by a transmission permitted by law filed in accordance with the procedure established for the meeting, but no such proxy shall be voted or acted upon after three (3)&#160;years from its date, unless the proxy provides for a longer period. The revocability of a proxy that states on its face that it is irrevocable shall be governed by the provisions of Section&#160;212 of the DGCL. A proxy may be in the form of an electronic transmission which sets forth or is submitted with information from which it can be determined that the electronic transmission was authorized by the stockholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than white, which shall be reserved for the exclusive use by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section214ListofStockholders_144059"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.14</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">List of Stockholders Entitled to Vote</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Corporation shall prepare, at least ten (10)&#160;days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting (<i style="font-style:italic;">provided, however</i>, that if the record date for determining the stockholders entitled to vote is less than ten (10)&#160;days before the date of the meeting, the list shall reflect the stockholders entitled to vote as of the tenth (10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>) day before the meeting date), arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. The Corporation shall not be required to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting for a </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">period of at least ten (10)&#160;days prior to the meeting: (i)&#160;on a reasonably accessible electronic network, <i style="font-style:italic;">provided</i> that the information required to gain access to such list is provided with the notice of the meeting, or (ii)&#160;during ordinary business hours, at the Corporation&#8217;s principal executive office. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders of the Corporation. If the meeting is to be held at a place, then the list shall be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present. If the meeting is to be held solely by means of remote communication, then the list shall also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided with the notice of the meeting. Such list shall presumptively determine the identity of the stockholders entitled to vote at the meeting and the number of shares held by each of them. Except as otherwise provided by law, the stock ledger shall be the only evidence as to who are the stockholders entitled to examine the list of stockholders required by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.14</span> or to vote in person or by proxy at any meeting of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section215InspectorsofElection_173837"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.15</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Inspectors of Election</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Before any meeting of stockholders, the Corporation shall appoint an inspector or inspectors of election to act at the meeting or its adjournment and make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If any person appointed as inspector or any alternate fails to appear or fails or refuses to act, then the person presiding over the meeting shall appoint a person to fill that vacancy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Such inspectors shall:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>determine the number of shares outstanding and the voting power of each, the number of shares represented at the meeting and the validity of any proxies and ballots;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>count all votes or ballots;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>count and tabulate all votes;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>determine and retain for a reasonable period a record of the disposition of any challenges made to any determination by the inspector(s); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>certify its or their determination of the number of shares represented at the meeting and its or their count of all votes and ballots.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Each inspector, before entering upon the discharge of the duties of inspector, shall take and sign an oath faithfully to execute the duties of inspection with strict impartiality and according to the best of such inspector&#8217;s ability. Any report or certificate made by the inspectors of election is <i style="font-style:italic;">prima facie</i> evidence of the facts stated therein. The inspectors of election may appoint such persons to assist them in performing their duties as they determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section216DeliverytotheCorp_48293"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.16</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delivery to the Corporation</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Whenever this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;II</span> requires one or more persons (including a record or beneficial owner of stock) to deliver a document or information to the Corporation or any officer, employee or agent thereof (including any notice, request, questionnaire, revocation, representation or other document or agreement), such document or information shall be in writing exclusively (and not in an electronic transmission) and shall be delivered exclusively by hand (including, without limitation, overnight courier service) or by certified or registered mail, return receipt requested, and the Corporation shall not be required to accept delivery of any document not in such written form or so delivered. For the avoidance of doubt, the Corporation expressly opts out of Section&#160;116 of the DGCL with respect to the delivery of information and documents to the Corporation required by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;II</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section217StockholderAction"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.17</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stockholder Action by Written Consent Without a Meeting</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Subject to the rights of the holders of any series of Preferred Stock of the Corporation, any action required or permitted to be taken by the stockholders of the Corporation may be effected only at a duly called annual or special meeting of stockholders and may not be effected by any consent in writing by such stockholders in lieu of such meeting. Notwithstanding the foregoing, any action </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">required or permitted to be taken by the holders of any series of preferred stock of the Corporation, voting separately as a series or separately as a class with one or more other such series, may be taken without a meeting, without prior notice and without a vote, to the extent expressly so provided by the applicable certificate of designation relating to such series of preferred stock of the Corporation, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding shares of the relevant series of preferred stock of the Corporation having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation in accordance with the applicable provisions of the DGCL.</p><a id="I_ARTICLEIIIDIRECTORS_585329"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;III &#8212; </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DIRECTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section31Powers_574621"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Powers</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Except as otherwise provided by the Certificate of Incorporation or the DGCL, the business and affairs of the Corporation shall be managed by or under the direction of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section32NumberofDirectors_205163"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Number of Directors</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Subject to the Certificate of Incorporation, the total number of directors constituting the Board shall be determined from time to time by resolution of the Board. No reduction of the authorized number of directors shall have the effect of removing any director before that director&#8217;s term of office expires.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section33ElectionQualification_433638"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Election, Qualification and Term of Office of Directors</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Except as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.4</span>, and subject to the Certificate of Incorporation, each director, including a director elected to fill a vacancy or newly created directorship, shall hold office until the expiration of the term of the class, if any, for which elected and until such director&#8217;s successor is elected and qualified or until such director&#8217;s earlier death, resignation, retirement, disqualification or removal. Directors need not be stockholders. The Certificate of Incorporation or these bylaws may prescribe qualifications for directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section34ResignationandVaca_554826"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Resignation and Vacancies</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Any director may resign at any time upon notice given in writing or by electronic transmission to the Corporation. The resignation shall take effect at the time specified therein or upon the happening of an event specified therein, and if no time or event is specified, at the time of its receipt. When one or more directors so resigns and the resignation is effective at a future date or upon the happening of an event to occur on a future date, a majority of the directors then in office, including those who have so resigned, shall have the power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold office as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.3</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Unless otherwise provided in the Certificate of Incorporation or these bylaws, vacancies resulting from the death, resignation, retirement, disqualification or removal of any director, and newly created directorships resulting from any increase in the authorized number of directors shall be filled only by a majority of the directors then in office, although less than a quorum, or by a sole remaining director. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#8217;s successor shall have been elected and qualified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section35PlaceofMeetings_483833"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Place of Meetings; Meetings by Telephone</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Board may hold meetings, both regular and special, either within or outside the State of Delaware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Unless otherwise restricted by the Certificate of Incorporation or these bylaws, members of the Board, or any committee or subcommittee designated by the Board, in each case, may participate in a meeting of the Board, or any committee or subcommittee, by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting pursuant to this bylaw shall constitute presence in person at the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Section36RegularMeetings_561436_I"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regular Meetings</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Regular meetings of the Board may be held within or outside the State of Delaware and at such time and at such place as which has been designated by the Board and publicized among all directors, either orally or in writing, by telephone, including a voice-messaging system or other system designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other means of electronic transmission. No further notice shall be required for regular meetings of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section37SpecialMeetingsNotice_713621"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Special Meetings; Notice</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Special meetings of the Board for any purpose or purposes may be called at any time by the Chairperson of the Board, the Chief Executive Officer, the President or the Secretary of the Corporation or a majority of the total number of directors constituting the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Notice of the time and place of special meetings shall be:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>delivered personally by hand, by courier or by telephone;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>sent by United States first-class mail, postage prepaid;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>sent by facsimile or electronic mail; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>sent by other means of electronic transmission,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">directed to each director at that director&#8217;s address, telephone number, facsimile number or electronic mail address, or other address for electronic transmission, as the case may be, as shown on the Corporation&#8217;s records.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">If the notice is (i)&#160;delivered personally by hand, by courier or by telephone, (ii)&#160;sent by facsimile or electronic mail, or (iii)&#160;sent by other means of electronic transmission, it shall be delivered or sent at least twenty-four (24) hours before the time of the holding of the meeting. If the notice is sent by U.S. mail, it shall be deposited in the U.S. mail at least four (4)&#160;days before the time of the holding of the meeting. The notice need not specify the place of the meeting (if the meeting is to be held at the Corporation&#8217;s principal executive office) nor the purpose of the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section38Quorum_854477"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quorum</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">At all meetings of the Board, unless otherwise provided by the Certificate of Incorporation, a majority of the total number of directors shall constitute a quorum for the transaction of business. The vote of a majority of the directors present at any meeting at which a quorum is present shall be the act of the Board, except as may be otherwise specifically provided by statute, the Certificate of Incorporation or these bylaws. If a quorum is not present at any meeting of the Board, then the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section39BoardAction_99847"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board Action by Written Consent without a Meeting</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Unless otherwise restricted by the Certificate of Incorporation or these bylaws, any action required or permitted to be taken at any meeting of the Board, or of any committee or subcommittee thereof, may be taken without a meeting if all members of the Board or committee or subcommittee, as the case may be, consent thereto in writing or by electronic transmission. After an action is taken by written consent without a meeting, the consent or consents relating thereto shall be filed with the minutes of the proceedings of the Board, or the applicable committee or subcommittee thereof, in the same paper or electronic form as the minutes are maintained. Such action by written consent or consent by electronic transmission shall have the same force and effect as a unanimous vote of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section310FeesandCompensation_272710"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fees and Compensation of Directors</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Unless otherwise restricted by the Certificate of Incorporation or these bylaws, the Board shall have the authority to fix the compensation, including fees and reimbursement of expenses, of directors for services to the Corporation in any capacity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="I_Section311RemovalofDirectors_458011"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Removal of Directors</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Subject to any special rights of the holders of one or more outstanding series of preferred stock of the Corporation to elect directors, the Board or any individual director may be removed from office at any time, but only for cause and only by the affirmative vote of the holders of at least two-thirds (66 and 2/3%) of the voting power of all the then outstanding shares of voting stock of the Corporation entitled to vote generally in an election of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_ARTICLEIVCOMMITTEES_373489"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;IV &#8212; </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COMMITTEES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section41CommitteesofDirectors_911707"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Committees of Directors</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Board may designate one (1)&#160;or more committees, each committee to consist of one (1)&#160;or more of the directors of the Corporation. The Board may designate one (1)&#160;or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board or in these bylaws, shall have and may exercise all the powers and authority of the Board in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers that may require it; but no such committee or subcommittee shall have the power or authority to (i)&#160;approve or adopt, or recommend to the stockholders, any action or matter expressly required by the DGCL to be submitted to stockholders for approval, or (ii)&#160;adopt, amend or repeal any bylaw of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section42CommitteeMinutes_147257"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Committee Minutes</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Each committee shall keep regular minutes of its meetings and report the same to the Board when required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section43MeetingsandActions_720103"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Meetings and Actions of Committees</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Meetings and actions of committees shall be governed by, and held and taken in accordance with, the provisions of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.5</span> (<i style="font-style:italic;">Place of Meetings; Meetings by Telephone</i>);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.6</span> (<i style="font-style:italic;">Regular Meetings</i>);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.7</span> (<i style="font-style:italic;">Special Meetings; Notice</i>);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.9</span> (<i style="font-style:italic;">Board Action Without a Meeting</i>); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.13</span> (<i style="font-style:italic;">Waiver of Notice</i>),</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">with such changes in the context of those bylaws as are necessary to substitute the committee and its members for the Board and its members; <i style="font-style:italic;">provided, however</i>, that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>the time of regular meetings of committees may be determined either by resolution of the Board or by resolution of the committee;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>special meetings of committees may also be called by resolution of the Board or the chairperson of the applicable committee; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>the Board may adopt rules&#160;for the governance of any committee to override the provisions that would otherwise apply to the committee pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.3</span>, <i style="font-style:italic;">provided</i> that such rules&#160;do not violate the provisions of the Certificate of Incorporation or applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="I_Section44Subcommittees_229181"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subcommittees</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Unless otherwise provided in the Certificate of Incorporation, these bylaws or the resolutions of the Board designating the committee, a committee may create one (1)&#160;or more subcommittees, each subcommittee to consist of one (1)&#160;or more members of the committee, and delegate to a subcommittee any or all of the powers and authority of the committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_ARTICLEVOFFICERS_139004"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;V &#8212; </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OFFICERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section51Officers_765372"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Officers</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The officers of the Corporation shall include a Chief Executive Officer and a President. The Corporation may also have, at the discretion of the Board, a Secretary, a Chairperson of the Board, a Vice Chairperson of the Board (each of such Chairperson or Vice Chairperson shall be a director but need not be elected as an officer), a Chief Legal Officer, a Chief Financial Officer or principal financial officer, a Treasurer, one (1)&#160;or more Vice Presidents, one (1)&#160;or more Assistant Vice Presidents, one (1)&#160;or more Assistant Treasurers, one (1)&#160;or more Assistant Secretaries, and any such other officers as may be appointed in accordance with the provisions of these bylaws. Any number of offices may be held by the same person. No officer need be a stockholder or director of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section52AppointmentofOfficers_124847"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appointment of Officers</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Board shall appoint the officers of the Corporation, except such officers as may be appointed in accordance with the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.3</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section53SubordinateOfficers_114592"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subordinate Officers</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Board may appoint, or empower the Chief Executive Officer or, in the absence of a Chief Executive Officer, the President, to appoint, such other officers and agents as the business of the Corporation may require. Each of such officers and agents shall hold office for such period, have such authority, and perform such duties as are provided in these bylaws or as the Board may from time to time determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section54RemovalandResignation_834611"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Removal and Resignation of Officers</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Subject to the rights, if any, of an officer under any contract of employment any officer may be removed, either with or without cause, by the Board or, except in the case of an officer chosen by the Board, by any officer upon whom such power of removal may be conferred by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Any officer may resign at any time by giving written notice to the Corporation. Any resignation shall take effect at the date of the receipt of that notice or at any later time specified in that notice. Unless otherwise specified in the notice of resignation, the acceptance of the resignation shall not be necessary to make it effective. Any resignation is without prejudice to the rights, if any, of the Corporation under any contract to which the officer is a party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section55VacanciesinOffices_214942"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vacancies in Offices</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Any vacancy occurring in any office of the Corporation shall be filled by the Board or as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.2</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section56RepresentationofShares_259852"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representation of Shares of Other Corporations</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Chairperson of the Board (if an officer), the Chief Executive Officer, or the President of this Corporation, or any other person authorized by the Board, the Chief Executive Officer or the President, is authorized to vote, represent and exercise on behalf of this Corporation all rights incident to any and all shares or voting securities of any other corporation or other person standing in the name of this Corporation. The authority granted herein may be exercised either by such person directly or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="I_Section57AuthorityandDuties_847791"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authority and Duties of Officers</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">All officers of the Corporation shall respectively have such authority and perform such duties in the management of the business of the Corporation as may be provided herein or designated from time to time by the Board and, to the extent not so provided, as generally pertain to their respective offices, subject to the control of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section58Compensation_534007"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The compensation of the officers of the Corporation for their services as such shall be fixed from time to time by or at the direction of the Board. An officer of the Corporation shall not be prevented from receiving compensation by reason of the fact that he or she is also a director of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_ARTICLEVIRECORDS_393670"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;VI &#8212; </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RECORDS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">A stock ledger consisting of one or more records in which the names of all of the Corporation&#8217;s stockholders of record, the address and number of shares registered in the name of each such stockholder, and all issuances and transfers of stock of the corporation are recorded in accordance with Section&#160;224 of the DGCL shall be administered by or on behalf of the Corporation. Any records administered by or on behalf of the Corporation in the regular course of its business, including its stock ledger, books of account, and minute books, may be kept on, or by means of, or be in the form of, any information storage device, or method, or one or more electronic networks or databases (including one or more distributed electronic networks or databases), <i style="font-style:italic;">provided</i> that the records so kept can be converted into clearly legible paper form within a reasonable time and, with respect to the stock ledger, that the records so kept (i)&#160;can be used to prepare the list of stockholders specified in Sections 219 and 220 of the DGCL, (ii)&#160;record the information specified in Sections 156, 159, 217(a)&#160;and 218 of the DGCL, and (iii)&#160;record transfers of stock as governed by Article&#160;8 of the Uniform Commercial Code as adopted in the State of Delaware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_ARTICLEVIIGENERALMATTERS_263642"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;VII &#8212; </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GENERAL MATTERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section71ExecutionofCorporate_24875"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Execution of Corporate Contracts and Instruments</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Board, except as otherwise provided in these bylaws, may authorize any officer or officers, or agent or agents, to enter into any contract or execute any instrument in the name of and on behalf of the Corporation; such authority may be general or confined to specific instances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section72StockCertificates_59692"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Certificates</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The shares of the Corporation shall be represented by certificates or shall be uncertificated. Certificates for the shares of stock, if any, shall be in such form as is consistent with the Certificate of Incorporation and applicable law. Every holder of stock represented by a certificate shall be entitled to have a certificate signed by, or in the name of the Corporation by, any two officers authorized to sign stock certificates representing the number of shares registered in certificate form. The Chairperson or Vice Chairperson of the Board (in each case, if an officer), the Chief Executive Officer, the President, Vice President, the Treasurer, any Assistant Treasurer, the Secretary or any Assistant Secretary of the Corporation shall be specifically authorized to sign stock certificates. Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he or she were such officer, transfer agent or registrar at the date of issue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Corporation may issue the whole or any part of its shares as partly paid and subject to call for the remainder of the consideration to be paid therefor. Upon the face or back of each stock certificate issued to represent any such partly paid shares, or upon the books and records of the Corporation in the case of uncertificated partly paid shares, the total amount of the consideration to be paid therefor and the amount paid thereon shall be stated. Upon the declaration of any dividend on fully paid shares, the Corporation shall declare a dividend upon partly paid shares of the same class, but only upon the basis of the percentage of the consideration actually paid thereon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="I_Section73SpecialDesignation_998775"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Special Designation of Certificates</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">If the Corporation is authorized to issue more than one class of stock or more than one series of any class, then the powers, the designations, the preferences and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or on the back of the certificate that the Corporation shall issue to represent such class or series of stock (or, in the case of uncertificated shares, set forth in a notice provided pursuant to Section&#160;151 of the DGCL); <i style="font-style:italic;">provided, however</i>, that except as otherwise provided in Section&#160;202 of the DGCL, in lieu of the foregoing requirements, there may be set forth on the face of back of the certificate that the Corporation shall issue to represent such class or series of stock (or, in the case of any uncertificated shares, included in the aforementioned notice) a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, the designations, the preferences and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section74LostCertificates_778832"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lost Certificates</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Except as provided in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7.4</span>, no new certificates for shares shall be issued to replace a previously issued certificate unless the latter is surrendered to the Corporation and cancelled at the same time. The Corporation may issue a new certificate of stock or uncertificated shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or such owner&#8217;s legal representative, to give the Corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate or uncertificated shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section75SharesWithout_866623"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares Without Certificat</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">es</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Corporation may adopt a system of issuance, recordation and transfer of its shares of stock by electronic or other means not involving the issuance of certificates, provided the use of such system by the Corporation is permitted in accordance with applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section76Construction_346247"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Construction; Definitions</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Unless the context requires otherwise, the general provisions, rules&#160;of construction and definitions in the DGCL shall govern the construction of these bylaws. Without limiting the generality of this provision, the singular number includes the plural and the plural number includes the singular.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section77Dividends_494899"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dividends</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Board, subject to any restrictions contained in either (i)&#160;the DGCL or (ii)&#160;the Certificate of Incorporation, may declare and pay dividends upon the shares of its capital stock. Dividends may be paid in cash, in property or in shares of the Corporation&#8217;s capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Board may set apart out of any of the funds of the Corporation available for dividends a reserve or reserves for any proper purpose and may abolish any such reserve. Such purposes shall include but not be limited to equalizing dividends, repairing or maintaining any property of the Corporation, and meeting contingencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section78FiscalYear_592689"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fiscal Year</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The fiscal year of the Corporation shall be fixed by resolution of the Board and may be changed by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section79Seal_816838"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Seal</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Corporation may adopt a corporate seal, which shall be adopted and which may be altered by the Board. The Corporation may use the corporate seal by causing it or a facsimile thereof to be impressed or affixed or in any other manner reproduced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="I_Section710TransferofStock_118360"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer of Stock</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Shares of the stock of the Corporation shall be transferable in the manner prescribed by law and in these bylaws. Shares of stock of the Corporation shall be transferred on the books of the Corporation only by the holder of record thereof or by such holder&#8217;s attorney duly authorized in writing, upon surrender to the Corporation of the certificate or certificates representing such shares endorsed by the appropriate person or persons (or by delivery of duly executed instructions with respect to uncertificated shares), with such evidence of the authenticity of such endorsement or execution, transfer, authorization and other matters as the Corporation may reasonably require, and accompanied by all necessary stock transfer stamps. No transfer of stock shall be valid as against the Corporation for any purpose until it shall have been entered in the stock records of the Corporation by an entry showing the names of the persons from and to whom it was transferred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section711StockTransfer_128740"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Transfer Restrictions; Stock Forfeitures</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The Corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes or series of stock of the Corporation to restrict the transfer of shares of stock of the Corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The Corporation&#8217;s Earnout Shares (as defined in the Merger Agreement referenced below in this sentence) are subject to the restrictive transfer and forfeiture provisions set forth in that certain Agreement and Plan of Merger, dated March&#160;23, 2022, by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation, OmniAb,&#160;Inc., a Delaware corporation, the Corporation and Orwell Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section712RegisteredStock_398770"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.12</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registered Stockholders</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Corporation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends and to vote as such owner; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of another person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of the State of Delaware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section713WaiverofNotice_972371"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.13</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Notice</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Whenever notice is required to be given under any provision of the DGCL, the Certificate of Incorporation or these bylaws, a written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time of the event for which notice is to be given, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders need be specified in any written waiver of notice or any waiver by electronic transmission unless so required by the Certificate of Incorporation or these bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_ARTICLEVIIINOTICE_944409"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;VIII &#8212; </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section81DeliveryofNotice_512518"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;8.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delivery of Notice; Notice by Electronic Transmission</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the Corporation under any provisions of the DGCL, the Certificate of Incorporation, or these bylaws may be given in writing directed to the stockholder&#8217;s mailing address (or by electronic transmission directed to the stockholder&#8217;s electronic mail address, as applicable) as it appears on the records of the Corporation and shall be given (1)&#160;if mailed, when the notice is deposited in the U.S. mail, postage prepaid, (2)&#160;if delivered by courier service, the earlier of when the notice is received or left at such stockholder&#8217;s address or (3)&#160;if given by electronic mail, when directed to such stockholder&#8217;s electronic mail address unless the stockholder has notified the </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Corporation in writing or by electronic transmission of an objection to receiving notice by electronic mail. A notice by electronic mail must include a prominent legend that the communication is an important notice regarding the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the Corporation under any provision of the DGCL, the Certificate of Incorporation or these bylaws shall be effective if given by a form of electronic transmission consented to by the stockholder to whom the notice is given. Any such consent shall be revocable by the stockholder by written notice or electronic transmission to the Corporation. Notwithstanding the provisions of this paragraph, the Corporation may give a notice by electronic mail in accordance with the first paragraph of this section without obtaining the consent required by this paragraph.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Any notice given pursuant to the preceding paragraph shall be deemed given:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of (A)&#160;such posting and (B)&#160;the giving of such separate notice; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>if by any other form of electronic transmission, when directed to the stockholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Notwithstanding the foregoing, a notice may not be given by an electronic transmission from and after the time that (1)&#160;the Corporation is unable to deliver by such electronic transmission two (2)&#160;consecutive notices given by the Corporation and (2)&#160;such inability becomes known to the Secretary or an Assistant Secretary of the Corporation or to the transfer agent, or other person responsible for the giving of notice; <i style="font-style:italic;">provided, however</i>, that the inadvertent failure to discover such inability shall not invalidate any meeting or other action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">An affidavit of the Secretary or an Assistant Secretary of the Corporation or of the transfer agent or other agent of the Corporation that the notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_ARTICLEIXINDEMNIFICATION_874383"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;IX &#8212; </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">INDEMNIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section91Indemnification_65369"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification of Directors and Officers</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Corporation shall indemnify and hold harmless, to the fullest extent permitted by the DGCL as it presently exists or may hereafter be amended, any director or officer of the Corporation who was or is made or is threatened to be made a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proceeding</span>&#8221;) by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director or officer of the Corporation or, while serving as a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership (a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">covered person</span>&#8221;), joint venture, trust, enterprise or non-profit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including, without limitation, attorneys&#8217; fees, judgments, fines, ERISA excise taxes or penalties, and amounts paid in settlement) reasonably incurred by such person in connection with any such Proceeding. Notwithstanding the preceding sentence, except as otherwise provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9.4</span>, the Corporation shall be required to indemnify a person in connection with a Proceeding initiated by such person only if the Proceeding was authorized in the specific case by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section92Indemnificationof_194376"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification of Others</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Corporation shall also have the power to indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, any employee or agent of the Corporation who was or is made or is threatened to be made a party or is otherwise involved in any Proceeding by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was an employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or non-profit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses reasonably incurred by such person in connection with any such Proceeding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="I_Section93PrepaymentofExpenses_529491"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prepayment of Expenses</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Corporation shall to the fullest extent not prohibited by applicable law pay the expenses (including, without limitation, attorneys&#8217; fees) incurred by any covered person, and may also pay the expenses incurred by any employee or agent of the Corporation, in defending any Proceeding in advance of its final disposition; <i style="font-style:italic;">provided, however</i>, that such payment of expenses in advance of the final disposition of the Proceeding shall be made only upon receipt of an undertaking by the person to repay all amounts advanced if it should be ultimately determined that the person is not entitled to be indemnified under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span> or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section94Determination_834603"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Determination; Claim</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">If a claim for indemnification (following the final disposition of such Proceeding) under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span> is not paid in full within sixty (60) days, or a claim for advancement of expenses under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span> is not paid in full within thirty (30) days, after a written claim therefor has been received by the Corporation the claimant may thereafter (but not before) file suit to recover the unpaid amount of such claim and, if successful in whole or in part, shall be entitled to be paid the expense of prosecuting such claim to the fullest extent permitted by law. In any such action the Corporation shall have the burden of proving that the claimant was not entitled to the requested indemnification or payment of expenses under applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section95NonExclusivity_329070"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Exclusivity of Rights</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The rights conferred on any person by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span> shall not be exclusive of any other rights which such person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, these bylaws, agreement, vote of stockholders or disinterested directors or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section96Insurance_881924"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust enterprise or non-profit entity against any liability asserted against him or her and incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not the Corporation would have the power to indemnify him or her against such liability under the provisions of the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section97OtherIndemnification_843266"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Indemnification</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Corporation&#8217;s obligation, if any, to indemnify or advance expenses to any person who was or is serving at its request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, enterprise or non-profit entity shall be reduced by any amount such person actually collects as indemnification or advancement of expenses from such other corporation, partnership, joint venture, trust, enterprise or non-profit enterprise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section98Continuation_459073"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continuation of Indemnification</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The rights to indemnification and to prepayment of expenses provided by, or granted pursuant to, this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span> shall continue notwithstanding that the person has ceased to be a director or officer of the Corporation and shall inure to the benefit of the estate, heirs, executors, administrators, legatees and distributees of such person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_Section99Amendment_654665"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment or Repeal; Interpretation</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span> shall constitute a contract between the Corporation, on the one hand, and, on the other hand, each individual who serves or has served as a director or officer of the Corporation (whether before or after the adoption of these bylaws), in consideration of such person&#8217;s performance of such services, and pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span> the Corporation intends to be legally bound to each such current or former director or officer of the Corporation. With respect to current and former directors and officers of the Corporation, the rights conferred under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span> are present contractual rights and such rights are fully vested, and shall be deemed to have vested fully, immediately upon adoption of theses bylaws. With respect to any directors or officers of the Corporation who commence service following adoption of these bylaws, the rights conferred under this provision shall be present contractual rights and such rights shall fully vest, and be deemed to have vested fully, immediately upon such director or officer </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">commencing service as a director or officer of the Corporation. Any repeal or modification of the foregoing provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span> shall not adversely affect any right or protection (i)&#160;hereunder of any person in respect of any act or omission occurring prior to the time of such repeal or modification or (ii)&#160;under any agreement providing for indemnification or advancement of expenses to an officer or director of the Corporation in effect prior to the time of such repeal or modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Any reference to an officer of the Corporation in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span> shall be deemed to refer exclusively to the Chief Executive Officer, the President and the Secretary of the Corporation, or other officer of the Corporation appointed by (x)&#160;the Board pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</span> or (y)&#160;an officer to whom the Board has delegated the power to appoint officers pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;V</span>, and any reference to an officer of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be deemed to refer exclusively to an officer appointed by the board of directors (or equivalent governing body) of such other entity pursuant to the certificate of incorporation and bylaws (or equivalent organizational documents) of such other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise. The fact that any person who is or was an employee of the Corporation or an employee of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise has been given or has used the title of &#8220;Vice President&#8221; or any other title that could be construed to suggest or imply that such person is or may be an officer of the Corporation or of such other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall not result in such person being constituted as, or being deemed to be, an officer of the Corporation or of such other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise for purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;IX</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_ARTICLEXAMENDMENTS_983065"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;X &#8212; </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AMENDMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Board is expressly empowered to adopt, amend or repeal the bylaws of the Corporation. The stockholders also shall have power to adopt, amend or repeal the bylaws of the Corporation; <i style="font-style:italic;">provided, however</i>, in addition to any vote of the holders of any class or series of stock of the Corporation required by applicable law or by the Certificate of Incorporation (including any Certificate of Designation in respect of one or more series of Preferred Stock), the adoption, amendment or repeal of the bylaws of the Corporation by the stockholders of the Corporation shall require the affirmative vote of the holders of at least two-thirds (66 and 2/3%) of the voting power of all of the then outstanding shares of voting stock of the Corporation entitled to vote generally in an election of directors, voting together as a single class.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="I_ARTICLEXIDEFINITIONS_199693"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE&#160;XI &#8212; </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DEFINITIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">As used in these bylaws, unless the context otherwise requires, the following terms shall have the following meanings:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">An &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">electronic transmission</span>&#8221; means any form of communication, not directly involving the physical transmission of paper, including the use of, or participation in, one or more electronic networks or databases (including one or more distributed electronic networks or databases), that creates a record that may be retained, retrieved and reviewed by a recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">An &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">electronic mail</span>&#8221; means an electronic transmission directed to a unique electronic mail address (which electronic mail shall be deemed to include any files attached thereto and any information hyperlinked to a website if such electronic mail includes the contact information of an officer or agent of the Corporation who is available to assist with accessing such files and information).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">An &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">electronic mail address</span>&#8221; means a destination, commonly expressed as a string of characters, consisting of a unique user name or mailbox (commonly referred to as the &#8220;local part&#8221; of the address) and a reference to an internet domain (commonly referred to as the &#8220;domain part&#8221; of the address), whether or not displayed, to which electronic mail can be sent or delivered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The term &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">person</span>&#8221; means any individual, general partnership, limited partnership, limited liability company, corporation, trust, business trust, joint stock company, joint venture, unincorporated association, cooperative or association or any other legal entity or organization of whatever nature, and shall include any successor (by merger or otherwise) of such entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">I-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8e24509c_4785_4ac3_987f_9613369776c6"></a><a id="ANNEXJ_803280"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.55pt 0pt;"><b style="font-weight:bold;">Annex J</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 5pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">THE COMPANIES ACT (AS REVISED)</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">OF THE CAYMAN ISLANDS</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">COMPANY LIMITED BY SHARES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.1pt 0pt;"><b style="font-weight:bold;">AMENDED AND RESTATED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.1pt 0pt;"><b style="font-weight:bold;">MEMORANDUM AND ARTICLES OF ASSOCIATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.25pt 0pt;"><b style="font-weight:bold;">OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.69pt 0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(ADOPTED BY SPECIAL RESOLUTION DATED 9 AUGUST 2021 AND EFFECTIVE ON 9 AUGUST 2021)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE COMPANIES ACT (AS REVISED)</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">OF THE CAYMAN ISLANDS</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">COMPANY LIMITED BY SHARES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AMENDED AND RESTATED</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">MEMORANDUM OF ASSOCIATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.69pt 0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(ADOPTED BY SPECIAL RESOLUTION DATED 9 AUGUST 2021 AND EFFECTIVE ON 9 AUGUST 2021)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span>The name of the Company is <b style="font-weight:bold;">Avista Public Acquisition Corp. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2</span></span>The Registered Office of the Company shall be at the offices of Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1- 1104, Cayman Islands, or at such other place within the Cayman Islands as the Directors may decide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></span>The objects for which the Company is established are unrestricted and the Company shall have full power and authority to carry out any object not prohibited by the laws of the Cayman Islands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4</span></span>The liability of each Member is limited to the amount unpaid on such Member&#39;s shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span>The share capital of the Company is US$55,500 divided into 500,000,000 Class A ordinary shares of a par value of US$0.0001 each, 50,000,000 Class B ordinary shares of a par value of US$0.0001 each and 5,000,000 preference shares of a par value of US$0.0001 each.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6</span></span>The Company has power to register by way of continuation as a body corporate limited by shares under the laws of any jurisdiction outside the Cayman Islands and to be deregistered in the Cayman Islands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7</span></span>Capitalised terms that are not defined in this Amended and Restated Memorandum of Association bear the respective meanings given to them in the Amended and Restated Articles of Association of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE COMPANIES ACT (AS REVISED)</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">OF THE CAYMAN ISLANDS</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">COMPANY LIMITED BY SHARES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AMENDED AND RESTATED</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">ARTICLES OF ASSOCIATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(ADOPTED BY SPECIAL RESOLUTION DATED 9 AUGUST 2021 AND EFFECTIVE ON 9 AUGUST 2021)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1</b></span><b style="font-weight:bold;">Interpretation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.1</span></span>In the Articles Table A in the First Schedule to the Statute does not apply and, unless there is something in the subject or context inconsistent therewith:</p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Affiliate&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">in respect of a person, means any other person that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such person, and (a) in the case of a natural person, shall include, without limitation, such person&#8217;s spouse, parents, children, siblings, mother-in-law and father-in-law and brothers and sisters-in-law, whether by blood, marriage or adoption or anyone residing in such person&#8217;s home, a trust for the benefit of any of the foregoing, a company, partnership or any natural person or entity wholly or jointly owned by any of the foregoing and (b) in the case of an entity, shall include a partnership, a corporation or any natural person or entity which directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such entity.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Applicable Law&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means, with respect to any person, all provisions of laws, statutes, ordinances, rules, regulations, permits, certificates, judgments, decisions, decrees or orders of any governmental authority applicable to such person.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Articles&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means these amended and restated articles of association of the Company.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Audit Committee&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means the audit committee of the board of directors of the Company established pursuant to the Articles, or any successor committee.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Auditor&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means the person for the time being performing the duties of auditor of the Company (if any).</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Business Combination&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means a merger, share exchange, asset acquisition, share purchase, reorganisation or similar business combination involving the Company, with one or more businesses or entities (the &#8220;<b style="font-weight:bold;">target business</b>&#8221;), which Business Combination: (a) as long as the securities of the Company are listed on the Nasdaq Capital Market, must occur with one or more target businesses that together have an aggregate fair market value of at least 80 per cent of the assets held in the Trust Account (excluding the deferred underwriting discounts and taxes payable on the income earned on the Trust Account) at the time of the signing of the definitive agreement to enter into such Business Combination; and (b) must not be solely effectuated with another blank cheque company or a similar company with nominal operations.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;business day&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions or trust companies are authorised or obligated by law to close in New York City.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Clearing House&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means a clearing house recognised by the laws of the jurisdiction in which the Shares (or depositary receipts therefor) are listed or quoted on a stock exchange or interdealer quotation system in such jurisdiction.</p></td></tr></table></div></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Class A Share&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means a Class A ordinary share of a par value of US$0.0001 in the share capital of the Company. </p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Class B Share&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means a Class B ordinary share of a par value of US$0.0001 in the share capital of the Company. </p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Company&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means the above named company.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Company&#8217;s Website&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means the website of the Company and/or its web-address or domain name (if any).</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Compensation Committee&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means the compensation committee of the board of directors of the Company established pursuant to the Articles, or any successor committee.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Designated Stock Exchange&#8221; </b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means any United States national securities exchange on which the securities of the Company are listed for trading, including the Nasdaq Capital Market.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Directors&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means the directors for the time being of the Company.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Dividend&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means any dividend (whether interim or final) resolved to be paid on Shares pursuant to the Articles.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Electronic Communication&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means a communication sent by electronic means, including electronic posting to the Company&#8217;s Website, &#160;transmission to any number, address or internet website (including the website of the Securities and Exchange Commission) or other electronic delivery methods as otherwise decided and approved by the Directors.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Electronic Record&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">has the same meaning as in the Electronic Transactions Act.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Electronic Transactions Act&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means the Electronic Transactions Act (As Revised) of the Cayman Islands.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Equity-linked Securities&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means any debt or equity securities that are convertible, exercisable or exchangeable for Class A Shares issued in a financing transaction in connection with a Business Combination, including but not limited to a private placement of equity or debt.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Exchange Act&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means the United States Securities Exchange Act of 1934, as amended, or any similar U.S. federal statute and the rules and regulations of the Securities and Exchange Commission thereunder, all as the same shall be in effect at the time.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Forward Purchase Agreement&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means an agreement that provides for the sale of equity securities in a private placement that will close substantially concurrently with the consummation of a Business Combination.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Forward Purchase Share&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means a Class A Share to be issued pursuant to a Forward Purchase Agreement.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Forward Purchase Warrant&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means a warrant to purchase a Class A Share to be issued pursuant to a Forward Purchase Agreement.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Founders&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means all Members immediately prior to the consummation of the IPO.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Independent Director&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">has the same meaning as in the rules and regulations of the Designated Stock Exchange or in Rule 10A-3 under the Exchange Act, as the case may be.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;IPO&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means the Company&#39;s initial public offering of securities.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Member&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">has the same meaning as in the Statute.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Memorandum&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means the amended and restated memorandum of association of the Company.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Nominating Committee&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means the nominating committee of the board of directors of the Company established pursuant to the Articles, or any successor committee.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Officer&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means a person appointed to hold an office in the Company.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Ordinary Resolution&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means a resolution passed by a simple majority of the Members as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at a general meeting, and </p></td></tr></table></div></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">includes a unanimous written resolution. In computing the majority when a poll is demanded regard shall be had to the number of votes to which each Member is entitled by the Articles.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Over-Allotment Option&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means the option of the Underwriters to purchase up to an additional 15 per cent of the firm units (as described in the Articles) issued in the IPO at a price equal to US$10 per unit, less underwriting discounts and commissions.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Preference Share&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means a preference share of a par value of US$0.0001 in the share capital of the Company.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Public Share&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means a Class A Share issued as part of the units (as described in the Articles) issued in the IPO.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Redemption Notice&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means a notice in a form approved by the Company by which a holder of Public Shares is entitled to require the Company to redeem its Public Shares, subject to any conditions contained therein.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Register of Members&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means the register of Members maintained in accordance with the Statute and includes (except where otherwise stated) any branch or duplicate register of Members.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Registered Office&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means the registered office for the time being of the Company.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Representative&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means a representative of the Underwriters.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Seal&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means the common seal of the Company and includes every duplicate seal.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Securities and Exchange Commission&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means the United States Securities and Exchange Commission.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Share&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means a Class A Share, a Class B Share or a Preference Share and includes a fraction of a share in the Company.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Special Resolution&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">subject to Article 29.4 and Article 47.2, has the same meaning as in the Statute, and includes a unanimous written resolution.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Sponsor&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means Avista Acquisition LP II, a Cayman Islands exempted limited partnership, and its successors or assigns.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Statute&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means the Companies Act (As Revised) of the Cayman Islands.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Treasury Share&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means a Share held in the name of the Company as a treasury share in accordance with the Statute.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Trust Account&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">means the trust account established by the Company upon the consummation of the IPO and into which a certain amount of the net proceeds of the IPO, together with a certain amount of the proceeds of a private placement of warrants simultaneously with the closing date of the IPO, will be deposited.</p></td></tr><tr><td style="vertical-align:top;width:34.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">&#8220;Underwriter&#8221;</b></p></td><td style="vertical-align:top;width:65.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">means an underwriter of the IPO from time to time and any successor underwriter.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.2</span></span>In the Articles:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;padding-left:29.25pt;text-indent:-29.25pt;"><span style="display:inline-block;min-width:28.95pt;text-indent:0pt;white-space:nowrap;">(a)</span>words importing the singular number include the plural number and vice versa;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;padding-left:29.25pt;text-indent:-29.25pt;"><span style="display:inline-block;min-width:28.95pt;text-indent:0pt;white-space:nowrap;">(b)</span>words importing the masculine gender include the feminine gender;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;padding-left:29.25pt;text-indent:-29.25pt;"><span style="display:inline-block;min-width:28.95pt;text-indent:0pt;white-space:nowrap;">(c)</span>words importing persons include corporations as well as any other legal or natural person;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;padding-left:29.25pt;text-indent:-29.25pt;"><span style="display:inline-block;min-width:28.95pt;text-indent:0pt;white-space:nowrap;">(d)</span>&#8220;written&#8221; and &#8220;in writing&#8221; include all modes of representing or reproducing words in visible form, including in the form of an Electronic Record;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;padding-left:29.25pt;text-indent:-29.25pt;"><span style="display:inline-block;min-width:28.95pt;text-indent:0pt;white-space:nowrap;">(e)</span>&#8220;shall&#8221; shall be construed as imperative and &#8220;may&#8221; shall be construed as permissive;</div></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;padding-left:29.25pt;text-indent:-29.25pt;"><span style="display:inline-block;min-width:28.95pt;text-indent:0pt;white-space:nowrap;">(f)</span>references to provisions of any law or regulation shall be construed as references to those provisions as amended, modified, re-enacted or replaced;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;padding-left:29.25pt;text-align:justify;text-indent:-29.25pt;"><span style="display:inline-block;min-width:28.95pt;text-indent:0pt;white-space:nowrap;">(g)</span>any phrase introduced by the terms &#8220;including&#8221;, &#8220;include&#8221;, &#8220;in particular&#8221; or any similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;padding-left:29.25pt;text-align:justify;text-indent:-29.25pt;"><span style="display:inline-block;min-width:28.95pt;text-indent:0pt;white-space:nowrap;">(h)</span>the term &#8220;and/or&#8221; is used herein to mean both &#8220;and&#8221; as well as &#8220;or.&#8221; The use of &#8220;and/or&#8221; in certain contexts in no respects qualifies or modifies the use of the terms &#8220;and&#8221; or &#8220;or&#8221; in others. The term &#8220;or&#8221; shall not be interpreted to be exclusive and the term &#8220;and&#8221; shall not be interpreted to require the conjunctive (in each case, unless the context otherwise requires);</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;padding-left:29.25pt;text-indent:-29.25pt;"><span style="display:inline-block;min-width:28.95pt;text-indent:0pt;white-space:nowrap;">(i)</span>headings are inserted for reference only and shall be ignored in construing the Articles;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;padding-left:29.25pt;text-indent:-29.25pt;"><span style="display:inline-block;min-width:28.95pt;text-indent:0pt;white-space:nowrap;">(j)</span>any requirements as to delivery under the Articles include delivery in the form of an Electronic Record;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;padding-left:29.25pt;text-align:justify;text-indent:-29.25pt;"><span style="display:inline-block;min-width:28.95pt;text-indent:0pt;white-space:nowrap;">(k)</span>any requirements as to execution or signature under the Articles including the execution of the Articles themselves can be satisfied in the form of an electronic signature as defined in the Electronic Transactions Act;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;padding-left:29.25pt;text-indent:-29.25pt;"><span style="display:inline-block;min-width:28.95pt;text-indent:0pt;white-space:nowrap;">(l)</span>sections 8 and 19(3) of the Electronic Transactions Act shall not apply;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;padding-left:29.25pt;text-align:justify;text-indent:-29.25pt;"><span style="display:inline-block;min-width:28.95pt;text-indent:0pt;white-space:nowrap;">(m)</span>the term &#8220;clear days&#8221; in relation to the period of a notice means that period excluding the day when the notice is received or deemed to be received and the day for which it is given or on which it is to take effect; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:29.25pt;text-indent:-29.25pt;"><span style="display:inline-block;min-width:28.95pt;text-indent:0pt;white-space:nowrap;">(n)</span>the term &#8220;holder&#8221; in relation to a Share means a person whose name is entered in the Register of Members as the holder of such Share.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2</b></span><b style="font-weight:bold;">Commencement of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</span></span>The business of the Company may be commenced as soon after incorporation of the Company as the Directors shall see fit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2</span></span>The Directors may pay, out of the capital or any other monies of the Company, all expenses incurred in or about the formation and establishment of the Company, including the expenses of registration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3</b></span><b style="font-weight:bold;">Issue of Shares and other Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.1</span></span>Subject to the provisions, if any, in the Memorandum (and to any direction that may be given by the Company in general meeting) and, where applicable, the rules and regulations of the Designated Stock Exchange, the Securities and Exchange Commission and/or any other competent regulatory authority or otherwise under Applicable Law, and without prejudice to any rights attached to any existing Shares, the Directors may allot, issue, grant options over or otherwise dispose of Shares (including fractions of a Share) with or without preferred, deferred or other rights or restrictions, whether in regard to Dividends or other distributions, voting, return of capital or otherwise and to such persons, at such times and on such other terms as they think proper, and may also (subject to the Statute and the Articles) vary such rights, save that the Directors shall not allot, issue, grant options over or otherwise dispose of Shares (including fractions of a Share) to the extent that it may affect the ability of the Company to carry out a Class B Ordinary Share Conversion set out in the Articles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.2</span></span>The Company may issue rights, options, warrants or convertible securities or securities of similar nature conferring the right upon the holders thereof to subscribe for, purchase or receive any class of Shares or other securities in the Company on such terms as the Directors may from time to time determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.3</span></span>The Company may issue units of securities in the Company, which may be comprised of whole or fractional Shares, rights, options, warrants or convertible securities or securities of similar nature conferring the right upon the holders thereof to subscribe for, purchase or receive any class of Shares or other securities in the Company, upon such terms as the Directors may from time to time determine. The securities comprising any such units which are issued pursuant to the IPO can only be traded separately from one another on the 52nd day following the date of the prospectus relating to the IPO unless the Representative(s) determines that an earlier date is acceptable, subject to the Company having filed a current report on Form 8-K with the </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 36pt;">Securities and Exchange Commission and a press release announcing when such separate trading will begin. Prior to such date, the units can be traded, but the securities comprising such units cannot be traded separately from one another.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.4</span></span>The Company shall not issue Shares to bearer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4</b></span><b style="font-weight:bold;">Register of Members</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1</span></span>The Company shall maintain or cause to be maintained the Register of Members in accordance with the Statute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2</span></span>The Directors may determine that the Company shall maintain one or more branch registers of Members in accordance with the Statute. The Directors may also determine which register of Members shall constitute the principal register and which shall constitute the branch register or registers, and to vary such determination from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5</b></span><b style="font-weight:bold;">Closing Register of Members or Fixing Record Date</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.1</span></span>For the purpose of determining Members entitled to notice of, or to vote at any meeting of Members or any adjournment thereof, or Members entitled to receive payment of any Dividend or other distribution, or in order to make a determination of Members for any other purpose, the Directors may, after notice has been given by advertisement in an appointed newspaper or any other newspaper or by any other means in accordance with the rules and regulations of the Designated Stock Exchange, the Securities and Exchange Commission and/or any other competent regulatory authority or otherwise under Applicable Law, provide that the Register of Members shall be closed for transfers for a stated period which shall not in any case exceed forty days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2</span></span>In lieu of, or apart from, closing the Register of Members, the Directors may fix in advance or arrears a date as the record date for any such determination of Members entitled to notice of, or to vote at any meeting of the Members or any adjournment thereof, or for the purpose of determining the Members entitled to receive payment of any Dividend or other distribution, or in order to make a determination of Members for any other purpose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.3</span></span>If the Register of Members is not so closed and no record date is fixed for the determination of Members entitled to notice of, or to vote at, a meeting of Members or Members entitled to receive payment of a Dividend or other distribution, the date on which notice of the meeting is sent or the date on which the resolution of the Directors resolving to pay such Dividend or other distribution is passed, as the case may be, shall be the record date for such determination of Members. When a determination of Members entitled to vote at any meeting of Members has been made as provided in this Article, such determination shall apply to any adjournment thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6</b></span><b style="font-weight:bold;">Certificates for Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1</span></span>A Member shall only be entitled to a share certificate if the Directors resolve that share certificates shall be issued. Share certificates representing Shares, if any, shall be in such form as the Directors may determine. Share certificates shall be signed by one or more Directors or other person authorised by the Directors. The Directors may authorise certificates to be issued with the authorised signature(s) affixed by mechanical process. All certificates for Shares shall be consecutively numbered or otherwise identified and shall specify the Shares to which they relate. All certificates surrendered to the Company for transfer shall be cancelled and, subject to the Articles, no new certificate shall be issued until the former certificate representing a like number of relevant Shares shall have been surrendered and cancelled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2</span></span>The Company shall not be bound to issue more than one certificate for Shares held jointly by more than one person and delivery of a certificate to one joint holder shall be a sufficient delivery to all of them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.3</span></span>If a share certificate is defaced, worn out, lost or destroyed, it may be renewed on such terms (if any) as to evidence and indemnity and on the payment of such expenses reasonably incurred by the Company in investigating evidence, as the Directors may prescribe, and (in the case of defacement or wearing out) upon delivery of the old certificate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.4</span></span>Every share certificate sent in accordance with the Articles will be sent at the risk of the Member or other person entitled to the certificate. The Company will not be responsible for any share certificate lost or delayed in the course of delivery.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.5</span></span>Share certificates shall be issued within the relevant time limit as prescribed by the Statute, if applicable, or as the rules and regulations of the Designated Stock Exchange, the Securities and Exchange Commission and/or any other competent regulatory authority or otherwise under Applicable Law may from time to time determine, whichever is shorter, after the allotment or, except in the case of a Share transfer which the Company is for the time being entitled to refuse to register and does not register, after lodgement of a Share transfer with the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7</b></span><b style="font-weight:bold;">Transfer of Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.1</span></span>Subject to the terms of the Articles, any Member may transfer all or any of his Shares by an instrument of transfer provided that such transfer complies with the rules and regulations of the Designated Stock Exchange, the Securities and Exchange Commission and/or any other competent regulatory authority or otherwise under Applicable Law. If the Shares in question were issued in conjunction with rights, options, warrants or units issued pursuant to the Articles on terms that one cannot be transferred without the other, the Directors shall refuse to register the transfer of any such Share without evidence satisfactory to them of the like transfer of such right, option, warrant or unit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.2</span></span>The instrument of transfer of any Share shall be in writing in the usual or common form or in a form prescribed by the rules and regulations of the Designated Stock Exchange, the Securities and Exchange Commission and/or any other competent regulatory authority or otherwise under Applicable Law or in any other form approved by the Directors and shall be executed by or on behalf of the transferor (and if the Directors so require, signed by or on behalf of the transferee) and may be under hand or, if the transferor or transferee is a Clearing House or its nominee(s), by hand or by machine imprinted signature or by such other manner of execution as the Directors may approve from time to time. The transferor shall be deemed to remain the holder of a Share until the name of the transferee is entered in the Register of Members.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8</b></span><b style="font-weight:bold;">Redemption, Repurchase and Surrender of Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.1</span></span>Subject to the provisions of the Statute, and, where applicable, the rules and regulations of the Designated Stock Exchange, the Securities and Exchange Commission and/or any other competent regulatory authority or otherwise under Applicable Law, the Company may issue Shares that are to be redeemed or are liable to be redeemed at the option of the Member or the Company. The redemption of such Shares, except Public Shares, shall be effected in such manner and upon such other terms as the Company may, by Special Resolution, determine before the issue of such Shares. With respect to redeeming or repurchasing the Shares:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.15pt;margin-top:0pt;padding-left:30pt;text-align:justify;text-indent:-30pt;"><span style="display:inline-block;min-width:29.8pt;text-indent:0pt;white-space:nowrap;">(a)</span>Members who hold Public Shares are entitled to request the redemption of such Shares in the circumstances described in the Business Combination Article hereof;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.15pt;margin-top:0pt;padding-left:30pt;text-align:justify;text-indent:-30pt;"><span style="display:inline-block;min-width:29.8pt;text-indent:0pt;white-space:nowrap;">(b)</span>Class B Shares held by the Sponsor shall be surrendered by the Sponsor for no consideration on a pro-rata basis to the extent that the Over- Allotment Option is not exercised in full so that the Founders will own 20 per cent of the Company&#39;s issued Shares after the IPO (exclusive of any securities purchased in a private placement simultaneously with the IPO); and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:35.15pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.8pt;text-indent:0pt;white-space:nowrap;">(c)</span>Public Shares shall be repurchased by way of tender offer in the circumstances set out in the Business Combination Article hereof.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.2</span></span>Subject to the provisions of the Statute, and, where applicable, the rules and regulations of the Designated Stock Exchange, the Securities and Exchange Commission and/or any other competent regulatory authority or otherwise under Applicable Law, the Company may purchase its own Shares (including any redeemable Shares) in such manner and on such other terms as the Directors may agree with the relevant Member. For the avoidance of doubt, redemptions, repurchases and surrenders of Shares in the circumstances described in the Article above shall not require further approval of the Members.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.3</span></span>The Company may make a payment in respect of the redemption or purchase of its own Shares in any manner permitted by the Statute, including out of capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.4</span></span>The Directors may accept the surrender for no consideration of any fully paid Share.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9</b></span><b style="font-weight:bold;">Treasury Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.1</span></span>The Directors may, prior to the purchase, redemption or surrender of any Share, determine that such Share shall be held as a Treasury Share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.2</span></span>The Directors may determine to cancel a Treasury Share or transfer a Treasury Share on such terms as they think proper (including, without limitation, for nil consideration).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10</b></span><b style="font-weight:bold;">Variation of Rights of Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.1</span></span>Subject to Article 3.1, if at any time the share capital of the Company is divided into different classes of Shares, all or any of the rights attached to any class (unless otherwise provided by the terms of issue of the Shares of that class) may, whether or not the Company is being wound up, be varied without the consent of the holders of the issued Shares of that class where such variation is considered by the Directors not to have a material adverse effect upon such rights; otherwise, any such variation shall be made only with the consent in writing of the holders of not less than two-thirds of the issued Shares of that class (other than with respect to a waiver of the provisions of the Class B Ordinary Share Conversion Article hereof, which as stated therein shall only require the consent in writing of the holders of a majority of the issued Shares of that class), or with the approval of a resolution passed by a majority of not less than two-thirds of the votes cast at a separate meeting of the holders of the Shares of that class. For the avoidance of doubt, the Directors reserve the right, notwithstanding that any such variation may not have a material adverse effect, to obtain consent from the holders of Shares of the relevant class. To any such meeting all the provisions of the Articles relating to general meetings shall apply <i style="font-style:italic;">mutatis mutandis</i>, except that the necessary quorum shall be one person holding or representing by proxy at least one-third of the issued Shares of the class and that any holder of Shares of the class present in person or by proxy may demand a poll.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.2</span></span>For the purposes of a separate class meeting, the Directors may treat two or more or all the classes of Shares as forming one class of Shares if the Directors consider that such class of Shares would be affected in the same way by the proposals under consideration, but in any other case shall treat them as separate classes of Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.3</span></span>The rights conferred upon the holders of the Shares of any class issued with preferred or other rights shall not, unless otherwise expressly provided by the terms of issue of the Shares of that class, be deemed to be varied by the creation or issue of further Shares ranking pari passu therewith or Shares issued with preferred or other rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11</b></span><b style="font-weight:bold;">Commission on Sale of Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company may, in so far as the Statute permits, pay a commission to any person in consideration of his subscribing or agreeing to subscribe (whether absolutely or conditionally) or procuring or agreeing to procure subscriptions (whether absolutely or conditionally) for any Shares. Such commissions may be satisfied by the payment of cash and/or the issue of fully or partly paid-up Shares. The Company may also on any issue of Shares pay such brokerage as may be lawful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12</b></span><b style="font-weight:bold;">Non Recognition of Trusts</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 35.15pt;">The Company shall not be bound by or compelled to recognise in any way (even when notified) any equitable, contingent, future or partial interest in any Share, or (except only as is otherwise provided by the Articles or the Statute) any other rights in respect of any Share other than an absolute right to the entirety thereof in the holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">13</b></span><b style="font-weight:bold;">Lien on Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.1</span></span>The Company shall have a first and paramount lien on all Shares (whether fully paid-up or not) registered in the name of a Member (whether solely or jointly with others) for all debts, liabilities or engagements to or with the Company (whether presently payable or not) by such Member or his estate, either alone or jointly with any other person, whether a Member or not, but the Directors may at any time declare any Share to be wholly or in part exempt from the provisions of this Article. The registration of a transfer of any such Share shall operate as a waiver of the Company&#39;s lien thereon. The Company&#39;s lien on a Share shall also extend to any amount payable in respect of that Share.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.2</span></span>The Company may sell, in such manner as the Directors think fit, any Shares on which the Company has a lien, if a sum in respect of which the lien exists is presently payable, and is not paid within fourteen clear days after notice has been received or deemed to have been received by the holder of the Shares, or to the person entitled to it in consequence of the death or bankruptcy of the holder, demanding payment and stating that if the notice is not complied with the Shares may be sold.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.3</span></span>To give effect to any such sale the Directors may authorise any person to execute an instrument of transfer of the Shares sold to, or in accordance with the directions of, the purchaser. The purchaser or his nominee shall be registered as the holder of the Shares comprised in any such transfer, and he shall not be bound to see to the application of the purchase money, nor shall his title to the Shares be affected by any irregularity or invalidity in the sale or the exercise of the Company&#39;s power of sale under the Articles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.4</span></span>The net proceeds of such sale after payment of costs, shall be applied in payment of such part of the amount in respect of which the lien exists as is presently payable and any balance shall (subject to a like lien for sums not presently payable as existed upon the Shares before the sale) be paid to the person entitled to the Shares at the date of the sale.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">14</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Call on Shares</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.1</span></span>Subject to the terms of the allotment and issue of any Shares, the Directors may make calls upon the Members in respect of any monies unpaid on their Shares (whether in respect of par value or premium), and each Member shall (subject to receiving at least fourteen clear days&#39; notice specifying the time or times of payment) pay to the Company at the time or times so specified the amount called on the Shares. A call may be revoked or postponed, in whole or in part, as the Directors may determine. A call may be required to be paid by instalments. A person upon whom a call is made shall remain liable for calls made upon him notwithstanding the subsequent transfer of the Shares in respect of which the call was made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.2</span></span>A call shall be deemed to have been made at the time when the resolution of the Directors authorising such call was passed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.3</span></span>The joint holders of a Share shall be jointly and severally liable to pay all calls in respect thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.4</span></span>If a call remains unpaid after it has become due and payable, the person from whom it is due shall pay interest on the amount unpaid from the day it became due and payable until it is paid at such rate as the Directors may determine (and in addition all expenses that have been incurred by the Company by reason of such non-payment), but the Directors may waive payment of the interest or expenses wholly or in part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.5</span></span>An amount payable in respect of a Share on issue or allotment or at any fixed date, whether on account of the par value of the Share or premium or otherwise, shall be deemed to be a call and if it is not paid all the provisions of the Articles shall apply as if that amount had become due and payable by virtue of a call.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.6</span></span>The Directors may issue Shares with different terms as to the amount and times of payment of calls, or the interest to be paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.7</span></span>The Directors may, if they think fit, receive an amount from any Member willing to advance all or any part of the monies uncalled and unpaid upon any Shares held by him, and may (until the amount would otherwise become payable) pay interest at such rate as may be agreed upon between the Directors and the Member paying such amount in advance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.8</span></span>No such amount paid in advance of calls shall entitle the Member paying such amount to any portion of a Dividend or other distribution payable in respect of any period prior to the date upon which such amount would, but for such payment, become payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">15</b></span><b style="font-weight:bold;">Forfeiture of Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.1</span></span>If a call or instalment of a call remains unpaid after it has become due and payable the Directors may give to the person from whom it is due not less than fourteen clear days&#39; notice requiring payment of the amount unpaid together with any interest which may have accrued and any expenses incurred by the Company by reason of such non-payment. The notice shall specify where payment is to be made and shall state that if the notice is not complied with the Shares in respect of which the call was made will be liable to be forfeited.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.2</span></span>If the notice is not complied with, any Share in respect of which it was given may, before the payment required by the notice has been made, be forfeited by a resolution of the Directors. Such forfeiture shall include all Dividends, other distributions or other monies payable in respect of the forfeited Share and not paid before the forfeiture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.3</span></span>A forfeited Share may be sold, re-allotted or otherwise disposed of on such terms and in such manner as the Directors think fit and at any time before a sale, re-allotment or disposition the forfeiture may be cancelled on such terms as the Directors think fit. Where for the purposes of its disposal a forfeited Share is to be transferred to any person the Directors may authorise some person to execute an instrument of transfer of the Share in favour of that person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.4</span></span>A person any of whose Shares have been forfeited shall cease to be a Member in respect of them and shall surrender to the Company for cancellation the certificate for the Shares forfeited and shall remain liable to pay to the Company all monies which at the date of forfeiture were payable by him to the Company in respect of those Shares together with interest at such rate as the Directors may determine, but his liability shall cease if and when the Company shall have received payment in full of all monies due and payable by him in respect of those Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.5</span></span>A certificate in writing under the hand of one Director or Officer that a Share has been forfeited on a specified date shall be conclusive evidence of the facts stated in it as against all persons claiming to be entitled to the Share. The certificate shall (subject to the execution of an instrument of transfer) constitute a good title to the Share and the person to whom the Share is sold or otherwise disposed of shall not be bound to see to the application of the purchase money, if any, nor shall his title to the Share be affected by any irregularity or invalidity in the proceedings in reference to the forfeiture, sale or disposal of the Share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.6</span></span>The provisions of the Articles as to forfeiture shall apply in the case of non payment of any sum which, by the terms of issue of a Share, becomes payable at a fixed time, whether on account of the par value of the Share or by way of premium as if it had been payable by virtue of a call duly made and notified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">16</b></span><b style="font-weight:bold;">Transmission of Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.1</span></span>If a Member dies, the survivor or survivors (where he was a joint holder), or his legal personal representatives (where he was a sole holder), shall be the only persons recognised by the Company as having any title to his Shares. The estate of a deceased Member is not thereby released from any liability in respect of any Share, for which he was a joint or sole holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.2</span></span>Any person becoming entitled to a Share in consequence of the death or bankruptcy or liquidation or dissolution of a Member (or in any other way than by transfer) may, upon such evidence being produced as may be required by the Directors, elect, by a notice in writing sent by him to the Company, either to become the holder of such Share or to have some person nominated by him registered as the holder of such Share. If he elects to have another person registered as the holder of such Share he shall sign an instrument of transfer of that Share to that person. The Directors shall, in either case, have the same right to decline or suspend registration as they would have had in the case of a transfer of the Share by the relevant Member before his death or bankruptcy or liquidation or dissolution, as the case may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.3</span></span>A person becoming entitled to a Share by reason of the death or bankruptcy or liquidation or dissolution of a Member (or in any other case than by transfer) shall be entitled to the same Dividends, other distributions and other advantages to which he would be entitled if he were the holder of such Share. However, he shall not, before becoming a Member in respect of a Share, be entitled in respect of it to exercise any right conferred by membership in relation to general meetings of the Company and the Directors may at any time give notice requiring any such person to elect either to be registered himself or to have some person nominated by him be registered as the holder of the Share (but the Directors shall, in either case, have the same right to decline or suspend registration as they would have had in the case of a transfer of the Share by the relevant Member before his death or bankruptcy or liquidation or dissolution or any other case than by transfer, as the case may be). If the notice is not complied with within ninety days of being received or deemed to be received (as determined pursuant to the Articles), the Directors may thereafter withhold payment of all Dividends, other distributions, bonuses or other monies payable in respect of the Share until the requirements of the notice have been complied with.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">17</b></span><b style="font-weight:bold;">Class B Ordinary Share Conversion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">17.1</span></span>The rights attaching to the Class A Shares and Class B Shares shall rank <i style="font-style:italic;">pari passu </i>in all respects, and the Class A Shares and Class B Shares shall vote together as a single class on all matters (subject to the Variation of Rights of Shares Article and the </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 36pt;">Appointment and Removal of Directors Article hereof) with the exception that the holder of a Class B Share shall have the conversion rights referred to in this Article.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">17.2</span></span>Class B Shares shall automatically convert into Class A Shares on a one-for-one basis (the &#8220;<b style="font-weight:bold;">Initial Conversion Ratio</b>&#8221;) automatically on the day of the consummation of a Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">17.3</span></span>Notwithstanding the Initial Conversion Ratio, in the case that additional Class A Shares or any other Equity-linked Securities, are issued, or deemed issued, by the Company in excess of the amounts offered in the IPO and related to the consummation of a Business Combination, all Class B Shares in issue shall automatically convert into Class A Shares at the time of the consummation of a Business Combination at a ratio for which the Class B Shares shall convert into Class A Shares will be adjusted (unless the holders of a majority of the Class B Shares in issue agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance) so that the number of Class A Shares issuable upon conversion of all Class B Shares will equal, on an as- converted basis, in the aggregate, 20 per cent of the sum of: (a) all Class A Shares and Class B Shares in issue upon completion of the IPO; plus (b) all Class A Shares and Equity-linked Securities issued or deemed issued in connection with a Business Combination (including any Forward Purchase Shares but not including any Forward Purchase Warrants), excluding any Shares or Equity-linked Securities issued, or to be issued, to any seller in a Business Combination and any private placement warrants issued to the Sponsor or its Affiliates or any Director or Officer upon conversion of working capital loans made to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">17.4</span></span>Notwithstanding anything to the contrary contained herein, the foregoing adjustment to the Initial Conversion Ratio may be waived as to any particular issuance or deemed issuance of additional Class A Shares or Equity-linked Securities by the written consent or agreement of holders of a majority of the Class B Shares then in issue consenting or agreeing separately as a separate class in the manner provided in the Variation of Rights of Shares Article hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">17.5</span></span>The foregoing conversion ratio shall also be adjusted to account for any subdivision (by share subdivision, exchange, capitalisation, rights issue, reclassification, recapitalisation or otherwise) or combination (by share consolidation, exchange, reclassification, recapitalisation or otherwise) or similar reclassification or recapitalisation of the Class A Shares in issue into a greater or lesser number of Shares occurring after the original filing of the Articles without a proportionate and corresponding subdivision, combination or similar reclassification or recapitalisation of the Class B Shares in issue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">17.6</span></span>Each Class B Share shall convert into its pro rata number of Class A Shares pursuant to this Article. The pro rata share for each holder of Class B Shares will be determined as follows: each Class B Share shall convert into such number of Class A Shares as is equal to the product of 1 multiplied by a fraction, the numerator of which shall be the total number of Class A Shares into which all of the Class B Shares in issue shall be converted pursuant to this Article and the denominator of which shall be the total number of Class B Shares in issue at the time of conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">17.7</span></span>References in this Article to &#8220;<b style="font-weight:bold;">converted</b>&#8221;, &#8220;<b style="font-weight:bold;">conversion</b>&#8221; or &#8220;<b style="font-weight:bold;">exchange</b>&#8221; shall mean the compulsory redemption without notice of Class B Shares of any Member and, on behalf of such Members, automatic application of such redemption proceeds in paying for such new Class A Shares into which the Class B Shares have been converted or exchanged at a price per Class B Share necessary to give effect to a conversion or exchange calculated on the basis that the Class A Shares to be issued as part of the conversion or exchange will be issued at par. The Class A Shares to be issued on an exchange or conversion shall be registered in the name of such Member or in such name as the Member may direct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">17.8</span></span>Notwithstanding anything to the contrary in this Article, in no event may any Class B Share convert into Class A Shares at a ratio that is less than one-for- one.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">18</b></span><b style="font-weight:bold;">Amendments of Memorandum and Articles of Association and Alteration of Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">18.1</span></span>The Company may by Ordinary Resolution:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.15pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.8pt;text-indent:0pt;white-space:nowrap;">(a)</span>increase its share capital by such sum as the Ordinary Resolution shall prescribe and with such rights, priorities and privileges annexed thereto, as the Company in general meeting may determine;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.15pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.8pt;text-indent:0pt;white-space:nowrap;">(b)</span>consolidate and divide all or any of its share capital into Shares of larger amount than its existing Shares;</div></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.15pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.8pt;text-indent:0pt;white-space:nowrap;">(c)</span>convert all or any of its paid-up Shares into stock, and reconvert that stock into paid-up Shares of any denomination;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.15pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.8pt;text-indent:0pt;white-space:nowrap;">(d)</span>by subdivision of its existing Shares or any of them divide the whole or any part of its share capital into Shares of smaller amount than is fixed by the Memorandum or into Shares without par value; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:35.15pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.8pt;text-indent:0pt;white-space:nowrap;">(e)</span>cancel any Shares that at the date of the passing of the Ordinary Resolution have not been taken or agreed to be taken by any person and diminish the amount of its share capital by the amount of the Shares so cancelled.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">18.2</span></span>All new Shares created in accordance with the provisions of the preceding Article shall be subject to the same provisions of the Articles with reference to the payment of calls, liens, transfer, transmission, forfeiture and otherwise as the Shares in the original share capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">18.2</span></span>Subject to the provisions of the Statute, the provisions of the Articles as regards the matters to be dealt with by Ordinary Resolution, Article 29.4 and Article 47.2, the Company may by Special Resolution:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(a)</span>change its name;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(b)</span>alter or add to the Articles;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(c)</span>alter or add to the Memorandum with respect to any objects, powers or other matters specified therein; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(d)</span>reduce its share capital or any capital redemption reserve fund.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">19</b></span><b style="font-weight:bold;">Offices and Places of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 36pt;">Subject to the provisions of the Statute, the Company may by resolution of the Directors change the location of its Registered Office. The Company may, in addition to its Registered Office, maintain such other offices or places of business as the Directors determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">20</b></span><b style="font-weight:bold;">General Meetings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20.1</span></span>All general meetings other than annual general meetings shall be called extraordinary general meetings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20.2</span></span>The Company may, but shall not (unless required by the Statute) be obliged to, in each year hold a general meeting as its annual general meeting, and shall specify the meeting as such in the notices calling it. Any annual general meeting shall be held at such time and place as the Directors shall appoint. At these meetings the report of the Directors (if any) shall be presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20.3</span></span>The Directors, the chief executive officer or the chairman of the board of Directors may call general meetings, and, for the avoidance of doubt, Members shall not have the ability to call general meetings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20.4</span></span>Members seeking to bring business before the annual general meeting or to nominate candidates for appointment as Directors at the annual general meeting must deliver notice to the principal executive offices of the Company not less than 120 calendar days before the date of the Company&#8217;s proxy statement released to Members in connection with the previous year&#8217;s annual general meeting or, if the Company did not hold an annual general meeting the previous year, or if the date of the current year&#39;s annual general meeting has been changed by more than 30 days from the date of the previous year&#8217;s annual general meeting, then the deadline shall be set by the board of Directors with such deadline being a reasonable time before the Company begins to print and send its related proxy materials.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">21</b></span><b style="font-weight:bold;">Notice of General Meetings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">21.1</span></span>At least five clear days&#39; notice shall be given of any general meeting. Every notice shall specify the place, the day and the hour of the meeting and the general nature of the business to be conducted at the general meeting and shall be given in the manner hereinafter mentioned or in such other manner if any as may be prescribed by the Company, provided that a general meeting of the Company shall, whether or not the notice specified in this Article has been given and whether or not the provisions of the Articles regarding general meetings have been complied with, be deemed to have been duly convened if it is so agreed:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(a)</span>in the case of an annual general meeting, by all of the Members entitled to attend and vote thereat; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(b)</span>in the case of an extraordinary general meeting, by a majority in number of the Members having a right to attend and vote at the meeting, together holding not less than ninety-five per cent in par value of the Shares giving that right.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">21.2</span></span>The accidental omission to give notice of a general meeting to, or the non receipt of notice of a general meeting by, any person entitled to receive such notice shall not invalidate the proceedings of that general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">22</b></span><b style="font-weight:bold;">Proceedings at General Meetings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">22.1</span></span>No business shall be transacted at any general meeting unless a quorum is present. The holders of one-third of the Shares being individuals present in person or by proxy or if a corporation or other non-natural person by its duly authorised representative or proxy shall be a quorum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">22.2</span></span>A person may participate at a general meeting by conference telephone or other communications equipment by means of which all the persons participating in the meeting can communicate with each other. Participation by a person in a general meeting in this manner is treated as presence in person at that meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">22.3</span></span>A resolution (including a Special Resolution) in writing (in one or more counterparts) signed by or on behalf of all of the Members for the time being entitled to receive notice of and to attend and vote at general meetings (or, being corporations or other non-natural persons, signed by their duly authorised representatives) shall be as valid and effective as if the resolution had been passed at a general meeting of the Company duly convened and held.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">22.4</span></span>If a quorum is not present within half an hour from the time appointed for the meeting to commence, the meeting shall stand adjourned to the same day in the next week at the same time and/or place or to such other day, time and/or place as the Directors may determine, and if at the adjourned meeting a quorum is not present within half an hour from the time appointed for the meeting to commence, the Members present shall be a quorum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">22.5</span></span>The Directors may, at any time prior to the time appointed for the meeting to commence, appoint any person to act as chairman of a general meeting of the Company or, if the Directors do not make any such appointment, the chairman, if any, of the board of Directors shall preside as chairman at such general meeting. If there is no such chairman, or if he shall not be present within fifteen minutes after the time appointed for the meeting to commence, or is unwilling to act, the Directors present shall elect one of their number to be chairman of the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">22.6</span></span>If no Director is willing to act as chairman or if no Director is present within fifteen minutes after the time appointed for the meeting to commence, the Members present shall choose one of their number to be chairman of the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">22.7</span></span>The chairman may, with the consent of a meeting at which a quorum is present (and shall if so directed by the meeting) adjourn the meeting from time to time and from place to place, but no business shall be transacted at any adjourned meeting other than the business left unfinished at the meeting from which the adjournment took place.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">22.8</span></span>When a general meeting is adjourned for thirty days or more, notice of the adjourned meeting shall be given as in the case of an original meeting. Otherwise it shall not be necessary to give any such notice of an adjourned meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">22.9</span></span>If, prior to a Business Combination, a notice is issued in respect of a general meeting and the Directors, in their absolute discretion, consider that it is impractical or undesirable for any reason to hold that general meeting at the place, the day and the hour specified in the notice calling such general meeting, the Directors may postpone the general meeting to another place, day </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 36pt;">and/or hour provided that notice of the place, the day and the hour of the rearranged general meeting is promptly given to all Members. No business shall be transacted at any postponed meeting other than the business specified in the notice of the original meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">22.10</span></span>When a general meeting is postponed for thirty days or more, notice of the postponed meeting shall be given as in the case of an original meeting. Otherwise it shall not be necessary to give any such notice of a postponed meeting. All proxy forms submitted for the original general meeting shall remain valid for the postponed meeting. The Directors may postpone a general meeting which has already been postponed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">22.11</span></span>A resolution put to the vote of the meeting shall be decided on a poll.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">22.12</span></span>A poll shall be taken as the chairman directs, and the result of the poll shall be deemed to be the resolution of the general meeting at which the poll was demanded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">22.13</span></span>A poll demanded on the election of a chairman or on a question of adjournment shall be taken forthwith. A poll demanded on any other question shall be taken at such date, time and place as the chairman of the general meeting directs, and any business other than that upon which a poll has been demanded or is contingent thereon may proceed pending the taking of the poll.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">22.14</span></span>In the case of an equality of votes the chairman shall be entitled to a second or casting vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">23</b></span><b style="font-weight:bold;">Votes of Members</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">23.1</span></span>Subject to any rights or restrictions attached to any Shares, including as set out at Article 29.4 and Article 47.2, every Member present in any such manner shall have one vote for every Share of which he is the holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">23.2</span></span>In the case of joint holders the vote of the senior holder who tenders a vote, whether in person or by proxy (or, in the case of a corporation or other non- natural person, by its duly authorised representative or proxy), shall be accepted to the exclusion of the votes of the other joint holders, and seniority shall be determined by the order in which the names of the holders stand in the Register of Members.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">23.3</span></span>A Member of unsound mind, or in respect of whom an order has been made by any court, having jurisdiction in lunacy, may vote by his committee, receiver, curator bonis, or other person on such Member&#39;s behalf appointed by that court, and any such committee, receiver, curator bonis or other person may vote by proxy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">23.4</span></span>No person shall be entitled to vote at any general meeting unless he is registered as a Member on the record date for such meeting nor unless all calls or other monies then payable by him in respect of Shares have been paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">23.5</span></span>No objection shall be raised as to the qualification of any voter except at the general meeting or adjourned general meeting at which the vote objected to is given or tendered and every vote not disallowed at the meeting shall be valid. Any objection made in due time in accordance with this Article shall be referred to the chairman whose decision shall be final and conclusive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">23.6</span></span>Votes may be cast either personally or by proxy (or in the case of a corporation or other non-natural person by its duly authorised representative or proxy). A Member may appoint more than one proxy or the same proxy under one or more instruments to attend and vote at a meeting. Where a Member appoints more than one proxy the instrument of proxy shall specify the number of Shares in respect of which each proxy is entitled to exercise the related votes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">23.7</span></span>A Member holding more than one Share need not cast the votes in respect of his Shares in the same way on any resolution and therefore may vote a Share or some or all such Shares either for or against a resolution and/or abstain from voting a Share or some or all of the Shares and, subject to the terms of the instrument appointing him, a proxy appointed under one or more instruments may vote a Share or some or all of the Shares in respect of which he is appointed either for or against a resolution and/or abstain from voting a Share or some or all of the Shares in respect of which he is appointed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">24</b></span><b style="font-weight:bold;">Proxies</b></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24.1</span></span>The instrument appointing a proxy shall be in writing and shall be executed under the hand of the appointor or of his attorney duly authorised in writing, or, if the appointor is a corporation or other non natural person, under the hand of its duly authorised representative. A proxy need not be a Member.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24.2</span></span>The Directors may, in the notice convening any meeting or adjourned meeting, or in an instrument of proxy sent out by the Company, specify the manner by which the instrument appointing a proxy shall be deposited and the place and the time (being not later than the time appointed for the commencement of the meeting or adjourned meeting to which the proxy relates) at which the instrument appointing a proxy shall be deposited. In the absence of any such direction from the Directors in the notice convening any meeting or adjourned meeting or in an instrument of proxy sent out by the Company, the instrument appointing a proxy shall be deposited physically at the Registered Office not less than 48 hours before the time appointed for the meeting or adjourned meeting to commence at which the person named in the instrument proposes to vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24.3</span></span>The chairman may in any event at his discretion declare that an instrument of proxy shall be deemed to have been duly deposited. An instrument of proxy that is not deposited in the manner permitted, or which has not been declared to have been duly deposited by the chairman, shall be invalid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24.4</span></span>The instrument appointing a proxy may be in any usual or common form (or such other form as the Directors may approve) and may be expressed to be for a particular meeting or any adjournment thereof or generally until revoked. An instrument appointing a proxy shall be deemed to include the power to demand or join or concur in demanding a poll.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24.5</span></span>Votes given in accordance with the terms of an instrument of proxy shall be valid notwithstanding the previous death or insanity of the principal or revocation of the proxy or of the authority under which the proxy was executed, or the transfer of the Share in respect of which the proxy is given unless notice in writing of such death, insanity, revocation or transfer was received by the Company at the Registered Office before the commencement of the general meeting, or adjourned meeting at which it is sought to use the proxy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">25</b></span><b style="font-weight:bold;">Corporate Members</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">25.1</span></span>Any corporation or other non-natural person which is a Member may in accordance with its constitutional documents, or in the absence of such provision by resolution of its directors or other governing body, authorise such person as it thinks fit to act as its representative at any meeting of the Company or of any class of Members, and the person so authorised shall be entitled to exercise the same powers on behalf of the corporation which he represents as the corporation could exercise if it were an individual Member.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">25.2</span></span>If a Clearing House (or its nominee(s)), being a corporation, is a Member, it may authorise such persons as it sees fit to act as its representative at any meeting of the Company or at any meeting of any class of Members provided that the authorisation shall specify the number and class of Shares in respect of which each such representative is so authorised. Each person so authorised under the provisions of this Article shall be deemed to have been duly authorised without further evidence of the facts and be entitled to exercise the same rights and powers on behalf of the Clearing House (or its nominee(s)) as if such person was the registered holder of such Shares held by the Clearing House (or its nominee(s)).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">26</b></span><b style="font-weight:bold;">Shares that May Not be Voted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Shares in the Company that are beneficially owned by the Company shall not be voted, directly or indirectly, at any meeting and shall not be counted in determining the total number of outstanding Shares at any given time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">27</b></span><b style="font-weight:bold;">Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">27.1</span></span>There shall be a board of Directors consisting of not less than one person provided however that the Company may by Ordinary Resolution increase or reduce the limits in the number of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">27.2</span></span>Commencing at the Company&#8217;s first annual general meeting, and at each annual general meeting thereafter, Directors appointed to succeed those Directors whose terms expire shall be appointed for a term of office to expire at the second succeeding annual general meeting after their appointment. Except as the Statute or other Applicable Law may otherwise require, in the interim between annual general meetings or extraordinary general meetings called for the appointment of Directors and/or the removal </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 36pt;">of one or more Directors and the filling of any vacancy in that connection, additional Directors and any vacancies in the board of Directors, including unfilled vacancies resulting from the removal of Directors for cause, may be filled by the vote of a majority of the remaining Directors then in office, although less than a quorum (as defined in the Articles), or by the sole remaining Director. All Directors shall hold office until the expiration of their respective terms of office and until their successors shall have been appointed and qualified. A Director appointed to fill a vacancy resulting from the death, resignation or removal of a Director shall serve for the remainder of the full term of the Director whose death, resignation or removal shall have created such vacancy and until his successor shall have been appointed and qualified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">28</b></span><b style="font-weight:bold;">Powers of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">28.1</span></span>Subject to the provisions of the Statute, the Memorandum and the Articles and to any directions given by Special Resolution, the business of the Company shall be managed by the Directors who may exercise all the powers of the Company. No alteration of the Memorandum or Articles and no such direction shall invalidate any prior act of the Directors which would have been valid if that alteration had not been made or that direction had not been given. A duly convened meeting of Directors at which a quorum is present may exercise all powers exercisable by the Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">28.2</span></span>All cheques, promissory notes, drafts, bills of exchange and other negotiable or transferable instruments and all receipts for monies paid to the Company shall be signed, drawn, accepted, endorsed or otherwise executed as the case may be in such manner as the Directors shall determine by resolution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">28.3</span></span>The Directors on behalf of the Company may pay a gratuity or pension or allowance on retirement to any Director who has held any other salaried office or place of profit with the Company or to his widow or dependants and may make contributions to any fund and pay premiums for the purchase or provision of any such gratuity, pension or allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">28.4</span></span>The Directors may exercise all the powers of the Company to borrow money and to mortgage or charge its undertaking, property and assets (present and future) and uncalled capital or any part thereof and to issue debentures, debenture stock, mortgages, bonds and other such securities whether outright or as security for any debt, liability or obligation of the Company or of any third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">29</b></span><b style="font-weight:bold;">Appointment and Removal of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.1</span></span>Prior to the consummation of a Business Combination, the Company may by Ordinary Resolution of the holders of the Class B Shares appoint any person to be a Director or may by Ordinary Resolution of the holders of the Class B Shares remove any Director. For the avoidance of doubt, prior to the consummation of a Business Combination, holders of Class A Shares shall have no right to vote on the appointment or removal of any Director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.2</span></span>The Directors may appoint any person to be a Director, either to fill a vacancy or as an additional Director provided that the appointment does not cause the number of Directors to exceed any number fixed by or in accordance with the Articles as the maximum number of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.3</span></span>After the consummation of a Business Combination, the Company may by Ordinary Resolution appoint any person to be a Director or may by Ordinary Resolution remove any Director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.4</span></span>Prior to the consummation of a Business Combination, Article 29.1 may only be amended by a Special Resolution passed by at least 90 per cent of such Members as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at a general meeting of which notice specifying the intention to propose the resolution as a Special Resolution has been given, or by way of unanimous written resolution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">30</b></span><b style="font-weight:bold;">Vacation of Office of Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 35.15pt;">The office of a Director shall be vacated if:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(a)</span>the Director gives notice in writing to the Company that he resigns the office of Director; or</div></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-align:justify;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(b)</span>the Director absents himself (for the avoidance of doubt, without being represented by proxy) from three consecutive meetings of the board of Directors without special leave of absence from the Directors, and the Directors pass a resolution that he has by reason of such absence vacated office; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(c)</span>the Director dies, becomes bankrupt or makes any arrangement or composition with his creditors generally; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(d)</span>the Director is found to be or becomes of unsound mind; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-align:justify;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(e)</span>all of the other Directors (being not less than two in number) determine that he should be removed as a Director, either by a resolution passed by all of the other Directors at a meeting of the Directors duly convened and held in accordance with the Articles or by a resolution in writing signed by all of the other Directors.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">31</b></span><b style="font-weight:bold;">Proceedings of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31.1</span></span>The quorum for the transaction of the business of the Directors may be fixed by the Directors, and unless so fixed shall be a majority of the Directors then in office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31.2</span></span>Subject to the provisions of the Articles, the Directors may regulate their proceedings as they think fit. Questions arising at any meeting shall be decided by a majority of votes. In the case of an equality of votes, the chairman shall have a second or casting vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31.3</span></span>A person may participate in a meeting of the Directors or any committee of Directors by conference telephone or other communications equipment by means of which all the persons participating in the meeting can communicate with each other at the same time. Participation by a person in a meeting in this manner is treated as presence in person at that meeting. Unless otherwise determined by the Directors, the meeting shall be deemed to be held at the place where the chairman is located at the start of the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31.4</span></span>A resolution in writing (in one or more counterparts) signed by all the Directors or all the members of a committee of the Directors or, in the case of a resolution in writing relating to the removal of any Director or the vacation of office by any Director, all of the Directors other than the Director who is the subject of such resolution shall be as valid and effectual as if it had been passed at a meeting of the Directors, or committee of Directors as the case may be, duly convened and held.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31.5</span></span>A Director may, or other Officer on the direction of a Director shall, call a meeting of the Directors by at least two days&#39; notice in writing to every Director which notice shall set forth the general nature of the business to be considered unless notice is waived by all the Directors either at, before or after the meeting is held. To any such notice of a meeting of the Directors all the provisions of the Articles relating to the giving of notices by the Company to the Members shall apply <i style="font-style:italic;">mutatis mutandis.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31.6</span></span>The continuing Directors (or a sole continuing Director, as the case may be) may act notwithstanding any vacancy in their body, but if and so long as their number is reduced below the number fixed by or pursuant to the Articles as the necessary quorum of Directors the continuing Directors or Director may act for the purpose of increasing the number of Directors to be equal to such fixed number, or of summoning a general meeting of the Company, but for no other purpose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31.7</span></span>The Directors may elect a chairman of their board and determine the period for which he is to hold office; but if no such chairman is elected, or if at any meeting the chairman is not present within five minutes after the time appointed for the meeting to commence, the Directors present may choose one of their number to be chairman of the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31.8</span></span>All acts done by any meeting of the Directors or of a committee of the Directors shall, notwithstanding that it is afterwards discovered that there was some defect in the appointment of any Director, and/or that they or any of them were disqualified, and/or had vacated their office and/or were not entitled to vote, be as valid as if every such person had been duly appointed and/or not disqualified to be a Director and/or had not vacated their office and/or had been entitled to vote, as the case may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31.9</span></span>A Director may be represented at any meetings of the board of Directors by a proxy appointed in writing by him. The proxy shall count towards the quorum and the vote of the proxy shall for all purposes be deemed to be that of the appointing Director.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">32</b></span><b style="font-weight:bold;">Presumption of Assent</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 36pt;">A Director who is present at a meeting of the board of Directors at which action on any Company matter is taken shall be presumed to have assented to the action taken unless his dissent shall be entered in the minutes of the meeting or unless he shall file his written dissent from such action with the person acting as the chairman or secretary of the meeting before the adjournment thereof or shall forward such dissent by registered post to such person immediately after the adjournment of the meeting. Such right to dissent shall not apply to a Director who voted in favour of such action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">33</b></span><b style="font-weight:bold;">Directors&#39; Interests</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">33.1</span></span>A Director may hold any other office or place of profit under the Company (other than the office of Auditor) in conjunction with his office of Director for such period and on such terms as to remuneration and otherwise as the Directors may determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">33.2</span></span>A Director may act by himself or by, through or on behalf of his firm in a professional capacity for the Company and he or his firm shall be entitled to remuneration for professional services as if he were not a Director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">33.3</span></span>A Director may be or become a director or other officer of or otherwise interested in any company promoted by the Company or in which the Company may be interested as a shareholder, a contracting party or otherwise, and no such Director shall be accountable to the Company for any remuneration or other benefits received by him as a director or officer of, or from his interest in, such other company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">33.4</span></span>No person shall be disqualified from the office of Director or prevented by such office from contracting with the Company, either as vendor, purchaser or otherwise, nor shall any such contract or any contract or transaction entered into by or on behalf of the Company in which any Director shall be in any way interested be or be liable to be avoided, nor shall any Director so contracting or being so interested be liable to account to the Company for any profit realised by or arising in connection with any such contract or transaction by reason of such Director holding office or of the fiduciary relationship thereby established. A Director shall be at liberty to vote in respect of any contract or transaction in which he is interested provided that the nature of the interest of any Director in any such contract or transaction shall be disclosed by him at or prior to its consideration and any vote thereon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">33.5</span></span>A general notice that a Director is a shareholder, director, officer or employee of any specified firm or company and is to be regarded as interested in any transaction with such firm or company shall be sufficient disclosure for the purposes of voting on a resolution in respect of a contract or transaction in which he has an interest, and after such general notice it shall not be necessary to give special notice relating to any particular transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">34</b></span><b style="font-weight:bold;">Minutes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Directors shall cause minutes to be made in books kept for the purpose of recording all appointments of Officers made by the Directors, all proceedings at meetings of the Company or the holders of any class of Shares and of the Directors, and of committees of the Directors, including the names of the Directors present at each meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">35</b></span><b style="font-weight:bold;">Delegation of Directors&#39; Powers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">35.1</span></span>The Directors may delegate any of their powers, authorities and discretions, including the power to sub-delegate, to any committee consisting of one or more Directors (including, without limitation, the Audit Committee, the Compensation Committee and the Nominating Committee). Any such delegation may be made subject to any conditions the Directors may impose and either collaterally with or to the exclusion of their own powers and any such delegation may be revoked or altered by the Directors. Subject to any such conditions, the proceedings of a committee of Directors shall be governed by the Articles regulating the proceedings of Directors, so far as they are capable of applying.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">35.2</span></span>The Directors may establish any committees, local boards or agencies or appoint any person to be a manager or agent for managing the affairs of the Company and may appoint any person to be a member of such committees, local boards or agencies. Any such appointment may be made subject to any conditions the Directors may impose, and either collaterally with or to the exclusion of their own powers and any such appointment may be revoked or altered by the Directors. Subject to any such </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 36pt;">conditions, the proceedings of any such committee, local board or agency shall be governed by the Articles regulating the proceedings of Directors, so far as they are capable of applying.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">35.3</span></span>The Directors may adopt formal written charters for committees. Each of these committees shall be empowered to do all things necessary to exercise the rights of such committee set forth in the Articles and shall have such powers as the Directors may delegate pursuant to the Articles and as required by the rules and regulations of the Designated Stock Exchange, the Securities and Exchange Commission and/or any other competent regulatory authority or otherwise under Applicable Law. Each of the Audit Committee, the Compensation Committee and the Nominating Committee, if established, shall consist of such number of Directors as the Directors shall from time to time determine (or such minimum number as may be required from time to time by the rules and regulations of the Designated Stock Exchange, the Securities and Exchange Commission and/or any other competent regulatory authority or otherwise under Applicable Law). For so long as any class of Shares is listed on the Designated Stock Exchange, the Audit Committee, the Compensation Committee and the Nominating Committee shall be made up of such number of Independent Directors as is required from time to time by the rules and regulations of the Designated Stock Exchange, the Securities and Exchange Commission and/or any other competent regulatory authority or otherwise under Applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">35.4</span></span>The Directors may by power of attorney or otherwise appoint any person to be the agent of the Company on such conditions as the Directors may determine, provided that the delegation is not to the exclusion of their own powers and may be revoked by the Directors at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">35.5</span></span>The Directors may by power of attorney or otherwise appoint any company, firm, person or body of persons, whether nominated directly or indirectly by the Directors, to be the attorney or authorised signatory of the Company for such purpose and with such powers, authorities and discretions (not exceeding those vested in or exercisable by the Directors under the Articles) and for such period and subject to such conditions as they may think fit, and any such powers of attorney or other appointment may contain such provisions for the protection and convenience of persons dealing with any such attorneys or authorised signatories as the Directors may think fit and may also authorise any such attorney or authorised signatory to delegate all or any of the powers, authorities and discretions vested in him.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">35.6</span></span>The Directors may appoint such Officers as they consider necessary on such terms, at such remuneration and to perform such duties, and subject to such provisions as to disqualification and removal as the Directors may think fit. Unless otherwise specified in the terms of his appointment an Officer may be removed by resolution of the Directors or Members. An Officer may vacate his office at any time if he gives notice in writing to the Company that he resigns his office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">36</b></span><b style="font-weight:bold;">No Minimum Shareholding</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company in general meeting may fix a minimum shareholding required to be held by a Director, but unless and until such a shareholding qualification is fixed a Director is not required to hold Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">37</b></span><b style="font-weight:bold;">Remuneration of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">37.1</span></span>The remuneration to be paid to the Directors, if any, shall be such remuneration as the Directors shall determine, provided that no cash remuneration shall be paid to any Director by the Company prior to the consummation of a Business Combination. The Directors shall also, whether prior to or after the consummation of a Business Combination, be entitled to be paid all travelling, hotel and other expenses properly incurred by them in connection with their attendance at meetings of Directors or committees of Directors, or general meetings of the Company, or separate meetings of the holders of any class of Shares or debentures of the Company, or otherwise in connection with the business of the Company or the discharge of their duties as a Director, or to receive a fixed allowance in respect thereof as may be determined by the Directors, or a combination partly of one such method and partly the other.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">37.2</span></span>The Directors may by resolution approve additional remuneration to any Director for any services which in the opinion of the Directors go beyond his ordinary routine work as a Director. Any fees paid to a Director who is also counsel, attorney or solicitor to the Company, or otherwise serves it in a professional capacity shall be in addition to his remuneration as a Director.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">38</b></span><b style="font-weight:bold;">Seal</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">38.1</span></span>The Company may, if the Directors so determine, have a Seal. The Seal shall only be used by the authority of the Directors or of a committee of the Directors authorised by the Directors. Every instrument to which the Seal has been affixed shall be signed by at least one person who shall be either a Director or some Officer or other person appointed by the Directors for the purpose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">38.2</span></span>The Company may have for use in any place or places outside the Cayman Islands a duplicate Seal or Seals each of which shall be a facsimile of the common Seal of the Company and, if the Directors so determine, with the addition on its face of the name of every place where it is to be used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">38.3</span></span>A Director or Officer, representative or attorney of the Company may without further authority of the Directors affix the Seal over his signature alone to any document of the Company required to be authenticated by him under seal or to be filed with the Registrar of Companies in the Cayman Islands or elsewhere wheresoever.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">39</b></span><b style="font-weight:bold;">Dividends, Distributions and Reserve</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">39.1</span></span>Subject to the Statute and this Article and except as otherwise provided by the rights attached to any Shares, the Directors may resolve to pay Dividends and other distributions on Shares in issue and authorise payment of the Dividends or other distributions out of the funds of the Company lawfully available therefor. A Dividend shall be deemed to be an interim Dividend unless the terms of the resolution pursuant to which the Directors resolve to pay such Dividend specifically state that such Dividend shall be a final Dividend. No Dividend or other distribution shall be paid except out of the realised or unrealised profits of the Company, out of the share premium account or as otherwise permitted by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">39.2</span></span>Except as otherwise provided by the rights attached to any Shares, all Dividends and other distributions shall be paid according to the par value of the Shares that a Member holds. If any Share is issued on terms providing that it shall rank for Dividend as from a particular date, that Share shall rank for Dividend accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">39.3</span></span>The Directors may deduct from any Dividend or other distribution payable to any Member all sums of money (if any) then payable by him to the Company on account of calls or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">39.4</span></span>The Directors may resolve that any Dividend or other distribution be paid wholly or partly by the distribution of specific assets and in particular (but without limitation) by the distribution of shares, debentures, or securities of any other company or in any one or more of such ways and where any difficulty arises in regard to such distribution, the Directors may settle the same as they think expedient and in particular may issue fractional Shares and may fix the value for distribution of such specific assets or any part thereof and may determine that cash payments shall be made to any Members upon the basis of the value so fixed in order to adjust the rights of all Members and may vest any such specific assets in trustees in such manner as may seem expedient to the Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">39.5</span></span>Except as otherwise provided by the rights attached to any Shares, Dividends and other distributions may be paid in any currency. The Directors may determine the basis of conversion for any currency conversions that may be required and how any costs involved are to be met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">39.6</span></span>The Directors may, before resolving to pay any Dividend or other distribution, set aside such sums as they think proper as a reserve or reserves which shall, at the discretion of the Directors, be applicable for any purpose of the Company and pending such application may, at the discretion of the Directors, be employed in the business of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">39.7</span></span>Any Dividend, other distribution, interest or other monies payable in cash in respect of Shares may be paid by wire transfer to the holder or by cheque or warrant sent through the post directed to the registered address of the holder or, in the case of joint holders, to the registered address of the holder who is first named on the Register of Members or to such person and to such address as such holder or joint holders may in writing direct. Every such cheque or warrant shall be made payable to the order of the person to whom it is sent. Any one of two or more joint holders may give effectual receipts for any Dividends, other distributions, bonuses, or other monies payable in respect of the Share held by them as joint holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">39.8</span></span>No Dividend or other distribution shall bear interest against the Company.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">39.9</span></span>Any Dividend or other distribution which cannot be paid to a Member and/or which remains unclaimed after six months from the date on which such Dividend or other distribution becomes payable may, in the discretion of the Directors, be paid into a separate account in the Company&#39;s name, provided that the Company shall not be constituted as a trustee in respect of that account and the Dividend or other distribution shall remain as a debt due to the Member. Any Dividend or other distribution which remains unclaimed after a period of six years from the date on which such Dividend or other distribution becomes payable shall be forfeited and shall revert to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">40</b></span><b style="font-weight:bold;">Capitalisation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Directors may at any time capitalise any sum standing to the credit of any of the Company&#39;s reserve accounts or funds (including the share premium account and capital redemption reserve fund) or any sum standing to the credit of the profit and loss account or otherwise available for distribution; appropriate such sum to Members in the proportions in which such sum would have been divisible amongst such Members had the same been a distribution of profits by way of Dividend or other distribution; and apply such sum on their behalf in paying up in full unissued Shares for allotment and distribution credited as fully paid-up to and amongst them in the proportion aforesaid. In such event the Directors shall do all acts and things required to give effect to such capitalisation, with full power given to the Directors to make such provisions as they think fit in the case of Shares becoming distributable in fractions (including provisions whereby the benefit of fractional entitlements accrue to the Company rather than to the Members concerned). The Directors may authorise any person to enter on behalf of all of the Members interested into an agreement with the Company providing for such capitalisation and matters incidental or relating thereto and any agreement made under such authority shall be effective and binding on all such Members and the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">41</b></span><b style="font-weight:bold;">Books of Account</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">41.1</span></span>The Directors shall cause proper books of account (including, where applicable, material underlying documentation including contracts and invoices) to be kept with respect to all sums of money received and expended by the Company and the matters in respect of which the receipt or expenditure takes place, all sales and purchases of goods by the Company and the assets and liabilities of the Company. Such books of account must be retained for a minimum period of five years from the date on which they are prepared. Proper books shall not be deemed to be kept if there are not kept such books of account as are necessary to give a true and fair view of the state of the Company&#39;s affairs and to explain its transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">41.2</span></span>The Directors shall determine whether and to what extent and at what times and places and under what conditions or regulations the accounts and books of the Company or any of them shall be open to the inspection of Members not being Directors and no Member (not being a Director) shall have any right of inspecting any account or book or document of the Company except as conferred by Statute or authorised by the Directors or by the Company in general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">41.3</span></span>The Directors may cause to be prepared and to be laid before the Company in general meeting profit and loss accounts, balance sheets, group accounts (if any) and such other reports and accounts as may be required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">42</b></span><b style="font-weight:bold;">Audit</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">42.1</span></span>The Directors may appoint an Auditor of the Company who shall hold office on such terms as the Directors determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">42.2</span></span>Without prejudice to the freedom of the Directors to establish any other committee, if the Shares (or depositary receipts therefor) are listed or quoted on the Designated Stock Exchange, and if required by the rules and regulations of the Designated Stock Exchange, the Securities and Exchange Commission and/or any other competent regulatory authority or otherwise under Applicable Law, the Directors shall establish and maintain an Audit Committee as a committee of the Directors and shall adopt a formal written Audit Committee charter and review and assess the adequacy of the formal written charter on an annual basis. The composition and responsibilities of the Audit Committee shall comply with the rules and regulations of the Designated Stock Exchange, the Securities and Exchange Commission and/or any other competent regulatory authority or otherwise under Applicable Law. The Audit Committee shall meet at least once every financial quarter, or more frequently as circumstances dictate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">42.3</span></span>If the Shares (or depositary receipts therefor) are listed or quoted on the Designated Stock Exchange, the Company shall conduct an appropriate review of all related party transactions on an ongoing basis and shall utilise the Audit Committee for the review and approval of potential conflicts of interest.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">42.4</span></span>The remuneration of the Auditor shall be fixed by the Audit Committee (if one exists).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">42.5</span></span>If the office of Auditor becomes vacant by resignation or death of the Auditor, or by his becoming incapable of acting by reason of illness or other disability at a time when his services are required, the Directors shall fill the vacancy and determine the remuneration of such Auditor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">42.6</span></span>Every Auditor of the Company shall have a right of access at all times to the books and accounts and vouchers of the Company and shall be entitled to require from the Directors and Officers such information and explanation as may be necessary for the performance of the duties of the Auditor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">42.7</span></span>Auditors shall, if so required by the Directors, make a report on the accounts of the Company during their tenure of office at the next annual general meeting following their appointment in the case of a company which is registered with the Registrar of Companies as an ordinary company, and at the next extraordinary general meeting following their appointment in the case of a company which is registered with the Registrar of Companies as an exempted company, and at any other time during their term of office, upon request of the Directors or any general meeting of the Members.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">42.8</span></span>Any payment made to members of the Audit Committee (if one exists) shall require the review and approval of the Directors, with any Director interested in such payment abstaining from such review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">42.9</span></span>At least one member of the Audit Committee shall be an &#8220;audit committee financial expert&#8221; as determined by the rules and regulations of the Designated Stock Exchange, the Securities and Exchange Commission and/or any other competent regulatory authority or otherwise under Applicable Law. The &#8220;audit committee financial expert&#8221; shall have such past employment experience in finance or accounting, requisite professional certification in accounting, or any other comparable experience or background which results in the individual&#8217;s financial sophistication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">43</b></span><b style="font-weight:bold;">Notices</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">43.1</span></span>Notices shall be in writing and may be given by the Company to any Member either personally or by sending it by courier, post, cable, telex, fax or e-mail to him or to his address as shown in the Register of Members (or where the notice is given by e-mail by sending it to the e-mail address provided by such Member). Notice may also be served by Electronic Communication in accordance with the rules and regulations of the Designated Stock Exchange, the Securities and Exchange Commission and/or any other competent regulatory authority or by placing it on the Company&#8217;s Website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">43.2</span></span>Where a notice is sent by:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.15pt;margin-top:0pt;padding-left:30pt;text-align:justify;text-indent:-30pt;"><span style="display:inline-block;min-width:29.8pt;text-indent:0pt;white-space:nowrap;">(a)</span>courier; service of the notice shall be deemed to be effected by delivery of the notice to a courier company, and shall be deemed to have been received on the third day (not including Saturdays or Sundays or public holidays) following the day on which the notice was delivered to the courier;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.15pt;margin-top:0pt;padding-left:30pt;text-align:justify;text-indent:-30pt;"><span style="display:inline-block;min-width:29.8pt;text-indent:0pt;white-space:nowrap;">(b)</span>post; service of the notice shall be deemed to be effected by properly addressing, pre paying and posting a letter containing the notice, and shall be deemed to have been received on the fifth day (not including Saturdays or Sundays or public holidays in the Cayman Islands) following the day on which the notice was posted;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.15pt;margin-top:0pt;padding-left:30pt;text-align:justify;text-indent:-30pt;"><span style="display:inline-block;min-width:29.8pt;text-indent:0pt;white-space:nowrap;">(c)</span>cable, telex or fax; service of the notice shall be deemed to be effected by properly addressing and sending such notice and shall be deemed to have been received on the same day that it was transmitted;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.15pt;margin-top:0pt;padding-left:30pt;text-align:justify;text-indent:-30pt;"><span style="display:inline-block;min-width:29.8pt;text-indent:0pt;white-space:nowrap;">(d)</span>e-mail or other Electronic Communication; service of the notice shall be deemed to be effected by transmitting the e-mail to the e-mail address provided by the intended recipient and shall be deemed to have been received on the same day that it was sent, and it shall not be necessary for the receipt of the e-mail to be acknowledged by the recipient; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:35.15pt;margin-top:0pt;padding-left:30pt;text-align:justify;text-indent:-30pt;"><span style="display:inline-block;min-width:29.8pt;text-indent:0pt;white-space:nowrap;">(e)</span>placing it on the Company&#8217;s Website; service of the notice shall be deemed to have been effected one hour after the notice or document was placed on the Company&#8217;s Website.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">43.3</span></span>A notice may be given by the Company to the person or persons which the Company has been advised are entitled to a Share or Shares in consequence of the death or bankruptcy of a Member in the same manner as other notices which are required to </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 36pt;">be given under the Articles and shall be addressed to them by name, or by the title of representatives of the deceased, or trustee of the bankrupt, or by any like description at the address supplied for that purpose by the persons claiming to be so entitled, or at the option of the Company by giving the notice in any manner in which the same might have been given if the death or bankruptcy had not occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">43.4</span></span>Notice of every general meeting shall be given in any manner authorised by the Articles to every holder of Shares carrying an entitlement to receive such notice on the record date for such meeting except that in the case of joint holders the notice shall be sufficient if given to the joint holder first named in the Register of Members and every person upon whom the ownership of a Share devolves by reason of his being a legal personal representative or a trustee in bankruptcy of a Member where the Member but for his death or bankruptcy would be entitled to receive notice of the meeting, and no other person shall be entitled to receive notices of general meetings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">44</b></span><b style="font-weight:bold;">Winding Up</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">44.1</span></span>If the Company shall be wound up, the liquidator shall apply the assets of the Company in satisfaction of creditors&#39; claims in such manner and order as such liquidator thinks fit. Subject to the rights attaching to any Shares, in a winding up:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.15pt;margin-top:0pt;padding-left:30pt;text-align:justify;text-indent:-30pt;"><span style="display:inline-block;min-width:29.8pt;text-indent:0pt;white-space:nowrap;">(a)</span>if the assets available for distribution amongst the Members shall be insufficient to repay the whole of the Company&#39;s issued share capital, such assets shall be distributed so that, as nearly as may be, the losses shall be borne by the Members in proportion to the par value of the Shares held by them; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:35.15pt;margin-top:0pt;padding-left:30pt;text-align:justify;text-indent:-30pt;"><span style="display:inline-block;min-width:29.8pt;text-indent:0pt;white-space:nowrap;">(b)</span>if the assets available for distribution amongst the Members shall be more than sufficient to repay the whole of the Company&#39;s issued share capital at the commencement of the winding up, the surplus shall be distributed amongst the Members in proportion to the par value of the Shares held by them at the commencement of the winding up subject to a deduction from those Shares in respect of which there are monies due, of all monies payable to the Company for unpaid calls or otherwise.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">44.2</span></span>If the Company shall be wound up the liquidator may, subject to the rights attaching to any Shares and with the approval of a Special Resolution of the Company and any other approval required by the Statute, divide amongst the Members in kind the whole or any part of the assets of the Company (whether such assets shall consist of property of the same kind or not) and may for that purpose value any assets and determine how the division shall be carried out as between the Members or different classes of Members. The liquidator may, with the like approval, vest the whole or any part of such assets in trustees upon such trusts for the benefit of the Members as the liquidator, with the like approval, shall think fit, but so that no Member shall be compelled to accept any asset upon which there is a liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">45</b></span><b style="font-weight:bold;">Indemnity and Insurance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">45.1</span></span>Every Director and Officer (which for the avoidance of doubt, shall not include auditors of the Company), together with every former Director and former Officer (each an &#8220;<b style="font-weight:bold;">Indemnified Person</b>&#8221;) shall be indemnified out of the assets of the Company against any liability, action, proceeding, claim, demand, costs, damages or expenses, including legal expenses, whatsoever which they or any of them may incur as a result of any act or failure to act in carrying out their functions other than such liability (if any) that they may incur by reason of their own actual fraud, wilful neglect or wilful default. No Indemnified Person shall be liable to the Company for any loss or damage incurred by the Company as a result (whether direct or indirect) of the carrying out of their functions unless that liability arises through the actual fraud, wilful neglect or wilful default of such Indemnified Person. No person shall be found to have committed actual fraud, wilful neglect or wilful default under this Article unless or until a court of competent jurisdiction shall have made a finding to that effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">45.2</span></span>The Company shall advance to each Indemnified Person reasonable attorneys&#39; fees and other costs and expenses incurred in connection with the defence of any action, suit, proceeding or investigation involving such Indemnified Person for which indemnity will or could be sought. In connection with any advance of any expenses hereunder, the Indemnified Person shall execute an undertaking to repay the advanced amount to the Company if it shall be determined by final judgment or other final adjudication that such Indemnified Person was not entitled to indemnification pursuant to this Article. If it shall be determined by a final judgment or other final adjudication that such Indemnified Person was not entitled to indemnification with respect to such judgment, costs or expenses, then such party shall not be indemnified with respect to such judgment, costs or expenses and any advancement shall be returned to the Company (without interest) by the Indemnified Person.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">45.3</span></span>The Directors, on behalf of the Company, may purchase and maintain insurance for the benefit of any Director or Officer against any liability which, by virtue of any rule of law, would otherwise attach to such person in respect of any negligence, default, breach of duty or breach of trust of which such person may be guilty in relation to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">46</b></span><b style="font-weight:bold;">Financial Year</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 35.15pt;">Unless the Directors otherwise prescribe, the financial year of the Company shall end on 31st December in each year and, following the year of incorporation, shall begin on 1st January in each year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">47</b></span><b style="font-weight:bold;">Transfer by Way of Continuation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">47.1</span></span>If the Company is exempted as defined in the Statute, it shall, subject to the provisions of the Statute and with the approval of a Special Resolution, have the power to register by way of continuation as a body corporate under the laws of any jurisdiction outside the Cayman Islands and to be deregistered in the Cayman Islands. For the purposes of a Special Resolution to be passed pursuant to this Article, a holder of Class B Shares shall have ten votes for every Class B Share of which he is the holder and a holder of Class A Shares shall have one vote for every Class A Share of which he is the holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">47.2</span></span>Prior to the closing a Business Combination, Article 47.1 may only be amended by a Special Resolution which shall include the affirmative vote of a simple majority of the Class B Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">48</b></span><b style="font-weight:bold;">Mergers and Consolidations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">The Company shall have the power to merge or consolidate with one or more other constituent companies (as defined in the Statute) upon such terms as the Directors may determine and (to the extent required by the Statute) with the approval of a Special Resolution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">49</b></span><b style="font-weight:bold;">Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">49.1</span></span>Notwithstanding any other provision of the Articles, this Article shall apply during the period commencing upon the adoption of the Articles and terminating upon the first to occur of the consummation of a Business Combination and the full distribution of the Trust Account pursuant to this Article. In the event of a conflict between this Article and any other Articles, the provisions of this Article shall prevail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">49.2</span></span>Prior to the consummation of a Business Combination, the Company shall either:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(a)</span>submit such Business Combination to its Members for approval; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-align:justify;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(b)</span>provide Members with the opportunity to have their Shares repurchased by means of a tender offer for a per-Share repurchase price payable in cash, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of such Business Combination, including interest earned on the Trust Account (net of taxes paid or payable, if any), divided by the number of then issued Public Shares, provided that the Company shall not repurchase Public Shares in an amount that would cause the Company&#39;s net tangible assets to be less than US$5,000,001 prior to or upon consummation of such Business Combination.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">49.3</span></span>If the Company initiates any tender offer in accordance with Rule 13e-4 and Regulation 14E of the Exchange Act in connection with a proposed Business Combination, it shall file tender offer documents with the Securities and Exchange Commission prior to completing such Business Combination which contain substantially the same financial and other information about such Business Combination and the redemption rights as is required under Regulation 14A of the Exchange Act. If, alternatively, the Company holds a general meeting to approve a proposed Business Combination, the Company will conduct any redemptions in conjunction with a proxy solicitation pursuant to Regulation 14A of the Exchange Act, and not pursuant to the tender offer rules, and file proxy materials with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">49.4</span></span>At a general meeting called for the purposes of approving a Business Combination pursuant to this Article, in the event that such Business Combination is approved by Ordinary Resolution, the Company shall be authorised to consummate such Business Combination, provided that the Company shall not consummate such Business Combination unless the Company has </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 36pt;">net tangible assets of at least US$5,000,001 immediately prior to, or upon such consummation of, or any greater net tangible asset or cash requirement that may be contained in the agreement relating to, such Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">49.5</span></span>Any Member holding Public Shares who is not the Sponsor, a Founder, Officer or Director may, at least two business days&#8217; prior to any vote on a Business Combination, elect to have their Public Shares redeemed for cash, in accordance with any applicable requirements provided for in the related proxy materials (the &#8220;<b style="font-weight:bold;">IPO Redemption</b>&#8221;), provided that no such Member acting together with any Affiliate of his or any other person with whom he is acting in concert or as a partnership, limited partnership, syndicate, or other group for the purposes of acquiring, holding, or disposing of Shares may exercise this redemption right with respect to more than 15 per cent of the Public Shares in the aggregate without the prior consent of the Company and provided further that any beneficial holder of Public Shares on whose behalf a redemption right is being exercised must identify itself to the Company in connection with any redemption election in order to validly redeem such Public Shares. If so demanded, the Company shall pay any such redeeming Member, regardless of whether he is voting for or against such proposed Business Combination, a per-Share redemption price payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the Business Combination, including interest earned on the Trust Account (such interest shall be net of taxes payable) and not previously released to the Company to pay its taxes, divided by the number of then issued Public Shares (such redemption price being referred to herein as the &#8220;<b style="font-weight:bold;">Redemption Price</b>&#8221;), but only in the event that the applicable proposed Business Combination is approved and consummated. The Company shall not redeem Public Shares that would cause the Company&#8217;s net tangible assets to be less than US$5,000,001 following such redemptions (the &#8220;<b style="font-weight:bold;">Redemption Limitation</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">49.6</span></span>A Member may not withdraw a Redemption Notice once submitted to the Company unless the Directors determine (in their sole discretion) to permit the withdrawal of such redemption request (which they may do in whole or in part).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">49.7</span></span>In the event that the Company does not consummate a Business Combination within 18 months from the consummation of the IPO, or such later time as the Members may approve in accordance with the Articles, the Company shall:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(a)</span>cease all operations except for the purpose of winding up;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-align:justify;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(b)</span>as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-Share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company (less taxes payable and up to US$100,000 of interest to pay dissolution expenses), divided by the number of then Public Shares in issue, which redemption will completely extinguish public Members&#39; rights as Members (including the right to receive further liquidation distributions, if any); and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-align:justify;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(c)</span>as promptly as reasonably possible following such redemption, subject to the approval of the Company&#39;s remaining Members and the Directors, liquidate and dissolve, subject in each case to its obligations under Cayman Islands law to provide for claims of creditors and other requirements of Applicable Law.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">49.8</span></span>In the event that any amendment is made to the Articles:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:35.15pt;margin-top:0pt;padding-left:30pt;text-align:justify;text-indent:-30pt;"><span style="display:inline-block;min-width:29.8pt;text-indent:0pt;white-space:nowrap;">(a)</span>to modify the substance or timing of the Company&#39;s obligation to allow redemption in connection with a Business Combination or redeem 100 per cent of the Public Shares if the Company does not consummate a Business Combination within 18 months from the consummation of the IPO, or such later time as the Members may approve in accordance with the Articles; or</div><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:5.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:29.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">with respect to any other provision relating to Members&#8217; rights or pre-Business Combination activity, each holder of Public Shares who is not the Sponsor, a Founder, Officer or Director shall be provided with the opportunity to redeem their Public Shares upon the approval or effectiveness of any such amendment at a per-Share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes, divided by the number of then outstanding Public Shares. The Company&#8217;s ability to provide such redemption in this Article is subject to the Redemption Limitation.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">49.9</span></span>A holder of Public Shares shall be entitled to receive distributions from the Trust Account only in the event of an IPO Redemption, a repurchase of Shares by means of a tender offer pursuant to this Article, or a distribution of the Trust Account </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 36pt;">pursuant to this Article. In no other circumstance shall a holder of Public Shares have any right or interest of any kind in the Trust Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">49.10</span></span>After the issue of Public Shares, and prior to the consummation of a Business Combination, the Company shall not issue additional Shares or any other securities that would entitle the holders thereof to:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(a)</span>receive funds from the Trust Account; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(b)</span>vote as a class with Public Shares on a Business Combination.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">49.11</span></span>The uninterested Independent Directors shall approve any transaction or transactions between the Company and any of the following parties:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(a)</span>any Member owning an interest in the voting power of the Company that gives such Member a significant influence over the Company; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:35.1pt;margin-top:0pt;padding-left:30pt;text-indent:-30pt;"><span style="display:inline-block;min-width:29.85pt;text-indent:0pt;white-space:nowrap;">(b)</span>any Director or Officer and any Affiliate of such Director or Officer.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">49.12</span></span>A Director may vote in respect of a Business Combination in which such Director has a conflict of interest with respect to the evaluation of such Business Combination. Such Director must disclose such interest or conflict to the other Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">49.13</span></span>As long as the securities of the Company are listed on the Nasdaq Capital Market, the Company must complete one or more Business Combinations having an aggregate fair market value of at least 80 per cent of the assets held in the Trust Account (excluding the deferred underwriting discounts and taxes payable on the income earned on the Trust Account) at the time of the Company&#39;s signing a definitive agreement in connection with a Business Combination. A Business Combination must not be solely effectuated with another blank cheque company or a similar company with nominal operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">49.14</span></span>The Company may enter into a Business Combination with a target business that is Affiliated with the Sponsor, a Founder, a Director or an Officer. In the event the Company seeks to consummate a Business Combination with a target that is Affiliated with the Sponsor, a Founder, a Director or an Officer, the Company, or a committee of Independent Directors, will obtain an opinion from an independent investment banking firm or another valuation or appraisal firm that regularly renders fairness opinions on the type of target business the Company is seeking to acquire that is a member of the United States Financial Industry Regulatory Authority or an independent accounting firm that such a Business Combination is fair to the Company from a financial point of view.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">50</b></span><b style="font-weight:bold;">Certain Tax Filings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 35.15pt;">Each Tax Filing Authorised Person and any such other person, acting alone, as any Director shall designate from time to time, are authorised to file tax forms SS-4, W-8 BEN, W-8 IMY, W-9, 8832 and 2553 and such other similar tax forms as are customary to file with any US state or federal governmental authorities or foreign governmental authorities in connection with the formation, activities and/or elections of the Company and such other tax forms as may be approved from time to time by any Director or Officer. The Company further ratifies and approves any such filing made by any Tax Filing Authorised Person or such other person prior to the date of the Articles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:35.2pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">51</b></span><b style="font-weight:bold;">Business Opportunities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">51.1</span></span>To the fullest extent permitted by Applicable Law, no individual serving as a Director or an Officer (&#8220;<b style="font-weight:bold;">Management</b>&#8221;) shall have any duty, except and to the extent expressly assumed by contract, to refrain from engaging directly or indirectly in the same or similar business activities or lines of business as the Company. To the fullest extent permitted by Applicable Law, the Company renounces any interest or expectancy of the Company in, or in being offered an opportunity to participate in, any potential transaction or matter which may be a corporate opportunity for Management, on the one hand, and the Company, on the other. Except to the extent expressly assumed by contract, to the fullest extent permitted by Applicable Law, Management shall have no duty to communicate or offer any such corporate opportunity to the Company and shall not be liable to the Company or its Members for breach of any fiduciary duty as a Member, Director and/or Officer solely by reason of the fact </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 36pt;">that such party pursues or acquires such corporate opportunity for itself, himself or herself, directs such corporate opportunity to another person, or does not communicate information regarding such corporate opportunity to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">51.2</span></span>Except as provided elsewhere in this Article, the Company hereby renounces any interest or expectancy of the Company in, or in being offered an opportunity to participate in, any potential transaction or matter which may be a corporate opportunity for both the Company and Management, about which a Director and/or Officer who is also a member of Management acquires knowledge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:35.2pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">51.3</span></span>To the extent a court might hold that the conduct of any activity related to a corporate opportunity that is renounced in this Article to be a breach of duty to the Company or its Members, the Company hereby waives, to the fullest extent permitted by Applicable Law, any and all claims and causes of action that the Company may have for such activities. To the fullest extent permitted by Applicable Law, the provisions of this Article apply equally to activities conducted in the future and that have been conducted in the past.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">J-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c8a2814a_2ff2_4ce3_8381_8c2950a176f0"></a><a id="AnnexK_373714"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Annex K</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Execution Version</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EMPLOYEE MATTERS AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">This EMPLOYEE MATTERS AGREEMENT (this &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</span>&#8221;), dated as of March 23, 2022, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</span>&#8221;), OmniAb, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo</span>&#8221;), Avista Public Acquisition Corp. II, a Cayman Islands exempted company (which will migrate to and domesticate as a Delaware corporation) (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent</span>&#8221;), and Orwell Merger Sub Inc., a Delaware corporation and wholly owned Subsidiary of Parent (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Sub</span>&#8221;). &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Party</span>&#8221; or &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</span>&#8221; means the Company, SpinCo, Parent or Merger Sub, individually or collectively, as the case may be. Capitalized terms used in this Agreement, but not otherwise defined in this Agreement, the Separation Agreement or the Merger Agreement, shall have the meaning set forth in Section 1.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">W I T N E S S E T H:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, the Company, acting through its direct and indirect Subsidiaries, currently conducts the Company Retained Business and the SpinCo Business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, the Company Board has determined that it is appropriate, desirable and in the best interests of the Company and its stockholders to separate the Company into two separate companies, one for each of (i) the Company Retained Business, which shall be owned and conducted, directly or indirectly, by the Company and its Subsidiaries (other than SpinCo and its Subsidiaries) and (ii) the SpinCo Business, which shall be owned and conducted, directly or indirectly, by SpinCo and its Subsidiaries, in the manner contemplated by the Separation and Distribution Agreement by and among the Parties, dated as of the date hereof (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Agreement</span>&#8221;) and the other Transaction Documents;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, following the Domestication and the Separation and pursuant to the Merger Agreement, Merger Sub shall merge with and into SpinCo and SpinCo will be the surviving corporation and a wholly owned Subsidiary of Parent; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">WHEREAS, in connection with the transactions contemplated by the Separation Agreement and the Merger Agreement, the Parties have agreed to enter into this Agreement for the purpose of allocating assets, Liabilities and responsibilities with respect to certain employee matters and employee compensation and benefit plans and programs among them and to address certain other employment-related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">NOW, THEREFORE, in consideration of the foregoing and the mutual agreements, provisions and covenants contained in this Agreement, the Parties hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DEFINITIONS AND INTERPRETATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</span>. As used in this Agreement, the following terms shall have the following meanings:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">401(k) Plan Transition Date</span>&#8221; shall mean (i) December 31 of the calendar year in which the Distribution Time occurs, or (ii) such earlier date as mutually agreed by the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjusted Parent Equity Award</span>&#8221; shall mean an Adjusted Parent Option, Adjusted Parent RSU Award or Adjusted Parent PSU Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjusted Parent Option</span>&#8221; shall have the meaning set forth in Section 4.2(d).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjusted Parent PSU Award</span>&#8221; shall have the meaning set forth in Section 4.4(f).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjusted Parent RSU Award</span>&#8221; shall have the meaning set forth in Section 4.3(d).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</span>&#8221; shall have the meaning set forth in the Preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Benefit Plan</span>&#8221; shall mean an &#8220;employee benefit plan&#8221; (within the meaning of Section 3(3) of ERISA but regardless of whether such plan is subject to ERISA) and each compensation plan, program, agreement or arrangement, including each pension, retirement, profit sharing, 401(k), severance, health and welfare, disability, deferred compensation, employment, termination, change-in-control, retention, fringe benefit, stock purchase, cash bonus or equity-based incentive or other benefit plan, program, agreement, policy or other arrangement, in each case, that is or was maintained for the benefit of current and/or former directors, officers, consultants or employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</span>&#8221; means the Internal Revenue Code of 1986, as amended, or any successor federal income tax law. Reference to a specific Code provision also includes any proposed, temporary or final regulation in force under that provision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</span>&#8221; shall have the meaning set forth in the Preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company 2021 TSR PSU Award</span>&#8221; shall mean a Company PSU Award granted in 2021 (or portion thereof) the vesting of which is tied to the Company&#8217;s total shareholder return for the three-year performance period ending December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company 401(k) Plan</span>&#8221; shall mean the Company&#8217;s Section 401(k) Savings/Retirement Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Allocation Factor</span>&#8221; shall mean the quotient obtained by dividing (i) the Company Post-Adjustment Stock Value, by (ii) the sum of (A) the Company Post-Adjustment Stock Value, plus (B) the product of (x) the SpinCo Stock Value times (y) the Distribution Ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(m)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Benefit Plan</span>&#8221; shall mean any Benefit Plan sponsored, maintained or contributed to (or required to be contributed to) by any member of the Company Group that (i) is or has been maintained, sponsored, contributed to or entered into by any member of the Company Group for the benefit of any SpinCo Employee or SpinCo Independent Contractor or for which any member of the SpinCo Group could have any Liability and (ii) that is not a SpinCo Benefit Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(n)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Employee</span>&#8221; shall mean each employee of the Company or any of its Subsidiaries or Affiliates who does not qualify as a SpinCo Employee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(o)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Employee List</span>&#8221; shall have the meaning set forth in Section 2.2(d).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(p)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Equity Award</span>&#8221; shall mean a Company Option, Company RSU Award or a Company PSU Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(q)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Equity Plan</span>&#8221; shall mean the Company&#8217;s 2002 Stock Incentive Plan, as amended from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"> (r)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company ESPP</span>&#8221; shall mean the Company&#8217;s 2002 Employee Stock Purchase Plan, as amended from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(s)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Group</span>&#8221; shall mean (i) the Company, the Company Retained Business and each Person that is a direct or indirect Subsidiary of the Company as of immediately following the Distribution Time and (ii) each Business Entity that becomes a Subsidiary of the Company after the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(t)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Independent Contractor</span>&#8221; shall mean each individual who is engaged as an independent contractor or consultant by the Company or any of its Subsidiaries or Affiliates who does not qualify as a SpinCo Independent Contractor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(u)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Individual Agreement</span>&#8221; shall mean each Benefit Plan sponsored, maintained entered into or contributed to by the Company under which no more than one service provider is eligible to receive compensation and/or benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Option</span>&#8221; shall mean an option to purchase shares of Company Common Stock granted pursuant to the Company Equity Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(w)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Post-Adjustment Stock Value</span>&#8221; shall mean the average closing price per share of Company Common Stock trading on an ex-dividend basis on the Nasdaq Stock Market during regular trading hours for the five (5) trading days ending on the date on which the Distribution Time occurs (or, if the Distribution Time occurs prior to regular trading hours, for the five (5) trading days ending on the date prior to the date on which the Distribution Time occurs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(x)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Pre-Adjustment Stock Value</span>&#8221; shall mean the average closing price per share of Company Common Stock trading &#8220;regular way with due bills&#8221; (if applicable) on the Nasdaq Stock Market during regular trading hours for the five (5) trading days ending on the date on which the Distribution Time occurs (or, if the Distribution Time occurs prior to regular trading hours, for the five (5) trading days ending on the date prior to the date on which the Distribution Time occurs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(y)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company PSU Award</span>&#8221; shall mean a performance stock unit award granted pursuant to the Company Equity Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(z)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Ratio</span>&#8221; shall mean the quotient obtained by dividing the Company Pre-Adjustment Stock Value by the Company Post-Adjustment Stock Value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(aa)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company RSU Award</span>&#8221; shall mean a restricted stock unit award granted pursuant to the Company Equity Plan that vests solely based on the continued employment or service of the recipient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(bb)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Service Provider</span>&#8221; shall mean a Company Employee, a Company Independent Contractor or a member of the Company Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(cc)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Severance Plan</span>&#8221; shall mean the Company&#8217;s Amended and Restated Severance Plan, as amended from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(dd)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Distribution Ratio</span>&#8221; shall mean the number of shares (and/or fraction of a share, expressed as a decimal) of SpinCo Common Stock to be distributed in respect of one share of Company Common Stock in the Distribution, as determined by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 6pt 18pt;"><span style="white-space:pre-wrap;">  </span><span style="margin-bottom:0pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ee)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Distribution Time</span>&#8221; shall mean the effective time of the Distribution pursuant to the Separation Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ff)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Time</span>&#8221; shall mean the &#8220;Effective Time&#8221; as defined in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(gg)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ERISA</span>&#8221; shall mean the Employee Retirement Income Security Act of 1974, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(hh)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Former Company Service Provider</span>&#8221; means (i) any individual (other than a SpinCo Employee or SpinCo Independent Contractor) who, as of the Distribution Time is a former employee or independent contractor of the Company or any of its Subsidiaries, or (ii) any individual who is a Company Employee or Company Independent Contractor as of the Distribution Time or thereafter who ceases to be an employee or independent contractor of the Company or any of its Subsidiaries following the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Former SpinCo Service Provider</span>&#8221; shall mean any individual who is a SpinCo Employee or SpinCo Independent Contractor as of the Distribution Time and thereafter ceases to be an employee or independent contractor of the SpinCo Group following the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(jj)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Agreement</span>&#8221; shall mean the Agreement and Plan of Merger, dated as of March 23, 2022, by and among the Company, SpinCo, Parent, and Merger Sub.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(kk)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent</span>&#8221; shall have the meaning set forth in the Preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ll)</span></span>&#8221;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Equity Plan</span>&#8221; shall have the meaning set forth in Section 4.6.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">(mm) &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Equity Plan Share Reserve</span>&#8221; shall have the meaning set forth in Section 4.6.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(nn)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent ESPP</span>&#8221; shall have the meaning set forth in Section 4.6.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(oo)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent ESPP Share Reserve</span>&#8221; shall have the meaning set forth in Section 4.6.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(pp)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Party</span>&#8221; and &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</span>&#8221; shall have the meanings set forth in the Preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(qq)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan Transition Date</span>&#8221; shall mean the date that is the earlier to occur of (i) January 1, 2023 or (ii) such earlier date as agreed among the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(rr)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo</span>&#8221; shall have the meaning set forth in the Preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ss)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo 401(k) Plan</span>&#8221; shall have the meaning set forth in Section 3.3(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(tt)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Allocation Factor</span>&#8221; shall mean the quotient obtained by dividing (i) the product of (A) the SpinCo Stock Value times (B) the Distribution Ratio, by (ii) the sum of (A) the Company Post-Adjustment Stock Value, plus (B) the product of (x) the SpinCo Stock Value times (y) the Distribution Ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(uu)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Benefit Plan</span>&#8221; shall mean any Benefit Plan sponsored, maintained or contributed to exclusively by any member of the SpinCo Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 6pt 18pt;"> <span style="margin-bottom:0pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vv)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Common Stock</span>&#8221; shall mean the common stock, par value $0.001 per share, of SpinCo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ww)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Employee</span>&#8221; shall mean each individual listed on the SpinCo Employee List.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xx)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Employee List</span>&#8221; shall have the meaning set forth in Section 2.2(d).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(yy)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Equity Award</span>&#8221; shall mean a SpinCo Option, SpinCo RSU Award or SpinCo PSU Award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(zz)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Equity Plans</span>&#8221; shall have the meaning set forth in Section 4.5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(aaa)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Group</span>&#8221; shall mean SpinCo and each SpinCo Entity as of the Distribution Time (but after giving effect to the Separation), and, following the Effective Time, Parent and each Person that becomes a Subsidiary of Parent or SpinCo thereafter, provided, however, that for the avoidance of doubt, no member of the Company Group shall be treated as a member of the SpinCo Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(bbb)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Independent Contractor</span>&#8221; shall mean each individual engaged as an independent contractor or consultant by the SpinCo Group as of the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ccc)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Individual Agreement</span>&#8221; shall mean each Benefit Plan sponsored, maintained entered into or contributed to by SpinCo under which no more than one service provider is eligible to receive compensation and/or benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ddd)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Option</span>&#8221; shall mean an option to purchase shares of SpinCo Common Stock issued pursuant to the SpinCo Equity Plans as part of an equitable adjustment to a Company Option made in connection with the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(eee)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo PSU Award</span>&#8221; shall mean an award of restricted stock units covering SpinCo Common Stock issued pursuant to the SpinCo Equity Plans as part of an equitable adjustment to a Company PSU Award made in connection with the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(fff)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Ratio</span>&#8221; shall mean the quotient obtained by dividing the Company Pre-Adjustment Stock Value by the SpinCo Stock Value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ggg)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo RSU Award</span>&#8221; shall mean an award of restricted stock units covering SpinCo Common Stock that vests solely based on the continued employment or service of the recipient issued pursuant to the SpinCo Equity Plans as part of an equitable adjustment to a Company RSU Award made in connection with the Distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(hhh)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Service Provider</span>&#8221; shall mean a SpinCo Employee, a SpinCo Independent Contractor or a member of the board of directors of SpinCo, or any individual independent contractor, consultant or director who is reasonably expected to become a SpinCo Service Provider prior to the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Severance Plan</span>&#8221; shall have the meaning set forth in Section 5.2(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(jjj)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Stock Value</span>&#8221; shall mean (i) the Base Exchange Ratio, multiplied by (ii) $10 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 6pt 18pt;"><span style="white-space:pre-wrap;">  </span><span style="margin-bottom:0pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(kkk)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Agreement</span>&#8221; shall have the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(lll)</span></span>&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specified Service Provider</span>&#8221; shall mean a Company Service Provider or SpinCo Service Provider who, in either case, is set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule C</span> attached hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">References; Interpretation</span>. References in this Agreement to any gender include references to all genders, and references to the singular include references to the plural and vice versa. Unless the context otherwise requires, the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; when used in this Agreement shall be deemed to be followed by the phrase &#8220;without limitation&#8221;. Unless the context otherwise requires, references in this Agreement to Articles, Sections, Annexes, Exhibits and Schedules shall be deemed references to Articles and Sections of, and Annexes, Exhibits and Schedules to, this Agreement. Unless the context otherwise requires, the words &#8220;hereof&#8221;, &#8220;hereby&#8221; and &#8220;herein&#8221; and words of similar meaning when used in this Agreement refer to this Agreement in its entirety and not to any particular Article, Section or provision of this Agreement. The words &#8220;written request&#8221; when used in this Agreement shall include email. Reference in this Agreement to any time shall be to New York City, New York time unless otherwise expressly provided herein. Unless the context requires otherwise, references in this Agreement to the &#8220;Company&#8221; shall also be deemed to refer to the applicable member of the Company Group, references to &#8220;SpinCo&#8221; shall also be deemed to refer to the applicable member of the SpinCo Group (including, with respect to periods of time following the Effective Time, Parent), and, in connection therewith, any references to actions or omissions to be taken, or refrained from being taken, as the case may be, by the Company or SpinCo shall be deemed to require the Company, SpinCo or Parent, as the case may be, to cause the applicable members of the Company Group or the SpinCo Group, respectively, to take, or refrain from taking, any such action. In the event of any inconsistency or conflict which may arise in the application or interpretation of any of the definitions set forth in Section 1.1, for the purpose of determining what is and is not included in such definitions, any item explicitly included on a Schedule referred to in any such definition shall take priority over any provision of the text thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GENERAL PRINCIPLES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nature of Liabilities</span>. All Liabilities assumed or retained by a member of the Company Group under this Agreement shall be &#8220;Ligand Retained Liabilities&#8221; for purposes of the Separation Agreement. All Liabilities assumed or retained by a member of the SpinCo Group under this Agreement shall be &#8220;OmniAb Liabilities&#8221; for purposes of the Separation Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfers of Employees and Independent Contractors Generally</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule A</span> attached hereto sets forth a complete list of each Company Employee as of the date hereof (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Employee List</span>&#8221;), and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule B</span> attached hereto sets forth a complete list of each employee of the Company Group whose employment will be transferred to SpinCo prior to the Distribution Time (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Employee List</span>&#8221;). The Company and SpinCo shall mutually update the Company Employee List and the SpinCo Employee List from time to time between the date hereof and the Distribution Time to remove terminated employees and to add any new Company Employees or SpinCo Employees hired following the date hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>All SpinCo Employees who are employed by the SpinCo Group as of the Distribution Time shall continue to be employees of the SpinCo Group immediately after the Distribution Time. The Company and SpinCo will cooperate to cause each of the SpinCo Employees to be employed by a member of the SpinCo Group prior to the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 6pt 18pt;"> <span style="margin-bottom:0pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>The Company and SpinCo will cooperate to cause the contract of any individual who is engaged as an independent contractor or consultant and who provides services on behalf of the SpinCo Business to the extent of such service, to be transferred to a member of the SpinCo Group prior to the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>The Company Group and SpinCo Group agree to execute, and to seek to have the applicable SpinCo Employees execute, such documentation, if any, as may be necessary to reflect the transfers described in this Section 2.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assumption and Retention of Liabilities Generally</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Except as pursuant to this Agreement, from and after the Distribution Time, the Company shall, or shall cause one or more members of the Company Group to, accept, assume (or, as applicable, retain) and perform, discharge and fulfill (i) all Liabilities under all Company Benefit Plans with respect to Company Employees, Former Company Service Providers and their respective dependents and beneficiaries (and any alternate payees in respect thereof), whenever incurred, unless this Agreement expressly provides for such Liabilities to be assumed by the SpinCo Group or subject to reimbursement by the SpinCo Group; (ii) all Liabilities with respect to the employment, service, termination of employment or termination of service of all Company Employees, Former Company Service Providers and their respective dependents and beneficiaries (and any alternate payees in respect thereof), in each case to the extent arising in connection with or as a result of employment with or the performance of services to any member of the Company Group; and (iii) all other Liabilities or obligations expressly assigned to or assumed by a member of the Company Group under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Except as pursuant to this Agreement, from and after the Distribution Time, SpinCo shall, or shall cause one or more members of the SpinCo Group to, accept, assume (or, as applicable, retain) and perform, discharge and fulfill (i) all Liabilities under all SpinCo Benefit Plans, whenever incurred; (ii) all Liabilities with respect to the employment, service, termination of employment or termination of service of all SpinCo Employees, Former SpinCo Service Providers and SpinCo Independent Contractors and their respective dependents and beneficiaries (and any alternate payees in respect thereof), in each case to the extent arising in connection with or as a result of employment with or the performance of services to any member of the SpinCo Group or the Company Group; and (iii) all other Liabilities or obligations expressly assigned to or assumed by a member of the SpinCo Group under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>The Parties shall promptly reimburse one another, upon reasonable request of the Party requesting reimbursement and the presentation by such Party of such substantiating documentation as the other Party shall reasonably request, for the cost of any obligations or Liabilities satisfied or assumed by the Party requesting reimbursement or its Affiliates that are, or that have been made pursuant to this Agreement, the responsibility of the other Parties or any of its Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>Notwithstanding any provision of this Agreement or the Separation Agreement to the contrary, SpinCo shall, or shall cause one or more members of the SpinCo Group to, accept, assume (or, as applicable, retain) and perform, discharge and fulfill all Liabilities that have been accepted, assumed or retained under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Treatment of Compensation and Benefit Plans; Terms of Employment</span>. Except as otherwise (i) required by applicable Law, or (ii) expressly provided for in this Agreement, for a period of twelve (12) months following the Distribution Time (or if shorter, during the period of employment), SpinCo shall, or shall cause a member of the SpinCo Group to provide or cause to be provided to each SpinCo Employee (A) a base salary or hourly wage rate, as applicable, that is at least equal to the base salary or hourly wage rate provided to such SpinCo Employee immediately prior to the Distribution Time, (B) subject to Section 5.1, a cash incentive or sales commission opportunity no less favorable than the cash incentive or sales commission opportunity in effect for such SpinCo Employee, if any, immediately prior to the Distribution Time, (C) health, welfare and retirement benefits that are substantially similar in the aggregate to those provided to such SpinCo Employee immediately prior to the Distribution Time, and (D) severance benefits (including severance payments, transition payments and continued health coverage) that are substantially similar to those provided to such SpinCo Employee immediately prior to the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Participation in Company Benefit Plans</span>. Except as otherwise provided pursuant to this Agreement or as required by Applicable Law, effective no later than the Plan Transition Date, (i) SpinCo and each member of the SpinCo Group, to the extent applicable, shall cease to be a participating company in any Company Benefit Plan and (ii) each then active SpinCo Employee shall cease to participate in, be covered by, accrue benefits under, be eligible to contribute to or have any rights under any Company Benefit Plan (except to the extent of previously accrued obligations that remain a Liability of any member of the Company Group pursuant to this Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Service Recognition</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>From and after the Distribution Time, and in addition to any applicable obligations under applicable Law, SpinCo shall, and shall cause each member of the SpinCo Group to, give each SpinCo Employee full credit for purposes of eligibility, vesting, and determination of level of benefits under any SpinCo Benefit Plan for such SpinCo Employee&#8217;s prior service with any member of the Company Group or SpinCo Group or any predecessor thereto, to the same extent such service was recognized by the applicable Company Benefit Plan; provided, that, such service shall not be recognized to the extent it would result in the duplication of benefits or accruals under any defined benefit pension plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Except to the extent prohibited by applicable Law, as soon as administratively practicable on or after the Plan Transition Date with respect to any applicable SpinCo Benefit Plan that is a health or welfare benefit plan: (i) SpinCo shall waive or cause to be waived all limitations as to preexisting conditions or waiting periods with respect to participation and coverage requirements applicable to each SpinCo Employee under any SpinCo Benefit Plan in which SpinCo Employees participate (or are eligible to participate) to the same extent that such conditions and waiting periods were satisfied or waived under an analogous Company Benefit Plan, and (ii) SpinCo shall use commercially reasonable efforts to provide or cause each SpinCo Employee to be provided with credit for any co-payments, deductibles or other out-of-pocket amounts paid during the plan year in which the SpinCo Employees become eligible to participate in the SpinCo Benefit Plans in satisfying any applicable co-payments, deductibles or other out-of-pocket requirements under any such plans for such plan year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">WARN</span>. Notwithstanding anything set forth in this Agreement to the contrary, none of the transactions contemplated by or undertaken by this Agreement is intended to and shall not constitute or give rise to an &#8220;employment loss&#8221; or employment separation within the meaning of the federal Worker Adjustment and Retraining Notification (WARN) Act, or any other federal, state, or local law or legal requirement addressing mass employment separations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Termination; No Change in Control</span>. No Company Employee or SpinCo Employee shall be deemed to (a) terminate employment or service solely by virtue of the consummation of the Distribution, any transfer of employment or other service relationship contemplated hereby, or any related transactions or events contemplated by the Separation Agreement, this Agreement, the Merger Agreement, or any other Transaction Document, or (b) become entitled to any severance, termination, separation or similar rights, payments or benefits, whether under any Benefit Plan, the Company Equity Plan, the SpinCo Equity Plans, the Company Severance Plan, any Company Individual Agreement or any other compensatory agreement or arrangement maintained by the Company or SpinCo or otherwise, in connection with any of the foregoing. The Parties hereto agree that none of the transactions contemplated by the Separation Agreement, the Merger Agreement, or this Agreement, constitutes a &#8220;change in control,&#8221; &#8220;change of control&#8221; or similar term, as applicable, within the meaning of any Benefit Plan, the Company Equity Plan, the SpinCo Equity Plans, the Company Severance Plan, any Company Individual Agreement or any other compensatory agreement or arrangement maintained by the Company or SpinCo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTAIN BENEFIT PLAN PROVISIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Health and Welfare Benefit Plans</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>(i) Effective as of the Plan Transition Date, the participation of each then-active SpinCo Employee who is a participant in a Company Benefit Plan shall automatically cease and (ii) SpinCo shall or shall cause a member of the SpinCo Group to (A) have in effect, no later than the Business Day immediately prior to the Plan Transition Date, SpinCo Benefit Plans providing health and welfare benefits for the benefit of each such SpinCo Employee with terms that are substantially similar to those provided to the applicable SpinCo Employee immediately prior to the date on which such SpinCo Benefit Plans become effective; and (B) effective on and after the Plan Transition Date, fully perform, pay and discharge all claims of SpinCo Employees or Former SpinCo Service Providers, including but not limited to any claims incurred under any Company Benefit Plan (to the extent not fully covered by insurance) on or prior to the date on which such SpinCo Benefit Plans become effective, that remain unpaid as of the date on which such SpinCo Benefit Plans become effective, regardless of whether any such claim was presented for payment prior to, on or after such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Without duplication of amounts otherwise already covered in this Agreement or the Transition Services Agreement, the applicable member of the SpinCo Group shall reimburse the Company or the applicable Company Benefit Plan in the ordinary course of business consistent with past practice for any premiums and its proportionate share of any administrative or services costs related to SpinCo Employees or Former SpinCo Service Providers paid by a Company Benefit Plan (whether prior to or after the Distribution Time) and not charged back to the appropriate and applicable member of the SpinCo Group prior to the Plan Transition Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Notwithstanding anything to the contrary in this Section 3.1, SpinCo Employees will continue to be considered to be &#8220;participants&#8221; in any Company Benefit Plan that is either a health care flexible spending account program or a dependent-care flexible spending account program for the duration of any grace period and/or claims run-out period following the calendar year in which the Plan Transition Date occurs (in either case, solely as provided under the terms of such Company Benefit Plans), provided that such SpinCo Employees will be considered to be participants solely for purposes of utilizing such grace period and/or claims run-out period; will not be allowed to make any deferral or contribution elections under such Company Benefit </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Plans beyond the Plan Transition Date; and will cease to be participants in such Company Benefit Plans upon the expiration of any grace period and/or claims run-out period. Effective as of the Plan Transition Date, SpinCo shall establish a health care flexible spending account program or a dependent-care flexible spending account program for SpinCo Employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"> <span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disability</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>To the extent any SpinCo Employee is, as of the Plan Transition Date, receiving payments as part of any short-term disability program that is part of a Company Benefit Plan, such SpinCo Employee&#8217;s rights to continued short-term disability benefits (a) will end under any Company Benefit Plan as of the Plan Transition Date; and (b) all remaining rights will be recognized under a SpinCo Benefit Plan as of the Plan Transition Date, and the remainder (if any) of such SpinCo Employee&#8217;s short-term disability benefits will be paid by a SpinCo Benefit Plan. In the event that any SpinCo Employee described above shall have any dispute with the short-term disability benefits they are receiving under a SpinCo Benefit Plan, any and all appeal rights of such employees shall be realized through the SpinCo Benefit Plan (and any appeal rights such SpinCo Employee may have under any Company Benefit Plan will be limited to benefits received and time periods occurring prior to the Plan Transition Date). Any SpinCo Employee or Former SpinCo Service Provider who is receiving short-term disability benefits under a Company Benefit Plan as of the Plan Transition Date and thereafter becomes entitled to long-term disability benefits upon the expiration of such short-term disability period (whether under a Company Benefit Plan or SpinCo Benefit Plan), shall be provided long-term disability benefits under the long-term disability plan which is a Company Benefit Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>For any Former SpinCo Service Provider who is, as of the Distribution Time, receiving payments as part of any long-term disability program that is part of a Company Benefit Plan, and has been receiving payments from such plan for twelve (12) months or fewer before the Distribution Time, to the extent such Former SpinCo Service Provider may have any &#8220;return to work&#8221; rights under the terms of such Company Benefit Plan, such Former SpinCo Service Provider&#8217;s eligibility for re-employment shall be with SpinCo or a member of the SpinCo Group, subject to availability of a suitable position (with such availability to be determined in the sole discretion by SpinCo or the applicable member of the SpinCo Group), provided however that, notwithstanding the foregoing, no Former SpinCo Service Provider described in this subsection will be eligible for re-employment as described in this subsection after the first anniversary of the Distribution Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">401(k) Plans</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>From the Distribution Time and continuing until the 401(k) Plan Transition Date, SpinCo shall become an &#8220;adopting employer&#8221; (as defined in the Company 401(k) Plan) and the Company 401(k) Plan shall provide for the SpinCo Group to participate in the Company 401(k) Plan for the benefit of SpinCo Employees and Former SpinCo Service Providers, and the Company consents to such adoption and maintenance, in accordance with the terms of the Company 401(k) Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="white-space:pre-wrap;">     (i) Effective no later than the 401(k) Plan Transition Date, SpinCo shall establish a defined contribution savings plan and related trust that satisfies the requirements of Sections 401(a) and 401(k) of the Code in which each SpinCo Employee who participated in the Company 401(k) Plan immediately prior thereto shall be eligible to participate (the &#8220;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo 401(k) Plan</span>&#8221;), with terms that are substantially similar to those provided by the Company 401(k) Plan immediately prior to the date on which such SpinCo 401(k) Plan become effective, (ii) the active participation of each SpinCo Employee who is a participant in the Company 401(k) Plan shall automatically cease effective upon the date on which the SpinCo 401(k) Plan becomes effective, and (iii) as soon as practicable after the SpinCo 401(k) Plan becomes effective, subject to the consent of the SpinCo 401(k) Plan administrator and reasonable proof of qualification of the Company 401(k) Plan, the Company shall cause the accounts (including any outstanding participant loan balances) in the Company 401(k) Plan attributable to SpinCo Employees and all of the assets in the Company 401(k) Plan related thereto to be transferred in-kind to the SpinCo 401(k) Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>The Company shall retain all accounts and all assets and Liabilities relating to the Company 401(k) Plan in respect of each Former SpinCo Service Provider whose employment terminated prior to the 401(k) Plan Transition Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chargeback of Certain Costs</span>. Without duplication of amounts otherwise already covered in this Agreement or the Transition Services Agreement, nothing contained in this Agreement shall limit the Company&#8217;s ability to charge back any Liabilities that it incurs in respect of any SpinCo Service Provider under a Company Benefit Plan which is a retirement plan or health or welfare benefit plan to any of its operating companies in the ordinary course of business consistent with its past practices. Subject, and in addition, to the foregoing, the Company shall allocate and charge back to SpinCo or a member of the SpinCo Group (without duplication) its proportionate share of Liabilities (other than those arising from the Company&#8217;s or its agent&#8217;s gross misconduct or negligence) that the </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Company incurs by reason of the continued participation of SpinCo Employees, SpinCo Independent Contractors and Former SpinCo Service Providers in such Company Benefit Plans following the Distribution Time (which Liabilities shall, for the avoidance of doubt, be subject to reimbursement under Section 2.3(c) of this Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE IV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EQUITY INCENTIVE AWARDS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Awards</span>. The Parties shall use commercially reasonable efforts to take all actions necessary or appropriate so that each outstanding Company Equity Award and SpinCo Equity Award held by any individual shall be adjusted as set forth in this Article IV and in accordance with applicable Law, the applicable equity plan and the applicable award agreement. The adjustments set forth below shall be the sole adjustments made with respect to Company Equity Awards in connection with the Distribution. The adjustments set forth below shall be the sole adjustments made with respect to SpinCo Equity Awards in connection with the Merger and are subject to the terms and conditions of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Treatment of Company Options</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Options Other than (i) Company Options Held by Former Company Service Providers or (ii) SpinCo Service Providers who are Specified Service Providers</span>. As determined by the Compensation Committee of the Company Board (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Compensation Committee</span>&#8221;) pursuant to its authority under the Company Equity Plan, each Company Option outstanding as of immediately prior to the Distribution Time, other than (x) any Company Option held by a Former Company Service Provider and (y) any Company Option held by a Specified Service Provider, shall, immediately prior to the Distribution Time, be converted into both a SpinCo Option and a Company Option and shall otherwise be, subject to Section 4.2(d) below, subject to the same terms and conditions after the Distribution Time as the terms and conditions applicable to such Company Option immediately prior to the Distribution Time; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that from and after the Distribution Time:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares Subject to Post-Distribution Company Option</span>. The number of shares of Company Common Stock subject to such Company Option shall be equal to the product obtained by multiplying (I) the number of shares of Company Common Stock subject to such Company Option immediately prior to the Distribution Time by (II) the Company Ratio by (III) the Company Allocation Factor, and rounding such result down to the nearest whole share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares Subject to Post-Distribution SpinCo Option</span>. The number of shares of SpinCo Common Stock subject to such SpinCo Option shall be equal to the product obtained by multiplying (I) the number of shares of Company Common Stock subject to the Company Option immediately prior to the Distribution Time by (II) the SpinCo Ratio by (III) the SpinCo Allocation Factor, and rounding such result down to the nearest whole share. Each SpinCo Option that is outstanding as of the Effective Time will be further adjusted to reflect the Transactions as set forth in Section 4.2(d) below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise Price of Post-Distribution Company Option</span>. The per share exercise price of such Company Option shall be equal to the quotient obtained by dividing (I) the per share exercise price of such Company Option immediately prior to the Distribution Time by (II) the Company Ratio, and rounding such quotient up to the nearest whole cent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise Price of Post-Distribution SpinCo Option</span>. The per share exercise price of such SpinCo Option shall be equal to the quotient obtained by dividing (I) the per share exercise price of the Company Option immediately prior to the Distribution Time by (II) the SpinCo Ratio, and rounding such quotient up to the nearest whole cent. Each SpinCo Option that is outstanding as of the Effective Time will be further adjusted to reflect the Transactions as set forth in Section 4.2(d) below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Options Held by (i) Former Company Service Providers and (ii) Specified Service Providers who are Company Service Providers</span>. As determined by the Company Compensation Committee pursuant to its authority under the Company Equity Plan, each Company Option outstanding as of immediately prior to the Distribution Time (x) that is held by a Former Company Service Provider or (y) that is held by a Specified Service Provider who is a Company Service Provider, shall be subject to the same terms and conditions after the Distribution Time as the terms and conditions applicable to such Company Option immediately prior to the Distribution Time; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that from and after the Distribution Time:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares Subject to Post-Distribution Company Option</span>. The number of shares of Company Common Stock subject to such Company Option shall be equal to the product obtained by multiplying (A) the number of shares of Company Common Stock subject to such Company Option immediately prior to the Distribution Time by (B) the Company Ratio, and rounding such product down to the nearest whole share.</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise Price of Post-Distribution Company Option</span>. The per share exercise price of such Company Option shall be equal to the quotient obtained by dividing (A) the per share exercise price of such Company Option immediately prior to the Distribution Time by (B) the Company Ratio, and rounding such quotient up to the nearest whole cent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Options Held by Specified Service Providers who are SpinCo Service Providers</span>. As determined by the Company Compensation Committee pursuant to its authority under the Company Equity Plan, each Company Option outstanding as of immediately prior to the Distribution Time that is held by a Specified Service Provider who is an SpinCo Service Provider, shall, immediately prior to the Distribution Time, be converted solely into an SpinCo Option and shall otherwise be, subject to Section 4.2(d) below, subject to the same terms and conditions after the Distribution Time as the terms and conditions applicable to such Company Option immediately prior to the Distribution Time; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that from and after the Distribution Time:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares Subject to Post-Distribution SpinCo Option</span>. The number of shares of Company Common Stock subject to such SpinCo Option shall be equal to the product obtained by multiplying (A) the number of shares of Company Common Stock subject to such Company Option immediately prior to the Distribution Time by (B) the SpinCo Ratio, and rounding such product down to the nearest whole share. Each SpinCo Option that is outstanding as of the Effective Time will be further adjusted to reflect the Transactions as set forth in Section 4.2(d) below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise Price of Post-Distribution SpinCo Option</span>. The per share exercise price of such Company Option shall be equal to the quotient obtained by dividing (A) the per share exercise price of such Company Option immediately prior to the Distribution Time by (B) the SpinCo Ratio, and rounding such quotient up to the nearest whole cent. Each SpinCo Option that is outstanding as of the Effective Time will be further adjusted to reflect the Transactions as set forth in Section 4.2(d) below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Options Outstanding as of Immediately Prior to the Effective Time.</span> As of the Effective Time, each SpinCo Option that is then outstanding and unexercised shall be converted into the right to receive an option relating to shares of Domesticated Parent Common Stock upon substantially the same terms and conditions as are in effect with respect to such option immediately prior to the Effective Time (other than terms that have been rendered inoperative by the Transactions), including with respect to vesting and termination-related provisions (each, an &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjusted Parent Option</span>&#8221;), except that (A) such Adjusted Parent Option shall relate to that whole number of shares of Domesticated Parent Common Stock (rounded down to the nearest whole share) equal to the number of shares of SpinCo Common Stock subject to such SpinCo Option, multiplied by the Base Exchange Ratio, and (B) the exercise price per share for each such Adjusted Parent Option shall be equal to the exercise price per share of such SpinCo Option in effect immediately prior to the Effective Time, divided by the Base Exchange Ratio (the exercise price per share, as so determined, being rounded up to the nearest full cent). In addition, at the Effective Time, Parent will issue to each holder of a SpinCo Option a number of Earnout Shares equal to the product of (A) the number of shares of SpinCo Common Stock subject to the SpinCo Option, multiplied by (B) the Earnout Exchange Ratio, which Earnout Shares will be subject to the restrictions set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Treatment of Company RSU Awards</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company RSU Awards Other than (i) Company RSU Awards Held by Former Company Service Providers and (ii) Company RSU Awards Held by Specified Service Providers</span>. As determined by the Company Compensation Committee pursuant to its authority under the Company Equity Plan, each Company RSU Award outstanding as of immediately prior to the Distribution Time, other than (x) any Company RSU Award held by a Specified Service Provider and (y) any Company RSU Award held by a Former Company Service Provider, shall, immediately prior to the Distribution Time, be converted into both a SpinCo RSU Award and a Company RSU Award and shall otherwise be, subject to Section 4.3(d) below, subject to the same terms and conditions after the Distribution Time as the terms and conditions applicable to such Company RSU Award immediately prior to the Distribution Time; provided, however, that from and after the Distribution Time:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares Subject to Post-Distribution Company RSU</span>. The number of shares of Company Common Stock subject to such Company RSU Award shall be equal to the number of shares of Company Common Stock subject to such Company RSU Award immediately prior to the Distribution Time, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares Subject to Post-Distribution SpinCo RSU.</span> The number of shares of SpinCo Common Stock subject to such SpinCo RSU Award shall be equal to the product obtained by multiplying (A) the number of shares of Company Common </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">Stock subject to the Company RSU Award immediately prior to the Distribution Time by (B) the Distribution Ratio, and rounding such product down to the nearest whole share. Each SpinCo RSU Award that is outstanding as of the Effective Time will be further adjusted to reflect the Transactions as set forth in Section 4.3(d) below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company RSU Awards Held by (i) Former Company Service Providers or Former SpinCo Service Providers and (ii) Specified Service Providers who are Company Service Providers</span>. As determined by the Company Compensation Committee pursuant to its authority under the Company Equity Plan, each Company RSU Award that is outstanding as of immediately prior to the Distribution Time (x) that is held by a Former Company Service Provider or a Former SpinCo Service Provider or (y) that is held by a Specified Service Provider who is a Company Service Provider, shall be subject to the same terms and conditions after the Distribution Time as the terms and conditions applicable to such Company RSU Award immediately prior to the Distribution Time; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that from and after the Distribution Time, the number of shares of Company Common Stock covered by such Company RSU Award held by the participant, as applicable, rounded to the nearest whole share, shall be equal to the product obtained by multiplying (i) the number of shares of Company Common Stock covered by such Company RSU Award immediately prior to the Distribution Time by (ii) the Company Ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company RSU Awards Held by Specified Service Providers who are SpinCo Service Providers</span>. As determined by the Company Compensation Committee pursuant to its authority under the Company Equity Plan, each Company RSU Award that is outstanding as of immediately prior to the Distribution Time that is held by a Specified Service Provider who is a SpinCo Service Provider shall, immediately prior to the Distribution Time, be converted solely into a SpinCo RSU Award and shall otherwise be, subject to Section 4.3(d) below, subject to the same terms and conditions after the Distribution Time as the terms and conditions applicable to such Company RSU Award immediately prior to the Distribution Time; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that from and after the Distribution Time the number of shares of SpinCo Common Stock subject to such SpinCo RSU Award shall be equal to the product obtained by multiplying (x) the number of shares of Company Common Stock subject to the Company RSU Award immediately prior to the Distribution Time by (y) the SpinCo Ratio, and rounding down to the nearest whole share. Each SpinCo RSU Award that is outstanding as of the Effective Time will be further adjusted to reflect the Transactions as set forth in Section 4.3(d) below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo RSU Awards Outstanding as of the Effective Time</span>. As of the Effective Time, each SpinCo RSU Award that is outstanding immediately prior to the Effective Time shall be converted into the right to receive restricted stock units relating to shares of Domesticated Parent Common Stock (each, an &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjusted Parent RSU Award</span>&#8221;) with substantially the same terms and conditions as were applicable to such SpinCo RSU Award immediately prior to the Effective Time (other than terms that have been rendered inoperative by the Transactions), including with respect to vesting and termination-related provisions, except that such Adjusted Parent RSU Award shall relate to that whole number of shares of Domesticated Parent Common Stock as is equal to the product of (B) the number of shares of SpinCo Common Stock subject to such SpinCo RSU Awards immediately prior to the Effective Time, multiplied by (B) the Base Exchange Ratio, with any fractional shares rounded down to the nearest whole share. In addition, at the Effective Time, Parent will issue to each holder of a SpinCo RSU Award a number of Earnout Shares equal to the product of (A) the number of shares of SpinCo Common Stock subject to the SpinCo RSU Award, multiplied by (B) the Earnout Exchange Ratio, which Earnout Shares will be subject to the restrictions set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Treatment of Company PSU Awards</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company PSU Awards (Other than Company 2021 TSR PSU Awards) Not Held by Former Company Service Providers</span>. As determined by the Company Compensation Committee pursuant to its authority under the Company Equity Plan, each Company PSU Award outstanding as of immediately prior to the Distribution Time, other than (x) any Company PSU Award held by a Former Company Service Provider and (y) any Company PSU Award that is a Company 2021 TSR PSU Award, shall, immediately prior to the Distribution Time, be converted into both a SpinCo PSU Award and a Company PSU Award and shall, subject to Sections 4.4(e) and (f) below, otherwise be subject to the same terms and conditions after the Distribution Time as the terms and conditions applicable to such Company PSU Award immediately prior to the Distribution Time; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that from and after the Distribution Time:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares Subject to Post-Distribution Company PSU.</span> The number of shares of Company Common Stock subject to such Company PSU Award shall be equal to the number of shares of Company Common Stock subject to such Company PSU Award immediately prior to the Distribution Time, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares Subject to Post-Distribution SpinCo PSU.</span> The number of shares of SpinCo Common Stock subject to such SpinCo PSU Award shall be equal to the product obtained by multiplying (A) the number of shares of Company Common </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">Stock subject to the Company PSU Award immediately prior to the Distribution Time by (B) the Distribution Ratio, and rounding such product down to the nearest whole share. Each SpinCo PSU Award that is outstanding as of the Effective Time will be further adjusted to reflect the Transactions as set forth in Section 4.4(f) below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company 2021 TSR PSU Awards Not Held by Former Company Service Providers</span>. As determined by the Company Compensation Committee pursuant to its authority under the Company Equity Plan, each Company 2021 TSR PSU Award outstanding as of immediately prior to the Distribution Time, other than any 2021 TSR PSU Award that is held by a Former Company Service Provider, shall, immediately prior to the Distribution Time, be converted into both an SpinCo PSU Award and a Company PSU Award and shall, subject to Sections 4.4(e) and (f) below, otherwise be subject to the same terms and conditions after the Distribution Time as the terms and conditions applicable to such Company PSU Award immediately prior to the Distribution Time; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that from and after the Distribution Time:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares Subject to Post-Distribution Company PSU.</span> The number of shares of Company Common Stock subject to such Company PSU Award shall be equal to (x) the number of shares of Company Common Stock subject to such Company 2021 TSR PSU Award immediately prior to the Distribution Time, multiplied by (y) such percentage (not to exceed 200%) as is mutually determined by the Company and SpinCo prior to the Distribution Time, and rounding such product down to the nearest whole share, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares Subject to Post-Distribution SpinCo PSU.</span> The number of shares of SpinCo Common Stock subject to such SpinCo PSU Award shall be equal to the product obtained by multiplying (A) (x) the number of shares of Company Common Stock subject to the Company PSU Award immediately prior to the Distribution Time, multiplied by (y) such percentage (not to exceed 200%) as is mutually determined by the Company and SpinCo prior to the Distribution Time by (B) the Distribution Ratio, and rounding such product down to the nearest whole share;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">provided, further, that from and after the Distribution Time, such Company 2021 TSR PSU Award shall no longer vest based on the performance objectives applicable to such Company 2021 TSR PSU Award immediately prior to the Distribution Time and shall instead be amended to vest solely based on continuous employment or service on December 31, 2023. Each SpinCo PSU Award that is outstanding as of the Effective Time will be further adjusted to reflect the Transactions as set forth in Section 4.4(f) below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company PSU Awards (Other than Company 2021 TSR PSU Awards) Held by Former Company Service Providers</span>. As determined by the Company Compensation Committee pursuant to its authority under the Company Equity Plan, each Company PSU Award that is not a Company 2021 TSR PSU Award and is held by a Former Company Service Provider outstanding as of immediately prior to the Distribution Time shall be, subject to Sections 4.4(e) and (f) below, subject to the same terms and conditions after the Distribution Time as the terms and conditions applicable to such Company PSU Award immediately prior to the Distribution Time; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that from and after the Distribution Time, the number of shares of Company Common Stock covered by such Company PSU Award held by the participant, as applicable, rounded to the nearest whole share, shall be equal to the product obtained by multiplying (i) the number of shares of Company Common Stock covered by such Company PSU Award immediately prior to the Distribution Time by (ii) the Company Ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company 2021 TSR PSU Awards Held by Former Company Service Providers</span>. As determined by the Company Compensation Committee pursuant to its authority under the Company Equity Plan, each Company 2021 TSR PSU Award held by a Former Company Service Provider that is outstanding as of immediately prior to the Distribution Time shall be, subject to Sections 4.4(e) and (f) below, subject to the same terms and conditions after the Distribution Time as the terms and conditions applicable to such Company 2021 TSR PSU Award immediately prior to the Distribution Time; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that from and after the Distribution Time, the number of shares of Company Common Stock covered by such Company 2021 TSR PSU Award held by the participant, as applicable, rounded to the nearest whole share, shall be equal to the product obtained by multiplying (i) the number of shares of Company Common Stock covered by such Company 2021 TSR PSU Award immediately prior to the Distribution Time by (ii) such percentage (not to exceed 200%) as is mutually determined by the Company and SpinCo prior to the Distribution Time by (iii) the Company Ratio; provided, further, that from and after the Distribution Time, such Company 2021 TSR PSU Award shall no longer vest based on the performance objectives applicable to such Company 2021 TSR PSU Award immediately prior to the Distribution Time and shall instead be amended to vest solely based on continuous employment or service on December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment to Vesting Terms</span>. Prior to the Distribution Time, the Company and SpinCo may mutually agree to amend the vesting terms of any or all outstanding Company PSU Awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo PSU Awards Outstanding as of the Effective Time</span>. As of the Effective Time, each SpinCo PSU Award that is outstanding immediately prior to the Effective Time shall be converted into the right to receive (i) performance-vesting restricted stock units relating to shares of Domesticated Parent Common Stock (each, an &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjusted Parent PSU Award</span>&#8221;) with substantially the same terms and conditions as were applicable to such SpinCo PSU Award immediately prior to the Effective Time (other than terms that have been rendered inoperative by the Transactions), including with respect to vesting and termination-related provisions, except that such Adjusted Parent PSU Award shall relate to that whole number of shares of Domesticated Parent Common Stock as is equal to the product of (A) the number of shares of SpinCo Common Stock subject to such SpinCo PSU Awards immediately prior to the Effective Time, multiplied by (B) the Base Exchange Ratio, with any fractional shares rounded down to the nearest whole share. Any performance targets to which an Adjusted Parent PSU Awards are subject will be adjusted to reflect the Transactions contemplated hereby. In addition, at the Effective Time, Parent will issue to each holder of a SpinCo PSU Award a number of Earnout Shares equal to the product of (A) the number of shares of SpinCo Common Stock subject to the SpinCo PSU Award, multiplied by (B) the Earnout Exchange Ratio, which Earnout Shares will be subject to the restrictions set forth in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Equity Plans</span>. Effective as of immediately prior to the Distribution Time, SpinCo shall have adopted the SpinCo 2022 Incentive Award Plan (Company Service Provider Awards) and the SpinCo 2022 Incentive Award Plan (SpinCo Service Provider Awards) (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Equity Plans</span>&#8221;), which shall permit the grant and issuance of equity incentive awards denominated in SpinCo Common Stock as described in this Article IV. In addition, prior to the Distribution Time, the Company shall approve the SpinCo Equity Plans as the sole stockholder of SpinCo. As of the Effective Time, Parent will assume the SpinCo Equity Plans and all outstanding equity awards thereunder in accordance with the terms of this Article IV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 6pt 0pt;"> <span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Equity Plan and Parent ESPP</span>. Prior to the Effective Time, Parent shall approve and adopt, subject to receipt of Parent Shareholder Approval: (i) an incentive equity plan (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Equity Plan</span>&#8221;); and (ii) an employee stock purchase plan (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent ESPP</span>&#8221;), in each case, in form and substance reasonably acceptable to the Company and SpinCo in consultation with Parent, and effective as of the Effective Time. The Parent Equity Plan will provide for the grant of awards of Domesticated Parent Common Stock with a total pool of shares equal to (i) 14% of the aggregate number of Fully Diluted SpinCo Shares as of the Effective Time, plus (ii) any shares which, as of the effective date of the Parent Equity Plan, are subject to Adjusted Parent Equity Awards under the SpinCo Equity Plans which, on or following such effective date, become available for issuance under the Parent Equity Plan pursuant to its terms, plus (iii) an annual &#8220;evergreen&#8221; increase of 5% of the shares of Parent Common Stock outstanding as of the day prior to such increase (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Equity Plan Share Reserve</span>&#8221;). The ESPP will provide for the grant of purchase rights with respect to Domesticated Parent Common Stock with a total pool of shares equal to 1.5% of the aggregate number of Fully Diluted SpinCo Shares as of the Effective Time, plus an annual &#8220;evergreen&#8221; increase of 1% of the shares of Parent Common Stock outstanding as of the day prior to such increase (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent ESPP Share Reserve</span>&#8221;). As soon as reasonably practicable following the expiration of the sixty (60) day period following the date Parent has filed current Form 10 information with the SEC reflecting its status as an entity that is not a shell company, Parent shall file an effective registration statement on Form S-8 (or other applicable form, including Form S-1 or Form S-3) with respect to the Domesticated Parent Common Stock issuable under the Parent Equity Plan and the Parent ESPP, and Parent shall use commercially reasonable efforts to maintain the effectiveness of such registration statement(s) (and maintain the current status of the prospectus or prospectuses contained therein) for so long as awards granted pursuant to the Parent Equity Plan and the Parent ESPP remain outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting; Accelerated Vesting</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The Distribution Time shall not constitute a termination of employment or service for any SpinCo Service Providers for purposes of any Company Equity Award and, except as otherwise provided in this Agreement, with respect to grants adjusted pursuant to this Article IV, continued employment with the SpinCo Group shall be treated as continued employment with the Company Group with respect to Company Equity Awards held by SpinCo Service Providers and continued employment with the Company Group shall be treated as continued employment with the SpinCo Group with respect to SpinCo Equity Awards (or, following the Effective Time, Adjusted Parent Equity Awards) held by Company Service Providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>Notwithstanding the foregoing, with respect to any unvested SpinCo Equity Awards (or, following the Effective Time, Adjusted Parent Equity Awards) granted to a Company Service Provider in accordance with this Agreement, if the original Company Equity Award (that was partially adjusted into the SpinCo Equity Award (or, following the Effective Time, Adjusted Parent Equity Award)) was subject, as of immediately prior to the Distribution, to accelerated vesting provisions (i) by reference to a termination of employment or service with the Company and/or (ii) in connection with a &#8220;Change in Control&#8221; (as defined in the applicable award agreement and/or Company Equity Plan) of the Company, then the SpinCo Equity Awards (or, following the </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Effective Time, Adjusted Parent Equity Awards) also shall be subject to such same acceleration provisions upon the Company Service Provider&#8217;s termination of employment or service with the Company Group and/or in connection with a &#8220;Change in Control&#8221; (as defined in the applicable award agreement and/or Company Equity Plan) of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>Further notwithstanding the foregoing, with respect to any unvested Company Equity Awards or unvested SpinCo Equity Awards (or, following the Effective Time, Adjusted Parent Equity Awards) granted to an SpinCo Service Provider in accordance with this Agreement, if the original Company Equity Award (including any Company Equity Award that was solely or partially adjusted into the SpinCo Equity Award (or, following the Effective Time, Adjusted Parent Equity Award)), was subject, as of immediately prior to the Distribution, to accelerated vesting provisions (i) by reference to a termination of employment or service with the Company and/or (ii) in connection with a &#8220;Change in Control&#8221; (as defined in the applicable award agreement and/or Company Equity Plan) of the Company, then the Company Equity Award or SpinCo Equity Award (or, following the Effective Time, Adjusted Parent Equity Award), as applicable, also shall be subject to such same acceleration provisions upon the SpinCo Service Provider&#8217;s termination of employment or service with the relevant member of the SpinCo Group and/or in connection with a &#8220;Change in Control&#8221; (as defined in the applicable award agreement and/or SpinCo Equity Plan) of SpinCo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"> <span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>In addition, with respect to any unvested SpinCo Equity Awards (or, following the Effective Time, Adjusted Parent Equity Awards) held by a Company Service Provider following the Distribution Time, notwithstanding anything herein or in the applicable award agreement to the contrary, such SpinCo Equity Awards (or, following the Effective Time, Adjusted Parent Equity Awards) will vest in full upon a &#8220;Change in Control&#8221; (as defined in the applicable award agreement and/or SpinCo Equity Plans) of SpinCo (or, following the Effective Time, Parent). Further, with respect to any unvested Company Equity Awards which are adjusted as of immediately prior to the Distribution Time and continue to be held by a SpinCo Service Provider following the Distribution, in each case, in accordance with this Agreement, notwithstanding anything herein or in the applicable award agreement to the contrary, such Company Equity Awards will vest in full upon a &#8220;Change in Control&#8221; (as defined in the applicable award agreement and/or Company Equity Plan) of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>Additionally, notwithstanding anything herein or in the applicable award agreement to the contrary, if, following the Distribution Time, the Company Board determines, in its discretion, to accelerate in full the vesting of all Company Equity Awards then held by Company Service Providers and Former Company Service Providers (other than in connection with a &#8220;Change in Control&#8221; (as defined in the applicable award agreement and/or Company Equity Plan)), the Company Board shall also accelerate in full the vesting of all outstanding Company Equity Awards which are then held by SpinCo Service Providers and Former SpinCo Service Providers. Further notwithstanding anything herein or in the applicable award agreement to the contrary, if, following the Distribution Time, the SpinCo Board or Parent Board determines, in its discretion, to accelerate in full the vesting of all SpinCo Equity Awards (or, following the Effective Time, Adjusted Parent Equity Awards) then held by SpinCo Service Providers and Former SpinCo Service Providers (other than in connection with a &#8220;Change in Control&#8221; (as defined in the applicable award agreement and/or SpinCo Equity Plans)), the SpinCo Board or Parent Board shall also accelerate in full the vesting of all outstanding SpinCo Equity Awards (or, following the Effective Time, Adjusted Parent Equity Awards) which are then held by Company Service Providers and Former Company Service Providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>The Parties hereto acknowledge and agree that in no event shall the vesting of any Company Equity Awards or SpinCo Equity Awards (or, following the Effective Time, Adjusted Parent Equity Awards), in any case, accelerate solely by reason of the transactions or events contemplated by the Separation Agreement, this Agreement, the Merger Agreement or any other Transaction Document.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Terms</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>The adjustments contemplated by this Article IV are all intended to comply in all respects with the requirements of Sections 409A and 424 of the Code, in each case, to the extent applicable, and all such provisions shall be interpreted and implemented in accordance with the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The Parties shall use their commercially reasonable efforts to maintain effective registration statements with the Securities Exchange Commission with respect to the awards described in this Article IV, to the extent any such registration statement is required by applicable Law. For the avoidance of doubt, Parent shall use commercially reasonable efforts to file an effective registration statement on Form S-8 (or other applicable form, including Form S-1 or Form S-3) with respect to the Domesticated Parent Common Stock issuable under the Adjusted Parent Equity Awards issuable under the SpinCo Equity Plans, </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">and Parent shall use commercially reasonable efforts to maintain the effectiveness of such registration statement(s) (and maintain the current status of the prospectus or prospectuses contained therein) for so long as such awards remain outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</span></span>The Parties hereby acknowledge that the provisions of this Article IV are intended to achieve certain tax, legal and accounting objectives and, in the event such objectives are not achieved, the Parties agree to negotiate in good faith regarding such other actions that may be necessary or appropriate to achieve such objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</span></span>After the Distribution Time, Company Equity Awards adjusted pursuant to this Article IV, regardless of by whom held, shall be settled by the Company pursuant to the terms of the Company Equity Plan, and SpinCo Equity Awards (or, following the Effective Time, Adjusted Parent Equity Awards), regardless of by whom held, shall be settled by SpinCo or Parent (as applicable) pursuant to the terms of the SpinCo Equity Plan. Accordingly, it is intended that, to the extent of the issuance of such SpinCo Equity Awards (or, following the Effective Time, Adjusted Parent Equity Awards) and in connection with the adjustment provisions of this Article IV, the SpinCo Equity Plan shall be considered a successor to the Company Equity Plan and to have assumed the obligations of the Company Equity Plan to make the adjustments of the Company Equity Awards as set forth in this Article IV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</span></span>The Parties acknowledge and agree that each of the applicable tax deductions for which they may be eligible for federal income tax purposes with regard to the Company Equity Awards and SpinCo Equity Awards (or, following the Effective Time, Adjusted Parent Equity Awards), in any case, shall be determined in accordance with Revenue Ruling 2002-1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</span></span>By approving the form, terms and conditions of, and the entrance by the Parties into, this Agreement, the Company Board, the SpinCo Board and the Parent Board intend to exempt from the short-swing profit recovery provisions of Section 16(b) of the Exchange Act, by reason of the application of Rule 16b&#8722;3 thereunder, all acquisitions and dispositions of Company Equity Awards, SpinCo Equity Awards and/or Adjusted Parent Equity Awards by directors and executive officers of each of the Parties contemplated herein, and the Company Board, the SpinCo Board and the Parent Board also intend to expressly approve, in respect of any Company Equity Awards, SpinCo Equity Awards and/or Adjusted Parent Equity Awards, the use of any method for the payment of an exercise price and the satisfaction of any applicable tax withholding (specifically including the actual or constructive tendering of shares in payment of an exercise price and the withholding of shares from delivery in satisfaction of applicable tax withholding requirements) to the extent such method is permitted under the Company Equity Plan or SpinCo Equity Plan (as applicable) and the applicable award agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</span></span>Each of the Parties shall establish an appropriate administration system in order to handle, in an orderly manner that complies with applicable Laws, (i) exercises of Ligand Options and SpinCo Options (or, following the Effective Time, Adjusted Parent Options), (ii) the settlement of other Ligand Equity Awards and SpinCo Equity Awards (or, following the Effective Time, Adjusted Parent Equity Awards), (iii) the vesting of Ligand Equity Awards and SpinCo Equity Awards (or, following the Effective Time, Adjusted Parent Equity Awards) and (iv) the satisfaction of applicable withholding taxes with respect to Ligand Equity Awards and SpinCo Equity Awards (or, following the Effective Time, Adjusted Parent Equity Awards). The Parties shall work together to unify and consolidate all indicative data and payroll and employment information on regular timetables and make certain that each applicable entity&#8217;s data and records in respect of such awards are correct and updated on a timely basis. The foregoing shall include employment status and information required for tax withholding/remittance and reporting, compliance with trading windows and compliance with the requirements of the Exchange Act and other applicable Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ADDITIONAL MATTERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash Incentive Programs</span>. SpinCo shall assume all Liabilities with respect to all cash incentive compensation, commissions or similar cash payments earned by or payable to SpinCo Employees for the year in which the Distribution Time occurs and thereafter. The Company shall retain all Liabilities with respect to any cash incentive compensation, commissions or similar cash payments earned by or payable to Company Employees for the year in which the Distribution Time occurs and thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severance</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Effective as of the Distribution Time, SpinCo shall have adopted a severance plan (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SpinCo Severance Plan</span>&#8221;) for the benefit of eligible SpinCo Employees containing terms substantially similar to those set forth in the Company Severance Plan. Following the Distribution Time, the Company shall be responsible for any and all Liabilities and other obligations with respect </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">to the Company Severance Plan, and SpinCo shall be responsible for any and all Liabilities and other obligations with respect to the SpinCo Severance Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>A SpinCo Employee shall not be deemed to have terminated employment for purposes of determining eligibility for severance benefits in connection with or in anticipation of the consummation of the transactions contemplated by the Separation Agreement or Merger Agreement. SpinCo shall be solely responsible for all Liabilities in respect of all costs arising out of payments and benefits relating to the termination or alleged termination of any SpinCo Employee&#8217;s employment that occurs on or after the Distribution Time, including as a result of, in connection with or following the consummation of the transactions contemplated by the Separation Agreement or Merger Agreement, including any amounts required to be paid (including any payroll or other taxes), and the costs of providing benefits, under any applicable severance, separation, redundancy, termination or similar plan, program, practice, contract, agreement, law or regulation (such benefits to include any medical or other welfare benefits, outplacement benefits, accrued vacation, and taxes).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time-Off Benefits</span>. Unless otherwise required under applicable Law (or as would result in duplication of benefits), SpinCo shall (i) credit each SpinCo Employee with the amount of accrued but unused vacation time, paid time-off and other time-off benefits as such SpinCo Employee had with the Company Group as of immediately before the date on which the employment of the SpinCo Employee transfers to SpinCo and (ii) permit each such SpinCo Employee to use such accrued but unused vacation time, paid time off and other time-off benefits in the same manner and upon the same terms and conditions as the SpinCo Employee would have been so permitted under the terms and conditions of the applicable Company policies in effect for the year in which such transfer of employment occurs, up to and including full exhaustion of such transferred unused vacation time, paid-time off and other time-off benefits (if such full exhaustion would be permitted under the applicable Company policies in effect for that year in which the transfer of employment occurs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Workers&#8217; Compensation Liabilities</span>. Effective no later than the Distribution Time, SpinCo shall assume all Liabilities for SpinCo Employees, SpinCo Independent Contractors and Former SpinCo Service Providers related to any and all workers&#8217; compensation injuries, incidents, conditions, claims or coverage, whenever incurred (including claims incurred prior to the Distribution Time but not reported until after the Distribution Time), and SpinCo shall be fully responsible for the administration, management and payment of all such claims and satisfaction of all such Liabilities. Notwithstanding the foregoing, if SpinCo is unable to assume any such Liability or the administration, management or payment of any such claim solely because of the operation of applicable Law, the Company shall retain such Liabilities and SpinCo shall reimburse and otherwise fully indemnify the Company for all such Liabilities, including the costs of administering the plans, programs or arrangements under which any such Liabilities have accrued or otherwise arisen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COBRA Compliance</span>.The Company shall retain responsibility for compliance with the health care continuation requirements of COBRA with respect to SpinCo Employees or Former SpinCo Service Providers who, as of the Plan Transition Date, were covered under a Company Benefit Plan or who had incurred a COBRA qualifying event and were eligible to elect COBRA under a Company Benefit Plan. SpinCo shall be responsible for administering compliance with the health care continuation requirements of COBRA, and the corresponding provisions of the SpinCo Benefit Plans with respect to SpinCo Employees and their covered dependents who incur a COBRA qualifying event or loss of coverage at any time after the Plan Transition Date<span style="color:#0000ff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code Section 409A</span>. Notwithstanding anything in this Agreement to the contrary, the Parties shall negotiate in good faith regarding the need for any treatment different from that otherwise provided herein with respect to the payment of compensation to ensure that the treatment of such compensation does not cause the imposition of a Tax under Section 409A of the Code. In no event, however, shall any Party be liable to another in respect of any Taxes imposed under, or any other costs or Liabilities relating to, Section 409A of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payroll Taxes and Reporting</span>. The Parties shall, to the extent practicable, (i) treat SpinCo or a member of the SpinCo Group as a &#8220;successor employer&#8221; and the Company (or the appropriate member of the Company Group) as a &#8220;predecessor,&#8221; within the meaning of Sections 3121(a)(1) and 3306(b)(1) of the Code, with respect to SpinCo Employees for purposes of Taxes imposed under the United States Federal Unemployment Tax Act or the United States Federal Insurance Contributions Act, and (ii) cooperate with each other to avoid, to the extent reasonably practicable, the filing of more than one IRS Form W-2 with respect to each SpinCo Employee for the calendar year in which the Distribution Time occurs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Filings</span>. Subject to applicable Law and the Tax Matters Agreement, the Company shall retain responsibility for all employee-related regulatory filings for reporting periods ending at or prior to the Distribution Time, except for Equal Employment Opportunity Commission EEO-1 reports and affirmative action program (AAP) reports and responses to Office of Federal Contract </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Compliance Programs (OFCCP) submissions, for which the Company shall provide data and information (to the extent permitted by applicable Laws) to SpinCo, which shall be responsible for making such filings in respect of SpinCo Employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Requirements</span>. Notwithstanding anything in this Agreement to the contrary, if applicable Law requires that any assets or Liabilities be retained by the Company Group or transferred to or assumed by the SpinCo Group in a manner that is different from that set forth in this Agreement, such retention, transfer or assumption shall be made in accordance with the terms of such applicable Law and shall not be made as otherwise set forth in this Agreement and the Parties shall reasonably cooperate to adjust for any related economic consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE VI</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OBLIGATIONS OF PARENT AND MERGER SUB</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Obligations of Parent</span>. Following the Merger Effective Time, Parent agrees to cause, and to take all actions to enable, SpinCo and the members of the SpinCo Group to adhere to each provision of this Agreement which requires an act on the part of SpinCo or any member of the SpinCo Group or any of its or their Affiliates, and to cause or enable SpinCo and the SpinCo Group to comply with their obligations to provide or establish compensation or benefits to SpinCo Service Providers in accordance with this Agreement pursuant to a Benefit Plan sponsored or maintained by Parent or any of its Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE VII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GENERAL AND ADMINISTRATIVE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employer Rights</span>. Nothing in this Agreement shall be deemed to be an amendment to any Company Benefit Plan or SpinCo Benefit Plan or to prohibit any member of the Company Group or SpinCo Group, as the case may be, from amending, modifying or terminating any Company Benefit Plan or SpinCo Benefit Plan at any time within its sole discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect on Employment</span>. Nothing in this Agreement is intended to or shall confer upon any employee or former employee of the Company, SpinCo or any of their respective Affiliates any right to continued employment, or any recall or similar rights to any such individual on layoff or any type of approved leave.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consent of Third Parties</span>. If any provision of this Agreement is dependent on the consent of any third party and such consent is withheld, the Parties shall use their reasonable efforts to implement the applicable provisions of this Agreement to the fullest extent practicable. If any provision of this Agreement cannot be implemented due to the failure of such third party to consent, the Parties hereto shall negotiate in good faith to implement the provision (as applicable) in a mutually satisfactory manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Access to Employees</span>. On and after the Distribution Time, the Parties shall, or shall cause each of their respective Affiliates to, make available to each other those of their employees who may reasonably be needed in order to defend or prosecute any legal or administrative action (other than a legal action among the Parties) to which any employee or director of the Company Group or the SpinCo Group or any Company Benefit Plan or SpinCo Benefit Plan is a party and which relates to a Company Benefit Plan or SpinCo Benefit Plan. The Party to whom an employee is made available in accordance with this Section 7.4 shall pay or reimburse the other Parties for all reasonable expenses which may be incurred by such employee in connection therewith, including all reasonable travel, lodging, and meal expenses, but excluding any amount for such employee&#8217;s time spent in connection herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Beneficiary Designation/Release of Information/Right to Reimbursement</span>. To the extent permitted by applicable Law and except as otherwise provided for in this Agreement, all beneficiary designations, authorizations for the release of information and rights to reimbursement made by or relating to SpinCo Employees under Company Benefit Plan shall be transferred to and be in full force and effect under the corresponding SpinCo Benefit Plan until such beneficiary designations, authorizations or rights are replaced or revoked by, or no longer apply, to the relevant SpinCo Employee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Third Party Beneficiaries</span>. This Agreement is solely for the benefit of the Parties and, except to the extent otherwise expressly provided herein, nothing in this Agreement, express or implied, is intended to confer any rights, benefits, remedies, obligations or Liabilities under this Agreement upon any Person, including any SpinCo Employee or other current or former employee, officer, director or contractor of the Company Group or SpinCo Group, other than the Parties and their respective successors and assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employee Benefits Administration</span>. At all times following the date hereof, the Parties will cooperate in good faith as necessary to facilitate the administration of employee benefits and the resolution of related employee benefit claims with respect to </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">SpinCo Employees, Former SpinCo Service Providers and employees and other service providers of the Company, as applicable, including with respect to the provision of employee level information necessary for the other Parties to manage, administer, finance and file required reports with respect to such administration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Audit Rights With Respect to Information Provided</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>Each Party, and their duly authorized representatives, shall have the right to conduct reasonable audits with respect to all information required to be provided to it by the other Parties under this Agreement. The Party conducting the audit (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Auditing Party</span>&#8221;) may adopt reasonable procedures and guidelines for conducting audits and the selection of audit representatives under this Section 7.8. The Auditing Party shall have the right to make copies of any records at its expense, subject to any restrictions imposed by applicable laws and to any confidentiality provisions set forth in the Separation Agreement, which are incorporated by reference herein. The Party being audited shall provide the Auditing Party&#8217;s representatives with reasonable access during normal business hours to its operations, computer systems and paper and electronic files, and provide workspace to its representatives. After any audit is completed, the Party being audited shall have the right to review a draft of the audit findings and to comment on those findings in writing within thirty business days after receiving such draft.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>The Auditing Party&#8217;s audit rights under this Section 7.8 shall include the right to audit, or participate in an audit facilitated by the Party being audited, of any Subsidiaries and Affiliates of the Party being audited and to require the other Parties to request any benefit providers and third parties with whom the Party being audited has a relationship, or agents of such Party, to agree to such an audit to the extent any such Persons are affected by or addressed in this Agreement (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-parties</span>&#8221;). The Party being audited shall, upon written request from the Auditing Party, provide an individual (at the Auditing Party&#8217;s expense) to supervise any audit of a Non-party. The Auditing Party shall be responsible for supplying, at the Auditing Party&#8217;s expense, additional personnel sufficient to complete the audit in a reasonably timely manner. The responsibility of the Party being audited shall be limited to providing, at the Auditing Party&#8217;s expense, a single individual at each audited site for purposes of facilitating the audit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation</span>. Each of the Parties hereto will use its commercially reasonable efforts to share information and promptly take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable under applicable Laws to consummate the transactions contemplated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE VIII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.1</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</span>. This Agreement, the Separation Agreement, the Merger Agreement, and the other Transaction Documents, including the Exhibits and Schedules thereto, shall constitute the entire agreement among the Parties with respect to the subject matter hereof and shall supersede all previous negotiations, commitments, course of dealings and writings with respect to such subject matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.2</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</span>. This Agreement may be executed in two or more counterparts (including by electronic or .pdf transmission), each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of any signature page by facsimile, electronic or .pdf transmission shall be binding to the same extent as an original signature page.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.3</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival of Agreements</span>. Except as otherwise contemplated by this Agreement, all covenants and agreements of the Parties contained in this Agreement shall survive the Distribution Time and Merger Effective Time and remain in full force and effect in accordance with their applicable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.4</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</span>. All notices and other communications among the Parties shall be in writing and shall be deemed to have been duly given (a) when delivered in person, (b) when delivered after posting in the national mail having been sent registered or certified mail return receipt requested, postage prepaid, (c) when delivered by FedEx or other internationally recognized overnight delivery service or (d) when delivered by facsimile (solely if receipt is confirmed) or email (so long as the sender of such email does not receive an automatic reply from the recipient&#8217;s email server indicating that the recipient did not receive such email), addressed as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">To the Company:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Ligand Pharmaceuticals Incorporated</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">3911 Sorrento Valley Boulevard, Suite 110</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">San Diego, California 92121</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Attn: Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Email: tespinoza@ligand.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">with a copy (which shall not constitute notice) to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Latham &amp; Watkins, LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">12670 High Bluff Dr.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">San Diego, California 92130</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Attention:&#160;&#160;&#160;&#160;&#160;Matthew Bush</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 72pt;">Scott Shean</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Email:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;matt.bush@lw.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 72pt;">scott.shean@lw.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">To SpinCo:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">OmniAb, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">5980 Horton Street, Suite 405</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Emeryville, California 94608</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Attention: Chief Legal Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Email: cberkman@omniab.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">with a copy (which shall not constitute notice) to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Latham &amp; Watkins, LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">12670 High Bluff Dr.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">San Diego, California 92130</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Attn:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Matthew Bush</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 72pt;"><span style="white-space:pre-wrap;"> Scott Shean</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Email:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;matt.bush@lw.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 72pt;"><span style="white-space:pre-wrap;"> scott.shean@lw.com</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">To Parent or Merger Sub:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Avista Public Acquisition Corp. II</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">65 East 55<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Street, 18<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">New York, New York 10022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Attn: General Counsel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Email: Silbert@avistacap.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">with a copy (which shall not constitute notice) to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Weil, Gotshal &amp; Manges LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">767 5th Avenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">New York, New York 10153</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Attention:&#160;&#160;&#160;&#160;&#160;&#160;Jaclyn L. Cohen, Esq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 72pt;"><span style="white-space:pre-wrap;"> Raymond O. Gietz, Esq.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Email:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;jackie.cohen@weil.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 72pt;">&#160;Raymond.gietz@weil.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">or to such other address or addresses as the Parties may from time to time designate in writing by like notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.5</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consents</span>. Any consent required or permitted to be given by any Party to the other Parties under this Agreement shall be in writing and signed by the Party giving such consent and shall be effective only against such Party (and its Group).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.6</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</span>. This Agreement shall not be assignable, in whole or in part, directly or indirectly, by any Party hereto without the prior written consent of the other Parties, and any attempt to assign any rights or obligations arising under this Agreement without </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">such consent shall be void. Notwithstanding the foregoing, and subject to any restrictions on assignment by SpinCo pursuant to Article IV of the Tax Matters Agreement, this Agreement shall be assignable to (i) with respect to the Company, an Affiliate of the Company, and with respect to SpinCo, and Affiliate of SpinCo, or (ii) a bona fide third party in connection with a merger, reorganization, consolidation or the sale of all or substantially all the assets of a party hereto so long as the resulting, surviving or transferee entity assumes all the obligations of the relevant party hereto by operation of Law or pursuant to an agreement in form and substance reasonably satisfactory to the other Parties to this Agreement; provided however that in the case of each of the preceding clauses (i) and (ii), no assignment permitted by this Section 8.6 shall release the assigning Party from liability for the full performance of its obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.7</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</span>. The provisions of this Agreement and the obligations and rights hereunder shall be binding upon, inure to the benefit of and be enforceable by (and against) the Parties and their respective successors and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.8</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination and Amendment</span>. This Agreement may be amended or modified, in whole or in part, only by a duly authorized agreement in writing executed by the Parties in the same manner (but not necessarily by the same Persons) as this Agreement, and which makes reference to this Agreement. This Agreement shall terminate automatically without any further action of the Parties upon a termination of the Merger Agreement, and no Party will have any further obligations to the other Parties hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.9</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsidiaries</span>. Each of the Parties shall cause to be performed, and hereby guarantees the performance of, all actions, agreements and obligations set forth herein to be performed by any Subsidiary of such Party or by any entity that becomes a Subsidiary of such Party at and after the Distribution Time, to the extent such Subsidiary remains a Subsidiary of the applicable Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.10</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title and Headings</span>. Titles and headings to sections herein are inserted for the convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.11</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</span>. This Agreement, and all claims, disputes, controversies or causes of action (whether in contract, tort, equity or otherwise) that may be based upon, arise out of or relate to this Agreement (including any schedule or exhibit hereto) or the negotiation, execution or performance of this Agreement (including any claim, dispute, controversy or cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this Agreement or as an inducement to enter into this Agreement), shall be governed by and construed in accordance with the Laws of the State of Delaware, without regard to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware. Each of the Parties agrees that any Action related to this agreement shall be brought exclusively in the <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chosen Courts</span>. By executing and delivering this Agreement, each of the Parties irrevocably: (a) accepts generally and unconditionally submits to the exclusive jurisdiction of the Chosen Courts for any Action relating to this Agreement; (b) waives any objections which such party may now or hereafter have to the laying of venue of any such Action contemplated by this Section 8.11 and hereby further irrevocably waives and agrees not to plead or claim that any such Action has been brought in an inconvenient forum; (c) agrees that it will not attempt to deny or defeat the personal jurisdiction of the Chosen Courts by motion or other request for leave from any such court; (d) agrees that it will not bring any Action contemplated by this Section 8.11 in any court other than the Chosen Courts; (e) agrees that service of all process, including the summons and complaint, in any Action may be made by registered or certified mail, return receipt requested, to such party at their respective addresses provided in accordance with Section 8.4 or in any other manner permitted by Law; and (f) agrees that service as provided in the preceding clause (e) is sufficient to confer personal jurisdiction over such party in the Action, and otherwise constitutes effective and binding service in every respect. Each of the parties hereto agrees that a final judgment in any Action in a Chosen Court as provided above may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law, and each party further agrees to the non-exclusive jurisdiction of the Chosen Courts for the enforcement or execution of any such judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.12</span></span>WAIVER OF JURY TRIAL. THE PARTIES HEREBY UNCONDITIONALLY AND IRREVOCABLY WAIVE THEIR RIGHT TO TRIAL BY JURY IN ANY JUDICIAL PROCEEDING IN ANY COURT RELATING TO ANY DISPUTE, CONTROVERSY OR CLAIM ARISING OUT OF, RELATING TO OR IN CONNECTION WITH THIS AGREEMENT (INCLUDING ANY SCHEDULE OR EXHIBIT HERETO) OR THE BREACH, TERMINATION OR VALIDITY OF THIS AGREEMENT OR THE NEGOTIATION, EXECUTION OR PERFORMANCE OF THIS AGREEMENT. NO PARTY TO THIS AGREEMENT SHALL SEEK A JURY TRIAL IN ANY LAWSUIT, PROCEEDING, COUNTERCLAIM OR ANY OTHER LITIGATION PROCEDURE BASED UPON, OR ARISING OUT OF, THIS AGREEMENT OR ANY RELATED INSTRUMENTS. NO PARTY WILL SEEK TO CONSOLIDATE ANY SUCH ACTION IN WHICH A JURY TRIAL HAS BEEN WAIVED WITH ANY OTHER ACTION IN WHICH A JURY TRIAL CANNOT BE OR HAS NOT BEEN WAIVED. EACH PARTY TO THIS AGREEMENT CERTIFIES THAT IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT OR INSTRUMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS SET FORTH ABOVE IN THIS SECTION 8.12. </p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">NO PARTY HAS IN ANY WAY AGREED WITH OR REPRESENTED TO ANY OTHER PARTY THAT THE PROVISIONS OF THIS SECTION 8.12 WILL NOT BE FULLY ENFORCED IN ALL INSTANCES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.13</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</span>. If any provision of this Agreement, or the application of any such provision to any Person or circumstance, shall be held invalid, illegal or unenforceable in any respect by a court of competent jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision hereof. The Parties further agree that if any provision contained herein is, to any extent, held invalid or unenforceable in any respect under the Laws governing this Agreement, they shall take any actions necessary to render the remaining provisions of this Agreement valid and enforceable to the fullest extent permitted by Law and, to the extent necessary, shall amend or otherwise modify this Agreement to replace any provision contained herein that is held invalid or unenforceable with a valid and enforceable provision giving effect to the intent of the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.14</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</span>. The Parties have participated jointly in the negotiation and drafting of this Agreement. This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the Party drafting or causing any instrument to be drafted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.15</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Duplication; No Double Recovery</span>. Nothing in this Agreement is intended to confer to or impose upon any Party a duplicative right, entitlement, obligation or recovery with respect to any matter arising out of the same facts and circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.16</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Waiver</span>. No failure to exercise and no delay in exercising, on the part of any Party, any right, remedy, power or privilege hereunder shall operate as a waiver hereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.17</span></span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Admission of Liability</span>. The allocation of Assets and Liabilities herein is solely for the purpose of allocating such Assets and Liabilities among the Parties and is not intended as an admission of liability or responsibility for any alleged Liabilities vis-&#224;-vis any third party, including with respect to the Liabilities of any non-wholly owned subsidiary of any Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature Page Follows]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"> <span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the day and year first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">LIGAND PHARMACEUTICALS INCORPORATED</b></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Matthew Korenberg</p></td><td style="vertical-align:bottom;width:46.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:42.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Matthew Korenberg</p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Executive Vice President, Finance and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">OMNIAB, INC.</b></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Matthew W. Foehr </p></td><td style="vertical-align:bottom;width:46.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:42.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Matthew W. Foehr</p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;"> /s/ Benjamin Silbert</span></p></td><td style="vertical-align:bottom;width:46.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:42.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Benjamin Silbert</p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General Counsel</p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">ORWELL MERGER SUB INC.</b></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:48.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;"> /s/ David Burgstahler</span></p></td><td style="vertical-align:bottom;width:46.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:42.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">David Burgstahler</p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">President</p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature Page to Employee Matters Agreement]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;text-align:center;margin:0pt;"><span style="font-size:0pt;font-style:italic;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">K-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_498ebc11_3985_4e74_b9df_db08fcd41aaf"></a><a id="AnnexL_166744"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Annex L</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OMNIAB, INC. 2022 INCENTIVE AWARD PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">[To be filed by amendment]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;text-align:right;margin:0pt;"><span style="font-size:0pt;font-style:italic;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">L-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5fb21e0d_8609_45ab_909d_99e1ff5997d0"></a><a id="AnnexM_106574"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Annex M</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OMNIAB, INC. 2022 EMPLOYEE STOCK PURCHASE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">[To be filed by amendment]<br /><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;text-align:center;margin:0pt;"><span style="font-size:0pt;font-style:italic;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">M-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_df8ca25b_e82f_4d8d_b025_88de230bb397"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;II</b></p><a id="Main_INFORMATIONNOTREQUIREDINPROSPEC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INFORMATION NOT REQUIRED IN PROSPECTUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Item&#160;20. Indemnification of Directors and Officers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Cayman Islands Companies Law does not limit the extent to which a company&#8217;s memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against willful default, willful neglect, civil fraud or the consequences of committing a crime. The Cayman Constitutional Documents provided for indemnification of APAC&#8217;s officers and directors to the maximum extent permitted by law, including for any liability incurred in their capacities as such, except through their own actual fraud, willful default or willful neglect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">APAC has entered into agreements with APAC&#8217;s officers and directors to provide contractual indemnification in addition to the indemnification provided for in the Cayman Constitutional Documents. APAC has purchased a policy of directors&#8217; and officers&#8217; liability insurance that insures officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against APAC&#8217;s obligations to indemnify APAC&#8217;s officers and directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, APAC has been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_097eba5b_00e0_4920_817e_2776371e3bd7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Item&#160;21. Exhibits and Financial Statement Schedules.</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Exhibits.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.05%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:10.1%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2.1+</p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#AnnexA_695339"><span style="font-style:normal;font-weight:normal;">Agreement and Plan of Merger, dated March&#160;23, 2022, by and among Avista Public Acquisition Corp. II, Orwell Merger Sub&#160;Inc., Ligand Pharmaceuticals Incorporated and OmniAb,&#160;Inc. (included as Annex A to the proxy statement/prospectus/information statement).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2.2+</p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#AnnexB_187430"><span style="font-style:normal;font-weight:normal;">Separation and Distribution Agreement, dated March&#160;23, 2022, by and among Avista Public Acquisition Corp. II, Ligand Pharmaceuticals Incorporated and OmniAb,&#160;Inc. (included as Annex B to the proxy statement/prospectus/information statement).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2.3*</p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Plan of Domestication, dated [&#8226;], 2022.</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">3.1</p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1846253/000110465921104194/tm2110146d14_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Memorandum and Articles of Association of Avista Public Acquisition Corp. II (incorporated by reference to Exhibit&#160;3.1 to Avista Public Acquisition Corp. II&#8217;s Current Report on Form&#160;8-K filed with the SEC on August&#160;12, 2021).</span></a> </p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">3.2</p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#AnnexH_950033"><span style="font-style:normal;font-weight:normal;">Form&#160;of Certificate of Incorporation of OmniAb,&#160;Inc., to become effective upon Domestication (included as Annex H to the proxy statement/prospectus/information statement).</span></a> </p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">3.3</p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#AnnexI_90446"><span style="font-style:normal;font-weight:normal;">Form&#160;of Bylaws of OmniAb,&#160;Inc., to become effective upon Domestication (included as Annex I to the proxy statement/prospectus/information statement).</span></a> </p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">4.1</p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1846253/000110465921082716/tm2110146d7_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Unit Certificate (incorporated by reference to Exhibit&#160;4.1 to Avista Public Acquisition Corp. II&#8217;s Form&#160;S-1/A filed with the SEC on July&#160;28, 2021).</span></a> </p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">4.2</p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1846253/000110465921082716/tm2110146d7_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Class&#160;A Ordinary Share Certificate (incorporated by reference to Exhibit&#160;4.2 to Avista Public Acquisition Corp. II&#8217;s Form&#160;S-1/A filed with the SEC on July&#160;28, 2021).</span></a> </p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">4.3</p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1846253/000110465921097011/tm2110146d9_ex4-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Warrant Certificate (incorporated by reference to Exhibit&#160;4.3 to Avista Public Acquisition Corp. II&#8217;s Form&#160;S-1/A filed with the SEC on July&#160;28, 2021).</span></a> </p></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">II-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.05%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:10.1%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">4.4</p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1846253/000110465921104194/tm2110146d14_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Warrant Agreement, dated August&#160;9, 2021, between Avista Public Acquisition Corp. II and Continental Stock Transfer&#160;&amp; Trust Company, as warrant agent (incorporated by reference to Exhibit&#160;4.1 to Avista Public Acquisition Corp. II&#8217;s Form&#160;8-K filed with the SEC on August&#160;12, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">4.5*</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Specimen Common Stock Certificate of OmniAb,&#160;Inc.</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">4.6*</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Form&#160;of Certificate of Corporate Domestication of OmniAb,&#160;Inc., to be filed with the Secretary of the State of Delaware.</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">5.1*</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Opinion of Weil Gotshal&#160;&amp; Manges&#160;LLP.</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">8.1*</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Tax Opinion of Weil Gotshal&#160;&amp; Manges&#160;LLP.</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1846253/000110465921104194/tm2110146d14_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Investment Management Trust Agreement, dated August&#160;9, 2021, between Avista Public Acquisition Corp. II and Continental Stock Transfer&#160;&amp; Trust Company, as trustee (incorporated by reference to Exhibit&#160;10.1 to Avista Public Acquisition Corp. II&#8217;s Current Report on Form&#160;8-K filed with the SEC on August&#160;12, 2021).</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1846253/000110465921104194/tm2110146d14_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration and Shareholders Rights Agreement, dated August&#160;9, 2021, among Avista Public Acquisition Corp. II, the Sponsor and certain other security holders named therein (incorporated by reference to Exhibit&#160;10.2 to Avista Public Acquisition Corp. II&#8217;s Current Report on Form&#160;8-K filed with the SEC on August&#160;12, 2021).</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1846253/000110465921104194/tm2110146d14_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Private Placement Warrants Purchase Agreement, dated August&#160;9, 2021, between Avista Public Acquisition Corp. II and Avista Acquisition LP II (incorporated by reference to Exhibit&#160;10.3 to Avista Public Acquisition Corp. II&#39;s Current Report on Form&#160;8-K filed with the SEC on August&#160;12, 2021).</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1846253/000110465921104194/tm2110146d14_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Administrative Services Agreement, dated August&#160;9, 2021, between Avista Public Acquisition Corp. II and Avista Acquisition LP II (incorporated by reference to Exhibit&#160;10.4 to Avista Public Acquisition Corp. II&#39;s Current Report on Form&#160;8-K filed with the SEC on August&#160;12, 2021).</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.5#</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1846253/000110465921104194/tm2110146d14_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Letter Agreements, dated August&#160;9, 2021, by and among Avista Public Acquisition Corp. II, each of Avista Public Acquisition Corp. II&#39;s officers and directors and Avista Acquisition LP II (incorporated by reference to Exhibit&#160;10.5 to Avista Public Acquisition Corp. II&#39;s Current Report on Form&#160;8-K filed with the SEC on August&#160;12, 2021).</span></a> </p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1846253/000110465921104194/tm2110146d14_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Indemnity Agreements, dated August&#160;9, 2021, between Avista Public Acquisition Corp. II, each of its officers and directors and Avista Acquisition LP II (incorporated by reference to Exhibit&#160;10.6 to Avista Public Acquisition Corp. II&#39;s Current Report on Form&#160;8-K filed with the SEC on August&#160;12, 2021).</span></a> </p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.7</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1846253/000110465921104194/tm2110146d14_ex10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Forward Purchase Agreement, dated August&#160;9, 2021, between Avista Public Acquisition Corp. II and Avista Acquisition LP II (incorporated by reference to Exhibit&#160;10.7 to Avista Public Acquisition Corp. II&#39;s Current Report on Form&#160;8-K filed with the SEC on August&#160;12, 2021).</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.8</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1846253/000110465921082716/tm2110146d7_ex10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Securities Subscription Agreement, dated February&#160;12, 2021, between Avista Public Acquisition Corp. II and the Sponsor (incorporated by reference to Exhibit&#160;10.7 to Avista Public Acquisition Corp. II&#39;s Form&#160;S-1/A filed with the SEC on July&#160;28, 2021).</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1846253/000110465921082716/tm2110146d7_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Promissory Note, dated February&#160;12, 2021, between Avista Public Acquisition Corp. II and Avista Acquisition LP II (incorporated by reference to Exhibit&#160;10.5 to Avista Public Acquisition Corp. II&#39;s Form&#160;S-1/A filed with the SEC on July&#160;28, 2021).</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.10</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1846253/000110465922033379/tm229188d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Promissory Note, dated March&#160;14, 2022, issued by Avista Public Acquisition Corp. II to the Sponsor (incorporated by reference to Exhibit&#160;10.1 of Avista Public Acquisition Corp. II&#39;s Current Report on Form&#160;8-K filed with the SEC on March&#160;14, 2022).</span></a></p></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">II-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.05%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:10.1%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.11</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#AnnexC_741582"><span style="font-style:normal;font-weight:normal;">Sponsor Insider Agreement, dated March&#160;23, 2022, by and among OmniAb,&#160;Inc., Avista Public Acquisition Corp. II, Avista Acquisition LP II and the other parties signatory thereto (included as Annex C to the proxy statement/prospectus/information statement).</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.12</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#AnnexD_88451"><span style="font-style:normal;font-weight:normal;">Amended and Restated Forward Purchase Agreement, dated March&#160;23, 2022, by and among Avista Public Acquisition Corp. II, Avista Acquisition LP II and OmniAb,&#160;Inc. (included as Annex D to the proxy statement/prospectus/information statement).</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.13+</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#AnnexK_373714"><span style="font-style:normal;font-weight:normal;">Employee Matters Agreement, dated March&#160;23, 2022, by and among Avista Public Acquisition Corp. II, Orwell Merger Sub&#160;Inc., Ligand Pharmaceuticals Incorporated and OmniAb,&#160;Inc. (included as Annex K to the proxy statement/prospectus/information statement).</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.14+</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#AnnexE_433829"><span style="font-style:normal;font-weight:normal;">Form&#160;of Tax Matters Agreement, by and between Ligand Pharmaceuticals Incorporated and OmniAb,&#160;Inc. (included as Annex E to the proxy statement/prospectus/information statement).</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.15+</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#AnnexF1_497487"><span style="font-style:normal;font-weight:normal;">Form&#160;of Transition Services Agreement, by and between Ligand Pharmaceuticals Incorporated and OmniAb,&#160;Inc., with respect to services provided by Ligand Pharmaceuticals Incorporated to OmniAb,&#160;Inc. (included as Annex F-1 to the proxy statement/prospectus/information statement).</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.16+</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#AnnexF2_966364"><span style="font-style:normal;font-weight:normal;">Form&#160;of Transition Services Agreement, by and between Ligand Pharmaceuticals Incorporated and OmniAb,&#160;Inc., with respect to services provided by OmniAb,&#160;Inc. to Ligand Pharmaceuticals Incorporated (included as Annex F-2 to the proxy statement/prospectus/information statement).</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.17</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#AnnexG_313259"><span style="font-style:normal;font-weight:normal;">Form&#160;of Amended and Restated Registration and Shareholders Rights Agreement, by and among Avista Public Acquisition Corp. II, Avista Acquisition LP II and the other parties to be set forth on the signature pages&#160;thereto (included as Annex G to the proxy statement/prospectus/information statement).</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.18#*</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#AnnexL_166744"><span style="font-style:normal;font-weight:normal;">Form&#160;of OmniAb,&#160;Inc. 2022 Incentive Award Plan (included as Annex L to the proxy statement/prospectus/information statement).</span></a> </p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.19#*</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#AnnexM_106574"><span style="font-style:normal;font-weight:normal;">Form&#160;of OmniAb,&#160;Inc. 2022 Employee Stock Purchase Plan (included as Annex M to the proxy statement/prospectus/information statement).</span></a> </p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.20#*</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Form&#160;of OmniAb,&#160;Inc. Non-Employee Director Compensation Program.</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.21#*</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Form&#160;of OmniAb,&#160;Inc. Change in Control Severance Agreement for Executive Officers. </p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.22#*</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Form&#160;of OmniAb,&#160;Inc. Severance Plan. </p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.23</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ahpa-20220416xex10d23.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of OmniAb,&#160;Inc. Indemnification Agreement for Directors and Officers.</span></a> </p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.24+</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ahpa-20220416xex10d24.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lab Lease Between Emery Station Office II, LLC and Crystal Bioscience,&#160;Inc., dated February&#160;16, 2009, as amended.</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.25&#8224;</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ahpa-20220416xex10d25.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Antibody License Agreement between CNA Development LLC and OmniAb,&#160;Inc., dated December&#160;20, 2012.</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.26&#8224;</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ahpa-20220416xex10d26.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Research, Development and Commercialization Agreement between Cystic Fibrosis Foundation and Icagen,&#160;L</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">LC</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, dated May&#160;1, 2018, as amended.</span></a> </p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10.27&#8224;</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ahpa-20220416xex10d27.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated License Agreement between F. Hoffmann-La Roche Ltd, Hoffmann-La Roche lnc. and Icagen, LLC, dated May&#160;29, 2020, as amended.</span></a> </p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ahpa-20220416xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of subsidiaries of OmniAb, Inc.</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">II-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.05%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:10.1%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ahpa-20220416xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Marcum LLP</span></a>. </p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">23.2</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ahpa-20220416xex23d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Ernst&#160;&amp; Young&#160;LLP.</span></a> </p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">23.3*</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Consent of Weil Gotshal&#160;&amp; Manges LLP (included as part of Exhibit&#160;5.1).</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">24.1</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#POWEROFATTORNEY_97281"><span style="font-style:normal;font-weight:normal;">Power of Attorney (included on signature page&#160;to the initial filing of the Registration Statement).</span></a> </p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ahpa-20220416xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Proxy Card for Avista Public Acquisition Corp. II&#8217;s extraordinary general meeting.</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">99.2</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ahpa-20220416xex99d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of John L. Higgins to be named as a director.</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">99.3</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ahpa-20220416xex99d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Sarah Boyce to be named as a director.</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">99.4</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ahpa-20220416xex99d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Jennifer Cochran to be named as a director.</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">99.5</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ahpa-20220416xex99d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Sunil Patel to be named as a director.</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">99.6</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ahpa-20220416xex99d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Carolyn Bertozzi to be named as a director.</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">99.7</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ahpa-20220416xex99d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Matthew W. Foehr to be named as a director.</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">99.8*</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Consent of [&#8226;] to be named as a director.</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">101</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Interactive Data File</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">107</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ahpa-20220416xexfilingfees.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Filing Fee Table</span></a></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">To be filed by amendment.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">+</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Schedules and exhibits have been omitted pursuant to Item&#160;601(b)(2)&#160;of Regulation S-K. Avista Public Acquisition Corp. II agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">#</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Indicates management contract or compensatory plan.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Portions of this exhibit have been omitted for confidentiality purposes.</p></td></tr></table><a id="_2de246d9_1173_4359_86c3_c44ac2481275"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Item&#160;22. Undertakings.</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Avista Public Acquisition Corp. II hereby undertakes:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To include any prospectus required by section 10(a)(3)&#160;of the Securities Act of 1933;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&#160;424(b)&#160;if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement;</p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">II-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment that contains a form of prospectus will be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time will be deemed to be the initial bona fide offering thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule&#160;424(b)&#160;as part of a registration statement relating to an offering, other than registration statements relying on Rule&#160;430B or other than prospectuses filed in reliance on Rule&#160;430A, will be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">That, for the purpose of determining liability of Avista Public Acquisition Corp. II under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#160;424;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">2.</span>Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of Avista Public Acquisition Corp. II pursuant to the foregoing provisions, or otherwise, Avista Public Acquisition Corp. II has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by Avista Public Acquisition Corp. II of expenses incurred or paid by a director, officer or controlling person of Avista Public Acquisition Corp. II in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, Avista Public Acquisition Corp. II will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by them is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">3.</span>The undersigned registrant hereby undertakes as follows: that prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule&#160;145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">4.</span>The registrant undertakes that every prospectus: (1)&#160;that is filed pursuant to the immediately preceding paragraph, or (2)&#160;that purports to meet the requirements of Section&#160;10(a)(3)&#160;of the Act and is used in connection with an offering of securities subject to </div></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">II-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;">Rule&#160;415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act of 1933, each such post-effective amendment will be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time will be deemed to be the initial bona fide offering thereof.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">5.</span>Avista Public Acquisition Corp. II hereby undertakes to respond to requests for information that is incorporated by reference into the prospectus pursuant to Items 4, 10(b), 11, or 13 of this Form&#160;S-4, within one business day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the Registration Statement through the date of responding to the request.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">6.</span>Avista Public Acquisition Corp. II hereby undertakes to supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the Registration Statement when it became effective.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">II-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.88%;margin-right:5.88%;max-width:100%;position:relative;"><div style="padding-top:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_59858670_be58_4a23_9e8a_82833c6fd5f6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Act of 1933, Avista Public Acquisition Corp. II has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in New York County, New York on the 27th day of April, 2022.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:39.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:48.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">AVISTA PUBLIC ACQUISITION CORP. II</b></p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">/s/ John Cafasso</p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">/s/ David Burgstahler</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:39.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">John Cafasso</p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">David Burgstahler</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:39.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="POWEROFATTORNEY_97281"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">POWER OF ATTORNEY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">KNOW ALL BY THESE PRESENTS, that each of the undersigned constitutes and appoints each of Benjamin Silbert and John Cafasso, each acting alone, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement on Form&#160;S-4 (including all pre-effective and post-effective amendments and registration statements filed pursuant to Rule&#160;462 under the Securities Act of 1933), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that any such attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:43.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:middle;width:35.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:middle;width:17.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:bottom;width:2.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;width:1.7%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:43.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:37.89%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:18.75%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">/s/ David Burgstahler</p></td><td style="vertical-align:bottom;width:2.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td rowspan="2" style="vertical-align:middle;width:35.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">President and Chief Executive Officer,<br />Director<br />(Principal Executive Officer)</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">April 27, 2022</p></td></tr><tr><td style="vertical-align:top;width:43.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">David Burgstahler</p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="display:none;vertical-align:middle;width:35.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:17.05%;margin:0pt;padding:0pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:37.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:18.75%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">/s/ John Cafasso</p></td><td style="vertical-align:bottom;width:2.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:35.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">April 27, 2022</p></td></tr><tr><td style="vertical-align:top;width:43.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">John Cafasso</p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:35.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Principal Financial and Accounting Officer)</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:17.05%;margin:0pt;padding:0pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:37.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:18.75%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">/s/ Thompson Dean</p></td><td style="vertical-align:bottom;width:2.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:35.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Executive Chairman</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">April 27, 2022</p></td></tr><tr><td style="vertical-align:top;width:43.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Thompson Dean</p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:35.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:37.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">/s/ William E. Klitgaard</p></td><td style="vertical-align:bottom;width:2.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:35.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">April 27, 2022</p></td></tr><tr><td style="vertical-align:top;width:43.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">William E. Klitgaard</p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:35.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:37.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">/s/ L&#226;le White</p></td><td style="vertical-align:bottom;width:2.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:35.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">April 27, 2022</p></td></tr><tr><td style="vertical-align:top;width:43.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">L&#226;le White</p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:35.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:37.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">/s/ Wendel Barr</p></td><td style="vertical-align:bottom;width:2.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:35.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">April 27, 2022</p></td></tr><tr><td style="vertical-align:top;width:43.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Wendel Barr</p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:17.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;padding-bottom:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">II-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>2
<FILENAME>ahpa-20220416xex10d23.htm
<DESCRIPTION>EXHIBIT-10.23
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/27/2022 11:10:55 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.23</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">OMNIAB, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">INDEMNIFICATION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Indemnification Agreement (&#8220;Agreement&#8221;) is made as of ________ __, 20__ by and between OmniAb, Inc., a Delaware corporation (the &#8220;Company&#8221;), and ______________, [a member of the Board of Directors/ an officer] of the Company (&#8220;Indemnitee&#8221;). &#160;This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnification and advancement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, the Board of Directors of the Company (the &#8220;Board&#8221;) believes that highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers, or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification and advancement of expenses against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, the Board has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities. &#160;Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher premiums and with more exclusions. &#160;At the same time, directors, officers, and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself. &#160;The Bylaws and Certificate of Incorporation of the Company require indemnification of the officers and directors of the Company. &#160;Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;). &#160;The Bylaws, Certificate of Incorporation, and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification and advancement of expenses;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, the uncertainties relating to such insurance, to indemnification, and to advancement of expenses may increase the difficulty of attracting and retaining such persons;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company and its stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, this Agreement is a supplement to and in furtherance of the Bylaws, &#160;Certificate of Incorporation and any resolutions adopted pursuant thereto, and is not a substitute therefor, nor diminishes or abrogates any rights of Indemnitee thereunder; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, Indemnitee does not regard the protection available under the Bylaws, Certificate of Incorporation, DGCL and insurance as adequate in the present circumstances, and may not be willing to serve or continue to serve as an officer or director without adequate additional protection, and the Company desires Indemnitee to serve or continue to serve in such capacity. &#160;Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that Indemnitee be so indemnified and be advanced expenses.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 1.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Services to the Company.</u><font style="font-size:12pt;"> Indemnitee agrees to serve as a [director/officer] of the Company. &#160;Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law). &#160;This Agreement does not create any obligation on the Company to continue Indemnitee in such position and is not an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 2.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions.</u><font style="font-size:12pt;"> As used in this Agreement:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">&#8220;Agent&#8221; means any person who is authorized by the Company or an Enterprise to act for or represent the interests of the Company or an Enterprise, respectively.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">A &#8220;Change in Control&#8221; occurs upon the earliest to occur after the date of this Agreement of any of the following events:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">i.</font><font style="display:inline-block;width:29.67pt;"></font><font style="font-size:12pt;">Acquisition of Stock by Third Party. Any Person (as defined below) is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing fifteen percent (15%) or more of the combined voting power of the Company&#8217;s then outstanding securities unless the change in relative beneficial ownership of the Company&#8217;s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">ii.</font><font style="display:inline-block;width:26.33pt;"></font><font style="font-size:12pt;">Change in Board of Directors. During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections 2(b)(i), 2(b)(iii) or 2(b)(iv)) whose election by the Board or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">2</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">iii.</font><font style="display:inline-block;width:23pt;"></font><font style="font-size:12pt;">Corporate Transactions. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 50% of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving entity;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">iv.</font><font style="display:inline-block;width:23.67pt;"></font><font style="font-size:12pt;">Liquidation. The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">v.</font><font style="display:inline-block;width:27pt;"></font><font style="font-size:12pt;">Other Events. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">vi.</font><font style="display:inline-block;width:23.67pt;"></font><font style="font-size:12pt;">For purposes of this Section 2(b), the following terms have the following meanings:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:144pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">1</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">&#8220;Exchange Act&#8221; means the Securities Exchange Act of 1934, as amended from time to time.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:144pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">2</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">&#8220;Person&#8221; has the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act; provided, however, that Person excludes (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:144pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">3</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">&#8220;Beneficial Owner&#8221; has the meaning given to such term in Rule 13d-3 under the Exchange Act; provided, however, that Beneficial Owner excludes any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of the Company with another entity.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">&#8220;Corporate Status&#8221; describes the status of a person who is or was acting as a director, officer, employee, fiduciary, or Agent of the Company or an Enterprise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:12pt;">&#8220;Disinterested Director&#8221; means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">3</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="font-size:12pt;">&#8220;Enterprise&#8221; means any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other entity for which Indemnitee is or was serving at the request of the Company as a director, officer, employee, or Agent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(f)</font></font><font style="font-size:12pt;">&#8220;Expenses&#8221; includes all reasonable attorneys&#8217; fees, retainers, court costs, transcript costs, fees of experts and other professionals, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, ERISA excise taxes and penalties, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. &#160;Expenses also include (i) Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent, and (ii) for purposes of Section 14(d) only, Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee&#8217;s rights under this Agreement, by litigation or otherwise. &#160;The parties agree that for the purposes of any advancement of Expenses for which Indemnitee has made written demand to the Company in accordance with this Agreement, all Expenses included in such demand that are certified by affidavit of Indemnitee&#8217;s counsel as being reasonable in the good faith judgment of such counsel will be presumed conclusively to be reasonable. &#160;Expenses, however, do not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(g)</font></font><font style="font-size:12pt;">&#8220;Independent Counsel&#8221; means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent: &#160;(i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. &#160;Notwithstanding the foregoing, the term &#8220;Independent Counsel&#8221; does not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&#8217;s rights under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(h)</font></font><font style="font-size:12pt;">&#8220;Potential Change in Control&#8221; means the occurrence of any of the following events: (i) the Company enters into any written or oral agreement, undertaking or arrangement, the consummation of which would result in the occurrence of a Change in Control; (ii) any Person or the Company publicly announces an intention to take or consider taking actions which if consummated would constitute a Change in Control; (iii) any Person who becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing 5% or more of the combined voting power of the Company&#8217;s then outstanding securities entitled to vote generally in the election of directors increases his beneficial ownership of such securities by 5% or more over the percentage so owned by such Person on the date hereof; or (iv) the Board adopts a resolution to the effect that, for purposes of this Agreement, a Potential Change in Control has occurred.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(i)</font></font><font style="font-size:12pt;">The term &#8220;Proceeding&#8221; includes any threatened, pending or completed action, suit, claim, counterclaim, cross claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">4</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, legislative, or investigative (formal or informal) nature, including any appeal therefrom, in which Indemnitee was, is or will be involved as a party, potential party, non-party witness or otherwise by reason of Indemnitee&#8217;s Corporate Status or by reason of any action taken by Indemnitee (or a failure to take action by Indemnitee) or of any action (or failure to act) on Indemnitee&#8217;s part while acting pursuant to Indemnitee&#8217;s Corporate Status, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification, reimbursement, or advancement of Expenses can be provided under this Agreement. &#160;A Proceeding also includes a situation the Indemnitee believes in good faith may lead to or culminate in the institution of a Proceeding.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 3.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnity in Third-Party Proceedings.</u><font style="font-size:12pt;"> The Company will indemnify Indemnitee in accordance with the provisions of this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. &#160;Pursuant to this Section 3, the Company will indemnify Indemnitee to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding had no reasonable cause to believe that Indemnitee&#8217;s conduct was unlawful.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 4.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnity in Proceedings by or in the Right of the Company.</u><font style="font-size:12pt;"> The Company will indemnify Indemnitee in accordance with the provisions of this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. &#160;Pursuant to this Section 4, the Company will indemnify Indemnitee to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company. &#160;The Company will not indemnify Indemnitee for Expenses under this Section 4 related to any claim, issue or matter in a Proceeding for which Indemnitee has been finally adjudged by a court to be liable to the Company, unless, and only to the extent that, the Delaware Court of Chancery or any court in which the Proceeding was brought determines upon application by Indemnitee that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 5.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification for Expenses of a Party Who is Wholly or Partly Successful.</u><font style="font-size:12pt;"> Notwithstanding any other provisions of this Agreement, to the fullest extent permitted by applicable law, the Company will indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee in connection with &#160;any Proceeding the extent that Indemnitee is successful, on the merits or otherwise. &#160;If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company will indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with or related to</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">5</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">each successfully resolved claim, issue or matter to the fullest extent permitted by law. &#160;For purposes of this Section 5 and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, will be deemed to be a successful result as to such claim, issue or matter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 6.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification For Expenses of a Witness.</u><font style="font-size:12pt;"> Notwithstanding any other provision of this Agreement and to the fullest extent permitted by applicable law, the Company will indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with any Proceeding to which Indemnitee is not a party but to which Indemnitee is a witness, deponent, interviewee, or otherwise asked to participate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 7.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Partial Indemnification.</u><font style="font-size:12pt;"> If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of Expenses, but not, however, for the total amount thereof, the Company will indemnify Indemnitee for the portion thereof to which Indemnitee is entitled.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 8.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Indemnification.</u><font style="font-size:12pt;"> Notwithstanding any limitation in Sections 3, 4, or 5, the Company will indemnify Indemnitee to the fullest extent permitted by applicable law (including but not limited to, the DGCL and any amendments to or replacements of the DGCL adopted after the date of this Agreement that expand the Company&#8217;s ability to indemnify its officers and directors) if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 9.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exclusions.</u><font style="font-size:12pt;"> Notwithstanding any provision in this Agreement, the Company is not obligated under this Agreement to make any indemnification payment to Indemnitee in connection with any Proceeding:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except to the extent provided in Section 15(b) and except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">for (i) an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act (as defined in Section 2(b) hereof) or similar provisions of state statutory law or common law, (ii) any reimbursement of the Company by the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act) or (iii) any reimbursement of the Company by Indemnitee of any compensation pursuant to any compensation recoupment or clawback policy adopted by the Board or the compensation committee of the Board, including but not limited to any such policy adopted to comply with stock exchange listing requirements implementing Section 10D of the Exchange Act; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">6</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Proceeding or part of any Proceeding is to enforce Indemnitee&#8217;s rights to indemnification or advancement, of Expenses, including a Proceeding (or any part of any Proceeding) initiated pursuant to Section 14 of this Agreement, (ii) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (iii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 10.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Advances of Expenses.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">The Company will advance, to the extent not prohibited by law, the Expenses incurred by Indemnitee in connection with any Proceeding (or any part of any Proceeding) not initiated by Indemnitee or any Proceeding (or any part of any Proceeding) initiated by Indemnitee if (i) the Proceeding or part of any Proceeding is to enforce Indemnitee&#8217;s rights to obtain indemnification or advancement of Expenses from the Company or Enterprise, including a proceeding initiated pursuant to Section 14 or (ii) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation. The Company will advance the Expenses within thirty (30) days after the receipt by the Company of a statement or statements requesting such advances from time to time, whether prior to or after final disposition of any Proceeding.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">Advances will be unsecured and interest free. Indemnitee undertakes to repay the amounts advanced (without interest) to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company, thus Indemnitee qualifies for advances upon the execution of this Agreement and delivery to the Company. &#160;No other form of undertaking is required other than the execution of this Agreement. &#160;The Company will make advances without regard to Indemnitee&#8217;s ability to repay the Expenses and without regard to Indemnitee&#8217;s ultimate entitlement to indemnification under the other provisions of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 11.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Procedure for Notification of Claim for Indemnification or Advancement.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">Indemnitee will notify the Company in writing of any Proceeding with respect to which Indemnitee intends to seek indemnification or advancement of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof. &#160;Indemnitee will include in the written notification to the Company a description of the nature of the Proceeding and the facts underlying the Proceeding and provide such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of such Proceeding. &#160;Indemnitee&#8217;s failure to notify the Company will not relieve the Company from any obligation it may have to Indemnitee under this Agreement, and any delay in so notifying the Company will not constitute a waiver by Indemnitee of any rights under this Agreement. &#160;The Secretary of the Company will, promptly upon receipt of such a request for indemnification or advancement, advise the Board in writing that Indemnitee has requested indemnification or advancement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">The Company will be entitled to participate in the Proceeding at its own expense.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">7</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 12.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Procedure Upon Application for Indemnification.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">Unless a Change of Control has occurred, the determination of Indemnitee&#8217;s entitlement to indemnification will be made:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">i.</font><font style="display:inline-block;width:29.67pt;"></font><font style="font-size:12pt;">by a majority vote of the Disinterested Directors, even though less than a quorum of the Board;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">ii.</font><font style="display:inline-block;width:26.33pt;"></font><font style="font-size:12pt;">by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Board;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">iii.</font><font style="display:inline-block;width:23pt;"></font><font style="font-size:12pt;"> if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by written opinion provided by Independent Counsel selected by the Board; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">iv.</font><font style="display:inline-block;width:23.67pt;"></font><font style="font-size:12pt;">if so directed by the Board, by the stockholders of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">If a Change in Control has occurred, the determination of Indemnitee&#8217;s entitlement to indemnification will be made by written opinion provided by Independent Counsel selected by Indemnitee (unless Indemnitee requests such selection be made by the Board).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">The party selecting Independent Counsel pursuant to subsection (a)(iii) or (b) of this Section 12 will provide written notice of the selection to the other party. &#160;The notified party may, within ten (10) days after receiving written notice of the selection of Independent Counsel, deliver to the selecting party a written objection to such selection; </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:12pt;">, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#8220;Independent Counsel&#8221; as defined in Section&#160;2 of this Agreement, and the objection will set forth with particularity the factual basis of such assertion. &#160;Absent a proper and timely objection, the person so selected will act as Independent Counsel. &#160;If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or the Delaware Court has determined that such objection is without merit. &#160;If, within thirty (30) days after the later of submission by Indemnitee of a written request for indemnification pursuant to Section&#160;11(a) hereof and the final disposition of the Proceeding, Independent Counsel has not been selected or, if selected, any objection to has not been resolved, either the Company or Indemnitee may petition the Delaware Court for the appointment as Independent Counsel of a person selected by such court or by such other person as such court designates. &#160;Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 14(a) of this Agreement, Independent Counsel will be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:12pt;">Indemnitee will cooperate with the person, persons or entity making the determination with respect to Indemnitee&#8217;s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. &#160;The Company will advance and pay any Expenses incurred by Indemnitee in so cooperating with the person, persons or entity making the indemnification determination irrespective of the determination as to Indemnitee&#8217;s entitlement to indemnification and the Company hereby indemnifies and agrees to hold Indemnitee</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">8</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">harmless therefrom. The Company promptly will advise Indemnitee in writing of the determination that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been denied and providing a copy of any written opinion provided to the Board by Independent Counsel.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="font-size:12pt;">If it is determined that Indemnitee is entitled to indemnification, the Company will make payment to Indemnitee within thirty (30) days after such determination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 13.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Presumptions and Effect of Certain Proceedings.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination will, to the fullest extent not prohibited by law, presume Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 11(a) of this Agreement, and the Company will, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption. &#160;Neither the failure of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, will be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">If the determination of the Indemnitee&#8217;s entitlement to indemnification has not been made pursuant to Section 12 within sixty (60) days after the later of (i) receipt by the Company of Indemnitee&#8217;s request for indemnification pursuant to Section 11(a) and (ii) the final disposition of the Proceeding for which Indemnitee requested Indemnification (the &#8220;Determination Period&#8221;), the requisite determination of entitlement to indemnification will, to the fullest extent not prohibited by law, be deemed to have been made and Indemnitee will be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law. &#160;The Determination Period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto; and provided, further, the Determination Period may be extended an additional fifteen (15) days if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section 12(a)(iv) of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">nolo contendere</u><font style="font-size:12pt;"> or its equivalent, will not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that Indemnitee&#8217;s conduct was unlawful.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">9</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:12pt;">For purposes of any determination of good faith, Indemnitee will be deemed to have acted in good faith if Indemnitee acted based on the records or books of account of the Company, its subsidiaries, or an Enterprise, including financial statements, or on information supplied to Indemnitee by the directors or officers of the Company, its subsidiaries, or an Enterprise in the course of their duties, or on the advice of legal counsel for the Company, its subsidiaries, or an Enterprise or on information or records given or reports made to the Company or an Enterprise by an independent certified public accountant or by an appraiser, financial advisor or other expert selected with reasonable care by or on behalf of the Company, its subsidiaries, or an Enterprise. &#160;Further, Indemnitee will be deemed to have acted in a manner &#8220;not opposed to the best interests of the Company,&#8221; as referred to in this Agreement if Indemnitee acted in good faith and in a manner Indemnitee &#160;reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan. &#160;The provisions of this Section 13(d) is not exclusive and does not limit in any way the other circumstances in which the Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="font-size:12pt;">The knowledge and/or actions, or failure to act, of any director, officer, trustee, partner, managing member, fiduciary, Agent or employee of the Enterprise may not be imputed to Indemnitee for purposes of determining Indemnitee&#8217;s right to indemnification under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 14.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remedies of Indemnitee.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">Indemnitee may commence litigation against the Company in the Delaware Court of Chancery to obtain indemnification or advancement of Expenses provided by this Agreement in the event that (i) a determination is made pursuant to Section 12 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) the Company does not advance Expenses pursuant to Section&#160;10 of this Agreement, (iii) the determination of entitlement to indemnification is not made pursuant to Section 12 of this Agreement within the Determination Period, (iv) the Company does not indemnify Indemnitee pursuant to Section&#160;5 or 6 or the second to last sentence of Section 12(d) of this Agreement within thirty (30) days after receipt by the Company of a written request therefor, (v) the Company does not indemnify Indemnitee pursuant to Section 3, 4, 7, or 8 of this Agreement within thirty (30) days after a determination has been made that Indemnitee is entitled to indemnification, or (vi) in the event that the Company or any other person takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or Proceeding designed to deny, or to recover from, the Indemnitee the benefits provided or intended to be provided to the Indemnitee hereunder. &#160;Alternatively, Indemnitee, at Indemnitee&#8217;s option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. &#160;Indemnitee must commence such Proceeding seeking an adjudication or an award in arbitration within one hundred and eighty (180) days following the date on which Indemnitee first has the right to commence such Proceeding pursuant to this Section 14(a); </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:12pt;">, that the foregoing clause does not apply in respect of a Proceeding brought by Indemnitee to enforce Indemnitee&#8217;s rights under Section&#160;5 of this Agreement. &#160;The Company will not oppose Indemnitee&#8217;s right to seek any such adjudication or award in arbitration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">If a determination is made pursuant to Section 12 of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">10</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">pursuant to this Section&#160;14 will be conducted in all respects as a </font><i style="font-size:12pt;font-style:italic;">de novo</i><font style="font-size:12pt;"> trial, or arbitration, on the merits and Indemnitee may not be prejudiced by reason of that adverse determination. &#160;In any judicial proceeding or arbitration commenced pursuant to this Section 14 the Company will have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be and will not introduce evidence of the determination made pursuant to Section 12 of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">If a determination is made pursuant to Section&#160;12 of this Agreement that Indemnitee is entitled to indemnification, the Company will be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section&#160;14, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:12pt;">The Company is, to the fullest extent not prohibited by law, precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 14 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and will stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="font-size:12pt;">It is the intent of the Company that, to the fullest extent permitted by law, the Indemnitee not be required to incur legal fees or other Expenses associated with the interpretation, enforcement or defense of Indemnitee&#8217;s rights under this Agreement by litigation or otherwise because the cost and expense thereof would substantially detract from the benefits intended to be extended to the Indemnitee hereunder. &#160;The Company, to the fullest extent permitted by law, will (within thirty (30) days after receipt by the Company of a written request therefor) advance to Indemnitee such Expenses which are incurred by Indemnitee in connection with any action concerning this Agreement, Indemnitee&#8217;s right to indemnification or advancement of Expenses from the Company, or concerning any directors&#8217; and officers&#8217; liability insurance policies maintained by the Company, and will indemnify Indemnitee against any and all such Expenses unless the court determines that each of the Indemnitee&#8217;s claims in such Proceeding were made in bad faith or were frivolous or are prohibited by law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 15.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-exclusivity; Survival of Rights; Insurance; Subrogation.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">The indemnification and advancement of Expenses provided by this Agreement are not exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the Bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. &#160;The indemnification and advancement of Expenses provided by this Agreement may not be limited or restricted by any amendment, alteration or repeal of this Agreement in any way with respect to any action taken or omitted by &#160;Indemnitee in Indemnitee&#8217;s Corporate Status occurring prior to any amendment, alteration or repeal of this Agreement. &#160;To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Bylaws, Certificate of Incorporation, or this Agreement, it is the intent of the parties hereto that Indemnitee enjoy by this Agreement the greater benefits so afforded by such change. &#160;No right or remedy herein conferred is intended to be exclusive of any other right or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">11</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">remedy, and every other right and remedy is cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. &#160;The assertion or employment of any right or remedy hereunder, or otherwise, will not prevent the concurrent assertion or employment of any other right or remedy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">The Company hereby acknowledges that Indemnitee may have certain rights to indemnification, advancement of Expenses and/or insurance provided by one or more other Persons with whom or which Indemnitee may be associated. &#160;The relationship between the Company and such other Persons, other than an Enterprise, with respect to the Indemnitee&#8217;s rights to indemnification, advancement of Expenses, and insurance is described by this subsection, subject to the provisions of subsection (d) of this Section 15 with respect to a Proceeding concerning Indemnitee&#8217;s Corporate Status with an Enterprise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">i.</font><font style="display:inline-block;width:29.67pt;"></font><font style="font-size:12pt;">The Company hereby acknowledges and agrees:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">1)</font><font style="display:inline-block;width:26pt;"></font><font style="font-size:12pt;">the Company is the indemnitor of first resort with respect to any request for indemnification or advancement of Expenses made pursuant to this Agreement concerning any Proceeding arising from or related to Indemnitee&#8217;s Corporate Status with the Company;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2)</font><font style="display:inline-block;width:26pt;"></font><font style="font-size:12pt;">the Company is primarily liable for all indemnification and indemnification or advancement of Expenses obligations for any Proceeding arising from or related to Indemnitee&#8217;s Corporate Status, whether created by law, organizational or constituent documents, contract (including this Agreement) or otherwise;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">3)</font><font style="display:inline-block;width:26pt;"></font><font style="font-size:12pt;">any obligation of any other Persons with whom or which Indemnitee may be associated to indemnify Indemnitee and/or advance Expenses to Indemnitee in respect of any proceeding are secondary to the obligations of the Company&#8217;s obligations;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4)</font><font style="display:inline-block;width:26pt;"></font><font style="font-size:12pt;">the Company will indemnify Indemnitee and advance Expenses to Indemnitee hereunder to the fullest extent provided herein without regard to any rights Indemnitee may have against any other Person with whom or which Indemnitee may be associated or insurer of any such Person; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">ii.</font><font style="display:inline-block;width:26.33pt;"></font><font style="font-size:12pt;">the Company irrevocably waives, relinquishes and releases any other Person with whom or which Indemnitee may be associated from any claim of contribution, subrogation, reimbursement, exoneration or indemnification, or any other recovery of any kind in respect of amounts paid by the Company to Indemnitee pursuant to this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">iii.</font><font style="display:inline-block;width:23pt;"></font><font style="font-size:12pt;">In the event any other Person with whom or which Indemnitee may be associated or their insurers advances or extinguishes any liability or loss for Indemnitee, the payor has a right of subrogation against the Company or its insurers for all amounts so paid which would otherwise be payable by the Company or its insurers under this Agreement. &#160;In no event will payment by any other Person with whom or which Indemnitee may be associated or their insurers affect the obligations of the Company hereunder or shift primary liability for the Company&#8217;s obligation to indemnify or advance of Expenses to any other Person with whom or which Indemnitee may be associated.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">12</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">iv.</font><font style="display:inline-block;width:23.67pt;"></font><font style="font-size:12pt;">Any indemnification or advancement of Expenses provided by any other Person with whom or which Indemnitee may be associated is specifically in excess over the Company&#8217;s obligation to indemnify and advance Expenses or any valid and collectible insurance (including but not limited to any malpractice insurance or professional errors and omissions insurance) provided by the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, or Agents of the Company, the Company will obtain a policy or policies covering Indemnitee to the maximum extent of the coverage available for any such director, officer, employee or Agent under such policy or policies, including coverage in the event the Company does not or cannot, for any reason, indemnify or advance Expenses to Indemnitee as required by this Agreement. &#160;If, at the time of the receipt of a notice of a claim pursuant to this Agreement, the Company has director and officer liability insurance in effect, the Company will give prompt notice of such claim or of the commencement of a Proceeding, as the case may be, to the insurers in accordance with the procedures set forth in the respective policies. &#160;The Company will thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies. &#160;Indemnitee agrees to assist the Company efforts to cause the insurers to pay such amounts and will comply with the terms of such policies, including selection of approved panel counsel, if required.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:12pt;">The Company&#8217;s obligation to indemnify or advance Expenses hereunder to Indemnitee for any Proceeding concerning Indemnitee&#8217;s Corporate Status with an Enterprise will be reduced by any amount Indemnitee has actually received as indemnification or advancement of Expenses from such Enterprise. The Company and Indemnitee intend that any such Enterprise (and its insurers) be the indemnitor of first resort with respect to indemnification and advancement of Expenses for any Proceeding related to or arising from Indemnitee&#8217;s Corporate Status with such Enterprise. &#160;The Company&#8217;s obligation to indemnify and advance Expenses to Indemnitee is secondary to the obligations the Enterprise or its insurers owe to Indemnitee. &#160;Indemnitee agrees to take all reasonably necessary and desirable action to obtain from an Enterprise indemnification and advancement of Expenses for any Proceeding related to or arising from Indemnitee&#8217;s Corporate Status with such Enterprise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="font-size:12pt;">In the event of any payment made by the Company under this Agreement, the Company will be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee from any Enterprise or insurance carrier. &#160;Indemnitee will execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 16.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Duration of Agreement.</u><font style="font-size:12pt;"> This Agreement continues until and terminates upon the later of: (a) ten (10) years after the date that Indemnitee ceases to have a Corporate Status or (b) one (1) year after the final termination of any Proceeding then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any Proceeding commenced by Indemnitee pursuant to Section&#160;14 of this Agreement relating thereto. &#160;The indemnification and advancement of Expenses rights provided by or granted pursuant to this Agreement are binding upon and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor by purchase, merger,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">13</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">consolidation or otherwise to all or substantially all of the business or assets of the Company), continue as to an Indemnitee who has ceased to be a director, officer, employee or Agent of the Company or of any other Enterprise, and inure to the benefit of Indemnitee and Indemnitee&#8217;s spouse, assigns, heirs, devisees, executors and administrators and other legal representatives.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 17.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability.</u><font style="font-size:12pt;"> If any provision or provisions of this Agreement is held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) will not in any way be affected or impaired thereby and remain enforceable to the fullest extent permitted by law; (b) such provision or provisions will be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) will be construed so as to give effect to the intent manifested thereby.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 18.</font></font><font style="font-size:12pt;">Interpretation. &#160;Any ambiguity in the terms of this Agreement will be resolved in favor of Indemnitee and in a manner to provide the maximum indemnification and advancement of Expenses permitted by law. &#160;The Company and Indemnitee intend that this Agreement provide to the fullest extent permitted by law for indemnification and advancement in excess of that expressly provided, without limitation, by the Certificate of Incorporation, the Bylaws, vote of the Company stockholders or disinterested directors, or applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 19.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Enforcement.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving or continuing to serve as a director or officer of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; provided, however, that this Agreement is a supplement to and in furtherance of the Certificate of Incorporation, the Bylaws and applicable law, and is not a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 20.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Modification and Waiver.</u><font style="font-size:12pt;"> No supplement, modification or amendment of this Agreement is binding unless executed in writing by the parties hereto. &#160;No waiver of any of the provisions of this Agreement will be deemed or constitutes a waiver of any other provisions of this Agreement nor will any waiver constitute a continuing waiver.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 21.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice by Indemnitee.</u><font style="font-size:12pt;"> Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">14</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company does not relieve the Company of any obligation which it may have to the Indemnitee under this Agreement or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 22.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices.</u><font style="font-size:12pt;"> All notices, requests, demands and other communications under this Agreement will be in writing and will be deemed to have been duly given if (a) delivered by hand to the other party, (b) sent by reputable overnight courier to the other party or (c) sent by facsimile transmission or electronic mail, with receipt of oral confirmation that such communication has been received:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee provides to the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">If to the Company to:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:108pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:76.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">OmniAb, Inc.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:108pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:76.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">Address:</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">5980 Horton Street, Suite 405</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 184pt;"><font style="font-size:12pt;">Emeryville, CA 94608</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:108pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:76.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">Attention:</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">Chief Legal Officer</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:108pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:76.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">Email:</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">[CBerkman]@OmniAb.com</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">or to any other address as may have been furnished to Indemnitee by the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 23.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contribution.</u><font style="font-size:12pt;"> To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, will contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault of the Company (and its directors, officers, employees and Agents) and Indemnitee in connection with such event(s) and/or transaction(s).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 24.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Applicable Law and Consent to Jurisdiction.</u><font style="font-size:12pt;"> This Agreement and the legal relations among the parties are governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. &#160;Except with respect to any arbitration commenced by Indemnitee pursuant to Section 14(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or Proceeding arising out of or in connection with this Agreement may be brought only in the Delaware Court of Chancery and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or Proceeding arising out of or in connection with this Agreement, (iii) waive any objection to the laying of venue of any such action or Proceeding in the Delaware Court, and (iv) waive, and agree not to plead or to make, any claim that any such</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">15</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">action or Proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 25.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Identical Counterparts.</u><font style="font-size:12pt;"> This Agreement may be executed in one or more counterparts, each of which will for all purposes be deemed to be an original but all of which together constitutes one and the same Agreement. &#160;Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 26.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings.</u><font style="font-size:12pt;"> The headings of this Agreement are inserted for convenience only and do not constitute part of this Agreement or affect the construction thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written.</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;</u></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:44.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">OMNIAB, INC.</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;&#160;&#160;&#160;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">INDEMNITEE</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:44.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:44.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:bottom;width:44.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:48.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:bottom;width:42.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:9.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:bottom;width:39.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Office:</font></p></td><td style="vertical-align:bottom;width:42.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Address:</font></p></td><td style="vertical-align:bottom;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:42.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:39.15%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:42.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:39.15%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">16</font><font style="font-size:12pt;">-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>3
<FILENAME>ahpa-20220416xex10d24.htm
<DESCRIPTION>EXHIBIT-10.24
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/27/2022 11:11:00 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.24</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LAB LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BETWEEN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EMERY STATION OFFICE II, LLC (LANDLORD)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AND</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CRYSTAL BIOSCIENCE, INC. (TENANT)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EMERY STATION NORTH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Emeryville, California</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:83.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.92%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE&#160;1</p></td><td style="vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">BASIC LEASE PROVISIONS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">1.1</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BASIC LEASE PROVISIONS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">1.2</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ENUMERATION OF EXHIBITS AND RIDER</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">1.3</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DEFINITIONS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 2</p></td><td style="vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">PREMISES, TERM, FAILURE TO GIVE POSSESSION, AND PARKING</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">2.1</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LEASE OF PREMISES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">2.2</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TERM</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">9</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">2.3</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FAILURE TO GIVE POSSESSION</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">9</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">2.4</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CONDITION OF PREMISES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">10</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">2.5</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PARKING</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">10</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 3</p></td><td style="vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">RENT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">11</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 4</p></td><td style="vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">RENT ADJUSTMENTS AND PAYMENTS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">11</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">4.1</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RENT ADJUSTMENTS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">11</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">4.2</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">STATEMENT OF LANDLORD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">11</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">4.3</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BOOKS AND RECORDS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">12</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">4.4</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT OR LEASE SPECIFIC TAXES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">13</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 5</p></td><td style="vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">SECURITY DEPOSIT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">13</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 6</p></td><td style="vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">SERVICES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">14</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">6.2</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ELECTRICAL SERVICES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">14</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">6.3</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ADDITIONAL AND AFTER HOUR SERVICES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">15</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">6.4</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TELEPHONE SERVICES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">15</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">6.5</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DELAYS IN FURNISHING SERVICES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">16</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">6.6</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CHOICE OF SERVICE PROVIDER</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">16</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">6.7</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SIGNAGE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">17</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 7</p></td><td style="vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">POSSESSION, USE AND CONDITION OF PREMISES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">17</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">7.1</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">POSSESSION AND USE OF PREMISES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">17</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">7.2</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD ACCESS TO PREMISES; APPROVALS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">7.3</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">QUIET ENJOYMENT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 8</p></td><td style="vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">MAINTENANCE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">8.1</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD&#8217;S MAINTENANCE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">8.2</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT&#8217;S MAINTENANCE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 9</p></td><td style="vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">ALTERATIONS AND IMPROVEMENTS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">9.1</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT ALTERATIONS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">9.2</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LIENS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE&#160;10</p></td><td style="vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">ASSIGNMENT AND SUBLETTING</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">10.1</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ASSIGNMENT AND SUBLETTING</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">10.2</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RECAPTURE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">32</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">10.3</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXCESS RENT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">33</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">10.4</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT LIABILITY</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">33</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">10.5</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ASSUMPTION AND ATTORNMENT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">10.6</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROCESSING EXPENSES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 11</p></td><td style="vertical-align:top;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">DEFAULT AND REMEDIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">11.1</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EVENTS OF DEFAULT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">11.2</p></td><td style="vertical-align:bottom;width:83.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD&#8217;S REMEDIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">35</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">11.3</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ATTORNEY&#8217;S FEES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">37</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">11.4</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BANKRUPTCY</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">38</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">11.5</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD&#8217;S DEFAULT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">39</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 12</p></td><td style="vertical-align:top;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">SURRENDER OF PREMISES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">39</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">12.1</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">IN GENERAL</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">39</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">12.2</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD&#8217;S RIGHTS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">40</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 13</p></td><td style="vertical-align:top;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">HOLDING OVER</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">40</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 14</p></td><td style="vertical-align:top;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">DAMAGE BY FIRE OR OTHER CASUALTY</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">40</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">14.1</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SUBSTANTIAL UNTENANTABILITY</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">40</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">14.2</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INSUBSTANTIAL UNTENANTABILITY</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">41</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">14.3</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RENT ABATEMENT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">42</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">14.4</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">WAIVER OF STATUTORY REMEDIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">42</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 15</p></td><td style="vertical-align:top;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">EMINENT DOMAIN</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">42</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">15.1</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TAKING OF WHOLE OR SUBSTANTIAL PART</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">42</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">15.2</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TAKING OF PART</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">42</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">15.3</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COMPENSATION</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">43</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 16</p></td><td style="vertical-align:top;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">INSURANCE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">43</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">16.1</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT&#8217;S INSURANCE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">43</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">16.2</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FORM OF POLICIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">44</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">16.3</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD&#8217;S INSURANCE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">44</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">16.4</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">WAIVER OF SUBROGATION</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">44</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">16.5</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NOTICE OF CASUALTY</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">45</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 17</p></td><td style="vertical-align:top;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">WAIVER OF CLAIMS AND INDEMNITY</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">46</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">17.1</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">WAIVER OF CLAIMS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">46</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">17.2</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INDEMNITY BY TENANT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">46</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 18</p></td><td style="vertical-align:top;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">RULES AND REGULATIONS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">47</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">18.1</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RULES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">47</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">18.2</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ENFORCEMENT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">47</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 19</p></td><td style="vertical-align:top;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">LANDLORD&#8217;S RESERVED RIGHTS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">47</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 20</p></td><td style="vertical-align:top;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">ESTOPPEL CERTIFICATE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">48</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">20.1</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">IN GENERAL</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">48</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">20.2</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ENFORCEMENT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">48</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 21</p></td><td style="vertical-align:top;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">RELOCATION OF TENANT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">48</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 22</p></td><td style="vertical-align:top;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">REAL ESTATE BROKERS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">49</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 23</p></td><td style="vertical-align:top;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">MORTGAGEE PROTECTION</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">49</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">23.1</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SUBORDINATION AND ATTORNMENT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">49</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">23.2</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MORTGAGEE PROTECTION</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">50</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE 24</p></td><td style="vertical-align:top;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">NOTICES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">50</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARTICLE&#160;25</p></td><td style="vertical-align:top;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">MISCELLANEOUS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">51</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.1</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LATE CHARGES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">51</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.2</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NO JURY TRIAL; VENUE; JURISDICTION</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">51</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.3</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DICRIMINATION</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">53</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.4</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">OPTION</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">53</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.5</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT AUTHORITY</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">53</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.6</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ENTIRE AGREEMENT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">53</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.7</p></td><td style="vertical-align:bottom;width:83.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MODIFICATION OF LEASE FOR BENEFIT OF MORTGAGEE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">53</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.8</p></td><td style="vertical-align:bottom;width:83.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXCULPATION</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">54</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.9</p></td><td style="vertical-align:bottom;width:83.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ACCORD AND SATISFACTION</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">54</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.10</p></td><td style="vertical-align:bottom;width:83.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD&#8217;S OBLIGATIONS ON SALE OF BUILDING</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">54</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.11</p></td><td style="vertical-align:bottom;width:83.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BINDING EFFECT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">54</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.12</p></td><td style="vertical-align:bottom;width:83.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CAPTIONS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">54</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.13</p></td><td style="vertical-align:bottom;width:83.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TIME; APPLICABLE LAW; CONSTRUCTION</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">55</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.14</p></td><td style="vertical-align:bottom;width:83.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ABANDONMENT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">55</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.15</p></td><td style="vertical-align:bottom;width:83.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD&#8217;S RIGHT TO PERFORM TENANT&#8217;S DUTIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">55</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.16</p></td><td style="vertical-align:bottom;width:83.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SECURITY SYSTEM</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">55</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.17</p></td><td style="vertical-align:bottom;width:83.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NO LIGHT, AIR OR VIEW EASEMENTS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">56</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.18</p></td><td style="vertical-align:bottom;width:83.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RECORDATION</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">56</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.19</p></td><td style="vertical-align:bottom;width:83.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SURVIVAL</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">56</p></td></tr><tr><td style="vertical-align:top;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;">25.20</p></td><td style="vertical-align:bottom;width:83.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RIDERS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">56</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OFFICE LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BASIC LEASE PROVISIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">1.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">BASIC LEASE PROVISIONS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of any conflict between these Basic Lease Provisions and any other Lease provision, such other Lease provision shall control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(1) BUILDING AND ADDRESS:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Emery Station North</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">5980 Horton Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Emeryville, California 94608</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(2) LANDLORD AND ADDRESS:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Emery Station Office II, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">1120 Nye Street, Suite 400</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">San Rafael, California 94901</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(3) TENANT AND CURRENT ADDRESS:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 54pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Name: Crystal Bioscience, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 54pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>State of incorporation: California</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 54pt;">Notices to Tenant shall be addressed:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 54pt;">At the Premises</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Attention: Robert Etches</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(4) DATE OF LEASE: as of ____________, 2009</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(5) LEASE TERM: Sixty (60)&#160;Months (plus any partial month following the Commencement Date).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(6) PROJECTED COMMENCEMENT DATE: February&#160;23, 2009</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(7) PROJECTED EXPIRATION DATE: The last day of the sixtieth (60th) full calendar month following the Commencement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(8) MONTHLY BASE RENT: For any partial month following the Commencement Date plus for the full twelve (12)&#160;calendar months following, Monthly Base Rent shall be $15,208.60 (said amount to be pro-rated in any partial month). Upon the start of the thirteenth (13th) full calendar month of the Term and annually thereafter, Monthly Base Rent shall increase by three percent (3%).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tenant shall prepay twelve calendar months&#8217; Monthly Base Rent (i.e. $182,503.92) as well as prepay twelve (12)&#160;calendar months of Rent Adjustment Deposits (hereafter defined) on the Date of Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(9) RENTABLE AREA OF THE PREMISES: 6,820 square feet</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(10) SUITE NUMBER: 405</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(11) SECURITY DEPOSIT: $51,352.24 (representing three (3)&#160;months&#8217; Monthly Base Rent based on the rental rate applicable to the last year of the Lease Term). The Security Deposit shall be paid on the Date of Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(12) TENANT&#8217;S USE OF PREMISES: General office and research and development use, including lab and related uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(13) PARKING: Up to ten (10)&#160;unreserved parking spaces in the Terraces garage, free of charge</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(14) BROKERS:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 18pt;">Landlord&#8217;s Broker:<font style="display:inline-block;width:13.08pt;"></font>Mike Raffetto at CB Real Estate</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 18pt;">Tenant&#8217;s Broker:<font style="display:inline-block;width:21.97pt;"></font>Rico Chung at GVA/Kidder Matthews</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(15) TENANT IMPROVEMENT ALLOWANCE: Tenant will accept the Premises in their as-is condition subject only to Landlord&#8217;s agreement, at its sole cost and expense, to provide a $25,000.00 Tenant Improvement Allowance to be applied pursuant to the Workletter Agreement (Exhibit B).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">ENUMERATION OF EXHIBITS AND RIDER</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Exhibits and Rider set forth below and attached to this Lease are incorporated in this Lease by this reference:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 0pt 24.45pt;">EXHIBIT A &#160;&#160;&#160;&#160;&#160;Plan of Premises</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 0pt 24.45pt;">EXHIBIT B &#160;&#160;&#160;&#160;&#160;Workletter Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 0pt 24.45pt;">EXHIBIT C-1 &#160;&#160;Laboratory Rules and Regulations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 0pt 24.45pt;">EXHIBIT C-2 &#160;&#160;Rules and Regulations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 0pt 24.45pt;">RIDER 1 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Extension Option</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 7.4pt 24.45pt;">RIDER 2 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Commencement Date Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">1.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DEFINITIONS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes hereof, the following terms shall have the following meanings:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">AFFILIATE: Any corporation or other business entity that is currently owned or controlled by, owns or controls, or is under common ownership or control with Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">BUILDING: The building located at the address specified in Section&#160;1.1. The Building may include office, lab, retail and other uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">COMMENCEMENT DATE: The date specified in Section&#160;1.1 as the Projected Commencement Date, unless changed by operation of Article Two.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">COMMON AREAS: All areas of the Project made available by Landlord from time to time for the general common use or benefit of the tenants of the Building, and their employees and invitees, or the public, as such areas currently exist and as they may be changed from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">DECORATION: Tenant Alterations which do not require a building permit and which do not involve any of the structural elements of the Building, or any of the Building&#8217;s systems, including its electrical, mechanical, plumbing, security, heating, ventilating, air-conditioning, communication, and fire and life safety systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">DEFAULT RATE: Two (2)&#160;percentage points above the rate then most recently announced by Bank of America N.T.&amp; S.A. at its San Francisco main office as its base lending reference rate, from time to time announced, but in no event higher than the maximum rate permitted by Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">EXPIRATION DATE: The date specified in Section&#160;1.1, as determined under Article Two.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">FORCE MAJEURE: Any accident, casualty, act of God, war or civil commotion, strike or labor troubles, or any cause whatsoever beyond the reasonable control of a party, including water shortages, energy shortages or governmental preemption in connection with an act of God, a national emergency, or by reason of Law, or by reason of the conditions of supply and demand which have been or are affected by act of God, war or other emergency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">INDEMNITEES: Collectively, Landlord, any Mortgagee or ground lessor of the Property, the property manager and the leasing manager for the Property and their respective partners, members, directors, officers, agents and employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">LAND: The parcel(s) of real estate on which the Building and Project are located.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">LANDLORD WORK: The construction or installation of improvements to the Premises, to be furnished by Landlord, as specifically described in the Workletter or exhibits attached hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">LAWS OR LAW: All laws, ordinances, rules, regulations, other requirements, orders, rulings or decisions adopted or made by any governmental body, agency, department or judicial authority having jurisdiction over the Property, the Premises or Tenant&#8217;s activities at the Premises and any covenants, conditions or restrictions of record which affect the Property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">LEASE: This instrument and all exhibits and riders attached hereto, as may be amended from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">LEASE YEAR: The twelve month period beginning on the Commencement Date and ending on the last day of the 12th full month thereafter, and each subsequent twelve month, or shorter (if applicable), period until the Expiration Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">MONTHLY BASE RENT: The monthly rent specified in Section&#160;1.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">MORTGAGEE: Any holder of a mortgage, deed of trust or other security instrument encumbering the Property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NATIONAL HOLIDAYS: New Year&#8217;s Day, Memorial Day, Independence Day, Labor Day, Thanksgiving Day and Christmas Day and other holidays recognized by the Landlord and the janitorial and other unions servicing the Building in accordance with their contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">OPERATING EXPENSES: All costs, expenses and disbursements of every kind and nature which Landlord shall pay or become obligated to pay in connection with the ownership, management, operation, maintenance, replacement and repair of the Building and the Property (including, without limitation, property management fees, costs and expenses, and the amortized portion of any Permitted Capital Expenditure, together with interest thereon, and the costs of changing utility service providers) including the cost of operating the health center and conference room in Emery Station 1 for the benefit of the Project. Operating Expenses shall not include, (i)&#160;costs of alterations of the premises of tenants of the Project, (ii)&#160;costs of capital improvements to the Project (except for amortized portion of capital improvements installed for the purpose of reducing or controlling Operating Expenses or complying with applicable Laws which were not in force or enforced against the Property as of the Commencement Date of this Lease (collectively, &#8220;Permitted Capital Expenditures&#8221;), (iii) depreciation charges, (iv)&#160;interest, amortization, attorney fees, costs of environmental investigations or reports, points, fees, and other lender costs and closing costs on any mortgage or mortgages, ground lease payments, principal payments on loans or other debt instrument encumbering the Building or the Project (except for loans for Permitted Capital Expenditures as provided above), (v) depreciation, interest, and amortization on ground rental payments, (vi)&#160;real estate brokerage and leasing commissions, (vii)&#160;advertising and marketing expenses, (viii)&#160;costs of Landlord reimbursed by insurance proceeds, or a third party. Insurance proceeds which reimburse Landlord for any casualty loss or damage which was previously passed through as an Operating Expense shall be deducted from Operating Expenses in the year in which they are received, except that any deductible amount under any insurance policy shall be included within Operating Expenses; (ix)&#160;legal fees and expenses incurred in negotiating leases of tenants or prospective tenants or other prospective occupants of the Project or enforcing lease obligations of tenants in the Project; (x)&#160;Landlord&#8217;s general corporate overhead, and general administrative expenses, including the salaries of management personnel who are not directly related to the Building or Project and primarily engaged in the operation, maintenance, and repair</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">of the Building or Project, except to the extent that those costs and expenses are included in the management fees; (xi)&#160;the cost of providing any service directly to and paid directly by any tenant; (xii)&#160;The cost of maintaining the interior portions of the Premises; the costs of maintaining the HVAC, fire sprinkler system, or other systems; security; trash disposal or janitorial services within the leased Premises, which are paid directly by Tenant; (xiii)&#160;any costs expressly excluded from Operating Expenses elsewhere in this Lease; (xiv)&#160;insurance premiums to the extent of any refunds of those premiums; and insurance deductibles in excess of commercially reasonable levels for comparable buildings; (xv)&#160;any bad debt loss, rent loss, or reserves for bad debt or rent loss; (xvi)&#160;interest or penalties resulting from: (a)&#160;late payment of any Operating Expense by Landlord due to Landlord&#8217;s negligence or willful misconduct (unless Landlord in good faith disputes a charge and subsequently loses or settles that dispute); or (b)&#160;Any amount payable by Landlord to any tenant resulting from Landlord&#8217;s default in its obligations to that tenant; (xvii)&#160;Costs, fees, and compensation paid to Landlord, or to Landlord&#8217;s subsidiaries or affiliates, for services in or to the Building or the Project to the extent that they exceed the charges for comparable services rendered by an unaffiliated third party of comparable skill, competence, stature, and reputation; (xviii)&#160;management fees in excess of three and one-half (3 1/2%) percent of the Gross Receipts from the Building; (xix)&#160;costs associated with (a)&#160;operation of the business of the ownership of the Building or Project or entity that constitutes Landlord or Landlord&#8217;s property manager, as distinguished from the cost of Building or Project operations, including the costs of partnership or corporate accounting and legal matters; defending or prosecuting any lawsuit with any mortgagee, lender, ground lessor, broker, tenant, occupant, or prospective tenant or occupant; selling or syndicating any of Landlord&#8217;s interest in the Building or Project; and disputes between Landlord and Landlord&#8217;s property manager; (b)&#160;wages, salaries, and other compensation paid to any executive employee of Landlord or Landlord&#8217;s property manager above the grade of building manager for the Building or Project (accounting is presently handled off-site); (xxi) costs arising from the presence of any Hazardous Material in or about the Premises, Building, or Real Property (including Hazardous Material in the ground, water, or soil) that was not placed in the Premises, Building, or Real Property by Tenant; (xxii)&#160;costs incurred because the Building, Project, or Common Areas violate any valid, applicable building code, regulation, or law in effect and as interpreted by government authorities before the date on which this Lease is signed. This exclusion from Operating Expenses shall include fines, penalties, interest, and the costs of repairs, replacements, alterations, or improvements necessary to make the Building, Project, or Common Areas comply with applicable past laws in effect and as interpreted by government authorities before the date on which this Lease is signed, such as sprinkler installation or requirements under the Americans with Disabilities Act of 1990 (42 USC &#167;&#167;12101-12213); (xxiii) costs of: (a)&#160;initial construction of the Building; (b)&#160;reconstruction of the Building (other than any allowable deductibles); (c) modification, alteration, or repair of any portion of the Building due to faulty construction (other than by Tenant) or latent defects in that construction where the obligation for the same is otherwise described herein as an obligation of Landlord; or (d)&#160;correcting latent defects in the Building or any equipment or fixtures appurtenant to, or used in, the Building, except as otherwise provided in this Lease; (xxiv)&#160;Costs incurred in installing, operating, and maintaining any specialty service that is not necessary for Landlord&#8217;s provision, management, maintenance, and repair of required services for the operation of the Building or Project or any associated parking facilities. The following are examples of these specialty services: observatory; broadcasting facilities (other than the life-support and security system for the Building); luncheon club, cafeteria, or other dining facility; newsstand; flower service; shoeshine service; carwash; and helicopter pad (other than the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Building&#8217;s emergency and life-safety helicopter facilities if any); provided that this exclusion shall not apply to such improvements as are required by any governmental agency or owner&#8217;s association; (xxv)&#160;any costs or expenses relating to the financing of the Building or Projectcosts made in connection with any child-care facilities, , housing replacement or linkage fees,; (xxvi) charitable or political contributions made by Landlord; (xxvii)&#160;fees or dues payable to trade associations, industry associations, or similar associations; (xxviii)&#160;entertainment, dining, or travel expenses for any purpose; (xxix)&#160;flowers, gifts, balloons, or similar items provided to any entity, including Tenant, other tenants, employees, vendors, contractors, prospective tenants, and agents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any Operating Expense, though paid in one year, relates to more than one calendar year, at the option of Landlord such expense may be proportionately allocated among such related calendar years. Operating Expenses for the Building that are not, in Landlord&#8217;s reasonable discretion, allocable solely to either the lab, office or retail portion of the Building shall be equitably allocated by Landlord between such uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">PREMISES: The space located in the Building at the Suite Number listed in Section&#160;1.1 and depicted on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u> attached hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">PROJECT or PROPERTY: The Project consists of the office building located at the street address specified in Section&#160;1.1 in Emeryville, California, associated surface and garage parking as designated by Landlord from time to time, landscaping and improvements, together with the Land, any associated interests in real property, and the personal property, fixtures, machinery, equipment, systems and apparatus located in or used in conjunction with any of the foregoing. The Project may also be referred to as the Property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">REAL PROPERTY: The Property excluding any personal property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">RENT: Collectively, Monthly Base Rent, Rent Adjustments and Rent Adjustment Deposits, and all other charges, payments, late fees or other amounts required to be paid by Tenant under this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">RENT ADJUSTMENT: Any amounts owed by Tenant for payment of Operating Expenses or Taxes. The Rent Adjustments shall be determined and paid as provided in Article Four.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">RENT ADJUSTMENT DEPOSIT: An amount equal to Landlord&#8217;s estimate of the Rent Adjustment attributable to each month of the applicable calendar year. On or before the beginning of each calendar year or with Landlord&#8217;s Statement (defined in Article Four), Landlord may estimate and notify Tenant in writing of its estimate of the Operating Expenses and of Taxes for such calendar year. Prior to the first determination by Landlord of the amount of Operating Expenses and of Taxes for the first calendar year, Landlord may estimate such amounts in the foregoing calculation. The last estimate by Landlord shall remain in effect as the applicable Rent Adjustment Deposit unless and until Landlord notifies Tenant in writing of a change, which notice may be given by Landlord from time to time during a calendar year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">RENTABLE AREA OF THE PREMISES: The amount of square footage set forth in Section&#160;1.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">SECURITY DEPOSIT: The funds specified in Section&#160;1.1, if any, deposited by Tenant with Landlord as security for Tenant&#8217;s performance of its obligations under this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">STANDARD OPERATING HOURS: Monday through Friday from 8:00 A.M. to 6:00 P.M. and Saturdays from 9:00 A.M. to 1:00 P.M., excluding National Holidays.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">SUBSTANTIALLY COMPLETE or SUBSTANTIAL COMPLETION: The completion of the Landlord Work, except for minor insubstantial details of construction, decoration or mechanical adjustments which remain to be done and which do not materially interfere with Tenant&#8217;s use or occupancy of the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TAXES: All federal, state and local governmental taxes, assessments and charges of every kind or nature, whether general, special, ordinary or extraordinary, which Landlord shall pay or become obligated to pay because of or in connection with the ownership, leasing, management, control, sale, transfer or operation of the Property or any of its components (including any personal property used in connection therewith), which may also include any rental or similar taxes levied in lieu of or in addition to general real and/or personal property taxes. For purposes hereof, Taxes for any year shall be Taxes which are assessed for any period of such year, whether or not such Taxes are billed and payable in a subsequent calendar year. There shall be included in Taxes for any year the amount of all fees, costs and expenses (including reasonable attorneys&#8217; fees) paid by Landlord during such year in seeking or obtaining any refund or reduction of Taxes. Taxes for any year shall be reduced by the net amount of any tax refund received by Landlord attributable to such year. If a special assessment payable in installments is levied against any part of the Property, Taxes for any year shall include only the installment of such assessment and any interest payable or paid during such year. Taxes shall not include any federal or state inheritance, general income, gift or estate taxes, except that if a change occurs in the method of taxation resulting in whole or in part in the substitution of any such taxes, or any other assessment, for any Taxes as above defined, such substituted taxes or assessments shall be included in the Taxes. Notwithstanding the foregoing, any real estate documentary transfer tax shall be excluded from Taxes hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TENANT ADDITIONS: Collectively, Landlord Work and Tenant Alterations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TENANT ALTERATIONS: Any alterations, improvements, additions, installations or construction in or to the Premises or any Building systems serving the Premises (excluding Landlord Work); and any supplementary air-conditioning systems installed by Landlord or by Tenant at Landlord&#8217;s request pursuant to Section&#160;6.1(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TENANT DELAY: Any event or occurrence that delays the completion of the Landlord Work which is caused by or is described as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(1) special work, changes, alterations or additions requested or made by Tenant in the design or finish in any part of the Premises after approval of the plans and specifications (as described in the Workletter);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(2) Tenant&#8217;s delay in submitting plans, supplying information, approving plans, specifications or estimates, giving authorizations or otherwise;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(3) failure to approve and pay for such Tenant Work as Landlord undertakes to complete at Tenant&#8217;s expense;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(4) the performance or completion by Tenant or any person engaged by Tenant of any work in or about the Premises; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(5) failure to perform or comply with any obligation or condition binding upon Tenant pursuant to the Workletter, including the failure to approve and pay for such Landlord Work or other items if and to the extent the Workletter provides they are to be approved or paid by Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TENANT WORK: All work installed or furnished to the Premises by Tenant pursuant to the Workletter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TENANT&#8217;S SHARE: The percentage that represents the ratio of the Rentable Area of the Premises to the Rentable Area of the Building, as determined by Landlord from time to time. Tenant acknowledges that the Rentable Area of the Building may change during the Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TERM: The term of this Lease commencing on the Commencement Date and expiring on the Expiration Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">TERMINATION DATE: The Expiration Date or such earlier date as this Lease terminates or Tenant&#8217;s right to possession of the Premises terminates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WORKLETTER: The Agreement regarding the manner of completion of Landlord Work and Tenant Work set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u> attached hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PREMISES, TERM, FAILURE TO GIVE POSSESSION, AND PARKING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LEASE OF PREMISES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(a) Landlord hereby leases to Tenant and Tenant hereby leases from Landlord the Premises for the Term and upon the terms, covenants and conditions provided in this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(b) Tenant and its employees shall have the non-exclusive right to use of the conference room located on the second floor of Emery Station I and the health center in Emery Station I (or in such other buildings in which those facilities may be located in the future), in accordance with the standard Building policy regulating such usage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(c) Concurrently with the execution of this Lease, an Affiliate of Landlord and Tenant have entered into a lease for a space in which tenant improvements for Tenant are to be constructed for Tenant by Landlord (the &#8220;Hollis Improvements&#8221;). In the event that the Hollis Improvementshave not been substantially completed (as defined in said lease) within six (6)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">months of the Commencement Date, Tenant shall have the right to terminate this Lease by delivery of ten (10)&#160;days&#8217; advance notice to Landlord; provided, that if Landlord substantially completes the Hollis Improvements prior to the expiration of such ten-day period, then Tenant&#8217;s notice of cancellation shall be null and void, and this Lease and the other lease shall remain in full force and effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TERM</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(a) The Commencement Date shall be the date determined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(1) Subject to Tenant Delay, if the Landlord Work is Substantially Complete on or before the Projected Commencement Date, then on the date which is the earlier to occur of: (a)&#160;the Projected Commencement Date, or (b)&#160;the date Tenant first occupies all or part of the Premises for the conduct of business; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(2) Subject to Tenant Delay, if the Landlord Work is not Substantially Complete by the Projected Commencement Date, then on the date on which the Landlord Work is Substantially Complete.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In either event, Tenant shall have at least ten (10)&#160;business days prior to the Commencement Date in which to move in to the suite, said days possibly occurring during Landlord&#8217;s prosecution of Landlord&#8217;s Work if reasonably acceptable to both Landlord and Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(b) Within thirty (30)&#160;days following the Commencement Date, Landlord and Tenant shall amend this Lease (the form of which is attached hereto as Rider 1) confirming the Commencement Date and the Expiration Date. If Tenant fails to execute such amendment, then the Commencement Date and the Expiration Date shall be the dates designated by Landlord in such agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2.3 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FAILURE TO GIVE POSSESSION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Landlord shall be unable to give possession of the Premises on the Projected Commencement Date by reason of the following: (i)&#160;the Building has not been sufficiently completed to make the Premises ready for occupancy, (ii)&#160;the Landlord Work is not Substantially Complete, (iii)&#160;the holding over or retention of possession of any tenant, tenants or occupants, then Landlord shall not be subject to any liability for the failure to give possession on said date. Under such circumstances the Rent reserved and covenanted to be paid herein shall not commence until ten (10)&#160;days after the Premises are delivered to Tenant by Landlord, and no such failure to give possession on the Projected Commencement Date shall affect the validity of this Lease or the obligations of the Tenant hereunder. The Lease shall be amended so that the Term shall be extended by the period of time possession is delayed. The Premises shall be deemed to be ready for Tenant&#8217;s occupancy in the event Landlord&#8217;s Work is Substantially Complete, or if the delay in the availability of the Premises for occupancy shall be due to any Tenant Delay and/or default on the part of Tenant. In the event of any dispute as to whether the Landlord Work is Substantially Complete, the decision of Landlord&#8217;s architect shall be final and binding on the parties. Notwithstanding the foregoing, if the Premises have not been delivered to Tenant within thirty (30) days following the Projected Commencement Date, Tenant shall have the right to terminate this Lease by delivery of written notice thereof to Landlord; in which event, all sums deposited by Tenant shall be restored to Tenant and neither party shall have any further obligations or rights hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2.4 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CONDITION OF PREMISES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tenant shall notify Landlord in writing within thirty (30)&#160;days after the Commencement Date of any defects in the Premises claimed by Tenant or in the materials or workmanship furnished by Landlord in completing the Landlord Work. Except for defects stated in such notice, Tenant shall be conclusively deemed to have accepted the Premises &#8220;AS IS&#8221; in the condition existing on the date Tenant first takes possession, and to have waived all claims relating to the condition of the Premises. Landlord shall proceed diligently to correct the defects stated in such notice unless Landlord disputes the existence of any such defects. In the event of any dispute as to the existence of any such defects, the decision of Landlord&#8217;s architect shall be final and binding on the parties. No agreement of Landlord to alter, remodel, decorate, clean or improve the Premises or the Real Property and no representation regarding the condition of the Premises or the Real Property has been made by or on behalf of Landlord to Tenant, except as may be specifically stated in this Lease or in the Workletter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2.5 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PARKING</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the Term as the same may be extended, Tenant may use the number of spaces specified in Section&#160;1.1 for parking, free of charge to Tenant. The locations and type of parking shall be designated by Landlord or Landlord&#8217;s parking operator from time to time. Tenant acknowledges and agrees that the parking spaces serving the Project may include tandem parking and a mixture of spaces for compact vehicles as well as full-size passenger automobiles, and that Tenant shall not use parking spaces for vehicles larger than the striped size of the parking spaces. All vehicles utilizing Tenant&#8217;s parking privileges shall prominently display identification stickers or other markers, and/or have passes or keycards for ingress and egress, as may be required and provided by Landlord or its parking operator from time to time. Tenant shall comply with any and all parking rules and regulations from time to time established by Landlord or Landlord&#8217;s parking operator, including a requirement that Tenant pay to Landlord or Landlord&#8217;s parking operator a charge for loss and replacement of passes, keycards, identification stickers or markers, and for any and all loss or other damage caused by persons or vehicles related to use of Tenant&#8217;s parking privileges. Tenant shall not allow any vehicles using Tenant&#8217;s parking privileges to be parked, loaded or unloaded except in accordance with this Section, including in the areas and in the manner designated by Landlord or its parking operator for such activities. If any vehicle is blocking the loading areas at any time and/or is persistently using the parking areas contrary to any provision of this Section and such abuse is not remedied immediately upon telephonic or other electronic notice from Landlord in the case of the loading areas and within five (5)&#160;days of delivery of written notice to Tenant thereof, Landlord or its parking operator shall have the right, in addition to all other rights and remedies of Landlord under this Lease, to remove or tow away the vehicle without further notice to Tenant, and the cost thereof shall be paid to Landlord within ten (10)&#160;days after notice from Landlord to Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Tenant agrees to pay to Landlord at the first office specified in Section&#160;1.1, or to such other persons, or at such other places designated by Landlord, without any prior demand therefor in immediately available funds and without any deduction or offset whatsoever, Rent, including Monthly Base Rent and Rent Adjustments in accordance with Article Four, during the Term. Monthly Base Rent shall be paid monthly in advance on the first day of each month of the Term, except that the first installment of Monthly Base Rent shall be paid by Tenant to Landlord concurrently with execution of this Lease. Monthly Base Rent shall be prorated for partial months within the Term. Unpaid Rent shall bear interest at the Default Rate from the date due until paid. Tenant&#8217;s covenant to pay Rent shall be independent of every other covenant in this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RENT ADJUSTMENTS AND PAYMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">4.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RENT ADJUSTMENTS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tenant shall pay to Landlord Rent Adjustments with respect to each Lease Year as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(1) The Rent Adjustment Deposit representing Tenant&#8217;s Share of Operating Expenses for the applicable Lease Year, monthly during the Term with the payment of Monthly Base Rent; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(2) The Rent Adjustment Deposit representing Tenant&#8217;s Share of Taxes for the applicable Lease Year, monthly during the Term with the payment of Monthly Base Rent; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(3) Any Rent Adjustments due in excess of the Rent Adjustment Deposits in accordance with Section&#160;4.2. Rent Adjustments due from Tenant to Landlord for any Lease Year shall be Tenant&#8217;s Share of Operating Expenses for such year and Tenant&#8217;s Share of Taxes for such year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">4.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">STATEMENT OF LANDLORD</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As soon as feasible after the expiration of each calendar year, Landlord will furnish Tenant a statement (&#8220;Landlord&#8217;s Statement&#8221;) showing the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(1) Operating Expenses and Taxes for the previous calendar year;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(2) The amount of Rent Adjustments due Landlord for the last calendar year, after credit for Rent Adjustment Deposits paid, if any; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(3) Any change in the Rent Adjustment Deposit due monthly in the current calendar year, including the amount or revised amount due for months preceding any such change pursuant to Landlord&#8217;s Statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tenant shall pay to Landlord within thirty (30)&#160;days after receipt of such statement any amounts for Rent Adjustments then due in accordance with Landlord&#8217;s Statement. Any amounts due from Landlord to Tenant pursuant to this Section shall be credited to the Rent Adjustment Deposit next coming due, or refunded to Tenant if the Term has already expired provided Tenant is not in default hereunder. No interest or penalties shall accrue on any amounts that Landlord is obligated to credit or refund to Tenant by reason of this Section&#160;4.2. Landlord&#8217;s failure to deliver Landlord&#8217;s Statement or to compute the amount of the Rent Adjustments shall not constitute a waiver by Landlord of its right to deliver such items nor constitute a waiver or release of Tenant&#8217;s obligations to pay such amounts. The Rent Adjustment Deposit shall be credited against Rent Adjustments due for the applicable calendar year. During the last complete Lease Year or during any partial Lease Year in which the Lease terminates, Landlord may include in the Rent Adjustment Deposit its estimate of Rent Adjustments which may not be finally determined until after the termination of this Lease. Tenant&#8217;s obligation to pay Rent Adjustments (and Landlord&#8217;s obligation to refund any overpayment) survive the expiration or termination of the Lease. Notwithstanding the foregoing, in no event shall the sum of Monthly Base Rent and the Rent Adjustments be less than the Monthly Base Rent payable, and if Landlord&#8217;s liability for refund exceeds the Rent Adjustments payable for one month, any excess shall carry over into the following month.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">4.3 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">BOOKS AND RECORDS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Landlord shall maintain books and records showing Operating Expenses and Taxes in accordance with generally accepted accounting and management practices, consistently applied. The Tenant or its representative (which representative shall be a certified public accountant licensed to do business in the state in which the Property is located and whose primary business is certified public accounting and who shall not be paid on a contingency basis) shall have the right, for a period of one hundred and ninety (90)&#160;days following the date upon which Landlord&#8217;s Statement is delivered to Tenant, to examine the Landlord&#8217;s books and records with respect to the items in the foregoing statement of Operating Expenses and Taxes during normal business hours, upon written notice, delivered at least three (3)&#160;business days in advance. If Tenant does not object in writing to Landlord&#8217;s Statement within thirty (30)&#160;days after Tenant&#8217;s receipt thereof,, then Landlord&#8217;s Statement shall be considered final and accepted by Tenant. If Tenant does dispute any Landlord&#8217;s Statement, and Tenant subsequently conducts a review of Landlord&#8217;s books within the 90-day period referenced above, Tenant shall deliver a copy of any such audit to Landlord at the time of its completion. If Tenant does not provide a copy of such audit to Landlord within the times outlined, it shall be deemed to have waived such right to dispute Landlord&#8217;s Statement. Any amount due to the Landlord as shown on Landlord&#8217;s Statement, whether or not disputed by Tenant as provided herein shall be paid by Tenant when due as provided above, without prejudice to any such written exception. In no event shall Tenant be permitted to examine Landlord&#8217;s records or to dispute any statement of Expenses unless Tenant has paid and continues to pay all Rent when due. Upon resolution of any dispute with respect to Operating Expenses and Taxes, Tenant shall either pay Landlord any shortfall or Landlord shall credit Tenant with respect to any overages paid by Tenant. In the event that Tenant&#8217;s audit reveals any overstatement of any Operating Expenses or Taxes of five (5%) percent or more, Landlord shall pay all reasonable, third-party costs of Tenant&#8217;s audit; otherwise, such audit shall be at Tenant&#8217;s sole cost and expense. The records obtained by Tenant shall be treated as confidential and neither Tenant nor any of its representatives or agents shall disclose or discuss the information set forth in the audit to or with any other person or entity (&#8220;Confidentiality Requirement&#8221;). Tenant shall indemnify and hold Landlord harmless for any losses or damages arising out of Tenant&#8217;s breach of the Confidentiality Requirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">4.4 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TENANT OR LEASE SPECIFIC TAXES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to Monthly Base Rent, Rent Adjustments, Rent Adjustment Deposits and other charges to be paid by Tenant, Tenant shall pay to Landlord, upon demand, any and all taxes payable by Landlord (other than federal or state inheritance, general income, gift or estate taxes) whether or not now customary or within the contemplation of the parties hereto: (a)&#160;upon, allocable to, or measured by the Rent payable hereunder, including any gross receipts tax or excise tax levied by any governmental or taxing body with respect to the receipt of such rent; or (b)&#160;upon or with respect to the possession, leasing, operation, management, maintenance, alteration, repair, use or occupancy by Tenant of the Premises or any portion thereof; or (c)&#160;upon the measured value of Tenant&#8217;s personal property located in the Premises or in any storeroom or any other place in the Premises or the Property, or the areas used in connection with the operation of the Property, it being the intention of Landlord and Tenant that, to the extent possible, such personal property taxes shall be billed to and paid directly by Tenant; (d)&#160;resulting from Landlord Work, Tenant Work or Tenant Alterations to the Premises, whether title thereto is in Landlord or Tenant; or (e)&#160;upon this transaction. Taxes paid by Tenant pursuant to this Section&#160;4.5 shall not be included in any computation of Taxes payable pursuant to Sections 4.1 and 4.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECURITY DEPOSIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tenant concurrently with the execution of this Lease shall pay to Landlord in immediately available funds the Security Deposit. The Security Deposit may be applied by Landlord to cure, in whole or part, any default of Tenant under this Lease, and upon notice by Landlord of such application, Tenant shall replenish the Security Deposit in full by paying to Landlord within ten (10)&#160;days of demand the amount so applied. Landlord&#8217;s application of the Security Deposit shall not constitute a waiver of Tenant&#8217;s default to the extent that the Security Deposit does not fully compensate Landlord for all losses, damages, costs and expenses incurred by Landlord in connection with such default and shall not prejudice any other rights or remedies available to Landlord under this Lease or by Law. Landlord shall not pay any interest on the Security Deposit. Landlord shall not be required to keep the Security Deposit separate from its general accounts. The Security Deposit shall not be deemed an advance payment of Rent or a measure of damages for any default by Tenant under this Lease, nor shall it be a bar or defense of any action that Landlord may at any time commence against Tenant. In the absence of evidence satisfactory to Landlord of an assignment of the right to receive the Security Deposit or the remaining balance thereof, Landlord may return the Security Deposit to the original Tenant, regardless of one or more assignments of this Lease. Upon the transfer of Landlord&#8217;s interest under this Lease, Landlord&#8217;s obligation to Tenant with respect to the Security Deposit shall terminate upon transfer to the transferee of the Security Deposit, or any balance thereof. If Tenant shall fully and faithfully comply with all the terms, provisions, covenants, and conditions of this Lease, the Security Deposit, or any balance thereof, shall be returned to Tenant within thirty (30)&#160;days after Landlord recovers possession of the Premises or such longer time as may be permissible under Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">SERVICES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(a) So long as the Lease is in full force and effect and Tenant has paid all Rent then due, Landlord shall furnish the following services the cost of which services shall be included in Operating Expenses:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(1) heat, ventilation and air-conditioning (&#8220;HVAC&#8221;) in the Premises as necessary in Landlord&#8217;s reasonable judgment for the comfortable occupancy of the Premises under normal business office and lab operations, subject to compliance with all applicable voluntary and mandatory regulations and Laws;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(2) tempered and cold water for use in the labs and in lavatories in common with other tenants from the regular supply of the Building;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(3) customary cleaning and janitorial services in the Premises five (5)&#160;days per week, excluding National Holidays;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(4) washing of the outside windows in the Premises weather permitting at intervals determined by Landlord; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(5) automatic passenger and swing/freight elevator service in common with other tenants of the Building. Freight elevator service will be subject to reasonable scheduling by Landlord and payment of Landlord&#8217;s standard charges.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(b) If Tenant uses heat generating machines or equipment in the Premises which generate an abnormal adverse effects on the temperature otherwise maintained by the air-cooling system or whenever the occupancy or electrical load adversely affects the temperature otherwise maintained by the air-cooling system, Landlord reserves the right to install or to require Tenant to install supplementary air-conditioning units in the Premises. Tenant shall bear all costs and expenses related to the installation, maintenance and operation of such units.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">6.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ELECTRICAL SERVICES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(a) So long as the Lease is in full force and effect and Tenant has paid all Rent then due, Landlord shall furnish to the Premises (subject to inclusion as an Operating Expense, unless such service is paid directly by Tenant to the utility provider), electric current for general office use, including normal lighting, normal business office machines and customary janitorial service. Notwithstanding any provision of the Lease to the contrary, without, in each instance, the prior written approval of Landlord, in Landlord&#8217;s prudent business judgment, Tenant shall not: (i)&#160;make any alterations or additions to the electric equipment or systems; or (ii)&#160;install or use or permit the installation or use of any computer or electronic data processing equipment in the Premises other than personal computers, laptop computers and ancillary equipment. Tenant&#8217;s use of electric current shall at no time exceed the capacity of the wiring, feeders and risers providing electric current to the Premises or the Building. The consent of Landlord to the installation of electric equipment shall not relieve Tenant from the obligation to limit usage of electricity to its capacity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(b) So long as the Lease is in full force and effect and Tenant has paid all Rent then due, Landlord shall furnish to the Premises replacement lamps, bulbs, ballasts and starters used in any normal Building lighting installed in the Premises, except that if the replacement or repair of such items is a result of negligence of Tenant, its employees, agents, servants, licensees, subtenants, contractors or invitees, such cost shall be paid by Tenant within thirty (30)&#160;days after notice from Landlord and shall not be included as part of Operating Expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">6.3 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ADDITIONAL AND AFTER HOUR SERVICES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(a) At Tenant&#8217;s written request, Landlord shall furnish additional quantities of any of the services or utilities specified in Section&#160;6.1, if Landlord can reasonably do so, on the terms set forth herein. For services or utilities requested by Tenant and furnished by Landlord, Tenant shall pay to Landlord as a charge therefor Landlord&#8217;s prevailing rates charged from time to time for such services and utilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">6.4 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TELEPHONE SERVICES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All telephone, and communication connections which Tenant may desire shall be subject to Landlord&#8217;s prior written approval, in Landlord&#8217;s reasonable discretion, and the location of all wires and the work in connection therewith shall be performed by contractors reasonably approved by Landlord and shall be subject to the direction of Landlord, except that such approval is not required as to Tenant&#8217;s telephone equipment (including cabling) within the Premises and from the Premises in a route designated by Landlord to any telephone cabinet or panel provided (as existing or as installed as part of Landlord&#8217;s Work, if any) on Tenant&#8217;s floor for Tenant&#8217;s connection to the telephone cable serving the Building so long as Tenant&#8217;s equipment does not require connections different than or additional to those to the telephone cabinet or panel provided. Except to the extent of such cabling within the Premises or from the Premises to such telephone cabinet or panel, Landlord reserves the right to designate and control the entity or entities providing telephone or other communication cable installation, removal, repair and maintenance in the Building and to restrict and control access to telephone cabinets or panels, so long as such entity is competitively priced with other similar vendors. In the event Landlord designates a particular vendor or vendors to provide such cable installation, removal, repair and maintenance for the Building, Tenant agrees to abide by and participate in such program. Tenant shall be responsible for and shall pay all costs incurred in connection with the installation of telephone cables and communication wiring in the Premises, including any hook-up, access and maintenance fees related to the installation of such wires and cables in the Premises and the commencement of service therein, and the maintenance thereafter of such wire and cables; and there shall be included in Operating Expenses for the Building all installation, removal, hook-up or maintenance costs incurred by Landlord in connection with telephone cables and communication wiring serving the Building which are not allocable to any individual users of such service but are allocable to the Building generally. If Tenant fails to maintain all telephone cables and communication wiring in the Premises and such failure affects or interferes with the operation or maintenance of any other telephone cables or communication wiring serving the Building, Landlord or any vendor hired by Landlord may enter into and upon the Premises on not less than 24 hours advance notice, and perform such repairs,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">restorations or alterations as Landlord deems necessary in order to eliminate any such interference (and Landlord may recover from Tenant all of Landlord&#8217;s costs in connection therewith). If required by Landlord, no later than the Termination Date Tenant shall remove all telephone cables and communication wiring installed by Tenant for and during Tenant&#8217;s occupancy. Tenant agrees that neither Landlord nor any of its agents or employees shall be liable to Tenant, or any of Tenant&#8217;s employees, agents, customers or invitees or anyone claiming through, by or under Tenant, for any damages, injuries, losses, expenses, claims or causes of action because of any interruption, diminution, delay or discontinuance at any time for any reason in the furnishing of any telephone or other communication service to the Premises and the Building, unless such interruption, diminution, delay or discontinuance is due to the gross negligence orintentional conduct by Landlord or its agents or employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">6.5 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DELAYS IN FURNISHING SERVICES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tenant agrees that Landlord shall not be in breach of this Lease nor be liable to Tenant for damages or otherwise, for any failure to furnish, or a delay in furnishing, or a change in the quantity or character of any service when such failure, delay or change is occasioned, in whole or in part, by repairs, improvements or mechanical breakdowns by the act or default of Tenant or other parties or by an event of Force Majeure. No such failure, delay or change shall be deemed to be an eviction or disturbance of Tenant&#8217;s use and possession of the Premises, or relieve Tenant from paying Rent or from performing any other obligations of Tenant under this Lease, without any deduction or offset. Failure to any extent to make available, or any slowdown, stoppage, or interruption of, the specified utility services resulting from any cause, including changes in service provider or Landlord&#8217;s compliance with any voluntary or similar governmental or business guidelines now or hereafter published or any requirements now or hereafter established by any governmental agency, board, or bureau having jurisdiction over the operation of the Property shall not render Landlord liable in any respect for damages to either persons, property, or business, nor be construed as an eviction of Tenant or work an abatement of Rent, nor relieve Tenant of Tenant&#8217;s obligations for fulfillment of any covenant or agreement hereof. Should any equipment or machinery furnished by Landlord break down or for any cause cease to function properly, Landlord shall use reasonable diligence to repair same promptly, but Tenant shall have no claim for abatement of Rent or damages on account of any interruption of service occasioned thereby or resulting therefrom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">6.6 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CHOICE OF SERVICE PROVIDER</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tenant acknowledges that Landlord may, at Landlord&#8217;s sole option, to the extent permitted by applicable law, elect to change, from time to time, the company or companies which provide services (including electrical service, gas service, water, telephone and technical services) to the Building, the Premises and/or its occupants. Notwithstanding anything to the contrary set forth in this Lease, Tenant acknowledges that Landlord has not and does not make any representations or warranties concerning the identity or identities of the company or companies which provide services to the Building and the Premises or its occupants and Tenant acknowledges that the choice of service providers and matters concerning the engagement and termination thereof shall be solely that of Landlord. The foregoing provision is not intended to modify, amend, change or otherwise derogate any provision of this Lease concerning the nature or type of service to be provided or any specific information concerning the amount thereof to be provided. Tenant agrees to cooperate with Landlord and each of its service providers in connection with any change in service or provider.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">6.7 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SIGNAGE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Initial Building standard signage will be installed by Landlord in the directory in the main lobby of the Building, in the listing of tenants in the elevator lobby for the floor on which the Premises is located and at Tenant&#8217;s main entry door to the Premises at Landlord&#8217;s expense. Any change in such initial signage shall be only with Landlord&#8217;s prior written consent, shall conform to Building standard signage and shall be at Tenant&#8217;s sole cost and expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 7</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">POSSESSION, USE AND CONDITION OF PREMISES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">7.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">POSSESSION AND USE OF PREMISES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(a) Tenant shall occupy and use the Premises only for the uses specified in Section&#160;1.1 to conduct Tenant&#8217;s business. Tenant shall not occupy or use the Premises (or permit the use or occupancy of the Premises) for any purpose or in any manner which: (1)&#160;is unlawful or in violation of any Law or Environmental Law; (2)&#160;may be dangerous to persons or property or which may increase the cost of (unless Tenant agrees to pay such increased cost), or invalidate, any policy of insurance carried on the Building or covering its operations; (3)&#160;is contrary to or prohibited by the terms and conditions of this Lease or the rules of the Building set forth in Article Eighteen; or (4)&#160;would tend to create or continue a nuisance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(b) Landlord shall provide Tenant with a Building Standard amount of Access Card Keys at no cost to Tenant, except that Tenant shall pay Landlord&#8217;s standard charge for additional cards if any of Tenant&#8217;s Access Key Cards are lost or stolen or not returned at the end of the Lease. .</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(c) Landlord and Tenant acknowledge that the Americans With Disabilities Act of 1990 (42 U.S.C. &#167;12101 et seq.) and regulations and guidelines promulgated thereunder, as all of the same may be amended and supplemented from time to time (collectively referred to herein as the &#8220;ADA&#8221;) establish requirements for business operations, accessibility and barrier removal, and that such requirements may or may not apply to the Premises, the Building and the Project depending on, among other things: (1)&#160;whether Tenant&#8217;s business is deemed a &#8220;public accommodation&#8221; or &#8220;commercial facility&#8221;, (2) whether such requirements are &#8220;readily achievable&#8221;, and (3)&#160;whether a given alteration affects a &#8220;primary function area&#8221; or triggers &#8220;path of travel&#8221; requirements. The parties hereby agree that: (a)&#160;Landlord shall be responsible for ADA Title III compliance in the Common Areas, except as provided below, (b)&#160;Landlord shall be responsible for ADA Title III compliance in the Premises if such requirements are triggered by or required in connection with the Landlord Work and Tenant shall be responsible for ADA Title III Compliance in the Premises except for the Landlord Work, (c)&#160;Landlord may perform, or require that Tenant perform, and Tenant shall be responsible for the cost of, ADA Title III &#8220;path of travel&#8221; requirements triggered by Tenant Additions in the Premises, and (d)&#160;Landlord may perform, or require Tenant to perform, and Tenant shall be responsible for the cost of, ADA Title III compliance in the Common Areas necessitated by the Building being deemed to be a &#8220;public accommodation&#8221; instead of a &#8220;commercial facility&#8221; as a result of Tenant&#8217;s unique use of the Premises. Tenant shall be solely responsible for requirements under Title I of the ADA relating to Tenant&#8217;s employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(d) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hazardous Materials</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(1) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u>. The following terms shall have the following meanings for purposes of this Lease:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(1) &#8220;Biohazardous Materials&#8221; means any and all substances and materials defined or referred to as a medical waste,&#8221; &#8220;biological waste,&#8221; &#8220;biohazardous waste,&#8221; &#8220;biohazardous material&#8221; or any other term of similar import under any Hazardous Materials Laws, including (but not limited to) California Health&#160;&amp; Safety Code Sections 25105 et seq., and any regulations promulgated thereunder, as amended from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(2) &#8220;Environmental Condition&#8221; means the Release of any Hazardous Materials in, over, on, under, through, from or about the Project (including, but not limited to, the Premises).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(3) &#8220;Environmental Damages&#8221; means all claims, suits, judgments, damages, losses, penalties, fines, liabilities, encumbrances, liens, costs and expenses of whatever kind or nature, contingent or otherwise, matured or unmatured, foreseeable or unforeseeable, arising out of or in connection with any Environmental Condition, including, to the extent arising out of an Environmental Condition, without limitation: (A)&#160;damages for personal injury, or for injury to Project or natural resources occurring on or off the Project, including without limitation (1)&#160;any claims brought by or on behalf of any person, (2)&#160;any loss of, lost use of, damage to or diminution in value of any Project or natural resource, and (3)&#160;costs of any investigation, remediation, removal, abatement, containment, closure, restoration or monitoring work required by any federal, state or local governmental agency or political subdivision, or otherwise reasonably necessary to protect the public health or safety, whether on or off the Project; (B)&#160;reasonable fees incurred for the services of attorneys, consultants, contractors, experts and laboratories in connection with the preparation of any feasibility studies, investigations or reports or the performance of any work described above: (C)&#160;any liability to any third person or governmental agency to indemnify such person or agency for costs expended or liabilities incurred in connection with any items described in clause (A)&#160;or (B) above; (D)&#160;any fair market or fair market rental value of the Project; and (E)&#160;the amount of any penalties, damages or costs a party is required to pay or incur in excess of that which the party otherwise would reasonably have expected to pay or incur absent the existence of the applicable Environmental Condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(4) &#8220;Handling,&#8221; when used with reference to any substance or material, includes (but is not limited to) any receipt, storage, use, generation, Release, transportation, treatment or disposal of such substance or material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(5) &#8220;Hazardous Materials&#8221; means any and all chemical, explosive, biohazardous, radioactive or otherwise toxic or hazardous materials or hazardous wastes, including without limitation any asbestos-containing materials, PCB&#8217;s. CFCs, petroleum and derivatives thereof, Radioactive Materials, Biohazardous Materials, Hazardous Wastes, any other substances defined or listed as or meeting the characteristics of a hazardous substance, hazardous material, hazardous waste, extremely hazardous waste, restricted hazardous waste, toxic substance, toxic waste, biohazardous material, biohazardous waste, biological waste, medical waste, radiation, radioactive substance, radioactive waste, or other similar term, as applicable, under any law, statute, ordinance, code, rule, regulation, directive, order, condition or other written requirement enacted, promulgated or issued by any public officer or governmental or quasi-governmental authority, whether now in force or hereafter in force at any time or from time to time to protect the environment or human health, and/or any mixed materials, substances or wastes containing more than one of the foregoing categories of materials, substances or wastes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(6) &#8220;Hazardous Materials Laws&#8221; means, collectively, (A)&#160;the Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42 U.S.C. Sections 9601-9657, (B) the Hazardous Materials Transportation Act of 1975, 49 U.S.C. Sections 1801-1812, (C) the Resource Conservation and Recovery Act of 1976, 42 U.S.C. Sections 6901-6987 (together with any amendments thereto, any regulations thereunder and any amendments to any such regulations as in effect from time to time, &#8220;RCRA&#8221;), (D) the California Carpenter-Presley-Tanner Hazardous Substance Account Act, California Health&#160;&amp; Safety Code Sections 25300 et seq., (E) the Hazardous Materials Release Response Plans and Inventory Act, California Health&#160;&amp; Safety Code Sections 25500 et seq., (F) the California Hazardous Waste Control Law, California Health&#160;&amp; Safety Code Sections 25100 et seq. (together with any amendments thereto, any regulations thereunder and any amendments to any such regulations as in effect from time to time, the &#8220;CHWCL&#8221;), (G) California Health&#160;&amp; Safety Code Sections 2501525027.8, (H) any amendments to or successor statutes to any of the foregoing, as adopted or enacted from time to time, (I)&#160;any regulations or amendments thereto promulgated pursuant to any of the foregoing from time to time, (J)&#160;any statutes, laws, ordinances, codes, regulations or other Legal Requirements relating to Biohazardous Materials, including (but not limited to) any regulations or requirements with respect to the shipping, use, decontamination and disposal thereof, and (K)&#160;any other Legal Requirement now or at any time hereafter in effect regulating, relating to or imposing liability or standards of conduct concerning any Hazardous Materials, including (but not limited to) any requirements or conditions imposed pursuant to the terms of any orders, permits, licenses, registrations or operating plans issued or approved by any governmental or quasi-governmental authority from time to time either on a Project-wide basis or in connection with any Handling of Hazardous Materials in, on or about the Premises or the Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(7) &#8220;Hazardous Wastes&#8221; means (A)&#160;any waste listed as or meeting the identified characteristics of a &#8220;hazardous waste&#8221; or terms of similar import under RCRA, (B)&#160;any waste meeting the identified characteristics of a &#8220;hazardous waste,&#8221; &#8220;extremely hazardous waste&#8221; or &#8220;restricted hazardous waste&#8221; under the CHWCL, and/or (C)&#160;any and all other substances and materials defined or referred to as a &#8220;hazardous waste&#8221; or other term of similar import under any Hazardous Materials Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(8) &#8220;Radioactive Materials&#8221; means (A)&#160;any and all substances and materials the Handling of which requires an approval, consent, permit or license from the Nuclear Regulatory Commission, (B)&#160;any and all substances and materials the Handling of which requires a Radioactive Material License or other similar approval, consent, permit or license from the State of California, and (C)&#160;any and all other substances and materials defined or referred to as &#8220;radiation,&#8221; a &#8220;radioactive material&#8221; or &#8220;radioactive waste,&#8221; or any other term of similar import under any Hazardous Materials Laws, including (but not limited to) Title 26, California Code of Regulations Section&#160;17-30100, and any statutes, regulations or other laws administered, enforced or promulgated by the Nuclear Regulatory Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(9) &#8220;Release&#8221; means any accidental or intentional spilling, leaking, pumping, pouring, emitting, discharging, injecting, escaping, leaching, migrating, dumping or disposing into the air, land, Surface water, groundwater or the environment (including without limitation the abandonment or discarding of receptacles containing any Hazardous Materials).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(10) &#8220;Tenant&#8217;s Contamination&#8221; means any Hazardous Material Release on or about the Property by Tenant and/or its agents, employees, contractors, vendors, suppliers, licensees, subtenants, and invitees (a &#8220;Tenant Party&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(11) &#8220;Landlord&#8217;s Contamination&#8221; means any hazardous materials (a)&#160;which exist in, on, under or in the vicinity of the Project as of the date of this Lease or (b)&#160;which migrate onto or beneath the Project from off-site sources during the term of the Lease or after termination of the Lease or (c)&#160;come onto, in, under or about the Project as a result of the grossly negligent acts or omissions of Landlord or its agents, servants, employees, contractors, suppliers, vendors, invitees or any other tenant in the Project. Tenant shall not be required to pay any costs with respect to the remediation or abatement of Landlord&#8217;s Contamination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">(2) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Handling of Hazardous Materials</u>. The parties acknowledge that Tenant wishes and intends to use all or a portion of the Premises as a radio/bio-pharmaceutical, research, development, preparation and dispensing facility and otherwise for the conduct by Tenant of its business in accordance with the Use, that such use, as conducted or proposed to be conducted by Tenant, would customarily include the Handling of Hazardous Materials, and that Tenant shall therefore be permitted to engage in the Handling in the Premises of necessary and reasonable quantities of Hazardous Materials customarily used in or incidental to the operation of a radio/bio pharmaceutical research, preparation and dispensing facility and the other business operations of Tenant in the manner conducted or proposed to be conducted by Tenant hereunder (&#8220;Permitted Hazardous Materials&#8221;), provided that the Handling of such Permitted Hazardous Materials by all Tenant Parties shall at all times comply with and be subject to all provisions of this Lease and all Legal Requirements, including all Hazardous Materials Laws. Without limiting the generality of the foregoing, Tenant shall comply at all times with all Hazardous Materials Laws applicable to any aspect of Tenant&#8217;s use of the Premises and the Project and of Tenant&#8217;s operations and activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:55.1pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">in, on and about the Premises and the Project, and shall ensure at all times that Tenant&#8217;s Handling of Hazardous Materials on and about the Premises does not violate (x)&#160;the terms of any governmental licenses or permits applicable to the Building (including, but not limited to, the Building Discharge Permit as defined below) or Premises or to Tenant&#8217;s Handling of any Hazardous Materials therein, or (y)&#160;any applicable requirements or restrictions relating to the occupancy classification of the Building and the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(3) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disposition or Emission of Hazardous Materials</u>. Tenant shall not Release or dispose of any Hazardous Wastes or Hazardous Materials except to the extent authorized by permit at the Premises or on the Project, but instead shall arrange for off-site disposal, under Tenant&#8217;s own name and EPA waste generator number (or other similar identifying information issued or prescribed by any other governmental authority with respect to Radioactive Materials, Biohazardous Materials or any other Hazardous Materials) and at Tenant&#8217;s sole expense, in compliance with all applicable Hazardous Materials Laws, with Landlord&#8217;s Rules and with all other applicable legal and regulatory requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(4) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Information Regarding Hazardous Materials</u>. Tenant shall provide the following information and/or documentation to Landlord in writing prior to the Commencement Date, and thereafter shall update such information and/or documentation (x)&#160;annually, in January of each calendar year, (y)&#160;upon any material change in Tenant&#8217;s Hazardous Materials inventory or in Tenant&#8217;s business operations involving Hazardous Materials, and (z)&#160;at such other times as Landlord may reasonably request in writing from time to time, which updates shall reflect any material changes in such information and/or documentation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(i) An inventory of all Hazardous Materials that Tenant receives, uses, handles, generates, transports, stores, treats or disposes of from time to time, or at the time of preparation of such inventory proposes or expects to use, handle, generate, transport, store, treat or dispose of from time to time, in connection with its operations at the Premises. Such inventory shall include, but shall separately identify, any Hazardous Wastes, Biohazardous Materials and Radioactive Materials covered by the foregoing description. If such inventory includes any Biohazardous Materials, Tenant shall also disclose in writing to Landlord the Biosafety Level designation associated with the use of such materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(ii) Copies of all then existing permits, licenses, registrations and other similar documents issued by any governmental or quasi-governmental authority that authorize any Handling of Hazardous Materials in, on or about the Premises or the Project by any Tenant Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(iii) All Material Safety Data Sheets (&#8220;MSDSs&#8221;), if any, required to be completed with respect to operations of Tenant at the Premises from time to time in accordance with Title 26, California Code of Regulations Section&#160;8-5194 or 42 U.S.C. Section&#160;11021, or any amendments thereto, and any Hazardous Materials Inventory Sheets that detail the MSDSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 18pt;">(iv) All hazardous waste manifests (as defined in Title 26, California Code of Regulations Section&#160;22-66481), if any, that Tenant is required to complete from time to time in connection with its operations at the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 18pt;">(v) A copy of any Hazardous Materials Business Plan required from time to time with respect to Tenant&#8217;s operations at the Premises pursuant to California Health&#160;&amp; Safety Code Sections 25500 et seq., and any regulations promulgated thereunder, as amended from time to time, or in connection with Tenant&#8217;s application for a business license from the City of Emeryville. If applicable law does not require Tenant to prepare a Hazardous Materials Business Plan, Tenant shall furnish to Landlord at the times and in the manner set forth above the information that would customarily be contained in a Hazardous Materials Business Plan, including (but not limited to) information regarding Tenant&#8217;s Hazardous Materials inventories. The parties acknowledge that a Hazardous Materials Business Plan would ordinarily include an emergency response plan, and that regardless of whether applicable law requires Tenant or other tenants in the Building to prepare Hazardous Materials Business Plans, Landlord in its discretion may elect to prepare a coordinated emergency response plan for the entire Building and/or for multiple Buildings on the Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 18pt;">(vi) Any Contingency Plans and Emergency Procedures required of Tenant from time to time, in connection with its operations at the Premises, pursuant to applicable law, Title 26, California Code of Regulations Sections 22-67140 et seq., and any amendments thereto, and any Training Programs and Records required under Title 26, California Code of Regulations Section&#160;22-66493, and any amendments thereto from time to time. Landlord in its discretion may elect to prepare a Contingency Plan and Emergency Procedures for the entire Building and/or for multiple Buildings on the Project, in which event, if applicable law does not require Tenant to prepare a Contingency Plan and Emergency Procedures for its operations at the Premises, Tenant shall furnish to Landlord at the times and in the manner set forth above the information that would customarily be contained in a Contingency Plan and Emergency Procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 18pt;">(vii) Copies of any biennial or other periodic reports furnished or required to be furnished to the California Department of Health Services from time to time, under applicable law, pursuant to Title 26, California Code of Regulations Section&#160;22-66493 and any amendments thereto, relating to any Hazardous Materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 18pt;">(viii) Copies of any industrial wastewater discharge permits issued to or held by Tenant from time to time in connection with its operations at the Premises. (The parties presently anticipate, however, that Tenant will not be required to maintain a separate, individual discharge permit.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 4.5pt 18pt;">(ix) Copies of any other lists, reports, studies, or inventories of Hazardous Materials or of any subcategories of materials included in Hazardous Materials that Tenant is otherwise required to prepare and file from time to time with any governmental or quasi-governmental authority in connection with Tenant&#8217;s operations at the Premises, including (but not limited to) reports filed by Tenant with the federal Food&#160;&amp; Drug Administration or any other regulatory authorities primarily in connection with the presence (or lack thereof) of any &#8220;select agents&#8221; or other Biohazardous Materials on the Premises, together with proof of filing thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 18pt;">(x) Any other information reasonably requested by Landlord in writing from time to time in connection with (A)&#160;Landlord&#8217;s monitoring (in Landlord&#8217;s reasonable discretion) and enforcement of Tenant&#8217;s obligations under this Section and of compliance with applicable Legal Requirements in connection with any Handling or Release of Hazardous Materials in the Premises or Building or on or about the Project by any Tenant Party, (B)&#160;any inspections or enforcement actions by any governmental authority pursuant to any Hazardous Materials Laws or any other Legal Requirements relating to the presence or Handling of Hazardous Materials in the Premises or Building or on or about the Project by any Tenant Party, and/or (C)&#160;Landlord&#8217;s preparation (in Landlord&#8217;s discretion) and enforcement of any reasonable rules and procedures relating to the presence or Handling by Tenant or any Tenant Party of Hazardous Materials in the Premises or Building or on or about the Project, including (but not limited to) any contingency plans or emergency response plans as described above. Except as otherwise required by Law, Landlord shall keep confidential any information supplied to Landlord by Tenant pursuant to the foregoing, provided, however, that the foregoing shall not apply to any information filed with any governmental authority or available to the public at large. Landlord may provide such information to its lenders, consultants or investors provided such entities agree to keep such information confidential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">(5) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification; Notice of Release</u>. Tenant shall be responsible for and shall indemnify, defend and hold Landlord harmless from and against all Environmental Damages to the extent arising out of or in connection with, (i)&#160;any Handling of Hazardous Materials by any Tenant Party in, on or about the Premises or the Project in violation of this Section, (ii)&#160;any breach of Tenant&#8217;s obligations under this Section or of any Hazardous Materials Laws by any Tenant Party, or (iii)&#160;the existence of any Tenant Contamination in, on or about the Premises or the Project to the extent caused by any Tenant Party, including without limitation any removal, cleanup or restoration work and materials necessary to return the Project or any improvements of whatever nature located on the Project to the condition existing prior to the Handling of Hazardous Materials in, on or about the Premises or the Project by any Tenant Party. In the event of any Tenant Contamination in, on or about the Premises or any other portion of the Project or any adjacent lands, Tenant shall promptly remedy the problem in accordance with all applicable Hazardous Materials Laws and Legal Requirements, shall give Landlord oral notice of any such non-standard or non-customary Release promptly after Tenant becomes aware of such Release, followed by written notice to Landlord within five (5)&#160;days after Tenant becomes aware of such Release, and shall furnish Landlord with concurrent copies of any and all notices, reports and other written materials filed by any Tenant Party with any governmental authority in connection with such Release. Landlord shall be responsible for and shall indemnify and hold Tenant harmless from and against all costs of any Environmental Damages due to Landlord&#8217;s Contamination or which arise during or after the Term of this Lease, as a result of the presence of, any Release of or the Handling of any Hazardous Material in, on, about or under the Premises, Building or Property, except to the extent caused by Tenant or any Tenant Party; provided that Tenant shall have the burden of reasonably demonstrating that such Hazardous Materials were not of the type used by Tenant in the Premises. Tenant shall be conclusively presumed to have met its burden to the extent that any</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:55.1pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Hazardous Materials are identified in any environmental report or other data on the date of commencement of this Lease as being present, or are not used by Tenant. Tenant shall have no obligation to remedy any Hazardous Materials contamination, nor to indemnify Landlord or any Landlord Parties therefrom, which was not caused or released by a Tenant Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">(6) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Notices</u>. Tenant shall promptly provide Landlord with copies of all notices received by Tenant relating to any actual or alleged presence or Handling by any Tenant Party of Hazardous Materials in, on or about the Premises or any other portion of the Project, including, without limitation, any notice of violation, notice of responsibility or demand for action from any federal, state or local governmental authority or official in connection with any actual or alleged presence or Handling by any Tenant Party of Hazardous Materials in or about the Premises or any other portion of the Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">(7) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Inspection by Landlord</u>. In addition to, and not in limitation of, Landlord&#8217;s rights under this Lease, upon reasonable prior request by Landlord, Tenant shall grant Landlord and its consultants, as well as any governmental authorities having jurisdiction over the Premises or over any aspect of Tenant&#8217;s use thereof, reasonable access to the Premises at reasonable times to inspect Tenant&#8217;s Handling of Hazardous Materials in, on and about the Premises, and Landlord shall not thereby incur any liability to Tenant or be deemed guilty of any disturbance of Tenant&#8217;s use or possession of the Premises by reason of such entry; provided, however that Landlord shall use reasonable efforts to minimize interference with Tenant&#8217;s use of the Premises caused by such entry. Landlord shall comply with any security precautions reasonably imposed by Tenant during any entry onto the Premises and shall minimize to the extent reasonably possible, any interference with Tenant&#8217;s use of the Premises caused by such entry. Notwithstanding Landlord&#8217;s rights of inspection and review of documents, materials and physical conditions under this Section with respect to Tenant&#8217;s Handling of Hazardous Materials, Landlord shall have no duty or obligation to perform any such inspection or review or to monitor in any way any documents, materials, physical conditions or compliance with Legal Requirements in connection with Tenant&#8217;s Handling of Hazardous Materials, and no third Party shall be entitled to rely on Landlord to conduct any such inspection, review or monitoring by reason of the provisions of this Section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">(8) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Monitoring by Landlord</u>. Landlord reserves the absolute right to monitor, in Landlord&#8217;s reasonable discretion and at Landlord&#8217;s cost (the reasonable cost of which shall be recoverable as an Operating Expense hereunder (except in the case of a breach of any of Tenant&#8217;s obligations under this Section, in which event such monitoring costs may be charged back entirely to Tenant and shall be reimbursed by Tenant to Landlord within thirty (30)&#160;days after written demand by Landlord from time to time, accompanied by supporting documentation reasonably evidencing the costs for which such reimbursement is claimed)), at such times and from time to time as Landlord in its reasonable discretion may determine, through consultants engaged by Landlord or otherwise as Landlord in its reasonable discretion may determine, (x)&#160;all aqueous and atmospheric discharges and emissions from the Premises during the Term by a Tenant Party, (y)&#160;Tenant&#8217;s compliance and the collective compliance of all tenants in the Building with requirements and restrictions relating to the occupancy classification of the Building (including, but not limited to, Hazardous Materials inventory levels of Tenant and all other tenants in the Building), and (z)&#160;Tenant&#8217;s compliance with all other requirements of this Section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:55.1pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(9) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Discovery of Discharge</u>. If Landlord, Tenant or any governmental or quasi-governmental authority discovers any Release from the Premises during the Term by a Tenant Party in violation of this Section that, in Landlord&#8217;s reasonable determination, jeopardizes the ability of the Building or the Project to meet applicable Legal Requirements or otherwise adversely affects the Building&#8217;s or the Project&#8217;s compliance with applicable discharge or emission standards, or if Landlord discovers any other breach of Tenant&#8217;s obligations under this Section, then upon receipt of written notice from Landlord or at such earlier time as Tenant obtains actual knowledge of the applicable discharge, emission or breach, Tenant at its sole expense shall within a reasonable time (x)&#160;in the case of a Release in violation of this Lease, cease the applicable discharge or emission and remediate any continuing effects of the discharge or emission until such time, if any, as Tenant demonstrates to Landlord&#8217;s reasonable satisfaction that the applicable discharge or emission is in compliance with all applicable Legal Requirements and any other applicable regulatory commitments and obligations to the satisfaction of the appropriate governmental agency with jurisdiction over the release, and (y)&#160;in the case of any other breach of Tenant&#8217;s obligations under this Section, take such corrective measures as Landlord may reasonably request in writing in order to cure or eliminate the breach as promptly as practicable and to remediate any continuing effects of the breach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(10) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Post-Occupancy Study</u>. If Tenant or any Tenant Party Handles any Hazardous Materials in, on or about the Premises or the Project during the Term of this Lease, then no later than fifteen (15)&#160;days prior to the termination or expiration of this Lease, Tenant at its sole cost and expense shall obtain and deliver to Landlord an environmental study, performed by an expert reasonably satisfactory to Landlord, evaluating the presence or absence of any Tenant Contamination in, on and about the Premises and the Property. Such study shall be based on a reasonable and prudent level of tests and investigations of the Premises and surrounding portions of the Project (if appropriate) which tests shall be conducted no earlier than the date of termination or expiration of this Lease. Liability for any remedial actions required or recommended on the basis of such study shall be allocated in accordance with the applicable provisions of this Lease. To the extent any such remedial actions are the responsibility of Tenant, Tenant at its sole expense shall promptly commence and diligently pursue to completion the required remedial actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(11) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Emergency Response Plans</u>. If Landlord in its reasonable discretion adopts any emergency response plan and/or any Contingency Plan and Emergency Procedures for the Building or for multiple Buildings on the Project as contemplated above, Landlord shall provide copies of any such plans and procedures to Tenant and, so long as such plans and procedures are reasonable and do not unreasonably interfere with Tenant&#8217;s Use at or access to the Premises or materially increase the cost incurred by Tenant with respect to the Premises, Tenant shall comply with all of the requirements of such plans and procedures to the extent applicable to Tenant and/or the Premises. If Landlord elects to adopt or materially modify any such plans or procedures that apply to the Building during the Term of this Lease, Landlord shall consult with Tenant in the course of preparing such plans, procedures or modifications in order to try to ensure that they will accurately reflect and be consistent with Tenant&#8217;s operations in the Premises, but Landlord alone shall determine, in its good faith reasonable discretion, the appropriate scope of such consultation and nothing in this paragraph shall be construed to give Tenant any right of approval or disapproval over Landlord&#8217;s adoption or modification of any such plans or procedures so long as such plans and procedures are reasonable and do not unreasonably interfere with Tenant&#8217;s Use of or access to the Premises or materially increase the cost incurred by Tenant with respect to the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(12) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Radioactive Materials</u>. Without limiting any other applicable provisions of this Section, if Tenant Handles or proposes to Handle any Radioactive Materials in or about the Premises, Tenant shall provide Landlord with copies of Tenant&#8217;s licenses or permits for such Radioactive Materials and with copies of all radiation protection programs and procedures required under applicable Legal Requirements or otherwise adopted by Tenant from time to time in connection with Tenant&#8217;s Handling of such Radioactive Materials. In addition, Tenant shall comply with any and all rules and procedures issued by Landlord in its good faith discretion from time to time with respect to the Handling of Radioactive Materials on the Project (such as, by way of example but not limitation, rules implementing a label defacement program for decayed waste destined for common trash and/or rules relating to transportation and storage of Radioactive Materials on the Project), provided that such rules and procedures shall be reasonable and not in conflict with any applicable Legal Requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(13) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Deemed Holdover Occupancy</u>. Notwithstanding any other provisions of this Lease, Tenant expressly agrees as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(i) If Tenant Handles any Radioactive Materials in or about the Premises during the term of this Lease, and another entity handling Radioactive Materials which is a prospective tenant of Landlord is legally prohibited from occupying a portion of the Premises for a use similar to the Use as long as Tenant&#8217;s permit or license for handling the same remains open, then for so long as any license or permit relating to such Radioactive Materials remains open following any otherwise applicable termination or expiration of the Term of this Lease, Tenant shall be deemed to be occupying that portion of the Premises on a holdover basis without Landlord&#8217;s consent (notwithstanding such otherwise applicable termination or expiration of the Term of this Lease) and shall be required to continue to pay Rent and other charges in accordance with the holdover provisions of this Lease solely for that portion of the premises which is covered by the Radioactive Materials license, until such time as all such Radioactive Materials licenses and permits have been fully closed out in accordance with the requirements of this Lease and with all applicable Hazardous Materials Laws and other Legal Requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(ii) If Tenant Handles any Hazardous Materials in or about the Premises during the term of this Lease and at the otherwise applicable termination or expiration of the Term of this Lease Tenant has failed to remove from the Premises and the Building all known Hazardous Materials Handled by a Tenant Party or has failed to complete any remediation or removal of Tenant&#8217;s Contamination and/or to have fully remediated, in compliance with the requirements of this Lease and with all applicable Hazardous Materials Laws and other Legal Requirements, the Tenant&#8217;s Handling and/or Release (if applicable) of any such Hazardous Materials during the Term of this Lease, then for so long as such circumstances continue to exist, Tenant shall be deemed to be occupying the Premises on a holdover basis without Landlord&#8217;s consent (notwithstanding such otherwise applicable termination or expiration of the Term of this Lease) and shall be required to continue pay Rent and other charges in accordance with the holdover provisions of this Lease until such time as all such circumstances have been fully resolved in accordance with the requirements of this Lease and with all applicable Hazardous Materials Laws and other Legal Requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(14) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival of Obligations</u>. Each party&#8217;s obligations under this Section shall survive the expiration or other termination of this Lease and shall survive any conveyance by Landlord of its interest in the Premises. The provisions of this Section and any exercise by either party of any of the rights and remedies contained herein shall be without prejudice to any other rights and remedies that such party may have under this Lease or under applicable law with respect to any Environmental Conditions and/or any Hazardous Materials with respect to any breach of the other party&#8217;s obligations under this Section. Either party&#8217;s exercise or failure to exercise, at any time or from time to time, any or all of the rights granted in this Section shall not in any way impose any liability on such party or shift from the other party to such party any responsibility or obligation imposed upon the other party under this Lease or under applicable law with respect to Hazardous Materials, Environmental Conditions and/or compliance with Legal Requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(15) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Laboratory Rules and Regulations</u>. Tenant agrees for itself and for its subtenants, employees, agents, and invitees to comply with the laboratory rules and regulations (&#8220;Laboratory Rules and Regulations&#8221;) attached to this Lease as Exhibit C-1 and with all reasonable modifications and additions thereto which Landlord may make from time to time, so long as such modifications and additions neither materially increase Tenant&#8217;s obligations nor materially diminish Tenant&#8217;s rights hereunder..</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">7.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LANDLORD ACCESS TO PREMISES; APPROVALS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a) Upon not less than 24 hours advance notice (except in an emergency, in which case only such notice as is reasonable under the circumstances shall be required), Tenant shall permit Landlord to erect, use and maintain pipes, ducts, wiring and conduits in and through the Premises, so long as Tenant&#8217;s use, layout or design of the Premises is not materially affected or altered, and Landlord or Landlord&#8217;s agents shall have the right to enter upon the Premises in the event of an emergency, or to inspect the Premises, to perform janitorial and other services, to conduct safety and other testing in the Premises and to make such repairs, alterations, improvements or additions to the Premises or the Building or other parts of the Property as Landlord may deem necessary or desirable (including all alterations, improvements and additions in connection with a change in service provider or providers). Janitorial and cleaning services shall be performed after normal business hours. Any entry or work by Landlord may be during normal business hours and Landlord shall use reasonable efforts to ensure that any entry or work shall not materially interfere with Tenant&#8217;s occupancy of the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b) If Tenant shall not be personally present to permit an entry into the Premises when for any reason an entry therein shall be necessary or permissible, Landlord (or Landlord&#8217;s agents), after attempting to notify Tenant (unless Landlord believes an emergency situation exists), may enter the Premises without rendering Landlord or its agents liable therefor, and without relieving Tenant of any obligations under this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c) Upon not less than 24 hours advance notice (except in an emergency, in which case only such notice as is reasonable under the circumstances shall be required), Landlord may enter the Premises for the purpose of conducting such inspections, tests and studies as Landlord may deem desirable or necessary to confirm Tenant&#8217;s compliance with all Laws and Environmental Laws or for other purposes necessary in Landlord&#8217;s reasonable judgment to ensure the sound condition of the Property and the systems serving the Property. Landlord&#8217;s rights under this Section&#160;7.2(c) are for Landlord&#8217;s own protection only, and Landlord has not, and shall not be deemed to have assumed, any responsibility to Tenant or any other party as a result of the exercise or non-exercise of such rights, for compliance with Laws or Environmental Laws or for the accuracy or sufficiency of any item or the quality or suitability of any item for its intended use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(d) Landlord may do any of the foregoing, or undertake any of the inspection or work described in the preceding paragraphs without such action constituting an actual or constructive eviction of Tenant, in whole or in part, or giving rise to an abatement of Rent by reason of loss or interruption of business of the Tenant, or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(e) The review, approval or consent of Landlord with respect to any item required or permitted under this Lease is for Landlord&#8217;s own protection only, and Landlord has not, and shall not be deemed to have assumed, any responsibility to Tenant or any other party, as a result of the exercise or non-exercise of such rights, for compliance with Laws or Environmental Laws or for the accuracy or sufficiency of any item or the quality or suitability of any item for its intended use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">7.3 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">QUIET ENJOYMENT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Landlord covenants, in lieu of any implied covenant of quiet possession or quiet enjoyment, that so long as Tenant is in compliance with the covenants and conditions set forth in this Lease, Tenant shall have the right to quiet enjoyment of the Premises without hindrance or interference from Landlord or those claiming through Landlord, and subject to the covenants and conditions set forth in the Lease and to the rights of any Mortgagee or ground lessor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 8</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MAINTENANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">8.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LANDLORD&#8217;S MAINTENANCE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the provisions of Articles Four, Fourteen and Fifteen, Landlord shall maintain and make necessary repairs to the foundations, roofs, exterior walls, and the structural elements of the Building (which costs shall not be included in Operating Expenses except to the extent qualifying as a Permitted Capital Expenditure), and, subject to inclusion in Operating Expenses, the electrical, plumbing, heating, ventilating, air-conditioning, mechanical, communication, security and the fire and life safety systems of the Building and those corridors, washrooms and lobbies which are Common Areas of the Building, except that: (a)&#160;Landlord shall not be responsible for the maintenance or repair of any floor or wall coverings in the Premises or any of such systems which are located within the Premises and are supplemental or special to the Building&#8217;s standard systems; and (b)&#160;the cost of performing any of said maintenance or repairs whether to the Premises or to the Building caused by the negligence of Tenant, its employees, agents, servants, licensees, subtenants, contractors or invitees, shall be paid by Tenant, subject to the waivers set forth in Section&#160;16.4. Landlord shall not be liable to Tenant for any expense, injury, loss or damage resulting from work done in or upon, or in connection with the use of, any adjacent or nearby building, land, street or alley.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">8.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TENANT&#8217;S MAINTENANCE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tenant ashall periodically inspect the Premises to identify any conditions that are dangerous or in need of maintenance or repair. Tenant shall promptly provide Landlord with notice of any such conditions. Tenant shall, at its sole cost and expense, perform all maintenance and repairs to the Premises that are not Landlord&#8217;s express responsibility under this Lease, and keep the Premises in good condition and repair, reasonable wear and tear excepted. Tenant&#8217;s repair and maintenance obligations include, without limitation, repairs to: (a)&#160;floor covering; (b)&#160;interior partitions; (c)&#160;doors; (d) the interior side of demising walls; (e)&#160;electronic, phone and data cabling and related equipment that is installed by or for the exclusive benefit of Tenant (collectively, &#8220;Cable&#8221;); (f) supplemental air conditioning units, kitchens, including hot water heaters, plumbing, and similar facilities exclusively serving Tenant; and (g)&#160;Alterations. To the extent Landlord is not reimbursed by insurance proceeds, Tenant shall reimburse Landlord for the cost of repairing damage to the Building caused by the acts of Tenant, Tenant Related Parties and their respective contractors and vendors. If Tenant fails to make any repairs to the Premises for more than 30 days after notice from Landlord (except that in the event of an emergency only such notice as is reasonable under the circumstances shall be required), Landlord may make the repairs, and Tenant shall pay the reasonable cost of the repairs, together with an administrative charge in an amount equal to 10% of the cost of the repairs. Tenant hereby waives all right to make repairs at the expense of Landlord or in lieu thereof to vacate the Premises and its other similar rights as provided in California Civil Code Sections 1932(1), 1941 and 1942 or any other Legal Requirement (whether now or hereafter in effect). In addition to the foregoing, Tenant shall be responsible for repairing all special tenant fixtures and improvements, including garbage disposals, showers, plumbing, and appliances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 9</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ALTERATIONS AND IMPROVEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TENANT ALTERATIONS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(a) Except for completion of Tenant Work undertaken by Tenant pursuant to the Workletter, the following provisions shall apply to the completion of any Tenant Alterations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(1) Tenant shall not, except as provided herein, without the prior written consent of Landlord, which consent shall not be unreasonably withheld, conditioned or delayed make or cause to be made any Tenant Alterations in or to the Premises or any Property systems serving the Premises. Prior to making any Tenant Alterations, Tenant shall give Landlord ten (10)&#160;days prior written notice to permit Landlord sufficient time to post appropriate notices of non-responsibility. Subject to all other requirements of this Article Nine, Tenant may undertake Decoration work without Landlord&#8217;s prior written consent. Tenant shall furnish Landlord with the names and addresses of all contractors and subcontractors and copies of all contracts with them. All Tenant Alterations shall be completed at such time and in such manner as Landlord may from time to time designate, and only by contractors or mechanics approved by Landlord, which approval shall not be unreasonably withheld, provided, however, that Landlord may, in its sole</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">discretion, specify the engineers and contractors to perform all work relating to the Building&#8217;s systems (including the mechanical, heating, plumbing, security, ventilating, air-conditioning, electrical, communication and the fire and life safety systems in the Building). The contractors, mechanics and engineers who may be used are further limited to those whose work will not cause or threaten to cause disharmony or interference with Landlord or other tenants in the Building and their respective agents and contractors performing work in or about the Building. Landlord may further condition its consent upon Tenant furnishing to Landlord and Landlord approving prior to the commencement of any work or delivery of materials to the Premises related to the Tenant Alterations such of the following as specified by Landlord: architectural plans and specifications, opinions from Landlord&#8217;s engineers stating that the Tenant Alterations will not in any way adversely affect the Building&#8217;s systems, necessary permits and licenses, certificates of insurance, and such other documents in such form reasonably requested by Landlord. Landlord may, in the exercise of reasonable judgment, request that Tenant provide Landlord with appropriate evidence of Tenant&#8217;s ability to complete and pay for the completion of the Tenant Alterations such as a performance bond or letter of credit. Upon completion of the Tenant Alterations, Tenant shall deliver to Landlord an as-built digitized (if available) set of plans and specifications for the Tenant Alterations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(2) Tenant shall pay the cost of all Tenant Alterations and the cost of Decorating the Premises and any work to the Property occasioned thereby. Upon completion of Tenant Alterations, Tenant shall furnish Landlord with contractors&#8217; affidavits and full and final waivers of lien and receipted bills covering all labor and materials expended and used in connection therewith and such other documentation reasonably requested by Landlord or Mortgagee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(3) Tenant agrees to complete all Tenant Alterations (i)&#160;in accordance with all Laws, Environmental Laws, all requirements of applicable insurance companies and in accordance with Landlord&#8217;s standard construction rules and regulations, and (ii)&#160;in a good and workmanlike manner with the use of good grades of materials. Tenant shall notify Landlord immediately if Tenant receives any notice of violation of any Law in connection with completion of any Tenant Alterations and shall immediately take such steps as are necessary to remedy such violation. In no event shall such supervision or right to supervise by Landlord nor shall any approvals given by Landlord under this Lease constitute any warranty by Landlord to Tenant of the adequacy of the design, workmanship or quality of such work or materials for Tenant&#8217;s intended use or of compliance with the requirements of Section&#160;9.1(a)(3)(i) and (ii)&#160;above or impose any liability upon Landlord in connection with the performance of such work.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(b) All Landlord Work and Tenant Additions whether installed by Landlord or Tenant, shall without compensation or credit to Tenant, become part of the Premises and the property of Landlord upon the expiration or earlier termination of this Lease and shall remain in the Premises, unless pursuant to Article Twelve, Tenant may remove them or is required to remove them at Landlord&#8217;s request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LIENS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tenant shall not permit any lien or claim for lien of any mechanic, laborer or supplier or any other lien to be filed against the Building, the Land, the Premises, or any other part of the Property arising out of work performed, or alleged to have been performed by, or at the direction of, or on behalf of Tenant. If any such lien or claim for lien is filed, Tenant shall within ten (10)&#160;days of receiving notice of such lien or claim (a)&#160;have such lien or claim for lien released of record or (b)&#160;deliver to Landlord a bond in form, content, amount, and issued by surety, satisfactory to Landlord, indemnifying, protecting, defending and holding harmless the Indemnitees against all costs and liabilities resulting from such lien or claim for lien and the foreclosure or attempted foreclosure thereof. If Tenant fails to take any of the above actions, Landlord, in addition to its rights and remedies under Article Eleven, without investigating the validity of such lien or claim for lien, may pay or discharge the same and Tenant shall, as payment of additional Rent hereunder, reimburse Landlord upon demand for the amount so paid by Landlord, including Landlord&#8217;s expenses and attorneys&#8217; fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 10</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ASSIGNMENT AND SUBLETTING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">10.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ASSIGNMENT AND SUBLETTING</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(a) Except as provided in subsection (d)&#160;below, without the prior written consent of Landlord, which may be withheld in Landlord&#8217;s sole discretion, Tenant may not sublease, assign, mortgage, pledge, hypothecate or otherwise transfer or permit the transfer of this Lease or the encumbering of Tenant&#8217;s interest therein in whole or in part, by operation of Law or otherwise or permit the use or occupancy of the Premises, or any part thereof, by anyone other than Tenant, provided, however, if Landlord chooses not to recapture the space proposed to be subleased or assigned as provided in Section&#160;10.2, Landlord shall not unreasonably withhold, delay or condition its consent to a subletting or assignment under this Section&#160;10.1. Tenant agrees that the provisions governing sublease and assignment set forth in this Article Ten shall be deemed to be reasonable. If Tenant desires to enter into any sublease of the Premises or assignment of this Lease, Tenant shall deliver written notice thereof to Landlord (&#8220;Tenant&#8217;s Notice&#8221;), together with the identity of the proposed subtenant or assignee and the proposed principal terms thereof and financial and other information sufficient for Landlord to make an informed judgment with respect to such proposed subtenant or assignee at least twenty (20)&#160;days prior to the commencement date of the term of the proposed sublease or assignment. Landlord shall notify Tenant in writing of its approval or disapproval of the proposed sublease or assignment or its decision to exercise its rights under Section&#160;10.2 within fifteen (15)&#160;days after receipt of Tenant&#8217;s Notice (and all required information). In no event may Tenant sublease any portion of the Premises or assign the Lease to any other tenant of the Project if Landlord has space then available that would satisfy such other tenant&#8217;s space needs. Tenant shall submit for Landlord&#8217;s approval (which approval shall not be unreasonably withheld, conditioned or delayed) any advertising which Tenant or its agents intend to use with respect to the space proposed to be sublet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(b) With respect to Landlord&#8217;s consent to an assignment or sublease, Landlord may take into consideration any factors that Landlord may deem relevant, and the reasons for which Landlord&#8217;s denial shall be deemed to be reasonable shall include, without limitation, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(1) the business reputation or creditworthiness of any proposed subtenant or assignee is not acceptable to Landlord in Landlord&#8217;s reasonable judgment; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(2) in Landlord&#8217;s reasonable judgment the proposed assignee or sublessee would diminish the value or reputation of the Building or Landlord; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(3) any proposed assignee&#8217;s or sublessee&#8217;s use of the Premises would violate Section&#160;7.1 of the Lease or would violate the provisions of any other leases of tenants in the Project; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(4) the proposed sublessee or assignee is a bona fide prospective tenant of Landlord in the Project as demonstrated by a written proposal dated within ninety (90)&#160;days prior to the date of Tenant&#8217;s request, but only if and to the extent that Landlord then has space available in the Project suitable and acceptable to the prospective sublessee or assignee; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(5) the proposed sublessee or assignee would materially increase the estimated pedestrian and vehicular traffic to and from the Premises and the Building.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(c) Any sublease or assignment shall be expressly subject to the terms and conditions of this Lease. Any subtenant or assignee shall execute such documents as Landlord may reasonably require to evidence such subtenant or assignee&#8217;s assumption of the obligations and liabilities of Tenant under this Lease to the extent applicable to that portion of the Premises sublet or assigned. Tenant shall deliver to Landlord a copy of all agreements executed by Tenant and the proposed subtenant and assignee with respect to the Premises. Landlord&#8217;s approval of a sublease, assignment, hypothecation, transfer or third party use or occupancy shall not constitute a waiver of Tenant&#8217;s obligation to obtain Landlord&#8217;s consent to further assignments or subleases, hypothecations, transfers or third party use or occupancy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(d) So long as Tenant is not entering into a transaction described herein for the purpose of avoiding or otherwise circumventing the remaining terms of this Article, Tenant may, subject to Section&#160;10.5, assign its entire interest under this Lease or sublease all or a portion of the Premises, without the consent of Landlord, to (i)&#160;an Affiliate, or (ii)&#160;a successor to Tenant by purchase or other acquisition of Tenant&#8217;s capital stock or substantially all of Tenant&#8217;s assets, merger, consolidation or reorganization, provided that all of the following conditions are satisfied: (1)&#160;Tenant is not then in Default under this Lease; (2)&#160;Tenant shall give Landlord written notice at least fifteen (15)&#160;days prior to the effective date of the proposed transfer together with the information required hereunder and such entity shall expressly assume Tenant&#8217;s obligations hereunder; (3)&#160;with respect to an assignment to an Affiliate, Tenant continues to have a net worth equal to or greater than Tenant&#8217;s net worth at the date immediately prior to such transfer; and (4)&#160;with respect to a purchase, merger, consolidation or reorganization which results in Tenant ceasing to exist as a separate legal entity, Tenant&#8217;s successor shall have a net worth equal to Tenant&#8217;s net worth at the date immediately prior to such transfer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">10.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RECAPTURE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Tenant proposes to assign this Lease in its entirety, or to sublet substantially all of the Premises for substantially all of the remaining Term hereof, Landlord shall have the option to terminate this Lease (&#8220;recapture&#8221;) effective as of the proposed commencement date of such sublease or assignment. If Landlord elects to recapture, Tenant shall surrender possession of the Premises on the effective date of recapture, such date being the Termination Date of the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">10.3 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXCESS RENT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tenant shall pay Landlord on the first day of each month during the term of the sublease or assignment, fifty percent (50%) of the amount by which the sum of all Rent and other consideration (direct or indirect) due from the subtenant or assignee for such month exceeds: (i)&#160;that portion of the Monthly Base Rent and Rent Adjustments due under this Lease for said month which is allocable to the space sublet or assigned; and (ii)&#160;the following costs and expenses for the subletting or assignment of such space: (1)&#160;brokerage commissions and attorneys&#8217; fees and expenses, (2)&#160;the actual costs paid in making any improvements or substitutions in the Premises required by any sublease or assignment; and (3) &#8220;free rent&#8221; periods, costs of any inducements or concessions given to subtenant or assignee, moving costs, and other amounts in respect of such subtenant&#8217;s or assignee&#8217;s other leases or occupancy arrangements.. All such costs and expenses shall be amortized over the term of the sublease or assignment pursuant to sound accounting principles. Notwithstanding the foregoing or any other provision of this Lease, Landlord shall not be entitled to any portion of any sums paid or payable by the sublessee or assignee attributable to (a)&#160;the fair market value of any furniture, equipment or furnishings transferred to such sublessee or assignee; (b)&#160;good will and/or the fair market value of the Tenant as an ongoing business, if the sublease or assignment occurs in connection with the sale of Tenant&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">10.4 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TENANT LIABILITY</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of any sublease or assignment, whether or not with Landlord&#8217;s consent, Tenant shall not be released or discharged from any liability, whether past, present or future, under this Lease, including any liability arising from the exercise of any renewal or expansion option, to the extent such exercise is expressly permitted by Landlord. Tenant&#8217;s liability shall remain primary, and in the event of default by any subtenant, assignee or successor of Tenant in performance or observance of any of the covenants or conditions of this Lease, Landlord may proceed directly against Tenant without the necessity of exhausting remedies against said subtenant, assignee or successor. After any assignment, Landlord may consent to subsequent assignments or subletting of this Lease, or amendments or modifications of this Lease with assignees of Tenant, without notifying Tenant, or any successor of Tenant, and without obtaining its or their consent thereto, and such action shall not relieve Tenant or any successor of Tenant of liability under this Lease but in no event shall such amendments, modifications, or further actions of Landlord occurring after the effective date of such assignment and subletting materially increase Tenant&#8217;s obligations or liability hereunder. If Landlord grants consent to such sublease or assignment, Tenant shall pay all reasonable attorneys&#8217; fees and expenses incurred by Landlord with respect to such assignment or sublease; provided that if such consent is sought in connection with a sublease or assignment not involving a change of use or alterations of the Premises the attorneys fees recoverable by Landlord shall not exceed $500. In addition, if Tenant has any options to extend the Term or to add other space to the Premises, such options shall not be available to any subtenant or assignee, directly or indirectly without Landlord&#8217;s express written consent, which may be withheld in Landlord&#8217;s sole discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">10.5 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ASSUMPTION AND ATTORNMENT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Tenant shall assign this Lease as permitted herein, the assignee shall expressly assume all of the obligations of Tenant hereunder in a written instrument satisfactory to Landlord and furnished to Landlord not later than fifteen (15)&#160;days prior to the effective date of the assignment. If Tenant shall sublease the Premises as permitted herein, Tenant shall, at Landlord&#8217;s option, within fifteen (15)&#160;days following any request by Landlord, obtain and furnish to Landlord the written agreement of such subtenant to the effect that the subtenant will attorn to Landlord and will pay all subrent directly to Landlord upon notice from Landlord of the event of a Tenant Default.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">10.6 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PROCESSING EXPENSES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tenant shall pay to Landlord, as Landlord&#8217;s cost of processing each proposed assignment or subletting (whether or not the same is ultimately approved by Landlord or consummated by Tenant), an amount equal to the sum of $750.00 for the cost of Landlord&#8217;s administrative, accounting and clerical time (collectively, &#8220;Processing Costs&#8221;). Notwithstanding anything to the contrary herein, Landlord shall not be required to process any request for Landlord&#8217;s consent to an assignment or subletting until Tenant has paid to Landlord the amount of Landlord&#8217;s estimate of the Processing Costs. When the actual amount of the Processing Costs is determined, it shall be reconciled with Landlord&#8217;s estimate, and any payments or refunds required as a result thereof shall promptly thereafter be made by the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 11</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DEFAULT AND REMEDIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">11.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EVENTS OF DEFAULT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The occurrence or existence of any one or more of the following shall constitute a &#8220;Default&#8221; by Tenant under this Lease:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(1) Tenant fails to pay any installment or other payment of Rent including Rent Adjustment Deposits or Rent Adjustments when due;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(2) Tenant fails to observe or perform any of the other covenants, conditions or provisions of this Lease or the Workletter and fails to cure such default within thirty (30)&#160;days after written notice thereof to Tenant, unless the default involves a hazardous condition, which shall be cured forthwith or unless the failure to perform is a Default for which this Lease specifies there is no cure or grace period;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(3) the interest of Tenant in this Lease is levied upon under execution or other legal process, which is not challenged within thirty (30)&#160;days following such event;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">(4) a petition is filed by or against Tenant to declare Tenant bankrupt or seeking a plan of reorganization or arrangement under any Chapter of the Bankruptcy Act, or any amendment, replacement or substitution therefor, or to delay payment of, reduce or modify Tenant&#8217;s debts, which in the case of an involuntary action is not discharged within thirty (30)&#160;days;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(5) Tenant is declared insolvent by Law or any assignment of Tenant&#8217;s property is made for the benefit of creditors;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(6) a receiver is appointed for Tenant or Tenant&#8217;s property, which appointment is not discharged within thirty (30)&#160;days;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(7) any action taken by or against Tenant to reorganize or modify Tenant&#8217;s capital structure in a materially adverse way which in the case of an involuntary action is not discharged within thirty (30)&#160;days;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(8) upon the dissolution of Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;">(9) So long as the then-landlord under the Lease dated </font><u style="font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><font style="font-size:10pt;"> between Tenant and Hollis General Partnership, an affiliate of Landlord, for the premises commonly known as 1601B 63</font><sup style="font-size:6.37pt;vertical-align:top;">rd</sup><font style="font-size:10pt;"> Street (as such premises may change over time), located at that address in Emeryville, California (the &#8220;Hollis Lease&#8221;), is an affiliate of the then-Landlord under this Lease, Tenant is in Default (beyond any applicable cure period set forth therein) under the Hollis Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">11.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LANDLORD&#8217;S REMEDIES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(a) A Default which remains uncured after notice and the expiration of any applicable grace period shall constitute a Breach of the Lease for which Landlord shall have the rights and remedies set forth in this Section&#160;11.2 and all other rights and remedies set forth in this Lease or now or hereafter allowed by Law, whether legal or equitable, and all rights and remedies of Landlord shall be cumulative and none shall exclude any other right or remedy now or hereafter allowed by applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(b) With respect to a Breach, at any time Landlord may terminate Tenant&#8217;s right to possession by written notice to Tenant stating such election. Any written notice required pursuant to Section&#160;11.1 shall constitute notice of unlawful detainer pursuant to California Code of Civil Procedure Section&#160;1161 if, at Landlord&#8217;s sole discretion, it states Landlord&#8217;s election that Tenant&#8217;s right to possession is terminated after expiration of any period required by Law or any longer period required by Section&#160;11.1. Upon the expiration of the period stated in Landlord&#8217;s written notice of termination (and unless such notice provides an option to cure within such period and Tenant cures the Default within such period), Tenant&#8217;s right to possession shall terminate and this Lease shall terminate, and Tenant shall remain liable as hereinafter provided. Upon such termination in writing of Tenant&#8217;s right to possession, Landlord shall have the right, subject to applicable Law, to re-enter the Premises and dispossess Tenant and the legal representatives of Tenant and all other occupants of the Premises by unlawful detainer or other summary proceedings, or as otherwise permitted by Law, regain possession of the Premises and remove their property (including their trade fixtures, personal property and those Tenant Additions which Tenant is required or permitted to remove under Article Twelve), but Landlord shall not be obligated to effect such removal, and such property may, at Landlord&#8217;s option, be stored elsewhere, sold or otherwise dealt with as permitted by Law, at the risk of, expense of and for the account of Tenant, and the proceeds of any sale shall be applied pursuant to Law. Landlord shall in no event</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">be responsible for the value, preservation or safekeeping of any such property. Tenant hereby waives all claims for damages that may be caused by Landlord&#8217;s removing or storing Tenant&#8217;s personal property in accordance with Law under this Section or Section&#160;12.1, and Tenant hereby indemnifies, and agrees to defend, protect and hold harmless, the Indemnitees from any and all loss, claims, demands, actions, expenses, liability and cost (including attorneys&#8217; fees and expenses) arising out of or in any way related to such removal or storage in accordance with Law. Upon such written termination of Tenant&#8217;s right to possession and this Lease, Landlord shall have the right to recover damages for Tenant&#8217;s Default as provided herein or by Law, including the following damages provided by California Civil Code Section&#160;1951.2:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(1) the worth at the time of award of the unpaid Rent which had been earned at the time of termination;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(2) the worth at the time of award of the amount by which the unpaid Rent which would have been earned after termination until the time of award exceeds the amount of such Rent loss that Tenant proves could reasonably have been avoided;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(3) the worth at the time of award of the amount by which the unpaid Rent for the balance of the term of this Lease after the time of award exceeds the amount of such Rent loss that Tenant proves could be reasonably avoided; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(4) any other amount necessary to compensate Landlord for all the detriment proximately caused by Tenant&#8217;s failure to perform its obligations under this Lease or which in the ordinary course of things would be likely to result therefrom, including, without limitation, Landlord&#8217;s unamortized costs of tenant improvements, leasing commissions and legal fees incurred in connection with entering into this Lease. The word &#8220;rent&#8221; as used in this Section&#160;11.2 shall have the same meaning as the defined term Rent in this Lease. The &#8220;worth at the time of award&#8221; of the amount referred to in clauses (1)&#160;and (2) above is computed by allowing interest at the Default Rate. The worth at the time of award of the amount referred to in clause (3)&#160;above is computed by discounting such amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of award plus one percent (1%). For the purpose of determining unpaid Rent under clause (3)&#160;above, the monthly Rent reserved in this Lease shall be deemed to be the sum of the Monthly Base Rent, monthly storage space rent, if any, and the amounts last payable by Tenant as Rent Adjustments for the calendar year in which Landlord terminated this Lease as provided hereinabove.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(c) Even if Tenant is in Default and/or has abandoned the Premises, this Lease shall continue in effect for so long as Landlord does not terminate Tenant&#8217;s right to possession by written notice as provided in Section&#160;11.2(b) above, and Landlord may enforce all its rights and remedies under this Lease, including the right to recover Rent as it becomes due under this Lease. In such event, Landlord shall have all of the rights and remedies of a landlord under California Civil Code Section&#160;1951.4 (lessor may continue Lease in effect after Tenant&#8217;s Default and abandonment and recover Rent as it becomes due, if Tenant has the right to sublet or assign, subject only to reasonable limitations), or any successor statute. During such time as Tenant is in Default, if Landlord has not terminated this Lease by written notice and if Tenant requests Landlord&#8217;s consent to an assignment of this Lease or a sublease of the Premises, subject to Landlord&#8217;s option to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">recapture pursuant to Section&#160;10.2, Landlord shall not unreasonably withhold its consent to such assignment or sublease. Tenant acknowledges and agrees that the provisions of Article Ten shall be deemed to constitute reasonable limitations of Tenant&#8217;s right to assign or sublet. Tenant acknowledges and agrees that in the absence of written notice pursuant to Section&#160;11.2(b) above terminating Tenant&#8217;s right to possession, no other act of Landlord shall constitute a termination of Tenant&#8217;s right to possession or an acceptance of Tenant&#8217;s surrender of the Premises, including acts of maintenance or preservation or efforts to relet the Premises or the appointment of a receiver upon initiative of Landlord to protect Landlord&#8217;s interest under this Lease or the withholding of consent to a subletting or assignment, or terminating a subletting or assignment, if in accordance with other provisions of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(d) In the event that Landlord seeks an injunction with respect to a breach or threatened breach by Tenant of any of the covenants, conditions or provisions of this Lease, Tenant agrees to pay the premium for any bond required in connection with such injunction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(e) Tenant hereby waives any and all rights to relief from forfeiture, redemption or reinstatement granted by Law (including California Civil Code of Procedure Sections 1174 and 1179) in the event of Tenant being evicted or dispossessed for any cause or in the event of Landlord obtaining possession of the Premises by reason of Tenant&#8217;s Default or otherwise;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(f) For purposes of Code of Civil Procedure Section&#160;1162, Tenant&#8217;s &#8220;place of residence&#8221;, &#8220;usual place of business&#8221;, &#8220;the property&#8221; and &#8220;the place where the property is situated&#8221; shall mean and be the Premises, whether or not Tenant has vacated same at the time of service, unless Tenant has provided Landlord with written notice of a different &#8220;place of residence,&#8221; &#8220;usual place of business.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(g) The voluntary or other surrender or termination of this Lease, or a mutual termination or cancellation thereof, shall not work a merger and shall terminate all or any existing assignments, subleases, subtenancies or occupancies permitted by Tenant, except if and as otherwise specified in writing by Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(h) No delay or omission in the exercise of any right or remedy of either party upon any Default or Breach by the other party, and no exercise by a party of its rights pursuant to Section&#160;25.15 to perform any duty which such party fails timely to perform, shall impair any right or remedy or be construed as a waiver. No provision of this Lease shall be deemed waived by a party unless such waiver is in writing signed by the party claimed to have waived. The waiver by any party of any breach of any provision of this Lease shall not be deemed a waiver of any subsequent breach of the same or any other provision of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">11.3 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ATTORNEY&#8217;S FEES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event any party brings any suit or other proceeding with respect to the subject matter or enforcement of this Lease, the prevailing party (as determined by the court, agency or other authority before which such suit or proceeding is commenced) shall, in addition to such other relief as may be awarded, be entitled to recover attorneys&#8217; fees as actually incurred, including court costs, expert witness fees, costs and expenses of investigation, and all attorneys&#8217; fees, costs and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">expenses in any such suit or proceeding (including in any action or participation in or in connection with any case or proceeding under the Bankruptcy Code, 11 United States Code Sections 101 et seq., or any successor statutes, in establishing or enforcing the right to indemnification, in appellate proceedings, or in connection with the enforcement or collection of any judgment obtained in any such suit or proceeding).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">11.4 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">BANKRUPTCY</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following provisions shall apply in the event of the bankruptcy or insolvency of Tenant:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(a) In connection with any proceeding under Chapter 7 of the Bankruptcy Code where the trustee of Tenant elects to assume this Lease for the purposes of assigning it, such election or assignment, may only be made upon compliance with the provisions of (b)&#160;and (c) below, which conditions Landlord and Tenant acknowledge to be commercially reasonable. In the event the trustee elects to reject this Lease then Landlord shall immediately be entitled to possession of the Premises without further obligation to Tenant or the trustee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(b) Any election to assume this Lease under Chapter 11 or 13 of the Bankruptcy Code by Tenant as debtor-in-possession or by Tenant&#8217;s trustee (the &#8220;Electing Party&#8221;) must provide for:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Electing Party to cure or provide to Landlord adequate assurance that it will cure all monetary defaults under this Lease within fifteen (15)&#160;days from the date of assumption and it will cure all nonmonetary defaults under this Lease within thirty (30)&#160;days from the date of assumption. Landlord and Tenant acknowledge such condition to be commercially reasonable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(c) If the Electing Party has assumed this Lease or elects to assign Tenant&#8217;s interest under this Lease to any other person, such interest may be assigned only if the intended assignee has provided adequate assurance of future performance (as herein defined), of all of the obligations imposed on Tenant under this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the purposes hereof, &#8220;adequate assurance of future performance&#8221; means that Landlord has ascertained that each of the following conditions has been satisfied:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(1) The assignee has submitted a current financial statement, certified by its chief financial officer, which shows a net worth and working capital in amounts sufficient to assure the future performance by the assignee of Tenant&#8217;s obligations under this Lease; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(2) Landlord has obtained consents or waivers from any third parties that may be required under a lease, mortgage, financing arrangement, or other agreement by which Landlord is bound, to enable Landlord to permit such assignment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(d) Landlord&#8217;s acceptance of rent or any other payment from any trustee, receiver, assignee, person, or other entity will not be deemed to have waived, or waive, the requirement of Landlord&#8217;s consent, Landlord&#8217;s right to terminate this Lease for any transfer of Tenant&#8217;s interest under this Lease without such consent, or Landlord&#8217;s claim for any amount of Rent due from Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">11.5 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LANDLORD&#8217;S DEFAULT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Landlord shall be in default hereunder in the event Landlord has not cured any failure of Landlord to meet its obligations hereunder within thirty (30)&#160;days after the receipt by Landlord of written notice from Tenant of the alleged failure to perform; provided that if the nature of such default is such that it cannot reasonably be cured within thirty (30)&#160;days, then Landlord shall not be in default hereunder so long as it commences such cure within such thirty (30)&#160;day period and thereafter diligently prosecutes the same to conclusion. In no event shall Tenant have the right to terminate or rescind this Lease as a result of Landlord&#8217;s default as to any covenant or agreement contained in this Lease. Tenant hereby waives such remedies of termination and rescission and hereby agrees that Tenant&#8217;s remedies for default hereunder and for breach of any promise or inducement shall be limited to a suit for damages and/or injunction. In addition, Tenant hereby covenants that, prior to the exercise of any such remedies, it will give the Mortgagee notice and a reasonable time to cure any default by Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 12</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SURRENDER OF PREMISES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">12.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IN GENERAL</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(a) Upon the Termination Date, Tenant shall surrender and vacate the Premises immediately and deliver possession thereof to Landlord in as clean, good and tenantable condition as existed at the Commencement Date, ordinary wear and tear, and damage caused by casualty or Landlord excepted; provided, however, that under no circumstances will Tenant be required to remove the Landlord Work or Tenant Work performed pursuant to the Workletter attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u>, or any Tenant Alterations as to which Landlord failed to advise Tenant of its required removal pursuant to this Section&#160;12.1(b). Tenant shall deliver to Landlord all keys to the Premises. All improvements in and to the Premises, including any Alterations (collectively, &#8220;Leasehold Improvements&#8221;) shall remain upon the Premises at the end of the Term without compensation to Tenant. Landlord, however, by written notice to Tenant in accordance with this Section&#160;12.1(b) may require Tenant, at its expense, to remove (a)&#160;any Cable installed by or for the benefit of Tenant, and (b)&#160;any Alterations that, in Landlord&#8217;s reasonable judgment, are of a nature that would require removal and repair costs that are materially in excess of the removal and repair costs associated with standard office improvements (collectively referred to as &#8220;Required Removables&#8221;). Required Removables may include, without limitation, internal stairways, raised floors, personal baths and showers, vaults, rolling file systems and structural alterations and modifications. The designated Required Removables shall be removed by Tenant before the Termination Date. Tenant shall repair damage caused by the installation or removal of Required Removables. If Tenant fails to perform its obligations in a timely manner, Landlord may perform such work at Tenant&#8217;s expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(b) Tenant, at the time it requests approval for a proposed Alteration, may request in writing that Landlord advise Tenant whether the Alteration or any portion of the Alteration is a Required Removable. Within 10 days after receipt of Tenant&#8217;s request, Landlord shall advise Tenant in writing as to which portions of the Alteration are Required Removables. If any of the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Tenant Additions which were installed by Tenant involved the lowering of ceilings, raising of floors or the installation of specialized wall or floor coverings or lights, then, unless otherwise approved by Landlord in writing, Tenant shall also be obligated to return such surfaces to their condition prior to the commencement of this Lease. Tenant shall also be required to close any staircases or other openings between floors. In the event possession of the Premises is not delivered to Landlord when required hereunder, or if Tenant shall fail to remove those items described above, Landlord may (but shall not be obligated to), at Tenant&#8217;s expense, remove any of such property and store, sell or otherwise deal with such property, and undertake, at Tenant&#8217;s expense, such restoration work as Landlord deems necessary or advisable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">12.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LANDLORD&#8217;S RIGHTS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All property which may be removed from the Premises by Landlord shall be conclusively presumed to have been abandoned by Tenant and Landlord may deal with such property as provided in Section&#160;11.2(b), including the waiver and indemnity obligations provided in that Section. Tenant shall also reimburse Landlord for all costs and expenses incurred by Landlord in removing any of Tenant Additions and in restoring the Premises to the condition required by this Lease at the Termination Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 13</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">HOLDING OVER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that Tenant holds over in possession of the Premises after the Termination Date, Tenant shall pay Landlord 150% of the monthly Rent payable for the month immediately preceding the holding over (including increases for Rent Adjustments which Landlord may reasonably estimate. Tenant shall also pay all damages sustained by Landlord by reason of such retention of possession. The provisions of this Article shall not constitute a waiver by Landlord of any re-entry rights of Landlord and Tenant&#8217;s continued occupancy of the Premises shall be as a tenancy in sufferance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 14</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DAMAGE BY FIRE OR OTHER CASUALTY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">14.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SUBSTANTIAL UNTENANTABILITY</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(a) If any fire or other casualty (whether insured or uninsured) renders all or a substantial portion of the Premises or the Building untenantable, Landlord shall, with reasonable promptness after the occurrence of such damage, estimate the length of time that will be required to substantially complete the repair and restoration and shall by notice advise Tenant of such estimate (&#8220;Landlord&#8217;s Notice&#8221;). If Landlord estimates that the amount of time required to substantially complete such repair and restoration will exceed one hundred and eighty (180)&#160;days from the date such damage occurred, then Landlord, or Tenant if all or a substantial portion of the Premises is rendered untenantable, shall have the right to terminate this Lease as of the date of such damage upon giving written notice to the other at any time within twenty (20)&#160;days after delivery of Landlord&#8217;s Notice, provided that if Landlord so chooses, Landlord&#8217;s Notice may also constitute such notice of termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(b) Unless this Lease is terminated as provided in the preceding subparagraph, Landlord shall proceed with reasonable promptness to repair and restore the Premises to its condition as existed prior to such casualty, subject to reasonable delays for insurance adjustments and Force Majeure delays, and also subject to zoning Laws and building codes then in effect. Landlord shall have no liability to Tenant, and Tenant shall not be entitled to terminate this Lease if such repairs and restoration are not in fact completed within the time period estimated by Landlord so long as Landlord shall proceed with reasonable diligence to complete such repairs and restoration. Notwithstanding the foregoing, if the required repairs and restorations are not complete by the date which is 270 days from the date of casualty, Tenant may terminate this Lease by delivery of written notice thereof to Landlord (&#8220;Tenant&#8217;s Notice&#8221;), specifying a termination date not less than ten (10)&#160;days from the date of delivery of Tenant&#8217;s Notice; provided, however, that if such repairs and restoration are completed prior to the date of termination set forth in Tenant&#8217;s Notice, then Tenant&#8217;s Notice shall be null and void and this Lease shall continue in full force and effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(c) Tenant acknowledges that Landlord shall be entitled to the full proceeds of any insurance coverage, whether carried by Landlord or Tenant, for damages to the Premises, except for those proceeds of Tenant&#8217;s insurance of its own personal property, trade fixtures and equipment which would be removable by Tenant at the Termination Date. All such insurance proceeds shall be payable to Landlord whether or not the Premises are to be repaired and restored, provided, however, if this Lease is not terminated and the parties proceed to repair and restore Tenant Additions at Tenant&#8217;s cost, to the extent Landlord received proceeds of Tenant&#8217;s insurance covering Tenant Additions, such proceeds shall be applied to reimburse Tenant for its cost of repairing and restoring Tenant Additions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(d) Notwithstanding anything to the contrary herein set forth: (i)&#160;Landlord shall have no duty pursuant to this Section to repair or restore any portion of any Tenant Additions or to expend for any repair or restoration of the Premises or Building amounts in excess of insurance proceeds paid to Landlord and available for repair or restoration; and (ii)&#160;Tenant shall not have the right to terminate this Lease pursuant to this Section if any damage or destruction was caused by the gross negligence or willful misconduct of Tenant, its agent or employees. Whether or not the Lease is terminated pursuant to this Article Fourteen, in no event shall Tenant be entitled to any compensation or damages for loss of the use of the whole or any part of the Premises or for any inconvenience or annoyance occasioned by any such damage, destruction, rebuilding or restoration of the Premises or the Building or access thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(e) Any repair or restoration of the Premises performed by Tenant shall be in accordance with the provisions of Article Nine hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">14.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">INSUBSTANTIAL UNTENANTABILITY</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Premises or the Building is damaged by a casualty but neither is rendered substantially untenantable and Landlord estimates that the time to substantially complete the repair or restoration will not exceed one hundred eighty (180)&#160;days from the date such damage occurred, then Landlord shall proceed to repair and restore the Building or the Premises, other than Tenant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additions, with reasonable promptness, unless such damage is to the Premises and occurs during the last six (6)&#160;months of the Term, in which event either Tenant or Landlord shall have the right to terminate this Lease as of the date of such casualty by giving written notice thereof to the other within twenty (20)&#160;days after the date of such casualty. Notwithstanding the aforesaid, Landlord&#8217;s obligation to repair shall be limited in accordance with the provisions of Section&#160;14.1 above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">14.3 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RENT ABATEMENT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If all or any part of the Premises are rendered untenantable by fire or other casualty and this Lease is not terminated, Monthly Base Rent and Rent Adjustments shall abate for that part of the Premises which is untenantable on a per diem basis from the date of the casualty until Landlord has Substantially Completed the repair and restoration work in the Premises which it is required to perform, provided, that as a result of such casualty, Tenant does not occupy the portion of the Premises which is untenantable during such period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">14.4 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">WAIVER OF STATUTORY REMEDIES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The provisions of this Lease, including this Article Fourteen, constitute an express agreement between Landlord and Tenant with respect to any and all damage to, or destruction of, the Premises or the Property or any part of either, and any Law, including Sections 1932(2), 1933(4), 1941 and 1942 of the California Civil Code, with respect to any rights or obligations concerning damage or destruction shall have no application to this Lease or to any damage to or destruction of all or any part of the Premises or the Property or any part of either, and are hereby waived.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 15</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EMINENT DOMAIN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">15.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TAKING OF WHOLE OR SUBSTANTIAL PART</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event the whole or any substantial part of the Building or of the Premises is taken or condemned by any competent authority for any public use or purpose (including a deed given in lieu of condemnation) and is thereby rendered untenantable, this Lease shall terminate as of the date title vests in such authority, and Monthly Base Rent and Rent Adjustments shall be apportioned as of the Termination Date. Notwithstanding anything to the contrary herein set forth, in the event the taking is temporary (for less than the remaining Term of the Lease), Landlord may elect either (i)&#160;to terminate this Lease or (ii)&#160;permit Tenant to receive the entire award attributable to the Premises in which case Tenant shall continue to pay Rent and this Lease shall not terminate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">15.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TAKING OF PART</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event a part of the Premises is taken or condemned by any competent authority (or a deed is delivered in lieu of condemnation), and the remaining portions of the Premises are not, in Tenant&#8217;s reasonable business judgment, adequate or feasible for Tenant&#8217;s economic continued operations therein, then Tenant shall have the right to terminate this Lease by delivery of written notice to Landlord delivered within ten (10)&#160;days after such taking or condemnation. If this Lease</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">is not so terminated, the Lease shall be amended to reduce or increase, as the case may be, the Monthly Base Rent and Tenant&#8217;s Share to reflect the Rentable Area of the Premises or Building, as the case may be, remaining after any such taking or condemnation. Landlord, upon receipt and to the extent of the award in condemnation (or proceeds of sale) shall make necessary repairs and restorations to the Premises (exclusive of Tenant Additions) and to the Building to the extent necessary to constitute the portion of the Building not so taken or condemned as a complete architectural and economically efficient unit. Notwithstanding the foregoing, if as a result of any taking, or a governmental order that the grade of any street or alley adjacent to the Building is to be changed and such taking or change of grade makes it necessary or desirable to substantially remodel or restore the Building or prevents the economical operation of the Building, Landlord shall have the right to terminate this Lease upon ninety (90)&#160;days prior written notice to Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">15.3 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COMPENSATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Landlord shall be entitled to receive the entire award (or sale proceeds) from any such taking, condemnation or sale without any payment to Tenant, and Tenant hereby assigns to Landlord Tenant&#8217;s interest, if any, in such award; provided, however, Tenant shall have the right separately to pursue against the condemning authority a separate award for loss of good will and moving expenses, and in respect of the loss, if any, to Tenant Additions paid for by Tenant without any credit or allowance from Landlord so long as there is no diminution of Landlord&#8217;s award as a result.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 16</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INSURANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">16.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TENANT&#8217;S INSURANCE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tenant, at Tenant&#8217;s expense, agrees to maintain in force, with a company or companies acceptable to Landlord, during the Term: (a)&#160;Commercial General Liability Insurance on a primary basis and without any right of contribution from any insurance carried by Landlord covering the Premises on an occurrence basis against all claims for personal injury, bodily injury, death and property damage, including contractual liability covering the indemnification provisions in this Lease, and such insurance shall have a combined single limit of Five Million and No/100 Dollars ($5,000,000.00); (b) Workers&#8217; Compensation and Employers&#8217; Liability Insurance to the extent required by and in accordance with the Laws of the State of California; (c) &#8220;All Risks&#8221; property insurance in an amount adequate to cover the full replacement cost of all Tenant Additions, equipment, installations, fixtures and contents of the Premises in the event of loss; (d)&#160;in the event a motor vehicle is to be used by Tenant in connection with its business operation from the Premises, Comprehensive Automobile Liability Insurance coverage with limits of not less than One Million and No/100 Dollars ($1,000,000.00) combined single limit coverage against bodily injury liability and property damage liability arising out of the use by or on behalf of Tenant, its agents and employees in connection with this Lease, of any owned, non-owned or hired motor vehicles; and (e)&#160;such other insurance or coverages as Landlord reasonably requires.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">16.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FORM OF POLICIES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each policy referred to in 16.1 shall satisfy the following requirements. Each policy shall (i)&#160;name Landlord and the Indemnitees as additional insureds (except Workers&#8217; Compensation and Employers&#8217; Liability Insurance), (ii) be issued by one or more responsible insurance companies licensed to do business in the State of California reasonably satisfactory to Landlord, (iii)&#160;where applicable, provide for deductible amounts satisfactory to Landlord and not permit co-insurance, (iv)&#160;shall provide that such insurance may not be canceled or materially amended without thirty (30)&#160;days&#8217; prior written notice to the Landlord, and (v)&#160;each policy of &#8220;All-Risks&#8221; property insurance shall provide that the policy shall not be invalidated should the insured waive in writing prior to a loss, any or all rights of recovery against any other party for losses covered by such policies. Tenant shall deliver to Landlord, certificates of insurance and at Landlord&#8217;s request, copies of all policies and renewals thereof to be maintained by Tenant hereunder, not less than ten (10)&#160;days prior to the Commencement Date and not less than ten (10)&#160;days prior to the expiration date of each policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">16.3 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LANDLORD&#8217;S INSURANCE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(a) Landlord agrees to purchase and keep in full force and effect during the Term hereof, including any extensions or renewals thereof, insurance under policies issued by insurers of recognized responsibility, qualified to do business in the State of California on the Building in amounts not less than the then full replacement cost (without depreciation) of the Building (above foundations and excluding Tenant Additions) or an amount sufficient to prevent Landlord from becoming a co-insurer under the terms of the applicable policies, against fire and such other risks as may be included in standard forms of all risk coverage insurance reasonably available from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(b) Landlord agrees to maintain in force during the Term, Commercial General Liability Insurance covering the Building on an occurrence basis against all claims for personal injury, bodily injury, death, and property damage. Such insurance shall be for a combined single limit of not less than Five Million and No/100 Dollars ($5,000,000.00). Neither Landlord&#8217;s obligation to carry such insurance nor the carrying of such insurance shall be deemed to be an indemnity by Landlord with respect to any claim, liability, loss, cost or expense due, in whole or in part, to Tenant&#8217;s negligent acts or omissions or willful misconduct. Without obligation to do so, Landlord may, in its reasonable discretion from time to time, carry insurance in amounts greater and/or for coverage additional to the coverage and amounts set forth above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">16.4 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">WAIVER OF SUBROGATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(a) Landlord agrees that, if obtainable at no, or minimal, additional cost, and so long as the same is permitted under the laws of the State of California, it will include in its &#8220;All Risks&#8221; policies appropriate clauses pursuant to which the insurance companies (i)&#160;waive all right of subrogation against Tenant with respect to losses payable under such policies and/or (ii)&#160;agree that such policies shall not be invalidated should the insured waive in writing prior to a loss any or all right of recovery against any party for losses covered by such policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(b) Tenant agrees to include, if obtainable at no, or minimal, additional cost, and so long as the same is permitted under the laws of the State of California, in its &#8220;All Risks&#8221; insurance policy or policies on Tenant Additions, whether or not removable, and on Tenant&#8217;s furniture, furnishings, fixtures and other property removable by Tenant under the provisions of this Lease appropriate clauses pursuant to which the insurance company or companies (i)&#160;waive the right of subrogation against Landlord with respect to losses and to the extent payable under such policy or policies and/or (ii)&#160;agree that such policy or policies shall not be invalidated should the insured waive in writing prior to a loss any or all right of recovery against any party for losses covered by such policy or policies. If Tenant is unable to obtain in such policy or policies either of the clauses described in the preceding sentence, Tenant shall, if legally possible at no or minimal additional cost and without necessitating a change in insurance carriers, have Landlord named in such policy or policies as an additional insured. If Landlord shall be named as an additional insured in accordance with the foregoing, Landlord agrees to endorse promptly to the order of Tenant, without recourse, any check, draft, or order for the payment of money representing the proceeds of any such policy or representing any other payment growing out of or connected with said policies, and Landlord does hereby irrevocably waive any and all rights in and to such proceeds and payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(c) Provided that Landlord&#8217;s right of full recovery under its policy or policies aforesaid is not adversely affected or prejudiced thereby, Landlord hereby waives any and all right of recovery which it might otherwise have against Tenant, its servants, agents and employees, for loss or damage occurring to the Real Property and the fixtures, appurtenances and equipment therein, to the extent the same is covered by Landlord&#8217;s insurance, notwithstanding that such loss or damage may result from the negligence or fault of Tenant, its servants, agents or employees. Provided that Tenant&#8217;s right of full recovery under its aforesaid policy or policies is not adversely affected or prejudiced thereby, Tenant hereby waives any and all right of recovery which it might otherwise have against Landlord, its servants, and employees and against every other tenant of the Real Property who shall have executed a similar waiver as set forth in this Section&#160;16.4 (c) for loss or damage to Tenant Additions, whether or not removable, and to Tenant&#8217;s furniture, furnishings, fixtures and other property removable by Tenant under the provisions hereof to the extent the same is covered by Tenant&#8217;s insurance required under this Lease, notwithstanding that such loss or damage may result from the negligence or fault of Landlord, its servants, agents or employees, or such other tenant and the servants, agents or employees thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(d) Landlord and Tenant hereby agree to advise the other promptly if the clauses to be included in their respective insurance policies pursuant to subparagraphs (a)&#160;and (b) above cannot be obtained on the terms hereinbefore provided and thereafter to furnish the other with a certificate of insurance or copy of such policies showing the naming of the other as an additional insured, as aforesaid. Landlord and Tenant hereby also agree to notify the other promptly of any cancellation or change of the terms of any such policy that would affect such clauses or naming. All such policies which name both Landlord and Tenant as additional insureds shall, to the extent obtainable, contain agreements by the insurers to the effect that no act or omission of any additional insured will invalidate the policy as to the other additional insureds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">16.5 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTICE OF CASUALTY</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tenant shall give Landlord, and Landlord shall give to Tenant, notice in case of a fire or accident in the Premises promptly after such party is aware of such event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 17</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WAIVER OF CLAIMS AND INDEMNITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">17.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">WAIVER OF CLAIMS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent permitted by Law, Tenant releases the Indemnitees from, and waives all claims for, damage to person or property sustained by the Tenant or any occupant of the Premises or the Property resulting directly or indirectly from any existing or future condition, defect, matter or thing in and about the Premises or the Property or any part of either or any equipment or appurtenance therein, or resulting from any accident in or about the Premises or the Property, or resulting directly or indirectly from any act or neglect of any tenant or occupant of the Property or of any other person, including Landlord&#8217;s agents and servants, except to the extent caused by the gross negligence or willful and wrongful act of any of the Indemnitees. To the extent permitted by Law, Tenant hereby waives the right to collect against Landlord any consequential damages, compensation or claims for inconvenience or loss of business, rents, or profits as a result of such injury or damage, whether or not caused by the gross negligence or willful and wrongful act of any of the Indemnitees; provided, however, that if such damage or injury was material and was caused by any other tenant in the Project whose lease renders such tenant liable for losses or damages to other tenants, then Landlord shall assign to Tenant, or pursue on Tenant&#8217;s behalf and at Tenant&#8217;s sole cost and expense, Tenant&#8217;s reasonable claims against such other responsible tenant. If any such damage, whether to the Premises or the Property or any part of either, or whether to Landlord or to other tenants in the Property, results from any act or neglect of Tenant, its employees, servants, agents, contractors, invitees or customers, Tenant shall be liable therefor and Landlord may, at Landlord&#8217;s option, repair such damage and Tenant shall, upon demand by Landlord, as payment of additional Rent hereunder, reimburse Landlord within ten (10)&#160;days of demand for the total cost of such repairs, in excess of amounts, if any, payable to Landlord under insurance covering such damages. Tenant shall not be liable for any such damage caused by its acts or neglect if Landlord or a tenant has recovered the full amount of the damage from proceeds of insurance policies and the insurance company has waived its right of subrogation against Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">17.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">INDEMNITY BY TENANT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except to the extent caused by the gross negligence or willful misconduct of Landlord, its agents, employees, or contractors, and to the extent permitted by Law, Tenant hereby indemnifies, and agrees to protect, defend and hold the Indemnitees harmless, against any and all actions, claims, demands, liability, costs and expenses, including attorneys&#8217; fees and expenses for the defense thereof, arising from Tenant&#8217;s occupancy of the Premises, from the undertaking of any Tenant Additions or repairs to the Premises, from the conduct of Tenant&#8217;s business on the Premises, or from any breach or default on the part of Tenant in the performance of any covenant or agreement on the part of Tenant to be performed pursuant to the terms of this Lease, or from any willful act or negligence of Tenant, its agents, contractors, servants, employees, customers or invitees, in or about the Premises or the Property or any part of either. In case of any action or proceeding brought against the Indemnitees by reason of any such claim, upon notice from Landlord, Tenant covenants to defend such action or proceeding by counsel chosen by Landlord,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">in Landlord&#8217;s sole discretion. Landlord reserves the right to settle, compromise or dispose of any and all actions, claims and demands related to the foregoing indemnity. The foregoing indemnity shall not operate to relieve Indemnitees of liability to the extent such liability is caused by the willful and wrongful act of Indemnitees. Further, the foregoing indemnity is subject to and shall not diminish any waivers in effect in accordance with Section&#160;16.4 by Landlord or its insurers to the extent of amounts, if any, paid to Landlord under its &#8220;All-Risks&#8221; property insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 18</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RULES AND REGULATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">18.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RULES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tenant agrees for itself and for its subtenants, employees, agents, and invitees to comply with the rules and regulations listed on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C-2</u> attached hereto and with all reasonable modifications and additions thereto which Landlord may make from time to time, provided that such modifications and additions shall not materially increase Tenant&#8217;s obligations, or diminish Tenant&#8217;s rights, under this Lease..</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">18.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ENFORCEMENT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nothing in this Lease shall be construed to impose upon the Landlord any duty or obligation to enforce the rules and regulations as set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</u> or as hereafter adopted, or the terms, covenants or conditions of any other lease as against any other tenant, and the Landlord shall not be liable to the Tenant for violation of the same by any other tenant, its servants, employees, agents, visitors or licensees. Landlord shall use reasonable efforts to enforce the rules and regulations of the Project in a uniform and non-discriminatory manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 19</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LANDLORD&#8217;S RESERVED RIGHTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Provided that Tenant&#8217;s use of or access to the Premises is not thereby materially impaired, Landlord shall have the following rights exercisable without notice to Tenant and without liability to Tenant for damage or injury to persons, property or business and without being deemed an eviction or disturbance of Tenant&#8217;s use or possession of the Premises or giving rise to any claim for offset or abatement of Rent: (1)&#160;to change the Building&#8217;s name or street address upon thirty (30)&#160;days&#8217; prior written notice to Tenant; (2)&#160;to install, affix and maintain all signs on the exterior and/or interior of the Building; (3)&#160;to designate and/or approve prior to installation, all types of signs, window shades, blinds, drapes, awnings or other similar items, and all internal lighting that may be visible from the exterior of the Premises; (4)&#160;upon reasonable notice to Tenant, to display the Premises to prospective purchasers and lenders at reasonable hours at any time during the Term and to prospective tenants at reasonable hours during the last six (6)&#160;months of the Term; (5)&#160;to grant to any party the exclusive right to conduct any business or render any service in or to the Building, provided such exclusive right shall not operate to prohibit Tenant from using the Premises for the purpose permitted hereunder; (6)&#160;to change the arrangement and/or location of entrances or passageways, doors and doorways, corridors, elevators, stairs, washrooms or public portions of the Building, and to close entrances, doors, corridors, elevators or other facilities,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">provided that such action shall not materially and adversely interfere with Tenant&#8217;s access to the Premises or the Building; (7)&#160;to have access for Landlord and other tenants of the Building to any mail chutes and boxes located in or on the Premises as required by any applicable rules of the United States Post Office; and (8)&#160;to close the Building after Standard Operating Hours, except that Tenant and its employees and invitees shall be entitled to admission at all times, under such regulations as Landlord prescribes for security purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 20</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ESTOPPEL CERTIFICATE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">20.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IN GENERAL</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Within ten (10)&#160;business days after request therefor by Landlord, Mortgagee or any prospective mortgagee or owner, or Tenant (the party requesting the same being referred to herein as the &#8220;Requesting Party&#8221; and the other party as the &#8220;Responding Party&#8221;) the Responding Party agrees as directed in such request to execute an Estoppel Certificate in recordable form, binding upon the Responding Party, certifying (i)&#160;that this Lease is unmodified and in full force and effect (or if there have been modifications, a description of such modifications and that this Lease as modified is in full force and effect); (ii) the dates to which Rent has been paid; (iii)&#160;that Tenant is in lawful possession of the Premises if that is the case; (iv)&#160;that the Requesting Party is not in default under this Lease, or, if the Responding Party believes the Requesting Party is in default, the nature thereof in detail; (v)&#160;that the Responding Party has no offsets or defenses to the performance of its obligations under this Lease (or if the Responding Party believes there are any offsets or defenses, a full and complete explanation thereof); (vi) that the Premises have been completed in accordance with the terms and provisions hereof or the Workletter, that Tenant has accepted the Premises and the condition thereof and of all improvements thereto and that the Responding Party has no claims against the Requesting Party or any other party with respect thereto; (vii)&#160;that if an assignment of rents or leases has been served upon the Tenant by a Mortgagee, Tenant will acknowledge receipt thereof and agree to be bound by the provisions thereof; (viii)&#160;that Tenant will give to the Mortgagee copies of all notices required or permitted to be given by Tenant to Landlord; and (ix)&#160;to any other information reasonably requested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">20.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ENFORCEMENT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that a Responding Party fails timely to deliver an Estoppel Certificate, then the Requesting Party shall have the right to execute an Estoppel Certificate on behalf of the Responding Party, and the Responding Party shall be bound thereby and estopped to deny the truth of the matters therein stated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 21</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RELOCATION OF TENANT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">At any time after the date of this Lease, Landlord may substitute for the Premises, other premises in the Project, EmeryStation I, EmeryStation East, Heritage Square or any other building which Landlord or its affiliates may own or control in Emeryville (the &#8220;New Premises&#8221;), in which event the New Premises shall be deemed to be the Premises for all</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">purposes under this Lease, provided that (i)&#160;the New Premises shall be substantially similar to the Premises in area and interior layout of the premises; (ii)&#160;if Tenant is then occupying the Premises, Landlord shall pay the actual and reasonable expenses of physically moving Tenant, its property and equipment to the New Premises; (iii)&#160;Landlord shall give Tenant not less than sixty (60)&#160;days&#8217; prior written notice of such substitution; and (iv)&#160;Landlord, at its expense, shall improve the New Premises with improvements substantially similar to those in the Premises at the time of such substitution, if the Premises are then improved.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 22</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REAL ESTATE BROKERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tenant represents that, except for the broker(s) listed in Section&#160;1.1, Tenant has not dealt with any real estate broker, sales person, or finder in connection with this Lease, and no such person initiated or participated in the negotiation of this Lease, or showed the Premises to Tenant. Tenant hereby agrees to indemnify, protect, defend and hold Landlord and the Indemnitees, harmless from and against any and all liabilities and claims for commissions and fees arising out of a breach of the foregoing representation. Landlord agrees to pay any commission to which the brokers listed in Section&#160;1.1 are entitled in connection with this Lease pursuant to Landlord&#8217;s written agreement with such broker.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 23</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MORTGAGEE PROTECTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">23.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SUBORDINATION AND ATTORNMENT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The effectiveness of this Lease shall be conditioned upon Landlord&#8217;s representation and warranty to Tenant that there is not an existing Mortgagee on the property. This Lease is and shall be expressly subject and subordinate at all times to (i)&#160;any ground or underlying lease of the Real Property, now or hereafter existing, and all amendments, extensions, renewals and modifications to any such lease, and (ii)&#160;the lien of any mortgage or trust deed hereafter encumbering fee title to the Real Property and/or the leasehold estate under any such lease, and all amendments, extensions, renewals, replacements and modifications of such mortgage or trust deed and/or the obligation secured thereby, unless such ground lease or ground lessor, or mortgage, trust deed or Mortgagee, expressly provides or elects that the Lease shall be superior to such lease or mortgage or trust deed. If any such mortgage or trust deed is foreclosed (including any sale of the Real Property pursuant to a power of sale), or if any such lease is terminated, upon request of the Mortgagee or ground lessor, as the case may be, Tenant shall attorn to the purchaser at the foreclosure sale or to the ground lessor under such lease, as the case may be, provided, however, that such purchaser or ground lessor shall not be (i)&#160;subject to any offset, defense or damages arising prior to the date of such sale out of a default of any obligations of any preceding Landlord; or (ii)&#160;bound by any amendment or modification of this Lease made without the written consent of the Mortgagee or ground lessor (if such consent is required under the terms of such Mortgage or ground lease); or (iii)&#160;liable for any security deposits not actually received in cash by such purchaser or ground lessor. This subordination shall be self-operative and no further certificate or instrument of subordination need be required by any such Mortgagee or ground lessor. In confirmation of such subordination, however, Tenant shall execute promptly any reasonable certificate or instrument</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">that Landlord, Mortgagee or ground lessor may request. Tenant hereby constitutes Landlord as Tenant&#8217;s attorney-in-fact to execute such certificate or instrument for and on behalf of Tenant upon Tenant&#8217;s failure to do so within fifteen (15)&#160;days of a request to do so. Upon request by such successor in interest, Tenant shall execute and deliver reasonable instruments confirming the attornment provided for herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">23.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MORTGAGEE PROTECTION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tenant agrees to give any Mortgagee or ground lessor, by registered or certified mail, a copy of any notice of default served upon the Landlord by Tenant (&#8220;Tenant&#8217;s Notice of Default&#8221;), provided that prior to such Notice Tenant has received notice (by way of service on Tenant of a copy of an assignment of rents and leases) of the address of such Mortgagee or ground lessor. Tenant further agrees that if Landlord shall have failed to cure such default within the time provided for in this Lease, then the Mortgagee or ground lessor shall have an additional thirty (30)&#160;days from delivery of Tenant&#8217;s Notice of Default within which to cure such default or if such default cannot be cured within that time, then such additional time as may be necessary, so long as any Mortgagee or ground lessor has commenced its cure within such thirty (30)&#160;days, and is diligently pursuing the remedies necessary to cure such default (including commencement of foreclosure proceedings or other proceedings to acquire possession of the Real Property, if necessary to effect such cure). Such period of time shall be extended by any period within which such Mortgagee or ground lessor is prevented from commencing or pursuing such foreclosure proceedings or other proceedings to acquire possession of the Real Property by reason of Landlord&#8217;s bankruptcy. Until the time allowed as aforesaid for Mortgagee or ground lessor to cure such defaults has expired without cure, Tenant shall have no right to, and shall not, terminate this Lease on account of default. This Lease may not be modified or amended so as to reduce the Rent or shorten the Term, or so as to adversely affect in any other respect to any material extent the rights of the Landlord, nor shall this Lease be canceled or surrendered, without the prior written consent, in each instance, of the ground lessor or the Mortgagee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 24</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTICES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(a) All notices, demands or requests provided for or permitted to be given pursuant to this Lease must be in writing and shall be personally delivered, sent by Federal Express or other reputable overnight courier service which provides proof of delivery, or mailed by first class, registered or certified United States mail, return receipt requested, postage prepaid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(b) All notices, demands or requests to be sent pursuant to this Lease shall be deemed to have been properly given or served by delivering or sending the same in accordance with this Section, addressed to the parties hereto at their respective addresses listed in Sections 1.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(c) Notices, demands or requests sent by mail or overnight courier service as described above shall be deemed delivered on the date of delivery shown on the return receipt or overnight courier&#8217;s proof of delivery or, if delivery is refused, then on the date that such delivery was refused. Notices may also be served by personal service upon any Registered Agent of Landlord or Tenant, and shall be effective upon such service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(d) By giving to the other party at least thirty (30)&#160;days written notice thereof, either party shall have the right from time to time during the term of this Lease to change their respective addresses for notices, statements, demands and requests, provided such new address shall be within the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE 25</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.1 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LATE CHARGES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(a) All non-scheduled payments required hereunder (i.e., other than the Monthly Base Rent, Rent Adjustments, and Rent Adjustment Deposits, which shall be due as hereinbefore provided) to Landlord shall be paid within thirty (30)&#160;days after Landlord&#8217;s demand therefor. All such amounts (including Monthly Base Rent, Rent Adjustments, and Rent Adjustment Deposits) not paid when due shall bear interest from the date due until the date paid at the Default Rate in effect on the date such payment was due.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(b) In the event that Landlord has not received any installment of Rent due under this Lease on the date it is due, Tenant shall pay Landlord a late charge equal to five percent (5%) of the delinquent installment of Rent. The parties agree that (i)&#160;such delinquency will cause Landlord to incur costs and expenses not contemplated herein, the exact amount of which will be difficult to calculate, including the cost and expense that will be incurred by Landlord in processing each delinquent payment of rent by Tenant, (b)&#160;the amount of such late charge represents a reasonable estimate of such costs and expenses and that such late charge shall be paid to Landlord for each delinquent payment in addition to all Rent otherwise due hereunder. The parties further agree that the payment of late charges and the payment of interest provided for in subparagraph (a)&#160;above are distinct and separate from one another in that the payment of interest is to compensate Landlord for its inability to use the money improperly withheld by Tenant, while the payment of late charges is to compensate Landlord for its additional administrative expenses in handling and processing delinquent payments. Notwithstanding the foregoing, no late charge shall be payable by Tenant on the first occasion in any twelve-month period of a delay in receipt of any payment hereunder, provided that Tenant delivers such payment to Landlord within two (2)&#160;business days after the date that it is otherwise due. Under no circumstances shall interest be payable on any late charge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(c) Payment of interest at the Default Rate and/or of late charges shall not excuse or cure any default by Tenant under this Lease, nor shall the foregoing provisions of this Article or any such payments prevent Landlord from exercising any right or remedy available to Landlord upon Tenant&#8217;s failure to pay Rent when due, including the right to terminate this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.2 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NO JURY TRIAL; VENUE; JURISDICTION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(a) To the fullest extent permitted by law, including laws enacted after the Commencement Date, each party hereto (which includes any assignee, successor, heir or personal representative of a party) shall not seek a jury trial, hereby waives trial by jury, and hereby further waives any objection to venue in the County in which the Project is located, and agrees and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">consents to personal jurisdiction of the courts of the State of California, in any action or proceeding or counterclaim brought by any party hereto against the other on any matter whatsoever arising out of or in any way connected with this Lease, the relationship of Landlord and Tenant, Tenant&#8217;s use or occupancy of the Premises, or any claim of injury or damage, or the enforcement of any remedy under any statute, emergency or otherwise, whether any of the foregoing is based on this Lease or on tort law. No party will seek to consolidate any such action in which a jury has been waived with any other action in which a jury trial cannot or has not been waived. It is the intention of the parties that these provisions shall be subject to no exceptions. The provisions of this Section shall survive the expiration or earlier termination of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(b) In the event that the foregoing waiver of jury trial is deemed invalid or unenforceable for any reason, any dispute with respect to the subject matter of this Lease (except an unlawful detainer action by Landlord) shall be resolved by a referee pursuant to the provisions of California Code of Civil Procedure Section&#160;638 et seq., for a determination to be made which shall be binding upon the parties as if tried before a court or jury. The parties agree specifically as to the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(i) Within thirty (30)&#160;business days after service of a demand by a party hereto, the parties shall agree upon a single referee who shall then try all issues, whether of fact or law, and then report a finding or judgment thereon. If the parties are unable to agree upon a referee either party may seek to have one appointed, pursuant to California Code of Civil Procedure Section&#160;640, by the presiding judge of the County Superior Court where the Shopping Center is located.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(ii) The compensation of the referee shall be such charge as is customarily charged by the referee for like services. The cost of such proceedings shall initially be borne equally by the parties. However, the prevailing party in such proceedings shall be entitled, in addition to all other costs, to recover its contribution for the cost of the reference as an item of damages and/or recoverable costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(iii) If a reporter is requested by either party, then a reporter shall be present at all proceedings, and the fees of such reporter shall be borne by the party requesting such reporter. Such fees shall be an item of recoverable costs. Only a party shall be authorized to request a reporter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(iv) The referee shall apply all California Rules of Procedure and Evidence and shall apply the substantive law of California in deciding the issues to be heard. Notice of any motions before the referee shall be given, and all matters shall be set at the convenience of the referee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(v) The referee&#8217;s decision under California Code of Civil Procedure Section&#160;644, shall stand as the judgment of the court, subject to appellate review as provided by the laws of the State of California.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(vi) The parties agree that they shall in good faith endeavor to cause any such dispute to be decided within four (4)&#160;months. The date of hearing for any proceeding shall be determined by agreement of the parties and the referee, or if the parties cannot agree, then by the referee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(vii) The referee shall have the power to award damages and all other relief; provided, however, that the referee shall have no power to award punitive or consequential damages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.3 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DISCRIMINATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tenant agrees for Tenant and Tenant&#8217;s heirs, executors, administrators, successors and assigns and all persons claiming under or through Tenant, and this Lease is made and accepted upon and subject to the following conditions: that there shall be no discrimination against or segregation of any person or group of persons on account of race, color, creed, religion, sex, marital status, national origin or ancestry (whether in the leasing, subleasing, transferring, use, occupancy, tenure or enjoyment of the Premises or otherwise) nor shall Tenant or any person claiming under or through Tenant establish or permit any such practice or practices of discrimination or segregation with reference to the use or occupancy of the Premises by Tenant or any person claiming through or under Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.4 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NO OPTION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Lease shall not become effective as a lease or otherwise until executed and delivered by both Landlord and Tenant. The submission of the Lease to Tenant does not constitute a reservation of or option for the Premises, but when executed by Tenant and delivered to Landlord, the Lease shall constitute an irrevocable offer by Tenant in effect for fifteen (15)&#160;days to lease the Premises on the terms and conditions herein contained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.5 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AUTHORITY</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each party represents and warrants to the other that it has full authority and power to enter into and perform its obligations under this Lease, that the person executing this Lease is fully empowered to do so, and that no consent or authorization is necessary from any third party. Landlord may request that Tenant provide Landlord evidence of Tenant&#8217;s authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.6 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ENTIRE AGREEMENT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Lease, the Exhibits attached hereto, including the Workletter, contain the entire agreement between Landlord and Tenant concerning the Premises and there are no other agreements, either oral or written, and no other representations or statements, either oral or written, on which either party has relied, except as expressly set forth herein. This Lease shall not be modified except by a writing executed by Landlord and Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.7 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MODIFICATION OF LEASE FOR BENEFIT OF MORTGAGEE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Mortgagee of Landlord requires a modification of this Lease which shall not result in any increased cost or expense to Tenant or in any other substantial and adverse change in the rights and obligations of Tenant hereunder, then Tenant agrees that the Lease may be so modified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.8 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXCULPATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tenant agrees, on its behalf and on behalf of its successors and assigns, that any liability or obligation under this Lease shall only be enforced against Landlord&#8217;s equity interest in the Property up to a maximum of Five Million Dollars ($5,000,000.00) and in no event against any other assets of the Landlord, or Landlord&#8217;s officers or directors or partners, and that any liability of Landlord with respect to this Lease shall be so limited and Tenant shall not be entitled to enforce against Landlord any judgment in excess of such amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.9 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ACCORD AND SATISFACTION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No payment by Tenant or receipt by Landlord of a lesser amount than any installment or payment of Rent due shall be deemed to be other than on account of the amount due, and no endorsement or statement on any check or any letter accompanying any check or payment of Rent shall be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord&#8217;s right to recover the balance of such installment or payment of Rent or pursue any other remedies available to Landlord. No receipt of money by Landlord from Tenant after the termination of this Lease or Tenant&#8217;s right of possession of the Premises shall reinstate, continue or extend the Term. Receipt or acceptance of payment from anyone other than Tenant, including an assignee of Tenant, is not a waiver of any breach of Article Ten, and Landlord may accept such payment on account of the amount due without prejudice to Landlord&#8217;s right to pursue any remedies available to Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.10 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LANDLORD&#8217;S OBLIGATIONS ON SALE OF BUILDING</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of any sale or other transfer of the Building, Landlord shall be entirely freed and relieved of all agreements and obligations of Landlord hereunder accruing or to be performed after the date of such sale or transfer, and any remaining liability of Landlord with respect to this Lease shall be limited to the dollar amount specified in Section&#160;25.08 and Tenant shall not be entitled to any judgment in excess of such amount. Landlord shall have the right to assign this Lease to an entity comprised of the principals of Landlord or affiliates of such entities. Upon such assignment and written assumption of the obligations of Landlord hereunder, Landlord shall be entirely freed and relieved of all obligations hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.11 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">BINDING EFFECT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the provisions of Article Ten, this Lease shall be binding upon and inure to the benefit of Landlord and Tenant and their respective heirs, legal representatives, successors and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.12 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CAPTIONS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Article and Section captions in this Lease are inserted only as a matter of convenience and in no way define, limit, construe, or describe the scope or intent of such Articles and Sections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.13 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TIME; APPLICABLE LAW; CONSTRUCTION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Time is of the essence of this Lease and each and all of its provisions. This Lease shall be construed in accordance with the Laws of the State of California. If more than one person signs this Lease as Landlord or Tenant, the obligations hereunder imposed shall be joint and several. If any term, covenant or condition of this Lease or the application thereof to any person or circumstance shall, to any extent, be invalid or unenforceable, the remainder of this Lease, or the application of such term, covenant or condition to persons or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected thereby and each item, covenant or condition of this Lease shall be valid and be enforced to the fullest extent permitted by Law unless doing so would materially alter the parties&#8217; essential bargain as set forth herein. Wherever the term &#8220;including&#8221; or &#8220;includes&#8221; is used in this Lease, it shall have the same meaning as if followed by the phrase &#8220;but not limited to&#8221;. The language in all parts of this Lease shall be construed according to its normal and usual meaning and not strictly for or against either Landlord or Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.14 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ABANDONMENT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event Tenant vacates or abandons the Premises but is otherwise in compliance with all the terms, covenants and conditions of this Lease, Landlord shall (i)&#160;have the right to enter into the Premises in order to show the space to prospective tenants, (ii)&#160;have the right to reduce the services provided to Tenant pursuant to the terms of this Lease to such levels as Landlord reasonably determines to be adequate services for an unoccupied premises, and (iii)&#160;during the last six (6)&#160;months of the Term, have the right to prepare the Premises for occupancy by another tenant upon the end of the Term. Tenant expressly acknowledges that in the absence of written notice pursuant to Section&#160;11.2(b) or pursuant to California Civil Code Section&#160;1951.3 terminating Tenant&#8217;s right to possession, none of the foregoing acts of Landlord or any other act of Landlord shall constitute a termination of Tenant&#8217;s right to possession or an acceptance of Tenant&#8217;s surrender of the Premises, and the Lease shall continue in effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.15 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LANDLORD&#8217;S RIGHT TO PERFORM TENANT&#8217;S DUTIES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Tenant fails timely to perform any of its duties under this Lease or the Workletter, and such failure remains uncured after notice and any applicable grace period, Landlord shall have the right (but not the obligation), to perform such duty on behalf and at the expense of Tenant without prior notice to Tenant, and all sums expended or expenses incurred by Landlord in performing such duty shall be deemed to be additional Rent under this Lease and shall be due and payable within ten (10)&#160;days following written demand by Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.16 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECURITY SYSTEM</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Landlord shall not be obligated to provide or maintain any security patrol or security system. Landlord shall not be responsible for the quality of any such patrol or system which may be provided hereunder or for damage or injury to Tenant, its employees, invitees or others due to the failure, action or inaction of such patrol or system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.17 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NO LIGHT, AIR OR VIEW EASEMENTS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any diminution or shutting off of light, air or view by any structure which may be erected on lands of or adjacent to the Project shall in no way affect this Lease or impose any liability on Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.18 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RECORDATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Neither this Lease, nor any notice nor memorandum regarding the terms hereof, shall be recorded by Tenant. Any such unauthorized recording shall be a Default for which there shall be no cure or grace period. Tenant agrees to execute and acknowledge, at the request of Landlord, a memorandum of this Lease, in recordable form.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.19 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SURVIVAL</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The waivers of the right of jury trial, the other waivers of claims or rights, the releases and the obligations of Tenant under this Lease to indemnify, protect, defend and hold harmless Landlord and/or Indemnitees shall survive the expiration or termination of this Lease, and so shall all other obligations or agreements which by their terms survive expiration or termination of the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">25.20 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RIDERS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All Riders attached hereto and executed both by Landlord and Tenant shall be deemed to be a part hereof and hereby incorporated herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[Signatures on Following Page]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, this Lease has been executed as of the date set forth in Section&#160;1.1 hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:36.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT:</p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD:</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Crystal Bioscience, Inc., a California corporation</p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emery Station Office II, LLC, a California limited liability company</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:36.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">/s/ Robert J. Etches</p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:48.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Richard K. Robbins</p></td></tr><tr><td style="vertical-align:top;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print&#160;Name:</p></td><td style="vertical-align:top;width:36.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert J. Etches</p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard K. Robbins</p></td></tr><tr><td style="vertical-align:top;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td style="vertical-align:top;width:36.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President&#160;&amp; CEO</p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Member</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:36.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:36.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print&#160;Name:</p></td><td style="vertical-align:top;width:36.66%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td style="vertical-align:top;width:36.66%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:36.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td colspan="2" style="vertical-align:top;width:40%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;2/19/2009</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">RIDER 1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXTENSION OPTION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Landlord hereby grants Tenant one (1)&#160;option to extend the term of the Lease for one additional period of five (5)&#160;years (&#8220;Option Term&#8221;), commencing immediately after the expiration of the initial term, upon the same material terms and conditions contained herein, except that (i)&#160;the Monthly Base Rent for the Premises shall be equal to ninety-five percent (95%) of the fair market rent for the Premises based upon comparable space in the area of Berkeley and/or Emeryville, California as determined in the manner set forth below, but in no event shall the Monthly Base Rent for the Option Term be less than the Monthly Base Rent at the time of Tenant&#8217;s Option Notice to the Landlord, and (ii)&#160;Tenant shall accept the Premises in an &#8220;as is&#8221; condition without any obligation of Landlord to repaint, remodel, repair, improve or alter the Premises. Tenant&#8217;s election to exercise the option granted herein must be given to Landlord in writing no more than eleven (11)&#160;months and no less than nine (9)&#160;months prior to expiration of the initial term (the &#8220;Notice Period&#8221;). In determining fair market rent for the Premises, any Improvements made at Tenant&#8217;s expense shall be disregarded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If Tenant properly exercises the option granted herein, references in the Lease to the term shall be deemed to mean and include the Option Term unless the context clearly provides otherwise. Notwithstanding anything to the contrary contained, herein, all option rights of Tenant pursuant to this Section shall automatically terminate without notice and shall be of no further force and effect, whether or not Tenant has timely exercised the option granted herein, if (i)&#160;a Default exists at the time of exercise of the option or at the time of commencement of the Option Term, or (ii)&#160;Tenant has sublet more than 50% of the Premises or Tenant has assigned the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Within thirty (30)&#160;days after receipt of Tenant&#8217;s notice of exercise, Landlord shall provide Tenant with a notice of its estimate of Monthly Base Rent during the Option Term (&#8220;Landlord&#8217;s Notice&#8221;). If Tenant does not accept the Monthly Base Rent set forth in Landlord&#8217;s Notice, then Tenant shall notify Landlord of its objection to Landlord&#8217;s determination within twenty (20)&#160;business days following receipt of Landlord&#8217;s Notice by providing its determination of the fair market rent for the Premises in accordance with (i)&#160;below. If Tenant fails to so notify Landlord within said twenty (20)&#160;business days, Landlord&#8217;s determination of Monthly Base Rent for the Premises shall be final and binding upon the parties and Tenant shall have no further rights to rescind the option. If the parties are unable to agree upon the fair market rent for the Premises within ten (10)&#160;days after Landlord&#8217;s receipt of notice of Tenant&#8217;s objection, the amount of Monthly Base Rent as of commencement of the Option Term shall be determined as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Within twenty (20)&#160;days after receipt of Landlord&#8217;s Notice specifying fair market rent, Tenant, at its sole expense, shall obtain and deliver in writing to Landlord a determination of the fair market rent for the Premises for a term equal to the Option Term from a broker (&#8220;Tenant&#8217;s broker&#8221;) licensed in the State of California and engaged in the office brokerage business in the area of Emeryville, California, for at least the immediately preceding five (5)&#160;years. If Landlord accepts such determination, the Monthly Base Rent for the Option Term shall be set to an amount equal to the amount determined by Tenant&#8217;s broker.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">If Landlord does not accept such determination, within fifteen (15)&#160;days after receipt of the determination of Tenant&#8217;s broker, Landlord shall designate a broker (&#8220;Landlord&#8217;s broker&#8221;) licensed in the State of California and engaged in the office brokerage business in the area of Emeryville, California, for at least the immediately preceding five (5)&#160;years. Landlord&#8217;s broker and Tenant&#8217;s broker shall name a third broker, similarly qualified, within five (5)&#160;days after the appointment of Landlord&#8217;s broker, without informing such third broker of the determinations by Landlord&#8217;s broker or Tenant&#8217;s broker. The third broker shall independently assess the fair market value of the Premises within fifteen (15)&#160;days following the appointment of the third broker. At the end of such 15-day period, the determinations of the three brokers shall be compared, and the Monthly Base Rent as of the commencement of the Option Term shall be that figure submitted by Landlord&#8217;s broker or Tenant&#8217;s broker which is closest to the fair market rent as determined by the third broker.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Landlord shall pay the costs and fees of Landlord&#8217;s broker in connection with any determination hereunder, and Tenant shall pay the costs and fees of Tenant&#8217;s broker in connection with such determination. The costs and fees of any third broker shall be paid one-half by Landlord and one-half by Tenant. If the amount of the fair market rent is not known as of the commencement of the Option Term, then Tenant shall continue to pay the Monthly Base Rent in effect at the expiration of the initial term until the amount of the fair market rent is determined. When such determination is made, Tenant shall pay any deficiency to Landlord upon demand.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COMMENCEMENT DATE AMENDMENT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Emery Station Office II, LLC, a California limited liability company (&#8220;Landlord&#8221;), and (&#8220;Tenant&#8221;), have entered into a certain Lease dated as of&#160;_________, 2007 (the &#8220;Lease&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Landlord and Tenant wish to confirm and memorialize the Commencement Date and Expiration Date of the Lease as provided for in Section&#160;2.2(b) of the Lease;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the foregoing and the mutual covenants contained herein and in the Lease, Landlord and Tenant agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">1. Unless otherwise defined herein, all capitalized terms shall have the same meaning ascribed to them in the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2. The Commencement Date (as defined in the Lease) of the Lease is _________.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3. The Expiration Date (as defined in the Lease) of the Lease is ___________.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">4. Tenant hereby confirms the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a) That it has accepted possession of the premises pursuant to the terms of the Lease;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b) That the Landlord Work is Substantially Complete; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c) That the Lease is in full force and effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5. Except as expressly modified hereby, all terms and provisions of the Lease are hereby ratified and confirmed and shall remain in full force and effect and binding on the parties hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6. The Lease and this Commencement Date Agreement contain all of the terms, covenants, conditions and agreements between the Landlord and the Tenant relating to the subject matter herein. No prior other agreements or understandings pertaining to such matters are valid or of any force and effect.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:45.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT:</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:52.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD:</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:45.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:45.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:52.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emery Station Office II, LLC, a California limited liability company</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:45.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:36.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:49.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print&#160;Name:</p></td><td style="vertical-align:top;width:36.52%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Richard K. Robbins</p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td style="vertical-align:top;width:36.52%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Managing Member</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">FIRST AMENDMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">LEASE BETWEEN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EMERY STATION OFFICE II, LLC (LANDLORD)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">And</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">CRYSTAL BIOSCIENCE, INC. (TENANT)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EMERYSTATION NORTH PROJECT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Emeryville, California</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Reference is made to that certain Lease dated February&#160;16, 2009 by and between Emery Station Office II, LLC, as Landlord, and Crystal Bioscience, Inc. The Lease is hereby amended by this First Amendment, as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Effective Date of this First Amendment shall be May&#160;20, 2010. From and after the First Amendment Effective Date, the existing Lease and this First Amendment thereto shall collectively be referred to as the &#8220;Lease&#8221;.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">II.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Pursuant to the existing Lease, the Premises currently totals 6,820 rentable square feet on the Fourth Floor. The approximately 500 rentable square foot space adjacent to the existing Premises, as more fully identified on Exhibit A-1 hereto, shall be referred to as the &#8220;Expansion Space&#8221;. Landlord and Tenant hereby agree that, upon completion of the Expansion Space Landlord Work (as such is more fully defined in Section III below), and upon delivery of the Expansion Space to Tenant, the Expansion Space shall be added to the existing Premises such that together they shall thereafter constitute the &#8220;Premises&#8221; for all purposes under the Lease. The date of said delivery to Tenant shall be referred to as the &#8220;Expansion Premises Commencement Date&#8221;. From and after the Expansion Premises Commencement Date, the Premises shall total 7,320 rentable square feet and Tenant&#8217;s Share of Operating Expenses and Taxes shall be adjusted accordingly.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">III.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Tenant shall accept the Expansion Space in its then as-is condition subject only to Landlord&#8217;s obligation, at its sole cost and expense, to complete the following Expansion Space Landlord Work:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Securely locking (or at Landlord<font style="font-family:'Symbol';">&#8217;</font>s option, removal) of the two doors leading east into adjacent space(s) not controlled by Tenant.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Addition of a building standard door between the two rooms in the Expansion Space and addition of a building standard door from one of them into Tenant<font style="font-family:'Symbol';">&#8217;</font>s existing Premises.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">IV.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Effective upon the Expansion Space Commencement Date, Tenant&#8217;s Monthly Base Rent shall be increased by $1,245.00. The new, increased Monthly Base Rent will remain subject to three percent (3%) increases as called for by Section&#160;1.1(9) of the Lease.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">V.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Tenant hereby represents to Landlord that it has represented itself in this transaction and that no broker fee shall be payable by Landlord to any representative of Tenant as a result hereof.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">VI.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Except for those terms outlined above, all other terms and conditions of the Existing Lease and WorkLetter shall apply.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In witness hereof, the parties have executed this First Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT:</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD:</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Crystal Bioscience, Inc., a California Corporation</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emery Station Office II, LLC, a California limited liability company</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Robert J. Etches</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Richard K. Robbins</p></td></tr><tr><td style="vertical-align:top;width:10%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print Name:</p></td><td style="vertical-align:top;width:39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert J. Etches</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print Name:</p></td><td style="vertical-align:top;width:39.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard K. Robbins</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td style="vertical-align:top;width:39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President &amp; CEO</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td style="vertical-align:top;width:39.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated:</p></td><td style="vertical-align:top;width:39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5/21/2010</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated:</p></td><td style="vertical-align:top;width:39.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">SECOND AMENDMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">LEASE BETWEEN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EMERY STATION OFFICE II, LLC (LANDLORD)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">And</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">CRYSTAL BIOSCIENCE, INC. (TENANT)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EMERYSTATION NORTH PROJECT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Emeryville, California</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Reference is made to that certain Lease dated February&#160;16, 2009 by and between Emery Station Office 11, LLC, as Landlord, and Crystal Bioscience, Inc., as Tenant, as such Lease was amended by First Amendment whose Effective Date was May&#160;20, 2010 (the &#8220;First Amendment&#8221;). Pursuant to the terms of the First Amendment, the Lease and First Amendment collectively constitute the existing Lease for all purposes thereunder. The Lease is hereby further amended by the terms of this Second Amendment, as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Effective Date of this Second Amendment shall be April&#160;11, 2011 (the &#8220;Second Amendment Effective Date&#8221;). From and after the Second Amendment Effective Date, the existing Lease and this Second Amendment thereto shall collectively constitute and be referred to as the &#8220;Lease&#8221; for all purposes thereunder.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">II.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Pursuant to the terms of the Lease, Tenant leases the 7,320 rentable square foot Premises through an Expiration Date of March&#160;31, 2014. Landlord and Tenant hereby agree to extend the Expiration Date of the Lease by six (6)&#160;months to become September 30. 2014. Effective April&#160;1, 2014, Monthly Base Rent shall be increased by three percent (3%) from the amount immediately prior.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">III.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">In consideration of the above-referenced agreement to extend the Lease Term, Landlord agrees to defer receipt of Monthly Base Rent for the months of April and May, 2011 with no applicable late fees nor interest to be applied to late Base Rent for that period as a result. Monthly Base Rent for April and May of 2011 shall be due along with all other Rent due effective June&#160;1, 2011. Notwithstanding the preceeding sentence, Tenant shall continue to pay currently, as called for in the Lease, all other charges including Tenant&#8217;s estimated monthly Operating Expenses and Taxes as well as any directly-measured and billed electrical charges.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">IV.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Tenant hereby represents to Landlord that it has represented itself in this transaction and that no broker fee shall be payable by Landlord to any representative of Tenant as a result hereof.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">V.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Except for those terms outlined above, all other terms and conditions of the existing Lease and WorkLetter shall apply.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In witness hereof, the parties have executed this Second Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:34.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:47.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT:</p></td><td colspan="2" style="vertical-align:top;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD:</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Crystal Bioscience, Inc., a California Corporation</p></td><td colspan="2" style="vertical-align:top;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emery Station Office II, LLC, a California Limited Liability Company</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:34.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">/s/ Robert J. Etches</p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Richard K. Robbins</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print&#160;Name:</p></td><td style="vertical-align:top;width:34.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert J. Etches</p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print&#160;Name:</p></td><td style="vertical-align:top;width:47.37%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td style="vertical-align:top;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President&#160;&amp; CEO</p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td style="vertical-align:top;width:47.37%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated:</p></td><td style="vertical-align:top;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4/11/2011</p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated:</p></td><td style="vertical-align:top;width:47.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4/13/2011</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">THIRD AMENDMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">LEASE BETWEEN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EMERY STATION OFFICE II, LLC (LANDLORD)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">And</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">CRYSTAL BIOSCIENCE, INC. (TENANT)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EMERYSTATION NORTH PROJECT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">Emeryville, California</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Reference is made to that certain Lease dated February&#160;16, 2009 by and between Emery Station Office II, LLC, as Landlord, and Crystal Bioscience, Inc., as Tenant, as such Lease was amended by First Amendment whose Effective Date was May&#160;20, 2010 (the &#8220;First Amendment&#8221;) and via Second Amendment whose Effective Date was April&#160;11, 2011 (the &#8220;Second Amendment&#8221;). Pursuant to the terms of the Second Amendment, the Lease and First and Second Amendments collectively constitute the existing Lease for all purposes thereunder. The Lease is hereby further amended by the terms of this Third Amendment, as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Effective Date of this Third Amendment shall be May&#160;30, 2011 (the &#8220;Third Amendment Effective Date&#8221;). From and after the Third Amendment Effective Date, the existing Lease and this Third Amendment thereto shall collectively constitute and be referred to as the &#8220;Lease&#8221; for all purposes thereunder.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">II.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Pursuant to the Second Amendment, Landlord agreed to defer receipt of Monthly Base Rent for the months of April and May, 2011 with no applicable late fees nor interest to be applied to said two months&#8217; of Base Rent so long as those two months of Base Rent were repaid to Landlord on or before June&#160;1, 2011 along with June Rent as called for in the Lease. Landlord hereby further agrees to defer Monthly Base Rent for the Month of June, 2011. Notwithstanding the preceeding sentence, Tenant shall continue to pay currently, as called for in the Lease, all other charges including Tenant&#8217;s estimated monthly Operating Expenses and Taxes as well as any directly-measured and billed electrical charges. Effective July&#160;1, 2011, in addition to all other Rent called for in the Lease, Tenant will be responsible to repay the previously-deferred April, May and June&#8217;s Monthly Base Rent along with interest thereon applied commencing June&#160;1, 2011 at an annual rate of ten percent (10%).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">III.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Tenant hereby represents to Landlord that it has represented itself in this transaction and that no broker fee shall be payable by Landlord to any representative of Tenant as a result hereof.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">IV.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Except for those terms outlined above, all other terms and conditions of the existing Lease and WorkLetter shall apply.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In witness hereof, the parties have executed this Third Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:34.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:47.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT:</p></td><td colspan="2" style="vertical-align:top;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD:</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Crystal Bioscience, Inc., a California Corporation</p></td><td colspan="2" style="vertical-align:top;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emery Station Office II, LLC, a California Limited Liability Company</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:34.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">/s/ Robert J. Etches</p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Richard K. Robbins</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print&#160;Name:</p></td><td style="vertical-align:top;width:34.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert J. Etches</p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print&#160;Name:</p></td><td style="vertical-align:top;width:47.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard K. Robbins</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td style="vertical-align:top;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President&#160;&amp; CEO</p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td style="vertical-align:top;width:47.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated:</p></td><td style="vertical-align:top;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6/10/2011</p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated:</p></td><td style="vertical-align:top;width:47.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6/14/2011</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">FOURTH AMENDMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">LEASE BETWEEN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EMERY STATION OFFICE II, LLC (LANDLORD)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">And</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CRYSTAL BIOSCIENCE, INC. (TENANT)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">And</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">ASSIGNMENT OF LANDLORD&#8217;S INTEREST IN THE LEASE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">To</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">EMERY STATION JOINT VENTURE, LLC (NEW LANDLORD)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Reference is made to that certain Lease dated February&#160;16, 2009 by and between Emery Station Office II, LLC, as Landlord, and Crystal Bioscience, Inc., as Tenant, (the &#8220;Original Lease&#8221;), as such was amended by First Amendment whose Effective Date was May&#160;20, 2010 (the &#8220;First Amendment&#8221;), by Second Amendment whose Effective Date was April&#160;11, 2011 (the &#8220;Second Amendment&#8221;), and by Third Amendment whose Effective Date was May&#160;30, 2013 (the &#8220;Third Amendment&#8221;). The Original Lease and First, Second and Third Amendments thereto collectively constitute the existing Lease for all purposes thereunder. The Lease is hereby further amended by the terms of this Fourth Amendment, as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">EFFECTIVE DATE:</b> The Effective Date of this Fourth Amendment shall be November&#160;20, 2013 (the &#8220;Fourth Amendment Effective Date&#8221;). From and after the Fourth Amendment Effective Date, the Lease and this Fourth Amendment thereto shall collectively constitute and be referred to as the &#8220;Lease&#8221; for all purposes thereunder.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">II.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">TERM:</b> The Lease currently expires on September&#160;30, 2014. Landlord and Tenant hereby agree to extend the Term of the Lease by five and one-half (5 1/2 ) years such that it will now expire on February&#160;28, 2020, such five and one-half (5 1/2) year period referred to as the &#8220;Extension Term&#8221;. Tenant shall retain one five (5)&#160;year option to extend the Lease as it applies to the entire Premises at the time of said extension pursuant to the terms of Rider 1 to the Existing Lease.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">III.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">NEW PREMISES:</b> Pursuant to the existing Lease, Tenant&#8217;s existing Premises is that 7,320 rentable square foot space on the 4th floor of the EmeryStation North Building owned by Landlord and located at 5980 Horton Street in Emeryville, CA (the &#8220;Existing Premises&#8221;). Subject to Tenant&#8217;s ability to raise additional funding for its ongoing operations (the &#8220;New Funding&#8221;, more specifically described in Section IV below), Tenant wishes to relocate to an alternate, larger space on the 4th floor of the EmeryStation 1 Building at 5858 Horton Street in Emeryville, CA (the &#8220;New Premises&#8221;), as more specifically identified in Exhibit A hereto. The New Premises is envisioned to measure approximately 9,500 rentable square feet; the exact rentable square footage of the New Premises shall be determined by final space plan mutually approved by Tenant and New Landlord. The EmeryStation 1 Building is owned by Emery Station Joint Venture, LLC (&#8220;New Landlord&#8221;), an affiliate of Landlord.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 36pt;">New Landlord shall modify the New Premises for Tenant&#8217;s occupancy at New Landlord&#8217;s sole cost and expense in conformance with the space plans and specifications and pursuant to the terms of the Workletter Agreement, all attached hereto as Exhibit B (&#8220;New Premises Landlord Work&#8221;).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">IV.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">CONTINGENCY:</b> Landlord, New Landlord, Tenant acknowledge and agree that the provisions of this Fourth Amendment pertaining to Tenant&#8217;s expansion and relocation to the New Premises are contingent on Tenant successfully securing adequate funding for its ongoing operations (the &#8220;New Funding&#8221;) prior to December&#160;31, 2013 (the &#8220;New Funding Deadline&#8221;). In the event either New Landlord or Tenant determine, in their respective sole and absolute discretions, that Tenant&#8217;s financial resources are insufficient to justify the expansion contemplated herein, either party may terminate the terms of this Fourth Amendment relating to such expansion and relocation via formal written notice to the other made on or before the New Funding Deadline. In the event of such a notice from one party to the others, this Fourth Amendment will continue to be in full force and effect, but only as it relates to the 7,320 rentable square foot Existing Premises and the extension of Lease Term defined in Section II above; Sections V and VIII shall not apply in such event.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Between the Fourth Amendment Effective Date and the New Funding Deadline, Tenant hereby agrees to provide both Landlord and New Landlord with reasonable information on the status and potential business terms of any new funding for purposes of New Landlord&#8217;s review and analysis as such information might bear on New Landlord&#8217;s right to terminate the contemplated relocation of Tenant&#8217;s Premises to New Landlord&#8217;s property. Prior to the New Funding Deadline, either party may waive its right of termination by written notice to the other. While New Landlord may elect, in its sole and absolute discretion, to expend resources towards the design of the New Premises Landlord Work prior to the New Funding Deadline, Tenant hereby agrees and acknowledges that Landlord is under no obligation to do so and if any such design is commenced, New Landlord may elect to discontinue efforts at any time. In the event neither party has terminated the terms of the Fourth Amendment as they relate to the expansion and relocation on or before the New Funding Deadline, New Landlord shall commence and pursue design and construction of the New Premises Landlord Work with commercially-reasonable promptness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 28.79pt 54pt;">Additionally, New Landlord shall not be obligated to commence and/or to continue build-out of the New Premises Landlord Work at any point in which Tenant is in material, uncured default under the Lease. Any such material, uncured default will not forestall Tenant&#8217;s rent obligations for the existing Premises under this Fourth Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">V.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">RELOCATION:</b> Tenant shall make reasonable efforts to relocate to the New Premises as soon as is practical after Substantial Completion of the New Premises Landlord Work, it being understood and agreed by the parties that, notwithstanding the date of Substantial Completion of the New Premises Landlord Work, Tenant shall have no obligation to relocate to the New Premises prior to June&#160;30, 2014 if such an earlier date is not reasonably convenient for Tenant&#8217;s business operations. The New Premises Commencement Date shall be the date upon which New Landlord achieves Substantial Completion of the New Premises Landlord Work and delivers possession of the New Premises to Tenant subject to the aforementioned right by Tenant to defer occupancy prior to June&#160;30, 2014. Tenant shall be deemed to be in Default if Tenant has not both: a) relocated to the New Premises and b) delivered possession of the Existing Premises back to Landlord in broom-clean, de-commissioned and de-contaminated condition as specified in the Lease within seven (7)&#160;days after New Landlord&#8217;s delivery of possession of the New Premises, again subject to the April&#160;30, 2014 date. Tenant hereby agrees and acknowledges that prior to the New Premises Commencement, the Landlord under this Lease shall be Landlord and that following said date the Landlord under this Lease shall become New Landlord, and that following the New Premises Commencement Date Landlord shall have no further obligations nor liabilities to Tenant, and that this Lease shall thereafter be construed as a lease agreement solely between Tenant and New Landlord.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">VI.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">RENT:</b> Prior to the New Premises Commencement Date, Monthly Base Rent as well as Tenant&#8217;s Share of Operating Expenses and Taxes shall be calculated based on the rentable square footage of the Existing Premises as it relates to the total square footage of the EmeryStation North Building. Following the New Premises Commencement Date, the Monthly Base Rent and Tenant&#8217;s Share of Operating Expenses and Taxes shall be calculated based on the rentable square footage of the New Premises as it relates to the total square footage of the EmeryStation 1 Building. The Monthly Base Rent applicable to the Existing Premises is presently calculated on the basis of $2.53 per rentable square foot. Pursuant to the terms of the Existing Lease, that Monthly Base Renal Rate is set to increase by three percent (3%) effective September&#160;1, 2014. The Monthly Base Rental shall continue to increase three percent (3%) annually every September 1st during the Extension Term and shall apply to the Existing Premises prior to the New Premises Commencement Date and to the New Premises after the New Premises Commencement Date.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">VII.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">SECURITY DEPOSIT:</b> Within no more than forty-five (45)&#160;days after both Landlord and Tenant formally waive (via written notice to the other) their respective rights to terminate the contemplated expansion of Tenant&#8217;s Premises as more fully described in Section IV above, but in no event later than February&#160;15, 2014, Tenant shall remit to Landlord additional funds to increase the existing Security Deposit in proportion to the increase in rentable area of the New Premises compared to the Existing Premises (i.e. to increase it by the ratio of the rentable square footage of the New Premises compared to the 7,320 rentable square footage of the Existing Premises). By way of example, if the New Premises is determined to measure 9,700 rentable square feet pursuant to the</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 30.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">mutually-approved space plan referenced in Section III above, the Security deposit required under this Section would be the product of 9,700 divided by 7,320 times the amount of the existing Security Deposit. Upon the New Premises Commencement Date Landlord agrees to transfer Tenant&#8217;s Security Deposit to New Landlord.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">VIII.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">REPRESENTATION:</b> Tenant hereby represents to Landlord that it has represented itself in this transaction and that no broker fee shall be payable by Landlord to any representative of Tenant as a result other than a consulting fee payable to Rico Cheung of Kidder Mathews pursuant to a separate agreement between he and Landlord.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">IX.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">MISCELLANEOUS:</b> Upon the New Premises Commencement Date, the Lease shall be further modified as follows:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Section&#160;1.1(1) BUILDING AND ADDRESS shall become EmeryStation 1, 5858 Horton Street, Emeryville, CA 94608</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Section&#160;1.1(2) LANDLORD AND ADDRESS shall become Emery Station Joint Venture, LLC, c/o Wareham Development.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Section&#160;1.1(9) RENTABLE AREA OF THE PREMISES shall be the rentable area of the New Premises, as referenced in Section III above.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Section&#160;1.1(11) SUITE NUMBER shall become (to be inserted later).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">X.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">GENERAL: </b>Except for those terms outlined above, all other terms and conditions of the existing Lease and WorkLetter shall apply.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In witness hereof, the parties have executed this Fourth Amendment.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:34.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:47.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT:</p></td><td colspan="2" style="vertical-align:top;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD:</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Crystal Bioscience, Inc., a California Corporation</p></td><td colspan="2" style="vertical-align:top;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emery Station Office II, LLC, a California Limited Liability Company</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:34.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">/s/ Robert J. Etches</p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Richard K. Robbins</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print&#160;Name:</p></td><td style="vertical-align:top;width:34.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert J. Etches</p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print&#160;Name:</p></td><td style="vertical-align:bottom;width:47.37%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td style="vertical-align:top;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President&#160;&amp; CEO</p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td style="vertical-align:bottom;width:47.37%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated:</p></td><td style="vertical-align:top;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11/20/2013</p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated:</p></td><td style="vertical-align:bottom;width:47.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11/20/2013</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:40.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NEW LANDLORD:</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emery Station Office Joint Venture, LLC, a California Limited Liability Company</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:40.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Richard K. Robbins</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print&#160;Name:</p></td><td style="vertical-align:bottom;width:40.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td style="vertical-align:bottom;width:40.66%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated:</p></td><td style="vertical-align:bottom;width:40.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11/20/2013</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">FIFTH AMENDMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">LEASE BETWEEN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EMERY STATION OFFICE II, LLC (LANDLORD)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">And</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">CRYSTAL BIOSCIENCE, INC. (TENANT)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Reference is made to that certain Lease dated February&#160;16, 2009 by and between Emery Station Office II, LLC, as Landlord, and Crystal Bioscience, Inc., as Tenant, (the &#8220;Original Lease&#8221;), as such was amended by First Amendment whose Effective Date was May&#160;20, 2010 (the &#8220;First Amendment&#8221;), by Second Amendment whose Effective Date was April&#160;11, 2011 (the &#8220;Second Amendment&#8221;), by Third Amendment whose Effective Date was May&#160;30, 2013 (the &#8220;Third Amendment&#8221;), and by Fourth Amendment whose Effective Date was November&#160;20, 2013 (the &#8220;Fourth Amendment&#8221;). The Original Lease and First, Second, Third and Fourth Amendments thereto collectively constitute the existing Lease for all purposes thereunder. The Lease is hereby further amended by the terms of this Fifth Amendment, as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">EFFECTIVE DATE:</b> The Effective Date of this Fifth Amendment shall be January&#160;30, 2013 (the &#8220;Fifth Amendment Effective Date&#8221;). From and after the Fifth Amendment Effective Date, the Lease and this Fifth Amendment thereto shall collectively constitute and be referred to as the &#8220;Lease&#8221; for all purposes thereunder.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">II.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">TERM:</b> Pursuant to the Fourth Amendment, the Lease expires on February&#160;28, 2020, subject to Tenant&#8217;s option to further extend the Term of the Lease by one additional five (5)&#160;year period (i.e. to February&#160;28, 2025), as described in Section II of the Fourth Amendment.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">III.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">PREMISES:</b> In the Fourth Amendment, Tenant, Landlord and New Landlord Emery Station Joint Venture, LLC (an affiliate of Landlord) all agreed that Tenant would expand its space via its relocation to a larger space on the 4th floor of the EmeryStation 1 Building at 5858 Horton Street in Emeryville, which building is owned by New Landlord. Tenant has subsequently requested, and both Landlord and New Landlord have agreed, to allow Tenant to remain in its existing 7,320 rentable square foot Premises (as more fully defined in Exhibit A hereto) for the extended Term of the Lease rather than to expand and relocate. This agreement for Tenant to remain in its existing Premises is subject to Landlord&#8217;s agreement to, at its sole cost and expense, to make alterations to that existing Premises as more fully outlined on Exhibit B hereto (the &#8220;Landlord Alterations&#8221;).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">IV.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">EXPANSION:</b> Tenant&#8217;s interest in remaining in the existing Premises rather than expanding and relocating to alternate premises is based on Tenant&#8217;s belief that it will not reasonably likely have additional space needs for at least eighteen months following the Effective Date hereof. Landlord hereby agrees to make commercially-reasonable efforts to negotiate mutually-satisfactory solutions and transaction terms to any additional space needs Tenant may have following said eighteen month period in buildings in Emeryville owned by Landlord or Landlord&#8217;s affiliates, it being understood and agreed by both Landlord and Tenant that the terms of any such expansion may be different from the terms contained in Tenant&#8217;s existing Lease and must be satisfactory to both Landlord and to Tenant in their respective sole and absolute discretion.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">V.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">PARKING:</b> Tenant may elect to convert up to two of its existing unreserved, non-premium parking spaces under the Lease to unreserved, &#8220;premium&#8221; spaces in the Building&#8217;s ground floor parking level, and agrees to pay Landlord&#8217;s quoted rates therefore. At Landlord&#8217;s election, in its sole and absolute discretion, it may make additional premium spaces available to Tenant on a month-to month basis, again bearing Landlord&#8217;s quoted rates therefore.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">V.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">RENT:</b> Monthly Base Rent for the 7,320 rentable square foot Premises during the Extension Term (as &#8220;Extension Term&#8221; is defined in the Fourth Amendment) shall be:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;" align="center"><tr><td style="vertical-align:bottom;width:71.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">PERIOD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:25.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MONTHLY&#160;BASE&#160;RENT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/1/2014 &#8211; 8/31/2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:24.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,075,19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/1/2015 &#8211; 8/31/2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,647.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/1/2016 &#8211; 8/31/2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,236.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/1/2017 &#8211; 8/31/2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,843.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/1/2018 &#8211; 8/31/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21,469.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/1/2019 &#8211; 2/28/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,113.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">VI.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">SECURITY DEPOSIT:</b> With the agreement referenced above to not increase the size of Tenant&#8217;s Premises, the Security Deposit will remain unchanged and not need to be increased as had otherwise been set forth in Section VII of the Fourth Amendment.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">VII.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">REPRESENTATION:</b> Tenant hereby represents to Landlord that it has represented itself in this transaction and that no broker fee shall be payable by Landlord to any representative of Tenant as a result other than a consulting fee payable to Rico Cheung of Kidder Mathews pursuant to a separate agreement between he and Landlord, this transaction being deemed to replace and be a substitute for that expansion and relocation of Tenant&#8217;s Premises that had been contemplated in the Fourth Amendment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">VIII.<b style="font-weight:bold;">GENERAL:</b> Except for those terms outlined above, all other terms and conditions of the existing Lease and WorkLetter shall apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In witness hereof, the parties have executed this Fifth Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT:</p></td><td colspan="2" style="vertical-align:top;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD:</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Crystal Bioscience, Inc., a California Corporation</p></td><td colspan="2" style="vertical-align:top;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emery Station Office II, LLC, a California Limited Liability Company</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:34.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:34.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">/s/ Robert J. Etches</p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Richard K. Robbins</p></td></tr><tr><td style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print&#160;Name:</p></td><td style="vertical-align:top;width:34.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert J. Etches</p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print&#160;Name:</p></td><td style="vertical-align:bottom;width:47.37%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its: President&#160;&amp; CEO</p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td style="vertical-align:bottom;width:47.37%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: 1/30/2014</p></td><td colspan="2" style="vertical-align:top;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: 2/2/2014</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NEW LANDLORD:</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emery Station Office Joint Venture, LLC, a California Limited Liability Company</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Richard K. Robbins</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print&#160;Name:</p></td><td style="vertical-align:bottom;width:47.37%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td style="vertical-align:bottom;width:47.37%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:56.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: 2/2/2014</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">SIXTH AMENDMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">LEASE BETWEEN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EMERY STATION OFFICE II, LLC (LANDLORD)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">And</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">CRYSTAL BIOSCIENCE, INC. (TENANT)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Reference is made to that certain Lease dated February&#160;16, 2009 by and between Emery Station Office II, LLC, as Landlord, and Crystal Bioscience, Inc., as Tenant, (the &#8220;Original Lease&#8221;), as such was amended by First Amendment whose Effective Date was May&#160;20, 2010 (the &#8220;First Amendment&#8221;), by Second Amendment whose Effective Date was April&#160;11, 2011 (the &#8220;Second Amendment&#8221;), by Third Amendment whose Effective Date was May&#160;30, 2013 (the &#8220;Third Amendment&#8221;), by Fourth Amendment whose Effective Date was November&#160;20, 2013 (the &#8220;Fourth Amendment&#8221;), and by Fifth Amendment whose Effective Date was January&#160;30, 2013 (the &#8220;Fifth Amendment&#8221;). The Original Lease and First, Second, Third, Fourth and Fifth Amendments thereto collectively constitute the existing Lease for all purposes thereunder. The Lease is hereby further amended by the terms of this Sixth Amendment, as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">EFFECTIVE DATE:</b> The Effective Date of this Sixth Amendment shall be September&#160;25, 2014 (the &#8220;Sixth Amendment Effective Date&#8221;). From and after the Sixth Amendment Effective Date, the Lease and this Sixth Amendment thereto shall collectively constitute and be referred to as the &#8220;Lease&#8221; for all purposes thereunder.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">II.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">TERM:</b> The Lease currently expires on February&#160;28, 2020. Landlord and tenant hereby agree to extend the Term of the Lease by one (1)&#160;year such that it will now expire on February&#160;28, 2012, such one year extension period to be referred to as the &#8220;Sixth Amendment Expansion Term&#8221;. Tenant shall retain one option to further extend the Term of the Lease by one additional five (5)&#160;year period (i.e. to February&#160;28, 2026), as described in Section II of the Fourth Amendment.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">III.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">MONTHLY BASE RENT: Monthly Base Rent prior to the commencement of the Sixth Amendment Extension Term shall be as called for in Section V of the Fifth Amendment. Monthly Base Rent during the Sixth Amendment Extension Term shall be as follows:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;" align="center"><tr><td style="vertical-align:bottom;width:71.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">PERIOD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:25.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MONTHLY&#160;BASE&#160;RENT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3/1/2020 &#8211; 8/31/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:24.38%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,113.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/1/2020 &#8211; 2/28/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:24.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,776.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">IV.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">PARKING:</b> As of the Fifth Amendment, Tenant held rights to use up to ten (10)&#160;unreserved parking spaces at the Terraces Garage. With this Sixth Amendment, Tenant&#8217;s rights to use unreserved parking space in the Terraces Garage shall be increased by an additional five (5)&#160;spaces to become a total of fifteen (15)&#160;spaces. Tenant&#8217;s use of the parking spaces shall be governed by the terms of the Lease and Tenant shall pay Landlord&#8217;s quoted monthly rates therefore. In addition, Tenant shall be entitled to park two (2)&#160;motorcycles in the garage of the Building free of charge during the term of the Lease.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">V.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">REPRESENTATION:</b> Tenant hereby represents to Landlord that it has represented itself in this transaction and that no broker fee shall be payable by Landlord to any representative of Tenant as a result.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">VI.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">GENERAL:</b> Except for those terms outlined above, all other terms and conditions of the existing Lease and WorkLetter shall apply.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In witness hereof, the parties have executed this Sixth Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:37.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:46.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT:</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD:</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:46.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Crystal Bioscience, Inc., a California Corporation</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emery Station Office II, LLC, a California Limited Liability Company</p></td></tr><tr><td style="vertical-align:top;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:37.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">/s/ Robert J. Etches</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard K. Robbins</p></td></tr><tr><td style="vertical-align:top;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print&#160;Name:</p></td><td style="vertical-align:top;width:37.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert J. Etches</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print&#160;Name:</p></td><td style="vertical-align:bottom;width:42.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Richard K. Robbins</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:46.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its: President &amp; CEO</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its: Managing Member</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:46.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: 9/26/2014</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: 9/29/2014</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">SEVENTH AMENDMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">LEASE BETWEEN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EMERY STATION OFFICE II, LLC (LANDLORD)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">And</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">CRYSTAL BIOSCIENCE, INC. (TENANT)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EMERYSTATION NORTH PROJECT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Emeryville, California</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Reference is made to that certain Lease dated February&#160;16, 2009 by and between Emery Station Office II, LLC, as Landlord, and Crystal Bioscience, Inc., as Tenant, (the &#8220;Original Lease&#8221;), as such was amended by First Amendment whose Effective Date was May&#160;20, 2010 (the &#8220;First Amendment&#8221;), by Second Amendment whose Effective Date was April&#160;11, 2011 (the &#8220;Second Amendment&#8221;), by Third Amendment whose Effective Date was May&#160;30, 2013 (the &#8220;Third Amendment&#8221;), by Fourth Amendment whose Effective Date was November&#160;20, 2013 (the &#8220;Fourth Amendment&#8221;), by Fifth Amendment whose Effective Date was January&#160;30, 2013 (the &#8220;Fifth Amendment&#8221;) and by Sixth Amendment whose Effective Date was September&#160;25, 2014 (the &#8220;Sixth Amendment&#8221;). The Original Lease and First, Second, Third, Fourth, Fifth and Sixth Amendments thereto collectively constitute and are referred to as the Lease for all purposes thereunder. The Lease is hereby further amended by the terms of this Seventh Amendment, as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Effective Date of this Seventh Amendment shall be February&#160;17, 2016 (the &#8220;Seventh Amendment Effective Date&#8221;). From and after the Seventh Amendment Effective Date, the existing Lease and this Seventh Amendment thereto shall collectively constitute and be referred to as the &#8220;Lease&#8221; for all purposes thereunder.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">II.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Pursuant to the terms of the Lease, Tenant presently leases the 7,320 rentable square foot Premises through an Expiration Date of February&#160;28, 2021. Landlord and Tenant hereby agree to extend the Expiration Date of the Lease by six (6)&#160;months to become August&#160;31, 2021.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">III.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Effective March&#160;1, 2021, Monthly Base Rent shall be increased by three percent (3%) from the amount immediately prior.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">IV.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">In consideration of the above-referenced agreement to extend the Lease Term, Landlord agrees to defer receipt of an amount equal to fifty percent (50%) of Monthly Base Rent and Rent Deposit Adjustments (on account of Tenant&#8217;s Share of Operating Expenses and Taxes) otherwise due from Tenant to Landlord for the months of March and April, 2016, (this 50% amount to be referred to as the &#8220;2016 Deferrals&#8221;). Tenant shall pay to Landlord the full amount of the 2016 Deferrals plus all other Rent otherwise then due effective the earlier of: a) May&#160;1, 2016 and b) Tenant&#8217;s successful closing of a sale or financing. In the event Tenant timely repays the 2016 Deferrals as required above, Landlord shall apply no late fees nor interest to the Deferrals as would otherwise be allowed under the terms of the Lease. Notwithstanding the preceeding, Tenant shall continue to pay currently, the 50% of Base Rent and Rent Adjustment Deposits as called for in the Lease, along with any and all other charges pursuant to the Lease.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">V.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Tenant hereby represents to Landlord that it has represented itself in this transaction and that no broker fee shall be payable by Landlord to any representative of Tenant as a result hereof.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">VI.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Except for those terms outlined above, all other terms and conditions of the existing Lease shall apply.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In witness hereof, the parties have executed this Seventh Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:41.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT:</p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Crystal Bioscience, Inc., a California Corporation</p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:41.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">/s/ Robert J. Etches</p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print&#160;Name:</p></td><td style="vertical-align:bottom;width:41.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert J. Etches</p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its: </p></td><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President&#160;&amp; CEO</p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: </p></td><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2/18/2016</p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD:</p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emery Station Office II, LLC, a California limited <br>liability company</p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Emery Station Associates II, LLC, a California <br>limited liability company its Managing<br>Member</p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Wareham-NZL, LLC, <br>a California limited liability company <br>its Managing Member</p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:41.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Richard K. Robbins</p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard K. Robbins, Manager</p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: </p></td><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3/14/2016</p></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EIGHTH AMENDMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(5980 Horton Street, Emeryville, California)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This Eighth Amendment (this &#8220;<b style="font-weight:bold;">Amendment</b>&#8221;), dated as of May&#160;13, 2021, is entered into by and between EMERY STATION OFFICE II, LLC, a California limited liability company (&#8220;<b style="font-weight:bold;">Landlord</b>&#8221;), and CRYSTAL BIOSCIENCE, INC., a California corporation (&#8220;<b style="font-weight:bold;">Tenant</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recitals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A. Landlord and Tenant entered into that certain Lease dated February&#160;16, 2009, as amended by that certain First Amendment to Lease dated May&#160;21, 2010, that certain Second Amendment to Lease dated April&#160;13, 2011, that certain Third Amendment to Lease dated June&#160;14, 2011, that certain Fourth Amendment to Lease dated November&#160;20, 2013, that certain Fifth Amendment to Lease dated February&#160;2, 2014, that certain Sixth Amendment to Lease dated September&#160;29, 2014, and that certain Seventh Amendment to Lease dated March&#160;14, 2016 (collectively, the &#8220;<b style="font-weight:bold;">Lease</b>&#8221;), whereby Tenant leases certain space known as Suite 405 and consisting of approximately 7,320 rentable square feet (the &#8220;<b style="font-weight:bold;">Premises</b>&#8221;) within the building located at 5980 Horton Street, Emeryville, California (the &#8220;<b style="font-weight:bold;">Building</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">B. Tenant&#8217;s parent company, Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#8220;<b style="font-weight:bold;">Ligand Phama</b>&#8221;), and Landlord have entered into that certain Office/Laboratory Lease dated substantially concurrently herewith for space (the &#8220;<b style="font-weight:bold;">Ligand Pharma Space</b>&#8221;) on the 6th Floor of the Building (the &#8220;<b style="font-weight:bold;">Ligand Pharma Lease</b>&#8221;). Pursuant to the terms of the Ligand Pharma Lease, Ligand Pharma intends to complete certain improvement work within the Ligand Pharma Space designated as the &#8220;Phase II Tenant Work&#8221; in the Ligand Pharma Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">C. The current Term of the Lease expires as of August&#160;31, 2021 (the &#8220;<b style="font-weight:bold;">Prior Expiration Date</b>&#8221;), and the parties now desire to extend the Term of the Lease to the date that is thirty (30)&#160;days after completion of the Phase II Tenant Work under the Ligand Pharma Lease, on the following terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">NOW THEREFORE, in consideration of the foregoing and the mutual covenants contained herein, the parties agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">1. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions; Recitals</u>. Unless otherwise specified herein, all capitalized terms used in this Amendment are used as defined in the Lease. The parties acknowledge the truthfulness of the foregoing Recitals, which are hereby incorporated into this Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Inconsistencies</u>. To the extent that there are any inconsistencies between the terms of the Lease and this Amendment, the terms of this Amendment shall control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Extension</u>. The Term of the Lease is hereby extended for a period of approximately ten (10)&#160;months and shall expire the date that is thirty (30)&#160;days after Substantial Completion of the Phase II Tenant Work under the Ligand Pharma Lease (the &#8220;<b style="font-weight:bold;">Extended Expiration Date</b>&#8221;), unless sooner terminated in accordance with the terms of the Lease. The Extended Expiration Date is estimated to be on or about June&#160;30, 2022. Tenant acknowledges and agrees that Tenant and Ligand Pharma shall confirm the actual Extended Expiration Date in a Commencement Date Memorandum to be executed in connection with the Ligand Pharma Lease. That portion of the Term commencing the day immediately following the Prior Expiration Date (the &#8220;<b style="font-weight:bold;">Extension Date</b>&#8221;) and ending on the Extended Termination Date shall be referred to herein as the &#8220;<b style="font-weight:bold;">Extended Term</b>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">4. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Monthly Base Rent</u>. As of the Extension Date, the schedule of Monthly Base Rent shall remain as set forth in the Lease. All such Monthly Base Rent shall continue to be payable by Tenant in accordance with the terms of the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Premises &#8220;As-Is</u>&#8221;. Tenant is in possession of the Premises and accepts the same &#8220;as is&#8221; without any agreements, representations, understandings or obligations on the part of Landlord to perform any alterations, repairs or improvements, except as may be expressly provided otherwise in this Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a) This Amendment sets forth the entire agreement between the parties with respect to the matters set forth herein. There have been no additional oral or written representations or agreements. Under no circumstances shall Tenant be entitled to any Rent abatement, improvement allowance, leasehold improvements, or other work to the Premises, or any similar economic incentives that may have been provided Tenant in connection with entering into the Lease, unless specifically set forth in this Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b) Except as herein modified or amended, the provisions, conditions and terms of the Lease shall remain unchanged and in full force and effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(c) In the case of any inconsistency between the provisions of the Lease and this Amendment, the provisions of this Amendment shall govern and control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(d) Submission of this Amendment by Landlord is not an offer to enter into this Amendment but rather is a solicitation for such an offer by Tenant. Landlord shall not be bound by this Amendment until Landlord has executed and delivered the same to Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(e) The capitalized terms used in this Amendment shall have the same definitions as set forth in the Lease to the extent that such capitalized terms are defined therein and not redefined in this Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(f) Tenant hereby represents to Landlord that Tenant has dealt with no broker in connection with this Amendment. Tenant agrees to indemnify and hold Landlord, its members, principals, beneficiaries, partners, officers, directors, employees, mortgagee(s) and agents, and the respective principals and members of any such agents (collectively, the &#8220;<b style="font-weight:bold;">Landlord Related Parties</b>&#8221;) harmless from all claims of any brokers claiming to have represented Tenant in</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:55.1pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">connection with this Amendment. Landlord hereby represents to Tenant that Landlord has dealt with no broker in connection with this Amendment. Landlord agrees to indemnify and hold Tenant, its members, principals, beneficiaries, partners, officers, directors, employees, and agents, and the respective principals and members of any such agents (collectively, the &#8220;<b style="font-weight:bold;">Tenant Related Parties</b>&#8221;) harmless from all claims of any brokers claiming to have represented Landlord in connection with this Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(g) This Amendment may be executed in counterparts each of which counterparts when taken together shall constitute one and the same agreement. Any facsimile, PDF or other electronic signature shall constitute a valid and binding method for executing this Amendment. Executed counterparts of this Amendment exchanged by facsimile transmission, PDF email, or other electronic means shall be fully enforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">IN WITNESS WHEREOF, the parties have executed this Amendment as of the date set forth above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:5.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT:</p></td><td style="vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:top;width:48.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD:</p></td></tr><tr style="height:13.5pt;"><td colspan="2" style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><div style="height:13.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"><div style="height:13.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:middle;width:48.1%;margin:0pt;padding:0pt;"><div style="height:13.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CRYSTAL BIOSCIENCE, INC., <br>a California corporation</p></td><td style="vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EMERY STATION OFFICE II, LLC,<br>a California limited liability company</p></td></tr><tr><td style="vertical-align:top;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">/s/ Matthew W. Foehr</p></td><td style="vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emery Station Associates II, LLC, <br>its Managing Member</p></td></tr><tr><td style="vertical-align:top;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew W. Foehr</p></td><td style="vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its: </p></td><td style="vertical-align:top;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President/COO</p></td><td style="vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Wareham-NZL, LLC,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">its Managing Member</p></td></tr><tr><td style="vertical-align:top;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Charles Berkman</p></td><td style="vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:44.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Richard K. Robbins</p></td></tr><tr><td style="vertical-align:top;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:top;width:44.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Charles Berkman</p></td><td style="vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:44.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard K. Robbins</p></td></tr><tr><td style="vertical-align:top;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its: </p></td><td style="vertical-align:top;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SVP, General Counsel&#160;&amp; Secretary</p></td><td style="vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its Manager</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>4
<FILENAME>ahpa-20220416xex10d25.htm
<DESCRIPTION>EXHIBIT-10.25
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/27/2022 11:11:03 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.25</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ANTIBODY LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Antibody License Agreement (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;) is entered into effective December&#160;20, 2012 (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u>&#8221;) by Open Monoclonal Technologies, Inc. (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OMT</u>&#8221;), a Delaware corporation having its principal place of business at 2747 Ross Road, Suite A, Palo Alto, CA 94303 and CNA Development LLC (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensee</u>&#8221;), a Delaware limited liability company, having its principal place of business at [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS Licensee is in the business of performing research aimed at discovering and developing biopharmaceutical products, and has proprietary or license rights relating to certain technology used in such research and molecules discovered or developed in such research;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, OMT owns, controls and/or possesses certain intellectual property rights, know-how, and other trade secrets relating to generation of human antibodies using a transgenic rat platform;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS Licensee wishes for OMT to use certain antigens delivered by Licensee to OMT with OMT&#8217;s transgenic rats to generate and deliver to Licensee sera and OMT rats that have been immunized with such antigens;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of their mutual promises to each other, hereinafter stated, the Parties agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.1</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliate</u>&#8221; shall mean, with respect to a Party, any corporation or other entity that controls, is controlled by, or is under common control with that Party. For the purpose of this definition, &#8220;control&#8221; means: (a) the possession, directly or indirectly, of the power to direct the management or policies of an entity, whether through the ownership of voting securities, by contract or otherwise, or (b) the ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities of such entity; and in the case of both (a) and (b), only for so long as such control shall continue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.2</font></font> &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Antigen</u>&#8221; shall mean an agent Licensee provides to OMT hereunder that OMT shall use to perform immunizations, in accord with the protocol reflected in the Research Plan in Appendix A, of Rats and subsequently provide Licensee with immunized OMT Rats, or the spleens or other sources of antibodies derived from such OMT Rats.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.3</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Antigen Restrictions</u>&#8221; shall mean that OMT shall not use the specific Antigen(s) materials delivered by Licensee for any purpose other than the performance of the research and development activities described in this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.4</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercialization</u>&#8221; shall mean (including variations such as Commercialize and the like) the performance of any and all activities directed to promoting, marketing, importing, exporting, distributing, selling or offering to sell (including pre marketing), and post marketing drug surveillance of Licensed Product or, to the extent expressly permitted under this Agreement, to have any of those activities performed by a Third Party.</p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.5</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercial Fee</u>&#8221; means the Commercial Fee of $[***] as further described in Section&#160;4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.6</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Deliverable</u>&#8221; shall mean those materials OMT provides to Licensee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">following receipt of Antigen, as described in the Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.7</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Field</u>&#8221; means the treatment or diagnosis of all diseases in humans and animals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.8</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Commercial Sale</u>&#8221; means, with respect to any country, the first sale to a Third Party of a Licensed Product in such country by or on behalf of Licensee or any of its Affiliates or licensees after the granting of Regulatory Approval with respect to such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.9</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Product</u>&#8221; means a pharmaceutical product developed by or on behalf of Licensee derived from an OMT Antibody(ies).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.10</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Marketing Authorization</u>&#8221; means, with respect to a jurisdiction, any approval (including all applicable pricing and governmental reimbursement approvals) required from the relevant Regulatory Authority to market and sell a Licensed Product in such jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.11</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Milestone Event</u>&#8221; means each event described in Section&#160;4.3 below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.12</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OMT Antibody(ies)</u>&#8221; means a molecule or a gene encoding a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains, or any existing or future fragments, variants, fusion proteins, modifications or derivatives of such molecule or gene generated through use of Rats and/or OMT Rats.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.13</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OMT Intellectual Property</u>&#8221; shall mean all patents and patent applications listed in Appendix E, and continuations, divisionals, renewals, substitutes, extensions, conversions, continuations-in-part, reissues, provisionals, and reexaminations thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.14</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Party</u>&#8221; means OMT or Licensee. &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</u>&#8221; means both OMT and Licensee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.15</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase I Clinical Trial</u>&#8221; shall mean a human clinical trial of a Licensed Product that is designed to initially evaluate the safety, metabolism and pharmacokinetics of a Licensed Product or that would otherwise satisfy the requirements defined in 21 C.F.R. 312.21(a) or other comparable regulation imposed by the FDA, the EMEA, or their foreign counterparts for an equivalent clinical trial in a country in the Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.16</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase II Clinical Trial</u>&#8221; means a well-controlled clinical trial in patients, designed to evaluate clinical efficacy and safety of a Licensed Product, for one or more indications, as well as to obtain an indication of the dosage regimen required, or that would otherwise satisfy the requirements defined in 21 CFR 312.21(b), or other comparable regulation imposed by the FDA, the EMEA or their foreign counterparts for an equivalent clinical trial in a country in the Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.17</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase III Clinical Trial</u>&#8221; means a pivotal human clinical trial in any country, designed to be used to establish safety and efficacy of a Licensed Product as a basis for a Marketing Authorization application that would satisfy the requirements defined in 21 C.F.R. 312.21(c), or other comparable regulation imposed by the FDA, the EMEA or their foreign counterparts for an equivalent clinical trial in a country in the Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.18</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rats</u>&#8221; means rats that have been genetically modified by OMT to have inactivated endogenous immunoglobulin loci and transgenic immunoglobulin loci.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.19</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Authority</u>&#8221; means the FDA, the EMEA or any national or local agency, authority, department, inspectorate, minister, ministry official, parliament or public or statutory person (whether autonomous or not) of any government of any country having jurisdiction over any of the activities contemplated by this Agreement or the Parties, or any successor bodies thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.20</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Research Plan</u>&#8221; means the activities described in Appendix A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.21</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Research Term</u>&#8221; means the period from the Effective Date until OMT receives the full Commercial Fee from Licensee or termination of the Agreement, if earlier.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.22</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sequence Report</u>&#8221; shall have the meaning set forth in Section&#160;2.4.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.23</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sera Research Term</u>&#8221; means the period from OMT&#8217;s delivery of the Sera to Licensee, until Licensee&#8217;s selection of Rats pursuant to Section&#160;2.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.24</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Territory</u>&#8221; means worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.25</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party</u>&#8221; means any individual or entity other than a Party or a Party&#8217;s Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Research Activities</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OMT Services</u>. Within [***] days after the Effective Date, Licensee shall deliver to OMT [***] Antigens. OMT shall use the Antigens provided by Licensee solely for executing the activities under the Research Plan in Appendix A. OMT will use commercially reasonable efforts to (a) immunize Rats with such Antigens, (b) deliver to Licensee sera from such immunized Rats (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sera</u>&#8221;) for Licensee analysis, and (c) deliver to Licensee the Rats that have received such immunizations and have been selected by Licensee pursuant to such Sera analysis (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OMT Rats</u>&#8221;); all of the foregoing, pursuant to the OMT Research Plan attached hereto as Exhibit&#160;A (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OMT Services</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensee Activities</u> During the Research Term, pursuant to the Licensee Research Plan attached hereto as Appendix B (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensee Activities</u>&#8221;) and all terms and conditions herein, Licensee may perform research and development activities with respect to the Sera, OMT Rats, and OMT Antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">2.2.1<font style="display:inline-block;width:16pt;"></font>Licensee may only use the Sera internally, during the Sera Research Term, subject to compliance with all the terms and conditions herein, for the sole purpose of determining which Rats to select pursuant to Section&#160;2.1. Licensee shall not (and shall not permit others to) reverse engineer or modify the Sera in any manner. For avoidance of doubt, OMT owns the [***] ([***], and Licensee hereby makes all assignments necessary to achieve ownership of such [***]).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Substitutions</u>. If the Sera or OMT Rats fail to provide OMT Antibodies suitable for further development, Licensee may provide written notice to OMT and identify [***] additional Antigen to be used for immunization of Rats at no additional cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reports</u>. During the Research Term, within [***] of each [***] anniversary of the Effective Date, Licensee shall deliver to OMT a semi-annual report, in a form reasonably acceptable to OMT, (a) detailing the [***] pursuant to this Agreement during the previous [***] [***] period, including without limitation Licensee&#8217;s use of the OMT Rats, and (b) detailing the [***] the OMT Rats, including without limitation identification of each facility in which OMT Rats are kept. Upon OMT&#8217;s receipt of the Commercial Fee from Licensee, until OMT&#8217;s receipt of the last milestone payment hereunder, upon each [***] anniversary of the end of the Research Term, Licensee shall deliver to OMT an [***] report, in a form reasonably acceptable to OMT, detailing [***] with respect to the OMT Antibodies and Licensed Products during the previous calendar year (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual Report</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">2.4.1<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sequence Reporting</u>. Licensee shall deliver to OMT a report describing the amino acid sequence(s) of any OMT Antibodies first described or claimed in any patent application filed by Licensee (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sequence Report</u>&#8221;). Licensee shall submit the Sequence Report to OMT within [***] of the filing date of any patent application first describing or claiming any OMT Antibodies. OMT shall treat the Sequence Report as Licensee&#8217;s Confidential Information until such time that the sequence information becomes publicly available, or is otherwise no longer Confidential Information. OMT shall use the information reflected in the Sequence Report solely for purposes of monitoring the development or Commercialization activities of Licensee using OMT Antibodies and/or Licensed Products and assessing Licensee&#8217;s financial obligations associated with such activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.5</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Maintenance of the OMT Rats</u>. Licensee will be responsible for the keeping and maintenance of the OMT Rats transferred to Licensee, and shall at all times keep and maintain the OMT Rats in accordance with the provisions set forth on Appendix C, at facilities within the United States that are owned and controlled by Licensee. Notwithstanding the foregoing, Licensee may keep and maintain the OMT Rats at a facility within the United States or Europe that is owned and controlled by [***] (&#8220;[***]&#8221;); provided Licensee must provide prior written notice thereof to OMT, and provided Licensee shall remain responsible for [***] acts and omissions as if [***] were Licensee. Except as expressly set forth in the previous sentence, Licensee shall not provide or make available any OMT Rats to any third party without OMT&#8217;s express prior written consent, given on a case-by-case basis, in OMT&#8217;s sole discretion. OMT may inspect any facility in which OMT Rats are kept or maintained at any time upon reasonable prior notice to Licensee (and Licensee shall require [***] afford OMT the same right). Licensee acknowledges and agrees that the OMT Rats, together with any related biological material or substance that is replicated, synthesized or in any way derived from the OMT Rats, include and constitute valuable trade secrets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of OMT, and OMT has used diligent efforts to maintain such items as its trade secrets and Confidential Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property Rights</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ownership of and License to OMT Rats- Research Term</u>. During the Research Term, subject to compliance with all of the terms and conditions herein, OMT hereby grants to Licensee a [***] license [***] the (a) OMT Rats, [***] pursuant to the Licensee Research Plan of Appendix B, and (b) OMT Intellectual Property, [***] in (a). Licensee shall not (and shall not permit others to) reverse engineer or modify the OMT Rats in any manner, breed or attempt to breed the OMT Rats or otherwise produce or attempt to produce any progeny or derivatives of any OMT Rats, or subject the OMT Rats to testing procedures or protocols that may reveal information regarding ingredients or quantities. For avoidance of doubt, OMT owns the OMT Rats (and any derivative, modification, progeny or improvement (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OMT Rat Progeny</u>&#8221;) thereof created in violation of this Agreement, and Licensee hereby makes all assignments necessary to achieve such ownership of such OMT Rat Progeny).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ownership of and License to OMT Antibodies - Research Term</u>. During the Research Term, subject to compliance with all of the terms and conditions of this Agreement, OMT hereby grants Licensee a [***] right and license [***] the (a) OMT Antibodies to execute under the Licensee Research Plan, and (b) OMT Intellectual Property, [***]. Unless and until OMT receives the full Commercial Fee from Licensee during the Research Term, [***] shall own the OMT Antibodies and Licensed Products and all rights therein (and Licensee hereby makes all assignments necessary to achieve such ownership).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ownership of and License to OMT Antibodies &amp; Commercial Payment</u>. Upon OMT&#8217;s receipt of the full Commercial Fee from Licensee, OMT grants to Licensee a non-royalty, fee-bearing, non-exclusive, worldwide license, with the right to sublicense, to the OMT Intellectual Property, solely to the extent necessary to develop and Commercialize Licensed Product(s). Upon payment of the Commercial Fee, Licensee shall become the sole and exclusive owner, even as to OMT, of the OMT Antibodies and any Licensed Products and all rights therein, and OMT hereby makes all assignments necessary to perfect ownership in such OMT Antibodies and/or Licensed Products wherein said assignments are contingent upon payment of the Commercial Fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;365(n) of the Bankruptcy Code</u>. All rights and licenses granted under or pursuant to any section&#160;of this Agreement, are rights to &#8220;intellectual property&#8221; (as defined in Section&#160;101(35A) of Title 11 of the United States Code, as amended (such Title 11, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bankruptcy Code</u>&#8221;)). OMT and Licensee hereby acknowledge that (i) copies of research data, (ii)&#160;laboratory samples, (iii) product samples and inventory, (iv) formulas, (v) laboratory notes and notebooks, (vi) all Data and results related to pre-clinical and clinical Studies, (vii) Regulatory Filings and Regulatory Approvals, (viii) rights of reference in respect of Regulatory Filings and Regulatory Approvals, (ix) and pre-clinical research data and results, constitute &#8220;embodiments&#8221; of intellectual property pursuant to Section&#160;365(n) of the Bankruptcy Code. Provided that the other Party at all times remains in good standing under the terms of this Agreement, each of OMT and Licensee agree not to interfere with the other Party&#8217;s exercise of rights and licenses to intellectual property licensed hereunder and embodiments thereof in accordance with this Agreement and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">agree to use reasonable efforts to assist the other Party to obtain such intellectual property and embodiments thereof as reasonably necessary for the other Party to exercise such rights and licenses in accordance with this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.5</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Prosecution</u>. During the Research Term, neither Party shall file any patent application with respect to the OMT Antibodies or Licensed Products, without the written consent of the non-filing party, such consent not to be unreasonably withheld. Unless and until OMT receives the full Commercial Fee from Licensee, neither Party shall have the right to file, prosecute, and maintain any patents or patent applications relating to the OMT Antibodies or Licensed Products., without the written consent of the non-filing party, such consent not to be unreasonably withheld. At Licensee&#8217;s request and expense, OMT shall reasonably assist Licensee with such prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.6</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reservation of Rights</u>. Except for the rights specifically and unambiguously granted in this Agreement, no right or license under any intellectual property right controlled by either Party is granted or implied. Nothing herein shall be construed to limit or restrict, in any manner, OMT&#8217;s ability to use and exploit, or allow any party to use or exploit, the Rats and/or any materials derived or developed therefrom (including antibodies or pharmaceutical products) outside the scope of this Agreement. Licensee understands and agrees that, notwithstanding anything to the contrary herein, OMT may perform immunization services to third parties with respect to targets provided by such third parties, which may produce similar or identical antibodies to the OMT Antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Terms</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Research Fee</u>. Within [***] after the Effective Date, Licensee shall pay OMT a research fee (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Research Fee</u>&#8221;) of [***] ($[***]). The Initial Research Fee is consideration for OMT conducting immunizations of Rats with [***] substitutable Antigens provided by Licensee to OMT, and providing OMT Rats, or other Deliverables (which may include Sera), to Licensee as specified in the Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Research Renewal Fees</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Licensee shall have the option to renew the Agreement on a [***] during the first [***] of the Research Term. Licensee shall provide written notice to OMT, so long as the Agreement is not otherwise terminated, no later than [***] prior to the end of each [***] period during [***] advising whether Licensee will continue under the Agreement into the next [***] term based on Licensee&#8217;s evaluation of the current Research period&#8217;s activities. Upon providing written notice of Licensee&#8217;s intent to continue with the Agreement for the next period, Licensee shall pay [***], payable within [***] after the end of each [***] period. (&#8220;Supplemental License Fee&#8221;). Failure to timely pay such fees shall result in termination of any Research License(s). Licensee shall pay no more than [***] in Supplemental License Fees during the Research Term. Should Licensee provide written notice of its intent to discontinue work under the Agreement during the Research Term, the Agreement would terminate in its entirety [***] subsequent to the date Licensee provided such written notice and no further Supplemental License Fees shall be due to OMT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Milestones</u>. Licensee shall pay to OMT the following milestone payments, provided that each milestone payment shall only be payable once, for the first Licensed Product generated against each Antigen to achieve such Milestone Event, regardless of whether each Milestone Event was achieved by Licensee, its Affiliates, or any licensees, or regardless of how many Licensed Products to such Antigen are developed or Commercialized:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:80%;" align="center"><tr><td style="vertical-align:top;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Milestone Event</b></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(U.S.$) <b style="font-weight:bold;">Payment</b></p></td></tr><tr><td style="vertical-align:top;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:51.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For avoidance of doubt, Licensee shall be responsible for all marketing, regulatory, development, and Commercialization costs directed towards obtaining Regulatory Approval and/or sale of Licensed Products in the Territory. Each milestone payment due shall be made within [***] after the achievement of the applicable Milestone Event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reports</u>. All Milestone Event payments shall be accompanied by a report that includes reasonably detailed information regarding the development and commercialization activities that occurred with respect to the achievement of a particular Milestone Event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.5</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Records</u>. Licensee shall keep complete and accurate books and records pertaining to its development and Commercialization activities hereunder (including activities and events that led to the achievement of Milestone Events) for a period of at least [***] after the relevant payment is owed pursuant to this Agreement or for the period of time required by applicable law, whichever is longer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Method of Payment</u>. OMT shall submit invoices in accordance with the instructions supplied to OMT by the [***]. All invoices must reference a valid Purchase Order (PO) Number which Licensee shall provide to OMT within [***] after the Effective Date. Invoices shall be sent to the [***] group via [***], since OMT is established with a web invoice account, and copies of the invoice should concurrently be sent to [***]. OMT should contact the [***] at [***] with any questions related to OMT status, payments or invoices. Invoices shall provide sufficient detail and supporting documentation for and including a breakdown of all relevant expenses. Invoices shall be due and payable within [***] after Licensee&#8217;s receipt thereof. Licensee reserves the right to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">return to OMT unprocessed and unpaid any invoices that do not contain or reference the foregoing information. Invoices will be provided to Licensee no more than [***] after the date on which the applicable payment becomes due. [***], acting as paying agent for Licensee, will make certain payments due under this Agreement, and Licensee shall reimburse [***] for all such payments. OMT shall not send any invoices with respect to the Research Plan, and no claim from OMT for payment (including any amount for fees or expenses) will be allowed for any work conducted by OMT with respect to the Research Plan, prior to both parties&#8217; duly authorized representatives executing this Agreement and Licensee issuing a PO to OMT with respect to such Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All payments hereunder shall be made to Open Monoclonal Technology, Inc. with Tax ID [***] and either mailed to [***] or wire transferred to [***], using ABA number [***] and account number [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event that the Research Plan set forth in Appendix A is modified and supplemental funding is required, the budget and reimbursement of costs may be modified by mutual written consent of the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the avoidance of doubt, OMT shall be solely responsible for paying its personnel any and all compensation due (including without limitation under the terms of their employment by OMT or under operation of law) on account of their performance of any Research activities or any work hereunder on behalf of OMT, including without limitation any compensation that may become due on account of Licensee&#8217;s exercise of any rights granted to it by OMT hereunder, including without limitation in relation to any inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Nothing contained in this Agreement shall be construed in any manner as an obligation or inducement for any OMT personnel who are healthcare professionals to recommend that patients purchase any products of Licensee or of any of its Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.6</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.6.1<font style="display:inline-block;width:16pt;"></font>Any amounts payable by Licensee to OMT hereunder are exclusive of any and all applicable sales, use, VAT, GST, excise, property, withholding, and other taxes, levies, duties or fees (collectively, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</u>&#8221;). Licensee will make all payments to OMT under this Agreement without deduction or withholding for Taxes except to the extent that any such deduction or withholding is required by law in effect at the time of payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.6.2<font style="display:inline-block;width:16pt;"></font>Licensee and OMT will cooperate with respect to all documentation required by any taxing authority or reasonably requested by Licensee to secure a reduction in rate of applicable withholding taxes. On the date of execution of this Agreement, OMT will deliver to Licensee an accurate and complete Internal Revenue Service Form W-9.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.6.3<font style="display:inline-block;width:16pt;"></font>Any Tax required to be withheld on amounts payable under this Agreement will promptly be paid by Licensee on behalf of OMT to the appropriate governmental authority, and Licensee will furnish OMT with proof of payment of such Tax. Any such Tax required to be withheld will be an expense of and borne by OMT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.6.4<font style="display:inline-block;width:16pt;"></font>If Licensee had a duty to withhold taxes in connection with any payment it made to OMT under this Agreement but Licensee failed to withhold, and such Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">were assessed against and paid by Licensee, then OMT will indemnify and hold harmless Licensee from and against such taxes (including interest). If Licensee makes a claim under this Section&#160;4.8(d), it will comply with the obligations imposed by Section&#160;4.8(c) as if Licensee had withheld Taxes from a payment to OMT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.7</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Late Payments</u>. Any amount owed under this Agreement that is not paid on or before the date such payment is due shall bear interest at a rate per annum equal to the lesser of [***], calculated on the number of days such payments are paid after such payments are due and compounded monthly. In addition, a non-paying Party shall reimburse the other Party for all costs, including attorneys&#8217; fees and legal expenses, incurred in the collection of late payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term and Termination</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u>. The term of this Agreement shall commence on the Effective Date and shall continue until all of Licensee&#8217;s payment obligations are met, unless earlier terminated as set forth herein. For clarity, upon expiration of this Agreement, Licensee shall, subject to the terms and conditions of this Agreement, continue to enjoy the rights granted hereunder to enable Licensee to research, develop, Commercialize, or otherwise exploit any Licensed Products or OMT Antibodies identified by Licensee prior to termination of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination for Convenience</u>. Licensee may terminate this Agreement at any time upon [***] written notice to OMT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination for Breach</u>. Either Party may terminate this Agreement upon a material breach of this Agreement by the other Party by providing [***] written notice to the other Party. The termination shall become effective at the end of the notice period unless the breaching Party cures such breach during such notice period or within a period otherwise agreed to in writing by the Parties. Notwithstanding the foregoing, (a) if the breach, by its nature, is incurable, the non-breaching Party may terminate this Agreement immediately upon written notice to the breaching Party, and (b) if Licensee misreports or fails to report any Milestone Event (in an Annual Report or otherwise), OMT may terminate this Agreement [***] after written notice to Licensee. The termination shall become effective at the end of the notice period unless Licensee cures the alleged misreporting and/or failure to pay during the notice period. Payments subsequently made under [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination for Insolvency</u>. Either Party may terminate this Agreement immediately if the other Party files in any court or agency pursuant to any statute or regulation of any state, county or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of that Party or of its assets, or if such other Party is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is not dismissed within [***] after the filing thereof, or if such other Party shall propose to be a party to any dissolution or liquidation, or if such other Party shall make an assignment for the benefit of its creditors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.5</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Expiration or Termination</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">5.5.1<font style="display:inline-block;width:16pt;"></font>Upon termination or expiration of this Agreement for any reason, all rights and licenses granted hereunder shall terminate, however the following provisions shall</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">survive termination or expiration of this Agreement: Sections&#160;3.6, 5, 6, 7.2.3, 8-11 (inclusive), and, to the extent development and Commercialization is permitted pursuant to the following sentence, the second sentence of Section&#160;2.4, Section&#160;2.4.1, the first sentence of Section&#160;3.3, and Section&#160;4. Licensee shall discontinue all development and Commercialization of the OMT Antibodies or Licensed Products; provided, however, unless this Agreement is terminated as a result of any violation of Licensee&#8217;s (or its Affiliates&#8217; or licensees&#8217;) obligations hereunder, with respect to each Licensed Product for which Licensee has made a payment under Section&#160;4.3, Licensee may continue to develop and commercialize such Licensed Product unless and until Licensee ceases to pay in full all amounts set forth in Section&#160;4.3 with respect to such Licensed Product as they become due; upon any failure to pay such amounts, Licensee shall cease all development and Commercialization of such Licensed Product (and shall cause its Affiliates and licensees to cease all such development and Commercialization). [***]. For avoidance of doubt, without limiting the foregoing, if this Agreement terminates prior to the end of the Research Term, neither party shall have any right to use, exploit, or file for patent protection on the OMT Antibodies or Licensed Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">5.5.2<font style="display:inline-block;width:16pt;"></font>Within [***] after the date of termination of this Agreement, Licensee shall pay to OMT all amounts that have accrued and are due hereunder on or prior to the date of termination. Upon termination or expiration of this Agreement, each Party shall destroy (and certify destruction of) all Confidential Information of the other Party, including any extracts, notes, modifications, or derivatives thereof; the foregoing shall include, without limitation, Licensee&#8217;s destruction of, any and all OMT Rats and OMT Antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definition</u>. &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u>&#8221; means the terms and provisions of this Agreement and other proprietary information and data of a financial, commercial or technical nature that the disclosing Party (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosing Party</u>&#8221;) or any of its Affiliates has supplied or otherwise made available to the other Party (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Receiving Party</u>&#8221;) or its Affiliates. Notwithstanding anything to the contrary, (i) during the Research Term, OMT Antibodies and Licensed Products are the Confidential Information of both Parties, deemed disclosed by both Parties and (ii) upon OMT&#8217;s receipt in full of the Commercial Fee from Licensee, the OMT Antibodies and Licensed Products will become the Confidential Information of Licensee, deemed disclosed by Licensee. The exceptions set forth in Section&#160;6.3.2 and 6.3.4 below shall not apply with respect to OMT Antibodies and Licensed Products. For avoidance of doubt, the OMT Rats and the Sera are the Confidential Information of OMT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Obligations</u>. The Receiving Party will protect all Confidential Information against unauthorized disclosure to Third Parties with the same degree of care as the Receiving Party uses for its own similar information, but in no event less than a reasonable degree of care. The Receiving Party will not use the Confidential Information except as necessary to exercise its rights and fulfill its obligations under this Agreement. The Receiving Party may disclose the Confidential Information to its Affiliates, and their respective directors, officers, employees, subcontractors, licensees, consultants, attorneys, accountants and banks (collectively, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recipients</u>&#8221;), who have a need-to-know such information in order for Receiving Party to exercise its rights or fulfill its obligations under this Agreement or in connection with diligence activities pursuant to financing or acquisition events, provided that the Receiving Party shall hold such</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recipients to written obligations of confidentiality with terms and conditions at least as protective of Disclosing Party&#8217;s Confidential Information as those set forth in this Agreement. Receiving Party shall be liable for any breach of such written obligations or this Section&#160;6 by its Recipients. Notwithstanding the foregoing, Licensee may not disclose or make available OMT Rats or any information or materials relating thereto to any Affiliate, Third Party, or Recipient, except to the extent expressly allowed under Section&#160;2.5 of this Agreement. For the avoidance of doubt, no Antigen shall be deemed Confidential Information, however the provision of the Antigen by Licensee to OMT shall be deemed Confidential Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exceptions</u>. The obligations under this Section&#160;6 shall not apply to any information to the extent the Receiving Party can demonstrate by competent evidence that such information:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">6.3.1<font style="display:inline-block;width:16pt;"></font>is (at the time of disclosure) or becomes (after the time of disclosure) generally known to the public through no breach of this Agreement by the Receiving Party or any Recipients to whom it disclosed such information;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">6.3.2<font style="display:inline-block;width:16pt;"></font>was rightfully known by, or was otherwise in the rightful possession of, the Receiving Party prior to the time of disclosure by the Disclosing Party;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">6.3.3<font style="display:inline-block;width:16pt;"></font>is disclosed to the Receiving Party on a non-confidential basis by a Third Party who is entitled to disclose it without breaching any confidentiality obligation to the Disclosing Party; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">6.3.4<font style="display:inline-block;width:16pt;"></font>is independently developed by or on behalf of the Receiving Party or any of its Affiliates, as evidenced by its written records, without use of, reliance upon or access to the Confidential Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.4</font></font>The restrictions set forth in this Section&#160;6 shall not apply to any Confidential Information that the Receiving Party is required to disclose under applicable laws or a court order or other governmental order, provided that the Receiving Party: (a) provides the Disclosing Party with prompt notice of such disclosure requirement if legally permitted, (b) affords the Disclosing Party an opportunity to oppose or limit, or secure confidential treatment for such required disclosure and (c) if the Disclosing Party is unsuccessful in its efforts pursuant to subsection&#160;(b), discloses only that portion of the Confidential Information that the Receiving Party is legally required to disclose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties; Disclaimer</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties of Each Party</u>. Each Party represents and warrants to the other Party as of the Effective Date that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">7.1.1<font style="display:inline-block;width:16pt;"></font>it is a corporation duly organized, validly existing, and in good standing under the laws of its jurisdiction of formation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">7.1.2<font style="display:inline-block;width:16pt;"></font>it has full corporate power and authority to execute, deliver, and perform under this Agreement, and has taken all corporate action required by applicable law and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">its organizational documents to authorize the execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">7.1.3<font style="display:inline-block;width:16pt;"></font>to such Party&#8217;s knowledge, this Agreement constitutes a valid and binding agreement enforceable against it in accordance with its terms;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">7.1.4<font style="display:inline-block;width:16pt;"></font>all consents, approvals and authorizations from all governmental authorities or other Third Parties required to be obtained by such Party in connection with this Agreement have been obtained; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">7.1.5<font style="display:inline-block;width:16pt;"></font>the execution and delivery of this Agreement and all other instruments and documents required to be executed pursuant to this Agreement, and the consummation of the transactions contemplated hereby do not and shall not: (i) conflict with or result in a breach of any provision of its organizational documents, (ii) result in a breach of any agreement to which it is a party that would impair the performance of its obligations hereunder; or (iii) violate any applicable law</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OMT Representations and Warranties</u>. OMT represents and warrants to Licensee that to OMT&#8217;s knowledge, as of the Effective Date:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">7.2.1<font style="display:inline-block;width:16pt;"></font>it has the right to grant the licenses granted hereunder; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">7.2.2<font style="display:inline-block;width:16pt;"></font>there are no existing Third Party rights that would prevent Licensee from making use of the OMT Rats or OMT Antibodies as contemplated herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">7.2.3<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclaimer</u>. EXCEPT AS EXPRESSLY STATED IN THIS SECTION 7, (A) OMT DOES NOT MAKE ANY REPRESENTATIONS OR EXTEND ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, (B) THE OMT RATS, SERA, AND ANYTHING ELSE PROVIDED BY OMT PURSUANT TO THIS AGREEMENT ARE PROVIDED &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AS IS,</u>&#8221; (C) OMT DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND OR NATURE, WHETHER EXPRESS OR IMPLIED, RELATING TO PERFORMANCE, MARKETABILITY, TITLE OR OTHERWISE IN ANY RESPECT RELATED TO THE SUBJECT MATTER HEREUNDER, (D) OMT FURTHER DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTY REGARDING INFRINGEMENT OF ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER RIGHTS OF THIRD PARTIES IN CONNECTION WITH THE USE OR EXPLOITATION OF THE OMT ANTIBODIES, OR THE MAKING, USING OR SELLING OR OTHER DISTRIBUTION OF PRODUCTS BY ANY PERSON OR ENTITY. LICENSEE ASSUMES THE ENTIRE RISK AND RESPONSIBILITY FOR THE SAFETY, EFFICACY, PERFORMANCE, DESIGN, MARKETABILITY, TITLE AND QUALITY OF ALL PRODUCTS.&#160;Without limiting the generality of the foregoing, OMT does not warrant (i) the patentability of any of the OMT Antibodies or Licensed Products, or (ii) the accuracy, safety, or usefulness for any purpose of any of the Sera, OMT Rats, OMT Antibodies or Licensed Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitation of Liability</u>. In no event shall OMT or its Affiliates, including its and its Affiliates&#8217; directors, officers, employees, consultants and agents (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agents</u>&#8221;), be</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">responsible or liable for [***]. The above limitations on liability apply even though OMT or its Agents may have been advised of the possibility of such damage. Licensee shall not, and shall require that its licensees and Affiliates do not, make any statements, representations or warranties or accept any liabilities or responsibilities whatsoever on behalf of OMT or the Agents and with regard to any person or entity that are inconsistent with any disclaimer or limitation in Section&#160;7.2 or this Section&#160;8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification of Licensee</u>. Subject to Section&#160;9.3 below, OMT agrees to indemnify, hold harmless and defend Licensee, its Affiliates, and their respective agents (each a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensee Indemnitee</u>&#8221;) from and against any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys&#8217; fees and expenses) (collectively, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Losses</u>&#8221;) payable to unaffiliated Third Parties incurred by Licensee Indemnitees in connection with any and all suits, investigations, claims or demands of third parties (collectively, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Claims</u>&#8221;) relating to [***]. Notwithstanding anything to the contrary herein, in no event shall OMT be obligated to indemnify Licensee Indemnitees for (i) any Third Party Claims to the extent such Third Party Claims would be subject to indemnification by Licensee pursuant to Section&#160;10.2, or (ii) any Third Party Claims relating to (a) anything produced or derived from the OMT Rats including without limitation the OMT Antibodies and Licensed Products, (b) any modifications or combinations of the OMT Rats not made by OMT, (c) any use by Licensee of the OMT Antibodies or OMT Rats that is not strictly in accordance with this Agreement, or (d) a Licensee Indemnitee&#8217;s willful misconduct or gross negligence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification of OMT</u>. Subject to Section&#160;9.3 below, Licensee agrees to indemnify, hold harmless and defend OMT, its Affiliates, and their respective agents (each an &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OMT Indemnitee</u>&#8221;) from and against all Losses incurred by OMT Indemnitees arising out of or resulting from [***], provided that Licensee shall not be obligated to indemnify OMT Indemnitees for Losses to the extent arising from an OMT Indemnitee&#8217;s willful misconduct or gross negligence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification Procedure</u>. All indemnification claims provided for in Sections&#160;9.1 and 9.2 shall be made solely by such Party to this Agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Party</u>&#8221;). The Indemnified Party shall promptly notify the indemnifying Party (an &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification Claim Notice</u>&#8221;) of any Losses or the discovery of any fact upon which the Indemnified Party intends to base a request for indemnification under Sections&#160;9.1 and 9.2, but in no event shall the indemnifying Party be liable for any Losses that result from any delay in providing such notice. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss is known at such time). The Indemnified Party shall furnish promptly to the indemnifying Party copies of all papers and official documents received in respect of any Losses and Third Party Claims. The Indemnified Party shall: (a) cooperate with the Indemnifying Party, at the Indemnifying Party&#8217;s expense, in connection with the defense and settlement of the Third Party Claim, and (c) permit the Indemnifying Party to control the defense and settlement of the Third Party Claim; provided, however, that the Indemnifying Party may not settle the Third Party Claim without the Indemnified Party&#8217;s prior written consent, which shall not be unreasonably withheld or delayed, in the event such settlement materially adversely impacts the Indemnified Party&#8217;s rights or obligations. Further,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Indemnified Party shall have the right to participate (but not control) and be represented in any suit or action by advisory counsel of its selection and at its own expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dispute Resolution</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continuance of Rights and Obligations During Pendency of Dispute Resolution</u>. If there are any disputes in connection with this Agreement, including disputes related to termination of this Agreement, all rights and obligations of the Parties shall continue until such time as any dispute has been resolved in accordance with the provisions of this Section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Informal Resolution</u>. In the event of any controversy, dispute or claim arising out of, in connection with, or in relation to the interpretation, performance, or alleged breach of this Agreement, including any claim of inducement by fraud or otherwise, (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dispute</u>&#8221;), the Parties shall attempt in good faith to settle such Dispute first by negotiation and consultation between themselves. If the Parties are unable to resolve a Dispute within [***] from the date such Dispute is first brought to the other Party&#8217;s attention, the matter shall be referred to a senior executive designated by each Party, who shall use their good faith efforts to mutually agree upon the proper course of action to resolve the Dispute. In the event said executives are unable to resolve such Dispute or agree upon a mechanism to resolve such Dispute within [***] of the first written request for dispute resolution under this Section&#160;then the Parties shall resolve such Dispute in accordance with the Mediation and/or Arbitration provisions set forth hereunder, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mediation</u>. Any Dispute which the Parties have not resolved under the Informal Resolution provisions hereunder, shall, with the consent of both Parties, be mediated through non-binding mediation in accordance with The CPR Mediation Procedure for Business Disputes then in effect of the CPR Institute for Dispute Resolution (CPR), except where that procedure conflicts with these provisions, in which case these provisions shall prevail. The mediation shall be conducted in New York and shall be attended by a senior executive with authority to resolve the dispute from each Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Parties shall promptly confer in an effort to select by mutual agreement a neutral, independent and disinterested mediator from a professional mediation firm such as ADR Associates or JAMS/ENDISPUTE or CPR. In the absence of such an agreement within [***] of initiation of the mediation, the mediator shall be selected by CPR as follows: CPR shall provide the Parties with a list of at least [***] names from the CPR Panels of Distinguished Neutrals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each Party shall exercise challenges for cause, [***] peremptory challenges, and rank the remaining candidates within [***] of receiving the CPR list. The Parties may together interview the [***] top-ranked candidates for no more than [***] each and, after the interviews, may each exercise [***] peremptory challenge. The mediator shall be the remaining candidate with the highest aggregate ranking. The mediator shall confer with the Parties to design procedures to conclude the mediation within no more than [***] after initiation (such date of initiation being the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dispute Date</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under no circumstances may the commencement of Arbitration hereunder be delayed more than [***] by the mediation process specified herein absent contrary agreement of the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No statements made by either Party during the mediation may be used by the other or referred to during any subsequent proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arbitration</u>. If any Dispute has not been resolved by good faith negotiations or mediation between the Parties pursuant to the Informal Resolution or Mediation provisions above or the Parties have not agreed to mediate, then the Parties shall settle the Dispute by submitting the matter to binding arbitration the using the English language in accordance with the Arbitration Rules and Procedures of JAMS then in effect, by one or more commercial arbitrator(s) with substantial experience in resolving complex commercial contract disputes, who may or may not be selected from the appropriate list of JAMS arbitrators. The arbitration will be held in New York City, New York.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the Parties cannot agree upon the number and identity of the arbitrators within [***] following the Dispute Date, then a single arbitrator shall be selected on an expedited basis in accordance with the Arbitration Rules and Procedures of JAMS.&#160;Any arbitrator so selected shall have substantial experience with the life science/biotech industry. The arbitrator(s) shall have the authority to grant specific performance and to allocate between the parties the costs of arbitration (including service fees, arbitrator fees and all other fees related to the arbitration) in such equitable manner as the arbitrator(s) may determine. The prevailing party in the arbitration shall be entitled to receive reimbursement of its reasonable expenses (including reasonable attorneys&#8217; fees, expert witness fees and all other expenses) incurred in connection therewith. Judgment upon the award so rendered may be entered in a court having jurisdiction or application may be made to such court for judicial acceptance of any award and an order of enforcement, as the case may be. Notwithstanding anything to the contrary in this Agreement, each Party shall have the right at any time to seek injunctive or other forms of equitable relief from any court of competent jurisdiction. For all purposes of this Agreement, the parties consent to exclusive jurisdiction and venue in the United States federal Courts located in the Southern District of New York.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Provisions</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Publication</u>. OMT may not submit a publication in any form (including written, graphic, oral, or audio) containing any information or results relating to any Deliverable or services performed hereunder to any journal or other forum for publication or presentation without Licensee&#8217;s prior written approval of the proposed abstract, manuscript, poster, presentation slides, or other material, which approval it may withhold at its discretion. Licensee may not submit a publication in any form (including written, graphic, oral, or audio, but excluding patent applications, which may only be submitted to the appropriate patent authority without the approval required herein) containing any information on technologies owned or controlled by OMT to any journal or other forum for publication or presentation without OMT&#8217; prior written approval of the proposed abstract, manuscript, poster, presentation slides, or other material, which approval it may withhold at its discretion. No material that incorporates the other Party&#8217;s Confidential Information will be submitted for publication by a Party without the other Party&#8217;s prior written consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Publication</u>. Each Party agrees to notify the other within a reasonable period, not less than [***] prior to the submission for publication of any writing or disclosure concerning such work under this Agreement. The receiving Party is entitled to review</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">such proposed publication or disclosure. The receiving Party reserves the right to delete from any such proposed publication or disclosure any Confidential Information of such Party, and, a Party may file or cause to be filed any relevant patent applications prior to publication or disclosure. Such Party may request the delay of any such proposed publication or disclosure for an additional [***] period in order to file any patent applications on the inventions disclosed therein. For the avoidance of doubt, the rights and covenants set forth in this paragraph are at all times subject to each party&#8217;s obligations and covenants under Section&#160;3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Publicity</u>. Upon the execution of this Agreement, OMT shall issue one press release with respect to this Agreement in substantially the form attached hereto as Appendix D and may only make subsequent public disclosure of the contents of such press release (&#8220;Subsequent Disclosures&#8221;) without further approval of the other Party. The Parties agree that, except as provided for above, each will not make, issue or release any public announcement, press release, statement, promotion, or reveal publicly the terms, conditions and status of, this Agreement without the prior written approval of the other Party as to the content and time of release of and the media in which such statement or announcement is to be made. Notwithstanding the foregoing, in the case of announcements, statements, acknowledgments or disclosures that either Party is required by law to make, issue or release, the making, issuing or releasing of any such announcement, statement, acknowledgment or disclosure by the Party so required by law shall not constitute a breach of this Agreement if such Party shall have given, to the extent reasonably possible, not less than [***] prior notice to the other Party, and shall have attempted, to the extent reasonably possible, to clear the content of such announcement, statement, acknowledgment or disclosure with the other Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Use of Name</u>. OMT shall not use the name or any logo, symbol, or trademark of Licensee, or any of its Affiliates, or any of their employees, for advertising, marketing, or promotional purposes without the prior written consent of Licensee. For avoidance of doubt, Subsequent Disclosures shall not be deemed a breach of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.5</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Research &amp; Legal Compliance</u>. All research conducted at OMT shall be performed in accordance with applicable laws, regulations, and established OMT policies and procedures, including, but not limited to, policies and procedures pertaining to research involving laboratory animals or hazardous agents and materials, as applicable. OMT agrees that any animals used in the research will be handled in accordance with established guidelines for the care and use of laboratory animals. All research conducted at Licensee or its Affiliates shall be performed in accordance with applicable laws, regulations, and established Licensee policies and procedures, including, but not limited to, policies and procedures pertaining to research involving laboratory animals or hazardous agents and materials, as applicable. Licensee agrees that any animals used in the research will be handled in accordance with established guidelines for the care and use of laboratory animals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.6</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Healthcare Compliance</u>. OMT and Licensee shall each comply with applicable local, state and federal laws and regulations and ordinances, including without limitation the Federal Food, Drug and Cosmetic Act, as amended, and applicable regulations, the Medicare/Medicaid Anti-kickback Statute, Health Insurance Portability and Accountability Act of 1996 (HIPAA), the False Claims Act, applicable state fraud and abuse laws, the AMA Guidelines on Gifts to Physicians from Industry, the Foreign Corrupt Practices Act, the Economic Espionage</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Act of 1996 and applicable laws and government regulations relating to services and the privacy, professional confidentiality and security thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.7</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Debarment</u>. Each party warrants that it is not debarred by a competent Health Authority (including, if applicable, the US FDA) or by the Professional Council of Physicians; OMT shall not employ, contract with or retain any person directly or indirectly to perform work under this Agreement if such a person is or becomes debarred by a competent Health Authority (including, if applicable, the US FDA) or by the Professional Council of Physicians. Upon written request from the other party, each party shall, within [***], provide written confirmation that it has complied with the foregoing obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.8</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Relationship of the Parties</u>. The Parties to this Agreement recognize and agree that each is operating as an independent contractor and not as an agent of the other. This Agreement shall not constitute a partnership or joint venture, and neither Party may be bound by the other to any contract, arrangement or understanding except as specifically stated herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.9</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</u>. This Agreement is not assignable or transferable by Licensee to non-Affiliate Third Parties, nor may Licensee assign, delegate, or subcontract any of its rights or obligations hereunder to non-Affiliate Third Parties except as expressly provided in Section&#160;2.5 of this Agreement, without the prior written consent of OMT, except that Licensee may assign this Agreement to a successor to all or substantially all of Licensee&#8217;s assets or business relating to the subject matter of this Agreement. OMT may freely (a) assign this Agreement and (b) assign, delegate, and/or subcontract its rights and obligations hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.10</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. Any notice, report, approval or consent required or permitted hereunder shall be in writing and will be deemed to have been duly given to a Party if delivered personally or mailed by first-class, registered or certified mail, postage prepaid to the address of that Party as set forth on the first page of this Agreement; or such other address as is provided by that Party to the other upon [***] written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.11</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Force Majeure</u>. Except for payment obligations, a Party shall not be held liable or responsible to the other Party or be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement when such failure or delay is caused by or results from events beyond the reasonable control of the non-performing Party, including fires, floods, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotion or acts of God. The non-performing Party shall provide reasonable notice to the other Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.12</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</u>. No failure to exercise, and no delay in exercising, on the part of either Party, any privilege, any power or any rights hereunder will operate as a waiver thereof, nor will any single or partial exercise of any right or power hereunder preclude further exercise of any other right hereunder. Any waivers or amendments shall be effective only if made in writing and signed by authorized representatives of the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.13</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. If any provision of this Agreement shall be adjudged by any court of competent jurisdiction to be unenforceable or invalid, that provision shall be limited or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and enforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.14</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. This Agreement shall be governed by and construed pursuant to the laws of the New York without regard to conflicts of laws provisions thereof and without regard to the United Nations Convention on Contracts for the International Sale of Goods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.15</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. This Agreement is the complete and exclusive statement of the agreement and understanding of the Parties and supersedes and cancels all previous written and oral agreements, understandings and communications relating to the subject matter of this Agreement. No amendment or change hereof or addition hereto shall be effective or binding on either of the Parties hereto unless reduced to writing and duly executed on behalf of both Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.16</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings</u>. The headings to the sections&#160;in this Agreement are not a part of this Agreement, but are included merely for convenience of reference only and shall not affect its meaning or interpretation. Any use of the term &#8220;including&#8221; shall mean &#8220;including without limitation.&#8221;</p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the Parties hereto have caused this Agreement to be executed so as to be effective on the date set forth above.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Open Monoclonal Technology, Inc.</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CNA Development LLC</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: [***]</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: [***]</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: [***]</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: [***]</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: CEO</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: President</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">APPENDIX D</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">News Release</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">As enclosed.</p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 30pt 0pt;"><img src="ahpa-20220416xex10d25001.jpg" alt="Graphic" style="display:inline-block;height:44.24pt;width:69.74pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Open Monoclonal Technology Announces OmniRat&#8482; Collaboration with CNA</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Development LLC, an affiliate of Janssen Pharmaceuticals, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Palo Alto, CA, December&#160;21, 2012</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Open Monoclonal Technology, Inc. (OMT) today announced a discovery collaboration with CNA Development LLC, an affiliate of Janssen Pharmaceuticals, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">OMT will employ its OmniRat&#8482; transgenic animal platform to generate human antibodies with great specificity, affinity and manufacturability. OmniRat&#8482; enables developers to skip the need to humanize animal-derived antibodies before initiating preclinical pharmacokinetic evaluations of their compounds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dr.&#160;Roland Buelow, Founder and CEO of OMT, said: &#8220;OmniRat makes antibodies with fully human idiotypes as well as normal rats make normal rat antibodies. We look forward to making the technology available to Janssen, one of the pioneers and leaders in therapeutic human antibodies.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Open Monoclonal Technology, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for the development of human therapeutic antibodies &#8211; <font style="font-style:italic;font-weight:bold;">naturally optimized human antibodies</font>&#8482;. OMT has created <b style="font-weight:bold;">OmniRat</b>&#8482;, the first fully human monoclonal antibody platform based on transgenic rats. OmniRat uses an improved understanding of B cell development and a new approach to inactivation of endogenous antibody expression, which enables them to make antibodies with human idiotypes as efficiently as wild type rats make normal antibodies. OmniRat represents a novel and proprietary technology with unrestricted development options for fully human monoclonal antibodies, available worldwide for all targets and indications. OMT also develops a transgenic mouse, <b style="font-weight:bold;">OmniMouse</b>&#8482;, to complement OmniRat and further increase epitope coverage in human antibody development. <b style="font-weight:bold;">OmniAb</b>&#8482; integrates OMT&#8217;s transgenic animal platforms, proven protein and DNA immunization, and Gel-Encapsulated Microenvironment (GEM) deep antibody screening to enable fast and cost-efficient generation and identification of preferred human therapeutic antibody candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">For more information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Brian Lundstrom</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Phone: +1-510-220-5599</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">E-mail: bl@omtinc.net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Web site: www.omtinc.net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">-- # # # --</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>5
<FILENAME>ahpa-20220416xex10d26.htm
<DESCRIPTION>EXHIBIT-10.26
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/27/2022 11:11:06 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.26</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BY AND BETWEEN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ICAGEN, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AND</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CYSTIC FIBROSIS FOUNDATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:93.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Clause</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.51%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:93.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:93.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">ARTICLE I &#8211; DEFINITIONS</p></td><td style="vertical-align:bottom;white-space:normal;width:6.51%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">1</p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:93.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:6.51%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:93.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">ARTICLE II &#8211; RESEARCH PLAN</p></td><td style="vertical-align:bottom;white-space:normal;width:6.51%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">6</p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:93.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:6.51%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:93.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">ARTICLE III &#8211; AWARD AMOUNT PAYMENTS; RECORDS</p></td><td style="vertical-align:bottom;white-space:normal;width:6.51%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">11</p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:93.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:6.51%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:93.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">ARTICLE IV &#8211; COMMERCIALIZATION; ROYALTIES</p></td><td style="vertical-align:bottom;white-space:normal;width:6.51%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">15</p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:93.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:6.51%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:93.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">ARTICLE V &#8211; CONFIDENTIALITY</p></td><td style="vertical-align:bottom;white-space:normal;width:6.51%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">18</p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:93.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:6.51%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:93.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">ARTICLE VI &#8211; PUBLICATION</p></td><td style="vertical-align:bottom;white-space:normal;width:6.51%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">21</p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:93.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:6.51%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:93.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">ARTICLE VII &#8211; INDEMNIFICATION</p></td><td style="vertical-align:bottom;white-space:normal;width:6.51%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">22</p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:93.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:6.51%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:93.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">ARTICLE VIII &#8211; INTELLECTUAL PROPERTY</p></td><td style="vertical-align:bottom;white-space:normal;width:6.51%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">24</p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:93.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:6.51%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:93.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">ARTICLE IX &#8211; TERM AND TERMINATION</p></td><td style="vertical-align:bottom;white-space:normal;width:6.51%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">26</p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:93.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:6.51%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:93.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">ARTICLE X &#8211; REPRESENTATIONS AND WARRANTIES</p></td><td style="vertical-align:bottom;white-space:normal;width:6.51%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">29</p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:93.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:6.51%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:93.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">ARTICLE XI &#8211; MISCELLANEOUS PROVISIONS</p></td><td style="vertical-align:bottom;white-space:normal;width:6.51%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">29</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Exhibit&#160;A &#8211; [***] &#8211; Icagen Research Collaboration and License Agreement (redacted)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Exhibit&#160;B - Research Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Exhibit&#160;C&#8211; Budget and Milestones</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">This Agreement (this &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;) is made on this 1st day of May, 2018 and shall be effective on the Effective Date by and between Icagen, Inc. (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Icagen</u>&#8221;), a corporation having a principal place of business at [***] acting on behalf of itself and Affiliates, and Cystic Fibrosis Foundation (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CFF</u>&#8221;), a nonprofit corporation with its principal offices at [***], and shall become effective on the Effective Date. Icagen and CFF are each referred to herein individually as a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Party</u>&#8221; and collectively as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</u>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, CFF&#8217;s principal charitable mission is the discovery and development of drugs to cure or mitigate Cystic Fibrosis, to which CFF brings significant scientific and human resources and financial support;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Icagen shall simultaneously enter into a certain agreement with [***] (the &#8220;[***]&#8221;), substantially in the form annexed hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</u>, under which Icagen will be able to review certain compounds in the [***], subject to certain terms and conditions set forth in the [***] in order to conduct the Research Plan as hereinafter described with the goal of commercializing a product for the treatment or cure of cystic fibrosis or other rare disease or sublicensing its finding to a Third Party for such purpose; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, CFF wishes to support the Research Plan as hereinafter provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW</b>, <b style="font-weight:bold;">THEREFORE</b>, in consideration of the mutual covenants set forth in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE I &#8211; DEFINITIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">For purposes of this Agreement, the terms defined in this Article&#160;I shall have the following meanings whether used in their singular or plural forms. All capitalized terms used herein without definition shall have the meanings ascribed in the [***]. Use of the singular shall include the plural and vice versa, unless the context requires otherwise. In the event, the [***] has been terminated and research efforts to develop a Product are continued under this Agreement, the definitions in the [***] shall continue to be applicable to this Agreement, and shall be adapted to apply to this</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Agreement that includes Icagen and CFF only. For example, and without limitation, the terms Combination Product and Commercialize shall continue to be applicable after such termination, but shall include any compound originating from the [***], and any derivative of the foregoing identified through the conduct of the Research Plan (as it may be amended from time to time) and through the conduct of a materially similar screen for the five (5)&#160;year period specified in Section&#160;2.10 of the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.1</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Agreement</b>&#8221; means this agreement, together with all appendices, exhibits and schedules attached hereto, as the same may be amended or supplemented from time to time hereinafter by a written agreement duly executed by authorized representatives of each Party hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.2</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Applicable Law</b>&#8221; shall mean all applicable foreign, federal, state or local laws, statutes, rules and regulations, and the applicable policies of any and all locations at which the Research Plan is conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.3</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Award Amount</b>&#8221; shall mean the total amount of funding CFF provides to Icagen, provided that it shall not exceed [***] Dollars ($[***]), and shall be funded by CFF to Icagen for the Research Plan in accordance with the terms, and subject to the conditions, set forth in this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.4</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Background Technology</b>&#8221; shall mean all technology owned or Controlled by Icagen prior to Icagen&#8217;s performance of the Research Plan under this Agreement to the extent necessary and actually used in performance of the Research Plan under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.5</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Breaching Party</b>&#8221; shall have the meaning set forth in Section&#160;9.4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.6</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Budget</b>&#8221; shall mean the total amount of monies estimated and agreed to by the Parties for the costs and expenses of the Research Plan as shown on Exhibit&#160;C, which (a)&#160;may be amended from time to time solely upon the mutual written agreement of the Parties, and (b)&#160;shall detail the projected allocation and use of: (i)&#160;the funds to be paid by CFF to Icagen with respect of the Award Amount; and (ii)&#160;the Matched Funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.7</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">CFF</b>&#8221; shall have the meaning set forth in the preamble of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.8</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">CFF Indemnitee</b>&#8221; shall have the meaning set forth in Section&#160;7.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.9</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">CFF Patents</b>&#8221; shall mean any Patents Controlled by CFF or its Affiliates relating to the Research Plan and directed to a CFF Sole Invention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.10</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">CFF Sole Invention</b>&#8221; shall mean all inventions invented, conceived or made and all data and know-how generated thereon exclusively by CFF or its Affiliates (directly or through others acting on its behalf) solely for the Research Plan. For clarity, there may be CFF inventions that relate not only to the Research Plan but have been invented by CFF for other purposes. CFF will discuss in good faith granting a license to such inventions to Icagen, but they are not included in the foregoing definition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.11</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">CPR</b>&#8221; shall have the meaning set forth in Section&#160;11.2(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.12</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Default</b>&#8221; shall have the meaning set forth in Section&#160;9.4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.13</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Disposition Royalty</b>&#8221; shall have the meaning set forth in Section&#160;4.2(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.14</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Disposition Transaction</b>&#8221; shall have the meaning set forth in Section&#160;4.2(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.15</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Dispute</b>&#8221; shall have the meaning set forth in Section&#160;11.2(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.16</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Effective Date</b>&#8221; shall mean the date specified in the first paragraph of this Agreement, or if later, the date the [***] is fully executed by CFF and the parties thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.17</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">GAAP</b>&#8221; shall mean generally accepted accounting principles consistently applied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.18</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Icagen Derivative Product</b>&#8221; means, for any license to Icagen from [***], a product that: (i) [***], or (ii) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.19</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Icagen Indemnitee</b>&#8221; shall have the meaning set forth in Section&#160;7.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.20</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Icagen Intellectual Property</b>&#8221; shall have the meaning set forth in the [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">1.21</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Icagen Library of Compounds</b>&#8221; shall have the meaning set forth in the [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.22</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Icagen Patents</b>&#8221; shall mean any Patents Controlled by Icagen or its Affiliates claiming Icagen Background Technology and directed to an Icagen Sole Invention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.23</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Icagen Sole Invention</b>&#8221; shall mean all inventions invented, conceived or made and all data and know-how generated thereon exclusively by Icagen or its Affiliates (directly or through others acting on its behalf) as a result of the Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.24</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Indemnified Party</b>&#8221; shall have the meaning set forth in Section&#160;7.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.25</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Indemnifying Party</b>&#8221; shall have the meaning set forth in Section&#160;7.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.26</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Joint Invention</b>&#8221; shall have the meaning set forth in Section&#160;8.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.27</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Joint Patents</b>&#8221; shall mean any Patents Controlled jointly by Icagen and CFF or their respective Affiliates claiming Research Results and directed to a Joint Invention. Joint Patents do not include any intellectual property that is jointly owned by Icagen and [***] in accordance with the terms of the [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.28</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Losses</b>&#8221; shall have the meaning set forth in Section&#160;7.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.29</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Matched Funds</b>&#8221; shall have the meaning set forth in Section&#160;3.1(e).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.30</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Net Sales</b>&#8221; shall have the meaning set forth in the [***]; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that in the event that Icagen Commercializes one or more Product(s) in the Field, the definition of Net Sales in the [***] shall be applicable to this Agreement with the following revisions: all references therein to [***] shall be replaced by Icagen, all references to Sales Product(s) shall be replaced by Product(s) and all references to Icagen shall be replaced with CFF.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.31</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Non-Publishing Party</b>&#8221; shall have the meaning set forth in Article&#160;VI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.32</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Option</b>&#8221; shall have the meaning set forth in the [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.33</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Owner</b>&#8221; shall have the meaning set forth in Section&#160;5.1(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.34</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Party(ies)</b>&#8221; shall have the meaning set forth in the preamble of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.35</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Patents</b>&#8221; means all existing patents and patent applications and all patent applications hereafter filed, including any continuation, continuation-in-part, division, provisional, priority, or any substitute applications, any patent issued with respect to any such patent applications, any reissue, reexamination, renewal or extension (including any supplementary protection certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent, and all foreign counterparts of any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.36</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Prime Rate</b>&#8221; shall mean the average prime rate published in the Wall Street Journal during the relevant period (calculated by dividing (a)&#160;the sum of the prime rates for each of the days during the relevant period, by (b)&#160;the number of days in the relevant period).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.37</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Product</b>&#8221; shall mean a Licensed Product, Derivative Product, Icagen Derivative Product, and any other product sold in the Field in which at least one of the active ingredients is a Lead Compound originating from the Icagen Library of Compounds through the conduct of the Research Plan (as it may be amended from time to time); and, for purposes of applying the definitions specified in the [***], the term Product shall include a &#8220;Sales Product&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.38</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Proposals</b>&#8221; shall have the meaning set forth in Section&#160;11.2(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.39</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Publishing Party</b>&#8221; shall have the meaning set forth in Article&#160;VI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.40</b>&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recipient</u>&#8221; shall have the meaning set forth in Section&#160;5.1(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.41</b>&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recipient Notice Requirement</u>&#8221; shall have the meaning set forth in Section&#160;5.1(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.42</b>&#160;&#160;&#160;&#160;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Research Plan</u>&#8221; shall mean the research plan attached hereto in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;B</u>, which shall cover the work performed under the Agreement through the Research Term. The Research Plan will include all work undertaken by Icagen prior to the Effective Date that was retroactively funded by the Award Amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.43</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Research Results</b>&#8221; shall have the meaning set forth in the [***] and shall also include results from work undertaken by Icagen prior to the Effective Date that was retroactively funded by the Award Amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.44</b>&#160;&#160;&#160;&#160;&#8220;<b style="font-weight:bold;">Securities Regulatory Authority</b>&#8221; shall have the meaning set forth in Section&#160;5.1(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE II &#8211; RESEARCH PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2.1&#160;&#160;&#160;&#160;Commencement; Objective;</b> [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Research Plan</u>. Icagen shall be solely responsible for the conduct of the Research Plan as set forth herein. [***] shall provide the financial support hereinafter specified, and consultation and advice through its participation on the PAG as provided below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;[***]. Pursuant to the terms of the [***], Icagen will have access to certain compounds in the [***] and [***] has been granted an Option to obtain a worldwide, exclusive, royalty-bearing license, with the right to sublicense in the Field to: (i)&#160;Icagen&#8217;s interest in the Research Results, (ii)&#160;Icagen Intellectual Property, and (iii)&#160;Lead Compounds from the Icagen Library of Compounds, and (B)&#160;non-exclusive option to any Icagen Background Technology necessary to Develop and Commercialize Licensed Products or Derivative Products in the Field solely as set forth in the [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2.2</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Duration of the Research Plan.</b> The Research Plan shall commence on the Effective Date and shall conclude on the expiration or earlier termination of the Research Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2.3&#160;&#160;&#160;&#160;Research Diligence.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Generally</u>. Icagen shall use Commercially Reasonable Efforts to conduct the Research Plan in accordance with, and to complete, the Research Plan. In furtherance of the foregoing, and in accordance with the terms and conditions of this Agreement (including, without limitation, Section&#160;2.3(b) below), Icagen shall commit to the Research Plan (i)&#160;the level of staffing required by the Research Plan that possess the necessary experience, training and scientific expertise in order for Icagen to fulfill its obligations hereunder, and (ii)&#160;the infrastructure (e.g., laboratories, offices, equipment, supplies and facilities) required by the Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Obligations of Icagen</u>. Subject to the terms and conditions of this Agreement and the [***], and without limiting the generality of Section&#160;2.3(a) above, Icagen shall be solely responsible for the sponsorship, conduct and oversight of the Research Plan. In the event of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">termination of the [***] in accordance with Section&#160;10.4, 10.6 or 10.7(a) of such agreement, such responsibilities on the part of Icagen shall include, without limitation, utilizing Commercially Reasonable Efforts to Develop and Commercialize a Product in the Field in accordance with Section&#160;4.1; and responding to all reasonable requests and inquiries of [***] for information regarding any of the subject matter hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2.4</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Research Plan.</b> At each PAG meeting, the PAG shall consider, review, reevaluate and discuss the Research Plan, taking into consideration ongoing research outcomes and other scientific and commercial developments. Modifications to the Research Plan may be proposed by any Party and [***] and shall be discussed by the PAG and recommendations shall be made in accordance with Section&#160;2.5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2.5&#160;&#160;&#160;&#160;Project Advisory Group.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Composition and Purposes</u>. During the term of the Research Plan, the PAG shall facilitate communication between [***], Icagen and CFF and review results and make recommendations, with respect to the Research Plan. The PAG shall consist of [***] voting members, [***] of whom shall be the Icagen Designees, [***] of whom shall be the [***] Designees, and [***] of whom shall be the [***] Designees; [***]. Each Party and [***] shall select a program coordinator from among its designees to the PAG (who may be changed at any time or from time to time by such Party and [***]), and may, along with [***], change any of its designees to the PAG at any time or from time to time and invite additional persons who have executed a confidentiality agreement acceptable to the PAG. The program coordinator of Icagen shall serve as the chairperson of the PAG.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Without limiting the generality of the foregoing, the PAG shall:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">i.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consider and review the Research Results from the Research Plan (including modifications thereto), and discuss the status of the Research Plan and timelines;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">ii.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">taking into consideration existing data, make recommendations to Icagen&#8217;s research team, as needed, on next steps to implement the Research Plan;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">iii.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">oversee progress of the Research Plan (which takes into consideration recommendations received from the PAG), and reporting thereon to the Parties and [***];</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">iv.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">iv.monitor the Budget and ensure that the Award Amount is used solely for the Research Plan and in accordance with the Budget approved by the Parties;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">v.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">attempt to resolve any Dispute regarding the Budget;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">vi.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">discuss and agree upon any changes to the criteria for activity of Confirmed Hits;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">vii.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">discuss and agree upon any changes to the criteria for qualifying activity of Confirmed Hits to declare Qualified Confirmed Hits;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">viii.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">review, discuss and make recommendations as to whether the key deliverables and interim and final milestones under the Research Plan have been achieved with the objective of identifying Confirmed Hits, Qualified Confirmed Hits, and Lead Compounds. No Lead Compounds shall be named without the approval of the [***] Designee(s);</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">ix.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">in accordance with Section&#160;3.1(b) of the [***], review [***] that Icagen wishes to evaluate in combination with Qualified Confirmed Hits, Approved Qualified Confirmed Hits (and their derivatives), or Lead Compounds that are not currently, or never were, considered as standard of care [***], or are not a reference standard in the Field;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">x.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">[***];</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">xi.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">discuss a tentative finding of Scientific Cause by Icagen or [***], and in the event Icagen desires to terminate this Agreement for Scientific Cause pursuant to Section&#160;9.3 of this Agreement; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">xii.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">discuss and advise on the inclusion of the Additional Research Program as further described in Section&#160;3.2 of the [***].</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2.6&#160;&#160;&#160;&#160;PAG Meetings.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Timing and Attendance</u>. The PAG shall meet no less frequently than [***] in each [***] period during the Research Plan; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that the PAG may meet more or less frequently upon mutual agreement of the program coordinators. The first meeting of the PAG shall be held within [***] of the Effective Date. Meetings of the PAG shall be held at such times and locations as may be mutually agreed by the program coordinators, which times and locations shall be communicated in writing (including, without limitation, by e-mail) to the other members of the PAG with reasonable advance notice of the meeting. At least [***] Icagen Designee, [***] CFF Designee and [***] Designee shall be required to participate in a meeting for such meeting to be deemed a quorum. So long as a quorum is present at a meeting, the PAG may make, or decide to make, recommendations to Icagen, or take, or decide to take, such actions as are within the scope of the PAG&#8217;s authority hereunder. Members of the PAG may attend each meeting either in person or by means of telephone or other telecommunications device that allows all participants to hear and speak at such meeting simultaneously. At least [***] prior to each meeting, Icagen shall deliver (including by e-mail) to CFF and Sanofi a written report detailing the progress made on the Research Plan since the last meeting of the PAG. Within [***] after the date of each meeting, the Icagen Designees shall prepare and deliver (including by e-mail) to the CFF Designees and the [***] Designee written minutes of such meeting setting forth in detail all discussions and/or recommendations of the PAG made at such meeting, which minutes shall be subject to the prior approval of CFF&#8217;s program coordinator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Discussions/Recommendations</u>. As a general matter, and except as otherwise provided for herein, the PAG shall discuss the items set forth in Section&#160;2.5, make unanimous, non-binding recommendations to Icagen as a result of such discussions, and facilitate communication between the Parties and [***] with respect to the Research Plan. While Icagen shall take into consideration any recommendations from the PAG when conducting the Research Plan, any decisions with respect to the conduct of the Research Plan shall be in Icagen&#8217;s sole discretion, provided that, any modification to the criteria for confirming activity of Confirmed Hits and for declaring Qualified Confirmed Hits shall be decided by the PAG and require approval by the [***] Designees. Notwithstanding the foregoing, in the event the PAG cannot reach a unanimous decision as to the item set forth in Section&#160;2.5(ix), the final decision as to whether to permit such activity shall be in [***] sole discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(c)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses</u>. Each Party and [***] shall pay its own expenses (including travel and lodging expenses) incurred in connection with its participation on the PAG.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2.7</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Delivery of Information to the PAG.</b> Upon the reasonable request of a PAG program coordinator Icagen shall deliver to each PAG member such information and other data as soon as practicable following its availability as is necessary to facilitate mutual understanding of the status of, and developments relating to, the Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2.8</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Obligations of the PAG and the Parties to </b>[***]<b style="font-weight:bold;"> under Section&#160;2 of this Agreement.</b> All obligations and responsibilities of the Parties and the PAG hereto to [***] under Section&#160;2 of this Agreement shall terminate upon [***] termination of the [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2.9&#160;&#160;&#160;&#160;Noncompetition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Icagen Non-Compete</u>. During the Research Term and thereafter during any period in which either the Research Program License or Interruption License are effective, Icagen shall not (i)&#160;Commercialize any Product or any derivative of a Product that would compete with a Product in the Field nor (ii)&#160;fund the Commercialization of any Product or any derivative of a Product that would compete with a Product in the Field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ramifications of Termination of Subparagraph (a)</u>. If CFF terminates this Agreement during the Research Term (other than pursuant to Section&#160;9.4) or Icagen terminates this Agreement under Section&#160;9.4, Subparagraph(a) of this Section&#160;2.9 shall no longer be applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2.10</b>&#160;&#160;&#160;&#160;[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">[***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE III &#8211; AWARD AMOUNT PAYMENTS; RECORDS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.1&#160;&#160;&#160;&#160;Research Funding.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contract Execution Milestone</u>. Within [***] of execution of this Agreement, CFF shall make a one-time payment of Three Hundred Thirty-Seven Thousand Five Hundred Dollars ($337,500) for work conducted by Icagen during the first and second quarter of 2017 as described in the <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;B</u>, which payment shall be in addition to the payments set forth below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments</u>. In accordance with the terms, and subject to the conditions, set forth in this Agreement, Icagen shall send invoices in United States Dollars (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dollars</u>&#8221;) to CFF for payment of the Award Amount. Invoices shall be submitted within [***] after the completion of each calendar month and shall be accompanied by documentation evidencing the expenditure of funds, FTEs devoted to the Research Plan in accordance with the Budget, and applicable milestones. CFF shall use good faith efforts to pay amounts invoiced by Icagen within [***] of receipt of an invoice and supporting documentation from Icagen or verification of the achievement of the milestone by the PAG and in no event shall payment be made later than [***] from receipt of an invoice. The Parties acknowledge and agree that Icagen will invoice CFF in accordance with the terms of this Section&#160;3.1(b) for work performed during the fourth quarter of 2017 as well as during the first quarter of 2018 prior to the Effective Date. All payments to be made hereunder (including, without limitation, pursuant to Article&#160;IV) shall be made in Dollars and, at the option and direction of the receiving party, shall be made by cashier&#8217;s or certified check or by wire transfer of immediately available funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(c)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitations</u>. Notwithstanding Section&#160;3.1(a) above or any contrary provision contained herein, CFF shall not be required to make any payment or additional payment including the initial payment described in Section&#160;3.1 (a) in respect of the Award Amount; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, in the case of clauses (iii)&#160;and (iv) below, payments shall be for work already performed:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 24.45pt;">(i)&#160;&#160;&#160;&#160;in excess of [***] ($[***]);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 24.45pt;">(ii)&#160;&#160;&#160;&#160;unless at the time such work was performed, the Research Plan was in compliance with all Applicable Laws;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 24.45pt;">(iii)&#160;&#160;&#160;&#160;for work performed after the occurrence and/or during the continuance of any uncured Default and/or any material breach by Icagen of any of its covenants or obligations under this Agreement until such time as notice of a breach is provided to Icagen and thereafter for any wind up costs;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 24.45pt;">(iv)&#160;&#160;&#160;&#160;if a case or proceeding (a)&#160;under the bankruptcy laws of the United States, or relevant non-U.S.&#160;law, now or hereafter in effect is filed against Icagen or all or substantially all of its assets and such petition or application is not dismissed within [***] after the date of its filing or Icagen shall file any answer admitting and not contesting such petition, or (b)&#160;under the bankruptcy laws of the United States, or relevant non-U.S.&#160;law, now or hereafter in effect or under any insolvency, reorganization, receivership, dissolution or liquidation law or statute of any jurisdiction now or hereafter in effect (whether at law or equity) is filed by Icagen for all or substantially all of its assets; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 24.45pt;">(v)&#160;&#160;&#160;&#160;if this Agreement is terminated by any Party in accordance with Article&#160;IX.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Budget</u>. Icagen hereby covenants and agrees to use the Award Amount provided by CFF to Icagen hereunder solely to fund the Research Plan in accordance with the Budget (including, without limitation, making applicable payments to subcontractors and vendors). Icagen shall repay to CFF upon demand any Award Amount that CFF reasonably determines were not used in accordance with the Budget. In addition, if, upon conclusion of the Research Plan or the termination of this Agreement in accordance herewith, Icagen is in possession of unspent Award Amount, then, Icagen shall, within [***] following conclusion of the Research Plan or termination of this Agreement, as applicable, refund such unspent Award Amount to CFF in such manner as CFF shall reasonably instruct Icagen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(e)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Matched Funds</u>. The Parties agree, acknowledge and recognize that the Award Amount represents only partial financial support for the Research Plan, and Icagen agrees throughout the Research Term (i)&#160;to fund the Research Plan in such amounts as set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;B</u> (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Matched Funds</u>&#8221;); and (ii)&#160;to provide additional financial support once the Award Amount has been paid in full to conduct the Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(f)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Competition</u>. Icagen hereby agrees and acknowledges that nothing contained in this Agreement shall restrict or prevent CFF&#8217;s ability to provide funding to, or take any other action with respect to, any Person that competes with a Product, the business, operations, and/or research of Icagen; and Icagen hereby waives any claim against CFF with respect to any such competing activities; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that CFF shall use Icagen Confidential Information only in accordance with the provisions of this Agreement and for the purpose of the Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.2&#160;&#160;&#160;&#160;Records; Reporting Obligations; Audits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Records</u>. Subject to the terms of the [***], Icagen shall prepare and maintain complete and accurate books and records in connection with the Research Plan (including financial records of expenditures under the Award Amount and the Matched Funds) and, in the event Icagen assumes responsibility for the Development and Commercialization in accordance with GAAP pursuant to Section&#160;10.4, 10.8 or 10.7(a) pursuant to the [***], Icagen shall keep all such books and records in a manner that is consistent with its document retention policy. CFF shall have the right to inspect such books and records [***] per year at the offices of Icagen during normal business hours upon at least [***] prior written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Response to Inquiries</u>. Icagen personnel (including, without limitation, licensees, sublicensees, transferees, successors and subcontractors) shall be available to discuss (whether in person or via telephone) with CFF the books and records and/or reports delivered by Icagen to CFF at such time or times as CFF may reasonably request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(c)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Audit</u>. At the request of CFF, from time to time prior to the [***] anniversary of the Research Term, Icagen shall permit agents of an independent, certified public accounting firm appointed by CFF who sign Icagen&#8217;s standard confidentiality agreement, upon reasonable notice, no more than [***] per year to audit and examine such books and records of Icagen as may be necessary for verifying Icagen&#8217;s compliance with the terms and conditions hereunder. Any and all records audited and examined by agents of such accounting firm shall be deemed Icagen&#8217;s Confidential Information. CFF shall pay the costs of such audit and examination of the books and records of Icagen; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that, if such audit and examination reveals a material breach of this Agreement or a material discrepancy with respect to other information previously provided by Icagen to CFF (which discrepancy shall be in excess of [***]%), then the costs of such audit and examination shall be borne by Icagen and Icagen shall reimburse CFF for all of the costs and expenses incurred by CFF in connection with such audit and examination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reports; Notices</u>. Icagen shall furnish to CFF the following reports and/or notices:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 24.45pt;">(i)&#160;&#160;&#160;&#160;As soon as practicable, and in any event within [***] after the end of each calendar quarter (including the calendar quarter ending December&#160;31), financial reports which describe the use of the Award Amount and the Matched Funds, the progress made toward achieving the purposes of the Research Plan, and the development of any Product in the event Icagen assumes responsibility for Development and Commercialization pursuant to Section&#160;10.4, 10.8 or 10.7(a) pursuant to the [***], and any other information that CFF reasonably requests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 24.45pt;">(ii)&#160;&#160;&#160;&#160;As soon as practicable after the Research Term, a closing report customary for a Research Plan at such stage of development which shall (A)&#160;be prepared by Icagen or an Icagen-approved Third Party, (B)&#160;be reasonably satisfactory to CFF, and (C)&#160;set forth Icagen&#8217;s final analysis, summary tables, data listings, results and conclusions from the Research Plan and such other information and materials as CFF may reasonably request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 24.45pt;">(iii)&#160;&#160;&#160;&#160;As soon as practicable, and in any event within [***] after January&#160;1 and June&#160;1 of each fiscal year in the event Icagen assumes responsibility for Development and Commercialization pursuant to Section&#160;10.4, 10.8 or 10.7(a) pursuant to the [***], progress reports and status updates on Icagen&#8217;s activities with respect to the Research Results and/or a Product including, without limitation, the Development and/or Commercialization, Icagen&#8217;s compliance with the terms of this Agreement, and any other information that CFF reasonably requests. Icagen shall include the requirements of this Section&#160;3.2(d)(iii) in any agreements with sublicensees relating to the Development and/or Commercialization of any Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE IV &#8211; COMMERCIALIZATION; ROYALTIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4.1&#160;&#160;&#160;&#160;Development and Commercialization of a Product.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development and Commercialization of a Product</u>. Upon completion of the Research Term and subject to the terms of the [***], following the successful identification of Lead Compounds as a result of the work conducted under the Research Plan, Icagen shall use Commercially Reasonable Efforts to develop a Lead Compound and, if appropriate under its sole discretion, clinically Develop and Commercialize a Product in the Field in the United States and in a Major European Market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exclusive Rights to Icagen</u>. [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(c)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subject to the</u> [***]. For purposes of clarity, the Development and Commercialization of a Product by Icagen as described in this Section&#160;4.1, is only applicable if the [***] is terminated, and then, such applicability is determined in accordance with the terms of the [***]. The foregoing example is only one example and is not meant to be exhaustive of all of the various termination scenarios set forth in the [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4.2&#160;&#160;&#160;&#160;Royalties.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In consideration of CFF&#8217;s payments and licenses to Icagen hereunder, so long as Icagen is Commercializing a Product, Icagen shall make the following payments to CFF:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;A royalty equal to [***], such royalty to be paid by Icagen to CFF in the following increments within [***] of each of the following milestones:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 24.45pt;">(i)&#160;&#160;&#160;&#160;[***];</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 24.45pt;">(ii)&#160;&#160;&#160;&#160;[***]; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 24.45pt;">(iii)&#160;&#160;&#160;&#160;[***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;Royalties on Net Sales, to be paid within sixty (60)&#160;days of the end of any calendar quarter in which Net Sales occur, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 24.45pt;">(i)&#160;&#160;&#160;&#160;[***] ([***]%) of the annual Net Sales in the Field up to [***] ($[***]); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 24.45pt;">(ii)&#160;&#160;&#160;&#160;[***] ([***]%) of the annual Net Sales in the Field in excess of [***] ($[***]), [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(c)&#160;&#160;&#160;&#160;In connection with a Change of Control (except for an Excluded Change of Control as defined in subparagraph (d)&#160;below) or any option, license, sublicense, sale, co-development agreement or other transfer of the Product by Icagen to a Third Party prior to the First Commercial Sale, including any of the aforementioned with respect to [***], (each such transaction a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disposition Transaction</u>&#8221;), Icagen shall pay to CFF a royalty payment (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disposition Royalty</u>&#8221;) equal to [***] ([***]%) of any amount Icagen receives in connection with such Disposition Transaction; provided, that, the Disposition Royalty shall not exceed and shall be subtracted from the Royalty Cap and, to the extent the Disposition Royalty does not exceed the Royalty Cap, the remaining amount shall be allocated among the payments specified in subparagraph (a)&#160;above by allocating [***] of such remaining amount to the payment specified in subdivision (i), and allocating [***] of such remaining amount to each of the payments specified in subdivisions (ii)&#160;and (iii). Pursuant to the terms of the [***], [***] will pay to CFF directly all Disposition Royalty amounts set forth in Sections&#160;7.1 and 7.2(a) of such Agreement. Icagen shall notify CFF promptly of any transaction that would cause the payment of a Disposition Royalty. The Disposition Royalty shall be paid whether the gross proceeds of such transaction received by Icagen are in the form of upfront license fees, milestone payments or other fees (and whether paid in cash or other property), provided that such gross proceeds shall be reduced [***]. The Disposition Royalty shall be paid within sixty (60)&#160;days of the date Icagen receives any payment with respect to a Disposition Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;&#160;&#160;&#160;For purposes of subparagraph (c)&#160;of this Section&#160;4.2 an Excluded Change of Control shall mean the Change of Control described in Section&#160;10.13(b) of the [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(e)&#160;&#160;&#160;&#160;In connection with any Disposition Transaction, Icagen shall require any transferee, licensee or successor to agree either to be jointly and severally liable with Icagen for the royalties specified in this Section&#160;4.2, or to withhold payments from Icagen, and to pay to CFF, amounts sufficient to fully cover Icagen&#8217;s obligations to CFF under Section&#160;4.2. Absent agreement by any such transferee, licensee or successor to assume such liability or obligation, any such Disposition Transaction shall be null and void.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4.3</b>&#160;&#160;&#160;&#160;[***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4.4&#160;&#160;&#160;&#160;Sales Reports.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;In the event Icagen is responsible for Commercialization of a Product, commencing within [***] after the first calendar quarter following the First Commercial Sale, and within [***] after the end of each quarter thereafter, Icagen shall furnish or cause to be furnished to CFF a written sales report or reports covering the relevant period setting forth in detail the Net Sales during such period. With respect to Net Sales invoiced in Dollars, the Net Sales amounts and the amounts due to CFF hereunder shall be expressed in Dollars. With respect to sales of Products invoiced in a currency other than Dollars, the Net Sales and amounts due to CFF hereunder shall be expressed in the domestic currency of the party making the sale, together with the Dollar equivalent of the amount payable to CFF, calculated by translating foreign currency sales into Dollars in accordance with Icagen&#8217;s accounting policies. If any licensee or sublicensee makes any sales invoiced in a currency other than its domestic currency, the Net Sales shall be converted to its domestic currency in accordance with the licensee&#8217;s or sublicensee&#8217;s normal accounting principles. Icagen shall keep accurate records in sufficient detail to enable the amounts due hereunder to be verified by CFF.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;Upon the written request of CFF, at CFF&#8217;s expense and not more than [***] in a [***] period, Icagen shall permit an independent accountant selected by CFF that signs Icagen&#8217;s standard confidentiality agreement, to have access during normal business hours to those records of Icagen as may be reasonably necessary to verify the accuracy of the sales report furnished by Icagen pursuant to this Section&#160;4.4. CFF shall pay the cost of any such examination, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that if such examination determines that actual Net Sales were [***] ([***]%) or greater than the amount reported by Icagen to CFF, in addition to promptly paying CFF for any additional royalty then due, Icagen shall reimburse CFF for its expenses associated with such examination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(c)&#160;&#160;&#160;&#160;In case of any delay in payment by Icagen to CFF not occasioned by force majeure in accordance with Section&#160;11.4, interest shall be calculated at a rate equal to [***]% percent per month from the [***] ([***]) day after the date upon which the applicable payment first becomes due from Icagen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE V &#8211; CONFIDENTIALITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5.1&#160;&#160;&#160;&#160;Confidentiality.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definition of Confidential Information</u>. For purposes of this Agreement, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u>&#8221; shall mean all information Recipient received from the Owner in connection with this Agreement. Without limitation, Confidential Information shall also include (i)&#160;the financial terms of this Agreement and any other terms of this Agreement that a Party believes disclosure of which would be harmful to it, and (ii)&#160;any other trade secrets, confidential or proprietary information, or any other knowledge, information, data, reports, documents or materials, owned, developed or possessed by Owner (as defined below) that the Recipient can prove was already known to it, whether in tangible or intangible form, the confidentiality of which Owner takes reasonable measures to protect. &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u>&#8221; shall not, however, include any information of Owner that: (i)&#160;is already known to Recipient (as defined below) at the time of its disclosure as evidenced by written documentation; (ii)&#160;becomes publicly known through no wrongful act of Recipient; (iii)&#160;is received from a Third Party free to disclose it to Recipient and without any obligations to Owner to keep confidential; (iv)&#160;is independently developed by Recipient without use of the Confidential Information as evidenced by written documentation; or (v)&#160;is communicated to a Third Party without confidentiality requirements with express written consent of Owner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Disclosure</u>. During the term of this Agreement and for a period of [***] thereafter, each Party (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recipient</u>&#8221;) shall hold all Confidential Information it receives or received from the other Party (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Owner</u>&#8221;) in strict confidence, and, other than as provided herein or without first obtaining the prior written consent of Owner, Recipient shall not disclose any Confidential Information of Owner to any Person, except to (i)&#160;directors, officers, employees, consultants, committee members, volunteers, contractors, subcontractors, licensees, sublicensees, accountants or counsel of Recipient who have a need to know and who are subject to terms of confidentiality that are no less stringent than such confidentiality terms under this Agreement, and (ii)&#160;directors, officers, employees, consultants, committee members, volunteers, contractors, subcontractors,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">licensees, sublicensees, accountants and counsel of Owner, who have a need to know and who have been informed of the confidential nature of the information. Recipient shall use not less than a reasonable degree of care to protect such Confidential Information of Owner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(c)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Required Disclosure</u>. Notwithstanding Section&#160;5.1(b) above, Recipient&#8217;s disclosure of Confidential Information shall not be prohibited if such disclosure is required by a legally binding requirement; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that Recipient, if not legally prohibited, shall have first given prompt notice to Owner of any possible requirement and Owner shall have been afforded a reasonable opportunity to prevent or limit such disclosure (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recipient Notice Requirement</u>&#8221;); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</u>, that the Recipient Notice Requirement shall not apply to proceedings which, by Applicable Law, are of a nature that the existence of such proceedings may not be disclosed or made public in which case Recipient shall take all legally available measures to minimize or avoid the public disclosure of Owner Confidential Information. In the event that Recipient discloses any Owner Confidential Information pursuant to the immediately preceding sentence, Recipient shall cooperate with Owner, at Owner&#8217;s sole cost and expense, in the prosecution of any appeal that Owner decides to pursue. For any disclosures of this Agreement required by the Securities and Exchange Commission or other body regulating Icagen&#8217;s or its Affiliates&#8217; securities (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities Regulatory Authority</u>&#8221;), Icagen shall exercise good faith efforts to give confidential treatment of the information described in Section&#160;5.1(a), and Icagen shall provide CFF with contemporaneous copies of the requests for confidential treatment filed with such Securities Regulatory Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Use of Confidential Information</u>. Recipient hereby agrees and acknowledges that, other than as provided herein or without first obtaining Owner&#8217;s prior written consent, Recipient shall not use any of Owner&#8217;s Confidential Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(e)&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Injunctive Relief</u>. The parties acknowledge and agree that the Owner could be irreparably harmed by any unauthorized disclosure or use of the Confidential Information in violation of the terms of this Agreement, thus making any remedy at law or in damages inadequate. The Owner shall have the right to apply to any court of competent jurisdiction for an order enjoining any breach or threatened breach of this Agreement, which right shall be in addition to all other remedies available to the Owner at law or in equity, without the necessity of posting a bond and without the necessity of proving actual damage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5.2&#160;&#160;&#160;&#160;Publicity; Use of Name.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;During the Agreement Term set forth in the [***], publicity will be governed by Section&#160;8.10 of such agreement. After the Agreement Term so specified, publicity as between the Parties shall be governed by paragraph (b)&#160;below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;Except to the extent already disclosed in a press release or other public announcement, and except as may be otherwise provided herein, neither Party shall issue any press release or make any public announcement concerning the terms of this Agreement or the transactions described herein without the prior written consent of the other Party, such consent shall not be unreasonably withheld, conditioned or delayed; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that it shall not be unreasonable for any Party to withhold consent with respect to any press release or public announcement containing any of such Party&#8217;s Confidential Information; and, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</u>, that this Section&#160;5.2(b) shall not preclude any Party from issuing any such press release or making any such public announcement if such Party reasonably believes that any such release or announcement is (a)&#160;required by Applicable Law, or (b)&#160;required by the rules of any stock exchange on which such Party&#8217;s (or such Party&#8217;s Affiliates) securities are listed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(c)&#160;&#160;&#160;&#160;In each instance, the Party desiring to issue any press release or to make any public announcement shall provide the other Party with a written copy of the proposed release or announcement at least [***] prior to public release to allow such other Party to comment upon such release or announcement prior to its public release. If a Party does not provide its comments within such time period, the other Party may assume there are no comments and issue such release or announcement. Each press release and/or public announcement issued or made pursuant to this Section&#160;5.2 shall include CFF-approved language acknowledging CFF&#8217;s funding of the Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;&#160;&#160;&#160;Except as may be otherwise provided herein, no Party shall have any right, express or implied, to use in any manner the name or other designation of the other Party or any other trade name, trademark or logos of the other Party for any purpose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(e)&#160;&#160;&#160;&#160;Notwithstanding the foregoing or any contrary provision contained herein, in connection with: (a)&#160;any description by CFF of its research portfolio and of its industry discovery</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and development program, and/or (b)&#160;CFF&#8217;s fundraising activities, marketing materials and/or its customary reporting to the Cystic Fibrosis community, CFF shall be entitled to use and/or disclose after initial approval by Icagen, (i)&#160;the mark &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Icagen,</u>&#8221; Icagen&#8217;s logo and a general description of Icagen, (ii)&#160;the existence and a general description of the nature of this Agreement (excluding financial terms), and (iii)&#160;a general description of the nature of the Research Plan consistent with the confidentiality terms herein; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, CFF shall properly use any and all Icagen trademarks in a manner so as to not diminish its goodwill. Notwithstanding the foregoing or any contrary provision contained herein, in connection with any description by Icagen or its Affiliates of its research portfolio and of its industry discovery and development program, Icagen shall be entitled to use and/or disclose, and CFF hereby pre-approves Icagen&#8217;s use and/or disclosure of: (i)&#160;a general description of CFF, (ii)&#160;the existence and a general description of the nature of this Agreement (excluding financial terms), and (iii)&#160;a general description of the nature of the Research Plan and any other terms deemed necessary for compliance with any Applicable Law consistent with the confidentiality terms herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE VI &#8211; PUBLICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;During the Agreement Term set forth in the [***], publication will be governed by Section&#160;8.9 of such agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;After the Agreement Term set forth in the [***], publication will be governed by this paragraph (b). Icagen may publish or publicly present the data generated during the performance of, or as a result of, the Research Results, subject to the following terms and conditions. To the extent Icagen decides not to publish or publicly present the Research Results, Icagen consents to CFF publishing or publicly presenting such Research Results in accordance with this paragraph (b)&#160;of Article&#160;VI, provided that such consent will be binding, if and only if, provided in writing in accordance with the notice provisions contained herein. The Party proposing to publish or publicly present the Research Results (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Publishing Party</u>&#8221;) will submit a draft of any proposed manuscript, speech, poster or other disclosure to the other Party (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Publishing Party</u>&#8221;) for comments at least [***] prior to submission for publication or oral presentation. The Non-Publishing Party shall notify the Publishing Party in writing within [***] of receipt of such draft with its comments, which shall be reasonably incorporated by the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Publishing Party. The comments of the Non-Publishing Party shall include but not be limited to whether such draft contains (a)&#160;information of the Non-Publishing Party which it considers to be Confidential Information under the provisions of Article&#160;V hereof, (b)&#160;information that if published would have an adverse effect on a Patent which the Non-Publishing Party intends to file or has filed, or (c)&#160;information, including but not limited to chemical structures of a Product, which the Non-Publishing Party reasonably believes would be likely to have a material adverse impact on the development or commercialization of a Product. In any such notification, the Non-Publishing Party shall indicate with specificity its suggestions regarding the manner and degree to which the Publishing Party may disclose such information. In the case of item (a)&#160;above, no Party shall publish the Confidential Information of the other Party without the prior written consent of such other Party in violation of Article&#160;V of this Agreement. In the case of item (b)&#160;above, the Non-Publishing Party may request a delay and the Publishing Party shall delay such publication, for a period not exceeding an additional [***], to permit the timely preparation and filing of a patent application or an application for a certificate of invention on the information involved. In the case of item (c)&#160;above, if the Publishing Party shall disagree with the Non-Publishing Party&#8217;s assessment of the impact of the publication, then the issue shall be referred to the Program Coordinator of each Party who shall attempt in good faith to reach a fair and equitable resolution of this disagreement. If the disagreement is not resolved in this manner within [***] of referral to the respective program coordinators, then the decision of publication shall be subject to the Dispute resolution provisions at Section&#160;11.2, subject always to the confidentiality provisions of Article&#160;V hereof. The Parties agree that authorship of any publication will be determined based on the customary standards then being applied in the relevant scientific journal. Icagen shall acknowledge the financial support of CFF in all publications related to the conduct of the Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE VII &#8211; INDEMNIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7.1</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Indemnification by Icagen.</b> Icagen shall indemnify, defend and hold harmless CFF, its Affiliates, and their respective directors, officers, employees and agents (including, without limitation, the CFF Designees) (each, a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CFF Indemnitee</u>&#8221;), from and against any and all claims, suits and demands of Third Parties and losses, liabilities, damages for personal injury, property damage or otherwise, costs, penalties, fines and expenses (including reasonable fees of attorneys) (collectively, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Losses</u>&#8221;) arising out of or resulting from:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;the conduct of the Research Plan by Icagen and any breach of, or inaccuracy in, any representation or warranty made by Icagen in this Agreement, or any breach or violation of any covenant or agreement of Icagen in or pursuant to this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;any Product developed in whole or in part as a result of the Research Plan; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(c)&#160;&#160;&#160;&#160;any claim of infringement or misappropriation of intellectual property with respect to the Research Plan or any Product developed in whole or in part as a result of the Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Icagen will have no obligation to indemnify CFF to the extent that the Losses arise out of or result from, directly or indirectly, any product developed by CFF after the effective date of the Interruption License or by a Third Party other than Icagen or its Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7.2</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Indemnification by CFF.</b> CFF shall indemnify, defend and hold harmless Icagen, its Affiliates, and their respective directors, officers, employees and agents (each, an &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Icagen Indemnitee</u>&#8221;) from and against any and all claims, suits and demands of Third Parties and losses, liabilities, damages for personal injury, property damage or otherwise, costs, penalties, fines and expenses (including reasonable fees of attorneys) arising out of or resulting from any Product after the effective date of the Interruption License.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7.3</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Claims Procedures.</b> Each party entitled to be indemnified by the other party (an &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Party</u>&#8221;) pursuant to Sections&#160;7.1 or 7.2 hereof shall give notice to the other party (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnifying Party</u>&#8221;) promptly after receipt by an Indemnified Party of notice of the commencement of any action, suit or proceeding. Subject to Section&#160;7.4, the Indemnifying Party shall have the right to assume and manage the defense thereof (with counsel reasonably satisfactory to the Indemnified Party), including the right to settle, compromise and/or litigate with respect to any such claim (but only after obtaining the Indemnified Party&#8217;s prior written consent with respect to any proposed settlement, compromise or litigation; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that the Indemnifying Party shall not be required to obtain the Indemnified Party&#8217;s prior written consent in connection with any proposed settlement, compromise or litigation if, in connection with and following any such settlement, compromise or litigation, the Indemnified Party (a)&#160;has no liability (monetary or otherwise), (b) has not waived any of its rights and has not admitted to any wrongdoing or guilt, (c)&#160;is not subject to any injunction or other equitable or non-monetary relief, and (d)&#160;receives a full and unconditional release of all applicable claims and liability).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7.4</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Participation; Assuming Control of the Defense.</b> Notwithstanding Section&#160;7.3 above, the Indemnified Party may participate in the defense of any claim at the Indemnified Party&#8217;s sole expense, with counsel reasonably acceptable to the Indemnifying Party; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, if there is a conflict of interest that would prevent the Indemnifying Party, on the one hand, and the Indemnified Party, on the other hand, from being represented by a single law firm in the defense of such action; in each such instance, or (b)&#160;there shall be one or more additional or other defenses available to the Indemnified Party that are not available to the Indemnifying Party, then in each such instance the Indemnifying Party shall pay the reasonable fees and expenses of one law firm serving as counsel for the Indemnified Party, which law firm shall be subject to the prior consent of the Indemnifying Party, which consent shall not be unreasonably withheld, conditioned or delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7.5</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Limitation of Liability.</b> Neither Party shall be liable to the other Party for any special, indirect, incidental, consequential, punitive or exemplary damages, including, but not limited to, lost profits, in connection with such Party&#8217;s breach of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE VIII &#8211; INTELLECTUAL PROPERTY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8.1</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Ownership.</b> Any intellectual property related issues associated with the [***] are governed by the [***]. Icagen shall own, or Control through licenses from Third Parties, all Icagen Background Technology, whether existing as of the Effective Date or identified or developed prior to the expiration or earlier termination of the Research Term or thereafter, and all other Patent Rights of Icagen and Icagen Know-How, whether existing as of the Effective Date or identified or developed during the term of the Agreement or thereafter, that are developed independently by Icagen outside the scope of the Research Plan even if used to support the aims of the Research Plan. [***] shall own, or Control through licenses from Third Parties, all [***] Background Technology, whether existing as of the Effective Date or identified or developed during the term of the Agreement or thereafter, and all other Patent Rights of [***] and [***] Know-How, whether existing as of the Effective Date or identified or developed during the term of the Agreement or thereafter, that are developed independently by [***] outside the scope of the Research Plan, even</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">if used to support the aims of the Research Plan. In addition, in the conduct of the Research Plan, all compounds derived from compounds originating in the [***] shall be [***] Sole Intellectual Property. CFF shall not own any compounds originating from the Icagen Library of Compounds or the [***] except as may be subject to the Interruption License. All inventions relating to the Research Plan invented, conceived or made and all data and know-how generated thereon exclusively by Icagen or its Affiliates (directly or through others acting on its behalf) during the term of this Agreement (an &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Icagen Sole Invention</u>&#8221;) and all inventions relating to the Research Plan invented, conceived or made and all data and know-how generated thereon exclusively by CFF or its Affiliates (directly or through others acting on its behalf) during the term of this Agreement (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CFF Sole Invention</u>&#8221;) shall be solely owned by the Party conceiving or making the invention or generating the data or know-how claimed. All inventions relating to the Research Plan invented, conceived or made and all data and know-how generated thereon by both Parties or their respective Affiliates (directly or through others acting on its behalf) during the term of this Agreement (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Joint Invention</u>&#8221;) shall be jointly owned by CFF and Icagen. A Joint Invention does not include any intellectual property that is jointly owned by Icagen and [***] in accordance with the terms of the [***]. Inventorship shall be determined in accordance with United States laws of inventorship. Icagen hereby grants to CFF, a non-exclusive license to use any inventions relating to the Research Plan that are invented, conceived or made and all data and know-how generated thereon during the term of this Agreement that have applicability to Icagen&#8217;s general business solely for purposes of conducting research under the Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8.2</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Exclusive License Grant.</b> CFF hereby grants and agrees to grant to Icagen, the consideration of which is acknowledged, an exclusive (even as to CFF) fully paid up worldwide license with the right to grant sublicenses to all its rights under CFF Patents and Joint Patents for all purposes. CFF acknowledges and agrees that it does not retain any rights to any CFF Sole Invention or any Joint Invention or any Patents claiming such Inventions for any purpose whatsoever.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8.3</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Preparation.</b> Icagen will control in its sole discretion the preparation, filing, prosecution, maintenance and enforcement of all Icagen Patents, CFF Patents and Joint Patents. CFF will have the right to review, and Icagen will deliver to CFF, all patent applications directed to CFF Sole Inventions and Joint Inventions prior to their filing. Notwithstanding the foregoing, nothing herein shall obligate Icagen to prepare or file a patent application directed to any Sole Invention or Joint Invention. CFF agrees to execute any documents of assignment, declaration, or otherwise reasonably necessary for Icagen to file, prosecute, maintain and enforce the Icagen Patents, CFF Patents and Joint Patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8.4</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Costs.</b> Icagen shall be responsible for all costs incurred in the preparation, prosecution, maintenance and enforcement of Icagen Patents, CFF Patents, and Joint Patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8.5</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Abandonment.</b> Notwithstanding any contrary provision contained herein, prior to Icagen (or any Affiliate, licensee, sublicensee, transferee or successor of Icagen) abandoning any Patent or patent application related to any Product (including abandonment for failure to pay any required fees) for any reason other than an insurmountable prosecution obstacle as solely determined by Icagen, Icagen shall promptly notify CFF, or cause CFF to be notified, of such pending abandonment, whereupon CFF shall have the right and opportunity to prosecute or maintain the applicable Patent at CFF&#8217;s own expense. Icagen hereby agrees to exercise its good faith efforts to obtain such consents, on CFF&#8217;s behalf, as may be necessary, advisable and/or appropriate for CFF to exercise its rights under this Section&#160;8.5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE IX &#8211; TERM AND TERMINATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.1</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Term.</b> This Agreement shall become effective as of the Effective Date and, unless earlier terminated pursuant to the other provisions of this Article&#160;IX, shall terminate at such time as when there are no longer any payment obligations owing from Icagen to CFF under Article&#160;IV hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.2</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Termination by CFF Without Cause.</b> CFF may terminate this Agreement without cause on or after the [***] ([***]) month anniversary of the Effective Date by providing Icagen with [***]&#8217; prior written notice, provided that if Icagen is unable to demonstrate within [***] after the Effective Date that one or more Confirmed Hits from its pilot screen (which pilot screen may</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">be expanded to include in addition to the Icagen Diversity Collection, one or more core compound sets from the [***] (Exhibit&#160;F of the [***])) are active in [***] derived from [***] then Icagen shall have the following [***] to develop a revised discovery assay or approach and evaluate whether hits from a pilot screen conducted in the revised discovery assay or approach are active in [***], and failing that CFF may terminate this Agreement after such period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.3</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Termination by Icagen for Scientific Cause.</b> Icagen shall have the right to terminate this Agreement for Scientific Cause, provided that Icagen shall give CFF prior notice of its intention to terminate the Agreement for Scientific Cause and a meeting of the PAG shall be scheduled prior to the effective date of such termination to specifically discuss the reasons for such termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.4</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Termination for Cause.</b> Notwithstanding any provision contained herein or in any other document to the contrary, either Party may, without prejudice to any other remedies available to it at law or in equity, terminate this Agreement upon the occurrence of any of the following events (each, a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Default</u>&#8221;); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that, in the case of subparagraphs (a)&#160;and (b) below, the Party breaching the Agreement (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Breaching Party</u>&#8221;) shall have [***] following the earlier of such Breaching Party&#8217;s receipt of written notice from the other Party of the occurrence of a Default or the Breaching Party becoming aware of such Default to cure such Default:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;Any material breach or default by a Party in the performance of any of its material covenants or obligations hereunder;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;Any material representation or warranty made by a Party in this Agreement is not true in any material respects as of the date made; and/or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(c)&#160;&#160;&#160;&#160;A case or proceeding (i)&#160;under the bankruptcy laws of the United States now or hereafter in effect is filed against a Party or all or substantially all of its assets and such petition or application is not dismissed within [***] after the date of its filing or the Party shall file any answer admitting and not contesting such petition, or (ii)&#160;under the bankruptcy laws of the United States now or hereafter in effect or under any insolvency, reorganization, receivership, dissolution or liquidation law or statute of any jurisdiction now or hereafter in effect (whether at law or equity) is filed by a Party for all or substantially all of its assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.5&#160;&#160;&#160;&#160;General Effect of Termination; Survival.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;Termination or expiration of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination or expiration. Such termination or expiration shall not relieve any Party from obligations which are expressly indicated to survive termination of this Agreement. If this Agreement is terminated for any reason, all of the Parties&#8217; rights and obligations under, and/or the provisions contained in, Sections&#160;2.9, 3.1(b), 3.1(d), 3.1(f), 3.2, 9.5 and 9.6 and Articles I, IV, V, VI, VII, VIII, X and XI shall survive termination or expiration of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;Subject to the license that may be granted under Section&#160;9.6, upon termination or expiration of this Agreement, Icagen will retain ownership or exclusive rights to the Icagen Background Technology and the inventions licensed to it by CFF pursuant to Article&#160;VIII of this Agreement (including intellectual property rights).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.6&#160;&#160;&#160;&#160;Interruption License.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;[***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">[***]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;[***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(c)&#160;&#160;&#160;&#160;[***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;&#160;&#160;&#160;[***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(e)&#160;&#160;&#160;&#160;[***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE X &#8211; REPRESENTATIONS AND WARRANTIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10.1</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Representations and Warranties of Icagen.</b> Icagen represents and warrants to CFF that: (i)&#160;this Agreement has been duly executed and delivered by Icagen and constitutes the valid and binding obligation of Icagen, enforceable against Icagen in accordance with its terms, except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors&#8217; rights generally and by general equitable principles; (ii)&#160;the execution, delivery and performance of this Agreement have been duly authorized by all necessary action on the part of Icagen and its directors and stockholders; (iii)&#160;the individual executing this Agreement on behalf of Icagen is duly authorized to do so; and (iv)&#160;no provision contained in this Agreement violates any other agreement to which Icagen is bound or otherwise subject.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10.2</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Representations and Warranties of CFF.</b> CFF represents and warrants to Icagen that: (a)&#160;this Agreement has been duly executed and delivered by CFF and constitutes the valid and binding obligation of CFF, enforceable against CFF in accordance with its terms, except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors&#8217; rights generally and by general equitable principles; (b)&#160;the execution, delivery and performance of this Agreement have been duly authorized by all necessary action on the part of CFF and its directors; (c)&#160;the individual executing this Agreement on behalf of CFF is duly authorized to do so; and (d)&#160;no provision contained in this Agreement violates any other agreement to which CFF is bound or otherwise subject.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARTICLE XI &#8211; MISCELLANEOUS PROVISIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.1</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Governing Law.</b> This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.2&#160;&#160;&#160;&#160;Dispute Resolution.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;In the event of any dispute, claim or controversy arising out of, relating to or in any way connected to the interpretation of any provision of this Agreement, the performance of either Party under this Agreement or any other matter under this Agreement, including any action in tort, contract or otherwise, at equity or law (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dispute</u>&#8221;), either Party may at any time provide the other Party written notice specifying the terms of such Dispute in reasonable detail. As soon as practicable after receipt of such notice, officers empowered to reach a resolution of the Dispute shall meet at a mutually agreed upon time and location for the purpose of resolving such Dispute. The officers shall engage in good faith discussions and/or negotiations for a period of up to thirty (30)&#160;days to resolve the Dispute or negotiate an interpretation or revision of the applicable portion of this Agreement which is mutually agreeable to both Parties without the necessity of formal Dispute resolution procedures relating thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;In the event that any non-business type Dispute is not resolved by the designated officers pursuant to Section&#160;11.2(a), then the Dispute shall be referred to an independent scientific expert in the Field appointed by agreement of the Parties. The independent expert&#8217;s decision shall be final and binding and its costs shall be borne as directed by the independent expert. Each Party shall cooperate in good faith with the expert. In the event that the Parties are unable to agree as to whether a particular Dispute is governed by this Section&#160;11.2(b), then this Section&#160;11.2(b) shall be utilized to resolve such Dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">(c)&#160;&#160;&#160;&#160;In the event any business-related Dispute is not resolved by the designated officers pursuant to Section&#160;11.2(a), then the Parties shall resolve such Dispute by final and binding arbitration. Whenever a Party decides to institute arbitration proceedings, it shall give written notice to that effect to the other party. Arbitration shall be held in Washington, D.C., according to the then-current commercial arbitration rules of the Center for Public Resources (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CPR</u>&#8221;), except to the extent such rules are inconsistent with this Section&#160;11.2. The arbitration will be conducted by one (1)&#160;arbitrator who shall be reasonably acceptable to the Parties and who shall be appointed in accordance with CPR rules. If the Parties are unable to select an arbitrator, then the arbitrator shall be appointed in accordance with CPR rules. Any arbitrator chosen hereunder shall have educational training and industry experience sufficient to demonstrate a reasonable level of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">relevant scientific, financial, medical and industry knowledge. Within twenty (20)&#160;days of the selection of the arbitrator, each Party shall submit to the arbitrator a proposed resolution of the Dispute that is the subject of the arbitration (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proposals</u>&#8221;). The arbitrator shall thereafter select one of the Proposals so submitted as the resolution of the Dispute, but may not alter the terms of either Proposal and may not resolve the Dispute in a manner other than by selection of one of the submitted Proposals. In order to assist the arbitrator in reaching its decision, the arbitrator may request briefs from each Party to support its Proposal. Thereafter, the arbitrator shall hold such hearing as he or she considers to be appropriate. If a Party fails to submit a Proposal in accordance with the terms of this Section&#160;11.2(c), the arbitrator shall select the Proposal of the other Party as the resolution of the Dispute. The arbitrator shall agree to render its opinion within [***] of the final arbitration hearing. No arbitrator shall have the power to award punitive damages under this Agreement regardless of whether any such damages are contained in a Proposal, and such award is expressly prohibited. The proceedings and decisions of the arbitrator shall be confidential, final and binding on all of the Parties. Judgment on the award so rendered may be entered in a court having jurisdiction thereof. The Parties shall share the costs of arbitration according to the decision of the arbitrator. Nothing in this Section&#160;11.2(c) will preclude either Party from seeking equitable relief or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a Dispute either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.3</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Waiver.</b> No provision of this Agreement may be waived except in writing by both Parties hereto. No failure or delay by either Party hereto in exercising any right or remedy hereunder or under Applicable Law will operate as a waiver thereof, or a waiver of any right or remedy on any subsequent occasion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.4</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Force Majeure.</b> Neither Party will be in breach hereof by reason of its delay in the performance of or failure to perform any of its obligations hereunder, if that delay or failure is caused by strikes, acts of God or the public enemy, riots, incendiaries, interference by civil or military authorities, compliance with governmental priorities for materials, or any fault beyond its reasonable control. In such event, Icagen or CFF, as the case may be, shall immediately notify the other Party of such inability and of the period for which such inability is expected to continue. The</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Party giving such notice shall thereupon be excused from such of its obligations under this Agreement as it is thereby disabled from performing for so long as it is so disabled. To the extent possible, each Party shall use reasonable efforts to minimize the duration of any force majeure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.5</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Severability.</b> Should one or more provisions of this Agreement be or become invalid, then the Parties hereto shall attempt to agree upon valid provisions in substitution for the invalid provisions, which in their economic effect come so close to the invalid provisions that it can be reasonably assumed that the Parties would have accepted this Agreement with those new provisions. If the Parties are unable to agree on such valid provisions, the invalidity of such one or more provisions of this Agreement shall nevertheless not affect the validity of the Agreement as a whole, unless the invalid provisions are of such essential importance for this Agreement that it may be reasonably presumed that the Parties would not have entered into this Agreement without the invalid provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.6</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Assignment.</b> This Agreement may not be assigned or otherwise transferred by either Party without the prior written consent of the other Party; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that (i)&#160;either Party may assign this Agreement, without the consent of the other Party (a)&#160;to any of its Affiliates, if the assigning Party unconditionally guarantees the full performance of its Affiliate&#8217;s obligations hereunder, or (b)&#160;in connection with such Party&#8217;s merger, consolidation or transfer or sale of all or substantially all of the assets of such Party, and (ii)&#160;Icagen may assign this Agreement to [***] without CFF&#8217;s consent, provided that in both (i)&#160;above the successor, surviving entity, purchaser of assets, transferee, or other similar party, as applicable, or in the case of (ii)&#160;above [***], expressly assumes in full in writing such Party&#8217;s obligations under this Agreement. Notwithstanding the foregoing sentence, in no event will [***] be required to assume any noncompetition requirement set forth in this Agreement or any other provision that is inconsistent with the [***] as part of, or a condition to, the assignment. Any purported assignment in contravention of this Section&#160;11.6 shall, at the option of the non-assigning Party, be null and void and of no effect. No assignment shall release either Party from responsibility for the performance of any accrued obligation of such Party hereunder. This Agreement shall be binding upon and enforceable against the successor to or any permitted assignees from either of the Parties hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.7</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Counterparts.</b> This Agreement may be executed in duplicate, each of which shall be deemed to be original and both of which shall constitute one and the same Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.8</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">No Agency.</b> Nothing herein contained shall be deemed to create an agency, joint venture, partnership or similar relationship between CFF and Icagen. Notwithstanding any of the provisions of this Agreement, neither Party to this Agreement shall at any time enter into, incur, or hold itself out to Third Parties as having authority to enter into or incur, on behalf of the other Party, any commitment, expense, or liability whatsoever, and all contracts, expenses and liabilities in connection with or relating to the obligations of each Party under this Agreement shall be made, paid, and undertaken exclusively by such Party on its own behalf and not as an agent or representative of the other.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:10pt;font-weight:bold;">11.9</b><font style="font-size:10pt;">&#160;&#160;&#160;&#160;</font><b style="font-size:10pt;font-weight:bold;">Notice.</b><font style="font-size:10pt;"> All communications between the Parties with respect to any of the provisions of this Agreement will be sent to the addresses set out below, or to such other addresses as may be designated by one party to the other by notice pursuant hereto, by prepaid, certified air mail (which shall be deemed received by the other Party on the seventh (7</font><sup style="font-size:6.37pt;vertical-align:top;">th</sup><font style="font-size:10pt;">) business day following deposit in the mails), or by facsimile transmission, or other electronic means of communication (which shall be deemed received when transmitted), with confirmation by first class letter, postage pre-paid, given by the close of business on or before the next following business day:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">if to CFF, at:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">President and CEO</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">Phone: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">Fax: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">E-mail: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">with a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">Schaner&#160;&amp; Lubitz, PLLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">Phone: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">Fax: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">E-mail: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">if to Icagen, at:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">Icagen, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">4222 Emperor Blvd, Suite 350, Durham, NC 27703</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">Attention: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">Tel.: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">Fax: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">E-mail: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">with a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">Gracin&#160;&amp; Marlow, LLP The Chrysler Building</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">Tel.: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">Fax: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">Email: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.10</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Headings.</b> The Section&#160;and paragraph headings are for convenience only and will not be deemed to affect in any way the language of the provisions to which they refer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.11</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Entire Agreement.</b> This Agreement contains the entire understanding of the Parties relating to the matters referred to herein, and may only be amended by a written document, duly executed on behalf of the respective Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.12</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">No Impairment.</b> Icagen will not, by amendment of its organizational or governing documents, or through reorganization, recapitalization, consolidation, merger, dissolution, sale, transfer or assignment of assets, issuance of securities, or any other voluntary action, avoid or seek</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to avoid the observance or performance of any of the terms, provisions, covenants or agreements of this Agreement, but rather will at all times in good faith assist in the carrying out of all such terms, provisions, covenants and agreements and in the taking of all such actions as may be necessary, advisable or appropriate in order to protect the rights of CFF against impairment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.13</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">OFAC Compliance.</b> In accordance with the U.S.&#160;Department of the Treasury Anti-Terrorist Financing Guidelines, Icagen shall take reasonable steps to ensure that the payments received from CFF are not distributed to terrorists or their support networks or used for activities that support terrorism or terrorist organizations and Icagen shall periodically apprise CFF of the steps taken to meet this goal. Icagen certifies that it is in compliance with all laws, statutes and regulations restricting U.S.&#160;persons from dealing with any individuals, entities, or groups subject to Office of Foreign Assets Control (OFAC) sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[<i style="font-style:italic;">Remainder of page intentionally left blank</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the undersigned have executed this Research, Development and Commercialization Agreement as of the date first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CYSTIC FIBROSIS FOUNDATION</p></td><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:52.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:52.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and CEO</p></td><td style="vertical-align:bottom;width:52.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ICAGEN, INC.</p></td><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:52.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:52.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and CEO</p></td><td style="vertical-align:bottom;width:52.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">[<i style="font-style:italic;">Signature Page to Research, Development and Commercialization Agreement</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Exhibit G</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Icagen Press Release</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">NEWS RELEASE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Icagen Receives Award from the Cystic Fibrosis Foundation to Discover Transformative Therapies to Treat Cystic Fibrosis</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Tucson, AZ (** **, 2018)</b>: Icagen, Inc., a company focused on the discovery of innovative therapies to treat patients with serious diseases, today announces an award from the Cystic Fibrosis Foundation. The project is focused on the discovery of therapeutics to treat patients with cystic fibrosis (CF) caused by nonsense mutations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The CF Foundation brings extensive resources and expertise to the project and, additionally, has awarded Icagen up to USD $11&#160;million to support an integrated, multi-year drug discovery initiative. Icagen expects to screen over 2&#160;million compounds as well as leverage its state-of-the-art <i style="font-style:italic;">in silico </i>drug discovery platform to interrogate an additional ten million virtual structures for molecules that suppress nonsense mutations. Through these efforts, Icagen intends to discover and evolve families of molecules that are suitable for clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cystic fibrosis is a genetic disease marked by defects in a protein, known as the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Nonsense mutations in the CFTR gene result in the premature termination of protein synthesis and the formation of truncated, non-functional CFTR. Patients with these mutations in both copies of their CFTR genes currently have no therapies that treat the underlying cause of their disease. The aim of this program is to provide these patients with a transformative therapeutic that will markedly improve their quality of life and lifespan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8220;We are excited to collaborate with the Cystic Fibrosis Foundation to seek the discovery of life-transforming therapies for people with CF through this unique model. Icagen&#8217;s innovative platform is built for programs such as these to discover and advance novel therapeutic candidates for clinical development,&#8221; said Richie Cunningham, President and CEO of Icagen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">About Icagen, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Icagen (www.icagen.com) Icagen specializes in the early stage of drug discovery to generate high-quality, advanced leads in multi-year, integrated drug discovery programs. Through both high throughput experimental and advanced computational approaches, Icagen creates innovative solutions that leverage an interplay of open discovery with the predictive potential of artificial intelligence and machine learning. Icagen is applying these approaches to its internal programs as well as toward its collaborations with external partners within the pharmaceutical and biotechnology industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For more information email <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">info@icagen.com</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">SOURCE Icagen, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 In some cases forward-looking statements can be identified by terminology such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; and similar expressions, and include statements regarding Icagen&#8217;s intent to discover and evolve families of molecules that are suitable for clinical development</i>, <i style="font-style:italic;">the expected screening of over 2M compounds in search of molecules that suppress premature termination and the success of the collaboration. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, among others, Icagen&#8217;s ability to successfully leverage expertise with in silico drug design, medicinal chemistry, and in vitro/in vivo biology capabilities and the other factors described in Icagen&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2016, and its other filings with the SEC. The information in this release is provided only as of the date of this release, and Icagen does not undertake any obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">For further information, contact:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Douglas S. Krafte, PhD</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Chief Scientific Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Icagen, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">4222 Emperor Blvd, Suite 350</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Durham, NC 27703</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Tel +1 919-433-3209</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Email: dkrafte@icagen.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AMENDMENT NO. 1 TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">BY AND BETWEEN ICAGEN INC. AND CYSTIC FIBROSIS FOUNDATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">This Amendment, dated June&#160;13, 2018 (this &#8220;<font style="font-style:italic;font-weight:bold;">Amendment</font>&#8221;), to the Research, Development and Commercialization Agreement, dated May&#160;1, 2018 (the &#8220;<font style="font-style:italic;font-weight:bold;">Agreement</font>&#8221;), is entered into by and between Icagen, Inc. (&#8220;<font style="font-style:italic;font-weight:bold;">Icagen</font>&#8221;) and Cystic Fibrosis Foundation (&#8220;<font style="font-style:italic;font-weight:bold;">CFF</font>&#8221;)<i style="font-style:italic;">. </i>Capitalized terms used herein without definition shall have the meanings assigned in the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS, </b>the parties desire to amend and restate the provisions of Subsection&#160;3.1 (a) entitled &#8220;<font style="font-style:italic;font-weight:bold;">Contract Execution Milestone</font>&#8221; and Subsection&#160;3.1(b) entitled &#8220;<font style="font-style:italic;font-weight:bold;">Payments</font>&#8221;, of the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW THEREFORE, </b>in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree to amend the Agreement as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Subsection<font style="font-family:'Symbol';">&#160;</font>3.1 (a) entitled <font style="font-family:'Symbol';">&#8220;</font><font style="font-style:italic;font-weight:bold;">Contract Execution Milestone</font>&#8221; and Subsection&#160;3.1(b) entitled &#8220;<font style="font-style:italic;font-weight:bold;">Payments</font>&#8221; are hereby deleted in their entirety and replaced with the following:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 24.45pt;"><b style="font-weight:bold;">ARTICLE III - AWARD AMOUNT PAYMENTS; RECORDS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 24.45pt;">&#8220;<b style="font-weight:bold;">3.1</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Research Funding</b>.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contract Execution Milestone</u>. Within [***] of execution of this Amendment, CFF shall make a one-time payment of [***] ($[***]) (the &#8220;<font style="font-style:italic;font-weight:bold;">Contract Execution Milestone Payment</font>&#8221;) for work conducted by Icagen during the first, second and fourth quarters of 2017 as well as the months of January, February, March and April of 2018 as described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;B,</u> which payment shall be in addition to the payments set forth below. For clarity, the Contract Execution Milestone Payment is part of the Award Amount, not in addition to the Award Amount.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:30.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments</u>. In accordance with the terms, and subject to the conditions, set forth in this Agreement, Icagen shall send invoices in United. States Dollars (&#8220;<font style="font-style:italic;font-weight:bold;">Dollars</font>&#8221;) to CFF for payment of the Award Amount. Invoices shall be submitted within [***] after the completion of each calendar month (except for the invoice with respect to payments under Section&#160;3.1 (a) which have been annexed to this Amendment) and shall be accompanied by documentation evidencing the expenditure of funds, FTEs devoted to the Research Plan in accordance with the Budget, and applicable milestones. CFF shall use good faith efforts to pay amounts invoiced by Icagen within [***] of receipt of an invoice and supporting documentation from Icagen or verification of the achievement of the milestone by the PAG (except for the payments under Section&#160;3.1 (a) which shall be subject to the provision of Section&#160;3.1 (a)) and in no event shall payment be made later than [***] from receipt of an invoice. The Parties acknowledge and agree that Icagen will invoice CFF for work performed during the time periods outlined in 3.1(a) prior to the Effective</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 55.05pt;">Date. All payments to be made hereunder (including, without limitation, pursuant to Article&#160;IV) shall be made in Dollars and, at the option and direction of the receiving party, shall be made by cashier&#8217;s or certified check or by wire transfer of immediately available funds.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;&#160;All other terms of the Agreement shall remain in full force and effect. The Agreement, as amended by this Amendment, constitutes the entire agreement between the parties with respect to the subject matter thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">3.&#160;&#160;&#160;&#160;This Amendment may be executed in one or more counterparts, each of which shall be deemed an original but both of which together shall constitute one and the same instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">4.&#160;&#160;&#160;&#160;This Amendment is made and shall be construed and performed under the laws of the remaining provisions will nevertheless continue to be valid and enforceable in the State of Delaware without regard to its choice or conflict of law principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF, </b>the parties hereto have caused this Agreement to be duly executed as of the day and year first above written.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CYSTIC FIBROSIS FOUNDATION</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ICAGEN, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:41.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:41.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:41.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President &amp; CEO</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">3.&#160;&#160;&#160;&#160;This Amendment may be executed in One&#160;&amp;more counterparts, each of which Shall be deemed an original but both of which together shall constitute.one and the same instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;">4.&#160;&#160;&#160;&#160;This Amendment is made and shall be construed and performed under the Jaws of the remaining: provisions</font><sup style="font-size:6.37pt;vertical-align:top;">.</sup><font style="font-size:10pt;"> will nevertheless continue to be valid and. enforceable in the State of Delaware Without regard to its choice or conflict of</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF, </b>the; parties hereto have caused this Agreement to be duly executed as of the day and year first above written.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CYSTIC FIBROSIS FOUNDATION</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ICAGEN, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:41.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:41.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.15%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:41.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SVP &amp; Chief Legal Officer</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.15%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">April&#160;1, 2020 (the &#8220;Assignment Effective Date&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">This Agreement (this &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;) is entered into by and between Icagen, Inc., a Delaware corporation (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent</u>&#8221;), Icagen Corp., a Nevada corporation, XRPro Sciences, Inc., a Delaware corporation, and Caldera Discovery, Inc., a Delaware corporation (each, a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsidiary</u>&#8221;, and the Subsidiaries, together with Parent, collectively referred to as &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Seller</u>&#8221;), Ligand Pharmaceuticals, Incorporated (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ligand</u>&#8221;) and its subsidiary Adjacent Acquisition Co., LLC, a Delaware limited liability company (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Buyer</u>&#8221;), and Cystic Fibrosis Foundation (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CFF</u>&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WITNESSETH:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Seller and Buyer are parties to that certain Asset Purchase Agreement, dated as of even date herewith (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchase Agreement</u>&#8221;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">),</u> pursuant to which, among other things, Seller agreed to sell, assign, transfer, convey and deliver to Buyer, and Buyer agreed to purchase from Seller, all of Seller&#8217;s right, title and interest in and to the Assumed Contracts, and Buyer agreed to assume, perform and discharge all of the Assumed Liabilities; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Parent and CFF are parties to that certain Research, Development and Commercialization Agreement dated as of May&#160;1, 2018 as amended on June&#160;12, 2018 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CFF Agreement</u>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, in accordance with the terms of the Purchase Agreement, all of Seller&#8217;s right, title and interest in, to and under all of the properties, rights and assets of every kind and nature, whether real, personal or mixed, tangible or intangible, wherever located, whether now owned, leased, used or held for use or hereafter owned, leased, used or held for use (other than certain excluded assets), which are located at its Durham, North Carolina location (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assets</u>&#8221;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">)</u> are being transferred to Buyer; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, the Assets also include all of Parent&#8217;s interests in the CFF Agreement; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, CFF desires to (i)&#160;assign the CFF Agreement to Buyer and (ii)&#160;amend the terms of the CFF Agreement and Buyer has agreed to assume all rights, duties and obligations under the CFF Agreement as of the Assignment Effective Date to continue performing the Research Program therein; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, based on the foregoing representations and those set forth below, each Party desires to consent to such assignment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, pursuant to the terms and conditions of the Purchase Agreement, and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Seller and Buyer hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">1.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Defined Terms</u>. Capitalized terms used but not defined herein shall have the respective meanings assigned to such terms in the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment of Assumed Contracts</u>. Effective as of the Closing, Seller hereby sells, assigns, transfers, conveys and delivers to Buyer all of Seller&#8217;s right, title and interest in, to and under the CFF Agreement. Effective as of the Closing, Buyer hereby accepts the foregoing assignment. CFF hereby consents to the assignment and transfer of the CFF Agreement and all obligations of Parent under the CFF Agreement to Buyer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">3.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assumption of Liabilities</u>. Effective as of the Closing, Buyer hereby assumes and agrees to pay, perform and discharge when due all obligations of Parent under the CFF Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">4.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment to CFF Agreement</u>. The CFF Agreement is hereby amended to add the following new Subparagraph (f)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 24.45pt;">&#8220;(f) In the event Buyer is required to pay to Seller or to any other person on behalf of Seller any contingent earnout payment (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CEP</u>&#8221;) pursuant to the Purchase Agreement, Buyer shall withhold and pay to CFF the following: (i) [***] ([***]%) of any CEP, plus (ii) [***] ([***]%) of any CEP is attributable to the CFF non-sense mutation program (collectively (i)&#160;and (ii) shall be the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CFF-CEP Payment</u>&#8221;), provided, however, that: (A)&#160;the calculation of the CFF-CEP Payment in (i)&#160;and (ii) above (A)&#160;shall exclude any portion of the CEP that is required to be paid to the Parent&#8217;s creditors; (B)&#160;shall exclude any CEP not to exceed $[***] paid to the Seller prior to December&#160;31, 2020 solely for the purpose of allowing the Seller to satisfy its continuing budget for 2020, provided that, the portion of such CEP otherwise payable to CFF pursuant to (i)&#160;and (ii) above (the &#8220;Deferred Amount) shall be added to the next CFF-CEP Payment payable to CFF pursuant to this Section&#160;until the full Deferred Amount has been repaid to CFF; and (C)&#160;in no event shall the aggregate CFF-CEP Payment exceed $[***]. The CFF-CEP Payment shall reduce the Royalty Cap.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">5.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Additional Buyer Payments</u>. The terms of this Agreement shall not be interpreted in any manner that increases the obligations of Buyer to Seller or changes the timing of any payment due under the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">6.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Buyer To Operate Independently</u>. Ligand intends that Buyer will conduct Parent&#8217;s former business independently of Ligand and its other subsidiaries and affiliates (collectively the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ligand Group</u>&#8221;), so that confidential information and data of the CF Program including information furnished by [***] and CFF (&#8220; collectively CF Program Data&#8221;) conducted by Icagen prior to the date of this Agreement will not be available to other members of the Ligand Group. Accordingly, CFF agrees that as long as (i)&#160;CF Program Data has not been disclosed to a member of the Ligand Group, or (ii)&#160;a member of the Ligand Group has not provided assistance in the performance of the CF Program, such member shall not be governed by the terms of the CFF Agreement, provided that once a member of the Ligand Group no longer meets the requirements of (i)&#160;or (ii) above, such member shall be subject to the CFF Agreement. Nothing in this Section&#160;6 is intended to conflict with the guarantee of payment and performance by Ligand of the obligations of Buyer set forth in this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">7.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances</u>. At any time or from time to time hereafter, Seller shall, at the reasonable request of Buyer, execute, acknowledge and deliver such further instruments of conveyance, power of attorney, sale, transfer or assignment, and take such other actions as Buyer may reasonably request in order to more effectively consummate the transactions contemplated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">8.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Agreement</u>. This Agreement is made without representation or warranty, except as provided in the Purchase Agreement. Nothing contained in this Agreement shall be construed to supersede, limit or qualify any provision of the Purchase Agreement. As between Buyer and Seller, to the extent there is a conflict between the terms and provisions of this Agreement and the terms and provisions of the Purchase Agreement, the terms and provisions of the Purchase Agreement shall govern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">9.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Agreement may be executed in multiple counterparts, and by the different parties hereto in separate counterparts, each of which shall for all purposes be deemed to be an original, and all of which taken together shall constitute one and the same instrument. A signature delivered on any counterpart by facsimile or other electronic means shall for all purposes be deemed to be an original signature to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">10.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</u>. This Agreement may not be amended or modified except by an instrument in writing signed by each of Seller, CFF and Buyer. In addition, the Purchase Agreement shall not be amended or modified in any way that would affect the calculation of the CFF-CEP Payment without the written consent of CFF.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">11.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. This Agreement shall in all respects be construed in accordance with and governed by the substantive laws of the State of Delaware, without reference to its choice of law rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">12.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</u>. This Agreement and the various rights and obligations arising hereunder shall inure to the benefit of and be binding upon Buyer, CFF and Seller, and their respective successors and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">13.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</u>. Neither this Agreement nor any of the rights, interests or obligations hereunder may be assigned by any party hereto, in whole or in part (whether by operation of law or otherwise), without the prior written consent of the other parties hereto; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that without such prior written consent: (a)&#160;Buyer may assign its rights and/or delegate its obligations under this Agreement(in whole but not in part), at any time and in their sole discretion, to any of its Affiliates; (b)&#160;any or all of the rights and interests and/or obligations of Buyer under this Agreement: (i)&#160;may be assigned and/or delegated to any purchaser of a substantial portion of the assets of Buyer or any of its Affiliates (whereupon Buyer shall cease to have any further liabilities or obligations hereunder); and (ii)&#160;may be assigned as a matter of law to the surviving entity in any merger, consolidation, share exchange or reorganization involving Buyer or any of its Affiliates; and (c)&#160;Buyer and its Affiliates shall be permitted to collaterally assign their respective rights hereunder to any lender or lenders providing financing to Buyer or any of its Affiliates (including any agent for any such lender or lenders) or to any assignee or assignees of such lender, lenders or agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">14.&#160;&#160;&#160;&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ligand Guarantee</u>. Ligand hereby guarantees the payment of the CFF-CEP Payment and the performance by its Affiliate to which the performance of the CFF Agreement is assigned in accordance with the terms of the CFF Agreement, as amended by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">[Signature Page Follows]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the parties hereto have caused this Agreement to be duly executed as of the date first set forth above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">SELLER:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ICAGEN, INC.:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:48.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 28pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: [***] </p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ICAGEN CORP:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:48.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 28pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: [***] </p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">XR PRO SCIENCES, INC.:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:48.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 28pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: [***] </p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CALDERA DISCOVERY, INC.:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:48.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 28pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: [***] </p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LIGAND PHARMACEUTICALS</b> (solely as to Section 14.)</p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:48.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Richard Cunningham</p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 28pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 3pt 0pt;">SIGNATURE PAGE TO ASSIGNMENT AND ASSUMPTION AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the parties hereto have caused this Agreement to be duly executed as of the date first set forth above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">SELLER:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ICAGEN, INC.:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:48.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 28pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ICAGEN CORP:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:48.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 28pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">XR PRO SCIENCES, INC.:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:48.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 28pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CALDERA DISCOVERY, INC.:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:48.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 28pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LIGAND PHARMACEUTICALS</b> (solely as to Section 14.)</p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:48.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: [***]</p></td></tr><tr><td style="vertical-align:bottom;width:48.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 28pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: SVP, GC, and Secretary</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">SIGNATURE PAGE TO ASSIGNMENT AND ASSUMPTION AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BUYER:</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ADJACENT ACQUISITION CO., LLC:</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 28pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: [***]</p></td></tr><tr><td style="vertical-align:bottom;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 28pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Manager</p></td></tr><tr><td style="vertical-align:bottom;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CFF:</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CYSTIC FIBROSIS FOUNDATION</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 28pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: [***]</p></td></tr><tr><td style="vertical-align:bottom;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 28pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: President and CEO</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">SIGNATURE PAGE TO ASSIGNMENT AND ASSUMPTION AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Amendment No.&#160;3 to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research, Development and Commercialization Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">This Amendment No.&#160;3 to Research, Development and Commercialization Agreement (this &#8220;<b style="font-weight:bold;">Amendment No.&#160;3</b>&#8221;), dated September&#160;10, 2021, is made by and between Icagen, LLC, a Delaware limited liability company (&#8220;<b style="font-weight:bold;">Icagen, LLC</b>&#8221;) and Cystic Fibrosis Foundation, a Delaware not-for-profit corporation (&#8220;<b style="font-weight:bold;">CFF</b>&#8221;), with respect to that certain Research, Development and Commercialization Agreement which was (a)&#160;entered into by and between Icagen, Inc., a Delaware corporation, and CFF on May&#160;1, 2018, (b) amended by Icagen, Inc. and CFF by an Amendment dated June&#160;12, 2018, and (c)&#160;further amended, and assigned (with CFF&#8217;s consent) by Icagen, Inc. to Icagen, LLC (then known as Adjacent Acquisition Co., LLC), and assumed (with CFF&#8217;s consent) by Icagen, LLC (then known as Adjacent Acquisition Co., LLC), all pursuant to an Agreement dated April&#160;1, 2020 among Icagen, LLC, CFF, Ligand Pharmaceuticals Incorporated and other parties (such Research, Development and Commercialization Agreement, as so amended, assigned and assumed to date, the &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;). Capitalized terms used herein without definition shall have the meanings assigned in the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS, </b>the parties desire to amend certain provisions of the Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b><i style="font-style:italic;">, </i>in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:30.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Funding, Additional Time</u>. CFF agrees to increase the Award Amount and the Budget so as to provide up to an additional $[***] in funding to Icagen, LLC, pursuant to the budget described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u> to this Amendment No.&#160;3, for the periods of 2021-Q4 (inclusive of any applicable portion of 2021-Q3 after exhaustion of prior &#8220;2021-Q3&#8221; funding) and 2022-Q1. Such additional funding amount shall be paid by CFF to Icagen, LLC pursuant to Section&#160;3.1 of the Agreement and consistent with past practice. Sections 1.3, 1.6 and 3.1(c)(i) of the Agreement are hereby revised accordingly.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:30.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement Continuing Effect</u>. All other terms of the Agreement shall remain in full force and effect. The Agreement, as amended by this Amendment No.&#160;3, constitutes the entire agreement between the parties with respect to the subject matter thereof.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:30.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Amendment No. 3&#160;may be executed in any number of counterparts, each of which shall be an original instrument and all of which, when taken together, shall constitute one and the same agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[<i style="font-style:italic;">Remainder of this page intentionally left blank</i>.]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the parties have caused this Amendment No.&#160;3 to Research, Development and Commercialization Agreement to be duly executed and delivered as of the day and year first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cystic Fibrosis Foundation</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EVP, CSO</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Icagen, LLC</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As agreed:</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Ligand Pharmaceuticals Incorporated</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:42.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>6
<FILENAME>ahpa-20220416xex10d27.htm
<DESCRIPTION>EXHIBIT-10.27
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/27/2022 11:11:10 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.27</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Amended and Restated License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">This Amended and Restated License Agreement (&#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) is made on May&#160;29, 2020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">by and between</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">F. Hoffmann-La Roche Ltd</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">with an office and place of business at [***] (&#8220;<b style="font-weight:bold;">Roche </b>[***]&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Hoffmann-La Roche lnc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">with an office and place of business at [***] (&#8220;<b style="font-weight:bold;">Roche US</b>&#8221;; Roche [***] and Roche US together referred to as &#8220;<b style="font-weight:bold;">Roche</b>&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">on the one hand</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">lcagen, LLC</b> (formerly known as Adjacent Acquisition Co., LLC; as assignee from lcagen, lnc., the party to the original License Agreement)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">with an office and place of business at [***] (&#8220;<b style="font-weight:bold;">lcagen</b>&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">on the other hand,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">with respect to an original License Agreement which was entered into with effect as of the Effective Date (the &#8220;<b style="font-weight:bold;">Original Agreement</b>&#8221;, as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Table of Contents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">1.</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:91.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Definitions</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.1</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Affiliate</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.2</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agreement</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.3</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agreement Term</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.4</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Applicable Law</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.5</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Calendar Quarter</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.6</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Calendar Year</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.7</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CCS</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.8</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CCS Criteria</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.9</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change of Control</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.10</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change of Control Group</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.11</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CLS</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.12</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CLS Criteria</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.13</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical Study</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.14</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Combination Product</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.15</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercially Reasonable Efforts</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.16</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Companion Diagnostic</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.17</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Composition of Matter Claim</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.18</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compound</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.19</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compound lP</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.20</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compulsory Sublicense Compensation</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.21</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Confidential lnformation</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.22</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Continuation Election Notice</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.23</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Control</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.24</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.25</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative Compound</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.26</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective Date</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.27</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EU</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.28</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Excluded Claim</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.29</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expert</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.30</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FDA</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.31</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FDCA</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.32</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Field</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.33</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Filing</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.34</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">First Commercial Sale</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.35</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FTE</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.36</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FTE Rate</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.37</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Generic Product</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.38</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Handle</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.39</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lcagen lP</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.40</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lcagen Know-How</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.41</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lcagen Patent Rights</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.42</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lcagen Technology</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.43</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lCD-10</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.44</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lFRS</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.45</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lND</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.46</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lndication</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.47</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lnitiation</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.48</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lnitiation of GLP Tox Study</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.49</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lnsolvency Event</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.50</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lnvention</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.51</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joint Know-How</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.52</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joint Patent Rights</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.53</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">JOT</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.54</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">JRC</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.55</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Know-How</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.56</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LSl</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.57</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LSl Criteria</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.58</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Major Countries</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.59</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NDA</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.60</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net Sales</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.61</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Party</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.62</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patent Rights</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.63</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Phase l Study</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.64</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Phase ll Study</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.65</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Phase lll Study</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.66</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.67</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Qualified Hit Class</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.68</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Qualified Hit Criteria</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.69</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Regulatory Filing</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.70</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Regulatory Approval</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.71</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Regulatory Authority</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.72</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Regulatory Exclusivity</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.73</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research Plan</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.74</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research Program</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.75</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research Term</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.76</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roche Group</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.77</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roche lP</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.78</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roche Know-How</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.79</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roche Patent Rights</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.80</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roche Technology</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.81</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalty Term</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.82</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.83</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sublicensee</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.84</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Target</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.85</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Territory</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.86</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third Party</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.87</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.88</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US$</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.89</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valid Claim</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.90</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additional Definitions</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">2.</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:91.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Grant of License</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.1</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Licenses</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.2</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sublicense</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">13</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">3.</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:91.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research Collaboration</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">13</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Conduct of the Research Program</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">13</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Records; Reports</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">14</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">4.</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:91.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diligence</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">5.</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:91.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Development, Manufacturing, Regulatory Affairs and Commercialization</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">6.</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:91.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Governance</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.1</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joint Research Committee</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.2</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Members</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.3</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Responsibilities of the JRC</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.4</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Meetings</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">16</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.5</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Minutes</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">16</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.6</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Decisions</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">16</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.7</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lnformation Exchange</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">17</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.8</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joint Operational Teams</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">17</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.9</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Alliance Director</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">17</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.10</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Limitations of Authority</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">17</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.11</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expenses</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">17</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.12</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lifetime</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">17</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.13</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Updates to lcagen</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">17</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">7.</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:91.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payment</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">17</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.1</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lnitiation Payment</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">17</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.2</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New Program lnitiation Payments</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">17</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.3</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Target 2 Achievement of Qualified Hit Criteria Payment</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">17</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.4</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research Funding</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.5</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Development Event Payments</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.6</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales Based Events</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">19</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.7</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalty Payments</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">19</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.8</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Disclosure of Payments</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">8.</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:91.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounting and reporting</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.1</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Timing of Payments</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.2</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Late Payment</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.3</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Method of Payment</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.4</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Currency Conversion</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.5</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Blocked Currency</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.6</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reporting</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">22</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">9.</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:91.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxes</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">22</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">10.</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:91.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Auditing</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">22</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lcagen Right to Audit</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">22</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Audit Reports</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">23</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Over-or Underpayment</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">23</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">11.</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:91.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intellectual Property</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">23</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.1</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ownership of lnventions</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">23</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.2</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">German Statute on Employee&#8217;s lnventions</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">24</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.3</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prosecution of Patent Rights Claiming lcagen lnventions</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.4</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prosecution of Patent Rights Claiming Roche lnventions and Joint lnventions</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.5</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patent Coordination Team</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.6</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unified Patent Court (Europe)</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">26</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.7</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CREATE Act</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">26</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.8</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lnfringement</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">26</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.9</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Defense</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.10</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common lnterest Disclosures</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.11</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hatch-Waxman</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.12</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patent Term Extensions</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">12.</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:91.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lcagen Representations and Warranties</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.1</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Safety Data</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.2</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third Party Patent Rights</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.3</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lnventors</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.4</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Grants</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.5</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Authorization</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.6</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Validity of Patent Rights</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.7</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ownership and Validity of Know-How</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.8</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">No Claims</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.9</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">No Conflict</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.10</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">No Other Representations</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">13.</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:91.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indemnification</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">13.1</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lndemnification by Roche</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">13.2</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lndemnification by lcagen</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">13.3</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Procedure</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">14.</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:91.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liability</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">14.1</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Limitation of Liability</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">15.</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:91.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Obligation Not to Disclose Confidential lnformation</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">15.1</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-Use and Non-Disclosure</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">15.2</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permitted Disclosure</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">15.3</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Press Releases</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">15.4</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Publications</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">15.5</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial Considerations</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">16.</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:91.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Term and Termination</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">32</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">16.1</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commencement and Term</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">32</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">16.2</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Termination</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">32</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">16.3</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consequences of Termination</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">16.4</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Survival</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">37</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">17.</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:91.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bankruptcy</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">37</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">18.</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:91.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Miscellaneous</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">37</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">18.1</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Governing Law</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">37</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">18.2</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Disputes</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">37</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">18.3</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Arbitration</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">38</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">18.4</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assignment</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">39</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">18.5</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debarment</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">39</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">18.6</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lndependent Contractor</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">39</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">18.7</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unenforceable Provisions and Severability</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">18.8</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Waiver</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">18.9</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Appendices</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">18.10</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Entire Understanding</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">18.11</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amendments</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">18.12</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lnvoices</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40</p></td></tr><tr><td style="vertical-align:top;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:6.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">18.13</p></td><td style="vertical-align:bottom;white-space:normal;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Notice</p></td><td style="vertical-align:bottom;white-space:normal;width:5.4%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Amended and Restated License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, lcagen is a biotechnology company with an integrated platform for ion channel drug discovery, and expertise in ion-channel biology and possesses proprietary technology and intellectual property rights relating thereto; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Roche is a pharmaceutical company with drug development knowledge and expertise in the field of neuroscience, and specifically neurodevelopmental disorders, and has expertise in the research, development, manufacture and commercialization of pharmaceutical products; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Roche and lcagen (as assignee of lcagen, lnc.) are parties to a License Agreement effective December&#160;4, 2018 (the &#8220;<b style="font-weight:bold;">Original Agreement</b>&#8221;) and intend that this Agreement amend and restate in its entirety the Original Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Roche and lcagen have been applying lcagen&#8217;s ion channel integrated drug discovery platform to identify, research and develop (i) [***] and (ii) [***] of both Roche and lcagen, for subsequent clinical development and commercialization, and now wish to enter one or more subsequent project collaborations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Definitions</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Affiliate</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Affiliate&#8221; shall mean any individual, corporation, association or other business entity that directly or indirectly controls, is controlled by, or is under common control with the Party in question. As used in this definition of &#8220;Affiliate,&#8221; the term &#8220;control&#8221; shall mean the direct or indirect ownership of more than fifty percent (&gt;50%) of the stock having the right to vote for directors thereof or the ability to otherwise control the management of the corporation or other business entity whether through the ownership of voting securities, by contract, resolution, regulation or otherwise. Anything to the contrary in this paragraph notwithstanding, neither [***] and/or its subsidiaries (if any) nor [***] and/or its subsidiaries (if any) shall be deemed as Affiliates of Roche unless Roche provides written notice to lcagen of its desire to include [***], [***] and/or their respective subsidiaries (as applicable) as Affiliate(s) of Roche.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Agreement</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Agreement&#8221; shall mean this document including any and all appendices and amendments to it as may be added and/or amended from time to time in accordance with the provisions of this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Agreement Term</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Agreement Term&#8221; shall mean the period of time commencing on the Effective Date and, unless this Agreement is terminated sooner as provided in Article 16, expiring on the date when no royalty or other payment obligations under this Agreement are or will become due.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Applicable Law</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;">The term &#8220;Applicable Law&#8221; shall mean any law, statute, ordinance, code, rule or regulation that has been enacted by a government authority (including without limitation, any Regulatory Authority) and is in force as of the Effective Date or comes into force during the Agreement Term, in each case to the extent that the same is applicable to the performance by the Parties of their respective obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.5</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Calendar Quarter</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Calendar Quarter&#8221; shall mean each period of three (3)&#160;consecutive calendar months, ending March&#160;31, June&#160;30, September&#160;30, and December 31.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.6</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Calendar Year</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Calendar Year&#8221; shall mean the period of time beginning on January&#160;1 and ending December&#160;31, except for the first year which shall begin on the Effective Date and end on December 31.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.7</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">CCS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;CCS&#8221; shall mean a clinical candidate selected Compound identified by the JRC as having met the CCS Criteria; this is also known as [***] within Roche.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.8</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">CCS Criteria</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;CCS Criteria&#8221; shall mean the criteria set forth in Appendix 1.8.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.9</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Change of Control</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Change of Control&#8221; shall mean, with respect to a Party: (a)&#160;the acquisition by any Third Party of beneficial ownership of fifty percent (50%) or more of the then outstanding common shares or voting power of such Party, other than acquisitions by employee benefit plans sponsored or maintained by such Party; (b)&#160;the consummation of a business combination involving such Party, unless, following such business combination, the stockholders of such Party immediately prior to such business combination beneficially own directly or indirectly more than fifty percent (50%) of the then outstanding common shares or voting power of the entity resulting from such business combination; or (c)&#160;the sale of all or substantially all of such Party&#8217;s assets or business relating to the subject matter of the Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.10</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Change of Control Group</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Change of Control Group&#8221; shall mean with respect to a Party, the person or entity, or group of persons or entities, that is the acquirer of, or a successor to, a Party in connection with a Change of Control, together with affiliates of such persons or entities that are not Affiliates of such Party immediately prior to the completion of such Change of Control of such Party.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.11</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">CLS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;CLS&#8221; shall mean a clinical lead selected Compound formally identified by the JRC as having met the CLS Criteria.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.12</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">CLS Criteria</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;CLS Criteria&#8221; shall mean the criteria set forth in Appendix 1.12.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.13</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Clinical Study</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Clinical Study&#8221; shall mean a Phase l Study, Phase ll Study, or Phase lll Study, as applicable.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.14</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Combination Product</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Combination Product&#8221; shall mean</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:30.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">a single pharmaceutical formulation containing as its active ingredients both a Compound and one or more other therapeutically or prophylactically active ingredients,</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:30.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">a combination therapy comprised of a Compound and one or more other therapeutically or prophylactically active products, priced and sold in a single package containing such multiple products or packaged separately but sold together for a single price, or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:30.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">a combination therapy comprised of a Compound and a Companion Diagnostic, priced and sold in a single package containing such multiple products or packaged separately but sold together for a single price,</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">in each case, including all dosage forms, formulations, presentations, line extensions, and package configurations. All references to Product in this Agreement shall be deemed to include Combination Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For clarity, with respect to Net Sales of a Combination Product, the Net Sales of a Combination Product shall only include the Relative Commercial Value as set forth in Section&#160;7.7.3.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.15</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Commercially Reasonable Efforts</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Commercially Reasonable Efforts&#8221; shall mean such level of efforts consistent [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">However, Roche (and its Affiliates) does not always seek to market its own products in every country or seek to obtain regulatory approval in every country or for every potential indication. As a result, the exercise of diligence by Roche is to be determined [***].</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.16</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Companion Diagnostic</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Companion Diagnostic&#8221; shall mean any product that is used for predicting and/or monitoring the response of a human being to treatment with a Product (e.g. device, compound, kit, biomarker or service that contains a component that is used to detect or quantify the presence or amount of an analyte in body or tissue that affects the pathogens of the disease).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.17</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Composition of Matter Claim</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Composition of Matter Claim&#8221; shall mean, for a given Product in a given country of the Territory, a Valid Claim of an lcagen Patent Right or Joint Patent Right which claims the composition of matter of the Compound alone per se included in such Product.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.18</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Compound</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Compound&#8221; shall mean any compound that modulates the Target and is identified by or on behalf of the Parties under a Research Plan and during the applicable Research Term using lcagen Technology.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.19</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Compound lP</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Compound lP&#8221; shall mean any and all intellectual property and know-how covering the making, using, selling, offering for sale or importing of a Compound.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.20</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Compulsory Sublicense Compensation</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Compulsory Sublicense Compensation&#8221; shall mean, for a given country or region in the Territory, the compensation paid to Roche by a Third Party (a &#8220;<b style="font-weight:bold;">Compulsory Sublicensee</b>&#8221;) under a license or sublicense of lcagen Patent Rights and Joint Patent Rights granted to the Compulsory Sublicensee (the &#8220;<b style="font-weight:bold;">Compulsory Sublicense</b>&#8221;) through the order, decree or grant of a governmental authority having competent jurisdiction in such country or region, authorizing such Third Party to manufacture, use, sell, offer for sale, import or export a Product in such country or region.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.21</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Confidential lnformation</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Confidential lnformation&#8221; shall mean any and all information, data or know-how (including Know-How), whether technical or non-technical, oral or written, that is disclosed by one Party or its Affiliates (&#8220;<b style="font-weight:bold;">Disclosing Party</b>&#8221;) to the other Party or its Affiliates (&#8220;<b style="font-weight:bold;">Receiving Party</b>&#8221;). Confidential lnformation shall not include any information, data or know-how that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:42.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">was generally available to the public at the time of disclosure, or becomes available to the public after disclosure by the Disclosing Party other than through fault (whether by action or inaction) of the Receiving Party or its Affiliates,</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:42.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">can be evidenced by written records to have been already known to the Receiving Party or its Affiliates prior to its receipt from the Disclosing Party,</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:42.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">is obtained at any time lawfully from a Third Party under circumstances permitting its use or disclosure,</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:42.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(iv)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">is developed independently by the Receiving Party or its Affiliates as evidenced by written records other than through knowledge of Confidential lnformation, or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:42.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(v)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">is approved in writing by the Disclosing Party for release by the Receiving Party.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The terms of this Agreement shall be considered Confidential lnformation of both Parties.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.22</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Continuation Election Notice</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Continuation Election Notice&#8221; shall mean the notice lcagen provides to Roche under Section&#160;16.3.1 or 16.3.3 describing (i)&#160;lcagen&#8217;s bona fide intentions to continue ongoing development and commercialization of Product(s) and (ii)&#160;lcagen&#8217;s request for Roche&#8217;s continuation of activities during the termination period and/or transfer of the data, material and information relating to the Product(s) in accordance with Section&#160;16.3.1 or 16.3.3.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.23</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Control</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Control&#8221; shall mean (as an adjective or as a verb including conjugations and variations such as &#8220;Controls&#8221; &#8220;Controlled&#8221; or &#8220;Controlling&#8221;) (a) with respect to Patent Rights and/or Know-How, the possession by a Party of the ability to grant a license or sublicense of such Patent Rights and/or Know-How without violating the terms of any agreement or arrangement between such Party and any other party and (b)&#160;with respect to proprietary materials, the possession by a Party of the ability to supply such proprietary materials to the other Party as provided herein without violating the terms of any agreement or arrangement between such Party and any other party.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.24</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Cover</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Cover&#8221; shall mean (as an adjective or as a verb including conjugations and variations such as &#8220;Covered,&#8221; &#8220;Coverage&#8221; or &#8220;Covering&#8221;) that the developing, making, using, offering for sale, promoting, selling, exporting or importing of a given compound, formulation or product would infringe a Valid Claim in the absence of a license under or ownership in the Patent Rights to which such Valid Claim pertains. The determination of whether a compound, formulation, process or product is Covered by a particular Valid Claim shall be made on a country-by-country basis.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.25</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Derivative Compound</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Derivative Compound&#8221; shall mean a compound which is derived from a Compound during a Research Term or the [***] period following the end of such Research Term by or on behalf of Roche, or by lcagen in performance of medicinal chemistry optimization directed [***]. A compound will be deemed to have been &#8220;derived&#8221; from a Compound if it (i)&#160;is the result of a chemical modification made to a Compound, (ii) [***], or (iii) [***]. However, a compound is not a Derivative Compound (a) [***], or (b) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.26</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Effective Date</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Effective Date&#8221; shall mean December&#160;4, 2018.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.27</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">EU</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;EU&#8221; shall mean the European Union and all its then-current member countries but including in any case [***] regardless of whether they are then-current member countries.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.28</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Excluded Claim</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Excluded Claim&#8221; shall mean a dispute, controversy or claim between the Parties that concerns (a)&#160;the validity or infringement, scope, enforceability or inventorship of a patent, trademark or copyright, or (b)&#160;any antitrust, anti-monopoly or competition Applicable Law, whether or not statutory.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.29</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Expert</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Expert&#8221; shall mean a person with no less than [***] years of pharmaceutical industry experience and commercial expertise having occupied at least [***] senior position within a large pharmaceutical company relating to product development and/or licensing but excluding any current or former employee or consultant of either Party. Such person shall be fluent in the English language.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.30</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">FDA</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;FDA&#8221; shall mean the Food and Drug Administration of the United States of America.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.31</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">FDCA</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;FDCA&#8221; shall mean the Food, Drug and Cosmetics Act of 1938 and applicable regulations promulgated thereunder, as amended from time to time.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.32</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Field</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Field&#8221; shall mean all therapeutic, prophylactic and diagnostic uses of small molecule modulators of the Target.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.33</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Filing</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Filing&#8221; shall mean the filing of an application by the FDA as defined in the FDCA and applicable regulations, or the equivalent application to the equivalent agency in any other country or group of countries, the official approval of which is required before any lawful commercial sale or marketing of Products.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.34</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">First Commercial Sale</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;First Commercial Sale&#8221; shall mean, on a country-by-country basis, the first invoiced sale of a Product to a Third Party by the Roche Group following the receipt of any Regulatory Approval required for the sale of such Product, or if no such Regulatory Approval is required, the date of the first invoiced sale of a Product to a Third Party by the Roche Group in such country.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.35</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">FTE</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;FTE&#8221; shall mean a full-time equivalent person-year, based upon a total of no less than [***] working hours per year, undertaken in connection with the conduct of research in a Research Program.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.36</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">FTE Rate</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;FTE Rate&#8221; shall mean the amount of [***] United States Dollars (US$[***]) per FTE, on a fully burdened cost basis. Notwithstanding the foregoing, during the second extension period pursuant to Section&#160;3.1.5, the FTE Rate shall mean the amount of [***] United States Dollars (US$[***]).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.37</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Generic Product</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Generic Product&#8221; shall mean a product that is not produced, licensed or owned by the Roche Group that (i)&#160;contains a pharmaceutically active ingredient that is the same as the Compound in the Product and (ii)&#160;has the same or substantially the same labelling as the applicable Product for at least one lndication of such Product.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.38</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Handle</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Handle&#8221; shall mean preparing, filing, prosecuting (including interferences, reissue, re-examination, post-grant reviews, inter-parties reviews, derivation proceedings and opposition proceedings) and maintaining.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.39</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lcagen lP</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;lcagen lP&#8221; shall mean lcagen Know-How and lcagen Patent Rights.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.40</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lcagen Know-How</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;lcagen Know-How&#8221; shall mean the Know-How that lcagen Controls at the Effective Date and during the Agreement Term, relating to or arising from the discovery, manufacture, development or commercialization of or Covering a Product, or that relate to lcagen Technology.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.41</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lcagen Patent Rights</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;lcagen Patent Rights&#8221; shall mean the Patent Rights that lcagen Controls at the Effective Date and during the Agreement Term, relating to or arising from the discovery, manufacture, development or commercialization of or Covering a Product, or that relate to lcagen Technology.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.42</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lcagen Technology</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;lcagen Technology&#8221; shall mean lcagen&#8217;s proprietary integrated platform for ion-channel drug discovery.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.43</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lCD-10</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;lCD-10&#8221; shall mean the Tenth Revision of the lnternational Classifications of Diseases and Related Health Problems, as may be revised or amended from time to time, or a successor classification.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.44</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lFRS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;lFRS&#8221; shall mean lnternational Financial Reporting Standards.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.45</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lND</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;lND&#8221; shall mean an application as defined in the FDCA and applicable regulations promulgated by the FDA, or the equivalent application to the equivalent agency in any other country or group of countries, the filing of which is necessary to commence clinical testing of a Product in humans.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.46</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lndication</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The term &#8220;lndication&#8221; shall mean a disease (i)&#160;for which the Product is indicated for treatment and (ii)&#160;that is either (a)&#160;described in the Product label as required by the Regulatory Approval granted by the applicable Regulatory Authority, or (b)&#160;anticipated to be described in the Product label in the case of a Product that has yet to receive Regulatory Approval. [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.47</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lnitiation</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;lnitiation&#8221; shall mean the date that a human is first dosed with the Product in a Clinical Study approved by the respective Regulatory Authority.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.48</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lnitiation of GLP Tox Study</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;lnitiation of GLP Tox Study&#8221; shall mean the date that an animal is first dosed with the Product in a study of the relationship between dose and its effects on the exposed animal, where (i)&#160;the study is to be conducted in accordance with Good Laboratory Practice standards and (ii)&#160;the study has been designed in expectation that the results may support establishment of a safe starting dose of the Product in human Clinical Studies.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.49</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lnsolvency Event</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;lnsolvency Event&#8221; shall mean circumstances under which a Party (i)&#160;has a receiver or similar officer appointed over all or a material part of its assets or undertaking; (ii)&#160;passes a resolution for winding-up (other than a winding-up for the purpose of, or in connection with, any solvent amalgamation or reconstruction) or a court makes an order to that effect or a court makes an order for administration (or any equivalent order in any jurisdiction); (iii) enters into any composition or arrangement with its creditors (other than relating to a solvent restructuring); (iv) ceases to carry on business; (v)&#160;is unable to pay its debts as they become due in the ordinary course of business.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.50</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lnvention</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;lnvention&#8221; shall mean an invention that is conceived or reduced to practice in connection with any activity carried out pursuant to this Agreement. Under this definition, an lnvention may be made by employees of lcagen solely or jointly with a Third Party (an &#8220;<b style="font-weight:bold;">lcagen lnvention</b>&#8221;), by employees of the Roche Group solely or jointly with a Third Party (a &#8220;<b style="font-weight:bold;">Roche lnvention</b>&#8221;), or jointly by employees of lcagen and employees of the Roche Group with or without a Third Party (a &#8220;<b style="font-weight:bold;">Joint lnvention</b>&#8221;).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.51</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Joint Know-How</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Joint Know-How&#8221; shall mean Know-How that is made jointly by employees of lcagen and the Roche Group, with or without a Third Party in connection with any activity carried out pursuant to this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.52</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Joint Patent Rights</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Joint Patent Rights&#8221; shall mean all Patent Rights Covering a Joint lnvention.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.53</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">JOT</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;JOT&#8221; shall mean a joint operating team described in Section&#160;6.8.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.54</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">JRC</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;JRC&#8221; shall mean the joint research committee described in Section&#160;6.1.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.55</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Know-How</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The term &#8220;Know-How&#8221; shall mean data, knowledge and information, including materials, samples, chemical manufacturing data, toxicological data, pharmacological data, preclinical and clinical data, assays, platforms, formulations, specifications, quality control testing data, that are confidential and necessary or useful for the discovery, manufacture, development or commercialization of Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.56</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">LSl</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;LSl&#8221; shall mean a lead series identified Compound formally identified by the JRC as having met the LSl Criteria; this is also known as [***] within Roche.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.57</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">LSl Criteria</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;LSl Criteria&#8221; shall mean the criteria set forth in Appendix 1.57.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.58</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Major Countries</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Major Countries&#8221; shall mean the [***].</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.59</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">NDA</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;NDA&#8221; shall mean a new drug application, including all necessary documents, data, and other information concerning a Product, required for Regulatory Approval of the Product as a pharmaceutical product by the FDA or an equivalent application to the equivalent agency in any other country or group of countries (e.g. the marketing authorization application (MAA) in the EU).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.60</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Net Sales</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Net Sales&#8221; shall mean, for a Product in a particular period, the amount calculated by subtracting from the Sales of such Product for such period: [***]. For clarity, no deductions taken in calculating Sales under Section&#160;1.82 may be taken a second time in calculating Net Sales.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.61</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Party</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Party&#8221; shall mean lcagen or Roche, as the case may be, and &#8220;Parties&#8221; shall mean lcagen and Roche collectively.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.62</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Patent Rights</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Patent Rights&#8221; shall mean all rights under any patent or patent application, in any country of the Territory, including any patents issuing on such patent application, and further including any substitution, extension or supplementary protection certificate, reissue, re-examination, renewal, divisional, continuation or continuation-in-part of any of the foregoing.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.63</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Phase l Study</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Phase l Study&#8221; shall mean a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. &#167; 312.21(a) (FDCA), as amended from time to time, and the foreign equivalent thereof.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.64</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Phase ll Study</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Phase ll Study&#8221; shall mean a human clinical trial, for which the primary endpoints include a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. &#167; 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof. For the avoidance of doubt, for purposes of this Agreement, a Phase ll Study is designed to demonstrate efficacy of the Product at one or more selected dose(s) but may not provide the optimal clinical dose(s) of the Product for a Phase lll Study.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.65</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Phase lll Study</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The term &#8220;Phase lll Study&#8221; shall mean a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. &#167; 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.66</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Product</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Product&#8221; shall mean any product, including without limitation any Combination Product, containing a Compound or a Derivative Compound as a pharmaceutically active agent regardless of its finished form or formulation or dosage. One Product may be distinguished from another Product by the Compound or a Derivative Compound being a distinctive active pharmaceutical ingredient.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.67</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Qualified Hit Class</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term Qualified Hit Class&#160;shall mean a qualified hit class formally identified by the JRC as having met the Qualified Hit Class&#160;Criteria.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.68</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Qualified Hit Criteria</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Qualified Hit Criteria&#8221; shall mean the criteria set forth in Appendix 1.68.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.69</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Regulatory Filing</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Regulatory Filing&#8221; shall mean the filing by a Regulatory Authority of an NDA for the Product.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.70</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Regulatory Approval</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Regulatory Approval&#8221; shall mean any approvals including pricing and reimbursement approvals), licenses, registrations or authorizations by Regulatory Authority, necessary for the manufacture and sale of a Product in the Field in a regulatory jurisdiction in the Territory.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.71</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Regulatory Authority</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Regulatory Authority&#8221; shall mean any national, supranational (e.g., the European Commission, the Council of the European Union, the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity including the FDA, in each country involved in the granting of Regulatory Approval for the Product.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.72</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Regulatory Exclusivity</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Regulatory Exclusivity&#8221; shall mean any exclusive marketing rights or data exclusivity rights conferred by any governmental authority under Applicable Law with respect to a Product in a country or jurisdiction in the Territory to prevent Third Parties from selling such Product in such country or jurisdiction, other than a Patent Right, including orphan drug exclusivity, pediatric exclusivity, rights conferred in the U.S. under the FD&amp;C Act, in the EU under Directive 2001/83/EC, or rights similar thereto in other countries or regulatory jurisdictions in the Territory.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.73</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Research Plan</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Research Plan&#8221; shall mean the plan of research agreed by the Parties for the conduct of activities designed to identify, research and develop compounds that modulate a Target [***] and outlining the work expected to be performed and budget. The initial Research Plans for Target&#160;1 and Target&#160;2 are attached as Appendix 1.73.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.74</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Research Program</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Research Program&#8221; shall mean the activities undertaken by the Parties pursuant to a Research Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.75</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Research Term</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The term &#8220;Research Term&#8221; shall mean the period of time in which a Research Program shall be conducted, commencing for Target 1 on the Effective Date and continuing until [***] after the Effective Date and for Target 2 commencing on the date the Research Program for Target 2 begins and continuing for [***] thereafter, unless extended pursuant to Section&#160;3.1.5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.76</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Roche Group</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Roche Group&#8221; shall mean collectively Roche, its Affiliates and its Sublicensees.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.77</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Roche lP</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term Roche lP shall mean Roche Know-How and Roche Patent Rights.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.78</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Roche Know-How</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Roche Know-How&#8221; shall mean all Know-How that Roche Controls during the Agreement Term relating to the Compounds, Products and Roche Technology.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.79</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Roche Patent Rights</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Roche Patent Rights&#8221; shall mean all Patent Rights Covering a Product that Roche Controls during the Agreement Term.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.80</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Roche Technology</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Roche Technology&#8221; shall mean all Roche proprietary information, including assays, compounds, and models, used for activities under a Research Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.81</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Royalty Term</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Royalty Term&#8221; shall mean, with respect to a Product and for a given country, the period of time commencing on the date of First Commercial Sale of such Product in such country and ending on the later of the date that is (a)&#160;ten (10) years after the date of the First Commercial Sale of such Product in such country, or (b)&#160;the expiration of the last to expire lcagen Patent Right or Joint Patent Right containing a Composition of Matter Claim claiming such Product. [***].</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.82</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Sales</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Sales&#8221; shall mean, for a Product in a particular period, the sum of (i)&#160;and (ii):</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:6.1pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the amount stated in the Roche Holding AG &#8220;Sales&#8221; line of its externally published audited consolidated financial statements with respect to such Product for such period (excluding sales to any Sublicensees that are not Affiliates of Roche). This amount reflects the gross invoice price at which such Product was sold or otherwise disposed of (other than for use as clinical supplies or free samples) by Roche and its Affiliates to such Third Parties (excluding sales to any Sublicensees that are not Affiliates of Roche) in such period reduced by gross-to-net deductions, if not previously deducted from such invoiced amount, taken in accordance with the then currently used lFRS.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 48.95pt;">By way of example, the gross-to-net deductions taken in accordance with lFRS as of the Effective Date include items such as the following:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:42.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">credits, reserves or allowances granted for (i)&#160;damaged, outdated, returned, rejected, withdrawn or recalled Product, (ii)&#160;wastage replacement and short-shipments; (iii)&#160;billing errors and (iv)&#160;indigent patient and similar programs (e.g., price capitation);</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:42.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">governmental price reductions and government mandated rebates;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:42.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:43.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">chargebacks, including those granted to wholesalers, buying groups and retailers;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:42.85pt;text-indent:-42.85pt;margin:0pt 0pt 0pt 42.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:42.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">customer rebates, including cash sales incentives for prompt payment, cash and volume discounts; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:42.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">taxes and any other governmental charges or levies imposed upon or measured by the import, export, use, manufacture or sale of a Product (excluding income or franchise taxes).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 48.95pt;">For purposes of clarity, sales by Roche and its Affiliates to any Sublicensee shall be excluded from &#8220;Sales&#8221;.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:6.1pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">for Sublicensees that are not Roche Affiliates (and excluding Compulsory Sublicensees), the sales amounts reported to Roche and its Affiliates in accordance with the sublicensee contractual terms and their then-currently used accounting standards. For the purpose of clarity, any such Sublicensee sales as reported to Roche in accordance with Compulsory Sublicense agreements shall be excluded from the sales amount.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.83</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Sublicensee</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Sublicensee&#8221; shall mean an entity to which Roche has licensed rights (through one or multiple tiers), other than through a Compulsory Sublicense, pursuant to this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.84</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Target</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Target&#8221; shall mean (i) [***] (&#8220;<b style="font-weight:bold;">Target 1</b>&#8221;), (ii) [***] (&#8220;<b style="font-weight:bold;">Target 2</b>&#8221;), or (iii)&#160;a subsequent target agreed by the Parties (&#8220;<b style="font-weight:bold;">Target 3</b>&#8221;, et seq.).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.85</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Territory</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Territory&#8221; shall mean all countries of the world.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.86</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Third Party</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Third Party&#8221; shall mean a person or entity other than (i)&#160;lcagen or any of its Affiliates or (ii)&#160;a member of the Roche Group.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.87</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">US</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;US&#8221; shall mean the United States of America and its territories and possessions.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.88</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">US$</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;US$&#8221; shall mean US dollars.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.89</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Valid Claim</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;Valid Claim&#8221; shall mean a claim in any (a)&#160;unexpired and issued Patent Right or (b)&#160;a pending patent application that has been pending for no more than [***] from the earliest date from which such patent application claims priority, which has not been disclaimed, revoked or held invalid by a final nonappealable decision of a court of competent jurisdiction or government agency.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1.90</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Additional Definitions</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Each of the following definitions is set forth in the Section of this Agreement indicated below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;" align="center"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:72.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:25.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:72.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Definition</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:25.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Section</b></p></th></tr><tr><td style="vertical-align:bottom;width:72.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounting Period</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:25.43%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8.1</p></td></tr><tr><td style="vertical-align:bottom;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired Party</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16.2.3</p></td></tr><tr><td style="vertical-align:bottom;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Alliance Director</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.9</p></td></tr><tr><td style="vertical-align:bottom;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bankruptcy Code</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:72.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Definition</b></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:25.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Section</b></p></td></tr><tr><td style="vertical-align:top;width:72.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Breaching Party</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16.2.1</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairperson</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.2</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.1</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compulsory Profit Share Percentage</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7.7.6</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compulsory Sublicensee</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.19</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Decision Period</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11.5</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Disclosing Party</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.21</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expert Committee</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7.7.3</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.1</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">H-W Suit Notice</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11.11</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lcagen</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">cover page</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lcagen lnvention</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.50</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lcagen-Originated Transfer Activities</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16.3.5.4</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lndemnified Party</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13.3</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lndemnifying Party</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13.3</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lnitiating Party</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11.5</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joint lnvention</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.50</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Members</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.2</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Minimum Transfer Payment</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16.3.5.4</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-Acquired Party</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16.2.3</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-Breaching Party</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16.2.1</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Original Agreement</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Whereas clause</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patent Term Extensions</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11.12</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payment Currency</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8.3</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Peremptory Notice Period</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16.2.1</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pll/Samples</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16.3.5.4</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Publishing Notice</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15.4</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Publishing Party</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15.4</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Receiving Party</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.21</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Register</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11.6</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Relative Commercial Value</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7.7.3</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roche</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">cover page</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roche Basel</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">cover page</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roche lnvention</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.50</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roche Transfer Activities</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16.3.5.4</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roche US</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">cover page</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sensitive lnformation</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16.2.3</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Settlement</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11.5</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SPCs</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11.12</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Suit Notice</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11.5</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Target 1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.84</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Target 2</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.84</p></td></tr><tr><td style="vertical-align:top;width:72.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Target 3</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.84</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Grant of License</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">2.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Licenses</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Research Cross License</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Each Party grants to the other Party during the relevant Research Term a non-exclusive, non-transferable (except in accordance with Section&#160;18.4), right and license under Know-How and Patent Rights Controlled by such Party solely to enable the other Party, directly or through its Affiliates or subcontractors, to perform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the activities contemplated under such Research Plan under this Agreement. Neither Party shall use the other Party&#8217;s Know-How or Patent Rights licensed under this Section&#160;2.1.1 for any other purpose, and shall not offer or grant a sublicense to use such Know-How or Patent Rights to any Third Party, without the express prior written consent of the other Party (not to be unreasonably withheld).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.1.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Commercial License</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lcagen hereby grants to Roche an exclusive (even as to lcagen), non-transferable (except in accordance with Section&#160;18.4), right and license, including the right to sublicense in accordance with Section&#160;2.2, under the lcagen lP and lcagen&#8217;s interest in the Joint Patent Rights and Joint Know-How to research, have researched, develop, have developed, register, have registered, use, have used, make, have made, import, have imported, export, have exported, market, have marketed, distribute, have distributed, sell and have sold Compounds and Products in the Field in the Territory.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">2.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Sublicense</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Subject to the terms of this Agreement, Roche shall have the right to grant sublicenses within the scope of the license provided under Section&#160;2.1.2 to its Affiliates and to Sublicensees. For the avoidance of doubt, the right for Roche to grant sublicenses is intended to include the right to further sublicense provided that Roche or its Sublicensee shall inform lcagen in writing of such further sublicense. The right of Roche to grant sublicenses under this Section&#160;2.2 is subject to the requirement that each such sublicense with any entity that is not either [***] or an Affiliate shall be in writing and shall include provisions (i)&#160;acknowledging that such sublicense is subject to the applicable license(s) granted hereunder, (ii)&#160;requiring each sublicensee to perform all applicable obligations of Roche hereunder in the applicable portion of the Territory (including the obligation under Section&#160;11.1) and obligations to make reports and keep and maintain records of sales to at least the same extent as required under this Agreement, and (iii)&#160;allowing lcagen the same access and audit rights with respect to such records as permitted with respect to Roche&#8217;s records hereunder. Roche shall at all times remain responsible for the performance of any of its Sublicensees. Roche shall provide a copy of each sublicense it enters into with any entity that is not [***] or an Affiliate (redacted as to financial terms) to lcagen promptly following execution. Subject to the terms of this Agreement, each Party shall have the right to subcontract the work performed under this Agreement without prior approval of the other Party. Each Party shall at all times remain responsible for the performance of any of its subcontractors.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Research Collaboration</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">3.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Conduct of the Research Program</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Scope</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roche and lcagen shall conduct mutually agreed Research Programs each pursuant to a Research Plan during the Research Term. The activities conducted in connection with a Research Program will be overseen by the JRC with the objective to discover Compounds and identify Compounds meeting the CCS Criteria. A Research Plan will be divided in several phases as shown below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Phase</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:29.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Icagen Responsibility</b></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:26.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Roche Responsibility</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preparation</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:29.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:26.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finding Qualified Hits</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:29.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:26.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From qualified hits to LSl</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:29.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:26.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From LSl to CLS</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:29.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:26.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From CLS to CCS</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:29.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:26.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During the Research Term for Target 1, as described in the Research Plan for Target 1, there shall be between [***] and [***] FTEs per year at lcagen (for a total of [***] FTEs up to CLS) working on the Research Program for Target 1. During the Research Term for Target 2, as described in the Research Plan for Target 2, there shall be between [***] and [***] FTEs per year at lcagen (for a total of [***] FTEs up to CLS) working on the Research Program for Target 2. Specific FTE requirements for future Targets (i.e., Target 3, etc.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">will be determined by Research Plans specific to those targets, but are anticipated to be similar to totals for Target 1 and Target 2 for programs beginning at a similar stage. Additional FTEs, if required, will be defined by JRC for CLS to CCS activities. FTEs shall be charged at the applicable FTE Rate pursuant to Section&#160;1.36. Roche will also pay any other external expenses as budgeted and set forth in each Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lf CLS for Target 1 has been achieved within [***] after the Effective Date, or if CLS for Target 2 has been achieved within [***] after the Parties agreeing to begin the Target 2 Research Program, then the relevant Research Term will terminate upon such achievement and no further FTE funding commitment from Roche will remain, unless otherwise agreed by the JRC.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.1.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Diligent Efforts</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Roche and lcagen shall each use Commercially Reasonable Efforts to perform their respective tasks and obligations in conducting all activities ascribed to it in each then-current Research Plan, in accordance with the time parameters set forth therein.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.1.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Research Plan</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Parties will conduct each Research Program in accordance with its Research Plan. Unless decided otherwise by the JRC, each Research Plan will be updated annually by the JRC and approved by the JRC. Each Research Plan will set forth (i)&#160;the scope of the relevant Research Program and the resources that will be dedicated to the activities contemplated within the scope of such Research Program, including the responsibilities of each Party and the budget for activities by lcagen, (ii)&#160;specific objectives for each year, which objectives will be updated or amended, as appropriate, by the JRC as research progresses, and (iii)&#160;in the case of CLS to CCS activities by lcagen or extensions to such Research Term under Section&#160;3.1.5, budgets for such activities at lcagen. The Parties shall prepare a plan for activities to be conducted no later than [***] before the first anniversary of the Effective Date. The JRC shall review each Research Plan on an ongoing basis and may amend the Research Plan. Any such changes shall be reflected in written amendments to such Research Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.1.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Duration</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Each Research Program shall be conducted during its Research Term.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.1.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Extension</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A Research Term may be extended by Roche in its sole discretion for an additional [***] period, up to a maximum of [***] times, by notifying lcagen at least [***] prior to the expiry of such Research Term. During the first and second extension period, as applicable, Roche would continue to fund FTE at lcagen at the applicable FTE Rate pursuant to Section&#160;1.36.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">3.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Records; Reports</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Progress Reports</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At least [***] per Calendar Year during a Research Term, lcagen shall prepare and provide to the JRC a detailed written report summarizing the progress of the work performed by lcagen in the course of the relevant Research Program during the preceding Calendar Quarter. Promptly upon expiry of the relevant Research Term, lcagen shall provide a final written report summarizing its activities under the Research Program and the results thereof. Upon the written request of Roche and not more than [***] in each Calendar Year, lcagen shall permit Roche, at Roche&#8217;s expense, to have access during normal business hours to those records of lcagen that may be necessary to verify the basis for any payments hereunder provided that any Third Party provided access shall sign a confidentiality agreement with lcagen before having such access.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7.4pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Research Records</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Each Party shall maintain records of each Research Program (or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of such Party in the performance of such Research Program. All laboratory notebooks shall be maintained for no less than [***].</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Diligence</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Roche and lcagen shall use Commercially Reasonable Efforts to perform their respective activities contemplated by this Agreement or as may be agreed upon in any subsequent written agreements with respect to the subject matter hereof. Specifically, Roche agrees to use Commercially Reasonable Efforts to pursue further development and commercialization of Products in the Field in the Territory. Roche shall be deemed to use Commercially Reasonable Efforts if it develops and commercializes at least one Product in at least one indication.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Development, Manufacturing, Regulatory Affairs and Commercialization</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Roche, at its sole cost, shall be solely responsible for all clinical development, manufacturing, regulatory affairs and commercialization of Products.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Governance</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Joint Research Committee</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Within [***] after the Effective Date of this Agreement, the Parties shall establish a JRC to oversee the research activities under this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Members</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The JRC shall be composed of [***] persons (&#8220;<b style="font-weight:bold;">Members</b>&#8221;). Roche and lcagen each shall be entitled to appoint [***] Members with appropriate seniority and functional expertise. Each Party may replace any of its Members and appoint a person to fill the vacancy arising from each such replacement. A Party that replaces a Member shall notify the other Party at least [***] prior to the next scheduled meeting of the JRC. Both Parties shall use reasonable efforts to keep an appropriate level of continuity in representation. Both Parties may invite a reasonable number of additional experts and/or advisors to attend part or the whole JRC meeting with prior notification to the JRC. Members may be represented at any meeting by another person designated by the absent Member. The JRC shall be chaired by a Roche Member (&#8220;<b style="font-weight:bold;">Chairperson</b>&#8221;).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Responsibilities of the JRC</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The JRC shall have the responsibility and authority to:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">approve each Research Plan;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">revise and approve any revisions to each Research Plan;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">review and oversee the execution of each Research Plan;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">establish timelines and criteria for decision points;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">determine whether criteria have been met;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(f)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">review the efforts of the Parties and allocate those resources for each Research Plan (including the budget);</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(g)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">identify appropriate resources necessary to conduct each Research Plan;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(h)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">establish and set expectations and mandates for JOT;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:42.85pt;text-indent:-42.85pt;margin:0pt 0pt 4.5pt 6.1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">create or disband JOT as deemed appropriate or adjust membership;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(j)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">oversee the JOTs, if applicable;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(k)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">monitor and implement the transfer of the lcagen Technology to Roche and the transfer of Roche Technology to lcagen;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(l)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">discuss data, results and reports regardless of where generated during each Research Term and ensure that all such data, results and reports are available to both Parties during such Research Term;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(m)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">monitor and implement the transfer of Compounds and Products to Roche;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(n)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">monitor the budget spend and manage reimbursement for lcagen activities under each Research Plan; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(o)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">attempt to resolve any disputes on an informal basis.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The JRC shall have no responsibility and authority other than that expressly set forth in this Section.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6.4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Meetings</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Chairperson or his/her delegate will be responsible for sending invitations and agendas for all JRC meetings to all Members at least [***] before the next scheduled meeting of the JRC. The venue for the meetings shall be agreed by the JRC. The JRC shall hold meetings at least twice per Calendar Year, either in person or by tele-/video-conference, and in any case as frequently as the Members of the JRC may agree shall be necessary, but not more than [***] times a year. The Alliance Director of each Party may attend the JRC meetings as a permanent participant.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6.5</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Minutes</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Chairperson will be responsible for designating a Member to record in reasonable detail and circulate draft minutes of JRC meetings to all members of the JRC for comment and review within [***] after the relevant meeting. The Members of the JRC shall have [***] to provide comments. The Party preparing the minutes shall incorporate timely received comments and distribute finalized minutes to all Members of the JRC within [***] of the relevant meeting. The Chairperson approves the final version of the minutes before its distribution.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6.6</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Decisions</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.6.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Decision Making Authority</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The JRC shall decide matters within its responsibilities set forth in Section&#160;6.3.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.6.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consensus; Good Faith</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Members of the JRC shall act in good faith to cooperate with one another and seek agreement with respect to issues to be decided by the JRC. The Parties shall endeavor to make decisions by consensus.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.6.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Escalation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lf the JRC is unable to decide a matter by consensus, then such matter shall be referred to the President of lcagen&#8217;s parent company Ligand Pharmaceuticals lncorporated or his/her nominee and the Head of Roche Partnering or equivalent position or his/her nominee for resolution, who together shall use reasonable and good faith efforts to reach a decision by consensus within [***] after the date such matter is referred to them. lf the Parties still fail to reach a decision within such [***], then the final decision shall be Roche&#8217;s, which shall be exercised in good faith. Any such decision shall constitute a decision of the JRC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6.7</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lnformation Exchange</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lcagen and Roche shall exchange the information in relation to its activities under this Agreement through the JRC and lcagen and Roche may ask reasonable questions in relation to the above information and offer advice in relation thereto and Roche shall give due consideration to lcagen&#8217;s input. The JRC may determine other routes of information exchange. There will also be direct communication amongst the JOT members as part of the day-to-day operation of the project.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6.8</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Joint Operational Teams</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The JRC shall have the right to establish JOTs, which may include but will not be limited to a Research JOT.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6.9</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Alliance Director</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Each Party shall appoint one person to be its point of contact with responsibility for facilitating communication and collaboration between the Parties (each, an &#8220;<b style="font-weight:bold;">Alliance Director</b>&#8221;). The Alliance Directors shall be permanent participants of the JRC meetings (but not members of the JRC) and may attend JOT meetings as appropriate. The Alliance Directors shall facilitate resolution of potential and pending issues and potential disputes to enable the JRC to reach consensus and avert escalation of such issues or potential disputes.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6.10</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Limitations of Authority</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The JRC shall have no authority to amend or waive any terms of this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6.11</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Expenses</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Each Party shall be responsible for its own expenses including travel and accommodation costs incurred in connection with the JRC.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6.12</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Lifetime</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The JRC shall exist during the Research Terms.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6.13</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Updates to lcagen</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">After a Research Term, upon request of lcagen, Roche shall update lcagen regarding the development and commercialization of the Product in the Territory in the Field by the Roche Group. lf requested by lcagen, upon [***] advance written notice, Roche shall provide a high level summary, in writing and/or through a meeting (face to face/ tele-presence/videoconference or telephone) no more than [***] per Calendar Year.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Payment</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">7.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lnitiation Payment</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Within [***] after the Effective Date and receipt of an invoice from lcagen, Roche shall pay to lcagen five million US dollars (US$5,000,000).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">7.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">New Program lnitiation Payments</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For Target 2 and each Target thereafter, upon the Parties agreeing to begin a new Research Program and within [***] after receipt of an invoice from lcagen, Roche shall pay to lcagen [***].</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">7.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">[***]</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">7.4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Research Funding</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During each Research Term, Roche shall fund FTEs at lcagen and external expenses actually incurred by lcagen under the relevant Research Plan according to Section&#160;3.1.1, including Section&#160;3.1.5 in the event that the relevant Research Term is extended. For the Target 1 and Target 2 Research Plans, FTE funding shall be in a ratio of [***] (Roche:lcagen). For the Target 3 Research Plan, if applicable, the FTE funding shall be in a ratio of [***] (Roche:lcagen). For the Target 4 and subsequent Research Plans, if applicable, the FTE funding shall be in a ratio of [***] (Roche:lcagen).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Based on the budget for activities scheduled to be performed by FTEs at lcagen during the respective Calendar Year in accordance with the relevant Research Plan, such funding of FTEs shall be paid by Roche in [***]. Furthermore, based on the expenses actually incurred by lcagen for external activities scheduled to be performed by lcagen in accordance with the relevant Research Plan, such reimbursement of actually incurred external expenses shall be paid by Roche retrospectively on a [***] basis unless otherwise agreed to in the relevant Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Such research funding of FTEs and external expenses shall be paid by Roche within [***] from receipt of an invoice from lcagen, provided that Roche receives a correct invoice in reasonable detail together with copies of the corresponding Third Party invoices for external expenses incurred by lcagen within [***] prior to the beginning of the next Calendar Quarter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For clarity, the first installment of FTEs funding shall be made within [***] after the Effective Date and receipt of an invoice from lcagen. Furthermore, external expenses reimbursed by Roche shall not exceed the budget set forth in the relevant Research Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">7.5</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Development Event Payments</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Roche shall pay up to a total of one hundred forty-three million seven hundred thousand US dollars (US$143,700,000) in relation to the achievements of events with respect to Products for each respective Target. The development event payments under this Section&#160;7.5 shall be paid by Roche according to the following schedule of development events.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Development Event</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:45.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Amount (in millions of US$)</p></td></tr><tr><td style="vertical-align:bottom;width:51.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Each development event payment shall be paid only once as to all of the Products for a particular respective Target, the first time the first Product for such particular Target reaches the applicable triggering event, regardless the number of times such events are reached and by how many Products for such particular Target. On the date any one milestone set forth in items [***] of this Section&#160;7.5 is achieved by a Product for a particular Target, all lower numbered unachieved milestones as to such particular Target shall be deemed to have been achieved and shall be paid (except to the extent they have been previously paid).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roche shall promptly notify lcagen upon the occurrence of each development event (and in any event within [***] following the occurrence of such event), and the applicable development event payment shall be paid by Roche to lcagen within [***] after occurrence of the applicable event and receipt of an invoice from lcagen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">7.6</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Sales Based Events</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roche shall pay to lcagen sales-based event payments of up to a total of one hundred thirty million US dollars (US$130,000,000) based on Calendar Year Net Sales on which royalties are paid of a Product in the Territory:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:32.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Calendar Year Net Sales Threshold</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:32.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount (in millions of US$)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Calendar Year Net Sales on which royalties are paid in the Territory of a Product exceed [***] US dollars (US$[***])</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:32.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Calendar Year Net Sales on which royalties are paid in the Territory of a Product exceed [***] US dollars (US$[***])</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:32.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Calendar Year Net Sales on which royalties are paid in the Territory of a Product exceed [***] US dollars (US$[***])</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:32.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Each of the sales based event payments shall be paid no more than once for a given Product and only if they occur during the Royalty Term for a given Product, sixty (60)&#160;days after the end of the Calendar Year in which the event first occurs for the Product in the Territory first reaching the respective Net Sales Threshold, irrespective of whether or not the previous sales based event payment was triggered by the same or by a different Product, and shall be non-refundable. lf two (2) (or three (3)) Calendar Year Net Sales threshold events under this Section&#160;7.6 occur in the same Calendar Year, then the payments for such two (2) (or three (3)) Calendar Year Net Sales threshold events shall be made within [***] after the end of the Calendar Year in which both (all) events occurred.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">7.7</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Royalty Payments</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">7.7.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Royalty Term</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Roche shall pay to lcagen royalties on Net Sales of Products on a Product-by-Product and country-by-country basis during the Royalty Term. The licenses granted to Roche shall become fully paid up, irrevocable and royalty-free on a Product-by-Product and country-by-country basis on the expiration of the Royalty Term.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">7.7.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Royalty Rates</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following royalty rates shall apply to the respective tiers of aggregate Calendar Year Net Sales of a Product in the Territory, on an incremental basis, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;" align="center"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:57.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:39.58%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:57.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">Tier of Calendar Year Net Sales in million US$</b>&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3.12%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:39.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent&#160;(%)&#160;of&#160;Net&#160;Sales</b>&#160;</p></th></tr><tr><td style="vertical-align:bottom;width:57.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:39.58%;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:39.58%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:39.58%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:39.58%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:39.58%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For example, if Net Sales of a Product in the Territory, for a given Calendar Year, are US$3,500&#160;million, then royalties owed to lcagen on such Net Sales of such Product for that Calendar Year shall equal US$ [***] (US$ [***]) calculated as follows: [[***]] = US$[***] royalty payment.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">7.7.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Relative Commercial Value of the Product</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lf Roche or its Affiliates intend to sell a Combination Product in a particular country, and the Combination Product includes a Compound that is being commercialized separately from the Combination Product in</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">such country, then the Net Sales to reflect the relative commercial value contributed by the Compound to the Combination Product in such country shall be calculated by multiplying the Net Sales of such Combination Product by the fraction A/B, where &#8220;A&#8221; is the price of the Compound included in such Combination Product when sold separately from any other products or services included in the Combination product and &#8220;B&#8221; is the price of the Combination Product. lf Roche or its Affiliates intend to sell a Combination Product and the Combination Product includes a Compound that is not being commercialized separately from the Combination Product, then the Parties shall meet approximately [***] prior to the anticipated First Commercial Sale of such Combination Product in the Territory to negotiate in good faith and agree on how to calculate the Net Sales to reflect the relative commercial value contributed by the Compound to the Combination Product (the &#8220;<b style="font-weight:bold;">Relative Commercial Value</b>&#8221;). lf, after such good faith negotiations not to exceed [***], the Parties cannot agree on the Relative Commercial Value, the dispute shall be initially referred to the executive officers of the Parties in accordance with Section&#160;18.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lf the Parties are unable to agree on the Relative Commercial Value within [***] of such referral, then the Relative Commercial Value shall be determined by the following procedure. Roche will select one (1)&#160;individual who would qualify as an Expert, lcagen will select (1) [***], and those [***] (the &#8220;<b style="font-weight:bold;">Expert Committee</b>&#8221;), each with a single deciding vote. The Expert Committee will promptly hold a meeting to review the issue under review, at which it will consider memoranda submitted by each Party at least [***] before the meeting, as well as reasonable presentations that each Party may present at the meeting. The determination of the Expert Committee as to the issue under review will be binding on both Parties. The Parties will share equally in the costs of the Expert Committee. Unless otherwise agreed to by the Parties, the Expert Committee may not decide on issues outside the scope mandated under terms of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For the purpose of calculating royalties of a Product, Calendar Year Net Sales and the royalty rates shall be subject to the following adjustments, as applicable:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">7.7.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">No Valid Claim or Generic Competition</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For a given Product, if in a given country within the Territory there is no Composition of Matter Claim that Covers such Product then the royalty payments due to lcagen based on the applicable royalty rates pursuant to Section&#160;7.7.2 for such Product in such country shall be reduced by [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For a given Product, if in a given country in the Territory there is entry of a Generic Product and if in any [***] at any time after entry of a Generic Product there has been a decline of the Sales of the applicable Product in such country greater than [***] of the level of the Sales of such Product achieved in any of the four Calendar Quarters immediately prior to such entry, then the royalty payments due to lcagen for such Product in such country shall be reduced by [***].</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">7.7.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Third Party Payments</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roche shall be responsible for and pay or have paid any consideration owed to any Third Party in relation to Third Party intellectual property rights necessary to make, use or sell Products. Roche shall have the right to deduct a maximum of [***] of such consideration actually paid to a Third Party to avoid such infringement of such Third Party intellectual property rights solely with respect to the composition of matter or methods of use for such Product by the use, having used, making, having made, importing, having imported, exporting, having exported, marketing, having marketed, distributing, having distributed, selling and having sold Products in the Field in the Territory from any payments otherwise due and payable by Roche to lcagen under Section&#160;7.5, Section&#160;7.6 or Section&#160;7.7; provided that such deductions shall not exceed [***] of the amounts otherwise payable to lcagen in any Calendar Quarter with respect to such Product; and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</u>, that any amounts not deducted in any Calendar Quarter shall be deductible against amounts due to lcagen under Section&#160;7.5, Section&#160;7.6 or Section&#160;7.7 in the future Calendar Quarters until the full amount that Roche is entitled to deduct from amounts payable to lcagen is fully deducted. lf any deduction remains at the time of termination of this Agreement, then any such remaining deduction shall be paid by lcagen to Roche within [***] after the effective date of termination. Each deduction under this Section&#160;7.7.5 shall be permitted on a Product-by-Product and country-by-country basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7.4pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">7.7.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Apportionment of Compulsory Sublicensee Consideration</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compulsory Sublicense Compensation received by the Roche Group from a Compulsory Sublicensee during the Royalty Term shall be shared with lcagen on an equivalent profit share percentage (the &#8220;<b style="font-weight:bold;">Compulsory Profit Share Percentage</b>&#8221;) calculated for the respective Calendar Year as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:80%;" align="center"><tr><td rowspan="2" style="vertical-align:middle;width:16.66%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">[***]&#160;x&#160;</p></td><td style="vertical-align:top;width:83.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(royalties payable to lcagen for the Product in the Territory)</p></td></tr><tr><td style="display:none;vertical-align:top;width:16.66%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:83.33%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Net Sales related to the royalties payable for the Product in the Territory)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At the end of the Calendar Year, Roche shall pay to lcagen the Compulsory Sublicense Compensation under a given country or region of the Territory multiplied by the Compulsory Profit Share Percentage. For clarity, any sales or payments by Compulsory Sublicensees under a Compulsory Sublicense shall not be considered as Net Sales and shall not give rise to any royalty payment under Section&#160;7.7.2 of this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">7.8</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Disclosure of Payments</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lcagen acknowledges that Roche may be obligated to disclose this financial arrangement, including all fees, payments and transfers of value, as may be advisable or required under Applicable Law, including the US Sunshine Act.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Accounting and reporting</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">8.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Timing of Payments</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Roche shall calculate royalty payments set forth in Section&#160;7.7 as of the end of each Calendar Quarter (each being the last day of a reporting period). Roche shall pay such payments within [***] after the end of each Calendar Quarter reporting period in which Net Sales occur.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">8.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Late Payment</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any payment under this Agreement that is not paid on or before the date such payment is due shall bear interest, to the extent permitted by Applicable Law, at [***] percentage points above the average one-month Euro lnterbank Offered Rate (EURlBOR), as reported by Reuters from time to time, calculated on the number of days such payment is overdue.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">8.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Method of Payment</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Royalties on Net Sales and all other amounts payable by Roche hereunder shall be paid by Roche in US dollars (the &#8220;<b style="font-weight:bold;">Payment Currency</b>&#8221;) to account(s) designated by lcagen.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">8.4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Currency Conversion</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">When calculating the Sales of any Product that occur in currencies other than the Payment Currency, Roche shall convert the amount of such sales into Swiss Francs and then into the Payment Currency using Roche&#8217;s then-current internal foreign currency translation method actually used on a consistent basis in preparing its audited financial statements (at the Effective Date, YTD average rate as reported by Reuters).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">8.5</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Blocked Currency</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ln a given country, if proceeds related to Net Sales are received in a local currency that cannot be removed from such country (for example due to governmental restrictions on foreign exchange trade), then Roche may, it its discretion, notify lcagen in writing and</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:5.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:43.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">lcagen will have the right to receive the applicable royalties of Net Sales in such country in local currency by deposit in a local bank designated by lcagen, or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:42.85pt;text-indent:-42.85pt;margin:0pt 0pt 0pt 6.1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:6.1pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:42.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">if such local currency payment is not allowed by reason of Applicable Law or if otherwise requested by lcagen, then the royalties related to such Net Sales in such country shall continue to be accrued and shall continue to be reported, but such royalties will not be paid until the sales proceeds related to such Net Sales may be removed from such country. At such time as Roche, its Affiliates or their Sublicensees, as the case may be, is able to remove the sales proceeds related to such Net Sales from such country, Roche shall also pay such accrued royalties in Payment Currency using the actual exchange rate which is used to remove such sales proceeds from such country.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">8.6</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Reporting</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">With each payment Roche shall provide lcagen in writing for the relevant Calendar Quarter on a Product-by-Product basis the following information:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Sales in Swiss Francs;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Net Sales in Swiss Francs;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">exchange rate used for the conversion of Net Sales from Swiss Francs to the Payment Currency pursuant to Section&#160;8.4;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Sales and Net Sales in the Payment Currency;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">royalty rate pursuant to Section&#160;7.7.2;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(f)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">adjustments made pursuant to Sections 7.7.4 - 7.7.5; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(g)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">total royalty payable in the Payment Currency after adjustments made pursuant to Sections 7.7.4 - 7.7.5.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">9.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Taxes</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lcagen shall pay all sales, turnover, income, revenue, value added, and other taxes levied on account of any payments made to lcagen under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To the extent permitted by applicable law, all payments to lcagen under this Agreement shall be made by lcagen free and clear of and without deduction or withholding for any taxes. lf provision is made in law or regulation of any country for withholding of taxes of any type, levies or other charges with respect to any royalty or other amounts payable under this Agreement to lcagen, then Roche shall promptly pay such tax, levy or charge for and on behalf of lcagen to the proper governmental authority, and shall promptly furnish lcagen with receipt of payment. Roche shall be entitled to deduct any such tax, levy or charge actually paid from royalty or other payment due lcagen or be promptly reimbursed by lcagen if no further payments are due to lcagen. Each Party agrees to reasonably assist the other Party in claiming exemption from and/or minimizing such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Auditing</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">10.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lcagen Right to Audit</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roche shall keep, and shall require its Affiliates and Sublicensees to keep, full, true and accurate books of account containing all particulars that may be necessary for the purpose of calculating all royalties payable under this Agreement. Such books of accounts shall be kept for a period of at least [***] following the Calendar Quarter to which they pertain at their principal place of business. At the expense of lcagen, lcagen shall have the right to engage an internationally recognized independent public accountant reasonably acceptable to Roche to perform, on behalf of lcagen, an audit of such books and records of Roche and its Affiliates that are deemed necessary by the independent public accountant to report on Net Sales of Product for the period or periods requested by lcagen and the correctness of any financial report or payments made under this Agreement. Pursuant to Section&#160;10.2, the internationally recognized independent public accountant shall have the right to disclose to lcagen and/or lcagen Affiliates its conclusions regarding any royalty payments owed with regard to the royalty statements subject to the audit under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Upon timely request and at least [***] prior written notice from lcagen, such audit shall be conducted for those countries lcagen has specifically requested, during regular business hours in such a manner as to not unnecessarily interfere with Roche&#8217;s normal business activities at such place or places where such records are customarily kept. Such audit shall be limited to results in the [***] Calendar Years prior to audit notification, and if lcagen requests an audit for a given Calendar Year, no additional audits may be conducted in the Territory for such Calendar Year unless a discrepancy exceeding [***] percent ([***]%) of the aggregate amount of royalty payments owed with regard to the royalty statements subject to the audit has previously been discovered. lf lcagen does not request an audit of a given Calendar Year on or before the [***] anniversary of the end of such Calendar Year, then lcagen will be deemed to have accepted the royalty payments and reports in such Calendar Year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Such audit shall not be performed more frequently than [***] per Calendar Year nor more frequently than [***] with respect to records covering any specific period of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All information, data documents and abstracts herein referred to shall be used only for the purpose of verifying royalty statements, shall be treated as Roche&#8217;s Confidential lnformation subject to the obligations of this Agreement and need neither be retained more than [***] after completion of an audit hereof, if an audit has been requested; nor more than [***] from the end of the Calendar Year to which each shall pertain; nor more than [***] after the date of termination of this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">10.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Audit Reports</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The auditors shall only state factual findings in the audit reports and shall not interpret the agreement. The auditors shall share all draft audit findings with Roche before sharing such findings with lcagen and before the final audit report is issued. The final audit report shall be shared with Roche at the same time it is shared with lcagen.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">10.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Over-or Underpayment</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lf the audit reveals an overpayment, lcagen shall reimburse Roche for the amount of the overpayment within [***] after the issuance of the final audit report. lf the audit reveals an underpayment, Roche shall make up such underpayment with the next royalty payment or, if no further royalty payments are owed by Roche, Roche shall reimburse lcagen for the amount of the underpayment within [***] after the issuance of the final audit report. Roche shall pay for the audit costs if the underpayment of Roche exceeds [***] percent ([***]%) of the aggregate amount of royalty payments owed with regard to the royalty statements subject to the audit. Section&#160;8.2 shall apply to this Section&#160;10.3.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lntellectual Property</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">11.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Ownership of lnventions</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">This Agreement does not convey to lcagen any rights in any Roche Patent Rights, Roche Know-How, Roche&#8217;s interest in Joint Know-How or Joint Patent Rights or any other intellectual property or Patent Rights of Roche by implication, estoppel or otherwise except for the rights expressly granted in Section&#160;2.1.1 and Section&#160;16.3. Title to the Roche Patent Rights, Roche Know-How, Roche&#8217;s interest in Joint Know-How or Joint Patent Rights, and any other intellectual property or Patent Rights of Roche shall at all times remain vested in Roche. This Agreement does not convey to Roche any rights in any lcagen Patent Rights, lcagen Know-How, lcagen&#8217;s interest in Joint Know-How or Joint Patent Rights or any other intellectual property or Patent Rights of lcagen by implication, estoppel or otherwise except for the rights expressly granted in Sections 2.1.1 and 2.1.2. Title to the lcagen Patent Rights, lcagen Know-How, lcagen&#8217;s interest in Joint Know-How or Joint Patent Rights, and any other intellectual property or Patent Rights of lcagen shall at all times remain vested in lcagen.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:42.85pt;text-indent:-42.85pt;margin:0pt 0pt 0pt 6.1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">lcagen shall own any invention solely related to improvements to the lcagen Technology regardless of inventorship. Roche shall own any invention solely related to improvements to the Roche Technology regardless of inventorship. Roche shall own any lnvention related to a Compound, Derivative Compound or a Product, as well as any improvements to the process or specifications provided by Roche to lcagen, regardless of inventorship. Notwithstanding the assignment by lcagen to Roche of any lnvention related to a Compound, Derivative Compound or Product, the obligation of Roche to pay lcagen the milestone fees, sales events payments and royalties due lcagen under Section&#160;7.5, Section&#160;7.6 and Section&#160;7.7 with respect to Products that embody the lcagen lnventions and Joint lnventions owned by Roche pursuant to this Section&#160;11.1(b) shall not be affected.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Subject to the provisions of preceding portion of this Section&#160;11.1, lcagen shall own all lcagen lnventions, Roche shall own all Roche lnventions, and lcagen and Roche shall jointly own all Joint lnventions. lcagen and Roche each shall require all of its employees and/or consultants to assign all inventions related to Products made by them to Roche and lcagen, as the case may be.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The determination of inventorship for lnventions shall be in accordance with US inventorship laws as if such lnventions were made in the US. lf required, patent counsel mutually acceptable to the Parties shall determine inventorship of lnventions in accordance with US patent law. The Parties will share equally costs for such advice.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Subject to the licenses granted under this Agreement and Section&#160;11.1(b) (and subject to Roche complying with its payment obligation for its exclusive license rights under lcagen&#8217;s interest in such Joint Patent Rights), lcagen and Roche will each have an equal undivided share in the Joint Patent Rights, without obligation to account to the other for exploitation thereof, or to seek consent of the other Party for the grant of any license thereunder.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(f)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Roche, in its sole discretion, may file for patent protection on its invention as set forth above in its own name and lcagen shall promptly sign and deliver any and all documents or information necessary for the transferring of ownership rights and/or securing of such invention in any country as determined by Roche.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(g)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">With respect to Know-How (other than lnventions) made during a Research Program, lcagen shall own such Know-How made by employees of lcagen solely or jointly with a Third Party, Roche shall own such Know-How made by employees of the Roche Group solely or jointly with a Third Party, and the Parties shall jointly own such Joint Know-How. lf required, patent counsel mutually acceptable to the Parties shall determine ownership of Know-How in accordance with US intellectual property law. The Parties will share equally costs for such advice.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(h)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Each of lcagen and Roche shall promptly disclose to the other in writing reasonably detailed written reports describing any Know-How or lnvention that might, under the applicable U.S. patent laws, be patentable and constitute Joint Patent Rights. lcagen shall promptly disclose to Roche any lcagen lnvention that arises during the term of the Agreement after such time as lcagen has taken steps deemed necessary by lcagen in its sole discretion to protect such lcagen lnvention that constitutes lcagen Patent Rights, and Roche shall promptly disclose to lcagen any Roche lnvention after such time as Roche has taken steps deemed necessary by Roche in its sole discretion to protect such Roche lnvention that constitutes Roche Patent Rights. Within [***] days following the date of disclosure regarding the existence of Joint lnventions, the Parties shall confer and mutually agree as to appropriate protection for such Joint Program lntellectual Property, including an application, preparation, prosecution and maintenance strategy. Notwithstanding the provisions of this Section&#160;11.1(h), neither Party shall file any Joint Patent Right relating to Joint lnventions without the other Party&#8217;s prior written consent (which shall not be unreasonably withheld or delayed).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">11.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">German Statute on Employee&#8217;s lnventions</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ln accordance with the German Statute on Employees&#8217; lnventions to the extent such statute is applicable to a Party, each Party agrees to claim the unlimited use of any lnvention conceived, reduced to practice, developed, made or created in the performance of, or as a result of, any Research Program by employees of any German Affiliates or any other persons acting on behalf of such German Affiliates. For the avoidance of doubt, each Party is responsible for fulfilling the obligations towards their employees under the German Statute of Employee&#8217;s lnventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">11.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Prosecution of Patent Rights Claiming lcagen lnventions</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lcagen shall, at its own expense and discretion, (i)&#160;Handle all lcagen Patent Rights, (ii)&#160;consult with Roche as to the Handling of such lcagen Patent Rights, and (iii)&#160;furnish to Roche copies of all documents relevant to any such Handling. lcagen shall furnish such documents and consult with Roche in sufficient time before any action by lcagen is due to allow Roche to provide comments thereon, which comments lcagen shall consider in good faith; provided that nothing herein shall obligate lcagen to adopt or follow such comments. ln the event that lcagen elects not to file for patent protection, or elects not to prosecute or maintain a patent or patent application under the lcagen Patent Rights described in this Section&#160;11.3 in a particular country(ies), lcagen shall notify Roche of such decision as soon as possible no later than [***] days prior to the final deadline for any pending action or response that may be due with respect to such lcagen Patent Right with the applicable patent authority. ln the event Roche provides written notice expressing its interest in prosecuting and maintaining such lcagen Patent Right, lcagen shall cooperate with Roche to permit Roche to Handle such lcagen Patent Rights, at Roche&#8217;s sole expense, subject to the provisions of Section&#160;11.4. lcagen shall transfer such patent rights to Roche at Roche&#8217;s expense. At lcagen&#8217;s expense and reasonable request, Roche shall cooperate, in all reasonable ways with the Handling of all lcagen Patent Rights.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">11.4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Prosecution of Patent Rights Claiming Roche lnventions and Joint lnventions</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Roche shall, at its own expense and discretion, Handle (including abandon) all Roche Patent Rights, Joint Patent Rights and lcagen Patent Rights for which lcagen has the first right to file but abandons pursuant to Section&#160;11.3. With respect to Joint Patent Rights, Roche shall use outside patent counsel reasonably acceptable to both Parties, and such outside counsel shall be responsible to both Roche and lcagen, and shall use reasonable efforts to solicit both Roche&#8217;s and lcagen&#8217;s advice on material prosecution matters related thereto. Such outside patent counsel shall confer with Roche and lcagen patent counsel on a regular basis as needed to discuss strategy for the preparation, filing, prosecution and maintenance of the Joint Patent Rights. Roche shall instruct outside counsel to promptly furnish or have furnished to lcagen copies of all patents, patent applications, substantive patent office actions, and substantive responses received or filed in connection with such applications for Joint Patent Rights, if possible, at least [***] before filing or mailing, as the case may be. Roche shall use reasonable efforts to solicit lcagen&#8217;s advice and review of Joint Patent Rights and material prosecution matters related thereto in reasonable time prior to filing thereof, and Roche shall consider in good faith lcagen&#8217;s reasonable comments and suggestions related thereto; provided that nothing herein shall obligate Roche to adopt or follow such comments or suggestions. ln the event that Roche elects not to file for patent protection, or elects not to prosecute or maintain a patent or patent application under the Roche Patent Rights or Joint Patent Rights described in this Section&#160;11.4 in a particular country(ies), Roche shall notify lcagen of such decision as soon as possible no later than [***] prior to the final deadline for any pending action or response that may be due with respect to such Roche Patent Right or Joint Patent Right with the applicable patent authority. ln the event lcagen provides written notice expressing its interest in prosecuting and maintaining such Roche Patent Rights or Joint Patent Rights, Roche shall cooperate with lcagen to permit lcagen to Handle such Roche Patent Rights or Joint Patent Rights, at lcagen&#8217;s sole expense. Roche shall transfer such patent rights to lcagen at lcagen&#8217;s expense. At Roche&#8217;s expense and reasonable request, lcagen shall cooperate, in all reasonable ways with the Handling of all any Roche Patent Rights or Joint Patent Rights.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">11.5</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Patent Coordination Team</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Where the Parties need to consult with each other on the Handling of Patent Rights, the Parties shall establish a patent coordination team and shall adopt procedures for interacting on patent matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">11.6</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Unified Patent Court (Europe)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At any time prior to the end of the &#8220;transitional period&#8221; as such term is used in Article 83 of the Agreement on a Unified Patent Court between the participating Member States of the European Union, for a given relevant EU Patent Right, Roche may request in writing that lcagen either (i)&#160;opt out from the exclusive competence of the Unified Patent Court or (ii)&#160;if applicable, withdraw a previously-registered opt-out, and lcagen shall notify the Registry, pay any such registry fee and take such other action as may be necessary to effect the opt-out or opt-out withdrawal (&#8220;<b style="font-weight:bold;">Register</b>&#8221;). lcagen shall Register within [***] of receipt of Roche&#8217;s written request, or such other time parameters specified by Roche.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">11.7</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">CREATE Act</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lt is the intention of the Parties that this Agreement is a &#8220;joint research agreement&#8221; as that phrase is defined in 35 USC &#167;103(c)(3).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">11.8</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lnfringement</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Each Party shall promptly provide written notice to the other Party during the Agreement Term of any (i)&#160;known infringement or suspected infringement by a Third Party of any lcagen Patent Rights, or Joint Patent Rights, or (ii)&#160;known or suspected unauthorized use or misappropriation by a Third Party of any lcagen Know-How, Roche Know-How or Joint Know-How, and shall provide the other Party with all evidence in its possession supporting such infringement or unauthorized use or misappropriation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Within [***] after Roche provides or receives such written notice (&#8220;<b style="font-weight:bold;">Decision Period</b>&#8221;), Roche, in its sole discretion, shall decide whether or not to initiate a suit or action in the Territory regarding such infringement or unauthorized use or misappropriation and shall notify lcagen of its decision in writing (&#8220;<b style="font-weight:bold;">Suit&#160;Notice</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lf Roche decides to bring a suit or take action, once Roche provides Suit Notice, Roche may immediately commence such suit or take such action. ln the event that Roche (i)&#160;does not in writing advise lcagen within the Decision Period that Roche will commence suit or take action, or (ii)&#160;fails to commence suit or take action within a reasonable time after providing Suit Notice, lcagen shall thereafter have the right (subject to Roche&#8217;s written consent, not to be unreasonably withheld) to commence suit or take action in the Territory and shall provide written notice to Roche of any such suit commenced or action taken by lcagen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Upon written request, the Party bringing suit or taking action (&#8220;<b style="font-weight:bold;">lnitiating Party</b>&#8221;) shall keep the other Party informed of the status of any such suit or action and shall provide the other Party with copies, to the extent the lnitiating Party is lawfully permitted to do so, of all substantive documents or communications filed in such suit or action. The lnitiating Party shall have the sole and exclusive right to select counsel for any such suit or action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The lnitiating Party shall, except as provided below, pay all expenses of the suit or action, including the lnitiating Party&#8217;s attorneys&#8217; fees and court costs. Unless otherwise agreed by the Parties, and subject to the Parties&#8217; respective obligations under Article 13, all monies recovered upon the final judgment or settlement of any action described in this Section&#160;11.8 shall be used as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">First, to reimburse the lnitiating Party for its costs and, if any remains, to the other Party for any advisory counsel fees and costs; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Second,</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>if a member of the Roche Group is the lnitiating Party,</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(A)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">any remaining amount that represents compensation for lost sales, a reasonable royalty or lost profits, shall be retained by or paid to the lnitiating Party; provided, however, any such amount (after relevant adjustment to convert to Net Sales of Products shall be subject to the royalty obligations set forth in Section&#160;7.7; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:42.85pt;text-indent:-42.85pt;margin:0pt 0pt 0pt 91.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(B)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">any remaining amount that represents additional damages (e.g., enhanced or punitive damages) shall be allocated to the lnitiating Party; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">if lcagen is the lnitiating Party, the balance, if any, shall be allocated [***] percent ([***]%) to the lnitiating Party, and [***] percent ([***]%) to the other Party.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lf the lnitiating Party believes it is reasonably necessary or desirable to obtain an effective remedy, upon written request the other Party agrees to be joined as a party to the suit or action but shall be under no obligation to participate except to the extent that such participation is required as the result of its being a named party to the suit or action. At the lnitiating Party&#8217;s written request, the other Party shall offer reasonable assistance to the lnitiating Party in connection therewith at no charge to the lnitiating Party except for reimbursement of reasonable out-of-pocket expenses incurred by the other Party in rendering such assistance. The other Party shall have the right to participate and be represented in any such suit or action by its own counsel at its own expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The lnitiating Party may settle, consent judgment or otherwise voluntarily dispose of the suit or action (&#8220;<b style="font-weight:bold;">Settlement</b>&#8221;) without the written consent of the other Party but only if such Settlement can be achieved without adversely affecting the other Party (including any of its Patent Rights). lf a Settlement could adversely affect the other Party, then the written consent of the other Party would be required, which consent shall not be unreasonably withheld.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For any patent that is not a lcagen Patent Right, Roche, in its sole discretion, shall decide whether or not to initiate such suit or action in the Territory. Roche shall have full discretion as to how it wishes to handle such suit and may reach Settlement and retain all damages, settlement fees or other consideration under any terms and conditions it desires and retain whatever. Only if a Settlement could adversely affect lcagen shall the written consent of lcagen be required, which consent shall not be unreasonably withheld.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">11.9</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Defense</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lf an action for infringement is commenced against either Party, its licensees or its sublicensees related to lcagen&#8217;s conduct of a Research Program within the scope of the relevant Research Plan or the discovery, development, manufacture, use or sale of a Product, then Roche shall have the right (but not the obligation) to defend such action at its own expense, and lcagen shall assist and cooperate with Roche, at Roche&#8217;s expense, to the extent necessary in the defense of such suit. Roche shall have the right to settle the suit or consent to an adverse judgment thereto, in its sole discretion, so long as such settlement or adverse judgment does not adversely affect the rights of lcagen and its Affiliates (including any patent rights Controlled by any of them). Subject to Section&#160;7.7.5, Roche shall assume full responsibility for the payment of any award for damages, or any amount due pursuant to any settlement entered into by it with such Third Party.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">11.10</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Common lnterest Disclosures</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With regard to any information or opinions disclosed pursuant to this Agreement by one Party to each other regarding intellectual property and/or technology owned by Third Parties, the Parties agree that they have a common legal interest in determining whether, and to what extent, Third Party intellectual property rights may affect the conduct of a Research Program and/or Compounds and/or Products, and have a further common legal interest in defending against any actual or prospective Third Party claims based on allegations of misuse or infringement of intellectual property rights relating to the conduct of the relevant Research Program and/or Compounds and/or Products. Accordingly, the Parties agree that all such information and materials obtained by lcagen and Roche from each other will be used solely for purposes of the Parties&#8217; common legal interests with respect to the conduct of the Agreement. All information and materials will be treated as protected by the attorney-client privilege, the work product privilege, and any other privilege or immunity that may otherwise be applicable. By sharing any such information and materials, neither Party intends to waive or limit any privilege or immunity that may apply to the shared information and materials. Neither Party shall have the authority to waive any privilege or immunity on behalf of the other Party without such other Party&#8217;s prior written consent, nor shall the waiver of privilege or immunity resulting from the conduct of one Party be deemed to apply against any other Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">11.11</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Hatch-Waxman</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Should a Party receive a certification for a Product pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417, known as the Hatch-Waxman Act), as amended, or its equivalent in a country other than the US, then such Party shall immediately provide the other Party with a copy of such certification. Roche shall have [***] from date on which it receives or provides a copy of such certification to provide written notice to lcagen (&#8220;<b style="font-weight:bold;">H-W Suit Notice</b>&#8221;) whether Roche will bring suit, at its expense, within a [***] period from the date of such certification. Should such [***] period expire without Roche bringing suit or providing such H-W Suit Notice, then lcagen shall be free to immediately bring suit in its name.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">11.12</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Patent Term Extensions</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Parties shall use Commercially Reasonable Efforts to obtain all available patent term extensions, adjustments or restorations, or supplementary protection certificates (&#8220;<b style="font-weight:bold;">SPCs</b>&#8221;, and together with patent term extensions, adjustments and restorations, &#8220;<b style="font-weight:bold;">Patent Term Extensions</b>&#8221;). lcagen shall execute such authorizations and other documents and take such other actions as may be reasonably requested by Roche to obtain such Patent Term Extensions, including designating Roche as its agent for such purpose as provided in 35 USC &#167; 156. All filings for such Patent Term Extensions shall be made by Roche; provided, that in the event that Roche elects not to file for a Patent Term Extension, Roche shall (a)&#160;promptly inform lcagen of its intention not to file and (b)&#160;grant lcagen the right to file for such Patent Term Extension. Each Party shall execute such authorizations and other documents and take such other actions as may be reasonably requested by the other Party to obtain such extensions. The Parties shall cooperate with each other in gaining patent term restorations, extensions and/or SPCs wherever applicable to such lcagen Patent Rights.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lcagen Representations and Warranties</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">12.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Safety Data</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lcagen has disclosed to Roche and will promptly (in compliance with Applicable Law) continue to disclose to Roche (i)&#160;the results of all preclinical testing and human clinical testing of Product in its possession or Control and (ii)&#160;all information in its possession or Control concerning side effects, injury, toxicity or sensitivity reaction and incidents or severity thereof with respect to Product.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">12.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Third Party Patent Rights</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lcagen has no knowledge of the existence of any patent or patent application owned by or licensed to any Third Party that could prevent Roche from making, having made, using, offering for sale, selling or importing Product in the Territory or using the lcagen lP as contemplated by this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">12.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lnventors</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lcagen warrants that the inventors of the inventions disclosed and/or claimed in lcagen Patent Rights have transferred to lcagen full ownership of the Patent Rights and Know-How licensed under this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">12.4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Grants</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To the best of lcagen&#8217;s knowledge and belief, lcagen has the lawful right to grant Roche and its Affiliates the rights and licenses described in this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">12.5</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Authorization</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The execution, delivery and performance of this Agreement by lcagen and all instruments and documents to be delivered by lcagen hereunder: (i)&#160;are within the corporate power of lcagen; (ii)&#160;have been duly authorized by all necessary or proper corporate action; (iii)&#160;are not in contravention of any provision of the certificate of formation or limited liability company agreement of lcagen; (iv)&#160;to the knowledge of lcagen, will not violate any law or regulation or any order or decree of any court of governmental instrumentality; (v)&#160;will</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">not violate the terms of any indenture, mortgage, deed of trust, lease, agreement, or other instrument to which lcagen is a party or by which lcagen or any of its property is bound, which violation would have an adverse effect on the financial condition of lcagen or on the ability of lcagen to perform its obligations hereunder; and (vi)&#160;do not require any filing or registration with, or the consent or approval of, any governmental body, agency, authority or any other person, which has not been made or obtained previously (other than approvals required under the HSR Act, Regulatory Approvals required for the sale of Products and filings with Regulatory Authorities required in connection with Products).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">12.6</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Validity of Patent Rights</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lcagen is not in possession of information that could render invalid and/or unenforceable any claims that are in any of the lcagen Patent Rights. lcagen has no knowledge of any inventorship disputes concerning any lcagen Patent Rights.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">12.7</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Ownership and Validity of Know-How</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lcagen&#8217;s Know-How is legitimately in the possession of lcagen and has not been misappropriated from any Third Party. lcagen has taken reasonable measures to protect the confidentiality of its Know-How.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">12.8</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">No Claims</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There are no claims or investigations pending or threatened against lcagen or any of its Affiliates, at law or in equity, or before or by any governmental authority relating to the matters contemplated under this Agreement or that would materially adversely affect lcagen&#8217;s ability to perform its obligations hereunder.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">12.9</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">No Conflict</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Neither lcagen nor any of its Affiliates is or will be under any obligation to any person, contractual or otherwise, that is conflicting with the terms of this Agreement or that would impede the fulfillment of lcagen&#8217;s obligations hereunder.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">12.10</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">No Other Representations</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">EXCEPT AS OTHERWlSE PROVlDED lN THlS AGREEMENT, THE FOREGOlNG REPRESENTATlONS AND WARRANTlES ARE lN LlEU OF ALL OTHER REPRESENTATlONS AND WARRANTlES, EXPRESS OR lMPLlED, lNCLUDlNG WlTHOUT LlMlTATlON, WARRANTlES OF MERCHANTABlLlTY OR FlTNESS FOR A PARTlCULAR PURPOSE OF PRODUCTS.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">13.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lndemnification</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">13.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lndemnification by Roche</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Roche shall indemnify, hold harmless and defend lcagen and its directors, officers, employees and agents from and against any and all losses, expenses, cost of defense (including without limitation attorneys&#8217; fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts lcagen becomes legally obligated to pay any Third Party arising from or related to (a)&#160;the breach of the Agreement by Roche or (b)&#160;activities related to the Product (e.g. product liability claims) conducted by or on behalf of Roche or any governmental investigation in connection with this Agreement due to the action or inaction of Roche, except to the extent such losses, expenses, costs and amounts are due to the breach of the Agreement by lcagen or the gross negligence or willful misconduct or failure to act of lcagen.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">13.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lndemnification by lcagen</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lcagen shall indemnify, hold harmless and defend Roche and its directors, officers, employees and agents from and against any and all losses, expenses, cost of defense (including without limitation attorneys&#8217; fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts Roche becomes legally obligated to pay any Third Party arising from or related to (a)&#160;the breach of the Agreement by lcagen or (b)&#160;activities related to the Product conducted by or on behalf of lcagen, or any governmental investigation in connection with this Agreement due to the action or inaction of lcagen, except to the extent such losses, expenses, costs and amounts are due to the breach of the Agreement by Roche or the gross negligence or willful misconduct or failure to act of Roche.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">13.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Procedure</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ln the event of a claim by a Third Party against a Party entitled to indemnification under this Agreement (&#8220;<b style="font-weight:bold;">lndemnified Party</b>&#8221;), the lndemnified Party shall promptly notify the other Party (&#8220;<b style="font-weight:bold;">lndemnifying Party</b>&#8221;) in writing of the claim and the lndemnifying Party shall undertake and solely manage and control, at its sole expense, the defense of the claim and its settlement. The lndemnified Party shall cooperate with the lndemnifying Party and may, at its option and expense, be represented in any such action or proceeding by counsel of its choice. The lndemnifying Party shall not be liable for any litigation costs or expenses incurred by the lndemnified Party without the lndemnifying Party&#8217;s written consent. The lndemnifying Party shall not settle any such claim unless such settlement fully and unconditionally releases the lndemnified Party from all liability relating thereto, unless the lndemnified Party otherwise agrees in writing.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">14.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Liability</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">14.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Limitation of Liability</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">EXCEPT FOR lNDEMNlFlCATlON UNDER ARTlCLE 13, NElTHER PARTY SHALL BE ENTlTLED TO RECOVER FROM THE OTHER PARTY ANY SPEClAL, lNClDENTAL, CONSEQUENTlAL OR PUNlTlVE DAMAGES lN CONNECTlON WlTH THlS AGREEMENT OR ANY LlCENSE GRANTED HEREUNDER. This Section&#160;14.1 is not intended to affect the development event payments under Section&#160;7.5, sales based event payments under Section&#160;7.6 or royalty payments under Section&#160;7.7 that are payable by Roche to lcagen pursuant to terms of this Agreement, including lcagen&#8217;s right to bring a claim to recover such payments in the event that they are not paid in accordance with the terms of this Agreement. No Party excludes any liability for death or personal injury caused by its negligence or that of its employees, agents or subcontractors.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">15.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Obligation Not to Disclose Confidential lnformation</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">15.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Non-Use and Non-Disclosure</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the Agreement Term and for [***] thereafter, a Receiving Party shall (i)&#160;treat Confidential lnformation provided by Disclosing Party as it would treat its own information of a similar nature, (ii)&#160;take all reasonable precautions not to disclose such Confidential lnformation to Third Parties, without the Disclosing Party&#8217;s prior written consent, and (iii)&#160;not use such Confidential lnformation other than for fulfilling its obligations under this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">15.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Permitted Disclosure</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the obligation of non-use and non-disclosure set forth in Section&#160;15.1, the Parties recognize the need for certain exceptions to this obligation, specifically set forth below, with respect to press releases, patent rights, publications, and certain commercial considerations and as required by Applicable Law, including the rules and regulations pertaining to lcagen under the Securities Exchange Act of 1934, as amended.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">15.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Press Releases</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lcagen may issue a press release for each respective Research Program announcing the existence and selected key terms of this Agreement applicable to such respective Research Program, in a form substantially similar to the template attached as Appendix 15.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roche shall issue press releases in accordance with its internal policy that typically does not issue a second press release until human proof of concept has been achieved for a Compound. Roche shall provide lcagen with a copy of any draft press release related to the activities contemplated by this Agreement at least [***] prior to its intended publication for lcagen&#8217;s review. lcagen may provide Roche with suggested modification to the draft press release. Roche shall consider lcagen&#8217;s suggestions in issuing its press release. No press release shall include Confidential lnformation of the other Party without such other Party&#8217;s prior written consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lcagen shall only issue press releases related to the activities contemplated by this Agreement that either (i)&#160;have been approved by Roche or (ii)&#160;are required to be issued by lcagen as a matter of law or regulatory compliance and lcagen has a competent legal opinion to that effect. ln all circumstances, lcagen shall provide Roche with a draft press release at least [***] prior to its intended publication for Roche&#8217;s review. During such period, Roche shall (i)&#160;approve the draft press release and permit lcagen to issue the press release, (ii)&#160;contact lcagen to discuss modification to the draft press release, or (iii)&#160;contact lcagen and disapprove the press release. lf Roche asks for modification, then lcagen shall either make such modification or work with Roche to arrive at a press release that Roche approves. lf lcagen issues a press release without Roche&#8217;s approval, then lcagen must obtain a competent legal opinion that the release was required to be issued by lcagen as a matter of law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To ensure communication alignment, responses (if any) to inquiries by media or other Third Parties after issuance of a permitted press release by lcagen (solely or jointly with Roche) shall consist solely of the press release language or shall follow the response guidelines that may be mutually developed by the Parties. Once approved for disclosure, any disclosure consented to in any press release or other announcement shall be deemed to be consented to in future press releases or other announcements.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">15.4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Publications</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the Agreement Term, the following restrictions shall apply with respect to disclosure by any Party of Confidential lnformation relating to the Product in any publication or presentation:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Both Parties acknowledge that it is their policy for the studies and results thereof to be registered and published in accordance with their internal guidelines. Roche, in accordance with its internal policies and procedures, shall have the right to publish all studies, clinical trials and results thereof on the clinical trial registries that are maintained by or on behalf of Roche provided that it does not include any lcagen Confidential lnformation (unless required by Applicable Law or regulatory compliance). lcagen shall not publish any studies, clinical trials or results thereof on its clinical trial registry.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A Party (&#8220;<b style="font-weight:bold;">Publishing Party</b>&#8221;) shall provide the other Party with a copy of any proposed publication or presentation at least [***] prior to submission for publication so as to provide such other Party with an opportunity to recommend any changes it reasonably believes are necessary to continue to maintain the Confidential lnformation disclosed by the other Party to the Publishing Party in accordance with the requirements of this Agreement. The incorporation of such recommended changes shall not be unreasonably refused; and if such other Party notifies (&#8220;<b style="font-weight:bold;">Publishing Notice</b>&#8221;) the Publishing Party in writing, within [***] after receipt of the copy of the proposed publication or presentation, that such publication or presentation in its reasonable judgment (i)&#160;contains an invention, solely or jointly conceived and/or reduced to practice by the other Party, for which the other Party reasonably desires to obtain patent protection or (ii)&#160;could be expected to have a material adverse effect on the commercial value of any Confidential lnformation disclosed by the other Party to the Publishing Party, the Publishing Party shall prevent such publication or delay such publication for a mutually agreeable period of time. ln the case of inventions, a delay shall be for a period reasonably sufficient to permit the timely preparation and filing of a patent application(s) on such invention, and in no event less than [***] from the date of the Publishing Notice.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">15.5</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Commercial Considerations</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nothing in this Agreement shall prevent Roche or its Affiliates from disclosing Confidential lnformation of lcagen to (i)&#160;governmental agencies to the extent required or desirable to secure government approval for the development, manufacture or sale of Product in the Territory, (ii)&#160;Third Parties acting on behalf of Roche, to the extent reasonably necessary for the development, manufacture or sale of Product in the Territory, provided such Third Parties are bound to maintain the confidentiality of such Confidential lnformation of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lcagen to the same extent as the provisions contained in this Agreement, (iii)&#160;Third Parties requesting clinical trial data information (in accordance with Roche&#8217;s then-current data sharing policy) or (iv)&#160;Third Parties to the extent reasonably necessary to market the Product in the Territory. The Receiving Party may disclose Confidential lnformation of the Disclosing Party to the extent that such Confidential lnformation is required to be disclosed by the Receiving Party to comply with Applicable Law, to defend or prosecute litigation or to comply with governmental regulations, provided that the Receiving Party provides prior written notice of such disclosure to the Disclosing Party and, to the extent practicable, takes reasonable and lawful actions to minimize the degree of such disclosure.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">16.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Term and Termination</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">16.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Commencement and Term</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This Agreement shall commence upon the Effective Date and continue for the Agreement Term.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">16.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Termination</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">16.2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Termination for Breach</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A Party (&#8220;<b style="font-weight:bold;">Non-Breaching Party</b>&#8221;) shall have the right to terminate this Agreement in its entirety or on a country-by-country basis in the event the other Party (&#8220;<b style="font-weight:bold;">Breaching Party</b>&#8221;) is in breach of any of its material obligations under this Agreement. The non-Breaching Party shall provide written notice to the Breaching Party, which notice shall identify the breach and the countries in which the Non-Breaching Party intends to have this Agreement terminate. The Breaching Party shall have a period of [***] after such written notice is provided (&#8220;<b style="font-weight:bold;">Peremptory Notice Period</b>&#8221;) to cure such breach. lf the Breaching Party has a <i style="font-style:italic;">bona fide</i> dispute as to whether such breach occurred or has been cured, it will so notify the Non-Breaching Party, and the expiration of the Peremptory Notice Period shall be tolled until such dispute is resolved pursuant to Section&#160;18.2. Upon a determination of breach or failure to cure, the Breaching Party may have the remainder of the Peremptory Notice Period to cure such breach. lf such breach is not cured within the Peremptory Notice Period, then absent withdrawal of the Non-Breaching Party&#8217;s request for termination, this Agreement shall terminate in its entirety or such identified countries effective as of the expiration of the Peremptory Notice Period.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">16.2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">lnsolvency</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A Party shall have the right to terminate this Agreement, if the other Party incurs an lnsolvency Event; provided, however, in the case of any involuntary bankruptcy proceeding, such right to terminate shall only become effective if the Party that incurs the lnsolvency Event consents to the involuntary bankruptcy or such proceeding is not dismissed within [***] after the filing thereof.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">16.2.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Effects of Change of Control</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lf there is a Change of Control, then the Party experiencing such Change of Control (&#8220;<b style="font-weight:bold;">Acquired Party</b>&#8221;) shall provide written notice to the other Party (&#8220;<b style="font-weight:bold;">Non-Acquired Party</b>&#8221;) [***] of such Change of Control, subject to any confidentiality obligations of the Acquired Party then in effect (but in any event shall notify the Non-Acquired Party within [***] after completion of such Change of Control).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Change of Control Group in connection with such Change of Control shall agree in writing with the Non-Acquired Party that it will not utilize any of the Non-Acquired Party&#8217;s Know-How, Patent Rights, lnventions, Materials or Confidential lnformation or Joint Know-How, Joint Patent Rights or Joint lnventions (collectively, &#8220;<b style="font-weight:bold;">Sensitive lnformation</b>&#8221;) for the research, development or commercialization of any product for the treatment of any indication or patient population for which a Product may be developed or commercialized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Following consummation of the Change of Control, the Non-Acquired Party and the Change of Control Group shall adopt in writing reasonable procedures to prevent the disclosure of Sensitive lnformation beyond the Acquired Party&#8217;s personnel who need to know the Sensitive lnformation solely for the purpose</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of fulfilling the Acquired Party&#8217;s obligations under this Agreement. The Non-Acquired Party may restrict the Acquired Party&#8217;s participation in the JRC and any other committee in effect at the time of the Change of Control, and decisions of the JRC and other such committees shall be made by Roche.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">16.2.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Termination by Roche without a Cause</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Roche shall have the right to terminate this Agreement at any time as a whole or on a Product-by-Product or country-by-country basis upon [***] prior written notice before First Commercial Sale of the Product or upon [***] prior written notice after the First Commercial Sale of the Product. The effective date of termination under this Section&#160;16.2.4 shall be the date [***] (or [***] (as the case may be) after Roche provides such written notice to lcagen.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">16.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Consequences of Termination</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">16.3.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Termination by lcagen for Breach by Roche</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Upon any termination by lcagen for breach by Roche, the rights and licenses granted by lcagen to Roche under this Agreement shall terminate in their entirety or on a country-by-country and Product-by-Product basis, as applicable, on the effective date of termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lf lcagen desires to continue development and/or commercialization of Product(s), lcagen shall give a Continuation Election Notice to Roche within [***] of lcagen&#8217;s notice of termination for breach by Roche. lf Roche receives such a timely Continuation Election Notice:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">After the effective date of termination Roche shall, to the extent Roche has the right to do so, assign and transfer to lcagen all regulatory filings and approvals including any orphan drug status or break though designations, all final pre-clinical and clinical study reports and clinical study protocols, and all data, including clinical data, in Roche&#8217;s possession and control related to Product(s) in the country necessary for lcagen to continue to develop and commercialize the Product(s). All data shall be transferred in the form and format in which it is maintained by Roche. Copies of original papers shall be provided to lcagen unless original paper copies are legally required. Roche shall not be required to prepare or finalize any new data, reports or information solely for purposes of transfer to lcagen.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Roche shall assign all clinical trial agreements, to the extent such agreements have not been cancelled and are assignable without Roche paying any consideration or commencing litigation in order to effect an assignment of any such agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">lcagen shall, upon transfer, have the right to disclose such filings, approvals and data to (i)&#160;governmental agencies of the country to the extent required or desirable to secure government approval for the development, manufacturing or sale of Product(s) in the country, (ii)&#160;Third Parties acting on behalf of lcagen, its Affiliates or licensees, to the extent reasonably necessary for the development, manufacture, or sale of Product(s) in the country, and (iii)&#160;Third Parties to the extent reasonably necessary to market Product(s) in the country.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">16.3.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Termination by Roche for Breach by lcagen or for lcagen lnsolvency</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Upon any termination by Roche for breach by lcagen or lcagen&#8217;s lnsolvency, the rights and licenses granted by one Party to the other Party under this Agreement shall terminate in their entirety or on a country-by-country and a Product-by-Product basis, as applicable, on the effective date of termination. Regardless of whether or not Roche has terminated the Agreement, lcagen shall compensate damages caused by such lcagen&#8217;s breach.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">16.3.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Termination by Roche without Cause</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Upon any termination by Roche without cause, the rights and licenses granted by lcagen to Roche under this Agreement shall terminate in their entirety or on a country-by-country and Product-by Product basis, as applicable, on the effective date of termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lf termination by Roche without cause takes place prior to the expiration of a Research Term, then Roche shall be obligated to fund FTEs through completion of the next research milestone set forth in such Research Plan; however, such funding obligation shall be limited to a maximum of [***] after the effective date of termination without cause with respect to the Research Plans for Target 2 and subsequent Targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lf lcagen desires to continue development and/or commercialization of Product(s), lcagen shall give a Continuation Election Notice to Roche within [***] of receipt of Roche&#8217;s notice of termination without cause. lf Roche receives such a timely Continuation Election Notice:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:50.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">After the effective date of termination Roche shall, to the extent Roche has the right to do so, transfer to lcagen all regulatory filings and approvals including any orphan drug status or break though designations, all final pre-clinical and clinical study reports and clinical study protocols, and all data, including clinical data, in Roche&#8217;s possession and control related to Product(s) in the country necessary for lcagen to continue to develop and commercialize the Product(s). All data shall be transferred in the form and format in which it is maintained by Roche. Copies of original papers shall be provided to lcagen unless original paper copies are legally required. Roche shall not be required to prepare or finalize any new data, reports or information solely for purposes of transfer to lcagen.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:50.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Roche shall assign all clinical trial agreements, to the extent such agreements have not been cancelled and are assignable without Roche paying any consideration or commencing litigation in order to effect an assignment of any such agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:50.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">lcagen shall, upon transfer, have the right to disclose such filings, approvals and data to (i)&#160;governmental agencies of the country to the extent required or desirable to secure government approval for the development, manufacture or sale of Product(s) in the country; (ii)&#160;Third Parties acting on behalf of lcagen, its Affiliates or licensees, to the extent reasonably necessary solely for the development, manufacture, or sale of Product(s) in the country, or (iii)&#160;Third Parties to the extent reasonably necessary to market Product(s) in the country.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:50.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">lcagen shall have the right to use all promotional materials for the terminated Product(s) (excluding the use of Roche house marks) and to make derivative works based thereon, solely in connection with the commercialization of the Product in the Field in the terminated country or countries. Roche shall assign to lcagen trademarks used in connection with the commercialization of the terminated Product(s) in such terminated country or countries and on the promotional materials as of the effective date of termination (excluding Roche house marks) at lcagen&#8217;s cost. lcagen shall have an exclusive license under the Roche Patent Rights and Roche&#8217;s rights to Joint Patent Rights directly related to, and actually used by Roche with respect to the development and/or commercialization of the terminated Product(s) in the terminated country or countries as of the effective date of termination, solely for the purpose of making, using, selling, offering for sale and importing such Product(s) throughout the Territory; provided, that (i)&#160;lcagen shall pay to Roche a royalty equal to (i)&#160;the applicable royalty rate(s) specified in Section&#160;7.7.2 of Net Sales of Product(s) (with such Net Sales calculated <i style="font-style:italic;">mutatis mutandis</i> in accordance with the definition of Royalty Term in Section&#160;1.81, Sales in Section&#160;1.82 and the definition of Net Sales in Section&#160;1.60 with all references to Roche in such definitions being deemed to refer to lcagen solely for purposes of such calculation and all references to Roche Group in such definitions being deemed to refer to lcagen and its Affiliates, and all references to lFRS in such definitions being deemed to refer to US Generally Accepted Accounting Principles) and (ii) [***] or (B) [***] and upon the expiration of such royalty obligation and payment of all such amounts due, such licenses shall become on a Product-by-Product, country-by-country basis, fully paid-up, non-exclusive, royalty-free, irrevocable and perpetual; and (ii)&#160;lcagen complies with Sections 8.1 through 8.6 and Sections 10.1 through 10.3 (with all references in such Sections to Roche being deemed to refer to lcagen, and all references in such Sections to lcagen being deemed to refer to Roche, in each case, solely for purposes of this Section&#160;16.3.3(d). For any Patent Right licensed to lcagen after</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:43.2pt;text-indent:-43.2pt;margin:0pt 0pt 0pt 42.49pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 85.65pt;">termination, lcagen shall be solely responsible for any costs incurred in Handling or enforcing such Patent Rights and shall promptly reimburse Roche for any costs incurred in this regard. Alternatively, Roche shall have the right to assign such Patent Rights to lcagen provided that such assignment will not extinguish lcagen&#8217;s obligations to pay royalties to Roche.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">16.3.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Direct License</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lrrespective of anything to the contrary in this Agreement,</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">any Compulsory Sublicense shall remain in full force and effect is may be required by Applicable Law, and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">any existing, permitted sublicense granted by Roche under Section&#160;2.2 of this Agreement (and any further sublicenses thereunder) shall, upon the written request of Roche, remain in full force and effect, provided that [***].</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">16.3.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Other Obligations</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">16.3.5.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Obligations Related to Ongoing Activities</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">[***] Notice, then Roche (a)&#160;shall have the right to cancel all ongoing obligations and (b)&#160;shall complete all non-cancellable obligations at its own expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lf lcagen provides such timely Continuation Election Notice, then from the date of notice of termination until the effective date of termination, Roche shall continue activities, including preparatory activities, ongoing as of the date of notice of termination. However, Roche shall not be obliged to initiate any new activities not ongoing at the date of notice of termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">After the effective date of termination, Roche shall have no obligation to perform and/or complete any activities or to make any payments for performing or completing any activities under this Agreement, except as expressly stated herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, in case of termination by lcagen under Section&#160;16.2.1 or 16.2.2 or by Roche under Section&#160;16.2.4, upon the request of lcagen, Roche shall complete any Clinical Studies related to the Product(s) that are being conducted under its lND for the Product(s) and are ongoing as of the effective date of termination; provided, however, that</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">both lcagen and Roche in their reasonable judgment have concluded that completing any such Clinical Studies does not present an unreasonable risk to patient safety;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Roche shall have no obligation to recruit or enroll any additional patients after the effective date of termination; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">lcagen agrees to reimburse Roche for all of its development costs that arise after the effective date of termination in completing such Clinical Studies.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">16.3.5.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Obligations Related to Manufacturing</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Clinical Supplies</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ln the case of termination by lcagen according to Section&#160;16.2.1 or 16.2.2 or by Roche under Section&#160;16.2.4, if lcagen elects to develop the Product(s), Roche shall transfer all existing and available clinical material to lcagen at Roche&#8217;s fully burdened manufacturing cost. Roche shall have no obligation to perform any additional activities concerning the clinical supplies (e.g. retesting, analyses). lcagen shall assume all liability for the use of such material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Commercial Supplies</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ln the case of termination by lcagen according to Section&#160;16.2.1 or 16.2.2 or by Roche under Section&#160;16.2.4, if a Product is marketed in any country of Territory on the date of the notice of termination of this Agreement, upon the request of lcagen, Roche shall manufacture and supply reasonable amounts of such Product to lcagen under a manufacturing transfer and transition plan for a period that shall not exceed [***] from the effective date of the termination of this Agreement at a price to be agreed by the Parties in good faith, but in no event exceeding (i)&#160;Roche&#8217;s fully burdened manufacturing cost, if Product is manufactured tor Roche through a Third Party contract, or (ii)&#160;Roche&#8217;s fully burdened manufacturing cost plus a mark-up of [***], if Roche manufactures Product itself, as calculated on a consistent basis according to its then current accounting procedures. lcagen shall use Commercially Reasonable Efforts to take over the manufacturing as soon as possible after the effective date of termination.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">16.3.5.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Ancillary Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise agreed by the Parties, the termination of this Agreement shall cause the automatic termination of all ancillary agreements related hereto, if any.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">16.3.5.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Limitations on Grant-Backs; Transfer Expenses</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For purposes of clarity, irrespective of anything to the contrary in this Agreement:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">All transfers and licenses from Roche to lcagen (or other obligations of Roche) under Section&#160;16.3 are solely with respect to Product(s) that are not Combination Product(s) and also exclude any Companion Diagnostics. Such transfers, licenses and obligations do not extend to other therapeutically active ingredients or products, even if physically mixed, combined or packaged together with a Product, and even if a Product is intended (according to the investigation plan, proposed labeling or actual labeling, as applicable) for use with such other therapeutically active ingredients or products.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">ln connection with research studies, clinical trials or other activities associated with the development and commercialization of Products, Roche may have collected (i)&#160;personally identifiable information about individual human subjects and/or (ii)&#160;human biological samples (collectively, &#8220;<b style="font-weight:bold;">Pll/Samples</b>&#8221;). Legal and contractual restrictions may apply to such Pll/Samples. Roche shall have no obligation to transfer such Pll/Samples unless necessary for the continued development of the Product, in which case Roche shall not be obliged to transfer any Pll/Samples that Roche in good faith believes would be prohibited or would subject Roche to potential liability by reason of Applicable Law, contractual restrictions or insufficient patient consent. lf Roche transfers any such Pll/Samples, lcagen shall use for the sole purpose of developing and commercializing the Product, and lcagen shall be responsible for the correct use of the Pll/Samples in line with the informed consent forms (including but not limited to potential re-consenting of the patients at lcagen&#8217;s costs).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">lcagen shall promptly reimburse Roche for all reasonable out-of-pocket costs and expenses (including FTE charges) incurred by or on behalf of Roche for transfer activities from Roche to lcagen under Sections 16.3.1 and 16.3.3 (&#8220;<b style="font-weight:bold;">Roche Transfer Activities</b>&#8221;); however transfer activities corresponding to the return of material remains, data, reports, records, documents, Regulatory Filings and Regulatory Approvals originally provided by lcagen to Roche no less than [***] from the effective date of termination (&#8220;<b style="font-weight:bold;">lcagen-Originated Transfer Activities</b>&#8221;) shall be returned to lcagen free of charge. lf lcagen desires Roche Transfer Activities other than lcagen-Originated Transfer Activities, lcagen shall make a payment to Roche of [***] US Dollars (US$[***]) (&#8220;<b style="font-weight:bold;">Minimum Transfer Payment</b>&#8221;). The Minimum Transfer Payment shall be non-refundable, but shall be fully creditable against lcagen&#8217;s reimbursement for the Roche Transfer Activities. Roche shall be under no obligation to provide Roche Transfer Activities (beyond than lcagen-Originated Transfer Activities) prior to receipt of the Minimum Transfer Payment or if the Minimum Transfer Payment is received after the effective date of the termination.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Unless otherwise agreed to by the Parties, transfer of physical materials that are required under Roche Transfer Activities shall be delivered, at Roche&#8217;s option, FCA international courier near location where materials stored at time of transfer (lncoterms 2010). lcagen pays for all shipping and arranges courier details.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:42.85pt;text-indent:-42.85pt;margin:0pt 0pt 4.5pt 6.1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">lcagen may not use any documents or materials provided by Roche as part of the license or transfer to lcagen under this Section&#160;16.3 as evidence in any legal proceedings against Roche.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">16.3.5.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Royalty and Payment Obligations</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Nothing herein shall be construed to release either Party of any obligation which matured prior to the effective date of any termination. A Party&#8217;s liability for any charges, payments or expenses due to the other Party that accrued prior to the termination date shall not be extinguished by termination, and such amounts (if not otherwise due on an earlier date or disputed by paying Party in good faith) shall be immediately due and payable on the termination date.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">16.4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Survival</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Article 1 (Definitions, to the extent necessary to interpret this Agreement), Articles 7, 8 and 10 (Payment, Accounting and Reporting, and Auditing, each to the extent payment obligations exist at the time of termination), Article 9 (Taxes, to the extent such were incurred at the time of termination), Section&#160;11.1 (Ownership of lnventions); Article 13 (lndemnification), Article 15 (Obligation Not to Disclose Confidential lnformation), Article 16 (Term and Termination), Section&#160;18.1 (Governing Law) and Section&#160;18.3 (Arbitration) shall survive any expiration or termination of this Agreement for any reason.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">17.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Bankruptcy</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All licenses (and to the extent applicable rights) granted under or pursuant to this Agreement by lcagen to Roche are, and shall otherwise be deemed to be, for purposes of Section&#160;365(n) of Title 11, US Code (the &#8220;<b style="font-weight:bold;">Bankruptcy Code</b>&#8221;) licenses of rights to &#8220;intellectual property&#8221; as defined under Section&#160;101(35A) of the Bankruptcy Code. Unless Roche elects to terminate this Agreement, the Parties agree that Roche, as a licensee or sublicensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code, subject to the continued performance of its obligations under this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">18.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Miscellaneous</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">18.1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Governing Law</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This Agreement shall be governed by and construed in accordance with the laws of the State of New York without reference to its conflict of laws principles, and shall not be governed by the United Nations Convention of lnternational Contracts on the Sale of Goods (the Vienna Convention).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding anything to the contrary in this Agreement, issues regarding the scope, construction, validity and/or enforceability of any Patent Rights shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions have issued the Patent Rights in question.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">18.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Disputes</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise set forth in this Agreement, in the event of any dispute in connection with this Agreement, such dispute shall be referred to the respective executive officers of the Parties designated below or their designees, for good faith negotiations attempting to resolve the dispute. The designated executive officers are as follows:</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:8%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For lcagen:</p></td><td style="vertical-align:top;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President of lcagen&#8217;s parent company Ligand Pharmaceuticals lncorporated</p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For Roche:</p></td><td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Head of Roche Partnering</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">18.3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Arbitration</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Except for an Excluded Claim and disputes that are within the scope of authority granted the JRC, should the Parties fail to agree within [***] after a dispute has first arisen, it shall be finally settled by arbitration in accordance with the Rules of American Arbitration Association (AAA) as in force at the time when initiating the arbitration. The tribunal shall consist of three arbitrators. The place of arbitration shall be New York City, New York, US. The language to be used shall be English.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">18.3.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Arbitrators</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Each Party shall nominate one arbitrator. Should the claimant fail to appoint an arbitrator in the request for arbitration within [***] of being requested to do so, or if the respondent should fail to appoint an arbitrator in its answer to the request for arbitration within [***] of being requested to do so, the other Party shall request the AAA to make such appointment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The arbitrators nominated by the Parties shall, within [***] from the appointment of the arbitrator nominated in the answer to the request for arbitration, and after consultation with the Parties, agree and appoint a third arbitrator, who will act as a chairman of the Arbitral Tribunal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Should such procedure not result in an appointment within the [***] time limit, either Party shall be free to request the AAA to appoint the third arbitrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Where there is more than one claimant and/or more than one respondent, the multiple claimants or respondents shall jointly appoint one arbitrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lf any Party-appointed arbitrator or the third arbitrator resigns or ceases to be able to act, a replacement shall be appointed in accordance with the arrangements provided for in this clause.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">New York shall be the seat of the arbitration. The arbitrators shall, in rendering any decision hereunder, apply the substantive law set forth in Section&#160;18.1 without regard to conflict of laws provisions. The Parties have agreed that English Rules of Evidence, and in particular common law discovery or disclosure, shall not apply to any arbitration under this clause. A request to produce documents by the Parties shall be considered by the Arbitral Tribunal according to Article 3 of the lBA (lnternational Bar Association) Rules of Evidence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Documents submitted in the arbitration (the originals of which are not in English) shall be submitted together with an English translation.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">18.3.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Decisions; Timing of Decisions</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The arbitrators shall render a written opinion setting forth findings of fact and conclusions of law with the reason therefor stated, within no later than [***] from the date on which the arbitrators were appointed to the dispute. A transcript of the evidence adduced at the arbitration hearing shall be made and, upon request, shall be made available to each Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the above, in the case of JRC disputes that are not finally resolved pursuant to Section&#160;6.6.3, the arbitrators shall render a written opinion setting forth findings of fact and conclusions of law with the reason therefor stated, within no later than [***] from the date on which the arbitrators were appointed to the dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The time periods set forth in the AAA Rules shall be followed; provided however that the arbitrators may modify such time periods as reasonably necessary to render a written opinion in accordance with this Section&#160;18.3.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Arbitrator is empowered to award any remedy allowed by law, including money damages, prejudgment interest and attorneys&#8217; fees, and to grant final, complete, interim, or interlocutory relief, including injunctive relief.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This arbitration agreement does not preclude either Party seeking conservatory or interim measures from any court of competent jurisdiction including, without limitation, the courts having jurisdiction by reason of either Party&#8217;s domicile. Conservatory or interim measures sought by either Party in any one or more jurisdictions shall not preclude the Arbitral Tribunal granting conservatory or interim measures. Conservatory or interim measures sought by either Party before the Arbitral Tribunal shall not preclude any court of competent jurisdiction granting conservatory or interim measures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ln the event that any issue shall arise which is not clearly provided for in this Section&#160;18.3, the matter shall be resolved in accordance with the AAA Rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any arbitration proceeding hereunder shall be confidential and the arbitrators shall issue appropriate protective orders to safeguard each Party&#8217;s Confidential lnformation. Except as required by law, neither Party shall make (or instruct the arbitrators to make) any public announcement with respect to the proceedings or decision of the arbitrators without prior written consent of the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrators, except as required in connection with the enforcement of such award or as otherwise required by Applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding anything to the contrary in this Agreement, any and all issues regarding the scope, construction, validity and/or enforceability of any Patent Rights shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the Patent Rights in question.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding anything to the contrary in this Agreement, any and all issues regarding a breach or alleged breach of a Party&#8217;s obligations under Article 15 (Obligation Not to Disclose Confidential lnformation) shall be determined in a court of competent jurisdiction under the laws of New York, with express exclusion of its conflict of laws principles.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">18.4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Assignment</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Neither Party may assign its rights or obligations under this Agreement absent the prior written consent of the other Party, except to any of its Affiliates or in the context of a merger, acquisition, sale or other transaction involving all or substantially all of the assets of the Party seeking to assign, in which case such Party in its sole discretion may assign its rights and obligations under this Agreement. Any permitted assignment shall be binding on the successors of the assigning Party.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">18.5</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Debarment</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lcagen represents and warrants that neither lcagen nor lcagen&#8217;s employees have ever been debarred under 21 U.S.C. &#167;335a, disqualified under 21 C.F.R. &#167;312.70 or &#167;812.119, sanctioned by a Federal Health Care Program (as defined in 42 U.S.C &#167;1320 a-7b(f)), including without limitation the federal Medicare or a state Medicaid program, or debarred, suspended, excluded or otherwise declared ineligible from any other similar Federal or state agency or program. ln the event lcagen or an employee of lcagen receives notice of debarment, suspension, sanction, exclusion, ineligibility or disqualification under the above-referenced statutes, lcagen shall immediately notify Roche in writing and Roche shall have the right, but not the obligation, to terminate this Agreement for breach, effective, at Roche&#8217;s option, immediately or at a specified future date.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">18.6</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lndependent Contractor</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">No employee or representative of either Party shall have any authority to bind or obligate the other Party to this Agreement for any sum or in any manner whatsoever or to create or impose any contractual or other liability on the other Party without said Party&#8217;s prior written approval. For all purposes, and not- withstanding any other provision of this Agreement to the contrary, lcagen legal relationship to Roche under this Agreement shall be that of independent contractor, and nothing contained in this Agreement shall be deemed or construed to create a partnership, joint venture, employment, franchise, agency or fiduciary relationship between the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">18.7</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Unenforceable Provisions and Severability</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lf any of the provisions of this Agreement are held to be void or unenforceable, then such void or unenforceable provisions shall be replaced by valid and enforceable provisions that will achieve as far as possible the economic business intentions of the Parties. However, the remainder of this Agreement will remain in full force and effect, provided that the material interests of the Parties are not affected, i.e. the Parties would presumably have concluded this Agreement without the unenforceable provisions.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">18.8</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Waiver</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The failure by either Party to require strict performance and/or observance of any obligation, term, provision or condition under this Agreement will neither constitute a waiver thereof nor affect in any way the right of the respective Party to require such performance and/or observance. The waiver by either Party of a breach of any obligation, term, provision or condition hereunder shall not constitute a waiver of any subsequent breach thereof or of any other obligation, term, provision or condition.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">18.9</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Appendices</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">All Appendices to this Agreement shall form an integral part to this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">18.10</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Entire Understanding</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This Agreement contains the entire understanding between the Parties hereto with respect to the within subject matter and supersedes any and all prior agreements, understandings and arrangements, whether written or oral.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">18.11</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Amendments</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">No amendments of the terms and conditions of this Agreement shall be binding upon either Party hereto unless in writing and signed by both Parties.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">18.12</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">lnvoices</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All invoices that are required or permitted hereunder shall be in writing and sent by lcagen to Roche at the following address or such other address as Roche may later provide:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Attn:[***]</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">18.13</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Notice</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All notices that are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:19.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">if to lcagen, to:</p></td><td style="vertical-align:top;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lcagen, LLC</p></td></tr><tr><td style="vertical-align:top;width:19.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:19.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn: [***]</p></td></tr><tr><td style="vertical-align:top;width:19.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: [***]</p></td></tr><tr><td style="vertical-align:top;width:19.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[no facsimile number provided]</p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:19.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:19.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">and:</p></td><td style="vertical-align:top;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">lcagen, LLC</p></td></tr><tr><td style="vertical-align:top;width:19.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">c/o Ligand Pharmaceuticals lncorporated</p></td></tr><tr><td style="vertical-align:top;width:19.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:19.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn: General Counsel</p></td></tr><tr><td style="vertical-align:top;width:19.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: [***]</p></td></tr><tr><td style="vertical-align:top;width:19.01%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[no facsimile number provided]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:19.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">if to Roche, to:</p></td><td style="vertical-align:top;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:19.16%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn: Legal Department</p></td></tr><tr><td style="vertical-align:top;width:19.16%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Facsimile No.: [***]</p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:19.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:19.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">and:</p></td><td style="vertical-align:top;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:19.16%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn. Corporate Secretary</p></td></tr><tr><td style="vertical-align:top;width:19.16%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Facsimile No.: [***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">[<i style="font-style:italic;">Signature Page Follows</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">IN WITNESS WHEREOF, the Parties have entered into this Amended and Restated License Agreement as of the date first set forth above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:43.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Icagen, LLC</b></p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12pt;"><td colspan="2" style="vertical-align:middle;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">[***]&#160;</p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.15pt;"><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:43.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">Manager</p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="5" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="5" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">F. Hoffmann-LaRoche Ltd</b></p></td></tr><tr style="height:12pt;"><td colspan="2" style="vertical-align:middle;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:3.5%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">[***]&#160;</p></td><td style="vertical-align:bottom;width:3.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:46.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">[***]&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:43.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:43.36%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Global Alliance&#160;&amp; Asset Director</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Hoffmann-LaRoche Ltd</b></p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12pt;"><td colspan="2" style="vertical-align:middle;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">[***]&#160;</p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:43.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:43.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Authorized Signatory</p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Appendix 15.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[***]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Target 2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;"><img src="ahpa-20220416xex10d27001.jpg" alt="Graphic" style="display:inline-block;height:67.5pt;width:177pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">++++NOT FOR RELEASE ++++ CONFIDENTIAL DRAFT FOR PARTNER REVIEW++++</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Contacts:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ligand Pharmaceuticals Incorporated</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patrick O&#8217;Brien</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email:&#160;&#160;investors@ligand.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Phone:&#160;&#160;(858) 550-7893</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Twitter:&#160;&#160;@Ligand LGND</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LHA Investor Relations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bruce Voss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email:&#160;&#160;bvoss@lhai.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Phone:&#160;&#160;(310) 691-7100</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Ligand Announces Icagen&#8217;s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><i style="font-style:italic;">Collaboration initiates second Roche program utilizing</i></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><i style="font-style:italic;">Icagen&#8217;s Ion Channel Drug Discovery Platform</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SAN DIEGO (May 29, 2020)&#8212;Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Icagen, a Ligand Company</b> announced today the expansion of Icagen&#8217;s license agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of neurological disorders, by adding a second program to the agreement. The new program incorporates Icagen&#8217;s ion channel technology and expertise and is directed at a specific novel ion channel target relevant to neurodegenerative disease. The new program is in addition to on-going work on another novel CNS target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">&#8220;Icagen&#8217;s collaboration with Roche was a key value-driver in the acquisition of the Icagen business, and we are very pleased to see this expansion and extension of the relationship,&#8221; said John Higgins, Chief Executive Officer of Ligand. &#8220;This type of deal fits perfectly within the Ligand strategy to establish and leverage partnerships with global leaders in the industry as they look to access our technology for their drug discovery and development needs. The Icagen team has been a great addition to Ligand&#8217;s business.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">&#8220;We are pleased to extend and expand our collaboration with Roche and its drug discovery team in Basel,&#8221; said Icagen Site Head Douglas Krafte, PhD. &#8220;Our initial neurology program with Roche continues to make great progress and we hope to assist Roche in bringing multiple meaningful therapies to patients in areas of neurological disease with major unmet needs through both our initial and this new program.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Terms of Expanded Icagen and Roche Collaboration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the terms of the license agreement, Roche made a cash upfront payment and will provide research funding to Icagen. In addition, Icagen is eligible to potentially receive development and commercial milestone payments of up to $274&#160;million and royalty payments should a drug be commercialized from any of the collaboration&#8217;s programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Icagen will be responsible for most preclinical activities up to lead optimization with both Icagen and Roche applying resources to identify candidates for entry into IND-enabling studies. Roche will be responsible for the further development and commercialization of the program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">About Icagen, a Ligand Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Icagen, a Ligand Company, is an early drug discovery company focused on ion channel and transporter drug discovery with research facilities located in Durham, N.C. Icagen partners with the pharmaceutical industry to develop first-in-class therapies for patients in need, typically under arrangements in which we work closely with our partners through the time of clinical candidate selection and our partners are responsible for the clinical development and commercialization. Icagen, a Ligand Company, is a subsidiary of Ligand Pharmaceuticals Incorporated. For more information, please visit www.ligand.com.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">About Ligand Pharmaceuticals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10pt;">Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Ligand&#8217;s OmniAb</font><sup style="font-size:6.37pt;vertical-align:top;">&#174;</sup><font style="font-size:10pt;"> technology platform is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. The Captisol</font><sup style="font-size:6.37pt;vertical-align:top;">&#174;</sup><font style="font-size:10pt;"> platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. The Vernalis Design Platform (VDP) integrates protein structure determination and engineering, fragment screening and molecular modeling, with medicinal chemistry, to help enable success in novel drug discovery programs against highly-challenging targets. Ab Initio</font><sup style="font-size:6.37pt;vertical-align:top;">&#8482;</sup><font style="font-size:10pt;"> technology and services for the design and preparation of customized antigens enable the successful discovery of therapeutic antibodies against difficult-to-access cellular targets. Icagen, a Ligand Company, focuses on ion channel and transporter drug discovery as it partners with the pharmaceutical industry to develop first-in-class therapies for patients in need. Ligand has established multiple alliances, licenses and other business relationships with the world&#8217;s leading pharmaceutical companies including Amgen, Merck, Pfizer, Sanofi, Janssen, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Follow Ligand on Twitter @Ligand_LGND.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand&#8217;s judgment as of the date of this release. Words such as &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; and &#8220;will,&#8221; and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding: the potential benefits of the Icagen/Roche license and collaboration agreement programs; Ligand&#8217;s belief that recent events in its partnered programs will enhance value; whether Ligand&#8217;s pipeline will provide a source of growth and future diversified cash flow; the potential entry into new license or partnering agreements; the timing of the initiation or completion of preclinical studies and clinical trials by Ligand and its partners; the timing of product launches by Ligand or its partners; and guidance regarding the full-year 2020 financial results. Actual events or results may differ from Ligand&#8217;s expectations due to risks and uncertainties inherent in Ligand&#8217;s business, including, without limitation: there can be no assurance that either the original or expansion Roche program with Icagen will be able to successfully identify any desirable drug candidates or that any drug candidates developed in such programs would be clinically or commercially successful, all of which might result in the potential milestone payments and royalties not being earned; Ligand may not receive expected revenue from royalties, Captisol sales, contract and service revenue; the COVID-19 pandemic has disrupted Ligand&#8217;s and its partners&#8217; business, including delaying manufacturing, pre-clinical studies and clinical trials and product sales, and impairing global economic activity, all of which could materially and adversely impact Ligand&#8217;s results of operations and financial condition; Ligand and its partners may not be able to timely or successfully advance any product(s) in its internal or partnered pipeline; Ligand may not achieve its guidance for 2020; development of product candidates by Ligand partners may not be successful; Ligand may not be able to create future revenues and cash flows by developing innovative therapeutics; results of any clinical study may not be timely, favorable or confirmed by later studies; products under development by Ligand or its partners may not receive regulatory approval; there may not be a market for the product(s) even if successfully developed and approved; Ligand or its partners may not be able to protect their intellectual property and patents covering certain products and technologies may be challenged or invalidated; Ligand&#8217;s partners may terminate any of its agreements or development or commercialization of any of its products; Ligand may not generate expected revenues under its existing license agreements; Ligand and its partners may experience delays in the commencement, enrollment, completion or analysis of clinical testing for its product candidates, or significant issues regarding the adequacy of its clinical trial designs or the execution of its clinical trials, which could result in increased costs and delays, or limit Ligand&#8217;s ability to obtain regulatory approval; unexpected adverse side effects or inadequate therapeutic efficacy of Ligand&#8217;s product(s) could delay or prevent regulatory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">approval or commercialization; Ligand may not be able to successfully implement its strategic growth plan and continue the development of its proprietary programs; and ongoing or future litigation could expose Ligand to significant liabilities and have a material adverse effect on the company. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand&#8217;s stock price. Additional information concerning these and other risk factors affecting Ligand can be found in prior press releases available at www.ligand.com as well as in Ligand&#8217;s public periodic filings with the Securities and Exchange Commission available at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release, including the possibility of additional contract revenue we may receive. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Amendment to Amended and Restated</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This amendment (&#8220;<b style="font-weight:bold;">First Amendment</b>&#8221;), effective as of June&#160;30, 2021 (&#8220;<b style="font-weight:bold;">First Amendment Effective Date</b>&#8221;), is made to the Amended and Restated License Agreement (&#8220;<b style="font-weight:bold;">Agreement</b>&#8221;), made on May&#160;29, 2020, by and between F. Hoffmann-La Roche Ltd (&#8220;<b style="font-weight:bold;">Roche Basel</b>&#8221;) and Hoffmann-La Roche Inc. (&#8220;<b style="font-weight:bold;">Roche US</b>&#8221;; Roche Basel and Roche US together referred to as &#8220;<b style="font-weight:bold;">Roche</b>&#8221;), on the one hand, and Icagen, LLC <b style="font-weight:bold;">(</b>&#8220;<b style="font-weight:bold;">Icagen</b>&#8221;) on the other hand. Each capitalized term not defined herein shall have the meaning ascribed in the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Roche and Icagen want to add [***] as a third Target under the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this First Amendment and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Agreement shall be amended as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Section&#160;1.36 shall be deleted in its entirety and replaced with the following new Section&#160;1.36:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">1.36 FTE Rate</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;<b style="font-weight:bold;">FTE Rate</b>&#8221; shall mean the amount of [***] US dollars (US$[***]) per FTE, on a fully burdened cost basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Section&#160;1.73 shall be deleted in its entirety and replaced with the following new Section&#160;1.73:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.73 Research Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;<b style="font-weight:bold;">Research Plan</b>&#8221; shall mean the plan of research agreed by the Parties for the conduct of activities designed to identify, research and develop compounds that modulate a Target [***]) and outlining the work expected to be performed and budget. The initial Research Plans for Target 1, Target 2 and Target 3 are attached as Appendix 1.73.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Section&#160;1.75 shall be deleted in its entirety and replaced with the following new Section&#160;1.75:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.75 Research Term</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The term &#8220;<b style="font-weight:bold;">Research Term</b>&#8221; shall mean the period of time in which a Research Program shall be conducted, commencing for Target 1 on the Effective Date and continuing until [***] after the Effective Date, and for Target 2 commencing on the date the Research Program for Target 2 begins and continuing for [***] thereafter, and for Target 3 commencing on the date the Research Program for Target 3 begins and continuing for [***] thereafter, in each case unless extended pursuant to Section&#160;3.1.5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Section&#160;1.84 shall be deleted in its entirety and replaced with the following new Section&#160;1.84:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.84 Target</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;<b style="font-weight:bold;">Target</b>&#8221; shall mean (i) [***] (&#8220;<b style="font-weight:bold;">Target 1</b>&#8221;), (ii) [***] (&#8220;<b style="font-weight:bold;">Target 2</b>&#8221;), (iii) [***] (&#8220;<b style="font-weight:bold;">Target 3</b>&#8221;), or (iv)&#160;a subsequent target agreed by the Parties (&#8220;<b style="font-weight:bold;">Target 4</b>&#8221;, et seq.).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;1.90 shall be amended by adding a new row at the end of the table therein to read in full as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Target 4</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.84</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Section&#160;3.1.1 shall be deleted in its entirety and replaced with the following new Section&#160;3.1.1:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Scope</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Roche and Icagen shall conduct mutually agreed Research Programs each pursuant to a Research Plan during the Research Term. The activities conducted in connection with a Research Program will be overseen by the JRC with the objective to discover Compounds and identify Compounds meeting the CCS Criteria. A Research Plan will be divided in several phases as shown below:</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;" align="center"><tr><td style="vertical-align:top;width:37.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Phase</p></td><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Icagen Responsibility</p></td><td style="vertical-align:top;width:30.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roche Responsibility</p></td></tr><tr><td style="vertical-align:top;width:37.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preparation</p></td><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:30.96%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:37.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finding Qualified Hits</p></td><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:30.96%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:37.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From qualified hits to LSI</p></td><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:30.96%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:37.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From LSI to CLS</p></td><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:30.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:37.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From CLS to CCS</p></td><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:30.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the Research Term for Target 1, as described in the Research Plan for Target 1, there shall be between [***] and [***] FTEs per year at Icagen (for a total of [***] FTEs up to CLS) working on the Research Program for Target 1. During the Research Term for Target 2, as described in the Research Plan for Target 2, there shall be between [***] and [***] FTEs per year at Icagen (for a total of [***] FTEs up to CLS) working on the Research Program for Target 2. During the Research Term for Target 3, as described in the Research Plan for Target 3, there shall be between [***] and [***] FTEs per year at Icagen (for a total of [***] FTEs up to CLS) working on the Research Program for Target 3. Specific FTE requirements for future Targets (i.e., Target 4, etc.) will be determined by Research Plans specific to those targets, but are anticipated to be similar to totals for Target 1 and Target 2 for programs beginning at a similar stage. Additional FTEs, if required, will be defined by JRC for CLS to CCS activities. FTEs shall be charged at the applicable FTE Rate pursuant to Section&#160;1.36. Roche will also pay any other external expenses as budgeted and set forth in each Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">If CLS for Target 1 has been achieved within [***] after the Effective Date, or if CLS for Target 2 has been achieved within [***] after the Parties agreeing to begin the Target 2 Research Program, then the relevant Research Term will terminate upon such achievement and no further FTE funding commitment from Roche will remain, unless otherwise agreed by the JRC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Section&#160;7.2 shall be deleted in its entirety and replaced with the following new Section&#160;7.2:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">7.2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">New Program Initiation Payments</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For Target 2 and each Target thereafter, upon the Parties agreeing to begin a new Research Program and within [***] after receipt of an invoice from Icagen, Roche shall pay to Icagen [***] US dollars (US$[***]). [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Appendices 1.8, 1.12, 1.57, 1.68, and 1.73 shall be replaced with the attached new appendices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Except as modified herein, all terms and conditions of the Agreement shall remain in full force and effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">[Signature Page Follows]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the Parties have entered into this First Amendment as of the First Amendment Effective Date.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:43.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Icagen, LLC</b></p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12pt;"><td colspan="2" style="vertical-align:middle;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">[***]&#160;</p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.15pt;"><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:43.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">Manager</p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="5" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="5" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">F. Hoffmann-La Roche Ltd</b></p></td></tr><tr style="height:12pt;"><td colspan="2" style="vertical-align:middle;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:3.5%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">[***]&#160;</p></td><td style="vertical-align:bottom;width:3.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:46.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">[***]&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:43.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:bottom;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:43.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Authorized Signatory</p></td><td style="vertical-align:bottom;width:3.5%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Global Alliance&#160;&amp; Asset Director</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Hoffmann-La Roche Inc.</b></p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12pt;"><td colspan="2" style="vertical-align:middle;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">[***]&#160;</p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:43.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:43.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Authorized Signatory</p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>7
<FILENAME>ahpa-20220416xex21d1.htm
<DESCRIPTION>EXHIBIT-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/27/2022 11:11:12 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">List of Principal Subsidiaries of OmniAb, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the separation of OmniAb, Inc. from Ligand Pharmaceuticals Incorporated, the following entities will become wholly owned subsidiaries of OmniAb, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:48.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Wholly Owned Subsidiary</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:48.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Place of Incorporation</p></td></tr><tr><td style="vertical-align:top;width:48.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ab Initio Biotherapeutics, Inc.</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware</p></td></tr><tr><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Crystal Bioscience, Inc.</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">California</p></td></tr><tr><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Icagen, LLC</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware</p></td></tr><tr><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taurus Biosciences, LLC</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware</p></td></tr><tr><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">xCella Biosciences, Inc.</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>ahpa-20220416xex23d1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/27/2022 11:11:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#8217;S CONSENT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We consent to the inclusion in this Registration Statement of Avista Public Acquisition Corp. II (the &#8220;Company&#8221;) on Form S-4 of our report dated March 25, 2022, which includes an explanatory paragraph as to the Company&#8217;s ability to continue as a going concern with respect to our audit of the financial statements of Avista Public Acquisition Corp. II as of December 31, 2021 and for the period from February 5, 2021 (inception) through December 31, 2021, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading &#8220;Experts&#8221; in such Prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">/s/ Marcum LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marcum LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, New York</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 27, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>9
<FILENAME>ahpa-20220416xex23d2.htm
<DESCRIPTION>EXHIBIT-23.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/27/2022 11:11:17 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We consent to the reference to our firm under the caption &quot;Experts&quot; and to the use of our report dated April 27, 2022, with respect to the combined financial statements of OmniAb, Inc. included in the Proxy Statement of Avista Public Acquisition Corp. II. that is made a part of the Registration Statement (Form S-4) and Prospectus of Avista Public Acquisition Corp. II. for the registration of shares of its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Ernst &amp; Young LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">San Diego, California</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 27, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>10
<FILENAME>ahpa-20220416xex99d1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/27/2022 11:11:21 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="ahpa-20220416xex99d1001.jpg" alt="New Microsoft Word Document_source_page_1.gif" style="display:inline-block;height:684pt;width:505.56pt;"></p></td><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="color:#ffffff;">20140 Avista Public Acquisition Corp. II Proxy Card REV1 Front YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY. Vote by Internet - QUICK &#61512;&#61512;&#61512; EASY IMMEDIATE - 24 Hours a Day, 7 Days a Week or by Mail Your Internet vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed and returned your proxy card. Votes submitted electronically over the Internet must be received by 11:59 p.m., Eastern Time, on Xxxxxx XX, 2022. INTERNET &#8211; www.cstproxyvote.com Use the Internet to vote your proxy. Have your proxy card available when you access the above website. Follow the prompts to vote your shares. AVISTA PUBLIC ACQUISITION CORP. II Vote at the Meeting &#8211; If you plan to attend the virtual online extraordinary general meeting, you will need your 12 digit control number to vote electronically at the extraordinary general meeting. To attend: https://www.cstproxy.com/[X]/sm2022 MAIL &#8211; Mark, sign and date your proxy card and return it in the postage-paid envelope provided. &#61555; FOLD HERE &#8226; DO NOT SEPARATE &#8226; INSERT IN ENVELOPE PROVIDED &#61555; AVISTA PUBLIC ACQUISITION CORP. II The undersigned appoints Xxxxxx Xxxxx and Xxxxxx Xxxxx, and each of them, as proxies, each with the power to appoint his substitute, and authorizes each of them to represent and to vote, as designated on the reverse hereof, all of the shares of common stock of Avista Public Acquisition Corp. II held of record by the undersigned at the close of business on Xxxx xx, 2022 at the extraordinary general meeting of Avista Public Acquisition Corp. II to be held virtually at: https://www.cstproxy.com/[X]/sm2022 on Xxxx xx, 2022, at XX:00 a.m. or at any adjournment or postponement thereof. THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED AS INDICATED. IF NO CONTRARY INDICATION IS MADE, THE PROXY WILL BE VOTED IN FAVOR OF ELECTING THE SEVEN NOMINEES TO THE BOARD OF DIRECTORS, AND IN FAVOR PROPOSALS 1 THROUGH 9, AND IN ACCORDANCE WITH THE JUDGMENT OF THE PERSONS NAMED AS PROXY HEREIN ON ANY OTHER MATTERS THAT MAY PROPERLY COME BEFORE THE ANNUAL MEETING. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. PLEASE MARK, SIGN, DATE AND RETURN THE PROXY CARD PROMPTLY. (Continued, and to be marked, dated and signed, on the other side) PLEASE DO NOT RETURN THE PROXY CARD IF YOU ARE VOTING ELECTRONICALLY. </font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:2pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="ahpa-20220416xex99d1002.jpg" alt="New Microsoft Word Document_source_page_2.gif" style="display:inline-block;height:690pt;left:0.3%;padding-bottom:0pt;position:relative;top:0pt;width:510pt;"></p></td><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="color:#ffffff;">20140 Avista Public Acquisition Corp. II Proxy Card Rev2 Back Important Notice Regarding the Internet Availability of Proxy Materials for the extraordinary general meeting of Avista Public Acquisition Corp. II PROXY CARD THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; PROPOSALS 1 THROUGH 9. Please mark your votes like this Shareholder Proposal No. 1 &#8212; The Business Combination Proposal &#8212; a proposal to approve by special resolution and adopt (i) the Agreement and Plan of Merger, dated as of March 23, 2022 (the &#8220;Merg-FOR AGAINST ABSTAIN 4f. Delaware as Exclusive Forum &#8211; To approve and adopt provisions in the Proposed Certificate of Incorporation to provide that, unless New OmniAb consents in writing to the selection of an alternative FOR AGAINST ABSTAIN er Agreement&#8221;), by and among APAC, Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#8220;Ligand&#8221;), OmniAb, Inc., a Delaware corporation and wholly-owned subsidiary of Ligand (&#8220;OmniAb&#8221;), and Orwell Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of APAC, (ii) the Transaction Documents (as defined in the Merger Agreement) and (iii) each of the trans-actions contemplated thereby, in each case, in accordance with the terms and subject to the conditions set forth in the Merger Agreement and such Transaction Documents, as more fully described elsewhere in the accompanying proxy state-ment/prospectus/information statement (the &#8220;Business Combination Proposal&#8221;). forum, the Court of Chancery of the State of Delaware shall be the sole and ex-clusive forum for the types of actions or proceedings under Delaware statutory or common law for the actions described in the proxy statement/prospectus/ information statement. 5. Proposal No. 5 &#8212; The Stock Issuance Proposal &#8212; a proposal to approve by ordinary resolution, for the purposes of complying with the applicable provisions of Nasdaq Rule 5635, the issuance of shares of common FOR AGAINST ABSTAIN stock, par value $0.0001, of New OmniAb pursuant to (a) the Domestication, (b) the Forward Purchase, (c) the Redemption Backstop and (d) the Merger, as each of the capitalized terms used in clauses (b), (c) and (d) are defined in the Merger Agreement and described in the accompanying proxy statement/prospectus/in-formation statement (the &#8220;Stock Issuance Proposal&#8221;). Proposal No. 2 &#8212; The Domestication Proposal &#8212; a proposal to approve by special resolution the change of APAC&#8217;s jurisdiction of incorporation (the &#8220;Domestica-tion&#8221;), by deregistering as an exempted company in the FOR AGAINST ABSTAIN Cayman Islands and continuing and domesticating under the name &#8220;OmniAb, Inc.&#8221; as a corporation incorporated under the laws of the State of Delaware (the &#8220;Domestication Proposal&#8221;). 6. Proposal No. 6 &#8212; The Incentive Plan Proposal &#8212; a proposal to approve by ordinary resolution, the Omni-Ab, Inc. 2022 Incentive Award Plan (the &#8220;Incentive Plan Proposal&#8221;) 7. Proposal No. 7 &#8212; The ESPP Proposal &#8212; a proposal to approve by ordinary resolution, the OmniAb, Inc. 2022 Employee Stock Purchase Plan (the &#8220;ESPP Proposal&#8221;). FOR AGAINST ABSTAIN Proposal No. 3 &#8212; The Organizational Documents Proposal &#8212; a proposal to approve by special resolution and adopt the proposed new certificate of incorporation (the &#8220;Proposed Certificate of Incorporation&#8221;) and the pro-FOR AGAINST ABSTAIN FOR AGAINST ABSTAIN posed new bylaws (the &#8220;Proposed Bylaws&#8221;) of APAC after giving effect to the Domestication (&#8220;New OmniAb&#8221;) (the &#8220;Organizational Documents Proposal&#8221;). Proposal No. 4 &#8212; The Non-Binding Governance Proposals &#8212; a proposal to approve a non-binding advisory basis, certain material differences between APAC&#8217;s Amended and Restated Memorandum and Articles of Association (as it may be amended from time to time, the &#8220;Cayman Constitutional Documents&#8221;) and the Proposed Certificate of Incorporation and Proposed Bylaws, presented separately in accordance with the United States Securities and Exchange Com-mission requirements (collectively, the &#8220;Non-Binding Governance Proposals&#8221;). Proposal No. 8 &#8212; The Director Election Proposal &#8212; a proposal to elect seven directors to serve staggered terms on the New OmniAb Board upon the con-summation of the Business Combination until the first, second and third annual meeting of stockholders following the date of effectiveness of the Proposed Cer-tificate of Incorporation, as applicable, or until the election and qualification of their respective successors in office, subject to their earlier death, resignation or removal (the &#8220;Director Election Proposal&#8221;). FOR AGAINST ABSTAIN Class I Nominees: 4a. Change the Authorized Capital Stock &#8211; To approve and adopt provisions in the Proposed Cer-tificate of Incorporation to authorize the change in the authorized capital stock of APAC from (i) 500,000,000 FOR AGAINST ABSTAIN 8a. Matthew W. Foehr 8b. Jennifer Cochran APAC Class A Ordinary Shares, 50,000,000 APAC Class B Ordinary Shares and 5,000,000 preference shares, par value $0.0001 per share, of APAC to (ii) 1,000,000,000 shares of New OmniAb common stock and 100,000,000 shares of New OmniAb preferred stock. FOR AGAINST ABSTAIN Class II Nominees: 8c. Sarah Boyce 4b. Change the Stockholder Vote Required to Amend the Certificate of Incorporation &#8211; To approve and adopt provisions in the Proposed Cer-tificate of Incorporation to require that the affirmative 8d. Sunil Patel FOR AGAINST ABSTAIN Class III Nominees: FOR AGAINST ABSTAIN 8e. John L. Higgins vote of holders of at least 66 2/3% of the voting power of all then-outstanding New OmniAb Common Stock entitled to vote generally in the election of direc-tors, voting together as a single class, to adopt, amend or repeal the Proposed Bylaws and the provisions in the Proposed Certificate of Incorporation related to preferred stock, the board of directors, stockholders, limitation on liability and indemnification of directors, forum selection and amendments to the Pro-posed Certificate. 8f. Carolyn Bertozzi 8g. [&#9679;] 9. Proposal No. 9 &#8212; The Adjournment Proposal &#8212; to consider and vote upon a proposal to approve the ad-journment of the extraordinary general meeting to a later date or dates, if necessary, to permit further solicitation FOR AGAINST ABSTAIN 4c. Establish a Classified Board of Directors &#8211; To approve and adopt provisions in the Proposed Cer-tificate of Incorporation to would divide the New Om-niAb Board of directors into three classes, with only FOR AGAINST ABSTAIN and vote of proxies in the event that there are insufficient shares represented to constitute a quorum necessary to conduct business at the extraordinary general meeting or for the approval of one or more proposals at the extraordinary general meeting or to the extent necessary to ensure that any required supplement or amendment to the accompanying proxy statement/prospectus/information state-ment is provided to APAC shareholders (the &#8220;Adjournment Proposal&#8221;). one class of directors being elected in each year and each class serving a three-year term. 4d. Action by Written Consent Stockholders &#8211; To approve and adopt provisions in the Proposed Certificate of Incorporation to provide that any action required or permitted to be taken by the New OmniAb FOR AGAINST ABSTAIN Stockholders may be effected at a duly called annual or special meeting of such stockholders, and may not be taken by written consent. 4e. Removal of Directors &#8211; To approve and adopt provisions in the Proposed Certificate of Incorporation to require the affirmative vote of the holders of at least 66 2/3% of the voting power of the outstanding shares FOR AGAINST ABSTAIN CONTROL NUMBER of New OmniAb entitled to vote to remove a director for cause. Signature Signature, if held jointly Date , 2022 Note: Please sign exactly as name appears hereon. When shares are held by joint owners, both should sign. When signing as attorney, executor, administrator, trustee, guardian, or corporate officer, please give title as such. X </font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>11
<FILENAME>ahpa-20220416xex99d2.htm
<DESCRIPTION>EXHIBIT-99.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/27/2022 11:11:22 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the filing by Avista Public Acquisition Corp. II of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a member of the board of directors of Avista Public Acquisition Corp. II following the consummation of the business combination. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: April 27, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ John L. Higgins</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: John L. Higgins</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>12
<FILENAME>ahpa-20220416xex99d3.htm
<DESCRIPTION>EXHIBIT-99.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/27/2022 11:11:25 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the filing by Avista Public Acquisition Corp. II of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a member of the board of directors of Avista Public Acquisition Corp. II following the consummation of the business combination. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: April 27, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Sarah Boyce</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Sarah Boyce</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>13
<FILENAME>ahpa-20220416xex99d4.htm
<DESCRIPTION>EXHIBIT-99.4
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/27/2022 11:11:27 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the filing by Avista Public Acquisition Corp. II of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a member of the board of directors of Avista Public Acquisition Corp. II following the consummation of the business combination. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: April 27, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jennifer Cochran</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Jennifer Cochran, Ph.D.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>14
<FILENAME>ahpa-20220416xex99d5.htm
<DESCRIPTION>EXHIBIT-99.5
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/27/2022 11:11:30 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the filing by Avista Public Acquisition Corp. II of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a member of the board of directors of Avista Public Acquisition Corp. II following the consummation of the business combination. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: April 27, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Sunil Patel</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Sunil Patel</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>15
<FILENAME>ahpa-20220416xex99d6.htm
<DESCRIPTION>EXHIBIT-99.6
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/27/2022 11:11:33 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the filing by Avista Public Acquisition Corp. II of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a member of the board of directors of Avista Public Acquisition Corp. II following the consummation of the business combination. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: April 27, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Carolyn R. Bertozzi</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Carolyn R. Bertozzi, Ph.D.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.7
<SEQUENCE>16
<FILENAME>ahpa-20220416xex99d7.htm
<DESCRIPTION>EXHIBIT-99.7
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/27/2022 11:11:35 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.7</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the filing by Avista Public Acquisition Corp. II of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a member of the board of directors of Avista Public Acquisition Corp. II following the consummation of the business combination. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: April 27, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Matthew W. Foehr</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Matthew W. Foehr</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>17
<FILENAME>ahpa-20220416xexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/27/2022 11:11:38 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Exhibit 107</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">EX-FILING FEES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Calculation of Filing Fee Tables</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">Form S-4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Form Type)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">Avista Public Acquisition Corp. II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="white-space:pre-wrap;"> (Exact Name of Registrant as Specified in its Charter)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Table 1: Newly Registered and Carry Forward Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div style="margin-left:-0.4pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:101.03%;"><tr style="height:1pt;"><td style="vertical-align:top;width:6.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:14.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:5.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:72pt;"><td style="vertical-align:top;width:6.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.24%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Security</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;width:7.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Security</b><br><b style="font-weight:bold;">Class</b><br><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;width:8.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fee</b><br><b style="font-weight:bold;">Calculation</b><br><b style="font-weight:bold;">or Carry</b><br><b style="font-weight:bold;">Forward</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Rule</b></p></td><td style="vertical-align:bottom;width:9.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b><br><b style="font-weight:bold;">Registered</b></p></td><td style="vertical-align:bottom;width:7.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Proposed</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Maximum</b><br><b style="font-weight:bold;">Offering</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Price</b><br><b style="font-weight:bold;">Per Unit</b></p></td><td style="vertical-align:bottom;width:14.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maximum</b><br><b style="font-weight:bold;">Aggregate</b><br><b style="font-weight:bold;">Offering Price</b></p></td><td style="vertical-align:bottom;width:3.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fee </b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Rate</b></p></td><td style="vertical-align:bottom;width:9.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount of</b><br><b style="font-weight:bold;">Registration</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Fee</b></p></td><td style="vertical-align:bottom;width:6.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carry</b><br><b style="font-weight:bold;">Forward</b><br><b style="font-weight:bold;">Form</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;width:5.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carry</b><br><b style="font-weight:bold;">Forward</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">File</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:6.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carry</b><br><b style="font-weight:bold;">Forward</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Initial</b><br><b style="font-weight:bold;">Effective</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:8.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing Fee</b><br><b style="font-weight:bold;">Previously</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Paid</b><br><b style="font-weight:bold;">In </b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Connection</b><br><b style="font-weight:bold;">with Unsold</b><br><b style="font-weight:bold;">Securities</b><br><b style="font-weight:bold;">to be Carried</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Forward</b></p></td></tr><tr style="height:15.75pt;"><td colspan="13" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Newly Registered Securities</b></p></td></tr><tr><td style="vertical-align:middle;width:6.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Fees to Be Paid</p></td><td style="vertical-align:top;width:6.24%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Equity</p></td><td style="vertical-align:top;width:7.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 1.45pt;"><font style="font-size:9pt;">New OmniAb Common Stock</font>(1) (2)</p></td><td style="vertical-align:top;width:8.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">457(f)(1)</p></td><td style="vertical-align:top;width:9.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">137,612,465</p></td><td style="vertical-align:top;width:7.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><font style="font-size:9pt;">$10.07&#160;</font>(6)</p></td><td style="vertical-align:top;width:14.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><font style="font-size:9pt;">$ 1,385,757,522.55</font>(6)</p></td><td style="vertical-align:top;width:3.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(8)</p></td><td style="vertical-align:top;width:9.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$128,459.73 </p></td><td style="vertical-align:top;width:6.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:6.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:8.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:middle;width:6.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Fees to Be Paid</p></td><td style="vertical-align:top;width:6.24%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Equity</p></td><td style="vertical-align:top;width:7.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 1.45pt;"><font style="font-size:9pt;">Warrants to acquire New OmniAb Common Stock</font>(3) (2)</p></td><td style="vertical-align:top;width:8.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">457(f)(1)</p></td><td style="vertical-align:top;width:9.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">7,666,667</p></td><td style="vertical-align:top;width:7.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><font style="font-size:9pt;">$0.65&#160;</font>(7)</p></td><td style="vertical-align:top;width:14.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><font style="font-size:9pt;">$4,983,333.55</font>(7)</p></td><td style="vertical-align:top;width:3.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(8)</p></td><td style="vertical-align:top;width:9.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$461.96</p></td><td style="vertical-align:top;width:6.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:6.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:8.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:middle;width:6.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Fees to Be Paid</p></td><td style="vertical-align:top;width:6.24%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Equity Awards</p></td><td style="vertical-align:top;width:7.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 1.45pt;"><font style="font-size:9pt;">New OmniAb Restricted Stock Units</font>(4)</p></td><td style="vertical-align:top;width:8.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">457(f)(1)</p></td><td style="vertical-align:top;width:9.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">489,715</p></td><td style="vertical-align:top;width:7.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><font style="font-size:9pt;">$10.07</font>&#160;(6)</p></td><td style="vertical-align:top;width:14.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><font style="font-size:9pt;">$4,931,430.05</font>(6)</p></td><td style="vertical-align:top;width:3.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(8)</p></td><td style="vertical-align:top;width:9.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$457.15</p></td><td style="vertical-align:top;width:6.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;width:6.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Fees to Be Paid</p></td><td style="vertical-align:top;width:6.24%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Equity Awards</p></td><td style="vertical-align:top;width:7.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 1.45pt;"><font style="font-size:9pt;">New OmniAb Performance Stock Units</font>(5)</p></td><td style="vertical-align:top;width:8.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">457(f)(1)</p></td><td style="vertical-align:top;width:9.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">303,913</p></td><td style="vertical-align:top;width:7.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><font style="font-size:9pt;">$10.07</font>&#160;(6)</p></td><td style="vertical-align:top;width:14.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><font style="font-size:9pt;">$3,060,403.91</font>(6)</p></td><td style="vertical-align:top;width:3.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(8)</p></td><td style="vertical-align:top;width:9.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$283.70</p></td><td style="vertical-align:top;width:6.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="13" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carry Forward Securities</b></p></td></tr><tr><td style="vertical-align:middle;width:6.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Carry Forward Securities</p></td><td style="vertical-align:top;width:6.24%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:top;width:7.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:top;width:8.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:top;width:9.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:top;width:7.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:14.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:top;width:3.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:9.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:6.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:top;width:5.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:top;width:6.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:top;width:8.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td></tr><tr><td style="vertical-align:top;width:6.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:top;width:31.1%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Offering Amounts</b></p></td><td style="vertical-align:top;width:7.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:14.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> $1,398,732,690.06</font></p></td><td style="vertical-align:top;width:3.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:9.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$129,662.54 </p></td><td style="vertical-align:top;width:6.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:6.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:8.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:6.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:31.1%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Fees Previously Paid</b></p></td><td style="vertical-align:top;width:7.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:top;width:6.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:31.1%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Fee Offsets</b></p></td><td style="vertical-align:top;width:7.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:top;width:6.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:top;width:31.1%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Fee Due</b></p></td><td style="vertical-align:top;width:7.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:14.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:9.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$129,662.54</p></td><td style="vertical-align:top;width:6.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:6.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:8.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The number of shares of common stock, par value $0.0001 per share (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">New OmniAb Common Stock</u>&#8221;), of Avista Public Acquisition Corp. II (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">APAC</u>&#8221;, and after the domestication (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Domestication</u>&#8221;) of APAC as a corporation incorporated in the State of Delaware, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">New OmniAb</u>&#8221;) being registered is equal to 137,612,465 and represents (i) 23,000,000 Class A ordinary shares, par value $0.0001 per share, of APAC (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">APAC Class A ordinary shares</u>&#8221;) underlying units issued in APAC&#8217;s initial public offering which will be canceled and automatically converted, on a one-for-one basis, into shares of New OmniAb Common Stock; (ii) 5,750,000 Class B ordinary shares, par value $0.0001 per share, of APAC held by Avista Acquisition LP II (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sponsor</u>&#8221;) and certain of APAC&#8217;s directors, which will be canceled and automatically converted, on a one-for-one basis, into shares of New OmniAb Common Stock; (iii) 15,000,000 OmniAb Earnout Shares (as defined in that certain Agreement and Plan of Merger, dated March 23, 2022 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Agreement</u>&#8221;), by and among APAC, Ligand Pharmaceuticals Incorporated, OmniAb, Inc. (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OmniAb</u>&#8221;) and Orwell Merger Sub Inc.); (iv) 82,431,885 shares of New OmniAb Common Stock to be issued in connection with the Merger to certain holders of shares of common stock of OmniAb after the Distribution and as of immediately prior to the consummation of the Merger (each as defined in the Merger Agreement) and (v) 11,430,580 shares of New OmniAb Common Stock underlying the New OmniAb Equity Awards.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Pursuant to Rule 416(a) of Securities Act of 1933, as amended (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities Act</u>&#8221;), there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The number of warrants to acquire shares of New OmniAb Common Stock being registered represents 7,666,667 public warrants.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(4)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The number of outstanding OmniAb, Inc. restricted stock units to be converted into New OmniAb restricted stock units following the consummation of the Merger.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(5)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The number of outstanding OmniAb, Inc. performance stock units to be converted into New OmniAb performance stock units following the consummation of the Merger.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(6)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the APAC Class A ordinary shares on the Nasdaq Capital Market (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nasdaq</u>&#8221;) on April 22, 2022 ($10.07 per APAC Class A ordinary share). This calculation is in accordance with Rule 457(f)(1) of the Securities Act.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(7)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the APAC public warrants on the Nasdaq on April 21, 2022 ($0.65 per warrant). This calculation is in accordance with Rule 457(f)(1) of the Securities Act.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(8)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Applicable fee rate is $92.70 per $1,000,000.</p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>ahpa-20220416.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8119.21675 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/27/2022 11:10:01 PM-->
<!--Modified on: 4/27/2022 11:10:01 PM-->
<xsd:schema targetNamespace="http://AvistaPublicAcquisitionCorpII.com/20220416" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ahpa="http://AvistaPublicAcquisitionCorpII.com/20220416">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet" id="StatementBalanceSheet">
        <link:definition>00100 - Statement - BALANCE SHEET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations" id="StatementStatementOfOperations">
        <link:definition>00200 - Statement - STATEMENT OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows" id="StatementStatementOfCashFlows">
        <link:definition>00400 - Statement - STATEMENT OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails" id="DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails">
        <link:definition>40101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical" id="StatementBalanceSheetParenthetical">
        <link:definition>00105 - Statement - BALANCE SHEET (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit" id="StatementStatementOfChangesInShareholdersDeficit">
        <link:definition>00300 - Statement - STATEMENT OF CHANGES IN SHAREHOLDERS' DEFICIT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacement" id="DisclosurePrivatePlacement">
        <link:definition>10401 - Disclosure - PRIVATE PLACEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>10501 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails">
        <link:definition>40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net income per ordinary share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomeLossPerOrdinaryShareDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNetIncomeLossPerOrdinaryShareDetails">
        <link:definition>40205 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Income (Loss) Per Ordinary Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails" id="DisclosureInitialPublicOfferingDetails">
        <link:definition>40301 - Disclosure - INITIAL PUBLIC OFFERING (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails" id="DisclosurePrivatePlacementDetails">
        <link:definition>40401 - Disclosure - PRIVATE PLACEMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" id="DisclosureRelatedPartyTransactionsFounderSharesDetails">
        <link:definition>40501 - Disclosure - RELATED PARTY TRANSACTIONS - Founder Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>40502 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails" id="DisclosureCommitmentsForwardPurchaseAgreementDetails">
        <link:definition>40602 - Disclosure - COMMITMENTS - Forward Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitPreferredStockSharesDetails" id="DisclosureShareholdersDeficitPreferredStockSharesDetails">
        <link:definition>40701 - Disclosure - SHAREHOLDERS' DEFICIT - Preferred Stock Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails" id="DisclosureShareholdersDeficitCommonStockSharesDetails">
        <link:definition>40702 - Disclosure - SHAREHOLDERS' DEFICIT - Common Stock Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails" id="DisclosureShareholdersDeficitWarrantsDetails">
        <link:definition>40703 - Disclosure - SHAREHOLDERS' DEFICIT - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>40801 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidity" id="DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidity">
        <link:definition>10101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOffering" id="DisclosureInitialPublicOffering">
        <link:definition>10301 - Disclosure - INITIAL PUBLIC OFFERING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitments" id="DisclosureCommitments">
        <link:definition>10601 - Disclosure - COMMITMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficit" id="DisclosureShareholdersDeficit">
        <link:definition>10701 - Disclosure - SHAREHOLDERS' DEFICIT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>10801 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassOrdinarySharesSubjectToPossibleRedemptionDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesClassOrdinarySharesSubjectToPossibleRedemptionDetails">
        <link:definition>40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A Ordinary Shares Subject to Possible Redemption (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithInitialPublicOfferingDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithInitialPublicOfferingDetails">
        <link:definition>40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Offering Costs associated with the Initial Public Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsDetails" id="DisclosureCommitmentsDetails">
        <link:definition>40601 - Disclosure - COMMITMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ahpa-20220416_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ahpa-20220416_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ahpa-20220416_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ahpa-20220416_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_UnitsIssuedDuringPeriodSharesNewIssues" name="UnitsIssuedDuringPeriodSharesNewIssues" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_SaleOfStockUnderwritingFees" name="SaleOfStockUnderwritingFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_SaleOfStockOtherOfferingCosts" name="SaleOfStockOtherOfferingCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_InitialPublicOfferingAbstract" name="InitialPublicOfferingAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_InitialPublicOfferingTextBlock" name="InitialPublicOfferingTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_NumberOfSharesIssuedPerUnit" name="NumberOfSharesIssuedPerUnit" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_NumberOfWarrantsIssuedPerUnit" name="NumberOfWarrantsIssuedPerUnit" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_EmergingGrowthCompanyPolicyTextBlock" name="EmergingGrowthCompanyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_PrivatePlacementAbstract" name="PrivatePlacementAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_PrivatePlacementTextBlock" name="PrivatePlacementTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" name="ClassOfWarrantOrRightPriceOfWarrantsOrRights" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_SponsorMember" name="SponsorMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_NumberOfSharesSubjectToForfeiture" name="NumberOfSharesSubjectToForfeiture" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" name="PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" name="ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" name="TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" name="TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" name="TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" name="ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_PromissoryNoteWithRelatedPartyMember" name="PromissoryNoteWithRelatedPartyMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_RelatedPartyLoansMember" name="RelatedPartyLoansMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" name="RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_DeferredFeePerUnit" name="DeferredFeePerUnit" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_CommonStockNumberOfVotesPerShare" name="CommonStockNumberOfVotesPerShare" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" name="RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" name="RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" name="ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_MaximumLoansConvertibleIntoWarrants" name="MaximumLoansConvertibleIntoWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" name="MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" name="ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_RedemptionPeriod" name="RedemptionPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_TransactionCosts" name="TransactionCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_MaximumNumberOfDemandsForRegistrationOfSecurities" name="MaximumNumberOfDemandsForRegistrationOfSecurities" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_AdministrativeSupportAgreementMember" name="AdministrativeSupportAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_PaymentsForInvestmentOfCashInTrustAccount" name="PaymentsForInvestmentOfCashInTrustAccount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_DeferredUnderwritingFeePayable" name="DeferredUnderwritingFeePayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_DeferredOfferingCostsNoncurrent" name="DeferredOfferingCostsNoncurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_PublicWarrantsMember" name="PublicWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_PrivatePlacementWarrantsMember" name="PrivatePlacementWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" name="ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_UnderwriterCashDiscount" name="UnderwriterCashDiscount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" abstract="false" xbrli:balance="debit" />
  <element id="ahpa_UnderwritingCashDiscountPerUnit" name="UnderwritingCashDiscountPerUnit" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_AggregateDeferredUnderwritingFeePayable" name="AggregateDeferredUnderwritingFeePayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_CommonClassaSubjectToRedemptionMember" name="CommonClassaSubjectToRedemptionMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_OfferingCostsIncludedInAccountsPayableAccruedExpenses" name="OfferingCostsIncludedInAccountsPayableAccruedExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_WorkingCapitalLoansWarrantMember" name="WorkingCapitalLoansWarrantMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" name="TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_WarrantExercisePriceAdjustmentMultiple" name="WarrantExercisePriceAdjustmentMultiple" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_WarrantRedemptionPriceAdjustmentMultiple" name="WarrantRedemptionPriceAdjustmentMultiple" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" name="RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" name="PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" name="PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" name="MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_WarrantExercisePeriodConditionTwo" name="WarrantExercisePeriodConditionTwo" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_WarrantRedemptionConditionMinimumSharePrice" name="WarrantRedemptionConditionMinimumSharePrice" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="ahpa_ProceedsFromIssuanceInitialPublicOfferingNet" name="ProceedsFromIssuanceInitialPublicOfferingNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="InvestmentsMaximumMaturityTerm" id="ahpa_InvestmentsMaximumMaturityTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" id="ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" id="ahpa_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" id="ahpa_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ThresholdBusinessDaysForRedemptionOfPublicShares" id="ahpa_ThresholdBusinessDaysForRedemptionOfPublicShares" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MaximumNetInterestToPayDissolutionExpenses" id="ahpa_MaximumNetInterestToPayDissolutionExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="WorkingCapitalLoansOutstanding" id="ahpa_WorkingCapitalLoansOutstanding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MonthsToCompleteInitialBusinessCombination" id="ahpa_MonthsToCompleteInitialBusinessCombination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FounderSharesMember" id="ahpa_FounderSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SharesToBePurchasedPursuantToAgreements" id="ahpa_SharesToBePurchasedPursuantToAgreements" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommitmentsAndContingenciesTable" id="ahpa_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommitmentsAndContingenciesLineItems" id="ahpa_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsToBePurchasedPursuantToAgreements" id="ahpa_WarrantsToBePurchasedPursuantToAgreements" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ConvertibleStockConversionRatios" id="ahpa_ConvertibleStockConversionRatios" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SharePriceTriggerUsedToMeasureDilutionOfWarrants" id="ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="AccruedExpenseRelatedPartyCurrent" id="ahpa_AccruedExpenseRelatedPartyCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedOfferingCostsAndExpensesCurrent" id="ahpa_AccruedOfferingCostsAndExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseInAccruedLiabilitiesRelatedParties" id="ahpa_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" id="ahpa_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="Repaymentfromrelatedpartydebt" id="ahpa_Repaymentfromrelatedpartydebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="TemporaryEquityProceedsAllocatedToWarrants" id="ahpa_TemporaryEquityProceedsAllocatedToWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TemporaryEquityIssuanceCosts" id="ahpa_TemporaryEquityIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CommonStockSubjectToPossibleRedemptionPolicyTextBlock" id="ahpa_CommonStockSubjectToPossibleRedemptionPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OfferingCostsIncludedInPromissoryNoteRelatedParty" id="ahpa_OfferingCostsIncludedInPromissoryNoteRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" id="ahpa_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="WorkingCapitalSurplus" id="ahpa_WorkingCapitalSurplus" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OfferingCostsReductionOfTemporaryEquity" id="ahpa_OfferingCostsReductionOfTemporaryEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="WeightedAverageSharesPricePerShare" id="ahpa_WeightedAverageSharesPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ContributionFromSubsidiaries" id="ahpa_ContributionFromSubsidiaries" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OmniabMember" id="ahpa_OmniabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>ahpa-20220416_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8119.21675 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/27/2022 11:10:01 PM-->
<!--Modified on: 4/27/2022 11:10:01 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#StatementBalanceSheet" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#StatementStatementOfOperations" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#StatementStatementOfCashFlows" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails" />
  <calculationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEET">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_637866978007891566" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent_637866978007891566" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637866978007891566" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637866978007891566" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637866978007891566" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637866978007891566" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637866978007891566" order="1" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_637866978007891566" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637866978007891566" xlink:to="us-gaap_PrepaidExpenseCurrent_637866978007891566" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637866978007901575" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637866978007901575" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_DeferredOfferingCostsNoncurrent" xlink:label="ahpa_DeferredOfferingCostsNoncurrent_637866978007901575" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637866978007901575" xlink:to="ahpa_DeferredOfferingCostsNoncurrent_637866978007901575" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637866978007901575" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637866978007901575" xlink:to="us-gaap_LiabilitiesCurrent_637866978007901575" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637866978007901575" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637866978007901575" xlink:to="us-gaap_AccountsPayableCurrent_637866978007901575" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_AccruedExpenseRelatedPartyCurrent" xlink:label="ahpa_AccruedExpenseRelatedPartyCurrent_637866978007901575" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637866978007901575" xlink:to="ahpa_AccruedExpenseRelatedPartyCurrent_637866978007901575" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_AccruedOfferingCostsAndExpensesCurrent" xlink:label="ahpa_AccruedOfferingCostsAndExpensesCurrent_637866978007901575" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637866978007901575" xlink:to="ahpa_AccruedOfferingCostsAndExpensesCurrent_637866978007901575" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_637866978007901575" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637866978007901575" xlink:to="us-gaap_DueToRelatedPartiesCurrent_637866978007901575" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637866978007901575" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637866978007901575" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637866978007911563" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637866978007901575" xlink:to="us-gaap_CommonStockValue_637866978007911563" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637866978007911563" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637866978007901575" xlink:to="us-gaap_PreferredStockValue_637866978007911563" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637866978007911563" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637866978007901575" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637866978007911563" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637866978007911563" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637866978007911563" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637866978007911563" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_637866978007911563" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations" xlink:type="extended" xlink:title="00200 - Statement - STATEMENT OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses_637866978007921565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingCostsAndExpenses_637866978007921565" order="1" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - STATEMENT OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637866978007921565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637866978007921565" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ProceedsFromIssuanceInitialPublicOfferingNet" xlink:label="ahpa_ProceedsFromIssuanceInitialPublicOfferingNet_637866978007921565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637866978007921565" xlink:to="ahpa_ProceedsFromIssuanceInitialPublicOfferingNet_637866978007921565" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637866978007921565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637866978007921565" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637866978007921565" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_637866978007921565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637866978007921565" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_637866978007921565" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_Repaymentfromrelatedpartydebt" xlink:label="ahpa_Repaymentfromrelatedpartydebt_637866978007921565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637866978007921565" xlink:to="ahpa_Repaymentfromrelatedpartydebt_637866978007921565" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637866978007921565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637866978007921565" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637866978007921565" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637866978007921565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637866978007921565" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637866978007921565" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637866978007931565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637866978007931565" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637866978007931565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637866978007931565" xlink:to="us-gaap_ProfitLoss_637866978007931565" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_637866978007931565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637866978007931565" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_637866978007931565" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_637866978007931565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637866978007931565" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_637866978007931565" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" xlink:label="ahpa_IncreaseDecreaseInAccruedLiabilitiesRelatedParties_637866978007931565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637866978007931565" xlink:to="ahpa_IncreaseDecreaseInAccruedLiabilitiesRelatedParties_637866978007931565" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_637866978007931565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637866978007931565" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_637866978007931565" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637866978007931565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637866978007931565" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PaymentsForInvestmentOfCashInTrustAccount" xlink:label="ahpa_PaymentsForInvestmentOfCashInTrustAccount_637866978007941552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637866978007931565" xlink:to="ahpa_PaymentsForInvestmentOfCashInTrustAccount_637866978007941552" order="1" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails" xlink:type="extended" xlink:title="40101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY (Details)">
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TransactionCosts" xlink:label="ahpa_TransactionCosts" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SaleOfStockUnderwritingFees" xlink:label="ahpa_SaleOfStockUnderwritingFees_637866978007941552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ahpa_TransactionCosts" xlink:to="ahpa_SaleOfStockUnderwritingFees_637866978007941552" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_DeferredOfferingCostsNoncurrent" xlink:label="ahpa_DeferredOfferingCostsNoncurrent_637866978007941552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ahpa_TransactionCosts" xlink:to="ahpa_DeferredOfferingCostsNoncurrent_637866978007941552" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SaleOfStockOtherOfferingCosts" xlink:label="ahpa_SaleOfStockOtherOfferingCosts_637866978007941552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ahpa_TransactionCosts" xlink:to="ahpa_SaleOfStockOtherOfferingCosts_637866978007941552" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>ahpa-20220416_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8119.21675 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/27/2022 11:10:01 PM-->
<!--Modified on: 4/27/2022 11:10:01 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#StatementBalanceSheet" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#StatementBalanceSheetParenthetical" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#StatementStatementOfOperations" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#StatementStatementOfChangesInShareholdersDeficit" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNetIncomeLossPerOrdinaryShareDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomeLossPerOrdinaryShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureInitialPublicOfferingDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosurePrivatePlacementDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureRelatedPartyTransactionsFounderSharesDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureCommitmentsForwardPurchaseAgreementDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureShareholdersDeficitCommonStockSharesDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureShareholdersDeficitWarrantsDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureSubsequentEventsDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="ahpa-20220416.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" xlink:title="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain_1" xlink:title="us-gaap_AdjustmentsForErrorCorrectionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1 To us-gaap_AdjustmentsForErrorCorrectionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEET" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_AccruedExpenseRelatedPartyCurrent" xlink:label="ahpa_AccruedExpenseRelatedPartyCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="ahpa_AccruedExpenseRelatedPartyCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_AccruedOfferingCostsAndExpensesCurrent" xlink:label="ahpa_AccruedOfferingCostsAndExpensesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="ahpa_AccruedOfferingCostsAndExpensesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_DeferredOfferingCostsNoncurrent" xlink:label="ahpa_DeferredOfferingCostsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="ahpa_DeferredOfferingCostsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical" xlink:type="extended" xlink:title="00105 - Statement - BALANCE SHEET (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_CommonClassaSubjectToRedemptionMember" xlink:label="ahpa_CommonClassaSubjectToRedemptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CommonClassAMember" xlink:to="ahpa_CommonClassaSubjectToRedemptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations" xlink:type="extended" xlink:title="00200 - Statement - STATEMENT OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit" xlink:type="extended" xlink:title="00300 - Statement - STATEMENT OF CHANGES IN SHAREHOLDERS' DEFICIT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PublicWarrantsMember" xlink:label="ahpa_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ahpa_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PrivatePlacementWarrantsMember" xlink:label="ahpa_PrivatePlacementWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ahpa_PrivatePlacementWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails" xlink:type="extended" xlink:title="40101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PrivatePlacementWarrantsMember" xlink:label="ahpa_PrivatePlacementWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WarrantMember" xlink:to="ahpa_PrivatePlacementWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PublicWarrantsMember" xlink:label="ahpa_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WarrantMember" xlink:to="ahpa_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:label="ahpa_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="ahpa_UnitsIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_UnitsIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TransactionCosts" xlink:label="ahpa_TransactionCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_TransactionCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SaleOfStockUnderwritingFees" xlink:label="ahpa_SaleOfStockUnderwritingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_SaleOfStockUnderwritingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_DeferredOfferingCostsNoncurrent" xlink:label="ahpa_DeferredOfferingCostsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_DeferredOfferingCostsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SaleOfStockOtherOfferingCosts" xlink:label="ahpa_SaleOfStockOtherOfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_SaleOfStockOtherOfferingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_InvestmentsMaximumMaturityTerm" xlink:label="ahpa_InvestmentsMaximumMaturityTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_InvestmentsMaximumMaturityTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MonthsToCompleteInitialBusinessCombination" xlink:label="ahpa_MonthsToCompleteInitialBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_MonthsToCompleteInitialBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:label="ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" xlink:label="ahpa_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" xlink:label="ahpa_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ThresholdBusinessDaysForRedemptionOfPublicShares" xlink:label="ahpa_ThresholdBusinessDaysForRedemptionOfPublicShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_ThresholdBusinessDaysForRedemptionOfPublicShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MaximumNetInterestToPayDissolutionExpenses" xlink:label="ahpa_MaximumNetInterestToPayDissolutionExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_MaximumNetInterestToPayDissolutionExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WorkingCapitalSurplus" xlink:label="ahpa_WorkingCapitalSurplus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_WorkingCapitalSurplus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" xlink:label="ahpa_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="ahpa_UnitsIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="ahpa_UnitsIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails" xlink:type="extended" xlink:title="40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net income per ordinary share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomeLossPerOrdinaryShareDetails" xlink:type="extended" xlink:title="40205 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Income (Loss) Per Ordinary Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails" xlink:type="extended" xlink:title="40301 - Disclosure - INITIAL PUBLIC OFFERING (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PublicWarrantsMember" xlink:label="ahpa_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ahpa_PublicWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="ahpa_UnitsIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_UnitsIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_NumberOfSharesIssuedPerUnit" xlink:label="ahpa_NumberOfSharesIssuedPerUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_NumberOfSharesIssuedPerUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_NumberOfWarrantsIssuedPerUnit" xlink:label="ahpa_NumberOfWarrantsIssuedPerUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_NumberOfWarrantsIssuedPerUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PRIVATE PLACEMENT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PrivatePlacementWarrantsMember" xlink:label="ahpa_PrivatePlacementWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ahpa_PrivatePlacementWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - RELATED PARTY TRANSACTIONS - Founder Shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_FounderSharesMember" xlink:label="ahpa_FounderSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ahpa_FounderSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SponsorMember" xlink:label="ahpa_SponsorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ahpa_SponsorMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_NumberOfSharesSubjectToForfeiture" xlink:label="ahpa_NumberOfSharesSubjectToForfeiture" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ahpa_NumberOfSharesSubjectToForfeiture" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" xlink:label="ahpa_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ahpa_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" xlink:label="ahpa_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ahpa_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:label="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:label="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="ahpa_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ahpa_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" xlink:title="40502 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PromissoryNoteWithRelatedPartyMember" xlink:label="ahpa_PromissoryNoteWithRelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ahpa_PromissoryNoteWithRelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_AdministrativeSupportAgreementMember" xlink:label="ahpa_AdministrativeSupportAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ahpa_AdministrativeSupportAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_RelatedPartyLoansMember" xlink:label="ahpa_RelatedPartyLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ahpa_RelatedPartyLoansMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="ahpa_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ahpa_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_OfferingCostsIncludedInPromissoryNoteRelatedParty" xlink:label="ahpa_OfferingCostsIncludedInPromissoryNoteRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ahpa_OfferingCostsIncludedInPromissoryNoteRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:label="ahpa_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ahpa_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MaximumLoansConvertibleIntoWarrants" xlink:label="ahpa_MaximumLoansConvertibleIntoWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ahpa_MaximumLoansConvertibleIntoWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WorkingCapitalLoansOutstanding" xlink:label="ahpa_WorkingCapitalLoansOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ahpa_WorkingCapitalLoansOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails" xlink:type="extended" xlink:title="40602 - Disclosure - COMMITMENTS - Forward Purchase Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_CommitmentsAndContingenciesTable" xlink:label="ahpa_CommitmentsAndContingenciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ahpa_CommitmentsAndContingenciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ahpa_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_CommitmentsAndContingenciesLineItems" xlink:label="ahpa_CommitmentsAndContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ahpa_CommitmentsAndContingenciesLineItems" xlink:to="ahpa_CommitmentsAndContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SharesToBePurchasedPursuantToAgreements" xlink:label="ahpa_SharesToBePurchasedPursuantToAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ahpa_CommitmentsAndContingenciesLineItems" xlink:to="ahpa_SharesToBePurchasedPursuantToAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WarrantsToBePurchasedPursuantToAgreements" xlink:label="ahpa_WarrantsToBePurchasedPursuantToAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ahpa_CommitmentsAndContingenciesLineItems" xlink:to="ahpa_WarrantsToBePurchasedPursuantToAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ahpa_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ahpa_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - SHAREHOLDERS' DEFICIT - Common Stock Shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_CommonClassaSubjectToRedemptionMember" xlink:label="ahpa_CommonClassaSubjectToRedemptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CommonClassAMember" xlink:to="ahpa_CommonClassaSubjectToRedemptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_CommonStockNumberOfVotesPerShare" xlink:label="ahpa_CommonStockNumberOfVotesPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ahpa_CommonStockNumberOfVotesPerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ConvertibleStockConversionRatios" xlink:label="ahpa_ConvertibleStockConversionRatios" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ahpa_ConvertibleStockConversionRatios" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - SHAREHOLDERS' DEFICIT - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PublicWarrantsMember" xlink:label="ahpa_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WarrantMember" xlink:to="ahpa_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:label="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" xlink:label="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WarrantExercisePeriodConditionTwo" xlink:label="ahpa_WarrantExercisePeriodConditionTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ahpa_WarrantExercisePeriodConditionTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:label="ahpa_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ahpa_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:label="ahpa_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ahpa_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WarrantRedemptionConditionMinimumSharePrice" xlink:label="ahpa_WarrantRedemptionConditionMinimumSharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ahpa_WarrantRedemptionConditionMinimumSharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_RedemptionPeriod" xlink:label="ahpa_RedemptionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ahpa_RedemptionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xlink:label="ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:label="ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:label="ahpa_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ahpa_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WarrantExercisePriceAdjustmentMultiple" xlink:label="ahpa_WarrantExercisePriceAdjustmentMultiple" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ahpa_WarrantExercisePriceAdjustmentMultiple" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" xlink:label="ahpa_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ahpa_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WarrantRedemptionPriceAdjustmentMultiple" xlink:label="ahpa_WarrantRedemptionPriceAdjustmentMultiple" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ahpa_WarrantRedemptionPriceAdjustmentMultiple" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="ahpa_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ahpa_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - SUBSEQUENT EVENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_OmniabMember" xlink:label="ahpa_OmniabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ahpa_OmniabMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SponsorMember" xlink:label="ahpa_SponsorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ahpa_SponsorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WorkingCapitalLoansWarrantMember" xlink:label="ahpa_WorkingCapitalLoansWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ahpa_WorkingCapitalLoansWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDefaultLongtermDebtAmount" xlink:label="us-gaap_DebtDefaultLongtermDebtAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtDefaultLongtermDebtAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ContributionFromSubsidiaries" xlink:label="ahpa_ContributionFromSubsidiaries" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ahpa_ContributionFromSubsidiaries" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WeightedAverageSharesPricePerShare" xlink:label="ahpa_WeightedAverageSharesPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ahpa_WeightedAverageSharesPricePerShare" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>ahpa-20220416_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8119.21675 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/27/2022 11:10:01 PM-->
<!--Modified on: 4/27/2022 11:10:01 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BALANCE SHEET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A ordinary shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class B ordinary shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash held outside the Trust Account</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash held outside of the Trust Account</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldInTrustNoncurrent" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities held in Trust Account</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash held in trust account</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND SHAREHOLDERS' DEFICIT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_AccruedExpenseRelatedPartyCurrent" xlink:label="ahpa_AccruedExpenseRelatedPartyCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_AccruedExpenseRelatedPartyCurrent" xlink:to="ahpa_AccruedExpenseRelatedPartyCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_AccruedExpenseRelatedPartyCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the accrued expense pertaining to related party as of balance sheet date. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_AccruedExpenseRelatedPartyCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expense, Related Party, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_AccruedExpenseRelatedPartyCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_AccruedOfferingCostsAndExpensesCurrent" xlink:label="ahpa_AccruedOfferingCostsAndExpensesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_AccruedOfferingCostsAndExpensesCurrent" xlink:to="ahpa_AccruedOfferingCostsAndExpensesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_AccruedOfferingCostsAndExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the accrued offering costs and expenses as of balance sheet date. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_AccruedOfferingCostsAndExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Offering Costs And Expenses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_AccruedOfferingCostsAndExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_DeferredOfferingCostsNoncurrent" xlink:label="ahpa_DeferredOfferingCostsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_DeferredOfferingCostsNoncurrent" xlink:to="ahpa_DeferredOfferingCostsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_DeferredOfferingCostsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_DeferredOfferingCostsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred underwriting fee payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_DeferredOfferingCostsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred underwriting fee payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ahpa_DeferredOfferingCostsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred underwriting fee payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments (see Note 6)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A ordinary shares subject to possible redemption</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A ordinary shares, $0.0001 par value, subject to possible redemption; 23,000,000 shares at redemption value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Shareholders' Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_CommonClassaSubjectToRedemptionMember" xlink:label="ahpa_CommonClassaSubjectToRedemptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_CommonClassaSubjectToRedemptionMember" xlink:to="ahpa_CommonClassaSubjectToRedemptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_CommonClassaSubjectToRedemptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classification of common stock representing ownership interest in a corporation that is subject to redemption.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_CommonClassaSubjectToRedemptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A Common Stock Subject to Redemption</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value, (per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value, (per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred shares, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred shares, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred shares, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares, par value, (per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional shares of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A common stock subject to possible redemption, outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENT OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Formation and operating costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net loss per ordinary share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net loss per ordinary share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENT OF CHANGES IN SHAREHOLDERS' DEFICIT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PublicWarrantsMember" xlink:label="ahpa_PublicWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_PublicWarrantsMember" xlink:to="ahpa_PublicWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_PublicWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents a redeemable warrant (Public Warrant) that entitles the holder to purchase shares of common stock subject to adjustment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_PublicWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Warrants</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PrivatePlacementWarrantsMember" xlink:label="ahpa_PrivatePlacementWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_PrivatePlacementWarrantsMember" xlink:to="ahpa_PrivatePlacementWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_PrivatePlacementWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents a redeemable warrant (Private Placement Warrant) that entitles the holder to purchase shares of common stock if the underwriter's option is exercised in full.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_PrivatePlacementWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Class B ordinary shares to Sponsor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate purchase price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Class B ordinary shares to Sponsor (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Initial Public Offering Costs allocated to Warrants (net of offering costs)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Accretion to Redemption Value, Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Re-measurement of Class A ordinary shares to redemption value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of carrying value to redemption value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENT OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Operating Activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to related party</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" xlink:label="ahpa_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" xlink:to="ahpa_IncreaseDecreaseInAccruedLiabilitiesRelatedParties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_IncreaseDecreaseInAccruedLiabilitiesRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in accrued expenses, related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_IncreaseDecreaseInAccruedLiabilitiesRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities, Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_IncreaseDecreaseInAccruedLiabilitiesRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Investing Activities:</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PaymentsForInvestmentOfCashInTrustAccount" xlink:label="ahpa_PaymentsForInvestmentOfCashInTrustAccount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_PaymentsForInvestmentOfCashInTrustAccount" xlink:to="ahpa_PaymentsForInvestmentOfCashInTrustAccount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_PaymentsForInvestmentOfCashInTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash outflow for investment of cash in trust account.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_PaymentsForInvestmentOfCashInTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for investment of cash in Trust Account</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ahpa_PaymentsForInvestmentOfCashInTrustAccount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment of cash into Trust Account</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Financing Activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of Class B ordinary shares to Sponsor</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ProceedsFromIssuanceInitialPublicOfferingNet" xlink:label="ahpa_ProceedsFromIssuanceInitialPublicOfferingNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_ProceedsFromIssuanceInitialPublicOfferingNet" xlink:to="ahpa_ProceedsFromIssuanceInitialPublicOfferingNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_ProceedsFromIssuanceInitialPublicOfferingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash inflow from initial public offering after deducting offering expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_ProceedsFromIssuanceInitialPublicOfferingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Initial Public Offering, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ahpa_ProceedsFromIssuanceInitialPublicOfferingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from initial public offering, net of underwriter's discount paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of Private Placement Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Related Party Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sponsor note</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_Repaymentfromrelatedpartydebt" xlink:label="ahpa_Repaymentfromrelatedpartydebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_Repaymentfromrelatedpartydebt" xlink:to="ahpa_Repaymentfromrelatedpartydebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_Repaymentfromrelatedpartydebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of repayment from related party debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_Repaymentfromrelatedpartydebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment From Related Party Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ahpa_Repaymentfromrelatedpartydebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of Sponsor note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net change in cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash - end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash - beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Disclosure of Non-Cash Investing and Financing Activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash investing and financing activities</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" xlink:label="ahpa_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" xlink:to="ahpa_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Accretion of Class A ordinary shares subject to redemption to redemption value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of Class Ordinary Shares Subject to Redemption to Redemption Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Re-measurement of Class A ordinary shares to redemption value</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_OfferingCostsIncludedInAccountsPayableAccruedExpenses" xlink:label="ahpa_OfferingCostsIncludedInAccountsPayableAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_OfferingCostsIncludedInAccountsPayableAccruedExpenses" xlink:to="ahpa_OfferingCostsIncludedInAccountsPayableAccruedExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_OfferingCostsIncludedInAccountsPayableAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of offering costs included in accounts payable or accrued expenses that were incurred during a noncash or partial noncash transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_OfferingCostsIncludedInAccountsPayableAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering Costs Included In Accounts Payable Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_OfferingCostsIncludedInAccountsPayableAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs included in accrued offering costs</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_DeferredUnderwritingFeePayable" xlink:label="ahpa_DeferredUnderwritingFeePayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_DeferredUnderwritingFeePayable" xlink:to="ahpa_DeferredUnderwritingFeePayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_DeferredUnderwritingFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of underwriting fee payable deferred during the period, classified as non-cash investing and financing activity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_DeferredUnderwritingFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Underwriting Fee Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_DeferredUnderwritingFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred underwriting fee payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS [TEXT BLOCK]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [TEXT BLOCK]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_InitialPublicOfferingAbstract" xlink:label="ahpa_InitialPublicOfferingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_InitialPublicOfferingAbstract" xlink:to="ahpa_InitialPublicOfferingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_InitialPublicOfferingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_InitialPublicOfferingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INITIAL PUBLIC OFFERING</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_InitialPublicOfferingTextBlock" xlink:label="ahpa_InitialPublicOfferingTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_InitialPublicOfferingTextBlock" xlink:to="ahpa_InitialPublicOfferingTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_InitialPublicOfferingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on information about initial public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_InitialPublicOfferingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_InitialPublicOfferingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INITIAL PUBLIC OFFERING</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PrivatePlacementAbstract" xlink:label="ahpa_PrivatePlacementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_PrivatePlacementAbstract" xlink:to="ahpa_PrivatePlacementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_PrivatePlacementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_PrivatePlacementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PRIVATE PLACEMENT</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PrivatePlacementTextBlock" xlink:label="ahpa_PrivatePlacementTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_PrivatePlacementTextBlock" xlink:to="ahpa_PrivatePlacementTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_PrivatePlacementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on information about private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_PrivatePlacementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_PrivatePlacementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PRIVATE PLACEMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHAREHOLDERS' DEFICIT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHAREHOLDERS' DEFICIT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_EmergingGrowthCompanyPolicyTextBlock" xlink:label="ahpa_EmergingGrowthCompanyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_EmergingGrowthCompanyPolicyTextBlock" xlink:to="ahpa_EmergingGrowthCompanyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the accounting policy on Emerging Growth Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Emerging Growth Company [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_CommonStockSubjectToPossibleRedemptionPolicyTextBlock" xlink:label="ahpa_CommonStockSubjectToPossibleRedemptionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_CommonStockSubjectToPossibleRedemptionPolicyTextBlock" xlink:to="ahpa_CommonStockSubjectToPossibleRedemptionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_CommonStockSubjectToPossibleRedemptionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the accounting policy on common stock subject to possible redemption.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_CommonStockSubjectToPossibleRedemptionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Subject to Possible Redemption [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_CommonStockSubjectToPossibleRedemptionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A Ordinary Shares Subject to Possible Redemption</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering Costs associated with the Initial Public Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Ordinary Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Standards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of reconciliation of Class A ordinary shares subject to possible redemption reflected in the condensed balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of calculation of basic and diluted net income per ordinary share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-allotment option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:label="ahpa_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:to="ahpa_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum number of businesses which the reporting entity must acquire with the net proceeds of the offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condition for future business combination number of businesses minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condition for future business combination, number of businesses, minimum</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="ahpa_UnitsIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_UnitsIssuedDuringPeriodSharesNewIssues" xlink:to="ahpa_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new units issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Units Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Units, net of underwriting discounts (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ahpa_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of units issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price, per unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issued price per Unit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance initial public offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds received from initial public offering, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants to purchase shares issued</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:to="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per share or per unit of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate purchase price</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TransactionCosts" xlink:label="ahpa_TransactionCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_TransactionCosts" xlink:to="ahpa_TransactionCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_TransactionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of transaction costs incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_TransactionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ahpa_TransactionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ahpa_TransactionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering Costs</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SaleOfStockUnderwritingFees" xlink:label="ahpa_SaleOfStockUnderwritingFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_SaleOfStockUnderwritingFees" xlink:to="ahpa_SaleOfStockUnderwritingFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_SaleOfStockUnderwritingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of offering fees incurred and paid for underwriters.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_SaleOfStockUnderwritingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Underwriting fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_SaleOfStockUnderwritingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting fees</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SaleOfStockOtherOfferingCosts" xlink:label="ahpa_SaleOfStockOtherOfferingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_SaleOfStockOtherOfferingCosts" xlink:to="ahpa_SaleOfStockOtherOfferingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_SaleOfStockOtherOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of other offering costs incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_SaleOfStockOtherOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Other Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_SaleOfStockOtherOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_InvestmentsMaximumMaturityTerm" xlink:label="ahpa_InvestmentsMaximumMaturityTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_InvestmentsMaximumMaturityTerm" xlink:to="ahpa_InvestmentsMaximumMaturityTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_InvestmentsMaximumMaturityTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum maturity term of investments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_InvestmentsMaximumMaturityTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments Maximum Maturity Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_InvestmentsMaximumMaturityTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity term of U.S. government securities</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MonthsToCompleteInitialBusinessCombination" xlink:label="ahpa_MonthsToCompleteInitialBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_MonthsToCompleteInitialBusinessCombination" xlink:to="ahpa_MonthsToCompleteInitialBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_MonthsToCompleteInitialBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Duration of months to complete initial business combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_MonthsToCompleteInitialBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Months to Complete Initial Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_MonthsToCompleteInitialBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Months to complete initial business combination</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:label="ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:to="ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of obligation to redeem public shares if Entity does not complete business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Obligation to Redeem Public Shares If Entity Does Not Complete Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Obligation to redeem public shares if entity does not complete a business combination (as a percent)</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" xlink:label="ahpa_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" xlink:to="ahpa_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the minimum net tangible assets upon consummation of the Business Combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Net Tangible Assets upon Consummation of Business Combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum net tangible assets upon consummation of the business combination</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" xlink:label="ahpa_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" xlink:to="ahpa_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the threshold percentage of Public Shares subject to redemption without the Company's prior written consent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Percentage of Public Shares Subject to Redemption Without Company's Prior Written Consent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold percentage of public shares subject to redemption without the company's prior written consent</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ThresholdBusinessDaysForRedemptionOfPublicShares" xlink:label="ahpa_ThresholdBusinessDaysForRedemptionOfPublicShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_ThresholdBusinessDaysForRedemptionOfPublicShares" xlink:to="ahpa_ThresholdBusinessDaysForRedemptionOfPublicShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_ThresholdBusinessDaysForRedemptionOfPublicShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the threshold business days for redemption of public shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_ThresholdBusinessDaysForRedemptionOfPublicShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Business Days for Redemption of Public Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_ThresholdBusinessDaysForRedemptionOfPublicShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold business days for redemption of public shares</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MaximumNetInterestToPayDissolutionExpenses" xlink:label="ahpa_MaximumNetInterestToPayDissolutionExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_MaximumNetInterestToPayDissolutionExpenses" xlink:to="ahpa_MaximumNetInterestToPayDissolutionExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_MaximumNetInterestToPayDissolutionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum net interest to pay dissolution expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_MaximumNetInterestToPayDissolutionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Net Interest to Pay Dissolution Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_MaximumNetInterestToPayDissolutionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum net interest to pay dissolution expenses</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WorkingCapitalSurplus" xlink:label="ahpa_WorkingCapitalSurplus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_WorkingCapitalSurplus" xlink:to="ahpa_WorkingCapitalSurplus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_WorkingCapitalSurplus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of working capital surplus.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_WorkingCapitalSurplus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working Capital Surplus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_WorkingCapitalSurplus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working capital surplus</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" xlink:label="ahpa_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" xlink:to="ahpa_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount for initial public offering and sale of the private placement warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Initial Public Offering And Sale Of Private Placement Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the Initial Public offering and sale of the private placement warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits accrued for interest and penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, FDIC Insured Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal Depository Insurance Coverage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Redeemable Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TemporaryEquityProceedsAllocatedToWarrants" xlink:label="ahpa_TemporaryEquityProceedsAllocatedToWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_TemporaryEquityProceedsAllocatedToWarrants" xlink:to="ahpa_TemporaryEquityProceedsAllocatedToWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_TemporaryEquityProceedsAllocatedToWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of gross proceeds allocated from temporary equity to warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_TemporaryEquityProceedsAllocatedToWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity , Proceeds Allocated To Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_TemporaryEquityProceedsAllocatedToWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds allocated to Public Warrants</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TemporaryEquityIssuanceCosts" xlink:label="ahpa_TemporaryEquityIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_TemporaryEquityIssuanceCosts" xlink:to="ahpa_TemporaryEquityIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_TemporaryEquityIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of issuance costs related to temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_TemporaryEquityIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_TemporaryEquityIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs allocated to Class A ordinary shares</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_OfferingCostsReductionOfTemporaryEquity" xlink:label="ahpa_OfferingCostsReductionOfTemporaryEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_OfferingCostsReductionOfTemporaryEquity" xlink:to="ahpa_OfferingCostsReductionOfTemporaryEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_OfferingCostsReductionOfTemporaryEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of offering costs reduction of temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_OfferingCostsReductionOfTemporaryEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering Costs Reduction Of Temporary Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_OfferingCostsReductionOfTemporaryEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs reduction of temporary equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs as a reduction of equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and diluted net loss per share:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from computation of earnings per share</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_NumberOfSharesIssuedPerUnit" xlink:label="ahpa_NumberOfSharesIssuedPerUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_NumberOfSharesIssuedPerUnit" xlink:to="ahpa_NumberOfSharesIssuedPerUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_NumberOfSharesIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of shares in a unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_NumberOfSharesIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares Issued Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_NumberOfSharesIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares in a unit</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_NumberOfWarrantsIssuedPerUnit" xlink:label="ahpa_NumberOfWarrantsIssuedPerUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_NumberOfWarrantsIssuedPerUnit" xlink:to="ahpa_NumberOfWarrantsIssuedPerUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_NumberOfWarrantsIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of warrants in a unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_NumberOfWarrantsIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants Issued Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_NumberOfWarrantsIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants in a unit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issuable per warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares per warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_FounderSharesMember" xlink:label="ahpa_FounderSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_FounderSharesMember" xlink:to="ahpa_FounderSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_FounderSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_FounderSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Founder Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SponsorMember" xlink:label="ahpa_SponsorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_SponsorMember" xlink:to="ahpa_SponsorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_SponsorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for sponsor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_SponsorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sponsor</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_NumberOfSharesSubjectToForfeiture" xlink:label="ahpa_NumberOfSharesSubjectToForfeiture" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_NumberOfSharesSubjectToForfeiture" xlink:to="ahpa_NumberOfSharesSubjectToForfeiture_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_NumberOfSharesSubjectToForfeiture_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares owned by the founders subject to forfeiture if the underwriter overallotment option is not exercised in the proposed public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_NumberOfSharesSubjectToForfeiture_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Shares Subject To Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_NumberOfSharesSubjectToForfeiture_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares subject to forfeiture</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" xlink:label="ahpa_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" xlink:to="ahpa_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The expected ownership percentage by the founders after completion of the proposed public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Issued And Outstanding Shares After The Initial Public Offering Collectively Held By Initial Stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" xlink:label="ahpa_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" xlink:to="ahpa_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of time which must elapse after completion of a business combination before the Sponsor can transfer, assign or sell any Founder Shares unless other specified conditions are met.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Period For Not To Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:label="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:to="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The share price threshold that must be achieved in order to waive the restriction on transfer of shares during a restricted period after a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Stock Price Trigger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:label="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:to="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">When determining the condition for transfer of shares without restriction after a business combination, the number of days in which the share price must exceed the specified amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:to="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">When determining the condition for transfer of shares without restriction after a business combination, the number of consecutive trading days used to observe the share price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="ahpa_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:to="ahpa_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Period After Business Combination In Which Specified Trading Days Within Any Specified Trading Day Period Commences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PromissoryNoteWithRelatedPartyMember" xlink:label="ahpa_PromissoryNoteWithRelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_PromissoryNoteWithRelatedPartyMember" xlink:to="ahpa_PromissoryNoteWithRelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_PromissoryNoteWithRelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for promissory note with related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_PromissoryNoteWithRelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Promissory Note with Related Party</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_AdministrativeSupportAgreementMember" xlink:label="ahpa_AdministrativeSupportAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_AdministrativeSupportAgreementMember" xlink:to="ahpa_AdministrativeSupportAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_AdministrativeSupportAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Administrative Support Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_AdministrativeSupportAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Administrative Support Agreement</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_RelatedPartyLoansMember" xlink:label="ahpa_RelatedPartyLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_RelatedPartyLoansMember" xlink:to="ahpa_RelatedPartyLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_RelatedPartyLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for related party loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_RelatedPartyLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Loans</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="ahpa_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:to="ahpa_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of maximum borrowing capacity of related party promissory note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Borrowing Capacity of Related Party Promissory Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity of related party promissory note</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_OfferingCostsIncludedInPromissoryNoteRelatedParty" xlink:label="ahpa_OfferingCostsIncludedInPromissoryNoteRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_OfferingCostsIncludedInPromissoryNoteRelatedParty" xlink:to="ahpa_OfferingCostsIncludedInPromissoryNoteRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_OfferingCostsIncludedInPromissoryNoteRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of  offering costs included in promissory note - related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_OfferingCostsIncludedInPromissoryNoteRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering Costs Included In Promissory Note - Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_OfferingCostsIncludedInPromissoryNoteRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs paid by Sponsor and included in promissory note - related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Related Party Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of related party promissory note</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:label="ahpa_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:to="ahpa_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The contractual monthly amount to be paid for support services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Expenses from Transactions with Related Party Per Month</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses per month</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses incurred and paid</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MaximumLoansConvertibleIntoWarrants" xlink:label="ahpa_MaximumLoansConvertibleIntoWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_MaximumLoansConvertibleIntoWarrants" xlink:to="ahpa_MaximumLoansConvertibleIntoWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_MaximumLoansConvertibleIntoWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum amount which a potential loan could have repaid through issuance of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_MaximumLoansConvertibleIntoWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">maximum Loans Convertible Into Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_MaximumLoansConvertibleIntoWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan conversion agreement warrant</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WorkingCapitalLoansOutstanding" xlink:label="ahpa_WorkingCapitalLoansOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_WorkingCapitalLoansOutstanding" xlink:to="ahpa_WorkingCapitalLoansOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_WorkingCapitalLoansOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of working capital loans, outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_WorkingCapitalLoansOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working capital loans, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_WorkingCapitalLoansOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working capital loans, outstanding</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MaximumNumberOfDemandsForRegistrationOfSecurities" xlink:label="ahpa_MaximumNumberOfDemandsForRegistrationOfSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_MaximumNumberOfDemandsForRegistrationOfSecurities" xlink:to="ahpa_MaximumNumberOfDemandsForRegistrationOfSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_MaximumNumberOfDemandsForRegistrationOfSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum number of demands for registration of securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_MaximumNumberOfDemandsForRegistrationOfSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Number Of Demands For Registration Of Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_MaximumNumberOfDemandsForRegistrationOfSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of demands for registration of securities</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_DeferredFeePerUnit" xlink:label="ahpa_DeferredFeePerUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_DeferredFeePerUnit" xlink:to="ahpa_DeferredFeePerUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_DeferredFeePerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the deferred fee per unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_DeferredFeePerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Fee Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_DeferredFeePerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred fee per unit</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_AggregateDeferredUnderwritingFeePayable" xlink:label="ahpa_AggregateDeferredUnderwritingFeePayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_AggregateDeferredUnderwritingFeePayable" xlink:to="ahpa_AggregateDeferredUnderwritingFeePayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_AggregateDeferredUnderwritingFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value as of the underwriting compensation deferred in the aggregate if the underwriter's option to purchase additional units is exercised in full.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_AggregateDeferredUnderwritingFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate deferred underwriting fee payable</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_UnderwritingCashDiscountPerUnit" xlink:label="ahpa_UnderwritingCashDiscountPerUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_UnderwritingCashDiscountPerUnit" xlink:to="ahpa_UnderwritingCashDiscountPerUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_UnderwritingCashDiscountPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the cash underwriting discount per unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_UnderwritingCashDiscountPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting cash discount per unit</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_UnderwriterCashDiscount" xlink:label="ahpa_UnderwriterCashDiscount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_UnderwriterCashDiscount" xlink:to="ahpa_UnderwriterCashDiscount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_UnderwriterCashDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the cash underwriting discount per unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_UnderwriterCashDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriter cash discount</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_CommitmentsAndContingenciesTable" xlink:label="ahpa_CommitmentsAndContingenciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_CommitmentsAndContingenciesTable" xlink:to="ahpa_CommitmentsAndContingenciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discloses the commitment and contingencies information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies Table</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_CommitmentsAndContingenciesLineItems" xlink:label="ahpa_CommitmentsAndContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_CommitmentsAndContingenciesLineItems" xlink:to="ahpa_CommitmentsAndContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SharesToBePurchasedPursuantToAgreements" xlink:label="ahpa_SharesToBePurchasedPursuantToAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_SharesToBePurchasedPursuantToAgreements" xlink:to="ahpa_SharesToBePurchasedPursuantToAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_SharesToBePurchasedPursuantToAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares to be purchased pursuant to agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_SharesToBePurchasedPursuantToAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares To Be Purchased Pursuant To Agreements</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WarrantsToBePurchasedPursuantToAgreements" xlink:label="ahpa_WarrantsToBePurchasedPursuantToAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_WarrantsToBePurchasedPursuantToAgreements" xlink:to="ahpa_WarrantsToBePurchasedPursuantToAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_WarrantsToBePurchasedPursuantToAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to be purchased pursuant to agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_WarrantsToBePurchasedPursuantToAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to be purchased pursuant to agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_CommonStockNumberOfVotesPerShare" xlink:label="ahpa_CommonStockNumberOfVotesPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_CommonStockNumberOfVotesPerShare" xlink:to="ahpa_CommonStockNumberOfVotesPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_CommonStockNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of votes that each common share is entitled.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_CommonStockNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Number Of Votes Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_CommonStockNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares, votes per share</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ConvertibleStockConversionRatios" xlink:label="ahpa_ConvertibleStockConversionRatios" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_ConvertibleStockConversionRatios" xlink:to="ahpa_ConvertibleStockConversionRatios_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_ConvertibleStockConversionRatios_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The ratio to be applied to the stock in a conversion of convertible stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_ConvertibleStockConversionRatios_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Stock Conversion Ratios</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_ConvertibleStockConversionRatios_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ratio to be applied to the stock in the conversion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:label="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:to="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for the scenario, where redemption of warrants when the price per share of class a common stock equals or exceeds $18.00.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" xlink:label="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" xlink:to="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for the scenario, where redemption of warrants when the price per share of class a common stock equals or exceeds $10.00.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $10.00</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WarrantExercisePeriodConditionTwo" xlink:label="ahpa_WarrantExercisePeriodConditionTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_WarrantExercisePeriodConditionTwo" xlink:to="ahpa_WarrantExercisePeriodConditionTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_WarrantExercisePeriodConditionTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The alternate period of time after completion of an initial public offering before a warrant may be exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_WarrantExercisePeriodConditionTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Exercise Period Condition Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_WarrantExercisePeriodConditionTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant exercise period condition two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Warrants expiration term</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:label="ahpa_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:to="ahpa_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of time after completion of a business combination in which the reporting entity is required to file a registration statement with the SEC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Period After Business Combination In Which To File Registration Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum period after business combination in which to file registration statement</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:label="ahpa_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:to="ahpa_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of time after filing within which the registration statement filed with the SEC is expected to become effective.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period Of Time Within Which Registration Statement Is Expected To Become Effective</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of time within which registration statement is expected to become effective</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WarrantRedemptionConditionMinimumSharePrice" xlink:label="ahpa_WarrantRedemptionConditionMinimumSharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_WarrantRedemptionConditionMinimumSharePrice" xlink:to="ahpa_WarrantRedemptionConditionMinimumSharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_WarrantRedemptionConditionMinimumSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_WarrantRedemptionConditionMinimumSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Redemption Condition Minimum Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_WarrantRedemptionConditionMinimumSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant redemption condition minimum share price</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:to="ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption price per share or per unit of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Redemption Price Of Warrants Or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption price per public warrant (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:to="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold number of specified trading days for stock price trigger considered for redemption of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold trading days for redemption of public warrants</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:to="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold consecutive trading days for redemption of public warrants</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_RedemptionPeriod" xlink:label="ahpa_RedemptionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_RedemptionPeriod" xlink:to="ahpa_RedemptionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_RedemptionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_RedemptionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_RedemptionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption period</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xlink:label="ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xlink:to="ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cutoff price used to measure whether dilution of the warrant has occurred. Shares issued below this price will cause the exercise price of the warrant to be adjusted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price Trigger Used To Measure Dilution Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price trigger used to measure dilution of warrant</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:label="ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:to="ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The ratio of gross proceeds from a future offering to total equity proceeds which is used to measure whether dilution of the warrant has occurred. If aggregate gross proceeds from a new offering exceeds a specified percentage of total equity proceeds, the warrant exercise price will be adjusted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Gross New Proceeds To Total Equity Proceeds Used To Measure Dilution Of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:label="ahpa_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:to="ahpa_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of trading days after a business combination during which the share price is compared to the specified dilution trigger share price in order to determine whether the warrant exercise price should be adjusted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Period After Business Combination Used To Measure Dilution of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading period after business combination used to measure dilution of warrant</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WarrantExercisePriceAdjustmentMultiple" xlink:label="ahpa_WarrantExercisePriceAdjustmentMultiple" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_WarrantExercisePriceAdjustmentMultiple" xlink:to="ahpa_WarrantExercisePriceAdjustmentMultiple_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_WarrantExercisePriceAdjustmentMultiple_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_WarrantExercisePriceAdjustmentMultiple_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Exercise Price Adjustment Multiple</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_WarrantExercisePriceAdjustmentMultiple_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant exercise price adjustment multiple</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" xlink:label="ahpa_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" xlink:to="ahpa_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of adjustment of redemption price of stock based on market value and newly issued price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Adjustment of Redemption Price of Warrants or Rights, Percent, Based On Market Value And Newly Issued Price 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment one of redemption price of stock based on market value and newly issued price (as a percent)</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WarrantRedemptionPriceAdjustmentMultiple" xlink:label="ahpa_WarrantRedemptionPriceAdjustmentMultiple" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_WarrantRedemptionPriceAdjustmentMultiple" xlink:to="ahpa_WarrantRedemptionPriceAdjustmentMultiple_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_WarrantRedemptionPriceAdjustmentMultiple_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted redemption price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_WarrantRedemptionPriceAdjustmentMultiple_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Redemption Price Adjustment Multiple</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_WarrantRedemptionPriceAdjustmentMultiple_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant redemption price adjustment multiple</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="ahpa_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:to="ahpa_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of time after completion of a business combination during which the shares or warrant may not be transferred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restrictions On Transfer Period Of Time After Business Combination Completion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ahpa_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restrictions on transfer period of time after business combination completion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_OmniabMember" xlink:label="ahpa_OmniabMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_OmniabMember" xlink:to="ahpa_OmniabMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_OmniabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the OmniAb member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_OmniabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OmniAb</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WorkingCapitalLoansWarrantMember" xlink:label="ahpa_WorkingCapitalLoansWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_WorkingCapitalLoansWarrantMember" xlink:to="ahpa_WorkingCapitalLoansWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_WorkingCapitalLoansWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working capital loans warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_WorkingCapitalLoansWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working Capital Loans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDefaultLongtermDebtAmount" xlink:label="us-gaap_DebtDefaultLongtermDebtAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDefaultLongtermDebtAmount" xlink:to="us-gaap_DebtDefaultLongtermDebtAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDefaultLongtermDebtAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Debt Default, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDefaultLongtermDebtAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of drew down promissory note</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ContributionFromSubsidiaries" xlink:label="ahpa_ContributionFromSubsidiaries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_ContributionFromSubsidiaries" xlink:to="ahpa_ContributionFromSubsidiaries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_ContributionFromSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of contribution to related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_ContributionFromSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contribution From Subsidiaries</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market Funds, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-money equity value</label>
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WeightedAverageSharesPricePerShare" xlink:label="ahpa_WeightedAverageSharesPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ahpa_WeightedAverageSharesPricePerShare" xlink:to="ahpa_WeightedAverageSharesPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ahpa_WeightedAverageSharesPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of weighted average share price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ahpa_WeightedAverageSharesPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Shares Price Per Share</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>ahpa-20220416_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8119.21675 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/27/2022 11:10:01 PM-->
<!--Modified on: 4/27/2022 11:10:01 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DocumentDocumentAndEntityInformation" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#StatementBalanceSheet" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#StatementBalanceSheetParenthetical" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#StatementStatementOfOperations" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#StatementStatementOfChangesInShareholdersDeficit" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#StatementStatementOfCashFlows" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidity" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureInitialPublicOffering" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosurePrivatePlacement" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureRelatedPartyTransactions" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureCommitments" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureShareholdersDeficit" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureSubsequentEvents" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureSummaryOfSignificantAccountingPoliciesClassOrdinarySharesSubjectToPossibleRedemptionDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassOrdinarySharesSubjectToPossibleRedemptionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithInitialPublicOfferingDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithInitialPublicOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNetIncomeLossPerOrdinaryShareDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomeLossPerOrdinaryShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureInitialPublicOfferingDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosurePrivatePlacementDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureRelatedPartyTransactionsFounderSharesDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureCommitmentsDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureCommitmentsForwardPurchaseAgreementDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureShareholdersDeficitPreferredStockSharesDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitPreferredStockSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureShareholdersDeficitCommonStockSharesDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureShareholdersDeficitWarrantsDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="ahpa-20220416.xsd#DisclosureSubsequentEventsDetails" roleURI="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637866978008561563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_637866978008561563" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637866978008561563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_637866978008561563" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637866978008561563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_637866978008561563" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637866978008561563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_637866978008561563" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637866978008561563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637866978008561563" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637866978008561563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_637866978008561563" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637866978008561563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637866978008561563" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637866978008571578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_637866978008571578" order="8" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEET" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637309996491150416" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637866978008571578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637309996491150416" xlink:to="us-gaap_StatementTable_637866978008571578" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637866978008571578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637866978008571578" xlink:to="us-gaap_StatementClassOfStockAxis_637866978008571578" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637866978008571578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637866978008571578" xlink:to="us-gaap_ClassOfStockDomain_637866978008571578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637866978008571578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637866978008571578" xlink:to="us-gaap_CommonClassAMember_637866978008571578" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_637866978008571578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637866978008571578" xlink:to="us-gaap_CommonClassBMember_637866978008571578" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637866978008571578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637866978008571578" xlink:to="us-gaap_StatementLineItems_637866978008571578" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637866978008571578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008571578" xlink:to="us-gaap_AssetsAbstract_637866978008571578" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637866978008581573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637866978008571578" xlink:to="us-gaap_AssetsCurrentAbstract_637866978008581573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637866978008581573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637866978008581573" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637866978008581573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_637866978008581573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637866978008581573" xlink:to="us-gaap_PrepaidExpenseCurrent_637866978008581573" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637866978008581573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637866978008581573" xlink:to="us-gaap_AssetsCurrent_637866978008581573" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_637866978008581573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637866978008571578" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent_637866978008581573" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637866978008581573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637866978008571578" xlink:to="us-gaap_Assets_637866978008581573" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637866978008581573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008571578" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637866978008581573" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637866978008581573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637866978008581573" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637866978008581573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637866978008581573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637866978008581573" xlink:to="us-gaap_AccountsPayableCurrent_637866978008581573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_AccruedExpenseRelatedPartyCurrent" xlink:label="ahpa_AccruedExpenseRelatedPartyCurrent_637866978008581573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637866978008581573" xlink:to="ahpa_AccruedExpenseRelatedPartyCurrent_637866978008581573" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_AccruedOfferingCostsAndExpensesCurrent" xlink:label="ahpa_AccruedOfferingCostsAndExpensesCurrent_637866978008581573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637866978008581573" xlink:to="ahpa_AccruedOfferingCostsAndExpensesCurrent_637866978008581573" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_637866978008591557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637866978008581573" xlink:to="us-gaap_DueToRelatedPartiesCurrent_637866978008591557" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637866978008591557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637866978008581573" xlink:to="us-gaap_LiabilitiesCurrent_637866978008591557" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_DeferredOfferingCostsNoncurrent" xlink:label="ahpa_DeferredOfferingCostsNoncurrent_637866978008591557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637866978008581573" xlink:to="ahpa_DeferredOfferingCostsNoncurrent_637866978008591557" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637866978008591557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637866978008581573" xlink:to="us-gaap_Liabilities_637866978008591557" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637866978008591557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637866978008581573" xlink:to="us-gaap_CommitmentsAndContingencies_637866978008591557" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637866978008591557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637866978008581573" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637866978008591557" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637866978008591557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637866978008581573" xlink:to="us-gaap_StockholdersEquityAbstract_637866978008591557" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637866978008591557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637866978008591557" xlink:to="us-gaap_PreferredStockValue_637866978008591557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637866978008601553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637866978008591557" xlink:to="us-gaap_CommonStockValue_637866978008601553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637866978008601553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637866978008591557" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637866978008601553" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637866978008601553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637866978008591557" xlink:to="us-gaap_StockholdersEquity_637866978008601553" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637866978008601553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637866978008581573" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637866978008601553" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical" xlink:type="extended" xlink:title="00105 - Statement - BALANCE SHEET (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637309996491800131" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637866978008611561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637309996491800131" xlink:to="us-gaap_StatementTable_637866978008611561" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637866978008611561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637866978008611561" xlink:to="us-gaap_StatementClassOfStockAxis_637866978008611561" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637866978008611561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637866978008611561" xlink:to="us-gaap_ClassOfStockDomain_637866978008611561" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637866978008611561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637866978008611561" xlink:to="us-gaap_CommonClassAMember_637866978008611561" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_CommonClassaSubjectToRedemptionMember" xlink:label="ahpa_CommonClassaSubjectToRedemptionMember_637866978008611561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonClassAMember_637866978008611561" xlink:to="ahpa_CommonClassaSubjectToRedemptionMember_637866978008611561" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_637866978008611561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637866978008611561" xlink:to="us-gaap_CommonClassBMember_637866978008611561" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637866978008611561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637866978008611561" xlink:to="us-gaap_StatementLineItems_637866978008611561" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637866978008611561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008611561" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637866978008611561" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637866978008611561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008611561" xlink:to="us-gaap_PreferredStockSharesAuthorized_637866978008611561" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637866978008611561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008611561" xlink:to="us-gaap_PreferredStockSharesIssued_637866978008611561" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637866978008621557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008611561" xlink:to="us-gaap_PreferredStockSharesOutstanding_637866978008621557" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637866978008621557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008611561" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637866978008621557" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637866978008621557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008611561" xlink:to="us-gaap_CommonStockSharesAuthorized_637866978008621557" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637866978008621557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008611561" xlink:to="us-gaap_CommonStockSharesIssued_637866978008621557" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637866978008621557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008611561" xlink:to="us-gaap_CommonStockSharesOutstanding_637866978008621557" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637866978008621557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008611561" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637866978008621557" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations" xlink:type="extended" xlink:title="00200 - Statement - STATEMENT OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637866978008621557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable_637866978008621557" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637866978008621557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637866978008621557" xlink:to="us-gaap_StatementClassOfStockAxis_637866978008621557" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637866978008631563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637866978008621557" xlink:to="us-gaap_ClassOfStockDomain_637866978008631563" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637866978008631563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637866978008631563" xlink:to="us-gaap_CommonClassAMember_637866978008631563" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_637866978008631563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637866978008631563" xlink:to="us-gaap_CommonClassBMember_637866978008631563" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637866978008631563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637866978008621557" xlink:to="us-gaap_StatementLineItems_637866978008631563" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses_637866978008631563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008631563" xlink:to="us-gaap_OperatingCostsAndExpenses_637866978008631563" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637866978008631563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008631563" xlink:to="us-gaap_NetIncomeLoss_637866978008631563" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637866978008631563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008631563" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637866978008631563" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637866978008631563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008631563" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637866978008631563" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637866978008631563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008631563" xlink:to="us-gaap_EarningsPerShareBasic_637866978008631563" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637866978008631563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008631563" xlink:to="us-gaap_EarningsPerShareDiluted_637866978008631563" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit" xlink:type="extended" xlink:title="00300 - Statement - STATEMENT OF CHANGES IN SHAREHOLDERS' DEFICIT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_637309996491800131" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637866978008641555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_637309996491800131" xlink:to="us-gaap_StatementTable_637866978008641555" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637866978008641555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637866978008641555" xlink:to="us-gaap_StatementClassOfStockAxis_637866978008641555" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637866978008641555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637866978008641555" xlink:to="us-gaap_CommonClassAMember_637866978008641555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_637866978008641555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637866978008641555" xlink:to="us-gaap_CommonClassBMember_637866978008641555" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637866978008641555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637866978008641555" xlink:to="us-gaap_ClassOfStockDomain_637866978008641555" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637866978008641555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637866978008641555" xlink:to="us-gaap_StatementEquityComponentsAxis_637866978008641555" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637866978008641555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637866978008641555" xlink:to="us-gaap_CommonStockMember_637866978008641555" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637866978008641555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637866978008641555" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637866978008641555" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637866978008641555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637866978008641555" xlink:to="us-gaap_RetainedEarningsMember_637866978008641555" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637866978008641555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637866978008641555" xlink:to="us-gaap_EquityComponentDomain_637866978008641555" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637866978008641555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637866978008641555" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637866978008641555" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PublicWarrantsMember" xlink:label="ahpa_PublicWarrantsMember_637866978008651561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637866978008641555" xlink:to="ahpa_PublicWarrantsMember_637866978008651561" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PrivatePlacementWarrantsMember" xlink:label="ahpa_PrivatePlacementWarrantsMember_637866978008651561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637866978008641555" xlink:to="ahpa_PrivatePlacementWarrantsMember_637866978008651561" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637866978008651561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637866978008641555" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637866978008651561" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637866978008651561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637866978008641555" xlink:to="us-gaap_StatementLineItems_637866978008651561" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637866978008651561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008651561" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637866978008651561" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637866978008651561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637866978008651561" xlink:to="us-gaap_StockholdersEquity_637866978008651561" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_637866978008651561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637866978008651561" xlink:to="us-gaap_SharesIssued_637866978008651561" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637866978008651561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637866978008651561" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637866978008651561" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637866978008651561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637866978008651561" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637866978008651561" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_637866978008651561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637866978008651561" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_637866978008651561" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_637866978008661552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637866978008651561" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_637866978008661552" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637866978008661552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637866978008651561" xlink:to="us-gaap_NetIncomeLoss_637866978008661552" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637866978008661552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637866978008651561" xlink:to="us-gaap_StockholdersEquity_637866978008661552" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_637866978008661552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637866978008651561" xlink:to="us-gaap_SharesIssued_637866978008661552" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - STATEMENT OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637866978008661552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637866978008661552" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637866978008671571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637866978008661552" xlink:to="us-gaap_ProfitLoss_637866978008671571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637866978008671571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637866978008661552" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637866978008671571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_637866978008671571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637866978008671571" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_637866978008671571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_637866978008671571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637866978008671571" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_637866978008671571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_637866978008671571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637866978008671571" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_637866978008671571" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_IncreaseDecreaseInAccruedLiabilitiesRelatedParties" xlink:label="ahpa_IncreaseDecreaseInAccruedLiabilitiesRelatedParties_637866978008671571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637866978008671571" xlink:to="ahpa_IncreaseDecreaseInAccruedLiabilitiesRelatedParties_637866978008671571" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637866978008671571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637866978008661552" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637866978008671571" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637866978008671571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637866978008671571" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PaymentsForInvestmentOfCashInTrustAccount" xlink:label="ahpa_PaymentsForInvestmentOfCashInTrustAccount_637866978008671571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637866978008671571" xlink:to="ahpa_PaymentsForInvestmentOfCashInTrustAccount_637866978008671571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637866978008671571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637866978008671571" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637866978008671571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637866978008671571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637866978008671571" order="3" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637866978008681557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637866978008671571" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637866978008681557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ProceedsFromIssuanceInitialPublicOfferingNet" xlink:label="ahpa_ProceedsFromIssuanceInitialPublicOfferingNet_637866978008681557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637866978008671571" xlink:to="ahpa_ProceedsFromIssuanceInitialPublicOfferingNet_637866978008681557" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637866978008681557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637866978008671571" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637866978008681557" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_637866978008681557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637866978008671571" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_637866978008681557" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_Repaymentfromrelatedpartydebt" xlink:label="ahpa_Repaymentfromrelatedpartydebt_637866978008681557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637866978008671571" xlink:to="ahpa_Repaymentfromrelatedpartydebt_637866978008681557" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637866978008681557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637866978008671571" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637866978008681557" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637866978008681557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637866978008671571" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637866978008681557" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637866978008681557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637866978008681557" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637866978008681557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637866978008681557" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637866978008691554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637866978008691554" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637866978008691554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637866978008691554" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue" xlink:label="ahpa_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue_637866978008691554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637866978008691554" xlink:to="ahpa_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue_637866978008691554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_OfferingCostsIncludedInAccountsPayableAccruedExpenses" xlink:label="ahpa_OfferingCostsIncludedInAccountsPayableAccruedExpenses_637866978008691554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637866978008691554" xlink:to="ahpa_OfferingCostsIncludedInAccountsPayableAccruedExpenses_637866978008691554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_DeferredUnderwritingFeePayable" xlink:label="ahpa_DeferredUnderwritingFeePayable_637866978008691554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637866978008691554" xlink:to="ahpa_DeferredUnderwritingFeePayable_637866978008691554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidity" xlink:type="extended" xlink:title="10101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_637866978008701567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_637866978008701567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637866978008701567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637866978008701567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOffering" xlink:type="extended" xlink:title="10301 - Disclosure - INITIAL PUBLIC OFFERING" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_InitialPublicOfferingAbstract" xlink:label="ahpa_InitialPublicOfferingAbstract" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_InitialPublicOfferingTextBlock" xlink:label="ahpa_InitialPublicOfferingTextBlock_637866978008701567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ahpa_InitialPublicOfferingAbstract" xlink:to="ahpa_InitialPublicOfferingTextBlock_637866978008701567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacement" xlink:type="extended" xlink:title="10401 - Disclosure - PRIVATE PLACEMENT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PrivatePlacementAbstract" xlink:label="ahpa_PrivatePlacementAbstract" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PrivatePlacementTextBlock" xlink:label="ahpa_PrivatePlacementTextBlock_637866978008701567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ahpa_PrivatePlacementAbstract" xlink:to="ahpa_PrivatePlacementTextBlock_637866978008701567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="10501 - Disclosure - RELATED PARTY TRANSACTIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637866978008701567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637866978008701567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitments" xlink:type="extended" xlink:title="10601 - Disclosure - COMMITMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637866978008711569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637866978008711569" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficit" xlink:type="extended" xlink:title="10701 - Disclosure - SHAREHOLDERS' DEFICIT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637866978008711569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637866978008711569" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="10801 - Disclosure - SUBSEQUENT EVENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637866978008711569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_637866978008711569" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637866978008711569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637866978008711569" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_EmergingGrowthCompanyPolicyTextBlock" xlink:label="ahpa_EmergingGrowthCompanyPolicyTextBlock_637866978008711569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ahpa_EmergingGrowthCompanyPolicyTextBlock_637866978008711569" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637866978008711569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637866978008711569" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637866978008721566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637866978008721566" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_CommonStockSubjectToPossibleRedemptionPolicyTextBlock" xlink:label="ahpa_CommonStockSubjectToPossibleRedemptionPolicyTextBlock_637866978008721566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ahpa_CommonStockSubjectToPossibleRedemptionPolicyTextBlock_637866978008721566" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_637866978008721566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_637866978008721566" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637866978008721566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637866978008721566" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637866978008721566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637866978008721566" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637866978008721566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637866978008721566" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_637866978008721566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_637866978008721566" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637866978008721566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637866978008721566" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock_637866978008721566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_TemporaryEquityTableTextBlock_637866978008721566" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637866978008731565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637866978008731565" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails" xlink:type="extended" xlink:title="40101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_637326625217147953" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637866978008731565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_637326625217147953" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637866978008731565" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637866978008731565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637866978008731565" xlink:to="us-gaap_StatementClassOfStockAxis_637866978008731565" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637866978008731565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637866978008731565" xlink:to="us-gaap_ClassOfStockDomain_637866978008731565" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637866978008731565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637866978008731565" xlink:to="us-gaap_CommonClassAMember_637866978008731565" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637866978008731565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637866978008731565" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637866978008731565" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637866978008731565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637866978008731565" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637866978008731565" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637866978008731565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637866978008731565" xlink:to="us-gaap_IPOMember_637866978008731565" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637866978008731565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637866978008731565" xlink:to="us-gaap_PrivatePlacementMember_637866978008731565" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637866978008731565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637866978008731565" xlink:to="us-gaap_OverAllotmentOptionMember_637866978008731565" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637866978008731565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637866978008731565" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637866978008731565" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637866978008741559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637866978008731565" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637866978008741559" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637866978008741559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637866978008741559" xlink:to="us-gaap_WarrantMember_637866978008741559" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PrivatePlacementWarrantsMember" xlink:label="ahpa_PrivatePlacementWarrantsMember_637866978008741559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_637866978008741559" xlink:to="ahpa_PrivatePlacementWarrantsMember_637866978008741559" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PublicWarrantsMember" xlink:label="ahpa_PublicWarrantsMember_637866978008741559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_637866978008741559" xlink:to="ahpa_PublicWarrantsMember_637866978008741559" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637866978008731565" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:label="ahpa_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_637866978008741559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="ahpa_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_637866978008741559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="ahpa_UnitsIssuedDuringPeriodSharesNewIssues_637866978008741559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="ahpa_UnitsIssuedDuringPeriodSharesNewIssues_637866978008741559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637866978008741559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="us-gaap_SharesIssuedPricePerShare_637866978008741559" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637866978008741559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637866978008741559" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637866978008741559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637866978008741559" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights_637866978008751554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights_637866978008751554" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_637866978008751554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_637866978008751554" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TransactionCosts" xlink:label="ahpa_TransactionCosts_637866978008751554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="ahpa_TransactionCosts_637866978008751554" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SaleOfStockUnderwritingFees" xlink:label="ahpa_SaleOfStockUnderwritingFees_637866978008751554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="ahpa_SaleOfStockUnderwritingFees_637866978008751554" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_DeferredOfferingCostsNoncurrent" xlink:label="ahpa_DeferredOfferingCostsNoncurrent_637866978008751554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="ahpa_DeferredOfferingCostsNoncurrent_637866978008751554" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SaleOfStockOtherOfferingCosts" xlink:label="ahpa_SaleOfStockOtherOfferingCosts_637866978008751554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="ahpa_SaleOfStockOtherOfferingCosts_637866978008751554" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637866978008751554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637866978008751554" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_637866978008751554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_637866978008751554" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637866978008751554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="us-gaap_SharePrice_637866978008751554" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_InvestmentsMaximumMaturityTerm" xlink:label="ahpa_InvestmentsMaximumMaturityTerm_637866978008761553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="ahpa_InvestmentsMaximumMaturityTerm_637866978008761553" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MonthsToCompleteInitialBusinessCombination" xlink:label="ahpa_MonthsToCompleteInitialBusinessCombination_637866978008761553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="ahpa_MonthsToCompleteInitialBusinessCombination_637866978008761553" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination" xlink:label="ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_637866978008761553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination_637866978008761553" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination" xlink:label="ahpa_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination_637866978008761553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="ahpa_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination_637866978008761553" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent" xlink:label="ahpa_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent_637866978008761553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="ahpa_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent_637866978008761553" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ThresholdBusinessDaysForRedemptionOfPublicShares" xlink:label="ahpa_ThresholdBusinessDaysForRedemptionOfPublicShares_637866978008771683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="ahpa_ThresholdBusinessDaysForRedemptionOfPublicShares_637866978008771683" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MaximumNetInterestToPayDissolutionExpenses" xlink:label="ahpa_MaximumNetInterestToPayDissolutionExpenses_637866978008771683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="ahpa_MaximumNetInterestToPayDissolutionExpenses_637866978008771683" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WorkingCapitalSurplus" xlink:label="ahpa_WorkingCapitalSurplus_637866978008771683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="ahpa_WorkingCapitalSurplus_637866978008771683" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants" xlink:label="ahpa_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants_637866978008771683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008741559" xlink:to="ahpa_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants_637866978008771683" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637866978008781731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_637866978008781731" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637866978008781731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637866978008781731" xlink:to="us-gaap_StatementClassOfStockAxis_637866978008781731" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637866978008781731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637866978008781731" xlink:to="us-gaap_ClassOfStockDomain_637866978008781731" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637866978008781731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637866978008781731" xlink:to="us-gaap_CommonClassAMember_637866978008781731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637866978008781731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637866978008781731" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637866978008781731" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637866978008781731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637866978008781731" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637866978008781731" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637866978008781731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637866978008781731" xlink:to="us-gaap_OverAllotmentOptionMember_637866978008781731" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637866978008781731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637866978008781731" xlink:to="us-gaap_IPOMember_637866978008781731" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637866978008791730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637866978008781731" xlink:to="us-gaap_StatementLineItems_637866978008791730" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="ahpa_UnitsIssuedDuringPeriodSharesNewIssues_637866978008791730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008791730" xlink:to="ahpa_UnitsIssuedDuringPeriodSharesNewIssues_637866978008791730" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_637866978008791730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008791730" xlink:to="us-gaap_UnrecognizedTaxBenefits_637866978008791730" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_637866978008791730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008791730" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_637866978008791730" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount_637866978008791730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008791730" xlink:to="us-gaap_CashFDICInsuredAmount_637866978008791730" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassOrdinarySharesSubjectToPossibleRedemptionDetails" xlink:type="extended" xlink:title="40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A Ordinary Shares Subject to Possible Redemption (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637866978008791730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637866978008791730" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TemporaryEquityProceedsAllocatedToWarrants" xlink:label="ahpa_TemporaryEquityProceedsAllocatedToWarrants_637866978008791730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="ahpa_TemporaryEquityProceedsAllocatedToWarrants_637866978008791730" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TemporaryEquityIssuanceCosts" xlink:label="ahpa_TemporaryEquityIssuanceCosts_637866978008791730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="ahpa_TemporaryEquityIssuanceCosts_637866978008791730" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_637866978008801566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_637866978008801566" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637866978008801566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637866978008801566" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithInitialPublicOfferingDetails" xlink:type="extended" xlink:title="40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Offering Costs associated with the Initial Public Offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_4" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TransactionCosts" xlink:label="ahpa_TransactionCosts_637866978008801566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="ahpa_TransactionCosts_637866978008801566" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SaleOfStockUnderwritingFees" xlink:label="ahpa_SaleOfStockUnderwritingFees_637866978008801566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="ahpa_SaleOfStockUnderwritingFees_637866978008801566" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_DeferredOfferingCostsNoncurrent" xlink:label="ahpa_DeferredOfferingCostsNoncurrent_637866978008801566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="ahpa_DeferredOfferingCostsNoncurrent_637866978008801566" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SaleOfStockOtherOfferingCosts" xlink:label="ahpa_SaleOfStockOtherOfferingCosts_637866978008801566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="ahpa_SaleOfStockOtherOfferingCosts_637866978008801566" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_OfferingCostsReductionOfTemporaryEquity" xlink:label="ahpa_OfferingCostsReductionOfTemporaryEquity_637866978008801566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="ahpa_OfferingCostsReductionOfTemporaryEquity_637866978008801566" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637866978008801566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637866978008801566" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails" xlink:type="extended" xlink:title="40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net income per ordinary share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637866978008801566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_3" xlink:to="us-gaap_StatementTable_637866978008801566" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637866978008811568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637866978008801566" xlink:to="us-gaap_StatementClassOfStockAxis_637866978008811568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637866978008811568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637866978008811568" xlink:to="us-gaap_ClassOfStockDomain_637866978008811568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637866978008811568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637866978008811568" xlink:to="us-gaap_CommonClassAMember_637866978008811568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_637866978008811568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637866978008811568" xlink:to="us-gaap_CommonClassBMember_637866978008811568" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637866978008811568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637866978008801566" xlink:to="us-gaap_StatementLineItems_637866978008811568" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_637866978008811568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637866978008811568" xlink:to="us-gaap_EarningsPerShareAbstract_637866978008811568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_637866978008811568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637866978008811568" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_637866978008811568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637866978008811568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_637866978008811568" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637866978008811568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637866978008811568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_637866978008811568" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637866978008811568" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637866978008811568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637866978008811568" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637866978008811568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637866978008811568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637866978008811568" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637866978008811568" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637866978008811568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637866978008811568" xlink:to="us-gaap_EarningsPerShareBasic_637866978008811568" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637866978008821553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637866978008811568" xlink:to="us-gaap_EarningsPerShareDiluted_637866978008821553" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomeLossPerOrdinaryShareDetails" xlink:type="extended" xlink:title="40205 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Income (Loss) Per Ordinary Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637866978008821553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_5" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637866978008821553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637866978008821553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637866978008821553" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637866978008821553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637866978008821553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637866978008821553" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637866978008821553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637866978008821553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637866978008821553" xlink:to="us-gaap_WarrantMember_637866978008821553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637866978008821553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637866978008821553" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637866978008821553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637866978008821553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637866978008821553" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637866978008821553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails" xlink:type="extended" xlink:title="40301 - Disclosure - INITIAL PUBLIC OFFERING (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_InitialPublicOfferingAbstract" xlink:label="ahpa_InitialPublicOfferingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637866978008821553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ahpa_InitialPublicOfferingAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637866978008821553" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637866978008821553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637866978008821553" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637866978008821553" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637866978008831565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637866978008821553" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637866978008831565" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637866978008831565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637866978008831565" xlink:to="us-gaap_IPOMember_637866978008831565" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637866978008831565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637866978008831565" xlink:to="us-gaap_OverAllotmentOptionMember_637866978008831565" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637866978008831565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637866978008821553" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637866978008831565" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637866978008831565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637866978008831565" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637866978008831565" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PublicWarrantsMember" xlink:label="ahpa_PublicWarrantsMember_637866978008831565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637866978008831565" xlink:to="ahpa_PublicWarrantsMember_637866978008831565" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_637866978008831565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637866978008821553" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_637866978008831565" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="ahpa_UnitsIssuedDuringPeriodSharesNewIssues_637866978008831565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008831565" xlink:to="ahpa_UnitsIssuedDuringPeriodSharesNewIssues_637866978008831565" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637866978008831565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008831565" xlink:to="us-gaap_SharesIssuedPricePerShare_637866978008831565" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637866978008831565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008831565" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637866978008831565" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_NumberOfSharesIssuedPerUnit" xlink:label="ahpa_NumberOfSharesIssuedPerUnit_637866978008831565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008831565" xlink:to="ahpa_NumberOfSharesIssuedPerUnit_637866978008831565" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_NumberOfWarrantsIssuedPerUnit" xlink:label="ahpa_NumberOfWarrantsIssuedPerUnit_637866978008831565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008831565" xlink:to="ahpa_NumberOfWarrantsIssuedPerUnit_637866978008831565" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_637866978008841555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008831565" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_637866978008841555" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637866978008841555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008831565" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637866978008841555" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PRIVATE PLACEMENT (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PrivatePlacementAbstract" xlink:label="ahpa_PrivatePlacementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637866978008841555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ahpa_PrivatePlacementAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637866978008841555" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637866978008841555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637866978008841555" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637866978008841555" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637866978008841555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637866978008841555" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637866978008841555" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637866978008841555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637866978008841555" xlink:to="us-gaap_OverAllotmentOptionMember_637866978008841555" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637866978008841555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637866978008841555" xlink:to="us-gaap_PrivatePlacementMember_637866978008841555" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637866978008841555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637866978008841555" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637866978008841555" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637866978008841555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637866978008841555" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637866978008841555" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PrivatePlacementWarrantsMember" xlink:label="ahpa_PrivatePlacementWarrantsMember_637866978008851560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637866978008841555" xlink:to="ahpa_PrivatePlacementWarrantsMember_637866978008851560" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_637866978008851560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637866978008841555" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_637866978008851560" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637866978008851560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008851560" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637866978008851560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights_637866978008851560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008851560" xlink:to="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights_637866978008851560" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_637866978008851560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008851560" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_637866978008851560" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_637866978008851560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008851560" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_637866978008851560" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637866978008851560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637866978008851560" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637866978008851560" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - RELATED PARTY TRANSACTIONS - Founder Shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637866978008861551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637866978008861551" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_637866978008861551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637866978008861551" xlink:to="us-gaap_RelatedPartyTransactionAxis_637866978008861551" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_637866978008861551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_637866978008861551" xlink:to="us-gaap_RelatedPartyTransactionDomain_637866978008861551" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_FounderSharesMember" xlink:label="ahpa_FounderSharesMember_637866978008861551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637866978008861551" xlink:to="ahpa_FounderSharesMember_637866978008861551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637866978008861551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637866978008861551" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637866978008861551" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637866978008861551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637866978008861551" xlink:to="us-gaap_RelatedPartyDomain_637866978008861551" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SponsorMember" xlink:label="ahpa_SponsorMember_637866978008861551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637866978008861551" xlink:to="ahpa_SponsorMember_637866978008861551" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637866978008861551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637866978008861551" xlink:to="us-gaap_StatementClassOfStockAxis_637866978008861551" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637866978008874408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637866978008861551" xlink:to="us-gaap_ClassOfStockDomain_637866978008874408" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_637866978008874408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637866978008874408" xlink:to="us-gaap_CommonClassBMember_637866978008874408" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637866978008874408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637866978008861551" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637866978008874408" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637866978008874408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637866978008874408" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637866978008874408" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637866978008874408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637866978008874408" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637866978008874408" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_NumberOfSharesSubjectToForfeiture" xlink:label="ahpa_NumberOfSharesSubjectToForfeiture_637866978008874408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637866978008874408" xlink:to="ahpa_NumberOfSharesSubjectToForfeiture_637866978008874408" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" xlink:label="ahpa_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders_637866978008881565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637866978008874408" xlink:to="ahpa_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders_637866978008881565" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination" xlink:label="ahpa_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination_637866978008881565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637866978008874408" xlink:to="ahpa_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination_637866978008881565" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:label="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_637866978008881565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637866978008874408" xlink:to="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_637866978008881565" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:label="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_637866978008881565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637866978008874408" xlink:to="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_637866978008881565" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_637866978008881565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637866978008874408" xlink:to="ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_637866978008881565" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="ahpa_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_637866978008881565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637866978008874408" xlink:to="ahpa_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_637866978008881565" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" xlink:title="40502 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637866978008891569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637866978008891569" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_637866978008891569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637866978008891569" xlink:to="us-gaap_RelatedPartyTransactionAxis_637866978008891569" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_637866978008891569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_637866978008891569" xlink:to="us-gaap_RelatedPartyTransactionDomain_637866978008891569" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PromissoryNoteWithRelatedPartyMember" xlink:label="ahpa_PromissoryNoteWithRelatedPartyMember_637866978008891569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637866978008891569" xlink:to="ahpa_PromissoryNoteWithRelatedPartyMember_637866978008891569" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_AdministrativeSupportAgreementMember" xlink:label="ahpa_AdministrativeSupportAgreementMember_637866978008891569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637866978008891569" xlink:to="ahpa_AdministrativeSupportAgreementMember_637866978008891569" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_RelatedPartyLoansMember" xlink:label="ahpa_RelatedPartyLoansMember_637866978008981558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637866978008891569" xlink:to="ahpa_RelatedPartyLoansMember_637866978008981558" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637866978008981558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637866978008891569" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637866978008981558" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="ahpa_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_637866978008981558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637866978008981558" xlink:to="ahpa_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_637866978008981558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_OfferingCostsIncludedInPromissoryNoteRelatedParty" xlink:label="ahpa_OfferingCostsIncludedInPromissoryNoteRelatedParty_637866978008981558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637866978008981558" xlink:to="ahpa_OfferingCostsIncludedInPromissoryNoteRelatedParty_637866978008981558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_637866978008981558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637866978008981558" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_637866978008981558" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_637866978008981558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637866978008981558" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_637866978008981558" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:label="ahpa_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_637866978008981558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637866978008981558" xlink:to="ahpa_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_637866978008981558" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637866978008981558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637866978008981558" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637866978008981558" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MaximumLoansConvertibleIntoWarrants" xlink:label="ahpa_MaximumLoansConvertibleIntoWarrants_637866978008981558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637866978008981558" xlink:to="ahpa_MaximumLoansConvertibleIntoWarrants_637866978008981558" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights_637866978008991563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637866978008981558" xlink:to="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights_637866978008991563" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WorkingCapitalLoansOutstanding" xlink:label="ahpa_WorkingCapitalLoansOutstanding_637866978008991563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637866978008981558" xlink:to="ahpa_WorkingCapitalLoansOutstanding_637866978008991563" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - COMMITMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MaximumNumberOfDemandsForRegistrationOfSecurities" xlink:label="ahpa_MaximumNumberOfDemandsForRegistrationOfSecurities_637866978008991563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ahpa_MaximumNumberOfDemandsForRegistrationOfSecurities_637866978008991563" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_DeferredFeePerUnit" xlink:label="ahpa_DeferredFeePerUnit_637866978008991563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ahpa_DeferredFeePerUnit_637866978008991563" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_AggregateDeferredUnderwritingFeePayable" xlink:label="ahpa_AggregateDeferredUnderwritingFeePayable_637866978008991563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ahpa_AggregateDeferredUnderwritingFeePayable_637866978008991563" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_UnderwritingCashDiscountPerUnit" xlink:label="ahpa_UnderwritingCashDiscountPerUnit_637866978008991563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ahpa_UnderwritingCashDiscountPerUnit_637866978008991563" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_UnderwriterCashDiscount" xlink:label="ahpa_UnderwriterCashDiscount_637866978008991563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ahpa_UnderwriterCashDiscount_637866978008991563" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails" xlink:type="extended" xlink:title="40602 - Disclosure - COMMITMENTS - Forward Purchase Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_CommitmentsAndContingenciesTable" xlink:label="ahpa_CommitmentsAndContingenciesTable_637866978009001569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="ahpa_CommitmentsAndContingenciesTable_637866978009001569" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637866978009001569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ahpa_CommitmentsAndContingenciesTable_637866978009001569" xlink:to="us-gaap_StatementClassOfStockAxis_637866978009001569" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637866978009001569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637866978009001569" xlink:to="us-gaap_ClassOfStockDomain_637866978009001569" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637866978009001569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637866978009001569" xlink:to="us-gaap_CommonClassAMember_637866978009001569" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637866978009001569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ahpa_CommitmentsAndContingenciesTable_637866978009001569" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637866978009001569" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637866978009001569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637866978009001569" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637866978009001569" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637866978009001569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637866978009001569" xlink:to="us-gaap_WarrantMember_637866978009001569" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_CommitmentsAndContingenciesLineItems" xlink:label="ahpa_CommitmentsAndContingenciesLineItems_637866978009001569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ahpa_CommitmentsAndContingenciesTable_637866978009001569" xlink:to="ahpa_CommitmentsAndContingenciesLineItems_637866978009001569" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SharesToBePurchasedPursuantToAgreements" xlink:label="ahpa_SharesToBePurchasedPursuantToAgreements_637866978009001569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ahpa_CommitmentsAndContingenciesLineItems_637866978009001569" xlink:to="ahpa_SharesToBePurchasedPursuantToAgreements_637866978009001569" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WarrantsToBePurchasedPursuantToAgreements" xlink:label="ahpa_WarrantsToBePurchasedPursuantToAgreements_637866978009001569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ahpa_CommitmentsAndContingenciesLineItems_637866978009001569" xlink:to="ahpa_WarrantsToBePurchasedPursuantToAgreements_637866978009001569" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637866978009001569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ahpa_CommitmentsAndContingenciesLineItems_637866978009001569" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637866978009001569" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_637866978009001569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ahpa_CommitmentsAndContingenciesLineItems_637866978009001569" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_637866978009001569" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitPreferredStockSharesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - SHAREHOLDERS' DEFICIT - Preferred Stock Shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637866978009011559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_637866978009011559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637866978009011559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637866978009011559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637866978009011559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_637866978009011559" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637866978009011559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_637866978009011559" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - SHAREHOLDERS' DEFICIT - Common Stock Shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_637866978009011559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_637866978009011559" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637866978009011559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637866978009011559" xlink:to="us-gaap_StatementClassOfStockAxis_637866978009011559" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637866978009021567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637866978009011559" xlink:to="us-gaap_ClassOfStockDomain_637866978009021567" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637866978009021567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637866978009021567" xlink:to="us-gaap_CommonClassAMember_637866978009021567" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_CommonClassaSubjectToRedemptionMember" xlink:label="ahpa_CommonClassaSubjectToRedemptionMember_637866978009021567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonClassAMember_637866978009021567" xlink:to="ahpa_CommonClassaSubjectToRedemptionMember_637866978009021567" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_637866978009021567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637866978009021567" xlink:to="us-gaap_CommonClassBMember_637866978009021567" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_637866978009021567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637866978009011559" xlink:to="us-gaap_ClassOfStockLineItems_637866978009021567" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637866978009021567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637866978009021567" xlink:to="us-gaap_CommonStockSharesAuthorized_637866978009021567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637866978009021567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637866978009021567" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637866978009021567" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_CommonStockNumberOfVotesPerShare" xlink:label="ahpa_CommonStockNumberOfVotesPerShare_637866978009021567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637866978009021567" xlink:to="ahpa_CommonStockNumberOfVotesPerShare_637866978009021567" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637866978009031708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637866978009021567" xlink:to="us-gaap_CommonStockSharesIssued_637866978009031708" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637866978009031708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637866978009021567" xlink:to="us-gaap_CommonStockSharesOutstanding_637866978009031708" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637866978009031708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637866978009021567" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637866978009031708" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ConvertibleStockConversionRatios" xlink:label="ahpa_ConvertibleStockConversionRatios_637866978009031708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637866978009021567" xlink:to="ahpa_ConvertibleStockConversionRatios_637866978009031708" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - SHAREHOLDERS' DEFICIT - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_637866978009031708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_637866978009031708" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637866978009031708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637866978009031708" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637866978009031708" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637866978009031708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637866978009031708" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637866978009031708" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637866978009041557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637866978009031708" xlink:to="us-gaap_WarrantMember_637866978009041557" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PublicWarrantsMember" xlink:label="ahpa_PublicWarrantsMember_637866978009041557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_637866978009041557" xlink:to="ahpa_PublicWarrantsMember_637866978009041557" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637866978009041557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637866978009031708" xlink:to="srt_StatementScenarioAxis_637866978009041557" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637866978009041557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637866978009041557" xlink:to="srt_ScenarioUnspecifiedDomain_637866978009041557" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:label="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_637866978009041557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637866978009041557" xlink:to="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_637866978009041557" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" xlink:label="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_637866978009041557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637866978009041557" xlink:to="ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_637866978009041557" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637866978009041557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637866978009031708" xlink:to="us-gaap_StatementClassOfStockAxis_637866978009041557" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637866978009041557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637866978009041557" xlink:to="us-gaap_ClassOfStockDomain_637866978009041557" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_637866978009041557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637866978009041557" xlink:to="us-gaap_CommonClassBMember_637866978009041557" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_637866978009041557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637866978009031708" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_637866978009041557" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WarrantExercisePeriodConditionTwo" xlink:label="ahpa_WarrantExercisePeriodConditionTwo_637866978009041557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637866978009041557" xlink:to="ahpa_WarrantExercisePeriodConditionTwo_637866978009041557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_637866978009051555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637866978009041557" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_637866978009051555" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:label="ahpa_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_637866978009051555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637866978009041557" xlink:to="ahpa_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_637866978009051555" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:label="ahpa_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_637866978009051555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637866978009041557" xlink:to="ahpa_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_637866978009051555" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WarrantRedemptionConditionMinimumSharePrice" xlink:label="ahpa_WarrantRedemptionConditionMinimumSharePrice_637866978009051555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637866978009041557" xlink:to="ahpa_WarrantRedemptionConditionMinimumSharePrice_637866978009051555" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_637866978009051555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637866978009041557" xlink:to="ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_637866978009051555" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_637866978009051555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637866978009041557" xlink:to="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_637866978009051555" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_637866978009051555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637866978009041557" xlink:to="ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_637866978009051555" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_RedemptionPeriod" xlink:label="ahpa_RedemptionPeriod_637866978009051555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637866978009041557" xlink:to="ahpa_RedemptionPeriod_637866978009051555" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants" xlink:label="ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants_637866978009051555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637866978009041557" xlink:to="ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants_637866978009051555" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:label="ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_637866978009061553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637866978009041557" xlink:to="ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_637866978009061553" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:label="ahpa_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_637866978009061553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637866978009041557" xlink:to="ahpa_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_637866978009061553" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WarrantExercisePriceAdjustmentMultiple" xlink:label="ahpa_WarrantExercisePriceAdjustmentMultiple_637866978009061553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637866978009041557" xlink:to="ahpa_WarrantExercisePriceAdjustmentMultiple_637866978009061553" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1" xlink:label="ahpa_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1_637866978009061553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637866978009041557" xlink:to="ahpa_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1_637866978009061553" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WarrantRedemptionPriceAdjustmentMultiple" xlink:label="ahpa_WarrantRedemptionPriceAdjustmentMultiple_637866978009061553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637866978009041557" xlink:to="ahpa_WarrantRedemptionPriceAdjustmentMultiple_637866978009061553" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="ahpa_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_637866978009061553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637866978009041557" xlink:to="ahpa_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_637866978009061553" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - SUBSEQUENT EVENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637866978009071559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventTable_637866978009071559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637866978009071559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637866978009071559" xlink:to="us-gaap_SubsequentEventTypeAxis_637866978009071559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637866978009071559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637866978009071559" xlink:to="us-gaap_SubsequentEventTypeDomain_637866978009071559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637866978009071559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637866978009071559" xlink:to="us-gaap_SubsequentEventMember_637866978009071559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_637866978009071559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637866978009071559" xlink:to="us-gaap_RelatedPartyTransactionAxis_637866978009071559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_637866978009071559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_637866978009071559" xlink:to="us-gaap_RelatedPartyTransactionDomain_637866978009071559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_OmniabMember" xlink:label="ahpa_OmniabMember_637866978009071559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637866978009071559" xlink:to="ahpa_OmniabMember_637866978009071559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637866978009071559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637866978009071559" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637866978009071559" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637866978009071559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637866978009071559" xlink:to="us-gaap_RelatedPartyDomain_637866978009071559" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_SponsorMember" xlink:label="ahpa_SponsorMember_637866978009071559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637866978009071559" xlink:to="ahpa_SponsorMember_637866978009071559" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637866978009081571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637866978009071559" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637866978009081571" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637866978009081571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637866978009081571" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637866978009081571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WorkingCapitalLoansWarrantMember" xlink:label="ahpa_WorkingCapitalLoansWarrantMember_637866978009081571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637866978009081571" xlink:to="ahpa_WorkingCapitalLoansWarrantMember_637866978009081571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637866978009081571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637866978009071559" xlink:to="us-gaap_SubsequentEventLineItems_637866978009081571" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDefaultLongtermDebtAmount" xlink:label="us-gaap_DebtDefaultLongtermDebtAmount_637866978009081571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637866978009081571" xlink:to="us-gaap_DebtDefaultLongtermDebtAmount_637866978009081571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights_637866978009081571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637866978009081571" xlink:to="ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights_637866978009081571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable_637866978009081571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637866978009081571" xlink:to="us-gaap_ProceedsFromNotesPayable_637866978009081571" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637866978009081571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637866978009081571" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637866978009081571" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_ContributionFromSubsidiaries" xlink:label="ahpa_ContributionFromSubsidiaries_637866978009081571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637866978009081571" xlink:to="ahpa_ContributionFromSubsidiaries_637866978009081571" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_637866978009081571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637866978009081571" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_637866978009081571" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637866978009091558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637866978009081571" xlink:to="us-gaap_CommonStockSharesIssued_637866978009091558" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ahpa-20220416.xsd#ahpa_WeightedAverageSharesPricePerShare" xlink:label="ahpa_WeightedAverageSharesPricePerShare_637866978009091558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637866978009081571" xlink:to="ahpa_WeightedAverageSharesPricePerShare_637866978009091558" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ahpa-20220416xex10d25001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xex10d25001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  [ %T# 2(  A$! Q$!_\0
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M%Q>-O^AFOO\ OI?\*/\ A<7C;_H9K[_OI?\ "N.HH]A1_D7W(/KF)_Y^R_\
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MU8O[K_E1_:L7]U_RKZ%-+1'Q+4F[O<^C/V5?%TRWFI^&I3FW*?;;?)^ZV0'
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FX5J@!0 !@#H!7#C,P6*IJ"C;6Y[&5Y+++ZSK2GS:6VMV\_(__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ahpa-20220416xex10d27001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xex10d27001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "' 6(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z0G%9^J
M:W:Z/8W%W>/]GMX#\SMT_P \UYUJ7[2'@C3;H0/JL;MD D9XY^E 'JNZEKG/
M#'C?1_&-O)-I-XEVD9PQ3M71#I0 M%%% !1110 4444 %%%% !1110 4AQ2T
MR3M0)B\4;:9CT(- 8YZ8'K2ND*[) ,4M1J_S8[>M/ZTRA:*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ IC, X7NU/IA7,@;TXH ;(ZQY:1E1>F2<
M"H!?VP&YKF(9[;Q7E?[3^I7VD?"/4YK.Y:VF53^]C.&'TKX'@\>^)O/;;X@O
M3N8!0TG0\4 ?JFK*V"N,'@'L122%(X6.X*H!&<XKCOA#<SW_ ,-O#=S<S/<3
MO:*[NQY)KG_CYJU]8^&(+:QN19-=7*(\K9PREE!48[D$C\: /13J<"Q B=<
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M$7_7%?\ T-:_-77/^0Q>?]=37Z5?'O\ Y)+XB_ZXK_Z&M?FKKG_(8O/^NIH
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M^P]:_/.V'^F@]BX%>R3?M 77B?X1ZIX;UN22]U!WW0W7/(QWKQRV_P"/E/\
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M=V%Y"LS^6Y0]#N R.:_,K6--_L#5KJS?):":2W=#SR.*_5R_=(K.:8?/M#'
M^G-?ES\3KB&7XB>(WC8&-[Z5U(Z9W=* /K+]BOQ6^J^$KC09R<6<OF(.X!)/
M7\*^@/&GAY/%GAO4=$F<PQ7D31&5>< C%?*?["MO(=5\07,LH"!8EVY[D-7V
M4(]B8Z#U/- 'S1X)_8M\/Z-J#W6L7DFL.&RD97RU4>^#S7T+HGAG3O#=E'::
M;:16L*C&(T )_$5IKC=D' Z8Q2J0"0#D]Z &*GE@A<X/J<UFZ_H-GX@TJ>QO
M(5FAE0H0XSU&*U&DC4@%@">@S2R$*A)&?I0!^8/QL\"?\*[^(-_I* I K"2
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M@2 ?Z6GM(* /U!^"G_)*?#/_ %YI7;5Q'P4_Y)3X8_Z\TKMZ "BBB@ HHHH
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MK0 \=*3^*E'2FO\ U% 'Y_?MD?\ ):[_ /Z](O\ T!:;^QS_ ,E@A_Z]V_\
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4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ahpa-20220416xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" .8 J@# 2(  A$! Q$!_\0
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M_:G\%Z-JVJVSQ:O<V&D:;!J^I:O;6):SM+:>%I;=F?(9FE"E51%9MQ ( .:
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ME\2V/BB9KJSF>^CEADLVDMAA@FQOL:D/U&XC:?O4_3?V>/&::Y)I=]XCT9_
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M';RI% +>6>0ONE)+;S.3T&WISC<9'^ .EZYXG^*5SXEBL]8T?QH;,?9&@Q)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK4_9S_:.\=_%WQ%X8&J>+O@W<V.IV7VVYT+P]J=Q)KD*F'?L\EG(#(Q4.#T
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M8W.Q@N3A@-@/:@+'U-16?X>_M7^P=._MS['_ &U]GC^W?V?O^S>?M'F>5O\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(_&OP9O\
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MY"X9WD'F.S,QS\O'X\5!^R9\9_\ HKWB[_PO9O\ Y64?\,F?&?\ Z*]XN_\
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M._LZZWH_PO\ CMX9EU/3WN_'^L:WJ-A,@D$=LE["(XUER,[E(RVW(QTS7/\
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M+/<()5P%*DJ#PW.",5VOQ?\ @'K]SXR\&^._A9?Z-X>\5>&+.?28]-U6V?\
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MQ[M_"/P;L?B7X6\#W7B_PQJ.FMKE_+IES:6[6MKY E,L@E=?,.W((7<V5/%
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M*VBS1N)X-P#O&^=IV@LQY_A(ZT ?+7[6%]H^G?MA:5-K/C#PIX)MSX#"I?\
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MHH **** "BBB@ J.X1I+>55^\RD#ZXJ2B@#XRLOV2?%.K? [X#>!];MK$?\
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MK1F>+S=IX8*5SCO^%;_[,_@*[^'\NOVO_"G_  _\++*Z$4I;0];%_P#;)!N
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ME].EF]I' L0)$,21,  "S9!))SD97C[]C-_&*^(X;;QS=:;8:]XM_P"$LO\
M3Y-,AN;>YD6"&.*WE1B/,B1H0^T\,Q&X':* -#5/VX/ ^E:+INJ2:)XH:WGT
M5/$=^@T]%ETC37D,<=S=(TH(#[68+'O<H-VW%;NE_M8>%->^*EQX'TC2=?U>
M:UOHM-N=7L+1);.">2$3)O D\X1["#YWE^4,C+BN*\;_ +%MQX]\0V/B/4_&
M\%SXD?3DTK5=0N_"]C="ZACG>2*2"*4,EM*JN8]X#!EZKG!K1\4?L;67BCXO
MZ5XRF\1K!:Z;J=IJEK!#HMK'J%M]G4!+2*_0+(MJ=HS"5;C(# '% '3_ +0'
MQ[U#X.>*/AII%AX9O=?'BK6_[.GEM$#F&-8F<JB[ES*< @$XV)(>2 #QGPS_
M &P?[2\6ZCX?\7:+?P>=X[U'PAIFMZ=8_P#$N\R)V^SPRNTA;S61&)95V9P"
M5/%>F_&SX-3_ !8D\&WVG>(6\-:UX5UI=9LKLV:W<;.(I(61XV9<@I*V"&&#
M@\]*Y.U_9/L+:*P0>([MA:?$.;X@C-LGSRR&3-J>?N#S#\W7B@#1^'?[6/@S
MXE^,[#P_IMOJULFKB\;0]6O;94L]9%JVVX^SD.7^7EAYB)N4$KD"K7Q9_:9\
M/_"/Q/)X>NM"\1:_J\>B2^(6M]#LDF"V<4FR5RS2( 5ZD$\CIDD"N6^!_P"Q
MYIOP0\90ZI8ZS;7NDV"W*:;8MH%E%=Q"9RW[^^"F:8HK,B'*85B&W5V7C?X"
M6OC7XBZGXMEUB>UFOO!]WX1-JL*LJ1SR^89P3SN7IMZ&@# \>_M@>$/ 'A[1
M?$5QHWB34?"^I:7::RVN65@HM+6UN6582[2.A=SN!,<0D=1RR@8S4\4?MH^#
MO"GB?5='N- \5W:Z7KL?ANZO[+3!+;I?RQJ\$*D2;G,F]5&U3@D;MH()X7QU
M_P $^-/\;Z7IFG2^-;F.UM/"5AX6)N=(M[J:,6BD)/;229^S&0X,JH/GP!N7
MK7>ZC^R98ZG>ZO<R>)+I)-2\<Z?XXDV6J +-:QPH( ,_<;R<ENHW=\4!H.B_
M;'\)W&@6EQ#H/B27Q%=:Y=^'4\*"UA&I"]MD\RX0YE$(5$*L7\W;\R@$DXK.
MU_\ ;6\)W'A>SO/"&FZYXHU&_P! N]>2&PTXR?V;!"SQ-)>*74J%G1HRB;G)
M1L @9JAXL_8ATOQ$UY>P^(5366\6ZCXJMIM4T>#4+2/[;$D4UK);2';*F(U(
M8D,&4$=.;4W[';V0TB70/'5WH%\OAN;POK-S;:/9@:G:22-*6$2(D<$HDD<A
MT4C#$$$\T!H=OX&^-?F?LOZ)\5?%<2J?^$7B\0:G'I<1P/\ 1Q+*(E9OK@%O
M3FN:3]M+P5!H_B'4=3T;Q/HL>D>'D\5+%J.FB.2_TQF"_:+==YR S*"KE6&1
MD8(-:?C#X,7VC?L?:S\+O#K/KFI6W@Z;0+ RE(#=2"U,29)(5-QQG)P,]:\_
MT_\ 8PU#Q7X(U2W\;>-[^^U?4_!,7@VUVV,"?V3:'9)*IV'$\ID109#M!"#
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M1110 4444 %%%% !1110 4444 %%%17-S%9VTMQ.ZQ0Q*7DD<X"J!DDGT H
MEHKX _9M_;F\:?$?]I>+3?$HB@^&GC"?4K7PDYLTB.^VD&P&4<R$H"IS_$XQ
M7T)^U_\ M&W_ , /!.C)X:TJ+7O&_B?48](T*PF)\IIFQEWP1D+E1MR,EUY
MR0#L>]UR_P 4/!]U\0?AWXC\,V6KRZ!<:O8RV(U*&$2O;K(I5F520"=I('/!
M.>U?).J:Q^V/\&Y]$\3:S+H7Q9TFXNHXM2\+Z!IOEW5LK]3$X1<[>1O)8 XR
M"I)'HW[6/[2OB?X;WW@GP'\-]%@U7XD^-I&2PBU$?NK&)<;Y9%R 2"3P3@!'
M)SC! L=Y\&?V8O!7P>^&6A>$(])T_7/[-A*2:E?:?"9KIV9F=VR#C)8\9X
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M&$8;&XR%2#L\W=SUW?+7L'QI_:PU'X/_ +-.C>/=1\'7>G>-=<\BQLO"U_\
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M%H_CNP_:\_;U\$>)O *7.I>!OAWIUP;[7Q R037$JR!8T+ $Y+* " 2%=L8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO+14E62.XEN$0O<3AHX@68JK!!E,\UX?JG[17Q$\8_L_^/KWQ/)HWB+1]1\
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M2*J#@!6)4?[M?/=CX5US2_VYO$4+>,]0OM0UGX>WMU9SW<<9BTI6U%$AC@@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX>W6NGQ7\@\E[FYACVPK<.J$;C\V%)[&O%KSX2>,_!FAZ-J7A3X4>(&MM0\
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MW DWDMO'.23G-7M.T/3M'EO9;#3[6QEOIS<W3VT*QM<2D!3)(0!N;"J-QR<
M>E7:* *6I:'IVLR64E_I]K?/93BZM6N85D,$P! D0D':P#$;A@\GUJE<>"O#
MMWJ$E]/H.F37TES#>/<R6<;2-/",0REBN2Z#A6ZJ.A%;5% &*O@GPZLB.- T
MP.E\VJ*PLX\K>,"&N =O$I!(,GWCD\UCS?!WP8%\1R67AG2=)O\ Q#;2VNI:
MCI^GP17-RDBD-O?9\Y.<_-D9Z@UV5% %#0-#LO#&A:;HVFP_9].TZVCM+:$$
MGRXHU"(N3R<* .:OT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 % &!@=*"<5\J?"3XK_M#?&[X>Z3XUT+3
M_AIIVD:OYLEM:ZA+J+3QHLTD8#E/E)^3.10!]5T 8&!TKP/?^TYMSL^$_3.-
MVJ9S^58VJ?%7XU_#/QK\/;3QS8> KS0_%/B&+P\Q\/R7PNH7D@GE60>=\I4>
M00?7/% 'TKCG/>C'.>]>:?M ?%FY^#7P^A\16NG1:G*^K:=IQ@FE,:A;F[B@
M+;@#RHD)QWQ7A.J?M\?V7%\=K&?PY!#K_P /Y;R32K>2Y<0ZS:V\RPR.&VY5
MT9EWJN<!U/K0!]@XQ0!BOFGXA?''XP>'?BWX=\'Z-X/\'7L'BF&\N-%N[W7+
MJ)C%;0QR2?:%6W;RV/F  +N''45SL7[7?BW5?B5XI\,6G_"K](_L7Q V@I;>
M)/%TECJ%X1Y?[R*#R6W!C)M7!Y88XH ^N*,<Y[U\9^//VXO$_@[6?B7-%HO@
MB71O!&K2Z?)I]]XF>UUG441(V+6]N86#LPDVJ-V"P(KMW_;&AL/VBM5^&>IZ
M"=.@.BP7VE:C-(RF>\>V:Y^QR@C".423;@DDQL,9Q0!]*,BN & ;!R,CO2D9
M&#TKXO7]N;Q%JA\!1VMCX!\.-XB\&6WBJ6Y\9>)9-,MT:6=XOL\3^4WF, @;
MG!QN]*[?XK_'WXH_#WP?X)\1:?X=\#:[IVOOING/<6WB"X>+[;>3&-#"ZVY$
MEM@Q-YN0QW'"G'(.Q],XS28'I6-X,G\07/ABPD\4VFG6.OE3]KM]*N7N+9&W
M' 21T1F&W')4<YK:H$&.<]Z*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *^>OV V _9&^'C$8S;7'('_3W/
M7T+7P'K'_!.!_A_H-_>VW[1/Q)\.^&M/66X6RTZ>0QVL6YG*I%$_.,DX5,DG
MIS0!]]YKY^_:O(/B3]G[_LI5E_Z07U?EY\+_  W\2/%OQ\N_"GB/XJ?%SP_X
M"-W=6UCXH_XFA,X5RMJQ4\+YORDY  SSBOT ^&O_  3RN?!OQ'\+^*M>^-7C
MOQO#X?O1J-MI6MW1EMS.$=%8AW?! =N0 <$C/)H ]Z^/WPFN/C/\/H?#UMJ,
M6F2IJNFZEY\T1E4BVNXIRF 0<L(\9SQG->%_%/\ 8'7XE> /&FEMXDAL/$>J
M>+]1\2:9J\=L^+6WO!&LUG*H<&1&1,-@@$A#C@@^X_M ?$_4_@YX,TWQ1:6M
MK<Z/:ZS8P:[)=!BUOITTPAFGCVD?-&71^<C:&X]/F?1?VY?B3XXL+O3_  UX
M1T0^+88]5UQ;&[2=HVT6&TCN+"3Y7!\VX,J1YSC(;@=@9]+>)O@_=:]\6OAE
MXP34X8H/"%EJ5I+:M"2UR;J&*-65LX4+Y1)!!SGMBO*;;]F;XB>&/'OC36O#
MNN> )K/Q!XAFU]/^$@\+2WMY;,XC4(LPN%Z>6",#J2:X[3/V]];\:>*YM'\,
M:%ISPZ_?:38^#;VZ25EO=\D::I),%<9%N'8@+C[G.:H7_P#P4'\0^%]02VU[
MPWIL:Z+!JEGXIEMUE M=5B>[6PMX@7.%N!9Y^;)_>K@CN >B^(?V*+37(?B#
MJJZG8V/CC5?%9\5^'/$T%@#<Z/,L<*QQLQ.Z1,QON3(5A(> 1FK?CO\ 9!E^
M)]]\3;_Q!KEM%J/BRPT8V-QI]NZ/I6HV$<H6YC8L207E.%&#MW DYS6QX\^,
M_CGPUX1^$VE1VFB67Q"\;W]OI=W+=Q2OI^ESFT>YN/W8D#N0$*(A=2202<5Y
M[\4OVE_BWX'T/PTUOI?A>]F-CJ$VN:QH%I=:]9VUQ;3;$C:"WD6>")EYDE*R
M")LKAB,D --_8U\9^$KOP1=Z%XC\'WESH/@RV\*7$?B3P]+?02F*XDF,T2B9
M=A.\#!). ?6O6/'7P4\0?$;X7>"O#^KZOH]KK.B:YI>KW-QI>G/#9R+:7(E\
MJ&$R$Q@JH498@=?:O!-=_:2\?:-X]^*OC/3-7T/6O">C?#73O$^F::JW#VKF
M9)7C9&W(3N=7W.R@L@C "$-6SXS_ &NOB)\--&\:?VQIGA;5]5M/!=GXTTAM
M,%PMND<MRMNUK/N<ER"VY9%*[AGY1B@#[)P/I]*\1O/V*?@M?^(YM>N/!$4F
MK37AU![DW]V"9S)YA? EQ]_G&,>V*\^U;XZ?&:#7M=\,1Q^!K/Q!X7\,'Q7K
M$US%=&UN4DEF\BTM_P!XK)MCA(DN&W#>1A *S=:_;,\5OXU^%6B:5I?AVT@^
M)VEZ9J6DR:M/(LNE"0@W*W2!AYFY>("NS?)E3TS0!]A 8HKYF\,?M)^,O$?Q
M6L_AH-*T:'Q5;:_K%MK#E)3%;Z5;0I):7:IO#;IC<VB\DC/FXZ#'&V'[<?B1
M_#&NZG=^&+$W/@KPG?:GXPLX3(#!JT5T]K#9Q,6.Q&:":4LP8B,H1S0(^RZ*
M^$_V@/VA/B]X3^'?C7PWJ6I^';3Q#)X.M_%EEKGAB*>+[-;M=QV]Q;@/(Y\S
M,JF.8$!@'^0$#'4>*/VIOB?X;\?:KX;L/#-GXAD\()I$.M6VFZ1>R'4Y;I%D
MF,$^\I:*B."@GWF1E89'% ['V)17C7QN^*_B/P[XN^'_ (*\%'2(M?\ %U[>
M0C4]9CDGM;..UMS-(#%&Z,\C?*JKO7'S'G&*X*X^/GQ-\1^(-&\(>'3X$L_$
ML/A2;Q-K&I23SZAIDS)<-;BWM6C>,X+HQ>1BWEY VL>:!'U%17PQK7[<WQ U
M7P=J_BOPWH7AZSTG2/ VD>,[FSU2.XDN)C<RRQRVR.CJ O[IBLI4\8.T[OE]
MY^!'Q9\8^+_B)\0?!_C*#1OMGAV+2[V"ZT6*6*-HKV%Y/*99&8EHS&1O!&[.
M=J]*!V/;J***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 -"!0 ,X'N:=110!R_P 2HO"][X.O-,\91VT_A[5GBTJXM[M"\4[7$BPQ
MQ$#GYG=5]L]1UK%\/^$/AWX4^(WD:3I6GV'BX^'X+0"&%A+_ &7"XCBCS]W8
MK84#KP.PJO\ M#:9J.H_#1Y=+T^YU:ZTW5=+U5K&R3?//%;7\$\JQKD;G\N-
MR%ZD@ <FO'_B-%>_%_5O'&O^'K#Q;::)%X3BT=+ZTTF:UO9YWOO.D6"WN/)D
MF5(U_> ;=X<HC%N@,]J\._ 3X>>$W\,2:1X1TRP;PR]W)HQAAP;%KHDW!CYX
MWY.?Z52\7?!;X6KIOBK6/$/AK1TL=0N(=<UN[O$PDLMJNY+B4D_\LU!.>G7.
M<FOE]_"7C2?P9HUA+H=U!X"M/$5XUS'%X=U:X@N4DMHF@E&CO<I=Q6Z3><GE
M+(R!RKA"IROL(\!:YK_[%/B/PSJ,&KZOJUUHFIK966H6[VMZ>96M(3&9Y77
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MNIR3A8;@V<JWH56;:92=BR$@MD+GD"@1])T444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;\.:?XGNIV\'R#0O"]IXPF6*PNAYL4OG!K%<S\,/L\A%Q[J/)')KV>T_9_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M79[M_$'A/QEK'C>?5/#=SI&IV]O<R6D&G)]@-S'(RMY:;98[MI8G&YF96"L
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M%% &'XR\9Z5X"T*35M8FECME=(8XK>!YYYY78*D4448+R.S$ *H)-<E#\>?
MNIZ?!]OOYM)BNY;FRDAUJQFLS!-%!Y\L$XE1?*?R29 'QO0%EW 9I_QW^$47
MQF\&6^DM/;07=CJ%OJEJ;ZW:XM7EB)^2:)70O&RLZD*RD9!!R!7E?_#'SZYX
M"?PCJU_H>D:+J&HMJVIP^&=*-L7ECB1;)$:5Y&(B=!*SN2SE$3"Q[E(,VO!O
M[1GPZ\)QZIX?TS1[SP[X1\/:;I5Q936^BW4<,POW988HXA""&9C'M')<R-Q\
MC5V:_M#>$/[<L-,D36K::ZFMK5[BXT.[CM[2ZN AAMKB4Q[(IF\R,;&((+J#
M@L >2OO@-XLUSQ"=5U3Q)I<\M\GA^;4FAL9(V>ZTR]\\O%\^%25&<;""4;&"
MP!%8_C?]ES7_ !;\3YO$S^(]+NH$URPUNQDU.RN+B\M!;S02&SB;SQ#%$?*;
MYUBW_.02>6(!W%[\<_AOXSN-3\*ZA+-?:==QWMFTMYI5Q_9VH^0CF[@AG9/+
MG9%CEW*I.0CXSM;%'5/VJ_ UAX435[+^UKE)K"?4;2-=$O,M9Q(&%XX$6Y+4
M[T F8!3DX)VMC$M_V</$@M=.\.3^*].D\&:!/>W>BVZ:8ZWIDFAN(H4N)C*5
M9(1=/RB*S[4W8PVZWJOP$\4V6FZ,/"OBG3=.U >$8O"&IR:CIKW,<L,:'R[B
M$+*A216>7ABRL)!D?*,@%SP[^TSH7]@V6I>(IXK2>]CTF.'3M,M;J\N1=7ME
M]I2#:L1WE@K;=F>!\V"<5N2?M'>#CX?TO5;4:UJ)U![I(].T_0[NXOHFMI!'
M="6W2,O$8G(5MX&"0!G(SQWA/]F2^\-:OX=NVUZWF32[S1KED6V8&06.E36+
M*#NXWM*'![ 8Y/-9WBS]EK6]>N4\OQ!IESITNK:O?3Z9JUG<S6F+RZ$Z2^3%
M/&))HAN3]Z60AN O.0#O]2_::^'VFS68.K75S;7%A::HU[::;<S6UO9W)(MY
MYI50K$CE6 +D8VG.,&N[TKQ;I6LZ_K>BV5P9M0T9X8[Z,1L%A>6,2HNXC:24
M*L0"<!ESC(KQKPI\"8_AM\.O$%CXADE\5:;-X*T[PU=6.DV3&>Y2SBND=HTR
M<M(MP-J#H5/)R*Z7]F?P!K/@?X0Z;%XKEFN/%^K%M3UN:=AYK7,@4!7VDC<D
M211'!Q^[X- #]+_:=^'FJ:TVG)J]Q;;X+N\M[V[TZX@L[JWM1FYFAN'01R1Q
M]V5L>F1@ET?[2O@5-&U/5-0N=4T6#3A;RRQZMHEY:3O%/,(()8XGB#R(TC!,
MH#@G!QD5\^>%OA!XS^(EYH?@/7+34]*\%^'M UG03)>:.+2>"*XA6WMQ]H\Y
MX[N15!PT*JA52SX9@@[SPQ^R3>Z5;7S7-QX4L;Z2;2Q'+H.B2VQ>.UU""\E:
M1I)Y&)D\@*$4A%.#\W8 ]-A_:)\'SZ%+J$9UB2ZBU)M(;15T:Z_M3[6(A,8O
MLGE^;_JB)=VW;L.XD"I+3]H3P5J&HZ+8VEY?7%YJL,ERD*:7<[K:&*5H9GN<
MH/LZQRJ4?S=NUN#BN$^*'[+<GCS7M7UU;W2;J\DUT:O:6.L64D]FT;:;!92P
MS*DB-D^2)%="-IP"&!.=#X??LXWG@B262'6K#3)Y_#UWI+2>']-^QK;W,]W)
M<?:(59WQLWJ!O+,Q3<Q))H D\1_M5>'HO".N:EH-M?7&HV%C%J5M:ZSIUUIR
M7]J\\<7GPM+&OF1@R+\R@_>3. P)[_Q_\5O#_P -Y-,M]8:^FOM5:9+"PTS3
MY[VXNFB3S'5(XD8DA,G\#Z5\]Z5^Q=KD<>JRWGB#0X[S4-";1I9K*PNC).WV
MNVN!<SRSW$LDCMY#@KD!=PQGG/T'XF\!3:]\1/!7B5+R.&'P^;XR6[1DM-Y\
M(C&TYXQC)R#G- '-Z#^U!\.?$,5Q<6NLW$5@FFR:M'J%WIUQ!;7=M&R),T$C
MQ@3&-Y(T94RP9@N,\5:@_:'\(2:-?7LYUFQN;.:"W?2+W1;N'4I))MWD".U:
M,2R>9LDV[5(_=OG&QL>?ZO\ LE/XB^'7A;PIJ&O0B/2/#U_HTEQ':D^9+//:
MS12A2W*(]J-R$_,&(R.M83?L8/J'AV^^UGP=9:R+^TOK2#3-"F6P?R%G4QW(
M>X:659!<2<!U\L[2N3G< >A:A^U!X?&N^$],T^TU"5M>?4())+O3[J%M,FM8
M!(R7,9BW1GE<AMN%(?E2"9;?]J3P-:6VEIJ&I3274MGIUS>W5AIEW)96:WJ*
M;>268Q 11R$@*9,$9&X#G')Z)^R[JF@Z=X>:RU+P]IU[:ZCJ%U>VVFZ3)!:/
M%=V@M66,&5G,B*D9$DC-NP00 % M:?\ LPZA8_#SQ-X</B"V:;5M)T/3DN!;
M-MB:P@CC9RN[)#F/(&>,]Z .Y_X:(\#CQQ!X6-[>C4;C4GT:WN/[,N39SWR*
MS26R7.SRC(@1MPW<%2.H('9^+?%VE>!O#]UKFM77V/2[789KC8SB,,ZH&(4$
M[06&3T R3@ FOF.S\)>.[CXMZ%X8M["_A\(:+XXO/$A-YH^Q5@D^U2EA?"8Q
MRHTMSE(UC\T;]LFT(2WO.J1W6N_!O5(?&^BO>27>E7$6IZ5H\;2R3(R,K1Q)
MDDLR'@9)R<9H$1>*_CKX1\(:A?:;=7=Y=:M:W4-@=.T[3Y[NXEN)83.D4:1H
M2[>4ID;;]U<%B 14_AOXU^#_ !;%;/IFJ-,9]/N=3$;VLL;I#;S"&<.K*"CQ
MRG8T; ,"",<5X_\ #/X ^,=+^&W@C79=8BM/BE9W-QJVH3ZU;FYAN6N8!!)!
M.D;J0R0QVR!T;AH/X@QSIQ_LX>+-&:WO]'\8:9_;M_::O:ZY=7NDNT,IU"X6
MX>6VC68>68W0*JN7!7[V3R09Z^/B5X=.C^%M4_M#%AXGD@BTJ8Q.!.TT32Q
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MI%YIESJ'ANS\C2?[-TW5M(T)X[XRJ\+Q74[23NI(-O'OBC"K)ELD#"@&>O\
MPP^-=M\4/&_B[1;/3KRPM]!MM/E8:G9SV=V)+@3DI)!,BLN%B1@>01)[5Z;7
MF/PM^'OBKP_XU\6^*O%VMZ5JFHZ];6%LL&D6,EM!;+;"<8'F2.S;C-NR3P<C
MIBO3J!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$$\&J6D_LV_#/0] T?1++P=IT.EZ3JJZW:6VUF"WR_=N7)8F24=G<L:]*HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI;QC\*]"UFYU231/%4OASQ"_AZ[:S@>V.H^991W,4T8#N(VM]Y^TI\P$:22
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MU/[1OP^Y_P")\>/^G&Y_^-4']HWX?<_\3X\?].-S_P#&JY'XQ_M2V7P^\%>
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MEJ*-NM;L;9[:9',<L,@R<,CHRGZ9'6J7P"_Y)P.O_(9UGK_V$[J@1Z)1110
M5X7\3?&VI>%?BEJ.F:='<Z=-K.CV"_\ "02:?+<6MA''/=B1EV(PDN/WJ;(C
MQSO;Y5VM[I01F@#YJ3P7\)X[);--:\31V44GVV&!1>[(=1W!O[17,/\ Q\[_
M )\DE-Y9MFYB3T?PP\<ZCXO^*%C8:E#<7EWHVC7L;ZY%I\UO9WZ2SVGE2#>@
M$<I$;[X<G:5RI*$&O<<4N* ,GQ-X5T?QCI@T_7=,M=6L5FBN1;WD0D021.)(
MWP>ZLJL#V(!KG+SX(_#[48;Q;CP=HDT=WJ,VL3[[)/WMY+$8I;AN.9'C9E+=
M2&([USW[3NGZKJWPO:STS0F\012ZA:_;;989;DI;"0,\AM8I8FNE!"Y@W@,"
M<A@"I\$^%/P6UC7-2\.:7XK\'WH\)P>+-7O3IM[IZ65FMI+ID/DYM(Y'CCA:
M8R8A)8!\[@&S@&?47BSP[X*T#P3:RZWI%A'X=\(1IJMI$;7='IWV2,M'+"@!
M*M&BG;M&0.!6/J7P"^%?CC0;"+4? OA[5=+CFGU&VBN].C=$EN6$DTH5APTA
MPS'J3R:^4?$'PEUX?#/4]*\0_#CQ+XLNY/"%SI'A3R,ROI%U'<WXVEFE!A9X
MGLRLI^]''Y>>BM]'_%[P%<^-?!WPTT2?29M2T]-=TYM7LPIV&U6"42"901F/
M.U64Y!S@@CB@#TSP9X(\.?#K0(-!\,:-8:!I$#.\5AI\"PPH78LQ"+P,L23Z
MDU:\->)=+\7Z+;:OHMY'?Z;<AC#<19VOABI(S_M*1^%?'ND?"'Q7:_')/MNC
MZFMPGBAKF/5;+0+<PG1MQ$<!U%K@$6XMBL#6OE[@<[4.!)4?PQ\)^)/A/X=T
M:TM?AYXC$8\.:YX>>QT^V7Y-1:\$L<CDN%\N2,#;/DK\N"1P" ?6\7PZ\+6^
MHZ7?IH&G)?:5/=W5A<"W7S+:6Y)-R\9QE6D+,6(^]DYK%U3X#_#?7%TP:AX'
M\/WZ:9:FPLUN-/BD%O <_NER.$&YL+T!)(Q7S&/@=K^I_#?QG/J'AC4IO$I\
M-^&],TV9]XN8P+6!+U(&W9C;(82%2"2HR3@5[W\'_A]_PKOXD_$FSTK1WT3P
MI<RZ=<Z?!$"EJ\IMRMP\:YP&)5-Y&,L,G)R2 =!I4'@/4KHZ!%I=M!>7Y75V
MTR[L7@EE^QRPP1W#(Z@_(T-N$8]0L97(P:MZ=X,\-KXXN-7L=,DT[4[&:=[B
M1+1H(KJ:YB@\R7>5 E.R&)2RD@%<'YAQX-\&OAKJ6@?%[P1XAU[PIJ NSI&O
MZ>-4EA,GV21M6DG@$K9)0/ \FQB,$/MSD@5I^,OA=J?C'XNWL6JZ%>W_ (6N
M/&^GWDJ/N^S36D>@31L6 ;#1?:-B,I&TL<$$&@#V7QC\/O =_JL/C3Q)X>T6
MZU'1H?/36;VS226VCBS(&#D$X3EAZ')&#7E/C?X3>"OCUJ$6F:!K-I9II=M]
MMGL7T&VO(-FI%YQ<P_:(\1SN1(V]20<_.C$+C2\+?#*\7]F_QMX'ET>58I)_
M$%EIFEW)X^RM<W/V-$W'B/88MG. NWH!7B=M\";C5OA_XJU6'P)J5GKFG^$O
M#T/AR.:V:&ZM+VW68S"!<_)*LF,L.2& R5;% 'UGI/PE\(:1X;;0$T2TN+"2
MRM;"X2YC$C74-L@2 2DCY]JJ,$U>\;?#SPO\1K&VL_%6@Z?K]I;S">&'4;=9
MECDP1N7<.#@D>X)'>OE:T^&7C3_AH:6_O].UC^TSXN?4(==L]$@=3I7F%HXV
MU-K@$0"#$+6WE[LYVH>'KJ?VAM.TC5OCYX?M]?\ !>J^/M-'A+4&72=,3SMD
MYN[=8Y&B+J,\LJR_\LBV[*_> ![YI7PT\(Z%$(=.\.Z981-:S60BM[9(U$$L
MAEEB"@8",[,Q4<9)-8GB?X1_#(QQ:WKGA/0&_L2Q6-+RYL8V:UM8!O50<9"H
M%RO]W!QWKY?E^$OC2UTN;3?$'A+7/$'Q6FAT@>'O&L,XEM]*\JWMT<-<^9F'
MRIDN'E&/](#])-V!9E^$7B&^^)7Q M+7P=?W]MKMOX@M[VYUK3A;R".X1W@V
MW\<_EWT32K"L44L6^!6^\FPA@#ZOUWPIX.^+>@Z6^LZ1IGB;2G\N_LA?6RS*
M"5W+(@894E6]N&(/!K)U#X!?#755TR.^\">'KQ=-MFL[..?38G$$#%B8U!'"
M99B!T!)(P37QIXS^'7BS4?"^FPZ)\-=5T^]T_P .:5'H[)H;3W<+P+OGV3R7
M*II\BS"4%8HS)*-K!GW #JM8M;+_ (6WH4TF@WMWXS?XHNK^+H)UDMY+,^>8
M;4NLFYO*B$<;6I7]VT3.54'>P!]6ZA\&O 6L?VDM]X1T:]_M"UM[.]6>S1_M
M$,',"R9'S>7QM)Y7 QC%:^@^#=(\%>&AHGAC3['PY91HXMX;&V2.*)VR=^P8
M!)8Y.>IZFOD/X!?"[XB:%XPTZ4VU_H/BRTTZ[BUG6+_PW$EC>W3!1NNKE+L2
M:B&D!D1EP5_B,>2AO?&7PU>:]\6-7T_Q1X6N_B'XB/@2VCL)?#EN]O;V>H27
ME^(9UC>=C;M@+BX+$IY;?,NX @'T1X*^"OA[PQ\-I?!FJP6_B>UU":XO-5;4
M[2(KJ-S/,9II7B V#,C$A0,*%4#[N:K2_#KX9'X:+:7?@S2[;PEI4LVH+I]Y
MHWE+!+$S[YQ"R!MQVN=P&74Y!8-S\V^(O /CR;XM:5?7OA:\NM>TWQ!H4DVO
MV6D&Y:XLX3:I<W"ZC)<?NHF'G[K2&$'[Q8,&9JC\1?##7'\.7<7BGX>^(?&$
M=SHVMV>A6UG^\?3=2?4[Z02D&1?)::&2UV3_ ,*Q,N5W , ?6O@/PUX/M=*T
MO6_"^D6%C:W.GH+2>TM1"?LLC&=4 P"JEI&?;ZL:Q=3^!'A+Q#\2+_QEK^E6
M.OW<UO8Q6D>H6<<JV36S3L)(V()!8S9/;,:'J*\Z^*_@CQ;JG[,G@O1]+LKB
M6XL4TDZWI4=JL\MQ:1Q*)X?L[.@EPVTM$7&]49><[3P?PZ^"%YKE_P""[/7_
M  WJEUX/_M[5;Q],U/2H].LH8&L(XXQ]BCE<1PO,)&$4G\9+;%!% CZGO_A]
MX8U71M8TJ]T#3KS2]8F:YU"TGMDDBNY2%S)(I&&;Y$Y//RCT%5=$^%O@WPS'
MIL6E^&=(T^/389XK2.WM$18$F*F?8,<>9M&\]6QR37RQI?PL^(.G^&_!_AZV
MT[68]+\5V:^&=>W2L'TFSM-1EDCE=BQ8"2Q>:W4@YYAST&)?#WPP\9V_[0"7
M^I:;J\>K)XKN-0;7++0X/+?3"\ABC;4FN-QM_(,<)MO+W*PX3@24#/<OA_\
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MJ? 7X:>,F^*GCKXK?$'3;+PWK7B.UL]+LO#EC>"[%A96V\CSIP LDCLY)VC
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M^?!.''RO)$-R\<D,!G@Y^W_CEX6U#QO\%?'OAS2(TEU75M"OK&UCDD$:M++
MZ("QX )(Y->>_LK>+=;\4ZI\;(]8U:[U--+^(6I:?8BZDW_9K9$A*0Q^B+N.
M![FOF2/Q9XE\6?%KXM6NHZY\?+R#3?&%WIMB/AUY4NG6EN FV-]X)5U+DX'
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M*/\ Q5GB>&^^S[-W^J^[MW;OFZYVKZ5ZE_PBNC8_Y!-C]?LR?X4?\(MHN?\
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M;"&!H(WM6',3A6)W$M\P!%>L?\(MHN?^018?^ R?X4#PKHW'_$IL?_ 9/\*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%!Z<=: ./L_BWX6O_BEJ'P[@U2.3Q98
M:=%JL]B.JP2.54Y[D8!(Z@.A/#"L3QM\=M/\&_$*U\&)X?UG7=9GL(]2(TYK
M1(XX7G,"DF>XB+-O!^5 QQVKQ/PS^P*_AOX^I\75^*.OW/BE]1>_N1)9VXBN
M%?Y9(& Y$9C.P '@*N.0*]UUCX(^'?$7Q;A\>ZO;6^JWEOI46FVMI>VD4R6S
M1W#3B>-F!*R98#(QPHH&8\'[2WAJ?Q-%IPTS7%TF;6G\.P^)FM%&F2ZBK%#;
MJ^_S/]8K1"0QB,N-H?-6;K]H70(?A!X?^(EOIFL7^EZZUC'8V%O#%]LD>[E6
M*%"K2*@)=U!R^!ZUB6_[,EO!XBA_XJO59/!MOKS^)X/"SQ0^3'?M*T^?.V^:
M8A.[3"(G&[N5&VL/3OV5M;L?AEIW@=_B5>SZ3HSZ?-H[MH]L)+22SN4GB9B/
M];GRPI#=CGK0!WEM\?\ P_+\-?%WC*>PU:QA\)BZ76=)N;=!?6DEO&)'C*AR
MC,8V1U*N58.I#5C^)_VJO!_ANYO[:*VU+6[BTDTF'9IGV=EEDU%YEMT5Y)D0
M$&!]^]E"@KR<\68OV?+:3X5>/?"6H>(+W4=1\;"[DUC77@B25YIX%@WI&H"*
M$CCC55_V>222:Y/Q9^QAX9UI-7&CW4'AR*_ET:X-I:Z1;/:B73GG96>$KLD\
MWSR'##HBT ;'BC]K#1/"-OIK7_A3Q']IO-*O=:>UB?3V>VM+618Y9'?[7Y;'
M+ A8W=B.P((K0T3]IK0O$_C./P[HN@ZYJ1*Z?))J"BT@@B2\@6>%BDUPDS8C
M8%@D;$$$8)XKF-3_ &-?#GBS2K&R\47D&J"RT2^TBT^Q:1;6,=HUQ<Q7"7,$
M<:[8IHFB&UE R68MG)S:B_9=GC^*B^.W\5P7NKS?V<]W)J'AVSN)))+6%8B\
M4K#? 9 I8[",%LB@#VL^(]*&OC0CJ=F-;-O]L&F^>OV@P;MOF^7G=LW<;L8S
MQ7F6E_M-^&[_ ,6R:-<:1KFE67]L7N@1:]?00KI\U]:J[2Q!UE9U^6*0J9$4
M-L(!SQ7>'X>>&3X[7QK_ &'9?\)8MA_9@UCRA]H%KOW^5N_N[N:\OTO]EZWA
M\63W>J^)[W6/#)U^_P#$T'AU[6&*)+VZ656+RJ/,=56>7:N1R03G % C<\ _
MM&^'_'VM:+I\>DZ]HR:_92:AH5]J]FL,&KV\85F>##LP^1U<+*J,4.X @'$=
MK^TUX0N_%>N^'4AU-=4T?7[3P]<1O;* \USQ',AW?-#N#*6Z@HPQTS4^'?[.
M">"==\-W=_XNU?Q+8>$[*73O#=A?101KI\,B+&2[QHK3R")%C5WZ+G@L2U5-
M3_98TC4?&FF>)QK=_;ZA9>)IO$+K'''LN8Y/*8VD@QS&LD,;JWW@0V/O&@9>
M\-_M0>'?%5YIL=EH7B(6FMQ74GA[49K...VUTP(SLELQER&9$9D\X1!U!*DC
MFM;X<?'6Q^(NE>(M3'AKQ#X>T_0I;BWNI]7A@^::W=TN(T6":5F:-D(/&#QM
M+5@^ OV9X/!6M>%VG\6ZMK7AWP@9F\-:'=Q0K'IYDC:(;Y50/-Y<3O&F\_*&
M.=QP1VG@OX76W@SPYXCTB#4[UTUK5-2U1[F-A#- UY,\K+&R]"A?"MUX!H$>
M>Z=^V'X5U3P*?%=OX?\ $;Z=)<Z?:VB>3:YO#>N4@,<GVCRAS]]7D5X^-ZKD
M9O>(OVI-+\,6>F2W?@SQ3+<7FFW^L/:6BV,TEK9V<B)/-(RW10C]XI"HSL1G
MC/%<<_[$5C<:)K=M=>+KF]U'4[G2YWO9]'LA')]@F>6)KBW1%CN)',C"260%
MF  X'%=-I_[)GAF^O?#$_BZ+2_%=OH-E?V=OILFA6MM9?Z3/#-O\B-=BLIB(
MR!\WF,3S0,Z7P_\ M'>#O%'Q _X1'3I+V:\;28]7BO6M]EK,C11S>2KD@^<(
M9H92A48213GJ!B?#C]K/PA\1B&73]7T"WDT"3Q-#<ZLEOY<FGQLJR2DPS2F,
MJ67*R!&YX!P<0V'[*>B:?XQ@\71:YJ__  DR>(;G7)+HW+F"2.:-H&M?LQ?R
ME00&.(.JA\0ISVKGM,_8B\/:!X0N/#NBZY>:/8ZKX<MO#FO?8[6*-M62&12+
MB0J!MF:/SHF<=5F/=5( .AE_:V\._P#"K;3Q[:^%_%-_H\EX;"[@BM;=+K3Y
MO-2)$N(Y)UVEVECV[2W#@G K5TK]HNRU;QX_A&/P?XC@U6V>SBO_ +0^GHMB
M]S$)45P;O<^U#EO*60#H,UFR_LK:)!X>\9Z!INMZM9Z-XDO].U-[>YN7O6MK
MBUDB9G66=GD;S1;PJ0S':$^7'0&J?LU+=_&Z^^(UKKMM#<WMU97,MK>:#:7;
MQ_9XEBVPW$@\R+<J\E3D$DB@#UU/$>DRZ_+H2:G9OK45N+N33EG4W"0EMHD,
M>=P0MQNQC->60_M6>#)?$FDZ*T&K0W.J/J\5M+);*(C)IT[PS1E@_#.T4AC!
M^\%/0\5Z%!\//#5MX[N/&D6B64?BJXL5TV75EB N'ME;>(BW]W=@_@/05Y'J
MO[(.BZMI6I63^(-1ADNHM4^SW4,<:R6<]WJ8U%)XSC[\,@"KV*YW=30(V/#7
M[5/A;Q;XQTSP[IFE:[=3WMO87#W"6L9CM!>6PN(!*@D,N-A&Z5$:)"=K.#FJ
M&G_M>>&[_P %Z_XM_P"$:\10>'='LKF^>\D%D3.L,WDLL<2W1D#%@V/,1!A3
MDCC-6/\ 9(LCXI\&ZI/XLU*YLO#7]G26UC+:6Q>.6SA2)!#<;/-@BDV!I(4;
M:Y+= [ X>B_L36>D^$O%'AC_ (2:-M)U[3[NQEFC\/V<5\HGG\[+W*KOEVG(
MVOD$8ST% SJ[G]K+0K3PIXPUN3PGXG8^$6C.M6$4=G)/:PO 9UGW+<F)TV#D
M)(S@D K7977QAL=*\,^&=8U?1-8T8Z_JMMI%O87<<)N(I9Y"D32".5D"'&[(
M8D CC.0.;'[-&B67@WXG>$-(O9-$\+^-HYC_ &79VT:Q:7--!Y4\EN,='(60
MH?E#;L8#8'6^./AA:^.--\+6<]]-:KH.KV.KQ-$BGS7MFW*C ] W0D<^E '/
M?"W]I3PE\7K?P[)H46I(VMP7\\<-Y;K');?9'@65)@&.UB+F%EQD,K YY&8M
M-_:0T;5O%?B'1K;P_K;0:#=WEE?:HS62VZ26T/FR80W/GL,$ ,(L$GL 2,_X
M;?LNZ1\,O&V@>(M/UF]E;3/#BZ!+9O&BPW3JL*"\; RLIC@BC.."$7/(%9MC
M^RE#IWQ \4>(X-?MS%X@O+V[N(IM!M'NH_M,'DO''=D>:J@8( /8@\$T 6M.
M_;%\":IX7T+Q!#;ZPNG:K:0WK&6U17LHWOHK)A<*7RC1S3)O SA06&0.;6O?
MM6>&='UM])M=$UW6;T:Q>Z*@M%M8DEGM((YK@J]Q/$NQ?-"9)!+HX .,G*T_
M]CSPY9W7B#S-7O[FQUOPK'X:N;)T01AQ'%&]XF!\LKB"$D?=W(&ZDU2UG]CJ
MPU+PCX#TE/$;37OAF6^N9;[5=(M=0&IW%YEKB:>&4%"Y=F8$#@GCB@#UCP=\
M5=+\9:]K&C0VM[I^H:196%]>)>B+;&MW&\D:!T=E9E$;!L$J#C#,.:X6Q_:V
M\)7=I%J$ND>(K'1KZPO=1T?5;NQ5;?6(K6)YI?L^)"P8Q1O(@E6/>H++D<T[
M1O@!K?ASQB^NZ7XY:SBOK'3+'5=.71+7[/>)9HR */\ EB'1W!5.%S\O2LBT
M_9&MXM+M=&N_&VMZAX>T73;[3?#FFRQ0*-*2ZMI+8L9%0-.T<,KQQ^8>%)SN
M/S  F'[9'AE+2'S_  OXHM-3N)=-2WTFXBLTGFCODF>UF#FY\D1M]GE!W2*5
M*\@9%=SX@^-.G>%OA+)X^U/1=6@LD,2'3$%O->%I+A8(U&R9HB2[KR),8/)!
MR*X?Q%^QYX0O/AOH?A30(-/\-G3=0L]3ENX-'MIAJ$UO"T2FYB==DN0Y/S=#
MTKH]7^ 5MXE^!9^&FK:G%)8O)"9)[#2X+.,QQW27 C%O&!&JG9L.!R"3U- &
M)<_M;^'K>6VLAX7\2OKLNIWFD2Z*4LH[BVN+:".XE$CR7*PX,4T;*4D;=NQU
MR*E;]K7PK=Z+I^J:-HGB;Q';7&@Q^);I=+TY6DT^PD+A)9U>1>3Y4N(X][L(
MV*J1@F?QC^R7\._&*>'K";0-.LO#6DKJ(;0;6QB2VN&O(A&\A 7Y77&Y7'S
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M@,(B"6] 2+'PH_:$T3XL7MG9V^BZ[X>N[_2(M>T^+6[>)/MUC(5 FB:*212
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MVR$*(P%R?]<<C -<SKOA#XL?LU?M9?#CXI^/_$EGXW@\2S'PUK%_HFCM:K#
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M^*NA^*_VP/V)OA]XS\.64UQ\0O#EU;:NVFSHT<MS=6VZ*X0*^/F8CS%!QD8
MZBH_%_[?OC;QWX6MO"GPR^%'B_3_ (M7CQPS1:KI'^AZ<VY?,8LWWEZKEP@
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M<#S>A8*)%7<<8'HG_!++3[O3?V8+B*[MI[2;_A(+]O+N8GC;!\O!PP!Q[XH
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MPMK6@_"WX>3R:D=8UJV^SO?W1VLJ1KW^:.,8!.%#%L$@$&<3\1/VMO&?P/\
MV^/%LFI:UJ^I_"[3[NTLM4TQY&DM-/@N+>'$R)T1EDRPQ][YUZM7N>D?$W7]
M4_X*.2^'+?Q->W7@R7P0FHPZ9%=%K)Y&*$3*GW22#PWH:X;PU\)['XK_ +:O
M[3_ACQ)IUPV@:YH5C;&?RF5<A("KQN1@NC*KC&<%17F?[$W@7QQ\/OVX[GPQ
MXTBO+FX\,^&;K0[:_DMW$,MI&\36^R0C#*4?*C.0#M_AH ^__P!H;XLI\#/@
MKXN\<M;+>2:/9--! YPLDS$)$K=\%W7..<9KY(\*?L[?M!_%?X6V7Q+N?CWX
MBTGQSJ]D-6T_0;$B'3(U=?,B@90P4;E*Y.TA<X(?!)^J_P!IWX37'QR^ OC/
MP39S)!?:I98M7D.%\]'66(,>RET4$^A-?)O@_P#;D\4?"?X/:?\ #O6_A%XS
M'Q9T73TTBSM8=,:2SN7C01Q3^8,DK@*2%5@<?*2#D D>L?%O]H+XC_L^?L<V
MOBKQOIFFCXIR>5I2PVD@FMGNY&*I,0N ?W:F0HO&X%0<5PEI^R/^T!)X,'BI
M_P!HCQ0GQ'-O]L&D9!TQ9MN[[.5SM(_AW;-N?X,"M7XS_!GXO_M"_L-V.G>+
MH[-OBO;30ZZEA:0K '>-FVP,-Q43&)VSC"[^.!S63!_P4M2+P4FCR_#+QH?B
MV+?[-_PCXTE_*-WMV[M_WO+W?-C9N[8[T#,SQ5^U9XK^)W_!.#Q/X_M;Z?PU
MXZTFZATN^NM)D,#K<QW<"NZ$'*;XW4E1TW,!Q7&>*]'U_P &? =OB':?M>^(
MG\0P:-#JD>B7FJVTZ2W#1J_V;R]Q8DL2@RIP>H.#5GQ-\!O$WP9_X)>>--'U
MZSE;Q9K-_%K=Y8VZ&9X));NW C(7.6"1J6 X!)&3C-)\7OV'=#\/? 7P1\5O
MAAX3LH?&>@:99:OJFBW-JUW!JZ>2CS"2WDW N#N8J -PW#&[;@ Z3]I;X[?$
M*^_82^$GC>'6;_P?XLU[4].COKK29&M7=)(IP6 '17VI)MZ<CL*Y_P#:%'Q$
M_8^L/#?C/0_VB-=\>W+ZK#:R>%_$,\4ZWT39+;44DX&,$@ C>"&!P#L?MN>/
M;;X_?L6?#CQ%H^D7D,=_XDL%NM*6UD$MFZQ3I-$4"[@%;(#8 (VD=17T-X$_
M8)^!?PY\2V6OZ/X$@;5;*19K::^NY[I87!R'5)'9<@\@D<$ CD4 >_6\C36\
M4C(8F=0Q1NJDCH:^3?VB?B!XG\/_ +:G[/?A[3-?U"PT+5_MO]HZ;;7#);W>
MT?+YJ#AL=LU[7\"OCMIGQZT+6=4TS1=9T2+2]4ETN2+6;80O*\84ET 8Y0[N
M#[5\^?M-Z==W'[=_[-5Q%:W$UO#]O\V:.)F2/*\;F POXXH$;'P.^('B;6OV
M\/CMX:U#7]1OO#VE6-B]AI4\[/;6K,D6XQIT4G)R1ZFOK:OC'X :?=P?\%$/
MVA;F6TN([66PT\1SO"PC<A(<[6(P<>QXK[.H!A1110(**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ QS1BBB@ (R****  # HQ110 4$9%%% !0!@444 &.:***
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@E"JQC?!.UMK*=IP<,#WH$7**** "BBB@ HHHH **** "BBB@ HHHH ****
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M]I77=2\)_"S3?'-G=7L2^%-3L=;U"WLF8&[LE;9=QLJ_?'DRR.%((W1J>H%
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MZRFT#")V6$@%#(>06S%I%DMMX!5KK4Y=5^$C>.;:36+?0=*O[33;>R^Q/O$
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M=3NY<0Y,D<9BA"$+A=C%1\WJW['&CZAINK:4;VPNK,#X7^%(";BW>("1&O\
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M!@JY&TD!DW!22N]<XW#/0ZQ>6ND:?=:M<6\LPL[>29OLULT\Y15+,J(@+LQ
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MB##[/"IVC<& S(0 ?9WA+QMH_CBWU*XT:Z-W#IVH7&E7#[&4+<0/LE49'(#
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M>^ O&>K_ !JT:]7P1?:2FG_$8:G=1Z;H4$5HMGNDB6^?4'<S7+R1M&66+:J
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MW@WXC>'O'>FB[TC5;.X=;>*XN;5+F-YK02('59E5CL;!Z&LCQ/\ &KPKX?\
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M-P708S-(#BUW$QD860.QX88(!]"?$GXA?\*_L-,^SZ%J/B35=6O5L+'3--5
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MAW7XKJ]UKPP[_P#"7:_:WMU<VMCJ N9RT<(,2+&&?9\[.^6&%&T'8^)'P?\
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M?E5/)/W1Z"NA(!ZC-+10 $9&#TH(R,'I110 8Q28'''3I2T4 (0#U&:6BB@
M Q1110 4 8HHH ",C!Z4444 &,TC(KC# ,/0C-+10 8S28&,8XI:*  C-)M!
M&,#'I2T4 )M 8M@;B,$]_P#/-+CG/>BB@ QBBBB@ HQBBB@!,#&,<4M%%  !
MB@# P.E%% !CG/>@C(P>E%% !1C-%% !C-&.<]Z**  C-9?A_P *Z+X3ANXM
M$TFRTB*[N9+RX2QMTA$T[G+RN% W.W=CR:U** #&:0@'J,TM% &5X;\*Z+X.
MTI-,T'2;+1=.1VD6TL+=(8@S'<S;5 &2223U).:U2,T44 &.<]Z",C!Z444
M%&,T44 &,48Q110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4
M$UA;7%U;W,MO%)<6^[R970%X]PPVTGD9'!QUJ>B@ HHHH @O+"VU"-$NK>*X
M1)%E194#A74AE89Z$$ @]0:GHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\N_
M:%\4_$/P1X(N?$/@*T\-7BZ5;7-_J<?B.6X3,$4+.!#Y(.7)4C#$#IS7J-<W
M\2_#-SXT^'/BKP]9RQ07>K:3=V$,L^?+1Y8612V 3@%@3@9Q0!\S0?M4?$OP
MQ\(O 'Q \::=X(LM(\8ZYHMK;-8W5R!9V%XLCSRW#2X5'10A&"4^]D\"M#XC
M_MI?V/XJ^)-IX,F\-^*]'\+?#^7Q7!?V=Y]I62\2=D^SR-$Y7;M"D@?-SUYK
M9\4_LNZQXG^ 7P6^']S=:-<S>#-3T2[U87*N]K>0V<92>.-2AW;\G < $=<5
MC?$[]C.;7?%GQ*O?!L/AOPQH_BCX>R>%+>RMK<VPCO7G9_/D6*/;LVE02,MQ
MTP!0/0YOQ[^V;XYM_'%AX7\/6_@30;\^%K'7U'C74)K3^VIKB(N;:Q8%5!4C
M;N=C\Q QU-?6O@;7-0\3>#=$U;5=(DT#4[RSBGNM+EE25K65E!>/>A*M@Y&X
M'!'-?,OQ"_9S^*VI06^E69^'OC[PO)H5EIHT3QS8.T>CW,4"Q23VDD<99UD*
M[RKD'.,$"O=?V?\ X73?!7X,>$?!%QJKZW/HEBMJ]\ZE1(<DD*I)*J-VU03P
MJJ* /#/BQ^T[\2- ^,GQ!\*>%[;P!;Z5X/TJSU627Q9J-Q:3W0FB=V2,IE20
M4(YP!N7/6N?U3]MWQ=XAU3X;V_AJV\#>$K?Q7X/3Q/)/\0-2FM(H9#/Y1@21
M.&)^\O R 3QTKTVX_9&T#Q=^T3XZ\?\ CG0?#?BS1]7L=,M]*M-1LQ<S6<EN
MCK,Q#KM4-E,;2<A>:M>.OV6]+^(?Q\TOQ1KNDZ!J_@>T\'S>'#H=Y;;F25KA
M71XUV[458P5#*0RD\8H#0\YT#]MKQ+XD^&^F)IGAC1M5^(VL>+[GP?I2V.H.
M^B7DD""62^2<KO-LJ$YP"21@'T[GP=\:/B;I_P 3+SX7^/M*\+VOB_4-#GUG
MPWK6BO<-IEX8B$DAFBD(E1D9T)P3E22,&N,M_P!D3X@:/X&T'2--\8:6VK_#
MSQ"^J> M1O8Y) ;%D9#8Z@H520$<IYD9)P%/:NET/X-?%S6OB!J'Q2\7:AX2
M7QOIV@7&B^%=%TI[DZ99O,P:2XN)G3S'8E4^55P%&.IR #+^#'[57CWXX>.(
M/!]AX-M?#NL>'K.Y'C>XU1)G@L+\,T=M;VVUAO$C(9,L>(\XYJKX:_;#\6>,
M+WPOX T_PQI]O\99-<GTSQ+I$YD:ST>TMB&GOL@AFB>-XC#DC<TF,G%7/@_^
MR+XF^!GCGPGXLT'Q3#JNJW]O-!\0CJ<LNW6Y)',PNH0 =LL4C,J@@ Q\$@Y)
M]*\+?!;4-"_:<\;_ !+EN;%],UW0M/TN&&/=]I22!W,C/\N-K!D PQ)V\@8%
M '=_$S6]7\-?#GQ/K&@6MO>ZYI^F7%W96MV&,4TT<;.B-M(.&( X/>OE#5/V
M_P#4%\0_!A-,T'3[O0?%.DZ7JGB6]+R$Z4+ZY%K&$P<#$HD'SYX Z5]I21K+
M&R, R,,,I&01W%?#?@?_ ()Z:WX9^%?QB\,WGB#3;G4/$HM[;PS=*TI73;:U
MN'N;1)"4!4B5P3L!Z<9H!'4VO[;6H1?%#3K#5H/#VC^!K[QMK/A=-:O;AX2L
M%A:JS3M([B,%IR8QGC ]>L7Q$_;AU'1=,^-6H^%(O#/B#3/!5YH%MI6H1W33
M6UV+\A9FEDC;;^[8D H>-ISTJYX9_8IO-/T;X#Z;K<^AZ_;^#+S5=1\2Q7L3
M31ZG<7L;EFC5T(?$KY_> <*#UJC\2?V(]7US3OC;I_A1_#&AZ=XTO?#]UI-@
M(7@M[86)5IUF2./ WL#C8#G)SB@-#5L_VDOB!IG@'XC^)]0UKX1>)X_#7A^?
M5(+;P7K<]]*)TY3SU;&V(A7Y!!R!CO5;X>?MPW/Q'TOX-266D65MJ?BCQ#-X
M=\2V$WF;],GCM7G_ '8R#AP$92P/ROZ@XL?\,[_$K7OA]\1O"NH^'OA!X5B\
M2^'+K2[>[\&V%S;3&Y<8C\\LG,(W.3@$YQ@=:IS_ +#U]8_'7X3?$31M7L;,
M:#!:+XFL&:39?7%O:&VCN(0%P7*L5);;\H'?- 'T_P".=?G\+>"-?UJWBCFN
M-.TZXO(XY<[&:.)G ;'."5 -?)GPG_;+^(&M:Y\(&\6Z5X(N=&^(Y$-K;^&-
M2GDU+3G: RJUQ#(,;1C#$'Y<]>Q^L_'6@3^*? _B#1;:6.*YU'3KBSCDESL5
MI(F0%L9. 6!/6O+/V:_V6?"?P)\$^%5;PQX<3QWI^EQ66H>(=-L56:YE"8D<
M2E0Y#'.2<$]_2@#YOM?^"@/Q A\"S^.+N+X7W&F6VIO9R>%+?6KB/Q%<*MV;
M?$,!# NP&]1T(Y[U[;K'QP^*OQ$^)OC+PU\(]"\+#3O!LD5GJ>I>+YK@?:[Y
MXA*;:!8/N[%90SL2-QX!%<-HO[".H>'/A!HHTB\T#2/C+X>URZUO2O%5M QC
MD\RZDD%O<L4#R1-$^Q@0=I&5Z<]?/\&OC%\-_B#XK\3_  RU'P=+#XV:"_UG
M2/$INA'8:DL*QO/;21+F2-@H)1PIX'(H Y;5OVU?%?B'PU\*Y/">A^'M'\0^
M*M7U/0]5MO%EW*MKI=Y9*?-0RQ=5+*P!(Y#)P,UD:C^W+XUL_ =XYTKP7;^*
M=-\>V_@N\U1]2FD\/LLUN\PN5G&'54P X;.WGZ#H+;]@^(V'PBTS6KO2?%VG
M:!K.JZ[XJ76+8E=6N;V-BYCAVLN!*5(5B,*@ZFNQ^/W[+2^*_AKX.\,_#31?
M"&@P>'O$MMK_ /9.IV9CTRY$22!HY(H4.[>74'(Y .30!R/B+]J3Q_X,^!/C
M[QU>ZA\+/%5YHLNGP62>#]7GO+96FN%CD^U$X*85U9=IYPV>@J/P;^UYXQ/Q
M*A\):Z?AWXL-]H6HZM;W_P /M8FO8[%K6/>!=AA\JR?=4@YSQ4OB;]F;XC^/
M?@GXX\"ZCI'PJ\)2:S)I\UH_@^RN;6*1X;I))?M(*?-^[0*N 3DG/%=;?_LN
M77@_XLZAXD^&;:+X;\-^)]'N-+\3^'O(,$$DHB86MW;K&A"R*S8<?*&7)^]0
M&AI>&?C-X^\?_LD:-\3/"V@:3?\ C6^T6+5TT*3S1;W!^])!&0VX,5!"$Y^;
M /!S5'X1_M3S?M!?$G2K#P#IUM<>#+70XM3\1:M>;_-M+N=<PZ?& 0/.7#&3
M=G:!C&2*J?LT_#3XY_!SP[X*\$Z[<?#R\\%:%9K8S7&G&^.I2(J-M*[P(\[]
MN<@#&<<UVW[.'P9U#X+Z5XXM=1GL+A]=\6ZEK]N; , EO<.ICC?<H^=0"#C(
M]#0!9_:B^+6I? OX$^*/'&D65IJ&H:2D#16]\6$+>9<1Q'=M(/ D)X]*X3X3
M?%SXF?$"\UVU/B/X-ZW<0:3+/90>$];N+Z9+HE1#]H0XQ"3N5B#D'&*[K]J3
MX3:I\<_@/XI\$:+=65EJ>JK;B&?4-_D*8[B*4[MH)Y$9' /6O// ?PN^,7@M
M->EL?#'P5\.ZA<Z5-;V5WX:T^ZM9?M65\DS,8SNA4[F*X))"@8R30!3^ W[5
M_B_XZ^.8M!@\&1>'H_#=A+_PF\NH>9FSU,,Z)9VI! ;)1I"S9PF!UKE?@%^U
MC\2/C*?"5]/K'P<TNTUB[$<VA/KERNMI&)F1U2W.092J,RJ3@@@]*Z?X/?LB
M>(/@-XV\.Z]X;\4)J8U/3I;/QZNJRREM8NF9I4OX>&"RK)(Z[3@&/ SG)/+_
M  &_9<^*OP8L_"FEMX?^"^IV^D70>37Y=.NVUAHVF9W=9M@'FA795)P!A0>*
M T.EC_:!^,_Q*@\4^*_A5X.\+ZMX*T'4[G38+'5[R=-4UQK9_+G:W*CRH06#
M*GF9SC)QTKT3X?\ QOUGQ?\ 'SQ9X$OM$BTFTTCP]I6L(LC%KM);KS/,AE(8
MI\A3'R]\\D8KS:?]FSXO^!K+Q;X0^&7CS0-!\!^)-2N=12\O;.X.L:&;F3?<
M):,CB-P6+%&?!7=WQFM;Q/\  [XI^"/BY<>._ACJ_AW6[K5?#MEH.J0^-7N%
MD:2U+^5=+) IW,V\[U(&3T// !P>L_M=?%P_LR0?&;2- \%-I5D;R/5;*]FN
MUGWQZ@UK%Y"KP5*[2VYASG'&*WOB?^T3\8/A/_PKG2-?C^&&EZ]XMO-05]0O
MM0O(=(M+>""&2,O*X#*[%Y%(P1G9CJ:U;S]D?6H/V(+WX*V6N6%QXCNX2\NJ
M7"/':&XDO1=2D*H9@@)95XSP,XR:U_VF?V?_ !7\5/$7PPUOPS%X0U&7PDU\
MUQIGC*&::RNO/ACB7*1J=VTJ6YQ@A30!S/B3]I+XE>'_ (7>&M4M9?AGXH\1
M^(?&=IX7LI_#VIW-WI4:31MS+*/G$BR+R!D!2.,UW7PE^-7C>X^+VI_"_P")
MV@:+I?B9-)77=-U#PW=RSV5]:>;Y,@VRJ'C='(!!Z@Y'OP?BG]GCXJ^)OAQX
M<TZWL?A=X8U_P[XRL_$]A:^'[:[MM+E2&-]PF4)N\QI&'*@94=<UWGPI^#?C
MK_A<6H?%+XGZOH%WXC_L9?#^F:;X8@F2RM+7SO.D=FF.]Y'<+Z!0,<YX -W]
MHCXQ:G\%;#P5JUM96=WH^I>*+#1=8DN=X:UMKEC&)D((&5?8/FX^:O$=._;Q
MO_\ A9/Q>TO5=#T^T\*^%M+UF]T+4E>3?J4FFNL=PC'.W&]\#;BO>_VD_A+<
M?'#X*>)O!ME<P6.I7\4;V-W<[MD%S%*DL+DJ"0 \:] 37S-XR_X)ZZ]XF^"O
MPJ\)P>(]-M]>T&[O3XDU$F7;J-O?2^;>HA"[F+,JX#  XYQ0!>_X;;\?Z;\/
M?'NJZOX8T*#7/#*>%"+2,SB-GU58WF5\MG]V) %P>HYKZ&_:=^+.H_ WX%>*
M?'&DV5K?ZAI,<#16U\6$+E[B.([MI!Z.3P>H%>-_%W]D'Q7XY?XVOH^JZ':?
M\)K>>'+G24NC,%METT)O6;:AQNV879GCKBMKXG?"CXY_'#X+>.O!'C"[^'MC
M-JUM;)IEQHAO@J2I<I+)YQD!.W8F!M&<GGB@#Z8MY3-;Q2$8+J&QZ9%>&?M8
M_'77_@=I'@J3P]'X>6Z\0Z_'HTEWXHN)(+&T5X97\V21#E5!C&2<@ UU'PGC
M^,<.J7,?Q'/@8Z0ML%M3X6^V>>9@P_UGG_+MVYZ<YQVKE_VL?@;XC^-FD^"!
MX9/AV6\\.^((]9DL_%*226-VB0RIY3K&K%@3(,C@8!H \MTW]L_QG;^"/C1>
MWVE^$/$&I> ]&AU:UUKPC?S7FBW;R*S?9FD(#"5=N2 >A'3OV_[/WQP\>_$[
MQ7IT&L>(/A%J&ESV+7<UAX2UR>ZU6'*J5S"W "LP#D],UY\?V+_'FO:-\5YM
M2N_ OA;4?%OA8>&[/1O!MG/::4KB0O\ :[@,,F4?=!5.%XYKT+X"?!WXC_#C
MQ3I3:SX8^$&FZ/!9M:7.H^%-.N8=6E C 7]XRA3N=4+YZ_7% 'H/[2OQ,U_X
M-_!W7/&OA_2[769M$\J[N[*Y#_/9B11<%-I'SK&689X^7FN+^(?[54/AGX@>
M'].T>WM=2\,)X3O?&_B'4SN:2UTR.,&V\D!@#)*^0-W8'%>[ZYHUIXBT6_TJ
M_B$]C?6\EK<1-T>-U*NOX@D5\N_L\?L3W/P\^'_Q!\/>.]=B\27'B73U\-V]
MW:%MUKHL4+Q6\(+J,.!([$#(SMY- %)_VFOC'X1\"Z!\6/&?@[PM:_"_5);6
M2YT_3;NX;6=+L[EU2&XE9AY,A'F(71<8#<'@U<\;_&CX_P"@?'/2_AWINC_#
M>>37;74-4TFZNKG4 !:V[J )\+Q(PD3A05SGGI6?-^S9\:?&?@#0OA%XR\4>
M%)?AEILEI#=ZQID-PNL:K96KJT-N\;#RHF;RXP\@9ONY KV+Q5\'-5US]I/P
M+\1+>\LH](T#0]2TN>U<L)W>X:(H4 7;M'EG.2#TP#0!XOXJ_:P^(,/Q?\?>
M$=-U3X2>&;7PM<6ML)/&^M7%C-=M+:I,S1@<,JLS G Q\O?-;^I_'+XU:[\8
M=6\!^"M'\ WMWHOAS3-9O;C4[N\2*XEN0X9+=HP<IN0[2P'!!-8WBK]ESXAI
M\:/B-XNT71/A-XITSQ5=VUS#'XYL+FZN+016R0E5VH54,5)."<\5KW?P6^.'
MA[XQ:E\0/"%W\.H[S6O#>EZ1J%IJBWWD03VP<R-;K& ?+WR':&.=H&<4 >O?
ML\?&5?CI\-+;Q'+I;:'JL5U<Z9JFEM+YOV2\MY6BFC#@#<NY<@XY!%<)^V!^
MTQK'[/VBZ'#X3T"#Q5XIU$W-ZVFS,P$>G6D)FNYSM(/RJ% [9;OC%=S^SK\&
MC\#/AG!X>N=3_MO6+B\NM4U34A%Y2W-Y<2M+,RID[5RV ,GA17FWCS]D:]^,
M'QS\0^-?%?BW5=(TE=,@T;0+7PKJ4EI<1VQ#-=BY;9@^;(P^521M49)P* (_
MV@/VL[GP-X;^%E_X1D\.VEGX])D@\3>+9Y8M)L(O(65!*8N2\@?:HW 94Y/%
M>G?L^?$'Q5\1_ 3ZEXPT;3-*U:&]FM5GT._2\T_485(V75M(K,?+<'[K'<"I
MSVKPS1?V8_B[\/OAAX<\)Z#XC\)^(M&\.ZAJ$">&_$]L\VGZKI,K[[5;A_*+
MQW$!+ ;04((],5Z3^R;\ =6^!.@>*_[8ET:UO/$>L/JQT3PS$\6E:6#&B>5;
MJ^#@[-S' R>W% &I\1_C3JW@SX\> / MKI]G<:?XBTK5[^XN92_G1/:1QM&J
M8.,,7.<CZ5\\> _^"BNI^-?@0_B4Z#IEGXWLO$&EZ;>Z4YE%N]G>W*Q1W462
M&((WCJ0&0]00*^AOB/\ !?6/&/Q\^'WCJSO;*'3/#NE:O87-O.7\^1[N.-8R
MF 1@%#G)!Z8S7SCK'_!.?6[SX7_!^SL]>TFS\;^$'AM=8NE:;[)J=BEX;I8^
M$W%HWP4W+C+-G'!H [JZ_:*^-NN>(_BS+X/\)^"]7\/> -9ETZ6SOKVZM]1O
MDCA28^60K1ABC<9P,CI5BW_;KL&O-:UR72T'@>R^'%GX[A>/<;YWFF>,VQR=
MG50HX^]DYQ5>7]G[XX^'/$OQ;C\(:[X$L?#WC_6)]1>]U**\FO[%)($A)1%"
MQLX5,@$D9[U+9?L*6D5[K.AW&IQOX&O/AM9^!8A&6%\LL,SR&Y((V<E@PY^]
MD8Q0!U7@/XA_'^;Q%X1OO%?@7PO<>$?$3 3P^';V9K_0E=-\<EP9ML<RCA6,
M8!!/ /?)U;]L&ZT[]JRQ^'2:';OX&:\C\/77B3>Q>/7);=KF.V'.W&P*IXSN
M;KQBK7A3X2_'S^V_"$'B?XB: /#7A,,\:>'K>XMKK7W2(QPK?%RR)'T+K&&R
M<XP<$>93?\$[M9OOA1=M=?$+5O\ A:=SJ#^)'ECU.7^P3K/G&1)_L_E[N!A=
M^-W&<=J .OU3XS?M#6GQW@^&D&C?#,WUWI$^OV]S+=:@(Q9I<B$*Y"9$IW X
M V]>:PYOVM?B+K7Q \?:+I6K_![PY:^'?$-QH=O;^,M;N+*]NA&1ME"+D$'<
M!D=P1CBO:H?A!XANOVDO#WQ-O[S35MK3P;)H%Y:0-(9#=O<I,SQY7!B^4@9(
M/3BO&!^RQ\3?#OC[X@:QI.@?!WQ/:>(_$5UKEK<>,=/NKF]MA)MV1[ECPH&P
M' )Y).: .LUWXU?&O7OC7\0?!7@#0/ ]]!X.M=.GF_MR[NX)KM[FW\WRXV0%
M1\RN 6  RN>]>N_ +XO6WQU^$^A^,[>QDTJ2^62.ZT^5P[6MQ%(T4T6X?>VN
MC 'N,'BO(-1^#WQR\-_&GQ]XV\#ZEX CC\86FF0W"ZXE[)):R6MMY1:-8P 1
MO9R Q.0%SCFNX^!?P<\4? K0_"'@_3]4TG5/"-C874FLWES#*FHW>J33>:98
M@#Y:Q$O+E3R/EP>M &O^T_\ %G4?@;\"?%7CC2;*UU#4=(C@>*VO=WDN7N(X
MCNVD'@.3QW KQ7QK^U-X_A^.'CGP1H%_\+/#UKX=>PC@D\=:O<65Q?-<VR2C
MRU7(;:S;3@<97N:]H_:B^$^I_''X#^*_ ^C7=G8ZGJT<"0W%^7$*%+B.4[M@
M+=$(X!Y(KG/"O[,>F1_&[XG^-O%NC^'/$EIXCETN328[NR6YGLOLUJ(I<^:A
M";G"L-A/ &>10![C9_:#:0_:A&+G8OF^224WX^;;GG&<XS7QM;_M\WR:K\?=
M OM%T^T\0>!HM5N_#H9I!!JT-EN$BN2<^8I$;,$/W7SQ@U]GU\5_$W]@;5/B
M'\-OB)IW]L:98^+M4\9ZGXF\/ZI&TH2WM[Q(XY;6<A=VUXU8,%##(4\\T =D
MG[1?Q)^)_BG3?"7PPT/PW'K-IX;T[7O$.K>)I+C[%:O>1"2&VACA^=V(#,6)
MP!ZFO2OV=OC/?_%_0-?@\0:/#X?\8>&-7FT+6].MI_.@6XC"L)(7(!:-T=67
M(R,D'ID^8Q?L\_$WX5>*M/\ %WPRU3PU>ZK>^&M-T'Q#H_B4SI:7$MG%Y<-S
M!+$I=2 64JRX(]#T]+_9S^#&I?"30O$5WXDU>WUWQEXIUB;7=:O;.$Q6WGNJ
MH(H4)R(T1%4$\GDGK@ 'K=%%% @HHHH **** "BBB@ HHHH **** "BBB@ K
MQ_\ :0^,.L_"_2O"ND^%+&ROO&7C#6HM!TC^TV86=O(Z,[SS;?F9$1&.U<$G
M S7L%>8_'OX*#XS^'M(2RUJ7PSXFT#4X=:T36H8%G^RW<8(!>-L"2-E9E921
MD'KQ0!YEJ_Q8^+O[//A#Q]XA^*-IH'C'PWHNC+J6FZYX>B:P>>Z,@C%E+;N\
MA&2RD2@X Z\\#(N/BY\;O@Y<^!_$OQ+E\(:QX3\4:I9Z3?Z;H=G/;7.B2W9V
MPLLKR,+A%<A7RJGG(K?A_96\3?$/3O'(^+OQ"E\32>*-%70DTW0;5M/TW3H0
M_F":.%I)-T^\!O,;D8*]#BJ%C^S5\4/&FH^#]+^*7Q#T?Q%X+\)7]OJ=O;:3
MI#VUYJ\]O_Q[&\=Y&4!3ABL8^8CGUH&>=_\ #>7B33];_:!\.:I9:;::OX67
M69O!]V;=Q;WWV#=YL$F7^>1!Y;G:5RK-P,<]!\2?C/\ '/1)?A3?Z)JW@F/2
M?B#<Z;IMI!>Z/<R36D\]D)I9)&6X 9-ZR850" 5&3@FK'Q&_8(C^(WPQ^(F@
MWFOVT&O:WXRO_%FBZO%:L/[/^TJB/!(-V75D5E;! .5..*]-\5_L\WOB/1O@
MA91ZS;P-\/=5L=1N&:W8B\6WM6@*H,_(26R"<XQB@#QKXP_M,?$;X8?%?0_
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MK95MDAV,23N.4)R,=:\N^)'['FJ^.=1^+%S#XELK5?&FO:!J\"R6CL;5=/\
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MUGPAHUS=Q2+96EI8C>]Q.BMND=4'W5*[B1T KU[X::_\5?!UQXKB^+9T"_\
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M\EE&4=%3=\N_/&[('?- 'FGCG]N-K[Q'\4Q\-]9\.^*O#OACX?MXBM+RV!N
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M;CQQXXU;QYI4GQ:U_1TT#3=0L=.DCTW0K,/O(AB9S([EB7W,P^8+Q@<@'/\
MP(_:-^*'[2>J:U;:/I&F>"XO#.CMI^L2ZK;FY+^)#N'DQ!91_HT>S<QY9@P
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MR274[.&B61P5 CY4<G/?>T#]D7Q9+JOP[3QK\6YO%?ASP/>6^H:5HUMX>M[
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M,O$M[?7LWB-A+;-;M.3Y2QPI+LVPC:%#9SMYXX%V\_92\<Q>)?!?B?0_B_\
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M ,35-6WES?";&/-R2,;=N.,5)X&_91T;1=5\4:UXT\2ZS\3?$/B+2CH%Y?\
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MX+T*XO+G2]-\XPRWTBO,WF2O*VXJJ@_-(<<#C% 'Y^_%#XW>)-+^(/QH:_\
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M+QCK_P 0+[4]3\+:G=ZO;?#/48OMUXZ2Q&VE+*1%)MB9=[@D$DD9SS]OZ?\
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M<FNA_91\5ZCH7QF7PQKVO_$S0M0U#0GD;PC\3(S>_:;F)U,EW8WP<J5 )#1
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M2^MGGCMXEBB\SRY5WL%4?,V23DDY)H"YY9<>$S\5?CWH'PB\37OB?0_!>@>
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MW55.P.Q\M<*,(N%'/'-=+0(**** "BBB@ HHHH **** "BBB@ HHHH ****
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MTH M9%+7YS_#J"]\#_L\?!/XIZ5XM\43^/=;U_3=/N;"]U^ZN[?68[B^:&:
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M9YQ2YYK\S/BAKVN1^-_&.J7^B^-/%FDZ#X&\/7<S:)XON=*&E/+;R;[J2))
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M[%S@&@1]'DXI:^(&L/#OQ(MOC7XZ^)'Q%\0^#=9\(^*+S3K6]T[6Y[8>'+.
MH+5H[6-MCF93O)='\S?@>E<O^US^T3J.B?&;2?["\2ZND'PWTVQUJ>SL[.X*
M:Y<SRQO+;W'E)L0"Q620>9M :48 QP#L?H,3C%+FO@C]ISQ/=>(/CZ-3TS1/
M%GCOPK;_  YM]>&G>%?$\^D-'&UW*?M0$<BF8E"!M +8P<'%1>#/#VI?$76_
MV<_#?B[QOJOB*RU/PAK>IW%]H?B*[A%WB>W>U#SQ-&\K1QR",LP!)5LCK0!]
M^4@.<U\[?LJ^(=3NO"'Q.T.;7;_Q+I/A;Q1J&CZ-K6H7)N)YK5(HW"--UE,3
MO)'O)S\@!.17SI^R1X;^(?BJ#X,^)M#T_P <6&)#=>)_$^O>)S=:3JUD5E5H
MXK-[B1M[/Y>T^7'M*DF@#]% <T9YQ7Y=? C4?%MUJ/P6E+^*?#NJ^(?$4KKX
MUUCQC<W.F:K;V]U+]HL19%G599(D,:(X3<4+ \5ZC;:99_$3X*_%SXP>)O'&
MOZ'\0= U/6Q;W%KKL]M#X=:SED2TM5ME<0E65(BPD1C+YIZY% 6/O7/-)GK[
M5^:OB'X]>+? OQTM?BCK^IZC#IMCX2T0ZQH8GD6TCN;_ $J\D5O)SL5A=6\2
MYQGY\5RWA=O&6F^$/#_AG7]1\8^++X?$\6-_I^F:[-;7]TK:!'<26\<QFCV*
M)7+!2Z@;3WH"Q^J>[Z]<=*7-?".J_"7Q;8_LP?%[6_%,_C'PU%HHU+6O!FF7
MOBJXEU+38ELAQ<SP3$2J949UC=Y-H/7FNI\+:$OPZ^(O[,EGINLZZUGK\6JZ
MCJ:ZEK5U>+<3'1XB-WG2-\@8;@GW58D@ F@#[%HKY)_:DA\<>!_B#I.H> ?$
M+6T?Q0,7@JZCNKF1X=*O&#-#J5NF2%=85N%95V[F$3=0:^G/!?A:V\$^$](T
M&SGNKJVTZUCM4N+VX>>>4*,;Y)&)+,W4D]2:!&U1110 4444 %%%% !1110
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MYI7VA0SM&K,<#CJ3TH$;5%?/-C^U[!>^)+24>#=07X?WOB<^$+7Q>;R';)J
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M2_;\T6U\'>$M1@\,LNNZW'J4LNDZIK-K81VBV,YM[@&YD(21VE&V-5Y?D_*
M:!V/JVBOG_P?^UG'\2?B)X<\.>$/!>J:S8:KH6G^(Y]8DNH+>*PLKII5#2(Q
MWF16BV[%SDD]E)JO\:/VP+3X1?%:R\#MX9>^NIK.WO3<7>K6VFFX668Q^79B
MX*K<RI@LR;UP,<D\4"/HBBOF2Z_:AO?#/BWQAHD&GZEXSUR3QO%X6T316-M9
MQHYT^.Z<"<#B)$WN7D#/DX (QCD?"W[:^I>'/">K7/BZQ2X\27_CS5] TG2M
M1O;32X;*WM55V2XNS^Z41@[=_P Q=F4#.> =C[)HKYN^'G[3[_$7XC?#*XL
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%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ahpa-20220416xex99d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xex99d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" .8 J@# 2(  A$! Q$!_\0
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MM.TG!K,D_:I\'#27OX8-4NEM;"34=3@AMU,NE1QSB!UN5+#8X??\@R2(W89
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MNR&#;>:]XT^Z>^L+:YDMI;-YHUD:WGQYD1(SM;:2,CH<$CWH L4444 %%%%
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MJL""ZDM%986EP-Y0-R%)S@'FKU% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHL^J^'K_ $NVT:'4H+<'SH[:V67+OC:"N%$C+D%C4ND?VC_PD'[3"?#_ .'
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MOB67>A)7*K*JAP<=": .@_8TL;G7_!>O_$[5(6BU;Q_JCZMAR"4M$ BM4''
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M\YYY XKT6B@#YNB_8XBBB_X1L>*I_P#A6_\ PD8\3_V!]EQ<&XW^9Y)N=_\
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MVO[*NM7OB*YUGQ%XX35KMO"-UX/A^SZ4MJL5O*%"2_+(<N,$GL=W&T5]&44
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M@ HHHH **** "BO/_%GA_P 8R:EJ&H:)JPC)>,6UHY)3:%3.Y2VW[P<\ $Y
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M^[\.Z-+H!N[?RE?4+)XMABN!LPV"%D! &&&?:@#YY\!_MZ>(M0\.MXCUK5O
M.I6]OI,NI7'AW1$ODU+<(\K$))1Y((<H&)8@#)&:]\\'^)/CM>R7UOK_ (=\
M'P->:4]YI5]87D[06MUD;+>Z1OG<$-G?&,?*>.1C'\)_L=6OA[1(_#FH?$+Q
M3XB\'"QDTU_#FH?91:26[1E I\N%6&W(8$-U45U/PT_9TMO 'C!?$VH>,O$W
MC+5+>S;3[%M>ND=;.W8J65%1%R3M7+-D\?C0!XWH_P"TS\8;2SU>XUC1_!>H
MRIXE?P5IUGILMS"TVJ[EVN[R,0L &\GC?\HP.<C9\9?M+_$3X4^'?'^F^,=&
M\-GQEH.@+XBTZYTN69M.O+<SK"RR*Y$B,KMCK@\'VKTR_P#V9O#&J^$O$^@W
M=U?NFM^()?$J7T3K'=6%ZY4K) X7Y2FW )R<$@Y!K#7]D31+WPQXOL-=\4^(
M?$^M>)[)--NO$&KRPRW<5JKAQ#$!&$5-P!(V_,0,]!0!YQ\,/VOO''C&P^(#
MVFC>'_B%)X?T(:I;3>#OM443W18@64BSKN\PKE_ESPA]17?_ ++O[0>M?&2[
MURPUVX\,7-W80PSJ= DN(I(P^=T<UM<*LJ$'&'Y4UT^O?LV^'=<U[Q#J$=]J
M&E0>(=,BT_5+/372!+B2(YAN]P7<LZ !0P."  0<4[X5_L_6WPW\7ZEXIO\
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M'." .,B@#F?&OQ)\7^ O@A\0/%^J:;IHUC0AJ%QI]NOF)!/;Q,WD-)N.X%E
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M*SO^&F?$4,_B/^S+"TU>*UCU35%>]DDC2.VM+6QFV1E(@S;_ +2VT,-P[]"
M ?4%%?-5]^UCK?\ PE'B/2[#P7YT>G6<DL)GO8XF,BP03*7+,%V-]H"C:3RH
M&1GB8_M4ZA!I?@W4I]'M4TW5+B>WU.[_ 'H:Q>.=8MA@(\P?>Y<!T!P,X(-
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ME4;U-=3\,OA+X@L;[PCJ/B1+@7-B+YKB,:G(ZKF2-K4,GF,I*CS. 649Z]
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MX'_=QB.<&%V*X..#FNK\8_&+X4>+?#VN6^KPSW5IJ%LMF[P6CK-J%M)="TS
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M5L6TS#([X(!^H%7O^$+T#C_B2V''_3NO^%5O$O\ R,/A+CC^T)>?^W2>NCH
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M_!OA7XH> +S1M TJ/68]#LK>^@ 6%# R%;LQ-U&US*;=LG<?F_A7- 'K5_\
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M^XC!^7=6_P#%CPMXJ\4>!?!/FQW<FN6TADU./2W4 R-I]Q&V><;/.= <=B:
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MCF"8&!D'MQ572?V<+J"SL[V;Q),?$.F+8PV0M)&CL4CM8A&L;Q=2&W3Y&?\
MEJ>/7@O&EA\7_$T%QIMQ;Z[]GO=$6&Z6!(]@D%HCG:0P4.9PZD*"3G&X# /H
ML&C?$*U\1W"V+WJ:3JFH2P2-<-$&M(E:*1+@$<Y>,3QGJ=QCSC!- '0_!?X4
MWOPW@8W[Z4)AI]IIH31[9H(Y5@WXFD!/,C;\>P4<FNI\-W[Z9HT%M<V-^DT9
M<,#$TG\;'[P&#7#_   B\?QC7/\ A.;F\GE+QE%NK9(HTE^?S1"RRN7C^[@X
M48Q@9W5Z]0!F?VZG_/G??^ S?X52UB].J6L=M#97+.;B!_WULP4!9D8DD],
M$Y^E=!10 5S^EW9TK[;#+97.YKN:0&&W8JP9B0<CKG-=!10!F?VZG_/G??\
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M@8,C]EP.XLO''A#X=6MIH_@K0KG5WUNYMS+/Y<AA>2XBW1>?.P/S-&%P&Z#
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MR(9X790IB!CQR<[B1_#D^I>+_&6B:+J]KI5[87&IW]Y P,=O8M<"*!F"EIB
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M (0.NQ7W'H0#R<C.=IOQ,\!77A+Q!KUCI#OH&BPM'-<Q:5A)D**7CA7&7XV
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M![/S3)'&!\R;E.03GDD<#%2:+\=OAE>7HTW0K!KZY:]6RBM]-TL,96/F-O4
M<)F&3).,%<]P3I>,?'-SX9\3>)]2MO"NG7UKX<T^&\OM0\W;?21NKLZQ*(SN
MVI%G!89X H X_2/V@/$?C/X3>(O$-M9:7H5Y97%B;:=KR.YA,$\D1/F;&;8P
M5F!SCUP*CM?V@_$?AGPKK5YK&FV>J20)+<64T%TJY0ZG):*)B=JJJ@*=X(
MY.3FNGM?CIX$U.XO-!T"TAU"0W\-M=6BVPCBE66Y2WFEQC#;7?D$ DCC(YJ5
M?CU\.AI6JSW,+V=I91RQW*7&GXS'L\W9M ).]2S!,;CALJ,4 4=8^/6K:/\
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M;<R1G(90AW)[=?0@YH AU?X7>#[;5=4\2:SJ7G:#:V5JCZ;YY^S*EI&[JTJ
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M2-L91;?*G&3@CO72I\+O!\<<6F6%R^G.;.[CAAL;W8RPW$R2RNJYY&]% ."
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M(&>* ':[X&^&_P .=&@T?4M9O=(C):]TWS-2E,UDL Q_HQ).U468C;R,-@Y
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MZR+<8BBW87+J)" ,\GL<5E:5\%/AEI6C&S,\-[837=NP6]OUE0R0;A'$ 3C
M$C ICG=R"3FL.R_9:M;33+*&.;3[&^AM+"!K_3[-8I4D@N)))98SC*NZ2!<Y
MR<<\5E:+^R4;+0+JRO)]'N+E]/O+..1K>66,RR01Q17++*S8D'EECMQC=@9Q
MF@#H7\#?"F2YTAEU%X_^$?NTT&.);ME47$+&Y5)<\L4):0DG'4G.*ZF/X=>!
MTOO#=[:WYM9-.L8K*T%KJ91+JUA.Z-)%#8E5"&(/;+<X)%>?^.?@!KUY9>(&
MM9=/U*&XNFO+.P, 'F7$SVH>2X+'#*B13+@<E9&&<U>NOV:)-5M=6:\N=)CN
MK[3YH(TBL=T-G+)<B8QQ@X/V<A0C)P6#-TSP =9XT^''@3XD:G;:GJVIFXEG
MMI8;/R-4V(,HR/)#AN&"E@2IQW(R,U3?X/\ P^EO+[Q"=2DW37!D:[&J8BAG
M\Z*8LO.T.98(V).3G(Z<5PVM?LU>(&<ZII]WH]A?N;F>>UTRV:.) Z$?9X$<
ME &(R7(5@SNPZ@!3^S'J6L^#]/6ZDTC3]226UFDTJW@>*Q<1VLD!WB-@WFGS
M2Q93C**.1DT =EK'PY^'?A?5WU'4=<N;&5[VV:*WEU5]EO*]SYD:HF?E5YI&
MR#D'>1P.FEX<^$G@CP3>6NNV=W(6TR+-C/?ZDTT-C;['C$<>YL+" [X&?QX&
M.4E_9QN[>_E-K)H-Q;QW5M>V]U?6+O>LT<ELQ@DE+']UMMR!]X_,O/RY:)/V
M>=<E\-:EI-]J&CWJ1V-I8:6%AFA55MYYI5DDVMD.?-&=N1\O0YH [SX5^&M,
M\"W.LZ2M]!?:_J=P^OW[VL+10XG<JFQ2S;4Q&0%W'HQ[UZ%7"?"?X?:AX#TN
M=-7U2+6-2ECMX#=0VZP+Y4,*QJ B\#YO,;@#[^.U=W0 4444 %%%% 'FGQBT
M"+5]1\'7-[X:/BG2K&_FDN[-;1+DJ&MI51MCD X<K].*\>F\(?%BSAM-,L8[
MZP\./;70M=)BC2X6.&66X/V>YD:<;2L30JNT.!C"]*]I^*VIW=MJGA"PA\0W
M'ABTO[Z:.ZOK8P [4MI9%4F9&4 LB]!FO,M/_:*US0=&!N[>VU]=/Y:9I%AO
M=;A>[EA@ELX5^5R4C5VZ [N ,T 3:/IOQ0MO%U[9P_VE::/#H_EVZ,4^S?:(
MXK=H40Y^0,RS(?E)P3N;)4"G./C/J7A:[GOH=1M+XW4,$<&GS1AA%(KSR2GD
M,WEL\<  *9\LDDKDGHI_VA[O1_#]QJ&JQ:%E=/O;U9+'4#+$CQ6\4T4#Y /F
M,)""HSG;D=>*]S\?O$]G+<74VAZ6FEQ"^N@%GE:=K:TNDMY>B;1(QD1E&>@(
M/K0!@:II7QDO/#4=^;[6;/5+G4+:.[@M5BE\FW%A&6:&+>F/]*+!OG)X/5<@
M^C^/AXR_X1WPQY1U>>1;<MJG_".K!%=O=B-/+P)6*+'O\S<,D?=ZKFN+T#]I
M+Q'XL$Z6/ARRL)+G4;>RT]KZYW8$DTL3>?'&Q=&!B)Y"]<=1FL]/VD?$D.F:
M[KXL["?35DL9(K:4LKV,#V7G3,5X>8;P<; 3@GCY<4 7Y['XI:OXCEM%D\0:
M;%<WNW4[GSH/LL-O]MB$7V(CY@?LWF%R1U)ZG%4?#MS\1M8\.ZM/I5SXAFA:
M6[ANI[J>!Y<)J 0"PR,;_LR2C<_&[;U.:]H\6>+);-?"4=BXC77=2BMC/M)V
M1F&28XR."PBV@GH7KR*']IG6[G3?$$MEX=LF^PM#- _G@+]GD:=68H6#NRF
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MDDC[G4\%APH)]!6\WQJ\"1VTMQ)XLTJ**&00RF2Y53'(03L8'HP"L2#R,'-
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MC5\/7N+>S.DW%_)>MLT^*/2?,&H)%YA+P9&)$0HW(Z9!'# GJO%&C^%_%/B
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M.*V+GX:?$"P\5^&'L+B_;2-.U%W8_P!I!V6U&H2.$;>_*M;,BXVLWR@$KCD
MTYOV5[*XN?#,\OBG57N-*L4T^[O]Q%YJ,*^9^[EE#?-&?-8;9%<@ 8(.2:VG
M_LJFRM)(3XQO"WV/3-.3R+584:ULA*L<,JJ^9%99CN&5!*@],K5#3?!?BSP]
MXD\">&X=2O7;4H5N_%#LTTJ(+:3S%>.9B55I6(A9 >5P0HQFO2?B+X+U[Q/K
MUO=:3J'V%;;1=0AMI#,ZK%J$GDBWE95(WA0LG4'&: . \*_L>Z1X:T*STEO$
M5_>6EOJUKJ9#(%+K!8&R$/!X4H=Q(_BZ"F>)?V5M%U7PKX?T;6?%<J-IC_8-
M-N#!% ?L[VPMA;X4J9',:Y!8GYL_+M^6LZP^%GQ)LM"T+;=:E<7]MJ)D-KJ&
MIQR0Q(5C#2.T1C8C<KLNUF(R<K\V DWP:^(>J74*371A>"8RWE[<:@9EU"X\
MUS'=0ID_9]B,1M 'W@ #M!H ]$^('P6\#^+-=\,:CXKATZ[TWP_87%O;:9J4
M:&WPQ@/FX8X!01*.G1S4%[^S[:"::[TO5WTN_77Y=>M'6U1X;=I+,6C0^7D!
MD\O)ZCD@]L'@;WX7_$;Q'?\ ]I7=FUG>1VDEE9[]460VY-K;1F5BI 8,\,AP
M.?G4D9SB]-\*?'^L>+H%OI9X=,_M22XU:]36'V:K;-<;H8XXE(,'E1?(0-N<
M_P 74 $OA3]EU]$\3/!+JK?\(C8R:--9VQ DN+I[& HOF/QL4.<[0#G'5>14
M%O\ LO\ AS4K.\\/CQ5'J=_I-C9Z9;QO$AETZWB>26#>(W5Q+^];;*&1L 8[
MY]=^&T6M:/X<TG0]=CGN-1LM.@^T:D[ATFERRE V<LP"@DGKN'->2^*?@[XK
ML_$GB34M$M#=VFKZC<W:VUKJC6<J7#V]M';W3OGYEB:.?,?HRX5L 4 .\=?L
M@P^/4TE=0\;ZS.VG6L5O%-=#S9 RV\D#L#N &\2EFXR653NP,5Z:W@'PEXMT
M_3+2:8ZG_9EG';QM9:C+"!'MPI*PR <[3@GTXZ4_X4^$=1\*Z#>IK=Q/>ZQ=
MW]S-<7,URTOF*9G,97)PB["N% &/2O*?AM\#_$WA";2;F-#I=W8/86[^3>EH
M9;>,W N,(&Q\WF(1N!(& ,8P #VKPO\ #_0_!L]Q-I-O<0R3J%D,U[/."!Z"
M1V _"LC7+:T\=II4]YX8O=1MM/NS=VP,MOY;R!)(LLID^88=L CK@]JYWX >
M!_%_@RVU8>+-3OK^>8QJ#=WD<Z22*7#S1A4!0/E3ACG@<#'/H'@G'_",66
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M"6ZE>2&^))/[N)HU4*2!C"DD4 /G_9LU'6[;4-+N"BP6<]HT$EU))'!>@1W
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M@V1G [G;3_$4'Q3AU^^CTAO$4M\EW*D;2O =,,*LOV-EY#'/'G9()'F@\[*
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M^G".2YEM]9F/E[;PM)$RR2L'5[<XQ\WS?+N"J,^F:-\.=;L?V6?^$'EMT7Q
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M3!X6CA"!H]D?[ODCH< @@UAZ?\(?%.B_"K0M+>_U35W@EA?4="748K4O"BR
MP0W,:(V-[(WSOR$QN&>8?B/?>+](^)NDZ'HOB>>PMIK;2888Y[-[E&87$ZS2
MD^8"WRB/?N/.Y,GU;I'QK\:ZQXS\$V'V"PLK#5+*TN+D7%M,'N6D9UG\GKL\
MK:I(;^\,G!!H I67P3\>+I&IW4NL7T?B,O#;6<QUF65$LWA\J9<?*"Z*V0Y
M9GB#9YJ&]^'/Q4D3PO?N99M;6<76H26^JD102+-$NT1LX4JUO%S@-EV;[N=Q
MZ;QY\7/$'AW7?%D4%U:6RZ5;N;;3)-,EEFEC\J%A>>=O">6'D=2#M'R_>R#7
M,^&?V@/%FM:AHMM,UA%>O%&S:8MBS2ZF3?S0,8G$F(PL,:RY(;(.>E $/BKX
M*>+[O09;=+&^U=[W[6[1_P#"121FWN6O&>*9MS;606X1 HSMQC9R37IOC'X5
M7OC7QSJUS-JDVF:#?Z)!IDZV21&:XQ+.SJ6=&*86489<'YCZ"O%%^-GCKPWX
M:U/4!J"7=Y.]C]EM+NPDVPJ;!Y&4%Y 6WR1D \DMD $UIZI\<-?\.2ZU=SW\
MVG->-_Q+_MMJUS$LKNNV/.]8TC5=YW$Y !^\<*0#=3X6>-]2UJRTW4(K]=!L
M[E4DN$UYE%U ;Z68G"L'XB=$P<'Y<<@"JTWP1\4:_!;V^I6EU%<V<MQ-)J3>
M()G:\N&L[B..>(*P,*[WBRHQT^[A03)IOQL\>Q>)+JRDATO7(;/2VN4&G64X
M.I$6?G"X@P6S&9@8@,^V=V,Q1^._$^M^ /B/J%MXN-U-97NG?9M4LM.>".WC
MVV[3A8V<Y W2;R&_O#@@T 6]8^'GQ(U#QO<W DO(M/N-->TN+NSU8(TA-BJC
M8'+>6PN 2"$P,DY;<=M#P]\+_BA_;7A.YU&>>RL;!F5(+#5=IMP+EFWW"2&4
M2;X2%(1CC!' .5L0_&'XB:MXMN]'B_LS38I-72Q1SITTTUFAF**77<%.^/$@
M)8=1U'2Q:?%+XB"4W#W&GW5JC-=FV71I8W>$:B;3R0YEP#L DW;2?1<4 >E>
M)1J>N7O@S44L+BUMK75IOM5M+RR9BGAAE90>5WM&W? 8' P<<'X4\#^*-.C\
M,P:CIUW;ZO#KEO=7-Z^LR7B2A+5UNIP&SY22%M@C[EP2!BG>%/C%XHU?X<>/
MM2FBCN=:T!V\J2UL6:V8;=Q5 KEI2H!)!"L,@%<U5\1?'S7(X=.U;2%MKC0Y
M]>FT]?*LGFN+N%3$L9A0NH;.Z0G!W84%5(!H S[[X$>($NKV?3[2>SNK6;6K
MVQN+;6'B$MQ<WL$\+8W=XU=2&&T%3\IW GL_A5X$\7>'?B)XFU/7;_4+FRNI
M+CRS/J"36\P:8/"T<(0-'LC_ '?)'0X!!#5P^D?'?QQ>_;AJPTW0+<WPMIKM
MM-N)O[%&)LK.N5!)\J,!BP&90<;2M:D_Q"\7:9\'/AKJ-D[ZEKNI(D=Q>75M
M)@,T3#S)(MZDX)SM)[>N* ,:T^ _CW2_#<"6VJ33ZE%X;FL;+S[V*)M,N'EB
M,L4<D<0+++&@59&+&,KSD-P^]^$'C>]TW2;*[L[S5;6,V[VT=[KGS::R7OFR
M&4(528&((%&&VD8SCFO2)/'/B2R^%5WJ=T(/[9M-1ET^>^6T;R8X4O&@:\,.
M_.P1CS"N[L>:\CU[X[^,_#FEZKJEK>P:J6FC:&5M+GBMIE2R639%&[!QYK98
M!=S$_=!'- &OHOP/\;W.K)#X@U36;VQDU(S:A)_;QCBN5\FY"R1K$%D5<O "
MA8?='&$W'+U/X7>.=+U?1=/,>J:Q]NTMWD*:[<1K!J0MXUDN&D\SA1)A@G?#
M$*2*ZZX^.FNW<FK65HMG:ZK8:;JEU-#=6LH2%HKJ%;5V;)&UX9"_OPWR@&L7
M0/CWXZU_7O#%K;:?:06U[;*[-J5G)&U^_FRQR-#Y32 *@C0Y!8$.&X#"@!'^
M#OCJRO/$;64,B?;)KJXN7M]7>!=3\R2P9E3YB8'=(;E _&TMZ-FK_@CX2^-]
M,\01:S>R7=LL6K6SV-@VN2S_ &+3LS>=!)EBLIPR=03T 8A0:T?#7Q<\1Z[\
M)/%>J7#*VK:9>+9"^M[/R[<!O*#RQ'>PD6,2,2?E(*D,H(-9K_$;Q-I^O^/=
M.CUAKB*UFU)T@>U/GZ9%%:I)#,92VUHVD&P)M&=_7(:@"WXS^&GB_5?BKJ6H
M6-I<2Z7/JFF:A TU[;"PS;I&&,L90SY!4E1&P&X*3WKG-&^%_P 3+?1+R+4[
M&ZOK6:[CGETN#Q#);RRD6TJ,R3B1B@\XQ/@L<[2V 0%KV/Q/XSN&\ 6U_:O]
MGN9;FRM+YHV&ZQ\V6)9L\\,BR$]>*XC6?B;XE6X\7Q1WL-O=:26DM]'33IC/
M&([J-(B\VXI(MPA)"@*V'XSM- '.CX,^/+.R\66\D]S=Q:A/)>V"6&H"+R ;
MR21[5@S*)!(K)(SY1B=R[U^6EE^$OCBW>[N[G1SJ7VV6PGU2RT[Q#-;&]$=@
MT)CCE9MR;)MCX9AN'.XD8KL/B!\6M?\ "OQCT'P_:PP2:1=F!)HY+<F1Q(9
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M5Q_T+&M_]^H?_CM0:%+=ZIXRO=2DTJ\TZV^P0VZM>*@+N))&( 5FZ!AUQUH
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M5RY_X5'K&J6/B6>XT&YNM5N'C@NFG4I=3!#;L2F=K.$)C+$9P0N>@H R;/\
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M/^UGD5FW?A7X::7\)C?6VE+XD\/Q-&V;.;S);J3 M@-Q=0>&*%20H!(P!Q0
MJ_'C0[J[U&TE\-WB:,1-(^H,(?)G6,0&=R@;<-B7",2PYV-CH,PZI\>+&ZUB
M.SL-!F\2Q/,@TZ&U:$>=(C7G[Y9'D"E?]#?;QGH>0>$37O VJVE_H#,_P_\
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MK5O*DB0)L!0KC:0.F!QCBOFSXX>-/B?X \2>/I],\?(FF:-X9?Q):6,N@02
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M=_$OPVLO 0M%\674=A!JW]H+=I$S3QSK-]L+;1$?W74[BNW8?O<@U<^'>C^
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MG73YHG@4QR+,6*D*Z!?) !W,SGISZ?XBN/%$-U$-"L-)N[8IF1M0O)87#9/
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M6!DRS<%F^4DAAVOQB^%DOQ"T*.STQK>PG:2Y>>7<8C+YEE<VZY95).&G!Y[
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M C!Y.*NV?C#X:_#9;W1[:*#3%T6)A,T.F.$+?NE=%D6/;)*V^'<JDL21D<4
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M/SW_ #Z:E<__ !RJVH@?\)_H1_ZA]Z/_ !^VKHZ ,4^$-/)SOO\ OTU&X_\
MCE5/!3,C:];F:::*VU)XHO.E:0HOEQMMRQ)QEC^==+7->#CF\\3_ /86?_T3
M%0 GB]#<ZIX:M&EN(X+B^D65;>9XBZBVF(!*$'&0I^H'I5P^$-/)^_?_ /@Q
MN/\ XY5;Q-_R,'A(XS_Q,)?_ $DN*Z.@#%/A#3R<[[_OTU&X_P#CE4?"\1L_
M$OB.S2:XDMHFMVC2>X>786CYP7)(S@<5U%<UH7_(Y^*/^W7_ -%F@!WCIY!I
MMA%'-+ L^HVL,AAD:-F1I5#+N4@C(]*LGPAIY!^>_&?34;C_ ..54\=8^QZ3
MG_H+6?\ Z.6NEH Q3X0T\G[]_P#^#&X_^.5GZ5;_ -F^.;VSAFN6M3IT,WE3
M7$DH#F60$C>QQP!T]*ZJN:A_Y*/=_P#8)A_]'2T =+7*GXF:"OCJ#P>\UU%K
MUQ%+-#!)93*DL<84NZR%=A W*,YQD@=>*ZJO/6\!:Q!X^\5^+K/4+*;4[VQM
M--TJ.[B9HK.&-F>4, 027=R3M(^ZF1QR 2>/OC9X)^'VK?V-XFU-K.>6U6ZE
M5K*:6&.W>0Q"25U0HB%@5RY ]:ZH^)M&CMWE_M6P6")Q$S_:4"HV.%)S@'CI
M7GGC7X :1\1?BD/$OB+-_I*Z-'IHTL32QK(RSO*WFA&"RQD, 4<,..GKQ>L?
MLKW%QX1T^PLKK16U"WU'6+N:.[L-UG<+?&<*SHN"9(5E4(3Z,.,Y ![]'K6G
MS7SV4=];/>("S6ZS*9% QDE<Y'4?F/6J[^)]$-B+IM6T\V<C^2)C<IY;-C[N
M<X)QGBOFWP9^RSKD6IZS#>ZA;Z?90W=Y':ZO]F5M5O8Y-,CLE>24'!3(:0 X
M.Y%!&!FDU;]C_6-1\/7:0ZGH.G:V]Q UL]E8O':VPCM!;^;Y>2LDCX!<.I4C
M"C&-Q /HGQ#X[\/>$K.\N-4U:UM8[-$>=-X9XE9E56*+E@"77G&.165XN^,G
M@WP+J]UI6N:Y!I^HVVEOK4ELZL7^QHQ5Y1@<@$<@<^U>*_$K]E;Q+X[\;W6M
MOXLTZ..4&*%&LRA9&BA4HZJ=K8>%F[DAP,C8,[G[1?[+<OQTU'5;^'6H=(O)
M=$CTRQG>W\QH)!+*TF[^]%)',R,OT/84 >[6VLV%[<M;07L$MRJ"1H%D!D52
M 02O4#D=1WK!\8_$S0? =[IEMK4UU;/J-Q%:6TB64TL;S2-MCCWHA4,3V)SC
MGIS7EFC?L\:]X6\?7OB;2M:TLW44FHW=E+<VK^=/-=I$OE7;*P+P1&/Y%4@X
M"=-O/HWB;P/-XD^(/@S6KN^B&GZ MU.-/Q_KKR1%CCEY[(AG [YDZ]00#MZY
MWQYX^T;X:^'Y=;U^:XM],B.)9K>TEN/+&"2S"-6*J "2Q&!W-4M>^'(U[5);
MT^)O$>GF3;_H]AJ)BA7 QPN.,]Z@UWX=27WPP\2^%+?5[R\FU6PNK1+W693<
MLC2Q%!NZ949SCZT 1>#/CAX,\>ZA)8:5JS+?)'%-]EO[66SE=)2XC*+,JE@W
MEMC&>E=7+X@TV'3[^]^VPR6UBKM<O$X?RM@W,"%S@@#IUKQ'Q5^S%)XFUBYU
M-M3M5O3:Z#;VMR\&9K8V%PTLK(^,KYBMMX_&I?@M^S3<_"CPOXNTR76HKZXU
MJT%BDT4;(NU4D599%)(\P^8=VT=%')H ZNT_:0\!W?AN;7UU&^BTE/LX2XN-
M)NXA<&=ML*PAH@92QZ!,GOTJM/\ M2?#2U6W:7Q!)''+$9WD.GW.VV02F$M.
M?+_<@2*5/F;<$5YAX3_9;\6:!\.+KPH]]X,C;RK0(R:;<SQWQ@XQ=)+,<!N#
MNAV,IQ@C&*UO"'[(\*ZO:77CO61XH@33FLSI\<L\-N"UW).(=OF$RVZJX0)*
M7SMYH ]0T7X\>"?$'C ^&++5I&U<W5Q91K)9SQQ33P F6..9D$;LH5B0K$X!
M-1V/[0'@34/%,WAY=:,&HQ7-Q9EKJTF@MVF@!,T:SN@C9E"L2 W12:Q_AO\
ML\:-X+\5:MXFOR^J:Y<:Q?:E9R//*8;-+AC\L<);8KA"5+!<D$\UQ^N?L@Z;
MK7A?X@1W%VESXD\17.IS6-[>22RVM@+LD#$!;8&"L5+* 2"1GF@#WNW\1:5=
MLBP:G9S-)&9D$=PC%D!P6&#R >IZ4W_A)M'^Q2WG]K6/V2)MDD_VE/+1O0MG
M /M7@GBC]F2^G\1:EJND7NG1Z<\HU*"""T"7:RIISVBVL<F0BPN6WGCJ2.^:
MY?P=^RGKUAX3\/ZEJ4WAZQU6SMM.630;NR#Z:QALIK=FN "0TY:X)+KD?NE
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M QQR%T;RY"A8;E5UY4_*ZJP(((&*H#PIJ/\ :EUJ7_",>$_[1NE"SW?S>;*
M00'?R<L 57K_ '1Z"KD+Z]H+&4Z3HL-M<7:-<_8IW$C-(ZHTG,8#-R"23DXH
M ;\7/B-!\+/ M]K\D4-S/&T<%K:SS^2MQ/(X2./?@[<D]<' !-<.W[25C<:G
MHTUI'IH\.WK6*/?75\R2G[5%YB-&BQL"H'!+LF2"!TKV.ZL;:]:!KBWBG,$@
MFB,B!O+< @,N>AP3R/4UY[<>#(=:OY+B'P9X4ECLY);6VEO8AYJH&(.,1':"
M2QP#W/J: .%L/VLH-7\&#6=.T%;Z]W7*?V;%>KO+));")-VW +I=(>< $$9[
MU:B_:<EUGQ19Z9HFBV=Q9W5X]BM_>W[0@3;Q&J%%C<JV\X(;'(*@E@17HCZ'
MK4DK2-H'A=I" I=G<D@;0!GRNP1?^^1Z5G:KH=UIDG]OW?A;PM)<:=YMTEU&
MK-<1DC,C(?)R&;'.#S0!8\"?$6_U?P!J'BCQ/9:?HEM:-=%OL=ZURBQ6[NDC
MLQC3',;G SQCOP/*S^U\UUX=T34[#0+6[>X2\DU"W2^=_LOV>2$%0R1,,F.=
M'W/L0="U?0AT/3CI<NFFPMCITH<26GDKY3AR2^5Q@Y))/J2:XK6_"UMXD\1W
MLD?A/PSJ+V,Z_P"DZI#^^\TQ1MN!\IOX?+&0?X .U '#R?M&:[=?\)'_ &?X
M9TW=I=S&D4=YJK(9X'N3;+*"D+J<N ?E+  D,0PVT1?M3VLMUXBLTL+&XO-'
MOXK-DM]0W+*I$J2R#* X6>"5-N,D!6XSBO0K?PUJMI->RP>'/"L,M](LMV\9
M=3<.,89R(OF((&"<]*AN?#.I""-G\,>%)!:HWE*2YV#.XA<Q<9;)^IH A^$?
MQA@^*IU&)+!M-O--@M&O+220/)!-,C.8VP,<!00?XE=3T(KT6LW0[:U^R1WT
M-C!93WD,3S>4BACA %#$==HX'H*TJ "BBB@ HHHH \V^-_@/PKXVT*W_ .$K
MU:31[.V$^+B.2-3L:)O-Y=&"D(I;>H#*%)# 9S0M/A7X,\3VMWI]EJMU<&T%
MU;2B"=5>*6XGAO6? 7&\.(F4XQ@X.<U>^,WP]N_']G#;6ZP313:=J6F/%=Q^
M9"CW-OLCF=><A67:<<XD;W!XO4OV;;V_AUBXLKK3O#^L:D9XVO=/B.Y('TV*
MV6$L I=%EB#@<# '<4 =?JOPY\-Z5\-]7TO6-?NWT[4K[[?<ZM=O"TC3M(C!
ML>7Y1&Y%^4H5QP17#:-X&^&>I7EIX9T_Q3JT<MNYL9H73RXK_P"SW<MUY+2/
M"$?9*93B,@[01R!7I'PF^&*>!?!,N@W\%M/!)=/<"V\UKF) =O +JO<%L!5
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M7:3O/S \T =O_P *;\.P67D?VA=1W$,=FIN@\*R*UO<O=1.0$V@^9(W&W;C
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M1GJU;'CO]I_6]!TZTU>RTZVN8EU.9'T>T<O?+;1QW:,;F,KF)5> 2EER=JD
M,>O>_$[Q%K_]K>"K72+C6'34+:ZN;@>%Q:,TI00%3FZ^7R_WC=.3D4 <=XVL
M?BOI'@Z\LM"?6M2O;749GLKEYXFGG3[+"\8?[N5\YIT^8@#:,Y&T5)KEUX[\
M/2Z;$-<NY-?\6:M=Z8--N)T_T&U,S&.\@0#@10ISUSYBDXP*GO?VA-=\(^&Y
M[36+&PNO%NGR/:W5L)=GS)81W/F%5R2I=RF4!'''I5KQM\6?%-I_:UC;1Z)9
M:IITL%FQ-PPN'G8VSEXHW3YK<K*5)Z\$CD8H N_%71_B'+?>(KOPWJ&HQ6XC
MT^VMHK<APL1=C>2QQ[E+RA0@'S+@$XYKF)H?C39W-I):-J&J73Z.T96X$-I'
M!,(Y"'8;Y$>0L(P <$$YW%<BMV3]H35[3Q/X<T>XT2U+W5Z;'4'BF.$;[=):
M*\18@%2T>_!RV,\#&:R=6_::\0Z<E]:IX:M)-734EM([<W06**)HY71Y)BPC
M;=Y+ ;6!!X*@@ @%:UTOXC6/BNTUF&R\0WNCZ>"EN^IS0OJ$MLUSI[SQNBD
ME@ESLR<[5([@56T7P]\3E\0S^(%TW4QJ]Y(9(X-2N(3#"J0ZDL*N02!AGM0=
MO9^I&:[OQ_XM\17UUX#738O$%C_:ME<7EW9:";)[A&5;<JK-<90JID8$H><\
M9KAY_P!HCQ5\/+*6W\26D&LZM!J(BO8HE$9@A2VLC*$(PK$27+-D$_W0#Q@
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M:V2MO/E 1N!)C@*=H!SE;.D_M,ZC?ZOX6LCI%M+]ON$MM0*%XVMW>Y, "[\
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M$M]<L&!2$6UK&\49#'H9%>1L@D8QC.2* -SXPV.M:IXTM(K6^U&SMK:/3;B
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M/VFI9)+P-X:FL"UG%=Z?#>M)YERK^2-P\N-T(!G4;49I,C[G(H ZGX8V6O\
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M3(LJEE5D#@'.#M8J2.W%3:IX9T/4[*2WU'2K"ZM#*MR\5S;H\9D7&V0@C&X
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MRC9LQ_%]XE34?Q1^,_BOP3X]U'1]*T>+65&DRW5A9VT+22R3)"\F9CD%$RN
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M*W:1&E#9VNQ:)OW04<$?,2,$ \[G^-7Q"36+VPM$T:2TB@MA;W,EM.\\B2"
M)=; <%':23@L.G4D$5L:Y\1OB)IUQK:VEUI5TMDNI-%&^E2!I?L<<+A=WG8S
M*9&&<?+CC.*OZK^T_#HD\]K=^"==74+2T;4;NTC>W=H+0&$++N$FUBWGKA%)
M;Y6R..7W'[15Q8^(YH+KPM?PZ=8VCRZJ 8GFL'2X$3,2)-LBX96 3+8SZ8H
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MC(P:\V\1?%CQ]X)NKJR6+[;=V%GIEG/J&H1R"T596N2+UMHQN?9"C ?=8G/
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M?_"?XI+\4AJMY;VSVVGQ+:2VR3Q-',%FMDE(D!.,@L1QQ7H% !1110 4444
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M%73V6;.]1+R64$8. #T]ZG\,?M!?#S67DN;F&'3M:_LZ+5+T&U#L'6!)3&'
MW.Z+( ./4#D$#I_#'C71?&GAOQ*]]X?DL-+T*[>VEL=0LOFVI!',6\G![2'
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MZ=X8Y+G5(5>/9<^4YDB\P,<K\ZC"Y]\@GLO&?Q+U$?#3P7XETB[TVUEU:^L
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MJFV('RUP"2><<4 ;GA\?#;RSJ-G%IL#::4M?-DD!:)<RVT8SN/#;I4&?[Q!
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MO']W]P0>^&XJG\2?@G#\1=?;4KI=.?&G06<0N;42/$R7:3L58CA652I ZYH
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MN!\V0.>/FJ?Q#X \;7>J^(IEL;R\6:Y,DDL/B%[==3L_M"LEK'$#B!EA^0R
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ML/-7R7BECN(L/$L,A9OE*RA]P!P>0!RK8M?&'XH>(_ _C?0=-TB".]MM0MY
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MG86"A<Y.0 17:6WQGO;GX-7/BQ+.V?5H;@V;6NV18UF\X1[<'DXW=C@D<-Z
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MA3K&TIF9?;,C%^.<\ULZ%H-AX9TJ#3=,MDM+*'.R)"3@DEF))Y)))))Y))H
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M")'+?>9C+(6SUW4 <-\1_C+H?@3Q1'966D^&]0M9[>WU"21[M8IKLRW)B A
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M& %&,#BK]Q^SSX2N+6]MA_:$4%Q$UM'&EVVVU@:3S)((5.0D;L!E<?PKTVC
M!CWWQA\%>#8K_3M#TZ-M7T32BUK:R1^07@C\K,:NP+*J^;'DL,?-P3S6Y%X^
ML/%>LW$WA;0H=;U73+TV%S=W(6$Q("RR%)""?E8 %#M.&S@CK%!^SIX,MKNZ
MECM[M8+BU^QO9_:281%LC0@*>Y6&+DG^#W.>FT'X=:1X>\5ZQXCM_M$VJZH
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M@K"N%(!&?R -GX*^,=8\;>#&O/$%HNFZW;WMQ9W5@BMBV,;D*N\_ZS*;&W@
M'?P!6QXH\0Z[H]W#%I7A2YU^%T+//#>P0"-L_=(D8$^N1Q7%:U\4M>^&_A]=
M9\6VUEJEO>^0ME:Z!#)]H$TK!1$59FWJ,Y\P;>A&WIFQX5_:#T3Q))<2W-C?
M:!IT MXFO-806_\ I,J;Q;B,G?N !R<;3C@G- 'J*DE02-I(Y![5X)82?$F'
M2FO=>U36+&QO-:NHY/[-MX[J\M+-?/$!2(6WR[F$.<B7@@Y&3CU+Q+:R:KXK
MT73S>WEI:O:W<SBSN&A+LK0!<E>3@.W'3FI?^$%M\8_M;6__  :3?_%4 >0?
M#/6/B]/X^TZY\5P7-KX?N)#;3PL(W".+*%U/EI"&0-*9/WGF%0RE=HW CZ$K
MFO\ A!;?/_(6UO\ \&DW_P 52>!_-B76[62ZN+N.UU%X8GNI#(X3RXVQN/)Y
M8T >6ZOXM^*$FO\ BV*'2;^QT"=XSI=_#;133P113QQ7+)'R2[QL\B"0')0X
M!X!H^'_''Q/?4_#(70=:N-#@N)TU2[U..%)I8Y)6C@?:(XV(0 /\J*<$;@.M
M>O\ C*.6[O\ P[9+=W5I#=7SI,;29HG91;3.!N'.-RJ?PIW_  @MOG/]K:W_
M .#.;_XJ@#PA/%/QO%BN^QN72Y==MREE'YMJRZ4'?=$0NY&N&^7D$.C+T(%=
M/\-H?B'J^H>$+O6]<UV"U*WQO[>:T@2.;RY$\@MFW1U#AGZK&Q"C@8RWJ!\"
MVY_YBVM_^#.;_P"*J+PG#+8>(/$-@;R[N[>!H&B^USM*R;HR6 +<XR,T <3\
M2_%7Q!TWQW#'X;T6[NO#<-D\%U<1Q(W^DRQR&)T4_.^QUA!VC&)'ST&/+X?%
M/QI7P=;W"R:Q<7L=XC%5T\>;<$VX_<Y>U3:HE#9+1A>0/.7&:^C/'CR_V590
MQ7,]I]HU"U@>2WD,;[&E4, PY&1QQ2?\(+;Y_P"0MK?7/_(4F_\ BJ /&_$-
M[\6?#4^J?V)_;OB::'5C)##>Q6B1/816\4C ,(TRSRR-& "Q.PXZ$U/J7BSX
MM0ZG-<V-A/=:3).L"VYL0LT2/J4RK,"<;@MND89<$X</VY]=_P"$%M\Y_M;6
M_P#P9S?_ !55M"LY-'\:WU@M_?75J=/AG"7ERTVUS+("06)(X _*@#KJ***
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M%C7_ ,><5N5@^.?"[>,_"U[I"7KZ=).8WCNDC$AC=)%D4E3PPR@R.,C/(ZT
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M $%GY_[8Q5L?VUIW_/\ VO\ W^7_ !K%\$RI/<>))(W$D;:JY5U.0?W,70T
M2>)O^1@\)< _\3"7K_UZ3UT=<SXKGCMM<\)R2NL<8U"7+N0 /]$G[GWQ6S_;
M>G?\_P#:_P#?Y?\ &@"[7-:%_P CGXHY_P"?7_T6:V/[:T[_ )_[7_O\O^-8
MGANXCN?%WB>2&1)8R;4!T.1GRSQF@!_CK_CSTG'_ $%K/K_UV6NEKF/'TBQ:
M?I;NP1%U6S+,3@ ><O)-;7]M:<?^7^U_[_+_ (T 7:YJ'_DH]Y_V"8/_ $=+
M6Q_;>G?\_P#:_P#?Y?\ &L.QN8;OXB7KP2QS*-*@!:-@P!\Z7C(H ZFBBB@
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MU>'5SJ-I"D+6SBRFMI5\F5I ^\^2Q_VF<]:X^P\9>*Y]>\/:7I?BC4Y]8O\
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M+[01GD8JMX>\7?#MO%F@7FD:#,EQ>0VUM%JD-N%@M6E@)@AD^;Y9#$NT$*<
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MX<GB]>?LU>-W;59]-UJ+2-3U.77TGOX+Z;=Y%T@^Q#'0;'Y.!\N21DU]344
M?)-O^S)\0MWA:0Z[);P6UQ,\UC'JYVV&Z>!Q)"?(P3LB<;0!@R$ X9A78?#G
MX*^)_!]YXKBU"QL]9TF]OK>YLXK[5)'N7<7;3/+),J+N"A@R*RELKM+$&OH:
MB@ HHHH **** ,OQ)?Z19:5+'K=S;6UA= VSBZD")(&4Y3)/.1GCZUQFLCX9
M:_'IT=_>Z/-'IZ"*W07H0(@ _=D*PW)P/E;(X''%=)XFY\0>$AQ@W\N0>_\
MHD]=%CG/>@#A_#\_@"PUBWFTB]TI-2>-[2(P78+NLDIE*8W?-F1BPST+'&,U
MW-97B8$Z8F Y/VJV^YC/^N3U[>OMGO6K0!FZ[X;TOQ/;P6^K6,.H6\,RW"0W
M"[D\Q<[6*G@XR>N>>>PKS[Q%\,/A3I]S:QZQ8Z792I D<4$UXT0:*,MY>4W@
M,$W,%)!V]%Q@5ZG7-0C_ (N1>'_J$P]O^FTM '*1Z3\(X0GE)X<A5%4*L4L:
M*H'EXP <9_<Q^_R#TJQH_@OX8:IXACN])M='FU6.X>_VV4XRTI?S#*T:MAR'
M.\%@<,<C!->CXS63J0/]OZ.<-C]]R",?<'6@"WI.D6FAV2VEC"+>V#O((P2?
MF=R[GGU9F/XU2\1>#M#\7"W76])M-62WWF)+R(2*A="C$ \9*DC/H3ZULT4
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M()H ]Z\"?$WPU\2[:[G\.:DNH1VK(LO[IXRH= \;8< E64A@W0BH_&OQ'L?
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M^TYX,TS2;*\TRZEUU[J>TA\FT@E'DB>Z^S*TK%,18D#C#X)*,*;:?LT>"_\
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MO+LCD<Q)(!Y;.1$Y&&Y&#T-=MK?PMT+Q''X5BU.)KZ#PY+YUK#<JDB2MY#P
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M'%>+WEQJ>E>#;V\^'OAKQ!HFM[+8:M<ZA92[V^<"9DC<,9IE&XEXU<$9 W'
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MV6/(Z<MC'&%TW]FO1=(\4Z=K5IJ^HQM97K7D<+B%B 7W"%92GF+&,!=H;E0
M<]: .^\%^/-#^(>EOJ6@7;WMDLC1&9[:6$%E.& $BJ3@@@X[@CJ*L>*O%^C>
M"-+74==U&'2[%IX[83SG"F21@J+^)(^G4\ TGA'PQ;^#]#CTNU=I(4FGG#.
M#F69Y6& ,8!<BL/XH?"?1_BYIMGIVNS7JV%O))+Y%G.8M[M$\0+$<_*LC$#I
MD\YZ4 %Y\9O!NGZCJME=:TEM/I:2/=^;!*J((RH<!RNUR"Z JI)^8<<U57X\
M>!FNH+?^VRLDUI)?*6LYU001Y\QV8Q[5"$8;<05/!P3BN0D_97T>XUK6=2GU
M[49YM3BDCE\VWMG)+QQ(V\F(^8O[E3L;*Y[<#&U+^SWH]UX:L]$N=5U&6V@L
M+G37E5D222">XBGD0$+\J_N@@"X 4D>A !T=O\7_  9=7&C01^(;,R:S!'<Z
M>&8J+E)%D9"A(P21#)\O7Y#Q73:3JMIKNEV>I6$PN+*[A2>"900'1@"K#//(
M(KRN']F3PU#+:#[?JLEM9I)':P23JWDAFN&4JQ7=N1KIBISD;$ZX.?2O"GAZ
M'PEX8TC1+>::Y@TVTBLXYK@@R2+&@4,Q  R<9. .: -6BBB@ HHHH **** "
MBBB@ HHHH **** "N-^+OB;5?"'@&_U715M&U**6VCC%\S+%AYXXVR0"1PQP
M<<'!KLJR/%4NCQZ'.NO103:3,R03QW40EB;>X50ZD$8W$<G@=Z / +OX_P#B
MO3-<?4;NV@;PY:Q#?:6MQ&US*YO+N(DDQ $!;4@!6!YR<\XZ/6/V@KO2)],L
MM8T#3)3<3I'>1V6I?:Q''))$D; "/@YF7(DV=.-V16SXH^*7PS\'Q7<,]K;S
M-IXED:.UTMG2*2-Y,*7";(RTOFJNX@,Y8 DDU#I/B+X3ZE?>%]&?0],L=1NH
M([K3["ZT<(;9ID\P1Y,>V.1@"VW()VYYXH YWP]^T+JSZYHVG:AX:M+S4KJ2
M?[9<6-XN;>V_M"6UBV[E&\@Q@L,CMW(%=C\3/C--X$\1G2[33;2^^S6":C>&
MYOQ;R>7)-Y,:P)M/F-O!R"5 &!G+ 54\??$'X;?#UM0N;S2;:YU+0A->H+72
M6D,=TT9F,:2K&56>11OVYW$?,0:G\1_$3PI#JO@N?Q7X>V7MW9/JEK>3Z>US
M_9;*T(.YQ&3#S,OSG:!MYH J>%_'?B>;X/\ A+Q!JUU:_P!LZOJEBD_E(KQ)
M#/=HAC7"C/R-@$C()Y)QFLO2OVA]8U'3K,2>&].M=4U-+>?3TDU;%MY,JW!5
MIY?*^0_Z*XPH;[R\]<=+-\7?!-C=0>'M.@6YDMK^"TAM([0PP _:8X7DA=U$
M;B&21=VPDJ1ZUSU_\8OA9/'=Z5J.DQG05M+81-<Z,YAO$<SLB0Q&/+HHBD?<
M!LP3@YS0!3UW]IVXTV6Y:TT*PO;?[='I-NJZNAF>\:*.0[U5"!#B3 D!8DA3
MMVL"+>M?M&7?A<ZV^JZ-I_DV-S/I\1M=2)=[F*.-B90\:B*$F3'F$G& 2.:V
M;CX@?"Y+V;5TL;:[NEDBTP7]KHLDSS$QB58HW6,F15158A20N%SCBK?B&?X>
M_"FYU#4M6M(UN_$+3SW<WV![J:6$*IE,FQ&80* N=WRKD9ZT <M+^T5J\-WJ
M]J_A_2R^B6TDFHW":JSPF42(B+!MA+2 F1<DJI!##!.,X^G?M%:OJFNVM]/I
M%I;:4D4$4T<$VZ[CE^V74,X7?&-Z-]E&%!5LXS[=;X/\6^"-9\ :WJQ\'Q:1
MX7M+FXT>*!M+R;V$3;6"0+'DH\A)"@')//.0+O@3Q%X \7ZW=IX>\-VQ&BV<
M%S;ZBFEK%'LD9V"1L5&UE>,Y7C#9[@X ..?]I+5;E+>./PMI%WJCVXU2W2/6
M/-A2U:TGG!:1825FQ"Z[,8^<'<0:[;Q_\4[[PQ!X,U6RMH)M(U%+FZOX97(G
M,$=C+<!8N,%\H.I ]^:R?#7Q3^%EM9QP1V6GZ+<W5H-6NK*+3LK&\EL)'5F1
M-C2F%CD EBN>M;LWQ2\ :M!X?DFQ=/)=R)80/I<KS6TT0V.QC\LM#M#A2Q P
M''8T 4-$^-=S?>$_&VH7>EV/]I^&K$7[6UAJ0GMYD>W,\:^<478Q ((*\<$9
M!!K#U7]HS5?#NOMIVH^$/-CM;-+B^GLM01@CO \R+&'"%QMCVGH<DX!"DUHQ
M_$3P7X=^"MEXATWPS!8:#KDJ0)I4EHEE&[S,8V\X,H4+@$EB#E1QG(S1T'XP
M^&/&/Q T6T'AK37UB2VC@-])=6KS0K+&TFR ]9H]H!)0_P ?0D,  5?^&D]1
ML+_Q#8ZGX>TZ.YTJP>]5[/5Q+',=MJRQY:-2I(NN<CC9W#"IM6_:%O\ 0AKC
M)HT>HV^F-(CRR77ER&5]0GLX(P!'M";HLLY.0.S'FKMUX;\(>&/&\>CW/PWT
MZ'1]7O=T-Z8K=XA/%:ES*+<#,:!(]IDX^;&1R#5<?%[2KVTNDOO 1BL]2TN2
M_CBF-NS7=H9D4M-'_"C&<O\ -D_ZPD<9(!M:E\4-=NOAEH7B'3]-LM/U2]UB
MTT^XL[VZWQ1AKQ8) )$4\D9QQQGD9!%<IIO[0?B"PTJ^75-%L9[TS2?V=(EZ
M<3I]OEM561$C+!AY8X0/D<G'..S^'OCSPG\1K5O#]CHUO;:=;V<$W]GW4,:*
MK, YC6$CGRPT1+ 8S(.X-<[\2OBA\-_#6FZQ92>&H_$=W:M]D.F6^D,\5RYF
M1I(DD\LQN5>4.X4D@[B1G- &O\)OBQJ_Q)C\2W[Z?:V-E;VUG/I\#7&^0&6U
M65A*5&!ACC()X'2N/^'/Q^\4W;64_B72["YTZZ@M=T^F76YXYGTTWC;(R@W*
M1&_!8,"P !'-=3K7Q/\ "_PJ\3C18_"-S:3RVU@7ETG2V=66:66-(_W:$L4*
M,=O7YN!P<:&A>./A?:ZWHNBZ2NF6MW?>7=V"6VG^7'YC1MY>&"!4D,>_ )#;
M<CO0 GPM^+;?$;PYJ>N:CH<6DKIZK=0$W23;X'A\Q7S@%#M)!SQZ$BO-M3_:
M"\;>+8;.+PMI^DZ9<QWTT5PUW=/MGC%@;J+9O@RH(^]O53\HP<-FO7X_%7@3
MP+#J,$/V#1(8[N9+R."U\I5E6'SI'<*O3R\'>>#D#.2!7(Z+\3?AM#KW_",Z
M-H,-G)MCGGB;2&M$A::58-LBF,%9&60$!@-RG@XS0!F:?\<?%%M$FFKI-AK.
MHVTL=G<W-S?F -<2:C+9( $@QLW1%B< XP,$\U)'^T9K":=/)=^&+.VO9%7[
M'$FIF59'^U/:NK;8BW^LC)78K94@G:<@=+9_&+X<W6G?VE;AF#W,:1Q)HT_V
MB:1E:Y1TB\K>ZX\R0. 1PQSG-6O$>L_#JV\+Z3?:AI%KJ&DZY&%LX8=&>Z-P
MC!KG'E)&S8X:0Y YY/- 'GEA^T=X@U&&35H]"ADT][BT^SZ?!>(;@QOIDMW*
M'^0@L#&0H4Y.!R!FMK4_VDKA=4TV/1_#!UG3;YI;B*]CO4C#V:2I"9E# #)=
MF(&<;5!W98"MJQ^(/PITWQ!:V%E'IMO=&6&&WNK?3"MOYQ0&.-9Q'Y>\1SD[
M0V55VS@9INJ?%#X4QZ#H][<FPN=.M65]-5-+>7R'S(!Y2",E"/(D/ & F>A&
M0#L_$5MJD7B/2=3T^P748X+>Y@EB,XB*F1HBK#(Y_P!6P_$4O]N^(O\ H5__
M "H1_P"%-\/_ !)\/^*+S5(--O'N$TU$>YNS!(ELH>-95Q,RA&^1U;@G /-<
MG'^T-H&J>)/#FBZ)::CJUQK%X;8O]CF@6WB\II1.V]!F-E0[6'#8;!^4T ==
M_;OB(?\ ,KY^FH1_X5)X-L;^TCU6?4+9;2:]OGN5@642;%*(HR0,9^4UA^(?
MC/H&A:CJ.F(T]YJUB8_,M5B:,,&DBC)21@$;;YR%@I)'UJKJ'QOTS3?!/AKQ
M')IU\\6O%DM[>*)G9&%O--\Y ^5<0L-QX&03Q0!TOBVSU"6YT.\T^T6^>QO&
MFDA,PB)4P2Q\$C&<N/UIG]N^(O\ H5__ "H1_P"%<M%^T;X(7PY!J][?W.FJ
M[K'):W-C.L\+&%9CNCV;MH1@V\#;@C!YKH=(^*OAG7/$=UH=I?NU];J[,SV\
MB0MM$98)*RA'($T>0K$C<* +']N^(L_\BO\ ^5"/_"CPO9ZE_;&M:CJ-DMA]
MK:$10K.)3A$P22!CJ:S+_P"-/A#3/$$^C7.J-'=P2"!W^S2F#SB$;R1*%V&3
M;(K; Q8 YQP:SM1^/GAG2?$&IZ==?;%@L;=)6O8[262.65KF6W,"!5):0/$>
M!USQD F@#JO&FGWNH:;:FP@6YN+:]M[GR6D$>]4D#, 3QG /6H?[=\1#_F5\
M_34(_P#"N9G_ &@?"UC<:V+W^T+2UTN2WC:X?3YR)?-M_M *@)G"IG<?X<<X
MK1?XV>#X[_4[1M3D633HFEFD^R3>6P7R]RQOLVRL/.B^5"Q^<<4 :O\ ;OB+
M_H5__*A'_A3-#MM6NO%5WJFH:<FG0M916T:?:!*S,)'8G@<##"N1L?VC?#<\
M]VMS:ZG9B&X:UCB:PG>YF?S/+4"!8RXW-T!&>.E;D?QK\(SZII=A!J$UQ+J1
M@6WDALYGA#3 M$KR!-L;,%) 8@X% '=4444 %%%% !1110 45\K^+?VG-?\
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M(9OM& K*R, W\+*PQU!IGPZ^%&@_#S[3%I.I7=U'=6WV>2*YFC<.%EE?=\J
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M-()+:($AMB1R@(3CF*,X&,  W/&W@+P3>W^K^(==F,#W>FC2[F4731JD4KJ
MZ[3E9"1&H<<_*M9EE^SWH":[-JMSK>M:OJTK0&]GO;I)#<&&6.6#>@0*NSRP
M!M"\,V<DYKA]?_9;NM1N[]+<:*;;SY;B*XN%<W%]&TD3):7/RE?)C$05<;N$
M3"K\V>M^%WP6U+P#XV\3:[=WZ7?]I_:")HII#+)YDQD3<A 1?+4^6.6R%&-H
MR* (/%OP,B_LS3_^$1UB/2-5TY;:U6]N'!:**&"2V"C"XR4F<$,""<8VGFMC
M4OA%]NT;P%H=GX@FTU?"\?EO<6@07,B"T:WPNY650=^3D'CI@\UX3H/[//B;
MQO;".[T6#P]%8I907,=QFV769(UN5DGDV!R),3(Q;Y@2, G[P](U#]FF_N;7
M5&MM9@L=8OO.A;6(T=KEK=]-CME21R=T@$L0DP6]#UH Z8_L^>#_ "I;6"^O
M[?1IHG\C28+P+;03&W$!N(N-WF",'JQ4$EMN3FL74/@_\,M'L[/PXNI'2[B2
M_CU.R,+1EHY'0VX$:M&T>QAYF05/S,S<'!K,T']F>]TG3]3"MI,5U)I%S9:>
M)P]X+.:5\E@SJN%(R"%4#YB,$9W5-%_9GU:P2W_M6ZTZ^T^"?S7L50RMY'G-
M(T,9"(!D,P 55&6. * /9++PGH/A#2==A9I9-.U29&N8)6,BKNABM@BA1D*5
MC7\2QSZ<[X<^#_AKP5?P>(I=9U#4KC1X\1WFI7*2?9;:."2-8<JHPB)+(V3\
MQ+$DFL+P'\./$>I_"W48-:NY8M=U*]@>.2]3RY4M+:6-;=)0N1O:.+<V/XI&
MZ=K7@KX#MX4\.:SI0DL(TU;0$TR[6UB*QRW7[\/.RX^8LLJ D\D)CH!0!':?
M"#P)X[\8ZQXFL]7GU"\GD7SXHVBVQ%A;38!\O>01' PW,0-QVXR174W7PFT3
M4?!NA:"NH7RV&C,Q@N(YU,CJ8I875V*D$%)7!X]#QBN T/\ 9MNM)@GFM;G3
M=#U:Y6:![[3(2LB0OI<=HJ9"KO"S1B4 X' [BK&@? #5-)^"?BCP:FH6]A?:
MMS&\$\LL*$)&#N)"D!RA#;5& W\1R2 :.L_!;P/XAUA[<ZG=P:I:0V]T'BDC
M)AMC!]E4+O1D"NL/.!D,H8%3BMS6?AIX'T?S]4UY+:2QA>ZNYHM3$;VX\XP[
MV*LO0&&/'H:\RN_V6]6N/#\5BNIP+;*;=GTMKJ1HI%CEN7,'FE,JG^D*00F,
MI]P UH>(OV<M6UG1[G3W_L'4FETF&PBO=56:::W\NV\HQ+G.Z-W 9F=CG)^4
MG! !T^J_ _PCXQFOI1JFIVUC<WCSQ:?;S+#!;7Z 1&XA0IG>OE\ EDR2VTYS
M4\'P T"33=0MX]9U*<WT+P7D[FVF,[-<R7.]U:$H6#S28&W;AONY (Y37?V?
M?$.I70D@O=(+2-<&&XNED:31W>^DN!-:8 !<QR!"#M_U:<D9!Z[X8?!AOAWH
M>JZ=;74-B+_3+.T,E@"I2YC@:.6XQ@9=B5.[J=HS0!S/BCX'_#ZTTS2_#][K
M^IP6VH3V]A:6AE2Z,LL-JT 4!XW(/E'+-QM*A@5-:^M_"SP'IWV'0K[4+J"\
MNC.;1(F'FAG:V#.-J':5:* @G Y.<CIB> /V;)/#?C30/$%[;Z';G2"J+;Z?
M$Q65EMY8C=$N,B>1I$+8[1KEF/-&J?L_:WJ7Q MM:^T:3$D&H3WKZFA?[==(
M]W!.D,GR8VQI#Y:_,>-O3F@#J]'^!GA^PUFVU1M;U2_U 7GVUY9KF(?:)A)Y
MI+*B*IYQP .!6+8_ *?3_&.ARZ9XAEB\+:7);3S67F%YKFXMT*1B0XQ@ CIM
MZ<J3AAB_\,Q75MJG@66RO;6UMM"TVWM91;R/ T=S'('DN8]B_.TG(;=M)P,D
MC(KL?A3\)M3\#VL"7%Y::8T#Q^>NB*-NK%8@AFNS(F?,;&?W>WW9NP!ZK111
M0 4444 %%%% &-<>#/#]WJ5WJ$^AZ;-?WD/V:YNI+2-I)XL8V.Q&67'&#Q4^
MD^&M(T$(-,TNRT\)"MNOV6W2/;$I)5!M ^4%F('3)/K7EWC#]JGP5X$U7Q)9
MZQ'JL$>A),9[M;3=#+)%%'*\49#9+!98\9 4EL D@X]3\/ZQ'XAT+3]4BADM
MXKVW2X2*;;O0,H8!MI(SSV)'O0!H5FZKX;TG7+BSN-2TNRU">RD\VUENK=)&
M@?\ O(6!*GW%:5<?\0/B99> &TZW?3-4UW5-19Q;:7HML)[F1$ ,DF"RJJ*"
M,DL.64#)(% &O-X+\/7-]=7LVA:;+>7:JEQ</:1F28*0RAV(RP! (SW J5_"
MVC22S2MI-BTLPE$CFW3+^:%$N3CG>%4-Z[1GI6'8?%OPK>)IBSZK'I5[J-K]
MLAT_5 ;:Z$84L=T3X92 K$@_W2>E+8_%[P3J5QIT%KXITJXFU$@6:1W2DSY.
M!MYYR>!ZGI0!I:[X#\->)X;.'6/#VEZK%9#%LE[91S" <<(&4[?NKT]!Z5:7
MPSHZ6%Q8KI5D+*XF-Q-;BW3RY)2P8NRXP6+ ')YR,UR?A+XZ^"_&'AN'6X-9
M@L;:201&&_=89HW+.J!U)X+>6Y'J :W_  WX_P##GC&*[DT'6K+65M51IOL4
MRR; Z[D)P?XEY![T 3:AX,T34I;B>73+9;R82!KR*,)< O'Y;,LHPRL4 7(.
M< >E>7R?LB?#Z30-2TCRM22VU*X%S=LEX0TK"/RU!&-H"@DC &&).<DU/\/?
MVI_"/C^:X4VVI^'H(M._M9;K6HHXH9+;S!&7#)(P4[F4;7VDYX!P<=#XB_:
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MS,A3*V^TMB3KP,J-PH O_$&Y\6?\)==:SX6?49(9?"Q-FL<0DMVE^THSMY;
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M8;2632;.YTNWU5[JY:.%+G&V-A#(Q;D'^%67@?Q54/A2U.<^%M'.?5Q_\:H
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MV@5R.L?!?P-I/BZ;7M2U:YCU+4KX,L3-$ [B*<M%M6/+[HI)@6;<^T !A@4
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M&&XD^\0 ;&G_ +,&I6.BND-_866MS1M;S:G;>8)&@_LR*U$08 ,$\V,OMS@
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M6NG^#O[/FH_#?XBQZY<:II-]:6FE7>F1R6UH8[RY\^\6X$D[Y()&&3CK@'V
M![;/J]A:WBVDU[;Q73(9%@>55<J.K!2<X'K63X-\?:%\0- ;6] OAJ&E"62)
M;I8V5'*'#%=P&X9!&1P<<5YOXQ^ MUXE^*\?BDW^FKIQO-/OIC<VF^\@^R!_
MW,,F<+'+N^?/;<.<\=/\$?AVGPT^%&F>%8[JRNGM/M :XTZ(1Q,TDKR<*.A
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M6OF_Q3\)/&"77B;^R-+GE@U'5[^]A6UUU[+]_-##]FO"0Q.(F656CQU8,%;
MKZ0KYVUWXR>+-*\;ZIIMFMO#;0:@Z6EM<6<US+J[B6-&MH75\1%8SOZ'[X.
M%8T =9XO\'>,=2\6Z)<P[[Q(=/AA2_M]3DM8[&\!D\VX> '$ZL#& A!^Z0<
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MR5%7D*2I^96QH:C\</'GAKQG?Z&]M;>(7M+"1]L.G/"SRBT%PK[%D=RN24P
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M#^$OC/PM\3;.^U'7=5U3388P3<'4E-NRFW"R1O RERQGW2#!P 1\PQM./8?
MC7]-\5:GJ=E;26-Q#=W%U97,6K2".5I=3^T,S1A^<P,RX8;=V[CYLUM^//B%
MXC\(?$'Q%$NL)9:,ZZ<B37>GO<0Z9$Z3^;<X1@6!=$0YPH+J2>#FE\0OCAXL
M\.?"SPSXAM;*"WU*^2YEE2:QDV3>4K&-5C9@Z&4 ,$PSX.,'!- '0_"[P'XO
M\/?$'Q1J>MZA?W-I=/<")I]126WFW3!X62$)NCV1_NSEAT. 00U<!H7PO^)4
M&CW4&L6-QJ%C->1SSZ3'KSQ/,?LTT;LDOFDJOFM"^TOSM)X.%'6?%SXE^(?"
M&N"\TJ?R[6?1[5@L\!DMX9)+K:TS$LJC"GDD^G!X!X&'XZ?$!-,N]82:UC;4
M)]/W17UA,L&E(]BS.>6SAYTV9(X8E3SB@#W[X3^&=<\)>#=&TS6+RVD%GIMI
M:I:6\&W[.T<2JX,F\^8,C@X6MCP7G_A&K/.<_/UDWG[[?Q=ZYKX7^(O$WB?4
MO$4VN/:VUO9W$-K#I\%HZ-&YM8)9&,KMF0;Y7 ^1< 8/(-=+X)_Y%BRQM_C^
MZFP??;MVH W*R/% !TI-VW NK8_.,C/GQ_KZ>^*UZRO$V3I:@;\_:;;[F,_Z
M]/7MZ^W3F@#5K'\- "WOL!0/MUQ]Q<?\M#U]ZV*R?#@807N[?_Q^SXWD'C>>
MF.U &M6-XSS_ ,(CK.,Y^R2_=D\L_=/1OX?KVK9K%\:X_P"$0UK.,?8Y<[H_
M,'W3U7O]* -D=.>M8VA@_P!L>(<[O^/N/&9-P_X]XN@_A^GX]ZV1TYZUBZ%@
M:SXBQM_X_(\XCVG_ (]XNI_B^OX=J -NJ]_C[#<YQCRVSGIT-6*@OO\ CRN,
M9SY;=.O2@"KX=P/#^F8VX^RQ8V# ^X.@]*T:H>'P1H.FAMV[[-'G>03]T=<<
M9J_0 4444 %%%% !574]*LM;L)K'4;2"_LI@!);W,8DC<9SAE((/('6K5<7\
M8M>U?PS\/-1U'0I+>'4XI+=8Y+H9C4-/&CEO;:S4 >*^"_ 'C7P+9>%;#1-*
MOM"6.VL2+;3EMELS+YI^VF_/#.QBVA"N<<8YJU\9=8^)FA^)?%>H:7_:MKX>
MALI4CEADB*$?9PR/$20(W\X;1N5CR2Q"E15'4?CGXNTG6'UVXF\_PY:P_+IU
ML@\RYD-[>1DL?++8"VN!C'#+U))KH]7_ &C-0TF?1;22RT36'GG1;Y],NS)&
MD;RPQC:6P Z^<"5)8_*<#F@#$-]\01XW&EVDWB8I':&ZTB*ZN(<G]\B_Z>,9
MV_ZX C/R@'KMJ_JFD?%&TM!-#<>(Y[J<WUQ:Q6]U;LL=X+IEM8IPPP+8P!3Q
MGJV>=M1^'?C]XL@U+0=*O-&L]<NKNYN!=7\,T=MB$:A+;!$21E)>-51BH!)#
M+QDY/;_%CXP:IX"UX6-AI^GSQPV,=])]NN6CENP\QB\JU102\BD D'^^@'7@
M XWQ7I/QC>TN;:UOKNWMK"\2S6\M"DL]Y:.TDCW"H'4ET'V>+&4/RRD Y%:'
MQ+E^*</AKP.-"BU"ZUB.T\[4IH!'&)+E?)PDL8; # R_Q% 1T;BKWA?QAXGC
M^"'A37]3U1]0UO4]3LVN98XDC7RIKM5,2*57:H0[><GKR3@U1LOC]XBFTFU:
MZTK1=-O+N*VNH[J[O6CLH(9K26X"RN1D./)*Y Q\P/:@!-0TSXEV5]?7%O<Z
MU>6FHS7AN(4EAS:VZZC&(1;*V-LAM&F())Y R,XJ$:+XVT?X)6UGHUIK<&K7
M.N7DLA>6-;Z.VDN9W227!^9B&C)"LI)/) W5+JW[1FK6EY=):Z1IERLES-8V
MMHM[NN8'CDC0S7"@?+"V_*E><-'Q\_!+^T'XATU;P7NDZ-*RW5U8H]I>L4LW
MANH[;SKO(_=Q,9"_'(53WH Y?7=/^+>M3:'>OIVLMXEL2L\ 2:WCTT Z4RN[
M+DXE^TO(H#9'(/*BEN[SXB6WB:'2;:;Q:UN]G?7&BI<7%O\ :I9D%H$:\XP(
M1+)*!GG;U!RN.F?]H/Q%+::U);Z/I4HTB-8Y+A+AY(KN9[J2W1K?:/FCRF>2
M#DD9XS63X9_:&UWQ [ZU-91QZ:\FGPPZ=: /<AW>Y6=<\@AF@XYQ]T ]30!,
MEMXD\)?#?P=H]R?%%M>W/BB]BOUL;I'O9(6%[*IC=OO(<1L ,''TQ5F32/B?
M-;O=ZI<Z\@,EC;WD&D74(D^S_909Y;<%0/,\\(&[[3)MZBJ4G[2WB.2=H;?1
M=!U P:-+XBFN+:^DEAAMTC#FW)52?M !.1C&&4UW7Q5^)^J>!=3T#4;:*.?1
M&TK4=0O;4_ZV4Q1Q-&$(&>-[$X!X#''% '#:CH_QAOO#36$ZW<RSVO\ :#2M
M-;F=94W1)9MCY<N/)E8A2H991GD"I)[3XLQ^,]1^RVMWJ=M'J-Q<6=W?2110
MH3;W2PH(R6P@)@!=&&<\J#N%=YH'Q:O=4\)>++\VUAJ%]X=<":72IGEL[E?*
M29O*?&2RH^".?F&,\\<=H_[3MUXGL1<6&D6VGPS7D6G17FJR-%;Q2S"2:%Y2
M!D(;=8F[9>9%!YS0!A6VG?%B[O[R:RD\6V^EV-B]S8QZI<VPN+J^#6Q:*0*"
M#$<S;0<='[;:[;P_:^/O[1^(]KJ27M]8S6]PVF7-SL13(3((XHX<L,!-GS!@
MK=U!)QR-W^U/<Z_X%OKK3(+?3-5-Y<6D1#^8T<<5JLPN%1@#)&[$A2!@J0>M
M=EX$^+&K>-/BK#IYGTV'0WL=3DCL;=F>Z5[>\AMU:?(&P_ZP@#J&_P!G- "_
M#;0/'.F>+[>XU>^OFTJ6.YAFL9&3[-"JQVOV<QJ!E3N^T=SGGT&.*^%_P^\<
M^%+K2-01=:MIX_[.L+RUO+J.5)8E-R+AY"<EPI=-I!! (QWJ34_C_P")K[Q]
MHMGI;Z4++4);RUMM-21C.98KN.W0W)*'RP2'X7J&]0#6Q??M#:A>2:7?:;I#
MPV5X7M(?MTGDQ+<;K5)&GRI(CB>=E+(>L;CGB@"IX1T+XFZM\)?B%IWBQ[W4
M-6O])GAMK6>&.$_:FBE5EAD65P8R?+VG"CG( R0-7P]\(?$/A?5?#TEG>VNE
MVUQ.O]IVOAJQ&G6NR*WF,?F)O<L6E9 S @D*HZ5C:%^T!XHAU;1M)ET:VUN2
M\O;DW%_#=Q1Q&$:C+; 6^YEW^6JH>A8@KQDY.Y\4O'OC71/B;:Z-H5YIEO9S
MKI@ABO(V8R237$Z2 E02%VQKDCI\N.IH X&74_B5;ZUX;L=5;QC;0:C*ZZ@L
M$ML9WOUM[AF6UV\"U!6-N3_=_P!JNE5/BW)JEY'=MK$.JM!)%/<V0MWTQ8/L
M8*O;QLP8W'VCC!*\;N0NVM+PI^T7J?BSQSH.E0^&!%I=];VSS74EPB.DDT32
M9C5RK.B[2I(4]^1@BJWQ:^)_BSP1XD\936MUC0+;3[."!A;+(UE>2ERLI[LC
M;=A!!PQ3'!:@#$TB+XT7.K^%#(VHZ;80*5D$J)="=Q<D.UR6D1D5H2"H(<C!
MY+ 5O?#SPOXTO)?%UW?_ -LV6N:AX<@LEO=5>(!-0!N=_D%"<1*TB%>._&:@
MB_:6UL7WB&:X\*I%HVDSW ,GVD&X,4<K0#,2DNK-)Y; LJC:QX)'/=>%/B?J
MOBSX;:WXIAT0P2VUM(]II[!VEDGCAS)&PP#Q,'CXY.T\ T >>ZUX=UFR\.W+
M^ ?!6I>$=9,-M;:EJ.V-99H_.!E\N)9<3R[=["4L&PQ 8DXKI/AMI7Q+BDO;
MW5[V6:\7[)!%!K++';O#Y:F:01PE]LVX;>6(Z^M8#_%#7_#NI:%!HGB:V^($
MFMVL<DJ7:Q11V,LMS!%&^Z%05C/G./+8,W[OKP:Z/P7\<M5U:\^SZMX>DGDG
MC:6!-"22=D5+B2VD,@<+@;XBP/\ =89&: /0-1_Y'_0NO_(/O?\ T.VKHZYS
M4<?\)]H1[_8+WG_@=M71T %<UX-_X_/$_P#V%G_]$Q5TM<UX-_X_/$^?^@L_
M_HF*@!WB;GQ!X2_["$O?_ITN*Z.N<\2_\C#X2_["$O\ Z23UT= !7-:%_P C
MGXH_[=?_ $6:Z6N:T+_D<_%'_;K_ .BS0 >.AFSTG_L+6?\ Z.6NEKFO'6/L
M>DY_Z"UG_P"CEKI: "N:A_Y*/>=/^03!]?\ 72UTM<U#_P E'O/^P3!_Z.EH
M Z6O$-;^,5E\/-<ELM(\,&+0$U&^74+\-%$L]VL!GD";I 0Q8C+N,'#8/ S[
M?7EGB'2_A/<>(M=EU>32!J]O&9]2\RZ*-"&5(S(P# *2K1J6&#RO/2@#F(OV
MJ;9A=7[>'KUM)6SM_(2/#7,E[)>36WD;0>06A)# = 2>HKT23XI6O_"!Z9XD
MATR^>74WC@L]*F007$D[MM6([R IR#RQ P,UQ>M#X-^'_#]A*\>FW5KJ0CM[
M.&"Y+R7 :ZR&3+YW"9F;=G<&WX.<UW&IZ5X(;PY+X9ODTZ/2+"2&%[.20(+>
M1B'BYR"K$D,&!!R<YH I> /BW%\0M<O=.L]%O;0:?"#?3W,D6V"?S)(S!A6)
M9@T4GS+E< <\UR-W^TC]DOKJZ?09$T#^SHKNPGDNH%EOFDN/)0J-^%4^C8;.
M..<5L>#O'?PK\-7&G:9X7O\ 2H8=1AF$<EA*IA"VRAWWMG@@2ELGKN)/K2Z;
MX$^$VH^'[S7;"UTEM' W2WT%R4BMQ$YD^5@P$6UR6PNWDY[T <RG[5=JMO<W
MY\-:A=Z?/+9Q:4EB!+<77G6?VERZ Y38 1SU./7([GP]\9M,\1^.(_#D5A>6
M<D]DE[;SWP6 W"-&'^2)B'8 $@D @,I!Q7&:)!\'/$WB:P\):!H]GJ[75HNI
M^=I[Y@MTMR848L'!5_F:,!021D-\M;$NK?"&\-WK\6L:0DEJJV+WUO>$?9]Z
MA%50#A694"949.TKGJ* )_C1\4M:\":AH>EZ!IT.H:CJKHBFX"F.$&ZMX2[
MR(3_ *_  [D$D <ZWBKXMV_A+QC9Z%<:1>W43K:-<ZE 8Q%;?:)GABW*6WG+
MI@[0< YI^H^(/AWX@UI;F\U+1[S4]*D\@2-.I>W;*S[3SQS;AOK'[4V^\5>
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M-L^TK$.251=H*^F2<G-0^!/!_@G2]%\5V6CW9F35+FX.KRSW&9C( 8'+$X(
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M?$'.-)L/;.H/_P#&:;X7TJ\TX:I+>B%);V]:Y$<,A<(I1% W%1D_)GIWJ_\
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M$$S2*[;DBD6X/E[F/[P'YB*L^(O@SXWN/ATFDW!?Q)J%Y9ZI#?J=3>%7O)I
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M;SPYJ5JES+:V%SJ(\MK>WOYK<3K;D!MY 5E!< J&8#/4@ X3Q-XT\>:5X_\
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MJ6\K;R"1N8+G- '(2?'7XBV\OBR272-*,FE74B6VE1I,UU(1.4B@;C&9(@9
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M<U\1M!T?Q)X.O['7[Z33M';8]Q<)<"#:JN&^9SP%) !!X(XH XM?VH/ '_"
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MQG<UG<M.)",C&\N58 ^X->E?$OPN/&OA2?0EUR;P_<7KJL-U L;EG4[]C1R
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MTSPI:7NJ>&M576Y;B"U.E6B),[M):_:0Z[&;"^7DX)R#@'UK>\7?%NYT/5O
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MS&!*[0,A36]H/PK\8VMSH=Y=7^KR3V"V'EFYU569$%_,]PCJFU'(MW1#D$8
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M -N QY.%Q<TK]GFRTC3(;4:Q>7RPRI+MF.P2;;"6SV%ADA2)2W .".E>NT4
M>5_!7P#XB\,#6YO$XL@UU#:6%K!:,&*6UO&R+O(51D[CT'Y9P(/#?[/MOH&O
M^'=3?7KFY_X1]4MM.@6!(56T2.9$BDV_?8>>3OX^Z/E&23ZW10 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6Z*PFB2)LJD:KNV1ICCJ"3DDT =?+\5=%/C73?#%M]HNKV[GEMS,D$@@C:.
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M_+C X.*Q-)_9\\(Z-/:747@S5I;^TF2>VO9KV!IH)!,969#YN 69B6P,$<4
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MXV>,+OP5H$;>(_$L=R?%]UH]Q-IOA^%M<:UCLY)8UGLRC!)&90V0@RFTX&:
M/L6BOEGQGX_\3Z%X%\"O:^)/'X;5_$$]M<W,WAJW_M@PK:S2"-;7R -N^('<
M$SC//2O1?V9/%WB'QMX0U75-5O[W5]%DU!AH>I:K:16M[<6H10QFCCPJE91*
MH^53@#(SS0![#1110 4444 %%%% !1110 4444 %%%% !1110 5Q'QH\/WOB
MGX;:MI>GV46HW<[V^VUG.(Y L\;,&/IM4Y_D:[>N%^-MGJ%[\--532WU&.[6
M2WE!TI ]SL2XC9]B[6W?(&RH!)&0.M 'GUM^SM>O;^))Y?[%LK_4-/\ LMC%
M:1N8=/S/+(\"-A6$+HX0E0I^9^,8%9MK^S+K$D.H;[W2M'L]6EGDOM TY7:R
M147-G%&2!\JR9D?Y0"78*!U/3^!=:\=W/Q U*#57U66R6*]%S;W.FI#9VY68
M?8VM9@ TA>(DL"SX(Y"$8KEHKWXP:;J7P_C34-0NX;NPM[G41>Z;&_F73R S
MPRF.-1"L<>-I)3O\SD8H NV_[/>O6_C9-2AN],@L=]A+.Q+2R2M ]LWRYC#1
M@"%\+YC+E@=J\U0T;]E^_DUO3GUV/0I]*LY(_M%K!YKC5G6*Y!O+I7&&F+SI
MP=W1CO/ &-9_$[XAZ;K$D,W_  E>IR1Z6D]_:/HL>ZVO)(;P!8E2,,\0F2%0
MXW+P,L1FM^>;XI/<ZZ=(-Y972V5U>01OIT:I<W0M-/6)9'9<-\S7/"E<E,9P
MM &YX!^".O>#_B-HNNR7UE+:0:3'9ZB[2-/-<3);QQ+Y6^/="@*EB!(5/]P,
M2U0^'_V>KS2_$5OK<\UB^I6^J0W<5VK/]H2!9[IY(O,VY(9;A1MX!P<]!3;*
M?QQJ?PCM+G5K[5Y=1B\064OGV>GF"\-DMS"7WQ,@+#'F9^097L>IY"V_X6UX
M1^'VFV.FWFJRK]GL;FYN;C3%DFLU=[D2PQ(D9=MNRWSE7<!R>_ !U7B']G&7
MQ%>^)))[30UCNY]6N[&5%99EGNHH!%,Q"?)(DD3G>"QY!&#Q6Y\-_@OJ/@SX
MG:YXGO;Z.]^W^?\ Z1]IE:259'1U1HR H\O:RAMS9!X"Y-9/Q7\0_$K2?AIX
M8DT<7K^)IK5WO)M/T[S ;E8@R(\020J'8$$?*,\;TXSR6H?#3Q-+X\\0^*OM
M6O7LTFIK-;6;VT?D;"M@J@ QY(59;H YR C#J&) .SD_9NBO?"4]E?ZA+JFH
MM>3W$,.HW+SV5NLMYYS^7&0,,8B4S@_>;L:Y/QY^SKKDNHI/I.D>'+VWBUJ*
MZ D\U)+ZU-Q$RVMRH&U8(54[<;^(TVHO(.GI</Q4G&D3W'B+Q KS0:>]U$--
MM50/<7<D=P K197R80C#)XX)W=*Q(]=^+ESK$.DW,VM3V[6MW92R_P!EB)9E
M$-TL4^]8MJ2&18.=X&6XC"G- '0Z_P#L\ZYJ5MI<-O+HRB.)H4:4RAM#W7C7
M!>QV@98(PB!/EG$:'.,K7/W'[*WB&[T@6$M]I_V"*_>>*P2[="P:(KYSW"0J
M[2*V& 96;K^]S@C9\+7OQ&T[2X_L%MJ=PFJ7,6F^=?:>D<]H6L[0B^FW!=X4
MK<JW!^;8,<&N@^#5U\2M6N?%%MXNOY8'5'CMV?3O*%M.7<*8F*A94"[#GYP>
M,MG*@ L:3\']6L?BM8>(YX]%N+>UNI[DZGB3^T'C>U\E+?E2 BG+<N<YZ YS
M8/PX\6#0]5\(PW>F6_AVY-^\6L&25]10W!E=<)@*K(\Q_>!\X08 )R.+\0>(
M?BS-IZZC-_:^B1W(G@@L](TN*\FCNX8T6'S 0V()Y1<$L0,*(OF3.3C:)/\
M&#1=,\'V<%YJ,;275\=1>ZTOSLW+7K%8WVI\L(B)*MD*>?G)"B@!]E^R%<2^
M%9[#4DTNXG;3KN&&UFNI;BV@N9/LFV2/?'\F?LSDE5!&_P#B))/5C]G2X_X3
MV^\2(-)MYY[NWFC>*,[XXH[R*<I]WKMC('(&<< 5?^*VN^.K?QLMAH::U%;2
M0VZV TW3XIK2X9Y&6Y-S,X)B,:89>5!XQO.5KB/$G@KQ1H_PA\":3I3^(HK@
M>';R"Z6"W$S"[DCA=3<*J]01*0>!N&"?FP0"UXD_9K\2:SX2CT:V7P[ITBOB
M2\M7E6>>3R-@O&D,;;9MX#$(H;_IKUS)K/[,&L:IJ.G3"[T](;74KRY\N"YG
MMP//NA<?:L(O-P/]61D9"J=X&5J?7M3^+^G^(M*T^POKU],@O[FV%_<:6DSW
MF)(_+,WEH%5-C288",':?FW  ]3X@L_&%C\79]4TJZU)-*>YTRWDL1;I):7,
M+)<"9LE=R%#Y9+*P P,@YH F^(GP?U'QCXZBU6,:5/:.MH@N[[S#=::L4I>4
M6Z@;2)E.ULE??>/EK'UC]G>XNOA'X6\'6+Z=9_V5;W$,VS<J.98)(SL8+QDR
M9)Q7%+K'Q<O+RRN8H]=O;FSMKF:?[=I4<"6VHM;7 ,4*KM$T*93827!;;\[9
M(#+"_P#BG:>*W.AWNM?V%>ZN[+=ZQHA%Q<OY5J@\Y!$NR+:LN&VQC(/S9 R
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M26#:;=ZWJ>KQ27L5L1_JX6"A8E!^;"KR>3DU[/\ V=:?\^L/_?L4O]G6O/\
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MU?$_Q=\=ZUX]N=&T_6M7TI;I)K.6S^P0C[.3I)N(I(!Y;-S-@"5Y,%B5"<9
M!]@45\3Z7\=O$7@OX:>&;.#Q!K5_<7W@^QEL+FYT<S.^HK>^7<HS+%@&.,A6
M#XR%W DY)W/&7Q ^)6@Z)KNNOXGUBUTR7QK=Z4[)IUNRZ5I\'G&-T(@=L2,L
M:EW#C! X)W4 ?7E%<;\'-;UKQ'\,/#FI^(GBEUFYM0]S)#"\*N<G#;'564D8
M)! P2<<8KLJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ)B()+2X99%W*0G.PAF&.QZT >QT5\FP:'K5A^QKX5-I?WX\0ZG?:/=W-\L
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M"Y*YK UKQA\+;:RU+7]0L=/E LS;7<[:2999+?S9(/*8",LR%[=UV]/D';%
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MZ</AQJ$'VJX%K/.VK.4M93<W%LJG%Q\^9+9\;,X!!JYXA\*_!O0OB1>>#%\
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MB6^FK?+H>H+!I5_<H9%W2210RR1H' R"[QY/*E&_'TF^\(Z-J.J+JDNF6O\
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M,+SV ]!0!\NZUI7P4T7Q1XHT1O =_-+H5LTYEBU*4).XDAC,:DS@*0]Q'RV
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ahpa-20220416xs4006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xs4006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !Q 5T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]2I-2M(7*
MO=0HPZAG -3131S+NC=9%]5.17Y)WFL:EJ5U+<W.HW4]Q(<M(\I))_.OK3]@
MK6-1O5\3VMWJ%Q=VT0C:**9RPCSG.,TVK ?7=%%%( HHHH **** "BBB@ HH
MHH **** "BBDS0 M%,$J$XW#/IFG9S0 M%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% #6KX$\>?M;?$,^,-6M;*XM-/M;*\E@BCA0G
M<J.5&XGOQ7WYZ5^3WC(?\5OXB.>?[2N?_1K4T!]T?LH?&?7_ (N^'M6?Q!';
MBZL+@1++;@C>N/XAZU[)XKUK_A&_#.J:KL\W[';23[,XW;5)Q^E?,7[ ?_(!
M\5_]?B_^@U]4ZII\&K:=<V5R@DM[B-HI$/=2,&A[@?(6L^)]'M+#1-=\8Z3%
MXHU7Q)!)J*+=@F.UC'W88\9Q]35_Q-\7;O\ 9R@TU=/B?4-%\00_;[2QNFYL
M,8#QJ1U4D@UWL/@?Q/\ #H#3;3PY9^-=)C#QV$DTBQ2VL+]8CGJ/>KVG? EO
M&9EU'QXL$]P<)9:?;C]U8P@?<![DGDFF(_//O7UI^P)C[7XLQ_=B_F:^2\;N
ME?6?[ >/M?BS_=B_F:;*9]C4445 @HHHH **0UYCXB_:1^'?A?5Y]-U#Q) E
M[;MMEB16;8?0X% 'I]%<?\/_ (M>%?B>ETWAO5X=1-J0)D4$,F>F0>U=A0 4
M4F:YOQ=\2/#'@2(2:_K=GI8;[JSR?,?HO6@#I:*^>M<_;>^'NE71AMS?ZD <
M>9;P84_0FJ$'[=_@:255DL-5B0G&\Q X_(T[,#Z4KQC]J7QSJO@SP);KI%P;
M.ZOK@0M<+]Y$ R<>YKIO _QY\#?$!XX=(\06SWCC(M)CY<OY&D^-?PLC^+/A
M(::MS]CO()1/;S]0K#J"/0UYV80K5,+4A0^-K0]++:E&EC*4\1\">O4^(QXR
M\20/YT?B#4!*IW!C.>M?;'P"\8ZAXX^&VG:CJCB6]^:*211C=CO7SY'^R!XO
MED"2ZG8)$3AI%W$@?3%?4'PV\"VWPY\)66AVLK3) ,M*W5V/4U\EP_A,=0KR
MEB$U&W7N?8\18S 8C#QC0:E._1;+U.IHK)\0>*]'\*VAN=7U.UTZ <[[B4(/
MUKRGQ'^U_P##70-RQZP^J..UC"SC\SBOO3\\/;**^:O^&\? G:PU8C_KB/\
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M_P"PE<_^C6H0+<^K_P!@/C0/%7<?;%_]!KZQ(S7R=^P'_P @#Q7S_P OB_\
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M?05X-8:=/J=_%9:?:2W^H3'$<,"%Y'/T%,$;*$C@0O(Y"(@ZL3P!7Z(?LS?
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M^+G@V53R-2B_G7T#^WJ<:AX;_P!UZ^>OA#_R5CP?V_XF47\ZI;!T/U-'(%?
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M O'BOQ9_U[1?^A&OM"_O$T^QN+J3_5P1M*V/0 D_RKXO_8%_Y&KQ7_U[1_\
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MG_KW3'Y5%^QQ_P ETT__ *]YO_0#7(_&WXD1?%?XBZAKUM T%CQ%;"3[S(.
MQ';/I77_ +'1Q\=-/_Z]YO\ T"JZ!T/T.?[K?2OS ^.W_)8O$_\ U]'^5?J
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MR,B[4X'TKZUKA/A/\&_#WP<T:73]!BD"S-YDTTS;GD;U)KNZD HHHH ****
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MZ\]^#OP8T+X,: VGZ2C2W$Y#W5[-S).WJ?0#L!7H5)Z@%%%%( HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** &O\ <;Z5\O?'[_6M1136X'R?XK^^?PJ/PMUHHJ@/
MH?X&_P#(9M?K7V5:?\>\?^Z***E@34444@"BBB@ HHHH **** "BBB@ HHHH
C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>ahpa-20220416xs4007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xs4007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !2 6@# 2(  A$! Q$!_\0
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MQ)DY/W()2?7HK$^@-?> ;-2U8I.XM%%%(84444 %%%% !1110 4444 %%%%
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M5L3B\31J/2#LOO9]7FV P^%P6%K4E:4U=Z^2_P S4HHHKZ4^4"BBB@ HHHH
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M:MZW_P KGU_"DZD<SBH;-._I:_YI'T#\&=>?Q-\+/#.I29,DUD@8GN5RI/\
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MU\4OCSX]'D?VKXNOP>-EE;O"3[?(HHY0N?I5\0_C=X'^%UD]SXC\1V5CC(6
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%15$G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>ahpa-20220416xs4014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xs4014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &< J4# 2(  A$! Q$!_\0
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M;XM\&2'E1INK2-&I]D<D4@^&GQ\\$/N\/_$?3?%ULI!%IXDLMCD=QYL?/Z4
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MVED8@'!!P>QKXFG\?6NO_L;:QI=K?C7G\,^*;+3TDMI%<S0KJ,+0E23@Y0@
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MV_&.<XH Z6BN9D^)W@^'7[70I/%6B)K=U+)!;Z8VHPBYFDC7=(B1;MS,B\L
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M=+.W=I'.68_4UV. >U $5I;Q6EO'!!$D,$:A$C1<*H'0 >E2@8HQ2T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A
M&1CK2T4 ><^/OV>?AW\3'\WQ!X3TZ[NARMVD0CG4^H=<&N#@_9(C\*C/@CX@
M^+/#!486!K\W=N!_N29Z?6OH*B@#YVG\%?M%>&F4Z5X]\.>)X%X,6L:689&'
M^_&V ?PIB_$C]HG0&9=4^%>@Z]&O271M;*,W_ 9%P/SKZ,I,C.* /G%?VHO'
M&G[EUKX ^,[)D."UG-;72D>HVOFDE_;2M+*-GO?A7\2+95&6(T(N!CKDAL8]
MZ[GXN?M(>$OA)>6VDW+76O>*;WBR\.:)#]IOISV^0'Y5_P!IL 5YW_PIOXA?
MM#W!G^+E^/#7@YCNC\#Z%<L#.O87EPN"XQU1<#W- &=X>_X*,> O%S3)H7@W
MXA:S)#(89?L'AQYXXY!U5G5BH/U-;P_;.M[@8M?A/\29SV#Z"8^?Q:O=O"OA
M+1_ ^A6NB^'],M='TJU79#:6<0CC0>P'\ZUP* /G)_VH_'6HE1HOP \9WFXX
MWWD]M:JON=SYIQ^(O[17B!@NF_"[P_H$9ZS:QK1D91_NQKR?QKZ+Q10!\\0>
M"?VB/$A9M5\?^'?#$3\>3H^EF9T'^_(W)_"IKC]D:W\4C/C;Q[XL\4@_>MSJ
M!M;<_P# (\?SKZ"HH \\\!?L_?#WX9C=X>\*:=93]3=-"))F/J7;)_6O0E&!
M2T4 %%%% !1110 A%<WXP^'/AGQ_8-9>(] T_6K9N"E[;K)^1(R*Z6B@#Y^?
M]BWP7I=P]SX4U/Q#X*G/*C1=4DCB4]OW;97]*9=_"7XV^'T;_A&_BS;:BB_<
MA\0Z2DOX%T()KZ$HH ^<CXF_:7\.LGVGP?X-\50K]][/49+20^X5E(_6D/[1
MWQ2T>0+K/[/_ (B= .;C2M2MIT_(L#7T:: * /G,_MBRVG%_\'_B+:N.JQZ0
M)L?BK5D^(O\ @H'X.\':=)J'B#P)\2-'L(QN>[N?#,@B0>K/NPOXFOJ+%0W5
MI#>V\EO<1)-!*I5XY%#*P/4$'J* /FO1OV[= \2Z;!J&B_#KXB:K97"[X;BW
MT F.1?4-NQ5[_AK+Q#?*3I'P.\>W[8RHG@AML_\ ?;\5!K7[/OBGX-ZS<^(_
M@A?V]G:S2&>^\#:DQ&FW3$Y9H&Y,$A]OE)ZBNZ^$G[1?AWXI:G=:!-!=>&/&
M=@N;WPWK">5=1<X+(.DB9Z,O!H XP?&;X[:Z@.D_!"/22PX&O:[$NWZ^4&IR
MZ=^TOXFD47&J^#/!\!Y86MO+>R?0%B!^E?1612T > -^S?XN\41!?&/Q;\17
MZ,<O;Z.$T^-O]GY 3C\:V/!_[(7PN\'WJWR>&TU?4EY%[K,K7DN?7,A->ST4
M 06MI#8P+#;PQP0H,+'$H50/8"IZ** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#TH 6D)Q4<LR
MPQL\C*BJ,EF. !ZDU\^Z[^U!/X^\0WOA#X+Z2/&^M6I,=[XA<E-#TUN00]P.
M)7!_Y9Q[CZXH ]G\:^/_  ]\.M"GUCQ'JUKI&G0KN::YD"Y]E'4GV'->"6OQ
M"^)W[2,Q7P3:3_#KP*QP?$6J6_\ I]ZGK;PM]P$=&;\JWO /[+T,FOP^+OB=
MJG_"?>,4;?$]RF+*Q/800GA<?WCS7O:HJ* H  Z =J /-_A+\ /"?P?6XN=+
MMY=0UV\.Z\UW4Y//O;D_[4AY ]A@5Z3C%+10 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 (5!.:\V^+WP!\+?&2&TFU2*;3]<L'$
MMAKFFR>1>VKCD;9!R5]5.0:]*HH ^8XOB[XY_9RU"+3?BI;S>)?!SNL5MXVT
MZW),&3@"\B7[N.[CBOHW1==T_P 1Z;!J&EWD&H6,ZAXKBWD#HX/<$59NK2&\
MMY89XEFAD4J\;C*L#U!!KYRUK]GKQ+\)=;G\2_!2^@L$F?S+[P?J,C#3KL=3
MY1&?)D)[CCUH ^D@<TM>1_!_]HS0OB=J=[X:O[:?PGX^TT#^T/"^K8CND'_/
M2+M-$>SH2/7%>MJ<B@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM-'TJV7;#:6<0CC0>P'?WK9HH 0=*6BB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "FDX-,N+B.UB:6:1(HD!9G=@ H]237SWXB_:<U'Q]JU]X6^"FC)XNUV
MW;R[G7KW=%HMAZEIADRL/[B ^YH ]E\=_$7PW\,] N-:\3ZS::+IL"EFFNI
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M_P *H?\ Q%'_  LO]J#_ *(SX4_\*H?_ !%?2U% 'S3_ ,++_:@_Z(SX4_\
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M\U?#W_D_?XN?]BKHO_H4U?2M?-7P]_Y/W^+G_8JZ+_Z%-7TK0 4444 %%%%
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MB@ HHHH ^??V,?\ D4?B'_V/VN?^E%?05?/O[&/_ "*'Q#_['[7/_2BOH*@
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M8NM$G%]=ZLK-/;L%=DVQME"3P3@^H%=A]H_;$_Y\/@=_X':Q_P#&:U?V,_\
MD6/B5_V4#7/_ $>*^@J /FC[1^V)_P ^'P._\#M8_P#C-'VC]L3_ )\/@=_X
M':Q_\9KZ7HH ^:/M'[8G_/A\#O\ P.UC_P",T?:/VQ/^?#X'?^!VL?\ QFOI
M>B@#YH^T?MB?\^'P._\  [6/_C-'VC]L3_GP^!W_ (':Q_\ &:^EZ* /'/V7
MOA?XJ^%7@+5;/QG<://XCU;7;[6[H:"\KVD9N)-^Q#*JN0/<?G7L=%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!\Q>/?A+\:] _:'\1_$7X72> ;NUU[2;/3;BV\7
M3WL<D1@+D%/L\; YW]S^%3?:/VQ/^?#X'_\ @=K'_P 9KZ7HH ^:/M'[8G_/
MA\#O_ [6/_C-'VC]L3_GP^!W_@=K'_QFOI>B@#YH^T?MB?\ /A\#O_ [6/\
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M\,V?"G_HG?AO_P %L7^%'_#-GPI_Z)WX;_\ !;%_A0!J?\+M^'W_ $._A_\
M\&4/_P 51_PNWX??]#OX?_\ !E#_ /%5E_\ #-GPI_Z)WX;_ /!;%_A1_P ,
MV?"G_HG?AO\ \%L7^% &I_PNWX??]#OX?_\ !E#_ /%4?\+M^'W_ $._A_\
M\&4/_P 567_PS9\*?^B=^&__  6Q?X4?\,V?"G_HG?AO_P %L7^% &I_PNWX
M??\ 0[^'_P#P90__ !5'_"[?A]_T._A__P &4/\ \567_P ,V?"G_HG?AO\
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M\\?;?VLO^@-\&?\ P;:M_P#(U(;W]K''.C_!G_P;:M_\C4 3_L9_\BO\2O\
MLH&N?^CQ7T%7Q_\ "?X<_M2?"C3M?M+&S^$-ZFL:Y>:Y*UQJNJ QR7#AF1<6
MOW1CC/-=Q]M_:R_Z WP9_P#!MJW_ ,C4 ?1%%?._VW]K+_H#?!G_ ,&VK?\
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M_8]_Y!OQ._[';4__ $,5]!5\^_L>_P#(-^)W_8[:G_Z&*^@J "BBB@ HHHH
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M60&(&[J0N<#JO$O[/NL:S\,_C%X;BU&QCNO&MQ<36<KE_+@$B!0)/ESV[ T
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M7/7TI0!\^_L:_P#(O_%#_LH>N?\ HU:^@J^??V-?^1?^*'_90]<_]&K7T%0
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M0!Z5_P $U/\ DR#X7?\ 7K=_^EMQ7TU7S+_P34_Y,@^%W_7K=_\ I;<5]-4
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MOV-BT@W!84$,F\A?[[1C/&>]=U:>*](N]6O=*BU"W?4["-);NS$@,D"L,J7
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MEST [5V7_#X'XY_\^'@__P %DW_Q^@#]I:*_%K_A\#\<_P#GP\'_ /@LF_\
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MP/QS_P"?#P?_ ."R;_X_1_P^!^.?_/AX/_\ !9-_\?H _:6BOQ:_X? _'/\
MY\/!_P#X+)O_ (_1_P /@?CG_P ^'@__ ,%DW_Q^@#]I:*_%K_A\#\<_^?#P
M?_X+)O\ X_1_P^!^.?\ SX>#_P#P63?_ !^@#]I:*_%K_A\#\<_^?#P?_P""
MR;_X_1_P^!^.?_/AX/\ _!9-_P#'Z /VEHK\6O\ A\#\<_\ GP\'_P#@LF_^
M/T?\/@?CG_SX>#__  63?_'Z /VEHK\6O^'P/QS_ .?#P?\ ^"R;_P"/T?\
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MH_X? _'/_GP\'_\ @LF_^/T ?M+17XM?\/@?CG_SX>#_ /P63?\ Q^C_ (?
M_'/_ )\/!_\ X+)O_C] '[2T5^+7_#X'XY_\^'@__P %DW_Q^C_A\#\<_P#G
MP\'_ /@LF_\ C] '[2T5^+7_  ^!^.?_ #X>#_\ P63?_'Z4?\%@/CF?^7#P
MA_X+)O\ X_0!]@>-_P#D\+XM_P#8)\/_ /HN[HKP;]D?XW>(?VDOB'\4/&GB
<N.RAU>6#2+5ETV)HH=D:W07Y69CGGGFB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>ahpa-20220416xs4016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xs4016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (0 I0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 0\53U76K'0M/FOM2NX+"SA4O)<7$@2- .Y8\"LKQYX\T;X;>%-0\1:_
M>)8Z991F221SR?15'=B> !UKYWT'X?\ BG]K/6K+Q3\2+1M!^&4)$^C^"22)
M[TY^6XOB.V.1$..>: +NN?'WQW\;]2N-!^!FE00Z4CF&Z^(6N1-]AA[-]DAX
M-PX['(3([UU/@S]D;PGI>I6^O>+[N^^)'BU/G?5_$;^:JOU/E0#]W$,] !GW
M->U:=IEII%E#9V-M%9VD"A(H($"(BC@  < 59Z4 1P6T5K$L4,:11J,*B+@
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M?2<0F6ZGUG2Y+*.W;C$8:4+YI)+<Q[@-O)&1GO5SCF@!:*** "BBB@ HHHH
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M/A&C4J/; Q4]>4?LQ?$-_B3\&M!O[I6BU>S0Z=J,+_>CN83Y<@(^JY_&O5Z
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M(O%_Q@\7:9X_^,"16<=A)]HT3P1 PDMK!OX99V_Y:3 ?@O:OI'%  % I:**
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M:4P@\<^#O%?@*X'WVU#3FFMP>_[V/(- 'T917F/AK]ICX7>+L#3/'&CRN?\
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M7?AN#Y]HC'\\5TM-8XH \7UG]C?X0ZTQ=O!UK92GK+I\CV[_ )HPKFIOV%O
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M((X(H GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVFZ99Z/8P65A:PV5G @2*WMXPD<:C@!5' 'TJR!@4M% !1110 4444 %%%%
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MMZ-?L_!OQ'\+>.;=,6?B?2/#5Q%=1D=%<@8D3U5L\4 ?;&12U\7?!/\ ;/\
M&-K9W.D?$OX=^+;BXLSMM_$&EZ!/LOTSPS0D;HVQU[5ZG_PV3X=_Z$CX@?\
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MP5T_Y.[F_P"P%9?^U** /VYHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB@#YU_;E_P"29^#/^Q]\.?\ IPBKZ*KYU_;E_P"29^#/^Q]\.?\ IPBKZ*H
M**** "BBB@ HHHH **** "BBB@ HHHH **** /Q&_P""NG_)W<W_ & K+_VI
M11_P5T_Y.[F_[ 5E_P"U** /VYHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "O /VU?^26^'?^QQT'_TOBKW^O)/VGOAKXA^*7PU@TSPLUA_;=GJ
M]AJT":G*T4$AMKA)=C,JL1G;C(!H ];HKP#_ (23]ID]/!'PWQ_V,-Y_\BT?
M\))^TU_T)'PV_P#"AO?_ )%H ]_HKP#_ (23]IG_ *$CX;?^%#>__(M'_"2?
MM,_]"1\-O_"AO?\ Y%H ]_HKP#_A)/VF?^A(^&W_ (4-[_\ (M'_  DG[3/_
M $)'PV_\*&]_^1: /?Z*\ _X23]IG_H2/AM_X4-[_P#(M<AXH^.O[0/A+Q_X
M*\'WO@7P"^J^+6O$T]X==NVA4VT/G2>8QMP5RO3 .3UQUH ^KJ*\ _X23]IG
M_H2/AM_X4-[_ /(M'_"2?M,_]"1\-O\ PH;W_P"1: /?Z*\ _P"$D_:9_P"A
M(^&W_A0WO_R+1_PDG[3/_0D?#;_PH;W_ .1: /?Z*\ _X23]IG_H2/AM_P"%
M#>__ "+1_P ))^TS_P!"1\-O_"AO?_D6@#W^O /!_P#R>Y\1_P#L4-'_ /1]
MS1_PDG[3/_0D?#;_ ,*&]_\ D6E^"_@#XE0_&OQA\0/B%8^'=+?5=(L=*MK/
M0+Z:Z \F25B[F2),9\P#C/2@#WZBD'-+0 4444 %%%% !1110 4444 %%%%
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M?/VG_P#@GY\<_P!J?XHR>.-7F\$^&[IK.&R%E::C<SIMCSAMS0J<G<>,=J*
M/T]HHHH **** "BBB@ HHIK.J*68A5 R2>@% #J*RO\ A*M%_P"@Q8?^!2?X
MT?\ "5Z)_P!!BP_\"D_QH U:*RO^$KT3_H,:?_X%)_C1_P )7HG_ $&-/_\
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M_P!$^TO_ +ZE_P#BZ]HHH \7_P"&-/@M_P!$^TO_ +ZE_P#BZ/\ AC3X+?\
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M ,77L]% 'B__  QI\%O^B?:7_P!]2_\ Q='_  QI\%O^B?:7^<O_ ,77M%%
M'B__  QI\%O^B?:7_P!]2_\ Q='_  QI\%O^B?:7_P!]2_\ Q=>T44 >+_\
M#&GP6_Z)]I?_ 'U+_P#%T?\ #&GP6_Z)]I?_ 'U+_P#%U[110!XO_P ,:_!;
MM\/M,_[ZE_\ BZY+]E[PKI?@7XP?&WP]H5HNG:+8ZE8_9K&-F,<6ZU4MM!)Q
MD\U]*UX#\"O^3AOCW_V$M/\ _21: /?1TI:** "BBB@ HHHH **** "BBB@
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M ,)^?_X[1_PB/[4O_10O '_A/S__ !VOI&B@#YN_X1']J7_HH7@#_P )^?\
M^.T?\(C^U+_T4+P!_P"$_/\ _':^D:* /F'7=&_:CT+1-0U*3Q]X"E2SMY+A
MD70)@6"*6('[WOBO7?V??'NH?%#X(^!O%NJQQ1ZEK6CVU]<I ,1B1T#-M'89
M-=#\0?\ D0O$O_8,N?\ T4U>=?L:<_LI?"<]SX;LO_12T >RT444 %%%% !1
M110 4444 %%%% !1110 4444 >,_M7?$WQ+\*_AE8ZAX2>RBUW4M=TW1;>;4
M(C+#%]JN%A+LH()QNSC-<I_PB7[4AZ?$+P#_ .""?_X[4_[<AQ\,_!O_ &/O
MAS_TX15]%4 ?-W_"(_M2_P#10O '_A/S_P#QVC_A$?VI?^BA> /_  GY_P#X
M[7TC10!\W?\ "(_M2_\ 10O '_A/S_\ QVC_ (1']J7_ **%X _\)^?_ ..U
M](T4 ?-W_"(_M2_]%"\ ?^$_/_\ ':/^$1_:F_Z*%X _\$$__P =KZ1HH ^0
MO$'P(_:0\2>._#/BRZ^(G@<:GX>6X6T":%,$(F4*^X>;SP!BNL_X1']J7_HH
M7@#_ ,)^?_X[7TC10!\W?\(C^U+_ -%"\ ?^$_/_ /':/^$1_:E_Z*%X _\
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M$+QQX6\2:#H^D2^&)((FFTS49+KSS+$LBD!HDP,-CUR*]B08% #J^8_VX?\
MC[_9U_[*]H?_ *)NZ^G*^8_VX?\ C[_9U_[*]H?_ *)NZ /IRBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "OG?X>?\GR?&'_L5O#__ *'>
M5]$5\[_#S_D^3XP_]BMX?_\ 0[R@#Z(HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH Y_X@_P#(A>)?^P9<_P#HIJ\Z_8T_Y-1^$_\ V+=E_P"BEKT7X@_\
MB%XE_P"P9<_^BFKSK]C3_DU'X3_]BW9?^BEH ]EHHHH **** "BBB@ HHHH
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M<_\ 3A%7T50 445R/Q,^*_A3X.^'?[=\8ZQ%HFD>:L'VJ6-W7>W0816/XXH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^=_AY_R?)\8?^Q6\/_\
MH=Y7T17SO\//^3Y/C#_V*WA__P!#O* /HBBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#G_B#_ ,B%XE_[!ES_ .BFKSK]C3_DU'X3_P#8MV7_ **6O1?B
M#_R(7B7_ +!ES_Z*:O.OV-/^34?A/_V+=E_Z*6@#V6BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#YU_;E_P"29^#/^Q]\.?\ IPBKZ*KYU_;E_P"29^#/
M^Q]\.?\ IPBKZ*H **** "BBB@ HHHH **** "BBB@ HHHH **** /Q&_P""
MNG_)W<W_ & K+_VI11_P5T_Y.[F_[ 5E_P"U** /TB_X)M?\F1_"W_KSN?\
MTLGKZ7KYH_X)M?\ )D?PM_Z\[G_TLGKZ7H 0C-)M IU% #=M+MI:* $VC%&V
MEHH 3%&T4M% "8% %+10 FT44M% !7S'^W#_ ,??[.O_ &5[0_\ T3=U].5\
MQ_MP_P#'Y^SM_P!E>T/_ -%7= 'TY1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7SO\//^3Y/C#_V*WA__ -#O*^B*^=_A[_R?'\8?^Q6\
M/_\ H=Y0!]$4444 %%%% !1110 4444 %%%% !1110 4444 <_\ $'_D0O$O
M_8,N?_135YU^QI_R:C\)_P#L6[+_ -%+7HOQ!_Y$+Q+_ -@RY_\ 135YU^QI
M_P FI?"?_L6[+_T4M 'LM%%% !1110 4444 %%%% !1110 4444 %%%% 'SK
M^W+_ ,DS\&?]C[X<_P#3A%7T57SK^W+_ ,DS\&?]C[X<_P#3A%7T50 4444
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M_"M;_P"-U],T4 ?,W_#">C_]%<^+O_A6M_\ &Z/^&$]'_P"BN?%W_P *UO\
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M@O8[K2KCR+F&:%P\;H^#@A@#TKR/_AA31V S\6_BX/IXL;_XW7TS10!\S?\
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M!OV3O%&C6T7Q2\[5["+?XWU)UWW*#<I*X(YY% 'TE16/_P )EH'_ $'--_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=0EGGM;IV='DCD=BRYV@X!P#T H ^Q;BX6VMY9F5F6-"Y"#+$ 9X'<UQ]O\
M%_PZOPOC\?ZI)=>'?#QMOM<K:S:O;SVZ9Q^\B(W*W^SC/(KQK2+*Y^'GQ4\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M &#+G_T4U>=?L:?\FH_"?_L6[+_T4M 'LM%%% !1110 4444 %%%% !1110
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MC\)_^Q;LO_12UZ+\0?\ D0O$O_8,N?\ T4U>=?L:?\FH_"?_ +%NR_\ 12T
M>RT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&69E7:N0BJH '' KM>E &!\0?^1"\2_]@RY_]%-7G7[&G_)J/PG_ .Q;LO\
MT4M>B_$'_D0O$O\ V#+G_P!%-7G7[&G_ ":C\)_^Q;LO_12T >RT444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3X%_]#/??^"6\_\ C5'_  \4^!?_ $,]]_X);S_XU0!]*T5\U?\ #Q3X%_\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>ahpa-20220416xs4017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xs4017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ', E8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3(KSGXB_M#?#KX5R>
M1XD\6Z997YX33EG62[D/]U85RY)^E 'H]%?,-_\ M3>//'3-;?"SX.Z[JF\'
MRM6\4(VEV7L<.-Y'?ITJ,_"O]H[XBACXG^)^F>!;-QM^Q^$['?.@[_OI._X<
M4 ?3T]Q%;)OFE2)?[SL /UKA?%'QY^'/@I96U[QQH.DK$,N;J_C3:/?)KS*R
M_8D\*W1$GBKQ5XS\:S$8==6UV<PMZ_NE8+S76Z%^R-\&/#:(MC\,?#(V_P 4
M^FQSD^Y+@Y_&@#E-8_;_ /@9HP8CQM%J07_H%VTMUGZ>6IS64G_!0'P)J2*^
MB^&O&NN(XRC6OARY 8=L;E%?0VD>#]!T!0NEZ)IVG*O06EI'$/\ QT"MB@#Y
MB/[;;2<6_P &/B=<GJ1'H+# ]>34"?MM:V9V$G[//Q9BM<\73:(I1O3@/G]*
M^I** /F/_AM^*$9NO@_\3+3'W_,T!SM^N#4<O_!0KX;:7&9-<TGQAH,:D!GO
M?#EWA<G'.U#WQ7U!2$ C!&10!X!I/[>/P,U;;GX@6&G9_P"@F&M<?]_ *]1\
M,_%WP3XQ"G1/%FCZKN&X?9;V-\C\#5[6_AYX5\2HZ:OX9T?5%<887MA%,"/0
M[E-><ZY^QS\%M?.^;X;Z#;3@[DN+"T%M(A]5:/:0: /98Y$E0,C*ZGHRG(IU
M?-U_^Q7I^GK))X,^(_COP7.1\@M=:DN(8S[12DK^%9LWA+]I[X<[VT;Q9X;^
M)=B@RMKK=N;*Z8CJ#*G'(QVZT ?4=%?-&F_M?ZGX7D^S?%#X7^*/!3H<2:E;
M6C7^G_[WFQ@[5]R*]E^'GQA\$?%:T-QX1\5:5X@51ETL;I'DC_WD!W+U'44
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MJ: /=5Y%.K@O@=\6=+^-WPOT'QCI1VPZA &E@)!:"8?+)$V.C*P(/TKO,YH
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M33(--EU& Q/.L;W&XLA&8WRV?+;# %20":]\I@&#[ 4[.32 6BBB@!#7S/\
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MOHA+;SQW$9Z/$X93^(J;- "T4F:0M0 ZBFAA4=Q=0VD1DGECAC'5Y&"@?B:
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M+*QA6**,>RJ,5KXP:6@!H&#3J** "BBB@ HHHH **** "BBB@ HHHH ****
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MND[  OV2QC3 'T%=G12 CB@CA3;&BHHZ!1@4_ I:* $Q2T44 %%%% !1110
M4F.<TM% ";1FC;Q2T4 9>K>%]'U^W>#4M+L[^%_O)<0*X/YBO+_$?['GP7\5
M3&:_^'&@-<$;?/ALUBDQZ;E ->R44 ?,MS_P3N^#@O#=Z;8ZWH5SC ?3-<NH
M0/HHDQ^E)_PPMI-M\NG?$WXBZ;'_ '(/$$I'_CV:^FZ* /EZX_8EU1H\6GQ^
M^*]C+_SUBUP$X_X$A%?/GQ&^"7Q:^!/B"YU?QM\4_B;XQ^&!<E]=\.:PYO\
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MY0N-LT#]GBD'S(P[%2*\A_X8+\&?]#S\4/\ PMKW_P"*H_X8+\&?]#S\4/\
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M/_[?G_)FWQ8_[ K_ /H:U[5X3_Y%71O^O*'_ - %>*_M^?\ )FWQ8_[ K_\
MH:U[5X3_ .15T;_KRA_] % &M1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?/_[?G_)FWQ8_[ K_ /H:U[5X3_Y%71O^O*'_ - %>*_M^?\ )FWQ
M8_[ K_\ H:U[5X3_ .15T;_KRA_] % &M1110 4444 %%%% !1110!\U7/\
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M9\LO;&&!SCFM7PG\<="\4ZGJNE26.KZ!K6FV7]HRZ7K=F;:X>UR1YR+D[DW
MKD'@\4 >B4A.*\7\*?M9^"/&-GX;U+3[;75T'Q \4-CKEQICQV3RR<+$9#T8
MGY>F,\9KH/%GQZ\-^%O$]QH'V;5=9U"RB2?41H]BUTNG1MC:\Y7[O'S8 +8&
M<4 >D4M>%_L2>/\ 4_BA^S9X;\3:OJTNN7M]>ZMB_F.6EB34[J.'L.!&B*/8
M"O=* "BBB@ HHHH ^5?^"7'_ "8G\,O^XG_Z=+NOJJOE7_@EQ_R8G\,O^XG_
M .G2[KZJH **** "BBB@ HHHH **** /G_\ ;\_Y,V^+'_8%?_T-:]J\)_\
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M)+&XUW5[6/;Y((AN+CR]TD44F/+9QALHK%AM/'!H ]:HI <TM !1110!\_\
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M:9XYT'1K?3+OP5-*HUI[N"%8S!%9Y\V5G9?D**P;(()'->4>$_A?J/P^T?\
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M*** /E7_ ()<?\F)_#+_ +B?_ITNZ^JJ^5?^"7'_ "8G\,O^XG_Z=+NOJJ@
MHHHH **** "BBB@ HHHH ^?_ -OS_DS;XL?]@5__ $-:]J\)_P#(JZ-_UY0_
M^@"O%?V_/^3-OBQ_V!7_ /0UKVKPG_R*NC?]>4/_ * * -:BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ^?_ -OS_DS;XL?]@5__ $-:]J\)_P#(
MJZ-_UY0_^@"O%?V_/^3-OBQ_V!7_ /0UKVKPG_R*NC?]>4/_ * * -:BBB@
MHHHH **** "BBB@#YJN?^4D>G?\ 9)KG_P!/$%?2M?-5S_RDCT[_ +)-<_\
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M/1_V8O\ HIO_ )0-4_\ D:C_ (>C_LQ?]%-_\H&J?_(U?55% 'Y]?M:?M_\
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ML/A9\0/!VA:=X'ET>27QEH3:<9+AK^.8+'EF#?+GOGY3QC!)7WMBB@!:***
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M /$T ?2M%?-7_#>G@S_H1OBA_P"$3>__ !-'_#>G@S_H1OBA_P"$3>__ !-
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M?^$3>_\ Q- 'TK7S_P#M^?\ )FWQ8_[ K_\ H:UE?\-Z>#/^A&^*'_A$WO\
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MIKZ7M+J.^M8;F$[HID61#ZJ1D4 34444 %%%% !1110 444C=* %HKQSXO\
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MT +17/:#\1/"GBG5;K2]%\3:-J^IVJEKBRL+^*>:$ A2716)4 D#D=2*Z#-
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M44 ?/_[?G_)FWQ8_[ K_ /H:U[5X3_Y%71O^O*'_ - %>*_M^?\ )FWQ8_[
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MFB\\(ZUX3UKPYXKAM=7T3PW#X9>;4M)%VDD$84>;$HE0PR';GJZ]BIJCX?\
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M?%C_ + K_P#H:U[5X3_Y%71O^O*'_P! %>*_M^?\F;?%C_L"O_Z&M>U>$_\
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M4].M+72A:W$DV"$-Q-YK*X4'I''%D]?2O7** "BBB@#Y_P#V_/\ DS;XL?\
M8%?_ -#6O:O"?_(JZ-_UY0_^@"O%?V_/^3-OBQ_V!7_]#6O:O"?_ "*NC?\
M7E#_ .@"@#6HHHH **** "BBB@ HHHH ^:KG_E)'IW_9)KG_ -/$%?2M?-5S
M_P I(]._[)-<_P#IX@KZ5H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P AT?\ #;?[0/\ T5?4/_!)I'_R'0!^RE%?C7_PVW^T#_T5?4/_  2:1_\
M(='_  VW^T#_ -%7U#_P2:1_\AT ?LI17XU_\-M_M _]%7U#_P $FD?_ "'1
M_P -M_M _P#15]0_\$FD?_(= '[*45^-?_#;?[0/_15]0_\ !)I'_P AT?\
M#;?[0/\ T5?4/_!)I'_R'0!^RE%?C7_PVW^T#_T5?4/_  2:1_\ (='_  VW
M^T#_ -%7U#_P2:1_\AT ?LI17XU_\-M_M _]%7U#_P $FD?_ "'1_P -M_M
M_P#15]0_\$FD?_(= '[*45^-?_#;?[0/_15]0_\ !)I'_P AT?\ #;?[0/\
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MMO\ :!_Z*OJ'_@DTC_Y#H _92BOQK_X;;_:!_P"BKZA_X)-(_P#D.C_AMO\
M:!_Z*OJ'_@DTC_Y#H _92BOQK_X;;_:!_P"BKZA_X)-(_P#D.C_AMO\ :!_Z
M*OJ'_@DTC_Y#H ^P/CDI?]OC12 2!\,YQP/^HK'17C7[(>M>(_CW\=-9\6^/
D_%.H>(M:TWPX=*MI7M[2V5+=KJ.0C;! @)W+G)]3[8* /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>ahpa-20220416xs4018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xs4018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (L 6,# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z**3I0
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MA0&78J@Y/'K7<:S^SEXCT7XLZ1XR\/>);_7//L+G2=93Q#>*6:W=#Y9C\N(
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M3?LY>%?A7<R:I$D^M^)[@?Z3K^JOYUU*3UPQ^Z/9<"O5MHS1@ T "KMI:**
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M\J^(M'UO]C7Q;-XD\,VUSJWP6U6X\S6?#L*F1] F<_-=VPZ^2QY>/G!)(XX
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M9S2U3TS5+36+"WOK&YCN[.X0213PL&1U(R"".H-6P<T +1110 4444 %%%%
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MBEH **** "BBB@ HINZA6R30 ZBBB@ HIK-BG4 %%%% !1110 4444 %%%%
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M1&8\6<TG5H1T1CR 0N< 8 /JVBHH9X[F))8G$D3@,K*<A@>A%2T %%%(>*
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M,Y'W(47+$]\8'6KWP.^!,?PRBOM;UK4&\1>.M8(FU769AU?_ )YQ#^"->@%
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MW,\S[V:1SD\^G8#L*\%\%^!Y-87X]?#J:7[ ^LSSRV\Q7.([N KOQW ;/Y4
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MM(_]C!IO_IL@KZ%H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* /</[6L?^?RW_[^K_C0=6L@/^/RW_[^K_C7A_\ PPS\&/\ H5'_ /!A<_\
MQRC_ (89^#'_ $*C_P#@PN?_ (Y0!F?L.:E:1?!C4%>Z@0_\)/K1P9 /^7Z6
MOH/^UK'_ )_+?_OZO^->%6_[!_P2LXS'!X.$$9);;'?7"C).2<!^IJ7_ (89
M^#'_ $*C_P#@QN?_ (Y0![A_:UC_ ,_EO_W]7_&C^UK'_G\M_P#OZO\ C7A_
M_##/P8_Z%1__  8W/_QRC_AAGX,?]"H__@PN?_CE 'N']K6/_/Y;_P#?U?\
M&C^UK'_G\M_^_J_XUX?_ ,,,_!C_ *%1_P#P87/_ ,<H_P"&&?@Q_P!"H_\
MX,+G_P".4 >X?VM8_P#/Y;_]_5_QI&U:R_Y_;?\ [^K_ (UXA_PPS\&/^A4?
M_P &%S_\<I&_8:^#(Z>%'_\ !A<__'* /=[>YBN5+12I*H.,HP(J6OF;]DGP
MU8>!OBA\>?"^C++;Z'I6NV"6=I),\H@5["*1@I8D\LS'\:^F: "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#8P:;_ .FR"OH6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *XKXW?\D8\??]B_J'_I-)7:UQ7QN_Y(QX
M^_[%_4/_ $FDH P_V6SC]FWX8?\ 8N6'_HA*]/W"O+_V7/\ DVWX8?\ 8N6'
M_HA*\X?Q/K5O'\=O'VDQ2W^J6!;3=+CWQK]GCMX/F9=_R_ZPNY!'/3F@#Z8!
MS2UX3X)^/.L6GP=\$:MXD\.WMUXJ\016UO86%M- TNJ3M!YK2C:0D2X#L=V-
MH'2NY\ _%9/%^NZIX?U'1[GPYXDTU4EN--NI4E_=/]R170E6!P>G3% '=-][
M-+MS[5\UM\4/%&B_M-?$#1]-T?6O%]O!I5C<0:7!>+';6_#[ROFL$5VXX'+5
MV%O^U!X>U[0?"U[X8LKC7[_Q';RW-IIWFQVSQI$Q2;S6D(5"D@9"#_$"* /9
M-O/6@K[UQWPM^*.F_%;P]-J6GPS6DMM<R65Y9SD%[>=#AT)4D'MR#@YKE_"/
M[0EMXNN?$<\?AZ^L/#WAVZN[34]:NY8UBB> 9.U<[G!'<#C/- 'K.VC;7COA
M?]I2PU[7_#=E>:!>:38^)P_]B:A+<0RK=%8FE =$8M$6C5F 8=L=:Y[_ (;&
MTR/18M?E\&Z^GADZJVBR:FJQ-MNMYC15B#;G#, H(&,D9H ^@]GO1M]Z\R\,
M_&[^V=>\0:!J'AC4](\0Z391ZBNF,T<TEU;.2J/&48C.X$%200:KV?QUFM=5
MU'2_$GA._P##FI6VF2:M!#)<PW NH8_O[6C8A6!QP?6@#U>BO$_"O[3,7B&3
MP7<W?A#5M%T/Q<ZP:7J=Y+$0TQ0NL;QJQ9<A6PQ&#BF:S^U1H^F?VKJ,&B7E
M]X3TF^;3[[78IX0L<JN$D*0EO,D1&."P&,AO2@#VXT YKPKXE_M!.FE^-[+P
MOX>U;7DT/397O]6TV5$%F[0EE\M2P>1@"&^3D5U/[-&L7OB#X">!-2U*[N;^
M^NM(MY9KF[E:261B@)9V8DD^YYH X?\ 9X_Y."_:1_[&#3?_ $V05]"U\]?L
M\?\ )P7[2/\ V,&F_P#IL@KZ%H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "N*^-W_)&/'W_8OZA_Z325VM
M<5\;O^2,>/O^Q?U#_P!)I* ,+]EP9_9L^&'_ &+EA_Z(2N*\#:(=0NOC?\/#
M+]FO;B[EGA=UX,5W!E7]P&+#\*[;]EO_ )-M^&'_ &+EA_Z(2O1$T:PCU674
MUM(5U"6-89+D(/,9 20I/4@$G\Z /![#X9^.+;P5\,;E--L8?$W@&011V+7H
M:#4H#:-;2$2!?W;$-N&0<8YKL/AYX&UQOB)KOCOQ):P:5J.H6L5A#IEO.)Q%
M%&2=S28 )8GH!QBO5,48% '@NH>"OB%X2^-OC'QIX>TG2]<T[5]/M;6"TN+W
M[/*)8PWS%MI&W)''4UP]C^R1=>"K+P'>KI.B^/KW1;.]MM2TW4D6*&>6[NGN
MIIH2X8)B:1L ]5XXKZLN;B*SB>:>1(88P6:21@JJ!U))Z"JNF:WIVM+(=/U"
MUOE3&\VLRR!?K@G% &%\-?#,'A;PVEO#X;TOPJTLC32:=I 7RD8]R550S'N<
M5P/@;X)ZC9?#;XC>%M:GCMQXFU+4IHIK=MYCAN.%)SW&<XKVL?2C% 'S_P#"
M#X/W'@^?0;._^&GA33[G2+<0'Q-9F,SS,L9021H(PR,_4Y;@%JP6_9V\4GX&
M6'A(-9_VK#XPAUQCYO[O[.M\)SSC[VP=/6OIUR$&X\ =36/H'BW1/%>ER:CH
M^JVFI:?'(\3W-M*'C5D.'4L. 000?2@#R#Q]\)/&6J?%#QGXI\-:C;Z3/J7A
M"/1M/O"V9(KI;@R$D$<#:<9]:Y3PS\ /$L?B"?59-*.D!_#MUI+)>^(KC5)9
M9Y N)-TI(0$@Y"@?2OH_4/$NE:5H-QK5WJ-K;Z1!$9Y;Z251"D8ZL7SC ]:O
M65U!?V<%U;R)/;S()(Y4.5=2,@@]P0: /"X_@OKZ^!_@II)-J;KP?J=I>:B?
M,^4I'!+&VP_Q'+BN>\,?L[S^"]2U339?AYX5\965WJMQ?V^OZEY23Q1S2F39
M*AC9G*%B 0>0%KZ;P*,"@#YZU/X6>./#&I_$2S\+V>F7VF^,49H[NZN/*_LV
M1H?*.8\$R+T(P1Z5Z9\#O!VH?#[X1^$O#6JM$^HZ7IT-K<-"V4+JH!P?2NYP
M*6@#YZ_9X_Y."_:1_P"Q@TW_ --D%?0M?/7[/'_)P7[2/_8P:;_Z;(*^A: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KBOC=_R1CQ]_P!B_J'_ *325VM<5\;O^2,>/O\ L7]0_P#2:2@#
M#_9;_P"3;?AA_P!BY8?^B$KU&O+OV6_^3;?AA_V+EA_Z(2O4: "BBB@#P_XY
MQ1^*OB?\-?!>IAG\.ZE<7-Y>6VXA+IH(P8XI,?>7)R5/!QR#7._%?0-/^%7Q
M;^%NI>#M/MM#N-5U)]+OK/38%ABN[<Q,WSH@ )4C(;&17L?Q$^&NF_$6UL!=
M2W%CJ&FW N[#4;-]DUM* 1N4]P02"#P:R=#^#EM9^(;77M<U>_\ %.L62.EE
M<:@5 M0PPVQ5 &2._6@#P"S^,GQ6;X5:/X^;Q-ILC3^(O[(_L@Z4@@D@>Y:%
M7=P=_F+P<J54XY!S78ZK\6?&7@34/B]X>O\ 68]=OM \*P^)]+U*2SCA,1D6
M=# R( K*KV^X$\X<@DX!KOHOV>?#\7P\L?!PN;S^S;34UU5)-X\PRB?SL$XZ
M;OTJ[XD^!VB>)]?\7:M<SW*7'B70(_#MVJ, JVZ-,0R\?>_?MS["F!YEX2^)
MGCS2/$OPC/B'7;;7;'Q[ISO<64=A' MC,+/[2K1,OS,/E*D.3UR,8Q7$:K\8
MKC4OV<8]+NWTZQU;Q=XFN?#<301):Q) 9V$TA"X&1$K9/4EA7T4WP6T9[KX?
MSF:YW^"XC#I_S#YP;8V_S^OR$GZUS.B_LI^#=,U'2+B[BDUNVTN2\FM['4D2
M: 2W+[Y'*$8)'0>@I > VFN6/ASX#_M%?"NPO+:YM_"T%U=Z3Y4OF)]@NXS,
MB@@GA)&D3VP/:O3?!_BSQY\-X/A*NO:[9Z[I_B6""QFTVULE@BL3]G5HVA?F
M1@ ,-O)R22-O2NS\7_LJ>"?$VJ:E>V=H/#O]IZ+/H5]!H\4=O'<02$'+*JCY
ME(X/O5_PG^SWI?AG4] N)]8U36K7P]$(M(M-0E#I:?(%W XRQQQELXI@>KT4
M44@"BDHSF@#Y[_9X_P"3@OVD?^Q@TW_TV05]"U\]?L\?\G!?M(_]C!IO_IL@
MKZ%H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "N*^-W/P8\??\ 8OW_ /Z325VM<5\;?^2,>/O^P!?_ /I-
M)0!Q'P,\9Z/X!_9.^'.LZY>+96%OX<T\,Y!8LQA0*J@<LQ/  ZUO:1\?M&N]
M=TG2M7T37_"<NL,4TV?7;1(H;R3&[RU='<*Y4$A7VDX.,X->#7R7%O\ LK?L
M]:EY<DFDZ:VBW.I>6,A(1 !O8#^$,037>?M/Z]I?CSPEX5T#P]?VVLZY>^(]
M.GM(K&03-$D<PDDE.W.U50-DG'7% 'T5N![T%@*^$;'P_P##KQ#K/[1]UXLF
M@N_$&F>(+MM-6^G/F:>Q@C9);)2?W4I<+F2/#G:H)P !);Z?KWQ-\5:18?$.
MU\+ZRB>%+":&S\>!O(\^1#YTL:%2GG=,MC<.Q% 'W3O&<4NX5\AP?"]-6\7_
M  5\'>--5C\<6,6CZBUT\DK36^H+'Y9C2;?_ *]!D9$F0Q4$Y(%4/VL+SP?)
M!XSTZU\":7?:]X;TF$V^M7MQ%!-I9,>^ 6 ?YD  !/D[1D8.2* /J*Z^(^D6
MGQ'LO \GG_VW=Z<^IQXCS%Y*OL.6SP<]L5:\):]J.O0WSZEH-SH#V]W);Q1W
M,J2&XC4_+,NPG"MV!YXYKY:A\%>$=8_:B^&6M>)/#VAW5YJ'@K[0;_4K&%GG
MO5D0J^]URTH!X.=P%<W:W,S>&(-,O)Y;;P;JGQ6O+/Q))'(T<;67ES,L4KJ1
MMB>985?G!!*G@D%@?=&:-PKXA^*6A:%X7L_C!I/P_$6F>#)?"L<UU8Z(PCT^
MVOO/55:!$^2)RF2VP#.%)YQ77:'X0TCX6?&[X6Q>&H%T9=>\.W1UBX5B\E^Z
M)&R37#L299%+$[W)/;.*0'UAN%175REG:S7$F?+B1I&P,G &37R?^SXFD_"7
MXDOX4O\ 2M!O-3N["YU%_'6AS@RZDBR;Y)-2/4S%GR&D+<AL$5]-WNJV>L^$
M+J^L+F*\LKBR>2&XA<.DBE#@@CJ* &^!_&>G_$#PIIOB+2O..G:A%YT/GIL?
M;DCD9..E;>:^(=+\/V/BOP_^RQH^JQ&ZTJ[>^6ZLR[+%<H+=F\N100'0D#*-
ME6'!!%5M2N)_!?AKXM>$M&,NE>"M/\?6%@]E8DQQ:?IUQ%;O<QQA?]5$2[DA
M<!0QQ@4 ?<Y.:XK0/B%)J7Q-\2>$+NR6UETVVM[RWG$F?M$,F1G';#*161X'
MTSX5_"ZQO7\(_P!@>'=,GEACGATN9(K3S6^6/$:GRU=LXR "QQG-8LYW?M;6
M7V?D?\(E)]IQ_P!?(\O/_CU &%^SQ_R<%^TA_P!C!IO_ *;(*^A:^>OV>/\
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M)2']DW6Q_P W!?%K_P &EE_\B4 >VV7@S0=-TB;2[71K&WTV;_66D5NBQ/\
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M4^'-+9;]3IUJ5U!M]V/)7%P<!<OQ\W  Y["O#/\ ADS6_P#HX+XM?^#2R_\
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MOE2+PK?R Q373R1G*Q$<JP..U>O?\/"_A3_SZ>-/_"0U#_XU7TQBEH ^9O\
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<5\;O\
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M CXE7GQ1\+-K4VL>'-;M92IAN/#CR;(S@[X95=F(=&&"<C.2-HQR >FT444
M?/7[/'_)P7[2/_8P:;_Z;(*^A:^>OV>/^3@OVD?^Q@TW_P!-D%?0M !1110
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MZ)]X<_\ !;%_\31_PSG\+?\ HGWAS_P6Q?\ Q- $O_#07PR_Z'[PY_X,HO\
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=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>ahpa-20220416xs4023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xs4023.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *8 Y # 2(  A$! Q$!_\0
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MIGVUQ_RTK$U6[\O4IEW<"J@OF/\ %7[GS16A^#K#S:3N=-]M?/\ K*/MK_\
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M!(]M ?,.R1.!M<?>/WAQZ9WP1^#7@GXAK*=8\&7=EI6N22IH]_=7LZS0# P
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M[=;6Y4NW[V)6W*#ECG! /X5]&CP7^S4,'^R]2^F7_P :/^$)_9L(S_9>I_\
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MW9+I\\QN!%.&86[DDGR\2#:/F_0>E<=<>*I?$OC$ZMJ%Y%<:G?3!IY0_#$
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M[M:TWR^\_P"N_P" *UKLZ3XB?&K5['X@^&K?3M=%GIGB"PBGT_\ <;U\YGD
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MVCV$FJ*/*?(,9Z88L<8# @CCI6AX$\?#QN-1_P")9<Z:;.X-OBX_Y:853N'
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MI/\ E?W,S@JX^Z/RIZJH_A'Y5H+X5\1D?\B[J?\ X#-_A2CPKXCP?^*<U/\
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MYM_\:KO<"D/?TI@< =.^(>2?[0T4Y]=W_P :IITWXAC_ )B.BC\&_P#C5/\
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M8>?W8I5L(".8Q6;X;PW_ #\E^'^12XJQK_Y=0_'_ #/O'_A=FC$'_BMO#_\
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M4?9(?[@K+^V*O\J_KYC_ +>Q'_/N/XGV9_PM:V_Z&S0?^_?_ -KI?^%JVO\
MT-F@_P#?O_[77QC]DA_YYBE^QP_\\Q1_:]7^5!_;V(_Y]Q_$^S!\5K;I_P )
M9H/_ '[_ /M=9WBSXBPZMX)\0VD/B;1[FYDM&V0PKR1W_@'8&OD3['#GB,5<
MT*R@2^NG$0#?97Y_X"U;T,WJNO33BM91[]UYD2SS$3BX.G'6ZZ]C[:_9:/\
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M/^A3E_&9O_C='_":^)/^A3E_[_-_\;HL%SN<BD(S7#GQMXD_Z%*7_O\ -_\
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MTG_?IO\ "@ZE;_WI/^_;?X5^C?\ 9^A$X_X13P]_X%1__$TO]G:$/^93\/\
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M -"AX=_\"H__ (BC[#HX'_(H^'?_  )C_P#B:S>8P?V']X_]6,1_S_C]S_\
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M_0%U'Z^0_P#\3727^M:;I:QF[N8H!)]S?_%]*+K6-/L8!/-/'%"5W!VZ$>M
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MA^(8Y_X3*^_S^-8/+\P7_,3^+'_:^5?] 7X0/J0_ #X8@?\ (D:E_P!^S_\
M$5+'^S[\,2F?^$)O_P 8S_\ $5\LK\7_ (AGKXROO\_C4@^+_P 1 O\ R.5]
M^7_UZP>"QRWQ'YC6;Y4_^8+\(?YGU)_PSY\,.#_PA-__ -^S_P#$4I_9^^&)
M(_XHB^_[]G_XFOEH?%_XA@?\CE??E_\ 7IR_%_XAX_Y'.]_+_P"O6+PN,7_+
M_P#%C_M;*_\ H"_"'^9]2']G_P"&6?\ D2+[_OV?_B:7_AG_ .&2G/\ PA%]
M_P!^S_\ $U\N+\7OB&>/^$SO?R_^O3O^%N?$/G_BLKW\O_KU@Z&+6];\65_:
MF5_] 7X0_P SZ@_X9_\ AE_T)-]_W[/_ ,11_P * ^&7_0D7W_?L_P#Q-?,0
M^+GQ#_Z'.]_+_P"O2CXM_$/_ *'.\_[Y_P#KU@Z>)6]7\6/^T\K_ .@+\(?Y
MGTX/@#\,_P#H2+__ +]G_P")I1\ OAGT_P"$(O\ _OV?_B*^95^+7Q"(_P"1
MRO?^^?\ Z].7XL?$/_H<KW_OD?XU@U76]7\P_M/+/^@+\(?YGTQ_PH+X9]O!
M5_\ ]\'_ .(J#_A1/PSR?^**U$?]LS_\17S=_P +8^(?_0Y7G_?(_P :7_A:
MOQ!)Y\8WG_?/_P!>L'*JOM_F/^T\L_Z OPA_F?2)^!/PS/\ S)6H_P#?L_\
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M]/%4]I>")8?-BBD)VCV*XYJNB^$TU&*[_P"$SNS*@"G,4F& _"CZU6O>_P"
M<JZ'$^&OV7?%_P -9=2T?P-\2!H7A:]OEO#9-:[YX#F/>$?>!EEC"_=[FM/P
MO^R$GASP1\3] ;Q+-<OXV=99;N2+YXGW.S$\\Y+GTKL+G4/"5UJMY=_\)5,L
M5T/G@$4F >Q!VY';IZ5C:M9^'KZR:WMO'EW!O?+GRGSMP>!\ON*3Q-5]?P[
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M/VE1CJ._K7-O\1_"KDL=;0D]<PR?_$TL'Q(\)Q2[SK2-C@#RI/\ XF@#RO\
ML9I=.U;2]5TJ:X\9RWP,%\(FP^7&UP^-H ()ZUK7>B>);O7-DUS?QI(T5O.(
M5^0((0<J<'^)1S]:]&_X6AX2WA_[4BWC^+R9,C\=M./Q4\*#_F+)S_TRD_\
MB:0SS_['X@U.\N8)UOD@T>T5[)E&#/)@_>R.>57@8ZU4\2:-X@\=O9;[-;*_
M\AG:6>W9XN-V1MR.2HP.>I%>F?\ "U?"F?\ D+I_WZD_^)I&^*OA0_\ ,70^
MG[J3_P")I@>4WNK:GH^F>&;'2?#NIOJ%F/+%QAA$K C=N79]TL..>@ZFN[^$
MVD0:'?>(K6$7Y(O6;=>9P?D0?+\HXX]^];0^*?A7I_:T?X12?_$T#XI>% <C
M5HQ](I/_ (FD!UXI:Y(?%7PJ!_R%T_[]2?\ Q-'_  M;PI_T%T_[]2?_ !-
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M(,U_Y]+_ ,"1\TH >O2I1RO8BOI+_ADSX;@<>-;\_P#;!ZE3]DOX;E?^1TU
M_P#;!ZY99I@WM-_<4L@S7_GTO_ E_D?-)]\4Y/NU]+#]DSX;]_&6H?\ ?EZ4
M?LG?#?I_PF6H#_MB]<TLQPK^T_N+60YI_P ^E_X$O\CYJ2GK@9KZ4'[*'PW7
M_F<K_P#[\O2_\,H?#?G'C*__ ._+US2QN'>TOP-%D69_\^E_X%_P#YM7D4_M
M[5](K^RI\.0N/^$RO_\ OP]'_#+'PZ'_ #.=]_WX?_"N:6*HO9_@7_8>9?\
M/M?^!(^<DYZ4[\:^C1^RW\.L8_X3*^)_ZX/_ (4G_#+?PZ''_"97W_?A_P#"
MN65>F]G^!?\ 8F9?\^U_X$CYT&#3E]J^BQ^R[\.\<>,K[_OP_P#A48_9B^'B
M\#QK>Y_ZX/\ X5RRG%[,/[%S'_GVO_ D?/0''44[C%?0@_9E^'@_YG2]_P#
M=_\ "E_X9F^'G_0ZWG_@._\ A7-)7V*_L7,?^?:_\"1\]8Q@YIP'%?0G_#,_
MP\[^-+P_]L'_ ,*7_AFKX=X_Y'.\/_;!_P#"N25*3V&LES'_ )]K_P "1\^+
M]13NA%?00_9K^':C_D<[S'_7!_\ "@?LU_#P]/&=X?\ M@_^%<LL-4>R+639
MA_S[7_@2/  WI0.>:^@!^S=\/1G_ (K.\_[\/_A1_P ,W_#X=/&EYC_K@_\
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MEQU_I3E@8K:HOZ_RZCCCI-ZTW_6WR?0^D(=+\.W-W+:PPZ?+<P_ZR%-C.GU
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M>@ZT7 Z'_A'](_Z!-G_WZ'^%/MO#ND/< '2;09'41#C]*M#D9Z&IK,9N1]*
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MBG1A$XEB52PW$D '@=F[5#H/QDUBRT"]\3:AJ%KJGA[S1$&BB99;<MM5-RD
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MK+_OP*\\!Q3^]<,ZM1?:9HL9BO\ G[+[V>A#X^^,^[67_?@4J_'WQD6ZV?\
MWX%>?4Y,YK@GB*RVF_O*6,Q7_/V7WL] _P"%]^,MW6RQ_P!<!3O^%\^,#U-E
M_P!^!7GXZT^O/J8JNMIO[RUC,5_S]E][.^7X]^,%;<#99'_3 5(?V@_&>?\
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MR=/V-->'_,WZ;^=2I^Q?KK*,^+]/_"JG_#5>X_\ )/\ 3_S;_P".U-'^U4F
M#\/K'\&;_P".US2JYEUM^!7)PX_Y_P#R<L+^QAK>/^1OL/R_^O3E_8RUM?\
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M '\H ZW[9!_SU3\Z/MD'_/5/SKDO^%1^'/\ GWD_[^4?\*C\.?\ /O)_W\H
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MU+9G_21].E)]FEQ]S%26MLZW&YAA<4@/'7\1:KX@\-W_ (W74)[*?3[EHH+
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MT6+5);9;2*?]Y:J#S)$>4<_4$'\:T@/_ *]/M]-^PV=K9P1[+>UB6&)?15
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MN[7^V-3=_,NA"-D0!Z!,\]1SD=*+L#6_X5E-QCQ#?C\%J*Z^&;O@/XBO\GH
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M\,7]YO'/\S>]1?\ @*_S/H]?VI_![#A/$?\ XY_\72_\-1^$#_!XC_\ '/\
MXNOG6-CGK4P8XZFO)JX>E#9?B;K/,Q?VU_X"CZ%'[4'A$X^3Q$/KL_\ BZL1
M?M2^$$0*4\0GWPG_ ,77SNK''4T\,<#DUY%:7)L6L\S'^=?^ K_,^B1^U)X0
M;HGB'\D_^+IP_:@\)$_<\0C\$_\ BZ^>$8XZFI0QQU/2O%K8RK#9_@C99UF#
M^VO_  %?YGT(/VG/"3#(7Q#^2?\ Q=-D_:>\(!X(F7Q"//E6(, G!/0_?KP)
M6)7J<U'.S"6S.X_\?*5Y?]J8E2M=?<O\A2SK,%%M37_@*_S/OZ#X;O<1)*NO
MW^UQD<"GCX929_Y#]_\ I78:2<Z9;'UC'\JMU]<F['Z.M4<*?AB__0>OOTH_
MX5E(/^8_??I7=44[C.&_X5E)_P!!^^_2L]_AMAF_XJ.^Z]*](/2L:7[[?6BX
M'('X;J!D>)+[GM0?AN!U\1WQKKJ*+@<A_P *V4_\S%?TI^&HQ_R,=]BNNHHN
M(Y$?#@XX\2WP_ 4O_"N3_P!#-??D*ZVBB["QR(^')_Z&:^Q]!2GX<'MXEOOR
M%=;11<+'*0_#4M*,>);\MZ8%7#\,IB?^1AOOR6NEL_\ CX6M6BX'"_\ "LIC
M_P S#?\ Y"C_ (5E-_T,-_\ D*[JBB["QPO_  K*;_H8;_\ (4?\*RF_Z&&_
M_(5W5%%V%CA?^%93?]##?_D*/^%93?\ 0PW_ .0KNJ*+L+'"_P#"LIO^AAO_
M ,A1_P *RF_Z&&^_(5W5%%V!Y]=_#5QMW^([Y?P%0+\-SGCQ+??D*[O4>BU1
MHN!R)^'#'_F9;[\A1_PKIO\ H9K[\A77447"QR7_  KEO^AFOO\ OD4?\*X;
M_H9K[\A76T47 Y+_ (5R?^AFOO\ OD4?\*Y;_H9K[_OD5UM%%P.2_P"%<L/^
M9FOO^^12'X;Y'/B6^S]*ZZD/2BX'.P?#20Q#;XBOV'K@5)_PK.;_ *&&_P#R
M6NRL?^/<?C5BB["QPO\ PK*;_H8;_P#):/\ A64P_P"9AO\ \EKNJ*+L+'"_
M\*SF_P"A@O\ \EH_X5E-_P!##?\ Y"NZHHNP.%_X5E,/^9AO_P A2_\ "LYO
M^AAOOR%=S11=@<+_ ,*RE'_,Q7_Y"L#XA^ );#X>>)&.MW<^;-CAP.W/]*]9
MKE/BK_R3CQ%_UY2?RK:AK5A?NOS,,1_!GZ/\CDOV7#CX$^%.,?Z-W^IKU?->
M!_L[Z5XBN?@GX7>RU9(8VA+!#'G STSGZUZ+_8'B_'&N1?\ ?H_XUOCM<55_
MQ/\ ,YLN_P!RH_X8_DCN**X;^P/&'_0<B_[]?_7H_L#QA_T'(O\ OU_]>N*Q
MZ)W-)7#_ -@>,/\ H.1?]^O_ *]+_8'B_P#Z#D7_ '[_ /KT6 [?I7EG[0'P
M7/QT\+VOAV;59M-TO[5%/>+ 0&F5)$<+DJ?[I].M;G]@^+_^@Y#_ -^__KTT
MZ!XO'_,;B^GE?_7JHR<&I)ZB>I\[_$G]BZ]\/V6L7_PLOY;;4=46"*:QO94,
M"A!&/,&X=?W2GK_$>*QY/V3FTK2;*^U'Q>Z_%--7BU:37S WV=IU=6VA5AVX
MWKD?+WZU]/'P_P","/\ D-Q9'_3,C^M1W'A3Q+>($N=4MKE0<A98,@'UY/:N
ME8FI:S9G[-)W1X3IW[/,'A7XM6_C"U\4Q/H]Z!+K>G7D!87%SY6S=&?*R!D1
MM]X=#5FU_9A\#V2?$RX;5I9O^$PO);ZW=HW)T^9VE;,8"< &7H<C@5[%=?#_
M %J\C2&>\M'C1@RCR1C-<[XFOXO 5S$OB+5;;2;.8_N[PP+Y6[T.2 /_ *U5
M"=6H^6%V_+R,ZDJ=*+E4:2[LS?V9O@?)\.+S6M?UKQ$?%'BC4R$EO50(BP#;
ML7:$09!W=N]>_P!>.>'M7M-2OQ8^'?&^EW5Y/EUMH"I9AC)( ;T4_E75?V!X
MN_Z#D/\ W[/^-<]7G<KST?W&M/EY?=_ [FBN'&@>+_\ H.1?]^__ *]']@>+
M_P#H.1?]^S_C65C0[BFD9KB?[ \7_P#0<B_[]G_&D_L'Q?\ ]!R+'_7/_P"O
M181-XA\$V'B+Q%:ZEJ"-<QVD;1);'[OS$'=]?E]>]9.A_"?1O#GB&VUBVC>1
MK2,Q6L39(A!W X_[[/6IY-#\8J[?\3Z #IRI']:;_8?C'_H8(/\ OD_XT 3S
M_#S3;CQ^GC.43'58[;[*L0/R;<J>GK\@KG[+X-BUU2-6U&2;PS#<_;(=.;[R
MRY!QG;G'RIW[&MDZ%XP(YU^$?13_ (T?V%XQ(P=?@^N#_C0 W_A5NCVNO/KV
ME))IVJF$PQXR44DC)QSZ?K62?A#,;-;I[\-XK$AFCU(+\BL3G[NW'4#MVK8.
MA^,<X_M^ '_=/^-)_87C#/\ R'X?7[I_QHL!H^$O"=MX,TAK&TC9FE?S9Y>3
MYDG3/MP .@K9V-C[C#\*Y==#\8X_Y#\'_?)_QH_L3Q@/^8_!_P!\G_&@#J"C
M<?*WY5+:*PNAP1\O<5R?]B^,,X_M^WS_ +I_QIT6A^,'D_Y#T!'H$)_K0!%<
M?"H_VNZVMX8?#]Q+Y]UIO9WSG@XS@X&>:V5^'&F)?)<H9$9)!(JC& 0FS'3T
MJC_8'B__ *#L6.W[L_XTIT'Q?@8UV+CK^Z/^- %JW^&6E6UWJ4Z-+OOX1!+D
MC@8(X_[Z-1P?"O1X(C%^]:$P-;LC'AE.>?J"<_A47]@^+_\ H.0_]^__ *]!
MT#Q?C_D.1#_MG_\ 7H BL/@SH5CX?72/WTUNL+0;Y&^<J>G(]!P*KQ?#2^FM
MI;V_U(3^)<".'4U&#'&#G:!MQU+]N]7/[ \7 ?\ (>B_[]G_ !I/^$?\79_Y
M#L?O^[/^-%@,^'X1"&#3K87K/#%=F^N78_/)*=V<$#I\Y]*U?!?@+_A#M0NQ
M;-"=-ED,L,9'[R,GJ,X],=ZC.@>+O^@[%SZ1?_7I!H/B_D'7(L]>(_\ Z]%@
M.ZI#7#_V!XP_Z#D7_?K_ .O1_8'B\8SKD/\ W[/^-%AC/&W@N;Q)>6VHZ==G
M3/$%D"EO>@9 5LA@001]UF'3O5?3?AO:6$,3R2R2ZDV6O+K'^OE8Y8]/7/0#
MK2G0?&&XY\00C_@)']:%T+Q@ ,:_"?3*GK^=%A%)OA/!!>(UC=-#ITEH;.^M
M7'^N3+'(XSGYNQ'2F:9\)XHFG74[MKVW6 VFGQ*,&W@)!VG@<Y'O5_\ L#QA
M@XU^$CZ'_&C^PO&!/_(?@_[Y/^-%@,/_ (4Q]EMVM+2[+Z5:0,=,L6X\N;&
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MMI?->)1\SR \'..G7OWK O?A(J^*+C6]&U4Z;<75J+6ZA S'+RV6Q@C.&Q^
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M_<ZU<*%NHG,BEHPP).T?,!ST[4@/>M/U.UU:"2:RE,T,3F)F(P,@X./;BK!
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MAR-&L!_VU7_XJE_M?XA<8TFQ/_;5?_BJZ2RU:UU!HUBN46>2(3^2S?,JG_\
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M8?\ ?U?_ (JE&I^._P#H"6 _[:K_ /%5V&6]3^=(2WJ: .0_M+QX?^8)8?\
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M%%ID-L^CQ2Q7$,SXW1O&^]4/KG"C\:V/^%ERKR/"NHC_ (&M*/B9* ,>%=1
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MG_"RY?\ H5M2_P"^UH_X69+_ -"MJ7_?2T6 [(D49'J*XW_A9<O_ $*VH_\
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M*%<#.<_7WKTC_A;?AK_G]_0?XURW[,-O%<? KPH9(D;_ $;^[[]:]2&FVO\
MS[Q_]\UOCO\ >JM_YG^9RY=_N5&W\L?R1R__  MOPU_S^'\A_C2?\+=\-?\
M/X?R'^-=5_9UK_SPC_[YH_LZU_YX1_\ ?-<6AZ!RO_"W/#?_ #]G\A_C0?BU
MX;[W9_(<_K74MIMJ>#;QGZJ*\1\!_M1?#OQIX_O?" F@TO689V@BCN_D%PP&
M<*6 &>#QDGCWK>G0J5E*5.+:CJ_(QJ5J=)QC4E9O1>9Z)_PMKPV?^7L_D/\
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MA'_WS1_9UK_SPC_[YHT Y3_A;OAK_G\/Y#_&E'Q;\-MG%X>/8?XUU7]G6O\
MSPC_ .^:0Z=:D\V\?UVBC0-3AV^*_A<NX^TR,IZJ54K^6:!\6?#(X%U*!C&
MJX'ICGBNBOIM/TY))KLV-E;H0/-N"J+GZD@=Z=;K;7<*36T5M=6\@W)-  Z,
M#W!'!H YP_%KPR<9NI&P<C<BG!]N:3_A;/A@'*W4B\Y.U%&3[\UTJVZ,K'[)
M#@=3Y=$D4$"&2:WMX85&6DD4*H'U- ',R_%?PK-')'+,TB2*4=6C7YU/4'GF
MLN'QE\/H8I(X[**-9#EML" G]?85W7D0L@=;:%XS]UU3((]C2M;1HN3:0@>I
MCHT Y=OBMX7<DFYF!_W5_P :0_%3PM_S]2_]\K_C74&&)>MK ,]C'2&* ?\
M+M#_ -\4P.;A^*WA<3(PNY,CU _QJ_\ \+8\-8S]L_0?XULV\,+3HIMH0#Z)
M0^H:!'>?96O-/6ZSM\AID#Y]-N<TM ,0?%GPT.?M?/T'^-*/BUX:'_+X?R'^
M-=#?R:3I4(EO9;2SB8[0\[JBD^F3]/TI+F;2+.!)YY;."%QE9)'558>Q-&@:
MG/\ _"V/#1.?MI!^@_QH_P"%L^&A_P OA_(?XUT5B=*U2'SK-[6[ASCS(&5U
MS]15G^SK7_GA'_WS1H&IR@^+?AH?\OAS]!_C2'XL^&3_ ,O9/U _QKK/[.M?
M^>$?_?-']G6V?^/>/_OFC0-3E!\6_#0Y^V$?@/\ &H;KXN>&EV$W;MCGY0/\
M:['^S[;_ )X1_P#?(JO<Z?; H/LT1!..5%&@:GR]XG^ ?PN\:>)M2\07&HZD
MMWJ4S3R".3 W$DG^+WK-'[+WPHZ_VGJQ_P"VI_\ BZ\^^*GQ\^(?A_XI>*M)
MT_71;V%G>/%!"-^%0,P QO\ 05S(_:4^)Y;_ )&(8^C_ /Q=?H%+ YRZ47#$
MI*RMJ]K:=#\RJX_(O:R4\)=W=W9;WUZGM'_#+_PGQC^TM6_[^G_XN@?LP?"<
M?\Q+5A_VU/\ \77C0_:2^*&W_D8E_)__ (NG#]I'XH$?\C"OY/\ _%USU,)F
MJ^+$?B_\B5CLB?\ S!O[E_F>R?\ #,?PH'_,3U;/_78__%TX?LT?"D=-4U?_
M +_'_P"+KQT?M&_%#@?\)"I_X"__ ,74H_:)^)Q.?^$A3_OF3_XNO-J4,<OB
MJ_G_ )%K&9'TP;^Y?YGL"_LW?"M>FJ:M_P!_3_\ %T[_ (9Q^%9'_(4U7_OZ
M?_BZ\A'[0_Q-)_Y&%/\ OE__ (NI1^T)\3<'_BH(_P#OA_\ XNO-J0KKXIW-
M/KF2_P#0&_N7^9ZV/V=/A6#D:GJO'_34_P#Q=3Q_LX_"MDS_ &EJ>3W,[?\
MQ=>0#]H#XF,/^1@C_P"^'_\ BZD3]H+XEJ.==B./]A__ (NO,J-+XG<M8S)O
M^@1_<O\ ,]?_ .&<OA8/^8IJ7_?]O_BJ>/V=?A:>/[3U+_O^W_Q5>0C]H#XD
MM_S'8<?[C_\ Q=2#X^_$<C_D.0_]\/\ _%UY-6MAU\4+FJQ>4?\ 0*_N7^9Z
MW_PSU\+E7']IZC_W_;_XJF2?L]?"KS(7?4;]FAD$H!F;J.G\5>5K\>_B)M_Y
M#4)_X __ ,73'^/_ ,1HY[/&LPNK7"*R['&5/7/SUP+%8'F_AZA+%Y/;7"O[
ME_F?9MO\5O#,,*1I>$*HP,X_QJ3_ (6YX:_Y_#^0_P :Z.QM+>XM(I6MXMSJ
M&)"U/_9MK_S[Q_\ ?-?1JUC] 1RO_"W/#7_/X?R'^-+_ ,+;\-?\_A_(?XUU
M/]FVO_/O'_WS1_9UK_SPC_[YIZ <L/BWX;/_ "^'\A_C6:WQ4\+[C_I<F<]E
M7_&N[.FVO_/O'_WS66\,&YA]EAQ[I0!S'_"U/"__ #]R_P#?*_XT?\+3\+G_
M )>I?^^5_P :Z?R8?^?:#_OW1Y,/_/M!_P!^Z+@<Q_PM/PO_ ,_4O_?*_P"-
M)_PM+PM_S]2_]\K_ (UTYCAS_P >T/\ WQ2^3!_SZP?]\4: <N/BEX6_Y^I?
M^^5_QI?^%I^%A_R]R_\ ?*_XUT_E0CI;0?\ ?% BA_Y]H/\ OB@1S'_"T_"W
M_/W+_P!\K_C2?\+4\+][J7_OE?\ &NF\J'/_ !ZP?]\4[RH>]M!_WQ3'8YNW
M^*WA=901=R _[07_ !J]_P +;\-_\_A_(?XUMVUO!),%-O"![)BK_P#9]MG_
M %$?_?-+0#E?^%N>&O\ G\/Y#_&C_A;?AK_G\/Y#_&NJ_LZU_P">$?\ WS1_
M9UK_ ,\(_P#OFC0-3EO^%M^&O^?P_D/\:3_A;?AK_G\/Y#_&NJ_LZU_YX1_]
M\T?V=:_\\(_^^:- .5_X6YX:_P"?P_D/\:/^%N>&O^?P_D/\:ZK^SK7_ )X1
M_P#?-']G6O\ SPC_ .^:- U.5_X6[X:_Y_#^0_QH'Q<\-?\ /Y^@_P :ZK^S
MK7_GA'_WS2?V=:\_Z/'_ -\BC0-3CKWXK>&6*AKQC_N@?XU5_P"%I^%@?^/J
M7/\ NK_C78WEE;P;=MM%@^JU6\F'_GV@_P"_=&@'+_\ "T_"_P#S]R_]\K_C
M1_PM/PN#_P ?<O\ WRO^-=.8H?\ GV@/_ *7R8<_\>T'_?N@#F/^%I^%_P#G
MZE_[Y7_&D_X6EX6_Y^I?^^5_QKJ/)A_Y]H/^_='DP_\ /M!_W[H Y@?%/PL/
M^7J7_OE?\:7_ (6GX7_Y^Y?^^5_QKIC%#_S[0?\ ?%)Y4/\ SZP?]\4: <S_
M ,+4\+_\_<O_ 'RO^-(?BIX7YS=R_P#?*_XUTXBA/_+M!_WQ1Y4//^C0?]\4
M 8MO\6?#*1 "[; ]0/\ &I?^%N^&O^?P_D/\:Z2UL+:2(,;>+/LM3?V;:_\
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M;7-KIANK>QCB %U+EQSQTP!QD=*HR^*M5UC3[JVEG:_@U'37N;N!%VFTG#H
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M_C0,T**SO^$FT/\ Z#=G_P!_!_C0?$VA#_F-V?\ W\'^-,#1HK._X2;0L?\
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M:0^)M"X_XG=G_P!_!_C2$:-%9X\2:$!_R&[/_OX/\:/^$ET/K_;5GC_KH/\
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M_P#" Z!_T#8_^^F_QJY:?Z]:U/6BX&!_P@/A_P#Z!L?_ 'TW^-'_  @/A_\
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MM)!;F^#!O,W#D@Y!/T/-:!T[2&N?M&RW\[=OW[AG.,9Z^E8'_"JM&Z^9??\
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M^52Q^%O#\-A/:1101Q3@!]KCYL=*S_\ A5&C8^_>Y_Z_I_\ XNC_ (51H_\
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M_<:-Q_T]I_\ '*F7]E/XH*>;?1O_  *3_P".5V7_  UAX$ .?#GB(9]+AO\
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M?[;;_P#/>/\ [[%<=!\+M%N(5D66^VL,C_39A_[/4O\ PJG1O^>E]_X'3_\
MQ=?1JUC[Y;'6_;;?_GO%_P!]BC[;;_\ />+_ +[%<E_PJG1O^>E]_P"!\_\
M\71_PJG1O^>E]_X'S_\ Q=/0#K?MD'_/>/\ [[%9;[2S$21')[2#_&L;_A5.
MC=I+X?\ ;]/_ /%UG-\,M&#$?:=2'/\ S^3?_'*- .JP/^>D7_?Q?\:,#_GI
M%_W\7_&N5_X5EHO_ #\ZG_X&3?\ QRC_ (5GHO\ S\ZE_P"!DW_QRC0#J0H
M_P!9%_W\'^-& #_K8O\ OX*Y;_A66C?\_.I_^!DW_P <I/\ A6>BX_X^=2_\
M#)O_ (Y1H!U>!_STB_[^+_C28'_/2+_OX/\ &N6_X5CHQ_Y>M2'_ &^3?_'*
M3_A6.C?\_6I?^!DW_P 71H!U(QC_ %D.?^NB_P"-* #_ ,M8C_VT7_&N5'PR
MT7_GXU+_ ,#)O_CE'_"LM&'2YU(?]ODW_P <IZ =?;,D<REI8@/^N@_QJ_\
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MR2_\!?\ D82D^M2*?>M]/A9XZQ_R+-Q_WVG_ ,54@^%7CH8_XIJX_P"^T_\
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M>GX>^)_^AYN/_ 5O_CM'_"O?$_\ T/-Q_P" K?\ QVO0J*=Q'GO_  KWQ/\
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MWB#_ *'VX_\  =O_ (]2IX#\1.V%\>7)/H+=O_CM=?CW%2V>?M(P,\=/ZT7
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M_P S]<?^ [?_ !ZC_A!O$!_YGVX_\!V_^/5V'XTAY_\ U4KC./\ ^$&\0_\
M0^W'_@.W_P =I?\ A!O$(_YGVY_\!W_^/5U^T>U&,=\4[B.23P%XC=\+X\N&
M/I]F;_X]4W_"OO$_3_A.+CZ_9F_^.UUMID3KS6M2N!Y[_P *]\3_ /0\7'_@
M,W_QVC_A7OB?_H>+C_P&;_X[7H5%%QGGO_"O?$^?^1XN/_ 9O_CM'_"O?$__
M $/%Q_X#-_\ ':]"HHN!Y[_PK[Q/_P!#Q<?^ S?_ !VC_A7OB?\ Z'BX_P#
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M_P#':=_PKSQ/_P!#S<?^ S?_ !VN[LO]0*L4KC//1\/?$_\ T/%Q_P" S?\
MQVC_ (5[XG_Z'BX_\!F_^.UZ%11<#SW_ (5[XG_Z'BX_\!F_^.T?\*]\3_\
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M_H*C^'_R1\,*9\\6<_\ WR/\:E3S\?\ 'G/_ -\C_&ON7_A:EF.?^$C\,?\
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MZ!^E?K_\<I/M_CW_ *!VE_K_ /'*+ =O17$?;_'O_0/TK]?_ (Y1]O\ 'O\
MT#]*_7_XY18#MZ3O7%?;_'G_ $#]*_7_ ..4GV[QYVT_2_U_^.46 ZG4A]PX
MJE7.W%YX]?;_ *%I:?B?_CE1?:?'W_/KI?Y__;*!'3TE<S]J\??\^NE_F?\
MXY1]J\??\^NE_F?_ (Y0!T_'^32=:YG[5X^_Y]=+_,__ !R@W/CXC_CUTO\
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MT:\\0:S<J-9GN7;[+:$D%(>2(PW/KC&* -GP7XSMO&NFRW5O%+ T,K0RQ2@
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ML2(8NV>GS9+=O2N\Q33ON@::=F<+_P )AXF_Z%M_^^E_^+H_X3#Q-_T+;_\
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M)P 3G@YKI_MT SF51@!CD] >A_44 <7_ ,)AXE_Z%M_^^E_^+I?^$O\ $O\
MT+;?]]+_ /%UVCWD"+&6E4"0X3)^\?:L7Q+X[TCPI&K7\Y1F( C7!8^^">E
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M77H)%07&04Y/WNQ]C2N!XI?^#-,UF]GOK[P'82WEPQ>61Y<,S'DD_O/>H/\
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MT?\ "8>)O^A;?_OI?_BZ[NB@#A/^$P\3?]"V_P#WVO\ \71_PF'B7'_(MO\
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M@P/]Z('_ -FI'^+?A\J!]GU *.N(AS_X]19@=4Q^<]^>M%<B/BMX>[0:B/\
MMD/_ (JE_P"%K>'\_P#'OJ.?^N(_^*HL!UM2VAQ< >U<;_PM7P__ ,\-0_[\
MC_XJGP_%GP_'+E;;4"W3F(?_ !5%@.-C\+ZQ8Z)J7@^?36NKJ\O/,AU-BI!B
M9@"Q(.00%)QQUZ5/<_"[5[S6EDG2>:+?''(ZSJH>)8<8QG^\!^5=M_PN#1<_
M\>NH?]^5_P#BJ/\ A<&B_P#/K?\ _?E?_BJ+#.27P'KUU>WJWEN7MK.S5-+7
MS5^20 \\-DG(7K3=5\"^*?%1LUU)WLY8X&_TNW:+>&^;Y<'<,$8'3OU%=?\
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M_P"%P:+_ ,^VH?\ ?E?_ (JBS [JBN%_X7!HO_/MJ'_?E?\ XJC_ (7!HO\
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M5#10(F^V2_WLTOVR7^]4%% $WVR7^]2_;)?[U044 3_;)?[U(;R4_P 50T4
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MB+X:!./$&G#G)Q.G_P 53AX;T8#_ ) ]ICU"4H\-Z*03_9-FHQ]YDP /<T:
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MR1X54_\ )58_^_$?_P ?KC1^U9XP&/\ B2:-_P" _P#]>IA^U-XN/71='_\
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M_P! >T_[XH_X1K1/^@1:?]\4: 4V\=>%V_YF"Q_[_I_\50/'?A8#'_"06/\
MW_3_ .*JV?#6B?\ 0'M/^^*/^$:T0_\ ,'M/^^*- (8/'OA=)0?^$@L#[&XC
M'_LU7_\ A8OAC_H/:=_X%1_XU%;>%]$>8#^R+4>^RKW_  ANA_\ 0+MO^^!1
MH!6_X6-X8_Z#VG?^!4?^-'_"QO#'_0>T[_P*C_QJU_PAVB?] NV_[XH_X0[1
M/^@7;?\ ?%&@:E7_ (6-X8_Z#VG?^!4?^-'_  L;PQ_T'M._\"H_\:M?\(=H
MG_0+MO\ OBC_ (0[1/\ H%VW_?%&@:E3_A8WAG_H.Z=_X%1__%4?\+&\,?\
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MP3T[BO0-1^'?@O5='U32KK3;&73]3F6>\@,A ED4J0V0<@_(O3'2M7PGX?\
M#O@?1X]*T*&UTZPC.5@BDR!^))- '15R7Q1TN#6OA_KMC=0-<6\UN5>)>K#(
MX%=+]OMB/^/F+_OL4QKVT92&GA(/8N* //OV</#]GX;^#?ARTLK.2PB,'F-!
M+]Y6)YS^0KTRJD=W9QJ%2XA51T <8I_V^V_Y^8?^^Q0!8IOK4/V^V_Y^8O\
MOL4&_M?^?B(_]M!0!YE\;M'M+[2],N9_-69;Y85:%RGR'.0<=>@K@M7UC4O
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MT%\__H;UQHR3Q7TG\1_V3_%?BSXB^(M>L=;TY;74+MIXD>1,A2S$#[WO7/\
M_#&/C4GC7=+'_ T_^+K]=H9E@HT(1=:-TE^2/Q*OE>8.M-JA)IR;Z=_4\14$
MC%2(*]K'[&7C7'_(?TK_ +[3_P"*I5_8S\:KUU[2_P#OM/\ XJN*MC\'+:JA
M++<P7_,/+\/\SQ@'I5A37LG_  QQXTQ_R'M+S_OI_P#%5*G['OC->NNZ8?\
M@:?_ !5>)6Q6'EM41T1R['W_ -WE^'^9XXIYZU,HXKV)?V0?&(/_ "&]+_[[
M7_XJI#^R+XQ*C_B=Z7_WVO\ \57B5JE.6TCH67X[_GQ+\/\ ,\>4&GC@YKV%
M?V2/%ZCG6],S_OK_ /%5,G[(_BTKDZ[I@)[;E_\ BJ\2M'FV-%@,;_SYE^'^
M9XZAX]ZD7TKV-?V2/%8'_(=TW/\ O+_\53S^R5XK[ZYIO_?2_P#Q5>#7P]66
MT3=8#&6_@R_#_,\=3[M1W!^>S.3_ ,?*8Q]:]J7]D[Q2BX_MS3?^^E_^*J*7
M]DKQ3)-9L=?T]!%.LCA67[HSZGZ5X_U'$.7P,)X#&N+2HR_#_,^S=)_Y!EM_
MUS'\JN51L[JU@MHH_M4+;5 SO%3?VA:G_EYA_P"^Q7VRV/U):(L456^W6O\
MS\1?]_!_C2_;[;_GYA_[['^-,9.>E8LGWC]:TOM]L1_Q\P_]]C_&LQI(2Q(N
MK<\]/,7_ !H 6BF^9#G_ (^8/^_J_P"-'F0@_P#'U!_W]7_&@!3P0*6D\R'_
M )^8/^_J_P"-'F0?\_4'_?U?\:!"T4F^#_GY@_[^K_C2;X/^?F#_ +^K_C0
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M_%4#X5Z!_P \KG_P*D_QKKZ*+C.0_P"%6:!G_57/_@5)_C1_PJO0,_ZJY_\
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M\51_PJS0/^>5S_X%2?\ Q5=?12N!R'_"J] _YY7/_@7)_C2?\*KT#_GE<_\
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M&?E':LG_ (5?X<*WL;V >UO(_)EMO,8+LSG ^;UJE+\.+E9LMXMOU/\ =/\
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M2L#G<5SCKZ"M?_A$-(^U_:1; 2AQ(")& !"[1QGTK"_X5M?-G/BG4,].I_\
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M4+#==!R6*YSMP3C'X=JQ_P#A6]\2"?%&H#\__BJ3_A6UZ1C_ (2?4.>O)_\
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MZ&W4/\_\"I =C]G?^X?^^A1Y$G]P_F*X[_A75Q_T-NH?D?\ XJC_ (5U<?\
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M:A^1_P#BJ3_A75P?^9MO_P ?_P!J@#T&U^6( D#\:GW#U%<%#\.+PQ#;XIU
MCUR?_BJ?_P *VOL_\C3J&/Q_^*H [K</44;AZBN%'PVO?^AHU'\S_P#%4'X:
MWQ_YFG4?S/\ \50!W.X>H_.C</4?G7#?\*VOO^AHU'\S_P#%4?\ "MKW_H:-
M1_,__%4: =SN'J/SHW#U'YUPW_"M;W_H:-1_,_\ Q5'_  K6]_Z&C4?S/^-
MSN=P]1^=<K\5"#\.O$6",_8I._M5#_A6U]_T-.H_K_\ %5@_$+P)<V/P]\2-
M)X@OKC-FV YXXY]:VH?Q8>J_,Y\1_!GZ/\A?V6ACX$>%/3[-_6O6*\G_ &6O
M^2$>%>,?Z-_6O6*WQ_\ O=7_ !/\SERW_<J/^&/Y(0]#7S9\3-3UGXN?':P^
M&VF:G<:/H.E6ZZIK$ULVR:?#D")3S\I+1D]#P>:^DSP*^?\ XN?#WQ1X2^)%
MK\4O L U2]CMQ9ZMH.YD>^AR3E' ;Y@=G!4\+UKFIVN5C5*5-))M75[;VZ_\
M'R/"/B5;>(_AO\6?%^M)J^J>&[JPA-SH(FGWV&H01LY:%L[L.08,?=ZMS7TC
MXI^*.OW?P3TSQ3H&GN;B_AB:>3;N-JC.JO)M!R< L< 'ITKQOXLV?CO]K^'2
M/"$?@J\\!Z);SBYU+5]75F<#A3'"-BY/+9^89P*^B/$GPWOC\/;/0/"VKR:%
M=Z?&@M90&,3[2#MD0,-RM@@@G^+O6E5W23W.#+X.-6I*FVZ;U3=]6V[Z/MM]
MQY_\,/&5_/XRL8-/\:1^)M-NH,WEOJD)@EA?*Y,7[M <$L,<\'I6J?VDK*2X
M>*?3;G3+2Y#Q6>H3%&1I0OR@A6)')4=.]<_I7P$\9^)_%.FZCXRU72K*WTL-
M);?\([;?9I'E)'+,I7 QNXYY(K&?]F#Q?=^'M)T*XUO3!;Z;<^>M^ML3/<<J
M?GYSGY?[QZUS'O'HOP;^,<GBI+S1]6CD;6]/CEN)Y54!&C#_ "X]]KI7'+^T
MM?ZG\0K0Z)H]_J^@3Z;+,;*!$$RRH,DG<P'(8=^QJ]!\"?&/A#41J?A;Q#9"
M\NX'MM0%[;DJZGH5^8X(VI^M8_AW]G/QYX N='U3P_XJL9M5@LY+>Y6[M3Y;
MNRJ P^<]"#V[T =M<_M+:9,=.M-)T/4]6UB[0E["W1=]L1NW"3<P ("YX/<5
MEV?[02Z1:7;W5C?WFJW%XT4>FA5!@()^5F)"C!P/O=JT/AU\"=2\%^,8/$=Q
MK,=Q=W,4AU%$B*B65@P!4[C@#Y?RK.UCX&^)8;W4]0TS5;"]EN]2DO/L6HVV
MZ/8SLP!))]<9VT 97Q,^.&HW7AOPQ<V-S-X7CO=3^Q:A*R+*\2X4_*%W_P!X
M#OUK.T/XMZO:^)?$VCVFO3>)='M;$3I>20^5/"^4X4,J!OO-V/2D;]F?QE:Z
M6+NS\1:>=8&H_;TL;FV,ME$"$!55+8'"GD*.WI6E!\ /&_B'4+O4_$.MZ587
MT<>VT71K/RD8G&3+M*[AQT([T =!>_M)6FGP^?I^D:EXAT>S5?M^L6J)Y4))
MYR"RDD#DX!XKV+1-:M-?TJTU&RE$UK=1B2-QW!KY^NOV?O&F@:=?^&O"OB&R
MM?"FJY-XEQ;'S8RXVR%,-SE0...E>[>$?#=OX0\.:=H]KEH;.(1JQ[GJ3^))
M./>@#9I#3J:>M SS?XF>,=5\+WVG6VFVL"1WCD2ZA>*6AA.1@';R.I/3M5/7
MOB<^B?$/PYX<2*SNK#4HLW%ZCY,4F),#[W&2B]OXJW_'7A:Z\6PFS@OEL[=L
MI/')'YBLIZLHR/F]ZYRV^!OA^VM;J,O+-=SSQW"7KC,L!1D8;&)R!E.Q'WC3
M$0WWQ<N[#P_K&H'2XC/9ZDVGVZ<[7 #D,WS?['ZUGW/Q5\10:J?"WV"Q_P"$
MLC@:YE8AOLYB4$\<YW'8_P"E:$WP7-U9:E83:T\MA=W"W:$J0\<P4KS\W((9
MC]<4^Y^#K7%W#J?]LN/$84Q3:B8S\\;##(/FST+]_P"*@"I>_%V^C@\+7UO;
M6WV+59I+:>.56WHZ%U)!SM S&>I[BO3YHU61@O*UP=]\*(+JPM=*CO-FA0OY
MSP[,RF7))*MGY<DL?QKN!A%6-<[%4*NXY./>@!1THQBDW8//6C<#2 ,5-9C-
MT",<+4.[-2V1+78P"0!^%,#SF;XJZW=6]SX@T^UM)/#%G.(I=^[SW4$;BHSC
M.TCK6U<_&G1[>\:V6WNIG"H5:-.'9D#[![@$_D::_P )4CN[JWMK]K?0+N=;
MB?35C^4L&R0OS8 . ,8Z"M!?AAIZ:BMTDC)LE$JH!PI$>SU]*0QMU\5M,A%H
M(X9[B66,2SQ(HW6RG!R^3]>F>AK(\=_%230HH&L);,0S#?\ :IP[(HST^7G)
M(QTZD5KV_P +K"VO-5N$N)"VH0""3(Z !AUS_M&F6WPETF!X1+_I4$<1B^SS
MIO0YR<X)QD$YZ=A0 ZU^(I@T70[_ %*T-K%?1AI9BZA8\@8;&[.""2.#QUJU
MX$\<R^,CJ/FZ5=:8;2X,.+D*-^%4Y&">/F_2N?U/X'6>KBSCN]5NYK:V8E(2
MS%0F?E3&[  ' ^E=?X?\-R:%J&I3F^ENX[R8S+'+D^42 ,#)/]WVZT ;XZ4M
M-7FG4 %--.I#]: /+_B+\1+[P7XM\/Z9:Z;%>66I%C=W,O6W7#8/WA@9 '0]
M:SX_BNQ^)>MZ--;V\'A?2;(3OJ;'YG<JK#!S@CEN@]*ZOQ7X*LO%>HM<7DK!
M/LK6AB"Y!!W8;KU!;/3M7,VWP.T6/0%TBYO)[N#[']B:1P2\B[0JDDL<X Q3
M$3/\6[?=H\-OHEW->7]P(9+5-I:!./WA.[&.3T)Z=*L^(?B1%I4>O6D%H8]6
ML+<W%NDC*WG*"H.,,>[ <XI-,^&\VG:99QI?K;ZK:S;EO(E.7CP,JQR#_>[G
MK61'\"[5-8U;4[C6+J:YOXGB24EBT6YE<G);H"O\J0&A8_%FPF\.6E]=Z?<P
MZO.JJNE8 DED('W><=3CK40^*3W&KWD=F($M+>) \<X.Z"4[25;'?#9_&HD^
M#LAL;-I]<DN]>L9%EM=0D4D)M((!!8G&1ZU:C^#6F(+R62]D-U?,LEW*%P)'
M 49QNXX4#\*8&YHOC*UU[6KRPL[&<P6S&-[\@>47!(('.>H]*W<#H37,^&/!
M$OA+5;^:+4Y)M*N)GN$LF!^5V8L0?F([CMVKI>_(([X% $EL,W*>AZUP/B7X
MKZCX=\6W$#VD-QI%J$698%9K@;F(W8SC:.#^!KOK8?Z3&3SC]*JP>!]-AU?5
M=1,0DN-13RIF=03MYX!_X$?SI#.8_P"$O\7#2=6UL:7:3:<D)EL((RQFF&1@
MM\V.F>X[5CZE\;9= \.^%Y[J."ZU#7;I;1$A!VPRN4"J^2-N"XSFNFT7X?ZC
MH<5S:P:_<-9%V>VB?<?)R2=I._E1DC' QCTK,'P-TF^L)8]3E>YN)KIKXNB[
M$BG."&C7)V8(!X]!Z4",[Q1\6]9\*:A"+RSMEMD9(YQAMS,X!!0YP1AA^1KU
MY3NYK@-1^%XUN#3K#4[TWVGV3>:ID3,KODXW,2> #COT%=\O4]_>@8^BBB@
MJO<=8^?XO\:L57N3AH_][^AH _,;XUJ#\;/&^54YOGZ@?WWKCE1<\(N/]T5W
M?QGT;6)/C+XSG30M2E@EOI-DB0%E8;WY'YUQXTC6 ?\ D :H?^W8U^VX>2^K
MT]?LKKY(_ <1"?MZGNOXI='W9 %7'W$_[Y%2)&HZJA_X"*E_LK6=O_(O:K_X
M#&GII>KCD^']5'_;L:\^NUW_ !",&OLO[F-"*2,HN?\ =%6$1/[J_P#?(I!I
MNKG'_%/ZK_X#&ITT_5O^@!JW_@*:\"N_,Z(JSV?W,1%7/W%_[YJ=57'W5_[Y
M%-2QU;_H :M_X"FI19ZMC_D7]6_\!C7@5S=-+I^#'(BCJJ_D*>%7GY5_[YH%
MGJHZ^'M6Q_UZFGBRU;<?^*=U?_P%-?/8A,T4EV?W/_(557NJ_P#?(J157^ZO
MY"D2SU8?\R[J_P#X"FI5L]6S_P B[J__ ("FOG,1%LV4X]G]S_R'*JE?NK],
M5%<*IDLSL7(N4QE1ZU.MGJP )\/:O_X"G_&D.F:W=3V*)X;U9A]J0L3;D#'/
M_P!:O%=*?-HA3J1<6M?N?^1^EVE'=IML3W0?RJW573%*:?;J000@&",$5:K[
MY;(_95L%%%%,85B.!YC=>M;1Z5BO_K6^M !28HW"@'- "XHHS3=XH$+@48^E
M .102 *!AVH'2D!'6@D$4Q%BSP+A:U:R;0YN$K6H!"8HI:*0Q*6BB@!*6BB@
M I*6B@"CJ/1*I5=U'A4JCF@!<\4AQ2;AS2[@30(,#-+VHS2;J #'.:,4A?%&
M\4#%_&@]*7--+<X]J -6Q_X]UJQ5>Q&+=?Q_G5B@ HHHH *3%+10 4444 %<
MK\5/^2=>(O\ KRD_E755ROQ4_P"2<^(O^O.3^5;T/XT/5?F88C^#/T?Y'E/[
M/6E^*[SX,>&7L-9M+: P919(2Q"Y]OQKT,>'_'7_ $,5C_X#-6)^RV/^+$^%
M/^O;^M>K@8K?':8JJO[S_,Y<NUP5'_#'\D<)_P (_P".O^ACL?\ P&-(?#OC
MD_\ ,QV?X6YKO:*XKGHG #PYXW7/_%1V@_[=C22Z'XYB0M_PD%A@#)+0$8_6
MN]9L'IFOGSXF:%XT_: U:^\/:!K\W@OP?:GRKO5K4%KFZE!W;8L8PO\ J\G>
M#@MQZ[T::J2M)V75F<Y.*]U79UD6O:K/J#:>GC[P\U\H^:W1E+CZC=[UN?V!
MXY<#_BHK''J+=J_.?XV?"OQ/^R3XDM-6U+79/$&GW\C):WD,T@N"1R1*&Z'K
MT9NE?='P*^-EGX@^!5GXRUZY-K;JS1N\Q!.>,+[DE@/QKW,;E4*.'AB,-4YX
MRTVZGS^#S.O5Q,\/BJ/):[3Z-+]=?0[#_A'O'/\ T,=E_P" YI?^$>\=?]#'
M9?\ @.:@TOXT:9=6\5U?:;J&CV5Q,(+:>]1 )F()&-KGJ%8_A6IXK^*OAWP7
M<7L&K7GV>6TLVOI%./\ 5 ,3CGK\IKQ'0J\W+RZGNJO3<>;FT*7_  CWCK_H
M8[+_ ,!S1_PCWCK_ *&.R_\  <UEQ_M%>#UM+N>ZO&M#;HDC1R8RP<J$QSU)
M=<?6I+7X^:!ON(]2MK[1YH[-M1CBO40--;@ [UPY[,O7'6K^JU_Y&1]9H_S(
MT/\ A'?'7_0QV7_@,:/^$>\=?]#'9?\ @.:=I'QI\*ZYHVAZI9WYFL]8G^S6
MK #)DQG:>?<=,]:[NN><)T])JQM"<9ZQ=S@3X=\==?\ A([+_P !S2CP]XZ
MY\1V7_@.:[VBHN:'!_\ "/\ CK_H8K'_ ,!FI#X?\='_ )F*Q_\  9J[VD)Q
M1<#SJ71O':N0/$%A_P!^/_KTW^Q_'9_YC^G_ /?G_P"O5[QKXVC\)WMK:PV,
MNK:M>L?(LH",E<_>))X&2O3/6L#4?C)9:/XXTOPKJ.BWUMJ>H:;)J*.-IC78
MLS-&3N!SB ]NXIW$:)T?QY_T,%@/^V'_ ->C^Q_'><?\)#89_P"N'_UZJ1?%
MRQNM;\.:?%I-XRZV'VW(V[("K;2&^;/8],UW#+Y;%>X[T7 Y+^Q_'8_YF"P_
M[\?_ %Z7^R?'?_0>T_\ [\?_ %ZZSK12N!R?]D>.^^O:?_WX_P#KT'1_'9'_
M "']/_[\?_7KJR,T8S1<#E/['\=Y_P"0_I__ 'X_^O3HM&\=O+M_X2"P4>H@
M/^-=3CFI;/B[7Z4[@<S_ &!XZSG_ (2*Q_\  8TO_"/^.O\ H8K'_P !FJO=
M?%^"-KJ[M]+N;G1+2<6\VH(5V[MV#M&>0,@\XX-:US\5O"]E/+!<:M!#/$B2
M/$Y^90RAA^C"E<91_P"$?\=?]#'8_P#@,:/^$?\ '7_0QV/_ (#&M6[^(_AZ
MR&GF74HE_M !K?\ VP<8/ZBJ_BKXA1>';J*TBM7O+EU,A"D!0H&3SUS@'M1<
M12_X1_QU_P!#'8_^ QH_X1_QU_T,5C_X#-6AIOQ)TB^MM)DED:SEU/(MX9\!
MBP(!'!/<U+X-^(>C^.Q??V5*\ALIC!,' &&"J>Q/]X4#,K_A'_'7_0QV/_@,
M:#H'CK_H8K'_ ,!FKNP<BEI <'_PC_CK_H8['_P&-'_"/^.O^ABL?_ 8UWE(
M3@^M.X'G3Z-X[5R/^$@L#_VP_P#KTG]C^/"<?V_8?A!_]>KOB[QJOAK5K/3+
M:PEU76KX,\%K$0!M4$DL2>.%;H#TK.M?BMH']F27>K3G0[J&<VUQ;3X)20$@
MC@\C*G'2G<0_^QO'@.#X@L3[^1_]>D.C>/ ?^1@L"/\ KA_]>MF\\5Z-8:C9
MV$VI1B[NT\V&->2R<C=],J?RK/E^(FCM9ZT^G7(U&\TM29K8<$X(!Q^8I 5Q
MH_CS)_XJ"PX_Z8?_ %Z7^QO'8'/B"P_[\?\ UZOZ;XVT75-133UOXX]2, N'
MMO0<YY]L&H]+^(/AK7-7.E66LQ3:D,YM_P"(8ZFG<"I_8_COG_B?V!^L'_UZ
M#I'CL_\ ,?T__OQ_]>NCL-1M=429[.<3QPR-%(R] P)!'Y@U8QQ1<+'+1Z/X
M[9PIU_3\>OD'_&K/_"/^.O\ H8K'_P !C726P_TI!6?>^/;2Q&M%H)V_LM \
M@4+\V<\#GV[XI7 RO^$>\=9_Y&.Q_P# 8TO]@>.?^ACL?_ <UI:5\2="U6]M
M;!;Q(M2N($G%FY_>*&4, ??#"J9^+.AR^)Y-!M9?M-]"H,FW&U<DC&>N>#VH
MN!#_ ,(_XZ_Z&*Q_\!C1_P (_P".O^ACL?\ P&-;T7C;1Y#? 7L?^@@&YYXB
MR 0#_P!]#\ZSH_B3ILT]O)$P?3);9[G[;GY0%VG'UPWZ4#*7_"/^.O\ H8K'
M_P !C1_PC_CK_H8K'_P&-:L?Q(\.R:9::@NHQFVNYC!"V?OOW4>_(JY%XST6
M?7&T9-0A.J*-QM<_/CC_ !%(#GO^$?\ '7_0Q6/_ (#&HI]#\=HHV^(+$DG_
M )]R/ZUJ>%OB7HWC/7M3TO2IC<R:<$,THQM)8G&.?:NEN>L?^]_0T[@>$ZG\
M4-,T?4KK3]3^(.A0:C;.8YXI+9MR,#@@\>H-5_\ A</A\?\ -1O#X^ELW_Q-
M?'_QML;=_C;XW+0JV;^0_P#C[UQ@T^V+?ZA/IBOT.EPWAITHS=26J3Z=5Z'Y
MA5XJQ<*LH*E"R;77H['WF/C#X?//_"QM S_U[-_\32CXP^'_ /HH_A_/_7JW
M_P 37P>--M"O_'NGY5)'IEI_S[I^5<M3(</#:I+\ 7%.-?\ RZA^)]V_\+>T
M \_\+'\/_P#@,W_Q- ^+F@GI\1O#_P#X#-_\37PO_9EI@?Z.GY5833+0$?Z/
M'^0KS:F648;2?X&BXFQK_P"7</Q/N+_A;.B'_FHOA\_]NS?_ !-+_P +8T7/
M_)1?#_\ X#-_A7Q$FFV@Z6\8_P" BIETRSV\V\>?I7EU,-"&S9JN(\8_^7</
MQ/M<_%;1^?\ BX?A\_\ ;N?\*FC^*FCE!GXA^'L^\!_PKXG33;0 ?Z-'GZ"G
M_P!F6AQ_HT?_ 'R*\NK)0V*7$6,?_+N'XGVQ_P +2T?''Q"\/_\ ?D_X4O\
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MM)\=CIKVG_\ ?C_Z]!TCQU_T'M/_ ._!_P :ZL#'?-+1<#DQI'CK'_(?T_\
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M) UA<ZI;+IL,JRV\D=N1+P?XCO.>@["N@_X2GQM_T*L7_?\ '^-'_"4^-_\
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M5? +MZ#^=,#F(?B? )5/]AZB,=_*S5[_ (6G;D9_LG4O^_'_ ->NC@=C<JC
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M3)\3/&:C'_"37_\ WV/\*\RHU'?4M9IE[_YA/_23Z=7X*?#P9QX*U#_OPO\
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M_P!^/_KUG/\ $^W+$G0]1Y/7RL?UKT?R8_[B_E62SD,PXX/H* ../Q,MP/\
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MJ0?] G4?^_/_ ->NV\F/^XOY4>3'_<7\J .)_P"%J6__ $"=1_[\_P#UZ/\
MA:EO_P! G4O^_/\ ]>NV\F/^XOY4>3'_ '%_*@#B?^%J6_\ T"=2_P"_'_UZ
M/^%J6_\ T"=2_P"_'_UZ[;R8_P"XOY4>3'_<7\J .)_X6I;_ /0)U+_OQ_\
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M2/GM5(QQUIZ@@D8KZ%'[-OPX4?\ (Q:L3[(?_B*L1?LV?#9E)/B#53GUX_\
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M_P!^'_PH WZ*P/\ A87AS_G]E_[\/_A0?B%X<'_+[+_WX?\ PHL!OT=JP/\
MA87AL_\ +[+_ -^'_P */^%A^&L'_3)?^_#_ .%%@.RLN+=<U8KD;?XD^'EC
M 6\? ]86_P *D_X6;X?_ .?QO^_3?X4#.JHKEO\ A9?A_P#Y_&_[]-_A1_PL
MSP^/^7QO^_3?X46 ZFBN5_X6;X?_ .?QO^_3?X4O_"R_#_\ S^-_WZ;_  HL
M!U-%<M_PLOP__P _C?\ ?IO\*/\ A9GA_P#Y_&_[]-_A18#J,UROQ4/_ !;G
MQ%_UY2?RI1\3?#Y/_'VW_?IO\*YWXC>/=&U#X?>(DMYWFD^R.H01MEB>!@8]
MZVH?Q8>J_,PKZT9^C_(]!72+%%"K96ZJ.@$2@?RILFDV9Z6D'_?L?X5=KSG]
MH+XE_P#"H_A+K_B9$$MU:QJEO"'VM+([A0%X.2 2V #PIK W.X.DV9/-I!_W
MZ7G]*3^R[('_ (\X,]QY8_PKX"^#'[6_CK0_A7?:'JKWGB'XB2ZC%%8RZM&T
M.Y9ODVX8,=J,H)/^WV[[>J_MF^)M%:>\FTNZ?7K6WCLIM-1F,#7#S*H<'9C
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M\;?'MCIUI:7&DVCZYJ<N+,I(/+1%4LQ?Y<9^4C\:0SZ#_LJR_P"?2 ?6)?\
M"D.E6>>+.#_OTO\ A7S3XQ^-/B76=$TF'3+:_@U:>QFFFMM,5WFDD1%.V,*N
M>22.!W%64^/.M^&?!?AGRYH?$NMW=T;6_LI)!'=V08/M,B89N#L/(7@T ?1H
MTRRQ_P >D YY_=C_  H_LNSZ_9(/7_5+_A7DG@3QSK-YX"\8WGC/6[/3S87U
MW E]:NJ^3$C. 2<C! 'KVKS^?Q9XN35%L+CQF;/1Y+6/4M+U#&Y[O]ZP$+'>
M-Q;R]N,G[_0]P#Z<.F61X^R0?]^E_P *!IMFPS]C@]OW:_X5XEH'C&[L/B7X
MAMM<\4^7I']APWSP2RB-K*0K!DY+<9WL>@ZUK_"G4O%%AX0CN=4UB+Q&95GN
M[9PX,UQ%Y8,8498G)!Z9ZT >J_V99?\ /I!_WZ6E.EV7/^B0?]^Q_A7S!I?C
MOQ+>^%6\8/XMF&MQW<X7PD%^>54E>,)LWY'RJ'SL/T[UL:7\=?'=]-IEU+HM
MM;Z=,L%S<Q&7+QQ2')7[@^8 &@#Z'.F67_/G 1_UR7_"D_LNS!_X](#G_IF/
M\*\.TKXW^(/^$C>'5]-2+1KX3"QD@;=)&4A:3+#;ZQL.W45YJWQ<\=CP5J>G
MR:S<#7_$^H2IX=N4@8BTM\L-SG/&W?%Z4"V/KO\ LNSYS:0'T_=+_A2G2[+
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MF:O'_IRRR"(:5<#'[K<7^4G+\';]SIQP ?1 TRR[6D&/^N8H_LRR)_X](/\
MOV*^7K[Q)X[T+20=1\7 ZUI++):6L+9&L1,0!CYOF(PW0-UKZ>T6YFO=(L;B
MX0QSRP)(Z$8VL5!(_G0!*NEV6/\ CT@_[]#_  I?[+LO^?2#_OTO^%60<BEH
M J_V79?\^D'_ 'Z7_"C^R[+_ )](/^_2_P"%6J* *O\ 9=E_SZ0?]^E_PH_L
MNR_Y](/^_2_X5:HH J_V79?\^D'_ 'Z7_"C^R[+_ )](/^_2_P"%6J* *O\
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MX5:HH J_V79?\^D'_?I?\*/[+LO^?2#_ +]+_A5JB@"K_9=E_P ^D'_?I?\
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MP%=2X(Q]TJ",<]:8M69OBKQM\)_%5AX9N]72+4(?$LWDZ>[6L^96VD\X4%>
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M*P."-Q^\>* /;-;E\&ZG8745XUC<)>0^9)#YF'F0'J "">5[>E9TDO@3Q5X
MTJWOT@'AYX(FM;:Z=D*HJKM[AN 17GVN?L^F]^(L5V;=_L;Z=';PW=O,T9L7
M5 &"*!C#%68\CF0_C->?LZZCJ=WHOVZ_BN[&PT=M/-L^=IE\I$$@7IG*DYH
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M)98Q$V 0QE957J>%^<<#WXH R/$/QXU235?#VD>%]/L]4U/5HI2=YW1P2(S
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M8'9&*ATXX91PWW1C/3%,T7P/HV@V7V2UL4: ,SJL_P"\V%@ P&[. <#@<<4
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M(M)=-M<Q1QQ!OM1E&!EEWYV9R<[1P1S7J4?PST"+1TTS[$7M4N!<QAY&9HI
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MRSSD@^6?3M3_  7^R_I&F^%X+22P$#+;21K#>A9C;W!7"S1D  $-AOP'-%%
M'.ZG^S#JFH^'GT.!Y-/M=PEU*>)U\S5\,"$)!^4<)][=]RM>W_9X?P_J?@2]
M\*:0=+;1V,DPNY4D,:$QEH<@+G[H (X^7I113%8^C82[1@R#:Q'(J0# HHI#
M%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>ahpa-20220416xs4024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xs4024.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'F Y # 2(  A$! Q$!_\0
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M6X_V\?B-& #I/AY_=H)__CU?.F.*6LGE& >]%&RXDS9;8B7WGT>/V^?B*/\
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MOR4V#^])_P!_&_QIP9\8$TP]/WK?XU#X:A_S]_#_ ()K_P 1&J?] R_\"_\
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M?#IXSU;_ +_FH?#M7I47XG1'Q$P?VJ$OO1^J(ZT=Z_+./XT_$&-2%\9:H?\
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MG2-$:261@B1H,EF/  %)7NO[&7@[3_%GQ@CN-1A%Q'IL1FBB8X7S,/AB.^"
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MWX1:MX]AUBRMX;$2N+*4X+I&F]N>S$< 8Y]:\OC=9$!4YYYKW/P!\'M!UO\
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M#\\'"M+PQH<OBGQ3HFA6[;)M3O8;-7(SL\QU3=^&[-9@KZ!_8F\ OXI^+/\
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MP)+HUO-<1I$(VW6PBF**2<G'!YX'0=*K>$?'H\*_M=>+/"]U/&FDZ\@9?,;
M646X/!Z<B/'Y5E=-;]3W?[)R^KEU'#4YV4JSCSN*YD^5I+?:]NO78^/]*TJ^
MUV[^R:79RW]UMW&*%<L .I_45#+&T,C1NI5U.&4]0:^R?ACX2N/V>;/XL^*]
M7LA;N+AY-,:4!1,F96"J??Y>!Z"OC(/),6EF=GED;<[,<DGWJ=5N?!YIE/\
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M\SU'X4_M!>*? 'C>RU?5=8O=8TQ2RW-I(5.]2#TR.,'![=*]$T']H_P?X?\
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M25OE+3\['U63-5\+B\'+K#G7K#7_ -)YCYP-%-0[T4X[4X FO5/D]A>WX4$
MC!Z'K2T4A7/;/@Q^U!J7PNT$^&]5TY-?\.@,(82%#0AF+,.VX$LQY)_*K7C;
MXY^ K[PIJFE>%? 4>DWM^J_Z8RJ/+=3E6'S'H>:\)HQBO,E@*#J.HE9O5V;5
MWYH^BAG^/AAUAG).*32NDVD]+)M-I'T1?_M0>&/$WAK01XH\#G7/$6BJJV[O
M.R09 QOPK#J.<%3@_2LGXD?M*0?$#Q[X&\3?V&]H?#EU]IEA\S)F^>%L#GMY
M1_.O#L4<BLXY?AX2YDN_5Z7WL75XCS"M3=*<U9\M_=5WRVLV[7;TZL]>\4_'
M>V\1?'/2?B ND21P6"%#9N_S291USD' ^_Z]JU?$7[4%S<_&.Q\>Z)I1M3%;
M?9+FUG8$W$65.W/.W[O4>M>&#K2\T_J-#3W=ER_(R>?YA:252W-/GV7Q=]M#
MZ>;]K;PCIOBU?$ND_#X+K-PFV\OI) L@X(^4!B.F!GBN2TC]HZUTW]H+5OB.
MVCS-;W]F+06:L-ZX2-=W7'_+/U[UX?1SFLHY=AXIV6ZMN]C>IQ-F55Q;DERR
MYU:,5[VNNBUO=WON>R?#W]HF;P#\1O$&M1Z69O#^N2.]QI88$H6(RP)ZG Z9
MQ7?>'OVO/"G@K6+]O#O@+[#97A,TTZ2#SI)203D%B .O0^G%?+PZ48X%*IE^
M'JN\EOIN^A&%XES+!Q4*4UHVU>*=K[VNM$^RL>V_#']H33_".F>*O#VOZ%)J
M?A77;B>X-M ^V1!*-K(6W X*A1G.1S6AK'[3.B7/PIU;P'H_@TZ)I<\9BM1'
M.9-BF3>68LQ8G.3U/6O!**)8&A*7.UU3W>ZZV(I\0YA3H^PC)6M*/PQORRW5
M[7M?6USW/X-?M&Z;X&^'MQX+\5Z$VN:22WE&+;RC+M*,"1Z=>OS'TJE\//VA
M+3P5!KWAZ\\/G4? >IRNT6FB0B2W1L?+NSD]"?O=3UKQ@#F@@YJ7@J+<G;XM
M?GW\F*'$&805**FOW::6B^%[Q>FJ\GH>H>//'?PXOK#3[7P;X&DTOR+U+N>6
M\NI)/-10<Q8:1N#G]/>N]T#]HGX<^!9Y==\,^ +BP\42Q&)F%RP@Z8^YYA4?
M@M?.0^E*WOQ2E@Z<XJ$FVO5Z^O<FEGN*H576I1@I.UK0CI;9QTT?FC6\5^)+
MKQGXIU37[_:+S49VG=4  7)X4?08'X5DGK2CH*.?2NE144HK8\"I4G6FZDW=
MMW;\V-[THZ4=^E*. 30S,2D/2E*D4G8UFQB <9IU(!G%/(/%8O0! >*:0<Y[
M4X<]J3D5DQ"#@$=: .3[4Y1@48].:Q8'HW[./BA?!_QK\.7DA)BN9#9,N,Y\
MQ2@_5A57X]^&8_!_QG\3Z7"NR%94F7G/,D22'K[N:XK3M2ET75=/U.'_ %ME
M<QW"?56!'\J^@OVR=%\_5?"?BR*,M'JEA&MQ,HROF;1M&?7 /Y5YLVH8A/NK
M?U^)]=AT\5D5:"U=*<9?*2<7;YJ+/G4G.**5EQ]:2NH^11O_  _\6MX#\;:/
MXC%M]M.G3"7[/NQO_&NF^(_QJO\ QO\ %"R\;Z;;?V)J-DBI" 0QP-P.>W(8
MBO.CS[4A!)KFE2A*7,UJ>E2S'$T</]5ISM#F4M-[K2]]_P 3W'Q5^T[!XI\8
M^%O%<GA-(];T5@6E\\@3#@D<'ID=QWI=+^,'B?Q]^T)9>+/!^BHNK)9M$^E2
MR+_I,2^8SC<> <,<<_PBO"^:T?#^OZEX4UFWU?1[N2PU.W)\JXB^\N5*G\P2
M/QKCEAX6]U'M0XAQE2JGB*CY7*,I<JBG=65UIO;ON]S[F^&'B7Q)XM^(<NIW
M/PVM/"403&H:Q<.AFD(P/+7!/!()SQ]VO#=2_:!LO /[0_BSQ/I=DNNV%UBW
M5T;9DKNY7/;YN_I7FVO?'CXB>)]/>QU'Q3>26C_>2(^7N^I7!K@E4)A5&!Z5
MRQPW\Y[>8<5RE"G#!.7-&7.Y244[VMHHZ6[[ML]5\%?'=O!OQCU[QZ-'^UC5
ME=#9^9@Q F,YSW/[L?G4/A?X[7OA+XRZIX^M-.1EU)W,^GENB,V<!O49KS+!
M/M2$$UI[&'8^76=X]<MJGPR<UHOB>[V_#8]&^-GQ6TSXMZO;:C8^'(] N5!^
MTS*1ON#@ 9QQP *O? SXXP_!!=9EBT'^U-1U (%N3+M\L*'P,9]7]*\K'W>:
M6LG35N4B.<8N&.>80DE5?6RZJVUK?U<T!XEU=?$HUY=1N/[2%P+D2;_XO3'3
M&.,=*]>\:?M-#QMXN\%>)+GPYY>I>')1*S>;Q/RI8#!P,E?2O$,'TI1UJ)03
MU,L/FF+PL)TZ4])--]=8NZ>O6_W]3U;Q9\>7\3_&O2?B&-&$+:=#Y"V#2?ZP
M;9!DGM_K3_WS5?QY\=M0\6?%S3O'VFV0TJ]L%01PN0^[  .<Y'.*\Q(.:#R.
ME8>RBCHJ9YCZL91E4^*7.]$O>76]M#V_XJ?M(Z=\3)]&O_\ A#8K/6M-N8KA
M;XR?.51P^S(/(.".>F<U1\;?M%R>,OB=X.\9G0_L[^'45?L9DSYQ#%CS^->/
M8HK)P1I6X@S"O*4IS5Y.+>B5W'9Z+_ASZ8N?VS=/U;7[;5]3^'EI<WUD2;.Z
M\P-+'^)Z=J\J\1_'GQ3KOQ3A\>03+8:E;*([:W"JZ1QA<%#D<YY/([\=J\\.
M:2HY2L5Q#F6,BHU:NTN;1)/F6SNDG==#Z43]L32WU?\ MZ3X>6I\3^5Y?V\.
M.O;GKC/M7F/A_P".WB30OBS>>/FD2YU"\)2ZM2JJDD/&(Q\O&-J<CGY>>IKS
ME0<CK3^<UDXAB.(<RQ,H2G5LX/F5DE[W\SLM7YL^E;?]LNQTCQ#)JND^ ;:V
MN+TYU"?>!-,<Y!!_%_3.17GLL7C#X^?%M_&/A+1FM9TN8P2)%VVY55!+;CSP
M?0]:\JZ'-=-X.^)_BOX=QW,?AK6)=+CNCNE5%!W-@#//0X _*N>2;LF=JX@K
M8Z4:693E[)/FM!13OW6W?[]3Z+_;;^([-I.A>"DN4FOB4NM2\H_=94  /'0[
MR?\ @-?)A&:LZCJ-WK-_/?ZA<R7E]<-OEN)F+,Y]2:K8H>NK/-SK-)9OC9XJ
M2LGHEV2V_P WYMAC%-IP_2@\YK!GA#:<.E(!2@<5# ;2T8_*C%8,8E%+CUHQ
M4,  W J>A&*^XOV&?'C:YX$U#PW,<2Z+*#'GJT<C.V?P(Q^5?#HZ5[3^R'XQ
M/A#XT6T+9\C6;9K)LMA5.Y'#'Z;"/QITI\E5/Y'V/"6/> S>DV[1G[K^>WXV
M?R/T4HHHKW3^I HHHH **** "OGW]J/X->$/B+/HFH^(M=ET"\BS;0RQ+N,R
MY+;<!&/&YC^)KZ"KS7Q7:V^O_%OPW8W%O%<QV4#WA2:,.H+),@.#T/'6O1R^
MK.C7]K"37*F]/0\;-J%/$X;V-2*ES.*L[VW6NEGIZGRT?V5/A\I(_P"$\OQC
MUM7_ /C-'_#*OP^_Z'V^_P# 5_\ XS7V^=!TQN3IUH3WS O^%+_8&E_] VT_
M[\+_ (5[7^L&(_GE_P"2_P#R)\[_ *IX+_GU#[I?_)GP^/V5?A]_T/M]_P"
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M_)?_ )$/]4L#_P ^H?\ DW_R1\1_\,L?#_\ Z'R^_P# 5_\ XS1_PRS\/O\
MH?+[_P !7_\ C-?;O]@:7_T#;3_OPO\ A2?\(_I?_0-L_P#OPO\ A1_;U?\
MGE_Y+_\ (A_JE@?^?4/_ ";_ .2/B+_AE?X??]#Y??\ @*__ ,9H_P"&5OAY
M_P!#[?\ _@*__P 9K[>_L#2_^@;:?]^%_P *3^P-+_Z!MG_WX7_"C^W:[^W+
M[X__ "(_]4L%_P ^H?=+_P"2/B/_ (97^'G_ $/E_P#^ K__ !FC_AECX?#_
M )GR^_\  5__ (S7V[_8&E_] VT_[\+_ (4?V!I?_0-M/^_"_P"%+^W*_P#/
M+[X__(A_JE@?^?4/_)O_ )(^(_\ AECX>_\ 0^7W_@*__P 9I/\ AEGX??\
M0^7W_@*__P 9K[<_X1_2_P#H&V?_ 'X7_"C^P-+_ .@=9_\ ?A?\*7]N5OYY
M??'_ .1%_JE@?^?4/NE_\D?$8_9:^'V?^1\OO_ 5_P#XS1_PRS\/O^A\OO\
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M_P#X"O\ _&:#^R[\/<?\CY?_ /@*_P#\9K[8_L'3/^@;:?\ ?A/\*/[ TO\
MZ!MI_P!^%_PH_MFK_-+[X_\ R(?ZHX'_ )]0^Z7_ ,D?$X_9=^'F/^1[OS_V
MZO\ _&:/^&7?A[U_X3N__P# 5_\ XS7VS_8&E_\ 0-M/^_"_X4G_  C^E_\
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M+_Z!MI_WX7_"C^TY?S2^]?\ R(?ZH8#_ )\P^Z7_ ,D?%P_9F^'8_P"9ZO\
M_P !G_\ C-'_  S+\.Q_S/5__P" S_\ QFOM'_A']+_Z!MI_WX7_  H_L'2_
M^@=:?]^%_P *7]IOO+[U_P#(A_JA@/\ GS#[I?\ R1\6_P##,OP\S_R/5_\
M^ S_ /QFC_AF7X>?]#U?_P#@,_\ \9K[2_L#2_\ H'6G_?A?\*/[ TO_ *!M
MI_WX7_"E_:3[R^]?_(A_JA@/^?,/NE_\D?%O_#,OP]S_ ,CU?_\ @,__ ,9I
M/^&9/AZ?^9ZO\?\ 7L__ ,9K[3_X1_2_^@;9_P#?A?\ "C^P-+_Z!MI_WX7_
M  H_M'SE]Z_^1#_5# ?\^H?=+_Y(^+/^&8_AY_T/5_\ ^ S_ /QFG']F;X>D
M?\CU?_\ @,__ ,9K[1_L'2_^@=:?]^$_PH_L#2_^@=9_]^%_PJ?[0\Y?>O\
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MLOO7^0?ZI8#_ )\P^Z7_ ,D?%?\ PS'\._\ H>=1_P# 9O\ XS1_PS'\.O\
MH>M1_P# 9O\ XS7VH= TO_H&VG_?A?\ "C^P-,_Z!MI_WX3_  I>SP?\LOO7
M^0?ZI8'_ )\P^Z7_ ,D?%?\ PS'\.O\ H>=1_P# 9O\ XS1_PS%\._\ H>M1
M'_;LW_QFOM7^P-+_ .@;:?\ ?A?\*/[ TO\ Z!MI_P!^%_PJ?8X-_9E_X$O\
M@_U2P/\ SYA]TO\ Y(^*O^&8OASW\<ZC_P" S?\ QF@?LQ_#H?\ ,]:E_P"
MS?\ QFOM3^P-+_Z!MI_WX3_"C_A'M+_Z!MI_WX7_  H]A@OY9?>O\@_U2P/_
M #YA]TO_ )(^*_\ AF+X=?\ 0\ZC_P" S?\ QF@_LQ_#D_\ ,\ZC_P" S?\
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MGPWMA<)=6LRATE3H01D?SZ5XE\*+S1QI_BK5?%*0OX@2=Q>I>J"ZH% 55#=
M1CTY-9_@3Q VEZJB13G0?#TCR:U%;2J%S;;@P '8%77IQQ0!]$DX%9/B#Q3I
MGA:&TEU*Y%M'=3BWB)5FW.59@. >RG\J\0T[QEJFIV\<5]KC6FC7\D^H_;3@
M.UJ(CM1.G\41.01UIOAO4HM7MO#.G^(+DZE9?:;O4[6>X^\T4<IC3//]V8=S
M2"Y[VNJ6S2NCRK$PD\H"0[=S#' SUZCI5S/K7S6L=S\1=5\$Z/K&N/'K4-O+
MJ,<MM\BRDK\F=I&<-%GD5U'AWQ5K7BW7H/"-CJ1DN="N&;6K[: '&25C4CN5
MD0]ONFG8+GM@Z4M(.E+2&%>7>/?-E^,/P\C3YHA-<.Z_]NER ?SQ7J->:7-P
MFJ_'2R@!RVFZ:\^/=BR9_P#'ZZ*&CD_)_E8\O,$I0IP[SA^$D_T/2Z*04M<Y
MZ@4UV"J2>@Y-.J"]G-M:3RK&TS(C,(T&2Q S@?6@#SO3OB-KOB;Q:T.A:1!=
M^&K:=K>ZOY)%61'4X;"LZMP0P^Z<XR.*ZZU\;:'>ZG=V$.I1/<V@W3KR%C'/
M5B-O8]^U>,+!J^H^-]5O?"&EWVBR7=I)_:"7B,EO)*&0 H.0'('8 GYCZT#P
MVGB?X7C0=*\.WNDZA>316]Y<31E9@ R;V9_O$8+=?>G85SV*;Q]H$.G-?OJ2
M"S63RC*%8C=G&.GMUJ?4/&.C:4MB;J_CB6]8+;L02')( Y P/O#DX%>)^*O!
M-[;>-8-/OK>>/PHUA';V_P!AM@Z"<!"S..!DD/SDGFJ;?#FZC^(-_H6IC49/
M#UQ#!!92"(RQA5W!@K$_(?F7)7GIZ"@#WW4O%6DZ,8Q>:A!!O<1@%L_,>@..
MF?>G>(M:30= O=3*>>MO"TP1.KX&<#ZUX3X@^&>H>(/#OBS4/[,N1J>JW=M'
M:VTFYC#'') 2XSTXB8\#O7=?$/1-=_X5;H^F:2DL^J0BWBDVY)^6,AB?;.*
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MBSE$)\LQ>0H0+)D$?,K< =?K18#VZZ\<Z%9WUU9S:C&MS:Q&::-59MB  DY
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M&Z\"W2:I=3V=UJ=Q>VB:FVZ0Q!XBJ]6[.O>BPSVOQCX^TCP'I7]HZQ)-!9@
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M"\5 <1N2PQGH?N-T]*WF<(K,S!5 R2> *^9/#FL7WPRA\:6-QHT>D:U?:?\
M:(I;<E_M,XCE+2$M@Y#,I_&MFR:?2-;O[.77-4NC)X>-U>&XDRBESC*#=P06
M'0#H:+#/=3K%LPMVA?[5'._EK)!\Z@^Y&0*I^%?%NG^,;&>[TZ0R0PSM;L64
MC#@ D<_[PKP[PS=#P%X7\+QZ9K<]ZEAI,^IW$<SE_MA*P, ">>/FZX^]7/\
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MO$/^&^O!O3_A&?%7_@'!_P#'Z3_AOKP:/^99\5?^ <'_ ,?I?V/CU_RZ8_\
M6;)_^@F)Z]9? _PQ9V=S;F&>X%Q"MNTEPRLX17WA0=OKG\ZO>(OA3H?B6UL(
M+@3P?881!%);.$?8 !M)P>,*/RKQ3_AOKP;_ -"SXJ_\ X/_ (_1_P -]>#<
M?\BSXI_\ X/_ (_2_LC'_P#/IA_K-D__ $$Q/9Q\(?#JZ;I-@D$B6VF1/#;J
MK*,*ZE6SQZ,:Y35/A$NN7VE^&FLFB\&Z5+]O61R#)-.<C9_NXE?MU YK@_\
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M !^C^Q<P_P"?+#_67)_^@F/WGT_17S ?V_?!@_YECQ5_X!P?_'Z/^&_?!O\
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M_;\\&G_F6?%/_@'!_P#'Z4_M]>#1_P RSXI_\ X/_C]+^QLP7_+IA_K-D_\
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M.@(# Y!^N0*E-A;&>*<P1F:)=B/MY4>@KYM_X;U\'#_F6_%'_@'!_P#'Z/\
MAO3P=_T+?BC_ , X/_C]2\%B%]AA_K/DW_03'[SZ2EL;>:9)9(4>100KLO(S
MUH>QMY2Y>%&+IY;$KU7T/M7S;_PWKX-_Z%OQ3_X!P?\ Q^C_ (;U\&_]"WXH
M_P# .#_X_4/"UUO!A_K/DW_03$^BX=!TZW2!8[*!%MP5B"H!L!QD#TZ#\J;I
M?A[3-$29-/L(+-)6+2+#&%#$C!)Q]!7SM_PWIX._Z%OQ1_X!P?\ Q^@_MZ>#
MA_S+?BC_ ,!(/_C]2Z%5;Q8?ZSY-_P!!,?O/HG3/#^FZ*)Q86,%F)V+RB% N
M]LDY..IY/YUS_B+X?1WF@2Z9H4L7AY)V G>UBVETXW+P1U QFO%Q^WGX/SC_
M (1KQ1_X"0?_ !^C_AO+P=_T+?BC_P !(/\ X_4.E47V7]P?ZSY-_P!!,?O/
MH3PWX>M/"VC6VFV2!(85QD#EF[L?<G)-:M?,H_;S\'#_ )EOQ1_X"0?_ !^E
M_P"&\_!W_0M^)_\ P$@_^/U+A+L_N8?ZT9-_T$Q/IFBOF;_AO/P=C_D6_$__
M ("0?_'Z/^&\_!W_ $+?BC_P$@_^/U-GV?W,/]:,F_Z"8GTS17S-_P -Y>#_
M /H6_$__ ("0?_'J3_AO/P?_ -"WXG_\!(/_ (]2U[/[F'^M&3?]!,?O/IJB
MOF;_ (;R\''_ )EOQ/\ ^ D'_P ?H_X;R\']O#?B?'_7I!_\>I7\G]S#_6C)
MO^@F/WGTP:\^TA4U'XQZK=IAQ9:?]FW#L7,3$?\ D/\ 2O*1^WAX.8@?\(YX
MG_\  2#_ ./UTO[,_CA/B1=^,O$,-M/:VUS>1K#'<J%D"KO'(!([#O79A_@J
MR71?FTA0SG+\RQ%*AA:JF[W:79)O\['N=%%%<A]2%%%% !1110!YS\?87NOA
M?J\$3;998V1/=BC8^M=UI2%-,M%8 ,(E!Q]*X/XOWZF;PQI,A_=ZAJD43>X.
M1_6O18T"1JHZ* *[:GNX>G'NV_R7Z'FTDI8NK)=%%?F_U' 8I:**XCT@I,4M
M)0 8HKQ?4=6U(:Q?JNHSA%EPJ@C X^E5QJ^I D_VE.1]1_A7;]6;ZF'M5V/<
M:0UXC'J.J3MA=1N /7(_PK3LAJLQ"IJ-PSGC&1_A4O#VWD6IWZ'KE)FOECXR
M_M/V7P4U*#1;=+KQ1K;!&N8X-K);AF( )RO.!GOU%<A/^VO=W'B_1=-.F2Z5
MHDK+]NNW +*IVY/WCC&3VKMIY3BJL%4C'1_UMOZ'#/,,/3DXREJO+^OF?:]%
M>3W;WDL2SV>M27EE*-T5Q"ZLI'U K)EOM5@;!U.X/OD?X5Q+#\VS.YSLKK4]
MNHKPXZOJ7_01N,_4?X5T_P -=0O;K7[U+F\EN(Q!E5?& <I[?6E+#N,7*Y*J
M)NUCTJBBBN4V$-+2-2 G H 7%%+10 A&:.*6DZT '!HQ2'K2YH ,48I*=0 F
MT>E  H/2B@  Q1M%+10 FT>E&T>E+10 F*-H]*6B@#EOB9J:Z/X"UVX8+_QY
M3*-W3)C;%7/!&F_V1X5TVT*A2D6< 8'))Z?C7&?M'Q3W'PGU6&V8K/+B-<'&
M201BO1]-4KIUJ&^\(ES^0KH:M13[M_A8\J$G+'S3^S"/XN5_R19HHHKG/5"B
MHIW,2;AZU6^TRYZ?E181>HJ@;MZ/M<GJ*=@N7Z*H?;),T?:Y#Z46"Y?HJA]K
MDH^UR>U%@N7Z*H&\DH^UR'N*+!<OT50^V/0;Q_;-%@N7Z*Y&3Q)=KX]32%V?
M9OL_F'USAO\ XFM[[7)ZBJ<'&U^H7-"BJ'VN3VH^UR>U38+E^BJ'VN3VH^UR
M>U%@N7Z*H?;']J/MDGM18+HOT50^UR>HH^UR>HHL%R_15#[7)[5)!<.\@!Z4
M6"Y;HHHI#"BBB@!*6BB@#R_XUVPU"?PG: *9&U2&49&2 DL;'^5>G <UY5XP
MOC=?'+P;I,BDPF"YGZ<9$>1_(5ZO7/32YYR7]6/,PS4Z]>:Z-1^Z*?\ [<)2
MT45T'IA1110 4E+10 4444 )2T44 %%%% !1110 4444 )2T44 %)2T4 (!B
MEHHH 3%&*6B@!,48'I2T4 )BC I:* $P*"!Z4M% ";1Z48 [4M% "8HVBEHH
M BFD6")Y&'RHI8_A7!?":(7$GB'55552]O7"[1@'8[KGWKL]?S_8>HX.#]FD
MP?\ @)KA?V?S*?AS$9L[_MUYRW4C[0^/TKMIJV&J2[M+\W^AYM5WQE*#Z*3_
M "7ZGI-%%%<1Z04TMQ3J^8_^"@-QKMG\$H;C1WN8K:+4(FU&6UY=+?/) Z_>
MV] ::5W8F3Y5<^F@V1D<CUI<YK\]?$'[3'Q#^,1N+;X"7HM/!W@K3OM>H:Q>
M0A3>;4+B(B8*>D$@RH_BZ]*^POV?/BH?C-\*=$\4O;BUGNT82Q+G 9793C/^
M[FFXM+4F,U)V1!\6+,ZAXL\"Q)]^/5([@_[JL,_S%>GCI7FFI7PU#XY:7ID@
M^2VTR6Y7_>WQ?XUZ6.E==>ZITHOM?[VSAPMI5JTU_-;[DA:***XCT@I#2TAH
M \(UW4M-T:ZUO4M8OXM-TRV?=)<S$!0<# R2!UQWKYM;]O[P^NH3VP\&R7>F
M6SE9=0MYTY4=& \ON 3UKT_QQXWUO7-3\4>$K_1]-U#1KIPCJTA5BH 8'(<<
M@@?E7SIJ'[/VEVGA"ZBTK5$CMX+E?-11D]3@'/ISTKT\'G60Q;CBZRO\].^R
MW-Z_#^=2BI4*+U\XK?;?N?<'@Z\L?%_A?2O$>F!ETS4D+P+*,. "0<_BIKL]
M(A2VN8I-H8KV YKY_P##O[0VN:?;1Z+9Z/H\ZV4($<2.1N'<YWX[FM&/]IOQ
M6#,4T#1RD*!VQ(01[<R5X=3-\!*[C7C;UZ'J0R#,U9.B[_(^</VCOA3JGP>^
M*YO+G5#J6G>)K@2Q329W0L$P0V2>!Y8YSWZ5S=MH%U\3/$D?@7PTL5YKLDFZ
M6_*Y@2,G#;B,G +#\JZ?XV^(KCXO^-YM0ODVWL5@IAMX&_<JH9^1D]<[N]<?
M\,=9USP'=VNM6=Q'9ZF9 B*BAMHS_$>?05^KX.O[;"4JL&G*44T^CNKIZ=+'
MYGBL,Z5>K&>BIRLU?56=FM>M[Z=#[S^$/PBD^#/P]_X16;6Y_$#&X-PL\X(\
MG*HOEJ"S87Y,X!'WCQ3?''BCPGX%BSXD\16FESL-RV;LOFN/4 L*XE?VG_$%
MA+)'?Z1IQM8(<R71<Y\SG' ;IT[5X#^T%X&NOV@=2F\:7.H1:+>6-JHAAMLL
MDPP,'!SVK\Y6:X!XN:Q^*C%W?,UW^2/NJ>19@L)!X*@W%I<M^WS=SZ4\->,/
M#'C>^N++PUKMOJUW;KO>!&7>1ST 8Y^Z:[WX8?\ (RZ@",%8"".X.4KX,T?]
MFN7P7K6DZOH?BBXL/$UNL=Y#;C!\T@Y.<C&.#U-?8WP'^(NH^)_'>J:3J<5H
MEW;:>LDCVYRSL/)&3R1_%6N)S+*9R]G@\2IWTL[IW^[4BGE&;4Z;K8JARVU;
M3326Q[[1117$8G)_$WQ[;_#7PA>:Y<P/="$$)"AVEWVD@9[=.N#7(0MXA\'^
M5XK\4>+5GL& !T:WM2H9Y#LC57,F"<NA^[VKT+Q;X4T_QKH-UI&J1>=9W"%'
M )!&01D'UY-</#\%9+OPM>Z%K7B.^UBVD>.2WDE6-7MV1U=<;5 /*#KFO5P\
MZ$:5INSO[VEVXZ;=K:]CY_&4L7*NY4U=*/N^]9*:O\235T]$MUO=$DWQPL[.
M.ZANM'OH]7MY8XFTQ &F/F!F1@.#C &>.XI-*^.=CJ ADFT?4+.WDN)+4RRK
MP)%C#_B"& !]:N>'?A%::/KMOKEUJ%QJ6M1Q>3+=3!09E&W&Y0 ,@*!P!6'X
MD^$TN@?#4:7H!FU'4+:<36[7#J&W':I)/ X S6Z6 E)076VMW;S^2\^Y@WFD
M(^TELKNUDV[6LM.K5T[:::;EV/X]:;#;&[U'2=0TJR>:2WMYKI IG=6(PH/J
M%)'/059\>_%T^%TO+33='N-7UB VX^RH=H_>R; =P#'C!/3M6;!\$%U_P=/I
M_B#5KR[NKR!,O^[4VC[?F\O:H'<CG-7V^#,<^GW"SZU>RZE<7$4\E_A Y$;A
M@F-N,<$=.YHM@(S3[/;6SV^?>_X$IYM.FX[76C]VZ=G?357O9KI;<FG^+L5I
M<V,3Z5=36\\@MY+R/_5I+Y;.5''.-C+VY'2L73/BQ=:M"M]JMC=>';9-2DAM
MQGS!<PH4.YON[0V[ Z]ZT],^"L&G:O#-_;%Y-IL$K7$6GN$V"5E92V=N[^-S
MU[T6'P2M+:!(+C5KV[MT$H$<FS WA1V4=-O%">!CM]^OG\K[>78IQS.;3>FK
MT]VW3=K6V]K6??L/E^-=CIJSR:OI5[I$ &;=YP ;G+ #:#CDG/<\#-2V?QBM
M[FZU*QDT:_@U:T6)UT]ES),)-VTJ.O\ !SQQD517X&6E_IT]KK.LWNKNTH>&
M64(IA52"JKM4# QWSUK5\1?"N#6;^YU.VU*YT[6)BH6]A"%D4$_* P(QSW%0
M_J-[?CK;I\[;W_ N+S2W,[6[:7ZW\K[6Z=S%O/&^L>+M;T73M)631+N*X:2]
M@N 6WQ;"0 1CN/2O517G?A7X,6?A74]"OHM4O;JXTN.6,M.5_?[]_+X4=/,.
M,8Z"O1*Y,5*BW&-#X5_FST,!"O&,IXGXFUU\EVT76]MWJ.HHHKA/4"BBB@ I
M#TI:0\4 >8?&O4D27PEI#GY-3U:")@3U EC!X[_?KTZ- B*HZ*,"O)/C'I0U
MOQY\.(5;]Y;ZC]JP/1)8&_I7KM=-2RI0^?YGD89N6,Q#>RY5_P"2W_4****Y
MCUSC_B7XJ'A+1HKMHI)5,H4^6<$<&OG[X@?M3WET%T/PC;S6^H$J\NH71X3Y
MON #KD*>X^]7LGQ_#KX)#HN_;.IQ^!KXT\.6DFK^*&D"';),N"!Z5[M+#TI8
M%U&O>O9>K:1X%6M4CCU!2]VUVO))O\S[&\%_%"WUO0M/-_MM]4\E1.'8#>P&
M"P^O7\:L^,_B[X;\!:0U]J=TLDN,16<#*99#Z $CU%>32V:(@&#F-  >G0"O
M$]; U'X@<EI/**A=QR!EC715R^BJ<ZJ=E%7L<U#,*\JL*3UYG8^Y/#_B6P\3
MZ)9ZM9,PM[I=RH^-RX)!!Y]0:T9)8+:$SW$Z00#_ ):N<"O!?#MW?>'[&!+.
M<QJ5RR$9'/->9_%/QMX@\5^(H=!NM09=*C!8P1 +N;C&3U[>O>N2>72C&4U+
M2*N=5+,E.<:;CK)V_KY'V45P,@Y4]".]( 6.%4L1V%>1^#?B#=Z;HEE9WT;3
MB)"!*.N.>M<M\1_VC=4L]3L])\,VGDS"3?=3S#)*C VKGUR?TKFG@JT$VUHN
MIU4\?0J-13U9]"G(/?-'?TKG- \>:?X@TRWNEE$4SK\\3 @@]^U8.N?'3PMH
M7C#2_#9E>\O;UBLDL:L$M^ ?F.,'.>Q[5SRHU8WO%Z'3'$49VY9K4]!_E2$_
MC02FXJ'W$G@KWJ*"[M+B]>RBO(I+V,;W@1@64<<G\Q^=8F]T]F<C:7"S?&&^
MC/WHK-3^?F?X5VF.:\T\+W/VGX[>*(R=QBM(@!Z?--7IC(R?>&T^E=%=<LHK
MR7Y -S2TE+T%<XPS12=:7I0 'IUI  !@4M% !11C-% !_GK4MN3Y@]ZB[>M2
MV_$HH8(T:***@L**** "DS2TE 'F-S$FI_'>S=0&;3; ECUP9!(O_LM>G9YK
MRKP.9Y?CEX\:1<P):6:QM[[IL_S%>JUC2V;\V>9E[YH5)]YR_!\OY(6BBBMC
MTPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH P/'6J)H_A+5;F3&%MW4<XY*D"JOPSTX:;
MX*TQ  /-C^T<#^_\W]:R?CG&\OPRUA8^7*K@?\"%=)X(5E\&:"K##"PMP1[^
M6M=K5L*GWE^2_P"">:G?&M=H_F_^ ;=%%)FN(](#TKYY_:Z^-5]\/]$TWPOX
M=\-Q>+_%'B"3RX-(GC62-XP'=F9"K;A^[/&TU[SJVM6&@V3W>I7MOI]JG#3W
M,JQH#]20*\&_:@^$7B'X@VWASQS\.+Z"/QKX=E^T632.#%=0E75H\@CJ)6/W
MATJH[ZDRO;0\V^'OQ$\ ZC^R_P"+X-3\-6_PG.^31]?M-"M8[8P22+)&6(3R
MN/\ 6'G&.<5]-?!OP/HOPZ^'&B:%X>D6;2;:(F&8?\M S%B3R>['N:_.FXUC
MXM^.[3QSX-'PRU#3M9^(-\B7^H/:R);6BNTBL=Q/"@3L<DG[M?I5\/O#)\&^
M#=(T5G\QK. 1LWJ>I_G3EH1#T.6_LX3?'M;X<^1I+Q-_P)HR/_0:]+KSCX>W
MO]I_$#QRT@_>6MQ%"I_V<R?X"O1ZZ<5=2C!]$E^%_P!3CP23A.HOM2D_N=OT
M"BBBN,]$*0C-+2&@#XA\3Z,^M^.=9M=,M+K[>UYEV4$ )LR2"*XO4]<\%>&M
M6U2T;5XP$^>[@>0!6QG.1NZ]:^J=8\27&@'Q'J9<2"Q7<D+=&)PO_LU?G/XQ
M\#V/C.]FU"6)I-1FG:=WC& BL<D/D' X]NAHP7!^"Q<I3G.:2MLUUU['O5N,
M\=1481A#;K?IL>_Z/X!EU*V37-!TBZ@M$D\Y)H@Q^T1XVD9[C)/'M5+Q'X*U
M&VO[ASIFJQ)?KNM5B1PKL<DJ>1_>7UKUW]B'X^3>//#=UX-U=(+/6=%W?9_*
MRHF@^4YY8Y.7/3L.E?3GVJ?H&Y->3BN&<+AJLJ,^;3^]TZ=#T:'%^-J1511C
M]S_S/S'\66FJV.N""'3;G18&A$?VBX0IGJ2!G_/-:?AS3_ML2-!8B\^Q*&,,
M$>YYF'][\O?K7T#^V1K2WOBC1='O;M)="CM?M%U:VQW7"2CS"K8YP"5C'W?6
MO%/@S\4;CPYXIT_7M-MDTZ&2<6DMO("7GCW8Y /!(7]>E?K.'E4J8"/LEROE
MLK=+*R_+Y'Y/6]G'%MU%S1YKN^M[N[3_ *V+.G6/VV+4(]1TS4GDV/));2Q'
MR\!<Y//MZ=JDE\1>&+*'0=/BUF,;SNNX$D!*)S\F,]!P/PK[!_:)\8ZMX6^#
MFLZCHMD]U?3((1&Z$A$<A6) (Q@$G-?EJT"K!J)%OYADN#-<3PC)1VR6YYXR
M?Y5^=8#@[ XVG*<ZDXI.VZ?S>G_#GZ9B>-,?1DHTZ<'\G]R_K0^I+>,ZM93Z
MJD]UJ#Q[EM=2LB6/D=UW _W2>_>O3?V1;73;?X@>(C'!<OJ+V9/VNY3#-'NA
MRN223SC\J7]G3XMZ!XG^'MMX9\.6[:7?:-$OGQ(A$<F%&6!/!^X>]>S_  XU
M*XN_$-ZLTID'D$\^N4KF?#>&P%9S3G>#TNU\KJWZBK<4XO'X=TI1BHS5G:_X
M'I-9^MZQ;>'](O=2O)%AM;6)I9'<X  &:OYK!\1>'])\;V/V"]9;JV257DA1
MU(+*00&Z]" ?PKOIJ+DN?;J?+UG-4Y>RMS6TOM<\3\#?&&[U'QKXAU>;4KJ?
M1YM-%]::5<#;Y*CE2O)^^&]/X:Z34OBKXH;1-9BCTF/3];2."2S25R5&^98_
MFRGH2>AKN_%7PS\/^,K.VMM1L@T=OM\O9@%0HP!R#QBF^(/ACH/B:UNX+VW8
MK="(2,A ;$;JZ=0>Z"O9>)P<Y1DZ?;Y)6]+W6_YGSD<%F-.E.FJM][.]KN5^
MZE:SM:S:7;H<K8^.-9TEEL-0M);[Q-';6\4@A)$$TS1@NP&. &XZ=ZH3?&N_
ML)8]$-@^I^(I098A8@21R1 9+9P/[K=NU:'C+X:1VFF30Z-IJWLUXRK)-<3H
MC1$*0K*3@9Y/K5CPY\!M&T;PUX?TQ[FZ,VBS">WNXV02;N.,E<8(XZ#J>:KG
MP7+SS6_3Y>NBOT,W3S+G]E2=K=;^:TU6LK7=^C6NY@ZY\>M1TS1+G4XM!<PZ
M<!]M61RK*Q!^4#:>>#Z=*ZKXMW&K:AHECI.@ZA-IFIZA<Q 3VY(D6(2*92,<
M_<W5IW?PL\/7UKJ=M/:&6+4I%EN5;!WLH8 GC_:-1>/OA/H?Q&FTV?5!<1W&
MG,S6\]JZJZ[L9ZJ?05A&MA%4A*,>6S=]+]%;2^NM_D=4\/F$J-6$I<W,DDK\
MO5\UFEH^6UO/L>?:AXVG^"OB!K&]UF_\4V=XRPK%*YEFM;@H&5268G#*KMU[
MCC%;FG_%/79]6T^PU'1)]&BD<;[^Z7;&V"-R\C&2#Q6X_P %?##^#I?#CP2M
M9R2B>2<LOG-("2&)VXR,D=.E%W\+?#WB1]&>ZO+C4TT>,PQQM-&ZMG;DR87D
M_(.F.]:NO@YJ\HW?5V\M'9:?>81PN84FU":4=&HWVN_>3;3=DM4UZ))6,A_B
M'>&;5;+1K62XU!)/-8W,AV1Q;1\PX/!/MCFJ6J_&O4+70[BZM-(^U2:?ID>I
MWC[\+M:/?M4X.2=K>G2JOCKX.7%_%!HV@V'V2P8[I-469%E0%BQ0 ]1_P'\:
M]!M/AMHEKI\EF+?*36L5I+G&7CC4JH/'H3^=$I8.$8R:YK].O3?7KT0XPS&K
M.=-/ELM^EW?:ZZ.UWLUL<_XV^(-RWP\MKC1T>/Q!JJ8T^T+;7=U.YQZ_<5CP
M#7+?!_Q7K\UQ_9EU>7&I:SY\;ZM:W<K,=-!SE 3D]SC.W[M>D>-/AMHWCK2[
M6PU!)(X[5P\$EN0'C((Z9!';T[U4\._"+0/"WB$:W8)/'J+0>1-*67]^..7P
MO)X[8ZFLX5\+'#RIVU=WM]VO:WX^1K5PN.EC(55)<JLM[:6U=K;W[Z<O9ZG;
MT4F: <UXQ](+1110 4AZ4M(>E 'DM[J*WW[1%AI\HW+:Z=)*@/0%@IS_ ..B
MO6@<UY=H]O%J_P <M8OXAG^S[2.W9O0MO'_LE>I5TUM.5=DO\SRLOU56?><O
MPT_0****YCU3Y5_X*%^,-5\)?"*R?1KVXLKR>_2,/ Q!(VMUQVKX>^'?Q6\?
M_#[5+:[OO)U"P4YD,@#,N1C/*GZ]>U?:'_!2&WE;X4:3<02;)H-10@$<-\K\
M5^?@^(5E=QO:"W>/4&^7RD&0<UW4I-4_>DTKZ=KGGU81=1N,4W;7O8^M(OVH
MEGT:6^N;:TN59,A8653^07VKS+P;^T-H6H^,#/JFDSV23SJHE<_+C=[X]:\*
MTKPQ?6-V;^ZMDEMF?S'4'YU!YZ5Z-+K&BWFE2A;BW(V$"-C\^<>F>M=RKU9Q
ME2E))76ZWMJ<:PU&$HU80;=NCVNK'VQ:?$[P;<VV]=2:(A!M#[0.@_VJ\E@\
M0Z+XE^(UTT&L6IV.JCS) ,Y)Z<^U?+/A_P 5ZO%))92W#1V4CE4:53@"NDNO
MACHT41U!4*7BGS5G##[PY!Z>N*V6)JUJ=2E&*=[+?S3T]3FC@Z5"I3JN3TUM
M;R:U]#]!]/TQGLU:)EF4+@>6<YKQS6;"XN/B-=B2)L11C@CIS_\ 6KYI\._&
M[4IU_LN!7:\&5$D+ +QSGK6C::MXU\+7\NN0:I',9CNECEYPN2<#!'J:UEB/
M:4ZD%!MNR]-4V8T\(Z5:%5S5EKZZ-?F?;VC6:)9Y"D,J\D<5XW>V<5UX]OW5
M!E&&6'4G'K6/X9_:SOFTDB2:UN9>0(V1]Q/I]ZN4TGX^3VGB"]O-8\.&".ZD
MRDP4XQS[U<\53E3DN;=Q_P#2DV94,'6IU5*4=$I?^DM'UWI6JZI;Z42NIW!V
M@A6+$D<>N:^;/$'Q$\1?#3QM<>)=%OY;C4)[IK>X2>0L)D)+8.<]T7MVKUBR
M^.'A(:&S3_:+=,'.!GM]*\=T_4?#WQ%\=:;:6=V9"]\\WDM]_;EAGI_M"L\5
MR5*3A&UW)%8!5*-7VE1.T8MGK'C_ ,>>*/A_%XL\:V%C'%=:C8J(R_6T?,A!
M.5/0N/RKHOV;OC/?:OX::V\5ZA/?:I*3+'<RG/!8G:,GH <?A47Q+L1XB\+^
M/;&0')TV0HIZE@LA!_,"N&_9_P!*E2TLT!C;8K*0'!(PQ[5A+#QG72EMR_BD
MCK^MU5AI3?Q)K[F>^_$?XU6W@#0A?P6#:I)O 90<!5[D]??\J[71?$-IKNCV
M.I02(8KJ)9.&!"DCD5XA\:+%SX*OR(V)"$<#CH:H?!"#9X;55W(O.4/'I4/!
M4Y2:B[65_P 2(9C5C2YY*[;M^%SW>V\9Z+>^+)?#,-XLNLQP?:&B!& F0/7/
M<=JVD7S,D$$#J:^2OBA=7?A7XE^'-5TR0074K/&SG^(9C.#7LT]]>:WH5U'/
M+L$]LX8Q\<[3ZYK%X%ZM2T7^29T+,DHQYHZO_-K]#T\)D!@0ZGHRG@TT#CUY
MY-?.'[._Q,NK/P]=>%)X#*VE7,L45RW5U$C 9Y^G85TOQ'^+^L^!O%_A.\F>
M&+PS>/\ 9KR+:Q<.=P#<'IRO;M7,\-545*VYVK&47-PZH]JZ=32@^E<[!X[L
MKZ%VLHC=,4\R$#@/TQ_.L/X4?&'3/BCX*@UT1?V=,9#%-:N?FC8 =1U[UE*C
M4@[2B;1Q%&:;C+0[ZI;?_6BN:7X@^''\6Q^%UU%?[<EB,T=N00'48)P>AX85
MTELZM*,.G7&,C-9--;FZDGJF:5%)WI:@T"BBB@ I/2EI#Q0!YW\+"NJ:QXIU
MI0,W%Z8 ?9 #_P"S5Z)7E_[/5HUKX-U!F8LL^IS2H3_=*1@?RKU&L:/P)GGY
M>[X:,GUN_O=PHHJ!KR 7 MS-&)R,B(L-Q'KCK6QWW)Z*Q/%/BNS\*64<]T))
M9)7$<,$*%Y)&] HY/4?G3-"\4#5P1<6<VFONVJES\I?C/'K_ /6J.=7L9>VI
M\_L[ZF]16?<ZY8VMQ% ]S'YTC[%0-DY^E9.E_$7P]K.EWFHVFIPR6EG<FTFD
MS@)*-N5/_?:_G3YHKJ#K4XOE<E?U[;G345G7.OZ=9102SWL$*3@-&7D W \Y
M'M4EIJ]G?S316US'-)"<.J,"13NB^>-[7+M%(#FEIEA1110 4444 %%%% !1
M110 456U"^CTVTDN)<^6@R<#)K)3QG82+D>9_P!\'_"J46]B7)+<WZ*Q5\56
M;G@2?]\&IAXAM3V?_ODT<K'=&I16:-=M^/O<^QJ4:K"1QN_*E9A<NT52;585
M_O?@*?\ ;X0Q7>I<?P Y8?AUHL%UL6J*I?VI#CJ?RI#J\ _O?D:+,+HO45G'
M7+<'D/\ ]\FF'Q!:K_?_ .^319A=&I16,_BFSC/S;Q_P U?T^_CU*V$\6=AZ
M9&#3<6M6":>A:HHHJ1G!?&"\5-!L;%B!]OOH+?GT,BY_G7:6%JME96]NOW88
MUC&/8 5YM\<K62Z/A%(EW,-8@;'L)%)_05ZB*[:BMAZ=NK?Z'G4=<75;Z**_
M-BTA%+17$>B>7?M$_ Z#]H'X>R>%KC6KK04>9)OM5GN+97L0&7(_&O'/C/\
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M-<7:Q_* 1VKMO$/_ "![G_=-<E;1X1<^E=%-VB837O$T$1;ITJXB=L4R*/:
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MX_[]M_A1_:Y_Y]+C_OV?\*7M)OJ.T41GPQI>S:+"V4=ML0!'XCFJY\':<?\
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M3P^\8VHYF'F'C&0#MK53L]-&9.'=7/0]?T5?!VKCQ/J%\M_"%S):PLP!'(R
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M;[CT'4[M?$WA57U'754>5EFM@1GY?0**P/A'XDN)].N;*SM$FACE8+<28!Z
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MA$O^N\L%\>N*UM%&+,>N:R[C/7OCKZUJZ-G[&,\\UL]%8W1?I*6HY'6)&=B
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MYF+M*M0@_P":_P!R9ZQ124M;GIA2&EI.] &3KFH:7H2#4M0=(2F420J2QSV
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M;U]+_P!=^A\D+_P2)^'ZCCQ5XE^OVFW_ /D>G#_@D9\/P/\ D:O$O_@3;_\
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M3QN'C%2O>[2T3;NVELM=+Z]NMCY;?_@D[X#DZ^*?$F/:Y@_^1ZZGX0_\$UO
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M<PM[VQ1(S<0R>9Y8!7?CDX(^;H1]*K#X^M;)X?U/4/#>I67AW6WCC@O'C0-
MSLH4S#?A5^8=,]#QZTL!B=?<V=OFE>WW$2S? QL_:+5*6EWHW9-]E?0]AHJ.
M*5)HDD1@R.H92.X-25P'L!1110 4444 %%%% "&O,?@/J UG1=;U#^.;5;A&
M/^XYC_D@KT74[Q=.TZZNW^Y!$\I^B@G^E<!\ ](_LOP(9-N!=WUW<#Z-/)BN
MB-O8R?FOU/*K-O'48K91FW_Y*E^;/2:***YSU0HHHH *0TM% &7X@TAM<TV2
MR\]H(YOED9.I0@Y ]*Y;1O@_HNCQZ;:1Q;M,TQUDLK5N1$P(P2>Y^5?RKO:*
MTC4G%<J>ARU,+1JS52<;O;Y=CE/$G@2'Q)J$<\\[B%8]HA'0-QAA^59</PNC
MN3;7FMZ@^HZM%=17(N\; /+?<B@<X_.N^)Q7E_Q$U&]LO'.@I?W%Q!X;G)3S
M+9MNR?<@3S""#@D^IZ'(]=J4IS?(G8XL93H48NM.%[M+RU=KOR7?H:M[\-_[
M1\33WDFJ2?V9-*+B?3T &^0(%!)]!A3C':G3?#07LB+=7[RVT=S)+'"%QB-V
MR4)[\!1^%9]]XZDM2TFC637]]>2E(A)(?+V*A9G/)P/D(X'6H+CXH:I<Z6(]
M.LK>36H8#<3QR.1#M '"L 2<D\9 Z5KRUM+/\CEY\"G)M.^KZN_DOSL6[#X0
MP121"[OGN8;1S]A0+M\E#]Y3_>SE^>/O5U.F^%X-.URZU)9&=Y8TB1#TC51C
M _(5YPOQ+DTS4;O7KVXD_L^[M4BM+0]$GWD$?J.YK=D^)U]IOPNU'Q1J>DO;
MW-DCLULO(<*Q (R>A SVZT3A7E:^M]/O"CB,#"[2MRIRZO1=?NV7;T-N'P+;
MPZ1=V"W+B6ZN!<RRY^9C\N?P(4"N?\2^%E\-VQN;!;FXO/,5K01H7\J3:<YP
M.AY].HYJK;G_ (0OPJGB[Q-XAN+Z:%=\LJ$+$=W 4*-JXSSG&>:K2^.=5\3Q
M6M@KG3I+HB\MKZ _NY("#A22,[OG7MCY3S51C.]T[KJ14JX?E4)1Y9M72W=G
ML^RUO\^IL>!OA>VC:;IUSJ5PTFM1K*TKKC:'D0*V!ST^M=+I'@G2-*@M(UMT
MFELY'DBD?ED9RS,?_'S7.^'AXBG^'^M7-E>K+JUV9Y],EN.57<G[H'@\9[8-
M<SX7\=O8Z.\< NK[Q=-.;:YL;J3_ %,HR0S#<=JE &&!T9>!FE*-2IS/FZ_U
M\ATZN&P_LX^S:NKW>O;3SD[)]^IU]W\*-/NHM;3SYE_M2\2]E((X923@>W-6
M9OAGI]QJOVV261B5160G@[,8_P#016-J'Q-O] OS#J-I"++3K#[5JU^C_NXY
M,,1''TR?D?J!_#ZG%(?&=[8-%>6JPRW8W:9-_P LKC(R%)ZYP&Z ]*2AB'JG
M_7_#%.OET7:2M\GW?ZMKUT-_4?AJ-0UZ]N&OG&DWZXN]/V\3')[^GS-Q[UC1
M?"+3M'TV&"[N);_3M++2:?8H.8-V<^I/)8TK_%#6YK&VB@T94U)8GEO//8K%
M"J[<'(R?FRV./X3TJU?>/;=%EU6"UGGO$"6B6X;AI2PSQNQ@"0'/6FO;QTO_
M %_77L1+ZA-N?+KOJGUU?KKK;OYF+X9\ 7OBJ[U?4-9N9O[/NE6*QA=-CQHH
M*@D'G. .PK2\9^ ]0U#Q;;SZ+<'3WN@'N;MEWA=I+  9'4@"DT_XGZG>6\^G
M"P@'B&.=H#&KGR8\,1N9L9 &!VKK? OB*Z\3Z E[>6JVLY<J50Y5N <J>XY_
M2B<JL'SNW8JA2PE:"H1;;>M];Z/57Z;VMT6AA-\+C#J,6JV6IO;ZP\7D7=V5
MW&="02,=N57\!4_A[X86WA75=+GTVZDBM+*V^S?9WYWC#8.?7YJ[@=*6N9UJ
MC5FSTXX'#QESJ.N_]>ME?OU$QS2T45@=X4444 %%%(: .8^)FH#3? 6MSY S
M;F+G_;(3_P!FJ3X>:8ND^"]'@3I]F1S]64$_SKGOC]#-<?"K5HK=]DSSV:J1
M_P!?4.1^6:[+PQ$T/AO2HW^^EI$K?4(,UC_R\^1YJ=\=)6V@OQ;_ ,C3HHHK
M8](*3O2T4 )1WI:* &]J.<<TZB@"G;Z9;6UY/=1Q 3S8WOW.!Q5LBEHI6$DE
MHAHSFBG44QB=Z!2T4 (,YI:** "BBB@ HHHH *2EHH **** $-+110 4E+10
M 4444 %%%% !1110 5Y1\2;IX_BSX!A!_=N92P]P\6/YFO5Z\VUJ&/7?C#I$
M10%M+MI)<GL6,9'\J[L&^6HY/HI?DT>;CTY4HQ6[E'\T_P D>DT4E+7">D%-
M8A023@#J32YYK&U/Q)I4.HKHDU_%#J5TA$<#'YV!&,C\Z /B;]JGQ]\%/C=\
M3K'P#XA:^T_5K&86]KXQL=H@M+MGV)$\NT@ .%.-PXKJ/V>OV+/#OPZ^*]MX
MDU?QW_PF'B*P@\RRM)9T:2&)EPKE<EL%7.#P/F%?/'QPMF^!0\9?#[Q=H1GT
M_6]6&LZ/XD1-[@[VX9P=P*[4.,=Z]?\ @)XYM?CA^U=IOB+P6;E]!T3PY!8Z
MG>.76.XD5$4@*QZ@LHX ^[6UG;38YU9N[W/MSQ7J/]C^%M9OLX^RV<T^?]U"
M?Z5C?":V2#P)ICH,&57D;W)=JM_$E1)\._$\9.W?I=TF?K$PIGPSM9++P)H\
M,OWTB(/_ 'T:V5EA7YR_0YG=XU=E'\W_ , ZBBBBN,]$**** "BBB@ HHI,X
MH X7XU?#1/BQ\/-3\/\ VAK*[E"2VMVGWH9D=71A^*@?0FO(?!_[0OB3X6Z<
MOA_XL^&-6BNM.1;6+Q%IUI+<6^I;1MW_ '>&.T,?F/WJ^F#S5:\T^UU!%2[M
MH;E <A9HPX'YUI&:2Y9*Z%Z'RUXPN/&7[6FIVWARPT2_\)_#-)HY]0U+4X)(
MI=1$;"54C1@HV^8D8)^;^*O0?@3HM[IOCOQ^UWI+V-O'+:VME,\)4/!&C(H4
MD<@*%Z5[5#%';QK'$BQQKP$08 _"A8E0DJH4GDD#K5.KHXI60K=SYA_9*\-:
MMX>C^+,VH:'<:9/=Z]<3PM/ T;3J;6W *Y R,J1D>AKG8O"&LWS^!5O?#UW,
MD/B:[NG22V<B(&6YPYR. 0W7_:]Z^P%B2/=M15SR<#J:!#'Q\B\'(XZ&J=9M
MMV_JUB7"Z/'_ (W:9J.H>-? ,EGI\UW!;W%RTLL4;-Y>53&2!QG%<-X/^#]]
M\1?V?-5\,:C%-HVH/J4]S:R7,)!C=;J5E;!P<%21]&KZ:**Q!(!(Z9'2A45!
MA0%'H!BJI8B=%QE#1Q::?H8XC#4\52G1K*\9)IKR>A\]>&/VC[_P'8G1OBCX
M>U;2M7LL0C4K:V>>VOL##2(^ .ON>HYK0L/CKXG^(_BW3['P+X4NTT!9 ][K
MVL6[Q0M'@Y2,$ %LE>=Q[\=Z]MO-+L]1"_:[2"YV]/.C5\?F*DMK2WLHO+MX
M([>/^Y$@4?D*[)8K"N\U0]Y^;Y5YI;_>VCR(8#'+EIRQ3Y$_Y5S-+HY;>K23
M\SR_X3:9=VGQ"^(]S<V$MM'<7D1BGD0J)E$EQT)'(&1T_O5PNMZ5JZ2?$26/
M1[N5I]9L'B586_>H&M0S+QR  Q)']T^E?1P15)(4 GJ1WI#$G.44YZ\=:B..
M<:KJ<N_+_P"2V_.Q=3*E4HQI*;7*YN]E]M27X<WX'@\OBF_^$OQ0\0:KK6@S
MR>%M:B@EAU:RMWEDBD6,9CE ''+-@G'"?EL:K\11\4_ WBNVT[0M6ATQ[*2&
M.\FMWC:<LI4B-2O) 8'//Z5Z[<6L-W%Y<\,<T?=)%#+^1HBM8((?*BACCB_N
M(H"_E0\73ERS=/WU;6^FENG>R]/((9=6@IT55_=2YG9I7]Z[:OVN[K2_2Y\V
M_"G3=2_9RL],LGTJ\UGPMK $DE_!;LUQ93-AL3* ?E^9QG Q@5SS>#_#7PS\
M0>(+/QEIVO9OKUKVUU3386DAN%8#Y,A#A@5/&3]X5]:O!')'Y;QHZ?W6&1^5
M1W5C;7H7[1;Q3A>5$J!L?G72LT;G*<XZR^)IV;ML_7H^C]3AED,53A3A/2'P
MIJZ2:M);IM/=:W3ZVT/EK7O!D1_9_P#%<WAWPAJ>ER:K=V[+9SPLUU.B2J-Y
M0("!\N[IT(->I?%73[R\^"26UO8S7-WY<0^SQQDOG![ 9KUCRT*!-BE.FW'%
M+Y:LNUE!7T(XK*>82G*+<?ADY:MOHE;\#HHY+"BJBC*W/",-$DE9R=TMM7-Z
M%#P^C1Z#IJ.I1UMH@RD<@[1Q6E31QQT'I2@BO);NVSZ**Y4D+1112*"BBB@
MHHHH Y'XMW<EC\+O%T\7^LCTB[9?J(7(I?A4!_PKW0SMVEH-Q!]2Q)JE\:;E
M8OA[J5NW2^7[%CU\T%,?K72^%[%--\.Z=:H,+' @_3)KH;M02\_T/)BG+,92
MZ*"7WM_Y&K15*XBO7DS%,B)Z$<_RJ/R-1_Y^(_\ OG_ZU<YZQHT5G&#4?^?B
M/_OG_P"M1Y&H_P#/S'_WS_\ 6H T:*SA!J/_ #\1_P#?/_UJ7R-1Q_Q\1_\
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M3.T?F:Z&/28I=)6PO0+V+RQ'()1D2<=Q2>1J/_/Q'_WS_P#6H\C43_R\1_\
M?/\ ]:H<Y/=G3"A2@VXQM?0Y73_A79V=G?Z;-=SWVBW"XBL+EMZ0$="HZ#&
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M6O+<PVZLTDJ1JO)9V  KYZLO!EY:Z;?7^A^';O2]&2)$;25F032R"1'9ERY
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M7.>J%%%% !1110 4444 %%<_XL\6'PK#%*=,N]01S@FT"DI]02#^5<=_PO\
MT7S#'_9NKB0<;?L3]?3I4.<8NS9C.M3IZ3=CU&BN0LOB U[HESJ:Z'J"1P\B
M%P@D<9'(&[W_ $KAY_VJ_"%E.T%[;ZM9SJ2&CET^7@CJ,A2/UH<XK<B>)HT[
M<\K7[GL]%>,P_M4>$+I"8(=1F;H%%JZD_F!3F_:K\#0(?M-Q>6TH^]$UG*Q7
M\54@_A2]I'N9_7<,_P#EXOO/9**X'X>?&OPO\3(9I=(O&"QMM_TI#"6/'0.
M3U]*[Q6W<@Y!JTT]CHIU85H*I3=T^J'44@SBEIFH4444 %%%% !1110 4444
M %%%% !1110 4AI:0T >4:UJ(E_:.T/3VS^ZT@7*^F6-RO\ [+7K%>7:=:IK
M?QVO]3 !.FZ;'9EO??*<?^1*]1K&G]I^9Y> YFJLI=9R^[;] HI*I7&L6=M.
MT,LX211DJ0?\]ZV/4+U%9ZZY8OTN%/X'_"I/[5M<9\Y<?0T[,5T7**JC4[8C
MB4?D:<M_ YP)!GZ4AEBBH?M4?'SBE^T1Y^]^E $M%1?:HO[WZ4GVN(?Q?I0*
MY-14!O(1R7 _ TTZA;C_ ):C\C0,LT54_M6U'_+8?D::=9LP2#.!CV/^%.S%
M=%VBLX^(+!1S<K_WR?\ "K%G?P7Z%[>02*IP2 1@T6873+-%(2 ,D\4BL&&0
M00>XI#'45GZUK=EX?L);W4)Q;V\8R6()/X <D^PK,T#QK::^TI2"XM8$3S%F
MN4V(Z<8(STZC@X-3S).US)U81DH-Z]CHZ*KF]MUB64SQ")N5<N-I^AI8[N&5
MBJ31L0,D*P.!ZT[FET3T562^MI8VD2XB=$^\RN"%^IH-];AD7[1'N<94;QEA
M[>M%PNBS161HGB:QU^2[2TEW/:S-#(IX.58@G'ID&KZWL#QNZSQLB'#,'&%/
MN?RH33V)C.,US1>A8HJLU_;+$LIN(A$QPKEQ@GT!J.TU 74LR&,Q&-]OS$<\
M#G@^]%Q\RV+M%5Y+R")U1IHT9ONJS $_2K%,=[A1110,**** "O,/@SYO]I^
M./,W;?[<NMI;T^T35Z+J<_V73;J?./+B=\_0$UR7PCC27PFNH#EM1GENV;UW
MR,P_]"KLINV'J>;2_-GG55S8NDNRD_R1V]%)2UQGHC306"*2Q 4#))K-\1Z[
M;^%_#^I:Q>%OLMA;2W4I52QV(I8X !)X!KXW^/?[3WAWX]_L^7B_#GQ@FE:F
MUX([R.99()T@'F(X D52?FV'C--*Y+=C[-TW6K#5U<V-W#=!#AC$X;'UQ5W-
M?G3J_P"RMXI^#_@2+XH_"/XB7VIRZ5:_VI<V%Q<*T%Y%&OFN"-J$952,;@>:
M^U/@#\3#\8?A#X<\6O!]FFOXI!+%@_+)'*\3]2?XHR?QIM65T)2;=FBK\4+[
M9X]^'^GL,I<W,LI!Z9C>#'_H5>FCBO,_'EBNK_%'P.L9)EL3<3.!V!: _P#L
MIKT2XEFCQY,7F9]P*ZZ]O94EY/\ ]*9P8:[KUY/;F5O_  %?K<LT50^TWO\
MSZ?^/#_&D^TWW_/H/^^Q_C7$>C<T**S_ +3??\^@_P"^Q_C2BZO.]I_X\/\
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MIRDTHMZ(A1A&3DEJ]R^1FF30K<0R1/RCJ5(]B,54^TWW_/H/^^A_C1]IOO\
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MC!R]"Z]>=)I0IN5^UM/6[1Y_?^%KV7XMZWX7T_7%L_ 4Q.I:P87V,CD[C&9
M-R[FD8\,/NGI63X'\0ZS\5QJ=K\(?!NC^%O"]G.%M/$>J6B$7;X#$I\DNX ;
M>2 >?:NB_:,^&ND?#/\ 97\=6>EB=8KJ RZG>D[IY@22SLP&3RW>O9O@M;Z1
M:_"OPU#H+I)HZ6@%JT9!4ID]".*K"86%"DZDXIMM^:2WM^)Y. R]4I.56*YW
MKWY4WI&+>R7DEJSY8\1:#X2M?C!I]I\=?AGIEQ=W*I%;>-K4NMI=W&Q=JR -
M&O"!Q_JS_JZ^V+>**W@2.%$CB485(P H'H *\2_;/TWPKJO[/'BB'QA<1VNF
M"+<DSD!EEP0"N0?FVE^G.,UP>A_%_P"+WB+_ (I_P?X5@E;2+./S]3U20 3R
M#=\H5F4Y.S&<G&X5Z;BZT%):6\].A[G-R.S/JZBOD1_VG_B1XL\+7?BKPYX4
M@M-*\/3?9]7MKXGS;B4/Y;^425PH;)SANG7O6MK?[4/BOQ+\4?"_@OP3X>AE
MDUS1O[5:ZO'XMD*(P)SMSC<3C()Q6?L)C51-M'TIKFOZ=X;L'O=4O(K&T0@-
M-,<*"3@?J17+>+/B)<:/J.AV>CZ5-K3ZG&\RRP;?+2-=F&)W \^8,8!Z&O#?
M%OQ2UAOA3XKL/BAX4T_4=;TB[MR=-BVM#<P-+"%E'W@,-)ZG[M=U?:*=<\6_
M#Z[L+N71[5]))ALH#A8E*VY"C&.@P.E<&-4Z-'FANVET\CDQ56:I_NM[Q^YN
MSW.N/Q-O]+@LFUG0KBQDO+K[/&@ )Z [C\W3D_E7=VU];WC2""593&VUPIZ'
MTKS7XJVTEG:^%86G:5TOP#*W5JN)XMM]"L]3ETS1,W\UXT$=O#P9Y-S#<2!Q
MR.I]:X85W2J2A4>BMZ[>0H5G3G*%1W2MZ[>1Z-2UPNC:EXUBUNVBU73+:33I
ME)DFMW ,+<X&,G(X'YUW(^E>A3J*HKI->JL=L)J:NDUZZ"T445J:!1110 45
M'+*D,;/(XC11DLQP /<UD6/C3P]J=\UE9Z[IMU>*<&W@NXWDZ9^Z#GI0!MT4
MWZ49S0 ZF22+$NYV"+ZL<"N8\:?$_P +_#U(#KVLVMA).^R*!Y 99#@GY4^\
M>!V%>#>*?'.I?&[XWGP':7<FA>%M'BAO[B4R&&?5'W.PCC#8+!3$-V W#]JK
MEDES-:#::5[:'U#YB;@-RY/09ZTZOGCX":UK_P 1?'WB#6?$OF:*^C.VGV7A
MV1B)(HQM FD4G/S!=P.T<2CKU/T*#4DK4=124M PHHHH **** "JNI3K;:=<
MRL<*D;$G\*LGI6%XXD$?A#5V)VXMGY_"JBKM(SJ2Y82EV1S/P+MU7P,MXN#_
M &A.UYN'\6]5.:]$KA?@=:36?PC\)Q3J5E73H-P/4'8*[JM:[O5EZG#EJM@Z
M-_Y5^*N%%%%8'I!1110 4444 %?&_P 0?%E[X,^-_B"\M+Z* , #$<;C\\F>
MH]#7V17PG\;+"RUCXQ:_*J!;RT< G'7]X_\ ]>N'&4XU:?)-73/.QM:IAXQK
M4I6:>_R=UYI]B'4M:F\7R3W]](+*RCYFNI3@8]!^.*G\-W&@ZZD-SIMUY^FA
MMC.OWD.>-W/U[GI53P_;Z'X@T+6M/\3/.EW,T<=CIJ(2LW*Y;.".QK;U[X8R
M?"I-+M_#:B.PNUW:C93)A@/EP=W /#/VK@IUE":I1C[OET[)]CL>#P]3!O%U
MJ]ZTM;/K_P '\.AS7A8>*]+U&YOOB*MCI.BB4Q:?J%@3')-(<;,%43WSSV-=
M*\D6HZG>VXN9;G58%$ADF.3(AS@@]^GZU+=PZ3JOA.6SOHA>/',LL%M(N5R"
M,D-C .-W^35'6;\2V@%I"()(H56-Q]\$# 7/H*^CPTH2336Q\3F5'&+$TJL9
M0]FTG9;K1W4O/:QU/A2WT'4--EM]9MX+J:!S)Y.H(&P>,$ Y_P BN2\:^.KK
MP;XDTZ'3_"5QKEA=Y:"XL5 C5N/E<;E]2.AZ5] ^%?!7AOXT>"--U;4;8+?[
M3%+-;85]RD\$D'L13(OV<AITDBZ;XAO+.W<\Q _X8K3#SC0J.H];]&?08B#Q
M&'HTZ-&*Y?M)ZRTW>G^9X:-'N-!\2ZCX@U+6%NGU"W*M8!\^0W/48 ].F:O>
M"? >L?%'5$MH4>'2$)-Q>/D*5Z;4X//.>W0U[OHW[.GAFPG2XO1+J,ZMN_?%
M2A^H(J]\4?&EM\,?"\5II,,45Y*?+MK>,8"#!.[ [<8_&LI-2>B,:F'E-*KB
M[)1^;^\T?%7C_P -?"O0Q%(ZH+>+;!8V^&=L<*H!(]AR:\,UWX]^-O$\YET,
MQ:)IS<".9%,WID@JP'0]^]<UI4<LAO-5U"WDNUMV\^74YE+)$_4;FQZCUJ[8
M::8M2MX=5M[B&._S+#<NA1&ZX()'3'O7-4JT53:B[R7X@JN-Q%27N.G22OS/
M\/OZ6*EKXH\?I<M<Q^-I1)'AC#)'&1GTQL-:MU\:?B[:A6@72[V%%RRH5\\C
M^]M\K'ZU%XBT^PTB6VMXA*TES=(CWD2%AC< 3D#WSUKC=<^"-DWQ(/B[P3XG
MDN%\@V]U-]I4BTEV\@J"#Z?]]5X]?$RI:/3YG?EV78_&8:6*;<8*]GJT[=+O
M8]J^#7[1VH^+O$T?A[7M/*74J_N[F$#:6R 0PXQU'0>M?0HKXV^$/AR:Q^+&
M@O%="_N+>/9?2JP)+;H_F89R,D-U]Z^R17HX:<IPO(G+Z\J]-N3O9V%HHHKK
M/4"BBB@ HHHH **** "O/_CKME^%^MVC?\OD#VP'NR,*] KRWX\WS0:=X9MM
MI:.ZUJWA?'H=U957:#/.S%I82I?JK??H>C:5:_8=/@@/5%VU<I,8I:T6AZ"5
ME82N8U<XU:4@ Y !![C KJ*Y756SJ\P] /Y"M(;BD8 \((&$4=_.FF,VY[-6
M/XJ#G.TCC&:U;[P^EV()K!SI]U"NR.2/@%>>".AZ^AJQ'U%78N0*P^KTDFK;
M_P!:=C=XBK=/FV_K7O\ ,S[/PM;0Z5<VD[/<M=_\?$SL=['GW]STQUJ/3_"?
MV2[AGN[V6_2V)^S1R'A,@C)]3R1SFMT=*/TI>PIZ:;"^L5=?>W_KY?(YZ\\'
MFXO+B2SOI-/BNR6NHD/#D\EAUP3D],59U#6-,\'6%A'=R&.*:9+6$CDL[,%&
M<GU85L'M7GGQGYT[PWP#_P 3JU_]'15=.C",KQ5KDRJSJI*;O8]$=3$2K8S[
M4T'=T!-&K7]MI<=Q=WLJV]I"H:25S@**\\TM_&7Q C75K:['A+3&&V&SFA9I
M77KO/S+CKC!'\-;QCS*^QQU*B@U%*[['HPB?^[36!4X*D9]:XO\ X5]K<V#<
M>,;AFSD["5!_#=5;PQ)K/ASQ]/X?U74Y-7M+VW-Q9S2*W[K;G*Y)(/&WTI\B
MMHR%5DFE*-D_-'>D U5NQF/WJPQVDC\S5.Z.6XZ5*.E%.;':M/PK_JKG_?\
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M_!KQ/8?"#QQX?G-N-3U:\DFM=F NTSEQGC^Z:QOAI\!/%?ACXZ>#_%%\;?\
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M2Z;I/=I'313<917]:GU[:>(],N[E[:'4+>6XB^^JR#(Z?XUH+/&[%5=68#)
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M)A\/_*R1_:C;P/3[//\ UQ5?]E'XKW'QH^!GAKQ-=J5O9K=$N"3G=($0L?\
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M:N.ZQ(S,=JJ,DGM3+6ZBO81+"P>,D@,*?)'FYK:E<L%+FLKD]%%%:&@4444
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M:R6,;5$2G ^E:%*M/VE24WU;*P\%2HPIKHDON04445B=!\4_'_\ 9&\;:/\
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M/GI;N8O,\OS-NX#&=OO63#^SGI#VQEN]1OI]8?4$U.6^$S#=,K!E&W.-H8'
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MUQ7P.DBO_ D>J1_,]]=W<CGU(N95'\JB&E*;[V7Z_H>)72GC:$>L5*7X*/\
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MN.@J35/B]J>FVFIZFD"76G65RNG1PQ &:>8[1NP< #YO7MTJG3K2ERJ7]/\
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MA]WL>]2I85:6[=R4Z/8]4@<RPHY(RR@_*<CI4E16ELEI:PP(#Y<2!%R23@#
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M8%8P7OR?H>7ADI8JO43_ )8_<K_^W"T445L>H%%%% !1244 +1244 +1124
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M5_\ H#6?_@<__P 9H_X69J__ $!K/_P.?_XS113^I8?^7\6+^TL5_/\ @O\
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MS2_\+,U;_H#6?_@>W_QFBBG]2P_\OYA_:.*_G_!?Y!_PLS5_^@-9_P#@<_\
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M (69J_\ T!K/_P #G_\ C-%%/ZEA_P"7\6']I8K^?\%_D'_"S-7_ .@-9_\
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M!S__ !FC_A9FK_\ 0&L__ Y__C-%%+ZEA_Y?Q8?VEBOY_P %_D'_  LS5_\
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M!HUGC/\ S_-_\:HHK"E@L/S3]WKW?9>9S4<=B(2JN,MY:Z+^6/D'_"S-7_Z
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M5_\ H#6?_@<__P 9HHI_4L/_ "_BQ?VCBOY_P7^0?\+,U?\ Z UG_P"!S_\
MQFC_ (69J_\ T!K/_P #G_\ C-%%+ZEA_P"7\P_M+%?S_@O\@_X69J__ $!K
M/_P.?_XS1_PLS5_^@-9_^!S_ /QFBBCZE0_E_,/[1Q7\_P""_P @_P"%F:O_
M - :S_\  Y__ (S1_P +,U?_ * UG_X'/_\ &:**/J6'_E_,7]I8K^?\%_D'
M_"S-7_Z UG_X'/\ _&:/^%F:O_T!K/\ \#G_ /C-%%/ZEA_Y?Q8?VEBOY_P7
M^0?\+,U?_H#6?_@<_P#\9H_X69J__0&L_P#P.?\ ^,T44OJ6'_E_,?\ :6*_
MG_!?Y!_PLS5_^@-9_P#@<_\ \9H_X69J_P#T!K/_ ,#G_P#C-%%'U+#_ ,OY
MB_M+%?S_ (+_ "#_ (69J_\ T!K/_P #G_\ C-'_  LS5_\ H#6?_@<__P 9
MHHH6"P_\OYA_:6*_G_!?Y!_PLS5_^@-9_P#@<_\ \9H_X69J_P#T!K/_ ,#G
M_P#C-%%'U+#_ ,OYA_:6*_G_  7^0?\ "S-7_P"@-9_^!S__ !FC_A9FK_\
M0&L__ Y__C-%%'U*A_+^8_[1Q7\_X+_(5/B7JK. =&M,$XXOV_\ C-5/!CW?
MBKXBZAK5];6]G]AB%O;I#,TK,&W!BQ*+C[B\#-%%9UL/2HT*DZ:L[?FT:4<7
;7KXFC3J2NFWT71-K\3U&BBBOF3[4**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>ahpa-20220416xs4025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xs4025.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '* G # 2(  A$! Q$!_\0
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MN 'V;<20 )!GCKWKRM?&]_<"'3;J>WU-K>_=UNF7"O#']X8_O#UKE;.ZN=
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M*/\ A'=._P"?5*TJ*+@9O_".Z=_SZI^M'_".Z=_SZI^M:5%%P,W_ (1W3O\
MGU2C_A'=.'_+JGZUI4478&;_ ,(]IW_/JGZT?\([IW_/JE:5%%Q6,W_A'-._
MY]4H_P"$=T[_ )]4K2HI#,W_ (1W3O\ GU2C_A'=._Y]4_6M*BG<#-_X1W3O
M^?5/UH_X1S3O^?5*TJ*+@9O_  CNG?\ /JGZT?\ ".Z=_P ^J5I4478K&;_P
MCFG?\^J4?\([IW_/JE:5%%QF;_PCFG?\^J4?\(YIW_/JE:5%%V!F_P#".Z</
M^75/UH_X1S3O^?5*TJ*+@9O_  CNG?\ /JGZT?\ ".Z=_P ^J?K6E11=@9O_
M  CNG?\ /JE'_".Z=_SZI6E11=@9O_".Z=_SZI1_PCNG9_X]4K2HHN!F_P#"
M.Z<?^75/UH_X1W3A_P NJ?K6E11<#-_X1[3O^?5/UH_X1W3O^?5/UK2HHNP,
MW_A'M._Y]4_6C_A'=._Y]4K2HHN!F_\ ".Z=_P ^J4?\([IP_P"75/UK2HHN
MP,W_ (1[3O\ GU3]:/\ A'-._P"?5*TJ*+L#-'AW3A_RZI1_PCNG?\^J?K6E
M11=@9O\ PCFG?\^J4?\ ".Z=_P ^J?K6E11=@9O_  CNG?\ /JGZT?\ ".Z=
M_P ^J5I447 S?^$=T[_GU2C_ (1W3O\ GU2M*BBX&;_PCNG#_EU2C_A'-._Y
M]4K2HHN!F_\ ".Z=_P ^J4?\([IW_/JE:5%%P,W_ (1S3O\ GU2C_A'=._Y]
M4K2HHN!F_P#".Z=_SZI1_P (YIW_ #ZI6E12 S?^$>T[_GU3]:@O]#L8+&=D
MMU5@A((K9JKJG_(.N/\ <-.XK%?PY_R!+3_<K*UWPO<:EXOT#5X)EBCL/-69
M#UD5A@ ?C6KX<_Y EI_N5I4AG$Z=\(/#>F>*;O78;0^?<L)6MRV85D'_ "T"
M=-WO72ZGX?L=8FAENX!,\0(3/;/6M ,#G!SC@T9H QE\'Z0JZ:!91@:<YDM0
M!_JV/4BHO%'@?2/&'V=M1MR\]L28+B-BDD1/4JPZ5O9HS0!SL7P_T**WM85L
M4"6\3PIZX?[Q/J3ZU*G@?141T%BFU]FX'OL^[6]10!RUY\-="OM=&JRVI\\E
M6>)6Q#*R_=9DZ$CUJU+X&T:>VN[=[0&*ZN1=S+G[T@Q@_I6_10!R=_\ #30[
MO61JIM6%P"':%7*PR,.A9>A/O4_@_P )?\(])J%Y<R+<:IJ$QEN)U& 0/N*/
M8#BNEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***0L%ZD#ZT +129&* P/>@!:*0G% .: %HI-P]:,T +12 @TM !1110 444
M4 %%%% !1110 4444 %%%% !575.=.N/]PU:JKJG_(.N/]PT 5_#G_(%M?\
M=JEXZGU:V\*ZA)HB;]16,^6 ,L/4J.Y]*N^'/^0+:?[E,\36-]J.C3PZ9>?8
M+_&Z&;;D!AT!'H:8'B?P.O8]2N)9=+\77ESJ8AD%[H^K AC-VDYYX/7%:>IG
MQ-X,U_PM#+XMN=9UK4=0"W.F!5\HP'.XA<955]:C\'>%?&&L^)H-;UO1[/2;
MW2(IXXY(\9OI6Z,<=%JS\/\ PWXQT#Q ^H:SHEMJ.IWTS?:=5:X!:*(]$C'8
M#TH$8EUXLOKOQ=XBN-5\3Z]HFD6NJ);6QMK<"V5>F&)&<$]ZW=2OM=\::CXI
MN],\0W6E6>BQ>7;16VTK-*%W;G..0?2K_B;1/'.M1ZAX;>.TN--O9@T>KM@&
M&+.2K)W;L#4%_P"!?$7A*?5++PU;Q7NEZQ (6:60*UK+C:9#G[P([4 =Y\//
M$$WBCP9I.I7(474T ,VT8&\<''XUT=8O@SP]_P (IX7TW2?,$S6L*H\H&-[=
MS^=;5(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%>3_ !._:#TSX8Z['I=WIUU=2.F\/#C%<E_PV/H7_0%O
M_P!*\>KG&!HS=.I52:WW/;HY+F&(IJK2I-Q>ST/H6O"?VF?V1_"'[2NF6:ZK
M:VUGK%K/'(FJ+ &E,8;+1D\$@C\JH?\ #8^A9_Y M_\ I1_PV/H1_P"8)?\
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M_P#K^C_G73AOXT/5?F88C^#/T?Y'Z)#I2T@Z4M?T(?S>%%%% !1110 4444
M%%%% !535?\ D'7/^X:MU5U3_D'7'^X: *WAOG1+7_=K3K-\.?\ (%M/]VM*
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ^.OVK_P#DH-M_U[BO%*]J_:O_ .2@V_\ U[BO%:_"\Y_Y
M&%;U/WS)/^1=0_PA1117C'MATHHHH **** "BBB@ HHHH *W? '_ "/WAS_K
M^C_G6%6[X _Y'[PWS_R_1_SKHPW\:'JOS.?$?P9^C_(_1(=*6D'2EK^A3^<
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M%% !575/^0=<?[AJU575/^0=<?[AH K^'/\ D"6G^Y6E6;X<_P"0+:_[E:5
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MM#_Z&*^+NPK[1_:H_P"20:A_UVB_]#%?%N:_).*O]_7^%?FS]CX2_P"1<_\
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M/]PU:JIJO_(.N/\ <- %?PW_ ,@2T_W:TZS?#G.BVO\ NUI4 %%%% !1110
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MB@ HHHH **** "BBB@#XY_:PY^(-M_U[BO%:]J_:P_Y*#;?]>XKQ6OPO.?\
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MW_7N*\4K\+SG_D85O4_?<D_Y%M#_  A1117C'M!1110 4444 %%%% !1110
M5O?#_GQ]X<'_ $_1_P ZP:W? !QX^\.?]?T?\ZZ,-_'AZK\S#$?P9^C_ "/T
M2%+2#I2U_0I_-X4444 %%%% !1110 4444 %5-5_Y!MS_N&K=5=4_P"0=<?[
MAH K^'/^0+:_[M:59GAP8T2T_P!RM.@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /(/VJ/^20:A_UVA_\ 0Q7Q<1@"OM']JD9^$&H?]=H?_0Q7
MQ=VK\CXJ_P!_7^%?FS]CX2_Y%[_Q/\D!HHHKXX^T"BBB@ HHHH **** "BBB
M@ I#T-+2,.#]* /M_P#9J_Y)-IO_ %TD_G7J5>6?LU#'PFTW_??^=>IU^]Y9
M_N5'_"OR/Y\S7_?JW^)_F%%%%>D>6%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!\<_M8?\ )0;?_KW%>*XXKVK]K ?\7!M_^O<5XKVK\+SG_D85
MO4_?,D_Y%M#T"BBBO&/;"BBB@ HHHH **** "BBB@ K=\ '_ (K[PY_U_1_S
MK"K>\ <^/?#?_7]'_.NC#?QX>J_,PQ'\&?H_R/T1'2EI!TI:_H4_F\**** "
MBBB@ HHHH **** "JNJ?\@ZX_P!PU:JIJO\ R#KC_<- $'AS_D"6G^Y6E6;X
M<_Y EI_N5I4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y!^U3
M_P D@U#_ *[0_P#H8KXN[5]H_M4?\D@U#_KM#_Z&*^+AR*_(^*O]_7^%?FS]
MCX2_Y%S_ ,3_ "0448]J*^./M HHHH$':BBCM0,**** "BBCK0 4C?=-+2'H
M: /M_P#9J_Y)-IO^_)_.O4J\M_9K_P"23Z;_ -=)/YUZE7[UEG^Y4?\ "OR/
MY\S7_?JW^)_F%%%%>F>6%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!\<_M8?\E"MO\ KW%>*GZU[5^UA_R4&V_Z]Q7BM?A><_\ (PK>I^^9)_R+
MJ'H%%%%>,>V%%%% !1110 49HHH **** 05O> #_ ,5]X;_Z_H_YU@BMWX?_
M /(_>&_^OZ/^==.&_CP]5^9SXC^#/T?Y'Z)#I2T@Z4M?T(?S@%%%% !1110
M4444 %%%% !535>-.N/]PU;JIJO_ "#KG_<- $'AS_D"VO\ N5I5F^'!C1+3
MO\E:5 !125$EW#).\*RHTT8!>,,-RY]10!-129]J,T +124M !1110 4444
M%%%% !1110 4444 >0?M4_\ )(-0_P"NT/\ Z&*^+NU?:/[5'_)(-0_Z[1?^
MA5\6CH*_(^*O]_7^%?FS]CX2_P"1<_\ $_R0M%%%?''V@4444 %%%% !128I
M:!!]:*** "@_=-%(>E S[?\ V:O^23:;_P!=)/YUZE7EG[-7_))M-_ZZ2?SK
MU.OWK+/]RH_X5^1_/F:_[]6_Q/\ ,****],\L**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#XZ_:Q_Y*#;?]>XKQ2O:OVL #\0;;_KW%>*U^%YS_
M ,C"MZG[YDG_ "+J'^$****\8]L**** "BBB@ HHHH *#110 5O> /\ D?O#
M?_7]'_.L&MWP!_R/_AP]_MT?\ZZ<-_'AZK\S#$?P9^C_ "/T2'2EI!TI:_H0
M_F\**** "BBB@ HHHH **** "JFJ_P#(.N/]PU;JKJG_ "#KC_<- %?PY_R!
M+7G/RUI5F^'/^0):?[G]:TJ *NJ1W,VG7*6<BPW31L(I&&0K8X)KYM^']KI>
ME_$".R\0?VWHGBB*_+"]EF9K:^)_@SG!!["OI34+,:A93VS.\:RH4+H<,N>X
M/K7CNG_"WQ=J6OQ6?B'4X+SP]87@O+>YP#<S8^ZC>@%,1R^K:>T?B7Q+KWBK
M3/$PT]-41;>6UOGCCBB& "(P<%<]:W;K34^)=]XNU9]3OH8M*B\G3UM+EXT1
ME4L)" >3GUKHM<\ >+M5DOM&_MR.3PW>S"0S2@FY@3.3$O8CW-&M_#'6=.O+
MU/"UW;6FF:K;BVNX)P<P\8,L>.K$>M '5_#+6;G7_ NCWMX_F73P!99/[[#@
MG\<5U%9?A?0(?"_A^PTF!S)%:1+$';JV.I/UK4I#"BBB@ HHHH **** "BBB
M@ HHHH \@_:HX^$&H?\ 7:+_ -#%?%W85]H_M4\_"#4/^NT/_H8KXNK\CXJ_
MW]?X5^;/V/A+_D7O_$_R044=_:BOCC[0*,T44 %%%% !1110 4444 %(1D&E
MI#PI/:@#[?\ V:O^23:;_P!=)/YUZE7EG[-/_))=,_WW_G7J=?O66?[E1_PK
M\C^?,U_WZM_B?YA1117IGEA1110 4444 %%%% !1110 4444 %%%% !1110
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M10** "BBB@ HHHHL 4444 %;O@#_ )'[PY_U_1_SK"K=\ ?\C]X<_P"OZ/\
MG73AOX\/5?F88C^#/T?Y'Z)"EI!2U_0A_-X4444 %%%% !1110 4444 %5=4
M_P"0=<?[AJU575/^0=<_[AH K>'/^0):?[G]:TZS/#?_ "!+7/\ =_K6G0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D'[5/_ "1_4?\ KM#_
M .ABOB[' K[1_:I_Y)!J'_7:'_T,5\6CH.:_(^*O]_7^%?FS]CX2_P"1>_\
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MEKD/A/K%SK?@/2Y[MVEN43RGE;K(5XW?C77TAA14<TRPKN;./85 =3A'9_\
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MYH_M*'T?_OF@"W15,ZI".S_]\FE_M.$]G_[YH MT54_M.'T?_OFC^TX?1_\
MOF@"W15/^U(?1_\ OFC^U(?1_P#OF@"Y15/^U(?1_P#OFC^U(?1_^^: /D7]
MK _\7"MO^O<5XJ>M?1_[0OPS\3^.?&<-]HNFM=6J0A2Y('->8?\ "@/'W_0$
M.?\ KH*_&\UR_&5<=5G"E)IO>S/VS*,QP5+ 483K132V;1Y_17H'_"@/'W_0
M$/\ W\%'_"@/'W_0#/\ W\%>5_9>._Y\R^YGK_VI@/\ G_'_ ,"1Y_VHKT#_
M (4!X^_Z A_[^"C_ (9_\??] -O^_@H_LO'?\^9?<P_M7 ?\_P"/_@2//Z*]
M 'P!\??] ,X_ZZ"@_ #Q]VT,_P#?P4?V7CO^?,ON8?VI@/\ G_'_ ,"1Y_1F
MO0/^% ^/O^@&?^_@H'P!\?'_ )@9_P"_@H_LO'?\^9?<P_M7 ?\ /^/_ ($C
MS^@5Z ?@#X^_Z 9Q_P!=!1_PH#Q]GG0S_P!_!1_9>._Y\R^YA_:N _Y_Q_\
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MK/\ >;'4GW-:E%% "$9HVCT%+10 F!Z"C:/04M% ";1Z"C:/04M% ";1Z"C
M]!2T4 )@>@HVCT%+10 F!Z48I:* $Q1@>E+10 F*,5S'CKQ=>>%[6V73M(GU
MG4+J3RXH(CM4>K,W8"N5B^,T]BNOVNKZ*;35M*6-A;QS!A<%_NA3VH ]1QFC
M%>:Z5\6;^+4Y=-U_0)--OFLS?6T<,GF^<HZKQT:J]G\7-7M=1T9=>\--I%CJ
MSM'!(TX+QD#(WK[@9H ]2Q1@5Y/+\;+ZW;^TIO#KKX9-X+-;\3 N<G ?;_=S
M6M\2_BP/ %]I%M%IKZDUXQ>9D; MX1]Z0TP/0L"C%16=W%?VD-S"X>&9!(C#
MH5(R#4U(!,48I:* $P*,#T%+10 FT>@HVCT%+10 F!Z"C ]!2T4 )M'H*-H]
M!2T4 )M'H*,#T%+10 F!Z"C:/04M% ";1Z"C:/04M% ";1Z"C ]*6B@!,#T%
M&!Z"EHH 3 ]!1M'H*6B@!,#THQ2T4 )BC I:0T &**\\\1_$;7;+6M1LM(\,
M2W\&GQ"6:ZFE$:2?[*>IJK<?&&:_.E6NA:0=1U*]MVN&@>4(L(7[P)[F@#TW
M HKS-/BY?WVC:?)I_AV>ZU:YG-O+:!_EMF'4NWI33\8Y]-T/6KC5M'^QZEIL
MJQ&U$P*R;OND-V%.P'I])BO.;;XCZ[;^&=8UG5?#\%K#96QGB6"\6;S3C.TX
MZ55\/>/_ !OX@LM-O5\(P0VEVBR[C= E5/M2 ]0P*,4D99HU++M8CD>AIU "
M8%%+10 FT>@HP/04M% ";1Z"C:/04M% "8'H*,#T%+10 FT>@HP/04M% ";1
MZ"C:/04M% !575/^0=<?[AJU535>-.N?]PT 0>'/^0):?[E:59OAPYT6U_W:
MTJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@_B
MY\1I/A[H<4MM8RWU_=OY,"(N50]W8^@_6O,I=&L]1\%:C=Z;=7.MZ]%=PW^I
M3M$5>;:<[$'H!T%?0LL$<X DC60#LR@TV&T@MR3%#'%NZ[% S3 \7?Q?!KWC
M^S\2V=K<2:5I.E2/<2>601(1Q&!ZUF>%=?M/B9KZZOK<L]OJ<T<D.EZ2\1\N
MUR"-[-W8^M>]164$".D<,<:N<LJH "?4TBZ?:I('6WB5QT8( 10(^>7U!YO
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M!Z?17F'VVX_Y[R_]]FFK>W&/^/B7_OLT6"YZC17EYO;C'_'Q+_WV:;]NN?\
MGXE_[[-%@N>I45Y;]NN?^?B7_OLT"^N>?](E_P"^S18+GJ55=4_Y!UQ_N&O-
9_MUSD?Z1+_WV:>+R=@09Y"#U!<T6"Y__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>ahpa-20220416xs4026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xs4026.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'E P@# 2(  A$! Q$!_\0
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MJE:5%%P,W_A'M/\ ^?5*7_A'M._Y]4_*M&BBX&;_ ,(]IW_/JGY4O_"/:?\
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M?\^J4#P]IP_Y=4K2HHN!F_\ ".Z=_P ^J4?\([IW_/JE:5%%P,[_ (1[3_\
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M '\J_13 H?:;_'_'HG_?RC[3?_\ /HG_ '\J_10!0^TW_P#SZ)_W\H^TW_\
MSZ)_W\J_12 S_M-__P ^B?\ ?RE^TW__ #Z)_P!_*OT4P,_[3?\ _/FG_?RE
M^TW_ /SZ)_W\J_10!0^TW_\ SZ)_W\I!<W__ #Z)_P!_*T**0%#[3?\ _/HG
M_?RD^TW_ /SZ)_W\K0HH SS<W_\ SZ)_W\H^TW__ #YI_P!_*T**8%#[3?\
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M3_OY2?:;_P#Y]$_[^5H44 4/M-__ ,^B?]_*3[3?_P#/FG_?RM"BD!GFYO\
M_GS3_OY2_:;_ /Y]$_[^5?HH S_M-_\ \^:?]_*/M5__ ,^:9_ZZ5H44P,_[
M3?\ _/FG_?RC[3?_ //HG_?RM"B@"A]IO_\ GT3_ +^4?:;_ /Y]$_[^5?HI
M 4/M-_\ \^B?]_*/M-__ ,^B?]_*OT4 4/M-_P#\^B?]_*/M-_\ \^B?]_*O
MT4 4/M-__P ^B?\ ?RC[3?\ _/HG_?RK]%,"A]IO_P#GT3_OY1]IO_\ GT3_
M +^5?HI 9_VF_P#^?1/^_E+]IO\ _GT3_OY5^BF!0^TW_P#SZ)_W\I/M-_\
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MS%<GHI,YI:0PHHHH **** "BBB@ HHHH ***1F"*2Q"@=S0 M%0B\@/2:/\
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MT :%%9^W4_[]M_WRU&W4_P"_;?\ ?+4 :%%9^W4_[]M_WRW^-&W4_P"_;?\
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MU3UVFORK\49_X2;5=V"WVALD?6OLN'=ZGR/ S7:'S,RI]/\ ^0I8_P#7=/\
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M?\5?\C1JW_7R_P#.OLN'=ZGR/ S7:'S,NIK#_D*6/_7=/_0A4%3V'_(4L?\
MKNG_ *$*^S>Q\\?K;I?_ "#;3_KDG\A5JJNE_P#(,M/^N*?R%6J_&WNS[];!
M1112&%%%% !1110 4444 %><_M#_ /)&O$__ %ZG^=>C5YS^T/\ \D;\3_\
M7J?YBNG"_P >GZK\S&M_#EZ,_,6+_5BG4V(?(*><U^NO<^%/1/V<?^2^^"/^
MOMO_ $!J_3FOS&_9Q_Y+YX)S_P _;?\ H#5^G-?!\0_QX?X?U9]+E7\.?K^B
M"BBBOE3VPK\X/VLA_P 7RUOZ+_*OT?K\X?VLN?CGK0[[4_E7TW#_ /O,O3]4
M>-FG\%>IX_39?]4U.ILW^K;GM7Z MSY=['Z9?LU'/P/\)_\ 7FM>G5YC^S5_
MR0_PE_UYK_,UZ=7Y'B_]XJ>K_,^ZH?P8>B_(****Y3<H:[_R"+K_ '**-=_Y
M!%U_N44$2&>'O^0-:_[M:59OAW_D#6O^[5C4]1ATJQFNYR?+B4L0HR3[ =S0
M66J*\X\*_&6V\0>#]:\1W&GW&GV6G2.OERC]XP4XSCWJ/PE\2]9O-=L[/Q#I
M,6F6^IQ^;I\\4N\/WVMZ-@T >ET4E+0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1129H 6BBB@ HHHH **3-+0 4
M444 %%%% !1110!6U+_D'77_ %R?^1K\GO%)_P"*HU8?]/+_ ,Z_6'4O^0==
M?]<G_D:_)[Q4,>*-6_Z^7_G7V7#N]3Y'@9KM#YF74^G_ /(3L?\ KNG_ *$*
MAJ;3_P#D*6/_ %W3_P!"%?9O8^>/UMTK_D&6G_7%/Y"K55=+_P"09:?]<4_D
M*M5^-O=GWZV"BBBD,**** "BBB@ HHHH *\Y_:&_Y(WXH_Z]3_,5Z-7G/[0_
M_)&_$_\ UZG^==.%_CP]5^9C6_A2]&?F+'_JU^E.IL?^K%/K]=9\*>B?LX_\
ME]\$?]?;?^@-7Z<U^8W[./\ R7WP1_U]M_Z U?IS7P?$/\>'^']6?2Y5_#EZ
M_H@HHHKY4]L*_.']K+_DN>M_[J?RK]'J_.#]K/\ Y+GK?^ZG\J^FX?\ ]ZEZ
M?JCQLT_@KU/(*;+_ *MO6G4V;_5M]*_0%N?+L_3/]FK_ )(?X2_Z\U_G7IM>
M9?LU_P#)$/"6/^?-?ZUZ;7Y'B_\ >*GJ_P S[JA_!AZ+\@HHHKE-S/U[_D$7
M7^Y12Z[_ ,@BZ_W**")#/#O_ "!K7_=J_(BR(0RAAZ$50\/?\@:U[_+6E06>
M(V^@ZCJ?@#Q[8P6KFZFN)&@C(QOPV0!^5.T[5$\?:WX,LM.BD#:*!<7LCJ5$
M3!0NSZYKVH(%S@ 9]!3(K:&!F,<21ESEBB@$GWI@24R:(RI@,4]Q4E%("B=.
MD/\ R]2"C^SI/^?J3\JO44"L43ILA_Y>I/RI/[-D_P"?J3\JOT4!8H_V=(/^
M7J3\J!IT@_Y>I/RJ]10!1.G2$Y^U2?E2?V:__/U)5^B@"A_9L@_Y>I/RI?[.
MD_Y^I/RJ]10!1_LZ3.?M4GY4?V=)_P _4GY5>HH"Q1_LU_\ GZDH_LU_^?J2
MKU% %#^S7_Y^I/RI?[.DQ_Q]2?E5ZB@+%$Z:Y_Y>I/RH_LZ3_GZD_*KU% RC
M_9LG_/U)^5']FO\ \_4GY5>HH$4?[.D'_+U)^5']G2?\_4GY5>HH"Q0_LV3_
M )^I/RH_LV3_ )^I/RJ_10,H_P!G2?\ /U)^5!TZ0_\ +U)^57J* *)TZ0G_
M (^I/RI/[-D_Y^I/RJ_10!0_LV3_ )^I/RH_LV3_ )^I*OT4"L4?[-D_Y^I/
MRH_LY_\ GZD_*KU% %'^S7_Y^I/RI/[-?_GZDJ_10%BA_9LG_/U)^5*=.D/_
M "]2?E5ZB@+%#^S9/^?J3\J/[-D_Y^I/RJ_10,H_V=)C_CZD_*D_LU_^?J2K
M]% BA_9LG_/U)^5']FR?\_4GY5?HH&4/[-D_Y^I/RI?[-?\ Y^I/RJ]10*Q1
M_LYQ_P O4GY4'3I#_P O4GY5>HH HC3I!_R]2?E2?V;)_P _4GY5?HH&4?[.
MD_Y^I/RI/[.D_P"?N3\JOT4"*']FR?\ /U)^5+_9TF,?:I/RJ]10%BA_9LG_
M #]2?E7C/[5?C/Q#\-/AO%J?AW4S9WINEC,CH'!!]C7NM?.W[<O_ "2"'_K^
MC_D:]'+XQGBZ<9*ZN<N+;C0FXNSL?,R_M9?%15'_ !4,1_[=5I?^&L_BKC_D
M8(?_  %2O(AT%+7Z1]2PO_/J/W(^1^L5OYW][/L']DCXR>-/B?X\UW3O$FL_
M;+6"S$T2)&$P=P&>/K7U=_9L@_Y>I/RKX@_8-_Y*GX@_[!@_]#%?=M?!9S3A
M2Q;C322LMO0^FRZ4IT$Y.[N_S*/]FR?\_4GY4G]FR?\ /U)^57Z*\,]*QEWM
MBT=A>$SNX,+C!_W37Y4>*!M\3:J"<XN&_G7ZQ:E_R#KK_KD_\C7Y/>*O^1HU
M;_KY?^=?9<.[U/D>#FNT/F9E2V(SJ5B/^FZ?^A"H:GL/^0I8_P#7=/\ T(5]
MF]CYX_6'3[!Y-.LR+AU_<H,#_=%3_P!FR?\ /U)^52Z5_P @RT_ZXI_(5:K\
M;>Y]^MBA_9LG_/U)2_V;)G_CZDJ]12&4?[/D_P"?J3\J/[-?_GZD_*KU% K%
M$:=(/^7J3\J/[.D_Y^I/RJ]10%BC_9LA_P"7J2D_LU_^?J2K]% 6*']FR?\
M/U)^5>??M V;1_!KQ,#,[_Z.3S]17J%><_M#_P#)&_$__7J?YUTX;^/3]5^9
ME6_AR]&?F+%R@IU-B_U8I^,5^NL^%/0_V=%W_'OP2N<?Z83D?[C5^EATYR21
M<R"OS5_9Q_Y+YX)_Z_&_] :OTXKX/B'_ 'B'^']6?2Y5_"EZ_HBA_9LG_/U)
M^5+_ &=)_P _4GY5>HKY4]LI1Z>Z.K&X=@#T-?G7^U;'Y7QQUL;B^0IR?I7Z
M0U^</[67_)<]:_W4_E7TV0?[U+T_5'C9I_!7J>09YJ.7_5M3Z;+_ *LU^@+<
M^79^E'[.%DTGP/\ ">V=T_T0'BO2O[-?_GZDKS_]FH?\60\)_P#7FO\ ,UZ=
M7Y'BO]XJ>K_,^YH+]U#T7Y$4$)A3:6+^YJ6BBN4Z"AKO_((NO]RBDU__ ) ]
MU_N44$L;X>_Y UK_ +E:59OAWC1K7O\ +6E04%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%9/BGQ-8^#M!N]8U)VCLK5-\C*NX@?
M2O'XOVT_A?*H;^U;E?8VK_X5TTL+7KKFI0;7DC&=:E2=IR2]3W:BO#?^&SOA
M?_T%[C_P$?\ PJ[X9_:S^'GB_P 4Z=H&F:C/-J%_)Y<*M;LH)P3U(]JV> Q2
M3;I.R\F9K%4&TE-:^9[+12 YI:X#J"BBB@ HHHH **** "BBB@ KYV_;E./A
M!#_U_1_R-?1-?.O[<HS\((?^OZ/^1KT\L_WREZG'C/\ =Y^A\%C[HI:0=!2U
M^IGQ9](?L&_\E3\0?]@P?^ABONVOA+]@T8^*?B#_ +!@_P#0Q7W;7YSGO^^O
MT7Y'U>6_[NO5_F%%%%?/GJE;4O\ D'77_7)_Y&OR?\5?\C/JW_7R_P#.OU@U
M+_D'77_7)_Y&OR>\5<>*-6_Z^7_G7V7#N]3Y'@9KM#YF94UA_P A.Q_Z[I_Z
M$*@J?3_^0G8_]=T_]"%?9O8^>/UMTK_D&6G_ %Q3^0JU572O^09:?]<4_D*M
M5^-O=GWZV"BBBD,**** "BBB@ HHHH *\Y_:&_Y(WXG_ .O4_P Q7HU><_M#
M_P#)&_$__7J?YBNG"_QZ?JOS,:W\.7HS\Q8O]6*>,4R/_5K3J_76?"GHO[./
M_)??!'_7VW_H#5^G-?F-^SC_ ,E^\$\_\O;?^@-7Z<U\'Q#_ !X?X?U9]+E7
M\.?K^B"BBBOE3VPK\X?VL_\ DN6M?[J?RK]'J_.']K+GXYZU_NI_*OIL@_WF
M7I^J/&S3^"O4\@IDW$9I],FYC;Z5^@+<^7>Q^F?[-?\ R1#PG_UYK7IM>9?L
MU?\ )$/"7_7FM>FU^1XO_>*GJ_S/NJ'\&'HOR"BBBN4W*&O?\@BZ_P!RBDU[
M_D$77^Y101(;X>_Y UK_ +M:59WA[_D#6O\ NUHT%A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'G?[0?_ "1_Q+_U['^=?F(G"].Y
MK].OVA/^2/>)?^O?^HK\QEZ?C7WG#W\"?K^A\SFO\6/H+VKO?V?A_P 7S\%'
M_I_ _P#'6K@J[W]G_P#Y+GX*_P"O\?\ H+5]%B?X%3_"_P CR:?\2'JOS/U
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MBPTR3R[^>W9(6W;?F],]O2O,/"WA*^G\2>'9-/T$>'O[.3&HW7"F<XP4&/O
MGG- 'MXH+!1DD >]%-EA29=KC(H /-3^^OYT>:G]]?SJ#^SK?_GF*/[.M_\
MGF* )_-3^^OYT>:G]]?SJ#^S;?\ YYT?V9;_ //,4 3^:G]]?SH\U/[Z_G4'
M]F6__/,4?V9;_P#/,4 3^:G]]?SH\U/[Z_G4']F6_P#SS%']F6__ #S% $_F
MI_?7\Z/-3^^OYU!_9MO_ ,\Q1_9MO_SS% $_FI_?7\Z/-3^^OYU!_9EO_P \
MQ1_9MOC[E $_FI_?7\Z/-3^^OYU!_9MO_P \Z/[-M_\ GG0!/YJ?WU_.CS4_
MOK^=0?V;;G_EG1_9MO\ \\Z )_-3^^OYT>:G]]?SJ Z;;G_EG1_9MO\ \\Z
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MJ?WU_.CS4_OK^=0?V=;_ //,4?V=;_\ /,4 3^:G]]?SH\U/[Z_G4']FV_\
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M7^\5/5_F?=4/X4/1?D60P89!!'M2TR*%(5VH,"GUR&YGZ]_R"+K_ '**-?\
M^0/=?[E%!$AOAW_D#6O^[6E6;X=_Y UK_NUI4%A28I:* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSFG\6/H+VKO?V?O^2Y>"O^O\?^@M7!=*[OX!2"/XW^"V8X U <_\!:OH<3_
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MN5?PI>OZ(T**SO\ A(-/_P"?E:/^$@T\?\O*_K7RA[9HU^</[67_ "7/6_\
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MNM[V\G[V4<?WS7Z7?LT(LOP8\.EU#GR1RW)K\TIQ^XD^AK]+OV9/^2+>'/\
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MW_((NO\ <HH(D)X>_P"0-:_[M:-9WA[_ ) ]K_N5HT,L**** "BBB@ HHHH
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MS/U HHHK\B/O HHHH _-S]K#_DOWB7_=@_\ 0!7DE>M_M7_\E^\2_P"[!_Z
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M5_R#+3_KBG\A5JJNE_\ (,M/^N*?R%6J_&WNS[];!1112&?$G[?7_(Z>$O\
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MXO\ WBIZO\S[JA_"AZ+\@HHHKE-S/U[_ )!%U_N44:]_R"+K_<HH(D-\._\
M(&M?]VM*LWP]QHUM_NUI4%F3XJ\2V/A#0;O5M1E$-K;)N8^OH*\5^&/B%-2^
M,$U]<Z]'>W&IV/F):1R92$9&U0/7'6O=]0TVUU6U:WO+>.Z@;K'*H93^!KD[
M#X4Z)I7C=?$=G:Q6TRV_D"&.,!1S][ZT =H*CN+A;:/>RLP]%&34M% % ZS$
M/^64W_?LTG]LQ?\ /*;_ +]FM"BF!GC68B?]5/\ ]^S0=9B'_+*?_OV:T**
M,_\ MJ'/^JG_ ._9H_MF+_GE/_W[-:%% &?_ &U%_P \I_\ OV:/[9B_YY3?
M]^S6A12 SO[:B_YY3_\ ?LTO]M0_\\I_^_9K0HI@9_\ ;,7_ #RF_P"_9H_M
MF+_GE-_W[-:%% C/_MJ'_GE-_P!^S0-9B/\ RRG_ ._9K0HI#,_^V8O^>4W_
M '[-']LQ?\\I_P#OV:T** ,\ZU"/^64__?LT?VU%_P \I_\ OV:T**>@&?\
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MHY7_ !I>AZ'_ &U%_P \I_\ OV:/[:BS_JI_^_9K0HKX(^H,_P#MF+_GE/\
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M?\D-\-_]<F_F:];KQO\ 9<GG3X&^'"L._P"1@.>V:]7^TW7_ #[?K7Y+C/\
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MZ;(/]ZEZ?JCQ\T_@KU/(J;+_ *MOI3J;+@1MZ8K] 1\N]C],OV:O^2(>$_\
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M HHHH _-S]J_GX_^)?\ =A_] %>25ZW^UA_R7_Q+_NP?^@"O)*_6L'_NU/\
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M_(U^3_BK_D:-6_Z^7_G7V7#N]3Y'@9KM#YF6*FT__D)V/_7=/_0A4.*FL/\
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M\"J< ?2OOK]MS_DD/_;TE? HZ"OT;(O]S^;/D\R_WCY"BOH']AO_ )++>?\
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M"BBBOGSU2MJ7_(.NO^N3_P C7Y/>*O\ D9]6Y_Y>7_G7ZPZE_P @ZZ_ZY/\
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MR"?,;O[&OTVKX/B'^/#T_5GTV5?PY>OZ!1117RI[85^<G[77_)>-9_ZXP_\
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MIJ  ]Q_A7TWN&<9YHR,XSS7;1QN(H1Y*4VD<]3#4:LN:<;L^9/\ A@[P@?\
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M32-%NGEM7<R9G&2#7HM&1G&>:FKC<37AR59MHJ&&HTY<T(I,I^5>_P#/9/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*6BB@ HHHH **** "BBB@
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MAFU\.Z9OBO=;G6U%T%++ ,[BQQVXQ7&WUAXD^'GC>PO]5GCU6QU+3VTR3[#
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M_$1MDN%'D1S"9X@.)2.F[UK;50BA0, #  I:* "BBB@ HHHH **** "BBB@
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M #-(?&]R/^6$?YFBBBR$FP'C>Z)_U$?YFE_X3:Y_YX1_F:**+(+L0>-[D_\
M+"/\S2GQM<@9\B/\S1119#N-'CBY/_+"/\S2_P#";W//[B/\S113L@N'_";W
M/_/"/\S2_P#":W/_ #QC_,T44K(5Q#XWNA_RPC_,TH\;7)&?(C_,T4460-B'
MQO=#_EA'^9I?^$VN<?ZB/\S113:07 >-KDC/D1_F:/\ A-;G/^IC_6BBE9#N
M'_";7/\ SPC_ #-)_P )Q<_\\(_S-%%%D),7_A-KG_GA'^9I/^$WNO\ GA'^
M9HHHL@N._P"$TN?^>,?ZTG_";7/_ #PC_,T44K(+L4^-;D?\L8_S--_X3>Y_
MYX1_F:**=D*['?\ ":7/_/&/]::?&]T#CR(_S-%%"2*N+_PFMS_SQC_,T?\
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2;<7EK+$T*!6&#@T444FD!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>ahpa-20220416xs4028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xs4028.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $! JP# 2(  A$! Q$!_\0
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M>/\ A@/X'?\ 0EP_]_Y/\:/^& _@=_T)</\ W_D_QKZ'HH ^>/\ A@/X'?\
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M\#O^A+A_[_R?XT#]@/X'?]"7#_W_ )/\:^AZ* /GC_A@/X'?]"7#_P!_Y/\
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M/@KXRVDLGV:'2?$B?/!J=GA)5?MNQU%>#-23]]6O\CZFFX2BE"5[>=SVY6#
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M0W)<12I)L.UMC X/H:!7):YWQO\ \>%E_P!?L/\ .NBKG?&__(/LO^OV'^=
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MZ<K^3]J\B+S%_A+0*,_K7FX:C"K"K*;^%)_^3)?DSVL9B:E"I1C35^>33_\
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MPSK46FRR:1;6+(]V,;%8YXKWJBN&ABI4)SFE?F37WGIXG!1Q-.%.4FN5Q?\
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M2;2W GHI <C(Y%+3 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OQW_;5_Y.?\>?]?,7_HB.OV(K\=_VU/\
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M5+\CO8WA4A._*[V"BBBM#0**** "BBB@#F?"_P#R'?$?_7T/_01735S/A?\
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M]1?^B(Z!H_0#_@GO_P F??#C_KR?_P!&O7T37SK_ ,$]_P#DS_X<_P#7D_\
MZ->OHJ@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%';10R2.D:H\AR[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBW6V,C:I<RAU6(GY4A4Y*H!CI7EOP\EF\5>!_P!HCQRRYTW53-;V<N,!TB#
M,/S%=Y^R5^S]H,GPNT7Q)XFMD\0:WJ-L"7O1O2&/^%54\#CO6\:DH1E&+M??
M^NP1DTK(^@_#'B7PSXBT<:QH5]I]WIS DW5JR;!ZY(Z?C6-I_P =/A_JNO\
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M'9>'5:QT;Q9I\K76G(<0B96X=5Z"MSPQC_AM_P 6$$X_X1RWX]]]%@/9?B@
M?AOXI_[!ES_Z+:O+/V()&D_9S\.;CG!F S_UT->J?$__ ))OXI_[!ES_ .BV
MKYM^!/Q#?X7_ +$<GB:*-9;C3X9WA1^A<N0N?Q->I1@ZF$E".[E'\F;Q5X->
M:/H'Q]\:_!'PP:./Q+XDL=,GD&4MY)096'KL'.*;X1^./@7QUIUY?:)XFT^]
M@LXS+<;9@&B0#)9E/(&.]>6?LU? 324\,6OCCQ9!'XC\9^((Q>W5Y?*)1$'Y
M"(&R  "*3]J#]G+1/$7@#7/$/ARUC\/^*=.L)I8KFP7RA.@0EHY%7 8$9%+V
M.%]I[%R=[VOI:_IO;SO\A)1O9GLEY\4O"EAX>T[7;C7;.'2=0=8[6[:0!)6;
MH%/>NH5@ZA@<@]#7P3\2-DG[&GP=8*!_Q,+/\]S9K[RM/^/6'_<7^598G#QH
M133ZR7W,)0Y5<RIO&NB0>*8?#;ZE;KKDT)N([$O^\:,=6QZ5B:S\:/!.@:9J
ME_?>)+""WTR4P71,PW1R?W,=<^U>->)XU7]N_P (.!\S>'KD$_2N%^!?PGT?
MQU^T[\6=8UFV6^L]-U!5AL9ANA\U@/G*]"<5T1PE+D]I.3LHJ7WNU@48[L^M
M? _CK1?B+X?AUK0+Q;[3IB0DR@C)'7K7055T[3+32+1+6QM8;.W3[L4"!%'X
M"K5>5+E;?+L9OR"BBBI$%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X[_MJ?\G/^//^
MOJ+_ -$1U^Q%?CO^VI_R<_X\_P"OJ+_T1'0-'W]_P3W_ .3/OAQ_UY/_ .C7
MKZ*KYU_X)[_\F??#C_KR?_T:]?15 @HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y+XI?#72/BSX)U'PUK4/F
M6EVG#CAHG'W74]B#S7SYX5^-OBC]FIK?P=\5]-O-0T2V_=:=XNL(S-') .%$
MP'(8# KZPJM?Z;:ZI:R6UY;Q75O(,/%,@96^H-,5CR%_VQ?A MF;@>,[1AMW
M>6L4AD/MMVYS7F'BKXH^+OVK0_A+X;6%[X?\(SMLU7Q5J$9A+PYPT<"GG+#O
M7O2? CX=QWHNU\&:,MR#N\P6B9S^5=K:65O80)!;0I!"@PL<:A5 ]@*- /(_
MB-X'TGX;_LR>)O#^CP+:V%EHLR*!_$0G+'U)ZUJ_LT2"3X%>#&4[@=/CY_"O
M1=2TVUUBPGLKV".ZM)T,<L,HRKJ>H(]*9I.D66A:?!8:?;1V=G NR*")<*B^
M@% 'SOKDR#]NC0DW#=_PC3_+_P #:O9_BVP7X7>+6)P!I5SS_P!LFK8D\*Z/
M+X@CUU].MVUB.(PI>E!YJI_=W>E7KVR@U&TFM;J)9[:9#')$XRK*1@@B@9\B
MZA/&O_!/FS8L-ATM!G_@1KZ7^%)5OACX3*\K_95KC'_7):OMX*T%O#8\/G2;
M4Z($\L6!C'E!?3;6I964&FV<-K:Q+!;0H(XXD&%10, #VH;$?-?QEN(_^&O?
MA-$6 <6LYQ]6_P#K5;\+2HW[;OBU PW#P]!D?\"%>]7WA/1M2UNTUBZTVVGU
M2T4K;W;Q@R1 ]0I[4Z+POI,&OS:W'IUNFKS1"&2]5 )&0=%)]*+@9?Q28)\-
M?%+,< :7<DG_ +9-7S?\ ? (^*O[$K^&8I4CFU"&>.*1ONK)O)4GVR*^LKRS
M@U"TFMKF)9[>9#')&XRK*1@@BJ7A[PWI?A/2XM-T>P@TVPBSLM[==J+GDX%=
ME+$^RI.$=^9-/TN:J5HV/ OV<OC]H]CX;M? 7C6ZC\->-/#\0L[FUOR(EF"<
M+)&QX8$8IG[37[2F@Z1X \0>'_"UXGB+Q->V$T:PZ?\ O4MHRA#22,.  ">,
MUZ[X_P#@MX)^*!C;Q/X<LM5FC&$GECQ(H] PP:;X/^"?@;P%IUU8Z%X9L+"W
MNXS%<!(LF5",$,3R0:Z/;87VGMG%WO>VEK^N]O+\1IQO=GS'K'@K4/&7["W@
MF?1+<ZA?:,D&I?9D^]*(V)<#WQFO?/A[^TK\/_&W@^UU>/Q)8V#"(?:+6\F$
M4L#@?,K*>>#7I.BZ%I_AS2X--TRSBL;"!=L5O"N$0>@%>=>(?V7?A;XIU=M3
MU#P9ILMZ[[Y)%C*>8?5@#@T2Q%&NG&JFE=M->>Z8.2EHSR/X<:]_PO+]K2[\
M;Z#&\WA#P[ILFF1ZDRE4N9F/.S/4=>:W?V5Y8I?B=\;6C(;_ (GR#/TCQ7O_
M (<\,:3X1TF'3-%T^WTS3X1B.WMD"(OX"FZ-X4T?P]=ZA=:;IUO97&H2^==2
M0IM,S_WF]34U,7&490C&RLDOD[Z^HG)6:-:BBBO,,PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "OQW_;4Y_:?\>?\ 7U%_Z(CK]B*_'7]M4?\ &4'CS_KZB_\
M1$= T?H#_P $^/\ DS_X<?\ 7D__ *->OHFOFK]@76=.TW]DCX=VUSJ-G#,E
MDP9'G4$'S'X()KZ"_P"$GT;_ *"UC_X$I_C0!IT5F?\ "4:-_P!!:Q_\"4_Q
MH_X2C1O^@M8_^!*?XT"-.BLS_A*-&_Z"UC_X$I_C1_PE&C?]!:Q_\"4_QH T
MZ*S/^$GT;_H+6/\ X$I_C1_PD^C?]!:Q_P# E/\ &@#3HK,_X2?1O^@M8_\
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M?XT?\)/HW_06L?\ P)3_ !H TZ*S/^$HT;_H+6/_ ($I_C1_PE&C?]!:Q_\
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4]:Z[PM_J+[_KY/\ Z E%% F?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>ahpa-20220416xs4029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xs4029.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &X Y # 2(  A$! Q$!_\0
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M !5,_P"">O\ R:#\._\ KR;_ -#:OHR@;9\[?\.^?@!_T3K3O^^G_P#BJ/\
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M'?/P _Z)SIO_ 'T__P 51_P[Y^ '_1.=-_[Z?_XJOHFB@+L^=O\ AWS\ /\
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M  [Y^ '_ $3G3?\ OI__ (JOHFB@+L^=O^'?/P _Z)SIO_?3_P#Q5'_#OGX
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MZK/_  [Z^  _YISIW_?3_P#Q52_"OXG0>%?AKXPA%RFJ'PQ-)Y1C;*M&Q)C
M]A74^ ='\>ZM#I.OW_BF)HKU?/GL%MQL6-N4"\<$#% 79PP_80_9UD@N9HO
M.ES);%A+Y3NQ4CJ#ANM4?"G[$W[.7C/2_M^G?#NR, =H_P!X)%.1P>-U1_![
MPKXHE;Q_+IOBIK%H-6G$@\H,)'!)W<]*VM&^*/B33_"W@_6+BX2>V.JR:=J>
MR(*KJ3A9.!Q@@\^]%@NQ_P#P[Z^ '_1.M._[Z?\ QH_X=]? #_HG6G?]]/\
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M+IT:>;IMZ6XNU!VMCZ'/2O1M9\1:;X>A634;V&S5SA?-<+N/MZU\M:CJVO\
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M/J0!P5O(E*@'\0#181[_ 'GB_1=/U*/3[C4[:&\DP%B>0 Y[9]*V <]*^5?
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M!\0^-_AGJNA:O?6B:C?.K*T"D1QJ&4XZ9/0UW^BV#:9H]C9LP=K>!(BP[E5
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M[U*TA6%DTC3[*,E;M"GWMPXSG/!K&L= U&/X>?"VW?3YC)!=AI8V7F,;L\T
M>N>#OB_IWBWQ#<:(]E>:3J4<?GI#?1[#+'_>%<AXZ^/FD7.@:_#IUMJ-S:0*
MUN=4M8B8EE] ?0>M:7BG3;JX^/GA^:*W?[/_ &1<QM.!\JL3P":\X\&ZW/X)
M^$6L^"+_ $.\G\2QR3@6:0[A,KG(D#=,4 >X?!^XENOAGX=FFE:>1[4,9'.2
MW)ZUV5<=\'K::S^&7AV&XB:"9+50\;#!4Y/!KL:0PHHHH *\%_;O_P"31/B?
M_P!@P?\ HV.O>J\%_;O_ .31/B=_V#!_Z-CH&MS._P"">W_)H/P[_P"O-O\
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M\5S>-O!.EZU<0K!-=Q[VC7H#7)ZQ\8-6C\6:WHVB^%Y=871U1KJ99U3&X9P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UU#J58 J1@@C@TZB
M@#G$^'?AJ.\^TKHED)=V_/DC ;UQTS71 8%+10 4444 %%%% !1110 4444
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MMQ7MY?7NH6D%Q]JM["XDS%%+V8#VKT8<4#%HHHI %%%% !7@O[=__)HGQ/\
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M4DLOL(7A8W("D'U&37L0K@K/X4PV^M"634)9](CG^U0Z8Z_)'+V.?;'2N^H
MBFG2!0S9P?05#_:<']YO^^:M$ CD4FQ?[H_*D!6_M.#^\?\ ODT?VG!_>/\
MWR:L[%_NC\J-B_W1^5 %;^TX/[Q_[Y-']IP?WC_WR:L[%_NC\J-B^@_*@17_
M +2@_O-_WR:/[2@_O-_WR:L[1Z"C:/04 5?[3@_O'_OFE_M*#^\W_?)JQL7^
MZ/RI=H]!0!5_M.#^\?\ ODT?VG!_>;_OFK6T>@HVCT% %7^TX/[Q_P"^30=3
M@'\1_*K.Q?[H_*C8O]T?E0!6_M.#^\?RH_M.#^\?^^35G8O]T?E1L7^Z/RH
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MZ][KP7]N_P#Y-$^)_P#V#!_Z-CKN.);F;_P3V_Y-!^'?_7DW_H;5]&5\Y_\
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M_6_Q,_>\I_W"A_A7Y'V/^S/_ ,D>TC_KI/\ ^C6KU*O+?V9_^2/:1_UTG_\
M1K5ZE7[%E7^X4/\ #'\D?C.;?\C"O_CE^;"O!?V[_P#DT3XG_P#8,'_HV.O>
MJ\%_;O\ ^31/B?\ ]@P?^C8Z]4\M;F;_ ,$]?^30?AW_ ->3?^AM7T97SG_P
M3U.?V0/AW_UYM_Z&U?1E /<****!!1110 4444 %%%% !1110 4444 %%%%
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MOZ#CLC^=I;L****HD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO5_^^S0!9R/449'J*K?V=%ZO_P!]FC^SHO63_OLT#+.1ZBC(]15;^SHO5_\
MOLT?V=%ZR?\ ?9H$2SW,5M"\LLBQQ(-S.QP /4UD?\)SX>QG^V[#_P "%_QK
M-^(^GQ+X!\0'YCBRE/+'^Z:^#H(46(?+S7R><YU/*ZD(0@I<ROO8^NR3)(9K
M3G.<W'E=M%<_0BU\6Z+?3I!;ZK9SS.<+'',I9OP!K6!!KX4^#=O&?BEX?R.L
M_8U]S0VJ0L2N<GU-=N39G+-*,JDH\MG8X\ZRN.55HTH2YKJ^NG4FHHHKWSYX
M***JZC=/964LT4+3R*/EC7^(]A0!:HKSZW^*RQVE_%?V+6VKVLZ6WV0'(DD<
M90*?<5M^#/&8\4K?036S66HV$ODW-NW(#>H/<4 =-1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?''[2
M_P#R56X_Z]X_Y5Y:1P:]2_:7&?BK<?\ 7O'_ "KRTG@U^$9K_O\ 6_Q,_>\I
M_P!PH?X5^1]C_LS_ /)'M(_ZZ3_^C6KU*O+/V9_^2/Z1_P!=)_\ T:U>IU^Q
MY5_N%#_#'\C\9S;_ )&%?_'+\V%>"_MW?\FB_$[_ +!@_P#1L=>]5X)^W?\
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MV3Z,:M44 4QI4 [-_P!]&D_LFWST?_OHU=HH%8I?V3;^C_\ ?1I?[*M_1_\
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MK<S?^">O_)H/P[_Z\F_]#:OHROG/_@GK_P F@?#O_KS;_P!#:OHR@'N%%%%
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD;QC\??'&E>+-5L
MK74H([6"=DC4VR$@ ^I%?7-? WQ!_P"1YUS_ *^G_F:^)XHQ-;#TJ3HS<;M[
M.W0^XX6PU'$UJJK04K);J_4ZE?VC/B 9X%_M2 JTBALVR="?I7V%HMS)>:19
MSRD-+)$KL0,9)%?GK'S/!_UT7^=?H-X<_P"0!IW_ %[I_P"@BN7A?%5\3*JJ
MTW*UMVWW.OBK"X?#0HNC34;WV278Y7XZ?\DJ\0_]>Y_F*^(4^XOTK[>^.?\
MR2KQ#_U[G^8KXAC^XOTKRN+/][I_X?U9ZO"/^YS_ ,7Z(]2_9G_Y*U9?]>TW
M_H!K[(KXW_9H_P"2MV?_ %[3?^@&OLBOH^%/]P?^)_DCYOBS_?X_X5^;/EC]
MK/\ Y&[1\?\ /J?_ $(UX:>E>Y?M9?\ (W:/_P!>I_\ 0C7AN,U\%GG_ ",:
MWK^B/T#(O^1;1]/U9]=?LM?\DJM_^OJ;_P!"->MW'^HD_P!T_P J\D_9:_Y)
M5;_]?,W_ *$:];N/]1)_NG^5?J^4?\B^A_A7Y'Y)F_\ R,:_^)_F?G]XH_Y&
M?5?^OA_YFJ6G_P#(3L?^OA/_ $(5=\4_\C-JO_7P_P#,U2T\_P#$SL1W\]/_
M $(5^)S_ (S]?U/W&G_!7I^A^AEG_P >D'^XO\JFJ"S_ ./2#_KFO\A4]?T%
M'9'\[RW844451(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 <W\2?^1!\0?\ 7C+_ .@F
MO@B'[@K[W^)/_(@^(/\ KQE_]!-?!$/W!7YAQ=_'I>C_ #/U/@__ '>KZK\C
MM?@S_P E2\/_ /7>ON:OACX,G_BZ?A[_ *[_ -*^YZ];A+_=:G^+]$>1Q?\
M[U3_ ,/ZL****^Y/@PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^./VE_P#DJUQ_U[Q_
MRKRT]#7J?[2__)5;C_KWC_E7EC?=-?A&;?[_ %O\3/WO*?\ <*'^%?D?8_[,
M_P#R1[2/^ND__HUJ]2KRS]F?_DC^D?\ 72?_ -&M7J=?L>5?[A0_PQ_(_&<V
M_P"1A7_Q2_-A7@O[=_\ R:)\3_\ L&#_ -&QU[U7@O[=_P#R:)\3O^P8/_1J
M5ZAY:W,W_@GK_P F@?#O_KS;_P!#:OHO-?.G_!/7_DT'X=_]>3?^AM7O?B+[
M>=$O?[+"'4/*;R!(?EW8XS0#W,V/X@Z#+=:Q;K?Q[]) ^UG^%,C.,]SVI_A3
MQOI7C*.=M.F9F@;#QRH4<9Z'!YP?6O!4T#Q'IT/B>VN/#'D0-'%//)#(9#.^
M06QZ]S7H_@7?K7Q%O=:M+::#3%TR&U)E0H&D!SP.^.E,1ZG1145PDKQXBD$;
M^I7-("6BL_[-J/\ S^Q_]^A1]FU'_G]C_P"_0IB-"BL_[-J/_/ZG_?H4?9M0
M_P"?U/\ OT*0S0HK/^S:A_S^I_WZ%'V;4/\ G]3_ +]"F!H45G?9=1_Y_H_^
M_(I1:ZC_ ,_J?]^A0(T**S_LVH?\_J?]^A1]FU#_ )_4_P"_0H&:%%9_V;4/
M^?U/^_0H^RZC_P _J?\ ?H4 :%%9_P!FU'_G]3_OT*#;:A_S^I_WZ% &A7P-
M\0O^1XUO_KZ?_P!"-?=26U^&!:\0CN!$*^$_'P9?&NLAF#,+E\D#&>:^ XN_
M@TO5_D?H'!_\>MZ+\S#C'[^'G_EHO\Z_07PW_P @#3O^N"?^@U^?$?\ KX>Q
M\Q<?G7WSX>M[\Z#IVV\0#R$ZQ ]A7)PA\=;T7ZG9QA\%#U?Z&%\=/^25>(?^
MO<_S%?$2?<7Z5]I?&V&\3X6^(#)=*Z^1R!'C(R.*^+4.4'TKCXM_WRG_ (?U
M9V<(_P"YU/\ %^B/4OV:/^2MV?\ U[3?^@&OLBOC/]G!9&^+%D(G$;?9YLDC
M/&PU]>?9=0Q_Q^I_WZ%?2<*?[@_\3_)'S7%G^_Q_PK\V?-'[6?\ R-VC_P#7
MJ?\ T(UX=7MG[5:2IXKTCS9!(?LIZ+C^(UXE7P.>?\C&MZ_HC] R+_D6T?3]
M6?77[+/_ "2FW_Z^9O\ T,UZW<?ZB7_=/\J\:_9BANG^%T)BN%C4W,N%*9Q\
MQKU:6WOQ#*3>(1M/ B [5^L93_R+Z'^%?D?DN<?\C*O_ (G^9\&^*?\ D9]5
M_P"OA_YFJ6G?\A2Q_P"OB/\ ]"%6_$P8>)-3#G<WGOD^O-4[$$ZG98X/GI@_
M\"%?B-3^,_7]3]QA_"7I^A^AMG_QZ0?[B_RJ:LW3H+Q8+8O<JZ!%RNS&>*TJ
M_H1;(_G9[L****8@HHHH YC6?B)H^@:[;:5>R2Q7%PP57,1\L$] 6Z"BZ^(V
MA6?B*/19+L?;'(3<%S&K'HI;H"?2N1^('B1-6\4VWA5[.>*P+I+>7IB)5QD$
M1J??CFN*UK3KNXM/$7ARWL+B/4KK5HI;:0H<-&"#OW>@%,1[$OQ&T)O$IT/[
M7B]SLR5/EE_[F[IN]JZBOGV2TNM2@L]!@L+B+5H->CNI7:,@&-2"S[O0U] C
MI0,6BH+J.>1 ()5B;/)*[JK?9M1_Y_4_[]"D!H45G_9=1_Y_4_[]"D^RZC_S
M^I_WZ% &C16?]FU#_G]3_OT*3[+J/_/ZG_?H4P-&BL_[-J'_ #^I_P!^A1]F
MU#_G]3_OT*!&A16?]FU'_G]C_P"_0H^S:A_S^I_WZ% S0HK/^RZC_P _J?\
M?H4?9M0_Y_4_[]"@#0HK/^S:C_S^I_WZ%'V;4/\ G]3_ +]"@#0HK/-KJ/\
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ML+T'_ED_Y4AO@/\ EF_Y4!<M455-[Q_JG_*C[</^>4GY4!<M455^VC/^J?\
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MBC[9=_\ /D?^^Q0!>HJC]LN_^?(_]]BC[9=_\^1_[[% %ZBJ/VR[_P"?(_\
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M1/VB'_KHO\Z_0;PWSH&G?]>Z?R%?GU%_KX?^NB_SK]!/#?\ R+^F_P#7!/\
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M_(U\[=J^B?V0\[O$O^]%_(U^9</?\C*E\_R9^H\1?\BRK\OS1](5\3_'T_\
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M<JT98>NZ,]XNWW'YWO\ Z^?_ *Z-_.MCP3_R._AW'_/_  _^ABLA_P#7S?\
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MRV\[N2MR47TV@T@+5%4OLES_ ,_A_P"^!1]DN?\ G\;_ +X% %VBJ8M+D?\
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M\KXM_P![I_X?U9^K<(?[I4_Q?HCO/@8/^+M^'O\ KH__ *":^WZ^'?@BC/\
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M_8<N_P!QI?X5^1^-9E_R,*O^)_F?GQ(/W\W_ %T;^9K6\%9_X3CP[_U_P_\
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M +G/_%^B/"XN_P!\I_X?U9X!^UT?^*>T/_KZ;^5?,O.?:OIK]KO_ )%W0_\
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M^]T_\/ZL]CA'_=*G^+]$=Y\"Q_Q=OP]_UT?_ -!-?;]?$'P,X^+7A[_KH_\
MZ":^WZ]WA+_<Y_XOT1X7%W^^4_\ #^K/G_\ :[_Y%[0_^OH_RKYGKZ9_:[_Y
M%[0_^OIOY5\S5\CQ)_R,I^B_(^OX:_Y%E/U?YGOW[(7_ "%O$O\ URB_F:^F
MJ^9?V0_^0MXDQ_SRB_F:^FJ^_P"'/^1;3^?YL_/N)?\ D9U/2/Y(^.?VE_\
MDJMQ_P!>\?\ *O+#T->I?M,''Q5N/^O:/^5>6FOR[-?]_K?XF?J>4_[A0_PK
M\C['_9G_ .2/:1_UTG_]&M7J5>6?LS_\D>TC_KI/_P"C6KU.OV+*O]PH?X8_
MDC\9S;_D85_\<OS85X+^W?\ \FB?$_\ [!@_]&QU[U7@O[=__)HGQ._[!@_]
M&QUZIY:W,W_@GM_R:!\._P#KS;_T-J^C*^<_^">O_)H'P[_Z\V_]#:OHR@'N
M%%%% @HHHH **** "BBB@#X<^-?'Q1U__KO_ $%<0YPN:[?XUC_BZ.O_ /7?
M^@KB'^Z:_ ,=_O57_$_S/Z$P'^ZTO\,?R1]^^!O^1/T?_KV3^55/B?\ \D^\
M0?\ 7G)_Z":M^!O^1/T?_KV3^55/B?\ \D^\0?\ 7G)_Z":_;I_[D_\ #^A^
M&P_WY?X_U/@R'_5)]*]&_9__ .2L:-]7_P#037G$7^I7Z5Z-^S\<_%C1OJ__
M * :_%<M_P!\H_XH_F?M^9?[G6_PR_(^UJ^:?VON+WPS])?Z5]+5\T_M??\
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M3V5>-I'R#^T^?^+EI_UZK_,UY&YPAKUS]I__ )*4A_Z=5_F:\C<94U^*9O\
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MU/E^:/R;AO\ Y&=/Y_DSY]Q7U%^R+_R).K_]?[?^@BOEX=:^HOV1O^1)U?\
MZ_V_]!%? \,_\C&/H_R/T#B;_D63]8_F>[5\#_$+_D>=;_Z^G_G7WOFO@?X@
M_P#(\:W_ -?4G\Z^EXN_@T?5_D?,<'_QZWHOS,&/_7P_]=%_G7Z">&_^1?TW
M_K@G_H-?GU'@3P_]=%_G7Z#>'/\ D :=_P!<$_\ 0:X^$/CK?+]3MXP^"CZO
M]#E?CI_R2GQ#_P!>Y_F*^(4^XOTK[>^.?/PI\1?]>Y_F*^($'[M?I7)Q9_OE
M/_#^K.OA'_<ZG^+]$>I_LT_\E;L_^O:;_P! -?9%?&W[,_\ R5JSS_S[3?\
MH!K[)KZ/A3_<'_B?Y(^;XL_W^/\ A7YL^6/VL_\ D;M'_P"O4_\ H1KPZO<?
MVLS_ ,5=H_\ UZG_ -"->&U\%GG_ ",:WK^B/T#(O^1;1]/U9]=?LM?\DJM_
M^OF;_P!#->MW'^HD_P!T_P J\C_99/\ Q:J#/_/S-_Z&:]<G_P!1)_NG^5?J
M^4_\B^C_ (5^1^29Q_R,:_\ B?YGY_>*/^1FU3_KX?\ G5+3_P#D)6/?_2$_
M]"%7/%(_XJ?51_T\/_.J5A_R$['_ *^(_P#T(5^)S_C/U_4_<8?P5Z?H?H;9
M_P#'I!_N+_*IJAL_^/.#_<7^535_04=D?SO+=A1115$A1110 445PFC_ !/3
M7/&&H:':Z;)BPE\J>Y>55QQG(7.2* .[HKS^+XMPMJD4<NE74&ES77V*/46*
M[#+G &,YP37?CF@!:*** "BBB@ HHHH **** /)OVFQGX77'_7Q'_.OCY>@S
M7V#^TUS\+[C_ *^(_P"=?'XX%?D?%/\ OZ_PK]3]?X4_Y%[_ ,3_ $/:OV3!
MCQ[J_O89_P#'UKZOKY0_9-_Y'[5_^O#_ -G%?5]?8\,?\BZ/J_S/C>*/^1E+
MTC^1\@_M/G'Q*3_KU7^9KR-_NFO7/VG_ /DI2?\ 7JO\S7D;\H:_-<W_ .1A
M6_Q,_3<G_P"1?0_PH^SOV=1CX6:=_OO_ #%>B:C_ ,>%S_US;^5>=_L[?\DM
MT[_??^=>B:@?] N?^N;?RK]AR_\ W"E_A7Y'XWF7_(PJ_P")_F?G?)_Q\3?]
M=&_G6QX)'_%;^'?^O^'_ -#%8\G^OF_ZZ-_.MCP3SXW\.X_Y_P"'_P!"%?AU
M'^-#U7YG[K6_A3]'^1]_CI7A_P"UG_R)&E_]?P_]!->X#I7A_P"UE_R)&F?]
M?P_]!-?M.=_\BZMZ?JC\2R+_ )&5'U_1GRMT%?17[(?WO$O^]%_(U\[#I7T3
M^R&,-XE_WHOY&OS'A[_D94OG^3/U#B+_ )%E7Y?FCZ0KXG^/G_)5M6^B_P J
M^V*^)_C[_P E5U;Z+_*OM.+/]SA_B7Y,^)X2_P!]G_A_5'GK_<-?=WPH_P"2
M<^'_ /KU2OA!^4-?=_PI_P"2<^'_ /KU2O$X2_WFK_A_4]SB_P#W:E_B_0L?
M$C_D0O$'_7C+_P"@FO@B'_5BOO?XD''@'Q!_UXR_^@FO@>'B,57%W\>EZ/\
M,GA#_=ZWJOR.V^#1_P"+I>'_ /KO_2ON:OAGX,\_%+P\/^F_]*^YJ];A+_=:
MG^+]$>3Q?_O5/_#^K"BBBON3X,**** .3^)LVMP>%)CX?$QU NH!MU#.%[D
MU#\,M974]&FB?5KC5+ZUD\JZ%T@26&3'*,!6]X@TB;6;'R(+V:PD#!A+#U^E
M9W@OP/;>#8KTQ3RW5U?3FXN)Y3\SN>] '2U5EU*VA<H\JJPZ@U:IIC5CDJ"?
MI0!5&L69_P"7A/SH_M>S_P"?A/SJUY:?W5_*CRT_NK^5 %3^V+/_ )^$_.E_
MM>S_ .?A/SJUY:?W5_*CRT_NK^5 %7^U[,_\O"?G1_;%G_S\)^=6O+3^ZOY4
M>6G]U?RH JG5[,?\O"?G0=7LQ_R\)^=6O+3^ZOY4>6G]U?RH JC5[,C_ (^$
M_.C^U[/_ )^(_P ZM>6G]U?RH\M/[J_E0!5_M>SX_?H3[5\B?M+2I-\592AR
M/LD0_G7V)Y2?W%_*OCW]IL8^*TN!_P ND7]:^/XJ_P!P7^)?J?9<*?\ (P?^
M%_FCRMONFOL/]GC4+>W^%>EJ\@5EW @CWKX\;[IK[*_9T16^%.E94'[W;WKY
M?A3_ 'V7^%_FCZKBS_<(_P")?DST,:O:,<+,K'VKX"\0L'\1ZNPZ&[E/_CQK
M]!O*3^Z/RK\^?$?_ ",NL#'_ "^2_P#H1KUN+_X='U?Z'C\'?Q*_I']2A'@3
MP$]!(O\ ,5^@.E:O:+I=IF8#,2]>.U?G]&,SPYY_>)_,5^A>DQJ=+M,JO^J7
MM[5CPA\5?_MW]3?C'X:'_;WZ'%_&74[:7X8>(524,6MF Q7Q+%_JU^E?<?QH
MC1?A=XB^4?\ 'JW:OAR+_5K]*X^+?][I_P"']6=G"'^Z5/\ %^B.Y^",J0?%
MCP^[G:HD?)_X":^U?[8LP<&=17Q9\# #\6O#V>1YC]?]TU]N^4G]T?E7N\)_
M[G/_ !?HCP>+O]\I_P"']6?/G[6=[#<Z!H:QON/VDG@=L5\V'I7TS^URH7P]
MH9  _P!);_T&OF>OD>)/^1E/T7Y(^PX:_P"19#U?YGO'[)5W%;:KXC\UPF8H
M\9^IKZ4_M>SS@3J3[5\X?LB*&U;Q)D9_=1?S-?3/EI_='Y5]_P .?\BVG\_S
M9^>\2_\ (SJ>D?R1\;_M(3I<?%*Y:-MRB",9]\5Y@>AKU']I88^*MQ@ #[/'
MT^E>7'H:_+LU_P!_K?XF?JF4_P"X4/\ "OR/K[]F[4(+?X1:2DD@5A)/QC_I
MJU>LHZR(&4Y4]#7EO[-**WP>TC(!_>3]1_TU:O4P,5^QY5_N%#_#'\C\9S;_
M )&%?_'+\V+7@O[=_P#R:)\3_P#L&#_T;'7O5>"_MW_\FB?$_P#[!@_]&QUZ
MAY:W,W_@GM_R:!\._P#KS;_T8U?1$S.L3M&H=P#M4G&3Z5\[_P#!/7_DT'X=
M_P#7DW_H;5]&4 ]SQ,>#?&&L'QE]LTVTL6U"6.XM&2;?N9, *WU KJ?!'AS6
M9O%=UXBURUBTZX-I'8QVT,F\,JG)<GM]*]#HH$%1SPB=-I9E]U.#4E% ',^)
M-:T;PE%!+JVJM8I,Q2-I9,!B.U89^)W@SI_PE$7_ '^KS[]L",2:'X<R,XNI
M/_05KYG\M3V&*^#S7B'$8#%RP\()I6WOU5S[_*>'</F&#CB*DVF[[6Z.Q]Y>
M'-;T3Q>D[Z3JS7RPMMD,4N<&MM=*12#YTYQZR&OG_P#8]4+9^)@!C]_'_*OH
MZOJ,KQD\=A(8B:LW?;UL?*YK@X8#&3P\'=*V_FDSX9^,J"+XG:\H)($YY8^P
MKBF^Z:[CXU#_ (NEK^/^>_\ 05P\GW>M?BF._P!ZJ_XG^9^WX#_=:/\ AC^2
M/O+P1ID;>#]'/FS#_1D/#^U5?B9ID:^ ->/FS'%I(>7S_":UO W'@_1_^O9/
MY54^)_\ R3[Q!_UYR?\ H)K]OF_]B?\ A_0_#(+_ &Y?X_U/@R+_ %2_2O0O
M@)&)OBIHZ$D#+<@\_=->>P_ZI/I7HO[/V/\ A;&C?5__ $ U^)Y;_OE'_%'\
MT?M^9?[E6_PR_(^R#I,9_P"6T_\ W\-?./[6]LMO>>&0K.V5E&6.?2OIROFG
M]KW_ (_?#'TE_I7ZQQ&W_9E3Y?FC\EX;7_"I3^?_ *2SY\ Q7TU^R=9)<^"]
M69G=3]O(^1L?PBOF8=:^H?V1O^1)U?\ Z_V_]!%? <,Z9E'T?Y'Z#Q-_R+)^
ML?S/:ETM%8$33'ZO7PCX_0)XUUI020+E^I]Z^^Z^!OB#_P CQK?_ %]/_.OI
M>+OX-+U?Y'S'!_\ 'K>B_,P(@#-"/61?YU]\^'M*C;0=-_>S#]PG1\=J^!D_
MUT/_ %T7^=?H-X<_Y &G?]>Z?^@BN3A#XZWHOU.SC#X*'J_T.*^-VG1Q_"S7
MV\R5BL&0&?.>17Q8GW%^E?;WQSX^%/B+_KW/\Q7Q#']Q?I7'Q;_OE/\ P_JS
MLX1_W.I_B_1'I_[-T0F^+%DI+*!;S'Y3C^ U]>C28Q_RVG_[^&OD7]FG_DKE
MG_U[3?\ H!K[(KZ/A3_<'_B?Y(^:XL_Y&$?\*_-GRI^U; L/BS1P&9O]%_B.
M?XC7B/6O<OVM/^1MTC_KU/\ Z$:\-ZBO@L\_Y&-;U_1'Z!D7_(MH^GZL^L?V
M8;!)_A?"YDD4M<R\*V.C&O5YM+002?O9C\AZO[5YC^RU_P DJM_^OF;_ -#-
M>MW'^HD_W3_*OUC*7_PGT/\ "OR/R7.%_P *5?\ Q/\ ,_/WQ,FWQ)J@!SB=
MQD]>IJE8KG4K($X!G0?^/"KWBG_D9M4_Z^'_ )FJ.GG_ (FEC_U\)_Z$*_$I
M_P 9^OZG[C#^"O3]#] ]/T]([>V<22G$:\%N#Q6A4-G_ ,>D'^XO\JFK^@H[
M(_G9[L****H04444 %>3^*/!FK:_XD=+31;;2$>X#OK=O-^^9!URO?->L4F*
M /'HO GB*_FM-#O+2"/1K/45O4OTER[A2"H*^I->PCBEHH AN+87*A2SICNA
MQ5?^R8_^>T__ '\-7J* */\ 9*#_ );3_P#?=']DI_SVG_[[J]10!1_LE!_R
MVG_[[H_LI/\ GM/_ -]U>HIW H_V2G_/:?\ [^&C^R4_Y[3_ /?PU>HHN!X]
M^TG9+;_"^X*R2-_I$?WFSWKY'' %?8'[3?\ R2^X_P"OB/\ G7Q_VK\BXI_W
M]?X5^I^O\*:9>_\ $_R1[+^RK;K<^/-5!9EVV&?E./XQ7U+_ &1'G_73_P#?
MPU\O_LF?\C]J_P#UX?\ LZU]7U]EPP_^$Z/J_P SXSBC_D92](_D?'G[2\"V
M_P 2  S-FV4_,<]S7E#G"$UZY^T_C_A92?\ 7JO\S7D;\J:_-,W_ .1A6_Q,
M_3LG_P"1?0_PH^Q/V?-/2?X7Z>3)*N7<_*^/2O0+_2HQI]UB:8YB8<N3VKB?
MV=O^26Z=_OO_ #KT34.;"Y_ZYM_(U^Q9>_\ 8:7^%?D?C69+_A0J_P")_F?G
M@_\ KI?^NC?SK6\%KN\:^'@<@&_AY'^\*R'XGG_ZZ-_.MCP3_P CQX=_Z_X?
M_0Q7X;1_C0]5^9^[5OX4O1_D?>;:6C$GS9AGL'->*?M5V:P>"-+*N[8O@/F;
M/\)KW<=*\0_:R./ ^F?]?R_^@FOVG.W_ ,)U;T_5'XCD2_X4J/K^C/E8=*^@
MOV2[1;E_$9+.N&BQM;'8U\_=:^B/V0^OB7_>B_D:_,N'O^1G2^?Y,_4.(O\
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MM?5U?8\,?\BZ/J_S/C>*/^1E+T7Y'R%^T_\ \E*3_KU7^9KR)_NFO7/VGO\
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MY*O+_P!>D7]:^.XJ_P!P7^)?J?9\)_\ (P?^%_H>5'D'TK[-_9SX^%.D_P#
MOYU\9MT-?9?[.9S\*=*_X%_.OE^%/]]E_A?YH^IXL_W&/^)?DSTZOSV\1_\
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M7U%^R*<^"-7/_3^W_H(KX'AK_D8Q]'^1^@<3?\BR?K'\SW>O@;XA?\CSK?\
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MI7V!^TWQ\+K@_P#3Q'_.OC\<@5^1\4_[^O\ "OU/V#A3_D7O_$_T/:OV3?\
MD?\ 5_\ KP_]G6OJ^OD_]DPY\?:Q[6&/_'Q7UA7V/#'_ "+H^K_,^,XH_P"1
ME+TC^1\@_M/_ /)2D_Z]5_F:\C<90UZW^T^V?B4G_7LO\S7DDAPC'VK\US?_
M '^M_B9^FY/_ ,B^A_A1]G?LZ_\ )+=._P!]Z]$U'_CPN?\ KFW\J\[_ &=A
MCX6Z=_OO7HFH<6%S_P!<V_E7[#E_^XTO\*_(_&\Q_P"1A5_Q/\S\[W_U\_\
MUT;^=;'@D?\ %<>'<?\ /_#_ .ABL9CF:8_]-&_G6QX)Y\<>'1W^WPG_ ,>%
M?AU'^-#U7YG[K6_A3]'^1^@ Z5X?^UG_ ,B/IG_7\/\ T$U[@.E>'_M:?\B/
MIG_7\O\ Z":_:<[_ .1=6]/U1^(Y%_R,J/K^A\KCI7T3^R'U\2?[T7\C7SL!
MQ7T3^R$<GQ+_ +\0_0U^9</?\C*E\_R9^H\1?\BRK\OS1](5\3_'S_DJNK?1
M?Y5]L5\3_'PY^*VK?1?Y5]GQ9_N</\2_)GQ/"7^^3_P_JCSR3E#7W=\*/^2<
M^'_^O5:^$)2%0FOO#X4C'PZT ?\ 3JM>)PE_O%7_  _J>YQ?_NU+_%^A8^)'
M_(@^(/\ KRE_]!-? \/^K%??'Q(_Y$'Q!_UXR_\ H)KX'A.8P<U7%W\>EZ/\
MR>$/]WJ^J_([7X,C_BZ7A[_KO_2ON>OACX,G_BZ?A[_KO7W/7K<)?[K4_P 7
MZ(\GB_\ WJG_ (?U84445]R?!A1110 453U35;71;*2[O)A#;QC+,?\ #O5?
M0/$NG>*+'[7IMRMQ"&*L0""I]"#R#0!J4444 %%%% !1110 4444 %5KS4+7
M3D5KJXBMU8X!D<*"?QJS7@/[7HSX9\/\D?Z:W0X_@->=F&*>"PL\0E?EZ?,]
M'+L(L=BH89RMS=?E<]L_X272?^@E:_\ ?Y?\:GL]4L]1+_9;J&X*_>\IPV/R
MK\\ #C[S?G7T#^R(/]-U\;F(^3J<^M?+Y=Q)/'8J&'=*W-UOY>A]5F/#4,#A
M9XA56^6VEK=;=SZ9KX[_ &F_^2KR_P#7G%_6OL2OCO\ :<X^*TGO9Q_UKHXJ
M_P!P7^)?J<_"G_(P?^%_H>5'H:^R_P!G/_DE6E?\"_G7QFQPIS7V;^SG_P D
MITG_ (%_.OE^%/\ ?9?X7^:/J>+/]QC_ (E^3/3:_/;Q&?\ BI=8_P"OR7_T
M(U^A-?GMXDX\3:R/2\E_]"KU^+_@H^K_ $/'X._B5_2/YLHQ_P"O@_ZZ+_,5
M^AFD?\@NT_ZY+_*OSRC.+BW]3*@_45^AFD?\@NT_ZY+_ "%8\(?%7_[=_4WX
MQ^&A_P!O?H<K\:O^26^(_P#KU:OAJ+_5K]*^Y?C3_P DN\1_]>K5\-1?ZM?I
M7'Q;_O=/_#^K.SA'_=*G^+]$=Y\"Q_Q=OP]_UT?_ -!-?;]?$'P+.?BYX?'H
M[G_QTU]OU[O"?^YS_P 7Z(\+B[_?*?\ A_5G@'[7?_(O:'_U]'^5?,U?3/[7
M?_(NZ'_U]'^5?,U?(\2?\C*?HOR/K^&O^193]7^9[]^R%_R%O$O7_51?S-?3
M5?,O[(1!U7Q+CH(XA^M?35??\.?\BVG\_P V?GW$O_(SJ>D?R1\<?M+_ /)5
MKC_KWC_E7EIZ&O4OVE^/BM<>]M'_ "KRQB I)]*_+LV_W^M_B9^J93_N%#_"
MOR/LC]F?_DCVD?\ 72?_ -&M7J5>6_LSG/P>T?\ WYC_ .16KU*OV/*O]PH?
MX8_D?C&;?\C"O_CE^;"O!?V[_P#DT3XG?]@P?^C8Z]ZKP7]N_P#Y-$^)_P#V
M#!_Z-CKU#RUN9O\ P3U_Y- ^'?\ UYM_Z&U?1E?.?_!/7_DT#X=_]>;?^AM7
MT90)[F8\VIC65C6&(Z=MYDS\X/TK3HHH *BN%E>/$+JC^K#(J6B@#SSXD_"2
M#XI6EC;ZM?R1):.9$-LNTY..N?I7##]D301Q_;&H8_X#_A7O><49KS*^68/$
MS=6M24I/J>K0S3&X6FJ5&JXQ70\[^&OP@M_A9!?1:3?23"[<.YN5W$$#MBNV
M$6HY&;B#\(S_ (U?HKMHT:>'@J5*-HKH<->O5Q-1U:TN:3W;/&/%/[,VD^+M
M?O-7N]4NX[JZ;<XBP%!]@162?V0] 8#.KW[8(/)7_"O?*6O-GD^ G)SE15V>
ME#.<QIQ4(UI)+8Q-)T>]T;3;:RANHWB@01J7CR2!Z\U'K_A^Z\1Z->:9=7:)
M!=1F)S$F#@]<<UOT5ZO)%PY&M-OD>2IR4_:)ZWO?S/ E_9"T!% 75[]0.V5_
MPK:\&?LWZ7X&\16^M6.IW4MU!G:L^"IR,=J]BR,XS2UY<,HP%.2G"BDUJCUJ
MF<YA5@X3K-IZ,S_*U'G_ $B#_OV?\:X7XE?!BU^*4NGR:M?RPM9AO+^S +G/
M7.:]*I,@5Z-:C3Q--TJT4XOH>;0KU<+456C)QDNJ/!!^R)H./^0QJ&/3*_X5
MW_PW^%L?POTFXT_2;YI8)I?.8W"[CNQCM7>9S2UQT,MP>%G[2C249=T=N(S3
M&XJG[*M5<H]F4!%J.1FX@Q[1G_&O'M:_98T77=7N]1FU6]CGN7,CA-H )].*
M]PI,UMB<'A\8E'$04DMKG/AL9B,&W+#S<6]['@@_9%T%9(Y/[7OV*,&&=O4'
MZ5[+9:=?:?9P6T5U$R0H$!>,Y('XUKT5.&P.&P=WAX*-][%XK'XK&I+$5'*V
MUSF/%GA*;QEX>O-'O;Q8[:Z78YA3#8]N:\J7]D/0% "ZQJ  &.J_X5[Y29J<
M3E^%Q<E.O34FM-2L-F.+P<7##U'%/70\D\!_L]:=\/?$2:UIVHW$UTB-'B<
MJ01@]*],$6HD?\?$'_?H_P"-:%%;X?#4<)#V="*BM[(PQ.*K8R?M,1-REM=G
ME_Q&^!MG\3M1M;W5+^:&:WC\I?LP !&<]ZY,_LB:#CG6+\CT^7_"O?**XZN5
M8&O-U*M).3W9V4<VQ^'IJE2K-16R.+^'_P //^%<>'4T?3+WS;9'9P;A-S9)
MR>E=&]OJ$BLK7$(# CY8S_C6C17HTZ<*4%3@K);(\ZK5G6FZM1WD]6SPO4?V
M4-#U+4;F\?5;Y))W+L$VXR?3(J&']DC0;>Z@G&K7S/$X==Q7&0?I7O.:6O*>
M39>WS.C&YZRSO,DK*O(S[2UO+?RD:>-XD 7 3!('XUH445[)X@4444 %%%%
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M5OXO;TKTK0-!M/#>FQV5FA6-<DLQRSL>K$]R:8&E5.?5;.&\2R>ZA2\E4M'
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M?>)=-_LZ6"4NMJ#A9<<!W'Z@4Q'?1N)$5AT89%(\BQ(SNP5%&2S'  I>%7L
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M3;Z]92Z+XKM8"VGZC;2$QRJ,G*=B>O% ">'?'^O^&=$$NJ:'?S.MSC4+B<@
M,QQ^['<#BO9;>9;F".5,E74,,C'%>=^$;;5?B%I-I<^*;%K);:3*6X.T7!'2
M1E[?2O1@ J@   =J '5Q?CO7S/X9U5-%O(I[NU91=) X:2*/(W\#OMS3O%'C
M&]L]=M]#TFUCGU"6$W :=ML94'&T'UKSG9#Y.H>*?#MA<:=XKM[D+J.DOE_M
M!)VE2/[ISD-0!T7A+XG&XN],CB@1M N_]'MF#[KA''&9%[ \UZJ*X_P?X+L+
M4Q:S-H\.G:M.-\D2$D1$]0.V:[ D 9)Q2 9//';0O+*ZQQH-S.QP /4FO/\
MQOH>J^/K!FTG68;?3%A\VWEM'W-)*.F2.U5/$/Q!N;\:Y;P:$=2T>PD:UO\
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M2 *\%_;O_P"31/B?_P!@P?\ HV.O>J\%_;O_ .31/B?_ -@P?^C8Z!K<S?\
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MRCMY+ES)*ZCEB??T]J #PEX<3PMH%GIJR>>8%(,I7!)))/';K6S110 4444
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M  T/\,/^A_\ #G_@RB_^*H_X:(^&'_0_^'/_  91?_%444!8/^&A_AA_T/\
MX<_\&47_ ,51_P -#_##_H?_  Y_X,HO_BJ** L'_#0_PP_Z'_PY_P"#*+_X
MJC_AH?X8?]#_ .'/_!E%_P#%444!8/\ AH?X8?\ 0_\ AS_P91?_ !5'_#0_
MPP_Z'_PY_P"#*+_XJBB@+!_PT/\ ##_H?_#G_@RB_P#BJ/\ AH?X8?\ 0_\
MAS_P91?_ !5%% 6#_AH?X8?]#_X<_P#!E%_\51_PT/\ ##_H?_#G_@RB_P#B
MJ** L'_#0_PP_P"A_P##G_@RB_\ BJ/^&A_AA_T/_AS_ ,&47_Q5%% 6#_AH
M?X8?]#_X<_\ !E%_\51_PT/\,/\ H?\ PY_X,HO_ (JBB@+!_P -#_##_H?_
M  Y_X,HO_BJ/^&A_AA_T/_AS_P &47_Q5%% 6#_AH?X8?]#_ .'/_!E%_P#%
M4?\ #0_PP_Z'_P .?^#*+_XJBB@+!_PT/\,/^A_\.?\ @RB_^*H_X:'^&'_0
M_P#AS_P91?\ Q5%% 6#_ (:'^&'_ $/_ (<_\&47_P 51_PT/\,/^A_\.?\
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M *'_ ,.?^#*+_P"*HHH"P?\ #0_PP_Z'_P .?^#*+_XJC_AHCX8?]% \.?\
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1?1R22-YB'  .3T-%% 6/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>ahpa-20220416xs4030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xs4030.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $^ Y # 2(  A$! Q$!_\0
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M8S<?I0?B)XF_Z#,_Z5SI-%'M:G\S^\/:U/YG][.B_P"%B^)C_P QFX'Y4?\
M"Q/$W_0:G_2N=H/M1[6I_,_O#VM3^9_>SHA\1/$__0:N/TH/Q%\3D8_MF?\
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MY#4_Z5SI.:7@<T>UJ?S/[P]K4_F?WLZ$_$7Q/C/]LS_I2?\ "Q/$^/\ D,W
M_*N>SQ2CD4>UJ?S/[P]K4_F?WLZ(?$3Q. /^)S<?I2?\+$\3D_\ (9G_ $KG
M:/PH]K4_F?WB]K4_F?WLZ(_$7Q.?^8S/^E!^(?B;_H-3\?2N=Z&C-'M:G\S^
M\?M:G\S^]F]-X_\ $LR%6UF<GMTKZW_9G^);^._!9M+Z;S-6TUO*F)X+K_"U
M?%0-=O\ !3QT_P /OB/IU\TA6PN&^S7:Y^78W&X_0X/X5Z67XR5"NG-^Z]&>
MA@,9+#XB,IR;3T?^9^@-%,CD65%=&#*PR".A%/K]$/T8**** "BBB@ HHHH
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MTD[6M9.V_GW2V/%Z*.E%>.>:%':BC&30 #ZT=:,T9H **,T=Z #-%&/2CJ*
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M6^VCZG.7FMZAJ&FVNGW-Y+-8VIW00,?EC.<\?C6S?_$_Q=J>FMI]YK]U<V;
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M[\I'S'^E?2Y'&HZTI+X;:GT.1QJ/$2E'X4M?T_4[*BBBOMC[H**** "BBB@
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MR)H\J\,Z>H[UT_[0'CZV\;OX;6RU 7L-O9KYX7.!+_%GWKR<#:.!@>U 4)T
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M!U>0]2?Y5V-?I&7X;ZK04'N]6?I.787ZIAU!_$]7ZA1117I'IA1110 4444
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MY/Q0?V7C/^??XK_,^<OQI#7T;_PQ=?X_Y&>#_P !S2_\,7W_ /T,\'_@.?\
M&C^R\9_)^*'_ &7C?^??XK_,^<?YTM?1O_#%]_\ ]#/#_P!^#_C2?\,77_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?6M%(.E+7OGO!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;3YG0#7=2+$?;Y^1_?/%>8>!?$FLR^(=?CDU2Z=5CEP#(>.M>T#X7^*=Y/\
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MA:>'TU'7=6M3J%U:+)A8+9?O-GUZ4!<^D:*\2U#]H-V\5?#^RT^Q6;3_ !-
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M^DJ*^8_''[4.O?#CP_X*OKG3++Q$^M73K<-I4VY8X5ZL..HK<\7?M,2Z/?\
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M,@@CV- #J*:)%./F'/3F@NN3R..O- #J*8LT; E74@=2#TI5D1L893GI@]:
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M_P""@_\ W#Q_Z+--$L^QZ*0=*6D4%%%% !1110 4444 %%%% !1110 4444
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M_$T6871[[7G&N_"2]UG6+J^C\9ZY8I.^X6]O(H2/V''2N)_X;G^#O_0RR?\
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M>(TB?,5D^]TZUZ%IWB?67T^U+:I<L3&I)+GTKFPV-CB:\Z"C;E47_P"!)/\
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M?-7O#WB'59/$6GH^I7+(SX(+\'BOH.4^9/=[CP3H=W.\TVFPR2N<LQ!YJ/\
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M_P :]*HH"QY[I_[/_P /M*U"WOK3PQ9074#;HY5!RI]>M>@@8&*6B@84444
M>1_%GPIJVN>(+>>RM&GA6':6'8YKQGXH?"KQ=J>E64=II$LY60EE49Q7V%17
M+B\/'&8>>'D[*7^=SMP6*E@<3#$P5W%WU]+'Q;XS^$GC&\L?#*P:-+(8$7S
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MOW4917FI;W/FX?#SQ$%&=.DX'85<T'P%K]MK]E-)I[I$CY8D=*^A:*][F/G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7QPW_ "D'/_8/'_HLU]CU\;O_ ,I"
M#Z?8!_Z+-4B6?8XZ4M(.E+4E!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?^ 8_6O;CC:/L.6^OL>79[W/FWE^(>)YU'3ZQS;KX>7<RFA1HI@5S\AKQ'X
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H)8SM8XR!V^6M#3/@M+I^J6MV;U&6)LD;CD_I7Q,FG)GZ+#2"7DC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>ahpa-20220416xs4031.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xs4031.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "I G<# 2(  A$! Q$!_\0
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M(OCG3?A_X6O-5U.8QQ*A6-$&7D<C@*/6NAM;N&]@6:WE2:)NCQMN!_&OE_\
M;LTVYN/"&DW>G:T++4(Y_+CLRP/FY[@>HH&> _"WQ3??$+Q/XH_M6?4(W$S&
M&$,0[IG(YK4^('[0&O7FAZ7X#L-0N(BL_EW+GAVASPK'O7(?"KQ;?:1>0V^O
M+&+]F,:WEO\ *X'O6UKO@NT@O=9N(8OMVHR /%<B3)4'KGWH$:7Q$\2WMSX;
MT+0=/U69%:X5+JWB7$.S^\6'>F>#9[#3_%%W)IFG/!:V4JK--;IS<'N?>O.M
M$@9I]0T73[XR&9<,Q;<=W?&?2O2-$\,WWAWPE:V4&J3:G<JVZ2"%,2+[D]Z
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M0DA[\CS!(2>F3D"OI$ "O+/VEM(NM2^$NIW.GJ6U'3)(M0MRH^8-&X8X_P"
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M/]I+_L.V/_I.U?2FFV$.E:?;6=NI6""-8XPQR0H&!S7S7^RX1_PT)^TB._\
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M29]1%\TI#*\?1=O<5YUH'[9.E^'?AEH7B'QZ\5I=:GJ<UB%M5X2-'*^:1Z#
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M3H'CG2U U/0ISAE[>="3_K(6ZAATS@\UT37.O:1^?^?HQ>1Z51117.,****
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M&P-PX!QS1#'\LXS<+\J26O9W_P"'"-3E=['QQJO@[Q-K?C[Q+;Z?87<-W?>
M8;2VNFRH,X3E-W][M7$:/$/'.F_"'PCX<\":AHGBWPWJ<4VKW4EGY7V5(_\
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M??MJ_!+4+6:UN/%MK<03(T<D1B8AE(P01CTKR7PK^US\/_@?<-I>GZU=>)O
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MPSG[5"?^6H/0_0TFD:OKOBJQF98[?0[+2YV%OG&9MIY&?Z4 >B?$"VU/Q5"
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M'@#PP.GAS20?^O&+_P")KF/&_P"SUX ^(5WH%SK/AG3YIM#NQ>612W1 DGN
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80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>ahpa-20220416xs4032.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xs4032.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "J GL# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"EJFC6>LQ)'>6Z3HCB10W9AT-7 ,  =!7,>+_B5X=\"R6\>LZC
M':2SGY(SRV/7'I[UT%AJ%MJEG%=6D\=S;2J&CEB8,K#U!K&-:G*;IQDG);KJ
MC:5&I""J2BU%[.VC+%%%%;&(445D^)/%6E^$=.:^U:\BLK93C=(V-Q] .YJ)
MSC3BY3=DBX0E4DH05V^AK5AZ_P""]'\2S13W]FDEQ%PDZG:ZCTR.U6/#WB73
M?%6G)?Z5=QWEJ_ >-LX/H?0UJ4XRC-*47=,4X2A)QFK-%#1M"L/#]F+73K6.
MTM\EMD8P"3U)]ZOT451(4444 %%%% !1110 4444 %%%% !1110 4444 %)2
MT4 9UCX?L--U*]O[:W6*[O2IGD'5\<#-:-%% !1110 4444 -=%D1E90RL,$
M'H17,67PS\-Z??)=0:7$KQN9(U_@C8]64= :ZFB@ I,4M% !1110!2UK6+70
M-*NM1O91#:VT9ED<]@!7S%!'XI_:HUJ>874N@>";238B+G=-]<?>./P%=G^U
MSK5Q;>"+#2('*#5+H1N0<<+@X_.O5_ .@6WAGP=I&GVD2Q1Q6R$A1C+%023[
MDUX=9/&XEX9NT(I-^;>R]#QJT7C,0\/)^Y%)M=V]EZ+\3C]"_9N\!Z':+$-'
M6Z?&&EG8EF/K5W6/@)X)UGP'JW@^72%BT/5#NN88G(+-Z@]C72^*/'6@>"X/
M.UK5K;3U/W5FD 9OH.IKS>\_:P\"VTNR.:\N5_YZ1097\\UNY8'!R7PQDO2_
M^9NW@L(TGRQ:]$?/G[3/['?BLP>';OX?RC4?#WANV1+?P]/(6D0J<[DSPQ/?
MO7>_LZ?MJ:;XSU2#P1XUTQO!_B^#%NL4XV0S,. HSC8WMTKVW_A>W@B'P9!X
MIOM>MM+T6:7R%N+UO+'F?W?K7@7[6W@KX8?&7P!=>)M.\1:3:>)=.B^T6FHV
MLZAYL<A&QR<]CU%>K"<:L5*+NGU.V,E)*<'=,^NP:6OGW]AWXH:K\4?@1IMW
MK3//J%A*]BUR^3YRH<*<]SCK7T%3:L:[A1112 **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBF22+"C.[!449+$X % "R2+$A9V
M"J.I-)'*DR!D8,I[BN"3XF>%O&6HMI.E:U;W-_$Q_<*V/,QU"GO6E8:A+I\V
M0"8R<,AIT73KP<J4D_0YU7C)WB[KR.NHJ*VN8[J(21MN4_I4M+8WO<*0G R>
ME#,%!). .I-<YJ^L&YS#"<19Y;^]5P@YO0F4E%'013QS9V.&QUP:DK@;_P 9
M:+X B6\UW4HK"*;Y8XV/S2'U ]*Z_1-<L/$>F0ZAIMU'>6<PRDL1R#64ITU4
M=*,DVNG4B%2,GRWU[%^L?Q5XKT[P9HMQJFJ3>3:PC)(&68]@!W-;%<9\6/A\
MGQ(\(7&E^=]GN 1+!)V#CIGVK*NZD:4G25Y6T]1U7-4Y.FKRZ'S/\6]2L/BQ
MJ)\3^'GEN4MH?+NK*X3;-&O]\+W7Z55^#?QDN_AE>BUN-]WX=G;]Y"#EH#_>
M3^HKDKVRUKP!XE:">-]/U:T;\''_ +,IK3U#2[;Q=:SZMHENL%]$N^^TM/UD
MB'<>H[5^159UUB'C*'NU4[M=^]E^:^:\OLN&>),/F5!9+FR2>T7LGY>4ET[G
MW%H^KVFNZ=!?V$Z7-I.H>.1#D$5=KXB^$7Q@O?A?J)5_,N]!G8>?:DY,9_OH
M.Q]N]?57BKXIZ+X6\%1^)))3/:3HK6R1_>E+#@#^OI7Z#EV=X?&X=U9OE<5[
MR[>?H<^9Y%B,#B(TH+FC-VB^_D_,O^._'FE_#[0I=2U.7"CB.%?ORMV517Q;
MX_\ 'FJ_$[Q#]LO@Q1FV6E@AR(QV'N?>F>,O&FK_ !(\1F]O2\\TC;+6RCR5
MB!Z*H_K5K?#X$A>*%EN/$D@Q)..4L@>H4_W_ '[5\1F.95,XJ.$'RT8_C_P>
MR^;/J%'!<(8/ZYC7S5I;);M]H_K+^GZ;\&O'?A_X*6;:-KMU-_:-_,)'CMX]
M\=MGH'/8^M?3MK=17MO'/!(LL,BAD=3D,#T-?"?P^^'>J?%#7A:6BM]F5P]W
M?2<J@SSSW)]*^X= T>'P_HUGIUN2T-M$(E+=2!7V&0U*LJ/)RVIQTCW_ ."?
MD\,SQ6;8BKB\0DE)Z6_+SMW-"BBBOJCK"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \1_:Q\-SZK\/8
MM4M5W3Z5.LV .<$@$_A6/XK_ &AAIWP_T"T\,XO_ !)J$*0*H&?(<* 21W.>
ME>W>+GTY/#.J'5F1--^SN)RYP-N/YU\S_LM>!K?6_%>H^(O)9]*TYS%8-*,[
MF)X;Z@5\OC8UJ>,4<.[.JK/NK=?N/G\5&I#%*-&5G45GW5NOW.QU?@3]F;^U
M'_MOX@WL^M:K<8=K620F-/8^I^E>B7OP_P#AQX8M=M[I6B:=!C&;DHF?^^C7
MFOQZ^._B0>,+7X8?"JUAU+QU=IYM[>3<P:3 ?^6C]BQ[ ]*R]"_85\.:N5U/
MXCZ]J_CSQ%*-T]Q>7)6$,>H1!T [5[5'+\-1C;E3\WJV>C1P="BK0@GYO5OU
M9Z#XG^&'PL^,7@Q/"A_LN[TR*3SH8=/N$W12?WE /6O(1_P34^'XNUD_X2#Q
M";8-DVOVD;"/3ITKJM<_8(^&=S'YV@IJ7A35(^8;[2[ME9&['!X-9'@3XK>.
M/@-\0-/^'_Q;O!K.B:H_DZ%XS"X\U^T-QCHQZ FN^*48\L-D=:2C96T/H?P#
MX!T/X9^%[/P_X>L4T_3+482).Y/5B>Y)ZFNBI <C-+2- HHHH **** "BBL_
M5?$.EZ$T"ZCJ-K8&X?RXA<S+'YC>BY/)H T*3-<O\3[N:T^'NOW%M,T,T=G(
MZ2(>5('45XI\-?A3K_C?P5IFMMX[U:V>[0N8T?(7FO.KXJ=.JJ-.GS.U]TOS
M.*KB)0J*E"',VK[K]3Z3HR#7DOA7X*:MX<\36>JW'C34]2BM\[K:=OD?ZUE?
M #5]1O\ QU\3+>]O9KJ*VU0)#'*V1&I!X'M3AB:CE&-2GRMM]4]EY$?6I1G"
M%2#3FVEJNBO^A[A15&PUO3]4GN(;.]@NI;=MLJ12!C&?0XZ5>KO34E=,[TT]
M@HHHIC"BBB@ HHHH **** "BBB@ K/U[2_[:T:]L/,,7VB)H]Z]1D8S6A14R
MBI)Q?435U9GP)XJ\':O\,O$GV*\#6EY$_FVUY <"09X96%>^_"7XOP^.8(])
MU>1+?Q%&,(YX6\4=QZ/[=Z]7\?\ P^TKXB:')IVI1 M@F&X4?/"_9E/]*^+?
M'?@W5?A=KOV74BT#1-YEK?H<*X!X93V/M7PLZ>(R'$>VH>]3?3]'Y]F?)U:5
M3+)\\-8/^M?T9]E6=[+ITV5^[_%&>]=1;WD5S;^<C?)WSVKR3X0^*-1\<?#:
MTU?5D(O5D,/G[=OGJ.C'WKN;&0KIEV >,BOT&E4ABZ,:T-+GO4*RE!3CLU<?
MJNKM=DQQ$K#W/]ZN+\=^/=-^'&E"[OL7%]*/]%L5/S.?5O1:Z"XF>STK4;R&
M W,]K TL<(_C8#BOC6?4M8^(_BI_];JFMW4A41*,E.>F.P%>'G.9SP$%0P\?
M?EU[?\$X,9BW022^*6W]?H2:YK.M?$7Q()KG?J&IW;^7#;J,J@/15'8"OL+X
M(^!+KX=^ K32KZ4271=II%4Y$9;G:/I65\&?@I:?#NR2^OE6Z\03+^\F/(A!
M_@3^IKU.N#*,MGAV\3B'[\OP]?,O 8*5)^WJ_&_U_4****^F/;.#^*OPGTSX
MEZ04E5;?5(03;7BCYE/H?53Z5\=:OI'B#X?>*$LYK:XMM8AD B:%25E&>"".
MH-?H#5>>QMKF6.66".62/[CNH)7Z&O!Q^4T\9-58OEFNO<\G&9?'$OGB^67?
M^NOF?%?QI\*P>';S2;M+86=WJ-JLUW;*,(LAZD#MGTI/&-W._P (?!"22LZ"
MXG&TG(P.E=A^ULH_X2?2_P#K@?YUQ?C/CX2^"O\ KXG_ )"OS?'4U1Q6+A#1
M)+\XG] 99*57!8&51\SON]](R+OA_P .OIGPAU#Q7ID$D^L-<" RJNYH(OXB
MH['WK)^&?PSU;XI:N(K9);;34;-W?2J1@=P,]6-?0/[+"+)\.958!E:=@01D
M&O9+:UALXQ'!$D,8_AC4 ?I7U>7Y/2Q6'H5I.T;:KN_^"?C_ !/A)8W.*M2M
M4;C%VMY+HNR,KPCX0TSP3HL&F:5;K!;QCD@?,[=V8]S6U5;4=0@TJPN+RZD$
M5M!&TDCMT50,DU\V>#_V^O 'BKQ\_A^2.ZTRQDD\FUU>Y&(9FSCD=5!]37W,
M(*$5&"LD<<5&"45HCZ<HID<BRQJZ,'1AD,IR"/6GU10444UW6-"S,%4#)).
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M1NA[$,.<U>^&W@JY\ ^'1I$^L7&LQ12-Y$MU]^./LF>^*[Z4L0I\M5)KNO\
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M\_/LCPZ>,KXK$)4-(+?T_K8]LHHHKZT^@"BBB@ HHHH **** "BBB@ HHHH
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MJ)2A"2@Y*[Z=2.=)\K>K.HHHHJBPHHHH **** "BBB@ HHHH **** "BBB@
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MQO\ #K6X_P!D_P#:*\0>"=?D^R^#?&MS_:6AZ@_RQ03GAH6/09)Q^5?8ZL&
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M;UKO**RJTJ=:/+4C=>9G4IPJQY:BNO,^4?VP-.ATJ7PC!;((;:..2*.->B@
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>ahpa-20220416xs4033.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xs4033.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %, Y # 2(  A$! Q$!_\0
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M^&M7M]#BUJ73+J+1YGV1WSQ$1.WH&Z5G=*!A0.M)U[TO:@ [TN>:,&DQCI0
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M2G4CJVWO^&Q35.6B26WX[GGGC']GOP/JGP=UWQU\/-=U.YCT-E6ZM]5M3&9
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M.37<?'SX@^&_%7P/^$VBZ1J<=[J6D6'E7MNJD&%]JC!R,=0>E4_V2_B=X<\
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MJ]T?D_N4=Q1O4'[PK]8/^&&O@_\ ]"Y)_P"!<G^-!_8:^#Q_YEN3_P "Y/\
M&CZW3\P^HU>Z/R>$BY/(H+J.]?K#_P ,-?!__H7)/_ N3_&@?L-?!\?\RW)_
MX%R?XT?6Z?9A]1J]T?D]N4?Q"E\Q>Q%?K ?V&O@__P!"W)_X%R?XT?\ ##7P
M?'_,N2?^!<G^-'URGV8?4:O='Y/AUQ]X4;T)^]7ZP?\ ##?P?_Z%R3_P+D_Q
MH_X8;^#_ /T+DG_@7)_C1];I]F/ZC5[H_)_>IQR*-ZG'(K]7_P#AAKX/?]"W
M)_X%R?XTO_##7P?Q_P BY)_X%R?XT?7*?9B^HU>Z/R?W@=2*0NH'WA7ZP_\
M##7P?Q_R+DG_ (%R?XT?\,-?!_\ Z%N3_P "Y/\ &CZW3[,?U&KW1^3V]>N1
M1YBD<-S7ZP_\,-?!_/\ R+<G_@7)_C7G'QO_ &3OA=X*\/:=<Z?H<L$L]]'
M2+AVRK=1R:TIXB%6:A'=B^HU>Z/SE#+_ 'J-Z@_>K]6=/_8@^$$]C;R-X=D)
M>-6)^U2=2/K5C_AAKX/Y_P"1<D_\"Y/\:S^MP[,/J-7NC\GO,7UI3(JC[PK]
M8/\ AAOX/Y_Y%R3_ ,"Y/\:!^PW\'Q_S+<G_ (%R?XT?6Z?9A]0J]T?D_O7(
MYI"Z^H%?K#_PPU\'_P#H6Y/_  +D_P :/^&&_@__ -"W)_X%R?XT?6Z?F/ZC
M5[H_)_S$SC-&]?45^L'_  PU\'_^A<D_\"Y/\:#^PW\'S_S+<G_@7)_C1];I
M^8OJ-7NC\GS*H/44>8H/6OU@_P"&&_@__P!"Y)_X%R?XT?\ ##?P?_Z%N3_P
M+D_QH^MT^S#ZC5[H_)\R+ZYH#J>]?K ?V&_@^?\ F7)/_ N3_&C_ (8:^#__
M $+DG_@7)_C1]<I]F'U&KW1^3YD3^]0'7^]7ZP?\,-_!_P#Z%N3_ ,"Y/\:/
M^&&O@^3_ ,BW)_X%R?XT?6Z?9A]1J]T?D]O7(^:@R+GJ*_6'_AAKX/\ _0N2
M?^!<G^-'_##?P?\ ^A<D_P# N3_&CZW3\P^HU>Z/R?$BGN*"Z^HK]8/^&&O@
M]_T+<G_@7)_C7-_$K]C7X4^'/AWXGU.Q\/O%>6>FW%Q#(;EVVNL;,#@GU%"Q
M=-NUF)X&JE>Z/S$Z4=:9"Q:,$GFG@5VGG[ASFE')]*0^M*O!!H&SA]0U-+2Z
MO5F;*EL'':LO5/$[V>G+;QW3%VP$/^S6+XCNI8?$>IPDY1FK'D8R%,Y=@>,5
M[/MY6LCU848Z-GO?A.VN-.\)'4B"&N#A">I^E<IXTFUF:Q-M)$4DE/#R#!45
MIZUX[CG^%NBZ=9R^5?VK$OZ@5QEWKM]K]R+B_NGN90H4,W&!7I5:T>7V:['+
M3HN_.S#A\/Q6Q'G3&5CU ]:U4C$,:K$,*.U).FWG'6G1-DC->>DHNR.UMM"+
M=<D,HXK<T?QKJ.CVEQ:03,UI<(4D@?E&'T]:YVYC>%SW![U7:[>WC9Y2(T'<
M]35*<H:W#D4D:**H)..M(0,\5AKXB@&<DDU!<^*6.1;PX)XRW2N26+H15W(T
M5.3Z'19 /I]:KW&H6]L,O*J_4UR<^HW<Y.Z=@/[JXJF5)8EF+GW-<%3,XKX(
M_>;1H/JSIIO$T"9" R'U6JJ^(9FE5MB[5.<'O6,HYXXI0<=ZX'CZTGV-HTHH
M],MOC-?V:J+?3K6WV@#,?!-='I7[1.LKY(E(C>$YB<-]T_6O$U;D<T\2'IVK
M2&.G'=O[V6X1?1?<?5.G_M:Z_K[1V&N7D4J<>3,R+\OMG%=L/BAJD\:26TL,
M:E< A017Q(KM_>Z5OZ/XTU72$$<<[/"/X&.:]"CCX)<LEH9RH7UB?85E\=/$
M]I$MN]VJQ)\HQ&N,?E7=Z!^T1XV-DD%MKCK&GW1Y:D ?E7Q?I_Q#FN$&\G(/
M(->O_#S49[NQ,TH(5N0O2NV<\-5@[JYBHU%(^B9/V@/B!'&"OB!P?^N:_P"%
M,C_:/^(BC_D8GSCO$G^%>9Q7/GA5'S^WI3O*Y(9=^.WI7AUJ5)OW4;J4EH>D
M+^TG\164[?$4F1_TS7_"@?M*_$9?O^(9/?\ =K_A7F;!5;(.[Z=J16,I8D<#
M^+M7+[&'8KF9ZDG[3OQ'AC)7Q#)C/4Q)G^5-;]JKXE*"#XB? /7RD_PKR]P0
MPP=P/\8Z"H)DRQ(&1G[W:H=&'8/:21ZQ%^U9\2E4 ^(W )ZF)/\ "FO^U;\2
ML_\ (R.!Z^4G/Z5Y P*X8]/[QZ4S/(S\N>A/0UG[&'8KVC/7?^&J?B2>3XB;
MV_=)S^E36/[47Q)N-0LHI?$#"*29%8>4@R">>U>-@'=@G'UJUI@)U6R/0><G
M)^HI.E&VQ49ML_5F-<Z"\A.7>P+,3W)CYK\8-<YU[5/^OJ7_ -"-?LM%<;/#
MH'_4-Z?]LZ_&G7?^0]JG_7S+_P"A&NK"?:^1X^/WC\_T*?3WI!P:*,=J[SR@
M[49_&D'6GQC+C%-">QZA\-/AE9_$;X;Z];375LDB2AX@%RRD>M?.OC7P]K>H
M>.[ZS.EE8;% BS6\1*MCCTKM_@/XZU[2/B3=:-I4_P!LCNYL2V>W.%R.:^UM
M9NK#25DLK72K59Y5'FL4!;=7S<OB9]7#X4?#GP2^#GCJU\7Z3XCM[.:VLC<J
M)5F!4.FX9./I7MG[07C*7PQKQTS2DC@'E!Y7/0DCD"O9FCO6T7S9G%O#""RH
M@QTKXW_:9\;PZS?I!;_\?^X(&0Y+=JDL\ULX-0^(WQ*LX'_>B&569EZ#FOK;
MQM\>-+^$7AJSTR5A+,$"8!KB?V;OA.-)\/W.M7Z$WTJ;E+#D>E>;^*_AGKOQ
M ^+T?VZ-_P"R89002O'6@1]6?"_7[CQ=;V^J(&2&0!AGW%>ZZ#IFC3JC7M_'
M$1@MN:ODKX@_&#3?@SX-BTO3 C7@C"*JGD$5\PZK\??&NNSO)_:TULC'A(SC
M H _9.VNOAQINGJ;O5[=I<=-XKS/XLZ%\,OBAH,^F3:M D;C &\?XU^5<7BW
MQAJ[8&NW3ENVZM)M$^(,15VOKQ$;E6(/- 'U-:_L^^ _AKJ,MSINJ0EVY^5^
MOZU#XIT+2?'MI_9[7JA.@PU?+;>'_'-Q+MDU*Z8GN10UCX\\.#[3#=32^7R>
M* /JOX1?LE6/A#5QK$#^8 <X&>:]NNM"GM-P5"JXXP*\/_9'_:.;Q7/_ &#K
M4@6\4[<,<9YK[-/A^+5K$N@YQV[T ?EI^U3IUSIOCVTN[@-Y.X=>G6OO']CW
MQS:P_#JWM5F7+P@$<>E>-?M>_"0:WHL\\49:X@4L,+7DO[)'Q2GT74QHUU+M
M='$1#'&,'% 'VIXSUV2+5BN25W$UG&YENT#J#TZU-XE@2\@BND8'>,^M5M+N
M=ML4P,CO0,XKX_WTC_"RY@/ $D9Q_P "%?+QZ^M?1_QWN_,\ WD>0<R)R/\
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MKAQ$958-,WA:.QB^7@=* M7GL9H^JGGTJ2'3991PAW>F*\MX:3=K&_.MS/\
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MSEN"Y*C X;-?N=XK\'6^H:!.AA$EP%)1CVXK\YOVO_@A<ZIX<NKR.VQ-;AY
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M@V>9#70^%_!^K^-=2^P:'9M?76W>R@@!1ZDGI7O05U<]3:*, KM!/Z5WND?
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MIY #''<=*XW"YTQJN)XJG@ZZ_P">"C\*U=,\(F!@\@ QVKT2:T&TY )^E53
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M=":XXUZ^#^!^IXF._B+T$%!/%':CK7<>:)CB@G(%'?%'7B@8N>:!THQ1U/\
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M4XQ_Q+AT_P"N=?D3J_\ R&=1_P"OB3_T(U^Q+6Y?PO&YYSI@Y_[95^.VL_\
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MM)/^BZE.@ Z;B14&L_&GQ/8 F2>.Z&/^6JUZ4*L;ZGF/#S6S-SQ23)K<*XW
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M'1DOM9D/]O70*0P9R5SZU] ?LG_"%=-TNX\4:T$AFG_>>9*< <UX9\'- O\
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M_%SX3WGC?X@6SM.38Q2JS*#UQ75_%V^_X1?X7PZ#')A' 3;GK0!PGQP^+O\
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M?="^OP_E9W_[$'C^)=>D\,7ERDA#8C!/4$U]/?M<?"]M#^!VNZPMNZQ/%D.
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M[66H7C./LXZ'O%E+MLCP!\OI7GFM0+)ID;LNX-<GK^-4M"^(GB/4X3#'#;,
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M[409'2L+3HA&HQS6HLV$ S7RM67,[GT,%RJQH^:I. ,UX+^UOM5?#9[^6_\
M.O:Q+SG->$_M;2?NO#)/_/-^G;FIHK][$=7X&?/;_,2>M1G)Z4TOSQ^=*&R#
MGGWKV6<2)]H*Y!I0V.,9]ZCY4^U*['<,@8]:RDRTB7< 21R?6F2' .?SI'92
M=QZCH1TJ.67>V[KC\JP<C5(C=@#Z^]03N,DCGWJ263*EOXO4=*KD%CDG_"N>
M3-4B,MSP.?6E)SQ^M*!UI@.#S6;-$A<\_2D/3KB@X['%(<8J"QKX-,W'O0S
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M!K] ;H:9>\3V-K*#_>C%8>L> /!_B"+R[_0;*9!S@)C^5/F78B2=MSXH\/\
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M"*\HGRT*+U+.HQ^->L_M J8M=\+1 J=FE1#((/\ "*^OP&F7U'_B_)'S-?\
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M/^$EUKMK%[_W^;_&OH,?LU>& /\ C^U;_O\ 1?\ QN@?LU^&2/\ C_U;_O\
M1?\ QNCG0N27<^??^$HUL#_D,7W_ '_;_&E_X2G7!_S&;_\ [_M_C7T!_P ,
MU^& 3_IVK?\ ?Z+_ .-TH_9K\,G_ )?]6_[_ $7_ ,;HYT')+N> #Q;X@0?+
MKFH+]+AA_6GCQKXD4\>(-2'_ &\O_C7OG_#-?AG'_'_JW_?Z+_XW3?\ AFOP
MS_S_ .K?]_HO_C='.A\DNYX.OCGQ.IR/$>J#_MZ?_&GCQ]XJ'3Q+JH^EV_\
MC7NP_9K\,8_X_P#5O^_T7_QNE7]FOPR<?Z?JW_?Z+_XW1SH.27<\)/C_ ,5_
M]#/JWT^UO_C2+\0/%0_YF?5O_ M_\:]W_P"&:O#'_/\ ZM_W^B_^-T?\,U>&
M!_R_ZM_W^B_^-TN9"Y9=SPG_ (6!XK/_ #,^K#_M[?\ QH/C_P 5$<^)M6/_
M &]O_C7NO_#-?AC'_']JW_?Z+_XW3O\ AFKPQ_S_ &K?]_HO_C=',A\DNYX,
M?'OBIA@^)M5/UNW_ ,:C?QGXCD'SZ_J3?6Y;_&O?/^&:O#'_ #_:M_W^B_\
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M[_1?_&Z.=![-GS63@4#I7TI_PS5X8_Y_M6_[_1?_ !NC_AFKPQN_X_\ 5O\
MO]%_\;HYT'(SYK)H/6OI7_AFKPQ_S_:M_P!_HO\ XW2?\,U>&,_\?VK?]_HO
M_C='.@]FSYKZT=Z^E#^S5X8_Y_\ 5O\ O]%_\;H'[-7AC)_T[5O^_P!%_P#&
MZ.=![-GS7G'O0>HQ7TH?V:O#&/\ C^U;_O\ 1?\ QND'[-7AC/\ Q_ZM_P!_
MHO\ XW1SH.1GS9TI:^D_^&:O# /_ !_:MT_Y[1?_ !N@?LU>&#_R_:M_W^B_
M^-T<Z#V;/FSM[T G/K7TG_PS7X8X_P!.U;_O]%_\;H/[-7AC_G_U;_O]%_\
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M_P"-T<Z%R,^:^M(P_*OI;_AFKPQ_S_ZM_P!_HO\ XW2?\,U>&/\ G^U;_O\
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M )?]6_[_ $7_ ,;I3^S5X8 _X_M6_P"_T7_QNCG0N1GS70:^E#^S7X9_Y_\
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4:O#''^GZM_W^B_\ C='.@Y&?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>ahpa-20220416xs4034.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ahpa-20220416xs4034.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'D KP# 2(  A$! Q$!_\0
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M?M8:JP;0--#?(WF3NOH1@#^M?/1:O4_VE-8&H_$AX%.5L[=82/\ :ZG^=>5
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MJ ?I7QSX=B\_Q5H47]Z^A'_CPK[*' I=0%HHHI@%%%% !1110 4444 %%%%
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M<A?X1^7\ZZ?=Q63U!#LYI":;FBD,<>E'>FT _C0 [-!.*:>U% "YQ1FFYI:
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M-2YYI6 >#Q2;NE)G% S0,?NI<^],%(<&D!#D]J4&F9H[51([O29Q2!N*3.:
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MP<TX,!U- $5(6'2F@YH/%, +<4F<T$BC/% !FC-)FDSVI +FC/--S^!HSUH
M7/%(6_"FYYI,\T#'9%-SS32V*9GFE<+$NZ@/A@:A+4F_!HW'8^-?BKIATCXC
M:_!C"O=/*@']UCD?SKEAUKUG]I?219>-[2^ .+VV'/NG!_F*\ER<BD,<1FD
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M@9_&B@!":.M+3>* %'6C/%)UHSSUH 6D-%)G- !WHZ4G2@GF@!<T4G?K1VH
M*]*^$"8T[47Q]Z8?RKS7&.>M>I_":+;X:EDQR]PX_*@#ND:IT/%0(,U81<4
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M&@IABQ6@8O:F-'[4 9S1U&T0K1: $<5$]O[4 9YA%126^1TK0:$^E1M%[9H
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MUYKN- \!F0J\J\>AJ- .6T#PF]UM"IM3Z5Z3H?AB*Q084%O6M_3]!2TC"JH
M%:L5CZ"D!GP68CJY';^@J['9D=JL+:\4#*209ZU.D'' JVEKCM4P@]L4 4UM
M^.:F6"K2P>U3+;8H JI#Z5,D/-65M\U*L(]* *ZP<U,L.*G6,>E2+%P* (XX
MJG2/':GK'4JI0 Q(ZE6/-.6/VJ=(Z &I%FK$<>*5$J95YH 55Q4B+D4BBI4&
M* 'QCFIU%1(.*F S0!(HJ5 *B48%2KTH E7@U*O&*B3K4J'-)"9(.1@T].]1
MY)IZ'GFJ$2BI!SCBHEJ3/'%(HE4^U+FF*<BG9H Z^@TII,59 T]Z3CVIQI*
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MO]DJ#]T4#/&X? !/_+(XJW%X"Q_RQ_.O6O[-4'H/RIRZ<!_"* L>6Q^ N?\
M5"KL'@09'R ?A7I*:?[5:AL53G;0!Q.F^"X;<AF3<1[5N1:.L8&% QVKH1;@
M=L4OD<T 8B:>!VJ5;+:.E:_D8-'DX/M0!EBUQT%2"VX'%:'DTX04 4!;T];>
MKOD\4X1 "@"F(<=JD$/'2K?E4X1\4 51'3UCJRL=.$1H @$9%/"5.L52+%ST
MH @6/VJ=(\FI5AJ5(_PH B6/UJ9(_:G[*>%H :JU( :-N14@7D4 -4&ID% 2
MI%7(Z4"%0=ZE4<4U5Q4BT#%49J5!T[TU1_DU(HS]#2$.6I0,TQ1DU*!@4(3%
M%/7DBD XIX7I5 .6GBFA:>*0QX&/2G;::HR*?BA =?2'BEQ2&J)$/(I"#2]Z
M#R*8#<"FD?C3C2$<XH 9C%)3L?C28H 3&::>!3O6DQFD PBFD9Z4\BD(YH8[
MD)'-)MJ3;UII7C%(HB9:C*?K5@C(Z4PBBXBNRTPKQ5AEQR.E,*^E,5B K2$9
M[U+LII7/2@1$5XI".*EVFFXI6&1[:;MJ7%(5H A*\TFTFIB,CI3=N*!D6WBD
M\NIL4A6@9 8Z;Y?%6 M(4-&@BL8_I33'STJR4I"H-("H8Z0QXJUY=-,?% %0
MQ\TTIQ5OR^^*8R<4"L56C'I3?*JVT7M33'^= RHT%1F"KOETTIS0*Y2,7--,
M?/O5TQYYQBHV2D.Y4,?--9:LLGK3&3-%QE4H,5!)"#VJX4/X4QDSUI@9DMJK
M9R*JR6*^E;+Q9%0M!F@##?3QGVJ!K#VK>: ^E,\CVH P38>U*MASC%;OV<#M
M2&W]J ,86?M2_92..:V/L]--O[4 9/V4BC[/[5J^0/2E, ]* ,G[.12_9R:U
M/(]J3R0.U &8(#TI?LY K2,0/:D\GF@#/%OGJ*40<]*O^0 *41#TH HB#/O3
MUM\5=$?M2^6* *8A%.$-6A'@TNS/;% %<08YIXB%3!/:G!* (ECQ3@O-2B,^
ME/$7- $02G!*F$=.$9]*!$00XJ18^:D"4\+@T#&".G!*>%S2A<4 (%IX3BG!
M:<%]>M*X HJ1%S0J9J11BE85Q0.?:G 4!:>%XJA"J.]/ H4>U/ H& %/5>*%
M'K3@,]*!BCM3J ,FEQ^%,#K3WH)-*:6F0,QBD(IQ&12=Z $/KTI*=^M-/7VI
M@(?IFF[>:<12T 1D<TGK3R.*8>M "8S3<=<TZ@C/>E8",CBFD<5(132/2@8S
M'%,9<U*5II&*0$1%,9#C%3;::5IH9"R&F$"K!6F[* ("*0KD=*G*9IK+B@5B
MN5(I,5,5II% $>*;MR:FVCO32OI181&5II7/:I,44K%$97K32#4I%(1S0*Y&
M5YI"*D(I#@<]Z 1&5S32F/K4N*3%%PN18SUI-H]*E*TA7(H&0%>M-V\U,5I-
MM("N5]J:PJP4IA3)I#*Y7TIA7-6=F.U,*^M,5BN5]JC:+TJTR?A3"AH$5&CY
MZ4QHZNE/PIAB]:5AW*1C--,9]*NF+-(8A3"Y1\DGH*;Y/M^=7_)]\4TQ=:0%
M(Q8I/*JX8\TWRO7BBXRF8P,\4WR/:KIC%)Y5,"EY'H,4GDFKOEY]J/*Z4 4O
M)I/)XZ5=,7--\N@"F82*3R:N>7SBD\N@"IY.>U'D^U7/+HV"@"GY1'&*%A)J
MWLY_K2B/- %7R?:@Q&K1CXZ4!* *_E>U.6+BK BSSTH"8H A$=.V5-Y>!2A.
M: (MG%*%]JF"8-*%]J5P(@E*$XJ8)D4[RLT 0B/BGB/O4P2E"#%&XKD2KGM4
M@2GA:<J9IV$-"TX+U-/"?E3@F* &JN.M/QFG*E."T%" 8Z4X#GFG!0*>!@>M
M #0.*>!2XI0N*8A .:?MS0%IP'O0!U6,&B@TF*9(?YZ4W&.:=C(I.WI0 E)B
MG'O28H :12=*<:.,4P$II%.I,4 1D4G2I"*9T- #2,TF,?UIV,T$9I -_I33
MS3\4FV@"/'>D(P#BI",'%-*]:0R,K2%<YJ0]Z3'XTAD6W%-*@U*1@TW'%,9&
M4R:84P<5-BD(%,5B%L"FXJ5DR2::5P,T"&$4TKGZT\@DT;:8$17 I"*E(Q32
M*0B/%!&:>5&*1@!0,9MI"*?12L.Y'MYI-E28IN*0AA7--*_G4O>FD>E R(K2
M%<U*>*:5S]:87(MM,*5,5Q2%>>: *^W%)LYJ<KFD*4@*Y3VH*9[5.$P:-F:
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MZ7K2']:7WH/2J$-/ H(I>HI,4  I#3B,&FFD F*.,^]*128YHN A%(:=BD-
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,*0(D"BEVBBB@H__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389910765080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AVISTA PUBLIC ACQUISITION CORP. II<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001846253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389909679752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 189,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">744,542<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">934,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Cash held in trust account</a></td>
<td class="nump">235,750,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">236,684,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">15,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_AccruedExpenseRelatedPartyCurrent', window );">Accrued expenses</a></td>
<td class="nump">107,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_AccruedOfferingCostsAndExpensesCurrent', window );">Accrued offering costs</a></td>
<td class="nump">314,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related party</a></td>
<td class="nump">884<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">438,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting fee payable</a></td>
<td class="nump">8,050,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">8,488,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (see Note 6)</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A ordinary shares, $0.0001 par value, subject to possible redemption; 23,000,000 shares at redemption value</a></td>
<td class="nump">235,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(7,554,273)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Deficit</a></td>
<td class="num">(7,553,698)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT</a></td>
<td class="nump">236,684,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock</a></td>
<td class="nump">$ 575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_AccruedExpenseRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the accrued expense pertaining to related party as of balance sheet date. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_AccruedExpenseRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_AccruedOfferingCostsAndExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the accrued offering costs and expenses as of balance sheet date. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_AccruedOfferingCostsAndExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_DeferredOfferingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_DeferredOfferingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389909534920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value, (per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Class A common stock subject to possible redemption, outstanding (in shares)</a></td>
<td class="nump">23,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value, (per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ahpa_CommonClassaSubjectToRedemptionMember', window );">Class A Common Stock Subject to Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value, (per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">23,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">23,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Class A common stock subject to possible redemption, outstanding (in shares)</a></td>
<td class="nump">23,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value, (per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ahpa_CommonClassaSubjectToRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ahpa_CommonClassaSubjectToRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389911788664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENT OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Formation and operating costs | $</a></td>
<td class="nump">$ 516,442<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss | $</a></td>
<td class="num">$ (516,442)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic | shares</a></td>
<td class="nump">9,857,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted | shares</a></td>
<td class="nump">9,857,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per ordinary share | $ / shares</a></td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per ordinary share | $ / shares</a></td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic | shares</a></td>
<td class="nump">5,321,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted | shares</a></td>
<td class="nump">5,321,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per ordinary share | $ / shares</a></td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per ordinary share | $ / shares</a></td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389909901704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENT OF CHANGES IN SHAREHOLDERS' DEFICIT - 11 months ended Dec. 31, 2021 - USD ($)<br></strong></div></th>
<th class="th">
<div>Class A ordinary shares </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Class B ordinary shares </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Public Warrants</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Private Placement Warrants</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Public Warrants</div></th>
<th class="th"><div>Private Placement Warrants</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Feb. 04, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the beginning (in shares) at Feb. 04, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class B ordinary shares to Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class B ordinary shares to Sponsor (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Proceeds from Initial Public Offering Costs allocated to Warrants (net of offering costs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,232,604<span></span>
</td>
<td class="nump">$ 12,298,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,232,604<span></span>
</td>
<td class="nump">$ 12,298,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Re-measurement of Class A ordinary shares to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,555,404)<span></span>
</td>
<td class="num">(7,037,831)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,593,235)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(516,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(516,442)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,554,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,553,698)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389909669048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENT OF CASH FLOWS<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (516,442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(744,542)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable</a></td>
<td class="nump">15,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Due to related party</a></td>
<td class="nump">884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_IncreaseDecreaseInAccruedLiabilitiesRelatedParties', window );">Accrued expenses</a></td>
<td class="nump">107,734<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,136,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_PaymentsForInvestmentOfCashInTrustAccount', window );">Investment of cash into Trust Account</a></td>
<td class="num">(235,750,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(235,750,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of Class B ordinary shares to Sponsor</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ProceedsFromIssuanceInitialPublicOfferingNet', window );">Proceeds from initial public offering, net of underwriter's discount paid</a></td>
<td class="nump">225,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from sale of Private Placement Warrants</a></td>
<td class="nump">12,350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from Sponsor note</a></td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_Repaymentfromrelatedpartydebt', window );">Repayment of Sponsor note</a></td>
<td class="num">(175,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="num">(698,103)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">237,076,897<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash</a></td>
<td class="nump">189,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash - end of period</a></td>
<td class="nump">189,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue', window );">Re-measurement of Class A ordinary shares to redemption value</a></td>
<td class="nump">28,593,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_OfferingCostsIncludedInAccountsPayableAccruedExpenses', window );">Offering costs included in accrued offering costs</a></td>
<td class="nump">314,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_DeferredUnderwritingFeePayable', window );">Deferred underwriting fee payable</a></td>
<td class="nump">$ 8,050,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount Accretion of Class A ordinary shares subject to redemption to redemption value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_DeferredUnderwritingFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of underwriting fee payable deferred during the period, classified as non-cash investing and financing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_DeferredUnderwritingFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_IncreaseDecreaseInAccruedLiabilitiesRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_IncreaseDecreaseInAccruedLiabilitiesRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_OfferingCostsIncludedInAccountsPayableAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of offering costs included in accounts payable or accrued expenses that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_OfferingCostsIncludedInAccountsPayableAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_PaymentsForInvestmentOfCashInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow for investment of cash in trust account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_PaymentsForInvestmentOfCashInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_ProceedsFromIssuanceInitialPublicOfferingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash inflow from initial public offering after deducting offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_ProceedsFromIssuanceInitialPublicOfferingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_Repaymentfromrelatedpartydebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of repayment from related party debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_Repaymentfromrelatedpartydebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389910836216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</b><b style="font-weight:bold;"> AND LIQUIDITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Avista Public Acquisition Corp. II (the &#8220;Company&#8221;) is a blank check company incorporated in the Cayman Islands on February 5, 2021. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with one or more businesses (a &#8220;Business Combination&#8221;). The Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2021, the Company had not commenced any operations. All activity for the period from February 5, 2021 (inception) through December&#160;31,&#160;2021 relates to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;), which is described below. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on August 9, 2021. On August 12, 2021, the company consummated the Initial Public Offering of 23,000,000 units (the &#8220;Units&#8221; and, with respect to the Class&#160;A ordinary shares included in the Units sold, the &#8220;Public Shares&#8221;), including 3,000,000 Units that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at $10.00 per Unit, generating gross proceeds of $230,000,000 (see Note&#160;3).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 8,233,333 warrants (the &#8220;Private Placement Warrants&#8221;), including 900,000 Private Placement Warrants that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at a price of $1.50 per Private Placement Warrant in a private placement to Avista Acquisition LP II (the &#8220;Sponsor&#8221;), generating gross proceeds of $12,350,000 (see Note&#160;4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transaction costs amounted to $13,662,256 consisting of $4,600,000 of underwriting fees, $8,050,000 of deferred underwriting fees, and $1,012,256 of other offering costs. In addition, as of December 31, 2021, cash of $189,971 is held outside of the Trust Account (as defined below) and is available for the payment of accrued offering costs and for working capital purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon closing of the Initial Public Offering and the sale of the Private Placement Warrants, a total of $235,750,000 ($10.25 per Public Share) was placed in a trust account (the &#8220;Trust Account&#8221;) and will be invested only in U.S. government treasury obligations with maturities of 185 days or less or in money market funds meeting certain conditions under Rule&#160;2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of: (i)&#160;the consummation of the initial Business Combination within 18 months from the closing of the Initial Public&#160;Offering, (ii) the redemption of the Company&#8217;s Public Shares if the Company has not consummated an Business Combination within 18 months from the closing of the Company&#8217;s Initial Public Offering, subject to applicable law, and (iii) the redemption of the Company&#8217;s Public Shares properly submitted in connection with a shareholder vote to approve an amendment to the Amended and Restated Memorandum and Articles of Association (A) that would modify the substance or timing of the obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the Company&#8217;s Public Shares if the Company does not complete the initial Business Combination within 18 months from the closing the Company&#8217;s Initial Public Offering or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will provide its holders of the outstanding Public Shares (the &#8220;public shareholders&#8221;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a shareholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account ($10.25 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants. The Public Shares subject to redemption was recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480, <i style="font-style:italic;">Distinguishing Liabilities from Equity </i>(&#8220;ASC 480&#8221;)<i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 either prior to or upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association (the &#8220;Amended and Restated Memorandum and Articles of Association&#8221;), conduct the redemptions pursuant to the tender offer rules&#160;of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required by law, or the Company decides to obtain shareholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules&#160;and not pursuant to the tender offer rules. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note&#160;5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each public shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or don&#8217;t vote at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the above, if the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Amended and Restated Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor has agreed to waive (i) redemption rights with respect to its Founder Shares and Public Shares held by it in connection with the completion of a Business Combination, (ii)&#160;redemption rights with respect to any Founder Shares and Public Shares held by it in connection with a shareholder vote to amend the Amended and Restated Memorandum and Articles of Association to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with an initial Business Combination or to redeem 100% of its Public Shares if the Company does not complete an initial Business Combination within 18 months from the closing of the Initial Public Offering or with respect to any other material provision relating to shareholders&#8217; rights or pre-initial Business Combination activity and (iii) rights to liquidating distributions from the Trust Account with respect to any Founder Shares held if the Company fails to complete an initial Business Combination within 18 months from the closing of the Initial Public Offering. However, if the Sponsor acquires Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within 18 months from the closing of the Initial Public Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has until 18 months from the closing of the Initial Public Offering to complete a Business Combination (the &#8220;Combination Period&#8221;). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up; (ii)&#160;as promptly as reasonably possible but no more than <span style="-sec-ix-hidden:Hidden_MH-1shE-7UuVsRr2IwZGhQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> business&#160;days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay income taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish public shareholders&#8217; rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining shareholders and board of directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#8217;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note&#160;6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Indemnity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company (other than the Company&#8217;s independent registered public accounting firm), or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i)&#160;$10.25 per Public Share and (ii)&#160;the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.25 per Public Share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay tax obligations, provided that such liability will not apply to any claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had $189,971 in cash held outside of the Trust Account and a working capital surplus of $496,302. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. Moreover, the Company may need to obtain additional financing either to complete a Business Combination or if the Company becomes obligated to redeem a significant number of public shares upon completion of a Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination. Of the total proceeds from the Initial Public Offering and sale of the Private Placement Warrants, an amount of approximately $2<span style="white-space:pre-wrap;"> million was deposited in an operating account for the Company&#8217;s working capital needs. The amounts held in the operating account are not  expected to provide the Company with sufficient funds to meet its operational and liquidity obligations over the next twelve months.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Going Concern Consideration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had $189,971 in cash held outside of the Trust Account and a working capital surplus of $496,302. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company ability to continue as a going concern for a period of time within one year after the date that the financial statements are issued. Management plans to address this uncertainty through the Business Combination as discussed above. There is no assurance that the Company&#8217;s plans to consummate the Business Combination will be successful or successful within the Combination Period. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s financial position, results of its operations, and/or search for a prospective partner company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389910883304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section&#160;102(b)(1)&#160;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class A Ordinary Shares Subject to Possible Redemption</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of the 23,000,000 shares of Class A ordinary shares sold as part of the Units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company&#8217;s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company&#8217;s amended and restated certificate of incorporation. In accordance with SEC and its staff&#8217;s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class A ordinary shares have been classified outside of permanent equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional paid-in capital and accumulated deficit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">As of December 31, 2021, the Class A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Gross proceeds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Proceeds allocated to Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,813,334)</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Issuance costs allocated to Class A ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,029,901)</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Plus:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Accretion of carrying value to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,593,235</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A ordinary shares subject to possible redemption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 235,750,000</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Offering Costs associated with the Initial Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company complies with the requirements of ASC 340-10-S99-1 and SEC Staff Accounting Bulletin Topic 5A - <i style="font-style:italic;">Expenses of Offering</i>. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $13,662,256 as a result of the Initial Public Offering (consisting of $4,600,000 of cash underwriting discounts, $8,050,000 in deferred underwriting fees and $1,012,256 of other offering costs). As such, the Company recorded $13,029,901 of offering costs as a reduction of temporary equity and $632,355 of offering costs as a reduction of permanent equity in connection with the issuance of the Units in the Initial Public Offering and the Private Placement Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under ASC 740, <i style="font-style:italic;">Income Taxes</i> (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statements recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. Based on the Company&#8217;s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company&#8217;s financial statements. Since the Company was incorporated on February 5, 2021, the evaluation was performed for the 2021 tax year which will be the only period subject to examination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is considered an exempted Cayman Islands Company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. Consequently, income taxes are not reflected in the Company&#8217;s financial statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss Per Ordinary Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 15,900,000 shares in the calculation of diluted income per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Period from February 5,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021 (inception) Through</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class B</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (335,384)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (181,058)</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 12pt;">Basic and diluted weighted average shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,857,143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,321,429</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_6OA0VirRwEuN8iLMAj_gFA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.03)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__fz-Sh5S5EuPKCGy7i67kQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.03)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company applies ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts reflected in the balance sheet for cash, deferred offering costs, accrued offering costs, promissory note &#8212; related party, and advance from anchor investor approximate fair value due to their short-term nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 1 &#8212; Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 2 &#8212; Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 3 &#8212; Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if converted method for all convertible instruments. ASU 2020-06 is effective for the Company on January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company adopted ASU 2020-06 effective January 1, 2021 using the modified retrospective method of transition. The adoption of ASU 2020-06 did not have a material impact on the financial statements for the period from February 5, 2021 (inception) through December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389910836216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INITIAL PUBLIC OFFERING<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_InitialPublicOfferingAbstract', window );"><strong>INITIAL PUBLIC OFFERING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_InitialPublicOfferingTextBlock', window );">INITIAL PUBLIC OFFERING</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;3. INITIAL PUBLIC OFFERING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on August 9, 2021. On August 12, 2021, the Company completed its Initial Public Offering of 23,000,000 Units, including 3,000,000 Units that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at $10.00 per Unit, generating gross proceeds of $230,000,000. Each Unit consists of one Class A ordinary share and <span style="-sec-ix-hidden:Hidden_d8ssFNr6LUCa3paVl1JKtw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-third of one</span></span> redeemable warrant (&#8220;Public Warrant&#8221;). Each Public Warrant entitles the holder to purchase one Class A ordinary share at an exercise price of $11.50&#160;per whole share (see Note 7).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_InitialPublicOfferingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_InitialPublicOfferingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_InitialPublicOfferingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on information about initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_InitialPublicOfferingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389911511400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRIVATE PLACEMENT<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_PrivatePlacementAbstract', window );"><strong>PRIVATE PLACEMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_PrivatePlacementTextBlock', window );">PRIVATE PLACEMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;4. PRIVATE PLACEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 8,233,333 Private Placement Warrants, including 900,000 Private Placement Warrants that were issued pursuant to the underwriter&#8217;s exercise of its over-allotment option in full, at a price of $1.50 per Private Placement Warrant ($12,350,000 in the aggregate). Each Private Placement Warrant is exercisable to purchase one Class A ordinary share at a price of $11.50 per share. The proceeds from the Private Placement Warrants were added to the net proceeds from the Initial Public Offering to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Placement Warrants.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_PrivatePlacementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_PrivatePlacementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_PrivatePlacementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on information about private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_PrivatePlacementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389911812056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;5. RELATED PARTY TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Founder Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 12, 2021, the Sponsor paid an aggregate of $25,000 to cover certain expenses on behalf of the Company in exchange for the issuance of 5,750,000 Class B ordinary shares (the &#8220;Founder Shares&#8221;). The Founder Shares include an aggregate of up to 750,000 Class B ordinary shares subject to forfeiture by the Sponsor to the extent that the underwriters&#8217; over-allotment option is not exercised in full or in part, so that the holders of the Founder Shares will own, on an as-converted basis, 20% of the Company&#8217;s issued and outstanding shares after the Initial Public Offering. On June 16, 2021, the Company transferred 35,000 Class B ordinary shares each to three members of the Company&#8217;s board of directors (or 105,000 Class B ordinary shares in total) at their original cost (see Note 7). The underwriters exercised their over-allotment option in full on August 12, 2021; thus, no ordinary shares remain subject to forfeiture (see Note 6).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor has agreed that, subject to certain limited exceptions, the Founder Shares will not be transferred, assigned, or sold until the earlier of (i)&#160;one year&#160;after the completion of a Business Combination or (ii) the date on which the Company completes a liquidation, merger, share exchange or other similar transaction after an initial Business Combination that results in all of the Company&#8217;s shareholders having the right to exchange their Class A ordinary shares for cash, securities or other property. Notwithstanding the foregoing, if (1) the closing price of the Company&#8217;s Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30- trading day period commencing at least 150 days after an initial Business Combination or (2) if the Company consummates a transaction after an initial Business Combination which results in the Company&#8217;s shareholders having the right to exchange their shares for cash, securities or other property, the Founder Shares will be released from the lock-up.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Promissory Note&#160;&#8212; Related Party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 12, 2021, the Company issued an unsecured promissory note to the Sponsor (the &#8220;Promissory Note&#8221;), pursuant to which the Company could borrow up to an aggregate of $300,000 to cover expenses related to the Initial Public Offering. The Promissory Note was non-interest bearing and was payable on the earlier of (i) December 31, 2021 or (ii) the consummation of the Initial Public Offering. The Company&#8217;s Sponsor paid certain offering costs totaling $55,725, which was included in the outstanding balance of the Promissory Note as of March 22, 2021, and the Company borrowed $119,275 on June 23, 2021. On August 12, 2021, the Company repaid the outstanding balance under the Promissory Note of $175,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Administrative Support Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company entered into an agreement, commencing on August 9, 2021, to pay an affiliate of the Sponsor a total of $10,000 per month for administrative, financial and support services. Upon the completion of an initial Business Combination, the Company will cease paying these monthly fees. Under this agreement, $46,129 of expenses were incurred during the period from February 5, 2021 (inception) through December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Due to Related Party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to related party consists of advances from the Sponsor to pay for offering costs and formation costs on behalf of the Company and are payable on demand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Related Party Loans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">In order to finance transaction costs in connection with an intended initial Business Combination, the Company&#8217;s sponsor or an affiliate of the sponsor or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (the &#8220;Working Capital Loans&#8221;). If the Company completes the initial Business Combination, it may repay such loaned amounts out of the proceeds of the trust account released to us. Otherwise, such loans may be repaid only out of funds held outside the trust account. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the trust account to repay such loaned amounts but no proceeds from the Company&#8217;s trust account would be used to repay such loaned amounts. Up to $2,000,000 of such loans may be convertible into warrants of the post-Business Combination entity at a price of $1.50&#160;per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. Except as set forth above, the terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans. Prior to the completion of the initial Business Combination, the Company does not expect to seek loans from parties other than the Company&#8217;s sponsor, its affiliates or any members of the management team as the Company does not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in the trust account. As of December 31, 2021, there was no balance outstanding under the Working Capital Loans.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389910870216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;6. COMMITMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Registration and Shareholder Rights Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to a registration rights agreement entered into on August 9, 2021, the holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants issued upon conversion of the Working Capital Loans) will have registration and shareholder rights to require the Company to register a sale of any of its securities held by them pursuant to a registration and shareholder rights agreement to be signed prior to or on the effective date of the Initial Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of an initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Underwriting Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The underwriters were paid a cash underwriting discount of $0.20&#160;per Unit, or $4,600,000 in the aggregate, upon the closing of the Initial Public Offering and exercise of the over-allotment in full on August 12, 2021. In addition, $0.35 per unit, or $8,050,000 in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Forward Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the consummation of the Initial Public Offering, the Company entered into a forward purchase agreement with the Sponsor, Avista Acquisition LP II, a Cayman Islands exempted limited partnership, which provides for the purchase of an aggregate of 10,000,000 Class A ordinary shares plus an aggregate of 3,333,333 redeemable warrants to purchase Class A ordinary shares at $11.50 per share, for an aggregate purchase price of $100,000,000, in the private placement. The obligations under the forward purchase agreement do not depend on whether any Class A ordinary shares are redeemed by the Company&#8217;s public shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The forward purchase securities will be issued in connection with the closing of the initial Business Combination. The proceeds from the sale of forward purchase securities will be used as part of the consideration to the sellers in the Company&#8217;s initial Business Combination, expenses in connection with the initial Business Combination or for working capital in the post-transaction company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389910838216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' DEFICIT<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>SHAREHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' DEFICIT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;7. SHAREHOLDERS&#8217; DEFICIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preference shares&#8212;</span> The Company is authorized to issue 5,000,000 preference shares with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. As of December&#160;31,&#160;2021, there were no preference shares issued or <span style="-sec-ix-hidden:Hidden_dLQndVmTokOqpzPEE6ShuQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class&#160;A ordinary shares&#8212;</span> The Company is authorized to issue 500,000,000 Class A ordinary shares with a par value of $0.0001 per share. Holders of Class A ordinary shares are entitled to one vote for each share. At December&#160;31,&#160;2021, there were 23,000,000 Class A ordinary shares issued and <span style="-sec-ix-hidden:Hidden_Z_H04b9q5UCcSUgqEMG3_g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, including 23,000,000 Class A ordinary shares subject to possible redemption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class&#160;B ordinary shares&#8212;</span> The Company is authorized to issue 50,000,000 Class B ordinary shares with a par value of $0.0001 per share. Holders of Class B ordinary shares are entitled to one vote for each share. As of December 31, 2021, there were 5,750,000 Class B ordinary shares issued and <span style="-sec-ix-hidden:Hidden_1ubnyfPiU0eaQzavzDHJNg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, and the holders of the Founder Shares own, on an as-converted basis, 20% of the Company&#8217;s issued and outstanding shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Except as described below, holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company&#8217;s shareholders except as required by law. Unless specified in the Company&#8217;s Amended and Restated Memorandum and Articles of Association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the ordinary shares that are voted is required to approve any such matter voted on by the shareholders. Approval of certain actions will require a special resolution under Cayman Islands law, being the affirmative vote of at least two-thirds of the ordinary shares that are voted, and pursuant to the Amended and Restated Memorandum and Articles of Association; such actions include amending the Amended and Restated Memorandum and Articles of Association and approving a statutory merger or consolidation with another company. The Company&#8217;s board of directors is divided into three classes, each of which will generally serve for a term of three years with only one class of directors being appointed in each year. There is no cumulative voting with respect to the appointment of directors, with the result that the holders of more than 50% of the shares voted for the appointment of directors can appoint all of the directors. The Company&#8217;s shareholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally available therefor. Prior to the Company&#8217;s initial Business Combination, (i) only holders of the founder shares will have the right to vote on the appointment of directors and (ii) in a vote to continue the Company in a jurisdiction outside the Cayman Islands (which requires the approval of at least two thirds of the votes of all ordinary shares), holders of the Company&#8217;s Class B ordinary shares will have ten votes for every Class B ordinary share and holders of the Class A ordinary shares will have one vote for every Class A ordinary share. These provisions of the Company&#8217;s Amended and Restated Memorandum and Articles of Association may only be amended by a special resolution passed by not less than 90% of the ordinary shares who attend and vote at the Company&#8217;s general meeting which shall include the affirmative vote of a simple majority of the Class B ordinary shares. Holders of the public shares will not be entitled to vote on the appointment of directors prior to the initial Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, prior to the completion of an initial Business Combination, holders of a majority of the founder shares may remove a member of the board of directors for any reason. In connection with the initial Business Combination, the Company may enter into a shareholders agreement or other arrangements with the shareholders of the target with respect to voting and other corporate governance matters following completion of the initial Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Redeemable Warrants&#8212;</span> Each whole warrant entitles the registered holder to purchase one Class A ordinary share at a price of $11.50 per share , subject to adjustment as discussed below, at any time commencing 30 days&#160;after the completion of the Company&#8217;s initial Business Combination, except as discussed in the immediately succeeding paragraph. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of Class A ordinary shares. This means only a whole warrant may be exercised at a given time by a warrant holder. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Accordingly, unless you purchase at least three units, you will not be able to receive or trade a whole warrant. The warrants will expire five years&#160;after the completion of the initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will not be obligated to deliver any Class A ordinary shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class A ordinary shares underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company&#8217;s satisfying of the obligations described below with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable and the Company will not be obligated to issue a Class A ordinary share upon exercise of a warrant unless the Class A ordinary share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the Class A ordinary share underlying such unit. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has agreed that as soon as practicable, but in no event later than 20 business&#160;days after the closing of the initial Business Combination, the Company will use commercially reasonable efforts to file with the SEC a registration statement (which may be a post-effective amendment to the registration statement of which the Company&#8217;s prospectus is a part or any other applicable registration statement) for the registration, under the Securities Act, of the Class A ordinary shares issuable upon exercise of the warrants, and the Company will use commercially reasonable efforts to cause the same to become effective within 60&#160;business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Company&#8217;s Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section 18(b)(1) of the Securities Act, the Company may, at it&#8217;s option, require holders of warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, will not be required to file or maintain in effect a registration statement, and will use commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent available. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section 3(a)(9) of the Securities Act or another exemption, and the Company will use commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class A ordinary shares equal to the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the &#8220;fair market value&#8221; (defined below) less the exercise price of the warrants by (y) the fair market value. The &#8220;fair market value&#8221; as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Redemption of warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in whole and not in part;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at a price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.01</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per warrant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">upon not less than </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30 days</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8217; prior written notice of redemption to each warrant holder; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if, and only if, the closing price of the Class A ordinary shares equals or exceeds </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$18.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> trading days within a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">-</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the Class A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class A ordinary shares is available throughout the 30-day redemption period. If and when the warrants become redeemable by the Company, the Company may exercise the Company&#8217;s redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and the Company issues a notice of redemption of the warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the Class A ordinary shares may fall below the $18.00 redemption trigger price (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) as well as the $11.50 (for whole shares) warrant exercise price after the redemption notice is issued. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No fractional Class A ordinary shares will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, the Company will round down to the nearest whole number of the number of Class A ordinary shares to be issued to the holder. If, at the time of redemption, the warrants are exercisable for a security other than the Class A ordinary shares pursuant to the warrant agreement (for instance, if the Company is not the surviving company in the Company&#8217;s initial Business Combination), the warrants may be exercised for such security. At such time as the warrants become exercisable for a security other than the Class A ordinary shares, the Company (or surviving company) will use its commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of the warrants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the number of outstanding Class A ordinary shares is increased by a capitalization or share dividend payable in Class A ordinary shares, or by a sub-division of ordinary shares or other similar event, then, on the effective date of such capitalization or share dividend, sub-division or similar event, the number of Class A ordinary shares issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding ordinary shares. A rights offering made to all or substantially all holders of ordinary shares entitling holders to purchase Class A ordinary shares at a price less than the &#8220;historical fair market value&#8221; (as defined below) will be deemed a share dividend of a number of Class A ordinary shares equal to the product of (i) the number of Class A ordinary shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Class A ordinary shares) and (ii) one minus the quotient of (x) the price per Class A ordinary share paid in such rights offering and (y) the historical fair market value. For these purposes, (i) if the rights offering is for securities convertible into or exercisable for Class A ordinary shares, in determining the price payable for Class A ordinary shares, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) &#8220;historical fair market value&#8221; means the volume weighted average price of Class A ordinary shares as reported during the 10 trading day period ending on the trading day prior to the first date on which the Class A ordinary shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if the Company, at any time while the warrants are outstanding and unexpired, pays a dividend or makes a distribution in cash, securities or other assets to all or substantially all of the holders of the Class A ordinary shares on account of such Class A ordinary shares (or other securities into which the warrants are convertible), other than (a) as described above, (b) any cash dividends or cash distributions which, when combined on a per share basis with all other cash dividends and cash distributions paid on the Class A ordinary shares during the 365-day period ending on the date of declaration of such dividend or distribution does not exceed $0.50 (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions that resulted in an adjustment to the exercise price or to the number of Class A ordinary shares issuable on exercise of each warrant) but only with respect to the amount of the aggregate cash dividends or cash distributions equal to or less than $0.50 per share , (c) to satisfy the redemption rights of the holders of Class A ordinary shares in connection with a proposed initial Business Combination, (d) to satisfy the redemption rights of the holders of Class A ordinary shares in connection with a shareholder vote to amend the Amended and Restated Memorandum and Articles of Association (A) to modify the substance or timing of the Company&#8217;s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the public shares if the Company does not complete its initial Business Combination within 18 months from the closing of the Initial Public Offering or (B) with respect to any other provision relating to the rights of holders of the Company&#8217;s Class A ordinary shares, or (e) in connection with the redemption of the Company&#8217;s public shares upon failure to complete the Company&#8217;s initial Business Combination, then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each Class A ordinary share in respect of such event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Whenever the number of Class A ordinary shares purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of Class A ordinary shares purchasable upon the exercise of the warrants immediately prior to such adjustment and (y) the denominator of which will be the number of Class A ordinary shares so purchasable immediately thereafter. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Company&#8217;s sponsor or its affiliates, without taking into account any founder shares held by the sponsor or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described above under &#8220;Redemption of warrants&#8221; will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No fractional warrants will be issued upon separation of the units and only whole warrants will trade. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exercise, round down to the nearest whole number the number of Class A ordinary shares to be issued to the warrant holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Private Placement Warrants have terms and provisions that are identical to those of the warrants being sold as part of the units in the Company&#8217;s Initial Public Offering except that the Private Placement Warrants (including the Class A ordinary shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until 30 days&#160;after the completion of the initial Business Combination (except pursuant to limited exceptions to the Company&#8217;s officers and directors and other persons or entities affiliated with the initial purchasers of the Private Placement Warrants). The Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the units being sold in the Initial Public Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Company accounts for the 15,900,000 warrants issued in connection with the Initial Public Offering (including 7,666,667 Public Warrants and 8,233,333 Private Placement Warrants), and will account for the 3,333,333 Forward Purchase Warrants to be issued in connection with the initial Business Combination, in accordance with the guidance contained in ASC 815-40, <i style="font-style:italic;">Derivatives and Hedging</i>. Such guidance provides that the warrants described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389910811288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE&#160;8. SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than the items disclosed below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">On March 14, 2022, the Company entered into a promissory note pursuant to the Working Capital Loans terms as outlined in Note 5 with the Sponsor (the &#8220;Sponsor Working Capital Loan&#8221;) to which the Company could borrow up to an aggregate of $750,000. The Sponsor Working Capital Loan is non-interest bearing and payable upon the earlier of (i) completion of the initial Business Combination or (ii) the date that the winding up of the Company is effective. The unpaid principal balance on the Sponsor Working Capital Loan may be convertible into warrants at the option of the Sponsor at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. On March 15, 2022, the Company drew down $500,000 under the Sponsor Working Capital Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Proposed Business Combination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">On March 23, 2022, we entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), by and among the Company, Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#8220;Ligand&#8221;), OmniAb, Inc., a Delaware corporation and wholly-owned subsidiary of Ligand (&#8220;OmniAb&#8221; and, together with Ligand, collectively, the &#8220;Companies&#8221;), and Orwell Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;), pursuant to which we will combine with OmniAb, Ligand&#8217;s antibody discovery business (the &#8220;OmniAb Business&#8221;), in a Reverse Morris Trust transaction. Also on March 23, 2022, and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;">in connection with the execution of the Merger Agreement, (a) the Company, Ligand, OmniAb and Merger Sub entered into that certain Employee Matters Agreement (the &#8220;Employee Matters Agreement&#8221;), (b) OmniAb and our sponsor entered into that certain sponsor insider letter agreement (the &#8220;Sponsor Insider Agreement&#8221;) with the Company and certain insiders of the Company (the &#8220;Insiders&#8221;) and (c) we amended and restated that certain forward purchase agreement, dated August 9, 2021, by entering into the amended and restated forward purchase agreement (the &#8220;A&amp;R FPA&#8221;), by and among the Company<span style="white-space:pre-wrap;">, our sponsor and OmniAb.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Immediately prior to the Merger (as defined below) and pursuant to a Separation and Distribution Agreement, dated as of March 23, 2022, among the Company, Ligand and OmniAb (the &#8220;Separation Agreement&#8221;), Ligand will, among other things and subject to the terms and conditions of the Separation Agreement, transfer the OmniAb Business, including certain related subsidiaries of Ligand, to OmniAb and, in connection therewith, will distribute (the &#8220;Distribution&#8221;) to Ligand stockholders 100% of the common stock of OmniAb, par value $0.001<span style="white-space:pre-wrap;"> (the &#8220;OmniAb Common Stock&#8221;).  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Immediately following the Distribution, in accordance with and subject to the terms and conditions of the Merger Agreement, Merger Sub will merge with and into OmniAb (the &#8220;Merger&#8221;), with OmniAb continuing as the surviving company in the Merger and as a wholly-owned subsidiary of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">The Merger Agreement, along with the Separation Agreement and the other transaction documents to be entered into in connection therewith, provides for, among other things, the consummation of the following transactions (collectively, the &#8220;OmniAb Business Combination&#8221;): (i) we will redomicile by way of continuation from the Cayman Islands to Delaware and domesticate as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law and with Section 206 of the Cayman Islands Companies Act (As Revised) at least one business day prior to the closing of the proposed OmniAb Business Combination (the &#8220;Domestication&#8221;), (ii) Ligand will transfer the OmniAb Business (the &#8220;Separation&#8221;) to its wholly-owned subsidiary, OmniAb, and contribute $15 million in capital thereto (less certain transaction and other expenses), and (iii) following the Separation, Ligand will distribute 100% of the shares of OmniAb Common Stock, to Ligand stockholders by way of the Distribution. Following the completion of the foregoing transactions and subject to the satisfaction or waiver of certain other conditions set forth in the Merger Agreement, the parties shall consummate the Merger. The Distribution and Merger are intended to qualify as &#8220;tax-free&#8221; transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">Upon consummation of the proposed OmniAb Business Combination, and after the Domestication, we will have one class of common stock, par value $0.0001 per share (the &#8220;APAC Common Stock&#8221;), which will be listed on Nasdaq under the ticker symbol &#8220;OABI.&#8221; Our then-outstanding warrants will be listed on Nasdaq under the ticker symbol &#8220;OABIW.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;">At the time the proposed OmniAb Business Combination is effected (the &#8220;Closing&#8221;), each share of OmniAb Common Stock outstanding after the Distribution and immediately prior to the effective time of the Merger will be converted into a number of shares of APAC Common Stock based on an exchange ratio determined by reference to a pre-money equity value for OmniAb of $850 million. Holders of OmniAb options, restricted stock units and performance stock units (determined after the Distribution and the division of Ligand equity awards into both Ligand equity awards and OmniAb equity awards pursuant to the Employee Matters Agreement) will have their awards rolled over into equity awards of the Company and adjusted pursuant to the exchange ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">In addition, at the Closing, holders of OmniAb Common Stock and equity awards will also receive earnout consideration in the form of an additional 15,000,000 shares of APAC Common Stock (the &#8220;OmniAb Earnout Shares&#8221;), with 50% of such earnout shares vesting upon the combined company&#8217;s achievement of a post-transaction volume-weighted average price (&#8220;VWAP&#8221;) of $12.50 per share of APAC Common Stock for any 20 trading days over a consecutive 30 trading-day period, and the remainder vesting upon achievement of a post-transaction VWAP of $15.00 per share of APAC Common Stock for any 20 trading days over a consecutive 30 trading-day period, in each case provided such vesting occurs during the five-year period following the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">In connection with the proposed OmniAb Business Combination, upon the Domestication (i) all issued and outstanding Class A ordinary shares and Class B ordinary shares will convert automatically, on a one-for-one basis, into shares of APAC Common Stock, (ii) all issued and outstanding warrants will convert automatically into warrants to acquire shares of APAC Common Stock and (iii) all issued and outstanding Units will separate and convert automatically into one share of APAC Common Stock and one-third of one warrant to purchase APAC Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The consummation of the proposed OmniAb Business Combination is subject to certain conditions as further described in the Merger Agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389909878472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging Growth Company</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emerging Growth Company</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section&#160;102(b)(1)&#160;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2021.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_CommonStockSubjectToPossibleRedemptionPolicyTextBlock', window );">Class A Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class A Ordinary Shares Subject to Possible Redemption</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of the 23,000,000 shares of Class A ordinary shares sold as part of the Units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company&#8217;s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company&#8217;s amended and restated certificate of incorporation. In accordance with SEC and its staff&#8217;s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class A ordinary shares have been classified outside of permanent equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional paid-in capital and accumulated deficit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">As of December 31, 2021, the Class A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Gross proceeds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Proceeds allocated to Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,813,334)</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Issuance costs allocated to Class A ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,029,901)</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Plus:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Accretion of carrying value to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,593,235</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A ordinary shares subject to possible redemption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 235,750,000</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Offering Costs associated with the Initial Public Offering</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Offering Costs associated with the Initial Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company complies with the requirements of ASC 340-10-S99-1 and SEC Staff Accounting Bulletin Topic 5A - <i style="font-style:italic;">Expenses of Offering</i>. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $13,662,256 as a result of the Initial Public Offering (consisting of $4,600,000 of cash underwriting discounts, $8,050,000 in deferred underwriting fees and $1,012,256 of other offering costs). As such, the Company recorded $13,029,901 of offering costs as a reduction of temporary equity and $632,355 of offering costs as a reduction of permanent equity in connection with the issuance of the Units in the Initial Public Offering and the Private Placement Warrants.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under ASC 740, <i style="font-style:italic;">Income Taxes</i> (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statements recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. Based on the Company&#8217;s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company&#8217;s financial statements. Since the Company was incorporated on February 5, 2021, the evaluation was performed for the 2021 tax year which will be the only period subject to examination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is considered an exempted Cayman Islands Company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. Consequently, income taxes are not reflected in the Company&#8217;s financial statement.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Ordinary Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss Per Ordinary Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 15,900,000 shares in the calculation of diluted income per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Period from February 5,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021 (inception) Through</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class B</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (335,384)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (181,058)</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 12pt;">Basic and diluted weighted average shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,857,143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,321,429</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_6OA0VirRwEuN8iLMAj_gFA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.03)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__fz-Sh5S5EuPKCGy7i67kQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.03)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company applies ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts reflected in the balance sheet for cash, deferred offering costs, accrued offering costs, promissory note &#8212; related party, and advance from anchor investor approximate fair value due to their short-term nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 1 &#8212; Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 2 &#8212; Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Level 3 &#8212; Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if converted method for all convertible instruments. ASU 2020-06 is effective for the Company on January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company adopted ASU 2020-06 effective January 1, 2021 using the modified retrospective method of transition. The adoption of ASU 2020-06 did not have a material impact on the financial statements for the period from February 5, 2021 (inception) through December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_CommonStockSubjectToPossibleRedemptionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the accounting policy on common stock subject to possible redemption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_CommonStockSubjectToPossibleRedemptionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_EmergingGrowthCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the accounting policy on Emerging Growth Company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_EmergingGrowthCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389912947848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Summary of reconciliation of Class A ordinary shares subject to possible redemption reflected in the condensed balance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Gross proceeds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Proceeds allocated to Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,813,334)</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Issuance costs allocated to Class A ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,029,901)</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Plus:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Accretion of carrying value to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,593,235</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A ordinary shares subject to possible redemption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 235,750,000</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of calculation of basic and diluted net income per ordinary share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Period from February 5,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021 (inception) Through</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class B</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (335,384)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (181,058)</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 12pt;">Basic and diluted weighted average shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,857,143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,321,429</p></td></tr><tr><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_6OA0VirRwEuN8iLMAj_gFA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.03)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__fz-Sh5S5EuPKCGy7i67kQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.03)</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389913467752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 12, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum', window );">Condition for future business combination, number of businesses, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_TransactionCosts', window );">Transaction Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,662,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_SaleOfStockUnderwritingFees', window );">Underwriting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_SaleOfStockOtherOfferingCosts', window );">Other offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,012,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash held outside of the Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_InvestmentsMaximumMaturityTerm', window );">Maturity term of U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">185 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_MonthsToCompleteInitialBusinessCombination', window );">Months to complete initial business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination', window );">Obligation to redeem public shares if entity does not complete a business combination (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent', window );">Threshold percentage of public shares subject to redemption without the company's prior written consent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ThresholdBusinessDaysForRedemptionOfPublicShares', window );">Threshold business days for redemption of public shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_MaximumNetInterestToPayDissolutionExpenses', window );">Maximum net interest to pay dissolution expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_WorkingCapitalSurplus', window );">Working capital surplus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants', window );">Proceeds from the Initial Public offering and sale of the private placement warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued | shares</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">15,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price per Unit | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance initial public offering</a></td>
<td class="nump">$ 230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_MonthsToCompleteInitialBusinessCombination', window );">Months to complete initial business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination', window );">Obligation to redeem public shares if entity does not complete a business combination (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination', window );">Minimum net tangible assets upon consummation of the business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,233,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,666,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,233,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from sale of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,350,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued | shares</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-allotment option | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A ordinary shares | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued | shares</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price per Unit | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance initial public offering</a></td>
<td class="nump">$ 230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A ordinary shares | Over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued | shares</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum number of businesses which the reporting entity must acquire with the net proceeds of the offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_DeferredOfferingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_DeferredOfferingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_InvestmentsMaximumMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum maturity term of investments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_InvestmentsMaximumMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_MaximumNetInterestToPayDissolutionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum net interest to pay dissolution expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_MaximumNetInterestToPayDissolutionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum net tangible assets upon consummation of the Business Combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_MonthsToCompleteInitialBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Duration of months to complete initial business combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_MonthsToCompleteInitialBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of obligation to redeem public shares if Entity does not complete business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for initial public offering and sale of the private placement warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_SaleOfStockOtherOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of other offering costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_SaleOfStockOtherOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_SaleOfStockUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of offering fees incurred and paid for underwriters.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_SaleOfStockUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_ThresholdBusinessDaysForRedemptionOfPublicShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold business days for redemption of public shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_ThresholdBusinessDaysForRedemptionOfPublicShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold percentage of Public Shares subject to redemption without the Company's prior written consent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of transaction costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_WorkingCapitalSurplus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of working capital surplus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_WorkingCapitalSurplus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ahpa_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ahpa_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ahpa_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ahpa_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389913444536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 12, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits accrued for interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal Depository Insurance Coverage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of Units, net of underwriting discounts (in shares)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of Units, net of underwriting discounts (in shares)</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">15,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A ordinary shares | Over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of Units, net of underwriting discounts (in shares)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A ordinary shares | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of Units, net of underwriting discounts (in shares)</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389911633064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A Ordinary Shares Subject to Possible Redemption (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Gross proceeds</a></td>
<td class="nump">$ 230,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_TemporaryEquityProceedsAllocatedToWarrants', window );">Proceeds allocated to Public Warrants</a></td>
<td class="num">(9,813,334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_TemporaryEquityIssuanceCosts', window );">Issuance costs allocated to Class A ordinary shares</a></td>
<td class="num">(13,029,901)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of carrying value to redemption value</a></td>
<td class="nump">28,593,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A ordinary shares subject to possible redemption</a></td>
<td class="nump">$ 235,750,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_TemporaryEquityIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuance costs related to temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_TemporaryEquityIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_TemporaryEquityProceedsAllocatedToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gross proceeds allocated from temporary equity to warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_TemporaryEquityProceedsAllocatedToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389909573640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Offering Costs associated with the Initial Public Offering (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_TransactionCosts', window );">Offering Costs</a></td>
<td class="nump">$ 13,662,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_SaleOfStockUnderwritingFees', window );">Underwriting fees</a></td>
<td class="nump">4,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting fee payable</a></td>
<td class="nump">8,050,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_SaleOfStockOtherOfferingCosts', window );">Other offering costs</a></td>
<td class="nump">1,012,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_OfferingCostsReductionOfTemporaryEquity', window );">Offering costs reduction of temporary equity</a></td>
<td class="nump">13,029,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs as a reduction of equity</a></td>
<td class="nump">$ 632,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_DeferredOfferingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_DeferredOfferingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_OfferingCostsReductionOfTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of offering costs reduction of temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_OfferingCostsReductionOfTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_SaleOfStockOtherOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of other offering costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_SaleOfStockOtherOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_SaleOfStockUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of offering fees incurred and paid for underwriters.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_SaleOfStockUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of transaction costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389909514120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net income per ordinary share (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss | $</a></td>
<td class="num">$ (335,384)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic | shares</a></td>
<td class="nump">9,857,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted | shares</a></td>
<td class="nump">9,857,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per ordinary share | $ / shares</a></td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per ordinary share | $ / shares</a></td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss | $</a></td>
<td class="num">$ (181,058)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic | shares</a></td>
<td class="nump">5,321,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted | shares</a></td>
<td class="nump">5,321,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per ordinary share | $ / shares</a></td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per ordinary share | $ / shares</a></td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389912871000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Income (Loss) Per Ordinary Share (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">15,900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389909999224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INITIAL PUBLIC OFFERING (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 12, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">15,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price, per unit</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds received from initial public offering, gross</a></td>
<td class="nump">$ 230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,666,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_NumberOfSharesIssuedPerUnit', window );">Number of shares in a unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_NumberOfWarrantsIssuedPerUnit', window );">Number of warrants in a unit</a></td>
<td class="nump">0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares issuable per warrant</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_UnitsIssuedDuringPeriodSharesNewIssues', window );">Number of units issued</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_NumberOfSharesIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares in a unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_NumberOfSharesIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_NumberOfWarrantsIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants in a unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_NumberOfWarrantsIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ahpa_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ahpa_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389911753144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRIVATE PLACEMENT (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-allotment option | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued | shares</a></td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued | shares</a></td>
<td class="nump">8,233,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrants | $ / shares</a></td>
<td class="nump">$ 1.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Aggregate purchase price | $</a></td>
<td class="nump">$ 12,350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares per warrant | shares</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ahpa_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ahpa_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389905657672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS - Founder Shares (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 16, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 12, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>D </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ahpa_FounderSharesMember', window );">Founder Shares | Sponsor | Class B ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_NumberOfSharesSubjectToForfeiture', window );">Shares subject to forfeiture | shares</a></td>
<td class="nump">105,000<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders', window );">Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination', window );">Threshold Period For Not To Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger', window );">Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays', window );">Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences', window );">Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">150 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_NumberOfSharesSubjectToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares owned by the founders subject to forfeiture if the underwriter overallotment option is not exercised in the proposed public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_NumberOfSharesSubjectToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected ownership percentage by the founders after completion of the proposed public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time which must elapse after completion of a business combination before the Sponsor can transfer, assign or sell any Founder Shares unless other specified conditions are met.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The share price threshold that must be achieved in order to waive the restriction on transfer of shares during a restricted period after a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>When determining the condition for transfer of shares without restriction after a business combination, the number of consecutive trading days used to observe the share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>When determining the condition for transfer of shares without restriction after a business combination, the number of days in which the share price must exceed the specified amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ahpa_FounderSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ahpa_FounderSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ahpa_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ahpa_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389906968248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 12, 2021</div></th>
<th class="th"><div>Jun. 23, 2021</div></th>
<th class="th"><div>Mar. 22, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from Sponsor note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ahpa_PromissoryNoteWithRelatedPartyMember', window );">Promissory Note with Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote', window );">Maximum borrowing capacity of related party promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_OfferingCostsIncludedInPromissoryNoteRelatedParty', window );">Offering costs paid by Sponsor and included in promissory note - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from Sponsor note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party promissory note</a></td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ahpa_AdministrativeSupportAgreementMember', window );">Administrative Support Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth', window );">Expenses per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses incurred and paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,129<span></span>
</td>
<td class="nump">$ 46,129<span></span>
</td>
<td class="nump">$ 46,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ahpa_RelatedPartyLoansMember', window );">Related Party Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_MaximumLoansConvertibleIntoWarrants', window );">Loan conversion agreement warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_WorkingCapitalLoansOutstanding', window );">Working capital loans, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum borrowing capacity of related party promissory note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_MaximumLoansConvertibleIntoWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount which a potential loan could have repaid through issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_MaximumLoansConvertibleIntoWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_OfferingCostsIncludedInPromissoryNoteRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of  offering costs included in promissory note - related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_OfferingCostsIncludedInPromissoryNoteRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The contractual monthly amount to be paid for support services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_WorkingCapitalLoansOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of working capital loans, outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_WorkingCapitalLoansOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ahpa_PromissoryNoteWithRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ahpa_PromissoryNoteWithRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ahpa_AdministrativeSupportAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ahpa_AdministrativeSupportAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ahpa_RelatedPartyLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ahpa_RelatedPartyLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389909682392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_MaximumNumberOfDemandsForRegistrationOfSecurities', window );">Maximum number of demands for registration of securities | item</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_DeferredFeePerUnit', window );">Deferred fee per unit | $ / shares</a></td>
<td class="nump">$ 0.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_AggregateDeferredUnderwritingFeePayable', window );">Aggregate deferred underwriting fee payable | $</a></td>
<td class="nump">$ 4,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_UnderwritingCashDiscountPerUnit', window );">Underwriting cash discount per unit | $ / shares</a></td>
<td class="nump">$ 0.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_UnderwriterCashDiscount', window );">Underwriter cash discount | $</a></td>
<td class="nump">$ 8,050,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_AggregateDeferredUnderwritingFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value as of the underwriting compensation deferred in the aggregate if the underwriter's option to purchase additional units is exercised in full.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_AggregateDeferredUnderwritingFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_DeferredFeePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the deferred fee per unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_DeferredFeePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_MaximumNumberOfDemandsForRegistrationOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum number of demands for registration of securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_MaximumNumberOfDemandsForRegistrationOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_UnderwriterCashDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the cash underwriting discount per unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_UnderwriterCashDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_UnderwritingCashDiscountPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the cash underwriting discount per unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_UnderwritingCashDiscountPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389911710664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS - Forward Purchase Agreement (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_WarrantsToBePurchasedPursuantToAgreements', window );">Warrants to be purchased pursuant to agreements</a></td>
<td class="nump">3,333,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity | $</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_SharesToBePurchasedPursuantToAgreements', window );">Shares To Be Purchased Pursuant To Agreements</a></td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_SharesToBePurchasedPursuantToAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares to be purchased pursuant to agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_SharesToBePurchasedPursuantToAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_WarrantsToBePurchasedPursuantToAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants to be purchased pursuant to agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_WarrantsToBePurchasedPursuantToAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389905693288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHAREHOLDERS' DEFICIT - Preferred Stock Shares (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>SHAREHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value, (per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, shares issued</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389909511496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' DEFICIT - Common Stock Shares (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Class A common stock subject to possible redemption, outstanding (in shares)</a></td>
<td class="nump">23,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_CommonStockNumberOfVotesPerShare', window );">Common shares, votes per share | Vote</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ahpa_CommonClassaSubjectToRedemptionMember', window );">Class A Common Stock Subject to Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="nump">23,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="nump">23,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Class A common stock subject to possible redemption, outstanding (in shares)</a></td>
<td class="nump">23,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_CommonStockNumberOfVotesPerShare', window );">Common shares, votes per share | Vote</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="nump">5,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ConvertibleStockConversionRatios', window );">Ratio to be applied to the stock in the conversion</a></td>
<td class="nump">50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_CommonStockNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of votes that each common share is entitled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_CommonStockNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_ConvertibleStockConversionRatios">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ratio to be applied to the stock in a conversion of convertible stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_ConvertibleStockConversionRatios</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ahpa_CommonClassaSubjectToRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ahpa_CommonClassaSubjectToRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389913386056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' DEFICIT - Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>D </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1', window );">Adjustment one of redemption price of stock based on market value and newly issued price (as a percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement', window );">Maximum period after business combination in which to file registration statement</a></td>
<td class="text">20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective', window );">Period of time within which registration statement is expected to become effective</a></td>
<td class="text">60 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $10.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights', window );">Redemption price per public warrant (in dollars per share)</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ahpa_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_WarrantExercisePeriodConditionTwo', window );">Warrant exercise period condition two</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Public Warrants expiration term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants', window );">Share price trigger used to measure dilution of warrant</a></td>
<td class="nump">$ 9.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant', window );">Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant</a></td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant', window );">Trading period after business combination used to measure dilution of warrant | D</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_WarrantExercisePriceAdjustmentMultiple', window );">Warrant exercise price adjustment multiple</a></td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_WarrantRedemptionPriceAdjustmentMultiple', window );">Warrant redemption price adjustment multiple</a></td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion', window );">Restrictions on transfer period of time after business combination completion</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ahpa_PublicWarrantsMember', window );">Public Warrants | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_WarrantRedemptionConditionMinimumSharePrice', window );">Warrant redemption condition minimum share price</a></td>
<td class="nump">$ 18.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights', window );">Redemption price per public warrant (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays', window );">Threshold trading days for redemption of public warrants</a></td>
<td class="text">20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days for redemption of public warrants | D</a></td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_RedemptionPeriod', window );">Redemption period</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ahpa_PublicWarrantsMember', window );">Public Warrants | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $10.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights', window );">Redemption price per public warrant (in dollars per share)</a></td>
<td class="nump">$ 18.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays', window );">Threshold trading days for redemption of public warrants</a></td>
<td class="text">365 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_RedemptionPeriod', window );">Redemption period</a></td>
<td class="text">10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants', window );">Share price trigger used to measure dilution of warrant</a></td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant', window );">Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant</a></td>
<td class="nump">100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of adjustment of redemption price of stock based on market value and newly issued price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days for stock price trigger considered for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time after completion of a business combination in which the reporting entity is required to file a registration statement with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ratio of gross proceeds from a future offering to total equity proceeds which is used to measure whether dilution of the warrant has occurred. If aggregate gross proceeds from a new offering exceeds a specified percentage of total equity proceeds, the warrant exercise price will be adjusted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time after filing within which the registration statement filed with the SEC is expected to become effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_RedemptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_RedemptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time after completion of a business combination during which the shares or warrant may not be transferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cutoff price used to measure whether dilution of the warrant has occurred. Shares issued below this price will cause the exercise price of the warrant to be adjusted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of trading days after a business combination during which the share price is compared to the specified dilution trigger share price in order to determine whether the warrant exercise price should be adjusted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_WarrantExercisePeriodConditionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The alternate period of time after completion of an initial public offering before a warrant may be exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_WarrantExercisePeriodConditionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_WarrantExercisePriceAdjustmentMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_WarrantExercisePriceAdjustmentMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_WarrantRedemptionConditionMinimumSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_WarrantRedemptionConditionMinimumSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_WarrantRedemptionPriceAdjustmentMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted redemption price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_WarrantRedemptionPriceAdjustmentMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ahpa_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ahpa_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140389913479288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 15, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 23, 2022</div></th>
<th class="th"><div>Mar. 14, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_WeightedAverageSharesPricePerShare', window );">Weighted Average Shares Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ahpa_OmniabMember', window );">OmniAb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value, (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ContributionFromSubsidiaries', window );">Contribution From Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Pre-money equity value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Additional shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_WeightedAverageSharesPricePerShare', window );">Weighted Average Shares Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value, (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Sponsor | Working Capital Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDefaultLongtermDebtAmount', window );">Aggregate borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Amount of drew down promissory note</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_ContributionFromSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of contribution to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_ContributionFromSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ahpa_WeightedAverageSharesPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of weighted average share price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ahpa_WeightedAverageSharesPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ahpa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDefaultLongtermDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDefaultLongtermDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ahpa_OmniabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ahpa_OmniabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ahpa_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ahpa_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ahpa_WorkingCapitalLoansWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ahpa_WorkingCapitalLoansWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>ahpa-20220416xs4_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ahpa="http://AvistaPublicAcquisitionCorpII.com/20220416"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ahpa-20220416.xsd" xlink:type="simple"/>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dKlB8yMYB0aeqkHBv0dRPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_16_2021_To_6_16_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember__BVIfHMD9Um_Bi-uIurswQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ahpa:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjNLK8smFEu-lbgIoNFmJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MNywhu2wKk6Z09hRF-PfiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_4_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jvgeKlnW-kGyt5FS8JRf2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-04</instant>
        </period>
    </context>
    <context id="As_Of_2_4_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gzEnwWnnx0WQYPJuULNY5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-04</instant>
        </period>
    </context>
    <context id="As_Of_2_4_2021_uo51c5vY7EuzHPYD_Z34hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <instant>2021-02-04</instant>
        </period>
    </context>
    <context id="As_Of_8_12_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_R55Po8B-UkKx2FU_T9LA_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="As_Of_8_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rQSd3ig2NUquGWKI1v8ycg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WhjEOWhW9Eij5ZolTKJnCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_4_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Vb1595K4sEa1hL_hS2lBeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-04</instant>
        </period>
    </context>
    <context id="As_Of_2_4_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0VgzW0WvDkOhioKaphSgNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-04</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k3wFYri590eu2YfxnM5VTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_f0P--mGylEyLNj8LG5U35g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_12_2021_To_8_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_PromissoryNoteWithRelatedPartyMember_gpdKERCYWkCPAQ7cpRLRyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_AdministrativeSupportAgreementMember_Km4Y9OkDw0uxggOurPog8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_AdministrativeSupportAgreementMember_NiMhJnR4mUi1x__B69WUPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_AdministrativeSupportAgreementMember_70Vvf8NJ3kSfQY4yJdgRgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="Duration_6_23_2021_To_6_23_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_PromissoryNoteWithRelatedPartyMember_w_DAgECzBE2Z5NwzDLL4EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-23</startDate>
            <endDate>2021-06-23</endDate>
        </period>
    </context>
    <context id="Duration_3_15_2022_To_3_15_2022_us-gaap_ClassOfWarrantOrRightAxis_ahpa_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_sgLs6LqHfEWSJdAhO6MFKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ahpa:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-15</startDate>
            <endDate>2022-03-15</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mvqSYAOLZUql2PhYI0lRvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RWEafoin-kCFfO1au4EhYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_23_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_JOtx4eLq2EWmvVpNUA4XHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_OmniabMember_K3bPyZi0602lWc8Dsxld3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:OmniabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_ahpa_CommonClassaSubjectToRedemptionMember_q28zW_K4z0OVkxWsAfxczw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ahpa:CommonClassaSubjectToRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_RHrFxFO2K0qVPKUowtOemA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_12_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_hpwJzLOcDk2-xk82YwbYBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_FMDt3RxfGEqzFwOF3AN7gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_d_YB9RSCPEWKNnaWk0ubPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5VcjzJoENE6qKN-GsE0NqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_6B_tQIqoTEmTyAmFq9B9mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_xNJIoD7-WEGyu2JOFYZBJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_12_2021_To_8_12_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_fKXwqT0SFUG_rtKtuXVz1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="Duration_8_12_2021_To_8_12_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_hccbOwsxJ0e0grYvrrxaLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="Duration_8_12_2021_To_8_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_ph3NAIUSSEif_XtyWxclIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="Duration_8_12_2021_To_8_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_W782mJY-OkWY82NrBIIpRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_-Ce3huUCEEmRf4OJGJJFJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_92SC9DBWKUyqMSwExfbIdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FE6zEVavvUymGkwGe3FEbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Gi4yVR_tj0CKg7dgp66JvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_07SLTebCGk63u2x-RfDH5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ahpa:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_FxrDQLlMwkKqESzq8z6bXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ahpa:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_c0jqdQLiPkuEslmiil_bNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_AdministrativeSupportAgreementMember_uzQQGS8H_0a5x4OT54OPfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_12_2021_To_2_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_dPb1k23M_k-pLZXh6JaJbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ahpa:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_HgSeUv3N6UGsnBDKOVV0aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_22_2021_To_3_22_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_PromissoryNoteWithRelatedPartyMember_CZvATsM0cEaCcdmjZWpMlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-22</startDate>
            <endDate>2021-03-22</endDate>
        </period>
    </context>
    <context id="As_Of_6_16_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_A7q41aYgok-ecWpRe_1YvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ahpa:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="As_Of_2_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_QkwL0AKjOUOWUMGK6d_M2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ahpa:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="Duration_8_12_2021_To_8_12_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_AvpvGzfBSk6euzkv_rNAng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tf5u2Z2hjkKPDF_uv_Xeig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_waiTR7W3qUWXhKuLp-042Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_eD2XDmIVE0OxfJPD7OTpMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_2_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_PromissoryNoteWithRelatedPartyMember_xyR3z7AzvE-9dwkUHu1Piw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_OmniabMember_Y-svE_WiIU2HjXgNBRRZFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:OmniabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_f60OhzulvUWffRFATFN0QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_c1CfbfmOgkajeLUmOnWY1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ahpa:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_V90sXGB5lUewxKhffVJUsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ahpa:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_Ng0NOicLVku1PX4eR69EBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ahpa:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_14_2022_us-gaap_ClassOfWarrantOrRightAxis_ahpa_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RZCYNy4TR02-s8x38wz2RQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ahpa:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-14</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mz3wLjizUUqg_78s5L5T6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ahpa:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_RelatedPartyLoansMember_t4HEn2WBv0-oLDiAcT-3nQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ahpa:RelatedPartyLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001846253</identifier>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_D_LMsaCzRsOkeKQp06MQlfMw">
        <measure>ahpa:D</measure>
    </unit>
    <unit id="Unit_Standard_Vote_PXooaeoQc0ms4cDX_kIEHg">
        <measure>ahpa:Vote</measure>
    </unit>
    <unit id="Unit_Standard_item_HhKYwaXu10-zi6ST7YVS-w">
        <measure>ahpa:item</measure>
    </unit>
    <unit id="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">
        <measure>shares</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      id="Hidden_lZEoWjr23kGWUV_psEI90Q"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      id="Hidden_-kr0UHfvPkyTvSBDqmMFmA"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA"
      decimals="2"
      id="Hidden_MflBZkpiEkecqXC1OaZ9GA"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg"
      decimals="2"
      id="Hidden_t9z7UsG5i0modg64DdHMtg"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="INF"
      id="Hidden_oIv_C0huWUWHJN148qo5_g"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_f60OhzulvUWffRFATFN0QQ"
      decimals="INF"
      id="Hidden_k2BHUUvoXEmMVvAsYFPM8w"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug"
      decimals="INF"
      id="Hidden_5ZdjLnlv1ESof1_Jdhm7Sw"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">5750000</us-gaap:CommonStockSharesOutstanding>
    <ahpa:ThresholdBusinessDaysForRedemptionOfPublicShares
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Hidden_MH-1shE-7UuVsRr2IwZGhQ">P10D</ahpa:ThresholdBusinessDaysForRedemptionOfPublicShares>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="INF"
      id="Hidden_dLQndVmTokOqpzPEE6ShuQ"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg"
      decimals="0"
      id="Hidden_fiOqIe0ry0GFxCNERUdq_A"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">5321429</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <ahpa:NumberOfWarrantsIssuedPerUnit
      contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_AvpvGzfBSk6euzkv_rNAng"
      decimals="2"
      id="Hidden_d8ssFNr6LUCa3paVl1JKtw"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">0.33</ahpa:NumberOfWarrantsIssuedPerUnit>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_ahpa_CommonClassaSubjectToRedemptionMember_q28zW_K4z0OVkxWsAfxczw"
      decimals="INF"
      id="Hidden_Z_H04b9q5UCcSUgqEMG3_g"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">23000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug"
      decimals="INF"
      id="Hidden_1ubnyfPiU0eaQzavzDHJNg"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">5750000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA"
      decimals="0"
      id="Hidden_pHnMixOZ00u6gK01mog1ng"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">9857143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg"
      decimals="0"
      id="Hidden_hskpw5GoZkCZsE4RzP1pWg"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">5321429</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA"
      decimals="2"
      id="Hidden_6OA0VirRwEuN8iLMAj_gFA"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg"
      decimals="2"
      id="Hidden__fz-Sh5S5EuPKCGy7i67kQ"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA"
      decimals="0"
      id="Hidden_u3BgSj_pgUiqduil4GUdSQ"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">9857143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <dei:EntityRegistrantName
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Hidden_nCFvCotUIEGnjq-A0N9Z0A">AVISTA PUBLIC ACQUISITION CORP. II</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tc_z9Owjk0kqEaouvYU7bw7LQ_2_1">0001846253</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tc_IWrT9X4am0SCt6AaTwm5gA_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Narr_JeAebxnH-02SdlqaM5ZMrg">S-4</dei:DocumentType>
    <dei:EntityFilerCategory
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Narr_itJrVe_E80m8UMN89boqLA">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Narr_6lH5o6dLHU2fucsdh-sIiw">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Narr_8ZUsvMkh9E6SaW2kEAp8_Q">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Narr_WWYcHdojaEGtGC56hybKVQ">false</dei:EntityExTransitionPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_hfos66Cemk21vjICGTJvzw_3_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">189971</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_RQC41xz_KEiJlJ2yWtGxjg_4_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">744542</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_NYAsgvO_n0ewcwk7q-xAew_5_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">934513</us-gaap:AssetsCurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_jjVnhHvVTEiRUgcO9JsFmg_6_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">235750000</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_pJcGUDgGSkyucZqcpoRapw_7_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">236684513</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_1aK8L3pZrk2B5VaM5HOT1w_11_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">15440</us-gaap:AccountsPayableCurrent>
    <ahpa:AccruedExpenseRelatedPartyCurrent
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_y_wg8asb902aVl4DVWN8wQ_12_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">107734</ahpa:AccruedExpenseRelatedPartyCurrent>
    <ahpa:AccruedOfferingCostsAndExpensesCurrent
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_5CAyrXb7REuIS7FtdONwyg_13_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">314153</ahpa:AccruedOfferingCostsAndExpensesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_zjoXIU5jGEWc7sT12_OQzA_14_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">884</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_EnkSiqTqPka9uFc77371Hw_15_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">438211</us-gaap:LiabilitiesCurrent>
    <ahpa:DeferredOfferingCostsNoncurrent
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_fj33QL002E-HjhM1LMWvxQ_16_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">8050000</ahpa:DeferredOfferingCostsNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_etURX6P5DkqQlTn0AM-RiA_17_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">8488211</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_ahpa_CommonClassaSubjectToRedemptionMember_q28zW_K4z0OVkxWsAfxczw"
      decimals="INF"
      id="Narr_N3-Z0UYRkE6FD6Tmw0AZkA"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_ahpa_CommonClassaSubjectToRedemptionMember_q28zW_K4z0OVkxWsAfxczw"
      decimals="INF"
      id="Narr_WZbeqyVQK0aTQfpnJ05Jrg"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">23000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_V8fdhb6ZlkCCv3orsHZn9w_20_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">235750000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="INF"
      id="Narr_XaOraFcZQ0OceKzjEOSCqQ"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="INF"
      id="Narr_LovODYejW0m7cj2pDTllDg"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="INF"
      id="Narr_Ckn7wyfk30esysRsOj9FlA"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_f60OhzulvUWffRFATFN0QQ"
      decimals="INF"
      id="Narr_IS9t-mhQhEqGhcDuoytEjQ"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_f60OhzulvUWffRFATFN0QQ"
      decimals="INF"
      id="Narr__7hpkfu0KUi3MGX_6cqO8g"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_f60OhzulvUWffRFATFN0QQ"
      decimals="INF"
      id="Narr_olPTrtCEr0GDDHMyy0X6TQ"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_ahpa_CommonClassaSubjectToRedemptionMember_q28zW_K4z0OVkxWsAfxczw"
      decimals="INF"
      id="Narr_XzCnKKIjnkGB-2E4PCc8ng"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">23000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug"
      decimals="INF"
      id="Narr_d-MCLzVTSEq6fRmxDkxJyw"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug"
      decimals="INF"
      id="Narr_JpquoZUhEka_lw5NDJZsRA"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug"
      decimals="INF"
      id="Narr_PF_PErwWnE2Poh7XDfMrvw"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">5750000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug"
      decimals="0"
      id="Tc_KZBZWuvFuEW2ymXKGubLdw_25_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">575</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_BGEKrGqmf0KjKK1MCfR5-A_27_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">-7554273</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_Sq79z-Lz1EijTtXENU2pdA_28_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">-7553698</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_zqb8jlhSQk2phD7pG_bVBA_29_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">236684513</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_XvMro7GRSkuUIBFfSYsNSw_1_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">516442</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_yKavmBc9CkSMH2DDOrNxUA_2_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">-516442</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA"
      decimals="0"
      id="Tc_BAJyI1rEs0KNuNjowgn3Iw_4_3"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">9857143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA"
      decimals="2"
      id="Tc_Wxv50j8TFkqVDN-lrtLYwA_5_3"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg"
      decimals="0"
      id="Tc_lvNYrvLuQkOHeMpGxI0CKQ_6_3"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">5321429</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg"
      decimals="2"
      id="Tc_NHsgobGVDUCfLoo3xZKK3w_7_3"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:SharesIssued
      contextRef="As_Of_2_4_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0VgzW0WvDkOhioKaphSgNQ"
      decimals="INF"
      id="Tc_ZtMDLyTMFU-dA8XI7DUcHg_4_2"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_2_4_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0VgzW0WvDkOhioKaphSgNQ"
      decimals="0"
      id="Tc_cugU9C2hw0Sag3ELzDrmkg_4_5"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="As_Of_2_4_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Vb1595K4sEa1hL_hS2lBeg"
      decimals="INF"
      id="Tc_CbVlxr62bUaj6OIXHo_6-g_4_7"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_2_4_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Vb1595K4sEa1hL_hS2lBeg"
      decimals="0"
      id="Tc_jYg7SBTa7E6BqdQePNdYqw_4_10"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_2_4_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gzEnwWnnx0WQYPJuULNY5A"
      decimals="0"
      id="Tc_Wfr2yVS9ck-ZlK39diQIzQ_4_13"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_2_4_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jvgeKlnW-kGyt5FS8JRf2A"
      decimals="0"
      id="Tc_jxMaer8x0UStqGA-XuMABQ_4_16"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_2_4_2021_uo51c5vY7EuzHPYD_Z34hQ"
      decimals="0"
      id="Tc_cq8r4Canc0e9ZfY5bqpn4Q_4_19"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">0</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjNLK8smFEu-lbgIoNFmJw"
      decimals="INF"
      id="Tc_6aAyHbbYvkyjrSkqNanHDA_5_7"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wjNLK8smFEu-lbgIoNFmJw"
      decimals="0"
      id="Tc_ofc_RzX8LEakO3udWxKTgg_5_10"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">575</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dKlB8yMYB0aeqkHBv0dRPQ"
      decimals="0"
      id="Tc__hgyC_V1QEylHpmEn6TXog_5_13"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">24425</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_N95ZNJtkckSt2acNkbpZ6g_5_19"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_d_YB9RSCPEWKNnaWk0ubPA"
      decimals="0"
      id="Tc_JK83tBQ6WkePqK1V80DQLQ_6_13"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">9232604</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_HgSeUv3N6UGsnBDKOVV0aw"
      decimals="0"
      id="Tc_lwUDDyByRE2kbpFxWO_jew_6_19"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">9232604</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5VcjzJoENE6qKN-GsE0NqA"
      decimals="0"
      id="Tc_ts3xkiutt0KN52_xV-TnIA_7_13"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">12298375</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_6B_tQIqoTEmTyAmFq9B9mg"
      decimals="0"
      id="Tc_9sprgmIcvkiKDQJThEMPbw_7_19"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">12298375</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dKlB8yMYB0aeqkHBv0dRPQ"
      decimals="0"
      id="Tc_MTNfNYNcQ0W8eq4Ovl5Hjw_8_13"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">21555404</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RWEafoin-kCFfO1au4EhYA"
      decimals="0"
      id="Tc_ExB167yezUSnUC-GCfEtvw_8_16"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">7037831</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_dzrn-SvDX06D3z8kdpLuiA_8_19"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">28593235</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RWEafoin-kCFfO1au4EhYA"
      decimals="0"
      id="Tc_cg0PhIpdo0KU-T5q1rly0A_9_16"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">-516442</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_-mQ7-ijHtECi69t3aC6Reg_9_19"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">-516442</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WhjEOWhW9Eij5ZolTKJnCw"
      decimals="INF"
      id="Tc_tuo8jx26X0KtelrUUKCEgQ_10_7"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">5750000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WhjEOWhW9Eij5ZolTKJnCw"
      decimals="0"
      id="Tc_SyiDBMLSJUODr03Rg0HHcQ_10_10"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">575</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MNywhu2wKk6Z09hRF-PfiQ"
      decimals="0"
      id="Tc_XUIVUDdYW0GG3-nCIFID9Q_10_16"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">-7554273</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_lHCChnZOuke_wbItnNNT3w_10_19"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">-7553698</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_irXY-IgZLkWfx0xVT46h2Q_2_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">516442</us-gaap:ProfitLoss>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_jb5f_1DQq0C7JF7Y32dQeA_4_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">744542</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_G5BfcQSgsk6eEGEGGd-AXw_5_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">15440</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_muwyKxFxiUamYOMPLr6YGw_6_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">884</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <ahpa:IncreaseDecreaseInAccruedLiabilitiesRelatedParties
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_8pVJWAmVUkGP-qs9mvBSGQ_7_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">107734</ahpa:IncreaseDecreaseInAccruedLiabilitiesRelatedParties>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_Fj736qVeckqRhhuKQBsqIQ_8_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">-1136926</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <ahpa:PaymentsForInvestmentOfCashInTrustAccount
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_Cx88RoX3OEGWtXs15VbmYQ_11_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">235750000</ahpa:PaymentsForInvestmentOfCashInTrustAccount>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_EjP-KmLPZE6WCdSfWVH0cA_12_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">-235750000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_JprRMnGXnESGzktryMzDIg_15_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">25000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ahpa:ProceedsFromIssuanceInitialPublicOfferingNet
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_H6j-xrU2xUC2GCezjb_cdQ_16_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">225400000</ahpa:ProceedsFromIssuanceInitialPublicOfferingNet>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_lwY2if9SgEWUrqXYz_hAYQ_17_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">12350000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_g2-Z4zCIbk60S_r-ECSRbQ_18_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">175000</us-gaap:ProceedsFromRelatedPartyDebt>
    <ahpa:Repaymentfromrelatedpartydebt
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_GzsXh6aLEEGvzIMbmmVKxg_19_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">175000</ahpa:Repaymentfromrelatedpartydebt>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_Itm_aHC520uuTI7X7nxesQ_20_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">698103</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_C64tm9ZuCUuU1PeaYrCBrg_21_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">237076897</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_tKoNW7SlxkCHc6WRnAAN9w_23_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">189971</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_R4gW6Mf_sUWrNMQa4qES3Q_25_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">189971</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <ahpa:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_DblCcpW0Xk-ol5MKU3e79w_28_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">28593235</ahpa:AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue>
    <ahpa:OfferingCostsIncludedInAccountsPayableAccruedExpenses
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_zTfG-hzV_EyyA4ysark_IQ_29_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">314153</ahpa:OfferingCostsIncludedInAccountsPayableAccruedExpenses>
    <ahpa:DeferredUnderwritingFeePayable
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_LZEflZxx-kyPQ_oUInN1MQ_30_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">8050000</ahpa:DeferredUnderwritingFeePayable>
    <us-gaap:NatureOfOperations
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_uMgxTMwWwUmRJD_2TtNjkw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE&#160;1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS&lt;/b&gt;&lt;b style="font-weight:bold;"&gt; AND LIQUIDITY&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Avista Public Acquisition Corp. II (the &#x201c;Company&#x201d;) is a blank check company incorporated in the Cayman Islands on February 5, 2021. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with one or more businesses (a &#x201c;Business Combination&#x201d;). The Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31,&#160;2021, the Company had not commenced any operations. All activity for the period from February 5, 2021 (inception) through December&#160;31,&#160;2021 relates to the Company&#x2019;s formation and the initial public offering (&#x201c;Initial Public Offering&#x201d;), which is described below. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The registration statement for the Company&#x2019;s Initial Public Offering was declared effective on August 9, 2021. On August 12, 2021, the company consummated the Initial Public Offering of 23,000,000 units (the &#x201c;Units&#x201d; and, with respect to the Class&#160;A ordinary shares included in the Units sold, the &#x201c;Public Shares&#x201d;), including 3,000,000 Units that were issued pursuant to the underwriter&#x2019;s exercise of its over-allotment option in full, at $10.00 per Unit, generating gross proceeds of $230,000,000 (see Note&#160;3).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 8,233,333 warrants (the &#x201c;Private Placement Warrants&#x201d;), including 900,000 Private Placement Warrants that were issued pursuant to the underwriter&#x2019;s exercise of its over-allotment option in full, at a price of $1.50 per Private Placement Warrant in a private placement to Avista Acquisition LP II (the &#x201c;Sponsor&#x201d;), generating gross proceeds of $12,350,000 (see Note&#160;4).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Transaction costs amounted to $13,662,256 consisting of $4,600,000 of underwriting fees, $8,050,000 of deferred underwriting fees, and $1,012,256 of other offering costs. In addition, as of December 31, 2021, cash of $189,971 is held outside of the Trust Account (as defined below) and is available for the payment of accrued offering costs and for working capital purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon closing of the Initial Public Offering and the sale of the Private Placement Warrants, a total of $235,750,000 ($10.25 per Public Share) was placed in a trust account (the &#x201c;Trust Account&#x201d;) and will be invested only in U.S. government treasury obligations with maturities of 185 days or less or in money market funds meeting certain conditions under Rule&#160;2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of: (i)&#160;the consummation of the initial Business Combination within 18 months from the closing of the Initial Public&#160;Offering, (ii) the redemption of the Company&#x2019;s Public Shares if the Company has not consummated an Business Combination within 18 months from the closing of the Company&#x2019;s Initial Public Offering, subject to applicable law, and (iii) the redemption of the Company&#x2019;s Public Shares properly submitted in connection with a shareholder vote to approve an amendment to the Amended and Restated Memorandum and Articles of Association (A) that would modify the substance or timing of the obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the Company&#x2019;s Public Shares if the Company does not complete the initial Business Combination within 18 months from the closing the Company&#x2019;s Initial Public Offering or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company will provide its holders of the outstanding Public Shares (the &#x201c;public shareholders&#x201d;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a shareholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account ($10.25 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#x2019;s warrants. The Public Shares subject to redemption was recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Financial Accounting Standards Board&#x2019;s (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480, &lt;i style="font-style:italic;"&gt;Distinguishing Liabilities from Equity &lt;/i&gt;(&#x201c;ASC 480&#x201d;)&lt;i style="font-style:italic;"&gt;.&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 either prior to or upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association (the &#x201c;Amended and Restated Memorandum and Articles of Association&#x201d;), conduct the redemptions pursuant to the tender offer rules&#160;of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required by law, or the Company decides to obtain shareholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules&#160;and not pursuant to the tender offer rules. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note&#160;5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each public shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or don&#x2019;t vote at all.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Notwithstanding the above, if the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Amended and Restated Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#x201c;group&#x201d; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Sponsor has agreed to waive (i) redemption rights with respect to its Founder Shares and Public Shares held by it in connection with the completion of a Business Combination, (ii)&#160;redemption rights with respect to any Founder Shares and Public Shares held by it in connection with a shareholder vote to amend the Amended and Restated Memorandum and Articles of Association to modify the substance or timing of the Company&#x2019;s obligation to allow redemption in connection with an initial Business Combination or to redeem 100% of its Public Shares if the Company does not complete an initial Business Combination within 18 months from the closing of the Initial Public Offering or with respect to any other material provision relating to shareholders&#x2019; rights or pre-initial Business Combination activity and (iii) rights to liquidating distributions from the Trust Account with respect to any Founder Shares held if the Company fails to complete an initial Business Combination within 18 months from the closing of the Initial Public Offering. However, if the Sponsor acquires Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within 18 months from the closing of the Initial Public Offering.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has until 18 months from the closing of the Initial Public Offering to complete a Business Combination (the &#x201c;Combination Period&#x201d;). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up; (ii)&#160;as promptly as reasonably possible but no more than &lt;span style="-sec-ix-hidden:Hidden_MH-1shE-7UuVsRr2IwZGhQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;ten&lt;/span&gt;&lt;/span&gt; business&#160;days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay income taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish public shareholders&#x2019; rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#x2019;s remaining shareholders and board of directors, liquidate and dissolve, subject in each case to the Company&#x2019;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#x2019;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note&#160;6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Indemnity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company (other than the Company&#x2019;s independent registered public accounting firm), or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i)&#160;$10.25 per Public Share and (ii)&#160;the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.25 per Public Share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay tax obligations, provided that such liability will not apply to any claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidity &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021, the Company had $189,971 in cash held outside of the Trust Account and a working capital surplus of $496,302. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. Moreover, the Company may need to obtain additional financing either to complete a Business Combination or if the Company becomes obligated to redeem a significant number of public shares upon completion of a Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination. Of the total proceeds from the Initial Public Offering and sale of the Private Placement Warrants, an amount of approximately $2&lt;span style="white-space:pre-wrap;"&gt; million was deposited in an operating account for the Company&#x2019;s working capital needs. The amounts held in the operating account are not  expected to provide the Company with sufficient funds to meet its operational and liquidity obligations over the next twelve months.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Going Concern Consideration&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021, the Company had $189,971 in cash held outside of the Trust Account and a working capital surplus of $496,302. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company ability to continue as a going concern for a period of time within one year after the date that the financial statements are issued. Management plans to address this uncertainty through the Business Combination as discussed above. There is no assurance that the Company&#x2019;s plans to consummate the Business Combination will be successful or successful within the Combination Period. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#x2019;s financial position, results of its operations, and/or search for a prospective partner company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <ahpa:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="INF"
      id="Narr_LG5K14ZWb0y45uoIMJ1tfQ"
      unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A">1</ahpa:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum>
    <ahpa:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_hccbOwsxJ0e0grYvrrxaLw"
      decimals="INF"
      id="Narr_Wu_rnwuYpEmLzCMGR24sZw"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">23000000</ahpa:UnitsIssuedDuringPeriodSharesNewIssues>
    <ahpa:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_fKXwqT0SFUG_rtKtuXVz1Q"
      decimals="INF"
      id="Narr_OoQjYKtW3kCedv51GTXcoA"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">3000000</ahpa:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_8_12_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_R55Po8B-UkKx2FU_T9LA_Q"
      decimals="2"
      id="Narr_W8_JOq5_u0qn6fC_q31peQ"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_hccbOwsxJ0e0grYvrrxaLw"
      decimals="0"
      id="Narr_r_BQwnuDQU-N--yK1lyRmQ"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">230000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mz3wLjizUUqg_78s5L5T6g"
      decimals="INF"
      id="Narr_0K3QK9hmeECIZ_D13eZ_8w"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">8233333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_RHrFxFO2K0qVPKUowtOemA"
      decimals="INF"
      id="Narr_wJd_vhlcwU2YZx8AaMlgaA"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">900000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ahpa:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mz3wLjizUUqg_78s5L5T6g"
      decimals="2"
      id="Narr_jLKb5pU6YkKuqEGyIVY6Dw"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">1.50</ahpa:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mvqSYAOLZUql2PhYI0lRvg"
      decimals="0"
      id="Narr_MR76zzA3tkWBJkuffilTcQ"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">12350000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <ahpa:TransactionCosts
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Narr_G08Nb1ixOUq8tN174FbQig"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">13662256</ahpa:TransactionCosts>
    <ahpa:SaleOfStockUnderwritingFees
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Narr_21o1LOLHHE-iY_9kZUpi3Q"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">4600000</ahpa:SaleOfStockUnderwritingFees>
    <ahpa:DeferredOfferingCostsNoncurrent
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Narr_xgbjvs38zEaygq4cp6afZQ"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">8050000</ahpa:DeferredOfferingCostsNoncurrent>
    <ahpa:SaleOfStockOtherOfferingCosts
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Narr_uG34oKy3FUiolgorfZW7Lg"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">1012256</ahpa:SaleOfStockOtherOfferingCosts>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Narr_tFnPisYWGUSyeq5mUkWZ7g"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">189971</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Gi4yVR_tj0CKg7dgp66JvQ"
      decimals="0"
      id="Narr_KSN1_gIPkkyS4mE-6F9MyQ"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">235750000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_k3wFYri590eu2YfxnM5VTw"
      decimals="2"
      id="Narr_cGlkmfPm_kGxTODgvZ1xxg"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">10.25</us-gaap:SharePrice>
    <ahpa:InvestmentsMaximumMaturityTerm
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Narr_gkIWx7DYn06HR7noZL_0Pw">P185D</ahpa:InvestmentsMaximumMaturityTerm>
    <ahpa:MonthsToCompleteInitialBusinessCombination
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Narr__J-ATPSHG0-eLgaEFkIxHA">P18M</ahpa:MonthsToCompleteInitialBusinessCombination>
    <ahpa:MonthsToCompleteInitialBusinessCombination
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Narr_5fkjJ9oCV0ajEwRaH8mLrw">P18M</ahpa:MonthsToCompleteInitialBusinessCombination>
    <ahpa:PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="INF"
      id="Narr_wsXsSyh6YkOcQ9kHWIfwVg"
      unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A">1</ahpa:PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination>
    <ahpa:MonthsToCompleteInitialBusinessCombination
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Narr_8ppjIBpaEESEJ0-ThCj4Zg">P18M</ahpa:MonthsToCompleteInitialBusinessCombination>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_waiTR7W3qUWXhKuLp-042Q"
      decimals="2"
      id="Narr_nCZsdcED1k-tkWZQiGuYgQ"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">10.25</us-gaap:SharePrice>
    <ahpa:MinimumNetTangibleAssetsUponConsummationOfBusinessCombination
      contextRef="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_waiTR7W3qUWXhKuLp-042Q"
      decimals="0"
      id="Narr__Mf2vZ3KnEOkJbAtdp6K5A"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">5000001</ahpa:MinimumNetTangibleAssetsUponConsummationOfBusinessCombination>
    <ahpa:ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="2"
      id="Narr_skRnBtB2NkOECUPyKWjUpA"
      unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A">0.15</ahpa:ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent>
    <ahpa:PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tf5u2Z2hjkKPDF_uv_Xeig"
      decimals="INF"
      id="Narr_cEocf_RyB0m87xPdUd1JCA"
      unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A">1</ahpa:PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination>
    <ahpa:MonthsToCompleteInitialBusinessCombination
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tf5u2Z2hjkKPDF_uv_Xeig"
      id="Narr_8vdQIdJwUkaHYeT54uk1zg">P18M</ahpa:MonthsToCompleteInitialBusinessCombination>
    <ahpa:MonthsToCompleteInitialBusinessCombination
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tf5u2Z2hjkKPDF_uv_Xeig"
      id="Narr_dgCk6upRBkGhFnx0P__QCA">P18M</ahpa:MonthsToCompleteInitialBusinessCombination>
    <ahpa:MonthsToCompleteInitialBusinessCombination
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tf5u2Z2hjkKPDF_uv_Xeig"
      id="Narr_N_jGlSzrIEuS2NamigPOEw">P18M</ahpa:MonthsToCompleteInitialBusinessCombination>
    <ahpa:MonthsToCompleteInitialBusinessCombination
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tf5u2Z2hjkKPDF_uv_Xeig"
      id="Narr_NDbyLU47qkOO35_I9uuSGw">P18M</ahpa:MonthsToCompleteInitialBusinessCombination>
    <ahpa:MaximumNetInterestToPayDissolutionExpenses
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Narr_2qYAnzb52kGTYA-YZRH5kg"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">100000</ahpa:MaximumNetInterestToPayDissolutionExpenses>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_waiTR7W3qUWXhKuLp-042Q"
      decimals="2"
      id="Narr__zvB-qia2kSPkXg4E80Bgw"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_waiTR7W3qUWXhKuLp-042Q"
      decimals="2"
      id="Narr_oY6P_zak6EuM289XvjQJNg"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">10.25</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_waiTR7W3qUWXhKuLp-042Q"
      decimals="2"
      id="Narr_xPytZVRvfEKnVpeCWZvO8g"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">10.25</us-gaap:SharePrice>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Narr_gU9NUmsGJE2NUa0ugBdfkA"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">189971</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <ahpa:WorkingCapitalSurplus
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Narr_wjM5q3sH-kqOgtdhzjw3SA"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">496302</ahpa:WorkingCapitalSurplus>
    <ahpa:ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="-6"
      id="Narr_qryYtUIV-ECKgXxzI-NbJQ"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">2000000</ahpa:ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Narr_lZ03agFI302Q5Uf0-6GTpg"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">189971</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <ahpa:WorkingCapitalSurplus
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Narr_NRRauEasaESXIQxxwgP_ew"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">496302</ahpa:WorkingCapitalSurplus>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_Zl7r0ucpHkmVzRL9xd7xww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE&#160;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the SEC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Emerging Growth Company&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Further, Section&#160;102(b)(1)&#160;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Class A Ordinary Shares Subject to Possible Redemption&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;All of the 23,000,000 shares of Class A ordinary shares sold as part of the Units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company&#x2019;s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company&#x2019;s amended and restated certificate of incorporation. In accordance with SEC and its staff&#x2019;s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class A ordinary shares have been classified outside of permanent equity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional paid-in capital and accumulated deficit.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2021, the Class A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;"&gt;Proceeds allocated to Public Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,813,334)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;"&gt;Issuance costs allocated to Class A ordinary shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,029,901)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;Plus:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion of carrying value to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,593,235&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class A ordinary shares subject to possible redemption&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 235,750,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Offering Costs associated with the Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company complies with the requirements of ASC 340-10-S99-1 and SEC Staff Accounting Bulletin Topic 5A - &lt;i style="font-style:italic;"&gt;Expenses of Offering&lt;/i&gt;. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $13,662,256 as a result of the Initial Public Offering (consisting of $4,600,000 of cash underwriting discounts, $8,050,000 in deferred underwriting fees and $1,012,256 of other offering costs). As such, the Company recorded $13,029,901 of offering costs as a reduction of temporary equity and $632,355 of offering costs as a reduction of permanent equity in connection with the issuance of the Units in the Initial Public Offering and the Private Placement Warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes under ASC 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC 740&#x201d;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold and measurement process for financial statements recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. Based on the Company&#x2019;s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company&#x2019;s financial statements. Since the Company was incorporated on February 5, 2021, the evaluation was performed for the 2021 tax year which will be the only period subject to examination.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is considered an exempted Cayman Islands Company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. Consequently, income taxes are not reflected in the Company&#x2019;s financial statement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Net Loss Per Ordinary Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 15,900,000 shares in the calculation of diluted income per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Period from February 5,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021 (inception) Through&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class A&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class B&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted net loss per share:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 12pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (335,384)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (181,058)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 12pt;"&gt;Basic and diluted weighted average shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,857,143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,321,429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted net loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_6OA0VirRwEuN8iLMAj_gFA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.03)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden__fz-Sh5S5EuPKCGy7i67kQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.03)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company applies ASC Topic 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt; (&#x201c;ASC 820&#x201d;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#x2019;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#x2019;s own assumptions based on market data and the entity&#x2019;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amounts reflected in the balance sheet for cash, deferred offering costs, accrued offering costs, promissory note &#x2014; related party, and advance from anchor investor approximate fair value due to their short-term nature.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 1 &#x2014; Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 2 &#x2014; Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 3 &#x2014; Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2020, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06, Debt &#x2014; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) (&#x201c;ASU 2020-06&#x201d;) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#x2019;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#x2019;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if converted method for all convertible instruments. ASU 2020-06 is effective for the Company on January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company adopted ASU 2020-06 effective January 1, 2021 using the modified retrospective method of transition. The adoption of ASU 2020-06 did not have a material impact on the financial statements for the period from February 5, 2021 (inception) through December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s financial statements.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_UsngzD_rtU6Yi7K60yvM0Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the SEC.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <ahpa:EmergingGrowthCompanyPolicyTextBlock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_vnCTVmp4fEqq23PB7n_53g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Emerging Growth Company&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Further, Section&#160;102(b)(1)&#160;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/p&gt;</ahpa:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb__3-ZSaM8ekCdPITj_jUskA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_sP2WtZ4v7kmri_hsNVaENQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2021.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <ahpa:CommonStockSubjectToPossibleRedemptionPolicyTextBlock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_DX85C11gRkWbduYm5XUO7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Class A Ordinary Shares Subject to Possible Redemption&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;All of the 23,000,000 shares of Class A ordinary shares sold as part of the Units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company&#x2019;s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company&#x2019;s amended and restated certificate of incorporation. In accordance with SEC and its staff&#x2019;s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class A ordinary shares have been classified outside of permanent equity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional paid-in capital and accumulated deficit.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2021, the Class A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;"&gt;Proceeds allocated to Public Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,813,334)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;"&gt;Issuance costs allocated to Class A ordinary shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,029,901)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;Plus:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion of carrying value to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,593,235&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class A ordinary shares subject to possible redemption&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 235,750,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ahpa:CommonStockSubjectToPossibleRedemptionPolicyTextBlock>
    <ahpa:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_92SC9DBWKUyqMSwExfbIdQ"
      decimals="INF"
      id="Narr_m0bDokW0VE2HE4_V2K-1Tg"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">23000000</ahpa:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_0vtrPU72xku59ZpGbmkutw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;"&gt;Proceeds allocated to Public Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,813,334)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;"&gt;Issuance costs allocated to Class A ordinary shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,029,901)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;Plus:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion of carrying value to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,593,235&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class A ordinary shares subject to possible redemption&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 235,750,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_O9B8lPYtW06gF4x84BfA2w_1_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">230000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <ahpa:TemporaryEquityProceedsAllocatedToWarrants
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_BbAz6kXdNkGlhGfasHEBog_3_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">-9813334</ahpa:TemporaryEquityProceedsAllocatedToWarrants>
    <ahpa:TemporaryEquityIssuanceCosts
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_770iXVUbj0ClGe6zNSDf4w_4_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">-13029901</ahpa:TemporaryEquityIssuanceCosts>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Tc_gXNzBZ1tmE6aCdqW5_VuGg_6_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">28593235</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Tc_Q4YAyOUINkmx9uN_-3Gj-w_7_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">235750000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_sxe0cMuVgEmJiPD24wFUKw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Offering Costs associated with the Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company complies with the requirements of ASC 340-10-S99-1 and SEC Staff Accounting Bulletin Topic 5A - &lt;i style="font-style:italic;"&gt;Expenses of Offering&lt;/i&gt;. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $13,662,256 as a result of the Initial Public Offering (consisting of $4,600,000 of cash underwriting discounts, $8,050,000 in deferred underwriting fees and $1,012,256 of other offering costs). As such, the Company recorded $13,029,901 of offering costs as a reduction of temporary equity and $632,355 of offering costs as a reduction of permanent equity in connection with the issuance of the Units in the Initial Public Offering and the Private Placement Warrants.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <ahpa:TransactionCosts
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Narr_sYasLXKgS0qICqQehy5h0g"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">13662256</ahpa:TransactionCosts>
    <ahpa:SaleOfStockUnderwritingFees
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Narr_6evRhFwRWkmmGIYxEIh2tQ"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">4600000</ahpa:SaleOfStockUnderwritingFees>
    <ahpa:DeferredOfferingCostsNoncurrent
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Narr_AAF1TbcqAkmA7KpM8kkz2A"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">8050000</ahpa:DeferredOfferingCostsNoncurrent>
    <ahpa:SaleOfStockOtherOfferingCosts
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Narr_dyAVekKGSkCjyz9od6KChQ"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">1012256</ahpa:SaleOfStockOtherOfferingCosts>
    <ahpa:OfferingCostsReductionOfTemporaryEquity
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Narr_lN4_MWace02gGwUCI3f2Ug"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">13029901</ahpa:OfferingCostsReductionOfTemporaryEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Narr_j72B93bPtUK6R4SN3yRcrg"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">632355</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_DvugoViq_UysPSJwyBSnsw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes under ASC 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC 740&#x201d;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold and measurement process for financial statements recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. Based on the Company&#x2019;s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company&#x2019;s financial statements. Since the Company was incorporated on February 5, 2021, the evaluation was performed for the 2021 tax year which will be the only period subject to examination.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is considered an exempted Cayman Islands Company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. Consequently, income taxes are not reflected in the Company&#x2019;s financial statement.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Narr_P9gwm0E0YEG_dxREKLemSg"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Narr_ECvrXwTxlE6_w8tEGfIjZg"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_3vwY8VX25EeA1fKa0r7OFA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Net Loss Per Ordinary Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 15,900,000 shares in the calculation of diluted income per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Period from February 5,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021 (inception) Through&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class A&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class B&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted net loss per share:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 12pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (335,384)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (181,058)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 12pt;"&gt;Basic and diluted weighted average shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,857,143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,321,429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted net loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_6OA0VirRwEuN8iLMAj_gFA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.03)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden__fz-Sh5S5EuPKCGy7i67kQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.03)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_FMDt3RxfGEqzFwOF3AN7gg"
      decimals="INF"
      id="Narr_-puOhCAA8Ea1SbZEW9mPYg"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">15900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_279CO8URfUijB3nu2HTIVA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Period from February 5,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021 (inception) Through&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class A&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Class B&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted net loss per share:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 12pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (335,384)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (181,058)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 6pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 12pt;"&gt;Basic and diluted weighted average shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,857,143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,321,429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted net loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_6OA0VirRwEuN8iLMAj_gFA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.03)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden__fz-Sh5S5EuPKCGy7i67kQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.03)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA"
      decimals="0"
      id="Tc_YzAGv4SdZkuEJGaA0R1gIg_7_3"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">-335384</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg"
      decimals="0"
      id="Tc_ytRdCFbcy0mzhA3fDZ7D6w_7_6"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">-181058</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA"
      decimals="0"
      id="Tc_lMvHgXViQkiyPBPCpyYjHg_9_3"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">9857143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg"
      decimals="0"
      id="Tc_bDoMoa_nY0-4lSxqIT4vHg_9_6"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">5321429</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA"
      decimals="2"
      id="Tc_CLVkFsdT-Ums_wZ4OX5ykw_10_3"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg"
      decimals="2"
      id="Tc_hzXF0rUP20y1UMKhSCzKow_10_6"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_cP6F0SsNdk-23pF6250S7Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="0"
      id="Narr_yTLyPxOW4kSZrQ72jx2M5Q"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_65Mza2VFBEGxYMK8SPrTMw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company applies ASC Topic 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt; (&#x201c;ASC 820&#x201d;), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company&#x2019;s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#x2019;s own assumptions based on market data and the entity&#x2019;s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amounts reflected in the balance sheet for cash, deferred offering costs, accrued offering costs, promissory note &#x2014; related party, and advance from anchor investor approximate fair value due to their short-term nature.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 1 &#x2014; Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 2 &#x2014; Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 3 &#x2014; Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_-BfWiPs-bUSo5iJ4h-YYIQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2020, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06, Debt &#x2014; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) (&#x201c;ASU 2020-06&#x201d;) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#x2019;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#x2019;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if converted method for all convertible instruments. ASU 2020-06 is effective for the Company on January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company adopted ASU 2020-06 effective January 1, 2021 using the modified retrospective method of transition. The adoption of ASU 2020-06 did not have a material impact on the financial statements for the period from February 5, 2021 (inception) through December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <ahpa:InitialPublicOfferingTextBlock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_icUv1krY606lVZGF0Y7URA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE&#160;3. INITIAL PUBLIC OFFERING&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;The registration statement for the Company&#x2019;s Initial Public Offering was declared effective on August 9, 2021. On August 12, 2021, the Company completed its Initial Public Offering of 23,000,000 Units, including 3,000,000 Units that were issued pursuant to the underwriter&#x2019;s exercise of its over-allotment option in full, at $10.00 per Unit, generating gross proceeds of $230,000,000. Each Unit consists of one Class A ordinary share and &lt;span style="-sec-ix-hidden:Hidden_d8ssFNr6LUCa3paVl1JKtw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one-third of one&lt;/span&gt;&lt;/span&gt; redeemable warrant (&#x201c;Public Warrant&#x201d;). Each Public Warrant entitles the holder to purchase one Class A ordinary share at an exercise price of $11.50&#160;per whole share (see Note 7).&lt;/p&gt;</ahpa:InitialPublicOfferingTextBlock>
    <ahpa:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_W782mJY-OkWY82NrBIIpRA"
      decimals="INF"
      id="Narr_Kux2AAeR_U-_ahSh4rAKfQ"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">23000000</ahpa:UnitsIssuedDuringPeriodSharesNewIssues>
    <ahpa:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_ph3NAIUSSEif_XtyWxclIw"
      decimals="0"
      id="Narr__KCrj6N5wkCjZzN3DlYsyQ"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">3000000</ahpa:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_8_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_rQSd3ig2NUquGWKI1v8ycg"
      decimals="2"
      id="Narr_zpdTi1so3Ey0FM2fY5J5Pg"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_W782mJY-OkWY82NrBIIpRA"
      decimals="0"
      id="Narr_HhpvT09KIUuCaavTvRmkJA"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">230000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <ahpa:NumberOfSharesIssuedPerUnit
      contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_AvpvGzfBSk6euzkv_rNAng"
      decimals="INF"
      id="Narr_jCZL0J2JWUqPaA4hWWJ_Xw"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">1</ahpa:NumberOfSharesIssuedPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_8_12_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_hpwJzLOcDk2-xk82YwbYBA"
      decimals="INF"
      id="Narr_1W__zrDhi0CH-AGpFjMr1g"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_12_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_hpwJzLOcDk2-xk82YwbYBA"
      decimals="2"
      id="Narr_Pa3fjcrl9ESYKQNtEG0mng"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ahpa:PrivatePlacementTextBlock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_rcFpbT1tG0OpoSSDf9QCJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE&#160;4. PRIVATE PLACEMENT&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 8,233,333 Private Placement Warrants, including 900,000 Private Placement Warrants that were issued pursuant to the underwriter&#x2019;s exercise of its over-allotment option in full, at a price of $1.50 per Private Placement Warrant ($12,350,000 in the aggregate). Each Private Placement Warrant is exercisable to purchase one Class A ordinary share at a price of $11.50 per share. The proceeds from the Private Placement Warrants were added to the net proceeds from the Initial Public Offering to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Placement Warrants.&lt;/p&gt;</ahpa:PrivatePlacementTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mz3wLjizUUqg_78s5L5T6g"
      decimals="INF"
      id="Narr__6INo3ImkU6zNHYlRe-FUA"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">8233333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_RHrFxFO2K0qVPKUowtOemA"
      decimals="INF"
      id="Narr_OLYIH6DHqEG69qkFnWfQvQ"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">900000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ahpa:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mz3wLjizUUqg_78s5L5T6g"
      decimals="2"
      id="Narr_jl7CBV2ejESNUabV0pUTyQ"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">1.50</ahpa:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mvqSYAOLZUql2PhYI0lRvg"
      decimals="0"
      id="Narr_aGAfoYPiokWzyJ45L1roWQ"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">12350000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mz3wLjizUUqg_78s5L5T6g"
      decimals="INF"
      id="Narr_O-C-YJnJk0uPa0cXfaGm0Q"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mz3wLjizUUqg_78s5L5T6g"
      decimals="2"
      id="Narr_3ky14D1jIEm7djMvo333Ug"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_USKgkCNLbU6h1uk1OOWokA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE&#160;5. RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Founder Shares&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 12, 2021, the Sponsor paid an aggregate of $25,000 to cover certain expenses on behalf of the Company in exchange for the issuance of 5,750,000 Class B ordinary shares (the &#x201c;Founder Shares&#x201d;). The Founder Shares include an aggregate of up to 750,000 Class B ordinary shares subject to forfeiture by the Sponsor to the extent that the underwriters&#x2019; over-allotment option is not exercised in full or in part, so that the holders of the Founder Shares will own, on an as-converted basis, 20% of the Company&#x2019;s issued and outstanding shares after the Initial Public Offering. On June 16, 2021, the Company transferred 35,000 Class B ordinary shares each to three members of the Company&#x2019;s board of directors (or 105,000 Class B ordinary shares in total) at their original cost (see Note 7). The underwriters exercised their over-allotment option in full on August 12, 2021; thus, no ordinary shares remain subject to forfeiture (see Note 6).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Sponsor has agreed that, subject to certain limited exceptions, the Founder Shares will not be transferred, assigned, or sold until the earlier of (i)&#160;one year&#160;after the completion of a Business Combination or (ii) the date on which the Company completes a liquidation, merger, share exchange or other similar transaction after an initial Business Combination that results in all of the Company&#x2019;s shareholders having the right to exchange their Class A ordinary shares for cash, securities or other property. Notwithstanding the foregoing, if (1) the closing price of the Company&#x2019;s Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30- trading day period commencing at least 150 days after an initial Business Combination or (2) if the Company consummates a transaction after an initial Business Combination which results in the Company&#x2019;s shareholders having the right to exchange their shares for cash, securities or other property, the Founder Shares will be released from the lock-up.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Promissory Note&#160;&#x2014; Related Party&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 12, 2021, the Company issued an unsecured promissory note to the Sponsor (the &#x201c;Promissory Note&#x201d;), pursuant to which the Company could borrow up to an aggregate of $300,000 to cover expenses related to the Initial Public Offering. The Promissory Note was non-interest bearing and was payable on the earlier of (i) December 31, 2021 or (ii) the consummation of the Initial Public Offering. The Company&#x2019;s Sponsor paid certain offering costs totaling $55,725, which was included in the outstanding balance of the Promissory Note as of March 22, 2021, and the Company borrowed $119,275 on June 23, 2021. On August 12, 2021, the Company repaid the outstanding balance under the Promissory Note of $175,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Administrative Support Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into an agreement, commencing on August 9, 2021, to pay an affiliate of the Sponsor a total of $10,000 per month for administrative, financial and support services. Upon the completion of an initial Business Combination, the Company will cease paying these monthly fees. Under this agreement, $46,129 of expenses were incurred during the period from February 5, 2021 (inception) through December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Due to Related Party&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Due to related party consists of advances from the Sponsor to pay for offering costs and formation costs on behalf of the Company and are payable on demand.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Related Party Loans&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In order to finance transaction costs in connection with an intended initial Business Combination, the Company&#x2019;s sponsor or an affiliate of the sponsor or certain of the Company&#x2019;s officers and directors may, but are not obligated to, loan the Company funds as may be required (the &#x201c;Working Capital Loans&#x201d;). If the Company completes the initial Business Combination, it may repay such loaned amounts out of the proceeds of the trust account released to us. Otherwise, such loans may be repaid only out of funds held outside the trust account. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the trust account to repay such loaned amounts but no proceeds from the Company&#x2019;s trust account would be used to repay such loaned amounts. Up to $2,000,000 of such loans may be convertible into warrants of the post-Business Combination entity at a price of $1.50&#160;per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. Except as set forth above, the terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans. Prior to the completion of the initial Business Combination, the Company does not expect to seek loans from parties other than the Company&#x2019;s sponsor, its affiliates or any members of the management team as the Company does not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in the trust account. As of December 31, 2021, there was no balance outstanding under the Working Capital Loans.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_dPb1k23M_k-pLZXh6JaJbQ"
      decimals="0"
      id="Narr_qW25s06B0UO3_Lw0_jA4Aw"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_dPb1k23M_k-pLZXh6JaJbQ"
      decimals="INF"
      id="Narr_K4wcte2EIk6aKya3ArIHew"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ahpa:NumberOfSharesSubjectToForfeiture
      contextRef="As_Of_2_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_QkwL0AKjOUOWUMGK6d_M2w"
      decimals="INF"
      id="Narr_QgRYFs0J2kiK4RYa5i5qJg"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">750000</ahpa:NumberOfSharesSubjectToForfeiture>
    <ahpa:PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders
      contextRef="Duration_2_12_2021_To_2_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_dPb1k23M_k-pLZXh6JaJbQ"
      decimals="2"
      id="Narr_TtxD3UIuVkqSQjJmcc5Vlg"
      unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A">0.20</ahpa:PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_16_2021_To_6_16_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember__BVIfHMD9Um_Bi-uIurswQ"
      decimals="INF"
      id="Narr_UeA7xUquA0662FVy6Ytr5g"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">35000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ahpa:NumberOfSharesSubjectToForfeiture
      contextRef="As_Of_6_16_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_A7q41aYgok-ecWpRe_1YvQ"
      decimals="INF"
      id="Narr_YEGlT5Xwq0OEcGedLuPOzA"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">105000</ahpa:NumberOfSharesSubjectToForfeiture>
    <ahpa:ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_07SLTebCGk63u2x-RfDH5A"
      id="Narr_2qdwkq2Ysk2PypvCFNE-hw">P1Y</ahpa:ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination>
    <ahpa:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_07SLTebCGk63u2x-RfDH5A"
      decimals="2"
      id="Narr_haU8QwFmn0ijEWIF9gxfjw"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">12.00</ahpa:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger>
    <ahpa:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_07SLTebCGk63u2x-RfDH5A"
      decimals="INF"
      id="Narr_g2X-aQeQL0OYcqpsZbCTgA"
      unitRef="Unit_Standard_D_LMsaCzRsOkeKQp06MQlfMw">20</ahpa:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays>
    <ahpa:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_07SLTebCGk63u2x-RfDH5A"
      decimals="INF"
      id="Narr_R3hqFGpzpUKsDHEPYCbILA"
      unitRef="Unit_Standard_D_LMsaCzRsOkeKQp06MQlfMw">30</ahpa:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays>
    <ahpa:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_07SLTebCGk63u2x-RfDH5A"
      id="Narr_aEo1S8xJ_0WMVmL3SRO41w">P150D</ahpa:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences>
    <ahpa:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote
      contextRef="As_Of_2_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_PromissoryNoteWithRelatedPartyMember_xyR3z7AzvE-9dwkUHu1Piw"
      decimals="0"
      id="Narr_y0RRFoiYWEKTYsRDEtgdvg"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">300000</ahpa:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote>
    <ahpa:OfferingCostsIncludedInPromissoryNoteRelatedParty
      contextRef="Duration_3_22_2021_To_3_22_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_PromissoryNoteWithRelatedPartyMember_CZvATsM0cEaCcdmjZWpMlg"
      decimals="0"
      id="Narr_HFZaMfl76kSRbYXi6wcIUg"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">55725</ahpa:OfferingCostsIncludedInPromissoryNoteRelatedParty>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="Duration_6_23_2021_To_6_23_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_PromissoryNoteWithRelatedPartyMember_w_DAgECzBE2Z5NwzDLL4EA"
      decimals="0"
      id="Narr_qhZErcudTUmGWDQ4NHtaWA"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">119275</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_PromissoryNoteWithRelatedPartyMember_gpdKERCYWkCPAQ7cpRLRyQ"
      decimals="0"
      id="Narr_MxfQDddtckSKKjy4Ez_irA"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">175000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <ahpa:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_AdministrativeSupportAgreementMember_uzQQGS8H_0a5x4OT54OPfw"
      decimals="0"
      id="Narr_TqGmEOFU3EK_4rNWcd8UQg"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">10000</ahpa:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_2_5_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_AdministrativeSupportAgreementMember_70Vvf8NJ3kSfQY4yJdgRgg"
      decimals="0"
      id="Narr_kc_TEbNfbEqMY5lsNn3ruQ"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">46129</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_AdministrativeSupportAgreementMember_NiMhJnR4mUi1x__B69WUPA"
      decimals="0"
      id="Narr_poC66TzfakGYgUctDs0s6g"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">46129</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_4_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_AdministrativeSupportAgreementMember_Km4Y9OkDw0uxggOurPog8g"
      decimals="0"
      id="Narr_sdw-ptjKJ0K3_4mfvlqPPg"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">46129</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <ahpa:MaximumLoansConvertibleIntoWarrants
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_RelatedPartyLoansMember_t4HEn2WBv0-oLDiAcT-3nQ"
      decimals="0"
      id="Narr_BtEe5AJ7GUWUaUm3B59hGA"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">2000000</ahpa:MaximumLoansConvertibleIntoWarrants>
    <ahpa:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_RelatedPartyLoansMember_t4HEn2WBv0-oLDiAcT-3nQ"
      decimals="2"
      id="Narr_5GHx5SXmwk2F-QRDnTM7eg"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">1.50</ahpa:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <ahpa:WorkingCapitalLoansOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_RelatedPartyLoansMember_t4HEn2WBv0-oLDiAcT-3nQ"
      decimals="0"
      id="Narr_Vx68voBvfU6y4q6ySTfpIQ"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">0</ahpa:WorkingCapitalLoansOutstanding>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_nSRiIsv9VkOfNCWpr9Kr2A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE&#160;6. COMMITMENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Registration and Shareholder Rights Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to a registration rights agreement entered into on August 9, 2021, the holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants issued upon conversion of the Working Capital Loans) will have registration and shareholder rights to require the Company to register a sale of any of its securities held by them pursuant to a registration and shareholder rights agreement to be signed prior to or on the effective date of the Initial Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#x201c;piggy-back&#x201d; registration rights with respect to registration statements filed subsequent to the completion of an initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Underwriting Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The underwriters were paid a cash underwriting discount of $0.20&#160;per Unit, or $4,600,000 in the aggregate, upon the closing of the Initial Public Offering and exercise of the over-allotment in full on August 12, 2021. In addition, $0.35 per unit, or $8,050,000 in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Forward Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the consummation of the Initial Public Offering, the Company entered into a forward purchase agreement with the Sponsor, Avista Acquisition LP II, a Cayman Islands exempted limited partnership, which provides for the purchase of an aggregate of 10,000,000 Class A ordinary shares plus an aggregate of 3,333,333 redeemable warrants to purchase Class A ordinary shares at $11.50 per share, for an aggregate purchase price of $100,000,000, in the private placement. The obligations under the forward purchase agreement do not depend on whether any Class A ordinary shares are redeemed by the Company&#x2019;s public shareholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;The forward purchase securities will be issued in connection with the closing of the initial Business Combination. The proceeds from the sale of forward purchase securities will be used as part of the consideration to the sellers in the Company&#x2019;s initial Business Combination, expenses in connection with the initial Business Combination or for working capital in the post-transaction company.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ahpa:MaximumNumberOfDemandsForRegistrationOfSecurities
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="INF"
      id="Narr_AQ7UFWkNhEyWrq2xIBg1Dw"
      unitRef="Unit_Standard_item_HhKYwaXu10-zi6ST7YVS-w">3</ahpa:MaximumNumberOfDemandsForRegistrationOfSecurities>
    <ahpa:DeferredFeePerUnit
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="2"
      id="Narr_EmTUDw_WbEqYl-11-bahfg"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">0.20</ahpa:DeferredFeePerUnit>
    <ahpa:AggregateDeferredUnderwritingFeePayable
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Narr_FOrZUAbntU2BE1gs15OW1Q"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">4600000</ahpa:AggregateDeferredUnderwritingFeePayable>
    <ahpa:UnderwritingCashDiscountPerUnit
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="2"
      id="Narr_q9ZjD5ZWJkGPmoD6E_wWjw"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">0.35</ahpa:UnderwritingCashDiscountPerUnit>
    <ahpa:UnderwriterCashDiscount
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="0"
      id="Narr_LjOIy2AvHE-OBCOv5cC5rg"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">8050000</ahpa:UnderwriterCashDiscount>
    <ahpa:SharesToBePurchasedPursuantToAgreements
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA"
      decimals="INF"
      id="Narr_M3e79GyPLEypj5wittA_Qw"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">10000000</ahpa:SharesToBePurchasedPursuantToAgreements>
    <ahpa:WarrantsToBePurchasedPursuantToAgreements
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      decimals="INF"
      id="Narr_Fpc6jDfQmkejksZjhH36Zg"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">3333333</ahpa:WarrantsToBePurchasedPursuantToAgreements>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="2"
      id="Narr_3CFn1LJs9Uy6L8uwedBzdQ"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_eD2XDmIVE0OxfJPD7OTpMA"
      decimals="0"
      id="Narr_ZgZGvLw0_EeE9KyvB_ymxA"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">100000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_6Jjr4VQbY0-AQaRlfUtXeQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE&#160;7. SHAREHOLDERS&#x2019; DEFICIT&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Preference shares&#x2014;&lt;/span&gt; The Company is authorized to issue 5,000,000 preference shares with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#x2019;s board of directors. As of December&#160;31,&#160;2021, there were no preference shares issued or &lt;span style="-sec-ix-hidden:Hidden_dLQndVmTokOqpzPEE6ShuQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Class&#160;A ordinary shares&#x2014;&lt;/span&gt; The Company is authorized to issue 500,000,000 Class A ordinary shares with a par value of $0.0001 per share. Holders of Class A ordinary shares are entitled to one vote for each share. At December&#160;31,&#160;2021, there were 23,000,000 Class A ordinary shares issued and &lt;span style="-sec-ix-hidden:Hidden_Z_H04b9q5UCcSUgqEMG3_g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt;, including 23,000,000 Class A ordinary shares subject to possible redemption.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Class&#160;B ordinary shares&#x2014;&lt;/span&gt; The Company is authorized to issue 50,000,000 Class B ordinary shares with a par value of $0.0001 per share. Holders of Class B ordinary shares are entitled to one vote for each share. As of December 31, 2021, there were 5,750,000 Class B ordinary shares issued and &lt;span style="-sec-ix-hidden:Hidden_1ubnyfPiU0eaQzavzDHJNg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt;, and the holders of the Founder Shares own, on an as-converted basis, 20% of the Company&#x2019;s issued and outstanding shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Except as described below, holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company&#x2019;s shareholders except as required by law. Unless specified in the Company&#x2019;s Amended and Restated Memorandum and Articles of Association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the ordinary shares that are voted is required to approve any such matter voted on by the shareholders. Approval of certain actions will require a special resolution under Cayman Islands law, being the affirmative vote of at least two-thirds of the ordinary shares that are voted, and pursuant to the Amended and Restated Memorandum and Articles of Association; such actions include amending the Amended and Restated Memorandum and Articles of Association and approving a statutory merger or consolidation with another company. The Company&#x2019;s board of directors is divided into three classes, each of which will generally serve for a term of three years with only one class of directors being appointed in each year. There is no cumulative voting with respect to the appointment of directors, with the result that the holders of more than 50% of the shares voted for the appointment of directors can appoint all of the directors. The Company&#x2019;s shareholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally available therefor. Prior to the Company&#x2019;s initial Business Combination, (i) only holders of the founder shares will have the right to vote on the appointment of directors and (ii) in a vote to continue the Company in a jurisdiction outside the Cayman Islands (which requires the approval of at least two thirds of the votes of all ordinary shares), holders of the Company&#x2019;s Class B ordinary shares will have ten votes for every Class B ordinary share and holders of the Class A ordinary shares will have one vote for every Class A ordinary share. These provisions of the Company&#x2019;s Amended and Restated Memorandum and Articles of Association may only be amended by a special resolution passed by not less than 90% of the ordinary shares who attend and vote at the Company&#x2019;s general meeting which shall include the affirmative vote of a simple majority of the Class B ordinary shares. Holders of the public shares will not be entitled to vote on the appointment of directors prior to the initial Business Combination.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, prior to the completion of an initial Business Combination, holders of a majority of the founder shares may remove a member of the board of directors for any reason. In connection with the initial Business Combination, the Company may enter into a shareholders agreement or other arrangements with the shareholders of the target with respect to voting and other corporate governance matters following completion of the initial Business Combination.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Redeemable Warrants&#x2014;&lt;/span&gt; Each whole warrant entitles the registered holder to purchase one Class A ordinary share at a price of $11.50 per share , subject to adjustment as discussed below, at any time commencing 30 days&#160;after the completion of the Company&#x2019;s initial Business Combination, except as discussed in the immediately succeeding paragraph. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of Class A ordinary shares. This means only a whole warrant may be exercised at a given time by a warrant holder. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Accordingly, unless you purchase at least three units, you will not be able to receive or trade a whole warrant. The warrants will expire five years&#160;after the completion of the initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company will not be obligated to deliver any Class A ordinary shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class A ordinary shares underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company&#x2019;s satisfying of the obligations described below with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable and the Company will not be obligated to issue a Class A ordinary share upon exercise of a warrant unless the Class A ordinary share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the Class A ordinary share underlying such unit. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has agreed that as soon as practicable, but in no event later than 20 business&#160;days after the closing of the initial Business Combination, the Company will use commercially reasonable efforts to file with the SEC a registration statement (which may be a post-effective amendment to the registration statement of which the Company&#x2019;s prospectus is a part or any other applicable registration statement) for the registration, under the Securities Act, of the Class A ordinary shares issuable upon exercise of the warrants, and the Company will use commercially reasonable efforts to cause the same to become effective within 60&#160;business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Company&#x2019;s Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a &#x201c;covered security&#x201d; under Section 18(b)(1) of the Securities Act, the Company may, at it&#x2019;s option, require holders of warrants who exercise their warrants to do so on a &#x201c;cashless basis&#x201d; in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, will not be required to file or maintain in effect a registration statement, and will use commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent available. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#x201c;cashless basis&#x201d; in accordance with Section 3(a)(9) of the Securities Act or another exemption, and the Company will use commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class A ordinary shares equal to the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the &#x201c;fair market value&#x201d; (defined below) less the exercise price of the warrants by (y) the fair market value. The &#x201c;fair market value&#x201d; as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Redemption of warrants&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;in whole and not in part;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;at a price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$0.01&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per warrant;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;upon not less than &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;30 days&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2019; prior written notice of redemption to each warrant holder; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;if, and only if, the closing price of the Class A ordinary shares equals or exceeds &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$18.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;20&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; trading days within a &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;30&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;-&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the Class A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class A ordinary shares is available throughout the 30-day redemption period. If and when the warrants become redeemable by the Company, the Company may exercise the Company&#x2019;s redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and the Company issues a notice of redemption of the warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the Class A ordinary shares may fall below the $18.00 redemption trigger price (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) as well as the $11.50 (for whole shares) warrant exercise price after the redemption notice is issued. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;No fractional Class A ordinary shares will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, the Company will round down to the nearest whole number of the number of Class A ordinary shares to be issued to the holder. If, at the time of redemption, the warrants are exercisable for a security other than the Class A ordinary shares pursuant to the warrant agreement (for instance, if the Company is not the surviving company in the Company&#x2019;s initial Business Combination), the warrants may be exercised for such security. At such time as the warrants become exercisable for a security other than the Class A ordinary shares, the Company (or surviving company) will use its commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of the warrants. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;If the number of outstanding Class A ordinary shares is increased by a capitalization or share dividend payable in Class A ordinary shares, or by a sub-division of ordinary shares or other similar event, then, on the effective date of such capitalization or share dividend, sub-division or similar event, the number of Class A ordinary shares issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding ordinary shares. A rights offering made to all or substantially all holders of ordinary shares entitling holders to purchase Class A ordinary shares at a price less than the &#x201c;historical fair market value&#x201d; (as defined below) will be deemed a share dividend of a number of Class A ordinary shares equal to the product of (i) the number of Class A ordinary shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Class A ordinary shares) and (ii) one minus the quotient of (x) the price per Class A ordinary share paid in such rights offering and (y) the historical fair market value. For these purposes, (i) if the rights offering is for securities convertible into or exercisable for Class A ordinary shares, in determining the price payable for Class A ordinary shares, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) &#x201c;historical fair market value&#x201d; means the volume weighted average price of Class A ordinary shares as reported during the 10 trading day period ending on the trading day prior to the first date on which the Class A ordinary shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, if the Company, at any time while the warrants are outstanding and unexpired, pays a dividend or makes a distribution in cash, securities or other assets to all or substantially all of the holders of the Class A ordinary shares on account of such Class A ordinary shares (or other securities into which the warrants are convertible), other than (a) as described above, (b) any cash dividends or cash distributions which, when combined on a per share basis with all other cash dividends and cash distributions paid on the Class A ordinary shares during the 365-day period ending on the date of declaration of such dividend or distribution does not exceed $0.50 (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions that resulted in an adjustment to the exercise price or to the number of Class A ordinary shares issuable on exercise of each warrant) but only with respect to the amount of the aggregate cash dividends or cash distributions equal to or less than $0.50 per share , (c) to satisfy the redemption rights of the holders of Class A ordinary shares in connection with a proposed initial Business Combination, (d) to satisfy the redemption rights of the holders of Class A ordinary shares in connection with a shareholder vote to amend the Amended and Restated Memorandum and Articles of Association (A) to modify the substance or timing of the Company&#x2019;s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the public shares if the Company does not complete its initial Business Combination within 18 months from the closing of the Initial Public Offering or (B) with respect to any other provision relating to the rights of holders of the Company&#x2019;s Class A ordinary shares, or (e) in connection with the redemption of the Company&#x2019;s public shares upon failure to complete the Company&#x2019;s initial Business Combination, then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each Class A ordinary share in respect of such event.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Whenever the number of Class A ordinary shares purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of Class A ordinary shares purchasable upon the exercise of the warrants immediately prior to such adjustment and (y) the denominator of which will be the number of Class A ordinary shares so purchasable immediately thereafter. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#x2019;s board of directors and, in the case of any such issuance to the Company&#x2019;s sponsor or its affiliates, without taking into account any founder shares held by the sponsor or such affiliates, as applicable, prior to such issuance) (the &#x201c;Newly Issued Price&#x201d;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the &#x201c;Market Value&#x201d;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described above under &#x201c;Redemption of warrants&#x201d; will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;No fractional warrants will be issued upon separation of the units and only whole warrants will trade. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exercise, round down to the nearest whole number the number of Class A ordinary shares to be issued to the warrant holder.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Private Placement Warrants have terms and provisions that are identical to those of the warrants being sold as part of the units in the Company&#x2019;s Initial Public Offering except that the Private Placement Warrants (including the Class A ordinary shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until 30 days&#160;after the completion of the initial Business Combination (except pursuant to limited exceptions to the Company&#x2019;s officers and directors and other persons or entities affiliated with the initial purchasers of the Private Placement Warrants). The Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the units being sold in the Initial Public Offering.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;The Company accounts for the 15,900,000 warrants issued in connection with the Initial Public Offering (including 7,666,667 Public Warrants and 8,233,333 Private Placement Warrants), and will account for the 3,333,333 Forward Purchase Warrants to be issued in connection with the initial Business Combination, in accordance with the guidance contained in ASC 815-40, &lt;i style="font-style:italic;"&gt;Derivatives and Hedging&lt;/i&gt;. Such guidance provides that the warrants described above are not precluded from equity classification. Equity-classified contracts are initially measured at fair value (or allocated value). Subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="INF"
      id="Narr_1W28NVJsoUa0QwYUmpgEng"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="INF"
      id="Narr_6TBjQu1jgEG8Q4AAOo0raQ"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="INF"
      id="Narr_LrotKBWfqk6tGRWqtfznBg"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_f60OhzulvUWffRFATFN0QQ"
      decimals="INF"
      id="Narr_HqHb4Efe_Eit9dOuEQlvOA"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_f60OhzulvUWffRFATFN0QQ"
      decimals="INF"
      id="Narr_wu-Bxs6YlkeIuQ3p71aM8g"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <ahpa:CommonStockNumberOfVotesPerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_f60OhzulvUWffRFATFN0QQ"
      decimals="INF"
      id="Narr_W5tpnZMLo0KG9vbiivk1tg"
      unitRef="Unit_Standard_Vote_PXooaeoQc0ms4cDX_kIEHg">1</ahpa:CommonStockNumberOfVotesPerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_ahpa_CommonClassaSubjectToRedemptionMember_q28zW_K4z0OVkxWsAfxczw"
      decimals="INF"
      id="Narr_gSSeO15Ni0m-U2tVw8AYfw"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">23000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw"
      decimals="INF"
      id="Narr_qHJgeIL9FU6Q-JQ7icgz2Q"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">23000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug"
      decimals="INF"
      id="Narr_torzilxiYEmZNzeYabqgSw"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug"
      decimals="INF"
      id="Narr_vt4rzJS7iUCPhiyRnTukXw"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <ahpa:CommonStockNumberOfVotesPerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug"
      decimals="INF"
      id="Narr_LKYi7GABFEKNRud2Uioehw"
      unitRef="Unit_Standard_Vote_PXooaeoQc0ms4cDX_kIEHg">1</ahpa:CommonStockNumberOfVotesPerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_-y4Jlz2zskWxsznI4qQ4ug"
      decimals="INF"
      id="Narr_wfh4QEOn2UiI0eiseuE0TA"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">5750000</us-gaap:CommonStockSharesIssued>
    <ahpa:ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg"
      decimals="2"
      id="Narr_HKnifrM9AUWd0TPYExr6KA"
      unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A">0.20</ahpa:ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1>
    <ahpa:ConvertibleStockConversionRatios
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg"
      decimals="0"
      id="Narr_cQifdEEDrECbgi55w-oLXA"
      unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A">50</ahpa:ConvertibleStockConversionRatios>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_f0P--mGylEyLNj8LG5U35g"
      decimals="2"
      id="Narr_1y_QzmMYf0-EUYFBJ16o6A"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">11.50</us-gaap:SharePrice>
    <ahpa:WarrantExercisePeriodConditionTwo
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_HgSeUv3N6UGsnBDKOVV0aw"
      id="Narr_eXwT6CFs-Eeh8H1QXns7sg">P30D</ahpa:WarrantExercisePeriodConditionTwo>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_c0jqdQLiPkuEslmiil_bNQ"
      id="Narr_Y8RAdwZbXUa-UpH07nkqMw">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ahpa:MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_eD2XDmIVE0OxfJPD7OTpMA"
      id="Narr_KYgwQYE9wUC2TNS5A7l1pA">P20D</ahpa:MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement>
    <ahpa:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_eD2XDmIVE0OxfJPD7OTpMA"
      id="Narr_o9WOa8vGLUK-7ArsWQzTxw">P60D</ahpa:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective>
    <ahpa:RedemptionPeriod
      contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_V90sXGB5lUewxKhffVJUsQ"
      id="Narr_H1R_ijc1h0mbAELSGarBJw">P10D</ahpa:RedemptionPeriod>
    <ahpa:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_Ng0NOicLVku1PX4eR69EBg"
      decimals="2"
      id="Narr_AS4g0qu0eEuQdSKlmUM4QA"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">0.01</ahpa:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
    <ahpa:RedemptionPeriod
      contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_Ng0NOicLVku1PX4eR69EBg"
      id="Narr_uuuuMw0jWEaxTpch_8DhOA">P30D</ahpa:RedemptionPeriod>
    <ahpa:WarrantRedemptionConditionMinimumSharePrice
      contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_Ng0NOicLVku1PX4eR69EBg"
      decimals="2"
      id="Narr_7L7VhW2eYECwT9wOLiKRVw"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">18.00</ahpa:WarrantRedemptionConditionMinimumSharePrice>
    <ahpa:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays
      contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_Ng0NOicLVku1PX4eR69EBg"
      id="Narr_5wFSr_FYO06qk9e3UroADg">P20D</ahpa:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays>
    <ahpa:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays
      contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_Ng0NOicLVku1PX4eR69EBg"
      decimals="INF"
      id="Narr_dAFMVCdeNEOgn8F8kJvR3g"
      unitRef="Unit_Standard_D_LMsaCzRsOkeKQp06MQlfMw">30</ahpa:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays>
    <ahpa:RedemptionPeriod
      contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_Ng0NOicLVku1PX4eR69EBg"
      id="Narr_TRy5y-Gf9UCTO8MKaAA7NA">P30D</ahpa:RedemptionPeriod>
    <ahpa:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_V90sXGB5lUewxKhffVJUsQ"
      decimals="2"
      id="Narr_RYjASgN_pkudwpUusDcczw"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">18.00</ahpa:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
    <ahpa:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_c1CfbfmOgkajeLUmOnWY1w"
      decimals="2"
      id="Narr_eDaHKybCBEmrz4klUNsjMQ"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">11.50</ahpa:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
    <ahpa:RedemptionPeriod
      contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_V90sXGB5lUewxKhffVJUsQ"
      id="Narr_ESl1E4yHxUWqIxHTRebEzQ">P10D</ahpa:RedemptionPeriod>
    <ahpa:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays
      contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_V90sXGB5lUewxKhffVJUsQ"
      id="Narr_O8Zd72Wt-kymHIHE-YUUcw">P365D</ahpa:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays>
    <ahpa:SharePriceTriggerUsedToMeasureDilutionOfWarrants
      contextRef="As_Of_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_FxrDQLlMwkKqESzq8z6bXg"
      decimals="2"
      id="Narr_7_YYjVdCYEuRyUsjn0vlqw"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">0.50</ahpa:SharePriceTriggerUsedToMeasureDilutionOfWarrants>
    <ahpa:SharePriceTriggerUsedToMeasureDilutionOfWarrants
      contextRef="As_Of_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_FxrDQLlMwkKqESzq8z6bXg"
      decimals="2"
      id="Narr_Xkqq48NZ_k6J7vFT57Rf6A"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">0.50</ahpa:SharePriceTriggerUsedToMeasureDilutionOfWarrants>
    <ahpa:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant
      contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_V90sXGB5lUewxKhffVJUsQ"
      decimals="0"
      id="Narr_x_-O4bMpNE61M_uE0iHIyA"
      unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A">100</ahpa:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant>
    <ahpa:SharePriceTriggerUsedToMeasureDilutionOfWarrants
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_c0jqdQLiPkuEslmiil_bNQ"
      decimals="2"
      id="Narr_u3Ij7HdO-0S6GyJQ9Ed1CA"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">9.20</ahpa:SharePriceTriggerUsedToMeasureDilutionOfWarrants>
    <ahpa:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_HgSeUv3N6UGsnBDKOVV0aw"
      decimals="0"
      id="Narr_Gfhnuiw3eUCOHNYjMf8j3A"
      unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A">60</ahpa:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant>
    <ahpa:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_HgSeUv3N6UGsnBDKOVV0aw"
      decimals="INF"
      id="Narr_jo0llk4l3US4rM__V9NzZg"
      unitRef="Unit_Standard_D_LMsaCzRsOkeKQp06MQlfMw">20</ahpa:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant>
    <ahpa:SharePriceTriggerUsedToMeasureDilutionOfWarrants
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_c0jqdQLiPkuEslmiil_bNQ"
      decimals="2"
      id="Narr_htSpMjbDCU6_Wl_G7hk2jA"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">9.20</ahpa:SharePriceTriggerUsedToMeasureDilutionOfWarrants>
    <ahpa:WarrantExercisePriceAdjustmentMultiple
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_HgSeUv3N6UGsnBDKOVV0aw"
      decimals="0"
      id="Narr_y0VAX4Upe0uWAFIHSTNx3Q"
      unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A">115</ahpa:WarrantExercisePriceAdjustmentMultiple>
    <ahpa:WarrantRedemptionConditionMinimumSharePrice
      contextRef="Duration_2_5_2021_To_12_31_2021_srt_StatementScenarioAxis_ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_Ng0NOicLVku1PX4eR69EBg"
      decimals="2"
      id="Narr_hQM6T2ABBES9dlfqh-FabA"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">18.00</ahpa:WarrantRedemptionConditionMinimumSharePrice>
    <ahpa:WarrantRedemptionPriceAdjustmentMultiple
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_HgSeUv3N6UGsnBDKOVV0aw"
      decimals="0"
      id="Narr_h9Ywmh7eE0mDa_vY8pTKHw"
      unitRef="Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A">180</ahpa:WarrantRedemptionPriceAdjustmentMultiple>
    <ahpa:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_HgSeUv3N6UGsnBDKOVV0aw"
      id="Narr_rqMq1VBnREil2kape6GUPg">P30D</ahpa:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion>
    <ahpa:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tf5u2Z2hjkKPDF_uv_Xeig"
      decimals="INF"
      id="Narr_mKnsBjEyqUOa-mTRbi8xmQ"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">15900000</ahpa:UnitsIssuedDuringPeriodSharesNewIssues>
    <ahpa:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FE6zEVavvUymGkwGe3FEbA"
      decimals="INF"
      id="Narr_hUkzNfvXrEqjlQI5bvwiJw"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">7666667</ahpa:UnitsIssuedDuringPeriodSharesNewIssues>
    <ahpa:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Gi4yVR_tj0CKg7dgp66JvQ"
      decimals="INF"
      id="Narr_cguSDQPOT0mJq6TMYZV4Dg"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">8233333</ahpa:UnitsIssuedDuringPeriodSharesNewIssues>
    <ahpa:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_5_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_-Ce3huUCEEmRf4OJGJJFJQ"
      decimals="INF"
      id="Narr_nyDs8SA9rkmqZo-_5ohUWw"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">3333333</ahpa:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug"
      id="Tb_4ZOUv1Lej0aj4LFdRHVWgw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE&#160;8. SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than the items disclosed below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;On March 14, 2022, the Company entered into a promissory note pursuant to the Working Capital Loans terms as outlined in Note 5 with the Sponsor (the &#x201c;Sponsor Working Capital Loan&#x201d;) to which the Company could borrow up to an aggregate of $750,000. The Sponsor Working Capital Loan is non-interest bearing and payable upon the earlier of (i) completion of the initial Business Combination or (ii) the date that the winding up of the Company is effective. The unpaid principal balance on the Sponsor Working Capital Loan may be convertible into warrants at the option of the Sponsor at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. On March 15, 2022, the Company drew down $500,000 under the Sponsor Working Capital Loan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Proposed Business Combination&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;On March 23, 2022, we entered into an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;), by and among the Company, Ligand Pharmaceuticals Incorporated, a Delaware corporation (&#x201c;Ligand&#x201d;), OmniAb, Inc., a Delaware corporation and wholly-owned subsidiary of Ligand (&#x201c;OmniAb&#x201d; and, together with Ligand, collectively, the &#x201c;Companies&#x201d;), and Orwell Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (&#x201c;Merger Sub&#x201d;), pursuant to which we will combine with OmniAb, Ligand&#x2019;s antibody discovery business (the &#x201c;OmniAb Business&#x201d;), in a Reverse Morris Trust transaction. Also on March 23, 2022, and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 11pt 0pt;"&gt;in connection with the execution of the Merger Agreement, (a) the Company, Ligand, OmniAb and Merger Sub entered into that certain Employee Matters Agreement (the &#x201c;Employee Matters Agreement&#x201d;), (b) OmniAb and our sponsor entered into that certain sponsor insider letter agreement (the &#x201c;Sponsor Insider Agreement&#x201d;) with the Company and certain insiders of the Company (the &#x201c;Insiders&#x201d;) and (c) we amended and restated that certain forward purchase agreement, dated August 9, 2021, by entering into the amended and restated forward purchase agreement (the &#x201c;A&amp;amp;R FPA&#x201d;), by and among the Company&lt;span style="white-space:pre-wrap;"&gt;, our sponsor and OmniAb.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Immediately prior to the Merger (as defined below) and pursuant to a Separation and Distribution Agreement, dated as of March 23, 2022, among the Company, Ligand and OmniAb (the &#x201c;Separation Agreement&#x201d;), Ligand will, among other things and subject to the terms and conditions of the Separation Agreement, transfer the OmniAb Business, including certain related subsidiaries of Ligand, to OmniAb and, in connection therewith, will distribute (the &#x201c;Distribution&#x201d;) to Ligand stockholders 100% of the common stock of OmniAb, par value $0.001&lt;span style="white-space:pre-wrap;"&gt; (the &#x201c;OmniAb Common Stock&#x201d;).  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Immediately following the Distribution, in accordance with and subject to the terms and conditions of the Merger Agreement, Merger Sub will merge with and into OmniAb (the &#x201c;Merger&#x201d;), with OmniAb continuing as the surviving company in the Merger and as a wholly-owned subsidiary of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;The Merger Agreement, along with the Separation Agreement and the other transaction documents to be entered into in connection therewith, provides for, among other things, the consummation of the following transactions (collectively, the &#x201c;OmniAb Business Combination&#x201d;): (i) we will redomicile by way of continuation from the Cayman Islands to Delaware and domesticate as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law and with Section 206 of the Cayman Islands Companies Act (As Revised) at least one business day prior to the closing of the proposed OmniAb Business Combination (the &#x201c;Domestication&#x201d;), (ii) Ligand will transfer the OmniAb Business (the &#x201c;Separation&#x201d;) to its wholly-owned subsidiary, OmniAb, and contribute $15 million in capital thereto (less certain transaction and other expenses), and (iii) following the Separation, Ligand will distribute 100% of the shares of OmniAb Common Stock, to Ligand stockholders by way of the Distribution. Following the completion of the foregoing transactions and subject to the satisfaction or waiver of certain other conditions set forth in the Merger Agreement, the parties shall consummate the Merger. The Distribution and Merger are intended to qualify as &#x201c;tax-free&#x201d; transactions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;Upon consummation of the proposed OmniAb Business Combination, and after the Domestication, we will have one class of common stock, par value $0.0001 per share (the &#x201c;APAC Common Stock&#x201d;), which will be listed on Nasdaq under the ticker symbol &#x201c;OABI.&#x201d; Our then-outstanding warrants will be listed on Nasdaq under the ticker symbol &#x201c;OABIW.&#x201d;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 11pt 0pt;"&gt;At the time the proposed OmniAb Business Combination is effected (the &#x201c;Closing&#x201d;), each share of OmniAb Common Stock outstanding after the Distribution and immediately prior to the effective time of the Merger will be converted into a number of shares of APAC Common Stock based on an exchange ratio determined by reference to a pre-money equity value for OmniAb of $850 million. Holders of OmniAb options, restricted stock units and performance stock units (determined after the Distribution and the division of Ligand equity awards into both Ligand equity awards and OmniAb equity awards pursuant to the Employee Matters Agreement) will have their awards rolled over into equity awards of the Company and adjusted pursuant to the exchange ratio.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 9pt 0pt;"&gt;In addition, at the Closing, holders of OmniAb Common Stock and equity awards will also receive earnout consideration in the form of an additional 15,000,000 shares of APAC Common Stock (the &#x201c;OmniAb Earnout Shares&#x201d;), with 50% of such earnout shares vesting upon the combined company&#x2019;s achievement of a post-transaction volume-weighted average price (&#x201c;VWAP&#x201d;) of $12.50 per share of APAC Common Stock for any 20 trading days over a consecutive 30 trading-day period, and the remainder vesting upon achievement of a post-transaction VWAP of $15.00 per share of APAC Common Stock for any 20 trading days over a consecutive 30 trading-day period, in each case provided such vesting occurs during the five-year period following the Closing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 9pt 0pt;"&gt;In connection with the proposed OmniAb Business Combination, upon the Domestication (i) all issued and outstanding Class A ordinary shares and Class B ordinary shares will convert automatically, on a one-for-one basis, into shares of APAC Common Stock, (ii) all issued and outstanding warrants will convert automatically into warrants to acquire shares of APAC Common Stock and (iii) all issued and outstanding Units will separate and convert automatically into one share of APAC Common Stock and one-third of one warrant to purchase APAC Common Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;The consummation of the proposed OmniAb Business Combination is subject to certain conditions as further described in the Merger Agreement.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtDefaultLongtermDebtAmount
      contextRef="As_Of_3_14_2022_us-gaap_ClassOfWarrantOrRightAxis_ahpa_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RZCYNy4TR02-s8x38wz2RQ"
      decimals="0"
      id="Narr_7mbtHTukdEaW5WmElBbQTg"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">750000</us-gaap:DebtDefaultLongtermDebtAmount>
    <ahpa:ClassOfWarrantOrRightPriceOfWarrantsOrRights
      contextRef="As_Of_3_14_2022_us-gaap_ClassOfWarrantOrRightAxis_ahpa_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RZCYNy4TR02-s8x38wz2RQ"
      decimals="2"
      id="Narr_pydLU-U7Qk2onFciQz-Vsw"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">1.50</ahpa:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="Duration_3_15_2022_To_3_15_2022_us-gaap_ClassOfWarrantOrRightAxis_ahpa_WorkingCapitalLoansWarrantMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_sgLs6LqHfEWSJdAhO6MFKg"
      decimals="0"
      id="Narr_TJCMrsXKxUWgPT9qU9tHxw"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_23_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_JOtx4eLq2EWmvVpNUA4XHg"
      decimals="INF"
      id="Narr_du2fPvnHPkKSEpplU68FxA"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <ahpa:ContributionFromSubsidiaries
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_OmniabMember_Y-svE_WiIU2HjXgNBRRZFQ"
      decimals="-6"
      id="Narr_tVMvoahYmUKBQgYK--DICA"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">15000000</ahpa:ContributionFromSubsidiaries>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_OmniabMember_K3bPyZi0602lWc8Dsxld3Q"
      decimals="INF"
      id="Narr_3Pl_YLTVL0ueFBOyumWN4w"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_OmniabMember_K3bPyZi0602lWc8Dsxld3Q"
      decimals="-6"
      id="Narr_g9PewK3FsEueoUgz2S9o6w"
      unitRef="Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ">850000000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_OmniabMember_K3bPyZi0602lWc8Dsxld3Q"
      decimals="INF"
      id="Narr_qMFXvdxdj0-R-S-v70V8Fw"
      unitRef="Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw">15000000</us-gaap:CommonStockSharesIssued>
    <ahpa:WeightedAverageSharesPricePerShare
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_OmniabMember_Y-svE_WiIU2HjXgNBRRZFQ"
      decimals="2"
      id="Narr_nRjyWBQybUm__B47wATIsg"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">12.50</ahpa:WeightedAverageSharesPricePerShare>
    <ahpa:WeightedAverageSharesPricePerShare
      contextRef="Duration_1_1_2021_To_12_31_2021_xNJIoD7-WEGyu2JOFYZBJg"
      decimals="2"
      id="Narr_WDOHhSVTLUGUeUrGm7ZGrQ"
      unitRef="Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg">15.00</ahpa:WeightedAverageSharesPricePerShare>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MA7UF:S8@V G)H@RL/(A(G/ZC7UD@C@!.NP)@9P#[6H"3 9P"H&57 %H9H%4
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MBK24I.<P>>0SQ1+PF&3Y*A8ANEV#PNI\(RF4LRO'W5/ME3"@_M0D$KJ<7*0
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MWX=W0[%$^RE8PR%O=Q6"/B!AR1"&'0VXB@HU@^'>^.),I'+K$!QF&*,- D:
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MSRMVQO&$[=3T %WEO+;-\H74F6N L7\_RX?B;P'0>5J"LZ">$21T1TF*@Z#
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MDVYB:CWGFFYJY:8(9?*=$OD@I(->I<G0,U]M;73:X9WK-J"=/NUE/>W5&MI
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MASHLWZ[!^2/R1^?J7^C%9"&7;!IT(@)1:6H9LE&YP2,?PA7\L4C9<ZLL6BD
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M^YQQBHR60T)(,DE\JN52,0 A]M+2$\)7*;#"LO%L2[+CPDU!MB!5?7A,UK)
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M?$]0A]WH6"Y>#<;GTR=TP1_*\?GD]8L4UI5C-!Q-3P[_@/R9(#C:@?DU<@;
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;*56;6_;-A#^*P>O&%K
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MW)TY_(;'?*X\7F:4#;]P:&T3-LX:ZTQU=&8&E=3MOW@\UN'$X3H^XY >'=+
MNPT46'X03LRG9 Y WIK1_"*D&KR9G-3^4+:.6"O9S\TW=S>?%_=KV/R^6*UO
MUQ_OIY%C6*^,LB/$LH5(ST D"=P:[4H+:YUC_AP@8CX]J;0CM4PO(G[ ; 3C
M9 AIG"87\,9]DN. -_YO23[#G/28DX Y^3^%NPSQ\1/[3T;P @JVLN*N$AI-
M8]43MX0KP94(F3)6ZCV8(FQOM'12*-@T.R4S^%042*P>!N6V-MH:@KJAK.2^
MS4'P)=CO"??"H8>X'J;C\7 \'L.&Y(,7;I3(D*^<@R^"2&AGAR!UIIK<1_TY
MCH=Q'%^PYL#"P0$)05K;<$R.;AM6@3.!5<,M0@>2#NG''Z[3Y-TO%O 1*9,V
M<)(,8AZ0?A)*&1? 31WNK]10-$H-@2,(J$EFP>%5,KJ*H48Z3PM>OTK2X?BJ
M9<\XGDA?B3<C6(NLO. N>XIBI]!GTM44C$98*6$M+, 05XD?-K"EX +\G6;/
M,ZA'<,\D:C(98FZA(%,%6A=J&\HJ<KYB73$U/]HO(<YTA7?:(92H\JX&]\0/
M#"RRS#3:C>"F[:J5J6JAGR W:$$;!QD+%#(I <N&^P\Y73;:<;;A9'Q['A%/
MQ1L.:_*V&5^RM$)AU\>7DI9*>=J-;=,NN(&"#V&.5=L9'4J;[]:7U\)KV^S^
MY*>_JQ7AMT920+?>0]0U6X<#5>+PAB]'_J^XX&/-,'[6N%)Q)<)!>L&1J#:G
MU,@/!8Y'H"3'S[DR?!*YM([DKO$F)R5Y=ASMI>=,ZI,DSI,;_=.3%IW,A0II
M'Z:?A8#?CHA>V@_813M7OINWT_E6T%XR684%N\:C=U>#-KENXTP=ILS..)Y9
M85GR1P*2-V!]88SK-CY _]DQ_PM02P,$%     @ ]Z*;5 ^]0*)("0  "AD
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M@$P9TG1NBKDC!OD/]-]!PBBW72=P3L3CR,ZG"@BT7 68O9(%0;O7K85"7_=
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M"D,;\'ZIM6L?R$!W/K[Z%U!+ P04    " #WHIM4KB8T5CT5   .30  &0
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M$#O!T@!90=P4^U WJZ2H?=6T;, J#]3MQU(AN!FQ[1$VQ;@ O2Z7&1@4"8%
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M_==X_Z,V*_X"CI,0&>!_+I4$DM "O)\;4\<?I*#]+Q&O_PM02P,$%     @
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M^ K-;W,N,W8/=^CAZEY8;**S=LRBI"#%2(LV_SOWQ<8G+[_[][T!"^0AB5(
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M[O3MJ;[_>?S+PW@TOO\-O!T1@:.8OSOO" E(F>T$I?/KPCEL<'Z5+]K A6<
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M_K@D."1,/2"_GU,JUA?JQ8CJ19C+?P!02P,$%     @ ]Z*;5(ZAL$P+ P
MFPD  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULO5;;;MLX$/V5@; /
M*=!&%U]R@6W E3== 4ULQ'47^TA+(YLH17I)*DZ*?GR'DJ(:C:--BD7]8/$V
M9\X9#H<<[97^8K:(%NX+(<W8VUJ[N_1]DVZQ8.94[5#23*YTP2QU]<8W.XTL
MJXP*X4=!,/0+QJ4W&55C"ST9J=(*+G&AP91%P?3#>Q1J/_9"[W'@EF^VU@WX
MD]&.;7")=K5;:.KY+4K&"Y2&*PD:\[$W#2_C,'(&U8K/'/?FH U.REJI+ZZ3
M9&,O<(Q08&H=!*//'<8HA$,B'O\VH%[KTQD>MA_1KRKQ)&;-#,9*_,TSNQU[
MYQYDF+-2V%NU_PL;00.'ERIAJG_8UVN'/0_2TEA5-,;$H."R_K+[)A '!F'_
M&8.H,8A>:M!K#'J5T)I9)6O&+)N,M-J#=JL)S36JV%36I(9+MXU+JVF6DYV=
M+%?7U]/;?V!^!<ODPTURE<33FT\PC>/YZN93<O,!%O./29S\N823&5K&A7D#
M[V"UG,')'V]&OB4.#LE/&W_O:W_1,_ZFY>84PN@M1$$4'C&/N\UGF)Y"+SQF
M[I/R5G[4RH\JO/XS>"NI,54;R;]B!I;=PQHEYMR:8]1JJ$$%Y8['W208^7='
MO/=:[[U?\T[9G>J2!NF< I<6-1H+3&9 QY<)R_$HP=K;\+\)]EN"_4Z"5YBA
M9@)FN%.&6Z4?()&FU$RF"+&ZH\D-'F/2?Q*J:!#0[SB=04MGT$EG3@[?,2&4
MI4)B0>U<)>C(@F&+.^S$73*!H')828K]6Y!4/:E72A*_U]QRN8&,FU25DK;F
MA$LP6T8[<C3]AT_VH!<$STL_:RF>=5),B!JGG5B4:\%3F.<Y:N+5(?Z\13[_
M;>+/GXB/?E9?Y\?3A>'@HB-,%ZV8BTXQL6#&P!24SKBD:ZDA"]_@M;D3!C\J
M:/#; MBX>G'ZA =U/OS%R+P^M<(?Y37LKJ__:VRBEV;72U;6@OR#F],]6ZZ9
MWG!I0&!.IL'I&14D7;\$ZHY5N^HR72M+5W/5W-+K";5;0/.Y4O:QX^[G]CTV
M^0Y02P,$%     @ ]Z*;5,Q"B2/7 @  %0<  !D   !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&ULI959<]HP$,>_RHZG#\E,$U\Q1P:8X4A29LHQ$)KIH[ 7
M[$:V7$F&Y-M7DL&AC>&E/&!=N__?KJ159\_XJX@1);RE-!-=*Y8RO[=M$<:8
M$G'+<LS4S(;QE$C5Y5M;Y!Q)9(Q2:GN.T[!3DF16KV/&YKS7886D289S#J)(
M4\+?!TC9OFNYUG%@D6QCJ0?L7B<G6URB7.5SKGIVY25*4LQ$PC+@N.E:??=^
MT-+KS8(?">[%21MT)&O&7G5G''4M1P,AQ5!J#T1]=CA$2K4CA?'[X-.J)+7A
M:?OH_='$KF)9$X%#1E^22,9=JV5!A!M24+E@^V]XB"?0_D)&A?F'_6&M8T%8
M",G2@[$B2).L_)*W0QY.##SWC(%W,/ ,=RED*$=$DEZ'LSUPO5IYTPT3JK%6
M<$FF-V4IN9I-E)WL+5>327_Q$V:/L!P_3<>/XV%_^@S]X7"VFCZ/IT\PGWT?
M#\</2[B!(25"0!]F/$HRM86PC E' <MB_4ME&22#.1,B65.$!4:8YB;S5R.4
M)*'BNF-+A:R%[?" -RCQO#-XK@L3ELE8P$,68?2W UO%6@7L'0,>>!<]CC"\
M!=_]"I[CN:OE"*Z^7%]PZU=Y](U;_[_S>$'LKA*[,V)W9\2>N,HRY)R%B)&H
MRVII'QA[?2]W/<]WRE_'WM5(!Y5T<%%Z?A %0BD+B<3(['JQIDD(+X1SDLE:
MHM)MXX3HIMUR?=^_JP=J5$"-BT!C(0J2A0@A$_(?K.-Y9<?S*LQYK<-K?,9S
M?<=KMQVWGJ]9\34O\O7#D*.Y!FP#H4K0>Y)M84=H@1J1?UP3,U;'UOS$YK6"
MMN_Y03U:JT)K740[DQY5H*OKG!^O\P=G'6&KYK@%S:#FN-DGI2I%OC4%6:C-
M*S)95JUJM*KY_;+4?2PO'XP)X=LD$T!QHTR=VZ;2YV41+CN2Y:;PK9E49=0T
M8_5N(=<+U/R&,7GL:('J)>S] 5!+ P04    " #WHIM4RD%DMLD"  !9!P
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M.CD";DI5IL\*-T&>W\"ZJ>UQ,Z!(2M#[*Q55R+4<N6:1@SW(XU6"!5)<7%2
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M/Q=ZCL;"'-#_9YRK[<(XR"?S[A]02P,$%     @ ]Z*;5*XUHVIS @  0 4
M !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL?919;]LP#,>_"N&G%=CJ
M(\V.PC&0N,<,- >:=L4P[$&UZ5BH)7F2W'3??I+LN FPQ ^V#O+/'VE*\5;(
M%U4A:GAC-5<3K]*ZN?1]E5?(B#H7#7*S4PK)B#93N?%5(Y$4SHG5?A0$GWU&
M*/>2V*VM9!*+5M>4XTJ":ADC\N\,:[&=>*&W6[BGFTK;!3^)&[+!->K'9B7-
MS!]4"LJ0*RHX2"PGWC2\G(VMO3/X07&K]L9@,WD6XL5.LF+B!18(:\RU52#F
M\XHIUK45,AA_>DUO"&D=]\<[]1N7N\GEF2A,1?U$"UU-O*\>%%B2MM;W8OL=
M^WP<8"YJY=ZP[6T##_)6:<%Z9T/ *.^^Y*VOPYY#=,PAZATBQ]T%<I171),D
MEF(+TEH;-3MPJ3IO T>Y_2EK+<TN-7XZ63_.Y]/[G["\@75VN\ANLG2Z>(!I
MFBX?%P_9XA96R[LLS:[7\ D6IDDRG@N&\.%.*'4&*Y2PE 7EYH?"NB+2[%RA
M)K169[&O#: -X^<]S*R#B8[ A"',!=>5@FM>8'$HX)O,AO2B77JSZ*3B%>;G
M, H_0A1$H;)\ZH3J:"C:R*E>'%%](E(2KD])70Q2%TYJ=$1JRC4M:-W:WH0U
MYJVDFJ(IP%M>MZ8&4$K!(!6L:35Q?2Q*N":24[Y1KOQ=U7_=&6'(-#+U^P36
M>, :G\SP $N]8^$!5GZ(A3NLQF"Y8O^O!;K GUU@>V6\)N'X6V"?V'_=1_;W
MNIJAW+BSJTS0ENNNP8?5X7J8=J?BW;R[6^9$;BA74&-I7(/S+P9"=N>UFVC1
MN#/R++0Y<6Y8F2L.I34P^Z40>C>Q 89+,_D'4$L#!!0    ( />BFU3B&+]A
M80,  +0+   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;+56WV^;,!#^
M5RRTAU;J H;\:I5$:M)UB]2U4;-N#],>'#@2JP8SVS2=M#]^-A @*V'1U/*0
MV.#ON^_.Y_.-MEP\R@V 0L\1B^78VBB57-BV]#<0$=GA"<3Z2\A%1)2>BK4M
M$P$DR$ 1LUW'Z=L1H;$U&67O%F(RXJEB-(:%0#*-(B)^38'Q[=C"UN[%/5UO
ME'EA3T8)6<,2U$.R$'IFERP!C2"6E,=(0#BV+O'%# \-(%OQE<)6UL;(N++B
M_-%,YL'8<HPB8. K0T'TWQ/,@#'#I'7\+$BMTJ8!UL<[]NO,>>W,BDB8<?:-
M!FHSMH86"B D*5/W?/L)"H=ZAL_G3&:_:)NO[74MY*=2\:@ :P41C?-_\EP$
MH@; AP!N 7"/!7@%P,L<S95E;ET1128CP;=(F-6:S0RRV&1H[0V-S38NE=!?
MJ<:IR?QV_F5^>8,6#].;^0S=75]_N)_??D0G5Z (9?(4O4</RRMT\NYT9"MM
MT,!LOR"?YN3N ?++=-U!V#U#KN/B!OBL'7X%?@=YN EN:S=+7]W25S?C\P[P
M+=.5I '5V7J&EH0!XB%:*NX_HN\W>BF:*XCDCQ9#7FG(RPQU#QCZ\ S"IQ)0
M(JB?F=D2(4BL9%,0<JYAQF5.W=,$XTYO9#\U*.B6"KJM"N8Q590PM$A7C/KH
M+@Q!T'C=XENO9.Z];1#[I:%^JPNW:;0"8>A3[8Q$5,H4@J8DS'GZM0"ZGI,]
M91#S2+]<B'OG^POWI Y*J8-6J8M4^!NRV^\SE&C=1G23V)RI5]?PM\S6)7L"
MAZ7 8;M P7V 0.K"ZX,NFP$*!8\0+;(DR;.$%UERAM:"RZ9<G0Y?2-N%^H#"
M\U+A^?\D+/J]>_.M\03MV<).5?2<MTUB7*NO^'72>%80U=-ST#?/H#FTN*I[
MV#U2@]P0 5J$OC\/9FA!MG=,#BBH"B)NKXB5@ETE_(>&G.Z\IL'I>-X!&555
MQ.UE\64@]&Z0E4X <V0+:8UZND?'I"JDN/=ZM\2T(#ONFL!5D<7M5?;N"<1[
MPAA7NC=3B">FN6I+_*HFXL$;G[&JNN'V\G;\55$0U??Q[ZLBUV#76BK3SWXF
M8DUCB1B$&NET!GH[1-XBYA/%DZS+6G&E>[9LN-%M-0BS0'\/.5>[B6G<RD9]
M\@=02P,$%     @ ]Z*;5(9ZD.\% P  GPD  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&ULO5;;3N,P$/V54;0/(+'-K3=06ZF%KA8)V(IR>5CM@YM,
M&XLDSMI.RTI\_-I.F@;1!K02FX?$MYESYC@S]F##^).($"4\)W$JAE8D979F
MVR*(,"&BQ3),U<R2\81(U>4K6V0<26B,DMCV'*=K)X2FUFA@QF9\-&"YC&F*
M,PXB3Q+"_TPP9INAY5K;@5NZBJ0>L$>#C*QPCO(^FW'5LRLO(4TP%92EP'$Y
MM,;NV<1M:P.SXH'B1M3:H$-9,/:D.Y?AT'(T(XPQD-H%49\UGF,<:T^*Q^_2
MJ55A:L-Z>^O]FPE>!;,@ L]9_$A#&0VMO@4A+DD>RUNV^8YE0!WM+V"Q,&_8
M%&L[;0N"7$B6E,:*04+3XDN>2R%J!G[O@(%7&GB&=P%D6%X0248#SC; ]6KE
M33=,J,9:D:.IWI6YY&J6*CLYFMU>/HSOIC"[&I]/KZ<W=W!T@9+06!P/;*D
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MT=T50=?_X*Z5&Y2IWJX^-2CCO]DE]P"97:%T/ZM2NA\JE7;MS$R0K\S-0$#
M\E06QV<U6MT^QL69NUM>7%VN"5_15$",2V7JM'IJ<WAQ&R@ZDF7F!%XPJ<YS
MTXS4#0JY7J#FEXS);4<#5'>RT5]02P,$%     @ ]Z*;5&9?"<)-!   FPT
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MA#'0^P7GZC@Q ?JO4_H'4$L#!!0    ( />BFU36Z5*@[ (   4(   9
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M9/ABD2K[),=J;H0KQJ72(G-@[&<\KW[9#V?$&8 .6@"A X27 OH.T+\4,'"
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MTDS ]UN!BES'W.GJ_Q*F_P)02P,$%     @ ]Z*;5-,"6R$? P  -!(   T
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MMJQW516:NJ682UH>+BH/EZP7OP%02P,$%     @ ]Z*;5(H3@V1C 0  MQ,
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W8S8Z",!2&X5LAO0#+
M.574B;B:C=N)-T"P@)&_T$Y&[WX(+O CLYB-Z5F1EG#Z)B1/"(<O6V?^VK6N
MNO8NNC=UZU)5>=]_:.WRRC:96W6];<<[13<TF1^70ZG[++]EI=4<QXD>7F>H
MX^%U9G1^]/8_$[NBN.;VL\N_&]OZ/P;KGVZXN<I:KZ)S-I36ITK?ZWG;Z>E"
MJW&RBDZ75 VG"RD=.H@AB,,'&0@RX8/6$+0.'[2!H$WXH 2"DO!!6PC:A@_:
M0= N?- >@O;A@RA&&6,!20NL!6A-R#4)\)H0;!(@-B'9),!L0K1)@-J$;),
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MZ^5?__%JUZ26JCGXL^ZWXNP+4$L! A0#%     @ ]Z*;5 =!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" #WHIM4L%JW"NT    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " #WHIM4F5R<(Q &  "<)P  $P
M    @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( />BFU3)
M$'W<P (  'P(   8              " @0P(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " #WHIM4Y7/.$6D$   ,#P  &
M    @($""P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M]Z*;5,\85P0O P  \ T  !@              ("!H0\  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( />BFU0Y*:(GZ@(  !D*   8
M          " @083  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    " #WHIM4[ZAXOE $  !)#P  &               @($F%@  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ ]Z*;5(65-Y"Y!   IQ
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M965T,3 N>&UL4$L! A0#%     @ ]Z*;5 ^]0*)("0  "AD  !D
M     ("!4$L  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M" #WHIM41UYML.L%   K#P  &0              @('/5   >&PO=V]R:W-H
M965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( />BFU2N)C16/14   Y-   9
M              " @?%:  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L!
M A0#%     @ ]Z*;5$=0.$5'"P  'B$  !D              ("!97   'AL
M+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #WHIM460)&;(\2
M  !B-P  &0              @('C>P  >&PO=V]R:W-H965T<R]S:&5E=#$U
M+GAM;%!+ 0(4 Q0    ( />BFU2VH:^PE@,  % )   9              "
M@:F.  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ ]Z*;
M5""_G@\Y!P  %",  !D              ("!=I(  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    " #WHIM4CJ&P3 L#  ";"0  &0
M        @('FF0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( />BFU3,0HDCUP(  !4'   9              " @2B=  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ ]Z*;5,I!9+;) @  60<
M !D              ("!-J   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    " #WHIM4$E4?E$L#  "E"P  &0              @($VHP
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( />BFU2N-:-J
M<P(  $ %   9              " @;BF  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ ]Z*;5.(8OV%A P  M L  !D
M ("!8JD  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #W
MHIM4AGJ0[P4#  "?"0  &0              @('ZK   >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( />BFU1F7PG"300  )L-   9
M          " @3:P  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#
M%     @ ]Z*;5)18#ST(!   +0\  !D              ("!NK0  'AL+W=O
M<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #WHIM4.[1S89L"  "I
M!@  &0              @('YN   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM
M;%!+ 0(4 Q0    ( />BFU36Z5*@[ (   4(   9              " @<N[
M  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ ]Z*;5%B6
M]IL] @  E@4  !D              ("![KX  'AL+W=O<FMS:&5E=',O<VAE
M970R.2YX;6Q02P$"% ,4    " #WHIM4P@*_Z,(#   /$   &0
M    @(%BP0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M />BFU2@64IU>@4  !(8   9              " @5O%  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ ]Z*;5&T##7B& P  ,0P  !D
M             ("!#,L  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    " #WHIM4TP);(1\#   T$@  #0              @ ')S@  >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( />BFU27BKL<P    !,"   +
M      "  1/2  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( />BFU253D7S7P,
M .@5   /              "  ?S2  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " #WHIM4BA.#9&,!  "W$P  &@              @ &(U@  >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #WHIM452F2CXD!  !>
M%   $P              @ $CV   6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    *  H ,\*  #=V0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>67</ContextCount>
  <ElementCount>167</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>23</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - BALANCE SHEET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet</Role>
      <ShortName>BALANCE SHEET</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - BALANCE SHEET (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical</Role>
      <ShortName>BALANCE SHEET (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - STATEMENT OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations</Role>
      <ShortName>STATEMENT OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - STATEMENT OF CHANGES IN SHAREHOLDERS' DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit</Role>
      <ShortName>STATEMENT OF CHANGES IN SHAREHOLDERS' DEFICIT</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - STATEMENT OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows</Role>
      <ShortName>STATEMENT OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidity</Role>
      <ShortName>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - INITIAL PUBLIC OFFERING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOffering</Role>
      <ShortName>INITIAL PUBLIC OFFERING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - PRIVATE PLACEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacement</Role>
      <ShortName>PRIVATE PLACEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitments</Role>
      <ShortName>COMMITMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - SHAREHOLDERS' DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficit</Role>
      <ShortName>SHAREHOLDERS' DEFICIT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>40101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails</Role>
      <ShortName>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidity</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A Ordinary Shares Subject to Possible Redemption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassOrdinarySharesSubjectToPossibleRedemptionDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A Ordinary Shares Subject to Possible Redemption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Offering Costs associated with the Initial Public Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithInitialPublicOfferingDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Offering Costs associated with the Initial Public Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net income per ordinary share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net income per ordinary share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40205 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Income (Loss) Per Ordinary Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomeLossPerOrdinaryShareDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Income (Loss) Per Ordinary Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40301 - Disclosure - INITIAL PUBLIC OFFERING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails</Role>
      <ShortName>INITIAL PUBLIC OFFERING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOffering</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40401 - Disclosure - PRIVATE PLACEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails</Role>
      <ShortName>PRIVATE PLACEMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacement</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40501 - Disclosure - RELATED PARTY TRANSACTIONS - Founder Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS - Founder Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40502 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40601 - Disclosure - COMMITMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsDetails</Role>
      <ShortName>COMMITMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40602 - Disclosure - COMMITMENTS - Forward Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails</Role>
      <ShortName>COMMITMENTS - Forward Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40701 - Disclosure - SHAREHOLDERS' DEFICIT - Preferred Stock Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitPreferredStockSharesDetails</Role>
      <ShortName>SHAREHOLDERS' DEFICIT - Preferred Stock Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40702 - Disclosure - SHAREHOLDERS' DEFICIT - Common Stock Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails</Role>
      <ShortName>SHAREHOLDERS' DEFICIT - Common Stock Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40703 - Disclosure - SHAREHOLDERS' DEFICIT - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails</Role>
      <ShortName>SHAREHOLDERS' DEFICIT - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ahpa-20220416xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40801 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>32</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-4" original="ahpa-20220416xs4.htm">ahpa-20220416xs4.htm</File>
    <File>ahpa-20220416.xsd</File>
    <File>ahpa-20220416_cal.xml</File>
    <File>ahpa-20220416_def.xml</File>
    <File>ahpa-20220416_lab.xml</File>
    <File>ahpa-20220416_pre.xml</File>
    <File>ahpa-20220416xex10d23.htm</File>
    <File>ahpa-20220416xex10d24.htm</File>
    <File>ahpa-20220416xex10d25.htm</File>
    <File>ahpa-20220416xex10d26.htm</File>
    <File>ahpa-20220416xex10d27.htm</File>
    <File>ahpa-20220416xex21d1.htm</File>
    <File>ahpa-20220416xex23d1.htm</File>
    <File>ahpa-20220416xex23d2.htm</File>
    <File>ahpa-20220416xex99d1.htm</File>
    <File>ahpa-20220416xex99d2.htm</File>
    <File>ahpa-20220416xex99d3.htm</File>
    <File>ahpa-20220416xex99d4.htm</File>
    <File>ahpa-20220416xex99d5.htm</File>
    <File>ahpa-20220416xex99d6.htm</File>
    <File>ahpa-20220416xex99d7.htm</File>
    <File>ahpa-20220416xexfilingfees.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ahpa-20220416xs4006.jpg</File>
    <File>ahpa-20220416xs4007.jpg</File>
    <File>ahpa-20220416xs4014.jpg</File>
    <File>ahpa-20220416xs4016.jpg</File>
    <File>ahpa-20220416xs4017.jpg</File>
    <File>ahpa-20220416xs4018.jpg</File>
    <File>ahpa-20220416xs4023.jpg</File>
    <File>ahpa-20220416xs4024.jpg</File>
    <File>ahpa-20220416xs4025.jpg</File>
    <File>ahpa-20220416xs4026.jpg</File>
    <File>ahpa-20220416xs4028.jpg</File>
    <File>ahpa-20220416xs4029.jpg</File>
    <File>ahpa-20220416xs4030.jpg</File>
    <File>ahpa-20220416xs4031.jpg</File>
    <File>ahpa-20220416xs4032.jpg</File>
    <File>ahpa-20220416xs4033.jpg</File>
    <File>ahpa-20220416xs4034.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="167">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ahpa-20220416xs4.htm": {
   "axisCustom": 0,
   "axisStandard": 9,
   "contextCount": 67,
   "dts": {
    "calculationLink": {
     "local": [
      "ahpa-20220416_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ahpa-20220416_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ahpa-20220416xs4.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ahpa-20220416_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ahpa-20220416_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ahpa-20220416.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 250,
   "entityCount": 1,
   "hidden": {
    "http://AvistaPublicAcquisitionCorpII.com/20220416": 2,
    "http://fasb.org/us-gaap/2021-01-31": 16,
    "http://xbrl.sec.gov/dei/2021q4": 3,
    "total": 21
   },
   "keyCustom": 72,
   "keyStandard": 95,
   "memberCustom": 12,
   "memberStandard": 10,
   "nsprefix": "ahpa",
   "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ahpa:PrivatePlacementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - PRIVATE PLACEMENT",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacement",
     "shortName": "PRIVATE PLACEMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ahpa:PrivatePlacementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - COMMITMENTS",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitments",
     "shortName": "COMMITMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - SHAREHOLDERS' DEFICIT",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficit",
     "shortName": "SHAREHOLDERS' DEFICIT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ahpa:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY (Details)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
     "shortName": "DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ahpa:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A Ordinary Shares Subject to Possible Redemption (Details)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassOrdinarySharesSubjectToPossibleRedemptionDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A Ordinary Shares Subject to Possible Redemption (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - BALANCE SHEET",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet",
     "shortName": "BALANCE SHEET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ahpa:TransactionCosts",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Offering Costs associated with the Initial Public Offering (Details)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithInitialPublicOfferingDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Offering Costs associated with the Initial Public Offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DeferredChargesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": "0",
      "lang": null,
      "name": "ahpa:OfferingCostsReductionOfTemporaryEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net income per ordinary share (Details)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Calculation of basic and diluted net income per ordinary share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_t_dsLkHGaU6hwJ7yTT13rA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_FMDt3RxfGEqzFwOF3AN7gg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40205 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Income (Loss) Per Ordinary Share (Details)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomeLossPerOrdinaryShareDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Income (Loss) Per Ordinary Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_FMDt3RxfGEqzFwOF3AN7gg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - INITIAL PUBLIC OFFERING (Details)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails",
     "shortName": "INITIAL PUBLIC OFFERING (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ahpa:InitialPublicOfferingTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_8_12_2021_To_8_12_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_AvpvGzfBSk6euzkv_rNAng",
      "decimals": "INF",
      "lang": null,
      "name": "ahpa:NumberOfSharesIssuedPerUnit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - PRIVATE PLACEMENT (Details)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails",
     "shortName": "PRIVATE PLACEMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ahpa:PrivatePlacementTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_ahpa_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mz3wLjizUUqg_78s5L5T6g",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - RELATED PARTY TRANSACTIONS - Founder Shares (Details)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
     "shortName": "RELATED PARTY TRANSACTIONS - Founder Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_12_2021_To_2_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ahpa_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_dPb1k23M_k-pLZXh6JaJbQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Details)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "RELATED PARTY TRANSACTIONS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "As_Of_2_12_2021_us-gaap_RelatedPartyTransactionAxis_ahpa_PromissoryNoteWithRelatedPartyMember_xyR3z7AzvE-9dwkUHu1Piw",
      "decimals": "0",
      "lang": null,
      "name": "ahpa:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ahpa:MaximumNumberOfDemandsForRegistrationOfSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_HhKYwaXu10-zi6ST7YVS-w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - COMMITMENTS (Details)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsDetails",
     "shortName": "COMMITMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ahpa:MaximumNumberOfDemandsForRegistrationOfSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_HhKYwaXu10-zi6ST7YVS-w",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ahpa:WarrantsToBePurchasedPursuantToAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - COMMITMENTS - Forward Purchase Agreement (Details)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails",
     "shortName": "COMMITMENTS - Forward Purchase Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ahpa:WarrantsToBePurchasedPursuantToAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - SHAREHOLDERS' DEFICIT - Preferred Stock Shares (Details)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitPreferredStockSharesDetails",
     "shortName": "SHAREHOLDERS' DEFICIT - Preferred Stock Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - BALANCE SHEET (Parenthetical)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical",
     "shortName": "BALANCE SHEET (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "As_Of_12_31_2021_tuaf0fDokEGliNM8DaYPbw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_az1K-giGnkys-SGm47-Ypw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - SHAREHOLDERS' DEFICIT - Common Stock Shares (Details)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails",
     "shortName": "SHAREHOLDERS' DEFICIT - Common Stock Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_f60OhzulvUWffRFATFN0QQ",
      "decimals": "INF",
      "lang": null,
      "name": "ahpa:CommonStockNumberOfVotesPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_Vote_PXooaeoQc0ms4cDX_kIEHg",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ahpa:ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - SHAREHOLDERS' DEFICIT - Warrants (Details)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails",
     "shortName": "SHAREHOLDERS' DEFICIT - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_YoXpIjlv1k24BNqYeu6Xfg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ahpa:ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_25V7SYZnzE6e40DR3Ff38A",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_xNJIoD7-WEGyu2JOFYZBJg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ahpa:WeightedAverageSharesPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_xNJIoD7-WEGyu2JOFYZBJg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ahpa:WeightedAverageSharesPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_uLWUwHra_kGNJlVEMLOHpg",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingCostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - STATEMENT OF OPERATIONS",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations",
     "shortName": "STATEMENT OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingCostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "As_Of_2_4_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0VgzW0WvDkOhioKaphSgNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - STATEMENT OF CHANGES IN SHAREHOLDERS' DEFICIT",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit",
     "shortName": "STATEMENT OF CHANGES IN SHAREHOLDERS' DEFICIT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "As_Of_2_4_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0VgzW0WvDkOhioKaphSgNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - STATEMENT OF CASH FLOWS",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows",
     "shortName": "STATEMENT OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_De7v5mxsIEuxunROFHqmIQ",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidity",
     "shortName": "DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ahpa:InitialPublicOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - INITIAL PUBLIC OFFERING",
     "role": "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOffering",
     "shortName": "INITIAL PUBLIC OFFERING",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ahpa-20220416xs4.htm",
      "contextRef": "Duration_2_5_2021_To_12_31_2021_TFEiUP3fwEim27O9P1ryug",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ahpa:InitialPublicOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 23,
   "tag": {
    "ahpa_AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount Accretion of Class A ordinary shares subject to redemption to redemption value",
        "label": "Accretion of Class Ordinary Shares Subject to Redemption to Redemption Value",
        "terseLabel": "Re-measurement of Class A ordinary shares to redemption value"
       }
      }
     },
     "localname": "AccretionOfClassOrdinarySharesSubjectToRedemptionToRedemptionValue",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_AccruedExpenseRelatedPartyCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the accrued expense pertaining to related party as of balance sheet date. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Expense, Related Party, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedExpenseRelatedPartyCurrent",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_AccruedOfferingCostsAndExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the accrued offering costs and expenses as of balance sheet date. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Offering Costs And Expenses, Current",
        "terseLabel": "Accrued offering costs"
       }
      }
     },
     "localname": "AccruedOfferingCostsAndExpensesCurrent",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_AdministrativeSupportAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Administrative Support Agreement.",
        "label": "Administrative Support Agreement"
       }
      }
     },
     "localname": "AdministrativeSupportAgreementMember",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ahpa_AggregateDeferredUnderwritingFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value as of the underwriting compensation deferred in the aggregate if the underwriter's option to purchase additional units is exercised in full.",
        "label": "Aggregate deferred underwriting fee payable"
       }
      }
     },
     "localname": "AggregateDeferredUnderwritingFeePayable",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of adjustment of redemption price of stock based on market value and newly issued price.",
        "label": "Class of Warrant or Right, Adjustment of Redemption Price of Warrants or Rights, Percent, Based On Market Value And Newly Issued Price 1",
        "terseLabel": "Adjustment one of redemption price of stock based on market value and newly issued price (as a percent)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ahpa_ClassOfWarrantOrRightPriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Price of Warrants or Rights",
        "terseLabel": "Price of warrant",
        "verboseLabel": "Price of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPriceOfWarrantsOrRights",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.",
        "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days for redemption of public warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ahpa_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days for stock price trigger considered for redemption of warrants.",
        "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Trading Days",
        "terseLabel": "Threshold trading days for redemption of public warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ahpa_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right, Redemption Price Of Warrants Or Rights",
        "terseLabel": "Redemption price per public warrant (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ahpa_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ahpa_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the commitment and contingencies information.",
        "label": "Commitments And Contingencies Table"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ahpa_CommonClassaSubjectToRedemptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation that is subject to redemption.",
        "label": "Class A Common Stock Subject to Redemption"
       }
      }
     },
     "localname": "CommonClassaSubjectToRedemptionMember",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "ahpa_CommonStockNumberOfVotesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of votes that each common share is entitled.",
        "label": "Common Stock, Number Of Votes Per Share",
        "terseLabel": "Common shares, votes per share"
       }
      }
     },
     "localname": "CommonStockNumberOfVotesPerShare",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ahpa_CommonStockSubjectToPossibleRedemptionPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the accounting policy on common stock subject to possible redemption.",
        "label": "Common Stock Subject to Possible Redemption [Policy Text Block]",
        "terseLabel": "Class A Ordinary Shares Subject to Possible Redemption"
       }
      }
     },
     "localname": "CommonStockSubjectToPossibleRedemptionPolicyTextBlock",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ahpa_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum number of businesses which the reporting entity must acquire with the net proceeds of the offering.",
        "label": "Condition for future business combination number of businesses minimum",
        "terseLabel": "Condition for future business combination, number of businesses, minimum"
       }
      }
     },
     "localname": "ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ahpa_ContributionFromSubsidiaries": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of contribution to related party.",
        "label": "Contribution From Subsidiaries"
       }
      }
     },
     "localname": "ContributionFromSubsidiaries",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_ConvertibleStockConversionRatios": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ratio to be applied to the stock in a conversion of convertible stock.",
        "label": "Convertible Stock Conversion Ratios",
        "terseLabel": "Ratio to be applied to the stock in the conversion"
       }
      }
     },
     "localname": "ConvertibleStockConversionRatios",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ahpa_DeferredFeePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the deferred fee per unit.",
        "label": "Deferred Fee Per Unit",
        "terseLabel": "Deferred fee per unit"
       }
      }
     },
     "localname": "DeferredFeePerUnit",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ahpa_DeferredOfferingCostsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails": {
       "order": 2.0,
       "parentTag": "ahpa_TransactionCosts",
       "weight": 1.0
      },
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.",
        "label": "Deferred underwriting fee payable.",
        "terseLabel": "Deferred underwriting fee payable",
        "verboseLabel": "Deferred underwriting fee payable"
       }
      }
     },
     "localname": "DeferredOfferingCostsNoncurrent",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithInitialPublicOfferingDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_DeferredUnderwritingFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of underwriting fee payable deferred during the period, classified as non-cash investing and financing activity.",
        "label": "Deferred Underwriting Fee Payable",
        "terseLabel": "Deferred underwriting fee payable"
       }
      }
     },
     "localname": "DeferredUnderwritingFeePayable",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_EmergingGrowthCompanyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the accounting policy on Emerging Growth Company.",
        "label": "Emerging Growth Company [Policy Text Block]",
        "terseLabel": "Emerging Growth Company"
       }
      }
     },
     "localname": "EmergingGrowthCompanyPolicyTextBlock",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ahpa_FounderSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Founder Shares"
       }
      }
     },
     "localname": "FounderSharesMember",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ahpa_IncreaseDecreaseInAccruedLiabilitiesRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, related party.",
        "label": "Increase (Decrease) in Accrued Liabilities, Related Parties",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesRelatedParties",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_InitialPublicOfferingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "INITIAL PUBLIC OFFERING"
       }
      }
     },
     "localname": "InitialPublicOfferingAbstract",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "xbrltype": "stringItemType"
    },
    "ahpa_InitialPublicOfferingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on information about initial public offering.",
        "label": "Initial Public Offering [Text Block]",
        "terseLabel": "INITIAL PUBLIC OFFERING"
       }
      }
     },
     "localname": "InitialPublicOfferingTextBlock",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOffering"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ahpa_InvestmentsMaximumMaturityTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum maturity term of investments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Investments Maximum Maturity Term",
        "terseLabel": "Maturity term of U.S. government securities"
       }
      }
     },
     "localname": "InvestmentsMaximumMaturityTerm",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ahpa_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maximum borrowing capacity of related party promissory note.",
        "label": "Maximum Borrowing Capacity of Related Party Promissory Note",
        "terseLabel": "Maximum borrowing capacity of related party promissory note"
       }
      }
     },
     "localname": "MaximumBorrowingCapacityOfRelatedPartyPromissoryNote",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_MaximumLoansConvertibleIntoWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount which a potential loan could have repaid through issuance of warrants.",
        "label": "maximum Loans Convertible Into Warrants",
        "terseLabel": "Loan conversion agreement warrant"
       }
      }
     },
     "localname": "MaximumLoansConvertibleIntoWarrants",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_MaximumNetInterestToPayDissolutionExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum net interest to pay dissolution expenses.",
        "label": "Maximum Net Interest to Pay Dissolution Expenses",
        "terseLabel": "Maximum net interest to pay dissolution expenses"
       }
      }
     },
     "localname": "MaximumNetInterestToPayDissolutionExpenses",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_MaximumNumberOfDemandsForRegistrationOfSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum number of demands for registration of securities.",
        "label": "Maximum Number Of Demands For Registration Of Securities",
        "terseLabel": "Maximum number of demands for registration of securities"
       }
      }
     },
     "localname": "MaximumNumberOfDemandsForRegistrationOfSecurities",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ahpa_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time after completion of a business combination in which the reporting entity is required to file a registration statement with the SEC.",
        "label": "Maximum Period After Business Combination In Which To File Registration Statement",
        "terseLabel": "Maximum period after business combination in which to file registration statement"
       }
      }
     },
     "localname": "MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ahpa_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the minimum net tangible assets upon consummation of the Business Combination.",
        "label": "Minimum Net Tangible Assets upon Consummation of Business Combination",
        "terseLabel": "Minimum net tangible assets upon consummation of the business combination"
       }
      }
     },
     "localname": "MinimumNetTangibleAssetsUponConsummationOfBusinessCombination",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_MonthsToCompleteInitialBusinessCombination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duration of months to complete initial business combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.",
        "label": "Months to Complete Initial Business Combination",
        "terseLabel": "Months to complete initial business combination"
       }
      }
     },
     "localname": "MonthsToCompleteInitialBusinessCombination",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ahpa_NumberOfSharesIssuedPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares in a unit.",
        "label": "Number of Shares Issued Per Unit",
        "terseLabel": "Number of shares in a unit"
       }
      }
     },
     "localname": "NumberOfSharesIssuedPerUnit",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ahpa_NumberOfSharesSubjectToForfeiture": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares owned by the founders subject to forfeiture if the underwriter overallotment option is not exercised in the proposed public offering.",
        "label": "Number Of Shares Subject To Forfeiture",
        "terseLabel": "Shares subject to forfeiture"
       }
      }
     },
     "localname": "NumberOfSharesSubjectToForfeiture",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ahpa_NumberOfWarrantsIssuedPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants in a unit.",
        "label": "Number of Warrants Issued Per Unit",
        "terseLabel": "Number of warrants in a unit"
       }
      }
     },
     "localname": "NumberOfWarrantsIssuedPerUnit",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ahpa_OfferingCostsIncludedInAccountsPayableAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of offering costs included in accounts payable or accrued expenses that were incurred during a noncash or partial noncash transaction.",
        "label": "Offering Costs Included In Accounts Payable Accrued Expenses",
        "terseLabel": "Offering costs included in accrued offering costs"
       }
      }
     },
     "localname": "OfferingCostsIncludedInAccountsPayableAccruedExpenses",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_OfferingCostsIncludedInPromissoryNoteRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of  offering costs included in promissory note - related party.",
        "label": "Offering Costs Included In Promissory Note - Related Party",
        "terseLabel": "Offering costs paid by Sponsor and included in promissory note - related party"
       }
      }
     },
     "localname": "OfferingCostsIncludedInPromissoryNoteRelatedParty",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_OfferingCostsReductionOfTemporaryEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of offering costs reduction of temporary equity.",
        "label": "Offering Costs Reduction Of Temporary Equity",
        "terseLabel": "Offering costs reduction of temporary equity"
       }
      }
     },
     "localname": "OfferingCostsReductionOfTemporaryEquity",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithInitialPublicOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_OmniabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the OmniAb member.",
        "label": "OmniAb"
       }
      }
     },
     "localname": "OmniabMember",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ahpa_PaymentsForInvestmentOfCashInTrustAccount": {
     "auth_ref": [],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash outflow for investment of cash in trust account.",
        "label": "Payments for investment of cash in Trust Account",
        "negatedLabel": "Investment of cash into Trust Account"
       }
      }
     },
     "localname": "PaymentsForInvestmentOfCashInTrustAccount",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ratio of gross proceeds from a future offering to total equity proceeds which is used to measure whether dilution of the warrant has occurred. If aggregate gross proceeds from a new offering exceeds a specified percentage of total equity proceeds, the warrant exercise price will be adjusted.",
        "label": "Percentage Of Gross New Proceeds To Total Equity Proceeds Used To Measure Dilution Of Warrant",
        "terseLabel": "Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant"
       }
      }
     },
     "localname": "PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ahpa_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected ownership percentage by the founders after completion of the proposed public offering.",
        "label": "Percentage Of Issued And Outstanding Shares After The Initial Public Offering Collectively Held By Initial Stockholders",
        "terseLabel": "Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders"
       }
      }
     },
     "localname": "PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ahpa_PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of obligation to redeem public shares if Entity does not complete business combination.",
        "label": "Percentage of Obligation to Redeem Public Shares If Entity Does Not Complete Business Combination",
        "terseLabel": "Obligation to redeem public shares if entity does not complete a business combination (as a percent)"
       }
      }
     },
     "localname": "PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ahpa_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time after filing within which the registration statement filed with the SEC is expected to become effective.",
        "label": "Period Of Time Within Which Registration Statement Is Expected To Become Effective",
        "terseLabel": "Period of time within which registration statement is expected to become effective"
       }
      }
     },
     "localname": "PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ahpa_PrivatePlacementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "PRIVATE PLACEMENT"
       }
      }
     },
     "localname": "PrivatePlacementAbstract",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "xbrltype": "stringItemType"
    },
    "ahpa_PrivatePlacementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on information about private placement.",
        "label": "Private Placement [Text Block]",
        "terseLabel": "PRIVATE PLACEMENT"
       }
      }
     },
     "localname": "PrivatePlacementTextBlock",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ahpa_PrivatePlacementWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a redeemable warrant (Private Placement Warrant) that entitles the holder to purchase shares of common stock if the underwriter's option is exercised in full.",
        "label": "Private Placement Warrants"
       }
      }
     },
     "localname": "PrivatePlacementWarrantsMember",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "ahpa_ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for initial public offering and sale of the private placement warrants",
        "label": "Proceeds From Initial Public Offering And Sale Of Private Placement Warrants",
        "terseLabel": "Proceeds from the Initial Public offering and sale of the private placement warrants"
       }
      }
     },
     "localname": "ProceedsFromInitialPublicOfferingAndSaleOfPrivatePlacementWarrants",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_ProceedsFromIssuanceInitialPublicOfferingNet": {
     "auth_ref": [],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash inflow from initial public offering after deducting offering expenses.",
        "label": "Proceeds From Issuance Initial Public Offering, Net",
        "verboseLabel": "Proceeds from initial public offering, net of underwriter's discount paid"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOfferingNet",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_PromissoryNoteWithRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for promissory note with related party.",
        "label": "Promissory Note with Related Party"
       }
      }
     },
     "localname": "PromissoryNoteWithRelatedPartyMember",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ahpa_PublicWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a redeemable warrant (Public Warrant) that entitles the holder to purchase shares of common stock subject to adjustment.",
        "label": "Public Warrants"
       }
      }
     },
     "localname": "PublicWarrantsMember",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the scenario, where redemption of warrants when the price per share of class a common stock equals or exceeds $10.00.",
        "label": "Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $10.00"
       }
      }
     },
     "localname": "RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ahpa_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the scenario, where redemption of warrants when the price per share of class a common stock equals or exceeds $18.00.",
        "label": "Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00"
       }
      }
     },
     "localname": "RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ahpa_RedemptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption period.",
        "label": "Redemption Period",
        "terseLabel": "Redemption period"
       }
      }
     },
     "localname": "RedemptionPeriod",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ahpa_RelatedPartyLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for related party loans.",
        "label": "Related Party Loans"
       }
      }
     },
     "localname": "RelatedPartyLoansMember",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ahpa_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The contractual monthly amount to be paid for support services.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party Per Month",
        "terseLabel": "Expenses per month"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_Repaymentfromrelatedpartydebt": {
     "auth_ref": [],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of repayment from related party debt.",
        "label": "Repayment From Related Party Debt",
        "negatedLabel": "Repayment of Sponsor note"
       }
      }
     },
     "localname": "Repaymentfromrelatedpartydebt",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time after completion of a business combination during which the shares or warrant may not be transferred.",
        "label": "Restrictions On Transfer Period Of Time After Business Combination Completion",
        "terseLabel": "Restrictions on transfer period of time after business combination completion"
       }
      }
     },
     "localname": "RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ahpa_SaleOfStockOtherOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails": {
       "order": 3.0,
       "parentTag": "ahpa_TransactionCosts",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of other offering costs incurred.",
        "label": "Sale of Stock, Other Offering Costs",
        "terseLabel": "Other offering costs"
       }
      }
     },
     "localname": "SaleOfStockOtherOfferingCosts",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithInitialPublicOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_SaleOfStockUnderwritingFees": {
     "auth_ref": [],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails": {
       "order": 1.0,
       "parentTag": "ahpa_TransactionCosts",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of offering fees incurred and paid for underwriters.",
        "label": "Sale of Stock, Underwriting fees",
        "terseLabel": "Underwriting fees"
       }
      }
     },
     "localname": "SaleOfStockUnderwritingFees",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithInitialPublicOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_SharePriceTriggerUsedToMeasureDilutionOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cutoff price used to measure whether dilution of the warrant has occurred. Shares issued below this price will cause the exercise price of the warrant to be adjusted.",
        "label": "Share Price Trigger Used To Measure Dilution Of Warrants",
        "terseLabel": "Share price trigger used to measure dilution of warrant"
       }
      }
     },
     "localname": "SharePriceTriggerUsedToMeasureDilutionOfWarrants",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ahpa_SharesToBePurchasedPursuantToAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares to be purchased pursuant to agreements.",
        "label": "Shares To Be Purchased Pursuant To Agreements"
       }
      }
     },
     "localname": "SharesToBePurchasedPursuantToAgreements",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ahpa_SponsorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for sponsor.",
        "label": "Sponsor"
       }
      }
     },
     "localname": "SponsorMember",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ahpa_TemporaryEquityIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuance costs related to temporary equity.",
        "label": "Temporary Equity, Issuance Costs",
        "terseLabel": "Issuance costs allocated to Class A ordinary shares"
       }
      }
     },
     "localname": "TemporaryEquityIssuanceCosts",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassOrdinarySharesSubjectToPossibleRedemptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_TemporaryEquityProceedsAllocatedToWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gross proceeds allocated from temporary equity to warrants.",
        "label": "Temporary Equity , Proceeds Allocated To Warrants",
        "terseLabel": "Proceeds allocated to Public Warrants"
       }
      }
     },
     "localname": "TemporaryEquityProceedsAllocatedToWarrants",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassOrdinarySharesSubjectToPossibleRedemptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_ThresholdBusinessDaysForRedemptionOfPublicShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold business days for redemption of public shares.",
        "label": "Threshold Business Days for Redemption of Public Shares",
        "terseLabel": "Threshold business days for redemption of public shares"
       }
      }
     },
     "localname": "ThresholdBusinessDaysForRedemptionOfPublicShares",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ahpa_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold percentage of Public Shares subject to redemption without the Company's prior written consent.",
        "label": "Threshold Percentage of Public Shares Subject to Redemption Without Company's Prior Written Consent",
        "terseLabel": "Threshold percentage of public shares subject to redemption without the company's prior written consent"
       }
      }
     },
     "localname": "ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ahpa_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares.",
        "label": "Threshold Period After Business Combination In Which Specified Trading Days Within Any Specified Trading Day Period Commences",
        "terseLabel": "Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences"
       }
      }
     },
     "localname": "ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ahpa_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time which must elapse after completion of a business combination before the Sponsor can transfer, assign or sell any Founder Shares unless other specified conditions are met.",
        "label": "Threshold Period For Not To Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination"
       }
      }
     },
     "localname": "ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ahpa_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of trading days after a business combination during which the share price is compared to the specified dilution trigger share price in order to determine whether the warrant exercise price should be adjusted.",
        "label": "Trading Period After Business Combination Used To Measure Dilution of Warrant",
        "terseLabel": "Trading period after business combination used to measure dilution of warrant"
       }
      }
     },
     "localname": "TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ahpa_TransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of transaction costs incurred.",
        "label": "Transaction Costs",
        "totalLabel": "Transaction Costs",
        "verboseLabel": "Offering Costs"
       }
      }
     },
     "localname": "TransactionCosts",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithInitialPublicOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The share price threshold that must be achieved in order to waive the restriction on transfer of shares during a restricted period after a business combination.",
        "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Stock Price Trigger",
        "terseLabel": "Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)"
       }
      }
     },
     "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "When determining the condition for transfer of shares without restriction after a business combination, the number of consecutive trading days used to observe the share price.",
        "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination"
       }
      }
     },
     "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ahpa_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "When determining the condition for transfer of shares without restriction after a business combination, the number of days in which the share price must exceed the specified amount.",
        "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Trading Days",
        "terseLabel": "Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination"
       }
      }
     },
     "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ahpa_UnderwriterCashDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the cash underwriting discount per unit.",
        "label": "Underwriter cash discount"
       }
      }
     },
     "localname": "UnderwriterCashDiscount",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_UnderwritingCashDiscountPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the cash underwriting discount per unit.",
        "label": "Underwriting cash discount per unit"
       }
      }
     },
     "localname": "UnderwritingCashDiscountPerUnit",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ahpa_UnitsIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new units issued during the period.",
        "label": "Units Issued During Period, Shares, New Issues",
        "terseLabel": "Sale of Units, net of underwriting discounts (in shares)",
        "verboseLabel": "Number of units issued"
       }
      }
     },
     "localname": "UnitsIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ahpa_WarrantExercisePeriodConditionTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The alternate period of time after completion of an initial public offering before a warrant may be exercised.",
        "label": "Warrant Exercise Period Condition Two",
        "terseLabel": "Warrant exercise period condition two"
       }
      }
     },
     "localname": "WarrantExercisePeriodConditionTwo",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ahpa_WarrantExercisePriceAdjustmentMultiple": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted exercise price.",
        "label": "Warrant Exercise Price Adjustment Multiple",
        "terseLabel": "Warrant exercise price adjustment multiple"
       }
      }
     },
     "localname": "WarrantExercisePriceAdjustmentMultiple",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ahpa_WarrantRedemptionConditionMinimumSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant.",
        "label": "Warrant Redemption Condition Minimum Share Price",
        "terseLabel": "Warrant redemption condition minimum share price"
       }
      }
     },
     "localname": "WarrantRedemptionConditionMinimumSharePrice",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ahpa_WarrantRedemptionPriceAdjustmentMultiple": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted redemption price.",
        "label": "Warrant Redemption Price Adjustment Multiple",
        "terseLabel": "Warrant redemption price adjustment multiple"
       }
      }
     },
     "localname": "WarrantRedemptionPriceAdjustmentMultiple",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ahpa_WarrantsToBePurchasedPursuantToAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to be purchased pursuant to agreements.",
        "label": "Warrants to be purchased pursuant to agreements"
       }
      }
     },
     "localname": "WarrantsToBePurchasedPursuantToAgreements",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ahpa_WeightedAverageSharesPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of weighted average share price per share.",
        "label": "Weighted Average Shares Price Per Share"
       }
      }
     },
     "localname": "WeightedAverageSharesPricePerShare",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ahpa_WorkingCapitalLoansOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of working capital loans, outstanding.",
        "label": "Working capital loans, Outstanding",
        "terseLabel": "Working capital loans, outstanding"
       }
      }
     },
     "localname": "WorkingCapitalLoansOutstanding",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ahpa_WorkingCapitalLoansWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital loans warrant.",
        "label": "Working Capital Loans"
       }
      }
     },
     "localname": "WorkingCapitalLoansWarrantMember",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ahpa_WorkingCapitalSurplus": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of working capital surplus.",
        "label": "Working Capital Surplus",
        "terseLabel": "Working capital surplus"
       }
      }
     },
     "localname": "WorkingCapitalSurplus",
     "nsuri": "http://AvistaPublicAcquisitionCorpII.com/20220416",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r61",
      "r66",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r61",
      "r66",
      "r113",
      "r160",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r19",
      "r211"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r162",
      "r163",
      "r164",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r149",
      "r156"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Offering costs as a reduction of equity"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOfferingCostsAssociatedWithInitialPublicOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r128",
      "r149",
      "r156"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "verboseLabel": "Proceeds from Initial Public Offering Costs allocated to Warrants (net of offering costs)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomeLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomeLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomeLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomeLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r50",
      "r96",
      "r98",
      "r102",
      "r105",
      "r115",
      "r116",
      "r117",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r126",
      "r127",
      "r178",
      "r182",
      "r192",
      "r209",
      "r211",
      "r229",
      "r236"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r25",
      "r50",
      "r105",
      "r115",
      "r116",
      "r117",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r126",
      "r127",
      "r178",
      "r182",
      "r192",
      "r209",
      "r211"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsHeldInTrustNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.",
        "label": "Marketable securities held in Trust Account",
        "terseLabel": "Cash held in trust account"
       }
      }
     },
     "localname": "AssetsHeldInTrustNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [TEXT BLOCK]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r17",
      "r43"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash held outside the Trust Account",
        "terseLabel": "Cash",
        "verboseLabel": "Cash held outside of the Trust Account"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r39",
      "r43",
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash - end of period",
        "periodStartLabel": "Cash - beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r39",
      "r193"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net change in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Federal Depository Insurance Coverage"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Disclosure of Non-Cash Investing and Financing Activities:",
        "terseLabel": "Non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r48",
      "r50",
      "r70",
      "r71",
      "r72",
      "r75",
      "r77",
      "r83",
      "r84",
      "r85",
      "r105",
      "r115",
      "r120",
      "r121",
      "r122",
      "r126",
      "r127",
      "r133",
      "r134",
      "r138",
      "r142",
      "r192",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r157",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants",
        "verboseLabel": "Exercise price of warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of shares issuable per warrant",
        "verboseLabel": "Number of shares per warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants issued",
        "verboseLabel": "Number of warrants to purchase shares issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r157",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r22",
      "r112",
      "r231",
      "r239"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments (see Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r114",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Class A ordinary shares",
        "terseLabel": "Class A ordinary shares"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Class B ordinary shares"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r53",
      "r54",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common shares, par value, (per share)",
        "verboseLabel": "Common shares, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common shares, shares authorized",
        "verboseLabel": "Common shares, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "netLabel": "Additional shares of common stock",
        "terseLabel": "Common shares, shares issued",
        "verboseLabel": "Common shares, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r12",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common shares, shares outstanding",
        "verboseLabel": "Common shares, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r12",
      "r211"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r89",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtDefaultLongtermDebtAmount": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.",
        "label": "Debt Instrument, Debt Default, Amount",
        "terseLabel": "Aggregate borrowings"
       }
      }
     },
     "localname": "DebtDefaultLongtermDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Offering Costs associated with the Initial Public Offering"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r19",
      "r51",
      "r118",
      "r120",
      "r121",
      "r125",
      "r126",
      "r127",
      "r204"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Due to related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Basic and diluted net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r33",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r67",
      "r70",
      "r75",
      "r76",
      "r77",
      "r80",
      "r81",
      "r187",
      "r188",
      "r233",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic net loss per ordinary share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r33",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r70",
      "r75",
      "r76",
      "r77",
      "r80",
      "r81",
      "r187",
      "r188",
      "r233",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per ordinary share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Ordinary Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r29",
      "r30",
      "r31",
      "r53",
      "r54",
      "r55",
      "r57",
      "r63",
      "r65",
      "r82",
      "r106",
      "r149",
      "r156",
      "r162",
      "r163",
      "r164",
      "r175",
      "r176",
      "r186",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r242",
      "r243",
      "r244",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r190",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENT OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r28",
      "r167",
      "r168",
      "r171",
      "r172",
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Due to Related Parties, Current",
        "terseLabel": "Due to related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r20",
      "r50",
      "r99",
      "r105",
      "r115",
      "r116",
      "r117",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r126",
      "r127",
      "r179",
      "r182",
      "r183",
      "r192",
      "r209",
      "r210"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r16",
      "r50",
      "r105",
      "r192",
      "r211",
      "r230",
      "r238"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' DEFICIT"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r50",
      "r105",
      "r115",
      "r116",
      "r117",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r126",
      "r127",
      "r179",
      "r182",
      "r183",
      "r192",
      "r209",
      "r210",
      "r211"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Pre-money equity value"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r86",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS [TEXT BLOCK]",
        "terseLabel": "DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r39",
      "r40",
      "r42"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r26",
      "r27",
      "r31",
      "r32",
      "r42",
      "r50",
      "r56",
      "r58",
      "r59",
      "r60",
      "r61",
      "r64",
      "r65",
      "r73",
      "r96",
      "r97",
      "r100",
      "r101",
      "r103",
      "r105",
      "r115",
      "r116",
      "r117",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r126",
      "r127",
      "r188",
      "r192",
      "r232",
      "r240"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r61",
      "r67",
      "r68",
      "r74",
      "r77",
      "r96",
      "r97",
      "r100",
      "r101",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Formation and operating costs"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS AND LIQUIDITY"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-allotment option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value, (per share)",
        "verboseLabel": "Preferred stock, par value, (per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitPreferredStockSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred shares, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitPreferredStockSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r11",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "verboseLabel": "Preferred shares, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitPreferredStockSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "verboseLabel": "Preferred shares, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitPreferredStockSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r11",
      "r211"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r107",
      "r108"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from issuance initial public offering",
        "terseLabel": "Proceeds received from initial public offering, gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of Class B ordinary shares to Sponsor"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from sale of Private Placement Warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassOrdinarySharesSubjectToPossibleRedemptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from sale of warrants",
        "verboseLabel": "Aggregate purchase price"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "verboseLabel": "Amount of drew down promissory note"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from Related Party Debt",
        "terseLabel": "Proceeds from Sponsor note"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r26",
      "r27",
      "r31",
      "r38",
      "r50",
      "r56",
      "r64",
      "r65",
      "r96",
      "r97",
      "r100",
      "r101",
      "r103",
      "r105",
      "r115",
      "r116",
      "r117",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r126",
      "r127",
      "r177",
      "r180",
      "r181",
      "r184",
      "r185",
      "r188",
      "r192",
      "r234"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net loss",
        "negatedLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r159",
      "r203",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r159",
      "r203",
      "r204",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Expenses incurred and paid"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r159",
      "r203",
      "r206",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r201",
      "r202",
      "r204",
      "r207",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of Related Party Debt",
        "terseLabel": "Repayment of related party promissory note"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r13",
      "r156",
      "r165",
      "r211",
      "r237",
      "r245",
      "r246"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r53",
      "r54",
      "r55",
      "r57",
      "r63",
      "r65",
      "r106",
      "r162",
      "r163",
      "r164",
      "r175",
      "r176",
      "r186",
      "r242",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomeLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of calculation of basic and diluted net income per ordinary share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r23",
      "r48",
      "r83",
      "r84",
      "r129",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r142",
      "r147",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance at the end (in shares)",
        "periodStartLabel": "Balance at the beginning (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Purchase price, per unit",
        "terseLabel": "Share issued price per Unit"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r48",
      "r50",
      "r70",
      "r71",
      "r72",
      "r75",
      "r77",
      "r83",
      "r84",
      "r85",
      "r105",
      "r115",
      "r120",
      "r121",
      "r122",
      "r126",
      "r127",
      "r133",
      "r134",
      "r138",
      "r142",
      "r149",
      "r192",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r24",
      "r29",
      "r30",
      "r31",
      "r53",
      "r54",
      "r55",
      "r57",
      "r63",
      "r65",
      "r82",
      "r106",
      "r149",
      "r156",
      "r162",
      "r163",
      "r164",
      "r175",
      "r176",
      "r186",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r242",
      "r243",
      "r244",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENT OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BALANCE SHEET"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENT OF CHANGES IN SHAREHOLDERS' DEFICIT"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r82",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r11",
      "r12",
      "r149",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Class B ordinary shares to Sponsor (in shares)",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r11",
      "r12",
      "r149",
      "r156"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Class B ordinary shares to Sponsor",
        "verboseLabel": "Aggregate purchase price"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r12",
      "r14",
      "r15",
      "r50",
      "r104",
      "r105",
      "r192",
      "r211"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Total Shareholders' Deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' Deficit"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' DEFICIT"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r49",
      "r134",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r148",
      "r156",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' DEFICIT"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r200",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r200",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r200",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r200",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r212",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureInitialPublicOfferingDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosurePrivatePlacementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.",
        "label": "Temporary Equity, Accretion to Redemption Value, Adjustment",
        "negatedLabel": "Re-measurement of Class A ordinary shares to redemption value",
        "verboseLabel": "Accretion of carrying value to redemption value"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassOrdinarySharesSubjectToPossibleRedemptionDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfChangesInShareholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r115",
      "r120",
      "r121",
      "r122",
      "r126",
      "r127"
     ],
     "calculation": {
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "terseLabel": "Class A ordinary shares subject to possible redemption",
        "verboseLabel": "Class A ordinary shares, $0.0001 par value, subject to possible redemption; 23,000,000 shares at redemption value"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassOrdinarySharesSubjectToPossibleRedemptionDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary equity, shares outstanding",
        "terseLabel": "Class A common stock subject to possible redemption, outstanding (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitCommonStockSharesDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r7",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Summary of reconciliation of Class A ordinary shares subject to possible redemption reflected in the condensed balance"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r166",
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits accrued for interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r87",
      "r88",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureCommitmentsForwardPurchaseAgreementDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsAndLiquidityDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomeLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Public Warrants expiration term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureShareholdersDeficitWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r69",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted average shares outstanding, diluted",
        "terseLabel": "Weighted average shares outstanding, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r67",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://AvistaPublicAcquisitionCorpII.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareDetails",
      "http://AvistaPublicAcquisitionCorpII.com/role/StatementStatementOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r248": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r249": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(b))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001104659-22-051436-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-051436-xbrl.zip
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M@$<CD6S=0(-4S9<WH7)6&V,?/PZ1 2$9&PS'<;F4DWRFGFXVQ%FXP2-X*&;
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MT)\.V19=2YX"HZ@"63SIK]_+?$=5+&(_(>E!/C840W?1WWY)SMB M2=?84Z
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MPYIC#?&+O0U>]XK>W<(Y>])AFU0HCS$O!]A-6<+GC?'^L25>8N=/QO.&3ZG
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MP#)@IS:9?/P[%R7]CW?X=_+_]#]02P,$%     @ ]Z*;5+YTCXNU!P  2U(
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M[979<7XZJ$9=%^;&I?._&/CY?U!+ P04    " #WHIM4'6[I9[HB  #X3@(
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MU "I7+.+ ,_J=1G $"2EAW& .P'&R-Y4+1AA-\ C1/]U3.?7B"3I?1E99W[
M[1]I0]\QERQC6B)G94PECH4K:;+Z*)6!^2[ !_A)Q5VAIW =%?N>K01*9HY
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M0D%K[;6#L&=(F4H0Z0%);9F.XR8 C"S7Z?L=:^6&EB<E14X?"'N),EER<(%
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M>I%W(CUKZ$8ZP O#'J#HGH69WIE8?=2F>;(+0[QT'9&>]>*K6"?PGQ$.77J
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MJBU[,T%C#-A<-Y3,?BWK ,<)V9A(,IWPF#:,#)(]NPTC@V!<!1=&EFQ0FWU
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MZP<L:B38TY]9((F  EB;P+RQ.ZZ,)IH$4X4@.+YD0WCLPZ:1Q;$HDT#D5\L
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M]UL]'+N?U:2^>RUCG$- MI2FGM.6%"2^,6(^^"!?S-Y SN)L'?:K%8*#U%K
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MTN>YBQ_\ZGA/E];!B2SWUF?+2;D'J;8.C3F8+4:7Y>Q\I68"=LO2IK_UKK5
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M&+J!__.GSI>33P;P[<!Q_=G/G^+PLQ7:KOOIO__K/_[//__OY\__<SN^-YS
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M:GDAJL@.@S",N0229M!;'!2,6I[ %-E@&$=A9/E.^HHVJSIV<N7-=ZK"&;]
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M3DYH;X\*_HA:,N"B<Z\3/HYI6J&ADV-HZ.2'ABJ:1BUO&DE.PFV>'52#2CE
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MA2]4-"OA/@#';L=- H\T903KAZ_G[2C/QOGR8*KRU+TP-=Z^5,\MUF2._ZJ
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M\=1V>_OM?G%X=K;E=GO)@RNV&2UY6*..B0UGY)S1]H>TQ0EAS)$\,]2UKA#
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M7B8EHR1+6N8&6>YU:<[;) QM?.*AG/$I(*OD^+$_FX@0_PD&G-S>/ U ADB
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M7TD(P(@<#W$?->@ .!T<&LI4E.]ZS!EH A>&"M5GI$J2+A8R/[2@8DD*O(]
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M-?$WZ]M==6K68%L1DM7*K;C1= .Z2EUCP8,63ZPG]FG:;@S0)<^MJ5/KW,J
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M7Y5G<1W>%W*MG5G/P)B^E#'MS&(W*MK>G/T,6M-N<J#[O[$#3]KAU3UMGO0
M1[D9DQITJ(&#?4LK'#C8TUCLP,%NX6 :AX*3%1YZMD/UU*JG3E[L;O74EY9*
M+<HLO:U2ZFA4IDOXS[29Y3_^?U!+ P04    " #WHIM4P-Y(^\(G 0"DUP@
M&0   &%H<&$M,C R,C T,39X97@Q,&0R-"YH=&WLO6ESVUB2+OQ7<'NF9Z0(
M6);DW:[;$31%V>S2]I)45?O3#9 $191!@ V DMF__LWM; !(+99)+;QQITOF
M IXE3YY<GGSRM__SXD4K&0?)(!QZ7WO'1]XP'<PF85)X@RP,"GCU*BK&7B^=
M3H/$.PZS+(IC[W,6#2]"S_NPL_=Z9W?GP]L7+_[Q&SRJ*=])DX_>ZY?[[U[N
M[^[O>WM['^'_[^YZ9\?>UGFON4V?/CAM]KZ=M?A7S\X_'[6;WM]>O'SYYZOF
MRY<'O0-^ QZ_Y_6R(,FC(DJ3('[YLG7R-^]OXZ*8?GSY\NKJ:N?JU4Z:7;SL
M=5Z.BTG\^F6<IGFX,RR&?_O';_@*_&\8#/_QVR0L F\P#K(\+/[OW\Y[AR_>
MPR>*J(C#?_SV4OV7/]M/A_-__#:,+KV\F,?A__W;),@NHN1%D4X_OMJ=%I_@
MFR_A[=)G?KRXBH;%^./>[N[?/TV#X3!*+E[$X:CX^&;G_7OS4A9=C/5K*4_M
M8Q;&01%=AOALZZF#. RRC_VT&'\J_T#=-Z?J>Z,T*5Z,@DD4SS_^;R^:A+EW
M$EYYG702)/_K\ROPWSS,HM'_?J)/Y]%_0G@T3(^G^U%FBF\ZC^4/PIN741[U
MHS@JYA_'T7 8)O#Q__FO]_N[KS[]]A(_"LLTO:]!%>&/XD401Q<P8UQ :Y0>
M_M_>/O^!0^X[OW@5TH+WTW@(;[9^C&'0\/G=G?W7O[WL_Z(Q#N 4A=E=!WG4
M^.P=M1K=UD,=X.=6[\]6Z^2A#J]UW.I\\[J]1J]]>N*='AZVFRVOW?:]HZ.F
MMW74.#DX.NT<;#_4X</X'NK0FIUOL*Q'WN?V:;?9;ITT6[[7/FGN>%N]UDGC
MI/=@U]05B9/33N_K@QWJ),SFEW#5AK[7A >.TBR)@GL>[35*WA[1#?4\7XG\
MO^-,/:T?#+Y?9.DL&;X8I'&:??RO7?I_GZRKS7UCS#\-B_4ICI+PA?Q[5X;\
M KY2I!.^B>4EZY:55^Q+MGQ]3X.+\$4?K)7O+X(1[-/'(+X*YODGOEW?OX>+
MX>^?^FDV##.Y<7=+U_*#N.QIH8N@'X=ZK7G,L)QQ,,W#C^H/>^_?P@+(BN*/
M#. =$%9G(8-9D;KK2*\XL^1UM.>(KUA#_IM'1P%F16<!C:T,_F^HQGH99D4T
M"&(Y,1,0K#C4#]C9>_5W6T3EIY2XOBR&-WW6^U<['^[K66]V/NQ?^ZB7-,]E
M<P5!O.E$?\%9;W1Z[>91ZW_^:^_M[J<]/KE+E\ ,]]JUO)_A.H*&2I-5:Y2
MZBD^OJ!7G"E];G3!?R"#R3OKG/[1[H*.[]Y@:JQ*/EV-HR)\D4^#0?@Q2:^R
M8'J##??4_[W;V?MPG]._UM+5MXBU>P]0ZFZWC7HY]U_SW'9N(IMJ U<IGAO1
M>_*BM_\81*]U<@XVK7)QO-:_OK8_MWM=#[P'K],^:'6>OA3N/VDI?/48I/"@
M==@^:?>>A]9[]:#EK<[,\VZBRAZ^A7?6:1VWNZVN[_5:G6/?.VRTC\X[+:]W
MZGUI_P%7[VD7WL6[UR?]=];H_-X^^?+T)?+]@Y;(G]. ^X_#!&3C#VY@):0;
MJ7O<4O<HK#_4@T]?T#X\:4%[% ;>XJMV(WZ/6_Q>/P;Q:YZ>'+25C_M\;MB]
MW2<M>F\>@^@]&R?B@0M;K5][D[OSX?NUG=9)[QG(U\..%M?*UTTNQ\<A7U[C
MX)_GW=XQ_-F5X,@W^L=&\![U+?KZ<81'RB*XD;I'+G6/(CR"0*\6RANZ#0KP
MMQ&]1RYZCR)@\OGT]'?)PK::('7/0>,]Y43LZ\<1*&'\K7?:$31*]ZS5;!^V
MFUZO\:]G$3%YA,G9FX1!'KZ3T6TUSSOMWC?OH'5VVFT_!X?V$<K:VR<B:YT_
MVLUGH<]>/V@9^[D[]>WC\"):1ZUFK]-N-HZ\C> ]$<%[%#Y$XX"37B!XZ$@T
M#GNMCO?U]+SSG.3PS9.6PT?B5!RUSKZ>GK0V<O=4Y.Y1I%X/6D>-;UVO?>(=
MGG=.VMVO[9,OSTD$WSYI$;R)*[)V$6Q^/<6J\=-#)7=<W_,LZBJ>N/R]>PSR
MUVU_.6E\:3T#87OWH(6M-IAR$PEZ^,$4NVKBO-LB5^.YXNT>MA#^G,9[]SB0
M D8<21+/GUM5Q1.7P4<1\5-0 :_1!$^CBZAW)8"?O,89FH"-HV<@B_M/6Q8?
M11#P_SMOMWI>Z^2?IX37>P9"][#KRFHMP?=/PA(\;K1/"$#0? 8.QP,7LY_3
M;>\?AZVG[EGD$=M[]ZGK;23PZ4C@H[#T&"_U3.7O81<VUEZT'Y[$1=LXZ@EG
M#T-$V\?H4K2>"3+^@<O=S^F]#X_CYA6<J"6(&[E[Y'+W*.[;HW;K.8C:JX==
M@5%WM0H5Z.[3N&"[F#BCRA^\7[OGGX]:O=ZS*.-^X*+WDW1XNX_C>MW(WY.5
MOT=QS79:S<99[[SS#+S85T^YZ@P&^2B2%*U_49[L>1!9O'K8=3\_+7&/!)-,
M#NQ1N_&Y?=3N?=N(W6,7NT<!20;#[OSXK*?0*8U>[[1S\CSRLJ^><D40#/)1
MX)'/.J=XTR(0OO6OL];)LX!$/7#)JTU4[#V-IBH'K</&^5%/B"R.6P?MC<"M
M7>!^4M4]DJ8JK3^(J^STT!,AW,C=8Y>[1Q$[J8!2GI'>*Q<]OJ3.<O^0?GZ_
M8+&=GH.;%H.;%H._NL7@XU.:=PD OGN_:K.7'.'6-ZTT#UOWHC#?[NR^>\@*
M\RD#Y$'V[A(*7+GL?6Z<_-XY/^LU[R,(^- %[BEC1D'@[A($7+G 52S$^W-0
M'KKX/6P(57TDYM;-SU8A4+?G/#OO=%HG!ZW./9=#;B1NC0KO;LW-5J[PVB?>
ME]9)J],XV@C<8Q>XN\1@UG_#=MI?OMX+-OZ!2]_K1]B$9>_675@>Y 7[]?3H
M /-JIW_<"[G/1M#N7]!NW8[E00K:0>.X\:7E??[F';8[+>3J/NU]!;NNV>B>
M-X[N!<JR$;XUWK%W:\FR\CNV>_ZYVVN<]-J-(^^<JQY[]P>FVDC@6B7P45AY
M[9/G+8-/&BE_MSXM*Y=!;DSU6?H$/0.A>])P^;MU:5FYT/W9:/_!@3SL4'7>
M.^U\NT^4P48$[]_UN'63E@?I>K2.VR>H\ Y.D>EB(VJ/6]N]>1R.1J_Q.\55
M#KT_OYX>D<-KVWUG<,8VDOC8)?%1.!Q&$C="]Q2$[E%X&,W38RS4():59R!R
M#[M*K=ZXNW57M =IW&$XI7-/U&4;*5NC8GO[2.PZESMO(WY/1OP>A3%W>-HY
M)E/N]*C=?!Z!DR=='G2WIGSKAZ8\)[WWQ 7PL06/SS]W3K\\%\?BB<O>HT"^
MGYSVI!W:,P*K/.Q.D/4>[:U;4SU(C]:HNN91HWTL9,DG!ZWCD^>!$'C*'?CV
M[M:0:HWW+0OA1NP>N]@]"O=6JSD$BG*H92-Y#_*NO77SGP=YUW;.CUI=X?GY
M<GYT;Z3P#UWBGG0%]]WZ *T>A(>RMY&UQRYKC^)>;9T<GG::SP7M^; EKOX^
MO76/GP=YG];02&$+^=;!\ZEE?(3"MW_K_A</4OA:W=[IV5GKR&NV8&*'[6:C
M]QS2$T^9'&7_;JTO-EP!&X&[L\!M#+J-Q-W#G7IK*N0'>:=V6D>G30J+8"SX
MV43D'J/ /0W&ITZK<>2UL$*LY7WNG/[>ZCP'I^%AT^_4R]O3($ Y/NWTOC2^
MM%K>6>>TUVH^$US)PQ:XG[3A7CT.IZ%[_OFT<] ^:?R:SBH;$5RK"#X*-^)Y
M:K\W#YL'I?ZZ?1HT4(RE>P8FW2.4,6Z&O/\TBOZ/V]UFZ^BH<=(Z/7\.XO:4
M:77V'TG-_Q$ZK<VOC<Z79Z'AGKC(/0H#[N34^^=YYYO7Z[0;1Y^\/UHGYZU/
M^%*[>]!^+N;<$Q?$1U$A!M+6:1^+,_L,9.XI%\."S#V*HK#3LXVP/05A>Q15
M8-)[NW'>^WK:>1:%.$]=[.[2^W@-B?X>\F4WOG1:SR3;_]3%[B95BFL7N^/3
M T;02>;_J-7HMKS#TX[WN772.FSW\$4=/7Z&0KEI$KII$KII$KI>37J3&K2R
M)GV[\H[>_VJ>'YW=GUN\_Y![*;]YRGP5('$WJ=)8N\0UFLW3S@$!"I" L7O8
MN+] X$;ZUID$N4F=QMK%KU(#=/KYJ,V$/?#W"<CD$9&I?#YO4^^IC5P^>KF\
M2W9NY7+YN7U"K<Y:AX>MYOWXT1NI6Z?4W25!MW*I:S;.[H]48"-OZY2WN^3A
M5BYOO?9QZY/7.#L[:C<;G^&F/6K\^<EK@@3V.N?/Q0Y\V.1E/R^)=\G.K=X-
M^0R&X.G]H9DW(K=.D;M+CF[]K@>Q#GB]4^^LU2'JY!)]]\%Y[[Y(E#?BN4[Q
MO$LN;^7BV6TUSS%U['6_=7NMXXW8/7JQNTLN;^5B=W+J':$>]+U&NX.-J/YH
MM_[T,*&'=_-ST'X/FV#OY\7P421".BT,2S^71,A3%[E'D0GIGG?^:/]Q3Z0L
M&WE;)QC_4:0^.NV#^^(K>%S2]FO1,/3KK_2O.\@8^M(5HRGZ:3S\=$.HC![C
M,,JG<3"']4]"%^U2WMWJ[]YA:OBHNXYY ^]9+;SGWH\5 W$JYVK?B'9_H5S3
M8X;A(,T"'&AIK\OOXKY^!)$(,_RK\C;]R,<\C:,AXN@/#['!!6'\?GO9+QV0
M7S;YY?.UN#%7.*9;;,C?_O&YT6TW!1IYUCG]H]WE3,^]CG;QV/9V]KS?9NI'
M?J%\+)KG[-YW10R"O?=+)]Y.O&(<>N$E?-9+1UZ0S+U!FHSB:%!X_;"X"D/Z
M1!YZGX,\&GA'80!_GV4I*MHTR>$;0_H6:((PD[>GZFW?RV>#<?U[7CX.XAA_
MK<C2>&<]\]_:V];H">8-.3CHM+K=C[].[/#_WK UUIJ$V=SK%B0IWDF:%>.5
M_.Z;#^]WO:_P<_"KW2(+P^(7GS)[OI=1'(>^UP2U,4JS) J\#Z_?[KY?T_[O
M;WLJU+WN_3\=C:)!Z+7;OG=TU%S) /;V]G>]DWDH4N![W1F8T=[KW=W5"$0W
M2+Q., K"N"00'W;WUB00K[8]59\$XM \[W1:^/<O%XNW9E4<ZU@9U5%"!F8_
M3@??G0GAL\3\>G]_QO6>MJ[Y DO2;!+$CKTM+\&:!=O:MJ;_G 23\*/7S.9Y
M$<3>YRC-!U&8#.#4MY/!?6KZ)[2&_=(:HE8(\4J.$K EIF).?+2.R4K6\20%
M9QN>5:1>+TP"7!2ZMONA!UY#%N9Y.%S-J6@49*J<9>$DRL-\-0JJ46!! 2U\
M)^V'6>&UBL'X7G_]-LKI];9W@,P8JHSHHQ?D*"/_S_I_OK>_N_MA30-\LRW&
M;:_5.?[H=:,?Q=S;>KN[S8PXQ_#D<>YM3>-93E;C-,B*"'3$!-_P1FD<IU?@
MBM).-]/)!+7&!&W3 S@-V^LR$M]NH['^SU:SUX(KX?3XN'7"A,&T&Q^]P["?
MS8)L+K0_K]:Z!>_LP;;^==;N<.D9#[4'"QL'>>$-@SE*#BYT#KL4A;#^L%'%
M>-L;S= N#^(P&0;9]5NS$@\-]__7W!P_52"V*")2"?[8Q42_W/O&8*\V]<3#
MW82]'G?8ZX:G__VV=WQZTOMZ],W[C'H8K5=04&EV>W7KD98&6X/>)J507(7Q
M9>AM[>V+0G>U1&X>Z7NDZ^,YQ@U"KQ/:EL-_[[WQ]W??[[S=];;R(!IZP02D
MKT CHT\1@A=@[81#,'VJH][>\<ZG*8<MP+S,"J7%BG&4%6&($]O:>[5(C\F'
M>V$VD=!%,H-1S?%5$#>4M<5#!U,LHR!&'S\/'I,W#3,\>M[6J[^OZW9RS+)I
M%DY!L<L^E79'L%HUT]N*=L(=V);W^_Z;W5<['\ K!L,"'A+C?]V'+MY\6%MZ
M6F/XURPO6(Y".A=PY>OE]8;A"'3&<-N373P00Y?B0^NZXC]LTU$AG&^CTVH0
M1_M7#-*UCMO=5O>C]]:'.\#+_PT7/9R&^XV9W"IBM;OM=<_;8 6>G!]_;G4^
M@KO^9EUCV8.Q*"C60>OLM-L&;?/?;_;\5V_V04=[6R ZX"2@#4UJ!L\,N-@L
M/]=)91_^&BHIR> 5T &H&+Q@.HVC 14+@\HHE$DS!]VL#C@'&_&8@\) HZ<;
M#F897.I*)(TVFJ(&>DBR" >LC*X\[Y+1;Z3Q2YB$&:Q'RD$C5&6XSD$V&-,_
MAN%E&*=3.H2S'#QOT%WQ#.\[6*N^?#XF+0MOYVN;ZBNP5AN=W]LG7SZ"7J?M
M#!,/A9QE9);@M+)+&"=< ]]Q_)3DS?%R$$V>T;\O@@R,!M\;H8S!%@[&\+/A
MNN8%GIIP[M^G=VP/X=7;^M">1#".8(O!9!N*".7>YRS]#H;4]8$1,6I>[>Q*
M+(2MWN/H>XC!NE$(MIT7%%[S,QQ3$,%6CJ&*%<Z2%EJFR;??72>YO[?SX9T]
MR4XT2+WF> 9B!C/\\D?CY>_H V3><5" M%VMR_'?>Z/#DNUC3!RQ^]DX.CK]
MLP'.Z$<5G;F*\,X>#,*I&RZ1XQ*!'9B_B'),NPS)7O7R6?^O< !F5()64.I5
M!">X@!.%BL3'-<'+/$]!\PY24+FH1\(?TS!!%0-?INS.$/21]]_[;WQP%79V
M=]70VA-\E^W+!IJ) 5B;8O.11L<S/LOR6<"F( [_SS3['H/ P0XTU#"\K=:/
M,;AHA??YE]E<^Z]WWBS=D19<OJV.)G5I_>MK^W.[)PUP$;NRKH'A72?KP\FY
M3H3RFX<%FO)@ ??A7KABV[<H@L$85IT6&X2"+TVT;TS0D<UPZVVR?>%?63@"
MDPZV\%<IN/JI[A*8:>?U&]X&7G>OX?%UL>A_S^(@P4OA%T0/[SKDS]<,N4[T
M'\"PFR_VG($?!7T4DS2;>YU9'(K,A1>SF +6#V&EFR_VG2$_M'&2OO#VKI&'
MY?_;^@%V$Z753Z<XGY5.Y]W.ZYH)[?_4A*KAB%]Q"IY;&'!_$P9\M&' :Q"4
M_$%X\[:PS:<\J"K0:W\U0*^#UF'[I-U;+[H+P[Y@48-,PB]@ "X=^1S,-9'?
M,)OD$@L9!Y=AZ>U)&"3PW_Q7V7C73*!Q>-@^:E/BJD'(-)T(]V!J#"OKSW+8
MCCSW,,A4H'&*7@IX.+,,8T;@U*17"<:1,H4UB^%?_;F/K^?6R[F/_X!OTA[#
MJY,)_@Y\.<O'T=3Z)'A98$BS6[.FR(D"K7%&KS^+8H[MI ,RV0/V_B1%[^73
M<!"-(K;EN^#MP0KR-;NWL\?QL<_J$9-@+L&B4*)+/H:,?##XBR"*R6[BE5]C
MX*@F"8N3&**=L'2R&,]FOSA%KQ<^5#$T?!" &%=M, Z2"Y(5+YV&2NY&7@,+
M$, #[EVE:YP^-CKKM!K=C^A,H]/&4 !K<K"5Z(I?PJY1K!3FH9Q[;Y2E$Z^
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M' 9CEL#8A>?/. &O9Z<NFMK?5[.HF,7Z?E$8#0U<5E8W1DAG7([/7B5Z'),
MD_B@D>#$J%P&^PIPSQ3J_L0,WRPJ%*S'N/2($";9\ETTBB\NK"_'S-<NAU_O
MJ-!-)Q_!2XZ#.7A6YC"J0:"'8KFM>G6U"I6+KF;E/JD0*ZLL17#J!)^OW;5/
M1EM=<0Q#.2-V4*169^#0PQ^TINC;""C&<<)O(C<6#O$B"PBG;0"E92Q/G0!M
M65(0D;N=LZH>XT]3?F,$UAUIYZT?8%HINRSC^(*64O[F(%1WT-?@/T$V!,\=
M"Z9#LD%8N\&(9VZ6U'=!JU1*7A,L7O!(GCO*FL^(-4Z4I5&\S8<2PPCH^U&P
M>F@<U1O\N&/X_"@%3+0KW@\9;N?";[6A"T]M,H*Z0<CFRRB-.5TX]R[!(T*W
MU\0?]>X-TF%HI\Q]AOM=D?;DQ+!@HDG<8?T%U682XCK3'9&(@QSP((<EE),.
M2L(?.7AHX7"'4[UDS5$MX2)S3M/A4)4 TKE@R$Z9+>4HF*.8V$W.G3P"'AP3
MB>8R##L$G(1X;0096>R3X/N-%YT#OI5H[Q03M*C-5K*J0H),:"IEV;LH+1<0
M(7$E?+@ AQ,VX+V#* _([\<Q-!C&N/?APZZW]7K?.^\VJ>#RW2?^W[W]O=V]
M%WO[^WNOY!1'^ARG(\N6!">$Z)5<)-FH?,?V=81RV0>]+59_!#%&60^HTA]7
MW3+'<4"#;;@_A@0ND_BT%@$QH%5>B3B@3); ^3DQ:\G.F[M3L$>BC_0VGR<R
MHO"R&Z@@EKK'U;?96R&30)N-6J?FP80VF'[A"A2*A8W#[V$FD@*5UG<M)<\F
M[U#KE0P]+J9FJ0[,U>!T@X"L3!6^913]D/CT=#K+Y!I%X$5*!3JH^?S2<1$?
M/+#'KT/;%?_,.&A-5P&B5<UBS&I4J0E?PL_&P27G&_/]%/55;K@JU$(M;4[X
M:,$%J C%[13E@A@<JQDZ4$-C_:J]JYB "RP\$EYC1RKVF5$PD!/(=5.F5@X]
MZ/!' !HG5.9D'E;GG7\$J<"_J6C^$YI(P7 0Y(7[=$=\R6^/1N$+!#S#26 ?
M2R$.."I0N?#AD,6S9# .,4T4S_H(-Q^%=(5:(84A;Y'\,(PG":]RV-4$I'0$
M,PNUH_()<2@A6)1):%X:!!G<M&,VK,8A:%B$:X%M!QYO:08/*33Z0(;QR"*T
M;S81VD<;H;U-;6FY:$P71NC:K1=2NV6=>$MU171G@_[1MXK$*QSCTB 4 JKB
M@&N<#"7'] MR2<N).J^#?S+PDU0:>N\&H2G:6T(33NQ.[*#,A)EYR=&/YDC+
MB'"L="\LO"?X*81+K:U\@=\9PY=>#(@S4"^0[_G>.)WE7,]EX#1HFH"!B+E0
M"C[QJ-%J&X/G18VAR&].\3&#0)IG1/T9Q[04/M:8&?1UY;]0$ :SK3/XKPJN
MX63)A;06BPSXX0QLH7GI972Q(I"_('/>4#^D?HGT"%[^?$WS%<-QLBRX#&.S
MZ"HE+) .MC=4+(>O'\0(1"/T$?IH2Y;'$6% W!(T<;(I/&-'1WHJ L%WDL+E
MZL(4*F<<4@6+@HO1/VJRJ9+;I^J6=94*+0CYHJE'>7**.*#KG7"JVY?<)T4^
M)^R\!/RVIO'DSPF8.9V6K58^G;)U"M2+H0DVS>'A,9O[4H(.;M@%?T>E79U?
MRFMA2Y6H!>??.9&+^UDU#JT _C "*SQ4[@2.A"*8:1RR?@DCL4A"+FF7.DOR
M-JBX?9&;H?/YJ(?P(-HSM0/4*J1$\UYC@;QABD0CE2@3-3E V:V0'>?>'R>$
MH $]E!>+*NBIVFX:$<H"UFHE?!J*\JV!;!H/I,)(:-;I/N@@QK/WC9=;>1'H
M4$:YP5>(N"UB:\BI"<O-2!LT2K#23L>WO99\EHT"X0=E@DSMR%"Y+$8H*C)<
M >@C 40RS!&>)V%C^XXN@RD5G-<ONU J*D2.+0&=IKK80L6)&,#AO*4\7/3W
M!NA]9/"B]H%]E11EI3S%M$4QRVUA-YXP[LA?X!.Y=[3L#H9T+E*8X8ZSB:CH
M@CBG0CDJOL[DFM%$$NO$='=:C:.J]'$<D[.RR@&OK.S:1HSU &YY:X7[UR\S
M22N^MGIZ:5_7I$CP7:$B#<2.@J_*!.)/<9XQ-\:E\(_CU:D#1CH:IV(B:UPV
MKW'PS_-N[YA6T&1*84I7H3UDO$2MY' ]&+87_% QC,I:6V@Z75"OD1(V$#)*
M=(G]83K+'L;:&";J1J*2R;#%(/IU:5I$NTXT4K>R&'C7D(FMS&6JUG'(Y*W(
MLF/A@(&3,!Y?1XNM>J(1/\GY!J?@BW%UE-0.B-E/A3^]O/;;IDJ<=):>%U4-
MI$4TTO*!L$>,9/,PB/^CM @U(D.IK1&+#>>O9^7A[X#NB4PJ>Q1E6 @E(L0Q
M-_N>4<O'.U0OJ)5?-0\NV:WUD^?0NQP3,7RTHL='#"31LF-:H^@OVX/E(Y&%
MQ,]AI0WRL@@LT%&*5 @GQ/5:^M&T.>@WUVY/((PW"JB34$<F97]?@ 9-KF'V
M&<X($1V4-FM]9W4)RW[/$0C%MI^FQ,)B2&Q_<<W8<POLO=T$]AYM8.^Q%Y)7
M^T=06H4@?M<P_G"<D2J^<7T=&\BY1BGYJM(EHVHM-]P[(^S$)TB&,ECL@9B
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MKT/(;6N?&XZQN7B,LB+*7BM1?VN.=@?M),E:WQJZ<Y'H]V\R4LN0\4O#OK%
MN0NJ",HU*T %WDQG87C3J1F:A_N:V'(Q%51:5 26H:1U%U/)NXG[FV@:#!R
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MJ9RGL;I+P2GY9+XICGV*T<-7F^CA$X@>ZK@<[VJ=&L'+TR+VC-B.#)T[@&]
M$^0?(@!:##U%G3.PZX=*K .Y=(>6U!JCB$5[N1IKIT9;)JEEW+.12D;3(F/>
M813VX>N9V[;*IK?!9^A_*\X%YMJ >U+5XUP%C <0[4\V-5U&?.6O!*Y>5[YF
M=A:)]U?B]GZQK1AV>1<4JK%]J*(/9>/+KFP02TO5_-@76#FC'0R*&>?NX(OA
M!7(C+PA[W3S8]7/VOM,=L>J5L>UB[&SMZ/K6B]J@TX33(*N4T,0!L&4H=MM-
M&^[9 2-JH\'64&V0^5<LZMT7=$T'Z-W*XD8JFFZG/?@(@9.*=XSH.?9A4._
M<EI^/AK$U60&7DI.Y$-,:RJBM&+)[':K:D1K""47]2+#OPW^""%'1>ZV/PS0
M"D7?-%_LX> Y!S6. O07> /Y,)* S&7)#B=)O12BRZ7L+H7BA;>F%1#3OS)1
M#=]#87](2!U2E=*X+;7#4FX)WJZ2MX:[1\/MSU6SOJ34>M$X$F"/#T.\V[P+
M\$@*#?D>1GDQR_JJOV,=WPT>)NQ.FSOG21:AKY()VDN&+<HL/T7'KMFH+\UA
M9K?D#)%#G]QAQ+E$"8CE?T+B!,M4C[XZJ$0=*8_QI<R8*NZN2W8$'PUA$2FI
M!+=%,%/<$-J#4I3YY@H1'Y2MF@(K4).*E&@'6L_(]76L'\!UCKBO+@7P[VWB
M<)GB RCV@@->=,21S<SH$"ZDOXQ )<(;NL3/MV(3E#<:SW/BW;*Z"]1$2:^I
M#[B6NZRT><I\&\[D(G+,.&E;:D)/UK1(1?&LR'J37*XR3Z^$!K!NOG[M9-.L
MDI"]61;VMDO .MOC9JI\26IOFU(G,3O8&7K<J4D-<L$*4]?5K(AOK8>5V':.
MMD01R]1?LKDKS,&\7]%=>NPLA'N7ZG5%4R:3YG78*C6-9V VT6&R)(MPP3>#
M"'A"KE'Y-$;1O*UB[*A+>E'38ULQ/"J9YKN+J+Q/=6^.%C-TV%QT$HR2>,Y
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M'0C-'?NQX"M6^B8H+V#.K @@!#,AFS7\Q4.Y8W*JH"AJY<AA8R[M.,9:C9$
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MCX*ZLY'$6B6>69$HMRP"K'[M/S4ON[E"F.(\6$.6B;&OLZ("2FB<$K(>><0
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M.(MJE'YV3(-3\2A1XXD8"CRO.?RZ+B^1U\22UN?HU26*_Q# D^_!&'TL]QG
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ME2/O>X643='] '7:N3,<EVX+_H^;;J3#NBZ<Z40V+*A)0V%^Q2+5I^V/8%N
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M&8/C*:52N?J8^*H)O<],Z?X>C72E) _3'P4;PKL; 6P"PRLTTBA7/I*C'?O
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M (T\JC7Y,@%CB<! J$SMB1_,R+;8J@A]@;Y?+K5:PL7HS+T;^_Z356LR0+P
M1U'3NM'\$)9&^G@Z>46VFWN PW(K$MK>)6NVFTT7W5SR4;"4M[23P3:%(]1^
MND:;T4(NWA%PG\Z1QGC1XDZA"AC3]^)W,:_7U"4FG)@U+8$EO(686'1EA#S9
M:-PCM""^8]W4=[_I"H:PU??<NW5'BR:$#W/6;/#M 9R.:,U'KQTA3;AM E0'
M>##6"$-M-%KUJ^MGK.[ ,2WV8>122^'O2,S'HGADDEGR"HN%(^7Y=1LK2.(F
M5J)[8:1C%,CS[&B/I4 K 1PS7L4C7DV)7;A1$HL>3&D[+^]-?.))PI5-S5TG
M1/+6D'GOH@(>+8.ABX[)7\2_VI124F4=OH70="^UOKW>!K!IP8KI%A><&RXR
M(B8%379,)",C#Q>_7/0.'"&8%(:>'H Q7&$%33_;C)W##L+@PO#8W'2!-C<R
ME3<MDO,)Y4]5*ZRR6\ %*JD>PVLBUR>Q:CDGXV6:>G6K=3CM;<+8'^^&ZTF#
M#ZZ<8_*>,IBFV0D,\D@8CC/;_Z656:8Q)/U$ +:V\TL7?.?RAJ!VX%D/<Y/!
M4E9Z;4;0$;H9NX!\ O8[ES6W/QO< %868AC+%LOO?3[Q *#1<C1H+"\3,OJI
M)C\E5^R$5P/+U4[KY*''N*2S-LQ#APGO7%\K)1WYM4E.<K6D7;^K3Z+DI!*Y
M5(9%F3&Q,U8?2>+76OTF''A_>)#5UYOY[A+$<*HB[5=EK_I[IOM^?DCW?8?I
MOOW]38G?]*B:MLZ!WB<+(M<3*["!.(T/\7LH:R9TJI?:IA4!VJ; 21;W:_FK
MWX'\FJRT.P)F@>!+ KYH;)WV[TPF):J,]IK($G)Y\ 5GQ_DI I+NBLNM$D4.
MBYJD%159JA3:ZQXI3R8_^+Q*3K]IP(#;<LF*1].CE$G=U/+,S#V9T\C9Z$OW
M3B>8#NN RIJY9[ >2PC5X631851YU--]5,1*W,[LCT.LA7?.XXF;:51;(G7B
MCGRO,X=F@JHC8DMQDJ#Q0=/%0>-9"GTFG>#:?F%!(M3]X$;J.[CYVQ8^&V-1
MY6+("-![<<(0TBN@3RN!BHGRM]^!"/]EQ6G*?%NZ >[K,1"_4!\Q?'"OZ0JC
MSR/1IPBB$4Q/KED+D"#GCBWR8DO;-E%8Y#(BFR0M@W@*+US[S? J?U82Y/%]
ME00Y^W!Z.CA^/3@%N8SWIX-W1V>;U 1YO"E-D*/C[-?!\>#TX.UV*0N5)>S<
MF(772(T529\)' TV "'\PIRTS60C!54Y012,2<O.O7Z##_"0*Q3<([>149H=
M[37>FW@O-657=*Q6HLP&AWPLD P'CEH[GF^@T9&N5;0$#2![8CJNAP6@ N=+
M&V(P+@UZS>6@S+.KYJ;$2 P-(ADZD'2HVN%BVF%TUY'E4/AL(-+D*:O\?4 I
MP[,STX]\1D?<2/ UJZLQGSO+RBV9F*G8D([-IRL7X<RS5[!DM=(JU%E&#I=.
ML"B2!T^$+?SHNO*<6P)=D]D2UI)P GK=VFZG[ESL[H6K5-9<D!)WO_\(,KR1
M!.Z>&_(DZ$K/6$6OIY4;:JS;)TWK?^%YC-TV1^;R6ET(B.:4>-E3G,VY?*S-
MV*CK*[&QL@P$U1Z?_S:+=1V'8Z*E8>4L8ZJ'7Y"G^B+WEH$#N5GESJY($0[X
M5F 3L\*.ZFDDZ-0MA9@IXX7S32=ZBK'0G,A25W?7:ADPS-XM[MX;YNZ@QY'E
M1JX0@AH))D3<P&T9BFRC=>B4#F_EMXNN:X85PJ"I1P$4WZB_'I*4X;H+5E'0
M<U\H3/Q4]L<IWM(]IY&52_P1WQDMW#+-WH!IF)IRK%5[@UYZ6U0([Y\T36LI
M\RZ*^57'$&&WNN!OUUC!<5\!NF&W-4 N)>N6SCQ/^9-,I@[38XV#^U,@E4Y0
MS%$)*2Z<L-33&,6WJ8@"JJE%V%OJ$(O, [^AWC% Y0Q<H0J>5O*D<6H\5AO4
MRTFM8.E +GE&TKHCO(:M&31URQ<)V(JH[)[7S?MLBV5<L_$5T5^9SF'2:P3V
M#L2DJPZDW[^Y&A+(_AG<;ECE",\'Z3. >_I+R>DS [H17R$W'T"9IOZKVT/F
M7'?O_4>9";8ET$ZTWM%P>RV6X2C-P]C3CX?7)<8'IF75RO*=50^IRR]/7;YX
M2%U^AZG+%52M-RBT9MT,W9DH!\?LMW!X2:=HB9AK/O7XEW3R"78F/!3&U)?B
MEM__8'L"-<?@-S#I0'AQ]\,$VS HYZ6=3KZ[)2ELZPU(%'D5DZ[I$<8ZOW_1
MU@(4;,?%L!0'%UT0"9F"W,?01DMA@T'ZEC:"&4Z 10=3)N N ("S\U6HQAU.
M^/0B,$'S& &EUB":1"B%'/A(W!LU%'4PFFHB\&6DT0VG<1!QP; K=$J<BS%L
MJPL('XE=)3B$=X"K=R5%[VZ^^DS.Y69LMD/27G*%&F3B+6G)A$R\IHG5*_,0
MP_8(*OT?R[7WY@P6\@<1V@\=",M;4\+3>ZHR.#KA\/K:2)>U>96M*4,<_?K;
M^1:;2PXFAMN43)46SLF35523;8=-*!IP5AIC!&C.7]@B+U$/*NF1@<C%#$(K
MEMQ=6(EB(B'N<T*X%S.D+@//UUX0?;PST0KHVYNVK*872%+7(\]+]'XH.5QD
M0Y5REO=B[[2@P?*&D0?1F?<RW&Q +<F^S>7/T_'&?<OS/KFO>=[?3MZ^!N7[
MDW\.3K_%&+^@\\LR44+RIB/5H%OXZ+54=TL"%=@-=*'N/WOT#[E40"XGI&Z2
M'\$_!JG5&40JN@.5^ )&&O1F#%OLR\4K)42)@]0<165:T1/-]-0N1<EDR+1Q
M::9;=%R,LALQZ.?G VH.2!7ZC9]/BOT3)!%"(N,/Y( MQ3=NVK(H=J.B)D*[
ME%Y86Y;UR% +<T$6L9'V*R][[]CSUG=(U%+CI[#T"&WHD$"[=QO_Z7W=^*\/
MWAW\.LA>_2M[<W0ZR$Y.LY/SWP:GV>'!V8>#M^?_VERMY^FF:CUG'UZ=G1\<
MGQ\=O,T^')\/CMV_#UX=O3TZWV+?"W:)T)895P0H9^5OJ8GL2.;%14$+EKY8
MU/S#;D;EH$XY DA\V.TM@&)&:9F8)NC5HIIP%XJO],09EERZ:S6Q"T7D&36%
M>KMKY>P%O(#&*5=#1J%?65_."2B+%5M,!5>25/2!CGD,8.>%EI.2+\'Y0ZZ:
MJ\/MF1,NEEHFCFL<U.XB ]J12D&<QC[&K_O,[I$Q7_)MP[SE@6_X4'=X#K;&
MR0?!Z2#69F14O7(KG& N[N:PB=VBV/]Y#23?S+Z\EU$$_<A-R:L:?][J01T6
M6'6(-K4K9Q7%?!*B6&@Z3OH([+BQ('-9H1/9KYYX4@8KLR70EQNW\=P</4Z@
M>3BR72:A'_36\SXRQ^\(%X%?-0V6HU9\'8]Q/*3-46GEF4+PQP,J\LM3BT\?
M/:06_[*IQ<\L>WR@])VQ'Y&46QSFEL9'=U9M5K3%95O,KGH5!.[&7'?,82(K
MLM5E+V1E3L<^3$+3?X2:XY,]8&,U]T5>&XH8\)3'RG!AP@88PQND'WY7_%%"
M096^(L0+76.O_#\-]GJ^+6[HFQ=RZ ^;$2'N:L_:V]-^0EM>-T8S16O7"=4V
MSMC9]LFDZ:_&]@#L^D=YBT O&-<82!OEV#3H1JY\,;A0SN0P_DFQ1Z]_YXQ*
M')8B)! ?UKVQ I?.'"Z#I64O?M*6EPUFD2LI42NP(GF=3A]:;\LE43P=64Z@
MRQ[_Q 6S7A>>7U?\3D*QR9"%V)Z#\?&:@ >)HQ2%;:&;E#-AU)*H'"W"$<<(
M#\>;N !E&VAF7-]8:$>9O/5J<-!=EIA?5D&"7NYN'R!05$T.A1VLY-]\[%HO
M)@13 "&-2*LG084^AH\SU3AX?[1)M]<6F:)YC<@MY4D#(X#=6W[?J2"=-W!8
MN<%P0>*=8=&V5;2CU6G-0R&L&"K$I&:4OX'2@[UQKP_&- (B:."F[@MBY9&0
M(;T/MZ=GTU@(1Y+*L2[ BF0E J"XX5-&HL/5Z9245%20F1ONOS CUDKW/.T
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MMXJ^&11(X3JIAB$K,[#'@GO/U/BHJK?DY);H[QE]K6XOLU>B;VFUL@;5D0"
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M+%!T&*U[3*@YU(FR0\A([MDE\7JKOK0*5&&@P(D,0%F/FK83Y@Y"!2)[!:*
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MS+R BD!MH1X,JQ.8G\?C^7)8I<3^WD#[1OO.^;CT]1&I(QE*V!6TQC0D95W
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M^CS?/8WI.6)V6TS]?[8\S+MGM #TP/[Y"&X[B/*;CLCT;Z5Z-%UN[9\39TR
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MSAP9:TPMZB<81XHCU[]GQP=.E7$(FY;#<24._SI8.TNR@-Z[KLX$^LSKKG&
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MH]+1M5SU4.*Z<RDK7;ESH$U2%GPH+'CH_IUX: >U2(5\]BE(_*&,_$&#PV1
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M_JWM91S[926W<;*?HOT.#WTQ%JBC62$"S8G0WHV^_KT?/,E9E/]^@[;B%W:
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M4Z@>\J7*) Z1)-)MSB-L2CGI1LTA.F\*#XL12\6EK[&1R(,%=$(+[_R"D3?
MXS)VY(=T45 UTGE0>I%:U+P307$PW(E%@$)5))%.&H=>!A3VS]GZ*M1KGKCU
M]RU;&0;A%XR"(4>+ E6@4@09<3XBMC,:63H%$8JQA<Q.EXP'C\[XP>4[8?B
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M>F1J7, 0IQ0'QL$HWYL#3RM*A 7@OQ 9!'D]<#@?(QQ)')BJV0K$0HA_(6I
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M734OD[&2Z:*'G7\3Z KO&L;8=1_*0)1KP.=R*=,3( 1,"P!90-E -40X#3=
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MQN9:#'SN(D/]53(/;!*]4]'+P062-PCS2JXS?]5].#SM_^>Z(IX/V&V2096
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M9A.4-L\ZH97V)-5UJRPTF>$XX/BTRY:M![J*<@L9921C)Q&C> AVHF0?<M$
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M^ZPT&8+E5[CE."T00)@;(QAV(.CH"+4(KSN6_D08Y-U1FR?/&V.L[."]P*U
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M(GCLHVZ0$U76"V^J:,A8$,NOPT/"-WSL0:5HHMAA#9Y*@ZW4QQ__-CH=#:D
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M=>)5*DCLU&5(UE:P[QUAW#\YO9>*W=T=[&TEVVL[0?<.S!WHJ6JR'@_GZW
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M4Y\_H45%G.;&VQ1C)BA ^R:;P &E8U?='$<E=R/OC&'M4>U)NUCLBD#H.&3
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MH(9+C2*VM014GU[D7>T,@\X3+KG-5*]N&40??77"" /X-Z+9A>O"U^FK#+8
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M(@Z ( J-%_Z0QLQOMA2%CD,!Y:BE&,BVJL)\Q3V4A4&MD^%>S2FZK\I%QY+
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M'E/!2!R'ED9HJ]C*3TJ3LL-1=42C?R6X.[\U=^UUL=,.UBL(MQ!:]'YU686
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M& _]Y,H%$/6%LN8>CK)EU8#5J'32V)*SG  O-,8^+\VMX!1.X TX.H:#UAR
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M7 V7,NTD8XM=7_F481/JQ23&8)]-D<O8NQ0.6X^YAC_;072[T#V5S >SQSN
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MQ8+8K"!\<40U@>.9J"+@$)UAE_O""']TE=9E\8Q^N"KPL",=D:BY0]LWTL
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M\:31B#TBQT-5/CHX67EQ<3+HW<.3_091Y^&%BM$X&':#E)\Y/&B(HX.CPX:
M[PQE/Q#="?6J&XP?@B 6YSW0Q9C*<!I"0N<C^2#30$3A,,3VHE"RY1&]9#B2
M\43L+=-=JUF[ESPADPR<MS@+NREH52;.T#;1S)1Z$">PKDGZ:I0F@W ,GT]'
M*K^]7!?:9V?E"7H(Q_<"//0HZ!$-X?A>0K,02<@P?N+Z/=R'O7OQ(#.Q)_=Y
MQDDG8.+"&)D.9T_V>=QKEL9J#8[OQ4#G!7SI%SE1ZXC+>/BN(?:Z,(DH"_ )
M:-UNT;Q(7[4DE27CYSP.5&-'NC5\8Z^G>C[(T_%]D.KF^:\RRT#5X?4]FCYH
M'B?T\.U)!IV.,VA^?ZH?,'!K_5'(8>Q_Q<E#C!=H6_T_)5H.T>K]G8=L5F&2
MN11LWWPU'R[]T:=\)(K$*$^S7#(EI;17E>>K-4K#R)K]HP.8F22^*ZL,] W^
M*[S#7E_?RW0(G\TI-LUP,M2Z(L<E/)#0_&JNS+TL!^%YDN U<(Q98BV57B9[
M]F!<.!1FZ%S*R-AF5BM.4[3E*!QC+[#-(!UF@H@]D>L3- >7*,EAUH)!&/-$
M9_<XOT0"BI\>!A*9LK.BE_ :_L%\[SG)/5>RZ0NG@UA.6YV&P.FP64[[$.:#
MUH[5 A@C J8*0S404<UG:D9XXN0(+Z]^;XA;'.;9U<TI.=>P'*C322*M?@^>
MQZD(?X21HAK"3D?98S7841H,PPR&@D)("Y^/<QG!PY^#&!2-M!<GR@@/:SM8
M>:4:=TG"(OQ91CG=DBA]B"4Y#7I!.&(=R7(DO@Z#N#?!7K ]1HN*[:,=[*%)
MB(+^'6J)O8825P;5:)!$4?*0<3*.KV9PZ/F_WQQ\ TL;12J4-#]G(]E3/S^2
M5Z"5HLWV/7C35_AB\!XZE$J]_SX^:+YYV2VJR1,>%;_"2)P_==B<M;_>6'=^
MR/6GJF?:Y2W*5QR(@YF#P>&O033/X!T8:$-8O\-1_/!M_F.3G"G)"<$^A'$/
MMBP9V[06^&WP$4.(7<9&WG_*0<[&9)CI#;('$'/E(^5C9/&5_Z8D%5K" ?>A
MXC8;)?^$K7>Y=3 ^O33LLA5=RWR=?KF'[2?X4IP5[LV<2+A!NDQJ!B*0],D.
M8OSYZM?78@\F,,HSI*N'WV(H*4<CL"ND<N FM2GAYX\%;0U%\.5>YIG^&_AD
M^(#R9>I!Y:CT/'*0"7\[>O7K85-TT,E:\ZYG6_+2L:OJHET(*:+"-:\$,/9"
M*.P/-=[FX92AIZ^3U<K&%")B!#.2V1CZ+N'=7M#4C63BL E3=MA\0R]!:Q"+
M[87[,]HL+%H:@(M!1]^#U<*11)/FG#33SAFSHUTT9D9(VM##,,Y1N$\' Q Q
M-F(MD&_VKAR[30D7JP#X;@QAR![!CZ#'O8#$,J"VFN+6?HD"4&L?LL BH"Z,
MPW$^1BL*;<#?,7B2YOMZ=V1[Y^F]6@"^OOLG_CB48S0,.*0@&7CA5Y\ZWD'A
M;Z,-#U*4FHRE?3I)(XY9%(=R@G8^^!+T\C%[3_1!<8[9$M2*GM580P02_(8)
M*8V; ">>I"$,%5Q)"(*=YL;HXQ/ZA0;\@R(M_\+_3\!O@[0V5#.%1L >/S#1
M0P;Z5*C%/+E>?Q;O_Q;O"6[(</1Y#LD.8'H7\Q^HZ>ASHXG Q*SH1C+^"S<0
MS7_[M+E/FV\A=L#"G?ECF_'S2_'[^>WE::<C*/-P1?G+\JZ5<BH]2?F7N3[W
MZ?EH3%D&HI^#QAH[B>_T@P@6#].:T@00?<G)S0E\1PS"%")<V86=OGA(0W#0
M\7/F=+8?D^'Q"L=*C8)3)8YS,_KE$L<EZA'6/[ U5<R];1Z_J<O0EJD;.6J^
M63MZYPN.Q\O=NBL;IV3)Y;)&+T'U&-K*TN9 S:(W:_40R@K5KS=L7H:<TG5O
MV)P<C/M"6:7(J*EE.T5@X7;GRLN1-V[U'FP]A;+6*:Q*P>H.+-?.VI"M&8^7
M.Y^S\EL[5R3(1S_>K#DGE#YGY67(95WWALW)P;@OE%N2L^H$,1:T_Q;V@@(]
MP N5MW3U'FP]A=+U!%9+W5KKKV;WZKD8.VLAMF8\]90[UXW 8@KKQR^B^^RV
M-Q^U&(^7.Y_=]DD@5R3(;XV\67-.*'UVV\N0R[KN#9N3@W%?*+<DNSU% [5]
M8K1>2%_';K1_[?7USTG8?^SV^K?=I#^!?^['P^C'_P=02P,$%     @ ]Z*;
M5.;=L)R#[   8$$) !D   !A:'!A+3(P,C(P-#$V>&5X,3!D,C<N:'1M['UK
M=]M&DO9?P>N9[$IS*%H77V0IF7,424XV:R<>29XY>_;LAR;0%#L& :0!2.+\
M^K<NW4"#!&79H42 [CF31"1QZ4L]U=5=3U5]__]V=LZ3B4A"&04_7[U_%T1I
M6$YE4@2AEJ* ;V]5,0FNTBP32?!>:JWB./A1J^A:!L&;X=Z+X>[PS:N=G;]_
M#X\Z-?>DR5'PXOG^Z^?[N_O[P=[>$?Y_-_CP/MCZ>'6Z35>?_79Z]3\?SOFM
M'S[^^.Z_3H-G.\^?_^O@]/GSLZLS_@$>OQ=<:9'DJE!I(N+GS\]_?18\FQ1%
M=O3\^>WM[?#V8)CJZ^=7%\\GQ31^\3Q.TUP.HR)Z]O?O\1OXMQ31W[^?RD($
MX43H7!8_//MX]7;G$*XH5!'+OW__W/Z7KQVET>SOWT?J)LB+62Q_>#85^EHE
M.T6:'1WL9L4QW/D<?IZ[YF[G5D7%!/JZ^]UQ)J)()=<[L1P71R^'AX?U5UI=
M3ZKO4N[:D9:Q*-2-Q&<[3PUC*?31*"TFQ_,O:+LSL_>-TZ38&8NIBF='_WFE
MIC(/?I6WP44Z%<E_#O@;^&\NM1K_YS%=G:M_2W@T=(^[>V1ZBC\V'LL7PH\W
M*E<C%:MB=C114203N/P__G*XOWMP_/USO!2&*5M5HPIY5^R(6%U#CW$ G58&
M^,_>/O^!31XUWG@K:<!':1S!C^=W$V@T7+\[W'_]_?/1([4Q!!1)_;6-/ $0
M1@ ED43!A<P+PM4[!0_-97!RK:5$E*ZQ]5<3E0</:V6PA3*QOWM\?X_=3M$-
M>\?; ;QD*B()*B5X+V;_\9>]5[O'^V\& 6B6W37U?#2C_HYD<2MELL)&?*6H
MO!T&/Z?C,;PAV7DGX%WA1 ;OBFC%PK&\=;1$P/( C8"II\')8@%_I>-@5.8J
MD7D>B"+XW[_][6__]S!AX$Y@#^@F*PYKFG'HT?JG>7&.XR0<]G^2/UXZ@#\V
M7>.GD%HQ%P5%>BV+B=2!EF.P0T#1%&D@\N#!;W+URI,,&>@L:#"H+AE,5BM"
MO1/>.!37,AD$[]Z=XC0$6^-43Z6.9\&G)+U-<!Y/HM\%=B8X"?\H%9LVP6DZ
MI)N.\0J1Y]!C*8.Q3J>!?22B8$ #G0E=S% J:-3!1E!@,"XN1T\S^8^ %^[Q
MVL28P(>"/'B4U]HQTS+/9%@0NI-[IC&XG:AP$MR"8! $0"&H!&ZBA\CQ&)\!
MO\%P8^O/Z0LPDH,S,%*"+?SN(6/^FWU_FWDRP!=$<@R3B?9 G-YN#Q]K;!I6
M^)/:W2O>#/"^B?\]T?91(Q%^NM9IF40[81JG^N@ON_2_8V?_T_QAPO,$<GH<
MPP3LF,^[IKT[<$N13GF[9KYRMF+F&W<G-K_'RP!M.R/8TG[:$6,0L",1WXI9
M?LQ;L,/#X?Z+[XY'J8ZD-MNRW;F]F]\1/MF.<&$9_-R*="5&,2GC4_@-;LX?
MS9*Z9\#V'SYB* #4U1^>H?S@T07UP.*'Y1 @$HLLET?V#[=9K^!M!B4H."%W
MO"F6+/BN4-) XZMV8C%+R^)(E$5Z[$@=-D7#/U&EG:0N5"AB,S4 *'/YP?#E
M=^[ F!?905K-P#>Z0R-,8J)@HYH41SOT36-R]EAG/R\BZ@2,7)X)&.;]9TLZ
MQ)KE&-:?0N[ M:$\2L"<$;'IYIN]X>[AXW>TT8DS7(4(_'FC-U_7@Y?#%\O:
M']A_7@_WWJRR._<<[^ DU;UZ3M+VIR7NT3K2:#>?6*Q@2EX-7[QY8IG:&^ZM
MH.&'+X8OG[KE)V!TQPH,/8\%CX4586&_KUBH-RX>"QX+*\'"0=^Q$%Q)/?6
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MH:].YS@4US+9U,!I#X:U5)GKJ]_9@.&_D_1VY^=T,^O,>4BL!1)]]4$;2'R
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M!4GIF],9HZ[I#/=0EB'-^2FTPC N.E%>G2*P60P&>#X2FIP=.2R#%$A0Z2^
M&XBWJZSH9&2*Y[197#^&7L47X]850Y;H\&54%OS4ZK!GS"='YOGX;C2NENBB
M;TXHP[X+)7\4"5Y_IL1UDN8P UV0LC59<2X->> & X'!%J4Y]AO- O+]5-8!
MP5+FF-_$?,2UB^G+.7]!*0KJ@1NKZ](D7!@&)_!L+<=2<S7Q(K7V8DL&@_E
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M.(Q'V"["6W)X/<1<5(KCT=B8' 2?%,!JI%)"NF8<ZQO*)X M,\8B8I#N2:K
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M-ZN!%_O#PT5%<'_1K<\K%WSJRW7JERW5+>;(K0 [3R92,^GH1JBXD5Z-#+7
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MB,.F= #G13<;):=L,^5FC2J3J7EO"Z.9MFKLNYO9G:E*&L64D/&/<42 ZCB
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M^H+*Q8K@"OHE"Q,<3=%391&S3P+??)OJ3R9+>57N)I,:3T$IJSHTN8S@ <,
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MJ=S4M^=[1HK9M5)KK%K/JWU59A[L>0JV-ZED^&F&GYHQ-2&W$02L24.1F60
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M2P[;>&_2D6'M2#-\Q-;31FQMRA'EY]7;N@\?-^B8:S7KB1_O%8_WF@\,-VO
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M<7&Y31H&#^GI_A?V=+][/=T?!I>9#&%?%>)C7+I=3M>-RZ*$%O/E2'\;RN'
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M(RI$_-L5)R$C1I&[4-(I^N]E7H"12^?>$Y7YM9"G]?=N3:M[;@ 3RLF:ZBA
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M-]P;.&?="[^^M.<K\H;Y3Z*XITPZ,GVQ\="B:!B\-<'(QM3:H[Y5EEBCC?D
MQX$&A++,V&-Z,KG(W5Q7C]FB(3SBWF\OO.:@^>2YE%A</6E5[WK!$0]U.<KY
M3JWPW8^WGCN"^Z.@0CV)FUJ$PM=K7EP=BL[\ E/ODT5R3IB=TVFG$&CCU(JZ
M3@+*)W#6;=(NRP-V;-OQ@[&B-]:, *&H'8PR:X[#O'%Q3CQ#&V!2C+J3#X(8
M)06VH'SH6)A[OZ9_S>0MN'U8:-RBCE@R"%H6.K5C#T] *H?-,H#904!_<'HI
M'*!;*B_ J0*0$IG<T]:GD<A+'@_SWOF);]>62T:BL4.C7=@#-FCFV#=BU6>'
ME *+,2L 3"S1'NV]K4'85?0%S7Z89D[Q%GH ^B*I7U<3I:.J>#0],F]*G^N@
MG!?31@<;I9YH]YHX>2,HJT0%Q'^4\$:IGV9&48>&L4 ZP,#$;^@<1S O8-JL
MQ-/T+NC)J8CDLK"3KSFZFM,,BZ-<(=&1HZK@%A)B"2E.'J9FFIK[L>/-3=?<
M[%G>"*>4;G!.QE$'SKKFCY/*C)FH10K80A@@/7 "J-)<0[Z8[1033*YBCVAS
MM/.J*XI)6N8(I+F3V[T7!X/7YNRVE=$>3A0\B),N8)Z5F];*W%6^N2KIOF,E
ML(G%A#O72\B&:&;&VJ7I-XQ7D*=EZT##'B8%!%U+;TG1F 4=&[WP4N-3IR,"
MAJX])>#=-K$CLUP>V3_<>4/DF;, W!Y3!?2D>00@RB)MG@#0-XW]^6X-8',-
M?F/V_K#7?A:0+H#M.-:GTZ0R;#/-ZTVZ\:5JA"%AGOER;_CJY7?N/GL.C<X)
M@/-\3$P[AC&UNVW[>0>5T1&?7MS"J'WV5,'@DUYL+Q4CHE;*8^>,H:LG"NZQ
MTIQ:F]?>J=72^\-UCOCB,%N%N%'#W9#R%R^'AR^\E*]NV&G1N]=8:=,R1H_:
M-3F[PW+NH+GMV>KR^?G3HW(X/R@+RWN;9?*U$%Y]<WG16_SW UK=AH0USP19
MLMPZ7L>:G3V9IB5,RQ98'L9N(2L##)/M.;OK:T405=Z3]OH^)TY7A.XSFN.A
MNN)KA7$]<^*((ME;]T[2U\F<%ZNUB)67'"\Y7G*\Y'C)\9+C)<=+CI<<+SE>
M<KSD>,GQDN,EQTO.O.^6C[<[,K!/$C._U.TZYUE-$^(5A535PZ30;X9MFB(H
M)D]+&0N]Z.IUR2 8:>U\M,&?5&T%"4'.<PP5CQ*CF$3[->4N*&"2KSF#*O5@
MX%;4(R),2644L+DT>/1XXZ_&BGC\7"ZM-9H%D_06*VS-FAUK;],P^"VI$Z+B
M3>A]AYF2>8%_-;@BJI#3W"TOT.;05KEUK5-C1&-@Q&(+!C05<7J+Z6&IHW!C
MF53/J-J2FYE;,KC5=)MRL7 EI?8822HH9IY&7,B&8&PA08:K53'7KC!%Z&;.
M_1E6DTA++/*$-ST2TW&>'*'3:8:59S#4=UQS:6T(4!H2NXHB<4V=F$4T;#E%
M;?B;)L6LHA4L/K$6L^U!E?S7D=N'0J\B-=2!0RWTJ.:[YU[%CW\87<H'E?B@
M$A]4XH-*OI[EU[/B+9<"5LB :?%$ WA*=E\+H:]6\SFV;(>Y['.<.-#?]Q+_
M8'V@DF?M8=E[![M58';-E6^2]G\%HX"'!E,=459,G<Y$S&&SVMJ%8\=$F4_<
M<?34:GO_X9#M+,7O]9OAFS>K9_EYBI^G^&TXQ>]@O4.^<4+^A8=J:Z;WM0S)
M?:O^LL7N:J)ECH52EQDQ73JNNZ^#R^F"#^I7"[+6/;F?H0S>GX;X/C[A@K7W
M54+? 4+AUUAP"]G6&B:="7_BDX8Y*Y*^;*V=WB6,/.Z1=@,9FT=??'(OB9?@
M]4BP%U(OI%Y(O>/PP8Y#XV2@(ZJ@]8BJZ<5HI#<E1R([M+"D45+A@*HBH:M1
MC=F'1&Z-1@ID@M:,<Y&T/&(0Y.H.?M]ZM;O-!F\D9KD30TZ9Z;GQ"UDJ&+UU
M+A1V35(;V MX;YI:OIJ\B2TI,5JV&(- :><*:-7MA+,(I)J"S[DX$OO.E@]U
M<(N>/?:"UI56<S&E%+/D1(S4F++.%O4P-5QY29KL:(FQ^"C/7+GQ-@VV]K>#
M+4YT*V6P=;"]O?20L+"=LI[5Y5&[K\RLF@&DAC8>ZQ1^K*2I\L'^V78]*-'
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MJ<P+6CARLU8V^$UI]; @H')[D9 _2(4DI>?.*GR4%$0OR_M@8F%!=#[;%'7
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MTNBH98S'HC.*^+7WFW%OBK[AE11-9?WN>H/MIL&Y+#&K2*)R:9#1P,A8$5B
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M1$^X09C1)OC&:'G@HZN10@324,I?K1$[\"J&>,6_LAHN@=8L]-NL1J7E'_[
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M"L9Q+I#Y!>IA]LQ=UKJ,3^_K"@?4CAWK%KZ>VA%FIPVF2CZB*N(0^5J:B/"
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M":KT\ 92L?=D %G<37]HTFIN!*+QM=E?% DE7N&WR'0P*+<P@(?<0AZVJ9O
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M ;\9F N<C,Z)3IK/W!' ??-0ZQ2AQIG!M/>FBF( V_W9IL,4LJAK:BC4]A1
MIU^ S+*A21ED"=C#IO<KKQ^,+8H5>!5_UK,.LSRE9\9RBM58E^85KE6V]MUY
MP"9V/BBA*LE21L.R*_7FD['% 13I(TP=C$F/.N24&EP0\AU8!+6]L8A$G@LK
M(J9/*];0;XE0>*M"==!NR('DH,"@?U1P&:7)/)_3H:O:P)GH9R=]NH2M+*==
MPCT'^5>3J@";7(Z(UQ9-NQSQY$HE("'23&'681DI:K,<'K-9&[*Z4?2!V)GF
MGA2P,>X'1A1RW!&BS^BL)$%^<Z=K-E%,%6;>IG^&[8 X[H\VZ= [&4J,P1'W
M$9\AXWS'($T_.EZB;73LLWN-KQL^@4U!ZEPZEDC#<NKC&7K'G!LC> F2%S19
M;FR$T D.-C;=,D>,4^:7K=S]\7N\"LGA5M'Y3U5[;25&:M&6N&:?RO;A5/-:
M>QL,VEG;9;EQ8W)G!=UD@+DDP\ 14"@I5T@(S;5:%JS/:^O9L%)AI(NPUG*&
MZ G-=0(MJ*A!EUZ3?2#SX3[0O)C8:?O K9.'5B= >OZC&O0N5P[:U0P4%MM!
M>KB0S43*](9;_XV8^0Z>U=)+>"!I?<N=T$M-@K"K%N54Z+W!A,5E>\.]R,*M
MH0S.P:V1]L#??<Q[O%T<X.0^:= ?F3"&DZ!]*W#( Q7X!1'6BG#G5PB)I<9B
MTXUG.<-G<9MU.T134<=1VV S]'K)9.!E<VSI($W!.0%IAD$4!J^C*$O#[3U-
M<R^"",=.GY2 9."(X==N+QI]]6D;EEY;B[P_W"B,Y&FPY<MRG>3J2Y_ ?LK3
M%8'^:ZQD<1.*'UU6#?/0:_:RK+O2:VXVP?0G1@3-)_V]I33[?-V6@\[R!OJ7
M+ML 24HV'4N9-MCBH5:L\]8DQ O!L85R-\$)7(TTY5M.E]+*QTD_T 6#UNE
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M-P4<^ _M;&5=^B;)V6E@4O]->SHG4: -$N XQP,8:Z:P!,;'A.'4N_L8?IY
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M7FBP,F5/.NJNN<=S6\*]7^X6]T:0+[K%96M@"ZIZ@ZR<##7G!M>6BR>Z>=N
M+X93>=!*,WGNF)65EYFC(JI>7F@?-4E#?37=3'0\_!>LH<2L$! <346"@"$:
M08T2P,1\1FU4V&%I>[H8K<\B10JG=:>AF7&#W-4W%WV--9&>"J/HK>!E:Y F
M]M$ +SB*0BM77F6RH 8 S@(3V' JAG+EB 0H@@@19\"D!G5M)U&,D\1RAZ!2
M0U!FMM?BN$5\(YW1,SR@X%-5M0_[*2>04&:6P-C%G&$8H62@-"PF)^;U$] !
M4G@'LCPC5,"P[M(\X9"A7>M8M;<H\!V'UKX__3YBN(\8[NO@_HQ.\&JW=()/
MI?$L%V1W2#*M &_"X8AH>TR+;Z+]-!)"T7,<Z)L.ZNJU*@3J,+JI<I(JG;M*
MBK"5[#\9?,!]A1.!HY1O,MK(.<] ?,._(@$I11'7V&N.P$R2VNOM308.R#N,
M$H.RWP#G:Z2_9FN79X53] LG*<62UH7]G#+N(1+L KV9'Z#:N0[^*05T.&>R
M"V(;CS1)3Z99E,[;Z:'#Z)RWA,9 <S ?J9'W"'?/0[6NFU%.E/16+,5L[,V5
MU:.6M([A_=P;'P.,YO5N,9K?$^Q+\ZB(=(KJU="B#5,7I'XGQQ;!U*;1P\B4
M$%PUI@P$)[;J6>5@DL>N'DZZ;):'=0#!+=6>*M)[<W0E8+X@[16G;%83<E_Q
MA=,F"R@OUE.@[Z@#\]1?%15!K5H3AX_ES>'^D/O;"7O=9^UA0@"E1 RL5L9%
M)SDF"B/(+;]0;T-EG@G;/Z^>P9Y[#'"/'W:+>YS,T<[,TPU NWFJ/1VBUQZ*
M/EF-^VPG.^"#X$N ]Q"]F2AHIS6%W.L!G.<]Z0XALC[9+=H]!W6N1DQ1S& 2
MU\WV(+.*?Z:1C!R::N=.=<A10DR]K093G*2N0*-/2R8;-RS!=MHJ4XV7<\%>
M,),'VL3^^QNW6YP\<'LME5PZL1Y]=KJN>']=_.NR8PC&)W#&&9WS8Z8G5%%B
MYN%VX&QTO0WK%D,V:"]"3M5/GCXEUT>ZI <Q(4+9)#L3'4.^;W)/VSYM[Q@^
M;5'>5!M18E8K*+E,(^HW&L4@K$G[&,CE#6EU63,*-NBYTHH>SC)*-J,T&+0B
MZ#;H3Q/=E@%35K@<3;P3/SZ<2Q[_1^3]M_^@LK<'3E245YVT;?FC?=_^0OL7
M>L=@Q-Y3QL$C7V=.>_@6M[E#_.6<*O<FMI4PCH$%CD6QB,V-GR0I)70H[FX#
MUW4V1]P/RA:O9])=3GZHQUI@O_DI9JC+[%(D7\HUF"&4$.IQU+\ W1K2%_C0
MOE,#%U"Q;5I-2]B@K/\+8C+RDU6OB]$7VR):U[Q6\R3/8FD&;UI\&_BA6+,J
M2H;[+G"ICW\8/3E^>!A3U[@^?AV&IQ!Y2O<JQ<R7>X,___# @,>]@)J>Z[MW
MI_<!Z5USW[<,I?=QM]I*T?TF/]@T25^)]EN]@:T^1Z&TW^O-\(ZR<E28LIN-
MK<V1]7=?3^"K,/<W($F_^A1"./N'/HB[)OK-J'U3&@HHOWNE9,]8S#33OU=?
MU=5C?PQ[W7#7-IEUPY]52?4<IU57-JK8;_I>2_RK[/6]M,2';:ZRI7GC^TSQ
MK<P4_^OZ)#?1"&H=GZ1T ?\*E^3&FT/].5&Q?,.W651L?)-9%WI'-55G"M.Y
MN$YZO^L/VJ7-".?WU6B94O1GG3?[7H0/X[QY?%;^-<Z;/?O^*S(29-\(?2C^
M&<3EJU6;U(O]QC\Z!_\N#*LPL8-KT(=SI2Q*$.;@7E<SC7R1ZWXE4[ #& "(
MJJ\F75WFS;4%Z78+U)TD$!]=$A-&,)OW6Y9%$S]FNF/E/]P""ZS\__XC]UY)
M?_^8M_#K%+Z^I/;A6,WS$5,XWG)*QC_^GO_'M\SDNL=\MX&*PFGXPGMOK&^E
ML;Z51/  D_KU??3[KU?OSR\OH]]_.;\X__ V]HL*"(FIY&RMO#35,#-"'F*\
M',7M"Z)WP.[*1KFEOR9/F[H6<-M*VPZ D'L>#$W_&W0ZWCV736A7W6%6>4VR
M7XY>OEBE:3BWR1D>4_TFP.;U1NI_'V&"ZX_,"6YAU^Z\H<)ZZ,7ZT63<5$77
M*F_9/C>\1Q?PY\]&SU;:-SN_PF>CI2<XH.'N_')?CIZO##_L_ *?/]G1Y;F&
M&?#(9IX GWKZMSO-G1=/-I(_X@N*5=GDO[II&D$:O%G8L[L7]OR'S8?*^A+0
M7=NZFN=:7KN[S]ASC&W@F->PO7?O_.YM-GR#NR@JCR[(F']!4-L\B[1)L;DM
M87O<&J/HE]BU8PW6\%6!VU4W<G3\XEOJ? \!-YC,U#H>WONI;@_OY-UVROH&
MU+261_(12.8J;XM[T<RR2KL-D9%GQY&4]/ JG*(V>>]O20EJ1KWMQ';O=7T3
M@C0;\>+NC2"%=+>5K%U8\RJ-^2VBHDTF".%Z]"[A&N)W;390D/F74RC7F.@*
M"YT,J?#RK[?\YW=9PIL---\]>T^X[ZJBN:Y#9MG"J#/%/*FM=_ QPY+]_S\L
MCM8[4Z'(W3K3N]6@O?+\U<KS-W=??D-'X=:<U*8E^;T361[[ MS;%+C[!FQ9
M[L=?]D9\Y=%M^DK\7%3CI(A.BB+'E L1B,EL_B8ZP:90T5E>*^[2\(T\;#MJ
MKVRGC;I)XVQ;CWB5>7:W;?8]GNM?S!#=O?/;1S;VD8T_H8/*46(:VF.>XY^T
MT+9G%?O8QU_;YGF@F9YP-S"$@.-<X,K-UO_+4]%WD16_K:FL^QKH[R6M^LX"
M *=F8YT6!E^BXQ<CBW*Z59.D83*58@D4[&9 D.&W2'P_$J H_M7[FE[R(ZD5
M5L9O;-6/MM KF()JHZ??>*U;QYF)K%X.:^#.C\2VS6?3J*G3?_];<CU/CIX^
M>?KTR?/CEU_4E^,GV=-73YX<C_Z83S''O/WWO_U<)_/K/#4R.\N;>9$L?LQ+
M8G?CHDH_:R;X\A7V5=2QZ5>OQ#6YN66ONO'_#_S?^P]7T=L/%]'%^;OSD\OS
M"#^+3C^\?_OKV?G[JU]/WD5G%R=O^9F/)Q=7[\_QV7_]>OX[/OF@1+1JZM@>
M-DE;1+C=$!D'-+-^T80N3$#A\K=O5T%QS_*(M3.:7FS:Q;P$C.S7$(SL 5[]
M,<%F6I^C#]+Q]J<Z5^5#O8QQD=R0<E[>J :L@N8_"]J#45K-'FRIUQ4("??M
M!Z]?O#Z,7KQX<O3J]0_/'K!FU'9VN46@[]J;Q7_*\;_[^?W9O6J!-T^GOYP
M4?*)11>Z4^]#G==/=9>JZ%]5\V!OZ-/C^ 9>]Y_%=9(_&"4&%#% E<^.GQQ&
M+W\X/GH%C&NC)B7-[>E:&L.CUF _64^ZR\4Z*4LPWA!^GZLW3'/O\R_SI-0M
MN4]1\(Q%8^2V21P0::OH3-VHHII3?>-I-9NI.LWA-OZ/PHY\H MA:21V+G^O
MNAKTU"E>U^@L;U32.)U$_FPCB>7=(>[@&'=VG"#8C4VT;W ^<MHW],A,O^UR
M,8.C_+\YJ/%Z..8HOWN\V:\L@?>I*B_!!@9QWD0-MI7-A,+F=36MDUD$@A^(
M*L?>8_DR7]*>B+X_(@K8UJ] 2:?725DJ8#)U-T5.DV)9WR+Z"#(9&Q>N(*!'
MY<B7)^^CLU_/?_X0'?R6+**G/\016)I/#FEM3]^LH0A'!^]/+L]._O>/I"\=
M$DO617F)AO4%'@V<G1IBPP/,_1%8(Y.FK,IE_,'N%E*VGGC]CZTLR!Q9D'JR
MH)EASY995:BT@SN*PZ=R3+,JZPIT?[.<H%9EM4H(@ SG4+J" ZQINMY-C.U1
MF"1A;<(R-+,0F! S3>X.6\()ZB=RNVT]T>=.KE7I=8EOYX9_L#EX]1MN19TW
M,)^:.DECRRB8QERE^21/HQ)(KO '8L=*K0IUDY34;I 6EJDI =!2X]N,Q>+
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M-DU8IN8-9U5V)A6S228*2+(>TWE4R'Z1J(2 /M;YC;3BU1OXSA+_!44LT6V
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MO\8OXAZS:7W+G%>N/<CU*YW?V<%>E"X/AW6O7^&0%G]B<>ZGOD="/J%R"3&
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MX$_R.CI^> @FW\0_S^'+[*?_ 5!+ P04    " #WHIM4V8 2T>H#  #L%P
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M=%\=I\$5" 8S*@F152O0C8&,*@$-E<QT^RFOVX: DV^-=M%J6Z-QME\ 5^(
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MQ/_2[$8(+3ZNC,:#A!\CVF1;I^X=>0\9[3#!X]$$9QY/VN?>P4B)Q^J#F7)
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MJBRY,4Y"+2G33XG/<^NNZY\-AUWO1+R"HC]?.KH?7HP'@][DF-P#^Y-77;B
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M/(X'HWT2!%C/[__A)<&_=<S^!%!+ P04    " #WHIM4JQ5EFQX$   X#0
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MC\?A8+3UOI_KN=<4_EV&>SDR^Q-02P,$%     @ ]Z*;5"G<D-4H#@  ',H
M !X   !A:'!A+3(P,C(P-#$V>&5X9FEL:6YG9F5E<RYH=&WM77MSVCH6_RK:
MW-Z]R8PQ-N:=M#.Y)-W-3!^9)IV[^Z>P!6AJ6ZXLA[*??H]D&PR!!!(@X*M.
M$X(M2^>M\SNVI8M_5"K7X0B'+O'0O^\_?T(><Y. A *YG& !1\=4C- ]BR(<
MHL^$<^K[Z$].O2%!J&/:==,R.\U*Y<,%=-7+KF%A%]6KM5:U9M5JR+:[\-]I
MH]O/Z/3[?>],M;[ZVKO_[^UU.NKM]S\_W?302:5:_<OI5:M7]U?I">C>1O<<
MAS$5E(78KU:OOYR@DY$04;=:'8_'YM@Q&1]6[[]51R+PZU6?L9B8GO!./ES(
M(_";8._#14 $1NX(\YB(]R??[S]6VM!"4.&3#Q?5_#-MVV?>Y,.%1Q]0+"8^
M>7\28#ZD846PJ.M8D3B'*ZMP>J'-K\J8>F+4M2WK]_,(>QX-AQ6?#$2W8;;;
MLT.<#D?38RQEK<N)CP5](++O0J^N3S#O]ID8G2\.L.S**+]NP$)1&>" ^I/N
M'_<T(#'Z0L;H&PMP^(>1'H'/F' Z^.-<M8[I_PAT#>P)\DM4L$^'T+FD]3SE
MOPOGD/QIIY]RP/[<@&.B6.LSWX.3U[]&M$\%LJW61;4/(HL.C<#_5#[>?+KY
M\B_T\?KZ;G<TNN!1A*]-9-I'#4XMH;F'?3>1"F<A8@/TD?I@4N@C(>@>]WT2
M[Y&+592WEU/^D?$ W57J^Z7P5 U[/XG(V6&*Y?*!QA":;I.^3UUTZ?Y,:.K8
MJ,=X9**;FSVK5#;/!QJ/J""5.,(NZ4:<5,8<1] &G5[_PJY 7W! I!5^(T-@
M N*T0#A&=Q%QZ8#"3$!#1$6,>A!V81Q0@.S[K7@!.4,X\JF8=$?4\T@(#?[Y
M6[MF.>?[)^RIL*0<&=E=.9P_R81+.,@3AQ[J8<XG"*QZC+F'[HB;<#"7K3O^
M:CDNQ*@UQ?IX-E4S8\4RZW((I&3U_D0>E/.R$D'6OL^X1WC%9;Z/HYAT\S^*
M)#>ADU$J13E/NG &Q#X_"TM>YN=@I2DY5,7'$Y:(+DX$.\\G6=NTG-\E]X+G
MI&1#V*E4A#>U+<(%=;&?J1P2A:R7IIKE"\+,",@%6Q!+H6\&_0U\-LXEFG]7
M_M?M0Y[UHS(&J3R;/DS/XW[,_$20<YG#R+$+F<0TF\E^"^\)UB 5$2R8<E>K
MOR%W*2WIP(\8W0J#+;/6+#6#;;/AE)K!CFDU2LU@RRRW"P+&[)1;@XY9+[<*
M.V:CW PV3<LN-8,-L]4J-8--TRGW/'C$$WU5\"4Y>*NV81*>P8B,$COZA6!X
MZJ'?+/4O/Z^@PLJS/!/-BM,RNWY\<K74-\ZU#Y&)5P/.]BL!<P:")PH"/]7P
MH@^6]%PC62N:@NF-L8)6T+,*XD\W[ODXCM=J>2^K]B]151H,M:J656D)64]+
MLSKT6NT93RM7:S7.JEO;\>=OR<N,)$6.VDB6U:P#EH1B+57.JI<OBZEZSELN
MUUO.()$B6_*1S_@7#9)@+8U^'0R F7"XG9%O.777BSBWA*/O(14OL:.LB* M
MZ96ZOQP..1EBL9[&<DM!,R5OJ+>T-*+5MGRB1EN:('-];CQ!-K1RGIH@$1ML
M,$?R0C+U6I7F6=R&&DWK6%JC2_/=%R6OS[<-WA:UII4]K?+MJ?S5ODLSO/+J
MGKXD09_PEP4"1P/D@[**&\A\*?;7&O@:\BY7%F&W,_35"_,#765YRL>SQ_;6
M@SZ</%"6Q/Z62IRWF*XW/]V$6\HQ>RP,I4VN62U2CQU_#T&?Z]&Y\!C4<\T%
M0WVBZE%T6PBZZ.Q3/UE^Y\*&.;<QO7GA,C^.</C^Q'9.UH*R\C9)*9WJU0_.
M/7I>;LG3<46]/!'( NIY/CGX^T=;"61S H:0%"/PCS\)2J/$LS&_>)^MM+>H
M.L^;YO7/1-WBV$!@);YEU(H>/94O?VRSWGCJD=*..BE'^!J$]+*/>BP(6(CN
M!'-_9,^3GMIGZ+1VMI&D2YR+K&&:]4;K=' &<MM(9B6^ ;*&S&RG933MFE%O
M-C;TZ;+&P-8:T_-37OW.MDRK]<_?[*:5/QI^VMS,),M<QW^U>)%M..V&T6JT
MC$:M9C8:+Q1RB8ON:\CXM+UIE"QM%7R-*/G.KK6->J-CMART8:YXJ*7F=3DX
MW,KI^CHXU"K?\:=U&F=JG*EQYGYF]!?CS+\PER^M*D/$\LU;3M SV-/1V%-C
MSUW+#)!GLPD_+8T\MP.-++/9F >>+0T\MR;=NM%I.X;C. 7,N:%\->;4F'-M
MS%EOVF:GJ>'FD7&@X>:..=!P4\/-'<%-="F?;H@UZMSNW<UO)!:<NG+5/(4R
MU0L.<9Y#U37.U#ASIS)K=XR6K>]O;O/^9N:\*=K4]S>W"S,=VZ@[(&5]:U/#
MS-W#S$;+W# X'B[,W-^J@%*T:RX*>/S8]ZC%>KB _*C%6N(\?&=BU:4+7;K0
MI8MC*EW<$CY@/)";!RRK731T[4+7+G8I,\=RC([MZ-J%KET<@7@=PVI:1MUR
MS(ZM:Q>Z=K'KVD6M[9@M2]<NWAX-ZMJ%KET<CUA+G(?OI7:AW^;?VMO\SVYT
MHPM'3Q>.5@M05Y#6M="*+AOM2EAEGVJV*JP2UWIVX88'&K)T*647ZC[<PLCQ
M%RMT\6 '!EOVDL!6A55VH*]SJIT(ZWE<6#2Q0P6%N=ZG987ZJJI"83JTS;]S
M*'YZE60FL(^FZ]*GRW3':RYNJA/,HS"2A=LCBQO$+];]5FUQ_<XVG$[;:#DU
MH]FQ3*OYDG*J3DV/QU!6+&_4,9K-&@A!+V]T;!P<;N9X_.E<B7*L7=]8VO .
MG4[UMIGJJ8=G9\NGH^G*YZ5(]P[,=/_.6>>BO3Z7=FY9M(>;:!Z9C98XW]U%
M;>Y0L]PCL[K#3;:/3)"'F_,?F2 /%WH<DB U M((Z/ 1D"QXQZ1,=>X#LU@-
M?#3P.78;U<!' Q\-?(Y6D!KX:."C@8]^O.9-$<<7(A3>N$K6W3#X"+!&"9+\
MXT^F=1:[X>,J)4EGCS^///X$[O@SIUG*4A6X[Q/X].C#P614!T)&*I/T]VBZ
M:7D?NS^&G"6A5X$TB?%N+F[7)YC+MYE'Y_,GLFW.:T"(3T-2R;[G"LI-PYD1
MG5I#0^6)V9'4 N8.2:T[J7:'I-+G!/^HX $$P2[VQW@2YV;8+KZRFAZSI$B
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M(#X,>LDHGZK&HYRX@G'@^(VT >JP&U-7R5I=8QZR1*"[M(M3B"$>&0#[6<#
M8LK1Y9 3$H#;*4IO?:R8_$SXD' #>2K(?,8<6 ./1#6K5MN_5E)J9J3.SSE@
M0$K(()>ATHZ!/M&AX@;8#R /293H8W13B)Q&)BM#'C7W.R4M"962W*]\#+E9
M)GMTE_05:6=2S0]GJ VATK&-=KOQO&7(^ I&.(LG8',A&*KTK#$5(S5G9.-
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M@RG8+^*SF.1C"#?6HDJND\SYN!)\$$C0(";$G^MT2?,6Q+,8GPPLKS-[0AD
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MPM$ZM^?5S^8W]>JR=C$.\$''%^3!JI,1H2AF.T^$Q-+[\&696/;(L**&Y1B
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M<]W)5.Z8R@WZE7)J3OI]I>P84[+'"VY2ME0VR,"FDH(.04U:BAE*(95,[]"
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M%.505AP6YA3P(V9;,=HA,EY%YA1ZJ]+T^!XPG84/HN&-3Z(2'>$"'.1>=%E
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MB$J(6N)?/*_?8QR %1SU6=<3__8RD4('<XHT&O^F(L.'ZO:!"WE2/,"X4H1
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M)Z0WZ8^/Y_I_??3TK<"?.D#_#:%_0/Z7 _]'SP'&M(-SV%>)L!,:?XW-B52
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M!G"AU (?EH #7<]U S"7)ZB?0?''>VE7=-(/_I)+B[_VV)X^P'7U#BM@YSB
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M!_EZD*^KB?A/BHUN2[$52C755N6;6K\LOI0%FPM1K#^C E,>!.H?*5 +R8-
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M[W>=XV/23:2[V4XAG^QV,J2K=PJY;+:3)L?)XVXVWZ?_]X[-^MIT(0";3 6
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MJWJ8-+">M\1+//7K5,29"&CDXR0H\,@S;PON:B"'(0X?,K&NW\LKC>1Z-"D
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M*:U!%32TN\WP>P^-Q:F"*?Y?4 C#H1=+O%7XS,?W)H 2H, .BQ3-RAY0M3
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M+W,E &A:TAM<4HE5 YR\T3QFX']3+A_()0@[(6R->%R)\*1Y/Z16;9S8@,S
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M).U%Y.(+C#&)0 RO!017?9TPN*\R]^ %S+(+*2:P3-B:9W,@)"UIH++$PW7
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M*";49H72\M%9^6>2HE*H%@W')"=8GA8NHA)83PE#M:A\GTNDMV"-;KP.  :
M1,F8=%\&BQIKB#=OP?$VQ]L6\S;3$7CI)H^]>I-'T^-QB7:0MM7$ :@#T,4
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M/QN]S^WCZ/-Z7?KYW>4070A%%L;]+LA]4^5H=?X;=:)E3UIKRINO2T1C"7\
M(5@FX:X+-70XN@2. K#+\:1!OZ7^QN73&09#T0#4.Z*.*T=B"NND!LUYF!=U
M!6)6$9BG:C@(=A"\&((O2QA]#_I4!IMK,M68M.:A!F"$0Y/YW!8M0 D1&.M-
M!?L5&=<-2X!T9^3C :H^2<-;U'TG$9PJ,0>[6TI+L4>."9G7)EQ%F=3QK/=W
M,9[\?.E]N.B99)6OJ)%XL0QD1G$DN&1U*!8R.\QRF+449ED"SR6^DK74-0>
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M7N<L5_X1;/4XR&H-B^H)JO.(MH-*!Y4+H%(S:2,2K %+3S]^>-?%#[OX85>
MR)'0U4FHJ'E,J]E$:=V#:B6/* _";8(@!9 T8($ *["FH>1X3!-[59H1ZL)M
M?<*:L%MQ?6!$ADJ8H8 ;(_EB=#!]3>*(*=BK7K-"%CG2UX3X6(81YB;(+^3
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MNG^<1>? RX'7\G1+\;RL") '8_#U0+(#-D=?JVFYA+E#)HZ;;$/)>(R5QN"
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M\&.25BGL=O$QFQ6 A$>A;%C4?U"DDJ."%MYQ!Z6I%<KG&H8RHV(_A"+\;5E
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M!Z4)K( "W_9 ?019 DOX5[+'^NS;.1E/HF0J 89%CO562^.-@U0'J=\!4@T
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M_1X?1*\)];"J:,QUM:WP;3@44!<R@HW*0=KR>E(38$M;(PIS*DT2 WL0Q(=
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M,8UA+;:LX]#@Q1'+WT93!&82N1@4=$^0)M;KR.73)9=LM!"9%5O,J4VJ:+4
M%9X#$KA]INXVBO'V2+-$F2FO7YDHMYL/8G-B::C4C%ZUGS?=" ([;95$6ELY
MT:])*B1,LFLH'[EQNEU0%[N]LO  8OB@P$@- %-2Q<+X%O7V&Y8PRXJTOJIX
M%(L;J3U$JMJLUHR!&!<9]B UN9@AO#9!:95\0I4F/U5]C[F*S1]4KB@Y!-0\
M2HH.$DP6+V7BMO7/6#246I4ML&70C>IIUU;NE%<*_X!S0%-6$8?YE!L@!9BW
M74G7X[Y#'>_7Y Z6F.HF%,2=K;9.M/$P>S3OA'KQNG*P1A>ZI&STLG?Z4CJ/
MTC=)WS<@T'D>571WMEU<IXOKW/S.YKTH'YD^./>CF#;=PRJ;F/1V*QN99X4N
M$B%=A]K.D'GLPF9\%-H1/4GPJD(J3&X"WF/L-(>K&PHVX:#-,$W#6](K5.P!
M5M")"C3%D+:2E6]3)3(VU'!)CQM 30J(X*J::B\;9,:JTFW3NGM9NFU\=B![
MW6$O,Y'5-IFMN,O+,/OB?>#SG'&/O70Y_+GK:[JQ@:(<M<K0W!R!BEWE11H3
M<%8LKY88K\OA**-'"/*22E/!*C"ZB*&$]_-IE:SPW$X;?+K:X#P6KFA, ^15
M.E1K0MK\_Q5KK[6P)=>=-I*9MB0"!KU1V@Q5 P36Q-XX"P99W9S3ZV-+?PP;
MND85H0"%BAA!]JJ,K@]0$X@BVU!W0HHOX@L>,&6X*YW7T/29MB/"BXMQGXMK
M+6PD@KC#08/$'U!Y.=$S7")_X')*QGU!###;D#I(R%@6S+Y*I:2FQK<SO&L3
M-/W5,>-$I#'&5S#,+8<;%9^A>.:(HA93/:<J<NAG=?SXM0PD:=H2U3MC!H49
M[X-,MYGB14@U:L4)J(4O5)OYN&UU>GO/%!QL7+:O62;;:_2IB0)HK2"61=VT
MTZ$,<]5/,T[J"^!)RX!--=,UG.(-E[(\H3!>C"8QK9%352+2;C=+7OCFXS6=
MO4SS.E,^P*ZYJ."+JP$.9DQ.0YA/Q#&5[K-PO6&$;QK*TX*O2-;R)$?%9 7*
MS,%-"DXLDUD9WENIO(_-J"C)BV\TU+$Q]2X&UG0G#)8]!DLJ3<H@T_B<"J0G
MU6Y5&K8JB-+>2KP2C+#<)[Y=X6@%'*/Z="LA6IG/48-5QP:_2X3CPS(]&WP5
M4^NL/LP:S!)@SU1#4N!T/E&VZ[(.DGIR>?5YIO*1>G0!C^IUC4QC$)NIBJQ>
M2G4"]#0UK*O"'?VY;>>05)<D:DNHU5@DH]Q&?_9AN9-@]B'O13$&6$HT4[')
M$)&M;:M25!/);*(!5/TQFI*(4<RC84N>D#?&_@W ^YCN;NU8ZVF4D<G'K]";
M^77EO'SKA/" ?H*)RV-I(%8KBB;W/"-SJ;5[K"Z3RUJ5(H%?.Z7Y,E)9(45^
ME6D04OQBR%Z/&?EP!MB:F<SL2!Q0(U\S4%.(576<06B<3YNB["PFW2OP@1K/
M1/DYKWGUYMVT?<W/K^?ASH[SUCAOS4K>FC&<M][*=F=/Y:F^<(OA"[!;*RT"
MN-$7R8Q'=5EH:EA3TLV**K955IFW^^:\XE0<D'DL%E>I?F\^:ZK%X8*=GI=Y
MN]?0.6.-2$L=4((:P<ZA?\#=+V;J )N"=HT>%%^']I!IA6.3]\Q8PX0KJZNA
M1C(R,I2NH+Y5&F6:$SA>&1%P9]=8KR9%'X0<-2[U4'CH$ZGH2*"B&3,##+Z]
MY[]5"Z&C^4VDJ:#JK;.'<>CO[.[ZN[N[_.I%&M[B*!<18 &)6/KCQM/16S_P
M]_?WX;\#-0IO7W^JM(@[H!*8.$T_:J\KMXA0DB5M#T\G,>%M%*A&@QY%0G>\
MZ'GG&@I(,.56($- _>1.F\]JE0R)XJDYEYG2&'/G&+'(LPZ,/DDI2.]![M?;
M0A,C:ADW[-!7T8':A]% )U]9L02J)&\8%:CW\@8",4&!&^,4WKSQ]QGN.]XI
M=2N :PB#<*)J#8N\?H3-72^,#EO!!QOB[;YG=K<X;-Y& =I?PS$SANW#3O=O
M)O"[;DMO[Q-O=-=&3J5/$MA=V9U(M5O!P/ *AAK8;AJJHDTOR[]>+;'Y@_W.
M[GJ;9U/$KJ6[VPA)HAY,JBL1U%>"+%);*AJ6M=<Y6&]5*MB$%S4!)19 &A2*
MK+08853@6);F%[+XQ$DC\!@U.*?&?ZD<R#%KNZ0MS.WA,@=H^_:4MIB";"/S
MWA[X;W:W_</#O>7LUXB]R#AJ+6)UB.DJ1JNJ76G.^K9-QXZEEF>#1-U,_B%)
MN<"4"2 N#7?R*W,&M//-VL;*]+B^,5-P3Z,D709CFPQJ,W8TNZF5Q:>:;45L
M7+RMK9X"*L8@Q^4Z#<2:Q?"SW$1S]*N OI@( GE!_P7V>=*]4#!*&R=#"%>G
M)9BW*?M*G-@PG %R"( )W4 *2#)C'"P:;4$8L*7#M;C$:5ZZD)J'(DY01S[$
M;X#-43BIW8RF>&0MTT5H9!P@P="'8J9^W%#P;M7?9%T/-_B)(HSCIKY.MR 2
M4/-/L^M( IG+6G23ZFTO2]^Q(FV9PM1\(2R5B"C']"!%;@TIK'Q?0@U#Y7:)
M[HM$GTRUTAZ@PZ.Q2]_<+8B\1OE_W.YV=O;08ZFDAS7 ? _X>0N<:W? ,J=@
MR=./>0JEC5=35&[A!N]U+8&_2F0ORR-X+X(OP"<F98X >3%YSW:+I35.>RQ@
MV<6XG;)<1!RZOZRMUXYPK-IA\0G&S$<Z?:7<YBI!\M^<;-2=:K=A%O;#*,RG
M[T;A8"!C<GX=[G1WRY*)2T=O6LM >Z-: =K= K;7_6S;.3$VH6KFI%^TV9+>
MZ9;F!?5.=\:0F:=Z87K+RG(WSZS!*KH:9>>PL_<W^X!JU@++EF@-CXF-0R".
M^M#TWZ_1-O*.[<1W<$P+C;16,3WSJNA3K4'YO0VVS0Y7^A(>+@DIEL&];H=I
MNX;MSJ&[AL>_AK>=@[=/XQH<G#UM.-L[>!K7X.#L:<.9HV<;LL%G#F=[^T_C
M&AR</6TX>_M$KF%].#M\&AM\YG!VN/TTKL'1L\V$,[*&MT:7K&2&><13.%SA
M%!X. )_6AH,DPA__ZX?M[1^6V?W^ 0GFRI*H8V8F7ZF?P,#3L9C?\'@.5PHP
M72*4C*SMRNVN?2S:66<"XVVW_+S0N<50,^_8J%_R1*2EI?6)0Y8C(B^2B.PN
M14-VMCL[.XMIB'I.O3N>-($Y2YAZE)XE_OM*N;6^+3UYK&/<= C<WFP(O _
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M(.%8L:637L[A# )0=?HJ&M8P9(9DKKM<_A,'@E6E8Q%52IBKGW[X1P];H</
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M55\3$ISO=T>6(0'_V[7L",(;I7+X7S_\Q_7Y41.-6(SFUT3) 6N/X"E 0&8
M6/S#NNYFL%UX?+8&O4T^^!\<\WAXYK&W:<S#B'';>X80*R)<%V?:A:@Y']6$
M)OE5ID$(' .'  D*1R,TST!F2].0B3Q)52W2E(BGED0%G&!6H,ILB0J0AH9L
M7.-&"T_/#/SW-PW\4<7@6^[+*+GS,@F0"#J$4GM)5/(2W3FXIJT(U+<9'T3>
MJCH [.+C^3@"4PYEB J1"(($5:<;)<Z%J0<L=YR]FP^FFQJ@M@+Z\#*04:L5
M(,,*F-']; L(:$NMR@?TB^;W](YE&;>""ZL20)[JA5E6WA]6"*/;?^,ZU<_W
M1/&7D_4[U3],PIJ[AN]R#8L*E6W.-3@X>^)PUEKI:G.N86TX.]A]&AM\YG#6
M7E%M<Z[!T;.G#6<'K14B-^<:UJ=G3V2#SQS.G@JZ.WKVM.'LV>L!>P[.OB6<
MK9[.V&Z'><1C^#:=&#>N1,^]-APD$?[X7S]L;_^PS.[W#SIOWSQJQO.#-Z(D
M(S 'S9QK.S/_&<;\O[ N]9S,Q^L%'.\]O33H]2'+49&7245VER(B.]N=-[M_
M>[2DA(?OK)PP>2CC8/CO*Q7ILA[!.'C$(]IPZ-E[1L"SU_W;-X&>?0<]"Z%G
MKOSR;*#K$\???0L(>XD"34VW[,X9I2I9OS& 6=O_4Q*5OD][[XT6GC;I"):K
M>?ALR-A9,>[+E*E6,M1]+OOM'_UG/_5^^L?"US@(Z!Y9I)M( S<,5EMJQ3T[
M6+V0*7XC;N3#PNE#P_UYD6>YB/$P-P&5+'7'H5*[7_S%H%*5[&\"E#J"O[17
M_<5 J2/X][50.%1J#QQX,:CDY/PG#:LO2B=U9/]YF0V_#RJM9^[;N/+(6,<$
MM[A]\'/F38I^% :<JZ4;OSZ/*M",B;/__Z$KH6Z(BV:5PFQE41MWUTWFKF=U
MU]W.X9H6G4V[Y37:0K87J'R"UUD6/W.HVV2X>%YWW=E?4S??M%M>!W5;JWP^
MP>LDF6MG9<!^_GC[W,2K[CH-7_<V\9+OU?#U\<-"=44)+G\2"2P1 2IJ'LHU
ME9P-BH?Y5C:@C<:L/7]W=Q?_<]>W<G[W!ES?FW55D8VA@@^3 KT!5^$P:?W,
MXDVXOLZ;]32#IX=)CQPNN%A+V_>[>SM^]]"ATI.4*;;W.VO<7'LJZY.0S3=.
MVU 5WK8^AC<@L;^"&9/@R_-R2GR?=NH;L.M5,/!PQW^SJ[H0N5N^AY=BHV_Y
MX,U:,LOS=D1L](TYO'P@%\1FW_+N.N;*3=GI-_(R;/:-.;Q\"5+1;N? N1$V
MP8WPC<'SQ9@!'K'RS,*6$S.]*^T#X?>L<MC?"@@V,KCR$50;!RA/,=ON^P+*
M,MET+QM0'$59.J'M90/*QJ9S?6>*LD2ZULL&%$=1G#"[O!KZ? 'EF3C<KI-<
M1,_1AC23]_8=C4I5L-\%L!\D!?9R>NPLRH<(2._Z!_M[_L[V&G%<[?'<L\>U
MH63B^X!6:]K*LP2M[EI1TW/<@T\ J!X\F>DY0L7;M_Z.HS??@=ZTIDX]1\A:
ME]ZL>%"; U0/GH'U'*'B[:'_YG#7?[OOZ(T3G3>!WLQQYSX!H*K[?'6_7:LC
MR_JS=W .9<A0AT"_6'W884%RW- 4IMKIQ>X/8XX9^^PFZ3L-5U8SFMGAJ+%T
M9U\:57^O4S:2CI-8FE/QL->NU_6Z.*_=N\4URBX7^O^S]^;-;6-9GNC_$S'?
M 9&=-2%%0$PMEBP[N^J-TDNENBO3:MO9^>I-3%2 X*6$,@@PL4AB??IWMKMA
M(2E9MD@+$9U=,DE<W.7<LY_?:=R&^S7*?KZYC;+5K72,QX[64SC;_ ;GU=^>
MVB%0YX0.#GDAFT) -)\'HR#G9+]K\<M')Z__]6\O3IZ_^'&C2,R=_[Q0U!N+
MA$YX<G02OC@^#((Z4[>JB)-2370K=<JO#W)"E2]_[*?!@;Z>.GU]]Y?G+X["
MD\-333KO/_Q64EFU_/L"_CU0T$!!RR@H/#DY@?^>>ZP(P<B""P8A^STJ0'VM
M!D(:"&D9(9V&AURZW$%(17(=52JX2&%Y,S""!IH::&H=FCKH9TZ:@H*D+&OX
M,,E(>7^;%S=1,0'>5<17$1 (BL--)K('-?(&&OL:-/93%'\")7T>V.Y/^JL9
M-X<*"OM-*2VA1MMN37YC[HC337-'G$^#*$V#?$J4)"!)!A'6)\BH0*>%$&L8
MP,+C*Z!!\F+0XU8:KY# (?W<7H*[,%<R-=9__'[W)M1;$=SD=3H)\IOL9;!S
ML,NX9M%\7N3P+"PN700'AZ/C/^D=)/#<$O^%1R46D;POR[M?M7/8/>[1Z&2M
M<8_W_]0U< "SWSGJ'/KP<'2ZUM!?CK5\23]\DDV VO@".GYX_ \G(6YX(*Q@
M6A>PS"*8J"I*4J#+4JD R?]P_\=_3[PI\EU**KC^\8^"G<V !$#H^3POHS3X
M-1_Q=A]H&#R"^0O0Z?=37<)DRS)XE<_&21;19NHG__V'Y"_!\A>Z8_VBBDMX
M[]EEH>ABW>'Q5T#6"4R:WH_/C6BY!PS6MQ[#USRVS6$?@DE^V9#$,CW[N^5P
MZ?_UL@\J?4L6\'-^$P +I9L=95E>9\*7A1-TDF@TG:H8T?+P%U41X4*#>9'$
M2C]&[/=5&I4E4_U9\*Z 7T7%(F"$^?_'W[=[*,/?+L6=O=QL@GJ7!;]$('GY
M: \/P^!P'_\_'CP<>65(8H*B?JRF><'*@*#)=]$9*!%Q3<0E'S3Y&0]?J'E>
M(.7%:5XZ5)<%OT;E)/K#H[_?L@3UBI6T2.I#EZ<IN(&;\?W!_NC@64C_NW]
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MWW@!LP8R2G.W)&^CK,?_I+3XO+D1SW?&[2W0>4W1?)XF/$-.EW>'IJH6+"B
MJQ@TBC>:A\*I[\D,0]AE+V^!9[4?F7XRAXV0$'@+[\*6$^O:&_(NVR@^E3K>
M8"G.F$;?FTCD8Q0XRO*06S6XDON<6&<N(Z R**Z2BCG#+[_)D#O$&#S&?Q:<
MY%K4@N*SNP9R$-$RW*(H*>"J%I]4%5Q':8WIL\A+@'5]?RQ5Q@4SY'%=X53"
ME5<_7&."MJ+Y8-\DV-"K;;5R5[Z-$\^D-4I\L953@Y=^R3MXJ<O'M!>ZO))Z
M[#B_Q!RT .-%P0YN"%HF:5Z6NWI7U*U?;K?\%% C[E/ZFZ:5M\?,2K":KL*Z
M+K:Q<S-%W#><9 C\%[BI2TW(E[D2*+.)1E5NL$&33#-&$G$3-..PJ@O3J"1'
M"#=-I)&*"I1S[,N9%SE5\G&1O!:D#3&& WS$:K,:MN&]NJQ3*2QC4=\4$H$C
M'':I\@PQ&71U>W-U/ACJLJT/=8GBQ'!^+E&7_"GV>U+=(,ROQ(3:(00X\.TM
MX-L.6(3FX*MTM1:K8X>+ETMHN1^F-1$'A 4@[\/_U=P#OYM'13MA_FX\PS"A
MS02N78+&0B<XR14[K1!EAI7?J^C:K^..ZUG-4:6@:T,L ,FJT_NBN#-W"$N=
MB\"[P8)K1EJIJ+)WPI)$3G^.47+.X"#]/<FN82TS+M6AG#DC..2)B[?GKXQ%
M@A*S3XN7/'1,8G*5>6U/M2V2: *\J.QP+S1JZ+O%;Z?!.E9I?N/D\<41 \L\
MC/6VV@OGVG=K()!T68#:[7<A)_563NK<GM0KR6Y\7P.W"5T?WUC%45U*07[2
MEQ5)7"S+39%6Q%$"7?8'Q%_APW":93(6W^GY^P^2R(/J6B&( _8]2"8;=!<0
M-#&EC#Q6>I)""HVP,@<$1FC_V:D.(;4*_T7Z).6"N*XP8J*J,4(8>#('-U;*
M=TBK ];ZE5129%B6 4@V3*)O/YY.(,@1% R:U 7ER_=I<$B,I/[#X>2T9?S;
ME2M@0 BQZO%U])@17Q/>Q1N=$L:N@0F&6=2$HR](I:FZ#4I5<?G[;%Y7.BA>
M(,F/@@\T*/XMF.T>JD$/0_@"+IS5=[S/R6.P"WX& ^L:(3^BEJ$ ^Z-5[>@Z
M3UC]IZ.D341YY6O/'9RTS..$I #1)CTL2=-=Q+J:0(',6D:-2NCM!FX#&(("
MY3+1<X=YSJ)/.!TBOI3SLD%Q@B7]UYNWP1MM"+G&"OYDHLH8+ XUV=QS-*)1
M)S4F!2(],\MP4L.0Z,FWUMJ]*P5780?KKVCU9/"AR@+?KJ.2DH--#RXQQ;*;
M 6"7 X,\HD_D%U!C07?;^X75V<99;,_^-\GY_L;I:&6FTG8DV)T,"79#@MWV
M)=B=F1@U)F1T*#JN<:>M8XW5>+<X)CSZ:Y[M/5S<9S4?6X<=WM-R6"]V-+(:
M1VOMK'30G!P[K6LKD=MJ'1&VE4-25'%%GH32-3ZU]Q(LBBAA42=B#O]-DE/S
M[5RTB\;,#._N3=% CK2YQCFJQ(ZVRG!@&DZ0UHFD25OF-G]H)/81%ACKQB:]
M9:+F5%V*BG-CK] 1E,1@T11!G!1Q/<,TGQ@)X P>U$>.H];%I05IP(O$!A/.
M"6STI*3:U<NHF.@I=UTD^'S6$Y PD&Q$-GE=!:FM0B67-L8;8Q>.3>"\8#R7
M^D+27548I'D,M(@_S#2EX)RPEG:$%C/L!AD!O%^5,0Z<1AKW3G2X0^>CS>$+
M W#ID\GK>9T'Y^SP=%J1D18U9/IN<8[.^318Y#7QZTAG,F)AIX-R78;T$SI[
MRIK$-[!^Q.F3G##!A '<FMH9(J_$YCC"&F& PA^4Z_P$Z9IC=C0.OHI!:W2Y
M=JPFM39))RJ:X#I=(U*EI;HA1% REN_1S6<4+"7]BP[(;]1I*-+*&]&[<(92
M<==-AOEXP9*-!2!%=^#'5[SH!8>[?06F6@5]C9=P%,AYWB2PL0C6(MTB^0!:
M-S<,YHB*H4CVD,C,2@S,BRN0CA=5^?7D$I8/3)!-F+?.%IW<PBB4/4SCZT=X
M?LTK5"),RK*';HI.M#;L>VA!.SA^AVKJ= K*A@1U2.5L/T<DDDE&D20E\0@W
M5_FL]RETA\>5[=>#+CH:R@G#H-T][PG1>S'X@Z.=R:[)*1?J>J-=RF=QM6NS
MGQ$=MTC()B+P*29VF@@HY#YM-[TE,^Y%%C',OFE.@#7HMF.G-P2HD7%,U267
M:*=AO*QS[Z,4TZ4%:ZA[4V@W2*WZ5#JWU,ZI;PXA9[,;-[,L#@LS;V.YJL2K
M< #2.<7S;"*L8HAH%K>L\\Y-A$&2A$!C&S>EM9U.H]AISEXS.[>N'DZD><]F
MD<N-NI@(3[ QIB8 *M">N-ACP$^#(JHB6%P:2W CJ$M>T$1A'2J\@G\*\IY3
MX9WE49NTH:#LVU<:"2(6I=JY9'"9*C)ME;DR:E LOR'%TM2=_!W4$=*6EJLB
M(/U8F*+Z0L1"OULOMHDL7_ >\,]Q2=$KXE>2<"@N@:4:5$,R.PB28\85DRHX
M01T#BBDB4P@IZ3;!3*F*.J X:<%A_[MCD$-CI2$J23'T]$S,-R)&+-*+?2BE
M#=)D>0"B\)*2W&:$F>$\/I3@/$6NN[8>/C#7+66NGM7>82RP([?3!+3&._&3
MMF'.UOZL+C>XFN$))<7N)+L;EA"[$XG=B,36I!U,!M E0 E3:?MG"%R#F$T,
M%& )SGI4=,DMTR?]K+,DV!^64BWY$X-'8,#EY1[@4WT:2,/<:AF&2_#-UDE<
M_5RNVL\J&P2R[>P7TTDVFP&7]1C-_BBX*9*J4IGUA>840\>60%B3PG'$CUA>
M-L4@&E5@1[/YC_ 9$KQ.AW6>T;'6L-FIC\< 19?ZCYOD'+P\)D?*8P:2?W%X
M=# ]1'+R_+5.S'.5WW99JUYT;X2Z_9"^]QB\Q'I*?+I4Z51#O=G$><?5C%\L
MJY'7:+\TE51=PL.(_QD&\RMT 4D_2.IQ,YG )6V@NGT1_>8IW<1-OXH3E2;7
M;#<V0PS^95QQH>97BU*P,8"N21(5>2:?:(%%/4\4I;CD8/3Q)=:)T_HRO_YH
M4MO[#+#'3QXPR1FX A/0;H1<IGHG!"77,T+]O=8UTE&64=LO'9V)QMAZP4CA
MXY?[^\PEYJ/9* S>1"46NP6X4"J+^#]2!?1_P^!P__ PV*EN<I-#SD].H@6"
MYDUS01E8:HA3(@A=9-WQR]K/;-EK=^TFI74(*],I6>M1<%(&*8(.NW#Z.H2S
M7@3G]ZN</!)7*IWK6!#8CGH0+W;#R9N/M6D.!<,>L8+8HT*RROBP&N0]E$>*
MS6FW#NG$3(MZ:A0BX4:\E%./N*:?@)(O*?MWADQI'&6?0C,&+?<;22I]/B25
M#DFE&Y)4VL^9L[P2+%BXMWP]];4TS2@6#\^!R*JF2*AHS?@_I8Q84'-(57"4
M%S_);S+1D!UT*A'S($7BZ@XBQ71TY7H KFOEU 4,]<$:\TT1FUU9&B:$Z4 )
M>%90ER;3C.!&-M[92.R0QO$4+89/)ZP8:E7(ZZUN0J6<O(H#=.LU7C.\=>.W
M;C*D[FA+%:A<_<2PV)@J2\DGG?/C6$+EHK'!7>,&LMR3>"?CTBE.S)U'"[S?
MNYP8"?M<8XM2JOBS)9N\TH9*%W*2#H?,*:N(]U':FV DY#:9<6O [\VS&$GN
M YASS\])1#;*K)J4^G!4S_(UFG@S2YE.(8V2F8&2,'<EQG:_W-A$E_6R11[;
ME=%I4B.4:UT[:@9K:@BFU["?%*3C8GV)(1B8PG)MF@4QH GC9< 'A2@D>"K8
M%G;JI!<UXF8KHV.4(U"0UAWJT+Z@W$VP/2U"..#O39: O\$8F:JI$12<0NW!
M"=GB=MBKRX12]&TB_J2VJ!"\>:/@]T:L4 "!V-_8NWP,1)OHHB26ZRB?>X-6
M;H4DQ] )9SE6&U+CJ\QE"IR%18&[6.$$*'1HG/':M])2)$%-I#)96XB@NQSQ
M#6:;Q>PX7YH.,EK7;M,LTAT1FUK/B>N;!/BU,TDV1!J<90[NBY:!0&[(XE!5
MGQ31#<5G[?9K,$CLV<+^/=E=&JC.A$R]ON0FV078HXC?,D\Y,;Q0..XNG0_^
MB$]1OSQ*38Y8QR1VF),TWH8+F.3L^L.W$$8#9>3OFLP_XYGL&/5._A!"VY$>
MWC$ZX#S)M-3FIEU&@XDT(3L1\?1+$;3,R)P&Y9:V)CT*= (!EA;J#>.GQPNM
MTN!+[[ T/@K/@<@PEF1TBQ&-'&O=E/S_TA8R.R+)<J8,>7K\ *SE%<^_#.YB
M>V_.+<,3* KF5.@.I@S"B7&+N_RN;3.34DKJ%K%(RGZX@\/.I4?BZ1502+9>
MJL=Z.1Q+P^R_6EURFGN<7/-4H*^\('>,X1U7C6H:/S48!0IAXHI3$Y[=D3+H
M9>[)W>4WVU(]M\!;1_/D=*TU-HG2CC>$',^G_4GL).G1Y#)%XSV'9YKF^689
MJCGF4+PB9O)P<LZHUL&ZB0^DNA&C:A*Z48]&BD]'JGRW%<(ZP7+=-ORRM@?G
MCC:I'Z]B0*UVG1:T'=5G&>Q#Y&7\DO:SNBD5%QV8'&6QU]RVXJR\;)OBLDY!
M!M$H_FIE>C^)2_,KVBZ4S;:R%;>#\9[(A+%>3U.,@:(7YS'DZW[[F6- ?.=@
MP'B4)SD:J)J<+\G5;>?^+X8^$-N>9V:2>)U8RQ*0_ZT(P9B4)"^U:.WHB\E5
M$F<PC=+E"R;^_*5<P68174Y@FI+U IL9?QGW+]EG7.!!^I34?!-@6'=,OM52
MP2I6=[)0P5IXS'#RZO*Z%D6V]V/(T'Z*<O;SFB0X3'!([+Y#BO FR=O.Z;$A
M%:MDSAAU6!U-:(""Z>66=#)TUI=I(?  N%E++#>J:S8TJYV@W,%8&W21@4=4
MUPA=L@Y"J#9GXHC]33[RW1;M'2/;+1YN'QJX-\'.=FS$*+CPJ],=N)4O"\FZ
MLJ&&UTNI9Q3C<G#!D.21]]X%P)M"V]7-M+<_O>=T2.\9TGLV.+U'%_\LY1HB
MRTB(N7F0^5?K970GKM.$8>OE/,UUF6Y)B%,@$%HI6%.K.KT] BZ[A^FG4:K;
M7F;2*O(X1N/+=7'[:@BZ/W\6> D/OVZ%TT&:!/HY(_,<[P2>=I<&OZPA!F[[
MC8)!HW+%*,OPQAQ<.+Y3G B @*T.F/+=YI4Y4,%?%B7Y_L!F7P5,O05]]@BD
M[X#M27\'#;.'3@<.WQ<8!L%\!&RZ-L?X.V> H&_(@>'K]IS=!<G.Z9_E)M(X
M%Z>5Z,#)+D-,X6GX.JY D*C,M'Y;)VQYQ_C=X/78WC##6R]"'*=Y*6T6/?=O
M@OT1@!>)_S2?3E7!Z%R93KI3V,D1B>S[PZ/C\+ENE<-4@^FK)AV4LA37&=Z(
MO3)*3:\6QL MDFMTZ5]@E)L 5G_7\0K$2J?@=S=I$S@(+@^TD30X/)"T6+X5
MG7>!&@&AM]S/CL55GAZ<TBJIYE\).FF1H"Q&W8%D@#B31*]AH%B:<:6[5.2P
MZ$OI4B'MB. E->>N3D'J'#O.<NP1I+A'$'PWRS.UT'V+> TZ#TSW$8!+S)J:
M[@B&/4:D+7&T]]RQXSOZD9PQ -[!BV?[E%$<P;<(1[6#OQ>]HOLQ6TK+Z73<
MEB;(,^I_+=&-M?:$5*92,R[)UB"XE>Z,"P0*FU>ZXJR1]&<RM#$S,%IP0K5-
M(H8!@"HH$A$5V#"3EF\ZJG-N!M7KF;Z9.J A??:86>ZLSFC==3J@=RO$/3DT
M%1Z!A)N:P&-1*SV9\KIGNM/<JV@!G(2LG2JI:C$G7N=QS?W9"#=N(H46J%<S
MPC!26Y7,NCB#/2@GV14-RVX$1MCHI++]G$SQ8\\^CA>@:(Z+.BH6@IYW2,&D
M(RY[/NK?/PO7UIJ ;G%39[H7Q_VGL<,Q05*QJ*,4C#NM"TH; U'%MX6"FI,:
MS@Y3QI Y+ MS2>:(Y'_"_]\-O1Y+QBQ$<.2O7.2Z1"O^#7.LUR^:6%L5L7E&
MMB)B+GDQ$A9W+.E&@O55;N^-"1BR(MZ1L:-Y@M6H00F78##FA&=E1P.6WI0S
M? J9T$U>?"*&',W1M*'/]9'K9KNV< /7(VOQD[>Z\[_6;U"/QU(L]*%<$$SK
M!P/3>F%A6L\=F%;S _%@?,CK(I8=^4UF^Y9.4;/;KFD.<-5/U^J@VCD1)*3C
MZ9SOWB(<@\ [C:[S8AD7<5**Z88NO]^#E;*]5LJ[1NZ&"P6]/KFL0R4-$-S>
ML21(Z"054Y@PP&X(EU>.>(NNHR0E\NJISM)&CKT872L5&-<ZUOV?;#=%NX82
M-96.IS='2T#OYR^J0,S$,\3A):U?8&9*6V_EFD2:4V#S"W;.VTVG;V0\[J8A
MQ@X57X9HFZ+.2NI8=84]04-^263&?24F+Z5#VPH;G!>HUG#L(#69#ASW_4]1
M_*D$\L1=UM5H5#S@T -EO''IG)Z5[G0S4U+DT_TUX1*[2!)8Z&0FW-P^@4SN
M^DK*(;E.*JJL']FT2NRE;<%3]M>3F2!$R,K/5&&I3&_JG%];*=Y*LHJTR8HW
M=@G,D5NEF"9_U-0Q+])P)]X0:[3ZC1II]L[1(X:^LVQK&&!"'%=!HGK..=M)
M218VY5]&A2@_OT;E)/IC%/R.^T(37N_^\[XTE<0DF];ETI).['1D=LV88\9\
M<=+SD6>,0$TCJX30J[)<<AKH5[9]0 M6QKIW..>?G=T4ZNEX.7IY8$^X32 V
M%:UT\R6IU",5GTL.R*PD&K+^B*/H.#C8.PAV+G>-R=T%D"Z)C&YC9G3#P'\'
M@U?[B>B7CEM+E[*9QO*>23\XK;_%5+U'UB$,Z!]K"_.D$)='882MXP$!>5XY
MK7>M7/\9YK/W(8:U[KW/87/SX S1,HC3G\\(EIK]<L8/^_S$]<.&#O*?D[QH
MVLQ3O!"?I\I8PKF.4G' :_^P];ZB'56#_LI=Y6AL/3C,+#);/5;5#>HZ?X/M
MS:CTE&0O5]\NN@=<>+V.V27<>-[IS2 US(TS,K?XF\W5>C'D:@VY6IN?J^7:
M"FP C<D"YQ9_R#BN+=_H80?2!UR1H?7/NDC*21([(Y))I;(HIG)=*7P"5G&)
M43[%G":-;A"M@?%(*K#-\H*,M3EL#T8KR-])?7Y@!^ ]NZ3\J@AMKHA< !%5
MO)JILR5 S.E*<%-MVT)JQ@,<DUST*OMG3G_2"XK\*ADSC^\KW_72-';T_FB<
M#+U@4R=N-5H<H$NQ;EFP.*PKEGISP&$OB2:;W><[;<&F@6NZ):#-HRTA^!V;
M/UZD(I\*X"R6:\5*%["AYD]SU9-E.1#*9$,K340H?ZC',@TZ.@;W405ZJ:6(
MB92]1,P+^)TIZY"\FM*ZZAVM((3GP J*C(#4$JZT$I2;A;75#;9 ["P0?T%/
M@MX%#R94SI:;Q#<T8XB:$)(&;R-M@MZ%&(1^3B[Z,<6^)Y@IY&BY=.59M\61
M(DRIB^)%0[416RQPT'<*!?<!U8#(HF1(35MB,];;7H6=Y-8+>[9I^@-7DIEX
MSFL7BTB[&D1QLN1/E?AX6WD]LL-V+&\.>@IT\LW8([ZB88)R-5[1:#*G2]^F
M2>J&;7[+*.Q$08[2::A+ QN+$R]/PIGOWF6@K"RE#Q3GFNSZ\_/: HCV9=/Z
MM-/G C4W+$\W[NRR=>OR,>IJ0NWP(GA3Y12LP!Z*,H7_T?U!_BH:'F:.Y7/@
M5A1,]YPX/(@%:O)59N$>.*8,OT0I:Z,M&"V:\]]</1KV?28>(3^>CI^\S8L;
MA-RYJ LX@M)ZK3H<<&8)H& 9VL2]XP0#3+"C;4'F<0L'+'A4P)@D=FB8#=$J
M7JI"9;')-O&;#R\+?:^Y+W"Z></$P-^#W0&GC?>>SAODID3U3%[FV03D:*E9
MB$F SO0IP>MB*=60/F]=U_JQTH41J([24]TFD-$8.P<[/.[.T'MK@P0Y*:0V
M:F1*K ^\[&Y*T5T:;Y(?=AFB0ZSSB?FB$#$H%T00SN'MHQZ60=HQ-1D<4-L;
MC^SE$!YZH'_>)KWE*@'A]D<-"AN'^S #<:A%?XK<PS;V1O4P2E H26U+3U?1
MY8&[5GC/4U\&AK.]#.=7@:+KLR\P<-SX5FP\BWM_%SKK)"\Q8OT"+^O-EN32
M\S*-,/#)R<!H3I'WNG!^^?JOK_XV<+RGS?$F8%.30]SZ+)@B\^)+<4/6U0<V
MN+UL\*PTV=L8(XK(5,1,=@H!@D:UT#:DV&4Z5N6X$HW7Z*?0YZ#:&P#J/ Z^
MG$I[*%+>PZRNP1 W*EU[J:AP=^ A)(:W*_<5%4_];G[;@H&2.JAS;J:DF3T2
MX<W K;>86Q-X.US]DOPC5!\4H4Q.J)SI=F$]]#_,;0&"ZR(T/V@V"3@##G0K
MKGIR>IH:ID)-52& =NA833)$T(1/J3">T?0D^Y>+]"K^5'RX"7=YN>EG:I0T
M%W%<D/!BRT;=%19]>!Q5BY;1$OU=*LDIEY,1H!'/'M48Q"(H2XK]=:3/X30U
M/" Y42431I9YCZUF?$EV5J@,2T*Y+\$MUB\5DT%Q?XK\V30V1]H<F/+V,N6/
M5ZLZ2!@(?6Q8!%+9P?%<A?%I^CMPB(UTZM]5DH;!7_,*@YIN&]Y?,+Q:!G_[
MVT48I'G,D*15\/SD>? VF0)K.[M66:T8K/WO>?$)_OI[<+!_<,SEG]=)%"!X
M:7"CQC$F3;AS'<7Y#&N/,;)F^L$XF=W4:"+3UH)>.@U'8R,'GM2%%C>F+4$/
M1GBAD"OC7V9;-8YZ9LO6W_.O7D?2 ZA:=1:V:\?:30&H+0D(% R/X0[A ]=)
M4=7.3S#TCHR?4',7NN,*I<(+HU]S=@EW\I$8G2U8Q#PSKJK6V>]]#>V_CN6S
MOQ[0%#&;"1X2B<1&EEWS6WSI2T80AK]:7_/(99XFR#__&\\/]OH7V ^,$;ZD
MC0<.1_LX890@!HZIZB+3=-<A?W4< 14!*K>G$RW4/$KPZ3F6NF;7*LWG:A3\
M9%ZB72%Z%/]=MG6:\T8>4@^F[PKJ#@FE64O3EM#>"$[O^I=^79)-$M!%:DQI
M^#:Z91[M#RF:0XKFYJ=H(ORX4>*=6U]Q@S9&P]8%6VM*%2ZZHA[3>.'Q<J/0
M'H&$1ZX!(R)DNUAZR'4<'M.<!]5*"I@Z2",2Q!&V+9JL,9<R#S3,NUF$EN^X
M.M..#GF217E8=WPCY'7[N!G#DV.3O,Q=A>Z8$F5Z,RC,WYP:SD(W?YS5:97,
M4Z4+N4H+M-K8,$Q9LJ^BW!B5E74A::L"<-%\#RV_ VO?EG1)N@P8C%C/AG2B
M<XETH_5(X/8MLCXG;64YUG )JCWW,Q%7#0O^):8HXZ^CR&/,_F7C-U?:7*+)
M9Y1T.#[Q]9I*Z49MRXES7%?:!7J)Y^^M"4Z8O /MBQ0*^G]# ?0I,RI)5YP)
MD(YD/]I&<X^5H/7(:M$YRMU,5:P:72?8R_7FYF;45.@/G\'NUYC5!SK3 A/
M@)$X\$@1& /JDP;R.3AX>?RBKT=!9XL"<GESJP!/X;KBS'"5<1=+FA^5]J@Q
M8I?L/A86X2,?VP6V\3/J+*+;,-AEFNY-@;\$.^BB$M%!6$\Y1D6R:!+MVKU?
M=]=Q^%W$?'V">[U>.S@\!]ZI;'UI:NQ%/)R5%N,2XQA)P,>L:3+.QA%S_Y*8
MV[_H+GW+)PNOH,NGWR#WSV$3-*:53O1*3#@O<H,]0FBZ]$9,A^[F[;Q^=!CS
M/E)5.^;8Q\D\6M<4)YO(U'][[HG'HN$5+:C6UQH,5#'7R\Q4E)7=:H]UCU!#
M!1;[(;?KR1MJA<53I78Y3H>?U@--/8&;,3?*)&0NI'S X7!!"J+RW60T08,.
M%7,;;,J/)Z\Y=X)V6OB(,D/#]DV)//)KJ@NZ;S1K4^75G51@<PT=;P\7"< .
M7P-+TAX#JO5<MHVTXEF./8JB4K;*.)Q0/5&IXFZMJ*CI5MI:7J,^H]>K4'D1
MO_!3]P)_V\$ 8!2S19=YLXQ-($N>+7JO3E1C^5,E?5:)^NP[D&//AK##%H<=
M3*W%>=MHU=03!=R)QO9_TW G[*>.#-%T&*12ND_Q6\4L5*C1,GZG!3 5STQ=
M&4&S0$)CYP;(-:X._921L"@[B%L7>J!=24(C81T&.6EXS^ K]?PTA5]3KH7J
M,*&]'GEAW\X@/&55NGW%-7_7MKN1&L;Q/[.@,XG%"64ABQO8$/,$<]AM_W/(
M7CNBHHI'9\F*4DPDH^ENMU3<1^0#Z1&FH^ WDS+DX./#"5]'19+79<#!>\&*
MPS)!^D=IB_Z4%/QI.]Z=1^A.!!16= VTY'D3R3T#5=XVHT<I/D/Y7I2Z*34Y
MOT2K6*8T]$;]G5*J;,( RZ"6JR6.EYXUD0]OK-)$8?PK39V\2?3=6X>+JU;I
MS 7MX'!N7WOIDJ=1<*^_^V\P5HS19\Z&D<[O>Y7"MEL)[8RV#D9XQ--UCX+0
MHTD!;/(49D)T<8D&D3M2%A,#'7=2MC^_I?1MKJXHR%U7IO.Y#MKA*='JG&4;
MYYAXOO1NP(AL)3J;HMLI:@\>L0\RCNHT*@SAX!=L';B_-N"_.L'2I1*##R!K
M"=M.7H'H8G>:9BSZE0@6S7Q8H'8C(P7X[4B9=)*:=9\%C6\(L3KUR%GHWT1%
M7;!65:+J ?H[AT__J/.BQLBSGJJ _*%KB@Y'1ZI7>RL'3><)JM944"ANKT+:
MAJ_A%F$E:E"0MU=!OF->3H?S>EFJSM=)RQEUI+QK+(U2RMRIL^+\:E$B,?$+
M".=06*L)U?R<WX R M(20S#L0<ZSRQPWXC+-Q]@M EZA9DDLB"$F!%F2RNNI
M*,:U$J[.&@(1DGNN/O%?-URBU/M"X[?8U$_CZW("9/#PP0GH0Y=)U71%^AHR
MYJ0Z'O"\:(A="OQ)VD?"(YLG-.:)Y-TXS<,8\'*9GI^LT$VX:]4*ZI3M%"J]
M1,<4##^G%M:]E#EJ;2&;A.8P2>5TW,-\U$MGXF%\@G0N*FQ>8!4<&AO]5Y2[
M-$GP3F!8%K4L>I%V+C>=X#!JA]>[H@LVYRANK)7G2L57&9%X6<_G.<Q!3IR!
M-.4J@Q91V3A]\WUI3KL(N]"G"VQ_/LW!D$\SY-/<-9_FJ>LRW[H*G!.. D)A
MILKF+*UC- T:\/9JP 8%=)K<PK&WU%M' ;AS(K41_M2F*VKJ;(P"Q?1%Z:_X
MH<'2[DGAMG[G%JD2B#K[^BI&*YZAYCOE1+*5<S6ZKS]1=-N2PXK>@7X.6#JJ
M:;:WT16%Z<HK:D2DW19>A)]"F]:AAPT#2"$<7!(#/^XO_9FAJLP1]HDNX1]X
M[9;SV@ZKR_(QC/BO7W2"3)@Q&KWLQV8"B 4M;3)3W9?Q3AQXW3(5]CP0ZS\\
M$F#5_34Z1@CL+-5#UA7U>Q#+?Q+8'I?-<7Y:<YR!FSY%;JJ[%W!@%7T.$C,8
MV.D6LU,Y0Z-+>JP5T4IT*R&.\6%AI:1I&:7/C&&<0Z*^K5>?,0TD1XNJ%?P
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M-UTGIN1(@1( >O8%=V3.<JVNT^!.VYFU%F9\F5&*O!JV^EHY641VPD,1YZ#
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M9H1-M\+0FFM,?*;K-R3C9"():>A;S@L0XY& ,P(;!+T4HUYD4]_'MZR-[4S
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M@/2RKB9=:23=!:<[>@I*$GM\#%MC2IB// !I$YW5Z4B-YJJ(R0G_IO+N$F8
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MG2WMVH=*,MJB6MY+$LNZO.8G6ERQ:3]346;UM:4-0;SV6[GV7'+H/%%V$-K
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MF4]TIJHM?(DXZ1C1*F!-' _L(D'/;BP[MMY:H3$0@UZ*E&X+:(";2-TN';
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M>,)4\^Q/P;[^R_!CW.F SCBP?_9?T)6K=;W0!Y361:>33/[\W3]^3C_!4R_
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M8E<J&Q\,SZ6IA#C:S0'A0^\:1.%W4%% !(D@3B.<R.@HN42@9KEE3/S#)PU
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M/&!U@ #[,_4B!C7P8D\ =U&[>%):7-%>5Y-A[P"2SBVP<0,Y>)2N!SRRN$U
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M=JJA<<;<3X,JW"?4,PQ/'V#_L[Z76DQ7%%6;H"3L*L66 I*4<"9KE/H^X7J
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M!(8CD2,<C=@GL-E^D^S7<]#KR7N:%7%%.BB@!V!E("MXE==F!=_KUZ7*>HV
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M/]^%F."CP!X=:C5..P1,"6E./RRW']GGH2$?2LC;+$P\?708<"0/GG(O-Q'
MU2. YTT$L(D -A' &D0 JT49YVE':$B@2Y5F+D4XGY95-)6L1&[@Y$Z..LOQ
MUIR)(M40S(7[2OEJ)DLE%V2Y-YDYNKI49GT,A!\^-%6=VR[V6;U;P?.7^VA_
MVS)!@[RS.8L[9+/TYKK?N5;9B'FI)V1.N9^[?9KO5^+F;+?:[>/,,V3K1$NU
M'D[S4A%># 7W^HL7A:Y&.4#Y=S M/&=LO0<;RO>26P=4,=OZ]2\_=;LG;X"*
M?L>SI]?^CJF5OO46[.ML_C*'+T5$PQ *&AVEM4D?A"@F/&()AU+J7$.I Q/C
M@QA$*:Q6ABV[Y%_N60?(9&2$E<('7HQF#:Z*XC6.-4PQ&108"B;;SA^]1D^1
M.7+P[Z&=)8BZ D^'@E4 >(>SPS"0-YF9,$<0D(VJ,9R8A4FS6%=ELGH^01R7
M-/C#:/)JJL"<LPYV<5!(/,TR;S.PV^3F"?U[%:)B[Y^C-LYOP> DGJ&+FX57
MTG@V6-RMW'#FWRCX?4 #!^)%V_T"'G-P$5M@=7E $9P@*0MP%*!<W_'&9-RX
M !Q/:]6%"B"Z@ID\[!M 1!P<74R864N'1:FU3(RKC+$T(T!R=&E),"P!I488
MBO_!6F1QF*48/X11<D<Y(0/A.FE<S-<W_+EE!2FJ;H0>YWO?<?%D=(S$ P>^
M@ZEM!8(\V$)Z.M6;E@N.<;1$&9/L'M.#^_)135W3([UF<(&!4Q+=4L8;'1O(
M!X#R=4K+-6]0:U\ZOCDF1WB&0 0I>L+(\?R8L_EEZ6$%^T$7H!>8Z#E$]NN%
MV,U"YV)3]L$L7I[9W1[.<^SQ2T',W".?NL9Z#:IST\-B,S%20,;8&Z<^< L1
MIK$_K8X*+Q7N7D;V 'OM26*B4 ?Y?L2/"?;6UTC<LBY!-7"\V5>7HY-I6G\%
M"3%!+]4[X7!ERCL'6 28]-$M\$5X/F5LQ+*4PE'#XTFEE)\%;#\<P]9TZ%!!
M?Q&@%:_IVR?'_2591AF7J'4SK$;;K+.V^34GL;(T@JIR+,#Q4'9U>)2PJTK\
M8%F'\C:-#/IEZD\!GYQ$U=6$ 1Y2590D5W-&O#8-C,0Q?-<(7H5)A9$S%,R1
MC<J_.V>89T\R' I*3\K,*8OR#XA9IA.I9,ZD/!02 A9/X>+G7#GQT/FS)!V"
M&?H82VXP"H[QN BSR5@Q(?4SE_SXJ'R6EO6O\ ''A]G6K8?A8;*SS5RA.>BB
M M2&^NA*9JT. P6SR9+9-"\4R$N5 \QH'#(<SZZ!SHQ4&CH@SC_*1)ZQ/LU]
M"ZB\O'PLP]W]0U"Y742_FB!B(^4:*;>>E,MIA;,Q$R(V(S%/Y4./9HT,G4]=
MX%EY*<;&(H44T1;5-\DZ5:*O@K/$3&_VQ@-L5S34O>0 @8["T=$$6"I0."C
M(J!J\<!-R:U2PF*0#._Y]6&05XL'XL[Q1]+- #:)ZF9!+"&D^?98R8]EJXDV
M1%3G(Q$A:9)EE:)1"H@CL)81*37UF!#+C)?8'%5>%34[;&B\H?$U:;Q0Y*R:
MBQG&]2+OGF%>8ZZUU#^PUP9(8@?^/9BLUC7SD%B)%KMFP9$SDSZX2KJ/V;EC
M8#@#"CZN"2P/H8$.KA)7%[=6P,0\]'Z25T5&I67BRX"J;1+0,4!ABQ/U4@TE
M8!6LP4Z%0^7>RHE4*#@F/YEN70,K3$@7O%/]-:1*Y17X5*%9B,EDS:Q^V1U%
M 0,8K<R&Y/2U$7-:75Z, $&>*B%"]=PT6U,FM1VH<(X3%!T90S$1E%< FA[#
M\)#@C"YF$"3H!I6M$4)*2!VF+I=JZP)O6[9[D:H.^;'R?%85WGC*?X!;Q4+O
M-$:)0)%JKA; A")VKCN,,@003D&'-:2N,$"<M4\M38&F1DX^-^\A-9JKVW73
MOI\[[5:W3\JAZ0HLM-M+N,D"]H&1;YVY01WT[!*<DO1[D;GR*GK(X/G*ZC8X
MKZIEHJCB.IJ4#0ZU!*TL&P\FGZ6=]T&C,U.EXF<)XAFE9(7]U)YA6D!DYX?I
MOK85D0X-.P;1%H1I,LV:8:"OD)(L2]'UB-&5,:T2F^@%K/&@4<%4'BDW)Q6V
M^+[A.L6:(X2M;#\U"^] &3M>^0+9-3]#.&![90VGZ1HLP]0CX'"\M'(,*FZC
M#$4%&2^O<QE?&_& FRQW^,)M3(9&G7B,8TRKYM)5;=92)H7?W0H?=+F-(=W)
MPWMLBC.4G%F)+!0I#V%$N8*N,\&D0Z.^):. G_MM]KTQZ_SD1.Z=#$OVV3Y7
MJ0MFE$^^-%>J*Q46MB1(/(TQ;!)1NKZPK:'1HLM\S;'N,7BG6UI<9S=?P<TR
MN_%0E<$,9'!%,A<-0E.U,J0?\=<PBD T<6.<GY7#4<=RE$YP4/0A*>6"'T?E
MS&@N!8D_-2%RR,ZB9@S59G+E^NTF5Z[)E6MRY9HQ5+NAC-1:"YD1IM35/*8A
M]-H0&0"N4?I,&E#IG(P>H-%#+KNL4R=VD531);C)][+&YV1T<?6A=I1PN88*
MX)?Z3)07,TLTTD7(90E6,K]AX6.K,QUTW0DFD\P,%2FJ361NHJSW9&/?&;,W
M$FBNL2M4:4;Y>O_B,_5EU ].&_:#%(VCK ZUVM+-6OW%:G[(AM:@2^>)N0CE
MTC#J+I5O! L>[J7-Q$8P-I@%#<\/G<!H2+?D,N298"NUQN:J)9O;!9NK+"["
M9@HIG5R=SW;#Q5^<\>3-%^O#]46N+[8(J&8:J.+/%#D:93!BIYIL6)#J(HS<
M!A[I4LK@M) "=RE#I)3\Z(VL0*!+Q(FF-OG*0(>-X00,'V>L+)OR;/*5G+NR
MNZ9VW$G+I\/F'ED_!Y136I8RA5FY65(N&#?%44\&Z.S9'BEW#D_N>$SW#UO[
M8\GH8[9$M=HYH\_JV,J"79Q)P.U,9 0>74XNB05XQLG)"?QWNL0SEDHYZUMC
M3*^47FM5-5#M?@ZSI_ YY1NC=K(S6VZ3I0_1FRQ/9,CP7V.F63)I8FG>$5YP
MU*O>UUF75SIVI"$MUQ93TK9&[>4IN+0JKVQIS\_GR'51'>J08Q5R;FV-1;*S
MCL'^*#U1>I15L_ABPU]9%WZA(@06-4K&.*XCZYI_]6X)^\B3ZGJ1FX[10>)R
M+6^6)O-5WH70_"!$ILPH-9-:/=!C;/50P$4@?M1Q<H%RO0)J'R=TRJ=B"GDN
M1,]%5M0H&(V"L2;A?0ZLB_062(T-J7-R7W:8MW_D<N XKVLX&EWE[QD-E?@L
MJRO"]-,SL<%MQU2RN='T)#=E0PT>H.QCW;>[U&@R'*#XV*Q_F*YNSC*'=55S
M4<Z31"A[/+=]E!V8U?P*O?J2^2!5#\\5\ZLZ$E.&@2F)P<N<-I@+&14#Q54I
MYJ0/8A4-'V60/87C3(H9R@"Q%'%9CLZB%S2<J.%$FP@OY1F$[IDS:_74AQ=5
M:EB*8(U>B?F1L0F1<.;5*5@G14W%-MD.1:?SU4FY1+WBZA_=Q;!H.\TY@)QJ
M@RI9!EV5_2Q5>Q\5^O,.*_3JEO=.%."8VZP($JR5D? 2:@$V(H,@*SY3=WV-
MO-M;9G;O2=E#RP2!%;HR-;"TR6/%2V6W2DJ (F=;%F0S<S*4;4P\=5A(@QQY
M(VH]&]!D(LQI+\GJD$^H-?]L-^RSONRS2)=?Q*W'O2#UL.U*V@R&1@U"YB;U
MU!P:<CBYH"3"@FD"N_%HU>TPP_D)$.#T",UN_:-9[!#J,EU^<9KPM62OQ6QR
M%R@4%[N<JZ#,&: 8-O=\D?O*6\;+L[\;8U*%)%7O:0]==E@J/715YO=%<(_7
M^,Z;L+S\(L_QFEM.?<V2XF2)#6ERW3<D(+#ITI;1-^OYM-M3-0TMQK0^N")<
M]BNF(*>,9^CD^<-E:W]MBSH+A#QL7OHU1BE)Q0&:-=AVH)!>K_/N=4<0U8V-
MLEMB#P#E1$:.7"@#5E_O5J]-=F3Z+!#TG3?P=%/RF)]#<3EL&X7JT ,F_]*J
M.8/S/O3OY:)M(\HR\)W@N^7>"2!S5Q>T3\R^$"J4IJ ]+YC6LCZ%D0BI@JLJ
M2VE>X34E0-/Q)50;(&?HZ.+X$17#PADG9$QQ+A-U7Z"T&WWFA:PI@APG5.I[
M 5_AG*+B$,LJT*M.<(P(EO- Q7.C# KA!..#::":B>*"9,8F*;( 4]1**%=:
M8RN/T\H":IDVFR&643B&A?M" W;D@>WJD=I#,^F22";$#E.\L] D/E'-;'5%
M%]PR @;(/0?,@F+5QUHJ7OQZ6A!FA!*CQ][74=GFIZK_V$!D7<15;ECV1B-,
M"!<Q;A9-;6Z"IN.,6;E(!<PEM+/>Y;#V C#-"C&OZB ,F6JHP1FT&;Q+-H8H
MH->"+'Z=4F].+ >U608^X]PQ.3QU!$! ZJYQ!.0TD),DX:*L47VD,%IW194#
M.[@)NO$(ZBF"\,'J>^-Y?!0L^W PF$^<DI)J(PMA[3J@^1&FQ+J&O?S5<AH=
M1LR"W+NSS>-OTOVO _JHW@!4'%@!5P YL4<3(KTX4W5FD&D1X!%Y)#IP_UE"
MU")E%*H^YN]/)1I3,G3Y09&0T! SJ@'6 BC[X^.L. J9#8N;?'*$K&TU4L(S
MXBK?.F TE8KFHXX"\S/EU-92-R&GB#>#P-9(;>PTJ8U-:F.3VEB#-H#K-N 6
M/\"8Y[Y I3IE-EG9N_44NT8]S@MX.@25LHS,6<;9KY12!41=5@2CWZ>:FYNO
M5=]E14 >YK'0Q%P>;VRX1BFG;X'7M"Y-I$V+*I\TH8?ND$$W;]Y.OBW9S&P=
M%'0$HK6&[)2GK^1'V^-0>VQ'4C;5 K?1LGX+L T6$-Q8S+7A<I'TLK:_#" -
MG\28;5 Q2!F4I#_ S,R*J_#&&',V$A7K*UMW6<5X,->,G/6B50U<,IMUS9FX
M5#P*8+6R0^<U-I.@.DO513E^HO$\!_F):>44>XA-E^+5Q_'4D0CGS2,R?"Y#
MT-B1-W*CO*H6"*R@J^RG;(KV@Y&9-.$^*F"2!.(V3-A-8U2MQK(]*UG9V2@2
M2\T65\9A&,UX,=D#LLB'J;O7D+$M1YFK2B!\RM@CYP.690+1RO5(3P=WHR3O
MD;+N2#7/;0!AJD>D(\JE[(W$J]%HCZ4O@+$[UET=9IZ$0QT#'2294ZZKI)1*
M(%YP!B4O^CAB>&1[F[E(0DR7H]*<9+UN]4HYHX4NI?$P<.0AMHN(C0 =)I-'
MR%@P;UVR(Y,Z\?%8X^R'<D/D Q>^S\,)O5'QG?@FP^,&C.Z+N%6COSX9;@!S
MA*#VPUDCX"[8<=,(%?K. X#EAG*P,WBRTY&Z_;(%JOTYH.H'X8,OAK><0U#H
M2)1-^TON:&0ECTG@A'9DXH49XOFL48PPH%5H^< [Y4X&(A X,@>;;CX$_&4D
MPI'R444\3X$X;ZPG9:N6 ^R2+0PLJ@N#FFW=8/+HL$J3FL^Q##95)(^EV!)Y
M<<M$Y\.=Z@;H@^TVG/*04L9;#6_%-6?F9#&* &K/-$O5F71F.P>>FZ%=8YZ:
MB:IXDTS$,16%NISJU[M<*]HBUU"[A4WH-@.D%Q3&$"Y4US("&!"Q1M0B-Z'F
M =]!C[\+PR%UE!LDLSUJEQOF0.$-W>5 9YEKGYC&3>P3 -H FPZJ^VDDLEFU
M/_=E(F?'1L9)X[UP#=1 (^,AAH-=0BH+($@7[5@D'+$P8%S"G=$1KT2!:\#<
MZ!"A9M4;5^:U&JV/TK.SBP+%W"FE0PY?R1AX<=C1*,PG?"V;$ ^Z7^F^4"<W
M.#@/A<LE+B^E(EBZD0,E3F@X9_71*-#P1.M"6;F\]'+AB'5!MJG]RS#NR ^=
M1 WD76KFGO3@,[X,=40D0QI#,!GCO4H.)WN*;<1B2*WP$NK:CR$,'LD+E,J!
MJDC2+;WTSS1,I#'B2SL^I ;C0SEVI_!6<DOS*>>EO9!J05U.=*Z*GDFYG-/B
MKV6B#N@-CF+B),+*Q@22%B.;?&7I!=DT/37I>9[4+5M$V0*D28!E'Z4R-D-3
MX-92R9]9$BI:<CQRJ@0^#P0?3.F,:?CCA/SAIHSE>>@F*QI,\T\^R&H:V+\W
M!_4/#8L#7XJCOR2>L=6IU-J5RGN :>=*,!;J.R607Z#OF$FOZA0TX)5:3[)
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M,CQ/,9V-\ST*;.:"XI)O"3XCA\YH#I7O1CEGL:KZ_7CBAU,AK$\RQ&]V9>
M"A4'2@_G.ZR3]@8I>[ H.U2G6Y? R[K%[ #TT*L</Z.U>%=V%B<OKM8S:93<
MQ/<2%=P* "YECR:90K_*$S6)R5;YKE.,-468R2E;8,HT1#"@/?2!ECV97Z\<
ME-RSDTY?#ED+5==2MG$Q=R Y4FA$K\G)/=WL@SW?SO"/E+3A,OPR6X/DF(,!
MH)*!>^R#'PN9BR@C?3(9L3C%BB[$>DPUGYD#=&J2#!PW#XY3U>O94-LL[\,H
MT"O=AC<>BZ''D>'<>#@3@=[H(1EV%B*5TZ<HFC(6."HOUI[4$NJ\OOE-O5-5
M?<HN2.2B'?EJ#(WY8MS0.,4</UB>S&-6QSUS:IS&K\=Y2-O:6/'L2A36 [)A
M\RD.W'EJ31)KDC#)9X;#3TD:!=:!=%=\O?FB.^NK,S<VAR>H2@$U7F:%"G)@
M#:R0)OQP5(OJ$9BH<0CG$0[UR4%<CAJNB9F\)6;%M08EG(JR@&7S!4JE5\HP
MB24NJ)3$J\ O\28JH5_-"'0])W>P*B'_1;M##==,G,[O7-KBD0?6E9N?A\.Q
M'+RM[*VRI)@2NGYX8R9G[+KJESZ3AT<L1?KJ_13A]*<5)U)@F U?7((O/CU#
M-.%&/6SA\0RA,%]'39(3UB,#M<LQK+KPG@N&TOO12-9$X*ML*F>2>/AY(M%(
M_OT%=VK(;]QY?L:4G7GG<N-:YM,-%WYEPR/ET%G5-,SH$*-79'RG5V5\QRO+
MZCWD.'ECG;*5WP#7B!E"_G0^+>$>:,R<00!R^:K1F<EI*_>JM"AS0AN_CR"7
MY6OJ,6Q>(-OOX"_3$LP.AN5S*$TT+O;G,;F T<'T2#<3*C !Q:%4YT5,^]')
M %_PWD+LURG'+CJ!K&J@0A@H1% E2D:B9J';E^35H8I#XVPTQ7JSF[).1&5=
MB KLM&Q!8Y0AS <E!-0Z\D!0B3"%558P;G-Z-' '"M-S\DE&%48Y9*Z3T=Q(
M3^8 PO-5(07J'R&"V.&T#XK;7&%ZL]36K!MLJ!1-<]=9'";48:&E#'UU^E\K
MI/E,0"?K$CT4"0Z[;#4^],:QA#%++'OC$F+ Y$LF-8_:;211Z%L7F)W/U4LO
MR+TD-1:58$[Y+QI06  HR_D*?8!=#3Y7@B^[2S>2E;G4A0#>K*=)L3KC1J4;
M24.D<(<4N=DZ>82J+.5;9;3 @_*.41^:83A)R@%@I!"OLG6COU2F4LR%1%[-
M#D"'*'/MV3Q?>I[*$9OVMF/@=H[Y2V8\T\WN.?K7;5RTR*M7(W3O^8ENH;QJ
M)N]M)/^LU^2?-?EG3?Y9,WFO49.75Y-+Y3"FZMU&SOCEZ,6/UR*QMX-03GC=
M%L8UH3H!DG=E+T$R[)7:RRTQ G1(T+0A3)OP BIDDOV 5&L:=C?2E3&Y(,*)
M=N5\R=R;^$!,=2]=U"ZJA*6_[98VMWU>VZ2Z;)757G[XC/E10-:_"HS1O6CN
MBLVKN$C(%<HKR)R*9]+$LFI,,8C_P8CA=21BJMFUK0]4MZ5L/DQ ^Z KN502
MFO;:VK.1FL*<HT"'@HQ%4-LTRZ?#XE7_=QHEUC]3L,-',4H"G@S_00RB%&Q4
M<ZQ2=W9ZAODXV_H4R?1Y_3AJ<*L:[W$5E6#>F'4FHZ)9QY>#)7X^/N;):"!_
M0B!]BH'&0#1'6!<<!BEYKG_NZXNX^:GZR>CZJKWAQ]SF"X_'>!FF >;#%"C8
M(H\B53J=PY1(L0X4T*#5$4@CWNZ4>GW@Y?(N0VSE;J$PO'$/IR(R@+@H%(-J
MU/F9*_YEN:D33(]D^W$*U6%[!G2#S (\\\QD9XZ1:L!@D,YS[YA=.X5X5)@\
MJZGMMMM=Z]K'/$F\8?$C%?ARS^-"-?28.SY6(TK9;:Z;ID;A1R6@'!D0T:.$
MQ\()9 '_E1,/G3]E%.,3MQS+"C?[)[W^@7MX<"R3/@_P;OG*#%L_ZC>R[UXE
M9,PB_KS<A,4 R6-5.>*0-B6#?[F< 95R,/.,+ 2HX\_E*F ^E\#<VIWJIJQI
MVALMCV7&_$%\%\9\7"?E89P5B0$'NO&X.3J09MT8?<2=69?E82F[F6GV:?"<
M? *QC/,SY!1%X?-]3Z2Z\X[VP^DK=*?V.Z$B[KKPB$DD?R/Y7[$;/2O*RDN=
M&]$(/_/9&>G,<!+\80S[O9,Q=,4G45'K=(W?BP-!=$/%#*AOC)3G;!:M9I)X
M\F!>>^-TG&>I*NM@Y,4N%CHIYI5O?3E[>O2^.2_L=&<#B?D=3R(Q]F Y=Z*\
MDQ:.G\PW<[T3V)TMZ]IJ5/IR$, 41T,Q$90;$+^1&>'W:K6N*WR,,F,>H>+?
M(TH&D'+$C.<S(1H)?=1-P"C#XHQ!$T*ZJ9@:R@3K-!,/):4$J/L2-+(+%YPR
MY]!@W[C;D!:7>9()_EQ&8(1>YQ$W:RJRZ9_NI1$)7\A>*Z[O>.BI!WA-$I4%
M8.@E9B/=?-,$52D=>91.G^L=R,;AO>K7Z.0'ARD25]-)B\%\4*C'V!7F\,C
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M@(^V&XEXDAT5(GR&P@^>[^,) 1$*&DJ'.P#QX62;D(\"H/?:%JC=<)T36;"
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M=11$1B 9 1Q3N-9"_:3HB1O!D\$^ 284L:7,MZ$TE3ZZW $JWY5"300RJ0/
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M@'3(40?\R??^3+TA7?FLUO1CI,N_F#_52Z3HK"3)6[LV9QH2FB,52N*$HXH
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M/Z RF2F["E+X$$7)GILJQ7;N9&\2IVSG9O=3"B0/)<0@P % R[Q__7;W>>
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MA0?H7G>8$?>,!-O%B#+IX3 G=OW+3A/,^-2MC]O/YD7PDCGJ\!S5ZP_]87?
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M-K]SFLU7AF&N-C\@AC?.#4 /D9 AR(;*AQ+S7@_]BW[7O[H:/#YO(_,PN\B
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MIXLTE_N]BI]K2QQ$8SW&!NY7J(D=^/3<>\HH\;%R+T1%[G?(,WHU,(D5(7A
M:F7W%(D4N)TYV;?[3>#^PR[5KM=)DKIO3<8U&PMXVS Y-M9LX>C-*X: ,P1\
M$[4@^#*OTCT?Z(>FN7J3WL5H.IQ._PRZEQ-<33OY,\"QG*/Q]: [N1YUKJZ'
M/%=OZUR]BYWGZI%>G&N]>,#1>*N%-82'1/KQ9)%*ZU*A-BA5IUWMH%+K74*K
M>I896P-^4RPJ<Z"W-/WG!>!DLT=;'EZD5UFL"^Y'0GJ+E<R!W#!I0GT5!JVX
MQRMSW/PZP[2+1X^F;G7F5,U!24\_*Z:>::IJ[U-J Z38AD6:Q<2RZD.0UP]>
M;2I6?/YS[P^<86J.9-5;\*71M]\?$QD4[,@42I'PS!;@&5NN\LJ-GZD1MJI_
M=IS:_8!JK'P,[+)53X"*?"P-P&O;3@804)?-)/VDY.AVBG2*^HRE#Y5ES%/]
M8/J550%V71I')AO452ZOS[O]O]L4JB0^+.MD73^!:TZCY%Y33?_]#)-!KZ2C
M<0]TVFKEK6*S^6@PRA(4B<J+6K[0ED25?L-U::K>>;]WK.\LOW[>'1SK"Z[-
M/?;(B3VMEVX/)S^[:K>^.7_@>@:6MUWD#5ZZ);S7W$MWS@=MM9:4G2\7@A[E
M&#Q'HF]XWJMF^N2/=A'[JP>(_9,JX0.JOCUH .XL_O _ONE]LY/JZY_WKY_T
M[:\>E$OKU&4)*D/P=4SS:V(B=>: _3D '*]A2SG@%QG5-L0&VZQ#B]B K45K
MK46MM)1((+-FJ_]MP ZHY(@&-,R_>C3TW-/EB39IB:(PES5J)];1B(!3LKGO
M"/E#6@GFC^T&I"7\\5AC490P7_UM/!9B.FV%_?@M3>3[R_*SR=J_H+)ZLLB"
M>)*];$Y9/(1*#TY9U%Q=<1^U1#RG>.[@VWS; %55FM#Y%[<4$V7^RY1XT>_[
M@U[_0&SF:IF&V7_7K)WS+_YL[*],KFOLWXR);:$]W0E[L%(\;T-<YHK2.]97
MW+LP^/PJS.N7P'[=;L<?7@[\7O>*&9D9>>^*V\$9^?K*O[CJ^]>73?"Q<]G4
MI\^?NN"&-!@26T,#GLYBNT S)R*7(PA.UL;F+ND\C#\ZY_T.!]_,P@^(KQUD
MX8LC#J"?V7*WP4QO+&;L&(9;:.]:HW[$< J;7B<0TCSM.^\=K#-G,6<]3?1\
M9-'JHZA\4N%K:9#"?#&*P*B1N5/S'=C//RX__V I:!<HL7LRKYB)P +  G *
M87%% ,@F]%YSC-R2&'D/TZ\GI/PCF,U?FQ&,\P#>163_S!;E!Z-;#6G60HFP
MV'*CYW559Z8E<TRV=%^^Z.&TL<7\*./C$PA:W(A^#ZX3!WZ_W\=_F8V9C=M;
MJ.Y>^IU!S^]<-<''SH7^1QGI[V'=U0RV%S^'MT$\>0F/D8P_ZZ"^.>/>;]JR
M'X^CV P8]Q#=(FXJUFW@=7<HM;LN+J:N/J4 ';BIAH7,.:KL#9%WAU('$K*U
MZ8PC%K+C2'F8*:/R%\^&"=C@;*W<]X'>UP7G51YN!9SJ]3FTON]9TV]=H0DW
M#[ (/+_+XQ1-N.U@3R^E9L_=_L]ZWC$.1&DSI#5]&AY?S&IFEY4'DNTRO-R:
MF;9Z.7(#SB^%EF-:/Z*'EL=)+ P-/9RDZG4\VGUC#T([_%;-9C?0NK8YL^O:
MYLSRQL#5F<O*@Q5R"\GV)21J=4*<U&U-4)LQN]=#N,RV2VS8OJ#VF*_Y/LZ%
M?KY=*'*'S1,O0G%Y#>YQ"VROI0*K]GUF#UI"-%=;AVBK><TBENIVHGIIQZ?9
M)+Q2"SQD+<RVYZK;B;O##A>6JD-)5;^E4F7,X,!PK^+7AG9Q5:V+7NM88^).
MU=YTCEDP+MP6C#7B@(PE5SLC@X_$.%B0<<#?JFTE,^\^6403W&\*[![2A2!F
M>?6X)>2'Y\9F]71YD4^%$P[.G?_XV_7E\/JU8QP*GL1E_]*_'O2\12R^BG0<
MHJ>@]#(A&KQ$#R%T5ZTQ(QV:D8;7??^R=Z4YY\/'WZ6KJO[^&_R=&8@9: ,#
M^9>7,CEB*R):E_F;;)KZ(TC3P-YSQWS$?+3"1U=^3T*(:_@H#;_@NK#?(G@]
M2C\Q2S%+[> DK5=-FH$H<(0?KLGUN,Q?C8:$S%[/P5XF3V?E[K:G[!X7+3Y%
M8;)W504/7=4O<MV!A1^T@JLM:YJO>4TSKVG>0BVUE%ETQOWI]=75GYW>\/+/
MBUY'_#F:C@9_3B[Z5T%_*BX[H^ ;>5?YC5^",/[SPT\?_^O'FS>?WG_XJ'[Y
MW&ROJ6[O<-ZX%@&>V%./?,!-R!OW3ENL$>;PTN-5&.(WW_\>1[A*EY;\(FM\
MS;T$U]/?@_H']?WO19B*S,=]PB(5\5C7=D/*CV=JY3%JN!XNT*!>X@]A]MG[
M,1CG29K1;[JO,3>N/B1#<5__0OWT7E1_LC#?Q0!>_3!9I/JGMR(6:1!%2_EL
M> <5Y1=IS'7;@L]M7?S\R\$W,A80+P.+*IMTJQN/08#E2[K$<^%ZAOOF^_^7
M++SLCO+&XP!.:H$GINL>]'(IO3$>\B)6A19L3/8F(ANGX0@KA@+.TP=BW ID
MS6+#=AA33EMY'I3(GG@BRL3]'6[4UIPZ3Y.O2WA(("G&6]_!W[,YL.XB^\Z^
M@OF A";L^%Q4R,GODDS(#=;W0E9E0J1=. WE"FZX!1 ^B+S1(J=O8-$&7R&)
MD8/7W&H:C)&-%]FY]WZ1PG<5&^ *ZBA+[!*5$H>UEZ)G"Z93_#APQ%)*.9S$
M# 0A1!&G]=7TJ.EGD>,9R3WG\"L!?TEFX;CTPUN1S!/P=&B;NOB"1L7W(,Z(
M;Z62B()[4ARW"C8-W)MZP7@,CH(LHBTBO.TT6L!)J$^$>(Y *9'E7@HD@]_#
MW]($WFKF>Q#,T$7@*:; 77B_6? 7_.!.!!&P!/P<7AF?#<1\@=28A%F0P17H
M:_*-X4?I8JX>:.J)KW.Y)]T0MWC'<^^FV/6^CK!XD+14G2IWG\'YC_$\%G1+
MS1'%!X!GL#Y'/!#.#%O0<<Z")?QL'H3PK-9Q^U89!G\.U%E$.3U],H=#5^<1
MA:"LX7&7])!34'7Q&"]MW@>T7G@HE?=@N_2'$B.MJ1]\ : 9K;K?^P(TWA=!
M#0B' ,$X2\4\28E5@BPL5KQ'P&'PAU0(V4>P!+\)C@,/X5[0F2*+8-$,73 C
MJK0P?CH-QR&F@%(4H 7]6E5P%08#N PKSZ"RIO"H,K1X#O/U  /PKQ"BP!35
M0+3T"_VGZ&\F):,P@WHQ5$2ZHOX!HZQI>HXI"R2J14E/Q*C5WXJQF(U$*G_3
M[_I>K].3_^T0J7J=[K6OY$/2\A[N]FW_XGR(%?.(&C>^[?7/^_JO]+5ONU?%
M3U!=D64 IS9:-O,T9E T/<Z+WO"\HV_W$A[H17=X?FE^(*]'S_6BV[=^47TR
M$ ^IN0B>0-@!R3U$=LVZFD7A_R(3@AAPN@#5* Q_8B5W',Z1'7."*:BOWL.-
M\6(0IV6$Q</%%'E(#A>\R#T>,,(A4&7CQ8,4K0?"+8#Z43*7N#I\WE#:GP15
M6YH 9R!5E*N6B_%=##'C[=*;@Y5 6^QK X07RP0\!7[>?%!=2WP-)10#/Q4#
MF^,X$Q KY+')I-"+0>1;JE"*5 P!*#U>R?@OP4[,I(*'+V=)'(L([Y0MYLBP
M]!2%NJ7/25H'A8T8)QGHY2#+$K@=\CAY*NI;^+#P2SU\35I>E&4GA!C]"^2H
M& ]_3/Z:.?V16((-40RGWA]9*_"^!&DHP.* *<*/DATJC!6]KK169*S@%K=I
M<@\DR7)4@+=+ \F$:P?@$\)!J \6I"9F)W:,A72)"P4*@1RX6&-$WUC'L$:9
M9HML59?2;_#S7C@E>5!?*'W(7Z/)]14)QJ:(5;XZ*;E_+X Y10J2@T2+XP7Z
M@5+?_:&N"[=,][ 1<+WU;R5UX5@#7.^,FC:G(/UR]5(6& E8!CZ'ND8?A]0:
M*!DD,N !29=T&H01_@*>:01>XDQ2.A4S^Y$B^9)D%M"43N!E@5)">J.)3!E^
M":*%N9T2#KJ88L;"+]+O"/=, PQ3Q\$<S;@ON6A2<I[*9E2Y3_7:"IX'!!V]
M/OCQ&(5)IS-KGTT^%SEN$BRSA% 'GBG"4"! O9625L+O+?&+4F%2@-$6+PR/
M>&\'2O'K_@[8'2@0'1X 5T[39(8<&":D!>2??(O5I7B09H+SL?A=?<F2X#*'
M:X^:W'7\U$@4@8&^7B$"<"W'7+"/(OT2CJ7P 351BQMZ8*2AU0FA;PL!L,RS
M"E24@--+(U&U696*NK#6$,>A<$T%A6@@(GDX,^8X($(!725F$1\ J)WK^\M<
MTVR&Z202//@D1&5C\ U2$*L )?T63 P8?Q6:+4O/0EJ3Y,YH20.)A \M\9J9
MMY@KQ:)TI;F3)?$6DK)R#VFYE<^ETS#H (V2"24!U//"TZ&BD8&9=F&D#DR6
M$)3B9T<$>U9/@^Y@%D02+(UL!4IR BR>29*DZ*< 2]2\]$UA3<D>D4D<D<&)
M20%7(VE;*"8"3+N,(&/[O)1. V( Z4%))H9] HU?5;2P'\8OTRJ,@8FDAU.<
M(SS6;1K,LD) "UZB$Z&/UQ\&Q?B:&HI<-0>2!G.QR-&7PIUI$\P7>/!WH)]D
MQ=U.2V9[+/Z-PL\0I-\EH#& /(:A9%"_B%7>JDRB,%,D)BZ+2^^KQNYB@@6%
M9KJ(U%-*SQ/N\1#F\I54A7)='%CLPC#!*2;1N?>#0F_**\,?IC(96PZ/I/T"
M#VYILE/@H9"250X+OK+^(_V</ &()<80\F9/9\2X(+>Y(#?L<$&."W);J'7L
MWJ6)JO?W+[7;AQZ?\3/MH)+R6:1M9\%GM$M%)%0$]?HJDQ C-8QUT3D%Y0TN
MCQ7 *)5<A+;65]%X!V3-L:!0BK.5\WF[ /L&_I(.1#&3 JK?,3<4#[0(=JFK
M4D:[JZ^\,\W#W*(LNJ6+S";PIB/1G3<EQPAOG(PQ<3-1L;2=Q3"64M9(;!>V
MWMI:^0Z?BCL88$3@3,CRW2LZF</#JQB^=VA\%94*T-V50<B,BC0JRJI)@\J,
M58(M-I15TR*QE!Y;26!>NPSL8\YS@?.L\ :3U,"#,BXS'%DDI^"/OLD1^.5\
M/GV]"%-E &.E$:0#@LB+9#4BMM,'9!J66I=2S1<SM_;-B@"RX'U97I;!"+P2
MZ6_\/TL 2\ 6"<ARS,4J#IY'0L?>FLTP8R(9K<2XH4XIP DQDS&3;6:R$'U"
M3.<IYL+*I%VZ] O&F@I*DY*'GR73_%ZN$%XJY B!54P:#]SO19:G;.F9!3>Q
M(!5P)Z'D*YW2)U015:JI<$B(3F/6RZE6N)]=1S6\:K,PLR"SX!8M.!&8&$?]
MAZ86+*UN#;%5F?$!E4^G2JWF&U\0615/LG$P%X6?*+]K@PRP;(TS_)0O.DM4
MOEQ?*)'@/UV]4SEYYF+FXCV"]0<4[#AD9_[;F_]6\,M8NLNI1I.I<CF!C1!B
M(N%D&@*=AID-YC;HQ3?O__NGMV?=:_DWA,F(63AF-F0VW#US5  [+#P,>92R
M_B1C&0GM Y;4FO NG+.]94;;Q&B&ETQW"*):DH5""$E$2-%:0BA Z[/@_XTQ
M-$$N=9G1.LQGA^4SBX=TPY2%-J]I<]HP1N]0[>H/*\DBMFF\F"TD,$!A;K,5
M:) J4BNP-G5OI;>5RJGL?5*%5PW"5=*X8]57@H,)?T35V3"CXJN-6EZY0_7)
M$@4[5F6&F1"YAI!;9?-I$6AB]&>U  31,I,:1=8\\.V-;R_!G=Y/TQ)4*JDK
MVEL5^[K;U]\H2777(%I0#:6J5/4UWE"RID]7F)I&#O.-VD]3J?J!3R41G/,4
M$:0%R'E&+9$X>DV>@,9$EWI!SKV/Y&FJ3\IKZ$_*[\EB.T'L[^_P/ZI!:$92
MAR\MOH3)(@/>D;YLI'HU)S;]19#&0/UL Q*B/9!J&]PH08$*/9AI>";(D^P?
MD,>AP(%+&U]96UHCN/,XF$OAP9*<ZK (R6**>4ZT&RTI-4U*3W?26'!.NJ?D
M)\<0)G\(78[9TD:$4J&)96,KIY0+2F4K:*6T.4\0B25[)JM%SLUP7/O(9.%^
MCO!S@I@7/2UV40D"-=DYJRJE5E,#6I^%@K88K'9Q\%:YE<X6WE-$(;[F+$E)
M*\S"K * )0BN?.=T<6N^B!P1200U%8.3>]63+1N92KCL().=#ZEJ2T\#DR<&
M2;Y+)MD*:!P=?]"EL=PUC>N34K_<G*&XWM=Y.WK$_ X%'3X9,WJ&'3?IN-GB
MH_#4F2TS!;8:QR?+UONE+0%Z9H#!C!?"KE3N1&0A,3<\[S0-9ESJ8)[<RI,6
M"XJO8KS(A4;_FQ9'_!7B6V1[A=VKBOI1,B;^%)V<%5M,OS5Q"5QEID<YR' 9
M#;IJ&5PPOS*_/H!?3<=J@- #/5Z&K+_M/RK?I0+>,LA$YCGFN6UVN]('57:U
MJ[_%MC9X8.)'=%$G"3C_51S-!JYK5R=/ESMYN)-G"[58C[(>O;^3H\]*:01@
MDA!.P>3 ,ARM #%/@"EN2GQ$XC88+ZWP/X@(:4VYX-),%9IGDF$"="S@EP1G
M,%XH37>0P'&90$;.9,//#+NY=$R))4PZ3^3RCA5?,I2-]_.[ +XUIKA<3>D9
MA8GE<9HI=72U*/+P<23/VKXJLR2SY!:6I (%54_&=[+"M=J"I69;Z-%$)@6;
MR2$;F34G@SF..6Z;$E2>G++61:$S34:++-=QMVW8F:N8JW;/XV@D/\;()BU#
M>HW!SLQ/#X@M;,2\9JK *JABVEG$>#1974&:JH\F/(APSE,0LUYC/GQ@EV:^
M,(EH!6E!71;C>ZIY7U2/#R7<H82S5R,(::)]D.<IE<J%'O10S%.VFTR25,^H
M3H")%1R*.94Y=7=<-&C N8%%!W/,QB"PPQHFJ!8IF/%WOY]_/)=(_!]QS!A>
MY&VZN/5N)G#1D$J'R.0O?GQ[\]+WWBU2N &\XB\(C$,>]FY %,9+[\6[7_ #
M$I@AQ_N"%@9J>\$BOTM25<*1X#:9 ;*8G10X 4[L!L U@]5,U5&9!CFS6<UQ
M+NKLQ9QU IIL'&7&4L92MJVA&AA[G!?]?WI(A5H5$(.DF87U%JI.#KAE/#BS
MV(-"*0T,!/5-6J^:&<KOTF1Q>U<>(8R-"#01F( ;A& -C@8[CDOJX4A&N+ $
M!YLO4L*/ZMYRFD%:PE[!>:8R>[8L0.;&*&BTN;&-:B.)C5\N4*J5M,BY]Z.:
M-DVF=L=9K/CX$H(<2+QQAO61$K;11PPR0I8I_8RM)OK/%D+4-PW+U%NG!E_+
M>6)PZ\58U []Q%TEB$<;"XVK+5Y'C['5.T&(*@](AJ,UIF&E2U6A*7"6B*$6
M<29=7$H22-P_(7YQH4JF&Z[5H-#RB-&BO3JL0%?QO;,2Z!0<$_@@3C4U<%*5
MZU=K4@IQ06A=1/Z+%IK0C"26_0$Y..^X3R/(O%ORC#*=@Z7?%W.,Y4FK^I;A
MKW7E+9H$5^+EVT6 .PV%HGKI'8FKU_85['Y U$=P+R<P+V)K_&L86S-P[0'E
M^/>M<E#&T/IUJU[\^B4Q$GJAMA_IG@^<.B\GLD=:'L6D57#ZO2= RK:S_0=(
M:O!^=?HOL0UN1,(N&!,0U$_/DB.(9$>YY5I7QE%C""SC7-T^$2=Z!*$L]1)P
MJT9O(=O$ONWV&V1B9?:'?!X]!=\MW']I_=4L >6SF>@TU0D^6PQ8KHMI+,M!
M_3"A6G!2G$,Q3KH,X$<HIZ%VCK.3L_KS55U.>I.>FEZIDA/E\>H62K0Z?!N>
M7R7@\,QIDP'X&;?6+@XJ;EGU^GE DX1J!J/3]A90<+B+Q\PHQUX?,Y6<&%9,
M"K[4-U@;&@I#LR).M'1U+1'/O?\,L2F(IJ*;SF+9]* VAA4 V<ID!8A"$[EY
M2XF K.V9,_?7F/ U4F#89N7X?#2 FB!^X='44Z+2%6+-)M6:0A<5"_P;;K$0
MA+FP)Z"7)\@C.?'CJ2#FW#)G7$FP5 OKE(;I<3-,,Q$(+\:^+=I-AR-6D['0
M2VRH^TR^BZU<D%THU"^HL+=468UNM <MDC/[;<=L]?S,\@*@>(ASS/%&DC>*
MED'Y\*M-/Y@8T=I9I1SK#[88N"\O+,\+/S\"+I^&>5'#L[#==FI2+C\I]@"2
M,[FR"*6R^<81Y?M3;*9"^>CK5#P@FZ(A^I7H:M&R.[,ICUZ7J@13<;]V=']Q
M@EJ43<15:]ED-ZD\"W..TSJK5L/M2>DH+<8J72FP%_#$"]SYM<&>)&EX2RM&
M@;/-P/P*1VQ>)+1BYB#HD8Q;;%:#:#6/1-GZWR7W('?(3G+E)-T8M, TB<*$
M? RC<&I, DJ643;$Y@([<>?PB/ JAV+#*N?5:_W<++) O1,E&:JHJOND<K/E
M%1,R9+"7@*7%VE7\^)I3K@8A9:-V$R\K3Z(&^E6>!ZX5K'N*VR"5"[3@6BU<
M3]!C4#.#FEU;3T!9FTVUC1+Z%9SC6-S*1$*M^5:F6^>G=<]7T02/HOV%-E33
M^C!EAMY7/D4Y,,P!Z9[YRLX\\Q#E8$.']Z5M>^J1LF"*P^SE1EY,F2?1%ZU,
M*IZ:?F]KCS#:A1I7IC7Y +-03ZIQN2#.7M$H=\7);*]:3&3:[BJ9$K-E#Q<7
M)G!,Y82.-MYK[T'C#O!)5)7,:M>C1CY@$;/!:AQD=]XT2NZ1\3!4P)%Q.-["
MK*Y+[?5V]N+?>I="UKA%*3NK'=)[2OR@%U=)):U9+;Q^H;!+.8(?=#F2!EC(
MC<N%-R73(/?"9%OI4TAU"2.&/V",#K)*<K-]B7QU(;F>TR"WJ4[L$Y6^H'UD
M:G>7Y5SJ429XF?LD_4RS+14C*: S_=F:\4J\I>(\DSF52\:^(F5DA7D&%+ZK
MOM!$0;/WW(\.8D#Z="W]=B;.*FUH,W9<IDP&O\RFTJDK]ERKI(JN!VI%."K6
M7^D>QXE--A(\.>N@LH>A%(G*O',I4:<JZ+0)O%@#O^^:>2.Y-D!@DSX!DY&D
MJMO]3LV_5_%1F&4+S!7+#+4<"8@(P!0.!$X:KYY3JF,B1KF691RG8CQ0?9,,
M"#'&5(8<[%(\A?E22=M\"<)(^@JQTFK5KF2*LG.$[;L4S\;*0II#T.M/B?S2
MGJX<@$DEY&KG:<W"49]2)XLT6PBOF(5G5ZZ1'M;0//I"'GP61?>.W$3S)4G5
M[E0J"!1#J:R)1F2T,-!;Q ;K,35G:G;R6@MNM?K3T:0E:&@0BRD>6H,F-0MV
M4)DZDYYX7Z39]$&5- ,I6YDU0RZES3YFSP]O[V&@P,.! MHSU .J%-[$9:P)
M\]"A>:@T6$E:#IT^LOV?PI&IC$HJ)SZE5<"/J7P_<Q]SWQ8-IALR37H=')I,
MT+P%W?56M[BI8#5[]EB6)1 .DJ'$A#^Z^<R"S((/9T'?7DM6QM:5E%XM[R';
M^6667>EKW[IB3(_0!%+CC[&_4SKP!NZE/\D<SAR^Q<3K:J[9?H(IE])\SD*G
MVMS(O,6\M=U]Q(GG"TPZ&6 \_EQO=_#T8@<,=&^C9$0)'<S:^C0EO8 LULRZ
M9OYC_MMBO36TB&8:WDEPJ@Y=D-6662YFTNC>A6EYF9A(LR2.153-Y]I(-JI^
MJ?2E0M4S5S)7[A14RTJGS,?/4S$/4LKJ36E2O$^P9QS027^Q\-8^8>/CB89B
M"TS5C^40SEP")LWT)'0BHPA3^A)B"CRMACG@7W").%;M"#C RRB8=7=FW4H\
M(\%'=A13WN5X!NI1Q+*O1BUT/(9>(UH%D2PR#^$]-*)';GY85PX;!RG.P3?
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MS++U49W\F%@7K7VL4G=NI8%R=1H![723^&\[Y))-LL2=> /3VB"+Z&9II%D
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M$#K/IKP+"B,2MV&F705L/]!3R,F8PL7@GE%P[YN$2X:9N@DZ7=977Z+&*7-
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M]=BH.2 ZQA'IVL6LW-&&A-K=2:A;=#6V *RJALI4YB K6'D+<Q':O1<6EHF
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ME?L#KZR[O:]P@ZJY4*IWS?@K_7R%^K>Z!;#RZT[F['V-2K+ZZ$Q2*%H6EL-
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M0LT#+3R*:!#(*D[N58=ICEP'D():YZ18TX/.& E/CB)C34T37=*S6G0=DUA
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MM\_RL;S1AN!5GW"/4,D2QZ@[%IOBX#K#9< +(;1*(X"U*%"OU":6(P:'J-3
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M@Z"DUY6(+5#*$OX0+][67!O>!'+C3.*C$;" OD$>5%74;2@44D6<H5A!=V!
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MQL)3#NX9]);Z&/KNKEG?@L3.8T8H * 5Q5,ZD(>F/+N)3J6\A81E4I)M7*+
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M]MIRPSL%BA*:<?KY9$NX. ;0[L\- <6F;C1OGRI^L;B#P^MAH0'^=$$#7-
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M_IM<()4S&8K.EJ5(+&AT_I(+@IL/:#EB4!30@5:H,9HSNC+B#V-#L@J*65R
M^ ?G3SSR*C= KG@%/^$^\?AE=E=\XC#@W^/N7N*GDY[K-C6ZZ+V*H<;VKWH9
MIV3BBYS,\1I')<,"PU"W<#]F)ES9<S[JE=WWX.PV6%"/MC.]$>@2:FYL#'=<
M;"*MK%FJ1G80LXZC"Q'WRL]!7@=#Q; X=%/\).1:4,&M7ZNUI!VDM%O&5N-5
MHCGP2[]C'V4!YNJC;A+J2S_B(6BZK"A1<JZ6(KWFBK:;LP5'O$[R-AU6SC\0
M_ACW\& RZ?$7__;ZORI<%_J*Q %="XXFA*+LIY-SDW.*, .)&@F."?!ST;9M
MXZ7PJ VC',>XV/%?>#<^IMVK)\CU_;4=2U33,ZJ%>RX\+IYBK S*?MXTPTI2
M-- ]8_N:+A\.-1HXE?$>ZX5B"$W)*N!!S)\QE^5P7AYFD^<-EH45 SN+A%48
M(>L+W98.6'I&)'&QQ<['[+ 4KOQD*,XY\.MUB_8AW@R;:?L0*XLO+I7%2V7Q
M["J+R^07TZ3+#YB#^L&$^T!SZ[OXYEL0N0(7&3+,H1\/__[%\E^:^/B=B7$Y
M9S>UDD3MEL3J@QY2M)4DL:MYX\:_\Y[?65+) N4 \[F/4P4(+,I<JYPM!B?<
MUCZLNKVZ_7<^F 86UG2SC&Y0D KNNWI=B=U&W:).V0(9:B[ZB;O00WXP3K&-
M"_W'GGJ>:=A#C/7B'8/#A8L?9;VH/,@TA?!COH!$_>6<_@Y@T?-I ':"9A64
MSD;J1V>6,/LY*#DC8'C:T2T#4AS<PMN!$]O7ZP#Q''1^[@^]B"-#._,05GWP
M--7E!<;O#'Z=:95:! A.)*6FS9R5KUO@],;G &@((BJ_F)5<J>0_2*Y-J"6R
MGU,,TQK"7<R/^Q_A,4*D!Y?WR'E59#R(__@AA/TQO2S,2-P&(UURCRU.2%Y;
MRKKK120,.XC(&^9LN,;O64F%$_!, A<=[[&69/ H3+ D2\I,Z=!$N=MK@S@2
MKCLJ#H(A#ZK25'R+L_'&*5"(7T D\['A N\]^%5-*SL@V?&4FMR 0Z)-OC%,
M;=;$FQF@\785M-ZAP3AEX?$[M7)?0#4#99"17M]V#5(;GYA22]W*9M:Q^A)3
M^)4DGW)+B'[K#ND]X0$ 51C2/)$:)TP1F6XCF8 A-:ZH7RA<A\K<,I=L0W-!
M?T]4#1=_Z02H2Q:&"<#P>7%,*Z'J)^^>_CO.&F*#\1WH:T"Y",&05$4A<'P"
M29!I)Z3^)'P>!WPNF_(M'D2\+#@+A&=O"]U23,'1YI=+Z58N[-73ERF; @"L
MQG@[,(KEEZ[!*Y3JHV"J3<T ^_.1V95MX-A5CA8!@TO>'9R(_*E% _L>(MA!
MRJ62 IFB5<>0/Y,^\!<E[;.AVXRWX)C(19L:=TG(-NT&\JN>N>+H%0/V"M_N
M7/;!S]@WQYIG<C'@CG4H^F,7G"1;E'T B9BAPCHRY"-%JSK%W1 ^V D:' %&
MMV!KG_LMFISW T!RPX&H;OH \B+H&<0M'79PG''@\6M/%YD<HOPP@NUFIW\X
MOI.4@CM>?M )X/.EHJHM;VX>IP,@T2E2PX!V.YT*MK_K*:[,@2C0AQ%RK07#
M0J3IOY(SR&=+[GE*I&%RF)\-V4E='K7 B7/<2-D/?@R^7@_74BD9P:'!J^C.
M7XJ/T)(OUMJW ;R1=+J0*N,N- G7-;)U>\1YO8+E)@XDJ$P,1(5%GWG,*CUZ
M.9&5<7=2M8"="K+G.U5 QTL9<SH=Y8<K8F':;J6DXB\RO;X\0:XX.^"1LS_/
M+CPF1YE]AGG(G=LZ)$?2>JD2;*#^$+J.NR AE"%DX#1T3)1->7E_,."]JKF'
MC?Z;LY6X3+=LAC'P@6S6R.5<^A= '15<]9.N9#1O$W"#3VQE-62QHZ-V%B<;
M?%_F_G4[/F-T&,88:,7EW='JKI%8:^APN@L?WS1;^G5H60/-):S4*<KG0%5,
M5/;9EGP%43VB*['B,TV/C)^)%W]P>]7I*N(FE6P>1 BE1V,>3]/P 8T!>H/N
MD,9I;$,?%VW4M*XJ!,DFP,TO!Y:BR8V,"1^<;3$HC-0]T/2TZ[11>AJCNQ,G
M<(.,+_B38]<MU/*1FU#84V[Z<2-AS17Y9M#LQ\W6;265:G"GN#QB[62!V,LX
MMA2XL=A!T=^@X\1+P,M"A =^@[))@E>KN&KKKXKDCG!;27?.VEEU<E]K7IU9
M\VZ9H>=_3'?[8Q"YN,;ICFJ=2*X4$4L7*<OF"G,?5XS=-7'JIL&Y9.B8+@.0
MQ\4[ AU[KF =TI@$VE4;@7K?E='9N'0,=+\2VW')JE>S7YK8C:S;0SGT-D$T
MJ(N"*$YHKWB3</Q&#4J'S$ZBR0DHVNUC._@@9_7EM*?+PK<:SCIAUN.$8=#H
M-64[58ZG6<W<JD2QGE6+;UL>MAZ=NUPHF!#%=_5J#^+-NNFV37=T,EVBSPYN
MZ=;V:33TONW.8&-!2^AN75<*=,[9YU.C+BUAJJ).U9E-&@7/UD ]K[F%2C<>
M-@-"3:CHX&+:= 0G08*XY.^5E$;3;[WC7XYS_J,DXUBS</'HI_?O?GS[F"\L
M#*(#J1#S_>'";Q+^LR I=Q;3V]M2G?#D==@$T= [L(R!O#5S&TIVRKN1Y7DC
MGDSW W8V#_98#1KY691A,%,'0%)L^X6M.T 'QT$]+79JEP%&W-9]'Z.#M6JP
MN2//[<N]6 MN9G;N H6]M]?=-L@LQW&*$!<-BJCG\EPQ>$G^/$UT5OO9P2JG
MH<NGK>(?PVKI)+"KC5_GU/JF9U'0S4P_YS)3>3BI^X%<B<XOS'6XZV3@B/)[
M'S;_BL\;?\DE*%43QN]B#EVFEN/"B@6W#I+"9&@;,@^36^B,(=LWW9F:^$A>
MYP$65[^\%%<OQ=5S*ZXZ$Y2GX\H7"QCDBHE=]9_@D\C]ZNL8B!5BIPY01,D?
M(6*KM,83)RST9(S#!D0J.+(81?<4;3&W096C_G.)"^"6%(E;C,0_%%)?/NTG
M']8(V',4;[*;1ZTN*7:B=",&]=#:!#;_EB-;!"W5 ]6CU/4&Q#P[_(WWW9=<
MJPBJ58WMERY^41<UR3%D=,J8-&CAA_VU$C__!48,X0,O(>0O<0&S\K2Z*?5V
MU&Z00M[PC@R9+_5H^B-&HGWIMJ5O, VQ5ADIWPIH6QA)B^>S,)(SV7,_.C^B
M4Q;S3;RH-U#,;ZA;:26"A#)SU_''XKOJ/9T<5DZB<CL)-EAPW?<?4XS+&]&/
M9GRC9E#I\S'(:5=-? "D?R'O@+!)!!.N09[/!_XD6IQQ7</-MAZQV4A W$#0
M1-XZN;*YOJ)X-P#2#$A\C)L2@LFCGGW8#@$3>4^C20?MP&AI4-QJQ 0MXOA4
M9D\8A)O.^7F;!KJJ]/ Z FM)(YGR-4\S<#BU2C4/'9C8YA4>3JO3:]/P%I\0
MT-#'Z@.%R$40(-$O;IN!$C^*,':9$&[+X1[E:)P(FB$!M.>%=A7\Y(B>$X+#
M31QC.]T%C$!T"E<P_;6''E,]S/Y#1P/5K)Z'\( K#7O+LWT<+.!PRGOH<N&-
M/3^;_NZ2<PJGRZ7\L@@3W\ "2/Y+$L\J.H@A$SPR*;I)(0RNL3!>=^M"T48K
M 9;2/1>;_6K@BI6EJ))>/5<YDDT.+Q)?M;+FTN\A&<T-UW^L%B^>/?^R7/"M
M&,?;#]RLKVIO!BI@HX0@UB":@8SHIH%@ +T-F@^YZV>HB%"J1QW_C:>+MZW!
MRXLO: IG_Q7JZ\.3]SM(D;T"[KU5O?@.7V18O(J[]1%\J/"'QU7A_&"'DZ@J
M(S2$7H1FAB8<WV@XQ(MKIR!HEG#]Q+6T"9O]3GGFN*N[/'NH8>MN&+Y5MXS2
M$/Z+.CE\M]3V<+_M\73Q*ODROC(,=RB/5W8CI+P6W5U+N[0BRB1WQ"C%![0N
MM_%UL.M,LD;2(IV\-IFUP?=87]=KRGD1($$^:24;F ;\P)*]4/>:X',VFKC'
ME>4,!KK.5Z I9%(<&/E@R&*_0XN*]]:F.%-/%^\;;.;^F,K[KI,4B;/ZK)^^
MH;P4]Z7,]!5H%61,@)<:FZUJ07@(_=*I+;!_S5A2RKDB4V7@O*5NHKQW@2N*
MQ?)T;_C=K-"9]C#0OG3=B<Z5RM!1V0BU;>N.+.>9W X_ENT6E3%5R\BW1\X%
ME^7Z,X_TMB[-_L"U\MN\8H<_YIS:6?I/9#UX0'3UDQTT X%J.=3ABA$?7%V
MI6*[189A/?4^V'0E3>)O\AY ="@F:+XDNLIZ]4'<&<T$Z_&*)YF>7Z_1\QDQ
MQ(TQTO@$RV4^;>EC<O<)ZO^IR"/#5\*8AN)KK +WS8V#Q]'#GB[^$B@ZQ^&
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M3-?$X9+(J<VU$CO0*APZT@*PV!D^%*T<NT=MN.I&E$9LB=:B#P"$1N1FGK'
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M+V/7.5HGE'<"<G7.&AZ[:-T#83\Q=W'%B#1*%'4WW8>0Q1Y&QRZ2#NP;.0)
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MT/T_I#3R^_/WSWB9,%0A$JEV0T2UM72,$JS9BA+2@I%LW"IMT,S2!A_!__+
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M'\<!W>;=-G:M7\Y^X/Q(IMK@5%9IZ(NC!R3;6G72,_7?$>*Z,,)>>V8K(5T
MMH_B,H-QI,$QXCM/BQ,;;7X(RV-3B(6(BN:4_I!$CYS]>N)+>7L 9$\=E&%!
MRGW!3?K4O)2=+'_D\/"V!_PY)UPF]3^2U]M3?/ 'E(>4QXM-2->ND [$@:U&
M_ER:*0?L#<P=9+T[B1,<?#]X,CCS?]VU>V7H,D)<:\!,EEGX%J^R]&ACQTHI
M\]O=1L\'[=_6/*BPU' :(HLRKNQ-14!A4HDU?]!W2CKBW71I<'4_1>8+>21E
MW.N+W4;*GU$<0E)DA]WN(=U).F$XS6@N4\@2W4>DO!1X0+XQ+1^XV%B$O*Y
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M$$YBEMQT$08( 3]'GN6<\N&89"1?YQ6A&Q?710B:$@QSN9U^"^CHQ0LXEZS
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ME.US7Z(6VGCOJ(489" =RTLB.$.;7RG=J(?>329EEJI@L@G*'=+,V,X16#I
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MN*E,^.9A"V" +<5=JT^YT,:JA'<A7<8=7X<Y>47:[[;L9-1<'K\A_"8/.O/
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ME%A@L6]ZWE<^2..\QB_5:IFWJ9"N6%_YHNF]X0#3N;H;R?OH<_7$X\C01AG
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M*_,%;LKBME )7*?'OBSFX7U_H:&T%CG#")HJ''(+:(M)1_--$X(@".$$XU2
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M9J>=(^<$1_4!:"++A^'"QY'FJ00]CVD5##_/IL(2\>!FZYU_A+IXEZKO0JB
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M#],:+\-&?M!>'9:+4V[=.$NM\\FK9EEV)"6)'[' L_L*%Z.LA)6Y3KUP\:U
M&L0 R&O&F]>?:)LW+\X.[3#28[ "0I(O:0^==I>KL!O\ -M2?L0B8N67R+'A
MT;3AUM1"FG?$7O6;SEE3!KF/:*YO']!<#VBN<T-S];;CW0S?"0?K*2[MY>Q[
MBF12[(WU\L(Q"2<@=9%Y)05JI1.3!$?"?!]G4U/@R "*,Q+:W6D"[DVT\U>)
M_AR&W1IP3F0,7E4[TC3:%@,3GFK-#86ZN.UHS*_[SG%]/.Z#S^0[AK4_X+MY
M%<>M49,*44>/G04=$G0ONE'=,"HC-]U$<GS'):5P3<(<G5],->A+<&_2)Q:$
MS=*TTM V<6AJ:?_=4)8^E2E11H(4QX:[=]IMI20FLQ_)+VU=KS!A#HJ/85A;
M%G[)I4L$/PFAB5^L"AB8X>T.H(1P<4^1/IO[1NO)QX6N]\?"P>!5#T';M> H
MK2IM/.;!&2*F_QKBT$Y@0QN[P&G/%Y_L5 "8Z4>'%<=M641ZV<9&%WV7- 3@
M8640E'1JJU)?5J)$?OABQE"AM:ZQ%WRIC:TP3CJ[W,N%*A-67DYKLBPXJA$$
MIP^2>F\ENO4^.=.ZS@)Y09GFOQJ()#NK(@^JS*_QBOS"Z.;+L$!:IJ[5X-Q.
M$(K]8T3=%;%WH2UZ(%/#E<J8S@9>Y6TH(,0,#:,AC]O+L)F"U5GJ-OWO7UZ^
M.;2(E[N6]6Y7P99<[,,RT^@E]3)>,7,A.OXB^WGLFAX?#&Q[6$ JMTE/D.QP
M6Y7+$!-MR\I)!L@=,Y9402^0;TB4&[X/CO$5DRM^CV0&96/HXLT"_4;+@?%"
MYF!\N#(9*!2<-!T9'65'SBWT!%95CU+@SH?"[W;^V^OX4#>WM)$<,'*15PO:
MF<6DF9QZ[SUO0)]7E]%]\>#<*7\'SRTNXD.G@$]8J&4:Z%72*1 ;Y_@GN@A'
M1B2VZYP<I3O)@C&Z<GR->V42UVUR7*"..D%CP_F!#D6R'=?YTFK9+N28W>DQ
M1B*<\5#.IRZ-_C#\&:E&$;+37%FLW8TL'"L0W6D%C0_J'W$&?N9&IZE7$=M=
M("]'L6L#8V< 9>Y#CD\>(U&!+:0^XC$]$LFP+^B!SVPCCMFR7@OGU)-X1;.#
MD4LYKF<?X=WYXKHLA$\#BKOA<%C&MW/HVE2DRC?EDH[/N)VE).#%Z>?[;.0U
MJC@-'[D'[Q1I2).G&,E6Z 8JE3\Z>*_=UMJO3EM@/=?@@,JDD(*9,BCX(OLO
M)[>WEL9'QZ5T$F_S4R]SAZS/B=".G-NU[P+ON!^&ZVV,>Y0E*]$#%.=IF46!
M2V(?T"#/I&A%>*]<;QH&[$O\D\(&I#$0);:X64"^JQF@=?%'IUF0-5/6U[29
MC$(T4O#-73E^D.60#),2#E(]1_G'()-"VN)ST?2.#(O_^>XMX62P \*J+YG(
MXKI ?B0LO2LF92-&?U"V(;V<HZ61CU'N=C]0.*=S7F/;HY'TZ6:*=3%+STFO
M"2(9TJ]A%W5+KK%S.8SYOT0!65>*W"<N0ULZHG#L5UC:*N9+[V"(PYE)D3Z5
M[),:?[2L:)15$S=H2N6!'K^-#.C_9^_-F]NVLGW1_U_5^PZHG$Z75 4S&JS!
M<7>_)P_II&\2^UCNTZ_KUJT4"&Z*B$& P2"9_>G?FO: B:1D2@)E5"6V)1(;
M>UA[S>NWG.R,=0?!S(E#X#03VU6N>Y\ST*H03#-GCEZ1-1M(+N#OAF?I!(0-
M&^*Y-46<YB1JFP9_=G*O."T"Z>CW,@G-1E$F':8B+=EWEI99P<6MEOG(!A$]
M2JO5&NE(+13M'I#(+!I'!?,=8$I W.HJB&^Q,,% L1E L)&Q* 9B*K;N1SXS
MV5R4N5$I7:JZD3 2JB&8-(ZV\[YZ#:"6+CJ#.P<+H+)'YF9$3G258?X<V-3Z
M:RQOU<=$2#TIP0"V#J\G9MA4RFBL^F>FGQV,Q!X=#)'8(1+;MTAL75L2YXP(
MEII.K.M.Z98[E:>H=6@$YI;(%KD<[8M\%L%^!>Z9X0:LI#1N.:<[*$JM2D_)
MU?CJETZSH/=9"@L"'OUK.A*8_:UBN7_LX-A;?<DE>C(SDR)75_ZV^B[Q5"*A
MR['M+#H]DC07*1-06L8E1C;P8>B_VT'6,U>&S5+ LS=%V#XG9*>QXN9IE*[F
MKU]U1Z>KS:#+_9HGPF*^B5*ZKBL7)3Q6VJ^ _OL#05D2:"YFR7'*OLV-6#=I
M0M/IU**(,0GKHO0W\3A*"):!(P1!W(5\D2B*@Q+LOM?-!1R[8Y*V+D/2DV,3
M[+<F6/TR-Z'HZ= UR)B$C;2=XJ$BP,DLE!_KM"L3UXQ>A" :U08DQTHL$2)=
MT$]@,FXVRNIM'7GO8\(3SFOM.TPGN(?EVETL63Y>PTSE6T^##7YTRCP[UBN6
M88+MVN'XXZ7.+NYA2&6%P]MZ(L4!TFA"9-T,-;^A[:^I/9#L )26<QISG"-/
M3)?52Z]L]^X.1HD<([E*<40+OV3>K>-BQG/()\!<R3<@&;"0./H/+<"FRW?9
MY-H<70]/V5;X$S@1;DK%KWMI3%1X@,,8:A?91#*D[#CJ-5=!VA7]WK27:52)
M5 L/Y$&^"@8*A]&JV16_YY!D11,QKI16Q&!)J,JI60']'BT7#;.]T@NC712&
MR>P/Y>'#G5AW)XAJ2-VDM&*J8+2@SW1=DEP78K;4EQ!<KSC1V/M;[XC:SMVU
M'Q_D($K&U;Y6(>BA1'T@Z=4D#004=F3::C].OE&L0SF]-3;-+S$RQO0-'V/7
M(=,-#IWRIKPMU'5$)KD-TTU +BU7AAX<A[^\@;0J*A$M2'?$:FC.76']6;<Q
M,C6YV'FB3"3"2Y/BWB\R(UZ #FF.E=/2;F^M#25W,]KVF;<8$>;,UYAFGMA,
MWBIGV(,3JO<H6Z6W8HV5:;;L-9@629!P#\@'WR.-.Z#=![=NM$E&EM3I5AI2
M&)\N%1G*&EUWCWAR]G<>D^*GCA/&A&0QO\6_5/.]P%7_E!O\PM8>NP6\%?.]
MFR9J,[YFHWWU$!]HVA/SGB#D()\=WN5XH7;6=;;]U5#&#C1^1Z?XFJZ\/0?^
M6G[CW?86.GZ2773SU$*[CB%OCL:4?9O,(LK\#[#(*JY%8&91O,*)BFR".QWU
MS#OT3[/$)7:[*=U,\W7Y))A?DRZ5;$V-K*GX&YTLNJ4@Z068EB]0H?H=B5M1
M:/!#,?,H36P_0^KPXYZ&9)@$4;8B42PHZ+1\W3F$*F'2@EN]?%+4A"K'>IQ8
M*@HVTO=]F2K=?2J#XG)[ON,3%<3LN99U40-H125.4D=C^FV;W6+C!!8_BQ:Y
M^S3V+:(6O]7T#;OUX@>#D>-8)5?4-NMVRAOUDFP?V/%*E&V$ ILO  I9&F-=
M&/!UW%8["JA\V(M80]M@V0%#P=?-,7=\+1\C24:CBJXYY4/H6((M[UF9?&DV
M^#;X$@VW;B.TNT:3UY@6Z+61!G9F?S\3'R@(^(3D&W_.MP?UAFB*H8_ 1'9;
MNV^2R%I#LE34DNO;4^%6<VJLQH >[F07\$!)SE*^."[TO:.B&Y ABJIETMK*
MIMENFM;37]EF-,P1BK8=DVR=NR!%-CI%0-?@R:DY6I8]7.NE9Z#XJV5/*D>L
M$JEA1C8)O@IQ2C*))@-GY9Q[R6S:>%VU2]1^CW,.&_V,;.9F3M?T%[A',_C2
MOS!&JV:9[_TCG27>SR/OQ^@*%@+LZW4 K'.9>!^PJ#8KTO_\)_*]][/1&]^[
M#+)@!B,O,75T%W.X#H<<KB&'JV\Y7/]021(A^M[K-)QE06)N&TBVV'N/]9 D
MF/^WN!+_#]YU#)3"9%IX1X,'U-BF$9^&?Y*RS 54J*R!Q,_=K.I&.8PI]=I0
MK.Z*F/JUGA]G8E65(C[347>1I84X^%+N/XZ28<X9O<S?T:62WOBZZ;(.>C$T
M  EX XADNI#KK!#4#\4U V=</-/)WL[#G*LR#R;*R,PK4!VNT)H05>)U!>@B
M:C2(<*+0F9(B"P>)3OI4LH$S44[RBPS5T%B<@FD*N><:2B$)4/^CAKF8WB2]
MV'MF?GY<OP\">V9A(9I@%3K[,2^SZTBH95/O.-W&))8$?^MT0^^/[8)(9\<I
M6F#S<%&$?ALY=:@BFPLTL4-KK=FM2?1N)W'CF-]5,I]*THA[D#@'.<;EIL2\
M$057"^"J46PZBSI!V8GHECMF,)\P6&_3T<OI0-\$27HDUCNNO+%6-D:@D!\4
M5T+);KW6,N9US5ZNU.95F[5^=,JK_O+=^%XYR'U7Y:_T&82\![F&\L>&W-R*
M:FP (06[4^#ZJ)4RB/VVMH34?KBW70DWZ<=;?-$&XKX87*H:1I% @[F)4Z;
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M?%1[X4;OB5!  \>::$$I4"Q!&*J8D')0$XV5J62;JX#M(XVR87 )[@(T4\<
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M3S'['D$8G:0"ESHM<9+<2F,=B#?)YC>*'8/,;L!6>6;:$TP,E= :1]Z_48;
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M#VRV3L4=;I)RML'#NG:-&F$L@LPZ?W><JM9SE-NYEW=HZ0-3J3*5XRZ>4J4
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M[M]_HNF=1SA3#%VP@-4M!SKI"YWTSI-;!)\1ZJ)0V<!->D,EO?/C!N.<8#S
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MZ,[^[W)24:^JL+(5XS2>P!._:.33BPF<=*Z\M],IW"*S[D4?BAK^B35BK9G
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M%K9ZJWC'4&IWS]KKT>'HM*&_[D7[/=-?K=# HLZ\C.D*TIV]4HG*" P1O2S
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MN K0_& SI.;@B"/$JDDJ.<.!$PC$S_>K7@YKQG0P(9@E D"@KT(X.5[E&!$
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M^W1.5902\F$]-?KNG+70H 0&);#)RD=(:Q!N*LH4LZGNOS5-15E'AQ0M?;\
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M!D>02W,YB\,LSTS)N:KP)J4M4NV([W%2&[/JK*3ROCV2&82HEJ1=M>OA+QH
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MA>T9,E92 E)JO-,%MD@)"P(<$YGUF*;BUUPIOQ9_0)%C5%;422.!D6'Y->5
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M,C85=?2P6P #Q07YB3>IN6<8C,1PVAY'V#_^>/2ZD;BV?ZZT<[4DYJF2G[F
M4RJ=<&#Q.WV3F:2YOLJ7_$YQ03W,HN]T'3_$O-7C(6\UY*WV+6]U!XR(24)=
M2%,2U%$UF,=+O;!^E;!LOF^QQ/<]%X#G2JZUU8HH2)DN54(5?EI*1X#3=KT?
M&.%E/N-.,>A[B\73;;:'MII$SPD(@GID09T; L;3H-S=7?H<RTC$QN>_@BG%
M%C9\7-[@0VL_#32PW$Z)94O#9 U.1B&%MM%.QZM^5&/*P=;<;W\*FN_<V*8
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M:C=)Z)BV!2BQ3H?VRA[W \>.D)D@7H11Q>1ZVI5;G@[5/LDAY?,>^!HM O[
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M/O\K[L$E$8)A^3]Q/: M?@/CKZ_RI:HYWT"U:LN#PFIK6FPR^QF[1SRKU D
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M7/RK%5:"(I<ZF)7:YH^G,"F1QT]=P70*&D/NG6OPQ%8+S8&W\^8;9^4?:I[
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M'N2C/;O(PUU]>IL4.O(WM@]FVQKMV/'QM$X+7X%9LGU9H(BE\_0VLA_+4),
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M6O_)/!]-@!DLU ]7^11VTOWWT4V5+G]@5_@&5FBK'\J#X1?K5],Q@92R5N#
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MDR<Q, CBC'%>#^ [=*?HC6Y;")I$0R ]IMD(M@"LG8KMF"K!=\##[\99<C1
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MH9-KY9M8KF$4HPAS1KQNV:B\H^*>@II' ^8\EOR4N&!=(E.F)D6?]>JN0=A
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M>J-V;XP1--0I#W;CVOK'EI&X*%<.\IY,%3$K F >*6PQ\2$3"B=G,2@KI<;
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M G;@H'$[;DWB'G:!Y+DE<I<95DJ@@:,QN@1%6VJB[GAN0S_VXG;2DKP*O1G
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M^Q9I[AKD5WFMA+U.1:_D4&UB',!K="+B:M05AJ8QD::ODS&(Q%&(D6?\ASR
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M&!/^;YR/J:2&M]T*),9,;M1__QC\?@U" :%25#J1WP;C:?"7'N/_<T+%7;J
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MTK$)33D[-[;R_+F+]_%:<,QXS[JB=LH)HODN'G++_G*>MW(I1]/7PI+\@<?
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M> +=$)0CAOW5IX),1%XBUAO-8'B"%".S>6LV(ZMUAT);>NK.Q'C,N04L]1I
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M.@W!<J$$OPQ;4,#X.NU0<N9-);)OYB,+PD$Q(=R=1',K'@L!SP7I[18%OS<
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M6?J9VP5B=TG"QZ*M:AUO\?;-V8]6CCVSU<YK9G>=)_.]D\%"^9ADQ]&MU,J
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M=VT-CIT3IE].MZC> #L +9WA0B=C: HPM%0V6>$D-T+G$1/BX*J>I@ +&03
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M?%-I?FJ9HN7&M$<?#)Q2>RD7;I$M&9YS(N8 ?@W*>Q!GG,,C.JV/L0AZ,O
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MK[CC=1M,AC6TY1A;VJ722ARO!*<\$7-^$L&&]DLY^VXTV)YL3)#CH.?FT*#
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M!R<>08V"),7/33QZ!RL6 IX'<(=?ED4R1:C#,M4E)]BK-K%PW_W:>N4 I(B
MPGUM"+I!-[!#&-),:VN<74PFV;@FF*Y1^NI&])5F,8"3E<_5[+0M -UQ:F!P
MJO-TEO'%/TLFT+B(71.Z7QZJGM(JXYP5%N7JB#Z]JS"Y*2NE0(_$3U2 ; ^.
M$YRR1JZ;#ITPH&C=*>V&2$X!63:L*@3=8 AIN<^WF#,M@AT-#>8Y?%S0MGE
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MN$^^6!5EWS/3IS1!.1\I6_*_=#^>TT'S0)E- NB@.%2:NMDZZ&!I-]?T=_@
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MA3A2(U47.]P) !!#.%C*=N9BW(F&%LJG&E9F[2>C>;9@U.)* ^^<;QKV#<W
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MH0U&RE4Y> >0Y)D:$7)");',(I5][9$&7':G?UWYIO=P9T<,-MGT2%X/+O?
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M.LRT;4F97"F7Y]K/B3E:75*92$Q,P8GU2HVU@5;RGG;OR)JM0EU!0:\96UP
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M@9N(Q4+'WG"C[):X!E1%J#!4%Q6U@W9O"<V5\8-N\0*#VDNJY3!W$A"A0PQ
MG2O'_-VPNQX_&QZK!=[-#758ED3=72S24Z\&D[KRIAIY/)*2J,\16H4S_'%%
M-2M*HC'T8$E>8O,[J@=CE\8T57?Y/ Q P6:$E,8E-T4V-;8HE?'!Y4D!!;_#
MS"L6#FYJ&SY% %^';2$=0,&2 5,"  .APN9$*B?@5T1,\5^C]]%(R@(&6'HX
MP[83^(@WSCT1EC;[5N(_S2&BOP-QX%M\1;H@ P,DHS57ADC9\D021_7EH#0Z
M/I_,%9*8ZLIXPLG,S6>Y^79\4V]L'2JQV@GHIP11[E&">U D XH4TL&NODR4
M5S;!F*]RM-3^W*TISK^Z@@*A.E@\WJKVUQ;N]U".O3QO(L_<I*)N<;I8M?!V
M%+-V7$[-\EPVZ> /U,5A^MJ716D74V]@WCAM\713 @"0#2RS9H#ZKJ/;+3;G
M5GV)[CV-7T.!HQXQKS],7^$P"3X:?$Z;KGY(#ZPX/A45A;B*V5[@?!BIM;N3
M .V':L"OU=@@1EM*9$G]R7B0LZ)Q'?'ODMJ,AA)MR#U+J3S@82FO3%B/34UE
M[J4E5%50%5?=]!Q"1?*$[8#!2QRVVPZ#BX677\M2V2NE%^K1P_Z=7V_DW4IQ
M\J0@587+:'76X7IO4IH6 ^52F5[>:9J-AI,,CW6^]Y4#"19T31)YV2=T/YB]
M "(R)#.<]DUTDTQ#ODC3;U2;9\6.'&X$M_I/*O],>9Y!:I7T@N/FNA#UG85)
M]RLVXGWBRY4#?WI!,GT%6J5%[?V7R64!K<M2I4\]JE8_Q,QJ(.).$!NAEA=@
MBXI(;1"[TVB1&Z<.R9I:4IGHWA9-<CN2Y!O7DH%1(E])/ &R3="MQU1H,1DN
M2<T!,.R !6G'WWFAM6]P.KF*Q0[4G7-_;^JA!;7'QYBU\R;%V3)U)P=+G! )
M LRV1A8@:1ZM"R\LDKNXT4FT?E'BYE7*::E0!,^-,%.D<GTG=5&&&ZEQ94)E
MR]15;=K%&= /&[@?)2W9Z[[BI:]X6;-:O2?UH+G.@YW*=3JW ]Y[IVY>OWG;
M/.I\)]C_RFE*)K53?E,Z*=[U.:M- +4,":M%O-I(+6R3[; [-;'JE<9A$[8*
M;=_4M*7.E+H7PS9LF;QR[+\!&?>W8+K/R$ZWW[!]#;PM8WXM_+J:HR_)R6R&
MNI*%DS+[@JT,R&R):T490@LTM<BNND23C=SV%=N+,+M9-N],+V[0 !RNS-N/
MANZP,F9M1Z8+]2BL%5XE#GYR-$!V8LP1PX=C*? ITYOB$SHZ@D5!U4PY-,N+
M?(Q/S_8\^ GMWC4VR&FVRJG53&VG4S$&9TG9CAC')^=0!W!DOW0WUJ 9.*3!
MY,J>LQ%JZ*-A])H]Q^DB&C[J'IZS&2@G%86#CJ)F_<N8V-Z?JY6+13>6IV\C
M>\"<G-WBA8..DT9UA$ LI5@9RBEK7,,HC"&._CJ,>#^Z"/0WVU2_@"B4W%",
M5\(<C1IYG*#]JL04UEF9?QNS<(-ANJN3YA2+\L)DTO5-FC#+L?+>/8""PH+>
MG:E+LQ!9T"$R<V9-*M/E;#QW(5I#W17/];Q9NA>ZJKPK6OL[666*^>PR@48-
M 'F+L-A1TQ#H2"'+FY0*,BBR=+)<,4KG\\I%H[!K?H*#M]L8L%??1D''G;N5
MCX)NG"35]9[1YK>=-1[HJE*>PQ>[((25#"HVW:E6$0=74?CH56K1!)B7:@#<
MV*Z]?W"'R[@$/"G1/JFM=K!\)\AL1XM3>4L##CG6@8LQT;F_\/XV/#2X8J\Q
M$)3>9,6JPF=.UXJ,7LJN6W@O;NI%/+ $ \V/R=-;,(,F?%Y;!@H57VZ)&*Z(
M_6RNB9VJTU"ES;H6<I)@.PH.C)*IT SC:;2W M%]7' ?O#>Y4%6N.="2U/%G
MHO*ZM<8=(O&Q*UV2Y2O2S$%([$X,.S;A+)X9[I6R["2*B00RX@) U*IU'%2A
M38Z42*7:[E7.?>(>5 E+J7KW%1([B#2$@JOJCM._];\0-_,XX:E7ZJ^TB+S+
MB<29FF$BRM(T%8"0._*CJV2>!KO2@B?:0Y=$T7+TJ:S_AE/D#56'A0$(8=3>
M]C:);ESH0SEBJ'<I &=TK[V3:P1EWPU<@EFG)D&K+]P:)MRF^3,2X<0(77Z6
M!%Y!=!LQQ_RUD0= 86,"OOIJ#FUU63E9+4 OP#$?V#:+ 5*O4L"FJW4#@^3>
MN.%./*B&A.)QD(*ZFR2;HU6CKL);A(G#6KZ\+HOYG(HL?53_O@)]%Z(R[W8J
M*M,6H>\#-%\O0*/A [YRD(;51\L6=@=B?HS<U- ]YH6%[Z95A[W[*^5(6FAW
M&X1'RE0#)FIP.IX:W8VLK]2]H8$2&E:'RTMHTLP9V$&0&@(+%1N0N>PYEQ)G
M"\#1PKW57U7W*(Y+N]9>X:T&7X7[+4-$"Y]S!<3YSZ+\Q'>?_L:@< J9.E?)
MU.C/8433O;W@Q=@B"VC3-\#-X.;6UPC>X>I:Q'?HX(X+4MT!U6SWOJVC+/0M
M$1/1Z)R$$W5RAD%-]%W!O4#536N9&[5,@C.2W3?<MUDU-II7>7"-6DQSBQ/(
M*J^ W8^]T%%AU]4+7*@DVT-==6N.^H$TK\0=:5UQ]"5<&7R/[]CO2"!D+;D8
M-6@9AK&!(=GRN,="J$7H>0FVG4#9?1B>_N>3\^,G\-_1N?[['A*/_3XZ_5/8
MQV+\S1"1CT;OHE_^C'X?GHZ/+\ZB]\.#<T!* H"\=^_&^'A\Y?'9R,+0&_YR
M_/LHEA>/3P%%[U!HSL9GT<71P>CT?#@^\GC.O@R^20WDW>A\=/IA?#02[#[]
M5@9I\I=5B,W4A+IQFW 8PZ,_8:75V' ?/)8T ^WTR)+K;_KD>I]<WS4XB>W3
M<:>;4)WN'%091B-N- )VF JI+;"!1B,;#7[IDL6Y9@%S_1687NUJ1@Q'+:Q4
MGD7?MQ$<>5M"VUM"R3]C, <#8OR^MJT)E14^?>ZV\C)7=]MK$OVB5M:]MJ"@
M%:4S._Y=H.^^*WE$: DUH+?-=?Y55I(2EQ1?L^W?!H"\]M[6MIA^ERVQ__S.
ML=O]N$NKTLS^S[XL_!]\0)*PW&)>'Q;;G$S[A,TA5P2-;5QWC-1F^6IQ2:@A
M'+-6_P)\&/:LS0Y@Y)WAR=U>(89G!]\%F##Y^_RT5:US)U@*RB4-&/[6SIR9
M#;4Z;\:<W4Q%.+!M:\0N&I2)R0KB-YJ"!>IP3[Q5:U1V8[& TVBB A@1.&U0
MOXJM#FI,&S(/V!P64C>/J6I^B6:U@"*$C"(;\NB.?BR=+\P8ZYBZ@YN30##^
MJDIE&I#/OE'K*!A ?N1ZS71P-RM"'J+X3_IY.4^P$!@;RF<KHG+=(1:L,3!7
MT?*"T,J=A-@0S/^D1GY58,P'YP60-PP5-&U@4F!(S\GEP1IC14S%"1*!3+[-
MT] )BY$<$<.*P2.*I@N'U@S>LGE<5D-5CY^F;WX:*REL]%:&S\#G3#.E@3$H
M8/]6/5VB%*@&T+21$B$*D*!]PJ@*+5$82F=I&>66)DX^Y8[P!NG4;E/([E:&
MJR7\"J*_13FFG!0,WTY& 8G4<I=*-L969<M"V6C::&S7,RB2>*,VP-W\=DM;
M-3.CIB>1L']M4M4(LBV4(9RI$0 +A0-QY2IS$-PVC0PE2B[=D%O0!/QA&A'\
MC2;I;)OI-YRA59AGWUTG=J/K+XSH!G.\9%T==]JM5E3-NLF<D5-M(S@*9$-'
M6'JG[1P\H?CW#<3$?I]A6))"*+E3+2HEZ](A5)WNNV;6@.%@^T!W;7FJ[%[;
M JI/.V(.ZL6F;]OHT4TKU4O@W"9@! U0YTF'#Y@F\&NZQ)7^+Z<&[ R+>F;9
MA*+!>Y2CKHT!8@",?%U+NDBI!##=JC!1BS;%F^MHX1P%UF4;"\S.!6QB-C2J
MN;34V"SE ;N'^<"4N0"?7$TVM'M<F?>MH'UM3WMJBCE[L:0 1Q%Z/?UE^[?Z
M3B^68YBZ D#UHYO3J3"P<B=2,PF7&MRV$[YWL=0%N;, Q&(U)_T+]5R0IU/V
M\"*9>^/7;5;-T>+YIJ^H,U\H)Y OUVN#>$SOFZ@-1^?  5B\+JPZLKR0@@5J
M(I1/*H&?06E,94R2K%X)(U#G[FN?R#5MN(Q:"D+@H-'Y*$'XJV(._X%2E!A3
MGW :6LI%&OXCKHBE[7?%2)@!EG6ZF7$:$G3?;PI[05K)R+IHVKO*7!7?/>+Q
M5=QK+ZPQU&YIHV*H$'0A*MY4ADE"7H*A: WG'V7=\9+JU*:PC--I-Y)'F!DV
M0YI &1&3%A:4;,UJ9J#+TWC[)W.KZQT=F;:+H\L!V9&SXE20@8IJYZM!U3!3
M_W2L2T@6Z^QU1V08[D1,^6H-214)L:&IY2<B.C/ZPLY:#@!7&9CIU5^Q8' O
M4!HL9<%EBAH<X 0L>SD 6>_>ZAUSB)E[T?6VJFW4*U7,-11L(&*0E2TSV!6Q
M$63GNM%3C$>VF$Q6I0MRXRYTDW1*NYVVW8-!]I8%:MTGY]G\6%VH''HZZ1BO
M<L.4+(:NO<:\E9*<S]U7RY6 =8QF&%\XO^T%;IVP=4V5/K$(3IF"&5:TH#&S
M1]G<_5.??^[SSX\___P5[,"=RDUS &NI#H]?[C7#]B1#04U=.366C/G0'L9*
M:[T_J-G >8675['<,LT4LUEZU\-T3K*I\2<:^.L (S)AME]H-0Z2_:*'06$H
M[6*T#D/=19-LB:T#KDPX$!V:AP$R4FL&T%B0!'F$I-I.F))GNCW478'6F%F[
M0=^1,TUJXS$@'),:/[:JUGQ!(KO& )('%**!I.<_T[+8NX=CT=H@-73\(%[6
M@%\9A#ZB%)U(\K0U#>UVE"":SK]6KGU']))[C.S%UXK!=,FB\FIT 4O!M1-R
ML"-'&VD63T5)N8'&N-/#T43S4Q/WDFRN<C341C007.V(R7[T!]P?$GC5-!=V
MQP_EY^"(S;-%1BU\L;TB9J86(:!%W&67=CN?X%"<&3J^@((NS*BEH;1DB-YD
M'(<0XMF+M+8'Y^T4:#,3G.LH +=T8 ,E0C_=% M9NLKR/-JVF3L*E&V2+58+
M0B[ 8"%&T"DV$F[%KW15RKIU@/URLK;A:=LI$@[T;R5LJ*S0A<%TIMP4/-D4
MGJ4O">65E.9Q7,O->(X=.Q-H&2:0>+[:Y7&U]$?XB =Z@4% E?I/IKI-$-$Z
MV%TJ":T,LLT&_:^YZT)B&Q%4VBI':[.MMHN=0NNQ8>#)]=7XCO_=9/6$5F.\
MYIVUZ[AFJ)764-I[ L5T5^O'Y>3^;R$F%"HOX "=ED@[_@@"TR7.H?7J%$I-
MLF7MKCYD5D518U-CP6Q0)FC*@A>'VXBW*:7$[(&I!O)"#5\6@'+B 83*(3O*
M+3'9''(;+/&;K)NZD-'N]L\&*(0MEPZ^ I%D\UJTDOT5;;.^'@N9\;<UEG;)
M<T.DE,0S;$7KMQNX5JO9@/E",XN]U&UZ\^.X+=*QY]<B>5>X 4JU;U!-E8Y\
M'0(?ZEQ4TVR&DC^!/K7Z-N7.)OZHMO$#6>GM' V; &4HA"?!L38K </F@9G<
MQMCE<LN'-PM:/0E\!&\$XN2K3)"?,)6^_DW8A.N\[_77QHZS^>T78&3Y%E=>
MJ',UO"E=UTFC@$8;C&K/GF '8?M5*YD=VVX4"(?-CWV[-(7@P=6%5]8!238E
MOL;$-'#X&]AZ^TH;!TUH&XWB\J[=\#1NOET&XXX!0A!3>1_4E?!E:BY=>34<
MR[3RZ ,M?V=77& +P<U2>H(=+_K%74*/*[K:0K$.;-K6:J5S$^:]& T47=O$
M&<&ZQCL3)=1F3:8=!".=R#SI,,5^!>7M*4FO&/7>3_5T/B]DVY GY.S#)"=%
MI3M66A28M(<S8276^@VJ--4%$#0^!O'!E8,&9PM91HDUONQ;US_X^LT*'>T]
M&O-PQ&FU.#H$1!(X1:T-9=)-_+!F'PX:8D$N@'R8NXRM_FNL774*C@7[QK?4
M4**-@,.=TX2U1T431-5) @NF@<WVUT/U^.UL&S_;'SCC!YD3XZB[%I(:<_CA
M0WJ%U/T%$."F4I-5(#I,M:DVL[_59GJ%H_#K+;]FN8XZI M4V(5+"ML"<B0N
M)-#?N%72:[[X%I,65$X+'F0<LLIT.:9X"O>W<?_0"]BRY7"+P?@Y&H?G]A$F
MP)\][1/@?0)\UQ+@JUS40*.AR-.PYEI('%/::-K6:%R;JMV/SN K:QWK[7QH
M&TH2\5VH?P)Z;O+44+>3P]P1\KMWM"]4V!2P*VQ('W1=-[HK;GF(?!F$+("U
MN7ACFCL0I;OB^$@1G#@@EQ7=>^I^6-777"#.+0W4Q#&=J@E7>OWM;O$D;!!I
M*,#NS/X\N8V;S^2:\>:#C0$ OD?S[W;;#;GLL5RUEU;EG_T\^'C"H2ZRSRF\
M4K1_Q4EXLEN@=IS.+#]%$F:;Y$#5U:PM O7[)[-2^2=*>:VXT2@LMXU#OU88
M2;2-(NAVM+J>K^%XM7)C\R*X95A":Z]98[6AA/^;67=Z_M91#)4=\)E'^(2M
M3$!C_BECL&LAO$5P)29H!ZZ!1S!;Z]XEMM6X]HF!S=P1135FX[0J+(XFPO<(
MGWV_ 4+B=AHD3K>N.JZ7CKF98 ^>2=1#+*#NW3V1;_BXL5B"1*AXB=61'UIN
M]06BJK<H:)M1'S>Q+)-=EMG$$ 'Z_?^AMU% SSZO.45/C0_2Y#?\VHF%8%#+
M.E$:N\U9QX[L@Z.D'(SKMN#4?=6F4996[.[+]:9%^N9LK8]F_DW]7V^J?W5/
M>$>TFS6R]/,2R0?#NQDTL+SN:P.0;^$78^+D-M7,!FH96;;@VUE><ULG]3.%
MD/,Y#=!U;VUHXNBFQRF!([9:GBQT;4_<Q/@,.@,8_Q7$4YL8(I(TK4>W.%>K
MES,@BN]Q--&S&VC=%B'YM%C6)MH%'9_(M*<ND1*GH:Q@I:ZP)$H]$!(27942
M]_*/-E^I73D>8V=T)*)54.1US'(S\"[_R@'04.==ZC'*7*C2-6^CVZ]8(O8J
M7FD6:E;<:-NA\D!\L&^NM9DM=D(GA"82K)FU\Q?;Y"S.?<K%#<M;I7WWL:0H
M3L22/+"Z!-VR\MTJ1(',$(1I4'*1F#D0Q!453V5(G();I.8LA-"A6@OF@#=+
M([S(-<\&MC%=3)5"TWBQOZ@.BBZ[O4G)-G.&2.^ZYK(J)LE6#^%2!_2LLCFU
M,5M.#GN6=%@H*>VW33@''16R10/4CDMF-Y!V@Y1E,RK]2C\G *TA'")Z:I+K
M:#)@57R_=X ,F/>8]&=5I:2S@ET-B4L0X;6 =W:<P,"ME6MM$\"08OL"M1*C
M-^OZT943V$0!4DP6X,KE.=BVH>J>JLN#U88L77>!K5MYF:N@1\+\5I*ETEMB
MZC/DCUMW@=Q:_EA];7'8PE+X#3R-F($4%SZ:?/#80KH\U9W!L(Z_))-/JR46
MY;,AM5M:UQYY2U>V%U+7<-]>"6BC<6)-1XPA3>82- :^V;##QMS.K7PZ&;/.
M@&D"9R9;9E)^!(J:( @EX< ? YS2E=+<O&^W9M^(*T$FC]]9)G>T1,WS"R=N
M7MGT<FCOJ&_ P&!G,.R,$Y,["XUE&IC!<'#&%3$-%2+A@YN#96B6P4W-*K57
ME739G,Q M\O38_B%A+E0TPO@\],RN15VED>6*'W6)TK[1.G#)$JWR5(USZ:D
M:PRX(;4[[$>G"  :=T8.YIET" S(U=]#&U.9%. 5=FL%21=(':1;N (:6KT
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M+8=0P*Q9"\6S*W[A%4[J!OM"]NU[([XF-B0LRG=!%/GZ2"+Z&$ PT()YIM(
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MT/I:>T9P @?8Q@-&6<DYGXIZ5<6&0HI8ZD+<Z'+8$PLRK#%;731=JX6%O:P
ME3Y> # G6;:H8Z7_8(U"?C0AAV_CG^Q2%,)SC2R,EV]%&]OB"FY7!6?'^1JW
MG&>/M%S\WHT'Y;R>*5#D!O!*X[QI")+M:\W89?H9MY[L,;F*\-J :PBA)7Z6
M?[S]%D?CB5*.=;'X&:1 ?E472[2"<51/YLE=L:I_GF7*BK,O=KG=Z#35I?K?
MU+MKWM#??JBG]A^_:!HW8/%,DCE?_"C<:KQOE=ZITR?J,$W@#KDMD^5;:Q!+
M*'_)KWBP__Z_?OKQ]4]O_7&Y'VKJA_L.></;K<U$L]/_2-R#Z:>THF+I@*-
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M#S.&3*8FGC#&%[8@=*FE]5UOTNX6*I/_=NS+TED?W0-/D) !E0?<C0CX!4"
M@:B;B_=D>1+!+KW !NJ"_+_H3CX6$^W1 0T.O[;EP5_8:"$LY2:13@.C%V;&
M#9U%<).OX/$E$@@576!^Q$79#F6GT>1"AN)6#I\-RIO?M91,[[5CX%%#DS>
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MP _GIZ,ACG(@2W)R##,<*\%X?W%^<:I&_-OPZ%=8]-]&IZ/SX[WOZ);[GCA
MC%. ZN?K;*K.$]>'/'WQUG:H'YGI]ZHW_7K3;\UJ)<KQ^=]_^_CZZ<LWTY^>
M__CQZ?/DS<>7SWY,/EZ^F+W^^/+U=#)+TI?/TNFSO]%;Z1L?U!7^4=T#YZ?C
M7RY LZAC_F%T^NOHE#_VO4_ MG?>!Z7*3D$;;7IG'8Y_!55VIO;R/ZW["^\
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M5?J2++TSM7>CLP,U)[5*OXR45#P4G'(GW('/;V.W,>Y8TZ;389E5!DE3734
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M<)/"Q8)%+W_;'LH 3[[2V]/P9N0/(=M3L]W3+1/"8"\"ZT:V_XV:H5=-Y 1
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M&&%Q[H$(WBF(X(7@!J[4??^W$2%=/J^'?%C& GCZ8>G$!I )K677HPFF>.]
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M(^8URICF<U0U S@":2(537"!!NGKI"[3SZ&?B"N3<46%UV9RL,!L)NBZ$"C
MZ93'2TLQX;>+Y>.G'UL8\A?@+H#+V:K;\X+]RX9)\*9.HT253+L&C 6"8/%C
M;^,IG.,E([WVYRW!'T8AU)3!VI&_M"D34#ULDAGC#>P+31A;FZ"/N%-92]!3
M+5XSNK%5!:J@03Q1-(U4:#J&8S=,M6.LPQ11)?*UF=5AE.&Q;;W^!L82!B#B
MUH UV]]C7\6M2)0O.GY/FVDKMD,UB9G> IH,QHKPER!H.NPK#UG%%I2VO:^:
M(8IX@@F5S4T@KW5V^#T_,HFE/"CSAFEE- %:%J-F2$G2$7R:P!^FJ/_]Y ?-
MXW[+LK06UPN4/Z!\V\&N!FZU1+KBZ"8K!IX%T1V:A*GB&:A9"- <G;J4[^?&
MC"H1WVY5X];Q81T0(&M=88NW &[P':O@ HHVK;5O=Z"5EYXD8&)BM=L,UKLL
MLK!\AM?RK0W5^VO9AX3T"Q$TK.E?61QA1\!4C4 O$XUQO")/VYAIUBD(Q:/0
MJ-H!+AY*&3<\915;9))U)S(*U@HOG_O!?3??]B"DJO",BA01!-,6'I['[X.#
M8=2@F)?0P<_,[Z"*O0B N/F><GRSEC[TQ[">CQY40:\GMKA<[(%Z[JMZDKGX
M_4L4_&2H?.L6Z7]$,[_AQ#+#)LLI'7CG6[VU?;>]YB+59JGP]V$"$=U2<(JD
MFO[6:'Y_C\"CFNC'[U]DX)+*V8_>@F6=HW%[#0(3#VDBWCQ%??& &KR-$?(K
MR -:(!KTNV8JK<@YGDZM;D),!$CQ.O5+^(=H0^<NS3;I'^#YT@!'1907=<<X
M;XO:VAC);%: 9ZENCAOHJ"%) FIV0HFC/82=5J@^"\X36MC<1;) =Q&S.Q3Y
M8XGR#!0WF[?3!$,$X&(,X'530U&,=(QOQH#(""U_],U3UE]2(A'-,#%(?Z0
M2P)NU9/]_T.N6$.(09BC+D<":F1@R%0"WZ+.6%[0-!&8;-B/ "F%05A8?G@H
MO/LS/3J);D0,3XTAM<-?F"<4,DW 70%)-L7B\'F)OGSNC7(O>IZ@=N[=;AQA
M)<WII;JTGA>[:/1%H%(QIM ,_HG'!@:,]@Y71-OUP"VK<*G@<E)\732^/_V8
M?GB;#-'7<$!N[\3C#@PPQ)%EO*2T\S H"@?!\> 3@;.E*(V$B^G0F*E$'0(P
M=NL%O&2%'L#.;:2:V-;YM;^H^,B.BRPKYASCZ+P$.P58G/8.X9WI_F)\QXM7
MW>Q'?ZH6N8?<NFK*JD$0&YV-*,%X/'.4H#E&& 4,+.8H2W+#4'3KAJHLD7IE
M.()D&L0^.1+XXC.1+&[EVX*I;X'GB%2'4^5?.8QDY@E=.\P=P#33VW348,$6
M'7Y/V,A!=H>($J=9P379/H,3WR$\XY4%V<)0;FD)9'_?2NU*],[<..CQ.[X^
MY[IP>P\Q-7JX38UN4Z/?)S5Z#UGUMBE%S:$^+JUAX:YHBZM&K'F.[H/KC<A/
MD3AMN0"W&94B.",4%V?M"*\B#4HRG=],)HK_'L1^-?4$%-J_6#[)H,04J%0(
M\<\QMH,8IY*R/FN9-HC&K,&I(3\1[1E032#^>"!W_9@LJ9$X686_?JBOQ4JE
MV6& O.3H!?QG&\+B+]607&@7H"PT2C-S[0'Y.RXV:;]#(0'[102I*!X7M 8Z
MN CEX<U#$XQ-%5V[I%(S8V1P7PA$M[3U#R8>:4-[EW#\9VBTDMNV26[-FZ0:
M)?\/W.B*S-:JQO*C$E2E&+390L/,?,26C3OOJ@Q(6\M,Z[WH/(\D,>I];&U
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M,"-O#EW$ K'/?(-V(P&Y' -C,-Y!I53*Q((G,%U"[;JW)-E?HJ:F(_N-?83
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M @HN3=.1],N;XU6+3TM 72Z48*)=0DF5]OY,EFHDI)FU7VHFI!2*\;U^?O'
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M)K*T6LB)FPM[-VPJ\,'@R6SF,L%>I6=<'?TA9GIQ=4 (P ]@6V%06680>*T
M$1Z.72^[!>ZT*E4M9K0K#C\,"=D@+%H'<72X?WA C8(GR2@Z>2S(/8Z!V6DJ
M!C@Z/-F/](]E 9.>!NM]>"*B:!=<(FDL;@\X5H.!H.,]]\0"P6?GA2-<DP@8
M//E?*0X6;LPT&5@ID%3NJ_#,"]"[B<4Q![RDI1%<)8./QR5A>&$I,RQ7PW'\
M6HQN/J4.1Y,MIK,)B&R.-57-C8%#LO[;QVE9U;LHS<.!3.%F8H0$SMT.IP N
M?W]$[.[5%.$K0Y!U4=8@P 0O7"F5<ZZ9-$HOC*P6+%D6?"4YBMD&OP1KRRV4
M%U[UG>[I#3$X-,%1(XQWI=$?XPX?W0K5)!&[5;=$'#]"GSK*BF)F+ZR5UE@]
MRNV'$0[4<./0T2WS4S8NA+TIJO2<[?R)L>$FLTJU9IRS,GUZ2U&/J[64?W_P
M9>^2.J9_O"Z:BG<4_PL.VO 39D4X288R>(!<TVA)U>V NY\;\FX@'0)6517"
M2W)A]Q\G0Q14^.V6Q<M?[E-G??,FKT650^1%[>E,3;$Z1!24ZJ\.Y8WGAD[<
MLHCC=>?#EC!I<:790TQUW18988-18IWL[[-,@^.46?X&!%(+NBL<CVI \0B2
M$29";HVMFF!+G2X/K L:N[4;"E9W4-T+BT<:%5F,I. 4*\BBQ<(VM3$UB#Q"
ME,'+EO<,[8(>-<[=UVV^(\,-I*F)]J1>]>X TDT&I4QVBV?KR0:@_N0C;V5B
MWR[7R:SR \5HQ<%3H]7>.FSX;7I;H)OJ=LX[KH$EQ1E?*5LA3X'"_TN'98_&
M_(*HV_6^T'^4!#G'# "QV>PB*#@'NT$*/H=\J2@ZH&RB&9E&S@2V(QND%KKH
MAL=O?I_P->=2H&$Q!X%3S<CP;&]EDZ=P\VSZ"S.DUMJHR)ND#)$H>[)+Z93A
MEK+1^RDOYAEZ/Z2VD]($HMIN6Y'CFL$/=FG8\/ZU-B;"G>DP)53J(=3WD\HJ
M%(R(\D:+4YT*S_ST8')2RJ"C#$QAL6O;QG#5H%KC<(>4^NBP9$_PO(-JG12C
M:CUKN?.F?L%YY2O+ :6:<WQ\H:M 1!61S2<B:72JTB,X1S 7UN:^LPT#'!BZ
MRR58"_0S"W;0Y+TOE3E<Y:>"X<P7NS&\=)<1L?BKW8X#'-M5W26'#73U/YL;
M4O0[Y\\NJD=Z4::P&7;$5,HU0[;;]VR\[%R<O]M]_PAT@ML=&,5R.(!=S7;P
MPA_/W)V,/M$#TRS)"1>JRV+@*9FJ&:KD]9>HXTR356XR$&/4$)ZU%<*;+0F0
M=9 %$N)Y-W*BV:3]CHG8UM%Q<'N^17P_;% 'HQ\#DF>AE!-GU[,0=S'&C%MN
MT0E@7H!N@B_KN727/PC*6*^#Z@Y0%S,&/;VY042KY\BDGL\<!LKVHNMBZGD@
M?-MZ7"VWH[[3128[SHDJ#?0),"04$PIH%1,M\/U13O/NIF54S$%W) /2J-C-
M-S.?M8$=YBE)REK)CPA]RW"M8X=+V-2,78>)%W.6\#=DVY2",;"'%W]H%[Q*
MB?T8LZCT,K+ZL+:C23,P;Q QC/AB;:9G%\N33SK?"E>3;X1,*IBR5IJQ@&/#
M"!-?(\1JT+&9U1-KS[8.")\+84>HA&C&%GV,0.2092)Z8Z#K17CZ?M^#"P-8
M=)0^,MC7(F\I(,@^GB@DZV.RHQ50>6OL<Y;.#'EI%.Z:I0A=T348IS>8N 81
M5,SW'F(.]/$V![K-@:Y:K2DLKTSEZ.AD[Y!'O>E)RQ=\+P]^)N$DE_U"+_NU
MO>SG>MFOY+)?R67_)JFG=6>:3F^BJAS^]P]8%[)[N']XN']\</JY.MX_/-K[
MY^SF!] 5]7__\!+,%_!1?M 1@Z8#0WSQ<YK3ZP=8JOU+:R_I+N'&,YF$#_I8
M/@M*M,$'YOAT?^\8!QC]M"E9NG-J R"%=:M-]=^3(:& R5;_)ZBA/,GBME?!
M)5I<T0\^"M@C( R)D(^B@A9;R(H#?D (9HD[=]K>"9JBGN6-;5C0%,/ SCA+
MIE,!?>:F 2O2.-]E#XQ:B;]:#66-<8Z9!VE&*:P3$"%%-WX\/#C9DP#'@ ,<
MJ,>J)),P\?&3SJP$8GH3#L3C$<(P(MHB-?A,9 S@J-A?Y4>AL4ZP-A!E/QZT
MWAA+KP;9)#"/$VX@0V!CT/>O$L3ZIB:Z:K35U%[THBEQ0-.B!%/T15+#V50<
M'NP*H9PUA="[)CI1Y)GX/",$*KGLL*-DA=$2'3V&)8IT=6 XA_M'^VSBC)/;
MHB19BWN^FZ6?R ;"/"6>%^<!M/(*%(\)HC#D0!!N=[RK8:'BL_S1>K(::X+I
M":P\MNP1:@1BG20X&QD%0Y)L#*,:@[V:ED-%HN,&F[(!5]RF8C+)IGIV5]J=
MCU)#=D)MDY%I@TT?V6%UGDJ7_^P\/O.)87*WI)3Z8@ID3POP@IL,O8)1HF9X
M<#JLQ'[F11JOY:WO;*H2%1^5F>+/7@CWQN'^P0'*ROV8 ,3-B$UFW.4G,9@P
MW?D%352$9_**$MZ^5TE'HG),'[2XF<RNP3XNY.OWK;%77N#2E>+':A6QC8+#
M:=5]KXL:?3/.^]!9G#(,-5C\'@3!A@CI9Z::$:Y4\P73 M>GF;J@K'_6L"A?
M"G?5DU?KV]57=R93M5T.U:2[4&[<AEFT\R X@@'BMFWL ,X5Q123&_P" L#!
MGV+8 /X8<S.<7MF+/I ;.454:P\F GPE+LO6BA<:)U+*X-D9:@4T^5Y>YG.R
MF!64/F415H!]C7X9 91ANEGZ+VJ0U Q:67?_.&C\:\0'"Y-EVK$,27.&;<C)
M:Y/DY!?'/".*T)3>5%BF2*4U'=B1/'C1\]!81BY#8 _-$V<2ZZ8@F'7@01UB
MUC_P0IE!"=9($A(D@TL_M.=YF7[6%Q>SF0G@A4#>+(VI.;+L*E(6C=']WHO.
M1PJHQV O?*,"8V&(\URN1B*7NY2DBF9G.>==38JR'F*Q]TTE2Y!A,LR+$:A,
MD5738R'#'#3@-N6*3K"^,#85Q2P9FK2^80&#]T^ 9,V1 RJ_J2>!C(";CO>Y
M<HK)3^TC 0ZRMI.J1I:E(1>?5-PTD28!Z^O/X_O%M]IH(T1$X:2D(E]#!20N
MB<5)J\]LH(0)IDH#*JOBTHZE6T2A=@ZH8^RUR=$JLG@OR=EP=,="$)A"(#>U
MDF%I_ 4N&;[?3$UYHY "O_R*%'JE14RMFT=)/8:Y)$P.L7PH2<IP3T*28]3M
M+[%;[60H2)*9#>YXL7P.\ZR)E'B(,9"S;0QD&P-9,P9R>'RZ=W+ZIP9!^BTG
M3F"Z8KY8;O0N9542$->+*L5/.5]/W(Q@0=C2FZ'4! 8I7K C%R':3#F[K!",
M/3LDP]0/)[0[4 X>PZ%GX$D57V?<GRU7M'A5H^&KBYR;\G((MT,&B[G13"F)
MY&+$6EBZ"M_D[ X>'Z=&TRE^;DW,_EP1YG\Q_RXZ4&J12C)J/"O2JM4ES..F
M&.+G83Q;8F:'',V.PU2'M\?<J!%K\!CF;),L@>[Q\T6N#KL%C^V%U0;8#5!B
M01(IS2>42_7 @ *)$".N"R+RYR_Z5XQ;'@9Q2U>5&EW))CR4\.3Q%X8GK9C5
M4./AWNF3S8HUONW/!-H"#'MEIA2Q4Z%");NW"F(U6/F*]MW"<8N"*:;";\D2
MVYB&BX=;"N8_GX)Y!2LK ]Z>"5;B7#7>%8(F+'GRMZ:%]@V)/X3M:.$V,-R:
MI9.B$&8ZOA3JU%EU;\N$&68$2JA48+Y#)888*G#Q[P?E3+\*D--[,JDXL$&*
MN:![%-9X-W)3%!\Z=+3"SIWK@#3%=Y<C:,T.8<W7Q8HYQ@<7]6BK>B^2Y6$Z
M,'8C[68L(,&B*;I<;Z\J!(LUZ)=]&\&!$K FFUJX/EJ>:X#8$WRT5X%$5)H,
MS?)&+P@[WQ]&R 9"+M2G)I,'I7J367(6Y'#0WUHJ1"K!GR1Y;O!$O.08I7 [
M@#1O9AGUV&'T5!7MO+RZ>%<]$H<;6=((,>)H/NASI".$_V])(BH]4^'4?100
MM06H6C^G@3,910G[Y$@GND\NAA7,9WA2Q<$[X8A9P>*^56'_[BKLFBIIG.JZ
M<'CQ[Z:_WK9D]^>KK%#X:#H$$RR9I7 T_>2*G\61FR"GGR_G2Y-%SW/X8469
MNE'T&A]D\MNT+')R%G=>/G_]J/>!L90<.9UILYR5H;X ((2>TF6EN'@2Q 4(
MY-U9GQ?6VR2(;*QK9'JBHBE8V0F(5XPG),3#/S?F4Q7D\7RVF3!SX*V:5R"%
M,L8P':0@[(/91*ZG"<\%UURSZ#8075%R)+<^816=7Y+FP?C'OPBCCTN/R?M&
M@@@S^'Y1+\#7Y80S?KL! 9"H2N6L VT6R+Y/$5)L5@D27^*ORV*:5F)J=-8V
MO"44&^O)70U!>'6#'I1OJ4*P)*!!R]]%ZA-7ESXP5.)K65#Z5GV31>W^5M)^
M3TE[J7<>S]\[ZLZA4O?[BEH_5YT(616>BQBE$.9JT&R%^TIY$^*?S<3*=PC6
MPHDT*L>GZ5FAPG79,^I* ?*WU$H<9,U.,[/GU(\/V';LY5H'@*9F3P$P#GK,
M$)6_3MOW)]NTR#8MLO%MW_^-],J&-0#S[3JO6@I;)0X3IO?V> %LH@D#VV2$
M48D>EQHYD$%86[_\>PR^$&BFJ^@YS'7Y-F$0(W+<(AQ_7:IFJ1P0I4.AW+\O
MF8"FOV]?,A>YOLPQ2I-J8\"BZ0RUV'09I<?@]E<8UL$F6PR,\ ,Z/GN!Q^,;
MAC?\H 4M_.?=$LS<<=84I:F&C*J[]'[":,?@5[!EG\S"3Q$2=3R%FFX3=-D6
MK6"3!,V55H$":H3%:"'%B/]?R"T8M,'5]3'5XP^PR;:RN<08>E*,KB.F8*87
M O)2!4I3V0]=B*8B'"\3V"<E>'AHG>2P[80CCH,E8UL([@FE<VLN#5HN]ES.
MW?K;H;64[KF$06;DDWA0B;:+(8:*%CB3.^[*\? P29Q$M4OHI3XW);_YP?$7
ML<&X-FT1.V&WZ.0C?A9&$[=*A>+HQB!2=#99*"C7JZ^$&\!.H80!HN0&Q)JK
ML\O-35&G3#O$3+\F6SA0DI?RX?%S&('<<H9&QE)]I)U4X'9,I4H9L; @EJ6Q
MIS9@H+EP!ST="LE'_0\Z1(YFM^@>^Y+=33XU>= 21/S9=1BSW7+)[76K+&PP
MS+?C?<47]L3'(3<$FQ$A->PO7K>P43'/*V3-F+IG:$D6!J+):S>Z93%EJ3.4
MY[(LJ  6;D]]8NU8([9"IXV1"E/5(&XJIF"#4>@PRF*19(P\S!'<)1#SL/3-
M<APYJI*4FB'RFB.H #U[#&D$.HC+FFFQL%*>1 B*ZO HV3UCS"%:%Y&!0U!,
MI;Z=L&,U%?(20RS,97V&EV@SR%TL>0HZ:ZW7HD6@I0X%TYK86'=*)8**#;!,
M4#[E4VFF(,RQS28%P+#>([&5POK\Q)9E$S.:C!E?6 ;$ZV84#%"$CS? =,RQ
M?_T3=:59FE'!?V!R9.I7LW072>\I.PJB,%*4)VPWM1YWUV8'AXZA.LIJ[<)R
M#(JW#82%E/UI82:8@R-.]1N3@:">QM%+DQ,)CN5F)^[VZ.\OD_-E G?<@VN3
MT..XW,;3DVJFT(FD"(",#^Q+/-]>SD@/'IJ7U\,RG<VJZ)V*D$L0%NG_S]Z7
M=K>-9%G^%9R:JC[V'(JIQ7OV]#FRO*2K;:>/[:R<GF\0"4I(DP +BV36KY^W
MQPL I&2GTZ*R^*&KG10)! (1+]YRW[U-BWW,/W\& S%-?BD")#;\&Z?I#5C*
M.8PJ-%O\BM(\5;C(MIQO+SB=Z$A*$I:/6O>FL1N"GNIP_^ QOWAA_R>JHK\>
MW1L_U,3L*/GKX='X2/^3?O;7@T?ADY@&8YQ\B]&@"9VC[T7#N7/X<+ROM[L+
M [IS\'#\P#[@(=TY.'*?=0?U$[RZLN(C*GY@!OE3/8SM$QV.F\\LY'V'D/:T
M%#*(WA'%[ EV7G0YW,B\[.%9+?#@;@^WJ>\RPN[4'( DG#1IK29D%4X!(TT[
MXZ8H.X>69<.L$\JQK1>,2!2HUA"(1)4N;$;X;H+\LZG$[FF2;;![=^H!_1FS
M.8JFQJZ@#1.7VI1%$T+46/+,JW W8H=:J.H;^M#ZF)[[*^FP<=GA$;%%1(M?
MIAW;R"IFZ AO(+S.D;H8#/>KR.MB,X%\Z/J&[&OXMNU;@;J27P"?;FI6Z?M@
MA]#:$_T[+Z7G+;HJ3B?Y&ITK6-TE^J "R>F%NJ A1Q9A !)9QW *ZN\C(A#J
M)J(OM0T\I7#:\4,RWET)UX43 ?T6=FBHS#'JOS6=W=3F-\%X3EKTW7OHM/D%
M*@/R:<MY.)69OF@TZ$5$(BG@'<$]83FB:WV!748,,(VE4N+>/9M?;*RI#9Y@
ME#8]5UR(=7"?4>.+BD4WJO?6=00%Q2"O;R(N.AUM8KZXC8QVC<$RMI&H%Q[N
M@TSQCJSW]I/UXL39EJ&!$W(%U2II[#E9_%E)Y<P=#G%76D0C\)SWUOKU.TSW
M&HIJCMF1$ZNGWR&-+8-/R&Q][]0Y<1ICA!6W)>+9D<^4* Q]@8"L$^(_[J[H
MAVR.X&BH6R)B.DIK$ADBYTWX93$19>T1:#7 T.9PKY;R7=@7MKX5PWB -E%]
M7T7;_(5DS5_*T-SOJ?[6?,U7T7]O+S)C9S]OV'YR>S\)^>*2SCZS2+3M<!32
MNS&0!D?M:K#Z&<&1ZM"1HSR[VMTHJS/8Q>QXUR-*3.-/OS[/'KE:?H\[G!LQ
M;%/\B[66<HD!2%MPA83M9W?2R;7"CF#\T-Y-4[74<!^)'')-,YQV4V-#TT2P
M6G&V.G6_UBA)X+R@\4U2\,A@C6O-JN86>_XUS0%!K9=M5;<A_2I@7%+%"M@Q
M"=?XNU-KN\?WT0%C=S)N+M6!WFK67&:2H9:,LC:_.:[W6K@J GN:Q3QM3>U;
MRLYI7.;:-K.FVRS(Q@=&U5&P\B,K3YUEQ77!<+<+AW-O?X?#V>%PMAZ'L_,B
M;AC@Z1N70Q>0/VFVPX\(9S78]S,^D/T(O[A6[P G(3IQ: 3J%1H0%SA+];BE
M((BY4%5%A"=S&E+S T()0H@<L$^. R=BFZ%#L59M$#K+PRSDPR^N/R6$R\BJ
M2(]Z+<70RDY886;!"#TCKTKJQ5++U7,XD,#+4\3D54(<SX^A"ZM#H.LHK,1=
MQ$<*SA:EE!0FNP9UI6Y::JP[4BJQ_/FM0;SO+.+-6D0I)G06#6.U0I*%516"
M>! G)!JW9_^=LE+98CDO5UBJ6<<$'K&5L;>O)9(!]WW,>NQ$=\:P.TU28\62
M(@9):F&M!;XDB@?"\/Q%!,^A2.6,O"..(# (7U89.;3XLL=TTQ0!8;MET;@R
M]LC,64#C>'(RQ&<$NQV50/_9YNRL89E4VI4U6 G4GB-O[83C15IK>XI3G4P>
MBK Y9!^)^T!DEFV*BLFH8Z@9R@]1+P-:>K2Y^+*E& #!]KKGPN98?+$2&PYA
M#S?2MVRS!?\WPI9OHP%_5GD453K%/G9GK=-8'8TDZ=354;?FYMW=198U@T5@
MD]=@T^8]MJ"7ATA<Q)A)L3VF1EIO<_]0-83O(X&0-]]6 .%WB!^ KTR4CT/*
M!WD=#D16!XD9I((7CZ2*A+X.>GR$_6/HWAS'U2YH=&WM6%\9'Q&RC<FBI/,4
MOGB95M/M;$;X'7""_\Y6*%&\S!I6C?O05,1866\1OJ"#ZN)Z>/=T-N('?9):
MGX2K41( \<L6NMGU5?S^&;HKO^].2=PTQT[#N*_ I=Q[V!/P"7U;!+\&+KL;
M/A^O ":S?W]XWX.S@AAT'YO%YCQ**= AH)@QQ8 '*2:XU1&!MSPDO4&,6FUH
M]$#"8[ATW)$!*A? Z1 ^Q \CA/U)C9!\5YK?^!21;&ATJWZ-/53+E)PP0*$=
M#DZIL$<4<H4%$]V7,9Z,E2>R<2L257G]"1OPR@G#$JS\WF>L0.8"9$! J]9+
M[?6R2)MKG=L8$^S,W4V;.R93:@;C2@6QC#3PI[754;3L8&P&$XHW6V872N>8
M,74SQ,?X5-F@H#I'ME?.]F C[R&MF1"("7FU,*=%D,6?A\.)0 _E6#\+7$Y.
M6'&(X"QBWD*O'R% 6:C6*GMT%\+38=D9IKCM#L!3WO;I;;5^X+J#Z7EYUL/$
M\G_;5$H TJHZ(]$THKJHT\OEW!AV1)'5NX[4_8#*_<[B[2S>.HOWSBWGM?*Z
MZ OD,>ON*L\0"5)DW42I,?E%4JQUUFQ@8[QAP_BVI'1 1(.HEFQ8S;['S\+Z
MT.!_X,.-D^<4L9?$^,>LVA:3XU7 [$X:E>!1*D"EC+%,LX\"1;[6<A-&7&4L
MB5'0KP7&-7JD6"G+I?\LI\+=(.SP:^DBKT$.>844>.>\H*_!NW"]D:>KP ".
MME&X'0</HA)E&B9Y@T$R]@!V)KX.N:.(C!'^._BR2JYH IKBZ<LJ5SY&4TCF
M\:?4+'Q95O/I'O@$Y27NGNX8ZRB#SA(.Q34.04^(:7/A$5<;59HW$&V&J$[O
M6*$2_ )5X*6!627@/=K7:X+0^]0&F'#N[XZBW5&T]BAZ+[TS6)(RAXOZ9W2_
M*K/*31\8N+D=!R&Q,#Y_$]LK%&\18L4A5D*A4^3&1^IYCU@!-U PHN>G. =U
M69FH!'S/AG-[1*TX8$3-M:3S8YHCEZ$H\=#A0_WG2)_C%%TBGL>H44"$VC"#
MS3[MD,EQ\W2>UL.N EVH;CK\/#(Q*\]UB(>8&Q4MEC!TZLW$[C^,RU3'0A+I
M[B(*E&UC4$C4W.B:"-?0^T3)$/(!Z/4PPR(5@C<P*W)K_Y+?+$O4]QIZZZRS
MHHB1R"=(E$:Z?S2(B 2<OJJ^%/0DKLB\^&%ND+G_\T!@#W80V!T$=@>!W7DG
MFR&P#@DC')^^(/=O!>2B4/"KR=IZS&L01A U#L<=1:10%Y66$%);HA_2Z8XF
M^*9KSBLY72;1IR@<L_QA-$"EHN"+5D04T_BS;EC/2HHC..TMX4_U(![N7^3^
M&<>C[V+M($XK%0Z\ZFDF( V.<P,]4DW_[HA(# CX,-\3=>4$)K=='G!GWC;
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M%MEZ<#1W;V,H=+0+A7:AT'5#H7N'X\.#/S04^M8'S3UWT+P/3LZQ.3EWR/?
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M'WW9A40N*]6 HX(*9VG8MF "V(0 :">8)X=DYOX)*4\6[" 7N+A5FY+<PM'
MNM_9.!P;KOXD%\Q=,0G]/R<2VDVA*_PQ^/^^$I7"Q6ND'Q2.:2K*H.>H0D\(
M*PO$@63X]D*Y-58V[_\>HX:6R]X1CS;GP*,JD+>647 3I,DY:\#EQ<AGMD;
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M#=WX1>D+3.>E4#M80P0]>Z#ZLLG3YX88/I^:OF9O8?5$D[_,2-DMAZS3G\$
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M7 948$\'$36@NLW1\6<([2NK9<GI/J=4HIV;Y+5*!7[=F7N*&MSE7-F\3""
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MXT3YJS-J; NL_-)H%6'I=6<6T^Y;U_@!FS88+0ZA(?5U;4^D]]&_L,B5<?T
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MJI7"F]88DRN)'7/+S4@=G2'1"9^7#6>_?[!6)#FQN/ILGB=Z+C@&?18813S
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MG)""X<X<+W+?Y]0+8%U6&@I*PT.SX^<;R@VV ? PP!/4O:D MHT?(VG"%.\
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M:U;R\B%9+==P[@EHB%3U2R^\]9:I3/S\O#?4*:67VAP\PO&<],[/?W#,C[A
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MH5O"ZUQGE&<.>.P$^SF&%P5I1N"723PW'W.RV/SC,6$@K?W>V!7X:_#O/)B
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M&ZUS_@IN?77^7G'^<WW^*8T?1ZIO"?::GV%OQV"&VV'TJ\<?$^\./B2UC.I
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M"\1M6KX+I##P@>I(!2:L4ZINXA#W(*0]4#$ ] W3#J"A<"4_2MJL]/R245'
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M"47!1MJ5I7*J:@\*?7R&0RP$G8,TBX!B/?!@ #J&=-H9F+^ -+-9G,C1T6,
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MC$K)5R)4F.^*<K<7"X5>__RGR^'YY:OJO"K58!>\C=M.><T@":MC<[Q,584
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M(QP"]Y1\\HTK;0EK4HO_W72Y?+%N1R,UC/DX*U_E#;^///X'U- MZ>#BB.B
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M(1>SH+AP'B+!4-$P-,R2*-47$R@*V*%:R]3*Y70=>R&UY#-DLI<M:AW8P2^
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MA9$0"V>JOK'HYB%G*J8CARE<((J6D3!FPD.!AU<E$OLX(/].I%*AE9NY@OJ
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M).NNL?'NI6E,U^)8A0$9!\J>ZR2XYBS.);7+V,T/2@!QP$SCELLHS@;6L-_
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ME0-A$1%4%D#V$5\ Z5Z&1KHV-&)#(\\3&MD:O%:Z&$ON\08!TCXO<W>#[BE
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MV6YYP?+"NKRP*^6WF0;\P[0'E5#4U)DV+>M IG$U).\ )O0Y3])<EHK<-N%
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MO%[E")+CM,?FM+!DKJ$>,*B7\+)LT,.C+(O0%BCIGED2S'%ZF267\N9H&5&
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M*N+OV3CU/O:\#_$(?EG\I:BF;95\0+YJC93HXJG+89H7L613&/A9__FSG>=
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MQL4XC_-@PITQVG.O76A0M&\T:*O)@PX>Z CTMNZL.XHNXX*W[@M,^RM*I'_
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M:A<*W+!5NU#@^JUZ8T.!']^_^?I__S_GZKM8H//T72S0Q0)=+-!)"!<+=+%
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M"+Z]"(;PZ5=!<A5<%\K1?=G;QN0)W9S[2M^2NX/SV>N]?/DGS_P3"=0B);_
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M[)07%81EA>@3^"^+D2@>$C2@-'8([*8890UAX5M";QB/"#01JP 6GAN@ODQ
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M!Z6(O.,L%]Y%B3^,8E$L,7#YTN$#GVPBJ^]O[Q_Z>[L[;G.?'MIHS_4/=/A
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M/ O*<@P?_*WGO<O$.'?Y$ >M= RPD; JQP ;#JUT#. DP-(8P'687$-DII,
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M-V_[X[9R4-R!?K #_7(]#[05SCVJ1A6HH/X^'>N^BN5B=G+$Q_4XRXD-T91
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M3$H]E&1J.]N1X* UD/;#U%;8.W@!1A+PVXPM[. NF8@B-4*$FL54!RH+A%S
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M1HW-.#7&4. L1N!;9YV 4.N85MQV:4675ERUM*)"%$J554>&=(#'L%6'<4Q
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M?(^Y3@$Q8*KF<^;J[1-.DAML1@LA;3V'QY$$*_P"E#D%GL!1EXXV:BL3WDG
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M!16)/ELDJM-&HAN0E;HHCA+15W6Y=&[L:]UJD6CV7<WQL?HYKQU?L\TY.Z1
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MKJ>2, &#7CAI-! :EPB6 +N7(F=(@@PQ<):3D(?<$Y1 II@4R&5'/7D)86[
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MD^NGYE7#^30VF\T_C>2?R4'/$@/93/R4_(14I/BCZPUMHV]JY_XH9Z(I;Z3
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MHG&HMP29)>C=*<DRKHC;3^P.D2 T@.I0SB;FMZ\\OQ1K]Y2A20.HW_%(L<E
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M0"= <OW%?"F^2_/JUN6QUO1C9=\^>0&O/+NOL&7Z7M2C'A4I50,1C[5D3:7
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MC:>>$"I4N!%VU0]3*6ZK9Q4L*EA97H+.*5Z3&8-Y.7UZ6C>17# 3W9S-]J.
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MM1>JP0OPT2RI&OQVK5 "55J:3;A+0R#H!H=R&^ELF05TD!;,828EFNNP<[4
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M,["O1<&+;K/Q6L8[\AW[OUE\.U"'6?+$^98L.CAO.8%!)]!T3-Y!$0HR*F"
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M:#;RTVE1*QP?>Q.\T1I^O7A\PF(KXGDI?Q_\]HH!@_,,5+J%<,\"=-&0"5J
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M@J/5W_&**-PJ3)ELS%A-8I\>%G=M^,RCU:O9^VTRU;?;LU(_K]_2U!W5*;;
MR*/5]U.#:2=Y]V"0RW7UEEN,"CW^'K[]>/7)7DUGNP_L/=E8Y[/JA&LVRF/X
M^N/53SMV*U[0EB2Y7?;*=Z(R>:2D,9\..*-T=R,.2EVUM]17?4JL5*?SQQ88
M>;1Z[?%I:0PMQ2#99D(F:\PXL>+@R*/5Y^_8<7E!5>]FC4GA\99EEL4BMP8C
MCU9?&RL/K<FLH9#R8#6EI.7]I,/"9QZOOOCP2.5ZE?M'LD-G9LWV=MZ8/J[Y
MS/&2U'E&'#(UZ9';BD]W4R!OQJ< R3/'2YH\Y+<K*:NDN!)%+9+=D1Z?QUM@
MY-&2,DK!V+9OTY->/+>^GW;U=8&9PF<>+4DMMXQ%1YP;7,?LSI1!NC-+]L9@
MY/&2*I96;'3*JQ%)5_FEP9)F;L+ )5',X5"^6:.L_$AZXCJEQXQ<!B>&H\;@
MF<?+[]MD/IX79ELR3N7+TT:#D:K:&@X]6G]U5J_=#I^X84\0[^A>JU"3I0X:
M>H30O7%]&*_S[+C7X%+DD[U2>NP #3VBU5:;SWN).6OUV&9.[PXV3ZUX)0N'
M'J'Y)$'?]RVMK7/S![F8&]<6&15 -!AZ#.?IC#JG[EN+VUDUER'!C;_6FD-$
M@F-RS=2'UE.\6FSVEERN)HXZXXSMC#V:KJ;7GWJ5,MV?Y<7:J!%/J8PXPW-P
MP?_KUAUA$C=,*LJBO\X*"#>)J&3,=6X=>Y.AHJV[RJVC;J)B/U>[<V=;$D5;
M%]JM8V^HJ$[3=6Y=)*5<[=:Q-^E(-[C.K8NDE&O=.?(F%96UN\ZMB_#R:K<N
MDE*N=NLBP+S:K4O?D)%:=YU;%P'FU6X=&15.OM:M2T6EYJ]UZR+ O-JM(V\R
M$6!>Y]9%$N9G;]TKT[N?#4@)#YW2BX $GD]+8CY_NWQUJHFZ"C_\OQ^)'V^E
M('M#?@;C/9MY$+'BM=/Q$LP94?1J.3,T5//XD'XK'Z9O4N_+B>D+,.+95#LP
M72B%">JEVHA_<YYZ'Q-41+6W6'^B>R ZLQ]U#V3>5U9^[WN@JUN'5T"DJ$9G
M[SIT :2H?F+CM_<^G*B8%*Y1F<7_:;CU\3I.?;QKEMU"?)]>1E/]'JR9^X*L
M&3Y&_+ZJ:E-0I+BB10P5&H9B,E?-4%E1M.>V*EBR%#%5:)CJRA4I=.M-P.^R
M83HUFR*UZ@NJ58%\]&:NP:+3\<\+X1).K_["8NB%9<WWM2I^$NO\.3BG;MCD
MEV:C[%RW->M:A($K@Z#TUS;21!#T01!TU%WF2[%1!$$?PD?8&O*%^2@O+)0C
MET[$2._ 2- *\H49J2"/%%&)$.G]&2GSM06D0$9ZFS7D8]LX!1)FKRYAZ@:6
MV$>T4C0)T.EW''_T9F+E!%701!ESFV 117EHV-"KXI7,5L"?%S!TZ]=%C^95
M=<@*I^W)L;9\/H^^JNG?679\AXZ 69-OC'B:3UR@J>S1E[FE#?88C%SH&FRS
M$/  ]&#G^^3]^*E/]E>%66.BZ%5A,>F,ZRU_@Z9*O;C?HNE)-G1),">'W9FP
M&E@Q35N6 GHQ/5JUPMVV6ROVXE(V_5!)%7IB>0R)@!F1HO\.: UX.9TR.MZ7
MH",3BN/]YLOEKXO9=*C@3H%?'^A@>[F"G%HEYQNSPMD;6VLWBN7EO-*Z9I0C
M7XAQ\*&.CPO/(0#I1'O<R^3IR9KL"&.&NWLJ&/,91+KD!R!=6"295W4VO +L
M<ZRXW_'$?[!HD[O0H;\?4LE,LIHP.8&:W/&3#JWFY/%[B#;YX;VZ,5AZV!.F
M;*/R4-9Y-@X/?"H2;:[D>./242$XWB$0;;XMT'VD:/-Q*'=)T68Z&*<ZN:Z0
MXMC<4FK)S;HT6*YA=R3R&\DV$=9]$:S#-4%"0(GKQ;JS<+7+L84AS!7-<<TY
MT#5^XK1U7],V9+\U:-[:O;OZ()E]+^CJCPQZ>]_)B+/XHUIE,I+2JCRAQFY,
M!%W7 UWI"+I\&< AH,07A:ZV; E@J1(G&!J@H>E@UG0UEJNJUH_/2ELK6>RD
M;]LC^MTP:[JI";*1WI"]CK4L9>,/=BV;0YC%1IAU/9B5B3 K$K?>AEEZDA*3
MJT&*LY_*S4&!?V02D_<S7"_31B(O:"(I9QY'@^1PN= 2"&XR+X6;T.5X7#R$
M@443@[9 &*: .MI#?9[($;J;_XD-IH2E$QUPM9BZ<0WA0Q?%WD^-/P@UFGC'
M*/21TE^!(9YK]!81Z04MU;[8J?GL2@]_Y []5.]GJ%GD';R9!=L0X*. /);$
M\EA7YRF:9Z@0&/[7T_I=-6W.BYP=5X?CBEXOSF_79]V;FCV7=,L9$"@A8A<G
M6#?8VR;8(UW"KD^PA^A/9H#4R K9;7DX'*QFVZG1F2WK@E8N9 '%4C_^2<92
M23)&DF2 V!A=@!]FZX^(]%W0[:5ZYI5#&_GGP'8OJ+9\#M?TD<BWGQ[2=YPP
M:S"VU-]4N^,Q(!?T=293R?>!M$C+BS#M<K:V"-/.8=H?^"ZEJII+;VN#'"G(
MRUDYMR*E=O.<8>Y=((J?C+=Y_IYJ<5NUO)AS&MM]T!%$,3_^H1.Q!!VAU.>Z
M*B,B?6X=X\CT<&4<\5R'I8A(T>4>=+EWBYS2:S*C-:?,Z50CTZ2,K7TN#O)=
M+N1Z)OE8O[5FXJQCT8)8GPT7CRRZD#/@0DX^8PGYEBG!V)_6-'0P=<DD1H8^
M)RJ 111!)9KV4%5$HC$:R7 3B+QN6B8AJ*HNPMJ%T,/F#.D+AB$ $8[XJ<D6
M=,KI[G=$^)U?44#$)SOE0L"EG^FGB]CF&I)-OP+=KC,U]=)2=L0WWR/O)X+I
M3]?7/CZ9Y"O0+3IN$4Q'Y^VC32;7=MX^RT7B>'L=K;IAM.%,D7M$F"P$'BO=
MKL[])J_O,^X5?I#+M#OY)M>OUC6A/R/M8?-<FL59:TY6FMJF!:=D=O43+W86
M<S+'_[::9JQ<B^W/Y.:R2MVGR4+KKL6SR-62B=$,'6/)Q/MY6Z(3?PVY8E^!
M;M>9649$HLEG,\YG)#I]!;I%HLE[BR;E<4?NK9@ZVRN96JY0;=S?D\*; \HN
M(4ZHZUZAL,UMVQP]&RZ*FWZ#G\IK*$YD7B9.?)=$JWW'D G("+T[34-9 2F3
M:*K@-,&=V#F +)VP)K*;>?7N_J (VZ*,K"@@/<K(BC*R(AS]WBD*$8Y&0? A
M(](W.S41CD;')@HO_53K ]9+/;7T'5TDR7MQ^G2K<W6.75;K\9+)D?7EI[I(
M+)/9S!3;LLAJ/4GSF_MX5ZMD^11RD5!TC,ZD8TR4-Q=EI(292%>0D7)Q5T?$
M$E%*2B0SA%1F8'.\U:HL]2XW[VZS\^(RD\O,WYS8<HE[/F,NC/&\(JYF2K70
MNNU.N%ISN(;W?.:%]_PW3G1IR_&Y+)BV@=T67OFX;%#Y.$.6Y#EJ=4>L8.I1
MY-R.LEBB\.AK8ILHBR7*8HE@^J,MOM^9;R*8CJ+JH^,6P72H^28Z;U\X5/2(
MCL3/J-*78W_I GU>-X"6CV>4%45#AN_NZFU/UT=51G:&F@ +3*U;']4'=;%%
M]M/R,M%8J<GR=,VG<=TO*I9,)F.)@/#1J S&9WM?(KI]R724:X.\$]V-VGU.
M&.E@DV?YXJA!"7:"FPS>[%.^#-9QFQS%IK;R4Z^C]?+Q4G[$62N$=>R/?U(Q
MDDG%T@P505V(CFR4"!1)=U=3ZNTR*"4]&5J\LRH\D&R!>4K/I,6=K60A2L'"
M;^E8,L/$:.;8)_;K3YUBU^<!J\L6H>JF>3F U@U)-MS32BTVA*FKBD3\BT3_
MBU#G19ZMSR-BN PZ4>CY"WU:T:F[@(,K.G51&-KK;.T1QT0X_2HC>X33T:F+
M<#HZ=E=%1,<4<LW'+@K3_Q0'2W3N+N!MN:)S]_GVR!"Z7NJR5=%$?2[?Z2;L
M4P$H]W\_XD$MW\=D<U)92#I9[<6[R25EJ%LRRV>0=R5)L;%$@GY'WTIT&E_B
M2(D@[7N)$I\/:9=UL;P8C>+S5BJN3,L6EU?8C,4(>;8MCR$:95Z$1M\RK\B9
MV'!O8FO\\*&N2N"/.4$5-%$F!(LHR"*Z</[?ORB6_)NA8O@7N.O__<_P7>O5
M[A]!!AQ!2;>'JNR=06> I2\BE+M8?E)HJ?[G&M99GO>TKPLQ=117?\GTI^OB
MRC<#[U\78K^3Z5#71<?PGNXHT.NBZ1_?E2U?6F( IWCSPA-5C8^5DC;;FO%.
M:9Y(Q0>+];ZHGC7YQNBLN<&I+X!Z5NZ9&O+Z?*YKZ,^Y-U4@P@] #W:^WY],
MN49_TL]PRC3YJ*O=ZJV6WZND7*D77]-H$Q'B=$DA6T]/-S3[0%8M635ZO6J>
M&[=XBN130"&(I9+DB9::T:7_Z0Z0:T>%$%SZ$;KN$?;"1I!K0]97-S"> ++)
MAHDG$H"NG:U2R-7N.K>]1L$@F?:8+)=%A*X4"> UL(1+)&]%R'KUR'HRT/ZZ
MZ'A!N372I\)QOD_D"%X77W[Z^3Z9,WA=='R5C^C\^;ZT ^EYV>DM3O!:?;N>
MV/2Z.F,?R<RD78PW1\J;<ZT#9:"3OJ>'7N6^5Y &?;)48N):OE*L%#)8&$*)
MALED(D:GF"#W4X29G^\CO_:S_NF8^0UDHK!AIF4+(W)4T&=<257JM71!&#2'
MEU7Y3L*=6L[G)]ICPY[)_'I8L;1ZO<NL$=QE,-PQ,3:3?@[ND,?]/Y8 ^.'=
M\,BWI2*X261CSS=.[;#G]TF,@K__AD4]%/&EJ!26Q2BG5_+CG^Y$)@11!)>L
MH&UA=S--M\#\! -\K!$*>/[8$%1B(1BHU*@UD4V9&"F:H(D*^-QT+VOS!FQT
MN-9]V4V4%'.A"EO(RO+?%UL9^8)9PR_"/QXAS!&)7GI=2LKJG_^"'^Y[1%46
M#(CO$R^.Q 5KF''KB!<D^>]WE!F.M]>A"YUP@==#W6(\Z5L(^OF__^-?T.X2
MBHNZJAN_W<O$MU+GY32Z5\9R?&C(PBPNC,"K?POJ6MB:[KV6OJ&](+K?WH7$
MP/DD;]+I?Q.[7R&!CLCKR#4H- >/<CY!]XOWT2;N(_1"-U%)H=^&K J6LI+A
MDWW/=/<)WID?MTD'5R&SVY+_"L3$@'?4O[J-_.G#I\&[2-UC9><C $7P#D#U
MC.&5!R#%XUGA>;Y]"?D$='7QPU%&2+ DRR<E<<0GAI+ "TF1XC,))L'0X,=H
MR/S ;_UH7G^!4)&]KW2Z6:+9R]U5\D0VW^I5.I5NI5$G\HUV\X:H5+S[%:\7
MC.YR-:[>;13SV4ZY>-?H=_@423$DQ5/A7:<W;:)1).#$"31S;W&?,&7$\Q3]
M,N&OV&@3W3)'-+EVI5$@BNU&C2ARN78OVQX0R1@!Y3?B9Z6>YYIP]WZ!P>U&
MKU0F"ER>J^6X-L%0>-3!?O(DFQ1E2DCR+"TS?((>97B!EBA>RI!L0DX.DW(F
MY>RKX%67T*QLK5GK/I"-::?7R3_46N4X$-9X\G#DMK98YPOM9)V<SX>+OE!M
MW,]Z8YX^'EF=J$;6$@M3CNZR_46<S9*C\AJ,I ]'6LG5=O!P7RWT&N+M7&V6
M%T"I6//,\3/[K7;SML[,M5F5FM6G>4.>I.TQGS@>.5QNV:>YT%W/Y)+5:_6X
MI9S,K?EDP#.YJ= SD_*4FV<DFA_*3U1\F.79XY&WVN-=?2ZI$MF)I^.Y#C>^
MZZ]:?.IXI)TLZ/D'U>1Z<65&2C*K]V:K,9\^'IFLCJ;B:,VDR<[8N.\*4E*K
MLTA,/G[H4ISFC/YH#AY:Z-NU[MIL/+9X*F"7&OW\8[P^U3>]."UPS;OEEA\O
M6U U.!K*DQ4F15F]."?;CQ2M:[W6-@Z&!M!TGNZI6:XB#'K+.F74$QF6FF6S
M/!5 5":[R&N+>-,@JPR_?J*Z*SFO@Z$!5'WH&,F4,1HVR;Z0;M:4GM"<%\'0
M +(JYCPY32US0S+>5U+UILZTRT]CG@J@*Q4WUF6&9A*]SMVV9HWF@X95 D_-
M' ]=/IA/=2%7-6;T?3-3R^<>'VXYP-(!6R LRMQ,+"8[LWQ+VTZV4[E67+=X
M.F +LF:%,>/+Q4-O:[;T;)F9%\<E,#2 J_/S(OFD/#W(7'_$SY)4:O!@Y< $
M K:@W>XV^8(Z[/:VMY-^5E+J+#7)PJ',T0DHIM+R;$L69W*BG67G,V&P;(/S
M%[!;-;*?;K32'7/6'R<FXZ'^)):763CTZ*P^3K)593$@.:Y4N%\^#$QKE8F#
MH0&[U>V;O?XCMUEP>6MSORG<#M6X!280L%MZ,3GO+-72D)1K=GFB2DJ9!><%
M##V:P$B4[$*UL&C,:#JQ?GJ*5^_')?#4@(V]WW*%085A^5[5:MVW[$&MMQR@
MH4=/+6Q6ZP=UV%F3 F5S=*-"Y<SIF&<">&"8ZI=4*9GHD3:9R*KFHM->SUIP
MJ/M4I*UZLB8V7@ Y4Q46IOS;_<5_U4 !S;EEH* B8@'G;[]@*-B6OB\7HD_V
MXKI]-A!G#'DD^5F&.S'W6L-WU<L"VM/,#7.V58U/^O(]7P?/'*GZVE4[W'_'
MH7GH-Y:LUX!.SXJU/MN?-U08FKIJ6_*GB+@OL5U2?V2[W.DP?VA_HV_8LXV1
MHZT+[=91-^S9:A31UH5WZ^@;AHWV[C/W[I5)6\X=%WI'V3GM,B^8$Z((^,4D
M1H8^)QH+&>;C:6,B*P(F 6P@F[\OY-?!]TK8R86ST(Y_7L2QREY!&.^E%XUQ
M+0RK?M8F<QIR_LRE_#9@"1577+!6YG/RY6=?+Y^6H79>=OL$LOQUN?/_F8?]
MRZ>U-PU]I%A.3ONA?UTQ'@;QROCQ;M8?;<C-?3?!3N@6F!CS'IGL5R(4Y2>"
M-@:/5S1"]T0>P31ERR3 5A.J(J #C\6?;R+ZA <%PTZI+RX=O0 P(^G(7TF\
M:<@+09$(>;.0-5..I*3O)"6%@BR1E/7N4E9%$PU9,.6"C/];T9QCS^%3'R![
M38?)$4\56DLRG[HMI@8,+;7D+(^<<*E$(I;\7K(7!LNL*(+) 4%K(6RA RR2
MKR+Y*HR4N@[1[+C:ZQ<#61<NFA@MLIK4L":RX5FJ[W:J6@ "EY*YD=CJC,T9
M*W,EKE22XMD'&-X#$)A* N4WJ&;#%Y),"[9,6#J!G#ZRA.*OMY%T&DFGWUXZ
M_?*X"4X^[!R&SGT3''N CWG;,(*[ALWM];:Z*6Z4GC ?-&K-.X,=E-8\"V$R
MG3[NW_H-9%3#EM]!H0_OPD,$%Z=DU.NM/QPZ&39TI/P&6"U,%D*P@ NQQB?'
M[J-V %RG%_>W_>S\OC<K->-+,S-?Y3HE&& .I5HR%4LQEX?LD!PNF#?Q7%0+
M=%:+,++%-@&&[_MXO+"6BT:UA(0X <AS1)[/!?5G8.>:"R^'@<@.WE\5E2^7
M*'_=]F6 6C <KVGH*T62I=RV!]"KHGF&CEU$WKET^N(TQ;#+>UF<+=N3B5UM
MY<QEI<6GT=40HQ@VEJ'9%R73?R&A'F5UO_[,^O,J/NP,7Z&>$!KXNS[C=FA(
M=QW6[@\EYE7+R2^X+@^#ORO:2C;?-?@[7+0)Y3D,N04Y-'0*H4GY"L I#/A^
MCF(8@F A(%C  ^GPBF;I1->P38MP7(&1D/7Y"'4-)L7K(^W7,-<>$?LZ]7)D
MKFT*6U26K*@;.VQJC*#H5-$0*CF@%*"*YS?I=%M_8!I<J6\]F%3R?C@?H#H<
M0!>GF=-=(_XX!"PD1^U-MEK%DT(C6VVH;;41'2]DC@TW>'\_BZNG![_,XLI-
MF_'J_*[YR+']O-09]>_+I)A%LWX6YK^RT37@8'[2.;Q":3]LPGVH*/7MTZ^"
M<_2O6E9\@[VRB,L'?TM[962>?"\P^#XG/PRP=VZM0"X#LY*<TZZ8IHUZA\/*
MOK#?&9$C@& -,,#8$KB-)8QT[RQTS=2-2&J(I(9O+C5\D:A)7Y$+A 9%  85
M!PL:(U_[P@#5['9AM&M:Z4'C.J6GF65L:T^%RA@6HH6J6?)$R]8O)$\=0"C8
M9MAM86$/544$0#H";]#&,4*3D;\%L+)LK W ]L;_^Q>3^=LD),5$UDT"YKE&
M8M4W$JM"09802F1?!%6Q<R, 4BL8(YH((AH.0M3E(/]&F9W&-T:/WO3R="DO
M/TV'O"BU8.UNB*X 7A/DJ:[8WTEP-07<CJ)I*"O!DHFF"A@=N;C[@F$(J$%%
M)*Q&PFKX*!7)N:&1<QWP\+ CJ)':>D KHTQGS/5[QO)A\,1/LM#=C+."Z!AS
MP@WQA05>QQB FI%%TNLWDEZ_M%'P"P.>+_-Q6Y"'03 WIN./B:=\93ACR0YO
MQ+E\ISULP=XN$.92[Z/4A^$./,?O;7F! Y6@H/DNJ!=V"H0'",-.J>]F!STB
MP)76H4,JNW?0H7SC5/5!17VD8+0L/9D/$U:XX[C2ZJE2&\[G]]7-&+:W.H.6
M7R7^T!$)=\CH6CS![ID75+M#M=SP &&HR/*E)<*O G&>2.A$73=&R+/CJL%Y
M>&H#0*YBS7FAG$_2I&UW*ZF'E+:1S19LS = CLVD8Q3)?*<ZFVZZ\XOBKA=.
M]",QW+H-N=\O]CJ\- L S]"$$4<9-U'&S>LL F>/_G6;"TX$;7O!@'M!VT<I
M.6S"FF<>[7S/[E%-61@8^9PQAGU94:QV*D:FV%@ZDPHP(/QYJ'9XC^.GQF5'
M9(FDYW!)S]\IR/)Y(1&URH&9>5!<C*3!3Q=9KL+(>):MW)-U$5:Z$BOD=Q+1
MH'P&_\\M;64%)#"@R;=ETS(4T9(E^(>L)NU_X!O9!+36I<,RF=Q&5&VXA> 7
M!$AMP9*YT4@6@ZR>5E6O]U,==3/+ET6VW]:RV7IFS=,,LGJF,[%,BOKZ(A[*
MEX'X0U%_$T,9C-.@:J^/B 6B<23!10G4[^<5"MOB7^=11\>&_M[2WQY^R)KD
M1XY("@RI%+A_[AAP[B3='JIR2(N_OIDY_WIW\?'**!E>X3-K\HV17]JT;&%$
MC@KZC"NI2KV6+@B#YG#]*=)F@/#83HS[;&W$F[V^4:^UA,22ZS MGDY^*^'Q
MDAT^(_$R,A!^*0/AY[>_#;W0=-:LJ&MQI[:C5^L+B)>1]SDTV!)V2D4QC)^.
M0*'BA[8<G\N":1NR&^J'2T1D@TI$&+(DSQ=(L@52H!UEAGRH'2Q D0H5W?YZ
M+QM8&!;^#=)*4)@T[*DEPW<U1@@(&@X*=! (=.SA5!8MV![110+_[_<0% (4
MP\)0S8N+/ODPB^MJLE;M,7(*>A50Y@F=CB4S3(QFDM\N^:2Q%U4-A#KHJL'%
M7 6GC^([!5Z'G3(APN _LV^% ;L^"K2OGU+?!>5=X$%QX14'=HX[AF,,XIQ6
MK@' _M0=E>*3IWN>VVZSB:TI&#.^TN)IE"3#4(D8E3R.'_]2\G-!!I0$<O&N
M!! $ZY$L$PM,Q$A&_F09.600$Q8).F1D^2[(Z^)%SP<715EV$#< 8N\>N9'Z
MN-G$9]MFB]=[%:U.U5H\@U)TTC'R9;4I_F/!QW_$[HDRH*OA9Z @1S#Z_;=B
M@>^(+T6+3YJ[<GKB/_[I3F0HJNMS,,LM1'Z8.FX20%<B!-B1P9+'!JP;)QC(
MMF)-9%-VS;7@<],2+&1X,6_ #G[J,J]DBZ:V:2FC[2&,PH89%[V:ON!*),5<
MJ,(6PH3\]\66!?_]'"?!+\(_'GDTCNCS4L%!4E;__!?\<-\CJK)@P+MQXMY7
MWM7'@A<[5R-)_OMCKK#]$T8GW,O>V]IBG/4M!/W\W__Q+VBG3,5%7=6-W^[-
M[%NI\W(:7=)C.3XT9&$6%T;@U;\%=2UL35=P3M_0"5<F^.W=[@R<3_(FG?XW
ML?L5$NB(O [SH7ZN>)3S";JKO8\V<1^A%[JIP*OH-TJV5U8R?++OF>X^(0GD
MPS9IGU4%8F)  >!?W4;^- 9J\&97][C7^0A< /!>169S*$^@DG0.FPJ?!N='
M.'+.I9B]KW2Z6:+9R]U5\D0VW^I5.I5NI5$G\HUV\X:H5#Q/8MB74F]TN0[1
M;1#%2CU;SU>R=P186I>K<?5N9^<//8,=+V%A 4EF0  CDRGF!]YH_!E\/U7@
M.OEVI0DIV"@VVJ5LG<]0J50BR5/.8"RIU>TY((]X$3GT(,]/L&Q#;HR<_M>Z
M9CK"Y)"W:^--M[;NKWOS]FV!I[M6?3I;8V%8T8"NG[7.C./A,.H'(0,A=0%>
M:!FV_&&*TFN8 #LYJ1O"MQE$HTB@[:@\9M&_L_4"D>MU*G6NTR$:3:Z-/L9\
M<C;("W[QK@+.2:'2'7S(X5" LJ"!#]*+(]^FCRQ9<'E: H$+D!)9<6DKF'T!
M-AD+>)*)GT  18&I-/EW'@NMZ%_4W[\(!8BMQ% 5M!DA3F01_,0#H%D:?%\W
M8,44:)J&S\@+6[ <HF*"\9))@'<4Y:%A0W=A,D9 9KTAH&SLO(18"R92D, 3
MP'_0(Q8V>*B)L!.=>B@]HY:5 @%.QE@V8MCS2,A.XD*,$$Q3MH"\[:W,'0*>
M!<:88(@AZ\98T)0GQ/D$>)>I@*T0#")GFX"XI@GG- 02./K[6K$F+]4FP4MD
MGD[>ISJ#1^V)8^4$66@SQ1&3SEY:G:S4BWL*9=R41:A4KL$-;LK:GD8)+AX)
M$:.H&T4;'GUWI;Z% K09RD9CY/Y)-FN*ILSM^:'&61<,@[\K):M4XK$_)+>)
MI*U7:K>4-6K]^ <(CD>*)B3Q7 =[,/0>3?P47"8+(KK+<?L< M@/Z$Z$"G8+
M\AGB Z@V*:(-=P\< 2 O _8"KQO+.M"J%A/ Y88\ACL&><KA)Q/U/P6@9\\!
M]5!,3.#6'[T=L#.X!]0M5,K&,HJKD2$CPD< 26P-&,4]$>!OD!D)TQ8G,7P>
M=L\QL8\,K4!5':V/,!1S9D(&UH'B!Q>(..]E+U1DJ!Z& V,0>0NR*$-^PCC+
M4#'\"V3N?7),! GM*E@'T')%L&SXJ>Y=3#=$%I#("5K:[J !Q<H[O6H.<(7X
M"?!(1N[&7V P$)''DW,3(G"M)Q2_X)L:BLY/_6TZIPPR$=P ..)$L7?BI\/3
M3J%G%VA=6[K+UC%B#3AS EE! C>EH0QAB1!9U=<'D*B I4/BC&4-TD/VTP:\
MSI!7,KB230!'E@*(!,5Z-#_(%*J,X6UT@KL!>UIH,.0PP#]6P+N]]X+C'-^]
M%\+]7':!'I('O@::,@SP'/?/:&_07KEU0X%J 20D:?>7$W3:G\D$'B-9E6&$
ML;>-!$/!XZ588'L4B$_$%JP#9E*$Y1S )4#L 9"$F<>SY'A,?,AH)\B!KD:
M_ #D  5DE)@'Z BOU*P]ALV;,^Z%VO ^HFC\6<QC"$A+#_5DZ=P&P.U\X96'
M0W]XX8FJQL=*29MMS7BG-$^DXH/%^L2EEX97G7OK[?[A2*?PV9A0.+P URG*
M;A33&X$[4Z _9VN('W9?MH>F(BDP'@%<6D%?KC0;SG<FHCALK,W-+2F38V.P
M,HR-<+<^=\N>,=M"LIBPFI(L@84"(N)D2QP5 5@._>G(0X8NT[[-&]K:'BRX
M^=U3OE9JTPGS<0V+9D##;:#Q%FV'N2>MH0DX$(/O'W2!@+<OG,L&\1PD&L:^
MXP N?W@!'(P>"9,O),Q&SIL<;L%+VX$:_C9DGR_+.XV5;(#[2,>MBM$5XSQC
M5'U8+[MDI]@K\895M>R'^R>J]?&\U-!;TT'5ZC.SO"RMDE2I^R#JV1__G&$E
MO,O6!-P':X#@J!L4X $@+<'28![G['4P<1!+WLB&J& 1'3Y$!_0!BKI#('!5
MH>T'W#2R517=.'^=YXV" BO/(+>,PQWV7;^W+AL"/RO5;]5[KG;7*"_&05DP
MGX@D[62RJ:=S\=ZLNJ&+/;Z;N<OR>[M/OR+K!N\SWO^FH8@RV'[T63!ZI/G;
MQC+)V^128T=Y?LE0"QF(XA1Y$[3;X!9'.QYS;W='F 32@7=1@]U\9I_>[D"[
M'O#_T\KR@>T^ K?0X'.MM6876KUX/1[?5BEUVYZWX 5 GCZV/TU9)NJZ)3LB
M[:^P2#X=H#6J@#]DW3;5+;Z%D!"BZJ8C7)R1/?;5@T.!Q6WX<?D;YBB3SN,W
MS(A.0Y&&T89$04P%L9H_[![@-AYY-6L>/LAYP/R)6=]-E:=>;SGF4VDS>9?L
MLF=- <^D] 4MQU7^.[)H&R@Y) ]0'%8 <Y?C# R^=,@JTZIF)G.9RU<>^0+%
MR(]\>@V=SS3#Q!CF.,('R+3XN7LBS.DV+A\C97PZ#YR6+]IEH[@I-N@JN;QO
M5GM ]V_(\VRXV&!]*_&KB2JN>_3@<9/."C5U+ #9(W,*PD[O]T>)(P*X]!3<
M^/(=)9-K1)67""S8NABT$B2V>!^>9YOI77687/38P:QJ+[G2MG(_8 L /:B;
MY GYY23?H+AHN*7HSPOOSX!G'-NWW^A]USRT>#OE_7=H\SDRT@FK<%AX9[7L
M#+*-N\?>4J6;DT&%5-NK"_?D<><<R#"U=HI]>LHRUJR?NYW9HY&B=L76V48\
MA])2(C324A>LTW3X!P?Y"W,88HLMW)=FL7>J%X" P+>2P&K2:.]*9+H^I)1-
MH[=,6W4JE2@.6\H8[!T38UDZ1B?9X[V#0J""<UG?X=2])TE\)^L@G"^8.C2E
M4W>-NW*9BRL#/C-[["T4!G!V(L:>ND/]O46=P&(S=E5$<@,>]T+.Z[H&9! C
MH!T7(M1F/)RN3";]Q G;\3(A+EAA]-@Z%^X("26="L4&%(.V_6NBFH^U&N &
M,_:H%T@SN\0D].J6*?8471WKQNBQG[J#1R]&4B=.'NSK !]^D&1T Y0W @;G
M.(Z$/9</P5"NZ1DEHE_/D?57/<EJA^5,LE8>4!&&< 8FL2$26T6MJ9B#?JG7
MV<K+Y+PWZS^FQJ=+FT 7T$16)4*W+7 9RZYNW#6@#=])MB!^(OO_"%PRCIOH
M%^)6Z)%<"8J*XHL\Q]BN(T=P@A@N!P!&KW5CACX5%C"$T_..AN5B["W@C?@B
MFX'GF'/- _#WT\H%X%APM\(U?P,A;F?Q*BF)[7V;MZ9DOCI.2>,%R]ZN6A>5
MVPP\"WAJK&W@":EVZA0_KC1GLVTG,>?B;#%3VR)35S*6.BF\?4W=;+<U,V9=
M'!A*,D/*-CT8;;1:\KZ[_B/[,=+  K= +*FS^:@Y![39=!N%\>J1VFS&R&!,
M'V?88H7+Y_'YA?R12+?">:B$A=!*<-'*IT_MX9@71P1/*_(O#V6G3 E$*4V%
M@41$[Z9S0XRAYJYAU<U Q0>VA ZF,,9! =BF.(=1;,A*X;,(7C)H[C"\1K*-
MH/":"EH"BM&O"1L8,E/#,]MV96/N(_QX5NEO4H6!1K+E=DK3'^]XL@D5W722
MD(2MZ=+>60,*G%&AVUZ'T2W$7-?D+5BU,9,M8F3#J*JY+",11I0-2X!EI-U(
M'Q.+.$3;5AV-AQ;B*>=#C*3NI#U;:U:TW, $]$=O2R3%@![$E^Q,S(E%V 46
M0-GA-_%3^86G@;W1;NP-#E#PAU2<C,$"\_B\+:Z!5TW,KI['@16N:3\@C,JW
MW?QM/-MM=LHE,B[?C06N.*MLREFXW7 KP?..]ML+C#A[[6%"[NSE/Q7E%XX@
MVA7?<+YX&&&PY[DEE+U!*- "A^+L;.Z"]I5V)#F:36\S>OZ>%*;<NBV4T_,[
M8_V6'7EAZ$9L+]9KL0!_0]*:*JRQQ@'V[HV;MS!@0 Z,#;.'<\5R(B_!#FBR
MN M<%+!K?Z*K\."O=" /X9D8X!S#W044U2371@;?FH4?H)V7"%C:#[$!N*9T
M<,=)]AQ]GH5!=RK&W:P3L 9?^3/[RS'<ZC80:N>ZI(RV6# #EZ$%102(998R
M]Y%RAQYP"D[+) +/V/1H<:KD# J< ]<S_.Y$ &L"GRB&^V=(5'D>3)IG40?.
M5'<><041H&=TQ:9LP+AY80QCOCURX[H<\ASSE>-T'G$ OZUM09>!"FZYIROP
M6#FB19SVNP#,![.SG;"#64-L96;E?F6TOD>RQ;%8]^\WH90$9N9&#**Y?=7K
M([U83"NYA<!Q'>Z6C'<G^6GB<?PJL'I-D!G@]I^Y7T<Q0RCB$)D T,DT(3UQ
MK@-\OKX[@.BHONS4AD7#/(IW=,$'^HX.E@(5='C(X;+W^=,O[SH!H3[,]3R7
M.]#1%PO=L"" ;'T @R*!#>B] '_<W0**<? Z&ZK%+PWR)&0%[9TG?CU[17@2
M)7+\^2\+^,Y3. E%$/R"(9!094$S\9PL&0F<R *!HSHA/"$F$E"\[7HBHPE:
MAUMARO)L;V)X&EAG/[%8,!$H -NB=?!J3]N8"V!WAUO_ZV(PODW&@B[<=TDQ
MG?I&>,(!6^H]3H98Z9#)V<:@+1OA?37 (,$ZW&#'W ]_U=RXNP/SS\=JOZ_1
M6]>"TFVG^LRRUW^85.V[19Q,T'\6]W1:;]7RCZ8D<@5J%K=F_<>64K('X]:+
M]=88T%EM$P&:MQ5>S#+0532DA.*09J1<(<-<X(Y &0A>00M#7BDXR@5@(NRE
M(1T$D2.11M@BSK*$C5]5PMD-ANQQD[97/L\!U=<=]\"(SX,+P(V\P.R]SZD^
M:=4W%:CO PT0YH9*T&E^6.0/T4.$6*^,%#@$K!4, !(C@'P9V8).K>.<40_7
MN )O17*C!Y]%+S?>V0XXUA7 3"*G@_]XBW4C\HO93LY#XL#OY:&P"L1S+,@Z
M7\MV\MZWNOH"S"Z1)F/$^8S_ O95V8HY@:^X4P24KPSM%.B&QM8Q J;S^]X#
MG^R^Z_SS=X4 #@2 KY#TG(J2GC\WZ?DHE3+*@ YY!O1EDIX_))O>SSP7*.3P
MDJ,%(-+)7<;0?C;/V<U??D6V,_W.R/EV50:Z9UP1/UA>1O;= ".@#"0 01LK
M\-BBC%HLSEL$E'&>C>'_<W?N^XBB+W:M.XFO==GJ.E3((B) CV3>9[O>)<L&
MV47\HBM?&]&K1Z:J<8W9[3!K20NVFLS^^"?IA'<'>(8=S6UA*-@.!7XB&0IF
ME!Y9T$]L,,H".MA@J%B9@9H5=(O.A:D./1>N;.;8T:#A4$(UB_!O,(126.F&
M.RPX?;8R"K(_.FF\!A0,#=P;7176G@OWR,X#=TA"9DOXE* G0OW*S2V&=,+V
M"NB=0!Z)0]TRMA=+"B7S/[)Y^M3_/WC.+N3056'WC<+F40#LGH)KV*KLI'4Y
M6X*\-;M 7O1NM\$?),=<,4V_J-OA\GL.NI&B'KQ#TD4;>;EVLCCXTHY#7<G^
M3$)U910#N[B65U[N?H!VCQ;GBXI3S$-FB1'[&90.CR"+@CY$GK# A[^249QU
M[Y1[+TT.;M+4UO:L*. =FRWJ5"0"41W]Y7#+\!#?7GF*Y+-[BT[3R\YQL!\@
M. <8;2(.>D70+XP-&2NQ^*R"S2[JV&OHFKM\P2C@1;N0RB3F&SBW T^%4WI!
M(B3;-37N<I7/:'\>Q."5G6.LK!.,)*CJ-@:T>8"1QX8;@&Y 'U5]"NX)@XUB
M.#HT2K,=^:U4VQWDP&6, :^9EKNY,'Y&VN-='1X;S5%'+?Q=&':NJF$Q@H(-
MA!SB&3>126JHK^17W!SGKR# 17ZK/4:WUR%;[(]=4XYIUTDL$ *X [Q#'^-]
MQD<&EG& L<6P&@-\'+IY_<N'#+ SC\N&Z9ZV]02H^4?#8;R6Z"300SI ISUZ
M!BRKXJ PU&T7;A*O_Z@Y9Q"?::=Z#>.BI0_F/8B'WGSP9RK#)%"$GN 0SW]?
M^0>[X ^K$S@&*</K[(4-%_C$H 58I@N&AR8G5.D#$%E#WL4QP).Q0[_PN=!>
MG./0!2JP";?1[TGS^\T"RM[W 6%TVW).C]F$UV3?@)Y:)$3Z(UOW7&CFK*WE
MK!Q=GS6X?*^YK?:GO04,&SBV<?[;*ZWBQKSY80PG@(,I./"D8/NXZ80'^HYV
M6+"H>_(V M(]@.*?RJ\ $^DA!P9<6A 9]B$>&7>'T#![RC?\LB(:.\_'\Q.#
M8/&'$SOASX=G^X\A$AW>EWCL#RW*^QY\F&^U]F]3T#*T$+O>WZ)]6J.D33_2
MD^FLVBP4>7O%/X C$'IWO<CIXHAO;W/D/)W:-*6>1-WFLV?<]?!LO=(]_]Q>
M_[EW_I(;]JX>_974JDBWZ]Y,* _D;C)ASZBGUWGTGW&9Z,89!SZ,Z#)0V:)
M3_ZATQH<;<^S#^T0<OSL-GHEFG9A3<ZWP;-5!>AO$GZ5!$OB*$,;RW[>"O<]
M;"^ 3NR>V^>^D:"HID\7C;AOQWW2.#]C[44[-RM-BMJ&;/)\*W^!<$1?V::R
MJ]H[V^+>Y:@>']RS ^C07J0*QK HO?_=(!?\J[GL>>[Y[DQ3YZ<EM?-D5#B[
M0]>!2#AN-K@W14R>8IH0B9Y^&S@.8_X..UP8;N]ZB=1RUF@P2;Z2L>U.Z9([
M_)(#=5!UU/L<USW:E8,\L($I<)^0<_'EA];Y_L$K HQ_7LR4" ,[<'R65Y80
MEAR5%[M2;KY2I6L%&U+LQ=\^[4! $;M (E:W! JG@#9',/4M ;YG(D\+ "L8
M [)3H/?<97#CX\HFCGUEO\OH/WRM'*?,"1=/]>Q[LVW0E?5C:=(*K+'^UE/U
M0B<O4&L]MQWZCV=IQ02 "0Z05&#E$/!C/OO;H=J*#32R$7=*M\*(H)C;+0>I
M$X(YB<'($L!MCLUH9VGPQU.!_95DY!8,#.3Q5Q/YN% @7![1$C9PK> *@G_[
MB?(\[,5[Y'Q_8.\2)_^E+EL5AYQ=O2EL"PI0,U5T%Y]J%873GY>#K/8T3-*S
M4G>0C0\>V^7D#$</G\SI]?;-(:^T>Q<XI/AEO\"GT/HGN;%_&BITXCD; *O$
M3P9XNM4Z_0%1$!]<O $[#BCM!/P$A0L>"-."N1],^'/'@WO1[(8LRM#H,;(-
M)+Y[T@UD:K]TXS+1K[]WLO>+06>D0W4=OAP)6;M%[J4NH!-VX*(YM (8\EP
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M'>@F,(-/R)<Z.S[_.9RG,MH^PXBGP[;SX#%#0P'O+D.AU (7"IP'P+3X\63
MLU[JYSZ*Y@DO*5Z[MK#&%ER^#O&^X)D33,6$^J,,<[W1 Z%2N9-#=@40FZA<
MB6QVP0QRJB[.?KB1"H]JRB!M<5&>S>^?VG>9C93:K-?'I;&"Q[F%M&0@?"W
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MR#'; /QJG3BZD"8!9&O#<8^)3!+4!IB>!$F]B4P#3=BT1&'4$GN:Y="99^)
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MG M9.BQF&1:BY"!#U$'3><R2-DL3\ !5<2SOT6S*%5>,<PQ,3'5K.E!)E3Z
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M%-*2@D&5?-:GO>?DH]-+WLR&DZ.3ZU*L2YLCE!D^WGGS@IZQY\&UW!=2C.O
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M([X,D':#BSF[?TMV:ZS7ZOW3A^/;]/792'N E&RBH"9SBT=,,#RAMB.96A6
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M5-^:^KSHIQ\+E=[Q-#Y^Z70J8_O&ZN0CQ>R./HT-1T\7Y_&+5"/=;T_,YQL
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M;3!@(+]BFQJTS@9SJ+_1!I;G%K[1W8P'I*MDB%?9,H;X75R!LC4NW2V#6%L
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M1I14@A; DGWC?\15%AB@987N>0BH&&"/#UE4$5-$@-'!QC\!UF&169BX8 S
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M5@;+$92?H3RBMO<MM-G'U41&MMA*69*R]/%ZJ(*:3Z>^O>--WWED]?O&J(\
MQE\;Z%YY<@M?RLI_#-^*R+]_&_CJ-EKXMWO7U@@IB?C^?_YE2!\A$CY"I"CU
MP])=(?N7@W&D>$CQ6%D\OK1W2]]YHY&^UY;5Q_P\@W)CQ1A,D$.NV<U-D(O4
MGJ,C]I$BRW?.:GW.?1>IXY1<+KG\9TQ 96G9I5>9M&FC8--&+B(CTT+;3LRF
MTFHJOG$<"2F%4@JE%+Y#"C-J)O7-L(W#TK,D-CS\%&,@(I2(G,[Q250*2Y1N
MC9LFBJ:&V=Q<S.CM>POCN^)I-9W=>+55I#A"2I*4I$^I6513^<6A'>12_M<(
MII1_PBG.KY;\<DJ_VK1,?55NWS[96_CF1O8\ R:2'M679H"K""E:BQD$T$H\
ML$9X;2-+&761@\!4:.*WZPSXV<!&A3/21HCDFP_<M/%N#L2WEU7UCVY,_OD/
M_A_^I):)-!L$L,MEQA4P,*6X_,7_]W/$R'^>R337*.YYGL2226$GY'__[_\1
M=^19\[&695KV;ZX>A*VRMR>)INB@6--&6B^FM?&[?VOF5)LY;.?Y_$$RS57/
M;U?%I&!!F8-\_G\5[Y] H07ZLIO"1.W1;_HM]A>B,-P_O<0$2@\MQX#VNM\V
M,K61,4'P9.&9_*!&UO 33VE.QE+>F?Q'4[HV:O_WU__4*D?AG#JP[+YF_EM4
M)NQ/V& 'S0;MA$?X4Q NEVFUMQEW%?)IBJ'_]U<CGT6Y9CR=;62;6K:1;B:3
MC4(SDV]H;=32VYE$,M-N_J)OW8'R@H4V0Y7NKW\J_8%1;*K4_2T/6E@#-:.C
M:9>M?*^H'(X=_'C'@5.^-#K@D-UT-7S^+30FQH"CX"U9]M"RL8;5]]V]T:,[
MJEP=EJ]+Q]5:L5:Z*EW7JI63RDWIKE@K5ZZKC61T3XVO7/&6KE1.%&_Q7^<4
MC0&^&*VQ@P_/\0Z(F"6N^J56&E:]IC9TT&_^#W&5H+/8 D%V6U3FW0N(*$O!
MBF.Z,KZ@Z48V?RO?+MW#:I&+;/)@J9,A*!OA\19^9-NTIOR:Y?]-3+C?]"*9
M8AJ\J<4%Y\']JM9T+',\0CO1Z.'6JO"@(3=RUW%^O"O[PXY0(2^/[HL>W7+7
M7AY=9(^N<)#,R:/[DD<G%>87/CJI,+_HT4F%^66/3BK,+WQT4F%^T:/#"C,I
MCVZ71_?.ZH^W8BC1(5/^0V3:ZEWR82+EUXKZ^:FV+.XGE@S[RX>;?OJT+!.(
M]M]?^5]KTBJ5.<CLMD5YV\1\1)I-R5<:Z$BG_SQ&+=1O(O9!*J'Z22NE4DKE
M!J0RN:Y4)N('F=2WELID/)E8()QD+,E8&V"LN&2L73!6.O_-&2M1D%;"E[<2
MUDS9KTJV!<;9&1UW4M&[,3KNB&QO19 EV:34KD3'C9EJ7_C&+#K4W+A#I(A7
M_RIF6=1E=&/6VK?EK;4LL\CWLRZCQQV=!N+\WJB019XDD6@2DLW0[S&NHD"I
M7<+4? W)VN!VI7A(\9#B(<5C([4*4:#4Y\,_12ITR*?3&=B&=Q!!>L#OPW:X
M-4 ;G$JW(S<OZF*PH\#>MEO.=Q]XV]0,CK2:S::_?&A-BH$4@P^)04)-Y3>(
M4"+%X(>)P=*ZU*\C!DDUEPF!%_D^\4EF$5:1/<%&X<9MP.AN/&J*X"L@ZWV*
M6QT:2XD<.;: :117X_F-6Z!2"*402B%\C_V;SR\.A9)"*(7PTX4P.&P:.7)L
M83*;FLE^>!YJI&*O/KQ=&6O]'%42-4'YS,L[:GO? IAN6LVE-S@*5<J2E*6?
M*DO)E)H,N'&E+$E9VK ]&[6];\&#S*NIQ(:LU\C[C4M16(?(UF#(L()>AE!R
M((M<H^-41XI2VX]<14JOA.S_AY7B2?&0XB'%0XI'I,1#5JI&X5Q97<(=<I!F
MM[JD5%5'$V1:PPV-(),.ZE<I2]KPY1<I45XS\%E0DZFD#-9(69"RD$RKN4)6
MRH*4!5FSFDBIR?BW#SPRV_ 4#9"MF<0TU/2^,3"<D4VP:J6'*#W$GQU 65-]
M9-5">H/#YJ4022'Z>4(45Y/)C;=/18%64HBB)D1?(%:YGA#EU6PF\:W*/YG1
M6NQ;>,&O&@Q,@/&>QF"D#3I&TT2.]%VE[_J#XSB)I%J0!6A2%J0LT!:D^&+O
ML90%*0L_+Z895U/QQ9[8[QG3K(RZR%:L^;))9<\8M*P^VE>5 =I<\CNZY(B:
MCO@*37B[C=Q$CAQ;T$1J,K'Q2UG*H)1!*8.K9_O5>$[*H)3!",C@-^C-7\YI
M83*XET_D][]5<-;7F[]@?<O(K&R'E*W%Z]_9.>S!9S9>5A III"R)&7I4V0I
MG5?SA<7,J)0E*4NR3?^]710)-95>K-3Y9I%E^LY+RW&4MFWUN7EK#39GUD9]
M\Q'2*%_ 890QK&W[SZF,FHT7%EUH*892#*48?IH8)K$8)E-2#*481D ,?VXT
M.9%2X\G<]PHHLW<NQ<8BI1ZTKD/98Z'F_<WB8T6+&I'1.Y$BRW>N?@S9[(9Q
M?")UG)++)9=++I=<_NVJ=U?D\F\6/65UN>7!"-G(&?&2 .DL1L%9C!2E?EAS
M])K.7H"?)R5(2I"4H)4E*",E2$J0Q!:(KYWV!]Y()!=YXRO'&WWM8S2FN-E6
ML8CL,W(*(6KQ>5EMM^&.KZR$EI2B)$5I Z)4D(@&4I1DW6K$#-@HV/C+V(/U
M9 F&K?1[H^#W1D[.9+W<]HWA3$'&GJ0,2AG<H0SF"Q);5LI@!&3P&Q2L1L#\
MCA1[D":Q)FI;-N*%J2/M17KKLH+I>];IK=BME593F?C&LZZ1.G8I#5(:5FR:
M2JFY9 #\CY0&*0W?J;IU![U+4??#RJY)B(W$ 6H;(Z]O23JCTAF5 :'/=T9S
M:BI@X)^402F#4@8_2P:S:B*W<4@N*8-2!G]D4'9-2SR337Y'"(%K-%),RY$0
MM)]:,I7"(J);XZ:)HJDR_K\M51Y&8=_;B%GEU'@Z0#U(49*B)$7I?0&OG)K)
M;+Z),U(L(45IIZ*T4,0;A7UO)W:<R0>@0!*C]5\C#>_W$XYQ?KGDER)2U8KL
MOGVZMQ" ,,P3/I'TR&[XUD#^_=L8X5^W\*=5A!2MU;+Z>,DSF.XPL$9X;2-+
M&761@Q3\21._75?:QD ;M S-Q$_31JB/7^L<_.=?QE;W^<:!^/:RJ@+2C<D_
M_\'_PY_4,I%F@P1VN="X$@;S+YCBB<?_]W/DR'^>R327)/<\3V+)E+ 3\K__
M]_^(._)\W5C+,BW[-]</PE;9VY-$5710K&DCK1?3VOC=OS5SJLT<MO-\_B"9
MYKKGMZMC4K"@S$$^_[^*]T^@T )]V55AHO;H-_T6^PO1&.Z?7F("I8>68P 8
M\V\;F=K(F"!XLO!,?E C:_B)IS0G8RGO3/ZC*5T;M?_[ZW]JE:-P3AU8=E\S
M_RTJ$_:G7__40+/![.LC_"D(E\NTVMN,NPKY-,70__NKD4SKF4*[G6VTF_EF
M(]U.H8;6RA4:B8*F9Y.)MI9$^B_ZUATHKW^_!0_8'QC%IDJ#0^5!Z\ %!HR"
MIEVV\KVB<CAV\.,=!T[YTNAH UVYZ6KX_%MH3*P!1X%DHCVT;*QA]7UW;_3H
MJK5BK715NJY5*R='9\7KTU*UD4\EXH5D(QG=$SNJ7!V6KTO'BK=\I7*BL TH
MY6OEANQSV3.*=_AG"G[23?'Z4;DNU?#/[DO5&CSMZS" ,<!WJC5V\+D[WMD2
MB\;5W-3"PUK;U(8.^LW_(:X2U!U;((A]BZH+]^XB>E:P )F:C2\HR9'-W\JW
M2_>P6E PGSC(I9=Y*(*B$IYOX6>V36O*KVC^W\3^^TTOH2DFPILW@.!YN%_5
MFHYECD=H)[=!N*DK/&C(+>1U/"?ONO^@-Y$\R"QU+N711?;H$@?9E#RZKWET
MZ8.X/+N=GMT[$U]OWG'1H5/^0W3:ZFWR82+EUS++5H<<%Q$[_>B=33]]L#4&
M1/OOK^2O=75 YB"[W8KG;1/K1K/Q$RB!6-0HB%I2TKZBI*WI :U*M@5V^C =
M-R:1.ZP%V;;$#A 35V,P0<X( K>;D-6H5V)5AF@ \>RF9FJ#%E*TD7*N#<::
M/5,2JI*,)PH;D\BHDR(:F3MP7*).J4WDZIB='X6M;KZH,QE/J_E\\J,E95&\
M[WE-F;*G.0J@FK,8[%>]MK^&1H@4638WF^(M7_^;Y.._G=5 W1M%,TVK1<;!
M0J[&Z>*_QIJ:@\#B[$-K%_E,&A#2@-BR!HG"?K?1&I+-+J)>?A,;8F1K Z>-
M;#98>D@U"HN52./B4[5%U#H\/E5U1&WSV_!&U&1A4XHD"JIV&7\<>H&,8]1"
M_2:RE10+96Q)K42=)!'2-!&GE+1+5M(GB;R:3*>^JV4BHQLRNB&C&RLU[GQ/
M$T)&-Z*M+J).*6E%K*)4"FHBNXA&_$UL"!G=B(ZVB)J#+Z,;F_5&,FHVOSAG
MZWN:)N'1C61<1C=VK6DB3BEIEZRD3U(9-9/*?5?+9$-X0-+DD/&,"(CXFO&,
M,$R?[VDTR'A&M-5%U"DE[895E$HBH\9_:$!#VA,RA"%#&!]0'7$UE]Z4QQ$%
M[;IF"",AC8\H&!_1 U#;73-*]&BQC8A'6DW%0_3/EK'DWL+,66B3E.AR$EWN
MD\\S&%TN+='E)+K<FNARF68FE8DG,HUT*EMHI-L%K9'/H'RCE4ZVVWJZC>+Q
M7'2QRGXRNMQ1L7IV<EEYJ.(#R^2^)J8<WH)"]O!USFV[H'"B=M3&(\NO',E?
M/ADW[JUA$A($R:_9HP1@]08FN3RZ"!_=\K&9\N@B>W1OS<B51Q?9HY,*\PL?
MG5287_3HI,+\LD<G%>87/CJI,+_HT;TU=UX>W;:/[NL/Y(P>6.K6)ZA%#Y8X
MORX(:BISD$E\:Q#41Z39E'RE@8YT^D]>I4'_*Y50/X2+*J522N5FH8GC!YG=
MEHEMFYBT,JHI&4LRUL89*RX9:Q>,E<Y_<\8"W'!I)7QQ*^$G#CJ@2O_K$E7R
MHN3%R-P#18=>HG<,E>"K&!M1E]&-V2#?EK?6LC>BT#7B*S3+'4!M,"&:,<!<
M,?H=HW]:FVJ5(;*U$=28:ZV1,3%&!G(V*I51H&'T.V^2$>&VJ%.*9JFC0*EW
MH1#X'<@?(ED;W*X4#RD>4CRD>&PD91\%2FU /+Y&!.WCYNL&0:IVY"=&72S>
M*D+ZHDW<;U4T1D&T/P9/)05!"L*/$H0PW'DI"%(0-E"R^84$83/C);]3F+.H
M/XWIG&Z"E&&CEC5H&292!GR&"_XK_+NE.5UE:%L30T>ZTIPI>V, /30&^XH5
M$ W]_6,\TNAHGJA3:F.^NPS82/&0XB'%0XJ'% \9S_SF\<Q$GBSMJ*L-.@C;
MFPIR1D8?:A64MF;8RD0SQP1M"G!H\$L 4=<T-"(U)"TOW=T?X^YN^ J-E$)8
M$Q173286AQ9+49"B\.-$(:G&<U(4I"C(2*BRET_D91A4-"^/$:9/RW 'N[2-
M%VQ@:HZ#1HX"\)9:W\*D>'6_8 Q&V" U #J1?DNZK-)E_=D1G34MU+1:R*0W
M?2]'@592B*00?980)=5L<G'V@!0B*40_,7BZ]@"A3"&U&;/X*]K U>T-,Y3.
M\D]TEK]'W"AD)*&4!2D+/TX6"FI"BH(4A>\50UU/%+)J-KN83OC9,=0VLFU2
M%(K-1Z2,M!?DJ% ]*CU2Z9'^[+#.<DX)S=/DU%0RL_'.C2@02TJ1E*+/DJ*L
MFLA+*9)2)*.C'[!W,YD/SU;_NJ'12^B$VNMHT.[4MJV^XG0M>Q0;(;N/K=T)
M8BU4TB66+O&WB ZM>=$FU&1V\Q=MI$Y="L./$X;U[DLX]43RZX/#2F'8M3WY
MC87A)X=+3[$UR8Q)S42LIA29)FJ-QIH)O?9#3(J98AHM-'"0]%NEW_JSHS^1
MNH>C0"PI15**/L^U*\3C,H8JI4C&4"-B!G]%F[<RZB);^L+2%_[!@:'LQIN=
M(G7@4@ZD'*Q65YU-2$&0@B"#HS(XNF@H4K@G!_">!'A1KQU?0'@B%:80/M5:
MSV,L5-"R)/%'I8LJ SV!^Y< BU(\I'A(\9#B(0.<$G_T;8,TE25+*[9:^+"P
M]6FC%C(F6M-$FVUMBA2S1T<M1(HL,HBSV 493Q1D&$>*@A2%5$H*@A2$;Q7/
M7,X#H;4B:359"*@5^9'Q3&8^DL2WTAK;-N#32\10Z63*&,S:^B6;VOQ8SRB0
M2LJ0E*%/NZ,+FY\(&@5221F*F@Q]Q6#GBC71Z0T9N5_1HG4#HD-MIA$8?$#)
M;[7L,=+E ";I#,NH$!O E$DL8@I+49"B\.-$(:GF,C)$*D5!ADB5O4Q.!DA]
MYJ0+'FJC"1J,9;N[=$IE8&<]L,-<0H9VI!1)*?J0UY9*YJ4,21F2X=$/A$?5
M?"X #?#'1$AEL_MGJ K+UI'-7YX8OBB.91JZ\C]Q\O^B1;9-W[U1V_M6E$@F
MD960HE*8I#!MPJJ-RP"L%*6MV[-1V_MVC-MT089P"=TR:;*T:S126IK3!>C2
MB:$C76G.E+VQ0R9"[8M]_*V1,=EL<4 42/A%%-,BI2(GK[N-7T6.'-O(/ZG9
MG"RBE5(HI7"7'6-J=O/-DU(&I0QN*@H=.7)LY29,%'YDE)JMK.E;V90^O&F9
M.OZP3$9;S9OL31D\D-5;WZ.0,62S&P8!BM1Q2BZ77"ZY7'+Y]Z_$W2!B512<
MJH_;>C>VA=>N._ZI4UL>91H%TOW_['UK;]M(LO;W YS_0&1G7B0 K='5DIV9
M 3*>F3U9S&Z")'L6^RF@J);%"45J2<J.SJ]_JZHO;.IF6Z'MIE0+;,:6J69W
M53W55=755<W0%*Y3BC,'[W7&VCT?<$R',<08.AA#W+*-4<3YMX^%HE.);%Y1
M*D(03;QIFE6: YB. 92M@'4+,C![LR@LQ$1]AD]G8L+.,3O'1Q$"<FHC=HKK
M#(:3 \-^&=AY4M@=^IUN_5<KG6([HX'CIO=,@,4,6"YB4(FO+K-P%N0P#; M
M%QDFO!8KLB\%F),+C*NR,\O.[&F'A Y4-WV_O:UD"J.(4<0H>L"ME>&@QRAB
M%'%@]5L<P<$))XQN3R*(DD+$L0B+91"7IF\<A2+)ZZOEY116W-$J3I'EF -'
M'$5E,# 8OC$_YJ+=9B@P%(XIA.K  ;T+IG8-QF6PHNQ3KTB]J__]X,W2>"(R
M3D9E3Y7C/8=XJL,NQTP90XPA][PW%XC%*'(-10V(F3I@ZS;0L.5:L%QSC\M7
M?J,U.VC7;\TZ)1,,)892DXU:IZ2"P?3L8&I:+5@';%L7S/\Z:\&J\J^JM !7
M?WUN5=2 (F_/&[)RCAR/DTS;W9+"Q"AD%#(*GRZ-\-R_&/'Y#,/0!1B>;@'8
M3M=O<P58,[-J!=C?HR1(0JX RZE;1YK%N&.Q7!N3I9REG*6<I;Q!:;CWE/*3
MC,O*F:G\6DZO?6Z=X#JE3BPU\%#7T6\/.(##*&(4?5,<U._Q:02CB!-LOPE%
M/;^]+3WN5**8F'!09$&23T4F2Q,L@JS.@EM.0<(AY>':"0$G"M9Z7;OM#_M#
MSA-D+#&6OA5+W8%_/CIG+#&6..?VF['4]KL7FW5$3C*TNYYRN\C2FV@B)MYX
MY4VWGM^SB_W\+K9S(.6$OT?661?^^47MIC1CD#'(&+R_W=#S>^<=!B&#\/E!
M> 0IMP<&E8;U&>^-LM3+4'64A)D(<H%7X]!H]Z7ICGTB;H(82Z#YVQJ3<=2
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M=46.2@UU2=QMS+]7"?:[2*%O6H 1HYZ$:2^D_>C!=*)TDDLZ:.4SPZT^U5)
M0E)L)1/:<MX<WI:AYE.Z<K].E)3%%3](.[:\-R&*"BP=;=Y%N;=D OR'PBB"
M'&8/ZQH+,,[QH5R*/KC,:#*K"6:9LE*4N!D$W8*)05-$LQ($U:QM<^W%+$N7
MU]+& 1:AE4CD!AK";@\<HE<%V8TX2Y?%KJ"6$_L=\GX*EE1Z2_/&+25'$N>T
M Y+ 2$)JET^Q3II66_@G_U"J.=HR)W\N)>AR$!ET,9.)(MYN7@+G\N4<;??_
M$Y)3TRFR4?$MLRV.9&VTLTA:'??;HQ404#D%=)/_)8$%1H)YYJ^>R'C<,+GV
M!R*WV&'&QOI%F0P?9T)8(1Y8!3'81/#DM3UT*8-%+B[U#_:D,>REYHOAGU"&
MC:I)%5;,7X7;VAO!LB+3;]6KEXNL)P79BE=9PZ-*1NVGC6_].P7\+V4L\A9H
M<&<@T#I.,H\&XSR-EX5XEJ#@[K,-:R"#^T..P\JH[R,GP3'K'&;=_D0]9IVS
MK+LK)9=9YRSK6&$VF'6L,!O*.E:8C64=*\P&LXX59D-9=]=U%V;=8[.N&=>X
M#R#3Z)O(Y/:5O=%!B9;WK[MDW_BOWOY?*Z\4IC$2[:<7HQ<'TJHW: TZSUK\
MZ[&)N1'3EC]@8+M*3X8B0[$&*'8/A6*GW1KTCAJ*']3Q4*UEXAI,#Q:N&HGY
MQIQ/LG@]AWCU1T<M7BHY;E*#S>#"Q:M]='A#">.7?/F0+Q\Z2*EFW/[=(-U)
M%CFL<;D,#X8'PX/A<1)7W^\)CR9'K/"Z,MJ:7,'SJ8U,I\C"I0LKI0M'PW:#
M@J^, D9!_2@8^NWV9NE"1@&CX*0*> Y@,SBB"IY[K<!/*=9Q")<97?63!2M.
MQ@MT1QNX3BDN'KA?9USXY_47@'>!5 P?AD]##4\72,7P<0@^#0@_'FBQGL/V
M<]'0_O)[S=.W21$DUQ'>NM;%U!)1L&_*ONEI1F@ZHW-_<-'E& WCX*1Q,& (
M, 1./$PY.M\:=#C...5?TW2"]2O9.V3OD(,K#SO;[OOM\W..KC!^3AT_^X5D
M%WY>CH:O&#V,'HY-'K3[]/R+X5'&)N71><U'YHXLT34MX!19.!)CX;L[&OG]
M#N=.,@Y.&P?GL,TQ"A@%IQV4[%X,_-YH$P='%I24[_RC;.O%5[;9,URG5&UW
M#!L:7#G)BZ4,#X8'PX/AX10\&A!<O"<\CB!L^"8,,VRN8S6%97^1_<73C)KT
M_/Z@]J-II]C-*& 4W)G-V.;((6/@M".'/?]BRTYP9'%#90)>J>O66)-7]=*4
M'1:%%XL@%X]B&[I+%=>4A.N4.IV$K0,SH_DF-F/GY+&S7TAV)CMV>ISLR.CA
M9,?#=I[CS7/4)8(X;,G.ZLD';#H]?WC!,1N&P6G#H#\:,@88 R<=M^ST_>YP
M$P;'&;C\54P%F($3+TK"="Z\(O@J:B[)XRX-7-,)KE/J=$(MA^9*^YT15[UC
M_)P\?@X,57;/VQRK9/APK/*P[6?D7W1K*G/N"..5E?JNF(G,B]/D^JP0V9Q#
MENRG<JRFXW<ON+<'H^#$4=!C"# $3CM@Z??:HQ.)5\JC:\ZF9#^1PRP'7TZX
M\,_;M6^;+M"*\</X>8(X2[_V1!$7",7@<0@\1QNDA,UGU-_<?)H<I)3O?!]0
M-F68SF%E*SQ!]Z+D1N3%'#ZNKYJ04VMV1RTX19::"Z$XA?H=BZVYZHE3[&0I
M9REG*6<I/[IPXSVE_#@CB7OM-7;LV+'CJ,C#HB+=D3]JUWY]P 5B,8 80$]1
M;WS8X\ BPX<#BX?M/[V!/^C5=&_'$<[O.O3V@F3B+9[$@'6$$JYI"Z?(P@EA
MW+Z&<< XX/8UC +.C;Q_^YH?BF <BR=@TOIL[RN:D^CFYQ_A'_V],!9!ALR;
M:89H@>^=PUN42+;;WS\-CT(P-$6FUXG&JM<N_P]S^/VL>VZMA/[][_^R5U3Z
M(F=A&J?9Y5_:]+_7UE+5V[LDAM?B;)R)X,M9,(5W7P;Q;;#*U<I'HU:W#_Y-
MFDW@3VT]L1Y.:- :C;[WRA^10AOT54HD%M/B4CZE/B%I-!]]/;,HO4CS"&M^
M7F8B#HKH1N#(UIB:446Z>$(NK2F(7LF3'P-OEHGI3R_^\NG=U9I<RE'Q9U '
MV3R(Y7MNY<#J(_!'$#98X_0*_@HRD!NA#>X6W/N0[VF(TNENUR46%2)PO**P
M0H5Q&D_@&U?I? SC3[R/15 (=+ERI,B[A<@"7$]N YGTC!%Y$D\4]SA8Y.)2
M_V!/'^5$S1SI%4HZO[;E,U@6:54\Z1,M;O2,I;G5,^T- 2PR/3%-*DF1>MQE
M2P:LX5,8<AJGMUK[Z=]);5]*?-\"F>X$E[7=FT>#<9[&RT(\"]!V[U#60 O#
MR0/,E5*3/K)%QZQSF'7[K4YFG;.LN\N_9-8YRSI6F UF'2O,AK*.%69C6<<*
ML\&L8X794-;=%;MEUCTVZYJ<<K"73*-O(I/;YT^C!P6[MU-M7)E$-6!HYU97
M\ZS'5?J$:8Q$^^G%Z,6!M.H-6H..CH-K3G467SU 833Q=(B]P<3\MP@R23Z1
M3,1$_OBK",5\+-0?>AU?_M!M=]M5(C,^&9\UX+-[*#X[[=:@=]3X_""P$YZ8
M;!"/A8N%ZUN)^6;RYU)G.;)X/;UX]4='+5X?1(Y'NI,:; 87,JTK!\+#%F91
M$+$B,)R2XO),?K2/6D 0,+?"&64=3\2-B-,%7Y+C2PI\Q^> TD'^Z(*;F3)^
M3AX_^X5D9X> BQ$W"&#T\!6Y0W>?X<5Y0V_(?;L=^U>1B"R(R8P-)O,HB?(B
MHR.,)OB0358<3I&%;PG9M:/;_B.4LW2*WPR#4X+!@79E9U"[7>D4MQD$CVPQ
M.@6"P_>"NOI'N6! ?[O%* LOI/).3W+MB:\+D>3<=(!]SQ..W!S86?S";[<Y
M\LGX.7G\'&JA=GH<^F3X<.CSL.UGY(\N.B<;^OPCS7-OFJ5S;<S2!75V=-G1
M/<EH3W?@#WOG'/%A(!P+$ Z,^'#W5,; T40]#]\,SKM;?*L3CGN2N3@6TS03
M7I2$Z5QX1?"5W4YV.SEJ\T#ETO-'_0X';AA!)X\@9TQ4%PC%X'$(/ V(>AZ^
M_0R[6U*F3R7N^=88KV#.)F(:%=Y+=8C_BEU>=GE/,^PS\"_ZFWD^C )&P2FA
MH-O=O K!&& ,-#/X>6B3D,ZPIE-Q%RSH;S<8_R$*+TYSSO!D9_-T(S4'.IN=
MH3^ZJ/]4W05J,8(808^_&_=Z%PP>!@_'.@_=?@:#X8Y8I^NMOIK;\2B<!<DU
MS#)*O/>R(^V5ZDB+MO1;JR-MN=JZ^B%QLZ,3JZS,I>A/D75<BKZAK./>'8UE
M'2O,!K..%69#6<<*L[&L8X798-:QPFPHZ[C9T7.SKAFIA >0B9NI[*<:-SMZ
M(F)R7R.&XE-"D5O/["0F]S5BX>*^1D<J7MS7J$FYGOOHH ZB0W40G8C"B\Q!
M-)D(G=?XGX[\#_SVMR!9!MG*Z_B>M*N.*/_F@3+$&3F/D)'3H-RUC75V.R._
M,QHP)A@3C FUSL&(X<!P>!0X-#%#$[>(;K]W3*&HVF\".;4Z=R#L%%F.](+L
M?O8_]84>ISC.0#@E(#AS+\<I9C,&'A,#KMT4/WPSV'V]YM@"B&C\%5F0Y%.1
MJ<+IBTI,\:B\OV;H!M<IQ;=;]VN0SH7?&W Q/\8/X^<@_)S[O1[#A^%S\O?#
M#RSW-?#/1TUM?G[P8;>GCKD]G43H]>H^XG:*&.[H"Z?(PN&<2N&_D3]J#SFD
MPS@X:1R<^\->FU' *#B2P.:!NT%OX ]ZF[O!4Y0-LE:#J;_1=&53=&T!1U])
MZ"K(9][O<7J;<ZT@OIC(-[F9=7R3^_A8QW4NFL$GUHY'R#K6CHZSCK5C,_C$
MVO$(6<?:T7'6<<D?)_C4_#-3KC/BP%U]+OFSDYC_%H$J]R.2B9C('[D.$..S
M*;4TCKQ4"]<!8N'B.D!'*EY<!^B^-H,+F:+[Z/!N(3+PX9)K+PC!E0-G3>27
MG#O-N=//2*D&W5/8H%-5]YX(C&I<+F.!L<!88"P<6_F?[5AH<ABJ,UIP$2!.
MCZ[GO-X%B'+%'Y;ZHY=Z+N_# O_8M1F=$OC#U?PIU/)11EP93\^](O4R$:9)
M&,6"KDJC=8>?XL\A7D!99.E--!$3;[SR7BYS^"%*7GDI1Q*=T""N4^K!#C*'
M0!@+C 7& F.!L<#A0%?#@?TNO?17,1591B9AF,Z%5P1?1>ZC[<B>(WN.C0J5
M'.@Y#OR+\S;'!UGH3TGHN]T!BSR+_"E%",^QX]?1!PB56?>NF(F,G39VVNK9
M\EQ85OVG9%1(M%O[C1H7B,5H8;347>S^O,-(8:34:E>ZL*RG0<H1A JO9D%R
M#>-'B7UVG.>BR+T@F7AQ%! :(A5 Q *(0?B?921+"M1XN.P(75Q3$DZ1Y5N.
MRIS2 3M65O.YF%.\8Y%FD6:19I%N<E"PQA-;%ZS4[4L]ER]]$X8P.S##,A&*
MZ ;+2]=[A.LN!5Q#M^N4.M*0QGZ)V)TU[+<?X6Z("\1BM#!:Z@YK^/W>@+'"
M6.$0X$$7L)H< EPW-!?!BIJ88-PO",-L*2KQ/_8A3\B'/(8TJ@,;+?F]+6V6
M6.19Y(]6Y/O=+@L\"WP30X2'ZOCAH"9;S@53=Z]Y9RZ#9.)&)$O!7AY[>1P1
MV:T;+OSAL/9"&RZ0BK'"6*D[UC[R^X,.Q]H9+1P_O$^LO=<='6,$L=Z+*8ZL
MS36H.T66TXV5((A['"UAD6^BR!]HY77Z?*^8)?Z$XH.@Y-M''Q^T:D=O5!3<
M5D>0W3MV[TXC&')HX/!B4/LYF@ND8JPP5NHOW-'K]3APR&CAP.$]$@_]\\YQ
MI1[*=_X>)4$2/E:U:J>6Z@[RG2(+W[YDD6:19I%VA'<LTO6*M&O1P'N*]/$&
M^HHL2/*IR+QIELZ]19!1]V[VOMC[.H58Q8&' 1=^;U#[D:\+M&*P,%AJ!@O%
M]1@KC!4.Z]U]"V7@GX_.CRJNM^],>;HEVL=NY FYD<>0076@"3GTVUM2?UGF
M6>:/5N8?Q1)TBK<L\G7:>$<@\MV>WZNK3+0+)N\^+G]<+A:QP&[%0>Q-HCR,
MTWR9":P/39;?-$YOO2B9IMD\P$K1W(68O<'GI-311%XVZ:0^H7&>4L08C Q&
M!B.#T4D18S">7)RU9C V.0X[: T']-KUZC]833S-)M0;&HL\KI<89T^=/?5F
M!Z=, T 69!;D)@LRU=9A,68Q;G;D=$V,R:KZH4!;XRGF]^<R+Z+IRJ;1FOC=
M5]@FT<W//\(_^GMA+((,V3'35-<BW#N'MR@A:[>_?QI&A"(I1*;7V>UK^3)\
M^/VL.[160O_^]W_9*RJM_[,PC=/L\B]M^M]K:ZGJ[5V2M6MQ-LY$\.4LF,*[
M+X/X-ECE:N6C4:O;!X\"C<WLLJTGUFN3=3H:?>^5/R*%-NBKU$(LIL6E?*IB
MS>N/OIY9E%ZDLBWA92;BH(AN!(YLC:D95:2+)^32&N1[)4]^#+Q9)J8_O?C+
MIW=7:W(I1\6?06]E\R"6[[F5 ZN/7OS\B4JVIU/O"OX*,I ;H0WN%MS[D.\Q
M13=* &_PP6BQD:;=Z1HJ?9H);YK&<7J+R2.D.G)OD8D<ONL5,_1I ,3DX^3+
M&-R9:9KAYS*M>P6K]42"+L^OX.;,QR*3?^AU?*_;[ESX-$8P056!YQFY-P\F
ML@H^_F&!HZ?+/%[!^(LT*V"@8"[]IB+U\N4<9@[KI(?!8Q8A-<F4\\J+H*!#
M$B]-UD8[B_(<*^R'Z7P,Q)GH_)@@]LRWS%*\!5 UG>1>-(>=#*?P,L(!8228
M9_ZJ1:Q^&OFU.+-+8*,"E%)8$=AQ&D_@&U=ZM;\$,:Q6>!]G0EA""ZL@!AN=
M1/H#]5$<+')QJ7^P)XU 5O-%@0XE$%[;"B18%FE5?] G6A_0,];^:44,JAJB
MR/3$-($D'>H)$5@@M89/84@\3=/;D_Z=CATOI0*^!3+=J?TL"\L\&HSS-%X6
MXEDTX6Z;T!JH#.,<8"&66]TC&]',.H=9M]_09]8YR[J[W'1FG;.L8X798-:Q
MPFPHZUAA-I9UK# ;S#I6F UEW5T1=&;=8[.NR6D6>\DT^B8RN7WD-WK0:<1V
MJHTKDZB&">VZ'-4:'>,J?<(T1J+]]&+TXD!:]0:M04<?5&A.=19?/4!A-/'T
M&4B#B;D1]I8_8.R[2D^&(D.Q!BAV#X5BI]T:](X:BA_4"=(&\5BX6+B^E9AO
MS!$FB]=SB%=_=-3B]4&>9D]JL!E<R#.OG/T.6YC18N<DG,F/]E'K39Z+HL:"
MM2Y0I1E9>TRI^X:"7:#4\Q<9=8$*=R^:X<'P8'@P/!R!1P/N ]X3'LV(:WV+
M08KYWFB1\H6^IS9%G2++0RZ0')I"X,*=DGM5XQGZPV&_08%<1@&CX!%*#P[:
MC '&P&/D1C0& T/_HKNY$YQDY%(9BI]2+-L6+C-L .$%%,@\&7?2'97A.J7J
MVTE=6.FCF)@7 Z[BQ/!A^#ABF[I * :/0^!I0!3S8*.VO[GWG$RH\Z]I.KF-
MXIB]6O9J3S.R,QSZG38WE6 8' L,]K-_%PQ>CLY?,0@8!*<=X<0&0UT.<6Z$
M.#FTR>XEQV8.Z65SWO5[78[/,( 80 <!Z+SVW!,7Z,38<0@[1QO;I,UG5-.1
M?:.,5SFS/Z* D!*)&J\7.84 =W2%4V2I+=.]">&=1[G+X!0[6<I9REG*6<J/
M+DIY3RD_Y?BCN8NS"%:U7L1Q@3[-4 >N4XI#*/O=P%'[G&,H#!X&ST%'@IN-
MZ!D[C!V./]YGXQD.3S#VJ S7*W4K""O516F"S8QD:R+AQ2+(X=\R.LD.[0DY
MM$>:=G:8BC!M9CGSC'%PPCC8W"@9 8R 9D8UZT+ *8<]JS?+'\-4=(%0S= 9
MKE.*0SAWI)#YG=X%1W$8/@R?@S;FVB_'N4 GQHY#V#G:".BYW^V<< ST5S$5
M8,%.O"@)T[GPBN"KR'TO$07[N>SGGF:DIS?P>R.^;\XP.!88[&<_WS=G$'#,
M<\]>T.;[YK;)^*Z8B<R+4QBE$-F<0Y_L?W+LYF %T^6ZF@P>!L^!=37YZCEC
MAP.?AUFV[<T3MY,)>\K#>\[O9 _WB,(\A^F!?M_O]&JW09WB-\. 87#G.2 C
M@!%PTJ%.W CZFW?I3C+4*6?V/J#<SC"= TE6>"CN1<F-R(LY#L ^)_N<:Y2J
MN=Z+"\M]_A(P+E"!X<'P8'@P/!H#CP:$+>\)CY.)2>ZU-MDM9;?T- ,SW<[(
M[XPX0,DX.&T<##@CF2%PVA%*W JZ_1Z'*/>=9'M!,O$63V)+ND#"9N@4URG%
MB69W:!YN$L0 8@ =#B!N$L38X4S-1V@2]$.!-=>?@&_KL[VG #^-/'6ZVTDJ
MA\&?+R.PDZ-0#GPK1QJG\02^<97.QS#^Q/M8!(5 "SG'6J#O%B(+L#!H;J^'
MR*V''Z?91&1G81K'P2(7E_H'>_KG,"LU\WGP%9Y-"GA#U?2WI/.,A(8^41AN
MM[_'9169?JNF@UQN/6'Q272S9?@4AIS&Z:WFL/Z=1/-RG(G@R]DMT.#U(LTC
M)-5E)F*@V8U8&]-2?.;18)RG\;(0:^M\;E5M#61\KT,4-ZS>_/NHP1IFG<.L
MVQ]08M8YR[J[XL;,.F=9QPJSP:QCA=E0UK'";"SK6&$VF'6L,!O*NKN.99EU
MC\VZ9J06'D"FT3>1R>W4DM$=0==0)(7(]E-M7)E$-1IH9Z%6,U+'5?J$:8Q$
M^^G%Z,6!M.H-6H/.]Z]5%%%QJK/XZ@$*HXGWES;]K\G$_+<(,DD^D4S$1/[X
MJPC%?"S4'WH=7_[0;7<NJD1F?#(^:\!G]U!\=MJM0>^H\?E!8/,S,=D@'@L7
M"]>W$O/-Y,^ESCAC\7IZ\>J/CEJ\/H@<SVLG-=@,+N0-[*/#'Q$0*Q>4V@FO
M@X6GB? R<2.2)?=;YXP:SD9[6$9-I^N?UW^ER 5:,7X8/T^0S<G88>QP-N>A
M>\]PL'F3H/FQKH\BNP$[M7:SU*E%NJ,'G"(+W]2U;^KZ@RY?UF44G#8*^K7?
MEG.*UPR!1[;^C@ "L!&<;VX$1QFAE-?0.2+)7B%'5 [R"D=^M[-9V8+QP_AA
M_-P'/VT.23)X."1YZ.;3Z]1DJ#K%^ \B%T$6SNC@? +&:9PNN)HFNZ2G&Y7I
M]/Q.;\B1&8;!2<-@N-GGA"' $#BEX"3L!-WVB40G_RH2D04QF8'!9!XE45YD
M="F.O47V%CG4\K"]T[\8UMXMSP52,7P8/D^0.SGD2"6#AR.5!X%GY)\/:FI1
MZ13?Y?%Y*BM.)M>>^+K "S_<EIS=TQ.-T/3:_N#B@J,T#(.3AL&PSXW)&0.G
M':GL=?Q>?]-I.LI(Y1]IGGO3+)UK8Y#*C[.?R'[BB099]@O)+I7QLH,M$\Y?
M<:2%$<0(.@A!Y_T.PX?A<_*!RD,WH)[?[@XW$=3\6"69J&,Q33/A14F8SH57
M!%_9/67WM.DA&K=L3:<XSD!@(#R+R>@4NQD%IQ2M=,'R<\$ZWD>2M\8 !),P
M$=.H\%ZJP^M7[#:RV\A1EP=NH8,MFH/AP_ Y,?@<=E)XP:F5C!V.6!ZV]0S.
MN\<8KOR'*+PXS3F5DCW24XW+H$?:[W%HAH%PXD 8]#E,SRC@ *4_&%WLL/5^
M*()Q+)Z 2^O3O:=L/HWT=+K;:2J'P9\OHP*X$LJ!JXV)KM+Y&,:?>!^Q/Q'6
M&\J]=.J%LR"YAEE&B?<^R.!3#QZ$L5<>FJAODQNAFV65JR5FZ)>K7DYA&L?!
M(A>7^@=[<><P9[6N>? 5GDT*&%++ZEDLIH4MO&<D4_2):?G::G>HZVN1Z1=;
M[6=?/, 3Z'-3Z7L!U1IHX41GXFZKVV?6-9)UG5:_PZQK).M&K1&W<F\FZUAA
M-I9UG5;O@EG72-:QPFPLZUAA-I9UK# ;RSI6F,_-NH<?I^X/HKA#I]$WT>E1
M-Y/'C\S>IY7Y(Y+-=(L?'=HMOC>064''VRW^5Q&*^5AD_^\OG?/VZU['ES]T
MVYV+;VT@SQ!]?HAN%9^#A47*QN:_54FQD=<]%'F=]K$C[X-8I%DA)AO$.Q91
MVBTMM4O*X*@EY<WDSZ4^ V-985G9KU5R/%V=U+%YNY#0^40IC!(1KB_8C306
M/$G;0BD%JB)=/"VBGB?M1<8,G"=#$[(F&7L/BS$Z+W2,O68D:C+P&'@,O&_/
M#6UV5 RMZ"(+DGPJ,E5C<R'S,$.9A]D$A[.I:F5_5EJCU813L#^P%]B%?SZJ
ML= TP^"@HW.&P3.WYFGW&0.,@9/&0+?M=R_:-=E_KKM<[ROVGY> A1B9>S@>
MRGZG\]K31\=8B-Z3!\;LDCY_'-8I2CVJUWD,:J4S\CNC&LNS,("^.:;C%*48
M0/L!--ALU<S88>PP=NZY^73[O6>Y\&ZM!I-;HNGJV^_ RX1B*[,ZC$60(8MG
MYF*W0DH/+X0_26[USMR.;E_+K.':[V?=T7J"]'__5R57W @BWG=/LTL=9+>6
MJM[>)<F\%F<R%3V8PKLO@_@V6.5:MD=2X5'P_M($ZGLXH4%K-/K>*W]$"FW0
M5VD?NCTOGU*?R.OS^J.O9Q:E[\J&UXS"LX2GX]*:&NF5//DQ\&:9F/[TXB^?
MWEWM+GN0I-D\B"ME#]1'+W[^1-4*TJEW)<L.Y$9H@[L%]S[D:V[QAZL@GWF_
MQ^EM;@.YKO(.MGP&RR*MBB=]\I *$/64?^"K)MN5?/5N"5^]8\YP[0;'.0/&
M\3ESQD7.=.^HRL6<>3YMQO>$W>0,:S-7.</:S%7.L#9SE3.@S?96IV7.?"-G
MFE8"?C<51D]U;/#LN3^UTJ">\@(-NX[X^H[[A_\6@:HE()*)F,@?'['( &/J
MF>_ROG[2R[L-*PEP%UKJKP'PN+6XG9*%(].<CW'+_X2DX>@T0SWW^!U)7J@<
MLPU;>#9-U(G 2$B*RS/Y484\[Q8B \\BN?:"$!P,<"%$?GFD63X&*J=X0?_0
M;(\:@GW.4VE/TL^:>JUMPSAF9#3L%B\C@Y'!R' )&=M;Q+I%I4.0T8S RT.M
M2)->V1DM'J5@U*DAX-DOK->7U;WWJ/=9D/E\Y9>>HX';LTOR,]^W94FNO9@1
MBW&3Q=BQ7JH/4<@UE09J:*QNW<HJ ]FY5Z1>)L(T":-8T#UR-+_P4_PYQ.3_
M19;>1!,Q\<8K[^4RAQ^BY)67GE;P[[DL.><(49M'NS.*X9B..8U Q7-MC,X1
M@N6;Y9OE^UMB;8V0[R,/I]&]7.P=,Q591A9;F,Z%5P1?1>ZC:<<!-@ZP.1:6
MD#42'ECX;K!9'($#%*<:H'!,H.\=H+C@,!M+L:MAMD/4\F PY&B;-L*N9D%R
M#5.($CMHEN>BR+T@F7AQ%! \(F6:8=6-(/S/,I*7<CBJQE$UCCIPU(&C#BS?
M#BR;Y9NC:J<:51OTY?%I& )KP'K+1"BB&RR%QC$UCJDU.@0Q\ ?G XY"<!2B
MX8+<\;O#>HNULQ@W68P="Z;=6Q_WL9D)IZQMVER+8$6U9S%R%H1AMA25"!K'
MRHX^5E;?!N?"TNI0%N?]4>VFFPNT>7;Y=S+6<#+R?\C)T[#>;B,,A.,'0B/B
M;??TXH=UV8R-,Q!-JELF;D2R%!R,XV"<>S&,E_T!(I3C$J<>EW!,--=,K9<=
MO]\=L*"RH#H80 /A' UMX3S9H-B[8B8RCGAQQ.M8//Y[.SH=_V*PY48WN_KL
MZC<; 8?$O#J=S;;WC 1&PHD$O< <[-=5W:,Y)J!5,(VJ=*C"'%OK<G LC&-A
MC@4<'I (,;CH<&(:!R2:+LCG[3Z+,8NQNW&U^R8*=RZV) J?3 P.IO)[E 1)
MR*7/3BT,QY?8.+1PS*$%EF^6;Y;O(XJ?G>0E32LP5F1!DD]%YDVS=.XM@HQ:
MMW$LC&-A3B'UH#.?"_]\=,[Q!(XG'(],G[?[+- LT&X&R X1Z&X;;W&>;JQL
MYV&EW5)@NB6:QL&THP^F<4;//NON_#&L.Q<(]>Q@<#(RP6!X6K/0!2HQ$DXZ
MO>V@;6%8GSWIO/$(4_FX7"QB@7VJ@MB;1'D8I_DR$U@@E\S(:9S>>E$R3;-Y
M@*5RZSN$/3UM\/S!O9J/GUP"^V.=-9V>F#Y_>(/%E,7TQ,34L5!<O2>;+MB)
MWQI86R]^02T]LXF\$1!LEJOE^!K'UTXYI(!"T.G6* 0<5CB)L,)QHH&*?3 6
M& L<8MN!!3(L?RC0='H&8:V\YPK6.LXB&/=_1'PCD&GXCB#)SS9?!&/=4])=
M1>#C2\V?R[R(IJN[Z/]0@@9>-/GIQ>?NA>CW+L*+SZ)]/OS<%T'X^6(\G7P>
MMX/!\+S3O6CW>O"Z'X(G8('T&+HE(,:5-][*+XW3> )_[+6\7X(\RC'8^CX3
M.09A,<9*A9<_+N<P[ K_]A%H&$U!"I/"4T6:\2S_?1I'(9WDCY](P#96M\E"
M_/DR*H#OX>LM2]Z]WJMT/HX2^OVIA%.Y?N3@[5[DIYD@_VX.<UHAW4.:*3A^
M*JTBB&&.04%!]-R;!3?"&PN1>*#S,!]VXN$*\9%D GA($_@S48'*:V?"F\"4
M;W XS*#]([J&S\EX'K[.X5U)#FR>P/!;WZ<]3YR7=$CSEH<SWC_)* GCY41X
M!3PYB_(BS7!C@A'R95P0?]0==WB];PVQ2&7#/)J[.1^@+[R;)]&;,3K#,&<\
M+@#T>K=1,?/^F40X^X_X^MR[%@F,',<KG+I8X%^L-2PRF%JTB.'!E_]L?6QY
M?WWSYOTKN:1R2K@Z>#+';ZCW(B'AW3=!%J7+W(O%-4P7UDJY+M[M+,4WIK>)
M3(B15&X1FC+<0>.5OTYZ;!,8)3<B+XC0,#A0*Z], YB8SV!0_&,<B272 8@9
M?H'7 5?-4.(_2Z2&'&(_:UJ.2+TBJR(TO#8$ZR6(DHH<KU$9N Z4CL(9'21E
MHA#6$JTS)*1;<!-$,6[VP(1<D5Y+L$PJQU0E)')0$-6L=ZW@EQL1^QZ(41K*
M(>>BF*63-$ZOB=\"Q"%8+( I$Z](S>1-G 8^4U^&Y^;F,RU,.:U@F6/!A^DR
MPQI@@&D0=<?84PHX+AB,1)BG$K%Y2D@LLC1&L<1/WU-V/JXN4%"'O_BX?L!1
M2HN< M73+-\  R(GRV?1@MB%@VU[=?6U/CVW5?^ 9DRS8NWO6KGXV_70%IV#
MW[^2BAE7!1*PO)[1I^9: CR%0+9Z@1HP%C#QG#0VJ.@P7%)T+Z"!_Q8D2]A\
M9?"SV^Z<@P:R97(LBEM4\4IN\?^5N61"BQK*WRRC>2GRJYUDBWZ13)7*KDCQ
M0!:? 9-?A(5>+BRCD.>UZI-<R*7H82O8B9#4TQB^KRJ7++-2_8R#&"@/0\X$
MT2:__PS?Q,!.RRK9/0/: 329:+.#R1,FK8TRB"9:.0*[HW2BA!BY0^(%FP*Q
MI^7]]G4A$M1'F8AI4T1TIQF($T'9*(3<WDYM:&>"-M4(Y%5^>RP4B6$3ACU"
M$GA"RHRD[3Y:6RNI @!?RI^D@7<;Y"98[(K^N+^) "35(6^%'\V! )D#?T5]
MLK75+BA16'>!6WV>I_ "Y!<)!))HO(3]6^2YSDE=65:$/71BJWE,2U"Z7!D2
MTHR:S*,$[!A4%2!58HN0@&8S'8"GRR0L=0I0]R8*X6D[91:1(N% >,R%)65F
M^%*$]69BBQI8>=+XDV3PEGEP#>8#[B2)F$:%#YLE"3<R#) DF]P9^F1B'D2D
M5LO!S9 S$4Q(O^!X@=13 )T03>IKRMZ0"J0L560F#5^0NGXN DSU0+T)X@L2
M!]\DH,-.%P''\Q(L>4$;!VW109XF<N/^*(3W8[3;_G_Q\S_20LC)O;QX)7_X
M@"Q!VL-F(A>KMR48_8/BUV]J<_GQA^AG"9D?)M'-SS_"/_IU82R"#(,H,W.T
M(R,JE]036H6'VNWOGR8P@I07F49<MV\=($G$_7[6O;!60O_^]W_9*RI#/6<A
M&#+9Y5_:]+_7UE+5V[L4^[D69V/@QY>S8 KOO@SBVV"5Z^C12!X>H=;)+MMZ
M8CV<T* U&GWOE3\BA3;H*[\@C\OD4^H3"@&9C[Z>6936._@EX0Z0B"-;8VI&
M%>GB";FTI@5[5K@J\&:P/_[TXB^?WEWM=F<3-%SCBCNK/@)%2IV2 &]7\%=4
MG,9Y#7Z^4W#O0[[GWRO>&57HH49"Y9L;1RN?P5_.I%Y" P!TC-34"S N:%\,
M+,U)=GM+*T@Q7\3I2J#F#3 T&BWP&=IO4U"XH(ZOLV .^II4O(<FH]H#U(9<
MO@UMA2V[# U#$XG,CC8I#1G+S59;H;4!5HS/EO<_Z2U,/I-&[<Y5*RT+.T,N
M-P;S4IP1O'BOB25-/^V/+&2(1$SN:8* LD[2 H:$O2P']L1HY$ZB4.Z)L)SI
MLL#4ON V0"<+B3H/5O0=922J?4<:W[0K*$[=ILMX(K<[7&$6"3 <)]*3L!U"
MZ9X]U<Y -AJJ%/R62E\$GPU^<<7,0CM9B:MMFI(9E8.Q2!&1>W/7[/X@Z,OY
M0HZU=_.V=^N* -_+]@..@WT"T]-B,A9K$O6M#EP9-**1I'P"4R/S)W3.I(4%
M=AJH"9BC7Q&YQ7(,$A63VX%35A&"R3)#JZ=T*2P\/:ITU!DM_2,"7W6"RZ$(
M:;# 1P$*.5BGH<C=BI.^D6H<V2J]+M]H#XRG"%",.(RW7*3&<28 2XQ$Z.NE
MV1>*L*J5TB/F[EJ&GGLF1=1'W:,&69(SXJ$%!OX K&6"H9\L#<(9>8<H<19
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MW=RK=E=).[-WVV*E=^DHG:B)F/#\6K(J-0FN9JCBJ<*?R\FUD$<F;R57RV>
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M"Z2YMV7S3+8,':VY3JCOZNE7Z A:ZN](U_<'[5I;%N*FXP*IW$=/UY$FF$\
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M.6.IA=;FI"GFK2(13]:TLI3U]O>JU1 53\<VK@O9.;3;;@]]#7)PX\.992_
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MM3H+BK,9(%Y'/2BRJ\X[=9(%?M>0%Z"KYI\N"S1#:)-)A-&J.!K9&K1P.\_
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M:;7EO;DIR/#J1"Q4TI\BH,4M=2"%(C$#L0>Q+".)4E@2%8Q=X+D8NB+V^A*
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M>_[Y:'"<-T?V8!\ODDC/X*0B \ZH!=<)=6HVPF%^Q:C;.48+X8T^["S[%'(
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MC9NU0SQ_ F=*'_F[N>[<?>\36*XUH0$\![9!/7X9/@2^Y?"#]Z8A"" ">%D
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M.Q XJ!0A\,PI]QH IO+G^%5R ]B_^"T9TR=T!TQ@D?@M*I,>-0+@T 1Y!S"
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MHG*DE\=*H23#.0=#)?;BRQ5&K,5GPOP_XV^).#M<B[\O@=[RTU3/#104*X@
M9X@,TD!=0>&JH!TZ:4SDE88\<VN4XE&+8@/+VY%/>.X3BP_,MB:6;*@7 90W
MV$LSZ83->)RU4 )@<OP1P 6YDA6@P]=+&OP)<EU%T^BAD[2K"@RS-:SCP0UA
MU[G$1\L:<-N!!2^I6XEQB_1_-6'>[ G8&"-C8-!_@X(5H+O+P<@4:$!VHO/
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MV#/B3IDG>LKY/%L/&Y-]LAZQ5QO^WW$#_(7"XN%/.&O78;Q/'W5F50)/-%G
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M6U]2^TN,)+UR-\Q>[MVJD40CR1*2U/MYB&(5\N]VG\Q\(3,?EB+*Y[F)8Q4
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M;_YU?W.Q($#%4_$S*#O>A-KB/7(2L?SJS:_W*-\YBX5? 0?\6+K27U]$W&W
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MH@_L[+RI=?31%?+HZM6F/KE"GERO6M?\LIA'!_RRK8^ND$=7KS;Z^N@*>73
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M:;*U.$TMTNK03X/VU'(2$$_)X/QF"BJ&<"0E02&.PSAW6?Z"_LU(N31L:DW
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MBB]=^KG02_\$I$M&2'VTL#.9Q;OJT(!-=E?*5(#7J8N9>BV?8&6M;((F*V!
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M\^#V0R.? '^C= '^K("Y<IXLSXW2D\LYIZ]Y>D7[C7QB^XU3B.UGA=5@-++
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MDP.PVZP_)4DG*V"N+LA'R][=R"\;*112UN03\M]ML)\*;'*/L+KW0C\@ \.
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MYX_;?Y/[V^O!I[+)F%.;%(+HD%=*P&GD!&2&%FR?BIJ)$Q OI9X5@FB04S9
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M,_-]7,0PZMO[; 7 *QR&%TZ 5\17 6#A*]BVA82@#.H7#94:"Z@T" AHV7[
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MJ QT5X7L\LTZ_ULEY$2BL<BK1ER:@UA\NUCTG/G48B'D-H/2V"WIZ#G?N"E
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MV9S'/-"OGG:ZCS0,7J=X9*7_A/?V4IMM>LUYJ:9A(VR]$9KA_X?: ;+A]$:
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MEK9:DG$_6N+0YO9CD7)W;PGW+V>4W"3[\OUO=.UO*J'^$!H<['^#MP6)S<3
M,,W+G/?\",,;9/>;9'<W .8?*4YQ2^+[ L2$FHJ1;J/VI$,&_/M)QFY Q#\B
M_.=>TM\$) IT +0P@57Y0JA>NRI;.G*L_FEM8!UMSV\0&&QL-0S-:K>7X=W
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M!AS0]K+1<PJ'9 ,A(H,%L5MRT7/VQL'?!V_SJ.[D';Q+C<'Z-,ZX^^P9VYH
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M6$ +W3(-KX=BSK[-L%?[!]]@S^_";FD3KN/+L*@&1NW=56+W*(,[(7!>H=U
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MED%UJ0*B)KBID#VANDQ*FQ0.<OBZN$Y*%13JCSHI5/ES[\M!A!6/?CF2QG+
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MT)&!KHS&OC$V@V(G.@(>YQ$!!DJQ"FQ0I_-".E:F2F'\2H ZB\MEB2CQE*)
MUG*@3\S@=12^@ NNT#/BN-&(,V4,.;KEV30\.P SD3I+=N: !:XH>\*9CHR^
MG2K8AC.*#.5E90>D V]A%9:@:??P"@2]\,MA7,$J6:<-.#PL+RH*9>F]Z7Z,
MKT6K0UG^"&;"+)-VL.!RDU$\>?O+Y"RX5E,< D8DY$EY09?*$U;VL(\/0*L
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M4'U&D5LW_!?7X!-QBLTA0I"R+AL#@-^N<)^%>S;]Z.N8-G3_L.[?J_BW\V#
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M.2;NO*NDJ&KCG3N<J+C;\[IR&[<)MR+R)N@F?M1$<+6MEN[IQ^A%??=(QD;
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M\U?A2S#AQ R52IIC/D;*TC(3'$\3=668?D@NYN%7@@=QGQMI6Z')KYCD8LG
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M^IO :HJK0\[C-N;"4LA7YA>P?H92XZ$NC-C*^*,VT4-R06E08QA #2 _*Z:
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MC;'@Z/GB+4MX><7B,\P:*D%>BZ^ET7&.=1P#V8CU# $._/G;-Z>2>32[;/\
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M0T''LE-Z;L:.?O L:;-Y#C^[Q%70<F*%N$RJ5CH[%XOB3(C=I^=%.2/+&1T
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M?(S@O*42Z%^Q48JH3([3\ A+E?R3'9+@RCQE+<M[YSX%"$E^V=')ZETT^QZ
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MK(K5&C%&"<JWL"N.PY\4+%D]*6U'UGP7$CS0K!E[-Y&1N;_M?]_X=NY(Y.2
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M+Z6G&[_"_X#<'"3C6H:40AS&;(]4N)L"<0+M[[R=-L729^_T'F@+MZ-PSF>
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M6^D%.IV>9%8L%23RA(:EHT=-WJ?JUU3C!DF*W]9=NYY?VY ]!*U&P .,IH&
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MVJ4T.I[=J>I.E3E5L7>JTJS)>,DFE(2+*0SX)\BY8IRP8+,E5QIAI^U0-2P
MH4AEQS'[^4AHL7-]R6 Z='FR7/@SA.LLIY)H##)&*<,/[7QTH%K]V+&'L80&
M+J7"4?7C1OI-M#.IN4@((_LSXSXC%(#,B%!<I?W6%2QV=Z:[,^;.3+P[XY"6
M<9OX,@ +IRB#?S\(85CP__?P6*5Q&91@,B0$7"D*1)?LP+$=QQQUJW?:J<?Q
M\^A@[\G>SL7NSEYMO^5=<B&V<7^[4]K.*;VHL1?NCMW7MRZ:>'YOQO&[Y46B
MU?QL5Z%\J_QL6P7*O3%G%.'PK4W5^GD*CZD2,[ F[;JBSVC[&=B;I5TCLT9=
M!O97419^!K8>DB M<R.RMJ]BQ0RJ$><SKLQH!+$;=CUSU9@(/XVH42ZF U4*
MPHV^>(PC7 9EWH]$?^KU]!;X2E+;:,/E.^T,^^X6-&?].#DO)1H6Z^TU=[G#
M.!^UPG3[2MD7QJ:1O3<EEX-9!0KA=P40=.CL&.6Z<DZZ@G"L2@B+&%6!9'*0
MI N_C)\PA)/W#3$%(\+LUZZI[[E(KJB/CD"G,BV&X/9HJ-5G)9IZ8ZQ;4E*!
M8K@)G+$H=^N$BM#*%N4+A>'/D9%>B3LMY2)!;#AE-(K*POV+36?!#$W4_X3R
M0VLVZ1H!&73Z*N]SGJH*WF0G*8PB22[W#4S'1L]?<J"%9&BA*)K&8Z2)I2//
MY(=9RM48]#0^8:9@;$P$'1XQ(;+I^ZMG/86I[)U'[(92G^49062R"-&<^N::
M!1/>6/_].S_WX.P&U]EBRK@4U)D8T!K#F\8+XKBD^EW.^5V <KN@58O6O$W!
M_VXBF%J11.JNOGRZ9RR,4*H-\J)L$BAMC&_HC@^& Z8'ASWO?SC[>BSW_^[G
M35J#MZR\SMK>K.?F,&EP@6@H-;*V!F8T$HVLA8.LH,_K%5;5/N\TUQUJKH<H
MI9_5BVF\\SO[N]V]7W_O'ZZ=:$E[C.'^/:E!@20EV#8CF#L\CAL2@>'_MP1^
MO$KD]=YMW<#=\'IM=(?NQH>.<6T/6UQVD9@N$M.,.*VF6$VUJ]=)F Y_G)?L
M@\5>-..^[^D^W5-$=BHA,E;-XNJDL-2A*P(3PE[\"^.;F#-CMF99"I[BDA$,
M<(=M/&Y3(Z/[C]'LF61Y*P8Q1HDLD^:^7F_9 _<Y:X,1LS*S!7RR0#F[+1*V
M$[!;(&!]-.&JA(]@4JFCN4\UX,'5:QNVZ89"5@#/!N4WI)%NF"VB$C6N _38
M\LSS.2\Z6]D!K\D[#@UC%>/WO2(<+HFKK>#;EIO7V3;;</5\R"5!PNWFW355
M77 E8M-C5G=INW]>C[T#IYD/E4["AZ/9G#@X3;,"VP03,*BN;!OE,96*8D%\
MJ5F;8O/#43R-KI$:AFI7A8"%+CC<67]UFBS![M9UMZX9M$GP^<%)/QBD5W#U
MG$JUTW@<SY@3\%TT^DYU6K>HM&1_6LYV[W_"'7E[&KS/\FLD2#Q9Y*-+]-&]
MFLM'4.3U\EE7Y-45>6U)D5<GJ!^8H/9QRTX6,@.!>1+G!46:<?P<08RXACY)
M%Q@/&2<8<,PH<ME*Q$%/P8>%'B7%:)H5B%HX&UW&XP75)*.W032,A@61O3&F
MTE7T'](V#.E^.!I46.&@]9Z:ZN<%_@S(<0G%FQIK$Y#R$');5%?07=!MN*"7
M*PA>K6,(=S!.KB1$H/Y^'OT5?&%Z36GZ^.D/\21LYT'A7S@287WIP14(/.\*
M!&Y3(/#</6);62!0&S);41_02//61GG ;0C9NLJ 7U#:^Y4!?<DS>>U87 70
ME0AT:9-'>1M^H$+ N25MU@4,?F\C-ZFK$AYW4<+S6Q0E2%L@=3@:4-_2F4=_
M7 3PZD]W%0U;!W3:EHJ&5D[=[<HA5K\TI*;FJCF 1_EZ$^QA6Z(PQ'FOV8<'
M.TFM;6Z$AVY4EA8^]!(LO6#G><L(T1>:;/S^BS5>M%@H\N+IRQ;?_:JU=Q]8
M^]UVH=!!B_M_L*Y0J$UT]$$M;-O>*@67;&-D[8 #[1&,+!OU_M]_T.[T]]6E
MZ4JD'E*)U 8F02=RUE[XMN[<BZX^BE]_9_51VW786SW4J^J?K&U[H%)R6P+0
M7?9]&R+0?F74<;8F/&+GY+/1:)%3NL1JS5+?-]5D=FPIJ A8#=JF.YW=Z6PN
M*VG ACB0;=40=.OJ]J+=G;LKV[/-UX=2N]>NH_K:-C+:J-V[QW>V8Y^;4I1M
MKA?L)/LV2':_:JD!_X$]^LB(K;:&7@R+9)Q(W8]#3[H>O&I+R"TI-_3@)5;Y
M85=EV-W7UN_K>I)Z!Z#;B+AEE.X?<3*MP>G6P7H[P'AW%%=7=-0[!90%MX[G
M*%H4L<VBS1_:Q'7 @\KZ9ZR4 GRO&.7)L%UOPM" ;#F0_3%4(>YU58A=%>)-
MJQ!5!4?O]'QP^*G_;?#?]U# 47>F:RHX7-$-9YS'& S^^Q[4U79#\9M7\+Q_
M^GEPW#L??#G>[N7Q:X?>?-OK:H=N7COT1N-S[KMVZ%PZI\-?+,B;$U.?14M*
M?9HN\\I_=IKKR,>B(?PUHU[QW&0=R396>968;>+>:L,8O,.8&M:BLK)-_+IF
M@5T1S^.VP/TBGN$RF"VHD;&J"C9QAII.-GQRNOA"=Z2:*V$\A Y('CXUU.#6
M3IBPBZ< X"8ER>EW1[J-[91C"@L3[+S9#68PGLO"$FP-"<P=_)O UN]+!WQ9
ME$4RCBDK) LCF/C=M_>FB!1#E(53C=A))F>"5E=I('_1W*9O+930O''R3N:P
MH#Z\BI(I.0!E1OH03EBY!)V'K! 2!8;#HZHHJ+)V-E>8><1Q6*'=@&.UWO11
M8:8ZO,4QA-H@,[4;':H4.IS:&0:V*68!WZ98QB61=>$?X")B@'<Q9;*@T"_V
ML*\'-LC#*^'?!XH&XTG?%C'<2>$MD,(^&F2E%%8=>'TJ*Y 7L\44BVW&V">W
MQ.@:_H,2#/0O:NI+U3G,Y(9&@>G!Z\;MA),MGFG^12MA(X)=PLQ97G_-"BP+
M&DT78]6?=X"#PKKSTSC++Z(T^1?CM93U['94IS3\\N9]C!FJI9L/PZ55?8)A
M0*J9,#5ZGT7?83N3Z32^@&=+VK[207C]+''\=+$KVP)#1* ?SAD_E(*\A&6,
M(Y)_G2K96)6,[DJ52*9/J8=;:)-Z/9(4S1IDA?:@.ZE>HMJG*E2C.E+;HBHZ
MBWT;=(6/S3)M1Q9SE'[B"4I77I=+,U3@V?A*?,0HP& X9^6K2-I0XVA-"IVN
M@[D;8CG!O?-=3O@<9WU"/LE:YMC8*(V1;04;9<.?$0S>P@",D6Q*:A%@K. [
M@2R:&):L;$C%A<%.LELI)-6"0_950SVCN0JZ#V-4R&"<HE6 +AF\DG[RZS/T
M#JH_Q!%,CX!POP4[?^U2P3[(VYWGSW;!J%TJ;XY2TG,Z$/YQ9-P_E1;O+'>9
MC\=RMDA>(LT^C@N,A]I!N]ZE_?6V-:J3G=>^\0/2LX9Y/M%,1[#4%M$1*SI"
MX;N20[2I5P416B40-@S'%B*5V@B? ,9" -E'&Y[!_\+Z#[H\%QA"!5-0RSW+
M.XN,W&D;DKG?MMBQ>FYVQD5G7#3# SV%T&!A:.?TCHT++$\ 7TUQQ;A&N6MX
MU,JJ;34[MNG^;XG9(?O7V1D;>^XN].HA&ANQ;6S4VYV=M?&XG)S.VNBLC69P
M\]KDXPKL@R\'*7Z=#<5^(,,E"JXR%(71]UC:D. ORX8G%V!)Q"7IOO%BNL3[
M#.)$E0A,D+(5Q0I#.J+QG]F"H]04\<N*$MXH(D7IHO9UQ@-1#),-HKVR8=I-
MQ?NY]^IM$2CTS8_'?6\9T[7>RN=/2D#DH'8BL!.!S:!Z5P3Z@H\["=AU5I2Z
M0W-=?415C9]B[@F.\9AS68>747KAH<Y6R+SND':'M+E50,TAQ1-9+7V&@Z;Q
M0JU2- X&@VJ)["PN/=(S3!O:PQ?N$/A(DBOV$);LOJ\LT]P-/!(URPMH.^:@
MM>HVE79U]WL+[G?BW>^5Y0I!@Q!P5(L)X%"T:._U,SMNLP+MI\(REGXZC2\0
M%\)ZC'H+TB<Y4 ,G?QI1:;&&4*O^A/U#BDA2+0^%J$9$+!1I_Z(W^N<BX>*1
MX"3/P&@7F :!9^"[909/ "4Z3N"E8.J9'@H<631(<:2W'2('+O97H)+G29(F
M-!P5F<)2EQR,TTKHC)ZU:DS@.3R68J[]KIBK*^;:DI9R&XKS>W?4.>!MPB (
M0%4$ Q2'L)D.T)%M)#=@K_;^N\N^"36G[-*=RQR5 *&HC.P,WL>.1U_MPGG_
M,0B?%V_G7PWS>'_2JYO+V1SL1PP3..&4&_<2W?+RXFJMVWY7ZW:;6K=]U_ZZ
MMP,OU')P'NNJW@9>.M>R=VHL-_NHMQ TM&2H,RP.EI#GR>V"&).;(O4*WNRK
M+&$@-/F%:2:&I&GZ07#K).+KX*>=->:T[>ANFE5L4IDZ:-(DQLZ0&AXKXYZ:
M2>5@CL_ F"HDFHEF+!&&]$947O8^CQ8$'/\CF4XGBVGPCC)A+4[ZOEX\6>3H
MT+N+??\:];5-9]927+X]DOHW3U_8ROB^HT?_K4-'3%K,]ZI8Y%>)W*N5DI'I
ML<$XGG"K6VK<4I%0*L>A KI2_;#ZR?=F'MR-==!UT;R5==!6%TW/KKUWRINN
MQGP+:LP=(U 2R94LJ2%":-D*-*%,A/^D5)-,)6!D^U6C=E4@U5 S!W+A&WAZ
M%K@P80HJY(F-=XK=('($]"2.5<0SF=BK@F\'O_:E1$%M(OR*4 ^#?W_Q+(1%
MH?\O(#7G:8KU^>4>J<.]_0V#J_#D ^O)Y-<FS8_?VY?G;QJ\A>>_TL\/=BSV
MPUFVP#^W4,E=+\-4,3<5&5XGF-+!JJX)1ZSMD*_!'$S@E05#'2E  3.2HQ"5
M#H8Q88@LV- _551V29:')5A]I@40K*H3L\@9F[?#.[<>MOI!R6&'AF1:9")H
M4;!:69[^7_,XQ:8,;? ]^&,XC9/9$%:05M:3&3]79* C/XU*G4*^SH*=_=W@
MW:* 611%<%0GB%7-LSQ-N!5UPW.]^#H7E:17&<*D)UE>MP=/@UX1$&TC>CR(
M:VIW/]P="&9QE'+TE14+!30HTA$564HK3SDX*<[%DO=%^22;/)F#D$ 80AP7
MTFJ$GP]J8%&2!P8KAOU'X"O__BH\4)HR216Y20['-K%WCDKHP2CH328@0V$W
MJ#4,F!ZI7 ;A(Z[MR=!4*U\9(,YP&EUCRY@9UIOS6:*/\F^PQ#P=(0-Q- :!
MGN7PNTP Z_B07)(#5-\^+3%9T"FG3CFM:$=2XL$MX*1(3GN)%NR%$BDC2F;G
ME19>KCE8W\IG=4Q10][\K(JZ-"ME-<%SZ(JVJP#;[JOTQ@;=APIM %IANI1J
M;+$WT(EA?8RBH4S*1<DU)-BG5O5CFH+V(:9I4')+4VT56K56H461D.36"PUA
M/#;!<J@4W,\1 7L>!N*S$7YW42*0]B).XQQ.#/QFFLP2,F^BO(1?<OMKC5X,
MX3"8>I K>5_![AH(P LD_G"J9T)=HK[1\"F_VMKX=\KL@GD!-<F]G@:<H:G9
MX19,*&5DG&+B/B:R.:S"\8TGM#CPM$TSZL!%>EI2#\5B,B%&Z A^+XD(90Y[
M+$L.S2*C\31S"ZMI>H]5NE,#!3=,__!W@NU=)T4<*J(60^E4/S,;AHM_EDR!
MFU8Q&/. $0U"#06#RQ/"16**J18&Y<^SB[L]:@WLTWH,W,.'Y[=0\2AD>IIC
M5(NL>K:!QXO8KF*P%$%(%\KJG"&T3QH89U<IB%H(;57+0/(175?4WN2QH@?*
M=Y0LWBCX<S&^8!5<%;-\'<U@LVM51P.6](:CKH;J<J7YU4 G$J%K=@1&65%Z
MIO6.L;N;OQ>599:G\;*0,A,RT7?K3'U:15XD&+,CL!/BY"JH=MF*BU$-49"C
M)Q?_$RTCV!*% <(RDYC_AC1T"Q GQ:5 B%=VKL24TQ^X2&<ER)0R^"\L3XJF
MV,72IORR6L?9VQ]<1[B*_UPDN:;_HN::Y65.+3F;OQ61=4=U,=R7(@SF8#\0
M$FB">A+$+R(%@YV#_]CM?)!. C9R#_2M9D%*YT:C[VEV/8W':# P6D[ PA;L
MK4H;T(+YK:W_'(4)W?T+- )MIB37_Z=(OT*=P)\+>U*ALPRF9M] E>N"#!S>
MK_.FQEDL%?C&[(_@;H*,0#X&C(? #%%TP4.G"4@"[IRGC#42^;:\9%%&6W*=
MD#LQ0P&+,L*2SA3"G*##R%(8Q"$()E0M)(_'0DJ8S>?PD04BJ.%/R(%]@0;9
M]64"KTKAAS(16ZHZYX1,K82)U"KUW?1T":7^A::[E5JOI_]S-XD#;3);W@9M
M.E)7I]D<+-M$BA1'T72T0*N1%0#8]B,0)EFZW;9<-7'_HDO<WR9Q_Z*EQ/U[
M%3_T JA/X1=< U%8IU9AJU2<YBP&&<57 )]ADW+Z'HH;[K')/EL1NB]TP,-J
M)(UB!V.S*JX*QHK-&-E +UH;Q(UU$:]E';4%LCZP SQ>>^HA&JML38(EYI75
M&RKXFR:5:J#95EOME.+BBKBCYLF&'9FHD3&0C=#,2K!;A]N'2T?K>=/#")69
M'4,;Z4T(F-?/( .U)N*O6BS Z:# OR%ZY;[(*IBPW:+Z,=0$/>]J@KJ:H!]M
M\/0 ^CO=>WNG;8OC-:_?Y\'98?_3I]YQ_\O7LZU>']\VWGO6]7>ZC7&\]ZR]
M!D_YHBB#GN Q_H@0*V%U>K(,I4JP09E-F* 83J/T>S"ZC$??R=G%;V@[<9Y=
M(P #38YYGER!VTK/4-4E\'6-Z("W#<4S=U^O$@J585!HU&F$R:'"C')1BT*:
MW/<6%SC1-V&P_VQ_KQU<C1Z3GP<R(!D,&%Q?/RWBT=.+[ JSDT-,.Y=<[2B\
M$C['3U'$'.@IDD*'4T91@3YVAOB-HN9;5)&-(1@,HX[@ Q,XR5*PC;N$?CK<
MGY&$D80F" :VR#D0P3S_-<-CY@C]:KN! FDOL9V#DHZ>@@*I@,@P3N-)4MJ)
M56R#BC%Y&8.,N"CA0BNF%I4/I[U 8 _^<O-)MW$<G)OGG8AU5R\I3:\6PK@X
M "J^%N+Q^07V.NX.%D8:Z_@/H[,NXZF^0JYDH-=*#S<P/>*H<+O5<BX&MV>2
M@T-TB;[T>?07^<%88H;=E.G$)"!1H]QM2&Z]SE30L2,N$Z;37#LP&1-(>\I^
MX(3@* KJV.1LYM,8X4B4R<R#6:8@:SIO2F^QPW]U,HF&FC+N P_Y"1PS_+:$
MVJP\1E$KEHP(>*NQS"H@J')::K -0U#P:7+ IU-P9W C,#$RA[.<<<A0QR@+
M$B%_RMY7BFZ]10_=RF.5GU<SXG0Q_,[;=0X65G))<EW56%0(!78*KH"T-9%[
MFYH7Z[M:<\W?NC!M&07^$760!1X0;KL,AAYK!]\(S)D)KN)5( 4QB^%0P&\6
M,P8V<+D3S0($;#9*(@5.G67C9,*S%ODWHD,%FT#NO/19,LEN^ XXW[#$ 9KP
MZ@,T7$M(X2;/B-0#)OP3#H:<725G<42SN8KM2AYQQ8#@/L)SIEB$A0*.SW1M
MO@_7_BG6<:MK09H)OJ,CR?)\LGUQR6HB]J$,DCEM6==,)LDHB=,104XD]@SW
M6#*GEI0<NPE2^4"2Y_%5A@E4L$TB0I00#S/:9/"%I)P2LEBE)?-@-(V2F5J=
M[PF!&TGN4K><)6NV1,E/0K=0)EE%TV#Q$LX.5,66E6C%CXZMN&+!R6 L.=TU
M) :%@F06<?P=%R:C9*^=7W;?($EF%NSZ^9JR$0M:76Q)6$5B5 J(%>9'IQU(
M?BLV%Y];ELZ$-%ILKSJ6T\=4%LRP/<;QJLK%.+\B44'2CMD,N4&2?8:T[-"D
MD02IP[O(IT3M@Y7>X49*5'$\T7^7,Z% -LIX(\6K,*J5O0SI><*9-5*8'25W
M^$$8@2W)AI0W-@1MUV5UG),IDYMH\E$Z@#(.LOD4?F@C#DD"W1)Q)*7,167;
M2/]A-%5-?[01F\<S6#N6$W4WB0'@%^!8P$?$I:@A]0M.M<0K=E=3;'AZL@&N
M[*C.W:" (Y3AHA4L!GGI3'*2BUDKNDC@43">R6(ZP62ANY3&3UI$@D9LFI54
M,2UW;WS2\4K3> M'<#8(.?>L^WX(0?T(ZH]W#H=(-+2-EJ4G":WO&L]!6YPD
MMFJL4[V;2D#)8+SGS(54A%!QT4B2%K3GFK.=!N!;X"R!Z>$58YR^991+S,J%
M0N>*J2:HST@[-XFNK9#S6K8\6NSC!9S,A 'YDN*NJ$MU+GV'&14:KBC^G2XE
MP9CEC,I(&=-R%8$ #1WF+NF71[/B&VWUO?L47<,J.13A]@!LH-12(:7XT*%C
MB*\8TE;@C,,:<16N00GR"2V9^]Y\4'F-TOG.O T5)U468$NT*8E.^#="$$(4
MRW&)$&Y/7*N'U9@3SD&PU+0X: 6#A@4FK+,UZL&6OZ7$OFN3R\GF;56GC&6*
MJ9$7<]P>W8[H_3FE@.@+M&9IK3H;QO"LB2P%S'SAX3Q)4&I4IZOJ;F_4./@W
M&Z)2LL#RV%8J+/\/ZFAY)^J'5@V_K$(>]7:ZR>4IF8W:&3Z+)WRI$2LTP#\7
M*:.U>8BA1,YBC$;A:/@(Z:.+= U@(X_9GT&>K=S(8S9"YI)WC+7/!!]G.TAG
M'=E3K+%.M 3F#=WN7&--Z+NC>[I=Z+LMOJ=C^,T9\99$%+<\]=MG_*';9]#!
MU<JV< +D3B2KD7UN-7NN6-%HX&A631LB8-?OX#6I:[OI]Y?="+D25J$K'J,+
M/JJOZ41Q[QLL9C,MG#F&@AE2L-'RB*$J1HQEM!IN?C*8M.:SAR>K]#0XM@H5
MO&8H.$_3#J6NA1))3-(N<5Z255:*((>%HQ56M:1>1?$-EV\S!AS[^_%?\6AA
MXF<\B&6#;[*6)\>8BN0I%[PZ2NNO'A5:?^2KX ])2EZH'I@V=L'T3!F9+;P]
MPK3%>'2_JJ=T2D_T#RUSB(7>373W,'2;&RJVM#H'>-6B5F/S9D5S*; 18(\X
MM (HZJ,JIK8^UB]U4% ,!?EUCSPA9;38KU"WB?Q6&*P4#B4<WI-T2!^DXX(_
M_UDV6)4>3YC3<9X5:ANS25L@]E\8,O2B@PQUD*';0H8L^[4C)+N=_=H6(QF#
M=5%!85OTX+\6X,..$QJ69:!653_5-U.P+T1G<[XHN3]<6N;XQ$+BTQ2HY?P7
M3W7'\BQ'$O''C"$ZN11]7CJUH[M.SMCVQR-J$R>N=B8N=EQC2GF><3$"FV+!
M[G7\%T<N4>N4F7:.K;Q$:-E-J*CLH'G%<O+>1,NC5\=>G*5>&FME_,E9D00]
MO;&RW5W#U+)+EUQ5QBFD];P95 W-U308'U0-^QIK8'9#X\I?T-%1!AHS88"1
M6X]JQG6%$Z:-1.HZ@#\<P<1@[+&AA\W!U<_U3$>7Q*N""P8FT#1A<EVD[M"6
M)ZT/;JD^7$TOT=7R]*D_K<,N!XTC[2:]()%*.\^A9H'/L9_@]RFIO+QM0EL<
MU%$&8JM4,S)1&<616;-SJ WXNQ\./YD(\>"P%^PX!:6[9@LK>91Y#G<CF4]9
M*N!FT1IZ6ZKY=6*K663=5WF;I&! +J:*87I;9K:KNNE/@]J*."L$:X4&K1M(
M=R+RW!J43U3*61J"A^E21= .LP57J6';J)'VO.K/*#%VU(7*0XL[PCU[&$>C
MY9*((PP0_*+2H$8F\9@H$S#E6Q;,SN#\3A>K5 :DTR'S>3PE*<M?X/1ONE1F
M>RL(J$/$T*2\OCXF[FGP;JD$N&XC0HYOM=(-EK;F+%CI_M\(#\0M3PK%0#%=
M2DY$=R6BWQ6+X2PIK>-<OVGB+]LST'7=]JG3-#%-U4'6%]095,^1W $JGW@V
MGRJ:K/NNK@$3YXUNEL1UF08]D1&XB#Q>*;OA&NB\Y/1AFETKMY[SM-R7EQ<7
M;#Q!S%S%Z2+60!03!*Y,OI5B*LO(HS,C&2"=8JL#EOBP#9""T=B@2K2(LB>K
M,7WJ)%!$BB!TV&XS$63!8O960%!NRHEK32G77.*BT7O!7F9.\W@2BR:9$VH-
MA,?Z(SU$%(NR4U@*H^A&@ Q#'' WM3#A'!5^$P=XU3R^8>X=_:W;9A4+9-GO
MF@?.$L%,O8EBGCUA*Y.H_3!-5!1^>!9!& HZ2,BN*)&N\=:RB/%,=N$0!0(V
M?XJ%?$WBE(A=BY(I)IK*19YJS)3L$X&A,OM:\BEP^7K @X:?T-ZW"R#;;CT"
M&Z*YSDU\EG<#+/DT5M:#G!KR@P@#<974[TE45"H\L0Z9LWAP,]%XQ/U,"H,W
M*QE\ET[X=7571ZMP7F%YLB*^H#)KY199(-/"ZM-%!8.2>5>#16H*BO3*1KDV
MSUST''M KNE#%'A3PT+BGBI"7]N'V%F6: C342=/  !,D5(QPD@^%(M$<V?H
M%S;MEGH);Y:4ID9ZX33*7R;#:B*% W)3/4RZFP>O!F2Y@Y:>44-^<.G&K@S]
M=N&:MNK0CT&/CJSJ\Q[KPF0DY@)?%(0V+%)Q@A"JG(F^J-3]6C2I)C6&2'BT
M,<<:M\&5%]BS&SP[^.=.M(L0@=1*9B%4@>1:&.P,*W]ELPV;>%L0/$XN@8A!
MU8,O(LP%O@HC&RL5U0H]A2^)J#%OC+2%,)Q193@@.=['X_Y?QB AR*X:$'/M
M9!<IG)!QP!$RM*1TUDQKYSS8&=<]?1*-J$@!%('D7L"C4X/E<FCD&8W'%'2*
M:4H[%OB/E'O,^:P)RQC^D&89$3(@-.VB19EA-F:$82%LJJCP%$B.,4]L>!T_
MA$!\..<QG1$Z'*J?N?I*,$[&SHO,(,#15ZJ>J.4XR57\MMVMM5H1<<B\Z5(&
MPW8K@L0R^S67K(9OB3(N__:?GY(+XE*XC$#DCN(%1JJF13  WR6?HT2,?VJ7
MW>:!;3&=5?.@&1 %LF:^Q-"HX;/P6(I8@>S>WWE\%*O[*0*A.0NHXV#P1U1^
M3Q"<\NG323O#V=M_^>I9\!$^&KR;@M<1'.7W9(WZ(SF#O3Q*X@N0<(>]X,W^
MWO-G[0RDA\SLE+3\G_]C[^6SM]7__1R5()NO$?5P><]C?+5/8VP:F?V_9Z.L
M1*1^'*7M+&0?M?YO&%E^:H]K"*OVOZ;73\'<W-[%*W#QGA:X>/<ZUBW3N9N8
M*1JGWMDEOB2!@951<,+5I'9'\4,P3)X&@T$[XPH>I.;<6KODP9S'/V*,U7[(
M2EPW,4$^1RF"\ELS0%Z]?!4<_+U8N"^F1[UZ>N _"S%%"+6B<XJN/1CZ E>#
M7\/C2E#(\+#_#'J4UGDT0+N##FC7 >UN"K2[]\N,#_U'EG\/@^-_!'O/]@Z>
M;ZL)_U_1:+I,@T]/8?$OXS0,^L4_[]OQN8$Y>AHM9UDZ#KX\#3XD<?FO5L;K
MF/6;C+KI?_\$:97$8%3#RO\ON!73[?8%<E[\IQ>X\O<\WJVU+>"US#9! 5XA
M%.#P+L'E=%)7PM(JAX#)/8XT8SD/1CGQO[H9FYU:&&)K]._*H+N_)-FM%KPF
M2W;09<ENE24[:"E+]C&.T,1P2^PNY9<U9/96\1/1K\#\2RJC(] I@V:(^US@
M7DY_<:O:)6%6^GR>QW3N^?L(BE5(%95V-T53*T;38AG,7=V<E]W-N=7->=G2
MS<&:,+@"^@@VU #84'<J;&,@/>>@SP1AKU ENXKYH*F"K:9YHRY(+?PN:C&/
MT*!O57-E6S?Y-7&,E6(*,P'("F252:$P<QV/8X%:)2X!D4MZ02)DDW>2.G5?
MVC8"7&%:BN@[N2NC:834["'"ZI)"33++QBH?7%.3RG6S:L$,R0U3/FY<"^H2
MK*M"52930Z8>JZ4.]N6<(B-<HLB_<J<X5:&/&[C4+8 :CW3'(K-K 8RF*M5;
M:]5S=^BA5YUTOY5T?]62=.\A9Z$1:DS4JZVD!V9M=-VA?K [5.1UA^KI(GMP
M[<) H.5,_D@Z42%9F"DAI+HOZ5T'"H4(IU#@#C,LWP*!/ 9%/2JY<S+BF";@
M_.6Z5A]AY8@HB[A#R+\0NT7 =]M0%@(ULJ.YOJ*.3@UA6*KTB'C)T"YI0;2_
M,@U$!#FL6I6KB\>\L6-FADBRM*9>D:KI+/O&\J,9?&I0QP4\5Z%B=U3#[31&
MI#@H=M/)@SXG-+.[[,<[?D9PG"D6+R%;\,I@!.LJS3\-UT(-7I!*MW3U'A\<
MY!U<# O$Z.$$_:>@N<6J7N"^U]'2L&H6NAH2QG:5Y*6I\:A[.D<Q1MPS=A1O
M/+>J9R9FA5<DAP=TD4XQ.@(FR309)=@VTFG:;",J]98Y354*KLR0/JN7(&$4
M@YS%J+8MK?RV.<GXZTCKH2>M/8=,H/:*E5B+&92JM8QB%,S &^%+X36BQ^L@
M=+>2B+'\[!G,0*>@]8X=C-&@KTC*AQ='?-W9R[>REU^W92]3H_ 9,0];!WX@
M],YOD2OJB=N6>\L/92>&[]AH/LZ,S2R-Y3GJP*8+U4PB=R$F1.#G\8(.42VQ
ML=6H5"P;%+Y@35$(S.(WYAR-G+NG =KM4JM)>'QU9JV72\&6:MX^::TT4MUD
M8U6E"Z0$ ZE_E27C2IS1E-9+61LQVS(EO#2?QQ6Q^GTXE?P<6'2K%$VQ']A:
MJ* R:?W!*U>@Q<C$QV#?29$#*L[9G*AUJSF#I!!^7/Z@'K+APS"E?S3\C(BF
MV<\YD9H9KSI49A#:9C"Q@("5;0Y0EG-!)_:,K>-HBW5O2KM>L8UM-^:+0GS9
MJ\9V<$WS%EH*:8]!7*%6DW-FBW,+#(=2CZ<LC,Z$[F1WLPD-]QQEK@KKXUWC
MBR]2A?F)\F4=4S9'S-51Q-^/?6;O^B@Z'EFVO:US*[R^H:;:$!YUPP[TPS1(
M/\AM9 ^;*LGUD&V!RPD?GD::$6UPG(<!.^,EL[H3^WMO@@UDN;>,"@R%=L (
MQA%=T"^QHC];QOA))H@2[N(PF%*!'/P#"Y73$54]<^]K^_NS>#:D?Z#?D]*_
MX"^I$J@NCZ0$ TBED^-$"G,$"XX)BPSWG*@15'/4*BF'1>:(3X))"CF_(N2P
M^1T]?255V+A,\F'F>> -%Q9JE6*27ANV E!-D$PCABTW1VM\I#>=CW0K'^E-
M2S[2F6HH<F+D1^<+_1+ZU/>%SGT2+5\CFC)C[$<E]KMJ_M+@$R'/(#%J8% <
M^Y=,00K.T Q6?,[(G(,LU8C!Q<)1<0_^7.1+T_G R=3K=BI:3(-&^R>U1A&Z
M)/@&4LQ5>V[7AXJK^O(ZEIXEAI6[D?%:]^31V0[ZMF'[8+\M!O>H1P\ 33?5
M67LQ/IAO&"FJZGBL:OGWB16(^?NSU&;SIYX!&;'XFX!]+)S \ .8[6ALZU]7
M9J\B[=I1E9WP^OZ(_;,&15 -$!)_E).3>C3E 2^[\H"N/&![RP-$\ZB6 F*E
MKJ2*WP8.J#>Z-7*HNY>8;CK743Y6/3^)U@CM?23UR*DUFV)N1(*MF'@I'?8@
MR^ ?Q[P26ARGGH=IB62AY. @"#VHL3T;AT<L;LNAZ0EDI*"]![F;J&<H6MVC
ME3^C>P?;Y+L6U5H<7""[+/-]1/+R;8FN=,&5+3 &J_E)8WTXC%QL1Z&A@M&Z
M./ZN+H8.;NI@Y20S7<I:)*P,M;]O()""5%#.. -7=.!?M]@T5I!JH22=G.QX
MCKE]:)0)BUF=.6S3_^EF8R+/&GKT,H@A9)-)=?2K8LY;7%U95$7F:UI]4"\+
MW4J9X!ZZ5Q:>#&Q2QET(]7>J'397/6&W7B9:*]_FL@SC"3:8CO^*\Q'C7WQ5
MRY/DX;:G48,=,MJQEPT.4JE79OPBS6.->1=UHLJ1<(R5N["I_IT6PV"E/4Z;
MN\&6SC9>'\Q$Y\2AO<%U,)V0UAMI%OYNTN;Y8OM&M<K5 M7+A7GS:9"O2-3&
MUI&B$C;-P--,\D;&-!2A1)YK-L1-#U5C(@J99P6O]A!+.O%<2V-ZJ]U3#0>_
MD.X;3*-YO+KF8MT1^D7>OP5GS:+:9!&]JALVAB=T[U?J]L<"GC+8:K)Z.<6;
M4 R!-KEF\^)V <;';5..?)O2Z0X0)Z5I%RFI$^*$=CIZ4C<+#C,YL2?AL'93
M7IN&H>K%9=N7$\?_1?K 'J&,EWYKBAZ2YCV4]1,"7;3#R;.<<;_WB93Q+HA<
MVV)C5[2_8)['Y,R&P7RZ*(+R.L:N(SO[SW9-\["C:,F@;S([K<)B1I/#H<A
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M(4[L;V6.U^\.KMI]2+7_^3_V7CY[RZI6M@7$$@JP_^_?GO_; YC WX?.2\3
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M"_=M$, C PM?88FEX%'(I9>=7.KDTM;*I<=A;.Y_V[L[-VW_A]VT[9'<=[5
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MO$QPY7\H=*HJ6/+8LM>FF:@J7SS@+#G9H^EXY>;$J=#SWS_>T93'Y<REJ$$
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M>:9Q(PZT NL-VK9!U4WB& 9L[?'F/M9BL^*U(LYH9[/@LUEAE@$:%2X@9M[
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MQ>%2(Q8.L[M5$<W"MCC:Q;@JDT<4B4+HH%%.H @QU)!G%!H,/<"!?3L0#]0
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M^(TUM7:%A\00B#C)N*;")^31'L @NP8.:V/#J-(>%\LHC141J06*$W0,WB!
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M!"HT] DL%AZ7A:X(!F#J:&UND]X!8]6>0(0&R<])3*5#\\\E%\NX&"4FB(/
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MU4*+JHI[;3:57'G7()V2_3'N/UL<$A:+1WX;D.RJ5>BN]O"$E\@)K#/B?;M
M[!N&Y2S7X+@<4?[$0)RL<5/#)_6$#M]M1YLS(QP_]J5NW[V)%)*7==&1^367
MWE<;U\K"9(PXP]^=#H036R^EZLJ::JUSU!+&GB0D"J=DDEV7EB-XA7$A"';Y
M[+<EB&D\YU]:.46#.SP=UF'A%)-9,W8FR%21%%@Q-V11R$"#2I_6:V5VHB(5
M36%;:94_PB&SAP=F+08K052BW&#B]U7$^GN!5EW;6+HU9D2!&&X&NM;R,JRS
MT63P8HU1 B)DN35 YKAI)B)Q%?F%37VD?E,=@=P0&B<GS1^M4,"-S5TF"4)"
M#:,SZ8U*;5L-T]X$]&F=C*OLAMB_]L2*:EPEU=,!K[[NP:L]>'7GP:OE9)_,
M6U#HY"4HPF[#G<DG<R1P-@?J<S*UP^D+"HJ_NF]"'.-?PS?I%(VI<E8VLJU-
MZ,%[33#NM<)P-=CK]#>N@&8R_5(?IMG$AQ'/Y7"5YQ+1 UXPLX5DC09<Q!XB
MPJQNRX!OW-;8S^% %.(I7W*_VK5/)8X- A\0[ZM78L23NV8P,N2O;Y,Y\P.V
M<N&P%^OWZ(['=B,8R)?G8&*-IAD,I2HG)RZ:WH,@[P6"?+D=$*1;1-RH)WY2
MA.3=GU0SB>9I#X5\HDYV"PIY</COY/A=\G[X^\'1VV3O^"CY;?#O@_?O\,/A
MV>D _H5?T.\^##[\-CC!;\[^/3"7_'YR_.DC&"7''XZ&![_=Z0YR"=^!?D1]
MU3\=O1V<G)[!WZ?\X>\G@\$I7'%PEB:#_SX<?#Q+#D[A7Q]/!J>G[_]*3@=G
MR;OCD[-_)_\>G R&1VDR/((K_X+_/QR^?W]P\A??X\/@Z"PY/C'?'AX?G0V/
M/@V/?D\.3DX.CGZG'Z3)T7'R\>#D[*_D[!@>.CQU%Z>K[HI?'<-KG?@?OST^
M_$3_QL<-/GQ\?W V>)O\]M>FMS[%F]!]_QR>#N#53I.3 ;[Y $?_.W[[)PV?
M_I)7^_/@KY3F#B<$GO5V>'KX_F#X 1[X_KV[_N!L>'S$DVSN,3A-<7+IU0?P
M+YA;^.2W3Z?#(YCL 8WF/:S:\/T0?TQO=3+\[1.\5)J<P2U.WPU.3N -<49.
M3^'5W^+]O)>70<$OSOB?YI&R*J?FM7\__F-P<H2S</ >]L;'D^,_#M[C^___
MGX;X#'A;^/G1X!#?@V[[YQ!V@;DQ_J'?!B[^-,!OW\'<OCW^ /^%_\&'G@X.
M/YT,8<F',$R8&WS\.W/IT?'1\.C=R=!N$+C/\"W^&FXU.(*==SC@"?G+WP<?
M#L[@;CC$0W@-N%X6F285?VJF%0_$Z2<X'[3O4IX[NP:_P7P<#O W>/7;P;O!
MD2S$R?#W?Y_1Q8.SXW?O6J]V>/P)WX>6/J&I@7?["--E)ON 9\[L,!X:'I_#
M]Y_>TL$XI'O@G!\.AG\<_/8>MJ",)#;8]X/?8:E./[U[-SP<PK#_,C^V^P2>
MAQ-[.OS]B&?3'!"P80<G9T.X$#8)']/3LQ,^.V\'[X>P%63OD(# )\)-_QC
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M \;UM KY-.CO1-,])=X2KU5!&I7P>)_=I @2*2OW5-&WH$UQ^#N>P0PYM/[
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M_,4"KSKMBF*S-"^:9._S/@ZW7K\,&(&%6>68T#5RY,WG.0M6V/ 8)D'0,4X
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M/YR(YM/Q5\OZZ<BF0O'(4"P*W8*2 -M!PH_R,!&P-7=#Q"<;X@>,T@DC5,E
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MA ;1AET]#J8=N(!II+YMR3S#U#5W4LKF3=B#)#@1+*"OJ/E)#?_!-]?TAC2
MU>Y(CI3Y!C/I+*(WV,'[(K=(T;HIR['$G'C:>2?<^M<EE\4U?E(5W$Z6!B"#
M1^:(>2M2:KNK!>VD[,8HJ^#@:\0K_\@&CD9ES3UQW6UPJ"N78)_FF$B_L_DH
M=PA/Y5BTV;RWY1*]283N<M_,VQ><' \4>8>38V@?^I/S<">G.T%AVX^$)\AL
MD)4GB'_T'9V@WFYX:@"54:P%&^<>K*$=19JCW:T,;&=:HSR+6]/Q:D($7,T(
M<HK5",BY3:<.S@KL>TIU"L L5S+)@[':ZX+*#3. 0!2E'C0MR+9HO)M[I^"'
M;;S(BA<,LK6AIZ#EXE8-S#0:[]>L4+LWYJV73O8-)+<JO<:!]!IZ096LKLM1
M03%![F0;'/.@^FL]79E_/:IN.!A2M]=I+9%H4H>',Q!;J0CQV S\N:!1LV''
M266>0K2>W"S:U(BMA9CFME77Q#3*S#\OL'=8S>)X"?^<^C5:WI-C%JW-=0>L
M"S2RIU)H\/I%7VC0%QKL;J&!"/65!D^ C76I1JY79/#[9F<^==+%VFL"\M%E
M66B'@-CFZM9(>:GG^O6>U;?K?_3J?.B;U1>W[$KW_8\V-V"<;G[E&S(/M0V#
M-216"%I%VV96A<6-3R 9W55P"&ZXS;5&_A/80J!6.\A=80$<IO\<M3KUSB5A
MK,W#(L\JK8L6A;%.RNFTO#'54-T-:(,(4"KA,!HPLBDD5UDUFV+K/!4XE_EK
M<E,,Q3T-G7MIRD/M1).">%_6MC@X>B\_HN<5)X7<O$1.D=4\-1XF)B(>P772
MT<MXJP=G%I-=QZ6A&_!#Q/Q<>)%%=DL]=6%!9_X _<KB;A1Q1) ')>Z4RV\3
M-9A@:BJ\!2O9F?<N]J/C.,!&NWAU^(5I0_N%S\5:LA$_6KK67ZB*N4VV?U?Y
MQ7).^Y5U8N3[5@.IF@.>S,"0M\XNOF->< VS-+@T11#1F*^X/E:QS["$KK%$
M#(^CM:13>:_;*J]7=O=1=EMJJQY1=@\\ M7A".W@[TC)>HG*D*^DDRO)2T_K
MQ,H:[2S2\ZMHY\B]OK5VCM$8W4$I>[/VA4HY3#G?71??2P?+8ZWJ#1J_?PN-
M:_GXG[+&3=Z98^"?6(N15 F?&*N01R6T.P=R9UI/!J*!DF1904'?;,4I?73>
M_P_G'ZMRE(^1,P8VL-*LO45T'XOHA^U81&X120P%!M+C"$WU:;,O;GW\4-OM
M+678@L;:R;'#/H>YLS,NU:'8,5]EZG6B53H/GU+[03=J)DNBI9U(I[5"/,D>
M_AH!%??G#G1W"\D"+40#,4AH.E1%0^H]EN*7CL^$LB*C0HWR"MR'<8X6'44\
M\,]+L/'F#,M ;#O^:8%7F>/C""T30[BX<?FYRU'RBC-F31*$[/H$4(3M:GYF
M_;.#64&)06B7J/FV]T5<DD9\$SJ.IB[8%[S^L!_0[;M]-L&EV_OAQ_UDG-VZ
M!*M9;P'+U U[-W 9?8U[J4'J-]A=(_;=LEFYG#?&L&G;;FR6YER/]L^\O)FG
M28R<&$NU3:G:#.S[<LPYY-EBV2A[&/TJ/%15CHP+PH6ZMD+/)ZY4J>[.+5O8
M@:-P"8^&\+9^AS27J2O*,'XH>I0\N.@F<9 Q4_ZB-XK;KZI^GX%DNL[,!#30
M+2FG.?A0_O;IN"4_VU$6PAY;4OP#*\VJ@OX)3MG?X%R/#-FD%.R8$R%O^1ST
M4?01-X5Y0H8^=<'[-GK(V"\%-9@7"^8M,G.D!.0V])A?.F+=S:84L,>8SUY3
M/D^&D\[E@XFJ]35R+YI%GIE4?#A;;LLA*<[FTN]D/F@KJ.?@F;-:?U1B.*2&
MN8754PH*JW1R OPJ3I2.P2JO>#CQCK?^E;Q)'7D5$4)84R@N/\,0:?+*:2[D
M2%CZF H2N 9)!L,4E:OQ-.7TFN<@C*X\N$(;#G<,7=>#ZW:"N^ZA-F+;Z'=Q
M<I27@O6MX-S/I!DJA;E<'$F+#.%AE,@G%FH43((=QF/"5&8LDJKJFCOQS'O9
M_2VXUJNW6,!K5X 1&B2>@:SK,>[&J=!ID(?/\YR,#AGK?(]DCT<MTET5;\B(
M:_BK)D5P8:*C7(&W*(1:6IXV$ISAN!PMF<N.U.FU8VI0@]2=:_&KU@SOLRU)
MUB'&Z<EH'6.*=YJ:K=&Z",<W6S13I@'R>=E%3Y!ADL%^YQVV]WF_P^JNDKW;
M_:2Y*9.]5_LVPIV\Q2^]8J )D8N.,4PLXW)X*X/(S(UJ8FN"EJS]RH$5$C-N
M)Z$)US45O?7K6;]NMFR,/K)[P@,HXF:!*T*[OD;\Z/QI6<YPOG#;I7&C;IQ/
M"VRF(B-K#R?=Y-#!*/=>O@B.T;[*!KGG6DRC.0;6M^P6.4\&>_RRQQ[WV..=
MQQX[#:]*-4;ELL*L&M*N[G^1ZG^>O!-T\0ZTZVA'DK40;K=?\-6RX35WF([R
M ?D*1E?Y> E[#Y9S[]>?]_>N';'<KOB0?876;M27JF2/&,DC8<-!0HNS[#-J
MVO$801*&A3K'CY,/LL,]7V5@JK-:W[;R1.ZFF3XF K!0A/XMC%@&E\]S^*1
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MI[]'Q/3>PGPJ]+?XE8A(W! (RI$]P8(:\"(%\IDVUL(602/L:89O3C;DDH!
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MOXC\U,C=0<445',)B1>!(6 2MWBT\Z<E[ZGK'.M,,T(,0*WNDGK'Z0%,U)B
M K$K';;\PYF5OM,7U@=D\KKF<Q7B(L@-E+;$*C-QV7=V+CU$[VK$*U5OX_H.
ME4#EYP;J1?KO<<I%N=GMRB[U09*HRQB7=/&&XP8^AA!2Z8X7BM<CCT"PC"D;
MEKY+\;#-TB+&U[P/T@;5GHIQS=J$U"A!7:LWK'6#)BO]'/9MUSJ1/WSM_IY&
M('K+08(K5##8_QX3!@9YGZQDMAO$6;G<D" :D*HXWDJ=&67E0=;0*35Q&$]/
MC")ZOBQ88X_V%I;G12%X["CZ!*@"(PP6)19+-];R!VTGF#(<8QXWBR0O>ME
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MHR!1?A8GZ7?.CAY87?@M'#<2RMV?.X@P6Z*^:@'U2(X$X(6XD#HK)5Z4>M*
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M))$>_K37Y9!V.:3KV)9+^)O#M"M/UFWI.9,Y*A03%60'6(#$Q&51TB@[:MI
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MI/$QM?NLS $KFXS\/U?>O/ YD&=;9W"B1TZO4<K)*W05,3!V&5,\'NI6YNJ
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MH=S!1#Q]%HJZ4*0%QCJA""O,/9_J3M'=5KRAG*= UH+]LS >03+C*8L,FQ(
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M0A"6,U(^'<B&5. N.(/)M&@2=B@XT/,?^WR0 ]?G<Q2:_[''X@#_VP&I #^
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M0L+2;DTRD+7,7H&"53X\"]"K]4:WLDCO/D;6T(J-9(9%5$5OMBK1W8329O
MB[IJA%?OH5;"IWJ@(W\0P0_SV,JF.Y3/JHQ1)0)A7:FE:ROTW<D5GT#(A)P?
M[#,@OF],GZ(Q-X4[*YEN)F-0C0E>'[\F!+/ 4%<3B-EM,,P.O07,W1FD(:4J
M-8.6F9<]"?BRKJOO6C7E^J0+F6_%/:9JV+'E\ ]FGF$FW>*.0$&[0JO89/!S
MS*GCHHZ+6N*B50TL)0<?6\8%X\!+2 <N@#<$]WR8C];;-?$D-=G10VNRAXS
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MN'.0SL]<MB^T&1IWOCS$6O>C'[*/W[6-=VHB8')2.&?*ZB'@W:J#@'F.W3_
MN_ 0FK::9+2TIX!I*1 \6$N! G9L93L!NT2$,X:ENP"1\NT[# 3-,_R1+0:L
MF2WK,5! ^S[-+@.=:O%TH,9_)V$VT!(=^*@.@M31VB.S?AJ"!+;21.<CFS0N
M=X@OGY$-9U6!_H:7:F6&/, HR$@"EIJI-R2T6OA&(D +@*")U(Y4=9H?JBQ:
M\UX]QV6J3EWUM>8D*F-5"6<7NKZN:.6H(Y1Z'Z[UD$P$+\2C/NZ*((>X+Z9N
M:\D'K@M'CD)(/E -\MDHP0D*"" ,!4M-F_*ZC0*/KGN9&B-IL:896<B=14QI
MZ35R6%M0#)6UL^I:&<T*9RB'8A/\%LV)-MB>E8_UKGRX<DH[!4VK8-.@V</L
M9EIOJ4*4U9*;&WJ/-)!SFH_^M!:0.Z&D11_1]O+*"_1S_F*DPOC*_2[MO<80
MFHP[EUUW:-V/$_PXU@G](T12]2UX&)B/X,E1I[-++H>P^,Y&C'D!NM?6WC:<
MBC]M709V#Y$Z/HRSY3UT%<&1GHNV./HXG6JU3Y VM-LH:B;<RE?F]*F4:>H[
M#F,^Z05D><O"VR%AL>T^&A#[@[76;KLR@:Y,H/TR@>7'B"H*[CRG6501.+1&
M[*P)WGT0O ')U#T0W,'E-GE@X(=G(&."LO^UI?JMLC L2UXP2SP#;UU1F4V+
M;!O4C/0A<U!-N&T3JJ6D5Y:6YT:(9:Z-HA\&J569/@F2E&K6O8O$FT]KS^=S
MK[/N'YDGJ:W61C?O0'DK:ZM2JFL7CJZPP#!(^WC:7%I!@GMH<FE D"=F)FD)
M$+D$H]BH%S<8[$U&^NU0EM=1 &R>O;>I8JRM5AX_OO?F#5MMMMI9L\DV9(&.
M<NVH:++I"2"]1*\\^'J,N.K4:P VGE@;_OU1[3BKM5'WUY?S]F_Z40TZ;_?F
M!^G4:=SK-^G3>8<VG1:<PV8TZ>P.C'4_,-KJ'W,REP"7K> VUCO8A*];P-BE
M7< .YEEV%*72\ABYX;+PT5L?&_1#!H"'G^%&P?BD?C4HUMO +1J<GE1\ERZ-
M,54>"$=Q),QCZI8)0S;U<'X\&P5145<]T1"0E4E3A IGWMFUCXR_V^K^\#Y.
M8"@15O)C:I5SBL=YX%L]HFQX;G-P:@ QG0CHZB1 5S>@U=#<14+2Z6IT,DMV
MN-K)X\=YPM%L 5\DX4%M;O"QUB/*\L>H@WDJLJ=()64(U(E,((]"[VJ2AZS*
M2"]<U[D()C@']*]CUI-N\L@3,?=@:[H(G5MV]M8<5A;K=XTH6[RUM$6R\(N5
MLQ'(B^?.O87.7B1S6_8(%4BI#K9,;5[Y@%4BL^JDLE8F_=;6'UF-YA9[05IK
MLEG3NW!YJ6'44HJA$!)<N??ZY4O.+F7U^2VGG5U65\!,=X21*TSC&WFHQ\'L
M84I( Y,PI])H60_7^1KX7S$VT+ 7W[]FG8;UI"5P6_U#JB9Y#W2#GWZ+(X69
MH?00%"SH92K9YK8R51:@NF:_*$JRU+",,A,R6L.FM 4K9<$ V"8X]/%7I>8:
M2R!1V-83/Y5:99'"AEG:Q)K53G.2V/.3?(!9SFB687F6.K-(S+>TU):AN?%7
M7&0\'3*< OLIM*BRFW4B^JB,O9!7N[:\XJ/DT[#GG/;.SP8GY_K"_=W=O:+5
M7S&[VC3$)$UUPI)U[9]Y$J3C0#<.)9\PV*U25E:9.NM[V@#G@XR.&A;;)O,)
M'^"6;L3^PGF 3IL(?])I5MYX!NJR3ME*=!(SY^=BPXJ2 _>"%K)]J,%K.:)0
MMIG&1%-PG31GOPN<9+Y2E,7.R5(CA0>$: 9Y0A<U3-ZUO-AX5SPV&(U>,@HR
MRC.7[E;:Y5^@==2#9LMG@F<P]J0DU:C(:# 9#+7,P&Q*V5_1&L!B+!79]-S7
M%:B![A1[C$U^>J-4H]A\!/7WH@:L0'6$R)L]-F6% ]D-B/Q2BK#U++8SS/#?
M-V &4WY2*]BX&<9J4<N4V(V&KJ:*SC3J1NN#5D^:HY^ !$:GA>X/:S6SUS9,
MD"""A.>+2R,EF-^.93N678-N/3?ORU4S_&_5E4O@N8NZRQ_?BTL]1.>MZWIA
M=VS=L77KK82><IL% RK_ ]LL5(#.VVH]8.DZU\8-E88[*X+ILI_72;"BXJ@Z
M[19;%90RH=IMWW$OS0JJ2]U6JX):TX2=QY(&_V*MPV5=&GR7!K].:?"K-<BU
MU1@W4$D\J&#Z]X ;) _"G#!P)O>*5JF%H_VSAV=*O6"SI=2 #2&2C3<KO);,
MBO,D3S.@1!^.HZP4B5K2TE?K*^7DOU'H15\=?ZK\KP;^O>ALC1C2DDR=H)--
MT8-BG5[G.>]TQLQAD3%3'<4D3SC^5!T-!7E*E9+TTB0F13M/Q>=0K=#7!?Z8
M;:CA7DK)!BV$1$[-H*NUDD7S5UC^JZNKG53Y.Q?QI4O0R)E'F4>(41A6(6V+
M/E-IJK)4(]SJJWPOG>I BI$ZV!Y3;Q>A@(>>+S)*/$1IQ;98,@H,X9F'6W"*
MBHY <>R W8-$Z#$1&NMBI"(U":K[XI(^CAU#9222(%9R1&EKQ^K\69I;&WO;
MQ&FFK]9U'&?*':HV9(!*LH('@ZX1%848G TS5:$A^M+K"Y-A1#8'9@"/JR5@
MF/3B<2OA"4(33!&!XMS[1DZ\>$9_\]Y+P-)"\7+M=QJ#B3)/QEJ($.4UCDX&
M!G)[A(E".*O0ROX)JI#-8"4KBLM&.DVZ8DOS^VP\K":)0X..>!F0<#FS*=6V
M(%G'W@Q'F#:*G()[[=2@RF@GP,<IYPSSL)<,AG9:'@SL!(88[A FJ\_AH(D%
MRROX*P\P73-UJ] -)="/RD94*ZMQ CKTKB>(NP^/"+(FFN DKE14%I,O)1RI
M1Z73'F$?@0DD!4M8,UI6W-W SF_I)BO)J;*D>!D>0M8]SF6<45XX!?]O6BE
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M\+(2%+LP,6,.HE>+<?&1FHF';R==V]F[PMQ@V7H"3!B4^HK)MI;,$,+]G^F
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M]U1*P' 2#&0I!'\DO,EOA5XO+202B7111]!TRDX?3!#\C$LRS$">9<ZO<4X
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MTA1*53)'Y?&4\4-E.OJ0TCTU9EZ6F6(1C#ZK,8;,L;21X.Y*3R^CH5;.-!0
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MDA%_>.$:*<./8.*T=L93*[3"3])QS9/FFFE+7/-!>>3-LC@&4QTTQBO_N I
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MM.;<WUW&1:Z\4)E*4F\D4TH3?E:[U_=MS_Z7[)=:\^?G[?^V]I1IW^;.Z&=
M 91 .^%:5LUF<31ZVEG0.4\5-6\QYW,QE+-3_'0I\B;\:B*U^_N^@'-N_;Y?
M8P1XF2_\,5>V_T?V HZ9)NG87_I6YVPNT-X3+E#K.M+:N=/\E7DQSU%]E[%2
M_)SZ*F?KY +W%^BE"S@\"$Y%E@<'!_E=<)6G4GI%S=^?IR]@YPCNS>=!DE3=
MU_[:^&LSQ;B%<?Z5I#\ZP?F_@IWM[=U=?WW\]7FZVI/G\:]3_(G^"ODK],@"
MY%!$@U_5S?G?@H*UH1AMA<EP40*Q[6:-^P"Q#Q OW+J>Y1&<RF,6=9%++[J>
M(P;:7\#)MZ\7Q^?_6B6GR7(=P,HY/9=K^Y^23WA!Y;2E3+:3)!UMK5YFX7*=
MW<J1SL);/=4<G/7,N]F"H7WFC:>8ES+9%^OP;Y:&XUU-BS7GY;I"G-D2_*[2
M_4\8#]Q?(7^%O*KGKXQ/#?$7:"$OD.<Y"S#GY;HR/BZ[@'->KBODX[(^+NOC
MLJNV+E^XNZB+7'J1;(YH?QEB-E<79^<GWU;)$%NN_5\YHV:YMG]JN/G;,(Z.
MNQU>Y%D<;JUJ='DICFKE*&7A;;?E1WCX*O+\#L;[8ROXG,B[]'G[[R/-GGK>
M=,ZMU[PO.\;#9'KW]WT!Y]SZ?5>1\"6^\1>IS*CK"+4V.+F+9#\XY0;E]S+X
MUN]'80W)SY/!8LVY=3)XJ9.^=2KPML$"S'FYZNU\.L+"S7FY+M#!AZ/MX.])
MFB>Q!ZI8A#DOU_6Y*J)<=2_:WS[P5\=?G2<OX'0HT_%]-!C(3G!R''S8/]P^
M\A?(7Z#GI46AK\1[219@SLMU=S@?"INI_^]D&$>BZS.AGI4)-6J[7ZJ=);4V
M.]S:_F";FS6T>56QC^T9)NY;&L[UY)[9TG"OG;ON6QKZEH9S;FDXA/W62]G9
M.M"3IB:'^X?=;M@7^S='LBMN]KN[!S='O7#GYG#O_<%AMR?$^U[_+SP/?N(X
MCN7/TYO]O;VCW0_JF]<G6+HNU3/ M%A]!E-Q#W#*P:E)/UF Z4ZX(ZI+;\,:
M/D>Q&("^F0[;[S!\??S/X.OQ]?7IY55P_/OEZ>G7T_/KA>:6[>Q3=TQ1)3%,
MXEN_/;7M.?['V=7U<7#Q_;<O9R?!\<G_\_WLZNSZ[-MY</+M\H+@2+)B5%=,
MWA,+*[T-^9Y.D&U0_O_RMQU8;C%J27U=Z%/X<O;[\?FGX.+OQY=?CT].OU^?
MG1Q_N0HPK?7RXMOE\?7I)[]KM5T#NO:[4MN5;U_/SXY_TQF?YR>OVBQX2??H
MD\!.S-QJ^:M(PSO>K=V]3K"K<7/;F=DL>^AHI+//=<N:I*ZY[*JM,'TY;%!M
MRZK_4\P@IUJC/AS)D*U#>!4/O'NP9;(8V0S7.Q:((D^"[6#;FCW\OV]SV^<L
M%P.^A)/^]SS))78+_Y2"C?AK<)T$Q8A:A,-G#"J&5V/G_<<LB,50!K"Q^;M>
M @O$-^(6+PDG\!Z7Q3H8[^7P7HZG>CD<G\9N3^[L2'$C#P^[-_O=_?[-T8=^
M_^9@1^[VMGO[!SN'AV_FN6@VH'_[<AI\^PR&SODUV,Y7"\T=YU51[%()2L\R
MD= G3R@ZIMF\ R:=%.JA)Y8AWS5YB-3==,X+7UV5E<PX-;?8VFL]##9!@!P]
M/<CP2WXWSSUI/0=S?CO2D+KYPMTYW#ILM=GIT2S&P#2'Z@6(4Z>8[\Y$OM>7
M])X1F%P3TIMA1UZ7]%"36H FP\^QPLN[6:-$&JHGPR0E(^L=ONM7T(EEBO^J
M?<T:&BW_62<SG;B?DNQ>.I,/>T3&5H7_]7^$H93]?MMI/9?79R=?3I7W*OAT
M^OGLG/S15\],[6^X@8NVUI<6/DZ\"T_8D=:YN(GU[^QO[5>,F].;*QDBM>S<
M[-PHB,_9K!UX:<V^F9IFM6AL_17V1#T\:5]F(:TV^7<US(O)I>_JK<_6BW&>
M!1?'_\*(\%6 @24,%E^>?OY^_FD"&YV8ME<]ZP7AH]//WS/6QQCK+C"1X\$@
M8<=PTO\L>\@3KL5/F<W&5797C]/.?Y/L:.B!4^,%-.!*L^-Z:O_+26P1V-"S
MJ6[7O4]7N<CEBTAN]X4DMUA[^":;5B9!&FW^!+@(^]H&32X^ >Z5&'J2PECQ
MBTAP;_6DWISWJ"+T>+PU$'H?O-#C^[1_ NL247R=BC@3].&+2&Y_+:3>?'=-
M#18XHZVGV'L-JEQ\$CSX)'.9#J.8^'!V*6]%BO/,[^2L5'BP>H)O[KM4'B\P
M P8P8N#(1<Q0/\[S-.H66DZNOGS<V?8"DN_=H:MPG0Y'@V0\E'$.5V!6XCQ<
M"Q$Y[WTK:ZIVP/64E*]"GXM/C._AL"]E'XYF9@7U_>J)QA?O"CP?J &\5%L+
MJ78$1_Z;C&4_RF>FI*.UD&,OWRFD+CV"EU-K(:<^7*11DA[?IE*BCC(SB7U8
M/6$UGZVA00([BA=;U8R)@R<MF)+"%X&13,N7. LN+D\OCB^/J?89<R8^GWTY
M._\="P0X>^+Z^Z6;A+8VG&;O9N<2 9/B,,DN939*8IU/,1M9[:U>HL"\MT@/
M9@KZRH.^8/L.MP[: #I^E/OL>*69+]+NU6B.E+8.^0'SW3,>ZK4(;Q'VLQ5:
M7'S"V[O$AZ^32WD?R0?R=N1%&L^H.^ZM7E[ O+>(!L,R=AXN8 <1#>@%W.H*
MN/V3)!E)+H:9E;;6(0%@'COE#.!%U^J*K@-BQ:,$5A+?7J28W1'.FB>RMWIQ
M_?EN$(LI-59@!O,B:W5%UJ$Y[Z1_*9/T5L31?UXDP-8A/#__?;-DE_2#\H!>
MO*VN>'M_(2@+(^F_(/]Q;_6"\G/:&37&HSEG2RS)GE$-NMJ2[.@8CKHG>\K.
M%G'O1*3I&-8R*U6M0X!^_ONFAM/^#NY[J4;\\7(*7(1-?90H]]92F'T 'JLS
M?6>792L7LY_/QJ!M9L=804'V#)I97E@#9Q?^761YU!]/B]S_ \/S[SY?GIX&
M5]?'U]^O*&+_]]/@T]G5]>79;]\QH.]!#SYZT(-X'\/THU1FH.YR10;(W3]
M[(HXCV;C./NKE\SP"KM4&8_4'3WBNO/I538X]F]V+V4&\CA4]52($AO?YLG,
M!57[:Y'2,/]]<X<+]'B('(Z%:)^BS)2>K8?ML?^ZR8X+E-GXC^#L_-/IU_.S
MZW\%WW[#/B,5,+W9^)/MYKBTS.G@9N<,C/!A#$K2MRZLBH73;/1U\&(]8+%V
M\ VVS(P4.$.M!_NIM\I^(?DM/JWMJN/NJUX4RNL\,[F]5 U80-J:[Q95!@OT
M:"NH;1]Z:0;79T^=\%<9WHDX"F<FK9=F+B[6[KWR=NGHF1EF/238W$EN\>EK
M_SJ5(N=PZTNEUTL3&!>0GN:W/68@#$FOL-AZO\X5=_\XH[(ZZKUS=3UW>W31
MV<GAS<YY@HF#LY'(X>JYG5^X(_SLHR6ZSPGY+#7'6%E%]_!F]TJ.1"IR^:+R
MD\.U\"3/:[?T((]5Z*QH;/4U:&_Q"6WOOY,HSOG$9R6RE2N#F\>VT "*E+S(
M6@.1M6]=W$D?&V]&<2%[J+/,2E?K4 (W_WVSP^D.J#1@\ K:XR)LL!=J]2MU
M<"7S?$"(/E2!/+/ZN')U<G/;&SM*P,/HG7+'TEV^HY@FVATDX0^U.]M;A^K>
M>=FX^K+Q\%K\I%[467XA<'G1Z 4U8H=K45LW[UW#Q&DU6E :;OU$XC/:HBQ[
M:M#967#R[=O%*8.>^91%O/#O;W9>U%SQ_5HD KUTEY[:@G*=N<N3J6SQ26KW
M!#&TLARQV75P;U;R6KG$GWENCQTH,".MN!+]RO)Z$;C*5!%^AM"DI^<$6_KM
M,_QQ\NWRT]7'X/CDY/1J'?%*C[!^!4F G$:7V'E]5LSZH]4+L\YQ=\PX#,=!
M(WEFLPY*\M'-[C%,-<ORA)"57D1BZQ"&G>.&\3A8NL-(5/,GNT78T$<I\1EM
MW);<3#_[)Y8R7WR_/@7A?O7MRW=OK&NR^G"S\RG*1@4F-V3)H)C= ?9A+<SV
M^>V7&B:PXW@6M+HLZ)_!U[.KD],O7X[/3[]]OPHN+K_]X^QJ'G6$J\&'=K9O
M=DY!%4ZEZ1:"EGB>%N&,AOS.]EHPI/EO'(]FN[9\#,R GDFMB0< ;M7N69S+
M5(*^'7\1N7Q900(0X\IY'>>]1WJL((D#'.W1PHT5\0CX)N_Z.NU=%62:)BD"
MQAQG&:QN=H);AR+$^6Z:'8G;2?-87N*MB<3;ORJZ6=2+1!K-"I\'9+=RA8GS
MV1EWA-46:+N^?2W=FQNX. ?,0\5+^DD!3;TT472Q=N]UMZLTQ-K)KE<AOD6G
M-+@YA^?)YZA7A,!@QPQ.!C;[732:F>1>F@.Z</0U]TTZ3P(S6N .MV;B[9=<
M= <2_MN+[O_V5_@?/:]P($6*:[K34W_'"_QU[Q &<QRU;[*:4**!K9>SN^\0
MEUY;Q$NCA=#__I__A[L@RP#?P5DFZ:__8YO^WT=GI>KENW1>M_)=-Y7BQSO1
MAU?_*@8/8IQI(CG:VMT'IIJD/?AJ6\]K#^=SL'5T]#\#^T]*Y*]N+S_P;B#[
M^:_\*_4)'9OYZ.<[9Z-'21;A-?TUI?MZ+W%D9TQ]3GDR>L-#JK"[/7LDEHZO
MOYW,FI@-MU/7*C6Z4Z;<VZ=L'UU_<T7H./%Z#,0HD[_J?[A[@/NJEH_CASRO
MC^YYBB)/RL=)G^CCH=\X+$']!C^AV;P;B'%2J(?*1SA1'MZ5]K6\BPX5X:L_
M+K3(_-AX3_#)(_CRR;#.=_/<D_8%XMQVI $5_86[0^W<%>$H ;$S^AEDR2#J
M!9K%ON+V'3U+<*BW=IL6WTT&O8^(:'4K__I+U]FWZ:KH&I#>CB>]E^_(ZY(>
MROPWI;MG:FR/[F:-$FFH'N9WD6[^#M_U*VAO,L5_U;YF78*6_ZR366<G#UA5
M[S\7:7XGT^,L*U(1S]P6$HS.ES886ZP-?/4=4\,$=ASO[UD3?\_159'>1_>S
M5H\!K;VT[=@B$M8+=T4_O68.G/4571\8M61V@?72+F*+M6VOM$_J82^;UD0V
M[6R?P,& YCX2Z0L2QG:V5U!"S6-OW!%67%3Y!NKFXNQ@%NZ+,C!WUB4?^H5;
MI9]>/X&UCMW1\<+LGOX<23CT%]#6*J8WOW1?]-->2*V+D-J[ENDPBLF?BMFX
MV*1[=BP.I*LUR6*>\\XY@W$JLQ[.R[1UD6G[UU$^D)@3_W<I<(HO$&ZKF-,\
MMPWB88C,]$!>X*V+P#NXDK"VE^8W[ZQ#@O.<MLL=P4NS=9%FAU0=.4IE_@*,
M5J2T5<QKGL_NE,?P(FQ=1-C[\^13,1JH+J?P1U)T!S/VD$(*6Y,DCKGNVWD2
M.&-]#/!O&H[@J6#'O*A;&U%W=)[\(2)8R^PDN(JY'2_=%R I?MQ+MG61;!]^
M1]89P]R^B(?9J6E-DCSFL5UFA "&\")K3436[O:G*,O3J$LP=OBZF8EM=Q63
M/N:U/^XH 0ZS9J),5YJ^>=7&$ZL!EJ.:Q._>C//2_;;B)%;UG/.8)/[]E!-N
M7-Q3RU16H#3;UV;[VNSGU68/8;_U4G:V#O2DH]Y__>5F]T-X*,1A]^:HUP]O
M]C_L]6^$D.+F<%_V][>[!V)7=/_"\VBGSNWZ^)_!U^/KZ]/+J^#X]\O3TZ^G
MY]?+P2=?89^B&%X+'QQ5F>7U790%C7L5;.3X'4YT=_MC:4'5PK\RPWA!U>!?
M_F904]7.T.MW/FYV I@+';/L!5&<)X'(\.)_%6EXQQ#!NWN=8'=[=S?HCBF8
M+(8)V%''L/NY""Z*[B *@^/PSR+B>PXTDXZV@K.S3B""3W#G'T0J0?-+1VIF
M?\V*45V,O"="*.TR4@\R%=S1AO:(?_D;YK85H[\%&V^\F1>PHH:=_!+=XOY<
MW E@(Z$L:,)9<!;KQ<O>I#UY\R5<RJ&(8&*U1> *O@WCZ+C;42#U<;BU,-.^
M&M4GC5/N!'ER*ZGH\"'*[P(^(5J,7BG\Y$Z^-=E1QT63:*AW>2LX$:,HAZO\
M'Z ZH+UA%A09$6! S,%0*ZT@3O(@P;4]1)D,>K(/[^T%\+>$WV=W8C ([L2]
MI/4-I4 W1P9D'())AL,G05:$=^HU] 897,F12&T:5LF ,R_O!#V\LXHCX&/X
M-[TXZ7<T.^C*_$%*'E8M%UG<FV^ULZ1)S&YK;>749'E^&9P&)\%9<!T<!U^"
MJ[7=H8F2_(^_GUZ>'E\Q^^@F(NTA-?2B5(8Y(K)2AR1F,4"&&=!G3DF.2'IW
M(@^B'$6LHKLNXBA'"E"Y_"S2*5]A:3[$/=AY_S$+ND4&(V99T$^38<!<L/[E
MJ$BS0@#7@+$J5&XY2KNT6:%(YMW]9#!('M [6YXU<O6 WI&+'\S?7$[UL;U+
ML7RWU]RSAPCDA>SWX?H&(>XL7$V\C8BC7Z1T"*F(,T%.0KAP24H;#W<++!DR
MBL0M7*9;."'X[:2KJ.4,?1W\#@;P*-@@ZF#IU95PXIO!*(UP_*1VMJU<TTN9
MI*#"1?^9=%5Q66$2Q^Q!Q4FG$O6-3N66HMEH5@*K4]OP<!>%\%L81/X,[T1\
M*WD(V..._@W+\RC+"HE/FF.#S^&4</O5#T^2(2CBP56.W=4])<Q "<B'XQXU
MW%+T4+N%<%3"I0=BZ55ELWKB'6;X.#CK7W\6('_[8U2DA+[3:>FN:566KE&@
M//19L'=P0-=N[_!H0VQN[&QN?-IDK5PI9"=)3_K#?\;AET4DB.>O,KU%J!(C
M'V<QAJV-P<39408(FU/J%5=%MQ6N5EUAS>0KB]\P&8X&4C=_K%)$QUT-B9(N
M&AWP48^)@;FDX7D=_E3Q+(04C.("7P4[BV-G!&V!'SAFI;_1SU1+M=W%3(<O
M-GZNSJI!\-+1/9TOX2$JD:XL3))$S*>8,IA'>>[TDK/4^MA0#KLR-6:WD5B3
M]*A.P-H(_ ?L<]*ID0XG#.<J9?9)DF?\;#\:2/,P]Z($U1#D$;H+D(B)M; _
M"]A%EV8">EP11SF"#G=%%K'FJ ?IRQYVA>_ [L)CG6"0A&) <X1?P3[Q:Y2.
MF9%+Q]^;V7A 3V;8)@LXL"''49K<1SUI=7ENX(/W ;=]$''90J2JA;#U;SY@
M:0C#@'Y:D)JD'3^@H,+Q@9D*"ND(VY+S_@2DQM*]2Y*15(9G%//TX$XIKN%<
M*/ZY.SU]8?@Z#D6>X\7ET D**.J-JN:YT57KRV2.#R,2H7H<<U-C$/.9DD<]
M.8QY@>Y0M!>P")G>"U?@Y>+GNSY(2[JM1=8D!^V])_FFWYOE<F2,G[(YL=C.
M)R>4-?O,MFS,6(=MZ1,GW@63E<.&F%@Y9OB4^*F3N50?CL(&6X=29Y+L'FQM
MF[@IQ<GUC@6(11QL!]LV7LK_^S8G->]0"!/$I/\]3W+B#)]2T<]_#:Z3H!B1
M3Q<^XX".L>1C,03B2#)0+!-88*Y2P!?[%ON4B 4]&)\>X=,CG@%=KY(AWA]\
MZ/7W]@]NWN]L]V[VQ>&'&W%TU+W9W>GN].51=U>*_3=(AIBH?YU_^Z,37*,2
M]OG;Y6E'>0>SJ*>5'Z4X#(N\0'576^"@]Y#.DY&3AS4FK:^@B2Q(L:@% SM:
M85;:T6V2].BC>S$HZ$A*;V>]*Y6AC$8<2,R*?C\*(QF'8YP:N2,##.FB9H<.
MC?!'G#P,9.\6-7M'J>PHRU+I36#R#^0MJ(&@ZB/I=LP .%4T)]FED/VZ'-+B
M30-N4Q':CTOMX0U6^\+-]!7=59]./Y^=GUUS"^K77?^+;Q#S*9M2?;-S\[N,
MT=)MDRV55J(UH2BF4;H##!>XSV\;D72P/T&IF77>3Q0G)3?2CM,=F__S1FY2
M=7#JK5O!\:2<#&7/6J<I)594\C#LUSHCXU5YX8HX-&:]N312"S=W8V>S?%G?
M.JNO]^\BR^M.?74;\>H%^'_F9Q2^C<=!E,LA_AL=@4/9"6X%^FD&20:BOB=[
MW%*]$X2I[$4YNO;P(=8ZZ%%!\3*\WNR.P6'1;3(28_B)&V01P><H!N7GDTJ+
M>'TKTM-".[2PVS(M]-'%*'(YD114+ J]EA3LQ<MY(=,,;[J]W_P)QU XRP?4
M7*  V&CU%PH ,%EO[\C=#E\-$]"A*:MG*%4KV0XI\FDRR"@:K/X8H,<>GL?A
M,A7L#3F.KWX1<#H!A<9@EE$_@D=X2EO!9_+?1IEVE'=TT$8]K)=,U*C6@0OG
M4!L\D<DL(\*>M#!EL(R2!TEI&?P-_BH4( TY"9 ^<\T;$8-9SNP%B!_.(XR8
M)U#BH=[BASN.F9O->P"!BWT)\9?W"7&33(9%&K') ?8$K4OP!$P&Y%9PC3Y:
MV&R]?'/TY3,'*Y=78;[/2EM33M:*AG1XN81=(=^"$T'S_&H%^=5>R_RJ.1X_
M(:$WL#$.%5T8I5(,T>A'VSM/_!5=P2NZW_(5C<-H,,"(KKFLV8RWM2D5]:..
M_*$#"23.O4P[U?QW'A\SX+O6O84YZ;%A_O5);JG9+<A-\R0Q1Y(X:)<D?M,)
MKI_$>(ZDX+GW"E[5PW:OZHFR.? 2HA^_^;Y.,HPP2X/".UEN0P%CG1M"::W:
M9"$MW_E]R?Y_NQ(#E3-[N*4A[RGF\5;O/]S2B.!L%KE2S%/W"E+W^[:INS?9
MTT$$2[B9Z'J[!,TJ+C@=$R_GSH>CPPXE?0XI1=U?SQ6\GD=M7T];#^'U)']5
MIUW5#^U>53>MTU]5?U6GQONV%^>N@@DZ)=AAZ_7AEYSI4Z]NRW2UCU<"5O.Z
MMAR?+@,#8J2X<E\Y.H7!-XXC1W%8I.C?@Q$H$(.526"7%H-<1YOZ(AH4J=1_
MPG/O/F/6V54I5]\HO]=.,;._XZMXQUN..T\"O_0ZA+^PS1>VY<#C*4C\9 P<
M\ZNJKGII)-+?W'6YN2W'(_GF4EP0Q/XTU1>12KXX98UNR>R46[M)V?6LBMCL
M>*YWQ%![%6#'R>)7>L=DXO(4L8H4T7(X\O3/ BMOCQ]$VFO6K9,1J;X=!I )
MQ&B4RC#B>T]53? 5P?]$(6*],<R,_C46=&<F^8J,10G:=)ZD8_5P+7+4@$Z#
M RA O@S_]I2PBI30<K3S,R,,$-KF4$Z7#\K>#*(A9E%B2B;"F5!@,S@.'/ *
M=>_S.\ZC+LL?+L>B;&H%Z-8)@#S$@-,7L>R/(Y(H+/#GF$:M/L1JL&%28,$7
MPV\1^6@+-TGE;0*JEB>45224E@.'FE"^T=6NTTD#<="E5(_=4B<574N WWP'
M(0&_0_\+)MBZ%#,.ZF3Y#*JY7@>J6<B"[XF5@8T8^+N^QMO7>#^WQKM] ET*
M:=%R'%_S[[J<L*[[!AX/3+LF9Y:,+[<_T:6XGRT'[QN*"Z>'1/OT .@.R:#0
M14P: (L@K(P"Y/[[ C8IZ5%-$GY:CDH9G"VA1H?91EQG]>^B=ZN@U&6(42IC
M2Y/\8A1)K',J4AJ*+&QDM_!D&F6]R**.!B&L($Z"01(CIE^7;'DI!I@];Y"P
M] PRF6L$+P-1>G9YA3C^X0"X,0(PFAQ[7%$8RA%J<4D?:Z8(R&(X2I,A(LY7
M0$G?[^SNX#/PWUW76&)5C1X4*4D/^PH> G_Y13R0LXQWP5UEUE$^-SJ<>\E5
M:YAPFLH23MFX\6@V0KT'\ 6Z[!Y$'#)>L8(PHS(VKF@MJX^PL:C5EF'1X+ +
M^'=<*@>3/T>1Q?; BS6BUV=!C[&3>064$5M[Z5",\=A2[IQK5>O249/:K;$X
MM0*\T7/6QCM7O<<(T1$."H+H@'%!?<ILA5YYVO@)W!WLZHNG1"!GN61"&$;<
M9IN\/ORH# VA"*PZ>J>@W.SINE?,WG"8//[LN,CODA1.S?/_%>3_NRTGQ'Q6
M\)$SNGWP(XU &:)EF8YUM;LMEVTT=(DNU0A8\DJ0;$#X7="((_W4A.'+%K-;
ME\OL(T*]2M7FL\E<BEY<(W$7,-2EO"T&BER1/[S_&.QL?=C>>;?K?5.>FF>A
MYI;SA30U3_)-+1<Q5UUA-58ELV?2J2=33Z9(IBVG/'VVF,W3";3IRI-OH$KG
MTN?FK>1%;3G5Z7<3K !N>8JEB[YHUU_9Z5>VY1PG0N6?[L(JMP/HU!LM*=-=
MY5RH7ZF&&UBT"Q, A>'/(DH]WUW-2]QR6M(9 ^[WQ]-KSZ>SW3>N'&<'VX&I
M'O>$L8J$T7*6DB*,7,Y2)> )PA/$W FBY6RDL\NKZ<I.V;U2PS2XDNE]%$KM
MY\F*,)19Q@H0PJ(Y81$.Z""4%(4Y&,,$\UO%+6.RIY*:P<0YY2AHWTR>)VDL
MQUY16LGKWW)ZQ7\G$6CHW WI<5\G_XZCP2+$G@*#L;K?"C!3#C0TIP.8J?%&
ME<K/]YZ?4H%9)QKX13QT2KBFTWN1E3MA3GG.-5 \*:TB*;6<"0(7U_MV_!6=
MBOC:<K":P81GO*75-J[^AJ[B#6TY &N;^_I;ZF_IQ%O:<OSQ'#YY%71+TJQ!
M4T8CT2-=>J1+3^Y$[BU'<3F.Y6'R_06==$%;CMFZ@=;)7ASU*^JP+4".8/NE
M/-,M5E2?:OX#]*\L4IUD?#.2M;C"+4=L5://Z;[XD6HQ3^@G7NRO^I5L.59Z
M(4#!OL#V3U$XX68N8+QT;^O QTM7F"A:CI=RZS+OZ/:W=.HM;3FL>9%D^;L2
M,"97:3X>XN3?!1O42#!5Q:]@N27]S: KX4CH9EN5N :([-9!]E4BI+A/HIZN
M!NTE15<Y??0;5'''59Z*7@],136))[UO:U5 //8\B(<'\5@^$ \O-^8I-UJ.
MX=?EQF6!'OYE4?[WMW8WPDVO_Z\NA>RWG$)PD<KY*U8R)G6)T\:Z$HM'7UVY
M4N\4N4+YZ.E$L9X8!SRY2<I6^S?5D]0\2:KEG(>+-+F#T\2$X.-PI@:W;<D:
M+VA6F"I:SK$ JF!@A>/PSR)BU=]MIC)%X@2Y_1E*%-P(R8G 3C,6$D6$U:1=
M41W.1LYRH>01?)_"$[?J6TSC4)XL388P9MG[>G"P(156DHOCB]&UZ; I\.2[
M]QU=1\#0#:GS0P3#*@:W@NH&4'#27#L8"R';&@$<DJ>N?1.17CAOFE)*W(>B
M##X;H?14R,2<.&TQM.&6B5N#W$5 W7?) #>N0\@QP1UHT1'";]F3ZU02PBL(
M9@P[H]ZT,:F68M.9Q$-2#'IP#.DM97QC9VZ\.-AOBK)M[":RQ[(!-HU?ZJ:,
M\T\S-?@&!T,'A+*A0Z.#\2:O*^6T=L.8R?"GY![]+5Y% LC EV4,1-ZO;R?E
M_- ;Z5 (^:Q+4#N5A81W>!4);2-YB&&J=]'(&3%K@CI'>+ <!HM)6F"Z$!)5
M]N1[NV'U+1L AMM#Z&R(S;9_\#_-]KE0=/CK>S$HI,8I2XK<$!:#O$_=%KXB
MIBR _C0*&H.%56\NEQDP?88B4]!KS030*8V$_QY@M*=$/.H-/ ##H'6=U>4)
M%O6;P[I/<ES:*'E <+UI:U:_7)JE;P7G28YWT:REA/""F'Z/,6O%GC&M31=^
M;$3.7HH>MPEHY#>\%LMF-/(_B%!8^$:D!XHR3(4#EM$X"I%9!LPTZ\.WHB^#
MOXNT"]__X^SL+-A@IQ*N+7'Y5L90A'&LREJ8))&J,B2=H]V=]Q\S_+./@E,9
M(1G7A&7$K]Q7G?USRHL0_@>X$Z(-$F_%Y2EP0,E-/=)-@@9\7(QL]#9=2XG.
MTNY.+&E/Y4^9ADC"0,@A2:A?D-6"J8:+Q*W&9S>HQ4@/01[OX&K?D\BA^A_D
MT&)@KR/?Y\;MPC>:US6\1&<\_H2%6JQ&[ XX$$4FG3,NX@&(A"#21QDIE$95
M6H0;Q\RM?,!/WS<Z,WB??F'IB*;=H:>_8@OA9TJLN*?@0QG D>5R69*C?,LC
MA$E4T&PZ:\<5L7@D\*D81<"9HO^H'ALD[VB78Z*CJ)\[7$CQJU0]W,,3T"R@
MPJ69AKO ^6"9J!R(B7-I>ER!3<:@Z<F?),L,6U3J0WUCZ!(0\IQ:(B4NI;(/
M^@ 2F^WWP9/3S$64?X-KHW3:<6GN=0UC*[@NOY$4-P>OTO5;X+5%U"RXKI2D
M.TS@F82[E PB8@9T_Y^L(!+B9M,5:M;]Z!ES*(3?-4HE+2X$I1HI:S#>"HX1
MWW4@P!;0\T_Z)"]8GX '62(8&,[)>F<)B'7Z>IQYP5Q&J./KUD?U#8[RS,Z?
MWLM789I[1R7Z6\%B281@0J<+)&^RKJ+)VG:><)KD2!OWLD(C>X>&1DY5@>S2
MN'GVM@Y![?6>GA4FFY:SER\)*IHBQ;^)+)J2 YK:7W;QET_QR!P>'NZ"TK6Q
MN[GQVR8JDAMG9W.2O^BH(-67[?,!:,<#!E&/^Z RH\PR)>]*^^%W*6LDA^,C
M]01%''W-X-M:@S) G)N>[E:1[EI.N;XD?/CID3O&D$=HDFC8+=),>4*3?A\D
M4T<!RUOG7I!%L&<"@W@QJ'A5G'O&WW1\2N3<JB'?R\PV'""\>IP#]@8 VQ,(
M @%84,@.QAU6RU'CO141J'\6^1VA<,48647)%':1;N$'0';L&JQ6Z)4 ]-6D
M/KZ9 -8VMSJ;SIN]6)GXYKW,IE +-XY,>ROL:1EE7[D6G'[J"AT9;3?R?)"I
MQ&[NG&.KQ,[Q,[;C0QF-:!#N"I$68F!<#/HVEL^S_"9@M \8P>V7/ QX0>G.
M>DZZBIRTY4H!C4GC2P3]%9UT15O.VS>P2<=];)]"C/B1>D'\/_OC6X);VA!*
M-J/#,HA*;2%*:O?.P?9^T*1@N[XEJTMOVH"<4,A-$P"?*,+(O_"$LHJ$TG+I
M@+EN;@?IZ66)(?_2!/3T$!TL6%11T/][>VM[>P<C1>SR]G=W%>]NR^G+YNY^
MBK(_07%6 ,C'30DSU#ZQ 9H$%.I2VJ-J$V)[S&'&3,@V7U]$@R+EIG+#B-N;
M4%@S+\%>XCN2(G>Z>[&RC^497(?./>CN98Q0)@AV(DBHH'B(8B>VC8FD7T$<
MI9$8,. @/CE57I"TXB 8!7/Q 09;T7DFJ@[>",8,*WUPW[#?VX BW6Q^U/>E
MA+\B@H9F@&YO/(Q"W:.9NU%*S*'/X*51?)\,[O'%*H17YR@Z4"<R4"(SO7-3
MUX_A3+<SW:J4"^W[<B%?+K0@Y4(EJ:69(G $BI47E+4NPK!(13BF<"MFN9=X
MGR)=%P!8M4#$J*Q*:[!\L8D;?@S^&C5L-Z4"A(Y/R>1Q_/67Z&^8NS-5:#0D
M[E ;JKFM$:0#Y5AROREGM11(9XGPV-(-;)9X]L3F,Z.6\J]W;*V/3J6"?=!9
M4ZE.C2#DW6P$2XNT.&L1-JQA\EX77D%=^*#E0B7#UG0?\!.;(MQS6X4_!?SZ
M^];55M!7 T759[D=<##1Q>+O]RK>[Y:KALIJ_N3K:WYG<+]40KP5F@;M:^S:
M&A^#2:F?<5(Q.4K-GTPP:+HC;U&(8BGN6LNU..;D@-^QTO-;D<%_LR=F,=V"
M^ATS:I=DS[%:P)?H%J]E;5@]GL>-6;.+WG(&G[GHZL;)Y[;&X+AU.3X]U3U3
M289PZIAZ'5-<0D9+$8,MEV+P'=^TR:RXE\BL9IU-9LZ>:%:1:%K/WTM28..J
MX&#&&'@J0W15^"Y'*WE#6\]TL^Z/9V.UEQB\"]8.EQJOLO&MT&UA]TJ*XH-Y
M>B] 8U!783FBPO7!>#33U:>!UG.4,'@5HE/B,<@6RDEBE!1.R2 @.LZV;L9%
M8>,R[F5!_I $&[LJWC26(E59'A15\1=[%2]VRYE-$TMMC@>P76PU7FDO_C)5
MW7C_^$J33<MY3A/)!E64WU3Z/D@*#,6+VVJ[X&=ECS#ZB?CY[E)E@']),BSP
M+6> ZWZI2OJH]P828Y(X-@)UW,'JL)I&?1]L8*AW,QA&<9%5']1)XT^?#ZIN
M+/",D0YJF=N'!Z\/]A77E;1.J;K7WE::6EO.['JZ/RJ8Y,.BW"'M#:I\1Q@C
M!CQD*,:@\OE[O(+W^+#EJ*SUY'L_D;^=M=O9<DRU*<[D:WK\=9UT75L.R[(L
M]Q?47]!)%[3E<*I2-N>4+/ -+*_CKL\16/=+W7*X4UWJIY>'N;^<5A+6L6"0
M_N*NXL5M.0JJ+N[ZU(;93/CI63'MUXBE\E:D/8*VI#IH!YI9A+F[G;R%Z)?$
M/5'(0B*8U+@$'_T>\WDC3@INTC=8^MPJTVK5!D^H4'/;U3I/TM^=6L':&]33
M\%UZ:@5-N8"&P5"#*<355$/S=H4JBU:>$FG UE+6A%OCZ(M3O"A^;5'<<C*&
MR_$F*X_J5XV)^P^13K(O9^_K9XCU1L.A[*&X&HPGM1#$_70S_7'PSM3>.K7L
M_TI&Z\3\_R5.1%V!>ND#7R_MZZ47I%YZU:1)VQE0C3'=.=8LE(REUZ]86,Q"
M,:^ S9-DVLY^*G<#G$XKN?A)C!;362W4J=/4D"ZV2I)]O(FA399]M*US^Y?)
MW_IYWOJVLXC01^#4OC>Y_8QT< !5N7^FTS'H>TSM"NDS\C>H'XW@17D4HH.H
MZ(+:$9';3SEER)W%PVA/@(6'I292!+W-K^0B^U(7&YY &F!6[R#HIV"7W*F&
M,AIVF!UN3>. 0?0@@:@%+_#I@^DI1G$PB&1AI&6 ZF2NO9K4TN:QU1#ANPC$
M'0OQW3'C913[$C\9)%=]"'-D"-ZL JE<:L7DF<8*,HWW;:=L$:E\TS+O.3PC
MFP_/,,1J)25?_I-D4("^*3I*) -;B1UF91E=Y]5);T$NM*>\>5)>V^EH=(M)
M#$VDNNI-U_&7"M5ZR;"*][/M_#/C>9XQ!\WG[*S+36TY$:VNMP";?/LYU/BX
MXV@P_5#QDYP3*\([.'7\1U_B__8*5E<&\I[^2]I6#O](M4K%:A#&WK/,Q()O
M,5$@QC^Q7RT/J?6K'Q&VWRMK;0KG3(64.\I$@H&P=2,AH?WNCGC*C16Q[+U1
MDU/=$A_-^M"6VFV:9)EN! *+X^:GW'<&%+=HR)Y&^3.D3M(9AN(Q1$7S'6("
M01@6(S7H*)7#J!CB&^->'[=VE";]B,:-[Z,T4:N O2ZR/!F:/<8&@C+-QQUJ
M<@H?%/BR013*&/]1RH/H<*O./@)D&4N2DCI05]4S$>,T&0PZ;EL2&#P)(QQ&
MAD4:X=N*V%TOT+9@)M1126.@E>+JG38X2E=]!UN-+42'Q=#>!'6/=$()LHHB
MITXZZ()EK;BY.4Y)/S:7)G54Y>;J/=NJ%3-C+"0"I1S;+C^4(F)ZRE"FYW@D
M@Y[,0AB4S6W3_%431A>N72!2N%8XV7(S;\[&V>".W/C/KI3Q9BD&B>^\U3DG
M$WZOG-(][H*I>G=QCH;Y*JIYT$UG&[T+N*].$]DY;45F]X*;U)8WIKPAE-/S
M$Q-&Z-RB(3=*2KJ#Z%9HOX6N9QR7VK,C RF&[ O!#JF\!=0IVBQ$)]HX+=:]
MY%Y%R=URMBU2V;'B--4B9$=Z4N,I8-B"FAH/J)[7<FG]-V9/B123ZM #_Q,Q
M+H8ZG4KU,H-GTG2,\@T%;'P/K) (%?U[#;^ X5"UY9)B(UK0*Q#=QI,>PO_@
MS/7/]/3TYSV0@R#H0O,%4/%]E!39@&(1Q!)85F8ZY&<%J7K(.#Q4;T(U$O"O
M0K>!YYDY>@,V+H;AD)]'N1SJ+FQ),>AA)QCJ\4QLK\S/!'"SC),4BQQSVFQD
MQ+.$560)+><Q.P %RP+GL;MUY-,)5Y@B6DXG1(HX 6N%@2FF69F4L>'\DL)9
M??@#!)--Y^Z448,Y_:-CL@11&_PB0#@,^7;_+S"[/@9_B/P'!L"_?+GH!'_(
M"$R=WY,<W^W^ZBOVG*<?:4^E$E#B075\1$T8J;8?88>Q&!-,8J8E+DC0NK=*
M8P\B4%:5EESY)>>2N."$G5*@G=S\W$?>D^4JDF7+>5E$EIB9ERV-H#K<VO&"
M:H4IHIIV]5:73%$>@BY]3J6D\%21:8?'64S>K$%PC7XTP0;*]*)*5=*D<)A,
MH\G89E'IAI-ECI^+'U1=?$L>L4ZP<:R=*.P^<:6%@G=2!)(%>P<'-.K>X=&&
MV-S8V=SX5.\D#T/^Y@Z9VR4A53.^%/Z82ZAZ>G;:?839(IGV3=O"+>V/U-NA
MNKB@XS9S>M[3))WR*9SLCOF[VH]SX^31F=I>ADXU @Z"+DRE-#2V3$0/;G(+
M6RFQ8D EP* W&GY*LV_JJ8$&LUF56P?D+J^#:Z)Y[&SO[0:EO;=Y !T=9")(
M(_6C1R>-$X,'[MQTGW[*FX)^6JS3S9PZB]+#[$TMO;11C]+I!%G1_;<JK2RC
ML1T<UEJGDE^6#'1TTI)U#E.5/T/T[Z%UKU6G3%UQ>"#1GU6P9L%"3RDY:0SS
ML]U8X8H-B\$M>3(;]M[T=2UMN1<3JR@F6LY3G" F6%6?02[P@\%D%L\<O9E)
M/L+%D2,X;$7QA6G,;R)M[1WL-\YB \E\9(@7MLX)'1"WHFC9?3E+L9%MJ=);
MDCV;6ZM2VW3H:YM\;=/RU39YF35'F774<IKL!)GU-(L&+ZT&L7BR@614\:GB
MTBMHJWC96\Y,1<_6&1@ATQW-:*90&;K.[!$(:X'&BA.()"<LAR+]55W%J]IR
MDBI>U2_B8;K50-&'O@XM$'1+D=\EZ5,2VSC[!Y^QW6+\35[%F]Q^$JL%N%J6
M@ )BZ0B/I;/*9+$ &6(J%CQ='7D =@Z69)"HP#&P[GE'L;\T1K$UOAL!J,D4
M0<<X-0R4>/EG(>.0G3/F.U?)ES]E2-$!D2%VI$D2M;43G<9 =S4>TJG7F:M<
M5+83J$16C$8#D'-@>2\*J2X%!2Q 0E0CCL$4'$<JBG0:?=G>)Z9/7819^".0
M'NKRZ>P/W?1$>2=MV8&Y/(%2NA;E$GE^/\_;O@#)3I?X96]IE* CGU6QTA31
M?IY1I9759$5H@BP@&%^W LVJ,%AO=HM%\'%/,7K,<Y>$Z(O0&52:AE_" RFF
MBV=4*1\6:=J<EJ<%##U7AN7@\9,B?Y?TWXW@J.7S!ORH*V^<E81<(X?I_K%.
MC.^)H4 %3F14@(4;QR-A7(RC>0&:_*I2A@!5096B_/W(2:Y7=3LC$5'UG(GV
M3X$-MGBW4WY4!QHH5=ZX04=;W46S@",MAR13'38\N[PJ*ZM53P=E3!#0)&8O
M=%0M$2FQ:3)DN ,-ZMR?YGAVG=2>X:TBPVL9O<N6WDVW^%+5W(S5V(Z;^4Q%
M.D,7[L< *..'O20LZ-\5M#M=Z9<5(QP2/XYB',DPBBR\D[T"=&"1YP+_K:L"
M'0@2^X">H8"7468UK$Q_%@Y$-"3%/)7](J::1-B2@2Z91X!N70^+#V[2K*C*
M+R<<;N GBK%U&NH9I_Q8/,H;)F1;]\JPYK80F5GH8* >L+Y6;82*'A:OZG)9
M_8.!>*"R+9ND1"6H]J?W4B^+RYV]+W9-.%#[&4HE^IC.AR;4RS/ D0DH +W<
MRC@<$XJF;IF 27[\@ XWJ ?_+$06O2O5]E/G^>@>ZP&[2<\TJ/]WD499+U*4
M=Z]L=TN;G2K9NH2:,CI 5"5;AR\JY6+3$]H*$MJ'MM,JGIP17G9VEAR=*'E]
M-L3JWM&VLR&<Y-!'4%[P'V5<20XD5T'TE594 EZ>H',]-Q!0!M+3GUG\O'H'
M&T\TJT@T;>=E-)0@3&?PZ81:!?9.1$-JID/_K40H!"$W2D8PT @L8"G(>\S"
M]F@%JWW/6\[:F-!]:XJ(T,5?V.+%P)7IGET:.0OLABS'WD_WE9J'C-H(BH"5
M>1AU;(L1>I3H1(7535%J75_ A*(:6[F5#]1T!K'[A?[)TWR P;&&<M6Q=VPQ
MKU"&Z#U/'"EX8#"2T0B6%?5I+IJ@$?8K3:5J5D,X2N6BC3\+=)>\,DZ1;S5S
M^NZ]+\?PY1B+5([1='/5SG1+KU6K[B8#9-W'E]=G)U]..91T=O;77[JO+WAG
MFNHKBJ^+XW]]/3V_O@J.SS\%U\?_#"Y//W\__W3UVIOQ8CXJ@JCW7W\YO5&!
M^-V;G9OC 4)9XE])_S,7'I-]\Q>^Q4NE3QWLMZ-/56"-=LJZU5LI5?8DD26I
MLRS9WEO!*1=-8B<\ VQH<IC: X+:5Q/LE*?MM,WCM7'253^!OQZR7Q>:U-Z>
M<(S*T616+(-5(EK"X=!WS@+&6XKQ=ZSYCI$&MX1W+*K<,>-B-*S&-.%5':PI
MI06CU/!UTTVI1L/A+_3B(#:NDX130Z)MZGF]&?0*6<M&JD>I308JL'J+U0+O
M_N\DBG.=!3"U;[/;WK3>NEE5Q%M\CJ=MC[-<-I1364%$3EP/[F]%!O<DRQKS
MK^K-N]D?Y4+)Q$YV4:71'[?,/G%^V=P0L/G=J6QZ=5NNL*E$YYIJ.+!G':_&
M.JJ\8T8J>74F,H5;/)<0)A"A%XLKIGIU6U:]3$\>6-VEDZ[D"C1KQ<PFM-UW
MO"&YK8%,;ETP-M'-\@G&964>X8(RCXJ$>Q.;;GUNZ]*J<7.Q %L0)B5+;Y+=
M0V;/;][L\?2RJ&9/2VK8REL]M=C.KAO:H=:7/K#SLL#.[B($=IP&J%MJ(HL?
MUG$F/3VHL]@TMF!*XS*(C[:".M4>P*_@6&AXA?<K>+^"9QU+[I1\A'54W0I;
M;W#,RRRYEM;P>9&CH#WAX/T$2\VMEY9<YN0G:%>K6GDW@==#EB:^P93PFJ'1
M^AN\ >,-F)6MP3GR-3B^!F>1:G!65&#V%E)@MI$.L,SJVM(:(G.PVWUXWYOM
M:T(M<S7;%RNXK^>XG)9Z+:"_5ZK53%)X6>Q#^B\+Z>\M0DA?G66I\BQ8AF)-
M=]Z^6'.M=/S6BC75G7M:9-]DR#PSR[/I)=XUMC2N,<\0UB=:_RA#\/'Z-;%D
M7I;8WR++]Z:_-_V7V/1O6UOR,7NOC2Q*S%[3@G&$S;^<N?H&;YIXT\0S@T6,
M1TYG!MXN61,U:RYVB8](>K-D3>AESF;)8L4D5T<1J<4G]T^X5[<#3N[#DR\+
M3^ZWH[BH@PPF-7'9"LZ3'&\RPNV;?E>D[F<$2=]F>^&LBL/;>;,9V!)Q[O[Z
M=N_5<6P?9UTQVZ4:9YTD#$>")=\$H5BC9.K^\C-$V[C>4\*UL+F[!#40[TH9
M5WLT/;?34J>QU=*=Z+$ SMW&%O2^$/Y5#+FA)_R:GN6^9<$#"&KL=N'\A)H=
M+^)=6S[]<5DIIAJ(K-A;CQ"*UA[KU."T \OO@ 0:?M*360AWNMWT',LR%EM_
M7(&"D@^^H,07E#RWH*1F-QV4#,OL4MZ*%'<5^(TWG68VG0[:,9W*9QF8PR2]
MQ4G[1#ESG#O-)OL5"^LS=BXN4E2V2$7S5M3;65&=B2FMMB'<3V0.IF,B=7_'
MYG%I3V"W-=.)E/-?X0)XRVS%],RJ9?9'Q;-7ZF"KT0]!J-!U(W/&)DRX%0O4
MI4_\)#$T!LG"9A@[+LDHJ]A.GV"L3C6(7&22?AD.0 0!]U$V7C=)?F3!4(("
MVU,=09MZC@9(_.\_!G"&!]N[[]X?=N#' [(532:ZN$TEFF1.: ")E>W3UEWX
MW@1;1!.LHZY'I^Z_R,4/8K.!-OYCB<X) 1<3+;/1*$U&:82.=" MO-6R3BAP
MR:4([^!^#[LRU7>^U"^:S#SN-VVEJS ^$!Y8_5&CL@KO'Z&@SW,F FR_&84T
MER_B82NH<@,6*-K*O,I3T)SAMZ:IB5 AM*A?&2KH)9+='/R^0$Q;G]F<*,\J
MFQ-/8AWP,7\G2E4I$7,GF'%/]@IU*F[0HZ=4'<D>)C:24V4GBR'V4<T:DS,P
M4*)>0@LH;T8@V:6L?$5="5014\0&C:+.A*,QHGHH>A(/!/O&9AR^:62"> .Q
M"6S:HU^1]TEM[%/O@\UP81XM?\KAB/:I0WOY@*I UJELH<E;"<4@1(ZK8T;P
M?W$!,@(5/]J)* RZ(HL:2VNZ,G] ]QC-6VTH.?604-3^JNV."WU=>F!.DN,/
MJ<1]D@D2Z-;&<1,;-NL$-FR&P\LT'^MO9E@-OHH:YF9 ?.A*K,7$2EUJ80#D
M1JP%E_R##=ORS!LVX3+A#)\P3.5J3AALUC-9;.]-S8H]=*L33X>C03(> I>$
M:^*-V)F-V,-%*$^TAUDQ4;]$@F\*R;7JSRQY&D'10YF;%=AA7M$!/R1E\!4$
MA4RSX!C5RF&+*N2\Z.$];,*E[,.6^P#X[ 3POAT"8).,#F\I?.G>1GFQ^5Y/
MRX.)1OF E0K\2%V(@)RY_+&.D\I@4.*%#W<1"'+4=5S-Q+RBS 4CE^O54ISF
M/@OU@BES6,0KY8WWMHQWE7$ ]ZF6<.#>:4X2Q;N)9I6,[MDNKCVM+. I-BS\
M0CVE;%KR?^E;K.S(R;344MQ52RHP;0*D3!,JCM!:VMC;WK35")]0Y[<V ^W7
M*#=F*&]CK3!$[;C:JPG[;9YIW&?S[92=G<0?5F=?JZ&515A>QSU0951'64,R
M*JKD_4SFG2!,92_*.];GDD7 &02Z3&+9C]!G;*QJ'5YRLQB$NT&AR.Y<C1TD
M@<UL5==+V<M2P#KY3FU$RF. GZ-3&W_#8D>X?FW8WWZ$0BP<")@D6,QT($]>
M"7DGHLDO ](@PT.G,L&;^0LG>\FZKBFO:"2B7B"Z&3[VO,G 8K!/\X9CUJ '
M(\'D)/$#%Q?%**S#$%U@G%5B77KD/*0LR<VMX+KD4*1C)T<<.<_XN,VE*)^F
MWF2]<LR%(M<7>_47X4KC1C'%INC]4GY2/!S<H^,"MBQ%504V&H-G=&H4=,]@
M]^E(4NTUF^+J 5&1$U_D'7$(G?;$_G[A&!JE&L4EW[;H_;O(J$!(GVO)K[G8
M1DC-!#Z"$_V-B<;;P+/;P$?MV<#Z](S+1V%2-54Q.+\GV45^T;+P(GI-DQS7
M!QQY;^]P0RJ>?CI0>0>=(.K;<$@2:PJ/LGJ^G@[C3#!DRDYM?#DS=#-@R;:R
M/GHM ZP(P/=H]I\Z-7RZ: 0F'"!%[&Y_;.%XU.G0!'8^;CH1'5ZINTPS8WU4
M)=W2/E/=:_-<73Z1ZH!?9>(>]@7/20S@SA._)_&FW\]#5RY%=4:=()9F;)6K
MK'*.47[PAQ4) D=F[6$2W96X4Z>J$.)/PC"E"$73',J%0K5I/,!^H10&.KA+
M!AQ-2(T*\3Q5E5Y>VT2,J>B-?**BX![KTF@+1_/0%AQ% +?&:*P<3RF)TI1U
M@](W954"1Z#-:?J-.@%]9XR&LNSNZ@\7:92DAG5Z>3V[O/[0CKRF [3"KR:S
M1:4LJT%61EQN$6&NDAOX'!8Y,DK<\&$<Y1B+Q9^S;$RZ@^A6Y0UI8]H,VRDE
MU8]HBL3E[D!%8*;I9!T(,WD*&Z<8Z UE9H+=CSHT6*6>ZETR"K7.TVP(0-<>
MT@'AZNM,HD M[(LE<LXT9*3L[KJOJV%<GB-9K21@X=)%<8'[1;G:G&;A;#MS
M<?PI,251]N2N0*+]SK;/M/>9]@O2NF&AHW5-)*5FVBV]5IU&%[17C/A?7I^=
M?#EE$79V=O;77[H+.M?7E*"7IQ?'E\?79]_.@^/S3\'GLR]GY[\'WSX'U\?_
M#"Y/K[]?GE^]]L[,6[7;N]G1TB6[U$8=C>)5O!E5O#U3%/'&*IX^2#SUG?<?
ML;S$/=!)B&*C%(MT.:T-W?!D(/-7H:!,<?+SJY_US.]Z'3 <0>TB;_?S7-ND
M[I7@SCI&"YP$)9-5K6Y69D"1P0S+TF 43ZSC)RVQ!;9WL\N*H2?2>1'I;CM$
MRL?X&(E.BJJW1*K-:#73*7+",\M.AWN7^+KKY%+>1_*!LOAH79X29Z;$EKIL
MT$&BZY2/T@E(6^=(@V-5*$?@!G[QQEY]GBF2&\VAXME7X6RLV$IBH.,Q)8C]
M1+>%B=:+WKU,,PG?B7Z?OU!N>&TC951L$VN@*B=,#[PF;'B#*?I0 Z'GI,'7
M@Q-0!1$8U]3>(G+9#JF\QSA3#2P)^=4M=%;Z&*I6.:< JPC8?6*#%;1OG>:/
M*TS62?'/2E$ ]0:Z#;PAO)<\00I<1&:!_4AYK]3N5(ZP8UZJ=B;HI:)O/<A3
M)Y TC4B[A_4]*5]KE %A,F0O7AZ C9SEI: #E1BP[TV-B&*",BA*H1U^*RMJ
M/.EATHOZX\<GVI4PD$1)I )CJERQ:?I&,II+)O7T7U=VS%]4[)\D6 U#Q^_%
MP\SBH2V4,WMX5ARH,%!DZA<4W;I4H30Q.)\T..[CI0=2RASVU\':I@C!T4*I
MR-.\"G^64,T<N\\;ZL;?K,P#UAD.)!_#/]#IPY&X)G<X\TR+7:!(G?/*FM1%
MW@K60_MX\/1HA;V;^CGV8+>U\#-S_E5<.Y YP$F9IU%!(%SG%(M2:P&46@DV
M"B=7>&+%9)2ITM6D;@ H3[\I#^\@5^QB>AE67T<YO+4A*<TUB]U([]0P292I
MQ0R'"6;"Z9DP)J9[6B;'G#7_RNML+F'M*<KQ2P:HAS0$5#Z^V5'K&_;F*!:H
M/$SH/J55 =[37H^T,HJOV4W4J;F.)F9N4H2:&M)+W]Z>4CVNRH&4S>6W%6ST
MK>",TDJ-6=?019%O5>W*5G)R6D@F*%&R)62>68G5</YI/9N6EDVZ$\7\*1.H
M=,O=_"+\?8&909RHQW1?RK:Q@L/*",5*,>6)%)TTC. '8U<!DGV,RY(, ;N\
M(.54Y!5[NW(PH8B;?0&<( 'R.I8*/0)^ P+['N8&'*8?H1H052Z<Y=SY'9#H
M+<.7%%S^[#Z%&GTY4(NZ9@_9"'RC9I,NO1O@@"Q_4GKCVPL=BO9:WLQ:7DN
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M<6B$5/;1Q*1B%=OFXY8*+AG)'5CGIJJX*,_PE56!ZMN 7CL5,SBJ\_SJ4PO
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MB?^.$[\EKAO[&FF#RHOT\NVF1;?/#-!:VF(.22*8L*(=3@(;=9"X$R9KT3)
MO",Y?5.5@^X5"R'A8ATX@K&B< B(B0G'QZ(4K.N=ZZV\RI\<9[=KID/&:=ZS
M@I>'4&KY>BRU'$LM;UIJV54_SUT';E0[WZYVMD0$Y+X^HVP.!TE[&-1'4&A4
MR:#X[!@SZFYPT8!K#+M/5;HHD@I[#'BG1<H/;1B&U8*KNJSIB?=-\_8S*3F
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M,\RAH?AZ_O+IJ[LAOH[5Q5T27?%4E5_@_O]9P,:*IJ/DNH'DTHW+H^3:Z!#
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M?@F(F]?:"HR-E66\_7E@6SB @M#@#^Z>069M9:"$<W%P%FJAY.Q$/#Q+0;Y
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MN@^3SN.CMN6;KA6<;B*7BCE&\?^#Q/]TN^*?N0YP+X-\.&CJ>5&FG4@K*8(
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M6/6"SRQZ5E/R'15U\F$=-=_"M4-0),+W"H.@6%H.]V&<N8:O]V(?$WCXK4.
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M_DC3\_EV3,]CA*C"8S9<033NMX=>Q= N.G0JOBR=ANAY1Y(;B2])=E%#QJ1
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MQ\)!<]W:MV?!6I+6A(0Q>GR,*X',,<G0]R('0YO$EYI+9^*^_AK%X*,6@VT
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MP<G7!7)F3CO(0?D;KI?25+(FI^#>J[<>E((/&I/=AK\P@J/#&$3<7'WQ$"3
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M2R'CX5U$.?M/.L%!/MO@U&C6S9*"8NG78/)2MI(,?+IRL'B[8,8N!&Z47+H
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MCM"Y=D))&E5?1XNPI)7B1"YQFEM]3ALZ6NG$&0@OA;S(RM90V0)I0DE*U(*
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MM/A#/S^K?2\N*2P;5$'@3SOU_UZ>H9-"O(N;:SPBMW5$9ITC0@1VO%EO]Z"
MX#ZR4<2^8^/DQM!7+TKAK'%82Z@B@VE+9E@9*YXV&=X5U6LGBNNCN.##(;N)
MHZ7V39@@M!5>"CE!ABS*SE58;)OF7]"QYZQ^MG++-[)5J)D(G:H4(BW W -7
M*6!Q0@&F./&P3/RD@CLYAU8)+;ZYBK)ZSD4"?*<=$Y5S+X.7 +Y18AF&C!$Y
M'OY'??@OMJL?3Y6X2N2[5_W575&EX_^Z@(L84O@/Z?EP2E<H %>;^O^4"%4P
MWT'Q.*ZE"DV:&P\9WZD*W8JH @OQZ9=JL<R*E2(_^X*3-Z4_;.H&T>R>?+5)
MYKD4Q\PA0V2*R*=(HYRJ>92YN7L]7]T*Q^5JOZL\(1\8/]2"H:]9!EG%50G6
M0]W' 3^>]D=]VN?;/NU"?_0-59S=O0XG,Z4S)E5MNMK.LHLNU&**GJ+7!?9K
M633+;^_\DI8U0P;50^7V:,N?_XHVFJ/_'IMH[G0331_ PL?3#[\?O7-P^A_C
M[G\P737[V^JJZ;%G=N\5$M=HB7QK2\FG99&W^J5MA[70,9J6W59CKE_NWB6F
MQ#_9<Z?J>V1TU1T-0@S:<D.H=UU?YS%9*L&IH)X+;7+;X>#&C><J:<#X., \
M481_!=*$-7%;C5TXBZWC6'0/GF^AA7<%U:)'0G0+;6K9+R7:DD4NR0;,W@V\
MJ;!%/$\=TI6#3S!(O"Q<U0Y?J*F0<4A(:T3Q$69@20IC+ :[2W _#=B1N+GI
M*S-0KA85*E5V+YT[>YZ?B]#0XB0;W(9WX/WJJ7^D*;7C 51X!&=ZF E;8S&X
MYVF[<^B9 KWT[N!WF&%8\\HA[$T$+XQ!#*HXRH0N."Z6:LT22(P/-P:^>_Q?
M(A\6& 3+"CU="6T=A1,"+.E#>!)\)'T/5]LC,@8.'K6Z;K< '<U"S8->SQ%.
M8O),<\'#]?/*;1?ND!^Z/,@V3H_BCO R9I$N8->5B131OT+YIENG71)SBJ49
M5>X$ B?JJRF<:?G_.]JJ&(2&<<1WE7X-)B_=^6F1.\&8PQ '/,@#%*2=J(:E
MX*9Y$<(954-'98KMX5P>S/4Y2$B?YWANIU&55CM8!(//+'J651(?%37V85DU
MW\(U2% VPO<*HZ%8:8Z4\G2/AJ_W@B 3>/BMHZVQ]NHU0G:H$3WOD&@CE?K,
MV0_2#D6S=29/5:I3[*%7"RWGM/E%!5&L5UM#>+S!G ?DSNYOQYWEM$*NLC>.
M5'HCH7R+%G&4.V']0;O&;&^P"RA%D-:TE=WCC.:1*2933IFQ;CK^)T@2-CZ7
M>FP>ZAYF+3T9*G5SJ;X1YT)\]P=N8.]K\QTHX'3]MTQ9'V0MOZCAIR:Y%:YU
M^>0G=$#Y7I+V,8.8',@(K[ >#FP:AM.8KK313!W>*E>SM+X6%FR-D(5%_447
M$<*#0)> ^81BWCS2^HZ@.&!C1Z4=)999DMVN6S)Y^=SUG[QU;V^3S/8MFU9^
M@8JJO8X2A #H]R>JW>!]4^+CT?4-V0PEY (6I/(*2*:RI]SO&E.CP3*C0DPR
MQQ>P+M07(EI.A_+QN^/HJA(8*\%Q=.+SLL*]0SULC8XA(-&? \F8,:!!S_C<
MZE#C*[7G$"6P"$Y;$6?187]%,X6]O=P5$3?4(6PKS]Q6%*I,K="Y=SOU<3;\
M/8\<)HYN6][^0G:O@2J#@5ZA:KN X1&.'.Y"&1P"$"PYM*%K>4/;MA#JBN/0
M%/B&L%=J;'BR64BJR TFKH-GD"C.^'IS-GL:@0/!5G!F &(+:PYXFMH"6Q]4
MR95**F=R'E@;7"L#Z5O'S1[@G#PNYUWKNF,&R.Y%;5Q,OLKQHU02C94RQ,Y&
MC)++5.2I.T;LE88-@[^&?SZ<#HS]L0-C[,"X<QT8\! XAY[&$\DBX@-; 2R*
M"7_6.L\BA=MBY&I>R$DO4?:6RKT]Z/_5&@FA:T_:][2(*Q%X%XLEF3C%E'LL
MM$2D1E*N'(.3,4-#IMW+O;F\=(*$:R8+5L#76"WKED5FXXA=R<^RE1:&C)T$
M5JOX7ME+5N:_OFMA"?^26^NSE71N4.MMV2P93FFQC%(VG?@@^$"Q/W"51R?R
M 3B1S[:$-%AP+T3MNHR]<.G=N CWFX*9YM>K212*G4CR=A;H5Q H<5SKBE1*
M",BSE1P+P7V@XP)/Z#W:OI&YA1S"1YE/S\JU .=[?DE>"O>WX[1=JU-'(V/G
MODX21YK]^A(YVP'VYF=OL HDS'#>-=AE-<4<XYIKBOM6"(5B]^8L0EWQ&%6Z
MB)I[<<0?;XM,TG$(9)+FJ%0(7DW-4XH&D-JM&=]$$,*I[4_ -[@,=/,ASJ/$
M@7ZJ27'!_<-@/2>,CCHC&\QUOY5V;_XI!63SXAO&6?GCU'D@KY1S_>D7+\6"
MN!$ ]A)KTR?2V$DX?3 \B^TW0^DP>2%Z>&IBX6"A[[@.CJC+>(X0?+I^KN_<
MF6+TOFE2.N^Z&K]*U;IJ5N =M&4W\,RA1654;)"$612KQ*"#NW>3+RV*-^ZY
M=+;BP)SDE9T?W>3Q:>6> Y' )D)A7$B)IX#]5WGH)^TJAPY@8_]0>G[8,[AN
MZ66_X4;CY6 .)Z8']NX4.5V,$$T&=RIM3IULIUP(@;@L%DUN$"?\16@IH2'[
MTD2,N*#;]DOT247[%GIF3 L3%TNA?!C:YW:*8@$2WB<!4G5?BQG=;_"B@_>%
MFI>[=E5N>H,YF#K_!2<XGZKRQW9SC);F[5B:S[=C:1XCEA.>JN$BFW%[/;"\
M?KL,SZF!LDP3HL4=.6WDN62;1<D8@P&A&TQ*R\U^^.DAR4=3%)+CIMUJI2+/
M5H*&D0M@K@%ZVA#.W*\([*8Y=(AH*-VA QM#VH;&4S73JHYRE-F9),C0LD@4
ML6U@C.I+B@^G5)D$-/""1$"'8\SW1+*^;O[*C'[2R<[M."0[)MGDU!?(:[DG
M]0OT8D*-_*PNR<X!\Y2P],D\%66\6*@RYG4V"3(E"XC8)[ ZB)6J[H O:O;(
MF;SJC@OVB9#%89IQ6L;- K>$M6#<Q*#$I_HVZ10;0;-$HXGIW%H47*!#AQN_
MM=&(>1 ,:HIPT<;D!79,)#MDO8U:6<;!S-V&,L0DIX>.55*(;.'J# Y/XIMG
M2]8(FS^;Y$+#9FL8<0=,&ZT[S_ZTV>R3PR,D%-+M"Z?!R8?3X.#D?X(/[X.C
M\[/@X/W[H^.C@_/#L^"W@_]"(DGX[O3PX^GAV>')^0$1B01PR1\'IZ<')^='
MAV=A</C?^#5]?/3;Q^.CPW>:UO#D[?&G=T<GO])=Y!)ZU&^'IV__ 7\<_ )/
MPX].@_='YR=XE_<XH. C=<A\.CZ H7XZ_?CA[# ,_H"APUC./AZ^/0_./R S
M4A_WY:BQ'YC&[E;B#>HE]GA-S9Q7R*YS]J1<8Q2C7&],9::,]LR%IE'%T!.E
M=:(R;2BR<FG5.)CG#2CMS=G9+"=J6U&TBF%JDHJ:VB ,XGF!] LU"Q!3C8$N
MGIYL8J=J"FJ'ZXF=2"L]I?(4[[?=EUS=B@"TXH9*L/T%LRB*QMWC$MYLI0GT
MJ*[7-1%\]]K3M50(S!&UA(MJHOX +I$<:AT>VH=[31>HUZ6 KEU&;RZ8(D@6
M#L^,:!1&#TP8M:&_CW*SNUCZ<)NL5]352XC8H:VP@&H;Q'O"ZP-,-G[7M^?=
MNF*GV][N_<VF0 C@>@:583?V!N?4L(6:W\]>8IY8Y$,>A?-($)#FWE>$2D*N
M%/M1XI68IYF*J>(JUY8BGU@=H>X;QS3E_IG"K;OEUA%:3%B)0.IM=1R_'<E2
M7]%:K2AX7"MF;>SQR^CS)JMYX/9A\'$LM"O7K7U[%JP :4U(O*(SQR *2):2
M#'TODBVTV7>I7W0F[FNDL3OB48O!-N;>'W(22I6EBJ "K"/''EPQ!1\UTG)2
M6Q)#XJG++=OOJ76:'X7BQ[A:\EB/G7>=^=@JTN4#YOJ!+'7@$4V>15>S)F,4
M!FS7$)0DKJ"QQ?F%X%IZA:#'T=4;QR_[JX=)0856@-Z)'"0*A4J:"X :XSO%
MY#H31@3QL4H\I7472RYU2666B%F(47L7>PE6Y.%4 SX;JP'':L [5PW8UB!1
M L>QHC96TM,D(0C46.4Z?M4ZR?;L3HM"8/,1$;A,JL"8HC;>+'+<7D6,+V1V
MD"3K%67SE$*4*]<%,^A2F\@ZJD\1:&82>G0Q![_$!-)E*/J^.)K+P<$XR6RI
M9;'#04E:4A(7 :]J_#D:1R7;8 QE#W?OO;ECA\*E7)?G6F:DP^RS=*$ZD9QJ
M?YTQ[% JH9DU5:N"FZWU=+DP'U1=E&&"%%^8-'C@*[C4;P#>&H:2#?@=L6T@
MQ0Y6I@S8<QR!-L/#BE#J*ZF:Y1)<8&V+VGR'CFD,!RT8:)HN;_6 N%=[P<I.
MO#]@=SZJJF:A2Q%!^^@4Q)H+?25)^M%.#U\I6@IN5:=^"3V[D!9W8'6U*B4<
MLY01SC"/0$PXN(DTZ;EMT6ZO<VI!&_J?CDTREP,G;-F4\3Q".I:,0EH%$LS
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M;8?-BR)=:G(-E[<&(,\L1"XTFWF!!BQH)+.S8+((K<$IWP624TX[F#SY&R[
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MHYN+8A! U1[5+ OA2S.1GA63^X:*D<Y]@4QYEC?I3"-%2C+R0Z2SX0D&'P3
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M8)^Q^-&E##DAJLZ-Q-A?2GXFQC24>;KV?+ID9AP'_#,TR@AI%!>T@3K*F%\
M8(+=-:$"YG[1>/'WP/ ROU^4I^1*@:\M J]W$17@V0&O(5XE/5Z.075X>/#C
MH802W!R<2CHK?/9!/'5;#^EYZH1ET(T]5\@4IW0@0-%0T#34[ND(LN(P,ZL
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MLJG[[OIO:(]LJ17(HK\]3\QAPMOB71YPD;K9F"Z4VMIR7,'GI:*X#*X@P'!
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M<*:UAZM#<W30Y[.<ZZ0W[WK7.$Y\..,$+4"H"5( [G)C9<]8TM8^'%/N>MF
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MWE'H.- *K*V CT5P6:M-9-E]_\9ZN[93U*N:HZR3UR54]AT \YBZ@+#!A(^
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M4$<PQT6)XC9.*3;AAB\3WR;(2@M7 GF=%&!)Z!$051)S=ZG W_^BE0/8H1S
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M,)DUHL]!%N^G"F;R7=SOED[;?11U9D4:LXJ,; .0@1W7C-HBWXN*IWRMXAM
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M@:]<=7RBNV_G%+*:(#0P[VD='5.ZV%)S+%,[^[^98$Z&K.U"VC.%VN3F]]C
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M"1'MR$L#AY@H@K\-QU)9CT0XJDFF#F(U$B1OX>[@7L4TY# ,$(<A<)-@(\)
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MC,L5UVA&HY+^D2P,/!R[/D'\C5WLYBUC$.+:7SHC]RB<93G]"@1FL=F^9'N
MC!<XOQ @1K**+"!QH7&)"G5M%K^6!9CMV'V/:E9G564>S4 1=[.>YT>WV;UQ
M_2!.9G8CGQR!>4$1FB8JT]P+AW"+ EF;:&<@7QAG8PLFF2D?L5F7P:9%93[>
MF+FT6;#A(K:BF<2O =E3Q"OHPRYH@S"&,<#X9;,7GY4[4PU7XB1#4-ZPZD?V
MU"A'%G\BHW22WHP'YU* 4LHM-;K,Y.I'S2;WT%$.F_[(#C<39Y+G)CMXPE,<
M[_,Y!BSY<CP,I_1V(!Z<AY8^<@_\R01.FZ/(!7EL6,G/'\O4-\F5K;2]Y%8S
M7OF^ BGQYB6YOX21P"(:7=JL/-]329/NQ-0C-JRB-H,/L".@8%5XNG*_5 /X
MDYWOEE377@%;TFU-B:U6!6^KX&TE@;=EU'4=L",G'MKWDO\_QJ(*6B-8S%8I
M2GY@DN>8$V+24@#R8"@*4H]68[@DFA_D(RI-"KT*'!DE33)&I<(3#J?>Y-F5
M/4VU@@<]1N$S6F>"90%/&ZN=RC)2DD?DDD 1F!_C!474P-ZQM6L=R\C 516-
M]<G&G,[QIJ+2?U14RGU;=5M?X#[G:?'M3RIW0CV>&+DU"T^+42K&7GLV\WAT
M L_F*X5$^ B;J;Q4\RIYNW>A[ZDV&UZ8#I):B5DJFJ=D$!,N)Q C/]%X7FIO
M0=165!.A1GY\Y;2GAW*5CVAVZ)G#[U4;D-%(4/3SQK_C%AF<AYJUMTVI18GI
MBL*1H/@IA\<)0?D@*V&:+PG[HTOY,<C 946$[@O=.%J)FU@X,3D:(6MOD54B
M7 E1O1SPDTV1!$\(_?V*\X$IGT[(!<D'\:#BD6J5%?1L"9"[B>*8LYBFT1#.
M0<9Z33Z].T2 MTI2)-\*N@\5OV1&]E#DN)HG$PW<#<\_(R%+<$4K EH&BK0P
M/6#6)*!SS>VWC0>93E4K'^1P2D^QM!*DM0Q4B%RKJG"49)665.U]Y[JVEE^I
M9?N5:JHBG(PODH,Q4\4_;T,5JEY$S\9/9JMR;R2OR20^-!:Q34+2X)=>E?V2
MUQ/JST";HO)Y8@U3HY+,#*WU@SL7'@+Q/*9.OER32I(N^1>0\-!-*W04?>A'
M(,GP!JEZOPB!$BZ'UMTD#CEA/6,ST&O@\&K<,5B)4/TF#;,AY=':/,FM);';
MKY;88?;KJDIEY=MVDRM?*VB9)UM,R.K4&B3G1NY-Y$YOR[((K*<D=UC;&H;<
MGT10I$]);"2P3#$>/>GY78OY2MJXE]$:G:(&-M%DZE)N5R+[=V;M+"O/16U[
M;DDP&SM#(-;JANKM:)-BO-*<WJ]95#)<1PE@'=VOO;,3^/^K*K&U*+%U;KDW
MR9=4LD8NS)LK!C>_ALK\"B@R**F[%60ET\P;LX'C&F-)\!\,S16RWDL\]/E[
MJM>$<(60_#AH+VK]SC"C#"R:N =GC#):G/ZM7LP5HFNO5MN72SVM5K9D^7HE
M,L=QB8HD']=<Q&X]<MD4L%MS_;PUH<'7_?[U3V#-,[#P';K9[EHF\B:^C\V4
MFY]U>.\QP]268&]K)7XLC9587-[L.2:;/6(I[:>E@)5Y=6AUF^OI[YKCC7OR
M4?%VK^>\=LV-HE*R$1:-U@VG>/E%P$F92D9Q$RM48O(>"I,="*E8D."4+<.7
M4)NMFS#TG)&+VJ.*"*+5&VFTG KQS$=V/H+(?;],>8&%ZQ? ?(!<@?#AVW]=
M4EF5-!+.-SA2OCE?R/J(__W3CWYNYIX?3\?NP\<@!*GY8LO8STB216Y:,\B"
M(UK!B[L%B+MVA;BK$'=/1=RYCN_][8?K]GZSWNR,.M>-5J=SW=IW#Z[=1L>[
M]@[<0=T3+>]@-/B!W[J>>,>9\WO_ZJQW>>G\_DOOHG?^I38C(3 P3C!JK] O
MDRG=)&N)606%=8Y!07H##/XO M!T/OV[YC3V&XURRYF$J$;=>[JC>.?'[C06
M']4_[&G@99$S0*(9,K%]LB\IULS.WE'Z1-TY^LT^\0W^(-*,G6;S 80&:$K\
M4/9>)I&:JMH$7GCBZ67C20[=L>2%S(?E*.W]_[8W3+Y>;9YU,:S!,0=B! ).
M;:+Z^\,]J&<?F>G=P[8]RG$L.:-_Z@X(\2_>FOO,EY3UIXI!^;^)M^ 0@,FJ
M$UCC <SN.C+__;?G_6^\^YDKT%KG"6S_%?@QB9!)O0Q#*JO(4.0&T@$__-L/
MC1\>O_CK7^D@\Q*I/0W",7KM_G7^]:S?_5QS^F?'>V#*#*R5OJLS?18#W\S%
M/8$_EGJ!%9V6B4X_/WQ<A?:D!BXE97WZW:' @J,,\ T]L8HVRT2;9^Y$/(<Z
M46\N&VG^B[V1LSK=O-?1&1YU#H[4&?( _ZZ(MIQ$>X4@C)6H=CL)\T?RE927
ML#8@@(&NOESI^'Y@E<0JB&FLP1QMK( O?XO0RQ/#+>\EN+)ZBZ(J$%,%8IX2
MB*F/6NUVNS6X/FH.#Z];PZ.C:W<T:EP?#0>=1OO@J-T8C&0@AI_H!H'XWK\^
MVF^U.F\0H>$+0[21WW!D:FK#%_EE:,82U*6],B68\QRJD(*F8"% "B,J_>^[
MX_5+25TTOBQ@^E+K%/\ZGP1^=U"3=!@,]_Y=[=L2,]UQ34$42ZO:K3:OS KV
MR\VK4D(K);120K=<"6V)]J#5['2NA^UF\[I5;S6O#P=-[[K='ATTAPWWH%YO
MO)FNN<ZDO:ONY].><_[%.3X_N^)<N74+X H/M,"A65\G&*C"HJ H:.RUZQ4<
M9>WG<+#7.JR.X8U008^#9C)G<_38'5G/EMC.C9<'83!!EBX4_IBT7>3(PG##
M?%C1:D1A]/*/_S4<"C$:K9M.M-K:O^YR#8/^\?G%M_.+[E7O_,N7_G'O\KI=
M[QP>'JRFU&:S/)T/&GJMNF[.:KE/IKK932U7U'N!FQ+>VO]0?TD2*Q'?>2TV
M4[(#?$6(35;W+1?WT/Z+1GVO,\-,+KGP:KU^(6ZPT$0D/+[OUYVC3K-57XV;
MP!2>P2X.-X )O\Z^F<$DUWT-IENR:SF7KRZQQL669DFN5N,<$Z.E%+UN- \;
M]?:JUZKQ_&M5OCOT<AM$ [V8PK)E%Z4,K. ME9#2BI&WT+W*L.HW4,<V4O<N
ML.7Z7WN]J_[9SY?G7RZOSH__\<OYZ4GOXO*ZT3AH'1Z]A$F'-IUZ"?K2[==4
MG++BE!6GW&Y.N27:=*/^;>P.13CZ*@26"(RO6YW#QF%S-1;9> D[M3S2Y%7V
MB,;"<+<:K9(69986R]VB1C<(4G<LCQ3HH]TX:JUZAU[ *"W7'K[^IO%(ZDI5
M7I[-ETO-RZD8^H8Z.JU&H[F_ZI5J;J-8>LDMDD.]V W:LNM2!H;PU!O4.J,N
M.^'H<QK#6'%\W:FWV_LK!C0;>ZUW(I9>=M_.=*LC-9PLV_59MK@9".R;X[B5
M\-H>X=56)'063OR ,)A@-+1:]<;*AE5[&R78B^^3N6W6B%2(M3>6+3%ER=7/
MH1MYVR?F6N].S'44#5V:3IE 1* *K2SI.N]$TKWXUIGK9X\H6Z&^G,.C#)O[
MV$7L;+>$._CJ!H&(PM'/U%+TNKU_='BXLGEVL(W"[26WB(?"B\6#.7S3/CG=
MT<CWW#NN+LX?;I]0>]Y=*@.W>.KU.OR?-(S2R?7AX6%GU7AE8^_PG<BQE]@M
M'N)=B*:#[19-1UWOSS"- N%)A8/9XG6]7>\<-5:]2T?;**)>8ZOTD$K?^[2U
M<FGV(JEYJ%'V]PZGB]/\MD)<U?>/P\!+AXGE-#NJ-PXZ*U^W^OX[D5TOO75R
M--OA6 FUS1=J]?IO(0=Y.HW&T<H:87T[\1DOL3D\Q/8)J<-W9SS5&Q=8^L [
M<1-490XZK=7A3.\%B_%B>\;#.#@.^=TM1Z!V %*G-<XM^)9&TS!^G6S(+;N*
MY;]WS6]1^-T7\?5!O;6_.EBCOI5HC9?9'3E&)::V0$RU3OTXR05?ZJW6?GMU
M]>Z]8#1>?.]PN'S<RNE9_=1!/7P?V:/;+J3:_8 :N(91'(X4*N"Z?M \7#U@
M7-]*=,8K;)49$"^;&G+[I-G1^Y-FG1,Q]F%E#PEV#\=R)]>MP\;1ZJ;7>T%A
MO/#.J<$4T,GJ^?DNY-?SKE[Y[]F!I:)TZ;.5;]A6PBY>;(-LSP6/@SUV?X^P
M,WN Q4IC[-7^NY_<AFGR@OC=+;M19> 9"R^931K\0U/GL\H-KG*#WW$5A?Y)
M_Z)W?'5^<7G=/FPW&\^KG.# @ Z!01N?'#WR]O%+C%UO<^W$BE.\<A6!94L_
MET,E;=:_A??H?VL?M#J-%2NU-9]:.<#L45DUT1?9%QYBU:W9, :YS&TH V-X
MZ@5IG*63 2+!3_R(O5_7C?UVO;.BA=]\:H6 F;M2KDU\FUWCT=#MJ,=[WK4J
MPR:^YDTK_;5J*O_Q_Z0P?^J,B?[I5K/9:1ZN>K6>&'O> #'T"MND1JPYF3$)
MUW$EH@G>,JX:^8+W;:LN5QF8QU/O6^M"Q/X-)]7"2?_F#MWK=KMUV.BL>MF>
M&*[>3#GVTMMF#4<7#@<,AD\&A53BK&37JSU39>RP>=A<64=\8DAZ P39BV[0
M3!DVDY^,;OXK,1;3VS!X(N:CDEFEN%2*8CH7XB8=NY&FF':GWFIVKONK7JHG
MQJ0W26"]TI[)T59,_M]((?6DXC8;)J0.LC7'8IDP>%!O/L/U]\0X] :(JE?8
MIER%MGBUM,KR"ZAGW)XR<(>G7BB=N]YNM0Y61-4UGYKIOTERZ66W:I4T_TH(
ME>S.'%'Q+L;D7!\=';96OC=/S.K? ,GS4GM#PRS /=T_#_=4R:&2W:GZ_A<A
M8C?PCL/)5 0Q.XD;!XV#^HJI2LTG)_%OIEAZ^9W#\<BU9X_XWB)7VRS L,W=
M)+QSQW9PL]4^W*^O#I_80OS$2^^2'&ZK8U*-+19;KX[4W0 !].+@N\T3#F^$
MT34;4UJ [F_'YU^_]J^N>KW+Z^9!\[FMS9S^;]BI6H]9\<:*-U:\\?WQQFW0
ML5MU,)XFZ+,0L:T_'M7K!ZOV<FAM'TCY-;;)C%AIVALJ30H(I:&/]:L?I(G
M>AL'C?;*5^D]8)A?>-/T8(X<[5TD=#_GHI7^5C55.-<-I-,^OCYH[-?W5X0U
MM;8/P/SB>Y0I0R<'1$EEY-86YB2^,VG5NDP'0WV>UXW&4?UP1:]AZUW E%]R
MQS(CO0\9U<Q=KQ\3=S 6);9[/?_N[S_!_ZCGAF/A1KC]MVI+/_!9?&SB+5/<
M -C!F^SR4 2)B-0Z&RWKWJL]]ZV%T/_^[_]E+\B0S8=A. ZCC_^U3__WR5JI
M?'F#Z.A&?!A$POWK@SN"5W]TQ_?N0ZPN\N%>HP6D&$8>?+6OYM7$^;3W#@__
MVS'_Q V:V5[;)<._DI\0.>F/OG^P-GH:QCY>S8^1&+N)?R=P9&M,=4[ ;][P
MD'*<N&F.Q'"5J_/CU3C'%=X:EL5P_D$RRST6T.TRVT?74I,('2>2Q]B=QN*C
M^H>]![BO<ODX_I#G]<D^3S=-PNQQTB?J>+0;3GW O\%/:#8?QNY#F,J'LD>X
MR?4DWJ1* !^@9%3UZ7<G#L>^YZBKODXYD>5@\K6#S&LE]0_"L8<9"<"!?OIQ
ML'*\8C.*1\Q&,7X[__*E?]R[N+RN-X_V]U?M ,XAC/_[7_7._B<,8ZA17T/_
MD'2'C+=<1+><<K(Q)=%>GX^4P^A]"UY9,K)\LT!%N5C@4M9KN\[)TU%\?=!I
M-P]6; 73?G:XHEQ[]ZJ;I09Y!\BZ)XF#S?*GMAO=Z33T@V0"VE<XTI11;[16
M1D*WGQVJ*-^=>85MLD8TY1^V+^KWC,M3!N;PU/O4O$Q1V<56ZL*02;W57K4]
M8/O9 8IR;>-;[9LUW@O=K3+LX[N652V)1W8#SZKI<7W8;'5613BWGQVK*-]5
M>H5M4D!P# #:Y50JN;4M<JNMJ^+X 1]I?-VHMXY:*XNMY]93*=<NOM&VZ>$<
M/Y!7JY):FRVU.A=B&@G, 26>&8XN;]T(R:1]=-A>^78]M[!*^:[2:^Q3=DCJ
M5T6#DN"B?HI6MX]*A&VV"#OHILEM&/G) Z@I)VF"K0/!.C\X6EDW?&Z=E7+M
MXAMMFQZ.M$4>\.44Q3)LZ:,7K[7%XNPPD[7=;K;V5X6]MY]=A:5\E^GE=L<>
M:-L$TY/N1]4@IVJ0L\%8QZI!CH5<P1XVYQ<GE]?-HV;G8,5J'UGD2M_YX,A1
MMQ"%/H=3;@NXJ6(1%8O(LXC^S[VSWD7W]&OWZ@I!;HU.L[.J.RW'*I!7R-$=
M.?S[X1F5=E5I5Q7KW%:[_*#>^RZ&*7M.E5-37#=:AP?MU7CGP?8E[[_\)NGQ
M. =#CDC9&)$[3#AELA_$291."M,SWI,EO_$NYH,&]3@^QF51#Q\17[>/.JM"
M5 [>14[_"V\:#>;8HU4.Y8T67$U9J/W$PJH<'1T>K"ZWMBZC_\7W2-7&/\EB
M>5[N5I7O"K7?EZ1JG89QDN&Y!P>'A\V5)=5[2.E_X4W#P=Z;H'K&+2O]E6HS
M=N1W+N1^?=CI=!HK5E0YV+YN8R^Y/1*D(X>JQ-+VB*4.MD, 8YC;+31;G<:J
MZ3,'V]Q;[#4VS![H$VA^(S_P7P#V5H9=?-=BZ>#$O_,]$7CQ=>NH=7BT8DGC
M@^WK*O926Z-'J83/1@N?PR]^#.OY0[C1=?NHT5FU^O?!NV@?]F+;Q<,X.$XE
M:C9:U!Q="G=\?5CO'#8/5[TZ6]=![ 5V!0>H9,M&RY;Z_E7D!O%(1.&(0A37
M]?IAL[,BQ.W@?;0">^%=4V-1G@^.]@[$36>+Q4V]3J>HCO6ZWC@\:*U^H[80
MSO""&\1Q57V%+D2<1#[7>O[$M\GY$D8CX2=IM'UNN&=<HS*PB2??K,:%N/'C
M1$3"8[[;Q&CBZG?K70 97G;7S%A\O6[#L?<^TN.V6F8U?W?].]1G9 O[HX-&
M\V#%5$JX6-N'97C1'>*A4.'CP2JYM#ERJ0)R5T#N*@>F. >F?W8._^Q='[5:
MK?UG-JG$X9P/#H^XA?DN<WADE2-7\8<MU# /ZR=BC$K/@U:@VO5&N[ZBZ_EP
M^[(\7GB'U&!&R?PD_^L,'IS>&%X:A8$_9-_)Q(_C+:S84.FA52?@JA/P.^F2
M_L_^V4GOZUG_2_^X>]4_/[L^/&@U#U?$<NI6Z?\$'30W\+9QR8.*2U9<LN*2
M[T(//ZKW T], @:F(SBWTVYV5C35C[9/"W_1_<D-E6F33BG6VUJ%>ILE2@'-
M-'(''8ZNZT>MYD%GU6OU'N*2+[UK!9>-:N6^A]#D,^Y;Z2]7\ULDINX#M[#I
M?<?JDIB*WSAJK5KJ]6C[4JU?89?,@'B5U)#;)JD.WY>D:IV(1$03WVJNL;^B
MA7ST+I*K7W+',B-]<H['KC_9?N'4V&+<S%'[+ QZWX?C-/;OP)Z\;C:.]E=%
M5AUM7W;UB^X/#/7!&@NET@7^HI))FRV3.OT@3B,W&(KKP\/Z46/%SM!'[R*S
M^J5V2X^R_0+H.?>I])?G@&S<O,_JL-5L=%;V/FQ=1O4K[!*WX<F-6 FBC19$
MAUC_T@]2IHY6&U25E6VC]Y!J_8(;9@^$BMV+7JPR[.6[%E)'W8D(/'0E77?:
MK4YGQ?)_1]N7A?U26Z-'<4),@IL*^!0N42*B:2222CB5O%[\ZP-F2RM6*IQP
ME4>0!7+]L_NU=W8"_W]U>7UTV-Q?F2?:7300QF7&W<)T@J.*'5;LL&*'6\@.
M^R>]+_VS/B)/+Z_K1T>=H^=A6B5#Q.0J:^1WP!)_3-S!6)3W(K_YO*PGITO#
M8:O=V[)Y>7X\';L/P"<"\>G%)HE_+T-YA8M;EN5[_MW??X+_4<,"=W,C9$ZW
MB@=]8$[UL8G>":7O@,+S)FQI*- "5]O0:%G^$L6D?-]:"?WO__Y?]HJ,K/X
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MD\+Q:.PP?K/@80'?CDSS\EG.FE@A0AM$CYDO+F@M6CC,#%R;L65QRHJ)9R4
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MW4*EC,R[6?)2Q;/2?LE[-:LIX.:F$\KH&^?#51A[2BS,XY/["A<J5@H_RTA
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M**(MJ[1,QAQ",GHSJ/03Q5HBE*DJ"@KOI'<$3T)A"QD+O"C=C)+F=2UM/H4
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MFM!1O[AV]<YV/Z >U,%=(>8Z5_3-I*8(H-)]4._[H'=#!AG.&GYE?G"").P
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M--OIKU$78G>T?62KZP=NX15"C#)LIVU3;CEZ>*W$.]$'WXMONR&W$&>0O"-
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MS)%83@X>4E50,-$8UBF(-EPSYB[48$,&A0$LY$74VSLE<KG>KB_HL<>L02/
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MG[;#8BEDF C&(DJ\,JO[[)?-L*UGEB[G_.,G\\\/EZ<'!P>[JR@N?R*>G.=
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M@=>;RAEIQK- \(D$..T0S?0N @-#OB9 >4T -&,8,ZLUK2N92ES5-FL(7'D
M<9 AA1'RW= _RVMSYQ)J\KCZCKAPL #]CG_C OS$Y^!JY\@I J1BP@0SWME
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M$@9^@XH$4J1A^B])K9;G+\ [@VFT".\#L+\T(XD'\I9,G LS:TYS,P 9@:N
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MY:M:9\]K,N]?C1WEMM2>:I!X%Z6"@!&J:?K"[;B^CI_/6X&_Q$RHS\4_?=X
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M\5:0ZL&('S?GM5$1%%-*,TX5@.O#T*^3\=#\V_P\Z8\AQ&/F":?G#6A==4L
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M8T;X_EBEWZ+!-;#*RW$>3:R59OD0+TLSHUFA+&_*I(S%*]>;=J\/U=W+UY=
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ME(_< O '4&#J;3[Z@3F ]@[KBR0?+K,>$W-G6H/>R<YI_5:X0M=FD[PQ-QK
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MRA?R2A82%FMZG2MD-B[1F+MHEE%MD\*Y"&S(V7S$X1>Z^3$F6)(!'%G$Y-1
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M807^EN0$A,#FWMFDL9WC9]D4T!!^"H?_@6H^CG$;Z?8T1B[TE!S/'"/'^)I
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MVGZ]Y:N) C-+ .+@\$G%%D-AUVA(H7]8_ !T 7=OS$P!>,Z%!F*/$G,R5'H
M%#>Q=[R33VKY$#A9?Q_HPN$C85,'_#GR,<///W]"#8LFP$5LEI-)8KFL[<%$
M&LWONQD#!*+[; W*,V,LP$O ./^RIA[FC4&:.M00I!Z.RTR*Y(S(#$K$6;.
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M]JW>]87>\7W>Z9TM+VX:+#Y!7=)Z:2G3E"D@$7S]EM#@'H_\FG+4H1>F7W(
M8^/X!R;03*[,>2YX%)B\:G0X>]1E6]=ED>X<;C&JQ@RH2Y+#E@Y+6PB%X<XB
M8W^_'93R/B@RH(QU-NAI? PNLV(6#2OQ/IOO$C.YB,HF+6K1T:8AM$QVY0ST
M5K04 XZYP:'D44BW+:2O;VLB2EQ7A+=K.B[)0R55$=9R00%=AP&&/HORO<#P
M=76ICND4E('5-1IHC4'X4GV?,))U(&.>NK0ET L+@YSC5Y(3*3!JV^98)G!9
M?>WO@M7J7^\I1@H)]2;V_,0/&8V)]T(\!*]!.>WH4.+O9-01B;X+P7X32TH8
MIO)8BW(315RG;+G6!'0?_I3 *AIG:[J;S%0&HY*%TF2EH#[Y"MVAAF!JETZ+
M2&N25::*3#R75B<?0N,-<>S:)S.$M+K!N1<8C,8%[4 F*R@Y:5WG:_U ^)%N
MJ((\Y?K!4N\I:GOS*^JQ31")D,1]V(ARK*68;=LKO(W:3,9.TASIG1!#=XVR
MCSP&0>\I"/IFTR#HS^+*JQ%$NSO-^*;7KH(06)ME6V5;.5 7;<@&^A1#+UC(
MW^8M935@B%DUY;2*]L0#;Y&4BVFFT&^S2]$<8SZ869Z# 5&3PSBI9LC^I6,]
M,J"0AF*71H0=E%^;9)ZW#M<0]W3RTL4"_1DD]-+.+=B\C0L*MP5,&EU4N;&G
M*-;(2\!RLEFZBKN4EZP0[4LR:1TS<]/BU[UL6G7%S-Z"VT9<41JZ=+B(QWC7
MKO9B"#I&Z,//&%%'N?O/"@\L@D>T#7?14^JH.3[6=*1>=#1U]V6*+YI,[-AV
M:&0_-$K=QV[H7Q#;'$%!O6/=-)D#DXI@&PC@HT=;AW*@QPR>0!JEF)WX/#G+
MK&[P-ZD-(X>-76*0I4&_VQD1%2)&HN9=31I+X2J4MCQ[#DO/'=+7J@:I<*#R
MLP$ML5YZA$G658]7F6[[:@PRP;)KQ:QQAMAI5AMS:^\TFECW9&)]MZF)):^)
M=MCOL/T_<$8#O9_9?K<9]]$I6KMP\*O&G54J\!!R1H]=E7V?PB,DP) G.$1L
M+S#>#(\[_BL--99-<<G/F8EZQJX\ES&84LH*>X58U!7L;.,":HB*((>9V@,6
M<=P'][0/OM]T'Y@XT^AB;-^L^3Z2>*Z=0S.+\=<2[5>C#0@_F4*X2#ZIC!%Q
M >??I68)<_4 Q1%ODC]T7RE+/H]Q/*0)4QQ[F753/EJ+?($'ETY$F:UM)K??
MAO&A"$U@"__,\1^'MRWLO3S/:P3/#;1RH[*=EHW"X=;(( ^(-DK=[M,F0\=,
MYE1-WQ($W6DP3']SR%!=+W-/OKT47T97T5'!,2ZR[.@7FDJ=:[SE5GP@1>=K
MF&USKWDVF+-2+,!6W&<P>Y%5S_C(I\MED4\)VO-;=D4[A+X@+I\:.X,@:9!)
M(F)'XP4\2'NEU%"K//+ U:H&;@W5M#AY3K?=M[?U!?'(!NBBNH0Q#@8D]]T(
MDAM!<GL"DKL=%Q[WLC*X:&^[LM\JM-VZ;"F;9N54&D90]:1N>0^Z&&1 PH#^
M./:'N37^^]:!6ZR/),:D5^SOF"[(TBP[BL13-'.BT0!G-=791AE*7 E=TNVT
MG31L?L@RAG>PHU%Q'F;^2*W#0Q;HYY]?.(:+X9$^(KZA.55#RU/J+K''J53#
MT%%0%;&;,4]:2/9/1*=RJ'"6DRNXX6QQDTIYK4,E& LQ62[Y(;X%\^.\YE.H
M:9R[F,"&/=?P1U*[1CE52\_N'9ZXNE@!+Y(1>4V23,*N!>>EB3\[+R^S0TM\
M2-67RIPIO%0SF^N:=]C+2@Y<-^-LBLA6W=!YXJDTH:+HAWX"NU@8#3)+M?%*
MC7[@_?B!;S?&W4N4S-$"HT>X?>/^[0KFEEBHU=BPIB]#5<-.ZA;F\#$]MG4C
M+VQLI6&&.I<-2K7?@HR'M/Q;D7;A>#+ XV?G]FCP+'\Z/4QTUG3/,[+F#$A<
MKG R*$\ENT\$ZL-[&-V)Q8(FI>F ;0%+W*_$U9U-VU#1-1(-OZ+<C]5)C%K(
MI5NL,R7L(6: 7%2]6XE;;:?@74.+BUK?[R3FQ/^=0WY52X7>,LH2RF>ZZMU[
MNOWVQ0]R[X:<CM0312%=7DI$QCF>@3<H'_C)K ;7!/X[R8G18(Z5[!=(A$S2
M+:EE=5ZU.9O1%C)"?[OU=V0A$L<K=5=F TZH$9#G0*N/WN;EYGLTERLT/X7D
M)DU4.0,98@H]ZP*;J@:=0L48D06ZN:Q./1P;W].0W?AYZU%8MRZL$=2M?5G]
M;)D3-%QBNC0Y!ZW8D>6/L->R$0N1J! (WT#=OEL84KJCD#9VK4Q"QE*BS')+
M-EF1U4B_+5:W[9='Z#+,P1H<FI-9Q;PB-4B:55?X]TPAJV.F]P;.FEJ((15D
MG4\Z/OQD3O-.:M&7Q JI%GFWL)TREUT-V[+1M?&"NG!1^WHETN@ZC**]==&.
M8'5]/.UF)@D!:ZNZ!I$"7:INM D%%DE[#C8/05DO8"D5Y7,I(<X$HJ3NEPKY
MQDDU-XV""X[T<4X=C;JVJP71VY42 9QFR[QER".9+EEML;IR<^HF O(]@8$Z
MHN<S_X95AA>4FOGAV5*5L\8Y3TA>&U#BB%54C6%;J[J60E=TYT9?<6.:AL ]
MVC0IX"3*"]GSU01DP+/5^K@?[N^-CS&B"._+I?MA4Y?NU DCHP1\BD1Z1A]O
M^_KIA]#'^^CVWL3T7K=86**C@0Y#&V;R L9 @WU!D-!/)@\?[>%)"4AS7E?U
M-]^&@D?*,P.>)[_JI,=EE3,N$GX\JSK4-\N[+(PS![[_J;Z_$WP"WY'UG28Q
M$R8R+_7BQ]?<68];9MM;9EV]ZR8RG&I6D7[$E8\]ZK'6"\#'\'B.F,PJU0BO
MC(;-1S+CG,RD#"G.4*Z8Y]>F<_M L84->312:':=+[K%X\N^'Z18AG2?IJ/J
M/:OQ;]?0,>4[RLNVY>7U/9S\#NWV"4,4RH(B,-E"4=<#9(N-Q'/!#J=RP0F5
M%14*:;!^>('BE$P%:N!POJ+"T?!I%VL[JY*F2OG0=#F:B;FYYI(A]"P0BRBT
MB*FEL".BMT@?< Y]2BV5()LUD#"GW''.(B_EVI+3LONCB3^RH=&E4*Q.(!*;
M%Q+R9F6^P"HT+-V"F^PX('6([LJK%QLW#LALA9\4N3F'VT,[*M'\_IOG)V]H
MQ=#<J,R<>JE6*G6<4A8TG_](TW0P#0\Q40WGP7F^<]$H.&?[$6))7A <QA6X
M%SV!VU2P%C F"Q,HG[=OEA$=>Y&WZAD,-$6IN*JS)0Q\E!V+!'B)9MR3L0+*
M(%A-5A=O=U#M; 55/0%YEZ"06/C0(X=#?3_"H48XU&WA4(]"Z:RR !]:#TVB
M>HAJ*]L&J2\;5<R3H_F*F(0N4F++R-1/L5W%W+D:M5,K-NHP9X:((HL(G0_
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MR4GXKF"C</</I#-V,-FU(G).:O<X4^B#&.IDGTXI\(LTI1*/<J,C+SR_!7,
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M6E1.(UN'&"@OG8Z*7N&[-R AP!ND[6 ZCY2"AV5;B_E&E$+>=%*/$[)?H(F
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MJ,?Z'2D>9W#WED_>Z]^-:\U5ZK13Z&INDHA(7AJ%81)\UA*LC79KD[<J:&8
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MO+M F->CM["URM>8R.Q_MUQ !J*0+PU5Z[=+#5H] K-L_1*K?IK'5*'-@P?
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MWHPHM1&EMB<HM=MQ8,6L<]1FNN>*9YGGBX6:H:56W!A[)C5F.FW_P%8W33[
M&\.C+^(-4"H '#AM;BR,%A1,E%A!-MB?P6!\&2\G&1#I2K=@C\_/@S3X@_Z8
MI[9W!)J ^,9\I_+JHL*C#0\4LHFP(3O6B&;)KY7 Z370KW(JQ*BPU<AJSU<7
M!E!K>Z,D<O*S' R_J4)@%$[HPI\L&IE$6SH7T4UC?@H!O&UW'D>Z'0[=>64X
M)$T7[,!0/,(O-RIW^_@'F ':_G5+W<*3O*S<YA:ZFZA?DH?3/X4E+ZAAM_!.
M>4TE!+E(5Q.1%4,.9#2VOK'_#_T*K7Z$T0O-59H4^2+73;_-A\U-28A_)M;C
MV^#!N8R;7%-<4BJU$ZE*N32Z67)RW;*+H2I1UZJ><KOPO.DY/3T4OZ6D.'F#
MSYI,';*&7DC$CSEIJ#Z'XG-)=CJ_=XOAK3!TM2ZZ8V^&8:_DX5EPB']K)A%#
MTC]&V6;]!S-\87H!9LD"(TTY*@S03A@75?#3L+PD7OCB#$\[1;J<,/\/#'$)
MBFE6W,@F83GSIDQ5(4TE99&ZYZQO6&(%#/W%3=EP)'P EE=L-G6>U3,N1D.\
M"XLMBQ]L;^Y_2)I"HX(9:KO:L?2CC>8I'RS:^,W!1OSL?F*-TF)5+C4^0Q""
MI!4XMNXO=LNKNH9>=D'<EJ$,P9_X*C'P3H/<)5PIL^N]$99I,/)4+92Z6'N5
MESKEOXG*M.HR^8B#^DH3>0<(=M-WT 0&H)7[2LGR?#9</.LRS9BJ(19]I=WC
M+\3J8*N07=\ZW&JAO<$ZW^+H<=;Q-]3K67@"C7G&^[6O@@;/I_HHQW,.Y0?5
M]:S.KD"I.>]&LWJBC<()L[:_9[L8QMPB9HYX,X!1U"!=""S8M%8X^C'M=KQ*
MZ$1D"HR3"?>P;O-ZY!2U$S2G8D)9H2)!IB4P$$;YN6?Y"7HOOX\J.-,[N5)-
M&.L9"'+A2X=W=O(6F:;:B\8V]XX=7F"QDL7&! /D'[;P@%J#Z]PB]5R3\/!
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MA4B-.NN>=-;)K;EE_S#X'!""O6>7/0B;]<U)2"C[I1+P4%$0I(@YF[GLK&7
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M/#<Q)PI.R8_S4>'O3$^)^6%T"T#X#4$S5D8*A2W)?2K:?T['7=_7V>G^^VY
M<(=PW4FL$97L5<D0O3!W&7?O%IC8=TS%WHO9KMZ\:C['TL!+9IW01IDW2.@.
MQ1J&CF?6TY;Z^8YYVL^,&*\7>9F:_Q-]+1T,\]QT#>VWP!U%_6F+^OF..:V)
M)WJUA)MJ*8?,ZST3KWY6TZZFJENVGTY^^/ZUZXZ,TOVTI?MBQP3$OS)G]H;Q
M*.8FQN(IO-@IOSAB8F]";_<X/=:2[QQC,44JY5'Q1#@56PG!MW+&'2KQV)2G
MQ':N#)Y("DKZ83?\P9JPVZH'8<A K;@D"^\R55FC&O&\LO)>'V]=@=FH?IZV
M^LEWS,@LZD>3\FT>#1_8K+>F_5JU53&BZ.S5N^]3CSQLW)'CCES%+KUC>NG0
M_5IM^9K+:+-0IA9DGL=(">$VDRWV>U9/+Y*7KXC,^67*U'[PY:+R,1*I[)94
M>MNE=)G,"HZV<7\\[?WQ=<<\T"R58PN!48B_A>4Y2O-\LF4A7LN4M&GCT.]&
M>;[7QSA:+(Z3G>@U#W/UF?)\GQ2"J.(QWE% 1H6W&=WMCOENM70/L6&-@CP*
M\F;\M#LFJ'4$>=3/HUC?&T/MCBEJ0:S;L"\;^OT[F$:NFHWV4O-$W+L#J(U_
M-=;&C[7Q8VW\PQ- [Y@!FKS6+W56\NM,?LG:-=@DJL'6;)Z$S\O@1HIJM*GV
MFEI'Y<?)_\[*#HDUI1FAR1I3=W'](QH-L1T8%7=CVW*N'-2YL/O'>'3[H]XQ
M*31G5L;8]2C$WT+PO&.&9TFFK^O#N9GK^^KYJZ/)2*_QQ$6ZW3$)LHCT@S3=
M=%M@GJYK@?G34 O,L2_GN&WW;MMV.^92CK1U7(U8NU-?3G4]A:T#3BER'L3Z
M8;KHLGVII8MNB;$^;A<<R#LF08X4F:X^UJ9\);&%P+&1U<DEG0;__N+YBQ<G
MEJHNM26LXT&P%S).D<6=$!SOF.$X0!UOWK6B )O&DMB$X&7L/3F*]EZ(]N[H
M1G?,-QJ3R6_PM\=^J*-0_\?1S8[Y++50;]@/52[7[5#E3Z\;JGPVMD(=)9S)
M*W?,7NE+./J;FX$:A@!";T:!W@N!WIF)G>V:==*-<@PK:[G*]&O4^X#[):XJ
M]CN"/Z1/XCF8Y[ 5F*JES\)R3"5):5#(Y]-;Z.JE>.?(H9:-\AM[GMCJPU0W
MPH(;7U172&^6\F":A#R[K/(949[!2+.JF[0I==6*LO]Q*2(OW 0T -REU111
M>QI=&I7 SI7 9->TF2MK>3=WN]6=NT1ZE;PKU,FX4Y[V3IGNFEG3[I2=M'F4
MVX\='L=]]L#<G3LF[_1B ZNR?ZM;/,:H./.FZ2+LZ!'7#D\BL$XIGX[;&+\B
M>&QFD_'P:\MEP].%+3U3Z.?!_BW%U:-F/N&1-NZRI[W+U*Y)-L/PVLJ-QLT%
M8"M$>P\T(.W@/*';MN5-9V8_[KO'M>]VR/*Y8YI/'>K>;@^</A1LW A[L1%V
M=@"=[YH$-,SY/-P!=,^-;A[R0/LT'FCC/KXEV^F.Z4YO3S08HG)2^]'F37<F
ME6B$60X[$RYRG+Y4TW<Z <IX2#)U Y+P(SV8IC^L5=94)6S9&^SZH*8Z'$/9
M!COM\.']KJ1C*',_]^P.*4)WS!%JQ'9MCZ#-LMEOGK\\R@X+@W0 -?JOQQK]
ML49_K-'? K_LC@EF^][]L/6EB]A^PFCYV?7T(BO/E:Y(6X EE"^+G&,-5)SV
M[R<O;(' OM3"> L[]I5Z)*[*UUT3S<;:/MVQ=/^3FH(K7XS9TOV0Z1W2SD9Y
M9[>I^T$2YSDUZ+Q]X]N>XUH-=@[@AB(@_BJGQB13.$!2])'MWH!]M;7'GEZH
M60>FT,_RF$G6MAE^F"# KQT+V+[M,1[A7CQY_M+?B=N2Q4]J#B(';G3S+GF/
M7AE8(6WFH!>>)_82/D!@VUB>?XP PUX\5P3MR<MIT<TPWFQ^@A? WN4+&J;O
M][\F"@$XJ+HB&QJ!2 **KLX*^CWM;7#_F^QY\K>R4$UC@N'PL DU'[K*&QSE
M7UU>8UL?_/X*'+Q&<PC*C43#I,''381UD+^"B>KOKBY4F72-[E7GK8O!TL[P
M PF\"4;8MCQ=7M1HRLH-,$9>=6U2Y(N<WX'<:>.GK->\JM.ZS<&G@BLE^@'_
M.BU+=8T?G5U?P'YN&WIFK:.:WI/X;T:/R#^20<''XQ>];NRV2H-9WOV%HNJL
MYN'[Q$\G-Y&WB5_DI?L%CX9]=&']41:U ;7J/=-JL(AZG\.5^+CP3YANR\TM
MRLKL%TRLY%.2>%E!\TKP&",,7)-S[]YP@;Z$3WY5YRWXT[0XJFDW%T^]V=0B
MRPMGHP_O<^3@<'#B%6G"_Z[JK\G/< ZD]D^ZL.-7:5^?=!\N;@Q\/>'W$'WM
M^F7; =9+N--ATND,;FT(,'LK?ULZ;U EV1(\R"G%*58@Y=-@$\@-V?BXG_MY
MR.(CHWI23J3I#LR('H-CIV*YI37?I Q!ERSX*3JJ+L#A4WK5@0[7.QMFN,B;
MAOY@I=9F7U5):0OX2<W9?NJJ/E$T#?XZDW>+^FZ1W<"7:=#XV;'?(MI3A"'6
M&P9_:+K#1&X#OYYFL!'B*][$BR&DC,)]#ZE>=V+?H''QX=Q'EW;RV5=Z5S@:
M,0+RZCV'$Y99!2\I33N7/ ^F<;#RNYS>"'QV#E-L!2B+3Y'5N'O$?9,GT+HB
M]TYM/:H\$S53S?G51:/?8$NEIF9DV=7+JN&*$6G/S?J/"1%1A\%_4(V)YB#5
M0D_HW(B?.V_5 O<[3#5OBQO[BXJR:-H$)BFK^17GI5TQ.YX( ZXTIZ8P0XTI
M<U:DOJ:$=XR:H^7#X$'M:,_>]"WE/;",8X%V,8TGWFW%$IU4!9J#IY^^O/_Y
MM[/D_?O_]9?)GL[R :WAOYY]./MT^EOR\=/[#S^___C;V>>'7H;]EJ*#\:]>
M/C_9C7_U(6N[FC3J;WE&;],2BC]'BC?W<SB]FF[!M$^HT#5P+L0/^"<55U4,
M^1]BF_R6GZ/Z_J1'=>ZJ#18\!>0$,&=BM-G\7:?MV30;S?J/19F?3KYILKO;
M(^-N?KC=O*-H"9%)S\5FU! @-HSBZ)\F^:LJ50U2K=L9C )Y\''UL#1^ZW'E
MTX&X,KH C?@ &172%6#F$^T4"C35^_7Z6]NR5N(S9\LZ.7(<[6T]7V]J??8A
M]FRW'\G_Z1M6W#8.CIWN5Q?HD3GHWJM<%^FS+A+G20[7U>"]G;RV]9Q1QQS4
MT@].,4(W$+#HV@Y5:-(MA:%?]>44A]4]FJ/<:>*;XS+@^N!_)ZJ]4JKL2;<>
MIK^ %(E85)AB)?^8>!*4=Q)@M&0V(^^T!-T23K1QXASVLXL<WZ,?O'%F-&:$
MGO:1$A(MH 7>DR'$_6(+,!''V6U9"F2WZ9H"">]9X8Z9\?D"#/\<!!5V)].E
MQ%'#0QN<M-FTJI9@)+7*ANI(,_HWM _J36R]J[''@.:1(W</-UO(U7!+T=4I
M#/0 ;)#7@/D%G7\'TA%*4EU4.G?2Z"J?!F.J$P6;=Q[(_T]= ZO<F!PJK+-$
MGBG(*K]/=2#?MR@>ZYX:CZN=[Z"0A>%+SZQU]I%\@!$;)CA7TZY5J;:E&J6^
MXG\-KLW)X/1.!O-C3B)4TPYMYHR9&G/:BY0CXM00V&>P>QJDV^+$7$%)M0N[
M%9H$]MD49-O)HCKDI4\XP7! P:17NW'73S%JNM0T-AB:1;0 9[+<Z.I6(TC?
M+G0'4'SR9BP^&8M/QN*3K0=*SZZG"AX'"\^]^G0W1Y1R& <UY@I_,_5B1.37
M$DQ#/%RRTY%T##XB%K*54!!$J653G%HJJ:[D",MOT70WMD@JJ:]CFAKX!'-X
MS#2!US"]@#>FZ.-Y5\S1:\!"EBQ(HG%"##_5=W>IUYH>\*<75TJ37^&6,,80
M0+K1<:V\=I LB?$\^'OF4IOF68VS.J*%1L>G@,7&<%>RS,C4RDL[&PY2':>$
M.</"3(1[=#41Q74:V.5E^GI(,(J2LMGFK@I[)CK!& MHT*\F_Y15J56^F(#P
M\%TBU[_CTJ!P]</5)6_)!%U3QU62L)\<U#[M0O"EP\+@OM>]>F.Y\/P18LIW
M$Q%UA+'("),#UJ@C.2R,!\YIL!#Z"H(4\4;01+3&8Q4\X8J\-H,RJ=Z85H]
M@-X[0P=Y F=ZQO@F*U(@+G#2LQ=+,S72<_M,^NC*/NTS*HR\WN<9Y28Y;G,\
M>?IOVZ=3I,U9$U'\.]2S853 J-F!ZJ#&C48,Y?&?E"(.#]C=*.>U>*$]]X1'
M;7LOH7?IEB[*$<S%Q1(!Q<;2(TV9E22"8&XNJ])2WRA=%*%E"@>[T1_BGO(-
M1IWX16'5@4,43;)+^;<F>-Y-&@S+YQF-X\4:-0R=MP7_CJ?OD/+()"S\>EHU
M)F'@[IW*WUE(?=Q0U:2_?39X/(2+@ZXZG8.>QZ1=P_QBW#ZOYC\HSCK!K#C1
M>*TZY9A:C$BA93_H9;8/+KI ,.G^W4?;ZFGO]C!-\*%J\<C";44\D1& O^=$
MZAJ-".Y3GZ"<3*MO]M;8"@VD8 _RS="/CH%LQT/Q4',2KW<%<%494SM2I-1G
MVO=M_G?)%[#"'22LPTCQ/+%NDJW^0[]"RKC8WK.)O-^R*]J3Y#-$J@3G5.C4
M=[.(7(]+X&B_7JD"=L[1R<MCV,LEJ)( 4A5!Q.'(<*1?5#7UU9EUM;[8CFMM
MZN,UBF2E#=N:W#UE]ADM0 $N\Z"8 '4[%6D &S97SXC[$\[_@AH$U<E%U=6P
M2E<9Z!3$(/3T4*LKM]JD ,.C11;/K-"Z<<UHWJ3(Y DGY8)_5@,"4NKU[L3I
M+/O:"5(H@M.#96F8FT&_"A<UPP)A[/[+U89)M5S"*T+*U!ML'D%!Q7EV"7),
M#2(NA'GXEB.AU\6-G4SXL<?PJ//&MWK<GX^3"P6>WP7XQJJ8(RZ+2]^Q()B#
MD]*TPMA@CDF)8$==AJS+_LY![L\%:=(2*O1>7Q Y=+_ 2S+$>F:"MO[4^19\
M67P,+,7&9#G7ZND/:31+3LLKP4RW(%['ZQ[Y(9YP!-X?Y$'Y9C<');DVTWS)
MAR-LT6C29N5Q:&1[V,62\(Y[:)X&AZ8R%=ZH%#..-HHNI)X]7^SN_(7."#R&
MP\9XPX=6&L:BG.-%#CZ5F7,L$V8#6AA0%U-9%2GMC2V2CB0=\TS:"[)ZZ8G"
MS1[<S]X*:Z-3O#]I&%HHLM/KSM%B]&KI*K>MD&U6) $ILKVI !Y%S40^AV9_
MI/C5]A!V8,-<YE5'(2^:R<QSZDD#ULB\@/70V@.XT?[_JC3%L+P\+(WIJ-.V
MI-.^VU']D,3%/\$%YUQ\_S@@1V/HY9NA%[]NE+ B!H@2RUOX0)'D@>/(N2I.
M-&=P8/GN$X[H^D]K3B,*P)SCV1#UDN8=#@0'0-[V*H19Z9,PI=1102@Z9H;K
MPN23"C!R"_R'?W;0LT;27X.N XKJR??O&K%,=9J*TC+KE+PM$C)_<SA,S0BT
MRK$OK#$S)W23+<P!Y.*[P:5#&X(V]?_86+'S8F(GVSNGQ2P>5JD_)K\TY *9
M*'=P_QR$L:ZJKICI_)3X,K/.H3!QEAD?$L_*K'"7G+A E$ZOM0D&)<C9@%D>
M5 CY *"3WXW0R1$Z.4(G=P5+\;4O*'"BW8N'6S-L*<2YRFR&5$]PW&?,;06_
M1!=,CG2BF;)V0<RK[.$Z K,@=FJ:X*0.#V'K$@F5&54/%_[H>JQ\[%QE$MMS
M8ZCTX8P2*I9!D=H84=Q5J>N\$:>TG.4FM0H_HT\UD5J/8,WS]#FNQ6$L[9=+
MQ,L^[5 0=[45 6<C,W[UJEI<1Q?CU53DZ?BPSO?',6. 5II.;^?1J9HL?':%
M(3DWORR+JF<._Y,5U3FXM5&;(;7.O/>^\"5A %;54P[T.0EZ-<?R^"8:'(^N
M8A QI_?EV'PXIVGUS(8GX:(.A'E2""J%4M-5USZKYL^6L+55FV0+.)):7.A\
MYF4 \+W<* ["\LN)%J1*3YV!=Z*MGAARB@C4:,%O=,;3$:3;/H<GD%;:Z-4O
MZ7;&5#6/-OIVAQ R^'XW(8,_3S]],$'.2/J^O8@PT,<X.VV>OJ1<_-R6X6GJ
M2:(%A2V7R7D&DDS3)())=FI\"M:&N!%+21]83Q.=%BRK;?,6PWXP#GF4Q+%(
M%VJ&# =*5U2-X9Z"'SC?-!9]@$\O>UUSQ\J#S,%K0_;B/ZOZ*VQ*I^&EE'XA
M>21>#VN8S[5K=(3+>YR<3EO3%8QWO0P'+EE+(5WX$J02QB^R*_I#G6>%JPW0
M9<><*MYBD35-_ %V!L@9E<.#*H>W.^*^JP@B((&5=R#;R<_<LH7R);#AJ\)1
M'GU*ESY12HP9]B@[MF0L WTP=>_,F^0RK]O.*!BJKE\L3"0BC'LQEZFN!NX#
MD7D[ZKNP3P-#7N1+7UTQ#;79Q70ASM[5;ZA6+NGD#C7=$,@I),]F1-[OJCY'
M'6,_]73'%WO/Y!<!+3+V8G)L#)D2=&.A]>:-S?IZN.S4U7VXV)*]Y<1):I/!
M\)T.\1!2G.9AS1/?@O3(?6P_TM2SO)P^I?XO_+9PJ9>W>6])&/P,FUF;J4:\
M5/4-5Z2;:^H:)9?^Q)R-93ET[VX%5LL&LU9'@-L.22\<C>J\ M7,+"D:-2D,
M4E(8CR;\QD?C*H$9$)!0DNP!B1Z:'(A3LWVGO'U3?2;Z%\ <Y0+GS#3)?85H
MN "I$C\Z#U0ZMF=R[]NA^LVTQ$^3E_CGLT]?3M]_2'XZ^W#VZ_LOR<??3C\D
M'S_]\??WG]__\6$D*3X,0^W5KDB*_Y/C;^B*_"D!N"B,992Q XLBAUE@#+3:
MEA&6*BX.)*((F1<=U926".)Y-@#B$?XK!RG$[5*R.+Y&VFAT;856^I2BAXP
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M7;@B'W:;O!RYDY1(R,7N-*@G$@)&G E^3WI=+"/S$G\+-F>AV9E#YV_3E?!
MGA'MP[>F%C%[ 69<:;>D9I).*3<1KK. R<7=G]LO<#JG0" %EY1DM:39V4,V
M<+IMLF=0DCWM"MXD=!N>()BFGQ "O^DS8!ZH.X9'< +L8.10^B#1)-H#H1?(
M5'#YZP"5/C!>9 -*BK7Z2K,K1F* BV -F+I_Q$(OP)P :KT:Y]Q=$KCZU3,4
M//GJ;BWO.RML3,4%A$-%CKT\13-OMV<D$"UY%A(V]GZWFB7G!V9R,N!L?!JY
M<<DSU_BL!BT_1/$?,)4!%ZF7$;9[Z4^4;D6I(T39E!'@D=(A@$09/0."(8X"
MX>HSRM=, ,$(9>L@"QA\'B9).+1BE63A:K^A-IF,+>2$*:CKY?2PJ$M1R*T@
MMTU_./H/X1E40>B-;.R10D&U#3@/T8?03\2FZ)0 W<00A24WUZ3 #LG?D"]/
MQTU)DA<%V%N072"42!,5TQZ#6DA5O>*:&WD),9,]6T(O>E#*;>F9BE2+LK9(
M+TZ%29%W_,02JRJD*2-FO<*P4BCTX/BPA]#-;>?LHNW\^I>WO36=Y&MV4#H_
M[]QVKBY;%\Z7UNUM^Z;[VMNPWD2T-0F(A_7&BIJ,,U"9\DX=UW$TB)G1;+/0
M.42V=,!_7OB,SMZO$*'X=Q>_FR//NT:'<6*T,IF&0JR)#WL+HHC>D69- G(G
MEIV "35@HK#2E1R6X/")-M<F\ 9*'^VYJZ@FC%PWD]8O&>24U2#$3;%-1LQ)
M CZZ5.%B>Z6E:F/I!=>Z-&9A><6K\8KFBKH3(48XJCXV47E+[>URHG*YY]2,
ML/#L]E(,;%1)-*MKVZ&+V]1,*CJ/:,[:XR%'US!Z0E7 9TKDR#R@O%UTL5FE
MXO+D'8L2/MUC+B_L,N>$69U/J(_541T42!@-5<$IU4:D++UR.\0,>19DVM8D
M0A[:1$B;"+GVB9"E\'"1'12R6%[CLA=AMTJ\:$UDJ W[KD<=1JLL!0W =DHL
MX".>I]<H%*TBOG<9A5UE(U#O/Q*V=)0BIU93HY3(255*D<  0,'K^N-"YQ5J
MG#4:%7Z7SFRI.Z=.%,>8:@D[=2MED>K4Y2Q=RE)0D_JP) @5'P,AH^L\$^V%
ME&6(EUBOW^SWK=+$-%09C<4'W"LCF!FX^.KHM//6.!OR]4J347YO7B:@ ?X'
ML\1%94%*\?[J4RKZR%_U< J30^8XPFQ7HYI&H B-F3\%8JA<Y[JLA6($NWFL
M6YP6GA!5XN-[ZGAJ,LI9"@!K.J[!/]4",(?0@\?A]Y-:^1R5]C@F$3 6'IF:
M:CO$:Q+,@L ,\S4'[ %?%FY]^M0.^=XU]6![,.E!%[%NC!P82WW@01\]]/EZ
M@!AA#J[8Z/S7S'5C!.Z_9ZY<#.T.[90U";?!O["_&O\"SO[-5;_O?)"TIKV0
M7T.1;9NJ;ASZ+LL[5PBK4%D:L*6'* L\Q9J +7E9(45'4?1NR8#%<*X+W_9E
M[*LL]_)<5F(LQ&/EE0 6"3/*$N-V4&"K)K@-_O--U.\;NIG^E;ZGJHBD/.R0
M>3.1E:= U7H<HV?TJ.AX:+H*34S+8HZQ&HMX<1\3@G*'J^[,*;L?T]Y4SA0C
MEHE,T7_"SCB/[8RTG0GG4X;G11@Q,OY0F8<FFQI/G201""DL/<Y#K..IREF9
MD=I6SD;1R>I SJX4]J)&:8;;EC9(;749;)0D,<B4L7 S>X90(S ;_GW(LD31
M<N%3XE[,VNLW"^WUCB\_6AY,[!G*SXJ=>LIN@+HQ[<6>NQNO*UUL+[)5B9N#
MU8B;;U'\![ XJ0P3P:JXC:FS:R&4.T/#R$'-5,)B+>(4G1$YZQNI;\JYJ-_L
MP#K&G(Y)@&JQ/'7S,=@N,A44%'CN'W@H+MD,5<$]_#V+?0%HYOHX:E(S&![\
M.V#^*!'IB:C3#F"1#T-@&/>$*D[%E 6-6KZ@__0(TB>*"+0F148&\974#^:9
M(;O5'I)^%E288J)LPTP&JZ$4@64HY+%"2J7"MY"+H$;.Y;PB]8QQI'7GD;9
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M-J62%Q>T,R/P49L]5<MNMI'=K*A1^;6,! F*16%[HPH%-..9JMPHPR[(D(U
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ME7<:YXLQDU@H:4W;:;&Y(L&N>I+SY$!&4XG (M6WDE5J7U,I/"]0DG!QA%8
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M.?@9G5 7-O#6 ;+!M7^ >X$+IM&ZDMSQOM>W)MFPN6>3#6VRX3HF&VJVAJQ
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M00N// <XJ3<!FT19^J[O?^>>J6'_G@$K[D],,U 9K&(GB]E1/S3W,J8OSH*
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M-.N-_WIB9=,:T_L+=Z%8%?D6%ZAC)Q3H;MT=G1[N[Y\^+XJ2M]U$F^<Z8&0
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M$NC:$6A1&/WC;O]X_[AQ\#QIU!Z-@VC".<@7!!.IP.QZ&<%S%3_P('"^\'@
MUD\WZYEVU84_P*]=#QG,RN49;7X"QIL1T5Y80/W#"B@KH+;Z_EL!E0NH RN@
MUH] BP*J?7>POW_2/'V>@"J 9V!KO@I!):61RE5^47'2MN+$BI.MOJU6G.3B
MY-"*D_4CT*(X^=BX.S@]/C@Y?@EY@@E2PE2I BU^*;E2$[FQ,2>!@0(E4:.!
M%+GW/9&QN\CWX=V%Q-;'-PTKN*S@VFJ^8 57+KB.K.!:/P(M":[FW>G1T?[1
M,SUU:RRXIB42/+G(H)6"JVD%EQ5<6\T7K.#*!9?%!5P_^BS*K4]W^XW]YN%+
M^.\J<Q^>VDGU99,>IE/R0/KT. BZU $9 ](/'L>'1*9>%H-<8@.>B#7-2=K[
M9,68%6-;S2:L&,O%V,F?_G/C*'2#4?5,^71QUS@Z.CYX";-JVI#!= >T68 O
M8VNSELC2"UA8Q?(O7H3E6T1SR_/7]NI9GI_S_%/+\U?%\[_<-?:.#H]?D>?K
MQ+AN&KE_Y(G9LWC_%\O[+>^WO/\GX?W-/<O[ES;O1]CU912^T=SZ7#8Z<LZB
MT9B'B6"VUW$TB-FHOKTT:;FKY:[;0<DXB8;EKNO"7<^&+!QPQP\)]RR. J?+
M84$,@06U4QX]Y4[[.W<S\I)<R=9S=:O.6H:[KG1O&:[!<)N6X:X+P\W9*[H:
M+ NU+'1M*=FR4(.%[F\<?6XJ WUUO'$V'+,WZ 7>.V@<?4>\<*^YOY)NT=/B
M0?:/!@6;%9MED0Y^7NCSK/5PZV&V\F03+K:5)[D\V<#*9BM0GB!0#I8E4"Y8
MS[G@&+O\(.L!VB,>3YQN*B2(D!*4*7EQ<4:"XRR>)"D+G ]^E+@^-I$H% 54
MMHPZ0FR0O=,:AD29R/.TB8Q6[&S"];=B)Q<[A[C8YL'3N/@ZD*D5/D\0/H?+
M$CZM,/5[D8?%S2X/36!#79UV=MERSOD]#Z(Q_5X)H8IJ-"%XSKG+L<.&!*7:
M0\'3:%IA8X7-)EQW*VQR87-DA<U/(&R6UMOVAB<<T0IK!7E"!DTT IO']>%0
M_E7VFVDY!#:/[SH?_5X<)3ZVE<U"+Z]*Z[ALP$,ICB[4]7Q]Z^UL:4/EB(_*
MIB/)>C++I+.N1"MFUY;163&;B]EC*V9_ C%[O#2;KJJ*>[9]]['N?([Z?1@Q
M?'/!8&QWR)V+U*M5_#K $)<A;=$8G!)+S5."(=ZS<LG*I8WC#%8NB4&:\*N-
M(T\KCQ:41\V&M[0.ZQ=^DF)?YB3K);[GLQA!//+<":S>MKY!*QPVX9K^D'!X
M2PW$_SJW#[EJ!2[[(B^O-?O,[L>J2;OZ'\RATWFS;W14I__^^[^9*^HQ]X]!
MC/X9[) >Q>]4\V%CJ7+T)AWE@+_IQ9S]\8;U8>QW+'A@DT0=_0G=7='6^)UN
M8+R/$SJLGYS\AY/_$W=H:G_%"Z+?NGA*_D8T7%>_>KP#O/%-=5#897EYIY13
M(QV'.IOW9OWU[=79\ZJN;ZF_/3!F+"0!&DBFF/(<PGUT^T:PWVHIC?JAF#3=
M"$TTHF\U$$S Q@E_I_YA[@KNM/P*CNB*F>IK0T=L, =YPGM3Y_.C;;A52_.%
M.G&O49/S(CN;U\:\+70/:F'>BYVW\Y^^S##@5^QW_E(]N@OMXT6;[MD;FR+P
MYIC%2!4KW5RABD[_]V7:=!?V1,K&]:.VF4)%,;!&SK_F4=<Y3]S8'R-#*9)8
MKB'^:,OSA2XR,OLE[^M2N\:_R'7-=39Q5[=E<UY@0U:EQ!H3_#U+4K\_>95-
MVC9[K;EO72!;[ +97YX+!#3J!%WNH%Q_8;&;C9R+BVM#O;95A-;KL;XWT[K$
MM3S8O-[?5AXL+@^:*Y '[3A,4FD@LM'XO?-;E(4#F<5T<6WCIE9(;,1UM4)"
M"XE]B]6QK'D;C/0;]P/G4Y0F0Q:8_/0+XB,EJ' 784&QG0 Q8"%1Q"N']<:N
M1:&S;'9=Z=VR6<5F#ZQO9IFZN PN7E]]:]]<?6S=WE[=7+9_NSL];IXTGA=N
MO(X>>(P,N)6F41SRB<&>$7^YT,Y%=G,1",Y^Z*<^"YP^T'XXP$_@;PMM:KH6
MO=ER]LVZ8Y:SBT%.3RUGWUXOR^GI\KSN!:2F:X+]/\/V, C$]'A?,KQOC>/W
MB4.;$L5P-"R>. ,>\AB$SXCS% [+9BY:Z;()]]Q*%RU=K ]_FZ7+*GSX?X^&
MH7-1=S[[ UB\ZE 9LI'P-#''D[!_5EI8:;$)]]9*"RTM+&SL-DN+I:'&&M*B
MRV(V=#Y$$Y=;26$EA944VT#)("D.-HX\K:187%(L#0[6M"MX&/I]CLW2W&$,
MXUIQ8<6%%1=;0,D@+@XWCCRMN%A<7"P-P-4T+++0#YQKEO+ 2@HK*:RDV 9*
M!DEQM''D:27%XI)B:>BKAJ0X8W$43$+G YQ&]*]_^59<6'%AQ<4V4#*(B^.-
M(T\K+A87%TM#$2W4+*?I$#[XK>Y\C/@PMN+"B@LK+K:!DD%<G-AJM67-VV"I
M_TN0WT?O_V\N+]U6LK,,U#+0[:#DQM[F%2ML/75V$&L.-''_GCOG+&7.1S_@
MVTN#EIMN.+U:;JJYZ>8Y+[:?.I?MY1!UO7W.DZ55BHE*XH^<.X2"/-N+H4"\
M#13DYV\]0HG*O5:PK?0; RH93H./*N"4BW#&BT!OJR\B$4U]#I%-]^I'7,/L
M'M;W-.1V&(5<DX3#,K!8]IP]'-<  %\0RUFC>/^B&=>,2X"8E?,YULF2[X.&
MUFWFQT8;1V-7FM'K,[U;,C/A:H&9V9N(MCQ8(%^V,A6!_]S'68&8^LM?_VN=
M3[ARQEUWR+TL@+&Q9Y/DV(DS9* 8][#W4S3R4^S=-,[B)&-ABMZ(3LIEV>S1
M7F.GM[O3W-55M#=\D 428N'-/^H+E-$Z#!M.44U4/XM#/QDZ238>!X3.P((
M2!%4E_$$G2(LG.@9)7+J3A2KB3L2_Z';/G.R,8P1\W]F/+$D/./*_VF=Z16M
M- ]V-X6!8 @V$$W)$-$?U0L\=C<:C7F8L#2*)\XX8*$]Z.J=G-,^<'TF>1W%
MR!@2@=?B)_I63W.C/AU^V/=!@4:D%U"GD4.!V@(JX0P:8([O_?<O=TV/-P^.
MO-.[1N-X_^Y@__#T[N3(W;]S#PZ8VSPX:32/#W\1BMUR>G3@9BB,^QDH.3[P
M0=\M:*82^#YGQ<UFW?D: OVF[ \XSZ1NFA-/:*/Q2D>^5R&0<%)O C:)LO1=
MW__./5-I59=1;$SQ.AIW[)<I@OZA5;S$16_4'[EC/VJMZ-DN:+PL((.'/.:@
M]&62@'CR3I///,O&.%&ZTUKC?TV<>C_$6R]V?O9= G46==F:XV4QFFZH.HQA
ME,AS_-"!\W2'P&CZ/$Y0DB2,=* 8^0P^/6(>O,H<X"CI&PZ/"5^A5HJ%I@$\
MJAI4ZAW=NK78! F9)=8?1\D8EI(EI!GYL5#U$UP=3+^QM\-V=_9S98YT*>["
M!J;8DJWE4F2J<;J__WY]%ACS?@ +P%/%^1IKQ"7W056@$^;WV+$(CAAH'\D!
MVTC1"_GI8I=2+7RJ#];9B<1;(R ,&!J[ELPA$KQ647]7D%L-I@B7P_<RTFKA
M0W+*;  :\ !&J,$7QS&G$" #;3CTF%""'7>(()7J!3_LX]VFJ24\17&8#L4?
M9\Z\[EQ&Z8.?#H$5A,B-Z$OP)A]$\%.-=@N()>8L(9W:X_+?\-W[*,A&M#=)
M3@YT>X""=GQ!*6F$,_50FL3./0NR62\\1%G@.6&4@H1W.?PB';)47LD'AK2)
M"\!'=\DLP9EY_-X7*^K'T8C&"Z('G.<0",>!'5<P;Z#O^R/J-SMBW_U1-A+C
MXHICVL01FZ"E*^F&>VI7<4_Q(P8%"6L8=XV>P";T?I+@+$Q[Z :L$'%G#IH'
M8 ^)?_O]6L4!XX_B,!-C8W&5X]AWN4$ 801$!@P)-B=TFGO_4:(!M3C][7R9
MXDLEPN .*8%[[\]8X"H331AL.;5\Y)R>:KQWA,H@7\V).S8?3Q1QO7^T_=>F
M]*T[L'WK;-^Z)_6M>V72?9:@1_X7(P*F*2F(C0%S0=ZF/"5H-./.>'BI_5Y&
M#R)G!BYT[T=9 H(*_N8&8%EYCT@89,:%P27#@J&2S!T6YC+_2^^1(:Z+A@&R
MJ48&)^V7,#)IRS@L<^2'2KD,?"8".T*+GJ,\U1S.W*'8E#FZ Q/.#H: 0:Q*
M.CWX08"2S,-^[9[,$V)."/M2S:8=0;0H^\7Q5PAGTEG\L$8R"9_18H4Z].*\
M\Y>8G"=(7%X]'1..M1>%L ZPV?-O2@VIOBZ'C>KD*(*#("VCL(N@*(\X$^Z)
M.88!N2C[Y=T55D6NV$AM!P:#XP6"2<"<%[L)6T9DI06T>09KLT^+7(K%+P32
M"MDG60P\ Z8K;\B4)O:XUF7@MK-%;@&Q/[&Y-2="<A0*5_6KJ)L&$[H,H3F!
M_;T/R/V,]_.I<S5Y'[\*FQ*"<E9^O56KOCYZ+:'G:/!CJ93-6!U+%-60/>.#
M980SB,%>R9")"\M'DV[(DZ2.X)=@F'"OY@RC!S"5XIJXV*"$YE]&HQ@'G[FQ
ML 7&D=$'_/P\YLP97LP_[D5N1K^%!4= 63$I\V21T,X4?@VW$K0#N%*XJWXH
M^=I+SP_/IH8[BQ23DZD0J4RP/_A"[IONDT<!-?$HU@)0'T(-(QP\AM,@2VL4
M>7Y_0C<@'U+81"S1&_.T=3VP)V\\#H_3S/=_!-OM8[7PI+0292GK%6TH8T)P
M\<>=8T]F7[F=+@1?0;N:$@["**1!$-,<B%H=%IQ![I&3](HW! YCA%"S!=%L
MBO)Y7S1Y*.E@U:2!OH@!B[T ^$/ABP\X"KK(>#J,/,%3D"XXL*^2U%-*9L[6
M_2G)B#XWI7N@(PX%H2*S?$,+PC>7L/TH"*('G(T+IGD68K@(0PASMU0Q6D9S
MYO'4-(G;JJ?@3B? &6.Q2IHIS1.76U:'IN:]+G[ %CG_0/B,!$:QP2V*O&,^
MZ935Q]RQHKR)J9%$,%-8KXOS$'>E'W/07"5)%_RC,Y8*VXC=HTGRH,@'Q9 /
M6=!_9.O@4;HI\/\DK]1F3>:\M"[[=(N70P3G]/TC3>?)FR?M&>%AKS!162_*
MTD>V$?,3C#LWEIK+T\YCG2S,EM[/ A/3^HE24954T;M)DGLN!4VQ-B&G7R0W
M[6EA7O)1504!R_M4<O& Z!P';/+.#VFP7A"Y?U#^FQ%^,[^!WZP(UOWRUZ8*
MB'; V.JS&+4Y?&<4^GVUXZ@W*.5 R"81+'A4 9 NY3&J&!2@AGU753H@C.#$
M?!<C32A82$D$N45W!GXI(]X+Z"%%R6TX[\4E2(3D4W;(@X^*YB*Q/Y:(Z#KS
MX&'ECE?$-H;KFFLMF%DCG3G%K4,Z':"K A4,&FL<P7\GN,W\._JTD]QRF;&+
M9.0(V0T\$A97@YWGR!Y<CBX\F*UT1]]K#9DY;L#\$1U=>4YJ0C1A\UQW#$.-
MK@>;D,(+=VF!_8+IPHIXF) +'U8B59<Q\T7FG#YZ??(B6:5\[@L>N]PT6(4+
MN]C/0)\$"1(*O1:9,:/P'1H5OK(%,*P" ^W2N<#6Q])6$MK[@M.#@>&WH8P.
MZBC('+?&0O0FC*DL),URFLR0O[M1!NL+9* C18-54VG"TU3F*!;FC,$XCQ37
M).N-1#(89HYETH(>P[: XHR6R^\P_\3S7<EFN4-98K3((2?2J*1QP6I'+T;K
M2L4<1&!PAV))=*]!20O@-OZ>>6IHY7OSDR1#8ZOLL/YIV/B^8N.WLX7>5#(#
M'HPP%9)W@FUH<U;8;72(Z(C,[:D2I1NN._R\D@AQE V&J-E)KZ#AG"4''Y**
M88?/L;9Z$Y6B0)PAIK<F\)D(/U)T\8:Y)2:=$"HH"#:2G'^N<3<.#G?<76$2
M$?W$4U8ET9:Q_K*36>IM4\%GEP6!3,>2M O7#/:2 BZ%E9+[NAR!R$=,\'TE
M#7'-4J+*=1O+32BJBD$J<7NC!28EV#V\/=(6CC%/?/-GOE('YI6:XWI MZ!I
M.KYS=AK2ZZI4U6G#CPZGX$="-DTTQF(V@!D,2671.<3B>J+C)D[)HL8^.M*%
M14:F\,,BFIT03)+(JW)7D.$*I4(87Q4"S?#_EKPH($5^EW1:*&/8[/CVH8UO
MV_CV4^/;:\H5Q08:KJ7&81Y&$:R(F?(7-K:4P#<[B*+4,XR%P]>(?61AZDNG
M7_X=S%-6L105-%4^:)62O(1P\5;%@G]:47RH1/%S4G:%1I6,H] 3_R2K)I&F
M<:X?*6&]0!S-T /+!4")<U##C-$>:):-!LGPQK[6<O/.>MTW!S6EHD8A=WI9
MXF/,T?$8N?%1'_#'J:8H.6U)<QA7D+17F*Z*49'>**)0;@"&+NB-<$5U*!:^
M1;F6L(X1C$$AA+IS.Q2KQVAJ4E0=A9XK5(5\#,%+0"%(<'(Y\ZA*'9W59U8;
M"SHR2XNGXS)N85ZQM,Q+L%>Z R085W4)CG[T$E#YV&3AA(T@*-. "^8X\6D'
M->%$^5<4%\2R(V3APOO!7!G[\,/[*+@WV::.Q*(4$3X<H5/.B.C/H)R'(0\Q
MCM_C+DP[I[H*(EEJ0G[SI*S7G,PI93$+5Q8@QT4+Y;= )S^R.KG5R9^JD\MR
MML/3D\.3H^.]NQX_/+D[8,W]NU-^PNY.FB?[^^Y1WSOL'[UN.=M,8J\J<.O-
M9 F__+7;^739NOUZT^[^Y6WOKVL2G+LN^3+*3HAY:ON"L1<O V'E,I%(,2>]
M5BC1TMV)[GG4?D2L<SH(**,H&6IR- #+TF$4PYYXY$##W?LMBO^ J< SDUK^
M"^D2;QZG0Z6CM<:Q']0<1."H/[6>4!P#7FIY DC<KK@4I7N>QNJ3!A3%+POA
MH.S7]_?GP: 8]\SX-OK=^T'TH"2,^OD-:B+O! ]]@-4]SL#4WUDOB8(LE7@9
MR^=DU46D].939:K\[X) -,#W[0&L\@#V3^N')_8$5G@"S?K!7"@F>P"O?@"G
M1_8 5BL$[ U8Y0$<[-GM?ZWM-Z$4?U0=?7U33$$\+0V)\#$%< N7_*C*M85K
M?DS)6<WE-AT)3URP1D7=GXN**MCK27T5YUU<_#P72NO73O>VY5Q__7#1.7-:
M9__SM=/MW':N+IVSJYMK]#AHUXKE:9:G69ZV2IZVVB7/-Y6V<,F/&2=;N.3Y
MYL"F+7@+A-6'R;MJY6,^)+LXS,/Z04-%[G3VRO@[EDSZGJ."@FNWYK?)6^?O
MT3!TSEB?)4ED6?-&LN8?)-V3@PTEW7-V#U/\D,6#)&7#@,=;Q9!>7WN6ATX9
M*>M_XI=LQ-\]1V'>K&5:?KSQ_/CU5>7-(NFGW]R#O4U;HY5%6^;)N?73X'GR
M9NV6<C;T>=_YZ(<L=#'!_TJ4%EOI8J7+9CAB%KZ+PGY99Q?+=<P3:HU 6>;B
M9K:_<S>CU/>IFUE =U_7CF@BW_7ZZEO[YNICZ_;VZN:R_=O=Z7'SI+$A^:TT
M=^?JHZ-FOT9IKO^XO/KFM"XNG ^_.;>?V]VV<WT#_[V\[<HJ!BI!JX#407BL
MU$^S5+808N-QY&-NK'KA P]_AP6%3M</>G"1Z"G3_I#E;5AD@=44013RFH-I
ML(CMC85Q<28 L@/V@. 7#&Y?'/)) DM[@_#N8MP!9N2*2B,''@N<<?2 R!9]
MJMNA*1(F2(A0 >:O1*F>J*X3Q?>B-,.< S9?KB%8KBNFDJ2<B3Q:PM_ \;%*
MGHV9JR#=(LK4G8^7&Q;KI)P=41 B]B' 6FFS8@4QPF<4L21R7=68E7/AN(Z:
MCQ8@[NIB+/R2*&2A#1$5U#!3W3B*DH[32+P@:K#R,JIB^34]BE^HY= BQOCX
M@?9W"2&< Z_7G $6IPM4'MQD!%V93Q(5Y&40"#TI<J/3">'V1&*K>4R8!>)M
M;(Y%Y>_JXUC/)G'/$C\5IP,KXTF"^&HB5=O#>C=?T%..; 6G"FM!&D%4B@S+
MTQ"'@JJ04GV6NG04'AH22F2"^ YXN05:"T+H>XCZ+*FVIFJA\/S[$U%FZHDN
M.5AW.I!X.0KE4>W9]);5!*I^DE\<,;[^"::.\ SB/B) =$13P@QV<^4PEWL_
M3N'VKA?([X^D],^[SCE"C6"-"LU%8Q0J? M9[96S"W%;0ET:2,A4U/K*>_>B
M^?:JT$87NJI?B.(=_,T/IN2/0(0'JOOD 5B:ZY<0> A+H[H^O-_OZ%_P-M_9
MJ[V!/^V6=F#Q-+R"7MA<;2JD44@WO0G/76#A;/</ZWN'/^?9-NK'6WVTC>,M
M/-K''63JC&>U^I+<;(51K)/GV2<+EM_!%UB:Q;R8(O84=C=K:^BP$#4U3)>^
M/8LGSPF%V/SO$W=B%N%(5KFMA$..D^<0#?'1;:.9%Z4<R8FWE7+.@7]7)J26
MI4OS&5KG,T,[B^<W%-6AX_K)Z3R9^<SO-D[JQW-E\9.C/ZL78T_WLSV>B[%!
M8FH!!ZEB(L;JXNCA2?3XF'J^FE-<R#-=^TLO=M[^]5S"U(J?=JYC/W3],0NF
M7]A]EN19NR.>?ZR/R(AU.VG"#'":QP(VX'F!ZA_CY*M9]POQJ'4E3H7R%$8A
M+W=+?AH#VO+KNMC=?&FE9]T*LYY<=?E*VM=J>,'*]N-)6N,3/;Q;H4D^,0%R
M6Y3(S54<GY]>M/&2Q"I^&Z'X_3A+V3"Z7&=V85B+.<] D[/E8F\1R@7XF8Q'
MJXU:;70SM-%MUSQOA]%HC%EFYYR%5O7< %F2NQO/ALR/1T\_MDV4&%;KW BM
M\P78R881YCJSBI<OF]AX/K)2IO&BP!-;IA%;'7C%6N\&V4"+)\]MNGK^S0\"
MGXV<=MWY!^S-@+'8LUKZ!HA>G2WP$\A4JYMOA&[^<KQDP^ASG?F$5=&MBKXI
M*KIU6J^QTWJ#J.$G<:U?_/E/S>;1^X [WU!#LFK[!HACJ[9;M7W-UOTB;&3#
M2'.=6835V*W&;C5VJ[%;C7WK-/9O//1XX'Q@\<]4RK>YHMAJZU9;7[-U_S +
MV1"R-!!@5\0;K%+^V,EL@4:^,AC0Y^E*A.]C0 >Y 6<QDM)00YM)W6 ?(=&6
MTHAR)L-J'DAXC#T-C]'IO#DNMYO\]W\KP#TQ]X]!'&6AAXAO4?Q.,6)CJ7)T
MM)W$4 +@[;!^HI&B)<);X5?(X/<%E0[X&P'0Q/HPX7?L/O(]N5LG)_6F%@KO
M]M[GX$J]R)O _PW34?#7_P]02P,$%     @ ]Z*;5%$G2;(T'   V!T  !<
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M-!>R/#[A=<C^88M] E_;K[T&.RDGCR(>$:1VBR/NO&8<:\I:++BZ[V3)8I3
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M>1'5&T5_YC#_S'E/ZT4FF8E?Y%7.2P34UGY-A7*TE$AIW*KWWC4E=':E[H]
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MFJA0,*;Y;&5+$&4L8O35\?!]BL-Q0^]GUPFO/VA-JBLUUYT^<3/%72CFD8*
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M#4L)<?0,;9I^?-NN/R5/W1^3Q )4+6/E,7DZ-^6S8X&_?2^(LDJ=AC:A /L
M;\-:FL8++3T[J,JEI@:/FBW(J)]>Q$:(0@/;7U'#C1 IA.(L2NAV#'$C3=I!
M9="YW6&,ZW>DU#$KR2NB.@.+D$K;. SV K,[O;(TVC5I8EE-4>?":,3A)\PM
M2"_.''N<>@H_C0NK@ NX=U01S*JN"^\^ /W&CWU$MV*<S=>6A>]9AH69&NCJ
M&@C?Y+@1D&KMXLM?<E%WR4 G%J#_851"756)Q2TQ+5>X#X!Y/;;X\6*<K6M;
M8?&QS5Y2,3*]V")&+%9#H\4[ZLWR2%Y;6O.^V/Z9B86]_#C4YP]2JZ&PS\D3
M/Q5F,4T?O&-QA^C&T]]G)W9M6C*E@SM4@DF)F]^-IJYCNB!#!2W5<##.;5S!
MM/9AE+KW5:/:B.J/6;&+8RI.I.+QH^502_RIU,1 RWYA80L#X/_6 ^3656DV
M[BR@G/BU+,+$,ZA9K&/!P'WQN05>_(_#**@/X.B$,])1[J57*5$]FU\++KW\
MLMS,UZF=MW7K+.V;S)0++%]S^3:\TFBM ()O*E@9<<Q70PD-G7SI_-Y?5\M(
M#A'6)J,E9 ?]-KGVRYNFXWXELMHN=*!.OZB,YM![H2U%;"-;L$8JO]B4SSZ#
M9"!\*TY!K&5"_AO1-7ISYY.>KF1IKJ'AZ5FY;PSC^M+/;#? D?;;JZ3 %>]"
MIOV1PML <AU,./-U3>'W[Z^ON*(^^?\8)62MNMP6>S<SK9\SV>/-\-?B$2P@
M05K'N"YAOL"/<,PI7.[2:8?JFOV,L*;ZS^P=91B69T\XWWOL .8.+ 9W$RJ1
M;2AP?!%F@OJ#?,KS483=L/-C%\T)%A Z%6)F2G.D0Z_X?76:6;V.Z\$H(P*-
MB&V@C2&&H1&=VW8!,IR"*F<!%;Z+/YD.3$8(>)#-MH4E7325CK342<HN>=\>
MY@#."Q:9Z8"="+"]03A?$TX127OXU,E[1G^C0(98.K+G0]$FD9OWT1$865X?
M2J?V;<:4ST+F_CV-&02;(J"*+25^HB+[E1B,%?DN@9-,=UYZ9H<QJMX+9'..
MX_LY"!^S#T6VW\2M?L*1,97!JOCH;?3^]BL6<$V$!%_7A,[LPE&$JZAYN$>
M*].@4X[Y\Q0+Z.8)MC%E 3+\KE2<3<@".VY/C8&IJ'_<>PQ$* 4-4;J^_CQQ
M NJ_>T8;<8'&M\\E%*EK/R>TN)_QO2YUD3+3NN!V\\OTF?;"H5K4B] [H90N
MC\5F:XK:6._WONB<]97/GB.+KO=G)#6LWC5Y!O&7 ["WXB"9?B5+[7T+Q[/9
M+.#1'334XFN0I(%BR7R?\1.9MO4*$Y$RL'25TR)!V/:3Z<6%UXMBJ#-,U$""
M^1?[#@6K]&IV>E):V=4187Q\-D>J7E>?CJF!JZY+1*;AH1,&%\ +"COO;.=P
M:^M%2F$X=YR 8@.9V57XZY[_DZTK;_&K\)*I.4*U3*-^879LXK_9^B""[-22
MB&H$T^P=%7$;+6FQ%H31WRG&[/WI1)9G\"!-J>G>5',6@$#DQ^RBO4@FTJ-C
M>'D([<Q=8]=E%M"\>0P2@P9KZ<[X5M*>]);DUHJ.5NU],/1;K Q@ 6N=M#N0
M$2Y+$D\E(8;0U+-L0QH[EC%WI>R![J_Z5F6'Q?5S(+HJ"TC K8$U60 >0>ZK
MQ\J1U#-2/@>H-@$?$L341%5>A&WE<F!O65XY^VM\7<_VVC"ENA5%E7\8,RU@
MZ*G0<$DH(&-#UFV"Z<X[ @*)W_61GOW\,8B0T,(">*2I*2)M22@PU;OM =2O
M>TR:+OZ+L(7)PW(@6R8$J!:YH^,(T<?4Y.9OAJ7:G=LF)#TJ=XF\43O'K+99
MD,8+K$2 ;4NZ_?)(=<SVZ.JEX\%%GC?#MF<C#+H]GD/6=FGWJ(C92-+2KC($
M3"TLNE]@OF<<VGH#UH,;7PUS[)R%'G=#@>NN^I928RPC3/L4TU1@5^\=';ZV
M<GL;>(K8$J/$40W\:<KT!WU?M"[[J RIO2I:VFJ?U#J/28TL6P'!'B.^8OOI
M%K208'B?FMO$[#_$Z 3W$]51NBY1;<<GN]O6W[Q?.[23/:ZWZ$#B8O):%+(
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MF!^J]%Q7NM"-%:A'72/2=#CI!7$S9D-JL3'P1H,,&2]&0#VKD;S.G0*W5)W
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MCBD8EM&,^A-DNYW-U>LGH.B?YSI\;/+"4.H'Z+.<@U!NBBN!.ZY%0JS#3K(
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M),>3;A,RXH;-(RQ15FF7, W)%BCCI,W2W#IC7OUGAT4F&P7>OW1^:7T9PH-
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M,[Z;Z$JB<:4Y2[L0A+FQ8C\2PVOG,L2G6S1:G5R\_*!W_/EDZ:-8V59MP^?
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M!*9W5Q9/GYC#AOVEUK?5T[U99W576#9*O>BC(K=?3/$K?BJJW,0M,N5Y9CI
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M#[XR0Z9H.)<M/E[*=&BS0X\?51 MT?;G87UZR^LM*YM,SF[$]9YDY-U)G_9
M<-L+K1 SLS@S/K*4\D%[U5>7],]V'GL.YMB&(L[>)B#*4)THSBWYK61V\BN%
MQR[!BKFP\1X/UKO9_@@!Z\_"S9IZ@TEYS\3145C7=0%$43N&K::*C'REBX,+
M=7OOOW@S04YL'XF21,N^&2TO.3DG_R39BAF3"!(@P%;F&0B.KPFMYN6#F^O"
ML"4/V8*QXP^V.7SR] \[/W;H.?WFT+F#VI5?$=K64SES^!0.HT!1.[W>7I9N
M%,&4!NRHP")16]^]:4"ASW#_TPT8A0])O92!<]X/N(Y<O+ZU6?A_;_\!2P^V
M'#Q!?D\#G#KR*?V-AK/<R4*XZ%9N/G+I+"\-N&UC\J"X*>7+FXL12:/M ?XK
MT=N0X\@18C$-4$7?)DY'K$ .([1L"4/%A9NK5D,FQDW+58,1R:$NH/:J1E!'
MH'-3$?$-8OX*3,Q^,;[4:*_5=:V9$0TGW5(/N'/_.5@C^$=Y\&EB$-XPC@:X
MF$H.7.Y7=2:\RL6]\# M+:L:S4/,/K[&?2;!]IU*F WK=N09D52?CKEI#LRQ
MI6P %NU?-QR=0R \]-W1U@>9'<U7RPNK-ZU-,"C[J)Z^823A%6BM[T/(MR&L
MMY>"VO]7-]\9U=3:K1L$ 2DB(M*;@* (2)<N($TV15!"#P+*ADB3%B$0BDCO
M FZD2!?I75HB704$@@0)+21 ! 02:H  )YX[[AWWTSV^\]T[QKEGG/M[O6.M
MN>9ZWV<^SRQ+@^-D*/V/:,-D[<ZZKU?3Q.*F'EEN"XDG\75'*"J.FF@\O,VO
M2P%0W'YL*#]$M<]FHVKA+W\0W<J)+*(>CI)2L&_Q[I\,9L<T;WTSXO;DFA5Q
MC6RRZ13N/P4TABPGUT#B!GLT^,>;CD!,;]*MLLPF]?)E#@+K;?07/XJE7#7A
M*S3W5O)-S:H)_<(]5TX0ZW>@2[:H-=:WG93R-_"TA65P&_I=99B7"@3<]);)
M;@DFJ-I3C$G>/?;M07L]WUV3OJ#F:Z^/U?7/_/+ K*10@BG/4=#53>+CVC#
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MNNQ[%@[R)<)DHAJ0)59:K\"C2A^\)Q18YLYF4Q<=L!X]^# U#^PN$*MQ.=\
MN6NP>T0WWF2(0O>ON%KP#16GL+(0+VIA@H"O(1Q[?XWZ>[CVM;G&^7L(W^Y
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M;VL:G[0/U;3WJ5%AZE_B<!I\[H&!=+V*'"W2@8KY[X8O&@F[O)H^'TE@3OX
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M[T?T?+%RV6)R,A3RNWYO7P9]>^2MPIX46G&4[B.<]3TQ,!%^%<J/:NJ\.>W
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MTQ+!Y9*NW-,_N-HB70)=$'^?B]GM<F!$F@USFN(JWCN5VR0-3'ZE&]Q7@V3
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MIF:NKL95^U/C\80RFO::U,R]<L& 2!^^GIJ@4QYPH?(FD\Y'YPM,8EZ?!4"
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M?B:P P^]#_/ P=O.W:@]"!\JM] 3Y8>?]K$;,Q^1OCUR3V;MA,F3-H'.&'K
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M=J;?R7N&>^JJ$%.:&2,_0TV@WM"R'AV T(!6E6?C\*ODDWB]@@JWX+,\8)\
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M ,OHZ7Z\#R$M"V$T'YX+SDWZ+FEW]U KZO!"$@4XDL<V@46M&>4AI#I[%R@
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ML:]%1X'MA ]YG X(DM.UK&IZ1!Y7SW)=K*]+O5A8>=[I9L Q?5KS_VFHO*,
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M/TZ>=F"/.KRLID].K$<'HP$<BI3SHQ-UP*6(.H3X: M3@'\3>3%\;JF3(*5
MZ2G ESW,P.%Y78=+H3%[TX1O%"#9>6'@ ()4I0#%1TN77O_MQ??H!^HR Z5:
MNE A\Y90_\P1BA>IHL*TIV:H-COHU_7O%. -=SIYE"KDZ?(/2K14*]3#8>]4
M,W5&*WMT*, PL71^Y3>\$M#\WX,14JT:$ H@48^'D+M8J7_ISTRT3(0@H&28
M#Q9Z&", I;HS#XSZ-U\^!?UPF$XG&^:&05>#<#_(ST70^:6_997\715X03+3
M,G6H_BJ'(64MA"*N_P./7?"ZDG;GD?RF6G=8\J?[#(LW<KM5OU43]1<?+J1B
M<F38]A:3E<]\:)_]<"(AG'V\*:PK1]*.D\!:-;%CK 7A>&C/-E(A43UJ]]'N
M7"0'LIOV7*_J9Y],8%_Q_(EC.@SOBF:DOB=&0R$:UA@/T2X.HDW/A;I:W,LD
M5W]%M?H4%7IS.C.9PILT/:J]V)KF,R1OO$1'(M"!M:X!'W7=U"^L*)QZ4/Y@
M$(:<!FG<?W73\GAH]LP@PZ JUQW+D!LD3WQ43/-)*V)@V_[=%.ZBB;"U)C.X
MW]TGSSZ]O9QCT2FJ(;*5(^\FQ$R(&]<ZZ=H"+M=0*/XRY4X6KWG7F%TCM %W
M>Z+<>Y;K46?=U0 3AD%#>0,KT<@S]^_[A"VY7<;!)I6W+)L3L2DKX[AIM[!N
M_U)%Y<T,$3/1V'7.SV"'[O?K?\AO, ,%Z%U'ZE.]>Y'Z,;2KM+&S( RFIOH,
M,9$"W(ZD?A2LN_S](/UG:&_BKR3B7V7^]R47O/0P]HP'9L8/%ZV;(+BW^J.R
MOFOZ7;QH+W\?)]5(*VD9DSY1^N/QPT<=*4!HYJ8#']*X'N^PZH^Q7;N]^7/>
MI')B=5O3*R]9]VDO_,&)YT*YYV9XSQ]_TAZB-3JC8)2YYX_9C?'0.HZ(Q>K'
M^!:\;L.E7!E.6Z,O_A&A\I@Q_0,G><M54%_C#OX&!5B=QLZS$P5[RAVQ*],9
M/_#S48FQY9B&C,)CLV4)$\?T4S9+#$7:$]<S@8.C9Q4M^W-ID/S.^(Y6'@IP
MK.G:PY+9E5\;C#R;.D'2HK!H)Z<$R50KR59[;S9#I>V@IN#KE[,R""$JJKWG
MUX.6CMC\H?Q"V5L6*G(W_7U07YBH/9N;J3Z)>X1\=1U^0&.-6KLL"2)\_T?O
M&C2!"&-4#_^^@D,.Y6+>DW_#"M$D_T&<!<5'#(#R$(UL!K^EKF%'5XNK'IHX
M/3$4/'D3[-6H]-42\K:VKI0D5$]T+D.LK#4?#Q*0$>!D2W@RP*'';MJW%WYN
M*H0]]/E$@U_!\4&&SOECP<>MIY&F^+3R<J)[EXK 3I-R$M%^T0C7]W-\5^;X
M2=/,6QYG+AZTRJ/%;K(%K8PHP2:S3(C1\%?N:N--OAZ.739"M=GHJ=BCGC;*
M!A^3X**0V:#O"_3\7RV'WG'=-&'(1.@OI*:'DRQ=*[I>P32H +P6]R9BT>2E
MI--#VGI(IU%2PG.F[]L.DR_E&)>TV*-T\,<) C\B=3LMILK&H\\FGYZI3NKE
MT185N_GH7 R!9%I-324:7"SF"HKI'DF'8\6R8:V[YG5?Z8R=0\26QB3W19HZ
M$+POJ8>_QVVCBZ^@")#YU9L@&*C+X-==+5'JRO.B@ (L'63N[O\VLQ1I-K;_
MVK^D_ N$7#GPIFI5P#D?)C8?IP CX>;;YG^5^?M+XH?38H!-&">YG\R)W^UB
MSN5'- R#N50( :[C @\*[B7KW Z-;11'1??R:X5Q?Y9;C<*L*4_<&%$TOF#'
MW-&04.>(UBVPGC[QZ#.6-:LS>/BI64?ELOU!J!X=<!_%K\5M0W+&W<)U%P3)
MO$S1_"0_U\5!?W#= !,GDQ/S!3BPY'\5W*M%4X>'AFOH8NQ$^MHR>Z+\Z!IX
MU<PS3S?62?8JE65KZ5N(:C9,U"W\>MYJB$$_RD2'3 6"F1##BP:XT0F8_V&J
M4KB_#,T#Z166PD<QAF)'RN/P]I7')%\8\4P!,[.P^N(%TS]Y=Y>D1P$>-:!Z
M9_LIP$TIN<-7NA"<)6Q/O;YEE<Z) OS:;9C^QZ@'/&U)-H1'H5:]!E';S6=^
MS>:?<X#=_;^OX/_CLOK7Z'_);9NPJ4 ,^G'P::12V!7<6RN4Q^1/@D UXZN/
M0SHG:]\9/E X4\D_'1?B AI?0@-4D)M"R-#48,?-0PAGYU";,A!<<O"( [5'
M4*;V")&[%"#IE\O^2_(74L;4D;E46DBQ^B2QW.H!:O/ VH)[\9Z:CC;4*:+B
M"8S8X<M?"-J# D2P;E  D2%J=RNQIO"K8^V DR3AJ#V>7_4/!R8:0EUSJ:A:
M$(6Y&$@!/M1\0!0LHM= &#D(4:IMMYD.Q_RS6<:]<V1.Z,':BVL>X&R)9]TS
MW!^W6U4UO<9#M"KRFT!D#MB4,Q741\X33>8HP!\,@/X?&- $:J/>+S"7"EU7
M3:@BVT']O[VW:S S$82]#A4@W<*#L-R)4;YU8[ZQ0F>F!K2;,Y? XH96C1DB
M5YP_@>*V?W413WR,_JU-&X@:>:9E\PJ)G]HI;$1!MS'<0=SV*@?F2#F\1!<J
MLB$X&Z-0C/)T;2!DE.L(ERITP>4F/<UNQRV5Z3U8/"'0I44U71TA@6FA>BB7
M%/N[3IGA-V[ZK8<&&5J&[&E^ZZ;$OYSB:FI%M@Q!M1L>7/FU\X&;IC:=@O-D
MW8+?S",0>,B]B7ZLI4(>#!; ST=JG/)?< "47V&YW[FKQ-HWGI.,N*BUZ=%V
MG#T.1+2T_-V]E?YQC%7_]MZ_P/Q_()!0M$CEGL.X7PQMR+.6/T]F-/*PF-KB
MY.925PLW5(P\8M$RJTU+L,']_+V(U)<%/FH>B><]^IF>9_?$/:"B$-B?X_;,
MSR5%SR),Y V7Z "UF(_4$93J4H"\KB@RG03Q5W3:1U, G5@PB0F&SV.UD9(B
M<[SG)(<)H/[L?#R4 AQ)(;F +'ZG GV)JJ([EXKC#,F*J';+?-2@(XP"M!92
M  %@++^J!2,U!%TZ]VO89JAX""YU*7>;;X0"X$Y#NT.47,]E]OW;2ES*T,3+
MU;!]%BO4WSR]33WM2@&(7+F+^J13 1*'](H4X ^&[DTO1D%JZE8'U1^211?)
MF-3UW#]3T1Q(G,0*R<*G.@B>F9J7AS"1</:'R=(_S15>+GBJ+DHDN("6,_\7
MO?7FOP4*6\M:_KXM?V,8OYE4'LB?7"X-_2<]]2\8^?NH&NN3N3QB%O>^:%3%
M@(WYXHG[8(PVSS_J)O^4KE;_Q2:T, CO0[Y:O!!UZ$4%P]L7?NUKD*@X/^4U
M\20%N.&'.N1(W1C]L\=AS_+3_J)=C26.B#U!"N-'*]7U15Q45BN*Z0SJD,?<
MJRND%OU)28D0U)>6$M2RXE.:!8>W*JN5N.*N^;?%':P^UCB[R()2-WO^$;3L
MAH0K2TK_J>I[ZSTHL\Z4'?1E"A"I2)2A )=^E8;F(@J _?EC-8("B!?C_,E=
MK!(4P% $?2,/S/M'0:,_""[]EK4R)?F_*:KT!S[IV[^N\\^N_9T@'Y6K3)3[
M4\%E*"9>BQDUI#5, 39>H8@-A!A)4!<%^"-7E<JD"@7_R=??R/SNROB6VU28
M S]C0 '8MM-\/W=KW9+*8=,*EIK^1\;\<83_DLU_)KB,PL0W,^?N%4\Y_*!:
MR&L_H L@6DCGBMO@^Q)_X.G_]]?#G=_)#/U>!OTG,M2[L'C@',C1A'0*$$3]
MUC7Q=DA;F'J*Q15G^R?LH3]R]OI^B56;_@.Q_]+W+PNZXVSK.M84R/O4,[$5
M1@1[7$7Z@D,<1!"I^<)&-CO_RT\+Z-W*^&<]/"OF,M4<7BG]05+V()P4^:K@
MXOQA>#4%.!2C IXA:K_R/]_$:@V61?6.(8]1@ JU%G+TY=V?.$AL[J:? RUT
M)0%- ?+-WN__!K5JG26R+J*F+ FA1.,\I/:(AMU"D$#'#<.[D=V+NIG6)YD5
M>AZU:X-G/@>M-%.+DCZ!.L'Y$0M@DL0/"K!8 R9QPG._I&!<-PCJN8?2.<WI
M>>"L%@S[X2O4T@O$KT<I>]0BN ;!/2:/MFR;-%%A23B)6@@?-"=1[^WY6XU4
M2"!Z8$9M&2[@&,B<6Q0 /[6O1\7YC61VR%0Z.88W!(K+I5;^A''G&"V!X)&<
MT[CQ\OPYY 4<9%))RK#L^^8V?VJM080@0_\")C[(T% ;(H%4)ZI3@U %!X[2
MD"@BZ>#D")Y1Q;;+M7,/(A1:TEG<!=;ABG<P>L:^T/_\.*E1<S1QC1HMNLRM
M$")L@ +TN"\+2(*^;Q OH=P<]B7MJ2"F/1A%5K^1&T<^00HF2F#G(S:P&QR(
MBYT"X!CDK5N8V%@/E<O)<W=XF:4>ADY=.,\N?&[&<J)F"[+6MCD7_/G+(EEV
M/1*ZR3T+!*G^,]O%#O+$^9Y</N2M@XN(@E8'MIT6UB4!5-1V/-0DS<[]:O+R
M=_>T9S>Y_5J%82L.QI:?*0 81G*&=+-/D]GAU"YNR?\IC>W_W%!]D@BT1NZ0
M2PY 8:#414\(7>CR;X9-32_1=D%_[21&CA>![GS@P*[!!B<9*BK,,2J>CJ%/
M.">P)@P_SK1/^/=FZ-\=^*T)7_A4XH4A)=;+, B"Z?K;NF1,DB]CZ,T8J]"#
M.2+:[C 7&5B"-"&*+L!Y?E9V"1>5NQ F)DX#G;?UM?NK'_ K#9)TJ-B7N;.%
MP%)/#3YC>[\# 9^#TT@)S8'(U99MLT&&JJ&_\SK+(K3&OW.>@R1%='(L01BN
MYD_XR?@;#WE\'Q61[^"=JN#A6,U[Y-5XOM\[%Q<=/!I5W"E'M7WA$=7V:^29
M* @+2?!/FAEMB,IOLP#Z&V<$B>H"R-G?.MGEKTSC=CP7S9;_7[JYX->49?U^
MRG3^V^]/FG1PHH0G>(D$D@*V#_TXAT$@-RH-XW'$Y1JMB!/30536 '"[8> O
M)]'!8.C_<N!R4T_]B!$+G!3@/N/OE1KHN8 V-PAIA\U:&L%]#IQW<'HU<N$D
M?82,R'O>M%H.[:P[GWE=O;V5<X*6T,S4%;L^N:5FM)4#BM7]PU[$L!Q1?(*4
M 6F?W]^BAL%P[\IRP%X!F;&&"I+T<77DIG74=E7 _J__148_A[I"N*>IJS2W
M!FOQBO!)O' 4IB]6:G*])^INDZ'0D],6J*I'Q..;B)T\<$'5:?=O4'KRT%LB
M\T)+E))=H&7-:$JGS2>"UO&Q)MV2'H_C:;:S^3GKBT\ G0FZQ+XGMHH-46M5
M,AI"6,%9=8-A#5BY2\-<=J&:B]K'F2]V,C./7XE9T@3$]YQIO8E^#P299RHX
MJ!L?Z! )$'9B1X=$Z[[A.$GE=F;U,.LM<M^IMU+'7L]9;*A\$Q5\0+74[CF*
M$WEM$1QEHQ)#XLYSK3-Q<"TV]1V'S\V[3B=QK,;W>C8]H0,":O7+^='/\HGS
M18B13BB3AAUOU#K=W%M,WYK-?'#^DDSM)7ZLR\37%#'V=]O=NO9$U &,&-N9
M-L]:X^'?-MX@'K:8P5J>U5&2L7XSRU$M@[./N;+V^+')Y21MB/Y7T\P]_78*
M(%B(DTTLLB):MD/N->!5.NT<=,[:K\B?-[1<XWC?O6MQTC!*RPJCH^X3 K[E
M=7#YIPUO%-)>"<UF*Q&C 2V==FG__!F?,XZUC;"(Z"R+^?@,E265E+!-LS')
M5;.(8@B61;SM@1YK\L+ .5S4M)+D(L4>B6==&;W3L/6I4CI&VR4%Q)IX(X8@
MQL<%_-Q+)& H0&++Y 3Y(R&*&H6>*\L??\M< BU__&<>@._-8WZ0<B6Z(0?<
M3=28?3%G.<2]U=(QL*<%BX,2I! H"G"Q*0^<__?ZBQ_D$]1V/@+K<$!/;2*6
M7J+5#N.A7T>#J5'_I8X:M/EI[WFQ8-)C^U,4X(W3 #G&;0O]981LK(^!'L8^
M<-@_[0*:_'O]S/_=-M\_GUH8DBX.4S,?3>;'.TP-B0S+>'IDCJ6(.ZC 5=?B
M++VHP)76X2WWYR2/HT,[7\K%AYH,E5LPV\E'AFS%9OH]3@Q(=A5^O1G?(23E
MB 6WH;F0%KA+-OJ/_0[5I#[LE J9*;^I=HHYO_;=4-E[.MHC*F5$:74GHI X
MKSNAH5NV9*'2JU5>L(?RK#W:VO9=]FNO*(-H#F,>FS#\454?'MR3(TX>T<XY
M-90_G#;?IQJ2Y]7T?"M[5K/T\P;J3FRO-)+?S4^(T[9ND*2U+SA)##,^L*M2
M3;*R:V-7M[![\32-(;XIP6?#GA>/M#^C5A)[==27 JP>3%3!UP0=P<_[XGIY
M8/W\ ZSS]'4JB^C+P-Y*.ZJJD,P_I"7D^L,^$DZ\M,W\GCO#XV/TI][J\_Q[
MVMOEQBH$SYR.MI:CB@KE>FL+ZIT-R;<8CVS<\WP&@LK-#V#LL58Q*L)0&P"G
MJ4"X]6X$C92X[_<A]P#<(Q 5^_$Q>,/BNWKXL02$U(^P7()[].%+,J?=LCT7
MOK90_%UC)=[A\79CZ5M7STTAK3G)<96D,;8?)M>%S\4E7MX7M26F%RY!CB'E
M%J:+WI$G\%PJ/I//%NE/U/XL%R=\UF=[M_"]H9^Z.GL<IMIXB';F2 ]N&W27
M+SPC9;UK,CSUM';8SOZ\B,N7CY\VUYAR536<X=I2RR?UAF* +D &V7-PG[HB
MS*^N4 "GP(O4!47%;_O;7^'ZTFQ_^V?V#9$;N"TR+&41?!@S!Z$ @QM22S&_
MR5 3AJ'?/Q(QF9GIH;;/QB(76=SLOCZ@N<Y6F#)H0CMJ^7R9 E1#0G8TK\Y]
M%'(=JW#:E%DO'EF_59UY-=0,L\BN>GZ1S6=::2EP:P27QS!T9;;;A25@$+14
MX=!!AKZ=*%,JG:@:]8WU$/_I;IU[O>8L?+-51CK(7T\'T[@P?C<;_[;=9J,C
M2+_'1JO0#\5FI:OQ%N;!R7 X[A^2P/75\46W"ZCQ_[7WG5%-;>VZ"U&0#E*D
M!P1$#47I)20J300$+"!=0:0)B$@O05"1+B"P12D*2 V17H30B_0>"24$4(I$
M$H48(20G[G/O'7?O;]_OV^-^[9PQSH_Y9XXQYSOG.]_YSN>9ZUEKO:X.TT3:
M!N6>G]CQ/+TTOGNP,7[03@UM;F#H'&US]5<X,O(': ;^OIA"I_B5WG3*IB\?
MHM@%^L'=3#]^;PSD[O--K3I6%E&RDCO@>P)_ NY\0^+IO4B/M.>2H&0_&G")
MQVKLVA]5_AS./1@O%$R^LK@5 Z\/<R[7?^TN[M%.*G$.M,>/WN1/7HX#/A>7
MPXZ0T7H$^",?B''YAOD'-\NG(B5(N]1X<>4&9VGBAULYDSFL1%0\D;>#)'Z,
M@/^Z$:*Z*R1?D2YT,(Z%^>,-P7M<!UF!^==9(BHO$@%HG+N'NC#@SQ^S1 .$
MW1881S].[>#/RZMUJ%U5ZF,3<+I;6II7?09RR-QHNY@"6LZ6Z@WQQ+I-#*GP
M]#GY-]9D3>O=_-!["IS<Y8>)U&(%YQ"W$K=I0 R4:PIB7!J;E/VF#<T;?Y_K
M^!C:3?H65;6D8"/%4\L^>Q^%.S1Y$A+:PSEMW@DEJS $Q-$S7Y</&5Q$R9[#
MD@[\*OFPH &'Z-L^[=T+:INEX][E.&#_&#U]>L'?IU#HM![YO_@>,@NV^,+Q
MZRTX&_SS,!T*&<LB"]?H?-0D#K#YL8>3F3L=,9$KTE5M*"1[L2V $;;V"?6@
M0MN*K+N(Y/9,\]3*?+3];M[2"^6R,MWO$MX:*#^Y7 N$%2YCGQP5%H\-:<HI
MA!]_Y$<\9:QS'H-Q_594<UBP*^%PQZT#5WE2VA"PQU>"G#M@'+4#>">L;>L8
MQ&IIF2FQP'K#2V:VRV]E=G!$J=RS,Q4A 3A#T_&Y_*A#=!1H18=T>/3CX<S"
M>;?=RJFL_MV)P6K4TS>=JZ<65SAU.>^= L7D5N^\R3P:_XD89F/Y3CW6_S"R
M:,*KG.1.0ET^F.B46.778RQN!)UD^'8'*CGI$Z9)5.^LR\R:CBEP7]"9N+/I
M96O.X>O,7L9FS#HDFLKQ;H @5ODRE'-D*>E5&44D;5D^^4&%C]>A^H=+D_C1
M(9D!VV'K5*.T8.G3)O5B:-7MJ9A.119W2T575]R0$F;J8U) '/@6Z[CA=]&$
M>U:,3+4C,37HR:))X8YYI+>DP#<[P0?!QU97G.>#(:&CS'V[5H\HRC@DIGY1
M@_"EQ"\,#16;DFTT\EE8.>/I%C <>*;S?72J%G[=T05],B],CA#SR,>KH@;.
MOI[E-53IQSX]79PLOL,Z>T%("&#=J,X"?GT>_V]$'>#W,(\!^\O?2>'$+BTE
M2":B""45OZ7DV\P5WHBT?=,D%W?MF5)*U.$^%89OAKUX5]WIUEO%F_>#$:NY
MYC65=6/X18G&AGG0,WY#B2@8N_"**I+%>&GD*"4PV6YRQUDQAB);,.+BPY0O
M=V;67D3DL?LS,#MT#9V+Y-\>3B.DM6<)5*B:PCIV[7->"[VTZ_2(PR5?YM10
M?1LF7Z S7'87XU+2,.5T77'E# ?:HK2JM _^Y-!M0'S0C?$3B*'=[[4'#3BH
MVC7E#VZQZEX0RUBV:6AJ3CT7+&4MC8M+J^'WZP':EIJ_M4]_=Q CJQ)R>]6:
M4 C%V"V()V>N7[ O7 [E7SXQF,PHZ55XFDECF3%K+T+Q\-IH10:O<<VY0KT;
ME;.LR=6&];<_T( FM<C3VM?N$[ABKAA531S5?6NOU8_SQB/TFW[<'2Q(.59Q
M6O#()4,$$.9?03D[+0?EH!B-X0LF_>U=N^#<7RC:SH<:W8LNS#U.&[!+>Y@H
MK2%Z39]H$L':2IY=A&^&7]$=K=UB5ZM^W5TZ4UOB?JR6VZZT+/1U?>-QU&@=
MW:;<EE-SM.[;N UPB>)EEP>Z\EW1=U*CDYL[HT*RTAP(EH^68G&YEF.;.T*X
M6%R2\2_79BQZQ,Y)Y7,>WCH+ H=IU$U0Y/WV(/-D7?OF286=#QB.FP6HT.1:
M3+S:O>$"O'VJW UN)N6X/3Y_U:&@4%SKHV;YDO?%Z^+B$S4#J\G]GO&V+H8G
M>P>>:MT%O_E5S<$)_ZN0TW,LXF^!UDB=C+\B+N'*AGL[_C@>P4X_K;YWYN[>
MC4/%(?^@+N\ *F2_:ONSEVL'BFUBR\EZ\TNSA<O!,75# SE!4+'JMOSMS^*@
M"?^=>OM+/6P[]<^])7E[1 V/[:.%UGZNEL5BBYDY445+=G,9^=S'7Y'!$=+4
M,B%YTK\ <PJ5=3UM) MY^&92I8Z?(_N.(N]G<6'R.9RV*<QT<ELD6]WBG2>'
MHV/#&**B0F"];7#4=G"PGT7R-',8T3&T$V<OCK5KF78:QSM/(5_9AKZ8>J17
M;="(29B_(*3!5+4%%2 ;FH\B[MOF<KBGN0N4WXH:0F0.Q,9*I]O=O6>T/!T)
MO3K9#%Z:-:(R!UEUBTM>X=]*V#E<$-^)F?QN1.)QOK?N+M/9S=O'-%KPC'ET
M-:N/C"UQAQ'JH!)D17,J^L5FB$*F"^XZ0K'P,=8LXYJ?9,"1DP=3A!1F?AAH
M$1UOSY)Y.Z=3UL]TOO[0DV62J!IYG2\\O9]/'@0Z>6I029O707?9+%)<:BK,
M?[G%\6(K89L$5:BKBX+C7S!E?>KLCWE_C/E*5$'8HKJ![/0OXJY+".7N+&RW
M=3.+P(M\#XQE.L[3L"K^&M%^(2D6'"73&(NK>=G?WC# DW1J^ '.%-X%XZ-R
MD%U[Q673[(+"0*'^)33 V4-)1.?2]=58Y]OAE3613,S:5C)^>,?SUA0!0C7Y
MRKG1G>Q3LUU&^1B9 G6M9\9R!2> E[EV]RNR9CNR=-Z\<@EERG3GF$]_9V-K
M\K0XZ*8TK_#+NP6E!)U#$AJ.232 K08>2^5\.Z:H^@.B&.X5RK&05M+1Y\#6
MT)B CY 6O5=4/"*%"%)K);KV-&5&0<[E!95^Z0^W[8""Q^7?$-5COL]BL+.0
ML<K \[W]=SG%&)6^H5]:3:.D"*B4);S&!T\;K[J2V]=A:?[<_GUK=T.GV!QC
M(H2J"/.],8NC*N0:XT@]3(AM\6.3G;F&=HH;XPH68]A=Z>F@3<85S6S@_6[>
M)/1WF1Y4SDABBPX-&0Q892"I6.OXUH]:&2YJFVIW.&B0P?2S-0(9&*8Z+_/"
MZINBPXJ]7MW&@')4%YBY[2 #6A#YZ@Z5+TC=K+JQMHZ 2N=H&:K_L)HHS\UR
M<V[H8SU(Z<MM#9WW95 0V1>7S+*A[.BV *+O[_?H6VF8V5)MQ3=GU_%GQ7[*
MCD!/L+_E;OF_TU\R[.K3,R^&CF"DR+8TP"$0MFNM$Z[HJ )O5VM=Z:,*T !T
M]@@UP\S1>)19G2C5K426:@NA 4\DJL(-O)3Z;6MJDS6?O4Y+@J:OYG)!P=B%
ML#,OE@3JE\RX@N([V8I$/F5VWH6N7:Q833YNQ6DHD?PL2I-_8T&BH:5V#'E\
MHAQM@;HPH.OV]4G7T/Y\[X/<*]UA3=CJH:U8BOVRF.TY@@J<3=X?RS7GOONH
MH2':NRQ0LO\BT?9=#ZM?IH;SNY>CS,V]Q,S.*H>@4Y.JZ!=+:QP]+_9R6 ]W
MQ<!ABOV&B*#>-BX,!NM(#L3M885I@+OJ_!>$;\'0$M<FCC,G$^2>JG'35;#]
ME)1]^\65A#J_:Q2915#L4:H*66&WZ.$5@_$P$1?Y-Z_\%%X=1$CG7.Q!"N>+
MOIK%<HQ(6&DO;D6#>%W)8J_"3DU#%+W>M#416YNF32E*W?QY*,^7=RP5;DL!
M "NE4^ZT/A#.Y4[,-$'[(ZY<G*C9OWWASDK6M*FW]FF2$<0SPW2V_E9(^FQ*
M EIJ$9N,\<J-A!SU#8:7!J'MB4(- MSKNT[Z_D&5H(765,%CQYCL*F] 7;YX
M9N7BX/'E*#D:X!:D;3#9+%7H,#=GM,2E;9D4KGCY?(RG[AW[!#]EKX&'EQC>
MJSXBT(!%;%*$D"$AK<L31YKVY^)<;WJ34NHV_?VN7+N"2YQ>AGK@X;M.[2*-
M[#HG#F [DS$BEL3Q#2NTN&3#A%SFDLJ">-6#[8=':IM>+TU?NX$089IC>_E6
MBG]3&-D;SG66:)";OQ%RN['(%HOE4$);-;T],V-\S^]))V_K2V[!-Q,?LHA<
M+!1>\L,%ER_5KV>ML?9AICY\1NQ'4_I29E1NW%(+EB F%43YQB7WPCFA9\@T
MP'Y<OC;4=F @7+G'$E/:7U_G2P_=&W&7K082N#3Z^+XU))&'@) N;(U#S)([
MQ+6 '.[_J)FP;&_C85,3<)BT>V>LZ]:A[Z>Q3YE&\U:E-)A5FIA[LY5&.E!\
MB;F6Q)R6DG664L'M%AT!W&+;4%?*EZM/>'OF9T8 X4Z":T?K$;<%=O)0T;RU
M7*"#U-0.6XOJP;Z.ZQ]C+94N:-BEC"[SM[G# 8@9#F'8KE5+>E#V^>XLV0"K
M.RD'@2VYWW_WPO;)+V^U7S<\DM%MB,[0D+AASEQO%S$&Y4^=Z!Q?Y]EPD&Y
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MR,#(\J=>=/0A?S;@960ZKL[,9V+'<BN _X1&)*O N8S"]VW'9,Y<(0K>?CC
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M>.?CG2K^*=OZF?_I9YZ_?_R0?*$]>Y6DNG&F" S=[-1PAOMTYDOW(W1DS*O
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ME0G/3;[QGY4;#N@SZX*7+"4;N"Y Q$$?JZ/W\WFM>!9X88[U^T1!FIN;V5_
MILQ^\49\^HV^Y]F"6?Z6V/A@\'2.Q:'.[LT$9.^N=2E$%:+2WNS;K9X(Y%D-
M*3_RU1ML;Y]1TE>ZGBVB/&=;+J;0_B:R%0!.]<_9ZET9I'O;]%KI<E&$>)W
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M\_'^%(DUKLF4S1B5F8XP=U%X?XR?/N]W6Y8/_(E!")J^;&N[&2!,&L8!W[,
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MS?3]O3++CSRQ\IX*/.3FN6A.,<P]\$L$]D,7=D^.B!DX(9 @QEV5O)/DPKA
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M?SD^=''Z*!+.7;BK-<"V7]=#!:HWJ$"L5GFS!_&\0U)KOJ+*R<9!>BK06>S
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MXM1P\\(4&>SFB*0V7(8'D5CAZ/@]0'7]>9$WQ'Z^RRK3;4(53%^[!5[$69/
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M-/#\8YDK5/,?ZUQ2]B_AORV,U?QA//_YAW^$V!-]-EH;#S35J6\4!ZC91W)
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MY]/>.;O;YAC2F>^4C"M>RCE: ?7QZ14D@2:K="M(ZW&0X[")2U5Q%A/8CKK
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M/?%[_8YCX5GB^H!V?E6.\/V!$,X/ T0)O'_'NL#2=H GC**9U*E6EHW+>/W
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MRQ)8G/T(7.5NJ:O3S/"DQ8?R_.2$"NW0K-ZG2,O5L%"MO<G_ U!+ P04
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M^56?WCWM;-*HV]FD7^L_*+D*QRCJ/^]1:,\79%U:0$$[KT-8L>5_.YY^ +/
M8KMC<V:*3Y;KTE;(&54L?OM?KK+W!&FLZCY&I3D?XP>M1I47EVP:,571O6.5
MKCR??8>).F?#0[&8&33B,H"CPQOREDLTW%[TGJ8\$4MS+7[5@\OYR'$!@(FT
M7;BTMN"1:5P5XMK&".T<NTF$K:9<WHJQ;_&ZVELM6S@%?N,"H+TFU,* 3_K9
M*+]TSD'M)7_+X[AW:2#B F!Q'F,:?8BT1@KBQ[%W&2/O,%3F.#*BX[DWMBZ
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M>9F7B)#&YRZ?%?/.Q,BO)&D>JNMUYC&YT *A+%Q/^Q(&'"[>CW:EW#SU.K\
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M(MD[CIF5W+S11>6\4NRB3!3NEFSID@+Z*5'ZSU75E]=&B[(I>S@[HZ*DOL4
M<E>\6)Z1J&O?%A;J)PK#_; U[4X&4:?>8X=;0=$B9%I6LJ<[9W=594Z36[,9
M2GI ,L,!/'C'8\O)O9S1@SX)4>&1S_X S\]U $F+5UK<<5VRZNS"]R\YR4B<
MWYOFHPJ!R+PE<9)[=S8Y$G^R<[N;"GN/RO()3 @-CFJ6A@5#KQ->HMA,X>*1
MGJX4PAGH*K*4I*7*OITAHQ$QU>_=15&L+  +'7";),#5\<[8I9P^+)?F)[.$
M!& (C&J00C1&Z^Z"X6@!A[W+U?M48Z#LLRCLF>M[,',SY4DE00)''B"*/8 C
M0QHUQ0P-B-OL\ \]+Q;CW:PTK"6<+Q,3 O.9+4Q.=V*R R1;W8@W6.)]= &\
MAI6I-'ID?@I>.]?_IO-42B??;Y9=U^)14L=-3>; 7^O>E*#L.%3TDF@XD1,?
MGM?\">-/JS-9ROUB9F&F])O")VZPFZ7P!?#C+DQ8CB",ZV[!XLD^C#Y?G'=8
M^J-\;R=W2CV;\6O[V6I@+3)#+0)JOQ>V?NW2I4\S=F[Q;WGDS_H';X2[6R/2
MY+'T)I7GE0=?;NGP=1,I<6G!@JI__EK9CVJY9ND**WU -@'^S#5(">?6+A_+
MH#-].#].Z.0=XJHGQ6? ='[U\$:*Q^CM9:83(T0!K.;QQ#!8>\+S[!!1[UR>
M])3X>(BR^H[4R)I$:!$P$S.RPV*;[ 5PY#I+:8RPB/#=O;UIO'AE31(92;R*
MW4S^!BM4':VX *#2.#7"=*"L114%::.>^7FEPM7UU<?AW5+UR^OO/DKP^S_2
MFL]X2=_OD?0/&^+,JBQ)\'*8LM>@:V<F[QU2>Q8\:_D#6$@.',@>EKJRXA<Z
MB&0C^6,$M;*-4[:LJWVSF^QW2$D.7PFU&[6#JZ"==G-EL$HUO&MA"Z'!_KY_
M^3KCZ0;O-.,0Y\P0U#H>4"I5+H>5"RU$!/!&[&HI=TF+O+MZ 50PG4\SOJ@B
M"6+<,2N'O[@,M_!\BQD+S-.4=P1C)#O]H:K18]V_FU]? (_-_2;2PB\ &U>\
MAN0Z1 /G9)6,8:BAC139_D(G:_/I(&Z!7PP\_R;]>,O/^,UB'"TLB=J:Z_G#
ML;M%VP /Q1/*VV2_%.X&]&=>Q6<=.?74)#_"T2>0]IF/<&T?&R[3T8D?@GJB
M%LLA)KC"(T05>,:4/(N#($1]<BA/]<:TOYYAS[&'>1'A5KEC]62$M1_P"6^/
MGS9##W9_9"3P@6ZA,G2?EI[*HZ7J0RN#E?E3_[YL([\*XXNC06K/=:OX(#L7
MICK0@UT_D[8Z ]@K:\?YY'+&G8-J&B,;6-,A"@C._;ZL0 0+G$ZW&4PP::ZM
MC":1R&)[+,K7NI[CPNVO(4%RX&UJ>O*=\ 8_N2@Y@]E[+PX+FQ#;WP0Q-9H%
M_]E\3!^^5N:X@:@>[/C$K8S\XM269DSQ%<>6Z&;/OKG=@# %CC>% H<4% A2
MN"=\#@H0[ H647]C#,U/Y"JIJAP7D619</"F&#GMX'4[?491?^>!JCV)?<%:
MNCDFD"VJS*=XVF&C?G.3UH9X,$(.+BX7ZH2"%;A@AC)@0]Q>N 0./+]_^% )
M'+8)[!4A2<8N &=DV'#ORZ&\"8BUNZJA*,.&-/O+YKCBFL/22ES#DDY<?!J:
M\?VU=;9=!0OEKF,GUYJACT:BBF!U-MY,H7X%(>((F(%(.^."4XMTYFUV9^.Y
M-7:>0T3'DUC7Q-_KS'KC-YEE2J#"ERR5C< 5\97>-@ZB"R-P : JWD5AX^/*
M8( 2CU,+WN9,@B"-UW"?;.;!HCZ;-H9[UC<-2;/_$-M\.F+SPS\6\.E'QC1+
M$/Q1KGC5 SXLHKWR;7I/1()6J7;6?-20&X.:#Q>?O% S7NM,!F:$MOB=GJ>A
M4(/Q"R(F(S>1:Q9/=,S%SG*GW@J-5\<,!](#5QH<['/^1Y7K?^#I\V%%FBBU
MV-?/R[]^P"K3A6CG!#YL88&S8=ECJ0@Z$'#.IAW'G/P'FXK#;J=^2? ?L\6N
M1<0/O/YZ?N5 LK=(^4+!!*:)& 6<M(O^073(.I(/$VR6G.\8[48<3KWN.3_0
MDFEYS:,$"UD2C%^T4BH*(73Y<ZD \!NXRL6L3N3[:QM$/BA[ "\LK>UJ4GVC
MX;'&4<-C^5O/V%<-=F4G"_!Z1[:C!']T/]2\ M^W%.NJT1*A1=_I6\YF(*^P
MOC.*118*ALE]S+QC;?+JK<%PMS+#8MSA7V1$E;_KD23NS3P_MA\U4(8U,ZC=
ME\QB:"]0&[KEL6\QP]"L";)4>*O!%P=0/8*^U $LU9,<3VNB#@NT)WUWND</
MG[5RKA_H_.E9[ Y_6UD86-77EW!?L-FP%M'_$VF"/8Z0V&-9/_*M3O9C^%HP
MURT0O#K7D5N\KL2:K\@QS1@,AZ+MGXN 'X\>U Z]5,G_IA;?:SA (<("?,PE
M3?VO!\5/;6/^-?I(OX)I1UT?H]3O<RKG/Y<86A)+))Y1I>)SCRSP6DO,?(X+
MC ="G[AWQ6DE50>+A&(XT7LM+_9"F=63C$V=9+DCO.^,H*(C  +9J^:H@IJ'
MV8R?+P!TS!OGAZ/-_+ M;<M?Z0U08F@Z=B^BA9Y@X8/C'$2O=3#&$*5;<!)O
M*AV/*Q=*9AS>$9->N*_].$0B\).X9--QR!,%=H*XKO>29A?IF3Z9)R<W_7%!
MPL'^???BK:@](@.<%7L!M.G0T8NJA*XV?&D\5]:OMQ;H/VQ;64D9Y$_.E&4(
M#H3\Z#M2GNPJ?76V%-])VQ?#**Y3G1-V"J#$SF/>E ](@B,5Y,;TSI E/Q#K
M#Y&Y:D],@9.)OB,&O %SY2;;]$3MMGN/_L0]02JL2-0.7.Q,!"Z ]>-S@#)6
M<3FP[.YS#K]^Y:_Q9M^R1 4PJ!@5/NA];/@NP?0Q-)BZ7729PH2,\G*P+PU<
MY7\J2/X_@=5R=41HQL%YE\\D.^4)Q$6\-.]%\-TN 0#^R2]G$U%A%%5^V,^W
M8XIL\[=T/JZ7<'R=K%AK_?MR%$;)!E:(S+W((K@<A@?:)2N2698_I^)7>&D8
M81BV7_69[PUBE;5KQH7M*AO#Y*)-$O(2G]09Z8TQ68DL])02NS.%-1MNKXXW
M4V^Z8U8G),6UT%-3+1.B'BX:,N .1;"1G01*Y^DE!4;3^FUQ?=S=WKVJP8+]
M_MJ+CS=8-L2P[9]RM>Y_UJ;_.SY\ZLTFB5/:LZ3'Y2[=:_)&7@#M57@S;O9Y
M2&.\-&?,!2!9'DZS."@E6V-1/'N(R<'OX ;UXRVK\=;88?;G^/!O0+)%4#,]
MPRQV\D'F)S(!O>*'Y0N+A:WG7)=+ L+FKEGL9+2SMNG;/^-2V_3Q\)U\F$<H
M]Q4@>3&K+59TL>5]VE-4;8;AN OWK*/OW"K]P->W/:+\X9LPGC *WYL'V73/
MATA4+@/%_T](),GJ-DP'\OS7P9%.3L"+961.3'77GD1'TO*T?4&W,G-DDZ6N
M^@N=>\?-%0OU-G)OCA*)][:!"L^5B@*Z0#?L,LUB-1=="A7& (E*O"-Z)N9T
MNF(0VNHVW9P[ZB5G8=I.VW=GJ;ZJ5HE?[U%;XEA,,/4F_0.3$6'4W+TM[3'G
MW*:*^MB<]'D;NJ0['+PAT\UF6L\O@"-A'$]3Z)FY%9Q]S&[&U?<D\>"Z.38.
ML18D&$*0(#F,D&%!4:#&C-[AM,@C)<1O>R8R& 2M*Q47_5=%)2==FU$"<#E"
M4N)QN#[#4:\MU[ L>A'K">(MQ^^?:*PS+#@7'DH;/578\R\9CR@.@,#?CDG$
MV@ZB)SM6HO7PR27EUH^DNPH48=(/EG:#_H *ZG6"$*15@R&R*EO1D5Y9+$[7
M:,N<+!OD"ILR9H]4UK\]) T4P+-C-77PDNC"\$%GLT[?D/-"XTE!<'-S+:2R
M8KLI<%O,\B/E;=HHT_^J:A7L?C7C'R(K^M=^Y:LO_V9M_QW4JDZK6HS=]6OA
M$#Y,__-?I_NZ.+:*)3OL4=9YOA?_T430FKZA\=3W;Q$6WVM_DC:GNZ#VXX/@
M;$19;&%LH^SKAJ'#/D:._E(32RU'M'6BK<F-!#N2X>H47I!!_!-@=O)0AP,.
MPHF&YC7@Y">C#[Z\VG8XECH>4N9.5/_U!*(J82E^7]FNS-/4KN><7=^*ZN-.
M89P.DQ8_+4OIMZ-!KC=O%P\[T+!=QV]P61PBME$MVQ$DVSQR$S54>&:#R@Q9
MQ6"6')Z-2 1>S>4/O;Y67&YR =C..>DTXDJG%>IL[&LF&?W1!^EL;B\]!-KJ
M/N4=&B9DLF=GT]>U.&28H$1 '9K8[L)OYEN<S85YQF\\8P6<^*HUHJ75^RB!
M_6./."=] KS2F4]3S/[X.2Q<=\QFY.7PTR+P#M/^K=<;%6H"3=28RBK1P$I8
MP#$:DK"IP1] %[QS+_V9J>9/P?=\ZHS%_K\]MLPO@#BH3;05A]G,G.7,NNG1
MUY?E%HY'J;*'A=-O!$Q:#>/T>?\"Z,"'\D5DUD;G155S/)YFRNCS)UL68_!'
M\/O3!G6&,%'()P&NC$#K3OCW=0:W+D]9H^X[J'@>"Y@AF/'7=-SG!(4"MK^0
M&9J #8/%WMP&.L8R]W=9E6E3RW@?^=1/:!V:2RJ1P4A-NKR!/"B(UG0(0F72
M?V.A'SQ;U+SZD"IJ&)^/-7N.CUUJ8=SL P6]2M?::9J577XFNW4US^4Z6H.*
MB[_-D'R)#B9!TD%@QZ^4.)BZ5,_?&$59:&I= ._K]YY8O')(F> 9P0@8"+HI
MC<HW"<'AWB/-8#/8_$$;AMX_N<<)O>_$7R*DYB:"*KEK%JSZA^ICH>LK\^.2
M::OM$X3UHMPY"<K,.W6M<P<9&2PUKOPPN:^G_.'@$[3"?0(7#AQ^8*&J=?-U
M<PN.JK,/S-0^;%95XL">XDQS[7:WHM1RTD.2T/OR':T+K,E=F2(XJE#7JN(#
M42;["B4/R;R1TA)^9I>_*VJ6U+]D$^.HD>!Q!0E\31N"V85_K+O8._?N7)=7
M@48AQV*P!4XD:J;_.XVIQ0@;28;]<^TAH;$ 'H+$>!62!Q_= [K56)G5*=M4
M5OV9=Y0UM(IMB/TU4$OWV]2(/U.61 >':'> ^" 7-CF[<[JI2P5^C(C<[(T;
MSW^J\78)GP_U!*/-@X+[/U E$\QQ+OE>9Z*;"K>J<)V^:1&>6YUUTD3.,<4P
MFJ>M7*^&JGETS1R,!MR2K32V3"536_+G'.IC2XTFV'6K],Q^?TUZS$=^U<_H
M%X)=@7TK@ DO@-GR6W=&'NXQ]17^F3&!!8RH1D2P,FG"ZW[J\R?=?W@=61X*
MP-.^;G*F;6LA.W*WCD>M""QC]\@Y;0O%Q#6RGZRM!%M/D\(,H=Z!3IOX>]<V
M.5;"5)($GZVONY<6)B@==.GB!,,E!MGMTZ;OH5Y2%N8M/!HRGS;/AJVH<MQ5
M0GYJ%"MQ1%04M%@O[KP[W3/!*_F)IGW=\AZPR7IL"S'I%S1\[ZD*"7RT!KP@
MVYR^>]LN;I4_5?#:XT7Q'Y_#J+ZRBEPZ<W58-I".@\99<>TURI1,X1G;V*Q-
M\>$EW:8<5&(..$]IYBRT[A]0GOX"CX+T'%[VJ*.MF:XZW@P?6P:O-A1)C1N7
MF]6);^ D%D:-X+FP4I-HD;#<HH4%+8PHYU82[1=7JT:95,S3MY'GO<DYV8M7
M *L@,)G$!1"2SO/[QQ,O*S;'O_XEII.")P6-M9!,G1MJ*I:!1I_-">K->.]"
MN /N?8W1:?Y*6H1JRDL[#V^^&46Z9SXO7XF@*$\T^ $M?\DAHP%3T<"R /ZL
M6$N:\:1C+6?E3LI3VJS*'X'-3T'F%15<9HS7%T%CK:,XK[6X ,8.] +3)NA>
M6J=AFNF7@JQO&VE2W_/L[_$;'ROJ*I.6=H2)=+D@=_AR8J%/:S-T&FI2MRQD
M68;45<^,F$M!3KX%)S>7WR6  L?T" ]QD[%KPV\:G;ZMYSX>V7O9PJ<:9Z5P
M:FSF^4KG_BO)7KI'21H<_:^W+H#*-_6#D1"$#T,Q?6Q\A,3)\\['[_ML_&\6
M.<4I67+>-B:9TW8@*<-D32L,=A#Y.060X8?TEKM:K^V?<=DJ_ICU(35<B6@O
M>D&S,YC_M*5*,NO(O.]>N!][Q-)X7(2$CAAMTX"TVZUWVS/[+@<[)K+>K?+F
M:HM"96K&J-KQ V>7+8MQVS@I&@^)U4=]5[L?(3^R>GN@*#4D,Y86IAP9N6:=
MI-/Z<AV/KSEUF/^HF'!6&'[=\^OO;X]N)?*K.KS<;HI< 3?."ZL&:==-\XZG
MV;)/YU/*IV$!%X J2DBXPMR\U)7&$&UQ_5;L#WF=?.?";I]E' 8F#Y<1<DHT
M5BNVG(GN#0IC3\@6"XF7)H?/O&7GRU1QVSN3.FFF&3TH$>%KFV>HB^Y\9[I\
M1&0;Z<JO+&OX.CUC\#3I:OCJW?O4EF[)J,OLI[L09V<P D$-.>=\3Y?9.2Q^
MX?9M8[O\>O/@S8-9@"J%8Y,>< ]@P<^5P)Y;\<P[GJJ6E*R;ND;$EM8'?5%'
M1<XQ/;;7-M'_/B 6YSM^[K=4G8AMZ01?DZ3]2% NXY'3'Q6V_6YBJ!^[:V!
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MC\0EJTSFX^B/PR7H:762Y,AR-3EG)7^',_SFCQV[K0@L02:9!;>3BSJD.[5
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M]^I_)_F+((/]"W/J2)P1#/?,HDVSYMN8EK!/^ K=_1;LC[,P ."'9Q#$S[:
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M?TO+)4<;UPS6?N"TL7)-]1LLO?VC3S+U;HRZ<M61DUY'.A'U(52P=)XOT=N
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M[4BH=2N[T&VJ8E9X?CXP !$G1[ODE*>5.QO9=OKE3/<Z<.\\_-@[T%1LT_N
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M"EYIO%?M#5FSY<@)[C++XALH]8F5)-1W6AU7ZN*LKZN-O%U]E,7U0C%FX2T
M!'.AJ'SR!]8Z+Y1<2P/"=&6HU[-9JUNA=#[]K(CHKH"Z:H^B[TG?+2F-PWEZ
MKJ7;(0,\SE)97NGOMBO41I%".8@7IVWL-2N'N66V[JY/BHUM3K!*=F#PR8J8
MW4LRT3"R0A4-F-.!D>]]\*#&,<^.4H^?Q_Q@?Z0ZJ: *.;?BJ'N6W<K\O>&5
M+KJGK'*O/%LO"8)T\EZ1P5C<:F[:;EQDT?14KC_<T_M^DA8/.LV3KUL\/H#D
M\<MH\7\8O>7 00U0*AZ1\B^PF%1\.NGJ&&+>&G1;Y.O"E5N8\!I_G^]-3(/+
MN*Z5]%6IF&/VZ9EKW-9WDJ<5#[ -L2=C>E^0I[."PF^!6A<[M9_L6TD#+AXF
MP6D 8RJ,\E1->-QAY@.3WN"9P14?N$"0DL=6:J)5;@<-,*%G+&N)+.KQ=?,:
M>:#8^8IWYED7\_7\.Z^>/V!E.M2BN/\\F(V,)8"P>V5^9N0-TI61)2E[PZ%V
M\R735Q&7I(5%Q7VKA3J-.3[*?SJV!?T#4]<ZP$=]A,RPEJO)11;C9/^M)Y;,
MF9-*DR+I*?$?W@DFR<D%>=N (BF*161[;&-P9)&56$N:W?W4U.T99 G[61/8
M.[-(%/8,'+7Y ,:-(;HXT(!WS_Y00;=JA(!KART+VV8ZH^_TU(P?BZ^>N[-,
M^/J.$'4;_T$J=5__A:N9H=N.?8^UM>#A/M+& V#^=07+ 7J^.4(#%F9:I% S
M@WTT(/'LGU31C[DAZ?%E4'TE)1QCYN'$%"<E$BZW^]NYWKI/L@EJ)[=+82"D
M2J8..7/6@]=FJFQHZ>'V]L-/$O;+Q,[DF!VQW]"]S4-_D-A\:)5['?3;3/!?
MZ="AG$)H !_=GB8:QO:?<5"R9'&BB %9 JGMR?3$=YISJ>544]R&X;#*-4_!
M4?9&#1%]^UC&0\5"RF9%_T2JXI^70W11EO_H,X.R4';Q/T[C(O=C^4>I:;JP
M:V;]T-?=E$2;:]2NV .ITBVHR"G^J\^0+Z)0\R]3_[/"]$=J)?/H+_94K?(#
M#]Y>XV 2"P9'/WW^ER+"?BTF0M[F-<35Z&+7^G5_)26E=1N#,_)5"K?>/U %
M% ,.T /F/]##7_PA-6%YCP.K?X*L[><AN#V :/DV=0,D^ EQ:W_@\Z:#'?<1
M2.X+&@ Z1KY- R!9"@=:?>T 8A!,%L%57VA C ?Y;B":]?= !*-L4#H&CT<=
M0\T/=:')6JY@BFL\&0%K1__8)!51V?DC:0!_1:'SO][L&:KM:@MG%J2'8$ 1
M5011%6$WC=3 #,%]J#IP2# W1:%I@*)>2&['[>IYWVXQCFZO7Z?G'#40=9(\
M(5A"'S?\?9I(Q(1#-Q;_UO]NZB.((PV(#*><HP%H WX4_E0QBO0*^@OEEO3<
M_U8[HX,I/DHV1GW]6\O?#L2,;A[%& Q!:!(^OGAEB[@UNZY>J%\WFN#*+8?3
M8ZY:-1QXEQ-A/.<Y^):[)6 _"SHW@W$!>;#]SX"/)>1($N@ZV0[_TO=# !Y?
M8V%?'W7IM(MC0X8&LZ"11G9UDRQ MZH/B (^G\TRG<'\*Q44,SO\!S^L\$FB
M;=%+C?ZBXP^5/20VL\4(<;K^7]5/%T]6]E;RG603 *$)[DE4+M)(M0/<]\ G
M.!*3QF;3=M;\?=4-7B^V.:*Z8"+9D"G/R +"-9K<*2PPN'7O26O]R,#$$UWW
MLWSJ;:JDC.$)^9B87<-# WKG537@\>1HTC5-LI-;X?$;[FNU>I;SRP&V\86=
M\[:P_IHW6@D)ETP<G1X:&\J]SWVD+"'9CP23T@Q(T*@SQ$YJ;"E"M^,E$RYO
M<.L=WD+Z) .]J %+5=<,.QW=NOP[/JZ%8]A"9[K/M]P9G$2X#G^N$.10D4V?
MNR%VEX7N+A.]>*'SH4ZN=E<T!PW @\A6G@0H]T)]P(F:>OE)%R.M-.\N[Q#^
M9\HV3T^R"&]%%U,_!4@@#S>2BPK&)I;X;RKI(<X7GCZZ7E:;AVKF:F,XT7_R
M$].K >.:6#771H<7LQ6I]6SYXT=[;'I9H99-:N _HB;XGQY&_%/I^7](U^]$
MNM. )%G"VA[/%FC_3%+3'Y(R>&%5\Y1,#RQHC^<\=/.JF=">L2C.[$DP.R)W
MT:99,0>1_''8^IQ#R+WZI+-?[T##;2(,[G]KDOE'P1J2=LMM"M5R>BH>H69"
M2+PF2?^9+2 *^+%'Z,HK1!J0P.W]( 3<L'9XR\J#"_==OC8F6F[<HC7I1[_(
MN5/7&(^&!KN1V_@J+A!W0B@">-21X &T/9$:GD]^*JT(EES>?H!]6/?!/?]P
M*XN(N'B<?,;NWG5B830^46)A5S4B2>SDN_-N24+DQ1?9CJDPYH4-V_Y Z61[
MJ672#WEKQ2H^48/5:GNQH'A.N@UH1#-'+H*G$T/G*P72"],?5H1K2_D*D-/V
M3^_*.O.>7T=G6+,=F="7[9+L:^% &!B1NL-]8N&V))YP"I0DI-B#J:F5_#)'
M QY'2(8W>XVTV"F_5]>ZKKZ'D7%GE%R3+[2(J/6H4F\<WU>7C9_TC$^+3XN[
M].H6XMJU3$L;NTTWU2V[&%CM*[XN1J8UV:8B(6?Z>?1826N&4@[)C,"(*3;O
M+%X:"99,E!)O4A<?@WJ%9 AA=^Z/S94?%?0IDXDV>SHSC>O#^T77=N]=#(==
M&U90P*3MZY51!JUZ>!\N9 [R&';3QSAE[!X;U:NM3/*7*K.K]Y]^GY(;<RX1
MT]SA"_D6>TVW9GBYH!I3$[H]:/3T9$.,MD#\U7RV@P\Q>&I6AV&C <[0R&JR
MZS<I?2BK^5*:9<%^)E,4;T&M\Z#(::)NT[EQ-+YGT5;HP.F+W.5*:UL+Q:V\
M31O;^C[-)9725<82D^9EI;6^]N@]*PTX.X-,'U^!!;A A Z C?-(HVVZ4R&N
MLD_=Y=#UQUE?C>ET%(XKNJVL=+UPEII!R?$^9JX3IZ['W!$V./T;F -I]FES
M[; E=7"*Y]/Y[ &5*RK00MB9M#NA HCYQ/1[B2+6$M4,U@F,6@QSH[FN61P#
M5"&*(_$JV5L_3,L-CDTCF*2.'>HIEM,(M\7O]LXD^;V1ZIG/V+6<5Q_RX%\L
M'"H3A^>;K[(D2/(]\S%[]^/1\G$]Z10G%9*!6#Z['ONS.(T8[ANJ:I=FP#IJ
M2 L[@G)/"S^%D7@F/M\6$0'/;APIL;NS(,JMM);8%'@6JV-\)^MAQK=FO5EF
M#"ORW'XA!/P] )*#SW2L3^[D5RP;E\G<EBP\?2?+ZL(/<4T5P?@+9E.FC8R9
M11.BVXV^!<T]/$E)-PZ5G/?_V*J&]]+NUG?Q\#E^\59Z0?-0F?2<<PS+1FMY
MEYS7;=&@0?]N'>"'9FN=+7L5N8 8C(J .7%,+6Y GWQ[_4WW-P9ZN.U%4Y0\
MKQQR*F5K@;=T11YKJ1_M[>E9M/C05'Y"\(-4;:/&('@[ZI$!P=*8[L_O(/YJ
MN\![O K3^TKJL*O_Y%L4OY0_&"K)VE]NQI_11?Y)J+N_WZ\)7PJ &1TI;_8)
MV03O[)']FK^N N7'_:+P"Y]*;=:W:X]9R,K&ON),(3;[_N(KIXC?S4EKX0J9
M:)"H&?]JR"OU$IRE_A[[8N[]WZ)I "O^N:"P,SVX8YJ->A(IU$#<+B(< -;C
M\!:!8<4C"B6IGS:CH_E*S[RHZSSE(EW(WMT<#I405M\N6]'<3B$ZOBA!1.HS
MF32CL?5W^TWAJG(N>57V[+J-&B:M>E7G)H<J<LIU9\7*F_:NXLA^6%V\'@S+
M;]-2X?1JJ;[Q/1R\NC+'_N3NL>Y ^5<QI)",#0P+'+=5'XURD>+0)@:M-N^B
MGP9_</-V?6=OD:E7<ZO:Z3#;(=;5@*QS(9MF3ZB*"#BVRK)=>,>\\4T=STMX
M'DYUHGUB,SV%[I3J!_LE&E#3_\@G@I@DI!^XV&QR_'VC"K=2DH'86%@O>]>K
M/.6V=.!VS_RGT3@8!?09R4%X*VX\K&"#ZFA4R.*O'71 L2RQMWG"/4&&[Y+.
MD,=5O=N$)+VUR:J>^108F>.E<S#'FP'DQ1R7J5-[]\TN"@>.Z7K591GZW=5V
M.B=>?L&%;FE*@?SSBIKNB]AVA7VYYKW7I3MF%Q9O:PLE*5U^_HJZQC>O>B%(
M,FX$Y;SH0P/B^67"W'P")V^K??;Q+);:BDA76/TX")26%WFDU,R]: X8Y=J[
MOCC-V6SC3X@'65B2'RWL6#J'78]6B_MB9=TDXH^!IYHXVB+HU @8%9<%81!)
M/#3X)$5^M(BXO[^?@@E/OMYLQ64A6M,P421W2+-G5-2)-YLU\QIY/H<LHTG2
M*)F-%[#^7J=-.%=SA'>!!C@I<; 5G'\4PW'6>D;'WVUBLQRC35[#ZVGTVV8M
M64T>K[F4&K@7Y/A15SOW:77M]J6>VZ%T0IT(8_ 1%7.%%9V+ XZ3,ET<LPJF
MDAOF;M8&HX6:(T7[A<T77^)@E)LC4T/NZ<4(US[]FC=>2CU>TKR/!??Q#;Z$
M#& ;RD3]-,5'JH_M?KQ\OW8\Z,Y8>38[#=#.F))W[PA/"P24*F_1K45M+OW0
MG?&&MX#)TXX0,:MW*O:E"'\I'W^W&)@3M^G:FX$4H2?)R*9HCK#G@&S_\._Y
M*O^;-/SQ;$;WHG5:YSB4?0G*0M%UFUD<'.]D_]+;Z%.NQJPT5)_<.H]Q)4+#
MICE4%/%!]!VO;Q0AHK'3)S9MN'7?:F*GSC4U)$S4.&N_8*X6R;L 5;C'(ASZ
M"/)R!_KB+L*O'7<F+*AL>I'[-=:SU#:HBFJNCUQL%[7*G#COC E_\(!R%Y-V
MDVSD=5\J#-%U73>E[R[+> U&7&5=MM_UQ]Z,9@>4GW*%K$?BZ4C-T$B!AF]Z
M")(CM&<;$G'KZ] 5OIOQ)VYQJ[Z1H(\0?;D@FP"J>R+D>O9;5-"4==2>_@C.
M.VP!WNXSC3NSTP'F+R(ZU&2<B69A&^\_7EZU+K;Z4K!R3>:^.O-C0;9K[$&2
M&8,0N:(P!3"[3*2*3"'N^VYWQU$5>3L@I8/G8I4TP?NR:!;[Q8<F75?OV/\,
M7K!=XNTKZ>/G%,B49AQ8"CJL*R#ZY!A;KX8ZT\G1SF#IX2TWR5FGKL */F><
M1J544>A)%RDWG+I+0*C9)0G]3:8<@:>$LD#W"H(,!R(0GQI;@G!!2N5_P>9V
M(\[[NHB]S[XNT!/-TJ1&3Q>W5@ $:AO"!3JRP /-+@4V"[C:&OZ49[]9K.1C
M V/BLG>X9K7WKI/1G5,29(<\LN[UH<>V\L0W)('))2]E9KJ]O)I7"?=FKS:?
MZ+_<S93UF7KY0.N.JEB0TDP:B-1TAV(+V*)2\M*)7M)^HTNVLJU71[AQ%\1H
M:.J1ZCP6=;19"J_G[+H;_%N>L3FD-\U;:_!=HI,R9^4EZXT0FR#DVWSJJ-^3
M+.G'G7F(;T%@=3>O*4+;BLB-,X,F92]XFX[2T56!)!!\7$OH0Q Q6Z01L1I^
M&RXL.++B(&'70"3T5,F'M?"9C#WQL0OUDD]2BO&B6ZPY\*+_MV2'.9 SL(:?
M-Y6;W&0,K]AF+SYQIU2*ITX^O=W&]96$9&DA78Q:;;Y&"+*<-FUVDW,[,R4$
MF6@3-.R5/3679$Y-67YFR!2*@&\'D930KQ!TM2C> FK:3 _T4^E,]8GTH5[G
MD)0JK]83[UJ_=]YS1E75O<TE>W2T< K+<Y!O=P1L46N#7+?1;V/=W?D=0\7[
MF3\>O7Q9-*YV,X63;C880F8J1JH-*Y3 ]VT[FR\6PM2#G/@JP>ZULERG3F="
M)9+RQ%_R<=W:V7;<H%PNL1R'1TR;>W"CVF$%KL+Z:Y63+(=-;^\\>^D#R?D0
M^/9@2]M^N:>P-'4&0QHI*",72/N".1=T<S')\"I)M](..9:Y^,R<XF:+/2G=
M6<D2-UQ$6J#;?C1W_&DXO^L4[Z$S0V(-R-+[ 5FJD@NN9^F[5.CV5&E ^XE9
M4.25A.&60141_&U\#CBE?@6\A FD]N^69VU9V>RGKS2KER'5/A<-YT>AV*>^
M+'%7L"-';EOF&$-7[CV??=L>!6SL@[%9*GIRNZH&G=RW8+S7'R;AS)>OVU'<
M>9\G#]$+FCJU>X0ED9D[I\Z3-'*\G:2K9V6JI3HL;2K&RM0>0\"._HDQ,1;]
MXL>4S5[^)2'_WXT/*?</M["0-^F2?)B)  VH\)>L*5YUFVVN3SU*L+#[ZQ-O
MJD=^AGPY8N*@( 7TV :^,V4MMD; J@D%&KNAP.%Z0K)KENNP.4<;4VV  46!
M!RNS"VZ^3 /"SF+(KR*I?*/XP$KQGXA!6V6CL),&= S2 .QERH$,YP;A^RG<
M/ZL^,6"(GV LF(5@XCR5)9<&S!;3@(A0L@,-N+83"24Z\-  +B/4K]T&: #+
M/+&>^O1G&ZN#-AQJ/U]V54?*T8"</2R:+'?@\$7E4?F9\6G[H"E!&M#V#$8Q
MN?&';IH4>73[]*[X[TWNPRAZ@.Z!2WB8V$>-7&-%S?3*4"7BR<XR$;!-*,*;
M!C :H4@F/+_V 1,_HIA1"^B?+0Y7HD@*=#*_3@<4G]W"A_JT?\  W\%7=!K#
M?NWS!Q[_MTP-ZF!J?/85?W(93>7KQWOL<_S\O4Z&>B:!^A'-'&D0^;<A_-.6
MF\H6J6+DL;WKKAEZR_QQF=X5BUT"318,B5J,F<=>E%ZZ=#*^O26Y%'H,(:E&
M5'V6&BP\4%IC92$0B+4_U%$ZE7]6<.3K?RG?*-K8_P%02P,$%     @ ]Z*;
M5!+.<'QP+P( QUX" !<   !A:'!A+3(P,C(P-#$V>',T,#(S+FIP9YRW9UA3
M7?0]& 0%!*G2FS05$9!>!"*B5 $;1:I2!:0)2 M$14"0CH#42.\@O1-ZA] 1
M0@NAUX0:2)OXSO\WY7GFP\R<FP^YS[UWG[/.V6OMM8E_B2L !AT-;0T V14
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MC!"M*W#7W]\='_!WZB=GZZ9XLX3/$*PL;KZJ:";G>K%YW=<).-3O?%D_V6$
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MEA F@L30],&S74IY,PE@>P$3U469I^6X/_"O%R%XS;R /^-@.U+'^2#@&#-
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M:,G%I)WP)O:9^Q9;,6&Z=^9#UHPY,TXZ"GX":1\!W+55 (=6;R#DA!'RF+T
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M?UXTV3[B<,EIY*]C;LX'$+!!WCDK!J&F$EW-4=86/,+?G:KQ^>_7WAIR93(
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MC.V3-2V<(6F*LRE]CTN4FV?Q.%2%6DMX9#>53;/GT\W+RXB4M9F1F7K(_VU
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M+L::$K@U4&MBW MVDA)\=KT=+8KHA^=BA5B0ZGLZT1-L &O?M)]8V>!-2[@
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MD.O,D?0Y\\VDP176D5M3'1;Z,&8N7;L@.PU7QX(6)DFEI!,EWX!]&MZ3^U:
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MC&LL"+V$IV8:8(\B(YAT!-M;>"*94"#9 1=(<@:!I!E)FEW]-VD>(5$S7I'
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M]BVP4S#9Y'*M,JD@[K*^']+.S:5(R[M+1+\BIE.]HVH S-G@B]D\&+,+TH@
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MBES;@?NI'0KL#)3[X74/.1:DMPMB99ZTL/-(@*[7F21'*_=\/\2%%VO]VJ_
M!>S29NM+)WYYW^1E)4<HH'H8?H7O-R$/NU*'405STC=PRJ4\P[81?.$ P2VF
M#,UI3JY$4DH!#^#,)6U]UZH<8K0KM JX=7/FJ^C+O++WE!;3-A,J+>%7AP;
M(;8F)7\Z%0%)DUF%SM,1R6ZXYQ0^Y$481CU3O'(8L2+Y4!J^M@GW4YDF;TTR
M.]<-/4+V[#. #+-_!]PB@1M@R_NKB6Z+>I']$/,&9 =^"[7X%;-- 71-(_),
M8%_Z^Y!$YH:G:R*'[<LO<MT'_1Y-WTG:>>?M")";5 \LP"A(7DL5L:1P50^*
MQ"-DW9O:*4A4P"US X_'OUQ^SPX^BG.XBVONBXV=\5NP!>J+3 :R4YE1#C4)
M42(;/?FH?FFSM^\:?;,Z$^% /9BEWP>"=>G_!BM05PVO,T@,AD;A1 )E"N!W
M>VF@_]/WQTS[MW!FU\R1$W<=W!:/?4834?-*NZ#7^FC:#E=5-JK**&>4A4FC
MF_'@82Z4LBX&@(YNQOW$NXG _J^6B!UJY^'0_%/AN?<J_'DBG5$G<F&4=?%-
M9DF>_6%_"L=[8 JG$,C@R2N[H'=:C.D#PR\RLR^Q_F<D<.ZZ-O6&$T!).X&R
MA=75JC-'')E;.08=\DQ7>_& T=_#A+$19V C7+ZM+WD83UG_W^W]37+]'Y]=
M1A*X@$3%OY?H(/^JF:79J4?1_Z)=VO^MM?D.Y_^5^Y9,9$@JN$J;<AR6@S=/
MLO.] B4;[")176 RD=J!0W,@!]ZB6\K3\DU],6VX/[^YDK! 5F+U%R7!-EV)
M\:B)5F_$.IEP8$2G+OV2=:#-J>#G^^9UH ]0P:X+;^!X:V*SR(-SKRYJO,P$
MC7SAQ;<H;N8CACKJE(7*B3#<B=&AE;CQT8ZO4Q\& +/59Q&[F&@' (D9SW@O
M8,CHF:?3_3MQ$")^53L8V&51V#<LVV#-S'L"/K'^74C&)\()UF^G[_I2>J@J
M% 6RZ+6JSI4E]QHST:[#*>U6M*9G;QJR>><37!07K7ZC6?R5('IGH.-&["%6
M0N S??@R>FE3TI*78OD7135CNJ A/.%>#='!X4W)58[-CE\?I2CB31H_#KH.
M,'77  0T*GPN_J-B_GKO2$AI)+/I+F@(]'#;&$$57V%_A"HN$@JI-/E 1<A#
M#U7+"95F>(LO-KKI7M8ZF_^Y)#+\QV<=EBMS^-7\LP9WCT?8J42I7HZSRS))
M6V[U85.,8R]@=:.+]D17^&3J(C#M&1&ZU4/"Y:^#E*<$\T/Y!(0J%AQ;59DP
M5"ER<&[!*X12">G&L.3TCS#%-TKY02.OO<Z#F7NMC_OD006HNF0$(0#:((HS
M\Z<KDKA?-@O^",O4%GF3JU37?.0Y6#1XL%>KY0-&L%TDS0Q=\V7;)V72Z]%%
MVZ(XC_DSW*N)@EQ-]X)&Y0L[3CU"CIW).?>\^?-B IKXUE+6-U+=R+A=QL<S
MBWWMNL*30-=.]DJ)$]_4#W?Y6Q*BH/=J.\]U_4:<.:X6V1X:]L%ZQ[UCTGR,
MF,-HQJ*N3=^1<RCI+D8^7WDJ=/)MDK//;XKYJFB$_E#._)9VP_%B\ZL/_=Q.
M#TG/SKCXKJIXYN=,]F!$PN_%#_N<5DGWX9367#@\;[%%%8>S(CN 6*N=1Q.S
MJ8K(Z>$KZ[ZO]'\,R(<H]F"E#/,H%H*JO=3YP!YVQNM&%5"R4:  D#Q]H"O3
M$&*.J@H@RRK@7!WTTBMI?;3,XXRW=6ZXC$-6^Z#*4_AZ&!NRHP2]]9-Q+9 D
MU+N18RT:'DC'8,AB[%KZ\A-DQR-(U%,DL/;?LTB: YQLE"+00?4#<EY #Y.V
M47%7J>=0-BYK03K7AGOYN'[8R!/%;)MN51753OUSZ$^J_9/'=#JOFYU29E9L
M6O#U[=<EFQ,P<NDG_:-_U=I B)^K%<TA0\5 <=1GWM_;][6+JN1QH$L_Z_&:
ME@PB7NET5/SU#6N3V.;97\D7$U(MU;[HVWSZT9_.O41,YP5_?.1*-I8FPPF%
M3]R'KD"7NQA9!N?=L>GT%;+<E<J?V7.=W]4QD[4&ZOG!:WUCYNWPO-+#*?L*
MIZEW/6^0+/6(D%K^*[%9-_;M@C+?!A/L0G'+]/:WL0OK^S)KA8C%FK*',QY'
M(-15YT)*KMA\.^#"_\0'M#8G_C.C-B'3#.]H7:8<\#E@4/+J]V<TT/Y"?D)8
MZ-V7RN[/4#OV@'986G%,= L1(#N]/9BE-S."WO8-IE-R)&W+=+]1;HH*!J]9
ME%,EH$>1'2^P6ZMH</TNZ*C>^3L/SZ#AEZ- <U-=LH<W3F>KH[/44S]=_BE[
MR.: P',('UA]X]&PO:VAV/.!=E&OQ"(O.]X?K@,")JKJ'-Y.R%:&-:6HXE#
ML-7HK=6@]XLV&1)-K<P?$WD<8TY2<9VDIID/\;X6M_)>FPF?'^:[<X6I9P.:
M[#;VU\:K@ = "0;>;O0 1H^?MX<&D.SDP'L/X]9_RDU'15Q?1O"==WMS!7\P
MW]S,/MZP0ZU$OFSMUDC&&Y&[]NRY'+U$Y0$U8.LH''IM191&3:=S0<*@L[]@
ME&T=.[.+C-:P.=M=FTW0V<^!'LW(^G3B+)4")'PD=*?W7T=B0?VT8O;M!72R
ML&6]TIHA?:< ]M^9M*GB_S@NR.&G=I;%S?:G%PHL6#_WA-@R];SVSFX[:1A4
MRZJL57>;CR=$8%]/JH Q#U5\C%4U@P<6T[3@W^+H+TULD>\OC(-5OSTTQEVI
MX5S/*F<N\ILC54D87.[:J.7SB8R\_3AI!=9]<5AJP_;Q0X34?-Q$$3M.BO%X
MKM!Q0$L\@+5%3IO 7@.X2/\\4[KI>@D+MPHH=^MZ7]T&GLNJYP:1]BIAJ>RD
M%B;)333NJ&/U1G/=;&J>)K$5MZ_02>2 *[T8138.Y 'B]3 0KR?W(>\2QT(]
M^)VO*I3V.-MBHSZF_#[4=?;)T _3HRE9.04(1N1$J!W<TDWYW;\PO-U5(#SX
M.8\C+F%ZRDZ<S='47Y;X%:C$?NB\MY#00!X\-?A#@$@JVQO\DB?:+IQOW-3Z
M"N?C/,7;(*95+G_)-R61!T"M],)GZDA,OFN,_R4BKHG3M"D/.9]A"8 I;0(
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MYM1ZGGT@)>#Q5X$@LDOJ(^\WE)1>2.BX!TF05% 9?A%\FO&B)U"+3-:S"-D
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M(O][RIQQBC+UWW,XNBWC'T#!V18@QU.@-Q9SV&]<!*N <;I'-1$O,8.^XT9
M1ISYFQW-EO*0DZ.!<@_^YTZ:&2^=V5P"RL'>1;^S/RY=>(+],XR12,W^MQKV
M-,2^_8ZA/#U&.?RKA79 "WOSOD6V-0+JJR.'C1]V4A?RCHDN]U)W&B34+7>L
M8^X5&$Y@J+&H/T\7EJ7EF\(KJ6W2D&_H=&JTWJ:%(OD$X98T/6ILP;%OS0I,
M49FW.E-!%B5X%?>]X1T^_NVH3UW'S=E%JPA:T 35M0 (Y$ 4N9^\[/J'E+S_
M#RGY?;Z G\+T';(N$$&G(3?FZ'6D,!KXS-[7DGTGBN:2V\\^V04-"@$[3YV"
M,SZUC=$#YMP%[;!I[7UG=F?=E&TLP\=N>1_1@NI.K,&$V?;9]KAC2[74)NHT
M[.-$M(^\R:)D]>2[(*W)6'KPZ[TOV=;(S@E)0=;X(^:GD1L+Z:('/Z5\]$6K
M4'5I$1A_J$T>G'H!&S]RIX_[4&913=Q1EF/75;]]]:!UIV ;O/-\H(]FNDO>
M2RQK-_[&<O:81!C'PB\I# U[>#BG&0M^_54!D0HL72<1=T&1AP!G'KT'66]#
M+=X9]39L*']Y?-:HK.+V4V[3R_LVIC8+XE[E.,K;+75[:;^8'_O2)L1%+D5,
M'H%S-NRHS1U?]/688@YI[(C[XF[7TL3'4?Y+D/5>*>V=/_LC](F+_,;Q"/)-
MJ;.UY9Y1S3TSGG%?> _7';0*$PZR:O0 %C>KCCJ=LMHU>?UH>C-ONUOM.6Q$
MG8FTU,M2<^=S/QY2JG#[M\UKV'28=D'Y=P_W96_?]Z161R[<2#Y?861_<:F=
MEE@+;B9.K)D-;& X()S>Z8:GS]88'8H C11YOKCRVLMSQ0I@JDJ$9:L> RRW
MNB"I-L'#1]W2.57\7NAEG7TUG/2[?4AK[ZH_*O]"E^LP26Y9ZZ)]+]GV"1BK
M^_VX0."QD-0?LP*D"*.]"8[8!<TI\= HT,E[IIV_Q3[9?D4OL?/L@CJ?2E$V
MD=]C*6"@G@"> MGH  9HO="?@!P8](YH,*Z,3XUR$_SD?-P<4K5VS"L@$&ZU
M$9M&%>VJ5IK@=WXPK!"3+RQMUC!TYI@7$XJRM)$SU4E]4#!&4G_&]B$'TO^>
M%C8)V>$]!80PC-QY8(VJVN.B&I@B\_:FA^ER;4L1TZIS2TH*]E1!8.OX8&F?
ML''OH_>X2Z.T8D&EVM76UZ[)%?B69,K)(66>R$.S\!<!G+N@*,B@E;0P&!Z\
M&$R7!8V1[U:J%53O;+Y]8S^<\P(G=/F.KK"HP$Y@Z9O 8VU._?,K..\\'5N4
MP9%5B1/HJG)!C>7A,K:P28%)2B (^1,ZJ4L+F3P*Y+- "+P2^3UB7SI!ZO"(
MMXR.([_.4)+)FEU"[(QNC_HH2)EE:'"0$@EEF1[0)$5#IZ!@VBKR.VH)QLN^
MC?H&%%\T0&!2TUU7RZ<-AB6.I'V#2+E:H#>E(F50RQ3_71 P>3)WV"0XEJ[9
MR3%W#+VHP6'A+PX=_EU6'@IA']6;_6E?D[R6PB83')3B:!,H8/_*/^'\H^NZ
M!\+3>0^<:W-?_PP=W#/JDNDRY0M=-NL**?"@W.#714HZ77:?PQ@A/L[9*^=6
MU$4*^=KQJ>B#AR;I.W("$)9U[S/2@1MIE^2JA(7X;OGL/'<C&\$'U??<8^\[
MUI@KG:IPU#;;->@R&G"[9V<*R3)IIN0 =]28ODMA"?\4XD/.?-.Z  N&!Z<W
MGY]1@^U]03];%RVH?_VH:W!RJC/>@%;5UP&XTSX@(<[M=8 ["2-K4RW1VVSX
M%8:LID?)@1R'K'OR0Q95I2W?+R8\7&L6^_GAF++_;'>I/\^X%%FS]$B14V>R
M_+VCA=^U5X1%LW^H2?]*5P9'8.=4>-1CD!OS!X,GZ%<&SG0PD,UBE[7*9TT+
MZ"8X$LIPZQW&OX#<18I<_!,1LJ8/59W'*ZIU?9RSYP?L;I*87XLA? ]J&#=9
M7SD0T'^_I\:D)Y!_V%3S1/.%-POZ\=65^)UMTVD4S&*=*5^LT__^U]F&8RCR
M84A_2&>U->@[]O!Z2PHVF9M#M_;$-^8)N:@>S2S=QTXK^1;(@IM%39-*VU4<
MW8F9_J+AYY(]5,IJRDU9,]''(_F]#X/MQ]UB5DQV086J]X.C H^KAU$?T^M)
M0=!52#!]&SJI]0P'E!_I37//DI(JJ0PS#?S-(A?5BJ)GNOA;QSR6+7[%$5&-
MK.,!;KCR>/DG0U;J#\*5KCSYKO5TI-B74#6 W 4!B3#BAS95A"-0FPJ4LA?(
MQLG8B4,5DP"IB0*YF]DF)5V,RIQ_+<'KY)Q>9J M(AXRNYJ[CY^2OVUR(4DT
M$O2-= #R4G2G>Q?TP+L.LOTW5KNLE5L][KMGW=\0Y>KX26:9&&F$#_OJ;PTN
M7PR5.R+3<LMG.^Q <'#TH3GQ/%](I!Z*C-8(*(NE.>"IPO2+LW31&':*':,1
M(4L2O#[-.6#ZY\_W-4*_EC%.^0! O"O,_4 7=%Q&>$O-@9?.XP#@D<.WE5NS
M^R,N7PYZI_NS9WH7]-AW/7<71$21JTXA7:Y#EQ/W&D1J4^%C%A$IV"J&Z@I2
M#O3C@T\!A+QT\GAZC,BWZR(1(I._-Z8\E\V&LW U4B;$9$QHP;':6$['HZ^/
M([V#/,=3JE$W[T* >2P =WWUM_!I $D] @!/IYN*!K?MJ(_Y9,=8G6R(MXGS
M289'M>57IQ 11WFM)WL#2Q-]B)-W:WK<7]GVX1PKS<MC_+ZSG.@*_?7UR$BI
M)5!B79OI/U]"'J/(#']<FEHL>DBO (IO(:<4_3C[$F^)FOS*4I)%=TG2<P7)
M)SIW/KQVK8]^5]"/NQ&FU7/!2=+HI62ZZ6L[48<"B<0]6S+NMGO*;$0"QM3R
M(.R">)=O5ZYKBD*>H!9OU/G+D"+J B5KR-C)(ZV(HW +,YC_,F=1"*Y@<\K_
MUT83>UB*-!A*?+6@3831Q6L'^]2!XBS4^[ND!C;!FO__"/OOL*::YWT<CZ*B
M@D24WJ*"HA3I*C4B"B(" M)+5%":-"G2CXB U$A7!((4 >DE!&E1.M([ M([
M(@DU0,KW!/5YGM?[<UV_WQ^6 [MS9F=F[[GG[-D]91E/YF1?&Q1\FYB(0,@K
M?FK:>HE+=B=$6NYD@OR_H"8C<3I-0RR"N31*O[2"=]WF\P5C@:B8HN K(^CI
M?A0[,FA,C/H^I(H.D?H$/9N7 $S3 \T9V?O\7/\[[98?+AF823=$$DX!^&_P
MR13O"Y[>JJ"5:\#V$?I2=P?9Y7'MWNDB/TV*@#:;O2EO=SF::= KXA&9.]3G
MZ=J9?G(/*9 ;<;\O$0@D<HSI*?6<0*6E%K"^N:32A*7C03'F=DZ!Q8M'OUAY
ML(/RN$=JR]K8V_[M+SN,<B>F<,",5M_^.X=3GW1Q*F&0)N(Y&119B?HH?=F5
M@)\$=9%BZ5S7)%^.)[-F!E8@7P]8D@_MRQ.\GXS#C%F3(E^ 8-G92-MB.X%B
MI1XW&Y&Y2B[87VCP(SX8XJV5258HHD#PNIN1A.G)L7%&(0IDE7J<P5(;G),H
M;LY."'\ _6#120XRL]-MKPD02@,'J8@*@S?OG)<[/86#S]P#5;Q&@1 ^17HS
M3A^$@RIC]R]WA[SM<=T42$+X P!,?5,+(%;T3U:=4C@WY&M-K;-B]:%W$$P_
MK8K#6.]:3D/7%-01A]VQ5E2W:!.I7UK-4CB C]F^<D>./TL@-.;)$RL"6-FA
M$89 [2)N]9"W4B&Q%PS]C]A&+$-V.&V]VHDUT5OL&J '_0:A?8Z#V%+$8!N/
MYDMTLH2F 1"YXOE(W, XYW+/R8-0&[2)@)6"\,/8P=3'<OZST4WS&C+_X1F(
MFW%!/]+*4\L=?D+9 "K/V 3A(.T_C'1QR-+9H"/,E*R#?&A <QWO"\Q(@]A0
M9DFT^= M]^ 8; 0')8 _X!#BS1JN(VC.JJ&Q%8# ++;(&XP*10)\-9HL"3PB
M? ':OCKL)^#4+ZZRG'OA.]IV#K]0S8-BI/ I\M@9S#Z@]7!S-L(W8)B_Z!9V
M==MX+>T$:8"8$T]NP/LM3]$!>S/@-!,!<S8ML>TD,,Y/M*+)&@8JQF,Y-<'&
M^8@]3E#Y/R)Z '/W.G+@GTXL-/DE>JPT9_R6;MD\+X C;^*]KM$B7I"84,MZ
M0*$< M2W>?\L5 X(R,MY]VA^TRTR"89/^^]%"L-8R"0U6?RG!WP2A@=(M(]
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M;4+P9FO>+=KZYV7A/2*TB,;<YXS5#.HL-$"MT1G<:J#+LLIU3/MQ5<\ZPKP
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M1D/AA9 ]<V)YTYYO7T52_"NTJ869>H&-JL.,D/A-C)#<J&64$E!JB^J"/RV
M++.*"%7(D^)>1[WE&TC^IF,59?$BCS\>[>S?7ZFOA%?:BL8%U3F<M!J^L_B,
M$#BMC]E3?]?SR-9/?.;PI=DT^PXOO4[!W(_9%1JK&Y+(D_>=7'D1MW8I$./P
M*PJ,)S6/N[\WNOV8EVZK2594<7I^*__3]-3E).O)]%X7^9LU'[C.';6_3'YZ
MLIRA*7&#]D.^6^M6+ '(<C]MC.>SX*NX/(Y9U&>4U'=D<5%\^TYI6EQ$UJG=
M@GB-!-)>_.EZ#K<W"::_WCMEQQI?NBR4P3AZZCJ;,QO;3I#TJBY]397(M1[?
M7R JMKYNCSLOX&IKMEN0C,H(UWQ55G.,H/00H.<(2X@KR!I%SY)SKG 8!QO>
MA[U-##APA%8CDVLPY6I# <,!%!I/C40*)(@LZJZ)P,^'REV:/9\Q'S@M8=8J
MOA)NSFU2!(&(>G3:: :@V+Q%\%Z&@W95TC:#>C)J.W;9N>HS=W9XCXY<MU><
M.=T34EIT^EF.GDB:PZ #@5:>(^8L6^_'?K1:O[T+'%=&O-J[@DK9WR]G[VY+
M!J S\,:*V-Z\(I  XY%VJ?'_#=R'WT"R/XH;)))AS4 X#.PMJ:$PY+SQWTA/
M61S KM?"]V:T4FP<5_'F=71\;RO?G'IVFX9HG8VWK!-PKWR_<(,""7=E91Q6
M$M./&)!O1]]\<7"^RS)/N;9'^J9&7&2'/A!#@&+VACJ<OLX/==%**@BZ/U0]
M]^M>4SDHI6ZJ,_#&A)D:II>&:&N'EF<4'ILMD,PH"R^3:[2J%?0\G4@S&!)E
M7"UP+"7$NG1AKOP+)OP'C1IYHK.=H)7"QCLU&/A,[/G%+XMHIYTG8)5OQL$+
M>_H6^**/',#TV"D8MSSMSK6H?GW$Z_YC\91K7P43(](P3MH>CK =-W_XKWNT
MUQ2$W1\PDJ/YN<%Z7Z@'&LK##D&6W77^^9DHG1__+8CL0SU._^+:!PH$905?
M_7' ',PD 9F3#CN[\>0=!#Y;F"Q ,+UPR+0E$3@)FHX_%DK<4Z1 ?)?4#,Y$
M.7X<@XA]O]A%SXO7K^.LXTPQ<)%55EFF/A2R_8,Q4EBI@5 ['^Z8DN^W/$1&
M,1[,%D!J=+0^4)('S+\"08KC2.:E_?8J9 35H?%DEL% D(0CZW:@^/R</84_
M+NU7:RGU.AH6K_U]1)GMDD?2O8.>]-&#D<I^V9VP$#+[HV.5+=S':) #^_T5
MX8NO8-1(63(O*8F3<@GA5SX0&W/PJ/Q1R=6?>XB=21AI'>SY#1F:S &.G'HK
MZHH&9K)@A[@/14O_Z ?[_CM&YL(ALV#<$?[$78RW,6[$DC4(^9 LU0]8&H&0
M>Y0"64U0RC2*;J\"3%/#:72"'$+(K)>G5\3%DS_IWB$;IG@;XIHG3.\<$7N1
MX[<8X9X?LFL'UU"]4'GEBM["]77[XZGS2[>Y%P>6[9X?5[=C1O=7^3]3AS"$
M01U5CKR0KL/;UO&S5T06/KMZ+A%F;PV??$IXP)77%]JAT:<5O=KNDF,?ENO;
MPD"K,]O-=^]ZH&K>RF2 LI$JDX#?IN2!ME8\HK9$A>]96P]?B%9_&B))\Y['
M7/$D/KYNX5'4M9^IX1;2=H5G^#>WF']XG"RF-;8RD]@VU3F#-+\ST)TZ,WR#
M-CL"M,#(%"9@-,K^"2VI'[22$EZG=GQ]4X2TAITV50P\OVP+Z33G/AMR@ *Y
MW$6!C#-]F9LDY$TZB8M61O/V0?'4W?YE<E)AI!)P&AI?P=7VIKZWNJX0K+3$
M<>@YZK%MN[Q]":;9^HV"SY5YR5*:DZ"]NN97O$FTA!YDJ!D';&T_HKK&6](7
M[P4[/"XM"8[H6J](C5Z,WB!=NORD1VA"=3ZNXZC)8XO(?MV@(DDKCD0*A"B,
M/'$:5?;&UY]Z>$) R208ZR+[&8\YN =]VWOY*KHRZ-KZF<>NG7VZJ)_+_T8'
M--27>D\J9MSV%2)8@#3E._P>B#F=?UNI;+F6 =-CU.B@T8F!L1 EI?<>PEZ
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M3\O3D5\.O*- \E,Q34!U_Y\7[$C?D 3S'5Z;$+ 2?-5+?9L0G4DB,0&UUA^
M+K-.,CEDJFCA_8D!+%R!D=SJAF#QUL73:0WR]DEJGC2R 3WU9*SN4MC-K^86
M]N)0(><W[@45QHT),-+A//CJ0B8VQ"7FU=WA\,* <@8+",=J[;3 0UXI315!
MVP6GP=HZQHO?/-?&\41D<![QV)ZF#9D__HN^+_\5,L>K!\N/Z![6G+Q^CTT%
MZW9TGALII3_%^K,DG7B.4#3QUEOZ2,9S\SR/LJO;$JUSQ;_NO5_SY((O(AR0
M[%;N[/UYHCZ/F<\1<FZ[TT]K8<08Z(*/=!,&/3L$E?7#M/6LT_/<!GY.Q.G?
MN3]Z_L)F]4@U>HBXCF_N)W-[RU42E*90#$NJYK:^@WH)<>'T(EM#AC,QQPQK
MGB)EN0YLPQ7J)@M>%:"1P6,0!<:RJI#:IKKBUPY2?89R[\KRN^IH/_8O0+WU
M1W@;/5D1*[:B\.4LZK>:6Q5_6Y;,G%L2=/':)\_*<5-.F_;A\>Q7SUPR :L=
ME^*?J;_0"K0]-1S+-5*$ZFF SOMZ<7)K0\)L(NI[_)7C109M1<RQ:H>^M*P9
M>-=6((Y[N^ =ZL89%F$,V$FCC/EZG_.]ZB655XI\8J?"CO:H3_J-WLGFCT!O
MO7=ONOY(XM/W1*!72X5XP0CZVS=9<4\_G>>(B3:R?FXQ$+]AZTI(:!*:B4X4
M,%*OK+3'8#XM='86O$;0@UQM=?HJ\A$N+[MDSZ?X0NXW76W@;5$XV]J!"4<5
ML_*"=*P%C$65)<AUPI@"H<4&N"8=/&\<]8E>7V[:W:[-(/&E\Y*3V2(%<BP9
M1!M%6\V]W8L*8EU!Q :J%KE.[._KN[?$/T;IH3$5O69S?<\V@W)6'EYU^]$[
M8O8#O?34+\2H@4>R"U@0MH*O9*7]B6-@>T/_M>=<OU2Y%)(J&@0I12\X*)IJ
MZQOP=992$/12W_(@\.N:U=@^2=7214NU'U()NQ<_/!7*.+IC/!@E^+)F0 IQ
M:FD8%6;'5Q%BZ#*TXC+C>+#^H_*I.+-7KSRD9S8VF%?7"*CKZVV9^D7KM,J7
M,^*'N/J4ZGG8=8>EA&4?<MXAOOVZI)#DOIVB$OZUP)K#\I7#1I+;,&?.V8/J
MW$N2'_B38EB42E]"VT@O=C2EL@L6M_2VDNEQ/]IK-:<"Q22O^IK[V:?DW^:%
M;%P;A=[9 -#N9W-K:L>'PC-7Q7UB&AB1'AW&_Q]E?QX/5?_&C^,C2@M&"[).
M1:6$;"'+4"$D2<@Z=ZGL9-\=*I1M0HAB9(TLD7T;68MDC;(S=F'&.LSV.X?J
M[GU_/K_']_O]SYDYK^VZGM?S>E[.F=?+7BQ)6W'JU<GF@(S;[C28N6SP'G9+
MW*ES+OV.S?8OF$9];A&L,$?DY5RM:3#+89]03*&$9^,3E&?]'3=R=?6[OCR9
M1.)1QC#]<T:E3^SRAM>'IS4>;>GM.]ESAUU5)VQ7?72'^X(N4*?^!MK=$(QW
M."%9-7@Y/6=LW!1.?>P&;. A6HNV5*.:[UQP!Z0F.=[\07!2:&:+!FTO$HC9
M9(;.E_](E3I9^FQ5,(\>L#,LY64 2P3ZYJE AU53_6G#X1J%D-7<FN9_6J29
M7]WB?3E46=I;S-W@=S%:+V+OVEZ[%/<(6.ZNQ,>?!]7EM.6"Y\WB%=^-<2>J
M"FUF=J77/+TK%[?WGL[/(14CQ;/X6;N1?GVYBNDO)EV<T_MP<+9AL^&/TSEG
MTOO/=8G7E9?Y'!YT:4EZ.6^H>+9'"LT5>MPAL\&>05CTQP.1@II]GP5X)F!7
MI]^RS:<V)O$R1&;=?J0*7^*(5"(8!*ON[<D)DAE7288+.O"B+/DX.Z(U#@T/
M&9-+SW]%AA)?N'QB/.9M<!]?*&NW*$7R7#,L/L.^%O'#?X]8@<Q1':J6@V8N
M\:;-4WN!BFX^#\\(54%#Q>!29>W@!K^CI4F&*37=XPFZ\0*J-[[ZJO-:ON?=
MOYJ>HX-38 "^&'6#3(L<D^C S@A;@6I<18ZN6,L\PHNDCR2?2N"@[/X)9JF9
M9&+K)7D:S,;(@EH1<H[Q-5F'=(X&8_5!6N39@\#7U_3D<BS+YE1Z'A:S6?%D
MR20OW#-OH/6M504OSM#CX9#<[4\M/)O*+^]H[G+\--^^J]KBQC?RF6S5]:W
M]?BW1N4,]4Z'5#Y]Y.&)2$;4I:%1^ 8Q 3'KB[87\.$%5U[M2HFH==D5P/<
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M=3!5Q0)]R%()^+1C[U3J(5-X_OJW).0\5,?"0,NU/W,Y3H.)56X;)IIZR.X
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MD5;SV=8OJ=A@6X3Z_!:A&?\W$?KRIW-S[<4]R EN!&5]!&>8.XIF";I#B<5
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M$#'D@!Z6J<*0\]#14X_*'8CZ1M)D\AQ Y 3!PI.VW0Y'5?R+-,T8?Q%LUS]
M^U7L]I.O2>S8[9EFJEGQ<7"B4/?:1/V+TF2*-6J['Y ?7?E!UC-D >;!680+
M@B.WWD93BL"IWO(1[P2F<: U:T%JG43@<XKN=$W?1*QO0A/(3.;U_2#@?,;J
M+CVU8OOG W:@JDLB "-WRZ[Z<<SD"R(L>XP52S^ 8U9#ND]5X=Z?)&E$U^=;
M"#JC^?^;,SJ3>1W^5#BI?XJ7;5V9^8OU$1#KJV\/^#]IP!7[9W[H/VG=)(Y\
M-IR;M/'K+C7HBNJ% D9=(#7,M2?3='T % X<H'!@7@#E+/K_+) Z_(Y8-E.-
M_K2AZQQNXZF\I'40L122^Z\PD_HZ1!;N3.WW65 &AJK! /ZYAOHO%#I8WM%3
MO51H,("#;%D+3C82&&F$? B,&5IB5U:R@%$HE:-!))RAP>+^2,"9#I9,L&$#
M<@%R(6(GS>Z?1-<+'P%:?^,*-&4AZ,YIW5_NY*+K&07:;V.70,.'B_Q&3I\0
M:+G6/P+SY*^$<S\%L^G9@\6+.U!E05/>_BU/U9N WIWYVH#D$6B^#4@DF7D;
MD-L]\>\@- [Z:4(R;V-NCU@#6^93Q$:C]OHGY'05  JJ"R-C9N$"2L\<VGNW
M?&BP&?#^LXD[;O"!3"H,F_]+M2'^N+%<E*AW\5=)N[FC^V[-C*QT08)T>L<L
M_Q:X.G^&T_Q?_8;^3R>2]+FD>XB58>3_IS8YO]L8B!)4Q\\H\GJ$VKX%.B:^
M'O6ZA8+JW2X4?*?>S0/&$?6Y$EI$]_$+(<9U6JF8I,4'3;(S)A'?BN$[[^(^
MI3)1$!-J)&'@\_[?CW"7T3^<D?B4JC.8S75J\5QR[Y^-6MK^W:CE8LBU$'&A
M)ZLJ*=$GPD)@1D)!A MO<-RH(T;-J0,#IE:'1)=\.E=4NB.[1WK?@W ]Y#'?
M=.#MD-7Y@=D2G:%S^BFS=.YH?D<%[\-Z=WER.]:\A#XY%.<_==_86H]Y4-)A
M,I &/'B=W/_C8*S\8\H43V\X6#2RKJXO'[,1PIS]YE-NBNQK>_P1%_"\6JPW
MXL;TLH(@.J'* ,<01SU8T;-4%&I0_&B]2;^R,D3\B$Q3U^V'\'.>[QP]2L=W
M3^5LN5R(;2&H5$RY*9=(4^>V(M3,>WJ?=_K<&7_Y-7%<Y4/TE:H2#Q'^)W:1
MZK5,>]=V5_9*63FGYX9GZ>O8&:MEKLVXC#"[M)H*?4RXY_8\1UW@KL%9V0?\
ML8J9 9L&>K=<$B\H(*Z7%@:?$F0]L2@KP^9^HNA(XL#=3O5(54L!(ZMI^0=Q
M)YZOK2;#)8F9X\PV]5V&;99\S QB-J0!5]%SM]=Y.;@KMO9_[/$3M&'W.Q5=
M[TA)LEH\E]9C)\5PTYQ]7/KL[6G.H<,;BT)%A!'_'+);J /@[&ZWWWZ/D$7_
M2=WY*UCXJI5HU_S/KR<C:F>S+R<=/[XRDK_$]1(MW4$][Q&G3_24#W6X)V];
MJ%'2:W_=(M DN^6PW%/D:7[TJ^'<[Z"O&RH68B/'0]7MNJ_%>MC=?V\[=6DQ
MNSG?1&:AOU((&6C&UUTLU7.L)-X^]LOW<[E"/@7L^C*<34ZA7R7TWA#EQ@;L
MS+YNL54%VNW:U ^5\S2.>TYL-\$M)^_?TL\<1Q"O.ZSF%X?FBN4VM#NV;W&/
M7;U>QL.S_@[)7&R*NE72R__MGG&9[6*8OM<C"[L>SSME/*_Q'&^6;LRB]KCX
M<K6:E#RBP72%<B[8W[=Y9.)32\Y\.\/(^\[Y8\W^#_@]3Q)4XT]^Z76D?"OW
M_8E]-KV6S!R1:.6L6?!TYKIWEYU]BR4L2UC5WN#[@_@"&JS"VOB*HQ/+H&-/
M%^<D!H^QZ2]Y]M:CHLMR876 &WU*CI&!\\C!LH)V$^ETJT$?FZ0#8W:,0:)+
M 0>?3CU-C*I4Y0E83HI'QM@,DODZ\Z2@8S<NS@GVZTC\$$A3^LDMGVL##TY0
MJN90/FG(\.@&0\X1UE<RG*O)+&Y V%6!(!D7XZR)JU?ZLKD1]Q@LIC:]\,.)
M0J?'&1O3NQ=R,XK*8@^<-J7ZZ,2;E#S<TZ'&6:O8T&<#KP_G&O:]Y!*BM-'I
M*?% 7RZ.P8N4H(D*2F!+*[AHS+&<:ND?&9K'XLTGEP"K1X_?[XT<:X/K?+-E
M;G /R95?#SXQ='M73NMCLORRFL9W/$>HE/81P"I<6\U7<&#P9<IPP^93MJOR
M 8.8E@\BU/U$O\6I+GV;1F,W@2NEV@4?93^:X(I=$N!/[.05WLX9Q"Y?,]O2
M%4J+8M>3H??7YA6D=W6.L.J);S82%Z2SRO$K*C_R^@;C:X\1TYZ!)B[4D]70
M)^_+>MYX/W-X>>B&X-U=_FHH45[O7N:X1M_+6AP5>KWAHD^E?$7&<N]%=1R<
M2HG==>E\ X]@>WD>M@D++UKB4=]7Y?U*KM+GJ8.PP)D3CWO\9/D);UWR@RHN
M1-LX'#H0&PN[?+V+=^60DR;/"K%CCSM9V(8Q4:4DSM'Y7BS&IKR*N;'B?@ C
M>MU7S:B]AIB_3KFPQ>VK:,KG_D':C>/#!96&.R_L>9A\%^,5A!YH/ZE@7 ^O
M[@\M\ZD$"JOV2=@FR!=L!@']\B1=%^P314371,U#D47]J0O/S!,>G-C[F2'%
MN?83WVK#_1GL4=N\W*+XT]U3=HI;!R?FLG\8IM6.ACF^CG >CC<G9/2/;]VO
MPE.^8E*O[+.SPUQH41YX1+KT.$DLH4)Q_TQ)TUA1;UDITL+#SBXM)H';21GF
M[^3<W9?N;,3Q44MCY&-%7W"21:A&39RSD0;IL]U<8_WK]XR,81NSE^B[)86M
M?%32,I)C\RT8@L][!E.<W!S!H1%-^4G[<'M2"[NCU;MM7>9=[]C<WZ7,<OWZ
MMQNIF&0VD:;VRTIP,'>A7\S9G!AI+%3))@:*]G/;(;5OM(K)U$Z?_# ;\KU8
MC73E7@1%RSFAN<X4841@_OI.ON^?H2LGRDH,7ZH([JX((VR@-2[+AI\>STMW
M3+.>/?DU7C'9WJ=::F&"*>K*CWMN=&BZAW %F^0.>1U*>);I;$)>YLFI5"9-
MR?>;IV5D/RNIG_33-4".Z1#OWQMA>Q;,WM2S=^KAKDEMA#3JA;,V/K^>5[0N
MKMV;)WIXJ.@2XN+BI9^L%FB_S%S8W7E%T6^2F! NOJ0<E&;/FY$S,4<%S)G#
M+CSDGN3Q3EB-F2KG5.2:72$F*5A[A\:GH5^.NE/Z"1$PLDW>'G^$RBD5SB.P
MXMWM>Y ;V#=9S]Z*T"FB2#\HS#"_>SZV#L1J/U""YF]L43;R9)W-T@G!8^CP
M-41HS?GJ#_C!#?8XCJ^=5W->WA_^+E]:[83$9\O[5E)5C#&D620QFY()-T)_
M&_/,#W0UC23RG8AQ<-#=<"*FKZ/<)YQ'7SN&1(G[JCCDU^4C=D_7Q:$V^@'"
MK0FB'@X/3-PJ;R;-0IMR[_9ZD=2-\J+!Q%39#,B5<51ZT66QR^PG,FZJV,(#
MAQ40*V=-@1'H)&:]%\0[N(*^NK[+T+'&>AY2DXQ%<<,1+YLRR:2=9JR1(?'J
M \9"^-9FY*K0T$ZS6Y_!2P'@4X$3<G3[0.?'IID?4)[=1WNHZL"H*#GLGGG
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MB"T$U!_HAC4W7LOF:@[Z"- !\-\>!84-<HR! -<&\\WOVXYN2#YY:#7'*(H
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MUS%@BAFTAK/?9;+-ZLVE\?"25Z["&:GC*"9C5-V Q2/]S<C@&X!O7ZXR2(7
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MDQS.KJ9)?91*!);5ZO=;M+.#^!GA)UO?6B% GMF^L%E$$8UBS3'$JV0Q&@Q
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MLE)!1&'OW('!89,Y_<,-&PF^.>%5=1RRUPJ^*M[GU=:8RU.4()H-7G[5ZY:
ME#HDQ?2EIHQ1(=Q)4:I''DG0:+*Q.S-Q\>>Z>'ITRRL]-"S/U\D@I"[M-.$R
MT)U5+?N1].&;R]J,*^: B]"GU:D^*>\F[#=7_FGVTY.!>X^J'(71/1XHSULO
M()\QOQ _UJ;8ZSH@KW.V;(.MP"@M]NDSN9(C.BKBEQ*L>GJ/T-5[C#2S>EQ?
M__K%N W(&BZXL-Z!6WP<]CIR$/TU-7I<_]FA(?[0)]6E(ES-]&U.664QW!7F
M"B2N=(*[2CEA3X*P;1%Z02YC\'B%VL#)U\&ICXMPB&"-E@JBL2<RS':MKUQ]
M\4['@+9$4JZL81,.Y-E;NO3Z SAXT*+/061HE'% AC)__3D9/NNK:8_*AB*R
MO;LQXR41%37QMK%QT;>'7^B\%>2[93N]/\=]6I:_8-XDXQG>6;?+7J5RT!@#
M?Z4F/IN[\:#20E^<S['[RT*25T^":/W((<L2(X-  M.6I*Z*N_#\X>>?6AK%
MEM[#FP)X(]"X 5_-!HZ*DY/I7V-\=W&F2OQSCL#DTQJDF/H^BWP<9R?7?*&T
MU,CHZW.CK_\\>&GNO4M5=1\.;3TA.<)D4W.BN@_7EX,L7%S<E9[WSGYD#G<S
M^2RAZ=(CS[5<="!U[S=Y9KYR]G1OM@D#]UV:J'/_G'U$\51PA[?XRYE$#E(D
MKHK#==NK85.Q_JS1WS%?,PI/+X!*TZM'[^0;&DR#7J$\F05U@UA@=3_K14C+
M%$X]1)GM:T9(QM';KYW<+>@?=U6@B1HN,3*^JK"!R_\_QMX#GLK_[Q\_0J<R
M3LI>1U&*$)',HR2KK*RL4U165HBL2\D>ATI*9D@(D95ULD/V*K(WR3GFP1F_
MZZ(^X_Y^[__]?SPZ/5SGO.=K/9^O<]YC#(N+/H"*89DY2X ;=ZTMCL*'3!\.
M2I&:$LI#G=:%U'X<:!(\)!=5M$'@H2G/;I,\>^WP*YYPJD^U#1_A^!KB:?KU
M@SX7W]:6_-S\\"[Y9;,3=HVXB&C@E<?4)9F(I ]X2*S$J)2>4!58J?.G(N8\
M+R6HRGML)W2_O!VY1,.J%+%%L^_"&AG9\LH%]V#Q1M3@D$&%Q.?H6.LK=<LT
ML34RDW* "6R-A[\AWB\W\X:Y0*VXFZ*^WP''29R\[O@HZ[S?Z1W='D?#V9_=
M+].'B"+^+EMG\\7Q\+H.)KM^D_//3M.QI*R,EY=:OI$T$XKCGIJ$OYNS+\5=
M"7!-M>/\>O_&10>:TI/&Z4^LOM+JW\;4^LLQ:5ZS>+X .XTP,5%6XD9'R-]"
M!IT(&I%37[]FN"CBE#DX5G%JX=L9N?T*WOJRVE%%D=H:T@/2#!GRUZ9^#)J?
M%PC2NJA')3^M[=6![P_/:IKD$6Z(OU:Z$=N>2&>JF,38[USCSS>VMGJNI]BU
M'WO(T6G]H'NB!OOM\M[;]EFYZ!C'^FE5A<\"#][R=]_MNR?R:Z+D!?G$IY>.
MH=3KW*O;G!V]E:9O;0<=,SQ8FH;B:USE#W.7ZO;$+%H B%J2Z=6*\U_#/5A^
M)=QKPZ,47D]W:&N_]."Q+7>J4S#!QY\/E"PM^. KXWB0 L-,F!MK1HG7[G3"
MW]IN;R2_JSS<X)GE+BE\H33FPZ7DCNX70Q;=^4XFC0-Z0?:]BP> UR.586)!
MLNVOTDV^R=,OO5%:+<G^).:]@AE^%#'U<QWEG7'?#]FU_+I6MG=C4"OSSH0-
M>^[;#_V_WBMKI+^3NSAN'(6P@VUKG)Y(Y$F)O:MO&?7E^Z&ZQZA$E( 7V?W5
MN .[)U!GXO#(@$W3B:/"';EX<E"Z8%/D&:'_U8P_\E[3DNZ*VOM<S:8LMI")
M[O=G'*5X*H?-/F=;EG"3)LM<_;65!XMS@<DEF>U#DT5M=$8XBX\>F=], !L;
MK_>1YZYJ\0Y>2M7RE&'75ZCHYK"KF^B+'7G3U6KK:I]9N63OY"OQ+NKA\V@#
M-4O@T0[ H'X+?]PTUUZW:Z;+R:%8V(:AWO;XJ1N]CHT]%=6C%\T:,/[NB5?H
M%/:1:4H*N]=5>_76'[)1Q1L>@CN>7$<]*+>_!C?LRI>_^/['NW[K3P]V1%(%
MF(.?\C-TY(F'P;[CT!%+E?9O6]V=F#](2A1)-)R"Y5!_&8N?"W3&'JP4]!@W
MYUQW'/AB7U'Z2?/>;#.<X+K>/#]2$?TP!:ZKP@R+I6UW12J8PE>D+%,^C67N
MC'9VW_2[Z7.OH-0I,DE:44=P:86W:K/*)4"[=/BKD.]B/F$HVT2L<90K*)$Y
M?(M-X!'1R<QC(R/:B; 5CEQ&X/-_X(BC1IG86JP (#^AD-PO9#'*C#U_57+1
M#,@R\?%RR -Z<R])>?.);X!8N9Q*ECINM\%/M@!SBNI@PD B.OFKNNX*D8[N
MK0ERZV;Q7079;\CUTP;[\RW+*##-<)P+64K>JRH4Y&UEP'(!66IU?2OJY0[=
M&I'N=.80T,&2-:!=TK0=F]WZWACHF$)"1SRIE?<GJ1+]:O?6._NL^UEER?*B
M']TS-L6'&*UDBD1BB2LF>>7]R3'DUW!HU7UF7FGF% 7VMF9OJ?*LR\'XTYV_
ML/L&C:&%X.)Z(I'5J+ZP+-[BS 3@=R$[W=SYR8PU)+1ZO]KI\*M*ZRM#^9]+
MSN1N8(:CA(3#N5P5 M@_F;[[<BQD-EGC<K_;RJ>=>[NETS[UO[_<KR8:\^J7
MCD_$06Z2?5W1IS46]<XI#WL<2GLM+5'V6U(%K6EVO-Y2CT/0?1JK+8-R$NT]
MS*#AEU-OPJP.SQ0D/%UN7C0U"%M:Q?+,44FX])+=7!< V=/GE.@ZLHASL^#S
MW3"8ELO >AH>E2C"#+/Z079S^P7(GE/3+MXG6"2X1/<8D.UMN&,"--4:%E,?
M=LMX$P8[]?MU^K1-RB'9D/9V%_U/ZZA$BUXO$=TV&,>%7P"G%LCZ9,]=O/#V
MV$/P$^[MY/9G[ASK*3"PQY-1OMJS5Y36TYP5BV#84.*<0$P-/_Y-=-(I:L-6
MTJ7UK(4J#-$[SZ[A6""SKA+MG]?]9!;45*)G.+DRG6S0-W :KT.!-93CV4@/
MU8DY7LB&X&SB5W$D=#LE1HB42%3)_49DQM7>F(MTY:PU,)-8.3?P@G=]#HM[
M27A-#FQ$X: 5Z8MT&Z;-A*/C5U?)D8W>KA9YM'NWZ9 %MQ(^>>S$(G%-*ZIT
M8$X;'(J=,P5VY@%H;?A9O#2)SHD"\X6NJ34?/JD86^\%_S]*]<$S8 ^34GVS
M%^+$S<P)EV1F@G^I#7F(D5$&DJ]O$!7H.VW]& XR=S_LWNJ8807T3"YY'UJW
M,PL3%37X-*U;Y\*:ZN&71!<Q,NPO^."FP6<8XGDU?-@BH/A&676?8X;M6YS;
M$;7F@E>/;^?+(Y,S3U:=88K7 3A%656?#MHN6V55ISJ,%;-UYS79<DL\FLLV
M>]3S@25M?W[.T%4,VQ/+T,ZG[U.I:-:;VLPW,FP&-JZ;IG>;%H4'QI\\]GR#
MGV6F'!GF+A;\=-%04:SWQ3:7FS2KD0*O<=#] Y9^]QQ^V9W05=D9'8AQ>3M8
MR;;^8Q#-1GAY6K NPJ43;@'@M]&$J_+7DK=81\G;:++H:]RT5*)SVX3(7>W3
MCAW;/$\+CK-76&>V/1VN$JYLD%PNWQ__P/K_DCC+Y00QXDG>DV!NXP)&"NB"
MJWE$./$J,&,*-$ ;!/(6D1K*8;#5('QF2#V8'#!WP;%?94#B/X^(("ICME@Q
M^2-(HKF3Y\?&<NLGO/Q9(R]O)Y;4T=QF YP/<KL1%S)&ZQWV-]6?WQ88+!F:
M[_'D"CH:=,'I=<!*<G?X(S!A.I@<\IH#UWQARJ<.VCA'/HIF&L,0KKQ&+F/(
MHGD->%1==U[*I-$03VC]^Z\P05+RZWC?Y?I$MFLXHFQ;'_'#C:OC_*/^/SVG
M&(;WCX_X%R2-2.(Y]+CJ+@<,.4,;#G@E\'!J,E/09.97%*&\JXSP+,7$W#9:
M,9<".\8B0I,:5!<Q*^A1D"4YBIS;+OGDDFZR<&)Y?-+^,$VBWWR'@H)<&.P+
M!?8$BZ8FJP2!\;,)E)N&/'J"F@*3J -&K2 9M7;$591XKVK.@NFK M=J"J,8
M^2B/=SZ1GP&S"977JYE$'@X-&J7_,)DW#FU^,I]50T5BSUTWN;KL3/6 G[>(
MJB69W1/TIA*PA[@].2". IU%HYO=T$8F;UU"QOBP<+WN7"G;+:<;]=:_E@P%
M84>3&.TS=]RH96*OP*R>=?(&KS-3-5!@M;<FT-N_C22.?(0" _]UEOQN:5!A
MZD#!BUBEZ'$)/_S&>_01PK(:+MUN8/7Y7;X# [28ZH/S2NP!#>23'<1PA]]F
MHH0'0BL(#MA=\UC,+L#O3WXW-'B-MM<QSHZ7J>Q.$P]*-DZ[_TRQ[NF/Y6%3
MEX>XZVM*2JAJ-J?\W,P85:&I,"9Q_7<+[)3)2&%DVYLM"#Z[@W0+;N0]T40,
M_]M,)1,X1>$)J$@?-0%0X >Z.O+&.\@H]5WKZ2"VJD(_HC7TSX;[V+\E2 PM
MF11/FM:WE4A=7T5U'A%R.-K JGBL*[7O?7[?^Q,[><L1O&,K#\<ZX7)@_<R0
MC250O3:3)#RT<<C'=D+QW'C:(_(W:*J%3\?';JL[L@I&CS.-TF**]2L'EHI:
MN5J_+RM?M"9C6WT;$*DS_C(8PK7**VS4=9<QER ;3O6QGF"YE%:[P+RBVHHA
M,98/F:LXMAQP5*Y(>:Y2,?O-ZXC"!2D!HV3;,\<_J6LD,'&_XMO6@7/ZW)G8
MWZS((4"!5:)VY31 @<W=<-KY">#=OQ>UIT_H#8<:RG-J*VIOS8&"ZDIA5!1C
M)SS1..]Y<W8 ,O6%3>()\DG4JD@I"4S4S=U*5EH&#M!A%4*E],1XYC[:Q><E
ME89NY(JP:J;_0#W(=*99)3<3WU&SD8\L'Z6BP(X/ :.:T*YO!+OG2^!KR6]E
MN)>/7.AZ8>]IN"%S,N&=6LPC2PX/ZHBUIM7L0:#>]ZA!?V:/B."Y'\H5#Z^R
MT'I%S#QZ!>#B""__"E//"=AZ[)H(=G=,]G/8PV[7_$P)N8XU\4V*/EI*MZFY
M8Y(2,.U%:SR -O[\:];4M^:J'K9BPR].TB,F%(L.3 /CXO^T&-7?X<KA=[A:
M+&\0@3F#8.09ETQXN]=GSC"AI[X@4+#N]NKG,V"W7@=9:!LO:FF/_/2-%'XT
M$4>F[Y%Z_7TYOQ)^2V2ZCNV%:AS]UX<"Y-61% HLT"75FJR^\1ID'-@=!Q\
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MB[VP]=_%!' EN;;9;0XTFZ:!S[,S^N W_2RX,JW6W\(?*E8XV'6F;S]A*J+
M%@K']I-LPLU*G_XR5<'Z#U^2UN3%QW*O#GP;:$OB2UK5"= HLQ<>.GHWG*$Q
M^9CE9DZ9I9J6.@^&UGO@QH1W2'ZE,^JC0Q[OL.1K_ZZ:V!>GY0LPDE..LPJ:
M;HI%_AOAY@]&=2]M&'T8?K<S<CV('[<_0[IP?=B""4<E.H'G;V]4?U->Y"(;
M*/3B*S(B2D9.-7\DWZ7QX-1A1GC96YK&;1W9WI)2K=5 JX2(/JW,P8R/R'DE
M;_=TVE#W-D6ZJ8]/-VC+70-#ODC[&;@IJK*LICS 7.U;B]3B"JUT<?62#\^
M)R?<^_:=2^E>$FRRO\@Q5][@81ZSKZO>1W4+X8?\89+"[(?WJ0E8GXA;EZ3?
MS.TSW#0HZDD[8M;!?:A>:/FF]!&71XL6HK?QHFG>DG"]7KYK1[INA_:QD41P
MKA4#OS#MZ17/ZBTD!GP4\9=BM%*:CX_0*\%$DO8EOX9-1J6[*O$V[\^QO[]R
MYCI_Y6WA[ \GU.<0F1HEC/8-#(WYZ82X&[[GNUT%MK.7:>^_3\'RRTP2[=,(
MTN].9F28776_IJR3F+SYF+1/@EL,MN\*:GN-:AXV\R*:.\P$=OK@6L;;9QT
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M"53.\A.7 P*^B#1=[([U.3;NUC6D86I_ZV;322;QJ=71!]Y):U3M1%B?HQ1
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MSWGE#U[?XAE-@PD@F4(HFA^P0J575K;+X_^%<;JF'O*/RG\LU90RM5RY[HQ
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MT"8(JNB()1^*9AGU4=&@*Y .7M+,\-XPAF%5;M*=? -<, @UQZ(_0IU^!5Z
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MD]]+,E\=R;S.:>;;6_GL;4*\0'D[JZEH2]5X9?Y=[+G/NSN,7H,B>S)L1 *
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MPM:3H!2IDVW>3<=!5:[J4B-I$]1!*^,3U.UQDK0FFR6T<ZR/"WMHPJ+"VJ>
M7-X(L]SSG*BC$BE^&T^WT)T"DQ'NY&<!PT-U4Z]//\I_ZQ%:%,$?=/GIKEO(
MB%B3@SB@:/MW93PDP!Y\KR*Y2UA]O_V08IZ2<;; -M;K!]2^#'\O3(&(..K
MCS8Q$J3:42AJR:D_Q#+H;N\))@P73(]3\DCI=#H*DU?QFXK@!PY0K#>0HJ/A
M/E[P[09*V'!!H4"/+8LUT/&G=[NC2?.:!P.+Z4C)ZN>2"J;D=XKIEJ^A]Q8[
MQ&0S@77@"T\W#+<\>)T<5V\N0+'UKOFWWT#RU=#JIWR7  <(Q_+@*!RR9"U]
M"7@:*8?%X 30.B[^#Z*W(_\&;N6^Z57@IBI:XJ+^*:,'6YM(@H7YX!%/74DX
MS845%%F>P:-_3J5.L[>2"M';MBOZ$;S][$#N7BGY2FNC.1::)7=]U$U=L<1
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MOH@?R:S^]_DZ^)_P^1LP>26PTM%6F$7<(TP.7T/3B0[]'1]TOI&>PSXO_#H
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MO<8+8*=NH;"0B#(#1TQ RXHR<N?687:PL-WV%CE;B1DIUV_>F=),1M^ZXY,
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M$MIL=7^2S%%'HR7(2)$*?EBMNX )2#[O6!/(O)5G\PF%1<GU^-Y@^2X,> L
MMDY@HQL=>B&,8VT/_$;+2_O"C@T6 "$\YF\%+;(#R3H@R>6.M *)OT6;;IW5
M%TJ I;T2OM8@_[H&Q"&DIJ"B8,! 5_;YM(E\:Z6Y33NRQGOQ>NR)2=,]G6Z5
MXQ 16FTXQ#IN5$N]QGL2QTL-LKU&NVT<>T?=6FPHA8R'H(-M+@!4/<SS(I7L
MEI 6.Z5HJU<W 3"\YA7 @>12:K1L/54'K%\&#QTRV&=>ZGN"RJTO;W(=X3E4
MK6RFDS%<^L-;'+2_C6<G>#^[4SCK",.BHHP?0.6K9XVC-U]!W+Z^CUW8'F]S
MH"3J[2/CW"A]*R._<_C'1FJ_[LP:LES>V?B<M"D%%BO>.O7C9K?KE':-<?B8
M+1B4IG68@HX [$O@(%2L+%N%:,ZG;Q4+J,A[)+$=HS<\A^B1[B;PVO26K9)%
MFK/H#[&4^9DM*(K[F%5K[414]+W1 Q%3$:$4V-$&^#3468)ZO9 :UWD2S86U
M'<=LEWIF5@T"![IZ:!E)BXU@>4K%7<ITK#1"1AIUT,TX'%GJ-+K\)?K>X,\H
M+[K^_[V&Y</C1"GYN/*/5/O!IV2/M\I&,I-$%2Y +^+'/)O(ID/AT88-1)/:
MTF/?5/<C6)+9)#+4JMS9_Y<P,#56^=!$_E8&XD-=00!-?\-6-/MX<)265%4P
M]6:3S1P&SP;?C?P19=T9 6I 7EI81W,VZ#YK<[,[EFKG$VB8H!N/ 0>12OOV
MV+U/+@ S$(XSZ?<#-YM1IR>2+2HZG88H1_2; ,6)8HO(_=/#GES;DQ->A3DJ
ME+!&7ES7,1O.\KO_.3-A\=G#RZ'LWZSBTAVFP72%U+3C\3W+"=?FYD;U5TEL
M:OV0(L[M)=K-B+0/7&NC[^@/^E^7"U].%ZO@!'/LI5"TQ.F^BE'G5H)*'F*@
M]GIAMJOS<T/R$+W0<Z((Q*NW6;+K9A$"EX/I(-A:OC.Y )A1YO>W9>KG#4L-
M.1+.-,J$[]^[R;"^A\XMCGAQ ;@"5@XL-7,7S6.M;/A=G!5._+6U"7'O7,'V
M)V Z,+\+MZ;620-G<KE?G19=M&6BU,&6#'%4B^.X_:67_DJ^)NC+76XJA1.F
MN9=>9& 8Q\7I_$J!;TXYMOL,2Z/'HI5::R=E9!$2L.*N<#@,8S)8#$V^[L>7
M7_\Z$>2R.'ONG C:^DA5-::<,[/FY-W^E"KRZ&Z'VR,3F-AN7#-%R\SJ A#O
M3ISP^$Q03CB#&=]5HK2BG%;K;MTY0R-^ST=G7^E_>RY)15?/G5]OG&[3^^[L
MPK<>NP(_7!-^:W.'(9#$.BU:*"AP;KTB[6G;2,$ENX<\+7:$Y:VOV57T';(.
M(/KH*1J>-<9'_U(@J=<2TIZ#T%>\Z5T)GXD6(ZV' PR0'RJI1&FQGN-'TQ83
M5>25N48L7J$3"2>)[1=ZCN8N8:*K5B1]93FVIAY-=V,/HD_,[=[[6*LR\#&-
M+MJB9<_F3WT>GB.IB<AB[Q-M2OS<K$II17%CT?"V,!_T(8\B^=U:8"/<+^Q7
ME%:U;*(S* ZJD6VO_]DQ^X!2%_-F@QH!;/.)DNS*@V:R9-[Q87DJW\PDH7!;
M72R;03-Z?VM;!V1&0KZ,2(^/AO1[U/OFRVTJ.H=+\"F\NLD2&;'_"RK[$ND-
MY-Z"XGCBS"F-N/;/OOJ?F+Q"]3E]#E@K1T155\"DL.B<?SE/;Z7^V".LUS>]
MWC1XQ $V=G'[^>6F&B0GH8.E39OKXUR_VQH^Z]V+F9TJ/F2]X6UU,)NZ$LV:
M[9+ N6>ID>PM2J6860N3K_?3]X[,W6SW=1]W6AHHZ(".LFK^C"_*8"<Q(PQZ
ME!2-I9<)@\IZ"?IVTCGO4\O(0K:NA?*$D>E2GU/:DQ[[T*(G4[G<5O<X@O*+
M0O?V_+=;:[1\Q?YPI2=.\1FMU/[SSAO<F\<M(:%-5EOKX#"%JLDF+X%D<7PC
MA5&)!KRE:&%6XY$[9WJ,@ZWBJJS]TS05PB32=))TFS6R.%_2#*5>94\RU1M\
MDU$9>/O76\'@4.>CG8B:6 S,TP8S6:-$]6QK5$_353^/B@BK5NQ&TR@]98'O
M7@#ZGH37'#%_J)7N>F(T&7NE3$I'4'Y3@N6P&>GM<MV!6A#)7$/;-J7"+CNW
M"TL<3MNO^/! QJYTF$:(/6O2ROU,#Z&+-FPZLXB3(H=H9A?\9#CD-@D7TK^O
M_C!-,*O+[T"M)BRKJ\6Q9<*G9%*:I.L::G!;0(V8'; 4[*XE;SJ& !9YJ;@\
M;JPSB%'4J+P M,W8 3K]1VDZEP/[ '";/?(-4A70:+8,KDN(\M_5XV:W7W.[
M;238YBX!^+U;V=XA\(*Z13)YT?XEJSMPZSC/.'N2^.;I6X^-WU8/Y8:RLW83
M-M6/CK6LNS6@=8^F<E7DWIA#?L9[= UT\:<9^C1<3O2@IZ7QY2OI,_2TQ)NR
ML/8>+)S^71 SJ((KTZ\<EJ.6DA#Z;&]!S6+!V%B67WK7;%(?_R;!'CFTREJ-
MUR%4SXS@:!?*>EV%6#S)ZF/ODO\+NN;!5N:U\_-8.I#B7-[Q$\KE!(+-[KO?
M:)ZZMFPS*0#B'7[^'PU@<VFZ<5,IU>+>^ [HZYQ%4Q)!GUF8L7^4X20=B8\!
M#W4*<B-\5[XE:*":(HD\E2$SP@IS<TPD.7.YP(1#(P&V9]UE,]%C4HN/>5.X
MZ^;O^HF\T6^6S7L(2.6I8]-Q/[EW5OI]^O-6 >M$<#H0E^S+F;DU7)F@*'F5
MAD>(?Q4:>7Z;TH9%64(R:1S4P0.O7-Z%C0QJ]YVDVP/VT4P(NWVSQKV4+.ND
M)<LQ(NK 2$?$J;OL$S$;ITOB)PL 2UDFM+W1'"9<N^7 .!ZJQN(,XQYS#8'^
MK)MV?V]I;?5HAJ$]8B/I#[LWZ&;39&I]_NT3*Z=<U5 2V_:AOW6LQJYZE8 V
ML3K>+1;KUN EE:^@YQ\G8+V[<5,=[T4W?*Z\;X@G3/=> -@>#G$G7P 8%XN*
MBE?K\4:!BHR#>J*._$_]Y2*NC%*6\$!^L02$WFE\"8K0O7V?X#VZ6H4)^*R[
MA!-UR<X?IT$Y&^]O[W +LBFQRMDQ1W+==3TCS\@/(^)BD*V=I%+.WW>)Q_'E
M6Z?QV:?!R"<=&2:!O(@/\UR:S7L'-6LZ()AL?[X9A'?.UV76RK#2K$Q Z=/7
M(=]U&AE'>5>5Z,W#5OZT\&K5;A?><U@I%6DT(6HF<P'HO8K*6U_?S,$^[NS6
M6[=D#EBX_D48%_N%8IX:3IS\7C)!C)+GO-WYP"U /B,JXG ZZX$8U858D:RE
M\@-3IJ<1=!EKPR-^AR%KJ?"O\MEK^ZA?ZYTBZ.&NX^()5BS5WW%<*1[U0-/'
MP-$/B:2.-.+D$9])!XO=@.."S+M5[#?%KP*/I64 O[+.VB\ P" D<*O>;!V7
M[W6P?XBYXO#\^:B66ED(\,I61 XF8\2=C5]M_B57 C&AA\T@JHRNFXQ3A9.L
MF[.L)LA*#E7250^Z&%GJ,7C+%UP*L3KT[Y_/55D0.PAB?;8%RN],?IR+2 5'
MBCKXDFW,N24&\<O%0SQ_;-4!*32'0=]J9ZD,NK7-C7E+IDWQ59;]W),\@-4"
M#5 )6C46DYQJO')JHNSMF3R8HQVK?^+\XHP$1ML#*$Z:Q[G[V$;BID<]I3'/
M9RA(P8R_\(VI!(_KIE[SX 8U?;QE[Q(B>&I7R>+J(KSHCD/XO\E>U5,"ZM=3
MRDAJ=$&KRS7;?1&A.<NIU_1KTT8GS)Z[FBXK7 93PL$_-H,U&5F*I0I=E'75
MV,47&72B G5 [$0+ AV>T(Y+OUQ']-6Z<@%XT&%$WLBS>3U+GLUZ_ZGTJFO3
MI8;\#MFJL@XO)_BV1AE,>-Q)95K>D/\.;M*#Y[K'4O[;P=&Q+O[I<D/*-YUD
M0S/%'7WR_65'/,C@29+.@]@4<]L<?I;@"F@T[??*$.\C-<S I9VQEY\RRC1C
M "SI+ME!?V?LHC_?HY5P$S([>TI:JA;[5_LX*9A?)@II/,0W0S'S;,QI[>*3
MVEZR_,XS6],MUQ+\UF-Z(029S!S478F4\/#,9VT?_K:X**T&6XK*J^JM@UEG
M;^S>4R&:6"&HD"=_&GRP(H :9![+^<H/UNOUP091W E8#3U:CP%+:WN9/2'T
M]!XL;F;>J?:6Y@3X(1NX/8)>AP5?TF[3.*JN,:'6K##B9,7B&RNT%*8-\X;(
M*H04!5I_/@5@[DDBW>JN5GC-71PE(;.,L.3PK61.2;4"N\R8JQ!@*,9?8+'Q
M0(CJ2Z3*WC_<@<"& Z(*U&\]6^,0(09-[($*,#03%8DTSR\9#0AM0/X]C5U<
M@"VGB>/9.<7I-Y[O67__OR?0_Q_8A AHS-E@7D\=,.["/O' BYV^]JBO1NE\
M3 (<(I,$V1H%V>>IQEJL-QKK)V2 [V, W-)C 44WZ_-(I;_?:=<IBRMK78<M
MN#6%-(_;RPEU9'YZ(BTF!.()^;/Y-\+ E]]OE7T[KGQ,+O/;2(=&.7K_@Z>G
M5U2,0N^Y\\=_,]>P2>= T$ZU!9%@'-:XI@3\URZ'P22MXD<I1349/=IRFNFF
M0#0A29RVO7^G 58.SS)J^>%W_=\!*!R*[QM7(YL,5-X")(SJ@AA.*HK'<)P_
M(?R4]/0=LM](=3[24[QN_#L3_^!:[:AM]4X9GL%8O) MLK.C895P$A=,JMX*
M/54 5X!;A'6XE8(-4QVKH_<9PBQ6E 8[/*MT!12AL1XJ^P2SXS=[E45+@65X
M!5,I3I10/)YQ8UC)2J<M 2%,O1=6,R=@?]9#ZA&SF+Q5T&_RI5Y>XJE0[RWQ
M&77-5]^X@KJ1#3;#I_VO:MKTA%%S#R>AQQL6&5*9(T(*'*(*@6CY='7PF#X=
MJ^^Q"[:I$>O+IU9-_T\]LUJ..S1[E^F&6!RF'JL]L^T$3('0^Q2 *2[QF*&%
MD"K9?TNL12@&.H]G#(;]R?U(XM],X[4;./J)42#\SY]:_K ;:Z^56EYR-=/+
M3/H5 &XC-=IE=W9/(M+RJWN.H\0<TK9$42;P&$G>7G?V!(;2!>UX3LM+:,YS
MX)?&?:V-%(364X9S$:1/9#:?#7@'NRQ0KY@2<:*LZQ)S[:HW83YO82<7>YK:
MTOBCN.W60K[(/?8'M$&'!OFIG):7+1+^"%)3(2S4A3VRS)SUY$<4 ?]]KODM
M[";4 7XL^$8@Y;*<1C 7Z[=.IR!G2BR/7^'WJ9_?=L):N%I>CJ_RKT W^"9K
M_0V0P>(?8_C"SA1]><V?$Y=$O1 &!(\B BX+$=,CY+G(-.2^!I E.6V\A# [
M;[LPGFL3Y:-K+4KY[H]_#M#S?Q&C^&=P;S%)G"YWZ@+@.6)MU[B?]DJZ2VX;
M.[4-PA2&[_.\N#L$7HU;0YM/7@ N_1DZ-7A'A$N+U/ZC,'>/MR>"V_UI@"VS
MTF, #6O".<-?MOEW2\_D?N:E)Z+O/E^=((<QA4BLA!PJ(^1N,#&L\8LM+IQ(
M.B\=PY' G]'T[922C&#LV,R@7&N.B/P'>52BD$ST)B -XIQM90J%I+YH-6")
M\V4?* =T?DRZR_V?>#O_)0 O9O\'4$L#!!0    ( />BFU1II%0^_IP! ':R
M 0 7    86AP82TR,#(R,#0Q-GAS-# R-"YJ<&><N&= 4TWX/1B:(%6DUZCT
M(HA2I414NO1>HR!=>@L0$I4FO8."]"Y@E-XC74! NG0"2$<2:H"4Y?WM[G_W
MPW[8W<F]7^[<F3QGGIGGG'.)?XBK@%O:ZEKJ !)2 (#D^@<@+@"> <A(2?^[
MKAOY]45!14%!3DY!34EY@XJ6FI:6AIJ&AH[^]BTZ>D9Z&II;K+<8F9A96%AH
M&=C869G9;S.S,/\W"0G9]1ARBIL4%#>9Z6CHF/\_-^(/ ",5R299,AG)/0 I
M(PD9(PFQ%P"\CI."Y'\:X/]H)*37,=Z@I+I)37/]0L,M "D)&1DI.=E_45_W
MAEWW \@9*6[?E5*]P63XBO*>#_/#=RF%5'Q/OW>Q&(VC^1_9^[Z_2<W*QL[!
M*2 H)"PB*BTC*R>O\/C9<S5U#4TM;6,34S-S"TLKA]>.3LXNKFY^_@&!09#@
MD/"(R*CH#S&QJ6GI&9E9'S]E%Q67E):55U1^J:VK;VAL:FYI[>[I[>L?^#DX
M-#$Y-3TS^V=N'K6VOO%W<VM[9Q=S='QR>G:.O;C\#Q<)@(SD_VS_C[@8KW&1
MDI.3D5/^AXN$-.B_%QC)*>Y*W;BM:DCYRH?IWL-W5,Q/4PJ_=]WD>V2$9K'W
M':=FY9=&"6#^@_8_R/[? 7O__PO9_P+V?^&:!]"2D5PGCXP1  +@C8MBA4D8
MM*..@/7S^@SZ4AR/3MDKMXN=?60"'([T^\Y:H]^V>ZV!&)Z%/4C2Z\Q<Y%YM
M-A=E &H7L\4'8 ,_GL:5+IS[W%T_15C@:W&BG9S8]3 _6K7[#1:96X'R#U]Z
MX35!"9!W.V D2E2#):K<LNJ8GQ"FO['8'?%-?J@YH%P\^T*H_")7&L0,?>5U
M%X)3@U2'Y&XBGF&*!QHQ^TE]<D,=WIS-U9-5EJ^V.U8[-_S$[>X!Z=0[WQRN
M8XD C. ]:D@_7I.=W>T3W&4EEEI/R15^D81&/"[Z#E%ZM)P.VWA3)^XV7X]$
M"Q&<R\H/I#!: +)^N0@& U!W3=>5"=0HY@BJR]\S/ILTR?*7])UE.SWCH3;(
M][[37(3MS#TXEAGYZPP"<E^)0=\U_J(JU_YA#L];?P_?H"*@T219IM5T-:XU
M1GB.H"YN\&NO(S\O!38O*YRY\GR_?35W0@MJ$NK]H"4XJY8&6HGR!!W=MTXZ
MPV 3V $[*KSPP/=P@C+XL4.LU>!?=LH.YC?-:;+6]@+G^1I)"UMKPD3 1V!4
M$OY;/A&0-!E]<(ZA <I&HMJO5$%$ !"1\UUKIBY8A8P +4+.O%DGO.</DV,[
MP*^;FAY#%0I;"/?B'A(!!\_,^8B ]^^P:4&'2F)EC-NUFJ!*1*9+9;"$W7D)
M$G@LG<2\);5PBPA@F 9:J!$!%#>FNW$$QGJA:4]NN'8#$,=\;Y]Q$R)[3_&@
M_1414&O^LZ6T.D\M"SZ&Z","/L'W/ .1FW?QXT3 AOZWPNN_BKHSEKM:-N"1
MM44$)$R7_/=DIT_5BV(IZA_%]@ A#A%?&6KF^_/AX<4Y%GDLF\2^Y4,$9)T3
M 4W7T__,=]6XCH%F?.X;@;[#<._L&_Q,^_MU$&P]^R7(R,/?EV$%0'QF)_^@
M= 'I(\M.X# 1D(:!;[H26IW!Q]>3""1=  .L"<O+]&G..:7+W?H&6HIP@1IY
MD*<70'/@%YL/?6_O%@A[ "7K#V$82@? (V"F<:A%FNW97\M*/CDU?]F( $\$
MEG+;!-PXV^-LTW#PRWER?X(;OMX0 'I#!$2^@7EXOCZ_8E[!Z<+\WX#_(?[J
M'DU>Q26=NU/V?!2: 8<0 7P0S#^W)@/XV1X1\.@$ IL#4U]#Y*-%)L1?CQ+&
M?R<PUU'PWDT32GQ31@2LN1]_>!Z-93MB9B\FK"5AJ2J( #,T?$2R YX"WR.X
MXI*O2HF 06"I#VP&1"OX1C+&@1)?\1DN9;:&+X=Q_FH!,\VOXZN3ML"?5(S(
MSMF."OKSETCKH'*1.PHPX(9;^Y-?CR>C%XF 7_BG26<?L$$B $B5WM:,(W"F
M9@"S\./VEE><=&&2=?/ *6+X[NVM\CV]HZD0@E,QWJJ'"%#$T1 !'R(3P4>[
MH*2+_"]HW$NTVJ J,/;$H1T%GRS:( )63(OR0.@>AJS>;-5+\/46ZC/?0&86
M!'A=;4]VTX;M@ [7X0F.$IRE$\57":@UP;N2</K\8G?<V$P25J]=.@02K0TZ
MN[I>=Q9]WD?H*]J$(%V03C,1T(\4D&4XU"("X%PXUZY\=J87RJ"0E74#K!OP
M^!Q]O:_<B0!&SG(\F>1_,3: ;&\TE.=(-M)<@6N9DNJ#A_]NX??7,F1R54QI
MLV9&RXO%AS2.$=$JU'9-"42 4]*'/([F]E;WCMLB 1;YHR]_4-'WD7.O2_$^
M]@.#+"%5=E$4SV<#A*=]96LFWRI<SN;KW#NKJV1P=6;S:/^:Y,74OT>GG>#\
M%%/)M7,_VT.F*>5RIJGQX-PYH6Y[K<2296SH!YX.IH=(Q!E%BZV%V>HW[.?C
M3%_DWU9ZG>_7-S^_-7&I3Q!M@"JJ9+ M>B,874Y[D#@: LEEAX8;KCQI#9'X
MRD8ROJ$:WA!X@!O10[*W0Q]#QLR( .1F(?K +H-MS5^C]P5POE"R _B%KX9G
M[V@4E "ZY6#$UF]U?0I#GL!+K>+69WM=-,76KHXTOO;@9LKQ=@C<'D;Z.I_1
M;_?4X=$7^14FYIO/0?71O7_T><6;08=JC$3 G.@4O(&A3SB*K>\A_$=- >A*
MKQ!-N!M600!MF..>*[75B%R?=20NY=):'8(8N4Z4.T,LYI9&3-= 36X+$3!O
MZ@F<O][6[4^B9@O2+SLRD"?Q)DKA3+AQ'/SGA,I=1X^YR8I.P^LYDL:_O)C=
M>HFO51%-NHB= U[YQ5W'5FF/KR6(" :M_$'B6Z^+0>\,_(_%U[U#^(8' ?F7
MI_Q<DJ")IR]"JCC@ZPD"7U#EW_SVSDR( .K)!GPSSH]U7#DJ7^5Q<HZ?T=$+
MJX/S+%[E(:ZZ+;  P7G9/K.3-^X,@WF8ANR9261XH< 2"%PXM% C!=^T;@N)
MF;^NIE)A^7T\4NO05.LI=\(2?".L4@WJ!3PX]]5[C<YCPW]Z"#\1_03WJL/9
ML:2'45W#W!/*6)O]@TMLZ.<01_XE E:OB]@5=>P%!<BK(H:K_;XW)=3C^K7=
M7G!37Z+^)U15'W _D@A8SP#.?41N2.(]!N';=V&@C3 /-6@EV\%>809^\UU%
M50BY/D'!G _?#A6U",Z6K:Y*#.R[/B(\I?B<6,)3Y$Q[%N$]VSI!8_+$?,2;
ML-1)]>8BVZF^\^-[($'1?!W?3.!YP%4X8Y#7TIB4A(LQ0K-7'-YPIQ<:+&\4
M!,EY_;IDC47+X!MAG&F_YI,O%R2) #8]8&-3C][YX[>7\TD$T;K+/#Y"&+)Y
M!?]J"+0M"L3>5MZ-1??BZV <+60'YW'YUEZ$#G MOJ:3$^S9W_C[@ C(&V<9
MFTCKMF<]65FT\<.5Z0VS7)_+&/BG_73S++6K%SBYC&<,3%;QF"AYF4#0/ -J
M*H)D;4G&#[_C8]G*<EWR?,:Y%R0S_WR K^K@QIX7-=_%;*%V.'@E)Y"'V,KH
M_C%29@8BX*;=I_KX\*W$#)6AHBO)?S*6B=369M$$<N2O@^UJQ7PN%[,0:<[Z
M^9KZD-=_I):DPX???*8%]E<(]8&I-!]VWIO\><I$G6BI$OW\N_3=DK*L$1Y;
MEC$-#&6/WP.3F?V/>=V&9L48SP39IVZ!-8G-Z89#5\Q5$Z&Z8=NS116";>6:
M)-8+O@PE[\LX$RJY;:[K(YQ"C%.D;W]8VA3>M,";Q0A?L<\Z:"0"CI=!5_M&
MHMMYL=$'R;QIZO!5^W2;YR&:T=O=;UL%BK)Y]-6!N1)^.Q>_I5R*8@'"1<F?
M#4C'U01=2%Q*;KSU>T*CQFQ \K_?Z8!Z(Z/?)/_K@:"K"Z HK8.C@*(HF7OB
M_];!;$#Y,Q]M *=9M(.$=K>>,#K1W-R,75.SRW/.:!)JNFS$[:TE3E]&7FE#
MM$$<4%:,;DETCKL(PGBI*"$7;@C.\NG$9G2XG_YCZPVU8:@-[6HXW[NLNSA.
M? #K>72VYQ8#RC;#4Y1/^OR>K-K[=+% +5Q4^L%FJP$POI!ME4(A::4MJ@54
M8S8!A)=2OIO)3,[.)+T:UWQL- DH."WF-EPN 9R4'FAIN'T"&,[$VA4K[UK<
MU'X<JVTX4T)IJ,:2PT\IC4QB#N=R?=*G<RNZ!A!4%*YIGRCB2G&?_%MY8OJ0
M]X'1(&OBB:%1C]\2$>!@Z\L%CI6[I)@S=$;\T?*\/G>,)-] MT;LU-9M;X!I
ML),V$TXQA;*S>BSLMY[RFA">FUZS-^<>UGDM*R* 'RZL]L5:O(8(>/'K"S=\
M10&ABO\F;3;9*;>TJUU@[<YJ-FOXTN?=[4*\@\PZG(%W5FL <UV<!,-LLF9\
M!80P1I5>5X%N1,"E"9RI[VIB?"+V)"F5J>.^P'V \+:(*X.V%8""F6$F=N2?
MIJ$:\UO#F73_$AY7#>UW_^7U05'6)',&.?V!ZLZ3'1VC'ZH3\9AL2F-5&0 S
M)R4P@=R +%IU(OFDU*X^NL9ID/ZD*#6=,U.JA%1*\V=)V+A.-L,SR^\I%R+X
M\0OCD7;G+Q*P=/C-\KPG+.$TM5(>;-<*H$RF1*(4VK U7\X=Z[HW\GK"P2AL
MK!@&O( IXY.4P(6#GA*2T@KSUEY9?OQN+Y-3KN7ER0%8]ID'6WKS$_DN]D.[
MJZN[[DS#:_C0;CO[.%WW%[GD;QY]@C;N8!DFVL&]G(K8H-Z0QC0)Z+!8RRNA
M67J-$\3#U(TJ>1 826"_W)\!6PZC(14G>CFGB57HK%6G#R;^ZSMZST7].I"/
M UA^CQ_).?1./K\Q'&.,'.HU&:S:U?1MS9W/=_T(MZKV6XZ-$S1QTP/2? ]3
M>E;=KZ+K;O""" C\&WU:3@1TFZ]1*/#>F:;$=X"P,R\Y2H1DXB)"N<1- ^I7
MEMTUUD&WGVOI,^X6@T[.KHNL61$V>FW;A!RC4EW@*Q4LA)U5UN,1HZ0Z40OS
MNJ8Z$'!YM)LAG@!J$'7 P"JHX^EF)31VW?:!]6R]5=Y/(=U$ .7W]/P]&QI2
M6/JB,TM<.=OO[2C'A.@>.YT)?=R8MOZ\SIJ_&R5.($@W<;]WZ[3*D# %9S+8
M(MRF6SF\<5WVJX;I'QLQS7_W+_RS$Q7TJ>?-<R+@/QM2/7!E"M4S'3C;<-Z]
M5B-])H-7%E!===J #UP\\1YC!)#=4P9FINRMZW'C/C?<D)N"X%#E/,D%LK47
M:G6ASH*ATOH#!)"Y/;ZN\U[_EYN3GXF X$(X0:)=_+="I?_Z.!OAN],PP=[Q
MO&Y;&.2Q GQ^D3JFDQ)&K@<Z"^E@.)A>%YZ*D?90&*M8!-5 UU<Z[NY9:G_6
M1?5Q_)+M'3[&C97]QSP&)5[HT[B0M:>/+DW3\1VG?5<$EB:OTD'@U7UHQ\^2
M:D=='IJXX[[&_U'_?+L^5]!=[%:W0?Y5*!&P+^I"!'BU81((MUX$]5U;@5=@
M$:>TSP$5?S41IP-*1$!!$BX3A(LYQ9<?7)"(2T %Y F'6?X,6T=F$>"FY=@A
MI;&;NR1M![GZA&$P>Z*NHI!@G>N)7!*7L\_D IBP="WS724/3E$=*W)1,FJ\
M16J@B5+PPE8W<@!U8!$FFXW]/*EUV.<8S"6A,(K<6B,"?C@0-!:E",MY=&%M
M];:O_*8NW'PNIZZSL;1\8W TM\KG]P5?_DPG^[8P[HM-F4OSH8+UD"1A26/I
M.VR)ES2 HB9 ?G#_Y8YY$;Y1A4<1< Q69_#S=%]5[NQ.KA!*%A,R<IGV.?-$
M9A !"TBT_N]AKP4@JN:' [Y2"7)-C<D98YMN)_"&_!Y+TOR#:1LB(-1E8 _\
M.929"* J/9H$^ML7SE0T?I]FN.7'W['K#;_>(SNBL*E\NMSOUYS'\P7OJ$H$
MU)GL7;V RGDSX 2L0MX_N?CJ +R2@;E<:#(L,<\V)CX7-?"5RAY9$_TZ\!SZ
MK/^T&-B+#Z[M:)JJN==:GZV8XVKNJ\-TPXRW()'.$@' Q[7[0LW1L70J3H);
MZI\.V)O,C((J<9\9NCL('>Q:>J*:>(1$O\:#;J,^#3W__.+=3OTG1;&B8\^%
M_X>O8@%5E1;/OKB>FYE3\RYO"D:I*4^_(X>I(^\I:14-HY"W=UM?_!SO*.U1
M)Y.8T##P.<S&OU6:W:(\R$'%0$&8[G^8(L:N+]8:/AR4[S5^PD^HKSIO]_K:
MBQK 7<&;2-38L/P5U9=7(O:9: _HM?^A@ E%D\UGILUG(@V=4:^N6>:#MW10
M"5^9B ;+/6H1_1OQ3@4I4X9JFA0/<V>9'4!XMTS2=['"Q34 X4-->A$U]A)2
MH[.28NY0DY^D65@?+9W89%*I)WOJPJ0ESRJ*TBAGZNR9_4O[10!KL9DDJD7Q
M1B\EE'=<*:WLZF]WYSTV%EDOU1&(9#8TZOVP^?/I<(^DJ(8#6!WV6PH1WTD%
ME</,Y8\T:\+K!'Z,"3N2IYWJSW0&#I"'Q%[JHXJLL7MGZACUMS^/=CEY>O1)
M)8T_L5[7L_4-\Y0DV,A$=:N6T/8)O/ TF-_L7IX8%6%:=N)0N$$ *W2>+V_X
M(C+N><3I'29]Q).+Z]47OO5ORBC$Z#?@L>&3HKK,C4AFH]4)P'_$HK:G_=CD
M@Y6>WX&.VMU(R;]:B2)AHE0\:LP1:\DW]$(-NI-@]=S4OUZ*Z J(,%,9'FB&
M3&PEBC!8C:1R;*8'E90":W38YV_^+.4C36MXQI[?[;H1[U^&T/;9%KMQAS+6
M?3**07F'/3QV\-T<CF66"$"Q8KM0RL];8J7;;K61Q=\D2<KWRFL%S2?U2$&<
MU]6K7WJ<7<8*[,H^>#A4<KZ5"G]\U+SEKG4O5\7\_?-T8,!+>&D8RY6A##(6
MQH63QR24B"-=FJQ=-T#+4F3A1 !L)#B@X]=SQR7K4Y4!\LZF5'MOO.N0#-O8
M4M9FY_K6(TTZD1(["O^Z];ZB],23# #SY$P60ONIF"RI<31ICA[ 02:<A%[/
ME40HU@A2,EC]\0?F4$WBD>Z=X^S!MP5&$R+<<%%C"^6NF.789X.EU7^D]#NN
M%X5IIM;^=N(4B9K].?O'8I7Z^@B?$:<?IJN3E46YL4-/>@]UA;(#I&=H;]DG
MGM"G^U?_Z2O+J]_U>'4W1H]'I+[@M/H/B4+Q]42;WU^&45[=QOZ!!*U5SY,C
MXL(\;_RA>7F33QU*$(V F9Z/NA_I]%R>CD5"GY6YRR;5K@T%) //_** '_AA
M,I=UJ(1 !F:(E_;,_9RPSD)WEJG7M-"O[Z(G:P)1CL71#I=D/;@NLRY]2J$:
MN8#M:[^Q<JA>4%I2^G7]U.!Z@P#^^Y9'A4@%K1;8,5NV2Q9"/JD[UK58FZ\G
MQW,AKWK-9UDVX T:D5E]8#*H#F7FA*X7ITU?4X7(O>]X$H2#,.(4&B9R47H4
M E3N97>,'=J;A ^M+"&V88Y,.C/%[^*Z(Q)]QF9*$$L<N-KI>FH#CER^YZX"
M*>_Y71Y:)@%(M.SVKC@@BOH8YWZJ?S+L:KTA;]1=BAPBCQ]@[157W\*IU_K6
M^"(*'Q^9&YHKTR(IQ7M8]&DHG053@!'7DL[K T'R]T&#6F*/5B(JJ+2SF&_@
M@0U:>U]^#-QK_AFJC?6IP@E@0&?TG2^OO-*%S)OL'5[SOU6] _<_^[IUEHAM
M6X.SX$QG3[:F!>LG_-N*O=R= 4?='@8EEY]S!])P-J:(.2*@!PV%85LS88^;
M6V:,Q&09O_EPS'_I)7TRQC$2S+RWMF,$:3?)$D ,959]F;F\R#OCNYDU^[46
M1^MXH)!N4C*=KW[@P7)JU<' _).?]KV^&\V7SZR 2Z?.#]A<-!PU'57LN@J,
M/@^R&DCRE'S_:];H >OX&PGU@SB."Y])H0MS1[DN<&0>+Z8ANB<.00.)-IWZ
M.NV0U5LI%AFE\8/\%>E+UKWZ=XFATTK+L;%9X@VZ\_-S8356DTVP#]U*BC%^
MZ3R:+E->@;./KN2TKH81:M/%&PX#0DDUHLE+5"#MTWZL!\HK:H6]716%X$K0
M,?\VN7KLO^"AJ.*XEQII&%OXHP=T'FPXABC9(P)(E,0P#*O+56M(6@C8&"U;
M4\8WU-@T*ZCJ&UMRQ"4_*J_ @_^RZ^3OZBN;+U[CZNH1N ?O>9:7J!;S=??I
M0QOT9GO YGG0G,QY RQ+Q6T2*E?M;L;6=!F8%1!</B>Q5U5A[Y3(."#^XV4
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M3[56PR:-((JK\"@H(_K]Y !,;EQ&DF5EY=L#U\?04D,^<>;;!LY*:<,.!7W
M>9..SV[RR."Y^Q*'7[,7#EV2]FDUFG(IY#N?+^9WN,S-E?];/M].0^KDRR=J
ML//-9'6$(@Z8T&+::+;($Q GUHVKC8?)U&4M2Z\S;,R+K_@!V9T'*'J_/%V(
M?LANS]K=F/(#D0.\2[#\/IU-9UVA=1AOCO2I+@4PT:6 >MLY3_AL,S-;9.I:
M3XFD8R9*4[MCA2M?AI>&45RQ8M_5M(=58P--+&MD;%6>_6W^>4QBXPW9IH->
MV7IU2S*!PCN%(4%F6L])Q1*^'ORD'AK&NX=SZ2R\VJ+H0/)&-Z6N93(\*+;L
M8,[ \R:A6Z+7Z.[I,V#3+"9**5[7=F0O5G(G?#6_-.4\S9\O[M9'Z2=8_>H-
MI_^R>7:/ 2BU"#?#NP]6]$R;5G07[:8,?$3E,7"8A9O]30-_,*)/KS=7W>)9
MZ?8*Y^7'#E<LJA8.,,MF%@2?SRHPBB@SWZ*W.!YH""+(XU,"P%18(R+ MA[#
MDUE%%^&D\^%]QAV2M/"T494,Q!4_S@8]%ED_XMZU+-1J*\&C%I%LQ_-#ZB+&
MZ,>M\I3WWF**ZZ#]EE#TF&HKANU]0UN">X]H_HZACG^J9K&RED%A%F73"\Z+
M^8]?AMFW1VU26ANSC XK+^_3(LC$"^TK)LXFZS;K]U%S1R7_6AOQ@2JPVV6_
MM6CRC74V!9<6HE9L9B?SV+"ZZ$.4<Y>MV!I#TKZ$S,*(P=VH06?'^$>'D.FG
M).\-211C.&Y\:R<IQREB!S#GJG7C./'YH&C.\9'-7/'#8TT^W^MDTX]&?S8'
MSZY>_&5O8E\^U'%=,.[.8IB)*[XY%5MIV#_>UFH<J#LOJU,U<[;S&WUKR +P
M(^VWP6LU>8F":Y9,P Z@&*(X6;\'H<^[0I[/JCSH;(Y16ZS[:3;\KP702$)Q
M$]@W.]-!:8#E04D"]CK9T=5P^G*,24AX"6=4A\R>2+3?O8NW-P .H;R JX;X
MNL=N4FEQ-O.E1>,!T_BET0ITHZ"IJ+'IO2GQDME'VKKUQ276'M:VXJUMVU#7
MR;SE^JD,;I0%TRFB_&1E3E$/!$2<<"$:D.$>!YR7+$R2.7=7J89)\&OZJC_V
M;)T2T*!N^&V$DBYJ$GVTWK7^0E 99)F(^53>%4"K*JY 79ZR7!1<0S57U?#Z
MTA6>OV'*>WM@VO-^J82KFM!(5>)E17V6TWP+YOM+^HDG7D^#2\S-P@K?J;R=
MG023PE@@-+T@D@8B@!$RH)4:6L-GD*?@=2=W1OVY9JX)A?P6['&03&D ^AR5
MU0>\UBQ&&*](J+)D-*)^>ZYXR7O_PDPL^G[RCW4EOW^BI1\GXQ>Y[1)'=MSQ
MF\S-SHQ6$>Y/JR6%%2J6EDJ1<TWK"+W&"^N\C'D<'U:W"OH:(S.:4#)&5[5@
MG?.I/%_Q:93ICQ\;?P>X_65Z^',*;C\8&$X#&^,8&Z<(S+!1.S[,<GZY\G)'
MI<JP\@>;#ST.&93EY%N)TU]EZRLFVE4$)^RJ5W^BF3'-;?9,_JN?RST.6,*4
M;;-^7=?N6"* 1@8<P2NLRV::J1B5>5=:3HJ4I8O?(6^=%Z_F$SDEN_1#KE#F
MM/R  [4P!H2-J;!B1A8?#M3L!'XX]TF?UTH;9LC@D[=ANI@!]TA&YM-+7//1
M3YS76BYK:-5'5DL)B?O_^,V])>QD *0:NL6E/D:_F%U$ILTS+FS;\F8DH\K-
M'U1J7!/T4>CSC96NTE.M@\"&?6A[K1A3%"6/MWO@0-=C0B4J[I!QP;6V,=RQ
M=W:#D5V!C.-TF 2L"DE#72O%I!APW<%* A18J(7:JQ%7K'=R=@I+.7P=-K>4
M$L^8B)LM@U#VJ]P UHZ,EBG)B=MQO2?C^9?)'^0*AM!%"2FUC(8Z-XH]_A1G
MJ'<K:+-.GP!$/'LA2:,>X,RM!JFXDI,?M"WWN@IZ3;B?[]C1:8_U0:=I8 9Z
M$(R0[..^P$N/S5R.T%"ZGLV[%N&">D_DV5?/:W3Y5N_G55TIVT&UPIP@_U;O
MQ_&$#\E_<MC+6]TJ]8?3$( 0R0$@M8H(ME!:Z+VBEXKM0\'FL)GQR)04OSQ-
M+G4]O]@3KPCGGH&S^[GM9JG#!?RURK^\I<RA-I5JY*3!WD7?$+&?@6U"F#ZK
M8:=&VU%<DW"/>:QI99]=@I:(GXY9J:.(2XV7V$Z5^6_LQ,U42$I&>B9@E3-4
MWLXB\C+[LDH7&XIN6]?OL@7;HO/>R44'\-QCFR,D[R]D6+OXSM'2_]:[$=9G
M#P&BDM[!>' ,C=B$]259KUNVR[C?%B6_4B+L69[0)(9\3DO4*/4G ER>CF*"
M.FI*#\_S:%!0G4I>JV3_19N+?Q<FQG7(MM#RTAJ_S9.76W]?KFB_.:YFK'L$
M>#(F5!,FM Z/@I%CP]$/M];DWDD/MH."'(_U[8\?%9H*6-R:VRHDOR5_7N6^
MRA!%!) 3Z%QA=S&CT9(Q 6$.=[J%_!=^4AA[ GXH#&ZM-$@B>K*>'X9:UQ"(
M@*FD4^?;7V1$4\[<1*'GT/::N;"<I8[[[I^%/G226FZ# =<!?\#L^>G[^1IT
MI*DK%7#,011V'RB&S";RQXG^97]PAJA7D5O<UCC3'O=24G Q[]$*(*]T?B2%
MGPNBN/G3D_MTS.TX/XD(N-DN(PVG;= G=5V9"X'';%D'/]7\I1(8H=&3JMJ#
M_&OS\8U#B$EG;49[3<VGO2T;9?9Y"Q730;TT5]F+SRN2TIX-Y@UG*PY;:@%.
M=RVX [IVC-:1#:'F!\HH^$TH"/F?J%)2+.USKR@MTH?[URHJ.#1[*,@/_E!B
MT,:8*8NUYJI94;MZ0LT<WF?:QF2R^NH9+B^ &RL]OA672D63-2AQ3X+CG7*4
MEHL8-_G(?L>;CW,RV4$U\<D-RC)\EE^5Y$($G@:__)2VD)3Q36SK[0W- _!S
M6%_3S4IL=!^!K25GN'[*'W6O\-_PO41E@I^=YR--/R) [,7E*"=LEA/M,6<6
M7T!PU^_CVS+Q'J(ZU!;5R;DIG=,6QQ$EV)A2Y$/XO?>B)FCJPE6(=?*VV7PQ
M4/N4(09,^A?KL\K  ,D]=>PD3,TCWC#Q&M\:Z1KCHU:D=Q\N)P+,D%:7<6<)
M,?\Z2:"R#7&?O@HF2@O-OLD8L/*-*$A;O!2OHM1@BNB;JN0:8M13W%Y,W6DY
MZAN9?U+RC_N62L8_)%<GP!5(3>#>MA.8;+"NNCBEB8@L_J3^@X.C5HIP$*+?
MVR&'@N]/HVHHGTXKW5OF:YU.#VLT_Q0N%7\G<%3]X6M^BH&017R-_Q\E?733
M#RNGV$[3SL+JI\GATP;]%WO;CVPD;V\)-V\G59?VI'^#O'@M1?^HAFI ;032
MB+\=I.L1YG^*S2U[[E':4BI1T<+_\AS1[$F@M\;)34N#Z+%^J#YD3+W[MYAJ
MM]G9+P)=\QSI'&S<GO(T2=KK]8AW,#9TTX&^*ZKL.]OEC>*204AFVG#[DZU1
M+M\'$,;$EKV9I!JUY9_';FC8P_C"FUJV@VH[_&F9,QZAPVW6H/8+F?)X;E8@
MRCJ/#@VK6;\F+.OM$)[OK<B<O"O#T+I;]( N1$T["4-WA\[:^0<5SCGL7<97
M&IG6<W]3<#-&+39,R21^2:7F^(\>_N!K8XIS1Q/$;K0@FUH>+NR.]K9$"#$V
MJ?;?_$DF,.(HKCM9*]?C702)9:RQE=?SI.N_U K+-5HI;D#2X*91^21_EJ#&
M:=?R:0;UNZ@AN<\/6BU[2 XM2%76%YJH;]= (_7 \=E>[W#W$8(-[F'BAG"7
MUW*IED.-WMZ!B2&QI_!;NBA0++@AH#QZMD=J02!W@4[;*>,XY =] >.[G[@J
MO^X=5%(4N&%Z.9+W?2V/KH.L7W6\;DF4QN#&B5*8E,V_JI 5:Q[OG]_^G60G
MU9T-<9]GR95>%\/SHZGC_ 0B@$J)!!VMZB$+9-*%KVO&<MR/L;D6>(LM0PG5
M5#AE]QZC)^/_R!VXLR_7SQ*O_6>"T'I4;MDN@3&*L';3X7%4J0(\3S;BC<&7
MGCN>>@/_9D"]2>]"GN#+H +EKI=!::@PDYBRV-O:LMV1_<$_%-_B7-7+1<\3
MWRSP)0JQF._24TMO<4*KLG</2I8N5Y8\E,>/=N63_^JI^7>28L.^0E_,$@&U
M2J W0BVF*WR=3Y^WD(D_D=^S!1VPJ;R%B8(M(/9#7#P/NV6:O.[<XD_CN#]X
M77VODSIPQHR12(0W^#-/*.5ZL(UE&=/JYWWZ8?28UKFI1F'DR)97Q3)MO'>+
MYC["U+=L>OJT2:T<K RBP3IWZ4<&(IE@(B.H^T9GU@+O^!]JN;_7N2-$!M+^
MJW+7Q:R3%C/34+"PV/"+E>ECJGG_FC)^;\<KDB VWNYZ!::I(=,B]$5-3+A(
M9 6N^]TK^>2W<YX._Z&\5_A;!A2E(H ]7-,GR[\1?![TXFC938Y)L]M5E?QM
M2_=;FR.IB9;%^="\4_%PFM@N]5S1%.. S\PK<NTMIJE:RBNAUFT31 #K:]&-
M9,H:*:>$499W,B>SW5YS/4\P#'V'W);@DO-YH:A_I-86%UW0L[L?S-Z0];,U
M([2^8>^Z8O2U9D[&F""W5[H\'*62-*?$O_ZN>WZ3)ID?YC-[A_J3OO%(MW>4
M(HO.O&":IY:8<G!0F_;X_&#C5\(QZO+91.K#/@M9.3X6^;-RP]!=J$Q- ;WK
M$IU4R"1^3^&-X%WIY?KU;-=J]CO,<!:.@L00$ZGH$&VPE=YFRY^;VC=<1=1#
MS=Z\^CVN47KC^TN9J%-'OCNS*T3 ]^A$(@ EBM6GSY#.^7>BSEI]<T,C\X@(
MP$R3H1%OZY8[%LZD,8/H_+[HB=?>]V5^]D*\+G:K91T(EVZM1AL5.2<JZ^%U
M#!5.WXP"$_0#<&>X-[!PDG<ZFO1J]T,I3[8-U9@!_]VF]^T& ^X+GDW_?CQ&
MTV\:I3J48N[*(#U9URJHI24]]C.)<SL!A>"&I&F]OGFFK+W)HOI;=&B(<L?B
M]!^PT2MB( HF;[M4MDZ/H&KE&%C9[CD&U4#"8/CPK]_EW0*R3/(O\@<_Y7&L
M8AI<M*PS=:&(\E66%2@MMFR%DL"W<WG5?[RS=2Z77,@AE6SN?6X[-\#1_VC$
M6[K@V-JLE/KDKW91J]NOC9XUT5?NZAU"KFIE'89GE+WZ$=>22,%M!9WMDB>=
M]"S?:/Z<44E\X5NAK[GW_(KPV+H%Z,8KM$8W<MYO/UNP7:)>[1MDH_WS+=HK
ML&_X6 %N[V]T?:SZL*!^C>(^)GVN_LT)@E[!9IKCU5\[/3KYDHD)0IC'[\N0
M3P<BYE$2["[]1:GIV;[3-?[F]9[GRMHK:W1-[T"N-$BV!89&"U7HKQ%V#G^I
M='[GQ=E).^G94X8/CT<ZD:N'<9GSP.BOZV:I$]8O1UBE\CHN-WS M"3?GW"3
M3!2Z:]HVL7?)6,1_9?E[L]+*T*:UY%\'<-,Y?.TF*L,JX"Y$SV;&*-TJU(LU
MMV;\S#:I&NF<S^UR+4OEZF=.MSUQYC[<,:_6K#]V+>?< GP:I5*0/S&VA4="
MGY5@]5'.O71LYMBL:\T!ZQ"H3N+30;[ACU%Y/JA\G/SX9:AYK\?MQ^0OJ1/?
MYYQ91*GHY8KE->I3U_ENN:K8BG>.#:MM5/N_@N25<::[?M%J&*GY>X8(K=H]
MG%Y:T#U5^8+/@#Y#>?BM.L<0>-TNOVQ?)IQ.300GMOQZ\QW0,_67@:7P2A'W
M?%R%36LM*;(U_\.])D=?Z1%?9ORDY^"&\]VHTQ\;WNH0C@M.B^*/,#0II=\S
M?IC!LW?L.VE]++X?30-,RBZ<)ANSM0+ &\[//NR^6E?MSMXJ#PCML#_\UW"\
M9)FOBS-NQ<"C.H&[69SY?<TR<Z6D<])M+J0Y'Q8C/2$#%'4#VA?O_^K_^2R\
M$;^^G,]3;RB[8<!04:DZH'WR[:-7E6K_3M.<P 6OH$.2Q>Y0M?V$+7>I9+\N
M@55C"7@+!UH%QZ_0X(2*EB'S*UIA*L(;]+'@P*?OI5+FPMSCIU7$<2!\;B>/
M&R\S-L@_8(QQ$9=FMW]![ZM3Q[T%B)P7VP#7/H6_Y4R5L9AU2RB>;X\-EK;/
M>)S!79![X:]]WMEA=:02S=AWNU+.+I*JN\KFJU63N[7NF]S6^3.5;*SJ6@*;
M)CX)]ZIDV<V[K])F+"@NZ.K7V)O8@C#-&OTYX, R^[0*#Q@+[/=[TG@6=&-S
M6B)ZR&&QYMV [4;VA4+J ]0"U]5M'[U4_H]TZ]XL-6^^LMPU4AI1&,[&YZ<,
M/_O@9E"I;C<BWRU!IUR2>PC?*SPD IA@B@O >7T=#%UM&*(GCZ.9]0S3DY3W
M8(@G[4X 8SR,Y6!9%J.VU3NBWF.+]NJSAC-L^_T@/TM=B/)_J:</BN;V1T3\
M)@?0 [9%\AUC.NW?IKJ+MJB)B,)&YKJL7U_O:>L]OQ<@)O.(JE#(L7I)2W6I
M<#WNLU5@8^;)?IC'E0QD=$ ?N[/>-G8;DGK_Z3:P=F'7CP[IEL!>MDJI&JFG
MDK$*HO>G 3)#]5H:5 14F.C$4^=VMQ.25QW-WY<XL^\M-V<V:3&+23P]8=Y*
M>&U;_; S8Y+V=OGCM/CJC=0Y5T</UA6^D<J<*RL3E]'<:05MZ[9.IYRVCDNO
MT/PW[BK2=>BLK@X_36S:6A602VE#K;R$=7V$;U-!B.PSR3'30(T!UA%C#^2%
MTDXJ*91 &I2 :WA!*4;W#SW5L5R*T15\? M'8_W?K0=H/$T X_PB(L,5;L?(
M[SM'\BWN,(\,1%-/8T=H7MM:-M+". 'DHY&Z./:I[!"SDKVS?WE?/-3Y@!+^
MU?*/*Z=LY?HIICR;"'#-HRID+*&7HU *0'6TSL8#1XMC^2-NO15623^["\,
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M&ELWFVI26P[!#)WWL>8]R/J!#TJN80'2=L#V*+7WKQC%;=+[S2N 8J;YU+@
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M : !1  %%;I5-@N%8"RRUW1VE_-9E%]\1 1 .;&S-;#/L"E>)B(@ KE:_N'
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M15!_QH ;]6TH=2*/KG@M<*\!^.*.[E*2V? !0Z!$R%WLZCCGC<-TX(\IS8?
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MODL5_JA72,+MFO8%G1R8DW7OG<>?9DFDRUIFM>;0G4&96#\>R[9 0]41:)[
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M6/3A&FV'U]:\<B6B,V!!DO'ZV>[:N=&8R=O*J5.89=+MYOB;[ R];I23:(;
M<2-2;!O1JNI8:,V]6TV%@;AK,_G*.]'@,:6L?V6,")&YNYY*1,:;Z_3,$&RM
M0&S#'80!I"4[K3%N=GUHL,AQ&]?TG!')X;\?*&CANRCYGB#SVJ\ =Y/^XK1U
M*$/EEP;=QX*591>!D$BZ:>5*!X T_>[QT2H,2=I>153D_7$3.D&']XS/[19L
M-W5?GO&1?$V_*%Q'0ONY=#5<00FR9G<=O.4Q,^:;WE2;=PEXD_3PB).73I[=
M28@OONC7P,V[>Y-E%78TO4ZWZ*;TQRKII=GH'_)U_(H,"4DI,.C4W%69D+P$
M4%(1I9Z^6.ICUZ-6^J%?![;JJ,CAZ+'QNC/AR60-O>/6IH&(&NY,9V$QF\XN
M>E!@4%Z.SR@]H?_!3>E,FNCQD&W%P]4/(#OG I'B+C[W3[^N[VJ^ TI# TNI
MVSD=7;.WR$Q,W/QUJH?>C-T/=IFS(V[!#<5QNYN;386[67JO;/=6IY#VE!EX
MED6D =D?_,Y(C/C:X6*3)V*U&/\2$+Y=M(U6R)_M8XL]"YO;4_55IS+Y/-."
M%SY32-?IB4U[L18ZI92" ?M<"!LXZ4)Q[5W+Q.,I+)0\KQ]\7GM$^SSS_GMI
M*[D^KXU%</W>-4@J1=58@X)[,;BB@VZH7[XLY=>-OA-7#N[<: \FKO58>ET2
M-YKN-()!18I .8\.'K87H]KA4,(#X*]6PQ(9)O>#B-ENJ&>TY^+N<]E'7$U(
MF_V-)IK1$H-Y90@7[E[%F&RKMXA3,V!#JR!@^O[GI:93DTO L77'EK8'TZO%
ME?!<+K1 PN*277>*-X4VF.FSSLOX8, WI%W8803>KR['0A/W>\J_*"RSER//
M'A#'H C]6X&W#T$,27%#NR8Y539E;<(:%)^^214"[+^O-NQUZ#_S<.T2YVW0
M'60+Y!;(E?XY<SN)JSEBSX)&UFBEP7P1K'YA?6+R<\T$5Y5<,:NGH#6=RM4*
MP"UZ].V+N[B4)Z$+Y4!F3DWP)%N\(3E'[.N4"8!,UBAGY91;B0VSR3!1FIHZ
M>;RFM(&]F;A;P!#HAEN]1@62+=,QDX;%ST;3_1.7  /-U'W?MK5<6Z[,\:,Q
MA+KULT337.&Q,0_G*AAE0Y"3GR%KW)-OL$=;_5#_[*LD2R8>E4S1D01_YTFY
MSR?J4I;^0"8W#9[RXB!MO+)19JO=8Z%JN.)573TGKV&VLZ^O0GWX?9;*MQO0
MV\\'%2OW/HI\2?\Z?*BUAQ=VWM/X8^*YXTG3TVEGAL'GTH?7'K%L'<(36,>.
M[$@L@8A(@RW7Q&FCH[FH^WR2-$7,+0_D^N4DJ<4QR-7&A 4V?\],JX3A:8A=
MT:1)SZK1;E36_E-NE]T7,2,>AQDMCOFC#>JYZV?.?=O5-^\_ZW@F=^?ZZ_OO
MK^%>+)R.;M&WCW#;[/XD8T!R%] \?Z^D? "/JS A.=%&9(W5N<!%=M,+4;ZF
M\ZI< @9:G%P#H"/WQ:K*.7*(#T&$F5\KI'Y&U,:*.WE:#3J8WIONQ[!\S7?X
MI_9SF7B"_1(@&#6X "+=VLDR-5.IMI2O9ZUO4%'Y3CQO _Q4 ",\A,S=6O>(
M6]FM.>N+W:_L:]J@ ['Q?R3<?9%:T(6$,P]ZB11OUOV,T8GO/&C!L(SD,+3+
MC-+,KNC[3+]7\A"SYB88HC):%IL,FTF\'WR\8%#/?./;&CY(X>=A7H/&(IB/
MT(I\4ZS_&=[2"EZ\% )P1H?H8^]RE;DWR!QLHU<1<O/H)DM-/?LM//O[=BNV
MM%*[LB>C6I5EL ZJ9W3.X7#WO/6SG :7'E=F%Q5SPZBJ:!!^:3 WM4QDDE9U
M924XY--2U<=(L=Z%ZZK?:*6[\PV4A9]'TY(^W/;>6BW6G+SE*5>+Z"POLM8V
M,$7%*EBX#9/=^Q!_C]IE>RD-:'0X%VS*W8BP"'@K#")IGTSX"->VV7XI%4\H
MV-\U; TSM?P*-R]"K(57@*@VC3H"8[RJ726>M!)U/+*GCVZC7?=9<CHL7GT7
MW-M+^:B;_3W7*H@$0CU'G([,#NL,8XHJOGI2U#(8[&"V(_1QA8>9QS^R-Q=9
MG,0&4QG;VUX9%U'/9 \*&UVHB>'([A?T=\6C8@2L6WX=<);H*"=R"<",,NRM
M%$5Z;9+6TN+DH_0[ZJ"A;RWJA[,$%8AW;#MB0\4!40/GK0V2;6(*WTRI$0T>
M;ZJE-PVLA#9=R7I7,!-JW[[AN"^M;D4T&E\"@NRFY =9FA%OLEWS(:1W9J<G
M"U='KK]1NF^QAV]\,=N6B/5H8=]KB"G;UY\EV#S,(9+>3M45"#<<0.D/E*+*
MMN3"&<W;Z#I./AX]A1RG*/4OZB#DLZ[[W)148<?%9;1^73YT!*,%3VSX,#>-
M.]M(JB6>VC')_RP4_!$,8 _$=QRN6<66SBS[/34)_1"O!R/.LD!K%Z.@X[@A
MJSI!Z:*%I.N;R_RW(F_2RY%(NS'H5^HPG>-3:#_Z\[IIZHZ\WB<"I4.)CH3U
MX4^9,CAK%3R5/25O)!Y/4G?:]_*JJ(0F4@[RLFJOMX*U+P'E=-NMN?W+=6R7
M -S^+I'M)>HQ;;-30>D'P1PE0H._#]0I]/%07(,5UW5ES@HQ%MQ["4KKL(<"
MBK,J4>"LK+1"V\_SH?:KE6_13T<# Q!;[4;^KXHK8\LB&U4(-0D:O7868%.P
MEC.V3U:OO+@65=!Q=XM$OY8=L?N]&? X_EHCI<E'Q"K/,+N/OG,)$%I%_HHG
MO1;FWZ&G=6("']N!1AUE4^Y? M!B:_[-ZX9($.9:RR6@:UVV^G]<;UP"7KX!
M'FQ@\*!%OV0O\!Z?^46.]\HBYE)O=:%#9#@O =]49%$7[%=B(M ]OP?$L0/
MB=H@]-D+3/FK2\#AG3OK V0HGX$."9ZQ!)\<=?5(*D5&%3RFI1'";TB"5BB)
M6V;KV1O?O%_>F9K#IIP\47[18;3XI"P,MR5=X!3 ZG%_E0$TRS^R"8[/$'87
M1/]<\VV_;8'VY+"W_Q(:7+SGL=N(4&_S81E)W=WAO>9NGJAB[DSV?:,:PC_I
MX*.'+E370IFD;WJ4P/,T&)I\"E]543,;V @ '@',X6P-"ACZK99&V05:I/[?
MZY==:&J@DUTU_&< :KXTCJXSOP08ED'/;G[:&C/#10M86#C:ODB=-Y:OVF%M
MXQ)7]%Z0F]J"]</=0A8T@Q;!X!N\> CO0#(\';"X\@2 7K5EB5#V 1*$LH-?
MOP3\+%^$HW']+P$1@Y> 6T?ST]#OY8NPOT:&,-^[+@$#.< M4= E0$Y .MF+
M&;&Y4:?A)W</;!4E);I9E$FXJ5?>E4FW(@+ZH%YB9N5#!V$+::G3;;8S9/"_
M/YP<!MM=U-\9(8%@Y06>(NP9W" =LB@"@DL ,!?:YNDF['L)H!@/AB)(2#&R
M3R_BPLSV-T(NWG0WK[/)NA^F'(72Q<4>)P@451UT#JK2$P?J\,NA;[EC8 CV
MMCJ]OH;O=KPO*Z)6_?H7]2PI^W===K" L[1EJH]=RM[\$'3YWU0"[>S-#P^W
MF?Z)&^CXC1#&^^N5)^VPGIQ%2<Z7-1YG%Z#"5;/K:T?#LQG+:O83B&D='N[M
MF6 !Y&8%?9BR<:/EJJ'S^Q GW%NYMGTU2Q%'D"U3;ED[Z/7EM7]%2V+HIUI2
M9!?H_RC?-#4)V=((.NN+@?Y\ C*!S><&\@K/:';LK%@Z7U>N.4W@UA(WG3L<
M+-0Y7^@,R>OQOH]4&7"WC1]BB*@)I;7O,O8U9<2N:&=^[HP*_?02\/X=%'FF
M=]'H1=<>@5+Z9R3H?3O\:]N%Q97SV//6H=>\1!;FR-AJK5CW-PGS_)2^@'ZD
M 9I=<P#%Q7P+\5&9FR?553Y>9*9<-XNTOU7;]%2D?#[L6C'E@-J!KJ\!$6&H
MS$L 8/X2L'0(;?- B6$"FBF@\PQ M$_V/)+Q^1]%15;-N&B^;(B$2S8Q^9>*
MC:S40<;8+-Z=VN"P!@=(>LBW,R-4+5IE4+@N_Z-\M(H<&<?,B?CW_J542$OS
M0J,7_25 ?N[O^#^Z:)1B\'"SZP#^E2%Y;M8];E<AVK\*T?990JL9R69BXUBN
M=*%WSJ+E[OT'C_ '<3@W+@:?-*.4%R[4&-\\-(^]9;3"6Z(FZ/=*IYVLJY .
M.8"RDR6 _JQ>#+T$C"=CS8_!T/>T+-LO--_!B$9"D9L#$R-FKX/.!GY'QW3<
MAQCEV,X_I^S)L%L=U<'PV?D2$/\")VK_J!W2)S,\OQ=4[)2BV1'MZ9L7</[X
MH,;JILF4REMG^B2@$7+IW-U-%NLG+.;-W\=JBO69-265/>!!P2X!U^Y>>;(Q
M>5SYA.AOUQ4;H2D0*U41KL^W'-_9OC*DV[2BS-')MJ^L0IXH*MH@^-JH)MG2
M<_!JW>S6J,7(I8)?N5_?9L#FN$WA#^A" YH!A [QX?@#1&BQ!"QX@I&R&!RY
MJZ2CBYZ1K0TZ&_R]+.L*U.MLJ\0MZWA!$T-5CO:?<G<-LL4[5[4>2C\\IK@
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M591.+;(Q9<M750G8<.:B,J;+L4D+PF,ZC.HLO?M8*T\<X$1Y +PJ9[+K!G]
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M..[[PK A-A,#3F&[%*Q/X:U7%JM![9JO1YS&_P,'9A-84G!ZV/;WTK'94FX
M%JJGN5WA#XEN=K-O00?H-F%!)U_8QCD7/"T,J22.\J_P(#P=OVI_F@^Y4?^9
MY::W?F?YWRU#]D54Q'\8[7.P[@F]:5D53TW%O^%2:CC-T(?3CJ/BW>51F[/A
MXB&2[!(O.C@)5N*/>IRNY^/7!,'N2#3" MN]/?B7JJ_]UIG[M\XC/LXNOE.G
M_[#>.3XH=^- :FSL70M7<GGG>W)K]4;>?LP0!))DN5;]F>R^9EKA6HFRQVD]
MAGZI)1/S&DZ!97]_)S'T.NPTON%/FL"V&UY> A+>FFW):%Q5/9G(X<,DG@<=
M;XMV7E95:,FWD>-KIS;H-K]\_SCJAI92T(.:>;K30@S]W!5O<OMCXB%P:@EK
M\[\#1WP\'?!3ES^$'(Y:6UBY!'PB5,C>C+*2\$IO^@59IKX3T\)._+#SNHHT
MOAU*MI5*AO@GCU/]?1R::W?G23\GEZ)5V1J(KAJ77"!2XQ]W'%[U:&*Y:)9_
MFAOE$0'U;?XK3@[]3=L8G3,GYKXQUU8$6_I_PI' P<6-]*G%R1:EZG3+Y5=Z
M\\F%96=%.0V>!,5R?0;953!2^5]T/$2X7A#]0V#56UY23V!K[/+<;VQ4 ].[
MYZB^"F!2Q.,JVQ<:"RJMCJUUTP[)C6^'ZQW*C%YQ #@6;\'_W#W 2CRZPMM_
M)"JTCH-;_A#[C(6?3EM.ON9EOE33E!\?7/O*\(I4TW\_9\.':5CX\1?A\QO<
M0\]X[K71:+6'DML?4AY4H\5R?Q-JY7_N3N3Z!Z%[?HN_(KWJZ7IV5,"_8WD^
MD.$T0+I1QY%L8-#RAOWE_D<MWN/NA^*;[K(ICIA[*&_&55_>+^GJU$'1+CBN
ME2%63DL."&4M@42D_;D[2O;J)W$@V+[GYF^$O&I0KJARYM]4^8@D3O'8;/I?
M7>E28@M;("++L4F;:+Q RLY'*TGU0 <'#>OQWLSC \0[+%FT^R/MZJ#KP6]/
ML_\Q_$/]OYU!CB7\2S.VF6",.*5"8\G8^\C?@(8=^-V9R2+(KSISBU]_6/?+
M?YGZ)>#LGRF;H*LV"[LKJQ>A:+PK<-,9+S__#"VF%?M=0!,SFMY@#=E'V%_9
MUGX)^(^E7F"A^6^^'X>&3;==6/[=2+3 988H18"A'L63+SKB8<<V;:6.=\@N
M 9&7 +7]J',WMX<?@8APMS\=Q=$0IA<C#OI$[2.()!8=GIPRGE7ZVN60_HJP
MONLNN23)T:\@U(-N)[,D%:U^!W0/F5H@54%2XZ1)M-U!Z:Z3MJ(#4.?/DU#N
M UT3IEL+/G \C2I#\U<@%XZ)LW'G;&8-P4$#0"LK 5!M'L,WEY_41O<DZ,0C
M,)]"8Y=$^0BN&(:C5"#!@5-O[5GC8;\[A4Y8=Z^(CN<M2E"D/&T>>4>3G1&\
M*'TWJX.'%4"3T6"F/5K)7&16L"GTP?!=P8UO2QMZG?!\'-!Q[+*W,DK?;C1I
M\\6.OOFTU2VW4(_P?,D7SO3OI1UD6RNV PL%"!/#VAXNT0(7=!#'LXKY<^E;
ML5_@\3*"F.%C,WP1#F&P4QU2J:J%;E5<M P<^!+ SM5_W?.(\COH'#(S[=:L
M.*SYA3<N0ZWG>*L:4)8_%7,2+A S66^U(E[P58^%$7A4A0DB/B"6?BC^PPC.
MM[7J#5=TEYZ:52<?L"A6=7_-,4/9SEN4Y?VHZ(M=I0$]P=,:F5/@@K$Z:5^Y
M9/)V2:5T73!BJ7#3[)"L9F $&N"$31AGHJEBGR->.]::4+DX_<YK/SR]K=1)
MEJBYH@O8=LR'\C*"5T1O#PV)W&7'>4]-H3/XZ(:2Y6)\3#& @4Y Q6-H]3VQ
M=K":,X!M<.,1CO]0, #00:_(0P%(4LZF5\[&OOF<:7F8G?'^H=VGQ,1U#,ZX
M+0T?VOU)INN3SU.4CBUT=L?* 4Y3\NEJBLG7?+O9<Y>,+7: %"? FT<&-I^+
M]A=%6CI5\5XV C5TZISS[!KN&6/DZ^@J*<ZK40;[Z>S<7L/G_!&+*]!N*LN,
MX#5IK8R,E%[5&H]1NXJ>5%@<%9E'<)KM;$1E]R;G!*]91IYWV9/!XUK2;"JB
MA/4"("0:^\F.HM_*V0/?!NS[[Y[!W-1\@[HR$X?T7<=]5W]4H@0B-X%'/%4Q
M@;TYE_WL[1AX"5B$>.XX> 3G$M";Y1G_Q HM 5G+C+-7:EP)"II</L[<<;AZ
M;M,G./VX"WL1C;VHNQ([SIZ7>37S+R78&:KX;0WOF6(->,$9P9S$5S^AKF;$
MD4;*AQI_*W(3S6Z)\X5>-U [*AI'G1ZX8II,(+)BRM\D9L;00)_U/:OU>2TL
MEY9L&<IL"C<^'%I+3C@R[VT3D3A:K1,!UF$KPTZKSJ"B$]/GJ_.O.MC _;YE
MK?[W@=@_K]@*[4?XK-@XO7\9'\QQ34")TS(-KX.&*;9""^=E**$1QS5^CKL>
MV-DW*SRTWTM>O0D6#3;BP.',,KCG3N.5EQVQ8$S=:AG0GLH\JJ>G<WS4ND-#
M8%ZW-ELO#96=\ @G(?V5A07J]XD+4(L#3I0C69(D9L:]QYEEAS1BJ-ZJ\$6!
M>KWZ 31]==2U4\=_/>L2P'J6&J-(H4^V@2]<3;%Y&H$AQ+4O^84F#UQ2]OQ<
MG#%RST8);&K"<]"-"Y^=^DEG93+Q14;/<2/M%RU#A)'Q:K.TE]SY$R\%5+LM
M3Q..:0B(P(U+\]PTO<A4GF+61G[Q'ANAA]S='Q&+6T--K1<PF0? T#E")Q!%
M8TUEZ@Z-.OG:M;A?FD*87:N:BDHV(1V7QT J[O[TQ0&<=IB/M(ZD/V;SZ\ !
MY<92MGM.MI<(:;B1Z9>[ISP5W;;Z%SM(:)B'P8:)\V[^4,@.M+$\B,CJ6;$(
M>NP\FBJ8HX1EB%!!7<42MU5D1EUCL*2R4=V@.41CF ?FE"!TFX*!F#B:P-@5
MG@0^QB#.-N],D5[O=LT!/S1T)G(?CF.D(>6KP3N"@Y!=84>-CD^1RA_@A]YB
M6H,ER2R%*GK![VD8@AC\"%;,)*R!Y<<)5@M$>17%VBS5?BM>(]HQ(_,,9XY#
MC5),SI$=-8M;7.C#O;+IV6;2-9W@.$(^,_'BX[G:$P)_.+>7V8(W5[O'\]?#
M(O?Y<'[PS^/(#2SFU$O?HZBJ#=9(#S[&33R]!+0U5XC6YDXI9_Q:/Y/:>GV#
MK#U<:6%ZS4<R<3#B. EI($3Q4]@A,LVE_0/93F_<PD@?@KP^S&UJ/'U3X6[O
M:$S&WK[,NXO,)HI-&$$35U)/BM:FD>NG$KQ2#397^19^A5>I!/$/!WSB^J8L
MJ<WN2*D"?;V$2TTA9:IUX/U:7Q;V6S6AR3AM^R6P);N/)3)\*&Q43T5G.Y[G
MT+O1GSQ(AT7%C$O6CP,178;C4@2ND&+#:66+_"\X]S(")X70RC YL\+YK?.W
MK ^^6OW0UI )W]S8&.I:=2L2RC8MLLC(Y1+QUDM)'"_>RU78D_T@>R,+)80X
MP9 95M:B'W7.3W,?^$DE%_#%IY6_\'DR3W8203''X);9ZH,?(G,?29F3('FK
MY\UV$R1"BXAP4?\8AL3_4*8,S;+J'+OAR#KH"!-*?D>?JSDZ+UM![5O2;,FH
M9D=GO$EF61TO6L <.,4=0TS,P' ,[W\&>>]66^3S0,#5J\_UE&4W?]G0KU5N
M/D^,*H'GW&MF(%M*9(F4V&WV;+&GS6BGJ=C5MGX6[_6LLC3 '%8':41A^Q46
MWK0;+08W6&H>JJ&$E"\25Q"FE5F;9\!@7FXI#=O2605;?J\A$DT'@7#2IV;F
M7@2HD#P4K,LC)R:_PS+!9=*CFV4JN?SKOA+H/I02\JFW[$O/KWGD ]>A_HVY
MW9%@=R4;S:3BX/0>&["&<'Q7TZ B9?M+!^@=+T\[Q'@K=>)*+ZD3,]Y]#I<$
M[RS?U!F)^7%F(K>@%HQ^,%I[<32UY3V!4G7E ]IE218]1[:;/>GGC84_&\ +
M&K*==;?&H@H4UPRGF94!D4IRM 3C,<92LOBOZA&5NP'%;N'G!E512]&SJL]$
M/%V4]8UMM$@Y)%8;C:76E>)RMO?VK%R6<F:*X>9KR-A2AY(5#1..\Z:CZ,3F
M]AA]T.-J\ RY!K*UOU\RS[;"<_W(T]W\4T7[M1R9YV^4</U#KZ5*!FMP+:6$
MIS%'VP"URJNC%]6?<A=^BS(G1?G1 +RMUX)\R(PLSW:::IWSC*V-1NS=!6>>
M4-#&VG2N (C?I[W#?X&*61"N(VC3SEZ_;J.L596L83M.DE[-6* J10+HLXW'
MT=$RL2F>:<"H#]3ZNV>Q[+"6U5?&V(Z5#1?J:TY:Y:Q,8*2MOD[1-RJKC@@7
MLB>J>[J71'*FC'YL]=^DB!J0>^;EB71"F?#Q",\P+>F/W15=VLYSB9CM_LKX
M36 )[W#'\*O7;1-HR_ &YNXHG'<7?O=)\^[(I,Q<4L]DFBM+\N@Q2HCAS+MU
MH-BT)]_86%$J ?5H66G!S]Q6H(51,I'G?>CP]O'8@!W,$X.7FZ29%#YN).NR
M\6M.0V_O31W8P0K#VV'E:'YG0_\I>.!N=?2^[)$57WR_KGV_J.#QLE.1B=!B
MQU@QX9QUE9@I8Y6&FHI-IU>+(R&%9-+NSJUZ7+C'\+ ,84NN-:+OHM1=- FO
MV)XJ=4'TIJ&ANH7MWI+C>",5$*^8)TV%5P0R5>]$[LN0Q"\6P!CK--5Q<]Z\
M>@X.^W'N[L+9)92DL5$X/%.M,3DV-3GF?4Z:L&02GEC>7;BA7_<8\&9F#4"?
M_!774GPY^42*>*0*2E.\:UO)12L,08E %#^-@U[WQMP4LWD@<0D@D+*/TM6?
M?YV-29$N*2^:W=P="@HTE.<,T/4KJ-<E)G8=,!I%4K?6B"2=IVA.Z=0.5WX*
M#FC\P/Q*"_0#%T=@P%X+D^GI(S&5VS\UA^#E$ZX6JJRW\JG>;QK;F.YH0#:5
M+N[8*0Y7Q,4\K@]>R&KTFZ>:HVI]A&=><PC7HUSSH40)6"R8@.2;0G0;ZVJ&
MEN(%A^,N,!?H)@JG Q*!<+]&\EH!G8QI<X4%L]4!A6N$R-#<3Z@D$Z\$&VKP
ME&O>)D=&#4CKK_^\HF:DT %P#^IL5"4WNVE%XJ,!>N;'AG>$8]"RU#P'UPS#
MN9>WGHG3$+/$%"O2S.0E'@ ^B3^+F/PJ36Y ?Z9?,JZA_D#K%&,1%6AKT*O@
MR:MW"8B>.R+DN'JZ<@G#BLIS4U<*WLF(UA,,D#%L8: [/5\DV &Y.U$K(,(:
MQLY\'^QO4BM_.&V:QRV13UW:TR_S@I(TW20):7Z[:8^B0PVWQ4=;8SBL<!C+
MGM3<]="O5R=5,Z#6AGL<FQ9GN5%"=,.EY=1G*B?W59M[S^E;H!0\1XU$(+%S
MFR,0Z^.%B5O;UXE(X6:=1:B!Q;U -'Z6R'&N4YEZJ*(%+F>\POHUEA']&/4W
M']\_7Q4&,*4 X'?&OHWXW'4P G'DF73=?1WFI->S7N!8D!*KM^VHU<OUHXA3
MVCTEHE9*=A%,>F<]WJ,RAK^ZSN1'1%B/GQP!3 NBI/J\ZL. O80<X!(07_*.
MJ\5+TM5[X9R&O-^1+JZ'F9;AP-0"">J<O8LT^YC^T[;RNLD#?H.6VT2U-9T@
MT]G&K6AWITQ:#765PA3=<M:'G4GA92Z8)N5?BN\$270/61KOXH=3JI--Z$>A
MQ!9OS29E&!K.*0U_C/3EV KW&.=! H_#1KF/)*79VT13G[1JG#SM%50+O54(
M,X8-U>;Z%>--&?'FZDEY$X8I2AL><GZ7/E"&JJT)DS)98>X.\^S&:U/T-TL]
MN7'W9,= 8JT+VXZ:\@^A15][]DR-<=TO+<2KG@=^7B)XN.VI+Y4W&K9'G3[,
MH$@[%0]Y^A,:QRP;AI>SF'Y"[L8UF^&W.[1XM)W1$*P^T7GB2T.EW<5^ $QY
M:>=T;,%B]:[<ZT53Z,5ZT0C&QP*E;Q4.Z9/B<SR&A<]RA*9T<JF\9X()CVZ$
MAL+<;&3B!DT<?G!U^SP2$ZZ(;<1W#!529#<RC<6&R@H >/Z;F9H+:UW#>(Q4
M+9_ZSV;L;.E,(3G2_82QG-[OZHPE3@QVXK55,0&V7.1LW\AU&]%O\=+O7I'S
M87I,4U(A/QI(+!*6$B+H%'MO6KTIK6[:*$=W>!2;J[]!_UI]O9=(R3[K@ ;R
M+0?\=<KRSV\7__]\\4LY%[!%+/ \6WWRPF9&67PY'Z< +30<F#1?+ # [8O8
M82#=0\^-E?D\[-Q'"XY1R1@7S$._!3BEWGAF=MWR01LQ-T\+$\9H'/*L-7?6
M+/H2X.>>/T<W;HFQPURK5J3X@J6)N$--[A<E32)F7K*#PG-$*-<V>[?F#J:[
M,3W^*JDBT6*A!"YOY(MK?+:1%>,-FY.C@?ZO3CSB=II@ULG")X)%EJ0CD5PM
MS=:D'TR94?XV"P,,:/$F/UDZE(M9A:%P.+&^5IRSY?Z-35;SDR"UO+U\P<8*
MJ:F%O7808%.V[!(0,C^"%K%#)._%*(_O"',9[(22JY0I&7S8K[D$&+AW/NSP
M%D'8?3OC:X,'T;$%+&Q0V;!-WGOQ&=KSJ-<@IGNWJQ;>GQ1FOC@7OB/E.#^(
MZ-$:KH1]%/N><.8_^3U^+'CG7NDTB!!OVT'UO/),#W'>QM[2=&M(^!E4H&B>
MK-PC-?=T./Z#PL^5YO(/<TQC*,=E*[X[T&^)@K*'=(=U!Q%!U<V3T-M2#D.D
MLT;3BH2P8T=V%.&AQT:'B1J_-[E9P"7@:01>S(=-ODI.V=JI0VS$:@8><][H
MXV%.(_WH!<J4J5Y*>3/^I*+NW-/T]2\Y %MO](T2OJ?C4I0+Q6#="AM3_CMK
M];[+U\"T_4J[C9#-%//V!+IK2*8<8Q5N?0?Y&9ID/DR?63)& "$=$;KW9H3U
M4];(FY1<U]#G]TJ[22/?B1^O6[:\\R&BYM1T3%2;$ADW[6H$AR)'=%_0*-A6
M;Y3NG<F^?SU2'&/\TRDDCX<<])#MH\#Y8[=))<_0F*Y*'230KY(><AXD\::0
MW*QD2^\3 U=I]P-WX*R9T='<1-#2\JP48F;<W]G);\!PT-4;]N/'I[1337?S
MF 1I29*XP[7)W'7Z&%--KL!W-=9EF3(VLHW#N0J#Z1VHR2@]"O,3V0-9 ;2A
M5<'$EM\-IZD4JNL?E(]#/G"F9OG"#OJL4(Z@\[<J/PU"!DHYS(G)=MT_0SWW
M3[;,'F%^T0W-HC(5!_=LATP()<TJ3(RF&,=O<AP05CW\QFH.=!UK>#H_T$$?
M0>*6"QJOF'HUG!YM;\73\#XA57IB&;>%&6H:=];/I/?@.<MV M=*6;4Z%U_/
ML@\(_*N+:D:QCPE2O^597W$)* Z1<(Z8>CG",N+4I[H\L:]JPZW<\\UX^6!G
M8S(KH=V4IBQ(;GAQS)R^?ZN&_)$:NRR;T,]WLH3G!,>?D.'%"W;^B?V9&;^D
M1P^_,Y/5D9,Q!+Q\Q$*#ESR^4OBH\'J&8O/G5S5"QJ ;W<IOX]=2!:%Q/L[O
MY[=)1)-S)6*"-:=R#SR@;;"<EV[#0"4UX8T6-&RZN9@TGV=)HC+VK #DG"?E
M&3^N4\8:$37CBGLQY'D"U[B(LG&:@GYDNB?0XG 6\BOFN#ZV3=@S_<=R-$@<
MG0^U (5X$'S",$VY6;3%[V3/60[RP<B9R;H#:)^#"':9CK8O 20B7"'-MV>+
MAKX01()D:M56O<0"OSUSU'3U']KQ*BD^"ZZF6$2B7-6T@T-'4^ HIAC#L]E2
MFX6+>R<Z#5$O*BL_94=-SP.N6V,@!.VFP"$O._-CHC%PX:LX4Q7M$;\?<M?J
M#N\"6^LW\FIYO>M@?(9]3Q/*JD4JFL:E0-_F:&R/@'2H(/TDG3J8<I(&]5BB
MWK>IY;P5M7T?E!UHH21&!U6X&#@H\CESR'SXJ"+\)O>0/JO2:;QL$N>ZZCJD
M'JG?)DN*^M$_.:5==HNQ:8[OS36M3( #*4T.RG\AW'\1 J[ALYDH_OE1Y?NC
MMTJ;&R-,ZUR_W)(95F@EO)M4P4,G8(Q%OS+^Y^%L">OBD_+&DA6?S6?EE463
M)G4,Q1'A(BFL\6U:%?'G[8-3X(Z['Z+PAH6?UU\+!]A*N!;<\8(T?XV7OCTA
MD[O(*1?/_!(OJOLV+4\RZ6ZU[6CZ$E]@U*15C$*F5:&GR-*#;I'V]3 R0OFR
M&-]44+$!8NV;#;T28CSHL*NV3LBR_.;.[M(K<MNET+C.&TMIF^X%:RT.!WUV
MPRM;&<T*8B#!M6/=E.(Q#$3C65GES)E(R2I)+7)+>UA8/463![]7XAW0QI"A
MD.NVCY9HJIM,"E<!JMJ^T)J.-3PF;?..56)JNN/M.U/1]PT^!+]F8;CH&\UU
M192WC8_5I50<!QI4<E*!X]XR;J>_9X\X#E-<VOMP!FRWJOAU)&?/V)G<.W8P
M65=8LFU1 ),S4*HBT_V0R006\^8;!*MO%6.4=1&G'_)&/V3W]4:KH1O-1!*-
M9,#@@=*UR:"P7!37XO72QC$[]%,+MQ["#JXO;RIK.&AUXU^^^U$RXQDN $Z$
M=DB[>(-!7T><5 \ML^R;,!LNG1,L#OL"T:246+#']^+'D"2T1> 56]S/<&?G
M;G)4N<G\:2HT-&HXFQI*Y"6]J#R8NKF_]%2#28C8OF*PKLIEN3M@&>V?(SE6
MTD1BO1\VIV_'PQ@/<__PKC: ;80MULE:;')O5J-B)GI49#WZF2!PD7$A2:]L
ML/A5S0@Y2"2L-^B5O0V0?QX!JGI88 3O;)0?5ZBIJQB2&66#Y2CGS\J@><<B
M?$;%'[)#/)P*FB10#^VA%'2B_B^.U:]+9HU2O3+4HN+6PAV!?H/2'=*# B=9
M2V"LGZM_:$ HLVH[3<5'"OR[TF53R.-)R$(35YLU&\7&X8_%VP0*'PZ#XGM\
M$EPGMS(K9_O>.F)$4?X.<Z0\)<).;FBY@ASA<_DIDQG--:9F>P/$+8<Y K0^
MO,_^XHNSNWT^1,;+KM!HYD>OTT_'6+SE$_'^N7K3J"6L=K'PBGKP+;G[X9+Z
MI'CQRP2A?A*OR*:&&W41>ZT\N*VSS'0S?B"FC)_N=]0,H3[B*XB&5$GS_*(%
M,R(&J?PI?=?J&3C$1T:I\EW-ACFSGJI#(<].=J5+U<E>+I]%_M2@:N*U/K>N
M(:*K([TJ'CI#3+'7EJOK@N=\!JGHO#(=)C>&U-X?XOLE7P*6,AHM&<83+(^1
MUI< ALH05""T?(>E^LTA3P-T.VY3;QBLJ?>+[T"JJ%GOF?<:7QOH)[:K6)5^
MNF*&XC +%3&[Z76OS)ON>/''ON=AJ!2Q' O$N<L:Y;DPUV$'1,N,\I3L-:3(
MMVB^$@3TUM(,//!I]-2?!")TZ-W!"THQ]GA);/[:\M<8Q'Z@]=?F40&O7>DG
MB5PCM.P2?LA%.IJ,9(W*>FAP;4RNP9Z1.=.'/G49;XPHOG>1%^]-!]Y*@JC'
MO?IN8*B+D?,N[&V@/U>P-(H()3[+B9&.!DGDQ0WTA,VBCN"$0PT"WN8N=KO%
MT> W4($18(K<6K:'<%UGB'NV&M7B=-B'&Q/HTZX<CW$'^#/[.$Y55N>ZV<ED
MR"TE\C #N6K;"$@A\*V1ER;"IJ_J:"3QWFT;T@H2_XN"?0,IA0Q4PJ+(L%R1
M44IX@50WH%]U8Z#2JWSA$D"YB51EC:V^Q1@;KD>G)XY3IPX/E!#69I33REZ$
MB5@0RR"6F5)KBN/9BJV=.94X9WN@PH='#S/]L^6S)4I &C9V;)6'LG*'%P*I
M?49LAK&\!/&.B<B^-ZV+2XLB$]%L[=KA-S8&+@%&35:(O<X=-6=,CZ\)_+JN
M*A&@P3&U$@MM;N.MX_M;D=91O6\DL\--W]6RX^)Y)(X91%AI9E'0V_8,Z_X*
MDV+)-J(T'HUOJA,YA=E9CEG&NQ,J/-A7IEQRK;(W<3N^&+VN'6C@S,Y4&;$
MF^P_K8B^GSBV:OHH+.KDSL9)8>R0CPS(:I%HJL^\+?#&;M:/)Q1+#.>C Y2:
MNLNUU?:7@*&8-[K\SOFC.K%.:F9GZLKC'L\*"\ ;CTMRW[GX48:0*S/5PI.D
MY)!WVLUN2=G8+YI08<!A\IXYU36JR]QL\NK/UZ0'/5W@!F6HA07F]'+0<8A3
M2_]U3V^N+J<+Y;8Y,B_GG$G#F2]$<U*SZMX7M2]283N$ Y3=.C$?;%SO/[NF
MFZD_J:LY&&)1Y'8)Z$KE0$&I0Z0@+\P9](W"@C_V'%5X?9=[^/1G#;HPXR*I
M26C.&D,'L:/<O#-G'1W#[2J8C#!(R61/(P &*")YV]U"6C'2I9$,*:+RP1[Q
M1,P$!S@U=K\N 6IQ/-P_::9>ED4RD/-W5;[@EK(PX;3I066%-Q>/&EAIH%7A
MM:GG2."27O5[868HOK]UM-VU6 9\T^6C$W1AY:"7@E7)^K%$+#ES\"9K3" >
M)TN4*3,RHV/ #_X][-,-9=SPP#ROV_X6@:/Z#GP/%;JR%5J>QB:&5,9= LB9
M/X^&\;IS5>V@C$\\[6C7JYNX$]KX9[GK>M]YIV?@/6=[=#1@/UD5Y=4;*8>;
M#X]NXC Q0>DOF@6)F C*X8\4(<MAB[2A\^/E(&_WXG5][0'>%NGR0 %D__!6
M8L>\:;&Z(D8UA4A036 U'(Z>O" %W8RDN;WI(9AZ2YA$VGUYO!]8WMS>4RA+
M:N*FXT9<G&W<0Z'/,SJB\LT"EOO"A*\=&G(VX-M@MB#9G4K3((0-PIN&$ @U
MB2M@FBD9;CO:BQC5U2VNG2R--9Z6R)RL<Q9..].7) C?AJ>[E'V<$0 )WA8G
M'0;V?\50>+T8EN% /;CEI'B1(A#9(5((2Q0%.#-ZCNEDZI ,?:JPIWB3%%HA
MN1D_=V%98N5S%V6/!@,#QK7-=KI?"BG;RET;>9[,%!1(.026J,@D2;$/#1W3
M$*FMB_;(L=)6G8U/^_G[5HDTIQ4IQ;4U*!'A9F)7L',VKAAU#L [$O<24*Z?
MH9^ &7@6!IF?D?L2PGV6/)0N.\-) _S1J%2:B6!S/_5LHA/TML6<O,L(]H7?
MI<:9[J-)#OT8<JO=8ZGXK>MT:G [$A2\C>9\S7 BK_HJKOU="R%UM-(AX4-I
MY;4G/QNT1-XI=B1/0G8G\QWW$Y:D/"X!1P4/1[=?[^0?G$MNVFD;GDBLA!6W
M:TGW^CA%E&J):OK$Q62C%1''Y=FSUJ*)R8)&AM-)JEG].&JB*Z"+X^84&<N2
MM*VG(2L.^D<[M</:AN,2F)37%.0#GGB<XK=HW0'3I ^91EESX!90X4&P<9=P
M9+)$)HZB9,;IDJ=QO>+=A]DY!MK_]8V0MEXET?KAE"HOZT"\/SLN6]G33A=R
M7N4OEP O(*) V^ZE<?3T7$:I?L<S6S=RZ-SU'";F2FD8YE38H72&+O:9Y;@-
MZGSZG"[6^FM4Y]Z/N,]8/3HVSR@Q)_.<EP"[#P(FF\90P,,7*.>,%N=2Z^#L
MBWP2"=B/R$T$Z9Z/4@A_'9^V89=Q-4'D)>"D.P=XVPA^<@G8BU'\;((5+H3*
MZ1<ZL ,B</4/SU%'7"^D#"<\7CT?MH<\NYF;;AW,D4_;XO6\0??GV[<&OL?G
MZSRGAX*\T!27>*K"UZ_M;)M=:,8$(I[CNU=W<1GR1GS089UN,_ MW;ZO Y4S
MS>"JRJAB2JFK/F-R9K1W!J]G-(OR,%-4Z).MIYJ</T:3^!_[HCS9 TI$"HOQ
MF5XE[3SS#'GM>9O6098..1!Z"2#P>>CF<=(ZWGS3"VS.%)6V\<E"]$N><!C/
MLN_GA*F5.EB#1.KHT1<X%M 940I=9O10R!P0AN?6";J^.4M;7J6BET&Z&N@W
M$X%7<NT )"U>^"GY^.XXU"IB\L%Y.]-MQ-M4/!GZ\1(1CGM-(]VJY(M\HOQ=
MM@.Q ' :AL_ZXEJ5!=@R=&Y+]-;:',/X6@IL!W0NAR9'WD%Y=LY2@2AY@O9L
M6:M"DT(^ZR=8_H@?^$'ZR#[*S!S] #6%+61AEX!;P XF1IA A> GGKE[*HQR
M/[[>O>W!]&A+=\G3X&,WUTR,%W\E$!'C-GGAL]*9_A5H$G874[F>T3 WS[B<
M&.2[6AM+*FHBOUQZ=+HU!/%Z/>K./@RJ-5CM.6J3-SDZG[D$:&4$<X4>XD0.
M#3YBHB[(4"^PCE+Q,W@50TKO0/,<&F _RX8"I:$2'M>7#KU-&SR"1%7O&+2*
MM]"(;XP/-[H8)7&,.9-^!LX> M7@<?T.7'.Y.D[;\]ONNP+QT<J?T7<N/E?R
M!4)I8."ZD44Z)ZJ.^?AA%S;']]IE!/G29_K#'KF?=AJDTZP3=];OC8-\2^X3
MA<[C:,H^6"@2X?G(,@L@D'2<K;6;) 12N/DO-  1GTZI<3J?RA3F?K_F^5G^
M$/39L8WDVGEK3E%N>+O<>#28:R<7?5OU!4?/+[8S&#.JVA1I6H@DQ5 Q#D$M
M>3/ZK-\F9<A51C+63+6\A!)*";RPF[_0M'PY@NTS$LV=,.^XCR\! BRT!#33
M'DRC8GX5.4B+3SQ.-^9TAU8::^Z -X6,5,LFWA,Q__#U8WDQXGUVQM9U+%\^
M) 5QS3.QUK)V<1WT?=<+8/>M!XKY0+:V7G*\, K3MQ$V53F=?)=O*I93VX!&
M#SQ%12T,W$&_0 $IPZ,*IS82.PXE9Y4(7GUCB,7C57K$DNMQJG!LCV*!+ )I
M4/Z*2 61C(U6%;9/U%Q2OC_O)/O[=Z\V?4.LA,I<1_15?8) 60^INDZ>JI]$
M/K^5.14Q5FAM5.,T$4+G&*WKT#4RWO,"&=,VG*\4/=C(U =5.2EXT5B4KF-G
M6NAT">AY^A[EB2B40RE;.$,R2FL3-\I.N&L>-(H>R5P"4CR"VO"G%B7W0.6P
MU;@>6EP'E>Z2S 5/+K?X<X+[8.Q8W\?D3:6G2?7>&AN=_-:WGZEL-K%M[J]#
M2:54/6U7>!>&;9EN-;O]N/?RO6<TOIM^T.*8E!B)_^*4H9U33'[+,?50I7J"
MH_2P)!GOS>?7!V%IG5P;DA<24[KO%9S)^VB>+X!SE!6T-B58 PNJ-ERM8XK+
M/]TC11-?OP;T+>*?^/XS=WO:SA6>785I4H:%]N2&E!1R3L59+>]YS@VKOSU+
MY<M#&XUQ,S>_D.CA"[ROXOQ8#W>GQ#7H5]>/:P'(X3TGFL+Q.0HIA6SO3-/&
M\+ES3GK1.KUZV]0%4>)25B7^]M3< +C": -^UJ9$[5CTF'AE9<!"."(T;L8_
MV;5%V^ 20(*Y;=F$6^KPE;4__UU1M7Y1C94O.WS>WL3,H*7&41PR.>?3*.TZ
MULUEO.3VI$-W64]ZQKEI;$JS?K-J:*=^8CD=%>$V)DI74EL&YM'L."KDHG=I
MCY)/5\L7I[4I*W'O]$RMC( N-M.AIEK',!H_4#K2#BJ38_MV7^9?MG$ &):)
MG3$/CN,1/N$'5OM)-ZHWD)^+PV5'V1E([>*@#WK+4>"%^ENLA]\K1LZ)9GC6
MHCVX"ZN)99*H][.)W]#)[ =6[_C <V:JIYT%T6^'/Q3," ^76U6_KE>[!/1!
M1"#K[MM-TF/"H\/W:D<6 L&<S]IZ6/CRZO))T!$)JT^0L,9GXXOAQ>EN+GM=
M1H>1;0MOXIX1J5S?>/Q$OM#"<KF<26@*+C*K@!AO>^<6=C0ZM( 9M6Q_LP84
M'0R7E3,T94/9 #_!-(;>&&0BB@OO][T*"70G\T_K][BNM\14$>=U?SDF+,%$
MPEE]H!SMY_;$6URUU>>XH6"G<(>::TIQE*]C\R4JL[V).6F!JK! +,XJ;P9?
MPN'QFKV2?<6="H>GJ1<>XW'K3%Q-".%$[T.JR6!3:Q#5)^?,;H?7_*9W*IZH
M,SRO2+/OGAIJ2JT?XM[;F??S=(JFH1&V]. $^)[=,4SL\G62=OEQ-G8 "E:!
M@[W0#CL#LJ8:#V@VA1<W?M")N6[DP.#Y!D7E9$;VA9KP1II?9DUU.^.V8QL9
M4OT@H%OP_*8I76UMR./1(A[%K4WR]UOW7P=2\(K+\@,#Z,S:PR =J72(W?I;
MVQ)/R*7X58E_$"<(?=72#7VA)-=)ZI.LGV8M2X06*81:T,\(<B4,C_#4=W<_
M$NK:A"39!3AN-9,SCQ]]J**:?)NC3EFM432-SNY?2@8T!CTUDF\B5SVOJJIW
MWF[TPC %ZO'_^L!6S/OJ<&;':7<V?F74LA%3S-"8T+D#U?DZTJ!*%7H\J02[
M6Q%/% ^H)Z<TODV*E,#H47]J8D6ESBF,ID?O$F&W:F5#9?TC@3>O-%I /0?F
MTM!?<'#0-SH*NO!LCW@.MA&7B\(ADYH668W,_4*)A ].WF#-Z-8]4+"G*@N9
M\!-QCNL_9>\I6APUW'^3F)T#RX5*GB5>*# ^L!6$%_\_JKX[JHFNZS<(BH4F
MO4<%J0+2.Y%' 1$!!>DE(AVD]QH$$:5%0$"#%*E"@-!"Z+TCO41Z"=)"2:@!
M0G)]GW?=^]WOCUEKUIG9\]O[M+U_<];9)QM;_LE")UCY]R&")C##>$+MCE,+
MQ_3Q[4/3&V)K;:!9^D\Z3*/%% &VV8W63==$,\;5>#>5>$O]E'6H$D^YGC1/
MOHZG;\L>;E"W9(=]V>Y_!JN%'4T>>\JXC!8)306@=2TF=$1;L1O^T[%"Y8_'
M;@K]7(>(<  O2G0I*M? 5S?JZ@@Q>(5AM5>31GRV\S?<J0DF%72IZTM4JSJ9
M\I;3S)&SB44J[Z'ZDGUDP"A\'%[$L&]$;*4*4C1PI;YVOG!YX/'?E3A30C7I
M9FK)PA:(RK=?S.Y@T,4++B?]#HD]Q&KA:IC4+_.NMA^FKQ]>8O?) (((]&-9
MDRQ._UEC0W1!S(7>PW^R3\"SK1+&%KO&9Q*^0SB+AV>K(XLL-9PZ5J'Q_!EI
ML*"L'Q[X)_TR,.79]1W@ SUVFTN\P=8B0\.8@YOQG[SZ3UR_DGE]$O/I1+]5
M-N'0OP<L!Y*V)1/FZ)=HL>?C6^&RTQY[;/H-/B?"^FDHNOS0HD1=W_HE[48X
MW!55',-GWFXVLXB%U!US--G\<($I)D[+2O-2W6>6@JT398/@[3\+LE"JW5D9
MDET.)OP/5:NSE&*+O/+- T4H2G[/=S]8"DJ=ET*M!4]E*O>>@MAJZG=\L:!J
M*7JQM<\;5)%2U+P?:AM3GH4LZ<I?Q!N\,(F<*&\,VW!=]:!S#F><,#&:,-Q!
MOUR.H;$(U[O>?E* &XE#TG\T9C2_98?4X++[4FNZ$1]!7;EOJ?]^N8K@$;9&
M@.FN],\$]_[AX!:_%J;J"NXV1_XZ+"Q:[H9(!B6OO%A.O+Y,DLW-%C4@N#68
M-$I[KI]Z#,TTFG%6.WTFRC<DKA_H(V<E^Q7.VE6\LCN;?1MJJUH4QI\K:=0,
M<VBB/P.HUW3?;*:E9<F.$7=]#,WVJ.F2GU:F@AZ/%#@X9<DWXEKJ9N^7562A
M[]MF_N6U/\KX0([N)DZMFGN_"NB=+O\$2;PJ31BY(4VKLV/>/?ES^?5C_@1D
M3+GT<7G>/V@9!"7QU>BQLL*4/>T?1B6?$=*@I6-"*!=$6-=]S_<> WL7//XG
M__%(?1F"EM"HAQ>(J/4WEE 9P[U(?JC%,2P4^2JLE\4>.8UHZ2A9>%I?++\@
MF'LQ4FZ'IX)-H>/GYQUTU<8UO@$P7'9D "58V*E%KAE'';?>@)STH#%0?OC)
M3H'C1) E<Z65S;7!0CSSIPO4F?8HRVIZQ\&(?3F[B^1'#2WS;61FFA%M'KV;
MBC%H;V40'?NE:*.L7N#J&J(L@RBR*-^X=NT+)G"R46_6?/M2=LOAG'=P%9K0
M(H47C($I\((JE9('E7Z^D=PI.IM:B@+5Q). -6F]EDC48KQ_ZNL;W) JT7[B
M?3B65P!WZ)&\N,ABU3CIK; _Y&W,AEUIY3PSD1(OL0<))7S00G,<E=^09\W/
MT-[<1\#&7'TJ#>-S,4)%;F]KT(YP52Q&</?^RA#8=-3!3?SPDLYAT6;FP_!B
M]D/2/A:L3GB\>AHMVWQ-F'CVEL_IHT=-Q'7V$ULP8^@_C9,>,H8G//+]"6H.
MCNY1P&CUE5L+C*>=+J@#V<[(@(C\<Z^V'WHO4Z)<1JQ\#P[KI7[HY=N*JLI4
MH4<,MT!1)"$<,9N%J.-J6Z:NXFW9-W8'&,AQ@X1<")\PIT%#:,MDA4Z49L%/
M@@0OL+O[X"MF\[,SH<^<?9,NO['ZGZ4(6V'X"KVL8KK#]-8Q'1,<3:\&;RZ7
M_4S2LU#Q0H\73'WY"0_+0IG/'(ENXXS.,I8*:ANVP_ X5,BFTO-VNHUW04!U
MZ[NXQ5D(#?$%/B9&988OEBL"RREYHT\%@T-P$^3QG;V\O+C,U++XO44#$C9P
M %7HFC'1ZBS!Y03A<D<FA(GQIQUK?:_H>8:@_2W9:[ZPREA:HBWSMR\S7;?A
M+Q[X;I<Q=MD[ :K1KL<EH".(/OF_:F$%J2LU:1@.\<04S[!@"?"S8X^8X,6"
M4D*O?D@C.HF+[C9[M$IB;LL_E[D@UT8>GY4W6_)JO&GK-D',V!" ?:**._8@
M>]^V+$1^IQF_T1DNAU:1=XH5.[Z1^\3RUPV'LQ#;R<D>I/BSRI#6 ZX?1L^^
ME.5.X-5F*)EK(M;36GS/_[)Z(4 IA-7%40NW_B-8X6&7Y9M:T61"L7=:-CT2
MY:T8$4'O\U+>J=;&.GSXR\:,5$S;)@9XRY<C3_'BR14'M7PRX!S>5&ZQ\B&Q
M!8B[%E,DLFOA:L-.77NCO#!5UHGO 3?WPTF,V*3)&DO[8JAHY/YJ9FN"'CPX
MY;''&L2Q-&%-GGU><R><_;3\(*7U6>$7E"S\GTP_EI?60[+;M8[9Q$<3?K3R
M%A.AALXNYUWFWL^JG(L3-OQ'LAZ&6W4Z;VN]'#)"'XN9F+H)&M>.B\>_4:21
M^_5/DT^J'\TRH]SR>=:\B38&P49_PW3N*96 Z[>TZ\2S)TXW[GCK\VP7QF#,
M_)J5N(H^R:QKVGHQ[Q(!P&_Z'!R]SZ<97ZY[U6^\2@"Y*;FXR3MZJ,JVYIJ'
M#DMHCS:I.Z_2WENW8!*OERU.)IFQ(TOJ?S^UC(?;H9ZPO C4<[OO.Y<!HE?Z
MK?,@#E*D"3\<WC8<MAE]]W58'R2H=S58Q5IIXCCDAN/XGM&L8E,:TUW#K!!N
M1CH%55I="6B-:?G]6K:X!_B\ZNOM]@/%;^JY'2F+K+7*M/A!7SNWZ_S3]U5Y
M,[909<B]H%]+M'\Y^2T3G7EK<#>35E$XOO:>X@**?3M':%C9Q'9EZ6I_/J']
M^#I*W9$GWK_Q%M-Z79"VS[8G)F6$)7T%''<":TGW*5O2.=&5W+.>G9WO6(3T
M_2KM#EY.'?94BMV1"+7/^^WB::H;'+GZ2@K0*A7-\>?CLJ^JRP]."*-MIV$[
MDG,T]02Y5-9R<=G/%9E6;X@7[%RTB7>Y.7Y#I2HVOT(MWQ\<_AUJC@S!9')V
M&D7IP7"WOGTP=$DNFO/$J$VUJH1DH::%]H=;#B$RR.Y R*I>-H;+UB__.>NL
M<E%MTIZMTRG+/)?[CN-5_>='\)A5O8B[,/U:1KZPB.MS4L"3:VH0 ETPU-QZ
M7+4_4>3]:F%AZ4G TNBVT\^R#8N/:4^&T1P<[,6NC^'_]N^_%Z5$5X1<G"]H
M1K9[MO<@0LMEM^DQ&7 G)/M4U]MX;(5-+75,=U: R1HO<YMU:[S\GG^WE-!)
MA,O\=>ED83F#T:<K@C_A.@Q&W2(_[KSZVE']_L%MG==^"AS=CEY)7QT.')QL
MKQG]8SNOL##;%(^=%<]T+ )G,VL!/ZW7/?VN(_UU(0[0CTH:/0\H1;"C/H4Z
M_G#EQ 8.A4I[V/*]'T_Z<B6NSBU=4-$M)S%SVX,K5!G'3P9<;1J$4A7-"-@G
MB9EF3H]+&C&F0%?:;'LURF'>+\:M0KA3-QL29$Y(Y4TC[@?RZC2_\+2;^2@%
M_GA\-[5^4#A64ZL2M )^&.BZ#(U1 ?KES&J'J^@ZPKOH9^PSS5:H/]M29I9<
M6XQ!F)_ 09'63.-_!_(_*-B D8(9WV='4*H]?^Z1HWFPBY_TS!"'X. ;ZE C
M$SU%=MF^S7!>] <D?&!1O#G$]06CJ'#;32GFO=TD]&%YGDY#]HMQL7)Q9K%.
MB>%7GKV42;M#WA-=FOGU)MG#LSQ&G@<%+,)!X('S7,75 53=47E<IW"UCL:P
MIRM+S$!X:N,*GA2AAIP0_#'(4C:D))0_],8I:#_.'3.I)DAPU/B,JVQ>YEU6
M QW=/!(YI'7O_T,@ U8N4O^\&9^7QVS8GJ%_FCC<O<_I#)'8'@'=G,MT( ,R
M#IX*Y<9B5 $(:*N+1$067R,!X8QG6W&,K=FG"SS<V:*=2KUL?[J/>?'*CMFO
MCT*9OAYL_6M=P>J+^^O\Z./55OEP3B(5\K*JR1%#!C 26GM.9T&Q.TCGMW?&
M7WO:(2/OQ'&_XX@"#$:-TF>7689\T\_5"L'UKHSL4F-:$QN "6J" NGYFS!^
M.G9S'>[(+=,??AT]4M<_TGF=UA6#WKB*QO'H8.B:>;/54E9"X#.LXXON:AXB
M+/SB>A1W&Z?W=ZK+"9TK@CTCC*%,>+T&DOC$KABF8>S8[.M9/\.A5'GCURM:
MZ3V:#X/18Q V&^@S@DTYE\+T%5;I]^QD0%HQ;!&V 6</< X75#7S?IFI,29/
MH"?(%O)(MZ794H2/#GE?"U'C.D?[62YUUM-DTX=*"RBZB4]]/.]"%EV6:@'M
MLG'Q9$"TWCT]H\(E?V-&$?9@+ZOT-:<QLZ79-3)@L*#W\@*THG723@9DZT O
M3B =]<-PF,S7(4?(6S)@HF#D/X\?34.VIC&DRVQ<CKC]".Y"*VO=>99R_=G<
MU[.$?N)6-J[<%W*VNG0Z!TEP37 $'6"]R(#P$8)!IB7TS+>.#&AU)(J"G=76
M#GHKD\B FU@MJMNWO$A_WS:-:>>TI+G9M1ASFC""AK5>5D VQO\"H0@O+\O_
M>YN-*]@5.$\<>^+8R6D]E-LQH^56"=!:52S9:)_]"Y/F!CW?7,*8@&I!6_^5
M-.!Y30:,_+7KW -7O)[N.3H"N;+E,2U'!K3,$5TH<1M:@@*L@J0&><)TZ_\S
M>VE%YW\ 2XP$QV+''!X1 O(V+G6 !"Y(@O58J&"1D[R!Y>P3 S,V5\9?W@K'
M:AVED+? LZ/Z?PT4(OT&'6[Y_&OXBVU=N!SKIP+MV.'_K_3EO]9M_ >A=*!!
MQDM35/GB7U7_K6/U:4DR0#P=>+KSM[DH?)ZEL,#\<D!__EOM!:09,J#HO^T3
M49_W3L>L=8Z:%"8.V9_YS[FCNW\!U/Z?J&8*2^;_0.7]?QB/K#@5NL7^#JG_
M45L8@APAGEM"EJI)S%>'./^O2O_V"NW_^4J.N//+_X4)JJ7_*T8&_"LW5J#Q
MOS[ZO^J"33/5>#)1!EOZ/7RKGDC["%89<.O$K$=/Z@5TRS2;V2\JAT!IVDKM
M''M_0V%[&U1FR2:3;/7<]=6KXF=Y,P*D-9_L:N27:>"M'4:?]"#>1V$95"9%
M)HJXO45E\)7 ,%N@J.FC^0 !V?+$DIKZ$NVSKZ^=+QZ("?G'$B-CA4H3,2OZ
M!-'WM:/$:^-9.(=YEZ0]#*CC^,PZ2[B^(EDZYZG 1^C7IWF46Y]=3\"DFU<O
MU*S"QT WWAZ)ZGJK,IIZ8+)_I5**KIBZ*?H='R-&@LB 91@9P!8JEW$D!E:?
M3-+27G]E2_"0.19\,@*HJ41..7 6S&^QYL;XLR>E''&'IR*INP1;M,:&/M'?
M^2W^B,([$/.=E#H9&'/"3IAR\T7+*\F8)/?XU/8(I@2,QJ,%BT,E",A\N*D^
M#MJ54W1E5V8N,ZIV.;0T'.F5DC@;GJ]0[*YK3QEX0Z 1;1_V6,>GT7WG+.B(
MDJ-,3,<JHTON-IBH\JET'2C=E"WD=:1XNKM8Y^Q+SQKX(AH/_M#T:/IM$-.L
M3O2)<G)):P*2A],.0J?N9VM'OV\+6WAWB]3'?EK&QY]:1K*KD]L+7LRXC%X=
ME!#M:HB/,82F4*[1=G[67$1".O^&PL>J?(9DP'M_KM>U(.];&QJW:KAI3K<2
MIS"'V^$\4X50<YVI;,MXNR=K5Q8JXS>:?5E!#!:KK.D"23\S].F;;%T4OP;%
MQ-M1UB(-JR<T[586+(]4(1I@:A=,UWGTP5('FY1YQR\*[O@( ,\AP<30#X'H
M\J#AS^*L.!B\(_S@MZ;A678P7I^.,*B+2U@+OE;0VD4O\#S@;[#HDT5//3%=
MZXX,\VD_?]<B+9"]@N)P>F.;.J*W3'<)UU &X\F &+N& %3:TA^[8*TH/X)-
M_";IP=1&MF'OT#6I4LG?Y<KKWX"?]HA,JPDP*@?T\Z]_UAL>&>ECZM 4B*6M
MPU)K?MQ4S7EY :\*"IQ)1^>52CV-$B>^#K]#$+<(,S1%C;NG4F<ZY4OW>"6J
MO]8"/W-Y-@_?QYY^>Y60.X<>+%HH7B0<3(G[5OZ<!^>D37[K>[[Z_/7RZY!P
M)'QYGTM[%4'SOFI,KJ38*-F!>SDINTG7N],H1A,Y+I-6'6-P^/JJ?=T=RM[1
M<Y,;/JO:3;=6\>)P[U%G]&[M+2X.*6;,W*:^WO$V9J/_X[J5 3&I\T/1R+6L
MAJU+OB9<2X4*<'6FU._BFZV\6(.06+@?GX+B5F)N(>%=D(=SB!ODQZP.%?R.
MF-^=LU<^DXR05,\LA<GN^)/9X4_.ONE>%<[BXNT= NJ".;LITRB_;"9(A\WR
M^#@!QI$;6#5F'F%:0>+E/@\V2??-76X!X\B M6#N\FTPQ*/NB$=O-U1WQ2A,
MR\J(U]BL[!W'6=B5V#:"UJK.IR-LAJCR$QC[G]<HQM>\$0>TGF0 ;=.;B<TJ
M"UK>(>/?9RZ'VC&OI2CN)"J%(Z/R Y-Y)'K1N 5]F:KGE-$3&;=[Y##4'!M1
M9Q,GM2XZ" 3Q=HAH$2OB,C01VP-+Z(9"=PK1- $O6+M>FGL.2#5[LIW!T(2D
M8G/=%7AQF8Q<9MNZ0VB0+?IJ8YAH/^FN*_C-=$W&G"EL "1-"Q'=\]]J9^?-
M:H;KKPK&9AUVH+B.N8JO4Z[7&M8<$DT%H>9#0_?%]\^/Q1Z;D@'@M!B/92N#
M;A4)]X-M%%_B<[[4DUZ6;H*AJ3ROU*2[#'P=UO_4X+132K)]A(JS8!G">DN7
M;K+:;+9"3_"!).$ E.F=Q3QE?6C9VM0PX^7SX+OE(_\>#(J;#%!*#%&8\ZZ7
M",F*PGMT*S7A3'\+%#@&.3X8;.A@;_.)"!)\C2%=G3>I#N^3R@?62$0QBMW1
M?)[TP4NX"]*DY]5(7&U1(:2O&B'QS%)Q[#78S4=S]^OG#R*IJ5[S8@X0%7]G
MM&Q@=7;W$A?1=+2%WS4M8)$#UY(J(R7B\E";R;I\^2P![/[GKE>=7>A4!MQ_
MSWGG2!N(R"L7=@:LC:,EQ__-]+\&J9DND,O K3R_@\H,3%( +DCV07(0E@@I
MP@Q-<'=K3(TF1\B"MJ?RLI:@1Y<Q2_E6#51:2L_T69*^<=GI9O K)[Y')7(_
MEREFLS58ZK>B[Q;DWQFESB ^QY67K=(Z/@_<<3MVNR>3:E\#>\PEFIEAR4"!
MH5W"E?:3V+'.A=VO45[S6CPY+_D4J10R?LVUK3%(9@<?E[Z<Q)LJ2::X':ML
M+0OK>1<+[$L0@'](6LGF!#XKT@02?Z,Z4C0_06QMO"N[\74S4 ';BS5P5:.L
MQZ$_;"3W,*>.)>S\C/%-'O:LXVJT,:G;##P^CE3('V%NCG^K?Q+&#]-=.#[<
M"PK$[56A@O7RBK9.JKC@&F;O"4 '!Z,'_LM1?6I(@][EW;V,E5VP7N*>HGU#
M2ZQ3N8._ \.5C+Q^:@Z*!DAP\]N7HXG.%^S'U.EC*4WEIT2C[,6@":)<LBA\
M;M#4+:^AX;:%-*/>'=.IIX!(*3/F#42SG3.0]CA.FV^"XRZG6_R^#^U$?9 #
M2+Q-FRK>;2/K$HL.VY+LIHLWTZ?0:'%K7<:>9>D*=C:[&HRY^6XE+PX+99E1
M?UYC6-=\/4_G30?B3+'"M2#+ R$:GV0L0L2LQY># F[W'\Q%#!YB"#& Y:C3
M8!]K^/2[Z?3*3Q(4VH7EQ\9;$^[OC?NV/#C[VO-O?;CSFLEPPGEJ-%CGT5^2
MQOY2@YDB&P'I$\'$$Y&_+"3ZE.A$?T[W^/:3 0OE[KRVX WS[DW'^\4._ _:
M_.%C.;>@+G"*LY(#BOB;SVD\6 @E$QV<OO)LDH,J:/JU.?,VBB#P1#)UD>*^
MM>W*/G?H/X1HB%]!/TOK.S]1K7NN7 G)WU[?N2TBA\8F2R:=Z@8+)JJ(^JP^
MK;D8DOOC)MLL_*O6X]Z>UK TE[?"?</O)UMFX8RX<(070G_5@U6'RZ6J\\2I
M],ZZ<B!.BT:[7_G[$8]S=WY3^QFOH5LA(:!#J:7,RRUW6^W^6-,\=C9^O'9,
M$"3C9,<!"/K6Q@-?\BNSU:[%32W^^*G#/<OW:*ZV_,E'=:Y'QZ#I.M'LF$6Q
M"=OF45^Q9_.!K@:.8EY2V7+=ILDKFBN-:8*$\,WC<H0)[EHZ/% V]&'9?>1W
M]>=,-&R)&LI)%XXT%+L398K:SX8JD%!Y OBG\[2UP%,_$)UN_H)5=4N4_XX5
M;>7;B'"?FBPZR5%>5R1^I N-NYAWAM&E2WP,U6$.]T(^?^#U<UA'TF;& N!8
M8#@>RK,Z=VG>1DA_B;*2T.J8ZWZ;GS'>] !ZR%/DK,A]C/T[AS&6^H$^H%&+
MDKBIJ2KM8I;8O8ZS+I=?IE!)"[ZD=:9X8(,B1^&N@%Z7-0N.,_3)F!\]X_;Y
MY83U=A)[ 0,3X^Q[3[F(1G6^ 4J%C2P]EY@HM?O;).ZD4ME!MLE0-C<1,_/
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MG.S6S>/I16W@TT +,[5[N/5O)3*T;]%I6Y+1YS]>TRE/UXJN@68L,(B/,F3
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MA)29H]<3"U-D-V# +M7'8+SLCO')=)1F1>IR0VJ1FN_SXM;[<LOTWT+.IQ^
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MTNVUOK^%UVTE(_.<KEJDI,RV>./I=[EP*3VS92U)^(SER]X86=M[G9=%'C0
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M)MFJM1D*V(AJ/TM'E^GDR60XC2O\4H$],V_%DKCJ#]B(2K9MCRE)C-F,7F2
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M:OHJR3,Z=%J[#B'Q\O$,*'B%GA5ASP//]BB9>7!:G<022<(?(\;=XE)XT:@
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MZ1QM>%H23R3PRW&1WH)TM7R"3L"$Y_YCUDRC8&0.MV#G[ON'.$.&-K-=JC<
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M51FW1*LH*TSW5;7S.L,T5YMA=4@6ID(D(V,.'#N_,_FD%=$R4KEM9]?"]5U
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MJ!E#PG8&S?;$''3NFAG&N\"H6G7M\JFTS[ 60XE+$T69FFA;G6LA ;<#X[6
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MW@?W\9!&-P"K_QF*Z9/_AD4"X55E24OWH(CC!G#[F$F8"/:I$<.C&X#9S/R
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MTX\AEAUM9&B3(3PX"[2C7FR;H?^5,:OD7FEHE^VVV7[V#'#W<O(6,Y("EU*
M!%+O!UPSY=R1A'*L7V8L4'U>*9?UDT:7'#[WT58MTC2&(_ ;P"T;:57.ZW$9
MG9(4V8@4H B6I$@.OMITJPI_$G>]>KL<TL"!NT-W5)R#:FHBIVN[B-S2-DRJ
MTJ@[S.U#,[05:@".HPV7*P.PTX0OW,7:V M?E2FF"^P!-!3V&JY%5\GI]06
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M.5I+UX08.12Z/[7271:OWJ-<$%MNVPF75T@NE(Z![(D#IZ-4:T;]'H-)C&\
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M71<=8:J5+S -E/+-(S)Q0]N>E=[U20!*OMJ+!<4F"6RJRU=B:@A"UR7K5S<
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MKBXI\YY_^>MC,8\2S.ZC<_D^;QK9-\^@EZY%@%T8D^%$ UE)?LQW.L(\EOU
M7KJ?FATBWF5;8KE%ZRS+DGK.R$"9K*L\\Y#I@YYX]WNU,>^OX%31 A6I@F6Y
MT^LV^LH]BWRD[ '[8*7K,N6NI-%$P?BII? A]%,)3UWG;4*W[5U_LSS3GRD*
M#=-JJ+HXZ?+RUOVG.0C!P0]YRH\=?U KU-7*SK.ZN8W')*>^[>R:;<JZ^F:6
M,Y5*>#(>7 >W70Y(9H*))?P-)'Z"NAZP3@)_RUN69AP1^[V>$>+\:E5ZTHB
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MR.P2?3S;TC0&\_]L-<B<R0)-W@5*G1R?;&)[\WQSZ=<XJ4[F="P/'N4CG<U
M4%$XVKSCMQJ\MA.I=]U5[G<(Z^T56HAJH_[E-7G].'5SUEF2^]SGM.Q/7WML
MH9/>DWDD?=[[JD3WQI&9BV/Y+?OA0CUZY?0L*:NDYCIK/;#8>H#YA4IR\^18
MSZZ=MU/!/\#'[K9H.OV\T.5YX7Q*\0:YLJ+Q"K[8G2,?::&1]TO1$4V7:C"K
M?<@M3GX\OSL\:=T)A6X7KGG? !P-$'INF)G2R8$9?3[/D0W^%K_D7%Q(LW(
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MT\/E\VC@+;N@/I8);^,O]FZS:$/NSQ(]\D\L5=<@4BZQ\K8*PVE1-\PJZD0
MWS;>]@S8:H076=[FU\P8?9L[3@%@V_A2 R(THXF)SINRAP9F0Y=1Y8TS-#<)
MWK-$G:FC2FC5=/V[N+T,'UUR>C\B**;5<I*>V(P>O2%20*)[0+N-59BZ=,-*
MEJ4[5PX TY,_0E7:1[4#%20F<[<IMW(.N_%Y(<B'"A28H(T9__%BCW]P,=>3
MK'P054>?FCQI=VM]G.T>C=O!NAK9K=@^#=4D&)B0EU2-F)TVV'HJ"(%;*_",
M6N?,PS(40)&J;/:$EQ_2]'28.0*D6OBN<0K*G],@7<Z9/VL/A=+QI3[WV7\
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MOC0 D7\"LR1WC=H$%WH/S%J>Z0)6ZL$YEGX($&DRY^%KUAS!PQPUG2YN/8
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MHEY<[=ZA7 J ($4!$-N9U#>$P*MD(7!QH7$G47@5^)?O080B<>0.E1X%,.E
M :S$\:$V!$"MVWZ;T8+;%  -^>9?$:2162P**  Y.)C$@"2+*C"147YDXX;
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MMW9L7__ X-#PR.@8?GIF=FY^@;"X1%L7 \#$L/K[[;JXP74Q,C,S,;/1UL7
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MM=N"-@J9D$@ZGY'FZ&3[VK1NY]W4 PR)AX(_J>DQ!\#$GX,9!/G<EJ*<1P5
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M=G1-.='&:YF*,AQ49-DN%! ="IR&J*@UC(C9Q3.7S";0AEP*YS ]I<PJBE;
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M)/ID9FN^RSD>AUB+H\35)HQC+655#ON^Z1O,_ .[YEC $2CJM_\'4$L#!!0
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MMRDH&-93<#OIOG%G53/51)>1$Q8-S]TC@3:G"/8BS67AA*3DJI&-5 Q@T%0
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M%60K[<=-UD-Y?XJ6;XF4TVD7WM-,O_=:RH^5K7R&OW_=@YI+68ZQ((&]<5H
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M@B>\U>?1/>Q1(UJ T7FR[[,C2!T@\P5HM;!W%X;_\R-E[\K^U#L/6>\P6I=
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MS..S5QH%6GL(J^B%U#1CT8T_VL[7S@6.C:#%S%E,*2%=,;\F]K^U\+WQB+U
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MXUSYTUXPJ06<J[H7[%UKR9/+C?I2!ZHY60)-M<&I;!>D-)6GV#:]V)D[-]_
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MVBB#P#+QVH:^7"-Z[Y>HN'<D\7<! ]H3X$8_$HUE]B-77"FBFM0%:FRX-?S
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MCQH+80W#--::?Z6Q5NBPN@\* KA"T"!=EJ5TT:BN^3<[?@I3KJ/<,1U5=;9
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M&'^90_J(&<,D2=6.AVRODYOGAS3N/-&6,$MLRP.1R=;-GO)ETBOJE6L)_MR
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M94$)D6O//#+==NWKO?X.T2_G+W057\8QWL8'>U:UIWAL3+Y(=9<"$#A3M[R
MUGV73A;-XPPFO^OL_/RRPT$<KKF1RN+.B!3Q"> ,Q[Q9$>KEW/?<YMXS&MR*
MM5Y0TY[7;VT"S2*5E)Q2[>T7G*3FN_2@&>DAF0],^B/4<[_C9YE]>(_7: ?'
M&]4: ;P9U3$)KV.VRPE>:I0_JIX5[C3_9OT2;BZ[:,(A/H/101^L&O_6-CFO
MJSU?V94O4<^V1PO7[$<9?;<X-T^ /4IP%M4\0XV?0OYRGXB<+1+O"\0(NA\G
M +L%_Z756SB"W.#'<['C2ZW ,^B8-T@Y(&Y]L]"@W$J;+%6BU^?#+\/6V^YX
M\@7R<[S2^V>\BE=7]L'#50=WD/T;J<X12U*"!_JO.1KN E\@0=0@&W-*N"+Z
MX4Q3WJQINY>S,_**A-F6"ILG+7%\O/$ 0I]*S%Z[;.M:_GVZASG%L:_]Y_&.
MZ@1PYZ?JU1,)HV_\"YG4=Q\/X\T?!)#.+3[[N$1RZS^-6/K-[&3 ,ZB&D&!+
MI\;17MGJB3O;-)O&+<)#)P!1@C65ZZ<(2E<).GZIH*.S43[S*?^HX^),1E9&
M1$+4W]GL_YF7R/YSL*+^UPE]X7\R-)V5$VYO%/RZXGT^+=^^S#-F]<@*^="4
M[\M &)E+2_!FZF)#U@ZRWG%IOB_F!# O-2RU,WI]-2F^<D+9B>;*A.R.N8(&
MD;E?U8*IL7; IF[-T*1JB4F[XY'+4_W;L0O:Q4W(31HLO?$Q2"M@4COD0O#(
M<(3'57DO<SAE!0(!ET4SC2X-[T#O3DSODIN7S2I<867HD&T_AKP;E"4^CD9-
M@"\JN#3J521<?MI:4"WMX*MQYA8/6BR_Z$<3U0Y-'AC&5^+ 6U,?A50BJ^$&
M[@YB)8;%BV0-D;,44V9JOK;97>3&:M+3G/K:]Q.GSMS**VYDL*?V-&^56!X;
M4$0\4<FG:RW6&F-\Q#U3">3P%#J2'W8KLM6KCO$UUG.U"^(,4KP33+S]SA:J
M2*M-_!I='.R/4(10-!9.:$1(^U2%K7NHNU*,Z\>98(9T!JZG:,O=UJFN'1"K
M,+C>S?+56)++ZEXP^*E$,T()TS W2XV952T?VM'0%KW!<=-M/.[R$O_^K?55
M0V?X]=%=Q 5@XOLI@W;1MR53=@A;)MWPH9SY*<VS1JS[. I,"E6(CE;-L,@N
M.4D=N!(?W@DIWIH[9!UNNKA9KP1W04+$J>T%?7@4U9U:XVGME8F4!\OAO'/1
M=G"]&6ZTZ'1#[X[[">!QI=HC+BWP#/]JN_T/,XHT%71.19'<YRXZC&D)T6<+
M(G5*<W #6@K1X6+WWEZK.[O7O@]J!^#2M2WP&7L_)N@Q=[ !Y)S !)D(A+!8
M$X6R)KY=K*T%")&W):D9)I#0]'QJ9CT!D%L''@SOFFO%>!6*71J]0]>MU"+-
M:".,+QTD;H<55:1=\ QLW2O!A&SJHT7;>O8U-WK$&72J_4F)L^7WC4;V0Z7\
MZ5.L5H0G1>\D"6B= %RY])HU&G<+YJA"V:51.3EC^H>-:?G=+A(^=:%A!X4U
M1^_V&/,=@;2>P>=P\9#W\HT<#8U'UIL*B^]$DZ)\F*T$L,9HCG#K*I1C?HZ]
MFF76],RD"%HY7N3-88"O7$$A)C"]5VHXN3@=>:%\FFQTN@Q*["#*_YB_IN^.
M#EP!XR8>Z>I+V?'YN\C0@X:0I46F<SH55EAEC!>RCPY3V8)KU2O7N#+@?'WU
M53=WU]<W8[1$#2@/S1$I$+'AE'VIFDCA%^X$IW!V66QV ]JTP<;3;%:W8@ 9
M:Y!T :;D/+I:(3%YIF+YHG"?'Y>=9'D5<W$NHCOG1]+H>B6Y^[CZJ_GP#=]S
MWG1>MFT@@">BG5VT;%C$[397MA&?U8>:J-+7H,:9\H_?RRELV\SX*U"I?^6M
M,+@CG!-,3-0IOSX.NUPN<6A52T5D[\=;5X;6"X7E\>S7NHV]L'7Q2FJS/1I?
MC>@?P9(@-91$J?1B<(,<E^R^A3-I'NAPX3CLQS"P.4@::7O^E/FTZ&AFO@E+
M>+)$L,Y7Y8HSTK'!ZT@.:@R#45GMJ,%*5UZ?P_[T_6?CM^7DWG, 5K:-X _J
M^T4KA+LC&46W)>WY%Q/N8+66JHJ@R_X44FS"K3+?@QN+H3"8U 58T885Q],R
M1[+6ZMV\>A!JVZ0&71$:#E?VA8E^27,8[>^TSR*9'DE^)B<9(9!UC:-=CSDF
M-Z,/FFT6#=RX"ZCFYCWOU=DH_&EC%S\DGX4D]P]*0:*-6M4'LU/Q$:!X@_93
MRBD.DUVZ%2!HL"(%UC)6:41Q:)?\O+M"+,69V@/K9*(<Z,<(.=0+=YL_-EOI
M6%*JK?3,>4)=^&7MJDGB</]Y]9L3L4'6*/?&VHKUS;VU@58WZ-.C3*#5QEG*
M\:*Z@LU+$UB[TLJZX;@?92V]Y]X"8E)FAP?M."Y6'&RZ0GQ=M"JK!W8>4T%8
M!13JQ$G!_?H/WWO*X(<7=KOD+9/W"A#R>_WQW39#-$M-M%BO?'/32;' O.R<
MU[DKU.T^3Q&!UQ)[K,<]$)"_JEI9;*4U7<R,%V*?&2F'E:/9WSY(DZY7R[50
MU>/<;O?V3?E05AYR[KNU_+,T2Y4+^8)V%,2R^DA@2C[&>U9K! ;7\'1CVI ?
M+'+H8CGOMSB#VQG&S:!3JXHF9^T]F%V6DP30RO9'=[\HJ7$8I9J'X&3-65=D
M,*/E1Q5>I&41R"M^O?3>5/[>PZ.-[)AXMVEEW8$*EB<V(U"]F0UIW7G&BS C
MJZMP#60:+82#V-%-@U]+3?3N(!/]RO?FF4F9%]SI4OQ1NWV7-%"SS:+9+)-O
M(A< ]3X*X89DCQH=OQ9W[,^W@EJZ^\B,30H]&.B+R$U>S-51&M/1C05@%2SG
MS2DGGM36&ILO:W6RIH])3 D5DP*?$W&TB.H-KE \Z.(?]IN%7F6@KWVSF7#%
M)8I];BQ#GVH.=&Z%^491 <1HI$=?)N5([*QP<#0)ZFC,2<72I#/:5:W74=A&
MP["\2(9O6VSBQL2@ (YUCVYH+ UK@K(-@\,L'SW*7-$T,"I,WTAXR/]%:^#!
M;4V25$7DM%&?XHCH]?7[BZ:2V[KTWE!LKEC)"8!^T#M6P10<\F@$?@TMMM\:
MOZ(],ZZ6&_E*;[WJU6*?["%SU<W6(A\CE&NR6;:'-<P+*M25VVM'0TX_\RRB
M9J[O#(0^5;P&+=;@=7$?X5 9W^J8)90G+;I[O<TYF3]"5F.^B0:SMEJ%7KDT
M;H?<8K0\>^^9("? [T7T/(BA8KTO=->GR/AA&?2!GU@Q)721/XT?!H-E>[M@
MI8_,(^M5\TT?\)2.BB3TMY ( 9JEB[5!@8>[:S+ Z+P5]\$G1HH3T\;E3O'"
MY[Z,@%( /FRBG(P ;^U!)G--U6\E*:(V!L6&I-'C>/\= .G8%9:S;IGA1AU7
M(,+$*L TTR:P^N#)JZ] D=P8>3;A\8I;&X^&BK6_*(8L9UK2QDC2E31?J7_Y
M$3]=<IG7>%B,<(."='SRJV; /+:]KK@?<L]HB6+YBMZ;>XKKH5<@#/&F!M/=
MWR>$<=\Z$J#C^OT14YCX(LQKCI;:%S&9;$GQ3P=8PJS/JJRUWNK+%IF]4/$M
M9/M.Y7!18DN5A\;MCD_P_L+)U]=VB\LZ_(@3VXP>)]K:/14=;-%UJK9USNL0
M#&O&=#M,N(??J* OR3<T*<UN:&C(>J7#34V[@%ZLG0VM%4M_YZGW>4QWF'=X
M<V\SR>L-3^+DLJZL\5PD7OXO6_:[W?,?9?=L]3DN -WUR0_8(:7+*N<R(@28
MELQI7+V2%U<?#L,5;J2D3T[$X1UX2?W&TYFE?GV:])5&+O3U5-K^S0J6.@@D
M[WN2H4NIW0)@;<J'73@7$XG:;T\50 >G9EJ__QI]9?2J]="&M4BCH]_!;OZN
M/Q'FI>;+NZ.9PZ+<Z//);*Q"''PVCA+K$1;ZJ =%"(ULSTCY0$T&YIP4;M&&
M[W.B6^S/%HJ%4U&=X?5*0"((<W#'^WWFM<M3RGNESLZE-,''3F;AJ*/FFV:,
M0YMI6C5J#7J'2@EV\4_/>PL<ZH.L47XK5"'[C:R^BHI3+Q.F6YT+6LJD'YWU
M6)6/ @<U\B8?=<)L83[P0Y_EKNO]*TQ=:;+/>WV@7DVALA>*NY%U&A#SNDK_
M$N,#ZG;[+$?'-7!NA;<&5["U)T)C6,J7&:)Q [-<=<G"-]MOBQ*S7Y2\Z'?E
M26U?&%S8PS+=_D*.><^9R*2SZV:8_7=45WV]MYM3N4;'5(>+I:!BW0]ZASX?
M#=[._-B\NZ$(=ICH#);R/S=[ G"8-BW^\%T\/:5*^)$S*5N)L=E%#*QX.9EW
M)K@0;'GCA52-^J32O1 %K,V^W(H<RWQL6/:H*\EHA9K7VO4;CZMHN"C$&5D:
M UZ%[;)LTMJ= )A=5<3=!-XHU\584J14<UI0(E8@T6-P<__S\<@B[Q. 2?W0
M[C&?^Q'P;2Y-$,56=$.K!\)B#,L$+%IHHEKM<BYIS<D*0\5W.VX(OT1[M(KZ
MM%55[?5Y6!T^6@4,=5%M+L3*OI/[0=R("BD2JYOW%=9,N=OKXI!0S4;$S5<I
ME!J;HYQIIY<D<<FJ*MQ*VWONXL//"M3XF;=^YQXS(F1=3$JX[])T8YV+2Y5Z
M104/W[46V@TY#1^M'TZC]99^+!@<!Y,]\_+HSNI8PEU1;<_P(UG#HX(?=F$/
MH=:=S/MA1>)2:D4W?"_-B(8_/M+O%:PNV?VF4_ZF;I;=4_G!V"[4W?2:2L"$
M8G7$^:T9U8=A,^!^U]TB*.0C.T^H\;"4*(EF1:6O$6W,GG1<'.M%F,Y.(8P&
MRX:F+?EQ@_E&@1U]=&YGH_'ML*[+X 0U#D=OS?-ZKY%L_D95J,KH&^DN;"'Y
M;D)%7V\[\E9IWO^VMVS:UVJ\.DE%O8ICKFMXHQGSL5/D\A?G>0Z0H!PZHN"]
M)WF;=T-J9)ZJCQU5F&OXZWF)=.I:FH L=V0EC@,#TNRW':X0?;QRN\%8\ZDI
MTD3HW=%[D Q@[4=&A((TC/6)1^VPNY6H*=[#,Y'/.-Q6SX^MJ_N X 0*CT)W
M6%9-^77K7FJ\T:&O?+F=]I;/[Y'.\@_((%#,\UH;4*KD0_F FXKKD>L;WRGG
M_"N/UNK="^MF0V8XT22!_J6(S<)U<=''JH79Y6%!&@U$[#MMFN65HZZQ="MF
M=.6CQ>KZHQD02/BDB_'5HW'@SB;5,4(1D_(HRVZB?:8(4"::?X!HE$HLZ7L,
M? '#T<U&;"R,23%5^$!\O3>FH>N\T9233ECE%7M8"/ \6C^0^;;/9"\0V1,P
MI$IKHR:<6@CV!N3.'ZNUH> ^]4,54%6^H4>#&NT-A8 @=95,'G;<[NJ+3HYS
M)B> EB%SVN-L8,_U5NL]N$O"?%E:2QWSKVO(9__-17O5 T7^4T5"?VPB_&]/
MYOQ_>O[=KL/_]LG*_I\1_G>W"1)6Y*D@N.]/1O](Q_U_N!^(2$=O!.HJ)[FJ
MV?#*^.M$VY"&L.L]K03PO)E;-FX(1"%5I/2EH[L]29_!PY$[A'?ZI76_:W$N
MTB_-I0 NC99[\5;)IR#E!E(@@\TP61* [?7SA4MB+BP<7T.2!#MN8*_)TH_N
MYVU]ZFH1D(-,=Z,,X!J"7\H/C"8?%J?:OHQLT\O4ELAER6V,K3E4\_*BB\ZJ
MDOQ@D*F]UK;PEXE_*SA\[P1 L[:YJ";M^E64_TF4/LGB(S96'^9NS(+4\7X(
M%'X[!Q:Q;YP"5>S7[@9\07:R5;<[58VR\V"\%GS(C_4\=XW9U,!02?"'CYKW
M/M?H.S8XF3$MIXXQA.WD;R1-B"J-JH4>E8B\-\ Q%?N-(352B\5>JBO6)HWN
M&/9$<VI3/E5!"%6BW)+B44NMA]DYK] K!7D=BQ:Y/8 FZ;UVG3$1Z+K-B"BT
M_""]B9T[PG8\=/%N*T7:?< >E JI]++ WOM%5)GB(Z='-Q.T[>3%-X3QX:O9
M4'G5P[K&JDI;)BV1OU39Z\>^>&<9D:0MY"'*"T)'>6L4R!ECEJ3GT@]'4QH:
M7L1D%W0N%-RLKT]H]FL5[C"$IZ0]]:](!NQW]S[N:!'X5ET70)NX<>T3P#^W
MR +#@J1X&5VX81OIP&XZ51E6.'=01R72F)F,!I,;IMS6'7B,CLX:>@+.I1U*
M\NSVDK2-FPF*&@;25^*Z,.9.2(T;'0:@$JFZR%?<\?=+JD1N N0DY#GN=WJ=
M'>JZZ,+=S7XSXP.O7V:%4QHU4-@ 0Z(])++XUT96K4/W][1=&EMV:Q^;B *4
M<_M2/S^:=\)JV]#%U6!WJV^*XUDQ'XS",PVI' 9_6&A@:FPPKD8S5)2P-5XF
M@]"6.S^O0N50,UKHL#Z?C-PB]\P&9*IQ:D[91@U2>#R B%?ZULZNU72F+!;W
M'-I*;?MV5,'@LU1%LL8PX:EE_2U#DP(E]VOOYXW9QO[20)O(P,TX1L3T)@RP
M_'PEY[N?9CE"9Z\1'4]8 Q.JQEQ7JWF365:]+"./;<(%N("YLKJV;;7WOT:6
MY1L=OWI[ 3XR 1Z3FF/G^E V_*8]#17]58T]82]>V34O2 0Q"=LM>.G'/B1[
M$YE&<B,SAQ95,D16^JI;Z27C7/7N.^4&A8+Q+W&R'G$R7YQH#(DN<<",Q*1\
M6.[%+]8%\,:&BG.R^%5L9R>]<8'.3_NTR3Q.<>'-"7_O6Z52,:&TPWWI''MH
M1(,(]-&<IY1P'7\JF&:V:*C+A<FF]&P <>P=^3XK-$EL^3&'0J).E>NP58QB
M='!=2#,_ZZ%>'!KX*H0V^7#FPG?-%B9>HAJF#N$EX^LUS+FQUC'BY0K<$XPS
MH\2L#^XP"8&*V(5B*%CT1J3(&9O*'4/CANP8DM8>Q<VY7.X73E,W,U.TMI4:
M+J07B*N3D+70)RJ &R5_Z6Q-,'KB,C.UZOPI;C*43)>SBQ_8D8@L:1CVNSC;
M\/:2L:DJY/(!J"U0R!#<_[@&%.Y-@S9+1S6.3O@40/PEE6ZZ\Y\#N39T/G@>
MXGZSZ=*N'$/KV&%JP7Q780]E_D7V)WQ6G:SL([I8B_K!8M?-]1, A>DR_<U!
M$55O&\JP]7T%Z_CD#O1^$"_*MI6\VK]<?#>N2NM+W],.53J%,TZZ6.A"G3C;
M#V;]T.MJD#>KDS56LZ\,2+7\MDNXB6G;\/9&TRCT%2Y+SPZM?]DQW_GJ0ZI5
M5-S%(.^+8]"+RTYD:BSGHX<E/VQ0>,IXFK<U2J,?-SE9NL!RQPTG3@ V+3#1
M[H,%6$\KNKAS[G%97M?\ZW(Y2QZ9XG"N\E0];7H3UT>[C.]LG4#AUPL@)5"Q
M3 A;\VUXS@L%VR':U5D:NV2'D-L-2J,3\D3"(N^S;'//CGT!2M3@!BO1/-VV
M%(4#]A]9]"M%G3'<^Q$S+YK<YM7 -)X%G0PR,:_&?,I]P()9.OOU)2F-!QD?
M?8+W&G*7*U>EVM=HN,6^X<'4<:U3=M0V0-86MN K:3SYY/.]A'+YC4\.'N?K
M[[- U#3T6_N0$,'<H?,):&/ZJ!<*L;6^:-.EM4U::HS8G)&Q!L3>\9N$LN0+
MBVN;\N&B.+&5B49$\==E=KI4G)S0>N&,Y57-'IDXP1EQ3+\LC=<\Q!2L_%I,
MJN:B>L37(VG&;X>["([RLJ'8:" GFX[AZ(ZTS2A;PFVYSS$-KZR+W&9$!KG0
MRF&R%% H[\ANIH'I%;,O6:6-Y\DYS 2(!X%<<.TRU,5#D4O&<M\[<I]^Z&2%
M!KSWKNK7 5[!ZI=C?*2"G"?4O&TM'E.G6D2]]8J2DX1\BIY>BKE^#-*O&RKF
MAM(?"I,RQ6U8U-_V>S$ #$2:A^$$T6+YN::3=J/GJ=9^7-H:KXEWZF)_.V A
M!V[SDPAL3:KU7>M. 2XJ*E?WT6P<9>'X:GDM5AA9 R1)$:G?QS;$<*3V,F8U
MM&D31AJ#X_?7LBZP7A7J7A]L&&HMD'RB=V9NX^W=-WV-@A<'_C<C_1\/,<AL
M0>7G8#Z?\N=54'_>. #[O]XX<#:3MER3F)G'7>_1Q>Y//*X9!M:OB*X(_S7T
MM!<8 8B:;+,FM38-C*M&OAK56Q>,:V6*6Q#1M4'F9CP35LLUZI7LV4.7%WQR
MSKP2620SBDFOKHJQ"A4RO=-NF/&,L[JDJBZ*IS\K+Y?+U)FH4)S>\P:(UF[
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M   7    86AP82TR,#(R,#0Q-GAS-# R."YJ<&>\NV= 4UL6-ARDB3217J.
M B(@ E($(BH@HB"(A(Z(B! A(AU"HB*]*55ID0Y2(EU:Z" @O7<2>I.$&B#E
MY=YI=V;NS#O?^^,[R?IQDG7V66NO9Z_]K'/VIHQ1Y@!G[VGI: &H3@$ 5"<?
M &42<!M ?>K4;]^3@^;D2WN:EI:&AO8,/3W=::8S3$R,9Q@9F5G.G65F86-A
M9#S+=9:-G8.3DY.)E9N'BX/G' <GQV^-4%&?7$-#RT!+R\#!S,C,\?_YH#0
MV$Y349TJH*82!IQBHZ)FHZ*T ( G=M)2_7X _GI0G3JQD8[^-,,9QA.%\K.
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MI'FVI+*) F QN5B@SEY:U=#\P$.U S@5HS?=4>,K.!I0ZX>9Y;_YO*\\2<J
MWKKT?H'VD'OAT>%LNW4)2V"TH"NF>XA,AW]0N26U6/PAS-O$M>+.+V8WZ]+*
MMOS9X'VS[ "LN>:@JL,7W7TGK:%7HNVG'M,3S NY-FZD=O\CJW  .NSN"GN+
M/OGXY<K/=@#5#/H,":4*SO1J;XVOK-8."<QP<D[5'6]:?JFG\G'=VAAVCQ"
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M"ZCY/Q10*^2KY'X\41@OB$Z0"=B3,E-^>BXIWV9;6F<^K:/(]>]/"^N/V"F
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MI0]!7XTF,(R(1^5DO<:ZL#4_6HZO._?K6& L%-\\N.Q(2C ^$LG!(S<YYR@
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M'3$))NLAVI%_P]MO*TZ&*( 8)'Z9Y'=B6;K(EQ?'Q_^^N\Q:A0+X"PK) A3
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MUU:YT.<'%8[U 0X); 45\0C[<]W"'S\,.-/S[G*8V ]R+M0SD$4)DZWDZ_C
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M/^%;VG_C6X-@.0SBD(40148'D=])9O]U8L*"(S;A E[L9OB+RU<=1C9EK;>
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M^(^_I!@X45DPD20]PF8!3,-)\]E)$M&+;#!]V?@@1[G;$?:"X"G3"@T\Z@W
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M7LH_&_LF@[:CD$YTGE\G,9"&@"Z3:W:5%YQO1-07!+[?#A,,JSFCO7]5:.T
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M2Z^T;QE,,AM^+P1.SW/:(@J7Y7F82(J3@5)LY(UM^P:_]/FF +'9LLXS),9
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M9PNU55A5/[XHB5Z:IOCI#&KL#$CRX/\!4$L#!!0    ( />BFU2*Z-D-'+0
M .SG   7    86AP82TR,#(R,#0Q-GAS-# R.2YJ<&>\?'=<4TNW]J8K'0&1
M&A40$ $+16D!D29*4Z0)J*CT)AT" 1&0+J"@*(0J @+2D19Z$>E-:NB])-1
MVA<LYYSWG/.V^[O?C<P?F3VS9JTUSWIFS>R)A&^$28#QNHJZ"D!""@ DQ'\
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M,#\J<)-)5 A$<9KA!.3V9Z1O2#;=\?:;11HY[:\4>K]T)69G?F+].KXB+S
M$4%1U1N]SRNT-I(^%[VLT\S6X1\OH\:]^,GDG7X# 1@FV_5 !](.2<)H['+7
M2.1O]SF0:M-?E'<P^H:R6-7 2*)YKY8/[$216,7%,9I#TN'LET%-RS8#<(MQ
M,>T^7PXK,[M^>/$QM?9&28K-(8&YO3SG&=^BM)6D"\B% (F<40_QD+UQ1/I&
M\7EMR"?HY%T\,6HZK&"?+%91.4N#>Z4P!I>VW,QP=<X@Z!NU2=QR$=&C!V@
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MF[W;8$;%'),5J7CW"[F#,>=0H)=K42]GPLD&PRB&H?^.9(-5QDAVYA/5W/_
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M']W;4IDQN^)A7GMPI@RY-TV9Z4U27JV>:;E@(9,Z&E/I.4-96*68;#4B5DL
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M<%+@EO@O<XG?<@JNGXL6>&4"/&=JI$I9K;$;SX[.<2(FO=\3J5X/";2*#9X
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M!EN'S9GES($WQ=(.)RB&V&/S0CY>8!\&FR!.6_3;V\3U'L2 [=#M(QHJ9([
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MR.J.'69U(V:<]ZNT FM.7C01SH]N99KAY0U%E]!K^PA'A4$11/ %[UA8'"$
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MYVIOV'@\2!IE):!?$KJAL@:F"-EF^_^6O#)!^AQW-7#<GT9[&DK!PLI(>$B
M?&2>^ ZJ66$EUK#*I9LW&QF"F#Z+SFHSEG::+B](M)"3=CW"#[+OL&XC^R'Q
M2+< _(T9ENUI"",I3*%>6!M6*.X"$YB1$_88F45SE@+ EVD3#^X2"%$"SSC4
M.7Y!'1#QO#A*1RM%R-([YHTNR$9YC8@O,[P::E&%DE&M)N1'LJ_;CT_[M1^O
M4?CQY?_HQ_\A:NMMS?>Y:XF@Y/VLA=%U)>M?2B[ 1DB?T%19O;R)['+O)7^H
MUP$GEQ'?GH6?2-!N\SWQL3Z@*/K0M(GYM$6JOF'?A]%2;NVUV%>WT&-;TL^R
M'5V5=-O@'/\RF:TD^];*2 _7&TOV7!NF4;^SX".A&;KA64&6M 40_H#C>VSQ
MP:^=R/5\[_4V]6&QW!K:"Y5FG<JV\0%/BZJN=OKB:H6T&:*2"CEI(K8F/R9I
M2V?I3HT+Q_Z,VZHS8ET5]:P9'FX26,=[)9*3_%^%4%P)E$I??O:3\ZNTO,N1
M%F':!5W0P4\+BU7_" P=8;#!K'TW(S:RAEG4A4,T@W0')-13#UZ,<WD"<3GC
M,9J'KB6VV1>PS3">-UIEKW3<M442G\ZU!*+?UAM+)L&;\ R><-;A'F=^KIPE
MGI2>2S">&\ RRI2DMQF7@@#R(E01_Y7 C7)2L&=;CTA@IT(D<*H]41E4FNR[
M  P8\+H'?_]3]HBB9$,3E^:<"T.X;Y$9,',SPNIF3ZU&@P6'/@'3]3NX$$?&
M19,5I?X=*]U21"<]X;H3O%X)E)STE'7)ND4_CUTJJG'F1Z9"'2W(WZQ+8VG^
MW_V(L#*+2/USDZ&64Q"1^9>3#C+$NJ?WX<%/B+OH>1V>C&=3A-N:T,8B)QF)
M6ZC63IN+ERETG[-HO(D(FH[IMME_I,0RL2M%D,R=*1O&]:'&XP/"2DW"-R-*
MW]P^BM%?$]47/,;U!(_:2KTZ^'$*P;HM4_87L^6.#"8R7IX4 'RQ@*4$T8H(
MH$\8+K#@^,9:*>C/0!_L8A/26 ')AMGP5"^[=;OI4U96<M*UP!["%-N(?*"C
MX=++T/DDR+1]@3**C';\540I[(TH!UV($NFL$ZAUQ);(WMSWL!^_)BWC6\I#
MTK28L/?NEHUP$>MHS>[SP^SW;J5L6G$P[M"#49-HXQY];]2+,-_K?SK]S#'G
M!.FW>J9[Z7]1M<UC Z,T31WJR$8#MT=(&)C;+G CEN V"PL#*;Z48"'"NHN_
M7=H6Q0 SG]%:S@.1)(@O3-6N@>55 W['%2S;4:2#FR-DL ^L%(<PL;GH<P=\
M6S9AIVA+.W*]2U1O1U%@*B(4Y2N"T[/U?<&I8H2>'PS>\#8NK(&N=1W)R&*P
MZFC/5-3:K9I\N*EH:QIVA=9<Q/:576M+ "_-L"OT RD\X<+0-NRVA#$.R7C)
M^MAFGD>$H_D@L($5S.MKW0J$<1M@*E:D)PA6E<XI%9U-LQH&?#P'@R*,A*N%
MFE*T?#4G)6HPGC2>/39@\F@0GH;@%ASP6QH+'%,!JO1#RV56+OYR4DDXB"#G
M8Q8#*5?G:C]IY0]2"K.N(51U9%I0")993NYR+XT4KH0O:.$+@HBS)GEFPZ,P
M#4AP,A$$Q;L;6PYWQ%O*OH:)T#_/&,%X!R$=!)Z$727ZKUW"?ZPN"!(%1=NY
M.;Y[^R'L/XU32V)&SSJ2-6EP.RMHIBPTT6W?%J>C"\TQJ9[G7$$8;N%Z"6TL
MB"Q_ZJT%A]*=4K]]6CMYPK#<IQ7WW%>>LJ_?I7\^9>_Q6&V[.P%;&EBYT[KX
MKRKC_#$; =DB+W9RY)GYT2-5MI[;>F]4!^NI8P7Y'(VVD]\E.XG(?N=^[VCB
MY\Q\K3-R^;:[X,.MN=,@U3UUY2\V79DT)VR:7\F.,DHL"&#?4F2>2_$+\,+:
M.Q+'3@"XKKN:@COX!+=I,Z19C0>K@.XO-"&,X@XR57Q?)IUQKZ%T%EATFY%%
M\ ;J)_0E!?/"+'L])EK.$4_,%^-',*DO4F5OG0?=,%FNC&N5#.<+=CT1Z )K
MU3,2PQ]-WWT700G&"+)6*L7HYM]XKR#L>K,6_A9LY1#;I(V)<9WVP(D8/T:X
M8/+;':GAU*8S5"(N3A="&MEHU1X8.X%](Q2I/.$A1"D5.7*J]=2/-=KN/K?B
M%B$**6J_CF"_:%W[#[4^)\!UHE5,MPMXHH+E.:7V$;,:X-X^^N%#K,S%4[?#
M77[TR#:343ZR+9ZZN2BX?K&NYM("</D3[%S(DE )-83.D9.$VQ8[@6"C;B@Z
M^B/" ^&&'W0'.OT)+6Y$O.'KG5&T?"F,I+=ZTV_(2>L!$'20L=#*KA3( @FE
MLU)AH5ZX$,L5+R4\1 Z3([3G_$V0H%I(QG5P5JX4J9O)MF,]1?8[B<>?0H#U
M<)+]3GW'YV*7]X%H1ZM]S&PP[4=D^\3W6W_P4UW9-#(A @DF1"!B;I[ E>_@
MCF:([Y-Q0R<S\3T,:2S[*<S,H-9^0OJ%GW#O.&48[522>L-I9Y_WY@6XSUQ!
M/FY!O80HN=!Q.L5PJ&>2@(-;]/&C8<4_9/66 X??;AY.'^BA!&A3+H#&QS[B
M2803&PV<V"^"RA<_!I4.K!,*!=M1\.%&X CKUB8N8:O\.J7'] (@H*-C*7[1
M\6L+],42K\=MJI@O>9014>###4ZR4=RH8N1I@"P?B^Q?-,'#UQHJ:R;:I&DZ
M)CH%$'%K@K?DYQBNI$A 4#XV<F" "0"#0MD17:]T76'_HY#WM,?S1W[S+OY/
MB3IJ#G,*?:%;W#M\J>:QZZY'1S_T@H^\;JC5,<X^TX3&Q*6.FSSNZ?;S4'VV
M8[7S%/,+*3:!&N%V"SAFN/W7/2+[R7XA(S[?/*I]ZC2XG](ED0T40;D+, '?
MQ=09?-<T39_+M.$'(@[?F!5TX]:8W =FRSK5N U0[WMRMT1.,5/;-MD";C4Y
M$:6QI_'MHM(%/&=Q*;B1M0I_UKCO/21<*7*EM,E)9-Q;=P:8LFQ@IB>+[W#Y
MJ\#^J$Q!.Y2'^/.Z@[1YO&1@ZAEH^GH!N>@C_F=/C/8]?3WP;D6<OI'.>TH2
M=FN?FXO6K6,5CL((R^:N7^58NSF/\'/O2I2L++JPO%6LL46,_R4SOP0L(;5:
M'%(_0L2L;,4"C\)U:!;[&\L7-P'H?5L!VQ^+;%[&DN50*N  $YV+*,\>IQ1,
M\Y@]XHXTH3>Y^(B:O- S!3Z-S26>Y@@6A*1C/5]D*:M@B1#K8@![NP[#%;*1
MT'BH:K5 17;&4BFJUOJ[GZCZID)4#3Z[;5Y\@J@]B5)C-0Q)^-H!7_].TP2G
M#2UOE;3"+M04RE"T*MS-@\OY24^MWY=K?/0F^.C1JMOOYVK>6KEVHTJLY29X
ME__*Y6$&B8\6Z[TTN'5DS-E-*KIA-)O/L58CR&--YZ-['6Q_WW;9=^K[#Y^3
M+*+T1[CE6PDN+]4_4!/RW:)Z@VK=YMRD8885MMI/PIZZS<PJ/[EAS=<-.CL]
MQ'JS+OG<F&DA-G=O9WB/VWU8,QJ-WK#/Y.Z0]K*4WQMC"U=)4ZT'Y\YY%/'1
M:>4;W1.;/9=<6#=RJXW^2P"+..#GLH=0]K^1DY@?B'])NQ^%^UN",$K_BIQ$
M&V'R$:PQR <7J0XZX1?::1G0>R"3.*#XEY1@MD6JS<'PI3+^7'J_\3=]XW-Z
M__FM6<VJ*0YJZT1:SUET6C+%&-3U[L'(F.[KJ41XOS%Z_SN[('=K6FB&G!24
M\N.7_O+D@V^) %2:E9"*=#04\+\@#=QZ^"AM_^M@DTEN%Y,RC^O=/?_@(%M;
M(7D0LO7D) ]"ML*,/.XC#27BY5:3H611@D('RB!6B)3.GBJ:>5E.4L-,(J23
M/SG=Q7]S;+9V<&&*,"=I%34A&6YQ4>221OJCW7HY;YR[2Z1T^D1@47-88MGY
MRGM=^^A1B4^LVF_\L78E-?M"$HW1@P52""Q@58#;HW@&+)PHT)&=(&COPVQ8
M=N/1C=W4U+O:!N-4:>?NM<$6_I;7UA[[QN@:0C_7&SFW]D7.5Z26 L&VRGS"
M>"OJ?L/H>7,$F/4;LL[??XV[=_UJ0<UL5"\;483.$<K065&$Z<RXT+\(4Z>I
MQ&DQ<UC,^8"_TV]#64.1ZDCJLT>!FX87>SK^Q(6#&/K43TU:E"KR'W2GOU:9
M+F2?'%#>HGQ^K%?"COM%JX\U3DG;^,'Y&OF(WZ"6#19VID]%C:GT*?%</=N&
M[]N6U)U?Z77Y@?<VK2HGN]$GIY$%)L_8?[SEM[#F4V^,7-;Z*/[*DO\8O-\"
M1?VV4C+G2>;,#V_VG5LUYE&D["U97#='>I+2]IE(V*/?'\A)]\\SXH"K-AY"
MVJYX0ZN?28D*UJXZ:.\;AB]/:)5()&I.('6SX[*QP;CMB!J3V;PU/'(L9N)B
M/[U2EK_K&ZML*X@,"KSD)+<P7%O,'&Z6:M'.6BMCBD6L$$^8 #*UFYW'RW0_
MXX/6:8FB0B8NTR"09?EM)VDU16#>U@^BI/5 E)4"_796")M'TNFZX"=.Z'QS
M^T B/]/TOC:4A6[O8<>Q(&\F-C=?+"?5SQ=CSGX2_TXS(LSN2]DFY+&#93>B
M]_F\MXT__5[J0<%.4M\=Y_0B%AWP]OT$8A$/1"P'V8*==9/*ELUFCQ:=-155
MVN[Y7,R&5DCL%N"C]:EBRJ+W<E)Z5!VZ:.B"8S.Z$8JZ KF@'>^A=DU,>KGB
MD#*+*Y6F!'T>/7@CN,KJDI4>(RK+R5?C'LDVYOPAFN..?JXU68%DSNW5VD/3
M.](\68(/+3HBFXJQSX8O$5'^9OGF7^P'7YI^A"_ W2GQBZ& U50X,RPM<F:Z
MQNN[<M(JP\ZQZ-E:< <E&]5Z,KJ./1G=&O* C*[5>G#+BI+-@M+>+K>^WJF0
M)@E&4=_5=C/C[5/\?Q5]+U)$WS 1?4^3!457^)?OG]<:$_7I#5'[X?XE[O/B
M+:2RX,>5?-;7A?TRNR!V&M%3 VJEVE9QE/I""FS'BK ]<M*,/D S(]$J8MSG
M'$)YOW+PE?6I]\^[<7 C78$F4Q&(!T+=:*:FNUM!Q&GUS<8Q(R8': I$-EGX
M!8!G3O7#,[>C)Z>[X[' ^(]SLV]Z^3UXH40VO]8WH(NY9.-J3/<FESV[\>UZ
M1]O2_ZRP"WRJ%[+#2QRZ9I6.Z[YLDH>>6M45P6"[EROH<4:WA(>ZWI[?,=+P
MKQ61U]3BW-OLX@"FSYR];NVNLJWPL0NX^PC2"S.J8J=M[JR#:A\\&*EJ@R@W
M&D5Q?,B)-#6X^3/"66W^O8S8AF?G;[;!><36\V03VW3DK3D1<I+BO:/;B1VK
M;F(A"P,H,U1'YLYJ,ZPZMM [R;'S;N !T;70C:M>;T(6V:V7DTYRRW>@W4T/
MF  ] DOW"K6'Q=IO7:6M,MU<0[*(#^8F>@-VY4Q<4YNK*C(RIBS[_-3T]>U3
MUT@&AY7L>9_ZE[-(4^:S0$YR#B4$AE<.PL(_(A5E9./)O&[\])6_#2E?QF^5
M(3WL=QO"78N?BBI[/;+2B3SAG3H?@*[!:J)3E$KS KI]2RSJ!9F+*0^T0MV0
M9A#!S#0!X3R<0IB'YMD2M;*,17;:4JK5E%*5_"5+D/R! $N[!V#%*8@#O,L7
M*?47:XJ_G60]1/;[5I[#+))>W (CV$<?M.J 9:UX4<>TF6 _'X"#:ABA!'F0
M2+,I8%@E %0U"!DT??B@V6P]4<?,CP+K;0>63[)#1D@WSI>37'Q$054<WUYU
M%W/=B< NI%?<M95U<;_4FUTKHIX9A8Q)A-X(<+^0.P3@JAD(N.2D@8AKIG['
M7G:KB.$YTDTE=1(-W+'UD" ?'F:&1T?ZHPS+7'P_'Y$FP0+]C&:342Z"[@J-
M6I87/OIM&GC9E#Z8PXJOC+^ZK2CJAN[/U6RW_.:PWIB,(GB@OTX]</Z?VS.:
MD9PA3:0JR,T?3[)E:_H3"*'%Z@HDM$P$IM0N"AZ=GGK8,[(_:. S_A$T3!=I
M<-)0,L(U5U" J%WK<#GI#8<0RRX RXE&G.#^(.ENBB@L!I)(G*KAA6W,PS\3
M!KT@ >T%"70%2-#O 0D'9-?0*KT**TFU>IMA>X&GG#0&R7C-Y+39UQ9;$E*'
M^]>QZX+T9GT0SOV<&N^M01&?[M'36O77TU92!NII0_Y!3YOYWPGU!'R#^J\2
MXSVM&3ZP'L3JGHEN6C C[MYWJUE'PO_0F+.N#%=K:_V91C!*62<R]71ZT*"Y
M-I1E+(O*N]5F]."EK\NUZK?WW$%8><%HY))SB$EH>,/HB(8;?[YN/+YI]K>@
M1V7(BJ8Y#U:ORYKTG[/F27JJ@RC7*5WJPI ,AM1?O/7FIM\1>^*_S9UNET 0
M@ 9:F)'<D,O(H:1%R28Z:&YUWC3[&$]O,R/-#TA1@L4J<N>4>]=,.L[H?WA
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M12Y>?<*BMJ[4S+C4.P]4E@5_L+)[$KX]^I3N](V#@E5PHWE=?D@/&KX=L0(
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M\J;_, Y:[-\,)?_/S8/^CZ:[?WN4]1_]V-_<W'.27WR',)6,X2YQ7]/!?;\
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MAZFB1YGU)-A!C#9_N<[]ZD4\@W?5 UK'K=<Z!-,YS HLD^1UI1\W/$G8"&H
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MHFPKG\]X#_2S)^*A?0A9HGR=_RKA]0W^:FX6/>%.\<?@^%;)XI*\4$VL+N4
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MS(:;NE;2S\[8+\%JM*0^0^B:@=2)?Z'Z.+[%0U NY;ZY(A5&<B4*I2NBZ^Z
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MTUQYS@*@T%?%6T*O%OX'4$L#!!0    ( />BFU1I);S(Y)T  !VP   7
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MZ3^D$M*I(W+5,KKRKB<[N7XQ>1+O#72/6-(H]!5 Y<->B]>SU<C:SGZ9QE^
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MBLYI0%<6/WRXF_GP)O'C0)[<C7: MO85ZA<'_;O+H$3.Q$#FO72VOM4[Y,:
MXXB9;20?PWM/<91E9Y(GT%Q_<3&J*=Q%M4$4\*&5/4<TFPB.M-:=CX#'X8<4
MVKYG>/I?T+LHI\CFNS2:4P[Z0%%GMPLE'E^D['*^TG0G()]E" ,*Q#&GC2IS
M1,_=%O,U9[XO1#YB+CFR2 Y.H7)5#%1N'%35 '569E^KE,WJ[,J$JFYL2OX@
MWN:\=M7N[?H,S+Q;U"C#F*BA6+UI_8:UC2]%63"W?TC2%PANLK^(;!B#OD80
M '1=64?U7LV.9Z+5XLU;(F'&DS/Y"J.9>^D>K^ , ZH;^@-*A3WBI*'"H=O
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MSKN\0H<KX)U&?:W3+$:PH/))'+)O>D/R$S9>W[10@'@V3+D.$J]LY! M!7K
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M;0$D3!6]4YFH4U]1_/K\>LJ=^N[/E%%C'K.!&6OT*4*EU-FGS\YS 341&(-
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MN-8,(J#>[>+ 7ZKMH7^IWOB':EU&M6HCG; #Y04=R@U3XYA.R=?B9OC[HI9
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M'H!I-\%HI##*T6@]G6J.Y\MKF3&S/!PUYE=?BRR;JOP]EBX1,9X$J4W# WA
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MI3DJ3\&U$9EET[74%6*:8&%8DV8^/?.(D \,.K)+3:K"8EI,?10RWW3TO:-
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M%7:9<:X;_O^ND!*&T@'LLX1)6J@*Q][7'Y<8] */-B^:,A@W&9%'\XVOW=D
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M^6:3PH.=:IL3<'"P37WGA*+*R)147#>H+K??\@R:(C+D7D:Q@CSXG%_V[5-
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M2 >,-&R>WD3[$D=;(:K@DAM^-5*'=$ANHJA%:)I'D.]I6 TQJP1($\/<XDA
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MO/2;.D!;G>'E+77]1+.J2+R)\I2..\3KN]E&CUF"3>3#I$4#&?:HJM]$2&G
MA9K)J0KWI(<P25L](A@JP\LZW=L1VXI,PNOAJJC6LZLPF>W6KMSO4CX9CU0/
MDQVS*/G;$XW767'B I^EV;O40:'>;PV.A$$"RMCE^0KOS/1+541>"7.4;JS_
M0VW6-TG&Y=%?<+]\_*G\".C\Z58IB<P#-'L9-/3^_)=DD<"(-ET37<E#;<SO
MEJ^I^ FV3_NU#[PZKP&F@(N\3BL6/Q!Z^/D:.';;Z=!:25V</:QJ"USG6>)%
M7/UCPL8;,/#ZC18\VGT8JCM5^UFYMOZTJFKN[F+"H0D"B*LIQHMCDZ(O_TY;
MOGO7.&F!\&]?,O!Y2;HP!<F T: O8!L7 F\GUANT;X&D0NVQA#U(WMBM_^JS
M_U:#&8\R&NIM+X7D(B^JT*P/H=J5SAR\KL4[)G$ "-7*-0 EO J/.SD>5Y)?
MT^4WF<Y@,M/1/FLB@K-DTVC 4P-M#T#VXBBUJZYZT(7>]/&TW]"E^#5@H"-@
M GC*674-F/#,M@ 7%N=^&Y/,N! -&5JHK?^HA13@^5'[)I7!G6I'@$TY<H A
M> 2 5?^;YVTME+7(]075&M?;?%J$!:/OC'8M4^\8;ET8I=(-HSG?#51)'EX#
M(%#Z0(I' ^]W[FAZ7TH;PP*XBW'\EC/N0#HSJIDS"//1HIK@U=_QEGN#BS0S
MU2V(<+1'T4-"AEC*SS:GPG:?J1,=&E)[TY??3;9.93M?JIT;[;34(!\SVM92
M223P*OC7B.A4/WI'_.""^C'C2AISMS@[_I,W7MR!'B9Z//$&2UWAW*G-]-)U
M?=ZN<$6J\>A69=@5JV8'E-5>7$G]#N8\^5RF+.X1Z.S\@YW2<<_3+,E6QFL
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MA!\LF\DVM6,XIR\L>_O"K@$?6%KY2QU_X0H%#^@T12F_!>O;[+.H_)2'V^-
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MSS0<BW^U5,22-*WJN+#4AR. F(4/D1^(O!MB&ARS3C4DXBU(N^"1J)$(-"Z
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M^<J)?V@_%;ZFS_=#M3W,&L]Z\KOEZ,P]UB(O4M9(]PQ7EX&.J/J&@A&49UY
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MJ)EZ@-ST8A#N*D<<XF-LIQ9V1G5C[NG#&J?Z=W[FBRM--*BK$R>>DV/;YUK
M6;TW&V%1F6DK6U;$^KQ- O7;R3S>)]F>BT- <Z2MN*M"7.%2X:$%16#-PI>N
MYJQH/-T#'5]_\O. /KK,;UIWK=8MARUEE*P[K@&U^<Q<!NI0M/^CSHG$(3!M
M/_!LV%> A:MN<WQ"3#EUQYJP$U^&WP9ECF)?F KD-M-("^1& H1"6W)1L#B-
MMHG#7/JYI:<877IWF[?!(![(5C8-$R']A"*+&@4-I#HQ2VZ<P@NZKL\/<&^8
MW95TFJ5'$@D%).W+K +9']RPN^Y <C_=6JK3^[NYN\6D0Z?:9G^_7P.0<GTJ
M7Y$Y>$/L2,F*"XGYS@5-R&&K7?'GJ[A"AY'(HX3'BC]6:'R62MM*Q=JS]#F9
MPX^UE'1S'-ETAZI5?8GF^U^N!O_JZ-NT5$:+S]EI-,;I-8[AU4MQ3R]0/=+S
M\P2):<NK:1)B-[M8Q4=_(8/7 +( P8"I0%H5"5SLLE%#/<Z_V*JSK$BU<KL:
M_);2T:V*_!K I9#QS^II^UX\&LC^XA_^&:X=O>@CCWD_(3TP,00F;7SU>C&N
MI%R]:0%GN$(3?-S." -WHXC_@%8YJK)T:W6\O\8K]'_:V^07S4APFT)28*$K
M_D5?E.3@.Z:DH74@1G-'U."NG$[10OCAWCH1EU..DC-7:%O7*K(KC@8OA&EK
M#VN5>2=-$+MM\H[:/%G9..&3=F7FMSV_]DM1/P4L,>B>D@Z6XG7-S'&9D^6$
MHG0=5KALAZ[ZGE_??&>L OF%]YA6=+ED_ILO>KF?LU1V@%5Q(>(NE0]TK4UJ
M,9/+G ;BU/,C3!,4G?-IMFM>_#_ST<VC3%>C;,#(VL6G1,56LXN+EEW%?'MT
M-)*LN2\94W@X21^TF7X[SC92:GB&HUFMG?![;>OMY5K9A^:N,?"-N"76X9J5
MDE,II4.(E4Y75M-H;L6F1,A(Y=I*-U:*,?#EVY6_N=7?QZHT90G"J:^UAV:*
M3OGY8Q)?^9ZV)NZS]07+:+LY%--.[R_\HYS='IE<:EG^"JRE"541CTH7ELW2
MQ*J'$QE@9DHS=0F)9Y1AA^)YE:J%/#^G VV6*1;MF]W9G/-*[7UZ4SUDID.;
MK&7GRSR_K2/Y0PVWU(U_$9):^6USMI,M_8^1R<UI._]V#+13#\4TL?V!7,%M
MN9%J5>AVE@#RV9UQ7$IW<MIM7!ED2H1I0E=HQRE^,-+M.ZCS*FRF%;P2V#G*
M $M9*PK%V[GFXM)5)_SD[403BZ(V(*D-8K>?,)?&&:(0,[D_C)^;"N0_^G^Z
MQP+GP>5<*MA;,2K9%NPJY RW4E3OS'UJ=] _4WW;W^.SSG#K'VE/W!SUX [,
MV8_&UJFHK"A).?UYAQ1*-<&;$?*[O1H<[NR\VH8]C+">6J^V2'YD>B!X;S]C
M3>9$EX&\#W1CIDA16Q>,B/2/= 1NQ>]_@H+\PQS3NCJ:'R:5#I>8;">?(B<I
ME<8?W@4.YF)'(]$8N]"#.GG ^Q>\6H&1&JN:FY8V-Y9"FHF+=$K,0V!&_%XG
MU^,*'L-Z$XE>*B(AO XA%XW9:"JW-VI^TW8D:B;E/#H:!U:UXG5(=$15Y$-\
M"@::,B]6X"D?/X;G8Y@GFN*H8%W=AVOLBSJO&V7/('\VM-;9OW2;Q>];7!6)
MS#R4;:PUJFKJ2WI0R22UYV]/N]].J21<Y"<SV:J*?M56E6ZA\S%Y#$$93^-B
MBCXYG.?I^;=]EF8;DI0]12?9[AAS]QM][Y,MJH\7]3&ELR85;:G)^\XFIE3J
ML<_L+F,L0PK])&01M['\$7Y/LN8,S$S7F 99!F<OE^:R:>*4WJ*K<G%_1BL&
MW$HM++N7/C0D)%9K'+0B65=;ME:FG5>:&AV,=L#Q_;PT%<Y6#M]@!873+NN2
MLZ@48[6,A/,U&1?-<5"M=+IL3;V.L@E'D[>>@?[\[<_ W$P*''<>#'D*'3L&
M":%V7$2=WS89#@YE;'J]](7DXBA6PL+\'LZ8?F_V<X..]3)6#M%ICMDQ]@3T
M-9^&!S :.V <L> R4I<ZD]8\OT]>Y&VNEI=/QGY4VO5FT4B[</8Y$0I([.J=
MQA;X:8#%I!/-/@*LO46=<=0H[W]F#F/I,Q%YVI52]PTTI+[$6SV$9E7SQR@I
M5U!YZ=7\FNEVDXXK4A50O<]?3!6DDG0FRG +DQEW*8*+0LN%D^]XREW1_/):
M]J!PFM5T^J$,G78'S3T$A:)"VC9#3W2&]=??I%BAZ*A6E2$LP!!_<?7;55;@
M6C-V :>QM]9/&LL8])_\Y^(R353[2C'HZ'FKQ#7@K<8U8$QXJ=TV[ESN&D <
M."L+6K>DN ;<>7(-2("LQEV2RUU]MCR[%+D&#+3C>*XZ;CP$H;/=P/[2%%PJ
M?%;9-%( #N@_RD(%ZTSA^-!\U9C63$E)$?WAO"[F5-ZQU%=:^K[5E<;6.8!3
MN!@AJQ8<ZD/3+1#X"R^W%KB_+>K7Z %D-!D9<&!AE<A/H.0O CY?#W2(8[.?
MO!H[R^3 0F(+,)4IA3@N"SN=2.&^NFL F.X7O;,5XI5 I]<Q7(/PK=T!3(,W
MPIFM[(IJ]BD8M:TU[;EYN3"T\,=_SZB*_I<!T)7P4/YGT=Q6/0[GG_P0FA?(
M\6+,5#I80OASYX&RI"]RR*I*(Z\,:L5PI;+#=O6]F:E.ML%>S'TJ\<^]>(I;
M_[SZ#ZU,(7\"JU= F+' VEA?Z'_8TM27DN-U&'+OG&<!"F00Y_!+A!5^#)M^
M?2]0S;*EV)P0VXMVFQ"8NP;<!Q_#,Z^ NY]PBJ?OD:T0X<""'0J/8LW8\@.M
M)\K_(GN=A[6/6R1?_?1[+>2ZN(R=/%&@F=N8JXOQ10.C^)=/8S1-$X;E..(>
MWM:7O>1 UD.H,)JJ5C1^(IAU1*_)>FWLSMJ?RUX3@!?_\L.6-(&>7O+-LKBT
MDHCTV($Y'U'FOXQKRW7$&LN_916:$^ %CLD-9BG%[)U9XV6ST##<'-./:P"%
MTO.+[JJ.MU3I(T=:'TM?.EM-W<+-)$2EK6LF6G(<%P!Y1E64<9$N'+M<+#A(
MWG/=OO#!1<>COH&&R9>AB2J9=@M 0\NU(@>,@Z?1J6>\:%M%*Y1!__YO=2(
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MV]KZY@_%4E_7Y0)]ZUS9E-3Z%%PZ@60XM]]IH1'H9:H=5]VR16V[=?\DGFN
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MFO6#[)EBY$08?1@ 3\:,'$UO5I2$/+X[X;L2[-(?7-!Z\L_&,2!:SX/I?Z)
M^T_:@D>S.G[F2TY(#'@\,?^"+.M6 9Y;"^L3I5?Q)JD"W\W\9_7#WYQ[X^YS
M=+7[8L0D3* ?+N64S^8GQ(JY?6K)8YGASO,FD0*S*=^-M.J_Q*A..=\&1YR!
M[C89@3XE+LY:WTD^1_I1#QY.5)7^V+1^'?&0T.F'E^@A,+3J]@"4$URE/4#<
M%%N[]C'KH3#@_82(--@URS'^W%HHHDLC=DJ&_:)XE^A2):*''_N5EBG35[.-
M*T;F2H1)_1QCP8@$SW?%1LH;/#G<,7 3Z:OI"X<.V [N$8%LM[OYN\VDS&VW
M*0($A^1"4M1RP>8'NB"]Q\D<+%=,)696WQXL\:475HR6K&UR:@95SI/8&KUZ
MX"Y#OFDGYEH9M@)5DURTO9IF^"3(7C\F6B64<H:%Z"9&-8Q_SSO%1'2!\OG9
M67SK_D7&TQZ-AEP.WB=SR=Q[/9Z*O5S?4C5<6E7/JFHRNBY.D4G[74/E7$N/
MA9G>6,GZ(RT/;L$SM>$H)+8S$0FE+-\HX4+_PJF% "-3Q^G*KR++SJ,QMOJ:
ML<?MKOP_U^]3NX6U'_\D(O:=X<M_.U[.">"3/=T/33NXBE3#Q<!'R1I;![92
MM% -.WP:N>B3AS="]62WMO< J5QW+#W\:)W*$UFO3H'?%J"\[]NBS#4J2QHW
M.X/VUGLS[=&&DE+!O9V 9(,!.P,G\0<]%!-:8:2ET(@W.[9;%?>NJ O?/+,<
MY;"NK1L$ 4TL/$W9FL[^[)&Z)'@R?R$,H4)>2L/IS^*]/5(Q8F$N&5G8# >W
MY>G]M!N%N ?C'Y;&]#GK-4BC']71B-\>P#3 2Y KD#TQ ^;S&L_P&A!RU??X
M6=38C*^%5BE2E(F=: RZRU5^A&M2AH9YCB@@=20K3ZMF$-?*MRO1EUC7Q<93
MZQA-FX-NY9VZG.N*/*>8@5TAA?2*98IR56ZV?KCP1^L7L13_W/H\<T(Q(%2Q
M"X2!=U^+U%!;NV6.>(_[N:LOQ2(=HSF.#NUO'98%A4DFVYOXM1&^D:V8!**6
M[7A^HO:%/.T:/@E2QX967N>R4^@G1//.3;0@4B&L:JZ]B(S85%LTEB;'<?D+
MV0U=MN[84OCN2X#JT="=>Q0ZVX[^U0!$G[ ]Y_"I(MOC\Z7Y!@92#R\P&)0^
M4]+4,C@WO.Z1)7(_V>JQC FYLM?$N/N?NFN15FU<I)$?NXP%[I$U9 _D'VH%
MDKH9P;75G(B*-VW4%W+ -0N)?N#(F$8W"3&3WPD!XB#&.;W77-"AE,9ZM<K3
M:0X_K[P[7*IK--,,3D0>Q/LS^I/_QE]CH]"EWCLI??E?@FQ/_-6DLZ@';EZ@
M2Q]UI![G@EF$&60,5Z;"\A4N=+K[J4*U-G]1>%-*4_+A?7/I[\DOBQ8U/#QE
MG=%AR*?]8<MH;LJP5=>.1BH/BE=D-Q7CH#U.W:5)F^0C$]8*.146WFKS#8^/
M9V1$^G4.T))1U-H+7?"5$+R)Y^RR#*(K'1=5NT'/]$G>:*=ZC0,_">M.7B2C
MF?,=U 38D0@51_;RS/%0U^AFM:(TE)Y"SGW?O_J"3A:EOX,\]G. 5<.3?"AB
MMO)B3FKDKK8+R'!GZQ&&G]3-CYD_6AL_'[C83EKL/T1-^-BW-C56M_7;::S%
M3%&T::LON](W\(L-1RT(&'EE^PV]U0<A[_Z%]FX*M%NY^I*M/4M@7VEUQX!3
M5-6Q)VM2+W<]USP*T(QQ_>7&A%N.<,T\9DD.W:NMV&TSR]9G#3K+ZI\@.:\D
MR6I,X$I?Q2*!'X]BK :8#:@;P,OZ@T\7?^RIYI\[=JWVR3L#GFAG_,X;=PVO
M]3=AZK_J?UVV>&QH%4KKD@E#L \R(,?1L.-R3,7QP+ELE%DC"JL.^+!J].*B
MZ.)T=4XJ'L$2H?.>D7"-$WWA*LV=P7RK'!MCQEUE/9'%6[I,C:YI0?QI9GSL
MB@&(@90Z82TBL.)$&D">\C7V^G5&P)]-0W*4\'(L<'M_?,TB1;XM$;W<TJ3>
M_:(VEEXCU)_]<%MV%!=OQOAQC]Q73 ISV::M_Q:](.L"]BE(5.G4_:=&>B@T
ME>A>45"\];AMZ<QDA?^Q=_NV #&W/!]2!'"*[;)R+/6JH@4=/U=<=& C14%4
M^7,AOQ?TD.YG8.CZPLO#N?@S!7V2EEI)!X_L 4!./18_$M]0 ,PN3!->MTC%
M4S^[1XZP*35-/KE;'J1QU(LJ&)1BT1G:-.B[:F6MU@%^WMLH>,,PH6]? )A!
M6^%<B(NXP#5C&966+B#T!%O30$K06OBY<S%SDX?H!*>M*CKD<!Y%>@C&%-3@
M*5#L6>34K?!+>X ;(T6L<%Y*F5>H;TY0X;B%DEE;R/60)E->3; ITA47L8VQ
M,!U>JW3_6:G8D&HI(C'>;0*%..VW1_+A?,]G,;>S2LEB=N#=[*862&0$_W K
MX37[,U@(]9[L+5:!\H=]38LSTX6HGP67K;O&F/&?A4>V:EV%Q]<6$)9[_IPC
M'Q+=:@C>:0/9P'_YS$(X:AB:)DO)&2S@G1)&MF8\DW_8NE,D?)21?+]+<\'?
M6/:O8(XA'+9JXC';7KK@V:GI1;J]73)H,'S&)ZYG,D)[N?>MD:1[?WQ@YE95
MTAX@@9S^IJ[-;GW%1]T@* 3%['=L#AX.DM2X-JET6;Z(.&JJ<T"0$KO[#/]7
M.;N&$5L\1C+(&3+3RF9.?SA+LU,Y4@WY*_7\]/%]XT0 VR,4%VP)L9:@LI^V
MCU* .*@3RS=EQIHLO+A:@3JTB%:>*(@5&CD"-!J=LC.6J,&I=-(..V% -H^)
M]MO^F7N ER-(9B3._9_GIP#+_EU<]QZ@:VS7++ =\_TT]^_C&;-LW+*Q[$D6
ME ["/9L%=A*/H9X^B!=,>6FMCS0Y70 ,"GH[KK/1%UK&!,==#6!\D\_?8?VG
MB!F4D^Q9)R8DR0,#ZJ%)45)(YXIR"%Z.KI/SPA+@+3<+TRC7%HX1.O@HN[]'
M5JJ>5FD 9WPS5"NM&O',LMVX4O0NVJ0=L+UJ3+PI"V"^763TR4/^Q;K2O6</
M4$.+-#KILB"NUQ\7^+MD8*W[1[IUH'%&6*0NL)%L7A#U!$M'"E_IHL9OUBN6
MZ=A!=K-S]P 'P'% [L>G<![@7V)>'ZU3J@W7F=OV>) XI9.>+:_>M2\/L!3^
MFK\'Y@6.A#&K JD@9QS69F E_^K8*VHCQZQ P"M+YJU;Z//$+3C;!*]'#WDJ
MF/4) -2Q(["T60F[!4%$*=QLUW85+MY^6&OY:V'L:IY@#$=Y0%HKU^UGU5KX
M\C3L'E+4%7T.1[N"L7=!6PQJR]</8W]@YF[:A%'8C*9U8Z+]'VL .V&;ZHLP
M-K_X'D#DIJP>6YR.?=0L'6I>QR#IA2FM09NO6]^UK3[Y(3UJU67U^.&W2  ;
MY7[YSTJ"E7*BJ$GU([KP] ,B&\'[ QK4%B'_8N2\&1=I@-A.81_$L"P85XL9
M5#!J1_U%V2U+Z71+[0+E'S=%!D/IB& &,5Y/YP6C3?D#Y]*0?$M]?>H92=7"
M\9M*0(@:#M(-E_*F'& 3*]DEX?=DT+:U22O9XS)O.+XD#VC"_O";GF6E7"A+
MIQC%@G;PT;K%(^1E3]8^#?>>"ADS02LGDS_H$F4TC8D%?Y#K/F;_+JCYORT2
MG&!T#*??'2JPG?*:'6"3 V\UE1Y4*T*G;X'&FI><!.\;R;!M&6#0@HZ>-C&^
M=K2J.MGLD&&1SZ5=JPU$;Z3!.=B<RQ#A/U-)PZ(0((3:C7P8&IQD)(.+,1L,
MQ$A-V%/J<&X9SDH=@M!HOSKQ#O!#,5<P&_MJH7DNJ6#2V\'OP%P&Z.*'\Z'$
M[%;W62JQU038S7EV<>M9GXK5(,F]Q3K,\3+&[VI +8027DZ,,I);RC%28)8T
MYBFUM-*TG=>KIQ?.OQ/^2&"X2W!*IZ(@?RS9(<#(WQ$/S.?N^\=Y7P>!XV7%
M1C8G*@YR#4NT22.8PX-)%]]Z0/?[U0T.#9R/9BJ^[>?'7V2.2 DG,=KT9'3$
M/*_\J+<4MGPOGY[I/,V,9-_> WQJ*MH#T \CN;;806-I2@5=Z!!&_2?(%FP9
M%_(2EYZ2=?MNM.[O4$0^KR^?/Y]Q(5H$/K82&%(7V)(=V%1=;WS#L1K@<Z]P
MMUBK,<A9!@RO':G<S#^R%%R&=@]"GT&JSJO"Z4(ALE$S+X*M6759T\PGWE(E
M#9Z5.IGJCPT*?XV]#9^#T[0.<&2STT,#N]7X_Z>O$7*MU3'7ZC.FEB36Y-+<
M"M--5<!^Z$X,P0,,UDC47K7ZJ52YJIZU&S?Y_80#]+51;W%8W_%]OV/?<-6:
MANZ.X@UG3.5#8]MF'Y5^R[[^^7K9SAT22D6PCM%B[3R1L!:D=H[>*[#YYL;L
MIAQM@% /CZD3XAL'2Z$<K,-1TB^7K'KG8T.!2._?RA!IHNBXR[A%5MR]SYIU
M--9+"S0IQ0J;D(V94=&J>^ZXBKDWO?]6=^K!7M8A,MD)E:>18]T8APKL$QNR
MKYI(.-3V5>:NVQ):I<-(1:0&.?G-XFP5MD8A!S>1V\9"M#ZH_Y63O>'4JK.3
MV<LIDC;;!QN+%.FH'R?$1C6W->3MVO^(K3V?IVMP3)]&QJG8L.J+<?AKXZ$N
M7H,I9#\_*8'-&]O;9&DF-A9OP?J#82WB5PLO.#6E2?K&W)%("PI@(Q8OQ'"A
M:(;&H:\+57>\W)+<:XA;\>R$G0'@"[SFC4:6%@85,F>>MO8XX/E<6T95H ;0
MBR?U-"1P0KXNY#/R7@BI7/#?Z600A2,&5^IV]<*$S,=4)L[0?-)L6A[WOA*]
MGPCXOH6--3I"JY-1V -<8VZEC,YEB?J49*@^X=L=,(SWH3D(GO'Z%\2I,;!D
MD#2ZQ[4_9[[YTOEZD:92CT;UV/UA4VH&\ ,Q11@_%^P7IIF)J'F;]#'S>LV,
M5_&7=&>9E<-60R0M6[VICHXI?6O]P*/=^ZWK["R,!9S_RYLN\1\^FFYM!O#?
MSC^ %W</*7<Q^9,$=;?.FLV&R/U^N_7.(&#5R4B8J1[%W -8ZV'C RO"3W4U
MI77Z/!$@VH>-?2=5Z_@V2I(S\4 ZQGG[23T+EEQ'E5B64B]$57Q#C<M0$O!,
MY\5E?C?'6>DKWW].4+(.[ QKW:/(LQ3B2>R-[1(FMC-? M=I/Z;5Q>RB!8LL
M(+"W:ZY6&@?_)#IUL6MFJ!)X*!/;1>:WF.FS<!C:K,+ZE[AJ?5_28>H+,26;
MJ[Y'PK4$^MMJ+)S8%^B]CWI*684F@SQ)B)07XJA3+M?68S9!(4,G*O/7_<O5
MFN^_??-3(8UNKCK3\WO7@1=I7%,#O=W.$G*E=X.@K5YP *<1^NA%5;[--7&C
MUZ,&0HQ=+V\^CGEU,V\@?N67&4/R*6RM:DV9 ,+!+9A7B<*/7Z$&4*%XZ$&L
M;Z,=3WL.(H-WA,5P[>AM)F1US.8[];O9/U4">'5\F]"VD.G._ F@XQ\%K:IJ
M8X47!Q=V/DR^D)VU;0HI,3VB**YL+N(G8V$%V"E/_'VA?;JN/V5NI%6_#-?R
M=OQ!"IUT7Z6A@5HS(A7VY-/)5-=SA7&@\:*JW=<\J.NRZXF,><;V"PP#*::5
M4.AM659C4[C_59YAH[W_<W[C6SO-B=QEMC,K:=:HM!BG/K>_EK;55-?G-#XU
MM?2[(&[FXO?O5SI?ND93WK.!K#OK,],QIZFC6D6#VA]5RE2#0 =*-@I3K\,Z
MV+^CC@M\3MU@$&.#P,<5'ZT%GCA3U^42O37[<7:ZBHO"PYC]'5/'Q];K4J"F
M-<-;^K//DIY .RUYD-C S6O_W5O+_YP%[J0*X<A_58\$A8L-7Z-4ZY/FGQK4
M>BXOKGB?@,5.B0QS'7@*]0.JMVDO=+1_7M[_A'=C9/#_C*V0',^/#_QV;^G#
MW,X'E=R5H@W,]_3[=R)R9;<R(B1Q"-ZQ;A9L6S2--G(;^8BE.+^\[F+X?[NF
M_@?:]X-0VQ\5A'Q$!=;UG;!XWAEV"@C: QCR_72@:K6*TPFR.$_$R+&)CH:\
MT]4F\6@<Z,F7L"CDW_OY#D#EMLI#?5,\"HL2/- RY>]^3%YNG.PMTSK ):+U
MA8".X:8NP[Z!?==TUFN:1=WRNFX<Y-X $@VN/M6.OF*3KS_I>4)S$5F:+\$3
MQ,%F[F6&!+U9I",M0)BVJ,0K9R]^UN-IS^P!!& >A/AFET]H Y%IY-\;A?E]
M<L*A1Y3X [;-V) _%Z_/3_*41XH>D^_99P]FRZD2IMPFG^[<?UE=DP2O31S?
M?[3SV,,;,I%E"Q+_BP[^;4KFYP.;(O79\=O71U>W^JS@^[A71@V C-U[C+4@
MC-C8D/ZCN?0]P)C!U6DMLY892D)!I-%=&M7]H-;Z,3;AGUI9>!D;XC 4^&NX
M==8GIX,A\2.W*SX#KOT ^66\TY%IWE2*YBF/!.6++.<<O;5D= J7K2NOF7;#
M0?-G.2OYT(Y>HH#[)P-/ICGD."Z^H_E'25UPX=+34R="%.OMGDW<?^5TQM!D
MR5#(KQY2C1FAJ#=D=AG!1KG6]&>@JM<HBD1;R@.G3Z5*>,;&N;+/^\@%AF>\
M0-**7=B'XX2NBMU3&/,YK]45EZ^D64Z-H$2[844?5X"CL2P+8FD-O6<)KMLQ
M6_W[9>(2QP,UG[DIR?'8^+YDVD!@?#&_@11G&_DWL3U/9*BG.*CL0NQLDP[+
MBH\T_^3-X?NRG7.]HAOY'50 ]S*-I\;6,,_K['9"QN&U_>6K;RX[+*F2KGL>
M/%R8*PB6['?:%3!4DE$2)>;S9"/>;?_1F)E'.&8&S:D0,N(M[7SHN#FBJD"?
M,YO4A6HO$ X:'1O'*]2,84@:\U1;*Y[U]OG7 J @N]2"EB4ED,!_-?;^_XK6
M_QL)VAZ#B_2>BK,0<(1?4@$;,XT>,RK*?%7=[H; 6K\>,@068P?_K3$SD+VO
M_P%02P,$%     @ ]Z*;5%Y,QTWZ00  ;T4  !<   !A:'!A+3(P,C(P-#$V
M>',T,#,R+FIP9ZRZ!U134;<N&D1 >D>*@-(5 >F=B @(2"^A1Z2#@(CT0*P@
MH4F7&GK'T'L1:0+2>X?0>T() 4*X_/^]]YSSSOC?'>>>]U;VS%AK[)5DS>R]
MOOE]<\_KZ>ME (VFFH8:@. 6 $!P\P)<SP%4 (2W;OWCN&FW;PZB.T1$MV\3
MD9&0$-^A(*.@("<C)Z>DHJ.AI**E(B>G8:*AI6=@9&2DH+[+S,3 3,? R/"/
M+R$@O/G,;2)2(B)2!DIR2H;_ZW;]"T![!U!\*Y"0@ MPBY: D);@NA/ >;-.
M(H)_-L#_:@2W;M9(3'*'E(S\9D(-#> 6 2'AK=N$_UCUS=F@F_. V[1$= ]$
ME8GI]6U(N#P9Q#[&9-WA?E;1SF@P@N(1?_WN$RD9TUUF%E9>/GZ!AX\D)*6D
M963E5)ZKJJF_T- T-#(V 9F:F=O:V3LX.CF[>+WW]O'U\P_X_.5K2.BW,%AL
M7'Q"8M*/Y)3LG-R\_(+"HN+*JNJ:VKKZAL;?'9U=W3U_>OM&Q\8G)J>F9V97
MD*MKZQN;6]L[Z*/CDU/,&?;\XA]^$0 ("?YW^Y=^T=[X=>OV;<+;)/_PB^"6
M[S\FT-XF>B!*3*>L3V+C2<\E]O$.P[.8K(IV4FYQ Q3CZW<C9$P\$BN\Z'^X
M]D_/_FN.??IO>?9OCOV[7[, "D*"FXM'2 L  JX,LV$"@/^?C/ O7ARG.Q[,
MDA_F:5_04V@Q;W7G8")L/N9,,.I4I L*H\>*_$X$-2J6^EXD9F[5EFOJC-[I
MY8E6-@E^X.>S"T;SAS*8L94I\L2X6U3>JB=N/GR& H=[""FH4%6\/E+->SXI
MI^#1FZYEIZF([A+E2)7NLJ)6&:ENB@R^$)([."**GRNNBNGA)R/M:2A):F-0
M$"HP-;6>=Y5"SX&+7!W/HU-(+ 'B7?[IM3%E6,%NC;+Y+<,=#"A%P23P/D$*
M2Q+VA2+!:3[6<.6@KL!ED2;C4)>/L;FI.4.ZG>F3;F,\P0X3G XG'KA2-X6<
M6);3%%5K>&5$S-GQ21S^QBC L4N$W.7"'I/E5OIL,I%;6DRNTM]V/ 0PE>R7
M\^L"G:K77#N*P[IY__"([7UR>^3C,2,[:4F<DR%V"#SIW7](O6#NY%9P%3&S
M_'CJ>=HAP-=ZG&!+'Z*+ZDSA26F8L W7B>QT\Q13<*T_(>3F1Q5)4(=9LZ(5
M?!'Y.\/S0BF':31_;,$&S(31 6BK=]H!/2LG,2Y2]-;3%BYZD6)L?\G#LME3
MMT>K:T1(7!<5QW$:1>;;<5NBNOE='E0XGCBY]"Z__3D)@ETYSDXH%1;FG%TQ
M'JOQ0$6P)$?]B*I4FB#F0)!K$]D:6KH=4#_LW:1;:_9LE.7 %LJEX%F?]DXI
MX==V*Z$'[;;79Z86C@:/_%XWNAV=VZ*BS+.B$1ME,\(5)9!';:@>'->4E'E"
M:Z);BKH>G0:@F^%LR!S0$(3604*_6;.C.@-JFG4]"U)[-SXQ/13<[]OG">J8
M; R21CJDYF#5IHS0' T%=>F"W75,FANR=WAL0+?7;%/6JW7O[)HL/D1U=:;X
M".TW*[DY?"_LZZ]C\S(U%PF5O ;<<<(SC!>@<(VPZ=ZW25)W")P^RPK>9]\B
MG!X*%_*F)IUW#3 *][WUZZBS2S/D$>D:#:47!PNV)Z]WV8K:$LW^E]6J.X?V
M^W/8H R_#(!^MBXCL 7ZZRSO?8/$9=A^KND^3_=>@LSVKC7-I-*#88E#P!;&
MY,7%:5[\IXU1#>.73AJ]LIG41I-XL1GKZ6U/[-.NGSL!595F(;Q<;,''LO=I
MB)RQ=PW001.GG<$/W.C\C&S &@G),2W,]-:V-NZS"04A$- *.:FD>&:_9/I&
MTO=*<6DZF@ ZP<!V.<GY:P!#5$6^T]T )AAF3[AU>)I>$SJ#R:1V9*B.KPYA
MT%<%_&=C_(,S1EN=?<(Q!A9O][XYBZE\%%0!ZY1^PO):WLO*V_\:T&-%=]@)
MI/069%-4K-&P<^JMT:D4>&L:;$00F@EY.<4/I=ENS&U4\&T,^M&DK3F2O,_
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MAVOJ,B\,7@/N0&AB-0<_(3VKTR*H$J:#)_N *_RCUX#=CWCO+NQ0])=6LFL
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MMR$5KCUVJ!1H\4+E'F,$RO1BQ&;^XG,[D%&!&\TE"^Y0>E ^V8QHK:TBMK]
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M66(50O!]G!/VH2<*LZ&MKFO2@,(-;&E9T,^TM%!"J#P2![_DA>4V9(F$0:V
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M9(,MN;W_94=6.V=?:^]ST_%''XJ) 80 LK*P^?-'J^WPFL2/X?W0>UB/SEO
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MJVL[NN]\#3C%70,N* -T?^F>WUJZ43I"JOX;)?:>KJ@SS5A3GA=KC;ZW$6]
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MQ$G*XFU>N&!-R4$)0;LF!D&DPGDC3M0$9X.DOPZNI/(!E51E7/<8#5/.[5J
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MGG\Q\D4^;Q)P<=<YN1+9A+.Z**.QAMGBGSMG1Q"@&KQ96.@+-W!J,&K+GD3
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M0#AUZ/\,@L__I-S)O. ;)I4;-3"J<TO)LC[C309AXST@XPGHR=2$"+VAX3&
M<Z[EN95$]?HCGP2-=B+:TB?^NI2-XS7)(\RAD1Y1#@MK93KF]KUN-N0C>EJ5
M\T$X+2*$G-%@3VJ!9*>Z7_W61I&Q.* E^M*.1\R<>Q=% 8(K6\LUBA27O8?+
M"2:L>16J-HEDN!)]4A?%FKORY/< \]/B7<6*K1NV_C_K'"<[VMPF12(6U>N
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M$]6V_V^GJDD((<9S#QB@0]7=^MF!3A6G9-<^#*Z:K>7B<$8O3* NU5_? [1
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M)&JT+GBW^!+GD@*.8 -99'P'74$B,S_0OMU"6GG/12!CO5L_U6JG:=.5">6
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ML_0MXK=J2L2[O\8F,LN6=*UG;?Z9:H\%=<7=U+W"-:A5#V74ZE99-Z='5VV
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M+<VU6Q6U3MP=4H+XFQM"PV:E"EL9#;4=L^^P>KME#M_,AK-G@(>J%__"4!!
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MW*92MMQ=%2=+Z3DTRC"Q>&1UH$O@+;/-Q1RWW#MP&H/C0:$>ZU#\E6W1N'G
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MF.V+/PK;)4+W#>45W"FWA[I*=Z_VTZ4\%Z7Z,W#%V>;HRO?%[":"]W5;_FO
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MT' 9 X9RXQV()1$55/OOXZN?Q3LQ#B3&SB;KH(63/)9/JB8L*8X92(FE^W[
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M0*WJSGVQ%Z =T]+-W$\.%IW++_RBEB:-S@#)7X&R8V;ZL6_?#<I>/0.:5VU
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M!!Q\#Q;X*[MORZ-"A^XF(=5^AH<!)SL)6FN7<T[D[5PV\;D2G0FNXC\>2<5
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ME&?-X,BLSH-THQ)^&["%,15* O,_LM14D#@&5Q'%Y75G5(#S1[4.K9PC?*;
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M7RF,5;CQ*;<QYE\,$>0$'-$F0Y\F+'TP.GMNZ<&M<O5B_A3<6S(ABJU#%%&
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MH\2ULJ4'^/72\Z  4WHE?AZLA8SPDC%186[VX1HNLW<HB:E6H)VY7W3.[$4
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M-<MRU4CQ95=^0#IZ0-M12- 4*VCH-U<"!)A1@P?V!Z.7X+3=87YSZ.N#S2C
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M?S,)>[B-6T/II,%8Q'(-0["]$B"&'CRO_\P@BW!BE&%"+O5P/OE-ZHRECFA
MWA!SJ)(4;UP<\TTS\Y[0N6*ON"7F<D@9R::)WEFR-EF"*K&P[.LKCC";%9M;
M"&;,YH]04:(G/+X<&OX83\N%PH1H<V &=DN,0S#,316=N\2[7@("\2O74P-N
MRYMY)<SS>U)_K9]^)N<DM6;15^\7_)%I"*K*G&5IP*D5^ZCX3W4A[KW=LI3:
MECYJYGR/*J5NY,]MRA!R#\(RWW"? 5G]R5KLCK;968>QD?=:ODELTQ=\_;#F
MW9ZU!YN33U]SCJ@X5LOZ:ILU$J[ &JR?ZLGN4@5)5)!B")1QU'^8[9?;$WTT
M\S!L\-WP:CVK:(8^9 7<)A59!U(%O]B+,[8;LKYYWI/'Q9(D.PENFD,RNV5#
MGZ&=S$%YEB0/G P SB.1G_K#Z%2)XJHX2MS=,*&92SPRI\\(#VB8?%AD\N\O
MH:F"!-W0O-NT82.?]X-#?!@VNY29"O:Y.!;\MLN?7ZQ4YTL)<UE:,Q4<K@?-
MDUX;4_-#VLDX9)T[V,(:"+.I5#K^\/L22??4K6QHV(.+77!WY !ES(;+K;S"
MT\/R,UJ;_!90Y]4A\F![53#4]5=D'0P!B9["HJ:F^%Y.])SU4PX>C[2WM "<
MSJPRP%E\LQ4?DQLB'UJ2GRH\J_$SN<!P45UW_NBUR=B(WB1MPZ1WH6;P&? X
M2&!'7_M/7</+F+?'W=)K7\0_FLASW.-]AI+-FCO4RS>;T>6^*8",<E@[UIBI
M3Y1.3RPPG!A05V+-1P513=4/C(_'\D- +/GY;TL8&RW&ZF83&2^HU?*:R__I
M1GTXU]T*>T&JO-&(8;+@LTUDBUZY-<#\XZ<>+8#0%>=X)"Y2^T95Z9$B"B#%
M[7/<$RBY,6'3F.Q)M?#H1T88-KY"SY/=7Z XJ:D,N5LZ4)M(XO&WMRX)L[$6
MY5!H"+N;94V1[Q@]HB$^.EW6\-&FL14ZE<]<?C[-D%:Y&KIJ=5'-BTV'P!]9
M%U^2QM"SC7^/F&S[C!Y5-Z>6T("8X2%XY,4E4D[$TL&:L3HO3*^3KKQ'M9S9
MBX?ELH53LH;D-3[K"D6+M\N0=W![:V/)()Z2T2A&W<R[#M4B/[KY;(*=4#?N
M06S+W]DL&@_)"(*I)-Y9RPIX;74OF==%_.;1G2<7WBW?$.2XV$T S"$6=3>J
MZNR5+ND3 0O/I7C)%LL<-VX,,QFI;&&]_K@KYWP/:T2Y:R&>NQ;&IU<Y\_-J
M1Y>[EN'6]/EC^2DC:7?1-WSLSK__//5J&380286I[H!!6]99Z&$DP3HW1_^X
M-KMZQNN)[P6'WD_7X[PA*9?N\D4&KH=EQSU<[_A*Z3AND[[S\BO["I<4')7J
M?L_=":S"KLLCR(]G@;,/C3K7'7KMDK3)BE\+/KUB2\@??>_%^5E$9<N-Y\[7
MZ-SMH)+*JC<M+[X_M<F,&E4MI2@X5-EA99[=TX'U(L?T,T#Z"[ER6. 5?OQ5
MO:/C\Y<&8GG?.^(-=!+=EU# A(:G0/VKXLD73UYM+^%9I%7N>JB_$WBU-S-<
M(/1('@;J#E.VZ(.Z)YJ#ABRB\_KI)/@",:P7YZ7OFU%/QO$EN/IB+C"/H'3Z
M[5J.S1.UG@:ZZ05UMFW2\/ZY[IXS=!AM=U[FBCHUVFV[N%2D@CY@S;#%\C&4
M-:,]@N9^:D",T8WSUN^;+HK7LBU:N%@5JOB%N9"C"PP=M5XAJ),?H:(,TVE0
MY5BY='A-9%,TVZF:9+]*!:!&;8+#8JA0>I+/>U?9N5Y^]Z/UBQ393^Z3&ON-
M>L?>Z2QWH']4U#:,5--B#WG7V9FV]NIXY;W@E;KPFL-#MLK0ST51I2'O5PU"
M_"\43(Z].>!:6?8DU3%4KP?7A))3?_T*R-)*"M-Z=BS*\5)*A46<E)/(QKHO
M7_ @7<)FFQ!&&Y_+7^%J016]9ENY^@D VLN7SG%C:<P[DG_<$YW+JT%*WC/N
MEV>7?&S,:&-*:YP 8^*]7ZF7\7.0&F>?K 8\]NXI3Y.YF3:3XM!PP2WU0I><
MUT3X7/GGEA\E!#D978)C"L[ZN4WC,S!(S>8YT<ZTL%@;QFF]:?FFQ-S?$@?8
MZUB5$FV=AE9(J:]45$JU2T!DG!7:[>9R2*D^%<;4Q)"5A?J*%4&M4/ U7)4?
M$;]H 0\CS:6F&-Y][JE5R2\A9 6*?YGY##H&>%M!UH@*V+NF:J@$@O$\VCT
M]G553O*:\XXB,V_BSBY>A).#A]_+316O0*+ZP)B0P?ONF\5;<IJNGF%".NK]
MBL4[<C1X3'U(EM/D]EU5)1X':1D4);?$4OAU/=6>6)MPO??DT2TBWAP(LR&_
M4.))0=-9>)9=2TS!.8=0<@O 6*%=4]+M'*2W.2[IP,#?;7B2JZ A>(5^6D5N
MHLZ51M>GH/+_K8-KCV=Z___;&(LD]1F;CNM*^U 8XR"R7&<-N[B%+S&5T<VA
M0JJYI@\9Q]1:I=$NYEHGE*ZZC*B%3<ZQ;B(ZDE,<":5^.[\_WZ_WX_U\/=[O
MU_/Q?+_>C_?K\9KP\#6#I5]?0M[IMQJSJ$J[^>9AG;TOIC]IOB4T\T[][?*D
M.:'AQ4/Q)[]ZQ$IBXIU6F"Q<=FL<'W(Q(^2]V39?O)15[/BFZIA%NC30H_QO
MU-?F/3L^N]SY>\-JK4E2U.P3LV@5/?[E4_VO 6]/OMU^=.?UTM]U4X_R_QU_
M=C'P>HUY5TMF_EL1]''*!%=CEGI^N#%Y7RNWS<>[*/2VMRG,L'!-:MV>V^FR
M9\K\32J8R%(7H]7_?,NQ@)^P -50Y)Y;%0/<*D+W4PN8X39(W3J#%$W_X3.D
M_ G[C<[]4_R_ZM=;1(^@9FF-4*\\I67SHS1RR0&;P[=#?NOVS$,UI+WJWORR
M?>KB0&ZE^EI+:\19>MXLZ$@?8ZW+>)"O%)<-'0T+*LU]?&P6-./&I0H:W^N:
MATOC0Z?B*X9/BD-$NYY]G(^[I[S^5!FPRDEZ\ M@>EF[Q?0Q HY)/]G7XNZ2
ML4?+K:^-'9+S8<)%YL%(K<D=>W*B+7-[>(GV/]<3XCW4%>-U<RU2EV+_KDMI
MV'?$O8;C\0[LQ=G((Z^U\Q>'9@C$M>7@*P-""-)[<8BS]8P '.S/]P)?I@6+
M=/C=RCWCWK[DK%]H6W<&UEF76P1D9GU=.+)]:_O52]\SPI=Z/U<N5ILH^V)C
MA'W]>L^GHV!5%YL7BIX\/%-TM,<Q].6IK"-;.9'>H_'%5_ZZIF9;'7#8IE9:
M?$F[]"'UU#75_K;4B1LWCG3<K&SD+GN!N:G1,^;BT6'7H//;?_G>/O#_SYK9
MI@.&F5[_^)P)KEBV$W[^FE\0]?NA]\I;,3'H4P"RTYQ7L&<R>KTKO;X6EIJ"
M<;3-G'Y0AHPJL\^F.1%+S+\X!3)$X4[=I-6B0TZ!G;+?3<_AY#"_\J7GA5S@
M2^E26 \:YN16/TB?D_H;&T21O]&T6-3P JJR-NSQ#0!6=Z/!2$H<C.^2GG(7
MKF#%AM=UZ4:7$9AXX8K5X<5=*0!ZEPZ!=,I$3+X#0EZV81@A2^76L.+[![3%
M12JO_!P>;5U)YV97&!#6@!,27;>)VKC!D8/)>#[S T%9O0[!+VL0BMR)8T%R
M.HYMRE.:\SB^?P+/>&/!DU2=J]_9HL0+Z>1C2TJ$*_"08;K_-7LOP_)07YO?
MV(7P,^BU=>]4I,>8W?PG90:4 "1!CK#"W2$,27#5V4R4PK)#R\%-@I8-IW^1
MH'OD2'0O$VO;$\W:2"P(SY XS410DM+)DQ73I*AZ6EB :3M+3J@$4**!P=V;
MGD]PA_@#2K->&X\$*G0[41XPP$24^ M8VR*I84-EN3Q3O802M#!Q7D(\/@B_
M,#"X;W63,<=([C?_8Q!>G8 &SBR:V6VKV5JUSG]: 'MR1I&$V:5SI2T4]2*N
MP4"X=OI_62>)#V%>=5KR+S]A1;8?Y&&.2Y$FOYYLVZSG.Y\5L_/G?S]R;7.W
M=A3]DKLC\H=IWD>S@;QC_K"<1<-B3ZG1:]+0M"I[MJWAEU-IYG^_2F)XY O^
M^7*O:.9I(RLV7WW#R[?S3X_8I@UW%T*_>7G;PHJVF[U]M#_1\'3GRHG&W+94
M8MSK':XOZG+N+R]T&8Y'[KQ3-)+S^\HE<P._!$R[DEBU8S HZ/6;/_OVUQR^
M)4S[@%JV&Y_$S3HTO^WR['A%F&/%4U+5KYI+I$&>_ZS2\7'8P!7GO/6(??7!
MY(C-L&IZ+?'6,:?TZ,N$")&9!]/_3O?WF0-=HA@[:==JPZ;P_@+=SV(%F?BD
MR[O3>RW#YE1&]UGZW.5S<!V2^6!N85SHJF>O]G0/I"1]OG5E8K?W-LB]'!MS
M<CPD$,E1[)46W/^FL%HRO6:2G[@WS<K[$_VI;LS;T%/MIB$EZ-/?G5<(,0&E
M.FM6_37G$OF_F3,UHSQ'4I.4/?T<OOPN?_GR7T?U9-(%W]0Z<@_N3\$_1$/X
M.;W;#=TU=?VK8DB?S[_:IW>>.1E76;.0: =@:#%#U^>6D9MQ>O4P= .:*Q3I
MY!@G>G28W1,V7!VN4#=N;@%6BLKW-(64IW4VL%/+GCOFOP#@P?L6)B11MLK[
MT\S-[7A$O>\D<[WG\ZKK"LH5+@76?"6=N<E--D289&R*U8.5N=5G<,UD4V84
M&6DE^4,XESC.54O)?\-EQBF/TD:KUDC")SCH2+2UO;\U5*6#A\^4I1Q"KUEE
MN].9M 8OH^F="D!2[N 1X2.##5VVZZ<8-8KU-F1W#''N$_V=(-L\J]X(+]-U
M&ZV-KO1,(]>&;QWLD("/I;LY'DL&H$B^0RLT.\1+UO4[!T=\TR6:I'K2$"SB
MFZ&+Y(!D> &#)3A.^$%4NHN<G.ZVK<-;#GXD4''69Q[Z[XE/X1YX'[$CLPXZ
MXP7F^U$[YNN&LV2]\Y(*!<(25VWKJM&+!(@=QXZR]V'P(Z1R(N1K:4?=];A!
MFTGYEVI/8JKY3)<D\:^[+.T ]TDZ_W0,>$EL54HSML7TB9UWQ1)4.3<1<M<2
M][JG40T2>[;$NS<7*/4SYSTTFFM06-QQE"1?B:U-E&#J%[EEO*%BBR:KEWV$
MI(PZM7F;,'%"D#BF+LD5[)R78(*:<(9H+,1_.E'P'@JU,ZM?+&52$SG.:M@K
M?\;-@9$.AKECZH$>H&@U7JNO[03<-_U&5_YDK/GUSZ\&KQJM/D9JR7'406O?
MS";?V*5]M%^W]^:EASWZKHFL+SW-Q\?>OAMV*UX^F#IE]T;_Q=.@%WE'A_R[
M\T=U"[1IN/%["Y&_559B+7)EEQ>RQW[LJ%R(5#IE1FSX 5\,TWV8YK %]AVO
M;^$M_[Q\[_TY[]R&JYFP2XM))VR_KJT)X#]8!=X;MC5\!:R<N9$#"_W^AUM#
M6J:^Q6SWORW1/Q2T;,/>"S</6CS ZYO'6' Z?L+";#^::V,M+"T*LRGL'\]3
MUJ%##O?KKI4LV*_[#5N99OZ\P[CL:FZAEEE#C?'(8;E#A0*6:%.MFU*UM[VL
MJN7=SH%W(]]H.E%MW=L8^OMUT37O5 4 G!2C&GK=O.C)+"#IP216W2GEOMV4
MZ^/,@AP:DF[FQ6JP,W/S2T; L<#G*@^YAM)S0I2Q=\I%7(\LPK0*]QV/V, =
MDI"79=_ M\GP^C9+G=,=:,LX?YC+-EDY;8TH_/$DJ7#;:S%=[J(A>3\A;+=X
MF^J.2^"BBW7ILH'5JFC>2A60]%^I1H$<^/(.(KE)"R?#M,Y4@S7LT?+N7"[E
ML#JE%#J.)QV:.PG%,DQK_3PA'P.';$-KOD&GI&)!==KJEU$.MI3!O+J@3.2L
MQ4JJD5N&*K$B+92DHIHW"Z(FBK:45RALU)4'HMEQ!'*M372I="H"]7B2:EU2
MW/R$:B>/VM6-$SNVB E1G"8K["?&1TE5'T7;+Q+R<9,=%NP'HY*.LF^EQ#+0
M0A3EWZ!6 ;^TC/?JAC I)E,T^V&OQIRDXW'@K#Q*GTP;$$)=WF)B=Q_E#T9Y
M'9%3QQ(11INR,E06 )S6K2!*T0>>?()8&P$]>41I-C.GOGW@*)-ZXJ*6+1&-
MS6M>S%!>Z+?CE<:JJ#G?GJO,L[IL72F^'9J5+F<:_\A689W]N\+Q!%H0RJO^
MK>\"$^L\Q,?^KF[88UW?DWBWZH^9I+#-.LE:!G,SEU)R&[T:LH1;>7TX-<<Q
M^&2;[5_II1&?ACNGR?N6Z[0P.[XQEGEE[DW<:ZK@>VVPI&4>M+5O.OHN:4[L
M:$B!]7QS!^[ML6GSY*:$KE\U".=;>H''GY&:<*N]9)[5R5J>,>_KQ*O3E2V+
M,#WZZCFAGO7*;ZJA-^B,P.GMXY"&2L!;@VBC$>7'OKTT9)J.N[2XD+I6?6$-
MQSIJ)D1?0<%MY<V8$.&K*0<I_, 0HTN:\UX]*HI:E"&8#T;Z"7D>!RF9L<I"
M.<PR.C,$O,^^?RQ;>0,!59@0;7>+Z% $6JYU*>4@@)06CM;YU'T*112:#W[&
M8^"AX:.%YJTCSLI<: NS3LOFK$6AHX?J=5XP*):0GB:60VE8X.+?<,,6"N7(
M5+#7,1GGY*1 DW4\8O1K)Z4'387BH(0ITHI25=J?Q ^HONP(A).;I$).]B=R
M*3K.OS"QZ8PJ205$\O,GE(^A7=7LZ.2D345\4@.2?0N/0(!Z[S)DO;L%3R!D
M8@<#)##1D@J2T>CYZS82]18598F>8%2E85=*)<"XZK<K6T5V 8&"=%)S0*3
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M[+D.:NF*G[ IX<9H6,D3L;YB^S6<!/1)ZC>VUE>X;<3*7--"5E W!:R%?I.
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MQJ8)Z&H(1*S7 P]K?%W^.?Q_4$L! A0#%     @ ]Z*;5$A& KO3$0  M*T
M !$              ( !     &%H<&$M,C R,C T,38N>'-D4$L! A0#%
M  @ ]Z*;5+YTCXNU!P  2U(  !4              ( ! A(  &%H<&$M,C R
M,C T,39?8V%L+GAM;%!+ 0(4 Q0    ( />BFU0=;NEGNB(  /A. @ 5
M          "  >H9  !A:'!A+3(P,C(P-#$V7V1E9BYX;6Q02P$"% ,4
M" #WHIM4N%P>@-Q'  #=' 0 %0              @ '7/   86AP82TR,#(R
M,#0Q-E]L86(N>&UL4$L! A0#%     @ ]Z*;5%M1Y-E6,   6F@# !4
M         ( !YH0  &%H<&$M,C R,C T,39?<')E+GAM;%!+ 0(4 Q0    (
M />BFU2K,4_O*$,  (/> 0 9              "  6^U  !A:'!A+3(P,C(P
M-#$V>&5X,3!D,C,N:'1M4$L! A0#%     @ ]Z*;5,#>2/O")P$ I-<( !D
M             ( !SO@  &%H<&$M,C R,C T,39X97@Q,&0R-"YH=&U02P$"
M% ,4    " #WHIM47"\KJB15  !<+ ( &0              @ ''( ( 86AP
M82TR,#(R,#0Q-GAE>#$P9#(U+FAT;5!+ 0(4 Q0    ( />BFU2WXQ$1@XX
M -.$!  9              "  2)V @!A:'!A+3(P,C(P-#$V>&5X,3!D,C8N
M:'1M4$L! A0#%     @ ]Z*;5.;=L)R#[   8$$) !D              ( !
MW 0# &%H<&$M,C R,C T,39X97@Q,&0R-RYH=&U02P$"% ,4    " #WHIM4
MV8 2T>H#  #L%P  &               @ &6\0, 86AP82TR,#(R,#0Q-GAE
M>#(Q9#$N:'1M4$L! A0#%     @ ]Z*;5#7^><#- P  ( D  !@
M     ( !MO4# &%H<&$M,C R,C T,39X97@R,V0Q+FAT;5!+ 0(4 Q0    (
M />BFU18:&!P4 ,  'T)   8              "  ;GY P!A:'!A+3(P,C(P
M-#$V>&5X,C-D,BYH=&U02P$"% ,4    " #WHIM4& 62YML2  ";.P  &
M            @ $__0, 86AP82TR,#(R,#0Q-GAE>#DY9#$N:'1M4$L! A0#
M%     @ ]Z*;5)2RGP$A!   0 T  !@              ( !4! $ &%H<&$M
M,C R,C T,39X97@Y.60R+FAT;5!+ 0(4 Q0    ( />BFU1@LRM^'P0  #@-
M   8              "  :<4! !A:'!A+3(P,C(P-#$V>&5X.3ED,RYH=&U0
M2P$"% ,4    " #WHIM4+$O#<RD$  !)#0  &               @ '\& 0
M86AP82TR,#(R,#0Q-GAE>#DY9#0N:'1M4$L! A0#%     @ ]Z*;5*L599L>
M!   . T  !@              ( !6QT$ &%H<&$M,C R,C T,39X97@Y.60U
M+FAT;5!+ 0(4 Q0    ( />BFU2"^9S,+00  $\-   8              "
M :\A! !A:'!A+3(P,C(P-#$V>&5X.3ED-BYH=&U02P$"% ,4    " #WHIM4
M/%W*X' $  #P$0  &               @ $2)@0 86AP82TR,#(R,#0Q-GAE
M>#DY9#<N:'1M4$L! A0#%     @ ]Z*;5"G<D-4H#@  ',H  !X
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M:'!A+3(P,C(P-#$V>',T,#$V+FIP9U!+ 0(4 Q0    ( />BFU0_+TIT='0
M +"1   7              "  5>J% !A:'!A+3(P,C(P-#$V>',T,#$W+FIP
M9U!+ 0(4 Q0    ( />BFU1+LUDX.VP  *)Z   7              "  0 ?
M%0!A:'!A+3(P,C(P-#$V>',T,#$X+FIP9U!+ 0(4 Q0    ( />BFU02SG!\
M<"\" ,=> @ 7              "  7"+%0!A:'!A+3(P,C(P-#$V>',T,#(S
M+FIP9U!+ 0(4 Q0    ( />BFU1II%0^_IP! ':R 0 7              "
M 16[%P!A:'!A+3(P,C(P-#$V>',T,#(T+FIP9U!+ 0(4 Q0    ( />BFU1"
M1^%A#CD  &!/   7              "  4A8&0!A:'!A+3(P,C(P-#$V>',T
M,#(U+FIP9U!+ 0(4 Q0    ( />BFU2L/%2GLF\  .&9   7
M  "  8N1&0!A:'!A+3(P,C(P-#$V>',T,#(V+FIP9U!+ 0(4 Q0    ( />B
MFU26%WQ,'58  %1E   7              "  7(!&@!A:'!A+3(P,C(P-#$V
M>',T,#(X+FIP9U!+ 0(4 Q0    ( />BFU2*Z-D-'+0  .SG   7
M      "  <17&@!A:'!A+3(P,C(P-#$V>',T,#(Y+FIP9U!+ 0(4 Q0    (
M />BFU1I);S(Y)T  !VP   7              "  14,&P!A:'!A+3(P,C(P
M-#$V>',T,#,P+FIP9U!+ 0(4 Q0    ( />BFU0-!%\'NEH  &]=   7
M          "  2ZJ&P!A:'!A+3(P,C(P-#$V>',T,#,Q+FIP9U!+ 0(4 Q0
M   ( />BFU1>3,=-^D$  &]%   7              "  1T%' !A:'!A+3(P
M,C(P-#$V>',T,#,R+FIP9U!+ 0(4 Q0    ( />BFU31'TH9W,D  #30   7
M              "  4Q'' !A:'!A+3(P,C(P-#$V>',T,#,S+FIP9U!+ 0(4
M Q0    ( />BFU1=.Z/\LE,   ]7   7              "  5T1'0!A:'!A
I+3(P,C(P-#$V>',T,#,T+FIP9U!+!08     )P G (T*  !$91T    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
